Need	NN	O	O
for	IN	O	O
insulin	NN	i	IPM
therapy	NN	i	IPM
in	IN	O	O
type	NN	p	PC
II	NNP	p	PC
diabetes	VBZ	p	PC
mellitus	NN	p	PC
.	.	p	O

A	DT	O	O
randomized	JJ	O	O
trial	NN	O	O
.	.	O	O

To	TO	p	O
identify	VB	p	O
patients	NNS	p	O
with	IN	p	O
type	JJ	p	PC
II	NNP	p	PC
diabetes	VBZ	p	PC
mellitus	NN	p	PC
for	IN	p	O
whom	WP	p	O
insulin	NN	i	IPM
therapy	NN	i	IPM
is	VBZ	p	O
most	RBS	p	O
beneficial	JJ	p	O
,	,	p	O
we	PRP	p	O
conducted	VBD	p	O
a	DT	p	O
randomized	VBN	p	O
controlled	VBN	p	O
trial	NN	p	O
in	IN	p	O
the	DT	p	O
general	JJ	p	O
medicine	NN	p	O
clinic	NN	p	O
of	IN	p	O
a	DT	p	O
university	NN	p	O
hospital	NN	p	O
.	.	p	O

Asymptomatic	NNP	p	O
,	,	p	O
obese	JJ	p	PC
,	,	p	O
insulin-treated	JJ	p	O
patients	NNS	p	O
were	VBD	O	O
given	VBN	O	O
diet	JJ	i	IE
and	CC	i	IE
diabetes	VBZ	i	IE
education	NN	i	IE
and	CC	O	O
,	,	O	O
in	IN	O	O
half	NN	O	O
of	IN	O	O
these	DT	O	O
patients	NNS	O	O
,	,	O	O
insulin	JJ	i	IPM
therapy	NN	i	IPM
was	VBD	i	O
withdrawn	VBN	i	O
.	.	i	O

Over	IN	O	O
six	CD	O	O
months	NNS	O	O
,	,	O	O
patients	NNS	O	O
developing	VBG	O	O
hyperglycemic	JJ	o	OPH
symptoms	NNS	o	OPH
or	CC	o	OPH
acetonemia	NN	o	OPH
were	VBD	O	O
counted	VBN	O	O
as	IN	O	O
study	NN	O	O
failures	NNS	O	O
.	.	O	O

Failure	NN	o	OPH
criteria	NNS	o	OPH
developed	VBD	O	O
in	IN	O	O
13	CD	O	O
of	IN	O	O
25	CD	p	PSS
insulin-withdrawal	JJ	p	PSS
patients	NNS	p	O
,	,	O	O
at	IN	O	O
a	DT	O	O
median	NN	O	O
of	IN	O	O
four	CD	O	O
weeks	NNS	O	O
after	IN	O	O
withdrawal	NN	O	O
,	,	O	O
compared	VBN	O	O
with	IN	O	O
two	CD	O	O
of	IN	O	O
24	CD	p	PSS
control	NN	p	O
subjects	NNS	p	O
.	.	p	O

Elevated	VBN	o	OPH
stimulated	VBD	o	OPH
glucose	JJ	o	OPH
levels	NNS	o	OPH
predicted	VBD	O	O
the	DT	O	O
need	NN	O	O
for	IN	O	O
insulin	JJ	O	O
therapy	NN	O	O
.	.	O	O

Hyperglycemia	NNP	o	OPH
worsened	VBD	O	O
in	IN	O	O
insulin-withdrawal	JJ	O	O
patients	NNS	O	O
who	WP	O	O
did	VBD	O	O
not	RB	O	O
meet	VB	O	O
study	JJ	O	O
failure	NN	O	O
criteria	NNS	O	O
,	,	O	O
but	CC	O	O
it	PRP	O	O
improved	VBD	O	O
in	IN	O	O
control	NN	O	O
patients	NNS	O	O
.	.	O	O

Study	NNP	O	O
patients	NNS	O	O
were	VBD	O	O
insulin	JJ	O	O
deficient	NN	O	O
as	IN	O	O
shown	VBN	O	O
by	IN	O	O
low	JJ	O	O
baseline	NN	o	OPH
C	NNP	o	OPH
peptide	NN	o	OPH
values	NNS	o	OPH
(	(	o	O
0.43	CD	o	O
+/-	JJ	O	O
0.05	CD	O	O
nmol/L	NN	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
prompt	JJ	O	O
metabolic	JJ	O	O
decompensation	NN	O	O
precipitated	VBN	O	O
by	IN	O	O
insulin	NN	O	O
withdrawal	NN	O	O
suggests	VBZ	O	O
that	IN	O	O
insulin-deficient	JJ	O	O
patients	NNS	O	O
may	MD	O	O
benefit	VB	O	O
from	IN	O	O
insulin	NN	O	O
therapy	NN	O	O
and	CC	O	O
may	MD	O	O
need	VB	O	O
it	PRP	O	O
to	TO	O	O
prevent	VB	O	O
symptomatic	JJ	o	OPH
hyperglycemia	NN	o	OPH
.	.	o	O

Short-term	JJ	O	O
effects	NNS	O	O
of	IN	O	O
prednisolone	NN	i	IPM
and	CC	i	O
dexamethasone	NN	i	IPM
on	IN	O	O
circulating	VBG	o	OPH
concentrations	NNS	o	OPH
of	IN	o	OPH
leptin	NN	o	OPH
and	CC	o	OPH
sex	NN	o	OPH
hormone-binding	JJ	o	OPH
globulin	NN	o	OPH
in	IN	O	O
children	NNS	p	PA
being	VBG	p	O
treated	VBN	p	O
for	IN	p	O
acute	JJ	p	PC
lymphoblastic	JJ	p	PC
leukaemia	NN	p	PC
.	.	p	O

OBJECTIVE	NNP	O	O
Disturbances	NNPS	O	O
in	IN	O	O
body	NN	O	O
weight	JJ	O	O
regulation	NN	O	O
are	VBP	O	O
often	RB	O	O
encountered	VBN	O	O
during	IN	O	O
glucocorticoid	JJ	i	IPM
treatment	NN	i	O
and	CC	O	O
are	VBP	O	O
associated	VBN	O	O
with	IN	O	O
increased	JJ	O	O
insulin	NN	O	O
resistance	NN	O	O
and	CC	O	O
truncal	JJ	O	O
fat	NN	O	O
accumulation	NN	O	O
.	.	O	O

Children	NNP	p	PA
were	VBD	p	O
investigated	VBN	p	O
who	WP	p	O
were	VBD	p	O
receiving	VBG	p	O
glucocorticoid	JJ	i	IPM
treatment	NN	i	O
for	IN	p	O
acute	JJ	p	PC
lymphoblastic	JJ	p	PC
leukaemia	NN	p	PC
(	(	p	PC
ALL	DT	p	PC
)	)	p	PC
.	.	p	O

They	PRP	O	O
were	VBD	O	O
randomized	VBN	O	O
to	TO	O	O
receive	VB	O	O
either	CC	O	O
prednisolone	VB	i	IPM
or	CC	i	O
dexamethasone	VB	i	IPM
as	IN	O	O
part	NN	O	O
of	IN	O	O
induction	NN	O	O
of	IN	O	O
remission	NN	O	O
.	.	O	O

This	DT	O	O
randomization	NN	O	O
process	NN	O	O
provided	VBD	O	O
a	DT	O	O
suitable	JJ	O	O
opportunity	NN	O	O
to	TO	O	O
compare	VB	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
these	DT	O	O
two	CD	O	O
administered	VBD	O	O
steroid	NN	O	O
on	IN	O	O
surrogate	JJ	O	O
markers	NNS	O	O
of	IN	O	O
adipocyte	NN	O	O
activity	NN	O	O
(	(	O	O
leptin	NN	O	O
)	)	O	O
and	CC	O	O
hyperinsulinaemia/insulin	JJ	O	O
resistance	NN	O	O
(	(	O	O
SHBG	NNP	O	O
)	)	O	O
.	.	O	O

DESIGN	NNP	O	O
AND	CC	O	O
PATIENTS	NNP	O	O
Prospective	NNP	O	O
study	NN	O	O
over	IN	O	O
16	CD	O	O
weeks	NNS	O	O
of	IN	O	O
children	NNS	p	PA
randomized	VBN	O	O
to	TO	O	O
receive	VB	O	O
prednisolone	NN	i	IPM
(	(	i	O
40	CD	i	O
mg/m2	NN	i	O
)	)	i	O
or	CC	i	O
dexamethasone	NN	i	IPM
(	(	i	O
6.5	CD	i	O
mg/m2	NN	i	O
)	)	i	O
as	IN	i	O
part	NN	i	O
of	IN	i	O
the	DT	i	O
MRC-ALL97/99	NNP	i	O
induction	NN	i	IPM
chemotherapy	NN	i	IPM
for	IN	i	O
ALL	NNP	i	O
.	.	i	O

Nineteen	NNP	p	PSS
children	NNS	p	PA
(	(	p	O
8	CD	p	PSS
male	NN	p	PSE
,	,	p	O
11	CD	p	PSS
female	NN	p	PSE
)	)	p	O
with	IN	p	O
a	DT	p	O
median	JJ	p	O
age	NN	p	O
5.9	CD	p	PA
years	NNS	p	PA
(	(	p	O
range	VB	p	O
2.6-13	CD	p	PA
years	NNS	p	O
)	)	p	O
were	VBD	p	O
recruited	VBN	p	O
into	IN	p	O
the	DT	p	O
study	NN	p	O
.	.	p	O

Main	NNP	O	O
outcome	JJ	O	O
measures	NNS	O	O
were	VBD	O	O
body	JJ	o	OPH
mass	NN	o	OPH
index	NN	o	OPH
(	(	o	OPH
BMI	NNP	o	OPH
)	)	o	OPH
,	,	o	O
serum	JJ	o	OPH
leptin	NN	o	OPH
and	CC	o	OPH
sex	NN	o	OPH
hormone	NN	o	OPH
binding	VBG	o	OPH
globulin	NN	o	OPH
(	(	o	OPH
SHBG	NNP	o	OPH
)	)	o	OPH
.	.	o	O

RESULTS	NNP	O	O
Glucocorticoid	NNP	O	O
administration	NN	O	O
for	IN	O	O
5	CD	O	O
weeks	NNS	O	O
resulted	VBD	O	O
in	IN	O	O
significant	JJ	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
increases	NNS	O	O
in	IN	O	O
BMI	NNP	o	OPH
,	,	o	O
leptin	NN	o	OPH
(	(	o	OPH
corrected	VBN	o	OPH
for	IN	o	OPH
BMI	NNP	o	OPH
)	)	o	OPH
and	CC	o	OPH
the	DT	o	OPH
leptin	NN	o	OPH
:	:	o	OPH
SHBG	NNP	o	OPH
ratio	NN	o	OPH
and	CC	o	OPH
lowering	NN	o	OPH
of	IN	o	OPH
SHBG	NNP	o	OPH
.	.	o	O

Dose	NNP	O	O
for	IN	O	O
dose	NN	O	O
,	,	O	O
dexamethasone	NN	i	IPM
was	VBD	O	O
significantly	RB	O	O
more	RBR	O	O
potent	JJ	O	O
than	IN	O	O
prednisolone	NN	i	IPM
in	IN	O	O
altering	VBG	O	O
these	DT	O	O
parameters	NNS	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
Short-term	JJ	O	O
glucocorticoid	NN	O	O
treatment	NN	O	O
has	VBZ	O	O
significant	JJ	O	O
effects	NNS	O	O
on	IN	O	O
BMI	NNP	O	O
,	,	O	O
leptin	NN	O	O
and	CC	O	O
SHBG	NNP	O	O
.	.	O	O

The	DT	O	O
leptin	NN	O	O
:	:	O	O
SHBG	NNP	O	O
ratio	NN	O	O
increase	NN	O	O
indicates	VBZ	O	O
that	IN	O	O
this	DT	O	O
may	MD	O	O
be	VB	O	O
a	DT	O	O
novel	JJ	O	O
and	CC	O	O
sensitive	JJ	O	O
biochemical	JJ	O	O
marker	NN	O	O
of	IN	O	O
metabolic	JJ	O	O
change	NN	O	O
.	.	O	O

Our	PRP$	O	O
results	NNS	O	O
suggest	VBP	O	O
that	IN	O	O
glucocorticoid	JJ	i	IPM
treatment	NN	i	O
regimens	NNS	i	O
should	MD	O	O
be	VB	O	O
kept	VBN	O	O
as	RB	O	O
short	JJ	O	O
as	IN	O	O
possible	JJ	O	O
to	TO	O	O
avoid	VB	O	O
possible	JJ	O	O
detrimental	JJ	O	O
effects	NNS	O	O
associated	VBN	O	O
with	IN	O	O
increased	JJ	O	O
adiposity	NN	O	O
and	CC	O	O
insulin	NN	O	O
resistance	NN	O	O
.	.	O	O

Safety	NN	o	OOt
of	IN	O	O
ferumoxytol	NN	i	IPM
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
anemia	NN	p	PC
and	CC	p	O
CKD	NNP	p	PC
.	.	p	O

BACKGROUND	NNP	O	O
Iron	NNP	O	O
deficiency	NN	O	O
anemia	NN	O	O
is	VBZ	O	O
a	DT	O	O
common	JJ	O	O
complication	NN	O	O
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
chronic	JJ	p	PC
kidney	NN	p	PC
disease	NN	p	PC
(	(	p	PC
CKD	NNP	p	PC
)	)	p	PC
.	.	p	O

Currently	NNP	O	O
available	JJ	O	O
intravenous	JJ	O	O
(	(	O	O
IV	NNP	O	O
)	)	O	O
iron	NN	i	IPM
replacement	NN	i	IPM
therapies	NNS	i	IPM
have	VBP	O	O
either	DT	O	O
inconvenient	JJ	O	O
regimens	NNS	O	O
of	IN	O	O
administration	NN	O	O
or	CC	O	O
adverse	JJ	O	O
event	NN	O	O
profiles	NNS	O	O
that	WDT	O	O
limit	VBP	O	O
their	PRP$	O	O
utility	NN	O	O
in	IN	O	O
the	DT	O	O
outpatient	JJ	p	O
setting	NN	O	O
.	.	O	O

Ferumoxytol	NNP	i	IPM
is	VBZ	O	O
a	DT	O	O
novel	NN	O	O
,	,	O	O
semisynthetic	JJ	O	O
,	,	O	O
carbohydrate-coated	JJ	O	O
,	,	O	O
superparamagnetic	JJ	O	O
iron	NN	O	O
oxide	NN	O	O
nanoparticle	NN	O	O
that	WDT	O	O
is	VBZ	O	O
administered	VBN	O	O
IV	NNP	O	O
as	IN	O	O
an	DT	O	O
injection	NN	O	O
.	.	O	O

The	DT	O	O
main	JJ	O	O
objective	NN	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
assess	VB	O	O
the	DT	O	O
safety	NN	o	OOt
of	IN	O	O
ferumoxytol	NN	i	IPM
for	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
patients	NNS	p	O
with	IN	p	O
CKD	NNP	p	PC
stages	VBZ	p	PC
1	CD	p	PC
to	TO	p	PC
5	CD	p	PC
and	CC	p	PC
5D	CD	p	PC
.	.	p	O

STUDY	NNP	O	O
DESIGN	NNP	O	O
Phase	NNP	O	O
3	CD	O	O
,	,	O	O
randomized	VBN	O	O
,	,	O	O
double-blind	JJ	O	O
,	,	O	O
placebo-controlled	JJ	i	IC
,	,	O	O
crossover	NN	O	O
,	,	O	O
multicenter	NN	O	O
study	NN	O	O
of	IN	O	O
a	DT	O	O
single	JJ	O	O
510-mg	JJ	O	O
dose	NN	O	O
of	IN	O	O
ferumoxytol	JJ	i	IPM
versus	NN	i	O
saline	NN	i	IC
as	IN	i	IPM
placebo	NN	i	IPM
.	.	i	O

SETTING	NNP	O	O
&	CC	O	O
PARTICIPANTS	NNP	O	O
750	CD	p	PSS
patients	NNS	p	O
with	IN	p	O
CKD	NNP	p	PC
stages	VBZ	p	PC
1	CD	p	PC
to	TO	p	PC
5	CD	p	PC
and	CC	p	PC
5D	CD	p	PC
.	.	p	O

INTERVENTION	NNP	O	O
An	DT	O	O
IV	NNP	i	IPM
injection	NN	i	IPM
of	IN	O	O
either	CC	O	O
17	CD	O	O
mL	NN	O	O
of	IN	O	O
ferumoxytol	NN	i	IPM
or	CC	i	O
saline	NN	i	IC
placebo	NN	i	IPM
over	IN	O	O
17	CD	O	O
seconds	NNS	O	O
on	IN	O	O
day	NN	O	O
0	CD	O	O
and	CC	O	O
the	DT	O	O
alternate	NN	O	O
agent	NN	O	O
on	IN	O	O
day	NN	O	O
7	CD	O	O
.	.	O	O

OUTCOMES	NNP	O	O
&	CC	O	O
MEASUREMENTS	NNP	O	O
Descriptive	NNP	O	O
comparison	NN	O	O
of	IN	O	O
adverse	JJ	o	OA
events	NNS	o	OA
,	,	o	O
laboratory	NN	o	OPH
tests	NNS	o	OPH
,	,	o	OPH
and	CC	o	OPH
vital	JJ	o	OPH
signs	NNS	o	OPH
.	.	o	O

RESULTS	NNP	O	O
Of	IN	O	O
750	CD	p	PSS
randomly	NNS	p	O
assigned	VBD	p	O
patients	NNS	p	O
with	IN	p	O
CKD	NNP	p	PC
,	,	p	O
60	CD	p	O
%	NN	p	O
were	VBD	p	O
not	RB	p	O
on	IN	p	O
dialysis	NN	i	IPH
therapy	NN	i	IPH
.	.	i	O

713	CD	p	O
patients	NNS	p	O
received	VBD	p	O
ferumoxytol	JJ	i	IPM
,	,	p	O
and	CC	p	O
711	CD	p	PSS
received	VBD	p	O
placebo	NN	i	IC
.	.	i	O

There	EX	O	O
were	VBD	O	O
420	CD	p	O
adverse	JJ	o	OA
events	NNS	o	OA
reported	VBD	p	O
;	:	p	O
242	CD	p	O
in	IN	p	O
152	CD	p	PSS
patients	NNS	p	O
(	(	p	O
21.3	CD	p	O
%	NN	p	O
)	)	p	O
with	IN	p	O
ferumoxytol	NN	p	O
and	CC	p	O
178	CD	p	O
in	IN	p	O
119	CD	p	PSS
patients	NNS	p	O
(	(	p	O
16.7	CD	p	O
%	NN	p	O
)	)	p	O
with	IN	p	O
placebo	NN	i	IC
.	.	i	O

The	DT	O	O
incidence	NN	o	OA
of	IN	o	OA
related	JJ	o	OA
adverse	JJ	o	OA
events	NNS	o	OA
was	VBD	O	O
5.2	CD	O	O
%	NN	O	O
with	IN	O	O
ferumoxytol	NN	i	IPM
and	CC	O	O
4.5	CD	O	O
%	NN	O	O
with	IN	O	O
placebo	NN	i	IC
.	.	i	O

The	DT	O	O
most	RBS	O	O
common	JJ	O	O
related	JJ	O	O
adverse	JJ	o	OA
events	NNS	o	OA
after	IN	O	O
each	DT	O	O
treatment	NN	O	O
included	VBD	O	O
symptoms	NNS	o	OA
related	VBN	O	O
to	TO	O	O
the	DT	O	O
injection/infusion	NN	o	OA
site	NN	o	OA
,	,	o	OA
dizziness	NN	o	OA
,	,	o	OA
pruritus	NN	o	OA
,	,	o	OA
headache	NN	o	OA
,	,	o	OA
fatigue	NN	o	OA
,	,	o	OA
and	CC	o	OA
nausea	NN	o	OA
.	.	o	OA

Serious	JJ	o	OA
adverse	JJ	o	OA
events	NNS	o	OA
occurred	VBD	O	O
in	IN	O	O
21	CD	O	O
patients	NNS	O	O
(	(	O	O
2.9	CD	O	O
%	NN	O	O
)	)	O	O
after	IN	O	O
ferumoxytol	NN	i	IPM
and	CC	O	O
13	CD	O	O
patients	NNS	O	O
(	(	O	O
1.8	CD	O	O
%	NN	O	O
)	)	O	O
after	IN	O	O
placebo	NN	i	IC
.	.	i	O

Serious	JJ	o	OA
related	JJ	o	OA
adverse	JJ	o	OA
events	NNS	o	OA
were	VBD	O	O
observed	VBN	O	O
in	IN	O	O
1	CD	O	O
patient	NN	O	O
(	(	O	O
0.1	CD	O	O
%	NN	O	O
)	)	O	O
after	IN	O	O
each	DT	O	O
treatment	NN	O	O
.	.	O	O

There	EX	O	O
was	VBD	O	O
no	DT	O	O
meaningful	JJ	O	O
decrease	NN	O	O
in	IN	O	O
blood	NN	o	OPH
pressure	NN	o	OPH
after	IN	O	O
administration	NN	O	O
of	IN	O	O
ferumoxytol	NN	i	IPM
or	CC	i	O
placebo	NN	i	IC
.	.	i	O

LIMITATIONS	NNP	O	O
Follow-up	NNP	O	O
was	VBD	O	O
7	CD	O	O
days	NNS	O	O
after	IN	O	O
each	DT	O	O
study	NN	O	O
treatment	NN	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
Ferumoxytol	NNP	i	IPM
is	VBZ	O	O
well	RB	O	O
tolerated	VBN	o	OOt
and	CC	O	O
has	VBZ	O	O
a	DT	O	O
safety	NN	o	OOt
profile	NN	o	OOt
similar	JJ	O	O
to	TO	O	O
placebo	VB	i	IC
in	IN	O	O
anemic	JJ	p	PC
patients	NNS	p	O
with	IN	p	O
CKD	NNP	p	PC
stages	VBZ	p	PC
1	CD	p	PC
to	TO	p	PC
5	CD	p	PC
and	CC	p	O
5D	CD	p	O
.	.	p	O

[	JJ	O	O
Efficacy	NNP	O	O
of	IN	O	O
naftopidil	NN	i	IPM
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
overactive	JJ	p	PC
bladder	NN	p	PC
associated	VBN	p	PC
with	IN	p	PC
benign	JJ	p	PC
prostatic	JJ	p	PC
hyperplasia	NN	p	PC
:	:	p	O
prospective	JJ	O	O
randomized	NN	O	O
controlled	VBD	O	O
study	NN	O	O
to	TO	O	O
compare	VB	O	O
differences	NNS	O	O
in	IN	O	O
efficacy	NN	O	O
between	IN	O	O
morning	NN	O	O
and	CC	O	O
evening	VBG	O	O
medication	NN	O	O
]	NNP	O	O
.	.	O	O

A	NNP	O	O
total	NN	p	O
of	IN	p	O
100	CD	p	PSS
patients	NNS	p	O
with	IN	p	O
benign	JJ	p	PC
prostatic	JJ	p	PC
hyperplasia	NN	p	PC
(	(	p	PC
BPH	NNP	p	PC
)	)	p	PC
and	CC	p	PC
overactive	JJ	p	PC
bladder	NN	p	PC
(	(	p	PC
OAB	NNP	p	PC
)	)	p	PC
symptoms	NNS	p	O
(	(	p	O
BPH/OAB	NNP	p	O
)	)	p	O
,	,	p	O
enrolled	VBN	p	O
between	IN	p	O
June	NNP	p	O
2006	CD	p	O
to	TO	p	O
March	NNP	p	O
2008	CD	p	O
,	,	O	O
were	VBD	O	O
randomly	RB	O	O
divided	VBN	O	O
into	IN	O	O
2	CD	O	O
groups	NNS	O	O
of	IN	O	O
morning	NN	O	O
medication	NN	O	O
(	(	O	O
M	NNP	O	O
)	)	O	O
and	CC	O	O
evening	VBG	O	O
medication	NN	O	O
(	(	O	O
E	NNP	O	O
)	)	O	O
groups	NNS	O	O
,	,	O	O
then	RB	i	O
50	CD	i	O
mg	NN	i	O
of	IN	i	O
naftopidil	NN	i	IPM
was	VBD	i	O
given	VBN	i	O
once	RB	i	O
a	DT	i	O
day	NN	i	O
after	IN	i	O
breakfast	NN	i	O
or	CC	i	O
supper	NN	i	O
for	IN	i	O
8	CD	i	O
weeks	NNS	i	O
.	.	i	O

Data	NNS	O	O
were	VBD	O	O
available	JJ	O	O
for	IN	O	O
efficacy	NN	O	O
analysis	NN	O	O
on	IN	O	O
80	CD	O	O
patients	NNS	O	O
(	(	O	O
M	NNP	O	O
group	NN	O	O
;	:	O	O
43	CD	O	O
,	,	O	O
E	NNP	O	O
group	NN	O	O
;	:	O	O
37	CD	O	O
)	)	O	O
.	.	O	O

Naftopidil	NNP	i	IPM
significantly	RB	O	O
improved	VBD	O	O
the	DT	O	O
overall	JJ	o	OOt
international	JJ	o	OOt
prostatic	JJ	o	OOt
symptom	NN	o	OOt
score	NN	o	OOt
;	:	O	O
from	IN	O	O
19.2?7.9	CD	O	O
to	TO	O	O
11.7?5.8	CD	O	O
in	IN	O	O
the	DT	O	O
M	NNP	O	O
group	NN	O	O
and	CC	O	O
from	IN	O	O
19.4?6.4	CD	O	O
to	TO	O	O
12.3?6.8	CD	O	O
in	IN	O	O
the	DT	O	O
E	NNP	O	O
group	NN	O	O
(	(	O	O
p	JJ	O	O
<	NNP	O	O
0.0001	CD	O	O
)	)	O	O
,	,	O	O
QOL	NNP	O	O
score	NN	O	O
from	IN	O	O
4.9?0.8	CD	O	O
to	TO	O	O
3.2?1.4	CD	O	O
in	IN	O	O
the	DT	O	O
M	NNP	O	O
group	NN	O	O
and	CC	O	O
from	IN	O	O
5.0?0.8	CD	O	O
to	TO	O	O
3.6?1.3	CD	O	O
in	IN	O	O
the	DT	O	O
E	NNP	O	O
group	NN	O	O
(	(	O	O
p	JJ	O	O
<	NNP	O	O
0.0001	CD	o	O
)	)	o	O
,	,	o	O
and	CC	o	O
OAB	NNP	o	O
symptom	VBD	o	O
score	NN	o	O
from	IN	o	O
7.8?2.6	CD	O	O
to	TO	O	O
5.0?2.5	CD	O	O
in	IN	O	O
the	DT	O	O
M	NNP	O	O
group	NN	O	O
(	(	O	O
p	JJ	O	O
<	NNP	O	O
0.0001	CD	O	O
)	)	O	O
and	CC	O	O
from	IN	O	O
8.6?2.9	CD	O	O
to	TO	O	O
5.8?	CD	O	O
3.3	CD	O	O
in	IN	O	O
the	DT	O	O
E	NNP	O	O
group	NN	O	O
(	(	O	O
p	JJ	O	O
<	NNP	O	O
0.0001	CD	O	O
)	)	O	O
.	.	O	O

There	EX	O	O
was	VBD	O	O
no	DT	O	O
significant	JJ	O	O
difference	NN	O	O
in	IN	O	O
the	DT	O	O
incidence	NN	O	O
of	IN	O	O
adverse	JJ	o	O
effects	NNS	o	O
between	IN	o	O
the	DT	O	O
M	NNP	O	O
group	NN	O	O
(	(	O	O
6.1	CD	O	O
%	NN	O	O
)	)	O	O
and	CC	O	O
E	NNP	O	O
group	NN	O	O
(	(	O	O
2.2	CD	O	O
%	NN	O	O
)	)	O	O
.	.	O	O

These	DT	O	O
results	NNS	O	O
suggest	VBP	O	O
that	IN	O	O
naftopidil	JJ	O	O
improves	NNS	o	O
storage	NN	o	O
symptoms	NNS	o	O
as	RB	o	O
well	RB	o	O
as	IN	o	O
voiding	VBG	o	O
symptoms	NNS	o	O
regardless	RB	o	O
of	IN	O	O
timing	NN	O	O
of	IN	O	O
administration	NN	O	O
.	.	O	O

Efficacy	NN	o	OOt
of	IN	O	O
topical	JJ	O	O
azithromycin	NN	i	IPM
ophthalmic	JJ	O	O
solution	NN	O	O
1	CD	O	O
%	NN	O	O
in	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
posterior	JJ	p	PC
blepharitis	NN	p	PC
.	.	p	O

INTRODUCTION	NNP	O	O
Azithromycin	NNP	i	IPM
,	,	O	O
a	DT	O	O
broad-spectrum	JJ	O	O
antibiotic	JJ	O	O
with	IN	O	O
potent	JJ	O	O
anti-inflammatory	JJ	O	O
activities	NNS	O	O
,	,	O	O
has	VBZ	O	O
the	DT	O	O
potential	JJ	O	O
to	TO	O	O
effectively	RB	O	O
treat	VB	O	O
blepharitis	NN	o	OPH
,	,	p	O
an	DT	p	O
inflammatory	JJ	p	PC
disease	NN	p	PC
of	IN	p	O
the	DT	p	O
eyelid	JJ	p	O
with	IN	p	O
abnormal	JJ	p	O
eyelid	JJ	p	O
flora	NN	p	O
as	IN	p	O
an	DT	p	O
etiologic	JJ	p	O
determinant	NN	p	O
.	.	p	O

The	DT	O	O
present	JJ	O	O
study	NN	O	O
compared	VBN	O	O
the	DT	O	O
efficacy	NN	o	OOt
of	IN	O	O
topical	JJ	O	O
azithromycin	NN	i	IPM
ophthalmic	JJ	O	O
solution	NN	O	O
1	CD	O	O
%	NN	O	O
(	(	O	O
AzaSite	NNP	O	O
;	:	O	O
Inspire	NNP	O	O
Pharmaceuticals	NNP	O	O
,	,	O	O
Inc	NNP	O	O
,	,	O	O
NC	NNP	O	O
,	,	O	O
USA	NNP	O	O
)	)	O	O
combined	VBD	O	O
with	IN	O	O
warm	JJ	O	O
compresses	NNS	O	O
(	(	O	O
azithromycin	JJ	O	O
group	NN	O	O
)	)	O	O
to	TO	O	O
warm	JJ	O	O
compresses	NNS	O	O
alone	RB	O	O
(	(	O	O
compress	JJ	O	O
group	NN	O	O
)	)	O	O
in	IN	O	O
patients	NNS	O	O
with	IN	O	O
posterior	JJ	O	O
blepharitis	NN	O	O
.	.	O	O

METHODS	NNP	O	O
Twenty-one	CD	p	PSS
patients	NNS	p	O
diagnosed	VBN	p	O
with	IN	p	O
posterior	JJ	p	PC
blepharitis	NN	p	PC
were	VBD	O	O
randomized	VBN	O	O
in	IN	O	O
an	DT	O	O
open-label	JJ	O	O
study	NN	O	O
to	TO	O	O
receive	VB	O	O
either	DT	O	O
azithromycin	NN	i	IPM
plus	CC	i	O
warm	JJ	i	IPM
compresses	NNS	i	IPM
(	(	O	O
10	CD	O	O
patients	NNS	O	O
)	)	O	O
,	,	O	O
or	CC	O	O
compresses	VBZ	O	O
alone	RB	O	O
(	(	O	O
11	CD	O	O
patients	NNS	O	O
)	)	O	O
.	.	O	O

All	DT	O	O
patients	NNS	O	O
were	VBD	O	O
instructed	VBN	O	O
to	TO	O	O
apply	VB	O	O
compresses	NNS	O	O
to	TO	O	O
each	DT	O	O
eye	NN	O	O
for	IN	O	O
5-10	JJ	O	O
minutes	NNS	O	O
twice	RB	O	O
daily	RB	O	O
for	IN	O	O
14	CD	O	O
days	NNS	O	O
.	.	O	O

Each	DT	O	O
eye	NN	O	O
in	IN	O	O
the	DT	O	O
azithromycin	NN	i	IPM
group	NN	O	O
also	RB	O	O
received	VBD	O	O
azithromycin	JJ	O	O
solution	NN	O	O
(	(	O	O
1	CD	O	O
drop	NN	O	O
)	)	O	O
twice	RB	O	O
daily	RB	O	O
for	IN	O	O
the	DT	O	O
first	JJ	O	O
2	CD	O	O
days	NNS	O	O
followed	VBN	O	O
by	IN	O	O
once	RB	O	O
daily	JJ	O	O
for	IN	O	O
the	DT	O	O
next	JJ	O	O
12	CD	O	O
days	NNS	O	O
.	.	O	O

Patients	NNS	O	O
were	VBD	O	O
evaluated	VBN	O	O
at	IN	O	O
study	NN	O	O
initiation	NN	O	O
(	(	O	O
visit	IN	O	O
1	CD	O	O
)	)	O	O
and	CC	O	O
at	IN	O	O
end	NN	O	O
of	IN	O	O
treatment	NN	O	O
(	(	O	O
visit	IN	O	O
2	CD	O	O
)	)	O	O
for	IN	O	O
the	DT	O	O
severity	NN	O	O
of	IN	O	O
five	CD	O	O
clinical	JJ	O	O
signs	NNS	O	O
:	:	O	O
eyelid	JJ	o	OPH
debris	NN	o	OPH
,	,	o	O
eyelid	JJ	o	OPH
redness	NN	o	OPH
,	,	o	O
eyelid	JJ	o	OPH
swelling	NN	o	OPH
,	,	o	O
meibomian	JJ	o	OPH
gland	NN	o	OPH
(	(	o	OPH
MG	NNP	o	OPH
)	)	o	OPH
plugging	NN	o	OPH
,	,	o	O
and	CC	o	O
the	DT	o	O
quality	NN	o	OPH
of	IN	o	OPH
MG	NNP	o	OPH
secretion	NN	o	OPH
.	.	o	O

At	IN	O	O
visit	NN	O	O
2	CD	O	O
,	,	O	O
patients	NNS	O	O
also	RB	O	O
rated	VBD	O	O
their	PRP$	O	O
degree	NN	O	O
of	IN	O	O
overall	JJ	o	OOt
symptomatic	JJ	o	OOt
relief	NN	o	OOt
.	.	o	O

RESULTS	NNP	O	O
Twenty	NNP	p	PSS
patients	NNS	p	O
completed	VBD	p	O
the	DT	p	O
study	NN	p	O
.	.	p	O

At	IN	O	O
visit	NN	O	O
2	CD	O	O
,	,	O	O
patients	NNS	O	O
in	IN	O	O
the	DT	O	O
azithromycin	NN	i	IPM
group	NN	O	O
demonstrated	VBD	O	O
significant	JJ	o	OME
improvements	NNS	o	OME
in	IN	O	O
MG	NNP	o	OPH
plugging	NN	o	OPH
,	,	o	O
MG	NNP	o	OPH
secretions	NNS	o	OPH
,	,	o	O
and	CC	o	O
eyelid	JJ	o	OPH
redness	NN	o	OPH
as	IN	O	O
compared	VBN	O	O
with	IN	O	O
the	DT	O	O
compress	NN	O	O
group	NN	O	O
.	.	O	O

In	IN	O	O
the	DT	O	O
azithromycin	NN	i	IPM
group	NN	O	O
,	,	O	O
MG	NNP	o	OPH
plugging	VBG	o	OPH
resolved	VBN	O	O
completely	RB	O	O
in	IN	O	O
three	CD	O	O
patients	NNS	O	O
and	CC	O	O
MG	NNP	o	OPH
secretion	NN	o	OPH
returned	VBD	o	OPH
to	TO	o	OPH
normal	JJ	o	OPH
in	IN	O	O
two	CD	O	O
patients	NNS	O	O
;	:	O	O
no	DT	O	O
such	JJ	O	O
results	NNS	O	O
were	VBD	O	O
seen	VBN	O	O
in	IN	O	O
the	DT	O	O
compress	NN	O	O
group	NN	O	O
.	.	O	O

Furthermore	RB	O	O
,	,	O	O
a	DT	O	O
higher	JJR	O	O
percentage	NN	O	O
of	IN	O	O
patients	NNS	O	O
in	IN	O	O
the	DT	O	O
azithromycin	NN	O	O
group	NN	O	O
rated	VBD	O	O
overall	JJ	o	OPH
symptomatic	JJ	o	OPH
relief	NN	o	OPH
as	IN	O	O
excellent	NN	O	O
or	CC	O	O
good	JJ	O	O
.	.	O	O

Visual	JJ	o	OOt
acuity	NN	o	OOt
measurements	NNS	o	OOt
and	CC	o	OOt
biomicroscopic	JJ	o	OOt
evaluation	NN	o	OOt
revealed	VBD	O	O
no	DT	o	OOt
ocular	JJ	o	OOt
safety	NN	o	OOt
issues	NNS	o	OOt
.	.	o	O

CONCLUSION	NNP	O	O
Azithromycin	NNP	i	IPM
ophthalmic	JJ	O	O
solution	NN	O	O
in	IN	O	O
combination	NN	O	O
with	IN	O	O
warm	JJ	O	O
compresses	NNS	O	O
provided	VBD	O	O
a	DT	O	O
significantly	RB	o	O
greater	JJR	o	O
clinical	JJ	o	O
benefit	NN	o	O
than	IN	O	O
warm	JJ	O	O
compresses	NNS	O	O
alone	RB	O	O
in	IN	O	O
treating	VBG	O	O
the	DT	O	O
signs	NNS	o	OPH
and	CC	o	OPH
symptoms	NNS	o	OPH
of	IN	o	OPH
posterior	JJ	o	OPH
blepharitis	NN	o	OPH
.	.	o	O

A	DT	O	O
30-month	JJ	O	O
longitudinal	JJ	O	O
study	NN	O	O
of	IN	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
some	DT	O	O
oral	JJ	i	IPH
hygiene	NN	i	IPH
measures	NNS	i	IPH
on	IN	O	O
Streptococcus	NNP	o	OPH
mutans	NNS	o	OPH
and	CC	o	OPH
approximal	JJ	o	OPH
dental	JJ	o	OPH
caries	NNS	o	OPH
.	.	o	O

The	DT	O	O
effects	NNS	O	O
of	IN	O	O
some	DT	O	O
oral	JJ	i	IPH
hygiene	NN	i	IPH
measures	NNS	i	IPH
on	IN	O	O
Streptococcus	NNP	o	OPH
mutants	NNS	o	OPH
and	CC	p	O
approximal	JJ	o	OPH
dental	JJ	o	OPH
caries	NNS	o	OPH
were	VBD	O	O
evaluated	VBN	O	O
.	.	O	O

One	CD	p	O
hundred	CD	p	O
and	CC	p	O
eighty-seven	JJ	p	O
13-year-old	JJ	p	O
individuals	NNS	p	O
with	IN	p	O
high	JJ	p	O
levels	NNS	p	O
of	IN	p	O
salivary	JJ	p	O
S.	NNP	o	OPH
mutans	NNS	o	OPH
(	(	p	O
greater	JJR	p	O
than	IN	p	O
10	CD	p	O
(	(	p	O
6	CD	p	O
)	)	p	O
/mL	NN	p	O
)	)	p	O
were	VBD	p	O
selected	VBN	p	O
.	.	p	O

They	PRP	O	O
were	VBD	O	O
randomly	RB	O	O
distributed	VBN	O	O
into	IN	O	O
three	CD	O	O
groups	NNS	O	O
.	.	O	O

Group	NNP	O	O
I	PRP	O	O
initially	RB	O	O
received	VBD	O	O
professional	JJ	i	IPH
mechanical	JJ	i	IPH
tooth-cleaning	NN	i	IPH
,	,	i	IE
tongue-scraping	NN	i	IPH
,	,	i	IE
chlorhexidine	NN	i	IC
treatment	NN	i	IC
,	,	i	IE
and	CC	i	IE
oral	JJ	i	IE
hygiene	NN	i	IE
instructions	NNS	i	IE
concentrated	VBD	O	O
on	IN	O	O
the	DT	O	O
approximal	JJ	O	O
surfaces	NNS	O	O
most	RBS	O	O
colonized	VBN	O	O
by	IN	O	O
S.	NNP	O	O
mutans	NNS	O	O
.	.	O	O

The	DT	O	O
treatment	NN	O	O
was	VBD	O	O
given	VBN	O	O
four	CD	O	O
times	NNS	O	O
with	IN	O	O
intervals	NNS	O	O
of	IN	O	O
two	CD	O	O
days	NNS	O	O
,	,	O	O
followed	VBN	O	O
by	IN	O	O
one	CD	O	O
single	JJ	O	O
treatment	NN	O	O
every	DT	O	O
six	CD	O	O
months	NNS	O	O
throughout	IN	O	O
the	DT	O	O
experimental	JJ	O	O
period	NN	O	O
.	.	O	O

The	DT	O	O
initial	JJ	O	O
treatment	NN	O	O
period	NN	O	O
for	IN	O	O
group	NN	O	O
II	NNP	O	O
,	,	O	O
also	RB	O	O
consisting	VBG	O	O
of	IN	O	O
four	CD	O	O
visits	NNS	O	O
,	,	O	O
included	VBD	O	O
the	DT	O	O
same	JJ	O	O
oral	JJ	i	IE
hygiene	NN	i	IE
instructions	NNS	i	IE
as	IN	O	O
for	IN	O	O
group	NN	O	O
I	PRP	O	O
.	.	O	O

The	DT	O	O
instructions	NNS	O	O
were	VBD	O	O
repeated	VBN	O	O
every	DT	O	O
six	CD	O	O
months	NNS	O	O
.	.	O	O

Group	NNP	O	O
III	NNP	O	O
was	VBD	O	O
maintained	VBN	O	O
in	IN	O	O
the	DT	O	O
preventive	JJ	i	IE
program	NN	i	IE
provided	VBN	i	IE
by	IN	i	IE
the	DT	i	IE
local	JJ	i	IE
Dental	NNP	i	IE
Health	NNP	i	IE
Office	NNP	i	IE
,	,	O	O
based	VBN	O	O
on	IN	O	O
mechanical	JJ	i	IPH
plaque	NN	i	IPH
control	NN	i	IPH
and	CC	O	O
topical	JJ	i	IPM
use	NN	i	IPM
of	IN	i	IPM
fluorides	NNS	i	IPM
and	CC	i	IPM
chlorhexidine	NN	i	IPM
at	IN	O	O
individualized	JJ	O	O
intervals	NNS	O	O
.	.	O	O

Group	NNP	O	O
I	PRP	O	O
showed	VBD	O	O
a	DT	O	O
significant	JJ	O	O
immediate	JJ	O	O
reduction	NN	O	O
of	IN	O	O
S.	NNP	o	O
mutans	NNS	o	O
in	IN	o	O
saliva	NN	o	O
as	RB	O	O
well	RB	O	O
as	IN	O	O
an	DT	O	O
approximal	JJ	O	O
tooth	NN	O	O
surfaces	NNS	O	O
.	.	O	O

After	IN	O	O
six	CD	O	O
months	NNS	O	O
,	,	O	O
there	EX	O	O
were	VBD	O	O
no	DT	O	O
differences	NNS	O	O
among	IN	O	O
the	DT	O	O
three	CD	O	O
groups	NNS	O	O
regarding	VBG	O	O
these	DT	O	O
variables	NNS	O	O
.	.	O	O

Compared	VBN	O	O
with	IN	O	O
baseline	NN	O	O
,	,	O	O
there	EX	O	O
was	VBD	O	O
a	DT	O	O
significant	JJ	O	O
reduction	NN	O	O
of	IN	O	O
S.	NNP	o	O
mutans	NNS	o	O
in	IN	O	O
all	DT	O	O
groups	NNS	O	O
.	.	O	O

There	EX	O	O
was	VBD	O	O
no	DT	O	O
significant	JJ	O	O
difference	NN	O	O
in	IN	O	O
caries	NNS	o	OPH
progression	NN	o	OPH
among	IN	O	O
the	DT	O	O
three	CD	O	O
groups	NNS	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
the	DT	O	O
selected	VBN	O	O
high-risk	JJ	O	O
individuals	NNS	O	O
in	IN	O	O
group	NN	O	O
I	PRP	O	O
developed	VBD	O	O
0.25	CD	O	O
new	JJ	O	O
manifest	NN	O	O
caries	NNS	O	O
lesions	NNS	O	O
approximally/year	VBP	O	O
,	,	O	O
compared	VBN	O	O
with	IN	O	O
0.27	CD	O	O
for	IN	O	O
all	DT	O	O
children	NNS	O	O
of	IN	O	O
the	DT	O	O
same	JJ	O	O
age	NN	O	O
group	NN	O	O
in	IN	O	O
the	DT	O	O
area	NN	O	O
.	.	O	O

Seventeen	JJ	O	O
individuals	NNS	O	O
had	VBD	O	O
approximal	JJ	O	O
surfaces	NNS	O	O
with	IN	O	O
consistently	RB	O	O
high	JJ	O	O
or	CC	O	O
consistently	RB	O	O
low	JJ	O	O
S.	NNP	o	O
mutans	NN	o	OPH
levels	NNS	o	OPH
.	.	o	O

Forty-six	CD	O	O
percent	NN	O	O
of	IN	O	O
the	DT	O	O
surfaces	NNS	O	O
with	IN	O	O
high	JJ	O	O
values	NNS	O	O
developed	VBD	O	O
new	JJ	o	OPH
or	CC	o	OPH
progressive	JJ	o	OPH
caries	NNS	o	OPH
,	,	O	O
compared	VBN	O	O
with	IN	O	O
2	CD	O	O
%	NN	O	O
of	IN	O	O
the	DT	O	O
surfaces	NNS	O	O
with	IN	O	O
low	JJ	O	O
values	NNS	O	O
.	.	O	O

Safety	NN	O	O
and	CC	O	O
efficacy	NN	O	O
of	IN	O	O
donepezil	NN	i	IPM
in	IN	O	O
children	NNS	p	O
and	CC	p	O
adolescents	NNS	p	O
with	IN	p	O
autism	NN	p	O
:	:	p	O
neuropsychological	JJ	O	O
measures	NNS	O	O
.	.	O	O

OBJECTIVE	NNP	O	O
There	EX	O	O
has	VBZ	O	O
been	VBN	O	O
recent	JJ	O	O
interest	NN	O	O
in	IN	O	O
the	DT	O	O
use	NN	O	O
of	IN	O	O
cognitive	JJ	i	IPM
enhancing	VBG	i	IPM
drugs	NNS	i	IPM
,	,	O	O
such	JJ	O	O
as	IN	O	O
cholinesterase	NN	i	IPH
inhibitors	NNS	i	IPH
,	,	O	O
as	IN	O	O
a	DT	O	O
possible	JJ	O	O
treatment	NN	O	O
for	IN	O	O
executive	NN	o	OME
functioning	NN	o	OME
(	(	O	O
EF	NNP	O	O
)	)	O	O
deficits	NNS	O	O
in	IN	O	O
autism	NN	p	O
spectrum	NN	p	O
disorder	NN	p	O
(	(	p	O
ASD	NNP	p	O
)	)	p	O
.	.	p	O

The	DT	O	O
goal	NN	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
assess	VB	O	O
the	DT	O	O
tolerability	NN	o	OOt
,	,	o	OOt
safety	NN	o	OOt
,	,	o	OOt
and	CC	o	OOt
efficacy	NN	o	OOt
of	IN	O	O
donepezil	NN	O	O
on	IN	O	O
EF	NNP	O	O
in	IN	O	O
a	DT	O	O
sample	NN	p	O
of	IN	p	O
children	NNS	p	O
and	CC	p	O
adolescents	NNS	p	O
with	IN	p	O
ASD	NNP	p	O
.	.	p	O

METHOD	NNP	O	O
Thirty-four	JJ	p	O
children	NNS	p	O
and	CC	p	O
adolescents	NNS	p	O
with	IN	p	O
ASD	NNP	p	O
(	(	p	O
age	NN	p	O
range	NN	p	O
8-17	CD	p	O
years	NNS	p	O
;	:	p	O
IQ	NNP	p	O
>	NNP	p	O
75	CD	p	O
)	)	p	O
were	VBD	p	O
enrolled	VBN	p	O
in	IN	O	O
a	DT	O	O
10-week	JJ	O	O
,	,	O	O
double-blind	JJ	O	O
,	,	O	O
placebo-controlled	JJ	i	IC
trial	NN	O	O
of	IN	O	O
donepezil	NN	i	IPM
(	(	i	O
doses	NNS	i	O
of	IN	i	O
5	CD	i	O
and	CC	i	O
10	CD	i	O
mg	NN	i	O
)	)	i	O
,	,	i	O
followed	VBN	i	O
by	IN	i	O
a	DT	i	O
10-week	JJ	i	O
open	JJ	i	O
label	NN	i	O
trial	NN	i	O
for	IN	i	O
placebo	NN	i	O
nonresponders	NNS	i	O
.	.	i	O

RESULTS	VB	O	O
The	DT	O	O
effect	NN	O	O
of	IN	O	O
donepezil	NN	i	O
treatment	NN	i	O
on	IN	O	O
EF	NNP	O	O
was	VBD	O	O
examined	VBN	O	O
.	.	O	O

Despite	IN	O	O
improvement	NN	O	O
on	IN	O	O
a	DT	O	O
number	NN	O	O
of	IN	O	O
EF	NNP	o	O
measures	NNS	o	O
,	,	o	O
no	DT	O	O
statistically	RB	O	O
significant	JJ	O	O
between-group	JJ	O	O
differences	NNS	O	O
were	VBD	O	O
found	VBN	O	O
(	(	O	O
with	IN	O	O
gains	NNS	O	O
observed	VBN	O	O
for	IN	O	O
both	DT	O	O
the	DT	O	O
placebo	NN	O	O
and	CC	O	O
donepezil	NN	O	O
groups	NNS	O	O
)	)	O	O
.	.	O	O

CONCLUSIONS	VB	O	O
The	DT	O	O
results	NNS	O	O
suggest	VBP	O	O
that	IN	O	O
short-term	JJ	O	O
treatment	NN	O	O
with	IN	O	O
donepezil	NN	O	O
may	MD	O	O
have	VB	O	O
limited	VBN	O	O
impact	NN	O	O
on	IN	O	O
cognitive	JJ	O	O
functioning	NN	O	O
in	IN	O	O
ASD	NNP	O	O
.	.	O	O

Future	NNP	O	O
controlled	VBD	O	O
trials	NNS	O	O
may	MD	O	O
need	VB	O	O
to	TO	O	O
consider	VB	O	O
a	DT	O	O
longer	RBR	O	O
treatment	NN	O	O
period	NN	O	O
to	TO	O	O
detect	VB	O	O
significant	JJ	O	O
gains	NNS	O	O
on	IN	O	O
EF	NNP	O	O
measures	NNS	O	O
.	.	O	O

The	DT	O	O
instruction	NN	O	O
to	TO	O	O
refrain	VB	i	IE
from	IN	i	IE
blinking	VBG	i	IE
affects	NNS	O	O
auditory	JJ	o	OPH
P3	NNP	o	OPH
and	CC	o	OPH
N1	NNP	o	OPH
amplitudes	NNS	o	OPH
.	.	o	OPH

Often	NNP	O	O
subjects	VBZ	O	O
have	VBP	O	O
been	VBN	O	O
instructed	VBN	O	O
to	TO	O	O
refrain	VB	i	IE
from	IN	i	IE
blinking	VBG	i	IE
lest	JJS	O	O
their	PRP$	O	O
evoked	JJ	O	O
EEG	NNP	O	O
potentials	NNS	O	O
should	MD	O	O
be	VB	O	O
distorted	VBN	O	O
.	.	O	O

We	PRP	O	O
studied	VBD	O	O
whether	IN	O	O
these	DT	O	O
very	RB	O	O
instructions	NNS	O	O
have	VBP	O	O
any	DT	O	O
impact	NN	O	O
on	IN	O	O
P3	NNP	o	OPH
amplitude	NN	o	OPH
.	.	o	OPH

Two	CD	O	O
tones	NNS	O	O
were	VBD	O	O
presented	VBN	O	O
in	IN	O	O
random	JJ	O	O
order	NN	O	O
,	,	O	O
and	CC	O	O
subjects	NNS	O	O
had	VBD	O	O
to	TO	O	O
count	VB	O	O
the	DT	O	O
high-pitched	JJ	O	O
tones	NNS	O	O
.	.	O	O

Half	PDT	p	O
the	DT	p	O
subjects	NNS	p	O
were	VBD	p	O
instructed	VBN	i	IE
not	RB	i	IE
to	TO	i	IE
blink	VB	i	IE
,	,	O	O
whereas	IN	O	O
this	DT	O	O
instruction	NN	O	O
was	VBD	O	O
omitted	VBN	O	O
for	IN	O	O
the	DT	O	O
other	JJ	O	O
subjects	NNS	O	O
.	.	O	O

Target	NNP	O	O
tones	NNS	O	O
evoked	VBD	O	O
larger	JJR	O	O
P3s	NNP	o	OPH
than	IN	O	O
non-targets	NNS	O	O
in	IN	O	O
the	DT	O	O
latter	JJ	O	O
group	NN	O	O
but	CC	O	O
not	RB	O	O
in	IN	O	O
the	DT	O	O
former	JJ	O	O
,	,	O	O
in	IN	O	O
particular	JJ	O	O
not	RB	O	O
in	IN	O	O
those	DT	O	O
subjects	NNS	O	O
that	WDT	O	O
actually	RB	O	O
blinked	VBD	O	O
rarely	RB	O	O
.	.	O	O

The	DT	O	O
groups	NNS	O	O
also	RB	O	O
differed	VBN	O	O
in	IN	O	O
their	PRP$	O	O
N1	NNP	o	OPH
amplitudes	NNS	o	OPH
.	.	o	OPH

These	DT	O	O
findings	NNS	O	O
might	MD	O	O
be	VB	O	O
relevant	JJ	O	O
to	TO	O	O
P3	NNP	O	O
studies	NNS	O	O
working	VBG	O	O
with	IN	O	O
patients	NNS	O	O
and	CC	O	O
controls	NNS	O	O
:	:	O	O
the	DT	O	O
harder	NN	O	O
some	DT	O	O
frequently	RB	O	O
blinking	JJ	O	O
subjects	NNS	O	O
try	VBP	O	O
to	TO	O	O
refrain	VB	O	O
from	IN	O	O
blinking	NN	O	O
,	,	O	O
the	DT	O	O
smaller	JJR	O	O
might	MD	O	O
become	VB	O	O
their	PRP$	O	O
P3	NNP	o	OPH
amplitudes	NNS	o	OPH
.	.	o	OPH

Omitting	VBG	O	O
the	DT	O	O
instruction	NN	O	O
and	CC	O	O
using	VBG	O	O
off-line	JJ	O	O
blink	NN	O	O
subtraction	NN	O	O
procedures	NNS	O	O
seems	VBZ	O	O
a	DT	O	O
viable	JJ	O	O
alternative	NN	O	O
.	.	O	O

This	DT	O	O
study	NN	O	O
was	VBD	O	O
actually	RB	O	O
motivated	VBN	O	O
by	IN	O	O
discrepant	JJ	O	O
findings	NNS	O	O
on	IN	O	O
the	DT	O	O
effects	NNS	o	OPH
of	IN	o	OPH
the	DT	o	OPH
preceding	VBG	o	OPH
tone	NN	o	OPH
sequence	NN	o	OPH
on	IN	o	OPH
P3	NNP	o	OPH
.	.	o	O

These	DT	O	O
discrepancies	NNS	O	O
could	MD	O	O
be	VB	O	O
largely	RB	O	O
resolved	VBN	O	O
by	IN	O	O
the	DT	O	O
instructional	JJ	O	O
variable	NN	O	O
,	,	O	O
in	IN	O	O
conjunction	NN	O	O
with	IN	O	O
different	JJ	O	O
tone	NN	o	OPH
intensities	NNS	o	OPH
.	.	o	OPH

It	PRP	O	O
is	VBZ	O	O
suggested	VBN	O	O
that	IN	O	O
subjects	NNS	i	IE
who	WP	i	IE
are	VBP	i	IE
discouraged	VBN	i	IE
from	IN	i	IE
blinking	VBG	i	IE
try	NN	O	O
to	TO	O	O
protect	VB	O	O
themselves	PRP	O	O
against	IN	O	O
the	DT	O	O
arousing	JJ	O	O
effects	NNS	O	O
of	IN	O	O
stimuli	NN	O	O
.	.	O	O

The	DT	O	O
impact	NN	O	O
of	IN	O	O
a	DT	O	O
psychological	JJ	i	IE
intervention	NN	i	IE
on	IN	O	O
quality	NN	o	OPH
of	IN	o	OPH
life	NN	o	OPH
in	IN	O	O
non-metastatic	JJ	p	PC
breast	NN	p	PC
cancer	NN	p	PC
.	.	p	O

The	DT	O	O
aim	NN	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
determine	VB	O	O
whether	IN	O	O
psychological	JJ	i	IPS
intervention	NN	i	IPS
had	VBD	O	O
a	DT	O	O
beneficial	JJ	O	O
effect	NN	O	O
on	IN	O	O
the	DT	O	O
quality	NN	o	OPH
of	IN	o	OPH
life	NN	o	OPH
and	CC	o	O
behaviour	NN	o	OME
of	IN	O	O
women	NNS	p	PSE
diagnosed	VBN	p	O
with	IN	p	O
breast	NN	p	PC
cancer	NN	p	PC
.	.	p	O

36	CD	p	PSS
consecutive	JJ	p	O
patients	NNS	p	O
with	IN	p	O
non-metastatic	JJ	p	PC
breast	NN	p	PC
cancer	NN	p	PC
assigned	VBD	p	O
to	TO	p	O
surgery	VB	p	O
and	CC	p	O
systemic	VB	p	O
chemotherapy	NN	p	O
were	VBD	O	O
randomised	VBN	O	O
to	TO	O	O
receive	VB	O	O
either	DT	O	O
psychological	JJ	i	IPS
intervention	NN	i	IPS
(	(	i	IPS
weekly	JJ	i	IPS
cognitive	VBP	i	IPS
individual	JJ	i	IPS
psychotherapy	NN	i	IPS
and	CC	i	IPS
bimonthly	JJ	i	IPS
family	NN	i	IPS
counselling	VBG	i	IPS
)	)	i	IPS
or	CC	O	O
standard	JJ	i	IC
follow-up	NN	i	IC
.	.	i	O

Personality	NNP	o	OME
(	(	o	OME
16-PF	JJ	o	OME
and	CC	o	OME
IIQ	NNP	o	OME
)	)	o	OME
,	,	o	O
quality	NN	o	OPH
of	IN	o	OPH
life	NN	o	OPH
(	(	o	OPH
FLIC	NNP	o	OPH
)	)	o	OPH
,	,	o	O
and	CC	o	O
depression	NN	o	OME
(	(	o	OME
BDI	NNP	o	OME
)	)	o	OME
scores	NNS	o	OME
were	VBD	O	O
the	DT	O	O
endpoints	NNS	O	O
for	IN	O	O
this	DT	O	O
study	NN	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
questionnaires	NNS	O	O
were	VBD	O	O
completed	VBN	O	O
by	IN	O	O
the	DT	O	O
patients	NNS	O	O
at	IN	O	O
diagnosis	NN	O	O
,	,	O	O
and	CC	O	O
up	RB	O	O
to	TO	O	O
9	CD	O	O
months	NNS	O	O
after	IN	O	O
diagnosis	NN	O	O
.	.	O	O

Cognitive	JJ	O	O
psychotherapy	NN	O	O
and	CC	O	O
family	NN	O	O
counselling	NN	O	O
improved	VBD	O	O
both	DT	O	O
depression	NN	o	OME
and	CC	o	O
quality	NN	o	OPH
of	IN	o	OPH
life	NN	o	OPH
indexes	NNS	o	OPH
compared	VBN	O	O
with	IN	O	O
the	DT	O	O
control	NN	O	O
group	NN	O	O
.	.	O	O

Better	NNP	O	O
emotional	JJ	o	OME
coping	NN	o	OME
behaviours	NNS	o	OME
were	VBD	O	O
also	RB	O	O
revealed	VBN	O	O
by	IN	O	O
some	DT	O	O
changes	NNS	O	O
in	IN	O	O
personality	NN	O	O
traits	NNS	O	O
in	IN	O	O
the	DT	O	O
intervention	NN	O	O
group	NN	O	O
.	.	O	O

[	JJ	O	O
European	JJ	O	O
topic	NN	O	O
:	:	O	O
liver	NN	i	IPM
surgery	NN	i	IPM
II	NNP	i	IPM
--	:	i	IPM
regional	JJ	i	IPM
chemotherapy	NN	i	IPM
]	NN	i	O
.	.	O	O

The	DT	O	O
most	RBS	O	O
important	JJ	O	O
methods	NNS	O	O
of	IN	O	O
regional	JJ	i	IPM
chemotherapy	NN	i	IPM
are	VBP	O	O
exemplified	VBN	O	O
by	IN	O	O
657	CD	p	O
cases	NNS	p	O
of	IN	p	O
primary	JJ	p	O
and	CC	p	O
secondary	JJ	p	O
liver	NN	p	O
only	RB	p	O
malignancies	VBZ	p	O
.	.	p	O

I	PRP	O	O
.	.	O	O

Adjuvant	JJ	i	IS
portal	JJ	i	IS
therapy	NN	i	IS
of	IN	i	IS
the	DT	i	IS
liver	NN	i	IS
with	IN	i	IS
resection	NN	i	IS
of	IN	i	IS
the	DT	i	IS
colorectal	JJ	i	IS
primary	JJ	i	IS
malignancy	NN	i	IS
seems	VBZ	O	O
to	TO	O	O
be	VB	O	O
advantageous	JJ	O	O
for	IN	O	O
advanced	JJ	O	O
tumors	NNS	O	O
.	.	O	O

II	NNP	O	O
.	.	O	O

It	PRP	O	O
is	VBZ	O	O
still	RB	O	O
unresolved	JJ	O	O
whether	IN	O	O
survival	NN	o	OMO
is	VBZ	O	O
prolonged	VBN	O	O
by	IN	O	O
adjuvant	JJ	O	O
treatment	NN	O	O
of	IN	O	O
the	DT	O	O
liver	NN	O	O
following	VBG	O	O
curative	JJ	i	IS
resection	NN	i	IS
of	IN	i	IS
colorectal	JJ	i	IS
liver	NN	i	IS
metastases	NNS	i	IS
.	.	i	O

III	NNP	O	O
.	.	O	O

The	DT	O	O
median	JJ	o	OMO
survival	NN	o	OMO
time	NN	o	OMO
(	(	o	OMO
FUDR	NNP	o	OMO
,	,	o	OMO
pump	NN	o	OMO
)	)	o	OMO
is	VBZ	O	O
17	CD	O	O
months	NNS	O	O
for	IN	O	O
palliative	JJ	i	IPM
local	JJ	i	IPM
chemotherapy	NN	i	IPM
of	IN	O	O
unresectable	JJ	p	O
colorectal	JJ	p	O
liver	NN	p	O
metastases	NNS	p	O
.	.	p	O

IV	NNP	O	O
.	.	O	O

Primary	NNP	O	O
non-resectable	JJ	O	O
liver	NN	O	O
malignancies	NNS	O	O
show	VBP	O	O
the	DT	O	O
best	JJS	O	O
results	NNS	O	O
after	IN	O	O
chemoembolisation	NN	O	O
(	(	O	O
Frankfurt	NNP	O	O
method	NN	O	O
)	)	O	O
.	.	O	O

Long-term	JJ	O	O
growth	NN	O	O
hormone	NN	O	O
treatment	NN	O	O
in	IN	O	O
growth	NN	p	PC
hormone	NN	p	PC
deficient	NN	p	PC
adults	NNS	p	PA
.	.	p	O

Growth	NNP	i	IPM
hormone	NN	i	IPM
treatment	NN	i	IPM
in	IN	O	O
GH-deficient	NNP	p	PC
adults	NNS	p	PC
has	VBZ	O	O
proved	VBN	O	O
beneficial	JJ	O	O
in	IN	O	O
recent	JJ	O	O
short-term	JJ	O	O
trials	NNS	O	O
,	,	O	O
but	CC	O	O
long-term	JJ	O	O
results	NNS	O	O
have	VBP	O	O
not	RB	O	O
yet	RB	O	O
been	VBN	O	O
reported	VBN	O	O
.	.	O	O

Thirteen	JJ	p	PSS
GH-deficient	JJ	p	PC
adults	NNS	p	PC
(	(	p	PSS
4	CD	p	PSS
females	NNS	p	PSE
,	,	p	O
9	CD	p	PSS
males	NNS	p	PSE
;	:	p	O
mean	FW	p	O
(	(	p	O
SEM	NNP	p	O
)	)	p	O
age	NN	p	O
26.4	CD	p	PA
(	(	p	O
1.7	CD	p	O
)	)	p	O
years	NNS	p	O
)	)	p	O
,	,	O	O
who	WP	O	O
had	VBD	O	O
completed	VBN	O	O
4	CD	O	O
months	NNS	O	O
of	IN	O	O
GH	NNP	i	IPM
therapy	NN	i	IPM
in	IN	O	O
a	DT	O	O
double-blind	JJ	O	O
placebo-controlled	JJ	i	IC
cross-over	NN	O	O
study	NN	O	O
were	VBD	O	O
followed	VBN	O	O
,	,	O	O
for	IN	O	O
further	JJ	O	O
16.1	CD	O	O
(	(	O	O
0.8	CD	O	O
)	)	O	O
months	NNS	O	O
of	IN	O	O
uninterrupted	JJ	O	O
GH	NNP	i	IPM
therapy	NN	i	IPM
in	IN	O	O
an	DT	O	O
open	JJ	O	O
design	NN	O	O
.	.	O	O

A	DT	O	O
significant	JJ	O	O
mean	JJ	O	O
increase	NN	O	O
of	IN	O	O
1.3	CD	O	O
cm	NN	O	O
in	IN	O	O
linear	JJ	o	OPH
height	NN	o	OPH
was	VBD	O	O
recorded	VBN	O	O
,	,	O	O
whereas	IN	O	O
body	NN	o	OPH
mass	NN	o	OPH
index	NN	o	OPH
remained	VBD	O	O
unchanged	JJ	O	O
.	.	O	O

Mean	JJ	o	OOt
muscle	NN	o	OOt
volume	NN	o	OOt
of	IN	o	OOt
the	DT	o	OOt
thigh	NN	o	OOt
,	,	o	O
estimated	VBN	o	O
by	IN	o	O
computerised	JJ	o	O
tomography	NN	o	O
,	,	O	O
increased	VBD	O	O
significantly	RB	O	O
compared	VBN	O	O
with	IN	O	O
that	DT	O	O
of	IN	O	O
the	DT	O	O
initial	JJ	O	O
placebo	NN	i	IC
period	NN	O	O
(	(	O	O
p	JJ	O	O
=	NNP	O	O
0.01	CD	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
a	DT	O	O
slight	JJ	O	O
decrease	NN	O	O
was	VBD	O	O
recorded	VBN	O	O
in	IN	O	O
adipose	JJ	o	OPH
tissue	NN	o	OPH
volume	NN	o	OPH
of	IN	o	OPH
the	DT	o	OPH
thigh	NN	o	OPH
(	(	O	O
p	JJ	O	O
=	NNP	O	O
0.10	CD	O	O
)	)	O	O
and	CC	O	O
subscapular	JJ	o	OPH
skinfold	NN	o	OPH
thickness	NN	o	OPH
(	(	O	O
p	JJ	O	O
=	NNP	O	O
0.10	CD	O	O
)	)	O	O
.	.	O	O

Still	RB	O	O
,	,	O	O
the	DT	O	O
muscle	NN	o	OOt
to	TO	o	OOt
fat	VB	o	OOt
ratio	NN	o	OOt
of	IN	o	OOt
the	DT	o	OOt
thigh	NN	o	OOt
was	VBD	O	O
significantly	RB	O	O
lower	JJR	O	O
compared	VBN	O	O
with	IN	O	O
that	DT	O	O
of	IN	O	O
normal	JJ	p	PC
subjects	NNS	p	O
(	(	O	O
72.6/27.4	CD	O	O
vs	RB	O	O
77.9/22.1	CD	O	O
)	)	O	O
(	(	O	O
p	NN	O	O
less	JJR	O	O
than	IN	O	O
0.01	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
mean	JJ	o	OOt
isometric	JJ	o	OOt
strength	NN	o	OOt
of	IN	o	OOt
the	DT	o	OOt
quadriceps	JJ	o	OOt
muscles	NNS	o	O
increased	VBD	o	O
significantly	RB	O	O
during	IN	O	O
long-term	JJ	O	O
GH	NNP	O	O
therapy	NN	O	O
(	(	O	O
p	NN	O	O
less	JJR	O	O
than	IN	O	O
0.01	CD	O	O
)	)	O	O
,	,	O	O
but	CC	O	O
remained	VBD	O	O
lower	JJR	O	O
compared	VBN	O	O
with	IN	O	O
that	DT	O	O
of	IN	O	O
normal	JJ	O	O
subjects	NNS	O	O
(	(	O	O
1.66	CD	O	O
(	(	O	O
0.10	CD	O	O
)	)	O	O
vs	NN	O	O
2.13	CD	O	O
(	(	O	O
0.11	CD	O	O
)	)	O	O
Nm/kg	NNP	O	O
body	NN	O	O
weight	NN	O	O
)	)	O	O
.	.	O	O

Exercise	NN	o	OPH
capacity	NN	o	OPH
performed	VBN	o	O
on	IN	o	O
a	DT	o	O
bicycle	NN	o	O
ergometer	NN	o	O
increased	VBD	O	O
significantly	RB	O	O
after	IN	O	O
long-term	JJ	O	O
therapy	NN	O	O
(	(	O	O
p	NN	O	O
less	JJR	O	O
than	IN	O	O
0.05	CD	O	O
)	)	O	O
,	,	O	O
but	CC	O	O
still	RB	O	O
did	VBD	O	O
not	RB	O	O
reach	VB	O	O
the	DT	O	O
values	NNS	O	O
seen	VBN	O	O
in	IN	O	O
normal	JJ	O	O
subjects	NNS	O	O
(	(	O	O
22.5	CD	O	O
(	(	O	O
3.4	CD	O	O
)	)	O	O
vs	NN	O	O
37.4	CD	O	O
(	(	O	O
4.2	CD	O	O
)	)	O	O
watt.min.kg-1	NN	O	O
.	.	O	O

No	DT	O	O
adverse	JJ	o	OA
reactions	NNS	o	OA
were	VBD	O	O
recorded	VBN	O	O
during	IN	O	O
long-term	JJ	O	O
therapy	NN	O	O
and	CC	O	O
hemoglobin	NN	o	OPH
A1c	NNP	o	OPH
remained	VBD	O	O
unchanged	JJ	O	O
.	.	O	O

These	DT	O	O
data	NNS	O	O
suggest	VBP	O	O
that	IN	O	O
long-term	JJ	O	O
GH	NNP	O	O
replacement	NN	O	O
therapy	NN	O	O
in	IN	O	O
GH-deficient	NNP	O	O
adults	NNS	O	O
has	VBZ	O	O
beneficial	JJ	O	O
effects	NNS	O	O
on	IN	O	O
several	JJ	O	O
physiological	JJ	O	O
features	NNS	O	O
which	WDT	O	O
are	VBP	O	O
subnormal	JJ	O	O
in	IN	O	O
these	DT	O	O
patients	NNS	O	O
.	.	O	O

Isoniazid	NNP	i	O
prophylaxis	NN	O	O
for	IN	O	O
tuberculosis	NN	p	O
in	IN	p	O
HIV	NNP	p	O
infection	NN	p	O
:	:	p	O
a	DT	O	O
meta-analysis	NN	O	O
of	IN	O	O
randomized	VBN	O	O
controlled	JJ	O	O
trials	NNS	O	O
.	.	O	O

OBJECTIVES	NNP	O	O
To	TO	O	O
evaluate	VB	O	O
the	DT	O	O
efficacy	NN	O	O
of	IN	O	O
isoniazid	NN	i	IPM
for	IN	O	O
the	DT	O	O
prevention	NN	O	O
of	IN	O	O
tuberculosis	NN	O	O
in	IN	O	O
tuberculin	JJ	p	O
skin	JJ	p	O
test-positive	JJ	p	O
and	CC	p	O
negative	JJ	p	O
individuals	NNS	p	O
with	IN	p	O
HIV	NNP	p	O
infection	NN	p	O
.	.	p	O

DESIGN	NNP	O	O
Meta-analysis	NN	O	O
of	IN	O	O
randomized	VBN	O	O
controlled	JJ	O	O
trials	NNS	O	O
.	.	O	O

SETTING	NNP	O	O
Seven	NNP	p	O
trials	NNS	p	O
from	IN	p	O
Mexico	NNP	p	O
,	,	p	O
Haiti	NNP	p	O
,	,	p	O
the	DT	p	O
United	NNP	p	O
States	NNPS	p	O
,	,	p	O
Zambia	NNP	p	O
,	,	p	O
Uganda	NNP	p	O
and	CC	p	O
Kenya	NNP	p	O
.	.	p	O

PATIENTS	NNP	O	O
Individuals	NNP	p	O
free	JJ	p	O
from	IN	p	O
tuberculosis	NN	p	O
,	,	p	O
2367	CD	p	O
persons	NNS	p	O
in	IN	p	O
the	DT	p	O
intervention	NN	p	O
and	CC	p	O
2162	CD	p	O
in	IN	p	O
the	DT	p	O
control	NN	p	O
groups	NNS	p	O
.	.	p	O

INTERVENTION	NNP	O	O
Comparison	NNP	o	OPH
of	IN	o	OPH
isoniazid	NN	o	OPH
with	IN	o	OPH
placebo	NN	o	OPH
or	CC	o	OPH
no	DT	o	OPH
prophylaxis	NN	o	OPH
.	.	o	OPH

METHODS	NNP	O	O
A	NNP	O	O
systematic	JJ	O	O
search	NN	O	O
of	IN	O	O
the	DT	O	O
literature	NN	O	O
was	VBD	O	O
carried	VBN	O	O
out	IN	O	O
from	IN	O	O
1985	CD	O	O
to	TO	O	O
October	NNP	O	O
1997	CD	O	O
for	IN	O	O
randomized	VBN	O	O
controlled	JJ	O	O
trials	NNS	O	O
of	IN	O	O
isoniazid	JJ	i	IPM
prophylaxis	NN	p	O
in	IN	p	O
HIV-infected	JJ	p	O
persons	NNS	p	O
.	.	p	O

Two	CD	O	O
reviewers	NNS	O	O
evaluated	VBD	O	O
the	DT	O	O
relevance	NN	O	O
of	IN	O	O
each	DT	O	O
candidate	NN	O	O
study	NN	O	O
and	CC	O	O
the	DT	O	O
validity	NN	O	O
of	IN	O	O
eligible	JJ	O	O
trials	NNS	O	O
.	.	O	O

Studies	NNS	O	O
were	VBD	O	O
pooled	VBN	O	O
using	VBG	O	O
a	DT	O	O
random	JJ	O	O
effect	NN	O	O
model	NN	O	O
,	,	O	O
conducting	VBG	O	O
secondary	JJ	O	O
analyses	NNS	O	O
for	IN	O	O
tuberculin	JJ	O	O
skin	JJ	O	O
test-positive	JJ	O	O
and	CC	O	O
negative	JJ	O	O
persons	NNS	O	O
.	.	O	O

RESULTS	JJ	O	O
Mean	JJ	O	O
follow-up	NN	O	O
in	IN	O	O
trials	NNS	O	O
varied	VBD	O	O
between	IN	O	O
0.4	CD	O	O
and	CC	O	O
3.2	CD	O	O
years	NNS	O	O
.	.	O	O

Pooling	VBG	O	O
all	DT	O	O
seven	CD	O	O
trials	NNS	O	O
,	,	O	O
a	DT	O	O
risk	NN	o	OOt
ratio	NN	o	OOt
was	VBD	O	O
found	VBN	O	O
for	IN	O	O
persons	NNS	O	O
treated	VBN	O	O
with	IN	O	O
isoniazid	NN	i	IPM
for	IN	O	O
developing	VBG	O	O
tuberculosis	NN	O	O
of	IN	O	O
0.58	CD	O	O
[	JJ	O	O
95	CD	O	O
%	NN	O	O
confidence	NN	O	O
interval	NN	O	O
(	(	O	O
CI	NNP	O	O
)	)	O	O
,	,	O	O
0.43-0.80	JJ	O	O
]	NN	O	O
and	CC	O	O
0.94	CD	O	O
(	(	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
,	,	O	O
0.83-1.07	NNP	O	O
)	)	O	O
for	IN	O	O
death	NN	o	OMO
.	.	o	O

In	IN	O	O
groups	NNS	O	O
of	IN	O	O
tuberculin	JJ	O	O
skin	JJ	O	O
test-positive	JJ	O	O
and	CC	O	O
negative	JJ	O	O
persons	NNS	O	O
,	,	O	O
the	DT	O	O
risk	NN	o	OOt
ratio	NN	o	OOt
of	IN	o	OOt
tuberculosis	NN	o	OOt
was	VBD	O	O
0.40	CD	O	O
(	(	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
,	,	O	O
0.24-0.65	NNP	O	O
)	)	O	O
and	CC	O	O
0.84	CD	O	O
(	(	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
,	,	O	O
0.54-1.30	NNP	O	O
)	)	O	O
,	,	O	O
respectively	RB	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
difference	NN	o	OOt
in	IN	o	OOt
the	DT	o	OOt
effectiveness	NN	o	OOt
of	IN	O	O
isoniazid	JJ	i	IPM
versus	NN	O	O
placebo	NN	i	IC
between	IN	O	O
these	DT	O	O
groups	NNS	O	O
was	VBD	O	O
statistically	RB	O	O
significant	JJ	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.03	CD	O	O
,	,	O	O
for	IN	O	O
the	DT	O	O
difference	NN	O	O
of	IN	O	O
summary	JJ	O	O
estimates	NNS	O	O
)	)	O	O
.	.	O	O

Consistency	NN	O	O
of	IN	O	O
results	NNS	O	O
was	VBD	O	O
found	VBN	O	O
across	IN	O	O
trials	NNS	O	O
(	(	O	O
P	NNP	O	O
>	NNP	O	O
0.10	CD	O	O
,	,	O	O
heterogeneity	NN	O	O
value	NN	O	O
)	)	O	O
for	IN	O	O
all	DT	O	O
comparisons	NNS	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
Prophylaxis	NNP	O	O
with	IN	O	O
isoniazid	JJ	i	IPM
reduces	NNS	O	O
the	DT	O	O
risk	NN	O	O
of	IN	O	O
tuberculosis	NN	O	O
in	IN	O	O
persons	NNS	p	O
with	IN	p	O
HIV	NNP	p	O
infection	NN	p	O
.	.	p	O

The	DT	O	O
effect	NN	O	O
is	VBZ	O	O
restricted	VBN	p	O
to	TO	p	O
tuberculin	VB	p	O
skin	JJ	p	O
test-positive	JJ	p	O
persons	NNS	p	O
.	.	p	O

Green	JJ	i	IPM
banana-supplemented	JJ	i	IPM
diet	NN	i	IPM
in	IN	O	O
the	DT	O	O
home	NN	O	O
management	NN	O	O
of	IN	O	O
acute	NN	o	OPH
and	CC	o	OPH
prolonged	JJ	o	OPH
diarrhoea	NN	o	OPH
in	IN	o	OPH
children	NNS	o	OPH
:	:	o	OPH
a	DT	p	O
community-based	JJ	p	O
trial	NN	p	O
in	IN	p	O
rural	JJ	p	O
Bangladesh	NNP	p	O
.	.	p	O

SUMMARY	NNP	O	O
OBJECTIVE	NNP	O	O
To	TO	O	O
determine	VB	O	O
the	DT	O	O
effectiveness	NN	O	O
of	IN	O	O
green	JJ	i	IPM
banana	NN	i	IPM
in	IN	O	O
the	DT	O	O
home	NN	O	O
management	NN	O	O
of	IN	O	O
acute	NN	o	OOt
(	(	p	O
<	JJ	p	O
7	CD	p	O
days	NNS	p	O
)	)	p	O
or	CC	p	O
prolonged	VBN	o	OMO
(	(	p	O
?	.	p	O
7	CD	p	O
days	NNS	o	O
)	)	o	O
diarrhoea	VBP	o	O
at	IN	o	O
the	DT	O	O
community	NN	O	O
level	NN	O	O
.	.	O	O

METHODS	NNP	O	O
A	NNP	O	O
cluster	NN	O	O
randomized	VBD	O	O
field	NN	O	O
trial	NN	O	O
was	VBD	O	O
conducted	VBN	O	O
among	IN	p	O
2968	CD	p	PSS
Bangladeshi	NNP	p	O
rural	JJ	p	O
children	NNS	p	O
6-36	JJ	p	PA
months	NNS	p	PA
old	JJ	p	PA
.	.	p	O

Wards	NNP	O	O
(	(	O	O
villages	NNS	O	O
)	)	O	O
were	VBD	O	O
randomly	RB	O	O
assigned	VBN	O	O
to	TO	O	O
either	CC	O	O
a	DT	O	O
standard	JJ	i	O
care	NN	i	O
group	NN	i	O
or	CC	i	O
a	DT	i	O
standard	JJ	i	O
care	NN	i	O
plus	CC	i	O
green	JJ	i	O
banana	NN	i	O
group	NN	i	O
where	WRB	i	O
mothers	NNS	O	O
were	VBD	O	O
instructed	VBN	O	O
to	TO	O	O
add	VB	i	O
cooked	JJ	i	O
green	JJ	i	O
banana	NN	i	O
to	TO	i	O
the	DT	O	O
diets	NNS	O	O
of	IN	O	O
diarrhoeal	JJ	p	O
children	NNS	p	O
.	.	p	O

Through	IN	O	O
a	DT	O	O
village-based	JJ	O	O
surveillance	NN	O	O
system	NN	o	O
,	,	o	O
diarrhoeal	JJ	o	O
morbidity	NN	o	O
data	NNS	o	O
(	(	o	O
severity	NN	o	O
,	,	o	O
duration	NN	o	O
,	,	o	O
compliance	NN	o	O
)	)	o	O
were	VBD	o	O
collected	VBN	O	O
for	IN	O	O
14	CD	O	O
days	NNS	O	O
.	.	O	O

Treatment	JJ	O	O
effects	NNS	O	O
were	VBD	O	O
determined	VBN	O	O
by	IN	O	O
analysing	VBG	o	O
cumulative	JJ	o	O
probability	NN	o	O
of	IN	o	O
cure	NN	o	O
by	IN	o	O
testing	VBG	o	O
Cox	NNP	o	O
proportional	JJ	o	O
hazards	NNS	o	O
models	NNS	o	O
and	CC	o	O
relative	JJ	o	O
risk	NN	o	O
(	(	o	O
RR	NNP	O	O
)	)	O	O
.	.	O	O

RESULTS	VB	O	O
The	DT	o	O
cumulative	JJ	o	O
probability	NN	o	O
of	IN	o	O
cure	NN	o	O
was	VBD	o	O
significantly	RB	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.001	CD	O	O
)	)	O	O
different	JJ	O	O
in	IN	O	O
children	NNS	O	O
receiving	VBG	O	O
GB	NNP	O	O
for	IN	O	O
both	DT	o	O
acute	JJ	o	O
[	NNP	o	O
hazard	NN	O	O
ratio	NN	O	O
(	(	O	O
HR	NNP	O	O
)	)	O	O
=	VBZ	O	O
0.63	CD	O	O
(	(	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
:	:	O	O
0.56-0.67	NN	O	O
)	)	O	O
]	NN	O	O
and	CC	o	O
prolonged	VBD	o	O
diarrhoea	NNS	o	O
[	NNP	o	O
HR	NNP	O	O
=	VBZ	O	O
0.38	CD	O	O
(	(	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
:	:	O	O
0.26-0.59	NN	O	O
)	)	O	O
]	NN	O	O
.	.	O	O

The	DT	o	O
recovery	NN	o	O
rates	NNS	o	O
of	IN	o	O
children	NNS	o	O
with	IN	o	O
acute	JJ	o	O
diarrhoea	NN	o	O
receiving	VBG	o	O
GB	NNP	O	O
(	(	O	O
vs.	FW	O	O
control	NN	O	O
)	)	O	O
were	VBD	O	O
significantly	RB	O	O
more	JJR	O	O
by	IN	O	O
day	NN	O	O
3	CD	O	O
:	:	O	O
79.9	CD	O	O
%	NN	O	O
vs	NN	O	O
.	.	O	O

53.3	CD	O	O
%	NN	O	O
[	NN	O	O
(	(	O	O
RR	NNP	O	O
)	)	O	O
=	VBD	O	O
0.47	CD	O	O
,	,	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
:	:	O	O
0.41-0.55	JJ	O	O
]	NN	O	O
,	,	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.001	CD	O	O
)	)	O	O
and	CC	O	O
day	NN	O	O
7	CD	O	O
:	:	O	O
96.6	CD	O	O
%	NN	O	O
vs	NN	O	O
.	.	O	O

89.1	CD	O	O
%	NN	O	O
(	(	O	O
RR	NNP	O	O
=	NNP	O	O
0.32	CD	O	O
;	:	O	O
0.22-0.46	JJ	O	O
)	)	O	O
,	,	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.001	CD	O	O
)	)	O	O
.	.	O	O

Children	NNP	O	O
with	IN	O	O
prolonged	JJ	O	O
diarrhoea	NN	O	O
receiving	VBG	i	O
green	JJ	i	O
banana	NN	i	O
had	VBD	i	O
significantly	RB	O	O
higher	JJR	o	O
recovery	NN	o	O
rates	NNS	o	O
by	IN	o	O
day	NN	O	O
10	CD	O	O
:	:	O	O
79.8	CD	O	O
%	NN	O	O
vs	NN	O	O
.	.	O	O

51.9	CD	O	O
%	NN	O	O
(	(	O	O
RR	NNP	O	O
=	NNP	O	O
0.42	CD	O	O
;	:	O	O
0.23-0.73	JJ	O	O
)	)	O	O
,	,	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.001	CD	O	O
)	)	O	O
and	CC	O	O
day	NN	O	O
14	CD	O	O
:	:	O	O
93.6	CD	O	O
%	NN	O	O
vs	NN	O	O
.	.	O	O

67.2	CD	O	O
%	NN	O	O
(	(	O	O
RR	NNP	O	O
=	NNP	O	O
0.22	CD	O	O
;	:	O	O
0.08-0.54	JJ	O	O
)	)	O	O
,	,	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.001	CD	O	O
)	)	O	O
.	.	O	O

CONCLUSION	VB	O	O
A	DT	O	O
green	JJ	i	O
banana-supplemented	JJ	i	O
diet	NN	o	O
hastened	VBD	o	O
recovery	NN	o	O
of	IN	o	O
acute	NN	p	O
and	CC	p	O
prolonged	VBD	p	O
childhood	NN	p	O
diarrhoea	NN	p	O
managed	VBD	p	O
at	IN	O	O
home	NN	O	O
in	IN	O	O
rural	JJ	O	O
Bangladesh	NNP	O	O
.	.	O	O

Brief	JJ	O	O
report	NN	O	O
:	:	O	O
effect	NN	O	O
of	IN	O	O
a	DT	O	O
focused	JJ	i	IE
imitation	NN	i	IE
intervention	NN	i	IE
on	IN	O	O
social	JJ	o	OME
functioning	NN	o	OME
in	IN	O	O
children	NNS	p	PA
with	IN	p	O
autism	NN	p	PC
.	.	p	O

Imitation	NNP	O	O
is	VBZ	O	O
an	DT	O	O
early	JJ	O	O
skill	NN	O	O
thought	VBN	O	O
to	TO	O	O
play	VB	O	O
a	DT	O	O
role	NN	O	O
in	IN	O	O
social	JJ	O	O
development	NN	O	O
,	,	O	O
leading	VBG	O	O
some	DT	O	O
to	TO	O	O
suggest	VB	O	O
that	IN	O	O
teaching	VBG	O	O
imitation	NN	O	O
to	TO	O	O
children	NNS	p	PA
with	IN	p	O
autism	NN	p	PC
should	MD	O	O
lead	VB	O	O
to	TO	O	O
improvements	NNS	O	O
in	IN	O	O
social	JJ	o	OME
functioning	NN	o	OME
.	.	o	O

This	DT	O	O
study	NN	O	O
used	VBD	O	O
a	DT	O	O
randomized	JJ	O	O
controlled	VBN	O	O
trial	NN	O	O
to	TO	O	O
evaluate	VB	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
a	DT	O	O
focused	JJ	i	IE
imitation	NN	i	IE
intervention	NN	i	IE
on	IN	O	O
initiation	NN	O	O
of	IN	O	O
joint	JJ	o	OME
attention	NN	o	OME
and	CC	o	O
social-emotional	JJ	o	OME
functioning	NN	o	OME
in	IN	O	O
27	CD	p	PSS
young	JJ	p	PA
children	NNS	p	PA
with	IN	p	O
autism	NN	p	PC
.	.	p	O

Results	NNS	O	O
indicated	VBD	O	O
the	DT	O	O
treatment	NN	O	O
group	NN	O	O
made	VBD	O	O
significantly	RB	O	O
more	RBR	O	O
gains	NNS	O	O
in	IN	O	O
joint	JJ	o	OME
attention	NN	o	OME
initiations	NNS	o	OME
at	IN	O	O
post-treatment	JJ	O	O
and	CC	O	O
follow-up	JJ	O	O
and	CC	O	O
social-emotional	JJ	o	OME
functioning	NN	o	OME
at	IN	O	O
follow-up	NN	O	O
than	IN	O	O
the	DT	O	O
control	NN	O	O
group	NN	O	O
.	.	O	O

Although	IN	O	O
gains	NNS	o	OME
in	IN	o	OME
social	JJ	o	OME
functioning	NN	o	OME
were	VBD	O	O
associated	VBN	O	O
with	IN	O	O
treatment	NN	O	O
,	,	O	O
a	DT	O	O
mediation	NN	O	O
analysis	NN	O	O
did	VBD	O	O
not	RB	O	O
support	VB	O	O
imitation	NN	i	O
as	IN	O	O
the	DT	O	O
mechanism	NN	O	O
of	IN	O	O
action	NN	O	O
.	.	O	O

These	DT	O	O
findings	NNS	O	O
suggest	VBP	O	O
the	DT	O	O
intervention	NN	O	O
improves	VBZ	O	O
social	JJ	o	OME
functioning	NN	o	OME
in	IN	o	O
children	NNS	p	PA
with	IN	p	O
ASD	NNP	p	PC
.	.	p	O

Effect	NN	O	O
of	IN	O	O
a	DT	O	O
synthetic	JJ	i	IPM
appeasing	VBG	i	IPM
pheromone	NN	i	IPM
on	IN	O	O
behavioral	JJ	O	O
,	,	O	O
neuroendocrine	JJ	O	O
,	,	O	O
immune	JJ	O	O
,	,	O	O
and	CC	O	O
acute-phase	JJ	O	O
perioperative	JJ	O	O
stress	NN	O	O
responses	NNS	O	O
in	IN	O	O
dogs	NNS	p	O
.	.	p	O

OBJECTIVE	NNP	O	O
To	TO	O	O
study	VB	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
a	DT	O	O
synthetic	JJ	i	IPM
,	,	i	IPM
dog-appeasing	JJ	i	IPM
pheromone	NN	i	IPM
(	(	i	IPM
sDAP	NN	i	IPM
)	)	i	IPM
on	IN	O	O
the	DT	O	O
behavioral	JJ	O	O
,	,	O	O
neuroendocrine	JJ	O	O
,	,	O	O
immune	JJ	O	O
,	,	O	O
and	CC	O	O
acute-phase	JJ	O	O
perioperative	JJ	O	O
stress	NN	O	O
responses	NNS	O	O
in	IN	O	O
dogs	NNS	p	O
undergoing	VBG	p	O
elective	JJ	p	O
orchiectomy	NN	p	O
or	CC	p	O
ovariohysterectomy	NN	p	O
.	.	p	O

DESIGN	NNP	O	O
Randomized	NNP	O	O
,	,	O	O
controlled	VBD	O	O
clinical	JJ	O	O
trial	NN	O	O
.	.	O	O

ANIMALS	$	O	O
46	CD	p	PSS
dogs	NNS	p	PSS
housed	VBN	p	O
in	IN	p	O
animal	NN	p	O
shelters	NNS	p	O
and	CC	p	O
undergoing	VBG	p	O
elective	JJ	p	O
orchiectomy	NN	p	O
or	CC	p	O
ovariohysterectomy	NN	p	O
.	.	p	O

PROCEDURES	NNP	O	O
Intensive	NNP	O	O
care	NN	O	O
unit	NN	O	O
cages	NNS	O	O
were	VBD	O	O
sprayed	VBN	O	O
with	IN	O	O
sDAP	JJ	i	IPH
solution	NN	i	IPH
or	CC	i	O
sham	NN	i	IC
treated	VBN	i	IC
with	IN	i	IC
the	DT	i	IC
carrier	NN	i	IC
used	VBN	i	O
in	IN	i	O
the	DT	i	O
solution	NN	i	O
20	CD	i	O
minutes	NNS	i	O
prior	RB	i	O
to	TO	i	O
use	VB	i	O
.	.	i	O

Dogs	NNS	O	O
(	(	O	O
n	JJ	O	O
=	NN	O	O
24	CD	O	O
and	CC	O	O
22	CD	O	O
in	IN	O	O
the	DT	O	O
sDAP	NN	i	IPH
and	CC	O	O
sham	JJ	i	IC
treatment	NN	i	IC
exposure	NN	O	O
groups	NNS	O	O
,	,	O	O
respectively	RB	O	O
)	)	O	O
were	VBD	O	O
placed	VBN	O	O
in	IN	O	O
treated	JJ	O	O
cages	NNS	O	O
for	IN	O	O
30	CD	O	O
minutes	NNS	O	O
before	IN	O	O
and	CC	O	O
after	IN	O	O
surgery	NN	O	O
.	.	O	O

Indicators	NNS	O	O
of	IN	O	O
stress	NN	O	O
(	(	O	O
ie	NN	O	O
,	,	O	O
alterations	NNS	O	O
in	IN	O	O
behavioral	JJ	o	OME
,	,	o	OME
neuroendocrine	JJ	o	OME
,	,	o	OME
immune	JJ	o	OME
,	,	o	OME
and	CC	o	OME
acute-phase	JJ	o	OME
responses	NNS	o	OME
)	)	o	OPH
were	VBD	O	O
evaluated	VBN	O	O
perioperatively	RB	O	O
.	.	O	O

Behavioral	JJ	o	OPH
response	NN	o	OPH
variables	NNS	o	OPH
,	,	o	OPH
salivary	JJ	o	OPH
cortisol	NN	o	OPH
concentration	NN	o	OPH
,	,	o	OPH
WBC	NNP	o	OPH
count	NN	o	OPH
,	,	o	OPH
and	CC	o	OPH
serum	JJ	o	OPH
concentrations	NNS	o	OPH
of	IN	o	OPH
glucose	NN	o	OPH
,	,	o	OPH
prolactin	NN	o	OPH
,	,	o	OPH
haptoglobin	NN	o	OPH
,	,	o	OPH
and	CC	o	OPH
C-reactive	JJ	o	OPH
protein	NN	o	OPH
were	VBD	O	O
analyzed	VBN	O	O
.	.	O	O

RESULTS	NNP	O	O
Behavioral	NNP	o	OME
response	NN	o	OME
variables	NNS	o	OME
and	CC	o	OPH
serum	NN	o	OPH
prolactin	NN	o	OPH
concentration	NN	o	OPH
were	VBD	O	O
influenced	VBN	O	O
by	IN	O	O
sDAP	NN	O	O
exposure	NN	O	O
.	.	O	O

Dogs	NNS	O	O
exposed	VBD	O	O
to	TO	O	O
sDAP	VB	O	O
were	VBD	O	O
more	RBR	O	O
likely	JJ	O	O
to	TO	O	O
have	VB	O	O
alertness	NN	o	OME
and	CC	o	OME
visual	JJ	o	OME
exploration	NN	o	OME
behaviors	NNS	o	OME
after	IN	O	O
surgery	NN	O	O
than	IN	O	O
were	VBD	O	O
dogs	NNS	O	O
exposed	VBN	O	O
to	TO	O	O
sham	VB	O	O
treatment	NN	O	O
.	.	O	O

Decreases	VBZ	O	O
in	IN	O	O
serum	NN	o	OPH
prolactin	NN	o	OPH
concentrations	NNS	o	OPH
in	IN	O	O
response	NN	O	O
to	TO	O	O
perioperative	JJ	O	O
stress	NN	O	O
were	VBD	O	O
significantly	RB	O	O
smaller	JJR	O	O
in	IN	O	O
dogs	NNS	O	O
exposed	VBN	O	O
to	TO	O	O
sDAP	VB	O	O
,	,	O	O
compared	VBN	O	O
with	IN	O	O
findings	NNS	O	O
in	IN	O	O
dogs	NNS	O	O
exposed	VBN	O	O
to	TO	O	O
the	DT	O	O
sham	NN	O	O
treatment	NN	O	O
.	.	O	O

Variables	NNS	O	O
examined	VBD	O	O
to	TO	O	O
evaluate	VB	O	O
the	DT	O	O
hypothalamic-pituitary-adrenal	JJ	O	O
axis	NN	O	O
,	,	O	O
immune	JJ	O	O
system	NN	O	O
,	,	O	O
and	CC	O	O
acute-phase	JJ	O	O
responses	NNS	O	O
were	VBD	O	O
unaffected	VBN	O	O
by	IN	O	O
treatment	NN	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
AND	NNP	O	O
CLINICAL	NNP	O	O
RELEVANCE	NNP	O	O
sDAP	NN	O	O
appeared	VBD	O	O
to	TO	O	O
affect	VB	O	O
behavioral	JJ	o	OME
and	CC	o	OME
neuroendocrine	JJ	o	OME
perioperative	JJ	o	OME
stress	NN	o	OME
responses	NNS	o	OME
by	IN	O	O
modification	NN	O	O
of	IN	O	O
lactotropic	JJ	O	O
axis	NN	O	O
activity	NN	O	O
.	.	O	O

Use	NN	O	O
of	IN	O	O
sDAP	NN	i	IPM
in	IN	O	O
a	DT	O	O
clinical	JJ	O	O
setting	NN	O	O
may	MD	O	O
improve	VB	O	O
the	DT	O	O
recovery	NN	o	OOt
and	CC	O	O
welfare	NN	O	O
of	IN	O	O
dogs	NNS	p	O
undergoing	VBG	p	O
surgery	NN	p	O
.	.	p	O

Virtual	JJ	i	IE
reality	NN	i	IE
intervention	NN	i	IE
for	IN	O	O
older	JJR	p	PA
women	NNS	p	PSE
with	IN	p	O
breast	NN	p	PC
cancer	NN	p	PC
.	.	p	O

This	DT	O	O
study	NN	O	O
examined	VBD	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
a	DT	O	O
virtual	JJ	i	IE
reality	NN	i	IE
distraction	NN	i	IE
intervention	NN	i	IE
on	IN	O	O
chemotherapy-related	JJ	p	O
symptom	NN	o	OPH
distress	NN	o	OPH
levels	NNS	p	O
in	IN	p	O
16	CD	p	PSS
women	NNS	p	PC
aged	VBD	p	O
50	CD	p	PA
and	CC	p	PA
older	JJR	p	PA
.	.	p	O

A	DT	O	O
cross-over	JJ	O	O
design	NN	O	O
was	VBD	O	O
used	VBN	O	O
to	TO	O	O
answer	VB	O	O
the	DT	O	O
following	JJ	O	O
research	NN	O	O
questions	NNS	O	O
:	:	O	O
(	(	O	O
1	CD	O	O
)	)	O	O
Is	VBZ	O	O
virtual	JJ	O	O
reality	NN	O	O
an	DT	O	O
effective	JJ	O	O
distraction	NN	O	O
intervention	NN	O	O
for	IN	O	O
reducing	VBG	O	O
chemotherapy-related	JJ	O	O
symptom	NN	O	O
distress	NN	O	O
levels	NNS	O	O
in	IN	O	O
older	JJR	p	O
women	NNS	p	PC
with	IN	p	O
breast	NN	p	PC
cancer	NN	p	PC
?	.	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
Does	NNP	O	O
virtual	JJ	i	IE
reality	NN	i	IE
have	VBP	O	O
a	DT	O	O
lasting	JJ	O	O
effect	NN	O	O
?	.	O	O
Chemotherapy	NN	O	O
treatments	NNS	O	O
are	VBP	O	O
intensive	JJ	O	O
and	CC	O	O
difficult	JJ	O	O
to	TO	O	O
endure	VB	O	O
.	.	O	O

One	CD	O	O
way	NN	O	O
to	TO	O	O
cope	VB	O	O
with	IN	O	O
chemotherapy-related	JJ	O	O
symptom	NN	O	O
distress	NN	O	O
is	VBZ	O	O
through	IN	O	O
the	DT	O	O
use	NN	O	O
of	IN	O	O
distraction	NN	O	O
.	.	O	O

For	IN	O	O
this	DT	O	O
study	NN	O	O
,	,	O	O
a	DT	i	O
head-mounted	JJ	i	O
display	NN	i	O
(	(	i	O
Sony	NNP	i	O
PC	NNP	i	O
Glasstron	NNP	i	O
PLM	NNP	i	O
-	:	i	O
S700	NN	i	O
)	)	i	O
was	VBD	i	O
used	VBN	i	O
to	TO	i	O
display	VB	i	O
encompassing	VBG	i	O
images	NNS	i	O
and	CC	i	O
block	NN	i	O
competing	VBG	i	O
stimuli	NNS	i	O
during	IN	i	O
chemotherapy	JJ	i	O
infusions	NNS	i	O
.	.	i	O

The	DT	O	O
Symptom	NNP	o	OPH
Distress	NNP	o	OPH
Scale	NNP	o	OPH
(	(	o	OPH
SDS	NNP	o	OPH
)	)	o	OPH
,	,	o	O
Revised	VBN	o	OPH
Piper	NNP	o	OPH
Fatigue	NNP	o	OPH
Scale	NNP	o	OPH
(	(	o	OPH
PFS	NNP	o	OPH
)	)	o	OPH
,	,	o	OPH
and	CC	o	O
the	DT	o	O
State	NNP	o	OME
Anxiety	NNP	o	OME
Inventory	NNP	o	OME
(	(	o	OME
SAI	NNP	o	OME
)	)	o	O
were	VBD	i	O
used	VBN	i	O
to	TO	i	O
measure	VB	i	O
symptom	JJ	i	O
distress	NN	i	O
.	.	i	O

For	IN	O	O
two	CD	O	O
matched	JJ	O	O
chemotherapy	NN	O	O
treatments	NNS	O	O
,	,	O	O
one	CD	O	O
pre-test	NN	O	O
and	CC	O	O
two	CD	O	O
post-test	JJ	O	O
measures	NNS	O	O
were	VBD	O	O
employed	VBN	O	O
.	.	O	O

Participants	NNS	O	O
were	VBD	O	O
randomly	RB	O	O
assigned	VBN	O	O
to	TO	O	O
receive	VB	O	O
the	DT	O	O
VR	NNP	i	IE
distraction	NN	i	IE
intervention	NN	i	IE
during	IN	i	IE
one	CD	i	IE
chemotherapy	NN	i	IPS
treatment	NN	i	IE
and	CC	i	O
received	VBD	i	O
no	DT	i	IC
distraction	NN	i	IC
intervention	NN	i	IC
(	(	i	IC
control	VB	i	IC
condition	NN	i	IC
)	)	i	IC
during	IN	i	O
an	DT	i	O
alternate	JJ	i	O
chemotherapy	NN	i	O
treatment	NN	i	O
.	.	i	O

Analysis	NN	O	O
using	VBG	O	O
paired	VBN	O	O
t-tests	NNS	O	O
demonstrated	VBD	O	O
a	DT	O	O
significant	JJ	O	O
decrease	NN	o	OOt
in	IN	O	O
the	DT	O	O
SAI	NNP	o	OME
(	(	O	O
p	JJ	O	O
=	NNP	O	O
0.10	CD	O	O
)	)	O	O
scores	NNS	O	O
immediately	RB	O	O
following	VBG	O	O
chemotherapy	NN	O	O
treatments	NNS	O	O
when	WRB	O	O
participants	NNS	O	O
used	VBD	O	O
VR	NNP	O	O
.	.	O	O

No	NNP	O	O
significant	JJ	O	O
changes	NNS	O	O
were	VBD	O	O
found	VBN	O	O
in	IN	O	O
SDS	NNP	o	OPH
or	CC	o	OPH
PFS	NNP	o	OPH
values	NNS	o	OPH
.	.	o	O

There	EX	O	O
was	VBD	O	O
a	DT	O	O
consistent	JJ	O	O
trend	NN	O	O
toward	IN	O	O
improved	VBN	o	OPH
symptoms	NNS	o	OPH
on	IN	O	O
all	DT	O	O
measures	NNS	O	O
48	CD	O	O
h	NN	O	O
following	VBG	O	O
completion	NN	O	O
of	IN	O	O
chemotherapy	NN	O	O
.	.	O	O

Evaluation	NN	O	O
of	IN	O	O
the	DT	O	O
intervention	NN	O	O
indicated	VBD	O	O
that	IN	O	O
women	NNS	p	O
thought	VBD	O	O
the	DT	O	O
head	NN	O	O
mounted	VBD	O	O
device	NN	O	O
was	VBD	O	O
easy	JJ	O	O
to	TO	O	O
use	VB	O	O
,	,	O	O
they	PRP	O	O
experienced	VBD	O	O
no	DT	O	O
cybersickness	NN	o	OPH
,	,	O	O
and	CC	O	O
100	CD	O	O
%	NN	O	O
would	MD	O	O
use	VB	O	O
VR	NNP	O	O
again	RB	O	O
.	.	O	O

Primary	JJ	O	O
prophylaxis	NN	O	O
with	IN	O	O
pyrimethamine	NN	i	IPM
for	IN	O	O
toxoplasmic	JJ	O	O
encephalitis	NN	O	O
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
advanced	JJ	p	O
human	JJ	p	O
immunodeficiency	NN	p	O
virus	NN	p	O
disease	NN	p	O
:	:	p	O
results	NNS	O	O
of	IN	O	O
a	DT	O	O
randomized	JJ	O	O
trial	NN	O	O
.	.	O	O

Terry	NNP	O	O
Beirn	NNP	O	O
Community	NNP	O	O
Programs	NNP	O	O
for	IN	O	O
Clinical	NNP	O	O
Research	NNP	O	O
on	IN	O	O
AIDS	NNP	O	O
.	.	O	O

Pyrimethamine	NNP	i	IPM
,	,	O	O
25	CD	O	O
mg	NN	O	O
thrice	NN	O	O
weekly	RB	O	O
,	,	O	O
was	VBD	O	O
evaluated	VBN	O	O
as	IN	O	O
primary	JJ	O	O
prophylaxis	NN	O	O
for	IN	O	O
toxoplasmic	JJ	O	O
encephalitis	NN	O	O
(	(	O	O
TE	NNP	O	O
)	)	O	O
in	IN	O	O
a	DT	O	O
double-blind	NN	O	O
,	,	O	O
randomized	VBD	O	O
clinical	JJ	O	O
trial	NN	O	O
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
human	JJ	p	O
immunodeficiency	NN	p	O
virus	NN	p	O
(	(	p	O
HIV	NNP	p	O
)	)	p	O
disease	NN	p	O
,	,	p	O
absolute	JJ	p	O
CD4	NNP	p	O
lymphocyte	NN	p	O
count	NN	p	O
of	IN	p	O
<	$	p	O
200/microL	CD	p	O
(	(	p	O
or	CC	p	O
prior	RB	p	O
AIDS-defining	NNP	p	O
opportunistic	JJ	p	O
infection	NN	p	O
)	)	p	O
,	,	p	O
and	CC	p	O
the	DT	p	O
presence	NN	p	O
of	IN	p	O
serum	NN	p	O
IgG	NNP	p	O
to	TO	p	O
Toxoplasma	NNP	p	O
gondii	NN	p	O
.	.	p	O

Leucovorin	NNP	i	IPM
was	VBD	O	O
coadministered	VBN	O	O
only	RB	O	O
for	IN	O	O
hematologic	JJ	O	O
toxicity	NN	O	O
.	.	O	O

There	EX	O	O
was	VBD	O	O
a	DT	O	O
significantly	RB	O	O
higher	JJR	O	O
death	NN	o	OMO
rate	NN	o	OMO
among	IN	O	O
patients	NNS	O	O
receiving	VBG	O	O
pyrimethamine	NN	i	IPM
(	(	O	O
relative	JJ	O	O
risk	NN	O	O
[	NNP	O	O
RR	NNP	O	O
]	NNP	O	O
,	,	O	O
2.5	CD	O	O
;	:	O	O
95	CD	O	O
%	NN	O	O
confidence	NN	O	O
interval	NN	O	O
[	NNP	O	O
CI	NNP	O	O
]	NNP	O	O
,	,	O	O
1.3-4.8	JJ	O	O
;	:	O	O
P	NNP	O	O
=	NNP	O	O
.006	NNP	O	O
)	)	O	O
,	,	O	O
even	RB	O	O
after	IN	O	O
adjusting	VBG	O	O
for	IN	O	O
factors	NNS	O	O
predictive	CD	O	O
of	IN	O	O
survival	NN	O	O
.	.	O	O

The	DT	O	O
TE	NNP	o	OPH
event	NN	o	OPH
rate	NN	o	OPH
was	VBD	O	O
low	JJ	O	O
in	IN	O	O
both	DT	O	O
treatment	NN	O	O
groups	NNS	O	O
(	(	O	O
not	RB	O	O
significant	JJ	O	O
)	)	O	O
.	.	O	O

Only	RB	O	O
1	CD	O	O
of	IN	O	O
218	CD	p	O
patients	NNS	p	O
taking	VBG	p	O
trimethoprim-sulfamethoxazole	JJ	i	IPM
but	CC	O	O
7	CD	O	O
of	IN	O	O
117	CD	p	O
taking	VBG	p	O
aerosolized	JJ	i	IPM
pentamidine	NN	i	IPM
for	IN	O	O
prophylaxis	NN	O	O
against	IN	O	O
Pneumocystis	NNP	O	O
carinii	NN	O	O
pneumonia	NN	O	O
developed	VBD	O	O
TE	NNP	O	O
(	(	O	O
adjusted	VBN	O	O
RR	NNP	O	O
for	IN	O	O
the	DT	O	O
trimethoprim-sulfamethoxazole	JJ	i	IPM
group	NN	O	O
,	,	O	O
0.16	CD	O	O
;	:	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
,	,	O	O
0.01-1.79	NNP	O	O
;	:	O	O
P	NNP	O	O
=	NNP	O	O
.14	NNP	O	O
)	)	O	O
.	.	O	O

Thus	RB	O	O
,	,	O	O
for	IN	O	O
HIV-infected	JJ	p	O
patients	NNS	p	O
receiving	VBG	O	O
trimethoprim-sulfamethoxazole	JJ	i	IPM
,	,	O	O
additional	JJ	O	O
prophylaxis	NN	O	O
for	IN	O	O
TE	NNP	O	O
appears	VBZ	O	O
unnecessary	JJ	O	O
.	.	O	O

Comparison	NNP	O	O
of	IN	O	O
maintenance	NN	i	O
treatment	NN	i	O
regimens	NNS	i	O
for	IN	O	O
first	JJ	O	O
central	JJ	p	PC
nervous	JJ	p	PC
system	NN	p	PC
relapse	NN	p	PC
in	IN	p	O
children	NNS	p	PA
with	IN	p	O
acute	JJ	p	PC
lymphocytic	JJ	p	PC
leukemia	NN	p	PC
.	.	p	O

A	DT	O	O
Pediatric	NNP	O	O
Oncology	NNP	O	O
Group	NNP	O	O
study	NN	O	O
.	.	O	O

Eighty-seven	JJ	p	PSS
children	NNS	p	O
with	IN	p	O
central	JJ	p	PC
nervous	JJ	p	PC
system	NN	p	PC
(	(	p	PC
CNS	NNP	p	PC
)	)	p	PC
leukemia	NN	p	PC
were	VBD	O	O
randomized	VBN	O	O
to	TO	O	O
receive	VB	O	O
either	DT	i	O
induction	NN	i	IPH
intrathecal	JJ	i	IPH
chemotherapy	NN	i	IPH
(	(	i	IPM
ITC	NNP	i	IPM
)	)	i	IPM
and	CC	i	O
cranial	JJ	i	IPH
irradiation	NN	i	IPH
(	(	i	IPH
CRT	NNP	i	IPH
)	)	i	IPH
plus	CC	i	IPM
maintenance	NN	i	IPH
ITC	NNP	i	IPH
,	,	i	O
or	CC	i	O
induction	NN	i	IPH
ITC	NNP	i	IPH
and	CC	i	IPM
craniospinal	JJ	i	IPM
irradiation	NN	i	IPM
(	(	i	IPM
CSpRT	NNP	i	IPM
)	)	i	IPM
with	IN	i	IPM
no	DT	i	IPM
maintenance	NN	i	IPM
ITC	NNP	i	IPM
.	.	i	O

ITC	NNP	O	O
consisted	VBD	O	O
of	IN	O	O
six	CD	O	O
weekly	JJ	O	O
injections	NNS	O	O
of	IN	O	O
methotrexate	NN	i	IPM
,	,	i	O
hydrocortisone	NN	i	IPM
,	,	i	O
and	CC	i	O
arabinosylcytosine	NN	i	IPM
.	.	i	O

Also	RB	O	O
,	,	O	O
intensification	NN	i	IPH
of	IN	i	IPH
systemic	JJ	i	IPH
induction	NN	i	IPH
and	CC	i	O
maintenance	NN	i	IPH
chemotherapy	NN	i	IPH
was	VBD	O	O
given	VBN	O	O
.	.	O	O

CRT	NNP	i	IPH
+	NNP	i	IPM
ITC	NNP	i	IPH
was	VBD	O	O
given	VBN	O	O
as	IN	O	O
CRT	NNP	i	IPH
,	,	O	O
2400	CD	O	O
rad	NN	O	O
in	IN	O	O
12	CD	O	O
fractions	NNS	O	O
followed	VBN	O	O
by	IN	O	O
ITC	NNP	i	IPH
maintenance	NN	O	O
bimonthly	NN	O	O
for	IN	O	O
2	CD	O	O
years	NNS	O	O
.	.	O	O

Craniospinal	JJ	i	IPH
irradiation	NN	i	IPH
consisted	VBD	i	IPH
of	IN	i	IPH
CRT	NNP	i	IPH
+	NNP	O	O
1400	CD	O	O
rad	NN	O	O
in	IN	O	O
ten	JJ	O	O
fractions	NNS	O	O
to	TO	O	O
the	DT	O	O
spine	NN	O	O
.	.	O	O

Randomization	NN	O	O
was	VBD	O	O
stratified	VBN	O	O
according	VBG	O	O
to	TO	O	O
whether	IN	O	O
CNS	NNP	O	O
leukemia	NN	O	O
occurred	VBD	O	O
at	IN	O	O
initial	JJ	O	O
diagnosis	NN	O	O
of	IN	O	O
acute	JJ	O	O
lymphocytic	JJ	O	O
leukemia	NN	O	O
(	(	O	O
ALL	DT	O	O
)	)	O	O
(	(	O	O
Stratum	NNP	O	O
I	PRP	O	O
,	,	O	O
15	CD	O	O
patients	NNS	O	O
)	)	O	O
,	,	O	O
during	IN	O	O
first	JJ	O	O
bone	NN	O	O
marrow	NN	O	O
(	(	O	O
BM	NNP	O	O
)	)	O	O
remission	NN	O	O
(	(	O	O
Stratum	NNP	O	O
II	NNP	O	O
,	,	O	O
49	CD	O	O
patients	NNS	O	O
)	)	O	O
,	,	O	O
simultaneous	JJ	O	O
with	IN	O	O
first	JJ	O	O
BM	NNP	O	O
relapse	NN	O	O
(	(	O	O
Stratum	NNP	O	O
III	NNP	O	O
,	,	O	O
12	CD	O	O
patients	NNS	O	O
)	)	O	O
,	,	O	O
or	CC	O	O
during	IN	O	O
second	JJ	O	O
BM	NNP	O	O
remission	NN	O	O
(	(	O	O
Stratum	NNP	O	O
IV	NNP	O	O
,	,	O	O
11	CD	O	O
patients	NNS	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
median	JJ	O	O
follow-up	NN	O	O
for	IN	O	O
patients	NNS	O	O
who	WP	O	O
remain	VBP	O	O
at	IN	O	O
risk	NN	O	O
is	VBZ	O	O
15	CD	O	O
+	JJ	O	O
months	NNS	O	O
.	.	O	O

Eight	NNP	O	O
children	NNS	O	O
(	(	O	O
seven	CD	O	O
on	IN	O	O
CRT	NNP	O	O
+	NNP	O	O
ITC	NNP	O	O
,	,	O	O
one	CD	O	O
on	IN	O	O
CSpRT	NNP	O	O
)	)	O	O
developed	VBD	O	O
presumed	VBN	o	OPH
therapy	RB	o	OPH
related	VBN	o	OPH
encephalopathy	NN	o	OPH
.	.	o	OPH

In	IN	O	O
Stratum	NNP	O	O
II	NNP	O	O
,	,	O	O
16	CD	O	O
of	IN	O	O
29	CD	O	O
(	(	O	O
55	CD	O	O
%	NN	O	O
)	)	O	O
patients	NNS	O	O
receiving	VBG	O	O
CRT	NNP	O	O
+	NNP	O	O
ITC	NNP	O	O
experienced	VBD	O	O
adverse	JJ	o	OPH
events	NNS	o	OPH
:	:	o	OPH
3	CD	O	O
deaths	NNS	o	OPH
during	IN	o	OPH
continuous	JJ	o	OPH
complete	JJ	o	OPH
remission	NN	o	OPH
(	(	o	OPH
CCR	NNP	o	OPH
)	)	o	OPH
and	CC	O	O
13	CD	O	O
relapses	NNS	o	OPH
(	(	O	O
2	CD	O	O
CNS	NNP	O	O
,	,	O	O
1	CD	O	O
CNS	NNP	O	O
+	NNP	O	O
BM	NNP	O	O
,	,	O	O
1	CD	O	O
BM	NNP	O	O
+	NNP	O	O
testes	VBZ	O	O
,	,	O	O
and	CC	O	O
2	CD	O	O
testes	NNS	O	O
)	)	O	O
as	IN	O	O
compared	VBN	O	O
with	IN	O	O
only	RB	O	O
5	CD	O	O
relapses	NNS	o	OPH
in	IN	O	O
20	CD	O	O
(	(	O	O
25	CD	O	O
%	NN	O	O
)	)	O	O
patients	NNS	O	O
on	IN	O	O
CSpRT	NNP	O	O
(	(	O	O
1	CD	O	O
CNS	NNP	O	O
,	,	O	O
1	CD	O	O
CNS	NNP	O	O
+	NNP	O	O
BM	NNP	O	O
,	,	O	O
1	CD	O	O
BM	NNP	O	O
,	,	O	O
and	CC	O	O
2	CD	O	O
testes	NNS	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
children	NNS	O	O
on	IN	O	O
both	DT	O	O
regimens	NNS	O	O
were	VBD	O	O
comparable	JJ	O	O
for	IN	O	O
sex	NN	O	O
,	,	O	O
race	NN	O	O
,	,	O	O
age	NN	O	O
at	IN	O	O
initial	JJ	O	O
ALL	NNP	O	O
diagnosis	NN	O	O
,	,	O	O
time	NN	o	OPH
from	IN	o	OPH
ALL	NNP	o	OPH
diagnosis	NN	o	OPH
to	TO	o	OPH
first	JJ	o	OPH
episode	NN	o	OPH
of	IN	o	OPH
CNS	NNP	o	OPH
leukemia	NN	o	OPH
,	,	o	OPH
systemic	JJ	o	OPH
therapy	NN	o	OPH
both	DT	o	OPH
before	IN	o	OPH
and	CC	o	OPH
after	IN	o	OPH
CNS	NNP	o	OPH
relapse	NN	o	OPH
,	,	o	OPH
and	CC	o	OPH
number	NN	o	OPH
of	IN	o	OPH
blasts	NNS	o	OPH
in	IN	o	OPH
the	DT	o	OPH
spinal	JJ	o	OPH
fluid	NN	o	OPH
at	IN	o	OPH
diagnosis	NN	o	OPH
of	IN	o	OPH
CNS	NNP	o	OPH
leukemia	NN	o	OPH
.	.	o	OPH

The	DT	O	O
conclusion	NN	O	O
is	VBZ	O	O
that	IN	O	O
children	NNS	O	O
with	IN	O	O
isolated	JJ	O	O
CNS	NNP	O	O
leukemia	NN	O	O
can	MD	O	O
achieve	VB	O	O
prolonged	JJ	o	OPH
survival	NN	o	OPH
with	IN	o	OPH
aggressive	JJ	o	OPH
therapy	NN	o	OPH
,	,	O	O
and	CC	O	O
that	IN	O	O
CSpRT	NNP	o	OPH
is	VBZ	o	OPH
possibly	RB	o	OPH
less	RBR	o	OPH
toxic	JJ	o	OPH
and	CC	O	O
more	RBR	O	O
likely	JJ	O	O
than	IN	O	O
is	VBZ	O	O
CRT	NNP	O	O
+	NNP	O	O
ITC	NNP	O	O
to	TO	O	O
prevent	VB	O	O
subsequent	JJ	o	OPH
BM	NNP	o	OPH
and	CC	o	OPH
testicular	JJ	o	OPH
relapse	NN	o	OPH
(	(	O	O
P	NNP	O	O
less	JJR	O	O
than	IN	O	O
0.02	CD	O	O
)	)	O	O
,	,	O	O
but	CC	O	O
not	RB	O	O
subsequent	JJ	O	O
CNS	NNP	o	OPH
relapse	NN	o	OPH
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.7	CD	O	O
)	)	O	O
.	.	O	O

A	DT	O	O
possible	JJ	O	O
systemic	JJ	O	O
therapy	NN	O	O
effect	NN	O	O
of	IN	O	O
spinal	JJ	o	OPH
irradiation	NN	o	OPH
is	VBZ	O	O
postulated	VBN	O	O
to	TO	O	O
explain	VB	O	O
the	DT	O	O
superiority	NN	o	OPH
of	IN	o	OPH
CSpRT	NNP	o	OPH
.	.	o	OPH

Hypnosis	NNP	i	IPS
treatment	NN	i	IPS
for	IN	O	O
severe	JJ	o	OPH
irritable	JJ	o	OPH
bowel	NN	o	OPH
syndrome	NN	o	OPH
:	:	o	OPH
investigation	NN	O	O
of	IN	O	O
mechanism	NN	O	O
and	CC	O	O
effects	NNS	O	O
on	IN	O	O
symptoms	NNS	O	O
.	.	O	O

Hypnosis	NNP	i	IPS
improves	VBZ	O	O
irritable	JJ	o	OPH
bowel	NN	o	OPH
syndrome	NN	o	OPH
(	(	O	O
IBS	NNP	O	O
)	)	O	O
,	,	O	O
but	CC	O	O
the	DT	O	O
mechanism	NN	O	O
is	VBZ	O	O
unknown	JJ	O	O
.	.	O	O

Possible	JJ	O	O
physiological	JJ	O	O
and	CC	O	O
psychological	JJ	O	O
mechanisms	NNS	O	O
were	VBD	O	O
investigated	VBN	O	O
in	IN	O	O
two	CD	O	O
studies	NNS	O	O
.	.	O	O

Patients	NNS	p	O
with	IN	p	O
severe	JJ	p	O
irritable	JJ	p	O
bowel	NN	p	O
syndrome	NN	p	O
received	VBD	O	O
seven	CD	O	O
biweekly	JJ	i	IPS
hypnosis	NN	i	IPS
sessions	NNS	i	IPS
and	CC	i	IPS
used	VBD	i	IPS
hypnosis	NN	i	IPS
audiotapes	NNS	i	IPS
at	IN	O	O
home	NN	O	O
.	.	O	O

Rectal	JJ	O	O
pain	NN	O	O
thresholds	NNS	O	O
and	CC	O	O
smooth	JJ	O	O
muscle	NN	O	O
tone	NN	O	O
were	VBD	O	O
measured	VBN	O	O
with	IN	O	O
a	DT	O	O
barostat	NN	O	O
before	IN	O	O
and	CC	O	O
after	IN	O	O
treatment	NN	O	O
in	IN	O	O
18	CD	p	O
patients	NNS	p	O
(	(	p	O
study	VB	p	O
I	PRP	p	O
)	)	p	O
,	,	O	O
and	CC	O	O
treatment	NN	O	O
changes	NNS	O	O
in	IN	O	O
heart	NN	O	O
rate	NN	O	O
,	,	O	O
blood	NN	O	O
pressure	NN	O	O
,	,	O	O
skin	JJ	O	O
conductance	NN	O	O
,	,	O	O
finger	NN	O	O
temperature	NN	O	O
,	,	O	O
and	CC	O	O
forehead	JJ	O	O
electromyographic	JJ	O	O
activity	NN	O	O
were	VBD	O	O
assessed	VBN	O	O
in	IN	O	O
24	CD	p	O
patients	NNS	p	O
(	(	p	O
study	VB	p	O
II	NNP	p	O
)	)	p	O
.	.	p	O

Somatization	NN	O	O
,	,	O	O
anxiety	NN	O	O
,	,	O	O
and	CC	O	O
depression	NN	O	O
were	VBD	O	O
also	RB	O	O
measured	VBN	O	O
.	.	O	O

All	DT	o	OPH
central	JJ	o	OPH
IBS	NNP	o	OPH
symptoms	NNS	o	OPH
improved	VBN	O	O
substantially	RB	O	O
from	IN	O	O
treatment	NN	O	O
in	IN	O	O
both	DT	O	O
studies	NNS	O	O
.	.	O	O

Rectal	JJ	o	OPA
pain	NN	o	OPA
thresholds	NNS	o	OPA
,	,	o	O
rectal	JJ	o	OPH
smooth	JJ	o	OPH
muscle	NN	o	OPH
tone	NN	o	OPH
,	,	o	OPH
and	CC	o	OPH
autonomic	JJ	o	OPH
functioning	NN	o	OPH
(	(	o	OPH
except	IN	o	OPH
sweat	NN	o	OPH
gland	VBP	o	OPH
reactivity	NN	o	OPH
)	)	o	OPH
were	VBD	O	O
unaffected	VBN	O	O
by	IN	O	O
hypnosis	NN	O	O
treatment	NN	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
somatization	NN	o	OME
and	CC	o	OME
psychological	JJ	o	OME
distress	NN	o	OME
showed	VBD	O	O
large	JJ	O	O
decreases	NNS	O	O
.	.	O	O

In	IN	O	O
conclusion	NN	O	O
,	,	O	O
hypnosis	NN	i	IE
improves	NNS	O	O
IBS	NNP	o	O
symptoms	NNS	o	O
through	IN	O	O
reductions	NNS	O	O
in	IN	O	O
psychological	JJ	o	OME
distress	NN	o	OME
and	CC	o	OME
somatization	NN	o	OME
.	.	o	OPH

Improvements	NNS	O	O
were	VBD	O	O
unrelated	JJ	O	O
to	TO	O	O
changes	NNS	O	O
in	IN	O	O
the	DT	O	O
physiological	JJ	O	O
parameters	NNS	O	O
measured	VBD	O	O
.	.	O	O

Direct	JJ	O	O
and	CC	O	O
indirect	JJ	O	O
effects	NNS	O	O
of	IN	O	O
interdental	JJ	i	IE
hygiene	NN	i	IE
in	IN	O	O
a	DT	O	O
clinical	JJ	O	O
trial	NN	O	O
.	.	O	O

Many	JJ	O	O
randomized	VBD	O	O
controlled	JJ	O	O
trials	NNS	O	O
(	(	O	O
RCTs	NNP	O	O
)	)	O	O
in	IN	O	O
dental	JJ	O	O
research	NN	O	O
test	NN	O	O
the	DT	O	O
efficacy	NN	O	O
of	IN	O	O
interventions	NNS	O	O
on	IN	O	O
more	JJR	O	O
than	IN	O	O
one	CD	O	O
outcome	NN	O	O
variable	NN	O	O
.	.	O	O

Univariate	NNP	O	O
methods	NNS	O	O
,	,	O	O
such	JJ	O	O
as	IN	O	O
the	DT	O	O
t	JJ	O	O
test	NN	O	O
or	CC	O	O
analysis	NN	O	O
of	IN	O	O
covariance	NN	O	O
,	,	O	O
can	MD	O	O
not	RB	O	O
evaluate	VB	O	O
the	DT	O	O
efficacy	NN	O	O
of	IN	O	O
interventions	NNS	O	O
on	IN	O	O
multiple	JJ	O	O
outcomes	NNS	O	O
simultaneously	RB	O	O
.	.	O	O

The	DT	O	O
aim	NN	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
use	VB	O	O
structural	JJ	i	IE
equation	NN	i	IE
modeling	NN	i	IE
(	(	O	O
SEM	NNP	O	O
)	)	O	O
to	TO	O	O
re-analyze	VB	O	O
a	DT	O	O
RCT	NNP	O	O
,	,	O	O
comparing	VBG	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
pre-curved	JJ	i	IE
interdental	JJ	i	IE
brushes	NNS	i	IE
and	CC	i	IE
flossing	VBG	i	IE
on	IN	O	O
probing	VBG	O	O
pocket	NN	O	O
depth	NN	O	O
(	(	O	O
PPD	NNP	O	O
)	)	O	O
,	,	O	O
plaque	JJ	O	O
indices	NNS	O	O
,	,	O	O
and	CC	O	O
bleeding	VBG	O	O
on	IN	O	O
probing	VBG	O	O
(	(	O	O
BOP	NNP	O	O
)	)	O	O
measured	VBD	O	O
at	IN	O	O
baseline	NN	O	O
,	,	O	O
intermediate	NN	O	O
,	,	O	O
and	CC	O	O
final	JJ	O	O
examinations	NNS	O	O
.	.	O	O

Results	NNS	O	O
of	IN	O	O
SEM	NNP	O	O
showed	VBD	O	O
that	IN	O	O
the	DT	O	O
observed	JJ	O	O
greater	JJR	o	O
reduction	NN	o	O
in	IN	o	O
PPD	NNP	o	OPH
and	CC	o	O
BOP	NNP	o	OPH
in	IN	O	O
persons	NNS	p	PC
using	VBG	p	PC
interdental	JJ	p	PC
brushing	NN	p	PC
than	IN	p	PC
in	IN	p	PC
those	DT	p	PC
flossing	NN	p	PC
is	VBZ	O	O
due	JJ	O	O
mainly	RB	O	O
to	TO	O	O
the	DT	O	O
greater	JJR	O	O
efficiency	NN	o	OPH
in	IN	o	OPH
plaque	NN	o	OPH
removal	NN	o	OPH
with	IN	O	O
the	DT	O	O
interdental	JJ	O	O
brushes	NNS	O	O
(	(	O	O
indirect	JJ	O	O
effect	NN	O	O
)	)	O	O
rather	RB	O	O
than	IN	O	O
to	TO	O	O
the	DT	O	O
compression	NN	O	O
of	IN	O	O
the	DT	O	O
interdental	JJ	O	O
papillae	NN	O	O
(	(	O	O
direct	JJ	O	O
effect	NN	O	O
)	)	O	O
.	.	O	O

In	IN	O	O
contrast	NN	O	O
,	,	O	O
smokers	NNS	p	PC
showed	VBD	O	O
less	JJR	O	O
BOP	NNP	o	OPH
at	IN	O	O
baseline	NN	O	O
but	CC	O	O
also	RB	O	O
less	RBR	O	O
improvement	NN	O	O
in	IN	O	O
BOP	NNP	o	OPH
through	IN	O	O
direct	JJ	O	O
effects	NNS	O	O
.	.	O	O

Menopausal	NNP	o	OOt
quality	NN	o	OOt
of	IN	o	OOt
life	NN	o	OOt
:	:	o	O
RCT	NNP	i	O
of	IN	i	O
yoga	NN	i	IPH
,	,	i	O
exercise	NN	i	IPH
,	,	i	O
and	CC	i	O
omega-3	JJ	i	IPM
supplements	NNS	i	IPM
.	.	i	O

OBJECTIVE	IN	O	O
The	DT	O	O
purpose	NN	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
determine	VB	O	O
the	DT	O	O
efficacy	NN	O	O
of	IN	O	O
3	CD	i	O
nonhormonal	JJ	i	O
therapies	NNS	i	O
for	IN	O	O
the	DT	O	O
improvement	NN	O	O
of	IN	O	O
menopause-related	JJ	o	OOt
quality	NN	o	OOt
of	IN	o	OOt
life	NN	o	OOt
in	IN	O	O
women	NNS	p	O
with	IN	p	O
vasomotor	NN	p	O
symptoms	NNS	p	O
.	.	p	O

STUDY	NNP	O	O
DESIGN	NNP	O	O
We	PRP	O	O
conducted	VBD	O	O
a	DT	O	O
12-week	JJ	O	O
3	CD	O	O
?	.	O	O
2	CD	O	O
randomized	VBD	O	O
,	,	O	O
controlled	VBD	O	O
,	,	O	O
factorial	JJ	O	O
design	NN	O	O
trial	NN	O	O
.	.	O	O

Peri-	NN	p	O
and	CC	p	O
postmenopausal	JJ	p	O
women	NNS	p	O
,	,	p	O
40-62	JJ	p	O
years	NNS	p	O
old	JJ	p	O
,	,	p	O
were	VBD	O	O
assigned	VBN	O	O
randomly	RB	O	O
to	TO	i	O
yoga	VB	i	IPH
(	(	O	O
n	JJ	O	O
=	NNP	O	O
107	CD	O	O
)	)	O	O
,	,	O	O
exercise	NN	i	O
(	(	O	O
n	JJ	O	O
=	NNP	O	O
106	CD	O	O
)	)	O	O
,	,	O	O
or	CC	i	O
usual	JJ	i	IC
activity	NN	i	IC
(	(	O	O
n	JJ	O	O
=	NNP	O	O
142	CD	O	O
)	)	O	O
and	CC	O	O
also	RB	O	O
assigned	VBD	O	O
randomly	RB	O	O
to	TO	O	O
a	DT	O	O
double-blind	JJ	O	O
comparison	NN	O	O
of	IN	i	O
omega-3	JJ	i	IPM
(	(	O	O
n	JJ	O	O
=	NNP	O	O
177	CD	i	O
)	)	i	O
or	CC	i	O
placebo	NN	i	IC
(	(	O	O
n	JJ	O	O
=	NNP	O	O
178	CD	O	O
)	)	O	O
capsules	NNS	O	O
.	.	O	O

We	PRP	O	O
performed	VBD	O	O
the	DT	O	O
following	JJ	O	O
interventions	NNS	O	O
:	:	O	O
(	(	O	O
1	CD	i	O
)	)	i	O
weekly	JJ	i	O
90-minute	CD	i	O
yoga	NN	i	O
classes	NNS	i	O
with	IN	i	O
daily	JJ	i	O
at-home	JJ	i	O
practice	NN	i	O
,	,	i	O
(	(	i	O
2	CD	i	O
)	)	i	O
individualized	VBN	i	O
facility-based	JJ	i	O
aerobic	JJ	i	O
exercise	NN	i	O
training	NN	i	O
3	CD	i	O
times/week	NN	i	O
,	,	i	O
and	CC	O	O
(	(	O	O
3	CD	O	O
)	)	O	O
0.615	CD	O	O
g	JJ	O	O
omega-3	JJ	i	IPM
supplement	NN	i	IPM
,	,	i	O
3	CD	O	O
times/day	NN	O	O
.	.	O	O

The	DT	O	O
outcomes	NNS	O	O
were	VBD	O	O
assessed	VBN	O	O
with	IN	O	O
the	DT	O	O
following	JJ	O	O
scores	NNS	o	O
:	:	o	O
Menopausal	NNP	o	O
Quality	NNP	o	O
of	IN	o	O
Life	NNP	o	O
Questionnaire	NNP	o	O
(	(	o	O
MENQOL	NNP	o	O
)	)	o	O
total	NN	o	O
and	CC	o	O
domain	NN	o	O
(	(	o	O
vasomotor	NN	o	O
symptoms	NNS	o	O
,	,	o	O
psychosocial	JJ	o	O
,	,	o	O
physical	JJ	o	O
and	CC	o	O
sexual	JJ	o	O
)	)	o	O
.	.	o	O

RESULTS	NNP	p	O
Among	IN	p	O
355	CD	p	O
randomly	NNS	p	O
assigned	VBN	p	O
women	NNS	p	O
who	WP	p	O
average	VBP	p	O
age	NN	p	O
was	VBD	p	O
54.7	CD	p	O
years	NNS	p	O
,	,	p	O
338	CD	p	O
women	NNS	p	O
(	(	p	O
95	CD	p	O
%	NN	p	O
)	)	p	O
completed	VBD	p	O
12-week	JJ	p	O
assessments	NNS	p	O
.	.	p	O

Mean	NNP	o	O
baseline	NN	o	O
vasomotor	NN	o	O
symptoms	JJ	o	O
frequency	NN	o	O
was	VBD	O	O
7.6/day	CD	O	O
,	,	O	O
and	CC	O	O
the	DT	o	O
mean	JJ	o	O
baseline	NN	o	O
total	JJ	o	O
MENQOL	NNP	o	O
score	NN	o	O
was	VBD	O	O
3.8	CD	O	O
(	(	O	O
range	NN	O	O
,	,	O	O
1-8	CD	O	O
from	IN	O	O
better	JJR	O	O
to	TO	O	O
worse	VB	O	O
)	)	O	O
with	IN	O	O
no	DT	O	O
between-group	JJ	O	O
differences	NNS	O	O
.	.	O	O

For	IN	i	O
yoga	NN	i	O
compared	VBN	O	O
to	TO	O	O
usual	JJ	O	O
activity	NN	O	O
,	,	O	O
baseline	NN	O	O
to	TO	O	O
12-week	JJ	O	O
improvements	NNS	O	O
were	VBD	O	O
seen	VBN	O	O
for	IN	o	O
MENQOL	NNP	o	O
total	JJ	O	O
-0.3	NNP	O	O
(	(	O	O
95	CD	O	O
%	NN	O	O
confidence	NN	O	O
interval	NN	O	O
,	,	O	O
-0.6	VBP	O	O
to	TO	O	O
0	CD	O	O
;	:	O	O
P	NNP	O	O
=	NNP	O	O
.02	NNP	O	O
)	)	O	O
,	,	O	O
vasomotor	NN	o	O
symptom	NN	o	O
domain	NN	o	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
.02	NNP	O	O
)	)	O	O
,	,	O	O
and	CC	o	O
sexuality	NN	o	O
domain	NN	o	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
.03	NNP	O	O
)	)	O	O
scores	VBZ	O	O
.	.	O	O

For	IN	O	O
women	NNS	O	O
who	WP	O	O
underwent	VBP	i	O
exercise	NN	i	IPH
and	CC	i	O
omega-3	JJ	i	IPM
therapy	NN	i	IPM
compared	VBN	O	O
with	IN	O	O
control	NN	O	O
subjects	NNS	O	O
,	,	O	O
improvements	NNS	O	O
in	IN	O	O
baseline	NN	O	O
to	TO	O	O
12-week	JJ	O	O
total	JJ	o	O
MENQOL	NNP	o	O
scores	NNS	o	O
were	VBD	O	O
not	RB	O	O
observed	VBN	O	O
.	.	O	O

Exercise	NN	O	O
showed	VBD	O	O
benefit	NN	O	O
in	IN	O	O
the	DT	o	O
MENQOL	NNP	o	O
physical	JJ	o	O
domain	NN	o	O
score	NN	o	O
at	IN	O	O
12	CD	O	O
weeks	NNS	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
.02	NNP	O	O
)	)	O	O
.	.	O	O

CONCLUSION	NNP	O	O
All	NNP	O	O
women	NNS	O	O
become	VBP	O	O
menopausal	JJ	O	O
,	,	O	O
and	CC	O	O
many	JJ	O	O
of	IN	O	O
them	PRP	O	O
seek	VBP	O	O
medical	JJ	O	O
advice	NN	O	O
on	IN	O	O
ways	NNS	O	O
to	TO	O	O
improve	VB	o	O
quality	NN	o	O
of	IN	o	O
life	NN	o	O
;	:	o	O
little	JJ	O	O
evidence-based	JJ	O	O
information	NN	O	O
exists	NNS	O	O
.	.	O	O

We	PRP	O	O
found	VBD	O	O
that	IN	O	O
,	,	O	O
among	IN	p	O
healthy	JJ	p	O
sedentary	JJ	p	O
menopausal	NN	p	O
women	NNS	p	O
,	,	p	O
yoga	NN	i	O
appears	VBZ	O	O
to	TO	O	O
improve	VB	o	O
menopausal	NN	o	O
quality	NN	o	O
of	IN	o	O
life	NN	o	O
;	:	o	O
the	DT	O	O
clinical	JJ	O	O
significance	NN	O	O
of	IN	O	O
our	PRP$	O	O
finding	NN	O	O
is	VBZ	O	O
uncertain	JJ	O	O
because	IN	O	O
of	IN	O	O
the	DT	O	O
modest	JJ	O	O
effect	NN	O	O
.	.	O	O

Environmental	JJ	O	O
enrichment	NN	O	O
as	IN	O	O
an	DT	O	O
effective	JJ	O	O
treatment	NN	O	O
for	IN	O	O
autism	NN	o	OPH
:	:	o	O
a	DT	O	O
randomized	NN	O	O
controlled	VBN	O	O
trial	NN	O	O
.	.	O	O

Enriched	NNP	O	O
sensorimotor	NN	O	O
environments	NNS	O	O
enable	JJ	O	O
rodents	NNS	O	O
to	TO	O	O
compensate	VB	O	O
for	IN	O	O
a	DT	O	O
wide	JJ	O	O
range	NN	O	O
of	IN	O	O
neurological	JJ	O	O
challenges	NNS	O	O
,	,	O	O
including	VBG	O	O
those	DT	O	O
induced	VBN	O	O
in	IN	O	O
animal	JJ	O	O
models	NNS	O	O
of	IN	O	O
autism	NN	O	O
.	.	O	O

Given	VBN	O	O
the	DT	O	O
sensorimotor	NN	O	O
deficits	NNS	O	O
in	IN	O	O
most	JJS	O	O
children	NNS	p	O
with	IN	p	O
autism	NN	p	PC
,	,	O	O
we	PRP	O	O
attempted	VBD	O	O
to	TO	O	O
translate	VB	O	O
that	DT	O	O
approach	NN	O	O
to	TO	O	O
their	PRP$	O	O
treatment	NN	O	O
.	.	O	O

In	IN	O	O
a	DT	O	O
randomized	NN	O	O
controlled	VBN	O	O
trial	NN	O	O
,	,	O	O
3-12	JJ	p	PA
year-old	JJ	p	PA
children	NNS	p	PA
with	IN	p	O
autism	NN	p	PC
were	VBD	O	O
assigned	VBN	O	O
to	TO	O	O
either	VB	O	O
a	DT	O	O
sensorimotor	NN	i	IPH
enrichment	NN	i	IPH
group	NN	i	IPH
,	,	O	O
which	WDT	O	O
received	VBD	O	O
daily	RB	O	O
olfactory/tactile	JJ	i	IPH
stimulation	NN	i	IPH
along	IN	i	O
with	IN	i	O
exercises	NNS	i	IPH
that	WDT	i	O
stimulated	VBD	i	O
other	JJ	i	O
paired	JJ	i	O
sensory	JJ	i	O
modalities	NNS	i	O
,	,	i	O
or	CC	i	O
to	TO	i	O
a	DT	i	O
control	NN	i	IC
group	NN	i	IC
.	.	i	O

We	PRP	O	O
administered	VBD	O	O
tests	NNS	O	O
of	IN	O	O
cognitive	JJ	O	O
performance	NN	O	O
and	CC	O	O
autism	NN	O	O
severity	NN	O	O
to	TO	O	O
both	DT	O	O
groups	NNS	O	O
at	IN	O	O
the	DT	O	O
initiation	NN	O	O
of	IN	O	O
the	DT	O	O
study	NN	O	O
and	CC	O	O
after	IN	O	O
6	CD	O	O
months	NNS	O	O
.	.	O	O

Severity	NNP	o	OPH
of	IN	o	OPH
autism	NN	o	OPH
,	,	O	O
as	IN	O	O
assessed	VBN	O	O
with	IN	O	O
the	DT	O	O
Childhood	NNP	o	OOt
Autism	NNP	o	OOt
Rating	NNP	o	OOt
Scale	NNP	o	OOt
,	,	O	O
improved	VBN	O	O
significantly	RB	O	O
in	IN	O	O
the	DT	O	O
enriched	JJ	O	O
group	NN	O	O
compared	VBN	O	O
to	TO	O	O
controls	NNS	O	O
.	.	O	O

Indeed	RB	O	O
,	,	O	O
42	CD	O	O
%	NN	O	O
of	IN	O	O
the	DT	O	O
enriched	VBN	O	O
group	NN	O	O
and	CC	O	O
only	RB	O	O
7	CD	O	O
%	NN	O	O
of	IN	O	O
the	DT	O	O
control	NN	O	O
group	NN	O	O
had	VBD	O	O
what	WP	O	O
we	PRP	O	O
considered	VBD	O	O
to	TO	O	O
be	VB	O	O
a	DT	O	O
clinically	RB	O	O
significant	JJ	O	O
improvement	NN	O	O
of	IN	O	O
5	CD	O	O
points	NNS	O	O
on	IN	O	O
that	DT	O	O
scale	NN	O	O
.	.	O	O

Sensorimotor	NNP	O	O
enrichment	NN	O	O
also	RB	O	O
produced	VBD	O	O
a	DT	O	O
clear	JJ	o	OOt
improvement	NN	o	OOt
in	IN	o	OOt
cognition	NN	o	OOt
,	,	O	O
as	IN	O	O
determined	VBN	O	O
by	IN	O	O
their	PRP$	O	O
Leiter-R	JJ	O	O
Visualization	NNP	O	O
and	CC	O	O
Reasoning	NNP	O	O
scores	NNS	O	O
.	.	O	O

At	IN	O	O
6	CD	O	O
months	NNS	O	O
,	,	O	O
the	DT	O	O
change	NN	O	O
in	IN	O	O
average	JJ	O	O
scores	NNS	O	O
for	IN	O	O
the	DT	O	O
enriched	JJ	O	O
group	NN	O	O
was	VBD	O	O
11.3	CD	O	O
points	NNS	O	O
higher	JJR	O	O
than	IN	O	O
that	DT	O	O
for	IN	O	O
the	DT	O	O
control	NN	O	O
group	NN	O	O
.	.	O	O

Finally	RB	O	O
,	,	O	O
69	CD	O	O
%	NN	O	O
of	IN	O	O
parents	NNS	O	O
in	IN	O	O
the	DT	O	O
enriched	JJ	O	O
group	NN	O	O
and	CC	O	O
31	CD	O	O
%	NN	O	O
of	IN	O	O
parents	NNS	O	O
in	IN	O	O
the	DT	O	O
control	NN	O	O
group	NN	O	O
reported	VBD	O	O
improvement	NN	O	O
in	IN	O	O
their	PRP$	O	O
child	NN	O	O
over	IN	O	O
the	DT	O	O
6-month	JJ	O	O
study	NN	O	O
.	.	O	O

Environmental	JJ	O	O
enrichment	NN	O	O
therefore	RB	O	O
appears	VBZ	O	O
to	TO	O	O
be	VB	O	O
effective	JJ	O	O
in	IN	O	O
ameliorating	VBG	o	OOt
some	DT	o	OOt
of	IN	o	OOt
the	DT	o	OOt
symptoms	NNS	o	OOt
of	IN	o	OOt
autism	NN	o	OOt
in	IN	O	O
children	NNS	O	O
.	.	O	O

Divalproex	NNP	i	IPM
sodium	NN	i	IPM
vs.	FW	i	O
placebo	NN	i	O
in	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
repetitive	JJ	o	OME
behaviours	NNS	o	OME
in	IN	O	O
autism	NN	p	PC
spectrum	NN	p	PC
disorder	NN	p	PC
.	.	p	O

Autism	NNP	O	O
is	VBZ	O	O
a	DT	O	O
neurodevelopmental	JJ	O	O
disorder	NN	O	O
characterized	VBN	O	O
by	IN	O	O
impairment	NN	O	O
in	IN	O	O
three	CD	O	O
core	NN	O	O
symptom	NN	O	O
domains	NNS	O	O
:	:	O	O
socialization	NN	O	O
,	,	O	O
communication	NN	O	O
,	,	O	O
and	CC	O	O
repetitive/stereotyped	VBD	O	O
behaviours	NNS	O	O
.	.	O	O

Other	JJ	O	O
associated	JJ	O	O
symptom	NN	O	O
domains	NNS	O	O
are	VBP	O	O
also	RB	O	O
affected	JJ	O	O
including	VBG	O	O
impulsivity/aggression	NN	O	O
,	,	O	O
self-injury	NN	O	O
,	,	O	O
anxiety	NN	O	O
,	,	O	O
and	CC	O	O
mood	NN	O	O
lability	NN	O	O
.	.	O	O

Divalproex	NNP	i	IPM
has	VBZ	O	O
been	VBN	O	O
shown	VBN	O	O
to	TO	O	O
have	VB	O	O
efficacy	NN	O	O
in	IN	O	O
treating	VBG	O	O
epilepsy	NN	O	O
,	,	O	O
bipolar	JJ	O	O
disorder	NN	O	O
,	,	O	O
mood	NN	O	O
lability	NN	O	O
,	,	O	O
and	CC	O	O
impulsive	JJ	O	O
aggression	NN	O	O
.	.	O	O

The	DT	O	O
present	JJ	O	O
study	NN	O	O
evaluated	VBD	O	O
the	DT	O	O
use	NN	O	O
of	IN	O	O
divalproex	NN	i	IPM
in	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
repetitive	JJ	o	OPH
,	,	o	OPH
compulsive-like	JJ	o	OPH
symptoms	NNS	o	OPH
of	IN	o	OPH
autism	NN	o	OPH
spectrum	NN	o	OPH
disorder	NN	o	OPH
(	(	o	O
ASD	NNP	o	O
)	)	o	O
.	.	o	O

Thirteen	JJ	p	PSS
individuals	NNS	p	O
with	IN	p	O
ASD	NNP	p	PC
participated	VBD	O	O
in	IN	O	O
an	DT	O	O
8-wk	JJ	O	O
,	,	O	O
double-blind	JJ	O	O
,	,	O	O
placebo-controlled	JJ	i	IC
trial	NN	O	O
of	IN	O	O
divalproex	NN	i	IPM
sodium	NN	i	IPM
vs.	FW	i	O
placebo	NN	i	IC
.	.	i	O

There	EX	O	O
was	VBD	O	O
a	DT	O	O
significant	JJ	O	O
group	NN	O	O
difference	NN	O	O
on	IN	O	O
improvement	NN	O	O
in	IN	O	O
repetitive	JJ	o	OME
behaviours	NNS	o	OME
as	IN	O	O
measured	VBN	O	O
by	IN	O	O
the	DT	O	O
Children	NNP	o	OME
's	POS	o	OME
Yale-Brown	JJ	o	OME
Obsessive	NNP	o	OME
Compulsive	NNP	o	OME
Scale	NNP	o	OME
(	(	o	OME
C-YBOCS	NNP	o	OME
)	)	o	OME
(	(	O	O
p=0.037	NN	O	O
)	)	O	O
and	CC	O	O
a	DT	O	O
large	JJ	O	O
effect	NN	O	O
size	NN	O	O
(	(	O	O
d=1.616	NN	O	O
)	)	O	O
.	.	O	O

This	DT	O	O
study	NN	O	O
provides	VBZ	O	O
preliminary	JJ	O	O
support	NN	O	O
for	IN	O	O
the	DT	O	O
use	NN	O	O
of	IN	O	O
divalproex	NN	i	IPM
in	IN	O	O
treating	VBG	O	O
repetitive	JJ	o	OME
behaviours	NNS	o	OME
in	IN	O	O
ASD	NNP	p	O
.	.	p	O

Further	NNP	O	O
research	NN	O	O
is	VBZ	O	O
needed	VBN	O	O
to	TO	O	O
evaluate	VB	O	O
the	DT	O	O
specificity	NN	O	O
and	CC	O	O
mechanism	NN	O	O
of	IN	O	O
action	NN	O	O
of	IN	O	O
these	DT	O	O
findings	NNS	O	O
.	.	O	O

RCT	NNP	O	O
of	IN	O	O
a	DT	O	O
manualized	JJ	O	O
social	JJ	i	IE
treatment	NN	i	IE
for	IN	O	O
high-functioning	JJ	p	O
autism	NN	p	O
spectrum	NN	p	O
disorders	NNS	p	O
.	.	p	O

This	DT	O	O
RCT	NNP	O	O
examined	VBD	O	O
the	DT	O	O
efficacy	NN	O	O
of	IN	O	O
a	DT	O	O
manualized	VBN	i	IE
social	JJ	i	IE
intervention	NN	i	IE
for	IN	O	O
children	NNS	p	O
with	IN	p	O
HFASDs	NNP	p	O
.	.	p	O

Participants	NNS	O	O
were	VBD	O	O
randomly	RB	O	O
assigned	VBN	O	O
to	TO	O	O
treatment	NN	i	IE
or	CC	O	O
wait-list	JJ	i	IC
conditions	NNS	i	IC
.	.	i	IC

Treatment	NNP	i	O
included	VBD	O	O
instruction	NN	i	IE
and	CC	i	IE
therapeutic	JJ	i	IE
activities	NNS	i	IE
targeting	VBG	i	IE
social	JJ	i	IE
skills	NNS	i	IE
,	,	i	IE
face-emotion	NN	i	IE
recognition	NN	i	IE
,	,	i	IE
interest	NN	i	IE
expansion	NN	i	IE
,	,	i	IE
and	CC	i	IE
interpretation	NN	i	IE
of	IN	i	IE
non-literal	JJ	i	IE
language	NN	i	IE
.	.	i	IE

A	DT	O	O
response-cost	JJ	O	O
program	NN	O	O
was	VBD	O	O
applied	VBN	O	O
to	TO	O	O
reduce	VB	O	O
problem	NN	O	O
behaviors	NNS	O	O
and	CC	O	O
foster	JJ	O	O
skills	NNS	O	O
acquisition	NN	O	O
.	.	O	O

Significant	NNP	O	O
treatment	NN	O	O
effects	NNS	O	O
were	VBD	O	O
found	VBN	O	O
for	IN	O	O
five	CD	o	O
of	IN	o	O
seven	CD	o	O
primary	JJ	o	O
outcome	JJ	o	O
measures	NNS	o	O
(	(	o	O
parent	NN	o	OME
ratings	NNS	o	OME
and	CC	o	O
direct	JJ	o	O
child	NN	o	O
measures	NNS	o	O
)	)	o	O
.	.	O	O

Secondary	JJ	O	O
measures	NNS	O	O
based	VBN	O	O
on	IN	O	O
staff	NN	o	OOt
ratings	NNS	o	OOt
(	(	O	O
treatment	NN	O	O
group	NN	O	O
only	RB	O	O
)	)	O	O
corroborated	VBD	O	O
gains	NNS	O	O
reported	VBN	O	O
by	IN	O	O
parents	NNS	O	O
.	.	O	O

High	JJ	O	O
levels	NNS	O	O
of	IN	O	O
parent	NN	o	OOt
,	,	o	OOt
child	NN	o	OOt
and	CC	o	OOt
staff	NN	o	OOt
satisfaction	NN	o	OOt
were	VBD	O	O
reported	VBN	O	O
,	,	O	O
along	IN	O	O
with	IN	O	O
high	JJ	O	O
levels	NNS	O	O
of	IN	O	O
treatment	NN	o	OME
fidelity	NN	o	OME
.	.	o	OME

Standardized	JJ	O	O
effect	NN	O	O
size	NN	O	O
estimates	NNS	O	O
were	VBD	O	O
primarily	RB	O	O
in	IN	O	O
the	DT	O	O
medium	NN	O	O
and	CC	O	O
large	JJ	O	O
ranges	NNS	O	O
and	CC	O	O
favored	VBD	O	O
the	DT	O	O
treatment	NN	O	O
group	NN	O	O
.	.	O	O

Comparison	NNP	O	O
of	IN	O	O
three	CD	O	O
solutions	NNS	O	O
of	IN	O	O
ropivacaine/fentanyl	NN	i	IPM
for	IN	O	O
postoperative	JJ	p	O
patient-controlled	JJ	p	O
epidural	JJ	p	O
analgesia	NN	p	O
.	.	p	O

BACKGROUND	NNP	O	O
Ropivacaine	NNP	i	IPM
,	,	O	O
0.2	CD	O	O
%	NN	O	O
,	,	O	O
is	VBZ	O	O
a	DT	O	O
new	JJ	O	O
local	JJ	O	O
anesthetic	JJ	O	O
approved	VBN	O	O
for	IN	O	O
epidural	JJ	O	O
analgesia	NN	O	O
.	.	O	O

The	DT	O	O
addition	NN	O	O
of	IN	O	O
4	CD	O	O
microg/ml	NNS	O	O
fentanyl	JJ	i	IPM
improves	NNS	O	O
analgesia	VBP	O	O
from	IN	O	O
epidural	JJ	O	O
ropivacaine	NN	O	O
.	.	O	O

Use	NNP	O	O
of	IN	O	O
a	DT	O	O
lower	JJR	O	O
concentration	NN	O	O
of	IN	O	O
ropivacaine-fentanyl	NN	i	IPM
may	MD	O	O
further	VB	O	O
improve	VB	O	O
analgesia	NN	o	O
or	CC	O	O
decrease	JJ	O	O
side	NN	o	OA
effects	NNS	o	OA
.	.	o	OA

METHODS	NNP	O	O
Thirty	NNP	p	O
patients	NNS	p	O
undergoing	VBG	p	O
lower	JJR	p	O
abdominal	JJ	p	O
surgery	NN	p	O
were	VBD	p	O
randomized	VBN	p	O
in	IN	O	O
a	DT	O	O
double-blinded	JJ	O	O
manner	NN	O	O
to	TO	O	O
receive	VB	O	O
one	CD	O	O
of	IN	O	O
three	CD	O	O
solutions	NNS	O	O
:	:	O	O
0.2	CD	i	IPM
%	NN	i	IPM
ropivacaine-4	JJ	i	IPM
microg	NN	i	IPM
fentanyl	VBD	i	IPM
0.1	CD	i	IPM
%	NN	i	IPM
ropivacaine-2	JJ	i	IPM
microg	NN	i	IPM
fentanyl	NN	i	IPM
,	,	i	O
or	CC	i	O
0.05	CD	i	IPM
%	NN	i	IPM
ropivacaine-1	JJ	i	IPM
microg	NN	i	IPM
fentanyl	NN	i	IPM
for	IN	O	O
patient-controlled	JJ	O	O
epidural	JJ	O	O
analgesia	NN	O	O
after	IN	O	O
standardized	VBN	O	O
combined	JJ	O	O
epidural	JJ	O	O
and	CC	O	O
general	JJ	O	O
anesthesia	NN	O	O
.	.	O	O

Patient-controlled	JJ	O	O
epidural	JJ	O	O
analgesia	NN	O	O
settings	NNS	O	O
and	CC	O	O
adjustments	NNS	O	O
for	IN	O	O
the	DT	O	O
three	CD	O	O
solutions	NNS	O	O
were	VBD	O	O
standardized	VBN	O	O
to	TO	O	O
deliver	VB	O	O
equivalent	JJ	O	O
drug	NN	O	O
doses	NNS	O	O
.	.	O	O

Pain	NN	o	OPA
scores	NNS	o	OPA
(	(	o	OPA
rest	NN	o	OPA
,	,	o	OPA
cough	NN	o	OPA
,	,	o	OPA
and	CC	o	OPA
ambulation	NN	o	OPA
)	)	o	OPA
,	,	o	OPA
side	JJ	o	OPA
effects	NNS	o	OPA
(	(	o	OPA
nausea	NN	o	OPA
,	,	o	OPA
pruritus	NN	o	OPA
,	,	o	OPA
sedation	NN	o	OPA
,	,	o	OPA
motor	NN	o	OPA
block	NN	o	OPA
,	,	o	OPA
hypotension	NN	o	OPA
,	,	o	OPA
and	CC	o	OPA
orthostasis	NN	o	OPA
)	)	o	OPA
,	,	o	OPA
and	CC	o	OPA
patient-controlled	JJ	o	OPA
epidural	JJ	o	OPA
analgesia	NN	o	OPA
consumption	NN	o	OPA
were	VBD	O	O
measured	VBN	O	O
for	IN	O	O
48	CD	O	O
h.	JJ	O	O
RESULTS	NNP	O	O
All	NNP	O	O
three	CD	O	O
solutions	NNS	O	O
produced	VBD	O	O
equivalent	JJ	O	O
analgesia	NN	O	O
.	.	O	O

Motor	NNP	o	OPH
block	NN	o	OPH
was	VBD	O	O
significantly	RB	O	O
more	JJR	O	O
common	JJ	O	O
(	(	O	O
30	CD	O	O
vs.	FW	O	O
0	CD	O	O
%	NN	O	O
)	)	O	O
and	CC	O	O
more	JJR	O	O
intense	JJ	O	O
with	IN	O	O
the	DT	O	O
0.2	CD	O	O
%	NN	O	O
ropivacaine-4	JJ	i	IPM
microg	NN	O	O
fentanyl	JJ	O	O
solution	NN	O	O
.	.	O	O

Other	JJ	O	O
side	NN	O	O
effects	NNS	O	O
were	VBD	O	O
equivalent	JJ	O	O
between	IN	O	O
solutions	NNS	O	O
and	CC	O	O
mild	NN	O	O
in	IN	O	O
severity	NN	o	OA
.	.	o	OA

A	DT	O	O
significantly	RB	O	O
smaller	JJR	O	O
volume	NN	O	O
of	IN	O	O
0.2	CD	O	O
%	NN	O	O
ropivacaine-4	JJ	o	OPH
microg	NN	o	OPH
fentanyl	JJ	o	OPH
solution	NN	o	OPH
was	VBD	O	O
used	VBN	O	O
,	,	O	O
whereas	IN	O	O
the	DT	O	O
0.1	CD	O	O
%	NN	O	O
ropivacaine-2	JJ	i	O
microg	NN	O	O
fentanyl	NN	O	O
group	NN	O	O
used	VBD	O	O
a	DT	O	O
significantly	RB	O	O
greater	JJR	O	O
amount	NN	O	O
of	IN	O	O
ropivacaine	NN	o	O
and	CC	o	O
fentanyl	NN	o	O
.	.	o	O

CONCLUSIONS	NNP	O	O
Lesser	NNP	O	O
concentrations	NNS	O	O
of	IN	O	O
ropivacaine	NN	i	IPM
and	CC	O	O
fentanyl	JJ	i	IPM
provide	NN	O	O
comparable	JJ	O	O
analgesia	NN	o	O
with	IN	O	O
less	JJR	O	O
motor	NN	o	OPH
block	NN	o	OPH
despite	IN	O	O
the	DT	O	O
use	NN	O	O
of	IN	O	O
similar	JJ	O	O
amounts	NNS	O	O
of	IN	O	O
ropivacaine	NN	O	O
and	CC	O	O
fentanyl	NN	O	O
.	.	O	O

This	DT	O	O
finding	NN	O	O
suggests	VBZ	O	O
that	IN	O	O
concentration	NN	O	O
of	IN	O	O
local	JJ	O	O
anesthetic	JJ	O	O
solution	NN	O	O
at	IN	O	O
low	JJ	O	O
doses	NNS	O	O
is	VBZ	O	O
a	DT	O	O
primary	JJ	O	O
determinant	NN	o	OA
of	IN	o	OA
motor	NN	o	OA
block	NN	o	OA
with	IN	O	O
patient-controlled	JJ	O	O
epidural	JJ	O	O
analgesia	NN	O	O
after	IN	O	O
lower	JJR	O	O
abdominal	JJ	O	O
surgery	NN	O	O
.	.	O	O

Behavioral	NNP	o	OME
and	CC	o	OME
physiological	JJ	o	OME
effects	NNS	o	OME
of	IN	O	O
remifentanil	NN	i	IPM
and	CC	i	O
alfentanil	NN	i	IPM
in	IN	O	O
healthy	JJ	p	PC
volunteers	NNS	p	O
.	.	p	O

BACKGROUND	IN	O	O
The	DT	o	O
subjective	JJ	o	OME
and	CC	o	OME
psychomotor	JJ	o	OME
effects	NNS	o	OME
of	IN	O	O
remifentanil	NNS	i	IPM
have	VBP	O	O
not	RB	O	O
been	VBN	O	O
evaluated	VBN	O	O
.	.	O	O

Accordingly	RB	O	O
,	,	O	O
the	DT	O	O
authors	NNS	O	O
used	VBD	O	O
mood	NN	O	O
inventories	NNS	O	O
and	CC	O	O
psychomotor	NN	O	O
tests	NNS	O	O
to	TO	O	O
characterize	VB	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
remifentanil	NN	i	IPM
in	IN	O	O
healthy	JJ	p	O
,	,	p	O
non-drug-abusing	JJ	p	PC
volunteers	NNS	p	O
.	.	p	O

Alfentanil	NNP	O	O
was	VBD	O	O
used	VBN	O	O
as	IN	O	O
a	DT	O	O
comparator	NN	O	O
drug	NN	O	O
.	.	O	O

METHODS	NNP	O	O
Ten	NNP	p	O
healthy	JJ	p	O
volunteers	NNS	p	O
were	VBD	O	O
enrolled	VBN	O	O
in	IN	O	O
a	DT	O	O
randomized	JJ	O	O
,	,	O	O
double-blinded	JJ	O	O
,	,	O	O
placebo-controlled	JJ	i	IC
,	,	O	O
crossover	JJ	O	O
trial	NN	O	O
in	IN	O	O
which	WDT	O	O
they	PRP	O	O
received	VBD	O	O
an	DT	O	O
infusion	NN	O	O
of	IN	O	O
saline	NN	i	IPM
,	,	i	O
remifentanil	NN	i	IPM
,	,	i	O
or	CC	i	O
alfentanil	NN	i	IPM
for	IN	i	O
120	CD	i	O
min	NN	i	O
.	.	i	O

The	DT	O	O
age-	JJ	i	O
and	CC	i	O
weight-adjusted	JJ	i	O
infusions	NNS	i	O
(	(	i	O
determined	VBN	i	O
with	IN	i	O
STANPUMP	NNP	i	IPM
,	,	i	O
a	DT	i	O
computer	NN	i	IPM
modeling	VBG	i	IPM
software	NN	i	IPM
package	NN	i	IPM
)	)	i	O
were	VBD	O	O
given	VBN	O	O
to	TO	O	O
achieve	VB	O	O
three	CD	O	O
predicted	VBN	O	O
constant	JJ	O	O
plasma	NN	O	O
levels	NNS	O	O
for	IN	O	O
40	CD	i	O
min	NNS	i	O
each	DT	i	O
of	IN	i	O
remifentanil	NN	i	IPM
(	(	i	O
0.75	CD	i	O
,	,	i	O
1.5	CD	i	O
,	,	i	O
and	CC	i	O
3	CD	i	O
ng/ml	NN	i	O
)	)	i	O
and	CC	i	O
alfentanil	NN	i	O
(	(	i	O
16	CD	i	O
,	,	i	O
32	CD	i	O
,	,	i	O
and	CC	i	O
64	CD	i	O
ng/ml	NN	i	O
)	)	i	O
.	.	i	O

Mood	NN	O	O
forms	NNS	O	O
and	CC	O	O
psychomotor	NN	O	O
tests	NNS	O	O
were	VBD	O	O
completed	VBN	O	O
,	,	O	O
and	CC	O	O
miosis	NN	O	O
was	VBD	O	O
assessed	VBN	O	O
,	,	O	O
during	IN	O	O
and	CC	O	O
after	IN	O	O
the	DT	O	O
infusions	NNS	O	O
.	.	O	O

In	IN	O	O
addition	NN	O	O
,	,	O	O
analgesia	NN	O	O
was	VBD	O	O
tested	VBN	O	O
at	IN	O	O
each	DT	O	O
dose	JJ	O	O
level	NN	O	O
using	VBG	O	O
a	DT	O	O
cold-pressor	JJ	O	O
test	NN	O	O
.	.	O	O

RESULTS	NNP	O	O
Remifentanil	NNP	i	IPM
had	VBD	O	O
prototypic	VBN	o	OME
micro-like	JJ	o	OME
opioid	JJ	o	OME
subjective	JJ	o	OME
effects	NNS	o	OME
,	,	o	OME
impaired	JJ	o	OME
psychomotor	NN	o	OME
performance	NN	o	OME
,	,	o	OME
and	CC	o	OME
produced	VBD	o	OME
analgesia	NN	o	OME
.	.	o	O

Alfentanil	NNP	O	O
at	IN	O	O
the	DT	O	O
dose	JJ	O	O
range	NN	O	O
tested	VBD	O	O
had	VBD	O	O
more	RBR	O	O
mild	JJ	O	O
effects	NNS	O	O
on	IN	O	O
these	DT	O	O
measures	NNS	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
analgesia	NN	o	OPH
data	NNS	O	O
indicated	VBD	O	O
that	IN	O	O
a	DT	O	O
40:1	CD	O	O
potency	NN	O	O
ratio	NN	O	O
,	,	O	O
rather	RB	O	O
than	IN	O	O
the	DT	O	O
20:1	CD	O	O
ratio	NN	O	O
we	PRP	O	O
used	VBD	O	O
,	,	O	O
may	MD	O	O
exist	VB	O	O
between	IN	O	O
remifentanil	NN	O	O
and	CC	O	O
alfentanil	NN	O	O
.	.	O	O

A	DT	O	O
psychomotor	NN	O	O
test	NN	O	O
administered	VBD	O	O
60	CD	O	O
min	NN	O	O
after	IN	O	O
the	DT	O	O
remifentanil	NN	O	O
infusion	NN	O	O
was	VBD	O	O
discontinued	VBN	O	O
showed	VBD	O	O
that	IN	O	O
the	DT	O	O
volunteers	NNS	O	O
were	VBD	O	O
still	RB	O	O
impaired	VBN	O	O
,	,	O	O
although	IN	O	O
they	PRP	O	O
reported	VBD	O	O
feeling	VBG	O	O
no	DT	O	O
drug	NN	O	O
effects	NNS	O	O
.	.	O	O

CONCLUSIONS	VB	O	O
The	DT	O	O
notion	NN	O	O
that	IN	O	O
the	DT	O	O
pharmacodynamic	JJ	o	OME
effects	NNS	o	OME
of	IN	O	O
remifentanil	NN	i	IPM
are	VBP	O	O
extremely	RB	O	O
short-lived	JJ	O	O
after	IN	O	O
the	DT	O	O
drug	NN	O	O
is	VBZ	O	O
no	DT	O	O
longer	RB	O	O
administered	VBN	O	O
must	MD	O	O
be	VB	O	O
questioned	VBN	O	O
given	VBN	O	O
our	PRP$	O	O
findings	NNS	O	O
that	IN	O	O
psychomotor	NN	o	OME
effects	NNS	o	OME
were	VBD	O	O
still	RB	O	O
apparent	JJ	O	O
1	CD	O	O
h	NN	O	O
after	IN	O	O
the	DT	O	O
infusion	NN	O	O
was	VBD	O	O
discontinued	VBN	O	O
.	.	O	O

Dexamethasone	NNP	i	IPM
effectively	RB	O	O
reduces	VBZ	O	O
postoperative	JJ	O	O
nausea	NN	O	O
and	CC	O	O
vomiting	NN	O	O
in	IN	O	O
a	DT	O	O
general	JJ	p	O
surgical	JJ	p	O
adult	NN	p	O
patient	JJ	p	O
population	NN	p	O
.	.	p	O

BACKGROUND	NNP	O	O
Postoperative	NNP	O	O
nausea	NN	O	O
and	CC	O	O
vomiting	NN	O	O
(	(	O	O
PONV	NNP	O	O
)	)	O	O
is	VBZ	O	O
still	RB	O	O
a	DT	O	O
common	JJ	O	O
and	CC	O	O
major	JJ	O	O
complication	NN	O	O
for	IN	O	O
surgical	JJ	p	O
patients	NNS	p	O
,	,	O	O
which	WDT	O	O
may	MD	O	O
delay	VB	O	O
post-anesthetic	JJ	O	O
care	NN	O	O
unit	NN	O	O
discharge	NN	O	O
,	,	O	O
prolong	JJ	O	O
hospital	NN	O	O
stay	NN	O	O
and	CC	O	O
thus	RB	O	O
increase	VB	O	O
the	DT	O	O
cost	NN	O	O
of	IN	O	O
hospitalization	NN	O	O
.	.	O	O

It	PRP	O	O
is	VBZ	O	O
understood	JJ	O	O
that	IN	O	O
PONV	NNP	O	O
is	VBZ	O	O
a	DT	O	O
multi-factorial	JJ	O	O
outcome	NN	O	O
and	CC	O	O
occurs	VBZ	O	O
more	RBR	O	O
often	RB	O	O
with	IN	O	O
general	JJ	O	O
anesthesia	NN	O	O
than	IN	O	O
with	IN	O	O
other	JJ	O	O
anesthetic	JJ	O	O
methods	NNS	O	O
.	.	O	O

Prophylactic	JJ	O	O
administration	NN	O	O
of	IN	O	O
antihistamines	NNS	O	O
,	,	O	O
antidopaminergics	NNS	O	O
,	,	O	O
anticholinergics	NNS	O	O
,	,	O	O
phenothiazines	NNS	O	O
,	,	O	O
serotonin	JJ	O	O
antagonist	NN	O	O
,	,	O	O
steroids	NNS	O	O
and	CC	O	O
even	RB	O	O
acupuncture	NN	O	O
has	VBZ	O	O
been	VBN	O	O
shown	VBN	O	O
to	TO	O	O
be	VB	O	O
effective	JJ	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
expenses	NNS	O	O
and	CC	O	O
side	JJ	O	O
effects	NNS	O	O
of	IN	O	O
these	DT	O	O
agents	NNS	O	O
have	VBP	O	O
also	RB	O	O
been	VBN	O	O
a	DT	O	O
concern	NN	O	O
for	IN	O	O
clinical	JJ	O	O
doctors	NNS	O	O
.	.	O	O

The	DT	O	O
aim	NN	O	O
for	IN	O	O
this	DT	O	O
prospective	JJ	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
find	VB	O	O
an	DT	O	O
agent	NN	O	O
that	WDT	O	O
is	VBZ	O	O
cost	RBS	O	O
effective	JJ	O	O
and	CC	O	O
side	JJ	O	O
effect	NN	O	O
free	JJ	O	O
(	(	O	O
or	CC	O	O
at	IN	O	O
least	JJS	O	O
with	IN	O	O
a	DT	O	O
low	JJ	O	O
incidence	NN	O	O
of	IN	O	O
side	JJ	O	O
effects	NNS	O	O
)	)	O	O
for	IN	O	O
the	DT	O	O
prevention	NN	O	O
of	IN	O	O
PONV	NNP	O	O
.	.	O	O

METHODS	NNP	O	O
A	NNP	p	O
total	NN	p	O
of	IN	p	O
700	CD	p	O
adult	NN	p	O
surgical	JJ	p	O
patients	NNS	p	O
who	WP	p	O
planned	VBD	p	O
to	TO	p	O
have	VB	p	O
surgery	NN	p	O
under	IN	p	O
general	JJ	p	O
anesthesia	NN	p	O
were	VBD	O	O
enrolled	VBN	O	O
in	IN	O	O
this	DT	O	O
double-blinded	JJ	O	O
,	,	O	O
randomized	JJ	O	O
and	CC	O	O
placebo-controlled	JJ	i	IPM
study	NN	O	O
.	.	O	O

Group	NNP	O	O
P	NNP	O	O
received	VBD	O	O
the	DT	O	O
placebo	NN	i	IC
(	(	O	O
0.9	CD	O	O
%	NN	O	O
normal	JJ	i	IC
saline	JJ	i	IC
2	CD	O	O
ml	NN	O	O
)	)	O	O
and	CC	O	O
Group	NNP	O	O
D	NNP	O	O
received	VBD	O	O
10	CD	O	O
mg	NNS	O	O
dexamethasone	RB	i	IPM
intravenously	RB	O	O
right	JJ	O	O
before	IN	O	O
the	DT	O	O
induction	NN	O	O
of	IN	O	O
anesthesia	NN	O	O
.	.	O	O

RESULTS	NNP	O	O
We	PRP	O	O
found	VBD	O	O
that	IN	O	O
during	IN	O	O
the	DT	O	O
postoperative	JJ	O	O
period	NN	O	O
of	IN	O	O
1-8	JJ	O	O
h	NN	O	O
,	,	O	O
patients	NNS	O	O
in	IN	O	O
Group	NNP	O	O
D	NNP	O	O
reported	VBD	O	O
a	DT	O	O
lower	JJR	O	O
incidence	NN	O	O
of	IN	O	O
PONV	NNP	o	OPH
(	(	O	O
24	CD	O	O
%	NN	O	O
)	)	O	O
than	IN	O	O
those	DT	O	O
in	IN	O	O
Group	NNP	O	O
P	NNP	O	O
(	(	O	O
39	CD	O	O
%	NN	O	O
,	,	O	O
p	NN	O	O
<	NNP	O	O
0.001	CD	O	O
)	)	O	O
.	.	O	O

Patients	NNS	O	O
in	IN	O	O
Group	NNP	O	O
D	NNP	O	O
also	RB	O	O
requested	VBD	O	O
less	JJR	O	O
rescue	JJ	O	O
anti-emetic	JJ	O	O
(	(	O	O
17	CD	O	O
%	NN	O	O
)	)	O	O
than	IN	O	O
those	DT	O	O
in	IN	O	O
Group	NNP	O	O
P	NNP	O	O
(	(	O	O
30	CD	O	O
%	NN	O	O
,	,	O	O
p	NN	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
same	JJ	O	O
phenomenon	NN	O	O
was	VBD	O	O
also	RB	O	O
noted	VBN	O	O
in	IN	O	O
the	DT	O	O
8-to-24-hour	JJ	O	O
interval	NN	O	O
(	(	O	O
PONV	NNP	O	O
4	CD	O	O
%	NN	O	O
vs.	FW	O	O
12	CD	O	O
%	NN	O	O
,	,	O	O
p	NN	O	O
<	VBD	O	O
0.05	CD	O	O
and	CC	O	O
rescue	VB	O	O
anti-emetic	JJ	O	O
3	CD	O	O
%	NN	O	O
vs.	FW	O	O
9	CD	O	O
%	NN	O	O
,	,	O	O
p	NN	O	O
<	VBD	O	O
0.05	CD	O	O
in	IN	O	O
Group	NNP	O	O
D	NNP	O	O
vs.	FW	O	O
Group	NNP	O	O
P	NNP	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

)	)	O	O
CONCLUSIONS	IN	O	O
We	PRP	O	O
conclude	VBP	O	O
that	IN	O	O
the	DT	O	O
prophylactic	JJ	O	O
intravenous	JJ	O	O
administration	NN	O	O
of	IN	O	O
10	CD	O	O
mg	NNS	O	O
dexamethasone	VBP	O	O
immediately	RB	O	O
before	IN	O	O
the	DT	O	O
induction	NN	O	O
of	IN	O	O
anesthesia	NN	O	O
is	VBZ	O	O
effective	JJ	O	O
in	IN	O	O
preventing	VBG	O	O
PONV	NNP	O	O
in	IN	O	O
the	DT	O	O
general	JJ	p	O
surgical	JJ	p	O
adult	NN	p	O
patient	JJ	p	O
population	NN	p	O
.	.	p	O

Family	RB	i	IE
economic	JJ	i	IE
empowerment	NN	i	IE
and	CC	O	O
mental	JJ	O	O
health	NN	O	O
among	IN	O	O
AIDS-affected	JJ	p	O
children	NNS	p	O
living	VBG	p	O
in	IN	p	O
AIDS-impacted	JJ	p	O
communities	NNS	p	O
:	:	p	O
evidence	NN	O	O
from	IN	O	O
a	DT	O	O
randomised	JJ	O	O
evaluation	NN	O	O
in	IN	O	O
southwestern	JJ	p	O
Uganda	NNP	p	O
.	.	p	O

OBJECTIVE	CC	O	O
The	DT	O	O
authors	NNS	O	O
examine	VBP	O	O
whether	IN	O	O
an	DT	O	O
innovative	JJ	O	O
family	NN	i	IE
economic	JJ	i	IE
empowerment	NN	i	IE
intervention	NN	O	O
addresses	VBZ	O	O
mental	JJ	O	O
health	NN	O	O
functioning	NN	O	O
of	IN	O	O
AIDS-affected	JJ	p	O
children	NNS	p	O
in	IN	p	O
communities	NNS	p	O
heavily	RB	p	O
impacted	VBN	p	O
by	IN	p	O
HIV/AIDS	NNP	p	O
in	IN	p	O
Uganda	NNP	p	O
.	.	p	O

METHODS	NNP	O	O
A	NNP	O	O
cluster	NN	O	O
randomised	VBD	O	O
controlled	VBN	O	O
trial	NN	O	O
consisting	VBG	O	O
of	IN	O	O
two	CD	O	O
study	NN	O	O
arms	NNS	O	O
,	,	O	O
a	DT	p	O
treatment	NN	i	O
condition	NN	i	O
(	(	p	O
n=179	JJ	p	O
)	)	p	O
and	CC	p	O
a	DT	p	O
control	NN	i	IC
condition	NN	i	IC
(	(	p	O
n=118	JJ	p	O
)	)	p	O
,	,	O	O
was	VBD	O	O
used	VBN	O	O
to	TO	O	O
examine	VB	O	O
the	DT	O	O
impact	NN	O	O
of	IN	O	O
the	DT	O	O
family	NN	i	IE
economic	JJ	i	IE
empowerment	NN	i	IE
intervention	NN	i	IE
on	IN	O	O
children	NNS	O	O
's	POS	O	O
levels	NNS	O	O
of	IN	O	O
hopelessness	NN	O	O
and	CC	O	O
depression	NN	O	O
.	.	O	O

The	DT	O	O
intervention	NN	O	O
comprised	VBD	O	O
matched	JJ	i	IE
children	NNS	i	IE
savings	NNS	i	IE
accounts	NNS	i	IE
,	,	i	IE
financial	JJ	i	IE
management	NN	i	IE
workshops	NNS	i	IE
and	CC	i	IE
mentorship	NN	i	IE
.	.	i	IE

Data	NNS	O	O
were	VBD	O	O
collected	VBN	O	O
at	IN	O	O
baseline	NN	O	O
and	CC	O	O
12	CD	O	O
months	NNS	O	O
post-intervention	NN	O	O
.	.	O	O

RESULTS	NNP	O	O
Using	VBG	O	O
multivariate	JJ	O	O
analysis	NN	O	O
with	IN	O	O
several	JJ	O	O
socioeconomic	JJ	O	O
controls	NNS	O	O
,	,	O	O
the	DT	O	O
authors	NNS	O	O
find	VBP	O	O
that	IN	O	O
children	NNS	O	O
in	IN	O	O
the	DT	O	O
treatment	NN	O	O
condition	NN	O	O
(	(	O	O
receiving	VBG	O	O
the	DT	O	O
intervention	NN	O	O
)	)	O	O
report	NN	O	O
significant	JJ	O	O
improvement	NN	O	O
in	IN	O	O
their	PRP$	O	O
mental	JJ	o	OME
health	NN	o	OME
functioning	NN	o	OME
.	.	o	OME

Specifically	RB	O	O
,	,	O	O
the	DT	O	O
intervention	NN	O	O
reduces	VBZ	O	O
hopelessness	NN	o	OME
and	CC	o	OME
depression	NN	o	OME
levels	NNS	o	OME
.	.	o	OME

On	IN	O	O
the	DT	O	O
other	JJ	O	O
hand	NN	O	O
,	,	O	O
children	NNS	O	O
in	IN	O	O
the	DT	O	O
control	NN	i	O
condition	NN	O	O
(	(	O	O
not	RB	O	O
receiving	VBG	O	O
the	DT	O	O
intervention	NN	O	O
)	)	O	O
report	NN	O	O
no	DT	O	O
changes	NNS	O	O
on	IN	O	O
both	DT	O	O
measures	NNS	O	O
.	.	O	O

CONCLUSIONS	VB	O	O
The	DT	O	O
findings	NNS	O	O
indicate	VBP	O	O
that	IN	O	O
children	NNS	p	O
with	IN	p	O
poor	JJ	p	O
mental	JJ	p	O
health	NN	p	O
functioning	VBG	p	O
living	NN	p	O
in	IN	p	O
communities	NNS	p	O
affected	VBN	p	O
by	IN	p	O
HIV/AIDS	NNP	p	O
may	MD	O	O
benefit	VB	O	O
from	IN	O	O
innovative	JJ	O	O
family	NN	O	O
economic	JJ	O	O
empowerment	NN	O	O
interventions	NNS	O	O
.	.	O	O

As	IN	O	O
measures	NNS	O	O
of	IN	O	O
mental	JJ	O	O
health	NN	O	O
functioning	NN	O	O
,	,	O	O
both	DT	O	O
hopelessness	NN	o	OME
and	CC	o	OME
depression	NN	o	OME
have	VBP	O	O
long-term	JJ	O	O
negative	JJ	O	O
psychosocial	NN	O	O
and	CC	O	O
developmental	JJ	O	O
impacts	NNS	O	O
on	IN	O	O
children	NNS	O	O
.	.	O	O

These	DT	O	O
findings	NNS	O	O
have	VBP	O	O
implications	NNS	O	O
for	IN	O	O
public	JJ	O	O
health	NN	O	O
programmes	NNS	O	O
intended	VBN	O	O
for	IN	O	O
long-term	JJ	O	O
care	NN	O	O
and	CC	O	O
support	NN	O	O
of	IN	O	O
children	NNS	p	O
living	VBG	p	O
in	IN	p	O
resource	JJ	p	O
poor	JJ	p	O
AIDS-impacted	JJ	p	O
communities	NNS	p	O
.	.	p	O

Effect	NN	O	O
of	IN	O	O
prophylactic	JJ	i	IPM
amiodarone	NN	i	IPM
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
rheumatic	JJ	p	O
valve	NNS	p	O
disease	NN	p	O
undergoing	VBG	p	O
valve	JJ	p	O
replacement	NN	p	O
surgery	NN	p	O
.	.	p	O

The	DT	O	O
study	NN	O	O
was	VBD	O	O
carried	VBN	O	O
out	IN	O	O
to	TO	O	O
evaluate	VB	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
prophylactic	JJ	O	O
single-dose	JJ	O	O
intravenous	JJ	O	O
amiodarone	NN	i	IPM
in	IN	O	O
patients	NNS	p	O
undergoing	VBG	p	O
valve	JJ	p	O
replacement	NN	p	O
surgery	NN	p	O
.	.	p	O

Maintenance	NN	O	O
of	IN	O	O
sinus	NN	O	O
rhythm	NN	O	O
is	VBZ	O	O
better	JJR	O	O
than	IN	O	O
maintenance	NN	O	O
of	IN	O	O
fixed	JJ	O	O
ventricular	JJ	O	O
rate	NN	O	O
in	IN	O	O
atrial	JJ	O	O
fibrillation	NN	O	O
(	(	O	O
AF	NNP	O	O
)	)	O	O
especially	RB	O	O
in	IN	O	O
the	DT	O	O
presence	NN	O	O
of	IN	O	O
irritable	JJ	O	O
left	NN	O	O
or	CC	O	O
right	JJ	O	O
atrium	NN	O	O
because	IN	O	O
of	IN	O	O
enlargement	NN	O	O
.	.	O	O

Fifty-six	JJ	p	O
patients	NNS	p	O
with	IN	p	O
valvular	JJ	p	O
heart	NN	p	O
disease	NN	p	O
with	IN	p	O
or	CC	p	O
without	IN	p	O
AF	NNP	p	O
were	VBD	p	O
randomly	RB	p	O
divided	VBN	p	O
into	IN	O	O
two	CD	O	O
groups	NNS	O	O
.	.	O	O

Group	NNP	O	O
I	PRP	O	O
or	CC	O	O
the	DT	O	O
amiodarone	NN	i	IPM
group	NN	i	IPM
(	(	O	O
n=28	NN	O	O
)	)	O	O
received	VBD	O	O
amiodarone	NN	i	IPM
(	(	O	O
3	CD	O	O
mg/kg	NN	O	O
in	IN	O	O
100	CD	O	O
ml	NNS	O	O
normal	JJ	O	O
saline	NN	O	O
)	)	O	O
and	CC	O	O
group	NN	O	O
II	NNP	O	O
or	CC	O	O
the	DT	O	O
control	NN	i	O
group	NN	O	O
received	VBD	O	O
same	JJ	O	O
volume	NN	O	O
of	IN	O	O
normal	JJ	i	IPM
saline	NN	i	IPM
.	.	i	O

The	DT	O	O
standardized	JJ	O	O
protocol	NN	O	O
for	IN	O	O
cardiopulmonary	JJ	O	O
bypass	NN	O	O
was	VBD	O	O
maintained	VBN	O	O
for	IN	O	O
all	PDT	O	O
the	DT	O	O
patients	NNS	O	O
.	.	O	O

AF	NNP	o	OPH
occurred	VBD	O	O
in	IN	O	O
7.14	CD	O	O
%	NN	O	O
patients	NNS	O	O
in	IN	O	O
group	NN	O	O
I	PRP	O	O
,	,	O	O
and	CC	O	O
in	IN	O	O
group	NN	O	O
II	NNP	O	O
,	,	O	O
28.57	CD	O	O
%	NN	O	O
(	(	O	O
P=0.035	NNP	O	O
)	)	O	O
;	:	O	O
ventricular	JJ	o	OPH
tachycardia/fibrillation	NN	o	OPH
was	VBD	O	O
observed	VBN	O	O
in	IN	O	O
21.43	CD	O	O
%	NN	O	O
patients	NNS	O	O
in	IN	O	O
group	NN	O	O
I	PRP	O	O
and	CC	O	O
46.43	CD	O	O
%	NN	O	O
patients	NNS	O	O
in	IN	O	O
group	NN	O	O
II	NNP	O	O
(	(	O	O
P=0.089	NNP	O	O
)	)	O	O
after	IN	O	O
release	NN	O	O
of	IN	O	O
aortic	JJ	O	O
clamp	NN	O	O
.	.	O	O

Most	JJS	O	O
of	IN	O	O
the	DT	O	O
patients	NNS	O	O
in	IN	O	O
group	NN	O	O
I	PRP	O	O
(	(	O	O
92.86	CD	O	O
%	NN	O	O
)	)	O	O
maintained	VBD	O	O
sinus	JJ	o	OPH
rhythm	NN	o	OPH
without	IN	o	OPH
cardioversion	NN	o	OPH
or	CC	o	OPH
defibrillation	NN	o	OPH
after	IN	O	O
release	NN	O	O
of	IN	O	O
aortic	JJ	O	O
cross	NN	O	O
clamp	NN	O	O
(	(	O	O
P=0.002	NNP	O	O
)	)	O	O
.	.	O	O

Defibrillation	NN	o	OPH
or	CC	o	OPH
cardio	NN	o	OPH
version	NN	o	OPH
was	VBD	O	O
needed	VBN	O	O
in	IN	O	O
7.14	CD	O	O
%	NN	O	O
patients	NNS	O	O
in	IN	O	O
group	NN	O	O
I	PRP	O	O
and	CC	O	O
28.57	CD	O	O
%	NN	O	O
patients	NNS	O	O
in	IN	O	O
group	NN	O	O
II	NNP	O	O
(	(	O	O
P=0.078	NNP	O	O
)	)	O	O
.	.	O	O

A	DT	O	O
single	JJ	O	O
prophylactic	JJ	O	O
intraoperative	NN	O	O
dose	NN	O	O
of	IN	O	O
intravenous	JJ	O	O
amiodarone	NN	i	IPM
decreased	VBD	O	O
post	NN	o	OPH
bypass	NN	o	OPH
arrhythmia	NN	o	OPH
in	IN	O	O
this	DT	O	O
study	NN	O	O
in	IN	O	O
comparison	NN	O	O
to	TO	O	O
the	DT	O	O
control	NN	O	O
group	NN	O	O
.	.	O	O

Single	NNP	O	O
dose	NN	O	O
of	IN	O	O
intraoperative	JJ	O	O
amiodarone	NN	i	IPM
may	MD	O	O
be	VB	O	O
used	VBN	O	O
to	TO	O	O
decrease	VB	O	O
postoperative	JJ	O	O
arrhythmia	NN	O	O
in	IN	O	O
open	JJ	O	O
heart	NN	O	O
surgery	NN	O	O
.	.	O	O

Comparison	NNP	O	O
of	IN	O	O
quality	NN	o	OOt
of	IN	o	OOt
life	NN	o	OOt
,	,	o	O
work	NN	o	OOt
productivity	NN	o	OOt
and	CC	O	O
medical	JJ	o	OOt
resource	NN	o	OOt
utilization	NN	o	OOt
of	IN	O	O
peginterferon	NN	i	IPM
alpha	NN	i	IPM
2a	CD	i	IPM
vs	IN	O	O
the	DT	O	O
combination	NN	O	O
of	IN	O	O
interferon	NN	i	IPM
alpha	NN	i	IPM
2b	CD	i	IPM
plus	CC	i	IPM
ribavirin	VB	i	IPM
as	IN	O	O
initial	JJ	O	O
treatment	NN	O	O
in	IN	O	O
patients	NNS	O	O
with	IN	O	O
chronic	JJ	O	O
hepatitis	NN	O	O
C.	NNP	O	O
The	DT	O	O
on-treatment	JJ	O	O
impact	NN	O	O
of	IN	O	O
interferon-based	JJ	O	O
therapies	NNS	O	O
on	IN	O	O
quality	NN	o	OOt
of	IN	o	OOt
life	NN	o	OOt
(	(	o	OOt
QOL	NNP	o	OOt
)	)	o	OOt
,	,	o	O
work	NN	o	OOt
productivity	NN	o	OOt
,	,	o	O
and	CC	o	O
medical	JJ	o	OOt
resource	NN	o	OOt
utilization	NN	o	OOt
has	VBZ	O	O
not	RB	O	O
been	VBN	O	O
systematically	RB	O	O
studied	VBN	O	O
.	.	O	O

We	PRP	O	O
evaluated	VBD	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
treatment	NN	O	O
with	IN	O	O
peginterferon	NN	i	IPM
alpha	NN	i	IPM
(	(	i	IPM
pegIFNalpha	NN	i	IPM
)	)	i	IPM
2a	CD	i	O
monotherapy	NN	i	IPH
and	CC	O	O
the	DT	O	O
combination	NN	i	IPM
of	IN	i	IPM
interferon	NN	i	IPM
alpha	NN	i	IPM
(	(	i	IPM
IFNalpha	NNP	i	IPM
)	)	i	IPM
2b	CD	i	IPM
plus	CC	i	IPM
ribavirin	NN	i	IPM
(	(	i	IPM
RBV	NNP	i	IPM
)	)	i	IPM
on	IN	O	O
health-related	JJ	o	OPH
QOL	NNP	o	OPH
,	,	o	O
work	NN	o	OOt
productivity	NN	o	OOt
and	CC	o	O
resource	NN	o	OOt
utilization	NN	o	OOt
.	.	o	O

A	DT	O	O
total	NN	O	O
of	IN	O	O
412	CD	p	PSS
patients	NNS	p	O
with	IN	p	O
hepatitis	NN	p	PC
C	NNP	p	PC
infection	NN	p	PC
were	VBD	O	O
randomized	VBN	O	O
to	TO	O	O
open-label	JJ	i	IPM
treatment	NN	i	IPM
with	IN	i	IPM
either	DT	i	IPM
pegIFNalpha	NN	i	IPM
2a	CD	i	IPM
(	(	i	IPM
n	JJ	i	IPM
=	NNP	i	IPM
206	CD	i	IPM
)	)	i	IPM
or	CC	i	O
IFNalpha	$	i	IPM
2b/RBV	CD	i	IPM
(	(	i	IPM
n	JJ	i	IPM
=	NNP	i	IPM
206	CD	i	IPM
)	)	i	IPM
.	.	i	O

PegIFNalpha	$	i	IPM
2a	CD	i	IPM
was	VBD	O	O
administered	VBN	O	O
subcutaneously	RB	O	O
at	IN	O	O
a	DT	O	O
dose	NN	O	O
of	IN	O	O
180	CD	O	O
microg	NN	O	O
once	RB	O	O
weekly	JJ	O	O
for	IN	O	O
48	CD	O	O
weeks	NNS	O	O
;	:	O	O
and	CC	O	O
IFNalpha	$	i	IPM
2b/RBV	CD	i	IPM
at	IN	O	O
doses	NNS	O	O
of	IN	O	O
3	CD	O	O
MU	NNP	O	O
thrice	JJ	O	O
weekly	RB	O	O
subcutaneously	RB	O	O
and	CC	O	O
1000-1200	JJ	O	O
mg/day	NN	O	O
orally	RB	O	O
.	.	O	O

Outcome	NNP	O	O
measures	NNS	O	O
included	VBD	O	O
the	DT	O	O
SF-36	NNP	o	OPH
Health	NNP	o	OPH
Survey	NNP	o	OPH
Questionnaire	NNP	o	OPH
and	CC	o	OPH
additional	JJ	o	OPH
generic	NN	o	OPH
and	CC	o	OPH
specific	JJ	o	OPH
scales	NNS	o	OPH
.	.	o	O

During	IN	O	O
treatment	NN	O	O
,	,	O	O
for	IN	O	O
all	DT	O	O
SF-36	NNP	O	O
summary	NN	O	O
and	CC	O	O
Hepatitis	NNP	o	OOt
Quality	NNP	o	OOt
of	IN	o	OOt
Life	NNP	o	OOt
Questionnaire	NNP	o	OOt
(	(	o	OOt
HQLQ	NNP	o	OOt
)	)	o	OOt
-specific	NN	o	OOt
scales	NNS	o	OOt
,	,	O	O
the	DT	O	O
pegIFNalpha	NN	i	IPM
2a	CD	i	IPM
group	NN	O	O
experienced	VBD	O	O
less	JJR	O	O
impairment	JJ	O	O
than	IN	O	O
did	VBD	O	O
the	DT	O	O
IFNalpha	NNP	i	IPM
2b/RBV	CD	i	IPM
patients	NNS	O	O
.	.	O	O

The	DT	O	O
between-treatment	JJ	O	O
differences	NNS	O	O
were	VBD	O	O
significant	JJ	O	O
for	IN	O	O
many	JJ	O	O
of	IN	O	O
the	DT	O	O
scores	NNS	O	O
particularly	RB	O	O
in	IN	O	O
the	DT	O	O
first	JJ	O	O
24	CD	O	O
weeks	NNS	O	O
of	IN	O	O
treatment	NN	O	O
.	.	O	O

Across	IN	O	O
all	DT	O	O
measures	NNS	O	O
of	IN	O	O
work	NN	O	O
functioning	NN	O	O
and	CC	O	O
productivity	NN	O	O
at	IN	O	O
each	DT	O	O
visit	NN	O	O
,	,	O	O
patients	NNS	O	O
randomized	VBD	O	O
to	TO	O	O
pegIFNalpha	VB	i	IPM
2a	CD	i	IPM
treatment	NN	O	O
showed	VBD	O	O
less	RBR	O	O
impairment	JJ	o	O
relative	NN	O	O
to	TO	O	O
the	DT	O	O
group	NN	O	O
treated	VBD	O	O
with	IN	O	O
IFNalpha	NNP	i	IPM
2b/RBV	CD	i	IPM
.	.	i	O

Hence	NNP	O	O
treatment	NN	O	O
with	IN	O	O
pegIFNalpha	JJ	i	IPM
2a	CD	i	IPM
relative	JJ	O	O
to	TO	O	O
IFNalpha	NNP	i	IPM
2b/RBV	CD	i	IPM
minimizes	VBZ	O	O
the	DT	O	O
adverse	JJ	O	O
impact	NN	O	O
of	IN	O	O
therapy	NN	O	O
on	IN	O	O
health-related	JJ	o	OOt
QOL	NNP	o	OOt
.	.	o	O

Patients	NNS	O	O
randomized	VBD	O	O
to	TO	O	O
pegIFNalpha	VB	i	IPM
2a	CD	i	IPM
had	VBD	O	O
improved	VBN	O	O
work	NN	o	OOt
productivity	NN	o	OOt
,	,	o	O
less	JJR	o	OOt
activity	NN	o	OOt
impairment	NN	o	OOt
,	,	o	O
decreased	VBD	o	OOt
need	NN	o	OOt
for	IN	o	OOt
prescription	NN	o	OOt
drugs	NNS	o	OOt
to	TO	o	OOt
treat	VB	o	OOt
adverse	JJ	o	OA
effects	NNS	o	OA
,	,	o	O
and	CC	o	O
better	JJR	o	OME
adherence	NN	o	OME
to	TO	o	OME
therapy	NN	o	OME
.	.	o	O

Anecortave	NNP	i	IPM
acetate	NN	i	IPM
treatment	NN	i	IPM
for	IN	O	O
retinal	JJ	p	O
angiomatous	JJ	p	O
proliferation	NN	p	O
:	:	p	O
a	DT	O	O
pilot	NN	O	O
study	NN	O	O
.	.	O	O

PURPOSE	VB	O	O
The	DT	O	O
purpose	NN	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
evaluate	VB	O	O
anecortave	JJ	i	IPM
acetate	JJ	i	IPM
treatment	NN	i	IPM
of	IN	O	O
retinal	JJ	p	O
angiomatous	JJ	p	O
proliferation	NN	p	O
(	(	p	O
RAP	NNP	p	O
)	)	p	O
,	,	O	O
a	DT	O	O
neovascular	JJ	O	O
form	NN	O	O
of	IN	O	O
age-related	JJ	O	O
macular	JJ	O	O
degeneration	NN	O	O
,	,	O	O
with	IN	O	O
specific	JJ	O	O
regard	NN	O	O
to	TO	O	O
inhibition	NN	o	OPH
of	IN	o	OPH
neovascularization	NN	o	OPH
and	CC	o	OPH
maintenance	NN	o	OPH
of	IN	o	OPH
vision	NN	o	OPH
.	.	o	OPH

METHODS	NNP	O	O
Thirty-four	JJ	p	O
patients	NNS	p	O
with	IN	p	O
RAP	NNP	p	O
with	IN	p	O
any	DT	p	O
stage	NN	p	O
of	IN	p	O
neovascularization	NN	p	O
were	VBD	O	O
randomized	VBN	O	O
1:1:1	CD	O	O
for	IN	O	O
treatment	NN	O	O
with	IN	O	O
three	CD	O	O
different	JJ	O	O
quantities	NNS	O	O
(	(	O	O
30	CD	O	O
mg	NN	O	O
,	,	O	O
15	CD	O	O
mg	NN	O	O
,	,	O	O
3	CD	O	O
mg	NN	O	O
)	)	O	O
of	IN	O	O
anecortave	NN	i	IPM
acetate	NN	i	IPM
sterile	JJ	i	IPM
suspension	NN	i	IPM
for	IN	i	IPM
juxtascleral	JJ	i	IPM
administration	NN	i	IPM
.	.	i	O

Best-corrected	JJ	o	OPH
visual	JJ	o	OPH
acuity	NN	o	OPH
(	(	o	OPH
Early	JJ	o	OPH
Treatment	NNP	o	OPH
Diabetic	NNP	o	OPH
Retinopathy	NNP	o	OPH
Study	NNP	o	OPH
chart	NN	o	OPH
)	)	o	OPH
,	,	o	OPH
intraocular	JJ	o	OPH
pressure	NN	o	OPH
measurement	NN	o	OPH
,	,	o	OPH
biomicroscopy	NN	o	OPH
,	,	o	OPH
funduscopy	NN	o	OPH
,	,	o	OPH
digital	JJ	o	OPH
fluorescein	NN	o	OPH
,	,	o	OPH
and	CC	o	OPH
indocyanine	NN	o	OPH
green	JJ	o	OPH
angiography	NN	o	OPH
were	VBD	O	O
recorded	VBN	O	O
at	IN	O	O
baseline	NN	O	O
and	CC	O	O
at	IN	O	O
3	CD	O	O
months	NNS	O	O
.	.	O	O

A	DT	O	O
6-month	JJ	O	O
retreatment	NN	O	O
interval	NN	O	O
was	VBD	O	O
established	VBN	O	O
for	IN	O	O
this	DT	O	O
study	NN	O	O
with	IN	O	O
a	DT	O	O
follow-up	NN	O	O
of	IN	O	O
12	CD	O	O
months	NNS	O	O
.	.	O	O

In	IN	O	O
selected	JJ	O	O
patients	NNS	O	O
optical	JJ	O	O
coherence	NN	O	O
tomography	NN	O	O
was	VBD	O	O
performed	VBN	O	O
.	.	O	O

The	DT	O	O
outcomes	NNS	O	O
were	VBD	O	O
mean	JJ	o	OPH
changes	NNS	o	OPH
in	IN	o	OPH
visual	JJ	o	OPH
acuity	NN	o	OPH
and	CC	o	OPH
lesion	NN	o	OPH
size	NN	o	OPH
at	IN	o	OPH
1	CD	o	OPH
year	NN	o	OPH
.	.	o	OPH

RESULTS	VB	O	O
The	DT	O	O
detachment	NN	o	OPH
of	IN	o	OPH
the	DT	o	OPH
neurosensory	JJ	o	OPH
retina	NN	o	OPH
and	CC	o	OPH
retinal	JJ	o	OPH
pigment	NN	o	OPH
epithelium	NN	o	OPH
improved	VBN	O	O
in	IN	O	O
all	DT	O	O
eyes	NNS	O	O
,	,	O	O
but	CC	O	O
all	DT	O	O
neovascular	JJ	o	OPH
lesions	NNS	o	OPH
increased	VBD	o	OPH
in	IN	o	OPH
size	NN	o	OPH
.	.	o	OPH

Vision	NNP	o	OPH
loss	NN	o	OPH
occurred	VBD	O	O
in	IN	O	O
the	DT	O	O
majority	NN	O	O
of	IN	O	O
study	NN	O	O
eyes	NNS	O	O
(	(	O	O
22	CD	O	O
out	IN	O	O
of	IN	O	O
34	CD	O	O
eyes	NNS	O	O
,	,	O	O
64.7	CD	O	O
%	NN	O	O
)	)	O	O
independent	JJ	O	O
of	IN	O	O
the	DT	O	O
concentration	NN	O	O
administered	VBD	O	O
.	.	O	O

CONCLUSION	NNP	O	O
The	DT	O	O
results	NNS	O	O
suggest	VBP	O	O
that	IN	O	O
a	DT	O	O
posterior	JJ	O	O
juxtascleral	JJ	O	O
injection	NN	O	O
of	IN	O	O
anecortave	JJ	i	IPM
acetate	NN	i	IPM
reduces	NNS	O	O
capillary	JJ	o	OPH
permeability	NN	o	OPH
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
RAP	NNP	p	O
.	.	p	O

However	RB	O	O
,	,	O	O
in	IN	O	O
spite	NN	O	O
of	IN	O	O
improvement	NN	O	O
of	IN	O	O
the	DT	O	O
exudation	NN	O	O
there	EX	O	O
is	VBZ	O	O
a	DT	O	O
progression	NN	O	O
of	IN	O	O
neovascularization	NN	o	OPH
and	CC	O	O
a	DT	O	O
significant	JJ	o	O
loss	NN	o	OPH
of	IN	o	OPH
vision	NN	o	OPH
in	IN	O	O
all	PDT	O	O
these	DT	O	O
patients	NNS	O	O
.	.	O	O

Like	IN	O	O
other	JJ	O	O
monotherapeutic	JJ	O	O
methods	NNS	O	O
used	VBN	O	O
to	TO	O	O
treat	VB	O	O
this	DT	O	O
variant	NN	O	O
of	IN	O	O
neovascular	JJ	O	O
age-related	JJ	O	O
macular	JJ	O	O
degeneration	NN	O	O
,	,	O	O
anecortave	VBP	i	IPM
acetate	JJ	i	IPM
alone	RB	O	O
does	VBZ	O	O
not	RB	O	O
appear	VB	O	O
to	TO	O	O
benefit	VB	O	O
these	DT	O	O
patients	NNS	O	O
.	.	O	O

Future	JJ	O	O
studies	NNS	O	O
should	MD	O	O
investigate	VB	O	O
a	DT	O	O
combination	NN	O	O
form	NN	O	O
of	IN	O	O
therapy	NN	O	O
.	.	O	O

MDM2	NNP	O	O
and	CC	O	O
Ki-67	NNP	O	O
predict	NN	O	O
for	IN	O	O
distant	JJ	o	OPH
metastasis	NN	o	OPH
and	CC	o	O
mortality	NN	o	OMO
in	IN	O	O
men	NNS	p	O
treated	VBN	p	O
with	IN	p	O
radiotherapy	NN	i	IPH
and	CC	p	O
androgen	NN	i	IPM
deprivation	NN	i	IPM
for	IN	p	O
prostate	JJ	p	O
cancer	NN	p	O
:	:	p	O
RTOG	NNP	O	O
92-02	CD	O	O
.	.	O	O

PURPOSE	NNP	O	O
MDM2	NNP	O	O
regulates	VBZ	O	O
p53	NN	O	O
,	,	O	O
which	WDT	O	O
controls	VBZ	O	O
cell	NN	O	O
cycle	NN	O	O
arrest	NN	O	O
and	CC	O	O
apoptosis	NN	O	O
.	.	O	O

Both	DT	O	O
proteins	NNS	O	O
,	,	O	O
along	IN	O	O
with	IN	O	O
Ki-67	NNP	O	O
,	,	O	O
which	WDT	O	O
is	VBZ	O	O
an	DT	O	O
established	VBN	O	O
strong	JJ	O	O
determinant	NN	O	O
of	IN	O	O
metastasis	NN	O	O
,	,	O	O
have	VBP	O	O
shown	VBN	O	O
promise	NN	O	O
in	IN	O	O
predicting	VBG	O	O
the	DT	O	O
outcome	NN	O	O
of	IN	O	O
men	NNS	O	O
treated	VBN	O	O
with	IN	O	O
radiation	NN	i	IPH
therapy	NN	i	IPH
(	(	i	IPH
RT	NNP	i	IPH
)	)	i	IPH
with	IN	i	O
or	CC	i	O
without	IN	i	O
short-term	JJ	i	IPM
androgen	NN	i	IPM
deprivation	NN	i	IPM
(	(	i	IPM
STAD	NNP	i	IPM
)	)	i	IPM
.	.	i	O

This	DT	O	O
report	NN	O	O
compares	VBZ	O	O
the	DT	O	O
utility	NN	O	O
of	IN	O	O
abnormal	JJ	O	O
expression	NN	O	O
of	IN	O	O
these	DT	O	O
biomarkers	NNS	O	O
in	IN	O	O
estimating	VBG	O	O
progression	NN	O	O
in	IN	O	O
a	DT	O	O
cohort	NN	O	O
of	IN	O	O
men	NNS	O	O
treated	VBN	O	O
on	IN	O	O
RTOG	NNP	O	O
92-02	CD	O	O
.	.	O	O

PATIENTS	NNPS	O	O
AND	CC	O	O
METHODS	NNP	O	O
Adequate	NNP	O	O
tissue	NN	O	O
for	IN	O	O
immunohistochemistry	NN	O	O
was	VBD	O	O
available	JJ	O	O
for	IN	O	O
p53	NN	O	O
,	,	O	O
Ki-67	NNP	O	O
,	,	O	O
and	CC	O	O
MDM2	NNP	O	O
analyses	NNS	O	O
in	IN	O	O
478	CD	p	O
patient	JJ	p	O
cases	NNS	p	O
.	.	p	O

The	DT	O	O
percentage	NN	O	O
of	IN	O	O
tumor	NN	o	OPH
nuclei	NN	o	OPH
staining	VBG	o	OPH
positive	JJ	o	OPH
(	(	O	O
PSP	NNP	O	O
)	)	O	O
was	VBD	O	O
quantified	VBN	O	O
manually	RB	O	O
or	CC	O	O
by	IN	O	O
image	NN	O	O
analysis	NN	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
per-sample	JJ	o	OOt
mean	JJ	o	OOt
intensity	NN	o	OOt
score	NN	o	OOt
(	(	o	OPH
MIS	NNP	o	OPH
)	)	o	OPH
was	VBD	O	O
quantified	VBN	O	O
by	IN	O	O
image	NN	O	O
analysis	NN	O	O
.	.	O	O

Cox	NNP	O	O
regression	NN	O	O
models	NNS	O	O
were	VBD	O	O
used	VBN	O	O
to	TO	O	O
estimate	VB	O	O
overall	JJ	o	OMO
mortality	NN	o	OMO
(	(	o	O
OM	NNP	o	O
)	)	o	O
,	,	O	O
and	CC	O	O
Fine	NNP	O	O
and	CC	O	O
Gray	NNP	O	O
's	POS	O	O
regressions	NNS	O	O
were	VBD	O	O
applied	VBN	O	O
to	TO	O	O
the	DT	O	O
end	NN	O	O
points	NNS	O	O
of	IN	O	O
distant	JJ	o	OPH
metastasis	NN	o	OPH
(	(	o	OPH
DM	NNP	o	OPH
)	)	o	OPH
and	CC	o	O
cause-specific	JJ	o	OMO
mortality	NN	o	OMO
(	(	o	OMO
CSM	NNP	o	OMO
)	)	o	OMO
.	.	o	O

Results	NNS	O	O
In	IN	O	O
multivariate	JJ	O	O
analyses	NNS	O	O
that	WDT	O	O
adjusted	VBD	O	O
for	IN	O	O
all	DT	O	O
markers	NNS	O	O
and	CC	O	O
treatment	NN	O	O
covariates	NNS	O	O
,	,	O	O
MDM2	NNP	o	OPH
overexpression	NN	o	OPH
was	VBD	O	O
significantly	RB	O	O
related	VBN	O	O
to	TO	O	O
DM	NNP	o	OPH
(	(	O	O
P	NNP	O	O
=	NNP	O	O
.02	NNP	O	O
)	)	O	O
and	CC	O	O
OM	NNP	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
.003	NNP	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
Ki-67	NNP	o	O
overexpression	NN	o	O
was	VBD	O	O
significantly	RB	O	O
related	VBN	O	O
to	TO	O	O
DM	NNP	o	OPH
(	(	O	O
P	NNP	O	O
<	NNP	O	O
.0001	NNP	O	O
)	)	O	O
,	,	O	O
CSM	NNP	o	OMO
(	(	O	O
P	NNP	O	O
=	NNP	O	O
.0007	NNP	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
OM	NNP	o	OMO
(	(	O	O
P	NNP	O	O
=	NNP	O	O
.01	NNP	O	O
)	)	O	O
.	.	O	O

P53	NNP	o	OPH
overexpression	NN	o	OPH
was	VBD	O	O
significantly	RB	O	O
related	VBN	O	O
to	TO	O	O
OM	NNP	o	OMO
(	(	O	O
P	NNP	O	O
=	NNP	O	O
.02	NNP	O	O
)	)	O	O
.	.	O	O

When	WRB	O	O
considered	VBN	O	O
in	IN	O	O
combination	NN	O	O
,	,	O	O
the	DT	O	O
overexpression	NN	o	OPH
of	IN	o	OPH
both	DT	o	OPH
Ki-67	NNP	o	OPH
and	CC	o	OPH
MDM2	NNP	o	OPH
at	IN	O	O
high	JJ	O	O
levels	NNS	O	O
was	VBD	O	O
associated	VBN	O	O
with	IN	O	O
significantly	RB	o	OOt
increased	VBN	o	OOt
failure	NN	o	OOt
rates	NNS	o	OOt
for	IN	O	O
all	DT	O	O
end	NN	O	O
points	NNS	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
.001	NNP	O	O
for	IN	O	O
DM	NNP	O	O
,	,	O	O
CSM	NNP	O	O
,	,	O	O
and	CC	O	O
OM	NNP	O	O
)	)	O	O
.	.	O	O

CONCLUSION	NNP	O	O
Combined	VBD	O	O
MDM2	NNP	o	OPH
and	CC	o	O
Ki-67	NNP	o	OPH
expression	NN	o	OPH
levels	NNS	o	OPH
were	VBD	O	O
independently	RB	O	O
related	VBN	O	O
to	TO	O	O
distant	JJ	o	OPH
metastasis	NN	o	OPH
and	CC	o	O
mortality	NN	o	OMO
and	CC	O	O
,	,	O	O
if	IN	O	O
validated	VBN	O	O
,	,	O	O
could	MD	O	O
be	VB	O	O
considered	VBN	O	O
for	IN	O	O
risk	NN	O	O
stratification	NN	O	O
of	IN	O	O
patients	NNS	p	O
with	IN	p	O
prostate	JJ	p	O
cancer	NN	p	O
in	IN	O	O
clinical	JJ	O	O
trials	NNS	O	O
.	.	O	O

[	RB	O	O
Long	NNP	O	O
term	NN	O	O
observation	NN	O	O
in	IN	O	O
effects	NNS	O	O
of	IN	O	O
potassium	NN	i	IPM
and	CC	i	O
calcium	NN	i	IPM
supplementation	NN	i	IPM
on	IN	O	O
arterial	JJ	o	OPH
blood	NN	o	OPH
pressure	NN	o	OPH
and	CC	o	O
sodium	NN	o	OPH
metabolism	NN	o	OPH
in	IN	O	O
adolescents	NNS	p	PC
with	IN	p	PC
higher	JJR	p	PC
blood	NN	p	PC
pressure	NN	p	PC
]	NNP	p	PC
.	.	O	O

OBJECTIVE	NNP	O	O
To	TO	O	O
investigate	VB	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
potassium	NN	i	IPM
and	CC	i	O
calcium	NN	i	IPM
supplementation	NN	i	IPM
in	IN	O	O
table	JJ	O	O
salt	NN	O	O
on	IN	O	O
reduction	NN	O	O
of	IN	O	O
arterial	JJ	o	OPH
blood	NN	o	OPH
pressure	NN	o	OPH
and	CC	o	O
sodium	NN	o	OPH
metabolism	NN	o	OPH
in	IN	O	O
adolescents	NNS	p	O
with	IN	p	O
higher	JJR	p	O
blood	NN	p	O
pressure	NN	p	O
.	.	p	O

METHODS	CC	O	O
A	DT	O	O
single	JJ	O	O
blind	NN	O	O
placebo-controlled	JJ	i	IC
trial	NN	O	O
was	VBD	O	O
carried	VBN	O	O
out	RP	O	O
for	IN	O	O
two	CD	O	O
years	NNS	O	O
in	IN	O	O
220	CD	p	O
adolescents	NNS	p	O
with	IN	p	O
higher	JJR	p	O
blood	NN	p	O
pressure	NN	p	O
,	,	p	O
aged	VBD	p	O
18	CD	p	O
-	:	p	O
22	CD	p	O
years	NNS	p	O
,	,	p	O
who	WP	p	O
were	VBD	p	O
randomly	RB	p	O
divided	VBN	p	O
into	IN	p	O
supplementary	JJ	p	O
group	NN	p	O
(	(	p	O
n	JJ	p	O
=	NNP	p	O
110	CD	p	O
)	)	p	O
and	CC	p	O
control	NN	p	O
group	NN	p	O
(	(	p	O
n	JJ	p	O
=	NNP	p	O
110	CD	p	O
)	)	p	O
.	.	p	O

Each	DT	p	O
of	IN	p	O
the	DT	p	O
subjects	NNS	p	O
in	IN	p	O
the	DT	p	O
supplementary	JJ	p	O
group	NN	p	O
and	CC	p	O
their	PRP$	p	O
family	NN	p	O
members	NNS	p	O
was	VBD	O	O
given	VBN	O	O
10	CD	i	O
mmol	NN	i	O
of	IN	i	O
potassium	NN	i	IPM
and	CC	i	O
10	CD	i	O
mmol	NN	i	O
of	IN	i	O
calcium	NN	i	IPM
mixed	VBN	i	O
in	IN	i	O
their	PRP$	i	O
table	JJ	i	O
salt	JJ	i	O
daily	RB	O	O
for	IN	O	O
24	CD	O	O
months	NNS	O	O
.	.	O	O

RESULTS	NNP	O	O
Night	NNP	o	OPH
urinary	JJ	o	OPH
sodium	NN	o	OPH
and	CC	o	O
potassium	JJ	o	OPH
excretion	NN	o	OPH
increased	VBD	O	O
(	(	O	O
urinary	JJ	O	O
Na	NNP	O	O
(	(	O	O
+	NNP	O	O
)	)	O	O
,	,	O	O
P	NNP	O	O
<	NNP	O	O
0.05	CD	O	O
;	:	O	O
urinary	JJ	O	O
K	NNP	O	O
(	(	O	O
+	NNP	O	O
)	)	O	O
,	,	O	O
P	NNP	O	O
<	NNP	O	O
0.01	CD	O	O
)	)	O	O
and	CC	O	O
blood	NN	o	OPH
pressure	NN	o	OPH
lowered	VBN	o	O
by	IN	O	O
5.3	CD	O	O
mm	NNS	O	O
Hg/1.8	NNP	O	O
mm	NN	O	O
Hg	NNP	O	O
in	IN	O	O
average	NN	O	O
from	IN	O	O
the	DT	O	O
baseline	NN	O	O
in	IN	O	O
the	DT	O	O
supplementary	JJ	O	O
group	NN	O	O
two	CD	O	O
years	NNS	O	O
after	IN	O	O
potassium	NN	i	IPM
and	CC	i	O
calcium	NN	i	IPM
supplementation	NN	i	IPM
,	,	O	O
as	IN	O	O
compared	VBN	O	O
with	IN	O	O
that	DT	O	O
in	IN	O	O
the	DT	O	O
control	NN	O	O
group	NN	O	O
increased	VBN	O	O
by	IN	O	O
(	(	O	O
1.3/1.7	CD	O	O
)	)	O	O
mm	NN	O	O
Hg	NNP	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
Adequate	NNP	O	O
supplement	NN	i	IPM
of	IN	i	IPM
potassium	NN	i	IPM
and	CC	i	O
calcium	NN	i	IPM
in	IN	O	O
daily	JJ	O	O
table	JJ	O	O
salt	NN	O	O
intake	NN	O	O
was	VBD	O	O
an	DT	O	O
effective	JJ	O	O
way	NN	O	O
to	TO	O	O
prevent	VB	O	O
form	NN	o	O
hypertension	NN	o	OPH
and	CC	O	O
could	MD	O	O
promote	VB	O	O
their	PRP$	O	O
urinary	JJ	o	OPH
sodium	NN	o	OPH
excretion	NN	o	OPH
and	CC	o	O
reduction	NN	o	OPH
of	IN	o	OPH
arterial	JJ	o	OPH
blood	NN	o	OPH
pressure	NN	o	OPH
in	IN	O	O
adolescents	NNS	p	O
with	IN	p	O
higher	JJR	p	O
blood	NN	p	O
pressure	NN	p	O
.	.	p	O

The	DT	O	O
effect	NN	O	O
of	IN	O	O
surgical	JJ	O	O
trauma	NN	O	O
and	CC	O	O
insulin	NN	i	IPM
on	IN	O	O
whole-body	NN	o	OPH
protein	NN	o	OPH
turnover	NN	o	OPH
in	IN	O	O
parenterally-fed	JJ	p	O
undernourished	JJ	p	PC
patients	NNS	p	O
.	.	p	O

Ten	CD	p	PSS
undernourished	JJ	p	PC
patients	NNS	p	O
receiving	VBG	p	O
total	JJ	p	O
parenteral	JJ	p	O
nutrition	NN	p	O
and	CC	p	O
undergoing	JJ	p	O
major	JJ	p	O
intestinal	JJ	p	O
surgery	NN	p	O
were	VBD	O	O
restarted	VBN	O	O
on	IN	O	O
intravenous	JJ	O	O
feeds	NNS	O	O
identical	JJ	O	O
to	TO	O	O
their	PRP$	O	O
pre-operative	JJ	O	O
regimens	NNS	O	O
within	IN	O	O
24	CD	O	O
h	NNS	O	O
of	IN	O	O
their	PRP$	O	O
operation	NN	O	O
.	.	O	O

Five	CD	O	O
,	,	O	O
chosen	VBN	O	O
at	IN	O	O
random	NN	O	O
,	,	O	O
received	VBD	O	O
post-operatively	RB	O	O
1-2	JJ	i	IPM
units	NNS	i	IPM
insulin/kg	VBP	i	IPM
body	NN	i	IPM
weight/24	JJ	i	IPM
h	NN	i	IPM
with	IN	i	IPM
their	PRP$	i	IPM
feed	NN	i	IPM
,	,	O	O
while	IN	O	O
the	DT	O	O
other	JJ	O	O
five	CD	O	O
received	VBD	i	IC
the	DT	i	IC
feed	NN	i	IC
only	RB	i	IC
.	.	i	O

Pre-operatively	RB	O	O
,	,	O	O
and	CC	O	O
2	CD	O	O
h	NN	O	O
after	IN	O	O
commencing	VBG	O	O
their	PRP$	O	O
post-operative	JJ	O	O
feeds	NNS	O	O
,	,	O	O
rates	NNS	o	OPH
of	IN	o	OPH
whole-body	NN	o	OPH
protein	NN	o	OPH
synthesis	NN	o	OPH
and	CC	o	OPH
breakdown	NN	o	OPH
were	VBD	O	O
measured	VBN	O	O
over	IN	O	O
a	DT	O	O
9-h	JJ	O	O
period	NN	O	O
following	VBG	O	O
intravenous	JJ	O	O
injection	NN	O	O
of	IN	O	O
a	DT	O	O
single	JJ	O	O
tracer	NN	O	O
dose	NN	O	O
of	IN	O	O
15N-glycine	JJ	i	IPM
by	IN	O	O
the	DT	O	O
ammonia	NN	O	O
and	CC	O	O
urea	JJ	O	O
end-product	NN	O	O
methods	NNS	O	O
.	.	O	O

During	IN	O	O
these	DT	O	O
9-h	CD	O	O
study	NN	O	O
periods	NNS	O	O
measurements	NNS	O	O
were	VBD	O	O
also	RB	O	O
made	VBN	O	O
of	IN	O	O
blood	NN	o	OPH
glucose	NN	o	OPH
,	,	o	O
plasma	JJ	o	OPH
insulin	NN	o	OPH
and	CC	o	OPH
glucagon	NN	o	OPH
,	,	o	O
urinary	JJ	o	OPH
ammonia	NN	o	OPH
,	,	o	O
nitrogen	NN	o	OPH
,	,	o	O
creatinine	NN	o	OPH
and	CC	o	O
3-methylhistidine	JJ	o	OPH
.	.	o	O

Blood	NNP	o	OPH
glucose	NN	o	OPH
and	CC	o	O
plasma	JJ	o	OPH
insulin	NN	o	OPH
and	CC	o	OPH
glucagon	NN	o	OPH
concentrations	NNS	o	OPH
rose	VBD	O	O
post-operatively	RB	O	O
whether	IN	O	O
or	CC	O	O
not	RB	O	O
insulin	NN	i	IPM
was	VBD	O	O
given	VBN	O	O
,	,	O	O
but	CC	O	O
the	DT	O	O
increment	NN	O	O
in	IN	O	O
insulin	NN	o	OPH
concentration	NN	o	OPH
was	VBD	O	O
significantly	RB	O	O
greater	JJR	O	O
when	WRB	O	O
insulin	NN	i	IPM
was	VBD	O	O
given	VBN	O	O
.	.	O	O

Apparent	JJ	o	OPH
nitrogen	NN	o	OPH
balance	NN	o	OPH
was	VBD	O	O
positive	JJ	O	O
pre-operatively	RB	O	O
and	CC	O	O
became	VBD	O	O
less	RBR	O	O
so	RB	O	O
post-operatively	RB	O	O
whether	IN	O	O
insulin	NN	i	IPM
was	VBD	O	O
given	VBN	O	O
or	CC	O	O
not	RB	O	O
.	.	O	O

Similarly	RB	O	O
,	,	O	O
post-operative	JJ	O	O
increments	NNS	O	O
in	IN	O	O
urinary	JJ	o	OPH
excretion	NN	o	OPH
of	IN	o	OPH
ammonia	NN	o	OPH
,	,	o	O
creatinine	NN	o	OPH
and	CC	o	OPH
3-methylhistidine	JJ	o	OPH
were	VBD	O	O
not	RB	O	O
altered	VBN	O	O
by	IN	O	O
addition	NN	O	O
of	IN	O	O
insulin	NN	i	IPM
.	.	i	O

Protein	NNP	o	OPH
turnover	NN	o	OPH
,	,	O	O
as	IN	O	O
estimated	VBN	O	O
by	IN	O	O
the	DT	O	O
ammonia	JJ	o	OPH
end-product	NN	o	OPH
method	NN	O	O
,	,	O	O
tended	VBD	O	O
to	TO	O	O
rise	VB	O	O
post-operatively	RB	O	O
,	,	O	O
but	CC	O	O
there	EX	O	O
was	VBD	O	O
no	DT	O	O
significant	JJ	O	O
difference	NN	O	O
between	IN	O	O
the	DT	O	O
increases	NNS	O	O
observed	VBD	O	O
with	IN	O	O
or	CC	O	O
without	IN	O	O
insulin	NN	i	IPM
.	.	i	O

The	DT	O	O
urea	JJ	O	O
end-product	NN	O	O
method	NN	O	O
suggested	VBD	O	O
that	IN	O	O
there	EX	O	O
was	VBD	O	O
no	DT	O	O
change	NN	O	O
in	IN	O	O
whole-body	NN	o	OPH
protein	NN	o	OPH
turnover	NN	o	OPH
after	IN	O	O
surgery	NN	O	O
,	,	O	O
whether	IN	O	O
or	CC	O	O
not	RB	O	O
insulin	NN	i	IPM
was	VBD	O	O
given	VBN	O	O
.	.	O	O

This	DT	O	O
study	NN	O	O
does	VBZ	O	O
not	RB	O	O
support	VB	O	O
the	DT	O	O
clinical	JJ	O	O
use	NN	O	O
of	IN	O	O
insulin	NN	o	OPH
as	IN	O	O
a	DT	O	O
means	NN	O	O
of	IN	O	O
modifying	VBG	O	O
protein	JJ	O	O
metabolic	JJ	O	O
losses	NNS	O	O
after	IN	O	O
major	JJ	p	O
surgery	NN	p	O
.	.	p	O

Effect	NN	O	O
of	IN	O	O
acarbose	NN	i	IPM
on	IN	O	O
additional	JJ	O	O
insulin	NN	i	IPM
therapy	NN	i	IPM
in	IN	O	O
type	NN	p	PC
2	CD	p	PC
diabetic	JJ	p	PC
patients	NNS	p	O
with	IN	p	O
late	JJ	p	PC
failure	NN	p	PC
of	IN	p	O
sulphonylurea	JJ	p	PC
therapy	NN	p	PC
.	.	p	O

AIM	VB	O	O
The	DT	O	O
present	JJ	O	O
study	NN	O	O
investigated	VBD	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
acarbose	NN	i	IPM
on	IN	O	O
insulin	NN	o	OPH
requirements	NNS	o	OPH
and	CC	O	O
glycaemic	JJ	o	OPH
control	NN	o	OPH
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
type	JJ	p	PC
2	CD	p	PC
diabetes	NNS	p	PC
receiving	VBG	p	O
exogenous	JJ	p	PC
insulin	NN	i	IPM
due	JJ	p	O
to	TO	p	O
secondary	JJ	p	O
failure	NN	p	PC
of	IN	p	O
maximum	NN	p	O
dose	JJ	p	O
sulphonylurea	JJ	p	PC
therapy	NN	p	PC
.	.	p	O

METHODS	VB	O	O
A	DT	O	O
single-centre	JJ	O	O
,	,	O	O
double-blind	JJ	O	O
,	,	O	O
randomized	VBN	O	O
,	,	O	O
placebo-controlled	JJ	i	IC
study	NN	O	O
was	VBD	O	O
performed	VBN	O	O
in	IN	O	O
48	CD	p	PSS
type	NN	p	PC
2	CD	p	PC
diabetic	JJ	p	PC
patients	NNS	p	O
with	IN	p	O
late-term	JJ	p	PC
failure	NN	p	PC
following	VBG	p	O
at	IN	p	O
least	JJS	p	O
3	CD	p	O
years	NNS	p	O
of	IN	p	O
sulphonylurea	JJ	i	IPM
therapy	NN	p	PC
requiring	VBG	p	O
additional	JJ	p	O
insulin	NN	i	IPM
therapy	NN	p	PC
to	TO	p	O
determine	VB	p	O
the	DT	p	O
impact	NN	p	O
of	IN	p	O
acarbose	NN	i	IPM
on	IN	p	O
glycaemic	JJ	p	O
control	NN	p	O
and	CC	p	O
insulin	NN	p	O
requirements	NNS	p	O
.	.	p	O

The	DT	O	O
primary	JJ	O	O
end	NN	O	O
points	NNS	O	O
were	VBD	O	O
glycaemic	JJ	o	OPH
response	NN	o	OPH
rate	NN	o	OPH
(	(	O	O
responders	NNS	O	O
being	VBG	O	O
predefined	VBN	O	O
as	IN	O	O
patients	NNS	O	O
who	WP	O	O
achieve	VBP	O	O
a	DT	O	O
decrease	NN	O	O
in	IN	O	O
HbA1c	NNP	O	O
to	TO	O	O
less	JJR	O	O
than	IN	O	O
8	CD	O	O
%	NN	O	O
or	CC	O	O
a	DT	O	O
reduction	NN	O	O
by	IN	O	O
at	IN	O	O
least	JJS	O	O
15	CD	O	O
%	NN	O	O
as	IN	O	O
compared	VBN	O	O
to	TO	O	O
the	DT	O	O
baseline	NN	O	O
values	NNS	O	O
)	)	O	O
and	CC	O	O
the	DT	O	O
daily	JJ	o	OPH
insulin	NN	o	OPH
dose	NN	o	OPH
at	IN	O	O
6	CD	O	O
months	NNS	O	O
.	.	O	O

Secondary	JJ	O	O
parameters	NNS	O	O
assessed	VBD	O	O
included	VBN	O	O
postprandial	JJ	o	OPH
changes	NNS	o	OPH
in	IN	o	OPH
blood	NN	o	OPH
glucose	NN	o	OPH
,	,	o	OPH
serum	JJ	o	OPH
insulin	NN	o	OPH
and	CC	o	OPH
C-peptide	NNP	o	OPH
during	IN	O	O
the	DT	O	O
treatment	NN	O	O
period	NN	O	O
.	.	O	O

RESULTS	CC	O	O
There	EX	O	O
were	VBD	O	O
significantly	RB	O	O
more	JJR	O	O
responders	NNS	O	O
in	IN	O	O
the	DT	O	O
acarbose-treated	JJ	O	O
group	NN	O	O
compared	VBN	O	O
with	IN	O	O
the	DT	O	O
placebo	NN	O	O
group	NN	O	O
(	(	O	O
20/24	CD	O	O
patients	NNS	O	O
vs.	FW	O	O
10/19	CD	O	O
patients	NNS	O	O
;	:	O	O
p	VB	O	O
<	$	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
mean	JJ	o	OPH
daily	JJ	o	OPH
insulin	NN	o	OPH
dose	NN	o	OPH
after	IN	O	O
24	CD	O	O
weeks	NNS	O	O
of	IN	O	O
treatment	NN	O	O
was	VBD	O	O
16.4	CD	O	O
+/-	JJ	O	O
10.1	CD	O	O
IU	NNP	O	O
in	IN	O	O
the	DT	O	O
acarbose	JJ	i	IPM
group	NN	O	O
and	CC	O	O
22.4	CD	O	O
+/-	JJ	O	O
12.2	CD	O	O
IU	NNP	O	O
in	IN	O	O
the	DT	O	O
placebo	NN	i	IC
group	NN	O	O
(	(	O	O
mean	JJ	O	O
+/-	JJ	O	O
s.d	NN	O	O
.	.	O	O

;	:	O	O
p	JJ	O	O
<	NNP	O	O
0.07	CD	O	O
)	)	O	O
.	.	O	O

Postprandial	JJ	o	OPH
increases	NNS	o	OPH
in	IN	o	OPH
blood	NN	o	OPH
glucose	NN	o	OPH
,	,	o	O
insulin	NN	o	OPH
and	CC	o	O
C-peptide	NNP	o	OPH
were	VBD	O	O
consistently	RB	O	O
lower	JJR	O	O
in	IN	O	O
the	DT	O	O
acarbose-treated	JJ	O	O
group	NN	O	O
than	IN	O	O
in	IN	O	O
the	DT	O	O
placebo	NN	i	IC
group	NN	O	O
.	.	O	O

For	IN	O	O
example	NN	O	O
,	,	O	O
the	DT	O	O
mean	JJ	o	OPH
increase	NN	o	OPH
in	IN	o	OPH
2-h	JJ	o	OPH
postprandial	JJ	o	OPH
serum	NN	o	OPH
insulin	NN	o	OPH
remained	VBD	O	O
almost	RB	O	O
unchanged	JJ	O	O
in	IN	O	O
the	DT	O	O
acarbose	JJ	O	O
group	NN	O	O
at	IN	O	O
the	DT	O	O
end	NN	O	O
of	IN	O	O
24	CD	O	O
weeks	NNS	O	O
of	IN	O	O
treatment	NN	O	O
compared	VBN	O	O
to	TO	O	O
an	DT	O	O
increase	NN	O	O
to	TO	O	O
43	CD	O	O
+/-	JJ	O	O
29	CD	O	O
microU/ml	NN	O	O
(	(	O	O
mean	JJ	O	O
+/-	JJ	O	O
s.d	NN	O	O
.	.	O	O

)	)	O	O
at	IN	O	O
the	DT	O	O
end	NN	O	O
of	IN	O	O
the	DT	O	O
study	NN	O	O
period	NN	O	O
for	IN	O	O
the	DT	O	O
placebo	NN	i	IC
group	NN	O	O
.	.	O	O

CONCLUSIONS	VB	O	O
The	DT	O	O
findings	NNS	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
suggest	VBP	O	O
that	IN	O	O
the	DT	O	O
addition	NN	O	O
of	IN	O	O
acarbose	NN	i	IPM
to	TO	O	O
sulphonylurea/insulin	VB	i	IPM
combination	NN	i	IPM
therapy	NN	i	IPM
can	MD	O	O
improve	VB	O	O
glycaemic	JJ	o	OPH
control	NN	o	OPH
in	IN	O	O
type	NN	p	PC
2	CD	p	PC
diabetic	JJ	p	PC
patients	NNS	p	O
.	.	p	O

Acarbose	NNP	i	IPM
may	MD	O	O
also	RB	O	O
reduce	VB	O	O
insulin	NN	o	OPH
resistance	NN	o	OPH
and	CC	o	OPH
hyperinsulinaemia	NN	o	OPH
.	.	o	OPH

Efficacy	NN	O	O
of	IN	O	O
intravenous	JJ	O	O
granisetron	NN	i	IPM
to	TO	O	O
control	VB	O	O
nausea	NN	O	O
and	CC	O	O
vomiting	VBG	O	O
during	IN	O	O
multiple	JJ	O	O
cycles	NNS	O	O
of	IN	O	O
cisplatin-based	JJ	i	IPM
chemotherapy	NN	i	IPM
.	.	i	O

The	DT	O	O
safety	NN	O	O
and	CC	O	O
efficacy	NN	O	O
of	IN	O	O
granisetron	NN	i	IPM
(	(	O	O
10	CD	O	O
micrograms/kg	NN	O	O
and	CC	O	O
40	CD	O	O
micrograms/kg	NN	O	O
)	)	O	O
were	VBD	O	O
evaluated	VBN	O	O
during	IN	O	O
a	DT	O	O
second	JJ	O	O
(	(	O	O
n	JJ	O	O
=	NNP	O	O
393	CD	O	O
)	)	O	O
and	CC	O	O
third	JJ	O	O
(	(	O	O
n	JJ	O	O
=	NNP	O	O
200	CD	O	O
)	)	O	O
cycle	NN	O	O
of	IN	O	O
chemotherapy	NN	O	O
in	IN	O	O
this	DT	O	O
multicenter	NN	p	O
,	,	p	O
double-blind	NN	p	O
,	,	p	O
randomized	VBN	p	O
,	,	p	O
parallel-group	JJ	p	O
study	NN	p	O
.	.	p	O

Granisetron	NNP	i	IPM
was	VBD	O	O
administered	VBN	O	O
as	IN	O	O
a	DT	O	O
single	JJ	O	O
intravenous	JJ	O	O
dose	NN	O	O
before	IN	O	O
the	DT	O	O
start	NN	O	O
of	IN	O	O
cisplatin	NN	i	IPM
chemotherapy	NN	i	IPM
(	(	p	O
>	CD	p	O
or	CC	p	O
=	VB	p	O
60	CD	p	O
mg/m2	NN	p	O
)	)	p	O
.	.	p	O

Total	JJ	o	OOt
control	NN	o	OOt
(	(	o	O
no	DT	o	OPH
vomiting	NN	o	OPH
,	,	o	O
no	DT	o	OPH
retching	NN	o	OPH
,	,	o	OPH
no	DT	o	OPH
nausea	NN	o	OPH
,	,	o	OPH
and	CC	o	OPH
no	DT	o	OPH
use	NN	o	OPH
of	IN	o	OPH
antiemetic	JJ	o	OPH
rescue	NN	o	OPH
medication	NN	o	OPH
)	)	o	O
after	IN	o	O
the	DT	o	O
first	JJ	o	O
24	CD	o	O
hr	NN	o	O
following	VBG	O	O
chemotherapy	NN	i	IPM
was	VBD	O	O
achieved	VBN	O	O
in	IN	O	O
40	CD	p	O
%	NN	p	O
and	CC	p	O
49	CD	p	O
%	NN	p	O
of	IN	p	O
patients	NNS	p	O
in	IN	p	O
Cycles	NNP	p	O
2	CD	p	O
and	CC	p	O
3	CD	p	O
,	,	p	O
respectively	RB	p	O
,	,	p	O
for	IN	p	O
the	DT	p	O
10	CD	p	O
micrograms/kg	NN	p	O
group	NN	p	O
,	,	p	O
and	CC	p	O
in	IN	p	O
42	CD	p	O
%	NN	p	O
and	CC	p	O
38	CD	p	O
%	NN	p	O
of	IN	p	O
patients	NNS	p	O
in	IN	p	O
Cycles	NNP	p	O
2	CD	p	O
and	CC	p	O
3	CD	p	O
,	,	p	O
respectively	RB	p	O
,	,	p	O
for	IN	p	O
the	DT	p	O
40	CD	p	O
micrograms/kg	NN	p	O
group	NN	p	O
.	.	p	O

Both	DT	O	O
dose	JJ	o	OPH
levels	NNS	o	OPH
of	IN	o	OPH
granisetron	NN	o	OPH
were	VBD	O	O
well	RB	O	O
tolerated	VBN	o	O
.	.	o	O

The	DT	O	O
results	NNS	O	O
demonstrate	VBP	O	O
comparable	JJ	O	O
efficacy	NN	O	O
between	IN	O	O
the	DT	O	O
10	CD	O	O
micrograms/kg	NN	O	O
and	CC	O	O
40	CD	O	O
micrograms/kg	NN	O	O
doses	NNS	O	O
of	IN	O	O
granisetron	NN	i	IPM
in	IN	O	O
preventing	VBG	O	O
nausea	NN	o	OPH
and	CC	o	OPH
vomiting	VBG	o	OPH
during	IN	O	O
repeat	NN	O	O
cycles	NNS	O	O
of	IN	O	O
high-dose	JJ	p	O
cisplatin-based	JJ	i	IPM
chemotherapy	NN	i	IPM
.	.	i	O

The	DT	O	O
results	NNS	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
show	NN	O	O
that	IN	O	O
granisetron	VBZ	i	IPM
10	CD	O	O
micrograms/kg	NN	O	O
is	VBZ	O	O
safe	JJ	O	O
and	CC	O	O
well	RB	O	O
tolerated	VBN	O	O
,	,	O	O
and	CC	O	O
remains	VBZ	O	O
effective	JJ	O	O
with	IN	O	O
repeat	NN	O	O
cycle	NN	O	O
use	NN	O	O
.	.	O	O

Chlorhexidine-based	JJ	i	IPM
antiseptic	JJ	i	IPM
solution	NN	i	IPM
vs	IN	O	O
alcohol-based	JJ	i	IPM
povidone-iodine	NN	i	IPM
for	IN	O	O
central	JJ	O	O
venous	JJ	O	O
catheter	NN	O	O
care	NN	O	O
.	.	O	O

BACKGROUND	NNP	O	O
Although	IN	O	O
chlorhexidine-based	JJ	i	IPM
solutions	NNS	i	IPM
and	CC	O	O
alcohol-based	JJ	i	IPM
povidone-iodine	NN	i	IPM
have	VBP	O	O
been	VBN	O	O
shown	VBN	O	O
to	TO	O	O
be	VB	O	O
more	RBR	O	O
efficient	JJ	O	O
than	IN	O	O
aqueous	JJ	O	O
povidone-iodine	NN	O	O
for	IN	O	O
skin	JJ	O	O
disinfection	NN	O	O
at	IN	O	O
catheter	NN	p	PC
insertion	NN	p	PC
sites	NNS	p	PC
,	,	O	O
their	PRP$	O	O
abilities	NNS	O	O
to	TO	O	O
reduce	VB	O	O
catheter-related	JJ	o	OPH
infection	NN	o	OPH
have	VBP	O	O
never	RB	O	O
been	VBN	O	O
compared	VBN	O	O
.	.	O	O

METHODS	NNP	O	O
Consecutively	RB	p	O
scheduled	VBD	p	O
central	JJ	p	O
venous	JJ	p	O
catheters	NNS	p	O
inserted	VBN	p	O
into	IN	p	O
jugular	NN	p	O
or	CC	p	O
subclavian	JJ	p	O
veins	NNS	p	O
were	VBD	O	O
randomly	RB	O	O
assigned	VBN	O	O
to	TO	O	O
be	VB	O	O
disinfected	VBN	O	O
with	IN	O	O
5	CD	i	IPM
%	NN	i	IPM
povidone-iodine	NN	i	IPM
in	IN	i	IPM
70	CD	i	IPM
%	NN	i	IPM
ethanol	NN	i	IPM
or	CC	i	IPM
with	IN	i	IPM
a	DT	i	IPM
combination	NN	i	IPM
of	IN	i	IPM
0.25	CD	i	IPM
%	NN	i	IPM
chlorhexidine	NN	i	IPM
gluconate	NN	i	IPM
,	,	i	IPM
0.025	CD	i	IPM
%	NN	i	IPM
benzalkonium	NN	i	IPM
chloride	NN	i	IPM
,	,	i	IPM
and	CC	i	IPM
4	CD	i	IPM
%	NN	i	IPM
benzylic	JJ	i	IPM
alcohol	NN	i	IPM
.	.	i	IPM

Solutions	NNS	O	O
were	VBD	O	O
used	VBN	O	O
for	IN	O	O
skin	JJ	O	O
disinfection	NN	O	O
before	IN	O	O
catheter	NN	O	O
insertion	NN	O	O
(	(	O	O
2	CD	O	O
consecutive	JJ	O	O
30-second	JJ	O	O
applications	NNS	O	O
separated	VBN	O	O
by	IN	O	O
a	DT	O	O
period	NN	O	O
sufficiently	RB	O	O
long	RB	O	O
to	TO	O	O
allow	VB	O	O
for	IN	O	O
dryness	NN	O	O
)	)	O	O
and	CC	O	O
then	RB	O	O
as	IN	O	O
single	JJ	O	O
applications	NNS	O	O
during	IN	O	O
subsequent	JJ	O	O
dressing	NN	O	O
changes	NNS	O	O
(	(	O	O
every	DT	O	O
72	CD	O	O
hours	NNS	O	O
,	,	O	O
or	CC	O	O
earlier	RB	O	O
if	IN	O	O
soiled	VBN	O	O
or	CC	O	O
wet	VBN	O	O
)	)	O	O
.	.	O	O

RESULTS	NNP	O	O
Of	IN	O	O
538	CD	p	PSS
catheters	NNS	p	O
randomized	VBD	p	O
,	,	p	O
481	CD	p	PSS
(	(	p	O
89.4	CD	p	O
%	NN	p	O
)	)	p	O
produced	VBD	p	O
evaluable	JJ	p	O
culture	NN	o	OOt
results	NNS	o	OOt
.	.	o	O

Compared	VBN	O	O
with	IN	O	O
povidone-iodine	NN	i	IPM
,	,	O	O
the	DT	O	O
chlorhexidine-based	JJ	i	IPM
solution	NN	i	IPM
was	VBD	O	O
associated	VBN	O	O
with	IN	O	O
a	DT	O	O
50	CD	O	O
%	NN	O	O
decrease	NN	O	O
in	IN	O	O
the	DT	O	O
incidence	NN	o	OPH
of	IN	o	OPH
catheter	NN	o	OPH
colonization	NN	o	OPH
(	(	O	O
11.6	CD	O	O
%	NN	O	O
vs	JJ	O	O
22.2	CD	O	O
%	NN	O	O
[	JJ	O	O
P	NNP	O	O
=	NNP	O	O
.002	NNP	O	O
]	NNP	O	O
;	:	O	O
incidence	NN	o	OPH
density	NN	o	OPH
,	,	O	O
9.7	CD	O	O
vs	NN	O	O
18.3	CD	O	O
per	IN	O	O
1000	CD	O	O
catheter-days	NN	O	O
)	)	O	O
and	CC	O	O
with	IN	O	O
a	DT	O	O
trend	NN	O	O
toward	IN	O	O
lower	JJR	O	O
rates	NNS	O	O
of	IN	O	O
catheter-related	JJ	o	OA
bloodstream	NN	o	OA
infection	NN	o	OA
(	(	O	O
1.7	CD	O	O
%	NN	O	O
vs	JJ	O	O
4.2	CD	O	O
%	NN	O	O
[	JJ	O	O
P	NNP	O	O
=	NNP	O	O
.09	NNP	O	O
]	NNP	O	O
;	:	O	O
incidence	NN	o	OPH
density	NN	o	OPH
,	,	O	O
1.4	CD	O	O
vs	NN	O	O
3.4	CD	O	O
per	IN	O	O
1000	CD	O	O
catheter-days	NN	O	O
)	)	O	O
.	.	O	O

Independent	JJ	O	O
risk	NN	O	O
factors	NNS	O	O
for	IN	O	O
catheter	NN	o	OPH
colonization	NN	o	OPH
were	VBD	O	O
catheter	JJ	O	O
insertion	NN	O	O
into	IN	O	O
the	DT	O	O
jugular	JJ	O	O
vein	NN	O	O
(	(	O	O
adjusted	VBN	O	O
relative	NN	O	O
risk	NN	O	O
,	,	O	O
2.01	CD	O	O
;	:	O	O
95	CD	O	O
%	NN	O	O
confidence	NN	O	O
interval	NN	O	O
,	,	O	O
1.24-3.24	JJ	O	O
)	)	O	O
and	CC	O	O
use	NN	O	O
of	IN	O	O
povidone-iodine	NN	i	IPM
(	(	O	O
adjusted	VBN	O	O
relative	NN	O	O
risk	NN	O	O
,	,	O	O
1.87	CD	O	O
;	:	O	O
95	CD	O	O
%	NN	O	O
confidence	NN	O	O
interval	NN	O	O
,	,	O	O
1.18-2.96	JJ	O	O
)	)	O	O
.	.	O	O

CONCLUSION	NNP	O	O
Chlorhexidine-based	JJ	i	IPM
solutions	NNS	i	IPM
should	MD	O	O
be	VB	O	O
considered	VBN	O	O
as	IN	O	O
a	DT	O	O
replacement	NN	O	O
for	IN	O	O
povidone-iodine	NN	i	IPM
(	(	i	IPM
including	VBG	i	IPM
alcohol-based	VBN	i	IPM
)	)	i	IPM
formulations	NNS	i	IPM
in	IN	O	O
efforts	NNS	O	O
to	TO	O	O
prevent	VB	O	O
catheter-related	JJ	o	OPH
infection	NN	o	OPH
.	.	o	O

Psychosocial	JJ	i	IPS
nursing	NN	i	IPS
therapy	NN	i	IPS
following	VBG	p	O
sudden	JJ	p	O
cardiac	JJ	p	PC
arrest	NN	p	PC
:	:	p	O
impact	NN	O	O
on	IN	O	O
two-year	JJ	o	OMO
survival	NN	o	OMO
.	.	o	O

BACKGROUND	NNP	O	O
Although	IN	O	O
psychosocial	JJ	i	IPS
therapy	NN	i	IPS
has	VBZ	O	O
been	VBN	O	O
shown	VBN	O	O
to	TO	O	O
reduce	VB	O	O
mortality	NN	o	OMO
after	IN	O	O
myocardial	JJ	O	O
infarction	NN	O	O
,	,	O	O
it	PRP	O	O
is	VBZ	O	O
unknown	JJ	O	O
whether	IN	O	O
the	DT	O	O
benefits	NNS	O	O
of	IN	O	O
psychosocial	JJ	i	IPS
therapy	NN	i	IPS
on	IN	O	O
mortality	NN	o	O
reduction	NN	o	O
extend	VBP	O	O
to	TO	O	O
out-of-hospital	JJ	O	O
sudden	JJ	O	O
cardiac	NN	O	O
arrest	NN	O	O
,	,	O	O
a	DT	O	O
main	JJ	O	O
cause	NN	O	O
of	IN	O	O
cardiovascular	JJ	o	OMO
mortality	NN	o	OMO
.	.	o	O

OBJECTIVE	NNP	O	O
Describe	NNP	O	O
efficacy	NN	O	O
of	IN	O	O
psychosocial	JJ	i	IPS
therapy	NN	i	IPS
on	IN	O	O
two-year	JJ	O	O
cardiovascular	JJ	o	OMO
mortality	NN	o	OMO
in	IN	O	O
sudden	JJ	p	O
cardiac	JJ	p	O
arrest	NN	p	O
survivors	NNS	p	O
.	.	p	O

METHOD	NNP	O	O
Survivors	NNPS	p	O
of	IN	p	O
out-of-hospital	JJ	p	O
ventricular	JJ	p	O
fibrillation	NN	p	O
or	CC	p	O
asystole	NN	p	O
(	(	p	O
N	NNP	p	O
=	NNP	p	O
129	CD	p	PSS
)	)	p	O
,	,	p	O
documented	VBN	p	O
by	IN	p	O
electrocardiograms	NNS	p	O
from	IN	p	O
registries	NNS	p	O
of	IN	p	O
a	DT	p	O
citywide	NN	p	O
Medic	NNP	p	O
One	NNP	p	O
unit	NN	p	O
and	CC	p	O
two	CD	p	O
countywide	NN	p	O
emergency	NN	p	O
units	NNS	p	O
,	,	O	O
were	VBD	O	O
randomized	VBN	O	O
into	IN	O	O
a	DT	O	O
two	CD	O	O
group	NN	O	O
,	,	O	O
experimental	JJ	O	O
,	,	O	O
longitudinal	JJ	O	O
design	NN	O	O
.	.	O	O

The	DT	O	O
intervention	NN	O	O
consisted	VBD	O	O
of	IN	O	O
11	CD	O	O
individual	JJ	O	O
sessions	NNS	O	O
,	,	O	O
implementing	VBG	O	O
three	CD	O	O
components	NNS	O	O
:	:	O	O
physiologic	JJ	O	O
relaxation	NN	O	O
with	IN	O	O
biofeedback	NN	O	O
training	NN	O	O
focused	VBD	O	O
on	IN	O	O
altering	VBG	O	O
autonomic	JJ	O	O
tone	NN	O	O
;	:	O	O
cognitive	JJ	i	IPS
behavioral	JJ	i	IPS
therapy	NN	i	IPS
aimed	VBN	O	O
at	IN	O	O
self-management	JJ	O	O
and	CC	O	O
coping	VBG	O	O
strategies	NNS	O	O
for	IN	O	O
depression	NN	O	O
,	,	O	O
anxiety	NN	O	O
,	,	O	O
and	CC	O	O
anger	NN	O	O
;	:	O	O
and	CC	O	O
cardiovascular	JJ	O	O
health	NN	O	O
education	NN	O	O
.	.	O	O

The	DT	O	O
primary	JJ	O	O
outcome	NN	O	O
measure	NN	O	O
was	VBD	O	O
cardiovascular	JJ	o	OMO
mortality	NN	o	OMO
.	.	o	O

RESULTS	NNP	O	O
Risk	NNP	o	OMO
of	IN	o	OMO
cardiovascular	JJ	o	OMO
death	NN	o	OMO
was	VBD	O	O
significantly	RB	O	O
reduced	VBN	O	O
86	CD	O	O
%	NN	O	O
by	IN	O	O
psychosocial	JJ	O	O
therapy	NN	O	O
,	,	O	O
p	NN	O	O
=	NNP	O	O
.03	NNP	O	O
.	.	O	O

Six	NNP	O	O
of	IN	O	O
the	DT	O	O
seven	CD	O	O
cardiovascular	JJ	o	OMO
deaths	NNS	o	OMO
in	IN	O	O
the	DT	O	O
control	NN	O	O
group	NN	O	O
were	VBD	O	O
caused	VBN	O	O
by	IN	O	O
ventricular	JJ	O	O
arrhythmias	NN	O	O
.	.	O	O

The	DT	o	OMO
cardiovascular	JJ	o	OMO
death	NN	o	OMO
in	IN	O	O
the	DT	O	O
therapy	NN	O	O
group	NN	O	O
was	VBD	O	O
due	JJ	O	O
to	TO	O	O
stroke	VB	O	O
.	.	O	O

Controlling	VBG	O	O
for	IN	O	O
depression	NN	o	OPH
,	,	o	O
previous	JJ	o	OPH
myocardial	JJ	o	OPH
infarction	NN	o	OPH
,	,	o	O
low	JJ	o	OPH
ejection	NN	o	OPH
fraction	NN	o	OPH
,	,	o	O
decreased	JJ	o	OPH
heart	NN	o	OPH
rate	NN	o	OPH
variability	NN	o	OPH
,	,	o	O
and	CC	o	O
ventricular	JJ	o	OPH
ectopic	NN	o	OPH
beats	NNS	o	OPH
had	VBD	O	O
little	JJ	O	O
impact	NN	O	O
on	IN	O	O
estimated	VBN	O	O
treatment	NN	O	O
effect	NN	O	O
.	.	O	O

The	DT	O	O
risk	NN	o	OMO
of	IN	o	OMO
all-cause	JJ	o	OMO
mortality	NN	o	OMO
was	VBD	O	O
reduced	VBN	O	O
by	IN	O	O
62	CD	O	O
%	NN	O	O
in	IN	O	O
the	DT	O	O
therapy	NN	O	O
group	NN	O	O
,	,	O	O
p	VBP	O	O
=	JJ	O	O
.13	NNP	O	O
.	.	O	O

There	EX	O	O
were	VBD	O	O
a	DT	O	O
total	NN	O	O
of	IN	O	O
three	CD	O	O
deaths	NNS	o	OMO
in	IN	O	O
the	DT	O	O
therapy	NN	O	O
group	NN	O	O
and	CC	O	O
eight	CD	O	O
deaths	NNS	o	OMO
in	IN	O	O
the	DT	O	O
control	NN	i	IC
group	NN	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
Psychosocial	NNP	i	IPS
therapy	NN	i	IPS
significantly	RB	O	O
reduced	VBD	O	O
the	DT	O	O
risk	NN	O	O
of	IN	O	O
cardiovascular	JJ	o	OMO
death	NN	o	OMO
in	IN	O	O
sudden	JJ	p	O
cardiac	JJ	p	O
arrest	NN	p	O
survivors	NNS	p	O
.	.	p	O

Action	NNP	O	O
observation	NN	O	O
treatment	NN	O	O
improves	VBZ	O	O
recovery	NN	O	O
of	IN	O	O
postsurgical	JJ	p	PC
orthopedic	JJ	p	PC
patients	NNS	p	PC
:	:	p	O
evidence	NN	O	O
for	IN	O	O
a	DT	O	O
top-down	JJ	O	O
effect	NN	O	O
?	.	O	O
OBJECTIVE	UH	O	O
To	TO	O	O
assess	VB	O	O
whether	IN	O	O
action	NN	i	IPH
observation	NN	i	IPH
treatment	NN	i	IPH
(	(	i	IPH
AOT	NNP	i	IPH
)	)	i	IPH
may	MD	O	O
also	RB	O	O
improve	VB	O	O
motor	NN	O	O
recovery	NN	O	O
in	IN	O	O
postsurgical	JJ	p	PC
orthopedic	JJ	p	PC
patients	NNS	p	O
,	,	O	O
in	IN	O	O
addition	NN	O	O
to	TO	O	O
conventional	JJ	O	O
physiotherapy	NN	O	O
.	.	O	O

DESIGN	NNP	O	O
Randomized	NNP	O	O
controlled	VBD	O	O
trial	NN	O	O
.	.	O	O

SETTING	NNP	O	O
Department	NNP	O	O
of	IN	O	O
rehabilitation	NN	O	O
.	.	O	O

PARTICIPANTS	JJ	O	O
Patients	NNPS	p	O
(	(	p	O
N=60	NNP	p	PSS
)	)	p	O
admitted	VBD	p	O
to	TO	p	O
our	PRP$	p	O
department	NN	p	O
postorthopedic	NN	p	O
surgery	NN	p	O
were	VBD	O	O
randomly	RB	O	O
assigned	VBN	O	O
to	TO	O	O
either	VB	O	O
a	DT	O	O
case	NN	O	O
(	(	O	O
n=30	NN	O	O
)	)	O	O
or	CC	i	O
control	NN	i	IC
(	(	O	O
n=30	JJ	O	O
)	)	O	O
group	NN	i	O
.	.	i	O

Exclusion	NN	p	O
criteria	NNS	p	O
were	VBD	p	O
age	NN	p	O
18	CD	p	PA
years	NNS	p	PA
or	CC	p	PA
younger	JJR	p	PA
and	CC	p	PA
90	CD	p	PA
years	NNS	p	PA
or	CC	p	PA
older	JJR	p	PA
,	,	p	O
Mini-Mental	JJ	p	O
State	NNP	p	O
Examination	NNP	p	O
score	NN	p	O
of	IN	p	O
21	CD	p	O
of	IN	p	O
30	CD	p	O
or	CC	p	O
lower	JJR	p	O
,	,	p	O
no	DT	p	O
ambulating	VBG	p	O
order	NN	p	O
,	,	p	O
advanced	JJ	p	O
vision	NN	p	O
impairment	NN	p	O
,	,	p	O
malignancy	NN	p	O
,	,	p	O
pneumonia	NN	p	O
,	,	p	O
or	CC	p	O
heart	NN	p	O
failure	NN	p	O
.	.	p	O

INTERVENTIONS	NNP	O	O
All	NNP	O	O
participants	NNS	O	O
underwent	JJ	O	O
conventional	JJ	p	O
physiotherapy	NN	p	O
.	.	p	O

In	IN	O	O
addition	NN	O	O
,	,	O	O
patients	NNS	O	O
in	IN	O	O
the	DT	O	O
case	NN	O	O
group	NN	O	O
were	VBD	O	O
asked	VBN	O	O
to	TO	O	O
observe	VB	i	IE
video	JJ	i	IE
clips	NNS	i	IE
showing	VBG	i	IE
daily	JJ	i	IE
actions	NNS	i	IE
and	CC	i	IE
to	TO	i	IE
imitate	VB	i	IE
them	PRP	i	IE
afterward	RB	i	IE
.	.	i	IPH

Patients	NNS	O	O
in	IN	O	O
the	DT	O	O
control	NN	O	O
group	NN	O	O
were	VBD	O	O
asked	VBN	O	O
to	TO	O	O
observe	VB	i	IE
video	JJ	i	IE
clips	NNS	i	IE
with	IN	i	IE
no	DT	i	IE
motor	NN	i	IE
content	NN	i	IE
and	CC	i	IE
to	TO	i	IE
execute	VB	i	IE
the	DT	i	IE
same	JJ	i	IE
actions	NNS	i	IE
as	IN	i	IE
patients	NNS	i	IE
in	IN	i	IE
the	DT	i	IE
case	NN	i	IE
group	NN	i	IE
afterward	RB	O	O
.	.	O	O

Participants	NNS	O	O
were	VBD	O	O
scored	VBN	O	O
on	IN	O	O
functional	JJ	O	O
scales	NNS	O	O
at	IN	O	O
baseline	NN	O	O
and	CC	O	O
after	IN	O	O
treatment	NN	O	O
by	IN	O	O
a	DT	O	O
physician	NN	O	O
blinded	VBD	O	O
to	TO	O	O
group	NN	O	O
assignment	NN	O	O
.	.	O	O

MAIN	NNP	O	O
OUTCOMES	NNP	O	O
MEASURES	NNP	O	O
Changes	NNP	o	OPH
in	IN	o	OPH
FIM	NNP	o	OPH
and	CC	o	OPH
Tinetti	NNP	o	OPH
scale	NN	o	OPH
scores	NNS	o	OPH
,	,	o	OPH
and	CC	o	OPH
dependence	NN	o	OPH
on	IN	o	OPH
walking	VBG	o	OPH
aids	NNS	o	OPH
.	.	o	OPH

RESULTS	NNP	O	O
At	IN	O	O
baseline	NN	O	O
,	,	O	O
groups	NNS	O	O
did	VBD	O	O
not	RB	O	O
differ	VB	O	O
in	IN	O	O
clinical	JJ	o	OOt
and	CC	o	OOt
functional	JJ	o	OOt
scale	NN	o	OOt
scores	NNS	o	OOt
.	.	o	OOt

After	IN	O	O
treatment	NN	O	O
,	,	O	O
patients	NNS	O	O
in	IN	O	O
the	DT	O	O
case	NN	O	O
group	NN	O	O
scored	VBD	O	O
better	JJR	O	O
than	IN	O	O
patients	NNS	O	O
in	IN	O	O
the	DT	O	O
control	NN	O	O
group	NN	O	O
(	(	o	OOt
FIM	NNP	o	OPH
total	NN	o	OPH
score	NN	o	OPH
,	,	O	O
P=.02	NNP	O	O
;	:	O	O
FIM	NNP	o	OPH
motor	NN	o	OPH
subscore	NN	o	OPH
,	,	O	O
P=.001	NNP	O	O
;	:	O	O
Tinetti	NNP	o	OPH
scale	NN	o	OPH
score	NN	o	OPH
,	,	O	O
P=.04	NNP	O	O
)	)	O	O
;	:	O	O
patients	NNS	O	O
in	IN	O	O
the	DT	O	O
case	NN	O	O
group	NN	O	O
were	VBD	O	O
assigned	VBN	O	O
more	RBR	O	O
frequently	RB	o	OOt
to	TO	o	OOt
1	CD	o	OOt
crutch	NN	o	OOt
(	(	O	O
P=.01	NNP	O	O
)	)	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
In	IN	O	O
addition	NN	O	O
to	TO	O	O
conventional	JJ	O	O
physiotherapy	NN	O	O
,	,	O	O
AOT	NNP	O	O
is	VBZ	O	O
effective	JJ	O	O
in	IN	O	O
the	DT	O	O
rehabilitation	NN	O	O
of	IN	O	O
postsurgical	JJ	p	O
orthopedic	JJ	p	O
patients	NNS	p	O
.	.	p	O

The	DT	O	O
present	JJ	O	O
results	NNS	O	O
strongly	RB	O	O
support	VB	O	O
top-down	JJ	O	O
effects	NNS	O	O
of	IN	O	O
this	DT	O	O
treatment	NN	O	O
in	IN	O	O
motor	NN	O	O
recovery	NN	O	O
,	,	O	O
even	RB	O	O
in	IN	O	O
nonneurologic	JJ	p	O
patients	NNS	p	O
.	.	p	O

A	DT	O	O
randomized	JJ	O	O
trial	NN	O	O
of	IN	O	O
external	JJ	i	IPH
beam	NN	i	IPH
radiotherapy	NN	i	IPH
versus	NN	O	O
cryoablation	NN	i	IPH
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
localized	JJ	p	PC
prostate	NN	p	PC
cancer	NN	p	PC
:	:	p	O
quality	NN	O	O
of	IN	O	O
life	NN	O	O
outcomes	NNS	O	O
.	.	O	O

BACKGROUND	VB	O	O
A	DT	O	O
recent	JJ	O	O
randomized	JJ	O	O
trial	NN	O	O
to	TO	O	O
compare	VB	O	O
external	JJ	i	IPH
beam	NN	i	IPH
radiation	NN	i	IPH
therapy	NN	i	IPH
(	(	i	IPH
EBRT	NNP	i	IPH
)	)	i	IPH
to	TO	O	O
cryoablation	NN	O	O
for	IN	O	O
localized	JJ	O	O
disease	NN	O	O
showed	VBD	O	O
cryoablation	NN	O	O
to	TO	O	O
be	VB	O	O
noninferior	JJ	O	O
to	TO	O	O
external	JJ	i	IPH
beam	NN	i	IPH
EBRT	NNP	i	IPH
in	IN	O	O
disease	NN	O	O
progression	NN	O	O
and	CC	O	O
overall	JJ	O	O
and	CC	O	O
disease-specific	JJ	O	O
survival	NN	O	O
.	.	O	O

We	PRP	O	O
report	VBP	O	O
on	IN	O	O
the	DT	O	O
quality	NN	o	OOt
of	IN	o	OOt
life	NN	o	OOt
(	(	o	OOt
QOL	NNP	o	OOt
)	)	o	OOt
outcomes	VBZ	O	O
for	IN	O	O
this	DT	O	O
trial	NN	O	O
.	.	O	O

METHODS	NN	O	O
From	IN	p	O
December	NNP	p	O
1997	CD	p	O
through	IN	p	O
February	NNP	p	O
2003	CD	p	O
,	,	p	O
244	CD	p	PSS
men	NNS	p	PSS
with	IN	p	O
newly	RB	p	O
diagnosed	VBN	p	O
localized	JJ	p	PC
prostate	NN	p	PC
cancer	NN	p	PC
were	VBD	O	O
randomly	RB	O	O
assigned	VBN	O	O
to	TO	O	O
cryoablation	NN	i	IPH
or	CC	i	O
EBRT	NNP	i	IPH
(	(	O	O
median	JJ	O	O
dose	NN	O	O
68	CD	O	O
Gy	NNP	O	O
)	)	O	O
.	.	O	O

All	DT	O	O
patients	NNS	O	O
received	VBD	O	O
neoadjuvant	JJ	i	IPM
antiandrogen	NN	i	IPM
therapy	NN	O	O
.	.	O	O

Patients	NNS	O	O
completed	VBD	O	O
the	DT	O	O
EORTC	NNP	O	O
QLQ	NNP	O	O
C30	NNP	O	O
and	CC	O	O
the	DT	O	O
Prostate	NNP	O	O
Cancer	NNP	O	O
Index	NNP	O	O
(	(	O	O
PCI	NNP	O	O
)	)	O	O
before	IN	O	O
treatment	NN	O	O
and	CC	O	O
at	IN	O	O
1.5	CD	O	O
,	,	O	O
3	CD	O	O
,	,	O	O
6	CD	O	O
,	,	O	O
12	CD	O	O
,	,	O	O
18	CD	O	O
,	,	O	O
24	CD	O	O
,	,	O	O
and	CC	O	O
36	CD	O	O
months	NNS	O	O
post-treatment	JJ	O	O
.	.	O	O

RESULTS	NNP	O	O
Regardless	NNP	O	O
of	IN	O	O
treatment	NN	O	O
arm	NN	O	O
,	,	O	O
participants	NNS	O	O
reported	VBD	O	O
high	JJ	O	O
levels	NNS	O	O
of	IN	O	O
QOL	NNP	o	OOt
with	IN	O	O
few	JJ	O	O
exceptions	NNS	O	O
.	.	O	O

cryoablation	NN	o	O
was	VBD	O	O
associated	VBN	O	O
with	IN	O	O
more	RBR	O	O
acute	JJ	o	OPH
urinary	JJ	o	OPH
dysfunction	NN	o	OPH
(	(	O	O
mean	JJ	O	O
PCI	NNP	O	O
urinary	JJ	O	O
function	NN	O	O
cryoablation=69.4	NN	O	O
;	:	O	O
mean	JJ	O	O
EBRT=90.7	NNP	O	O
;	:	O	O
P	NNP	O	O
<	NNP	O	O
.001	NNP	O	O
)	)	O	O
,	,	O	O
which	WDT	O	O
resolved	VBD	O	O
over	IN	O	O
time	NN	O	O
.	.	O	O

No	DT	o	OOt
late	JJ	o	OOt
arising	NN	o	OOt
QOL	NNP	o	OOt
issues	NNS	o	OOt
were	VBD	O	O
observed	VBN	O	O
.	.	O	O

Both	DT	O	O
EBRT	NNP	i	IPH
and	CC	O	O
cryoablation	NN	i	IPH
participants	NNS	O	O
reported	VBD	O	O
decreases	NNS	o	OPH
in	IN	o	OPH
sexual	JJ	o	OPH
function	NN	o	OPH
at	IN	O	O
3	CD	O	O
months	NNS	O	O
with	IN	O	O
the	DT	O	O
cryoablation	NN	O	O
patients	NNS	O	O
reporting	VBG	O	O
poorer	NN	O	O
functioning	NN	O	O
(	(	O	O
mean	JJ	O	O
cryoablation=7.2	NN	O	O
:	:	O	O
mean	JJ	O	O
EBRT=32.9	NNP	O	O
;	:	O	O
P	NNP	O	O
<	NNP	O	O
.001	NNP	O	O
)	)	O	O
.	.	O	O

Mean	JJ	o	OPH
sexual	JJ	o	OPH
function	NN	o	OPH
score	NN	o	OPH
was	VBD	O	O
15	CD	O	O
points	NNS	O	O
lower	JJR	O	O
at	IN	O	O
3	CD	O	O
years	NNS	O	O
for	IN	O	O
the	DT	O	O
cryoablation	NN	i	IPH
group	NN	O	O
and	CC	O	O
13	CD	O	O
%	NN	O	O
more	JJR	O	O
of	IN	O	O
the	DT	O	O
cryoablation	NN	i	IPH
men	NNS	O	O
said	VBD	O	O
that	IN	O	O
sexuality	NN	O	O
was	VBD	O	O
a	DT	O	O
moderate	JJ	O	O
or	CC	O	O
big	JJ	O	O
problem	NN	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
In	IN	O	O
this	DT	O	O
randomized	JJ	O	O
trial	NN	O	O
,	,	O	O
no	DT	O	O
long-term	JJ	O	O
QOL	NNP	o	OOt
advantage	NN	O	O
for	IN	O	O
either	DT	O	O
treatment	NN	O	O
was	VBD	O	O
apparent	JJ	O	O
with	IN	O	O
the	DT	O	O
exception	NN	O	O
of	IN	O	O
poorer	JJR	O	O
sexual	JJ	o	OME
function	NN	o	OME
reported	VBN	O	O
by	IN	O	O
those	DT	O	O
treated	VBN	O	O
with	IN	O	O
cryoablation	NN	i	IPH
.	.	i	O

Men	NN	O	O
who	WP	O	O
wish	VBZ	O	O
to	TO	O	O
increase	VB	O	O
their	PRP$	O	O
odds	NNS	O	O
of	IN	O	O
retaining	VBG	O	O
sexual	JJ	o	OME
function	NN	o	OME
might	MD	O	O
be	VB	O	O
counseled	VBN	O	O
to	TO	O	O
choose	VB	O	O
EBRT	NNP	i	IPH
over	IN	O	O
cryoablation	NN	i	IPH
.	.	i	O

Early	JJ	O	O
combination	NN	O	O
disease-modifying	JJ	O	O
antirheumatic	JJ	i	IPM
drug	NN	i	IPM
therapy	NN	i	IPM
and	CC	O	O
tight	JJ	O	O
disease	NN	O	O
control	NN	O	O
improve	VB	O	O
long-term	JJ	o	OOt
radiologic	JJ	o	OOt
outcome	NN	o	OOt
in	IN	O	O
patients	NNS	p	PC
with	IN	p	PC
early	JJ	p	PC
rheumatoid	NN	p	PC
arthritis	NN	p	PC
:	:	p	PC
the	DT	O	O
11-year	JJ	O	O
results	NNS	O	O
of	IN	O	O
the	DT	O	O
Finnish	NNP	O	O
Rheumatoid	NNP	O	O
Arthritis	NNP	O	O
Combination	NNP	O	O
Therapy	NNP	O	O
trial	NN	O	O
.	.	O	O

INTRODUCTION	NNP	O	O
Early	NNP	O	O
treatment	NN	O	O
of	IN	O	O
rheumatoid	NN	p	PC
arthritis	NN	p	PC
(	(	p	PC
RA	NNP	p	PC
)	)	p	PC
has	VBZ	O	O
been	VBN	O	O
shown	VBN	O	O
to	TO	O	O
retard	VB	O	O
the	DT	O	O
development	NN	o	OPH
of	IN	o	OPH
joint	JJ	o	OPH
damage	NN	o	OPH
for	IN	O	O
a	DT	O	O
period	NN	O	O
of	IN	O	O
up	IN	O	O
to	TO	O	O
5	CD	O	O
years	NNS	O	O
.	.	O	O

The	DT	O	O
aim	NN	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
evaluate	VB	o	OOt
the	DT	o	OOt
radiologic	JJ	o	OOt
progression	NN	o	OOt
beyond	IN	O	O
that	DT	O	O
time	NN	O	O
in	IN	O	O
patients	NNS	p	PC
with	IN	p	PC
early	JJ	p	PC
RA	NNP	p	PC
initially	RB	p	PC
treated	VBD	p	PC
with	IN	p	PC
a	DT	p	PC
combination	NN	p	PC
of	IN	p	PC
three	CD	i	IPM
disease-modifying	JJ	i	IPM
antirheumatic	JJ	i	IPM
drugs	NNS	i	IPM
(	(	i	IPM
DMARDs	NNP	i	IPM
)	)	i	IPM
or	CC	p	PC
a	DT	p	PC
single	JJ	i	IPM
DMARD	NNP	i	IPM
.	.	i	O

METHODS	NNP	O	O
A	NNP	O	O
cohort	NN	O	O
of	IN	O	O
199	CD	p	O
patients	NNS	p	O
with	IN	p	O
early	JJ	p	O
active	JJ	p	O
RA	NNP	p	O
were	VBD	O	O
initially	RB	O	O
randomized	VBN	O	O
to	TO	O	O
receive	VB	O	O
treatment	NN	O	O
with	IN	O	O
a	DT	O	O
combination	NN	i	O
of	IN	i	O
methotrexate	NN	i	IPM
,	,	i	O
sulfasalazine	NN	i	IPM
,	,	i	O
and	CC	i	O
hydroxychloroquine	NN	i	IPM
with	IN	i	IPM
prednisolone	NN	i	IPM
(	(	i	IPM
FIN-RACo	NNP	i	IPM
)	)	i	IPM
,	,	i	O
or	CC	i	O
treatment	NN	i	O
with	IN	i	O
a	DT	i	O
single	JJ	i	IPM
DMARD	NNP	i	IPM
(	(	i	IPM
initially	RB	i	IPM
,	,	i	IPM
sulfasalazine	NN	i	IPM
)	)	i	IPM
with	IN	i	O
or	CC	i	O
without	IN	i	O
prednisolone	NN	i	IPM
(	(	i	IPM
SINGLE	NNP	i	IPM
)	)	i	IPM
.	.	i	O

After	IN	O	O
2	CD	O	O
years	NNS	O	O
,	,	O	O
the	DT	O	O
drug-treatment	JJ	O	O
strategy	NN	O	O
became	VBD	O	O
unrestricted	JJ	O	O
,	,	O	O
but	CC	O	O
still	RB	O	O
targeted	VBN	O	O
remission	NN	O	O
.	.	O	O

The	DT	O	O
radiographs	NN	o	OOt
of	IN	O	O
hands	NNS	O	O
and	CC	O	O
feet	NNS	O	O
were	VBD	O	O
analyzed	VBN	o	OPH
by	IN	o	OPH
using	VBG	o	OPH
the	DT	o	OPH
Larsen	NNP	o	OPH
score	NN	o	OPH
at	IN	O	O
baseline	NN	O	O
,	,	O	O
2	CD	O	O
,	,	O	O
5	CD	O	O
,	,	O	O
and	CC	O	O
11	CD	O	O
years	NNS	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
radiographs	NN	O	O
of	IN	O	O
large	JJ	O	O
joints	NNS	O	O
,	,	O	O
at	IN	O	O
11	CD	O	O
years	NNS	O	O
.	.	O	O

RESULTS	VB	O	O
Sixty-five	JJ	O	O
patients	NNS	O	O
in	IN	O	O
the	DT	O	O
FIN-RACo	NNP	i	IPM
and	CC	O	O
65	CD	O	O
in	IN	O	O
the	DT	O	O
SINGLE	NNP	i	IPM
group	NN	O	O
had	VBD	O	O
radiographs	NN	O	O
of	IN	O	O
hands	NNS	O	O
and	CC	O	O
feet	NNS	O	O
available	JJ	O	O
at	IN	O	O
baseline	NN	O	O
and	CC	O	O
at	IN	O	O
11	CD	O	O
years	NNS	O	O
.	.	O	O

The	DT	O	O
mean	JJ	O	O
change	NN	O	O
from	IN	O	O
baseline	NN	O	O
to	TO	O	O
11	CD	O	O
years	NNS	O	O
in	IN	O	O
Larsen	NNP	o	OPH
score	NN	o	OPH
was	VBD	O	O
17	CD	O	O
(	(	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
,	,	O	O
12	CD	O	O
to	TO	O	O
26	CD	O	O
)	)	O	O
in	IN	O	O
the	DT	O	O
FIN-RACo	NNP	i	IPM
group	NN	O	O
and	CC	O	O
27	CD	O	O
(	(	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
,	,	O	O
22	CD	O	O
to	TO	O	O
33	CD	O	O
)	)	O	O
in	IN	O	O
the	DT	O	O
SINGLE	NNP	i	IPM
group	NN	O	O
(	(	O	O
P=0.037	NNP	O	O
)	)	O	O
.	.	O	O

In	IN	O	O
total	JJ	O	O
,	,	O	O
87	CD	O	O
%	NN	O	O
(	(	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
,	,	O	O
74	CD	O	O
to	TO	O	O
94	CD	O	O
)	)	O	O
and	CC	O	O
72	CD	O	O
%	NN	O	O
(	(	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
,	,	O	O
58	CD	O	O
to	TO	O	O
84	CD	O	O
)	)	O	O
of	IN	O	O
the	DT	O	O
patients	NNS	O	O
in	IN	O	O
the	DT	O	O
FIN-RACo	NNP	O	O
and	CC	O	O
the	DT	O	O
SINGLE	NNP	O	O
treatment	NN	O	O
arms	NNS	O	O
,	,	O	O
respectively	RB	O	O
,	,	O	O
had	VBD	O	O
no	DT	O	O
erosive	JJ	o	OPH
changes	NNS	o	OPH
in	IN	O	O
large	JJ	O	O
joints	NNS	O	O
at	IN	O	O
11	CD	O	O
years	NNS	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
Targeting	VBG	O	O
to	TO	O	O
remission	NN	O	O
with	IN	O	O
tight	JJ	O	O
clinical	JJ	O	O
controls	NNS	O	O
results	NNS	O	O
in	IN	O	O
low	JJ	O	O
radiologic	JJ	o	OOt
progression	NN	o	OOt
in	IN	O	O
most	JJS	O	O
RA	JJ	p	PSS
patients	NNS	p	PSS
.	.	p	PSS

Patients	NNS	O	O
treated	VBD	O	O
initially	RB	O	O
with	IN	O	O
a	DT	O	O
combination	NN	i	IPM
of	IN	i	IPM
DMARDs	NNP	i	IPM
have	VBP	O	O
less	RBR	O	O
long-term	JJ	o	OOt
radiologic	NN	o	OOt
damage	NN	o	OOt
than	IN	O	O
do	VBP	O	O
those	DT	O	O
treated	VBN	O	O
initially	RB	O	O
with	IN	O	O
DMARD	NNP	i	IPM
monotherapy	NN	i	IPM
.	.	i	O

TRIAL	NNP	O	O
REGISTRATION	NNP	O	O
Current	NNP	O	O
Controlled	NNP	O	O
Trials	NNP	O	O
ISRCTN18445519	NNP	O	O
.	.	O	O

[	JJ	O	O
Clinical	NNP	O	O
observation	NN	O	O
on	IN	O	O
acupuncture	NN	i	IPH
combined	VBN	O	O
with	IN	O	O
Yizhi	NNP	i	IPM
Jiannao	NNP	i	IPM
granules	NNS	i	IPM
for	IN	O	O
treatment	NN	O	O
of	IN	O	O
Alzheimer	NNP	O	O
's	POS	O	O
disease	NN	O	O
]	NNP	O	O
.	.	O	O

OBJECTIVE	NNP	O	O
To	TO	O	O
observe	VB	O	O
clinical	JJ	O	O
therapeutic	JJ	o	OA
effect	NN	o	OA
of	IN	O	O
acupuncture	NN	i	IPH
combined	VBN	O	O
with	IN	O	O
Yizhi	NNP	i	IPM
Jiannao	NNP	i	IPM
Granules	NNP	i	IPM
for	IN	O	O
treatment	NN	O	O
of	IN	O	O
Alzheimer	NNP	O	O
's	POS	O	O
disease	NN	O	O
and	CC	O	O
its	PRP$	O	O
effects	NNS	O	O
on	IN	O	O
intelligence	NN	o	OPH
,	,	o	OPH
daily	JJ	o	OPH
life	NN	o	OPH
and	CC	o	OPH
social	JJ	o	OPH
activity	NN	o	OPH
ability	NN	o	OPH
.	.	o	OPH

METHODS	NNP	O	O
Eighty-four	JJ	p	PSS
cases	NNS	p	O
were	VBD	p	O
randomly	RB	p	O
divided	VBN	p	O
into	IN	p	O
3	CD	p	O
groups	NNS	p	O
,	,	p	O
28	CD	p	PSS
cases	NNS	p	O
in	IN	p	O
each	DT	p	O
group	NN	p	O
.	.	p	O

The	DT	O	O
combined	JJ	O	O
acupuncture	NN	i	IPH
and	CC	O	O
medication	NN	O	O
group	NN	O	O
was	VBD	O	O
treated	VBN	O	O
with	IN	O	O
acupuncture	NN	i	IPH
at	IN	O	O
Baihui	NNP	O	O
(	(	O	O
GV	NNP	O	O
20	CD	O	O
)	)	O	O
,	,	O	O
Sishencong	NNP	O	O
(	(	O	O
EX-HN	NNP	O	O
1	CD	O	O
)	)	O	O
,	,	O	O
Dazhui	NNP	O	O
(	(	O	O
GV	NNP	O	O
14	CD	O	O
)	)	O	O
,	,	O	O
Guanyuan	NNP	O	O
(	(	O	O
CV	NNP	O	O
4	CD	O	O
)	)	O	O
,	,	O	O
etc	FW	O	O
.	.	O	O

and	CC	O	O
oral	JJ	O	O
administration	NN	O	O
of	IN	O	O
Yizhi	NNP	i	IPM
Jiannao	NNP	i	IPM
Granules	NNP	i	IPM
;	:	i	O
the	DT	O	O
Chinese	NNP	O	O
herb	NN	O	O
group	NN	O	O
was	VBD	O	O
treated	VBN	O	O
with	IN	O	O
Yizhi	NNP	i	IPM
Jiannao	NNP	i	IPM
Granules	NNP	i	IPM
,	,	O	O
and	CC	O	O
the	DT	O	O
western	JJ	i	IPM
medicine	NN	i	IPM
group	NN	i	IPM
with	IN	O	O
oral	JJ	O	O
administration	NN	O	O
of	IN	O	O
Aricept	NNP	i	IPM
.	.	i	O

The	DT	O	O
scores	NNS	o	OOt
for	IN	o	OOt
the	DT	o	OOt
Mini-Mental	JJ	o	OOt
State	NNP	o	OOt
Examination	NNP	o	OOt
(	(	o	OOt
MMSE	NNP	o	OOt
)	)	o	OOt
,	,	o	O
Ability	NNP	o	OPH
of	IN	o	OPH
Daily	NNP	o	OPH
Life	NNP	o	OPH
(	(	o	OPH
ADL	NNP	o	OPH
)	)	o	OPH
and	CC	o	O
the	DT	o	OA
therapeutic	JJ	o	OA
effects	NNS	o	OA
were	VBD	O	O
assessed	VBN	O	O
and	CC	O	O
compared	VBN	O	O
before	IN	O	O
treatment	NN	O	O
and	CC	O	O
after	IN	O	O
treatment	NN	O	O
for	IN	O	O
12	CD	O	O
weeks	NNS	O	O
among	IN	O	O
the	DT	O	O
groups	NNS	O	O
.	.	O	O

RESULTS	NNP	O	O
After	IN	O	O
treatment	NN	O	O
,	,	O	O
the	DT	O	O
scores	NNS	O	O
for	IN	O	O
MMSE	NNP	o	OPH
and	CC	o	OPH
ADL	NNP	o	OPH
were	VBD	O	O
improved	VBN	O	O
in	IN	O	O
the	DT	O	O
combined	JJ	i	IPH
acupuncture	NN	i	IPH
and	CC	i	IPH
medication	NN	i	IPH
group	NN	O	O
,	,	O	O
the	DT	O	O
Chinese	JJ	i	IPM
herb	NN	i	IPM
group	NN	O	O
and	CC	O	O
the	DT	O	O
western	JJ	i	IPM
medicine	NN	i	IPM
group	NN	O	O
,	,	O	O
which	WDT	O	O
were	VBD	O	O
better	RBR	O	O
in	IN	O	O
the	DT	O	O
combined	JJ	O	O
acupuncture	NN	i	IPH
and	CC	i	IPH
medication	NN	i	IPH
group	NN	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
total	JJ	o	OPH
effective	JJ	o	OPH
rate	NN	o	OPH
of	IN	O	O
85.7	CD	O	O
%	NN	O	O
in	IN	O	O
the	DT	O	O
combined	JJ	i	IPH
acupuncture	NN	i	IPH
and	CC	i	IPH
medication	NN	i	IPH
group	NN	O	O
was	VBD	O	O
better	JJR	O	O
than	IN	O	O
71.4	CD	O	O
%	NN	O	O
in	IN	O	O
the	DT	O	O
Chinese	JJ	O	O
herb	NN	O	O
group	NN	O	O
and	CC	O	O
67.9	CD	O	O
%	NN	O	O
in	IN	O	O
the	DT	O	O
western	JJ	O	O
medicine	NN	O	O
group	NN	O	O
.	.	O	O

CONCLUSION	NNP	O	O
Acupuncture	NNP	i	O
combined	VBN	i	O
with	IN	i	O
Yizhi	NNP	i	O
Jiannao	NNP	i	O
Granules	NNP	i	O
has	VBZ	O	O
a	DT	O	O
significant	JJ	O	O
therapeutic	JJ	o	OPH
effect	NN	o	OPH
on	IN	O	O
Alzheimer	NNP	O	O
's	POS	O	O
disease	NN	O	O
,	,	O	O
which	WDT	O	O
is	VBZ	O	O
better	JJR	O	O
than	IN	O	O
that	DT	O	O
of	IN	O	O
Yizhi	NNP	i	O
Jiannao	NNP	i	O
Granules	NNP	i	O
or	CC	O	O
Aricept	NNP	i	O
.	.	i	O

Comparative	NNP	O	O
dose	NN	O	O
efficacy	NN	o	OOt
study	NN	O	O
of	IN	O	O
atorvastatin	JJ	i	IPM
versus	NN	O	O
simvastatin	NN	i	IPM
,	,	i	O
pravastatin	NN	i	IPM
,	,	i	O
lovastatin	NN	i	IPM
,	,	i	O
and	CC	i	O
fluvastatin	NN	i	IPM
in	IN	O	O
patients	NNS	p	PC
with	IN	p	PC
hypercholesterolemia	NN	p	PC
(	(	O	O
the	DT	O	O
CURVES	NNP	O	O
study	NN	O	O
)	)	O	O
The	DT	O	O
objective	NN	O	O
of	IN	O	O
this	DT	O	O
multicenter	NN	p	PC
,	,	O	O
randomized	VBN	O	O
,	,	O	O
open-label	JJ	O	O
,	,	O	O
parallel-group	JJ	O	O
,	,	O	O
8-week	JJ	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
evaluate	VB	O	O
the	DT	O	O
comparative	JJ	O	O
dose	JJ	O	O
efficacy	NN	O	O
of	IN	O	O
the	DT	O	O
3-hydroxy-3-methylglutaryl	JJ	i	IPM
coenzyme	NN	i	IPM
A	NNP	i	IPM
(	(	i	IPM
HMG-CoA	NNP	i	IPM
)	)	i	IPM
reductase	NN	i	IPM
inhibitor	NN	i	IPM
atorvastatin	VBD	i	IPM
10	CD	i	IPM
,	,	i	IPM
20	CD	i	IPM
,	,	i	IPM
40	CD	i	IPM
,	,	i	IPM
and	CC	i	IPM
80	CD	i	IPM
mg	NNS	i	IPM
compared	VBN	i	O
with	IN	i	O
simvastatin	NN	i	IPM
10	CD	i	IPM
,	,	i	IPM
20	CD	i	IPM
,	,	i	IPM
and	CC	i	IPM
40	CD	i	IPM
mg	NN	i	IPM
,	,	i	O
pravastatin	NN	i	IPM
10	CD	i	IPM
,	,	i	IPM
20	CD	i	IPM
,	,	i	IPM
and	CC	i	IPM
40	CD	i	IPM
mg	NN	i	IPM
,	,	i	IPM
lovastatin	VBZ	i	IPM
20	CD	i	IPM
,	,	i	IPM
40	CD	i	IPM
,	,	i	IPM
and	CC	i	IPM
80	CD	i	IPM
mg	NN	i	IPM
,	,	i	O
and	CC	i	O
fluvastatin	$	i	IPM
20	CD	i	IPM
and	CC	i	IPM
40	CD	i	IPM
mg.	NN	i	IPM
Investigators	NNS	O	O
enrolled	VBD	O	O
534	CD	p	O
hypercholesterolemic	JJ	p	O
patients	NNS	p	O
(	(	p	O
low-density	JJ	p	O
lipoprotein	NN	p	O
[	NNP	p	O
LDL	NNP	p	O
]	NNP	p	O
cholesterol	NN	p	O
>	NN	p	O
or	CC	p	O
=	$	p	O
160	CD	p	O
mg/dl	NN	p	O
[	VBD	p	O
4.2	CD	p	O
mmol/L	NN	p	O
]	NN	p	O
and	CC	p	O
triglycerides	NNS	p	O
<	VBP	p	O
or	CC	p	O
=	VBP	p	O
400	CD	p	O
mg/dl	NN	p	O
[	VBD	p	O
4.5	CD	p	O
mmol/L	NNS	p	O
]	RB	p	O
)	)	p	O
.	.	p	O

The	DT	O	O
efficacy	JJ	O	O
end	NN	O	O
points	NNS	O	O
were	VBD	O	O
mean	JJ	O	O
percent	NN	O	O
change	NN	O	O
in	IN	O	O
plasma	NN	o	OPH
LDL	NNP	o	OPH
cholesterol	NN	o	OPH
(	(	o	OPH
primary	JJ	o	OPH
)	)	o	OPH
,	,	o	OPH
total	JJ	o	OPH
cholesterol	NN	o	OPH
,	,	o	OPH
triglycerides	NNS	o	OPH
,	,	o	OPH
and	CC	o	OPH
high-density	NN	o	OPH
lipoprotein	NN	o	OPH
cholesterol	NN	o	OPH
concentrations	NNS	o	OPH
from	IN	O	O
baseline	NN	O	O
to	TO	O	O
the	DT	O	O
end	NN	O	O
of	IN	O	O
treatment	NN	O	O
(	(	O	O
week	NN	O	O
8	CD	O	O
)	)	O	O
.	.	O	O

Atorvastatin	$	i	IPM
10	CD	O	O
,	,	O	O
20	CD	O	O
,	,	O	O
and	CC	O	O
40	CD	O	O
mg	NN	O	O
produced	VBN	O	O
greater	JJR	O	O
(	(	O	O
p	JJ	O	O
<	NN	O	O
or	CC	O	O
=	VB	O	O
0.01	CD	O	O
)	)	O	O
reductions	NNS	O	O
in	IN	O	O
LDL	NNP	o	OPH
cholesterol	NN	o	OPH
,	,	O	O
-38	CD	O	O
%	NN	O	O
,	,	O	O
-46	CD	O	O
%	NN	O	O
,	,	O	O
and	CC	O	O
-51	NNP	O	O
%	NN	O	O
,	,	O	O
respectively	RB	O	O
,	,	O	O
than	IN	O	O
the	DT	O	O
milligram	JJ	O	O
equivalent	JJ	O	O
doses	NNS	O	O
of	IN	O	O
simvastatin	NN	i	IPM
,	,	i	O
pravastatin	NN	i	IPM
,	,	i	O
lovastatin	NN	i	IPM
,	,	O	O
and	CC	O	O
fluvastatin	NN	i	IPM
.	.	i	O

Atorvastatin	$	i	IPM
10	CD	O	O
mg	NN	O	O
produced	VBN	O	O
LDL	NNP	o	OPH
cholesterol	NN	o	OPH
reductions	NNS	O	O
comparable	JJ	O	O
to	TO	O	O
or	CC	O	O
greater	JJR	O	O
than	IN	O	O
(	(	O	O
p	JJ	O	O
<	NN	O	O
or	CC	O	O
=	VB	O	O
0.02	CD	O	O
)	)	O	O
simvastatin	NN	i	IPM
10	CD	O	O
,	,	O	O
20	CD	O	O
,	,	O	O
and	CC	O	O
40	CD	O	O
mg	NN	O	O
,	,	O	O
pravastatin	NN	i	IPM
10	CD	O	O
,	,	O	O
20	CD	O	O
,	,	O	O
and	CC	O	O
40	CD	O	O
mg	NN	O	O
,	,	O	O
lovastatin	CC	i	IPM
20	CD	O	O
and	CC	O	O
40	CD	O	O
mg	NN	O	O
,	,	O	O
and	CC	O	O
fluvastatin	$	i	IPM
20	CD	O	O
and	CC	O	O
40	CD	O	O
mg.	NN	O	O
Atorvastatin	NNP	i	IPM
10	CD	O	O
,	,	O	O
20	CD	O	O
,	,	O	O
and	CC	O	O
40	CD	O	O
mg	NN	O	O
produced	VBN	O	O
greater	JJR	O	O
(	(	O	O
p	JJ	O	O
<	NN	O	O
or	CC	O	O
=	VB	O	O
0.01	CD	O	O
)	)	O	O
reductions	NNS	O	O
in	IN	O	O
total	JJ	o	OPH
cholesterol	NN	o	OPH
than	IN	O	O
the	DT	O	O
milligram	JJ	O	O
equivalent	JJ	O	O
doses	NNS	O	O
of	IN	O	O
simvastatin	NN	i	IPM
,	,	i	O
pravastatin	NN	i	IPM
,	,	i	O
lovastatin	NN	i	IPM
,	,	O	O
and	CC	O	O
fluvastatin	NN	i	IPM
.	.	i	O

All	DT	O	O
reductase	NN	O	O
inhibitors	NNS	O	O
studied	VBD	O	O
had	VBD	O	O
similar	JJ	O	O
tolerability	NN	o	OME
.	.	o	OOt

There	EX	O	O
were	VBD	O	O
no	DT	O	O
incidences	NNS	O	O
of	IN	O	O
persistent	JJ	O	O
elevations	NNS	O	O
in	IN	O	O
serum	NN	o	OPH
transaminases	NNS	o	OPH
or	CC	o	OPH
myositis	NN	o	OPH
.	.	o	OA

Reputation	NNP	O	O
management	NN	O	O
:	:	O	O
evidence	NN	O	O
for	IN	O	O
ability	NN	O	O
but	CC	O	O
reduced	JJ	O	O
propensity	NN	o	OME
in	IN	O	O
autism	NN	p	O
.	.	p	O

Previous	JJ	O	O
research	NN	O	O
has	VBZ	O	O
reported	VBN	O	O
that	IN	O	O
autistic	JJ	p	O
adults	NNS	p	O
do	VBP	O	O
not	RB	O	O
manage	VB	O	O
their	PRP$	O	O
reputation	NN	O	O
,	,	O	O
purportedly	RB	O	O
due	JJ	O	O
to	TO	O	O
problems	NNS	O	O
with	IN	O	O
theory	NN	O	O
of	IN	O	O
mind	NN	O	O
[	NNP	O	O
Izuma	NNP	O	O
,	,	O	O
Matsumoto	NNP	o	OPH
,	,	O	O
Camerer	NNP	O	O
,	,	O	O
&	CC	O	O
Adolphs	NNP	o	OPH
]	NNP	o	O
.	.	O	O

The	DT	O	O
current	JJ	O	O
study	NN	O	O
aimed	VBD	O	O
to	TO	O	O
test	VB	i	IE
alternative	JJ	i	IE
explanations	NNS	i	IE
for	IN	O	O
this	DT	O	O
apparent	JJ	O	O
lack	NN	O	O
of	IN	O	O
reputation	NN	O	O
management	NN	O	O
.	.	O	O

Twenty	NNP	p	O
typical	JJ	p	O
and	CC	p	O
19	CD	p	O
autistic	JJ	p	O
adults	NNS	p	O
donated	VBD	i	IE
to	TO	i	IE
charity	NN	i	IE
and	CC	i	IE
to	TO	i	IE
a	DT	i	IE
person	NN	i	IE
,	,	p	O
both	DT	p	O
when	WRB	p	O
alone	RB	p	O
and	CC	O	O
when	WRB	O	O
observed	VBN	O	O
.	.	O	O

In	IN	O	O
an	DT	O	O
additional	JJ	O	O
manipulation	NN	O	O
,	,	O	O
for	IN	O	O
half	NN	O	O
of	IN	O	O
the	DT	O	O
participants	NNS	O	O
,	,	O	O
the	DT	O	O
observer	NN	O	O
was	VBD	O	O
also	RB	O	O
the	DT	O	O
recipient	NN	O	O
of	IN	O	O
their	PRP$	O	O
donations	NNS	O	O
,	,	O	O
and	CC	O	O
participants	NNS	O	O
were	VBD	O	O
told	VBN	O	O
that	IN	O	O
this	DT	O	O
observer	NN	O	O
would	MD	O	O
subsequently	RB	O	O
have	VB	O	O
the	DT	O	O
opportunity	NN	O	O
to	TO	O	O
donate	VB	i	IE
to	TO	O	O
them	PRP	O	O
(	(	O	O
motivation	NN	O	O
condition	NN	O	O
)	)	O	O
.	.	O	O

This	DT	O	O
manipulation	NN	O	O
was	VBD	O	O
designed	VBN	O	O
to	TO	O	O
encourage	VB	O	O
an	DT	O	O
expectation	NN	O	O
of	IN	O	O
a	DT	O	O
reciprocal	JJ	O	O
tit-for-tat	NN	o	OPH
strategy	NN	O	O
in	IN	O	O
the	DT	O	O
participant	NN	O	O
,	,	O	O
which	WDT	O	O
may	MD	O	O
motivate	VB	O	O
participants	NNS	O	O
to	TO	O	O
change	VB	O	O
their	PRP$	O	O
behavior	NN	O	O
to	TO	O	O
receive	VB	O	O
more	JJR	O	O
donations	NNS	O	O
.	.	O	O

The	DT	O	O
remaining	VBG	O	O
participants	NNS	O	O
were	VBD	O	O
told	VBN	O	O
that	IN	O	O
the	DT	O	O
person	NN	O	O
watching	NN	O	O
was	VBD	O	O
just	RB	O	O
observing	VBG	O	O
the	DT	O	O
procedure	NN	O	O
(	(	O	O
no	DT	O	O
motivation	NN	O	O
condition	NN	O	O
)	)	O	O
.	.	O	O

Our	PRP$	O	O
results	NNS	O	O
replicated	VBD	O	O
Izuma	NNP	o	OPH
et	CC	O	O
al	NN	O	O
.	.	O	O

's	POS	O	O
finding	VBG	O	O
that	IN	p	O
autistic	JJ	p	O
adults	NNS	p	O
did	VBD	p	O
not	RB	o	O
donate	VB	o	O
more	JJR	o	O
to	TO	o	O
charity	NN	o	O
when	WRB	o	O
observed	VBN	O	O
.	.	O	O

Yet	CC	O	O
,	,	O	O
in	IN	O	O
the	DT	O	O
motivation	NN	O	O
condition	NN	O	O
,	,	O	O
both	DT	O	O
typical	JJ	O	O
and	CC	O	O
autistic	JJ	O	O
adults	NNS	i	O
donated	VBD	i	O
significantly	RB	i	O
more	RBR	O	O
to	TO	O	O
the	DT	O	O
observer	NN	O	O
when	WRB	O	O
watched	VBN	O	O
,	,	O	O
although	IN	O	O
this	DT	O	O
effect	NN	O	O
was	VBD	O	O
significantly	RB	O	O
attenuated	VBN	O	O
in	IN	O	O
autistic	JJ	p	O
individuals	NNS	p	O
.	.	p	O

Results	NNS	O	O
indicate	VBP	O	O
that	IN	O	O
,	,	O	O
while	IN	p	O
individuals	NNS	p	O
with	IN	p	O
autism	NN	p	O
may	MD	p	O
have	VB	O	O
the	DT	O	O
ability	NN	O	O
to	TO	O	O
think	VB	O	O
about	IN	O	O
reputation	NN	O	O
,	,	O	O
a	DT	O	O
reduced	JJ	O	O
expectation	NN	O	O
of	IN	O	O
reciprocal	JJ	O	O
behavior	NN	O	O
from	IN	O	O
others	NNS	O	O
may	MD	O	O
reduce	VB	O	O
the	DT	O	O
degree	NN	O	O
to	TO	O	O
which	WDT	O	O
they	PRP	o	O
engage	VBP	o	O
in	IN	o	O
reputation	NN	O	O
management	NN	O	O
.	.	O	O

Randomized	VBN	O	O
trial	NN	O	O
of	IN	O	O
recombinant	JJ	i	IPM
alpha	JJ	i	IPM
2b-interferon	JJ	i	IPM
with	IN	i	O
or	CC	i	O
without	IN	i	O
indomethacin	NNS	i	IPM
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
metastatic	JJ	p	PC
malignant	JJ	p	PC
melanoma	NN	p	PC
.	.	p	O

alpha-Interferon	NN	i	IPM
has	VBZ	O	O
antitumor	VBN	O	O
activity	NN	O	O
in	IN	O	O
a	DT	O	O
variety	NN	O	O
of	IN	O	O
malignancies	NNS	O	O
but	CC	O	O
is	VBZ	O	O
frequently	RB	O	O
associated	VBN	O	O
with	IN	O	O
unacceptable	JJ	O	O
toxic	JJ	o	OA
side-effects	NNS	o	OA
.	.	o	O

The	DT	O	O
routine	JJ	O	O
use	NN	O	O
of	IN	O	O
agents	NNS	O	O
potentially	RB	O	O
capable	JJ	O	O
of	IN	O	O
reducing	VBG	O	O
these	DT	O	O
side-effects	NNS	O	O
has	VBZ	O	O
not	RB	O	O
been	VBN	O	O
recommended	VBN	O	O
out	IN	O	O
of	IN	O	O
concern	NN	O	O
for	IN	O	O
possible	JJ	O	O
reductions	NNS	O	O
in	IN	O	O
the	DT	O	O
therapeutic	JJ	O	O
activity	NN	O	O
of	IN	O	O
interferon	NN	O	O
.	.	O	O

We	PRP	O	O
conducted	VBD	O	O
a	DT	O	O
prospective	JJ	O	O
randomized	VBN	O	O
trial	NN	O	O
of	IN	O	O
alpha-interferon	JJ	O	O
given	VBN	O	O
with	IN	O	O
or	CC	O	O
without	IN	O	O
indomethacin	JJ	i	IPM
to	TO	O	O
patients	NNS	p	O
with	IN	p	O
malignant	JJ	p	PC
melanoma	NN	p	PC
to	TO	O	O
determine	VB	O	O
what	WP	O	O
effect	NN	O	O
,	,	O	O
if	IN	O	O
any	DT	O	O
,	,	O	O
indomethacin	NN	i	IPM
might	MD	O	O
have	VB	O	O
on	IN	O	O
the	DT	O	O
toxic	NN	o	OA
,	,	o	O
immunomodulatory	NN	o	OPH
,	,	o	O
and	CC	o	O
therapeutic	JJ	o	OPH
properties	NNS	o	OOt
of	IN	O	O
interferon	NN	O	O
in	IN	O	O
this	DT	O	O
disease	NN	O	O
.	.	O	O

53	CD	p	PSS
patients	NNS	p	O
were	VBD	p	O
stratified	VBN	p	O
according	VBG	p	O
to	TO	p	O
performance	NN	p	O
status	NN	p	O
and	CC	O	O
randomized	VBN	O	O
to	TO	O	O
receive	VB	O	O
alpha	JJ	i	IPM
2b-interferon	CD	i	IPM
,	,	O	O
20	CD	O	O
million	CD	O	O
units	NNS	O	O
per	IN	O	O
m2	NN	O	O
i.v.	NN	O	O
,	,	O	O
5	CD	O	O
days	NNS	O	O
per	IN	O	O
week	NN	O	O
for	IN	O	O
4	CD	O	O
weeks	NNS	O	O
followed	VBN	O	O
by	IN	O	O
10	CD	O	O
million	CD	O	O
units	NNS	O	O
per	IN	O	O
m2	NN	O	O
s.c.	NN	O	O
three	CD	O	O
times	NNS	O	O
per	IN	O	O
week	NN	O	O
,	,	O	O
either	RB	O	O
with	IN	O	O
or	CC	O	O
without	IN	O	O
indomethacin	NN	i	IPM
,	,	O	O
25	CD	O	O
mg	NN	O	O
orally	RB	O	O
three	CD	O	O
times	NNS	O	O
a	DT	O	O
day	NN	O	O
.	.	O	O

The	DT	O	O
overall	JJ	o	OOt
major	JJ	o	OOt
response	NN	o	OPH
rate	NN	o	OPH
was	VBD	O	O
13	CD	O	O
%	NN	O	O
(	(	O	O
three	CD	O	O
complete	JJ	O	O
responders	NNS	O	O
and	CC	O	O
three	CD	O	O
partial	JJ	O	O
responders	NNS	O	O
among	IN	O	O
47	CD	O	O
evaluable	JJ	O	O
patients	NNS	O	O
)	)	O	O
and	CC	O	O
was	VBD	O	O
the	DT	O	O
same	JJ	O	O
on	IN	O	O
both	DT	O	O
arms	NNS	O	O
.	.	O	O

The	DT	O	O
mean	JJ	o	OPH
maximal	JJ	o	OPH
temperature	NN	o	OPH
elevation	NN	o	OPH
induced	VBN	O	O
by	IN	O	O
interferon	NN	O	O
was	VBD	O	O
significantly	RB	O	O
reduced	VBN	O	O
(	(	O	O
from	IN	O	O
102.1	CD	O	O
to	TO	O	O
100.7	CD	O	O
,	,	O	O
P	NNP	O	O
=	NNP	O	O
0.0002	CD	O	O
)	)	O	O
by	IN	O	O
indomethacin	NN	i	IPM
,	,	O	O
but	CC	O	O
the	DT	O	O
incidence	NN	o	OPH
and	CC	o	OPH
severity	NN	o	OPH
of	IN	o	OPH
interferon-related	JJ	o	OPH
fatigue	NN	o	OPH
,	,	o	O
reduction	NN	o	OPH
in	IN	o	OPH
performance	NN	o	OPH
status	NN	o	OPH
,	,	o	O
headache	NN	o	OPH
,	,	o	O
depression	NN	o	OME
,	,	o	O
confusion	NN	o	OME
,	,	o	O
elevations	NNS	o	OPH
in	IN	o	OPH
liver	JJ	o	OPH
function	NN	o	OPH
tests	NNS	o	OPH
,	,	o	O
and	CC	o	O
myelosuppression	NN	o	OPH
were	VBD	O	O
no	DT	O	O
different	JJ	O	O
in	IN	O	O
either	DT	O	O
arm	NN	O	O
of	IN	O	O
the	DT	O	O
study	NN	O	O
.	.	O	O

Indomethacin	NNP	i	IPM
did	VBD	O	O
not	RB	O	O
reduce	VB	O	O
the	DT	O	O
frequency	NN	o	OA
of	IN	o	OA
dose	JJ	o	OA
reductions	NNS	o	OA
for	IN	o	OA
toxic	JJ	o	OA
side-effects	NNS	o	OA
and	CC	O	O
did	VBD	O	O
not	RB	O	O
permit	VB	O	O
the	DT	O	O
administration	NN	o	OOt
of	IN	o	OOt
higher	JJR	o	OOt
interferon	NN	o	OOt
doses	NNS	o	OOt
.	.	o	O

Peripheral	NNP	o	OPH
blood	VBD	o	OPH
natural	JJ	o	OPH
killer	NN	o	OPH
activity	NN	o	OPH
was	VBD	O	O
significantly	RB	O	O
enhanced	VBN	O	O
in	IN	O	O
patients	NNS	O	O
during	IN	O	O
maintenance	NN	O	O
therapy	NN	O	O
whether	IN	O	O
or	CC	O	O
not	RB	O	O
they	PRP	O	O
received	VBD	O	O
indomethacin	NN	O	O
.	.	O	O

Indomethacin	NNP	i	IPM
appeared	VBD	O	O
to	TO	O	O
inhibit	VB	O	O
augmentation	NN	o	OPH
of	IN	o	OPH
natural	JJ	o	OPH
killer	NN	o	OPH
activity	NN	o	OPH
during	IN	O	O
high	JJ	O	O
dose	JJ	O	O
induction	NN	O	O
therapy	NN	O	O
.	.	O	O

Immunological	JJ	o	OPH
changes	NNS	o	OPH
did	VBD	O	O
not	RB	O	O
correlate	VB	O	O
with	IN	O	O
response	NN	O	O
status	NN	O	O
.	.	O	O

We	PRP	O	O
conclude	VBP	O	O
that	IN	O	O
indomethacin	NN	O	O
can	MD	O	O
reduce	VB	O	O
the	DT	O	O
fever	NN	o	OPH
associated	VBN	O	O
with	IN	O	O
interferon	NN	O	O
therapy	NN	O	O
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
malignant	JJ	p	PC
melanoma	NN	p	PC
without	IN	O	O
interfering	VBG	O	O
with	IN	O	O
its	PRP$	O	O
therapeutic	JJ	o	OPH
or	CC	o	OPH
chronic	JJ	o	OPH
immunomodulatory	NN	o	OPH
activities	NNS	o	OPH
.	.	o	O

Since	IN	O	O
fever	NN	o	OPH
is	VBZ	O	O
rarely	RB	O	O
the	DT	O	O
dose-limiting	JJ	O	O
toxicity	NN	O	O
of	IN	O	O
interferon	NN	O	O
,	,	O	O
indomethacin	NN	i	IPM
is	VBZ	O	O
of	IN	O	O
marginal	JJ	O	O
benefit	NN	O	O
to	TO	O	O
patients	NNS	p	O
with	IN	p	O
malignant	JJ	p	PC
melanoma	NN	p	PC
receiving	VBG	O	O
interferon	NN	O	O
at	IN	O	O
the	DT	O	O
doses	NNS	O	O
outlined	VBN	O	O
in	IN	O	O
this	DT	O	O
study	NN	O	O
.	.	O	O

LNH-84	JJ	O	O
regimen	NNS	O	O
:	:	O	O
a	DT	O	O
multicenter	NN	O	O
study	NN	O	O
of	IN	O	O
intensive	JJ	O	O
chemotherapy	NN	O	O
in	IN	O	O
737	CD	p	O
patients	NNS	p	O
with	IN	p	O
aggressive	JJ	p	O
malignant	JJ	p	O
lymphoma	NN	p	O
.	.	p	O

From	IN	p	O
July	NNP	p	O
1984	CD	p	O
to	TO	p	O
September	NNP	p	O
1987	CD	p	O
,	,	p	O
737	CD	p	O
patients	NNS	p	O
with	IN	p	O
aggressive	JJ	p	O
malignant	JJ	p	O
lymphoma	NN	p	O
(	(	p	O
ML	NNP	p	O
)	)	p	O
were	VBD	O	O
treated	VBN	O	O
by	IN	O	O
an	DT	O	O
intensive	JJ	i	IPM
regimen	NNS	i	IPM
(	(	i	IPM
LNH-84	NNP	i	IPM
)	)	i	IPM
comprising	VBG	O	O
three	CD	i	O
or	CC	i	O
four	CD	i	O
courses	NNS	i	O
of	IN	i	O
doxorubicin	NN	i	IPM
,	,	i	O
75	CD	i	O
mg/m2	NN	i	O
;	:	i	O
cyclophosphamide	NN	i	IPM
,	,	i	O
1,200	CD	i	O
mg/m2	NN	i	O
;	:	i	O
vindesine	NN	i	IPM
,	,	i	O
2	CD	i	O
mg/m2	NN	i	O
x	NN	i	O
2	CD	i	O
;	:	i	O
bleomycin	NN	i	IPM
,	,	i	O
10	CD	i	O
mg	NN	i	O
x	NN	i	O
2	CD	i	O
;	:	i	O
and	CC	i	O
prednisolone	NN	i	IPM
,	,	i	O
60	CD	i	O
mg/m2	NN	i	O
x	NN	i	O
5	CD	i	O
(	(	i	O
ACVB	NNP	i	O
)	)	i	O
,	,	i	O
consolidation	NN	i	O
with	IN	i	O
high-dose	JJ	i	O
methotrexate	NN	i	IPM
,	,	i	O
ifosfamide	NN	i	IPM
,	,	i	O
etoposide	RB	i	IPM
,	,	i	O
asparaginase	NN	i	IPM
,	,	i	O
and	CC	i	O
cytarabine	NN	i	IPM
,	,	i	O
and	CC	i	O
a	DT	i	O
randomized	VBN	i	O
late	JJ	i	O
intensification	NN	i	O
with	IN	i	O
two	CD	i	O
courses	NNS	i	O
of	IN	i	O
cytarabine	NN	i	IPM
,	,	i	O
cyclophosphamide	NN	i	IPM
,	,	i	O
teniposide	NN	i	IPM
,	,	i	O
bleomycin	NN	i	IPM
,	,	i	O
and	CC	i	O
prednisone	NN	i	IPM
(	(	i	O
AraCVmB	NNP	i	O
)	)	i	O
.	.	i	O

Four	CD	p	O
hundred	VBD	p	O
forty-two	JJ	p	O
patients	NNS	p	O
had	VBD	O	O
intermediate-grade	JJ	O	O
ML	NNP	O	O
,	,	O	O
221	CD	O	O
highgrade	NN	O	O
ML	NNP	O	O
,	,	O	O
and	CC	O	O
74	CD	O	O
unclassified	JJ	O	O
ML	NNP	O	O
.	.	O	O

Most	JJS	O	O
of	IN	O	O
the	DT	O	O
patients	NNS	O	O
had	VBD	O	O
advanced	JJ	O	O
disease	NN	O	O
:	:	O	O
stage	NN	O	O
IIE	NNP	O	O
(	(	O	O
23	CD	O	O
%	NN	O	O
)	)	O	O
,	,	O	O
III	NNP	O	O
(	(	O	O
13	CD	O	O
%	NN	O	O
)	)	O	O
,	,	O	O
or	CC	O	O
IV	NNP	O	O
(	(	O	O
47	CD	O	O
%	NN	O	O
)	)	O	O
;	:	O	O
38	CD	O	O
%	NN	O	O
disseminated	JJ	O	O
nodes	NNS	O	O
;	:	O	O
38	CD	O	O
%	NN	O	O
two	CD	O	O
or	CC	O	O
more	JJR	O	O
extranodal	JJ	O	O
sites	NNS	O	O
;	:	O	O
and	CC	O	O
41	CD	O	O
%	NN	O	O
a	DT	O	O
tumoral	JJ	O	O
mass	NN	O	O
greater	JJR	O	O
than	IN	O	O
10	CD	O	O
cm	NN	O	O
.	.	O	O

Five	CD	O	O
hundred	VBD	O	O
fifty-three	JJ	O	O
patients	NNS	O	O
(	(	O	O
75	CD	O	O
%	NN	O	O
)	)	O	O
went	VBD	O	O
into	IN	O	O
complete	JJ	o	OPH
remission	NN	o	OPH
(	(	o	OPH
CR	NNP	o	OPH
)	)	o	OPH
,	,	O	O
63	CD	O	O
(	(	O	O
9	CD	O	O
%	NN	O	O
)	)	O	O
into	IN	O	O
partial	JJ	o	OPH
remission	NN	o	OPH
,	,	O	O
62	CD	O	O
(	(	O	O
8	CD	O	O
%	NN	O	O
)	)	O	O
failed	VBD	o	OPH
to	TO	o	OPH
respond	VB	o	OPH
,	,	O	O
and	CC	O	O
59	CD	O	O
(	(	O	O
8	CD	O	O
%	NN	O	O
)	)	O	O
died	VBD	o	OMO
during	IN	O	O
ACVB	NNP	O	O
courses	NNS	O	O
,	,	O	O
17	CD	O	O
of	IN	O	O
them	PRP	O	O
from	IN	O	O
progression	NN	O	O
of	IN	O	O
the	DT	O	O
disease	NN	O	O
.	.	O	O

With	IN	O	O
a	DT	O	O
median	JJ	O	O
follow-up	NN	O	O
of	IN	O	O
23	CD	O	O
months	NNS	O	O
,	,	O	O
the	DT	O	O
estimated	VBN	O	O
2-year	JJ	O	O
overall	JJ	o	OPH
survival	NN	o	OPH
time	NN	o	OPH
to	TO	o	OPH
failure	NN	o	OPH
(	(	o	OPH
TTF	NNP	o	OPH
)	)	o	OPH
,	,	O	O
and	CC	O	O
time	NN	o	OPH
to	TO	o	OPH
relapse	VB	o	OPH
(	(	o	OPH
TTR	NNP	o	OPH
)	)	o	OPH
survival	NN	o	OPH
are	VBP	O	O
67	CD	O	O
%	NN	O	O
,	,	O	O
56	CD	O	O
%	NN	O	O
,	,	O	O
and	CC	O	O
67	CD	O	O
%	NN	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

Patients	NNS	O	O
receiving	VBG	O	O
a	DT	O	O
late	JJ	O	O
intensification	NN	O	O
had	VBD	O	O
the	DT	O	O
same	JJ	O	O
relapse	NN	o	OPH
rate	NN	o	OPH
as	IN	O	O
the	DT	O	O
other	JJ	O	O
patients	NNS	O	O
.	.	O	O

A	DT	O	O
persistent	JJ	o	OPH
fibronecrotic	JJ	o	OPH
mass	NN	o	OPH
was	VBD	O	O
found	VBN	O	O
in	IN	O	O
150	CD	O	O
patients	NNS	O	O
(	(	O	O
20	CD	O	O
%	NN	O	O
)	)	O	O
and	CC	O	O
did	VBD	O	O
not	RB	O	O
influence	VB	O	O
the	DT	O	O
relapse	NN	o	OPH
rate	NN	o	OPH
.	.	o	OOt

Toxicity	NNP	o	OA
was	VBD	O	O
mainly	RB	O	O
neutropenia	JJ	o	OA
and	CC	O	O
infection	NN	o	OPH
during	IN	O	O
the	DT	O	O
ACVB	NNP	O	O
courses	NNS	O	O
,	,	O	O
with	IN	O	O
40	CD	O	O
patients	NNS	O	O
(	(	O	O
5	CD	O	O
%	NN	O	O
)	)	O	O
dying	VBG	o	OMO
from	IN	o	OMO
septic	JJ	o	OMO
complications	NNS	o	OMO
while	IN	O	O
responding	VBG	O	O
to	TO	O	O
treatment	NN	O	O
.	.	O	O

Fifty-three	JJ	O	O
percent	NN	O	O
of	IN	O	O
the	DT	O	O
patients	NNS	O	O
had	VBD	O	O
a	DT	O	O
neutropenia	NN	o	OA
less	JJR	O	O
than	IN	O	O
0.500	CD	O	O
x	JJ	O	O
10	CD	O	O
(	(	O	O
9	CD	O	O
)	)	O	O
/L	NN	O	O
,	,	O	O
58	CD	O	O
%	NN	O	O
fever	NN	O	O
(	(	O	O
6	CD	O	O
%	NN	O	O
grade	JJ	O	O
4	CD	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
49	CD	O	O
%	NN	O	O
a	DT	O	O
documented	JJ	o	OA
infection	NN	o	OA
(	(	O	O
8	CD	O	O
%	NN	O	O
grade	JJ	O	O
4	CD	O	O
)	)	O	O
.	.	O	O

These	DT	O	O
results	NNS	O	O
obtained	VBD	O	O
with	IN	O	O
the	DT	O	O
LNH-84	JJ	O	O
regimen	NNS	O	O
demonstrate	VBP	O	O
that	IN	O	O
this	DT	O	O
therapeutic	JJ	O	O
scheme	NN	O	O
is	VBZ	O	O
an	DT	O	O
effective	JJ	O	O
treatment	NN	O	O
for	IN	O	O
aggressive	JJ	O	O
ML	NNP	O	O
.	.	O	O

The	DT	O	O
aging	VBG	O	O
motor	NN	O	O
system	NN	O	O
as	IN	O	O
a	DT	O	O
model	NN	O	O
for	IN	O	O
plastic	JJ	O	O
changes	NNS	O	O
of	IN	O	O
GABA-mediated	NNP	O	O
intracortical	JJ	O	O
inhibition	NN	O	O
and	CC	O	O
their	PRP$	O	O
behavioral	JJ	O	O
relevance	NN	O	O
.	.	O	O

Since	IN	O	O
GABAA-mediated	JJ	O	O
intracortical	JJ	O	O
inhibition	NN	O	O
has	VBZ	O	O
been	VBN	O	O
shown	VBN	O	O
to	TO	O	O
underlie	VB	O	O
plastic	NN	O	O
changes	NNS	O	O
throughout	IN	O	O
the	DT	O	O
lifespan	NN	O	O
from	IN	O	O
development	NN	O	O
to	TO	O	O
aging	VBG	O	O
,	,	O	O
here	RB	O	O
,	,	O	O
the	DT	O	O
aging	VBG	O	O
motor	NN	O	O
system	NN	O	O
was	VBD	O	O
used	VBN	O	O
as	IN	O	O
a	DT	O	O
model	NN	O	O
to	TO	O	O
analyze	VB	O	O
the	DT	O	O
interdependence	NN	O	O
of	IN	O	O
plastic	JJ	O	O
alterations	NNS	O	O
within	IN	O	O
the	DT	O	O
inhibitory	JJ	O	O
motorcortical	JJ	O	O
network	NN	O	O
and	CC	O	O
level	NN	O	O
of	IN	O	O
behavioral	JJ	O	O
performance	NN	O	O
.	.	O	O

Double-pulse	JJ	i	IPH
transcranial	JJ	i	IPH
magnetic	JJ	i	IPH
stimulation	NN	i	IPH
(	(	i	IPH
dpTMS	NN	i	IPH
)	)	i	IPH
was	VBD	i	IPH
used	VBN	i	IPH
to	TO	i	IPH
examine	VB	i	IPH
inhibition	NN	i	IPH
by	IN	i	IPH
means	NNS	i	IPH
of	IN	i	IPH
short-interval	JJ	i	IPH
intracortical	JJ	i	IPH
inhibition	NN	i	IPH
(	(	i	IPH
SICI	NNP	i	IPH
)	)	i	IPH
of	IN	i	IPH
the	DT	i	IPH
contralateral	JJ	i	IPH
primary	JJ	i	IPH
motor	NN	i	IPH
cortex	NN	i	IPH
in	IN	O	O
a	DT	O	O
sample	NN	O	O
of	IN	O	O
64	CD	p	O
healthy	JJ	p	O
right-handed	JJ	p	O
human	JJ	p	O
subjects	NNS	p	O
covering	VBG	p	O
a	DT	p	O
wide	JJ	p	O
range	NN	p	O
of	IN	p	O
the	DT	p	O
adult	NN	p	O
lifespan	NN	p	O
(	(	p	O
age	NN	p	O
range	NN	p	O
20-88	CD	p	O
years	NNS	p	O
,	,	p	O
mean	VB	p	O
47.6	CD	p	O
?	.	p	O
20.7	CD	p	O
,	,	p	O
34	CD	p	O
female	NN	p	O
)	)	p	O
.	.	p	O

SICI	NNP	o	O
was	VBD	O	O
evaluated	VBN	O	O
during	IN	O	O
resting	VBG	O	O
state	NN	O	O
and	CC	O	O
in	IN	O	O
an	DT	O	O
event-related	JJ	O	O
condition	NN	O	O
during	IN	O	O
movement	NN	O	O
preparation	NN	O	O
in	IN	O	O
a	DT	O	O
visually	RB	O	O
triggered	VBN	O	O
simple	JJ	O	O
reaction	NN	O	O
time	NN	O	O
task	NN	O	O
.	.	O	O

In	IN	O	O
a	DT	O	O
subgroup	NN	O	O
(	(	O	O
N	NNP	O	O
=	NNP	O	O
23	CD	O	O
)	)	O	O
,	,	O	O
manual	JJ	o	O
motor	NN	o	OPH
performance	NN	o	OPH
was	VBD	O	O
tested	VBN	O	O
with	IN	O	O
tasks	NNS	O	O
of	IN	O	O
graded	VBN	O	O
dexterous	JJ	O	O
demand	NN	O	O
.	.	O	O

Weak	JJ	o	O
resting-state	JJ	o	O
inhibition	NN	o	O
was	VBD	O	O
associated	VBN	O	O
with	IN	O	O
an	DT	O	O
overall	JJ	O	O
lower	JJR	O	O
manual	JJ	O	O
motor	NN	O	O
performance	NN	O	O
.	.	O	O

Better	RBR	o	O
event-related	JJ	o	O
modulation	NN	o	O
of	IN	o	O
inhibition	NN	o	O
correlated	VBN	O	O
with	IN	O	O
better	JJR	O	O
performance	NN	O	O
in	IN	O	O
more	RBR	O	O
demanding	JJ	O	O
tasks	NNS	O	O
,	,	O	O
in	IN	O	O
which	WDT	O	O
fast	RB	O	O
alternating	VBG	O	O
activation	NN	O	O
of	IN	O	O
cortical	JJ	O	O
representations	NNS	O	O
are	VBP	O	O
necessary	JJ	O	O
.	.	O	O

Declining	VBG	o	O
resting-state	JJ	o	O
inhibition	NN	o	O
was	VBD	O	O
associated	VBN	O	O
with	IN	O	O
weakened	JJ	O	O
event-related	JJ	O	O
modulation	NN	O	O
of	IN	O	O
inhibition	NN	O	O
.	.	O	O

Therefore	NN	O	O
,	,	O	O
reduced	VBD	o	O
resting-state	JJ	o	O
inhibition	NN	O	O
might	MD	O	O
lead	VB	O	O
to	TO	O	O
a	DT	O	O
subsequent	JJ	O	O
loss	NN	O	O
of	IN	O	O
modulatory	JJ	O	O
capacity	NN	O	O
,	,	O	O
possibly	RB	O	O
reflecting	VBG	O	O
malfunctioning	VBG	O	O
precision	NN	O	O
in	IN	O	O
GABAAergic	NNP	O	O
neurotransmission	NN	O	O
;	:	O	O
the	DT	O	O
consequence	NN	O	O
is	VBZ	O	O
an	DT	O	O
inevitable	JJ	O	O
decline	NN	O	O
in	IN	O	O
motor	NN	O	O
function	NN	O	O
.	.	O	O

Long	JJ	O	O
term	NN	O	O
follow	VBP	O	O
up	IN	O	O
of	IN	O	O
patients	NNS	p	O
treated	VBN	p	O
for	IN	p	O
Helicobacter	NNP	o	OPH
pylori	JJ	o	OPH
infection	NN	o	OPH
.	.	o	OPH

BACKGROUND	NNP	O	O
Helicobacter	NNP	O	O
pylori	POS	O	O
infection	NN	O	O
induces	NNS	O	O
progressive	JJ	O	O
inflammatory	JJ	o	OPH
changes	NNS	o	OPH
in	IN	O	O
the	DT	O	O
gastric	JJ	O	O
mucosa	NN	O	O
that	WDT	O	O
may	MD	O	O
lead	VB	O	O
to	TO	O	O
gastric	JJ	O	O
cancer	NN	O	O
.	.	O	O

Understanding	VBG	O	O
long	JJ	O	O
term	NN	O	O
effects	NNS	O	O
resulting	VBG	O	O
from	IN	O	O
the	DT	O	O
cure	NN	O	O
of	IN	O	O
this	DT	O	O
infection	NN	O	O
is	VBZ	O	O
needed	VBN	O	O
to	TO	O	O
design	VB	O	O
cancer	NN	O	O
prevention	NN	O	O
strategies	NNS	O	O
.	.	O	O

METHODS	NNP	O	O
A	NNP	O	O
cohort	NN	O	O
of	IN	O	O
795	CD	p	PSS
adults	NNS	p	PA
with	IN	p	O
preneoplastic	JJ	p	PC
gastric	JJ	p	PC
lesions	NNS	p	PC
was	VBD	p	O
randomised	VBN	p	O
to	TO	p	O
receive	VB	i	IPM
anti-H	JJ	i	IPM
pylori	NN	i	IPM
treatment	NN	i	IPM
and/or	JJ	i	IPM
antioxidants	NNS	i	IPM
.	.	i	IPM

At	IN	O	O
the	DT	O	O
end	NN	O	O
of	IN	O	O
six	CD	O	O
years	NNS	O	O
of	IN	O	O
intervention	NN	O	O
,	,	O	O
those	DT	O	O
who	WP	O	O
did	VBD	O	O
not	RB	O	O
receive	VB	O	O
anti-H	JJ	O	O
pylori	NN	O	O
treatment	NN	O	O
were	VBD	O	O
offered	VBN	O	O
it	PRP	O	O
.	.	O	O

Gastric	JJ	O	O
biopsies	NNS	O	O
were	VBD	O	O
obtained	VBN	O	O
at	IN	O	O
baseline	NN	O	O
,	,	O	O
and	CC	O	O
at	IN	O	O
3	CD	O	O
,	,	O	O
6	CD	O	O
,	,	O	O
and	CC	O	O
12	CD	O	O
years	NNS	O	O
.	.	O	O

A	DT	O	O
histopathology	NN	o	OPH
score	NN	o	OPH
was	VBD	O	O
utilised	VBN	O	O
to	TO	O	O
document	VB	O	O
changes	NNS	O	O
in	IN	O	O
gastric	JJ	o	OPH
lesions	NNS	o	OPH
.	.	o	OPH

Non-linear	JJ	O	O
mixed	JJ	O	O
models	NNS	O	O
were	VBD	O	O
used	VBN	O	O
to	TO	O	O
estimate	VB	O	O
the	DT	O	O
cumulative	JJ	O	O
effect	NN	O	O
of	IN	O	O
H	NNP	O	O
pylori	JJ	O	O
clearance	NN	O	O
on	IN	O	O
histopathology	NN	o	OPH
scores	NNS	o	OPH
adjusted	VBN	O	O
for	IN	O	O
follow	VB	O	O
up	RP	O	O
time	NN	O	O
,	,	O	O
interventions	NNS	O	O
,	,	O	O
and	CC	O	O
confounders	NNS	O	O
.	.	O	O

RESULTS	NNP	O	O
Ninety	NNP	p	O
seven	CD	p	O
per	IN	p	O
cent	NN	p	O
of	IN	p	O
subjects	NNS	p	O
were	VBD	p	O
H	NNP	o	OPH
pylori	JJ	o	OPH
positive	JJ	p	O
at	IN	p	O
baseline	NN	p	O
,	,	p	O
and	CC	p	O
53	CD	p	O
%	NN	p	O
were	VBD	p	O
positive	JJ	p	O
at	IN	p	O
12	CD	p	O
years	NNS	p	O
.	.	p	O

Subjects	NNS	O	O
accumulated	JJ	O	O
1703	CD	O	O
person	NN	O	O
years	NNS	O	O
free	JJ	o	OPH
of	IN	o	OPH
infection	NN	o	OPH
.	.	o	OPH

A	DT	O	O
multivariate	NN	O	O
model	NN	O	O
showed	VBD	O	O
a	DT	O	O
significant	JJ	O	O
regression	NN	o	OPH
in	IN	o	OPH
histopathology	NN	o	OPH
score	NN	o	OPH
as	IN	O	O
a	DT	O	O
function	NN	O	O
of	IN	O	O
the	DT	O	O
square	NN	O	O
of	IN	O	O
H	NNP	o	OPH
pylori	FW	o	OPH
negative	JJ	o	OPH
time	NN	o	OPH
.	.	o	OPH

Subjects	NNS	O	O
who	WP	O	O
were	VBD	O	O
H	NNP	o	OPH
pylori	JJ	o	OPH
negative	JJ	O	O
had	VBD	O	O
14.8	CD	O	O
%	NN	O	O
more	JJR	O	O
regression	NN	o	OPH
and	CC	O	O
13.7	CD	O	O
%	NN	O	O
less	JJR	O	O
progression	NN	o	OPH
than	IN	O	O
patients	NNS	O	O
who	WP	O	O
were	VBD	O	O
positive	JJ	O	O
at	IN	O	O
12	CD	O	O
years	NNS	O	O
(	(	O	O
p	JJ	O	O
=	NNP	O	O
0.001	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
rate	NN	o	OPH
of	IN	o	OPH
healing	NN	o	OPH
of	IN	o	OPH
gastric	JJ	o	OPH
lesions	NNS	o	OPH
occurred	VBD	O	O
more	RBR	O	O
rapidly	RB	O	O
as	IN	O	O
years	NNS	o	OA
free	JJ	o	OA
of	IN	o	OA
infection	NN	o	OA
accumulated	VBN	O	O
,	,	O	O
and	CC	O	O
was	VBD	O	O
more	RBR	O	O
pronounced	JJ	O	O
in	IN	O	O
less	RBR	O	O
advanced	JJ	O	O
lesions	NNS	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
Preneoplastic	NNP	o	OPH
gastric	JJ	o	OPH
lesions	NNS	o	OPH
regress	NN	O	O
at	IN	O	O
a	DT	O	O
rate	NN	O	O
equal	JJ	O	O
to	TO	O	O
the	DT	O	O
square	NN	O	O
of	IN	O	O
time	NN	O	O
in	IN	O	O
patients	NNS	O	O
rendered	JJ	O	O
free	JJ	O	O
of	IN	O	O
H	NNP	O	O
pylori	JJ	O	O
infection	NN	O	O
.	.	O	O

Our	PRP$	O	O
findings	NNS	O	O
suggest	VBP	O	O
that	IN	O	O
patients	NNS	p	O
with	IN	p	O
preneoplastic	JJ	p	PC
gastric	JJ	p	PC
lesions	NNS	p	PC
should	MD	O	O
be	VB	O	O
treated	VBN	O	O
and	CC	O	O
cured	VBN	O	O
of	IN	O	O
their	PRP$	O	O
H	NNP	o	O
pylori	NN	o	O
infection	NN	o	O
.	.	o	O

Aztreonam	NNP	i	IPM
versus	NN	i	O
gentamicin	NN	i	IPM
for	IN	O	O
short-term	JJ	O	O
prophylaxis	NN	O	O
in	IN	O	O
biliary	JJ	p	O
and	CC	p	O
gastric	JJ	p	O
surgery	NN	p	O
.	.	p	O

Short-term	NNP	O	O
antibiotic	JJ	O	O
prophylaxis	NN	O	O
was	VBD	O	O
studied	VBN	O	O
in	IN	O	O
80	CD	p	PSS
patients	NNS	p	O
undergoing	JJ	p	O
biliary	JJ	p	O
or	CC	p	O
gastric	JJ	p	O
surgery	NN	p	O
.	.	p	O

The	DT	O	O
patients	NNS	O	O
were	VBD	O	O
randomized	VBN	O	O
to	TO	O	O
receive	VB	O	O
1	CD	O	O
g	NN	O	O
of	IN	O	O
aztreonam	NN	i	IPM
or	CC	O	O
80	CD	O	O
mg	NN	O	O
of	IN	O	O
gentamicin	NN	i	IPM
intravenously	RB	O	O
30	CD	O	O
minutes	NNS	O	O
before	IN	O	O
surgery	NN	O	O
and	CC	O	O
8	CD	O	O
and	CC	O	O
16	CD	O	O
hours	NNS	O	O
after	IN	O	O
surgery	NN	O	O
.	.	O	O

Of	IN	O	O
samples	NNS	O	O
taken	VBN	O	O
from	IN	O	O
the	DT	O	O
abdominal	JJ	O	O
cavity	NN	O	O
for	IN	O	O
bacteriologic	NN	O	O
study	NN	O	O
,	,	O	O
53	CD	O	O
%	NN	O	O
were	VBD	O	O
culture	NN	O	O
positive	JJ	O	O
.	.	O	O

Wound	IN	o	OPH
infections	NNS	o	OPH
developed	VBN	O	O
in	IN	O	O
two	CD	O	O
(	(	O	O
4.5	CD	O	O
%	NN	O	O
)	)	O	O
of	IN	O	O
44	CD	O	O
patients	NNS	O	O
receiving	VBG	O	O
aztreonam	NN	i	IPM
and	CC	O	O
in	IN	O	O
seven	CD	O	O
(	(	O	O
19.4	CD	O	O
%	NN	O	O
)	)	O	O
of	IN	O	O
36	CD	O	O
patients	NNS	O	O
treated	VBN	O	O
with	IN	O	O
gentamicin	NN	i	IPM
.	.	i	IPM

Staphylococcus	NNP	o	O
epidermidis	NN	o	O
and	CC	o	O
Enterobacter	NNP	o	O
species	NNS	o	O
were	VBD	O	O
isolated	VBN	O	O
from	IN	O	O
sites	NNS	O	O
of	IN	O	O
wound	JJ	o	OPH
infection	NN	o	OPH
in	IN	O	O
the	DT	O	O
aztreonam	JJ	i	IPM
group	NN	O	O
;	:	O	O
Escherichia	NNP	O	O
coli	NNS	O	O
(	(	O	O
two	CD	O	O
isolates	NNS	O	O
)	)	O	O
,	,	O	O
Pseudomonas	NNP	O	O
aeruginosa	NN	O	O
(	(	O	O
two	CD	O	O
isolates	NNS	O	O
)	)	O	O
,	,	O	O
Enterobacter	NNP	o	O
species	NNS	o	O
,	,	o	O
Klebsiella	NNP	o	O
species	NNS	o	O
,	,	o	O
Enterococcus	NNP	o	O
faecalis	NN	o	O
,	,	o	O
and	CC	o	O
Aeromonas	NNP	o	O
hydrophila	NN	o	O
were	VBD	O	O
isolated	VBN	O	O
from	IN	O	O
the	DT	O	O
gentamicin	NN	O	O
group	NN	O	O
.	.	O	O

Our	PRP$	O	O
data	NNS	O	O
indicate	VBP	O	O
that	IN	O	O
aztreonam	NN	i	IPM
is	VBZ	O	O
safe	JJ	o	OOt
and	CC	o	OOt
effective	JJ	o	OOt
for	IN	O	O
the	DT	O	O
prevention	NN	O	O
of	IN	O	O
infections	NNS	O	O
following	VBG	O	O
biliary	JJ	p	O
and	CC	p	O
gastric	JJ	p	O
surgery	NN	p	O
.	.	p	O

Abstinence	NNP	o	OME
incentive	NN	o	OME
effects	NNS	o	OME
in	IN	O	O
a	DT	O	O
short-term	JJ	O	O
outpatient	JJ	O	O
detoxification	NN	O	O
program	NN	O	O
.	.	O	O

Despite	IN	O	O
being	VBG	O	O
widely	RB	O	O
available	JJ	O	O
,	,	O	O
outpatient	JJ	O	O
detoxification	NN	O	O
has	VBZ	O	O
limited	VBN	O	O
efficacy	NN	O	O
as	IN	O	O
a	DT	O	O
stand-alone	JJ	O	O
treatment	NN	O	O
.	.	O	O

This	DT	O	O
study	NN	O	O
examined	VBD	O	O
whether	IN	O	O
abstinence-contingent	JJ	i	IE
incentives	NNS	i	IE
would	MD	O	O
improve	VB	O	O
outcomes	NNS	O	O
for	IN	O	O
patients	NNS	p	O
entering	VBG	p	O
outpatient	JJ	p	O
opiate	JJ	o	OOt
detoxification	NN	o	OOt
.	.	o	OOt

Participants	NNS	p	O
(	(	p	O
N	NNP	p	O
=	NNP	p	O
211	CD	p	O
)	)	p	O
received	VBD	O	O
a	DT	O	O
100	CD	O	O
US	NNP	O	O
dollars	NNS	O	O
voucher	RB	O	O
on	IN	O	O
the	DT	O	O
last	JJ	O	O
day	NN	O	O
of	IN	O	O
detoxification	NN	i	O
either	CC	O	O
contingent	NN	O	O
on	IN	O	O
opiate	NN	O	O
and	CC	O	O
cocaine	NN	O	O
abstinence	NN	O	O
or	CC	O	O
noncontingently	RB	O	O
.	.	O	O

Urine	JJ	O	O
samples	NNS	O	O
were	VBD	O	O
collected	VBN	O	O
at	IN	O	O
intake	NN	O	O
,	,	O	O
on	IN	O	O
Wednesday	NNP	O	O
,	,	O	O
Friday	NNP	O	O
(	(	O	O
the	DT	O	O
last	JJ	O	O
day	NN	O	O
of	IN	O	O
detoxification	NN	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
following	JJ	O	O
Monday	NNP	O	O
.	.	O	O

Among	IN	O	O
contingent-voucher	JJ	i	IE
participants	NNS	O	O
,	,	O	O
31	CD	O	O
%	NN	O	O
were	VBD	O	O
drug-free	JJ	o	OME
on	IN	O	O
Friday	NNP	O	O
compared	VBN	O	O
with	IN	O	O
18	CD	O	O
%	NN	O	O
of	IN	O	O
noncontingent	NN	O	O
controls	NNS	O	O
(	(	O	O
Z	NNP	O	O
=	NNP	O	O
2.4	CD	O	O
,	,	O	O
p	NN	O	O
<	NNP	O	O
.05	NNP	O	O
)	)	O	O
.	.	O	O

Few	JJ	O	O
(	(	O	O
12-13	CD	O	O
%	NN	O	O
)	)	O	O
participants	NNS	O	O
tested	VBN	O	O
negative	JJ	o	O
on	IN	O	O
Monday	NNP	O	O
.	.	O	O

Results	NNP	O	O
support	VBD	O	O
the	DT	O	O
ability	NN	O	O
of	IN	O	O
vouchers	NNS	O	O
to	TO	O	O
produce	VB	O	O
modest	JJ	o	OME
improvements	NNS	o	OME
in	IN	o	OME
abstinence	NN	o	OME
initiation	NN	o	OME
rates	NNS	o	OME
during	IN	O	O
brief	JJ	O	O
detoxification	NN	O	O
but	CC	O	O
suggest	VBP	O	O
that	IN	O	O
additional	JJ	O	O
interventions	NNS	O	O
are	VBP	O	O
needed	VBN	O	O
to	TO	O	O
sustain	VB	O	O
improvements	NNS	O	O
.	.	O	O

Activation	NN	O	O
and	CC	O	O
intermuscular	JJ	O	O
coherence	NN	O	O
of	IN	O	O
distal	JJ	O	O
arm	NN	O	O
muscles	NNS	O	O
during	IN	O	O
proximal	JJ	O	O
muscle	NN	O	O
contraction	NN	O	O
.	.	O	O

In	IN	O	O
the	DT	O	O
human	JJ	O	O
upper	JJ	O	O
extremity	NN	O	O
(	(	O	O
UE	NNP	O	O
)	)	O	O
,	,	O	O
unintended	JJ	O	O
effects	NNS	O	O
of	IN	O	O
proximal	JJ	O	O
muscle	NN	O	O
activation	NN	O	O
on	IN	O	O
muscles	NNS	O	O
controlling	VBG	O	O
the	DT	O	O
hand	NN	O	O
could	MD	O	O
be	VB	O	O
an	DT	O	O
important	JJ	O	O
aspect	NN	O	O
of	IN	O	O
motor	NN	O	O
control	NN	O	O
due	JJ	O	O
to	TO	O	O
the	DT	O	O
necessary	JJ	O	O
coordination	NN	O	O
of	IN	O	O
distal	NN	O	O
and	CC	O	O
proximal	JJ	O	O
segments	NNS	O	O
during	IN	O	O
functional	JJ	O	O
activities	NNS	O	O
.	.	O	O

This	DT	O	O
study	NN	O	O
aimed	VBD	O	O
to	TO	O	O
elucidate	VB	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
concurrent	JJ	O	O
activation	NN	O	O
of	IN	O	O
elbow	NN	O	O
muscles	NNS	O	O
on	IN	O	O
the	DT	O	O
coordination	NN	O	O
between	IN	O	O
hand	NN	O	O
muscles	NNS	O	O
performing	VBG	O	O
a	DT	O	O
grip	NN	O	O
task	NN	O	O
.	.	O	O

Eleven	NNP	p	O
healthy	JJ	p	O
subjects	NNS	p	O
performed	VBN	O	O
precision	NN	i	IPH
grip	NN	i	IPH
tasks	NNS	i	IPH
while	IN	i	IPH
a	DT	i	IPH
constant	JJ	i	IPH
extension	NN	i	IPH
or	CC	i	IPH
flexion	NN	i	IPH
moment	NN	i	IPH
was	VBD	i	IPH
applied	VBN	i	IPH
to	TO	i	IPH
their	PRP$	i	IPH
elbow	NN	i	IPH
joints	NNS	i	IPH
,	,	O	O
inducing	VBG	O	O
a	DT	O	O
sustained	VBN	O	O
submaximal	JJ	O	O
contraction	NN	O	O
of	IN	O	O
elbow	NN	O	O
muscles	NNS	O	O
to	TO	O	O
counter	VB	O	O
the	DT	O	O
applied	JJ	O	O
torque	NN	O	O
.	.	O	O

Activation	NNP	O	O
of	IN	O	O
four	CD	O	O
hand	NN	O	O
muscles	NNS	O	O
was	VBD	O	O
measured	VBN	O	O
during	IN	O	O
each	DT	O	O
task	NN	O	O
condition	NN	O	O
using	VBG	O	O
surface	NN	i	IPH
electromyography	NN	i	IPH
(	(	i	IPH
EMG	NNP	i	IPH
)	)	i	IPH
.	.	i	IPH

When	WRB	O	O
concurrent	JJ	O	O
activation	NN	O	O
of	IN	O	O
elbow	NN	O	O
muscles	NNS	O	O
was	VBD	O	O
induced	VBN	O	O
,	,	O	O
significant	JJ	O	O
changes	NNS	O	O
in	IN	O	O
the	DT	O	O
activation	NN	o	OPH
levels	NNS	o	OPH
of	IN	o	OPH
the	DT	o	OPH
hand	NN	o	OPH
muscles	NNS	o	OPH
were	VBD	O	O
observed	VBN	O	O
,	,	O	O
with	IN	O	O
greater	JJR	O	O
effects	NNS	O	O
on	IN	O	O
the	DT	O	O
extrinsic	JJ	O	O
finger	NN	O	O
extensor	NN	O	O
(	(	O	O
23.2	CD	O	O
%	NN	O	O
increase	NN	O	O
under	IN	O	O
30	CD	O	O
%	NN	O	O
elbow	NN	O	O
extensor	NN	O	O
activation	NN	O	O
;	:	O	O
p	CC	O	O
=	VB	O	O
0.003	CD	O	O
)	)	O	O
than	IN	O	O
extrinsic	JJ	O	O
finger	NN	O	O
flexor	NN	O	O
(	(	O	O
14.2	CD	O	O
%	NN	O	O
increase	NN	O	O
under	IN	O	O
30	CD	O	O
%	NN	O	O
elbow	NN	O	O
flexor	JJ	O	O
activation	NN	O	O
;	:	O	O
p	CC	O	O
=	VB	O	O
0.130	CD	O	O
)	)	O	O
.	.	O	O

Elbow	NNP	o	OPH
muscle	NN	o	OPH
activation	NN	o	OPH
also	RB	O	O
induced	VBD	O	O
involuntary	JJ	O	O
changes	NNS	O	O
in	IN	O	O
the	DT	O	O
intrinsic	JJ	o	OPH
thumb	NN	o	OPH
flexor	NN	o	OPH
activation	NN	o	OPH
(	(	O	O
44.6	CD	O	O
%	NN	O	O
increase	NN	O	O
under	IN	O	O
30	CD	O	O
%	NN	O	O
elbow	NN	O	O
extensor	NN	O	O
activation	NN	O	O
;	:	O	O
p	CC	O	O
=	VB	O	O
0.005	CD	O	O
)	)	O	O
.	.	O	O

EMG-EMG	JJ	O	O
coherence	NN	O	O
analyses	NNS	O	O
revealed	VBD	O	O
that	IN	O	O
elbow	JJ	o	OPH
muscle	NN	o	OPH
activation	NN	o	OPH
significantly	RB	O	O
reduced	VBD	O	O
intermuscular	JJ	o	OPH
coherence	NN	o	OPH
between	IN	o	OPH
distal	JJ	o	OPH
muscle	NN	o	OPH
pairs	NNS	o	OPH
,	,	O	O
with	IN	O	O
its	PRP$	O	O
greatest	JJS	O	O
effects	NNS	O	O
on	IN	O	O
coherence	NN	O	O
in	IN	O	O
the	DT	O	O
?-band	NN	O	O
(	(	O	O
13-25	JJ	O	O
Hz	NNP	O	O
)	)	O	O
(	(	O	O
average	NN	O	O
of	IN	O	O
17	CD	O	O
%	NN	O	O
decrease	NN	O	O
under	IN	O	O
30	CD	O	O
%	NN	O	O
elbow	NN	O	O
flexor	JJ	O	O
activation	NN	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
results	NNS	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
provide	VBP	O	O
evidence	NN	O	O
for	IN	O	O
involuntary	JJ	O	O
,	,	O	O
muscle-specific	JJ	O	O
interactions	NNS	O	O
between	IN	O	O
distal	NN	O	O
and	CC	O	O
proximal	JJ	O	O
UE	NNP	O	O
muscles	NNS	O	O
,	,	O	O
which	WDT	O	O
may	MD	O	O
contribute	VB	O	O
to	TO	O	O
UE	NNP	O	O
motor	NN	O	O
performance	NN	O	O
in	IN	O	O
health	NN	O	O
and	CC	O	O
disease	NN	O	O
.	.	O	O

Effect	NN	O	O
of	IN	O	O
antipsychotic	JJ	i	IPM
drugs	NNS	i	IPM
on	IN	O	O
cortical	JJ	o	OPH
thickness	NN	o	OPH
.	.	o	OPH

A	DT	O	O
randomized	JJ	O	O
controlled	VBN	O	O
one-year	JJ	O	O
follow-up	NN	O	O
study	NN	O	O
of	IN	O	O
haloperidol	NN	i	IPM
,	,	i	O
risperidone	NN	i	IPM
and	CC	i	O
olanzapine	NN	i	IPM
.	.	i	O

BACKGROUND	NNP	O	O
Imaging	NNP	O	O
evidence	NN	O	O
indicates	VBZ	O	O
that	IN	O	O
brain	NN	O	O
alterations	NNS	O	O
are	VBP	O	O
primary	JJ	O	O
to	TO	O	O
the	DT	O	O
full-blown	JJ	O	O
onset	NN	O	O
of	IN	O	O
schizophrenia	NN	O	O
and	CC	O	O
seem	VBP	O	O
to	TO	O	O
progress	VB	O	O
across	IN	O	O
time	NN	O	O
.	.	O	O

The	DT	O	O
potential	JJ	O	O
effects	NNS	o	OOt
of	IN	o	OOt
antipsychotic	JJ	o	OOt
medication	NN	o	OOt
on	IN	O	O
brain	NN	O	O
structure	NN	O	O
represent	VBP	O	O
a	DT	O	O
key	JJ	O	O
factor	NN	O	O
in	IN	O	O
understanding	VBG	O	O
brain	NN	O	O
changes	NNS	O	O
in	IN	O	O
psychosis	NN	O	O
.	.	O	O

We	PRP	O	O
aimed	VBD	O	O
to	TO	O	O
investigate	VB	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
low	JJ	O	O
doses	NNS	O	O
of	IN	O	O
haloperidol	NN	i	IPM
,	,	i	O
risperidone	NN	i	IPM
and	CC	i	O
olanzapine	NN	i	IPM
on	IN	O	O
cortical	JJ	o	OPH
thickness	NN	o	OPH
.	.	o	O

METHOD	NNP	O	O
We	PRP	O	O
investigated	VBD	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
risperidone	NN	i	IPM
(	(	p	O
N=16	NNP	p	PC
)	)	p	O
,	,	p	O
olanzapine	JJ	i	IPM
(	(	p	O
N=18	NNP	p	PC
)	)	p	O
and	CC	p	O
low	JJ	p	O
doses	NNS	p	O
of	IN	p	O
haloperidol	NN	i	IPM
(	(	p	O
N=18	NNP	p	PC
)	)	p	O
in	IN	O	O
cortical	JJ	o	O
thickness	NN	o	O
changes	NNS	O	O
during	IN	O	O
1-year	JJ	O	O
follow-up	JJ	O	O
period	NN	O	O
in	IN	O	O
a	DT	O	O
large	JJ	p	O
and	CC	p	O
heterogeneous	JJ	p	O
sample	NN	p	O
of	IN	p	O
schizophrenia	NN	p	PC
spectrum	NN	p	PC
patients	NNS	p	O
.	.	p	O

The	DT	O	O
relationship	NN	O	O
between	IN	O	O
cortical	JJ	o	OPH
thickness	NN	o	OPH
changes	NNS	o	OPH
and	CC	O	O
clinical	JJ	o	OPH
and	CC	o	O
cognitive	JJ	o	OME
outcome	NN	o	OME
was	VBD	O	O
also	RB	O	O
assessed	VBN	O	O
.	.	O	O

A	DT	O	O
group	NN	p	O
of	IN	p	O
45	CD	p	PC
healthy	JJ	p	PC
volunteers	NNS	p	O
was	VBD	p	O
also	RB	p	O
longitudinally	RB	p	O
evaluated	VBN	p	O
.	.	p	O

Magnetic	JJ	O	O
resonance	NN	O	O
imaging	VBG	O	O
brain	NN	O	O
scans	NNS	O	O
(	(	O	O
1.5T	CD	O	O
)	)	O	O
were	VBD	O	O
obtained	VBN	O	O
and	CC	O	O
images	NNS	O	O
were	VBD	O	O
analyzed	VBN	O	O
by	IN	O	O
using	VBG	O	O
BRAINS2	NNP	O	O
.	.	O	O

RESULTS	NNP	O	O
There	EX	O	O
were	VBD	O	O
no	DT	O	O
significant	JJ	O	O
effects	NNS	O	O
of	IN	O	O
time	NN	O	O
(	(	O	O
F	NNP	O	O
(	(	O	O
1,47	CD	O	O
)	)	O	O
<	NN	O	O
1.66	CD	O	O
;	:	O	O
P	NNP	O	O
>	NNP	O	O
0.204	CD	O	O
)	)	O	O
,	,	O	O
treatment	NN	O	O
group	NN	O	O
(	(	O	O
F	NNP	O	O
(	(	O	O
2,47	CD	O	O
)	)	O	O
<	NN	O	O
1.47	CD	O	O
;	:	O	O
P	NNP	O	O
>	NNP	O	O
0.242	CD	O	O
)	)	O	O
or	CC	O	O
group-by-time	JJ	O	O
interaction	NN	O	O
(	(	O	O
F	NNP	O	O
(	(	O	O
2,47	CD	O	O
)	)	O	O
<	NN	O	O
1.82	CD	O	O
;	:	O	O
P	NNP	O	O
>	NNP	O	O
0.174	CD	O	O
)	)	O	O
for	IN	O	O
any	DT	O	O
of	IN	O	O
the	DT	O	O
cortical	JJ	o	OPH
thickness	NN	o	OPH
variables	NNS	o	OPH
.	.	o	OPH

When	WRB	O	O
the	DT	O	O
group	NN	O	O
of	IN	O	O
healthy	JJ	O	O
controls	NNS	O	O
was	VBD	O	O
included	VBN	O	O
in	IN	O	O
the	DT	O	O
analyses	NNS	O	O
,	,	O	O
it	PRP	O	O
is	VBZ	O	O
of	IN	O	O
note	NN	O	O
that	IN	O	O
group-by-time	JJ	O	O
interaction	NN	O	O
showed	VBD	O	O
a	DT	O	O
significant	JJ	O	O
result	NN	O	O
for	IN	O	O
the	DT	O	O
frontal	JJ	O	O
lobe	NN	O	O
at	IN	O	O
trend	NN	O	O
level	NN	O	O
(	(	O	O
F	NNP	O	O
(	(	O	O
3,81	CD	O	O
)	)	O	O
=2.686	NN	O	O
;	:	O	O
P=0.052	NNP	O	O
)	)	O	O
.	.	O	O

After	IN	O	O
the	DT	O	O
Bonferroni	NNP	O	O
adjustment	NN	O	O
for	IN	O	O
multiple	JJ	O	O
comparisons	NNS	O	O
,	,	O	O
there	EX	O	O
were	VBD	O	O
no	DT	O	O
significant	JJ	O	O
associations	NNS	O	O
between	IN	O	O
changes	NNS	o	OPH
in	IN	o	OPH
cortical	JJ	o	OPH
thickness	NN	o	OPH
and	CC	O	O
clinical	JJ	o	O
and	CC	o	O
cognitive	JJ	o	O
outcome	NN	o	O
.	.	o	O

CONCLUSIONS	NNP	O	O
Low	NNP	O	O
doses	NNS	O	O
of	IN	O	O
haloperidol	NN	i	IPM
,	,	i	O
risperidone	NN	i	IPM
,	,	i	O
and	CC	i	O
olanzapine	NN	i	IPM
seem	VBP	O	O
to	TO	O	O
equally	RB	O	O
affect	VB	O	O
gray	JJ	o	OPH
matter	NN	o	OPH
cortical	JJ	o	OPH
thickness	NN	o	OPH
,	,	o	OPH
overall	JJ	o	OPH
and	CC	o	OPH
lobes	JJ	o	OPH
,	,	O	O
at	IN	O	O
the	DT	O	O
medium-term	NN	O	O
(	(	O	O
1	CD	O	O
year	NN	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
clinical	JJ	O	O
effectiveness	NN	O	O
of	IN	O	O
treatments	NNS	O	O
was	VBD	O	O
not	RB	O	O
significantly	RB	O	O
related	VBN	O	O
to	TO	O	O
changes	NNS	O	O
in	IN	O	O
cortical	JJ	o	OPH
thickness	NN	o	OPH
.	.	o	O

A	DT	O	O
cost-benefit	JJ	o	OOt
comparison	NN	O	O
of	IN	O	O
intensive	JJ	i	IPH
diabetes	NNS	i	IPH
management	NN	i	IPH
with	IN	i	IPH
implantable	JJ	i	IPH
pumps	NNS	i	IPH
versus	IN	O	O
multiple	JJ	i	IPM
subcutaneous	JJ	i	IPM
injections	NNS	i	IPM
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
type	NN	p	PC
I	PRP	p	PC
diabetes	VBZ	p	PC
.	.	p	O

OBJECTIVE	NNP	O	O
To	TO	O	O
investigate	VB	O	O
if	IN	O	O
intraperitoneal	JJ	i	IPH
(	(	i	IPH
IP	NNP	i	IPH
)	)	i	IPH
insulin	NN	i	IPH
infusion	NN	i	IPH
via	IN	i	IPH
programmable	JJ	i	IPH
implantable	JJ	i	IPH
pumps	NNS	i	IPH
is	VBZ	O	O
a	DT	O	O
potential	JJ	O	O
alternative	NN	O	O
to	TO	O	O
subcutaneous	JJ	i	IPM
(	(	i	IPM
SC	NNP	i	IPM
)	)	i	IPM
insulin	NN	i	IPM
via	IN	i	IPM
multiple	JJ	i	IPM
injections	NNS	i	IPM
.	.	i	O

RESEARCH	NNP	O	O
DESIGN	NNP	O	O
AND	NNP	O	O
METHODS	NNP	O	O
We	PRP	O	O
compared	VBN	O	O
the	DT	O	O
cost-benefits	NNS	o	OOt
of	IN	O	O
the	DT	O	O
two	CD	O	O
methods	NNS	O	O
using	VBG	O	O
a	DT	O	O
randomized	VBN	O	O
,	,	O	O
prospective	JJ	O	O
,	,	O	O
6-month	JJ	O	O
,	,	O	O
crossover	JJ	O	O
design	NN	O	O
in	IN	O	O
10	CD	p	PSS
adult	NN	p	PA
type	NN	p	PC
I	PRP	p	PC
diabetic	JJ	p	PC
patients	NNS	p	O
.	.	p	O

RESULTS	NNP	O	O
When	WRB	O	O
judged	VBN	O	O
on	IN	O	O
the	DT	O	O
last	JJ	O	O
month	NN	O	O
of	IN	O	O
IP	NNP	O	O
versus	NN	O	O
SC	NNP	O	O
periods	NNS	O	O
in	IN	O	O
the	DT	O	O
nine	CD	O	O
patients	NNS	O	O
who	WP	O	O
completed	VBD	O	O
the	DT	O	O
study	NN	O	O
,	,	O	O
metabolic	JJ	o	OPH
data	NN	o	OPH
showed	VBD	O	O
better	JJR	O	O
glycemic	JJ	o	OPH
control	NN	o	OPH
(	(	O	O
HbA1c	NNP	O	O
:	:	O	O
7.2	CD	O	O
+/-	JJ	O	O
0.2	CD	O	O
IP	NNP	O	O
vs.	FW	O	O
8.5	CD	O	O
+/-	JJ	O	O
0.7	CD	O	O
%	NN	O	O
SC	NNP	O	O
,	,	O	O
mean	JJ	O	O
+/-	JJ	O	O
SE	NNP	O	O
,	,	O	O
P	NNP	O	O
=	NNP	O	O
0.02	CD	O	O
)	)	O	O
,	,	O	O
reduced	VBN	o	OPH
glycemic	JJ	o	OPH
fluctuations	NNS	o	OPH
(	(	O	O
SD	NNP	O	O
of	IN	O	O
capillary	JJ	O	O
glucose	JJ	O	O
values	NNS	O	O
:	:	O	O
3.4	CD	O	O
+/-	JJ	O	O
0.2	CD	O	O
IP	NNP	O	O
vs.	FW	O	O
4.6	CD	O	O
+/-	JJ	O	O
0.2	CD	O	O
mM	NN	O	O
SC	NNP	O	O
,	,	O	O
P	NNP	O	O
<	NNP	O	O
0.01	CD	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
fewer	JJR	O	O
mild	JJ	o	OPH
hypoglycemic	JJ	o	OPH
events	NNS	o	OPH
(	(	O	O
5.7	CD	O	O
+/-	JJ	O	O
2.0	CD	O	O
IP	NNP	O	O
vs.	FW	O	O
10.0	CD	O	O
+/-	JJ	O	O
3.1	CD	O	O
events/month	JJ	O	O
SC	NNP	O	O
,	,	O	O
P	NNP	O	O
=	NNP	O	O
0.02	CD	O	O
)	)	O	O
.	.	O	O

Quality	NN	o	OOt
of	IN	o	OOt
life	NN	o	OOt
,	,	o	O
judged	VBN	o	O
by	IN	o	O
Diabetes	NNP	o	OOt
Control	NNP	o	OOt
and	CC	o	OOt
Complications	NNP	o	OOt
Trial	NNP	o	OOt
questionnaires	NNS	o	OOt
,	,	O	O
was	VBD	O	O
unaffected	VBN	O	O
by	IN	O	O
pump	NN	i	IPH
therapy	NN	O	O
.	.	O	O

Direct	JJ	o	OOt
costs	NNS	o	OOt
,	,	o	OOt
including	VBG	o	OOt
pump	JJ	o	OOt
acquisition	NN	o	OOt
,	,	o	OOt
implantation	NN	o	OOt
,	,	o	OOt
and	CC	o	OOt
follow-up	NN	o	OOt
,	,	O	O
were	VBD	O	O
2.6-fold	JJ	O	O
higher	JJR	O	O
with	IN	O	O
IP	NNP	O	O
than	IN	O	O
with	IN	O	O
SC	NNP	O	O
delivery	NN	O	O
.	.	O	O

CONCLUSIONS	VB	O	O
The	DT	O	O
implantable	JJ	i	IPH
pump	NN	i	IPH
is	VBZ	O	O
more	RBR	o	O
effective	JJ	o	OOt
in	IN	O	O
the	DT	O	O
short	JJ	O	O
term	NN	O	O
,	,	O	O
equally	RB	O	O
accepted	VBN	o	OOt
,	,	O	O
but	CC	O	O
more	RBR	O	O
costly	JJ	o	OOt
than	IN	O	O
multiple	JJ	i	IPM
injections	NNS	i	IPM
and	CC	O	O
should	MD	O	O
be	VB	O	O
limited	VBN	O	O
to	TO	O	O
patients	NNS	O	O
with	IN	O	O
unsatisfactory	JJ	O	O
glycemic	JJ	o	OPH
control	NN	o	OPH
despite	IN	O	O
intensive	JJ	O	O
diabetes	NNS	O	O
management	NN	O	O
with	IN	O	O
SC	NNP	O	O
insulin	NN	O	O
.	.	O	O

In	IN	O	O
addition	NN	O	O
,	,	O	O
longer-term	JJ	O	O
,	,	O	O
larger-scale	JJ	O	O
,	,	O	O
and	CC	O	O
comparative	JJ	O	O
evaluation	NN	O	O
is	VBZ	O	O
required	VBN	O	O
.	.	O	O

The	DT	O	O
efficacy	NN	O	O
of	IN	O	O
melatonin	NN	i	IPM
for	IN	O	O
sleep	JJ	O	O
problems	NNS	O	O
in	IN	O	O
children	NNS	O	O
with	IN	O	O
autism	NN	O	O
,	,	O	O
fragile	JJ	O	O
X	NNP	O	O
syndrome	NN	O	O
,	,	O	O
or	CC	O	O
autism	NN	O	O
and	CC	O	O
fragile	JJ	O	O
X	NNP	O	O
syndrome	NN	O	O
.	.	O	O

STUDY	NNP	O	O
OBJECTIVE	NNP	O	O
To	TO	O	O
determine	VB	O	O
the	DT	O	O
efficacy	NN	O	O
of	IN	O	O
melatonin	NN	i	IPM
on	IN	p	O
sleep	NN	p	PC
problems	NNS	p	PC
in	IN	p	O
children	NNS	p	O
with	IN	O	O
autistic	JJ	O	O
spectrum	NN	O	O
disorder	NN	O	O
(	(	O	O
ASD	NNP	O	O
)	)	O	O
and	CC	O	O
fragile	JJ	O	O
X	NNP	O	O
syndrome	NN	O	O
(	(	O	O
FXS	NNP	O	O
)	)	O	O
.	.	O	O

METHODS	VB	O	O
A	DT	O	O
4-week	JJ	O	O
,	,	O	O
randomized	VBN	O	O
,	,	O	O
double	JJ	O	O
blind	NN	O	O
,	,	O	O
placebo-controlled	JJ	O	O
,	,	O	O
crossover	JJ	O	O
design	NN	O	O
was	VBD	O	O
conducted	VBN	O	O
following	VBG	O	O
a	DT	O	O
1-week	JJ	O	O
baseline	NN	O	O
period	NN	O	O
.	.	O	O

Either	CC	O	O
melatonin	NN	i	IPM
,	,	O	O
3	CD	O	O
mg	NN	O	O
,	,	O	O
or	CC	O	O
placebo	NN	i	IC
was	VBD	O	O
given	VBN	O	O
to	TO	O	O
participants	NNS	p	O
for	IN	p	O
2	CD	p	O
weeks	NNS	p	O
and	CC	O	O
then	RB	O	O
alternated	VBD	O	O
for	IN	O	O
another	DT	O	O
2	CD	O	O
weeks	NNS	O	O
.	.	O	O

Sleep	JJ	o	OPH
variables	NNS	o	OPH
,	,	O	O
including	VBG	O	O
sleep	JJ	o	OOt
duration	NN	o	OOt
,	,	o	OOt
sleep-onset	JJ	o	OOt
time	NN	o	OOt
,	,	o	OOt
sleep-onset	JJ	o	OOt
latency	NN	o	OOt
time	NN	o	OOt
,	,	o	OOt
and	CC	o	OOt
the	DT	o	OOt
number	NN	o	OOt
of	IN	o	OOt
night	NN	o	OOt
awakenings	NNS	o	OOt
,	,	O	O
were	VBD	O	O
recorded	VBN	O	O
using	VBG	O	O
an	DT	O	O
Actiwatch	NN	O	O
and	CC	O	O
from	IN	O	O
sleep	JJ	O	O
diaries	NNS	O	O
completed	VBN	O	O
by	IN	O	O
parents	NNS	O	O
.	.	O	O

All	DT	p	O
participants	NNS	p	O
had	VBD	O	O
been	VBN	O	O
thoroughly	RB	O	O
assessed	VBN	O	O
for	IN	O	O
ASD	NNP	O	O
and	CC	O	O
also	RB	O	O
had	VBD	O	O
DNA	NNP	O	O
testing	VBG	O	O
for	IN	O	O
the	DT	O	O
diagnosis	NN	O	O
of	IN	O	O
FXS	NNP	O	O
.	.	O	O

RESULTS	NNP	O	O
Data	NNP	O	O
were	VBD	O	O
successfully	RB	O	O
obtained	VBN	O	O
from	IN	O	O
the	DT	O	O
12	CD	p	PC
of	IN	p	O
18	CD	p	PC
subjects	NNS	p	O
who	WP	p	O
completed	VBD	p	O
the	DT	p	O
study	NN	p	O
(	(	p	O
11	CD	p	PC
males	NNS	p	O
,	,	p	O
age	NN	p	O
range	NN	p	O
2	CD	p	O
to	TO	p	O
15.25	CD	p	O
years	NNS	p	O
,	,	p	O
mean	JJ	p	O
5.47	CD	p	O
,	,	p	O
SD	NNP	p	O
3.6	CD	p	O
)	)	p	O
.	.	p	O

Five	CD	p	PC
participants	NNS	p	O
met	VBD	O	O
diagnostic	JJ	O	O
criteria	NNS	O	O
for	IN	O	O
ASD	NNP	O	O
,	,	O	O
3	CD	O	O
for	IN	O	O
FXS	NNP	O	O
alone	RB	O	O
,	,	O	O
3	CD	O	O
for	IN	O	O
FXS	NNP	O	O
and	CC	O	O
ASD	NNP	O	O
,	,	O	O
and	CC	O	O
1	CD	O	O
for	IN	O	O
fragile	JJ	O	O
X	NNP	O	O
premutation	NN	O	O
.	.	O	O

Eight	CD	p	PC
out	IN	p	O
of	IN	p	O
12	CD	p	PC
had	VBD	p	O
melatonin	VBN	i	IPM
first	RB	p	O
.	.	O	O

The	DT	O	O
conclusions	NNS	O	O
from	IN	O	O
a	DT	O	O
nonparametric	JJ	O	O
repeated-measures	NNS	O	O
technique	NN	O	O
indicate	VBP	O	O
that	IN	O	O
mean	JJ	o	OOt
night	NN	o	OOt
sleep	NN	o	OOt
duration	NN	o	OOt
was	VBD	O	O
longer	RBR	O	O
on	IN	O	O
melatonin	NN	i	IPM
than	IN	O	O
placebo	NN	i	IC
by	IN	O	O
21	CD	O	O
minutes	NNS	O	O
(	(	O	O
p	JJ	O	O
=	NNP	O	O
.02	NNP	O	O
)	)	O	O
,	,	O	O
mean	JJ	o	OOt
sleep-onset	JJ	o	OOt
latency	NN	o	OOt
was	VBD	O	O
shorter	JJR	O	O
by	IN	O	O
28	CD	O	O
minutes	NNS	O	O
(	(	O	O
p	JJ	O	O
=	NNP	O	O
.0001	NNP	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
mean	VB	o	OOt
sleep-onset	JJ	o	OOt
time	NN	o	OOt
was	VBD	O	O
earlier	RB	O	O
by	IN	O	O
42	CD	O	O
minutes	NNS	O	O
(	(	O	O
p	JJ	O	O
=	NNP	O	O
.02	NNP	O	O
)	)	O	O
.	.	O	O

CONCLUSION	VB	O	O
The	DT	O	O
results	NNS	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
support	VBD	O	O
the	DT	O	O
efficacy	NN	O	O
and	CC	O	O
tolerability	NN	O	O
of	IN	O	O
melatonin	NN	i	IPM
treatment	NN	O	O
for	IN	O	O
sleep	JJ	O	O
problems	NNS	O	O
in	IN	O	O
children	NNS	O	O
with	IN	O	O
ASD	NNP	O	O
and	CC	O	O
FXS	NNP	O	O
.	.	O	O

Dose	NNP	O	O
dependent	JJ	O	O
pharmacokinetics	NNS	O	O
of	IN	O	O
theophylline	NN	i	IPM
:	:	i	IPM
Michaelis-Menten	JJ	O	O
parameters	NNS	O	O
for	IN	O	O
its	PRP$	O	O
major	JJ	O	O
metabolic	JJ	O	O
pathways	NNS	O	O
.	.	O	O

Dose	NNP	O	O
Dependency	NNP	O	O
for	IN	O	O
pharmacokinetics	NNS	O	O
of	IN	O	O
theophylline	NN	i	IPM
and	CC	O	O
the	DT	O	O
formation	NN	O	O
of	IN	O	O
its	PRP$	O	O
major	JJ	O	O
metabolites	NNS	O	O
,	,	O	O
3-methylxanthine	JJ	O	O
(	(	O	O
3-MX	JJ	O	O
)	)	O	O
;	:	O	O
1-methyluric	JJ	O	O
acid	NN	O	O
(	(	O	O
1-MU	JJ	O	O
)	)	O	O
;	:	O	O
1,3-dimethyluric	JJ	O	O
acid	NN	O	O
(	(	O	O
DMU	NNP	O	O
)	)	O	O
,	,	O	O
were	VBD	O	O
examined	VBN	O	O
by	IN	O	O
administering	VBG	O	O
three	CD	O	O
single	JJ	O	O
oral	JJ	O	O
doses	NNS	O	O
(	(	O	O
250	CD	O	O
,	,	O	O
375	CD	O	O
,	,	O	O
500	CD	O	O
mg	NN	O	O
)	)	O	O
of	IN	O	O
theophylline	NN	i	O
to	TO	O	O
six	CD	p	PSS
healthy	JJ	p	O
adult	NN	p	PA
volunteers	NNS	p	O
.	.	p	O

The	DT	O	O
serum	NN	O	O
and	CC	O	O
urine	JJ	O	O
concentrations	NNS	O	O
of	IN	O	O
theophylline	NN	i	IPM
and	CC	O	O
the	DT	O	O
metabolites	NNS	O	O
in	IN	O	O
serum	NN	O	O
and	CC	O	O
urine	NN	O	O
were	VBD	O	O
determined	VBN	O	O
by	IN	O	O
high-performance	NN	O	O
liquid	NN	O	O
chromatography	NN	O	O
.	.	O	O

Total	JJ	o	OOt
clearance	NN	o	OOt
of	IN	O	O
theophylline	NN	i	IPM
decreased	VBN	O	O
and	CC	O	O
its	PRP$	O	O
half	JJ	O	O
life	NN	O	O
increased	VBD	O	O
over	IN	O	O
the	DT	O	O
range	NN	O	O
of	IN	O	O
doses	NNS	O	O
administered	VBN	O	O
(	(	O	O
p	JJ	O	O
<	NNP	O	O
0.01	CD	O	O
)	)	O	O
.	.	O	O

There	EX	O	O
was	VBD	O	O
a	DT	O	O
significant	JJ	O	O
dose	NN	O	O
related	JJ	O	O
decrease	NN	O	O
in	IN	O	O
the	DT	O	O
fractional	JJ	O	O
recovery	NN	O	O
of	IN	O	O
3-MX	JJ	O	O
and	CC	O	O
1-MU	JJ	O	O
(	(	O	O
p	JJ	O	O
<	NNP	O	O
0.001	CD	O	O
)	)	O	O
and	CC	O	O
a	DT	O	O
dose	NN	O	O
related	JJ	O	O
increase	NN	O	O
in	IN	O	O
fractional	JJ	o	OME
excretion	NN	o	OME
of	IN	o	OME
DMU	NNP	o	OME
and	CC	O	O
unchanged	JJ	O	O
theophylline	NN	O	O
(	(	O	O
p	JJ	O	O
<	NN	O	O
0.01	CD	O	O
and	CC	O	O
p	VB	O	O
<	JJ	O	O
0.001	CD	O	O
respectively	RB	O	O
)	)	O	O
.	.	O	O

No	DT	O	O
significant	JJ	O	O
dose	NN	O	O
related	VBN	O	O
changes	NNS	O	O
were	VBD	O	O
observed	VBN	O	O
in	IN	O	O
the	DT	O	O
renal	JJ	o	OME
clearance	NN	o	OME
of	IN	o	OME
3-MX	JJ	o	OME
,	,	o	O
1-MU	JJ	o	OME
and	CC	o	O
DMU	NNP	o	OME
,	,	O	O
indicating	VBG	O	O
linear	JJ	O	O
urinary	JJ	O	O
excretion	NN	O	O
kinetics	NNS	O	O
of	IN	O	O
the	DT	O	O
metabolites	NNS	O	O
.	.	O	O

Theophylline	NNP	o	OME
metabolic	JJ	o	OME
clearance	NN	o	OME
to	TO	o	OME
3-MX	JJ	o	OME
as	RB	O	O
well	RB	O	O
as	IN	O	O
to	TO	O	O
1-MU	CD	O	O
decreased	VBN	O	O
with	IN	O	O
increasing	VBG	O	O
dose	NN	O	O
but	CC	O	O
clearance	NN	O	O
to	TO	O	O
DMU	NNP	O	O
remained	VBD	O	O
unnaffected	JJ	O	O
by	IN	O	O
the	DT	O	O
size	NN	O	O
of	IN	O	O
dose	NN	O	O
.	.	O	O

The	DT	O	O
individual	JJ	O	O
Michaelis-Menten	NNP	o	OOt
parameters	NNS	o	OOt
Km	NNP	o	OOt
and	CC	o	OOt
Vmax	NNP	o	OOt
were	VBD	O	O
estimated	VBN	O	O
for	IN	O	O
six	CD	p	O
subjects	NNS	p	O
receiving	VBG	O	O
three	CD	O	O
different	JJ	O	O
single	JJ	O	O
doses	NNS	O	O
.	.	O	O

The	DT	O	O
Km	NNP	o	OOt
values	NNS	o	OOt
for	IN	o	OOt
theophylline	JJ	o	OOt
metabolism	NN	o	OOt
to	TO	o	OOt
3-MX	JJ	o	OOt
,	,	o	O
1-MU	JJ	o	OME
and	CC	o	O
DMU	NNP	o	OME
were	VBD	O	O
2.4+/-0.6	JJ	O	O
,	,	O	O
5.1+/-1.8+/-	JJ	O	O
and	CC	O	O
112.3+/-36.8	JJ	O	O
mg/L	NN	O	O
respectively	RB	O	O
and	CC	O	O
the	DT	O	O
Vmax	NNP	o	OOt
values	NNS	o	OOt
were	VBD	O	O
3.5+/-0.7	JJ	O	O
,	,	O	O
7.5+/-2.6	JJ	O	O
and	CC	O	O
112.3+/-36.8	JJ	O	O
mg/hr	NN	O	O
respectively	RB	O	O
.	.	O	O

The	DT	O	O
Km	NNP	o	OOt
values	NNS	o	OOt
for	IN	o	OOt
the	DT	o	OOt
N-demethylation	NNP	o	OOt
pathways	NNS	o	OOt
(	(	o	OOt
3MX	CD	o	OOt
and	CC	o	OOt
1-MU	JJ	o	OOt
)	)	o	OOt
were	VBD	O	O
lower	JJR	O	O
corresponding	VBG	O	O
to	TO	O	O
therapeutic	JJ	O	O
serum	NN	O	O
concentrations	NNS	O	O
of	IN	O	O
drug	NN	O	O
.	.	O	O

These	DT	O	O
results	NNS	O	O
suggest	VBP	O	O
that	IN	O	O
the	DT	O	O
elimination	NN	O	O
kinetics	NNS	O	O
of	IN	O	O
theophylline	NN	i	IPM
is	VBZ	O	O
nonlinear	JJ	O	O
in	IN	O	O
the	DT	O	O
human	NN	O	O
in	IN	O	O
the	DT	O	O
therapeutic	JJ	O	O
range	NN	O	O
of	IN	O	O
serum	JJ	o	OPH
concenntrations	NNS	o	OPH
and	CC	O	O
can	MD	O	O
be	VB	O	O
explained	VBN	O	O
by	IN	O	O
saturable	JJ	O	O
formation	NN	O	O
kinetics	NNS	O	O
of	IN	O	O
3-MX	JJ	O	O
and	CC	O	O
1-MU	JJ	O	O
.	.	O	O

In	IN	O	O
contrast	NN	O	O
to	TO	O	O
previous	JJ	O	O
studies	NNS	O	O
we	PRP	O	O
did	VBD	O	O
n't	RB	O	O
find	VB	O	O
obvious	JJ	O	O
indication	NN	O	O
for	IN	O	O
nonlinear	JJ	O	O
formation	NN	O	O
of	IN	O	O
DMU	NNP	O	O
at	IN	O	O
therapeutic	JJ	O	O
concentration	NN	O	O
range	NN	O	O
.	.	O	O

Morphological	JJ	O	O
onset	NN	O	O
and	CC	O	O
early	JJ	O	O
diagnosis	NN	O	O
in	IN	O	O
apical	JJ	p	O
hypertrophic	JJ	p	O
cardiomyopathy	NN	p	O
:	:	p	O
a	DT	O	O
long	JJ	O	O
term	NN	O	O
analysis	NN	O	O
with	IN	O	O
nuclear	JJ	i	IOt
magnetic	JJ	i	IOt
resonance	NN	i	IOt
imaging	NN	i	IOt
.	.	i	IOt

OBJECTIVES	VB	O	O
A	DT	O	O
long-term	JJ	O	O
follow-up	NN	O	O
study	NN	O	O
with	IN	O	O
nuclear	JJ	i	IOt
magnetic	JJ	i	IOt
resonance	NN	i	IOt
(	(	i	IOt
NMR	NNP	i	IOt
)	)	i	IOt
imaging	NN	i	IOt
was	VBD	O	O
undertaken	VBN	O	O
to	TO	O	O
detect	VB	O	O
the	DT	O	O
morphological	JJ	O	O
onset	NN	O	O
and	CC	O	O
to	TO	O	O
establish	VB	O	O
the	DT	O	O
early	JJ	O	O
diagnosis	NN	O	O
in	IN	O	O
apical	JJ	O	O
hypertrophic	JJ	O	O
cardiomyopathy	NN	O	O
(	(	O	O
HCM	NNP	O	O
)	)	O	O
.	.	O	O

BACKGROUND	VB	O	O
A	DT	O	O
spadelike	JJ	O	O
configuration	NN	O	O
on	IN	O	O
left	JJ	o	OPH
ventriculogram	NN	o	OPH
(	(	o	OPH
LVG	NNP	o	OPH
)	)	o	OPH
is	VBZ	O	O
regarded	VBN	O	O
as	IN	O	O
a	DT	O	O
diagnostic	JJ	O	O
criterion	NN	O	O
for	IN	O	O
the	DT	O	O
classical	JJ	O	O
apical	JJ	O	O
HCM	NNP	O	O
.	.	O	O

There	EX	O	O
also	RB	O	O
exists	VBZ	O	O
a	DT	O	O
segmented	JJ	o	O
hypertrophy	NN	o	O
at	IN	o	O
the	DT	o	O
apical	JJ	o	O
level	NN	o	O
without	IN	O	O
indicating	VBG	O	O
the	DT	O	O
spadelike	NN	O	O
features	NNS	O	O
(	(	O	O
a	DT	O	O
nonspade	NN	O	O
configuration	NN	O	O
)	)	O	O
.	.	O	O

To	TO	O	O
detect	VB	O	O
the	DT	O	O
hypertrophied	JJ	O	O
myocardium	NN	O	O
of	IN	O	O
the	DT	O	O
nonspade	JJ	O	O
configuration	NN	O	O
,	,	O	O
circumferential	JJ	O	O
scrutiny	NN	O	O
of	IN	O	O
the	DT	O	O
apex	NN	O	O
is	VBZ	O	O
required	VBN	O	O
.	.	O	O

Although	IN	O	O
both	DT	O	O
configurations	NNS	O	O
can	MD	O	O
be	VB	O	O
underlying	JJ	O	O
causes	NNS	O	O
of	IN	O	O
giant	JJ	O	O
negative	JJ	O	O
T	NNP	O	O
waves	NNS	O	O
,	,	O	O
etiological	JJ	O	O
relationship	NN	O	O
between	IN	O	O
the	DT	O	O
two	CD	O	O
is	VBZ	O	O
not	RB	O	O
clarified	VBN	O	O
.	.	O	O

METHODS	NNP	O	O
The	DT	O	O
criteria	NN	O	O
for	IN	O	O
the	DT	O	O
spadelike	NN	O	O
configuration	NN	O	O
defined	VBN	O	O
on	IN	O	O
left	JJ	O	O
ventricular	JJ	O	O
short-axis	JJ	O	O
NMR	NNP	i	IOt
images	NNS	i	IOt
were	VBD	O	O
as	IN	O	O
follows	VBZ	O	O
:	:	O	O
(	(	O	O
apical	JJ	O	O
maximal	NN	O	O
thickness	NN	O	O
>	NN	O	O
or	CC	O	O
=	$	O	O
15	CD	O	O
mm	NN	O	O
)	)	O	O
,	,	O	O
(	(	O	O
apical	JJ	O	O
anterior	NN	O	O
thickness	NN	O	O
over	IN	O	O
basal	JJ	O	O
anterior	JJ	O	O
thickness	NN	O	O
>	NN	O	O
or	CC	O	O
=	VB	O	O
1.3	CD	O	O
)	)	O	O
and	CC	O	O
(	(	O	O
apical	JJ	O	O
posterior	NN	O	O
thickness	NN	O	O
over	IN	O	O
basal	JJ	O	O
posterior	JJ	O	O
thickness	NN	O	O
>	NN	O	O
or	CC	O	O
=1.3	NN	O	O
)	)	O	O
.	.	O	O

Thirteen	JJ	p	O
patients	NNS	p	O
who	WP	p	O
had	VBD	p	O
predominant	JJ	p	O
hypertrophy	NN	p	O
(	(	p	O
>	CD	p	O
or	CC	p	O
=	VB	p	O
15	CD	p	O
mm	NN	p	O
)	)	p	O
at	IN	p	O
the	DT	p	O
apical	JJ	p	O
level	NN	p	O
without	IN	p	O
the	DT	p	O
spadelike	NN	p	O
configuration	NN	p	O
underwent	JJ	p	O
NMR	NNP	i	IOt
imaging	VBG	i	IOt
twice	RB	i	O
before	RB	i	O
and	CC	i	O
after	IN	i	O
54+/-10	JJ	i	O
months	NNS	i	O
'	POS	i	O
follow-up	NN	i	O
.	.	i	O

RESULTS	NNP	O	O
Apical	NNP	o	OPH
hypertrophy	NN	o	OPH
that	WDT	O	O
had	VBD	O	O
been	VBN	O	O
confined	VBN	O	O
to	TO	O	O
the	DT	O	O
lateral	JJ	O	O
wall	NN	O	O
in	IN	O	O
four	CD	O	O
,	,	O	O
the	DT	O	O
anterior-lateral	JJ	O	O
wall	NN	O	O
in	IN	O	O
two	CD	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
septal-anterior	JJ	O	O
wall	NN	O	O
in	IN	O	O
one	CD	O	O
developed	NN	O	O
to	TO	O	O
become	VB	O	O
circumferential	JJ	o	OPH
hypertrophy	NN	o	OPH
that	WDT	O	O
fulfilled	VBD	O	O
the	DT	O	O
criteria	NNS	O	O
for	IN	O	O
the	DT	O	O
spadelike	NN	O	O
configuration	NN	O	O
after	IN	O	O
the	DT	O	O
follow-up	JJ	O	O
period	NN	O	O
.	.	O	O

CONCLUSIONS	VB	O	O
The	DT	O	O
spadelike	NN	O	O
configuration	NN	O	O
can	MD	O	O
begin	VB	O	O
with	IN	O	O
the	DT	O	O
nonspade	JJ	O	O
configuration	NN	O	O
and	CC	O	O
therefore	NN	O	O
,	,	O	O
both	DT	O	O
can	MD	O	O
constitute	VB	O	O
a	DT	O	O
single	JJ	O	O
disease	NN	O	O
entity	NN	O	O
of	IN	O	O
apical	JJ	O	O
HCM	NNP	O	O
.	.	O	O

The	DT	O	O
early	JJ	O	O
diagnosis	NN	O	O
of	IN	O	O
apical	JJ	o	OPH
HCM	NNP	o	OPH
can	MD	O	O
be	VB	O	O
achieved	VBN	O	O
by	IN	O	O
identifying	VBG	O	O
the	DT	O	O
hypertrophy	NN	o	OPH
frequently	RB	O	O
confined	VBN	O	O
to	TO	O	O
the	DT	O	O
lateral	JJ	O	O
wall	NN	O	O
at	IN	O	O
the	DT	O	O
apical	JJ	O	O
level	NN	O	O
.	.	O	O

Involvement	NN	O	O
of	IN	O	O
cholecystokininA	NN	O	O
receptors	NNS	O	O
in	IN	O	O
transient	NN	O	O
lower	JJR	O	O
esophageal	NN	O	O
sphincter	NN	O	O
relaxations	NNS	O	O
triggered	VBN	O	O
by	IN	O	O
gastric	JJ	O	O
distension	NN	O	O
.	.	O	O

OBJECTIVE	CC	O	O
Transient	NNP	o	OPH
lower	JJR	o	OPH
esophageal	NN	o	OPH
sphincter	NN	o	OPH
relaxations	NNS	o	OPH
(	(	o	OPH
TLESRs	NNP	o	OPH
)	)	o	OPH
are	VBP	O	O
the	DT	O	O
main	JJ	O	O
mechanism	NN	O	O
underlying	VBG	O	O
gastroesophageal	JJ	O	O
reflux	NN	O	O
.	.	O	O

In	IN	O	O
the	DT	O	O
present	JJ	O	O
study	NN	O	O
we	PRP	O	O
evaluated	VBD	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
loxiglumide	NN	O	O
,	,	O	O
a	DT	O	O
specific	JJ	O	O
cholecystokininA	NN	O	O
(	(	O	O
CCKA	NNP	O	O
)	)	O	O
-receptor	NN	O	O
antagonist	NN	O	O
,	,	O	O
on	IN	O	O
the	DT	O	O
occurrence	NN	O	O
of	IN	O	O
TLESRs	NNP	O	O
evoked	VBN	O	O
by	IN	O	O
gastric	JJ	O	O
distension	NN	O	O
.	.	O	O

METHODS	NNP	O	O
Eight	NNP	p	PSS
healthy	JJ	p	PC
subjects	NNS	p	O
underwent	JJ	p	O
esophageal	JJ	p	PC
manometry	NN	p	PC
using	VBG	p	O
a	DT	p	O
10-lumen	JJ	i	IPH
sleeve	NN	i	IPH
assembly	NN	i	IPH
during	IN	i	IPH
placebo	NN	i	IPH
or	CC	i	O
loxiglumide	NN	i	IPM
(	(	p	O
10	CD	p	O
mg/kg/h	NN	p	O
)	)	p	O
in	IN	p	O
a	DT	O	O
randomized	JJ	O	O
double-blind	JJ	O	O
order	NN	O	O
.	.	O	O

Gastric	NNP	O	O
distension	NN	O	O
was	VBD	O	O
induced	VBN	O	O
by	IN	O	O
inflation	NN	i	O
of	IN	i	O
400	CD	i	O
ml	NN	i	O
of	IN	i	O
air	NN	i	O
.	.	i	O

RESULTS	VB	O	O
Basal	NNP	o	OPH
lower	JJR	o	OPH
esophageal	NN	o	OPH
pressure	NN	o	OPH
(	(	o	OPH
LESP	NNP	o	OPH
)	)	o	OPH
and	CC	o	O
swallow-induced	JJ	o	OPH
relaxation	NN	o	OPH
were	VBD	O	O
not	RB	O	O
affected	VBN	O	O
by	IN	O	O
loxiglumide	NN	O	O
.	.	O	O

Loxiglumide	NNP	O	O
significantly	RB	O	O
reduced	VBD	O	O
the	DT	O	O
number	NN	O	O
of	IN	O	O
TLESRs	NNP	o	OPH
,	,	O	O
from	IN	O	O
11.5	CD	O	O
(	(	O	O
5.8-18.3	JJ	O	O
)	)	O	O
to	TO	O	O
6.0	CD	O	O
(	(	O	O
3.3-14.3	JJ	O	O
)	)	O	O
during	IN	O	O
the	DT	O	O
total	JJ	O	O
recording	JJ	O	O
period	NN	O	O
of	IN	O	O
1	CD	O	O
h	NN	O	O
,	,	O	O
and	CC	O	O
from	IN	O	O
5.5	CD	O	O
(	(	O	O
4.25-7.5	JJ	O	O
)	)	O	O
to	TO	O	O
2.0	CD	O	O
(	(	O	O
0.5-6.8	JJ	O	O
)	)	O	O
during	IN	O	O
the	DT	O	O
first	JJ	O	O
15	CD	O	O
min	NN	O	O
.	.	O	O

The	DT	O	O
number	NN	o	OPH
of	IN	o	OPH
common	JJ	o	OPH
cavities	NNS	o	OPH
was	VBD	O	O
significantly	RB	O	O
decreased	VBN	O	O
by	IN	O	O
loxiglumide	NN	O	O
,	,	O	O
from	IN	O	O
8.0	CD	O	O
(	(	O	O
4.0-20.0	JJ	O	O
)	)	O	O
to	TO	O	O
5.0	CD	O	O
(	(	O	O
2.0-7.8	JJ	O	O
)	)	O	O
.	.	O	O

TLESRs	NNP	o	OPH
represented	VBD	O	O
the	DT	O	O
main	JJ	O	O
mechanism	NN	O	O
(	(	O	O
60	CD	O	O
%	NN	O	O
during	IN	O	O
placebo	NN	O	O
,	,	O	O
74	CD	O	O
%	NN	O	O
during	IN	O	O
loxiglumide	NN	O	O
)	)	O	O
underlying	VBG	O	O
common	JJ	O	O
cavities	NNS	O	O
,	,	O	O
followed	VBN	O	O
by	IN	O	O
swallow-induced	JJ	O	O
relaxation	NN	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
Loxiglumide	NNP	O	O
significantly	RB	O	O
reduces	VBZ	O	O
the	DT	O	O
number	NN	O	O
of	IN	O	O
TLESRs	NNP	o	OPH
triggered	VBN	O	O
by	IN	O	O
gastric	JJ	O	O
distension	NN	O	O
without	IN	O	O
interfering	VBG	O	O
with	IN	O	O
swallow-related	JJ	O	O
relaxation	NN	O	O
of	IN	O	O
the	DT	O	O
lower	JJR	O	O
esophageal	NN	O	O
sphincter	NN	O	O
,	,	O	O
suggesting	VBG	O	O
the	DT	O	O
involvement	NN	O	O
of	IN	O	O
CCKA	NNP	O	O
receptors	NNS	O	O
in	IN	O	O
the	DT	O	O
reflex	JJ	O	O
pathway	NN	O	O
mediating	VBG	O	O
TLESRs	NNP	O	O
.	.	O	O

Domperidone	NN	i	O
,	,	i	O
metoclopramide	NN	i	O
,	,	i	O
and	CC	i	O
placebo	NN	i	O
.	.	i	O

All	DT	O	O
give	JJ	O	O
symptomatic	JJ	o	OOt
improvement	NN	o	OOt
in	IN	o	OOt
gastroesophageal	JJ	o	OOt
reflux	NN	o	OOt
.	.	o	O

A	DT	O	O
double-blind	JJ	O	O
crossover	NN	O	O
study	NN	O	O
was	VBD	O	O
conducted	VBN	O	O
of	IN	O	O
two	CD	O	O
gastric	JJ	i	IPM
prokinetic	JJ	i	IPM
drugs	NNS	i	IPM
in	IN	O	O
23	CD	p	PSS
patients	NNS	p	PSS
with	IN	p	O
gastroesophageal	JJ	p	PC
reflux	NN	p	PC
.	.	p	O

Patients	NNS	O	O
were	VBD	O	O
divided	VBN	O	O
into	IN	O	O
two	CD	O	O
groups	NNS	O	O
on	IN	O	O
the	DT	O	O
basis	NN	O	O
of	IN	O	O
a	DT	O	O
dual-isotope	JJ	O	O
mixed-meal	JJ	O	O
study	NN	O	O
of	IN	O	O
their	PRP$	O	O
gastric	JJ	O	O
emptying	NN	O	O
(	(	O	O
GE	NNP	O	O
)	)	O	O
.	.	O	O

Group	NNP	p	O
I	PRP	p	O
had	VBD	O	O
normal	JJ	O	O
GE	NNP	O	O
and	CC	O	O
group	NN	O	O
II	NNP	O	O
delayed	VBD	O	O
GE	NNP	O	O
.	.	O	O

Nine	NNP	O	O
gastrointestinal	JJ	O	O
symptoms	NNS	O	O
were	VBD	O	O
assessed	VBN	O	O
for	IN	O	O
frequency	NN	O	O
and	CC	O	O
severity	NN	O	O
before	IN	O	O
treatment	NN	O	O
.	.	O	O

The	DT	O	O
trial	NN	O	O
had	VBD	O	O
three	CD	O	O
1-month	JJ	O	O
treatment	NN	O	O
periods	NNS	O	O
using	VBG	O	O
metoclopramide	RB	i	O
10	CD	O	O
mg	NN	O	O
q.i.d.	NN	O	O
,	,	O	O
domperidone	NN	i	IPM
20	CD	O	O
mg	NN	O	O
q.i.d.	NN	O	O
,	,	O	O
or	CC	i	O
placebo	NN	i	O
on	IN	O	O
a	DT	O	O
random	JJ	O	O
basis	NN	O	O
.	.	O	O

Symptoms	NNS	O	O
were	VBD	O	O
reassessed	VBN	O	O
at	IN	O	O
the	DT	O	O
end	NN	O	O
of	IN	O	O
each	DT	O	O
month	NN	O	O
.	.	O	O

Taken	NNP	O	O
as	IN	O	O
a	DT	O	O
whole	NN	O	O
,	,	O	O
the	DT	O	O
group	NN	O	O
showed	VBD	O	O
a	DT	O	O
significant	JJ	O	O
symptomatic	JJ	o	OPH
response	NN	o	OPH
in	IN	O	O
all	DT	O	O
three	CD	O	O
treatment	NN	O	O
periods	NNS	O	O
(	(	O	O
p	NN	O	O
less	JJR	O	O
than	IN	O	O
0.0001	CD	O	O
)	)	O	O
,	,	O	O
but	CC	O	O
patients	NNS	p	O
with	IN	p	O
delayed	JJ	p	O
or	CC	p	O
normal	JJ	p	O
GE	NNP	p	O
did	VBD	O	O
not	RB	O	O
differ	VB	O	O
significantly	RB	O	O
in	IN	O	O
their	PRP$	O	O
symptomatic	JJ	O	O
response	NN	O	O
.	.	O	O

Eleven	JJ	O	O
patients	NNS	O	O
complained	VBD	O	O
of	IN	O	O
side	NN	o	OA
effects	NNS	o	OA
with	IN	O	O
metoclopramide	NN	i	O
and	CC	O	O
three	CD	O	O
stopped	VBD	O	O
therapy	NN	O	O
before	IN	O	O
the	DT	O	O
1-month	JJ	O	O
course	NN	O	O
was	VBD	O	O
completed	VBN	O	O
.	.	O	O

Two	CD	O	O
patients	NNS	O	O
described	JJ	O	O
side	JJ	O	O
effects	NNS	O	O
with	IN	O	O
domperidone	NN	i	O
,	,	O	O
including	VBG	O	O
one	CD	O	O
woman	NN	O	O
with	IN	O	O
galactorrhea	NN	o	OPH
after	IN	O	O
36	CD	O	O
h	NN	O	O
of	IN	O	O
treatment	NN	O	O
.	.	O	O

Three	CD	O	O
patients	NNS	O	O
on	IN	O	O
placebo	NN	i	O
also	RB	O	O
complained	VBD	O	O
of	IN	O	O
important	JJ	o	OA
side	NN	o	OA
effects	NNS	o	OA
.	.	o	O

We	PRP	O	O
conclude	VBP	O	O
that	IN	O	O
a	DT	O	O
significant	JJ	O	O
placebo	NN	O	O
effect	NN	O	O
is	VBZ	O	O
present	JJ	O	O
in	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
gastroesophageal	JJ	O	O
reflux	NN	O	O
.	.	O	O

No	DT	O	O
significant	JJ	O	O
difference	NN	O	O
was	VBD	O	O
demonstrated	VBN	O	O
in	IN	O	O
symptomatic	JJ	o	OOt
improvement	NN	o	OOt
between	IN	O	O
placebo	NN	i	O
,	,	i	O
domperidone	NN	i	O
,	,	O	O
and	CC	O	O
metoclopramide	RB	i	IPM
in	IN	O	O
this	DT	O	O
study	NN	O	O
.	.	O	O

Effect	NN	O	O
of	IN	O	O
sport-tinted	JJ	i	IPH
contact	NN	i	IPH
lenses	NNS	i	IPH
for	IN	O	O
contrast	NN	O	O
enhancement	NN	O	O
on	IN	O	O
retinal	JJ	O	O
straylight	NN	O	O
measurements	NNS	O	O
.	.	O	O

PURPOSE	NNP	O	O
To	TO	O	O
investigate	VB	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
two	CD	O	O
tinted	JJ	i	IPH
contact	NN	i	IPH
lenses	NNS	i	IPH
(	(	i	IPH
CL	NNP	i	IPH
)	)	i	IPH
designed	VBN	O	O
for	IN	O	O
outdoor	JJ	O	O
sports	NNS	O	O
activity	NN	O	O
on	IN	O	O
the	DT	O	O
psychometric	JJ	O	O
determination	NN	O	O
of	IN	O	O
retinal	JJ	O	O
straylight	NN	O	O
using	VBG	O	O
the	DT	O	O
compensation	NN	O	O
comparison	NN	O	O
method	NN	O	O
.	.	O	O

METHODS	NNP	O	O
Thirteen	NNP	p	PSS
emmetropic	JJ	p	PC
subjects	NNS	p	O
were	VBD	O	O
randomly	RB	O	O
fitted	VBN	O	O
with	IN	O	O
two	CD	i	IPH
different	JJ	i	IPH
tinted	VBN	i	IPH
Nike	NNP	i	IPH
Maxsight	NNP	i	IPH
(	(	i	IPH
Bausch	NNP	i	IPH
&	CC	i	IPH
Lomb	NNP	i	IPH
,	,	i	IPH
Rochester	NNP	i	IPH
,	,	i	IPH
NY	NNP	i	IPH
,	,	i	IPH
USA	NNP	i	IPH
)	)	i	IPH
CL	NNP	i	IPH
in	IN	i	IPH
one	CD	i	IPH
eye	NN	i	IPH
,	,	i	O
while	IN	i	O
the	DT	i	O
contralateral	JJ	i	IC
eye	NN	i	IC
was	VBD	i	IC
fitted	VBN	i	IC
with	IN	i	IC
a	DT	i	IC
clear	JJ	i	IC
lens	NNS	i	IC
made	VBN	i	IC
of	IN	i	IC
the	DT	i	IC
same	JJ	i	IC
material	NN	i	IC
(	(	i	O
Optima	NNP	i	O
38	CD	i	O
,	,	i	O
Bausch	NNP	i	O
&	CC	i	O
Lomb	NNP	i	O
)	)	i	O
.	.	i	O

Three	CD	O	O
valid	JJ	O	O
straylight	NN	o	OOt
measurements	NNS	o	OOt
were	VBD	O	O
taken	VBN	O	O
on	IN	O	O
each	DT	O	O
eye	NN	O	O
before	IN	O	O
and	CC	O	O
a	DT	O	O
few	JJ	O	O
minutes	NNS	O	O
after	IN	O	O
lens	JJ	O	O
insertion	NN	O	O
,	,	O	O
when	WRB	O	O
lens	VBZ	O	O
stabilization	NN	O	O
had	VBD	O	O
occurred	VBN	O	O
.	.	O	O

RESULTS	VB	O	O
The	DT	O	O
subjects	NNS	O	O
'	POS	O	O
mean	NN	o	OPH
straylight	NN	o	OPH
values	NNS	o	OPH
were	VBD	O	O
0.90	CD	O	O
+/-	JJ	O	O
0.09	CD	O	O
at	IN	O	O
baseline	NN	O	O
and	CC	O	O
0.95	CD	O	O
+/-	JJ	O	O
0.10	CD	O	O
with	IN	O	O
the	DT	O	O
clear	JJ	O	O
Optima	NNP	O	O
38	CD	O	O
CL	NNP	O	O
.	.	O	O

Straylight	NNP	o	OOt
values	NNS	o	OOt
were	VBD	O	O
0.97	CD	O	O
+/-	JJ	O	O
0.10	CD	O	O
and	CC	O	O
1.0	CD	O	O
+/-	JJ	O	O
0.10	CD	O	O
log	JJ	O	O
units	NNS	O	O
with	IN	O	O
the	DT	O	O
amber	NN	O	O
and	CC	O	O
grey-green	JJ	O	O
tinted	JJ	O	O
CL	NNP	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

Differences	NNS	O	O
in	IN	O	O
straylight	NN	o	OOt
between	IN	O	O
baseline	NN	O	O
(	(	O	O
without	IN	O	O
CL	NNP	O	O
)	)	O	O
and	CC	O	O
with	IN	O	O
the	DT	O	O
clear	JJ	O	O
CL	NNP	O	O
in	IN	O	O
place	NN	O	O
were	VBD	O	O
neither	RB	O	O
statistically	RB	O	O
significant	JJ	O	O
(	(	O	O
p	JJ	O	O
=	NNP	O	O
0.066	CD	O	O
)	)	O	O
nor	CC	O	O
was	VBD	O	O
there	EX	O	O
a	DT	O	O
significant	JJ	O	O
difference	NN	O	O
between	IN	O	O
baseline	NN	O	O
and	CC	O	O
the	DT	O	O
amber	NN	O	O
CL	NNP	O	O
(	(	O	O
p	JJ	O	O
=	NNP	O	O
0.052	CD	O	O
)	)	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
the	DT	O	O
grey-green	JJ	O	O
CL	NNP	O	O
showed	VBD	O	O
a	DT	O	O
statistically	RB	O	O
significant	JJ	O	O
difference	NN	O	O
from	IN	O	O
baseline	NN	O	O
(	(	O	O
p	JJ	O	O
=	NNP	O	O
0.006	CD	O	O
)	)	O	O
.	.	O	O

Differences	NNS	O	O
in	IN	O	O
straylight	NN	O	O
with	IN	O	O
the	DT	O	O
clear	JJ	O	O
CL	NNP	O	O
compared	VBN	O	O
with	IN	O	O
the	DT	O	O
grey-green	JJ	O	O
CL	NNP	O	O
were	VBD	O	O
also	RB	O	O
statistically	RB	O	O
different	JJ	O	O
from	IN	O	O
zero	NN	O	O
(	(	O	O
p	JJ	O	O
=	NNP	O	O
0.002	CD	O	O
)	)	O	O
showing	VBG	O	O
an	DT	O	O
increased	VBN	O	O
straylight	NN	o	OPH
value	NN	o	OPH
for	IN	O	O
the	DT	O	O
tinted	JJ	O	O
CL	NNP	O	O
.	.	O	O

These	DT	O	O
differences	NNS	O	O
were	VBD	O	O
variable	JJ	O	O
,	,	O	O
but	CC	O	O
consistent	JJ	O	O
for	IN	O	O
each	DT	O	O
subject	NN	O	O
,	,	O	O
thus	RB	O	O
those	DT	O	O
showing	VBG	O	O
higher	JJR	O	O
or	CC	O	O
lower	JJR	O	O
changes	NNS	O	O
with	IN	O	O
one	CD	O	O
tinted	JJ	O	O
lens	VBZ	O	O
tended	VBN	O	O
to	TO	O	O
show	VB	O	O
the	DT	O	O
same	JJ	O	O
trend	NN	O	O
with	IN	O	O
the	DT	O	O
second	JJ	O	O
lens	NNS	O	O
(	(	O	O
r	NN	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
=	FW	O	O
0.736	CD	O	O
)	)	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
Despite	IN	O	O
increases	NNS	O	O
having	VBG	O	O
been	VBN	O	O
found	VBN	O	O
in	IN	O	O
straylight	JJ	O	O
values	NNS	O	O
with	IN	O	O
tinted	VBN	O	O
contact	NN	O	O
lenses	NNS	O	O
,	,	O	O
those	DT	O	O
changes	NNS	O	O
are	VBP	O	O
not	RB	O	O
likely	JJ	O	O
to	TO	O	O
induce	VB	O	O
clinically	RB	O	O
significant	JJ	O	O
changes	NNS	O	O
in	IN	O	O
visual	JJ	O	O
function	NN	O	O
under	IN	O	O
photopic	NN	O	O
conditions	NNS	O	O
,	,	O	O
even	RB	O	O
for	IN	O	O
the	DT	O	O
grey-green	JJ	O	O
CL	NNP	O	O
,	,	O	O
which	WDT	O	O
seems	VBZ	O	O
to	TO	O	O
increase	VB	O	O
straylight	JJ	O	O
values	NNS	O	O
more	RBR	O	O
significantly	RB	O	O
than	IN	O	O
the	DT	O	O
amber	JJ	O	O
CL	NNP	O	O
.	.	O	O

This	DT	O	O
difference	NN	O	O
between	IN	O	O
the	DT	O	O
tinted	JJ	O	O
CL	NNP	O	O
could	MD	O	O
suggest	VB	O	O
a	DT	O	O
wavelength	JJ	O	O
dependence	NN	O	O
of	IN	O	O
straylight	NN	O	O
values	NNS	O	O
,	,	O	O
although	IN	O	O
this	DT	O	O
should	MD	O	O
be	VB	O	O
investigated	VBN	O	O
further	JJ	O	O
by	IN	O	O
controlling	VBG	O	O
for	IN	O	O
pupil	NN	O	O
size	NN	O	O
and	CC	O	O
subjects	NNS	O	O
'	POS	O	O
pigmentation	NN	O	O
,	,	O	O
as	RB	O	O
well	RB	O	O
as	IN	O	O
by	IN	O	O
using	VBG	O	O
neutral	JJ	O	O
density	NN	O	O
filters	NNS	O	O
.	.	O	O

A	DT	O	O
controlled	VBN	O	O
study	NN	O	O
of	IN	O	O
the	DT	O	O
effect	NN	o	OOt
of	IN	O	O
indomethacin	NN	i	O
in	IN	O	O
uremic	JJ	o	OPH
pericarditis	NN	o	OPH
.	.	o	OPH

To	TO	O	O
determine	VB	O	O
the	DT	O	O
impact	NN	O	O
of	IN	O	O
indomethacin	NN	i	O
on	IN	O	O
the	DT	O	O
course	NN	O	O
of	IN	O	O
uremic	JJ	O	O
pericarditis	NN	O	O
we	PRP	O	O
performed	VBD	O	O
a	DT	O	O
prospective	JJ	O	O
,	,	O	O
double	JJ	O	O
blind	NN	O	O
study	NN	O	O
in	IN	O	O
which	WDT	O	O
24	CD	p	O
patients	NNS	p	O
with	IN	p	O
endstage	NN	p	O
chronic	JJ	p	O
renal	JJ	p	O
failure	NN	p	O
and	CC	p	O
pericarditis	NN	p	O
randomly	RB	p	O
received	VBD	p	O
indomethacin	JJ	i	O
,	,	p	O
25	CD	p	O
mg	NN	p	O
four	CD	p	O
times	NNS	p	O
daily	RB	p	O
,	,	p	O
(	(	p	O
11	CD	p	O
patients	NNS	p	O
)	)	p	O
or	CC	p	O
a	DT	p	O
placebo	NN	i	IC
(	(	p	O
13	CD	p	O
patients	NNS	p	O
)	)	p	O
for	IN	O	O
a	DT	O	O
3-week	JJ	O	O
period	NN	O	O
.	.	O	O

All	DT	O	O
patients	NNS	p	O
received	VBN	p	O
peritoneal	JJ	p	O
or	CC	p	O
hemodialysis	NN	p	O
treatment	NN	p	O
concurrently	RB	p	O
with	IN	O	O
the	DT	O	O
study	NN	O	O
drug	NN	O	O
.	.	O	O

In	IN	O	O
contrast	NN	O	O
to	TO	O	O
the	DT	O	O
placebo	NN	i	IC
,	,	i	O
indomethacin	NN	i	O
produced	VBD	O	O
an	DT	O	O
immediate	JJ	O	O
and	CC	O	O
sustained	JJ	O	O
reduction	NN	o	OPH
of	IN	o	OPH
fever	NN	o	OPH
in	IN	O	O
all	DT	O	O
but	CC	O	O
one	CD	O	O
patient	NN	O	O
.	.	O	O

On	IN	O	O
the	DT	O	O
other	JJ	O	O
hand	NN	O	O
,	,	O	O
indomethacin	NN	i	O
had	VBD	O	O
no	DT	O	O
effect	NN	O	O
on	IN	O	O
the	DT	O	O
duration	NN	o	OPA
of	IN	o	OPA
chest	NN	o	OPA
pain	NN	o	OPA
(	(	O	O
mean	JJ	O	O
days	NNS	O	O
+/-	JJ	O	O
SE	NNP	O	O
:	:	O	O
placebo	NN	i	IC
1.4	CD	O	O
+/-	JJ	O	O
0.6	CD	O	O
,	,	O	O
indomethacin	JJ	i	IPM
5.5	CD	O	O
+/-	JJ	O	O
3.3	CD	O	O
)	)	O	O
,	,	O	O
duration	NN	O	O
of	IN	O	O
pericardial	JJ	o	OPH
friction	NN	o	OPH
rub	NN	o	OPH
(	(	O	O
placebo	JJ	O	O
10.3	CD	O	O
+/-	JJ	O	O
1.7	CD	O	O
,	,	O	O
indomethacin	JJ	i	O
16.0	CD	O	O
+/-	JJ	O	O
3.8	CD	O	O
)	)	O	O
,	,	O	O
or	CC	O	O
on	IN	O	O
the	DT	O	O
amount	NN	O	O
of	IN	O	O
pericardial	JJ	o	OPH
effusion	NN	o	OPH
.	.	o	OPH

Further	NNP	O	O
,	,	O	O
indomethacin	NN	O	O
did	VBD	O	O
not	RB	O	O
diminish	VB	O	O
the	DT	O	O
need	NN	o	OPH
for	IN	o	OPH
invasive	JJ	o	OPH
surgical	JJ	o	OPH
procedures	NNS	o	OPH
for	IN	o	O
relief	NN	o	O
of	IN	o	O
tamponade	NN	o	OPH
(	(	O	O
three	CD	O	O
of	IN	O	O
13	CD	O	O
placebo	NN	O	O
patients	NNS	O	O
,	,	O	O
two	CD	O	O
of	IN	O	O
11	CD	O	O
indomethacin	JJ	O	O
patients	NNS	O	O
)	)	O	O
or	CC	O	O
result	NN	O	O
in	IN	O	O
decreased	JJ	O	O
mortality	NN	o	OMO
rate	NN	o	OMO
.	.	o	OMO

Death	NNP	o	OMO
(	(	O	O
not	RB	O	O
due	RB	O	O
to	TO	O	O
pericarditis	NN	O	O
)	)	O	O
occurred	VBD	O	O
in	IN	O	O
two	CD	O	O
patients	NNS	O	O
treated	VBN	O	O
with	IN	O	O
indomethacin	NN	O	O
and	CC	O	O
one	CD	O	O
patient	NN	O	O
who	WP	O	O
received	VBD	O	O
the	DT	O	O
placebo	NN	i	O
.	.	i	O

In	IN	O	O
our	PRP$	O	O
patients	NNS	O	O
pericarditis	VBP	O	O
encompassed	VBD	O	O
a	DT	O	O
wide	JJ	O	O
spectrum	NN	O	O
ranging	VBG	O	O
from	IN	O	O
a	DT	O	O
mild	JJ	o	OPH
illness	NN	o	OPH
of	IN	o	OPH
several	JJ	o	OPH
days	NNS	o	OPH
duration	NN	o	OPH
to	TO	O	O
a	DT	O	O
painful	JJ	o	OPH
and	CC	o	OPH
debilitating	JJ	o	OPH
disease	NN	o	OPH
lasting	JJ	o	OPH
weeks	NNS	o	OPH
and	CC	O	O
requiring	VBG	O	O
surgical	JJ	o	OOt
intervention	NN	o	OOt
.	.	o	O

Although	IN	O	O
the	DT	O	O
size	NN	O	O
of	IN	O	O
our	PRP$	O	O
population	NN	O	O
prohibits	VBZ	O	O
definitive	JJ	O	O
conclusions	NNS	O	O
,	,	O	O
it	PRP	O	O
would	MD	O	O
appear	VB	O	O
that	IN	O	O
,	,	O	O
except	IN	O	O
for	IN	O	O
fever	NN	O	O
,	,	O	O
the	DT	O	O
manifestations	NNS	O	O
and	CC	O	O
natural	JJ	O	O
history	NN	O	O
of	IN	O	O
this	DT	O	O
illness	NN	o	OPH
are	VBP	O	O
unaffected	VBN	O	O
by	IN	O	O
indomethacin	NN	i	O
.	.	i	O

The	DT	O	O
prophylactic	JJ	o	OOt
effect	NN	o	OOt
of	IN	O	O
valproate	NN	i	IPM
on	IN	O	O
glyceryltrinitrate	NN	o	OPH
induced	VBN	o	OPH
migraine	NN	o	OPH
.	.	o	OPH

In	IN	O	O
this	DT	O	O
study	NN	O	O
the	DT	O	O
human	JJ	O	O
glyceryltrinitrate	NN	O	O
(	(	O	O
GTN	NNP	O	O
)	)	O	O
model	NN	O	O
of	IN	O	O
migraine	NN	O	O
was	VBD	O	O
for	IN	O	O
the	DT	O	O
first	JJ	O	O
time	NN	O	O
used	VBN	O	O
to	TO	O	O
test	VB	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
a	DT	O	O
prophylactic	JJ	i	O
drug	NN	i	O
.	.	i	O

We	PRP	O	O
chose	VBD	O	O
to	TO	O	O
test	VB	O	O
valproate	NN	i	IPM
due	JJ	O	O
to	TO	O	O
its	PRP$	O	O
well	RB	O	O
documented	JJ	O	O
effect	NN	O	O
as	IN	O	O
a	DT	O	O
migraine	JJ	i	IPM
prophylactic	JJ	i	IPM
drug	NN	i	IPM
.	.	i	IPM

Efficacy	NN	o	OOt
of	IN	O	O
this	DT	O	O
compound	NN	O	O
would	MD	O	O
support	VB	O	O
the	DT	O	O
usefulness	NN	O	O
of	IN	O	O
the	DT	O	O
model	NN	O	O
in	IN	O	O
prophylactic	JJ	O	O
antimigraine	JJ	O	O
drug	NN	O	O
development	NN	O	O
.	.	O	O

Twelve	CD	p	PSS
patients	NNS	p	O
with	IN	p	O
migraine	NN	p	PC
without	IN	p	PC
aura	NN	p	PC
were	VBD	p	O
included	VBN	p	O
in	IN	p	O
a	DT	p	O
randomized	JJ	p	O
double	JJ	p	O
blind	NN	p	O
crossover	NN	p	O
study	NN	p	O
.	.	p	O

Valproate	VB	i	IPM
1000	CD	O	O
mg	NN	O	O
or	CC	i	O
placebo	NN	i	IC
was	VBD	O	O
given	VBN	O	O
daily	RB	O	O
,	,	O	O
each	DT	O	O
for	IN	O	O
a	DT	O	O
minimum	NN	O	O
of	IN	O	O
13	CD	O	O
days	NNS	O	O
.	.	O	O

On	IN	O	O
the	DT	O	O
last	JJ	O	O
treatment	NN	O	O
day	NN	O	O
of	IN	O	O
each	DT	O	O
arm	NN	O	O
a	DT	O	O
20	CD	O	O
min	NN	O	O
intravenous	JJ	O	O
infusion	NN	O	O
of	IN	O	O
GTN	NNP	i	IPM
(	(	O	O
0.25	CD	O	O
microg/kg/min	NN	O	O
)	)	O	O
was	VBD	O	O
given	VBN	O	O
.	.	O	O

Headache	NNP	o	OA
was	VBD	O	O
registered	VBN	O	O
for	IN	O	O
12	CD	O	O
h	NN	O	O
after	IN	O	O
the	DT	O	O
infusion	NN	O	O
and	CC	O	O
headache	NN	o	OA
intensity	NN	o	OA
was	VBD	O	O
scored	VBN	O	O
on	IN	O	O
a	DT	O	O
scale	NN	O	O
from	IN	O	O
0	CD	O	O
to	TO	O	O
10	CD	O	O
.	.	O	O

Fulfillment	NN	O	O
of	IN	O	O
IHS	NNP	O	O
criteria	NNS	O	O
was	VBD	O	O
recorded	VBN	O	O
for	IN	O	O
24	CD	O	O
h.	PDT	O	O
The	DT	O	O
middle	JJ	o	OPH
cerebral	JJ	o	OPH
arteries	NNS	o	OPH
were	VBD	O	O
evaluated	VBN	O	O
by	IN	O	O
transcranial	JJ	o	OPH
Doppler	NNP	o	OPH
and	CC	O	O
the	DT	O	O
diameter	NN	o	OPH
of	IN	o	OPH
the	DT	o	OPH
superficial	JJ	o	OPH
temporal	JJ	o	OPH
and	CC	o	OPH
radial	JJ	o	OPH
arteries	NNS	o	OPH
were	VBD	O	O
measured	VBN	O	O
with	IN	O	O
high	JJ	o	OPH
frequency	NN	o	OPH
ultrasound	NN	o	OPH
.	.	o	OOt

GTN	NNP	o	OPH
evoked	VBD	o	OPH
migraine	JJ	o	OPA
fulfilling	NN	o	OPA
IHS	NNP	o	OPA
criteria	NNS	o	OPA
1.1	CD	O	O
in	IN	O	O
6	CD	O	O
patients	NNS	O	O
after	IN	O	O
placebo	NN	i	IC
and	CC	O	O
in	IN	O	O
2	CD	O	O
patients	NNS	O	O
after	IN	O	O
valproate	NN	i	IPM
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.125	CD	O	O
)	)	O	O
.	.	O	O

Including	VBG	O	O
additionally	RB	O	O
3	CD	O	O
patients	NNS	O	O
on	IN	O	O
placebo	NN	i	IC
and	CC	O	O
1	CD	O	O
patient	NN	O	O
on	IN	O	O
valproate	NN	i	IPM
who	WP	O	O
felt	VBD	O	O
they	PRP	O	O
had	VBD	O	O
suffered	VBN	O	O
a	DT	O	O
migraine	JJ	o	OA
attack	NN	o	OA
,	,	O	O
but	CC	O	O
who	WP	O	O
had	VBD	O	O
as	IN	O	O
associated	VBN	o	O
symptoms	NNS	o	O
only	RB	O	O
photophobia	VBP	o	OPH
or	CC	O	O
phonophobia	VBP	o	OPH
,	,	O	O
a	DT	O	O
significant	JJ	O	O
reduction	NN	O	O
in	IN	O	O
the	DT	O	O
number	NN	o	OOt
of	IN	o	OOt
patients	NNS	o	OOt
with	IN	o	OOt
induced	JJ	o	OOt
migraine	NN	o	OOt
after	IN	O	O
valproate	NN	i	IPM
was	VBD	O	O
seen	VBN	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.031	CD	O	O
)	)	O	O
.	.	O	O

Median	JJ	o	OPH
peak	NN	o	OPH
headache	NN	o	OPH
intensity	NN	o	OPH
was	VBD	O	O
1	CD	O	O
(	(	O	O
range	VB	O	O
0-9	NN	O	O
)	)	O	O
after	IN	O	O
valproate	NN	i	IPM
compared	VBN	O	O
to	TO	O	O
4.5	CD	O	O
(	(	O	O
range	VB	O	O
0-8	NN	O	O
)	)	O	O
after	IN	O	O
placebo	NN	i	IC
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.120	CD	O	O
)	)	O	O
.	.	O	O

Pretreatment	NN	O	O
with	IN	O	O
valproate	NN	i	IPM
as	IN	O	O
compared	VBN	O	O
to	TO	O	O
placebo	VB	i	IC
reduced	VBN	O	O
the	DT	O	O
velocity	NN	o	OPH
in	IN	O	O
both	DT	O	O
middle	JJ	o	OOt
cerebral	NN	o	OOt
arteries	NNS	o	OOt
after	IN	O	O
GTN	NNP	O	O
(	(	O	O
left	VBN	O	O
P	NNP	O	O
=	NNP	O	O
0.021	CD	O	O
,	,	O	O
right	JJ	O	O
P	NNP	O	O
=	NNP	O	O
0.031	CD	O	O
)	)	O	O
.	.	O	O

No	DT	O	O
effect	NN	O	O
of	IN	O	O
valproate	NN	i	IPM
was	VBD	O	O
seen	VBN	O	O
in	IN	O	O
the	DT	O	O
diameter	NN	o	OPH
of	IN	o	OPH
the	DT	o	OPH
superficial	JJ	o	OPH
temporal	JJ	o	OPH
artery	NN	o	OPH
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.781	CD	O	O
)	)	O	O
or	CC	O	O
the	DT	O	O
radial	JJ	o	O
artery	NN	o	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.367	CD	O	O
)	)	O	O
before	IN	O	O
or	CC	O	O
after	IN	O	O
GTN	NNP	O	O
.	.	O	O

The	DT	O	O
study	NN	O	O
indicates	VBZ	O	O
that	IN	O	O
a	DT	O	O
prophylactic	JJ	O	O
effect	NN	O	O
of	IN	O	O
valproate	NN	i	IPM
may	MD	O	O
be	VB	O	O
demonstrated	VBN	O	O
using	VBG	O	O
the	DT	O	O
GTN	NNP	o	OPH
human	JJ	o	OPH
migraine	NN	o	OPH
model	NN	i	IPM
.	.	i	IPM

Although	IN	O	O
,	,	O	O
all	DT	O	O
headache	NN	o	OA
parameters	NNS	o	OA
were	VBD	O	O
reduced	VBN	O	O
after	IN	O	O
valproate	NN	i	IPM
compared	VBN	O	O
to	TO	O	O
placebo	VB	i	IC
,	,	O	O
only	RB	O	O
one	CD	O	O
parameter	NN	O	O
was	VBD	O	O
statistically	RB	O	O
significantly	RB	O	O
reduced	VBN	O	O
probably	RB	O	O
because	IN	O	O
of	IN	O	O
the	DT	O	O
small	JJ	O	O
number	NN	O	O
of	IN	O	O
patients	NNS	O	O
.	.	O	O

The	DT	O	O
size	NN	O	O
of	IN	O	O
the	DT	O	O
effect	NN	O	O
was	VBD	O	O
similar	JJ	O	O
to	TO	O	O
that	DT	O	O
of	IN	O	O
valproate	NN	O	O
in	IN	O	O
clinical	JJ	O	O
trials	NNS	O	O
.	.	O	O

The	DT	i	O
GTN	NNP	i	IPM
model	NN	i	IPM
may	MD	O	O
therefore	RB	O	O
be	VB	O	O
a	DT	O	O
valid	JJ	O	O
tool	NN	O	O
for	IN	O	O
testing	VBG	O	O
new	JJ	O	O
prophylactic	JJ	O	O
antimigraine	NN	O	O
drugs	NNS	O	O
.	.	O	O

Transurethral	JJ	i	IS
prostate	NN	i	IS
resection	NN	i	IS
and	CC	O	O
bleeding	NN	O	O
:	:	O	O
a	DT	O	O
randomized	JJ	O	O
,	,	O	O
placebo	NN	i	IC
controlled	VBD	O	O
trial	NN	O	O
of	IN	O	O
role	NN	O	O
of	IN	O	O
finasteride	NN	i	IPM
for	IN	O	O
decreasing	VBG	O	O
operative	JJ	O	O
blood	NN	O	O
loss	NN	O	O
.	.	O	O

PURPOSE	NNP	O	O
Bleeding	NNP	O	O
associated	VBN	O	O
with	IN	O	O
transurethral	JJ	O	O
prostate	NN	O	O
resection	NN	O	O
can	MD	O	O
often	RB	O	O
be	VB	O	O
significant	JJ	O	O
and	CC	O	O
lead	JJ	O	O
to	TO	O	O
increased	VBN	O	O
morbidity	NN	O	O
and	CC	O	O
occasionally	RB	O	O
mortality	NN	O	O
.	.	O	O

It	PRP	O	O
has	VBZ	O	O
been	VBN	O	O
shown	VBN	O	O
that	IN	O	O
finasteride	NN	i	IPM
decreases	VBZ	O	O
bleeding	VBG	O	O
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
hematuria	NNS	p	PC
of	IN	p	O
prostatic	JJ	p	O
origin	NN	p	O
.	.	p	O

We	PRP	O	O
hypothesized	VBD	O	O
that	IN	O	O
bleeding	VBG	O	O
in	IN	O	O
patients	NNS	p	O
undergoing	JJ	p	O
transurethral	JJ	p	PC
prostate	NN	p	PC
resection	NN	p	PC
could	MD	O	O
be	VB	O	O
decreased	VBN	O	O
by	IN	O	O
giving	VBG	O	O
finasteride	NN	i	IPM
for	IN	O	O
2	CD	O	O
weeks	NNS	O	O
before	RB	O	O
surgery	NN	O	O
.	.	O	O

MATERIALS	NNP	O	O
AND	NNP	O	O
METHODS	NNP	O	O
A	NNP	p	O
total	JJ	p	O
70	CD	p	PSS
patients	NNS	p	O
scheduled	VBN	p	O
to	TO	p	O
undergo	VB	p	O
elective	JJ	p	PC
transurethral	JJ	p	PC
prostate	NN	p	PC
resection	NN	p	PC
were	VBD	p	O
randomized	VBN	p	O
to	TO	O	O
receive	VB	O	O
5	CD	i	IPM
mg.	NNS	i	IPM
finasteride	JJ	i	IPM
daily	RB	i	IPM
or	CC	i	O
placebo	VB	i	IC
for	IN	O	O
2	CD	O	O
weeks	NNS	O	O
before	RB	O	O
surgery	NN	O	O
.	.	O	O

Serum	NNP	o	OPH
hemoglobin	NN	o	OPH
was	VBD	O	O
measured	VBN	O	O
before	IN	O	O
and	CC	O	O
after	IN	O	O
surgery	NN	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
following	JJ	O	O
day	NN	O	O
.	.	O	O

The	DT	O	O
volume	NN	o	OOt
of	IN	o	OOt
irrigation	NN	o	OOt
fluid	NN	o	OOt
used	VBN	O	O
and	CC	O	O
its	PRP$	O	O
hemoglobin	JJ	O	O
concentration	NN	O	O
as	RB	O	O
well	RB	O	O
as	IN	O	O
resected	VBN	O	O
prostate	NN	O	O
weight	NN	O	O
were	VBD	O	O
recorded	VBN	O	O
.	.	O	O

RESULTS	NNP	O	O
Of	IN	O	O
the	DT	O	O
68	CD	p	PSS
patients	NNS	p	O
who	WP	p	O
underwent	JJ	p	O
transurethral	JJ	p	PC
prostate	NN	p	PC
resection	NN	p	PC
2	CD	O	O
were	VBD	O	O
withdrawn	VBN	o	O
before	RB	O	O
surgery	NN	O	O
,	,	O	O
and	CC	O	O
so	RB	O	O
32	CD	O	O
received	VBD	O	O
finasteride	NN	i	IPM
and	CC	O	O
36	CD	O	O
received	VBD	O	O
placebo	NN	i	IC
.	.	i	O

There	EX	O	O
was	VBD	O	O
significantly	RB	O	O
less	JJR	O	O
mean	JJ	o	OPH
blood	NN	o	OPH
loss	NN	o	OPH
in	IN	o	OPH
irrigation	NN	o	OPH
fluid	NN	o	OPH
in	IN	O	O
the	DT	O	O
finasteride	NN	i	IPM
group	NN	O	O
than	IN	O	O
in	IN	O	O
the	DT	O	O
control	NN	O	O
group	NN	O	O
(	(	O	O
43.6	CD	O	O
versus	NN	O	O
69.3	CD	O	O
gm	NN	O	O
.	.	O	O

hemoglobin	NN	O	O
,	,	O	O
p	NN	O	O
=	NNP	O	O
0.011	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
mean	JJ	O	O
difference	NN	O	O
was	VBD	O	O
more	RBR	O	O
significant	JJ	O	O
when	WRB	O	O
blood	NN	o	OPH
loss	NN	o	OPH
per	IN	O	O
gm	NN	O	O
.	.	O	O

resected	JJ	O	O
prostate	NN	O	O
was	VBD	O	O
calculated	VBN	O	O
(	(	O	O
2.65	CD	O	O
versus	NN	O	O
4.65	CD	O	O
gm	NN	O	O
.	.	O	O

hemoglobin	NN	O	O
per	IN	O	O
gm	NN	O	O
.	.	O	O

prostate	NN	O	O
,	,	O	O
p	NN	O	O
<	NNP	O	O
0.01	CD	O	O
)	)	O	O
.	.	O	O

CONCLUSIONS	VB	O	O
This	DT	O	O
study	NN	O	O
shows	VBZ	O	O
that	IN	O	O
finasteride	NN	i	IPM
given	VBN	O	O
for	IN	O	O
2	CD	O	O
weeks	NNS	O	O
preoperatively	RB	O	O
decreases	VBZ	O	O
bleeding	VBG	o	OPH
in	IN	O	O
patients	NNS	p	O
undergoing	JJ	p	O
transurethral	JJ	p	PC
prostate	NN	p	PC
resection	NN	p	PC
.	.	p	O

Further	NNP	O	O
study	NN	O	O
is	VBZ	O	O
required	VBN	O	O
to	TO	O	O
determine	VB	O	O
the	DT	O	O
optimal	JJ	O	O
timing	NN	O	O
and	CC	O	O
dose	JJ	O	O
duration	NN	O	O
to	TO	O	O
minimize	VB	O	O
blood	NN	o	OPH
loss	NN	o	OPH
and	CC	O	O
identify	VB	O	O
how	WRB	O	O
relevant	JJ	O	O
such	JJ	O	O
a	DT	O	O
decrease	NN	O	O
in	IN	O	O
bleeding	NN	O	O
is	VBZ	O	O
in	IN	O	O
clinical	JJ	O	O
practice	NN	O	O
.	.	O	O

Levosulpiride	NNP	i	IPM
in	IN	O	O
functional	JJ	p	PC
dyspepsia	NN	p	PC
:	:	p	O
a	DT	O	O
multicentric	JJ	O	O
,	,	O	O
double-blind	JJ	O	O
,	,	O	O
controlled	JJ	O	O
trial	NN	O	O
.	.	O	O

Abnormalities	NNS	O	O
in	IN	O	O
gastrointestinal	JJ	O	O
motility	NN	O	O
have	VBP	O	O
been	VBN	O	O
reported	VBN	O	O
in	IN	O	O
a	DT	O	O
substantial	JJ	O	O
proportion	NN	O	O
of	IN	O	O
patients	NNS	p	O
with	IN	p	O
functional	JJ	p	PC
dyspepsia	NN	p	PC
,	,	p	O
supporting	VBG	p	O
the	DT	p	O
use	NN	p	O
of	IN	p	O
prokinetic	JJ	i	IPM
drugs	NNS	i	IPM
for	IN	p	O
treatment	NN	p	O
of	IN	p	O
dyspeptic	JJ	p	PC
symptoms	NNS	p	PC
.	.	p	O

To	TO	O	O
evaluate	VB	O	O
efficacy	NN	o	OOt
and	CC	o	OOt
safety	NN	o	OOt
of	IN	O	O
levosulpiride	NN	i	IPM
in	IN	O	O
short-term	JJ	O	O
treatment	NN	O	O
,	,	O	O
1298	CD	p	PSS
patients	NNS	p	O
were	VBD	p	O
enrolled	VBN	p	O
in	IN	p	O
a	DT	p	O
double-blind	JJ	p	O
multicentric	NN	p	O
study	NN	p	O
carried	VBD	p	O
out	IN	p	O
in	IN	p	O
45	CD	p	O
Italian	JJ	p	O
Gastroenterology	NNP	p	O
Departments	NNP	p	O
.	.	p	O

Patients	NNS	O	O
were	VBD	O	O
randomly	RB	O	O
assigned	VBN	O	O
to	TO	O	O
either	DT	O	O
levosulpiride	NN	i	IPM
(	(	O	O
25	CD	O	O
mg	RB	O	O
tid	NN	O	O
)	)	O	O
,	,	O	O
domperidone	NN	i	IPM
(	(	O	O
10	CD	O	O
mg	RB	O	O
tid	NN	O	O
)	)	O	O
,	,	O	O
metoclopramide	RB	i	IPM
(	(	O	O
10	CD	O	O
mg	RB	O	O
tid	NN	O	O
)	)	O	O
or	CC	O	O
placebo	NN	i	IC
(	(	O	O
1	CD	O	O
tablet	NN	O	O
tid	NN	O	O
)	)	O	O
for	IN	O	O
4	CD	O	O
weeks	NNS	O	O
.	.	O	O

Patients	NNS	p	O
were	VBD	p	O
selected	VBN	p	O
on	IN	p	O
the	DT	p	O
basis	NN	p	O
of	IN	p	O
:	:	p	O
a	DT	p	O
)	)	p	O
occurrence	NN	p	O
in	IN	p	O
the	DT	p	O
last	JJ	p	O
4	CD	p	O
weeks	NNS	p	O
of	IN	p	O
at	IN	p	O
least	JJS	p	O
5/10	CD	p	O
selected	VBN	p	O
symptoms	NNS	p	O
(	(	o	O
anorexia	NN	o	OPH
,	,	o	OPH
nausea	NN	o	OPH
,	,	o	OPH
vomiting	VBG	o	OPH
,	,	o	OPH
upper	JJ	o	OPH
abdominal	JJ	o	OPH
pain	NN	o	OPH
,	,	o	OPH
postprandial	JJ	o	OPH
bloating	NN	o	OPH
,	,	o	OPH
abdominal	JJ	o	OPH
fullness	NN	o	OPH
,	,	o	OPH
early	JJ	o	OPH
satiety	NN	o	OPH
,	,	o	OPH
belching	NN	o	OPH
,	,	o	OPH
heartburn	NN	o	OPH
,	,	o	OPH
regurgitation	NN	o	OPH
)	)	o	O
,	,	p	O
severity	NN	p	O
of	IN	p	O
which	WDT	p	O
should	MD	p	O
reach/exceed	VB	p	O
a	DT	p	O
total	JJ	p	O
score	NN	p	O
of	IN	p	O
8	CD	p	O
,	,	p	O
as	IN	p	O
assessed	VBN	p	O
by	IN	p	O
a	DT	p	O
specific	JJ	p	O
scale	NN	p	O
ranging	VBG	p	O
from	IN	p	O
0	CD	p	O
(	(	p	O
absent	NN	p	O
)	)	p	O
to	TO	p	O
3	CD	p	O
(	(	p	O
severe	JJ	p	O
)	)	p	O
;	:	p	O
b	VBN	p	O
)	)	p	O
normal	JJ	p	O
results	NNS	p	O
of	IN	p	O
routine	JJ	p	O
biochemical	NN	p	O
,	,	p	O
ultrasound	NN	p	O
and	CC	p	O
endoscopic	JJ	p	O
examinations	NNS	p	O
.	.	p	O

In	IN	O	O
addition	NN	O	O
,	,	O	O
each	DT	O	O
patient	NN	O	O
subjectively	RB	O	O
evaluated	VBD	O	O
efficacy	NN	o	OOt
of	IN	O	O
treatment	NN	O	O
by	IN	O	O
a	DT	O	O
visual	JJ	O	O
analogue	NN	O	O
scale	NN	O	O
.	.	O	O

Significant	JJ	O	O
improvement	NN	O	O
was	VBD	O	O
recorded	VBN	O	O
for	IN	O	O
all	DT	O	O
symptoms	NNS	O	O
at	IN	O	O
days	NNS	O	O
10	CD	O	O
and	CC	O	O
28	CD	O	O
in	IN	O	O
all	DT	O	O
groups	NNS	O	O
(	(	O	O
p	JJ	O	O
<	NNP	O	O
0.001	CD	O	O
)	)	O	O
,	,	O	O
but	CC	O	O
levosulpiride	NN	i	IPM
was	VBD	O	O
significantly	RB	O	O
(	(	O	O
p	JJ	O	O
<	NNP	O	O
0.01	CD	O	O
)	)	O	O
superior	NN	O	O
to	TO	O	O
domperidone	VB	i	IPM
,	,	i	O
metoclopramide	NN	i	IPM
and	CC	O	O
placebo	VB	i	IC
both	DT	O	O
in	IN	O	O
the	DT	O	O
overall	JJ	O	O
clinical	JJ	O	O
improvement	NN	O	O
scale	NN	O	O
as	RB	O	O
well	RB	O	O
as	IN	O	O
in	IN	O	O
a	DT	O	O
subgroup	NN	O	O
of	IN	O	O
symptoms	NNS	O	O
(	(	o	OPA
postprandial	JJ	o	OPH
bloating	NN	o	OPH
,	,	o	O
epigastric	JJ	o	OPA
pain	NN	o	OPA
,	,	o	O
heartburn	NN	o	OPH
)	)	o	O
.	.	O	O

Active	JJ	i	IPM
treatments	NNS	i	IPM
and	CC	O	O
placebo	NNS	i	IC
were	VBD	O	O
comparable	JJ	O	O
as	RB	O	O
far	RB	O	O
as	IN	O	O
concerns	NNS	O	O
occurrence	IN	O	O
of	IN	O	O
side-effects	NNS	O	O
(	(	O	O
12-20	CD	O	O
%	NN	O	O
)	)	O	O
including	VBG	O	O
galactorrhoea	NN	o	OPH
,	,	o	OPH
breast	NN	o	OPH
tenderness	NN	o	OPH
and	CC	o	OPH
menstrual	JJ	o	OPH
changes	NNS	o	OPH
.	.	o	O

Injection	NNP	i	IPM
sclerotherapy	NN	i	IPM
versus	NN	i	IPH
electrocoagulation	NN	i	IPH
in	IN	O	O
the	DT	O	O
management	NN	O	O
outcome	NN	O	O
of	IN	O	O
early	JJ	p	O
haemorrhoids	NNS	p	O
.	.	p	O

OBJECTIVE	NNP	O	O
To	TO	O	O
study	VB	O	O
the	DT	O	O
symptomatology	NN	O	O
of	IN	O	O
early	JJ	p	O
hemorrhoids	NNS	p	O
and	CC	O	O
to	TO	O	O
compare	VB	O	O
injection	NN	i	IPM
sclerotherapy	NN	i	IPM
(	(	i	IPM
IS	NNP	i	IPM
)	)	i	IPM
with	IN	i	O
electrocoagulation	NN	i	IPH
(	(	i	IPH
EC	NNP	i	IPH
)	)	i	IPH
in	IN	O	O
the	DT	O	O
management	NN	O	O
outcome	NN	O	O
of	IN	O	O
early	JJ	O	O
haemorrhoids	NNS	O	O
with	IN	O	O
respect	NN	O	O
to	TO	O	O
pain	VB	o	OPA
during	IN	o	OPA
the	DT	o	OPA
procedure	NN	o	OPA
,	,	o	O
reduction	NN	o	OPH
in	IN	o	OPH
bleeding	VBG	o	OPH
per	IN	o	OPH
rectum	NN	o	OPH
,	,	O	O
and	CC	O	O
overall	JJ	o	OOt
patient	NN	o	OOt
satisfaction	NN	o	OOt
score	NN	o	OOt
.	.	o	O

METHODS	NNP	O	O
A	NNP	O	O
total	NN	O	O
of	IN	O	O
102	CD	p	PSS
patients	NNS	p	PSS
were	VBD	p	O
included	VBN	p	O
in	IN	O	O
this	DT	O	O
experimental	JJ	O	O
study	NN	O	O
at	IN	p	O
the	DT	p	O
POF	NNP	p	O
Hospital	NNP	p	O
,	,	p	O
Wah	NNP	p	O
Cantt	NNP	p	O
from	IN	p	O
October	NNP	p	O
2004	CD	p	O
to	TO	p	O
June	NNP	p	O
2005	CD	p	O
.	.	p	O

A	DT	O	O
detailed	JJ	O	O
history	NN	O	O
was	VBD	O	O
taken	VBN	O	O
and	CC	O	O
proctoscopic	JJ	O	O
examination	NN	O	O
was	VBD	O	O
performed	VBN	O	O
.	.	O	O

Patients	NNS	O	O
were	VBD	O	O
then	RB	O	O
randomly	RB	O	O
divided	VBN	O	O
into	IN	O	O
two	CD	O	O
groups	NNS	O	O
(	(	O	O
Lottery	NNP	O	O
method	NN	O	O
)	)	O	O
.	.	O	O

One	CD	O	O
group	NN	O	O
was	VBD	O	O
subjected	VBN	O	O
to	TO	O	O
EC	NNP	O	O
and	CC	O	O
the	DT	O	O
other	JJ	O	O
to	TO	O	O
IS	NNP	O	O
.	.	O	O

In	IN	O	O
the	DT	O	O
EC	NNP	O	O
,	,	O	O
using	VBG	O	O
the	DT	O	O
EC	NNP	O	O
machine	NN	O	O
(	(	O	O
Wieda	NNP	O	O
,	,	O	O
China	NNP	O	O
)	)	O	O
,	,	O	O
direct	JJ	O	O
current	JJ	O	O
of	IN	O	O
10-20	JJ	O	O
mA	NN	O	O
was	VBD	O	O
applied	VBN	O	O
in	IN	O	O
the	DT	O	O
submucosal	JJ	O	O
plane	NN	O	O
of	IN	O	O
each	DT	O	O
pile	NN	O	O
core	NN	O	O
for	IN	O	O
5-7	JJ	O	O
minutes	NNS	O	O
.	.	O	O

In	IN	O	O
the	DT	O	O
IS	NNP	O	O
1-2	JJ	O	O
ml	NN	O	O
of	IN	O	O
5	CD	O	O
%	NN	O	O
phenol	NN	i	IPM
in	IN	i	IPM
almond	NN	i	IPM
oil	NN	i	IPM
was	VBD	O	O
injected	VBN	O	O
in	IN	O	O
the	DT	O	O
same	JJ	O	O
plane	NN	O	O
in	IN	O	O
each	DT	O	O
pile	NN	O	O
core	NN	O	O
.	.	O	O

Pain	NN	o	OPA
during	IN	o	OPA
the	DT	o	OPA
procedure	NN	o	OPA
,	,	o	O
reduction	NN	o	OPH
in	IN	o	OPH
bleeding	VBG	o	OPH
per	IN	o	OPH
rectum	NN	o	OPH
and	CC	o	O
overall	JJ	o	OOt
patient	NN	o	OOt
satisfaction	NN	o	OOt
,	,	O	O
were	VBD	O	O
studied	VBN	O	O
as	IN	O	O
outcome	JJ	O	O
measures	NNS	O	O
.	.	O	O

RESULTS	VB	O	O
The	DT	p	PA
mean	JJ	p	PA
age	NN	p	PA
of	IN	p	PA
the	DT	p	PA
patients	NNS	p	PA
was	VBD	p	PA
44	CD	p	PA
years	NNS	p	PA
,	,	p	O
86	CD	p	O
were	VBD	p	O
males	NNS	p	PSE
and	CC	p	O
16	CD	p	O
were	VBD	p	O
females	NNS	p	O
.	.	p	O

Two	CD	O	O
thirds	NNS	O	O
of	IN	O	O
the	DT	O	O
patients	NNS	O	O
were	VBD	O	O
having	VBG	O	O
symptoms	NNS	O	O
for	IN	O	O
more	JJR	O	O
than	IN	O	O
6	CD	O	O
months	NNS	O	O
.	.	O	O

A	DT	O	O
third	JJ	O	O
of	IN	O	O
patients	NNS	O	O
had	VBD	O	O
associated	VBN	O	O
local	JJ	o	OPA
pain	NN	o	OPA
while	IN	O	O
another	DT	O	O
third	JJ	O	O
had	VBD	O	O
associated	VBN	O	O
mucous	JJ	o	OPH
discharge	NN	o	OPH
.	.	o	O

Chronic	JJ	o	OA
constipation	NN	o	OA
was	VBD	O	O
present	JJ	O	O
in	IN	O	O
81	CD	O	O
%	NN	O	O
patients	NNS	O	O
.	.	O	O

Only	RB	O	O
24.5	CD	p	O
%	NN	p	O
of	IN	p	O
the	DT	p	O
patients	NNS	p	O
had	VBD	p	O
a	DT	p	O
positive	JJ	p	PC
family	NN	p	PC
history	NN	p	PC
of	IN	p	PC
haemorrhoids	NNS	p	PC
.	.	p	O

Patients	NNS	O	O
in	IN	O	O
the	DT	O	O
electrocoagulation	NN	O	O
(	(	O	O
EC	NNP	O	O
)	)	O	O
group	NN	O	O
experienced	VBD	O	O
more	JJR	O	O
pain	NN	o	OPA
during	IN	o	OPA
the	DT	o	OPA
procedure	NN	o	OPA
than	IN	O	O
the	DT	O	O
injection	NN	O	O
sclerotherapy	NN	i	O
(	(	i	O
IS	NNP	i	O
)	)	i	O
group	NN	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.000	CD	O	O
)	)	O	O
,	,	O	O
but	CC	O	O
EC	NNP	O	O
was	VBD	O	O
significantly	RB	O	O
more	RBR	O	O
effective	JJ	O	O
than	IN	O	O
IS	NNP	O	O
in	IN	O	O
terms	NNS	O	O
of	IN	O	O
reducing	VBG	O	O
the	DT	O	O
bleeding	NN	o	OPH
per	IN	o	OPH
rectum	NN	o	OPH
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.039	CD	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
also	RB	O	O
significantly	RB	O	O
higher	JJR	O	O
number	NN	O	O
of	IN	O	O
patients	NNS	O	O
were	VBD	O	O
fully	RB	o	OOt
satisfied	VBN	o	OOt
with	IN	O	O
EC	NNP	O	O
than	IN	O	O
with	IN	O	O
IS	NNP	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.04	CD	O	O
)	)	O	O
.	.	O	O

CONCLUSION	NNP	O	O
EC	NNP	O	O
,	,	O	O
although	IN	O	O
more	RBR	O	O
painful	JJ	o	OPA
,	,	O	O
is	VBZ	O	O
a	DT	O	O
safe	JJ	o	OOt
,	,	O	O
more	RBR	O	O
effective	JJ	o	OOt
and	CC	O	O
a	DT	O	O
highly	RB	o	OOt
satisfying	JJ	o	OOt
procedure	NN	O	O
for	IN	O	O
treating	VBG	O	O
early	JJ	O	O
hemorrhoids	NNS	O	O
.	.	O	O

Induction	NNP	i	IPM
chemotherapy	NN	i	IPM
in	IN	O	O
head	NN	p	PC
and	CC	p	PC
neck	NN	p	PC
cancer	NN	p	PC
:	:	p	O
results	NNS	O	O
of	IN	O	O
a	DT	O	O
phase	NN	O	O
III	NNP	O	O
trial	NN	O	O
.	.	O	O

Between	IN	p	O
December	NNP	p	O
1982	CD	p	O
and	CC	p	O
October	NNP	p	O
1986	CD	p	O
,	,	p	O
131	CD	p	PSS
patients	NNS	p	O
with	IN	p	O
stage	JJ	p	PC
II-III-IV	NNP	p	PC
squamous	JJ	p	PC
cell	NN	p	PC
carcinoma	NN	p	PC
of	IN	p	O
the	DT	p	O
oropharynx	NN	p	PC
or	CC	p	O
oral	JJ	p	PC
cavity	NN	p	PC
were	VBD	O	O
randomized	VBN	O	O
to	TO	O	O
induction	VB	i	O
chemotherapy	NN	i	IPM
,	,	i	O
consisting	VBG	i	O
of	IN	i	O
bleomycin	NN	i	IPM
(	(	i	O
10	CD	i	O
mg/m2/day	NN	i	O
in	IN	i	O
continuous	JJ	i	O
infusion	NN	i	O
from	IN	i	O
day	NN	i	O
1	CD	i	O
to	TO	i	O
day	NN	i	O
5	CD	i	O
)	)	i	O
,	,	i	O
methotrexate	NN	i	IPM
(	(	i	O
120	CD	i	O
mg/m2	NN	i	O
on	IN	i	O
day	NN	i	O
2	CD	i	O
)	)	i	O
followed	VBN	i	O
by	IN	i	O
folinic	JJ	i	IPM
acid	NN	i	IPM
,	,	i	O
5-fluorouracil	JJ	i	IPM
(	(	i	O
5	CD	i	O
FU	NNP	i	O
)	)	i	O
(	(	i	O
600	CD	i	O
mg/m2	NN	i	O
on	IN	i	O
day	NN	i	O
2	CD	i	O
)	)	i	O
,	,	i	O
and	CC	i	O
cisplatin	NN	i	IPM
(	(	i	O
120	CD	i	O
mg/m2	NN	i	O
on	IN	i	O
day	NN	i	O
4	CD	i	O
)	)	i	O
every	DT	i	O
4	CD	i	O
weeks	NNS	i	O
for	IN	i	O
a	DT	i	O
total	NN	i	O
of	IN	i	O
three	CD	i	O
cycles	NNS	i	O
followed	VBN	i	O
by	IN	i	O
definitive	JJ	i	O
locoregional	JJ	i	O
treatment	NN	i	O
versus	IN	i	O
locoregional	JJ	i	O
treatment	NN	i	O
alone	RB	i	O
.	.	i	O

The	DT	O	O
modalities	NNS	O	O
of	IN	O	O
definitive	JJ	O	O
treatment	NN	O	O
(	(	i	O
radiotherapy	JJ	i	IS
+/-	JJ	i	O
surgery	NN	i	IS
)	)	i	O
were	VBD	O	O
chosen	VBN	O	O
prior	RB	O	O
to	TO	O	O
randomization	NN	O	O
.	.	O	O

A	DT	p	O
total	NN	p	O
of	IN	p	O
116	CD	p	PSS
patients	NNS	p	O
were	VBD	p	O
evaluable	JJ	p	O
.	.	p	O

Of	IN	O	O
55	CD	O	O
patients	NNS	O	O
in	IN	O	O
the	DT	O	O
chemotherapy	NN	i	IPM
arm	NN	O	O
,	,	O	O
four	CD	O	O
(	(	O	O
7	CD	O	O
%	NN	O	O
)	)	O	O
had	VBD	O	O
a	DT	O	O
complete	JJ	O	O
response	NN	O	O
(	(	O	O
CR	NNP	O	O
)	)	O	O
and	CC	O	O
23	CD	O	O
(	(	O	O
42	CD	O	O
%	NN	O	O
)	)	O	O
a	DT	O	O
partial	JJ	O	O
response	NN	O	O
(	(	O	O
PR	NNP	O	O
)	)	O	O
following	VBG	O	O
the	DT	O	O
induction	NN	O	O
regimen	NNS	O	O
.	.	O	O

At	IN	O	O
the	DT	O	O
completion	NN	O	O
of	IN	O	O
locoregional	JJ	O	O
treatment	NN	O	O
,	,	O	O
76	CD	O	O
%	NN	O	O
(	(	O	O
42	CD	O	O
of	IN	O	O
55	CD	O	O
)	)	O	O
of	IN	O	O
patients	NNS	O	O
in	IN	O	O
the	DT	O	O
experimental	JJ	O	O
group	NN	O	O
were	VBD	O	O
in	IN	O	O
CR	NNP	O	O
compared	VBN	O	O
to	TO	O	O
89	CD	O	O
%	NN	O	O
(	(	O	O
54	CD	O	O
of	IN	O	O
61	CD	O	O
)	)	O	O
in	IN	O	O
the	DT	O	O
control	NN	O	O
group	NN	O	O
.	.	O	O

There	EX	O	O
was	VBD	O	O
no	DT	O	O
difference	NN	O	O
in	IN	O	O
survival	NN	o	OOt
,	,	o	O
cause-specific	JJ	o	OOt
survival	NN	o	OOt
,	,	o	O
and	CC	o	O
pattern	NN	o	OPH
of	IN	o	OPH
relapse	NN	o	OPH
between	IN	O	O
both	DT	O	O
groups	NNS	O	O
.	.	O	O

The	DT	O	O
median	JJ	o	OOt
survival	NN	o	OOt
was	VBD	O	O
22	CD	O	O
months	NNS	O	O
in	IN	O	O
the	DT	O	O
chemotherapy	NN	O	O
group	NN	O	O
and	CC	O	O
29	CD	O	O
months	NNS	O	O
in	IN	O	O
the	DT	O	O
control	NN	O	O
group	NN	O	O
.	.	O	O

Responders	NNS	O	O
to	TO	O	O
chemotherapy	VB	O	O
did	VBD	O	O
not	RB	O	O
fare	VB	O	O
better	JJR	O	O
than	IN	O	O
nonresponders	NNS	O	O
.	.	O	O

Chemotherapy-related	JJ	o	OA
toxicities	NNS	o	OA
were	VBD	O	O
few	JJ	O	O
and	CC	O	O
most	JJS	O	O
of	IN	O	O
them	PRP	O	O
related	VBN	O	O
to	TO	O	O
cisplatin	VB	O	O
which	WDT	O	O
was	VBD	O	O
reduced	VBN	O	O
to	TO	O	O
100	CD	O	O
mg/m2	NN	O	O
for	IN	O	O
35	CD	O	O
patients	NNS	O	O
.	.	O	O

There	EX	O	O
were	VBD	O	O
no	DT	O	O
treatment-related	JJ	O	O
deaths	NNS	o	OMO
and	CC	O	O
,	,	O	O
in	IN	O	O
the	DT	O	O
experimental	JJ	O	O
arm	NN	O	O
of	IN	O	O
the	DT	O	O
trial	NN	O	O
,	,	O	O
no	DT	O	O
increased	VBN	O	O
morbidity	NN	o	OA
from	IN	O	O
locoregional	JJ	O	O
treatment	NN	O	O
.	.	O	O

This	DT	O	O
induction	NN	O	O
regimen	NN	O	O
does	VBZ	O	O
not	RB	O	O
offer	VB	O	O
any	DT	O	O
advantages	NNS	O	O
over	IN	O	O
standard	JJ	O	O
treatment	NN	O	O
.	.	O	O

Central	JJ	O	O
5-HT4	JJ	O	O
receptor	NN	O	O
binding	NN	O	O
as	IN	O	O
biomarker	NN	O	O
of	IN	O	O
serotonergic	JJ	O	O
tonus	NN	O	O
in	IN	O	O
humans	NNS	p	O
:	:	p	O
a	DT	O	O
[	$	O	O
11C	CD	O	O
]	NNP	O	O
SB207145	NNP	O	O
PET	NNP	O	O
study	NN	O	O
.	.	O	O

Identification	NNP	O	O
of	IN	O	O
a	DT	O	O
biomarker	NN	O	O
that	WDT	O	O
can	MD	O	O
inform	VB	O	O
on	IN	O	O
extracellular	JJ	O	O
serotonin	NN	O	O
(	(	O	O
5-HT	JJ	O	O
)	)	O	O
levels	NNS	O	O
in	IN	O	O
the	DT	O	O
brains	NNS	O	O
of	IN	O	O
living	NN	p	O
humans	NNS	p	O
would	MD	O	O
enable	VB	O	O
greater	JJR	O	O
understanding	NN	O	O
of	IN	O	O
the	DT	O	O
way	NN	O	O
brain	NN	O	O
circuits	NNS	O	O
are	VBP	O	O
modulated	VBN	O	O
by	IN	O	O
serotonergic	JJ	O	O
neurotransmission	NN	O	O
.	.	O	O

Substantial	JJ	O	O
evidence	NN	O	O
from	IN	O	O
studies	NNS	O	O
in	IN	O	O
animals	NNS	O	O
and	CC	O	O
humans	NNS	O	O
indicates	VBZ	O	O
an	DT	O	O
inverse	NN	O	O
relationship	NN	O	O
between	IN	O	O
central	JJ	O	O
5-HT	JJ	O	O
tonus	NN	O	O
and	CC	O	O
5-HT	JJ	O	O
type	NN	O	O
4	CD	O	O
receptor	NN	O	O
(	(	O	O
5-HT4R	JJ	O	O
)	)	O	O
density	NN	O	O
,	,	O	O
suggesting	VBG	O	O
that	IN	O	O
5-HT4R	JJ	O	O
receptor	NN	O	O
density	NN	O	O
may	MD	O	O
be	VB	O	O
a	DT	O	O
biomarker	NN	O	O
marker	NN	O	O
for	IN	O	O
5-HT	JJ	O	O
tonus	NN	O	O
.	.	O	O

Here	RB	O	O
,	,	O	O
we	PRP	O	O
investigated	VBD	O	O
whether	IN	O	O
a	DT	O	O
3-week	JJ	O	O
administration	NN	O	O
of	IN	O	O
a	DT	O	O
selective	JJ	O	O
serotonin	NN	O	O
reuptake	NN	O	O
inhibitor	NN	O	O
,	,	O	O
expected	VBN	O	O
to	TO	O	O
increase	VB	O	O
brain	NN	O	O
5-HT	JJ	O	O
levels	NNS	O	O
,	,	O	O
is	VBZ	O	O
associated	VBN	O	O
with	IN	O	O
a	DT	O	O
decline	NN	O	O
in	IN	O	O
brain	NN	O	O
5-HT4R	JJ	O	O
binding	NN	O	O
.	.	O	O

A	DT	p	O
total	NN	p	O
of	IN	p	O
35	CD	p	O
healthy	JJ	p	O
men	NNS	p	O
were	VBD	p	O
studied	VBN	p	O
in	IN	O	O
a	DT	O	O
placebo-controlled	JJ	i	IC
,	,	O	O
randomized	VBN	O	O
,	,	O	O
double-blind	JJ	O	O
study	NN	O	O
.	.	O	O

Participants	NNS	O	O
were	VBD	O	O
assigned	VBN	O	O
to	TO	O	O
receive	VB	O	O
3	CD	O	O
weeks	NNS	O	O
of	IN	O	O
oral	JJ	i	IC
dosing	VBG	i	IC
with	IN	i	IC
placebo	NN	i	IC
or	CC	i	O
fluoxetine	NN	i	IPM
,	,	i	IPM
40	CD	i	IPM
mg	NNS	i	IPM
per	IN	i	IPM
day	NN	i	IPM
.	.	i	O

Brain	VB	o	OPH
5-HT4R	JJ	o	OPH
binding	NN	o	OPH
was	VBD	O	O
quantified	VBN	O	O
at	IN	O	O
baseline	NN	O	O
and	CC	O	O
at	IN	O	O
follow-up	JJ	O	O
with	IN	O	O
[	NNP	i	O
(	(	i	IPH
11	CD	i	IPH
)	)	i	IPH
C	NNP	i	IPH
]	NNP	i	IPH
SB207145	NNP	i	IPH
positron	NN	o	OOt
emission	NN	o	OOt
tomography	NN	o	OOt
(	(	o	O
PET	NNP	o	O
)	)	o	O
.	.	o	O

Three	CD	O	O
weeks	NNS	O	O
of	IN	O	O
intervention	NN	O	O
with	IN	O	O
fluoxetine	NN	O	O
was	VBD	O	O
associated	VBN	O	O
with	IN	O	O
a	DT	O	O
5.2	CD	O	O
%	NN	O	O
reduction	NN	O	O
in	IN	O	O
brain	NN	o	OPH
5-HT4R	JJ	o	OPH
binding	NN	o	OPH
(	(	O	O
P=0.017	NNP	O	O
)	)	O	O
,	,	O	O
whereas	JJ	O	O
placebo	NN	O	O
intervention	NN	O	O
did	VBD	O	O
not	RB	O	O
change	VB	O	O
5-HT4R	JJ	O	O
binding	NN	O	O
(	(	O	O
P=0.52	NNP	O	O
)	)	O	O
.	.	O	O

Our	PRP$	O	O
findings	NNS	O	O
are	VBP	O	O
consistent	JJ	O	O
with	IN	O	O
a	DT	O	O
model	NN	O	O
,	,	O	O
wherein	VBP	O	O
the	DT	O	O
5-HT4R	JJ	o	OPH
density	NN	o	OPH
adjusts	VBZ	O	O
to	TO	O	O
changes	NNS	O	O
in	IN	O	O
the	DT	O	O
extracellular	JJ	O	O
5-HT	JJ	O	O
tonus	NN	O	O
.	.	O	O

Our	PRP$	O	O
data	NNS	O	O
demonstrate	NN	O	O
for	IN	O	O
the	DT	O	O
first	JJ	O	O
time	NN	O	O
in	IN	O	O
humans	NNS	p	O
that	IN	O	O
the	DT	O	O
imaging	NN	O	O
of	IN	O	O
central	JJ	O	O
5-HT4R	JJ	O	O
binding	NN	O	O
may	MD	O	O
be	VB	O	O
used	VBN	O	O
as	IN	O	O
an	DT	O	O
in	IN	O	O
vivo	NN	O	O
biomarker	NN	O	O
of	IN	O	O
the	DT	O	O
central	JJ	O	O
5-HT	JJ	O	O
tonus	NN	O	O
.	.	O	O

Metformin	NNP	i	IPM
does	VBZ	O	O
not	RB	O	O
enhance	VB	O	O
ovulation	NN	O	O
induction	NN	O	O
in	IN	O	O
clomiphene	NN	p	O
resistant	JJ	p	O
polycystic	JJ	p	PC
ovary	JJ	p	PC
syndrome	NN	p	PC
in	IN	O	O
clinical	JJ	O	O
practice	NN	O	O
.	.	O	O

AIMS	NNP	O	O
To	TO	O	O
determine	VB	O	O
whether	IN	O	O
metformin	NN	i	IPM
pretreatment	NN	i	IPM
has	VBZ	O	O
beneficial	JJ	o	O
effects	NNS	o	O
in	IN	O	O
clomiphene	NN	p	PC
resistant	JJ	p	PC
infertile	JJ	p	PC
women	NNS	p	PSE
with	IN	p	O
polycystic	JJ	p	PC
ovary	JJ	p	PC
syndrome	NN	p	PC
(	(	p	O
PCOS	NNP	p	PC
)	)	p	O
in	IN	p	O
an	DT	p	O
infertility	NN	p	O
clinic	NN	p	O
.	.	p	O

METHODS	NNP	O	O
This	DT	O	O
was	VBD	O	O
a	DT	O	O
randomized	JJ	O	O
placebo	NN	O	O
controlled	VBD	O	O
double-blind	NN	O	O
crossover	NN	O	O
study	NN	O	O
of	IN	O	O
3	CD	O	O
months	NNS	O	O
metformin	RB	i	IPM
(	(	O	O
1500	CD	O	O
mg	IN	O	O
day-1	NN	i	O
)	)	i	O
/placebo	NN	i	IC
,	,	O	O
followed	VBN	O	O
by	IN	O	O
3	CD	O	O
months	NNS	O	O
metformin/placebo	VBN	i	IPM
together	RB	i	O
with	IN	i	O
clomiphene	NN	i	IPM
(	(	O	O
50-100	JJ	O	O
mg	NN	O	O
for	IN	O	O
5	CD	O	O
days	NNS	O	O
)	)	O	O
for	IN	O	O
three	CD	O	O
cycles	NNS	O	O
in	IN	O	O
clomiphene	NN	p	PC
resistant	JJ	p	PC
women	NNS	p	PSE
with	IN	p	O
PCOS	NNP	p	PC
.	.	p	O

The	DT	O	O
primary	JJ	O	O
outcomes	NNS	O	O
were	VBD	O	O
restoration	NN	o	OPH
of	IN	o	OPH
spontaneous	JJ	o	OPH
menses	NNS	o	OPH
,	,	o	OPH
ovulation	NN	o	OPH
induction	NN	o	OPH
(	(	o	OPH
spontaneous	JJ	o	OPH
or	CC	o	OPH
clomiphene	NN	o	OPH
induced	VBN	o	OPH
)	)	o	OPH
and	CC	o	OPH
pregnancy	NN	o	OPH
.	.	o	OPH

Secondary	JJ	o	OPH
endpoints	NNS	o	OPH
were	VBD	O	O
changes	NNS	O	O
in	IN	O	O
biochemical	JJ	O	O
parameters	NNS	O	O
related	VBN	O	O
to	TO	O	O
androgens	NNS	O	O
and	CC	O	O
insulin	NN	O	O
.	.	O	O

RESULTS	NNP	O	O
Twelve	NNP	p	PSS
women	NNS	p	PSE
completed	VBD	p	O
the	DT	p	O
metformin	NN	i	IPM
arm	NN	p	O
and	CC	p	O
14	CD	p	PSS
the	DT	p	O
placebo	NN	i	IC
arm	NN	p	O
.	.	p	O

Spontaneous	JJ	o	OPH
menstruation	NN	o	OPH
resumed	VBD	O	O
in	IN	O	O
five	CD	O	O
metformin	NNS	i	IPM
treated	VBD	O	O
patients	NNS	O	O
and	CC	O	O
in	IN	O	O
six	CD	O	O
placebo	NN	i	IC
treated	VBN	O	O
women	NNS	O	O
,	,	O	O
P=0.63	NNP	O	O
.	.	O	O

No	NNP	O	O
women	NNS	O	O
given	VBN	O	O
metformin	NNS	O	O
spontaneously	RB	o	OPH
ovulated	VBD	o	OPH
,	,	O	O
although	IN	O	O
one	CD	O	O
patient	NN	O	O
given	VBN	O	O
placebo	NN	i	IC
did	VBD	O	O
,	,	O	O
P=0.30	NNP	O	O
.	.	O	O

There	EX	O	O
was	VBD	O	O
no	DT	O	O
difference	NN	O	O
in	IN	O	O
the	DT	O	O
efficacy	NN	o	OPH
of	IN	o	OPH
clomiphene	NN	o	OPH
between	IN	O	O
the	DT	O	O
two	CD	O	O
groups	NNS	O	O
with	IN	O	O
ovulation	NN	o	OPH
being	VBG	o	OPH
induced	VBN	o	OPH
in	IN	O	O
five	CD	O	O
(	(	O	O
out	IN	O	O
of	IN	O	O
12	CD	O	O
)	)	O	O
metformin	NN	i	IPM
treated	VBN	O	O
women	NNS	O	O
and	CC	O	O
four	CD	O	O
(	(	O	O
out	IN	O	O
of	IN	O	O
14	CD	O	O
)	)	O	O
placebo	NN	i	IC
treated	VBN	O	O
women	NNS	O	O
,	,	O	O
P=0.63	NNP	O	O
.	.	O	O

Pregnancy	NN	o	OPH
occurred	VBD	O	O
in	IN	O	O
three	CD	O	O
(	(	O	O
out	IN	O	O
of	IN	O	O
12	CD	O	O
)	)	O	O
women	NNS	O	O
given	VBN	O	O
metformin	NNS	i	IPM
and	CC	O	O
two	CD	O	O
(	(	O	O
out	IN	O	O
of	IN	O	O
14	CD	O	O
)	)	O	O
women	NNS	O	O
given	VBN	O	O
placebo	NNS	i	IC
,	,	O	O
P=0.59	NNP	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
Metformin	NNP	i	IPM
is	VBZ	O	O
not	RB	O	O
always	RB	O	O
beneficial	JJ	O	O
when	WRB	O	O
given	VBN	O	O
to	TO	O	O
clomiphene	VB	p	PC
resistant	JJ	p	PC
infertile	JJ	p	PC
women	NNS	p	PSE
with	IN	p	O
PCOS	NNP	p	PC
in	IN	O	O
clinical	JJ	O	O
practice	NN	O	O
.	.	O	O

Allopurinol	NNP	i	IPM
use	NN	O	O
yields	NNS	O	O
potentially	RB	O	O
beneficial	JJ	O	O
effects	NNS	O	O
on	IN	O	O
inflammatory	JJ	O	O
indices	NNS	O	O
in	IN	O	O
those	DT	p	O
with	IN	p	O
recent	JJ	p	O
ischemic	JJ	p	O
stroke	NN	p	O
:	:	p	O
a	DT	O	O
randomized	JJ	O	O
,	,	O	O
double-blind	JJ	O	O
,	,	O	O
placebo-controlled	JJ	O	O
trial	NN	O	O
.	.	O	O

BACKGROUND	NNP	O	O
AND	CC	O	O
PURPOSE	NNP	O	O
Elevated	NNP	O	O
serum	NN	O	O
uric	JJ	O	O
acid	NN	O	O
level	NN	O	O
is	VBZ	O	O
associated	VBN	O	O
with	IN	O	O
poor	JJ	O	O
outcome	NN	O	O
and	CC	O	O
increased	VBD	O	O
risk	NN	O	O
of	IN	O	O
recurrent	NN	O	O
events	NNS	O	O
after	IN	O	O
stroke	NN	O	O
.	.	O	O

The	DT	O	O
xanthine	JJ	O	O
oxidase	NN	O	O
inhibitor	NN	O	O
allopurinol	NN	i	IPM
lowers	NNS	O	O
uric	JJ	O	O
acid	NN	O	O
but	CC	O	O
also	RB	O	O
attenuates	VBZ	O	O
expression	NN	O	O
of	IN	O	O
inflammatory	JJ	O	O
adhesion	NN	O	O
molecules	NNS	O	O
in	IN	O	O
murine	NN	O	O
models	NNS	O	O
,	,	O	O
reduces	NNS	O	O
oxidative	VBP	O	O
stress	NN	O	O
in	IN	O	O
the	DT	O	O
vasculature	NN	O	O
,	,	O	O
and	CC	O	O
improves	VBZ	O	O
endothelial	JJ	O	O
function	NN	O	O
.	.	O	O

We	PRP	O	O
sought	VBD	O	O
to	TO	O	O
investigate	VB	O	O
whether	IN	O	O
allopurinol	JJ	i	IPM
alters	NNS	O	O
expression	NN	O	O
of	IN	O	O
inflammatory	NN	O	O
markers	NNS	O	O
after	IN	O	O
acute	JJ	O	O
ischemic	JJ	O	O
stroke	NN	O	O
.	.	O	O

METHODS	NNP	O	O
We	PRP	O	O
performed	VBD	O	O
a	DT	O	O
randomized	VBN	O	O
,	,	O	O
double-blind	JJ	O	O
,	,	O	O
placebo-controlled	JJ	O	O
trial	NN	O	O
to	TO	O	O
investigate	VB	O	O
the	DT	O	O
safety	NN	O	O
,	,	O	O
tolerability	NN	O	O
,	,	O	O
and	CC	O	O
effect	NN	O	O
of	IN	O	O
6	CD	i	IPM
weeks	NNS	i	IPM
'	POS	i	IPM
treatment	NN	i	IPM
with	IN	i	IPM
high-	NN	i	IPM
(	(	i	IPM
300	CD	i	IPM
mg	NN	i	IPM
once	RB	i	IPM
a	DT	i	IPM
day	NN	i	IPM
)	)	i	IPM
or	CC	i	IPM
low-	JJ	i	IPM
(	(	i	IPM
100	CD	i	IPM
mg	NN	i	IPM
once	RB	i	IPM
a	DT	i	IPM
day	NN	i	IPM
)	)	i	IPM
dose	NN	i	IPM
allopurinol	NN	i	IPM
on	IN	O	O
levels	NNS	O	O
of	IN	O	O
uric	JJ	O	O
acid	NN	O	O
and	CC	O	O
circulating	VBG	O	O
inflammatory	JJ	O	O
markers	NNS	O	O
after	IN	O	O
ischemic	JJ	O	O
stroke	NN	O	O
.	.	O	O

RESULTS	NNP	O	O
We	PRP	O	O
enrolled	VBD	O	O
50	CD	p	O
patients	NNS	p	O
with	IN	p	O
acute	JJ	p	O
ischemic	JJ	p	O
stroke	NN	p	O
(	(	p	O
17	CD	p	O
,	,	p	O
17	CD	p	O
,	,	p	O
and	CC	p	O
16	CD	p	O
in	IN	p	O
the	DT	p	O
high	JJ	p	O
,	,	p	O
low	JJ	p	O
,	,	p	O
and	CC	p	O
placebo	NN	i	IC
groups	NNS	p	O
,	,	p	O
respectively	RB	p	O
)	)	p	O
.	.	O	O

Mean	NNP	p	O
(	(	p	O
+/-SD	NNP	p	O
)	)	p	O
age	NN	p	O
was	VBD	p	O
70	CD	p	O
(	(	p	O
+/-13	JJ	p	O
)	)	p	O
years	NNS	p	O
.	.	p	O

Groups	NNP	O	O
had	VBD	O	O
similar	JJ	O	O
characteristics	NNS	O	O
at	IN	O	O
baseline	NN	O	O
.	.	O	O

There	EX	O	O
were	VBD	O	O
no	DT	O	O
serious	JJ	O	O
adverse	JJ	O	O
events	NNS	O	O
.	.	O	O

Uric	NNP	o	OPH
acid	NN	o	OPH
levels	NNS	o	OPH
were	VBD	O	O
significantly	RB	O	O
reduced	VBN	O	O
at	IN	O	O
both	DT	O	O
7	CD	O	O
days	NNS	O	O
and	CC	O	O
6	CD	O	O
weeks	NNS	O	O
in	IN	O	O
the	DT	O	O
high-dose	JJ	O	O
group	NN	O	O
(	(	O	O
by	IN	O	O
0.14	CD	O	O
mmol/L	NNS	O	O
at	IN	O	O
6	CD	O	O
weeks	NNS	O	O
,	,	O	O
P=0.002	NNP	O	O
)	)	O	O
.	.	O	O

Intercellular	JJ	o	OPH
adhesion	NN	o	OPH
molecule-1	JJ	o	OPH
concentration	NN	o	OPH
(	(	O	O
ng/mL	JJ	O	O
)	)	O	O
rose	VBD	O	O
by	IN	O	O
51.2	CD	O	O
in	IN	O	O
the	DT	O	O
placebo	NN	O	O
group	NN	O	O
,	,	O	O
rose	VBD	O	O
slightly	RB	O	O
(	(	O	O
by	IN	O	O
10.6	CD	O	O
)	)	O	O
in	IN	O	O
the	DT	O	O
low-dose	JJ	O	O
allopurinol	NN	i	IPM
group	NN	O	O
,	,	O	O
but	CC	O	O
fell	VBD	O	O
in	IN	O	O
the	DT	O	O
high-dose	JJ	O	O
group	NN	O	O
(	(	O	O
by	IN	O	O
2.6	CD	O	O
;	:	O	O
difference	NN	O	O
between	IN	O	O
groups	NNS	O	O
P=0.012	NNP	O	O
,	,	O	O
Kruskal-Wallis	NNP	O	O
test	NN	O	O
)	)	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
Allopurinol	NNP	i	IPM
treatment	NN	O	O
is	VBZ	O	O
well	RB	O	O
tolerated	VBN	O	O
and	CC	O	O
attenuates	VBZ	O	O
the	DT	O	O
rise	NN	O	O
in	IN	O	O
intercellular	JJ	O	O
adhesion	NN	O	O
molecule-1	NN	O	O
levels	NNS	O	O
seen	VBN	O	O
after	IN	O	O
stroke	NN	O	O
.	.	O	O

Uric	JJ	O	O
acid	NN	O	O
levels	NNS	O	O
were	VBD	O	O
lowered	VBN	O	O
with	IN	O	O
high	JJ	O	O
doses	NNS	O	O
.	.	O	O

These	DT	O	O
findings	NNS	O	O
support	NN	O	O
further	JJ	O	O
evaluation	NN	O	O
of	IN	O	O
allopurinol	NN	i	IPM
as	IN	O	O
a	DT	O	O
preventive	JJ	O	O
measure	NN	O	O
after	IN	O	O
stroke	NN	O	O
.	.	O	O

Screening	VBG	i	IPH
,	,	i	IPH
brief	JJ	i	IPH
intervention	NN	i	IPH
,	,	i	IPH
and	CC	i	IPH
referral	JJ	i	IPH
to	TO	i	IPH
treatment	NN	i	IPH
(	(	i	IPH
SBIRT	NNP	i	IPH
)	)	i	IPH
in	IN	O	O
a	DT	O	O
Polish	JJ	p	O
emergency	NN	p	O
department	NN	p	O
:	:	p	O
three-month	JJ	O	O
outcomes	NNS	O	O
of	IN	O	O
a	DT	O	O
randomized	VBN	O	O
,	,	O	O
controlled	VBD	O	O
clinical	JJ	O	O
trial	NN	O	O
.	.	O	O

OBJECTIVE	CC	O	O
A	DT	O	O
randomized	VBN	O	O
,	,	O	O
controlled	VBD	O	O
trial	NN	O	O
of	IN	O	O
screening	NN	i	IPH
,	,	i	IPH
brief	JJ	i	IPH
intervention	NN	i	IPH
,	,	i	IPH
and	CC	i	IPH
referral	JJ	i	IPH
to	TO	i	IPH
treatment	NN	i	IPH
(	(	i	IPH
SBIRT	NNP	i	IPH
)	)	i	IPH
for	IN	O	O
drinking	NN	p	O
and	CC	p	O
related	JJ	p	O
problems	NNS	p	O
among	IN	p	O
at-risk	JJ	p	O
and	CC	p	O
dependent	JJ	p	O
drinkers	NNS	p	O
was	VBD	O	O
conducted	VBN	O	O
in	IN	O	O
an	DT	O	O
emergency	NN	p	O
department	NN	p	O
(	(	p	O
ED	NNP	p	O
)	)	p	O
in	IN	p	O
Sosnowiec	NNP	p	O
,	,	p	O
Poland	NNP	p	O
,	,	p	O
among	IN	p	O
patients	NNS	p	O
ages	VBZ	p	O
18	CD	p	O
years	NNS	p	O
and	CC	p	O
older	JJR	p	O
.	.	p	O

METHOD	NNP	O	O
Data	NNP	p	O
were	VBD	p	O
collected	VBN	p	O
over	IN	p	O
a	DT	p	O
23-week	JJ	p	O
period	NN	p	O
,	,	p	O
from	IN	p	O
4:00	CD	p	O
PM	NNP	p	O
to	TO	p	O
midnight	VB	p	O
,	,	O	O
and	CC	O	O
resulted	VBD	O	O
in	IN	O	O
446	CD	p	O
patients	NNS	p	O
being	VBG	p	O
recruited	VBN	p	O
into	IN	p	O
the	DT	p	O
study	NN	p	O
(	(	p	O
90	CD	p	O
%	NN	p	O
of	IN	p	O
those	DT	p	O
who	WP	p	O
screened	VBD	p	O
positive	JJ	p	O
)	)	p	O
and	CC	O	O
randomized	VBN	O	O
to	TO	O	O
three	CD	O	O
conditions	NNS	O	O
following	VBG	O	O
a	DT	O	O
two-stage	JJ	O	O
process	NN	O	O
:	:	O	O
screened	VBN	i	IPH
only	RB	i	IPH
(	(	O	O
n	JJ	O	O
=	NNP	O	O
147	CD	O	O
)	)	O	O
,	,	O	O
assessed	VBN	i	IE
(	(	O	O
n	JJ	O	O
=	NNP	O	O
152	CD	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
received	VBN	i	IPH
intervention	NN	i	IPH
(	(	O	O
n	JJ	O	O
=	NNP	O	O
147	CD	O	O
)	)	O	O
.	.	O	O

Patients	NNS	O	O
in	IN	O	O
the	DT	O	O
assessment	NN	i	O
(	(	O	O
85	CD	O	O
%	NN	O	O
)	)	O	O
and	CC	O	O
intervention	NN	i	IPH
(	(	O	O
83	CD	O	O
%	NN	O	O
)	)	O	O
conditions	NNS	O	O
were	VBD	O	O
blindly	RB	O	O
reassessed	VBN	O	O
at	IN	O	O
3	CD	O	O
months	NNS	O	O
via	IN	O	O
a	DT	O	O
telephone	NN	O	O
interview	NN	O	O
.	.	O	O

RESULTS	NNP	O	O
At	IN	O	O
3-month	JJ	O	O
follow-up	NN	O	O
,	,	O	O
both	DT	O	O
groups	NNS	O	O
showed	VBD	O	O
significant	JJ	O	O
decreases	NNS	O	O
in	IN	O	O
the	DT	O	O
proportion	NN	O	O
who	WP	O	O
were	VBD	O	O
positive	JJ	O	O
for	IN	O	O
at-risk	JJ	O	O
drinking	NN	O	O
,	,	O	O
the	DT	O	O
primary	JJ	O	O
outcome	NN	O	O
variable	NN	O	O
.	.	O	O

Both	DT	O	O
groups	NNS	O	O
also	RB	O	O
showed	VBD	O	O
significant	JJ	O	O
decreases	NNS	O	O
in	IN	O	O
drinking	NN	o	OME
days	NNS	o	OME
per	IN	o	OME
week	NN	o	OME
,	,	o	O
drinks	NNS	o	OME
per	IN	o	OME
drinking	NN	o	OME
day	NN	o	OME
,	,	o	O
maximum	JJ	o	OME
drinks	NNS	o	OME
per	IN	o	OME
occasion	NN	o	OME
,	,	o	O
and	CC	o	O
negative	JJ	o	OME
consequences	NNS	o	OME
of	IN	o	OME
drinking	NN	o	OME
.	.	o	O

Using	VBG	O	O
analysis	NN	O	O
of	IN	O	O
covariance	NN	O	O
to	TO	O	O
control	VB	O	O
for	IN	O	O
baseline	NN	O	O
measures	NNS	O	O
and	CC	O	O
demographic	JJ	O	O
characteristics	NNS	O	O
,	,	O	O
no	DT	O	O
difference	NN	O	O
in	IN	O	O
outcome	JJ	O	O
measures	NNS	O	O
was	VBD	O	O
found	VBN	O	O
between	IN	O	O
intervention	NN	i	IOt
and	CC	O	O
assessment	JJ	i	IE
conditions	NNS	O	O
.	.	O	O

Subgroup	NNP	O	O
analysis	NN	O	O
found	VBD	O	O
some	DT	O	O
significant	JJ	O	O
interactions	NNS	O	O
between	IN	O	O
intervention	NN	i	IPH
and	CC	O	O
secondary	JJ	O	O
outcomes	NNS	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
Although	IN	O	O
the	DT	O	O
main	JJ	O	O
findings	NNS	O	O
were	VBD	O	O
similar	JJ	O	O
to	TO	O	O
those	DT	O	O
from	IN	O	O
other	JJ	O	O
brief-intervention	NN	O	O
studies	NNS	O	O
in	IN	O	O
Western	JJ	O	O
cultures	NNS	O	O
,	,	O	O
findings	NNS	O	O
here	RB	O	O
also	RB	O	O
suggest	VBP	O	O
that	IN	O	O
intervention	NN	O	O
may	MD	O	O
have	VB	O	O
differential	JJ	O	O
benefits	NNS	O	O
for	IN	O	O
specific	JJ	O	O
subgroups	NNS	O	O
of	IN	O	O
patients	NNS	O	O
in	IN	O	O
the	DT	O	O
ED	NNP	O	O
,	,	O	O
an	DT	O	O
area	NN	O	O
of	IN	O	O
research	NN	O	O
that	WDT	O	O
may	MD	O	O
warrant	VB	O	O
additional	JJ	O	O
study	NN	O	O
of	IN	O	O
brief	JJ	O	O
intervention	NN	O	O
in	IN	O	O
the	DT	O	O
ED	NNP	O	O
setting	NN	O	O
.	.	O	O

Randomized	VBN	O	O
,	,	O	O
double-blind	JJ	O	O
,	,	O	O
placebo-controlled	JJ	i	IC
trial	NN	O	O
of	IN	O	O
oral	JJ	O	O
sirolimus	NN	O	O
for	IN	O	O
restenosis	NN	o	OPH
prevention	NN	O	O
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
in-stent	JJ	p	PC
restenosis	NN	p	PC
:	:	p	O
the	DT	O	O
Oral	NNP	O	O
Sirolimus	NNP	i	IPM
to	TO	O	O
Inhibit	NNP	O	O
Recurrent	NNP	O	O
In-stent	JJ	O	O
Stenosis	NNP	O	O
(	(	O	O
OSIRIS	NNP	O	O
)	)	O	O
trial	NN	O	O
.	.	O	O

BACKGROUND	NNP	O	O
Despite	IN	O	O
recent	JJ	O	O
advances	NNS	O	O
in	IN	O	O
interventional	JJ	O	O
cardiology	NN	O	O
,	,	O	O
including	VBG	O	O
the	DT	O	O
introduction	NN	O	O
of	IN	O	O
drug-eluting	JJ	O	O
stents	NNS	O	O
for	IN	O	O
de	FW	O	O
novo	FW	O	O
coronary	JJ	O	O
lesions	NNS	O	O
,	,	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
in-stent	JJ	O	O
restenosis	NN	O	O
(	(	O	O
ISR	NNP	O	O
)	)	O	O
remains	VBZ	O	O
a	DT	O	O
challenging	JJ	O	O
clinical	JJ	O	O
issue	NN	O	O
.	.	O	O

Given	VBN	O	O
the	DT	O	O
efficacy	NN	O	O
of	IN	O	O
systemic	JJ	O	O
sirolimus	JJ	O	O
administration	NN	O	O
to	TO	O	O
prevent	VB	O	O
neointimal	JJ	o	OPH
hyperplasia	NN	o	OPH
in	IN	O	O
animal	JJ	O	O
models	NNS	O	O
and	CC	O	O
to	TO	O	O
halt	VB	O	O
and	CC	O	O
even	RB	O	O
reverse	VB	O	O
the	DT	O	O
progression	NN	O	O
of	IN	O	O
allograft	NN	O	O
vasculopathy	NN	O	O
,	,	O	O
the	DT	O	O
aim	NN	O	O
of	IN	O	O
the	DT	O	O
present	JJ	O	O
double-blind	NN	O	O
,	,	O	O
placebo-controlled	JJ	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
evaluate	VB	O	O
the	DT	O	O
efficacy	NN	O	O
of	IN	O	O
a	DT	O	O
10-day	JJ	O	O
oral	JJ	O	O
sirolimus	NN	O	O
treatment	NN	O	O
with	IN	O	O
2	CD	O	O
different	JJ	O	O
loading	VBG	O	O
regimens	NNS	O	O
for	IN	O	O
the	DT	O	O
prevention	NN	O	O
of	IN	O	O
recurrent	JJ	O	O
restenosis	NN	O	O
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
ISR	NNP	p	PC
.	.	p	O

METHODS	NNP	O	O
AND	CC	O	O
RESULTS	NNP	O	O
Three	NNP	p	PSS
hundred	VBD	p	PSS
symptomatic	JJ	p	PC
patients	NNS	p	O
with	IN	p	O
ISR	NNP	p	PC
were	VBD	O	O
randomly	RB	O	O
assigned	VBN	O	O
to	TO	O	O
1	CD	O	O
of	IN	O	O
3	CD	O	O
treatment	NN	O	O
arms	NNS	O	O
:	:	O	O
placebo	NN	i	IC
or	CC	i	O
usual-dose	JJ	i	O
or	CC	i	O
high-dose	JJ	i	O
sirolimus	NN	i	IPM
.	.	i	O

Patients	NNS	O	O
received	VBD	O	O
a	DT	O	O
cumulative	JJ	O	O
loading	NN	O	O
dose	NN	O	O
of	IN	O	O
0	CD	O	O
,	,	O	O
8	CD	O	O
,	,	O	O
or	CC	O	O
24	CD	O	O
mg	NN	O	O
of	IN	O	O
sirolimus	JJ	O	O
2	CD	O	O
days	NNS	O	O
before	IN	O	O
and	CC	O	O
the	DT	O	O
day	NN	O	O
of	IN	O	O
repeat	NN	O	O
intervention	NN	O	O
followed	VBN	O	O
by	IN	O	O
maintenance	NN	O	O
therapy	NN	O	O
of	IN	O	O
2	CD	O	O
mg/d	NN	O	O
for	IN	O	O
7	CD	O	O
days	NNS	O	O
.	.	O	O

Angiographic	JJ	o	OPH
restenosis	NN	o	OPH
at	IN	o	OPH
6-month	JJ	o	OPH
angiography	NN	o	OPH
was	VBD	O	O
the	DT	O	O
primary	JJ	O	O
end	NN	O	O
point	NN	O	O
of	IN	O	O
the	DT	O	O
study	NN	O	O
.	.	O	O

Restenosis	NNP	o	OPH
was	VBD	O	O
significantly	RB	O	O
reduced	VBN	O	O
from	IN	O	O
42.2	CD	O	O
%	NN	O	O
to	TO	O	O
38.6	CD	O	O
%	NN	O	O
and	CC	O	O
to	TO	O	O
22.1	CD	O	O
%	NN	O	O
in	IN	O	O
the	DT	O	O
placebo	NN	O	O
,	,	O	O
usual-dose	JJ	O	O
,	,	O	O
and	CC	O	O
high-dose	JJ	O	O
sirolimus	NN	O	O
groups	NNS	O	O
,	,	O	O
respectively	RB	O	O
(	(	O	O
P=0.005	NNP	O	O
)	)	O	O
.	.	O	O

Similarly	RB	O	O
,	,	O	O
the	DT	O	O
need	NN	o	OOt
for	IN	o	OOt
target	NN	o	OOt
vessel	JJ	o	OOt
revascularization	NN	o	OOt
was	VBD	O	O
reduced	VBN	O	O
from	IN	O	O
25.5	CD	O	O
%	NN	O	O
to	TO	O	O
24.2	CD	O	O
%	NN	O	O
and	CC	O	O
to	TO	O	O
15.2	CD	O	O
%	NN	O	O
in	IN	O	O
the	DT	O	O
placebo	NN	O	O
,	,	O	O
usual-dose	JJ	O	O
,	,	O	O
and	CC	O	O
high-dose	JJ	O	O
groups	NNS	O	O
,	,	O	O
respectively	RB	O	O
(	(	O	O
P=0.08	NNP	O	O
)	)	O	O
.	.	O	O

The	DT	o	OPH
sirolimus	JJ	o	OPH
blood	NN	o	OPH
concentration	NN	o	OPH
on	IN	O	O
the	DT	O	O
day	NN	O	O
of	IN	O	O
the	DT	O	O
procedure	NN	O	O
correlated	VBD	O	O
significantly	RB	O	O
with	IN	O	O
the	DT	O	O
late	JJ	O	O
lumen	NNS	O	O
loss	NN	O	O
at	IN	O	O
follow-up	JJ	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.001	CD	O	O
)	)	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
In	IN	O	O
patients	NNS	O	O
with	IN	O	O
ISR	NNP	O	O
,	,	O	O
an	DT	O	O
oral	JJ	O	O
adjunctive	JJ	O	O
sirolimus	NN	O	O
treatment	NN	O	O
with	IN	O	O
an	DT	O	O
intensified	JJ	O	O
loading	NN	O	O
regimen	NNS	O	O
before	IN	O	O
coronary	JJ	O	O
intervention	NN	O	O
resulted	VBD	O	O
in	IN	O	O
a	DT	O	O
significant	JJ	O	O
improvement	NN	O	O
in	IN	O	O
the	DT	O	O
angiographic	JJ	o	OPH
parameters	NNS	o	OPH
of	IN	o	OPH
restenosis	NN	o	OPH
.	.	o	OPH

Effect	NN	O	O
of	IN	O	O
pravastatin	NN	i	IPM
on	IN	O	O
cardiovascular	JJ	o	OPH
events	NNS	o	OPH
in	IN	O	O
women	NNS	p	PC
after	IN	p	PC
myocardial	JJ	p	PC
infarction	NN	p	PC
:	:	p	PC
the	DT	O	O
cholesterol	NN	O	O
and	CC	O	O
recurrent	JJ	O	O
events	NNS	O	O
(	(	O	O
CARE	NNP	O	O
)	)	O	O
trial	NN	O	O
.	.	O	O

OBJECTIVES	IN	O	O
We	PRP	O	O
sought	VBD	O	O
to	TO	O	O
determine	VB	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
pravastatin	NN	i	IPM
on	IN	O	O
recurrent	NN	o	OPH
cardiovascular	JJ	o	OPH
events	NNS	o	OPH
in	IN	O	O
women	NNS	p	O
with	IN	p	O
average	JJ	p	O
cholesterol	NN	p	O
levels	NNS	p	O
after	IN	p	O
myocardial	JJ	p	O
infarction	NN	p	O
(	(	p	O
MI	NNP	p	O
)	)	p	O
.	.	p	O

BACKGROUND	NNP	O	O
Little	JJ	O	O
information	NN	O	O
is	VBZ	O	O
available	JJ	O	O
on	IN	O	O
the	DT	O	O
effectiveness	NN	O	O
of	IN	O	O
lipid	JJ	O	O
lowering	VBG	O	O
in	IN	O	O
secondary	JJ	O	O
prevention	NN	O	O
of	IN	O	O
coronary	JJ	p	O
heart	NN	p	O
disease	NN	p	O
(	(	p	O
CHD	NNP	p	O
)	)	p	O
in	IN	p	O
women	NNS	p	O
;	:	p	O
in	IN	p	O
particular	JJ	p	O
,	,	p	O
those	DT	p	O
with	IN	p	O
CHD	NNP	p	O
and	CC	p	O
average	JJ	p	O
cholesterol	NN	p	O
levels	NNS	p	O
.	.	p	O

METHODS	NNP	O	O
In	IN	O	O
the	DT	O	O
Cholesterol	NNP	O	O
and	CC	O	O
Recurrent	NNP	O	O
Events	NNP	O	O
(	(	O	O
CARE	NNP	O	O
)	)	O	O
trial	NN	O	O
,	,	O	O
576	CD	p	O
postmenopausal	NN	p	O
women	NNS	p	O
,	,	p	O
between	IN	p	O
3	CD	p	O
and	CC	p	O
20	CD	p	O
months	NNS	p	O
after	IN	p	O
MI	NNP	p	O
,	,	p	O
with	IN	p	O
a	DT	p	O
total	JJ	p	O
cholesterol	NN	p	O
level	NN	p	O
<	VBD	p	O
240	CD	p	O
mg/dl	NN	p	O
and	CC	p	O
a	DT	p	O
low	JJ	p	O
density	NN	p	O
lipoprotein	NN	p	O
cholesterol	NN	p	O
level	NN	p	O
115	CD	p	O
to	TO	p	O
174	CD	p	O
mg/dl	NNS	p	O
,	,	O	O
were	VBD	O	O
randomized	VBN	O	O
to	TO	O	O
receive	VB	O	O
pravastatin	NN	i	IPM
40	CD	i	IPM
mg/day	NN	i	IPM
or	CC	O	O
matching	VBG	O	O
placebo	NN	i	IC
for	IN	O	O
a	DT	O	O
median	JJ	O	O
follow-up	JJ	O	O
period	NN	O	O
of	IN	O	O
5	CD	O	O
years	NNS	O	O
.	.	O	O

The	DT	O	O
main	JJ	O	O
outcome	NN	O	O
measures	NNS	O	O
were	VBD	O	O
combined	VBN	o	OPH
coronary	JJ	o	OPH
events	NNS	o	OPH
(	(	o	OPH
coronary	JJ	o	OPH
death	NN	o	OPH
,	,	o	OPH
nonfatal	JJ	o	OPH
MI	NNP	o	OPH
,	,	o	OPH
percutaneous	JJ	o	OPH
transluminal	JJ	o	OPH
coronary	NN	o	OPH
angioplasty	NN	o	OPH
[	NNP	o	OPH
PTCA	NNP	o	OPH
]	NNP	o	OPH
or	CC	o	OPH
coronary	JJ	o	OPH
artery	NN	o	OPH
bypass	NN	o	OPH
graft	NN	o	OPH
surgery	NN	o	OPH
[	NNP	o	OPH
CABG	NNP	o	OPH
]	NNP	o	OPH
)	)	o	OPH
,	,	o	OPH
the	DT	o	OPH
primary	JJ	o	OPH
trial	NN	o	OPH
end	NN	o	OPH
point	NN	o	OPH
(	(	o	OPH
coronary	JJ	o	OPH
death	NN	o	OPH
or	CC	o	OPH
nonfatal	JJ	o	OPH
MI	NNP	o	OPH
)	)	o	OPH
and	CC	o	OPH
stroke	NN	o	OPH
.	.	o	OOt

RESULTS	NNP	O	O
Women	NNP	O	O
treated	VBD	O	O
with	IN	O	O
pravastatin	NN	O	O
had	VBD	O	O
a	DT	O	O
risk	NN	o	OPH
reduction	NN	o	OPH
of	IN	O	O
43	CD	O	O
%	NN	O	O
for	IN	O	O
the	DT	O	O
primary	JJ	O	O
end	NN	O	O
point	NN	O	O
(	(	O	O
p	JJ	O	O
=	NNP	O	O
0.035	CD	O	O
)	)	O	O
,	,	O	O
46	CD	O	O
%	NN	O	O
for	IN	O	O
combined	JJ	O	O
coronary	JJ	O	O
events	NNS	O	O
(	(	O	O
p	JJ	O	O
=	NNP	O	O
0.001	CD	O	O
)	)	O	O
,	,	O	O
48	CD	O	O
%	NN	O	O
for	IN	O	O
PTCA	NNP	O	O
(	(	O	O
p	JJ	O	O
=	NNP	O	O
0.025	CD	O	O
)	)	O	O
,	,	O	O
40	CD	O	O
%	NN	O	O
for	IN	O	O
CABG	NNP	O	O
(	(	O	O
p	JJ	O	O
=	NNP	O	O
0.14	CD	O	O
)	)	O	O
and	CC	O	O
56	CD	O	O
%	NN	O	O
for	IN	O	O
stroke	NN	O	O
(	(	O	O
p	JJ	O	O
=	NNP	O	O
0.07	CD	O	O
)	)	O	O
.	.	O	O

The	DT	p	O
3,583	CD	p	O
men	NNS	p	O
in	IN	p	O
the	DT	p	O
CARE	NNP	p	O
trial	NN	p	O
also	RB	O	O
showed	VBD	O	O
a	DT	O	O
reduction	NN	O	O
in	IN	O	O
risk	NN	o	OPH
,	,	O	O
but	CC	O	O
the	DT	O	O
magnitude	NN	O	O
tended	VBD	O	O
to	TO	O	O
be	VB	O	O
less	JJR	O	O
.	.	O	O

Pravastatin	NNP	i	IPM
improved	VBD	O	O
plasma	JJ	o	OPH
lipids	NNS	o	OPH
similarly	RB	O	O
in	IN	O	O
men	NNS	p	O
and	CC	p	O
women	NNS	p	O
.	.	p	O

There	EX	O	O
were	VBD	O	O
no	DT	O	O
differences	NNS	O	O
in	IN	O	O
risk	NN	o	OPH
of	IN	o	OPH
coronary	JJ	o	OPH
events	NNS	o	OPH
in	IN	O	O
the	DT	O	O
placebo	NN	O	O
group	NN	O	O
between	IN	O	O
men	NNS	O	O
and	CC	O	O
women	NNS	O	O
.	.	O	O

Minor	JJ	O	O
differences	NNS	O	O
between	IN	O	O
men	NNS	O	O
and	CC	O	O
women	NNS	O	O
were	VBD	O	O
present	JJ	O	O
in	IN	O	O
baseline	NN	O	O
characteristics	NNS	O	O
and	CC	O	O
treatment	NN	O	O
for	IN	O	O
MI	NNP	O	O
,	,	O	O
in	IN	O	O
general	JJ	O	O
,	,	O	O
conferring	VBG	O	O
a	DT	O	O
higher	JJR	O	O
risk	NN	O	O
status	NN	O	O
and	CC	O	O
a	DT	O	O
lower	JJR	O	O
incidence	NN	O	O
of	IN	O	O
CABG	NNP	o	O
in	IN	O	O
the	DT	O	O
women	NNS	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
Pravastatin	NNP	i	IPM
led	VBD	O	O
to	TO	O	O
significant	JJ	O	O
early	JJ	O	O
reduction	NN	O	O
of	IN	O	O
a	DT	O	O
wide	JJ	O	O
range	NN	O	O
of	IN	O	O
cardiovascular	JJ	o	O
events	NNS	o	O
in	IN	O	O
post-MI	JJ	p	O
women	NNS	p	O
with	IN	p	O
average	JJ	p	O
cholesterol	NN	p	O
levels	NNS	p	O
.	.	p	O

Randomized	VBN	O	O
trial	NN	O	O
of	IN	O	O
fenretinide	NN	i	IPM
in	IN	O	O
superficial	JJ	p	O
bladder	NN	p	O
cancer	NN	p	O
using	VBG	O	O
DNA	NNP	O	O
flow	JJ	O	O
cytometry	NN	O	O
as	IN	O	O
an	DT	O	O
intermediate	JJ	O	O
end	NN	O	O
point	NN	O	O
.	.	O	O

Retinoids	NNS	O	O
have	VBP	O	O
shown	VBN	O	O
a	DT	O	O
potential	JJ	O	O
activity	NN	O	O
in	IN	O	O
preventing	VBG	O	O
tumor	NN	O	O
recurrence	NN	O	O
in	IN	O	O
superficial	JJ	p	O
bladder	NN	p	O
cancer	NN	p	O
.	.	p	O

We	PRP	O	O
assessed	VBD	O	O
the	DT	O	O
activity	NN	O	O
of	IN	O	O
the	DT	O	O
synthetic	JJ	i	IPM
retinoid	NN	i	IPM
fenretinide	NN	i	IPM
in	IN	O	O
superficial	JJ	O	O
bladder	NN	O	O
cancer	NN	O	O
using	VBG	O	O
DNA	NNP	O	O
flow	JJ	O	O
cytometry	NN	O	O
and	CC	O	O
conventional	JJ	O	O
cytology	NN	O	O
as	IN	O	O
surrogate	JJ	O	O
biomarkers	NNS	O	O
.	.	O	O

A	DT	O	O
total	NN	p	O
of	IN	p	O
99	CD	p	O
subjects	NNS	p	O
with	IN	p	O
resected	JJ	p	O
superficial	JJ	p	O
bladder	NN	p	O
cancer	NN	p	O
(	(	p	O
pTa	NN	p	O
,	,	p	O
pT1	NN	p	O
)	)	p	O
were	VBD	O	O
randomized	VBN	O	O
to	TO	O	O
either	DT	O	O
fenretinide	NN	i	IPM
(	(	i	O
200	CD	i	O
mg	NNS	i	O
day	NN	i	O
p.o	NN	i	O
.	.	i	O

for	IN	i	O
24	CD	i	O
months	NNS	i	O
)	)	i	O
or	CC	i	O
no	DT	i	IC
intervention	NN	i	IC
.	.	i	O

Cystoscopy	NNP	O	O
and	CC	O	O
bladder	NN	O	O
washing	NN	O	O
for	IN	O	O
DNA	NNP	O	O
flow	NN	O	O
cytometry	NN	O	O
end	NN	O	O
points	NNS	O	O
(	(	O	O
proportion	NN	O	O
of	IN	O	O
DNA	NNP	O	O
aneuploid	JJ	O	O
histograms	NN	O	O
,	,	O	O
hyperdiploid	JJ	O	O
fraction	NN	O	O
,	,	O	O
and	CC	O	O
percentage	NN	O	O
of	IN	O	O
apoptotic	JJ	O	O
cells	NNS	O	O
)	)	O	O
and	CC	O	O
proportion	NN	O	O
of	IN	O	O
abnormal	JJ	o	OPH
cytological	JJ	o	OPH
examinations	NNS	o	OPH
were	VBD	O	O
repeated	VBN	O	O
every	DT	O	O
4	CD	O	O
months	NNS	O	O
for	IN	O	O
up	IN	O	O
to	TO	O	O
36	CD	O	O
months	NNS	O	O
.	.	O	O

The	DT	O	O
primary	JJ	O	O
study	NN	O	O
end	NN	O	O
point	NN	O	O
was	VBD	O	O
the	DT	O	O
proportion	NN	o	OPH
of	IN	o	OPH
DNA	NNP	o	OPH
aneuploid	JJ	o	OPH
histograms	NNS	o	OPH
after	IN	O	O
12	CD	O	O
months	NNS	O	O
.	.	O	O

This	DT	O	O
figure	NN	O	O
was	VBD	O	O
48.9	CD	O	O
%	NN	O	O
in	IN	O	O
the	DT	O	O
fenretinide	JJ	i	IPM
arm	NN	O	O
and	CC	O	O
41.9	CD	O	O
%	NN	O	O
in	IN	O	O
the	DT	O	O
control	NN	O	O
arm	NN	O	O
(	(	O	O
odds	NNS	O	O
ratio	NN	O	O
,	,	O	O
1.16	CD	O	O
;	:	O	O
95	CD	O	O
%	NN	O	O
confidence	NN	O	O
interval	NN	O	O
,	,	O	O
0.44-3.07	JJ	O	O
)	)	O	O
.	.	O	O

There	EX	O	O
was	VBD	O	O
no	DT	O	O
difference	NN	O	O
in	IN	O	O
any	DT	O	O
other	JJ	O	O
response	NN	o	OPH
biomarker	NN	o	OPH
between	IN	O	O
the	DT	O	O
two	CD	O	O
groups	NNS	O	O
up	RB	O	O
to	TO	O	O
36	CD	O	O
months	NNS	O	O
,	,	O	O
nor	CC	O	O
was	VBD	O	O
any	DT	O	O
biomarker	NN	O	O
able	JJ	O	O
to	TO	O	O
predict	VB	O	O
recurrence	NN	O	O
risk	NN	O	O
.	.	O	O

Recurrence-free	JJ	o	OMO
survival	NN	o	OMO
was	VBD	O	O
comparable	JJ	O	O
between	IN	O	O
the	DT	O	O
arms	NNS	O	O
(	(	O	O
27	CD	O	O
events	NNS	O	O
in	IN	O	O
the	DT	O	O
fenretinide	JJ	O	O
arm	NN	O	O
versus	NN	O	O
21	CD	O	O
in	IN	O	O
the	DT	O	O
control	NN	O	O
arm	NN	O	O
;	:	O	O
P	NNP	O	O
=	NNP	O	O
0.36	CD	O	O
)	)	O	O
.	.	O	O

Twelve	NNP	O	O
subjects	VBZ	O	O
in	IN	O	O
the	DT	O	O
fenretinide	JJ	O	O
arm	NN	O	O
complained	VBD	O	O
of	IN	O	O
diminished	JJ	O	O
dark	NN	o	OA
adaptability	NN	o	OA
,	,	O	O
and	CC	O	O
nine	CD	O	O
subjects	NNS	O	O
in	IN	O	O
the	DT	O	O
fenretinide	JJ	O	O
arm	NN	O	O
versus	IN	O	O
one	CD	O	O
control	NN	O	O
subject	NN	O	O
had	VBD	O	O
mild	JJ	o	OPH
dermatological	JJ	o	OPH
alterations	NNS	o	OPH
.	.	o	O

We	PRP	O	O
conclude	VBP	O	O
that	DT	O	O
fenretinide	NN	O	O
showed	VBD	O	O
a	DT	O	O
lack	NN	O	O
of	IN	O	O
effect	NN	O	O
on	IN	O	O
the	DT	O	O
DNA	NNP	O	O
content	NN	o	OPH
distribution	NN	o	OPH
and	CC	O	O
the	DT	O	O
morphology	NN	o	OPH
of	IN	o	OPH
urothelial	JJ	o	OPH
cells	NNS	o	OPH
obtained	VBN	O	O
in	IN	O	O
serial	JJ	O	O
bladder	NN	O	O
washings	NNS	O	O
.	.	O	O

Recurrence-free	JJ	o	OMO
survival	NN	o	OMO
was	VBD	O	O
comparable	JJ	O	O
between	IN	O	O
groups	NNS	O	O
.	.	O	O

Because	IN	O	O
our	PRP$	O	O
data	NNS	O	O
are	VBP	O	O
hampered	VBN	O	O
by	IN	O	O
the	DT	O	O
lack	NN	O	O
of	IN	O	O
predictivity	NN	O	O
of	IN	O	O
the	DT	O	O
selected	VBN	O	O
biomarkers	NNS	O	O
,	,	O	O
additional	JJ	O	O
studies	NNS	O	O
are	VBP	O	O
necessary	JJ	O	O
to	TO	O	O
assess	VB	O	O
the	DT	O	O
activity	NN	O	O
of	IN	O	O
fenretinide	NN	O	O
in	IN	O	O
preventing	VBG	O	O
bladder	NN	p	O
cancer	NN	p	O
.	.	p	O

Penetration	NN	o	OME
and	CC	o	OME
accumulation	NN	o	OME
of	IN	O	O
moxifloxacin	NN	i	IPM
in	IN	O	O
uterine	JJ	O	O
tissue	NN	O	O
.	.	O	O

OBJECTIVE	NN	O	O
To	TO	O	O
determine	VB	O	O
whether	IN	O	O
moxifloxacin	NN	i	IPM
penetrates	VBZ	O	O
the	DT	O	O
uterine	JJ	O	O
tissue	NN	O	O
and	CC	O	O
accumulates	NNS	O	O
at	IN	O	O
levels	NNS	O	O
sufficient	JJ	O	O
to	TO	O	O
eradicate	VB	o	OPH
the	DT	o	OPH
major	JJ	o	OPH
pathogens	NNS	o	OPH
causing	VBG	O	O
pelvic	JJ	p	PC
inflammatory	JJ	p	PC
disease	NN	p	PC
(	(	p	O
PID	NNP	p	PC
)	)	p	O
.	.	p	O

METHOD	NNP	O	O
In	IN	O	O
a	DT	O	O
prospective	JJ	O	O
,	,	O	O
multicenter	NN	O	O
,	,	O	O
open-label	JJ	O	O
,	,	O	O
parallel-group	JJ	O	O
study	NN	O	O
we	PRP	O	O
determined	VBD	O	O
the	DT	O	O
concentration	NN	O	O
of	IN	O	O
moxifloxacin	NN	O	O
in	IN	O	O
plasma	NN	O	O
and	CC	O	O
uterine	JJ	O	O
tissue	NN	O	O
after	IN	O	O
a	DT	O	O
single	JJ	O	O
,	,	O	O
400-mg	JJ	i	IPM
intravenous	JJ	i	IPM
dose	NN	i	IPM
of	IN	i	IPM
moxifloxacin	NN	i	IPM
.	.	i	O

Study	NN	O	O
participants	NNS	O	O
were	VBD	O	O
randomized	VBN	O	O
for	IN	O	O
time	NN	O	O
of	IN	O	O
tissue	NN	O	O
sampling	NN	O	O
,	,	O	O
which	WDT	O	O
was	VBD	O	O
performed	VBN	O	O
1	CD	O	O
,	,	O	O
2	CD	O	O
,	,	O	O
4	CD	O	O
,	,	O	O
7	CD	O	O
,	,	O	O
or	CC	O	O
24	CD	O	O
hours	NNS	O	O
following	VBG	O	O
the	DT	O	O
moxifloxacin	JJ	i	IPM
infusion	NN	O	O
.	.	O	O

RESULTS	NNP	O	O
Of	IN	O	O
43	CD	p	PSS
participants	NNS	p	O
,	,	p	O
40	CD	p	PSS
were	VBD	p	O
randomized	VBN	p	O
to	TO	p	O
tissue	VB	p	O
sampling	VBG	p	O
.	.	p	O

Moxifloxacin	NNP	o	OPH
accumulated	VBD	o	OPH
in	IN	o	OPH
uterine	JJ	o	OPH
tissue	NN	o	OPH
and	CC	o	OPH
concentrations	NNS	o	OPH
were	VBD	O	O
highest	JJS	O	O
1	CD	O	O
hour	NN	O	O
after	IN	O	O
infusion	NN	O	O
in	IN	O	O
both	DT	O	O
plasma	NN	O	O
and	CC	O	O
tissue	NN	O	O
.	.	O	O

Tissue	NN	o	OPH
to	TO	o	OPH
plasma	VB	o	OPH
ratios	NNS	o	OPH
remained	VBD	O	O
between	IN	O	O
1.7	CD	O	O
and	CC	O	O
2.1	CD	O	O
for	IN	O	O
24	CD	O	O
hours	NNS	O	O
.	.	O	O

Moxifloxacin	NNP	O	O
was	VBD	O	O
found	VBN	O	O
to	TO	O	O
be	VB	O	O
safe	JJ	o	OOt
and	CC	o	OOt
well	RB	o	OOt
tolerated	VBN	o	OOt
.	.	o	O

CONCLUSION	NNP	O	O
Based	VBD	O	O
on	IN	O	O
known	VBN	O	O
minimum	JJ	O	O
inhibitory	JJ	O	O
concentration	NN	O	O
data	NNS	O	O
,	,	O	O
the	DT	O	O
uterine	JJ	o	OPH
tissue	NN	o	OPH
concentrations	NNS	o	OPH
of	IN	O	O
moxifloxacin	NN	O	O
achieved	VBN	O	O
over	IN	O	O
24	CD	O	O
hours	NNS	O	O
would	MD	O	O
be	VB	O	O
sufficient	JJ	O	O
to	TO	O	O
eradicate	VB	O	O
the	DT	O	O
range	NN	O	O
of	IN	O	O
bacterial	JJ	O	O
pathogens	NNS	O	O
responsible	JJ	O	O
for	IN	O	O
PID	NNP	p	O
.	.	p	O

Transitions	NNS	O	O
during	IN	O	O
effective	JJ	O	O
treatment	NN	O	O
for	IN	O	O
cocaine-abusing	JJ	p	PC
homeless	JJ	p	O
persons	NNS	p	O
:	:	p	O
establishing	VBG	O	O
abstinence	NN	O	O
,	,	O	O
lapse	NN	O	O
,	,	O	O
and	CC	O	O
relapse	NN	O	O
,	,	O	O
and	CC	O	O
reestablishing	VBG	O	O
abstinence	NN	O	O
.	.	O	O

Data	NNS	O	O
are	VBP	O	O
reported	VBN	O	O
on	IN	O	O
drug	NN	O	O
use	NN	O	O
among	IN	O	O
cocaine-dependent	JJ	p	PC
homeless	NN	p	O
persons	NNS	p	O
who	WP	p	O
participated	VBD	p	O
in	IN	p	O
a	DT	p	O
clinical	JJ	p	O
trial	NN	p	O
that	WDT	p	O
compared	VBN	p	O
day	NN	i	IC
treatment	NN	i	IC
only	RB	i	IC
(	(	p	O
DT	NNP	p	O
,	,	p	O
n	JJ	p	O
=	NNP	p	O
69	CD	p	PSS
)	)	p	O
with	IN	p	O
day	NN	i	IC
treatment	NN	i	IC
plus	CC	i	O
abstinent-contingent	JJ	i	IC
housing	NN	i	IC
and	CC	i	IC
work	NN	i	IC
(	(	p	O
DT+	NNP	p	O
,	,	p	O
n	JJ	p	O
=	NNP	p	O
72	CD	p	PSS
)	)	p	PSS
.	.	p	O

Drug	NNP	o	OPH
use	NN	o	OPH
was	VBD	o	OPH
measured	VBN	o	OPH
with	IN	o	OPH
multiple	JJ	o	OPH
weekly	JJ	o	OPH
urine	NN	o	OPH
toxicologies	NNS	o	OPH
.	.	o	OPH

Compared	VBN	O	O
with	IN	O	O
DT	NNP	O	O
participants	NNS	O	O
,	,	O	O
more	JJR	O	O
DT+	JJ	O	O
participants	NNS	O	O
established	VBN	O	O
abstinence	NN	o	OME
,	,	o	OME
maintained	VBD	o	OME
abstinence	NN	o	OME
for	IN	o	OME
longer	JJR	o	OME
durations	NNS	o	OME
,	,	O	O
were	VBD	O	O
marginally	RB	O	O
significantly	RB	O	O
more	RBR	O	O
likely	JJ	O	O
to	TO	O	O
lapse	VB	o	OME
,	,	O	O
and	CC	O	O
significantly	RB	O	O
less	RBR	O	O
likely	JJ	O	O
to	TO	O	O
relapse	VB	o	OME
.	.	o	O

Of	IN	O	O
all	DT	O	O
participants	NNS	O	O
who	WP	O	O
established	VBD	O	O
abstinence	NN	O	O
and	CC	O	O
then	RB	O	O
relapsed	VBD	O	O
,	,	O	O
DT+	NNP	O	O
participants	NNS	O	O
relapsed	VBD	O	O
later	RB	O	O
and	CC	O	O
were	VBD	O	O
more	RBR	O	O
likely	JJ	O	O
to	TO	O	O
reestablish	VB	o	OME
abstinence	NN	o	OME
.	.	o	OOt

These	DT	O	O
analyses	NNS	O	O
yield	VBP	O	O
information	NN	O	O
on	IN	O	O
the	DT	O	O
processes	NNS	O	O
involved	VBN	O	O
in	IN	O	O
the	DT	O	O
manner	NN	O	O
in	IN	O	O
which	WDT	O	O
drug	NN	O	O
use	NN	O	O
changes	NNS	O	O
as	IN	O	O
a	DT	O	O
result	NN	O	O
of	IN	O	O
abstinent-contingent	JJ	i	IE
housing	NN	i	IE
and	CC	i	IE
work	NN	i	IE
.	.	i	O

Olanzapine	NNP	i	IPM
versus	NN	i	O
haloperidol	NN	i	IPM
in	IN	O	O
children	NNS	p	PA
with	IN	p	O
autistic	JJ	o	OPH
disorder	NN	o	OPH
:	:	o	O
an	DT	O	O
open	JJ	O	O
pilot	NN	O	O
study	NN	O	O
.	.	O	O

OBJECTIVES	NNP	O	O
Conventional	NNP	O	O
neuroleptics	NNS	i	IPM
ameliorate	VBP	O	O
symptoms	NNS	O	O
in	IN	O	O
children	NNS	p	PA
with	IN	p	O
autistic	JJ	p	PC
disorder	NN	p	PC
;	:	p	O
however	RB	O	O
,	,	O	O
they	PRP	O	O
are	VBP	O	O
known	VBN	O	O
to	TO	O	O
cause	VB	O	O
dyskinesias	NN	O	O
.	.	O	O

Atypical	JJ	i	IPM
neuroleptics	NNS	i	IPM
,	,	O	O
including	VBG	O	O
olanzapine	NN	O	O
,	,	O	O
may	MD	O	O
have	VB	O	O
less	JJR	O	O
risk	NN	O	O
for	IN	O	O
dyskinesia	NN	O	O
,	,	O	O
but	CC	O	O
their	PRP$	O	O
efficacy	NN	O	O
in	IN	O	O
autistic	JJ	O	O
disorder	NN	O	O
is	VBZ	O	O
not	RB	O	O
established	VBN	O	O
.	.	O	O

This	DT	O	O
study	NN	O	O
was	VBD	O	O
designed	VBN	O	O
to	TO	O	O
investigate	VB	O	O
the	DT	O	O
safety	NN	O	O
and	CC	O	O
effectiveness	NN	O	O
of	IN	O	O
open-label	JJ	O	O
olanzapine	NN	i	IPM
as	IN	O	O
a	DT	O	O
treatment	NN	O	O
for	IN	O	O
children	NNS	p	PA
with	IN	p	O
autistic	JJ	p	PC
disorder	NN	p	PC
by	IN	O	O
using	VBG	O	O
haloperidol	NN	i	IPM
as	IN	O	O
a	DT	O	O
standard	JJ	O	O
comparator	NN	O	O
treatment	NN	O	O
.	.	O	O

METHOD	NNP	O	O
In	IN	O	O
a	DT	O	O
parallel	JJ	p	O
groups	NNS	p	O
design	NN	p	O
,	,	p	O
12	CD	p	PSS
children	NNS	p	PA
with	IN	p	O
DSM-IV	NNP	p	PC
autistic	JJ	p	PC
disorder	NN	p	PC
(	(	p	O
mean	JJ	p	O
age	NN	p	O
7.8+/-2.1	CD	p	PA
years	NNS	p	O
)	)	p	O
were	VBD	p	O
randomized	VBN	p	O
to	TO	O	O
6	CD	O	O
weeks	NNS	O	O
of	IN	O	O
open	JJ	i	IPM
treatment	NN	i	IPM
with	IN	i	IPM
olanzapine	NN	i	IPM
or	CC	i	O
haloperidol	NN	i	IPM
.	.	i	O

Mean	NNP	O	O
final	JJ	O	O
dosages	NNS	O	O
were	VBD	O	O
7.9+/-2.5	JJ	O	O
mg/day	NN	O	O
for	IN	O	O
olanzapine	NN	i	IPM
and	CC	O	O
1.4+/-0.7	JJ	O	O
mg/day	NN	O	O
for	IN	O	O
haloperidol	NN	i	IPM
.	.	i	O

Outcome	NNP	O	O
measures	NNS	O	O
included	VBD	O	O
the	DT	O	O
Clinical	NNP	o	OME
Global	NNP	o	OME
Impressions	NNP	o	OME
(	(	o	OME
CGI	NNP	o	OME
)	)	o	OME
and	CC	o	O
the	DT	o	OME
Children	NNP	o	OME
's	POS	o	OME
Psychiatric	NNP	o	OME
Rating	NNP	o	OME
Scale	NNP	o	OME
(	(	o	OME
CPRS	NNP	o	OME
)	)	o	OME
.	.	o	O

RESULTS	NNP	O	O
Both	NNP	O	O
groups	NNS	O	O
had	VBD	O	O
symptom	VBN	o	OME
reduction	NN	o	OME
.	.	o	O

Five	CD	O	O
of	IN	O	O
six	CD	O	O
in	IN	O	O
the	DT	O	O
olanzapine	NN	i	IPM
group	NN	O	O
and	CC	O	O
three	CD	O	O
of	IN	O	O
six	CD	O	O
in	IN	O	O
the	DT	O	O
haloperidol	NN	i	IPM
group	NN	O	O
were	VBD	O	O
rated	VBN	O	O
as	IN	O	O
responders	NNS	O	O
according	VBG	O	O
to	TO	O	O
the	DT	O	O
CGI	NNP	o	OME
Improvement	NNP	O	O
item	NN	O	O
.	.	O	O

Subjects	NNS	O	O
showed	VBD	O	O
improvement	NN	O	O
on	IN	O	O
the	DT	O	O
CPRS	NNP	o	OME
Autism	NNP	o	OME
Factor	NNP	o	OME
(	(	O	O
F1,9	NNP	O	O
=	NNP	O	O
24.4	CD	O	O
,	,	O	O
p	NN	O	O
=	NNP	O	O
.0008	NNP	O	O
)	)	O	O
.	.	O	O

Side	JJ	O	O
effects	NNS	O	O
included	VBD	O	O
drowsiness	NN	o	OA
and	CC	o	OA
weight	JJ	o	OA
gain	NN	o	OA
.	.	o	O

CONCLUSIONS	VB	O	O
The	DT	O	O
findings	NNS	O	O
suggest	VBP	O	O
that	IN	O	O
olanzapine	NN	i	IPM
is	VBZ	O	O
a	DT	O	O
promising	JJ	O	O
treatment	NN	o	O
for	IN	O	O
children	NNS	p	PA
with	IN	p	O
autistic	JJ	p	PC
disorder	NN	p	PC
.	.	p	O

Further	JJ	O	O
placebo-controlled	JJ	O	O
and	CC	O	O
long-term	JJ	O	O
studies	NNS	O	O
of	IN	O	O
olanzapine	NN	i	IPM
in	IN	O	O
autistic	JJ	O	O
disorder	NN	O	O
are	VBP	O	O
required	VBN	O	O
.	.	O	O

Combination	NNP	O	O
hydrocodone	NN	i	IPM
and	CC	i	IPM
ibuprofen	JJ	i	IPM
versus	NN	O	O
combination	NN	O	O
codeine	NN	i	IPM
and	CC	i	IPM
acetaminophen	NN	i	IPM
for	IN	O	O
the	DT	O	O
treatment	NN	p	O
of	IN	p	O
chronic	JJ	p	PC
pain	NN	p	PC
.	.	p	O

OBJECTIVE	CC	O	O
The	DT	O	O
objective	NN	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
compare	VB	O	O
the	DT	O	O
effectiveness	NN	O	O
of	IN	O	O
combination	NN	O	O
hydrocodone	NN	i	IPM
7.5	CD	O	O
mg	NN	O	O
and	CC	O	O
ibuprofen	$	i	IPM
200	CD	O	O
mg	NN	O	O
with	IN	O	O
that	DT	O	O
of	IN	O	O
combination	NN	O	O
codeine	NN	i	IPM
30	CD	O	O
mg	NN	O	O
and	CC	O	O
acetaminophen	$	i	IPM
300	CD	O	O
mg	NN	O	O
for	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
chronic	JJ	O	O
pain	NN	O	O
.	.	O	O

BACKGROUND	NNP	O	O
Hydrocodone	NNP	i	IPM
7.5	CD	O	O
mg	NN	O	O
with	IN	O	O
ibuprofen	JJ	i	IPM
200	CD	O	O
mg	NN	O	O
is	VBZ	O	O
the	DT	O	O
only	JJ	O	O
approved	VBD	O	O
fixed-dose	JJ	O	O
combination	NN	O	O
analgesic	IN	O	O
containing	VBG	O	O
an	DT	O	O
opioid	NN	O	O
and	CC	O	O
ibuprofen	NN	O	O
.	.	O	O

METHODS	NNP	O	O
In	IN	O	O
this	DT	O	O
randomized	JJ	O	O
,	,	O	O
parallel-group	JJ	O	O
,	,	O	O
double-blind	JJ	O	O
,	,	O	O
repeated-dose	JJ	O	O
,	,	O	O
active-comparator	JJ	O	O
,	,	O	O
4-week	JJ	O	O
,	,	O	O
multicenter	NN	O	O
study	NN	O	O
,	,	O	O
469	CD	p	PSS
patients	NNS	p	O
were	VBD	O	O
randomly	RB	O	O
assigned	VBN	O	O
to	TO	O	O
receive	VB	O	O
a	DT	O	O
1-tablet	JJ	O	O
(	(	O	O
n	JJ	O	O
=	NNP	O	O
156	CD	O	O
)	)	O	O
or	CC	O	O
2-tablet	JJ	O	O
(	(	O	O
n	JJ	O	O
=	NNP	O	O
153	CD	O	O
)	)	O	O
dose	NN	O	O
of	IN	O	O
combination	NN	i	IPM
hydrocodone	NN	i	IPM
7.5	CD	i	IPM
mg	NN	i	IPM
and	CC	i	IPM
ibuprofen	$	i	IPM
200	CD	i	IPM
mg	NN	i	IPM
(	(	O	O
HI1	NNP	O	O
and	CC	O	O
HI2	NNP	O	O
,	,	O	O
respectively	RB	O	O
)	)	O	O
or	CC	O	O
a	DT	O	O
2-tablet	JJ	i	O
dose	NN	i	O
of	IN	O	O
combination	NN	O	O
codeine	NN	i	IPM
30	CD	i	IPM
mg	NN	i	IPM
and	CC	i	IPM
acetaminophen	$	i	IPM
300	CD	i	IPM
mg	NN	i	IPM
(	(	O	O
CA	NNP	O	O
,	,	O	O
n	RB	O	O
=	VBZ	O	O
160	CD	O	O
)	)	O	O
,	,	O	O
the	DT	O	O
active	JJ	O	O
comparator	NN	O	O
,	,	O	O
every	DT	O	O
6	CD	O	O
to	TO	O	O
8	CD	O	O
hours	NNS	O	O
as	IN	O	O
needed	VBN	O	O
for	IN	O	O
pain	NN	O	O
.	.	O	O

Efficacy	NN	O	O
was	VBD	O	O
measured	VBN	O	O
through	IN	O	O
pain	NN	o	OPA
relief	NN	o	OPA
scores	NNS	o	OPA
,	,	o	O
number	NN	o	OOt
of	IN	o	OOt
daily	JJ	o	OOt
doses	NNS	o	OOt
of	IN	o	OOt
study	NN	o	OOt
medication	NN	o	OOt
,	,	o	O
number	NN	o	OOt
of	IN	o	OOt
daily	JJ	o	OOt
doses	NNS	o	OOt
of	IN	o	OOt
supplemental	JJ	o	OOt
analgesics	NNS	o	OOt
,	,	o	O
number	NN	o	OOt
of	IN	o	OOt
patients	NNS	o	OOt
who	WP	o	OOt
discontinued	VBD	o	OOt
therapy	NN	o	OOt
due	JJ	o	OOt
to	TO	o	OOt
an	DT	o	OOt
unsatisfactory	JJ	o	OOt
analgesic	JJ	o	OOt
response	NN	o	OOt
,	,	O	O
and	CC	O	O
global	JJ	O	O
assessment	NN	O	O
scores	NNS	O	O
.	.	O	O

RESULTS	NNP	O	O
Of	IN	O	O
the	DT	O	O
469	CD	p	PSS
patients	NNS	p	O
,	,	p	O
255	CD	p	PSS
(	(	p	O
54.4	CD	p	O
%	NN	p	O
)	)	p	O
were	VBD	p	O
female	JJ	p	PSE
and	CC	p	O
214	CD	p	PSS
(	(	p	O
45.6	CD	p	O
%	NN	p	O
)	)	p	O
were	VBD	p	O
male	JJ	p	PSE
.	.	p	O

The	DT	O	O
mean	JJ	p	O
age	NN	p	O
was	VBD	p	O
51.1	CD	p	PA
years	NNS	p	PA
.	.	p	O

Types	NNS	p	O
of	IN	p	O
chronic	NN	p	PC
pain	NN	p	PC
included	VBD	p	O
back	RB	p	PC
(	(	p	O
214	CD	p	O
;	:	p	O
45.6	CD	p	O
%	NN	p	O
)	)	p	O
,	,	p	O
arthritic	JJ	p	PC
(	(	p	O
145	CD	p	O
;	:	p	O
30.9	CD	p	O
%	NN	p	O
)	)	p	O
,	,	p	O
other	JJ	p	PC
musculoskeletal	NN	p	PC
(	(	p	O
65	CD	p	O
;	:	p	O
13.9	CD	p	O
%	NN	p	O
)	)	p	O
,	,	p	O
cancer	NN	p	PC
(	(	p	O
6	CD	p	O
;	:	p	O
1.3	CD	p	O
%	NN	p	O
)	)	p	O
,	,	p	O
diabetic	JJ	p	PC
neuropathic	NN	p	PC
(	(	p	O
3	CD	p	O
;	:	p	O
0.6	CD	p	O
%	NN	p	O
)	)	p	O
,	,	p	O
postherpetic	JJ	p	PC
neuralgic	NN	p	PC
(	(	p	O
5	CD	p	O
;	:	p	O
1.1	CD	p	O
%	NN	p	O
)	)	p	O
,	,	p	O
other	JJ	p	PC
neurologic	NN	p	PC
(	(	p	O
21	CD	p	O
;	:	p	O
4.5	CD	p	O
%	NN	p	O
)	)	p	O
,	,	p	O
and	CC	p	O
other	JJ	p	O
unclassified	JJ	p	PC
chronic	JJ	p	PC
pain	NN	p	PC
(	(	p	O
10	CD	p	O
;	:	p	O
2.1	CD	p	O
%	NN	p	O
)	)	p	O
.	.	O	O

During	IN	O	O
the	DT	O	O
48	CD	O	O
hours	NNS	O	O
prior	RB	O	O
to	TO	O	O
the	DT	O	O
study	NN	O	O
,	,	O	O
351	CD	O	O
(	(	O	O
74.8	CD	O	O
%	NN	O	O
)	)	O	O
patients	NNS	O	O
had	VBD	O	O
been	VBN	O	O
treated	VBN	O	O
with	IN	O	O
opioid	JJ	O	O
or	CC	O	O
opioid-nonopioid	JJ	O	O
combination	NN	O	O
analgesics	NNS	O	O
.	.	O	O

The	DT	O	O
overall	JJ	o	OPA
mean	JJ	o	OPA
daily	JJ	o	OPA
pain	NN	o	OPA
relief	NN	o	OPA
score	NN	o	OPA
was	VBD	O	O
significantly	RB	O	O
greater	JJR	O	O
in	IN	O	O
the	DT	O	O
HI2	NNP	O	O
group	NN	O	O
(	(	O	O
2.25+/-0.89	CD	O	O
)	)	O	O
than	IN	O	O
in	IN	O	O
the	DT	O	O
HI1	NNP	O	O
group	NN	O	O
(	(	O	O
1.98+/-0.87	JJ	O	O
)	)	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.003	CD	O	O
)	)	O	O
or	CC	O	O
the	DT	O	O
CA	NNP	O	O
group	NN	O	O
(	(	O	O
1.85+/-0.96	JJ	O	O
)	)	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.001	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
overall	JJ	o	OOt
mean	JJ	o	OOt
number	NN	o	OOt
of	IN	o	OOt
daily	JJ	o	OOt
doses	NNS	o	OOt
of	IN	o	OOt
study	NN	o	OOt
medication	NN	o	OOt
was	VBD	O	O
significantly	RB	O	O
less	RBR	O	O
in	IN	O	O
the	DT	O	O
HI2	NNP	O	O
group	NN	O	O
(	(	O	O
2.94+/-0.99	CD	O	O
)	)	O	O
than	IN	O	O
in	IN	O	O
the	DT	O	O
HI1	NNP	O	O
group	NN	O	O
(	(	O	O
3.23+/-0.76	JJ	O	O
)	)	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.036	CD	O	O
)	)	O	O
or	CC	O	O
the	DT	O	O
CA	NNP	O	O
group	NN	O	O
(	(	O	O
3.26+/-0.75	JJ	O	O
)	)	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.014	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
overall	JJ	o	OOt
mean	JJ	o	OOt
number	NN	o	OOt
of	IN	o	OOt
daily	JJ	o	OOt
doses	NNS	o	OOt
of	IN	o	OOt
supplemental	JJ	o	OOt
analgesics	NNS	o	OOt
was	VBD	O	O
significantly	RB	O	O
less	RBR	O	O
in	IN	O	O
the	DT	O	O
HI2	NNP	O	O
group	NN	O	O
(	(	O	O
0.24+/-0.49	CD	O	O
)	)	O	O
than	IN	O	O
in	IN	O	O
the	DT	O	O
HI1	NNP	O	O
group	NN	O	O
(	(	O	O
0.34+/-0.58	JJ	O	O
)	)	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.021	CD	O	O
)	)	O	O
or	CC	O	O
CA	NNP	O	O
group	NN	O	O
(	(	O	O
0.49+/-0.85	JJ	O	O
)	)	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.010	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
number	NN	o	OOt
of	IN	o	OOt
patients	NNS	o	OOt
who	WP	o	OOt
discontinued	VBD	o	OOt
treatment	NN	o	OOt
due	JJ	o	OOt
to	TO	o	OOt
an	DT	o	OOt
unsatisfactory	JJ	o	OOt
analgesic	JJ	o	OOt
response	NN	o	OOt
was	VBD	O	O
significantly	RB	O	O
less	RBR	O	O
in	IN	O	O
the	DT	O	O
HI2	NNP	O	O
group	NN	O	O
(	(	O	O
2	CD	O	O
;	:	O	O
1.3	CD	O	O
%	NN	O	O
)	)	O	O
than	IN	O	O
in	IN	O	O
the	DT	O	O
CA	NNP	O	O
group	NN	O	O
(	(	O	O
12	CD	O	O
;	:	O	O
7.5	CD	O	O
%	NN	O	O
)	)	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.008	CD	O	O
)	)	O	O
.	.	O	O

HI2	NNP	O	O
was	VBD	O	O
more	RBR	O	O
effective	JJ	O	O
than	IN	O	O
HI1	NNP	O	O
and	CC	O	O
CA	NNP	O	O
as	IN	O	O
measured	VBN	O	O
by	IN	O	O
pain	NN	o	OPA
relief	NN	o	OPA
scores	NNS	o	OPA
for	IN	O	O
week	NN	O	O
1	CD	O	O
(	(	O	O
P	NNP	O	O
<	VBZ	O	O
0.001	CD	O	O
vs	NN	O	O
HI1	NNP	O	O
and	CC	O	O
CA	NNP	O	O
)	)	O	O
,	,	O	O
week	NN	O	O
2	CD	O	O
(	(	O	O
P	NNP	O	O
<	VBZ	O	O
0.001	CD	O	O
vs	NN	O	O
HI1	NNP	O	O
and	CC	O	O
CA	NNP	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
week	NN	O	O
3	CD	O	O
(	(	O	O
P	NNP	O	O
=	VBZ	O	O
0.008	CD	O	O
vs	NN	O	O
HI1	NNP	O	O
and	CC	O	O
P	NNP	O	O
<	NNP	O	O
0.001	CD	O	O
vs	NN	O	O
CA	NNP	O	O
)	)	O	O
;	:	O	O
daily	JJ	o	OOt
doses	NNS	o	OOt
of	IN	o	OOt
study	NN	o	OOt
medication	NN	o	OOt
for	IN	O	O
week	NN	O	O
1	CD	O	O
(	(	O	O
P	NNP	O	O
=	VBZ	O	O
0.019	CD	O	O
vs	NN	O	O
HI1	NNP	O	O
and	CC	O	O
P	NNP	O	O
=	NNP	O	O
0.011	CD	O	O
vs	NN	O	O
CA	NNP	O	O
)	)	O	O
;	:	O	O
daily	JJ	o	OOt
doses	NNS	o	OOt
of	IN	o	OOt
supplemental	JJ	o	OOt
analgesics	NNS	o	OOt
for	IN	O	O
week	NN	O	O
1	CD	O	O
(	(	O	O
P	NNP	O	O
=	VBZ	O	O
0.010	CD	O	O
vs	NN	O	O
HI1	NNP	O	O
and	CC	O	O
CA	NNP	O	O
)	)	O	O
;	:	O	O
and	CC	O	O
global	JJ	o	OOt
assessment	NN	o	OOt
scores	NNS	o	OOt
for	IN	O	O
week	NN	O	O
1	CD	O	O
(	(	O	O
P	NNP	O	O
=	VBZ	O	O
0.018	CD	O	O
vs	NN	O	O
HI1	NNP	O	O
and	CC	O	O
P	NNP	O	O
<	NNP	O	O
0.001	CD	O	O
vs	NN	O	O
CA	NNP	O	O
)	)	O	O
,	,	O	O
week	NN	O	O
2	CD	O	O
(	(	O	O
P	NNP	O	O
=	VBZ	O	O
0.005	CD	O	O
vs	NN	O	O
HI1	NNP	O	O
and	CC	O	O
P	NNP	O	O
<	NNP	O	O
0.001	CD	O	O
vs	NN	O	O
CA	NNP	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
week	NN	O	O
4	CD	O	O
(	(	O	O
P	NNP	O	O
=	VBZ	O	O
0.013	CD	O	O
vs	NN	O	O
HI1	NNP	O	O
and	CC	O	O
P	NNP	O	O
=	NNP	O	O
0.023	CD	O	O
vs	NN	O	O
CA	NNP	O	O
)	)	O	O
.	.	O	O

There	EX	O	O
were	VBD	O	O
no	DT	O	O
significant	JJ	O	O
differences	NNS	O	O
between	IN	O	O
HI1	NNP	i	O
and	CC	O	O
CA	NNP	i	O
in	IN	O	O
any	DT	O	O
efficacy	NN	o	OOt
variable	JJ	O	O
.	.	O	O

There	EX	O	O
were	VBD	O	O
no	DT	O	O
significant	JJ	O	O
differences	NNS	O	O
in	IN	O	O
the	DT	O	O
number	NN	o	OA
of	IN	o	OA
patients	NNS	o	OA
experiencing	VBG	o	OA
adverse	JJ	o	OA
events	NNS	o	OA
in	IN	O	O
the	DT	O	O
HI2	NNP	O	O
(	(	O	O
127	CD	O	O
;	:	O	O
83	CD	O	O
%	NN	O	O
)	)	O	O
,	,	O	O
HI1	NNP	i	O
(	(	O	O
124	CD	O	O
;	:	O	O
79.5	CD	O	O
%	NN	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
CA	NNP	i	O
(	(	O	O
129	CD	O	O
;	:	O	O
80.6	CD	O	O
%	NN	O	O
)	)	O	O
groups	NNS	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
the	DT	O	O
mean	JJ	o	OOt
number	NN	o	OOt
of	IN	o	OOt
patients	NNS	o	OOt
who	WP	o	OOt
discontinued	VBD	o	OOt
treatment	NN	o	OOt
due	JJ	o	OOt
to	TO	o	OOt
adverse	JJ	o	OOt
events	NNS	o	OOt
was	VBD	O	O
significantly	RB	O	O
greater	JJR	O	O
in	IN	O	O
the	DT	O	O
HI2	NNP	i	O
group	NN	O	O
(	(	O	O
40	CD	O	O
;	:	O	O
26.1	CD	O	O
%	NN	O	O
)	)	O	O
than	IN	O	O
in	IN	O	O
the	DT	O	O
HI1	NNP	i	O
group	NN	O	O
(	(	O	O
23	CD	O	O
;	:	O	O
14.7	CD	O	O
%	NN	O	O
)	)	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.013	CD	O	O
)	)	O	O
.	.	O	O

CONCLUSIONS	VB	O	O
The	DT	O	O
results	NNS	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
suggest	VBP	O	O
that	IN	O	O
2-tablet	JJ	O	O
doses	NNS	O	O
of	IN	O	O
combination	NN	O	O
hydrocodone	NN	i	IPM
7.5	CD	O	O
mg	NN	O	O
and	CC	i	O
ibuprofen	$	i	IPM
200	CD	O	O
mg	NN	O	O
may	MD	O	O
be	VB	O	O
more	RBR	O	O
effective	JJ	O	O
than	IN	O	O
either	DT	O	O
1-tablet	JJ	O	O
doses	NNS	O	O
of	IN	O	O
this	DT	O	O
combination	NN	O	O
or	CC	O	O
2-tablet	JJ	O	O
doses	NNS	O	O
of	IN	O	O
combination	NN	O	O
codeine	NN	i	IPM
30	CD	O	O
mg	NN	O	O
and	CC	i	O
acetaminophen	$	i	IPM
300	CD	O	O
mg	NN	O	O
.	.	O	O

Moreover	RB	O	O
,	,	O	O
1-tablet	JJ	O	O
doses	NNS	O	O
of	IN	O	O
combination	NN	i	IPM
hydrocodone	NN	i	IPM
7.5	CD	i	IPM
mg	NN	i	IPM
and	CC	i	IPM
ibuprofen	$	i	IPM
200	CD	O	O
mg	NN	O	O
may	MD	O	O
be	VB	O	O
as	RB	O	O
effective	JJ	O	O
as	IN	O	O
2-tablet	JJ	O	O
doses	NNS	O	O
of	IN	O	O
combination	NN	O	O
codeine	NN	i	IPM
30	CD	O	O
mg	NN	O	O
and	CC	i	O
acetaminophen	$	i	IPM
300	CD	O	O
mg	NN	O	O
.	.	O	O

Independent	NNP	O	O
prognostic	JJ	O	O
information	NN	O	O
provided	VBN	O	O
by	IN	O	O
sphygmomanometrically	RB	i	IPH
determined	VBN	i	IPH
pulse	JJ	o	OPH
pressure	NN	o	OPH
and	CC	i	O
mean	JJ	i	O
arterial	JJ	o	OPH
pressure	NN	o	OPH
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
left	JJ	p	PC
ventricular	JJ	p	PC
dysfunction	NN	p	PC
.	.	p	O

OBJECTIVES	CC	O	O
The	DT	O	O
purpose	NN	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
evaluate	VB	O	O
the	DT	O	O
relationship	NN	O	O
of	IN	O	O
baseline	NN	O	O
pulse	JJ	O	O
pressure	NN	O	O
and	CC	O	O
mean	JJ	O	O
arterial	JJ	O	O
pressure	NN	O	O
to	TO	O	O
mortality	NN	O	O
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
left	JJ	p	O
ventricular	JJ	p	O
dysfunction	NN	p	O
.	.	p	O

BACKGROUND	NNP	O	O
Increased	VBD	O	O
conduit	NN	O	O
vessel	NN	O	O
stiffness	NN	O	O
increases	VBZ	O	O
pulse	JJ	O	O
pressure	NN	O	O
and	CC	O	O
pulsatile	NN	O	O
load	NN	O	O
,	,	O	O
potentially	RB	O	O
contributing	VBG	O	O
to	TO	O	O
adverse	VB	O	O
outcomes	NNS	O	O
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
left	JJ	p	O
ventricular	JJ	p	O
dysfunction	NN	p	O
.	.	p	O

METHODS	NNP	O	O
Pulse	NNP	O	O
and	CC	O	O
mean	VB	O	O
arterial	JJ	O	O
pressure	NN	O	O
were	VBD	O	O
analyzed	VBN	O	O
for	IN	O	O
their	PRP$	O	O
effect	NN	O	O
on	IN	O	O
mortality	NN	o	OMO
,	,	O	O
adjusting	VBG	O	O
for	IN	O	O
other	JJ	O	O
modifiers	NNS	O	O
of	IN	O	O
risk	NN	O	O
,	,	O	O
using	VBG	O	O
Cox	NNP	O	O
proportional	JJ	O	O
hazards	NNS	O	O
regression	NN	O	O
analysis	NN	O	O
of	IN	O	O
data	NNS	O	O
collected	VBN	O	O
from	IN	O	O
6,781	CD	p	PSS
patients	NNS	p	O
randomized	VBN	p	O
into	IN	p	O
the	DT	p	O
Studies	NNPS	p	O
of	IN	p	O
Left	NNP	p	O
Ventricular	NNP	p	O
Dysfunction	NNP	p	O
trials	NNS	p	O
.	.	p	O

RESULTS	NNP	O	O
Pulse	NNP	o	OPH
and	CC	o	OPH
mean	VB	o	OPH
arterial	JJ	o	OPH
pressure	NN	o	OPH
were	VBD	O	O
related	VBN	O	O
positively	RB	O	O
to	TO	O	O
each	DT	O	O
other	JJ	O	O
,	,	O	O
age	NN	O	O
,	,	O	O
ejection	NN	O	O
fraction	NN	O	O
and	CC	O	O
prevalence	NN	O	O
of	IN	O	O
diabetes	NNS	O	O
and	CC	O	O
hypertension	NN	O	O
and	CC	O	O
inversely	RB	O	O
to	TO	O	O
prior	VB	O	O
myocardial	JJ	O	O
infarction	NN	O	O
and	CC	O	O
beta-adrenergic	JJ	O	O
blocking	NN	O	O
agent	NN	O	O
use	NN	O	O
.	.	O	O

Higher	JJR	o	OPH
pulse	JJ	o	OPH
pressure	NN	o	OPH
was	VBD	O	O
associated	VBN	O	O
with	IN	O	O
increased	JJ	O	O
prevalence	NN	O	O
of	IN	O	O
female	JJ	O	O
gender	NN	O	O
,	,	O	O
greater	JJR	O	O
calcium	NN	i	IPM
channel	NN	i	IPM
blocking	VBG	i	IPM
agent	NN	i	IPM
,	,	i	O
digoxin	NN	i	IPM
and	CC	O	O
diuretic	JJ	i	IPM
use	NN	O	O
,	,	O	O
lower	JJR	O	O
heart	NN	O	O
rate	NN	O	O
and	CC	O	O
a	DT	O	O
higher	JJR	O	O
rate	NN	O	O
of	IN	O	O
reported	VBN	O	O
smoking	NN	O	O
history	NN	O	O
.	.	O	O

Higher	JJR	o	OPH
mean	JJ	o	OPH
arterial	JJ	o	OPH
pressure	NN	o	OPH
was	VBD	O	O
associated	VBN	O	O
with	IN	O	O
higher	JJR	O	O
heart	NN	O	O
rate	NN	O	O
,	,	O	O
lower	JJR	O	O
calcium	NN	i	IPM
channel	NN	i	IPM
blocker	NN	i	IPM
and	CC	O	O
digoxin	NN	i	IPM
use	NN	O	O
and	CC	O	O
lower	JJR	O	O
New	NNP	O	O
York	NNP	O	O
Heart	NNP	O	O
Association	NNP	O	O
functional	JJ	O	O
class	NN	O	O
.	.	O	O

Over	IN	O	O
a	DT	O	O
61-month	JJ	O	O
follow-up	JJ	O	O
1,582	CD	O	O
deaths	NNS	o	OMO
(	(	O	O
1,397	CD	O	O
cardiovascular	NN	O	O
)	)	O	O
occurred	VBD	O	O
.	.	O	O

In	IN	O	O
a	DT	O	O
multivariate	NN	O	O
analysis	NN	O	O
adjusting	VBG	O	O
for	IN	O	O
the	DT	O	O
above	JJ	O	O
covariates	NNS	O	O
and	CC	O	O
treatment	NN	O	O
assignment	NN	O	O
,	,	O	O
higher	JJR	O	O
pulse	JJ	o	OPH
pressure	NN	o	OPH
remained	VBD	O	O
an	DT	O	O
independent	JJ	O	O
predictor	NN	O	O
of	IN	O	O
total	JJ	o	OMO
and	CC	o	OMO
cardiovascular	JJ	o	OMO
mortality	NN	o	OMO
(	(	O	O
total	JJ	O	O
mortality	NN	O	O
relative	NN	O	O
risk	NN	O	O
,	,	O	O
1.05	CD	O	O
per	IN	O	O
10	CD	O	O
mm	NN	O	O
Hg	NNP	O	O
increment	NN	O	O
;	:	O	O
95	CD	O	O
%	NN	O	O
confidence	NN	O	O
interval	NN	O	O
,	,	O	O
1.01	CD	O	O
to	TO	O	O
1.10	CD	O	O
;	:	O	O
p	NN	O	O
=	VBZ	O	O
0.02	CD	O	O
)	)	O	O
.	.	O	O

Mean	JJ	o	OPH
arterial	JJ	o	OPH
pressure	NN	o	OPH
was	VBD	O	O
inversely	RB	O	O
related	VBN	O	O
to	TO	O	O
total	JJ	o	OMO
and	CC	o	OMO
cardiovascular	JJ	o	OMO
mortality	NN	o	OMO
(	(	O	O
total	JJ	O	O
mortality	NN	O	O
relative	NN	O	O
risk	NN	O	O
,	,	O	O
0.89	CD	O	O
;	:	O	O
95	CD	O	O
%	NN	O	O
confidence	NN	O	O
interval	NN	O	O
,	,	O	O
0.85	CD	O	O
to	TO	O	O
0.94	CD	O	O
;	:	O	O
p	NN	O	O
<	VBZ	O	O
0.0001	CD	O	O
)	)	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
One	CD	O	O
noninvasive	JJ	i	IPH
blood	NN	i	IPH
pressure	NN	i	IPH
measurement	NN	i	IPH
provides	VBZ	O	O
two	CD	O	O
independent	JJ	O	O
prognostic	JJ	O	O
factors	NNS	O	O
for	IN	O	O
survival	NN	o	OMO
.	.	o	O

Increased	VBD	o	OPH
conduit	NN	o	OPH
vessel	NN	o	OPH
stiffness	NN	o	OPH
,	,	O	O
as	IN	O	O
assessed	VBN	O	O
by	IN	O	O
pulse	JJ	O	O
pressure	NN	O	O
,	,	O	O
may	MD	O	O
contribute	VB	O	O
to	TO	O	O
increased	VBN	O	O
mortality	NN	o	OMO
in	IN	O	O
patients	NNS	O	O
with	IN	O	O
left	JJ	O	O
ventricular	JJ	O	O
dysfunction	NN	O	O
,	,	O	O
independent	JJ	O	O
of	IN	O	O
mean	JJ	O	O
arterial	JJ	O	O
pressure	NN	O	O
.	.	O	O

[	JJ	O	O
Effect	NNP	O	O
of	IN	O	O
Selaginella	NNP	i	IPM
combined	VBD	O	O
with	IN	O	O
radiotherapy	NN	i	IPH
on	IN	O	O
nasopharyngeal	JJ	p	PC
carcinoma	NN	p	PC
]	NNP	p	O
.	.	O	O

OBJECTIVE	NNP	O	O
To	TO	O	O
observe	VB	O	O
the	DT	O	O
Chinese	JJ	O	O
herbal	JJ	O	O
medicine	NN	O	O
Selaginella-induced	NNP	O	O
radiosensitization	NN	O	O
of	IN	O	O
terminal	JJ	p	PC
nasopharyngeal	JJ	p	PC
carcinoma	NN	p	PC
(	(	p	O
NPC	NNP	p	PC
)	)	p	O
.	.	p	O

METHODS	NNP	O	O
Totally	RB	O	O
180	CD	p	PSS
patients	NNS	p	O
with	IN	p	O
NPC	NNP	p	PC
were	VBD	O	O
divided	VBN	O	O
equally	RB	O	O
into	IN	O	O
3	CD	O	O
groups	NNS	O	O
with	IN	O	O
the	DT	O	O
same	JJ	O	O
radiotherapeutic	JJ	O	O
protocols	NNS	O	O
.	.	O	O

The	DT	O	O
patients	NNS	O	O
in	IN	O	O
group	NN	i	O
A	NNP	i	O
received	VBD	i	O
radiotherapy	NN	i	IPH
alone	RB	i	IPH
,	,	i	O
those	DT	i	O
in	IN	i	O
group	NN	i	O
B	NNP	i	O
were	VBD	i	O
given	VBN	i	O
daily	JJ	i	IPM
Selaginella	NNP	i	IPM
(	(	i	IPM
30	CD	i	IPM
g	NN	i	IPM
)	)	i	IPM
prepared	VBD	i	IPM
into	IN	i	IPM
50	CD	i	IPM
ml	JJ	i	IPM
decoction	NN	i	IPM
during	IN	i	IPM
the	DT	i	IPM
entire	JJ	i	IPM
course	NN	i	IPM
of	IN	i	IPM
radiotherapy	NN	i	IPM
,	,	O	O
and	CC	O	O
those	DT	O	O
in	IN	O	O
group	NN	i	IPM
C	NNP	i	IPM
had	VBD	i	IPM
Selaginella	NNP	i	IPM
30	CD	i	IPM
g	JJ	i	IPM
daily	RB	i	IPM
in	IN	i	O
the	DT	i	O
late	JJ	i	O
course	NN	i	O
of	IN	i	O
radiotherapy	NN	i	IPM
.	.	i	O

RESULTS	VB	O	O
The	DT	O	O
complete	JJ	o	OPH
remission	NN	o	OPH
rate	NN	o	OPH
of	IN	o	OPH
nasopharyngeal	JJ	o	OPH
primary	JJ	o	OPH
lesions	NNS	o	OPH
in	IN	O	O
groups	NNS	O	O
B	NNP	O	O
and	CC	O	O
C	NNP	O	O
was	VBD	O	O
significantly	RB	O	O
higher	JJR	O	O
than	IN	O	O
that	DT	O	O
in	IN	O	O
group	NN	O	O
A	NNP	O	O
,	,	O	O
with	IN	O	O
also	RB	O	O
significantly	RB	O	O
higher	JJR	O	O
complete	JJ	O	O
remission	NN	o	OPH
rates	NNS	o	OPH
of	IN	o	OPH
the	DT	o	OPH
cervical	JJ	o	OPH
lymph	NN	o	OPH
nodes	NNS	o	OPH
.	.	o	O

The	DT	O	O
acute	JJ	o	OPH
toxicity	NN	o	OPH
of	IN	o	OPH
the	DT	o	OPH
skin	NN	o	OPH
and	CC	o	OPH
mucous	JJ	o	OPH
membrane	NN	o	OPH
was	VBD	O	O
milder	RBR	O	O
in	IN	O	O
the	DT	O	O
latter	JJ	O	O
two	CD	O	O
groups	NNS	O	O
,	,	O	O
but	CC	O	O
the	DT	O	O
differences	NNS	O	O
were	VBD	O	O
not	RB	O	O
significant	JJ	O	O
.	.	O	O

CONCLUSION	NNP	O	O
Selaginella	NNP	i	IPM
may	MD	O	O
induce	VB	O	O
radiosensitization	NN	O	O
for	IN	O	O
terminal	JJ	p	PC
NPC	NNP	p	PC
and	CC	O	O
does	VBZ	O	O
not	RB	O	O
increase	VB	O	O
the	DT	O	O
acute	JJ	O	O
toxicity	NN	O	O
of	IN	O	O
radiotherapy	NN	O	O
.	.	O	O

Treatment	NN	O	O
of	IN	O	O
recurrent	NN	p	O
chronic	JJ	p	O
hyperplastic	JJ	p	O
sinusitis	NN	p	O
with	IN	p	O
nasal	JJ	p	O
polyposis	NN	p	O
.	.	p	O

OBJECTIVE	UH	O	O
To	TO	O	O
demonstrate	VB	O	O
the	DT	O	O
long-term	JJ	O	O
efficacy	NN	O	O
of	IN	O	O
intranasal	JJ	O	O
furosemide	NN	i	IPM
,	,	O	O
an	DT	O	O
inhibitor	NN	O	O
of	IN	O	O
the	DT	O	O
sodium	NN	O	O
chloride	NN	O	O
cotransporter	NN	O	O
channel	NN	O	O
at	IN	O	O
the	DT	O	O
basolateral	JJ	O	O
surface	NN	O	O
of	IN	O	O
the	DT	O	O
respiratory	JJ	O	O
epithelial	JJ	O	O
cell	NN	O	O
,	,	O	O
vs	VBZ	O	O
no	DT	i	IC
therapeutic	JJ	i	IC
intervention	NN	i	IC
vs	NN	O	O
intranasal	NN	O	O
mometasone	NN	i	IPM
furoate	NN	i	IPM
,	,	i	IPM
a	DT	i	IPM
corticosteroid	NN	i	IPM
,	,	O	O
in	IN	O	O
preventing	VBG	O	O
relapses	NNS	O	O
of	IN	O	O
chronic	JJ	O	O
hyperplastic	JJ	O	O
sinusitis	NN	O	O
with	IN	O	O
nasal	JJ	O	O
polyposis	NN	O	O
.	.	O	O

DESIGN	NNP	O	O
Randomized	NNP	O	O
prospective	NN	O	O
controlled	VBD	O	O
study	NN	O	O
.	.	O	O

Patients	NNS	O	O
were	VBD	O	O
examined	VBN	O	O
every	DT	O	O
6	CD	O	O
months	NNS	O	O
during	IN	O	O
follow-up	NN	O	O
(	(	O	O
range	NN	O	O
,	,	O	O
1-9	JJ	O	O
years	NNS	O	O
)	)	O	O
.	.	O	O

PATIENTS	VB	O	O
One	CD	p	O
hundred	JJ	p	O
seventy	NN	p	O
patients	NNS	p	O
with	IN	p	O
bilateral	JJ	p	O
obstructive	CD	p	O
or	CC	p	O
minimally	RB	p	O
obstructive	JJ	p	O
chronic	JJ	p	O
hyperplastic	JJ	p	O
sinusitis	NN	p	O
with	IN	p	O
nasal	JJ	p	O
polyposis	NN	p	O
.	.	p	O

INTERVENTION	NNP	O	O
All	DT	p	O
patients	NNS	p	O
were	VBD	p	O
surgically	RB	p	O
treated	VBN	p	O
in	IN	p	O
the	DT	p	O
ENT	NNP	p	O
Department	NNP	p	O
,	,	p	O
University	NNP	p	O
of	IN	p	O
Siena	NNP	p	O
Medical	NNP	p	O
School	NNP	p	O
.	.	p	O

One	CD	p	O
month	NN	p	O
after	IN	p	O
surgery	NN	p	O
,	,	O	O
group	NN	O	O
1	CD	p	O
patients	NNS	p	O
(	(	O	O
n	JJ	O	O
=	NNP	O	O
97	CD	O	O
)	)	O	O
started	VBD	O	O
treatment	NN	i	O
with	IN	i	O
intranasal	JJ	i	IPM
furosemide	NN	i	IPM
,	,	O	O
group	NN	O	O
2	CD	O	O
(	(	O	O
n	JJ	O	O
=	NNP	O	O
40	CD	O	O
)	)	O	O
received	VBD	i	IC
no	DT	i	IC
therapeutic	JJ	i	IC
treatment	NN	i	IC
,	,	O	O
and	CC	O	O
group	NN	O	O
3	CD	O	O
(	(	O	O
n	JJ	O	O
=	NNP	O	O
33	CD	O	O
)	)	O	O
were	VBD	O	O
treated	VBN	i	O
with	IN	i	O
mometasone	NN	i	IPM
.	.	i	O

MAIN	NNP	O	O
OUTCOME	NNP	O	O
MEASURES	NNP	O	O
Clinical	NNP	o	O
and	CC	o	O
instrumental	JJ	o	O
evaluation	NN	o	O
of	IN	o	O
postoperative	JJ	o	O
outcomes	NNS	o	O
.	.	o	O

RESULTS	NNP	O	O
Seventeen	NNP	O	O
(	(	O	O
17.5	CD	O	O
%	NN	O	O
)	)	O	O
of	IN	O	O
97	CD	O	O
patients	NNS	O	O
in	IN	O	O
group	NN	O	O
1	CD	O	O
,	,	O	O
12	CD	O	O
(	(	O	O
30.0	CD	O	O
%	NN	O	O
)	)	O	O
of	IN	O	O
40	CD	O	O
patients	NNS	O	O
in	IN	O	O
group	NN	O	O
2	CD	O	O
,	,	O	O
and	CC	O	O
8	CD	O	O
(	(	O	O
24.2	CD	O	O
%	NN	O	O
)	)	O	O
of	IN	O	O
33	CD	O	O
patients	NNS	O	O
in	IN	O	O
group	NN	O	O
3	CD	O	O
experienced	VBD	O	O
nasal	JJ	o	OPH
polyposis	NN	o	OPH
relapses	NNS	o	OPH
.	.	o	OPH

We	PRP	O	O
noted	VBD	O	O
a	DT	O	O
prevalence	NN	O	O
of	IN	O	O
early-stage	JJ	o	OPH
relapse	NN	o	OPH
in	IN	O	O
patients	NNS	p	O
treated	VBN	p	O
with	IN	p	O
furosemide	NN	i	IPM
or	CC	p	O
mometasone	NN	i	IPM
,	,	O	O
whereas	JJ	O	O
patients	NNS	p	O
who	WP	p	O
did	VBD	p	O
not	RB	p	O
receive	VB	p	O
any	DT	p	O
treatment	NN	p	O
experienced	VBD	O	O
more	JJR	O	O
severe	JJ	O	O
grades	NNS	o	OPH
of	IN	o	OPH
chronic	JJ	o	OPH
hyperplastic	JJ	o	OPH
sinusitis	NN	o	OPH
with	IN	o	OPH
nasal	JJ	o	OPH
polyposis	NN	o	OPH
(	(	O	O
P	NNP	O	O
<	NNP	O	O
.005	NNP	O	O
)	)	O	O
.	.	O	O

CONCLUSION	NNP	O	O
Use	NNP	O	O
of	IN	O	O
intranasal	NN	O	O
furosemide	JJ	i	IPM
represents	VBZ	O	O
a	DT	O	O
valid	JJ	O	O
therapeutic	JJ	O	O
treatment	NN	O	O
in	IN	O	O
the	DT	O	O
prevention	NN	O	O
of	IN	O	O
chronic	JJ	p	O
hyperplastic	JJ	p	O
sinusitis	NN	p	O
with	IN	p	O
nasal	JJ	p	O
polyposis	NN	p	O
.	.	p	O

A	DT	p	O
limited	JJ	p	O
sampling	NN	p	O
method	NN	p	O
for	IN	p	O
the	DT	p	O
estimation	NN	o	OPH
of	IN	o	OPH
flunarizine	JJ	o	OPH
area	NN	o	OPH
under	IN	o	OPH
the	DT	o	OPH
curve	NN	o	OPH
(	(	o	OPH
AUC	NNP	o	OPH
)	)	o	OPH
and	CC	o	OPH
maximum	JJ	o	OPH
plasma	JJ	o	OPH
concentration	NN	o	OPH
(	(	o	OPH
Cmax	NNP	o	OPH
)	)	o	OPH
.	.	o	OPH

A	DT	O	O
limited	JJ	O	O
sampling	NN	O	O
model	NN	O	O
has	VBZ	O	O
been	VBN	O	O
developed	VBN	O	O
for	IN	O	O
flunarizine	NN	O	O
following	VBG	O	O
a	DT	O	O
30	CD	O	O
mg	JJ	O	O
oral	JJ	O	O
dose	NN	O	O
in	IN	O	O
epileptic	JJ	p	PC
patients	NNS	p	PC
who	WP	p	O
were	VBD	i	O
receiving	VBG	i	O
phenytoin	NN	i	IPM
or	CC	i	O
carbamazepine	NN	i	IPM
or	CC	i	O
both	DT	i	O
,	,	i	O
to	TO	i	O
estimate	VB	o	OPH
the	DT	o	OPH
area	NN	o	OPH
under	IN	o	OPH
the	DT	o	OPH
curve	NN	o	OPH
(	(	o	OPH
AUC	NNP	o	OPH
)	)	o	OPH
and	CC	o	OPH
maximum	JJ	o	OPH
plasma	JJ	o	OPH
concentration	NN	o	OPH
(	(	o	OPH
Cmax	NNP	o	OPH
)	)	o	OPH
.	.	o	OPH

The	DT	O	O
model	NN	O	O
was	VBD	O	O
developed	VBN	O	O
using	VBG	O	O
training	VBG	O	O
data	NNS	O	O
sets	NNS	O	O
from	IN	O	O
30	CD	p	O
,	,	p	O
20	CD	p	O
,	,	p	O
15	CD	p	O
,	,	p	O
or	CC	p	O
10	CD	p	O
patients	NNS	p	O
at	IN	p	O
one	CD	p	O
or	CC	p	O
two	CD	p	O
time	NN	p	O
points	NNS	p	O
.	.	p	O

The	DT	O	O
equations	NNS	O	O
describing	VBG	O	O
the	DT	O	O
models	NNS	O	O
for	IN	O	O
AUC	NNP	O	O
using	VBG	O	O
two	CD	O	O
time	NN	O	O
points	NNS	O	O
(	(	O	O
3	CD	O	O
and	CC	O	O
24h	CD	O	O
)	)	O	O
and	CC	O	O
Cmax	NNP	O	O
for	IN	O	O
the	DT	O	O
training	NN	O	O
data	NNS	O	O
set	NN	O	O
of	IN	O	O
30	CD	O	O
subjects	NNS	O	O
were	VBD	O	O
AUCpredicted	NNP	O	O
=	NNP	O	O
11.1	CD	O	O
C3h	NNP	O	O
+	VBD	O	O
121.4	CD	O	O
C24h	NNP	O	O
-	:	O	O
157	CD	O	O
(	(	O	O
r	NN	O	O
=	RB	O	O
0.80	CD	O	O
)	)	O	O
Cmax	NNP	O	O
(	(	O	O
predicted	VBN	O	O
)	)	O	O
=	$	O	O
0.036	CD	O	O
AUC	NNP	O	O
+	$	O	O
42.9	CD	O	O
(	(	O	O
r	NN	O	O
=	RB	O	O
0.74	CD	O	O
)	)	O	O
The	DT	O	O
model	NN	O	O
was	VBD	O	O
validated	VBN	O	O
on	IN	O	O
64	CD	p	PSS
patients	NNS	p	O
who	WP	O	O
received	VBD	O	O
flunarizine	JJ	O	O
orally	RB	O	O
.	.	O	O

The	DT	O	O
model	NN	O	O
provided	VBD	O	O
reasonably	RB	O	O
good	JJ	O	O
estimates	NNS	o	OPH
for	IN	o	OPH
both	DT	o	OPH
AUC	NNP	o	OPH
and	CC	o	O
Cmax	NNP	o	OPH
.	.	o	O

The	DT	O	O
mean	NN	o	OPH
predicted	VBD	o	OPH
AUC	NNP	o	OPH
of	IN	o	OPH
flunarizine	NN	o	OPH
was	VBD	O	O
1230	CD	O	O
+/-	JJ	O	O
717	CD	O	O
ng	JJ	O	O
h	NN	O	O
mL-1	NN	O	O
,	,	O	O
whereas	IN	O	O
the	DT	O	O
observed	JJ	o	OPH
AUC	NNP	o	OPH
was	VBD	O	O
1203	CD	O	O
+/-	JJ	O	O
900	CD	O	O
ng	JJ	O	O
h	JJ	O	O
mL-1	NN	O	O
.	.	O	O

The	DT	O	O
bias	NN	o	OOt
of	IN	o	OOt
the	DT	o	OOt
prediction	NN	o	OOt
was	VBD	O	O
2	CD	O	O
%	NN	O	O
and	CC	O	O
precision	NN	O	O
was	VBD	O	O
28	CD	O	O
%	NN	O	O
.	.	O	O

The	DT	O	O
mean	NN	O	O
predicted	VBD	o	OPH
Cmax	NNP	o	OPH
of	IN	o	OPH
flunarizine	NN	o	OPH
was	VBD	O	O
86	CD	O	O
+/-	JJ	O	O
32	CD	O	O
ng	JJ	O	O
mL-1	NN	O	O
as	IN	O	O
compared	VBN	O	O
to	TO	O	O
an	DT	O	O
observed	JJ	o	OPH
mean	NN	o	OPH
Cmax	NNP	o	OPH
of	IN	O	O
90	CD	O	O
+/-	JJ	O	O
42	CD	O	O
ng	JJ	O	O
mL-1	NN	O	O
.	.	O	O

The	DT	O	O
bias	NN	o	OOt
and	CC	o	OOt
precision	NN	o	OOt
of	IN	o	OOt
the	DT	o	OOt
prediction	NN	o	OOt
were	VBD	O	O
4	CD	O	O
%	NN	O	O
and	CC	O	O
24	CD	O	O
%	NN	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

The	DT	O	O
method	NN	O	O
described	VBD	O	O
here	RB	O	O
may	MD	O	O
be	VB	O	O
used	VBN	O	O
to	TO	O	O
estimate	VB	O	O
AUC	NNP	O	O
and	CC	O	O
Cmax	NNP	O	O
for	IN	O	O
flunarizine	NN	O	O
without	IN	O	O
detailed	JJ	O	O
pharmacokinetic	JJ	O	O
studies	NNS	O	O
.	.	O	O

Topical	JJ	i	IPM
treatment	NN	i	IPM
of	IN	O	O
alopecia	NN	O	O
areata	NN	O	O
.	.	O	O

It	PRP	O	O
has	VBZ	O	O
been	VBN	O	O
shown	VBN	O	O
previously	RB	O	O
that	IN	O	O
alopecia	JJ	O	O
areata	NNS	O	O
can	MD	O	O
be	VB	O	O
treated	VBN	O	O
with	IN	O	O
dinitrochlorobenzene	NN	i	IPM
(	(	i	IPM
DNCB	NNP	i	IPM
)	)	i	IPM
and	CC	O	O
other	JJ	O	O
contact	NN	i	IPM
allergens	NNS	i	IPM
.	.	i	O

Whether	IN	O	O
these	DT	O	O
agents	NNS	O	O
work	NN	O	O
by	IN	O	O
inducing	VBG	O	O
immunologic	JJ	O	O
stimulation	NN	O	O
or	CC	O	O
simply	RB	O	O
a	DT	O	O
nonspecific	JJ	O	O
inflammatory	NN	O	O
reaction	NN	O	O
has	VBZ	O	O
not	RB	O	O
been	VBN	O	O
definitively	RB	O	O
demonstrated	VBN	O	O
.	.	O	O

To	TO	O	O
test	VB	O	O
the	DT	O	O
relative	JJ	O	O
importance	NN	O	O
of	IN	O	O
these	DT	O	O
two	CD	O	O
mechanisms	NNS	O	O
,	,	O	O
we	PRP	O	O
have	VBP	O	O
randomly	RB	O	O
studied	VBN	O	O
22	CD	p	O
patients	NNS	p	O
with	IN	p	O
alopecia	JJ	p	O
areata	NNS	p	O
to	TO	p	O
whom	WP	p	O
either	DT	p	O
DNCB	NNP	i	IPM
or	CC	i	O
croton	VB	i	IPM
oil	NN	i	IPM
was	VBD	p	O
applied	VBN	p	O
topically	RB	p	O
.	.	p	O

Sixty-three	JJ	O	O
percent	NN	O	O
of	IN	O	O
patients	NNS	O	O
without	IN	O	O
spontaneous	JJ	O	O
regrowth	NN	o	OPH
of	IN	o	OPH
hair	NN	o	OPH
regrew	NNS	o	OPH
hair	NN	o	OPH
after	IN	O	O
DNCB	NNP	O	O
application	NN	O	O
.	.	O	O

None	NN	o	OPH
of	IN	O	O
those	DT	O	O
treated	VBN	O	O
with	IN	O	O
croton	NN	i	IPM
oil	NN	i	IPM
regrew	VBD	o	OPH
hair	NN	o	OPH
when	WRB	O	O
treated	VBN	O	O
later	RB	O	O
with	IN	O	O
DNCB	NNP	i	IPM
.	.	i	O

Therefore	NNP	O	O
,	,	O	O
a	DT	O	O
proved	JJ	O	O
contact	NN	O	O
allergen	NN	O	O
was	VBD	O	O
shown	VBN	O	O
to	TO	O	O
be	VB	O	O
required	VBN	O	O
for	IN	O	O
therapeutic	JJ	O	O
success	NN	O	O
.	.	O	O

Patient	JJ	o	OME
acceptance	NN	o	OME
of	IN	O	O
the	DT	O	O
induced	JJ	O	O
contact	NN	O	O
dermatitis	NN	O	O
was	VBD	O	O
excellent	JJ	O	O
.	.	O	O

In	IN	O	O
light	NN	O	O
of	IN	O	O
recent	JJ	O	O
data	NNS	O	O
on	IN	O	O
the	DT	O	O
mutagenicity	NN	O	O
of	IN	O	O
DNCB	NNP	i	IPM
to	TO	O	O
bacteria	NNS	O	O
,	,	O	O
other	JJ	O	O
contact	NN	O	O
allergens	NNS	O	O
for	IN	O	O
topical	JJ	O	O
immunotherapy	NN	O	O
are	VBP	O	O
being	VBG	O	O
sought	VBN	O	O
.	.	O	O

Healthcare	NN	O	O
costs	NNS	O	O
around	IN	O	O
the	DT	O	O
time	NN	O	O
of	IN	O	O
smoking	VBG	O	O
cessation	NN	O	O
.	.	O	O

BACKGROUND	IN	O	O
The	DT	O	O
Affordable	NNP	O	O
Care	NNP	O	O
Act	NNP	O	O
mandates	VBZ	O	O
that	IN	O	O
new	JJ	O	O
insurance	NN	O	O
plans	NNS	O	O
cover	VBP	O	O
smoking-cessation	NN	i	IE
therapy	NN	i	IE
without	IN	O	O
cost-sharing	NN	O	O
.	.	O	O

Previous	JJ	O	O
cost	NN	O	O
difference	NN	O	O
estimates	NNS	O	O
,	,	O	O
which	WDT	O	O
show	VBP	O	O
a	DT	O	O
spike	NN	O	O
around	IN	O	O
the	DT	O	O
time	NN	O	O
of	IN	O	O
cessation	NN	O	O
,	,	O	O
suggest	VBP	O	O
premiums	NNS	O	O
might	MD	O	O
rise	VB	O	O
as	IN	O	O
a	DT	O	O
result	NN	O	O
of	IN	O	O
covering	VBG	O	O
these	DT	O	O
services	NNS	O	O
.	.	O	O

PURPOSE	VB	O	O
The	DT	O	O
goal	NN	O	O
of	IN	O	O
the	DT	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
test	VB	O	O
(	(	O	O
1	CD	O	O
)	)	O	O
whether	IN	O	O
individuals	NNS	p	O
in	IN	p	O
an	DT	p	O
RCT	NNP	p	O
of	IN	p	O
pharmacotherapy	NN	i	IPM
and	CC	p	O
counseling	VBG	i	IE
for	IN	p	O
smoking	VBG	p	O
cessation	NN	p	O
differed	VBN	O	O
in	IN	O	O
their	PRP$	O	O
healthcare	NN	O	O
costs	VBZ	O	O
around	IN	O	O
the	DT	O	O
cessation	NN	O	O
period	NN	O	O
,	,	O	O
and	CC	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
whether	IN	O	O
the	DT	O	O
healthcare	NN	O	O
costs	NNS	O	O
of	IN	O	O
those	DT	O	O
in	IN	O	O
the	DT	O	O
trial	NN	O	O
who	WP	O	O
successfully	RB	O	O
quit	VBP	O	O
were	VBD	O	O
different	JJ	O	O
from	IN	O	O
a	DT	O	O
matched	JJ	O	O
sample	NN	O	O
of	IN	O	O
smokers	NNS	O	O
in	IN	O	O
the	DT	O	O
community	NN	O	O
.	.	O	O

METHODS	NNP	O	O
Generalized	NNP	i	O
linear	JJ	i	O
regression	NN	i	O
models	NNS	i	O
were	VBD	i	O
used	VBN	i	O
to	TO	i	O
analyze	VB	i	O
healthcare	NN	o	OOt
cost	NN	o	OOt
data	NNS	o	OOt
on	IN	i	O
individuals	NNS	i	O
enrolled	VBN	i	O
in	IN	i	O
a	DT	i	O
comparative	JJ	i	O
effectiveness	NN	i	O
trial	NN	i	O
of	IN	i	O
cessation	NN	i	O
therapies	NNS	i	O
between	IN	p	O
October	NNP	p	O
2005	CD	p	O
and	CC	p	O
May	NNP	p	O
2007	CD	p	O
(	(	p	O
1346	CD	p	O
total	NN	p	O
participants	NNS	p	O
;	:	p	O
1338	CD	p	O
with	IN	p	O
requisite	JJ	p	O
data	NNS	p	O
for	IN	p	O
further	JJ	p	O
analysis	NN	p	O
)	)	p	O
.	.	p	O

Cost	NN	o	OOt
differences	NNS	o	OOt
for	IN	O	O
the	DT	O	O
period	NN	O	O
preceding	NN	O	O
and	CC	O	O
subsequent	JJ	O	O
to	TO	O	O
the	DT	O	O
cessation	NN	O	O
attempt	NN	O	O
were	VBD	O	O
assessed	VBN	O	O
by	IN	O	O
trial	NN	O	O
participants	NNS	O	O
'	POS	O	O
12-month	JJ	O	O
sustained	VBD	O	O
quit	NN	O	O
status	NN	O	O
.	.	O	O

Healthcare	NNP	o	OOt
cost	NN	o	OOt
differences	NNS	o	OOt
between	IN	O	O
sustained	VBN	O	O
quitters	NNS	O	O
and	CC	O	O
a	DT	O	O
sample	NN	O	O
of	IN	O	O
community-dwelling	JJ	O	O
smokers	NNS	O	O
,	,	O	O
matched	VBD	O	O
to	TO	O	O
these	DT	O	O
quitters	NNS	O	O
on	IN	O	O
the	DT	O	O
basis	NN	O	O
of	IN	O	O
health	NN	O	O
services	NNS	O	O
use	VBP	O	O
around	IN	O	O
the	DT	O	O
time	NN	O	O
trial	NN	O	O
participant	NN	O	O
enrolled	VBN	O	O
and	CC	O	O
by	IN	O	O
demographics	NNS	O	O
,	,	O	O
were	VBD	O	O
also	RB	O	O
examined	VBN	O	O
.	.	O	O

Data	NNS	O	O
were	VBD	O	O
analyzed	VBN	O	O
in	IN	O	O
2011	CD	O	O
.	.	O	O

RESULTS	VB	O	O
All	DT	O	O
three	CD	O	O
groups	NNS	O	O
had	VBD	O	O
a	DT	O	O
spike	NN	O	O
in	IN	O	O
cost	NN	O	O
associated	VBN	O	O
with	IN	O	O
the	DT	O	O
index	NN	O	O
clinic	JJ	O	O
visit	NN	O	O
.	.	O	O

Regression	NNP	O	O
results	NNS	O	O
revealed	VBD	O	O
little	JJ	O	O
difference	NN	O	O
in	IN	O	O
healthcare	NN	o	OOt
costs	NNS	o	OOt
by	IN	O	O
quit	NN	O	O
status	NN	O	O
for	IN	O	O
trial	NN	O	O
participants	NNS	O	O
until	IN	O	O
the	DT	O	O
sixth	JJ	O	O
quarter	NN	O	O
post-quit	NN	O	O
.	.	O	O

By	IN	O	O
that	DT	O	O
quarter	NN	O	O
,	,	O	O
continuous	JJ	O	O
sustained	VBD	O	O
quitters	NNS	O	O
cost	VBD	o	OOt
$	$	O	O
541	CD	O	O
(	(	O	O
p	NN	O	O
<	RB	O	O
0.001	CD	O	O
)	)	O	O
less	JJR	O	O
than	IN	O	O
continuing	VBG	O	O
smokers	NNS	O	O
.	.	O	O

Continuous	JJ	O	O
sustained	VBD	O	O
quitters	NNS	O	O
cost	NN	o	OOt
less	JJR	O	O
than	IN	O	O
their	PRP$	O	O
matched	JJ	O	O
community-	JJ	O	O
dwelling	VBG	O	O
smokers	NNS	O	O
in	IN	O	O
almost	RB	O	O
every	DT	O	O
quarter	NN	O	O
observed	VBN	O	O
.	.	O	O

The	DT	O	O
cost	NN	O	O
difference	NN	O	O
ranged	VBD	O	O
from	IN	O	O
$	$	O	O
270	CD	O	O
(	(	O	O
p=0.01	NN	O	O
)	)	O	O
during	IN	O	O
the	DT	O	O
quarter	NN	O	O
of	IN	O	O
quit	NN	O	O
,	,	O	O
to	TO	O	O
$	$	O	O
490	CD	O	O
(	(	O	O
p	NN	O	O
<	RB	O	O
0.01	CD	O	O
)	)	O	O
in	IN	O	O
the	DT	O	O
6th	CD	O	O
quarter	NN	O	O
after	IN	O	O
quitting	VBG	O	O
.	.	O	O

CONCLUSIONS	VB	O	O
The	DT	O	O
inclusion	NN	O	O
of	IN	O	O
smoking-cessation	JJ	i	IE
therapy	NN	i	IE
does	VBZ	O	O
not	RB	O	O
appear	VB	O	O
to	TO	O	O
raise	VB	O	O
short-term	JJ	o	OOt
healthcare	NN	o	OOt
costs	NNS	o	OOt
.	.	o	O

By	IN	O	O
the	DT	O	O
sixth	JJ	O	O
quarter	NN	O	O
post-quit	NN	O	O
,	,	O	O
sustained	VBN	O	O
quitters	NNS	O	O
were	VBD	O	O
less	RBR	O	O
costly	JJ	O	O
than	IN	O	O
trial	NN	O	O
participants	NNS	O	O
who	WP	O	O
continued	VBD	O	O
smoking	NN	O	O
.	.	O	O

Blood	NNP	o	OPH
purification	NN	o	OPH
for	IN	O	O
critical	JJ	O	O
care	NN	O	O
medicine	NN	O	O
:	:	O	O
endotoxin	NN	O	O
adsorption	NN	O	O
.	.	O	O

Many	JJ	O	O
kinds	NNS	O	O
of	IN	O	O
blood	NN	i	IPH
purifying	VBG	i	IPH
technologies	NNS	i	IPH
have	VBP	O	O
been	VBN	O	O
applied	VBN	O	O
to	TO	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
critically	RB	p	PC
ill	JJ	p	PC
patients	NNS	p	PC
since	IN	O	O
1979	CD	O	O
when	WRB	O	O
plasma	JJ	O	O
exchange	NN	O	O
with	IN	O	O
hollow-fiber	JJ	O	O
membranes	NNS	O	O
was	VBD	O	O
developed	VBN	O	O
.	.	O	O

These	DT	O	O
technologies	NNS	O	O
have	VBP	O	O
been	VBN	O	O
applied	VBN	O	O
not	RB	O	O
only	RB	O	O
to	TO	O	O
the	DT	O	O
removal	NN	O	O
of	IN	O	O
toxic	JJ	O	O
substances	NNS	O	O
,	,	O	O
but	CC	O	O
also	RB	O	O
to	TO	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
objective	JJ	O	O
diseases	NNS	O	O
and	CC	O	O
the	DT	O	O
removal	NN	O	O
of	IN	O	O
the	DT	O	O
factors	NNS	O	O
relating	VBG	O	O
to	TO	O	O
the	DT	O	O
associated	VBN	O	O
inflammation	NN	O	O
.	.	O	O

This	DT	O	O
article	NN	O	O
summarizes	VBZ	O	O
these	DT	O	O
methods	NNS	O	O
and	CC	O	O
their	PRP$	O	O
efficacies	NNS	O	O
for	IN	O	O
critically	RB	p	O
ill	JJ	p	O
patients	NNS	p	O
,	,	p	O
especially	RB	p	O
those	DT	p	O
with	IN	p	O
severe	JJ	p	O
sepsis	NN	p	O
.	.	p	O

Attempts	NNS	O	O
have	VBP	O	O
been	VBN	O	O
made	VBN	O	O
to	TO	O	O
remove	VB	O	O
endotoxin	NN	O	O
,	,	O	O
the	DT	O	O
main	JJ	O	O
cause	NN	O	O
of	IN	O	O
sepsis	NN	O	O
,	,	O	O
from	IN	O	O
the	DT	O	O
circulation	NN	O	O
using	VBG	O	O
polymyxin	NN	i	O
B	NNP	i	O
immobilized	VBD	i	O
fiber	NN	i	O
,	,	i	O
charcoal	NN	i	O
hemoperfusion	NN	i	O
,	,	O	O
and	CC	O	O
plasma	NN	i	IPH
or	CC	i	IPH
whole	JJ	i	IPH
blood	NN	i	IPH
exchange	NN	i	IPH
.	.	i	O

Attempts	NNS	O	O
have	VBP	O	O
also	RB	O	O
been	VBN	O	O
made	VBN	O	O
to	TO	O	O
remove	VB	O	O
proinflammatory	NN	O	O
cytokines	NNS	O	O
,	,	O	O
eicosanoides	NNS	O	O
,	,	O	O
and	CC	O	O
coagulative	JJ	O	O
factors	NNS	O	O
from	IN	O	O
the	DT	O	O
circulation	NN	O	O
in	IN	O	O
the	DT	O	O
human	JJ	O	O
body	NN	O	O
.	.	O	O

Continuous	JJ	O	O
hemofiltration	NN	O	O
or	CC	O	O
hemodiafiltration	NN	O	O
is	VBZ	O	O
the	DT	O	O
representative	JJ	O	O
technology	NN	O	O
.	.	O	O

The	DT	O	O
efficacy	NN	o	OOt
of	IN	O	O
these	DT	O	O
methods	NNS	O	O
has	VBZ	O	O
been	VBN	O	O
established	VBN	O	O
,	,	O	O
but	CC	O	O
several	JJ	O	O
issues	NNS	O	O
remain	VBP	O	O
unresolved	JJ	O	O
.	.	O	O

All	DT	O	O
methods	NNS	O	O
of	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
severe	JJ	O	O
sepsis	NN	O	O
are	VBP	O	O
discussed	VBN	O	O
with	IN	O	O
reference	NN	O	O
to	TO	O	O
treatment	NN	O	O
indications	NNS	o	OOt
,	,	o	O
efficacy	NN	o	OOt
,	,	O	O
and	CC	O	O
outcome	JJ	o	O
parameters	NNS	o	O
.	.	o	O

In	IN	O	O
particular	JJ	O	O
,	,	O	O
the	DT	O	O
clinical	JJ	O	O
results	NNS	O	O
of	IN	O	O
endotoxin	JJ	O	O
removal	NN	O	O
with	IN	O	O
polymyxin	NN	i	O
B	NNP	i	O
immobilized	JJ	i	O
fiber	NN	i	O
are	VBP	O	O
summarized	VBN	O	O
in	IN	O	O
this	DT	O	O
article	NN	O	O
.	.	O	O

A	DT	O	O
double-blind	JJ	O	O
,	,	O	O
placebo-controlled	JJ	i	IC
study	NN	O	O
of	IN	O	O
valproate	NN	i	IPM
for	IN	O	O
aggression	NN	O	O
in	IN	O	O
youth	NN	p	O
with	IN	p	O
pervasive	JJ	p	O
developmental	NN	p	O
disorders	NNS	p	O
.	.	p	O

OBJECTIVE	IN	O	O
The	DT	O	O
aim	NN	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
study	VB	O	O
valproate	JJ	i	IPM
efficacy	NN	O	O
and	CC	O	O
safety	NN	O	O
for	IN	O	O
aggression	NN	O	O
in	IN	O	O
children	NNS	p	O
and	CC	p	O
adolescents	NNS	p	O
with	IN	p	O
pervasive	JJ	p	O
developmental	NN	p	O
disorders	NNS	p	O
(	(	p	O
PDD	NNP	p	O
)	)	p	O
.	.	p	O

METHODS	NNP	O	O
In	IN	O	O
this	DT	O	O
prospective	JJ	O	O
double-blind	NN	O	O
,	,	O	O
placebo-controlled	JJ	i	IC
study	NN	O	O
,	,	O	O
30	CD	p	O
subjects	NNS	p	O
(	(	p	O
20	CD	p	O
boys	NNS	p	O
,	,	p	O
10	CD	p	O
girls	NNS	p	O
)	)	p	O
6-20	CD	p	O
years	NNS	p	O
of	IN	p	O
age	NN	p	O
with	IN	p	O
PDD	NNP	p	O
and	CC	p	O
significant	JJ	p	O
aggression	NN	p	O
were	VBD	p	O
randomized	VBN	p	O
and	CC	O	O
received	VBN	O	O
treatment	NN	O	O
with	IN	O	O
valproate	NN	i	IPM
(	(	i	IPM
VPA	NNP	i	IPM
)	)	i	IPM
or	CC	O	O
placebo	NN	i	IC
(	(	i	IPM
PBO	NNP	i	IPM
)	)	i	IPM
for	IN	O	O
8	CD	O	O
weeks	NNS	O	O
as	IN	O	O
outpatients	NNS	p	O
.	.	p	O

Mean	NNP	o	OPH
VPA	NNP	o	OPH
trough	IN	o	OPH
blood	NN	o	OPH
levels	NNS	o	OPH
were	VBD	O	O
75.5	CD	O	O
mcg/mL	NNS	O	O
at	IN	O	O
week	NN	O	O
4	CD	O	O
and	CC	O	O
77.8	CD	O	O
mcg/mL	NN	O	O
at	IN	O	O
week	NN	O	O
8	CD	O	O
.	.	O	O

RESULTS	VB	O	O
No	DT	O	O
treatment	NN	O	O
difference	NN	O	O
was	VBD	O	O
observed	VBN	O	O
statistically	RB	O	O
between	IN	O	O
VPA	NNP	i	IPM
and	CC	O	O
PBO	NNP	i	IPM
groups	NNS	O	O
.	.	O	O

The	DT	O	O
Aberrant	NNP	o	OME
Behavior	NNP	o	OME
Checklist	NNP	o	OME
--	:	o	OME
Community	NNP	o	OME
Scale	NNP	o	OME
(	(	o	OME
ABC-C	NNP	o	OME
)	)	o	OME
Irritability	NNP	o	OME
subscale	NN	o	OME
was	VBD	O	O
the	DT	O	O
primary	JJ	O	O
outcome	NN	O	O
measure	NN	O	O
(	(	O	O
p	JJ	O	O
=	NNP	O	O
0.65	CD	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
CGI	NNP	o	OME
--	:	o	OME
Improvement	NNP	o	OME
(	(	O	O
p	JJ	O	O
=	NNP	O	O
0.16	CD	O	O
)	)	O	O
and	CC	O	O
OAS	NNP	o	OME
(	(	O	O
p	JJ	O	O
=	NNP	O	O
0.96	CD	O	O
)	)	O	O
were	VBD	O	O
secondary	JJ	O	O
outcome	NN	O	O
measures	NNS	O	O
.	.	O	O

Increased	VBN	o	OA
appetite	NN	o	OA
and	CC	o	OA
skin	NN	o	OA
rash	NN	o	OA
were	VBD	O	O
significant	JJ	O	O
side	NN	O	O
effects	NNS	O	O
.	.	O	O

Only	RB	O	O
1	CD	O	O
subject	NN	O	O
was	VBD	O	O
dropped	VBN	O	O
from	IN	O	O
the	DT	O	O
study	NN	O	O
owing	VBG	O	O
to	TO	O	O
side	VB	O	O
effects	NNS	O	O
,	,	O	O
notably	RB	O	O
a	DT	O	O
spreading	NN	o	OA
skin	NN	o	OA
rash	NN	o	OA
,	,	O	O
which	WDT	O	O
then	RB	O	O
resolved	VBD	O	O
spontaneously	RB	O	O
.	.	O	O

Two	CD	O	O
subjects	NNS	O	O
receiving	VBG	O	O
VPA	NNP	i	IPM
developed	VBD	O	O
increased	VBN	O	O
serum	NN	o	OA
ammonia	NN	o	OA
levels	NNS	o	OA
,	,	O	O
one	CD	O	O
with	IN	O	O
an	DT	O	O
associated	JJ	O	O
parent	NN	O	O
report	NN	O	O
of	IN	O	O
slurred	JJ	o	OME
speech	NN	o	OME
and	CC	o	OME
mild	JJ	o	OME
cognitive	JJ	o	OME
slowing	NN	o	OME
.	.	o	O

Poststudy	NNP	O	O
,	,	O	O
of	IN	O	O
16	CD	O	O
VPA	NNP	i	IPM
and	CC	O	O
PBO	NNP	i	IPM
subjects	NNS	O	O
receiving	VBG	O	O
VPA	NNP	i	IPM
,	,	O	O
10	CD	O	O
subjects	NNS	O	O
demonstrated	VBD	O	O
sustained	JJ	o	OPH
response	NN	o	OPH
,	,	O	O
4	CD	O	O
of	IN	O	O
whom	WP	O	O
later	RB	O	O
attempted	VBN	O	O
taper	NN	O	O
,	,	O	O
with	IN	O	O
significant	JJ	O	O
relapse	NN	o	OME
of	IN	o	OME
aggression	NN	o	OME
.	.	o	O

CONCLUSION	VB	O	O
The	DT	O	O
present	JJ	O	O
negative	JJ	O	O
findings	NNS	O	O
can	MD	O	O
not	RB	O	O
be	VB	O	O
viewed	VBN	O	O
as	IN	O	O
conclusive	JJ	O	O
,	,	O	O
partly	RB	O	O
owing	VBG	O	O
to	TO	O	O
the	DT	O	O
large	JJ	O	O
placebo	NN	i	IC
response	NN	O	O
,	,	O	O
subject	JJ	O	O
heterogeneity	NN	O	O
,	,	O	O
and	CC	O	O
size	NN	O	O
of	IN	O	O
the	DT	O	O
groups	NNS	O	O
.	.	O	O

Larger	JJR	O	O
studies	NNS	O	O
are	VBP	O	O
needed	VBN	O	O
to	TO	O	O
expand	VB	O	O
upon	IN	O	O
these	DT	O	O
findings	NNS	O	O
.	.	O	O

Brief	JJ	O	O
Report	NNP	O	O
:	:	O	O
social	JJ	o	OME
disability	NN	o	OME
in	IN	p	O
autism	NN	p	O
spectrum	NN	p	O
disorder	NN	p	O
:	:	p	O
results	NNS	O	O
from	IN	O	O
Research	NNP	p	O
Units	NNP	p	O
on	IN	p	O
Pediatric	NNP	p	O
Psychopharmacology	NNP	p	O
(	(	p	O
RUPP	NNP	p	O
)	)	p	O
Autism	NNP	p	O
Network	NNP	p	O
trials	NNS	p	O
.	.	p	O

There	EX	O	O
is	VBZ	O	O
growing	VBG	O	O
interest	NN	O	O
in	IN	O	O
measuring	VBG	O	O
social	JJ	o	OME
disability	NN	o	OME
as	IN	O	O
a	DT	O	O
core	NN	O	O
element	NN	O	O
of	IN	O	O
autism	NN	p	O
spectrum	NN	p	O
disorders	NNS	p	O
in	IN	O	O
medication	NN	O	O
trials	NNS	O	O
.	.	O	O

We	PRP	O	O
conducted	VBD	O	O
a	DT	O	O
secondary	JJ	O	O
analysis	NN	O	O
on	IN	O	O
the	DT	O	O
Aberrant	NNP	o	OME
Behavior	NNP	o	OME
Checklist	NNP	o	OME
Social	NNP	o	OME
Withdrawal	NNP	o	OME
subscale	JJ	o	OME
using	VBG	O	O
data	NNS	p	O
from	IN	p	O
two	CD	p	O
federally-funded	JJ	p	O
,	,	p	O
multi-site	JJ	p	O
,	,	p	O
randomized	JJ	p	O
trials	NNS	p	O
with	IN	p	O
risperidone	NN	i	IPM
.	.	i	O

Study	NNP	p	O
1	CD	p	O
included	VBD	p	O
52	CD	p	O
subjects	NNS	p	O
assigned	VBN	p	O
to	TO	p	O
placebo	VB	i	IC
and	CC	p	O
49	CD	p	O
subjects	NNS	p	O
to	TO	p	O
risperidone	VB	i	IPM
under	IN	p	O
double-blind	JJ	p	O
conditions	NNS	p	O
.	.	p	O

Study	NNP	p	O
2	CD	p	O
included	VBD	p	O
49	CD	p	O
subjects	NNS	p	O
assigned	VBN	p	O
to	TO	p	O
risperidone	VB	i	IPM
only	RB	i	IPM
and	CC	p	O
75	CD	p	O
subjects	NNS	p	O
assigned	VBN	p	O
to	TO	p	O
risperidone	VB	i	IPM
plus	JJ	i	IPM
parent	NN	i	IE
training	NN	i	IE
.	.	i	O

After	IN	O	O
8	CD	O	O
weeks	NNS	O	O
of	IN	O	O
treatment	NN	O	O
,	,	O	O
all	DT	O	O
active	JJ	O	O
treatments	NNS	O	O
were	VBD	O	O
superior	JJ	O	O
to	TO	O	O
placebo	VB	O	O
(	(	O	O
effect	NN	O	O
sizes	VBZ	O	O
ranging	VBG	O	O
from	IN	O	O
0.42	CD	O	O
to	TO	O	O
0.65	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
findings	NNS	O	O
suggest	VBP	O	O
that	IN	O	O
the	DT	O	O
Social	NNP	O	O
Withdrawal	NNP	O	O
subscale	NN	O	O
may	MD	O	O
be	VB	O	O
a	DT	O	O
useful	JJ	O	O
measure	NN	O	O
of	IN	O	O
social	JJ	o	OME
disability	NN	o	OME
in	IN	O	O
acute	JJ	O	O
treatment	NN	O	O
trials	NNS	O	O
.	.	O	O

Phonophoresis	NNP	i	IPM
versus	NN	O	O
topical	JJ	O	O
application	NN	O	O
of	IN	O	O
ketoprofen	NN	i	IPM
:	:	i	O
comparison	NN	O	O
between	IN	O	O
tissue	NN	O	O
and	CC	O	O
plasma	NN	O	O
levels	NNS	O	O
.	.	O	O

BACKGROUND	NNP	O	O
AND	CC	O	O
PURPOSE	NNP	O	O
Over	IN	O	O
the	DT	O	O
last	JJ	O	O
few	JJ	O	O
decades	NNS	O	O
,	,	O	O
application	NN	O	O
of	IN	O	O
ultrasound	NN	O	O
has	VBZ	O	O
been	VBN	O	O
attempted	VBN	O	O
to	TO	O	O
enhance	VB	O	O
transdermal	JJ	O	O
transport	NN	O	O
of	IN	O	O
several	JJ	O	O
drugs	NNS	O	O
,	,	O	O
a	DT	O	O
method	NN	O	O
referred	VBD	O	O
to	TO	O	O
as	IN	O	O
phonophoresis	NN	O	O
.	.	O	O

The	DT	O	O
purposes	NNS	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
were	VBD	O	O
to	TO	O	O
examine	VB	O	O
the	DT	O	O
influence	NN	O	O
of	IN	O	O
ultrasound	NN	O	O
on	IN	O	O
the	DT	O	O
transdermal	JJ	O	O
delivery	NN	O	O
of	IN	O	O
ketoprofen	NN	O	O
in	IN	O	O
humans	NNS	O	O
and	CC	O	O
to	TO	O	O
compare	VB	O	O
the	DT	O	O
concentrations	NNS	O	O
found	VBD	O	O
after	IN	O	O
continuous	JJ	O	O
and	CC	O	O
pulsed	JJ	O	O
application	NN	O	O
.	.	O	O

SUBJECTS	NNP	O	O
AND	NNP	O	O
METHODS	NNP	O	O
Twenty-six	NNP	p	PSS
patients	NNS	p	O
with	IN	p	O
knee	NN	p	PC
disorders	NNS	p	PC
requiring	VBG	p	PC
arthroscopy	NN	p	PC
were	VBD	O	O
randomly	RB	O	O
assigned	VBN	O	O
to	TO	O	O
1	CD	O	O
of	IN	O	O
3	CD	O	O
groups	NNS	O	O
.	.	O	O

Just	NNP	O	O
before	IN	O	O
surgery	NN	O	O
,	,	O	O
phonophoresis	NN	i	IPM
of	IN	i	IPM
a	DT	i	IPM
ketoprofen	NN	i	IPM
gel	NN	i	IPM
(	(	O	O
Fastum	NNP	O	O
gel	NN	O	O
)	)	O	O
was	VBD	O	O
given	VBN	O	O
to	TO	O	O
group	NN	O	O
A	NNP	O	O
using	VBG	O	O
continuous	JJ	i	IPH
ultrasound	NN	i	IPH
(	(	O	O
1	CD	O	O
MHz	NNP	O	O
,	,	O	O
1.5	CD	O	O
W/cm2	NNP	O	O
,	,	O	O
for	IN	O	O
5	CD	O	O
minutes	NNS	O	O
)	)	O	O
.	.	O	O

Group	NNP	O	O
B	NNP	O	O
received	VBD	O	O
the	DT	O	O
same	JJ	O	O
treatment	NN	O	O
but	CC	O	O
with	IN	O	O
pulsed	JJ	i	IPH
ultrasound	NN	i	IPH
(	(	O	O
100	CD	O	O
Hz	NNP	O	O
,	,	O	O
20	CD	O	O
%	NN	O	O
duty	NN	O	O
cycle	NN	O	O
)	)	O	O
.	.	O	O

Group	NNP	O	O
C	NNP	O	O
received	VBD	O	O
5	CD	O	O
minutes	NNS	O	O
of	IN	O	O
sham	NN	i	IC
ultrasound	NN	i	IC
with	IN	i	IC
the	DT	i	IC
ketoprofen	NN	i	IC
gel	NN	i	IC
.	.	i	O

The	DT	O	O
ultrasound	JJ	O	O
head	NN	O	O
was	VBD	O	O
moved	VBN	O	O
over	IN	O	O
a	DT	O	O
10-cm2	JJ	O	O
area	NN	O	O
using	VBG	O	O
small	JJ	O	O
,	,	O	O
continuous	JJ	O	O
,	,	O	O
circular	JJ	O	O
movements	NNS	O	O
.	.	O	O

Biopsies	NNS	O	O
of	IN	O	O
adipose	JJ	O	O
tissue	NN	O	O
and	CC	O	O
synovial	JJ	O	O
tissue	NN	O	O
were	VBD	O	O
taken	VBN	O	O
during	IN	O	O
surgery	NN	O	O
to	TO	O	O
evaluate	VB	o	OPH
the	DT	o	OPH
local	JJ	o	OPH
penetration	NN	o	OPH
of	IN	o	OPH
the	DT	o	OPH
drug	NN	o	OPH
.	.	o	O

Blood	NN	O	O
samples	NNS	O	O
also	RB	O	O
were	VBD	O	O
collected	VBN	O	O
to	TO	O	O
determine	VB	o	OOt
whether	IN	o	OOt
ketoprofen	NN	o	OOt
entered	VBD	o	OOt
the	DT	o	OOt
systemic	JJ	o	OOt
circulation	NN	o	OOt
.	.	o	O

RESULTS	VB	O	O
The	DT	O	O
concentration	NN	o	OPH
of	IN	o	OPH
ketoprofen	NN	o	OPH
in	IN	O	O
plasma	NN	O	O
was	VBD	O	O
negligible	JJ	O	O
in	IN	O	O
all	DT	O	O
3	CD	O	O
groups	NNS	O	O
.	.	O	O

The	DT	O	O
concentration	NN	o	OPH
of	IN	o	OPH
ketoprofen	NN	o	OPH
in	IN	O	O
synovial	JJ	O	O
tissue	NN	O	O
differed	VBD	O	O
from	IN	O	O
that	IN	O	O
in	IN	O	O
fat	JJ	O	O
tissue	NN	O	O
.	.	O	O

A	DT	O	O
difference	NN	O	O
in	IN	O	O
concentration	NN	o	OPH
of	IN	o	OPH
ketoprofen	NN	o	OPH
in	IN	O	O
synovial	JJ	O	O
tissue	NN	O	O
was	VBD	O	O
found	VBN	O	O
between	IN	O	O
group	NN	O	O
C	NNP	O	O
and	CC	O	O
groups	NNS	O	O
A	NNP	O	O
and	CC	O	O
B	NNP	O	O
.	.	O	O

The	DT	O	O
concentration	NN	o	OPH
of	IN	o	OPH
ketoprofen	NN	o	OPH
in	IN	o	OPH
fat	JJ	o	OPH
tissue	NN	o	OPH
and	CC	o	OPH
synovial	JJ	o	OPH
tissue	NN	o	OPH
was	VBD	O	O
consistently	RB	O	O
higher	JJR	O	O
in	IN	O	O
group	NN	O	O
B	NNP	O	O
than	IN	O	O
in	IN	O	O
group	NN	O	O
A	NNP	O	O
.	.	O	O

DISCUSSION	NNP	O	O
AND	CC	O	O
CONCLUSION	NNP	O	O
This	DT	O	O
study	NN	O	O
confirms	VBZ	O	O
that	IN	O	O
phonophoresis	NN	O	O
of	IN	O	O
ketoprofen	NN	O	O
allows	VBZ	O	O
the	DT	O	O
attainment	NN	O	O
of	IN	O	O
higher	JJR	O	O
local	JJ	O	O
concentrations	NNS	O	O
,	,	O	O
whereas	JJ	O	O
systemic	JJ	O	O
exposure	NN	O	O
is	VBZ	O	O
lower	JJR	O	O
.	.	O	O

The	DT	O	O
results	NNS	O	O
indicate	VBP	O	O
that	IN	O	O
,	,	O	O
in	IN	O	O
contrast	NN	O	O
to	TO	O	O
sham	VB	O	O
phonopheresis	NN	O	O
,	,	O	O
ultrasound	NN	O	O
can	MD	O	O
increase	VB	O	O
the	DT	O	O
transdermal	JJ	O	O
delivery	NN	O	O
of	IN	O	O
ketoprofen	NN	O	O
.	.	O	O

Comparison	NNP	O	O
of	IN	O	O
7-day	JJ	i	IPM
and	CC	i	IPM
14-day	JJ	i	IPM
proton	NN	i	IPM
pump	IN	i	IPM
inhibitor-containing	JJ	i	IPM
triple	JJ	i	IPM
therapy	NN	i	IPM
for	IN	O	O
Helicobacter	NNP	o	OPH
pylori	JJ	o	OPH
eradication	NN	o	OPH
:	:	o	O
neither	CC	O	O
treatment	NN	O	O
duration	NN	O	O
provides	VBZ	O	O
acceptable	JJ	O	O
eradication	NN	O	O
rate	NN	O	O
in	IN	O	O
Korea	NNP	p	O
.	.	p	O

BACKGROUND	NNP	O	O
AND	CC	O	O
AIMS	NNP	O	O
Although	IN	O	O
triple	JJ	i	IPM
combination	NN	i	IPM
therapy	NN	i	IPM
containing	VBG	O	O
a	DT	i	O
proton	NN	i	IPM
pump	NN	i	IPM
inhibitor	NN	i	IPM
(	(	i	IPM
PPI	NNP	i	IPM
)	)	i	IPM
and	CC	O	O
two	CD	i	IPM
antibiotics	NNS	i	IPM
is	VBZ	O	O
considered	VBN	O	O
as	IN	O	O
a	DT	O	O
standard	JJ	O	O
regimen	NN	O	O
for	IN	O	O
the	DT	O	O
first-line	JJ	O	O
anti-Helicobacter	JJ	O	O
pylori	NN	O	O
treatment	NN	O	O
,	,	O	O
there	EX	O	O
are	VBP	O	O
still	RB	O	O
debates	NNS	O	O
on	IN	O	O
the	DT	O	O
ideal	JJ	O	O
duration	NN	O	O
of	IN	O	O
treatment	NN	O	O
.	.	O	O

The	DT	O	O
aim	NN	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
compare	VB	O	O
the	DT	O	O
efficacies	NNS	o	OOt
of	IN	O	O
7-day	JJ	i	IPM
and	CC	i	IPM
14-day	JJ	i	IPM
PPI-containing	JJ	i	IPM
triple	NN	i	IPM
therapy	NN	i	IPM
.	.	i	O

MATERIALS	NNP	O	O
AND	CC	O	O
METHODS	NNP	O	O
This	DT	O	O
study	NN	O	O
was	VBD	O	O
performed	VBN	O	O
in	IN	O	O
a	DT	O	O
randomized	JJ	O	O
,	,	O	O
multicenter	NN	O	O
,	,	O	O
prospective	JJ	O	O
manner	NN	O	O
.	.	O	O

After	IN	p	O
upper	JJ	i	IS
gastrointestinal	JJ	i	IS
endoscopy	NN	i	IS
,	,	p	O
H.	NNP	p	O
pylori-infected	JJ	p	O
patients	NNS	p	O
with	IN	p	O
a	DT	p	O
gastric	JJ	p	PC
ulcer	NN	p	PC
and/or	VBZ	p	PC
a	DT	p	PC
duodenal	JJ	p	PC
ulcer	NN	p	PC
were	VBD	O	O
randomly	RB	O	O
assigned	VBN	O	O
to	TO	O	O
a	DT	O	O
PAC7	NNP	i	IPM
group	NN	O	O
(	(	i	O
omeprazole	JJ	i	IPM
20	CD	i	IPM
mg	NN	i	IPM
or	CC	i	IPM
equivalent	JJ	i	IPM
dose	NN	i	IPM
of	IN	i	IPM
other	JJ	i	IPM
PPIs	NNP	i	IPM
,	,	i	IPM
amoxicillin	NN	i	IPM
1000	CD	i	IPM
mg	NN	i	IPM
,	,	i	IPM
and	CC	i	IPM
clarithromycin	VBZ	i	IPM
500	CD	i	IPM
mg	NN	i	IPM
twice	RB	i	IPM
daily	RB	i	IPM
for	IN	i	IPM
7	CD	i	IPM
days	NNS	i	IPM
)	)	i	IPM
or	CC	O	O
to	TO	O	O
a	DT	O	O
PAC14	NNP	i	IPM
group	NN	O	O
(	(	i	O
the	DT	i	IPM
same	JJ	i	IPM
regimen	NN	i	IPM
as	IN	i	IPM
the	DT	i	IPM
PAC7	NNP	i	IPM
group	NN	i	IPM
but	CC	i	IPM
for	IN	i	IPM
14	CD	i	IPM
days	NNS	i	IPM
)	)	i	O
.	.	O	O

H.	NNP	O	O
pylori	NN	O	O
status	NN	O	O
was	VBD	O	O
evaluated	VBN	O	O
by	IN	O	O
(	(	o	OPH
13	CD	o	OPH
)	)	o	OPH
C	NNP	o	OPH
urea	JJ	o	OPH
breath	NN	o	OPH
test	NN	O	O
5	CD	O	O
weeks	NNS	O	O
after	IN	O	O
anti-ulcer	JJ	O	O
treatment	NN	O	O
completion	NN	O	O
.	.	O	O

RESULTS	VB	O	O
A	DT	O	O
total	NN	p	O
of	IN	p	O
598	CD	p	PSS
patients	NNS	p	O
were	VBD	p	O
enrolled	VBN	p	O
;	:	p	O
337	CD	O	O
were	VBD	O	O
randomized	VBN	O	O
to	TO	O	O
the	DT	O	O
PAC7	NNP	i	IPM
group	NN	O	O
and	CC	O	O
261	CD	O	O
to	TO	O	O
the	DT	O	O
PAC14	NNP	i	IPM
group	NN	O	O
.	.	O	O

The	DT	O	O
two	CD	O	O
groups	NNS	O	O
were	VBD	O	O
comparable	JJ	O	O
in	IN	O	O
terms	NNS	O	O
of	IN	O	O
baseline	NN	O	O
characteristics	NNS	O	O
.	.	O	O

The	DT	O	O
eradication	NN	O	O
rates	NNS	O	O
of	IN	O	O
the	DT	O	O
PAC7	NNP	i	IPM
group	NN	O	O
were	VBD	O	O
not	RB	O	O
inferior	JJ	O	O
to	TO	O	O
those	DT	O	O
of	IN	O	O
the	DT	O	O
PAC14	NNP	i	IPM
group	NN	O	O
in	IN	O	O
both	DT	O	O
intention-to-treat	JJ	O	O
analysis	NN	O	O
(	(	O	O
71.2	CD	O	O
%	NN	O	O
vs.	FW	O	O
75.5	CD	O	O
%	NN	O	O
)	)	O	O
and	CC	O	O
per-protocol	JJ	O	O
analysis	NN	O	O
(	(	O	O
83.6	CD	O	O
%	NN	O	O
vs.	FW	O	O
86.6	CD	O	O
%	NN	O	O
)	)	O	O
.	.	O	O

Incidences	NNS	O	O
of	IN	O	O
adverse	JJ	o	OA
events	NNS	o	OA
were	VBD	O	O
comparable	JJ	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
Although	IN	O	O
the	DT	O	O
7-day	JJ	i	O
PPI-containing	JJ	i	O
triple	JJ	i	O
anti-H.	JJ	i	O
pylori	NN	i	O
therapy	NN	i	O
is	VBZ	O	O
not	RB	O	O
inferior	JJ	O	O
to	TO	O	O
the	DT	O	O
14-day	JJ	i	IOt
therapy	NN	O	O
,	,	O	O
neither	CC	O	O
treatment	NN	O	O
duration	NN	O	O
provides	VBZ	O	O
acceptable	JJ	O	O
eradication	NN	o	OOt
rate	NN	o	OOt
reaching	VBG	O	O
90	CD	O	O
%	NN	O	O
in	IN	O	O
per-protocol	JJ	O	O
analysis	NN	O	O
.	.	O	O

New	NNP	O	O
combination	NN	O	O
regimen	NNS	O	O
with	IN	O	O
higher	JJR	O	O
efficacy	NN	O	O
should	MD	O	O
be	VB	O	O
developed	VBN	O	O
as	IN	O	O
a	DT	O	O
first-line	JJ	O	O
eradication	NN	O	O
therapy	NN	O	O
for	IN	O	O
H.	NNP	p	O
pylori	NN	p	O
in	IN	p	O
Korea	NNP	p	O
.	.	p	O

Validation	NN	O	O
of	IN	O	O
an	DT	O	O
FFQ	NNP	O	O
for	IN	O	O
evaluation	NN	O	O
of	IN	O	O
EPA	NNP	o	OME
and	CC	o	OME
DHA	NNP	o	OME
intake	VBP	o	OME
.	.	o	OPH

OBJECTIVE	NNP	O	O
To	TO	O	O
validate	VB	O	O
an	DT	O	O
FFQ	NNP	O	O
for	IN	O	O
the	DT	O	O
assessment	NN	O	O
of	IN	O	O
dietary	JJ	O	O
EPA	NNP	o	OPH
and	CC	o	OPH
DHA	NNP	o	OPH
against	IN	O	O
their	PRP$	O	O
relative	JJ	o	OPH
concentrations	NNS	o	OPH
in	IN	o	OPH
red	JJ	o	OPH
blood	NN	o	OPH
cells	NNS	o	OPH
(	(	o	OPH
RBC	NNP	o	OPH
)	)	o	OPH
.	.	o	OPH

DESIGN	NNP	O	O
Cross-sectional	JJ	O	O
analysis	NN	O	O
of	IN	O	O
baseline	NN	O	O
data	NNS	O	O
.	.	O	O

Intakes	NNS	O	O
of	IN	O	O
marine	NN	i	IPH
food	NN	i	IPH
products	NNS	i	IPH
and	CC	O	O
EPA	NNP	i	IPM
and	CC	O	O
DHA	NNP	i	IPM
were	VBD	O	O
estimated	VBN	O	O
by	IN	O	O
FFQ	NNP	O	O
on	IN	O	O
the	DT	O	O
basis	NN	O	O
of	IN	O	O
consumption	NN	O	O
of	IN	O	O
marine	NN	i	IPM
food	NN	i	IPM
products	NNS	i	IPM
in	IN	O	O
the	DT	O	O
last	JJ	O	O
month	NN	O	O
.	.	O	O

Fatty	NNP	O	O
acid	JJ	O	O
composition	NN	O	O
of	IN	O	O
RBC	NNP	O	O
membranes	NNS	O	O
was	VBD	O	O
quantified	VBN	O	O
by	IN	O	O
GC	NNP	O	O
.	.	O	O

SETTING	NNP	O	O
Saint-Fran?ois	JJ	p	O
d'Assise	NN	p	O
Hospital	NNP	p	O
,	,	p	O
Qu?bec	NNP	p	O
,	,	p	O
Canada	NNP	p	O
.	.	p	O

SUBJECTS	NNP	O	O
A	NNP	O	O
total	NN	O	O
of	IN	O	O
sixty-five	JJ	p	O
middle-aged	JJ	p	O
women	NNS	p	O
who	WP	p	O
participated	VBD	p	O
in	IN	p	O
a	DT	p	O
randomized	JJ	p	O
clinical	JJ	p	O
trial	NN	p	O
.	.	p	O

RESULTS	NNP	O	O
Spearman	NNP	O	O
's	POS	O	O
correlation	NN	O	O
coefficient	NN	O	O
between	IN	o	O
intake	NN	o	O
of	IN	o	O
EPA	NNP	o	O
,	,	o	O
DHA	NNP	o	O
and	CC	o	O
EPA	NNP	o	O
+	NNP	o	O
DHA	NNP	o	O
and	CC	o	O
their	PRP$	O	O
corresponding	JJ	o	O
concentration	NN	o	O
in	IN	o	O
RBC	NNP	o	O
was	VBD	o	O
0.46	CD	O	O
,	,	O	O
0.40	CD	O	O
and	CC	O	O
0.42	CD	O	O
,	,	O	O
respectively	RB	O	O
(	(	O	O
all	DT	O	O
P	NNP	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

Multiple	JJ	O	O
regression	NN	O	O
analysis	NN	O	O
of	IN	O	O
EPA+DHA	NNP	o	O
intake	NN	o	O
and	CC	o	O
RBC	NNP	o	O
EPA	NNP	o	O
+	NNP	o	O
DHA	NNP	o	O
concentration	NN	o	O
indicated	VBD	o	O
positive	JJ	O	O
and	CC	O	O
significant	JJ	O	O
correlations	NNS	O	O
for	IN	O	O
oily	RB	O	O
fish	JJ	O	O
(	(	O	O
beta	JJ	O	O
=	NN	O	O
0.44	CD	O	O
,	,	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
0.16	CD	O	O
,	,	O	O
0.72	CD	O	O
,	,	O	O
P	NNP	O	O
=	NNP	O	O
0.0027	CD	O	O
)	)	O	O
,	,	O	O
total	JJ	O	O
fish	NN	O	O
(	(	O	O
beta	JJ	O	O
=	NN	O	O
0.42	CD	O	O
,	,	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
0.19	CD	O	O
,	,	O	O
0.64	CD	O	O
,	,	O	O
P	NNP	O	O
=	NNP	O	O
0.0005	CD	O	O
)	)	O	O
and	CC	i	O
marine	VB	i	O
food	NN	i	O
products	NNS	i	O
(	(	i	O
beta	NN	O	O
=	RB	O	O
0.42	CD	O	O
,	,	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
0.20	CD	O	O
,	,	O	O
0.64	CD	O	O
,	,	O	O
P	NNP	O	O
=	NNP	O	O
0.0003	CD	O	O
)	)	O	O
.	.	O	O

No	UH	O	O
other	JJ	O	O
marine	VB	O	O
food	NN	O	O
products	NNS	O	O
significantly	RB	O	O
predicted	VBD	o	O
RBC	NNP	o	O
EPA	NNP	o	O
+	NNP	o	O
DHA	NNP	o	O
concentration	NN	o	O
.	.	o	O

CONCLUSIONS	NNP	O	O
Although	IN	O	O
the	DT	O	O
present	JJ	O	O
validation	NN	O	O
study	NN	O	O
was	VBD	O	O
undertaken	VBN	O	O
among	IN	p	O
middle-aged	JJ	p	O
women	NNS	p	O
with	IN	p	O
low	JJ	p	O
consumption	NN	p	O
of	IN	p	O
marine	NN	p	O
food	NN	p	O
products	NNS	p	O
(	(	p	O
<	$	p	O
3	CD	p	O
servings/week	NN	p	O
)	)	p	O
,	,	p	O
our	PRP$	O	O
FFQ	NNP	O	O
provided	VBD	O	O
estimates	NNS	O	O
of	IN	O	O
EPA	NNP	o	O
and	CC	o	O
DHA	NNP	o	O
intakes	NNS	o	O
that	WDT	o	O
correlated	VBD	O	O
fairly	RB	O	O
well	RB	O	O
with	IN	O	O
their	PRP$	o	O
RBC	NNP	o	O
concentrations	NNS	o	O
.	.	o	O

However	RB	O	O
,	,	O	O
the	DT	O	O
absence	NN	O	O
of	IN	O	O
correlations	NNS	O	O
between	IN	o	O
EPA	NNP	o	O
+	NNP	o	O
DHA	NNP	o	O
intakes	NNS	o	O
from	IN	o	O
different	JJ	O	O
marine	NN	O	O
species	NNS	O	O
suggests	VBZ	O	O
that	IN	O	O
a	DT	O	O
minimum	JJ	i	O
EPA	NNP	i	O
+	NNP	i	O
DHA	NNP	i	O
intake	NN	i	O
is	VBZ	O	O
necessary	JJ	O	O
to	TO	O	O
observe	VB	O	O
a	DT	O	O
relationship	NN	O	O
with	IN	o	O
RBC	NNP	o	O
EPA	NNP	o	O
+	NNP	o	O
DHA	NNP	o	O
concentrations	NNS	o	O
.	.	o	O

Automatic	JJ	p	O
detection	NN	p	O
of	IN	p	O
red	JJ	p	O
lesions	NNS	p	O
in	IN	p	O
digital	JJ	p	O
color	NN	p	O
fundus	NN	p	O
photographs	NN	p	O
.	.	p	O

The	DT	O	O
robust	JJ	O	O
detection	NN	i	IPH
of	IN	i	IPH
red	JJ	o	OOt
lesions	NNS	o	OOt
in	IN	i	IPH
digital	JJ	i	IOt
color	NN	i	IOt
fundus	NN	i	IOt
photographs	NN	i	IOt
is	VBZ	O	O
a	DT	O	O
critical	JJ	O	O
step	NN	O	O
in	IN	O	O
the	DT	O	O
development	NN	O	O
of	IN	O	O
automated	JJ	O	O
screening	VBG	O	O
systems	NNS	O	O
for	IN	O	O
diabetic	JJ	p	PC
retinopathy	NN	p	O
.	.	p	O

In	IN	O	O
this	DT	O	O
paper	NN	O	O
,	,	O	O
a	DT	O	O
novel	NN	i	IOt
red	JJ	i	IOt
lesion	NN	i	IOt
detection	NN	i	IOt
method	NN	i	IOt
is	VBZ	O	O
presented	VBN	O	O
based	VBN	O	O
on	IN	O	O
a	DT	O	O
hybrid	JJ	O	O
approach	NN	O	O
,	,	O	O
combining	VBG	O	O
prior	JJ	O	O
works	NNS	O	O
by	IN	O	O
Spencer	NNP	O	O
et	CC	O	O
al	NN	O	O
.	.	O	O

(	(	O	O
1996	CD	O	O
)	)	O	O
and	CC	O	O
Frame	NNP	O	O
et	NNP	O	O
al	NN	O	O
.	.	O	O

(	(	O	O
1998	CD	O	O
)	)	O	O
with	IN	O	O
two	CD	O	O
important	JJ	O	O
new	JJ	O	O
contributions	NNS	O	O
.	.	O	O

The	DT	O	O
first	JJ	O	O
contribution	NN	O	O
is	VBZ	O	O
a	DT	O	O
new	JJ	O	O
red	JJ	i	IOt
lesion	NN	i	IOt
candidate	NN	i	IOt
detection	NN	i	IOt
system	NN	i	IOt
based	VBN	O	O
on	IN	O	O
pixel	JJ	O	O
classification	NN	O	O
.	.	O	O

Using	VBG	O	O
this	DT	O	O
technique	NN	O	O
,	,	O	O
vasculature	NN	o	OOt
and	CC	o	OOt
red	JJ	o	OOt
lesions	NNS	o	OOt
are	VBP	O	O
separated	VBN	O	O
from	IN	O	O
the	DT	O	O
background	NN	O	O
of	IN	O	O
the	DT	O	O
image	NN	O	O
.	.	O	O

After	IN	O	O
removal	NN	O	O
of	IN	O	O
the	DT	O	O
connected	JJ	O	O
vasculature	NN	O	O
the	DT	O	O
remaining	VBG	O	O
objects	NNS	O	O
are	VBP	O	O
considered	VBN	O	O
possible	JJ	O	O
red	JJ	O	O
lesions	NNS	O	O
.	.	O	O

Second	NNP	O	O
,	,	O	O
an	DT	O	O
extensive	JJ	O	O
number	NN	O	O
of	IN	O	O
new	JJ	O	O
features	NNS	O	O
are	VBP	O	O
added	VBN	O	O
to	TO	O	O
those	DT	O	O
proposed	VBN	O	O
by	IN	O	O
Spencer-Frame	NNP	O	O
.	.	O	O

The	DT	O	O
detected	JJ	O	O
candidate	NN	O	O
objects	NNS	O	O
are	VBP	O	O
classified	VBN	O	O
using	VBG	O	O
all	DT	O	O
features	NNS	O	O
and	CC	O	O
a	DT	O	O
k-nearest	JJ	O	O
neighbor	NN	O	O
classifier	NN	O	O
.	.	O	O

An	DT	O	O
extensive	JJ	O	O
evaluation	NN	O	O
was	VBD	O	O
performed	VBN	O	O
on	IN	O	O
a	DT	O	O
test	NN	O	O
set	NN	O	O
composed	VBN	O	O
of	IN	O	O
images	NNS	O	O
representative	NN	O	O
of	IN	O	O
those	DT	O	O
normally	RB	O	O
found	VBN	O	O
in	IN	O	O
a	DT	O	O
screening	NN	O	O
set	NN	O	O
.	.	O	O

When	WRB	O	O
determining	VBG	O	O
whether	IN	O	O
an	DT	O	O
image	NN	O	O
contains	VBZ	O	O
red	JJ	o	OPH
lesions	NNS	o	OPH
the	DT	O	O
system	NN	O	O
achieves	VBZ	O	O
a	DT	O	O
sensitivity	NN	o	OOt
of	IN	O	O
100	CD	O	O
%	NN	O	O
at	IN	O	O
a	DT	O	O
specificity	NN	O	O
of	IN	O	O
87	CD	O	O
%	NN	O	O
.	.	O	O

The	DT	O	O
method	NN	O	O
is	VBZ	O	O
compared	VBN	O	O
with	IN	O	O
several	JJ	O	O
different	JJ	O	O
automatic	JJ	O	O
systems	NNS	O	O
and	CC	O	O
is	VBZ	O	O
shown	VBN	O	O
to	TO	O	O
outperform	VB	O	O
them	PRP	O	O
all	DT	O	O
.	.	O	O

Performance	NNP	o	OOt
is	VBZ	O	O
close	RB	O	O
to	TO	O	O
that	DT	O	O
of	IN	O	O
a	DT	O	O
human	JJ	O	O
expert	NN	O	O
examining	VBG	O	O
the	DT	O	O
images	NNS	O	O
for	IN	O	O
the	DT	O	O
presence	NN	O	O
of	IN	O	O
red	JJ	O	O
lesions	NNS	O	O
.	.	O	O

Tailored	NNP	i	IE
,	,	i	IE
iterative	JJ	i	IE
,	,	i	IE
printed	JJ	i	IE
dietary	JJ	i	IE
feedback	NN	i	IE
is	VBZ	O	O
as	RB	O	O
effective	JJ	O	O
as	IN	O	O
group	NN	O	O
education	NN	O	O
in	IN	O	O
improving	VBG	O	O
dietary	JJ	O	O
behaviours	NNS	O	O
:	:	O	O
results	NNS	O	O
from	IN	O	O
a	DT	O	O
randomised	VBN	O	O
control	NN	O	O
trial	NN	O	O
in	IN	O	O
middle-aged	JJ	p	PA
adults	NNS	p	PA
with	IN	p	O
cardiovascular	JJ	p	PC
risk	NN	p	PC
factors	NNS	p	PC
.	.	p	O

BACKGROUND	NNP	O	O
Tailored	NNP	O	O
nutrition	NN	O	O
interventions	NNS	O	O
have	VBP	O	O
been	VBN	O	O
shown	VBN	O	O
to	TO	O	O
be	VB	O	O
more	RBR	O	O
effective	JJ	O	O
than	IN	O	O
non-tailored	JJ	O	O
materials	NNS	O	O
in	IN	O	O
changing	VBG	O	O
dietary	JJ	O	O
behaviours	NNS	O	O
,	,	O	O
particularly	RB	O	O
fat	JJ	O	O
intake	NN	O	O
and	CC	O	O
fruit	NN	O	O
and	CC	O	O
vegetable	JJ	O	O
intake	NN	O	O
.	.	O	O

But	CC	O	O
further	JJ	O	O
research	NN	O	O
examining	VBG	O	O
efficacy	NN	O	O
of	IN	O	O
tailored	JJ	O	O
nutrition	NN	O	O
education	NN	O	O
in	IN	O	O
comparison	NN	O	O
to	TO	O	O
other	JJ	O	O
nutrition	JJ	O	O
education	NN	O	O
methods	NNS	O	O
and	CC	O	O
across	IN	O	O
a	DT	O	O
wider	NN	O	O
range	NN	O	O
of	IN	O	O
dietary	JJ	O	O
behaviours	NNS	O	O
is	VBZ	O	O
needed	VBN	O	O
.	.	O	O

The	DT	p	O
Stages	NNPS	p	O
to	TO	p	O
Healthy	NNP	p	O
Eating	NNP	p	O
Patterns	NNP	p	O
Study	NNP	p	O
(	(	p	O
STEPs	NNP	p	O
)	)	p	O
was	VBD	O	O
an	DT	O	O
intervention	NN	O	O
study	NN	O	O
,	,	O	O
in	IN	O	O
middle-aged	JJ	p	PA
adults	NNS	p	PA
with	IN	p	O
cardiovascular	JJ	p	PC
risk	NN	p	PC
factors	NNS	p	PC
,	,	O	O
to	TO	O	O
examine	VB	O	O
the	DT	O	O
effectiveness	NN	O	O
of	IN	O	O
printed	VBN	O	O
,	,	O	O
tailored	VBN	O	O
,	,	O	O
iterative	JJ	O	O
dietary	JJ	O	O
feedback	NN	O	O
delivered	VBN	O	O
by	IN	O	O
mail	NN	O	O
in	IN	O	O
improving	VBG	O	O
short-term	JJ	O	O
dietary	JJ	O	O
behaviour	NN	O	O
in	IN	O	O
the	DT	O	O
areas	NNS	O	O
of	IN	O	O
saturated	JJ	O	O
fat	NN	O	O
,	,	O	O
fruit	NN	O	O
,	,	O	O
vegetable	JJ	O	O
and	CC	O	O
grain	NN	O	O
and	CC	O	O
cereal	NN	O	O
intake	NN	O	O
.	.	O	O

METHODS	NNP	O	O
STEPs	NNP	O	O
was	VBD	O	O
a	DT	O	O
3-month	JJ	O	O
randomised	VBN	O	O
controlled	VBN	O	O
trial	NN	O	O
with	IN	O	O
a	DT	O	O
pre	NN	O	O
and	CC	O	O
post-test	JJ	O	O
design	NN	O	O
.	.	O	O

There	EX	O	O
were	VBD	O	O
three	CD	O	O
experimental	JJ	O	O
conditions	NNS	O	O
:	:	O	O
1	CD	O	O
)	)	O	O
tailored	VBN	i	IE
,	,	i	IE
iterative	JJ	i	IE
,	,	i	IE
printed	JJ	i	IE
dietary	JJ	i	IE
feedback	NN	i	IE
(	(	i	IE
TF	NNP	i	IE
)	)	i	IE
with	IN	O	O
three	CD	O	O
instalments	NNS	O	O
mail-delivered	JJ	O	O
over	IN	O	O
a	DT	O	O
3-month	JJ	O	O
period	NN	O	O
that	WDT	O	O
were	VBD	O	O
re-tailored	VBN	O	O
to	TO	O	O
most	RBS	O	O
recent	JJ	O	O
assessment	NN	O	O
of	IN	O	O
dietary	JJ	O	O
intake	NN	O	O
,	,	O	O
intention	NN	O	O
to	TO	O	O
change	VB	O	O
and	CC	O	O
assessment	NN	O	O
of	IN	O	O
self-adequacy	NN	O	O
of	IN	O	O
dietary	JJ	O	O
intake	NN	O	O
.	.	O	O

Tailoring	VBG	O	O
for	IN	O	O
dietary	JJ	O	O
intake	NN	O	O
was	VBD	O	O
performed	VBN	O	O
on	IN	O	O
data	NNS	O	O
from	IN	O	O
a	DT	O	O
validated	JJ	O	O
63-item	JJ	O	O
combination	NN	O	O
FFQ	NNP	O	O
designed	VBN	O	O
for	IN	O	O
the	DT	O	O
purpose	JJ	O	O
2	CD	O	O
)	)	O	O
small	JJ	O	O
group	NN	O	O
nutrition	NN	i	IE
education	NN	i	IE
sessions	NNS	i	IE
(	(	O	O
GE	NNP	O	O
)	)	O	O
:	:	O	O
consisting	NN	O	O
of	IN	O	O
two	CD	O	O
90-minute	JJ	O	O
dietitian-led	JJ	O	O
small	JJ	O	O
group	NN	O	O
nutrition	NN	O	O
education	NN	O	O
sessions	NNS	O	O
and	CC	O	O
3	CD	O	O
)	)	O	O
and	CC	O	O
a	DT	O	O
wait-listed	JJ	O	O
control	NN	O	O
(	(	O	O
C	NNP	O	O
)	)	O	O
group	NN	O	O
who	WP	O	O
completed	VBD	O	O
the	DT	O	O
dietary	JJ	i	IE
measures	NNS	i	IE
and	CC	i	IE
socio-demographic	JJ	i	IE
questionnaires	NNS	i	IE
at	IN	O	O
baseline	NN	O	O
and	CC	O	O
3-months	JJ	O	O
later	NN	O	O
.	.	O	O

Dietary	NNP	O	O
outcome	NN	O	O
measures	NNS	O	O
in	IN	O	O
the	DT	O	O
areas	NNS	O	O
of	IN	O	O
saturated	JJ	o	OME
fat	JJ	o	OME
intake	NN	o	OME
(	(	o	OME
g	NN	o	OME
)	)	o	OME
,	,	O	O
and	CC	O	O
the	DT	O	O
intake	NN	o	OME
of	IN	o	OME
fruit	NN	o	OME
(	(	o	OME
serves	NNS	o	OME
)	)	o	OME
,	,	o	OME
vegetables	NNS	o	OME
(	(	o	OME
serves	NNS	o	OME
)	)	o	OME
,	,	o	OME
grain	NN	o	OME
and	CC	o	OME
cereals	NNS	o	OME
as	IN	O	O
total	JJ	o	OME
and	CC	o	OME
wholegrain	NN	o	OME
(	(	o	OME
serves	NNS	o	OME
)	)	o	OME
were	VBD	O	O
collected	VBN	O	O
using	VBG	O	O
7-day	JJ	O	O
estimated	VBN	O	O
dietary	JJ	O	O
records	NNS	O	O
.	.	O	O

Descriptive	JJ	O	O
statistics	NNS	O	O
,	,	O	O
paired	VBD	O	O
t-tests	NNS	O	O
and	CC	O	O
general	JJ	O	O
linear	JJ	O	O
models	NNS	O	O
adjusted	VBN	O	O
for	IN	O	O
baseline	NN	O	O
dietary	JJ	O	O
intake	NN	O	O
,	,	O	O
age	NN	O	O
and	CC	O	O
gender	NN	O	O
were	VBD	O	O
used	VBN	O	O
to	TO	O	O
examine	VB	O	O
the	DT	O	O
effectiveness	NN	O	O
of	IN	O	O
different	JJ	O	O
nutrition	NN	O	O
interventions	NNS	O	O
.	.	O	O

RESULTS	VB	O	O
The	DT	O	O
TF	NNP	i	IE
group	NN	O	O
reported	VBD	O	O
a	DT	O	O
significantly	RB	O	O
greater	JJR	O	O
increase	NN	O	O
in	IN	O	O
fruit	JJ	o	OME
intake	NN	o	OME
(	(	O	O
0.3	CD	O	O
serves/d	NN	O	O
P	NNP	O	O
=	NNP	O	O
0.031	CD	O	O
)	)	O	O
in	IN	O	O
comparison	NN	O	O
to	TO	O	O
GE	NNP	O	O
and	CC	O	O
the	DT	O	O
C	NNP	O	O
group	NN	O	O
.	.	O	O

All	DT	O	O
three	CD	O	O
intervention	NN	O	O
groups	NNS	O	O
showed	VBD	O	O
a	DT	O	O
reduction	NN	O	O
in	IN	O	O
total	JJ	o	OME
saturated	JJ	o	OME
fat	JJ	o	OME
intake	NN	o	OME
.	.	o	O

GE	NNP	O	O
also	RB	O	O
had	VBD	O	O
a	DT	O	O
within-group	JJ	O	O
increase	NN	O	O
in	IN	O	O
mean	JJ	o	OME
vegetable	JJ	o	OME
intake	NN	o	OME
after	IN	O	O
3	CD	O	O
months	NNS	O	O
,	,	O	O
but	CC	O	O
this	DT	O	O
increase	NN	O	O
was	VBD	O	O
not	RB	O	O
different	JJ	O	O
from	IN	O	O
changes	NNS	O	O
in	IN	O	O
the	DT	O	O
other	JJ	O	O
groups	NNS	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
In	IN	O	O
this	DT	O	O
study	NN	O	O
,	,	O	O
printed	VBN	O	O
,	,	O	O
tailored	VBN	O	O
,	,	O	O
iterative	JJ	O	O
dietary	JJ	O	O
feedback	NN	O	O
was	VBD	O	O
more	RBR	O	O
effective	JJ	O	O
than	IN	O	O
small	JJ	O	O
group	NN	O	O
nutrition	NN	O	O
education	NN	O	O
in	IN	O	O
improving	VBG	O	O
the	DT	O	O
short-term	JJ	O	O
fruit	NN	O	O
intake	VB	O	O
behaviour	NN	O	O
,	,	O	O
and	CC	O	O
as	IN	O	O
effective	JJ	O	O
in	IN	O	O
improving	VBG	O	O
saturated	VBN	O	O
fat	JJ	O	O
intake	NN	O	O
of	IN	O	O
middle-aged	JJ	p	PA
adults	NNS	p	PA
with	IN	p	O
cardiovascular	JJ	p	PC
risk	NN	p	PC
factors	NNS	p	PC
.	.	p	O

This	DT	O	O
showed	VBD	O	O
that	IN	O	O
a	DT	O	O
low-level	JJ	O	O
dietary	JJ	O	O
intervention	NN	O	O
could	MD	O	O
achieve	VB	O	O
modest	JJ	O	O
dietary	JJ	O	O
behaviour	NN	O	O
changes	NNS	O	O
that	WDT	O	O
are	VBP	O	O
of	IN	O	O
public	JJ	O	O
health	NN	O	O
significance	NN	O	O
.	.	O	O

Magnocellular	JJ	i	IOt
visual	JJ	i	IOt
evoked	VBN	O	O
potential	JJ	O	O
delay	NN	O	O
with	IN	O	O
high	JJ	p	O
autism	NN	p	O
spectrum	JJ	p	O
quotient	NN	p	O
yields	NNS	O	O
a	DT	O	O
neural	JJ	O	O
mechanism	NN	O	O
for	IN	O	O
altered	JJ	o	OPH
perception	NN	o	OPH
.	.	o	OPH

Everyone	NN	O	O
has	VBZ	O	O
autistic	JJ	O	O
characteristics	NNS	O	O
to	TO	O	O
a	DT	O	O
greater	JJR	O	O
or	CC	O	O
lesser	JJR	O	O
degree	NN	O	O
,	,	O	O
encapsulated	VBN	O	O
in	IN	O	O
the	DT	O	O
Autism	NNP	o	OPH
Spectrum	NNP	o	OPH
Quotient	NNP	o	OPH
,	,	O	O
a	DT	O	O
scale	NN	O	O
that	WDT	O	O
measures	VBZ	O	O
the	DT	O	O
degree	NN	O	O
to	TO	O	O
which	WDT	O	O
an	DT	O	O
adult	NN	p	O
of	IN	p	O
normal	JJ	p	O
intelligence	NN	p	O
displays	NNS	O	O
traits	NNS	O	O
associated	VBN	O	O
with	IN	O	O
autism	NN	O	O
spectrum	NN	O	O
disorders	NNS	O	O
.	.	O	O

Recent	JJ	O	O
psychophysical	JJ	O	O
analyses	NNS	O	O
of	IN	O	O
autism	NN	O	O
spectrum	NN	O	O
disorders	NNS	O	O
point	VBP	O	O
to	TO	O	O
superior	VB	O	O
local	JJ	O	O
processing	NN	O	O
,	,	O	O
and	CC	O	O
impaired	VBD	O	O
or	CC	O	O
ignored	VBN	O	O
global	JJ	O	O
and	CC	O	O
contextual	JJ	O	O
processing	NN	O	O
.	.	O	O

The	DT	O	O
aim	NN	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
test	VB	O	O
whether	IN	O	O
low-	JJ	i	O
and	CC	p	O
high-scoring	JJ	i	O
individuals	NNS	i	O
on	IN	i	O
the	DT	i	O
Autism	NNP	i	O
Spectrum	NNP	i	O
Quotient	NNP	i	O
differ	NN	O	O
on	IN	O	O
a	DT	O	O
measure	NN	O	O
of	IN	O	O
local	JJ	o	OPH
and	CC	o	OPH
global	JJ	o	OPH
processing	NN	o	OPH
,	,	i	O
motion	NN	i	IOt
processing	NN	i	IOt
and	CC	i	O
visual	JJ	i	IOt
pathway	NN	i	IOt
integrity	NN	i	IOt
.	.	i	O

Fifteen	NNP	p	O
low-scoring	JJ	p	O
individuals	NNS	p	O
and	CC	p	O
14	CD	p	O
high-scoring	JJ	p	O
individuals	NNS	p	O
derived	VBN	p	O
from	IN	p	O
a	DT	p	O
normal	JJ	p	O
population	NN	p	O
participated	VBD	p	O
in	IN	p	O
the	DT	p	O
study	NN	p	O
.	.	p	O

The	DT	O	O
results	NNS	O	O
indicate	VBP	O	O
that	IN	O	O
the	DT	O	O
initial	JJ	O	O
cortical	JJ	o	OPH
response	NN	o	OPH
to	TO	O	O
the	DT	O	O
magnocellular	JJ	O	O
afferents	NNS	O	O
is	VBZ	O	O
weaker	JJR	O	O
at	IN	O	O
low	JJ	O	O
contrast	NN	O	O
in	IN	O	O
the	DT	O	O
high	JJ	O	O
autistic	JJ	O	O
tendency	NN	O	O
group	NN	O	O
and	CC	O	O
that	IN	O	O
a	DT	O	O
second-order	JJ	O	O
response	NN	O	O
,	,	O	O
reflecting	VBG	O	O
magnocellular	JJ	O	O
activity	NN	O	O
,	,	O	O
demonstrated	VBD	O	O
a	DT	o	OOt
delay	NN	o	OOt
for	IN	O	O
high	JJ	O	O
versus	NN	O	O
low	JJ	O	O
scorers	NNS	O	O
when	WRB	O	O
the	DT	O	O
parvocellular	JJ	O	O
pathway	NN	O	O
was	VBD	O	O
also	RB	O	O
active	JJ	O	O
in	IN	O	O
response	NN	O	O
to	TO	O	O
a	DT	O	O
high	JJ	O	O
contrast	NN	O	O
stimulus	NN	O	O
.	.	O	O

High-scoring	JJ	O	O
individuals	NNS	O	O
also	RB	O	O
demonstrated	VBD	O	O
difficulty	NN	O	O
in	IN	O	O
identifying	VBG	o	OOt
the	DT	o	OOt
global	JJ	o	OOt
components	NNS	o	OOt
of	IN	O	O
locally	RB	O	O
salient	JJ	O	O
hierarchical	JJ	O	O
Navon	NNP	O	O
figures	NNS	O	O
.	.	O	O

Furthermore	RB	O	O
,	,	O	O
cross-validated	JJ	O	O
discriminant	NN	O	O
analysis	NN	O	O
,	,	O	O
using	VBG	O	O
four	CD	O	O
physiologically	RB	O	O
and	CC	O	O
three	CD	O	O
psychophysically	RB	O	O
derived	JJ	O	O
parameters	NNS	O	O
,	,	O	O
correctly	RB	O	O
classified	VBD	O	O
83	CD	O	O
%	NN	O	O
of	IN	O	O
individuals	NNS	O	O
who	WP	O	O
scored	VBD	O	O
either	CC	O	O
high	JJ	O	O
or	CC	O	O
low	JJ	O	O
on	IN	O	O
the	DT	O	O
Autism	NNP	O	O
Spectrum	NNP	O	O
Quotient	NNP	O	O
.	.	O	O

These	DT	O	O
findings	NNS	O	O
in	IN	O	O
the	DT	O	O
group	NN	O	O
scoring	VBG	O	O
high	JJ	O	O
on	IN	O	O
the	DT	O	O
Autism	NNP	p	O
Spectrum	NNP	p	O
Quotient	NNP	p	O
indicate	VBP	O	O
that	IN	O	O
a	DT	O	O
delay	NN	O	O
in	IN	O	O
primary	JJ	O	O
visual/prestriate	JJ	O	O
cortical	JJ	O	O
processing	NN	O	O
of	IN	O	O
magnocellular	JJ	O	O
input	NN	O	O
diminishes	VBZ	O	O
the	DT	O	O
advantage	NN	O	O
of	IN	O	O
its	PRP$	O	O
early	JJ	O	O
arrival	NN	O	O
to	TO	O	O
primary	JJ	O	O
visual	JJ	O	O
cortex	NN	O	O
.	.	O	O

This	DT	O	O
appears	VBZ	O	O
to	TO	O	O
be	VB	O	O
associated	VBN	O	O
with	IN	O	O
impaired	JJ	o	OOt
global	JJ	o	OOt
visual	JJ	o	OOt
perception	NN	o	OOt
,	,	O	O
predicting	VBG	O	O
with	IN	O	O
high	JJ	O	O
accuracy	NN	O	O
behavioural	JJ	o	OPH
tendencies	NNS	o	OPH
associated	VBN	O	O
with	IN	O	O
autism	NN	O	O
spectrum	NN	O	O
disorders	NNS	O	O
.	.	O	O

It	PRP	O	O
has	VBZ	O	O
been	VBN	O	O
proposed	VBN	O	O
that	IN	O	O
perceptual	JJ	O	O
impairment	NN	O	O
in	IN	O	O
autism	NN	O	O
may	MD	O	O
be	VB	O	O
attributed	VBN	O	O
to	TO	O	O
a	DT	O	O
dysfunction	NN	O	O
of	IN	O	O
horizontal	JJ	O	O
connections	NNS	O	O
within	IN	O	O
early	JJ	O	O
visual	JJ	O	O
areas	NNS	O	O
,	,	O	O
presumably	RB	O	O
parvocellular	JJ	O	O
in	IN	O	O
nature	NN	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
the	DT	O	O
timing	NN	O	O
of	IN	O	O
such	JJ	O	O
form	NN	O	O
processing	NN	O	O
aberrations	NNS	O	O
is	VBZ	O	O
much	RB	O	O
later	RBR	O	O
than	IN	O	O
the	DT	O	O
timing	NN	O	O
of	IN	O	O
abnormal	JJ	O	O
magnocellular	JJ	O	O
visual	JJ	O	O
processing	NN	O	O
measured	VBN	O	O
directly	RB	O	O
here	RB	O	O
.	.	O	O

Thus	VB	O	O
it	PRP	O	O
is	VBZ	O	O
proposed	VBN	O	O
that	IN	O	O
a	DT	O	O
magnocellular	JJ	O	O
processing	NN	O	O
delay	NN	O	O
decreases	VBZ	O	O
the	DT	O	O
ability	NN	O	O
of	IN	O	O
autistic	JJ	p	O
individuals	NNS	p	O
to	TO	O	O
benefit	VB	O	O
perceptually	RB	O	O
from	IN	O	O
feedback	NN	O	O
normally	RB	O	O
associated	VBN	O	O
with	IN	O	O
the	DT	O	O
magnocellular	JJ	O	O
advantage	NN	O	O
.	.	O	O

A	DT	O	O
high	JJ	O	O
intake	NN	O	O
of	IN	O	O
trans	NNS	i	IPM
fatty	JJ	i	IPM
acids	NNS	i	IPM
has	VBZ	O	O
little	JJ	O	O
effect	NN	O	O
on	IN	O	O
markers	NNS	o	OPH
of	IN	o	OPH
inflammation	NN	o	OPH
and	CC	o	OPH
oxidative	JJ	o	OPH
stress	NN	o	OPH
in	IN	O	O
humans	NNS	p	O
.	.	p	O

Consumption	NN	i	O
of	IN	i	O
industrial	JJ	i	IPM
trans	NNS	i	IPM
fatty	JJ	i	IPM
acids	NNS	i	IPM
(	(	i	IPM
iTFA	NN	i	IPM
)	)	i	IPM
increases	VBZ	O	O
LDL	NNP	O	O
cholesterol	NN	O	O
,	,	O	O
decreases	VBZ	O	O
HDL	NNP	O	O
cholesterol	NN	O	O
,	,	O	O
and	CC	O	O
is	VBZ	O	O
strongly	RB	O	O
associated	VBN	O	O
with	IN	O	O
a	DT	O	O
higher	JJR	O	O
risk	NN	O	O
of	IN	O	O
cardiovascular	JJ	O	O
disease	NN	O	O
(	(	O	O
CVD	NNP	O	O
)	)	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
changes	NNS	O	O
in	IN	O	O
circulating	VBG	O	O
cholesterol	NN	O	O
can	MD	O	O
not	RB	O	O
explain	VB	O	O
the	DT	O	O
entire	JJ	O	O
effect	NN	O	O
.	.	O	O

Therefore	RB	O	O
,	,	O	O
we	PRP	O	O
studied	VBD	O	O
whether	IN	O	O
iTFA	NN	i	IPM
and	CC	O	O
conjugated	VBD	i	IPM
linoleic	JJ	i	IPM
acid	NN	i	IPM
(	(	i	IPM
CLA	NNP	i	IPM
)	)	i	IPM
affect	VBP	O	O
markers	NNS	o	OPH
of	IN	o	OPH
inflammation	NN	o	OPH
and	CC	o	OPH
oxidative	JJ	o	OPH
stress	NN	o	OPH
.	.	o	O

Sixty-one	CD	p	PSS
healthy	JJ	p	O
adults	NNS	p	PA
consumed	VBD	p	O
each	DT	p	O
of	IN	p	O
3	CD	p	O
diets	NNS	i	IOt
for	IN	p	O
3	CD	p	O
wk	NN	p	O
,	,	O	O
in	IN	O	O
random	JJ	O	O
order	NN	O	O
.	.	O	O

Diets	NNS	O	O
were	VBD	O	O
identical	JJ	O	O
except	IN	O	O
for	IN	O	O
7	CD	O	O
%	NN	O	O
of	IN	O	O
energy	NN	O	O
provided	VBN	O	O
by	IN	O	O
oleic	JJ	i	IC
acid	NN	i	IC
(	(	i	IC
control	VB	i	IC
diet	NN	i	IC
)	)	i	IC
,	,	i	O
iTFA	JJ	i	IPM
,	,	i	O
or	CC	i	O
CLA	NNP	i	IPM
.	.	i	O

At	IN	O	O
the	DT	O	O
end	NN	O	O
of	IN	O	O
the	DT	O	O
3	CD	O	O
wk	NN	O	O
,	,	O	O
we	PRP	O	O
measured	VBD	O	O
plasma	JJ	o	O
inflammatory	JJ	o	O
markers	NNS	o	O
IL-6	NNP	o	O
,	,	o	O
C-reactive	NNP	o	O
protein	NN	o	O
,	,	o	O
tumor	NN	o	O
necrosis	NN	o	O
factor	NN	o	O
receptors	NNS	o	O
I	PRP	o	O
and	CC	o	O
II	NNP	o	O
(	(	o	O
TNF-RI	NNP	o	O
and	CC	o	O
-RII	NNP	o	O
)	)	o	O
,	,	o	O
monocyte	JJ	o	O
chemotactic	JJ	o	O
protein-1	NN	o	O
and	CC	o	O
E-selectin	NNP	o	O
,	,	o	O
and	CC	o	O
urinary	JJ	o	O
8-iso-PGF	NN	o	O
(	(	o	O
2?	CD	o	O
)	)	o	O
,	,	o	O
a	DT	o	O
marker	NN	o	O
of	IN	o	O
lipid	JJ	o	O
peroxidation	NN	o	O
.	.	o	O

Consumption	NN	O	O
of	IN	i	O
iTFA	NN	i	O
caused	VBD	O	O
4	CD	O	O
%	NN	O	O
lower	JJR	o	O
TNF-RI	NNP	o	O
concentrations	NNS	o	O
and	CC	O	O
6	CD	O	O
%	NN	O	O
higher	JJR	o	O
E-selectin	JJ	o	O
concentrations	NNS	o	O
compared	VBN	O	O
with	IN	O	O
oleic	JJ	O	O
acid	NN	O	O
(	(	O	O
control	NN	O	O
)	)	O	O
and	CC	O	O
had	VBD	O	O
no	DT	O	O
significant	JJ	O	O
effect	NN	O	O
on	IN	O	O
other	JJ	o	O
inflammatory	JJ	o	O
markers	NNS	o	O
.	.	o	O

CLA	NNP	O	O
did	VBD	O	O
not	RB	O	O
significantly	RB	O	O
affect	JJ	o	O
inflammatory	NN	o	O
markers	NNS	o	O
.	.	o	O

The	DT	o	O
urine	JJ	o	O
concentration	NN	o	O
of	IN	o	O
8-iso-PGF	JJ	o	O
(	(	o	O
2?	CD	o	O
)	)	o	O
[	NN	o	O
geometric	JJ	O	O
mean	NN	O	O
(	(	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
)	)	O	O
]	NN	O	O
was	VBD	O	O
greater	JJR	O	O
after	IN	O	O
the	DT	O	O
iTFA	NN	O	O
[	VBZ	O	O
0.54	CD	O	O
(	(	O	O
0.48	CD	O	O
,	,	O	O
0.60	CD	O	O
)	)	O	O
nmol/mmol	FW	O	O
creatinine	NN	O	O
]	NN	O	O
and	CC	O	O
the	DT	O	O
CLA	NNP	O	O
[	NNP	O	O
1.2	CD	O	O
(	(	O	O
1.1	CD	O	O
,	,	O	O
1.3	CD	O	O
)	)	O	O
nmol/mmol	FW	O	O
creatinine	NN	O	O
]	NNP	O	O
diet	VBZ	O	O
periods	NNS	O	O
than	IN	O	O
after	IN	O	O
the	DT	O	O
control	NN	O	O
period	NN	O	O
[	VBD	O	O
0.45	CD	O	O
(	(	O	O
0.41	CD	O	O
,	,	O	O
0.50	CD	O	O
)	)	O	O
nmol/mmol	FW	O	O
creatinine	NN	O	O
;	:	O	O
P	NNP	O	O
<	VBD	O	O
0.05	CD	O	O
]	NN	O	O
.	.	O	O

In	IN	O	O
conclusion	NN	O	O
,	,	O	O
high	JJ	O	O
intakes	NNS	O	O
of	IN	O	O
iTFA	NN	i	O
and	CC	i	O
CLA	NNP	i	O
did	VBD	i	O
not	RB	O	O
substantially	RB	O	O
affect	JJ	o	O
plasma	NN	o	O
concentrations	NNS	o	O
of	IN	o	O
inflammatory	JJ	o	O
markers	NNS	o	O
,	,	o	O
but	CC	O	O
they	PRP	O	O
increased	VBD	O	O
the	DT	o	O
urine	JJ	o	O
8-iso-PGF	JJ	o	O
(	(	o	O
2?	CD	o	O
)	)	o	O
concentration	NN	o	O
.	.	o	O

However	RB	o	O
,	,	O	O
it	PRP	O	O
is	VBZ	O	O
unlikely	JJ	O	O
this	DT	O	O
plays	VBZ	O	O
a	DT	O	O
major	JJ	O	O
role	NN	O	O
in	IN	O	O
the	DT	O	O
mechanism	NN	O	O
by	IN	O	O
which	WDT	i	O
iTFA	JJ	i	O
increase	NN	i	O
the	DT	O	O
risk	NN	O	O
of	IN	O	O
CVD	NNP	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
more	JJR	O	O
research	NN	O	O
is	VBZ	O	O
needed	VBN	O	O
to	TO	O	O
fully	RB	O	O
understand	VB	O	O
the	DT	O	O
implications	NNS	O	O
of	IN	O	O
these	DT	O	O
findings	NNS	O	O
.	.	O	O

Wheelchair	NNP	i	IPH
skills	VBZ	i	IPH
training	NN	i	IPH
to	TO	O	O
improve	VB	O	O
confidence	NN	o	OME
with	IN	O	O
using	VBG	O	O
a	DT	O	O
manual	JJ	O	O
wheelchair	NN	O	O
among	IN	O	O
older	JJR	p	PA
adults	NNS	p	PA
:	:	p	O
a	DT	O	O
pilot	NN	O	O
study	NN	O	O
.	.	O	O

OBJECTIVE	NNP	O	O
To	TO	O	O
examine	VB	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
wheelchair	NN	i	IPH
skills	NNS	i	IPH
training	VBG	i	IPH
on	IN	O	O
confidence	NN	o	OME
in	IN	O	O
older	JJR	p	PA
adults	NNS	p	PA
who	WP	p	O
are	VBP	p	O
inexperienced	VBN	p	O
wheelchair	JJ	p	O
users	NNS	p	O
.	.	p	O

DESIGN	NNP	O	O
Parallel	NNP	O	O
group	NN	O	O
,	,	O	O
single-blind	JJ	O	O
randomized	VBD	O	O
controlled	JJ	O	O
trial	NN	O	O
.	.	O	O

SETTING	NNP	O	O
Research	NNP	O	O
laboratory	NN	O	O
in	IN	O	O
a	DT	O	O
rehabilitation	NN	O	O
hospital	NN	O	O
.	.	O	O

PARTICIPANTS	JJ	O	O
Participants	NNS	p	O
(	(	p	O
N=20	NNP	p	PSS
)	)	p	O
who	WP	p	O
were	VBD	p	O
community-living	JJ	p	O
older	JJR	p	PA
adults	NNS	p	PA
at	IN	p	O
least	JJS	p	O
65	CD	p	PA
years	NNS	p	PA
old	JJ	p	PA
(	(	p	O
mean	JJ	p	O
age	NN	p	O
,	,	p	O
70y	CD	p	PA
)	)	p	O
,	,	p	O
50	CD	p	O
%	NN	p	O
women	NNS	p	PSE
,	,	p	O
and	CC	p	O
who	WP	p	O
had	VBD	p	O
no	DT	p	O
experience	NN	p	O
of	IN	p	O
using	VBG	p	O
a	DT	p	O
wheelchair	NN	p	O
were	VBD	O	O
randomly	RB	O	O
allocated	VBN	O	O
to	TO	O	O
an	DT	O	O
intervention	NN	O	O
(	(	O	O
n=10	JJ	O	O
)	)	O	O
or	CC	O	O
control	NN	O	O
(	(	O	O
n=10	JJ	O	O
)	)	O	O
group	NN	O	O
.	.	O	O

INTERVENTIONS	VBZ	O	O
The	DT	O	O
intervention	NN	O	O
group	NN	O	O
received	VBD	O	O
two	CD	i	IPH
1-hour	JJ	i	IPH
training	NN	i	IPH
sessions	NNS	i	IPH
that	WDT	i	IPH
followed	VBD	i	IPH
the	DT	i	IPH
Wheelchair	NNP	i	IPH
Skills	NNP	i	IPH
Training	NNP	i	IPH
Program	NNP	i	IPH
(	(	i	IPH
WSTP	NNP	i	IPH
)	)	i	IPH
protocol	NN	i	IPH
.	.	i	O

The	DT	O	O
control	NN	O	O
group	NN	O	O
received	VBD	O	O
a	DT	O	O
single	JJ	i	IE
socialization	NN	i	IE
contact	NN	i	IE
.	.	i	O

MAIN	NNP	O	O
OUTCOME	NNP	O	O
MEASURE	NNP	O	O
The	DT	O	O
Wheelchair	NNP	o	OME
Use	NNP	o	OME
Confidence	NNP	o	OME
Scale-Manual	JJ	o	OME
(	(	o	OME
WheelCon-M	NNP	o	OME
)	)	o	OME
was	VBD	O	O
used	VBN	O	O
to	TO	O	O
evaluate	VB	o	OME
confidence	NN	o	OME
with	IN	O	O
using	VBG	O	O
a	DT	O	O
manual	JJ	O	O
wheelchair	NN	O	O
.	.	O	O

The	DT	O	O
WheelCon-M	NNP	O	O
is	VBZ	O	O
a	DT	O	O
self-report	JJ	O	O
questionnaire	NN	O	O
that	WDT	O	O
comprises	VBZ	O	O
65	CD	O	O
items	NNS	O	O
in	IN	O	O
6	CD	O	O
conceptual	JJ	O	O
areas	NNS	O	O
.	.	O	O

RESULTS	VB	O	O
A	DT	O	O
1-way	JJ	O	O
between-groups	JJ	O	O
analysis	NN	O	O
of	IN	O	O
covariance	NN	O	O
revealed	VBD	O	O
a	DT	O	O
significant	JJ	o	OME
difference	NN	o	OME
in	IN	O	O
postintervention	NN	o	OOt
WheelCon-M	JJ	o	OOt
scores	NNS	o	OOt
between	IN	O	O
the	DT	O	O
intervention	NN	O	O
and	CC	O	O
control	NN	O	O
groups	NNS	O	O
(	(	O	O
F1,17=10.9	NNP	O	O
,	,	O	O
P=.004	NNP	O	O
)	)	O	O
after	IN	O	O
controlling	VBG	O	O
for	IN	O	O
baseline	JJ	O	O
WheelCon-M	JJ	O	O
scores	NNS	O	O
.	.	O	O

A	DT	O	O
large	JJ	O	O
effect	NN	o	OME
size	NN	o	OME
was	VBD	O	O
also	RB	O	O
observed	VBN	O	O
(	(	O	O
partial	JJ	O	O
?	.	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
=.39	NN	O	O
)	)	O	O
.	.	O	O

Secondary	JJ	O	O
analyses	NNS	O	O
revealed	VBD	O	O
that	IN	O	O
the	DT	O	O
WSTP	NNP	O	O
had	VBD	O	O
greater	JJR	o	O
effects	NNS	o	O
on	IN	o	O
confidence	NN	o	O
in	IN	o	O
areas	NNS	o	O
related	VBN	o	O
to	TO	o	O
maneuvering	VBG	o	O
around	IN	o	O
the	DT	o	O
physical	JJ	o	O
environment	NN	o	O
,	,	o	O
knowledge	NN	o	O
and	CC	o	O
problem	NN	o	O
solving	NN	o	O
,	,	o	O
advocacy	NN	o	O
,	,	o	O
and	CC	o	O
managing	VBG	o	O
emotions	NNS	o	O
than	IN	o	O
in	IN	o	O
areas	NNS	o	O
related	VBN	o	O
to	TO	o	O
performing	VBG	o	O
activities	NNS	o	O
and	CC	o	O
behaving	VBG	o	O
in	IN	o	O
social	JJ	o	O
situations	NNS	o	O
.	.	o	O

CONCLUSION	NNP	O	O
Two	CD	O	O
1-hour	JJ	O	O
WSTP	NNP	O	O
sessions	NNS	O	O
improve	VBP	o	O
confidence	NN	o	O
with	IN	o	O
using	VBG	o	O
a	DT	o	O
manual	JJ	o	O
wheelchair	NN	o	O
among	IN	p	O
older	JJR	p	O
adults	NNS	p	O
who	WP	p	O
are	VBP	p	O
inexperienced	VBN	p	O
wheelchair	JJ	p	O
users	NNS	p	O
.	.	p	O

Effects	NNS	O	O
of	IN	O	O
cognitive-behavioral	JJ	i	IE
therapy	NN	i	IE
on	IN	O	O
anxiety	NN	o	O
in	IN	O	O
children	NNS	p	O
with	IN	p	O
autism	NN	p	O
spectrum	NN	p	O
disorders	NNS	p	O
:	:	p	O
a	DT	O	O
randomized	NN	O	O
controlled	VBN	O	O
trial	NN	O	O
.	.	O	O

We	PRP	O	O
compared	VBN	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
a	DT	O	O
16-week	JJ	O	O
Cognitive-Behavioral	JJ	i	IPS
Therapy	NNP	i	IPS
(	(	i	IPS
CBT	NNP	i	IPS
)	)	i	IPS
program	NN	i	IE
and	CC	i	O
a	DT	i	O
Social	NNP	i	IPS
Recreational	NNP	i	IPS
(	(	i	IPS
SR	NNP	i	IPS
)	)	i	IPS
program	NN	i	IPS
on	IN	O	O
anxiety	NN	O	O
in	IN	O	O
children	NNS	p	O
with	IN	p	O
Autism	NNP	p	O
Spectrum	NNP	p	O
Disorders	NNP	p	O
(	(	p	O
ASD	NNP	p	O
)	)	p	O
.	.	p	O

Seventy	JJ	p	O
children	NNS	p	O
(	(	p	O
9-16	CD	p	O
years	NNS	p	O
old	JJ	p	O
)	)	p	O
were	VBD	O	O
randomly	RB	O	O
assigned	VBN	O	O
to	TO	O	O
either	DT	O	O
of	IN	O	O
the	DT	O	O
programs	NNS	O	O
(	(	O	O
n	FW	O	O
(	(	i	O
CBT	NNP	i	IE
)	)	i	O
=	VBZ	O	O
36	CD	O	O
;	:	O	O
n	NNS	O	O
(	(	O	O
SR	NNP	O	O
)	)	O	O
=	VBP	O	O
34	CD	O	O
)	)	O	O
.	.	O	O

Measures	NNS	O	O
on	IN	O	O
child	NN	O	O
's	POS	O	O
anxiety	NN	O	O
using	VBG	O	O
the	DT	O	O
Spence	NNP	o	OME
Child	NNP	o	OME
Anxiety	NNP	o	OME
Scale	NNP	o	OME
--	:	o	OME
Child	NNP	o	OME
(	(	o	OME
SCAS-C	NNP	o	OME
)	)	o	OME
and	CC	O	O
the	DT	O	O
Clinical	JJ	o	OME
Global	NNP	o	OME
Impression-Severity	NNP	o	OME
scale	NN	o	OME
(	(	o	OME
CGI	NNP	o	OME
--	:	o	OME
S	NNP	o	OME
)	)	o	OME
were	VBD	O	O
administered	VBN	O	O
at	IN	O	O
pre-	JJ	O	O
,	,	O	O
post-treatment	JJ	O	O
,	,	O	O
and	CC	O	O
follow-ups	NNS	O	O
(	(	O	O
3-	CD	O	O
and	CC	O	O
6-month	JJ	O	O
)	)	O	O
.	.	O	O

Children	NNP	O	O
in	IN	O	O
both	DT	O	O
programs	NNS	O	O
showed	VBD	O	O
significantly	RB	O	O
lower	JJR	O	O
levels	NNS	O	O
of	IN	O	O
generalized	VBN	o	OME
anxiety	NN	o	OME
and	CC	o	OME
total	JJ	o	OME
anxiety	NN	o	OME
symptoms	NNS	o	OME
at	IN	O	O
6-month	JJ	O	O
follow-up	NN	O	O
on	IN	O	O
SCAS-C.	NNP	O	O
Clinician	NNP	O	O
ratings	NNS	O	O
on	IN	O	O
the	DT	O	O
CGI-S	NNP	o	OME
demonstrated	VBD	O	O
an	DT	O	O
increase	NN	O	O
in	IN	O	O
the	DT	O	O
percentage	NN	O	O
of	IN	O	O
participants	NNS	O	O
rated	VBN	O	O
as	IN	O	O
Normal	NNP	O	O
and	CC	O	O
Borderline	NNP	O	O
for	IN	O	O
both	DT	O	O
programs	NNS	O	O
.	.	O	O

Findings	NNS	O	O
from	IN	O	O
the	DT	O	O
present	JJ	O	O
study	NN	O	O
suggest	JJS	O	O
factors	NNS	O	O
such	JJ	O	O
as	IN	O	O
regular	JJ	i	O
sessions	NNS	i	O
in	IN	i	O
a	DT	i	O
structured	JJ	i	O
setting	NN	i	O
,	,	i	O
consistent	JJ	i	O
therapists	NNS	i	O
,	,	i	O
social	JJ	i	O
exposure	NN	i	O
and	CC	O	O
the	DT	O	O
use	NN	O	O
of	IN	O	O
autism-friendly	JJ	i	IE
strategies	NNS	i	IE
are	VBP	O	O
important	JJ	O	O
components	NNS	O	O
of	IN	O	O
an	DT	O	O
effective	JJ	O	O
framework	NN	O	O
in	IN	O	O
the	DT	O	O
management	NN	O	O
of	IN	O	O
anxiety	NN	O	O
in	IN	O	O
children	NNS	p	O
and	CC	p	O
adolescents	NNS	p	O
with	IN	p	O
ASD	NNP	p	O
.	.	p	O

A	DT	O	O
comparison	NN	O	O
of	IN	O	O
single-dose	JJ	i	IPM
versus	NN	O	O
conventional-dose	JJ	i	IC
antibiotic	JJ	i	IC
treatment	NN	i	IC
of	IN	O	O
bacteriuria	NN	p	PC
in	IN	p	PC
elderly	JJ	p	PC
women	NNS	p	PC
.	.	p	PC

The	DT	O	O
efficacy	NN	O	O
of	IN	O	O
single-dose	JJ	i	IPM
antibiotic	JJ	i	IPM
therapy	NN	i	IPM
for	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
bacteriuria	NN	p	O
in	IN	p	O
a	DT	p	O
group	NN	p	O
of	IN	p	O
non-catheterized	JJ	p	O
elderly	JJ	p	O
women	NNS	p	O
was	VBD	O	O
compared	VBN	O	O
with	IN	O	O
that	DT	O	O
of	IN	O	O
conventional	JJ	i	IPM
7-10	JJ	i	IPM
day	NN	i	IPM
courses	NNS	i	IPM
of	IN	i	IPM
antibiotic	JJ	i	IPM
therapy	NN	i	IPM
.	.	i	O

Thirty-one	JJ	p	O
women	NNS	p	O
received	VBD	p	O
single-dose	JJ	i	IC
treatment	NN	i	IC
and	CC	p	O
22	CD	p	O
conventional-dose	JJ	i	IC
treatment	NN	i	IC
.	.	i	O

The	DT	O	O
cure	NN	o	OOt
rates	NNS	o	OOt
at	IN	O	O
1	CD	O	O
and	CC	O	O
6	CD	O	O
weeks	NNS	O	O
for	IN	O	O
the	DT	O	O
single-dose	JJ	O	O
treatments	NNS	O	O
were	VBD	O	O
52	CD	O	O
%	NN	O	O
and	CC	O	O
38	CD	O	O
%	NN	O	O
,	,	O	O
respectively	RB	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
cure	NN	o	OOt
rates	NNS	o	OOt
for	IN	O	O
the	DT	O	O
conventional-dose	JJ	O	O
treatments	NNS	O	O
at	IN	O	O
1	CD	O	O
and	CC	O	O
6	CD	O	O
weeks	NNS	O	O
were	VBD	O	O
59	CD	O	O
%	NN	O	O
and	CC	O	O
52	CD	O	O
%	NN	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

It	PRP	O	O
is	VBZ	O	O
concluded	VBN	O	O
that	IN	O	O
there	EX	O	O
may	MD	O	O
be	VB	O	O
a	DT	O	O
place	NN	O	O
for	IN	O	O
the	DT	O	O
use	NN	O	O
of	IN	O	O
single-dose	JJ	i	IPM
antibiotic	JJ	i	IPM
therapy	NN	i	IPM
for	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
selected	VBN	p	O
elderly	JJ	p	O
women	NNS	p	O
with	IN	p	O
bacteriuria	NN	p	O
,	,	O	O
but	CC	O	O
larger	JJR	O	O
studies	NNS	O	O
are	VBP	O	O
needed	VBN	O	O
.	.	O	O

Anticholinergic	NNP	i	IPM
drugs	NNS	i	IPM
:	:	i	O
effects	NNS	O	O
on	IN	O	O
oxygen	NN	o	OPH
consumption	NN	o	OPH
and	CC	o	OPH
energy	NN	o	OPH
expenditure	NN	o	OPH
.	.	o	O

Premedication	NN	O	O
has	VBZ	O	O
been	VBN	O	O
shown	VBN	O	O
to	TO	O	O
affect	VB	O	O
both	DT	O	O
oxygen	NN	o	OPH
consumption	NN	o	OPH
(	(	O	O
VO2	NNP	O	O
)	)	O	O
and	CC	O	O
energy	NN	o	OPH
expenditure	NN	o	OPH
(	(	O	O
EE	NNP	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
metabolic	JJ	O	O
responses	NNS	O	O
to	TO	O	O
anticholinergic	VB	O	O
drugs	NNS	O	O
have	VBP	O	O
not	RB	O	O
been	VBN	O	O
studied	VBN	O	O
.	.	O	O

In	IN	O	O
this	DT	O	O
study	NN	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
anticholinergic	JJ	i	IPM
drugs	NNS	i	IPM
on	IN	O	O
VO2	NNP	O	O
and	CC	O	O
EE	NNP	O	O
(	(	O	O
calculated	VBN	O	O
from	IN	O	O
the	DT	O	O
measured	VBN	O	O
rates	NNS	O	O
of	IN	O	O
VO2	NNP	O	O
and	CC	O	O
carbon	NN	O	O
dioxide	NN	O	O
production	NN	O	O
[	NNP	O	O
VCO2	NNP	O	O
]	NN	O	O
:	:	O	O
EE	NNP	O	O
[	NNP	O	O
kcal/d	NNP	O	O
]	NNP	O	O
=	VBD	O	O
3.581	CD	O	O
x	NNP	O	O
VO2	NNP	O	O
[	NNP	O	O
L/d	NNP	O	O
]	NNP	O	O
+	VBD	O	O
1.448	CD	O	O
x	NNP	O	O
VCO2	NNP	O	O
[	NNP	O	O
L/d	NNP	O	O
]	NNP	O	O
-	:	O	O
32.4	CD	O	O
)	)	O	O
were	VBD	O	O
measured	VBN	O	O
in	IN	O	O
six	CD	p	PSS
healthy	JJ	p	O
female	NN	p	PSE
volunteers	NNS	p	O
.	.	p	O

They	PRP	O	O
were	VBD	O	O
given	VBN	O	O
intramuscular	JJ	O	O
atropine	NN	i	IPM
(	(	O	O
15	CD	O	O
micrograms/kg	NN	O	O
)	)	O	O
,	,	O	O
glycopyrrolate	NN	i	IPM
(	(	O	O
8	CD	O	O
micrograms/kg	NN	O	O
)	)	O	O
,	,	O	O
scopolamine	NN	i	IPM
(	(	O	O
8	CD	O	O
micrograms/kg	NN	O	O
)	)	O	O
,	,	O	O
and	CC	i	O
placebo	NN	i	IC
in	IN	O	O
a	DT	O	O
random	JJ	O	O
double-blind	JJ	O	O
cross-over	NN	O	O
design	NN	O	O
.	.	O	O

The	DT	O	O
consecutive	JJ	O	O
sessions	NNS	O	O
were	VBD	O	O
at	IN	O	O
least	JJS	O	O
1	CD	O	O
wk	JJ	O	O
apart	RB	O	O
for	IN	O	O
each	DT	O	O
subject	NN	O	O
.	.	O	O

VO2	NNP	o	OPH
and	CC	o	OPH
EE	NNP	o	OPH
were	VBD	O	O
measured	VBN	O	O
using	VBG	O	O
an	DT	O	O
indirect	JJ	O	O
calorimetry	NN	O	O
(	(	O	O
Deltatrac	NNP	O	O
)	)	O	O
.	.	O	O

Cardiovascular	JJ	o	OPH
responses	NNS	o	OPH
were	VBD	O	O
assessed	VBN	O	O
using	VBG	O	O
standard	JJ	O	O
noninvasive	JJ	O	O
monitoring	NN	O	O
.	.	O	O

Plasma	NNP	o	OPH
drug	NN	o	OPH
concentrations	NNS	o	OPH
were	VBD	O	O
analyzed	VBN	O	O
using	VBG	O	O
a	DT	O	O
sensitive	JJ	O	O
modification	NN	O	O
of	IN	O	O
radioreceptor	NN	O	O
assay	NN	O	O
.	.	O	O

Subjective	JJ	O	O
responses	NNS	O	O
were	VBD	O	O
measured	VBN	O	O
with	IN	O	O
visual	JJ	o	OPH
analog	NN	o	OPH
scale	NN	o	OPH
(	(	o	OPH
VAS	NNP	o	OPH
)	)	o	OPH
.	.	O	O

Atropine	NNP	i	IPM
and	CC	O	O
glycopyrrolate	NN	i	IPM
induced	VBD	O	O
a	DT	O	O
significant	JJ	O	O
increase	NN	O	O
in	IN	O	O
heart	NN	o	OPH
rate	NN	o	OPH
with	IN	O	O
a	DT	O	O
simultaneous	JJ	O	O
decrease	NN	O	O
in	IN	O	O
pressure	NN	o	OPH
rate	NN	o	OPH
quotient	NN	o	OPH
(	(	o	OPH
PRQ	NNP	o	OPH
)	)	o	OPH
,	,	O	O
while	IN	O	O
scopolamine	NN	O	O
caused	VBD	O	O
a	DT	O	O
significant	JJ	O	O
decrease	NN	O	O
in	IN	O	O
heart	NN	o	OPH
rate	NN	o	OPH
with	IN	O	O
a	DT	O	O
simultaneous	JJ	O	O
increase	NN	o	OPH
in	IN	o	OPH
PRQ	NNP	o	OPH
.	.	o	O

Scopolamine	NNP	i	IPM
significantly	RB	O	O
decreased	VBD	O	O
both	DT	O	O
VO2	NNP	o	OPH
and	CC	o	OPH
EE	NNP	o	OPH
,	,	O	O
whereas	JJ	O	O
glycopyrrolate	NN	i	IPM
increased	VBD	O	O
VO2	NNP	o	OPH
.	.	o	O

Atropine	NNP	i	IPM
had	VBD	O	O
no	DT	O	O
significant	JJ	O	O
effect	NN	O	O
on	IN	O	O
metabolic	JJ	o	OPH
variables	NNS	o	OPH
.	.	o	O

Only	RB	O	O
scopolamine	NN	O	O
induced	JJ	O	O
sedation	NN	o	OPH
in	IN	O	O
this	DT	O	O
study	NN	O	O
.	.	O	O

In	IN	O	O
conclusion	NN	O	O
,	,	O	O
atropine	NN	i	IPM
,	,	i	O
glycopyrrolate	NN	i	IPM
,	,	O	O
and	CC	O	O
scopolamine	NN	i	IPM
differ	NN	O	O
not	RB	O	O
only	RB	O	O
in	IN	O	O
their	PRP$	O	O
cardiovascular	NN	O	O
and	CC	O	O
central	JJ	O	O
nervous	JJ	O	O
system	NN	O	O
effects	NNS	O	O
,	,	O	O
but	CC	O	O
also	RB	O	O
in	IN	O	O
their	PRP$	O	O
effects	NNS	O	O
on	IN	O	O
metabolism	NN	O	O
.	.	O	O

A	DT	O	O
controlled	VBN	O	O
study	NN	O	O
of	IN	O	O
early	JJ	i	IE
discharge	NN	i	IE
after	IN	p	O
uncomplicated	JJ	p	O
myocardial	JJ	p	PC
infarction	NN	p	PC
.	.	p	O

Out	IN	O	O
of	IN	O	O
383	CD	p	PSS
myocardial	JJ	p	PC
infarction	NN	p	PC
(	(	p	PC
MI	NNP	p	PC
)	)	p	PC
patients	NNS	p	O
aged	VBN	p	O
below	IN	p	O
70	CD	p	PA
years	NNS	p	O
,	,	p	O
252	CD	p	PSS
(	(	p	O
66	CD	p	O
%	NN	p	O
)	)	p	O
were	VBD	p	O
judged	VBN	p	O
after	IN	p	O
the	DT	p	O
third	JJ	p	O
day	NN	p	O
in	IN	p	O
hospital	NN	p	O
to	TO	p	O
have	VB	p	O
had	VBN	p	O
uncomplicated	VBN	p	PC
infarctions	NNS	p	PC
.	.	p	O

These	DT	O	O
patients	NNS	O	O
were	VBD	O	O
allocated	VBN	O	O
at	IN	O	O
random	NN	O	O
to	TO	O	O
two	CD	O	O
groups	NNS	O	O
,	,	O	O
one	CD	i	IE
of	IN	i	IE
which	WDT	i	IE
was	VBD	i	IE
given	VBN	i	IE
treatment	NN	i	IE
for	IN	i	IE
8	CD	i	IE
days	NNS	i	IE
and	CC	i	IE
the	DT	i	IE
other	JJ	i	IE
for	IN	i	IE
15	CD	i	IE
days	NNS	i	IE
.	.	i	O

No	DT	O	O
significant	JJ	O	O
differences	NNS	o	O
in	IN	o	O
mortality	NN	o	OMO
,	,	o	O
morbidity	NN	o	OOt
or	CC	o	O
incapacity	NN	o	OPH
for	IN	o	OPH
work	NN	o	OPH
could	MD	O	O
be	VB	O	O
detected	VBN	O	O
during	IN	O	O
the	DT	O	O
three-month	JJ	O	O
period	NN	O	O
of	IN	O	O
follow-up	NN	O	O
.	.	O	O

The	DT	O	O
findings	NNS	O	O
thus	RB	O	O
support	VBP	O	O
previous	JJ	O	O
conclusions	NNS	O	O
that	WDT	O	O
early	RB	i	IE
discharge	VBP	i	IE
from	IN	O	O
hospital	NN	O	O
after	IN	O	O
uncomplicated	JJ	O	O
MI	NNP	O	O
is	VBZ	O	O
not	RB	O	O
associated	VBN	O	O
with	IN	O	O
greater	JJR	O	O
risk	NN	O	O
for	IN	O	O
the	DT	O	O
patient	NN	O	O
than	IN	O	O
later	RB	O	O
discharge	NN	O	O
.	.	O	O

Supplementation	NN	O	O
with	IN	O	O
n3	JJ	i	IPM
fatty	JJ	i	IPM
acid	NN	i	IPM
ethyl	NN	i	IPM
esters	NNS	i	IPM
increases	VBZ	O	O
large	JJ	O	O
and	CC	O	O
small	JJ	O	O
artery	NN	O	O
elasticity	NN	o	OPH
in	IN	O	O
obese	JJ	p	O
adults	NNS	p	O
on	IN	p	O
a	DT	p	O
weight	JJ	p	O
loss	NN	p	O
diet	NN	p	O
.	.	p	O

Increased	VBN	O	O
arterial	JJ	O	O
stiffness	NN	O	O
is	VBZ	O	O
associated	VBN	O	O
with	IN	O	O
enhanced	JJ	O	O
risk	NN	O	O
of	IN	O	O
cardiovascular	JJ	p	O
disease	NN	p	O
in	IN	p	O
obese	JJ	p	O
individuals	NNS	p	O
.	.	p	O

Whether	NNP	O	O
n3	JJ	i	IPM
fatty	RB	i	IPM
acid	JJ	i	IPM
ethyl	NN	i	IPM
ester	NN	i	IPM
(	(	i	IPM
FAEE	NNP	i	IPM
)	)	i	IPM
supplementation	NN	i	IPM
improves	VBZ	O	O
arterial	JJ	O	O
stiffness	NN	O	O
in	IN	O	O
obese	JJ	p	O
participants	NNS	p	O
on	IN	p	O
a	DT	p	O
weight	JJ	p	O
loss	NN	p	O
diet	NN	p	O
has	VBZ	O	O
not	RB	O	O
yet	RB	O	O
been	VBN	O	O
investigated	VBN	O	O
.	.	O	O

The	DT	O	O
objective	NN	O	O
of	IN	O	O
the	DT	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
carry	VB	O	O
out	RP	O	O
a	DT	O	O
12-wk	JJ	O	O
randomized	NN	O	O
,	,	O	O
single-blind	JJ	O	O
trial	NN	O	O
to	TO	O	O
test	VB	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
a	DT	O	O
25	CD	p	O
%	NN	p	O
energy	NN	i	IPH
deficit	NN	i	IPH
weight	VBD	i	IPH
loss	NN	i	IPH
diet	NN	i	IPH
alone	RB	i	O
(	(	i	O
WL	NNP	i	O
)	)	i	O
(	(	p	O
n	JJ	p	O
=	NNP	p	O
12	CD	p	O
)	)	p	O
or	CC	O	O
WL	NNP	i	IOt
plus	CC	i	IPM
4	CD	i	IPM
g/d	NN	i	IPM
Omacor	NNP	i	IPM
(	(	i	O
46	CD	i	IPM
%	NN	i	IPM
EPA	NNP	i	IPM
and	CC	i	O
38	CD	i	IPM
%	NN	i	IPM
DHA	NNP	i	IPM
)	)	i	IPM
supplementation	NN	i	IPM
(	(	i	IPM
WL+FAEE	NNP	i	IPM
)	)	i	IPM
(	(	p	O
n	JJ	p	O
=	NNP	p	O
13	CD	p	O
)	)	p	O
on	IN	O	O
arterial	JJ	O	O
elasticity	NN	O	O
in	IN	O	O
obese	JJ	p	O
adults	NNS	p	O
.	.	p	O

Large	NNP	o	OPH
(	(	o	OPH
C1	NNP	o	OPH
)	)	o	OPH
and	CC	o	OPH
small	JJ	o	OPH
artery	NN	o	OPH
elasticity	NN	o	OPH
(	(	o	OPH
C2	NNP	o	OPH
)	)	o	OPH
were	VBD	O	O
measured	VBN	O	O
by	IN	O	O
pulse	JJ	O	O
contour	NN	O	O
analysis	NN	O	O
of	IN	O	O
the	DT	O	O
radial	JJ	O	O
artery	NN	O	O
.	.	O	O

WL	NNP	O	O
alone	RB	O	O
reduced	VBD	o	O
(	(	O	O
P	NNP	O	O
<	VBZ	O	O
0.05	CD	O	O
in	IN	O	O
all	DT	O	O
)	)	O	O
body	NN	o	OPH
weight	NN	o	OPH
(	(	O	O
-3	CD	O	O
%	NN	O	O
)	)	O	O
,	,	O	O
waist	JJ	o	O
circumference	NN	o	O
(	(	O	O
-4	CD	O	O
%	NN	O	O
)	)	O	O
,	,	O	O
systolic	JJ	o	O
(	(	O	O
-3	CD	O	O
%	NN	O	O
)	)	O	O
and	CC	O	O
diastolic	JJ	o	O
(	(	O	O
-3	CD	O	O
%	NN	O	O
)	)	O	O
blood	NN	o	O
pressures	NNS	o	O
,	,	o	O
cardiac	JJ	o	O
output	NN	o	O
(	(	o	O
-4	CD	o	O
%	NN	o	O
)	)	o	O
,	,	o	O
plasma	JJ	o	O
TG	NNP	o	O
concentration	NN	o	O
(	(	O	O
-25	CD	O	O
%	NN	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
homeostasis	NN	o	O
model	NN	o	O
assessment	NN	o	O
(	(	o	O
HOMA	NNP	o	O
)	)	o	O
score	NN	o	O
(	(	O	O
-12	CD	O	O
%	NN	O	O
)	)	O	O
and	CC	O	O
increased	VBD	o	OPH
plasma	NN	o	OPH
HDL	NNP	o	OPH
cholesterol	NN	o	OPH
(	(	O	O
+9	CD	O	O
%	NN	O	O
)	)	O	O
and	CC	O	O
adiponectin	NN	o	O
(	(	O	O
+18	CD	O	O
%	NN	O	O
)	)	O	O
concentrations	NNS	o	O
.	.	o	O

However	RB	O	O
,	,	O	O
WL	NNP	i	IPH
alone	RB	O	O
did	VBD	O	O
not	RB	O	O
alter	VB	O	O
C1	NNP	O	O
and	CC	O	O
C2	NNP	O	O
.	.	O	O

The	DT	O	O
WL+FAEE	NNP	i	IPM
intervention	NN	i	IPM
significantly	RB	o	O
reduced	VBN	o	O
body	NN	o	O
weight	NN	o	O
(	(	O	O
-4	CD	O	O
%	NN	O	O
)	)	O	O
,	,	O	O
waist	JJ	o	O
circumference	NN	o	O
(	(	O	O
-4	CD	O	O
%	NN	O	O
)	)	O	O
,	,	O	O
systolic	JJ	o	OPH
(	(	O	O
-8	CD	O	O
%	NN	O	O
)	)	O	O
and	CC	O	O
diastolic	JJ	o	OPH
(	(	O	O
-5	CD	O	O
%	NN	O	O
)	)	O	O
blood	NN	o	O
pressures	NNS	o	O
,	,	o	O
pulse	JJ	o	OPH
pressure	NN	o	OPH
(	(	O	O
-5	CD	O	O
%	NN	O	O
)	)	O	O
,	,	O	O
heart	NN	o	O
rate	NN	o	O
(	(	O	O
-8	CD	O	O
%	NN	O	O
)	)	O	O
,	,	O	O
plasma	JJ	o	OPH
TG	NNP	o	OPH
concentration	NN	o	OPH
(	(	O	O
-36	CD	O	O
%	NN	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
HOMA	NNP	o	O
score	NN	o	O
(	(	O	O
-12	CD	O	O
%	NN	O	O
)	)	O	O
and	CC	O	O
increased	JJ	o	OPH
stroke	NN	o	OPH
volume	NN	o	OPH
(	(	O	O
+3	CD	O	O
%	NN	O	O
)	)	O	O
,	,	O	O
plasma	JJ	o	O
HDL	NNP	o	O
cholesterol	NN	o	O
(	(	O	O
+6	CD	O	O
%	NN	O	O
)	)	O	O
and	CC	O	O
adiponectin	JJ	o	O
concentrations	NNS	o	O
(	(	O	O
+28	CD	O	O
%	NN	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
C1	NNP	o	O
(	(	O	O
+20	NNP	O	O
%	NN	O	O
)	)	O	O
and	CC	O	O
C2	NNP	o	O
(	(	O	O
+22	NNP	O	O
%	NN	O	O
)	)	O	O
artery	NN	o	O
elasticity	NN	o	O
.	.	o	O

The	DT	O	O
changes	NNS	O	O
in	IN	O	O
systolic	JJ	o	OPH
blood	NN	o	OPH
pressure	NN	o	OPH
,	,	o	O
heart	NN	o	OPH
rate	NN	o	OPH
,	,	o	O
plasma	NN	o	OPH
TGs	NNP	o	OPH
,	,	o	O
C1	NNP	o	OPH
,	,	o	O
and	CC	o	O
C2	NNP	o	OPH
were	VBD	O	O
significantly	RB	o	O
greater	JJR	o	O
in	IN	O	O
the	DT	O	O
WL+FAEE	NNP	i	IPM
group	NN	O	O
than	IN	O	O
in	IN	O	O
the	DT	O	O
WL	NNP	i	IPH
group	NN	O	O
.	.	O	O

Supplementation	NN	O	O
with	IN	O	O
n3	JJ	i	IPM
FAEEs	NNP	i	IPM
improves	VBZ	O	O
C1	NNP	o	OPH
and	CC	o	O
C2	NNP	o	OPH
independently	RB	O	O
of	IN	O	O
weight	JJ	o	OPH
loss	NN	o	OPH
in	IN	O	O
obese	JJ	p	O
adults	NNS	p	O
.	.	p	O

Aerobic	NNP	i	IE
and	CC	i	IE
strength	NN	i	IE
training	NN	i	IE
reduces	NNS	O	O
adiposity	NN	o	OPH
in	IN	O	O
overweight	JJ	p	PC
Latina	NNP	p	O
adolescents	NNS	p	PA
.	.	p	O

PURPOSE	NNP	O	O
To	TO	O	O
date	NN	O	O
,	,	O	O
no	DT	O	O
study	NN	O	O
has	VBZ	O	O
examined	VBN	O	O
the	DT	O	O
synergistic	JJ	O	O
effects	NNS	O	O
of	IN	O	O
a	DT	O	O
nutrition	NN	i	IPM
and	CC	O	O
combination	NN	i	IE
of	IN	i	IE
aerobic	JJ	i	IE
and	CC	i	IE
strength	NN	i	IE
training	NN	i	IE
(	(	i	IE
CAST	NNP	i	IE
)	)	i	IE
on	IN	O	O
both	DT	O	O
adiposity	NN	o	OPH
and	CC	o	O
metabolic	JJ	o	OPH
parameters	NNS	o	OPH
in	IN	O	O
overweight	JJ	p	O
Latina	NNP	p	O
adolescent	NN	p	O
females	NNS	p	PSE
.	.	p	O

The	DT	O	O
goal	NN	O	O
was	VBD	O	O
to	TO	O	O
assess	VB	O	O
if	IN	O	O
a	DT	O	O
16-wk	JJ	O	O
nutrition	NN	i	IPM
plus	CC	O	O
CAST	NNP	i	IE
pilot	NN	O	O
study	NN	O	O
had	VBD	O	O
stronger	JJR	O	O
effects	NNS	O	O
on	IN	O	O
reducing	VBG	O	O
adiposity	NN	o	OPH
and	CC	O	O
on	IN	O	O
improving	VBG	O	O
glucose/insulin	NN	o	OPH
indices	NNS	o	OPH
compared	VBN	O	O
with	IN	O	O
control	NN	O	O
(	(	O	O
C	NNP	O	O
)	)	O	O
,	,	O	O
nutrition	NN	i	IPM
only	RB	i	O
(	(	O	O
N	NNP	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
a	DT	O	O
nutrition	NN	i	IPM
plus	CC	O	O
strength	NN	i	IPH
training	NN	i	IPH
(	(	O	O
N	NNP	O	O
+	NNP	O	O
ST	NNP	O	O
)	)	O	O
groups	NNS	O	O
.	.	O	O

METHODS	NNP	O	O
In	IN	O	O
a	DT	O	O
16-wk	JJ	O	O
randomized	JJ	O	O
trial	NN	O	O
,	,	O	O
41	CD	p	PSS
overweight	JJ	p	PC
Latina	NNP	p	O
girls	NNS	p	PSE
(	(	p	O
15.2	CD	p	PA
+/-	JJ	p	PA
1.1	CD	p	PA
yr	NN	p	PA
)	)	p	O
were	VBD	O	O
randomly	RB	O	O
assigned	VBN	O	O
to	TO	O	O
C	NNP	i	IPM
(	(	O	O
n	JJ	O	O
=	NNP	O	O
7	CD	O	O
)	)	O	O
,	,	O	O
N	NNP	i	IPM
(	(	O	O
n	JJ	O	O
=	NNP	O	O
10	CD	O	O
)	)	O	O
,	,	O	O
N	NNP	i	IPM
+	NNP	i	IPM
ST	NNP	i	IPM
(	(	O	O
n	JJ	O	O
=	NNP	O	O
9	CD	O	O
)	)	O	O
,	,	O	O
or	CC	O	O
N	NNP	i	IPM
+	NNP	i	IPM
CAST	NNP	i	IPM
(	(	O	O
n	JJ	O	O
=	NNP	O	O
15	CD	O	O
)	)	O	O
.	.	O	O

All	DT	O	O
intervention	NN	O	O
groups	NNS	O	O
received	VBD	O	O
modified	JJ	i	IPM
carbohydrate	NN	i	IPM
nutrition	NN	i	IPM
classes	NNS	i	IPM
(	(	O	O
once	RB	O	O
a	DT	O	O
week	NN	O	O
)	)	O	O
,	,	O	O
whereas	IN	O	O
the	DT	O	O
N	NNP	i	IPM
+	NNP	i	IPM
ST	NNP	i	IPM
also	RB	O	O
received	VBD	i	IE
strength	NN	i	IE
training	NN	i	IE
(	(	O	O
twice	RB	O	O
a	DT	O	O
week	NN	O	O
)	)	O	O
and	CC	O	O
the	DT	O	O
N	NNP	i	IPM
+	NNP	i	IPM
CAST	NNP	i	IPM
received	VBD	O	O
a	DT	i	O
combination	NN	i	IE
of	IN	i	IE
strength	NN	i	IE
and	CC	i	IE
aerobic	JJ	i	IE
training	NN	i	IE
(	(	O	O
twice	RB	O	O
a	DT	O	O
week	NN	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
following	VBG	O	O
were	VBD	O	O
measured	VBN	O	O
before	IN	O	O
and	CC	O	O
after	IN	O	O
intervention	NN	O	O
:	:	O	O
strength	NN	o	OPH
by	IN	O	O
one	CD	O	O
repetition	NN	O	O
maximum	NN	O	O
,	,	O	O
physical	JJ	o	OME
activity	NN	o	OME
by	IN	o	OME
the	DT	o	OME
7-d	JJ	o	OME
accelerometry	NN	o	OME
and	CC	O	O
the	DT	O	O
3-d	JJ	o	OME
physical	JJ	o	OME
activity	NN	o	OME
recall	NN	o	OME
,	,	o	O
dietary	JJ	o	OME
intake	NN	o	OME
by	IN	o	O
3-d	JJ	o	O
records	NNS	o	O
,	,	o	O
body	NN	o	OPH
composition	NN	o	OPH
by	IN	O	O
dual-energy	JJ	O	O
x-ray	JJ	O	O
absorptiometry	NN	O	O
(	(	O	O
DEXA	NNP	O	O
)	)	O	O
,	,	O	O
glucose/insulin	JJ	o	OPH
indices	NNS	o	OPH
by	IN	O	O
oral	JJ	O	O
glucose	JJ	O	O
tolerance	NN	O	O
test	NN	O	O
,	,	O	O
and	CC	O	O
intravenous	JJ	o	O
glucose	JJ	o	O
tolerance	NN	o	O
test	NN	o	O
with	IN	O	O
minimal	JJ	O	O
modeling	NN	O	O
.	.	O	O

Across	IN	O	O
intervention	NN	O	O
group	NN	O	O
,	,	O	O
effects	NNS	O	O
were	VBD	O	O
tested	VBN	O	O
using	VBG	O	O
ANCOVA	NNP	O	O
with	IN	O	O
post	NN	O	O
hoc	NN	O	O
pairwise	NN	O	O
comparisons	NNS	O	O
.	.	O	O

RESULTS	VB	O	O
There	EX	O	O
were	VBD	O	O
significant	JJ	O	O
overall	JJ	O	O
intervention	NN	O	O
effects	NNS	O	O
for	IN	O	O
all	DT	O	O
adiposity	NN	o	OPH
measures	NNS	o	O
(	(	o	O
weight	NN	o	OPH
,	,	o	O
body	NN	o	OPH
mass	NN	o	OPH
index	NN	o	OPH
[	NNP	o	OPH
BMI	NNP	o	OPH
]	NNP	o	OPH
,	,	o	O
BMI	NNP	o	OPH
z-scores	NNS	o	OPH
,	,	o	O
and	CC	o	O
DEXA	NNP	o	OPH
total	VBP	o	OPH
body	NN	o	OPH
fat	NN	o	OPH
)	)	o	O
,	,	O	O
with	IN	O	O
a	DT	O	O
decrease	NN	O	O
of	IN	O	O
3	CD	O	O
%	NN	O	O
in	IN	O	O
the	DT	O	O
N	NNP	i	IPM
+	NNP	i	IPM
CAST	NNP	i	IPM
group	NN	O	O
compared	VBN	O	O
with	IN	O	O
a	DT	O	O
3	CD	O	O
%	NN	O	O
increase	NN	O	O
in	IN	O	O
the	DT	O	O
N	NNP	i	IPM
+	NNP	i	IPM
ST	NNP	i	IPM
group	NN	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
or	CC	O	O
=	VB	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

There	EX	O	O
was	VBD	O	O
also	RB	O	O
an	DT	O	O
intervention	NN	O	O
effect	NN	O	O
for	IN	O	O
fasting	VBG	o	OPH
glucose	NN	o	OPH
with	IN	O	O
the	DT	O	O
N	NNP	i	IPM
group	NN	O	O
increasing	VBG	O	O
by	IN	O	O
3	CD	O	O
%	NN	O	O
and	CC	O	O
the	DT	O	O
N	NNP	i	IPM
+	NNP	i	IPM
CAST	NNP	i	IPM
group	NN	O	O
decreasing	VBG	O	O
by	IN	O	O
4	CD	O	O
%	NN	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
or	CC	O	O
=	VB	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

CONCLUSION	VB	O	O
The	DT	O	O
CAST	NNP	i	IPM
was	VBD	O	O
more	RBR	O	O
effective	JJ	O	O
than	IN	O	O
nutrition	NN	i	IPM
alone	RB	O	O
or	CC	O	O
nutrition	JJ	i	IPM
plus	CC	O	O
strength	NN	i	IE
training	NN	i	IE
for	IN	O	O
reducing	VBG	O	O
multiple	JJ	o	OPH
adiposity	NN	o	OPH
outcomes	NNS	o	OPH
and	CC	o	O
fasting	VBG	o	OPH
glucose	NN	o	OPH
in	IN	O	O
overweight	JJ	p	PC
Latina	NNP	p	O
girls	NNS	p	PSE
.	.	p	O

However	RB	O	O
,	,	O	O
further	JJ	O	O
research	NN	O	O
investigating	NN	O	O
and	CC	O	O
identifying	VBG	O	O
intervention	NN	O	O
approaches	NNS	O	O
that	WDT	O	O
improve	VBP	O	O
both	DT	O	O
adiposity	NN	o	OPH
and	CC	o	O
insulin	NN	o	OPH
indices	NNS	o	OPH
,	,	O	O
particularly	RB	O	O
in	IN	O	O
high-risk	JJ	O	O
populations	NNS	O	O
,	,	O	O
are	VBP	O	O
warranted	VBN	O	O
.	.	O	O

A	DT	O	O
randomised	JJ	O	O
open	JJ	O	O
multicentre	NN	O	O
comparative	JJ	O	O
trial	NN	O	O
of	IN	O	O
lamotrigine	NN	i	IPM
and	CC	i	O
carbamazepine	NN	i	IPM
as	IN	O	O
monotherapy	NN	O	O
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
newly	RB	p	O
diagnosed	VBN	p	O
or	CC	p	O
recurrent	JJ	p	O
epilepsy	NN	p	O
.	.	p	O

The	DT	O	O
efficacy	NN	o	OOt
and	CC	o	OOt
safety	NN	o	OOt
of	IN	O	O
lamotrigine	NN	i	IPM
and	CC	i	O
carbamazepine	NN	i	IPM
as	IN	O	O
monotherapy	NN	O	O
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
untreated	JJ	p	O
,	,	p	O
newly	RB	p	O
diagnosed	VBN	p	O
or	CC	p	O
recurrent	JJ	p	O
partial	JJ	p	O
and/or	NN	p	O
generalised	VBD	p	O
tonic-clonic	JJ	p	O
seizures	NNS	p	O
,	,	O	O
were	VBD	O	O
compared	VBN	O	O
in	IN	O	O
a	DT	O	O
randomised	JJ	O	O
,	,	O	O
open	JJ	O	O
,	,	O	O
multicentre	JJ	O	O
study	NN	O	O
.	.	O	O

Patients	NNS	O	O
received	VBD	O	O
24	CD	O	O
weeks	NNS	O	O
'	POS	O	O
treatment	NN	O	O
with	IN	O	O
oral	JJ	i	IPM
lamotrigine	NN	i	IPM
100	CD	i	IPM
mg	NN	i	IPM
(	(	i	IPM
LTG	NNP	i	IPM
100	CD	i	IPM
,	,	i	IPM
n	RB	i	IPM
=	VBZ	i	IPM
115	CD	i	IPM
)	)	i	IPM
or	CC	i	O
200	CD	i	IPM
mg	NN	i	IPM
(	(	i	IPM
LTG	NNP	i	IPM
200	CD	i	IPM
,	,	i	IPM
n	RB	i	IPM
=	VBZ	i	IPM
111	CD	i	IPM
)	)	i	IPM
or	CC	i	O
carbamazepine	$	i	IPM
600	CD	i	IPM
mg	NN	i	IPM
(	(	i	IPM
CBZ	NNP	i	IPM
600	CD	O	O
,	,	O	O
n	RB	O	O
=	VBZ	O	O
117	CD	O	O
)	)	O	O
.	.	O	O

Efficacy	NN	o	OOt
measurements	NNS	o	OOt
were	VBD	O	O
comparable	JJ	O	O
between	IN	O	O
the	DT	O	O
three	CD	O	O
treatment	NN	O	O
groups	NNS	O	O
,	,	O	O
although	IN	O	O
the	DT	O	O
higher	JJR	O	O
lamotrigine	NN	i	IPM
dose	NN	O	O
was	VBD	O	O
possibly	RB	O	O
most	RBS	O	O
effective	JJ	O	O
,	,	O	O
with	IN	O	O
60.4	CD	O	O
%	NN	O	O
completing	VBG	O	O
seizure	NN	O	O
free	JJ	O	O
compared	VBN	O	O
with	IN	O	O
51.3	CD	O	O
%	NN	O	O
(	(	O	O
LTG	NNP	O	O
100	CD	O	O
)	)	O	O
and	CC	O	O
54.7	CD	O	O
%	NN	O	O
(	(	O	O
CBZ	NNP	O	O
600	CD	O	O
)	)	O	O
.	.	O	O

Both	DT	O	O
dosage	NN	O	O
regimens	NNS	O	O
of	IN	O	O
lamotrigine	NN	i	IPM
were	VBD	O	O
well	RB	O	O
tolerated	VBN	o	OOt
.	.	o	OOt

More	JJR	O	O
patients	NNS	p	O
on	IN	p	O
CBZ	NNP	i	IPM
600	CD	p	O
reported	VBD	O	O
adverse	JJ	o	OA
experiences	NNS	o	OA
,	,	O	O
66	CD	O	O
%	NN	O	O
versus	IN	O	O
53	CD	O	O
%	NN	O	O
(	(	i	O
LTG	NNP	i	IPM
100	CD	O	O
)	)	O	O
and	CC	O	O
58	CD	O	O
%	NN	O	O
(	(	i	O
LTG	NNP	i	IPM
200	CD	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
of	IN	O	O
these	DT	O	O
a	DT	O	O
greater	JJR	O	O
proportion	NN	O	O
were	VBD	O	O
attributed	VBN	O	O
to	TO	O	O
CBZ	NNP	i	IPM
600	CD	O	O
treatment	NN	O	O
,	,	O	O
53	CD	O	O
%	NN	O	O
versus	IN	O	O
23	CD	O	O
%	NN	O	O
(	(	O	O
LTG	NNP	O	O
100	CD	O	O
)	)	O	O
and	CC	O	O
28	CD	O	O
%	NN	O	O
(	(	O	O
LTG	NNP	O	O
200	CD	O	O
)	)	O	O
.	.	O	O

Similarly	RB	O	O
,	,	O	O
a	DT	O	O
greater	JJR	O	O
proportion	NN	O	O
of	IN	O	O
the	DT	O	O
CBZ	NNP	i	IPM
600	CD	O	O
group	NN	O	O
required	VBD	O	O
a	DT	O	O
change	NN	O	O
in	IN	O	O
dose	NN	O	O
,	,	O	O
47	CD	O	O
%	NN	O	O
versus	IN	O	O
20	CD	O	O
%	NN	O	O
(	(	i	O
LTG	NNP	i	IPM
100	CD	O	O
)	)	O	O
and	CC	O	O
17	CD	O	O
%	NN	O	O
(	(	i	O
LTG	NNP	i	IPM
200	CD	O	O
)	)	O	O
or	CC	O	O
withdrew	$	O	O
completely	RB	O	O
due	JJ	O	O
to	TO	O	O
adverse	JJ	o	OA
experiences	NNS	o	OA
,	,	O	O
10.3	CD	O	O
%	NN	O	O
versus	IN	O	O
4.3	CD	O	O
%	NN	O	O
(	(	i	O
LTG	NNP	i	IPM
100	CD	O	O
)	)	O	O
and	CC	O	O
4.5	CD	O	O
%	NN	O	O
(	(	i	O
LTG	NNP	i	IPM
200	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
most	RBS	O	O
common	JJ	O	O
adverse	JJ	o	OA
experience	NN	o	OA
leading	VBG	O	O
to	TO	O	O
withdrawal	VB	O	O
was	VBD	O	O
rash	NN	o	OA
,	,	O	O
with	IN	O	O
approximately	RB	O	O
double	JJ	O	O
the	DT	O	O
proportion	NN	O	O
of	IN	O	O
reports	NNS	O	O
occurring	VBG	O	O
in	IN	O	O
patients	NNS	O	O
on	IN	O	O
CBZ	NNP	i	IPM
600	CD	O	O
(	(	O	O
5.1	CD	O	O
%	NN	O	O
)	)	O	O
compared	VBN	O	O
with	IN	O	O
lamotrigine	NN	i	IPM
(	(	O	O
1.7	CD	O	O
%	NN	O	O
on	IN	O	O
LTG	NNP	i	IPM
100	CD	O	O
and	CC	O	O
2.7	CD	O	O
%	NN	O	O
on	IN	O	O
LTG	NNP	i	IPM
200	CD	O	O
)	)	O	O
.	.	O	O

Overall	JJ	O	O
lamotrigine	NN	i	IPM
appeared	VBD	O	O
equally	RB	O	O
effective	JJ	O	O
but	CC	O	O
better	RB	O	O
tolerated	VBD	O	O
compared	VBN	O	O
with	IN	O	O
carbamazepine	NN	i	IPM
.	.	i	O

Unpacking	VBG	O	O
attitude	JJ	p	O
certainty	NN	p	O
:	:	p	O
attitude	NN	O	O
clarity	NN	O	O
and	CC	O	O
attitude	NN	O	O
correctness	NN	O	O
.	.	O	O

Attitude	NNP	p	O
certainty	NN	p	O
has	VBZ	O	O
been	VBN	O	O
the	DT	O	O
subject	NN	O	O
of	IN	O	O
considerable	JJ	O	O
attention	NN	O	O
in	IN	O	O
the	DT	O	O
attitudes	NNS	O	O
and	CC	O	O
persuasion	NN	O	O
literature	NN	O	O
.	.	O	O

The	DT	O	O
present	JJ	O	O
research	NN	O	O
identifies	VBZ	O	O
2	CD	O	O
aspects	NNS	O	O
of	IN	O	O
attitude	NN	p	O
certainty	NN	p	O
and	CC	O	O
provides	VBZ	O	O
evidence	NN	O	O
for	IN	O	O
the	DT	O	O
distinctness	NN	O	O
of	IN	O	O
the	DT	O	O
constructs	NNS	O	O
.	.	O	O

Specifically	RB	O	O
,	,	O	O
it	PRP	O	O
is	VBZ	O	O
proposed	VBN	O	O
that	IN	O	O
attitude	JJ	O	O
certainty	NN	O	O
can	MD	O	O
be	VB	O	O
conceptualized	VBN	O	O
,	,	O	O
and	CC	O	O
empirically	RB	O	O
separated	VBN	O	O
,	,	O	O
in	IN	O	O
terms	NNS	O	O
of	IN	O	O
attitude	NN	O	O
clarity	NN	O	O
(	(	O	O
the	DT	O	O
subjective	NN	O	O
sense	NN	O	O
that	WDT	O	O
one	CD	O	O
knows	VBZ	O	O
what	WP	O	O
one	CD	O	O
's	POS	O	O
attitude	NN	O	O
is	VBZ	O	O
)	)	O	O
and	CC	O	O
attitude	JJ	O	O
correctness	NN	O	O
(	(	O	O
the	DT	O	O
subjective	NN	O	O
sense	NN	O	O
that	IN	O	O
one	CD	O	O
's	POS	O	O
attitude	NN	O	O
is	VBZ	O	O
correct	JJ	O	O
or	CC	O	O
valid	JJ	O	O
)	)	O	O
.	.	O	O

Experiment	JJ	O	O
1	CD	O	O
uses	NNS	O	O
factor	NN	p	O
analysis	NN	p	O
and	CC	p	O
correlational	JJ	p	O
data	NNS	p	O
to	TO	O	O
provide	VB	O	O
evidence	NN	O	O
for	IN	O	O
viewing	VBG	O	O
attitude	JJ	o	OME
clarity	NN	o	OME
and	CC	O	O
attitude	NN	o	OME
correctness	NN	o	OME
as	IN	O	O
separate	JJ	O	O
constructs	NNS	O	O
.	.	O	O

Experiments	NNS	O	O
2	CD	O	O
and	CC	O	O
3	CD	O	O
demonstrate	NN	O	O
that	WDT	O	O
attitude	VBP	o	OME
clarity	NN	o	OME
and	CC	o	O
attitude	NN	o	OME
correctness	NN	o	OME
can	MD	o	O
have	VB	o	O
distinct	JJ	o	O
antecedents	NNS	o	O
(	(	o	O
repeated	VBN	o	O
expression	NN	o	O
and	CC	o	O
consensus	NN	o	O
feedback	NN	o	O
,	,	o	O
respectively	RB	o	O
)	)	o	O
.	.	o	O

Experiment	JJ	O	O
4	CD	O	O
reveals	NNS	O	O
that	IN	O	O
these	DT	O	O
constructs	NNS	O	O
each	DT	O	O
play	VBP	o	OME
an	DT	o	OME
independent	JJ	o	OME
role	NN	o	OME
in	IN	o	OME
persuasion	NN	o	OME
and	CC	o	OME
resistance	NN	o	OME
situations	NNS	o	OME
.	.	o	O

As	IN	O	O
clarity	NN	o	O
and	CC	o	O
correctness	JJ	o	O
increase	NN	o	O
,	,	o	O
attitudes	VBZ	o	OME
become	VBP	o	OME
more	RBR	o	OME
resistant	JJ	o	OME
to	TO	O	O
counterattitudinal	JJ	O	O
persuasive	JJ	O	O
messages	NNS	O	O
.	.	O	O

These	DT	O	O
findings	NNS	O	O
are	VBP	O	O
discussed	VBN	O	O
in	IN	O	O
relation	NN	O	O
to	TO	O	O
the	DT	O	O
existing	VBG	p	O
attitude	NN	p	O
strength	NN	p	O
literature	NN	O	O
.	.	O	O

Benefits	NNS	O	O
of	IN	O	O
adding	VBG	O	O
fluticasone	NN	i	IPM
propionate/salmeterol	NN	i	IPM
to	TO	O	O
tiotropium	VB	i	IPM
in	IN	O	O
moderate	JJ	p	PC
to	TO	p	PC
severe	VB	p	PC
COPD	NNP	p	PC
.	.	p	O

BACKGROUND	NNP	O	O
Combining	NNP	O	O
maintenance	NN	O	O
medications	NNS	O	O
with	IN	O	O
different	JJ	O	O
mechanisms	NNS	O	O
of	IN	O	O
action	NN	O	O
may	MD	O	O
improve	VB	O	O
outcomes	NNS	O	O
in	IN	O	O
COPD	NNP	O	O
.	.	O	O

In	IN	O	O
this	DT	O	O
study	NN	O	O
we	PRP	O	O
evaluated	VBD	O	O
the	DT	O	O
efficacy	NN	o	OOt
and	CC	o	OOt
safety	NN	o	OOt
of	IN	O	O
fluticasone/salmeterol	NN	i	IPM
(	(	i	IPM
FSC	NNP	i	IPM
)	)	i	IPM
(	(	O	O
250/50	CD	O	O
mcg	NN	O	O
twice	RB	O	O
daily	RB	O	O
)	)	O	O
when	WRB	O	O
added	VBN	O	O
to	TO	i	O
tiotropium	VB	i	IPM
(	(	O	O
18	CD	O	O
mcg	NN	O	O
once	RB	O	O
daily	RB	i	O
)	)	i	O
(	(	i	O
TIO	NNP	O	O
)	)	O	O
in	IN	O	O
subjects	NNS	p	O
with	IN	p	O
symptomatic	JJ	p	O
moderate	NN	p	O
to	TO	p	O
severe	VB	p	O
COPD	NNP	p	O
.	.	p	O

METHODS	NNP	O	O
This	DT	O	O
was	VBD	O	O
a	DT	O	O
24-week	JJ	O	O
,	,	O	O
randomized	VBN	O	O
,	,	O	O
double-blind	JJ	O	O
,	,	O	O
parallel	JJ	O	O
group	NN	O	O
,	,	O	O
multi-center	NN	O	O
study	NN	p	O
.	.	p	O

Subjects	VBZ	p	O
40	CD	p	O
years	NNS	p	O
or	CC	p	O
older	JJR	p	O
with	IN	p	O
cigarette	NN	p	O
smoking	VBG	p	O
history	NN	p	O
?10	JJ	p	O
pack-years	NNS	p	O
and	CC	p	O
with	IN	p	O
the	DT	p	O
diagnosis	NN	p	O
of	IN	p	O
COPD	NNP	p	O
and	CC	p	O
post-bronchodilator	NN	p	O
FEV	NNP	p	O
(	(	p	O
1	CD	p	O
)	)	p	O
?40	NN	p	O
to	TO	p	O
?	.	p	O
80	CD	p	O
%	NN	p	O
of	IN	p	O
predicted	VBN	p	O
normal	JJ	p	O
and	CC	p	O
FEV	NNP	p	O
(	(	p	O
1	CD	p	O
)	)	p	O
/FVC	NN	p	O
of	IN	p	O
?0.70	NN	p	O
were	VBD	p	O
enrolled	VBN	p	O
.	.	p	O

Following	VBG	O	O
a	DT	O	O
4-week	JJ	O	O
treatment	NN	O	O
with	IN	O	O
open-label	JJ	O	O
TIO	NNP	i	O
18	CD	i	O
mcg	NN	i	O
once	RB	O	O
daily	JJ	O	O
,	,	O	O
subjects	NNS	O	O
were	VBD	O	O
randomized	VBN	O	O
in	IN	O	O
a	DT	O	O
double-blind	JJ	O	O
fashion	NN	O	O
to	TO	O	O
either	VB	O	O
the	DT	O	O
addition	NN	O	O
of	IN	O	O
FSC	NNP	O	O
250/50	CD	O	O
DISKUS	NNP	O	O
twice	RB	O	O
daily	RB	O	O
or	CC	O	O
matching	VBG	O	O
placebo	NN	O	O
.	.	O	O

The	DT	O	O
primary	JJ	O	O
efficacy	NN	O	O
endpoint	NN	O	O
was	VBD	o	O
AM	NNP	o	O
pre-dose	JJ	o	O
FEV	NNP	o	O
(	(	o	O
1	CD	o	O
)	)	o	O
and	CC	o	O
secondary	JJ	O	O
endpoints	NNS	O	O
included	VBD	O	O
other	JJ	o	O
measures	NNS	o	O
of	IN	o	O
lung	NN	o	O
function	NN	o	O
,	,	o	O
rescue	NN	o	O
albuterol	NN	o	O
use	NN	o	O
,	,	o	O
health	NN	o	O
status	NN	o	O
and	CC	o	O
exacerbations	NNS	o	O
.	.	o	O

RESULTS	VB	o	O
The	DT	o	O
addition	NN	O	O
of	IN	O	O
FSC	NNP	i	O
to	TO	i	O
TIO	NNP	O	O
significantly	RB	o	O
improved	VBD	o	O
lung	JJ	o	O
function	NN	o	O
indices	NNS	o	O
including	VBG	o	O
AM	NNP	o	O
pre-dose	JJ	o	O
FEV	NNP	o	O
(	(	o	O
1	CD	o	O
)	)	o	O
,	,	o	O
2	CD	o	O
h	NN	o	O
post-dose	JJ	o	O
FEV	NNP	o	O
(	(	o	O
1	CD	o	O
)	)	o	O
,	,	o	O
AM	NNP	o	O
pre-dose	JJ	o	O
FVC	NNP	o	O
,	,	o	O
2	CD	o	O
h	NN	o	O
post-dose	JJ	o	O
FVC	NNP	o	O
and	CC	o	O
AM	NNP	o	O
pre-dose	JJ	o	O
IC	NNP	o	O
compared	VBN	O	O
with	IN	O	O
TIO	NNP	O	O
alone	RB	O	O
.	.	O	O

Furthermore	RB	O	O
,	,	O	O
this	DT	O	O
combination	NN	O	O
was	VBD	O	O
superior	JJ	O	O
to	TO	O	O
TIO	VB	O	O
alone	RB	O	O
in	IN	O	O
reducing	VBG	o	O
rescue	NN	o	OOt
albuterol	NN	o	OOt
use	NN	o	OOt
.	.	o	O

However	RB	o	O
,	,	O	O
there	EX	O	O
were	VBD	O	O
no	DT	O	O
significant	JJ	O	O
differences	NNS	O	O
between	IN	O	O
the	DT	O	O
treatment	NN	O	O
groups	NNS	o	O
in	IN	o	O
health	NN	o	O
status	NN	o	O
or	CC	o	O
COPD	NNP	o	O
exacerbations	NNS	o	O
.	.	o	O

The	DT	o	O
incidence	NN	o	O
of	IN	O	O
adverse	JJ	o	O
events	NNS	o	O
was	VBD	o	O
similar	JJ	o	O
in	IN	O	O
both	DT	O	O
groups	NNS	O	O
.	.	O	O

CONCLUSIONS	VB	O	O
The	DT	O	O
addition	NN	O	O
of	IN	O	O
FSC	NNP	p	O
to	TO	p	O
subjects	NNS	p	O
with	IN	p	O
COPD	NNP	p	O
treated	VBD	p	O
with	IN	O	O
TIO	NNP	O	O
significantly	RB	O	O
improves	VBZ	o	O
lung	JJ	o	O
function	NN	o	O
without	IN	o	O
increasing	VBG	O	O
the	DT	o	O
risk	NN	o	O
of	IN	o	O
adverse	JJ	o	O
events	NNS	o	O
.	.	O	O

NCT00784550	NNP	O	O
.	.	O	O

Bevacizumab	NNP	i	IPM
compared	VBN	O	O
with	IN	O	O
macular	JJ	i	IPH
laser	NN	i	IPH
grid	JJ	i	IPH
photocoagulation	NN	i	IPH
for	IN	O	O
cystoid	JJ	p	O
macular	JJ	p	O
edema	NN	p	O
in	IN	p	O
branch	JJ	p	O
retinal	JJ	p	O
vein	NN	p	O
occlusion	NN	p	O
.	.	p	O

INTRODUCTION	NNP	O	O
To	TO	O	O
evaluate	VB	O	O
the	DT	O	O
outcome	NN	O	O
of	IN	O	O
cystoid	JJ	O	O
macular	JJ	O	O
edema	NN	O	O
treated	VBN	O	O
with	IN	O	O
intravitreal	JJ	i	IPM
injections	NNS	i	IPM
of	IN	i	IPM
bevacizumab	NN	i	IPM
and	CC	i	O
macular	JJ	i	IPH
grid	NN	i	IPH
laser	NN	i	IPH
photocoagulation	NN	i	IPH
(	(	i	IPH
GLP	NNP	i	IPH
)	)	i	IPH
,	,	O	O
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
perfused	JJ	p	O
branch	NN	p	O
retinal	JJ	p	O
vein	NN	p	O
occlusion	NN	p	O
.	.	p	O

METHODS	NNP	O	O
Thirty	NNP	p	O
eyes	NNS	p	O
of	IN	p	O
30	CD	p	O
consecutive	JJ	p	O
patients	NNS	p	O
with	IN	p	O
cystoid	JJ	p	O
macular	JJ	p	O
edema	NN	p	O
secondary	JJ	p	O
to	TO	p	O
nonischemic	JJ	p	O
branch	NN	p	O
retinal	JJ	p	O
vein	NN	p	O
occlusion	NN	p	O
were	VBD	p	O
assigned	VBN	p	O
to	TO	O	O
either	DT	O	O
GLP	NNP	i	IPH
group	NN	i	O
or	CC	O	O
to	TO	O	O
intravitreal	VB	i	IPM
bevacizumab	NN	i	IPM
(	(	i	IPM
IB	NNP	i	IPM
)	)	i	IPM
group	NN	O	O
.	.	O	O

Complete	NNP	o	OPH
ophthalmologic	JJ	o	OPH
examinations	NNS	o	OPH
were	VBD	O	O
performed	VBN	O	O
just	RB	O	O
before	IN	O	O
GLP	NNP	i	IPH
and	CC	O	O
IB	NNP	i	IPM
injection	NN	O	O
at	IN	O	O
1	CD	O	O
,	,	O	O
3	CD	O	O
,	,	O	O
6	CD	O	O
,	,	O	O
and	CC	O	O
12	CD	O	O
months	NNS	O	O
after	IN	O	O
treatment	NN	O	O
.	.	O	O

Changes	NNS	O	O
in	IN	O	O
logarithm	NN	o	OPH
of	IN	o	OPH
minimum	JJ	o	OPH
angle	NN	o	OPH
of	IN	o	OPH
resolution	NN	o	OPH
(	(	o	OPH
logMAR	JJ	o	OPH
)	)	o	OPH
best-corrected	JJ	o	OPH
visual	JJ	o	OPH
acuity	NN	o	OPH
(	(	o	OPH
BCVA	NNP	o	OPH
)	)	o	OPH
,	,	o	OPH
central	JJ	o	OPH
macular	JJ	o	OPH
thickness	NN	o	OPH
(	(	o	OPH
CMT	NNP	o	OPH
)	)	o	OPH
shown	VBN	o	OPH
by	IN	o	OPH
optical	JJ	o	OPH
coherence	NN	o	OPH
tomography-3	NN	o	OPH
were	VBD	O	O
evaluated	VBN	O	O
.	.	O	O

RESULTS	NNP	O	O
Baseline	NNP	o	OPH
BCVA	NNP	o	OPH
(	(	o	OPH
logMAR	NN	o	OPH
)	)	o	OPH
and	CC	o	OPH
CMT	NNP	o	OPH
were	VBD	O	O
,	,	O	O
respectively	RB	O	O
,	,	O	O
0.89	CD	O	O
+/-	JJ	O	O
0.13	CD	O	O
and	CC	O	O
650	CD	O	O
+/-	JJ	O	O
140	CD	O	O
microm	NN	O	O
for	IN	O	O
the	DT	O	O
GLP	NNP	i	IPH
group	NN	O	O
,	,	O	O
0.87	CD	O	O
+/-	JJ	O	O
0.16	CD	O	O
and	CC	O	O
690	CD	O	O
+/-	JJ	O	O
120	CD	O	O
microm	NN	O	O
for	IN	O	O
the	DT	O	O
IB	NNP	i	IPM
group	NN	O	O
.	.	O	O

After	IN	O	O
the	DT	O	O
treatment	NN	O	O
,	,	O	O
at	IN	O	O
1	CD	O	O
,	,	O	O
3	CD	O	O
,	,	O	O
6	CD	O	O
,	,	O	O
and	CC	O	O
12	CD	O	O
months	NNS	O	O
in	IN	O	O
the	DT	O	O
GLP	NNP	i	IPH
group	NN	O	O
,	,	O	O
BCVA	NNP	o	OPH
had	VBD	O	O
improved	VBN	O	O
by	IN	O	O
0.19	CD	O	O
,	,	O	O
0.22	CD	O	O
,	,	O	O
0.21	CD	O	O
,	,	O	O
and	CC	O	O
0.20	CD	O	O
logMAR	NN	O	O
,	,	O	O
CMT	NNP	o	OPH
had	VBD	O	O
decreased	VBN	O	O
by	IN	O	O
40	CD	O	O
%	NN	O	O
,	,	O	O
41.3	CD	O	O
%	NN	O	O
,	,	O	O
40.5	CD	O	O
%	NN	O	O
,	,	O	O
and	CC	O	O
42	CD	O	O
%	NN	O	O
.	.	O	O

In	IN	O	O
the	DT	O	O
IB	NNP	i	IPM
group	NN	O	O
,	,	O	O
BCVA	NNP	o	OPH
had	VBD	O	O
improved	VBN	O	O
by	IN	O	O
0.31	CD	O	O
,	,	O	O
0.32	CD	O	O
,	,	O	O
0.30	CD	O	O
,	,	O	O
and	CC	O	O
0.31	CD	O	O
logMAR	NN	o	OPH
and	CC	O	O
CMT	NNP	o	OPH
had	VBD	O	O
decreased	VBN	O	O
by	IN	O	O
59.5	CD	O	O
%	NN	O	O
,	,	O	O
59	CD	O	O
%	NN	O	O
,	,	O	O
60	CD	O	O
%	NN	O	O
,	,	O	O
and	CC	O	O
60.3	CD	O	O
%	NN	O	O
.	.	O	O

The	DT	O	O
group	NN	O	O
receiving	VBG	O	O
bevacizumab	NN	i	IPM
had	VBD	O	O
better	JJR	O	O
BCVA	NNP	o	OPH
and	CC	O	O
lower	JJR	O	O
CMT	NNP	o	OPH
values	NNS	O	O
at	IN	O	O
all	DT	O	O
time	NN	O	O
points	NNS	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

CONCLUSION	NNP	O	O
Intravitreal	NNP	O	O
bevacizumab	NN	i	IPM
injection	NN	O	O
improves	VBZ	O	O
BCVA	NNP	o	OPH
and	CC	O	O
reduces	NNS	O	O
CMT	NNP	o	OPH
more	JJR	O	O
than	IN	O	O
GLP	NNP	O	O
.	.	O	O

Intravitreal	NNP	O	O
bevacizumab	JJ	i	IPM
injection	NN	O	O
was	VBD	O	O
well	RB	O	O
tolerated	VBN	O	O
and	CC	O	O
could	MD	O	O
be	VB	O	O
used	VBN	O	O
as	IN	O	O
primary	JJ	O	O
treatment	NN	O	O
in	IN	O	O
patients	NNS	O	O
with	IN	O	O
cystoid	JJ	O	O
macular	JJ	O	O
edema	NN	O	O
secondary	JJ	O	O
to	TO	O	O
perfused	VBN	O	O
branch	NN	O	O
retinal	JJ	O	O
vein	NN	O	O
occlusion	NN	O	O
.	.	O	O

Emotional	JJ	o	OME
reactivity	NN	o	OME
to	TO	O	O
social	JJ	O	O
rejection	NN	O	O
and	CC	O	O
negative	JJ	O	O
evaluation	NN	O	O
among	IN	O	O
persons	NNS	p	O
with	IN	p	O
borderline	JJ	p	PC
personality	NN	p	PC
features	NNS	p	O
.	.	p	O

The	DT	O	O
present	JJ	O	O
study	NN	O	O
examined	VBD	O	O
the	DT	O	O
emotional	JJ	o	OME
reactivity	NN	o	OME
of	IN	O	O
persons	NNS	p	O
with	IN	p	O
heightened	JJ	p	PC
borderline	NN	p	PC
personality	NN	p	PC
(	(	p	PC
BP	NNP	p	PC
)	)	p	PC
features	VBZ	p	O
to	TO	O	O
social	JJ	O	O
rejection	NN	O	O
and	CC	O	O
negative	JJ	O	O
evaluation	NN	O	O
in	IN	O	O
the	DT	O	O
laboratory	NN	O	O
.	.	O	O

Individuals	NNS	p	O
with	IN	p	O
high	JJ	p	PC
levels	NNS	p	PC
of	IN	p	O
BP	NNP	p	PC
features	NNS	p	O
(	(	p	O
n	JJ	p	O
=	NNP	p	O
30	CD	p	PSS
)	)	p	O
and	CC	p	O
controls	NNS	p	O
with	IN	p	O
low	JJ	p	PC
levels	NNS	p	PC
of	IN	p	O
BP	NNP	p	PC
features	NNS	p	O
(	(	p	O
n	JJ	p	O
=	NNP	p	O
44	CD	p	PSS
)	)	p	O
were	VBD	O	O
randomly	RB	O	O
assigned	VBN	O	O
to	TO	O	O
a	DT	O	O
condition	NN	i	IE
involving	VBG	i	IE
negative	JJ	i	IE
evaluation	NN	i	IE
based	VBN	i	IE
on	IN	i	IE
writing	NN	o	OME
(	(	i	IE
negative	JJ	i	IE
evaluation/academic	NN	i	IE
)	)	i	IE
,	,	i	IE
or	CC	i	IE
a	DT	i	IE
condition	NN	i	IE
involving	VBG	i	IE
negative	JJ	i	IE
evaluation	NN	i	IE
based	VBN	i	IE
on	IN	i	IE
personal	JJ	o	OME
characteristics	NNS	o	OME
as	RB	i	IE
well	RB	i	IE
as	IN	i	IE
social	JJ	o	OME
rejection	NN	o	OME
(	(	o	OME
negative	JJ	o	OME
evaluation/social	JJ	o	OME
rejection	NN	o	OME
)	)	o	OME
.	.	o	O

Hypothesis	$	O	O
1	CD	O	O
was	VBD	O	O
that	IN	O	O
high-BP	JJ	p	PC
individuals	NNS	p	O
,	,	O	O
but	CC	O	O
not	RB	O	O
low-BP	JJ	p	PC
controls	NNS	p	O
,	,	O	O
would	MD	O	O
show	VB	O	O
greater	JJR	O	O
emotional	JJ	o	OME
reactivity	NN	o	OME
to	TO	O	O
the	DT	O	O
negative	JJ	i	IOt
evaluation/social	JJ	i	IOt
rejection	NN	i	IOt
stressor	NN	i	IOt
,	,	O	O
compared	VBN	O	O
with	IN	O	O
the	DT	O	O
negative	JJ	i	IOt
evaluation/academic	JJ	i	IOt
(	(	i	IOt
writing	VBG	i	IOt
)	)	i	IOt
stressor	NN	i	IOt
.	.	i	O

Hypothesis	$	O	O
2	CD	O	O
was	VBD	O	O
that	IN	O	O
high-BP	JJ	p	PC
individuals	NNS	p	O
would	MD	O	O
specifically	RB	O	O
show	VB	O	O
greater	JJR	O	O
reactivity	NN	o	OME
of	IN	o	OME
shame-	JJ	o	OME
and	CC	o	OME
anger-related	JJ	o	OME
emotions	NNS	o	OME
to	TO	O	O
the	DT	O	O
negative	JJ	i	IE
evaluation/social	JJ	i	IE
rejection	NN	i	IE
stressor	NN	i	IE
compared	VBN	O	O
with	IN	O	O
the	DT	O	O
negative	JJ	i	IOt
evaluation/academic	JJ	i	IOt
stressor	NN	i	IOt
.	.	i	O

Findings	NNS	O	O
indicated	VBD	O	O
that	IN	O	O
high-BP	JJ	p	PC
individuals	NNS	p	O
showed	VBD	O	O
heightened	VBN	o	OME
emotional	JJ	o	OME
reactivity	NN	o	OME
to	TO	O	O
the	DT	O	O
social	JJ	i	IE
rejection	NN	i	IE
stressor	NN	i	IE
but	CC	O	O
not	RB	O	O
to	TO	O	O
the	DT	O	O
negative	JJ	i	IOt
evaluation	NN	i	IOt
stressor	NN	i	IOt
,	,	O	O
but	CC	O	O
the	DT	O	O
opposite	JJ	O	O
pattern	NN	O	O
occurred	VBD	O	O
for	IN	O	O
controls	NNS	O	O
.	.	O	O

In	IN	O	O
addition	NN	O	O
,	,	O	O
there	EX	O	O
was	VBD	O	O
evidence	NN	O	O
for	IN	O	O
heightened	JJ	o	OME
reactivity	NN	o	OME
of	IN	o	OME
irritability	NN	o	OME
,	,	o	OME
distress	NN	o	OME
,	,	o	OME
and	CC	o	OME
shame	NN	o	OME
for	IN	O	O
the	DT	O	O
high-BP	JJ	O	O
group	NN	O	O
,	,	O	O
specifically	RB	O	O
in	IN	O	O
the	DT	O	O
social	JJ	O	O
rejection	NN	O	O
condition	NN	O	O
.	.	O	O

Nutrient	JJ	O	O
retention	NN	O	O
in	IN	O	O
preterm	JJ	p	PC
infants	NNS	p	O
fed	VBN	p	O
standard	JJ	p	O
infant	NN	p	O
formulas	NN	p	O
.	.	p	O

Our	PRP$	O	O
purpose	NN	O	O
was	VBD	O	O
to	TO	O	O
compare	VB	o	OPH
nitrogen	NN	o	OPH
,	,	o	OPH
mineral	NN	o	OPH
,	,	o	OPH
and	CC	o	OPH
zinc	NN	o	OPH
balance	NN	o	OPH
in	IN	O	O
preterm	JJ	p	PC
infants	NNS	p	O
fed	VBN	p	O
standard	JJ	i	IPM
infant	NN	i	IPM
formulas	NNS	i	IPM
,	,	i	O
Similac	NNP	i	IPM
With	IN	i	IPM
Iron	NNP	i	IPM
and	CC	i	IPM
Similac	NNP	i	IPM
With	IN	i	IPM
Whey	NNP	i	IPM
+	NNP	i	IPM
Iron	NNP	i	IPM
.	.	i	O

Nitrogen	NNP	o	OPH
and	CC	o	OPH
magnesium	NN	o	OPH
balances	NNS	o	OPH
were	VBD	O	O
similar	JJ	O	O
during	IN	O	O
both	DT	O	O
feeds	NNS	O	O
,	,	O	O
and	CC	O	O
met	VBD	O	O
estimated	VBN	O	O
fetal	JJ	O	O
requirements	NNS	O	O
.	.	O	O

Infants	NNS	O	O
absorbed	VBD	O	O
and	CC	O	O
retained	VBD	O	O
(	(	O	O
milligrams	FW	O	O
per	IN	O	O
kilogram	FW	O	O
per	IN	O	O
day	NN	O	O
)	)	O	O
more	JJR	O	O
calcium	NN	o	OPH
,	,	o	OPH
phosphorus	NN	o	OPH
,	,	o	OPH
and	CC	o	OPH
zinc	NN	o	OPH
when	WRB	O	O
fed	VBN	O	O
Similac	NNP	i	IPM
With	IN	i	IPM
Iron	NNP	i	IPM
.	.	i	O

However	RB	O	O
,	,	O	O
retention	NN	o	OPH
of	IN	o	OPH
calcium	NN	o	OPH
,	,	o	OPH
phosphorus	NN	o	OPH
(	(	o	OPH
both	DT	o	OPH
formulas	NN	o	OPH
)	)	o	OPH
,	,	o	OPH
and	CC	o	OPH
zinc	NN	o	OPH
(	(	O	O
Similac	NNP	O	O
With	IN	O	O
Whey	NNP	O	O
+	NNP	O	O
Iron	NNP	O	O
)	)	O	O
was	VBD	O	O
inadequate	JJ	O	O
to	TO	O	O
meet	VB	O	O
estimated	JJ	O	O
fetal	JJ	O	O
requirements	NNS	O	O
.	.	O	O

These	DT	O	O
findings	NNS	O	O
are	VBP	O	O
important	JJ	O	O
in	IN	O	O
the	DT	O	O
rapidly	RB	p	O
growing	VBG	p	O
preterm	JJ	p	PC
infant	NN	p	PA
,	,	O	O
who	WP	O	O
is	VBZ	O	O
already	RB	O	O
at	IN	O	O
risk	NN	O	O
for	IN	O	O
the	DT	O	O
development	NN	O	O
of	IN	O	O
rickets	NNS	O	O
and	CC	O	O
zinc	NN	O	O
deficiency	NN	O	O
and	CC	O	O
may	MD	O	O
be	VB	O	O
fed	VBN	O	O
either	DT	O	O
formula	NN	O	O
on	IN	O	O
discharge	NN	O	O
from	IN	O	O
the	DT	O	O
newborn	JJ	O	O
nursery	NN	O	O
.	.	O	O

A	DT	O	O
comparison	NN	O	O
of	IN	O	O
sclerotherapy	NN	i	IS
with	IN	O	O
staple	JJ	i	IS
transection	NN	i	IS
of	IN	i	IS
the	DT	i	IS
esophagus	NN	i	IS
for	IN	O	O
the	DT	O	O
emergency	NN	O	O
control	NN	o	OPH
of	IN	o	OPH
bleeding	VBG	o	OPH
from	IN	p	PC
esophageal	JJ	p	PC
varices	NNS	p	PC
.	.	p	O

We	PRP	O	O
compared	VBN	O	O
two	CD	O	O
procedures	NNS	O	O
for	IN	O	O
the	DT	O	O
emergency	NN	O	O
treatment	NN	O	O
of	IN	O	O
bleeding	VBG	o	OPH
esophageal	JJ	p	PC
varices	NNS	p	PC
in	IN	p	PC
patients	NNS	p	PC
who	WP	p	PC
did	VBD	p	PC
not	RB	p	PC
respond	VB	p	PC
to	TO	p	PC
blood	VB	p	PC
transfusion	NN	p	PC
and	CC	p	PC
vasoactive	JJ	p	PC
drugs	NNS	p	PC
.	.	p	O

We	PRP	O	O
randomly	VBP	O	O
assigned	VBD	O	O
101	CD	p	O
patients	NNS	p	O
with	IN	p	PC
cirrhosis	NN	p	PC
of	IN	p	PC
the	DT	p	PC
liver	NN	p	PC
and	CC	p	PC
bleeding	VBG	p	PC
esophageal	JJ	p	PC
varices	NNS	p	PC
to	TO	O	O
undergo	VB	i	IS
either	DT	i	IS
emergency	NN	i	IS
sclerotherapy	NN	i	IS
(	(	i	O
n	JJ	i	O
=	NNP	i	O
50	CD	i	O
)	)	i	O
or	CC	i	O
staple	JJ	i	IS
transection	NN	i	IS
of	IN	i	IS
the	DT	i	IS
esophagus	NN	i	IS
(	(	i	O
n	JJ	i	O
=	NNP	i	O
51	CD	i	O
)	)	i	O
.	.	O	O

Four	CD	O	O
patients	NNS	O	O
assigned	VBN	O	O
to	TO	O	O
sclerotherapy	VB	i	IS
and	CC	O	O
12	CD	O	O
assigned	VBN	O	O
to	TO	O	O
staple	VB	O	O
transection	NN	O	O
did	VBD	O	O
not	RB	O	O
actually	RB	O	O
undergo	VBP	O	O
those	DT	O	O
procedures	NNS	O	O
,	,	O	O
but	CC	O	O
all	DT	O	O
analyses	NNS	O	O
were	VBD	O	O
made	VBN	O	O
on	IN	O	O
an	DT	O	O
intention-to-treat	JJ	O	O
basis	NN	O	O
.	.	O	O

Total	JJ	o	OMO
mortality	NN	o	OMO
did	VBD	O	O
not	RB	O	O
differ	VB	O	O
significantly	RB	O	O
between	IN	O	O
the	DT	O	O
two	CD	O	O
groups	NNS	O	O
;	:	O	O
the	DT	O	O
relative	JJ	o	OMO
risk	NN	o	OMO
of	IN	o	OMO
death	NN	o	OMO
for	IN	O	O
staple	JJ	O	O
transection	NN	O	O
as	IN	O	O
compared	VBN	O	O
with	IN	O	O
sclerotherapy	NN	O	O
was	VBD	O	O
0.88	CD	O	O
(	(	O	O
95	CD	O	O
percent	NN	O	O
confidence	NN	O	O
interval	NN	O	O
,	,	O	O
0.51	CD	O	O
to	TO	O	O
1.54	CD	O	O
)	)	O	O
.	.	O	O

Mortality	NN	o	OMO
at	IN	O	O
six	CD	O	O
weeks	NNS	O	O
was	VBD	O	O
44	CD	O	O
percent	NN	O	O
among	IN	O	O
those	DT	O	O
assigned	VBN	O	O
to	TO	O	O
sclerotherapy	VB	i	IS
and	CC	O	O
35	CD	O	O
percent	NN	O	O
among	IN	O	O
those	DT	O	O
assigned	VBN	O	O
to	TO	O	O
staple	VB	O	O
transection	NN	O	O
.	.	O	O

Complication	NN	o	OPH
rates	NNS	o	OPH
were	VBD	O	O
similar	JJ	O	O
for	IN	O	O
the	DT	O	O
two	CD	O	O
groups	NNS	O	O
.	.	O	O

An	DT	O	O
interval	NN	o	OPH
of	IN	o	OPH
five	CD	o	OPH
days	NNS	o	OPH
without	IN	o	OPH
bleeding	NN	o	OPH
was	VBD	O	O
achieved	VBN	O	O
in	IN	O	O
88	CD	O	O
percent	NN	O	O
of	IN	O	O
those	DT	O	O
assigned	VBN	O	O
to	TO	O	O
staple	VB	O	O
transection	NN	O	O
and	CC	O	O
in	IN	O	O
62	CD	O	O
percent	NN	O	O
of	IN	O	O
those	DT	O	O
assigned	VBN	O	O
to	TO	O	O
sclerotherapy	VB	i	IS
after	IN	O	O
a	DT	O	O
single	JJ	O	O
injection	NN	O	O
(	(	O	O
P	NNP	O	O
less	JJR	O	O
than	IN	O	O
0.01	CD	O	O
)	)	O	O
and	CC	O	O
82	CD	O	O
percent	NN	O	O
after	IN	O	O
three	CD	O	O
injections	NNS	O	O
.	.	O	O

In	IN	O	O
only	RB	O	O
2	CD	O	O
of	IN	O	O
the	DT	O	O
11	CD	O	O
patients	NNS	O	O
who	WP	O	O
received	VBD	O	O
a	DT	O	O
third	JJ	O	O
sclerotherapy	NN	i	IS
injection	NN	O	O
was	VBD	O	O
bleeding	VBG	o	OPH
controlled	VBN	o	OPH
for	IN	O	O
more	JJR	O	O
than	IN	O	O
five	CD	O	O
days	NNS	O	O
,	,	O	O
and	CC	O	O
9	CD	O	O
died	VBD	O	O
.	.	O	O

We	PRP	O	O
conclude	VBP	O	O
that	IN	O	O
staple	JJ	O	O
transection	NN	O	O
of	IN	O	O
the	DT	O	O
esophagus	NN	O	O
is	VBZ	O	O
as	RB	o	O
safe	JJ	o	OOt
as	IN	o	OOt
sclerotherapy	NN	o	OOt
for	IN	O	O
the	DT	O	O
emergency	NN	o	OPH
treatment	NN	o	OPH
of	IN	o	OPH
bleeding	VBG	o	OPH
esophageal	JJ	O	O
varices	NNS	O	O
and	CC	O	O
that	IN	O	O
it	PRP	O	O
is	VBZ	O	O
more	RBR	O	O
effective	JJ	O	O
than	IN	O	O
a	DT	O	O
single	JJ	O	O
sclerotherapy	NN	i	IS
procedure	NN	O	O
.	.	O	O

We	PRP	O	O
currently	RB	O	O
recommend	VBP	O	O
surgery	NN	O	O
after	IN	O	O
two	CD	O	O
injection	NN	O	O
treatments	NNS	O	O
have	VBP	O	O
failed	VBN	O	O
.	.	O	O

Small	NN	O	O
but	CC	O	O
important	JJ	O	O
errors	NNS	O	O
in	IN	O	O
cardiovascular	JJ	O	O
risk	NN	O	O
calculation	NN	O	O
by	IN	O	O
practice	NN	p	O
nurses	NNS	p	O
:	:	p	O
a	DT	O	O
cross-sectional	JJ	O	O
study	NN	O	O
in	IN	O	O
randomised	JJ	O	O
trial	NN	O	O
setting	NN	O	O
.	.	O	O

BACKGROUND	NNP	O	O
Practice	NNP	p	O
nurses	NNS	p	O
play	VBP	O	O
an	DT	O	O
increasingly	RB	O	O
important	JJ	O	O
role	NN	O	O
in	IN	O	O
the	DT	O	O
prevention	NN	O	O
of	IN	O	O
cardiovascular	JJ	O	O
diseases	NNS	O	O
but	CC	O	O
we	PRP	O	O
do	VBP	O	O
not	RB	O	O
have	VB	O	O
evidence	NN	O	O
about	IN	O	O
the	DT	O	O
accuracy	NN	o	O
of	IN	O	O
their	PRP$	O	O
cardiovascular	JJ	O	O
risk	NN	O	O
assessments	NNS	O	O
during	IN	O	O
real	JJ	O	O
practice	NN	O	O
consultations	NNS	O	O
.	.	O	O

OBJECTIVES	NNP	O	O
To	TO	O	O
examine	VB	O	O
how	WRB	O	O
nurses	NNS	p	O
perform	VBP	O	O
with	IN	O	O
regard	NN	O	O
to	TO	O	O
absolute	VB	O	O
10-year	JJ	O	O
cardiovascular	JJ	o	OOt
risk	NN	o	OOt
assessment	NN	o	OOt
in	IN	O	O
actual	JJ	O	O
practice	NN	O	O
.	.	O	O

DESIGN	NNP	O	O
Cross-sectional	JJ	O	O
study	NN	O	O
.	.	O	O

SETTING	NN	O	O
This	DT	p	O
study	NN	p	O
was	VBD	p	O
nested	VBN	p	O
in	IN	p	O
the	DT	p	O
IMPALA	NNP	p	O
study	NN	p	O
,	,	p	O
a	DT	p	O
clustered	VBN	p	O
randomised	VBN	p	O
controlled	VBN	p	O
trial	NN	p	O
involving	VBG	p	O
24	CD	p	O
general	JJ	p	O
practices	NNS	p	O
in	IN	p	O
The	DT	p	O
Netherlands	NNP	p	O
.	.	p	O

PARTICIPANTS	VB	O	O
24	CD	p	O
practice	NN	p	O
nurses	NNS	p	O
,	,	p	O
trained	VBN	p	O
in	IN	p	O
10-year	JJ	p	O
cardiovascular	JJ	p	O
risk	NN	p	O
assessment	NN	p	O
,	,	O	O
calculated	VBD	O	O
the	DT	O	O
risk	NN	O	O
of	IN	O	O
a	DT	O	O
total	NN	O	O
of	IN	O	O
421	CD	p	O
patients	NNS	p	O
without	IN	p	O
established	VBN	p	O
cardiovascular	JJ	p	O
diseases	NNS	p	O
but	CC	p	O
eligible	JJ	p	O
for	IN	p	O
cardiovascular	JJ	o	OOt
risk	NN	o	OOt
assessment	NN	o	OOt
.	.	o	OOt

METHODS	NNP	O	O
The	DT	O	O
main	JJ	O	O
outcome	NN	O	O
measure	NN	O	O
was	VBD	O	O
the	DT	O	O
accuracy	NN	o	OOt
of	IN	o	OOt
risk	NN	o	OOt
assessments	NNS	o	OOt
,	,	O	O
defined	VBN	O	O
as	IN	O	O
(	(	O	O
1	CD	O	O
)	)	O	O
the	DT	O	O
difference	NN	o	OOt
between	IN	o	OOt
the	DT	o	OOt
10-year	JJ	o	OOt
cardiovascular	JJ	o	OOt
risk	NN	o	OOt
percentage	NN	o	OOt
calculated	VBN	o	OOt
by	IN	o	OOt
nurses	NNS	o	OOt
and	CC	o	OOt
an	DT	o	OOt
independent	JJ	o	OOt
assessor	NN	o	OOt
,	,	O	O
and	CC	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
the	DT	o	O
agreement	NN	o	OOt
between	IN	o	OOt
the	DT	o	OOt
treatment	NN	o	OOt
categories	NNS	o	OOt
assigned	VBN	o	OOt
by	IN	o	OOt
the	DT	o	OOt
nurses	NNS	o	OOt
(	(	o	OOt
low	JJ	o	OOt
,	,	o	OOt
moderate	JJ	o	OOt
or	CC	o	OOt
high	JJ	o	OOt
risk	NN	o	OOt
)	)	o	OOt
and	CC	o	OOt
those	DT	o	OOt
assigned	VBN	o	OOt
by	IN	o	OOt
the	DT	o	OOt
independent	JJ	o	OOt
assessor	NN	o	OOt
.	.	o	O

RESULTS	VB	O	O
Thirty-one	NNP	O	O
(	(	O	O
7.4	CD	O	O
%	NN	O	O
)	)	O	O
of	IN	O	O
the	DT	O	O
calculated	JJ	O	O
risk	NN	O	O
percentages	NNS	O	O
differed	VBN	O	O
by	IN	O	O
more	JJR	O	O
than	IN	O	O
our	PRP$	O	O
preset	NN	O	O
limits	NNS	O	O
,	,	O	O
25	CD	O	O
(	(	O	O
81	CD	O	O
%	NN	O	O
)	)	O	O
being	VBG	O	O
underestimations	NNS	O	O
.	.	O	O

Elderly	JJ	p	O
patients	NNS	p	O
(	(	O	O
OR	NNP	O	O
1.1	CD	O	O
,	,	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
1.0-1.1	CD	O	O
)	)	O	O
,	,	O	O
male	JJ	p	O
patients	NNS	p	O
(	(	p	O
vs.	FW	p	O
female	NN	p	O
OR	NNP	O	O
3.1	CD	O	O
,	,	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
1.2-7.3	CD	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
smoking	NN	p	O
patients	NNS	p	O
(	(	p	O
vs.	IN	p	O
non-smoking	NN	p	O
OR	NNP	O	O
3.8	CD	O	O
,	,	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
1.7-8.9	CD	O	O
)	)	O	O
were	VBD	O	O
more	RBR	O	O
likely	JJ	O	O
to	TO	O	O
have	VB	O	O
their	PRP$	O	O
cardiovascular	JJ	o	OOt
risk	NN	o	OOt
miscalculated	VBD	o	O
.	.	o	O

Ten	NNP	p	O
(	(	p	O
28	CD	p	O
%	NN	p	O
)	)	p	O
of	IN	p	O
the	DT	p	O
36	CD	p	O
patients	NNS	p	O
who	WP	p	O
should	MD	p	O
be	VB	p	O
assigned	VBN	p	O
to	TO	p	O
the	DT	p	O
high-risk	JJ	p	O
treatment	NN	p	O
category	NN	p	O
according	VBG	O	O
to	TO	O	O
the	DT	O	O
independent	JJ	O	O
calculation	NN	O	O
,	,	O	O
were	VBD	O	O
missed	VBN	O	O
as	IN	O	O
high-risk	JJ	O	O
patients	NNS	O	O
by	IN	O	O
the	DT	O	O
practice	NN	O	O
nurses	NNS	O	O
.	.	O	O

CONCLUSIONS	VB	O	O
The	DT	O	O
overall	JJ	O	O
standard	NN	O	O
of	IN	O	O
accuracy	NN	O	O
of	IN	O	O
cardiovascular	JJ	i	IOt
risk	NN	i	IOt
assessment	NN	i	IOt
by	IN	O	O
trained	JJ	p	O
practice	NN	p	O
nurses	NNS	p	O
in	IN	p	O
actual	JJ	p	O
practice	NN	p	O
is	VBZ	O	O
high	JJ	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
a	DT	O	O
significant	JJ	O	O
number	NN	O	O
of	IN	O	O
high-risk	JJ	O	O
patients	NNS	O	O
were	VBD	O	O
misclassified	VBN	O	O
,	,	O	O
with	IN	O	O
the	DT	O	O
probability	NN	O	O
that	IN	O	O
it	PRP	O	O
led	VBD	O	O
to	TO	O	O
missed	VBN	O	O
opportunities	NNS	O	O
for	IN	O	O
risk-reducing	JJ	O	O
interventions	NNS	O	O
.	.	O	O

As	IN	O	O
cardiovascular	JJ	O	O
risk	NN	O	O
assessments	NNS	O	O
are	VBP	O	O
frequently	RB	O	O
done	VBN	O	O
by	IN	O	O
nurses	NNS	p	O
in	IN	p	O
general	JJ	p	O
practice	NN	p	O
,	,	O	O
further	JJ	O	O
specific	JJ	O	O
training	NN	O	O
should	MD	O	O
be	VB	O	O
considered	VBN	O	O
to	TO	O	O
prevent	VB	O	O
undertreatment	NN	O	O
.	.	O	O

Development	NNP	O	O
of	IN	O	O
an	DT	O	O
adaptive	JJ	i	O
low-pass	NN	i	O
filtered	VBD	i	O
speech	JJ	i	O
test	NN	i	O
for	IN	O	O
the	DT	O	O
identification	NN	O	O
of	IN	O	O
auditory	NN	o	OPH
processing	NN	o	OPH
disorders	NNS	o	OPH
.	.	o	O

OBJECTIVE	CC	O	O
One	CD	O	O
type	NN	O	O
of	IN	O	O
test	NN	O	O
commonly	RB	O	O
used	VBD	O	O
to	TO	O	O
examine	VB	O	O
auditory	JJ	p	O
processing	NN	p	O
disorders	NNS	p	O
(	(	p	O
APD	NNP	p	O
)	)	p	O
is	VBZ	O	O
the	DT	O	O
low-pass	NN	i	IPH
filtered	VBD	i	IPH
speech	JJ	i	IPH
test	NN	i	IPH
(	(	O	O
LPFST	NNP	O	O
)	)	O	O
,	,	O	O
of	IN	O	O
which	WDT	O	O
there	EX	O	O
are	VBP	O	O
various	JJ	O	O
versions	NNS	O	O
.	.	O	O

In	IN	O	O
LPFSTs	NNP	O	O
,	,	O	O
a	DT	O	O
monaural	JJ	O	O
,	,	O	O
low-redundancy	JJ	O	O
speech	NN	O	O
sample	NN	O	O
is	VBZ	O	O
distorted	VBN	O	O
by	IN	O	O
using	VBG	O	O
filtering	VBG	O	O
to	TO	O	O
modify	VB	O	O
its	PRP$	O	O
frequency	NN	O	O
content	NN	O	O
.	.	O	O

Due	JJ	O	O
to	TO	O	O
the	DT	O	O
richness	NN	O	O
of	IN	O	O
the	DT	O	O
neural	JJ	O	O
pathways	NNS	O	O
in	IN	O	O
the	DT	O	O
auditory	NN	O	O
system	NN	O	O
and	CC	O	O
the	DT	O	O
redundancy	NN	O	O
of	IN	O	O
acoustic	JJ	O	O
information	NN	O	O
in	IN	O	O
spoken	JJ	O	O
language	NN	O	O
,	,	O	O
a	DT	O	O
normal	JJ	O	O
listener	NN	O	O
is	VBZ	O	O
able	JJ	O	O
to	TO	O	O
recognize	VB	O	O
speech	NN	O	O
even	RB	O	O
when	WRB	O	O
parts	NNS	O	O
of	IN	O	O
the	DT	O	O
signal	NN	O	O
are	VBP	O	O
missing	VBG	O	O
,	,	O	O
whereas	IN	O	O
this	DT	O	O
ability	NN	O	O
is	VBZ	O	O
often	RB	O	O
impaired	VBN	O	O
in	IN	O	O
listeners	NNS	p	O
with	IN	p	O
APD	NNP	p	O
.	.	p	O

One	CD	O	O
limitation	NN	O	O
of	IN	O	O
the	DT	O	O
various	JJ	O	O
versions	NNS	O	O
of	IN	O	O
the	DT	O	O
LPFST	NNP	i	IPH
is	VBZ	O	O
that	IN	O	O
they	PRP	O	O
are	VBP	O	O
carried	VBN	O	O
out	IN	O	O
using	VBG	O	O
a	DT	O	O
constant	JJ	O	O
level	NN	O	O
of	IN	O	O
low-pass	JJ	O	O
filtering	NN	O	O
(	(	O	O
e.g	NN	O	O
.	.	O	O

a	DT	O	O
fixed	JJ	O	O
1kHz	CD	O	O
corner	NN	O	O
frequency	NN	O	O
)	)	O	O
which	WDT	O	O
makes	VBZ	O	O
them	PRP	O	O
prone	VB	O	O
to	TO	O	O
ceiling	NN	O	O
and	CC	O	O
floor	NN	O	O
effects	NNS	O	O
.	.	O	O

The	DT	O	O
purpose	NN	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
counter	VB	O	O
these	DT	O	O
effects	NNS	O	O
by	IN	O	O
modifying	VBG	O	O
the	DT	O	O
LPFST	NNP	O	O
using	VBG	O	O
a	DT	O	O
computer-based	JJ	O	O
adaptive	JJ	O	O
procedure	NN	O	O
,	,	O	O
and	CC	O	O
to	TO	O	O
evaluate	VB	O	O
the	DT	O	O
performance	NN	O	O
of	IN	O	O
normal-hearing	JJ	p	O
participants	NNS	p	O
of	IN	p	O
varying	VBG	p	O
ages	NNS	p	O
on	IN	O	O
the	DT	O	O
test	NN	O	O
.	.	O	O

METHODS	NNP	O	O
In	IN	O	O
this	DT	O	O
preliminary	JJ	O	O
study	NN	O	O
,	,	O	O
33	CD	p	O
adults	NNS	p	O
and	CC	p	O
30	CD	p	O
children	NNS	p	O
(	(	p	O
aged	VBN	p	O
8-11	CD	p	O
years	NNS	p	O
)	)	p	O
with	IN	p	O
no	DT	p	O
known	JJ	p	O
history	NN	p	O
of	IN	p	O
listening	VBG	p	O
difficulties	NNS	p	O
were	VBD	O	O
tested	VBN	O	O
.	.	O	O

The	DT	i	IE
University	NNP	i	IE
of	IN	i	IE
Canterbury	NNP	i	IE
Adaptive	NNP	i	IE
Speech	NNP	i	IE
Test	NNP	i	IE
(	(	i	IE
UCAST	NNP	i	IE
)	)	i	IE
platform	NN	i	IE
was	VBD	i	IE
used	VBN	i	IE
to	TO	i	IE
administer	VB	i	IE
a	DT	i	IE
four-alternative	JJ	i	IE
forced-choice	JJ	i	IE
adaptive	JJ	i	IE
test	NN	i	IE
that	WDT	i	IE
altered	VBD	i	IE
a	DT	i	IE
low-pass	JJ	i	IE
filter	NN	i	IE
(	(	i	IE
LPF	NNP	i	IE
)	)	i	IE
to	TO	i	IE
track	VB	i	IE
the	DT	i	IE
corner	NN	i	IE
frequency	NN	i	IE
at	IN	i	IE
which	WDT	i	IE
participants	NNS	i	IE
correctly	RB	i	IE
identified	VBN	i	IE
a	DT	i	IE
certain	JJ	i	IE
percentage	NN	i	IE
of	IN	i	IE
the	DT	i	IE
word	NN	i	IE
stimuli	NN	i	IE
.	.	i	IE

RESULTS	NNP	O	O
Findings	NNP	O	O
on	IN	O	O
the	DT	O	O
University	NNP	o	OOt
of	IN	o	OOt
Canterbury	NNP	o	OOt
Adaptive	NNP	o	OOt
Speech	NNP	o	OOt
Test-Filtered	NNP	o	OOt
Words	NNP	o	OOt
(	(	o	OOt
UCAST-FW	NNP	o	OOt
)	)	o	OOt
indicated	VBD	O	O
a	DT	O	O
significant	JJ	o	OPH
maturational	JJ	o	OPH
effect	NN	o	OPH
.	.	o	O

Adult	NN	p	O
participants	NNS	p	O
performed	VBD	O	O
significantly	RB	O	O
better	RBR	O	O
on	IN	O	O
the	DT	O	O
UCAST-FW	NNP	o	OOt
in	IN	O	O
comparison	NN	O	O
to	TO	O	O
the	DT	O	O
child	NN	p	O
participants	NNS	p	O
.	.	p	O

The	DT	O	O
UCAST-FW	JJ	i	O
test	NN	O	O
was	VBD	O	O
reliable	JJ	O	O
over	IN	O	O
repeated	JJ	O	O
administrations	NNS	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
An	DT	O	O
adaptive	JJ	O	O
low-pass	NN	O	O
filtered	VBD	O	O
speech	JJ	O	O
test	NN	O	O
such	JJ	O	O
as	IN	O	O
the	DT	O	O
UCAST-FW	NNP	o	OOt
is	VBZ	O	O
sensitive	JJ	O	O
to	TO	O	O
maturational	JJ	o	OPH
changes	NNS	o	OPH
in	IN	o	OPH
auditory	NN	o	OPH
processing	NN	o	OPH
ability	NN	o	OPH
.	.	o	O

Endobronchial	JJ	O	O
ultrasonography-guided	JJ	O	O
transbronchial	JJ	i	IS
needle	JJ	i	IS
aspiration	NN	i	IS
increases	VBZ	O	O
the	DT	O	O
diagnostic	JJ	o	OOt
yield	NN	o	OOt
of	IN	O	O
peripheral	JJ	p	PC
pulmonary	JJ	p	PC
lesions	NNS	p	PC
:	:	p	PC
a	DT	O	O
randomized	JJ	O	O
trial	NN	O	O
.	.	O	O

BACKGROUND	VB	O	O
The	DT	O	O
diagnostic	JJ	o	OPH
yield	NN	o	OPH
of	IN	O	O
endobronchial	JJ	i	IS
ultrasonography	NN	i	IS
(	(	i	IS
EBUS	NNP	i	IS
)	)	i	IS
-guided	VBD	i	IS
transbronchial	JJ	i	IS
needle	JJ	i	IS
aspiration	NN	i	IS
(	(	i	IS
TBNA	NNP	i	IS
)	)	i	IS
for	IN	O	O
peripheral	JJ	O	O
pulmonary	JJ	O	O
lesions	NNS	O	O
(	(	O	O
PPLs	NNP	O	O
)	)	O	O
has	VBZ	O	O
not	RB	O	O
been	VBN	O	O
evaluated	VBN	O	O
.	.	O	O

The	DT	O	O
diagnostic	JJ	O	O
impact	NN	O	O
of	IN	O	O
TBNA	NNP	O	O
when	WRB	O	O
the	DT	O	O
EBUS	NNP	O	O
probe	NN	O	O
is	VBZ	O	O
adjacent	JJ	O	O
to	TO	O	O
lesions	NNS	O	O
remains	VBZ	O	O
to	TO	O	O
be	VB	O	O
determined	VBN	O	O
.	.	O	O

DESIGN	VB	O	O
A	DT	O	O
prospective	JJ	O	O
,	,	O	O
randomized	JJ	O	O
trial	NN	O	O
.	.	O	O

METHODS	NNP	O	O
Two	CD	p	O
hundred	VBD	p	O
two	CD	p	O
patients	NNS	p	O
with	IN	p	O
PPLs	NNP	p	O
and	CC	p	O
positive	JJ	p	O
EBUS	NNP	p	O
findings	NNS	p	O
were	VBD	p	O
enrolled	VBN	p	O
.	.	p	O

They	PRP	O	O
were	VBD	O	O
randomly	RB	O	O
classified	VBN	O	O
into	IN	O	O
two	CD	O	O
groups	NNS	O	O
.	.	O	O

In	IN	O	O
the	DT	O	O
EBUS	NNP	O	O
conventional	JJ	O	O
diagnostic	JJ	O	O
procedures	NNS	O	O
(	(	O	O
CDPs	NNP	O	O
)	)	O	O
group	NN	O	O
(	(	O	O
103	CD	O	O
patients	NNS	O	O
)	)	O	O
,	,	O	O
both	DT	O	O
transbronchial	JJ	i	IPH
biopsy	NN	i	IPH
(	(	O	O
TBB	NNP	O	O
)	)	O	O
and	CC	O	O
bronchial	JJ	O	O
washing	NN	O	O
(	(	O	O
BW	NNP	O	O
)	)	O	O
were	VBD	O	O
performed	VBN	O	O
.	.	O	O

In	IN	O	O
the	DT	O	O
EBUS-TBNA	JJ	O	O
plus	CC	O	O
CDPs	NNP	O	O
group	NN	O	O
(	(	O	O
99	CD	O	O
patients	NNS	O	O
)	)	O	O
,	,	O	O
TBNA	NNP	O	O
,	,	O	O
TBB	NNP	O	O
,	,	O	O
and	CC	O	O
BW	NNP	O	O
were	VBD	O	O
performed	VBN	O	O
.	.	O	O

The	DT	O	O
diagnostic	JJ	o	OPH
yield	NN	o	OPH
in	IN	O	O
each	DT	O	O
group	NN	O	O
was	VBD	O	O
compared	VBN	O	O
.	.	O	O

RESULTS	VB	O	O
A	DT	p	O
total	NN	p	O
of	IN	p	O
182	CD	p	O
patients	NNS	p	O
(	(	p	O
94	CD	p	O
in	IN	p	O
the	DT	p	O
EBUS	NNP	p	O
CDPs	NNP	p	O
group	NN	p	O
and	CC	p	O
88	CD	p	O
in	IN	p	O
the	DT	p	O
EBUS-TBNA	JJ	p	O
plus	CC	p	O
CDPs	NNP	p	O
group	NN	p	O
)	)	p	O
were	VBD	p	O
analyzed	VBN	p	O
.	.	p	O

The	DT	O	O
yield	NN	o	OOt
in	IN	o	OOt
the	DT	o	OOt
EBUS-TBNA	JJ	o	OOt
plus	CC	O	O
CDPs	NNP	O	O
group	NN	O	O
(	(	O	O
78.4	CD	O	O
%	NN	O	O
)	)	O	O
was	VBD	O	O
significantly	RB	O	O
higher	JJR	O	O
than	IN	O	O
the	DT	O	O
EBUS	NNP	O	O
CDPs	NNP	O	O
group	NN	O	O
(	(	O	O
60.6	CD	O	O
%	NN	O	O
,	,	O	O
p	NN	O	O
=	NNP	O	O
0.015	CD	O	O
)	)	O	O
.	.	O	O

Cases	NNS	O	O
in	IN	O	O
which	WDT	O	O
the	DT	O	O
EBUS	NNP	O	O
probe	NN	O	O
was	VBD	O	O
located	VBN	O	O
within	IN	O	O
the	DT	O	O
lesions	NNS	O	O
had	VBD	O	O
a	DT	O	O
significantly	RB	O	O
higher	RBR	o	OPH
diagnostic	JJ	o	OPH
yield	NN	o	OPH
(	(	O	O
78.3	CD	O	O
%	NN	O	O
)	)	O	O
than	IN	O	O
when	WRB	O	O
the	DT	O	O
EBUS	NNP	O	O
probe	NN	O	O
was	VBD	O	O
adjacent	JJ	O	O
to	TO	O	O
them	PRP	O	O
(	(	O	O
47.2	CD	O	O
%	NN	O	O
,	,	O	O
p	NN	O	O
<	NNP	O	O
0.001	CD	O	O
)	)	O	O
.	.	O	O

Concerning	VBG	O	O
the	DT	O	O
three	CD	O	O
different	JJ	O	O
techniques	NNS	O	O
,	,	O	O
TBNA	NNP	O	O
showed	VBD	O	O
the	DT	O	O
highest	JJS	o	OPH
diagnostic	JJ	o	OPH
yield	NN	o	OPH
(	(	O	O
62.5	CD	O	O
%	NN	O	O
)	)	O	O
in	IN	O	O
comparison	NN	O	O
to	TO	O	O
TBB	NNP	O	O
(	(	O	O
48.9	CD	O	O
%	NN	O	O
)	)	O	O
and	CC	O	O
to	TO	O	O
BW	NNP	O	O
(	(	O	O
19.8	CD	O	O
%	NN	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
diagnostic	JJ	o	OPH
yield	NN	o	OPH
of	IN	o	OPH
TBNA	NNP	o	OPH
remained	VBD	O	O
unchanged	JJ	O	O
even	RB	O	O
when	WRB	O	O
the	DT	O	O
EBUS	NNP	O	O
probe	NN	O	O
was	VBD	O	O
adjacent	JJ	O	O
to	TO	O	O
the	DT	O	O
lesions	NNS	O	O
(	(	O	O
p	JJ	O	O
=	NNP	O	O
0.89	CD	O	O
)	)	O	O
.	.	O	O

No	DT	O	O
additional	JJ	O	O
adverse	JJ	o	OA
effects	NNS	o	OA
were	VBD	O	O
observed	VBN	O	O
in	IN	O	O
the	DT	O	O
EBUS-TBNA	JJ	O	O
plus	CC	O	O
CDPs	NNP	O	O
group	NN	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
Applying	NNP	O	O
TBNA	NNP	O	O
to	TO	O	O
EBUS-guided	NNP	O	O
CDPs	NNP	O	O
further	RBR	O	O
increased	VBD	O	O
the	DT	O	O
diagnostic	JJ	o	OPH
yield	NN	o	OPH
of	IN	O	O
PPLs	NNP	O	O
without	IN	O	O
additional	JJ	O	O
risk	NN	O	O
.	.	O	O

The	DT	O	O
diagnostic	JJ	o	OOt
advantage	NN	o	OOt
of	IN	O	O
TBNA	NNP	O	O
became	VBD	O	O
more	RBR	O	O
obvious	JJ	O	O
if	IN	O	O
the	DT	O	O
EBUS	NNP	O	O
probe	NN	O	O
was	VBD	O	O
adjacent	JJ	O	O
to	TO	O	O
the	DT	O	O
lesions	NNS	O	O
.	.	O	O

TRIAL	NNP	O	O
REGISTRATION	NNP	O	O
Clinicaltrials.gov	NNP	O	O
Identifier	NNP	O	O
:	:	O	O
NCT00626587	NN	O	O
.	.	O	O

Epidural	JJ	i	IPM
fentanyl-bupivacaine	JJ	i	IPM
compared	VBN	O	O
with	IN	O	O
clonidine-bupivacaine	NN	i	IPM
for	IN	O	O
analgesia	NN	p	O
in	IN	p	O
labour	NN	p	O
.	.	p	O

Alpha-adrenergic	JJ	O	O
agonists	NNS	O	O
produce	VBP	O	O
pain	NN	o	OPA
relief	NN	o	OPA
through	IN	O	O
an	DT	O	O
opioid	JJ	O	O
independent	JJ	O	O
mechanism	NN	O	O
and	CC	O	O
may	MD	O	O
be	VB	O	O
alternatives	NNS	O	O
to	TO	O	O
opioids	NNS	O	O
for	IN	O	O
combination	NN	O	O
with	IN	O	O
local	JJ	O	O
anaesthetics	NNS	O	O
for	IN	O	O
analgesia	NN	O	O
during	IN	p	O
labour	NN	p	O
.	.	p	O

We	PRP	p	O
studied	VBD	p	O
41	CD	p	PSS
pregnant	JJ	p	O
women	NNS	p	PSE
.	.	p	O

Epidural	JJ	O	O
block	NN	O	O
was	VBD	O	O
performed	VBN	O	O
with	IN	O	O
75	CD	O	O
microg	NNS	O	O
clonidine	NN	i	IPM
(	(	O	O
n	JJ	O	O
=	NNP	O	O
20	CD	O	O
)	)	O	O
or	CC	O	O
50	CD	i	IPM
microg	NNS	i	IPM
fentanyl	NN	i	IPM
(	(	O	O
n	JJ	O	O
=	NNP	O	O
21	CD	O	O
)	)	O	O
combined	VBN	i	IPM
with	IN	i	IPM
0.125	CD	i	IPM
%	NN	i	IPM
bupivacaine	NN	i	IPM
(	(	O	O
10	CD	O	O
mL	NN	O	O
)	)	O	O
.	.	O	O

Maternal	JJ	o	OPH
vital	JJ	o	OPH
parameters	NNS	o	OPH
were	VBD	O	O
measured	VBN	O	O
.	.	O	O

Analgesia	NNP	o	OPA
was	VBD	O	O
evaluated	VBN	O	O
using	VBG	O	O
a	DT	O	O
visual	JJ	O	O
analogue	NN	O	O
scale	NN	O	O
(	(	O	O
VAS	NNP	O	O
)	)	O	O
;	:	O	O
sedation	NN	o	OPH
was	VBD	O	O
scored	VBN	O	O
using	VBG	O	O
a	DT	O	O
five-point	JJ	O	O
scale	NN	O	O
.	.	O	O

There	EX	O	O
were	VBD	O	O
no	DT	O	O
differences	NNS	O	O
in	IN	O	O
maternal	JJ	o	OPH
vital	JJ	o	OPH
parameters	NNS	o	OPH
,	,	o	OPH
fetal	JJ	o	OPH
heart	NN	o	OPH
rate	NN	o	OPH
(	(	o	OPH
FHR	NNP	o	OPH
)	)	o	OPH
or	CC	o	OPH
Apgar	NNP	o	OPH
scores	NNS	o	OPH
between	IN	O	O
the	DT	O	O
groups	NNS	O	O
.	.	O	O

Analgesia	NNP	o	O
lasted	VBD	O	O
longer	RBR	O	O
in	IN	O	O
the	DT	O	O
bupivacaine-clonidine	JJ	i	IPM
group	NN	O	O
(	(	O	O
139.4	CD	O	O
+/-	JJ	O	O
31	CD	O	O
min	NN	O	O
)	)	O	O
compared	VBN	O	O
with	IN	O	O
the	DT	O	O
bupivacaine-fentanyl	JJ	i	IPM
group	NN	O	O
(	(	O	O
127.9	CD	O	O
+/-	JJ	O	O
48	CD	O	O
min	NN	O	O
)	)	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.42	CD	O	O
)	)	O	O
.	.	O	O

Additional	JJ	o	OPA
analgesic	JJ	o	OPA
requirement	NN	o	OPA
was	VBD	O	O
more	RBR	O	O
often	RB	O	O
in	IN	O	O
the	DT	O	O
fentanyl-bupivacaine	JJ	i	IPM
group	NN	O	O
and	CC	O	O
total	JJ	O	O
bupivacaine	NN	O	O
requirement	NN	O	O
was	VBD	O	O
less	RBR	O	O
in	IN	O	O
the	DT	O	O
clonidine-bupivacaine	JJ	i	IPM
group	NN	O	O
(	(	O	O
22.5	CD	O	O
+/-	JJ	O	O
12.5	CD	O	O
mg	NN	O	O
vs.	FW	O	O
30.9	CD	O	O
+/-	JJ	O	O
12.8	CD	O	O
mg	NN	O	O
)	)	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.04	CD	O	O
)	)	O	O
.	.	O	O

This	DT	O	O
small	JJ	O	O
study	NN	O	O
confirms	VBZ	O	O
that	IN	O	O
this	DT	O	O
combination	NN	O	O
of	IN	O	O
bupivacaine	NN	i	IPM
and	CC	O	O
clonidine	NN	i	IPM
provides	VBZ	O	O
satisfactory	JJ	o	OPA
analgesia	NN	o	OPA
for	IN	O	O
first-stage	JJ	O	O
labour	NN	O	O
,	,	O	O
and	CC	O	O
of	IN	O	O
longer	JJR	O	O
duration	NN	o	OOt
than	IN	O	O
bupivacaine-fentanyl	NN	i	IPM
.	.	i	O

Safety	NN	o	OOt
and	CC	o	OOt
efficacy	NN	o	OOt
of	IN	O	O
oral	JJ	O	O
DMSA	NNP	i	IPM
therapy	NN	i	IPM
for	IN	O	O
children	NNS	p	PA
with	IN	p	O
autism	NN	p	PC
spectrum	NN	p	PC
disorders	NNS	p	PC
:	:	p	O
part	NN	O	O
B	NNP	O	O
-	:	O	O
behavioral	JJ	O	O
results	NNS	O	O
.	.	O	O

BACKGROUND	NNP	O	O
This	DT	O	O
study	NN	O	O
investigated	VBD	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
oral	JJ	i	IPM
dimercapto	NN	i	IPM
succinic	JJ	i	IPM
acid	NN	i	IPM
(	(	i	IPM
DMSA	NNP	i	IPM
)	)	i	IPM
therapy	NN	i	IPM
on	IN	O	O
the	DT	O	O
behavioural	JJ	O	O
symptoms	NNS	O	O
of	IN	O	O
children	NNS	p	O
with	IN	p	O
autism	NN	p	O
spectrum	NN	p	O
disorders	NNS	p	O
(	(	p	O
ASD	NNP	p	O
)	)	p	O
ages	VBZ	p	O
3-8	JJ	p	O
years	NNS	p	O
.	.	p	O

METHODS	NNP	O	O
Phase	NNP	p	O
1	CD	p	O
involved	VBD	p	O
65	CD	p	PSS
children	NNS	p	PA
with	IN	p	O
ASD	NNP	p	PC
who	WP	p	O
received	VBD	p	O
one	CD	p	O
round	NN	p	O
of	IN	p	O
DMSA	NNP	p	O
(	(	p	O
3	CD	p	O
days	NNS	p	O
)	)	p	O
.	.	p	O

Participants	NNS	p	O
who	WP	p	O
had	VBD	p	O
high	JJ	p	PC
urinary	JJ	p	PC
excretion	NN	p	PC
of	IN	p	PC
toxic	JJ	p	PC
metals	NNS	p	PC
were	VBD	p	O
selected	VBN	p	O
to	TO	p	O
continue	VB	p	O
on	IN	p	O
to	TO	p	O
phase	VB	p	O
2	CD	p	O
.	.	p	O

In	IN	O	O
phase	NN	p	O
2	CD	p	O
,	,	p	O
49	CD	p	PSS
participants	NNS	p	O
were	VBD	p	O
randomly	RB	p	O
assigned	VBN	p	O
in	IN	p	O
a	DT	p	O
double-blind	JJ	p	O
design	NN	p	O
to	TO	p	O
receive	VB	p	O
an	DT	p	O
additional	JJ	p	O
6	CD	i	IPM
rounds	NNS	i	IPM
of	IN	i	IPM
either	DT	i	IPM
DMSA	NNP	i	IPM
or	CC	i	O
placebo	NN	i	IC
.	.	i	O

RESULTS	VB	O	O
The	DT	O	O
groups	NNS	O	O
receiving	VBG	O	O
one	CD	O	O
round	NN	O	O
and	CC	O	O
seven	CD	O	O
rounds	NNS	O	O
of	IN	O	O
DMSA	NNP	i	IPM
had	VBD	O	O
significant	JJ	O	O
improvements	NNS	O	O
on	IN	O	O
all	PDT	O	O
the	DT	O	O
assessment	JJ	O	O
measures	NNS	O	O
.	.	O	O

For	IN	O	O
the	DT	O	O
seven	CD	O	O
round	NN	O	O
group	NN	O	O
,	,	O	O
the	DT	O	O
degree	NN	O	O
of	IN	O	O
improvement	NN	o	OPH
on	IN	O	O
the	DT	O	O
assessment	NN	o	OOt
measures	NNS	o	OOt
could	MD	O	O
be	VB	O	O
partially	RB	O	O
explained	VBN	O	O
by	IN	O	O
a	DT	O	O
regression	NN	O	O
analysis	NN	O	O
based	VBN	O	O
on	IN	O	O
excretion	NN	o	OPH
of	IN	o	OPH
toxic	JJ	o	OPH
metals	NNS	o	OPH
and	CC	o	OPH
changes	NNS	o	OPH
in	IN	o	OPH
glutathione	NN	o	OPH
(	(	O	O
adjusted	VBN	O	O
R2	NNP	O	O
of	IN	O	O
0.28-0.75	NNP	O	O
,	,	O	O
p	NN	O	O
<	VBD	O	O
0.02	CD	O	O
in	IN	O	O
all	DT	O	O
cases	NNS	O	O
)	)	O	O
.	.	O	O

One	CD	O	O
round	NN	O	O
of	IN	O	O
DMSA	NNP	O	O
had	VBD	O	O
nearly	RB	O	O
the	DT	O	O
same	JJ	O	O
benefit	NN	O	O
as	IN	O	O
seven	CD	O	O
rounds	NNS	O	O
.	.	O	O

The	DT	O	O
assessment	JJ	O	O
measures	NNS	O	O
correlated	VBN	O	O
reasonably	RB	O	O
with	IN	O	O
one	CD	O	O
another	DT	O	O
at	IN	O	O
the	DT	O	O
beginning	NN	O	O
of	IN	O	O
the	DT	O	O
study	NN	O	O
(	(	O	O
r	JJ	O	O
=	NNP	O	O
0.60-0.87	NN	O	O
)	)	O	O
and	CC	O	O
even	RB	O	O
better	JJR	O	O
at	IN	O	O
the	DT	O	O
end	NN	O	O
of	IN	O	O
the	DT	O	O
study	NN	O	O
(	(	O	O
r	JJ	O	O
=	NNP	O	O
0.63-0.94	NN	O	O
)	)	O	O
.	.	O	O

CONCLUSION	NNP	O	O
Overall	NNP	O	O
,	,	O	O
both	DT	O	O
one	CD	O	O
and	CC	O	O
seven	CD	O	O
rounds	NNS	O	O
of	IN	O	O
DMSA	NNP	i	IPM
therapy	NN	O	O
seems	VBZ	O	O
to	TO	O	O
be	VB	O	O
reasonably	RB	O	O
safe	JJ	o	OOt
in	IN	O	O
children	NNS	p	PA
with	IN	p	O
ASD	NNP	p	PC
who	WP	p	O
have	VBP	p	O
high	JJ	p	PC
urinary	JJ	p	PC
excretion	NN	p	PC
of	IN	p	PC
toxic	JJ	p	PC
metals	NNS	p	PC
,	,	O	O
and	CC	O	O
possibly	RB	O	O
helpful	JJ	O	O
in	IN	O	O
reducing	VBG	O	O
some	DT	O	O
of	IN	O	O
the	DT	O	O
symptoms	NNS	O	O
of	IN	O	O
autism	NN	O	O
in	IN	O	O
those	DT	O	O
children	NNS	O	O
.	.	O	O

Cisplatin	NNP	i	IPM
,	,	i	IPM
epirubicin	NN	i	IPM
,	,	i	IPM
leucovorin	NN	i	IPM
and	CC	i	IPM
5-fluorouracil	JJ	i	IPM
(	(	i	IPM
PELF	NNP	i	IPM
)	)	i	IPM
is	VBZ	O	O
more	RBR	O	O
active	JJ	O	O
than	IN	O	O
5-fluorouracil	JJ	i	IPM
,	,	i	IPM
doxorubicin	JJ	i	IPM
and	CC	i	IPM
methotrexate	NN	i	IPM
(	(	i	IPM
FAMTX	NNP	i	IPM
)	)	i	IPM
in	IN	O	O
advanced	JJ	p	PC
gastric	JJ	p	PC
carcinoma	NN	p	PC
.	.	p	O

BACKGROUND	NNP	O	O
5-Fluorouracil	JJ	i	IPM
(	(	i	IPM
5-FU	JJ	i	IPM
)	)	i	IPM
,	,	i	IPM
doxorubicin	NN	i	IPM
and	CC	i	IPM
methotrexate	NN	i	IPM
(	(	i	IPM
FAMTX	NNP	i	IPM
)	)	i	IPM
and	CC	i	O
cisplatin	NN	i	IPM
,	,	i	IPM
epirubicin	NN	i	IPM
,	,	i	IPM
leucovorin	NN	i	IPM
and	CC	i	IPM
5-FU	JJ	i	IPM
(	(	i	IPM
PELF	NNP	i	IPM
)	)	i	IPM
have	VBP	O	O
both	DT	O	O
been	VBN	O	O
reported	VBN	O	O
to	TO	O	O
be	VB	O	O
superior	JJ	O	O
to	TO	O	O
the	DT	O	O
combination	NN	O	O
5-FU	JJ	O	O
,	,	O	O
doxorubicin	JJ	O	O
and	CC	O	O
mitomycin	JJ	O	O
C	NNP	O	O
(	(	O	O
FAM	NNP	O	O
)	)	O	O
in	IN	O	O
advanced	JJ	p	PC
gastric	JJ	p	PC
carcinoma	NN	p	PC
.	.	O	O

On	IN	O	O
the	DT	O	O
basis	NN	O	O
of	IN	O	O
the	DT	O	O
presence	NN	O	O
and	CC	O	O
dose	JJ	O	O
intensity	NN	O	O
of	IN	O	O
the	DT	O	O
included	JJ	O	O
agents	NNS	O	O
,	,	O	O
we	PRP	O	O
hypothesised	VBD	O	O
that	IN	O	O
PELF	NNP	O	O
would	MD	O	O
be	VB	O	O
superior	JJ	O	O
to	TO	O	O
FAMTX	NNP	i	IPM
.	.	i	O

PATIENTS	NNP	O	O
AND	CC	O	O
METHODS	NNP	O	O
Two	CD	p	PSS
hundred	VBD	p	PSS
patients	NNS	p	O
with	IN	p	O
untreated	JJ	p	PC
advanced	JJ	p	PC
gastric	JJ	p	PC
carcinoma	NN	p	PC
were	VBD	O	O
randomised	VBN	O	O
to	TO	O	O
receive	VB	O	O
PELF	NNP	i	IPM
or	CC	i	O
FAMTX	NNP	i	IPM
for	IN	O	O
a	DT	O	O
maximum	NN	O	O
of	IN	O	O
six	CD	O	O
cycles	NNS	O	O
or	CC	O	O
until	IN	O	O
disease	JJ	O	O
progression	NN	O	O
.	.	O	O

RESULTS	VB	O	O
The	DT	O	O
complete	JJ	o	OPH
response	NN	o	OPH
(	(	o	OPH
CR	NNP	o	OPH
)	)	o	OPH
rates	NNS	o	OPH
to	TO	O	O
PELF	NNP	O	O
and	CC	O	O
FAMTX	NNP	i	IPM
were	VBD	O	O
,	,	O	O
respectively	RB	O	O
,	,	O	O
13	CD	O	O
%	NN	O	O
[	JJ	O	O
95	CD	O	O
%	NN	O	O
confidence	NN	O	O
intervals	NNS	O	O
(	(	O	O
CI	NNP	O	O
)	)	O	O
6	CD	O	O
%	NN	O	O
to	TO	O	O
20	CD	O	O
%	NN	O	O
]	NN	O	O
and	CC	O	O
2	CD	O	O
%	NN	O	O
(	(	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
0	CD	O	O
%	NN	O	O
to	TO	O	O
5	CD	O	O
%	NN	O	O
;	:	O	O
P	NNP	O	O
=	NNP	O	O
0.003	CD	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
objective	JJ	o	OPH
response	NN	o	OPH
rates	NNS	o	OPH
[	VBP	O	O
CR	NNP	O	O
plus	CC	O	O
partial	JJ	o	OPH
response	NN	o	OPH
(	(	O	O
PR	NNP	O	O
)	)	O	O
rates	NNS	O	O
]	VBP	O	O
39	CD	O	O
%	NN	O	O
(	(	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
29	CD	O	O
%	NN	O	O
to	TO	O	O
49	CD	O	O
%	NN	O	O
)	)	O	O
and	CC	O	O
22	CD	O	O
%	NN	O	O
(	(	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
13	CD	O	O
%	NN	O	O
to	TO	O	O
30	CD	O	O
%	NN	O	O
;	:	O	O
P	NNP	O	O
=	NNP	O	O
0.009	CD	O	O
)	)	O	O
,	,	O	O
thus	RB	O	O
significantly	RB	O	O
favouring	VBG	O	O
the	DT	O	O
PELF	NNP	O	O
combination	NN	O	O
.	.	O	O

The	DT	O	O
survival	NN	o	OMO
rates	NNS	o	OMO
after	IN	O	O
12	CD	O	O
months	NNS	O	O
(	(	O	O
30.8	CD	O	O
%	NN	O	O
versus	IN	O	O
22.4	CD	O	O
%	NN	O	O
)	)	O	O
and	CC	O	O
24	CD	O	O
months	NNS	O	O
(	(	O	O
15.7	CD	O	O
%	NN	O	O
versus	IN	O	O
9.5	CD	O	O
%	NN	O	O
)	)	O	O
were	VBD	O	O
also	RB	O	O
higher	JJR	O	O
among	IN	O	O
patients	NNS	O	O
receiving	VBG	O	O
PELF	NNP	O	O
,	,	O	O
but	CC	O	O
these	DT	O	O
differences	NNS	O	O
were	VBD	O	O
not	RB	O	O
statistically	RB	O	O
significant	JJ	O	O
.	.	O	O

The	DT	O	O
toxicities	NNS	o	OA
were	VBD	O	O
qualitatively	RB	O	O
different	JJ	O	O
but	CC	O	O
quantitatively	RB	O	O
similar	JJ	O	O
.	.	O	O

Both	DT	O	O
regimens	VBZ	O	O
seem	VBP	O	O
to	TO	O	O
be	VB	O	O
feasible	JJ	O	O
provided	VBN	O	O
that	IN	O	O
careful	JJ	O	O
patient	JJ	O	O
monitoring	NN	O	O
is	VBZ	O	O
assured	VBN	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
PELF	NNP	i	IPM
is	VBZ	O	O
significantly	RB	O	O
more	RBR	O	O
active	JJ	O	O
than	IN	O	O
FAMTX	NNP	i	IPM
and	CC	O	O
deserves	VBZ	O	O
further	JJ	O	O
research	NN	O	O
in	IN	O	O
the	DT	O	O
adjuvant	JJ	O	O
setting	NN	O	O
.	.	O	O

Omega-3	JJ	i	IPM
fatty	JJ	i	IPM
acids	NNS	i	IPM
supplementation	NN	i	IPM
in	IN	O	O
children	NNS	p	O
with	IN	p	O
autism	NN	p	PC
:	:	p	O
a	DT	O	O
double-blind	JJ	O	O
randomized	NN	O	O
,	,	O	O
placebo-controlled	JJ	i	IC
pilot	NN	O	O
study	NN	O	O
.	.	O	O

BACKGROUND	NNP	O	O
There	EX	O	O
is	VBZ	O	O
increasing	VBG	O	O
evidence	NN	O	O
that	IN	O	O
fatty	JJ	O	O
acid	JJ	O	O
deficiencies	NNS	O	O
or	CC	O	O
imbalances	NNS	O	O
may	MD	O	O
contribute	VB	O	O
to	TO	O	O
childhood	VB	p	O
neurodevelopmental	JJ	p	PC
disorders	NNS	p	PC
.	.	p	PC

METHODS	NNP	O	O
We	PRP	O	O
conducted	VBD	O	O
a	DT	O	O
randomized	VBN	O	O
,	,	O	O
double-blind	JJ	O	O
,	,	O	O
placebo-controlled	JJ	i	O
6-week	JJ	O	O
pilot	NN	O	O
trial	NN	O	O
investigating	VBG	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
1.5	CD	i	IPM
g/d	NN	i	IPM
of	IN	i	IPM
omega-3	JJ	i	IPM
fatty	JJ	i	IPM
acids	NNS	i	IPM
(	(	i	IPM
.84	JJ	i	IPM
g/d	NN	i	IPM
eicosapentaenoic	NN	i	IPM
acid	NN	i	IPM
,	,	i	IPM
.7	NNP	i	IPM
g/d	NN	i	IPM
docosahexaenoic	NN	i	IPM
acid	NN	i	IPM
)	)	i	IPM
supplementation	NN	i	IPM
in	IN	O	O
13	CD	p	PSS
children	NNS	p	O
(	(	p	O
aged	VBN	p	PA
5	CD	p	PA
to	TO	p	PA
17	CD	p	PA
years	NNS	p	PA
)	)	p	O
with	IN	p	O
autistic	JJ	p	O
disorders	NNS	p	O
accompanied	VBN	p	O
by	IN	p	O
severe	JJ	p	PC
tantrums	NNS	p	PC
,	,	p	PC
aggression	NN	p	PC
,	,	p	PC
or	CC	p	PC
self-injurious	JJ	p	PC
behavior	NN	p	PC
.	.	p	O

The	DT	O	O
outcome	NN	O	O
measure	NN	O	O
was	VBD	O	O
the	DT	O	O
Aberrant	NNP	o	OME
Behavior	NNP	o	OME
Checklist	NNP	o	OME
(	(	o	OME
ABC	NNP	o	OME
)	)	o	OME
at	IN	O	O
6	CD	O	O
weeks	NNS	O	O
.	.	O	O

RESULTS	NNP	O	O
We	PRP	O	O
observed	VBD	O	O
an	DT	O	O
advantage	NN	O	O
of	IN	O	O
omega-3	JJ	i	IPM
fatty	JJ	i	IPM
acids	NNS	i	IPM
compared	VBN	O	O
with	IN	O	O
placebo	NN	i	IPM
for	IN	O	O
hyperactivity	NN	o	OPH
and	CC	o	OPH
stereotypy	NN	o	OPH
,	,	O	O
each	DT	O	O
with	IN	O	O
a	DT	O	O
large	JJ	O	O
effect	NN	O	O
size	NN	O	O
.	.	O	O

Repeated-measures	NNS	O	O
ANOVA	NNP	O	O
indicated	VBD	O	O
a	DT	O	O
trend	NN	O	O
toward	IN	O	O
superiority	NN	O	O
of	IN	O	O
omega-3	JJ	i	IPM
fatty	JJ	i	IPM
acids	NNS	i	IPM
over	IN	O	O
placebo	NN	O	O
for	IN	O	O
hyperactivity	NN	o	OPH
.	.	o	OPH

No	DT	O	O
clinically	RB	O	O
relevant	JJ	O	O
adverse	JJ	o	OA
effects	NNS	o	OA
were	VBD	O	O
elicited	VBN	O	O
in	IN	O	O
either	DT	O	O
group	NN	O	O
.	.	O	O

CONCLUSIONS	VBZ	O	O
The	DT	O	O
results	NNS	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
provide	VBP	O	O
preliminary	JJ	O	O
evidence	NN	O	O
that	IN	O	O
omega-3	JJ	i	IPM
fatty	JJ	i	IPM
acids	NNS	i	IPM
may	MD	O	O
be	VB	O	O
an	DT	O	O
effective	JJ	O	O
treatment	NN	O	O
for	IN	O	O
children	NNS	p	O
with	IN	p	O
autism	NN	p	O
.	.	p	O

Variations	NNS	O	O
in	IN	O	O
EEG	NNP	o	OPH
discharges	NNS	o	OPH
predict	VBP	O	O
ADHD	NNP	O	O
severity	NN	O	O
within	IN	O	O
individual	JJ	p	O
Smith-Lemli-Opitz	JJ	p	O
patients	NNS	p	O
.	.	p	O

OBJECTIVE	IN	O	O
We	PRP	O	O
sought	VBD	O	O
to	TO	O	O
examine	VB	O	O
the	DT	O	O
prevalence	NN	O	O
of	IN	O	O
EEG	NNP	O	O
abnormalities	NNS	O	O
in	IN	O	O
Smith-Lemli-Opitz	NNP	p	PC
syndrome	NN	p	PC
(	(	p	PC
SLOS	NNP	p	PC
)	)	p	PC
as	RB	O	O
well	RB	O	O
as	IN	O	O
the	DT	O	O
relationship	NN	O	O
between	IN	O	O
interictal	JJ	O	O
epileptiform	NN	O	O
discharges	NNS	O	O
(	(	O	O
IEDs	NNP	O	O
)	)	O	O
and	CC	O	O
within-subject	JJ	O	O
variations	NNS	O	O
in	IN	O	O
attentional	JJ	O	O
symptom	NN	O	O
severity	NN	O	O
.	.	O	O

METHODS	NNP	O	O
In	IN	O	O
the	DT	O	O
context	NN	O	O
of	IN	O	O
a	DT	O	O
clinical	JJ	O	O
trial	NN	O	O
for	IN	O	O
SLOS	NNP	O	O
,	,	O	O
we	PRP	O	O
performed	VBD	O	O
cross-sectional	JJ	O	O
and	CC	O	O
repeated-measure	JJ	O	O
observational	JJ	O	O
studies	NNS	O	O
of	IN	O	O
the	DT	O	O
relationship	NN	O	O
between	IN	O	O
EEG	NNP	i	IPH
findings	NNS	O	O
and	CC	O	O
cognitive/behavioral	JJ	O	O
factors	NNS	O	O
on	IN	O	O
23	CD	p	PSS
children	NNS	p	O
(	(	p	O
aged	VBN	p	PA
4-17	CD	p	PA
years	NNS	p	PA
)	)	p	O
.	.	p	O

EEGs	NNP	i	IPH
were	VBD	O	O
reviewed	VBN	O	O
for	IN	O	O
clinical	JJ	O	O
abnormalities	NNS	O	O
,	,	O	O
including	VBG	O	O
IEDs	NNP	O	O
,	,	O	O
by	IN	O	O
readers	NNS	O	O
blinded	VBD	O	O
to	TO	O	O
participants	NNS	O	O
'	POS	O	O
behavioral	NN	O	O
symptoms	NNS	O	O
.	.	O	O

Between-group	JJ	O	O
differences	NNS	O	O
in	IN	O	O
baseline	JJ	O	O
characteristics	NNS	O	O
of	IN	O	O
participants	NNS	O	O
with	IN	O	O
and	CC	O	O
without	IN	O	O
IEDs	NNP	O	O
were	VBD	O	O
analyzed	VBN	O	O
.	.	O	O

Within-subject	JJ	O	O
analyses	NNS	O	O
examined	VBD	O	O
the	DT	O	O
association	NN	O	O
between	IN	O	O
the	DT	O	O
presence	NN	O	O
of	IN	O	O
IEDs	NNP	O	O
and	CC	O	O
changes	NNS	O	O
in	IN	O	O
attention-deficit/hyperactivity	NN	o	OPH
disorder	NN	o	OPH
(	(	o	OPH
ADHD	NNP	o	OPH
)	)	o	OPH
symptoms	NNS	o	OPH
.	.	o	OPH

RESULTS	NNP	O	O
Of	IN	O	O
85	CD	O	O
EEGs	NNP	O	O
,	,	O	O
43	CD	O	O
(	(	O	O
51	CD	O	O
%	NN	O	O
)	)	O	O
were	VBD	O	O
abnormal	JJ	o	OPH
,	,	O	O
predominantly	RB	O	O
because	IN	O	O
of	IN	O	O
IEDs	NNP	O	O
.	.	O	O

Only	RB	O	O
one	CD	O	O
subject	NN	O	O
had	VBD	O	O
documented	VBN	O	O
clinical	JJ	o	OA
seizures	NNS	o	OA
.	.	o	OA

IEDs	NNP	O	O
clustered	VBD	O	O
in	IN	O	O
13	CD	p	O
subjects	NNS	p	O
(	(	p	O
57	CD	p	O
%	NN	p	O
)	)	p	O
,	,	p	O
whereas	$	p	O
9	CD	p	O
subjects	NNS	p	O
(	(	p	O
39	CD	p	O
%	NN	p	O
)	)	p	O
had	VBD	p	O
EEGs	NNP	p	O
consistently	RB	p	O
free	JJ	p	O
of	IN	p	O
IEDs	NNP	p	O
.	.	p	O

While	IN	O	O
there	EX	O	O
were	VBD	O	O
no	DT	O	O
significant	JJ	O	O
group	NN	O	O
differences	NNS	O	O
in	IN	O	O
sex	NN	o	OME
,	,	o	OME
age	NN	o	OME
,	,	o	OME
intellectual	JJ	o	OME
disability	NN	o	OME
,	,	o	OME
language	NN	o	OME
level	NN	o	OME
,	,	o	OME
or	CC	o	OME
baseline	VB	o	OME
ADHD	NNP	o	OME
symptoms	NNS	o	OME
,	,	o	OME
autistic	JJ	o	OME
symptoms	NNS	o	OME
tended	VBD	O	O
to	TO	O	O
be	VB	O	O
more	RBR	O	O
prevalent	JJ	O	O
in	IN	O	O
the	DT	O	O
IED	NNP	O	O
group	NN	O	O
(	(	O	O
according	VBG	O	O
to	TO	O	O
Autism	NNP	o	OME
Diagnostic	NNP	o	OME
Observation	NNP	o	OME
Schedule-2	NNP	o	OME
criteria	NNS	o	OME
)	)	o	OME
.	.	O	O

Within	JJ	O	O
individuals	NNS	O	O
,	,	O	O
the	DT	O	O
presence	NN	O	O
of	IN	O	O
IEDs	NNP	O	O
on	IN	O	O
a	DT	O	O
particular	JJ	O	O
EEG	NNP	O	O
predicted	VBD	O	O
,	,	O	O
on	IN	O	O
average	NN	O	O
,	,	O	O
a	DT	O	O
27	CD	O	O
%	NN	O	O
increase	NN	O	O
in	IN	O	O
ADHD	NNP	o	OME
symptom	NN	o	OME
severity	NN	o	OME
.	.	o	OME

CONCLUSIONS	NNP	O	O
Epileptiform	NNP	O	O
discharges	NNS	O	O
are	VBP	O	O
common	JJ	O	O
in	IN	O	O
SLOS	NNP	O	O
,	,	O	O
despite	IN	O	O
a	DT	O	O
relatively	RB	O	O
low	JJ	O	O
prevalence	NN	O	O
of	IN	O	O
epilepsy	NN	O	O
.	.	O	O

Fluctuations	NNS	O	O
in	IN	O	O
the	DT	O	O
presence	NN	O	O
of	IN	O	O
epileptiform	NN	O	O
discharges	NNS	O	O
within	IN	O	O
individual	JJ	O	O
children	NNS	O	O
with	IN	O	O
a	DT	O	O
developmental	JJ	O	O
disability	NN	O	O
syndrome	NN	O	O
may	MD	O	O
be	VB	O	O
associated	VBN	O	O
with	IN	O	O
fluctuations	NNS	O	O
in	IN	O	O
ADHD	NNP	O	O
symptomatology	NN	O	O
,	,	O	O
even	RB	O	O
in	IN	O	O
the	DT	O	O
absence	NN	O	O
of	IN	O	O
clinical	JJ	O	O
seizures	NNS	O	O
.	.	O	O

A	DT	O	O
placebo-controlled	JJ	i	IC
,	,	O	O
randomized	JJ	O	O
clinical	JJ	O	O
trial	NN	O	O
using	VBG	O	O
testosterone	NN	i	IPM
undecanoate	NN	i	IPM
with	IN	i	IPM
injectable	JJ	i	IPM
norethisterone	JJ	i	IPM
enanthate	NN	i	IPM
:	:	i	IPM
effect	NN	O	O
on	IN	O	O
anthropometric	NN	p	O
,	,	p	O
metabolic	JJ	p	O
and	CC	p	O
biochemical	JJ	p	O
parameters	NNS	p	O
.	.	p	O

Testosterone	CD	O	O
administered	VBD	O	O
alone	RB	O	O
or	CC	O	O
in	IN	O	O
combination	NN	O	O
with	IN	O	O
progestogens	NNS	O	O
in	IN	O	O
male	JJ	O	O
contraception	NN	O	O
induces	NNS	O	O
reversible	JJ	O	O
oligo-azoospermia	JJ	O	O
,	,	O	O
but	CC	O	O
its	PRP$	O	O
effects	NNS	O	O
on	IN	O	O
body	NN	O	O
composition	NN	O	O
and	CC	O	O
metabolism	NN	O	O
are	VBP	O	O
less	RBR	O	O
known	JJ	O	O
.	.	O	O

We	PRP	O	O
analysed	VBD	p	O
anthropometric	JJ	p	O
and	CC	p	O
metabolic	JJ	p	O
parameters	NNS	p	O
in	IN	p	O
five	CD	p	O
groups	NNS	p	O
of	IN	p	O
10	CD	p	O
males	NNS	p	O
:	:	p	O
four	CD	p	O
receiving	VBG	p	O
testosterone	NN	i	IPM
undecanoate	NN	i	IPM
(	(	O	O
TU	NNP	O	O
:	:	O	O
1000	CD	O	O
mg	NN	O	O
)	)	O	O
plus	CC	i	IPM
norethisterone	JJ	i	IPM
enanthate	NN	i	IPM
(	(	O	O
NETE	NNP	O	O
:	:	O	O
200	CD	O	O
mg	NN	O	O
)	)	O	O
at	IN	O	O
different	JJ	O	O
intervals	NNS	O	O
(	(	O	O
every	DT	O	O
8	CD	O	O
weeks	NNS	O	O
:	:	O	O
NETE-8	JJ	O	O
;	:	O	O
every	DT	O	O
12	CD	O	O
weeks	NNS	O	O
:	:	O	O
NETE-12	NN	O	O
;	:	O	O
every	DT	O	O
6	CD	O	O
weeks	NNS	O	O
for	IN	O	O
12	CD	O	O
weeks	NNS	O	O
and	CC	O	O
then	RB	O	O
every	DT	O	O
12	CD	O	O
weeks	NNS	O	O
:	:	O	O
NETE-6/12	JJ	O	O
;	:	O	O
every	DT	O	O
6	CD	O	O
weeks	NNS	O	O
for	IN	O	O
12	CD	O	O
weeks	NNS	O	O
and	CC	O	O
then	RB	O	O
TU	NNP	i	IPM
plus	CC	i	IPM
placebo	JJ	i	IPM
every	DT	O	O
12	CD	O	O
weeks	NNS	O	O
:	:	O	O
NETE-6/12/0	NNP	O	O
)	)	O	O
and	CC	O	O
one	CD	O	O
placebo	NN	i	IC
(	(	O	O
NETE-0/0	NNP	O	O
)	)	O	O
for	IN	O	O
a	DT	O	O
total	NN	O	O
of	IN	O	O
48	CD	O	O
weeks	NNS	O	O
.	.	O	O

Body	NNP	o	OPH
mass	NN	o	OPH
index	NN	o	OPH
(	(	o	OPH
BMI	NNP	o	OPH
)	)	o	OPH
and	CC	o	OPH
waist	JJ	o	OPH
circumference	NN	o	OPH
did	VBD	o	OPH
not	RB	o	OPH
change	VB	o	OPH
in	IN	O	O
any	DT	O	O
groups	NNS	O	O
except	IN	O	O
for	IN	O	O
the	DT	O	O
NETE-8	NNP	O	O
in	IN	O	O
which	WDT	O	O
BMI	NNP	o	OPH
increased	VBD	o	OPH
significantly	RB	o	OPH
(	(	O	O
p	JJ	O	O
=	NNP	O	O
0.02	CD	O	O
)	)	O	O
at	IN	O	O
the	DT	O	O
end	NN	O	O
of	IN	O	O
the	DT	O	O
treatment	NN	O	O
period	NN	O	O
.	.	O	O

Lean	JJ	o	OPH
body	NN	o	OPH
mass	NN	o	OPH
(	(	o	OPH
MAMC	NNP	o	OPH
or	CC	o	OPH
AMA	NNP	o	OPH
)	)	o	OPH
increased	VBD	o	OPH
significantly	RB	o	OPH
in	IN	O	O
the	DT	O	O
highest	JJS	O	O
hormonal	JJ	O	O
dose	NN	O	O
groups	NNS	O	O
(	(	O	O
p	JJ	O	O
=	NN	O	O
0.04	CD	O	O
,	,	O	O
NETE-6/12	NNP	O	O
;	:	O	O
p	VBZ	O	O
=	$	O	O
0.004	CD	O	O
,	,	O	O
NETE-8	NNP	O	O
)	)	O	O
.	.	O	O

No	UH	O	O
differences	NNS	O	O
were	VBD	O	O
observed	VBN	O	O
in	IN	O	O
glucose	JJ	o	OPH
levels	NNS	o	OPH
,	,	o	OPH
insulin	NN	o	OPH
sensitivity	NN	o	OPH
index	NN	o	OPH
and	CC	o	OPH
lipid	JJ	o	OPH
profile	NN	o	OPH
as	RB	O	O
well	RB	O	O
as	IN	O	O
in	IN	O	O
biochemical	JJ	o	OPH
and	CC	o	OPH
cell	NN	o	OPH
count	NN	o	OPH
parameters	NNS	o	OPH
in	IN	O	O
any	DT	O	O
groups	NNS	O	O
.	.	O	O

In	IN	O	O
conclusion	NN	O	O
,	,	O	O
NETE	NNP	O	O
and	CC	O	O
TU	NNP	O	O
for	IN	O	O
48	CD	O	O
weeks	NNS	O	O
were	VBD	O	O
not	RB	O	O
accompanied	VBN	O	O
by	IN	O	O
any	DT	O	O
metabolic	JJ	o	OPH
changes	NNS	o	OPH
and	CC	o	OPH
any	DT	o	OPH
adverse	JJ	o	OA
effects	NNS	o	OA
.	.	o	O

The	DT	O	O
weight	JJ	o	OPH
gain	NN	o	OPH
of	IN	O	O
the	DT	O	O
highest	JJS	O	O
NETE	JJ	O	O
plus	CC	O	O
TU	JJ	O	O
dosage	NN	O	O
was	VBD	O	O
mainly	RB	O	O
because	IN	O	O
of	IN	O	O
gain	NN	O	O
in	IN	O	O
muscle	NN	O	O
mass	NN	O	O
.	.	O	O

Intraperitoneal	NNP	O	O
application	NN	O	O
of	IN	O	O
bupivacaine	NN	i	IPM
plus	CC	O	O
morphine	NN	i	IPM
for	IN	O	O
pain	NN	o	OPA
relief	NN	o	OPA
after	IN	O	O
laparoscopic	JJ	p	PC
cholecystectomy	NN	p	PC
.	.	p	PC

BACKGROUND	NNP	O	O
AND	NNP	O	O
OBJECTIVE	NNP	O	O
Intraperitoneal	NNP	O	O
administration	NN	O	O
of	IN	O	O
a	DT	O	O
local	JJ	O	O
anaesthetic	NN	O	O
in	IN	O	O
combination	NN	O	O
with	IN	O	O
an	DT	O	O
opioid	NN	i	O
,	,	O	O
for	IN	O	O
the	DT	O	O
relief	NN	O	O
of	IN	O	O
postoperative	JJ	o	OPA
pain	NN	o	OPA
,	,	O	O
has	VBZ	O	O
already	RB	O	O
been	VBN	O	O
reported	VBN	O	O
except	IN	O	O
after	IN	O	O
laparoscopic	JJ	p	O
cholecystectomy	NN	p	O
.	.	p	O

This	DT	O	O
study	NN	O	O
was	VBD	O	O
aimed	VBN	O	O
at	IN	O	O
assessing	VBG	O	O
the	DT	O	O
analgesic	JJ	O	O
effect	NN	O	O
of	IN	O	O
the	DT	O	O
intraperitoneal	JJ	O	O
administration	NN	O	O
of	IN	O	O
bupivacaine	NN	i	IPM
and	CC	i	O
morphine	NN	i	IPM
in	IN	O	O
patients	NNS	p	O
undergoing	VBG	p	O
laparoscopic	JJ	p	O
cholecystectomy	NN	p	O
.	.	p	O

METHODS	NNP	O	O
At	IN	O	O
the	DT	O	O
end	NN	O	O
of	IN	O	O
laparoscopic	JJ	O	O
cholecystectomy	NN	O	O
,	,	O	O
in	IN	O	O
a	DT	O	O
double-blind	NN	O	O
,	,	O	O
randomized	JJ	O	O
manner	NN	O	O
,	,	O	O
one	CD	O	O
of	IN	O	O
the	DT	O	O
following	JJ	O	O
injections	NNS	O	O
was	VBD	O	O
given	VBN	O	O
intraperitoneally	RB	O	O
.	.	O	O

There	EX	O	O
were	VBD	O	O
30	CD	p	O
patients	NNS	p	O
in	IN	p	O
each	DT	p	O
group	NN	p	O
:	:	p	O
Group	NNP	O	O
1	CD	O	O
,	,	O	O
physiological	JJ	i	IPM
saline	NN	i	IPM
30	CD	O	O
mL	NN	O	O
;	:	O	O
Group	NNP	O	O
2	CD	O	O
,	,	O	O
bupivacaine	VBP	i	IPM
0.25	CD	O	O
%	NN	O	O
30	CD	O	O
mL	NN	O	O
;	:	O	O
Group	NNP	O	O
3	CD	O	O
,	,	O	O
bupivacaine	VBP	i	IPM
0.25	CD	O	O
%	NN	O	O
30	CD	O	O
mL	NN	O	O
plus	CC	i	IPM
morphine	JJ	i	IPM
2	CD	O	O
mg	NN	O	O
.	.	O	O

In	IN	O	O
addition	NN	O	O
,	,	O	O
Group	NNP	O	O
2	CD	O	O
received	VBD	O	O
2	CD	O	O
mg	NNS	O	O
intravenous	JJ	O	O
(	(	O	O
i.v	JJ	O	O
.	.	O	O

)	)	O	O
morphine	NN	i	IPM
in	IN	O	O
2	CD	O	O
mL	NNS	O	O
saline	NN	i	IPM
,	,	O	O
and	CC	O	O
Groups	NNP	O	O
1	CD	O	O
and	CC	O	O
3	CD	O	O
,	,	O	O
2	CD	O	O
mL	NN	O	O
saline	NN	i	IPM
intravenously	RB	O	O
.	.	O	O

Patients	NNS	O	O
'	POS	O	O
postoperative	JJ	o	OPA
pain	NN	o	OPA
was	VBD	O	O
evaluated	VBN	O	O
using	VBG	O	O
a	DT	O	O
visual	JJ	o	OOt
analogue	NN	o	OOt
scale	NN	o	OOt
and	CC	O	O
a	DT	O	O
verbal	JJ	o	OME
rating	NN	o	OME
score	NN	o	OME
.	.	o	O

The	DT	O	O
postoperative	JJ	O	O
analgesic	JJ	O	O
requirement	NN	O	O
was	VBD	O	O
assessed	VBN	O	O
by	IN	O	O
the	DT	O	O
total	JJ	O	O
dose	NN	O	O
of	IN	O	O
metamizol	NN	o	OPH
administered	VBN	O	O
by	IN	O	O
an	DT	O	O
i.v	NN	O	O
.	.	O	O

patient-controlled	JJ	o	OOt
analgesia	NN	o	OOt
(	(	o	OOt
PCA	NNP	o	OOt
)	)	o	OOt
device	NN	O	O
.	.	O	O

Pain	NNP	o	OPA
,	,	o	O
vital	JJ	o	OPH
signs	NNS	o	OPH
,	,	o	O
supplemental	JJ	o	OPH
analgesic	JJ	o	OPH
consumption	NN	o	OPH
and	CC	o	O
side-effects	NNS	o	OA
were	VBD	O	O
recorded	VBN	O	O
for	IN	O	O
all	DT	O	O
patients	NNS	O	O
for	IN	O	O
24	CD	O	O
h.	JJ	O	O
RESULTS	NNP	O	O
There	EX	O	O
were	VBD	O	O
no	DT	O	O
differences	NNS	O	O
between	IN	O	O
the	DT	O	O
three	CD	O	O
groups	NNS	O	O
regarding	VBG	O	O
pain	NN	o	OPA
scores	NNS	o	OPA
(	(	O	O
at	IN	O	O
rest	NN	O	O
and	CC	O	O
coughing	VBG	O	O
)	)	O	O
during	IN	O	O
the	DT	O	O
study	NN	O	O
except	IN	O	O
in	IN	O	O
the	DT	O	O
first	JJ	O	O
2	CD	O	O
h	NN	O	O
,	,	O	O
when	WRB	O	O
scores	NNS	O	O
were	VBD	O	O
lower	JJR	O	O
for	IN	O	O
patients	NNS	O	O
receiving	VBG	O	O
intraperitoneal	JJ	O	O
bupivacaine	NN	i	IPM
plus	CC	O	O
i.v	NN	O	O
.	.	O	O

morphine	NN	i	IPM
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

Supplemental	JJ	o	OPH
consumption	NN	o	OPH
of	IN	o	OPH
metamizol	NN	o	OPH
was	VBD	O	O
significantly	RB	O	O
lower	JJR	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
in	IN	O	O
Group	NNP	O	O
3	CD	O	O
than	IN	O	O
in	IN	O	O
Group	NNP	O	O
1	CD	O	O
during	IN	O	O
the	DT	O	O
first	JJ	O	O
6	CD	O	O
h	NN	O	O
after	IN	O	O
surgery	NN	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
the	DT	O	O
cumulative	JJ	o	OOt
doses	NNS	o	OOt
of	IN	O	O
metamizol	NN	O	O
were	VBD	O	O
also	RB	O	O
lower	JJR	O	O
in	IN	O	O
Group	NNP	O	O
2	CD	O	O
than	IN	O	O
in	IN	O	O
Groups	NNP	O	O
1	CD	O	O
and	CC	O	O
3	CD	O	O
over	IN	O	O
the	DT	O	O
entire	JJ	O	O
study	NN	O	O
(	(	O	O
2025	CD	O	O
+/-	NN	O	O
1044	CD	O	O
mg	NN	O	O
vs.	FW	O	O
4925	CD	O	O
+/-	JJ	O	O
1238	CD	O	O
and	CC	O	O
4125	CD	O	O
+/-	JJ	O	O
1276mg	CD	O	O
;	:	O	O
P	NNP	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
In	IN	O	O
patients	NNS	p	O
undergoing	VBG	p	O
laparoscopic	JJ	p	O
cholecystectomy	NN	p	O
,	,	O	O
the	DT	O	O
intraperitoneal	JJ	O	O
administration	NN	O	O
of	IN	O	O
morphine	JJ	i	IPM
plus	CC	O	O
bupivacaine	JJ	i	IPM
0.25	CD	O	O
%	NN	O	O
reduced	VBD	O	O
the	DT	O	O
analgesic	JJ	o	OPH
requirements	NNS	o	OPH
during	IN	O	O
the	DT	O	O
first	JJ	O	O
6	CD	O	O
postoperative	JJ	O	O
hours	NNS	O	O
compared	VBN	O	O
with	IN	O	O
the	DT	O	O
control	NN	O	O
group	NN	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
the	DT	O	O
combination	NN	O	O
of	IN	O	O
intraperitoneal	JJ	O	O
bupivacaine	JJ	i	IPM
0.25	CD	O	O
%	NN	O	O
and	CC	O	O
i.v	NN	O	O
.	.	O	O

morphine	NN	i	IPM
was	VBD	O	O
more	RBR	O	O
effective	JJ	O	O
for	IN	O	O
treatment	NN	O	O
of	IN	O	O
pain	NN	o	OPA
after	IN	O	O
laparoscopic	JJ	p	O
cholecystectomy	NN	p	O
.	.	p	O

First-line	JJ	i	IPM
cisplatin	NN	i	IPM
with	IN	i	IPM
docetaxel	NN	i	IPM
or	CC	i	O
vinorelbine	NN	i	IPM
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
advanced	JJ	p	O
non-small-cell	JJ	p	O
lung	NN	p	O
cancer	NN	p	O
:	:	p	O
a	DT	O	O
quality	NN	p	O
of	IN	p	O
life	NN	p	O
directed	VBN	p	O
phase	NN	p	O
II	NNP	p	O
randomized	VBD	p	O
trial	NN	p	O
of	IN	p	O
Gruppo	NNP	p	O
Oncologico	NNP	p	O
Italia	NNP	p	O
Meridionale	NNP	p	O
.	.	p	O

BACKGROUND	NNP	O	O
Quality	NNP	o	OME
of	IN	o	OME
life	NN	o	OME
(	(	o	OME
QoL	NNP	o	OME
)	)	o	OME
has	VBZ	O	O
gained	VBN	O	O
greater	JJR	O	O
importance	NN	O	O
in	IN	O	O
the	DT	O	O
management	NN	O	O
of	IN	O	O
metastatic	JJ	p	O
non-small-cell	JJ	p	O
lung	NN	p	O
cancer	NN	p	O
due	JJ	O	O
to	TO	O	O
the	DT	O	O
palliative	JJ	O	O
nature	NN	O	O
of	IN	O	O
treatment	NN	O	O
.	.	O	O

Docetaxel	NNP	i	IPM
(	(	i	IPM
DCT	NNP	i	IPM
)	)	i	IPM
and	CC	i	O
cisplatin	NN	i	IPM
(	(	i	IPM
CDDP	NNP	i	IPM
)	)	i	IPM
doublet	NN	i	IPM
has	VBZ	O	O
been	VBN	O	O
reported	VBN	O	O
to	TO	O	O
be	VB	O	O
associated	VBN	O	O
to	TO	O	O
a	DT	O	O
better	JJR	O	O
QoL	NNP	O	O
than	IN	O	O
the	DT	O	O
weekly	JJ	O	O
vinorelbine	NN	i	IPM
(	(	i	IPM
VNR	NNP	i	IPM
)	)	i	IPM
and	CC	i	O
CDDP	NNP	i	IPM
regimen	NNS	O	O
.	.	O	O

Recently	RB	O	O
a	DT	O	O
newer	NN	O	O
more	RBR	O	O
tolerated	JJ	O	O
schedule	NN	O	O
of	IN	O	O
the	DT	O	O
VNR/CDDP	NNP	i	IPH
regimen	NN	O	O
has	VBZ	O	O
been	VBN	O	O
published	VBN	O	O
and	CC	O	O
is	VBZ	O	O
widely	RB	O	O
employed	VBN	O	O
in	IN	O	O
medical	JJ	O	O
practice	NN	O	O
.	.	O	O

The	DT	O	O
impact	NN	O	O
of	IN	O	O
these	DT	O	O
regimens	NNS	O	O
on	IN	O	O
patients	NNS	O	O
'	POS	O	O
QoL	NNP	O	O
as	RB	O	O
well	RB	O	O
as	IN	O	O
symptoms	NNS	o	OPH
control	NN	o	OPH
and	CC	o	O
type	NN	o	O
and	CC	O	O
grading	VBG	O	O
chemo-related	JJ	O	O
side-effects	NNS	o	OPH
has	VBZ	O	O
been	VBN	O	O
compared	VBN	O	O
prospectically	RB	O	O
.	.	O	O

METHODS	NNP	O	O
Patients	NNPS	p	O
received	VBD	O	O
CDDP	NNP	i	IPM
75	CD	i	IPM
mg/m	NN	i	IPM
(	(	i	IPM
2	CD	i	IPM
)	)	i	IPM
plus	CC	i	IPM
DCT	NNP	i	IPM
75	CD	i	IPM
mg/m	NN	i	IPM
(	(	i	IPM
2	CD	i	IPM
)	)	i	IPM
on	IN	O	O
day	NN	O	O
1	CD	O	O
every	DT	O	O
weeks	NNS	O	O
(	(	O	O
arm	IN	O	O
A	NNP	O	O
)	)	O	O
or	CC	O	O
CDDP	$	i	IPM
80	CD	i	IPM
mg/m	NN	i	IPM
(	(	i	IPM
2	CD	i	IPM
)	)	i	IPM
on	IN	i	IPM
day	NN	i	IPM
1	CD	i	IPM
plus	CC	i	IPM
VNR	NNP	i	IPM
30	CD	i	IPM
mg/m	NN	i	IPM
(	(	i	IPM
2	CD	i	IPM
)	)	i	IPM
day	NN	O	O
1	CD	O	O
and	CC	O	O
8	CD	O	O
every	DT	O	O
3	CD	O	O
weeks	NNS	O	O
(	(	O	O
arm	NN	O	O
B	NNP	O	O
)	)	O	O
.	.	O	O

G-CSF	NNP	i	IPM
and/or	JJ	i	O
EPO	NNP	i	IPM
were	VBD	O	O
employed	VBN	O	O
as	IN	O	O
needed	VBN	O	O
.	.	O	O

Health-related	JJ	o	OME
QoL	NNP	o	OME
was	VBD	O	O
assessed	VBN	O	O
at	IN	O	O
entry	NN	O	O
and	CC	O	O
after	IN	O	O
every	DT	O	O
cycle	NN	O	O
by	IN	O	O
the	DT	O	O
EORTC-QLQ-C30	NNP	O	O
and	CC	O	O
LC13	NNP	o	OME
questionnaires	NNS	o	OME
,	,	o	O
toxicity	NN	o	OPH
by	IN	O	O
the	DT	O	O
NCI-NCCN	NNP	O	O
CTC	NNP	O	O
vs	NN	O	O
2	CD	O	O
,	,	O	O
and	CC	O	O
intent-to-treat	JJ	O	O
objective	JJ	o	OPH
response	NN	o	OPH
by	IN	O	O
the	DT	O	O
Recist	NNP	O	O
criteria	NNS	O	O
.	.	O	O

RESULTS	VB	O	O
The	DT	O	O
QoL	NNP	o	OPH
questionnaires	NNS	o	OPH
were	VBD	O	O
completed	VBN	O	O
by	IN	O	O
37	CD	p	O
pts	NNS	p	O
(	(	p	O
88	CD	p	O
%	NN	p	O
)	)	p	O
in	IN	p	O
the	DT	p	O
DCT/CDDP	NNP	i	IPM
arm	NN	p	O
and	CC	O	O
39	CD	p	O
pts	NNS	p	O
(	(	p	O
87	CD	p	O
%	NN	p	O
)	)	p	O
in	IN	p	O
the	DT	p	O
VNR/CDDP	NNP	i	IPM
one	NN	p	O
.	.	p	O

Baseline	JJ	O	O
mean	JJ	O	O
scores	NNS	O	O
and	CC	O	O
rates	NNS	O	O
at	IN	O	O
which	WDT	O	O
pts	NNS	O	O
failed	VBD	O	O
to	TO	O	O
complete	VB	O	O
QoL	NNP	O	O
assessment	NN	O	O
were	VBD	O	O
similar	JJ	O	O
in	IN	O	O
the	DT	O	O
two	CD	O	O
arms	NNS	O	O
.	.	O	O

Global	NNP	o	OME
health	NN	o	OME
status	NN	o	OME
of	IN	O	O
the	DT	O	O
EORTC	NNP	o	OPH
QLQ-C30	NNP	o	OPH
scale	NN	o	OPH
and	CC	O	O
specific	JJ	o	O
symptoms	NNS	o	O
control	NN	o	O
(	(	O	O
LC13	NNP	O	O
module	NN	O	O
)	)	O	O
improved	VBD	O	O
during	IN	O	O
treatment	NN	O	O
without	IN	O	O
any	DT	O	O
statistically	RB	O	O
significant	JJ	O	O
difference	NN	O	O
between	IN	O	O
the	DT	O	O
two	CD	O	O
arms	NNS	O	O
.	.	O	O

Emotional	JJ	o	OME
functioning	NN	o	OME
remained	VBD	O	O
stable	JJ	O	O
in	IN	O	O
both	DT	O	O
groups	NNS	O	O
during	IN	O	O
treatment	NN	O	O
,	,	O	O
whereas	JJ	O	O
physical	JJ	o	OME
and	CC	o	O
role	NN	o	OME
improved	VBN	O	O
slightly	RB	O	O
.	.	O	O

In	IN	O	O
the	DT	O	O
DCT/CDDP	NNP	i	O
arm	NN	O	O
14	CD	O	O
pts	NNS	O	O
(	(	O	O
33	CD	O	O
%	NN	O	O
;	:	O	O
95	CD	O	O
%	NN	O	O
CL	NNP	O	O
24-40	CD	O	O
%	NN	O	O
)	)	O	O
had	VBD	O	O
PR	NNP	O	O
,	,	O	O
and	CC	O	O
10	CD	O	O
(	(	O	O
24	CD	O	O
%	NN	O	O
)	)	O	O
SD	NNP	O	O
for	IN	O	O
a	DT	O	O
57	CD	O	O
%	NN	O	O
TGCR	NNP	O	O
.	.	O	O

In	IN	O	O
the	DT	O	O
VNR/CDDP	NNP	i	IPM
arm	NN	O	O
12	CD	O	O
pts	NNS	O	O
(	(	O	O
27	CD	O	O
%	NN	O	O
)	)	O	O
achieved	VBD	O	O
PR	NNP	o	OPH
,	,	O	O
18	CD	O	O
(	(	O	O
41	CD	O	O
%	NN	O	O
)	)	O	O
SD	VBZ	O	O
a	DT	O	O
68	CD	O	O
%	NN	O	O
TGCR	NNP	O	O
.	.	O	O

Differences	NNS	O	O
were	VBD	O	O
not	RB	O	O
statistically	RB	O	O
significant	JJ	O	O
.	.	O	O

Median	JJ	o	OPH
time-to-progression	NN	o	OPH
was	VBD	O	O
4.2	CD	O	O
months	NNS	O	O
in	IN	O	O
the	DT	O	O
DCT/CDDP	NNP	i	IPM
arm	NN	O	O
and	CC	O	O
4.5	CD	O	O
months	NNS	O	O
in	IN	O	O
the	DT	O	O
VNR/CDDP	NNP	i	IPM
one	CD	O	O
,	,	O	O
and	CC	O	O
median	JJ	o	OMO
overall	JJ	o	OMO
survival	NN	o	OMO
was	VBD	O	O
12.1	CD	O	O
(	(	O	O
range	VB	O	O
1-26+	JJ	O	O
months	NNS	O	O
)	)	O	O
and	CC	O	O
12.5	CD	O	O
months	NNS	O	O
(	(	O	O
range	VB	O	O
1-28+	JJ	O	O
months	NNS	O	O
)	)	O	O
for	IN	O	O
DCT/CDDP	NNP	i	IPM
and	CC	O	O
VNR/CDDP	NNP	i	O
arms	NNS	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

Febrile	NNP	o	OPH
neutropenia	JJ	o	OPH
rate	NN	o	OPH
was	VBD	O	O
higher	RBR	O	O
in	IN	O	O
the	DT	O	O
VNR/CDDP	NNP	i	IPM
arm	NN	O	O
(	(	O	O
p=0.02	NN	O	O
)	)	O	O
as	RB	O	O
well	RB	O	O
as	IN	O	O
G3-4	NNP	O	O
anemia	NN	o	OPH
(	(	O	O
p=0.005	NN	O	O
)	)	O	O
and	CC	O	O
G-CSF/EPO	NNP	O	O
use	NN	O	O
(	(	O	O
p=0.019	NN	O	O
)	)	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
Global	NNP	o	OPH
and	CC	o	OPH
specific	JJ	o	OPH
health-related	JJ	o	OPH
QoL	NNP	o	OPH
data	NNS	O	O
similar	JJ	O	O
in	IN	O	O
both	DT	O	O
treatment	NN	O	O
groups	NNS	O	O
with	IN	O	O
no	DT	O	O
statistically	RB	O	O
significant	JJ	O	O
difference	NN	O	O
.	.	O	O

Efficacy	NN	o	OOt
measures	NNS	o	OOt
,	,	o	O
overall	JJ	o	O
response	NN	o	OPH
rate	NN	o	OPH
,	,	o	O
time-to-progression	NN	o	OPH
and	CC	o	O
overall	JJ	o	OMO
survival	NN	o	OMO
were	VBD	O	O
equivalent	JJ	O	O
in	IN	O	O
both	DT	O	O
arms	NNS	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
severe	JJ	o	OPH
anemia	NN	o	OPH
and	CC	o	O
febrile	JJ	o	OPH
neutropenia	NN	o	OPH
are	VBP	O	O
statistically	RB	O	O
more	RBR	O	O
frequent	JJ	O	O
in	IN	O	O
the	DT	O	O
VNR/CDDP	NNP	i	IPM
arm	NN	O	O
than	IN	O	O
in	IN	O	O
the	DT	O	O
DCT/CDDP	NNP	i	IPM
one	NN	O	O
.	.	O	O

These	DT	O	O
data	NNS	O	O
should	MD	O	O
be	VB	O	O
considered	VBN	O	O
in	IN	O	O
treatment	NN	O	O
decision-making	NN	O	O
for	IN	O	O
pts	NNS	p	O
with	IN	p	O
advanced	JJ	p	O
non-small-cell	JJ	p	O
lung	NN	p	O
cancer	NN	p	O
and	CC	O	O
for	IN	O	O
the	DT	O	O
design	NN	O	O
of	IN	O	O
future	JJ	O	O
trials	NNS	O	O
with	IN	O	O
chemotherapy	NN	O	O
plus	CC	O	O
biologics	NNS	O	O
.	.	O	O

Can	MD	O	O
incentives	VB	i	IE
undermine	JJ	O	O
intrinsic	JJ	o	OME
motivation	NN	o	OME
to	TO	O	O
participate	VB	O	O
in	IN	O	O
epidemiologic	JJ	O	O
surveys	NNS	O	O
?	.	O	O
Response	JJ	O	O
rates	NNS	O	O
to	TO	O	O
surveys	NNS	O	O
are	VBP	O	O
decreasing	VBG	O	O
.	.	O	O

The	DT	O	O
purpose	NN	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
evaluate	VB	O	O
the	DT	O	O
use	NN	i	IE
of	IN	i	IE
lottery	JJ	i	IE
tickets	NNS	i	IE
as	IN	i	IE
incentives	NNS	i	IE
in	IN	O	O
an	DT	O	O
epidemiologic	JJ	p	O
control	NN	p	O
group	NN	p	O
.	.	p	O

A	DT	O	O
self-administered	JJ	p	O
questionnaire	NN	p	O
was	VBD	p	O
sent	VBN	p	O
to	TO	p	O
parents	NNS	p	O
in	IN	p	O
the	DT	p	O
municipality	NN	p	O
of	IN	p	O
Stockholm	NNP	p	O
,	,	p	O
Sweden	NNP	p	O
,	,	p	O
who	WP	p	O
were	VBD	p	O
to	TO	p	O
be	VB	p	O
used	VBN	p	O
as	IN	p	O
a	DT	p	O
control	NN	p	O
group	NN	p	O
in	IN	p	O
a	DT	p	O
study	NN	p	O
addressing	VBG	p	O
stress	NN	p	O
in	IN	p	O
parents	NNS	p	O
of	IN	p	O
children	NNS	p	PA
with	IN	p	O
cancer	NN	p	PC
.	.	p	O

A	DT	O	O
stratified	JJ	O	O
random	JJ	O	O
sample	NN	O	O
of	IN	O	O
450	CD	p	PSS
parents	NNS	p	O
were	VBD	O	O
randomized	VBN	O	O
into	IN	O	O
three	CD	i	O
incentive	JJ	i	O
groups	NNS	i	O
:	:	i	O
(	(	i	O
a	DT	i	O
)	)	i	O
no	DT	i	IC
incentive	NN	i	IC
;	:	i	O
(	(	i	O
b	NN	i	O
)	)	i	O
a	DT	i	O
promised	JJ	i	IE
incentive	NN	i	IE
of	IN	i	IE
one	CD	i	IE
lottery	NN	i	IE
ticket	NN	i	IE
to	TO	i	IE
be	VB	i	IE
received	VBN	i	IE
upon	IN	i	IE
reply	NN	i	IE
;	:	i	O
(	(	i	O
c	NN	i	O
)	)	i	O
a	DT	i	O
promised	JJ	i	IE
incentive	NN	i	IE
of	IN	i	IE
one	CD	i	IE
lottery	NN	i	IE
ticket	NN	i	IE
to	TO	i	IE
be	VB	i	IE
received	VBN	i	IE
upon	IN	i	IE
reply	NN	i	IE
and	CC	i	IE
an	DT	i	IE
additional	JJ	i	IE
lottery	NN	i	IE
ticket	NN	i	IE
upon	IN	i	IE
reply	NN	i	IE
within	IN	i	IE
1	CD	i	IE
week	NN	i	IE
.	.	i	O

The	DT	O	O
overall	JJ	O	O
response	NN	o	OME
rate	NN	o	OME
across	IN	O	O
the	DT	O	O
three	CD	O	O
groups	NNS	O	O
was	VBD	O	O
65.3	CD	O	O
%	NN	O	O
.	.	O	O

The	DT	O	O
response	NN	o	OME
rate	NN	o	OME
was	VBD	O	O
highest	JJS	O	O
in	IN	O	O
the	DT	O	O
no	DT	i	IC
incentive	NN	i	IC
group	NN	i	IC
(	(	O	O
69.3	CD	O	O
%	NN	O	O
)	)	O	O
and	CC	O	O
lowest	JJS	O	O
in	IN	O	O
the	DT	O	O
one	CD	i	IE
plus	CC	i	IE
one	CD	i	IE
lottery	NN	i	IE
ticket	NN	i	IE
group	NN	i	IE
(	(	O	O
62.0	CD	O	O
%	NN	O	O
)	)	O	O
.	.	O	O

In	IN	O	O
a	DT	O	O
survival	JJ	o	OMO
analysis	NN	o	OMO
,	,	O	O
the	DT	O	O
difference	NN	O	O
between	IN	O	O
the	DT	O	O
two	CD	O	O
response	NN	O	O
curves	NNS	O	O
was	VBD	O	O
significant	JJ	O	O
by	IN	O	O
the	DT	O	O
log-rank	JJ	O	O
test	NN	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.04	CD	O	O
)	)	O	O
,	,	O	O
with	IN	O	O
the	DT	O	O
no	DT	O	O
incentive	NN	O	O
group	NN	O	O
having	VBG	O	O
a	DT	O	O
shorter	JJR	O	O
time	NN	O	O
to	TO	O	O
response	NN	O	O
than	IN	O	O
the	DT	O	O
incentive	NN	i	IE
group	NN	i	IE
.	.	i	O

Our	PRP$	O	O
findings	NNS	O	O
suggest	VBP	O	O
that	IN	O	O
the	DT	O	O
use	NN	O	O
of	IN	O	O
lottery	JJ	i	IE
tickets	NNS	i	IE
as	IN	O	O
incentives	NNS	O	O
to	TO	O	O
increase	VB	o	OME
participation	NN	o	OME
in	IN	O	O
a	DT	O	O
mail	NN	o	OOt
questionnaire	NN	o	OOt
among	IN	O	O
parents	NNS	O	O
may	MD	O	O
be	VB	O	O
less	RBR	O	O
valuable	JJ	O	O
or	CC	O	O
even	RB	O	O
harmful	JJ	O	O
.	.	O	O

Incentives	NNS	i	IE
may	MD	O	O
undermine	VB	O	O
motivation	NN	o	OME
in	IN	O	O
studies	NNS	O	O
in	IN	O	O
which	WDT	O	O
the	DT	O	O
intrinsic	JJ	O	O
motivation	NN	O	O
of	IN	O	O
the	DT	O	O
respondents	NNS	p	O
is	VBZ	O	O
already	RB	O	O
high	JJ	O	O
.	.	O	O

Impact	NN	O	O
of	IN	O	O
a	DT	O	O
controlled	VBN	i	IPH
heated	VBN	i	IPH
breathing	VBG	i	IPH
tube	NN	i	IPH
humidifier	NN	i	IPH
on	IN	O	O
sleep	JJ	o	OPH
quality	NN	o	OPH
during	IN	O	O
CPAP	NNP	i	IPH
therapy	NN	i	IPH
in	IN	p	O
a	DT	p	O
cool	JJ	p	O
sleeping	NN	p	O
environment	NN	p	O
.	.	p	O

There	EX	O	O
are	VBP	O	O
conflicting	VBG	O	O
data	NNS	O	O
on	IN	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
adding	VBG	O	O
a	DT	O	O
heated	VBN	i	IPH
humidifier	NN	i	IPH
to	TO	O	O
nasal	RB	O	O
continuous	JJ	i	IPH
positive	JJ	i	IPH
airway	NN	i	IPH
pressure	NN	i	IPH
(	(	i	IPH
CPAP	NNP	i	IPH
)	)	i	IPH
therapy	NN	i	IPH
for	IN	O	O
patients	NNS	p	O
with	IN	p	O
obstructive	JJ	p	O
sleep	JJ	p	O
apnoea	NN	p	O
syndrome	NN	p	O
(	(	p	O
OSAS	NNP	p	O
)	)	p	O
.	.	p	O

The	DT	O	O
effects	NNS	O	O
of	IN	O	O
heated	JJ	O	O
humidification	NN	O	O
on	IN	O	O
sleep	JJ	o	OPH
quality	NN	o	OPH
and	CC	o	O
treatment	NN	o	OA
side-effects	NNS	o	OA
for	IN	O	O
patients	NNS	O	O
who	WP	O	O
prefer	VBP	O	O
a	DT	O	O
cold	JJ	O	O
bedroom	NN	O	O
environment	NN	O	O
have	VBP	O	O
not	RB	O	O
been	VBN	O	O
studied	VBN	O	O
.	.	O	O

A	DT	O	O
randomised	JJ	O	O
,	,	O	O
controlled	VBD	O	O
crossover	RB	O	O
trial	NN	O	O
involving	VBG	O	O
19	CD	p	O
patients	NNS	p	O
with	IN	p	O
a	DT	p	O
first-ever	JJ	p	O
diagnosis	NN	p	O
of	IN	p	O
OSAS	NNP	p	O
measured	VBD	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
conventional	JJ	i	IPH
heated	JJ	i	IPH
humidification	NN	i	IPH
added	VBD	i	IPH
to	TO	i	IPH
CPAP	NNP	i	IPH
compared	VBN	O	O
with	IN	O	O
a	DT	O	O
controlled	VBN	i	IPH
heated	VBN	i	IPH
breathing	VBG	i	IPH
tube	NN	i	IPH
humidifier	NN	i	IPH
(	(	i	IPH
ThermoSmart	NNP	i	IPH
(	(	i	IPH
R	NNP	i	IPH
)	)	i	IPH
;	:	i	IPH
Fisher	NNP	O	O
and	CC	O	O
Paykel	NNP	O	O
Healthcare	NNP	O	O
,	,	O	O
Auckland	NNP	O	O
,	,	O	O
New	NNP	O	O
Zealand	NNP	O	O
)	)	O	O
on	IN	O	O
sleep	JJ	o	OPH
quality	NN	o	OPH
.	.	o	OPH

During	IN	O	O
the	DT	O	O
night	NN	O	O
in	IN	O	O
the	DT	O	O
sleep	JJ	O	O
laboratory	NN	O	O
at	IN	O	O
a	DT	O	O
mean	JJ	O	O
room	NN	O	O
temperature	NN	O	O
of	IN	O	O
14	CD	O	O
degrees	NNS	O	O
C	NNP	O	O
,	,	O	O
less	JJR	O	O
condensation	NN	o	OOt
formed	VBN	O	O
with	IN	O	O
the	DT	O	O
controlled	VBN	i	IPH
heated	VBD	i	IPH
breathing	VBG	i	IPH
tube	NN	i	IPH
humidifier	NN	i	IPH
(	(	O	O
1.9	CD	O	O
mL	NN	O	O
versus	NN	O	O
35.3	CD	O	O
mL	NN	O	O
)	)	O	O
in	IN	O	O
the	DT	O	O
delivery	NN	O	O
system	NN	O	O
.	.	O	O

In	IN	O	O
addition	NN	O	O
,	,	O	O
the	DT	O	O
total	JJ	o	OPH
sleep	JJ	o	OPH
time	NN	o	OPH
,	,	o	OPH
time	NN	o	OPH
spent	VBN	o	OPH
in	IN	o	OPH
sleep	JJ	o	OPH
stages	NNS	o	OPH
3	CD	o	OPH
and	CC	o	OPH
4	CD	o	OPH
,	,	o	OPH
and	CC	o	OPH
rapid	JJ	o	OPH
eye	NN	o	OPH
movement	NN	o	OPH
sleep	JJ	o	OPH
phases	NNS	o	OPH
were	VBD	O	O
significantly	RB	O	O
longer	RBR	O	O
and	CC	O	O
the	DT	O	O
overall	JJ	o	OA
side-effect	JJ	o	OA
score	NN	o	OA
was	VBD	O	O
lower	JJR	O	O
than	IN	O	O
with	IN	O	O
conventional	JJ	O	O
heated	JJ	O	O
humidification	NN	O	O
.	.	O	O

Patients	NNS	O	O
on	IN	O	O
nasal	JJ	O	O
continuous	JJ	O	O
positive	JJ	O	O
airway	NN	O	O
pressure	NN	O	O
desiring	VBG	O	O
a	DT	O	O
cool	JJ	O	O
bedroom	NN	O	O
temperature	NN	O	O
could	MD	O	O
benefit	VB	O	O
from	IN	O	O
controlled	VBN	i	IPH
heated	VBN	i	IPH
breathing	VBG	i	IPH
tube	JJ	i	IPH
humidification	NN	i	IPH
technology	NN	i	IPH
(	(	O	O
with	IN	O	O
inputs	NNS	O	O
from	IN	O	O
ambient	JJ	O	O
temperature	NN	O	O
,	,	O	O
set	VBN	O	O
pressure	NN	O	O
and	CC	O	O
flow	NN	O	O
)	)	O	O
.	.	O	O

Use	NNP	O	O
of	IN	O	O
the	DT	O	O
electrothermal	JJ	i	IS
bipolar	JJ	i	IS
vessel	NN	i	IS
system	NN	i	IS
(	(	i	IS
EBVS	NNP	i	IS
)	)	i	IS
in	IN	O	O
laparoscopic	JJ	O	O
adrenalectomy	NN	O	O
:	:	O	O
a	DT	O	O
prospective	JJ	O	O
study	NN	O	O
.	.	O	O

BACKGROUND	NNP	O	O
Since	IN	O	O
laparoscopic	NN	p	PC
adrenalectomy	NN	p	PC
(	(	p	PC
LA	NNP	p	PC
)	)	p	PC
has	VBZ	O	O
been	VBN	O	O
adopted	VBN	O	O
as	IN	O	O
the	DT	O	O
gold	JJ	O	O
standard	NN	O	O
for	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
adrenal	JJ	O	O
diseases	NNS	O	O
,	,	O	O
the	DT	O	O
development	NN	O	O
of	IN	O	O
technology	NN	O	O
for	IN	O	O
vascular	JJ	O	O
control	NN	O	O
and	CC	O	O
dissection	NN	O	O
manoeuvres	NNS	O	O
,	,	O	O
amongst	VBZ	O	O
other	JJ	O	O
things	NNS	O	O
,	,	O	O
may	MD	O	O
play	VB	O	O
a	DT	O	O
pivotal	JJ	O	O
role	NN	O	O
in	IN	O	O
its	PRP$	O	O
further	JJ	O	O
improvement	NN	O	O
.	.	O	O

We	PRP	O	O
report	VBP	O	O
our	PRP$	O	O
experience	NN	O	O
with	IN	O	O
the	DT	O	O
electrothermal	JJ	i	IS
bipolar	JJ	i	IS
vessel	NN	i	IS
sealing	NN	i	IS
(	(	i	IS
EBVS	NNP	i	IS
)	)	i	IS
device	NN	O	O
for	IN	O	O
LA	NNP	O	O
.	.	O	O

METHODS	NNP	O	O
From	IN	p	O
January	NNP	p	O
2004	CD	p	O
to	TO	p	O
January	NNP	p	O
2006	CD	p	O
,	,	p	O
50	CD	p	O
patients	NNS	p	O
(	(	p	O
pts	NNS	p	O
)	)	p	O
undergoing	VBG	p	O
LA	NNP	p	O
were	VBD	O	O
selected	VBN	O	O
and	CC	O	O
randomized	VBN	O	O
for	IN	O	O
use	NN	O	O
of	IN	O	O
the	DT	O	O
EBVS	NNP	i	IS
(	(	i	IPH
25	CD	i	IPH
pts	NNS	i	IPH
,	,	i	IPH
group	NN	i	IPH
A	NNP	i	IPH
)	)	i	IPH
versus	IN	i	IPH
the	DT	i	IPH
UltraSonic	NNP	i	IPH
Shears	NNP	i	IPH
(	(	i	IPH
USS	NNP	i	IPH
)	)	i	IPH
device	NN	i	IPH
(	(	O	O
25	CD	O	O
pts	NNS	O	O
,	,	O	O
group	NN	O	O
B	NNP	O	O
)	)	O	O
.	.	O	O

Age	NNP	O	O
,	,	O	O
sex	NN	O	O
,	,	O	O
body	NN	O	O
mass	NN	O	O
index	NN	O	O
(	(	O	O
BMI	NNP	O	O
)	)	O	O
,	,	O	O
previous	JJ	O	O
surgery	NN	O	O
and	CC	O	O
associated	VBN	O	O
diseases	NNS	O	O
were	VBD	O	O
similar	JJ	O	O
between	IN	O	O
the	DT	O	O
two	CD	O	O
groups	NNS	O	O
.	.	O	O

The	DT	O	O
main	JJ	O	O
surgical	JJ	O	O
parameters	NNS	O	O
collected	VBN	O	O
for	IN	O	O
each	DT	O	O
patient	NN	O	O
(	(	O	O
pt	NN	O	O
)	)	O	O
concerned	VBD	O	O
operative	JJ	O	O
time	NN	O	O
,	,	O	O
major	JJ	O	O
and	CC	O	O
minor	JJ	O	O
complications	NNS	O	O
,	,	O	O
conversion	NN	O	O
rate	NN	O	O
,	,	O	O
blood	NN	O	O
loss	NN	O	O
,	,	O	O
hospital	JJ	O	O
stay	NN	O	O
and	CC	O	O
histology	NN	O	O
.	.	O	O

RESULTS	NNP	O	O
There	EX	O	O
was	VBD	O	O
no	DT	o	OMO
mortality	NN	o	OMO
in	IN	O	O
either	DT	O	O
group	NN	O	O
.	.	O	O

The	DT	O	O
right	JJ	O	O
adrenalectomy	NN	O	O
mean	VB	o	OOt
operative	JJ	o	OOt
time	NN	o	OOt
(	(	o	OOt
OpT	NNP	o	OOt
)	)	o	OOt
was	VBD	O	O
51.8	CD	O	O
mins	NNS	O	O
(	(	O	O
range	VB	O	O
40-90	JJ	O	O
mins	NNS	O	O
)	)	O	O
and	CC	O	O
68.6	CD	O	O
mins	NNS	O	O
(	(	O	O
range	VB	O	O
50-130	NNP	O	O
mins	NNS	O	O
)	)	O	O
in	IN	O	O
group	NN	O	O
A	NNP	O	O
and	CC	O	O
B	NNP	O	O
,	,	O	O
respectively	RB	O	O
(	(	O	O
P	NNP	O	O
not	RB	O	O
significant	JJ	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
left	JJ	o	OOt
adrenalectomy	JJ	o	OOt
mean	JJ	o	OOt
OpT	NNP	o	OOt
was	VBD	O	O
72.2	CD	O	O
mins	NNS	O	O
(	(	O	O
range	VB	O	O
55-100	NNP	O	O
mins	NNS	O	O
)	)	O	O
and	CC	O	O
94	CD	O	O
mins	NNS	O	O
(	(	O	O
range	VB	O	O
65-140	NNP	O	O
mins	NNS	O	O
)	)	O	O
for	IN	O	O
group	NN	O	O
A	NNP	O	O
and	CC	O	O
B	NNP	O	O
,	,	O	O
respectively	RB	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
mean	JJ	o	OPH
blood	NN	o	OPH
loss	NN	o	OPH
was	VBD	O	O
83	CD	O	O
ml	NN	O	O
(	(	O	O
group	NN	O	O
A	NNP	O	O
)	)	O	O
and	CC	O	O
210	CD	O	O
ml	NN	O	O
(	(	O	O
group	NN	O	O
B	NNP	O	O
)	)	O	O
(	(	O	O
p	JJ	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

Complications	NNS	O	O
were	VBD	O	O
not	RB	O	O
different	JJ	O	O
for	IN	O	O
the	DT	O	O
two	CD	O	O
groups	NNS	O	O
.	.	O	O

The	DT	O	O
mean	JJ	o	OOt
hospital	NN	o	OOt
stay	NN	o	OOt
was	VBD	O	O
2.9	CD	O	O
and	CC	O	O
3.1	CD	O	O
days	NNS	O	O
in	IN	O	O
group	NN	O	O
A	NNP	O	O
and	CC	O	O
B	NNP	O	O
,	,	O	O
respectively	RB	O	O
(	(	O	O
P	NNP	O	O
not	RB	O	O
significant	JJ	O	O
)	)	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
EBVS	NNP	O	O
in	IN	O	O
LA	NNP	O	O
may	MD	O	O
provide	VB	O	O
a	DT	O	O
significantly	RB	O	O
short	JJ	o	OPH
operating	NN	o	OPH
time	NN	o	OPH
and	CC	o	OPH
blood	NN	o	OPH
loss	NN	o	OPH
.	.	o	O

Untoward	NNP	O	O
effects	NNS	O	O
of	IN	O	O
fenfluramine	NN	i	IPM
in	IN	O	O
autistic	JJ	p	PC
children	NNS	p	PA
.	.	p	O

Several	JJ	O	O
recent	JJ	O	O
studies	NNS	O	O
have	VBP	O	O
described	VBN	O	O
the	DT	O	O
benefits	NNS	O	O
of	IN	O	O
fenfluramine	NN	i	IPM
for	IN	O	O
the	DT	O	O
symptomatic	JJ	O	O
treatment	NN	O	O
of	IN	O	O
infantile	JJ	p	PA
autism	NN	p	O
.	.	p	O

No	DT	O	O
large	JJ	O	O
surveys	NNS	O	O
of	IN	O	O
side	JJ	O	O
effects	NNS	O	O
of	IN	O	O
this	DT	O	O
drug	NN	O	O
have	VBP	O	O
been	VBN	O	O
reported	VBN	O	O
in	IN	O	O
autistic	JJ	p	O
children	NNS	p	O
.	.	p	O

To	TO	O	O
evaluate	VB	O	O
the	DT	O	O
untoward	JJ	O	O
effects	NNS	O	O
of	IN	O	O
fenfluramine	NN	i	IPM
in	IN	O	O
children	NNS	p	O
with	IN	p	O
autism	NN	p	O
,	,	p	O
12	CD	p	PSS
subjects	NNS	p	O
were	VBD	O	O
systematically	RB	O	O
studied	VBN	O	O
.	.	O	O

Medication	NNP	O	O
was	VBD	O	O
administered	VBN	O	O
in	IN	O	O
a	DT	O	O
double-blind	JJ	O	O
,	,	O	O
placebo-controlled	JJ	i	IC
cross-over	NN	O	O
study	NN	O	O
.	.	O	O

Parents	NNS	O	O
were	VBD	O	O
trained	VBN	O	O
in	IN	O	O
monitoring	VBG	O	O
untoward	JJ	O	O
effects	NNS	O	O
.	.	O	O

These	DT	O	O
observations	NNS	O	O
were	VBD	O	O
compiled	VBN	O	O
in	IN	O	O
detailed	JJ	O	O
daily	JJ	O	O
notes	NNS	O	O
.	.	O	O

In	IN	p	O
addition	NN	p	O
,	,	p	O
four	CD	p	O
cases	NNS	p	PC
describing	VBG	p	PC
unusual	JJ	p	PC
effects	NNS	p	PC
found	VBN	p	O
in	IN	p	O
a	DT	p	O
sample	NN	p	O
of	IN	p	O
170	CD	p	O
patients	NNS	p	O
treated	VBN	p	O
with	IN	p	O
fenfluramine	NN	i	IPM
are	VBP	p	O
also	RB	p	O
reported	VBN	p	O
.	.	p	O

In	IN	O	O
the	DT	O	O
initial	JJ	O	O
2	CD	O	O
weeks	NNS	O	O
of	IN	O	O
active	JJ	O	O
drug	NN	O	O
listlessness	NN	O	O
,	,	O	O
food	NN	o	OME
refusal	NN	o	OME
,	,	o	O
and	CC	o	O
stomach	NN	o	OPH
upset	NN	o	OPH
were	VBD	O	O
frequently	RB	O	O
seen	VBN	O	O
.	.	O	O

A	DT	O	O
different	JJ	O	O
pattern	NN	O	O
of	IN	O	O
untoward	JJ	o	OA
effects	NNS	o	OA
was	VBD	O	O
seen	VBN	O	O
in	IN	O	O
the	DT	O	O
final	JJ	O	O
14	CD	O	O
weeks	NNS	O	O
of	IN	O	O
treatment	NN	O	O
.	.	O	O

Irritability	NNP	o	OME
,	,	o	OME
agitation	NN	o	OME
,	,	o	OME
and	CC	o	OME
crying	VBG	o	OME
along	RB	o	OME
with	IN	o	OME
continued	VBN	o	OME
food	NN	o	OME
refusal	NN	o	OME
were	VBD	O	O
noted	VBN	O	O
.	.	O	O

The	DT	O	O
subjects	NNS	O	O
lost	VBD	O	O
2.1	CD	O	O
%	NN	O	O
of	IN	O	O
body	NN	o	OPH
weight	NN	o	OPH
during	IN	O	O
active	JJ	O	O
drug	NN	O	O
phase	NN	O	O
,	,	O	O
but	CC	O	O
there	RB	O	O
was	VBD	O	O
a	DT	O	O
rebound	NN	o	OPH
weight	NN	o	OPH
gain	NN	o	OPH
during	IN	O	O
the	DT	O	O
subsequent	JJ	O	O
placebo	NN	i	IC
phase	NN	O	O
.	.	O	O

A	DT	O	O
thorough	JJ	O	O
understanding	NN	O	O
of	IN	O	O
fenfluramine	NN	i	IPM
's	POS	i	IPM
side	NN	O	O
effects	NNS	O	O
and	CC	O	O
adverse	JJ	O	O
reactions	NNS	O	O
is	VBZ	O	O
necessary	JJ	O	O
so	RB	O	O
as	IN	O	O
to	TO	O	O
differentiate	VB	O	O
them	PRP	O	O
from	IN	O	O
the	DT	O	O
multiple	NN	O	O
symptoms	NNS	O	O
inherent	NN	O	O
in	IN	O	O
the	DT	O	O
syndrome	NN	O	O
of	IN	O	O
autism	NN	p	O
.	.	p	O

Impact	NN	O	O
of	IN	O	O
different	JJ	O	O
platelet	NN	O	O
glycoprotein	NN	O	O
IIb/IIIa	NNP	O	O
receptor	NN	O	O
inhibitors	NNS	O	O
among	IN	O	O
diabetic	JJ	p	O
patients	NNS	p	O
undergoing	VBG	p	O
percutaneous	JJ	p	O
coronary	JJ	p	O
intervention	NN	p	O
:	:	p	O
:	:	O	O
Do	VB	O	O
Tirofiban	NNP	O	O
and	CC	O	O
ReoPro	NNP	O	O
Give	NNP	O	O
Similar	NNP	O	O
Efficacy	NNP	O	O
Outcomes	NNP	O	O
Trial	NNP	O	O
(	(	O	O
TARGET	NNP	O	O
)	)	O	O
1-year	JJ	O	O
follow-up	NN	O	O
.	.	O	O

BACKGROUND	IN	O	O
The	DT	O	O
platelet	NN	O	O
glycoprotein	NN	O	O
IIb/IIIa	NNP	O	O
receptor	NN	O	O
inhibitor	NN	O	O
abciximab	NN	O	O
,	,	O	O
a	DT	O	O
monoclonal	JJ	O	O
antibody	NN	O	O
,	,	O	O
has	VBZ	O	O
been	VBN	O	O
shown	VBN	O	O
to	TO	O	O
improve	VB	O	O
early	JJ	O	O
and	CC	O	O
late	JJ	O	O
outcomes	NNS	O	O
among	IN	O	O
diabetic	JJ	p	O
patients	NNS	p	O
undergoing	VBG	p	O
percutaneous	JJ	p	O
coronary	JJ	p	O
intervention	NN	p	O
(	(	p	O
PCI	NNP	p	O
)	)	p	O
.	.	p	O

It	PRP	O	O
is	VBZ	O	O
unknown	JJ	O	O
whether	IN	O	O
small-molecule	JJ	O	O
agents	NNS	O	O
confer	VBP	O	O
similar	JJ	O	O
benefits	NNS	O	O
.	.	O	O

METHODS	NNP	O	O
AND	CC	O	O
RESULTS	NNP	O	O
In	IN	p	O
18	CD	p	O
countries	NNS	p	O
,	,	p	O
4809	CD	p	O
patients	NNS	p	O
undergoing	VBG	p	O
PCI	NNP	p	O
with	IN	p	O
stent	JJ	p	O
implantation	NN	p	O
were	VBD	O	O
randomized	VBN	O	O
to	TO	O	O
tirofiban	VB	i	IPM
or	CC	i	O
abciximab	VB	i	IPM
.	.	i	O

At	IN	O	O
the	DT	O	O
time	NN	O	O
of	IN	O	O
enrollment	NN	O	O
,	,	O	O
patients	NNS	O	O
were	VBD	O	O
stratified	VBN	O	O
according	VBG	O	O
to	TO	O	O
diabetes	NNS	O	O
status	NN	O	O
.	.	O	O

As	IN	O	O
compared	VBN	O	O
with	IN	O	O
non-diabetic	JJ	O	O
patients	NNS	O	O
,	,	O	O
patients	NNS	O	O
with	IN	O	O
diabetes	NNS	O	O
(	(	O	O
n=1117	NN	O	O
)	)	O	O
showed	VBD	O	O
similar	JJ	O	O
30-day	JJ	O	O
ischemic	JJ	O	O
outcomes	NNS	O	O
,	,	O	O
an	DT	O	O
increased	JJ	O	O
incidence	NN	o	OPH
of	IN	o	OPH
any	DT	o	OPH
target	NN	o	OPH
vessel	NN	o	OPH
revascularization	NN	o	OPH
(	(	o	OPH
TVR	NNP	o	OPH
)	)	o	O
at	IN	O	O
6	CD	O	O
months	NNS	O	O
(	(	O	O
10.3	CD	O	O
%	NN	O	O
versus	IN	O	O
7.8	CD	O	O
%	NN	O	O
;	:	O	O
P=	NNP	O	O
0.008	CD	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
a	DT	O	O
trend	NN	O	O
toward	IN	O	O
higher	JJR	o	OMO
1-year	JJ	o	OMO
mortality	NN	o	OMO
(	(	O	O
2.5	CD	O	O
%	NN	O	O
versus	IN	O	O
1.6	CD	O	O
%	NN	O	O
;	:	O	O
P=0.056	NNP	O	O
)	)	O	O
.	.	O	O

Among	IN	O	O
diabetic	JJ	O	O
patients	NNS	O	O
randomized	VBN	O	O
to	TO	O	O
tirofiban	VB	O	O
(	(	O	O
n=560	NN	O	O
)	)	O	O
,	,	O	O
the	DT	O	O
incidence	NN	o	OMO
of	IN	o	OMO
death	NN	o	OMO
,	,	o	O
myocardial	JJ	o	OPH
infarction	NN	o	OPH
(	(	o	OPH
MI	NNP	o	OPH
)	)	o	OPH
,	,	o	OPH
or	CC	o	O
urgent	JJ	o	OPH
TVR	NNP	o	OPH
at	IN	O	O
30	CD	O	O
days	NNS	O	O
was	VBD	O	O
6.2	CD	O	O
%	NN	O	O
,	,	O	O
and	CC	O	O
among	IN	O	O
those	DT	O	O
randomized	VBN	O	O
to	TO	O	O
abciximab	VB	O	O
(	(	O	O
n=557	NN	O	O
)	)	O	O
it	PRP	O	O
was	VBD	O	O
5.4	CD	O	O
%	NN	O	O
(	(	O	O
hazard	JJ	O	O
ratio	NN	O	O
[	NNP	O	O
HR	NNP	O	O
]	NNP	O	O
1.16	CD	O	O
;	:	O	O
P=0.540	NNP	O	O
)	)	O	O
.	.	O	O

At	IN	O	O
6	CD	O	O
months	NNS	O	O
,	,	O	O
the	DT	O	O
composite	NN	O	O
of	IN	O	O
death	NN	o	OMO
,	,	o	O
MI	NNP	o	O
,	,	o	O
or	CC	o	O
any	DT	o	O
TVR	NNP	o	OPH
occurred	VBD	O	O
in	IN	O	O
15.7	CD	O	O
%	NN	O	O
and	CC	O	O
in	IN	O	O
16.9	CD	O	O
%	NN	O	O
of	IN	O	O
tirofiban	NN	O	O
and	CC	O	O
abciximab	NN	O	O
patients	NNS	O	O
,	,	O	O
respectively	RB	O	O
(	(	O	O
HR	NNP	O	O
0.93	CD	O	O
;	:	O	O
P=0.610	NNP	O	O
)	)	O	O
.	.	O	O

Any	DT	O	O
TVR	NNP	o	OPH
occurred	VBD	O	O
in	IN	O	O
9.5	CD	O	O
%	NN	O	O
and	CC	O	O
11.1	CD	O	O
%	NN	O	O
,	,	O	O
respectively	RB	O	O
(	(	O	O
HR	NNP	O	O
0.84	CD	O	O
;	:	O	O
P=	NNP	O	O
0.366	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
1-year	JJ	o	OMO
mortality	NN	o	OMO
was	VBD	O	O
2.1	CD	O	O
%	NN	O	O
in	IN	O	O
the	DT	O	O
tirofiban	NN	O	O
group	NN	O	O
and	CC	O	O
2.9	CD	O	O
%	NN	O	O
in	IN	O	O
the	DT	O	O
abciximab	NN	O	O
group	NN	O	O
(	(	O	O
HR	NNP	O	O
0.74	CD	O	O
;	:	O	O
P=	NNP	O	O
0.436	CD	O	O
)	)	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
Among	IN	O	O
diabetic	JJ	p	O
patients	NNS	p	O
undergoing	VBG	p	O
PCI	NNP	p	O
,	,	O	O
tirofiban	NN	O	O
and	CC	O	O
abciximab	NN	O	O
were	VBD	O	O
associated	VBN	O	O
with	IN	O	O
comparable	JJ	O	O
event	NN	O	O
rates	NNS	O	O
,	,	O	O
including	VBG	O	O
similar	JJ	O	O
rates	NNS	O	O
of	IN	O	O
6-month	JJ	O	O
TVR	NNP	O	O
and	CC	O	O
1-year	JJ	O	O
mortality	NN	O	O
.	.	O	O

These	DT	O	O
findings	NNS	O	O
suggest	VBP	O	O
that	IN	O	O
the	DT	O	O
non-glycoprotein	JJ	O	O
IIb/IIIa	NNP	O	O
properties	NNS	O	O
of	IN	O	O
abciximab	NNS	O	O
do	VBP	O	O
not	RB	O	O
translate	VB	O	O
into	IN	O	O
a	DT	O	O
discernible	JJ	O	O
long-term	JJ	O	O
clinical	JJ	O	O
benefit	NN	O	O
among	IN	O	O
diabetic	JJ	p	O
patients	NNS	p	O
.	.	p	O

Locomoting-to-reach	NN	i	IPH
:	:	i	O
information	NN	O	O
variables	NNS	O	O
and	CC	O	O
control	NN	O	O
strategies	NNS	O	O
for	IN	O	O
nested	JJ	O	O
actions	NNS	O	O
.	.	O	O

Locomoting-to-reach	NNP	i	IPH
is	VBZ	O	O
a	DT	O	O
basic	JJ	O	O
perception/action	NN	O	O
behavior	NN	O	O
that	WDT	O	O
requires	VBZ	O	O
visual	JJ	O	O
information	NN	O	O
for	IN	O	O
the	DT	O	O
control	NN	O	O
of	IN	O	O
both	DT	O	O
locomotion	NN	O	O
and	CC	O	O
reaching	VBG	O	O
components	NNS	O	O
.	.	O	O

We	PRP	O	O
investigated	VBD	O	O
the	DT	O	O
visual	JJ	O	O
information	NN	O	O
and	CC	O	O
the	DT	O	O
control	NN	O	O
strategies	NNS	O	O
used	VBN	O	O
to	TO	O	O
guide	VB	O	O
both	PDT	O	O
the	DT	O	O
head	NN	O	O
and	CC	O	O
the	DT	O	O
hand	NN	O	O
on	IN	O	O
approach	NN	O	O
to	TO	O	O
a	DT	O	O
target	NN	O	O
in	IN	O	O
a	DT	O	O
locomotion-to-reach	JJ	i	IPH
task	NN	i	IPH
.	.	i	O

In	IN	O	O
this	DT	O	O
study	NN	O	O
,	,	O	O
participants	NNS	p	PC
were	VBD	p	PC
required	VBN	p	PC
to	TO	p	PC
locomote	VB	i	O
in	IN	i	O
the	DT	i	O
dark	NN	i	O
to	TO	i	O
a	DT	i	O
lit	NN	i	O
target	NN	i	O
in	IN	i	O
three	CD	i	O
different	JJ	i	O
conditions	NNS	i	O
:	:	i	O
monocular	JJ	i	O
vision/target	NN	i	O
with	IN	i	O
image	NN	i	O
size	NN	i	O
,	,	i	O
binocular	JJ	i	O
vision/target	NN	i	O
with	IN	i	O
image	NN	i	O
size	NN	i	O
,	,	i	O
and	CC	i	O
binocular	JJ	i	O
vision/point-light	JJ	i	O
target	NN	i	O
(	(	i	O
without	IN	i	O
image	NN	i	O
size	NN	i	O
)	)	i	O
.	.	i	O

In	IN	O	O
task	NN	O	O
one	CD	O	O
,	,	O	O
participants	NNS	O	O
brought	VBD	O	O
their	PRP$	O	O
eyes	NNS	O	O
to	TO	O	O
the	DT	O	O
target	NN	O	O
.	.	O	O

In	IN	O	O
task	NN	O	O
two	CD	O	O
,	,	O	O
participants	NNS	O	O
brought	VBD	O	O
their	PRP$	O	O
outstretched	JJ	O	O
hand	NN	O	O
to	TO	O	O
the	DT	O	O
target	NN	O	O
.	.	O	O

Movement	JJ	o	OPH
trajectories	NNS	o	OPH
for	IN	O	O
both	DT	O	O
tasks	NNS	O	O
were	VBD	O	O
analyzed	VBN	O	O
.	.	O	O

Results	NNP	O	O
show	VBP	O	O
that	IN	O	O
participants	NNS	p	O
were	VBD	O	O
significantly	RB	O	O
more	RBR	O	O
accurate	JJ	o	OOt
when	WRB	o	OOt
binocular	JJ	o	OOt
information	NN	o	OOt
was	VBD	o	OOt
present	JJ	o	OOt
.	.	o	O

In	IN	O	O
both	DT	O	O
tasks	NNS	O	O
,	,	O	O
participants	NNS	O	O
were	VBD	O	O
found	VBN	O	O
to	TO	O	O
use	VB	O	O
a	DT	O	O
proportional	JJ	o	O
rate	NN	o	O
control	NN	o	O
strategy	NN	o	O
rather	RB	o	O
than	IN	o	O
a	DT	o	O
constant	JJ	o	O
?	.	o	O
strategy	NN	o	O
.	.	o	O

In	IN	O	O
the	DT	o	O
walk-to-reach	NN	o	O
task	NN	o	O
,	,	o	O
they	PRP	O	O
used	VBD	o	O
monocular	JJ	o	O
and/or	NN	o	O
binocular	NN	o	O
?	.	o	O
information	NN	o	O
to	TO	o	O
guide	VB	o	O
the	DT	o	O
head	NN	o	O
and	CC	o	O
then	RB	O	O
switched	VBD	O	O
to	TO	O	O
using	VBG	o	O
relative	JJ	o	O
disparity	NN	o	O
?	.	o	O
to	TO	o	O
guide	VB	o	O
the	DT	o	O
hand	NN	o	O
to	TO	o	O
final	JJ	o	O
target	NN	o	O
acquisition	NN	o	O
,	,	o	O
switching	VBG	o	O
when	WRB	O	O
the	DT	O	O
hand	NN	O	O
centric	NN	O	O
?	.	O	O
became	VBD	O	O
less	JJR	O	O
than	IN	O	O
the	DT	O	O
head	NN	O	O
centric	JJ	O	O
?.	NNP	O	O
Dynamical	NNP	O	O
models	NNS	O	O
of	IN	O	O
the	DT	O	O
information	NN	O	O
and	CC	O	O
control	NN	O	O
strategies	NNS	O	O
were	VBD	O	O
used	VBN	O	O
to	TO	O	O
perform	VB	o	O
simulations	NNS	o	O
that	WDT	o	O
were	VBD	O	O
found	VBN	O	O
to	TO	O	O
fit	VB	O	O
the	DT	O	O
data	NN	O	O
well	RB	O	O
.	.	O	O

The	DT	O	O
conclusion	NN	O	O
is	VBZ	O	O
that	IN	O	O
proportional	JJ	o	O
rate	NN	o	O
control	NN	o	O
is	VBZ	o	O
used	VBN	o	O
sequentially	RB	O	O
with	IN	O	O
head	NN	o	O
centric	NN	o	O
,	,	o	O
then	RB	o	O
hand-centric	JJ	o	O
?-based	JJ	o	O
information	NN	o	O
,	,	o	O
using	VBG	o	O
at	IN	O	O
each	DT	O	O
moment	NN	O	O
the	DT	o	O
?	.	o	O
with	IN	O	O
the	DT	O	O
smallest	JJS	O	O
value	NN	O	O
.	.	O	O

Implementing	VBG	O	O
a	DT	O	O
simplified	JJ	i	IE
neonatal	JJ	i	IE
resuscitation	NN	i	IE
protocol-helping	JJ	i	IE
babies	NNS	p	PC
breathe	VBP	p	PC
at	IN	p	PC
birth	NN	p	PC
(	(	O	O
HBB	NNP	O	O
)	)	O	O
-	:	O	O
at	IN	O	O
a	DT	O	O
tertiary	JJ	O	O
level	NN	O	O
hospital	NN	O	O
in	IN	O	O
Nepal	NNP	p	O
for	IN	O	O
an	DT	O	O
increased	JJ	O	O
perinatal	NN	o	OMO
survival	NN	o	OMO
.	.	o	OMO

BACKGROUND	NNP	O	O
Reducing	NNP	O	O
neonatal	JJ	o	OMO
death	NN	o	OMO
has	VBZ	O	O
been	VBN	O	O
an	DT	O	O
emerging	VBG	O	O
challenge	NN	O	O
in	IN	O	O
low	JJ	p	O
and	CC	p	O
middle	JJ	p	O
income	NN	p	O
countries	NNS	p	O
in	IN	O	O
the	DT	O	O
past	JJ	O	O
decade	NN	O	O
.	.	O	O

The	DT	O	O
development	NN	O	O
of	IN	O	O
the	DT	O	O
low	JJ	O	O
cost	NN	O	O
interventions	NNS	O	O
and	CC	O	O
their	PRP$	O	O
effective	JJ	O	O
delivery	NN	O	O
are	VBP	O	O
needed	VBN	O	O
to	TO	O	O
reduce	VB	O	O
deaths	NNS	o	OMO
from	IN	O	O
birth	NN	O	O
asphyxia	NN	O	O
.	.	O	O

This	DT	O	O
study	NN	O	O
will	MD	O	O
assess	VB	O	O
the	DT	O	O
impact	NN	O	O
of	IN	O	O
a	DT	O	O
simplified	JJ	i	IE
neonatal	JJ	i	IE
resuscitation	NN	i	IE
protocol	NN	i	IE
provided	VBN	O	O
by	IN	O	O
Helping	VBG	O	O
Babies	NNS	O	O
Breathe	NNP	O	O
(	(	O	O
HBB	NNP	O	O
)	)	O	O
at	IN	O	O
a	DT	O	O
tertiary	JJ	p	O
hospital	NN	p	O
in	IN	p	O
Nepal	NNP	p	O
.	.	p	O

Perinatal	NNP	O	O
outcomes	NNS	O	O
and	CC	O	O
performance	NN	O	O
of	IN	O	O
skilled	JJ	p	O
birth	NN	p	O
attendants	NNS	p	O
on	IN	O	O
management	NN	o	OOt
of	IN	o	OOt
intrapartum-related	JJ	o	OOt
neonatal	JJ	o	OOt
hypoxia	NN	o	OOt
will	MD	O	O
be	VB	O	O
the	DT	O	O
main	JJ	O	O
measurements	NNS	O	O
.	.	O	O

METHODS/DESIGN	NNP	O	O
The	DT	O	O
study	NN	O	O
will	MD	O	O
be	VB	O	O
carried	VBN	O	O
out	RP	O	O
at	IN	O	O
a	DT	O	O
tertiary	JJ	p	O
level	NN	p	O
maternity	NN	p	O
hospital	NN	p	O
in	IN	p	O
Nepal	NNP	p	O
.	.	p	O

A	DT	O	O
prospective	JJ	O	O
cohort-study	NN	O	O
will	MD	O	O
include	VB	O	O
a	DT	O	O
six-month	JJ	O	O
baseline	NN	O	O
a	DT	O	O
six	CD	O	O
month	NN	O	O
intervention	NN	O	O
period	NN	O	O
and	CC	O	O
a	DT	O	O
three-month	JJ	O	O
post	NN	O	O
intervention	NN	O	O
period	NN	O	O
.	.	O	O

A	DT	O	O
quality	NN	O	O
improvement	NN	O	O
process	NN	O	O
cycle	NN	O	O
will	MD	O	O
introduce	VB	O	O
the	DT	O	O
neonatal	JJ	O	O
resuscitation	NN	O	O
protocol	NN	O	O
.	.	O	O

A	DT	O	O
surveillance	NN	O	O
system	NN	O	O
,	,	O	O
including	VBG	O	O
CCD	NNP	i	IPH
cameras	NNS	i	IPH
and	CC	i	IE
pulse	JJ	i	IPH
oximeters	NNS	i	IPH
,	,	O	O
will	MD	O	O
be	VB	O	O
set	VBN	O	O
up	RP	O	O
to	TO	O	O
evaluate	VB	O	O
the	DT	O	O
intervention	NN	O	O
.	.	O	O

DISCUSSION	NNP	O	O
Along	IN	O	O
with	IN	O	O
a	DT	O	O
technique	NN	O	O
to	TO	O	O
improve	VB	O	O
health	NN	o	OOt
workers	NNS	o	OOt
performance	NN	o	OOt
on	IN	O	O
the	DT	O	O
protocol	NN	O	O
,	,	O	O
the	DT	O	O
study	NN	O	O
will	MD	O	O
generate	VB	O	O
evidence	NN	O	O
on	IN	O	O
the	DT	O	O
research	NN	O	O
gap	NN	O	O
on	IN	O	O
the	DT	O	O
effectiveness	NN	O	O
of	IN	O	O
the	DT	O	O
simplified	JJ	O	O
neonatal	JJ	O	O
resuscitation	NN	O	O
protocol	NN	O	O
on	IN	O	O
intrapartum	NN	o	OMO
outcome	NN	o	OMO
and	CC	o	OMO
early	JJ	o	OMO
neonatal	JJ	o	OMO
survival	NN	o	OMO
.	.	o	OMO

This	DT	O	O
will	MD	O	O
generate	VB	O	O
a	DT	O	O
global	JJ	O	O
interest	NN	O	O
and	CC	O	O
inform	NN	O	O
policymaking	NN	O	O
in	IN	O	O
relation	NN	O	O
to	TO	O	O
delivery	NN	O	O
care	NN	O	O
in	IN	O	O
all	DT	O	O
income	NN	O	O
settings	NNS	O	O
.	.	O	O

TRIAL	NNP	O	O
REGISTRATION	NNP	O	O
ISRCTN97846009	NNP	O	O
.	.	O	O

Long	JJ	O	O
term	NN	O	O
response	NN	O	O
to	TO	O	O
therapy	NN	O	O
of	IN	O	O
chronic	JJ	p	PC
anti-HBe-positive	JJ	p	PC
hepatitis	NN	p	PC
B	NNP	p	PC
is	VBZ	O	O
poor	JJ	O	O
independent	JJ	O	O
of	IN	O	O
type	NN	O	O
and	CC	O	O
schedule	NN	O	O
of	IN	O	O
interferon	NN	O	O
.	.	O	O

OBJECTIVE	CC	O	O
The	DT	O	O
response	NN	o	OPH
rate	NN	o	OPH
to	TO	o	OPH
alpha	VB	o	OPH
interferon	NN	o	OPH
(	(	o	OPH
IFN	NNP	o	OPH
)	)	o	OPH
of	IN	O	O
chronic	JJ	O	O
anti-HBe-positive	JJ	O	O
hepatitis	NN	O	O
B	NNP	O	O
is	VBZ	O	O
variable	JJ	O	O
.	.	O	O

We	PRP	O	O
studied	VBD	O	O
whether	IN	O	O
type	NN	O	O
,	,	O	O
dose	NN	O	O
,	,	O	O
and	CC	O	O
schedule	NN	O	O
of	IN	O	O
IFN	NNP	i	IPM
,	,	O	O
and	CC	O	O
type	NN	O	O
and	CC	O	O
frequency	NN	O	O
of	IN	O	O
posttreatment	NN	O	O
monitoring	NN	O	O
,	,	O	O
influence	VB	O	O
the	DT	O	O
response	NN	O	O
rate	NN	O	O
.	.	O	O

METHODS	NNP	O	O
Seventy-two	JJ	p	PSS
consecutive	JJ	p	O
anti-HBe-positive	JJ	p	O
chronic	NN	p	O
hepatitis	NN	p	O
B	NNP	p	O
patients	NNS	p	O
(	(	p	O
59	CD	p	PSS
male	NN	p	PSE
and	CC	p	O
13	CD	p	PSS
female	NN	p	PSE
,	,	p	O
median	JJ	p	O
age	NN	p	O
41	CD	p	PA
yr	NN	p	PA
)	)	p	O
stratified	VBN	p	O
by	IN	p	O
sex	NN	p	O
and	CC	p	O
histology	NN	p	O
were	VBD	O	O
randomly	RB	O	O
allocated	VBN	O	O
to	TO	O	O
three	CD	O	O
treatment	NN	O	O
arms	NNS	O	O
.	.	O	O

Twenty-seven	JJ	O	O
patients	NNS	O	O
(	(	O	O
A	DT	O	O
)	)	O	O
received	VBD	O	O
10	CD	O	O
million	CD	O	O
units	NNS	O	O
alpha-N1	JJ	i	IPM
IFN	NNP	i	IPM
i.m	NN	i	IPM
.	.	i	IPM

t.w	NN	O	O
.	.	O	O

for	IN	O	O
24	CD	O	O
wk	NN	O	O
(	(	O	O
total	JJ	O	O
dose	NN	O	O
:	:	O	O
720	CD	O	O
million	CD	O	O
units	NNS	O	O
)	)	O	O
;	:	O	O
21	CD	O	O
(	(	O	O
B	NNP	O	O
)	)	O	O
received	VBD	O	O
9	CD	O	O
million	CD	O	O
units	NNS	O	O
alpha-2a	JJ	i	IPM
IFN	NNP	i	IPM
i.m	NN	i	IPM
.	.	i	IPM

t.w	NN	O	O
.	.	O	O

for	IN	O	O
4	CD	O	O
wk	NN	O	O
,	,	O	O
followed	VBN	O	O
by	IN	O	O
18	CD	O	O
million	CD	O	O
units	NNS	O	O
for	IN	O	O
12	CD	O	O
wk	NN	O	O
and	CC	O	O
9	CD	O	O
million	CD	O	O
units	NNS	O	O
for	IN	O	O
8	CD	O	O
wk	NN	O	O
(	(	O	O
972	CD	O	O
million	CD	O	O
units	NNS	O	O
)	)	O	O
;	:	O	O
24	CD	O	O
(	(	O	O
C	NNP	O	O
)	)	O	O
received	VBD	O	O
2	CD	i	IPM
alpha-2a	JJ	i	IPM
IFN	NNP	i	IPM
courses	NNS	i	O
(	(	O	O
9	CD	O	O
million	CD	O	O
units	NNS	O	O
i.m	RB	O	O
.	.	O	O

t.w	NN	O	O
.	.	O	O

for	IN	O	O
16	CD	O	O
and	CC	O	O
12	CD	O	O
wk	NN	O	O
separated	VBN	O	O
by	IN	O	O
a	DT	O	O
6-month	JJ	O	O
interval	NN	O	O
[	$	O	O
756	CD	O	O
million	CD	O	O
units	NNS	O	O
]	NNP	O	O
)	)	O	O
.	.	O	O

Primary	JJ	O	O
response	NN	O	O
was	VBD	O	O
defined	VBN	O	O
by	IN	O	O
normal	JJ	o	OPH
ALT	NNP	o	OPH
and	CC	o	O
serum	VB	o	OPH
HBV-DNA	NNP	o	OPH
levels	NNS	o	OPH
below	IN	O	O
10	CD	O	O
pg/ml	NN	O	O
at	IN	O	O
the	DT	O	O
end	NN	O	O
of	IN	O	O
therapy	NN	O	O
and	CC	O	O
sustained	VBN	O	O
response	NN	O	O
by	IN	O	O
normal	JJ	o	OPH
ALT	NNP	o	OPH
(	(	O	O
tested	VBN	O	O
monthly	RB	O	O
)	)	O	O
,	,	O	O
undetectable	JJ	o	OPH
HBV-DNA	NN	o	OPH
and	CC	O	O
IgM	NNP	O	O
anti-HBc	NN	O	O
(	(	O	O
<	JJ	O	O
7	CD	O	O
I.U	NNP	O	O
.	.	O	O

Paul	NNP	O	O
Ehrlich	NNP	O	O
Institute	NNP	O	O
)	)	O	O
(	(	O	O
tested	VBN	O	O
every	DT	O	O
3	CD	O	O
months	NNS	O	O
)	)	O	O
during	IN	O	O
the	DT	O	O
posttreatment	JJ	O	O
follow-up	NN	O	O
.	.	O	O

RESULTS	NNP	O	O
At	IN	O	O
the	DT	O	O
end	NN	O	O
of	IN	O	O
treatment	NN	O	O
,	,	O	O
12	CD	O	O
,	,	O	O
8	CD	O	O
,	,	O	O
and	CC	O	O
13	CD	O	O
patients	NNS	O	O
from	IN	O	O
groups	NNS	O	O
A	NNP	O	O
,	,	O	O
B	NNP	O	O
,	,	O	O
and	CC	O	O
C	NNP	O	O
,	,	O	O
respectively	RB	O	O
,	,	O	O
were	VBD	O	O
responders	NNS	O	O
.	.	O	O

At	IN	O	O
the	DT	O	O
18-month	JJ	O	O
follow-up	JJ	O	O
,	,	O	O
two	CD	O	O
patients	NNS	O	O
in	IN	O	O
group	NN	O	O
A	NNP	O	O
and	CC	O	O
only	RB	O	O
one	CD	O	O
in	IN	O	O
groups	NNS	O	O
B	NNP	O	O
and	CC	O	O
C	NNP	O	O
maintained	VBD	O	O
the	DT	O	O
response	NN	o	O
.	.	o	O

Overall	NNP	O	O
,	,	O	O
after	IN	O	O
34	CD	O	O
months	NNS	O	O
(	(	O	O
median	JJ	O	O
posttreatment	NN	O	O
follow-up	NN	O	O
)	)	O	O
,	,	O	O
three	CD	O	O
patients	NNS	O	O
were	VBD	O	O
long	JJ	O	O
term	NN	O	O
responders	NNS	O	O
,	,	O	O
whereas	NNS	O	O
three	CD	O	O
showed	VBD	O	O
a	DT	O	O
sustained	VBN	O	O
remission	NN	o	OOt
after	IN	O	O
relapse	NN	O	O
.	.	O	O

CONCLUSIONS	VB	O	O
The	DT	O	O
rate	NN	o	OPH
of	IN	o	OPH
long	JJ	o	OPH
term	NN	o	OPH
response	NN	o	OPH
to	TO	O	O
interferon	VB	O	O
of	IN	O	O
anti-HBe-positive	JJ	O	O
chronic	JJ	O	O
hepatitis	NN	O	O
B	NNP	O	O
is	VBZ	O	O
poor	JJ	O	O
,	,	O	O
independent	JJ	O	O
of	IN	O	O
IFN	NNP	O	O
type	NN	O	O
,	,	O	O
dose	VB	O	O
,	,	O	O
or	CC	O	O
schedule	NN	O	O
;	:	O	O
the	DT	O	O
more	RBR	O	O
stringent	JJ	O	O
the	DT	O	O
monitoring	NN	O	O
,	,	O	O
the	DT	O	O
higher	JJR	O	O
the	DT	O	O
relapse	NN	O	O
rate	NN	O	O
.	.	O	O

Ambulatory	NNP	i	IS
phlebectomy	NN	i	IS
versus	NN	O	O
compression	NN	i	IPH
sclerotherapy	NN	i	IPH
:	:	i	O
results	NNS	O	O
of	IN	O	O
a	DT	O	O
randomized	VBN	O	O
controlled	VBN	O	O
trial	NN	O	O
.	.	O	O

BACKGROUND	NNP	O	O
Although	IN	O	O
no	DT	O	O
randomized	VBN	O	O
controlled	VBN	O	O
trial	NN	O	O
has	VBZ	O	O
assessed	VBN	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
either	DT	O	O
compression	NN	i	IPH
sclerotherapy	NN	i	IPH
or	CC	O	O
ambulatory	JJ	i	IS
phlebectomy	NN	i	IS
,	,	O	O
both	DT	O	O
techniques	NNS	O	O
are	VBP	O	O
used	VBN	O	O
to	TO	O	O
treat	VB	O	O
varicose	JJ	O	O
veins	NNS	O	O
worldwide	RB	O	O
.	.	O	O

We	PRP	O	O
performed	VBD	O	O
a	DT	O	O
randomized	VBN	O	O
controlled	VBN	O	O
trial	NN	O	O
to	TO	O	O
compare	VB	O	O
recurrence	NN	O	O
rates	NNS	O	O
of	IN	O	O
varicose	JJ	O	O
veins	NNS	O	O
and	CC	O	O
complications	NNS	O	O
after	IN	O	O
compression	NN	i	IPH
sclerotherapy	NN	i	IPH
and	CC	O	O
ambulatory	JJ	i	IS
phlebectomy	NN	i	IS
.	.	i	O

METHODS	NNP	O	O
From	IN	O	O
September	NNP	p	O
1996	CD	p	O
to	TO	p	O
October	NNP	p	O
1998	CD	p	O
,	,	p	O
we	PRP	p	O
randomly	RB	p	O
allocated	VBD	p	O
49	CD	p	O
legs	NNS	p	O
to	TO	p	O
compression	VB	i	IPH
sclerotherapy	NN	i	IPH
and	CC	p	O
49	CD	p	O
legs	NNS	p	O
to	TO	p	O
ambulatory	JJ	i	IS
phlebectomy	NN	i	IS
.	.	i	O

Our	PRP$	O	O
primary	JJ	O	O
outcome	NN	O	O
parameters	NNS	O	O
were	VBD	O	O
as	IN	O	O
follows	VBZ	O	O
:	:	O	O
recurrence	NN	O	O
rates	NNS	O	O
at	IN	O	O
1	CD	O	O
and	CC	O	O
2	CD	O	O
years	NNS	O	O
and	CC	O	O
complications	NNS	O	O
related	VBN	O	O
to	TO	O	O
therapy	VB	O	O
.	.	O	O

Eighty-two	JJ	p	O
patients	NNS	p	O
were	VBD	p	O
included	VBN	p	O
,	,	p	O
of	IN	p	O
whom	WP	p	O
16	CD	p	O
were	VBD	p	O
included	VBN	p	O
with	IN	p	O
both	DT	p	O
of	IN	p	O
their	PRP$	p	O
legs	NNS	p	O
.	.	p	O

The	DT	p	O
number	NN	p	O
of	IN	p	O
treated	JJ	p	O
legs	NN	p	O
was	VBD	p	O
therefore	RB	p	O
98	CD	p	O
,	,	O	O
but	CC	O	O
two	CD	p	O
patients	NNS	p	O
were	VBD	O	O
lost	VBN	O	O
to	TO	O	O
follow-up	JJ	O	O
.	.	O	O

RESULTS	VB	O	O
One	CD	o	OPH
year	NN	o	OPH
recurrence	NN	o	OPH
amounted	VBD	O	O
to	TO	O	O
1	CD	O	O
out	IN	O	O
of	IN	O	O
48	CD	O	O
for	IN	O	O
phlebectomy	NN	i	IS
and	CC	O	O
12	CD	O	O
out	IN	O	O
of	IN	O	O
48	CD	O	O
for	IN	O	O
compression	NN	i	IPH
sclerotherapy	NN	i	IPH
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.001	CD	O	O
)	)	O	O
;	:	O	O
at	IN	O	O
2	CD	O	O
years	NNS	O	O
,	,	O	O
six	CD	O	O
additional	JJ	O	O
recurrences	NNS	o	OPH
were	VBD	O	O
found	VBN	O	O
,	,	O	O
but	CC	O	O
then	RB	O	O
solely	RB	O	O
for	IN	O	O
compression	NN	i	IPH
sclerotherapy	NN	i	IPH
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.001	CD	O	O
)	)	O	O
.	.	O	O

Significant	JJ	O	O
differences	NNS	O	O
in	IN	O	O
complications	NNS	O	O
occurring	VBG	O	O
more	RBR	O	O
in	IN	O	O
phlebectomy	NN	O	O
than	IN	O	O
in	IN	O	O
compression	NN	i	IPH
sclerotherapy	NN	i	IPH
therapy	NN	O	O
were	VBD	O	O
blisters	NNS	o	OA
,	,	o	OA
teleangiectatic	JJ	o	OA
matting	NN	o	OA
,	,	o	OA
scar	NN	o	OA
formation	NN	o	OA
,	,	o	OA
and	CC	o	OA
bruising	VBG	o	OA
from	IN	o	OA
bandaging	VBG	o	OA
.	.	o	OA

CONCLUSION	NNP	O	O
Our	PRP$	O	O
results	NNS	O	O
show	VBP	O	O
that	IN	O	O
ambulatory	JJ	i	IS
phlebectomy	NN	i	IS
is	VBZ	O	O
an	DT	O	O
effective	JJ	O	O
therapy	NN	O	O
for	IN	O	O
varicose	JJ	O	O
veins	NNS	O	O
of	IN	O	O
the	DT	O	O
leg	NN	O	O
.	.	O	O

Recurrence	NN	O	O
rates	NNS	O	O
are	VBP	O	O
significantly	RB	O	O
lower	JJR	O	O
than	IN	O	O
for	IN	O	O
compression	NN	i	IPH
sclerotherapy	NN	i	IPH
therapy	NN	i	IPH
.	.	i	O

If	IN	O	O
varicose	JJ	O	O
veins	NNS	O	O
persist	VBP	O	O
4	CD	O	O
weeks	NNS	O	O
after	IN	O	O
compression	NN	i	IPH
sclerotherapy	NN	i	IPH
,	,	O	O
it	PRP	O	O
can	MD	O	O
be	VB	O	O
argued	VBN	O	O
that	IN	O	O
to	TO	O	O
reduce	VB	O	O
the	DT	O	O
risk	NN	O	O
of	IN	O	O
future	JJ	O	O
recurrence	NN	O	O
ambulatory	JJ	i	IS
phlebectomy	NN	i	IS
should	MD	O	O
be	VB	O	O
considered	VBN	O	O
as	IN	O	O
the	DT	O	O
better	JJR	O	O
treatment	NN	O	O
option	NN	O	O
.	.	O	O

Torasemide	NNP	i	IPM
versus	NN	O	O
furosemide	NN	i	IPM
in	IN	O	O
cirrhosis	NN	p	O
:	:	p	O
a	DT	O	O
long-term	JJ	O	O
,	,	O	O
double-blind	JJ	O	O
,	,	O	O
randomized	JJ	O	O
clinical	JJ	O	O
study	NN	O	O
.	.	O	O

The	DT	O	O
effects	NNS	O	O
of	IN	O	O
long-term	JJ	O	O
therapy	NN	O	O
(	(	O	O
70	CD	O	O
days	NNS	O	O
)	)	O	O
with	IN	O	O
torasemide	NN	i	IPM
(	(	O	O
20	CD	O	O
mg/day	NN	O	O
)	)	O	O
,	,	O	O
a	DT	O	O
new	JJ	O	O
loop	NN	O	O
diuretic	JJ	O	O
,	,	O	O
were	VBD	O	O
compared	VBN	O	O
with	IN	O	O
those	DT	O	O
of	IN	O	O
furosemide	NN	i	IPM
(	(	O	O
50	CD	O	O
mg/day	NN	O	O
)	)	O	O
in	IN	O	O
a	DT	O	O
randomized	JJ	O	O
double-blind	JJ	O	O
trial	NN	O	O
.	.	O	O

Both	DT	O	O
drugs	NNS	O	O
were	VBD	O	O
administered	VBN	O	O
in	IN	O	O
association	NN	O	O
with	IN	O	O
spironolactone	NN	i	IPM
(	(	O	O
200	CD	O	O
mg/day	NN	O	O
)	)	O	O
in	IN	O	O
28	CD	p	O
nonazotemic	JJ	p	O
cirrhotic	JJ	p	O
patients	NNS	p	O
with	IN	p	O
controlled	JJ	p	O
ascites	NNS	p	O
.	.	p	O

The	DT	O	O
treatments	NNS	O	O
did	VBD	O	O
not	RB	O	O
modify	VB	O	O
creatinine	JJ	o	OPH
clearance	NN	o	OPH
and	CC	O	O
exhibited	VBD	O	O
a	DT	O	O
similar	JJ	O	O
effect	NN	O	O
on	IN	O	O
body	NN	o	OPH
weight	NN	o	OPH
,	,	o	OPH
urinary	JJ	o	OPH
volume	NN	o	OPH
,	,	O	O
and	CC	O	O
fractional	JJ	o	OPH
excretion	NN	o	OPH
of	IN	o	OPH
uric	JJ	o	OPH
acid	NN	o	OPH
,	,	o	OPH
sodium	NN	o	OPH
,	,	o	OPH
and	CC	o	OPH
chloride	NN	o	OPH
.	.	o	O

The	DT	O	O
effect	NN	O	O
of	IN	O	O
torasemide	NN	i	IPM
on	IN	O	O
fractional	JJ	o	OPH
potassium	NN	o	OPH
excretion	NN	o	OPH
was	VBD	O	O
lower	JJR	O	O
than	IN	O	O
that	DT	O	O
of	IN	O	O
furosemide	NN	i	IPM
.	.	i	O

Torasemide	VB	i	IPM
showed	VBD	O	O
higher	JJR	O	O
sparing	VBG	o	OOt
effect	NN	o	OOt
than	IN	O	O
furosemide	NN	i	IPM
on	IN	O	O
calcium	NN	o	OPH
,	,	o	OPH
inorganic	JJ	o	OPH
phosphate	NN	o	OPH
,	,	o	OPH
and	CC	o	OPH
magnesium	NN	o	OPH
excretion	NN	o	OPH
and	CC	O	O
stronger	JJR	O	O
action	NN	O	O
on	IN	O	O
free	JJ	o	OPH
water	NN	o	OPH
clearance	NN	o	OPH
.	.	o	O

No	DT	O	O
changes	NNS	O	O
in	IN	O	O
serum	NN	o	OPH
parameters	NNS	o	OPH
were	VBD	O	O
induced	VBN	O	O
by	IN	O	O
either	DT	O	O
treatment	NN	O	O
.	.	O	O

Two	CD	O	O
episodes	NNS	O	O
of	IN	O	O
hepatic	JJ	o	OPH
encephalopathy	NN	o	OPH
occurred	VBD	O	O
in	IN	O	O
the	DT	O	O
torasemide	NN	i	IPM
group	NN	O	O
.	.	O	O

In	IN	O	O
view	NN	O	O
of	IN	O	O
its	PRP$	O	O
effects	NNS	o	OPH
on	IN	o	OPH
sodium	NN	o	OPH
and	CC	o	OPH
water	NN	o	OPH
excretion	NN	o	OPH
and	CC	O	O
on	IN	o	OPH
other	JJ	o	OPH
urinary	JJ	o	OPH
parameters	NNS	o	OPH
,	,	O	O
torasemide	NN	i	IPM
can	MD	O	O
represent	VB	O	O
an	DT	O	O
alternative	JJ	O	O
tool	NN	O	O
for	IN	O	O
the	DT	O	O
long-term	JJ	O	O
treatment	NN	O	O
of	IN	O	O
ascites	NNS	p	O
.	.	p	O

Gemcitabine	NNP	i	IPM
and	CC	O	O
split-dose	JJ	O	O
paclitaxel	NN	i	IPM
or	CC	O	O
docetaxel	NN	i	IPM
in	IN	O	O
metastatic	JJ	O	O
breast	NN	O	O
cancer	NN	O	O
:	:	O	O
a	DT	O	O
randomised	JJ	O	O
phase	NN	O	O
II	NNP	O	O
study	NN	O	O
.	.	O	O

PURPOSE	VB	O	O
The	DT	O	O
purpose	NN	O	O
was	VBD	O	O
to	TO	O	O
evaluate	VB	O	O
the	DT	O	O
activity	NN	o	OOt
and	CC	o	OOt
toxicity	NN	o	OOt
of	IN	O	O
split-dose	JJ	i	IPM
paclitaxel	NN	i	IPM
or	CC	i	O
docetaxel	NN	i	IPM
in	IN	i	O
combination	NN	i	IPM
with	IN	i	IPM
gemcitabine	NN	i	IPM
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
metastatic	JJ	p	PC
breast	NN	p	PC
cancer	NN	p	PC
(	(	p	O
MBC	NNP	p	PC
)	)	p	O
who	WP	p	O
had	VBD	p	O
previously	RB	p	PC
received	VBN	p	PC
anthracyclines	NNS	p	PC
.	.	p	O

PATIENTS	NNP	O	O
AND	CC	O	O
METHODS	NNP	O	O
A	NNP	O	O
total	NN	p	O
of	IN	p	O
210	CD	p	PSS
patients	NNS	p	O
were	VBD	O	O
randomly	RB	O	O
assigned	VBN	O	O
to	TO	O	O
one	CD	O	O
of	IN	O	O
three	CD	O	O
treatment	NN	O	O
arms	NNS	O	O
:	:	O	O
gemcitabine	NN	i	IPM
1,250	CD	i	IPM
mg/m	NN	i	IPM
(	(	i	IPM
2	CD	i	IPM
)	)	i	IPM
Days	VBZ	i	IPM
1	CD	i	IPM
and	CC	i	IPM
8	CD	i	IPM
and	CC	i	IPM
paclitaxel	VB	i	IPM
175	CD	i	IPM
mg/m	NN	i	IPM
(	(	i	IPM
2	CD	i	IPM
)	)	i	IPM
as	IN	i	IPM
a	DT	i	IPM
3-h	JJ	i	IPM
infusion	NN	i	IPM
on	IN	i	IPM
Day	NNP	i	IPM
1	CD	i	IPM
(	(	i	IPM
GP1	NNP	i	IPM
)	)	i	IPM
;	:	i	O
gemcitabine	$	i	IPM
1,000	CD	i	IPM
mg/m	NN	i	IPM
(	(	i	IPM
2	CD	i	IPM
)	)	i	IPM
Days	VBZ	i	IPM
1	CD	i	IPM
and	CC	i	IPM
8	CD	i	IPM
and	CC	i	IPM
paclitaxel	VB	i	IPM
100	CD	i	IPM
mg/m	NN	i	IPM
(	(	i	IPM
2	CD	i	IPM
)	)	i	IPM
as	IN	i	IPM
a	DT	i	IPM
1-h	JJ	i	IPM
infusion	NN	i	IPM
on	IN	i	IPM
Days	NNP	i	IPM
1	CD	i	IPM
and	CC	i	IPM
8	CD	i	IPM
(	(	i	IPM
GP2	NNP	i	IPM
)	)	i	IPM
;	:	i	O
gemcitabine	$	i	IPM
1,000	CD	i	IPM
mg/m	NN	i	IPM
(	(	i	IPM
2	CD	i	IPM
)	)	i	IPM
Days	VBZ	i	IPM
1	CD	i	IPM
and	CC	i	IPM
8	CD	i	IPM
and	CC	i	IPM
docetaxel	VB	i	IPM
40	CD	i	IPM
mg/m	NN	i	IPM
(	(	i	IPM
2	CD	i	IPM
)	)	i	IPM
as	IN	i	IPM
a	DT	i	IPM
1-h	JJ	i	IPM
infusion	NN	i	IPM
on	IN	i	IPM
Days	NNP	i	IPM
1	CD	i	IPM
and	CC	i	IPM
8	CD	i	IPM
(	(	i	IPM
GD	NNP	i	IPM
)	)	i	O
.	.	O	O

Cycles	NNS	O	O
were	VBD	O	O
repeated	VBN	O	O
every	DT	O	O
3	CD	O	O
weeks	NNS	O	O
.	.	O	O

RESULTS	NNP	O	O
For	IN	O	O
the	DT	O	O
204	CD	p	PSS
patients	NNS	p	O
evaluable	JJ	p	O
for	IN	p	O
response	NN	p	O
assessment	NN	p	O
,	,	p	O
the	DT	p	O
response	NN	o	OPH
rates	NNS	o	OPH
were	VBD	p	O
48.6	CD	p	O
%	NN	p	O
for	IN	p	O
GP1	NNP	p	O
,	,	p	O
52.2	CD	p	O
%	NN	p	O
for	IN	p	O
GP2	NNP	p	O
,	,	p	O
and	CC	p	O
52.3	CD	p	O
%	NN	p	O
for	IN	p	O
GD	NNP	p	O
.	.	p	O

Median	JJ	o	OOt
response	NN	o	OOt
duration	NN	o	OOt
,	,	o	O
time	NN	o	OOt
to	TO	o	OOt
treatment	NN	o	OOt
failure	NN	o	OOt
,	,	o	O
and	CC	o	O
time	NN	o	OOt
to	TO	o	OOt
progression	NN	o	OOt
(	(	o	OOt
TTP	NNP	o	OOt
)	)	o	OOt
were	VBD	O	O
similar	JJ	O	O
in	IN	O	O
each	DT	O	O
arm	NN	O	O
.	.	O	O

Median	JJ	o	O
TTP	NNP	o	O
for	IN	O	O
GP1	NNP	O	O
,	,	O	O
GP2	NNP	O	O
and	CC	O	O
GD	NNP	O	O
was	VBD	O	O
7.5	CD	O	O
,	,	O	O
7.0	CD	O	O
and	CC	O	O
7.4	CD	O	O
months	NNS	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

For	IN	O	O
the	DT	O	O
208	CD	p	PSS
patients	NNS	p	O
evaluable	JJ	p	O
for	IN	p	O
safety	NN	o	OOt
,	,	O	O
the	DT	O	O
most	RBS	O	O
common	JJ	O	O
grade	NN	O	O
3/4	CD	O	O
toxicity	NN	o	OOt
for	IN	O	O
each	DT	O	O
regimen	NN	O	O
was	VBD	O	O
neutropaenia	RB	o	OPH
,	,	O	O
with	IN	O	O
64	CD	O	O
%	NN	O	O
,	,	O	O
57	CD	O	O
%	NN	O	O
,	,	O	O
and	CC	O	O
68	CD	O	O
%	NN	O	O
for	IN	O	O
GP1	NNP	O	O
,	,	O	O
GP2	NNP	O	O
,	,	O	O
and	CC	O	O
GD	NNP	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

Grade	VB	O	O
4	CD	O	O
neutropaenia	NN	o	OPH
,	,	O	O
grade	VBD	O	O
3/4	CD	O	O
anaemia	NN	o	OPH
,	,	o	O
febrile	JJ	o	OPH
neutropaenia	NN	o	OPH
,	,	o	O
and	CC	o	O
diarrhoea	NNS	o	OPH
were	VBD	O	O
more	JJR	O	O
common	JJ	O	O
in	IN	O	O
the	DT	O	O
docetaxel	NN	O	O
arm	NN	O	O
,	,	O	O
as	IN	O	O
was	VBD	O	O
the	DT	O	O
use	NN	O	O
of	IN	O	O
intravenous	JJ	O	O
antibiotics	NNS	O	O
and	CC	O	O
blood	NN	O	O
transfusions	NNS	O	O
.	.	O	O

CONCLUSION	VB	O	O
The	DT	O	O
study	NN	O	O
confirmed	VBD	O	O
the	DT	O	O
high	JJ	O	O
activity	NN	O	O
of	IN	O	O
gemcitabine-taxane	JJ	i	IPM
combinations	NNS	i	IPM
in	IN	O	O
MBC	NNP	O	O
.	.	O	O

Split-dose	JJ	O	O
paclitaxel	NN	i	IPM
had	VBD	O	O
similar	JJ	O	O
activity	NN	o	O
and	CC	O	O
toxicity	NN	o	OOt
to	TO	O	O
the	DT	O	O
3-weekly	JJ	O	O
administration	NN	O	O
.	.	O	O

The	DT	O	O
split-dose	JJ	O	O
docetaxel	NN	i	IPM
regimen	NNS	O	O
had	VBD	O	O
similar	JJ	O	O
activity	NN	o	O
to	TO	O	O
the	DT	O	O
paclitaxel	NN	i	IPM
combinations	NNS	i	IPM
though	IN	O	O
associated	VBN	O	O
with	IN	O	O
higher	JJR	O	O
toxicity	NN	o	O
.	.	o	O

Effect	NN	O	O
of	IN	O	O
light-cured	JJ	O	O
filled	VBN	O	O
sealant	NN	O	O
on	IN	O	O
shear	JJ	O	O
bond	NN	O	O
strength	NN	O	O
of	IN	O	O
metal	NN	O	O
and	CC	O	O
ceramic	JJ	O	O
brackets	NNS	O	O
bonded	VBN	O	O
with	IN	O	O
a	DT	O	O
resin-modified	JJ	O	O
glass	NN	O	O
ionomer	NN	O	O
cement	NN	O	O
.	.	O	O

INTRODUCTION	NNP	O	O
Our	PRP$	O	O
objective	NN	O	O
was	VBD	O	O
to	TO	O	O
evaluate	VB	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
a	DT	O	O
highly	RB	O	O
filled	VBN	O	O
light-cured	JJ	i	IPH
sealant	NN	i	IPH
(	(	i	IPH
HFLCS	NNP	i	IPH
)	)	i	IPH
on	IN	O	O
the	DT	O	O
shear	JJ	O	O
bond	NN	O	O
strength	NN	O	O
and	CC	O	O
bond	NN	O	O
failure	NN	O	O
site	NN	O	O
of	IN	O	O
metal	NN	O	O
and	CC	O	O
ceramic	JJ	O	O
brackets	NNS	O	O
bonded	VBN	O	O
with	IN	O	O
resin-modified	JJ	O	O
glass	NN	O	O
ionomer	NN	O	O
cement	NN	O	O
(	(	O	O
RMGIC	NNP	O	O
)	)	O	O
.	.	O	O

METHODS	NNP	O	O
Eighty	NNP	p	PSS
freshly	RB	p	PSS
extracted	VBD	p	PSS
maxillary	JJ	p	PSS
premolars	NNS	p	PSS
were	VBD	p	O
randomly	RB	p	O
divided	VBN	p	O
into	IN	p	O
4	CD	p	O
groups	NNS	p	O
(	(	p	O
20	CD	p	O
in	IN	p	O
each	DT	p	O
group	NN	p	O
)	)	p	O
.	.	p	O

In	IN	O	O
all	DT	O	O
groups	NNS	O	O
,	,	O	O
the	DT	O	O
teeth	NNS	p	O
were	VBD	O	O
etched	VBN	O	O
with	IN	O	O
37	CD	i	IPH
%	NN	i	IPH
phosphoric	JJ	i	IPH
acid	NN	i	IPH
for	IN	i	IPH
20	CD	i	IPH
seconds	NNS	i	IPH
,	,	i	O
and	CC	i	O
RMGIC	NNP	i	IPH
(	(	i	IPH
Fuji	NNP	i	IPH
Ortho	NNP	i	IPH
LC	NNP	i	IPH
,	,	i	IPH
GC	NNP	i	IPH
Europe	NNP	i	IPH
,	,	i	IPH
Leuven	NNP	i	IPH
,	,	i	IPH
Belgium	NNP	i	IPH
)	)	i	IPH
was	VBD	O	O
used	VBN	O	O
for	IN	O	O
bracket	NN	O	O
bonding	NN	O	O
.	.	O	O

In	IN	O	O
groups	NNS	O	O
1	CD	O	O
and	CC	O	O
3	CD	O	O
,	,	O	O
the	DT	O	O
brackets	NNS	O	O
were	VBD	O	O
bonded	VBN	O	O
directly	RB	O	O
to	TO	O	O
etched	VB	O	O
enamel	JJ	O	O
surfaces	NNS	O	O
;	:	O	O
in	IN	O	O
groups	NNS	O	O
2	CD	O	O
and	CC	O	O
4	CD	O	O
,	,	O	O
the	DT	O	O
etched	JJ	O	O
enamel	NN	O	O
was	VBD	O	O
covered	VBN	O	O
with	IN	O	O
HFLCS	NNP	i	IPH
(	(	i	IPH
Pro	NNP	i	IPH
Seal	NNP	i	IPH
,	,	i	IPH
Reliance	NNP	i	IPH
Orthodontic	NNP	i	IPH
Products	NNP	i	IPH
,	,	i	IPH
Itasca	NNP	i	IPH
,	,	i	IPH
Ill	NNP	i	IPH
)	)	i	IPH
.	.	i	O

Groups	$	O	O
1	CD	O	O
and	CC	O	O
2	CD	O	O
received	VBD	O	O
metal	JJ	i	IPH
brackets	NNS	i	IPH
,	,	O	O
and	CC	O	O
groups	NNS	O	O
3	CD	O	O
and	CC	O	O
4	CD	O	O
had	VBD	O	O
ceramic	JJ	i	IPH
brackets	NNS	i	IPH
.	.	i	O

The	DT	O	O
specimens	NNS	O	O
were	VBD	O	O
stored	VBN	O	O
in	IN	O	O
distilled	JJ	O	O
water	NN	O	O
at	IN	O	O
room	NN	O	O
temperature	NN	O	O
for	IN	O	O
24	CD	O	O
hours	NNS	O	O
and	CC	O	O
subsequently	RB	O	O
tested	VBN	O	O
in	IN	O	O
shear	JJ	O	O
mode	NN	O	O
with	IN	O	O
a	DT	O	O
universal	JJ	O	O
testing	NN	O	O
machine	NN	O	O
.	.	O	O

After	IN	O	O
debonding	VBG	O	O
,	,	O	O
the	DT	O	O
teeth	NNS	O	O
and	CC	O	O
the	DT	O	O
brackets	NNS	O	O
were	VBD	O	O
examined	VBN	O	O
under	IN	O	O
a	DT	O	O
stereomicroscope	NN	O	O
(	(	O	O
model	JJ	O	O
SMZ-1B	NNP	O	O
,	,	O	O
Nikon	NNP	O	O
,	,	O	O
Osaka	NNP	O	O
,	,	O	O
Japan	NNP	O	O
)	)	O	O
at	IN	O	O
20-times	JJ	O	O
magnification	NN	O	O
to	TO	O	O
assess	VB	O	O
the	DT	O	O
residual	JJ	O	O
adhesive	NN	O	O
on	IN	O	O
the	DT	O	O
tooth	NN	O	O
surfaces	NNS	O	O
.	.	O	O

RESULTS	NNP	O	O
Interaction	NNP	O	O
between	IN	O	O
HFLCS	NNP	O	O
and	CC	O	O
bracket	NN	O	O
type	NN	O	O
was	VBD	O	O
not	RB	O	O
statistically	RB	O	O
significant	JJ	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.15	CD	O	O
)	)	O	O
.	.	O	O

Pretreatment	NN	O	O
with	IN	O	O
HFLCS	NNP	o	O
did	VBD	o	O
not	RB	o	O
cause	VB	o	O
a	DT	o	O
statistically	RB	o	O
significant	JJ	o	O
change	NN	o	O
in	IN	o	O
the	DT	o	O
shear	JJ	o	OOt
bond	NN	o	OOt
values	NNS	o	OOt
of	IN	o	OOt
either	DT	o	OOt
metal	NN	o	OOt
or	CC	o	OOt
ceramic	JJ	o	OOt
brackets	NNS	o	OOt
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.38	CD	O	O
)	)	O	O
.	.	O	O

Shear	JJ	o	OOt
bond	NN	o	OOt
values	NNS	o	OOt
of	IN	o	OOt
the	DT	o	OOt
ceramic	JJ	o	OOt
brackets	NNS	o	OOt
were	VBD	O	O
higher	JJR	O	O
than	IN	O	O
those	DT	O	O
of	IN	O	O
the	DT	O	O
metal	JJ	O	O
brackets	NNS	O	O
independent	JJ	O	O
of	IN	O	O
HFLCS	NNP	O	O
application	NN	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.001	CD	O	O
)	)	O	O
.	.	O	O

No	DT	O	O
significant	JJ	O	O
differences	NNS	O	O
were	VBD	O	O
found	VBN	O	O
in	IN	O	O
bond	NN	o	OOt
failure	NN	o	OOt
modes	VBZ	o	OOt
in	IN	O	O
the	DT	O	O
4	CD	O	O
groups	NNS	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
HFLCS	NNP	O	O
application	NN	O	O
on	IN	O	O
enamel	NN	O	O
etched	VBN	O	O
with	IN	O	O
37	CD	O	O
%	NN	O	O
phosphoric	JJ	O	O
acid	NN	O	O
did	VBD	O	O
not	RB	O	O
affect	VB	O	O
the	DT	O	O
bond	NN	o	OOt
strength	NN	o	OOt
values	NNS	o	OOt
and	CC	O	O
the	DT	O	O
bond	NN	o	OOt
failure	NN	o	OOt
modes	NNS	o	OOt
of	IN	O	O
metal	NN	O	O
and	CC	O	O
ceramic	JJ	O	O
brackets	NNS	O	O
bonded	VBN	O	O
with	IN	O	O
RMGIC	NNP	O	O
.	.	O	O

RESULTS	NNP	O	O
Interaction	NNP	O	O
between	IN	O	O
HFLCS	NNP	O	O
and	CC	O	O
bracket	NN	O	O
type	NN	O	O
was	VBD	O	O
not	RB	O	O
statistically	RB	O	O
significant	JJ	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.15	CD	O	O
)	)	O	O
.	.	O	O

Pretreatment	NN	O	O
with	IN	O	O
HFLCS	NNP	O	O
did	VBD	O	O
not	RB	O	O
cause	VB	O	O
a	DT	O	O
statistically	RB	O	O
significant	JJ	O	O
change	NN	O	O
in	IN	O	O
the	DT	O	O
shear	JJ	o	OOt
bond	NN	o	OOt
values	NNS	o	OOt
of	IN	o	OOt
either	DT	o	OOt
metal	NN	o	OOt
or	CC	o	OOt
ceramic	JJ	o	OOt
brackets	NNS	o	OOt
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.38	CD	O	O
)	)	O	O
.	.	O	O

Shear	JJ	o	OOt
bond	NN	o	OOt
values	NNS	o	OOt
of	IN	o	OOt
the	DT	o	OOt
ceramic	JJ	o	OOt
brackets	NNS	o	OOt
were	VBD	O	O
higher	JJR	O	O
than	IN	O	O
those	DT	O	O
of	IN	O	O
the	DT	O	O
metal	JJ	O	O
brackets	NNS	O	O
independent	JJ	O	O
of	IN	O	O
HFLCS	NNP	O	O
application	NN	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.001	CD	O	O
)	)	O	O
.	.	O	O

No	DT	O	O
significant	JJ	O	O
differences	NNS	O	O
were	VBD	O	O
found	VBN	O	O
in	IN	O	O
bond	NN	O	O
failure	NN	O	O
modes	VBZ	O	O
in	IN	O	O
the	DT	O	O
4	CD	O	O
groups	NNS	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
HFLCS	NNP	O	O
application	NN	O	O
on	IN	O	O
enamel	NN	O	O
etched	VBN	O	O
with	IN	O	O
37	CD	O	O
%	NN	O	O
phosphoric	JJ	O	O
acid	NN	O	O
did	VBD	O	O
not	RB	O	O
affect	VB	O	O
the	DT	O	O
bond	NN	O	O
strength	NN	O	O
values	NNS	O	O
and	CC	O	O
the	DT	O	O
bond	NN	O	O
failure	NN	O	O
modes	NNS	O	O
of	IN	O	O
metal	NN	O	O
and	CC	O	O
ceramic	JJ	O	O
brackets	NNS	O	O
bonded	VBN	O	O
with	IN	O	O
RMGIC	NNP	O	O
.	.	O	O

Selected	VBN	O	O
polymorphisms	NNS	O	O
of	IN	O	O
GSTP1	NNP	O	O
and	CC	O	O
TERT	NNP	O	O
were	VBD	O	O
associated	VBN	O	O
with	IN	O	O
glioma	NN	p	PC
risk	NN	p	PC
in	IN	p	O
Han	NNP	p	O
Chinese	NNP	p	O
.	.	p	O

BACKGROUND	NNP	O	O
Current	NNP	O	O
evidence	NN	O	O
suggests	VBZ	O	O
that	IN	O	O
a	DT	O	O
majority	NN	O	O
of	IN	O	O
the	DT	O	O
inherited	JJ	O	O
risks	NNS	O	O
play	VBP	O	O
a	DT	O	O
major	JJ	O	O
role	NN	O	O
in	IN	O	O
glioma	JJ	p	O
susceptibility	NN	p	O
,	,	O	O
and	CC	O	O
glioma	NN	O	O
is	VBZ	O	O
due	JJ	O	O
to	TO	O	O
the	DT	O	O
co-inheritance	NN	O	O
of	IN	O	O
multiple	JJ	O	O
low-risk	JJ	O	O
variants	NNS	O	O
.	.	O	O

These	DT	O	O
variants	NNS	O	O
can	MD	O	O
be	VB	O	O
identified	VBN	O	O
through	IN	O	O
association	NN	O	O
studies	NNS	O	O
including	VBG	O	O
such	JJ	O	O
as	IN	O	O
genome-wide	JJ	O	O
association	NN	O	O
studies	NNS	O	O
(	(	O	O
GWAS	NNP	O	O
)	)	O	O
,	,	O	O
which	WDT	O	O
has	VBZ	O	O
led	VBN	O	O
the	DT	O	O
glioma	NN	O	O
epidemiology	NN	O	O
researchers	NNS	O	O
to	TO	O	O
focus	VB	O	O
on	IN	O	O
identifying	VBG	O	O
potential	JJ	O	O
disease-causing	JJ	O	O
factors	NNS	O	O
.	.	O	O

METHODS	NNP	O	O
We	PRP	O	O
evaluated	VBD	O	O
and	CC	O	O
validated	VBD	O	O
10	CD	p	O
tag	NN	p	O
single	JJ	p	O
nucleotide	JJ	p	O
polymorphisms	NN	p	O
(	(	p	O
tSNPs	NN	p	O
)	)	p	O
in	IN	p	O
seven	CD	p	O
genes	NNS	p	O
associated	VBN	p	O
with	IN	p	O
glioma	NN	p	PC
susceptibility	NN	p	O
in	IN	p	O
a	DT	p	O
Han	NNP	p	O
Chinese	NNP	p	O
population	NN	p	O
,	,	p	O
including	VBG	p	O
301	CD	p	PSS
glioma	NN	p	O
cases	NNS	p	O
and	CC	p	O
302	CD	p	PSS
controls	NNS	p	O
,	,	p	O
using	VBG	p	O
a	DT	p	O
multiplexed	JJ	i	IOt
single	JJ	i	IOt
nucleotide	NN	i	IOt
polymorphism	NN	i	IOt
(	(	i	IOt
SNP	NNP	i	IOt
)	)	i	IOt
MassEXTEND	NNP	i	IOt
assay	NN	i	IOt
.	.	i	O

We	PRP	O	O
ascertained	VBD	O	O
the	DT	O	O
genotypic	NN	O	O
frequencies	NNS	O	O
for	IN	O	O
each	DT	O	O
tSNP	NN	O	O
in	IN	O	O
control	NN	O	O
subjects	NNS	O	O
were	VBD	O	O
within	IN	O	O
Hardy-Weinberg	NNP	O	O
equilibrium	NN	O	O
(	(	O	O
HWE	NNP	O	O
)	)	O	O
using	VBG	O	O
an	DT	O	O
exact	JJ	O	O
test	NN	O	O
,	,	O	O
and	CC	O	O
then	RB	O	O
compared	VBN	O	O
the	DT	O	O
genotype	NN	O	O
and	CC	O	O
allele	JJ	O	O
frequencies	NNS	O	O
of	IN	O	O
glioma	NN	O	O
patients	NNS	O	O
and	CC	O	O
control	NN	O	O
subjects	NNS	O	O
using	VBG	O	O
the	DT	O	O
?2	JJ	O	O
test	NN	O	O
.	.	O	O

We	PRP	O	O
then	RB	O	O
applied	VBD	O	O
three	CD	O	O
genetic	JJ	O	O
models	NNS	O	O
(	(	O	O
dominant	JJ	O	O
,	,	O	O
recessive	JJ	O	O
,	,	O	O
and	CC	O	O
additive	JJ	O	O
)	)	O	O
using	VBG	O	O
PLINK	NNP	O	O
software	NN	O	O
to	TO	O	O
assess	VB	O	O
the	DT	O	O
association	NN	O	O
of	IN	O	O
each	DT	O	O
tSNP	NN	O	O
with	IN	O	O
glioma	NN	O	O
risk	NN	O	O
.	.	O	O

RESULTS	NNP	O	O
We	PRP	O	O
identified	VBD	O	O
two	CD	O	O
tSNPs	NN	O	O
to	TO	O	O
be	VB	O	O
associated	VBN	O	O
with	IN	o	O
glioma	NN	o	O
susceptibility	NN	o	O
(	(	O	O
rs1695	NN	O	O
,	,	O	O
GSTP1	NNP	O	O
,	,	O	O
P	NNP	O	O
=	NNP	O	O
0.019	CD	O	O
;	:	O	O
rs2853676	NN	O	O
,	,	O	O
TERT	NNP	O	O
,	,	O	O
P	NNP	O	O
=	NNP	O	O
0.039	CD	O	O
)	)	O	O
,	,	O	O
which	WDT	O	O
we	PRP	O	O
confirmed	VBD	O	O
using	VBG	O	O
dominant	NN	O	O
and	CC	O	O
additive	JJ	O	O
model	NN	O	O
analyses	NNS	O	O
.	.	O	O

The	DT	O	O
genotype	NN	O	O
&	CC	O	O
ldquo	NN	O	O
;	:	O	O
GA	NNP	O	O
&	CC	O	O
rdquo	NN	O	O
;	:	O	O
for	IN	O	O
rs1695	NN	O	O
was	VBD	O	O
recognized	VBN	O	O
to	TO	O	O
be	VB	O	O
a	DT	O	O
protective	JJ	O	O
genotype	NN	O	O
for	IN	o	O
glioma	NN	o	O
(	(	O	O
OR	NNP	O	O
,	,	O	O
0.67	CD	O	O
;	:	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
,	,	O	O
0.47-0.96	NNP	O	O
;	:	O	O
P	NNP	O	O
=	NNP	O	O
0.027	CD	O	O
)	)	O	O
,	,	O	O
while	IN	O	O
the	DT	O	O
genotype	NN	O	O
&	CC	O	O
ldquo	NN	O	O
;	:	O	O
AG	NNP	O	O
&	CC	O	O
rdquo	NN	O	O
;	:	O	O
for	IN	O	O
rs2853676	NN	O	O
was	VBD	O	O
shown	VBN	O	O
to	TO	O	O
be	VB	O	O
a	DT	O	O
risk	NN	O	O
genotype	NN	O	O
for	IN	o	O
glioma	NN	o	O
(	(	O	O
OR	NNP	O	O
,	,	O	O
1.50	CD	O	O
;	:	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
,	,	O	O
1.05-2.15	JJ	O	O
;	:	O	O
P	NNP	O	O
=	NNP	O	O
0.025	CD	O	O
)	)	O	O
.	.	O	O

CONCLUSION	NNP	O	O
Our	PRP$	O	O
results	NNS	O	O
,	,	O	O
and	CC	O	O
those	DT	O	O
from	IN	O	O
previous	JJ	O	O
studies	NNS	O	O
,	,	O	O
suggest	VBP	O	O
potential	JJ	O	O
genetic	JJ	O	O
contributes	NNS	O	O
for	IN	O	O
GSTP1	NNP	O	O
and	CC	O	O
TERT	NNP	O	O
in	IN	O	O
glioma	NN	O	O
development	NN	O	O
.	.	O	O

A	DT	O	O
placebo-controlled	JJ	i	IC
trial	NN	O	O
of	IN	O	O
maintenance	NN	O	O
therapy	NN	O	O
with	IN	O	O
fluconazole	JJ	i	IPM
after	IN	p	O
treatment	NN	p	O
of	IN	p	O
cryptococcal	JJ	p	PC
meningitis	NN	p	PC
in	IN	p	O
the	DT	p	O
acquired	JJ	p	PC
immunodeficiency	NN	p	PC
syndrome	NN	p	PC
.	.	p	PC

California	NNP	O	O
Collaborative	NNP	O	O
Treatment	NNP	O	O
Group	NNP	O	O
.	.	O	O

BACKGROUND	NNP	O	O
AND	NNP	O	O
METHODS	NNP	O	O
In	IN	O	O
patients	NNS	p	O
with	IN	p	O
the	DT	p	O
acquired	JJ	p	PC
immunodeficiency	NN	p	PC
syndrome	NN	p	PC
(	(	p	PC
AIDS	NNP	p	PC
)	)	p	PC
,	,	O	O
the	DT	O	O
rate	NN	O	O
of	IN	O	O
relapse	NN	O	O
after	IN	O	O
primary	JJ	O	O
treatment	NN	O	O
for	IN	O	O
cryptococcal	JJ	O	O
meningitis	NN	O	O
remains	VBZ	O	O
high	JJ	O	O
.	.	O	O

We	PRP	O	O
conducted	VBD	O	O
a	DT	O	O
controlled	VBN	O	O
,	,	O	O
double-blind	JJ	O	O
trial	NN	O	O
to	TO	O	O
evaluate	VB	O	O
the	DT	O	O
efficacy	NN	O	O
of	IN	O	O
maintenance	NN	O	O
therapy	NN	O	O
with	IN	O	O
fluconazole	NN	O	O
.	.	O	O

At	IN	O	O
entry	NN	O	O
into	IN	O	O
the	DT	O	O
study	NN	O	O
,	,	O	O
all	DT	p	O
participants	NNS	p	O
had	VBD	p	O
sterile	JJ	p	O
cultures	NNS	p	O
of	IN	p	O
cerebrospinal	JJ	p	O
fluid	NN	p	O
,	,	p	O
blood	NN	p	O
,	,	p	O
and	CC	p	O
urine	JJ	p	O
after	IN	p	O
following	VBG	p	O
a	DT	p	O
standardized	JJ	p	O
course	NN	p	O
of	IN	p	O
therapy	NN	p	O
for	IN	p	O
culture-proved	JJ	p	O
cryptococcal	JJ	p	PC
meningitis	NN	p	PC
.	.	p	O

The	DT	O	O
patients	NNS	O	O
were	VBD	O	O
randomly	RB	O	O
assigned	VBN	O	O
to	TO	O	O
take	VB	O	O
either	DT	O	O
fluconazole	NN	i	IPM
or	CC	i	O
placebo	NN	i	IC
as	IN	O	O
maintenance	NN	O	O
therapy	NN	O	O
.	.	O	O

The	DT	O	O
dose	NN	O	O
of	IN	O	O
fluconazole	NN	i	IPM
was	VBD	O	O
100	CD	O	O
mg	JJ	O	O
daily	RB	O	O
in	IN	O	O
the	DT	O	O
first	JJ	O	O
phase	NN	O	O
of	IN	O	O
study	NN	O	O
and	CC	O	O
200	CD	O	O
mg	NNS	O	O
daily	RB	O	O
in	IN	O	O
the	DT	O	O
second	JJ	O	O
phase	NN	O	O
.	.	O	O

RESULTS	NNP	O	O
Of	IN	p	O
84	CD	p	PSS
patients	NNS	p	O
initially	RB	p	O
enrolled	VBD	p	O
,	,	p	O
16	CD	p	PSS
(	(	p	O
19	CD	p	O
percent	NN	p	O
)	)	p	O
were	VBD	p	O
found	VBN	p	O
to	TO	p	O
have	VB	p	O
silent	JJ	p	O
,	,	p	O
persistent	JJ	p	O
infection	NN	p	PC
on	IN	p	O
the	DT	p	O
basis	NN	p	O
of	IN	p	O
cultures	NNS	p	O
that	WDT	p	O
became	VBD	p	O
positive	JJ	p	O
after	IN	p	O
entry	NN	p	O
into	IN	p	O
the	DT	p	O
study	NN	p	O
;	:	p	O
7	CD	p	PSS
other	JJ	p	O
patients	NNS	p	O
were	VBD	p	O
lost	VBN	p	O
to	TO	p	O
follow-up	NNS	p	O
shortly	RB	p	O
after	IN	p	O
entry	NN	p	O
.	.	O	O

Of	IN	O	O
the	DT	O	O
remaining	VBG	p	O
61	CD	p	PSS
patients	NNS	p	O
,	,	O	O
10	CD	O	O
of	IN	O	O
27	CD	O	O
assigned	VBN	O	O
to	TO	O	O
placebo	VB	i	IC
(	(	O	O
37	CD	O	O
percent	NN	O	O
)	)	O	O
and	CC	O	O
1	CD	O	O
of	IN	O	O
34	CD	O	O
assigned	VBN	O	O
to	TO	O	O
fluconazole	VB	i	IPM
(	(	O	O
3	CD	O	O
percent	NN	O	O
)	)	O	O
had	VBD	O	O
a	DT	O	O
recurrence	NN	o	OPH
of	IN	o	OPH
cryptococcal	JJ	o	OPH
infection	NN	o	OPH
at	IN	o	OPH
any	DT	o	OPH
site	NN	o	OPH
(	(	O	O
difference	NN	O	O
in	IN	O	O
risk	NN	O	O
,	,	O	O
34	CD	O	O
percent	NN	O	O
;	:	O	O
95	CD	O	O
percent	NN	O	O
confidence	NN	O	O
interval	NN	O	O
,	,	O	O
15	CD	O	O
to	TO	O	O
53	CD	O	O
)	)	O	O
.	.	O	O

Of	IN	O	O
the	DT	O	O
11	CD	O	O
recurrent	NN	O	O
infections	NNS	O	O
,	,	O	O
7	CD	O	O
were	VBD	O	O
detected	VBN	O	O
in	IN	O	O
urine	NN	O	O
obtained	VBN	O	O
after	IN	O	O
prostatic	JJ	O	O
massage	NN	O	O
.	.	O	O

There	EX	O	O
were	VBD	O	O
four	CD	O	O
recurrent	NN	o	OPH
meningeal	NN	o	OPH
infections	NNS	o	OPH
in	IN	O	O
the	DT	O	O
patients	NNS	O	O
taking	VBG	O	O
placebo	NN	i	IC
,	,	O	O
but	CC	O	O
none	NN	O	O
in	IN	O	O
those	DT	O	O
taking	VBG	O	O
fluconazole	JJ	i	IPM
(	(	O	O
mean	JJ	O	O
duration	NN	O	O
of	IN	O	O
follow-up	NN	O	O
,	,	O	O
164	CD	O	O
days	NNS	O	O
)	)	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.03	CD	O	O
)	)	O	O
.	.	O	O

In	IN	O	O
multivariate	NN	O	O
analyses	NNS	O	O
,	,	O	O
the	DT	O	O
best	JJS	O	O
predictors	NNS	O	O
of	IN	O	O
recurrence-free	JJ	o	OMO
survival	NN	o	OMO
were	VBD	O	O
fluconazole	JJ	i	IPM
treatment	NN	i	IPM
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.02	CD	O	O
;	:	O	O
relative	JJ	O	O
hazard	NN	O	O
,	,	O	O
13.2	CD	O	O
)	)	O	O
,	,	O	O
a	DT	O	O
lower	JJR	O	O
serum	NN	O	O
cryptococcal-antigen	NN	O	O
titer	NN	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.05	CD	O	O
;	:	O	O
relative	JJ	O	O
hazard	NN	O	O
,	,	O	O
1.2	CD	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
more	JJR	O	O
prolonged	JJ	O	O
primary	JJ	O	O
therapy	NN	O	O
with	IN	O	O
flucytosine	NN	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.09	CD	O	O
;	:	O	O
relative	JJ	O	O
hazard	NN	O	O
,	,	O	O
1.1	CD	O	O
)	)	O	O
.	.	O	O

Survival	NNP	o	OMO
and	CC	o	O
toxicity	NN	o	OOt
were	VBD	O	O
similar	JJ	O	O
in	IN	O	O
the	DT	O	O
two	CD	O	O
maintenance-treatment	JJ	O	O
groups	NNS	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
In	IN	O	O
patients	NNS	p	O
with	IN	p	O
AIDS	NNP	p	PC
,	,	O	O
silent	JJ	O	O
persistent	JJ	O	O
infection	NN	O	O
is	VBZ	O	O
common	JJ	O	O
after	IN	O	O
clinically	RB	O	O
successful	JJ	O	O
treatment	NN	O	O
for	IN	O	O
cryptococcal	JJ	O	O
meningitis	NN	O	O
.	.	O	O

Maintenance	NNP	O	O
therapy	NN	O	O
with	IN	O	O
fluconazole	NN	i	IPM
is	VBZ	O	O
highly	RB	O	O
effective	JJ	O	O
in	IN	O	O
preventing	VBG	O	O
recurrent	JJ	O	O
cryptococcal	JJ	O	O
infection	NN	O	O
.	.	O	O

Effects	NNS	O	O
of	IN	O	O
vacuum-compression	NN	o	OPH
therapy	NN	o	OPH
on	IN	O	O
healing	NN	O	O
of	IN	O	O
diabetic	JJ	o	OPH
foot	NN	o	OPH
ulcers	NNS	o	OPH
:	:	o	O
randomized	VBN	O	O
controlled	JJ	O	O
trial	NN	O	O
.	.	O	O

A	DT	O	O
single-blind	JJ	O	O
,	,	O	O
randomized	VBN	O	O
controlled	VBD	O	O
trial	NN	O	O
was	VBD	O	O
conducted	VBN	O	O
to	TO	O	O
evaluate	VB	O	O
vacuum-compression	NN	o	OPH
therapy	NN	o	OPH
(	(	o	OPH
VCT	NNP	o	OPH
)	)	o	OPH
for	IN	O	O
the	DT	O	O
healing	NN	O	O
of	IN	O	O
diabetic	JJ	o	OPH
foot	NN	o	OPH
ulcers	NNS	o	OPH
.	.	o	O

Eighteen	NNP	p	PSS
diabetic	JJ	p	PC
patients	NNS	p	O
with	IN	p	O
foot	JJ	o	OPH
ulcers	NNS	o	OPH
were	VBD	p	O
recruited	VBN	p	O
through	IN	p	O
simple	JJ	p	O
nonprobability	NN	p	O
sampling	VBG	p	O
.	.	p	O

Subjects	NNS	O	O
were	VBD	O	O
randomly	RB	O	O
assigned	VBN	O	O
to	TO	O	O
either	DT	O	O
an	DT	O	O
experimental	JJ	O	O
or	CC	O	O
a	DT	O	O
control	NN	i	IC
group	NN	O	O
.	.	O	O

Before	IN	O	O
and	CC	O	O
after	IN	O	O
intervention	NN	O	O
,	,	O	O
the	DT	O	O
foot	NN	o	OPH
ulcer	JJ	o	OPH
surface	NN	o	OPH
area	NN	o	OPH
was	VBD	O	O
estimated	VBN	O	O
stereologically	RB	O	O
,	,	O	O
based	VBN	O	O
on	IN	O	O
Cavalieri	NNP	O	O
's	POS	O	O
principle	NN	O	O
.	.	O	O

The	DT	O	O
experimental	JJ	O	O
group	NN	O	O
was	VBD	O	O
treated	VBN	O	O
with	IN	O	O
VCT	NNP	o	OOt
in	IN	i	IPH
addition	NN	i	IPH
to	TO	i	IPH
conventional	JJ	o	OPH
therapy	NN	o	OPH
for	IN	O	O
10	CD	O	O
sessions	NNS	O	O
.	.	O	O

The	DT	O	O
control	NN	O	O
group	NN	O	O
received	VBD	O	O
only	RB	O	O
conventional	JJ	o	OOt
therapy	NN	o	OOt
,	,	i	IC
including	VBG	i	IC
debridement	NN	o	OOt
,	,	o	OOt
blood	NN	o	OOt
glucose	NNS	o	OOt
control	NN	o	OOt
agents	NNS	o	OOt
,	,	o	O
systemic	JJ	o	OOt
antibiotics	NNS	o	OOt
,	,	o	O
wound	IN	o	OOt
cleaning	VBG	o	OOt
with	IN	o	OOt
normal	JJ	o	OOt
saline	NN	o	OOt
,	,	o	O
offloading	VBG	o	OOt
(	(	o	O
pressure	NN	o	O
relief	NN	o	O
)	)	o	O
,	,	i	IC
and	CC	i	IC
daily	RB	o	OPH
wound	JJ	o	OPH
dressings	NNS	o	OPH
.	.	o	O

The	DT	O	O
mean	JJ	O	O
foot	NN	o	OPH
ulcer	JJ	o	OPH
surface	NN	o	OPH
area	NN	o	OPH
decreased	VBD	O	O
from	IN	O	O
46.88	CD	O	O
+/-	JJ	O	O
9.28	CD	O	O
mm	NN	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
to	TO	O	O
35.09	CD	O	O
+/-	JJ	O	O
4.09	CD	O	O
mm	NN	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
in	IN	O	O
the	DT	O	O
experimental	JJ	O	O
group	NN	O	O
(	(	O	O
p	JJ	O	O
=	NNP	O	O
0.006	CD	O	O
)	)	O	O
and	CC	O	O
from	IN	O	O
46.62	CD	O	O
+/-	JJ	O	O
10.03	CD	O	O
mm	NN	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
to	TO	O	O
42.89	CD	O	O
+/-	JJ	O	O
8.1	CD	O	O
mm	NN	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
in	IN	O	O
the	DT	O	O
control	NN	O	O
group	NN	O	O
(	(	O	O
p	JJ	O	O
=	NNP	O	O
0.01	CD	O	O
)	)	O	O
.	.	O	O

After	IN	O	O
treatment	NN	O	O
,	,	O	O
the	DT	O	O
experimental	JJ	O	O
group	NN	O	O
significantly	RB	O	O
improved	VBN	O	O
in	IN	O	O
measures	NNS	o	OPH
of	IN	o	OPH
foot	NN	o	OPH
ulcer	JJ	o	OPH
surface	NN	o	OPH
area	NN	o	OPH
compared	VBN	O	O
with	IN	O	O
the	DT	O	O
control	NN	O	O
group	NN	O	O
(	(	O	O
p	JJ	O	O
=	NNP	O	O
0.024	CD	O	O
)	)	O	O
.	.	O	O

VCT	NNP	o	OOt
enhances	VBZ	O	O
diabetic	JJ	o	OPH
foot	NN	o	OPH
ulcer	NN	o	OPH
healing	VBG	o	OPH
when	WRB	O	O
combined	VBN	O	O
with	IN	O	O
appropriate	JJ	O	O
wound	NN	O	O
care	NN	O	O
.	.	O	O

Computer-navigated	JJ	i	IS
versus	NN	i	O
conventional	JJ	i	IS
total	JJ	i	IS
knee	NN	i	IS
arthroplasty	IN	i	IS
a	DT	O	O
prospective	JJ	O	O
randomized	VBN	O	O
trial	NN	O	O
.	.	O	O

BACKGROUND	VB	O	O
The	DT	O	O
literature	NN	O	O
lacks	VBZ	O	O
studies	NNS	O	O
that	IN	O	O
confirm	VBP	O	O
whether	IN	O	O
the	DT	O	O
improved	JJ	O	O
radiographic	JJ	O	O
alignment	NN	O	O
that	WDT	O	O
can	MD	O	O
be	VB	O	O
achieved	VBN	O	O
with	IN	O	O
computer-navigated	JJ	i	IS
total	JJ	i	IS
knee	NN	i	IS
arthroplasty	NN	i	IS
improves	VBZ	O	O
patients?	JJ	O	O
activities	NNS	O	O
of	IN	O	O
daily	JJ	O	O
living	NN	O	O
or	CC	O	O
the	DT	O	O
durability	NN	O	O
of	IN	O	O
total	JJ	O	O
knee	NN	O	O
prostheses	NNS	O	O
.	.	O	O

The	DT	O	O
purpose	NN	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
determine	VB	O	O
whether	IN	i	O
computer-navigated	JJ	i	IS
total	JJ	i	IS
knee	NN	i	IS
arthroplasty	NN	i	IS
improves	VBZ	i	O
the	DT	O	O
clinical	JJ	O	O
function	NN	O	O
,	,	O	O
alignment	NN	O	O
,	,	O	O
and	CC	O	O
survivorship	NN	O	O
of	IN	O	O
the	DT	O	O
components	NNS	O	O
.	.	O	O

METHODS	NNP	O	O
We	PRP	O	O
prospectively	RB	O	O
compared	VBN	O	O
the	DT	O	O
results	NNS	O	O
of	IN	O	O
520	CD	p	O
patients	NNS	p	O
with	IN	p	O
osteoarthritis	NN	p	O
who	WP	p	O
underwent	VBD	i	O
computer-navigated	JJ	i	IS
total	JJ	i	IS
knee	NN	i	IS
arthroplasty	NN	i	IS
for	IN	i	O
one	CD	i	O
knee	NN	i	O
and	CC	i	O
conventional	JJ	i	IS
total	JJ	i	IS
knee	NN	i	IS
arthroplasty	NN	i	IS
for	IN	i	O
the	DT	i	O
other	JJ	i	O
.	.	i	O

The	DT	O	O
assignment	NN	O	O
of	IN	O	O
the	DT	O	O
knee	NN	O	O
to	TO	O	O
navigation	NN	O	O
or	CC	O	O
not	RB	O	O
was	VBD	O	O
done	VBN	O	O
randomly	RB	O	O
.	.	O	O

There	EX	O	O
were	VBD	p	O
452	CD	p	O
women	NNS	p	O
(	(	p	O
904	CD	p	O
knees	NNS	p	O
)	)	p	O
and	CC	p	O
sixty-eight	JJ	p	O
men	NNS	p	O
(	(	p	O
136	CD	p	O
knees	NNS	p	O
)	)	p	O
with	IN	p	O
a	DT	p	O
mean	JJ	p	O
age	NN	p	O
of	IN	p	O
sixty-eight	JJ	p	O
years	NNS	p	O
(	(	p	O
range	NN	p	O
,	,	p	O
forty-nine	JJ	p	O
to	TO	p	O
eighty-eight	JJ	p	O
years	NNS	p	O
)	)	p	O
at	IN	p	O
the	DT	p	O
time	NN	p	O
of	IN	p	O
the	DT	p	O
index	NN	p	O
arthroplasty	NN	p	O
.	.	p	O

The	DT	O	O
mean	JJ	O	O
follow-up	JJ	O	O
period	NN	O	O
was	VBD	O	O
10.8	CD	O	O
years	NNS	O	O
(	(	O	O
range	NN	O	O
,	,	O	O
ten	VB	O	O
to	TO	O	O
twelve	VB	O	O
years	NNS	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
patients	NNS	O	O
were	VBD	O	O
assessed	VBN	O	O
clinically	RB	O	O
and	CC	O	O
radiographically	RB	O	O
with	IN	O	O
the	DT	o	O
rating	NN	o	O
system	NN	o	O
of	IN	o	O
the	DT	o	O
Knee	NNP	o	OPH
Society	NNP	o	OPH
and	CC	o	O
with	IN	O	O
the	DT	o	O
Western	NNP	o	OPH
Ontario	NNP	o	OPH
and	CC	o	OPH
McMaster	NNP	o	OPH
Universities	NNP	o	OPH
Osteoarthritis	NNP	o	OPH
Index	NNP	o	OPH
(	(	o	OPH
WOMAC	NNP	o	OPH
)	)	o	OPH
score	NN	o	OPH
at	IN	o	O
three	CD	O	O
months	NNS	O	O
,	,	O	O
one	CD	O	O
year	NN	O	O
,	,	O	O
and	CC	O	O
annually	RB	O	O
thereafter	RB	O	O
.	.	O	O

RESULTS	NNP	o	O
Total	JJ	o	OPH
knee	NN	o	OPH
scores	NNS	o	OPH
,	,	o	O
knee	NN	o	OPH
function	NN	o	OPH
scores	NNS	o	OPH
,	,	o	O
pain	NN	o	OPA
scores	NNS	o	OPA
,	,	o	O
WOMAC	NNP	o	OPH
scores	VBZ	o	OPH
,	,	o	O
knee	VB	o	OPH
motion	NN	o	OPH
,	,	o	O
and	CC	o	O
activity	NN	o	OPH
scores	NNS	o	OPH
did	VBD	o	O
not	RB	O	O
show	VB	O	O
statistically	RB	O	O
significant	JJ	O	O
differences	NNS	O	O
between	IN	O	O
the	DT	O	O
two	CD	O	O
groups	NNS	O	O
preoperatively	RB	O	O
or	CC	O	O
at	IN	O	O
the	DT	O	O
time	NN	O	O
of	IN	O	O
the	DT	O	O
final	JJ	O	O
follow-up	NN	O	O
.	.	O	O

Alignment	NNP	O	O
and	CC	O	O
the	DT	O	O
survivorship	NN	O	O
of	IN	O	O
the	DT	O	O
components	NNS	O	O
were	VBD	O	O
not	RB	O	O
significantly	RB	O	O
different	JJ	O	O
between	IN	O	O
the	DT	O	O
two	CD	O	O
groups	NNS	O	O
.	.	O	O

The	DT	o	O
Kaplan-Meier	NNP	o	O
survivorship	NN	o	O
with	IN	o	O
revision	NN	o	O
as	IN	o	O
the	DT	O	O
end	NN	O	O
point	NN	O	O
at	IN	O	O
10.8	CD	O	O
years	NNS	O	O
was	VBD	O	O
98.8	CD	O	O
%	NN	O	O
(	(	O	O
95	CD	O	O
%	NN	O	O
confidence	NN	O	O
interval	NN	O	O
[	NNP	O	O
CI	NNP	O	O
]	NNP	O	O
,	,	O	O
0.96	CD	O	O
to	TO	O	O
1.00	CD	O	O
)	)	O	O
in	IN	O	O
the	DT	i	O
computernavigated	JJ	i	IS
total	JJ	i	IS
knee	NN	i	IS
arthroplasty	NN	i	IS
group	NN	i	O
and	CC	O	O
99.2	CD	O	O
%	NN	O	O
(	(	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
,	,	O	O
0.96	CD	O	O
to	TO	O	O
1.00	CD	O	O
)	)	O	O
in	IN	O	O
the	DT	i	O
conventional	JJ	i	IS
total	JJ	i	IS
knee	NN	i	IS
arthroplasty	NN	i	IS
group	NN	i	O
.	.	O	O

CONCLUSIONS	NNP	O	O
Our	PRP$	O	O
data	NNS	O	O
demonstrated	VBD	O	O
no	DT	O	O
difference	NN	O	O
in	IN	O	O
clinical	JJ	O	O
function	NN	O	O
or	CC	O	O
alignment	NN	O	O
and	CC	O	O
survivorship	NN	O	O
of	IN	O	O
the	DT	O	O
components	NNS	O	O
between	IN	O	O
the	DT	p	O
knees	NNS	p	O
that	WDT	p	O
underwent	VBD	i	O
computer-navigated	JJ	i	IS
total	JJ	i	IS
knee	NN	i	IS
arthroplasty	NN	i	IS
and	CC	i	O
those	DT	p	O
that	WDT	p	O
underwent	JJ	i	O
conventional	JJ	i	IS
total	JJ	i	IS
knee	NN	i	IS
arthroplasty	NN	i	IS
.	.	i	O

A	DT	O	O
comparison	NN	O	O
of	IN	O	O
live	JJ	O	O
and	CC	O	O
videotape	JJ	O	O
ratings	NNS	O	O
:	:	O	O
clomipramine	NN	i	IPM
and	CC	i	O
haloperidol	NN	i	IPM
in	IN	p	PC
autism	NN	p	PC
.	.	p	O

This	DT	O	O
study	NN	O	O
compared	VBN	O	O
live	JJ	O	O
ratings	NNS	O	O
with	IN	O	O
ratings	NNS	O	O
of	IN	O	O
videotapes	NNS	O	O
and	CC	O	O
compared	VBN	O	O
response	NN	O	O
to	TO	O	O
clomipramine	VB	i	IPM
with	IN	O	O
response	NN	O	O
to	TO	O	O
haloperidol	VB	i	IPM
in	IN	O	O
8	CD	p	PSS
subjects	NNS	p	O
,	,	p	O
mean	JJ	p	O
age	NN	p	O
5.62	CD	p	PA
years	NNS	p	PA
,	,	p	O
who	WP	p	O
met	VBD	p	O
criteria	NNS	p	O
for	IN	p	O
autism	NN	p	O
.	.	p	O

They	PRP	O	O
were	VBD	O	O
consecutive	JJ	O	O
admissions	NNS	O	O
to	TO	O	O
a	DT	O	O
pilot	NN	O	O
study	NN	O	O
of	IN	O	O
clomipramine	NN	i	IPM
(	(	O	O
n	JJ	O	O
=	NNP	O	O
4	CD	O	O
)	)	O	O
or	CC	O	O
a	DT	O	O
double-blind	JJ	O	O
,	,	O	O
placebo	NN	i	IC
controlled	VBD	O	O
study	NN	O	O
of	IN	O	O
haloperidol	NN	i	IPM
(	(	O	O
n	JJ	O	O
=	NNP	O	O
4	CD	O	O
)	)	O	O
.	.	O	O

Live	JJ	O	O
ratings	NNS	O	O
were	VBD	O	O
performed	VBN	O	O
by	IN	O	O
two	CD	O	O
raters	NNS	O	O
at	IN	O	O
the	DT	O	O
end	NN	O	O
of	IN	O	O
the	DT	O	O
pre-treatment	JJ	O	O
placebo	NN	i	IC
baseline	NN	O	O
period	NN	O	O
and	CC	O	O
at	IN	O	O
the	DT	O	O
end	NN	O	O
of	IN	O	O
the	DT	O	O
drug	NN	O	O
treatment	NN	O	O
period	NN	O	O
on	IN	O	O
the	DT	O	O
CPRS	NNP	O	O
and	CC	O	O
the	DT	O	O
CGI	NNP	O	O
and	CC	O	O
were	VBD	O	O
videotaped	VBN	O	O
.	.	O	O

Employing	VBG	O	O
the	DT	O	O
same	JJ	O	O
instruments	NNS	O	O
,	,	O	O
these	DT	O	O
videotapes	NNS	O	O
were	VBD	O	O
rated	VBN	O	O
by	IN	O	O
two	CD	O	O
raters	NNS	O	O
who	WP	O	O
did	VBD	O	O
not	RB	O	O
know	VB	O	O
the	DT	O	O
subjects	NNS	O	O
and	CC	O	O
were	VBD	O	O
blind	NNS	O	O
to	TO	O	O
study	VB	O	O
design	NN	O	O
,	,	O	O
treatment	NN	O	O
,	,	O	O
and	CC	O	O
study	NN	O	O
phase	NN	O	O
.	.	O	O

Ratings	NNS	o	OOt
of	IN	o	OOt
videotapes	NNS	o	OOt
significantly	RB	O	O
differed	VBN	O	O
from	IN	O	O
live	JJ	o	OOt
ratings	NNS	o	OOt
.	.	o	O

A	DT	O	O
treatment	NN	O	O
effect	NN	O	O
for	IN	O	O
haloperidol	NN	O	O
was	VBD	O	O
detected	VBN	O	O
only	RB	O	O
on	IN	O	O
live	JJ	o	OOt
ratings	NNS	o	OOt
and	CC	O	O
not	RB	O	O
on	IN	O	O
ratings	NNS	o	OOt
of	IN	o	OOt
videotapes	NNS	o	OOt
.	.	o	O

No	DT	O	O
treatment	NN	O	O
effect	NN	O	O
was	VBD	O	O
detected	VBN	O	O
for	IN	O	O
clomipramine	NN	i	IPM
in	IN	O	O
either	CC	O	O
live	JJ	o	OOt
or	CC	o	O
videotape	JJ	o	OOt
ratings	NNS	o	OOt
.	.	o	O

A	DT	O	O
double-blind	JJ	O	O
,	,	O	O
placebo-controlled	JJ	i	IC
crossover	NN	O	O
study	NN	O	O
investigating	VBG	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
porcine	NN	i	IPM
secretin	NN	i	IPM
in	IN	O	O
children	NNS	p	PA
with	IN	p	O
autism	NN	p	PC
.	.	p	O

OBJECTIVES	CC	O	O
A	DT	O	O
recent	JJ	O	O
patient	NN	O	O
series	NN	O	O
reported	VBD	O	O
the	DT	O	O
incidental	JJ	O	O
findings	NNS	O	O
of	IN	O	O
improved	VBN	O	O
social	JJ	O	O
and	CC	O	O
language	NN	O	O
skills	NNS	O	O
in	IN	O	O
3	CD	p	O
children	NNS	p	PA
with	IN	p	O
autistic	JJ	p	PC
spectrum	NN	p	PC
disorders	NNS	p	PC
after	IN	p	O
the	DT	p	O
administration	NN	p	O
of	IN	p	O
secretin	NN	i	IPM
,	,	p	O
a	DT	p	O
peptide	NN	p	O
hormone	NN	p	O
.	.	p	O

However	RB	O	O
,	,	O	O
a	DT	O	O
subsequent	JJ	O	O
study	NN	O	O
did	VBD	O	O
not	RB	O	O
find	VB	O	O
evidence	NN	O	O
for	IN	O	O
a	DT	O	O
drug	NN	O	O
effect	NN	O	O
.	.	O	O

Parents	NNS	O	O
are	VBP	O	O
seeking	VBG	O	O
treatment	NN	O	O
with	IN	O	O
secretin	JJ	i	IPM
despite	IN	O	O
the	DT	O	O
absence	NN	O	O
of	IN	O	O
empirical	JJ	O	O
investigations	NNS	O	O
demonstrating	VBG	O	O
amelioration	NN	O	O
in	IN	O	O
autism	NN	O	O
symptomology	NN	O	O
.	.	O	O

In	IN	O	O
order	NN	O	O
to	TO	O	O
more	RBR	O	O
precisely	RB	O	O
measure	VB	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
secretin	NN	i	IPM
,	,	O	O
this	DT	O	O
study	NN	O	O
investigated	VBD	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
a	DT	O	O
single	JJ	O	O
intravenous	JJ	i	IPM
dose	NN	i	IPM
of	IN	i	IPM
porcine	NN	i	IPM
secretin	NN	i	IPM
on	IN	O	O
12	CD	p	PSS
autistic	JJ	p	O
children	NNS	p	PA
through	IN	O	O
a	DT	O	O
randomized	VBN	O	O
,	,	O	O
double-blind	JJ	O	O
,	,	O	O
placebo-controlled	JJ	i	IC
,	,	O	O
crossover	NN	O	O
study	NN	O	O
.	.	O	O

Children	NNP	O	O
were	VBD	O	O
assessed	VBN	O	O
on	IN	O	O
objective	JJ	o	OME
language	NN	o	OME
and	CC	o	OME
on	IN	o	OME
social	JJ	o	OME
,	,	o	OME
neuropsychological	JJ	o	OME
,	,	o	OME
and	CC	o	OME
gastrointestinal	JJ	o	OPH
measures	NNS	o	OPH
to	TO	O	O
evaluate	VB	O	O
drug	NN	O	O
effects	NNS	O	O
.	.	O	O

The	DT	O	O
study	NN	O	O
was	VBD	O	O
conducted	VBN	O	O
over	IN	O	O
a	DT	O	O
16-week	JJ	O	O
trial	NN	O	O
.	.	O	O

The	DT	O	O
results	NNS	O	O
indicated	VBD	O	O
that	IN	O	O
significant	JJ	O	O
differences	NNS	O	O
were	VBD	O	O
not	RB	O	O
observed	VBN	O	O
on	IN	O	O
the	DT	O	O
majority	NN	O	O
of	IN	O	O
the	DT	O	O
dependent	JJ	O	O
variables	NNS	O	O
.	.	O	O

Statistically	NNP	O	O
significant	JJ	O	O
differences	NNS	O	O
were	VBD	O	O
observed	VBN	O	O
on	IN	O	O
measures	NNS	o	OME
of	IN	o	OME
positive	JJ	o	OME
affect	NN	o	OME
and	CC	o	OME
activity	NN	o	OME
level	NN	o	OME
following	VBG	O	O
secretin	JJ	i	IPM
infusion	NN	O	O
.	.	O	O

In	IN	O	O
general	JJ	O	O
,	,	O	O
the	DT	O	O
autistic	JJ	p	O
children	NNS	p	PA
did	VBD	O	O
not	RB	O	O
demonstrate	VB	O	O
the	DT	O	O
improvements	NNS	O	O
described	VBN	O	O
in	IN	O	O
the	DT	O	O
initial	JJ	O	O
retrospective	JJ	O	O
report	NN	O	O
.	.	O	O

Cost-effectiveness	NN	o	OOt
of	IN	O	O
cognitive-behavioral	JJ	i	IPS
group	NN	i	IPS
therapy	NN	i	IPS
for	IN	O	O
dysfunctional	JJ	O	O
fear	NN	O	O
of	IN	O	O
progression	NN	O	O
in	IN	O	O
cancer	NN	p	O
patients	NNS	p	O
.	.	p	O

Anxiety	NNP	o	OME
and	CC	o	O
fear	NN	o	OME
are	VBP	O	O
often	RB	O	O
associated	VBN	O	O
with	IN	O	O
chronic	JJ	O	O
conditions	NNS	O	O
such	JJ	O	O
as	IN	O	O
cancer	NN	O	O
.	.	O	O

This	DT	O	O
paper	NN	O	O
targets	VBZ	O	O
the	DT	O	O
cost-effectiveness	JJ	o	OOt
analysis	NN	o	OOt
of	IN	O	O
a	DT	O	O
cognitive-behavioral	JJ	i	IPS
group	NN	i	IPS
therapy	NN	i	IPS
(	(	i	IPS
CBT	NNP	i	IPS
)	)	i	IPS
in	IN	O	O
comparison	NN	O	O
to	TO	O	O
a	DT	O	O
client-centered	JJ	i	IPS
,	,	i	IPS
supportive-experiential	JJ	i	IPS
group	NN	i	IPS
therapy	NN	i	IPS
(	(	i	IPS
SET	NNP	i	IPS
)	)	i	IPS
in	IN	O	O
cancer	NN	p	O
patients	NNS	p	O
with	IN	p	O
dysfunctional	JJ	p	O
fear	NN	p	O
of	IN	p	O
progression	NN	p	O
.	.	p	O

An	DT	O	O
incremental	JJ	O	O
cost-effectiveness	JJ	o	OOt
analysis	NN	o	OOt
was	VBD	O	O
performed	VBN	O	O
using	VBG	O	O
data	NNS	O	O
from	IN	O	O
a	DT	O	O
randomized	VBN	O	O
controlled	VBN	O	O
trial	NN	O	O
among	IN	O	O
cancer	NN	p	O
patients	NNS	p	O
receiving	VBG	p	O
inpatient	JJ	p	O
rehabilitation	NN	p	O
.	.	p	O

The	DT	O	O
means	NNPS	o	O
,	,	o	O
95	CD	o	O
%	NN	o	O
confidence	NN	o	O
intervals	NNS	o	O
[	VBP	o	O
95	CD	o	O
%	NN	o	O
CI	NNP	o	O
]	NNP	o	O
,	,	o	O
incremental	JJ	o	OOt
cost-effectiveness	JJ	o	OOt
graphic	NN	o	OOt
and	CC	o	OOt
acceptability	NN	o	OOt
curve	NN	o	OOt
were	VBD	O	O
obtained	VBN	O	O
from	IN	O	O
1,000	CD	O	O
bootstrap	NN	O	O
replications	NNS	O	O
.	.	O	O

A	DT	p	O
total	NN	p	O
of	IN	p	O
174	CD	p	O
patients	NNS	p	O
were	VBD	p	O
included	VBN	p	O
in	IN	p	O
the	DT	p	O
economic	JJ	p	O
evaluation	NN	p	O
.	.	p	O

The	DT	O	O
estimated	JJ	o	O
means	VBZ	o	O
[	JJ	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
]	NNP	O	O
of	IN	o	O
direct	JJ	o	OOt
costs	NNS	o	OOt
and	CC	o	O
reduction	NN	o	OME
of	IN	o	OME
fear	NN	o	OME
of	IN	o	OME
progression	NN	o	OME
were	VBD	O	O
<	JJ	O	O
euro	JJ	O	O
>	NN	O	O
9,045.03	CD	O	O
[	JJ	O	O
6,359.07	CD	O	O
;	:	O	O
12,091.87	CD	O	O
]	NN	O	O
and	CC	O	O
1.41	CD	O	O
[	JJ	O	O
0.93	CD	O	O
;	:	O	O
1.92	CD	O	O
]	NN	O	O
for	IN	O	O
patients	NNS	O	O
in	IN	O	O
the	DT	O	O
SET	NNP	O	O
and	CC	O	O
<	NNP	O	O
euro	VBP	O	O
>	$	O	O
6,682.78	CD	O	O
[	JJ	O	O
4,998.09	CD	O	O
;	:	O	O
8,440.95	CD	O	O
]	NN	O	O
and	CC	O	O
1.44	CD	O	O
[	JJ	O	O
1.02	CD	O	O
;	:	O	O
1.09	CD	O	O
]	NN	O	O
for	IN	O	O
patients	NNS	O	O
in	IN	O	O
the	DT	O	O
CBT	NNP	i	IPS
.	.	i	O

The	DT	O	O
incremental	JJ	o	OOt
cost-effectiveness	JJ	o	OOt
ratio	NN	o	OOt
[	VBD	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
]	NNP	O	O
amounts	NNS	O	O
to	TO	O	O
minus	NNS	O	O
<	NNP	O	O
euro	VBP	O	O
>	$	O	O
78,741.66	CD	O	O
[	NNP	O	O
-154,987.20	NNP	O	O
;	:	O	O
110,486.32	CD	O	O
]	NN	O	O
for	IN	O	O
an	DT	O	O
additional	JJ	O	O
unit	NN	O	O
of	IN	O	O
effect	NN	O	O
.	.	O	O

Given	VBN	O	O
the	DT	O	O
acceptability	NN	o	OOt
curve	NN	o	OOt
,	,	O	O
there	EX	O	O
is	VBZ	O	O
a	DT	O	O
92.4	CD	O	O
%	NN	O	O
chance	NN	O	O
that	IN	O	O
the	DT	O	O
CBT	NNP	i	IE
,	,	O	O
compared	VBN	O	O
with	IN	O	O
the	DT	O	O
SET	NNP	i	IE
,	,	O	O
is	VBZ	O	O
cost-effective	JJ	o	OOt
without	IN	O	O
the	DT	O	O
need	NN	O	O
of	IN	O	O
additional	JJ	O	O
costs	NNS	O	O
to	TO	O	O
payers	NNS	O	O
.	.	O	O

Our	PRP$	O	O
main	JJ	O	O
result	NN	O	O
is	VBZ	O	O
the	DT	O	O
superior	JJ	O	O
cost-effectiveness	NN	o	OOt
of	IN	O	O
the	DT	O	O
cognitive-behavioral	JJ	i	IE
intervention	NN	i	IE
program	NN	O	O
in	IN	O	O
comparison	NN	O	O
to	TO	O	O
the	DT	O	O
non-directive	JJ	O	O
encounter	NN	O	O
group	NN	O	O
for	IN	O	O
our	PRP$	O	O
sample	NN	O	O
of	IN	O	O
cancer	NN	p	O
patients	NNS	p	O
with	IN	p	O
high	JJ	p	O
levels	NNS	p	O
of	IN	p	O
anxiety	NN	o	OME
.	.	o	O

[	JJ	o	OOt
Effect	NNP	o	OOt
analysis	NN	o	OOt
on	IN	O	O
non-and-low	JJ	O	O
response	NN	O	O
infants	NNS	p	PA
after	IN	p	O
revaccinated	VBN	p	O
hepatitis	NN	i	IPM
B	NNP	i	IPM
vaccine	NN	i	IPM
]	NN	i	O
.	.	O	O

OBJECTIVE	UH	O	O
To	TO	O	O
evaluate	VB	O	O
the	DT	O	O
booster	NN	o	OPH
immunization	NN	o	OPH
effect	NN	o	OPH
to	TO	O	O
non-and-low	JJ	O	O
response	NN	O	O
children	NNS	O	O
after	IN	O	O
3	CD	O	O
doses	NNS	O	O
HepB	NNP	O	O
immunization	NN	O	O
.	.	O	O

METHODS	NNP	O	O
Non-and-low	JJ	p	O
response	NN	p	O
infants	NNS	p	PA
born	VBN	p	O
in	IN	p	O
2004	CD	p	PA
2005	CD	p	PA
administered	VBD	p	O
3	CD	i	IPM
doses	NNS	i	IPM
of	IN	i	IPM
HepB	NNP	i	IPM
at	IN	i	O
0	CD	i	O
,	,	i	O
1	CD	i	O
,	,	i	O
6	CD	i	O
months	NNS	i	O
in	IN	i	O
Guangzhou	NNP	i	O
,	,	i	O
Beijing	NNP	i	O
and	CC	i	O
Zhejiang	NNP	i	O
were	VBD	i	O
divided	VBN	i	O
into	IN	i	O
4	CD	i	O
groups	NNS	i	O
randomly	RB	i	O
,	,	i	O
and	CC	i	O
boosted	VBD	i	O
3	CD	i	O
dose	NN	i	O
of	IN	i	O
4	CD	i	O
different	JJ	i	O
types	NNS	i	O
of	IN	i	O
HepB	NNP	i	IPM
at	IN	i	O
0	CD	i	O
,	,	i	O
1	CD	i	O
,	,	i	O
6	CD	i	O
months	NNS	i	O
.	.	i	O

RESULTS	VB	O	O
The	DT	O	O
GMC	NNP	O	O
of	IN	O	O
non-and-low	JJ	p	O
response	NN	p	O
children	NNS	p	O
in	IN	O	O
group	NN	O	O
A	NNP	O	O
(	(	O	O
before	IN	O	O
booster	NN	O	O
)	)	O	O
,	,	O	O
group	NN	O	O
B	NNP	O	O
(	(	O	O
after	IN	O	O
1	CD	O	O
dose	JJ	O	O
booster	NN	O	O
)	)	O	O
and	CC	O	O
group	NN	O	O
C	NNP	O	O
(	(	O	O
after	IN	O	O
3	CD	O	O
dose	JJ	O	O
booster	NN	O	O
)	)	O	O
were	VBD	O	O
18.66	CD	O	O
mIUml	NN	O	O
,	,	O	O
88.82	CD	O	O
mIU/ml	NN	O	O
,	,	O	O
178.24	CD	O	O
mIU/ml	NN	O	O
respectively	RB	O	O
;	:	O	O
the	DT	O	O
proportion	NN	O	O
of	IN	O	O
non-responders	NNS	O	O
in	IN	O	O
three	CD	O	O
groups	NNS	O	O
were	VBD	O	O
20.4	CD	O	O
%	NN	O	O
,	,	O	O
9.1	CD	O	O
%	NN	O	O
,	,	O	O
1.9	CD	O	O
%	NN	O	O
respectively	RB	O	O
.	.	O	O

In	IN	O	O
103	CD	p	PSS
non-and-low	JJ	p	O
response	NN	p	O
children	NNS	p	PA
,	,	O	O
proportion	NN	o	OPH
of	IN	o	OPH
titers	NNS	o	OPH
of	IN	O	O
more	JJR	O	O
than	IN	O	O
100	CD	O	O
mIU/ml	NN	O	O
of	IN	O	O
group	NN	O	O
B	NNP	O	O
and	CC	O	O
group	NN	O	O
C	NNP	O	O
were	VBD	O	O
61.2	CD	O	O
%	NN	O	O
and	CC	O	O
84.5	CD	O	O
%	NN	O	O
,	,	O	O
and	CC	O	O
there	RB	O	O
was	VBD	O	O
statistical	JJ	O	O
significant	JJ	O	O
difference	NN	O	O
(	(	O	O
chi2	JJ	O	O
=	NN	O	O
14.13	CD	O	O
,	,	O	O
P	NNP	O	O
<	NNP	O	O
0.01	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
GMC	NNP	O	O
after	IN	O	O
3	CD	O	O
doses	NNS	O	O
revaccination	NN	i	IPM
with	IN	O	O
four	CD	O	O
kinds	NNS	O	O
of	IN	O	O
HepB	NNP	O	O
,	,	O	O
included	VBD	O	O
5	CD	O	O
microg	NN	O	O
HepB-Y	NNP	i	IPM
,	,	O	O
10	CD	O	O
microg	NN	O	O
HepB-Y	NNP	i	IPM
,	,	O	O
l0	JJ	O	O
microg	NN	O	O
HepB-CHO	NNP	i	IPM
,	,	O	O
10	CD	O	O
microg	JJ	O	O
HepB-HY	NNP	i	IPM
were	VBD	O	O
168.8	CD	O	O
mJU/ml	NN	O	O
,	,	O	O
174.7	CD	O	O
mIU/ml	NN	O	O
,	,	O	O
184.9	CD	O	O
mIU/ml	NN	O	O
,	,	O	O
182.9	CD	O	O
mIU/ml	NN	O	O
respectively	RB	O	O
.	.	O	O

Proportion	NN	o	OPH
of	IN	o	OPH
titers	NNS	o	OPH
of	IN	O	O
more	JJR	O	O
than	IN	O	O
100	CD	O	O
mIU/ml	NNS	O	O
for	IN	O	O
four	CD	O	O
kinds	NNS	O	O
HepB	NNP	O	O
were	VBD	O	O
79.0	CD	O	O
%	NN	O	O
,	,	O	O
85.7	CD	O	O
%	NN	O	O
,	,	O	O
88.2	CD	O	O
%	NN	O	O
and	CC	O	O
84.6	CD	O	O
%	NN	O	O
respectively	RB	O	O
,	,	O	O
and	CC	O	O
there	EX	O	O
was	VBD	O	O
no	DT	O	O
significant	JJ	O	O
difference	NN	O	O
(	(	O	O
chi2	JJ	O	O
=	NN	O	O
0.75	CD	O	O
,	,	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

CONCLUSION	NN	O	O
There	EX	O	O
were	VBD	O	O
no	DT	O	O
different	JJ	O	O
of	IN	O	O
seroconversion	NN	o	OPH
rate	NN	o	OPH
between	IN	O	O
study	NN	O	O
population	NN	O	O
received	VBD	O	O
1	CD	O	O
dose	NN	O	O
and	CC	O	O
3	CD	O	O
dose	JJ	O	O
booster	NN	O	O
(	(	O	O
P	NNP	O	O
>	NNP	O	O
0.05	CD	O	O
)	)	O	O
,	,	O	O
but	CC	O	O
high	JJ	O	O
titer	NN	O	O
was	VBD	O	O
observed	VBN	O	O
after	IN	O	O
3	CD	O	O
dose	JJ	O	O
booster	NN	O	O
.	.	O	O

The	DT	O	O
four	CD	O	O
kinds	NNS	O	O
of	IN	O	O
HepB	NNP	O	O
,	,	O	O
including	VBG	O	O
5	CD	O	O
microg	JJ	O	O
HepB-Y,10	NNP	O	O
microg	NN	O	O
HepB-Y	NNP	O	O
,	,	O	O
10	CD	O	O
microg	NN	O	O
HepB-CHO	NNP	O	O
,	,	O	O
10	CD	O	O
microg	NN	O	O
HepB-HY	NNP	O	O
had	VBD	O	O
the	DT	O	O
same	JJ	O	O
immunization	NN	O	O
effect	NN	O	O
after	IN	O	O
3	CD	O	O
doses	NNS	O	O
revaccination	NN	O	O
at	IN	O	O
0	CD	O	O
,	,	O	O
1	CD	O	O
,	,	O	O
6	CD	O	O
months	NNS	O	O
to	TO	O	O
non-and-low	JJ	O	O
response	NN	O	O
children	NNS	O	O
.	.	O	O

Pharmacokinetic	JJ	O	O
properties	NNS	O	O
of	IN	O	O
YM17E	NNP	i	IPM
,	,	i	IPM
an	DT	i	IPM
inhibitor	NN	i	IPM
of	IN	i	IPM
acyl	NN	i	IPM
coenzyme	NN	i	IPM
A	DT	O	O
:	:	O	O
cholesterol	NN	O	O
acyl	NN	O	O
transferase	NN	O	O
,	,	O	O
and	CC	O	O
serum	VB	o	OPH
cholesterol	NN	o	OPH
levels	NNS	o	OPH
in	IN	O	O
healthy	JJ	p	PC
volunteers	NNS	p	O
.	.	p	O

We	PRP	O	O
conducted	VBD	O	O
a	DT	O	O
single	JJ	O	O
and	CC	O	O
repeat	JJ	O	O
oral	JJ	O	O
dose	NN	i	IPM
study	NN	i	IPM
of	IN	i	IPM
YM17E	NNP	i	IPM
,	,	O	O
a	DT	O	O
novel	JJ	O	O
inhibitor	NN	O	O
of	IN	O	O
acyl	NN	O	O
coenzyme	NN	O	O
A	NNP	O	O
(	(	O	O
CoA	NNP	O	O
)	)	O	O
:	:	O	O
cholesterol	NN	O	O
acyltransferase	NN	O	O
,	,	O	O
in	IN	O	O
healthy	JJ	p	O
male	NN	p	PSE
volunteers	NNS	p	O
to	TO	O	O
evaluate	VB	O	O
the	DT	O	O
pharmacokinetic	JJ	o	OOt
profile	NN	o	OOt
,	,	o	OOt
tolerability	NN	o	OOt
and	CC	o	OOt
effect	NN	o	OOt
of	IN	o	OOt
the	DT	o	OOt
drug	NN	o	OOt
on	IN	o	OOt
serum	NN	o	OOt
cholesterol	NN	o	OOt
.	.	o	OOt

In	IN	O	O
the	DT	O	O
single	JJ	O	O
administration	NN	O	O
study	NN	O	O
,	,	O	O
YM17E	NNP	i	IPM
was	VBD	i	IPM
administered	VBN	i	IPM
after	IN	i	IPM
a	DT	i	IPM
meal	NN	i	IPM
to	TO	i	IPM
two	CD	i	IPM
groups	NNS	i	IPM
of	IN	i	IPM
subjects	NNS	i	IPM
(	(	i	O
each	DT	i	IPM
containing	VBG	i	IPM
six	CD	i	IPM
subjects	NNS	i	IPM
taking	VBG	i	IPM
the	DT	i	IPM
drug	NN	i	IPM
and	CC	i	O
three	CD	i	IC
taking	VBG	i	IC
placebo	NN	i	IC
)	)	i	O
receiving	VBG	i	O
3	CD	i	O
,	,	i	O
60	CD	i	O
and	CC	i	O
300	CD	i	O
mg	NN	i	O
or	CC	i	O
15	CD	i	O
,	,	i	O
60	CD	i	O
and	CC	i	O
450	CD	i	O
mg	NN	i	O
YM17E	NNP	i	O
,	,	i	O
respectively	RB	i	O
.	.	i	O

Plasma	NNP	o	OPH
concentrations	NNS	o	OPH
of	IN	O	O
unchanged	JJ	O	O
drug	NN	O	O
following	VBG	O	O
single	JJ	O	O
oral	JJ	O	O
administration	NN	O	O
at	IN	O	O
3-300	JJ	O	O
mg	NN	O	O
after	IN	O	O
a	DT	O	O
meal	NN	O	O
increased	VBN	O	O
with	IN	O	O
increasing	VBG	O	O
dose	NN	O	O
.	.	O	O

In	IN	O	O
contrast	NN	O	O
,	,	O	O
plasma	NN	o	OPH
concentrations	NNS	o	OPH
after	IN	O	O
administration	NN	O	O
of	IN	O	O
450	CD	O	O
mg	NNS	O	O
were	VBD	O	O
almost	RB	O	O
the	DT	O	O
same	JJ	O	O
as	IN	O	O
after	IN	O	O
300	CD	O	O
mg	NN	O	O
.	.	O	O

Unchanged	VBD	O	O
YM17E	NNP	i	IPM
was	VBD	O	O
not	RB	O	O
detected	VBN	O	O
in	IN	O	O
urine	NN	O	O
after	IN	O	O
single	JJ	O	O
administration	NN	O	O
,	,	O	O
suggesting	VBG	O	O
that	IN	O	O
it	PRP	O	O
was	VBD	O	O
excreted	VBN	O	O
via	IN	O	O
the	DT	O	O
bile	NN	O	O
or	CC	O	O
urine	NN	O	O
after	IN	O	O
metabolism	NN	O	O
.	.	O	O

Five	CD	O	O
active	JJ	O	O
metabolites	NNS	O	O
(	(	O	O
M1	NNP	O	O
,	,	O	O
M2-a	NNP	O	O
,	,	O	O
M2-b	NNP	O	O
,	,	O	O
M3	NNP	O	O
and	CC	O	O
M4	NNP	O	O
)	)	O	O
were	VBD	O	O
observed	VBN	O	O
in	IN	O	O
plasma	NN	O	O
at	IN	O	O
concentrations	NNS	O	O
comparable	JJ	O	O
to	TO	O	O
those	DT	O	O
of	IN	O	O
unchanged	JJ	O	O
YM17E	NNP	i	IPM
.	.	i	IPM

Their	PRP$	O	O
plasma	JJ	o	OPH
concentrations	NNS	o	OPH
increased	VBD	O	O
in	IN	O	O
a	DT	O	O
slightly	RB	O	O
greater	JJR	O	O
than	IN	O	O
dose-dependent	JJ	O	O
manner	NN	O	O
from	IN	O	O
3	CD	O	O
to	TO	O	O
300	CD	O	O
mg	NN	O	O
.	.	O	O

The	DT	O	O
effect	NN	O	O
of	IN	O	O
food	NN	O	O
was	VBD	O	O
studied	VBN	O	O
in	IN	O	O
an	DT	O	O
open	JJ	O	O
crossover	NN	O	O
design	NN	O	O
with	IN	O	O
a	DT	O	O
1-week	JJ	O	O
washout	NN	O	O
period	NN	O	O
.	.	O	O

Twelve	NNP	O	O
subjects	VBZ	O	O
received	VBD	O	O
150	CD	i	IPM
mg	NNS	i	IPM
YM17E	VBN	i	IPM
in	IN	O	O
both	DT	O	O
the	DT	O	O
fasted	VBN	O	O
and	CC	O	O
post-prandial	JJ	O	O
states	NNS	O	O
.	.	O	O

The	DT	O	O
AUC	NNP	o	OOt
and	CC	o	OOt
Cmax	NNP	o	OOt
after	IN	O	O
fasting	VBG	O	O
were	VBD	O	O
closely	RB	O	O
similar	JJ	O	O
to	TO	O	O
those	DT	O	O
after	IN	O	O
a	DT	O	O
meal	NN	O	O
,	,	O	O
showing	VBG	O	O
that	IN	O	O
bioavailability	NN	O	O
was	VBD	O	O
not	RB	O	O
affected	VBN	O	O
by	IN	O	O
food	NN	O	O
intake	NN	O	O
.	.	O	O

In	IN	O	O
the	DT	O	O
repeated	JJ	O	O
oral	JJ	O	O
dose	NN	O	O
study	NN	O	O
,	,	O	O
the	DT	O	O
subjects	NNS	O	O
received	VBD	O	O
test	JJ	i	IPM
drug	NN	i	IPM
at	IN	i	IPM
150	CD	i	IPM
mg	NN	i	IPM
or	CC	i	IPM
300	CD	i	IPM
mg	NN	i	IPM
(	(	O	O
n	JJ	O	O
=	RB	O	O
6	CD	O	O
each	DT	O	O
)	)	O	O
or	CC	O	O
placebo	NN	i	IC
(	(	i	IC
n	JJ	i	IC
=	NNP	i	IC
3	CD	i	IC
)	)	i	IC
twice	RB	i	IC
a	DT	i	IC
day	NN	i	IC
(	(	O	O
after	IN	O	O
breakfast	NN	O	O
and	CC	O	O
after	IN	O	O
dinner	NN	O	O
)	)	O	O
for	IN	O	O
7	CD	O	O
days	NNS	O	O
.	.	O	O

On	IN	O	O
days	NNS	O	O
1	CD	O	O
and	CC	O	O
7	CD	O	O
,	,	O	O
the	DT	O	O
subjects	NNS	O	O
received	VBD	O	O
YM17E	NNP	i	IPM
once	RB	i	IPM
a	DT	i	IPM
day	NN	i	IPM
(	(	O	O
after	IN	O	O
breakfast	NN	O	O
)	)	O	O
for	IN	O	O
evaluation	NN	O	O
of	IN	O	O
pharmacokinetic	JJ	O	O
properties	NNS	O	O
.	.	O	O

After	IN	O	O
repeated	VBN	O	O
oral	JJ	O	O
administration	NN	O	O
of	IN	O	O
150	CD	O	O
mg	NN	O	O
b.d.	NN	O	O
,	,	O	O
plasma	JJ	o	OPH
concentrations	NNS	o	OPH
reached	VBD	O	O
steady	JJ	O	O
state	NN	O	O
by	IN	O	O
day	NN	O	O
5	CD	O	O
(	(	O	O
mean	JJ	O	O
Cmin	NNP	O	O
48.6	CD	O	O
ng.ml-1	NN	O	O
)	)	O	O
.	.	O	O

After	IN	O	O
repeated	JJ	O	O
administration	NN	O	O
of	IN	O	O
300	CD	O	O
mg	NN	O	O
b.d.	NN	O	O
,	,	O	O
plasma	JJ	o	OPH
concentrations	NNS	o	OPH
prior	RB	O	O
to	TO	O	O
each	DT	O	O
daily	JJ	O	O
morning	NN	O	O
dose	NN	O	O
increased	VBD	O	O
up	RB	O	O
to	TO	O	O
the	DT	O	O
5th	JJ	O	O
day	NN	O	O
(	(	O	O
mean	JJ	O	O
Cmin	NNP	O	O
166.6	CD	O	O
ng.ml-1	NN	O	O
)	)	O	O
and	CC	O	O
then	RB	O	O
tended	VBD	O	O
to	TO	O	O
decrease	VB	O	O
until	IN	O	O
the	DT	O	O
7th	JJ	O	O
day	NN	O	O
.	.	O	O

No	DT	O	O
significant	JJ	o	OPH
signs	NNS	o	OPH
,	,	o	OPH
symptoms	NNS	o	OPH
or	CC	o	OPH
changes	NNS	o	OPH
in	IN	o	OPH
serum	NN	o	OPH
cholesterol	NN	o	OPH
levels	NNS	o	OPH
were	VBD	O	O
observed	VBN	O	O
during	IN	O	O
the	DT	O	O
single	JJ	O	O
and	CC	O	O
repeated	JJ	O	O
oral	JJ	O	O
dose	NN	O	O
studies	NNS	O	O
at	IN	O	O
150	CD	O	O
mg	NN	O	O
b.d	NN	O	O
.	.	O	O

Although	IN	O	O
statistical	JJ	O	O
analysis	NN	O	O
was	VBD	O	O
not	RB	O	O
conducted	VBN	O	O
because	IN	O	O
of	IN	O	O
the	DT	O	O
small	JJ	p	O
number	NN	p	O
of	IN	p	O
subjects	NNS	p	O
,	,	O	O
all	DT	O	O
subjects	NNS	O	O
receiving	VBG	O	O
repeated	VBD	O	O
oral	JJ	O	O
administration	NN	O	O
of	IN	O	O
300	CD	O	O
mg	JJ	O	O
twice	RB	O	O
daily	RB	O	O
showed	VBD	O	O
a	DT	O	O
25	CD	O	O
%	NN	O	O
decrease	NN	O	O
in	IN	O	O
serum	NN	o	OPH
cholesterol	NN	o	OPH
level	NN	O	O
on	IN	O	O
day	NN	O	O
7	CD	O	O
,	,	O	O
but	CC	O	O
also	RB	O	O
the	DT	O	O
simultaneous	JJ	O	O
occurrence	NN	O	O
of	IN	O	O
diarrhoea	NN	o	OA
.	.	o	O

Effect	NN	O	O
of	IN	O	O
micronutrient	NN	i	IPM
supplement	NN	i	IPM
on	IN	O	O
health	NN	o	OPH
and	CC	o	OPH
nutritional	JJ	o	OPH
status	NN	o	OPH
of	IN	O	O
schoolchildren	NNS	p	O
:	:	p	O
study	NN	O	O
design	NN	O	O
.	.	O	O

OBJECTIVE	IN	O	O
We	PRP	O	O
tested	VBD	O	O
the	DT	O	O
hypothesis	NN	O	O
that	WDT	O	O
supplementation	NN	i	O
with	IN	i	O
a	DT	i	O
micronutrient-fortified	JJ	i	IPM
beverage	NN	i	IPM
improves	VBZ	O	O
micronutrient	JJ	O	O
status	NN	O	O
and	CC	O	O
physical	JJ	O	O
and	CC	O	O
mental	JJ	O	O
development	NN	O	O
in	IN	O	O
apparently	RB	O	O
healthy	JJ	O	O
schoolchildren	NNS	O	O
.	.	O	O

METHODS	NNP	O	O
The	DT	O	O
study	NN	O	O
was	VBD	O	O
carried	VBN	O	O
out	RP	O	O
in	IN	O	O
middle-income	JJ	p	O
students	NNS	p	O
in	IN	O	O
two	CD	O	O
residential	JJ	O	O
schools	NNS	O	O
that	WDT	O	O
catered	VBD	O	O
to	TO	O	O
children	NNS	p	O
from	IN	p	O
a	DT	p	O
semi-urban	JJ	p	O
population	NN	p	O
near	IN	p	O
Hyderabad	NNP	p	O
,	,	p	O
India	NNP	p	O
.	.	p	O

Included	NNP	p	O
were	VBD	p	O
869	CD	p	O
children	NNS	p	O
who	WP	p	O
were	VBD	p	O
6	CD	p	O
to	TO	p	O
16	CD	p	O
y	NN	p	O
of	IN	p	O
age	NN	p	O
in	IN	p	O
grades	NNS	p	O
1	CD	p	O
to	TO	p	O
10	CD	p	O
.	.	p	O

Because	IN	O	O
children	NNS	O	O
at	IN	O	O
each	DT	O	O
grade	NN	O	O
were	VBD	O	O
distributed	VBN	O	O
across	IN	O	O
two	CD	O	O
classrooms	NNS	O	O
(	(	O	O
clusters	NNS	O	O
)	)	O	O
and	CC	O	O
were	VBD	O	O
homogeneous	JJ	O	O
,	,	O	O
each	DT	O	O
grade	NN	O	O
was	VBD	O	O
considered	VBN	O	O
to	TO	O	O
consist	VB	O	O
of	IN	O	O
a	DT	O	O
matched	JJ	O	O
pair	NN	O	O
.	.	O	O

There	EX	O	O
were	VBD	O	O
thus	RB	O	O
10	CD	O	O
pairs	NNS	O	O
available	JJ	O	O
for	IN	O	O
the	DT	O	O
study	NN	O	O
.	.	O	O

Classes	NNS	O	O
in	IN	O	O
each	DT	O	O
grade	NN	O	O
were	VBD	O	O
randomized	VBN	O	O
to	TO	O	O
receive	VB	O	O
a	DT	O	O
micronutrient-enriched	JJ	i	IPM
beverage	NN	i	IPM
or	CC	i	O
a	DT	i	O
placebo	NN	i	IC
without	IN	i	IC
added	JJ	i	IC
micronutrients	NNS	i	IC
.	.	i	O

The	DT	O	O
study	NN	O	O
was	VBD	O	O
double	RB	O	O
blinded	VBN	O	O
and	CC	O	O
the	DT	O	O
duration	NN	O	O
was	VBD	O	O
14	CD	O	O
mo	NN	O	O
,	,	O	O
with	IN	O	O
supervised	JJ	O	O
feeding	NN	O	O
of	IN	O	O
the	DT	O	O
micronutrient-enriched	JJ	i	IPM
beverage	NN	i	IPM
.	.	i	O

The	DT	O	O
effect	NN	O	O
of	IN	O	O
the	DT	O	O
micronutrients	NNS	i	IPM
on	IN	O	O
the	DT	O	O
outcome	NN	o	OPH
variables	NNS	o	OPH
growth	NN	o	OPH
,	,	o	OPH
biochemical	JJ	o	OPH
status	NN	o	OPH
,	,	o	O
mental	JJ	o	OME
function	NN	o	OME
,	,	o	O
and	CC	o	O
bone	NN	o	OPH
health	NN	o	OPH
were	VBD	O	O
assessed	VBN	O	O
.	.	O	O

RESULTS	VB	O	O
The	DT	O	O
number	NN	O	O
of	IN	O	O
matched	JJ	O	O
pairs	NNS	O	O
varied	VBD	O	O
between	IN	O	O
seven	CD	O	O
and	CC	O	O
eight	CD	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
required	JJ	O	O
number	NN	p	O
of	IN	p	O
children	NNS	p	O
per	IN	p	O
treatment	NN	p	O
group	NN	p	O
ranged	VBD	p	O
from	IN	p	O
32	CD	p	O
in	IN	p	O
the	DT	p	O
case	NN	p	O
of	IN	p	O
bone	NN	p	O
heath	NN	p	O
to	TO	p	O
177	CD	p	O
for	IN	p	O
body	NN	p	O
weight	NN	p	O
.	.	p	O

The	DT	O	O
power	NN	O	O
of	IN	O	O
the	DT	O	O
outcome	NN	O	O
variables	NNS	O	O
ranged	VBD	O	O
from	IN	O	O
74	CD	O	O
%	NN	O	O
to	TO	O	O
100	CD	O	O
%	NN	O	O
and	CC	O	O
was	VBD	O	O
adequate	NN	O	O
for	IN	O	O
successful	JJ	O	O
pairing	NN	O	O
.	.	O	O

The	DT	O	O
effect	NN	O	O
assessed	VBD	O	O
at	IN	O	O
the	DT	O	O
end	NN	O	O
of	IN	O	O
supplementation	NN	i	IPM
showed	VBD	O	O
that	IN	O	O
the	DT	O	O
intervention	NN	O	O
was	VBD	O	O
beneficial	JJ	o	OOt
.	.	o	O

CONCLUSIONS	NNP	O	O
Designing	VBG	O	O
an	DT	O	O
intervention	NN	O	O
,	,	O	O
choosing	VBG	O	O
outcome	NN	O	O
variables	NNS	O	O
,	,	O	O
and	CC	O	O
implementing	VBG	O	O
the	DT	O	O
protocol	NN	O	O
in	IN	O	O
a	DT	O	O
typical	JJ	O	O
Indian	JJ	O	O
school	NN	O	O
setting	VBG	O	O
were	VBD	O	O
achieved	VBN	O	O
.	.	O	O

Laparoscopically	RB	i	IPH
assisted	VBN	i	IPH
vaginal	JJ	i	IPH
hysterectomy	NN	i	IPH
versus	IN	O	O
abdominal	JJ	i	IPH
hysterectomy	NN	i	IPH
in	IN	O	O
stage	NN	p	PC
I	PRP	p	PC
endometrial	JJ	p	PC
cancer	NN	p	PC
.	.	p	O

The	DT	O	O
purpose	NN	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
evaluate	VB	O	O
and	CC	O	O
compare	VB	O	O
laparoscopic	JJ	i	IPH
treatment	NN	i	IPH
for	IN	O	O
stage	NN	p	PC
I	PRP	p	PC
endometrial	JJ	p	PC
cancer	NN	p	PC
with	IN	O	O
the	DT	O	O
traditional	JJ	i	IPH
transabdominal	JJ	i	IPH
approach	NN	i	IPH
.	.	O	O

From	IN	O	O
July	NNP	O	O
1996	CD	O	O
to	TO	O	O
July	NNP	O	O
1998	CD	O	O
,	,	O	O
61	CD	p	PSS
patients	NNS	p	O
with	IN	p	O
clinical	JJ	p	O
stage	NN	p	PC
I	PRP	p	PC
endometrial	JJ	p	PC
cancer	NN	p	PC
were	VBD	O	O
treated	VBN	O	O
at	IN	O	O
the	DT	O	O
Gynaecology	NNP	p	O
Oncology	NNP	p	O
Unit	NNP	p	O
at	IN	p	O
the	DT	p	O
Royal	NNP	p	O
North	NNP	p	O
Shore	NNP	p	O
of	IN	p	O
Sydney	NNP	p	O
,	,	p	O
Australia	NNP	p	O
.	.	p	O

Twenty-nine	JJ	p	PSS
patients	NNS	p	O
were	VBD	p	O
treated	VBN	p	O
with	IN	p	O
laparoscopic	NN	i	IS
assisted	VBN	i	IS
vaginal	JJ	i	IS
hysterectomy	NN	i	IS
(	(	i	IS
LAVH	NNP	i	IS
)	)	i	IS
and	CC	i	IS
bilateral	JJ	i	IS
salpingo-oophrectomy	NN	i	IS
(	(	i	IS
BSO	NNP	i	IS
)	)	i	IS
plus	CC	i	IS
minus	CC	i	IS
laparoscopic	JJ	i	IS
pelvic	JJ	i	IS
lymphadenectomy	NN	i	IS
(	(	i	IS
LPLA	NNP	i	IS
)	)	i	IS
,	,	p	O
while	IN	p	O
32	CD	p	PSS
patients	NNS	p	O
were	VBD	p	O
treated	VBN	p	O
with	IN	p	O
the	DT	p	O
traditional	JJ	p	O
laparotomy	NN	i	IPH
and	CC	p	O
underwent	JJ	p	O
total	JJ	i	IPH
abdominal	JJ	i	IPH
hysterectomy	NN	i	IPH
(	(	i	IPH
TAH	NNP	i	IPH
)	)	i	IPH
and	CC	p	O
BSO	NNP	p	O
plus	CC	p	O
minus	CC	p	O
pelvic	JJ	i	IPH
lymphadenectomy	NN	i	IPH
(	(	p	O
PLA	NNP	p	O
)	)	p	O
.	.	p	O

The	DT	O	O
main	JJ	O	O
outcomes	NNS	O	O
studied	VBN	O	O
were	VBD	O	O
operative	JJ	o	OOt
time	NN	o	OOt
,	,	o	O
blood	NN	o	OPH
loss	NN	o	OPH
,	,	o	O
blood	NN	o	OOt
transfusion	NN	o	OOt
,	,	o	O
intraoperative	JJ	o	OA
complications	NNS	o	OA
,	,	o	O
postoperative	JJ	o	OA
complications	NNS	o	OA
,	,	o	O
duration	NN	o	OOt
of	IN	o	OOt
hospital	NN	o	OOt
stay	NN	o	OOt
,	,	o	O
and	CC	o	O
number	NN	o	OOt
of	IN	o	OOt
lymph	JJ	o	OOt
nodes	NNS	o	OOt
obtained	VBN	O	O
.	.	O	O

In	IN	O	O
conclusion	NN	O	O
,	,	O	O
laparoscopic	JJ	i	IPH
treatment	NN	i	IPH
of	IN	O	O
endometrial	JJ	O	O
cancer	NN	O	O
is	VBZ	O	O
safe	JJ	o	O
in	IN	O	O
the	DT	O	O
hands	NNS	O	O
of	IN	O	O
experienced	JJ	O	O
operators	NNS	O	O
with	IN	O	O
minimal	JJ	O	O
intraoperative	JJ	O	O
and	CC	O	O
postoperative	JJ	O	O
complications	NNS	O	O
.	.	O	O

This	DT	O	O
procedure	NN	O	O
is	VBZ	O	O
associated	VBN	O	O
with	IN	O	O
significantly	RB	O	O
less	JJR	O	O
blood	JJ	o	OA
loss	NN	o	OA
and	CC	O	O
shorter	JJR	O	O
hospitalization	NN	o	OOt
;	:	o	O
however	RB	O	O
,	,	O	O
it	PRP	O	O
is	VBZ	O	O
associated	VBN	O	O
with	IN	O	O
significantly	RB	O	O
longer	RBR	O	O
operating	VBG	o	OOt
time	NN	o	OOt
.	.	o	O

Proper	NNP	O	O
selection	NN	O	O
of	IN	O	O
patients	NNS	O	O
for	IN	O	O
the	DT	O	O
laparoscopic	JJ	i	IPH
procedure	NN	i	IPH
is	VBZ	O	O
the	DT	O	O
vital	JJ	O	O
step	NN	O	O
in	IN	O	O
achieving	VBG	O	O
the	DT	O	O
major	JJ	O	O
goals	NNS	O	O
of	IN	O	O
this	DT	O	O
approach	NN	O	O
.	.	O	O

Therapy	NNP	o	OOt
effect	NN	o	OOt
of	IN	O	O
either	CC	O	O
paclitaxel	NN	i	IC
or	CC	i	O
cyclophosphamide	JJ	i	IC
combination	NN	i	IC
treatment	NN	i	O
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
epithelial	JJ	p	PC
ovarian	JJ	p	PC
cancer	NN	p	PC
and	CC	p	O
relation	NN	p	O
to	TO	p	O
TP53	NNP	p	O
gene	NN	p	O
status	NN	p	O
.	.	p	O

Cell	NNP	O	O
death	NN	O	O
after	IN	O	O
treatment	NN	O	O
with	IN	O	O
chemotherapy	NN	i	IPM
is	VBZ	O	O
exerted	VBN	O	O
by	IN	O	O
activation	NN	O	O
of	IN	O	O
apoptosis	NN	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
p53	NN	O	O
protein	NN	O	O
has	VBZ	O	O
been	VBN	O	O
shown	VBN	O	O
to	TO	O	O
actively	RB	O	O
participate	VB	O	O
in	IN	O	O
this	DT	O	O
process	NN	O	O
.	.	O	O

This	DT	O	O
recent	JJ	O	O
focus	NN	O	O
on	IN	O	O
TP53	NNP	o	OPH
status	NN	o	OPH
as	IN	O	O
a	DT	O	O
possible	JJ	O	O
determinant	NN	O	O
of	IN	O	O
cancer	NN	O	O
therapy	NN	O	O
response	NN	O	O
has	VBZ	O	O
raised	VBN	O	O
the	DT	O	O
question	NN	O	O
of	IN	O	O
whether	IN	O	O
or	CC	O	O
not	RB	O	O
mutations	NNS	O	O
in	IN	O	O
the	DT	O	O
TP53	NNP	O	O
gene	NN	O	O
have	VBP	O	O
an	DT	O	O
influence	NN	O	O
on	IN	O	O
paclitaxel	NN	i	IPM
therapy	NN	i	O
.	.	i	O

The	DT	O	O
TP53	NNP	o	OPH
status	NN	o	OPH
has	VBZ	O	O
been	VBN	O	O
analysed	VBN	O	O
at	IN	O	O
the	DT	O	O
DNA	NNP	O	O
level	NN	O	O
in	IN	O	O
tumours	NNS	O	O
from	IN	O	O
45	CD	p	PSS
ovarian	JJ	p	PC
cancer	NN	p	PC
patients	NNS	p	O
randomized	VBN	p	O
to	TO	p	O
treatment	NN	p	O
with	IN	O	O
paclitaxel	NN	i	IPM
and	CC	i	O
cisplatin	NN	i	O
or	CC	i	O
cyclophosphamide	NN	i	IPM
and	CC	i	O
cisplatin	NN	i	IPM
.	.	i	O

Therapy	NNP	o	OOt
response	NN	o	OOt
was	VBD	O	O
obtained	VBN	O	O
for	IN	O	O
38	CD	p	PSS
patients	NNS	p	O
with	IN	p	O
clinically	RB	p	O
evaluable	JJ	p	O
disease	NN	p	O
after	IN	p	O
initial	JJ	p	O
surgery	NN	p	O
.	.	p	O

The	DT	O	O
positive	JJ	o	OPH
response	NN	o	OPH
rate	NN	o	OPH
to	TO	O	O
the	DT	O	O
paclitaxel/cisplatin	NN	i	IPM
therapy	NN	i	O
was	VBD	O	O
85	CD	O	O
%	NN	O	O
vs	JJ	O	O
61	CD	O	O
%	NN	O	O
for	IN	O	O
the	DT	O	O
patients	NNS	O	O
who	WP	O	O
received	VBD	O	O
the	DT	O	O
cyclophosphamide/cisplatin	JJ	i	IPM
regimen	NNS	O	O
.	.	O	O

A	DT	O	O
significant	JJ	O	O
difference	NN	O	O
in	IN	O	O
relapse-free	JJ	o	OMO
survival	NN	o	OMO
in	IN	O	O
favour	NN	O	O
of	IN	O	O
paclitaxel/cisplatin	NN	i	IPM
chemotherapy	NN	i	IPM
was	VBD	O	O
found	VBN	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.001	CD	O	O
)	)	O	O
.	.	O	O

A	DT	O	O
total	NN	O	O
of	IN	O	O
33	CD	O	O
tumour	NN	O	O
samples	NNS	O	O
(	(	O	O
73	CD	O	O
%	NN	O	O
)	)	O	O
had	VBD	O	O
detectable	JJ	O	O
sequence	NN	o	OPH
alterations	NNS	o	OPH
in	IN	o	OPH
the	DT	o	OPH
TP53	NNP	o	OPH
gene	NN	o	OPH
.	.	o	OPH

When	WRB	O	O
relapse-free	JJ	o	OMO
survival	NN	o	OMO
was	VBD	O	O
estimated	VBN	O	O
for	IN	O	O
all	DT	O	O
patients	NNS	O	O
with	IN	O	O
TP53	NNP	o	OPH
alterations	NNS	o	OPH
in	IN	O	O
their	PRP$	O	O
tumours	NNS	O	O
,	,	O	O
a	DT	O	O
significant	JJ	O	O
better	RBR	O	O
outcome	NN	O	O
for	IN	O	O
the	DT	O	O
paclitaxel/cisplatin	NN	i	IPM
group	NN	O	O
was	VBD	O	O
found	VBN	O	O
compared	VBN	O	O
with	IN	O	O
the	DT	O	O
patient	NN	O	O
group	NN	O	O
receiving	VBG	O	O
cyclophosphamide	NN	i	IPM
and	CC	O	O
cisplatin	NN	i	IPM
therapy	NN	i	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.002	CD	O	O
)	)	O	O
.	.	O	O

We	PRP	O	O
did	VBD	O	O
not	RB	O	O
observe	VB	O	O
an	DT	O	O
association	NN	O	O
between	IN	O	O
TP53	NNP	o	OPH
tumour	NN	o	OPH
status	NN	o	OPH
and	CC	O	O
prognosis	NN	o	O
for	IN	O	O
patients	NNS	O	O
who	WP	O	O
received	VBD	O	O
paclitaxel/cisplatin	JJ	i	IPM
combination	NN	O	O
treatment	NN	O	O
,	,	O	O
indicating	VBG	O	O
that	IN	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
this	DT	O	O
therapy	NN	O	O
is	VBZ	O	O
not	RB	O	O
influenced	VBN	O	O
by	IN	O	O
this	DT	O	O
parameter	NN	O	O
.	.	O	O

Prognostic	JJ	O	O
value	NN	O	O
of	IN	O	O
postoperative	JJ	i	IS
CEA	NNP	i	IS
clearance	NN	i	IS
in	IN	O	O
rectal	JJ	o	O
cancer	NN	o	O
patients	NNS	p	PC
with	IN	p	PC
high	JJ	p	PC
preoperative	JJ	p	PC
CEA	NNP	p	PC
levels	NNS	p	PC
.	.	p	O

PURPOSE	NNP	O	O
We	PRP	O	O
determined	VBD	O	O
the	DT	O	O
prognostic	JJ	O	O
value	NN	O	O
of	IN	O	O
carcinoembryonic	JJ	O	O
antigen	NN	O	O
(	(	O	O
CEA	NNP	O	O
)	)	O	O
clearance	NN	O	O
after	IN	O	O
tumor	NN	i	IS
resection	NN	i	IS
with	IN	O	O
serial	JJ	O	O
evaluation	NN	O	O
of	IN	O	O
postoperative	JJ	O	O
CEA	NNP	O	O
levels	NNS	O	O
in	IN	O	O
rectal	JJ	p	O
cancer	NN	p	O
.	.	p	O

METHODS	NNP	O	O
Between	NNP	p	O
1994	CD	p	O
and	CC	p	O
2004	CD	p	O
,	,	p	O
we	PRP	p	O
retrospectively	RB	p	O
reviewed	VBD	p	O
122	CD	p	PSS
patients	NNS	p	O
with	IN	p	O
rectal	JJ	p	O
cancer	NN	p	O
whose	WP$	p	O
serum	JJ	o	OPH
CEA	NNP	o	OPH
levels	NNS	o	OPH
were	VBD	p	O
measured	VBN	p	O
on	IN	p	O
the	DT	p	O
preoperative	JJ	p	O
day	NN	p	O
and	CC	p	O
postoperative	JJ	p	O
days	NNS	p	O
7	CD	p	O
and	CC	p	O
30	CD	p	O
.	.	p	O

Patients	NNS	p	O
with	IN	p	O
preoperative	JJ	p	O
CEA	NNP	p	O
levels	NNS	p	O
<	VBP	p	O
5.0	CD	p	O
ng/ml	NNS	p	O
were	VBD	p	O
excluded	VBN	p	O
.	.	p	O

An	DT	O	O
exponential	JJ	O	O
trend	NN	O	O
line	NN	O	O
was	VBD	O	O
drawn	VBN	O	O
using	VBG	O	O
the	DT	O	O
three	CD	O	O
CEA	NNP	O	O
values	NNS	O	O
.	.	O	O

Patients	NNS	p	O
were	VBD	p	O
categorized	VBN	p	O
into	IN	p	O
three	CD	p	O
groups	NNS	p	O
based	VBN	p	O
on	IN	p	O
R	NNP	p	O
(	(	p	O
2	CD	p	O
)	)	p	O
values	NNS	p	O
calculated	VBN	O	O
through	IN	O	O
trend	NN	O	O
line	NN	O	O
,	,	O	O
which	WDT	O	O
indicates	VBZ	O	O
the	DT	O	O
correlation	NN	O	O
coefficient	NN	O	O
between	IN	O	O
exponential	JJ	O	O
graph	NN	O	O
and	CC	O	O
measured	VBD	O	O
CEA	NNP	o	OPH
values	NNS	o	OPH
:	:	o	O
exponential	JJ	p	O
decrease	NN	p	O
group	NN	p	O
(	(	O	O
group	NN	O	O
1	CD	O	O
:	:	O	O
0.9	CD	O	O
<	NN	O	O
R	NNP	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
<	NN	O	O
or	CC	O	O
=	VB	O	O
1.0	CD	O	O
)	)	O	O
,	,	O	O
nearly	RB	p	O
exponential	JJ	p	O
decrease	NN	p	O
group	NN	p	O
(	(	O	O
group	NN	O	O
2	CD	O	O
:	:	O	O
0.5	CD	O	O
<	NN	O	O
R	NNP	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
<	NN	O	O
or	CC	O	O
=	VB	O	O
0.9	CD	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
randomized	JJ	p	O
clearance	NN	p	O
group	NN	p	O
(	(	O	O
group	NN	O	O
3	CD	O	O
:	:	O	O
0.5	CD	O	O
<	NN	O	O
or	CC	O	O
=	VB	O	O
R	NNP	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
)	)	O	O
.	.	O	O

We	PRP	O	O
then	RB	O	O
analyzed	VBD	O	O
the	DT	O	O
CEA	NNP	O	O
clearance	NN	O	O
pattern	NN	O	O
as	IN	O	O
a	DT	O	O
prognostic	JJ	O	O
indicator	NN	O	O
.	.	O	O

RESULTS	NNP	O	O
With	IN	O	O
a	DT	O	O
median	JJ	O	O
follow-up	NN	O	O
of	IN	O	O
57	CD	O	O
months	NNS	O	O
,	,	O	O
the	DT	O	O
5-year	JJ	o	OMO
overall	JJ	o	OMO
survival	NN	o	OMO
was	VBD	O	O
62.3	CD	O	O
%	NN	O	O
vs.	FW	O	O
48.1	CD	O	O
%	NN	O	O
vs.	FW	O	O
25	CD	O	O
%	NN	O	O
and	CC	O	O
the	DT	O	O
5-year	JJ	o	OMO
disease-free	JJ	o	OMO
survival	NN	o	OMO
was	VBD	O	O
58.6	CD	O	O
%	NN	O	O
vs.	FW	O	O
52.7	CD	O	O
%	NN	O	O
vs.	FW	O	O
25	CD	O	O
%	NN	O	O
among	IN	O	O
groups	NNS	O	O
1	CD	O	O
,	,	O	O
2	CD	O	O
,	,	O	O
and	CC	O	O
3	CD	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.014	CD	O	O
,	,	O	O
P	NNP	O	O
=	NNP	O	O
0.027	CD	O	O
,	,	O	O
respectively	RB	O	O
)	)	O	O
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
stage	NN	p	PC
III	NNP	p	PC
rectal	JJ	p	PC
cancer	NN	p	PC
.	.	p	O

For	IN	O	O
those	DT	O	O
with	IN	O	O
stage	NN	O	O
II	NNP	O	O
rectal	NN	O	O
cancer	NN	O	O
,	,	O	O
the	DT	O	O
5-year	JJ	o	OMO
overall	JJ	o	OMO
survival	NN	o	OMO
rate	NN	o	OMO
of	IN	O	O
group	NN	O	O
1	CD	O	O
was	VBD	O	O
significantly	RB	O	O
better	JJR	O	O
than	IN	O	O
groups	NNS	O	O
2	CD	O	O
and	CC	O	O
3	CD	O	O
(	(	O	O
88.8	CD	O	O
%	NN	O	O
vs.	FW	O	O
74.1	CD	O	O
%	NN	O	O
,	,	O	O
respectively	RB	O	O
,	,	O	O
P	NNP	O	O
=	NNP	O	O
0.021	CD	O	O
)	)	O	O
.	.	O	O

CONCLUSIONS	VB	O	O
The	DT	O	O
postoperative	JJ	i	IS
pattern	NN	i	IS
of	IN	i	IS
CEA	NNP	i	IS
clearance	NN	i	IS
is	VBZ	O	O
a	DT	O	O
useful	JJ	O	O
prognostic	JJ	O	O
determinant	NN	O	O
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
rectal	JJ	p	O
cancer	NN	p	O
.	.	p	O

Patients	NNS	p	O
with	IN	p	O
a	DT	p	O
randomized	JJ	p	O
pattern	NN	p	O
of	IN	o	O
CEA	NNP	o	OPH
clearance	NN	o	OPH
after	IN	O	O
tumor	NN	O	O
resection	NN	O	O
should	MD	O	O
be	VB	O	O
regarded	VBN	O	O
as	IN	O	O
having	VBG	O	O
the	DT	O	O
possibility	NN	O	O
of	IN	O	O
a	DT	O	O
persistent	JJ	O	O
CEA	NNP	O	O
source	NN	O	O
and	CC	O	O
may	MD	O	O
require	VB	O	O
consideration	NN	O	O
of	IN	O	O
intensive	JJ	O	O
follow-up	NN	O	O
or	CC	O	O
adjuvant	JJ	O	O
therapy	NN	O	O
.	.	O	O

Efficacy	NN	o	OOt
of	IN	O	O
patient	JJ	i	IE
education	NN	i	IE
and	CC	i	O
supervised	VBD	i	IPH
exercise	NN	i	IPH
vs	NN	O	O
patient	JJ	i	IE
education	NN	i	IE
alone	RB	i	IE
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
hip	JJ	p	PC
osteoarthritis	NN	p	PC
:	:	p	O
a	DT	O	O
single	JJ	O	O
blind	NN	O	O
randomized	VBD	O	O
clinical	JJ	O	O
trial	NN	O	O
.	.	O	O

OBJECTIVE	UH	O	O
To	TO	O	O
compare	VB	O	O
the	DT	O	O
efficacy	NN	O	O
of	IN	O	O
patient	JJ	i	IE
education	NN	i	IE
and	CC	i	O
supervised	VBD	i	IOt
exercise	NN	i	IOt
with	IN	O	O
that	DT	O	O
of	IN	O	O
patient	JJ	i	IE
education	NN	i	IE
alone	RB	i	IE
for	IN	O	O
the	DT	O	O
management	NN	o	OPA
of	IN	o	OPA
pain	NN	o	OPA
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
hip	NN	p	O
osteoarthritis	NN	p	O
(	(	p	O
OA	NNP	p	PC
)	)	p	O
.	.	p	O

DESIGN	NNP	O	O
Single	NNP	O	O
blind	IN	O	O
randomized	JJ	O	O
clinical	JJ	O	O
trial	NN	O	O
.	.	O	O

SETTING	NNP	O	O
Recruitment	NNP	O	O
of	IN	O	O
patients	NNS	p	O
from	IN	p	O
hospitals	NNS	p	O
,	,	p	O
primary	JJ	p	O
health	NN	p	O
care	NN	p	O
and	CC	p	O
advertisement	NN	p	O
,	,	p	O
Oslo	NNP	p	O
,	,	p	O
Norway	NNP	p	O
.	.	p	O

PARTICIPANTS	NNP	O	O
109	CD	p	PSS
patients	NNS	p	O
with	IN	p	O
radiographic	JJ	p	O
and	CC	p	O
symptomatic	JJ	p	O
hip	NN	p	O
OA	NNP	p	O
with	IN	p	O
mild	NN	p	O
to	TO	p	O
moderate	VB	p	O
symptoms	NNS	p	O
.	.	p	O

INTERVENTIONS	NNP	O	O
Patient	NNP	i	IE
education	NN	i	IE
(	(	i	IE
PE	NNP	i	IE
)	)	i	IE
.	.	i	O

Patient	JJ	i	IE
education	NN	i	IE
and	CC	i	O
supervised	VBN	i	IPH
exercise	NN	i	IPH
(	(	i	O
PE+SE	NNP	i	O
)	)	i	O
.	.	i	O

PRIMARY	NNP	O	O
OUTCOME	NNP	O	O
MEASURE	NNP	O	O
The	DT	O	O
pain	NN	o	OPA
subscale	NN	o	OPA
of	IN	o	OPA
the	DT	o	OPA
Western	NNP	o	OPA
Ontario	NNP	o	OPA
and	CC	o	O
McMaster	NNP	o	OPA
Universities	NNP	o	OPA
Osteoarthritis	NNP	o	OPA
Index	NNP	o	OPA
(	(	o	OPA
WOMAC	NNP	o	OPA
pain	NN	o	OPA
)	)	o	OPA
.	.	o	O

RESULTS	NNP	O	O
No	NNP	O	O
significant	JJ	O	O
between	IN	O	O
group	NN	O	O
differences	NNS	O	O
were	VBD	O	O
found	VBN	O	O
for	IN	O	O
WOMAC	NNP	o	OPA
pain	NN	o	OPA
over	IN	O	O
the	DT	O	O
16-month	JJ	O	O
follow-up	NN	O	O
.	.	O	O

Significant	JJ	O	O
improvements	NNS	O	O
were	VBD	O	O
found	VBN	O	O
for	IN	O	O
the	DT	O	O
secondary	JJ	O	O
outcome	NN	O	O
WOMAC	NNP	o	OPH
physical	JJ	o	OPH
function	NN	o	OPH
(	(	O	O
P=0.011	NNP	O	O
)	)	O	O
in	IN	O	O
the	DT	O	O
group	NN	O	O
receiving	VBG	O	O
PE+SE	NNP	i	IPH
compared	VBN	O	O
to	TO	O	O
the	DT	O	O
group	NN	O	O
receiving	VBG	O	O
PE	NNP	i	IE
only	RB	O	O
.	.	O	O

No	DT	O	O
significant	JJ	O	O
differences	NNS	O	O
were	VBD	O	O
found	VBN	O	O
for	IN	O	O
WOMAC	NNP	o	OPH
stiffness	NN	o	OPH
,	,	O	O
the	DT	O	O
SF-36	JJ	O	O
subscales	NNS	O	O
or	CC	O	O
the	DT	O	O
activity	NN	O	O
scale	NN	O	O
.	.	O	O

The	DT	O	O
effect	NN	O	O
sizes	VBZ	O	O
(	(	O	O
95	CD	O	O
%	NN	O	O
confidence	NN	O	O
interval	NN	O	O
)	)	O	O
for	IN	O	O
WOMAC	NNP	o	OPA
pain	NN	o	OPA
were	VBD	O	O
-0.26	NNP	O	O
(	(	O	O
0.11	CD	O	O
,	,	O	O
-0.64	NN	O	O
)	)	O	O
,	,	O	O
-0.35	NNP	O	O
(	(	O	O
0.07	CD	O	O
,	,	O	O
-0.77	NN	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
-0.30	NNP	O	O
(	(	O	O
0.15	CD	O	O
,	,	O	O
-0.75	NN	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
for	IN	O	O
WOMAC	NNP	o	OPH
physical	JJ	o	OPH
function	NN	o	OPH
-0.29	NNP	O	O
(	(	O	O
0.09	CD	O	O
,	,	O	O
-0.67	NN	O	O
)	)	O	O
,	,	O	O
-0.48	NNP	O	O
(	(	O	O
-0.06	NNP	O	O
,	,	O	O
-0.91	NNP	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
-0.47	NNP	O	O
(	(	O	O
-0.02	NNP	O	O
,	,	O	O
-0.93	NNP	O	O
)	)	O	O
at	IN	O	O
4	CD	O	O
,	,	O	O
10	CD	O	O
and	CC	O	O
16	CD	O	O
months	NNS	O	O
,	,	O	O
respectively	RB	O	O
,	,	O	O
in	IN	O	O
favor	NN	O	O
of	IN	O	O
the	DT	O	O
group	NN	O	O
receiving	VBG	O	O
both	DT	O	O
PE	NNP	i	IE
and	CC	i	O
SE	NNP	i	IPH
.	.	i	O

All	DT	O	O
patients	NNS	O	O
attended	VBD	O	O
the	DT	O	O
three-session	JJ	O	O
PE	NNP	i	IE
program	NN	i	IE
,	,	O	O
and	CC	O	O
75	CD	O	O
%	NN	O	O
performed	VBN	O	O
?16	JJ	O	O
sessions	NNS	O	O
of	IN	O	O
the	DT	O	O
12-week	JJ	i	O
SE	NNP	i	O
program	NN	i	O
.	.	O	O

CONCLUSION	NNP	O	O
The	DT	O	O
study	NN	O	O
could	MD	O	O
not	RB	O	O
demonstrate	VB	O	O
a	DT	O	O
significant	JJ	O	O
difference	NN	O	O
in	IN	O	O
pain	NN	o	O
reduction	NN	o	O
over	IN	o	O
time	NN	O	O
between	IN	i	O
PE+SE	NNP	i	O
vs	NNP	i	O
PE	NNP	i	O
alone	RB	i	O
.	.	i	O

Adding	VBG	i	O
SE	NNP	i	O
to	TO	i	O
PE	NNP	i	O
may	MD	i	O
improve	VB	o	O
physical	JJ	o	O
function	NN	o	O
,	,	o	O
but	CC	O	O
the	DT	O	O
magnitude	NN	O	O
of	IN	O	O
possible	JJ	O	O
benefit	NN	O	O
is	VBZ	O	O
unknown	JJ	O	O
as	IN	O	O
the	DT	O	O
95	CD	O	O
%	NN	O	O
confidence	NN	O	O
intervals	NNS	O	O
around	IN	O	O
the	DT	O	O
mean	JJ	O	O
difference	NN	O	O
were	VBD	O	O
wide	JJ	O	O
.	.	O	O

TRIAL	NNP	O	O
REGISTRATION	NNP	O	O
Clinical	NNP	O	O
Trials	NNP	O	O
NCT00319423	NNP	O	O
.	.	O	O

Moclobemide	NNP	i	O
,	,	i	O
imipramine	NN	i	O
and	CC	i	O
placebo	NN	i	O
in	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
major	JJ	p	O
depression	NN	o	OPH
.	.	o	O

Moclobemide	NNP	i	IPM
was	VBD	O	O
compared	VBN	O	O
with	IN	O	O
imipramine	NN	i	IPM
and	CC	O	O
placebo	NN	i	IC
in	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
major	JJ	O	O
depressive	JJ	O	O
episodes	NNS	O	O
in	IN	O	O
75	CD	p	PSS
outpatients	NNS	p	O
.	.	p	O

The	DT	O	O
dosage	NN	O	O
of	IN	O	O
moclobemide	NN	i	IPM
(	(	i	IPM
25	CD	i	IPM
patients	NNS	i	IPM
)	)	i	IPM
was	VBD	i	IPM
300	CD	i	IPM
mg	JJ	i	IPM
daily	RB	i	IPM
for	IN	i	IPM
the	DT	i	IPM
first	JJ	i	IPM
5	CD	i	IPM
days	NNS	i	IPM
,	,	i	IPM
after	IN	i	IPM
which	WDT	i	IPM
it	PRP	i	IPM
could	MD	i	IPM
be	VB	i	IPM
increased	VBN	i	IPM
to	TO	i	IPM
600	CD	i	IPM
mg.	NNS	i	IPM
Imipramine	NNP	i	IPM
(	(	i	IPM
25	CD	i	IPM
patients	NNS	i	IPM
)	)	i	IPM
was	VBD	i	IPM
given	VBN	i	IPM
in	IN	i	IPM
a	DT	i	IPM
dosage	NN	i	IPM
starting	VBG	i	IPM
with	IN	i	IPM
33	CD	i	IPM
mg	NNS	i	IPM
and	CC	i	IPM
gradually	RB	i	IPM
increased	VBD	i	IPM
to	TO	i	IPM
100	CD	i	IPM
mg/day	NN	i	IPM
in	IN	i	IPM
the	DT	i	IPM
first	JJ	i	IPM
5	CD	i	IPM
days	NNS	i	IPM
,	,	O	O
after	IN	O	O
which	WDT	O	O
it	PRP	O	O
could	MD	O	O
be	VB	O	O
further	RB	O	O
increased	VBN	O	O
;	:	O	O
25	CD	p	PSS
patients	NNS	p	O
received	VBD	O	O
placebo	NN	i	IC
.	.	i	IC

Both	DT	O	O
drugs	NNS	O	O
were	VBD	O	O
equally	RB	O	O
effective	JJ	O	O
as	IN	O	O
measured	VBN	O	O
by	IN	O	O
the	DT	O	O
Hamilton	NNP	o	OPH
Rating	NNP	o	OPH
Scale	NNP	o	OPH
for	IN	o	OPH
Depression	NNP	o	OPH
,	,	O	O
the	DT	O	O
overall	JJ	o	O
assessment	NN	o	O
of	IN	o	O
efficacy	NN	o	O
and	CC	O	O
the	DT	O	O
Zung	NNP	o	OOt
Self-rating	NNP	o	OOt
Scale	NNP	o	OOt
,	,	O	O
and	CC	O	O
clearly	RB	O	O
superior	JJ	O	O
to	TO	O	O
placebo	VB	O	O
;	:	O	O
there	EX	O	O
were	VBD	O	O
no	DT	O	O
significant	JJ	O	O
differences	NNS	O	O
between	IN	O	O
the	DT	O	O
2	CD	O	O
active	JJ	O	O
drugs	NNS	O	O
.	.	O	O

Moclobemide	NNP	i	IPM
was	VBD	O	O
better	RBR	o	OOt
tolerated	VBN	o	OOt
than	IN	O	O
imipramine	NN	i	IPM
,	,	O	O
and	CC	O	O
was	VBD	O	O
almost	RB	O	O
comparable	JJ	O	O
to	TO	O	O
placebo	VB	O	O
in	IN	O	O
this	DT	O	O
respect	NN	O	O
.	.	O	O

Randomized	VBN	O	O
trial	NN	O	O
comparing	VBG	O	O
induction	NN	i	IPM
chemotherapy	NN	i	IPM
versus	NN	O	O
induction	NN	i	IPM
chemotherapy	NN	i	IPM
followed	VBN	i	O
by	IN	i	O
maintenance	NN	i	IPM
chemotherapy	NN	i	IPM
in	IN	O	O
small-cell	JJ	p	PC
lung	NN	p	PC
cancer	NN	p	PC
.	.	p	O

European	JJ	O	O
Lung	NNP	O	O
Cancer	NNP	O	O
Working	NNP	O	O
Party	NNP	O	O
.	.	O	O

PURPOSE	NNP	O	O
AND	CC	O	O
METHODS	NNP	O	O
The	DT	O	O
European	NNP	O	O
Lung	NNP	O	O
Cancer	NNP	O	O
Working	NNP	O	O
Party	NNP	O	O
(	(	O	O
ELCWP	NNP	O	O
)	)	O	O
performed	VBD	O	O
a	DT	O	O
randomized	JJ	O	O
trial	NN	O	O
with	IN	O	O
the	DT	O	O
primary	JJ	O	O
end	NN	O	O
point	NN	O	O
to	TO	O	O
determine	VB	O	O
if	IN	O	O
maintenance	NN	O	O
chemotherapy	NN	O	O
with	IN	O	O
12	CD	O	O
courses	NNS	O	O
of	IN	O	O
etoposide	NN	i	IPM
(	(	O	O
120	CD	O	O
mg/m2	NN	O	O
on	IN	O	O
days	NNS	O	O
1	CD	O	O
and	CC	O	O
3	CD	O	O
)	)	O	O
and	CC	O	O
vindesine	NN	i	IPM
(	(	O	O
3	CD	O	O
mg/m2	NN	O	O
on	IN	O	O
day	NN	O	O
3	CD	O	O
)	)	O	O
could	MD	O	O
improve	VB	O	O
progression-free	JJ	o	OMO
survival	NN	o	OMO
in	IN	O	O
small-cell	JJ	p	O
lung	NN	p	O
cancer	NN	p	O
(	(	p	O
SCLC	NNP	p	O
)	)	p	O
patients	NNS	p	O
who	WP	p	O
responded	VBD	p	O
to	TO	p	O
six	CD	p	O
courses	NNS	p	O
of	IN	p	O
induction	NN	i	IPM
chemotherapy	NN	i	IPM
with	IN	i	O
ifosfamide	NN	i	IPM
,	,	i	O
etoposide	RB	i	IPM
,	,	i	O
and	CC	i	O
an	DT	i	O
anthracycline	NN	i	IPM
(	(	i	O
doxorubicin	NN	i	IPM
or	CC	i	O
epirubicin	NN	i	IPM
)	)	i	O
.	.	i	O

RESULTS	NNP	O	O
Among	IN	p	O
235	CD	p	PSS
eligible	JJ	p	O
patients	NNS	p	O
initially	RB	p	O
registered	VBD	p	O
,	,	p	O
91	CD	p	PSS
were	VBD	p	O
randomized	VBN	p	O
to	TO	p	O
receive	VB	p	O
maintenance	NN	p	O
therapy	NN	p	O
,	,	p	O
including	VBG	p	O
seven	CD	p	PSS
patients	NNS	p	O
who	WP	p	O
were	VBD	p	O
no	RB	p	O
longer	RBR	p	O
responding	VBG	p	O
.	.	p	O

Among	IN	O	O
84	CD	O	O
randomized	JJ	O	O
responders	NNS	O	O
,	,	O	O
progression-free	JJ	o	OMO
survival	NN	o	OMO
was	VBD	O	O
significantly	RB	O	O
improved	VBN	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
.003	NNP	O	O
)	)	O	O
by	IN	O	O
maintenance	NN	O	O
therapy	NN	O	O
,	,	O	O
with	IN	O	O
median	JJ	O	O
durations	NNS	O	O
(	(	O	O
maintenance	NN	O	O
v	IN	O	O
follow-up	JJ	O	O
)	)	O	O
of	IN	O	O
25	CD	O	O
versus	NNS	O	O
12	CD	O	O
weeks	NNS	O	O
after	IN	O	O
the	DT	O	O
second	JJ	O	O
randomization	NN	O	O
,	,	O	O
but	CC	O	O
survival	NN	o	OMO
was	VBD	O	O
not	RB	O	O
significantly	RB	O	O
increased	VBN	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
.10	NNP	O	O
)	)	O	O
,	,	O	O
with	IN	O	O
median	JJ	O	O
durations	NNS	O	O
of	IN	O	O
48	CD	O	O
and	CC	O	O
38	CD	O	O
weeks	NNS	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
in	IN	O	O
a	DT	O	O
multi-variate	JJ	O	O
analysis	NN	O	O
that	WDT	O	O
took	VBD	O	O
into	IN	O	O
account	NN	o	OPH
disease	NN	o	OPH
extent	NN	o	OPH
,	,	o	OPH
maintenance	NN	o	OPH
therapy	NN	o	OPH
,	,	o	OPH
Karnofsky	NNP	o	OPH
performance	NN	o	OPH
status	NN	o	OPH
(	(	o	OPH
PS	NNP	o	OPH
)	)	o	OPH
,	,	o	OPH
and	CC	o	OPH
absolute	JJ	o	OPH
dose-intensity	NN	o	OPH
(	(	o	OPH
ADI	NNP	o	OPH
)	)	o	OPH
of	IN	o	OPH
anthracycline	NN	o	OPH
given	VBN	O	O
during	IN	O	O
induction	NN	O	O
,	,	O	O
limited	JJ	o	OPH
disease	NN	o	OPH
(	(	o	OPH
LD	NNP	o	OPH
)	)	o	OPH
and	CC	o	OPH
maintenance	NN	o	OPH
were	VBD	O	O
found	VBN	O	O
to	TO	O	O
be	VB	O	O
independent	JJ	O	O
positive	JJ	O	O
predictors	NNS	O	O
of	IN	O	O
survival	NN	o	OMO
.	.	o	OMO

CONCLUSION	NNP	O	O
We	PRP	O	O
conclude	VBP	O	O
that	DT	O	O
maintenance	NN	O	O
chemotherapy	NN	O	O
in	IN	O	O
responding	VBG	O	O
patients	NNS	O	O
is	VBZ	O	O
beneficial	JJ	O	O
in	IN	O	O
SCLC	NNP	O	O
.	.	O	O

[	JJ	O	O
Clinical	NNP	O	O
application	NN	O	O
of	IN	O	O
irradiated	JJ	O	O
drug-containing	JJ	i	IPM
porcine-cornea	NN	i	IPM
to	TO	O	O
patients	NNS	p	O
with	IN	p	O
ocular	JJ	p	PC
burns	NNS	p	PC
]	FW	p	O
.	.	O	O

OBJECTIVE	UH	O	O
To	TO	O	O
explore	VB	O	O
a	DT	O	O
new	JJ	O	O
method	NN	O	O
for	IN	O	O
the	DT	O	O
management	NN	O	O
of	IN	O	O
patients	NNS	p	O
with	IN	p	O
ocular	JJ	p	PC
burns	NNS	p	PC
.	.	p	O

METHODS	NNP	O	O
Fifty-five	JJ	p	PSS
cases	NNS	p	O
of	IN	p	O
patients	NNS	p	O
with	IN	p	O
ocular	JJ	p	PC
burns	NNS	p	PC
(	(	p	O
in	IN	p	O
88	CD	p	PSS
eyes	NNS	p	O
)	)	p	O
were	VBD	O	O
randomly	RB	O	O
divided	VBN	O	O
into	IN	O	O
treatment	NN	O	O
and	CC	O	O
control	NN	O	O
groups	NNS	O	O
.	.	O	O

Thirty	NNP	O	O
cases	NNS	O	O
in	IN	O	O
treatment	NN	O	O
group	NN	O	O
with	IN	O	O
49	CD	p	O
eyes	NNS	p	O
were	VBD	p	O
transplanted	VBN	p	O
with	IN	O	O
irradiated	JJ	i	IPM
drug-containing	NN	i	IPM
(	(	i	IPM
ofloxacin	UH	i	IPM
,	,	i	IPM
acetyl	JJ	i	IPM
cysteine	NN	i	IPM
and	CC	i	IPM
reduced	JJ	i	IPM
glutathione	NN	i	IPM
)	)	i	IPM
porcine-cornea	NN	i	IPM
.	.	i	O

25	CD	O	O
cases	NNS	O	O
in	IN	O	O
control	NN	O	O
group	NN	O	O
with	IN	O	O
39	CD	O	O
eyes	NNS	O	O
were	VBD	O	O
treated	VBN	O	O
with	IN	O	O
routine	JJ	O	O
program	NN	O	O
.	.	O	O

RESULTS	NNP	O	O
Thirty-two	JJ	O	O
eyes	NNS	o	OOt
were	VBD	o	OOt
rescued	VBN	o	OOt
in	IN	O	O
treatment	NN	O	O
group	NN	O	O
with	IN	O	O
the	DT	O	O
cure	NN	O	O
rate	NN	O	O
of	IN	O	O
65.3	CD	O	O
%	NN	O	O
.	.	O	O

But	CC	O	O
only	RB	O	O
17	CD	O	O
eyes	NNS	o	OOt
were	VBD	o	OOt
saved	VBN	o	OOt
in	IN	O	O
control	NN	O	O
group	NN	O	O
with	IN	O	O
the	DT	O	O
cure	NN	O	O
rate	NN	O	O
of	IN	O	O
43.59	CD	O	O
%	NN	O	O
,	,	O	O
indicating	VBG	O	O
significant	JJ	O	O
difference	NN	O	O
of	IN	O	O
the	DT	O	O
cure	NN	o	OOt
rate	NN	o	OOt
between	IN	O	O
the	DT	O	O
two	CD	O	O
groups	NNS	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

CONCLUSION	NNP	O	O
Irradiated	VBD	O	O
drug-containing	JJ	O	O
porcine-cornea	NN	i	IPH
might	MD	O	O
well	RB	O	O
be	VB	O	O
an	DT	O	O
ideal	JJ	O	O
therapeutic	JJ	O	O
material	NN	O	O
for	IN	O	O
the	DT	O	O
management	NN	O	O
of	IN	O	O
patients	NNS	p	O
with	IN	p	O
ocular	JJ	p	PC
burns	NNS	p	PC
.	.	p	O

[	RB	i	O
Dexmedetomidine	NNP	i	IPM
use	NN	O	O
for	IN	O	O
postoperative	JJ	o	OPH
adrenergic	JJ	o	OPH
analgesia	NN	o	OPH
and	CC	o	OPH
sedation	NN	o	OPH
in	IN	O	O
abdominal	JJ	O	O
surgery	NN	O	O
]	NN	O	O
.	.	O	O

Comparative	NNP	O	O
study	NN	O	O
of	IN	O	O
postoperative	JJ	o	O
analgesia	NN	o	O
and	CC	o	O
sedation	NN	o	O
with	IN	i	O
trimeperidine	NN	i	IPM
and	CC	i	O
dexmedetomidine	NN	i	IPM
and	CC	O	O
their	PRP$	O	O
effects	NNS	O	O
on	IN	O	O
haemodynamics	NNS	O	O
and	CC	O	O
vegetative	VBP	O	O
nervous	JJ	O	O
system	NN	O	O
was	VBD	O	O
performed	VBN	O	O
.	.	O	O

Assessment	NNP	O	O
of	IN	O	O
analgesia	NN	O	O
and	CC	O	O
sedation	NN	i	O
during	IN	O	O
vagotonia	NN	O	O
(	(	O	O
first	JJ	O	O
part	NN	O	O
of	IN	O	O
the	DT	O	O
study	NN	O	O
)	)	O	O
and	CC	O	O
hypokinetic	JJ	i	O
type	NN	i	O
of	IN	i	O
haemodynamics	NNS	i	O
(	(	O	O
second	JJ	O	O
part	NN	O	O
of	IN	O	O
the	DT	O	O
study	NN	O	O
)	)	O	O
was	VBD	O	O
carried	VBN	O	O
out	RP	O	O
with	IN	O	O
visual	JJ	o	OPH
analogue	NN	o	OPH
scale	NN	o	OPH
(	(	o	OPH
VAS	NNP	o	OPH
)	)	o	OPH
and	CC	o	O
Richmond	NNP	o	OPH
scale	NN	o	OPH
.	.	o	O

Results	NNS	O	O
of	IN	O	O
the	DT	O	O
study	NN	O	O
showed	VBD	O	O
that	IN	O	O
dexmedetomidine	NN	i	IPM
is	VBZ	O	O
more	RBR	O	O
effective	JJ	o	OOt
and	CC	o	OOt
safer	JJR	o	OOt
than	IN	O	O
trimeperidine	NN	i	IPM
for	IN	O	O
analgesia	NN	o	OPH
and	CC	o	OPH
sedation	NN	o	OPH
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
spontaneous	JJ	p	PC
breathing	NN	p	PC
after	IN	p	O
abdominal	JJ	p	O
surgery	NN	p	O
.	.	p	O

Dexmedetomidine	NNP	i	IPM
use	NN	O	O
allows	VBZ	O	O
keeping	VBG	O	O
optimal	JJ	O	O
type	NN	O	O
of	IN	O	O
haemodynamics	NNS	O	O
and	CC	O	O
vegetative	VBP	O	O
nervous	JJ	O	O
system	NN	O	O
parameters	NNS	O	O
on	IN	O	O
first	JJ	O	O
day	NN	O	O
of	IN	O	O
postoperative	JJ	O	O
period	NN	O	O
.	.	O	O

Butorphanol	NNP	i	IPM
and	CC	i	O
meperidine	NN	i	IPM
compared	VBN	O	O
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
acute	JJ	p	PC
ureteral	JJ	p	PC
colic	NN	p	PC
.	.	p	O

Pain	NNP	O	O
relief	NN	O	O
was	VBD	O	O
evaluated	VBN	O	O
in	IN	O	O
81	CD	p	PSS
patients	NNS	p	O
with	IN	p	O
acute	JJ	p	PC
ureteral	JJ	p	PC
colic	NN	p	PC
and	CC	p	O
the	DT	p	O
confirmed	JJ	p	O
presence	NN	p	O
of	IN	p	O
a	DT	p	O
calculus	NN	p	O
.	.	p	O

A	DT	O	O
randomized	JJ	p	O
double-blind	JJ	p	O
comparison	NN	p	O
of	IN	p	O
intramuscular	JJ	p	O
2	CD	p	O
and	CC	p	O
4	CD	p	O
mg.	NN	p	O
butorphanol	NN	i	IPM
and	CC	i	O
80	CD	p	O
mg.	NNS	p	O
meperidine	NN	i	IPM
was	VBD	p	O
used	VBN	p	O
.	.	p	O

Pain	NNP	o	OPA
intensity	NN	o	OPA
and	CC	O	O
pain	NN	o	OPA
relief	NN	o	OPA
were	VBD	O	O
evaluated	VBN	O	O
at	IN	O	O
half	JJ	O	O
hour	NN	O	O
and	CC	O	O
hourly	JJ	O	O
intervals	NNS	O	O
for	IN	O	O
4	CD	O	O
hours	NNS	O	O
.	.	O	O

A	DT	O	O
2	CD	O	O
mg.	NN	O	O
dose	NN	O	O
of	IN	O	O
butorphanol	NN	i	IPM
was	VBD	O	O
found	VBN	O	O
to	TO	O	O
be	VB	O	O
analgesically	RB	O	O
equivalent	JJ	O	O
to	TO	O	O
80	CD	O	O
mg.	NNS	O	O
meperidine	NN	i	IPM
,	,	O	O
while	IN	O	O
a	DT	O	O
4	CD	O	O
mg.	NN	O	O
dose	NN	O	O
of	IN	O	O
butorphanol	NN	i	IPM
was	VBD	O	O
found	VBN	O	O
to	TO	O	O
be	VB	O	O
more	RBR	O	O
effective	JJ	O	O
than	IN	O	O
80	CD	O	O
mg.	JJ	O	O
meperidine	NN	i	IPM
and	CC	O	O
2	CD	O	O
mg.	NN	O	O
butorphanol	NN	i	IPM
.	.	i	O

Each	DT	O	O
patient	NN	O	O
received	VBD	O	O
up	RB	O	O
to	TO	O	O
2	CD	O	O
doses	NNS	O	O
of	IN	O	O
analgesic	JJ	O	O
medication	NN	O	O
when	WRB	O	O
necessary	JJ	O	O
.	.	O	O

There	EX	O	O
was	VBD	O	O
no	DT	O	O
significant	JJ	O	O
difference	NN	O	O
in	IN	O	O
the	DT	O	O
incidence	NN	o	OA
of	IN	o	OA
side	JJ	o	OA
effects	NNS	o	OA
among	IN	O	O
treatments	NNS	O	O
.	.	O	O

One	CD	O	O
patient	NN	O	O
had	VBD	O	O
visual	JJ	o	OPH
hallucinations	NNS	o	OPH
after	IN	O	O
a	DT	O	O
2	CD	O	O
mg.	NN	O	O
dose	NN	O	O
of	IN	O	O
butorphanol	NN	i	IPM
,	,	O	O
possibly	RB	O	O
owing	VBG	O	O
to	TO	O	O
its	PRP$	O	O
antagonistic	JJ	O	O
activity	NN	O	O
to	TO	O	O
significant	JJ	O	O
narcotic	JJ	O	O
experience	NN	O	O
given	VBN	O	O
previously	RB	O	O
at	IN	O	O
another	DT	O	O
hospital	NN	O	O
.	.	O	O

There	EX	O	O
was	VBD	O	O
no	DT	O	O
other	JJ	O	O
evidence	NN	O	O
of	IN	O	O
toxicity	NN	o	OA
with	IN	O	O
butorphanol	NN	i	IPM
.	.	i	O

It	PRP	O	O
was	VBD	O	O
found	VBN	O	O
to	TO	O	O
be	VB	O	O
a	DT	O	O
safe	JJ	o	OOt
,	,	o	OOt
effective	JJ	o	OOt
and	CC	o	OOt
wall	RB	o	OOt
tolerated	JJ	o	OOt
drug	NN	O	O
for	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
ureteral	JJ	O	O
colic	NN	O	O
and	CC	O	O
is	VBZ	O	O
recommended	VBN	O	O
in	IN	O	O
place	NN	O	O
of	IN	O	O
narcotics	NNS	O	O
.	.	O	O

Long-term	JJ	O	O
use	NN	O	O
of	IN	O	O
Viozan	NNP	i	IPM
(	(	i	IPM
sibenadet	JJ	i	IPM
HCl	NNP	i	IPM
)	)	i	IPM
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
chronic	JJ	p	PC
obstructive	JJ	p	PC
pulmonary	JJ	p	PC
disease	NN	p	PC
:	:	p	O
results	NNS	O	O
of	IN	O	O
a	DT	O	O
1-year	JJ	O	O
study	NN	O	O
.	.	O	O

Viozan	NNP	i	IPM
(	(	i	O
sibenadet	JJ	i	IPM
HCl	NNP	i	IPM
,	,	i	O
AR-C68397AA	NNP	i	IPM
)	)	i	O
is	VBZ	O	O
a	DT	O	O
novel	JJ	O	O
dual	JJ	O	O
D2	NNP	O	O
dopamine	NN	O	O
receptor	NN	O	O
,	,	O	O
beta2-adrenoceptor	JJ	O	O
agonist	NN	O	O
that	WDT	O	O
has	VBZ	O	O
been	VBN	O	O
investigated	VBN	O	O
for	IN	O	O
efficacy	NN	O	O
in	IN	O	O
alleviating	VBG	O	O
the	DT	O	O
symptoms	NNS	O	O
of	IN	O	O
chronic	JJ	O	O
obstructive	JJ	O	O
pulmonary	JJ	O	O
disease	NN	O	O
(	(	O	O
COPD	NNP	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
slowly	RB	O	O
progressive	JJ	O	O
nature	NN	O	O
of	IN	O	O
this	DT	O	O
disease	NN	O	O
means	VBZ	O	O
that	IN	O	O
patients	NNS	O	O
will	MD	O	O
require	VB	O	O
ongoing	JJ	O	O
therapeutic	JJ	O	O
management	NN	O	O
for	IN	O	O
many	JJ	O	O
years	NNS	O	O
,	,	O	O
or	CC	O	O
even	RB	O	O
decades	NNS	O	O
.	.	O	O

With	IN	O	O
such	JJ	O	O
long-term	JJ	O	O
treatment	NN	O	O
,	,	O	O
the	DT	O	O
safety	NN	O	O
profile	NN	O	O
of	IN	O	O
new	JJ	O	O
agents	NNS	O	O
will	MD	O	O
be	VB	O	O
of	IN	O	O
paramount	JJ	O	O
importance	NN	O	O
.	.	O	O

As	IN	O	O
part	NN	O	O
of	IN	O	O
the	DT	O	O
large-scale	JJ	O	O
assessment	NN	O	O
of	IN	O	O
sibenadet	NN	i	IPM
,	,	O	O
a	DT	O	O
12-month	JJ	O	O
safety	NN	O	O
study	NN	O	O
has	VBZ	O	O
been	VBN	O	O
conducted	VBN	O	O
.	.	O	O

Following	VBG	O	O
completion	NN	O	O
of	IN	O	O
a	DT	O	O
2-week	JJ	O	O
baseline	NN	O	O
period	NN	O	O
,	,	O	O
435	CD	p	PSS
adults	NNS	p	PA
with	IN	p	O
stable	JJ	p	PC
,	,	p	PC
symptomatic	JJ	p	PC
,	,	p	PC
smoking-related	JJ	p	PC
COPD	NNP	p	PC
were	VBD	p	O
randomized	VBN	p	O
to	TO	O	O
receive	VB	O	O
either	RB	O	O
500	CD	i	IPM
microg	NN	i	IPM
sibenadet	NN	i	IPM
or	CC	i	O
placebo	NN	i	IC
delivered	VBN	O	O
via	IN	O	O
pressurized	VBN	O	O
metered	VBD	O	O
dose	JJ	O	O
inhaler	NN	O	O
(	(	O	O
pMDI	NN	O	O
)	)	O	O
,	,	O	O
three	CD	O	O
times	NNS	O	O
daily	RB	O	O
for	IN	O	O
52	CD	O	O
weeks	NNS	O	O
.	.	O	O

Sibenadet	NNP	i	IPM
therapy	NN	i	O
was	VBD	O	O
generally	RB	O	O
well	RB	o	OOt
tolerated	VBN	o	OOt
,	,	O	O
with	IN	O	O
the	DT	O	O
only	JJ	O	O
notable	JJ	o	OPH
differences	NNS	o	OPH
seen	VBN	O	O
in	IN	O	O
the	DT	O	O
incidence	NN	o	OPH
of	IN	o	OPH
tremor	NN	o	OPH
and	CC	o	OPH
taste	NN	o	OPH
of	IN	o	OPH
treatment	NN	o	OPH
(	(	O	O
16.9	CD	O	O
%	NN	O	O
vs.	FW	O	O
4.1	CD	O	O
%	NN	O	O
and	CC	O	O
14.5	CD	O	O
%	NN	O	O
vs.	FW	O	O
4.1	CD	O	O
%	NN	O	O
in	IN	O	O
the	DT	O	O
sibenadet	NN	O	O
and	CC	O	O
placebo	NN	i	IC
groups	NNS	O	O
respectively	RB	O	O
)	)	O	O
.	.	O	O

There	EX	O	O
were	VBD	O	O
a	DT	O	O
total	NN	O	O
of	IN	O	O
79	CD	p	PSS
patients	NNS	p	O
with	IN	p	O
serious	JJ	o	OA
adverse	JJ	o	OA
events	NNS	o	OA
(	(	p	O
SAEs	NNP	p	PC
)	)	p	O
,	,	p	O
43	CD	p	PSS
(	(	p	O
14.8	CD	p	O
%	NN	p	O
)	)	p	O
in	IN	p	O
the	DT	p	O
sibenadet	NN	p	PC
pMDI	NN	p	PC
group	NN	p	O
and	CC	p	O
36	CD	p	PSS
(	(	p	O
24.8	CD	p	O
%	NN	p	O
)	)	p	O
in	IN	p	O
the	DT	p	O
placebo	NN	i	IC
group	NN	i	O
.	.	i	O

No	DT	O	O
clinically	RB	o	OPH
significant	JJ	o	OPH
abnormal	JJ	o	OPH
laboratory	NN	o	OPH
values	NNS	o	OPH
or	CC	O	O
overall	JJ	o	OPH
differences	NNS	o	OPH
between	IN	O	O
treatment	NN	O	O
groups	NNS	O	O
were	VBD	O	O
noted	VBN	O	O
.	.	O	O

Similarly	RB	O	O
,	,	O	O
there	EX	O	O
were	VBD	O	O
no	DT	o	OPH
clinically	RB	o	OPH
significant	JJ	o	OPH
differences	NNS	o	OPH
between	IN	O	O
the	DT	O	O
two	CD	O	O
treatment	NN	O	O
groups	NNS	O	O
for	IN	O	O
cardiac	JJ	o	OPH
variables	NNS	o	OPH
,	,	o	OPH
or	CC	o	OPH
in	IN	o	OPH
vital	JJ	o	OPH
signs	NNS	o	OPH
.	.	o	OPH

The	DT	O	O
secondary	JJ	o	O
variables	NNS	o	O
showed	VBD	O	O
no	DT	o	OPH
notable	JJ	o	OPH
differences	NNS	o	OPH
with	IN	O	O
respect	NN	O	O
to	TO	O	O
lung	NN	o	OPH
function	NN	o	OPH
,	,	o	OPH
exacerbations	NNS	o	OPH
or	CC	o	OPH
health-related	JJ	o	OPH
quality	NN	o	OPH
of	IN	o	OPH
life	NN	o	OPH
.	.	o	OPH

Due	NNP	O	O
to	TO	O	O
the	DT	O	O
effective	JJ	O	O
beta2-agonist	NN	O	O
properties	NNS	O	O
,	,	O	O
patients	NNS	O	O
in	IN	O	O
the	DT	O	O
sibenadet	NN	O	O
group	NN	O	O
did	VBD	O	O
,	,	O	O
however	RB	O	O
,	,	O	O
report	NN	O	O
reduced	VBD	o	OOt
rescue	JJ	o	OOt
medication	NN	o	OOt
usage	NN	o	OOt
at	IN	o	OOt
all	DT	o	OOt
timepoints	NNS	o	OOt
.	.	o	O

While	IN	O	O
the	DT	O	O
results	NNS	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
show	NN	O	O
that	IN	O	O
,	,	O	O
overall	JJ	O	O
,	,	O	O
sibenadet	JJ	O	O
therapy	NN	O	O
was	VBD	O	O
well	RB	o	OOt
tolerated	VBN	o	OOt
,	,	O	O
the	DT	O	O
lack	NN	o	OOt
of	IN	o	OOt
sustained	JJ	o	OOt
benefit	NN	o	OOt
reported	VBD	O	O
in	IN	O	O
large-scale	JJ	o	OOt
clinical	JJ	o	OOt
efficacy	NN	o	OOt
studies	NNS	o	OOt
means	VBZ	O	O
that	IN	O	O
sibenadet	NN	O	O
development	NN	O	O
will	MD	O	O
not	RB	O	O
be	VB	O	O
continued	VBN	O	O
.	.	O	O

The	DT	O	O
relationship	NN	O	O
of	IN	O	O
alexithymia	NN	O	O
to	TO	O	O
emotional	JJ	O	O
dysregulation	NN	O	O
within	IN	O	O
an	DT	O	O
alcohol	NN	p	O
dependent	JJ	p	O
treatment	NN	p	O
sample	NN	p	O
.	.	p	O

Difficulties	NNS	O	O
regulating	VBG	O	O
emotions	NNS	O	O
have	VBP	O	O
implications	NNS	O	O
for	IN	O	O
the	DT	O	O
development	NN	O	O
,	,	O	O
maintenance	NN	O	O
,	,	O	O
and	CC	O	O
recovery	NN	O	O
from	IN	O	O
alcohol	NN	p	O
problems	NNS	p	O
.	.	p	O

One	CD	O	O
construct	NN	O	O
thought	NN	O	O
to	TO	O	O
impede	VB	O	O
the	DT	O	O
regulation	NN	O	O
of	IN	O	O
emotion	NN	O	O
is	VBZ	O	O
alexithymia	JJ	O	O
.	.	O	O

Alexithymia	NNP	O	O
is	VBZ	O	O
characterized	VBN	O	O
by	IN	O	O
difficulties	NNS	O	O
identifying	VBG	O	O
,	,	O	O
differentiating	VBG	O	O
and	CC	O	O
expressing	VBG	O	O
feelings	NNS	O	O
,	,	O	O
a	DT	O	O
limited	JJ	O	O
imagination	NN	O	O
and	CC	O	O
fantasy	JJ	O	O
life	NN	O	O
,	,	O	O
and	CC	O	O
an	DT	O	O
externally-oriented	JJ	O	O
thinking	NN	O	O
style	NN	O	O
(	(	O	O
e.g.	UH	O	O
,	,	O	O
prefer	VBP	O	O
talking	VBG	O	O
about	IN	O	O
daily	JJ	O	O
activities	NNS	O	O
rather	RB	O	O
than	IN	O	O
feelings	NNS	O	O
)	)	O	O
.	.	O	O

Given	VBN	O	O
that	IN	O	O
poor	JJ	O	O
emotion	NN	O	O
regulation	NN	O	O
skills	NNS	O	O
have	VBP	O	O
been	VBN	O	O
found	VBN	O	O
to	TO	O	O
predict	VB	O	O
posttreatment	NN	p	O
levels	NNS	p	O
of	IN	p	O
alcohol	NN	p	O
use	NN	p	O
,	,	O	O
and	CC	O	O
that	IN	O	O
several	JJ	O	O
defining	VBG	O	O
characteristics	NNS	O	O
of	IN	O	O
alexithymia	JJ	O	O
bear	JJ	O	O
similarity	NN	O	O
to	TO	O	O
deficits	NNS	O	O
in	IN	O	O
emotion	NN	O	O
regulation	NN	O	O
skills	NNS	O	O
,	,	O	O
it	PRP	O	O
is	VBZ	O	O
possible	JJ	O	O
that	IN	O	O
alexithymia	NN	O	O
may	MD	O	O
predict	VB	O	O
poorer	JJR	O	O
alcohol	NN	O	O
treatment	NN	O	O
outcomes	NNS	O	O
.	.	O	O

Thus	RB	O	O
,	,	O	O
the	DT	O	O
present	JJ	O	O
study	NN	O	O
first	RB	O	O
examined	VBD	O	O
the	DT	O	O
relationship	NN	O	O
of	IN	O	O
alexithymia	NN	i	IOt
to	TO	O	O
several	JJ	O	O
other	JJ	O	O
emotion	NN	o	OME
regulation	NN	o	OME
measures	NNS	o	OME
and	CC	O	O
then	RB	O	O
investigated	VBD	O	O
the	DT	O	O
impact	NN	O	O
of	IN	O	O
alexithymia	NN	i	IOt
on	IN	O	O
attrition	NN	O	O
and	CC	O	O
alcohol	NN	O	O
treatment	NN	O	O
outcomes	NNS	O	O
in	IN	O	O
men	NNS	p	O
and	CC	p	O
women	NNS	p	O
(	(	p	O
N=77	NNP	p	O
)	)	p	O
enrolled	VBD	p	O
in	IN	p	O
a	DT	p	O
12-week	JJ	i	IPS
cognitive-behavioral	JJ	i	IPS
intervention	NN	i	IPS
for	IN	i	IPS
alcohol	NN	i	IPS
dependence	NN	i	IPS
.	.	i	O

At	IN	O	O
baseline	NN	O	O
,	,	O	O
higher	JJR	O	O
scores	NNS	O	O
on	IN	O	O
alexithymia	NN	O	O
were	VBD	O	O
associated	VBN	O	O
poorer	JJR	o	OME
emotion	NN	o	OME
regulation	NN	o	OME
skills	NNS	o	OME
,	,	o	O
fewer	JJR	o	OME
percent	NN	o	OME
days	NNS	o	OME
abstinent	NN	o	OME
,	,	o	O
greater	JJR	o	OME
alcohol	NN	o	OME
dependence	NN	o	OME
severity	NN	o	OME
,	,	o	O
and	CC	o	O
several	JJ	o	OME
high-risk	JJ	o	OME
drinking	NN	o	OME
situations	NNS	o	OME
.	.	o	O

Alexithymia	NNP	O	O
was	VBD	O	O
unrelated	JJ	O	O
to	TO	O	O
attrition	NN	O	O
and	CC	O	O
to	TO	O	O
level	NN	O	O
of	IN	O	O
alcohol	NN	O	O
consumption	NN	O	O
at	IN	O	O
posttreatment	NN	O	O
.	.	O	O

Overall	UH	O	O
,	,	O	O
the	DT	O	O
construct	NN	O	O
of	IN	O	O
alexithymia	NN	O	O
is	VBZ	O	O
shown	VBN	O	O
to	TO	O	O
be	VB	O	O
related	VBN	O	O
to	TO	O	O
several	JJ	O	O
theoretically-related	JJ	O	O
constructs	NNS	O	O
(	(	O	O
e.g.	NN	O	O
,	,	O	O
emotion	NN	O	O
regulation	NN	O	O
,	,	O	O
mindfulness	NN	O	O
)	)	O	O
but	CC	O	O
demonstrated	VBD	O	O
a	DT	O	O
limited	JJ	O	O
relationship	NN	O	O
to	TO	O	O
drinking	VBG	O	O
outcomes	NNS	O	O
in	IN	O	O
those	DT	p	O
seeking	VBG	p	O
treatment	NN	p	O
for	IN	p	O
alcohol	NN	p	O
dependence	NN	p	O
.	.	p	O

Short-term	JJ	O	O
fluoxetine	NN	i	IPM
monotherapy	NN	i	IPM
for	IN	O	O
bipolar	JJ	p	PC
type	NN	p	PC
II	NNP	p	PC
or	CC	p	PC
bipolar	JJ	p	PC
NOS	NNP	p	PC
major	JJ	p	PC
depression	NN	p	PC
-	:	p	PC
low	JJ	p	PC
manic	JJ	p	PC
switch	NN	p	PC
rate	NN	p	PC
.	.	p	O

OBJECTIVES	CC	O	O
Current	NNP	O	O
guidelines	NNS	O	O
for	IN	O	O
the	DT	O	O
initial	JJ	O	O
treatment	NN	O	O
of	IN	O	O
bipolar	JJ	p	PC
type	NN	p	PC
II	NNP	p	PC
(	(	p	O
BP	NNP	p	PC
II	NNP	p	PC
)	)	p	O
major	JJ	p	O
depressive	JJ	p	O
episode	NN	p	O
(	(	p	O
MDE	NNP	p	O
)	)	p	O
recommend	VBP	O	O
using	VBG	O	O
either	CC	O	O
a	DT	O	O
mood	NN	O	O
stabilizer	NN	O	O
alone	RB	O	O
or	CC	O	O
a	DT	O	O
combination	NN	O	O
of	IN	O	O
a	DT	O	O
mood	NN	O	O
stabilizer	NN	O	O
plus	CC	O	O
a	DT	O	O
selective	JJ	O	O
serotonin	NN	O	O
re-uptake	NN	O	O
inhibitor	NN	O	O
(	(	O	O
SSRI	NNP	O	O
)	)	O	O
.	.	O	O

This	DT	O	O
recommendation	NN	O	O
is	VBZ	O	O
the	DT	O	O
result	NN	O	O
of	IN	O	O
concern	NN	O	O
over	IN	O	O
antidepressant-induced	JJ	O	O
manic	JJ	O	O
switch	NN	O	O
episodes	NNS	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
recent	JJ	O	O
evidence	NN	O	O
suggests	VBZ	O	O
that	IN	O	O
the	DT	O	O
manic	JJ	O	O
switch	NN	O	O
rate	NN	O	O
may	MD	O	O
be	VB	O	O
low	JJ	O	O
in	IN	O	O
BP	NNP	O	O
II	NNP	O	O
MDE	NNP	O	O
during	IN	O	O
SSRI	NNP	O	O
therapy	NN	O	O
.	.	O	O

METHODS	NNP	O	O
As	IN	p	O
part	NN	p	O
of	IN	p	O
a	DT	p	O
randomized	JJ	p	O
,	,	p	O
double-blind	JJ	p	O
,	,	p	O
placebo-controlled	JJ	i	IC
relapse-prevention	NN	p	O
study	NN	p	O
of	IN	p	O
fluoxetine	JJ	i	IPH
monotherapy	NN	i	IPH
in	IN	p	O
BP	NNP	p	PC
II	NNP	p	PC
MDE	NNP	p	O
,	,	p	O
37	CD	p	PSS
patients	NNS	p	O
received	VBD	O	O
open-label	JJ	i	IPM
fluoxetine	NN	i	IPM
20	CD	i	IPM
mg	NN	i	IPM
every	DT	i	IE
day	NN	i	IE
for	IN	i	IE
up	IN	i	IE
to	TO	i	IE
8	CD	i	IE
weeks	NNS	i	IE
.	.	i	O

Outcome	NNP	O	O
measures	NNS	O	O
included	VBD	O	O
the	DT	O	O
Hamilton	NNP	O	O
Depression	NNP	O	O
Rating	NNP	O	O
(	(	O	O
HAM-D	NNP	O	O
17	CD	O	O
)	)	O	O
rating	NN	O	O
and	CC	O	O
the	DT	O	O
Young	NNP	O	O
Mania	NNP	O	O
Rating	NNP	O	O
(	(	O	O
YMR	NNP	O	O
)	)	O	O
scale	NN	O	O
.	.	O	O

RESULTS	NNP	O	O
Eleven	NNP	O	O
of	IN	O	O
23	CD	O	O
patients	NNS	O	O
(	(	O	O
48	CD	O	O
%	NN	O	O
)	)	O	O
who	WP	O	O
completed	VBD	O	O
8	CD	O	O
weeks	NNS	O	O
of	IN	O	O
fluoxetine	NN	i	IPM
treatment	NN	O	O
showed	VBD	O	O
a	DT	O	O
HAM-D	JJ	o	OPH
17	CD	o	OPH
reduction	NN	o	OPH
of	IN	O	O
>	NN	O	O
or	CC	O	O
=50	CD	O	O
%	NN	O	O
,	,	O	O
while	IN	O	O
14	CD	O	O
(	(	O	O
38	CD	O	O
%	NN	O	O
)	)	O	O
of	IN	O	O
all	DT	O	O
treated	JJ	O	O
patients	NNS	O	O
had	VBD	O	O
>	VBN	O	O
or	CC	O	O
=50	CD	O	O
%	NN	O	O
reduction	NN	O	O
in	IN	O	O
baseline	JJ	O	O
HAM-D	JJ	O	O
17	CD	O	O
score	NN	O	O
.	.	O	O

Using	VBG	O	O
a	DT	O	O
conservative	JJ	O	O
YMR	NNP	o	OPH
score	NN	o	OPH
of	IN	o	OPH
>	NN	o	OPH
or	CC	o	OPH
=8	VB	o	OPH
to	TO	O	O
identify	VB	O	O
hypomanic	JJ	O	O
symptoms	NNS	O	O
,	,	O	O
the	DT	O	O
frequency	NN	O	O
of	IN	O	O
patients	NNS	O	O
with	IN	O	O
YMR	NNP	O	O
score	NN	O	O
>	NN	O	O
or	CC	O	O
=8	NN	O	O
during	IN	O	O
fluoxetine	NN	O	O
did	VBD	O	O
not	RB	O	O
differ	VB	O	O
from	IN	O	O
that	DT	O	O
seen	VBN	O	O
during	IN	O	O
the	DT	O	O
screen	NN	O	O
and	CC	O	O
baseline	JJ	O	O
period	NN	O	O
.	.	O	O

Only	RB	O	O
three	CD	O	O
patients	NNS	O	O
(	(	O	O
7.3	CD	O	O
%	NN	O	O
)	)	O	O
had	VBD	O	O
symptoms	NNS	O	O
suggestive	JJ	O	O
of	IN	O	O
hypomania	NN	o	OPH
,	,	O	O
and	CC	O	O
only	RB	O	O
one	CD	O	O
patient	NN	O	O
stopped	VBD	O	O
treatment	NN	O	O
because	IN	O	O
of	IN	O	O
a	DT	O	O
rapid	JJ	o	OME
mood	NN	o	OME
swing	VBG	o	OME
into	IN	o	OME
depression	NN	o	OME
.	.	o	O

LIMITATIONS	NNP	O	O
Fluoxetine	NNP	i	IPM
was	VBD	O	O
given	VBN	O	O
at	IN	O	O
a	DT	O	O
fixed	JJ	O	O
dose	NN	O	O
of	IN	O	O
20	CD	O	O
mg	NNS	O	O
everyday	JJ	O	O
.	.	O	O

Fluoxetine	NNP	i	IPM
was	VBD	O	O
prescribed	VBN	O	O
in	IN	O	O
an	DT	O	O
open-label	JJ	O	O
manner	NN	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
sample	NN	O	O
size	NN	O	O
was	VBD	O	O
limited	VBN	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
These	DT	O	O
observations	NNS	O	O
support	VBP	O	O
the	DT	O	O
findings	NNS	O	O
of	IN	O	O
a	DT	O	O
low	JJ	O	O
manic	JJ	O	O
switch	NN	O	O
rate	NN	O	O
during	IN	O	O
SSRI	NNP	O	O
monotherapy	NN	O	O
of	IN	O	O
BP	NNP	O	O
II	NNP	O	O
MDE	NNP	O	O
,	,	O	O
and	CC	O	O
suggest	VBP	O	O
that	IN	O	O
fluoxetine	JJ	i	IPM
monotherapy	NN	i	IPM
may	MD	O	O
be	VB	O	O
a	DT	O	O
safe	JJ	O	O
and	CC	O	O
effective	JJ	O	O
initial	JJ	O	O
treatment	NN	O	O
of	IN	O	O
BP	NNP	p	PC
II	NNP	p	PC
MDE	NNP	p	PC
.	.	p	O

Seven-star	NNP	i	IPH
needle	JJ	i	IPH
stimulation	NN	i	IPH
improves	VBZ	O	O
language	NN	o	OME
and	CC	o	OME
social	JJ	o	OME
interaction	NN	o	OME
of	IN	O	O
children	NNS	p	PA
with	IN	p	O
autistic	JJ	p	PC
spectrum	NN	p	PC
disorders	NNS	p	PC
.	.	p	O

This	DT	O	O
is	VBZ	O	O
a	DT	O	O
randomized	JJ	O	O
controlled	VBN	O	O
trial	NN	O	O
that	WDT	O	O
aimed	VBD	O	O
to	TO	O	O
evaluate	VB	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
the	DT	O	O
Seven-star	NNP	i	IPH
Needle	NNP	i	IPH
Stimulation	NNP	i	IPH
treatment	NN	O	O
on	IN	O	O
children	NNS	p	PA
with	IN	p	O
Autistic	NNP	p	O
Spectrum	NNP	p	O
Disorders	NNP	p	O
(	(	p	O
ASD	NNP	p	PC
)	)	p	O
.	.	p	O

Thirty-two	JJ	p	PSS
children	NNS	p	PA
with	IN	p	O
ASD	NNP	p	PC
were	VBD	O	O
assigned	VBN	O	O
randomly	RB	O	O
into	IN	O	O
the	DT	O	O
treatment	NN	O	O
and	CC	O	O
control	NN	O	O
groups	NNS	O	O
.	.	O	O

Children	NNP	O	O
in	IN	O	O
the	DT	O	O
treatment	NN	p	O
group	NN	p	O
underwent	VBD	O	O
30	CD	O	O
sessions	NNS	O	O
of	IN	O	O
stimulation	NN	O	O
over	IN	O	O
6	CD	O	O
weeks	NNS	O	O
,	,	O	O
while	IN	O	O
children	NNS	O	O
in	IN	O	O
the	DT	O	O
control	NN	p	O
group	NN	p	O
were	VBD	O	O
on	IN	O	O
a	DT	O	O
waiting	VBG	O	O
list	NN	O	O
and	CC	O	O
did	VBD	O	O
not	RB	O	O
receive	VB	O	O
treatment	NN	O	O
during	IN	O	O
this	DT	O	O
period	NN	O	O
of	IN	O	O
time	NN	O	O
.	.	O	O

Intervention	NNP	O	O
consisted	VBD	O	O
of	IN	O	O
a	DT	O	O
treatment	NN	O	O
regime	NN	O	O
comprising	NN	O	O
of	IN	O	O
30	CD	i	IPH
sessions	NNS	i	IPH
of	IN	i	IPH
Seven-star	NNP	i	IPH
Needle	NNP	i	IPH
Stimulation	NNP	i	IPH
,	,	O	O
delivered	VBD	O	O
over	IN	O	O
6	CD	O	O
weeks	NNS	O	O
.	.	O	O

Each	DT	O	O
session	NN	O	O
lasted	VBD	O	O
5	CD	O	O
to	TO	O	O
10	CD	O	O
min	NN	O	O
,	,	O	O
children	NNS	O	O
in	IN	O	O
the	DT	O	O
treatment	NN	O	O
group	NN	O	O
were	VBD	O	O
stimulated	VBN	O	O
at	IN	O	O
the	DT	O	O
front	NN	O	O
and	CC	O	O
back	RB	O	O
sides	NNS	O	O
of	IN	O	O
their	PRP$	O	O
body	NN	O	O
and	CC	O	O
the	DT	O	O
head	NN	O	O
by	IN	O	O
using	VBG	O	O
Seven-star	JJ	i	IPH
Needles	NNP	i	IPH
.	.	i	O

The	DT	O	O
change	NN	O	O
in	IN	O	O
the	DT	O	O
children	NNS	o	OME
's	POS	o	OME
behavior	NN	o	OME
was	VBD	O	O
evaluated	VBN	O	O
using	VBG	O	O
parents	NNS	O	O
'	POS	O	O
report	NN	O	O
and	CC	O	O
neurophysiological	JJ	O	O
changes	NNS	O	O
were	VBD	O	O
measured	VBN	O	O
by	IN	O	O
quantitative	JJ	O	O
EEG	NNP	O	O
(	(	O	O
qEEG	NN	O	O
)	)	O	O
.	.	O	O

Results	CC	O	O
showed	VBD	O	O
that	IN	O	O
the	DT	O	O
treatment	NN	O	O
group	NN	O	O
demonstrated	VBD	O	O
significant	JJ	O	O
improvement	NN	O	O
in	IN	O	O
language	NN	o	OME
and	CC	o	OME
social	JJ	o	OME
interaction	NN	o	OME
,	,	O	O
but	CC	O	O
not	RB	O	O
in	IN	O	O
stereotyped	JJ	o	OME
behavior	NN	o	OME
or	CC	o	OME
motor	NN	o	OME
function	NN	o	OME
,	,	O	O
compared	VBN	O	O
to	TO	O	O
the	DT	O	O
control	NN	O	O
group	NN	O	O
.	.	O	O

qEEG	JJ	o	OPH
spectral	JJ	o	OPH
amplitudes	NNS	o	OPH
in	IN	O	O
the	DT	O	O
treatment	NN	O	O
,	,	O	O
but	CC	O	O
not	RB	O	O
in	IN	O	O
the	DT	O	O
control	NN	O	O
group	NN	O	O
,	,	O	O
were	VBD	O	O
also	RB	O	O
reduced	VBN	O	O
significantly	RB	O	O
.	.	O	O

The	DT	O	O
results	NNS	O	O
suggested	VBD	O	O
that	IN	O	O
Seven-star	NNP	i	IPH
Needle	NNP	i	IPH
Stimulation	NNP	i	IPH
might	MD	O	O
be	VB	O	O
an	DT	O	O
effective	JJ	O	O
intervention	NN	O	O
to	TO	O	O
improve	VB	O	O
language	NN	o	OME
and	CC	o	OME
social	JJ	o	OME
functioning	NN	o	OME
of	IN	O	O
children	NNS	p	PA
with	IN	p	O
ASD	NNP	p	PC
.	.	p	O

Feedlot	NNP	O	O
performance	NN	O	O
and	CC	O	O
carcass	NN	O	O
characteristics	NNS	O	O
of	IN	O	O
Holstein	NNP	p	PC
steers	NNS	p	PSE
as	IN	O	O
affected	VBN	O	O
by	IN	O	O
source	NN	O	O
of	IN	O	O
dietary	JJ	O	O
protein	NN	O	O
and	CC	O	O
level	NN	O	O
of	IN	O	O
ruminally	RB	O	O
protected	VBN	O	O
lysine	NN	O	O
and	CC	O	O
methionine	NN	O	O
.	.	O	O

The	DT	O	O
objective	NN	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
determine	VB	O	O
the	DT	O	O
effects	NNS	o	OOt
of	IN	O	O
source	NN	O	O
of	IN	O	O
dietary	JJ	O	O
CP	NNP	O	O
and	CC	O	O
level	NN	O	O
of	IN	O	O
ruminally	RB	O	O
protected	VBN	O	O
lysine	NN	O	O
and	CC	O	O
methionine	NN	O	O
(	(	O	O
RPLM	NNP	O	O
)	)	O	O
on	IN	O	O
feedlot	NN	o	OOt
performance	NN	o	OOt
and	CC	o	OME
carcass	NN	o	OOt
characteristics	NNS	o	OOt
of	IN	O	O
Holstein	NNP	p	PC
steers	NNS	p	PC
during	IN	O	O
a	DT	O	O
growing-finishing	JJ	O	O
trial	NN	O	O
(	(	O	O
266	CD	O	O
d	NN	O	O
)	)	O	O
.	.	O	O

A	DT	O	O
total	NN	O	O
of	IN	O	O
168	CD	p	PSS
Holstein	NNP	p	PC
steers	NNS	p	PC
(	(	p	O
182.7	CD	p	PC
+/-	JJ	p	PC
27.5	CD	p	PC
kg	NN	p	PC
)	)	p	O
were	VBD	O	O
used	VBN	O	O
in	IN	O	O
a	DT	O	O
completely	RB	O	O
randomized	JJ	O	O
design	NN	O	O
experiment	NN	O	O
(	(	O	O
eight	CD	O	O
treatments	NNS	O	O
;	:	O	O
three	CD	O	O
pens	NNS	O	O
of	IN	O	O
seven	CD	O	O
steers/treatment	NN	O	O
)	)	O	O
.	.	O	O

Steers	NNPS	O	O
were	VBD	O	O
given	VBN	O	O
ad	NN	i	IPH
libitum	NN	i	IPH
access	NN	i	IPH
to	TO	i	IPH
high-concentrate	JJ	i	IPH
diets	NNS	i	IPH
(	(	i	IPM
13	CD	i	IPM
%	NN	i	IPM
CP	NNP	i	IPM
)	)	i	IPM
containing	VBG	i	O
71	CD	i	O
%	NN	i	O
whole	JJ	i	O
shelled	VBN	i	O
corn	NN	i	O
,	,	i	O
10	CD	i	O
%	NN	i	O
corn	NN	i	O
silage	NN	i	O
,	,	i	O
4	CD	i	O
%	NN	i	O
condensed	JJ	i	O
distillers	NNS	i	O
solubles	NNS	i	O
,	,	i	O
and	CC	i	O
15	CD	i	O
%	NN	i	O
protein	NN	i	O
supplements	NNS	i	O
(	(	i	O
DM	NNP	i	O
basis	NN	i	O
)	)	i	O
.	.	i	O

Treatments	NNS	O	O
were	VBD	O	O
arranged	VBN	O	O
as	IN	O	O
a	DT	O	O
2	CD	O	O
x	NN	O	O
4	CD	O	O
factorial	JJ	O	O
.	.	O	O

The	DT	O	O
main	JJ	O	O
factors	NNS	O	O
were	VBD	O	O
two	CD	O	O
sources	NNS	O	O
of	IN	O	O
dietary	JJ	O	O
CP	NNP	O	O
and	CC	O	O
four	CD	O	O
levels	NNS	O	O
of	IN	O	O
RPLM	NNP	O	O
.	.	O	O

The	DT	O	O
sources	NNS	O	O
of	IN	O	O
dietary	JJ	o	OOt
CP	NNP	o	OOt
were	VBD	O	O
soybean	JJ	O	O
meal	NN	O	O
(	(	O	O
SBM	NNP	O	O
)	)	O	O
or	CC	O	O
SBM	NNP	O	O
and	CC	O	O
urea	JJ	O	O
(	(	O	O
SBM-U	NNP	O	O
)	)	O	O
.	.	O	O

Urea-N	NNP	o	OOt
replaced	VBD	O	O
50	CD	O	O
%	NN	O	O
of	IN	O	O
SBM-N	NNP	O	O
in	IN	O	O
the	DT	O	O
SBM-U	NNP	O	O
diet	NN	O	O
.	.	O	O

The	DT	O	O
levels	NNS	O	O
of	IN	O	O
RPLM	NNP	O	O
were	VBD	O	O
0	CD	O	O
,	,	O	O
5	CD	O	O
,	,	O	O
10	CD	O	O
,	,	O	O
and	CC	O	O
15	CD	O	O
g	NN	O	O
per	IN	O	O
steer	NN	O	O
daily	RB	O	O
.	.	O	O

No	UH	O	O
interactions	NNS	O	O
(	(	O	O
P	NNP	O	O
>	NNP	O	O
.10	NNP	O	O
)	)	O	O
between	IN	O	O
source	NN	O	O
of	IN	O	O
dietary	JJ	o	OPH
CP	NNP	o	OPH
and	CC	o	OPH
level	NN	o	OPH
of	IN	o	OPH
RPLM	NNP	o	OPH
were	VBD	O	O
observed	VBN	O	O
for	IN	O	O
feedlot	NN	O	O
performance	NN	O	O
or	CC	O	O
carcass	NN	o	OOt
characteristics	NNS	o	OOt
.	.	o	OME

Feedlot	NNP	o	OOt
performance	NN	o	OOt
showed	VBD	O	O
an	DT	O	O
advantage	NN	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
.10	NNP	O	O
)	)	O	O
to	TO	O	O
feeding	VBG	O	O
SMB	NNP	O	O
during	IN	O	O
the	DT	O	O
first	JJ	O	O
84	CD	O	O
d	NN	O	O
of	IN	O	O
the	DT	O	O
trial	NN	O	O
and	CC	O	O
an	DT	O	O
advantage	NN	O	O
to	TO	O	O
feeding	VBG	O	O
SBM-U	NNP	O	O
during	IN	O	O
the	DT	O	O
last	JJ	O	O
98	CD	O	O
d	NN	O	O
of	IN	O	O
the	DT	O	O
trial	NN	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
feedlot	JJ	o	OOt
performance	NN	o	OOt
for	IN	O	O
the	DT	O	O
whole	JJ	O	O
trial	NN	O	O
and	CC	O	O
carcass	NN	O	O
characteristics	NNS	O	O
(	(	O	O
except	IN	O	O
for	IN	O	O
fat	JJ	o	OPH
thickness	NN	o	OPH
)	)	o	OPH
were	VBD	O	O
not	RB	O	O
affected	VBN	O	O
(	(	O	O
P	NNP	O	O
>	NNP	O	O
.10	NNP	O	O
)	)	O	O
by	IN	O	O
the	DT	O	O
source	NN	O	O
of	IN	O	O
dietary	JJ	O	O
CP	NNP	O	O
.	.	O	O

Steers	NNP	O	O
fed	VBD	O	O
diets	NNS	O	O
containing	VBG	O	O
SBM-U	NNP	O	O
had	VBD	O	O
12	CD	O	O
%	NN	O	O
less	JJR	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
.10	NNP	O	O
)	)	O	O
fat	VBZ	o	OPH
thickness	JJ	o	OPH
than	IN	O	O
those	DT	O	O
fed	JJ	O	O
diets	NNS	O	O
containing	VBG	O	O
SBM	NNP	O	O
.	.	O	O

Supplementation	NN	O	O
of	IN	O	O
diets	NNS	O	O
with	IN	O	O
increasing	VBG	O	O
levels	NNS	O	O
of	IN	O	O
RPLM	NNP	o	OPH
did	VBD	O	O
not	RB	O	O
affect	VB	O	O
(	(	O	O
P	NNP	O	O
>	NNP	O	O
.10	NNP	O	O
)	)	O	O
ADG	NNP	O	O
or	CC	O	O
carcass	NN	O	O
characteristics	NNS	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
DMI	NNP	O	O
and	CC	O	O
gain	NN	O	O
:	:	O	O
feed	NN	O	O
showed	VBD	O	O
cubic	JJ	o	OOt
(	(	o	OOt
P	NNP	o	OOt
<	NNP	o	OOt
.10	NNP	o	OOt
)	)	o	OOt
responses	VBZ	o	OOt
to	TO	O	O
increasing	VBG	O	O
dietary	JJ	O	O
level	NN	O	O
of	IN	O	O
RPLM	NNP	O	O
.	.	O	O

Supplementation	NN	O	O
of	IN	O	O
RPLM	NNP	O	O
at	IN	O	O
the	DT	O	O
10	CD	O	O
g/d	NNS	O	O
level	NN	O	O
improved	VBD	O	O
gain	NN	o	OPH
:	:	o	OPH
feed	VBN	o	OPH
by	IN	O	O
12	CD	O	O
%	NN	O	O
during	IN	O	O
the	DT	O	O
last	JJ	O	O
98	CD	O	O
d	NN	O	O
of	IN	O	O
the	DT	O	O
trial	NN	O	O
,	,	O	O
and	CC	O	O
this	DT	O	O
was	VBD	O	O
a	DT	O	O
direct	JJ	O	O
response	NN	O	O
to	TO	O	O
the	DT	O	O
cubic	JJ	O	O
effects	NNS	O	O
of	IN	O	O
RPLM	NNP	O	O
on	IN	O	O
DMI	NNP	O	O
.	.	O	O

Results	NNP	O	O
suggest	VBP	O	O
a	DT	O	O
cost	NN	O	O
advantage	NN	O	O
for	IN	O	O
replacing	VBG	O	O
50	CD	O	O
%	NN	O	O
of	IN	O	O
SBM-N	NNP	O	O
with	IN	O	O
that	DT	O	O
from	IN	O	O
urea	JJ	O	O
in	IN	O	O
high-corn	JJ	O	O
diets	NNS	O	O
without	IN	O	O
negative	JJ	O	O
effects	NNS	O	O
on	IN	O	O
feedlot	NN	O	O
performance	NN	O	O
or	CC	O	O
carcass	NN	O	O
characteristics	NNS	O	O
of	IN	O	O
growing-finishing	JJ	p	O
Holstein	NNP	p	PC
steers	NNS	p	PC
with	IN	p	O
extended	JJ	p	O
feeding	NN	p	O
periods	NNS	p	O
(	(	p	O
266	CD	p	O
d	NN	p	O
)	)	p	O
.	.	p	O

These	DT	O	O
types	NNS	O	O
of	IN	O	O
diets	NNS	O	O
seem	VBP	O	O
to	TO	O	O
meet	VB	O	O
the	DT	O	O
amino	NN	O	O
acid	NN	O	O
requirements	NNS	O	O
and	CC	O	O
are	VBP	O	O
not	RB	O	O
limiting	VBG	O	O
in	IN	O	O
lysine	NN	O	O
and	CC	O	O
methionine	NN	O	O
.	.	O	O

A	DT	O	O
randomized	VBN	O	O
,	,	O	O
controlled	VBN	O	O
study	NN	O	O
on	IN	O	O
the	DT	O	O
influence	NN	O	O
of	IN	O	O
acetaminophen	NN	i	IPM
,	,	i	O
diclofenac	NN	i	IPM
,	,	i	O
or	CC	i	O
naproxen	RB	i	IPM
on	IN	i	O
aspirin-induced	JJ	i	O
inhibition	NN	O	O
of	IN	O	O
platelet	NN	o	OPH
aggregation	NN	o	OPH
.	.	o	O

Nonsteroidal	NNP	i	IPM
anti-inflammatory	JJ	i	IPM
drugs	NNS	i	IPM
(	(	i	IPM
NSAID	NNP	i	IPM
)	)	i	IPM
may	MD	O	O
interfere	VB	O	O
with	IN	O	O
aspirin	NN	i	IPM
(	(	i	IPM
acetylsalicylic	JJ	i	IPM
acid	NN	i	IPM
)	)	i	IPM
and	CC	O	O
increase	VB	O	O
the	DT	O	O
risk	NN	O	O
for	IN	O	O
cardiovascular	JJ	o	OPH
events	NNS	o	OPH
.	.	o	O

The	DT	O	O
clinical	JJ	O	O
relevance	NN	O	O
is	VBZ	O	O
uncertain	JJ	O	O
.	.	O	O

The	DT	O	O
aim	NN	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
analyse	VB	O	O
the	DT	O	O
influence	NN	O	O
of	IN	O	O
a	DT	O	O
co-administration	NN	O	O
of	IN	O	O
aspirin	NN	i	IPM
and	CC	O	O
NSAID	NNP	i	IPM
on	IN	O	O
platelet	NN	o	OPH
aggregation	NN	o	OPH
.	.	o	O

In	IN	O	O
a	DT	O	O
randomized	JJ	O	O
,	,	O	O
placebo	NN	O	O
controlled	VBD	O	O
trial	NN	O	O
,	,	O	O
eleven	RB	p	O
healthy	JJ	p	O
volunteers	NNS	p	O
were	VBD	O	O
studied	VBN	O	O
during	IN	O	O
4	CD	O	O
separate	JJ	O	O
study	NN	O	O
periods	NNS	O	O
of	IN	O	O
4	CD	O	O
days	NNS	O	O
each	DT	O	O
.	.	O	O

Individuals	NNS	O	O
were	VBD	O	O
treated	VBN	O	O
on	IN	O	O
each	DT	O	O
occasion	NN	O	O
with	IN	O	O
100	CD	O	O
mg	NNS	O	O
aspirin	JJ	i	IPM
daily	RB	O	O
in	IN	O	O
combination	NN	O	O
with	IN	O	O
either	DT	O	O
3	CD	i	O
x	VBD	i	O
1	CD	i	O
g	NN	i	O
acetaminophen	NN	i	IPM
,	,	i	O
3	CD	i	O
x	NN	i	O
50	CD	i	O
mg	NN	i	O
diclofenac	NN	i	IPM
,	,	i	O
3	CD	i	O
x	NN	i	O
250	CD	i	O
mg	NN	i	O
naproxen	NN	i	IPM
,	,	i	O
or	CC	i	O
3	CD	i	O
x	JJ	i	O
1	CD	i	O
placebo	NN	i	IC
.	.	i	O

Primary	JJ	o	OPH
hemostasis	NN	o	OPH
was	VBD	O	O
assessed	VBN	O	O
with	IN	O	O
a	DT	O	O
platelet	NN	O	O
function	NN	O	O
analyser	NN	O	O
(	(	O	O
PFA-100	NNP	O	O
)	)	O	O
,	,	O	O
which	WDT	O	O
measures	VBZ	O	O
the	DT	o	OOt
closure	NN	o	OPH
time	NN	o	OPH
(	(	o	OPH
CT	NNP	o	OPH
)	)	o	OPH
of	IN	o	OOt
a	DT	o	OOt
collagen-	JJ	o	OOt
and	CC	o	OOt
epinephrine-coated	JJ	o	OOt
pore	NN	o	OOt
by	IN	o	OOt
aggregating	VBG	o	OOt
platelets	NNS	o	OOt
in	IN	o	OOt
flowing	VBG	o	OOt
blood	NN	o	OOt
.	.	o	O

Naproxen	NNP	i	IPM
enhanced	VBD	O	O
the	DT	O	O
anti-aggregatory	JJ	o	OPH
action	NN	o	OPH
of	IN	O	O
aspirin	NN	i	IPM
after	IN	O	O
24	CD	O	O
h	NN	O	O
(	(	o	O
CT	NNP	o	OPH
rising	VBG	O	O
from	IN	O	O
104+/-16	JJ	O	O
s	NN	O	O
at	IN	O	O
baseline	NN	O	O
to	TO	O	O
212+/-69	JJ	O	O
s	NN	O	O
at	IN	O	O
24	CD	O	O
h	NN	O	O
,	,	O	O
P	NNP	O	O
<	NNP	O	O
0.001	CD	O	O
)	)	O	O
,	,	O	O
which	WDT	O	O
was	VBD	O	O
not	RB	O	O
seen	VBN	O	O
with	IN	O	O
any	DT	O	O
other	JJ	O	O
drug	NN	O	O
combination	NN	O	O
.	.	O	O

Diclofenac	NNP	i	IPM
reduced	VBD	O	O
the	DT	O	O
anti-aggregatory	JJ	o	OPH
action	NN	o	OPH
of	IN	O	O
aspirin	NN	i	IPM
in	IN	O	O
the	DT	O	O
first	JJ	O	O
two	CD	O	O
days	NNS	O	O
,	,	O	O
since	IN	O	O
the	DT	O	O
CT	NNP	o	OPH
did	VBD	O	O
not	RB	O	O
rise	VB	O	O
significantly	RB	O	O
(	(	O	O
109+/-19	JJ	O	O
s	NN	O	O
,	,	O	O
148+/-56	JJ	O	O
s	NN	O	O
,	,	O	O
and	CC	O	O
168+/-66	JJ	O	O
s	NN	O	O
at	IN	O	O
0	CD	O	O
h	NN	O	O
,	,	O	O
24	CD	O	O
h	NN	O	O
,	,	O	O
48	CD	O	O
h	NN	O	O
,	,	O	O
respectively	RB	O	O
,	,	O	O
P	NNP	O	O
>	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

Acetaminophen	NNP	i	IPM
had	VBD	O	O
no	DT	O	O
effect	NN	O	O
compared	VBN	O	O
with	IN	O	O
placebo	NN	i	IC
.	.	i	O

After	IN	O	O
4	CD	O	O
days	NNS	O	O
of	IN	O	O
treatment	NN	O	O
platelet	NN	o	OPH
aggregation	NN	o	OPH
was	VBD	O	O
similarly	RB	O	O
inhibited	VBN	O	O
by	IN	O	O
all	DT	O	O
combinations	NNS	O	O
.	.	O	O

We	PRP	O	O
conclude	VBP	O	O
that	IN	O	O
a	DT	O	O
co-administration	NN	O	O
of	IN	O	O
NSAID	NNP	i	IPM
and	CC	O	O
aspirin	NN	i	IPM
may	MD	O	O
interfere	VB	O	O
with	IN	O	O
platelet	NN	o	OPH
inhibition	NN	o	OPH
at	IN	O	O
the	DT	O	O
beginning	NN	O	O
of	IN	O	O
a	DT	O	O
treatment	NN	O	O
with	IN	O	O
an	DT	O	O
increase	NN	O	O
of	IN	O	O
naproxen	JJ	i	IPM
and	CC	O	O
a	DT	O	O
decrease	NN	O	O
of	IN	O	O
diclofenac	NN	i	IPM
.	.	i	O

This	DT	O	O
effect	NN	O	O
is	VBZ	O	O
lost	VBN	O	O
after	IN	O	O
4	CD	O	O
days	NNS	O	O
,	,	O	O
suggesting	VBG	O	O
that	IN	O	O
a	DT	O	O
regular	JJ	O	O
daily	JJ	O	O
co-administration	NN	O	O
of	IN	O	O
NSAID	NNP	i	IPM
does	VBZ	O	O
not	RB	O	O
have	VB	O	O
an	DT	O	O
influence	NN	O	O
on	IN	O	O
platelet	NN	o	OPH
inhibition	NN	o	OPH
by	IN	O	O
aspirin	NN	i	IPM
.	.	i	O

Effect	NN	O	O
of	IN	O	O
adhesive	JJ	O	O
system	NN	O	O
type	NN	O	O
and	CC	O	O
tooth	DT	O	O
region	NN	O	O
on	IN	O	O
the	DT	O	O
bond	NN	O	O
strength	NN	O	O
to	TO	O	O
dentin	VB	O	O
.	.	O	O

PURPOSE	VB	O	O
This	DT	O	O
study	NN	O	O
evaluated	VBD	O	O
the	DT	O	O
bond	NN	O	O
strength	NN	O	O
of	IN	O	O
two	CD	O	O
etch-and-rinse	JJ	i	IPH
adhesive	JJ	i	IPH
systems	NNS	i	IPH
(	(	O	O
two-	JJ	O	O
and	CC	O	O
three-step	NN	O	O
)	)	O	O
and	CC	i	IPH
a	DT	i	IPH
self-etching	JJ	i	IPH
system	NN	i	IPH
to	TO	O	O
coronal	VB	o	OPH
and	CC	o	OPH
root	VB	o	OPH
canal	JJ	o	OPH
dentin	NN	o	OPH
.	.	o	O

MATERIALS	NNP	O	O
AND	CC	O	O
METHODS	NNP	O	O
The	DT	p	O
root	NN	p	O
canals	NNS	p	O
of	IN	p	O
30	CD	p	PSS
human	JJ	p	O
incisors	NNS	p	O
and	CC	p	O
canines	NNS	p	O
were	VBD	O	O
instrumented	VBN	O	O
and	CC	O	O
prepared	VBN	O	O
with	IN	O	O
burs	NNS	O	O
.	.	O	O

The	DT	O	O
posts	NNS	i	IPH
used	VBD	i	IPH
for	IN	i	IPH
luting	VBG	i	IPH
were	VBD	i	IPH
duplicated	VBN	i	IPH
with	IN	i	IPH
dual	JJ	i	IPH
resin	NN	i	IPH
cement	NN	i	IPH
(	(	i	IPH
Duo-link	NNP	i	IPH
)	)	i	IPH
inside	IN	i	IPH
Aestheti	NNP	i	IPH
Plus	NNP	i	IPH
#	#	i	IPH
2	CD	i	IPH
molds	NNS	i	IPH
.	.	i	O

Thus	RB	O	O
,	,	O	O
three	CD	O	O
groups	NNS	O	O
were	VBD	O	O
formed	VBN	O	O
(	(	O	O
n	JJ	O	O
=	NNP	O	O
10	CD	O	O
)	)	O	O
according	VBG	O	O
to	TO	O	O
the	DT	O	O
adhesive	JJ	O	O
system	NN	O	O
employed	VBN	O	O
:	:	O	O
All-Bond	JJ	i	IOt
2	CD	i	IOt
(	(	i	IOt
TE3	NNP	i	IOt
)	)	i	IOt
+	VBP	i	IOt
resin	JJ	i	IOt
cement	NN	i	IOt
post	NN	i	IOt
(	(	i	IOt
rcp	NN	i	IOt
)	)	i	IOt
+	VBZ	i	IOt
Duo-link	NNP	i	IOt
(	(	i	IOt
Dl	NNP	i	IOt
)	)	i	IOt
;	:	i	O
One-Step	JJ	i	IOt
Plus	NNP	i	IOt
(	(	i	IOt
TE2	NNP	i	IOt
)	)	i	IOt
+	VBP	i	IOt
rcp	JJ	i	IOt
+	NNP	i	IOt
Dl	NNP	i	IOt
;	:	i	IOt
Tyrian/One-Step	JJ	i	IOt
Plus	NNP	i	IOt
(	(	i	IOt
SE	NNP	i	IOt
)	)	i	IOt
+	VBP	i	IOt
rcp	JJ	i	IOt
+	NNP	i	IOt
Dl	NNP	i	IOt
.	.	i	O

Afterwards	NNP	O	O
,	,	O	O
8	CD	O	O
transverse	NN	O	O
sections	NNS	O	O
(	(	O	O
1.5	CD	O	O
mm	NN	O	O
)	)	O	O
were	VBD	O	O
cut	VBN	O	O
from	IN	O	O
4	CD	O	O
mm	NNS	O	O
above	IN	O	O
the	DT	O	O
CEJ	NNP	O	O
up	RB	O	O
to	TO	O	O
4	CD	O	O
mm	NNS	O	O
short	JJ	O	O
of	IN	O	O
the	DT	O	O
root	NN	O	O
canal	JJ	O	O
apex	NN	O	O
,	,	O	O
comprising	VBG	O	O
coronal	JJ	O	O
and	CC	O	O
root	JJ	O	O
canal	JJ	O	O
dentin	NN	O	O
.	.	O	O

The	DT	O	O
sections	NNS	O	O
were	VBD	O	O
submitted	VBN	O	O
to	TO	O	O
push-out	JJ	O	O
testing	NN	O	O
in	IN	O	O
a	DT	O	O
universal	JJ	O	O
testing	VBG	O	O
machine	NN	O	O
EMIC	NNP	O	O
(	(	O	O
1	CD	O	O
mm/min	NN	O	O
)	)	O	O
.	.	O	O

Bond	NNP	o	OOt
strength	NN	o	OOt
data	NNS	o	OOt
were	VBD	o	O
analyzed	VBN	o	O
with	IN	o	O
two-way	JJ	o	OOt
repeated	JJ	o	OOt
measures	NNS	o	OOt
ANOVA	NNP	o	OOt
and	CC	o	OOt
Tukey	NNP	o	OOt
's	POS	o	OOt
test	NN	o	OOt
(	(	O	O
p	JJ	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

RESULTS	VB	O	O
The	DT	O	O
relationship	NN	o	OOt
between	IN	o	OOt
the	DT	o	OOt
adhesives	NNS	o	OOt
was	VBD	O	O
not	RB	O	O
the	DT	O	O
same	JJ	O	O
in	IN	O	O
the	DT	O	O
different	JJ	O	O
regions	NNS	O	O
(	(	O	O
p	JJ	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

Comparison	NNP	O	O
of	IN	O	O
the	DT	O	O
means	NNS	O	O
achieved	VBN	O	O
with	IN	O	O
the	DT	O	O
adhesives	NNS	O	O
in	IN	O	O
each	DT	O	O
region	NN	O	O
(	(	O	O
Tukey	NNP	O	O
;	:	O	O
p	VBZ	O	O
<	$	O	O
0.05	CD	O	O
)	)	O	O
revealed	VBD	O	O
that	IN	O	O
TE3	NNP	O	O
(	(	O	O
mean	JJ	O	O
+/-	JJ	O	O
standard	NN	O	O
deviation	NN	O	O
:	:	O	O
5.22	CD	O	O
+/-	JJ	O	O
1.70	CD	O	O
)	)	O	O
was	VBD	O	O
higher	JJR	O	O
than	IN	O	O
TE2	NNP	O	O
(	(	O	O
2.60	CD	O	O
+/-	JJ	O	O
1.74	CD	O	O
)	)	O	O
and	CC	O	O
SE	NNP	O	O
(	(	O	O
1.68	CD	O	O
+/-	JJ	O	O
1.85	CD	O	O
)	)	O	O
.	.	O	O

CONCLUSION	NNP	O	O
Under	IN	O	O
the	DT	O	O
experimental	JJ	O	O
conditions	NNS	O	O
,	,	O	O
better	JJR	O	O
bonding	VBG	O	O
to	TO	O	O
dentin	VB	O	O
was	VBD	O	O
achieved	VBN	O	O
using	VBG	O	O
the	DT	O	O
three-step	JJ	O	O
etch-and-rinse	JJ	O	O
system	NN	O	O
,	,	O	O
especially	RB	O	O
in	IN	O	O
the	DT	O	O
coronal	JJ	O	O
region	NN	O	O
.	.	O	O

Therefore	RB	O	O
,	,	O	O
the	DT	O	O
traditional	JJ	O	O
etch-and-rinse	JJ	O	O
three-step	NN	O	O
adhesive	JJ	O	O
system	NN	O	O
seems	VBZ	O	O
to	TO	O	O
be	VB	O	O
the	DT	O	O
best	JJS	O	O
choice	NN	O	O
for	IN	O	O
teeth	NN	O	O
needing	VBG	O	O
adhesive	JJ	O	O
endodontic	JJ	O	O
restorations	NNS	O	O
.	.	O	O

Amphotericin	NNP	i	IPM
B	NNP	i	IPM
in	IN	p	O
children	NNS	p	O
with	IN	p	O
malignant	JJ	p	PC
disease	NN	p	PC
:	:	p	PC
a	DT	O	O
comparison	NN	O	O
of	IN	O	O
the	DT	O	O
toxicities	NNS	O	O
and	CC	O	O
pharmacokinetics	NNS	O	O
of	IN	O	O
amphotericin	NN	i	IPM
B	NNP	i	IPM
administered	VBN	i	IPM
in	IN	i	IPM
dextrose	JJ	i	IPM
versus	NN	i	O
lipid	JJ	i	IPM
emulsion	NN	i	IPM
.	.	i	O

In	IN	O	O
a	DT	O	O
prospective	JJ	O	O
,	,	O	O
randomized	JJ	O	O
clinical	JJ	O	O
trial	NN	O	O
,	,	O	O
the	DT	O	O
toxicity	NN	O	O
of	IN	O	O
1	CD	O	O
mg	NN	O	O
of	IN	O	O
amphotericin	NN	i	IPM
B	NNP	i	IPM
(	(	i	IPM
AmB	NNP	i	IPM
)	)	i	IPM
per	IN	O	O
kg	NN	O	O
of	IN	O	O
body	NN	O	O
weight	JJ	O	O
per	IN	O	O
day	NN	O	O
infused	VBN	O	O
in	IN	O	O
5	CD	O	O
%	NN	O	O
dextrose	NN	i	IPM
was	VBD	O	O
compared	VBN	O	O
with	IN	O	O
that	DT	O	O
of	IN	O	O
AmB	NNP	i	IPM
infused	VBD	i	IPM
in	IN	i	IPM
lipid	JJ	i	IPM
emulsion	NN	i	IPM
in	IN	O	O
children	NNS	p	O
with	IN	p	O
malignant	JJ	p	PC
disease	NN	p	PC
.	.	p	PC

In	IN	O	O
an	DT	O	O
analysis	NN	O	O
of	IN	O	O
82	CD	p	PSS
children	NNS	p	O
who	WP	p	O
received	VBD	p	O
a	DT	p	O
full	JJ	p	O
course	NN	p	O
of	IN	p	O
6	CD	p	O
days	NNS	p	O
or	CC	p	O
more	JJR	p	O
of	IN	p	O
AmB	NNP	i	IPM
(	(	p	O
117	CD	p	O
courses	NNS	p	O
)	)	p	O
,	,	O	O
it	PRP	O	O
was	VBD	O	O
shown	VBN	O	O
that	IN	O	O
there	EX	O	O
were	VBD	O	O
significant	JJ	O	O
increases	NNS	O	O
in	IN	O	O
plasma	JJ	O	O
urea	JJ	O	O
and	CC	O	O
creatinine	JJ	O	O
concentrations	NNS	O	O
and	CC	O	O
in	IN	O	O
potassium	NN	O	O
requirement	NN	O	O
after	IN	O	O
6	CD	O	O
days	NNS	O	O
of	IN	O	O
therapy	NN	O	O
with	IN	O	O
both	DT	O	O
AmB	NNP	i	IPM
infused	VBN	O	O
in	IN	O	O
dextrose	NN	i	IPM
and	CC	O	O
AmB	NNP	i	IPM
infused	VBD	O	O
in	IN	O	O
lipid	JJ	i	IPM
emulsion	NN	i	IPM
,	,	O	O
with	IN	O	O
there	EX	O	O
being	VBG	O	O
no	DT	O	O
difference	NN	O	O
between	IN	O	O
the	DT	O	O
two	CD	O	O
methods	NNS	O	O
of	IN	O	O
AmB	NNP	i	IPM
administration	NN	O	O
.	.	O	O

An	DT	O	O
intent-to-treat	JJ	O	O
comparison	NN	O	O
of	IN	O	O
the	DT	O	O
numbers	NNS	O	O
of	IN	O	O
courses	NNS	O	O
affected	VBN	O	O
by	IN	O	O
acute	JJ	O	O
toxicity	NN	O	O
(	(	O	O
fever	NN	O	O
,	,	O	O
rigors	NNS	O	O
)	)	O	O
and	CC	O	O
chronic	JJ	O	O
toxicity	NN	O	O
(	(	O	O
nephrotoxicity	NN	O	O
)	)	O	O
also	RB	O	O
indicated	VBD	O	O
that	IN	O	O
there	EX	O	O
was	VBD	O	O
no	DT	O	O
significant	JJ	O	O
difference	NN	O	O
between	IN	O	O
AmB	NNP	i	IPM
infused	VBD	i	O
in	IN	i	O
dextrose	NN	i	IPM
(	(	O	O
78	CD	O	O
courses	NNS	O	O
)	)	O	O
and	CC	O	O
AmB	NNP	i	IPM
infused	VBD	i	IPM
in	IN	i	IPM
lipid	JJ	i	IPM
emulsion	NN	i	IPM
(	(	O	O
84	CD	O	O
courses	NNS	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
pharmacokinetics	NNS	o	OPH
of	IN	o	OPH
AmB	NNP	o	OPH
were	VBD	O	O
investigated	VBN	O	O
in	IN	O	O
20	CD	O	O
children	NNS	O	O
who	WP	O	O
received	VBD	O	O
AmB	NNP	i	IPM
in	IN	i	O
dextrose	NN	i	IPM
and	CC	O	O
15	CD	O	O
children	NNS	O	O
who	WP	O	O
received	VBD	O	O
AmB	NNP	i	IPM
in	IN	i	IPM
lipid	JJ	i	IPM
emulsion	NN	i	IPM
.	.	i	O

Blood	NN	O	O
samples	NNS	O	O
were	VBD	O	O
collected	VBN	O	O
up	RB	O	O
to	TO	O	O
24	CD	O	O
h	NN	O	O
after	IN	O	O
administration	NN	O	O
of	IN	O	O
the	DT	O	O
first	JJ	O	O
dose	NN	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
concentration	NN	o	OPH
of	IN	o	OPH
AmB	NNP	o	OPH
in	IN	o	OPH
plasma	NN	o	OPH
was	VBD	O	O
analyzed	VBN	O	O
by	IN	O	O
a	DT	O	O
high-performance	NN	O	O
liquid	NN	O	O
chromatography	NN	O	O
assay	NN	O	O
.	.	O	O

The	DT	O	O
clearance	NN	o	OPH
(	(	o	OPH
CL	NNP	o	OPH
)	)	o	OPH
of	IN	o	OPH
AmB	NNP	o	OPH
in	IN	o	OPH
dextrose	NN	o	OPH
(	(	O	O
0.039	CD	O	O
+/-	JJ	O	O
0.016	CD	O	O
liter	NN	O	O
.	.	O	O

h-1	NN	O	O
.	.	O	O

kg-1	NN	O	O
)	)	O	O
was	VBD	O	O
significantly	RB	O	O
lower	JJR	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.005	CD	O	O
)	)	O	O
than	IN	O	O
the	DT	O	O
CL	NNP	O	O
of	IN	O	O
AmB	NNP	i	IPM
in	IN	i	IPM
lipid	JJ	i	IPM
emulsion	NN	i	IPM
(	(	O	O
0.062	CD	O	O
+/-	JJ	O	O
0	CD	O	O
.	.	O	O

024	CD	O	O
liter	NN	O	O
.	.	O	O

h-1	NN	O	O
.	.	O	O

kg-1	NN	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
steady-state	JJ	o	OPH
volume	NN	o	OPH
of	IN	o	OPH
distribution	NN	o	OPH
for	IN	o	OPH
AmB	NNP	o	OPH
in	IN	O	O
dextrose	NN	O	O
(	(	O	O
0.83	CD	O	O
+/-	JJ	O	O
0.33	CD	O	O
liter	NN	O	O
.	.	O	O

kg-1	NN	O	O
)	)	O	O
was	VBD	O	O
also	RB	O	O
significantly	RB	O	O
lower	JJR	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.005	CD	O	O
)	)	O	O
than	IN	O	O
that	DT	O	O
for	IN	O	O
AmB	NNP	i	IPM
in	IN	i	IPM
lipid	JJ	i	IPM
emulsion	NN	i	IPM
(	(	O	O
1.47	CD	O	O
+/-	JJ	O	O
0.77	CD	O	O
liter	NN	O	O
.	.	O	O

kg-1	NN	O	O
)	)	O	O
.	.	O	O

Although	IN	O	O
AmB	NNP	o	OPH
in	IN	o	OPH
lipid	JJ	o	OPH
emulsion	NN	o	OPH
is	VBZ	O	O
apparently	RB	O	O
cleared	VBN	O	O
faster	RBR	O	O
and	CC	O	O
distributes	VBZ	O	O
more	RBR	O	O
widely	RB	O	O
than	IN	O	O
AmB	NNP	o	OPH
in	IN	o	OPH
dextrose	NN	o	OPH
,	,	O	O
this	DT	O	O
study	NN	O	O
did	VBD	O	O
not	RB	O	O
reveal	VB	O	O
any	DT	O	O
significant	JJ	O	O
advantage	NN	O	O
with	IN	O	O
respect	NN	O	O
to	TO	O	O
safety	NN	o	OOt
and	CC	o	OOt
tolerance	NN	o	OOt
in	IN	O	O
the	DT	O	O
administration	NN	O	O
of	IN	O	O
AmB	NNP	i	IPM
in	IN	i	O
lipid	JJ	i	O
emulsion	NN	i	O
compared	VBN	O	O
to	TO	O	O
its	PRP$	O	O
administration	NN	O	O
in	IN	O	O
dextrose	NN	i	IPM
in	IN	O	O
children	NNS	p	PA
with	IN	p	O
malignant	JJ	p	PC
disease	NN	p	PC
.	.	p	O

Randomized	VBN	O	O
,	,	O	O
placebo-controlled	JJ	i	IC
,	,	O	O
crossover	NN	O	O
study	NN	O	O
of	IN	O	O
methylphenidate	NN	i	IPM
for	IN	O	O
attention-deficit/hyperactivity	NN	O	O
disorder	NN	O	O
symptoms	NNS	O	O
in	IN	p	O
preschoolers	NNS	p	O
with	IN	p	O
developmental	JJ	p	O
disorders	NNS	p	O
.	.	p	O

OBJECTIVE	IN	O	O
The	DT	O	O
aim	NN	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
investigate	VB	O	O
the	DT	O	O
short-term	JJ	O	O
efficacy	NN	o	OOt
and	CC	O	O
safety	NN	O	O
of	IN	O	O
methylphenidate	NN	i	IPM
(	(	i	IPM
MPH	NNP	i	IPM
)	)	i	IPM
to	TO	O	O
treat	VB	O	O
attention-deficit/hyperactivity	JJ	O	O
disorder	NN	O	O
(	(	O	O
ADHD	NNP	O	O
)	)	O	O
symptoms	NNS	O	O
in	IN	O	O
an	DT	O	O
understudied	JJ	p	O
population	NN	p	O
of	IN	p	O
preschoolers	NNS	p	O
with	IN	p	O
pervasive	JJ	p	O
developmental	JJ	p	O
disorder	NN	p	O
(	(	p	O
PDD	NNP	p	O
)	)	p	O
or	CC	p	O
intellectual	JJ	p	O
disability	NN	p	O
(	(	p	O
ID	NNP	p	O
)	)	p	O
.	.	p	O

METHODS	NNP	O	O
Fourteen	NNP	p	O
preschoolers	NNS	p	O
with	IN	p	O
developmental	JJ	p	O
disorders	NNS	p	O
(	(	p	O
DD	NNP	p	O
,	,	p	O
n	JJ	p	O
=	VBP	p	O
14	CD	p	O
;	:	p	O
PDD	NNP	p	O
,	,	p	O
n	JJ	p	O
=	VBP	p	O
12	CD	p	O
;	:	p	O
ID	NNP	p	O
,	,	p	O
n	JJ	p	O
=	NNP	p	O
2	CD	p	O
)	)	p	O
underwent	NN	O	O
MPH	NNP	i	IPM
titration	NN	i	IPM
in	IN	O	O
a	DT	O	O
single-blind	JJ	O	O
manner	NN	O	O
followed	VBN	O	O
by	IN	O	O
a	DT	O	O
4-week	JJ	O	O
double-blind	NN	O	O
crossover	NN	O	O
phase	NN	O	O
.	.	O	O

Each	DT	O	O
child	NN	O	O
was	VBD	O	O
administered	VBN	O	O
placebo	NN	i	IC
for	IN	O	O
2	CD	O	O
weeks	NNS	O	O
and	CC	O	O
optimal	JJ	i	IPM
dose	NN	i	IPM
for	IN	O	O
2	CD	O	O
weeks	NNS	O	O
.	.	O	O

The	DT	O	O
primary	JJ	O	O
outcome	NN	O	O
measure	NN	O	O
was	VBD	O	O
the	DT	O	O
Diagnostic	NNP	o	OME
and	CC	o	OME
Statistical	NNP	o	OME
Manual	NNP	o	OME
of	IN	o	OME
Mental	NNP	o	OME
Disorders	NNP	o	OME
,	,	o	OME
4	CD	o	OME
(	(	o	OME
th	NN	o	OME
)	)	o	OME
edition	NN	o	OME
(	(	o	OME
DSM-IV	NNP	o	OME
)	)	o	OME
ADHD	NNP	o	OME
subscale	NN	o	OME
of	IN	o	OME
the	DT	o	OME
Conners	NNP	o	OME
'	POS	o	OME
Parent	NN	o	OME
Rating	VBG	o	OME
Scale-Revised	JJ	o	OME
(	(	O	O
CPRS-R-DSM-IV-ADHD	NNP	O	O
)	)	O	O
.	.	O	O

RESULTS	NNP	O	O
MPH	NNP	i	IPM
improved	VBD	O	O
parent-rated	JJ	o	OME
ADHD	NNP	o	OME
symptoms	NNS	o	OME
of	IN	O	O
the	DT	O	O
preschoolers	NNS	O	O
;	:	O	O
50	CD	O	O
%	NN	O	O
were	VBD	O	O
rated	VBN	O	O
as	IN	O	O
responders	NNS	O	O
.	.	O	O

The	DT	O	O
CPRS-R-DSM-IV-ADHD	JJ	o	OME
subscale	NN	o	OME
was	VBD	O	O
significant	JJ	O	O
for	IN	O	O
the	DT	O	O
PDD	NNP	p	O
subgroup	NN	p	O
(	(	O	O
p	JJ	O	O
=	NN	O	O
0.005	CD	O	O
,	,	O	O
Cohen	NNP	O	O
d	VBZ	O	O
=	NNP	O	O
0.97	CD	O	O
)	)	O	O
and	CC	O	O
marginally	RB	O	O
significant	JJ	O	O
for	IN	O	O
the	DT	O	O
entire	JJ	O	O
DD	NNP	O	O
sample	NN	O	O
(	(	O	O
p	JJ	O	O
=	NN	O	O
0.08	CD	O	O
,	,	O	O
Cohen	NNP	O	O
d	VBZ	O	O
=	NNP	O	O
0.50	CD	O	O
)	)	O	O
.	.	O	O

Half	NN	O	O
of	IN	O	O
the	DT	O	O
preschoolers	NNS	p	O
experienced	VBD	O	O
side	JJ	o	OA
effects	NNS	o	OA
with	IN	O	O
MPH	NNP	i	IPM
,	,	O	O
including	VBG	O	O
reports	NNS	O	O
of	IN	O	O
increased	VBN	O	O
stereotypic	NN	o	OME
behavior	NN	o	OME
,	,	o	OME
upset	JJ	o	OME
stomach	NN	o	OME
,	,	o	OME
sleep-related	JJ	o	OME
difficulties	NNS	o	OME
,	,	o	OME
and	CC	o	OME
emotional	JJ	o	OME
lability	NN	o	OME
.	.	o	O

One	CD	O	O
child	NN	O	O
discontinued	VBN	O	O
during	IN	O	O
titration	NN	O	O
due	JJ	O	O
to	TO	O	O
side	VB	O	O
effects	NNS	O	O
.	.	O	O

CONCLUSION	VB	O	O
The	DT	O	O
predominant	JJ	O	O
direction	NN	O	O
of	IN	O	O
response	NN	O	O
in	IN	O	O
these	DT	O	O
preschoolers	NNS	p	O
with	IN	p	O
both	DT	p	O
ADHD	NNP	p	O
and	CC	p	O
PDD/ID	NNP	p	O
favored	VBD	O	O
MPH	NNP	i	IPM
,	,	O	O
even	RB	O	O
though	IN	O	O
the	DT	O	O
response	NN	O	O
was	VBD	O	O
more	RBR	O	O
subtle	JJ	O	O
and	CC	O	O
variable	JJ	O	O
than	IN	O	O
in	IN	O	O
older	JJR	O	O
and	CC	O	O
typically	RB	O	O
developing	VBG	O	O
children	NNS	O	O
.	.	O	O

Due	NNP	O	O
to	TO	O	O
high	JJ	O	O
rates	NNS	O	O
of	IN	O	O
adverse	JJ	O	O
effects	NNS	O	O
,	,	O	O
preschoolers	NNS	O	O
should	MD	O	O
be	VB	O	O
monitored	VBN	O	O
closely	RB	O	O
.	.	O	O

Effect	NN	O	O
of	IN	O	O
intravenous	JJ	i	IPM
fructose-1,6-diphosphate	NN	i	IPM
on	IN	O	O
myocardial	JJ	o	OPH
contractility	NN	o	OPH
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
left	JJ	p	PC
ventricular	JJ	p	PC
dysfunction	NN	p	PC
.	.	p	O

STUDY	NNP	O	O
OBJECTIVE	NNP	O	O
To	TO	O	O
examine	VB	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
fructose-1,6-diphosphate	NN	i	IPM
on	IN	O	O
myocardial	JJ	o	OPH
performance	NN	o	OPH
using	VBG	O	O
nuclear	JJ	O	O
scintigraphy	NN	O	O
.	.	O	O

DESIGN	NNP	O	O
Prospective	NNP	O	O
,	,	O	O
randomized	VBD	O	O
,	,	O	O
single-blind	JJ	O	O
,	,	O	O
parallel	JJ	O	O
study	NN	O	O
.	.	O	O

SETTING	NNP	O	O
Urban	NNP	p	O
teaching	VBG	p	O
hospital	JJ	p	O
clinical	JJ	p	O
research	NN	p	O
center	NN	p	O
.	.	p	O

PATIENTS	JJ	O	O
Individuals	NNS	p	O
with	IN	p	O
New	NNP	p	O
York	NNP	p	O
Heart	NNP	p	O
Association	NNP	p	O
functional	JJ	p	O
class	NN	p	O
II-III	NNP	p	O
heart	NN	p	PC
failure	NN	p	PC
(	(	p	O
mild	JJ	p	O
to	TO	p	O
moderate	VB	p	O
)	)	p	O
.	.	p	O

INTERVENTIONS	JJ	O	O
Subjects	NNPS	O	O
received	VBD	O	O
either	DT	O	O
intravenous	JJ	i	IPM
fructose-1,6-diphosphate	JJ	i	IPM
125	CD	i	IPM
mg/kg	NN	i	IPM
or	CC	i	O
normal	JJ	i	IPM
saline	JJ	i	IPM
1.3	CD	O	O
ml/kg	NN	O	O
every	DT	O	O
12	CD	O	O
hours	NNS	O	O
over	IN	O	O
10	CD	O	O
minutes	NNS	O	O
for	IN	O	O
four	CD	O	O
consecutive	JJ	O	O
doses	NNS	O	O
.	.	O	O

Left	NNP	O	O
ventricular	JJ	O	O
performance	NN	O	O
was	VBD	O	O
assessed	VBN	O	O
by	IN	O	O
radionuclide	NN	i	IPH
ventriculography	NN	i	IPH
at	IN	O	O
baseline	NN	O	O
and	CC	O	O
within	IN	O	O
60	CD	O	O
minutes	NNS	O	O
after	IN	O	O
the	DT	O	O
fourth	JJ	O	O
infusion	NN	O	O
.	.	O	O

Vital	JJ	O	O
signs	NNS	O	O
were	VBD	O	O
monitored	VBN	O	O
throughout	IN	O	O
the	DT	O	O
study	NN	O	O
period	NN	O	O
.	.	O	O

MEASUREMENTS	NNP	O	O
AND	CC	O	O
MAIN	NNP	O	O
RESULTS	NNP	O	O
Fructose-1,6-diphosphate	NNP	i	IPM
resulted	VBD	O	O
in	IN	O	O
a	DT	O	O
modest	JJ	O	O
7	CD	O	O
%	NN	O	O
increase	NN	O	O
in	IN	O	O
left	JJ	o	OPH
ventricular	JJ	o	OPH
ejection	NN	o	OPH
fraction	NN	o	OPH
(	(	O	O
p	JJ	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

Peak	JJ	o	OPH
ejection	NN	o	OPH
rate	NN	o	OPH
and	CC	o	OPH
peak	VB	o	OPH
diastolic	JJ	o	OPH
filling	VBG	o	OPH
rate	NN	o	OPH
did	VBD	O	O
not	RB	O	O
change	VB	O	O
significantly	RB	O	O
.	.	O	O

There	EX	O	O
were	VBD	O	O
no	DT	O	O
changes	NNS	O	O
in	IN	O	O
blood	NN	o	OPH
pressure	NN	o	OPH
or	CC	o	OPH
heart	NN	o	OPH
rate	NN	o	OPH
with	IN	O	O
either	DT	O	O
fructose-1,6-diphosphate	JJ	i	IPM
or	CC	O	O
placebo	NN	i	IC
.	.	i	O

CONCLUSIONS	NNP	O	O
Fructose-1,6-diphosphate	NNP	i	IPM
produces	VBZ	O	O
a	DT	O	O
modest	JJ	O	O
but	CC	O	O
significant	JJ	O	O
increase	NN	O	O
in	IN	O	O
left	JJ	o	OPH
ventricular	JJ	o	OPH
ejection	NN	o	OPH
fraction	NN	o	OPH
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
mild	JJ	p	O
to	TO	p	O
moderate	VB	p	O
heart	NN	p	PC
failure	NN	p	PC
.	.	p	O

Preschool	NNP	O	O
based	VBN	O	O
JASPER	NNP	i	IE
intervention	NN	i	IE
in	IN	O	O
minimally	RB	p	O
verbal	JJ	p	O
children	NNS	p	O
with	IN	p	O
autism	NN	p	O
:	:	p	O
pilot	NN	O	O
RCT	NNP	O	O
.	.	O	O

In	IN	O	O
this	DT	O	O
pilot	NN	O	O
study	NN	O	O
,	,	O	O
we	PRP	O	O
tested	VBD	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
a	DT	O	O
novel	JJ	O	O
intervention	NN	O	O
(	(	i	IE
JASPER	NNP	i	IE
,	,	i	IE
Joint	NNP	i	IE
Attention	NNP	i	IE
Symbolic	NNP	i	IE
Play	NNP	i	IE
Engagement	NNP	i	IE
and	CC	i	IE
Regulation	NNP	i	IE
)	)	i	IE
on	IN	O	O
3	CD	p	O
to	TO	p	O
5	CD	p	O
year	NN	p	O
old	JJ	p	O
,	,	p	O
minimally	RB	p	O
verbal	JJ	p	O
children	NNS	p	O
with	IN	p	O
autism	NN	p	O
who	WP	p	O
were	VBD	p	O
attending	VBG	p	O
a	DT	p	O
non-public	JJ	p	O
preschool	NN	p	O
.	.	p	O

Participants	NNS	O	O
were	VBD	i	O
randomized	VBN	i	O
to	TO	i	O
a	DT	i	O
control	NN	i	O
group	NN	i	O
(	(	i	O
treatment	NN	i	O
as	IN	i	O
usual	JJ	i	O
,	,	i	O
30	CD	i	O
h	NN	i	O
of	IN	i	O
ABA-based	JJ	i	O
therapy	NN	i	O
per	IN	i	O
week	NN	i	O
)	)	i	O
or	CC	i	O
a	DT	i	O
treatment	NN	i	O
group	NN	i	O
(	(	i	O
substitution	NN	i	O
of	IN	i	O
30	CD	i	O
min	NN	i	O
of	IN	i	O
JASPER	NNP	i	O
treatment	NN	i	O
,	,	i	O
twice	RB	i	O
weekly	RB	i	O
during	IN	i	O
their	PRP$	i	O
regular	JJ	i	O
program	NN	i	O
)	)	i	O
.	.	i	O

A	DT	i	O
baseline	NN	O	O
of	IN	O	O
12	CD	O	O
weeks	NNS	O	O
in	IN	O	O
which	WDT	O	O
no	DT	O	O
changes	NNS	O	O
were	VBD	O	O
noted	VBN	O	O
in	IN	O	O
core	NN	o	OME
deficits	NNS	o	OME
was	VBD	o	O
followed	VBN	O	O
by	IN	O	O
12	CD	O	O
weeks	NNS	O	O
of	IN	O	O
intervention	NN	O	O
for	IN	O	O
children	NNS	O	O
randomized	VBN	O	O
to	TO	O	O
the	DT	O	O
JASPER	NNP	i	O
treatment	NN	i	O
.	.	O	O

Participants	NNS	O	O
in	IN	O	O
the	DT	O	O
treatment	NN	O	O
group	NN	O	O
demonstrated	VBD	O	O
greater	JJR	o	O
play	NN	o	OME
diversity	NN	o	OME
on	IN	o	O
a	DT	o	O
standardized	JJ	o	O
assessment	NN	o	O
.	.	o	O

Effects	NNS	o	O
also	RB	O	O
generalized	VBD	O	O
to	TO	O	O
the	DT	O	O
classroom	NN	O	O
,	,	O	O
where	WRB	O	O
participants	NNS	O	O
in	IN	O	O
the	DT	O	O
treatment	NN	O	O
group	NN	O	O
initiated	VBD	O	O
more	JJR	O	O
gestures	NNS	o	O
and	CC	o	O
spent	VB	o	O
less	JJR	o	O
time	NN	o	O
unengaged	JJ	o	O
.	.	o	O

These	DT	o	O
results	NNS	O	O
provide	VBP	O	O
further	JJ	O	O
support	NN	O	O
that	WDT	O	O
even	RB	O	O
brief	VBP	O	O
,	,	O	O
targeted	JJ	O	O
interventions	NNS	O	O
on	IN	O	O
joint	JJ	O	O
attention	NN	O	O
and	CC	O	O
play	NN	O	O
can	MD	O	O
improve	VB	o	O
core	NN	o	O
deficits	NNS	o	O
in	IN	o	O
minimally	RB	p	O
verbal	JJ	p	O
children	NNS	p	O
with	IN	p	O
ASD	NNP	p	O
.	.	O	O

Serum	NNP	O	O
selenium	NN	i	IPM
concentration	NN	O	O
and	CC	O	O
antioxidant	JJ	O	O
activity	NN	O	O
in	IN	O	O
cervical	JJ	p	PC
cancer	NN	p	PC
patients	NNS	p	O
before	IN	p	O
and	CC	p	O
after	IN	p	O
treatment	NN	p	O
.	.	p	O

AIM	NNP	O	O
In	IN	O	O
the	DT	O	O
present	JJ	O	O
study	NN	O	O
,	,	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
chemo	NN	O	O
and	CC	O	O
radio	NN	O	O
therapies	NNS	O	O
on	IN	O	O
serum	NN	O	O
trace	NN	O	O
elements	NNS	O	O
content	NN	O	O
and	CC	O	O
antioxidant	JJ	o	OPH
activity	NN	o	OPH
in	IN	O	O
blood	NN	O	O
serum	NN	O	O
of	IN	O	O
cervical	JJ	p	PC
cancer	NN	p	PC
patients	NNS	p	O
was	VBD	O	O
evaluated	VBN	O	O
.	.	O	O

METHODS	NNP	O	O
Among	IN	O	O
104	CD	p	PSS
cervical	JJ	p	O
cancer	NN	p	O
patients	NNS	p	O
selected	VBN	p	O
for	IN	p	O
the	DT	p	O
present	JJ	p	O
study	NN	p	O
,	,	p	O
54	CD	p	PSS
and	CC	p	O
50	CD	p	PSS
patients	NNS	p	O
were	VBD	p	O
treated	VBN	p	O
with	IN	p	O
chemo-	JJ	i	IPH
and	CC	i	IPH
radiotherapy	NN	i	IPH
respectively	RB	p	O
.	.	p	O

Plasma	NNP	O	O
Se	NNP	O	O
,	,	O	O
Zn	NNP	O	O
,	,	O	O
Cu	NNP	O	O
and	CC	O	O
some	DT	O	O
enzymatic	JJ	O	O
antioxidants	NNS	O	O
activities	NNS	O	O
were	VBD	O	O
estimated	VBN	O	O
in	IN	O	O
serum	NN	O	O
before	IN	O	O
and	CC	O	O
after	IN	O	O
the	DT	O	O
treatment	NN	O	O
.	.	O	O

RESULTS	VB	O	O
The	DT	O	O
decreased	JJ	O	O
levels	NNS	O	O
of	IN	O	O
serum	NN	o	OPH
trace	NN	o	OPH
elements	NNS	o	OPH
,	,	o	O
glutathione	NN	o	OPH
peroxidase	NN	o	OPH
activity	NN	o	OPH
and	CC	o	OPH
total	JJ	o	OPH
antioxidant	JJ	o	OPH
capacity	NN	o	OPH
,	,	o	O
and	CC	o	O
increased	VBD	o	O
malondialdehyde	NN	o	OPH
,	,	o	OPH
glutathion	NN	o	OPH
reductase	NN	o	OPH
was	VBD	O	O
observed	VBN	O	O
in	IN	O	O
cervical	JJ	p	PC
cancer	NN	p	PC
patients	NNS	p	O
when	WRB	O	O
compared	VBN	O	O
to	TO	O	O
healthy	JJ	O	O
controls	NNS	O	O
.	.	O	O

The	DT	O	O
increased	JJ	O	O
concentration	NN	o	OPH
of	IN	o	OPH
serum	NN	o	OPH
Se	NNP	o	OPH
,	,	o	OPH
Zn	NNP	o	OPH
was	VBD	O	O
observed	VBN	O	O
in	IN	O	O
patients	NNS	p	O
treated	VBN	p	O
with	IN	p	O
chemotherapy	NN	i	IPM
.	.	i	O

Simultaneously	RB	O	O
there	EX	O	O
was	VBD	O	O
a	DT	O	O
significant	JJ	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.001	CD	O	O
)	)	O	O
increase	NN	O	O
in	IN	O	O
glutathione	JJ	o	OPH
peroxidase	NN	o	OPH
and	CC	o	OPH
total	JJ	o	OPH
antioxidant	JJ	o	OPH
capacity	NN	o	OPH
,	,	O	O
and	CC	O	O
significant	JJ	O	O
decrease	NN	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
in	IN	O	O
malondialdehyde	NN	o	OPH
and	CC	o	OPH
glutathion	NN	o	OPH
reductase	NN	o	OPH
levels	NNS	o	OPH
in	IN	O	O
the	DT	O	O
serum	NN	O	O
of	IN	O	O
patients	NNS	O	O
treated	VBN	O	O
with	IN	O	O
chemotherapy	NN	i	IPM
compared	VBN	O	O
to	TO	O	O
the	DT	O	O
patients	NNS	O	O
treated	VBN	O	O
with	IN	O	O
radiotherapy	NN	i	IPH
.	.	i	O

CONCLUSION	VB	O	O
The	DT	O	O
results	NNS	O	O
demonstrated	VBD	O	O
that	IN	O	O
chemotherapy	NN	i	IPM
but	CC	O	O
not	RB	O	O
radiotherapy	JJ	i	IPH
results	NNS	O	O
in	IN	O	O
significant	JJ	O	O
increase	NN	O	O
in	IN	O	O
the	DT	O	O
trace	NN	o	OPH
elements	NNS	o	OPH
levels	NNS	o	OPH
and	CC	o	OPH
antioxidant	JJ	o	OPH
activities	NNS	o	OPH
in	IN	O	O
blood	NN	O	O
serum	NN	O	O
of	IN	O	O
cervical	JJ	p	PC
cancer	NN	p	PC
patients	NNS	p	O
.	.	p	O

Cognitive	JJ	i	IE
behavioral	JJ	i	IE
therapy	NN	i	IE
for	IN	O	O
anxiety	NN	o	OME
in	IN	p	PC
children	NNS	p	PC
with	IN	p	PC
autism	NN	p	PC
spectrum	NN	p	PC
disorders	NNS	p	PC
:	:	p	PC
a	DT	O	O
randomized	NN	O	O
,	,	O	O
controlled	VBN	O	O
trial	NN	O	O
.	.	O	O

BACKGROUND	NNP	O	O
Children	NNP	p	O
with	IN	p	O
autism	NN	p	O
spectrum	NN	p	O
disorders	NNS	p	O
often	RB	O	O
present	JJ	O	O
with	IN	O	O
comorbid	NN	p	O
anxiety	NN	p	O
disorders	NNS	p	O
that	WDT	p	O
cause	VBP	p	O
significant	JJ	p	O
functional	JJ	o	OME
impairment	NN	o	OME
.	.	o	O

This	DT	O	O
study	NN	O	O
tested	VBD	O	O
a	DT	O	O
modular	JJ	i	O
cognitive	JJ	i	IE
behavioral	JJ	i	IE
therapy	NN	i	IE
(	(	i	IE
CBT	NNP	i	IE
)	)	i	IE
program	NN	O	O
for	IN	O	O
children	NNS	O	O
with	IN	O	O
this	DT	O	O
profile	NN	O	O
.	.	O	O

A	DT	O	O
standard	JJ	O	O
CBT	NNP	i	IE
program	NN	O	O
was	VBD	O	O
augmented	VBN	O	O
with	IN	O	O
multiple	JJ	O	O
treatment	NN	O	O
components	NNS	O	O
designed	VBN	O	O
to	TO	O	O
accommodate	VB	O	O
or	CC	O	O
remediate	VB	O	O
the	DT	O	O
social	JJ	O	O
and	CC	O	O
adaptive	JJ	O	O
skill	NN	O	O
deficits	NNS	O	O
of	IN	O	O
children	NNS	p	O
with	IN	p	O
ASD	NNP	p	O
that	WDT	O	O
could	MD	O	O
pose	VB	O	O
barriers	NNS	O	O
to	TO	O	O
anxiety	VB	o	OME
reduction	NN	o	OME
.	.	o	O

METHOD	NNP	O	O
Forty	NNP	p	O
children	NNS	p	O
(	(	p	O
7-11	CD	p	O
years	NNS	p	O
old	JJ	p	O
)	)	p	O
were	VBD	p	O
randomly	RB	p	O
assigned	VBN	p	O
to	TO	O	O
16	CD	O	O
sessions	NNS	O	O
of	IN	O	O
CBT	NNP	i	IE
or	CC	O	O
a	DT	O	O
3-month	JJ	i	IE
waitlist	NN	i	IE
(	(	O	O
36	CD	O	O
completed	VBN	O	O
treatment	NN	O	O
or	CC	O	O
waitlist	NN	O	O
)	)	O	O
.	.	O	O

Therapists	NNS	O	O
worked	VBD	O	O
with	IN	O	O
individual	JJ	O	O
families	NNS	O	O
.	.	O	O

The	DT	O	O
CBT	NNP	i	IE
model	NN	O	O
emphasized	VBD	O	O
behavioral	JJ	O	O
experimentation	NN	O	O
,	,	O	O
parent-training	NN	O	O
,	,	O	O
and	CC	O	O
school	NN	O	O
consultation	NN	O	O
.	.	O	O

Independent	JJ	O	O
evaluators	NNS	O	O
blind	VBP	O	O
to	TO	O	O
treatment	NN	O	O
condition	NN	O	O
conducted	VBN	O	O
structured	JJ	O	O
diagnostic	JJ	O	O
interviews	NNS	O	O
and	CC	O	O
parents	NNS	O	O
and	CC	O	O
children	NNS	O	O
completed	VBN	O	O
anxiety	NN	o	OME
symptom	NN	o	OME
checklists	NNS	o	OME
at	IN	O	O
baseline	NN	O	O
and	CC	O	O
posttreatment/postwaitlist	NN	O	O
.	.	O	O

RESULTS	NNP	O	O
In	IN	O	O
intent-to-treat	JJ	O	O
analyses	NNS	O	O
,	,	O	O
78.5	CD	O	O
%	NN	O	O
of	IN	O	O
the	DT	O	O
CBT	NNP	i	IE
group	NN	O	O
met	VBD	O	O
Clinical	JJ	o	OME
Global	NNP	o	OME
Impressions-Improvement	NNP	o	OME
scale	NN	o	OME
criteria	NNS	o	OME
for	IN	O	O
positive	JJ	O	O
treatment	NN	O	O
response	NN	O	O
at	IN	O	O
posttreatment	NN	O	O
,	,	O	O
as	IN	O	O
compared	VBN	O	O
to	TO	O	O
only	RB	O	O
8.7	CD	O	O
%	NN	O	O
of	IN	O	O
the	DT	O	O
waitlist	NN	i	IE
group	NN	O	O
.	.	O	O

CBT	NNP	i	IE
also	RB	O	O
outperformed	VBD	O	O
the	DT	O	O
waitlist	NN	i	IE
on	IN	O	O
diagnostic	JJ	O	O
outcomes	NNS	O	O
and	CC	O	O
parent	NN	o	OME
reports	NNS	o	OME
of	IN	o	OME
child	NN	o	OME
anxiety	NN	o	OME
,	,	O	O
but	CC	O	O
not	RB	O	O
children	NNS	O	O
's	POS	O	O
self-reports	NNS	O	O
.	.	O	O

Treatment	NN	O	O
gains	NNS	O	O
were	VBD	O	O
maintained	VBN	O	O
at	IN	O	O
3-month	JJ	O	O
follow-up	NN	O	O
.	.	O	O

CONCLUSIONS	VB	O	O
The	DT	O	O
CBT	NNP	i	IE
manual	JJ	O	O
employed	VBN	O	O
in	IN	O	O
this	DT	O	O
study	NN	O	O
is	VBZ	O	O
one	CD	O	O
of	IN	O	O
the	DT	O	O
first	JJ	O	O
adaptations	NNS	O	O
of	IN	O	O
an	DT	O	O
evidence-based	JJ	O	O
treatment	NN	O	O
for	IN	O	O
children	NNS	O	O
with	IN	O	O
autism	NN	O	O
spectrum	NN	O	O
disorders	NNS	O	O
.	.	O	O

Remission	NN	O	O
of	IN	O	O
anxiety	NN	o	OME
disorders	NNS	o	O
appears	VBZ	O	O
to	TO	O	O
be	VB	O	O
an	DT	O	O
achievable	JJ	O	O
goal	NN	O	O
among	IN	O	O
high-functioning	JJ	O	O
children	NNS	O	O
with	IN	O	O
autism	NN	O	O
.	.	O	O

Reversal	NNP	O	O
of	IN	O	O
skeletal	JJ	O	O
effects	NNS	o	OOt
of	IN	O	O
endocrine	NN	i	O
treatments	NNS	i	O
in	IN	O	O
the	DT	O	O
Intergroup	NNP	O	O
Exemestane	NNP	O	O
Study	NNP	O	O
.	.	O	O

The	DT	O	O
adjuvant	JJ	O	O
use	NN	O	O
of	IN	O	O
aromatase	NN	i	IPM
inhibitors	NNS	i	IPM
in	IN	O	O
breast	NN	O	O
cancer	NN	O	O
is	VBZ	O	O
associated	VBN	O	O
with	IN	O	O
adverse	JJ	O	O
effects	NNS	O	O
on	IN	O	O
bone	NN	O	O
health	NN	O	O
.	.	O	O

We	PRP	O	O
previously	RB	O	O
reported	VBD	O	O
a	DT	O	O
decline	NN	O	O
in	IN	O	O
bone	JJ	O	O
mineral	JJ	O	O
density	NN	O	O
(	(	O	O
BMD	NNP	O	O
)	)	O	O
following	VBG	O	O
the	DT	O	O
switch	NN	O	O
from	IN	O	O
tamoxifen	NN	i	IPM
to	TO	O	O
exemestane	VB	i	IPM
in	IN	O	O
the	DT	O	O
Intergroup	NNP	O	O
Exemestane	NNP	O	O
Study	NNP	O	O
(	(	O	O
IES	NNP	O	O
)	)	O	O
.	.	O	O

Here	RB	O	O
we	PRP	O	O
report	VBP	O	O
effects	NNS	O	O
of	IN	O	O
endocrine	JJ	i	IPM
treatment	NN	i	IPM
withdrawal	NN	O	O
on	IN	O	O
BMD	NNP	O	O
,	,	O	O
bone	NN	O	O
turnover	NN	O	O
markers	NNS	O	O
(	(	O	O
BTM	NNP	O	O
)	)	O	O
and	CC	O	O
fracture	JJ	O	O
rates	NNS	O	O
.	.	O	O

4,724	CD	p	PSS
patients	NNS	p	O
took	VBD	p	O
part	NN	p	O
in	IN	p	O
IES	NNP	p	O
,	,	p	O
and	CC	p	O
206	CD	p	PSS
patients	NNS	p	O
were	VBD	p	O
included	VBN	p	O
in	IN	p	O
a	DT	p	O
bone	NN	p	O
sub-study	NN	p	O
.	.	p	O

BMD	NNP	O	O
and	CC	O	O
BTM	NNP	O	O
were	VBD	O	O
assessed	VBN	O	O
pre-randomization	NN	O	O
,	,	O	O
during	IN	O	O
and	CC	O	O
after	IN	O	O
the	DT	O	O
end	NN	O	O
of	IN	O	O
treatment	NN	O	O
(	(	O	O
EOT	NNP	O	O
)	)	O	O
.	.	O	O

To	TO	O	O
evaluate	VB	O	O
treatment	NN	O	O
withdrawal	NN	O	O
effects	NNS	O	O
,	,	O	O
12-	JJ	O	O
and	CC	O	O
24-month	JJ	O	O
post	NN	O	O
EOT	NNP	O	O
BMD	NNP	O	O
results	NNS	O	O
are	VBP	O	O
available	JJ	O	O
for	IN	O	O
122	CD	O	O
and	CC	O	O
126	CD	O	O
patients	NNS	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

Similar	JJ	O	O
patient	NN	O	O
numbers	NNS	O	O
had	VBD	O	O
BTM	NNP	O	O
measured	VBD	O	O
post	NN	O	O
EOT	NNP	O	O
.	.	O	O

Following	VBG	O	O
treatment	NN	O	O
withdrawal	NN	O	O
,	,	O	O
the	DT	O	O
differences	NNS	O	O
in	IN	O	O
BMD	NNP	O	O
observed	VBD	O	O
between	IN	O	O
the	DT	O	O
two	CD	O	O
endocrine	NN	O	O
strategies	NNS	O	O
were	VBD	O	O
partially	RB	O	O
reversed	VBN	O	O
.	.	O	O

At	IN	O	O
24	CD	O	O
months	NNS	O	O
from	IN	O	O
EOT	NNP	O	O
,	,	O	O
spine	JJ	o	OPH
BMD	NNP	o	OPH
increased	VBN	o	O
by	IN	O	O
1.53	CD	O	O
%	NN	O	O
(	(	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
0.63-2.43	CD	O	O
;	:	O	O
p	CC	O	O
=	VB	O	O
0.001	CD	O	O
)	)	O	O
after	IN	O	O
stopping	VBG	O	O
exemestane	NN	O	O
and	CC	O	O
fell	VBD	O	O
by	IN	O	O
1.93	CD	O	O
%	NN	O	O
(	(	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
-2.91	NNP	O	O
to	TO	O	O
0.95	CD	O	O
;	:	O	O
p	NN	O	O
=	VBZ	O	O
0.0002	CD	O	O
)	)	O	O
following	VBG	O	O
tamoxifen	NN	i	IPM
withdrawal	NN	O	O
.	.	O	O

A	DT	O	O
similar	JJ	O	O
pattern	NN	O	O
of	IN	O	O
changes	NNS	O	O
was	VBD	O	O
observed	VBN	O	O
at	IN	O	O
the	DT	O	O
hip	NN	O	O
.	.	O	O

At	IN	O	O
2	CD	O	O
years	NNS	O	O
post	RB	O	O
EOT	NNP	O	O
,	,	O	O
BMD	NNP	o	OPH
changes	NNS	o	OPH
from	IN	o	O
baseline	NN	o	O
were	VBD	O	O
similar	JJ	O	O
with	IN	O	O
both	DT	O	O
treatment	NN	O	O
strategies	NNS	O	O
.	.	O	O

Corresponding	VBG	O	O
inverse	JJ	o	OPH
changes	NNS	o	OPH
in	IN	o	OPH
BTM	NNP	o	OPH
were	VBD	O	O
seen	VBN	O	O
,	,	O	O
with	IN	O	O
an	DT	O	O
increase	NN	O	O
following	VBG	O	O
tamoxifen	JJ	O	O
withdrawal	NN	O	O
and	CC	O	O
a	DT	O	O
reduction	NN	O	O
after	IN	O	O
exemestane	NN	O	O
.	.	O	O

A	DT	O	O
higher	JJR	O	O
number	NN	o	OPH
of	IN	o	OPH
fractures	NNS	o	OPH
occurred	VBD	o	OPH
during	IN	O	O
exemestane	NN	i	IPM
treatment	NN	O	O
,	,	O	O
but	CC	O	O
fracture	NN	o	OPH
rates	NNS	o	OPH
were	VBD	O	O
similar	JJ	O	O
after	IN	O	O
treatment	NN	O	O
withdrawal	NN	O	O
.	.	O	O

With	IN	O	O
the	DT	O	O
switch	NN	O	O
strategy	NN	O	O
used	VBN	O	O
in	IN	O	O
IES	NNP	O	O
,	,	O	O
the	DT	O	O
on	IN	O	O
treatment	NN	O	O
adverse	JJ	o	OA
bone	NN	o	OA
effects	NNS	o	OA
of	IN	O	O
exemestane	NN	i	IPM
are	VBP	O	O
reversed	VBN	O	O
.	.	O	O

Ongoing	VBG	O	O
monitoring	NN	O	O
of	IN	O	O
BMD	NNP	O	O
is	VBZ	O	O
therefore	RB	O	O
not	RB	O	O
routinely	RB	O	O
required	VBN	O	O
.	.	O	O

Pazopanib	NNP	i	IPM
in	IN	O	O
locally	RB	p	O
advanced	JJ	p	O
or	CC	p	O
metastatic	JJ	p	O
renal	NN	p	PC
cell	NN	p	PC
carcinoma	NN	p	PC
:	:	p	O
results	NNS	O	O
of	IN	O	O
a	DT	O	O
randomized	JJ	O	O
phase	NN	O	O
III	NNP	O	O
trial	NN	O	O
.	.	O	O

PURPOSE	NNP	O	O
Pazopanib	NNP	i	IPM
is	VBZ	O	O
an	DT	O	O
oral	JJ	i	IPM
angiogenesis	NN	i	IPM
inhibitor	NN	i	IPM
targeting	VBG	O	O
vascular	JJ	O	O
endothelial	JJ	O	O
growth	NN	O	O
factor	NN	O	O
receptor	NN	O	O
,	,	O	O
platelet-derived	JJ	O	O
growth	NN	O	O
factor	NN	O	O
receptor	NN	O	O
,	,	O	O
and	CC	O	O
c-Kit	NN	O	O
.	.	O	O

This	DT	O	O
randomized	JJ	O	O
,	,	O	O
double-blind	JJ	O	O
,	,	O	O
placebo-controlled	JJ	i	IC
phase	NN	O	O
III	NNP	O	O
study	NN	O	O
evaluated	VBD	O	O
efficacy	NN	O	O
and	CC	O	O
safety	NN	O	O
of	IN	O	O
pazopanib	JJ	i	IPM
monotherapy	NN	i	IPM
in	IN	O	O
treatment-naive	JJ	p	O
and	CC	p	O
cytokine-pretreated	JJ	i	IPM
patients	NNS	p	O
with	IN	p	O
advanced	JJ	p	O
renal	JJ	p	O
cell	NN	p	O
carcinoma	NN	p	O
(	(	p	O
RCC	NNP	p	PC
)	)	p	O
.	.	p	O

PATIENTS	NNP	O	O
AND	CC	O	O
METHODS	NNP	O	O
Adult	NNP	p	O
patients	NNS	p	O
with	IN	p	O
measurable	JJ	p	O
,	,	p	O
locally	RB	p	O
advanced	JJ	p	O
,	,	p	O
and/or	JJ	p	O
metastatic	JJ	p	O
RCC	NNP	p	O
were	VBD	O	O
randomly	RB	O	O
assigned	VBN	O	O
2:1	CD	O	O
to	TO	O	O
receive	VB	i	O
oral	JJ	i	IPM
pazopanib	NN	i	IPM
or	CC	i	O
placebo	NN	i	IC
.	.	i	O

The	DT	O	O
primary	JJ	O	O
end	NN	O	O
point	NN	O	O
was	VBD	O	O
progression-free	JJ	o	OMO
survival	NN	o	OMO
(	(	o	OMO
PFS	NNP	o	OMO
)	)	o	OMO
.	.	o	O

Secondary	JJ	O	O
end	NN	O	O
points	NNS	O	O
included	VBD	O	O
overall	JJ	o	OMO
survival	NN	o	OMO
,	,	o	O
tumor	NN	o	OPH
response	NN	o	OPH
rate	NN	o	OPH
(	(	o	O
Response	NNP	o	OPH
Evaluation	NNP	o	OPH
Criteria	NNP	o	OPH
in	IN	o	OPH
Solid	NNP	o	OPH
Tumors	NNP	o	OPH
)	)	o	O
,	,	o	O
and	CC	o	O
safety	NN	o	OOt
.	.	o	O

Radiographic	JJ	O	O
assessments	NNS	O	O
of	IN	O	O
tumors	NNS	O	O
were	VBD	O	O
independently	RB	O	O
reviewed	VBN	O	O
.	.	O	O

Results	NNS	O	O
Of	IN	p	O
435	CD	p	PSS
patients	NNS	p	O
enrolled	VBD	p	O
,	,	p	O
233	CD	p	PSS
were	VBD	p	O
treatment	NN	p	O
naive	JJ	p	O
(	(	p	O
54	CD	p	O
%	NN	p	O
)	)	p	O
and	CC	p	O
202	CD	p	PSS
were	VBD	p	O
cytokine	NN	p	O
pretreated	VBN	p	O
(	(	p	O
46	CD	p	O
%	NN	p	O
)	)	p	O
.	.	p	O

PFS	NNP	o	OMO
was	VBD	O	O
significantly	RB	O	O
prolonged	VBN	O	O
with	IN	O	O
pazopanib	NNS	i	IPM
compared	VBN	O	O
with	IN	O	O
placebo	NN	i	IC
in	IN	O	O
the	DT	O	O
overall	JJ	O	O
study	NN	O	O
population	NN	O	O
(	(	O	O
median	JJ	O	O
,	,	O	O
PFS	NNP	O	O
9.2	CD	O	O
v	NN	O	O
4.2	CD	O	O
months	NNS	O	O
;	:	O	O
hazard	PRP$	O	O
ratio	NN	O	O
[	NNP	O	O
HR	NNP	O	O
]	NNP	O	O
,	,	O	O
0.46	CD	O	O
;	:	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
,	,	O	O
0.34	CD	O	O
to	TO	O	O
0.62	CD	O	O
;	:	O	O
P	NNP	O	O
<	NNP	O	O
.0001	NNP	O	O
)	)	O	O
,	,	O	O
the	DT	O	O
treatment-naive	JJ	i	O
subpopulation	NN	O	O
(	(	O	O
median	JJ	O	O
PFS	NNP	O	O
11.1	CD	O	O
v	NN	O	O
2.8	CD	O	O
months	NNS	O	O
;	:	O	O
HR	NNP	O	O
,	,	O	O
0.40	CD	O	O
;	:	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
,	,	O	O
0.27	CD	O	O
to	TO	O	O
0.60	CD	O	O
;	:	O	O
P	NNP	O	O
<	NNP	O	O
.0001	NNP	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
cytokine-pretreated	JJ	O	O
subpopulation	NN	O	O
(	(	O	O
median	JJ	O	O
PFS	NNP	O	O
,	,	O	O
7.4	CD	O	O
v	NN	O	O
4.2	CD	O	O
months	NNS	O	O
;	:	O	O
HR	NNP	O	O
,	,	O	O
0.54	CD	O	O
;	:	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
,	,	O	O
0.35	CD	O	O
to	TO	O	O
0.84	CD	O	O
;	:	O	O
P	NNP	O	O
<	NNP	O	O
.001	NNP	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
objective	JJ	o	OPH
response	NN	o	OPH
rate	NN	o	OPH
was	VBD	O	O
30	CD	O	O
%	NN	O	O
with	IN	O	O
pazopanib	NN	i	IPM
compared	VBN	O	O
with	IN	O	O
3	CD	O	O
%	NN	O	O
with	IN	O	O
placebo	NN	i	IC
(	(	O	O
P	NNP	O	O
<	NNP	O	O
.001	NNP	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
median	JJ	o	OPH
duration	NN	o	OPH
of	IN	o	OPH
response	NN	o	OPH
was	VBD	O	O
longer	JJR	O	O
than	IN	O	O
1	CD	O	O
year	NN	O	O
.	.	O	O

The	DT	O	O
most	RBS	O	O
common	JJ	O	O
adverse	JJ	O	O
events	NNS	O	O
were	VBD	O	O
diarrhea	RB	o	OA
,	,	o	O
hypertension	NN	o	OA
,	,	o	O
hair	NN	o	OA
color	NN	o	OA
changes	NNS	o	OA
,	,	o	O
nausea	NN	o	OPH
,	,	o	O
anorexia	NN	o	OA
,	,	o	O
and	CC	o	O
vomiting	VBG	o	OA
.	.	o	O

There	EX	O	O
was	VBD	O	O
no	DT	O	O
evidence	NN	O	O
of	IN	O	O
clinically	RB	O	O
important	JJ	O	O
differences	NNS	O	O
in	IN	O	O
quality	NN	O	O
of	IN	O	O
life	NN	O	O
for	IN	O	O
pazopanib	JJ	i	IPM
versus	NN	i	O
placebo	NN	i	IC
.	.	i	O

CONCLUSION	NNP	O	O
Pazopanib	NNP	i	IPM
demonstrated	VBD	O	O
significant	JJ	O	O
improvement	NN	O	O
in	IN	O	O
PFS	NNP	O	O
and	CC	O	O
tumor	NN	O	O
response	NN	O	O
compared	VBN	O	O
with	IN	O	O
placebo	NN	i	IC
in	IN	O	O
treatment-naive	JJ	p	O
and	CC	p	O
cytokine-pretreated	JJ	i	IPM
patients	NNS	p	O
with	IN	p	O
advanced	JJ	p	O
and/or	NNS	p	O
metastatic	JJ	p	O
RCC	NNP	p	O
.	.	p	O

Randomized	VBN	O	O
controlled	JJ	O	O
trial	NN	O	O
:	:	O	O
Multimodal	NNP	i	IE
Anxiety	NNP	i	IE
and	CC	i	IE
Social	NNP	i	IPS
Skill	NNP	i	IPS
Intervention	NNP	i	IPS
for	IN	O	O
adolescents	NNS	p	PA
with	IN	p	O
autism	NN	p	PC
spectrum	NN	p	PC
disorder	NN	p	PC
.	.	p	O

Anxiety	NN	p	O
is	VBZ	p	O
common	JJ	p	O
among	IN	p	O
adolescents	NNS	p	O
with	IN	p	O
autism	NN	p	O
spectrum	NN	p	O
disorders	NNS	p	O
(	(	p	O
ASD	NNP	p	PC
)	)	p	O
and	CC	O	O
may	MD	O	O
amplify	VB	O	O
the	DT	O	O
core	NN	O	O
social	JJ	O	O
disability	NN	O	O
,	,	O	O
thus	RB	O	O
necessitating	VBG	O	O
combined	VBN	O	O
treatment	NN	O	O
approaches	NNS	O	O
.	.	O	O

This	DT	O	O
pilot	NN	O	O
,	,	O	O
randomized	VBN	O	O
controlled	VBN	O	O
trial	NN	O	O
evaluated	VBD	O	O
the	DT	O	O
feasibility	NN	o	OOt
and	CC	O	O
preliminary	JJ	o	OOt
outcomes	NNS	o	OOt
of	IN	O	O
the	DT	O	O
Multimodal	NNP	i	IE
Anxiety	NNP	i	IE
and	CC	i	IE
Social	NNP	i	IPS
Skills	NNP	i	IPS
Intervention	NNP	i	IPS
(	(	i	IPS
MASSI	NNP	i	IPS
)	)	i	IPS
program	NN	i	IPS
in	IN	p	O
a	DT	p	O
sample	NN	p	O
of	IN	p	O
30	CD	p	PSS
adolescents	NNS	p	PA
with	IN	p	O
ASD	NNP	p	PC
and	CC	p	PC
anxiety	NN	p	PC
symptoms	NNS	p	PC
of	IN	p	O
moderate	JJ	p	O
or	CC	p	O
greater	JJR	p	O
severity	NN	p	O
.	.	p	O

The	DT	O	O
treatment	NN	O	O
was	VBD	O	O
acceptable	JJ	O	O
to	TO	O	O
families	NNS	O	O
,	,	O	O
subject	JJ	o	OOt
adherence	NN	o	OOt
was	VBD	O	O
high	JJ	O	O
,	,	O	O
and	CC	O	O
therapist	JJ	o	OOt
fidelity	NN	o	OOt
was	VBD	O	O
high	JJ	O	O
.	.	O	O

A	DT	O	O
16	CD	O	O
%	NN	O	O
improvement	NN	O	O
in	IN	O	O
ASD	NNP	o	OME
social	JJ	o	OME
impairment	NN	o	OME
(	(	O	O
within-group	JJ	O	O
effect	NN	O	O
size	NN	O	O
=	NNP	O	O
1.18	CD	O	O
)	)	O	O
was	VBD	O	O
observed	VBN	O	O
on	IN	O	O
a	DT	O	O
parent-reported	JJ	O	O
scale	NN	O	O
.	.	O	O

Although	IN	O	O
anxiety	NN	o	OME
symptoms	NNS	o	OME
declined	VBD	O	O
by	IN	O	O
26	CD	O	O
%	NN	O	O
,	,	O	O
the	DT	O	O
change	NN	O	O
was	VBD	O	O
not	RB	O	O
statistically	RB	O	O
significant	JJ	O	O
.	.	O	O

These	DT	O	O
findings	NNS	O	O
suggest	VBP	O	O
MASSI	NNP	i	IPS
is	VBZ	O	O
a	DT	O	O
feasible	JJ	o	OOt
treatment	NN	O	O
program	NN	O	O
and	CC	O	O
further	JJ	O	O
evaluation	NN	O	O
is	VBZ	O	O
warranted	VBN	O	O
.	.	O	O

Efficacy	NN	O	O
of	IN	O	O
bepotastine	NN	i	IPM
besilate	NN	i	IPM
ophthalmic	JJ	i	IPM
solution	NN	i	IPM
1.5	CD	O	O
%	NN	O	O
for	IN	O	O
seasonal	JJ	o	OPH
allergic	JJ	o	OPH
conjunctivitis	NN	o	OPH
:	:	o	O
a	DT	O	O
randomized	JJ	O	O
,	,	O	O
placebo-controlled	JJ	i	IC
,	,	O	O
natural	JJ	O	O
exposure	NN	O	O
,	,	O	O
clinical	JJ	O	O
trial	NN	O	O
.	.	O	O

Allergic	NNP	O	O
conjunctivitis	NN	O	O
(	(	O	O
AC	NNP	O	O
)	)	O	O
affects	VBZ	O	O
an	DT	O	O
estimated	JJ	O	O
20	CD	O	O
%	NN	O	O
of	IN	O	O
the	DT	O	O
population	NN	O	O
in	IN	O	O
the	DT	O	O
Western	JJ	O	O
world	NN	O	O
,	,	O	O
with	IN	O	O
a	DT	O	O
large	JJ	O	O
fraction	NN	O	O
suffering	VBG	O	O
due	JJ	O	O
to	TO	O	O
seasonal	JJ	O	O
or	CC	O	O
perennial	JJ	O	O
allergen	NN	O	O
exposures	NNS	O	O
.	.	O	O

Bepotastine	NNP	i	IPM
besilate	NN	i	IPM
ophthalmic	JJ	i	IPM
solution	NN	i	IPM
(	(	i	IPM
BBOS	NNP	i	IPM
)	)	i	IPM
1.5	CD	O	O
%	NN	O	O
,	,	O	O
a	DT	O	O
dual-acting	JJ	i	IPM
histamine	NN	i	IPM
(	(	O	O
H	NNP	O	O
(	(	O	O
1	CD	O	O
)	)	O	O
)	)	O	O
receptor	NN	O	O
antagonist	NN	O	O
and	CC	O	O
mast	NN	O	O
cell	NN	O	O
stabilizer	NN	O	O
,	,	O	O
is	VBZ	O	O
indicated	VBN	O	O
for	IN	O	O
itching	VBG	O	O
associated	VBN	O	O
with	IN	O	O
AC	NNP	O	O
.	.	O	O

This	DT	O	O
study	NN	O	O
was	VBD	O	O
designed	VBN	O	O
to	TO	O	O
evaluate	VB	O	O
the	DT	O	O
efficacy	NN	O	O
and	CC	O	O
safety	NN	O	O
of	IN	O	O
BBOS	NNP	O	O
1.5	CD	O	O
%	NN	O	O
for	IN	O	O
reducing	VBG	O	O
ocular	JJ	p	PC
itching	NN	p	PC
associated	VBN	p	O
with	IN	p	O
AC	NNP	p	PC
in	IN	p	O
subjects	NNS	p	O
enrolled	VBN	p	O
in	IN	p	O
a	DT	p	O
natural	JJ	p	O
exposure	NN	p	O
trial	NN	p	O
.	.	p	O

Eligible	JJ	p	O
subjects	NNS	p	O
in	IN	O	O
a	DT	O	O
multicenter	NN	O	O
,	,	O	O
double-masked	JJ	O	O
,	,	O	O
randomized	VBN	O	O
,	,	O	O
parallel-group	JJ	O	O
,	,	O	O
placebo-controlled	JJ	i	IC
,	,	O	O
natural	JJ	O	O
exposure	NN	O	O
clinical	JJ	O	O
trial	NN	O	O
were	VBD	O	O
randomly	RB	O	O
assigned	VBN	O	O
to	TO	O	O
either	DT	O	O
BBOS	NNP	i	IPM
1.5	CD	O	O
%	NN	O	O
or	CC	i	O
placebo	NN	i	IC
eyedrops	NNS	i	IC
on	IN	O	O
a	DT	O	O
1:1	CD	O	O
basis	NN	O	O
and	CC	O	O
instilled	VBD	O	O
1	CD	O	O
drop	NN	O	O
of	IN	O	O
the	DT	O	O
test	NN	O	O
agent	NN	O	O
into	IN	O	O
both	DT	O	O
eyes	NNS	O	O
twice	RB	O	O
daily	RB	O	O
for	IN	O	O
2	CD	O	O
weeks	NNS	O	O
.	.	O	O

The	DT	O	O
mean	JJ	O	O
change	NN	O	O
from	IN	O	O
baseline	NN	O	O
in	IN	O	O
instantaneous	JJ	O	O
and	CC	O	O
reflective	JJ	o	OPH
ocular	JJ	o	OPH
itching	NN	o	OPH
scores	NNS	o	OPH
at	IN	O	O
the	DT	O	O
end	NN	O	O
of	IN	O	O
2	CD	O	O
weeks	NNS	O	O
of	IN	O	O
treatment	NN	O	O
were	VBD	O	O
evaluated	VBN	O	O
based	VBN	O	O
on	IN	O	O
subject-assessed	JJ	O	O
severity	NN	O	O
of	IN	O	O
instantaneous	JJ	O	O
and	CC	O	O
reflective	JJ	O	O
itching	NN	O	O
.	.	O	O

Subject-reported	JJ	o	OA
adverse	JJ	o	OA
events	NNS	o	OA
(	(	o	OA
AEs	NNP	o	OA
)	)	o	OA
were	VBD	O	O
also	RB	O	O
recorded	VBN	O	O
for	IN	O	O
safety	NN	O	O
.	.	O	O

Treatment	NN	O	O
with	IN	O	O
BBOS	NNP	O	O
1.5	CD	O	O
%	NN	O	O
significantly	RB	O	O
reduced	VBN	O	O
instantaneous	JJ	o	OOt
and	CC	o	OOt
reflective	JJ	o	OOt
ocular	JJ	o	OOt
itching	NN	o	OOt
scores	NNS	o	OOt
from	IN	O	O
baseline	NN	O	O
compared	VBN	O	O
with	IN	O	O
placebo	NN	O	O
over	IN	O	O
the	DT	O	O
2-week	JJ	O	O
study	NN	O	O
period	NN	O	O
(	(	O	O
p	JJ	O	O
=	NN	O	O
0.007	CD	O	O
and	CC	O	O
p	VB	O	O
=	JJ	O	O
0.005	CD	O	O
,	,	O	O
respectively	RB	O	O
)	)	O	O
.	.	O	O

BBOS	$	O	O
1.5	CD	O	O
%	NN	O	O
was	VBD	O	O
well	RB	O	O
tolerated	VBN	o	OOt
,	,	o	O
and	CC	o	O
AEs	NNP	o	OA
were	VBD	O	O
generally	RB	O	O
transient	JJ	O	O
and	CC	O	O
mild	JJ	O	O
.	.	O	O

This	DT	O	O
clinical	JJ	O	O
study	NN	O	O
indicates	VBZ	O	O
BBOS	NNP	O	O
1.5	CD	O	O
%	NN	O	O
effectively	RB	o	OOt
and	CC	o	O
safely	RB	o	OOt
treated	VBD	o	O
ocular	JJ	o	OPH
itching	NN	o	OPH
in	IN	O	O
a	DT	O	O
natural	JJ	O	O
exposure	NN	O	O
allergy	NN	O	O
study	NN	O	O
and	CC	O	O
is	VBZ	O	O
a	DT	O	O
useful	JJ	O	O
treatment	NN	O	O
option	NN	O	O
for	IN	O	O
the	DT	O	O
management	NN	O	O
of	IN	O	O
ocular	JJ	O	O
itching	NN	O	O
associated	VBN	O	O
with	IN	O	O
AC	NNP	O	O
.	.	O	O

(	(	O	O
ClinicalTrials.gov	NNP	O	O
identifier	VBZ	O	O
number	NN	O	O
:	:	O	O
NCT01174823	NNP	O	O
.	.	O	O

)	)	O	O
Poylmerized	VBN	i	IPM
whole	JJ	i	IPM
ragweed	NN	i	IPM
:	:	i	O
an	DT	O	O
improved	JJ	O	O
method	NN	O	O
of	IN	O	O
immunotherapy	NN	O	O
.	.	O	O

A	DT	O	O
single-blind	JJ	O	O
study	NN	O	O
compared	VBN	O	O
the	DT	O	O
effectiveness	NN	O	O
of	IN	O	O
glutaraldehyde-treated	JJ	i	IPM
polymerized	NNS	i	IPM
ragweed	VBP	i	IPM
with	IN	O	O
nonpolymerized	JJ	i	IPM
monomeric	JJ	i	IPM
ragweed	NN	i	IPM
.	.	i	IPM

These	DT	O	O
studies	NNS	O	O
are	VBP	O	O
an	DT	O	O
extension	NN	O	O
of	IN	O	O
those	DT	O	O
previously	RB	O	O
reported	VBN	O	O
for	IN	O	O
polymerized	JJ	O	O
AgE	NNP	O	O
using	VBG	O	O
a	DT	O	O
readily	RB	O	O
available	JJ	O	O
ragweed	NN	O	O
preparation	NN	O	O
containing	VBG	O	O
all	DT	O	O
ragweed	NN	i	IPM
antigens	NNS	O	O
.	.	O	O

Nineteen	JJ	p	PSS
ragweed-sensitive	JJ	p	PC
patients	NNS	p	O
were	VBD	p	PC
randomized	VBN	p	PC
into	IN	p	PC
2	CD	p	PC
groups	NNS	p	PC
;	:	p	PC
10	CD	p	PSS
received	VBD	p	O
the	DT	p	O
polymerized	JJ	i	IPM
form	NN	i	IPM
and	CC	p	PC
9	CD	p	PSS
received	VBD	p	O
the	DT	p	O
monomeric	JJ	i	IPM
form	NN	i	IPM
.	.	i	O

Four	CD	O	O
parameters	NNS	O	O
were	VBD	O	O
followed	VBN	O	O
:	:	O	O
serum-specific	JJ	i	O
IgE	NNP	i	O
against	IN	O	O
antigen	NN	O	O
E	NNP	O	O
,	,	O	O
total	JJ	O	O
blocking	VBG	O	O
antibody	NN	O	O
against	IN	O	O
antigen	NN	O	O
E	NNP	O	O
,	,	O	O
local	JJ	O	O
and	CC	O	O
systemic	JJ	O	O
reactions	NNS	O	O
to	TO	O	O
injection	NN	O	O
therapy	NN	O	O
,	,	O	O
and	CC	O	O
symptom	NN	O	O
score	NN	O	O
indices	NNS	O	O
.	.	O	O

Pretreatment	NNP	O	O
levels	NNS	O	O
of	IN	O	O
antigen	NN	O	O
E	NNP	O	O
--	:	O	O
specific	JJ	O	O
IgE	NNP	O	O
and	CC	O	O
blocking	VBG	O	O
antibody	NN	O	O
activity	NN	O	O
were	VBD	O	O
similar	JJ	O	O
in	IN	O	O
both	DT	O	O
groups	NNS	O	O
.	.	O	O

After	IN	O	O
a	DT	O	O
total	NN	O	O
of	IN	O	O
15,000	CD	O	O
protein	NNS	O	O
nitrogen	JJ	O	O
units	NNS	O	O
(	(	O	O
PNU	NNP	O	O
)	)	O	O
had	VBD	O	O
been	VBN	O	O
given	VBN	O	O
,	,	O	O
blocking	VBG	o	OPH
antibody	NN	o	OPH
activity	NN	o	OPH
in	IN	O	O
the	DT	O	O
monomer	NN	O	O
group	NN	O	O
rose	VBD	O	O
from	IN	O	O
a	DT	O	O
mean	NN	O	O
of	IN	O	O
170	CD	O	O
ng	JJ	O	O
AgE	NNP	O	O
bound	NN	O	O
per	IN	O	O
ml	NN	O	O
to	TO	O	O
a	DT	O	O
mean	NN	O	O
of	IN	O	O
2,813	CD	O	O
.	.	O	O

The	DT	O	O
rise	NN	o	OPH
in	IN	o	OPH
blocking	VBG	o	OPH
antibody	NN	o	OPH
activity	NN	o	OPH
in	IN	O	O
the	DT	O	O
polymer	NN	O	O
group	NN	O	O
was	VBD	O	O
from	IN	O	O
a	DT	O	O
mean	NN	O	O
of	IN	O	O
181	CD	O	O
ng	JJ	O	O
AgE	NNP	O	O
bound	NN	O	O
per	IN	O	O
ml	NN	O	O
to	TO	O	O
1,574	CD	O	O
.	.	O	O

At	IN	O	O
15,000	CD	O	O
PNU	NNP	O	O
,	,	O	O
blocking	VBG	o	OPH
antibody	NN	o	OPH
activity	NN	o	OPH
levels	NNS	o	OPH
were	VBD	O	O
not	RB	O	O
statistically	RB	O	O
different	JJ	O	O
in	IN	O	O
the	DT	O	O
2	CD	O	O
groups	NNS	O	O
.	.	O	O

After	IN	O	O
1	CD	O	O
year	NN	O	O
of	IN	O	O
treatment	NN	O	O
,	,	O	O
no	DT	O	O
consistent	JJ	O	O
decrease	NN	O	O
in	IN	O	O
postseasonal	JJ	o	OPH
specific	JJ	o	OPH
IgE	NNP	o	OPH
rise	NN	o	OPH
could	MD	O	O
be	VB	O	O
shown	VBN	O	O
in	IN	O	O
either	DT	O	O
group	NN	O	O
.	.	O	O

Forty	NNP	O	O
times	NNS	O	O
less	RBR	O	O
erythema	JJ	o	OPH
and	CC	O	O
15	CD	O	O
times	NNS	O	O
less	JJR	O	O
induration	NN	o	OPH
were	VBD	O	O
found	VBN	O	O
with	IN	O	O
polymerized	JJ	i	IPM
ragweed	NN	i	IPM
.	.	i	O

There	EX	O	O
were	VBD	O	O
7	CD	O	O
systemic	JJ	o	OA
reactions	NNS	o	OA
with	IN	O	O
the	DT	O	O
monomer	NN	O	O
and	CC	O	O
none	NN	O	O
with	IN	O	O
the	DT	O	O
polymer	NN	O	O
.	.	O	O

Both	DT	O	O
groups	NNS	O	O
experienced	VBD	O	O
symptomatic	JJ	o	OOt
improvement	NN	o	OOt
with	IN	O	O
treatment	NN	O	O
.	.	O	O

Most	RBS	O	O
effective	JJ	o	O
regimen	NNS	o	O
of	IN	o	O
tranexamic	JJ	o	O
acid	NN	o	O
in	IN	O	O
knee	NN	p	PC
arthroplasty	NN	p	PC
:	:	p	O
a	DT	O	O
prospective	JJ	O	O
randomized	NN	O	O
controlled	VBD	O	O
study	NN	O	O
in	IN	O	O
240	CD	p	PSS
patients	NNS	p	PSS
.	.	p	O

BACKGROUND	NNP	O	O
The	DT	O	O
antifibrinolytic	JJ	i	IPM
tranexamic	JJ	i	IPM
acid	NN	i	IPM
reduces	NNS	O	O
surgical	JJ	O	O
blood	NN	O	O
loss	NN	O	O
,	,	O	O
but	CC	O	O
studies	NNS	O	O
have	VBP	O	O
not	RB	O	O
identified	VBN	O	O
an	DT	O	O
optimal	JJ	O	O
regimen	NNS	O	O
.	.	O	O

QUESTIONS/PURPOSES	NNP	O	O
We	PRP	O	O
studied	VBD	O	O
different	JJ	O	O
dosages	NNS	O	O
,	,	O	O
timings	NNS	O	O
,	,	O	O
and	CC	O	O
modes	NNS	O	O
of	IN	O	O
administration	NN	O	O
to	TO	O	O
identify	VB	O	O
the	DT	O	O
most	RBS	O	O
effective	JJ	O	O
regimen	NNS	O	O
of	IN	O	O
tranexamic	JJ	i	IPM
acid	NN	i	IPM
in	IN	O	O
achieving	VBG	O	O
maximum	JJ	O	O
reduction	NN	O	O
of	IN	O	O
blood	NN	O	O
loss	NN	O	O
in	IN	O	O
TKA	NNP	O	O
.	.	O	O

METHODS	NNP	O	O
We	PRP	O	O
prospectively	RB	O	O
studied	VBD	O	O
five	CD	p	O
regimens	NNS	p	O
(	(	p	O
four	CD	p	O
intravenous	NN	i	IPH
,	,	p	O
one	CD	p	O
local	JJ	i	IPH
;	:	i	O
40	CD	p	O
patients	NNS	p	O
each	DT	p	O
)	)	p	O
with	IN	p	O
a	DT	p	O
control	NN	p	O
group	NN	p	O
(	(	O	O
no	DT	O	O
tranexamic	JJ	i	O
acid	NN	i	O
)	)	i	O
.	.	O	O

The	DT	O	O
four	CD	O	O
intravenous	JJ	i	IPH
(	(	O	O
10-mg/kg	JJ	O	O
dose	NN	O	O
)	)	O	O
regimens	VBZ	O	O
included	VBN	O	O
(	(	O	O
1	CD	O	O
)	)	O	O
intraoperative	NN	i	IS
dose	NN	i	IS
(	(	i	IS
IO	NNP	i	IS
)	)	i	IS
given	VBN	i	O
before	IN	i	O
tourniquet	JJ	i	O
deflation	NN	i	O
,	,	i	O
(	(	i	O
2	CD	i	O
)	)	i	O
additional	JJ	i	IPM
preoperative	NN	i	IPM
dose	NN	i	IPM
(	(	i	IPM
POIO	NNP	i	IPM
)	)	i	IPM
,	,	i	O
(	(	i	O
3	CD	i	O
)	)	i	O
additional	JJ	i	IPM
postoperative	NN	i	IPM
dose	NN	i	IPM
(	(	i	IPM
IOPO	NNP	i	IPM
)	)	i	IPM
,	,	i	O
and	CC	i	O
(	(	i	O
4	CD	i	O
)	)	i	O
all	DT	i	O
three	CD	i	O
doses	NNS	i	O
(	(	i	O
POIOPO	NNP	i	O
)	)	i	O
.	.	O	O

The	DT	O	O
fifth	JJ	O	O
regimen	NN	O	O
was	VBD	O	O
a	DT	O	O
single	JJ	O	O
local	JJ	i	IPM
application	NN	i	IPM
(	(	O	O
LA	NNP	O	O
)	)	O	O
.	.	O	O

Two	CD	O	O
independent	JJ	O	O
parameters	NNS	O	O
of	IN	O	O
drain	NN	o	OPH
loss	NN	o	OPH
and	CC	o	O
total	JJ	o	OPH
blood	NN	o	OPH
loss	NN	o	OPH
,	,	o	O
calculated	VBN	o	O
by	IN	o	O
the	DT	o	O
hemoglobin	NN	o	O
balance	NN	o	O
method	NN	o	O
,	,	O	O
were	VBD	O	O
evaluated	VBN	O	O
statistically	RB	O	O
.	.	O	O

RESULTS	NNP	O	O
Both	NNP	O	O
parameters	NNS	O	O
were	VBD	O	O
reduced	VBN	O	O
in	IN	O	O
all	DT	O	O
five	CD	O	O
regimens	NNS	O	O
as	IN	O	O
against	IN	O	O
the	DT	O	O
control	NN	O	O
.	.	O	O

A	DT	O	O
significant	JJ	O	O
reduction	NN	O	O
in	IN	O	O
drain	NN	o	OPH
loss	NN	o	OPH
was	VBD	O	O
seen	VBN	O	O
in	IN	O	O
the	DT	O	O
POIO	NNP	O	O
,	,	O	O
IOPO	NNP	O	O
,	,	O	O
and	CC	O	O
POIOPO	NNP	O	O
groups	NNS	O	O
whereas	VBP	O	O
total	JJ	O	O
blood	NN	o	OPH
loss	NN	o	OPH
was	VBD	O	O
significantly	RB	O	O
reduced	VBN	O	O
in	IN	O	O
the	DT	O	O
POIO	NNP	O	O
,	,	O	O
POIOPO	NNP	O	O
,	,	O	O
and	CC	O	O
LA	NNP	O	O
groups	NNS	O	O
.	.	O	O

The	DT	O	O
POIOPO	NNP	O	O
group	NN	O	O
had	VBD	O	O
the	DT	O	O
least	JJS	O	O
drain	JJ	o	OPH
loss	NN	o	OPH
(	(	O	O
303	CD	O	O
mL	NN	O	O
)	)	O	O
and	CC	O	O
least	JJS	O	O
total	JJ	O	O
blood	NN	o	OPH
loss	NN	o	OPH
(	(	O	O
688	CD	O	O
mL	NN	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
IO	NNP	O	O
group	NN	O	O
had	VBD	O	O
the	DT	O	O
greatest	JJS	O	O
drain	NN	o	OPH
loss	NN	o	OPH
and	CC	O	O
the	DT	O	O
IOPO	NNP	O	O
group	NN	O	O
the	DT	O	O
greatest	JJS	O	O
total	JJ	o	OPH
blood	NN	o	OPH
loss	NN	o	OPH
.	.	o	O

CONCLUSIONS	NNP	O	O
Single-dose	JJ	O	O
tranexamic	JJ	i	IPM
acid	NN	i	IPM
did	VBD	O	O
not	RB	O	O
give	VB	O	O
effective	JJ	O	O
results	NNS	O	O
.	.	O	O

The	DT	O	O
two-dose	JJ	O	O
regimen	NNS	O	O
of	IN	O	O
POIO	NNP	O	O
was	VBD	O	O
the	DT	O	O
least	JJS	O	O
amount	NN	O	O
necessary	JJ	O	O
for	IN	O	O
effective	JJ	O	O
results	NNS	O	O
.	.	O	O

When	WRB	O	O
compared	VBN	O	O
against	IN	O	O
the	DT	O	O
control	NN	O	O
,	,	O	O
this	DT	O	O
regimen	NNS	O	O
produced	VBD	O	O
reduction	NN	o	O
of	IN	o	O
drain	NN	o	OPH
loss	NN	o	OPH
and	CC	o	O
total	JJ	o	OPH
blood	NN	o	OPH
loss	NN	o	OPH
,	,	O	O
whereas	IN	O	O
the	DT	O	O
IOPO	NNP	O	O
regimen	NNS	O	O
did	VBD	O	O
not	RB	O	O
.	.	O	O

The	DT	O	O
three-dose	JJ	O	O
regimen	NNS	O	O
of	IN	O	O
POIOPO	NNP	O	O
produced	VBD	O	O
maximum	JJ	O	O
effective	JJ	O	O
reduction	NN	O	O
of	IN	O	O
drain	NN	o	OPH
loss	NN	o	OPH
and	CC	o	O
total	JJ	o	OPH
blood	NN	o	OPH
loss	NN	o	OPH
.	.	o	O

Osteoporosis	NN	i	IPM
and	CC	O	O
gait	NN	O	O
and	CC	O	O
balance	NN	O	O
disturbances	NNS	O	O
in	IN	O	O
older	JJR	p	PC
sarcopenic	JJ	p	PC
obese	JJ	p	PC
New	NNP	p	PC
Zealanders	NNP	p	PC
.	.	p	PC

UNLABELLED	NNP	O	O
Bone	NNP	O	O
,	,	O	O
muscle	NN	O	O
,	,	O	O
and	CC	O	O
fat	NN	O	O
may	MD	O	O
affect	VB	O	O
gait	NN	O	O
and	CC	O	O
balance	NN	O	O
in	IN	O	O
older	JJR	p	O
adults	NNS	p	O
.	.	p	O

Osteoporosis	NN	p	O
was	VBD	p	O
prevalent	JJ	p	O
in	IN	p	O
low	JJ	p	O
muscle	NN	p	O
mass	NN	p	O
participants	NNS	p	O
and	CC	p	O
related	VBN	p	O
to	TO	p	O
gait	VB	p	O
and	CC	p	O
balance	VB	p	O
deficits	NNS	p	O
.	.	p	O

Low	JJ	O	O
muscle	NN	O	O
combined	VBN	O	O
with	IN	O	O
high	JJ	O	O
fat	JJ	O	O
mass	NN	O	O
had	VBD	O	O
more	RBR	O	O
functional	JJ	O	O
deficits	NNS	O	O
and	CC	O	O
poorer	JJR	O	O
bone	NN	O	O
health	NN	O	O
,	,	O	O
which	WDT	O	O
has	VBZ	O	O
implications	NNS	O	O
for	IN	O	O
falls	NNS	O	O
risk	NN	O	O
and	CC	O	O
fractures	NNS	O	O
.	.	O	O

INTRODUCTION	NNP	O	O
Decreasing	VBG	O	O
bone	NN	O	O
density	NN	O	O
and	CC	O	O
muscle	NN	O	O
mass	NN	O	O
and	CC	O	O
increasing	VBG	O	O
fat	JJ	O	O
mass	NN	O	O
may	MD	O	O
act	VB	O	O
synergistically	RB	O	O
to	TO	O	O
affect	VB	O	O
gait	NN	O	O
and	CC	O	O
balance	NN	O	O
in	IN	O	O
older	JJR	O	O
adults	NNS	O	O
.	.	O	O

METHODS	NNP	O	O
One	CD	p	O
hundred	VBD	p	O
eighty-three	JJ	p	O
older	NN	p	O
adults	NNS	p	O
(	(	p	O
age	NN	p	O
72.7	CD	p	O
+/-	JJ	p	O
6	CD	p	O
years	NNS	p	O
,	,	p	O
range	VBP	p	O
56-93	JJ	p	O
;	:	p	O
body	NN	p	O
mass	NN	p	O
index	NN	p	O
28.2	CD	p	O
+/-	JJ	p	O
4.9	CD	p	O
,	,	p	O
range	VBP	p	O
16.6-46.0	JJ	p	O
)	)	p	O
were	VBD	p	O
recruited	VBN	p	O
from	IN	p	O
a	DT	p	O
New	NNP	p	O
Zealand	NNP	p	O
falls	VBZ	p	O
prevention	NN	p	O
intervention	NN	p	O
trial	NN	p	O
.	.	p	O

Total	JJ	o	OPH
and	CC	o	OPH
appendicular	JJ	o	OPH
skeletal	JJ	o	OPH
muscle	NN	o	OPH
mass	NN	o	OPH
(	(	o	OPH
ASM	NNP	o	OPH
)	)	o	OPH
,	,	o	O
percent	JJ	o	OPH
fat	NN	o	OPH
,	,	o	O
and	CC	o	O
bone	NN	o	OPH
mineralization	NN	o	OPH
were	VBD	p	O
assessed	VBN	p	O
by	IN	p	O
dual	JJ	i	IPH
energy	NN	i	IPH
X-ray	JJ	i	IPH
absorptiometry	NN	i	IPH
and	CC	p	O
used	VBD	p	O
to	TO	p	O
characterize	VB	p	O
normal	JJ	p	O
lean	JJ	p	O
(	(	p	O
NL	NNP	p	O
,	,	p	O
n	JJ	p	O
=	NNP	p	O
51	CD	p	O
)	)	p	O
,	,	p	O
sarcopenic	JJ	p	O
(	(	p	O
SS	NNP	p	O
,	,	p	O
n	JJ	p	O
=	NNP	p	O
18	CD	p	O
)	)	p	O
,	,	p	O
sarcopenic	JJ	p	O
obese	NN	p	O
(	(	p	O
SO	NNP	p	O
,	,	p	O
n	JJ	p	O
=	NNP	p	O
29	CD	p	O
)	)	p	O
,	,	p	O
and	CC	p	O
obese	JJ	p	O
(	(	p	O
OO	NNP	p	O
,	,	p	O
n	JJ	p	O
=	NNP	p	O
85	CD	p	O
)	)	p	O
phenotypes	NNS	p	O
.	.	p	O

Functional	JJ	O	O
performance	NN	O	O
was	VBD	O	O
assessed	VBN	O	O
using	VBG	O	O
timed	VBN	i	O
up	RP	i	O
and	CC	i	O
go	VB	i	O
,	,	i	O
chair	NN	i	O
stand	NN	i	O
,	,	i	O
single	JJ	i	O
leg	NN	i	O
stand	NN	i	O
,	,	O	O
and	CC	O	O
step	VB	i	IOt
test	NN	i	IOt
.	.	i	O

Regression	NN	O	O
models	NNS	O	O
were	VBD	O	O
adjusted	VBN	O	O
for	IN	O	O
age	NN	O	O
,	,	O	O
sex	NN	O	O
,	,	O	O
medications	NNS	O	O
,	,	O	O
and	CC	O	O
physical	JJ	O	O
activity	NN	O	O
.	.	O	O

RESULTS	NNP	O	O
Femoral	NNP	o	OPH
neck	NN	o	OPH
osteoporosis	NN	o	OPH
was	VBD	O	O
present	JJ	O	O
in	IN	O	O
22	CD	O	O
%	NN	O	O
SS	NNP	O	O
,	,	O	O
17	CD	O	O
%	NN	O	O
SO	NNP	O	O
,	,	O	O
12	CD	O	O
%	NN	O	O
NL	NNP	O	O
,	,	O	O
and	CC	O	O
7	CD	O	O
%	NN	O	O
OO	NNP	O	O
.	.	O	O

Femoral	NNP	O	O
neck	NN	O	O
osteoporosis	NN	O	O
with	IN	O	O
low	JJ	O	O
ASM	NNP	o	OPH
predicted	VBD	O	O
poor	JJ	O	O
chair	NN	o	OPH
stand	VBP	o	OPH
performance	NN	o	OPH
(	(	O	O
beta	JJ	O	O
-3.3	NNP	O	O
,	,	O	O
standard	JJ	O	O
error	NN	O	O
1.6	CD	O	O
,	,	O	O
p	NN	O	O
=	NNP	O	O
0.04	CD	O	O
)	)	O	O
.	.	O	O

SO	RB	O	O
scored	JJ	O	O
lowest	NN	O	O
on	IN	O	O
the	DT	O	O
chair	NN	O	O
stand	NN	O	O
(	(	O	O
p	JJ	O	O
=	NNP	O	O
0.03	CD	O	O
)	)	O	O
and	CC	O	O
step	JJ	O	O
test	NN	O	O
(	(	O	O
p	JJ	O	O
=	NNP	O	O
0.03	CD	O	O
)	)	O	O
.	.	O	O

Higher	JJR	o	OPH
ASM	NNP	o	OPH
predicted	VBD	O	O
faster	RBR	O	O
timed	VBN	O	O
up	RP	O	O
and	CC	O	O
go	VB	O	O
performance	NN	O	O
(	(	O	O
p	JJ	O	O
=	NNP	O	O
0.001	CD	O	O
)	)	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
Osteoporosis	NNP	O	O
was	VBD	O	O
prevalent	VBN	O	O
in	IN	O	O
low	JJ	p	O
ASM	NNP	p	O
groups	NNS	p	O
(	(	O	O
SS	NNP	O	O
and	CC	O	O
SO	NNP	O	O
)	)	O	O
and	CC	O	O
related	VBN	O	O
to	TO	O	O
gait	VB	O	O
and	CC	O	O
balance	VB	O	O
deficits	NNS	O	O
,	,	O	O
particularly	RB	O	O
in	IN	O	O
the	DT	O	O
SO	NNP	O	O
.	.	O	O

This	DT	O	O
has	VBZ	O	O
implications	NNS	O	O
for	IN	O	O
falls	NNS	O	O
risk	NN	O	O
,	,	O	O
fractures	NNS	O	O
,	,	O	O
and	CC	O	O
interventions	NNS	O	O
.	.	O	O

A	DT	O	O
web-based	JJ	i	IE
patient	NN	i	IE
activation	NN	i	IE
intervention	NN	i	IE
to	TO	O	O
improve	VB	O	O
hypertension	NN	O	O
care	NN	O	O
:	:	O	O
study	NN	O	O
design	NN	O	O
and	CC	O	O
baseline	NN	O	O
characteristics	NNS	O	O
in	IN	O	O
the	DT	O	O
web	NN	O	O
hypertension	NN	O	O
study	NN	O	O
.	.	O	O

BACKGROUND	NNP	O	O
Despite	IN	O	O
the	DT	O	O
known	JJ	O	O
health	NN	O	O
risks	NNS	O	O
of	IN	O	O
hypertension	NN	O	O
,	,	O	O
many	JJ	O	O
hypertensive	JJ	p	PC
patients	NNS	p	O
still	RB	O	O
have	VBP	O	O
uncontrolled	VBN	O	O
blood	NN	O	O
pressure	NN	O	O
.	.	O	O

Clinical	JJ	O	O
inertia	NN	O	O
,	,	O	O
the	DT	O	O
tendency	NN	O	O
of	IN	O	O
physicians	NNS	O	O
not	RB	O	O
to	TO	O	O
intensify	VB	O	O
treatment	NN	O	O
,	,	O	O
is	VBZ	O	O
a	DT	O	O
common	JJ	O	O
barrier	NN	O	O
in	IN	O	O
controlling	VBG	O	O
chronic	JJ	O	O
diseases	NNS	O	O
.	.	O	O

This	DT	O	O
trial	NN	O	O
is	VBZ	O	O
aimed	VBN	O	O
at	IN	O	O
determining	VBG	O	O
the	DT	O	O
impact	NN	O	O
of	IN	O	O
activating	VBG	O	O
patients	NNS	O	O
to	TO	O	O
ask	VB	O	O
providers	NNS	O	O
to	TO	O	O
make	VB	O	O
changes	NNS	O	O
to	TO	O	O
their	PRP$	O	O
care	NN	O	O
through	IN	O	O
tailored	VBN	O	O
feedback	NN	O	O
.	.	O	O

METHODS	NNP	O	O
Diagnosed	VBD	p	O
hypertensive	JJ	p	PC
patients	NNS	p	O
were	VBD	O	O
enrolled	VBN	O	O
in	IN	O	O
this	DT	O	O
RCT	NNP	O	O
and	CC	O	O
randomized	VBN	O	O
to	TO	O	O
one	CD	O	O
of	IN	O	O
two	CD	O	O
study	NN	O	O
groups	NNS	O	O
:	:	O	O
(	(	O	O
1	CD	O	O
)	)	O	O
the	DT	i	IE
intervention	NN	i	IE
condition	NN	i	IE
--	:	i	IE
Web-based	JJ	i	IE
hypertension	NN	i	IE
feedback	NN	i	IE
,	,	i	IE
based	VBN	i	IE
on	IN	i	IE
the	DT	i	IE
individual	JJ	i	IE
patient	NN	i	IE
's	POS	i	IE
self-report	NN	i	IE
of	IN	i	IE
health	NN	i	IE
variables	NNS	i	IE
and	CC	i	IE
previous	JJ	i	IE
BP	NNP	i	IE
measurements	NNS	i	IE
,	,	i	IE
to	TO	i	IE
prompt	VB	i	IE
them	PRP	i	IE
to	TO	i	IE
ask	VB	i	IE
questions	NNS	i	IE
during	IN	i	IE
their	PRP$	i	IE
next	JJ	i	IE
physician	NN	i	IE
's	POS	i	IE
visit	NN	i	IE
about	IN	i	IE
hypertension	NN	i	IE
care	NN	i	IE
(	(	O	O
2	CD	O	O
)	)	O	O
the	DT	i	IE
control	NN	i	IE
condition	NN	i	IE
--	:	i	IE
Web-based	JJ	i	IE
preventive	JJ	i	IE
health	NN	i	IE
feedback	NN	i	IE
,	,	i	IE
based	VBN	i	IE
on	IN	i	IE
the	DT	i	IE
individual	NN	i	IE
's	POS	i	IE
self-report	NN	i	IE
of	IN	i	IE
receiving	VBG	i	IE
preventive	JJ	i	IE
care	NN	i	IE
(	(	i	O
e.g.	UH	i	O
,	,	O	O
pap	JJ	i	O
testing	VBG	i	O
)	)	i	O
,	,	i	O
to	TO	i	IE
prompt	VB	i	IE
them	PRP	i	IE
to	TO	i	IE
ask	VB	i	IE
questions	NNS	i	IE
during	IN	i	IE
their	PRP$	i	IE
next	JJ	i	IE
physician	NN	i	IE
's	POS	i	IE
visit	NN	i	IE
about	IN	i	IE
preventive	JJ	i	IE
care	NN	i	IE
.	.	i	O

The	DT	O	O
primary	JJ	O	O
outcome	NN	O	O
of	IN	O	O
the	DT	O	O
study	NN	O	O
is	VBZ	O	O
change	VBN	o	OPH
in	IN	o	OPH
blood	NN	o	OPH
pressure	NN	o	OPH
and	CC	o	OPH
change	NN	o	OOt
in	IN	o	OOt
the	DT	o	OOt
percentage	NN	o	OOt
of	IN	o	OOt
patients	NNS	o	OOt
in	IN	o	OOt
each	DT	o	OOt
group	NN	o	OOt
with	IN	o	OOt
controlled	VBN	o	OOt
blood	NN	o	OOt
pressure	NN	o	OOt
.	.	o	OPH

CONCLUSION	NNP	O	O
Five	CD	p	PSS
hundred	VBD	p	PSS
participants	NNS	p	O
were	VBD	p	O
enrolled	VBN	p	O
and	CC	p	O
baseline	JJ	p	O
characteristics	NNS	p	O
include	VBP	p	O
a	DT	p	O
mean	JJ	p	O
age	NN	p	O
of	IN	p	O
60.0	CD	p	PA
years	NNS	p	PA
;	:	p	O
57.6	CD	p	O
%	NN	p	O
female	NN	p	PSE
;	:	p	O
and	CC	p	O
77.6	CD	p	O
%	NN	p	O
white	JJ	p	O
.	.	p	O

Overall	JJ	O	O
37.7	CD	p	O
%	NN	p	O
participants	NNS	p	O
had	VBD	p	O
uncontrolled	VBN	p	PC
blood	NN	p	PC
pressure	NN	p	PC
;	:	p	O
the	DT	p	O
mean	NN	p	O
body	NN	p	O
mass	NN	p	O
index	NN	p	O
(	(	p	O
BMI	NNP	p	O
)	)	p	O
was	VBD	p	O
in	IN	p	O
the	DT	p	O
obese	JJ	p	O
range	NN	p	O
(	(	p	O
32.4	CD	p	O
)	)	p	O
and	CC	p	O
21.8	CD	p	O
%	NN	p	O
had	VBD	p	O
diabetes	NNS	p	PC
.	.	p	O

By	IN	O	O
activating	VBG	O	O
patients	NNS	O	O
to	TO	O	O
become	VB	O	O
involved	VBN	O	O
in	IN	O	O
their	PRP$	O	O
own	JJ	O	O
care	NN	O	O
,	,	O	O
we	PRP	O	O
believe	VBP	O	O
the	DT	O	O
addition	NN	O	O
of	IN	O	O
the	DT	O	O
web-based	JJ	O	O
intervention	NN	O	O
will	MD	O	O
improve	VB	O	O
blood	NN	o	OPH
pressure	NN	o	OPH
control	NN	o	OPH
compared	VBN	O	O
to	TO	O	O
a	DT	O	O
control	NN	O	O
group	NN	O	O
who	WP	O	O
receive	VBP	O	O
web-based	JJ	O	O
preventive	JJ	O	O
messages	NNS	O	O
unrelated	VBN	O	O
to	TO	O	O
hypertension	NN	O	O
.	.	O	O

Effects	NNS	O	O
of	IN	O	O
fenoterol	NN	i	IPM
on	IN	O	O
inspiratory	JJ	O	O
effort	NN	O	O
sensation	NN	O	O
and	CC	O	O
fatigue	NN	O	O
during	IN	O	O
inspiratory	JJ	O	O
threshold	JJ	O	O
loading	NN	O	O
.	.	O	O

We	PRP	O	O
studied	VBD	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
a	DT	O	O
single	JJ	O	O
dose	NN	O	O
of	IN	O	O
fenoterol	NN	i	IPM
on	IN	O	O
the	DT	O	O
relationship	NN	O	O
between	IN	O	O
inspiratory	NN	O	O
effort	NN	O	O
sensation	NN	O	O
(	(	O	O
IES	NNP	O	O
)	)	O	O
and	CC	O	O
inspiratory	JJ	O	O
muscle	NN	O	O
fatigue	NN	O	O
induced	VBN	O	O
by	IN	O	O
inspiratory	NN	O	O
threshold	NN	O	O
loading	NN	O	O
in	IN	O	O
healthy	JJ	p	O
subjects	NNS	p	O
.	.	p	O

The	DT	O	O
magnitude	NN	O	O
of	IN	O	O
the	DT	O	O
threshold	NN	O	O
was	VBD	O	O
60	CD	O	O
%	NN	O	O
of	IN	O	O
maximal	JJ	O	O
static	JJ	O	O
inspiratory	NN	O	O
mouth	NN	O	O
pressure	NN	O	O
(	(	O	O
PI	NNP	O	O
,	,	O	O
mmax	NN	O	O
)	)	O	O
at	IN	O	O
functional	JJ	O	O
residual	JJ	O	O
capacity	NN	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
duty	NN	O	O
cycle	NN	O	O
was	VBD	O	O
0.5	CD	O	O
.	.	O	O

Subjects	NNS	p	O
continued	VBD	O	O
the	DT	O	O
threshold	NN	O	O
loaded	VBD	O	O
breathing	NN	O	O
until	IN	O	O
the	DT	O	O
target	NN	O	O
mouth	NN	O	O
pressure	NN	O	O
could	MD	O	O
no	RB	O	O
longer	RB	O	O
be	VB	O	O
maintained	VBN	O	O
(	(	O	O
endurance	JJ	O	O
time	NN	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
intensity	NN	O	O
of	IN	O	O
the	DT	O	O
IES	NNP	O	O
was	VBD	O	O
scored	VBN	O	O
with	IN	O	O
a	DT	O	O
modified	JJ	O	O
Borg	NNP	O	O
scale	NN	O	O
.	.	O	O

Either	CC	O	O
fenoterol	NN	i	IPM
(	(	i	IPM
5	CD	i	IPM
mg	NN	i	IPM
)	)	i	IPM
or	CC	i	O
a	DT	i	O
placebo	NN	i	IPM
was	VBD	O	O
given	VBN	O	O
orally	RB	O	O
2	CD	O	O
h	NN	O	O
before	IN	O	O
loading	VBG	O	O
in	IN	O	O
a	DT	O	O
randomized	JJ	O	O
double-blind	NN	O	O
crossover	NN	O	O
protocol	NN	O	O
.	.	O	O

The	DT	O	O
endurance	NN	o	OPH
time	NN	o	OPH
with	IN	O	O
fenoterol	NN	O	O
(	(	O	O
34.4	CD	O	O
+/-	JJ	O	O
8.6	CD	O	O
min	NN	O	O
)	)	O	O
was	VBD	O	O
longer	JJR	O	O
than	IN	O	O
that	DT	O	O
with	IN	O	O
the	DT	O	O
placebo	NN	O	O
(	(	O	O
22.2	CD	O	O
+/-	JJ	O	O
7.1	CD	O	O
min	NN	O	O
;	:	O	O
P	NNP	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
ratio	NN	o	OPH
of	IN	o	OPH
high-	JJ	o	OPH
to	TO	o	OPH
low-frequency	JJ	o	OPH
power	NN	o	OPH
of	IN	o	OPH
the	DT	o	OPH
diaphragmatic	JJ	o	OPH
electromyogram	NN	o	OPH
(	(	o	OPH
EMGdi	NNP	o	OPH
)	)	o	OPH
decreased	VBD	O	O
during	IN	O	O
loading	NN	O	O
;	:	O	O
the	DT	O	O
decrease	NN	O	O
was	VBD	O	O
less	RBR	O	O
with	IN	O	O
fenoterol	NN	i	IPM
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
EMGdi	NNP	o	OPH
also	RB	O	O
decreased	VBD	O	O
with	IN	O	O
loading	NN	O	O
;	:	O	O
the	DT	O	O
decrease	NN	O	O
was	VBD	O	O
greater	JJR	O	O
on	IN	O	O
fenoterol	NN	O	O
treatment	NN	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.01	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
PI	NNP	o	OPH
,	,	o	OPH
mmax	NN	o	OPH
and	CC	o	OPH
maximal	JJ	o	OPH
transdiaphragmatic	JJ	o	OPH
pressure	NN	o	OPH
(	(	o	OPH
Pdi	NNP	o	OPH
)	)	o	OPH
were	VBD	O	O
similarly	RB	O	O
decreased	VBN	O	O
after	IN	O	O
loading	VBG	O	O
on	IN	O	O
either	DT	O	O
treatment	NN	O	O
.	.	O	O

The	DT	O	O
intensity	NN	o	OPH
of	IN	o	OPH
the	DT	o	OPH
IES	NNP	o	OPH
rose	VBD	o	OPH
with	IN	o	OPH
time	NN	o	OPH
during	IN	O	O
loading	VBG	O	O
in	IN	O	O
both	DT	O	O
groups	NNS	O	O
but	CC	O	O
was	VBD	O	O
lower	JJR	O	O
with	IN	O	O
fenoterol	NN	i	IPM
than	IN	O	O
with	IN	O	O
the	DT	O	O
placebo	NN	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
ratio	NN	o	OPH
of	IN	o	OPH
Pdi	NNP	o	OPH
to	TO	O	O
integrated	JJ	O	O
activity	NN	O	O
of	IN	O	O
the	DT	O	O
EMGdi	NNP	O	O
increased	VBD	O	O
with	IN	O	O
fenoterol	NN	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

Fenoterol	NNP	O	O
treatment	NN	O	O
increased	VBD	O	O
both	DT	O	O
superimposed	VBN	o	OPH
Pdi	NNP	o	OPH
twitch	NN	o	OPH
and	CC	o	OPH
Pdi	NNP	o	OPH
twitch	NN	o	OPH
of	IN	o	OPH
relaxed	JJ	o	OPH
diaphragm	NN	o	OPH
and	CC	O	O
decreased	VBD	O	O
the	DT	O	O
value	NN	o	OPH
of	IN	o	OPH
(	(	o	OPH
1-superimposed	JJ	o	OPH
Pdi	NNP	o	OPH
twitch/Pdi	NN	o	OPH
twitch	NN	o	OPH
of	IN	o	OPH
relaxed	JJ	o	OPH
diaphragm	NN	o	OPH
)	)	o	OPH
.	.	o	OPH

Thus	IN	O	O
we	PRP	O	O
conclude	VBP	O	O
that	IN	O	O
in	IN	O	O
normal	JJ	p	O
subjects	NNS	p	O
fenoterol	JJ	O	O
reduces	NNS	O	O
diaphragmatic	JJ	O	O
fatigue	NN	O	O
and	CC	O	O
decreases	VBZ	O	O
the	DT	O	O
motor	NN	O	O
command	NN	O	O
to	TO	O	O
the	DT	O	O
diaphragm	NN	O	O
,	,	O	O
resulting	VBG	O	O
in	IN	O	O
a	DT	O	O
decrease	NN	O	O
in	IN	O	O
IES	NNP	O	O
during	IN	O	O
inspiratory	JJ	O	O
threshold	JJ	O	O
loading	NN	O	O
and	CC	O	O
a	DT	O	O
prolongation	NN	O	O
of	IN	O	O
endurance	NN	O	O
.	.	O	O

A	DT	O	O
randomized	JJ	O	O
trial	NN	O	O
of	IN	O	O
intranasal	NN	O	O
beclomethasone	NN	i	IPM
dipropionate	NN	i	IPM
after	IN	O	O
polypectomy	NN	O	O
.	.	O	O

Beneficial	JJ	O	O
effects	NNS	O	O
of	IN	O	O
intranasal	NN	i	IPM
beclomethasone	NN	i	IPM
dipropionate	NN	i	IPM
(	(	i	IPM
Bdp	NNP	i	IPM
)	)	i	IPM
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
nasal	JJ	p	PC
polyposis	NN	p	PC
have	VBP	O	O
been	VBN	O	O
reported	VBN	O	O
earlier	RBR	O	O
.	.	O	O

This	DT	O	O
study	NN	O	O
was	VBD	O	O
carried	VBN	O	O
out	IN	O	O
to	TO	O	O
investigate	VB	O	O
whether	IN	O	O
long-term	JJ	O	O
treatment	NN	O	O
with	IN	O	O
Bdp	NNP	i	IPM
after	IN	O	O
polypectomy	NN	O	O
could	MD	O	O
prevent	VB	O	O
formation	NN	O	O
of	IN	O	O
new	JJ	O	O
polyps	NNS	O	O
and	CC	O	O
reduce	VB	O	O
the	DT	O	O
number	NN	O	O
of	IN	O	O
surgical	JJ	O	O
removals	NNS	O	O
.	.	O	O

Forty	NNP	p	PSS
consecutive	JJ	p	O
patients	NNS	p	O
without	IN	p	O
laboratory	NN	p	O
or	CC	p	O
other	JJ	p	O
clinical	JJ	p	O
signs	NNS	p	O
of	IN	p	O
allergy	NN	p	O
but	CC	p	O
with	IN	p	O
severe	JJ	p	PC
nasal	JJ	p	PC
polyposis	NN	p	PC
were	VBD	p	O
included	VBN	p	O
in	IN	p	O
the	DT	p	O
study	NN	p	O
.	.	p	O

Twenty	CD	p	PSS
patients	NNS	p	O
were	VBD	p	O
treated	VBN	p	O
with	IN	p	O
intranasal	JJ	i	IPM
Bdp	NNP	i	IPM
and	CC	p	O
twenty	JJ	p	PSS
patients	NNS	p	O
received	VBD	p	O
no	DT	p	O
treatment	NN	p	O
after	IN	p	O
polypectomy	NN	i	IS
.	.	i	IS

All	DT	O	O
patients	NNS	p	O
were	VBD	p	O
followed	VBN	p	O
for	IN	p	O
at	IN	p	O
least	JJS	p	O
2.5	CD	p	O
years	NNS	p	O
.	.	p	O

The	DT	O	O
size	NN	o	OPH
of	IN	o	OPH
the	DT	o	OPH
polyps	NNS	o	OPH
that	WDT	o	OPH
recurred	VBD	o	OPH
was	VBD	O	O
estimated	VBN	O	O
at	IN	O	O
different	JJ	O	O
time-intervals	NNS	O	O
by	IN	O	O
the	DT	O	O
examining	VBG	O	O
doctor	NN	O	O
.	.	O	O

After	IN	O	O
six	CD	O	O
months	NNS	O	O
there	RB	O	O
was	VBD	O	O
already	RB	O	O
a	DT	O	O
significant	JJ	o	O
difference	NN	o	OOt
in	IN	O	O
favour	NN	O	O
of	IN	O	O
the	DT	O	O
group	NN	O	O
treated	VBD	O	O
with	IN	O	O
intranasal	JJ	O	O
Bdp	NNP	i	IPM
.	.	i	O

Further	NNP	O	O
results	NNS	O	O
of	IN	O	O
the	DT	O	O
study	NN	O	O
and	CC	O	O
the	DT	O	O
clinical	JJ	O	O
implications	NNS	O	O
are	VBP	O	O
discussed	VBN	O	O
.	.	O	O

Intervention	NN	i	IPH
for	IN	i	IPH
ineffective	JJ	o	OPH
airway	JJ	o	OPH
clearance	NN	o	OPH
in	IN	i	IPH
asthmatic	JJ	i	IPH
children	NNS	i	IPH
:	:	i	IPH
a	DT	O	O
controlled	VBN	O	O
and	CC	O	O
randomized	VBN	O	O
clinical	JJ	O	O
trial	NN	O	O
.	.	O	O

This	DT	O	O
study	NN	O	O
aimed	VBD	O	O
to	TO	O	O
analyse	VB	O	O
the	DT	O	O
effectiveness	NN	O	O
of	IN	O	O
an	DT	O	O
intervention	NN	O	O
for	IN	O	O
the	DT	O	O
nursing	NN	O	O
diagnosis	NN	O	O
of	IN	O	O
ineffective	JJ	o	OPH
airway	JJ	o	OPH
clearance	NN	o	OPH
in	IN	O	O
asthmatic	JJ	p	O
children	NNS	p	O
.	.	p	O

A	DT	O	O
blinded	JJ	O	O
,	,	O	O
randomized	VBN	O	O
and	CC	O	O
controlled	VBN	O	O
clinical	JJ	O	O
trial	NN	O	O
was	VBD	O	O
developed	VBN	O	O
in	IN	O	O
a	DT	O	O
paediatric	JJ	p	O
hospital	NN	p	O
located	VBN	p	O
on	IN	p	O
northeast	NN	p	O
of	IN	p	O
Brazil	NNP	p	O
with	IN	p	O
42	CD	p	O
asthmatic	JJ	p	O
children	NNS	p	O
aged	VBN	p	O
?	.	p	O
36	CD	p	O
months	NNS	p	O
.	.	p	O

The	DT	p	O
children	NNS	p	O
were	VBD	p	O
randomly	RB	O	O
divided	VBN	O	O
into	IN	O	O
two	CD	O	O
groups	NNS	O	O
(	(	O	O
intervention	NN	O	O
and	CC	i	O
control	NN	i	O
)	)	i	O
by	IN	i	O
means	NNS	O	O
of	IN	O	O
a	DT	O	O
simple	JJ	O	O
drawing	NN	O	O
.	.	O	O

The	DT	O	O
applied	JJ	O	O
intervention	NN	O	O
included	VBD	O	O
actions	NNS	O	O
related	VBN	O	O
to	TO	O	O
change	VB	i	O
of	IN	i	O
positioning	NN	i	O
and	CC	i	O
stimulation	NN	i	O
of	IN	i	O
cough	NN	i	O
.	.	i	O

The	DT	O	O
main	JJ	O	O
findings	NNS	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
show	VBP	O	O
that	IN	O	O
before	IN	O	O
the	DT	O	O
intervention	NN	O	O
,	,	O	O
no	DT	O	O
significant	JJ	O	O
difference	NN	O	O
was	VBD	O	O
observed	VBN	O	O
in	IN	O	O
the	DT	o	O
health	NN	o	O
status	NN	o	O
of	IN	o	O
the	DT	O	O
children	NNS	O	O
.	.	O	O

After	IN	O	O
the	DT	O	O
intervention	NN	O	O
,	,	O	O
the	DT	O	O
indicators	NNS	O	O
of	IN	O	O
choking	VBG	o	O
(	(	o	O
16.83	CD	O	O
vs.	FW	O	O
26.17	CD	O	O
,	,	O	O
P	NNP	O	O
=	NNP	O	O
0.007	CD	O	O
)	)	O	O
and	CC	o	O
adventitious	JJ	o	O
breath	NN	o	O
sounds	NNS	o	O
(	(	o	O
16.4	CD	O	O
vs.	FW	O	O
26.6	CD	O	O
,	,	O	O
P	NNP	O	O
=	NNP	O	O
0.005	CD	O	O
)	)	O	O
were	VBD	O	O
higher	JJR	O	O
,	,	O	O
on	IN	O	O
average	NN	O	O
,	,	O	O
in	IN	O	O
the	DT	O	O
intervention	NN	O	O
group	NN	O	O
.	.	O	O

It	PRP	O	O
was	VBD	O	O
observed	VBN	O	O
an	DT	O	O
improvement	NN	O	O
in	IN	O	O
obstructive	JJ	o	O
symptoms	NNS	o	O
in	IN	o	O
children	NNS	p	O
who	WP	p	O
received	VBD	p	O
the	DT	p	O
intervention	NN	p	O
proposed	VBN	p	O
.	.	O	O

Double-blind	NNP	O	O
,	,	O	O
placebo-controlled	JJ	i	IC
trial	NN	O	O
of	IN	O	O
risperidone	NN	i	IPM
plus	CC	i	IPM
amantadine	NN	i	IPM
in	IN	O	O
children	NNS	p	PA
with	IN	p	O
autism	NN	p	PC
:	:	p	O
a	DT	O	O
10-week	JJ	O	O
randomized	NN	O	O
study	NN	O	O
.	.	O	O

OBJECTIVE	NNP	O	O
This	DT	O	O
study	NN	O	O
aimed	VBD	O	O
to	TO	O	O
investigate	VB	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
adding	VBG	O	O
amantadine	NN	i	IPM
to	TO	i	IPM
risperidone	VB	i	IPM
for	IN	O	O
treatment	NN	O	O
of	IN	O	O
autism	NN	O	O
.	.	O	O

METHODS	NNP	O	O
Forty	NNP	p	PSS
outpatients	NNS	p	O
aged	VBD	p	O
4	CD	p	PA
to12	NN	p	PA
years	NNS	p	O
,	,	p	O
who	WP	p	O
were	VBD	p	O
diagnosed	VBN	p	O
with	IN	p	O
autism	NN	p	PC
spectrum	NN	p	PC
disorders	NNS	p	PC
based	VBN	p	O
on	IN	p	O
the	DT	p	O
Diagnostic	NNP	p	O
and	CC	p	O
Statistical	NNP	p	O
Manual	NNP	p	O
of	IN	p	O
Mental	NNP	p	O
Disorders	NNP	p	O
,	,	p	O
Fourth	NNP	p	O
Edition	NNP	p	O
,	,	p	O
Text	NNP	p	O
Revision	NNP	p	O
criteria	NNS	p	O
,	,	O	O
were	VBD	O	O
assigned	VBN	O	O
to	TO	O	O
this	DT	O	O
double-blind	JJ	O	O
clinical	JJ	O	O
trial	NN	O	O
.	.	O	O

The	DT	O	O
subjects	NNS	O	O
were	VBD	O	O
divided	VBN	O	O
randomly	RB	O	O
into	IN	O	O
2	CD	O	O
groups	NNS	O	O
.	.	O	O

One	CD	O	O
group	NN	O	O
received	VBD	O	O
risperidone	JJ	i	IPM
plus	CC	i	IPM
amantadine	JJ	i	IPM
,	,	i	O
and	CC	i	O
the	DT	i	O
other	JJ	i	O
group	NN	i	O
received	VBD	i	O
risperidone	JJ	i	IPM
plus	CC	i	IPM
placebo	NN	i	IC
.	.	i	O

The	DT	O	O
dose	NN	O	O
of	IN	O	O
risperidone	NN	O	O
was	VBD	O	O
titrated	VBN	O	O
between	IN	O	O
1	CD	O	O
and	CC	O	O
2.0	CD	O	O
mg/d	NN	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
dose	NN	O	O
of	IN	O	O
amantadine	NN	i	IPM
was	VBD	O	O
100	CD	O	O
or	CC	O	O
150	CD	O	O
mg/d	NNS	O	O
for	IN	O	O
patients	NNS	O	O
less	JJR	O	O
than	IN	O	O
30	CD	O	O
kg	NN	O	O
or	CC	O	O
more	JJR	O	O
than	IN	O	O
30	CD	O	O
kg	NNS	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

The	DT	O	O
patients	NNS	O	O
were	VBD	O	O
assessed	VBN	O	O
using	VBG	O	O
the	DT	O	O
Aberrant	NNP	o	OME
Behavioral	NNP	o	OME
Checklist-Community	NNP	o	OME
(	(	o	OME
ABC-C	NNP	o	OME
)	)	o	OME
and	CC	o	OME
adverse	JJ	o	OA
effects	NNS	o	OA
checklist	NN	o	OA
as	RB	O	O
well	RB	O	O
as	IN	O	O
clinical	JJ	o	OME
global	JJ	o	OME
impression-improvement	NN	o	OME
(	(	o	OME
CGI-I	NNP	o	OME
)	)	o	OME
at2	VBZ	O	O
checkpoints	NNS	O	O
of	IN	O	O
5-week	JJ	O	O
intervals	NNS	O	O
after	IN	O	O
the	DT	O	O
baseline	NN	O	O
.	.	O	O

Informed	NNP	O	O
consentwas	NN	O	O
obtained	VBN	O	O
from	IN	O	O
the	DT	O	O
parents	NNS	O	O
of	IN	O	O
each	DT	O	O
participant	NN	O	O
.	.	O	O

RESULTS	NNP	O	O
Among	IN	O	O
ABC-C	NNP	o	OME
subscales	NNS	o	OME
,	,	o	OME
Hyperactivity	NNP	o	OME
and	CC	o	OME
Irritability	NNP	o	OME
showed	VBD	O	O
significantly	RB	O	O
greater	JJR	O	O
reduction	NN	O	O
in	IN	O	O
the	DT	O	O
amantadine	NN	O	O
group	NN	O	O
than	IN	O	O
the	DT	O	O
placebo	NN	O	O
group	NN	O	O
.	.	O	O

There	EX	O	O
was	VBD	O	O
no	DT	O	O
significant	JJ	O	O
difference	NN	O	O
in	IN	O	O
adverse	JJ	o	OA
effects	NNS	o	OA
between	IN	O	O
the	DT	O	O
2	CD	O	O
groups	NNS	O	O
.	.	O	O

The	DT	O	O
CGI-I	JJ	o	OME
scores	NNS	o	OME
show	VBP	O	O
significant	JJ	O	O
improvement	NN	O	O
in	IN	O	O
the	DT	O	O
amantadine	NN	i	IPM
group	NN	O	O
compared	VBN	O	O
to	TO	O	O
the	DT	O	O
placebo	NN	O	O
group	NN	O	O
.	.	O	O

CONCLUSIONS	VB	O	O
The	DT	O	O
present	JJ	O	O
study	NN	O	O
suggests	VBZ	O	O
that	IN	O	O
amantadine	NN	i	IPM
may	MD	O	O
be	VB	O	O
a	DT	O	O
potential	JJ	O	O
adjunctive	JJ	O	O
treatment	NN	O	O
strategy	NN	O	O
for	IN	O	O
autism	NN	O	O
and	CC	O	O
it	PRP	O	O
was	VBD	O	O
generally	RB	O	O
well	RB	O	O
tolerated	VBN	O	O
.	.	O	O

Antibiotic	JJ	i	IPM
prophylaxis	NN	i	IPM
in	IN	O	O
high-risk	JJ	p	PC
head	NN	p	PC
and	CC	p	PC
neck	NN	p	PC
surgery	NN	p	PC
:	:	p	O
one-day	JJ	i	IPM
vs.	IN	O	O
five-day	JJ	i	IPM
therapy	NN	i	IPM
.	.	i	O

Patients	NNS	p	O
who	WP	p	O
undergo	VBP	p	O
major	JJ	p	O
contaminated	VBN	p	O
surgery	NN	p	O
of	IN	p	O
the	DT	p	O
head	NN	p	O
and	CC	p	O
neck	NN	p	O
benefit	NN	O	O
from	IN	O	O
perioperative	JJ	O	O
antibiotic	JJ	i	IPM
prophylaxis	NN	i	IPM
.	.	i	O

This	DT	O	O
study	NN	O	O
was	VBD	O	O
developed	VBN	O	O
to	TO	O	O
determine	VB	O	O
if	IN	O	O
5	CD	O	O
days	NNS	O	O
of	IN	O	O
antibiotic	JJ	o	OOt
administration	NN	o	OOt
would	MD	O	O
be	VB	O	O
more	RBR	O	O
effective	JJ	O	O
than	IN	O	O
1	CD	O	O
day	NN	O	O
.	.	O	O

A	DT	O	O
multi-institutional	JJ	O	O
prospective	JJ	O	O
randomized	VBN	O	O
double-blind	NN	O	O
study	NN	O	O
was	VBD	O	O
designed	VBN	O	O
.	.	O	O

Patients	NNS	p	O
who	WP	p	O
were	VBD	p	O
identified	VBN	p	O
as	IN	p	O
requiring	VBG	p	O
pedicled	VBD	p	O
flap	JJ	p	O
reconstruction	NN	p	O
were	VBD	p	O
potential	JJ	p	O
candidates	NNS	p	O
for	IN	p	O
the	DT	p	O
study	NN	p	O
.	.	p	O

Later	NNP	O	O
,	,	O	O
patients	NNS	O	O
were	VBD	O	O
randomly	RB	O	O
assigned	VBN	O	O
to	TO	O	O
receive	VB	O	O
cefoperazone	NN	i	IPM
sodium	NN	i	IPM
for	IN	O	O
either	DT	O	O
24	CD	i	O
hours	NNS	i	O
or	CC	i	O
120	CD	i	O
hours	NNS	i	O
.	.	i	O

In	IN	O	O
each	DT	O	O
case	NN	O	O
,	,	O	O
the	DT	O	O
drug	NN	O	O
was	VBD	O	O
administered	VBN	O	O
intravenously	RB	O	O
,	,	O	O
beginning	VBG	O	O
1	CD	O	O
to	TO	O	O
2	CD	O	O
hours	NNS	O	O
preoperatively	RB	O	O
and	CC	O	O
continued	VBD	O	O
for	IN	O	O
the	DT	O	O
prescribed	JJ	O	O
period	NN	O	O
.	.	O	O

One	CD	p	PSS
hundred	VBD	p	PSS
nine	CD	p	PSS
patients	NNS	p	O
were	VBD	p	O
evaluable	JJ	p	O
.	.	p	O

Fifty-three	JJ	O	O
patients	NNS	O	O
were	VBD	O	O
assigned	VBN	O	O
to	TO	O	O
1	CD	O	O
day	NN	O	O
of	IN	O	O
perioperative	JJ	O	O
prophylaxis	NN	O	O
.	.	O	O

Wound	NNP	o	OPH
infection	NN	o	OPH
developed	VBD	O	O
in	IN	O	O
ten	JJ	O	O
patients	NNS	O	O
(	(	O	O
18.9	CD	O	O
%	NN	O	O
)	)	O	O
.	.	O	O

Fifty-six	JJ	O	O
patients	NNS	O	O
were	VBD	O	O
assigned	VBN	O	O
to	TO	O	O
5	CD	O	O
days	NNS	O	O
of	IN	O	O
perioperative	JJ	i	IPM
antibiotic	JJ	i	IPM
prophylaxis	NN	i	IPM
.	.	i	O

Wound	NNP	o	OPH
infection	NN	o	OPH
developed	VBD	O	O
in	IN	O	O
14	CD	O	O
(	(	O	O
25	CD	O	O
%	NN	O	O
)	)	O	O
of	IN	O	O
these	DT	O	O
patients	NNS	O	O
(	(	O	O
P	NNP	O	O
greater	JJR	O	O
than	IN	O	O
.05	NN	O	O
)	)	O	O
.	.	O	O

These	DT	O	O
data	NNS	O	O
suggest	VBP	O	O
that	IN	O	O
no	DT	O	O
beneficial	JJ	O	O
effect	NN	O	O
from	IN	O	O
administration	NN	O	O
of	IN	O	O
antibiotics	NNS	i	IPM
for	IN	O	O
longer	JJR	O	O
than	IN	O	O
24	CD	O	O
hours	NNS	O	O
postoperatively	RB	O	O
can	MD	O	O
be	VB	O	O
achieved	VBN	O	O
in	IN	O	O
patients	NNS	O	O
who	WP	O	O
undergo	VBP	O	O
myocutaneous	JJ	O	O
flap	JJ	O	O
reconstruction	NN	O	O
.	.	O	O

Azelnidipine	NNP	i	IPM
and	CC	O	O
amlodipine	VB	i	IPM
anti-coronary	JJ	O	O
atherosclerosis	NN	O	O
trial	NN	O	O
in	IN	O	O
hypertensive	JJ	p	O
patients	NNS	p	O
undergoing	VBG	p	O
coronary	JJ	p	O
intervention	NN	p	O
by	IN	p	O
serial	JJ	p	O
volumetric	JJ	p	O
intravascular	NN	p	O
ultrasound	NN	p	O
analysis	NN	p	O
in	IN	p	O
Juntendo	NNP	p	O
university	NN	p	O
(	(	p	O
ALPS-J	NNP	p	O
)	)	p	O
.	.	O	O

PURPOSE	NNP	O	O
Many	JJ	O	O
trials	NNS	O	O
have	VBP	O	O
shown	VBN	O	O
that	IN	O	O
calcium	NN	O	O
channel	NN	O	O
blockers	NNS	O	O
(	(	O	O
CCBs	NNP	O	O
)	)	O	O
can	MD	O	O
reduce	VB	O	O
the	DT	O	O
cardiovascular	NN	o	OPH
(	(	o	OPH
CV	NNP	o	OPH
)	)	o	OPH
events	NNS	o	OPH
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
coronary	JJ	p	O
artery	NN	p	O
disease	NN	p	O
(	(	p	O
CAD	NNP	p	O
)	)	p	O
.	.	p	O

The	DT	O	O
mechanisms	NN	O	O
of	IN	O	O
this	DT	O	O
effect	NN	O	O
could	MD	O	O
be	VB	O	O
associated	VBN	O	O
with	IN	O	O
plaque	JJ	O	O
regression	NN	O	O
due	JJ	O	O
to	TO	O	O
the	DT	O	O
anti-atherosclerotic	JJ	O	O
properties	NNS	O	O
of	IN	O	O
CCBs	NNP	O	O
.	.	O	O

The	DT	O	O
goal	NN	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
is	VBZ	O	O
to	TO	O	O
determine	VB	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
CCB	NNP	O	O
on	IN	O	O
volumetric	JJ	O	O
quantitative	JJ	O	O
changes	NNS	O	O
of	IN	O	O
coronary	JJ	O	O
plaques	NNS	O	O
accessed	VBN	O	O
by	IN	O	O
intravascular	JJ	O	O
ultrasound	NN	O	O
(	(	O	O
IVUS	NNP	O	O
)	)	O	O
.	.	O	O

To	TO	O	O
confirm	VB	O	O
this	DT	O	O
hypothesis	NN	O	O
,	,	O	O
a	DT	O	O
multicenter	NN	O	O
randomized	VBN	O	O
trial	NN	O	O
of	IN	O	O
CCBs	NNP	O	O
treatment	NN	O	O
with	IN	O	O
azelnidipine	NN	i	IPM
or	CC	O	O
amlodipine	NN	i	IPM
will	MD	O	O
be	VB	O	O
conducted	VBN	O	O
in	IN	O	O
hypertensive	JJ	p	O
CAD	NNP	p	O
patients	NNS	p	O
undergoing	VBG	p	O
elective	JJ	p	O
percutaneous	JJ	p	O
coronary	JJ	p	O
intervention	NN	p	O
(	(	p	O
PCI	NNP	p	O
)	)	p	O
.	.	p	O

METHODS	NNP	O	O
AND	CC	O	O
RESULTS	NNP	O	O
Patients	NNPS	p	O
who	WP	p	O
have	VBP	p	O
hypertension	NN	p	O
and	CC	p	O
are	VBP	p	O
scheduled	VBN	p	O
for	IN	p	O
PCI	NNP	p	O
will	MD	p	O
be	VB	p	O
enrolled	VBN	p	O
.	.	p	O

Subjects	NNS	O	O
will	MD	O	O
be	VB	O	O
randomized	VBN	O	O
to	TO	O	O
azelnidipine	VB	i	IPM
or	CC	O	O
amlodipine	VB	i	IPM
and	CC	O	O
observed	VB	O	O
for	IN	O	O
48	CD	O	O
weeks	NNS	O	O
.	.	O	O

The	DT	O	O
primary	JJ	O	O
endpoint	NN	O	O
will	MD	O	O
be	VB	O	O
the	DT	O	O
percent	NN	o	OPH
change	NN	o	OPH
of	IN	o	OPH
coronary	JJ	o	OPH
plaque	NN	o	OPH
volume	NN	o	OPH
.	.	o	O

The	DT	O	O
secondary	JJ	O	O
endpoint	NN	O	O
will	MD	O	O
include	VB	O	O
inflammatory	JJ	o	OPH
markers	NNS	o	OPH
,	,	o	OPH
antioxidant	JJ	o	OPH
activity	NN	o	OPH
,	,	o	OPH
and	CC	o	OPH
incidence	NN	o	OPH
of	IN	o	OPH
composite	JJ	o	OPH
cardiovascular	JJ	o	OPH
events	NNS	o	OPH
.	.	o	O

CONCLUSIONS	NNP	O	O
In	IN	O	O
this	DT	O	O
study	NN	O	O
,	,	O	O
we	PRP	O	O
will	MD	O	O
investigate	VB	O	O
the	DT	O	O
improvement	NN	O	O
of	IN	O	O
coronary	JJ	o	OPH
plaque	NN	o	OPH
with	IN	O	O
IVUS	NNP	O	O
by	IN	O	O
treatment	NN	O	O
with	IN	O	O
two	CD	O	O
dihydropyridine	NN	O	O
CCBs	NNP	O	O
in	IN	O	O
hypertensive	JJ	p	O
patients	NNS	p	O
undergoing	VBG	p	O
elective	JJ	p	O
PCI	NNP	p	O
.	.	p	O

This	DT	O	O
result	NN	O	O
will	MD	O	O
lead	VB	O	O
to	TO	O	O
the	DT	O	O
discovery	NN	O	O
of	IN	O	O
more	RBR	O	O
effective	JJ	O	O
drug	NN	O	O
therapy	NN	O	O
for	IN	O	O
inhibition	NN	O	O
of	IN	O	O
coronary	JJ	o	OPH
events	NNS	o	OPH
.	.	o	O

[	NNP	p	O
Medical	NNP	p	PC
safety	NN	p	PC
and	CC	p	O
staff	NN	p	O
mental	JJ	p	O
health	NN	p	O
]	NNP	p	O
.	.	O	O

Improvement	NNP	O	O
in	IN	O	O
patient	JJ	O	O
safety	NN	O	O
is	VBZ	O	O
a	DT	O	O
high-priority	JJ	O	O
issue	NN	O	O
of	IN	O	O
great	JJ	O	O
social	JJ	O	O
import	NN	O	O
.	.	O	O

Several	JJ	O	O
studies	NNS	O	O
have	VBP	O	O
reported	VBN	O	O
that	IN	O	O
most	JJS	O	O
adverse	JJ	O	O
events	NNS	O	O
are	VBP	O	O
due	JJ	O	O
to	TO	O	O
errors	NNS	O	O
of	IN	O	O
hospital	JJ	O	O
staff	NN	O	O
,	,	O	O
and	CC	O	O
emphasized	VBD	O	O
the	DT	O	O
necessity	NN	O	O
of	IN	O	O
promoting	VBG	O	O
countermeasures	NNS	O	O
against	IN	O	O
medical	JJ	O	O
errors	NNS	O	O
.	.	O	O

Root	NNP	O	O
cause	NN	O	O
analysis	NN	O	O
(	(	O	O
RCA	NNP	O	O
)	)	O	O
has	VBZ	O	O
been	VBN	O	O
implemented	VBN	O	O
to	TO	O	O
prevent	VB	O	O
such	JJ	O	O
errors	NNS	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
the	DT	O	O
retrospective	NN	O	O
and	CC	O	O
qualitative	JJ	O	O
nature	NN	O	O
of	IN	O	O
RCA	NNP	O	O
is	VBZ	O	O
a	DT	O	O
limitation	NN	O	O
in	IN	O	O
scientific	JJ	O	O
analyses	NNS	O	O
examining	VBG	O	O
causal	JJ	O	O
relationships	NNS	O	O
.	.	O	O

We	PRP	O	O
showed	VBD	O	O
that	IN	O	O
prospective	JJ	O	O
design	NN	O	O
path	NN	O	O
analysis	NN	O	O
using	VBG	O	O
structural	JJ	i	IE
equation	NN	i	IE
modeling	NN	i	IE
(	(	i	IE
SEM	NNP	i	IE
)	)	i	IE
model	NN	O	O
for	IN	O	O
both	DT	O	O
direct	JJ	O	O
and	CC	O	O
indirect	JJ	O	O
effects	NNS	O	O
enabled	VBD	O	O
statistical	JJ	O	O
exploration	NN	O	O
of	IN	O	O
root	NN	O	O
causes	NNS	O	O
and	CC	O	O
estimation	NN	O	O
of	IN	O	O
their	PRP$	O	O
impact	NN	O	O
on	IN	O	O
the	DT	O	O
outcome	NN	O	O
.	.	O	O

Our	PRP$	O	O
findings	NNS	O	O
suggested	VBD	O	O
such	JJ	O	O
analysis	NN	O	O
to	TO	O	O
be	VB	O	O
useful	JJ	O	O
in	IN	O	O
devising	VBG	O	O
countermeasures	NNS	O	O
against	IN	O	O
medical	JJ	O	O
errors	NNS	O	O
.	.	O	O

The	DT	O	O
SEM	NNP	O	O
model	NN	O	O
constructed	VBN	O	O
in	IN	O	O
this	DT	O	O
study	NN	O	O
suggested	VBD	O	O
that	IN	O	O
one	CD	O	O
of	IN	O	O
the	DT	O	O
potential	JJ	O	O
root	NN	O	O
causes	NNS	O	O
was	VBD	O	O
sleep	JJ	o	OME
disturbance	NN	o	OME
.	.	o	O

We	PRP	O	O
conducted	VBD	O	O
a	DT	O	O
randomized	VBN	O	O
crossover	NN	O	O
study	NN	O	O
whether	IN	O	O
or	CC	O	O
not	RB	O	O
brief	JJ	O	O
bright	JJ	O	O
light	NN	O	O
(	(	i	O
BL	NNP	i	IPH
)	)	i	O
exposure	NN	O	O
on	IN	O	O
workday	JJ	O	O
mornings	NNS	O	O
can	MD	O	O
improve	VB	O	O
health	NN	O	O
,	,	O	O
performance	NN	O	O
and	CC	O	O
safety	NN	O	O
in	IN	O	O
nurses	NNS	p	PC
with	IN	p	PC
rapidly	RB	p	PC
rotating	VBG	p	PC
shifts	NNS	p	PC
.	.	p	O

Significant	JJ	O	O
improvements	NNS	O	O
were	VBD	O	O
noted	VBN	O	O
in	IN	O	O
the	DT	O	O
BL	NNP	O	O
periods	NNS	O	O
compared	VBN	O	O
with	IN	O	O
the	DT	O	O
non-BL	JJ	O	O
periods	NNS	O	O
for	IN	O	O
self-assessed	JJ	o	OME
sleepiness	NN	o	OME
at	IN	O	O
10	CD	O	O
:	:	O	O
00	CD	O	O
on	IN	O	O
day-shift	JJ	O	O
days	NNS	O	O
,	,	O	O
self-assessment	NN	o	OME
of	IN	o	OME
night	NN	o	OME
sleep	NN	o	OME
for	IN	o	OME
day-shift	JJ	o	OME
days	NNS	o	OME
and	CC	o	OME
for	IN	o	OME
fatigue	NN	o	OME
.	.	o	O

Mean	NNP	o	OPH
response	NN	o	OPH
time	NN	o	OPH
evaluated	VBN	O	O
using	VBG	O	O
the	DT	O	O
psychomotor	NN	O	O
vigilance	NN	O	O
task	NN	O	O
test	NN	O	O
(	(	O	O
PVT	NNP	O	O
)	)	O	O
showed	VBD	O	O
significant	JJ	O	O
improvement	NN	O	O
in	IN	O	O
the	DT	O	O
BL	NNP	O	O
periods	NNS	O	O
compared	VBN	O	O
with	IN	O	O
the	DT	O	O
non-BL	JJ	O	O
periods	NNS	O	O
.	.	O	O

The	DT	O	O
frequency	NN	o	OA
of	IN	o	OA
perceived	JJ	o	OA
adverse	JJ	o	OA
events	NNS	o	OA
and	CC	o	OA
near	JJ	o	OA
misses	NNS	o	OA
was	VBD	O	O
also	RB	O	O
lower	JJR	O	O
in	IN	O	O
the	DT	O	O
BL	NNP	O	O
than	IN	O	O
in	IN	O	O
the	DT	O	O
non-BL	JJ	O	O
periods	NNS	O	O
,	,	O	O
but	CC	O	O
not	RB	O	O
significantly	RB	O	O
so	RB	O	O
,	,	O	O
possibly	RB	O	O
indicating	VBG	O	O
that	IN	O	O
the	DT	O	O
one-month	JJ	O	O
observation	NN	O	O
period	NN	O	O
was	VBD	O	O
too	RB	O	O
short	JJ	O	O
to	TO	O	O
achieve	VB	O	O
any	DT	O	O
significant	JJ	O	O
success	NN	O	O
.	.	O	O

Despite	IN	O	O
our	PRP$	O	O
study	NN	O	O
's	POS	O	O
limitations	NNS	O	O
,	,	O	O
we	PRP	O	O
have	VBP	O	O
effectively	RB	O	O
demonstrated	VBN	O	O
the	DT	O	O
potential	NN	O	O
for	IN	O	O
preventing	VBG	O	O
medical	JJ	O	O
error	NN	O	O
risk	NN	O	O
among	IN	O	O
night-shift	JJ	p	O
workers	NNS	p	O
.	.	p	O

Heart	NNP	o	OPH
rate	NN	o	OPH
variability	NN	o	OPH
and	CC	O	O
QT	NNP	o	OPH
dispersion	NN	o	OPH
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
subclinical	JJ	p	PC
hypothyroidism	NN	p	PC
.	.	p	O

UNLABELLED	IN	O	O
The	DT	O	O
effect	NN	O	O
of	IN	O	O
subclinical	JJ	p	PC
hypothyroidism	NN	p	PC
(	(	p	O
SH	NNP	p	O
)	)	p	O
on	IN	O	O
cardiovascular	JJ	O	O
autonomic	JJ	O	O
function	NN	O	O
and	CC	O	O
ventricular	JJ	O	O
repolarization	NN	O	O
has	VBZ	O	O
not	RB	O	O
been	VBN	O	O
yet	RB	O	O
elucidated	VBN	O	O
.	.	O	O

The	DT	O	O
aim	NN	O	O
of	IN	O	O
the	DT	O	O
present	JJ	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
evaluate	VB	O	O
the	DT	O	O
dispersion	NN	O	O
of	IN	O	O
QT	NNP	O	O
interval	NN	O	O
,	,	O	O
i.e	NN	O	O
.	.	O	O

an	DT	O	O
index	NN	O	O
of	IN	O	O
inhomogeneity	NN	O	O
of	IN	O	O
repolarization	NN	O	O
,	,	O	O
and	CC	O	O
heart	NN	O	O
rate	NN	O	O
variability	NN	O	O
(	(	O	O
HRV	NNP	O	O
)	)	O	O
,	,	O	O
i.e	RB	O	O
.	.	O	O

a	DT	O	O
measure	NN	O	O
of	IN	O	O
cardiac	JJ	O	O
autonomic	JJ	O	O
modulation	NN	O	O
,	,	O	O
in	IN	O	O
SH	NNP	p	PC
patients	NNS	p	O
.	.	p	O

METHODS	NNP	O	O
The	DT	O	O
study	NN	O	O
included	VBD	O	O
42	CD	p	PC
patients	NNS	p	PC
(	(	p	O
29	CD	p	PC
women	NNS	p	PC
and	CC	p	O
13	CD	p	PC
men	NNS	p	PC
;	:	p	O
mean	JJ	p	O
age	NN	p	O
53.2+/-14.2	JJ	p	PA
years	NNS	p	O
;	:	p	O
body	NN	p	O
surface	JJ	p	O
area	NN	p	O
1.76+/-0.14	JJ	p	O
m2	NN	p	O
)	)	p	O
with	IN	p	O
SH	NNP	p	PC
,	,	p	O
as	IN	p	O
judged	VBN	p	O
by	IN	p	O
elevated	JJ	p	O
serum	NN	p	O
TSH	NNP	p	O
levels	NNS	p	O
(	(	p	O
>	$	p	O
3.6	CD	p	O
mIU/l	NN	p	O
;	:	p	O
range	NN	p	O
,	,	p	O
3.8-12.0	JJ	p	O
)	)	p	O
and	CC	p	O
normal	JJ	p	O
free	JJ	p	O
thyroid	NN	p	O
hormones	NNS	p	O
(	(	p	O
FT4	NNP	p	O
and	CC	p	O
FT3	NNP	p	O
)	)	p	O
and	CC	p	O
30	CD	p	O
euthyroid	JJ	p	O
volunteer	NN	p	O
.	.	p	O

Subjects	NNS	p	O
with	IN	p	O
cardiac	JJ	p	PC
,	,	p	PC
metabolic	JJ	p	PC
,	,	p	PC
neurological	JJ	p	PC
disease	NN	p	PC
or	CC	p	O
any	DT	p	O
other	JJ	p	O
systemic	JJ	p	PC
disease	NN	p	PC
that	WDT	p	O
could	MD	p	O
affect	VB	p	O
autonomic	JJ	p	O
activity	NN	p	O
were	VBD	p	O
excluded	VBN	p	O
from	IN	p	O
the	DT	p	O
study	NN	p	O
.	.	p	O

Patients	NNS	p	O
with	IN	p	O
SH	NNP	p	PC
and	CC	O	O
control	VB	O	O
subjects	NNS	O	O
underwent	VB	O	O
a	DT	O	O
full	JJ	O	O
history	NN	O	O
,	,	O	O
physical	JJ	O	O
examination	NN	O	O
,	,	O	O
standard	JJ	O	O
12-lead	JJ	i	IPH
ECG	NNP	i	IPH
,	,	i	IPH
and	CC	i	IPH
24-h	JJ	i	IPH
ambulatory	NN	i	IPH
ECG	NNP	i	IPH
monitoring	NN	i	IPH
.	.	i	O

To	TO	O	O
evaluate	VB	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
treatment	NN	O	O
with	IN	O	O
L-thyroxine	NNP	i	IPM
on	IN	O	O
QT	NNP	O	O
dispersion	NN	O	O
and	CC	O	O
HRV	NNP	O	O
,	,	O	O
15	CD	O	O
patients	NNS	O	O
with	IN	O	O
SH	NNP	O	O
were	VBD	O	O
randomly	RB	O	O
assigned	VBN	O	O
to	TO	O	O
receive	VB	O	O
therapy	NN	O	O
with	IN	O	O
L-thyroxine	NNP	i	IPM
.	.	i	O

All	PDT	O	O
the	DT	O	O
subjects	NNS	O	O
were	VBD	O	O
evaluated	VBN	O	O
at	IN	O	O
enrolment	NN	O	O
and	CC	O	O
after	IN	O	O
6	CD	O	O
months	NNS	O	O
.	.	O	O

RESULTS	NNP	O	O
Patients	NNPS	p	O
with	IN	p	O
SH	NNP	p	PC
showed	VBD	O	O
higher	JJR	O	O
QT	NNP	o	OPH
dispersion	NN	o	OPH
and	CC	O	O
lower	JJR	o	OPH
HRV	NNP	o	OPH
measures	NNS	o	OPH
than	IN	O	O
healthy	JJ	O	O
controls	NNS	O	O
(	(	O	O
P	NNP	O	O
<	VBZ	O	O
0.01	CD	O	O
for	IN	O	O
all	DT	O	O
)	)	O	O
.	.	O	O

In	IN	O	O
SH	NNP	O	O
patients	NNS	O	O
,	,	O	O
the	DT	O	O
standard	JJ	o	OPH
deviation	NN	o	OPH
of	IN	o	OPH
N-Ns	NNP	o	OPH
(	(	o	OPH
SDNN	NNP	o	OPH
)	)	o	OPH
was	VBD	O	O
negatively	RB	O	O
related	VBN	O	O
to	TO	O	O
TSH	NNP	O	O
(	(	O	O
r=-0.42	JJ	O	O
,	,	O	O
P=0.006	NNP	O	O
)	)	O	O
,	,	O	O
while	IN	O	O
low	JJ	o	OPH
frequency	NN	o	OPH
(	(	o	OPH
LF	NNP	o	OPH
)	)	o	OPH
/high	VBP	o	OPH
frequency	NN	o	OPH
(	(	o	OPH
HF	NNP	o	OPH
)	)	o	OPH
ratio	NN	o	OPH
was	VBD	O	O
positively	RB	O	O
related	VBN	O	O
to	TO	O	O
TSH	NNP	O	O
(	(	O	O
r=0.42	NN	O	O
,	,	O	O
P=0.006	NNP	O	O
)	)	O	O
.	.	O	O

Moreover	RB	O	O
,	,	O	O
in	IN	O	O
SH	NNP	p	PC
patients	NNS	p	O
both	DT	O	O
QT	NNP	o	OPH
dispersion	NN	o	OPH
and	CC	o	O
QTc	NNP	o	OPH
dispersion	NN	o	OPH
were	VBD	O	O
positively	RB	O	O
related	VBN	O	O
to	TO	O	O
TSH	NNP	O	O
(	(	O	O
r=0.64	NN	O	O
and	CC	O	O
r=0.63	NN	O	O
,	,	O	O
P	NNP	O	O
<	VBZ	O	O
0.001	CD	O	O
for	IN	O	O
both	DT	O	O
)	)	O	O
.	.	O	O

After	IN	O	O
6	CD	O	O
months	NNS	O	O
,	,	O	O
the	DT	O	O
patients	NNS	O	O
treated	VBN	O	O
with	IN	O	O
L-tiroxine	NNP	i	IPM
exhibited	VBD	O	O
a	DT	O	O
reduction	NN	O	O
of	IN	O	O
QT	NNP	o	OPH
dispersion	NN	o	OPH
and	CC	O	O
an	DT	O	O
increase	NN	O	O
of	IN	O	O
HRV	NNP	o	OPH
parameters	NNS	o	OPH
.	.	o	O

CONCLUSION	VB	O	O
The	DT	O	O
results	NNS	O	O
of	IN	O	O
the	DT	O	O
present	JJ	O	O
study	NN	O	O
demonstrated	VBD	O	O
that	IN	O	O
SH	NNP	O	O
can	MD	O	O
alter	VB	O	O
autonomic	JJ	O	O
modulation	NN	O	O
of	IN	O	O
heart	NN	o	OPH
rate	NN	o	OPH
and	CC	O	O
cause	NN	O	O
increased	VBD	O	O
inhomogeneity	NN	O	O
of	IN	O	O
ventricular	JJ	O	O
recovery	NN	O	O
times	NNS	O	O
.	.	O	O

Accordingly	RB	O	O
,	,	O	O
early	JJ	O	O
L-thyroxine	JJ	i	IPM
treatment	NN	O	O
may	MD	O	O
be	VB	O	O
advised	VBN	O	O
not	RB	O	O
only	RB	O	O
to	TO	O	O
prevent	VB	O	O
progression	NN	O	O
to	TO	O	O
overt	VB	O	O
hypothyroidism	NN	O	O
but	CC	O	O
also	RB	O	O
to	TO	O	O
improve	VB	O	O
abnormal	JJ	O	O
cardiac	JJ	O	O
autonomic	JJ	O	O
function	NN	O	O
and	CC	O	O
ventricular	JJ	O	O
repolarization	NN	O	O
inhomogeneity	NN	O	O
.	.	O	O

Effect	NN	O	O
of	IN	O	O
intravenous	JJ	O	O
dezocine	NN	i	IPM
on	IN	O	O
fentanyl-induced	JJ	p	O
cough	NN	o	OPH
during	IN	p	O
general	JJ	p	O
anesthesia	JJ	p	O
induction	NN	p	O
:	:	p	O
a	DT	O	O
double-blinded	JJ	O	O
,	,	O	O
prospective	JJ	O	O
,	,	O	O
randomized	VBN	O	O
,	,	O	O
controlled	VBN	O	O
trial	NN	O	O
.	.	O	O

PURPOSE	NNP	O	O
To	TO	O	O
evaluate	VB	O	O
the	DT	O	O
suppressive	JJ	O	O
effect	NN	O	O
of	IN	O	O
intravenous	JJ	O	O
dezocine	NN	i	IPM
on	IN	O	O
fentanyl-induced	JJ	O	O
cough	NN	o	OPH
during	IN	O	O
the	DT	O	O
induction	NN	O	O
of	IN	O	O
general	JJ	O	O
anesthesia	NN	O	O
.	.	O	O

METHODS	NNP	O	O
A	NNP	O	O
total	NN	p	O
of	IN	p	O
120	CD	p	O
patients	NNS	p	O
,	,	p	O
American	NNP	p	O
Society	NNP	p	O
of	IN	p	O
Anesthesiologists	NNP	p	O
(	(	p	O
ASA	NNP	p	O
)	)	p	O
physical	JJ	p	O
status	NN	p	O
I-II	NNP	p	O
,	,	p	O
were	VBD	p	O
randomized	VBN	p	O
into	IN	p	O
two	CD	p	O
equally	RB	p	O
sized	JJ	p	O
groups	NNS	p	O
(	(	p	O
n	JJ	p	O
=	NNP	p	O
60	CD	p	O
)	)	p	O
.	.	p	O

These	DT	O	O
two	CD	O	O
groups	NNS	O	O
were	VBD	O	O
given	VBN	O	O
either	RB	O	O
intravenous	JJ	i	IPM
dezocine	NN	i	IPM
0.1	CD	O	O
mg/kg	NN	O	O
or	CC	i	O
a	DT	i	O
matching	JJ	i	IC
placebo	NN	i	IC
(	(	O	O
equal	JJ	O	O
volume	NN	O	O
of	IN	O	O
0.9	CD	O	O
%	NN	O	O
saline	NN	O	O
)	)	O	O
10	CD	O	O
min	NN	O	O
before	IN	O	O
the	DT	O	O
induction	NN	O	O
of	IN	O	O
general	JJ	O	O
anesthesia	NN	O	O
.	.	O	O

Patients	NNS	O	O
were	VBD	O	O
induced	VBN	O	O
with	IN	O	O
midazolam	JJ	i	O
0.1	CD	i	O
mg/kg	NN	i	O
,	,	i	O
fentanyl	VBP	i	O
5	CD	i	O
?g/kg	NN	i	O
,	,	i	O
propofol	JJ	i	O
1-1.5	JJ	i	O
mg/kg	NN	i	O
,	,	i	O
and	CC	i	O
suxamethonium	NN	i	O
1.5	CD	O	O
mg/kg	NN	O	O
.	.	O	O

The	DT	O	O
injection	NN	O	O
time	NN	O	O
of	IN	O	O
fentanyl	NN	O	O
was	VBD	O	O
less	JJR	O	O
than	IN	O	O
2	CD	O	O
s	NNS	O	O
in	IN	O	O
all	DT	O	O
patients	NNS	O	O
.	.	O	O

The	DT	O	O
occurrence	NN	O	O
of	IN	o	O
cough	NN	o	O
was	VBD	O	O
recorded	VBN	O	O
2	CD	O	O
min	NN	O	O
after	IN	O	O
fentanyl	JJ	O	O
bolus	NN	O	O
.	.	O	O

RESULTS	NNP	p	O
No	NNP	p	O
patient	NN	p	O
in	IN	p	O
the	DT	p	O
dezocine	NN	p	O
group	NN	p	O
had	VBD	o	O
cough	VBN	o	OPH
,	,	o	O
and	CC	p	O
42	CD	p	O
patients	NNS	p	O
in	IN	p	O
the	DT	p	O
control	NN	p	O
group	NN	p	O
had	VBD	o	O
cough	NN	o	O
.	.	o	O

This	DT	O	O
difference	NN	O	O
was	VBD	O	O
statistically	RB	O	O
different	JJ	O	O
between	IN	O	O
these	DT	O	O
two	CD	O	O
groups	NNS	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.000	CD	O	O
)	)	O	O
.	.	O	O

CONCLUSION	NNP	O	O
These	DT	O	O
results	NNS	O	O
demonstrate	VBP	O	O
that	IN	O	O
intravenous	JJ	i	O
dezocine	NN	i	O
0.1	CD	O	O
mg/kg	NN	O	O
10	CD	O	O
min	NN	O	O
prior	RB	O	O
to	TO	O	O
induction	NN	O	O
was	VBD	O	O
effective	JJ	O	O
in	IN	O	O
suppressing	VBG	p	O
fentanyl-induced	JJ	o	O
cough	NN	o	O
in	IN	p	O
our	PRP$	p	O
patients	NNS	p	O
.	.	p	O

Pharmacokinetics	NNS	O	O
and	CC	O	O
pharmacodynamics	NNS	O	O
of	IN	O	O
six	CD	O	O
epoetin	JJ	i	IPM
alfa	NN	i	IPM
dosing	VBG	O	O
regimens	NNS	O	O
in	IN	O	O
anemic	JJ	p	O
critically	RB	p	O
ill	JJ	p	O
patients	NNS	p	O
without	IN	p	O
acute	JJ	p	O
blood	NN	p	O
loss	NN	p	O
.	.	p	O

OBJECTIVE	UH	O	O
To	TO	O	O
describe	VB	O	O
the	DT	O	O
pharmacokinetic	JJ	O	O
profiles	NNS	O	O
of	IN	O	O
six	CD	O	O
different	JJ	O	O
dosing	VBG	O	O
regimens	NNS	O	O
for	IN	O	O
epoetin	NN	i	IPM
alfa	NN	i	IPM
,	,	O	O
and	CC	O	O
whether	IN	O	O
more	JJR	O	O
rapid	JJ	O	O
and	CC	O	O
robust	JJ	O	O
reticulocytosis	NN	O	O
can	MD	O	O
be	VB	O	O
elicited	VBN	O	O
with	IN	O	O
more	RBR	O	O
frequent	JJ	O	O
administration	NN	O	O
of	IN	O	O
epoetin	JJ	i	IPM
alfa	NN	i	IPM
in	IN	O	O
anemic	JJ	p	O
critically	RB	p	O
ill	JJ	p	O
patients	NNS	p	O
.	.	p	O

DESIGN	NNP	O	O
Randomized	NNP	O	O
,	,	O	O
open-label	NN	O	O
,	,	O	O
multicenter	NN	O	O
,	,	O	O
28-day	JJ	O	O
clinical	JJ	O	O
trial	NN	O	O
.	.	O	O

SETTING	NN	O	O
Ten	CD	p	O
centers	NNS	p	O
in	IN	p	O
the	DT	p	O
United	NNP	p	O
States	NNPS	p	O
.	.	p	O

PATIENTS	VB	O	O
Adult	NNP	p	O
(	(	p	O
age	NN	p	O
>	VBN	p	O
or=18	CD	p	O
years	NNS	p	O
)	)	p	O
critically	RB	p	O
ill	JJ	p	O
patients	NNS	p	O
with	IN	p	O
hemoglobin	JJ	p	O
<	NNP	p	O
or=12	NN	p	O
g/dL	NN	p	O
,	,	p	O
expected	VBN	p	O
hospitalization	NN	p	O
of	IN	p	O
>	NNP	p	O
or=7	NNP	p	O
days	NNS	p	O
,	,	p	O
with	IN	p	O
no	DT	p	O
ongoing	VBG	p	O
acute	RB	p	O
blood	NN	p	O
loss	NN	p	O
.	.	p	O

INTERVENTIONS	NNP	O	O
One	CD	O	O
of	IN	O	O
six	CD	i	IPM
dosing	VBG	i	IPM
epoetin	NN	i	IPM
alfa	NN	i	IPM
regimens	VBZ	i	IPM
for	IN	O	O
15	CD	O	O
days	NNS	O	O
,	,	O	O
as	IN	O	O
follows	VBZ	O	O
:	:	O	O
40,000	CD	i	IPM
IU	NNP	i	IPM
once	RB	i	IPM
weekly	RB	i	IPM
,	,	O	O
subcutaneously	RB	O	O
(	(	O	O
group	NN	O	O
A	NNP	O	O
)	)	O	O
or	CC	O	O
intravenously	RB	O	O
(	(	O	O
IV	NNP	O	O
)	)	O	O
(	(	O	O
group	NN	O	O
B	NNP	O	O
)	)	O	O
;	:	O	O
15,000	CD	i	IPM
IU	NNP	i	IPM
every	DT	i	IPM
other	JJ	i	IPM
day	NN	i	IPM
,	,	i	IPM
subcutaneously	RB	i	IPM
(	(	O	O
group	NN	O	O
C	NNP	O	O
)	)	O	O
or	CC	O	O
IV	NNP	O	O
(	(	O	O
group	NN	O	O
D	NNP	O	O
)	)	O	O
;	:	O	O
or	CC	O	O
40,000	CD	i	IPM
IU	NNP	i	IPM
day	NN	i	IPM
1	CD	O	O
and	CC	O	O
3	CD	O	O
,	,	O	O
subcutaneously	RB	i	IPM
(	(	O	O
group	NN	O	O
E	NNP	O	O
)	)	O	O
or	CC	O	O
IV	NNP	O	O
(	(	O	O
group	NN	O	O
F	NNP	O	O
)	)	O	O
,	,	O	O
followed	VBN	O	O
by	IN	O	O
15,000	CD	O	O
IU	NNP	O	O
once	RB	O	O
every	DT	O	O
other	JJ	O	O
day	NN	O	O
on	IN	O	O
[	NN	O	O
corrected	VBN	O	O
]	JJ	O	O
days	NNS	O	O
5-15	JJ	O	O
[	NNP	O	O
corrected	VBD	O	O
]	NN	O	O
MEASUREMENTS	NNP	O	O
Serum	NNP	o	OPH
erythropoietin	NN	o	OPH
concentration	NN	o	OPH
,	,	o	O
absolute	JJ	o	OPH
reticulocyte	NN	o	OPH
count	NN	o	OPH
,	,	o	O
and	CC	o	O
adverse	JJ	o	OA
events	NNS	o	OA
.	.	o	O

MAIN	NNP	O	O
RESULTS	NNP	O	O
Of	IN	O	O
the	DT	O	O
60	CD	O	O
patients	NNS	O	O
who	WP	O	O
were	VBD	O	O
enrolled	VBN	O	O
(	(	O	O
60	CD	O	O
%	NN	O	O
men	NNS	O	O
,	,	O	O
mean	JJ	O	O
age	NN	O	O
53	CD	O	O
years	NNS	O	O
,	,	O	O
mean	VBP	O	O
Acute	NNP	O	O
Physiology	NNP	O	O
and	CC	O	O
Chronic	NNP	O	O
Health	NNP	O	O
Evaluation	NNP	O	O
II	NNP	O	O
score	NN	O	O
,	,	O	O
19.5	CD	O	O
)	)	O	O
,	,	O	O
30	CD	O	O
were	VBD	O	O
evaluable	JJ	O	O
for	IN	O	O
both	DT	O	O
pharmacokinetics	NNS	O	O
and	CC	O	O
pharmacodynamics	NNS	O	O
(	(	O	O
50	CD	O	O
%	NN	O	O
)	)	O	O
.	.	O	O

Erythropoietin	NNP	o	OPH
exposure	NN	o	OPH
was	VBD	O	O
approximately	RB	O	O
ten	JJ	O	O
times	NNS	O	O
greater	JJR	O	O
for	IN	O	O
IV	NNP	O	O
dosing	VBG	O	O
than	IN	O	O
for	IN	O	O
subcutaneous	JJ	i	IPM
dosing	NN	i	IPM
.	.	i	IPM

Mean	NNP	o	OPH
absolute	JJ	o	OPH
reticulocyte	NN	o	OPH
count	NN	o	OPH
peaked	VBD	O	O
at	IN	O	O
day	NN	O	O
11	CD	O	O
or	CC	O	O
15	CD	O	O
in	IN	O	O
each	DT	O	O
group	NN	O	O
and	CC	O	O
appeared	VBD	O	O
to	TO	O	O
be	VB	O	O
greater	JJR	O	O
for	IN	O	O
subcutaneous	JJ	O	O
dosing	NN	i	IPM
(	(	O	O
mean	JJ	O	O
peak	NN	O	O
response	NN	O	O
149-169	JJ	O	O
x	NN	O	O
10	CD	O	O
(	(	O	O
9	CD	O	O
)	)	O	O
/L	NN	O	O
)	)	O	O
compared	VBN	O	O
with	IN	O	O
IV	NNP	O	O
dosing	VBG	i	O
(	(	O	O
mean	JJ	O	O
peak	NN	O	O
response	NN	O	O
138-147	JJ	O	O
x	NN	O	O
10	CD	O	O
(	(	O	O
9	CD	O	O
)	)	O	O
/L	NN	O	O
)	)	O	O
at	IN	O	O
most	JJS	O	O
visits	NNS	O	O
.	.	O	O

The	DT	O	O
most	RBS	O	O
frequently	RB	O	O
reported	VBD	O	O
adverse	JJ	o	OA
events	NNS	o	OA
were	VBD	O	O
pyrexia	NNS	o	OA
(	(	O	O
18	CD	O	O
%	NN	O	O
)	)	O	O
,	,	O	O
hypokalemia	NN	o	OA
(	(	O	O
15	CD	O	O
%	NN	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
hypophosphatemia	NN	o	OA
(	(	O	O
15	CD	O	O
%	NN	O	O
)	)	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
In	IN	O	O
this	DT	O	O
study	NN	O	O
of	IN	O	O
anemic	JJ	O	O
critically	NN	O	O
ill	JJ	O	O
patients	NNS	O	O
treated	VBN	O	O
with	IN	O	O
epoetin	JJ	i	IPM
alfa	NN	i	IPM
,	,	O	O
all	DT	O	O
dosing	VBG	O	O
regimens	NNS	O	O
were	VBD	O	O
well	RB	O	O
tolerated	VBN	o	OOt
and	CC	O	O
appeared	VBN	O	O
to	TO	O	O
effect	NN	O	O
reticulocytosis	NN	o	OPH
,	,	O	O
with	IN	O	O
a	DT	O	O
peak	NN	O	O
at	IN	O	O
day	NN	O	O
11	CD	O	O
or	CC	O	O
15	CD	O	O
in	IN	O	O
most	JJS	O	O
patients	NNS	O	O
.	.	O	O

The	DT	O	O
pharmacokinetics	NNS	O	O
of	IN	O	O
epoetin	JJ	i	IPM
alfa	NN	i	IPM
did	VBD	O	O
not	RB	O	O
predict	VB	O	O
pharmacodynamic	JJ	o	OPH
response	NN	o	OPH
in	IN	O	O
anemic	JJ	O	O
critically	RB	O	O
ill	JJ	O	O
patients	NNS	O	O
.	.	O	O

Effectiveness	NN	O	O
of	IN	O	O
web-based	JJ	i	IE
tailored	JJ	i	IE
smoking	NN	i	IE
cessation	NN	i	IE
advice	NN	p	O
reports	NNS	p	O
(	(	O	O
iQuit	NN	O	O
)	)	O	O
:	:	O	O
a	DT	O	O
randomized	JJ	O	O
trial	NN	O	O
.	.	O	O

AIMS	NNP	O	O
To	TO	O	O
determine	VB	O	O
whether	IN	O	O
web-based	JJ	O	O
tailored	JJ	O	O
cessation	NN	O	O
advice	NN	O	O
,	,	O	O
based	VBN	O	O
on	IN	O	O
social	JJ	O	O
cognitive	JJ	O	O
theory	NN	O	O
and	CC	O	O
the	DT	O	O
perspectives	NNS	O	O
on	IN	O	O
change	NN	O	O
model	NN	O	O
,	,	O	O
was	VBD	O	O
more	RBR	O	O
effective	JJ	O	O
in	IN	O	O
aiding	VBG	O	O
a	DT	O	O
quit	NN	O	O
attempt	NN	O	O
than	IN	O	O
broadly	RB	O	O
similar	JJ	O	O
web-based	JJ	O	O
advice	NN	O	O
that	WDT	O	O
was	VBD	O	O
not	RB	O	O
tailored	VBN	O	O
.	.	O	O

DESIGN	JJ	O	O
Participants	NNS	p	O
were	VBD	p	O
allocated	VBN	p	O
randomly	RB	p	O
to	TO	p	O
one	CD	p	O
of	IN	p	O
two	CD	p	O
groups	NNS	p	O
,	,	O	O
to	TO	i	IE
receive	VB	i	IE
either	CC	i	IE
a	DT	i	IE
cessation	NN	i	IE
advice	NN	i	IE
report	NN	i	IE
and	CC	i	IE
progress	JJ	i	IE
report	NN	i	IE
that	WDT	i	IE
were	VBD	i	IE
tailored	VBN	i	IE
to	TO	i	IE
individual-level	JJ	i	IE
characteristics	NNS	i	IE
or	CC	i	IE
a	DT	i	IE
cessation	NN	i	IE
advice	NN	i	IE
report	NN	i	IE
that	WDT	i	IE
presented	VBD	i	IE
standardized	JJ	i	IE
(	(	i	IE
non-tailored	JJ	i	IE
)	)	i	IE
content	NN	i	IE
.	.	i	IE

Tailoring	NNP	O	O
was	VBD	O	O
based	VBN	O	O
on	IN	O	O
smoking-related	JJ	O	O
beliefs	NN	O	O
,	,	O	O
personal	JJ	O	O
characteristics	NNS	O	O
and	CC	O	O
smoking	NN	O	O
patterns	NNS	O	O
,	,	O	O
self-efficacy	NN	O	O
and	CC	O	O
outcome	JJ	O	O
expectations	NNS	O	O
.	.	O	O

SETTING	NN	O	O
Participant	JJ	O	O
enrolment	NN	O	O
and	CC	O	O
baseline	NN	i	IE
assessments	NNS	i	IE
were	VBD	O	O
conducted	VBN	O	O
remotely	RB	O	O
online	JJ	O	O
via	IN	O	O
the	DT	O	O
study	NN	O	O
website	NN	O	O
,	,	O	O
with	IN	O	O
the	DT	O	O
advice	NN	O	O
reports	NNS	O	O
presented	VBN	O	O
by	IN	O	O
the	DT	O	O
same	JJ	O	O
website	NN	O	O
.	.	O	O

PARTICIPANTS	JJ	O	O
Participants	NNS	p	O
(	(	p	O
n	IN	p	O
=	NNP	p	O
1758	CD	p	O
)	)	p	O
were	VBD	p	O
visitors	NNS	p	O
to	TO	p	O
the	DT	p	O
QUIT	NNP	p	O
website	NN	p	O
who	WP	p	O
were	VBD	p	O
based	VBN	p	O
in	IN	p	O
the	DT	p	O
United	NNP	p	O
Kingdom	NNP	p	O
,	,	p	O
aged	VBD	p	O
18	CD	p	PA
years	NNS	p	PA
or	CC	p	PA
over	RB	p	PA
and	CC	p	O
who	WP	p	O
smoked	VBD	p	O
cigarettes	NNS	p	O
or	CC	p	O
hand-rolled	JJ	p	O
tobacco	NN	p	O
.	.	p	O

MEASUREMENTS	NNP	p	O
Follow-up	JJ	O	O
assessments	NNS	O	O
were	VBD	O	O
made	VBN	O	O
at	IN	O	O
6	CD	O	O
months	NNS	O	O
by	IN	O	O
telephone	NN	O	O
interview	NN	O	O
.	.	O	O

The	DT	O	O
primary	JJ	O	O
outcome	NN	O	O
measure	NN	O	O
was	VBD	O	O
self-reported	JJ	o	O
3	CD	o	O
months	NNS	o	O
prolonged	VBN	o	OME
abstinence	NN	o	OME
,	,	o	O
and	CC	o	O
secondary	JJ	O	O
outcomes	NNS	O	O
were	VBD	O	O
1	CD	o	O
month	NN	o	O
prolonged	VBD	o	O
abstinence	NN	o	O
,	,	o	O
7-day	JJ	o	O
and	CC	o	O
24-hour	JJ	o	O
point	NN	o	O
prevalence	NN	o	O
abstinence	NN	o	O
.	.	o	O

FINDINGS	IN	o	O
The	DT	O	O
intervention	NN	p	O
group	NN	p	O
did	VBD	p	O
not	RB	O	O
differ	VB	O	O
from	IN	O	O
the	DT	O	O
control	NN	p	O
group	NN	p	O
on	IN	p	O
the	DT	O	O
primary	JJ	o	O
outcome	NN	o	O
(	(	o	O
9.1	CD	o	O
%	NN	O	O
versus	IN	O	O
9.3	CD	O	O
%	NN	O	O
;	:	O	O
odds	NNS	O	O
ratio	VBP	O	O
=	$	O	O
1.02	CD	O	O
95	CD	O	O
%	NN	O	O
confidence	NN	O	O
interval	JJ	O	O
0.73-1.42	NN	O	O
)	)	O	O
or	CC	O	O
on	IN	O	O
any	DT	O	O
of	IN	O	O
the	DT	o	O
secondary	JJ	o	O
outcomes	NNS	o	O
.	.	o	O

Intervention	NN	o	O
participants	NNS	p	O
gave	VBD	p	O
more	RBR	p	O
positive	JJ	O	O
evaluations	NNS	O	O
of	IN	O	O
the	DT	O	O
materials	NNS	p	O
than	IN	p	O
control	NN	p	O
participants	NNS	p	O
.	.	p	O

CONCLUSIONS	VB	p	O
A	DT	O	O
web-based	JJ	O	O
intervention	NN	O	O
that	WDT	O	O
tailored	VBD	O	O
content	JJ	O	O
according	VBG	O	O
to	TO	O	O
smoking-related	JJ	O	O
beliefs	NN	O	O
,	,	O	O
personal	JJ	O	O
characteristics	NNS	O	O
and	CC	O	O
smoking	NN	O	O
patterns	NNS	O	O
,	,	O	O
self-efficacy	NN	O	O
and	CC	O	O
outcome	NN	O	O
expectations	NNS	O	O
,	,	O	O
was	VBD	O	O
not	RB	O	O
more	RBR	O	O
effective	JJ	O	O
than	IN	O	O
web-based	JJ	O	O
materials	NNS	O	O
presenting	VBG	O	O
broadly	RB	O	O
similar	JJ	O	O
non-tailored	JJ	O	O
information	NN	O	O
.	.	O	O

Why	WRB	O	O
are	VBP	O	O
there	RB	O	O
sometimes	RB	O	O
concreteness	JJ	o	OME
effects	NNS	o	OME
in	IN	o	OME
memory	NN	o	OME
for	IN	O	O
prose	NN	O	O
?	.	O	O
Four	CD	p	PSS
experiments	NNS	p	O
explored	VBD	O	O
on-line	JJ	O	O
encoding	NN	O	O
strategies	NNS	O	O
and	CC	O	O
memory	NN	p	PC
for	IN	p	O
high	JJ	p	PC
imagery	NN	p	PC
and	CC	p	O
low	JJ	p	PC
imagery	NN	p	PC
texts	NN	p	O
.	.	p	O

Results	NNP	O	O
consistently	RB	O	O
indicated	VBD	O	O
that	IN	O	O
concreteness	NN	o	OME
effects	NNS	o	OME
in	IN	o	OME
memory	NN	o	OME
for	IN	o	OME
text	JJ	o	OME
depend	NN	O	O
on	IN	O	O
how	WRB	O	O
materials	NNS	O	O
are	VBP	O	O
presented	VBN	O	O
in	IN	O	O
several	JJ	O	O
different	JJ	O	O
respects	NNS	O	O
.	.	O	O

Most	JJS	O	O
importantly	RB	O	O
,	,	O	O
the	DT	O	O
experiments	NNS	O	O
clarified	VBD	O	O
apparently	RB	O	O
contradictory	JJ	O	O
results	NNS	O	O
of	IN	O	O
previous	JJ	O	O
studies	NNS	O	O
by	IN	O	O
indicating	VBG	O	O
that	IN	O	O
concreteness	NN	o	OME
effects	NNS	o	OME
generally	RB	O	O
do	VBP	O	O
not	RB	O	O
occur	VB	O	O
in	IN	O	O
memory	NN	O	O
for	IN	O	O
prose	NN	O	O
when	WRB	O	O
imageability	NN	O	O
is	VBZ	O	O
manipulated	VBN	O	O
between-subjects	NNS	p	O
,	,	O	O
and	CC	O	O
that	IN	O	O
their	PRP$	O	O
occurrence	NN	O	O
when	WRB	O	O
imageability	NN	O	O
is	VBZ	O	O
manipulated	VBN	O	O
within-subjects	NNS	O	O
depends	NNS	O	O
on	IN	O	O
the	DT	O	O
order	NN	O	O
occurrence	NN	O	O
when	WRB	O	O
imageability	NN	O	O
is	VBZ	O	O
manipulated	VBN	O	O
within-subjects	NNS	O	O
depends	NNS	O	O
on	IN	O	O
the	DT	O	O
order	NN	O	O
of	IN	O	O
presentation	NN	O	O
.	.	O	O

In	IN	O	O
addition	NN	O	O
,	,	O	O
moving	VBG	O	O
window	JJ	O	O
analyses	NNS	O	O
of	IN	O	O
text	JJ	i	IE
processing	NN	i	IE
strategies	NNS	i	IE
indicated	VBD	O	O
that	IN	O	O
differential	JJ	O	O
strategies	NNS	O	O
observed	VBN	O	O
in	IN	O	O
previous	JJ	O	O
studies	NNS	O	O
when	WRB	O	O
subjects	NNS	p	O
listened	VBD	O	O
to	TO	O	O
high	JJ	O	O
vs	NN	O	O
low	JJ	O	O
imagery	NN	O	O
text	NN	O	O
do	VBP	O	O
not	RB	O	O
generalize	VB	O	O
to	TO	O	O
reading	NN	O	O
of	IN	O	O
the	DT	O	O
same	JJ	O	O
materials	NNS	O	O
.	.	O	O

Potential	JJ	O	O
explanations	NNS	O	O
for	IN	O	O
the	DT	O	O
pattern	NN	O	O
of	IN	O	O
results	NNS	O	O
are	VBP	O	O
evaluated	VBN	O	O
,	,	O	O
and	CC	O	O
implications	NNS	O	O
for	IN	O	O
theories	NNS	O	O
of	IN	O	O
mental	JJ	O	O
imagery	NN	O	O
and	CC	O	O
memory	NN	O	O
are	VBP	O	O
considered	VBN	O	O
.	.	O	O

Double-blind	JJ	O	O
placebo-controlled	JJ	i	IC
trial	NN	O	O
of	IN	O	O
aprindine	NN	i	IPM
and	CC	i	O
digoxin	NN	i	IPM
for	IN	O	O
the	DT	O	O
prevention	NN	o	OPH
of	IN	o	OPH
symptomatic	JJ	o	OPH
atrial	JJ	o	OPH
fibrillation	NN	o	OPH
.	.	o	OPH

A	DT	O	O
multicenter	NN	O	O
,	,	O	O
placebo-controlled	JJ	i	IC
,	,	O	O
randomized	VBN	O	O
,	,	O	O
double-blind	JJ	O	O
trial	NN	O	O
compared	VBN	O	O
the	DT	O	O
preventive	JJ	o	OOt
effect	NN	o	OOt
of	IN	O	O
aprindine	NN	i	IPM
and	CC	i	O
digoxin	NN	i	IPM
on	IN	O	O
the	DT	O	O
recurrence	NN	o	OPH
of	IN	o	OPH
atrial	JJ	o	OPH
fibrillation	NN	o	OPH
(	(	o	OPH
AF	NNP	o	OPH
)	)	o	OPH
with	IN	O	O
placebo	NN	i	IC
,	,	O	O
and	CC	O	O
also	RB	O	O
compare	VBP	O	O
the	DT	O	O
effectiveness	NN	o	OOt
of	IN	O	O
these	DT	O	O
2	CD	O	O
drugs	NNS	O	O
in	IN	O	O
the	DT	O	O
prevention	NN	o	OPH
of	IN	o	OPH
AF	NNP	o	OPH
.	.	o	OPH

Patients	NNS	p	O
with	IN	p	O
symptomatic	JJ	p	PC
paroxysmal	NN	p	PC
or	CC	p	O
persistent	JJ	p	PC
AF	NNP	p	PC
who	WP	p	O
had	VBD	p	O
converted	VBN	p	O
to	TO	p	O
sinus	VB	p	PC
rhythm	NN	p	PC
(	(	p	PC
SR	NNP	p	PC
)	)	p	O
were	VBD	O	O
randomly	RB	O	O
assigned	VBN	O	O
aprindine	NN	i	IPM
(	(	O	O
40	CD	O	O
mg/day	NN	O	O
)	)	O	O
,	,	O	O
digoxin	NN	i	IPM
(	(	O	O
0.25	CD	O	O
mg/day	NN	O	O
)	)	O	O
or	CC	i	O
placebo	NN	i	IPM
and	CC	O	O
followed	VBD	O	O
up	RP	O	O
on	IN	O	O
an	DT	O	O
outpatient	JJ	O	O
basis	NN	O	O
every	DT	O	O
2	CD	O	O
weeks	NNS	O	O
for	IN	O	O
6	CD	O	O
months	NNS	O	O
.	.	O	O

Of	IN	p	O
the	DT	p	O
141	CD	p	PSS
patients	NNS	p	O
from	IN	p	O
36	CD	p	PSS
participating	VBG	p	O
centers	NNS	p	O
,	,	p	O
47	CD	p	PSS
were	VBD	p	PSS
given	VBN	p	PSS
aprindine	NN	i	IPM
,	,	p	O
47	CD	p	PSS
digoxin	NN	i	IPM
,	,	p	O
and	CC	p	O
47	CD	p	PSS
were	VBD	p	PSS
on	IN	p	PSS
placebo	NN	i	IC
.	.	i	O

After	IN	O	O
the	DT	O	O
6-month	JJ	O	O
follow-up	NN	O	O
,	,	O	O
the	DT	O	O
Kaplan-Meier	NNP	o	OPH
estimates	NNS	O	O
of	IN	O	O
the	DT	O	O
percentage	NN	O	O
of	IN	O	O
patients	NNS	O	O
remaining	VBG	O	O
free	JJ	O	O
of	IN	O	O
recurrent	JJ	o	OPH
symptomatic	JJ	o	OPH
AF	NNP	o	OPH
on	IN	O	O
aprindine	NN	i	IPM
,	,	i	O
digoxin	NN	i	IPM
and	CC	O	O
placebo	NN	i	IC
were	VBD	O	O
33.3	CD	O	O
%	NN	O	O
,	,	O	O
29.2	CD	O	O
%	NN	O	O
and	CC	O	O
21.5	CD	O	O
%	NN	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

In	IN	O	O
patients	NNS	O	O
remaining	VBG	O	O
in	IN	O	O
SR	NNP	O	O
for	IN	O	O
15	CD	O	O
days	NNS	O	O
after	IN	O	O
from	IN	O	O
the	DT	O	O
start	NN	O	O
of	IN	O	O
follow-up	NN	O	O
,	,	O	O
freedom	NN	o	OOt
from	IN	o	OOt
recurrence	NN	o	OOt
was	VBD	O	O
significantly	RB	O	O
more	RBR	O	O
prevalent	JJ	o	OPH
in	IN	O	O
the	DT	O	O
aprindine	NN	O	O
group	NN	O	O
than	IN	O	O
in	IN	O	O
the	DT	O	O
placebo	NN	i	IC
group	NN	O	O
(	(	O	O
p=0.0414	NN	O	O
)	)	O	O
,	,	O	O
but	CC	O	O
there	EX	O	O
was	VBD	O	O
no	DT	O	O
significant	JJ	o	OPH
difference	NN	o	OPH
between	IN	O	O
the	DT	O	O
digoxin	NN	O	O
and	CC	O	O
placebo	NN	O	O
groups	NNS	O	O
.	.	O	O

The	DT	O	O
rate	NN	o	OA
of	IN	o	OA
adverse	JJ	o	OA
events	NNS	o	OA
was	VBD	O	O
similar	JJ	O	O
in	IN	O	O
the	DT	O	O
3	CD	O	O
groups	NNS	O	O
.	.	O	O

In	IN	O	O
conclusion	NN	O	O
,	,	O	O
neither	CC	O	O
aprindine	JJ	O	O
nor	CC	O	O
digoxin	NN	i	IPM
had	VBD	O	O
a	DT	O	O
significant	JJ	o	OPH
effect	NN	o	OPH
on	IN	O	O
preventing	VBG	o	OOt
relapse	NN	o	OOt
of	IN	o	OOt
symptomatic	JJ	o	OOt
AF	NNP	o	OOt
;	:	o	OPH
however	RB	O	O
,	,	O	O
recurrence	NN	o	OOt
of	IN	o	OOt
AF	NNP	o	OOt
occurred	VBD	O	O
later	RBR	o	OPH
with	IN	O	O
aprindine	NN	i	IPM
than	IN	O	O
with	IN	O	O
placebo	NN	i	IC
or	CC	O	O
digoxin	NN	i	IPM
.	.	i	O

Effects	NNS	O	O
of	IN	O	O
two	CD	O	O
different	JJ	O	O
short-term	JJ	i	IPH
training	NN	i	IPH
programs	NNS	i	IPH
on	IN	O	O
the	DT	O	O
physical	JJ	O	O
and	CC	O	O
technical	JJ	O	O
abilities	NNS	O	O
of	IN	O	O
adolescent	JJ	p	O
basketball	NN	p	O
players	NNS	p	O
.	.	p	O

This	DT	O	O
study	NN	O	O
evaluated	VBD	O	O
and	CC	O	O
compared	VBN	O	O
the	DT	O	O
effectiveness	NN	O	O
of	IN	O	O
two	CD	O	O
different	JJ	O	O
off-season	JJ	i	IPH
,	,	i	IPH
short-term	JJ	i	IPH
basketball	NN	i	IPH
training	NN	i	IPH
programs	NNS	i	IPH
on	IN	O	O
physical	JJ	O	O
and	CC	O	O
technical	JJ	O	O
abilities	NNS	O	O
of	IN	O	O
young	JJ	p	O
basketball	NN	p	O
players	NNS	p	O
.	.	p	O

Twenty-seven	JJ	p	O
adolescent	JJ	p	O
basketball	NN	p	O
players	NNS	p	O
(	(	p	O
14.7+/-0.5	CD	p	O
years	NNS	p	O
;	:	p	O
Tanner	NNP	p	O
stage	NN	p	O
:	:	p	O
3.5+/-0.5	JJ	p	O
)	)	p	O
were	VBD	O	O
randomly	RB	O	O
divided	VBN	O	O
into	IN	O	O
a	DT	O	O
specialized	JJ	i	IPH
basketball	NN	i	IPH
training	NN	i	IPH
group	NN	i	IPH
(	(	O	O
SP	NNP	O	O
,	,	O	O
n=10	NN	O	O
)	)	O	O
,	,	O	O
a	DT	i	IPH
mixed	JJ	i	IPH
basketball	NN	i	IPH
plus	CC	i	IPH
conditioning	VBG	i	IPH
training	NN	i	IPH
group	NN	i	IPH
(	(	O	O
MX	NNP	O	O
,	,	O	O
n=10	NN	O	O
)	)	O	O
and	CC	i	O
a	DT	i	O
control	NN	i	IC
group	NN	i	IC
(	(	O	O
n=7	RB	O	O
)	)	O	O
.	.	O	O

Training	VBG	i	IPH
included	VBD	O	O
five	CD	O	O
sessions	NNS	O	O
per	IN	O	O
week	NN	O	O
(	(	O	O
100-120	JJ	O	O
min	NNS	O	O
each	DT	O	O
)	)	O	O
and	CC	O	O
was	VBD	O	O
performed	VBN	O	O
for	IN	O	O
4	CD	O	O
weeks	NNS	O	O
.	.	O	O

Maximal	NNP	o	OPH
oxygen	NN	o	OPH
uptake	NN	o	OPH
was	VBD	O	O
similarly	RB	O	O
improved	VBN	O	O
after	IN	O	O
SP	NNP	O	O
(	(	O	O
4.9+/-1.8	CD	O	O
%	NN	O	O
)	)	O	O
and	CC	O	O
MX	NNP	O	O
(	(	O	O
4.9+/-1.4	CD	O	O
%	NN	O	O
)	)	O	O
,	,	O	O
but	CC	O	O
there	EX	O	O
was	VBD	O	O
no	DT	O	O
effect	NN	O	O
on	IN	O	O
ventilatory	NN	o	OPH
threshold	NN	o	OPH
.	.	o	OPH

Peak	NNP	o	OPH
and	CC	o	OPH
mean	JJ	o	OPH
power	NN	o	OPH
output	NN	o	OPH
measured	VBD	O	O
during	IN	O	O
the	DT	O	O
Wingate	NNP	O	O
test	NN	O	O
were	VBD	O	O
also	RB	O	O
improved	VBN	O	O
by	IN	O	O
a	DT	O	O
similar	JJ	O	O
magnitude	NN	O	O
after	IN	O	O
SP	NNP	O	O
(	(	O	O
21+/-5	CD	O	O
%	NN	O	O
)	)	O	O
and	CC	O	O
MX	NNP	O	O
(	(	O	O
15+/-6	CD	O	O
%	NN	O	O
)	)	O	O
.	.	O	O

Trunk	NNP	o	OPH
muscle	NN	o	OPH
endurance	NN	o	OPH
was	VBD	O	O
equally	RB	O	O
increased	VBN	O	O
(	(	O	O
SP	JJ	O	O
:	:	O	O
23+/-4	JJ	O	O
%	NN	O	O
,	,	O	O
MX	NNP	O	O
:	:	O	O
25+/-5	CD	O	O
%	NN	O	O
)	)	O	O
,	,	O	O
but	CC	O	O
arms	NNS	o	OPH
endurance	NN	o	OPH
was	VBD	O	O
improved	VBN	O	O
significantly	RB	O	O
more	RBR	O	O
after	IN	O	O
MX	NNP	O	O
(	(	O	O
50+/-11	CD	O	O
%	NN	O	O
)	)	O	O
compared	VBN	O	O
to	TO	O	O
SP	NNP	O	O
(	(	O	O
11+/-14	CD	O	O
%	NN	O	O
,	,	O	O
p	NN	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

Performance	NN	o	OME
in	IN	O	O
four	CD	O	O
basketball	NN	o	OOt
technical	JJ	o	OOt
skills	NNS	o	OOt
was	VBD	O	O
similarly	RB	O	O
increased	VBN	O	O
(	(	O	O
by	IN	O	O
17-27	CD	O	O
%	NN	O	O
)	)	O	O
in	IN	O	O
both	DT	O	O
groups	NNS	O	O
,	,	O	O
with	IN	O	O
a	DT	O	O
tendency	NN	O	O
for	IN	O	O
greater	JJR	O	O
improvement	NN	O	O
of	IN	O	O
the	DT	O	O
SP	NNP	O	O
groups	NNS	O	O
in	IN	O	O
the	DT	O	O
technical	JJ	O	O
skills	NNS	O	O
of	IN	O	O
shooting	NN	o	OME
and	CC	o	OME
passing	NN	o	OME
.	.	o	O

These	DT	O	O
results	NNS	O	O
indicate	VBP	O	O
that	IN	O	O
a	DT	O	O
SP	NNP	O	O
basketball	NN	O	O
training	NN	O	O
program	NN	O	O
,	,	O	O
performed	VBD	O	O
exclusively	RB	O	O
on-court	NN	O	O
was	VBD	O	O
as	RB	O	O
effective	JJ	O	O
as	IN	O	O
a	DT	O	O
MX	NNP	O	O
training	NN	O	O
program	NN	O	O
in	IN	O	O
terms	NNS	O	O
of	IN	O	O
aerobic	NN	O	O
and	CC	O	O
anaerobic	JJ	O	O
fitness	NN	O	O
improvement	NN	O	O
.	.	O	O

Furthermore	RB	O	O
,	,	O	O
the	DT	O	O
decrease	NN	O	O
of	IN	O	O
the	DT	O	O
total	JJ	O	O
on-court	JJ	O	O
training	NN	O	O
time	NN	O	O
in	IN	O	O
the	DT	O	O
MX	NNP	O	O
group	NN	O	O
resulted	VBD	O	O
in	IN	O	O
a	DT	O	O
tendency	NN	O	O
for	IN	O	O
a	DT	O	O
smaller	JJR	O	O
improvement	NN	O	O
of	IN	O	O
basketball	NN	O	O
technical	JJ	O	O
skills	NNS	O	O
.	.	O	O

In	IN	O	O
conclusion	NN	O	O
,	,	O	O
both	DT	O	O
SP	NNP	O	O
and	CC	O	O
MX	NNP	O	O
training	NN	O	O
are	VBP	O	O
equally	RB	O	O
effective	JJ	O	O
in	IN	O	O
order	NN	O	O
to	TO	O	O
limit	VB	O	O
and/or	JJ	O	O
reverse	VB	O	O
the	DT	O	O
detraining	NN	O	O
effects	NNS	O	O
that	WDT	O	O
occur	VBP	O	O
during	IN	O	O
the	DT	O	O
off-season	NN	O	O
in	IN	O	O
basketball	NN	O	O
.	.	O	O

Immunologic	NNP	O	O
profiles	NNS	O	O
of	IN	O	O
persons	NNS	O	O
recruited	VBN	O	O
for	IN	O	O
a	DT	O	O
randomized	JJ	O	O
,	,	O	O
placebo-controlled	JJ	i	IC
clinical	JJ	O	O
trial	NN	O	O
of	IN	O	O
hookworm	NN	p	O
infection	NN	p	O
.	.	p	O

Data	NNS	O	O
from	IN	O	O
epidemiologic	JJ	O	O
studies	NNS	O	O
suggest	VBP	O	O
that	IN	O	O
hookworm	NN	O	O
infections	NNS	O	O
,	,	O	O
in	IN	O	O
establishing	VBG	O	O
an	DT	O	O
immunologic	JJ	O	O
phenotype	NN	O	O
conducive	NN	O	O
to	TO	O	O
parasite	VB	O	O
survival	NN	O	O
,	,	O	O
may	MD	O	O
protect	VB	O	O
against	IN	O	O
the	DT	O	O
development	NN	O	O
of	IN	O	O
allergic	JJ	O	O
disease	NN	O	O
.	.	O	O

We	PRP	O	O
describe	VBP	O	O
immunologic	JJ	O	O
findings	NNS	O	O
from	IN	O	O
a	DT	O	O
clinical	JJ	O	O
study	NN	O	O
designed	VBN	O	O
to	TO	O	O
investigate	VB	O	O
the	DT	O	O
safety	NN	O	O
of	IN	O	O
iatrogenic	JJ	i	IPH
hookworm	NN	i	IPH
infection	NN	i	IPH
in	IN	O	O
participants	NNS	p	O
with	IN	p	O
allergic	JJ	p	O
rhinitis	NN	p	O
.	.	p	O

The	DT	O	O
low	JJ	O	O
,	,	O	O
relatively	RB	O	O
safe	JJ	O	O
level	NN	O	O
of	IN	O	O
hookworm	NN	i	IPH
infection	NN	i	IPH
used	VBN	O	O
in	IN	O	O
this	DT	O	O
study	NN	O	O
was	VBD	O	O
immunogenic	JJ	O	O
,	,	O	O
inducing	VBG	O	O
eosinophilia	NNS	o	OPH
and	CC	O	O
a	DT	O	O
significant	JJ	O	O
specific	JJ	o	OPH
IgG	NNP	o	OPH
response	NN	o	OPH
.	.	o	OPH

Importantly	RB	O	O
,	,	O	O
no	DT	O	O
potentiation	NN	O	O
of	IN	O	O
IgE	NNP	o	OPH
responses	NNS	o	OPH
to	TO	o	OPH
the	DT	o	OPH
environmental	JJ	o	OPH
allergens	NNS	o	OPH
to	TO	o	OPH
which	WDT	o	OPH
the	DT	o	OPH
participants	NNS	o	OPH
were	VBD	o	OPH
sensitized	VBN	o	OPH
was	VBD	O	O
seen	VBN	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
no	DT	O	O
evidence	NN	O	O
of	IN	O	O
systemic	JJ	o	OPH
immune	JJ	o	OPH
regulation	NN	o	OPH
was	VBD	O	O
seen	VBN	O	O
in	IN	O	O
infected	JJ	O	O
participants	NNS	O	O
.	.	O	O

This	DT	O	O
finding	NN	O	O
may	MD	O	O
indicate	VB	O	O
that	IN	O	O
the	DT	O	O
level	NN	o	OPH
of	IN	o	OPH
infection	NN	o	OPH
or	CC	O	O
the	DT	O	O
frequency	NN	o	OPH
of	IN	o	OPH
infection	NN	o	OPH
may	MD	O	O
have	VB	O	O
to	TO	O	O
be	VB	O	O
altered	VBN	O	O
in	IN	O	O
future	JJ	O	O
trials	NNS	O	O
to	TO	O	O
induce	VB	O	O
a	DT	O	O
therapeutically	RB	O	O
conducive	JJ	O	O
immunologic	NN	O	O
phenotype	NN	O	O
.	.	O	O

The	DT	O	O
A-V	NNP	i	IPH
Impulse	NNP	i	IPH
System	NNP	i	IPH
reduces	VBZ	O	O
deep-vein	JJ	p	PC
thrombosis	NN	p	PC
and	CC	p	O
swelling	NN	p	O
after	IN	p	O
hemiarthroplasty	NN	p	PC
for	IN	p	PC
hip	NN	p	PC
fracture	NN	p	PC
.	.	p	O

We	PRP	O	O
performed	VBD	O	O
a	DT	O	O
prospective	JJ	O	O
randomised	VBN	O	O
controlled	JJ	O	O
trial	NN	O	O
of	IN	O	O
the	DT	O	O
A-V	NNP	i	IPH
Impulse	NNP	i	IPH
System	NNP	i	IPH
in	IN	O	O
82	CD	p	PSS
patients	NNS	p	O
treated	VBN	p	PC
by	IN	p	PC
hemiarthroplasty	NN	p	PC
for	IN	p	PC
subcapital	JJ	p	PC
fracture	NN	p	PC
of	IN	p	PC
the	DT	p	PC
femoral	JJ	p	PC
neck	NN	p	PC
.	.	p	O

The	DT	O	O
incidence	NN	O	O
of	IN	O	O
proximal	JJ	O	O
deep-vein	JJ	O	O
thrombosis	NN	O	O
as	IN	O	O
assessed	VBN	O	O
by	IN	O	O
Doppler	NNP	i	IPH
ultrasonography	NN	i	IPH
was	VBD	O	O
23	CD	O	O
%	NN	O	O
in	IN	O	O
the	DT	O	O
control	NN	O	O
group	NN	O	O
and	CC	O	O
0	CD	O	O
%	NN	O	O
in	IN	O	O
those	DT	O	O
using	VBG	O	O
the	DT	O	O
device	NN	O	O
(	(	O	O
p	NN	O	O
less	JJR	O	O
than	IN	O	O
0.01	CD	O	O
)	)	O	O
.	.	O	O

Calf	NNP	O	O
and	CC	O	O
thigh	JJ	O	O
circumferences	NNS	O	O
were	VBD	O	O
measured	VBN	O	O
in	IN	O	O
both	DT	O	O
groups	NNS	O	O
at	IN	O	O
seven	CD	O	O
to	TO	O	O
ten	VB	O	O
days	NNS	O	O
after	IN	O	O
operation	NN	O	O
.	.	O	O

In	IN	O	O
the	DT	O	O
treatment	NN	O	O
group	NN	O	O
there	EX	O	O
was	VBD	O	O
a	DT	O	O
mean	JJ	o	OOt
relative	JJ	o	OOt
reduction	NN	o	OOt
of	IN	o	OOt
postoperative	JJ	o	OOt
swelling	NN	o	OOt
of	IN	o	OOt
the	DT	o	OOt
thigh	NN	o	OOt
by	IN	O	O
3.27	CD	O	O
cm	NN	O	O
(	(	O	O
p	NN	O	O
less	JJR	O	O
than	IN	O	O
0.001	CD	O	O
)	)	O	O
and	CC	O	O
of	IN	O	O
the	DT	O	O
calf	NN	O	O
by	IN	O	O
1.55	CD	O	O
cm	NN	O	O
(	(	O	O
p	NN	O	O
less	JJR	O	O
than	IN	O	O
0.001	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
A-V	NNP	O	O
Impulse	NNP	O	O
System	NNP	O	O
appears	VBZ	O	O
to	TO	O	O
be	VB	O	O
a	DT	O	O
safe	JJ	o	OOt
and	CC	O	O
effective	JJ	O	O
method	NN	O	O
of	IN	O	O
reducing	VBG	O	O
the	DT	O	O
incidence	NN	o	OPH
of	IN	o	OPH
proximal	JJ	o	OPH
deep-vein	JJ	o	OPH
thrombosis	NN	o	OPH
,	,	o	O
and	CC	o	O
of	IN	o	O
postoperative	JJ	o	OA
swelling	NN	o	OA
.	.	o	O

Combining	VBG	O	O
weight-loss	JJ	O	O
counseling	NN	O	O
with	IN	O	O
the	DT	O	O
weight	NN	O	O
watchers	NNS	O	O
plan	VBP	O	O
for	IN	O	O
obese	JJ	p	O
breast	NN	p	O
cancer	NN	p	O
survivors	NNS	p	O
.	.	p	O

OBJECTIVE	IN	O	O
The	DT	O	O
objective	NN	O	O
was	VBD	O	O
to	TO	O	O
develop	VB	O	O
effective	JJ	O	O
weight-loss	JJ	O	O
methods	NNS	O	O
for	IN	O	O
women	NNS	p	O
who	WP	p	O
have	VBP	p	O
had	VBN	p	O
breast	VBN	p	O
cancer	NN	p	O
,	,	O	O
because	IN	O	O
obesity	NN	O	O
may	MD	O	O
result	VB	O	O
in	IN	O	O
an	DT	O	O
adverse	JJ	O	O
prognosis	NN	O	O
.	.	O	O

RESEARCH	NNP	O	O
METHODS	NNP	O	O
AND	NNP	O	O
PROCEDURES	NNP	O	O
This	DT	O	O
randomized	VBN	O	O
pilot	NN	O	O
study	NN	O	O
tested	VBD	O	O
an	DT	O	O
individualized	JJ	O	O
approach	NN	O	O
toward	IN	O	O
weight	JJ	o	OPH
loss	NN	o	OPH
in	IN	O	O
obese	JJ	p	O
women	NNS	p	O
who	WP	p	O
have	VBP	p	O
had	VBD	p	O
a	DT	p	O
diagnosis	NN	p	O
of	IN	p	O
breast	NN	p	O
cancer	NN	p	O
.	.	p	O

An	DT	O	O
individualized	JJ	O	O
approach	NN	O	O
was	VBD	O	O
applied	VBN	O	O
either	CC	O	O
alone	RB	i	IE
or	CC	i	IE
combined	VBN	i	IE
with	IN	i	IE
the	DT	i	IE
commercial	JJ	i	IE
Weight	NNP	i	IE
Watchers	NNP	i	IE
program	NN	i	IE
.	.	i	IE

Forty-eight	JJ	p	O
women	NNS	p	O
(	(	p	O
body	NN	p	O
mass	NN	p	O
index	NN	p	O
of	IN	p	O
30	CD	p	O
to	TO	p	O
44	CD	p	O
kg/m	NNS	p	O
(	(	p	O
2	CD	p	O
)	)	p	O
)	)	p	O
were	VBD	p	O
enrolled	VBN	p	O
.	.	p	O

RESULTS	NNP	O	O
Weight	NNP	o	OPH
change	NN	o	OPH
after	IN	O	O
12	CD	O	O
months	NNS	O	O
of	IN	O	O
intervention	NN	O	O
was	VBD	O	O
as	IN	O	O
follows	VBZ	O	O
(	(	O	O
mean	JJ	O	O
+/-	NNP	O	O
SD	NNP	O	O
)	)	O	O
:	:	O	O
0.85	CD	O	O
+/-	JJ	O	O
6.0	CD	O	O
kg	NN	O	O
in	IN	O	O
the	DT	O	O
control	NN	i	IC
group	NN	i	IC
,	,	O	O
-2.6	VBZ	O	O
+/-	JJ	O	O
5.9	CD	O	O
kg	NN	O	O
in	IN	O	O
the	DT	O	O
Weight	NNP	i	IE
Watchers	NNP	i	IE
group	NN	i	IE
,	,	O	O
-8.0	VBZ	O	O
+/-	JJ	O	O
5.5	CD	O	O
kg	NN	O	O
in	IN	O	O
the	DT	O	O
individualized	JJ	O	O
group	NN	O	O
,	,	O	O
and	CC	O	O
-9.4	VBD	O	O
+/-	JJ	O	O
8.6	CD	O	O
kg	NN	O	O
in	IN	O	O
the	DT	O	O
comprehensive	JJ	i	IE
group	NN	i	IE
that	WDT	i	IE
used	VBD	i	IE
both	DT	i	IE
individualized	JJ	i	IE
counseling	NN	i	IE
and	CC	i	IE
Weight	NNP	i	IE
Watchers	NNP	i	IE
.	.	i	IE

Weight	NNP	o	OPH
loss	NN	o	OPH
relative	NN	O	O
to	TO	O	O
control	VB	O	O
was	VBD	O	O
statistically	RB	O	O
significant	JJ	O	O
in	IN	O	O
the	DT	O	O
comprehensive	JJ	O	O
group	NN	O	O
3	CD	O	O
,	,	O	O
6	CD	O	O
,	,	O	O
and	CC	O	O
12	CD	O	O
months	NNS	O	O
after	IN	O	O
randomization	NN	O	O
,	,	O	O
whereas	JJ	O	O
weight	NN	o	OPH
loss	NN	o	OPH
in	IN	O	O
the	DT	O	O
individualized	JJ	O	O
group	NN	O	O
was	VBD	O	O
significant	JJ	O	O
only	RB	O	O
at	IN	O	O
12	CD	O	O
months	NNS	O	O
.	.	O	O

Weight	NNP	o	OPH
loss	NN	o	OPH
of	IN	O	O
10	CD	O	O
%	NN	O	O
or	CC	O	O
more	JJR	O	O
of	IN	O	O
initial	JJ	O	O
body	NN	O	O
weight	NN	O	O
was	VBD	O	O
observed	VBN	O	O
in	IN	O	O
6	CD	O	O
of	IN	O	O
10	CD	O	O
women	NNS	O	O
in	IN	O	O
the	DT	O	O
comprehensive	JJ	O	O
group	NN	O	O
at	IN	O	O
12	CD	O	O
months	NNS	O	O
.	.	O	O

In	IN	O	O
the	DT	O	O
comprehensive	JJ	O	O
and	CC	O	O
Weight	NNP	O	O
Watchers-only	NNP	O	O
groups	NNS	O	O
,	,	O	O
weight	JJ	o	OPH
loss	NN	o	OPH
was	VBD	O	O
significantly	RB	O	O
related	VBN	O	O
to	TO	O	O
frequency	NN	O	O
of	IN	O	O
attendance	NN	O	O
at	IN	O	O
Weight	NNP	O	O
Watchers	NNP	O	O
meetings	NNS	O	O
,	,	O	O
and	CC	O	O
attendance	NN	O	O
was	VBD	O	O
more	RBR	O	O
frequent	JJ	O	O
in	IN	O	O
the	DT	O	O
comprehensive	JJ	O	O
group	NN	O	O
.	.	O	O

DISCUSSION	NNP	O	O
These	DT	O	O
data	NNS	O	O
indicate	VBP	O	O
that	IN	O	O
the	DT	O	O
most	RBS	O	O
weight	JJ	o	OPH
loss	NN	o	OPH
was	VBD	O	O
achieved	VBN	O	O
when	WRB	O	O
the	DT	O	O
counseling	NN	O	O
approach	NN	O	O
combined	VBD	O	O
both	DT	O	O
Weight	NNP	O	O
Watchers	NNPS	O	O
and	CC	O	O
individualized	JJ	O	O
contacts	NNS	O	O
.	.	O	O

This	DT	O	O
was	VBD	O	O
effective	JJ	O	O
even	RB	O	O
though	IN	O	O
most	JJS	O	O
of	IN	O	O
the	DT	O	O
individualized	JJ	O	O
contacts	NNS	O	O
were	VBD	O	O
by	IN	O	O
telephone	NN	O	O
.	.	O	O

Zinc	NNP	o	OPH
and	CC	o	OPH
copper	NN	o	OPH
balances	NNS	o	OPH
in	IN	O	O
preterm	JJ	p	PC
infants	NNS	p	PA
.	.	p	O

Preterm	NNP	p	PC
infants	NNS	p	PA
are	VBP	O	O
at	IN	O	O
risk	NN	O	O
for	IN	O	O
copper	NN	O	O
and	CC	O	O
zinc	NN	O	O
depletion	NN	O	O
if	IN	O	O
sufficient	JJ	O	O
quantities	NNS	O	O
of	IN	O	O
these	DT	O	O
nutrients	NNS	O	O
are	VBP	O	O
not	RB	O	O
provided	VBN	O	O
in	IN	O	O
a	DT	O	O
bioavailable	JJ	O	O
form	NN	O	O
in	IN	O	O
postnatal	JJ	O	O
life	NN	O	O
.	.	O	O

The	DT	O	O
purpose	NN	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
determine	VB	O	O
whether	IN	O	O
the	DT	O	O
use	NN	O	O
of	IN	O	O
a	DT	O	O
whey-predominant	JJ	i	IPM
,	,	i	IPM
50	CD	i	IPM
%	NN	i	IPM
medium	NN	i	IPM
chain	NN	i	IPM
triglyceride	IN	i	IPM
formula	NN	i	IPM
with	IN	i	IPM
relatively	RB	i	IPM
high	JJ	i	IPM
concentrations	NNS	i	IPM
of	IN	i	IPM
zinc	NN	i	IPM
and	CC	i	O
copper	NN	i	IPM
would	MD	O	O
promote	VB	O	O
the	DT	O	O
achievement	NN	O	O
of	IN	O	O
the	DT	O	O
in	IN	o	OPH
utero	JJ	o	OPH
accretion	NN	o	OPH
rate	NN	o	OPH
for	IN	o	OPH
zinc	NN	o	OPH
and	CC	o	OPH
copper	NN	o	OPH
in	IN	O	O
the	DT	O	O
preterm	NN	p	PC
infant	NN	p	PA
.	.	p	O

Two	CD	p	O
groups	NNS	p	O
of	IN	p	O
five	CD	p	PSS
preterm	JJ	p	PC
infants	NNS	p	PA
were	VBD	O	O
fed	VBN	O	O
a	DT	O	O
diet	JJ	O	O
containing	VBG	O	O
12.5	CD	i	IPM
mg/L	NN	i	IPM
of	IN	i	IPM
zinc	NN	i	IPM
and	CC	O	O
either	DT	O	O
0.9	CD	i	IPM
mg/L	NN	i	IPM
or	CC	i	IPM
2.1	CD	i	IPM
mg/L	NN	i	IPM
of	IN	i	IPM
copper	NN	i	IPM
.	.	i	IPM

Seventy-two-hour	JJ	O	O
metabolic	JJ	O	O
balance	NN	O	O
studies	NNS	O	O
were	VBD	O	O
performed	VBN	O	O
at	IN	O	O
an	DT	O	O
average	JJ	O	O
postconceptual	JJ	O	O
age	NN	O	O
of	IN	O	O
34	CD	O	O
weeks	NNS	O	O
and	CC	O	O
an	DT	O	O
average	JJ	O	O
weight	NN	O	O
of	IN	O	O
1,549	CD	O	O
g.	NN	O	O
All	DT	O	O
infants	NNS	O	O
were	VBD	O	O
in	IN	O	O
positive	JJ	o	OPH
zinc	NN	o	OPH
balance	NN	o	OPH
and	CC	O	O
nine	CD	O	O
of	IN	O	O
ten	NNS	O	O
achieved	VBN	O	O
the	DT	O	O
in	IN	o	OPH
utero	JJ	o	OPH
accretion	NN	o	OPH
rate	NN	o	OPH
for	IN	o	OPH
zinc	NN	o	OPH
for	IN	O	O
a	DT	O	O
34-week	JJ	O	O
gestation	NN	O	O
fetus	NN	O	O
(	(	O	O
greater	JJR	O	O
than	IN	O	O
or	CC	O	O
equal	JJ	O	O
to	TO	O	O
0.432	CD	O	O
mg/d	NN	O	O
)	)	O	O
.	.	O	O

Three	CD	O	O
infants	NNS	O	O
receiving	VBG	O	O
the	DT	O	O
high	JJ	O	O
copper	NN	O	O
formula	NN	O	O
and	CC	O	O
two	CD	O	O
receiving	VBG	O	O
the	DT	O	O
lower	JJR	O	O
copper	NN	O	O
formula	NN	O	O
were	VBD	O	O
in	IN	O	O
positive	JJ	o	OPH
copper	NN	o	OPH
balance	NN	o	OPH
.	.	o	OPH

Two	CD	O	O
infants	NNS	O	O
from	IN	O	O
each	DT	O	O
group	NN	O	O
achieved	VBD	O	O
the	DT	O	O
in	IN	o	OPH
utero	JJ	o	OPH
accretion	NN	o	OPH
rate	NN	o	OPH
for	IN	o	OPH
copper	NN	o	OPH
for	IN	O	O
a	DT	O	O
34-week	JJ	O	O
gestation	NN	O	O
fetus	NN	O	O
(	(	O	O
0.088	CD	O	O
mg/d	NN	O	O
)	)	O	O
.	.	O	O

A	DT	O	O
formula	NN	O	O
that	WDT	O	O
provides	VBZ	O	O
12.5	CD	O	O
mg/L	NN	O	O
of	IN	O	O
zinc	NN	O	O
permits	NNS	O	O
positive	JJ	o	OPH
zinc	NN	o	OPH
balance	NN	o	OPH
and	CC	o	OPH
zinc	NN	o	OPH
retention	NN	o	OPH
similar	JJ	O	O
to	TO	O	O
in	IN	O	O
utero	JJ	O	O
rates	NNS	O	O
.	.	O	O

A	DT	O	O
formula	NN	O	O
that	WDT	O	O
provides	VBZ	O	O
as	RB	O	O
much	JJ	O	O
as	IN	O	O
2.1	CD	O	O
mg/L	NN	O	O
of	IN	O	O
copper	NN	O	O
,	,	O	O
however	RB	O	O
,	,	O	O
may	MD	O	O
not	RB	O	O
always	RB	O	O
permit	VBP	O	O
positive	JJ	O	O
copper	NN	o	OPH
balance	NN	o	OPH
.	.	o	O

Association	NNP	O	O
of	IN	O	O
severity	NN	O	O
of	IN	O	O
coexisting	VBG	O	O
patellofemoral	JJ	O	O
disease	NN	O	O
with	IN	O	O
increased	JJ	O	O
impairments	NNS	O	O
and	CC	O	O
functional	JJ	O	O
limitations	NNS	O	O
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
knee	JJ	p	O
osteoarthritis	NN	p	O
.	.	p	O

OBJECTIVE	UH	O	O
To	TO	O	O
evaluate	VB	O	O
the	DT	O	O
association	NN	O	O
between	IN	O	O
severity	NN	O	O
of	IN	O	O
coexisting	VBG	O	O
patellofemoral	JJ	O	O
(	(	O	O
PF	NNP	O	O
)	)	O	O
disease	NN	O	O
with	IN	O	O
lower	JJR	O	O
extremity	NN	O	O
impairments	NNS	O	O
and	CC	O	O
functional	JJ	O	O
limitations	NNS	O	O
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
tibiofemoral	JJ	p	O
(	(	p	O
TF	NNP	p	O
)	)	p	O
osteoarthritis	NN	p	O
(	(	p	O
OA	NNP	p	O
)	)	p	O
.	.	p	O

METHODS	NNP	O	O
Radiographic	NNP	i	IPH
views	NNS	i	IPH
of	IN	i	O
the	DT	i	O
TF	NNP	i	O
and	CC	i	O
PF	NNP	i	O
compartments	NNS	i	O
,	,	i	O
knee	VB	i	IPH
extension	NN	i	IPH
strength	NN	i	IPH
,	,	i	O
and	CC	i	O
knee	VB	i	IPH
range	NN	i	IPH
of	IN	i	IPH
motion	NN	i	IPH
were	VBD	O	O
obtained	VBN	O	O
for	IN	O	O
167	CD	p	O
patients	NNS	p	O
with	IN	p	O
knee	JJ	p	O
OA	NNP	p	O
.	.	p	O

Additionally	RB	O	O
,	,	O	O
knee-specific	JJ	o	OPH
symptoms	NNS	o	OPH
and	CC	O	O
functional	JJ	o	OPH
limitations	NNS	o	OPH
were	VBD	O	O
assessed	VBN	O	O
using	VBG	O	O
the	DT	O	O
Western	NNP	o	OPH
Ontario	NNP	o	OPH
and	CC	o	OPH
McMaster	NNP	o	OPH
Universities	NNP	o	OPH
Osteoarthritis	NNP	o	OPH
Index	NNP	o	OPH
(	(	o	OPH
WOMAC	NNP	o	OPH
)	)	o	OPH
and	CC	o	OOt
the	DT	o	OOt
Activities	NNS	o	OPH
of	IN	o	OPH
Daily	NNP	o	OPH
Living	NNP	o	OPH
Scale	NNP	o	OPH
(	(	o	OPH
ADLS	NNP	o	OPH
)	)	o	OPH
.	.	o	O

RESULTS	NNP	O	O
Moderate/severe	NNP	O	O
PFOA	NNP	O	O
was	VBD	O	O
associated	VBN	O	O
with	IN	O	O
lower	JJR	O	O
knee	NN	o	OPH
extension	NN	o	OPH
strength	NN	o	OPH
(	(	O	O
mean	VB	O	O
?	.	O	O
SD	NNP	O	O
1.4	CD	O	O
?	.	O	O
0.5	CD	O	O
Nm/body	NN	O	O
weight	VBD	O	O
[	NNP	O	O
BW	NNP	O	O
]	NNP	O	O
)	)	O	O
compared	VBN	O	O
to	TO	O	O
no	DT	O	O
PFOA	NNP	O	O
(	(	O	O
mean	VB	O	O
?	.	O	O
SD	NNP	O	O
1.8	CD	O	O
?	.	O	O
0.5	CD	O	O
Nm/BW	NNP	O	O
)	)	O	O
.	.	O	O

Additionally	RB	o	O
,	,	o	O
total	JJ	o	O
knee	NN	o	O
range	NN	o	O
of	IN	o	O
motion	NN	o	O
was	VBD	o	O
significantly	RB	O	O
lower	JJR	O	O
for	IN	O	O
patients	NNS	O	O
with	IN	O	O
moderate/severe	JJ	O	O
PFOA	NNP	O	O
(	(	O	O
mean	VB	O	O
?	.	O	O
SD	NNP	O	O
120.8?	CD	O	O
?	.	O	O
14.4?	CD	O	O
)	)	O	O
compared	VBN	O	O
to	TO	O	O
no	DT	O	O
PFOA	NNP	O	O
(	(	O	O
mean	VB	O	O
?	.	O	O
SD	NNP	O	O
133.5?	CD	O	O
?	.	O	O
10.7?	CD	O	O
)	)	O	O
and	CC	O	O
mild	JJ	O	O
PFOA	NNP	O	O
(	(	O	O
mean	VB	O	O
?	.	O	O
SD	NNP	O	O
125.8?	CD	O	O
?	.	O	O
13.0?	CD	O	O
)	)	O	O
.	.	O	O

Moderate/severe	NNP	O	O
PFOA	NNP	O	O
and	CC	O	O
mild	JJ	O	O
PFOA	NNP	O	O
were	VBD	O	O
also	RB	O	O
associated	VBN	O	O
with	IN	O	O
less	JJR	o	O
pain	NN	o	O
while	IN	o	O
standing	VBG	o	O
(	(	O	O
odds	NNS	O	O
ratio	VBP	O	O
[	CD	O	O
OR	NNP	O	O
]	$	O	O
0.2	CD	O	O
,	,	O	O
95	CD	O	O
%	NN	O	O
confidence	NN	O	O
interval	NN	O	O
[	VBD	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
]	NNP	O	O
0.1-0.7	JJ	O	O
and	CC	O	O
OR	NNP	O	O
0.2	CD	O	O
,	,	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
0.1-0.6	CD	O	O
,	,	O	O
respectively	RB	O	O
)	)	O	O
on	IN	O	O
the	DT	O	O
WOMAC	NNP	O	O
,	,	O	O
and	CC	O	O
moderate/severe	RB	O	O
PFOA	NNP	O	O
was	VBD	O	O
associated	VBN	O	O
with	IN	O	O
greater	JJR	o	O
difficulty	NN	o	O
with	IN	o	O
going	VBG	o	O
downstairs	NNS	o	O
(	(	o	O
OR	NNP	o	O
2.9	CD	O	O
,	,	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
1.0-8.1	CD	O	O
)	)	O	O
on	IN	O	O
the	DT	O	O
ADLS	NNP	O	O
.	.	O	O

CONCLUSION	VB	O	O
It	PRP	O	O
appears	VBZ	O	O
that	IN	O	O
knees	NNS	O	O
with	IN	O	O
more	RBR	O	O
severe	JJ	O	O
coexisting	VBG	O	O
PF	NNP	O	O
disease	NN	O	O
demonstrate	NN	O	O
features	NNS	O	O
distinct	VBP	O	O
from	IN	O	O
those	DT	O	O
observed	VBN	O	O
in	IN	O	O
TFOA	NNP	O	O
in	IN	O	O
isolation	NN	O	O
or	CC	O	O
in	IN	O	O
combination	NN	O	O
with	IN	O	O
mild	JJ	O	O
PF	NNP	O	O
disease	NN	O	O
.	.	O	O

Treatment	NNP	i	O
strategies	VBZ	i	O
targeting	VBG	i	O
the	DT	i	O
PF	NNP	i	O
joint	NN	i	O
may	MD	i	O
be	VB	O	O
warranted	VBN	O	O
to	TO	O	O
mitigate	VB	O	O
the	DT	O	O
specific	JJ	O	O
lower	JJR	O	O
extremity	NN	O	O
impairments	NNS	O	O
and	CC	O	O
functional	JJ	O	O
problems	NNS	O	O
present	JJ	O	O
in	IN	O	O
this	DT	O	O
patient	JJ	O	O
population	NN	O	O
.	.	O	O

Treatment	NN	O	O
with	IN	O	O
the	DT	O	O
dipeptidyl	JJ	i	IPM
peptidase-4	JJ	i	IPM
inhibitor	NN	i	IPM
vildagliptin	NN	i	IPM
improves	VBZ	O	O
fasting	VBG	O	O
islet-cell	JJ	O	O
function	NN	O	O
in	IN	O	O
subjects	NNS	p	O
with	IN	p	O
type	JJ	p	O
2	CD	p	O
diabetes	NNS	p	O
.	.	p	O

CONTEXT	NNP	O	O
Dipeptidyl	NNP	i	IPM
peptidase	NN	i	IPM
4	CD	i	IPM
(	(	i	IPM
DPP-4	NNP	i	IPM
)	)	i	IPM
inhibitors	NNS	i	IPM
are	VBP	O	O
proposed	VBN	O	O
to	TO	O	O
lower	VB	O	O
blood	NN	O	O
glucose	NN	O	O
in	IN	O	O
type	NN	p	O
2	CD	p	O
diabetes	NNS	p	O
mellitus	FW	p	O
(	(	p	O
T2DM	NNP	p	O
)	)	p	O
by	IN	O	O
prolonging	VBG	O	O
the	DT	O	O
activity	NN	O	O
of	IN	O	O
the	DT	O	O
circulating	NN	O	O
incretins	NNS	O	O
,	,	O	O
glucose-dependent	JJ	O	O
insulinotropic	NN	O	O
polypeptide	NN	O	O
(	(	O	O
GIP	NNP	O	O
)	)	O	O
and	CC	O	O
glucagon-like	JJ	O	O
peptide	NN	O	O
1	CD	O	O
(	(	O	O
GLP-1	NNP	O	O
)	)	O	O
.	.	O	O

Consistent	JJ	O	O
with	IN	O	O
this	DT	O	O
mechanism	NN	O	O
of	IN	O	O
action	NN	O	O
,	,	O	O
DPP-4	NNP	i	IPM
inhibitors	NNS	i	IPM
improve	VBP	O	O
glucose	JJ	O	O
tolerance	NN	O	O
after	IN	O	O
meals	NNS	O	O
by	IN	O	O
increasing	VBG	O	O
insulin	NN	O	O
and	CC	O	O
reducing	VBG	O	O
glucagon	NN	O	O
levels	NNS	O	O
in	IN	O	O
the	DT	O	O
plasma	NN	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
DPP-4	NNP	i	IPM
inhibitors	NNS	i	IPM
also	RB	O	O
reduce	VB	O	O
fasting	VBG	O	O
blood	NN	O	O
glucose	NN	O	O
,	,	O	O
an	DT	O	O
unexpected	JJ	O	O
effect	NN	O	O
because	IN	O	O
circulating	VBG	O	O
levels	NNS	O	O
of	IN	O	O
active	JJ	O	O
GIP	NNP	O	O
and	CC	O	O
GLP-1	NNP	O	O
are	VBP	O	O
low	JJ	O	O
in	IN	O	O
the	DT	O	O
postabsorptive	JJ	O	O
state	NN	O	O
.	.	O	O

OBJECTIVE	CC	O	O
The	DT	O	O
objective	NN	O	O
of	IN	O	O
the	DT	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
examine	VB	O	O
the	DT	O	O
effects	NNS	o	OPH
of	IN	o	OPH
DPP-4	NNP	o	OPH
inhibition	NN	o	OPH
on	IN	o	OPH
fasting	VBG	o	OPH
islet	NN	o	OPH
function	NN	o	OPH
.	.	o	O

DESIGN	NNP	O	O
We	PRP	O	O
conducted	VBD	O	O
a	DT	O	O
randomized	VBN	O	O
,	,	O	O
double-blind	JJ	O	O
,	,	O	O
placebo-controlled	JJ	i	IC
trial	NN	O	O
.	.	O	O

SETTING	VB	O	O
The	DT	O	O
study	NN	O	O
was	VBD	O	O
performed	VBN	O	O
in	IN	O	O
General	NNP	p	O
Clinical	NNP	p	O
Research	NNP	p	O
Centers	NNPS	p	O
at	IN	p	O
two	CD	p	O
University	NNP	p	O
Hospitals	NNP	p	O
.	.	p	O

SUBJECTS	NNP	O	O
Forty-one	JJ	p	O
subjects	NNS	p	O
with	IN	p	O
T2DM	NNP	p	O
were	VBD	O	O
treated	VBN	O	O
with	IN	O	O
metformin	NN	i	IPM
or	CC	O	O
diet	NN	i	O
,	,	O	O
having	VBG	O	O
good	JJ	O	O
glycemic	NNS	O	O
control	NN	O	O
with	IN	O	O
glycosylated	JJ	O	O
hemoglobin	NN	O	O
values	NNS	O	O
of	IN	O	O
6.2-7.5	JJ	O	O
%	NN	O	O
.	.	O	O

INTERVENTION	JJ	O	O
Subjects	NNPS	O	O
were	VBD	O	O
treated	VBN	O	O
with	IN	O	O
vildagliptin	NN	i	IPM
(	(	O	O
50	CD	O	O
mg	NN	O	O
twice	RB	O	O
daily	RB	O	O
)	)	O	O
or	CC	O	O
placebo	NN	i	IC
for	IN	O	O
3	CD	O	O
months	NNS	O	O
,	,	O	O
followed	VBN	O	O
by	IN	O	O
a	DT	O	O
2-wk	JJ	O	O
washout	NN	O	O
.	.	O	O

Major	JJ	O	O
Outcome	JJ	O	O
Measure	NN	O	O
:	:	O	O
We	PRP	O	O
measured	VBD	O	O
insulin	JJ	o	OPH
secretion	NN	o	OPH
in	IN	o	OPH
response	NN	o	OPH
to	TO	o	OPH
iv	VB	o	OPH
glucose	JJ	o	OPH
and	CC	o	OPH
arginine	JJ	o	OPH
before	NN	O	O
and	CC	O	O
after	IN	O	O
treatment	NN	O	O
and	CC	O	O
after	IN	O	O
drug	NN	O	O
washout	NN	O	O
.	.	O	O

RESULTS	CC	O	O
There	EX	O	O
were	VBD	O	O
small	JJ	O	O
and	CC	O	O
comparable	JJ	O	O
reductions	NNS	O	O
in	IN	O	O
glycosylated	JJ	o	OPH
hemoglobin	NN	o	OPH
in	IN	O	O
both	DT	O	O
groups	NNS	O	O
over	IN	O	O
3	CD	O	O
months	NNS	O	O
.	.	O	O

Vildagliptin	NNP	O	O
increased	VBD	O	O
fasting	VBG	O	O
GLP-1	NNP	o	OPH
levels	NNS	O	O
in	IN	O	O
subjects	NNS	O	O
taking	VBG	O	O
metformin	NN	i	IPM
,	,	O	O
but	CC	O	O
not	RB	O	O
those	DT	O	O
managed	VBN	O	O
with	IN	O	O
diet	JJ	i	O
,	,	O	O
and	CC	O	O
raised	VBD	O	O
active	JJ	O	O
GIP	NNP	O	O
levels	NNS	O	O
slightly	RB	O	O
.	.	O	O

DPP-4	JJ	i	IPM
inhibitor	NN	i	IPM
treatment	NN	O	O
improved	VBD	O	O
the	DT	O	O
acute	JJ	o	OPH
insulin	NN	o	OPH
and	CC	o	OPH
C-peptide	JJ	o	OPH
responses	NNS	o	OPH
to	TO	O	O
glucose	VB	O	O
(	(	O	O
50	CD	O	O
and	CC	O	O
100	CD	O	O
%	NN	O	O
respectively	RB	O	O
;	:	O	O
P	NNP	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
and	CC	O	O
increased	VBD	O	O
the	DT	O	O
slope	NN	O	O
of	IN	O	O
the	DT	O	O
C-peptide	NNP	o	OPH
response	NN	o	OPH
to	TO	O	O
glucose	VB	O	O
(	(	O	O
33	CD	O	O
%	NN	O	O
;	:	O	O
P	NNP	O	O
=	NNP	O	O
0.023	CD	O	O
)	)	O	O
.	.	O	O

CONCLUSION	NNP	O	O
Vildagliptin	NNP	i	IPM
improves	VBZ	O	O
islet	JJ	O	O
function	NN	O	O
in	IN	O	O
T2DM	NNP	O	O
under	IN	O	O
fasting	VBG	O	O
conditions	NNS	O	O
.	.	O	O

This	DT	O	O
suggests	VBZ	O	O
that	IN	O	O
DPP-4	NNP	O	O
inhibition	NN	O	O
has	VBZ	O	O
metabolic	JJ	O	O
benefits	NNS	O	O
in	IN	O	O
addition	NN	O	O
to	TO	O	O
enhancing	VBG	O	O
meal-induced	JJ	O	O
GLP-1	NNP	O	O
and	CC	O	O
GIP	NNP	O	O
activity	NN	O	O
.	.	O	O

Safety	NN	O	O
and	CC	O	O
acceptability	NN	O	O
of	IN	O	O
cellulose	JJ	i	IPM
sulfate	NN	i	IPM
as	IN	O	O
a	DT	O	O
vaginal	JJ	O	O
microbicide	NN	O	O
in	IN	O	O
HIV-infected	JJ	p	O
women	NNS	p	O
.	.	p	O

OBJECTIVES	NNP	O	O
Few	JJ	O	O
studies	NNS	O	O
of	IN	O	O
topical	JJ	O	O
microbicides	NNS	O	O
have	VBP	O	O
assessed	VBN	O	O
their	PRP$	O	O
safety	NN	o	OOt
in	IN	o	OOt
HIV-infected	JJ	o	OOt
women	NNS	o	OOt
.	.	o	O

We	PRP	O	O
conducted	VBD	O	O
this	DT	O	O
study	NN	O	O
to	TO	O	O
evaluate	VB	O	O
the	DT	O	O
safety	NN	o	OOt
and	CC	o	OOt
acceptability	NN	o	OOt
of	IN	O	O
6	CD	O	O
%	NN	O	O
cellulose	JJ	i	IPM
sulfate	NN	i	IPM
(	(	i	IPM
CS	NNP	i	IPM
)	)	i	IPM
gel	NN	O	O
as	IN	O	O
a	DT	O	O
vaginal	JJ	O	O
microbicide	NN	O	O
in	IN	p	O
sexually	RB	p	O
abstinent	JJ	p	O
and	CC	p	O
active	JJ	p	O
HIV-infected	JJ	p	O
women	NNS	p	O
.	.	p	O

METHODS	NNP	O	O
Fifty-nine	JJ	p	O
HIV-infected	JJ	p	O
women	NNS	p	O
were	VBD	O	O
enrolled	VBN	O	O
in	IN	O	O
a	DT	O	O
randomized	JJ	O	O
double-blind	JJ	O	O
placebo-controlled	JJ	i	IC
study	NN	O	O
comparing	VBG	O	O
6	CD	O	O
%	NN	O	O
CS	NNP	i	IPM
to	TO	i	O
placebo	VB	i	IC
gel	NNS	i	IC
used	VBN	O	O
for	IN	O	O
14	CD	O	O
days	NNS	O	O
.	.	O	O

Sexually	NNP	p	O
abstinent	JJ	p	O
women	NNS	p	O
applied	VBD	O	O
gel	JJ	O	O
once	RB	O	O
or	CC	O	O
twice	JJ	O	O
daily	JJ	O	O
and	CC	O	O
sexually	RB	O	O
active	JJ	O	O
women	NNS	O	O
used	VBN	O	O
gel	JJ	O	O
once	RB	O	O
daily	JJ	O	O
.	.	O	O

RESULTS	NNP	O	O
CS	NNP	O	O
gel	NN	O	O
was	VBD	O	O
safe	JJ	O	O
with	IN	O	O
no	DT	O	O
reported	VBN	O	O
severe	RB	o	OA
or	CC	o	OA
life-threatening	JJ	o	OA
adverse	JJ	o	OA
events	NNS	o	OA
(	(	o	OA
AE	NNP	o	OA
)	)	o	OA
.	.	o	O

Thirty-nine	NNP	O	O
(	(	O	O
66	CD	O	O
%	NN	O	O
)	)	O	O
of	IN	O	O
the	DT	O	O
participants	NNS	O	O
experienced	VBD	O	O
urogenital	JJ	o	OA
AE	NNP	o	OA
judged	VBD	O	O
as	IN	O	O
probably	RB	O	O
or	CC	O	O
possibly	RB	O	O
related	VBN	O	O
to	TO	O	O
gel	VB	O	O
.	.	O	O

The	DT	O	O
majority	NN	O	O
(	(	O	O
51	CD	O	O
%	NN	O	O
)	)	O	O
of	IN	O	O
these	DT	O	O
participants	NNS	O	O
reported	VBD	O	O
only	RB	O	O
mild	JJ	o	OA
events	NNS	o	OA
.	.	o	O

Fewer	JJR	O	O
women	NNS	O	O
(	(	O	O
62	CD	O	O
%	NN	O	O
)	)	O	O
who	WP	O	O
used	VBD	O	O
CS	NNP	O	O
experienced	VBD	O	O
urogenital	JJ	o	OA
AE	NNP	o	OA
than	IN	O	O
those	DT	O	O
assigned	VBN	O	O
to	TO	O	O
placebo	VB	i	IC
gel	NN	O	O
(	(	O	O
70	CD	O	O
%	NN	O	O
)	)	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.59	CD	O	O
)	)	O	O
.	.	O	O

Eleven	NNP	O	O
(	(	O	O
19	CD	O	O
%	NN	O	O
)	)	O	O
women	NNS	O	O
experienced	VBD	O	O
intermenstrual	JJ	o	OA
bleeding	NN	o	OA
judged	VBD	O	O
to	TO	O	O
be	VB	O	O
probably	RB	O	O
or	CC	O	O
possibly	RB	O	O
related	VBN	O	O
to	TO	O	O
gel	VB	O	O
use	NN	O	O
(	(	O	O
four	CD	O	O
in	IN	O	O
the	DT	O	O
CS	NNP	O	O
and	CC	O	O
seven	CD	O	O
in	IN	O	O
the	DT	O	O
placebo	NN	O	O
gel	NN	O	O
group	NN	O	O
)	)	O	O
.	.	O	O

There	EX	O	O
was	VBD	O	O
no	DT	O	O
increase	NN	O	O
in	IN	O	O
AE	NNP	o	OA
by	IN	O	O
frequency	NN	O	O
of	IN	O	O
gel	NN	O	O
use	NN	O	O
or	CC	O	O
sexual	JJ	O	O
activity	NN	O	O
with	IN	O	O
the	DT	O	O
exception	NN	O	O
of	IN	O	O
abdominal/pelvic	NN	o	OA
pain	NN	o	OA
which	WDT	O	O
was	VBD	O	O
noted	VBN	O	O
more	RBR	O	O
frequently	RB	O	O
with	IN	O	O
twice	RB	O	O
daily	JJ	O	O
use	NN	O	O
among	IN	O	O
sexually	RB	O	O
abstinent	JJ	O	O
women	NNS	O	O
.	.	O	O

Women	NNS	O	O
and	CC	O	O
men	NNS	O	O
found	VBD	O	O
the	DT	O	O
gel	NN	O	O
highly	RB	O	O
acceptable	JJ	O	O
.	.	O	O

CONCLUSIONS	VB	O	O
This	DT	O	O
Phase	NNP	O	O
I	PRP	O	O
study	VBP	O	O
demonstrated	VBD	O	O
that	IN	O	O
CS	NNP	i	IPM
vaginal	JJ	i	IPM
gel	NN	i	IPM
was	VBD	O	O
safe	JJ	o	OOt
,	,	o	OOt
well	RB	o	OOt
tolerated	VBN	o	OOt
and	CC	o	OOt
acceptable	JJ	o	OOt
by	IN	O	O
HIV-infected	JJ	p	O
women	NNS	p	O
and	CC	p	O
their	PRP$	p	O
male	JJ	p	O
partners	NNS	p	O
.	.	p	O

Thus	RB	O	O
,	,	O	O
further	JJ	O	O
development	NN	O	O
of	IN	O	O
CS	NNP	O	O
is	VBZ	O	O
warranted	VBN	O	O
as	IN	O	O
a	DT	O	O
potential	JJ	O	O
method	NN	O	O
to	TO	O	O
prevent	VB	O	O
HIV	NNP	o	OPH
transmission	NN	o	OPH
and	CC	o	OPH
acquisition	NN	o	OPH
.	.	o	O

Randomized	NNP	O	O
clinical	JJ	O	O
trial	NN	O	O
of	IN	O	O
cutting	VBG	i	IS
balloon	NN	i	IS
angioplasty	JJ	i	IS
versus	NN	O	O
high-pressure	NN	i	IS
balloon	NN	i	IS
angioplasty	NN	i	IS
in	IN	O	O
hemodialysis	NN	p	PC
arteriovenous	JJ	p	PC
fistula	NN	p	PC
stenoses	VBZ	p	PC
resistant	JJ	p	PC
to	TO	p	PC
conventional	JJ	p	PC
balloon	NN	p	PC
angioplasty	NN	p	PC
.	.	p	PC

PURPOSE	NNP	O	O
To	TO	O	O
compare	VB	O	O
the	DT	O	O
efficacy	NN	o	OOt
and	CC	o	OOt
safety	NN	o	OOt
of	IN	O	O
cutting	VBG	i	IS
balloon	NN	i	IS
angioplasty	NN	i	IS
(	(	i	IS
CBA	NNP	i	IS
)	)	i	IS
versus	IN	i	IS
high-pressure	NN	i	IS
balloon	NN	i	IS
angioplasty	NN	i	IS
(	(	i	IS
HPBA	NNP	i	IS
)	)	i	IS
for	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
hemodialysis	NN	p	PC
autogenous	JJ	p	PC
fistula	NN	p	PC
stenoses	VBZ	p	PC
resistant	JJ	p	PC
to	TO	p	PC
conventional	JJ	p	PC
percutaneous	JJ	p	PC
transluminal	JJ	p	PC
angioplasty	NN	p	PC
(	(	p	PC
PTA	NNP	p	PC
)	)	p	PC
.	.	p	O

MATERIALS	NNP	O	O
AND	CC	O	O
METHODS	NNP	O	O
In	IN	O	O
a	DT	O	O
prospective	JJ	O	O
,	,	O	O
randomized	JJ	O	O
clinical	JJ	O	O
trial	NN	O	O
involving	VBG	O	O
patients	NNS	p	O
with	IN	p	O
dysfunctional	JJ	p	PC
,	,	p	PC
stenotic	JJ	p	PC
hemodialysis	NN	p	PC
arteriovenous	JJ	p	PC
fistulas	NNS	p	PC
(	(	p	PC
AVFs	NNP	p	PC
)	)	p	PC
,	,	O	O
patients	NNS	O	O
were	VBD	O	O
randomized	VBN	O	O
to	TO	O	O
receive	VB	O	O
CBA	NNP	i	IS
or	CC	O	O
HPBA	NNP	i	IS
if	IN	O	O
conventional	JJ	O	O
PTA	NNP	O	O
had	VBD	O	O
suboptimal	JJ	O	O
results	NNS	O	O
(	(	O	O
ie	JJ	O	O
,	,	O	O
residual	JJ	O	O
stenosis	NN	O	O
>	VBD	O	O
30	CD	O	O
%	NN	O	O
)	)	O	O
.	.	O	O

A	DT	O	O
total	NN	p	O
of	IN	p	O
516	CD	p	PSS
patients	NNS	p	O
consented	VBN	p	O
to	TO	p	O
participate	VB	p	O
in	IN	p	O
the	DT	p	O
study	NN	p	O
from	IN	p	O
October	NNP	p	O
2008	CD	p	O
to	TO	p	O
September	NNP	p	O
2011	CD	p	O
,	,	p	O
85	CD	p	O
%	NN	p	O
of	IN	p	O
whom	WP	p	O
(	(	p	O
n	JJ	p	O
=	NNP	p	O
439	CD	p	PSS
)	)	p	O
had	VBD	p	O
technically	RB	p	O
successful	JJ	p	O
conventional	JJ	p	O
PTA	NNP	p	O
.	.	p	O

The	DT	O	O
remaining	VBG	O	O
71	CD	p	PSS
patients	NNS	p	O
(	(	p	O
mean	JJ	p	O
age	NN	p	O
,	,	p	O
60	CD	p	PA
y	NN	p	O
;	:	p	O
49	CD	p	PSS
men	NNS	p	O
)	)	p	O
with	IN	p	O
suboptimal	JJ	p	O
PTA	NNP	p	O
results	NNS	p	O
were	VBD	O	O
eventually	RB	O	O
randomized	VBN	O	O
:	:	O	O
36	CD	O	O
to	TO	O	O
the	DT	O	O
CBA	NNP	i	IPH
arm	NN	O	O
and	CC	O	O
35	CD	O	O
to	TO	O	O
the	DT	O	O
HPBA	NNP	O	O
arm	NN	O	O
.	.	O	O

Primary	JJ	O	O
and	CC	O	O
secondary	JJ	O	O
target	NN	O	O
lesion	NN	O	O
patencies	NNS	O	O
were	VBD	O	O
determined	VBN	O	O
by	IN	O	O
Kaplan-Meier	NNP	O	O
analysis	NN	O	O
.	.	O	O

RESULTS	NNP	O	O
Clinical	JJ	o	OOt
success	NN	o	OOt
rates	NNS	o	OOt
were	VBD	O	O
100	CD	O	O
%	NN	O	O
in	IN	O	O
both	DT	O	O
arms	NNS	O	O
.	.	O	O

Primary	JJ	o	OPH
target	NN	o	OPH
lesion	NN	o	OPH
patency	NN	o	OPH
rates	NNS	o	OPH
at	IN	O	O
6	CD	O	O
months	NNS	O	O
were	VBD	O	O
66.4	CD	O	O
%	NN	O	O
and	CC	O	O
39.9	CD	O	O
%	NN	O	O
for	IN	O	O
CBA	NNP	i	IPH
and	CC	O	O
HPBA	NNP	i	IPH
,	,	O	O
respectively	RB	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
.01	NNP	O	O
)	)	O	O
.	.	O	O

Secondary	JJ	o	OPH
target	NN	o	OPH
lesion	NN	o	OPH
patency	NN	o	OPH
rates	NNS	o	OPH
at	IN	O	O
6	CD	O	O
months	NNS	O	O
were	VBD	O	O
96.5	CD	O	O
%	NN	O	O
for	IN	O	O
CBA	NNP	i	IPH
and	CC	O	O
80.0	CD	O	O
%	NN	O	O
for	IN	O	O
HPBA	NNP	i	IPH
(	(	O	O
P	NNP	O	O
=	NNP	O	O
.03	NNP	O	O
)	)	O	O
.	.	O	O

There	EX	O	O
was	VBD	O	O
a	DT	O	O
single	JJ	O	O
major	JJ	o	OA
complication	NN	o	OA
of	IN	O	O
venous	JJ	o	OA
perforation	NN	o	OA
following	VBG	O	O
CBA	NNP	i	IPH
.	.	i	O

The	DT	O	O
30-day	JJ	o	OMO
mortality	NN	o	OMO
rate	NN	o	OMO
was	VBD	O	O
1.4	CD	O	O
%	NN	O	O
,	,	O	O
with	IN	O	O
one	CD	O	O
non-procedure-related	JJ	O	O
death	NN	O	O
in	IN	O	O
the	DT	O	O
HPBA	NNP	i	IPH
group	NN	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
Primary	NNP	O	O
and	CC	O	O
secondary	JJ	O	O
target	NN	O	O
lesion	NN	O	O
patency	NN	O	O
rates	NNS	O	O
of	IN	O	O
CBA	NNP	i	IPH
were	VBD	O	O
statistically	RB	O	O
superior	JJ	O	O
to	TO	O	O
those	DT	O	O
of	IN	O	O
HPBA	NNP	i	IPH
following	VBG	O	O
suboptimal	JJ	O	O
conventional	JJ	O	O
PTA	NNP	O	O
.	.	O	O

For	IN	O	O
AVF	NNP	O	O
stenoses	VBZ	O	O
resistant	JJ	O	O
to	TO	O	O
conventional	JJ	O	O
PTA	NNP	O	O
,	,	O	O
CBA	NNP	i	IPH
may	MD	O	O
be	VB	O	O
a	DT	O	O
better	JJR	O	O
second-line	JJ	O	O
treatment	NN	O	O
given	VBN	O	O
its	PRP$	O	O
superior	JJ	O	O
patency	NN	O	O
rates	NNS	O	O
.	.	O	O

Dexamethasone	NNP	i	IPM
therapy	NN	i	IPM
and	CC	O	O
cortisol	JJ	O	O
excretion	NN	O	O
in	IN	O	O
severe	JJ	p	PC
pediatric	JJ	p	PC
head	NN	p	PC
injury	NN	p	PC
.	.	p	PC

Glucocorticoids	NNS	i	IPM
are	VBP	O	O
used	VBN	O	O
in	IN	O	O
an	DT	O	O
attempt	NN	O	O
to	TO	O	O
reduce	VB	O	O
brain	NN	O	O
edema	NN	O	O
secondary	JJ	O	O
to	TO	O	O
head	VB	O	O
injury	NN	O	O
.	.	O	O

Nevertheless	RB	O	O
,	,	O	O
their	PRP$	O	O
usefulness	JJ	O	O
remains	NNS	O	O
uncertain	JJ	O	O
and	CC	O	O
contradictory	NN	O	O
.	.	O	O

In	IN	O	O
a	DT	O	O
randomized	JJ	O	O
study	NN	O	O
of	IN	O	O
24	CD	p	O
children	NNS	p	O
with	IN	p	O
severe	JJ	p	O
head	NN	p	O
injury	NN	p	O
,	,	p	O
urinary	JJ	p	O
free	JJ	p	O
cortisol	NN	p	O
was	VBD	O	O
measured	VBN	O	O
by	IN	O	O
radioimmunoassay	NN	i	O
.	.	i	O

Twelve	CD	p	O
patients	NNS	p	O
(	(	O	O
group	NN	O	O
1	CD	O	O
)	)	O	O
received	VBD	O	O
dexamethasone	NN	i	IPM
and	CC	O	O
12	CD	p	O
(	(	p	O
group	NN	p	O
2	CD	p	O
)	)	p	O
did	VBD	O	O
not	RB	O	O
.	.	O	O

All	DT	O	O
patients	NNS	O	O
were	VBD	O	O
treated	VBN	O	O
with	IN	O	O
a	DT	O	O
standardized	JJ	O	O
regimen	NN	O	O
.	.	O	O

In	IN	O	O
group	NN	O	O
1	CD	O	O
there	EX	O	O
was	VBD	O	O
complete	JJ	O	O
suppression	NN	o	OOt
of	IN	o	OOt
endogenous	JJ	o	OOt
cortisol	NN	o	OOt
production	NN	o	OOt
.	.	o	O

In	IN	O	O
group	NN	O	O
2	CD	O	O
free	JJ	O	O
cortisol	NN	O	O
was	VBD	O	O
up	RB	O	O
to	TO	O	O
20-fold	CD	O	O
higher	JJR	O	O
than	IN	O	O
under	IN	O	O
basal	JJ	O	O
conditions	NNS	O	O
and	CC	O	O
reached	VBN	O	O
maximum	JJ	O	O
values	NNS	O	O
on	IN	O	O
days	NNS	O	O
1-3	RB	O	O
.	.	O	O

Since	IN	O	O
the	DT	O	O
excretion	NN	o	OPH
of	IN	o	OPH
cortisol	NN	o	OPH
in	IN	o	OPH
urine	JJ	o	OPH
reflects	VBZ	O	O
the	DT	O	O
production	NN	O	O
rate	NN	O	O
closely	RB	O	O
and	CC	O	O
is	VBZ	O	O
not	RB	O	O
influenced	VBN	O	O
by	IN	O	O
liver	NN	O	O
function	NN	O	O
and	CC	O	O
barbiturates	NNS	O	O
,	,	O	O
the	DT	O	O
results	NNS	O	O
in	IN	O	O
group	NN	O	O
2	CD	O	O
show	NN	O	O
that	IN	O	O
the	DT	O	O
endogenous	JJ	O	O
production	NN	O	O
of	IN	O	O
steroids	NNS	O	O
is	VBZ	O	O
an	DT	O	O
adequate	JJ	O	O
reaction	NN	O	O
to	TO	O	O
severe	VB	O	O
head	JJ	O	O
injury	NN	O	O
.	.	O	O

Exogenous	JJ	O	O
glucocorticoids	NNS	i	IPM
are	VBP	O	O
thus	RB	O	O
unlikely	JJ	O	O
to	TO	O	O
have	VB	O	O
any	DT	O	O
more	JJR	O	O
beneficial	JJ	O	O
effects	NNS	O	O
than	IN	O	O
endogenous	JJ	O	O
cortisol	NN	i	IPM
.	.	i	O

The	DT	O	O
accuracy	NN	o	OOt
of	IN	O	O
clinical	JJ	o	OPH
neurosensory	NN	o	OPH
testing	VBG	o	OPH
for	IN	O	O
nerve	JJ	O	O
injury	NN	O	O
diagnosis	NN	O	O
.	.	O	O

PURPOSE	VB	O	O
The	DT	O	O
accuracy	NN	O	O
of	IN	O	O
the	DT	O	O
clinical	JJ	i	IPH
neurosensory	JJ	i	IPH
test	NN	i	IPH
to	TO	O	O
diagnose	VB	O	O
trigeminal	JJ	O	O
nerve	NN	O	O
injuries	NNS	O	O
has	VBZ	O	O
never	RB	O	O
been	VBN	O	O
statistically	RB	O	O
evaluated	VBN	O	O
.	.	O	O

The	DT	O	O
purpose	NN	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
determine	VB	O	O
the	DT	O	O
statistical	JJ	o	OOt
efficacy	NN	o	OOt
of	IN	o	OOt
the	DT	o	OOt
clinical	JJ	o	OOt
neurosensory	JJ	o	OOt
test	NN	o	OOt
using	VBG	O	O
surgical	JJ	O	O
findings	NNS	O	O
as	IN	O	O
the	DT	O	O
gold	JJ	O	O
standard	NN	O	O
,	,	O	O
and	CC	O	O
to	TO	O	O
determine	VB	O	O
whether	IN	O	O
a	DT	O	O
correlation	NN	O	O
existed	VBN	O	O
between	IN	O	O
the	DT	O	O
sensory	JJ	O	O
impairment	NN	O	O
score	NN	O	O
obtained	VBN	O	O
by	IN	O	O
preoperative	JJ	O	O
testing	NN	O	O
and	CC	O	O
the	DT	O	O
degree	NN	O	O
of	IN	O	O
nerve	NN	O	O
injury	NN	O	O
found	VBD	O	O
at	IN	O	O
surgery	NN	O	O
.	.	O	O

MATERIALS	NNP	O	O
AND	NNP	O	O
METHODS	NNP	O	O
A	NNP	O	O
multisite	NN	O	O
,	,	O	O
randomized	VBN	O	O
,	,	O	O
prospective	JJ	O	O
,	,	O	O
blinded	VBD	O	O
,	,	O	O
clinical	JJ	O	O
trial	NN	O	O
was	VBD	O	O
conducted	VBN	O	O
on	IN	O	O
130	CD	p	PC
patients	NNS	p	PC
with	IN	p	PC
inferior	JJ	p	PC
alveolar	JJ	p	PC
nerve	NN	p	PC
(	(	p	PC
IAN	NNP	p	PC
)	)	p	PC
and	CC	p	PC
lingual	JJ	p	PC
nerve	NN	p	PC
(	(	p	PC
LN	NNP	p	PC
)	)	p	PC
injuries	NNS	p	PC
.	.	p	PC

Preoperatively	RB	O	O
,	,	O	O
patients	NNS	i	O
were	VBD	i	O
provided	VBN	i	O
a	DT	i	O
sensory	JJ	i	O
impairment	NN	i	O
score	NN	i	O
using	VBG	i	O
a	DT	i	O
three-level	JJ	i	O
drop-out	JJ	i	O
clinical	JJ	i	O
neurosensory	NN	i	O
test	NN	i	O
(	(	i	O
NST	NNP	i	O
)	)	i	O
,	,	i	O
and	CC	i	O
blind	IN	i	IS
comparisons	NNS	i	IS
were	VBD	i	IS
made	VBN	i	IS
with	IN	i	IS
the	DT	i	IS
surgical	JJ	i	IS
findings	NNS	i	IS
postoperatively	RB	i	IS
.	.	i	O

RESULTS	VB	O	O
The	DT	O	O
positive	JJ	o	OME
predictive	NN	o	OME
and	CC	o	OME
negative	JJ	o	OME
predictive	NN	o	OME
values	NNS	o	OME
for	IN	O	O
LN-injured	JJ	O	O
patients	NNS	O	O
were	VBD	O	O
95	CD	O	O
%	NN	O	O
and	CC	O	O
100	CD	O	O
%	NN	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

The	DT	O	O
positive	JJ	O	O
predictive	NN	O	O
and	CC	O	O
negative	JJ	O	O
predictive	NN	O	O
values	NNS	O	O
for	IN	O	O
IAN	NNP	p	O
patients	NNS	p	O
were	VBD	O	O
77	CD	O	O
%	NN	O	O
and	CC	O	O
60	CD	O	O
%	NN	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

There	EX	O	O
were	VBD	O	O
statistically	RB	O	O
significant	JJ	O	O
differences	NNS	O	O
in	IN	O	O
the	DT	O	O
distribution	NN	O	O
of	IN	O	O
age	NN	O	O
,	,	O	O
duration	NN	O	O
of	IN	O	O
injury	NN	O	O
,	,	O	O
cause	NN	O	O
of	IN	O	O
injury	NN	O	O
,	,	O	O
presence	NN	O	O
of	IN	O	O
neuropathic	JJ	O	O
pain	NN	O	O
,	,	O	O
presence	NN	O	O
of	IN	O	O
trigger	NN	O	O
pain	NN	O	O
,	,	O	O
and	CC	O	O
degree	NN	O	O
of	IN	O	O
injury	NN	O	O
between	IN	O	O
the	DT	p	O
IAN	NNP	p	O
and	CC	p	O
LN	NNP	p	O
patient	JJ	p	O
populations	NNS	p	O
.	.	p	O

There	EX	O	O
was	VBD	O	O
a	DT	O	O
statistically	RB	o	OPH
significant	JJ	o	OPH
positive	JJ	o	OPH
relationship	NN	o	OPH
found	VBD	o	OPH
between	IN	o	OPH
the	DT	o	OPH
sensory	JJ	o	OPH
impairment	NN	o	OPH
score	NN	o	OPH
and	CC	o	OPH
the	DT	o	OPH
degree	NN	o	OPH
of	IN	o	OPH
nerve	NN	o	OPH
injury	NN	o	OPH
.	.	o	O

CONCLUSIONS	VB	O	O
The	DT	O	O
NST	NNP	i	IPH
is	VBZ	O	O
a	DT	O	O
clinically	RB	O	O
useful	JJ	O	O
method	NN	O	O
to	TO	O	O
diagnose	VB	O	O
IAN	NNP	O	O
and	CC	O	O
LN	NNP	O	O
injuries	NNS	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
the	DT	O	O
NST	NNP	i	O
results	NNS	O	O
are	VBP	O	O
less	RBR	o	OOt
efficient	JJ	o	OOt
for	IN	O	O
IAN	NNP	O	O
injuries	NNS	O	O
than	IN	O	O
LN	NNP	O	O
injuries	NNS	O	O
,	,	O	O
and	CC	O	O
have	VBP	O	O
a	DT	O	O
high	JJ	o	OPH
incidence	NN	o	OPH
of	IN	o	OPH
false-positive	JJ	o	OPH
(	(	O	O
23	CD	O	O
%	NN	O	O
)	)	O	O
and	CC	O	O
false-negative	JJ	o	OOt
(	(	O	O
40	CD	O	O
%	NN	O	O
)	)	O	O
results	NNS	O	O
when	WRB	O	O
testing	VBG	O	O
patients	NNS	p	O
with	IN	p	O
IAN	NNP	p	O
injuries	NNS	p	O
.	.	p	O

The	DT	O	O
different	JJ	O	O
rates	NNS	O	O
of	IN	O	O
statistical	JJ	o	OOt
efficiency	NN	o	OOt
between	IN	O	O
the	DT	O	O
two	CD	O	O
groups	NNS	O	O
of	IN	O	O
patients	NNS	O	O
may	MD	O	O
be	VB	O	O
attributable	JJ	O	O
to	TO	O	O
differences	NNS	O	O
in	IN	O	O
prevalence	NN	O	O
and	CC	O	O
biologic	NN	O	O
covariates	NNS	O	O
.	.	O	O

Placebo-controlled	JJ	i	IC
trial	NN	O	O
evaluating	VBG	O	O
safety	NN	O	O
with	IN	O	O
12-months	JJ	O	O
continuous	JJ	O	O
use	NN	O	O
of	IN	O	O
6	CD	i	IPM
%	NN	i	IPM
hydrogen	NN	i	IPM
peroxide	IN	i	IPM
whitening	VBG	i	IPM
strips	NNS	i	IPM
.	.	i	O

OBJECTIVE	NNP	O	O
To	TO	O	O
assess	VB	O	O
the	DT	O	O
safety	NN	O	O
and	CC	O	O
tolerability	NN	O	O
of	IN	O	O
6	CD	i	IPM
%	NN	i	IPM
hydrogen	NN	i	IPM
peroxide	IN	i	IPM
whitening	VBG	i	IPM
strips	NNS	i	IPM
over	IN	O	O
12	CD	O	O
months	NNS	O	O
.	.	O	O

METHODS	NNP	O	O
80	CD	p	O
adults	NNS	p	PA
were	VBD	p	O
randomly	RB	p	O
assigned	VBN	p	O
equally	RB	O	O
to	TO	O	O
one	CD	O	O
of	IN	O	O
two	CD	O	O
treatments	NNS	O	O
:	:	O	O
6	CD	i	IPM
%	NN	i	IPM
hydrogen	NN	i	IPM
peroxide	JJ	i	IPM
strips	NNS	i	IPM
or	CC	i	IPM
placebo	VB	i	IPM
strips	NNS	i	IPM
.	.	i	IPM

Strips	NNS	O	O
were	VBD	O	O
worn	JJ	O	O
5	CD	O	O
min	JJ	O	O
daily	RB	O	O
for	IN	O	O
12	CD	O	O
months	NNS	O	O
.	.	O	O

Safety	NNP	O	O
and	CC	O	O
tolerability	NN	O	O
were	VBD	O	O
assessed	VBN	O	O
via	IN	O	O
oral	JJ	O	O
status	NN	O	O
interviews	NNS	O	O
and	CC	O	O
oral	JJ	O	O
examinations	NNS	O	O
at	IN	O	O
baseline	NN	O	O
and	CC	O	O
after	IN	O	O
1	CD	O	O
,	,	O	O
2	CD	O	O
,	,	O	O
3	CD	O	O
,	,	O	O
6	CD	O	O
,	,	O	O
9	CD	O	O
,	,	O	O
and	CC	O	O
12	CD	O	O
months	NNS	O	O
of	IN	O	O
use	NN	O	O
.	.	O	O

RESULTS	NNP	O	O
Tooth	NNP	O	O
sensitivity	NN	O	O
and	CC	O	O
oral	JJ	O	O
irritation	NN	O	O
were	VBD	O	O
the	DT	O	O
two	CD	O	O
most	JJS	O	O
common	JJ	O	O
adverse	JJ	O	O
events	NNS	O	O
.	.	O	O

After	IN	O	O
12	CD	O	O
months	NNS	O	O
use	RB	O	O
,	,	O	O
tooth	DT	O	O
sensitivity	NN	O	O
was	VBD	O	O
reported	VBN	O	O
by	IN	O	O
10	CD	O	O
%	NN	O	O
of	IN	O	O
subjects	NNS	O	O
in	IN	O	O
the	DT	O	O
6	CD	i	IPM
%	NN	i	IPM
strip	NN	i	IPM
group	NN	O	O
with	IN	O	O
a	DT	O	O
95	CD	O	O
%	NN	O	O
confidence	NN	O	O
interval	NN	O	O
(	(	O	O
CI	NNP	O	O
)	)	O	O
of	IN	O	O
(	(	O	O
2.8	CD	O	O
%	NN	O	O
,	,	O	O
23.7	CD	O	O
%	NN	O	O
)	)	O	O
and	CC	O	O
5	CD	O	O
%	NN	O	O
of	IN	O	O
subjects	NNS	O	O
in	IN	O	O
the	DT	O	O
placebo	NN	i	IC
group	NN	O	O
with	IN	O	O
a	DT	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
of	IN	O	O
(	(	O	O
0.6	CD	O	O
%	NN	O	O
,	,	O	O
16.9	CD	O	O
%	NN	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
occurrence	NN	O	O
of	IN	O	O
reported	VBN	O	O
oral	JJ	O	O
irritation	NN	O	O
was	VBD	O	O
0	CD	O	O
%	NN	O	O
in	IN	O	O
the	DT	O	O
6	CD	i	IPM
%	NN	i	IPM
strip	NN	i	IPM
group	NN	O	O
with	IN	O	O
a	DT	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
of	IN	O	O
(	(	O	O
0	CD	O	O
%	NN	O	O
,	,	O	O
8.8	CD	O	O
%	NN	O	O
)	)	O	O
and	CC	O	O
2.5	CD	O	O
%	NN	O	O
in	IN	O	O
the	DT	O	O
placebo	NN	i	IC
strip	NN	i	IC
group	NN	O	O
with	IN	O	O
a	DT	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
of	IN	O	O
(	(	O	O
0.1	CD	O	O
%	NN	O	O
,	,	O	O
13.2	CD	O	O
%	NN	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
occurrence	NN	O	O
of	IN	O	O
observed	JJ	O	O
oral	JJ	O	O
irritation	NN	O	O
was	VBD	O	O
also	RB	O	O
similar	JJ	O	O
between	IN	O	O
groups	NNS	O	O
.	.	O	O

The	DT	O	O
groups	NNS	O	O
did	VBD	O	O
not	RB	O	O
differ	VB	O	O
significantly	RB	O	O
(	(	O	O
p	JJ	O	O
>	NNP	O	O
0.67	CD	O	O
)	)	O	O
for	IN	O	O
the	DT	O	O
percent	NN	O	O
of	IN	O	O
subjects	NNS	O	O
with	IN	O	O
each	DT	O	O
type	NN	O	O
of	IN	O	O
adverse	JJ	O	O
event	NN	O	O
.	.	O	O

In	IN	O	O
the	DT	O	O
6	CD	i	IPM
%	NN	i	IPM
strip	NN	i	IPM
group	NN	O	O
,	,	O	O
two	CD	O	O
subjects	NNS	O	O
discontinued	VBN	O	O
product	NN	O	O
use	NN	O	O
due	JJ	O	O
to	TO	O	O
an	DT	O	O
adverse	JJ	O	O
event	NN	O	O
(	(	O	O
tooth	JJ	O	O
sensitivity	NN	O	O
)	)	O	O
compared	VBN	O	O
to	TO	O	O
no	DT	O	O
subjects	NNS	O	O
in	IN	O	O
the	DT	O	O
placebo	NN	i	IC
group	NN	O	O
.	.	O	O

Groups	NNP	O	O
did	VBD	O	O
not	RB	O	O
differ	VB	O	O
significantly	RB	O	O
(	(	O	O
p	JJ	O	O
>	NNP	O	O
0.49	CD	O	O
)	)	O	O
with	IN	O	O
respect	NN	O	O
to	TO	O	O
this	DT	O	O
outcome	NN	O	O
.	.	O	O

CONCLUSION	NNP	O	O
Use	NNP	O	O
of	IN	O	O
6	CD	i	IPM
%	NN	i	IPM
hydrogen	NN	i	IPM
peroxide	IN	i	IPM
whitening	VBG	i	IPM
strips	NNS	i	IPM
over	IN	O	O
12	CD	O	O
months	NNS	O	O
resulted	VBN	O	O
in	IN	O	O
a	DT	O	O
safety	NN	O	O
profile	NN	O	O
similar	JJ	O	O
to	TO	O	O
that	DT	O	O
seen	VBN	O	O
with	IN	O	O
placebo	JJ	i	IC
strips	NNS	i	IC
.	.	i	O

Prevention	NN	O	O
of	IN	O	O
coronary	JJ	p	O
spasm	NN	p	O
by	IN	O	O
nicorandil	NNS	i	IPM
:	:	i	IPM
comparison	NN	O	O
with	IN	O	O
nifedipine	NN	i	IPM
.	.	i	IPM

The	DT	O	O
efficacy	NN	O	O
of	IN	O	O
nicorandil	NN	i	IPM
was	VBD	O	O
compared	VBN	O	O
with	IN	O	O
that	DT	O	O
of	IN	O	O
nifedipine	NN	i	IPM
in	IN	O	O
13	CD	p	O
patients	NNS	p	O
with	IN	p	O
vasospastic	JJ	p	O
angina	NNS	p	O
enrolled	VBN	O	O
in	IN	O	O
a	DT	O	O
randomized	JJ	O	O
,	,	O	O
placebo-controlled	JJ	i	IPH
,	,	O	O
crossover	NN	O	O
study	NN	O	O
.	.	O	O

All	DT	p	O
patients	NNS	p	O
had	VBD	p	O
a	DT	p	O
coronary	JJ	p	O
spasm	NN	p	O
during	IN	p	O
coronary	JJ	p	O
arteriography	NN	p	O
,	,	p	O
either	CC	p	O
spontaneously	RB	p	O
or	CC	p	O
ergometrine-induced	JJ	p	O
.	.	p	O

During	IN	O	O
two	CD	O	O
consecutive	JJ	O	O
periods	NNS	O	O
of	IN	O	O
2	CD	O	O
days	NNS	O	O
,	,	O	O
patients	NNS	O	O
received	VBD	O	O
active	JJ	i	IPM
drugs	NNS	i	IPM
or	CC	O	O
placebo	NN	i	IPM
in	IN	O	O
a	DT	O	O
randomized	JJ	O	O
order	NN	O	O
.	.	O	O

Each	DT	O	O
patient	NN	O	O
received	VBD	O	O
single	JJ	O	O
oral	JJ	O	O
doses	NNS	O	O
of	IN	O	O
30	CD	O	O
mg	NN	O	O
nicorandil	NN	i	IPM
,	,	O	O
10	CD	O	O
mg	NN	O	O
nifedipine	NN	i	IPM
,	,	O	O
and	CC	O	O
,	,	O	O
on	IN	O	O
2	CD	O	O
days	NNS	O	O
,	,	O	O
a	DT	O	O
placebo	NN	i	IPM
.	.	i	O

One	CD	O	O
hour	NN	O	O
after	IN	O	O
drug	NN	O	O
intake	NN	O	O
,	,	O	O
patients	NNS	O	O
underwent	VBD	O	O
an	DT	O	O
ergometrine	JJ	O	O
test	NN	O	O
with	IN	O	O
increasing	VBG	O	O
doses	NNS	O	O
of	IN	O	O
Methergin	NNP	i	IPM
(	(	i	IPM
ergometrine	NN	i	IPM
)	)	i	IPM
(	(	O	O
0.05	CD	O	O
,	,	O	O
0.10	CD	O	O
,	,	O	O
0.20	CD	O	O
,	,	O	O
and	CC	O	O
0.40	CD	O	O
mg	NN	O	O
every	DT	O	O
5	CD	O	O
min	NN	O	O
)	)	O	O
.	.	O	O

After	IN	O	O
placebo	NN	i	IPM
,	,	O	O
the	DT	O	O
tests	NNS	O	O
always	RB	O	O
were	VBD	O	O
positive	JJ	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
ECG	NNP	o	OOt
changes	NNS	o	OOt
occurred	VBD	O	O
at	IN	O	O
the	DT	O	O
same	JJ	O	O
+/-	JJ	O	O
1	CD	O	O
dose	NN	O	O
of	IN	O	O
ergometrine	NN	i	IPM
in	IN	O	O
10	CD	O	O
cases	NNS	O	O
,	,	O	O
showing	VBG	O	O
good	JJ	o	OOt
reproducibility	NN	o	OOt
.	.	o	O

After	IN	O	O
nicorandil	NN	i	IPM
,	,	O	O
the	DT	O	O
tests	NNS	O	O
were	VBD	O	O
negative	JJ	O	O
in	IN	O	O
nine	CD	O	O
patients	NNS	O	O
and	CC	O	O
positive	JJ	O	O
for	IN	O	O
a	DT	O	O
higher	JJR	O	O
or	CC	O	O
lower	JJR	O	O
dose	NN	O	O
of	IN	O	O
ergometrine	NN	i	IPM
in	IN	O	O
three	CD	O	O
and	CC	O	O
one	CD	O	O
patient	NN	O	O
,	,	O	O
respectively	RB	O	O
(	(	O	O
p	JJ	O	O
=	$	O	O
0.0034	CD	O	O
vs.	FW	O	O
placebo	NN	i	IPM
)	)	i	IPM
.	.	O	O

After	IN	O	O
nifedipine	NN	i	IPM
,	,	O	O
the	DT	O	O
tests	NNS	O	O
were	VBD	O	O
negative	JJ	O	O
in	IN	O	O
five	CD	O	O
patients	NNS	O	O
and	CC	O	O
positive	JJ	O	O
for	IN	O	O
a	DT	O	O
higher	JJR	O	O
or	CC	O	O
the	DT	O	O
same	JJ	O	O
dose	NN	O	O
of	IN	O	O
ergometrine	NN	i	IPM
in	IN	O	O
four	CD	O	O
and	CC	O	O
four	CD	O	O
patients	NNS	O	O
,	,	O	O
respectively	RB	O	O
(	(	O	O
p	JJ	O	O
=	$	O	O
0.0039	CD	O	O
vs.	FW	O	O
placebo	NN	i	IPM
)	)	i	O
.	.	O	O

Nifedipine	NNP	i	IPM
(	(	O	O
10	CD	O	O
mg	NN	O	O
)	)	O	O
and	CC	O	O
nicorandil	$	O	O
(	(	O	O
30	CD	O	O
mg	NN	O	O
)	)	O	O
were	VBD	O	O
equally	RB	O	O
effective	JJ	O	O
in	IN	O	O
eight	CD	O	O
patients	NNS	O	O
;	:	O	O
in	IN	O	O
the	DT	O	O
remaining	VBG	O	O
five	CD	O	O
patients	NNS	O	O
,	,	O	O
nicorandil	NNS	i	IPM
had	VBD	O	O
better	JJR	O	O
results	NNS	O	O
(	(	O	O
p	JJ	O	O
=	NNP	O	O
0.06	CD	O	O
)	)	O	O
.	.	O	O

Nicorandil	NNP	i	IPM
(	(	O	O
30	CD	O	O
mg	NN	O	O
)	)	O	O
prevents	VBZ	O	O
ergometrine-induced	JJ	o	OPH
coronary	JJ	o	OPH
spasm	NN	o	OPH
.	.	o	O

This	DT	O	O
compound	NN	O	O
may	MD	O	O
be	VB	O	O
beneficial	JJ	O	O
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
vasospastic	JJ	o	OPH
angina	NN	o	OPH
.	.	o	O

Financial	JJ	i	O
and	CC	i	O
quality-of-life	JJ	i	O
burden	NN	i	O
of	IN	O	O
dysfunctional	JJ	p	O
uterine	JJ	p	O
bleeding	NN	p	O
among	IN	p	O
women	NNS	p	O
agreeing	VBG	p	O
to	TO	p	O
obtain	VB	p	O
surgical	JJ	p	O
treatment	NN	p	O
.	.	p	O

PURPOSE	NN	O	O
In	IN	O	O
this	DT	O	O
study	NN	O	O
,	,	O	O
we	PRP	O	O
sought	VBD	O	O
to	TO	O	O
1	CD	O	O
)	)	O	O
describe	NN	O	O
elements	NNS	O	O
of	IN	O	O
the	DT	O	O
financial	JJ	i	IE
and	CC	i	IE
quality-of-life	JJ	i	IE
burden	NN	i	IE
of	IN	O	O
dysfunctional	JJ	p	O
uterine	JJ	p	O
bleeding	NN	p	O
(	(	p	O
DUB	NNP	p	O
)	)	p	O
from	IN	O	O
the	DT	O	O
perspective	NN	O	O
of	IN	p	O
women	NNS	p	O
who	WP	p	O
agreed	VBD	p	O
to	TO	p	O
obtain	VB	p	O
surgical	JJ	p	O
treatment	NN	p	O
;	:	p	O
2	CD	O	O
)	)	O	O
explore	NN	O	O
associations	NNS	O	O
between	IN	O	O
DUB	NNP	O	O
symptom	NN	O	O
characteristics	NNS	O	O
and	CC	O	O
the	DT	O	O
financial	JJ	i	IE
and	CC	i	IE
quality-of-life	JJ	i	IE
burden	NN	i	IE
;	:	i	O
3	CD	O	O
)	)	O	O
estimate	VBP	O	O
the	DT	O	O
annual	JJ	O	O
dollar	NN	O	O
value	NN	O	O
of	IN	O	O
the	DT	O	O
financial	JJ	O	O
burden	NN	O	O
;	:	O	O
and	CC	O	O
4	CD	O	O
)	)	O	O
estimate	VBP	O	O
the	DT	O	O
most	RBS	O	O
that	DT	O	O
could	MD	O	O
be	VB	O	O
spent	VBN	O	O
on	IN	O	O
surgery	NN	O	O
to	TO	O	O
eliminate	VB	O	O
DUB	NNP	O	O
symptoms	NNS	O	O
for	IN	O	O
which	WDT	O	O
medical	JJ	O	O
treatment	NN	O	O
has	VBZ	O	O
been	VBN	O	O
unsuccessful	JJ	O	O
that	WDT	O	O
would	MD	O	O
result	VB	O	O
in	IN	O	O
a	DT	O	O
$	$	O	O
50,000/quality-adjusted	JJ	O	O
life-year	JJ	O	O
incremental	JJ	O	O
cost-effectiveness	NN	O	O
ratio	NN	O	O
.	.	O	O

METHODS	NNP	O	O
We	PRP	p	O
collected	VBD	p	O
baseline	NN	i	IE
data	NNS	i	IE
on	IN	i	IE
DUB	NNP	i	IE
symptoms	NNS	i	IE
and	CC	i	IE
aspects	NNS	i	IE
of	IN	i	IE
the	DT	i	IE
financial	JJ	i	IE
and	CC	i	IE
quality-of-life	JJ	i	IE
burden	NN	i	IE
for	IN	p	O
237	CD	p	O
women	NNS	p	O
agreeing	VBG	p	O
to	TO	p	O
surgery	VB	p	O
for	IN	p	O
DUB	NNP	p	O
in	IN	p	O
a	DT	p	O
randomized	JJ	p	O
trial	NN	p	O
comparing	VBG	p	O
hysterectomy	NN	p	O
with	IN	p	O
endometrial	JJ	p	O
ablation	NN	p	O
.	.	p	O

Measures	NNS	O	O
included	VBD	O	O
out-of-pocket	JJ	o	OOt
pharmaceutical	JJ	o	OOt
expenditures	NNS	o	OOt
,	,	o	O
excess	JJ	o	OOt
expenditures	NNS	o	OOt
on	IN	o	OOt
pads	NNS	o	OOt
or	CC	o	OOt
tampons	NNS	o	OOt
,	,	o	O
the	DT	o	OOt
value	NN	o	OOt
of	IN	o	OOt
time	NN	o	OOt
missed	VBN	o	OOt
from	IN	o	OOt
paid	VBN	o	OOt
work	NN	o	OOt
and	CC	o	OOt
home	NN	o	OOt
management	NN	o	OOt
activities	NNS	o	OOt
,	,	o	O
and	CC	o	O
health	NN	o	OOt
utility	NN	o	OOt
.	.	o	O

We	PRP	O	O
used	VBD	O	O
chi2	NN	O	O
and	CC	O	O
t	NN	O	O
tests	NNS	O	O
to	TO	O	O
assess	VB	O	O
the	DT	O	O
statistical	JJ	O	O
significance	NN	O	O
of	IN	O	O
associations	NNS	O	O
between	IN	O	O
DUB	NNP	O	O
characteristics	NNS	O	O
and	CC	O	O
the	DT	O	O
financial	JJ	i	IE
and	CC	i	IE
quality-of-life	JJ	i	IE
burden	NN	i	IE
.	.	i	O

The	DT	O	O
annual	JJ	O	O
financial	JJ	O	O
burden	NN	O	O
was	VBD	O	O
estimated	VBN	O	O
.	.	O	O

RESULTS	NNP	O	O
Pelvic	NNP	o	OPA
pain	NN	o	OPA
and	CC	o	OPA
cramps	NNS	o	OPA
were	VBD	o	O
associated	VBN	o	O
with	IN	o	O
activity	NN	o	OPA
limitations	NNS	o	OPA
and	CC	O	O
tiredness	NN	o	OPH
was	VBD	o	O
associated	VBN	o	O
with	IN	o	O
a	DT	o	O
lower	JJR	o	OOt
health	NN	o	OOt
utility	NN	o	OOt
.	.	o	O

Excess	NNP	o	OOt
pharmaceutical	JJ	o	OOt
and	CC	o	OOt
pad	NN	o	OOt
and	CC	o	OOt
tampon	NN	o	OOt
costs	NNS	o	OOt
were	VBD	O	O
$	$	O	O
333	CD	O	O
per	IN	O	O
patient	NN	O	O
per	IN	O	O
year	NN	O	O
(	(	O	O
95	CD	O	O
%	NN	O	O
confidence	NN	O	O
interval	NN	O	O
[	NNP	O	O
CI	NNP	O	O
]	NNP	O	O
,	,	O	O
$	$	O	O
263-	JJ	O	O
$	$	O	O
403	CD	O	O
)	)	O	O
.	.	O	O

Excess	NNP	O	O
paid	VBD	o	OOt
work	NN	o	OOt
and	CC	o	OOt
home	NN	o	OOt
management	NN	o	OOt
loss	NN	o	OOt
costs	NNS	o	OOt
were	VBD	O	O
$	$	O	O
2,291	CD	O	O
per	IN	O	O
patient	NN	O	O
per	IN	O	O
year	NN	O	O
(	(	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
,	,	O	O
$	$	O	O
1847-	JJ	O	O
$	$	O	O
2752	CD	O	O
)	)	O	O
.	.	O	O

Effective	JJ	o	OOt
surgical	JJ	o	OOt
treatment	NN	o	OOt
costing	VBG	O	O
$	$	O	O
40,000	CD	O	O
would	MD	O	O
be	VB	O	O
cost-effective	JJ	o	OOt
compared	VBN	O	O
with	IN	O	O
unsuccessful	JJ	O	O
medical	JJ	O	O
treatment	NN	O	O
.	.	O	O

CONCLUSION	NNP	O	O
The	DT	O	O
financial	JJ	i	IE
and	CC	i	IE
quality-of-life	JJ	i	IE
effects	NNS	i	IE
of	IN	O	O
DUB	NNP	O	O
represent	VBP	O	O
a	DT	O	O
substantial	JJ	O	O
burden	NN	O	O
.	.	O	O

A	DT	O	O
short-term	JJ	i	IC
cognitive	JJ	i	IC
group	NN	i	IC
treatment	NN	i	IC
program	NN	i	IC
gives	VBZ	O	O
substantial	JJ	O	O
weight	NN	o	OPH
reduction	NN	o	OPH
up	RB	O	O
to	TO	O	O
18	CD	O	O
months	NNS	O	O
from	IN	O	O
the	DT	O	O
end	NN	O	O
of	IN	O	O
treatment	NN	O	O
.	.	O	O

A	DT	O	O
randomized	JJ	O	O
controlled	JJ	O	O
trial	NN	O	O
.	.	O	O

OBJECTIVE	UH	O	O
To	TO	O	O
describe	VB	O	O
and	CC	O	O
evaluate	VB	O	O
long-term	JJ	O	O
efficacy	NN	O	O
(	(	O	O
18	CD	O	O
months	NNS	O	O
from	IN	O	O
the	DT	O	O
end	NN	O	O
of	IN	O	O
treatment	NN	O	O
)	)	O	O
of	IN	O	O
a	DT	O	O
new	JJ	O	O
cognitive	JJ	i	IC
short-term	JJ	i	IC
weight	NN	i	IC
reducing	VBG	i	IC
treatment	NN	i	IC
program	NN	i	IC
for	IN	O	O
obese	JJ	p	O
patients	NNS	p	O
.	.	p	O

SUBJECTS	NNP	O	O
One	CD	p	O
hundred	CD	p	O
and	CC	p	O
five	CD	p	O
obese	JJ	p	O
[	NN	p	O
Body	NNP	p	O
Mass	NNP	p	O
Index	NNP	p	O
(	(	p	O
BMI	NNP	p	O
)	)	p	O
>	VBD	p	O
or	CC	p	O
=	$	p	O
30	CD	p	O
]	JJ	p	O
patients	NNS	p	O
participated	VBN	p	O
in	IN	p	O
the	DT	p	O
study	NN	p	O
.	.	p	O

Of	IN	O	O
these	DT	O	O
,	,	O	O
62	CD	p	O
took	VBD	p	O
part	NN	p	O
in	IN	p	O
the	DT	p	O
treatment	NN	p	O
program	NN	p	O
and	CC	p	O
43	CD	p	O
served	VBD	p	O
as	IN	p	O
controls	NNS	p	O
.	.	p	O

METHOD	NNP	O	O
From	IN	O	O
an	DT	O	O
obesity	NN	p	O
unit	NN	p	O
's	POS	p	O
waiting	VBG	p	O
list	NN	p	O
,	,	O	O
the	DT	O	O
patients	NNS	O	O
were	VBD	O	O
randomly	RB	O	O
assigned	VBN	O	O
to	TO	O	O
either	VB	O	O
a	DT	O	O
treatment	NN	O	O
group	NN	O	O
or	CC	O	O
remained	VBN	O	O
in	IN	O	O
the	DT	O	O
waiting	VBG	O	O
list	NN	O	O
to	TO	O	O
serve	VB	O	O
as	IN	O	O
a	DT	O	O
control	NN	i	IC
group	NN	O	O
.	.	O	O

The	DT	O	O
treatment	NN	O	O
group	NN	O	O
participated	VBD	O	O
in	IN	O	O
a	DT	O	O
10-week	JJ	i	IC
(	(	i	IC
30	CD	i	IC
hours	NNS	i	IC
)	)	i	IC
cognitive	VBP	i	IC
group	NN	i	IC
treatment	NN	i	IC
program	NN	i	IC
.	.	i	O

All	DT	O	O
participants	NNS	O	O
were	VBD	O	O
weighed	VBN	O	O
at	IN	O	O
the	DT	O	O
outset	NN	O	O
of	IN	O	O
the	DT	O	O
study	NN	O	O
,	,	O	O
directly	RB	O	O
after	IN	O	O
treatment	NN	O	O
and	CC	O	O
at	IN	O	O
a	DT	O	O
6-	JJ	O	O
,	,	O	O
12-	JJ	O	O
and	CC	O	O
18-month	JJ	O	O
post-treatment	JJ	i	O
follow-up	NN	O	O
without	IN	O	O
any	DT	O	O
booster	NN	O	O
treatment	NN	i	O
after	IN	O	O
the	DT	O	O
10-week	JJ	O	O
program	NN	O	O
.	.	O	O

RESULTS	NNP	O	O
Fifty-seven	NNP	p	O
(	(	p	O
92	CD	p	O
%	NN	p	O
)	)	p	O
patients	NNS	p	O
completed	VBN	p	O
treatment	NN	i	IC
.	.	i	O

For	IN	O	O
the	DT	O	O
34	CD	O	O
(	(	O	O
60	CD	O	O
%	NN	O	O
)	)	O	O
patients	NNS	O	O
who	WP	O	O
participated	VBD	O	O
in	IN	O	O
the	DT	O	O
study	NN	O	O
18	CD	O	O
months	NNS	O	O
after	IN	O	O
treatment	NN	O	O
was	VBD	O	O
terminated	VBN	O	O
,	,	O	O
the	DT	O	O
mean	JJ	o	OPH
weight	NN	o	OPH
loss	NN	o	OPH
at	IN	O	O
treatment	NN	O	O
's	POS	O	O
end	NN	O	O
was	VBD	O	O
8.5	CD	O	O
kg	NN	O	O
(	(	O	O
SD=16.1	NNP	O	O
)	)	O	O
.	.	O	O

Eighteen	JJ	O	O
months	NNS	O	O
later	RB	O	O
their	PRP$	O	O
mean	JJ	o	OPH
weight	NN	o	OPH
loss	NN	o	OPH
was	VBD	O	O
10.4	CD	O	O
kg	NN	O	O
(	(	O	O
SD=10.8	NNP	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
control	NN	O	O
patients	NNS	O	O
(	(	O	O
n=31.72	JJ	O	O
%	NN	O	O
)	)	O	O
that	WDT	O	O
participated	VBD	O	O
in	IN	O	O
the	DT	O	O
study	NN	O	O
during	IN	O	O
the	DT	O	O
same	JJ	O	O
period	NN	O	O
increased	VBD	O	O
in	IN	O	O
weight	NN	o	OPH
by	IN	O	O
2.3	CD	O	O
kg	NNS	O	O
(	(	O	O
SD=7.0	NNP	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
weight	NN	o	OPH
difference	NN	o	OPH
between	IN	O	O
the	DT	O	O
treatment	NN	O	O
and	CC	O	O
control	NN	O	O
group	NN	O	O
at	IN	O	O
the	DT	O	O
18-month	JJ	O	O
follow-up	NN	O	O
was	VBD	O	O
highly	RB	O	O
significant	JJ	O	O
(	(	O	O
p	JJ	O	O
<	NNP	O	O
0.001	CD	O	O
)	)	O	O
.	.	O	O

CONCLUSION	VB	O	O
The	DT	O	O
cognitive	JJ	i	O
group	NN	i	O
treatment	NN	i	O
program	NN	i	O
was	VBD	O	O
highly	RB	O	O
acceptable	JJ	O	O
among	IN	O	O
the	DT	O	O
participants	NNS	O	O
and	CC	O	O
was	VBD	O	O
completed	VBN	O	O
by	IN	O	O
nearly	RB	O	O
all	PDT	O	O
the	DT	O	O
patients	NNS	O	O
.	.	O	O

The	DT	O	O
10-week	JJ	O	O
treatment	NN	O	O
program	NN	O	O
resulted	VBD	O	O
in	IN	O	O
satisfactory	JJ	O	O
weight	JJ	o	OPH
loss	NN	o	OPH
.	.	o	OPH

The	DT	O	O
weight	NN	O	O
difference	NN	O	O
between	IN	O	O
the	DT	O	O
treatment	NN	i	IC
group	NN	O	O
and	CC	O	O
controls	NNS	i	O
was	VBD	O	O
nearly	RB	O	O
the	DT	O	O
same	JJ	O	O
at	IN	O	O
18	CD	O	O
months	NNS	O	O
after	IN	O	O
end	NN	O	O
of	IN	O	O
treatment	NN	O	O
as	IN	O	O
at	IN	O	O
six	CD	O	O
months	NNS	O	O
.	.	O	O

The	DT	O	O
study	NN	O	O
,	,	O	O
therefore	RB	O	O
,	,	O	O
does	VBZ	O	O
not	RB	O	O
provide	VB	O	O
support	NN	O	O
for	IN	O	O
the	DT	O	O
contention	NN	O	O
that	IN	O	O
a	DT	O	O
lengthy	JJ	O	O
therapy	NN	O	O
for	IN	O	O
obesity	NN	O	O
is	VBZ	O	O
necessary	JJ	O	O
if	IN	O	O
treatment	NN	O	O
results	NNS	O	O
are	VBP	O	O
lasting	VBG	O	O
.	.	O	O

Dose-response	JJ	o	OOt
effect	NN	o	OOt
of	IN	O	O
flecainide	NN	i	IPM
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
symptomatic	JJ	p	PC
paroxysmal	JJ	p	PC
atrial	JJ	p	PC
fibrillation	NN	p	PC
and/or	NN	p	PC
flutter	NN	p	PC
monitored	VBD	p	O
with	IN	p	O
trans-telephonic	JJ	p	O
electrocardiography	NN	p	O
:	:	p	O
a	DT	O	O
multicenter	NN	O	O
,	,	O	O
placebo-controlled	JJ	O	O
,	,	O	O
double-blind	JJ	O	O
trial	NN	O	O
.	.	O	O

BACKGROUND	VB	O	O
A	DT	O	O
double-blind	NN	O	O
,	,	O	O
randomized	VBN	O	O
,	,	O	O
parallel-group	JJ	O	O
,	,	O	O
placebo-controlled	JJ	i	IC
trial	NN	O	O
was	VBD	O	O
conducted	VBN	O	O
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
paroxysmal	JJ	p	PC
atrial	JJ	p	PC
fibrillation	NN	p	PC
or	CC	p	PC
flutter	NN	p	PC
(	(	p	PC
PAF/PAFL	NNP	p	PC
)	)	p	PC
experiencing	VBG	p	O
2	CD	p	O
or	CC	p	O
more	JJR	p	O
episodes	NNS	p	O
of	IN	p	O
symptomatic	JJ	p	PC
PAF/PAFL	NNP	p	PC
during	IN	p	O
a	DT	p	O
28-day	JJ	p	O
observation	NN	p	O
period	NN	p	O
to	TO	p	O
determine	VB	p	O
the	DT	p	O
dose-response	JJ	p	O
effect	NN	o	OOt
and	CC	o	OOt
safety	NN	o	OOt
of	IN	p	O
flecainide	NN	i	IPM
.	.	i	O

METHODS	NNP	O	O
AND	NNP	O	O
RESULTS	NNP	O	O
A	NNP	O	O
total	NN	O	O
of	IN	O	O
143	CD	p	PSS
patients	NNS	p	O
at	IN	p	O
30	CD	p	O
centers	NNS	p	O
were	VBD	O	O
randomized	VBN	O	O
to	TO	O	O
receive	VB	O	O
25	CD	O	O
,	,	O	O
50	CD	O	O
,	,	O	O
or	CC	O	O
100	CD	O	O
mg	NN	O	O
of	IN	O	O
flecainide	NN	i	IPM
or	CC	i	O
placebo	VB	i	IC
twice	JJ	O	O
daily	JJ	O	O
(	(	O	O
BID	NNP	O	O
)	)	O	O
.	.	O	O

In	IN	O	O
123	CD	p	PSS
patients	NNS	p	O
(	(	O	O
per	IN	O	O
protocol	NN	O	O
set	NN	O	O
)	)	O	O
,	,	O	O
those	DT	O	O
remaining	VBG	O	O
free	JJ	O	O
from	IN	O	O
PAF/PAFL	NNP	o	OPH
after	IN	O	O
the	DT	O	O
treatment	NN	O	O
were	VBD	O	O
3.1	CD	O	O
%	NN	O	O
on	IN	O	O
placebo	NN	i	IC
,	,	O	O
7.7	CD	O	O
%	NN	O	O
on	IN	O	O
25	CD	O	O
mg/BID	NN	O	O
,	,	O	O
9.4	CD	O	O
%	NN	O	O
on	IN	O	O
50	CD	O	O
mg/BID	NN	O	O
,	,	O	O
and	CC	O	O
39.4	CD	O	O
%	NN	O	O
on	IN	O	O
100	CD	O	O
mg/BID	NN	O	O
of	IN	O	O
flecainide	NN	i	IPM
.	.	i	O

As	IN	O	O
a	DT	O	O
whole	JJ	O	O
group	NN	O	O
,	,	O	O
a	DT	O	O
significant	JJ	o	OOt
linear	JJ	o	OOt
dose-response	NN	o	OOt
(	(	O	O
p	JJ	O	O
<	NNP	O	O
0.001	CD	O	O
)	)	O	O
was	VBD	O	O
observed	VBN	O	O
and	CC	O	O
a	DT	O	O
significant	JJ	O	O
difference	NN	O	O
between	IN	O	O
placebo	NN	O	O
and	CC	O	O
100	CD	O	O
mg/BID	NN	O	O
was	VBD	O	O
observed	VBN	O	O
(	(	O	O
p	JJ	O	O
<	NNP	O	O
0.001	CD	O	O
)	)	O	O
.	.	O	O

A	DT	O	O
similar	JJ	O	O
dose-response	NN	o	OOt
between	IN	O	O
the	DT	O	O
present	JJ	O	O
study	NN	O	O
and	CC	O	O
Caucasian	NNP	O	O
study	NN	O	O
was	VBD	O	O
demonstrated	VBN	O	O
.	.	O	O

Although	IN	O	O
there	EX	O	O
were	VBD	O	O
5	CD	O	O
patients	NNS	O	O
who	WP	O	O
needed	VBD	O	O
cardioversion	NN	o	OPH
or	CC	o	O
ablation	NN	o	OPH
because	IN	O	O
of	IN	O	O
frequent	JJ	O	O
episodes	NNS	O	O
of	IN	O	O
PAF/PAFL	NNP	O	O
(	(	O	O
2	CD	O	O
in	IN	O	O
25	CD	O	O
mg/BID	NN	O	O
,	,	O	O
1	CD	O	O
in	IN	O	O
50	CD	O	O
mg/BID	NN	O	O
,	,	O	O
and	CC	O	O
2	CD	O	O
in	IN	O	O
100	CD	O	O
mg/BID	NN	O	O
of	IN	O	O
flecainide	NN	i	IPM
)	)	i	O
,	,	O	O
neither	CC	O	O
death	NN	o	OMO
nor	CC	o	O
ventricular	JJ	o	OMO
proarrhythmic	JJ	o	OMO
event	NN	o	OMO
was	VBD	O	O
reported	VBN	O	O
.	.	O	O

CONCLUSIONS	VB	O	O
This	DT	O	O
study	NN	O	O
indicated	VBD	O	O
that	IN	O	O
flecainide	NN	i	IPM
exerted	VBD	O	O
a	DT	O	O
significant	JJ	O	O
dose-dependent	JJ	O	O
effect	NN	O	O
on	IN	O	O
the	DT	O	O
prevention	NN	O	O
of	IN	O	O
symptomatic	JJ	O	O
PAF/PAFL	NNP	O	O
recurrence	NN	O	O
and	CC	O	O
showed	VBD	O	O
that	IN	O	O
there	EX	O	O
was	VBD	O	O
no	DT	O	O
inter-ethnic	JJ	O	O
difference	NN	O	O
in	IN	O	O
the	DT	O	O
clinical	JJ	O	O
effect	NN	O	O
of	IN	O	O
flecainide	NN	i	IPM
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
PAF/PAFL	NNP	p	PC
.	.	p	O

Midazolam	NNP	i	IPM
vs	NN	i	O
ondansetron	NN	i	IPM
for	IN	O	O
preventing	VBG	O	O
postoperative	JJ	o	OA
nausea	NN	o	OA
and	CC	o	OA
vomiting	NN	o	OA
:	:	o	O
a	DT	O	O
randomised	JJ	O	O
controlled	VBN	O	O
trial	NN	O	O
.	.	O	O

We	PRP	O	O
compared	VBN	O	O
the	DT	O	O
prophylactic	JJ	O	O
anti-emetic	JJ	O	O
efficacy	NN	O	O
of	IN	O	O
midazolam	NN	i	IPM
and	CC	O	O
ondansetron	NN	i	IPM
in	IN	O	O
90	CD	p	PSS
patients	NNS	p	O
scheduled	VBN	p	O
for	IN	p	O
minor	JJ	p	PC
gynaecological	JJ	p	PC
(	(	p	O
hysteroscopy	NN	p	PC
)	)	p	O
or	CC	p	O
urological	JJ	p	PC
(	(	p	O
ureteroscopy	JJ	p	PC
)	)	p	O
procedures	NNS	p	O
planned	VBN	p	O
to	TO	p	O
last	JJ	p	O
1-2	JJ	p	O
h	NN	p	O
under	IN	p	O
sevoflurane	NN	p	O
anaesthesia	NN	p	O
with	IN	p	O
spontaneous	JJ	p	O
ventilation	NN	p	O
of	IN	p	O
the	DT	p	O
lungs	NNS	p	O
via	IN	p	O
a	DT	p	O
laryngeal	JJ	p	O
mask	NN	p	O
airway	NN	p	O
.	.	p	O

Midazolam	NNP	i	IPM
2	CD	i	IPM
mg	NN	i	IPM
or	CC	i	O
ondansetron	$	i	IPM
4	CD	i	IPM
mg	NN	i	IPM
were	VBD	O	O
administered	VBN	O	O
intravenously	RB	O	O
30	CD	O	O
min	NN	O	O
before	IN	O	O
the	DT	O	O
end	NN	O	O
of	IN	O	O
surgery	NN	O	O
.	.	O	O

The	DT	O	O
proportions	NNS	O	O
of	IN	O	O
patients	NNS	p	O
who	WP	p	O
experienced	VBD	p	O
postoperative	JJ	o	OA
nausea	NN	o	OA
and	CC	o	OA
vomiting	NN	o	OA
in	IN	p	O
the	DT	p	O
first	JJ	p	O
24	CD	p	O
h	NN	p	O
(	(	p	O
30	CD	p	O
%	NN	p	O
and	CC	p	O
27	CD	p	O
%	NN	p	O
for	IN	p	O
the	DT	p	O
midazolam	NN	i	IPM
and	CC	p	O
ondansetron	NN	i	IPM
groups	NNS	p	O
,	,	p	O
respectively	RB	p	O
)	)	p	O
were	VBD	p	O
similar	JJ	o	O
in	IN	p	O
the	DT	p	O
two	CD	p	O
groups	NNS	p	O
.	.	p	O

The	DT	O	O
incidence	NN	O	O
of	IN	O	O
postoperative	JJ	o	OA
nausea	NN	o	OA
and	CC	o	OA
vomiting	NN	o	OA
was	VBD	O	O
significantly	RB	O	O
smaller	JJR	o	O
in	IN	O	O
both	DT	O	O
groups	NNS	O	O
than	IN	O	O
predicted	VBN	O	O
according	VBG	O	O
to	TO	O	O
the	DT	O	O
patients	NNS	p	O
'	POS	p	O
underlying	JJ	p	O
risks	NNS	p	O
(	(	i	O
midazolam	JJ	i	IPM
group	NN	p	O
:	:	p	O
p	NN	p	O
=	VBZ	p	O
0.018	CD	p	O
;	:	p	O
ondansetron	VBN	i	IPM
group	NN	p	O
:	:	p	O
p	NN	p	O
=	VBZ	p	O
0.017	CD	p	O
)	)	p	O
.	.	p	O

There	EX	O	O
were	VBD	O	O
no	DT	o	OOt
significant	JJ	o	OOt
differences	NNS	o	OOt
in	IN	O	O
average	JJ	o	OPH
sedation	NN	o	OPH
scores	NNS	o	OPH
or	CC	o	O
pain	NN	o	OPH
scores	NNS	o	OPH
.	.	o	O

Treatment	NNP	O	O
using	VBG	O	O
ondansetron	NN	i	IPM
for	IN	O	O
anti-emetic	JJ	O	O
prophylaxis	NN	O	O
did	VBD	O	O
not	RB	O	O
provide	VB	O	O
a	DT	O	O
superior	JJ	O	O
benefit	NN	O	O
compared	VBN	O	O
to	TO	O	O
midazolam	VB	i	IPM
in	IN	O	O
the	DT	O	O
present	JJ	O	O
study	NN	O	O
.	.	O	O

Resistance	NNP	i	IPH
training	NN	i	IPH
increases	NNS	O	O
basal	VBP	O	O
limb	JJ	O	O
blood	NN	O	O
flow	NN	O	O
and	CC	O	O
vascular	JJ	O	O
conductance	NN	O	O
in	IN	O	O
aging	VBG	p	O
humans	NNS	p	O
.	.	p	O

Age-related	JJ	O	O
reductions	NNS	O	O
in	IN	O	O
basal	NN	O	O
limb	NN	O	O
blood	NN	O	O
flow	NN	O	O
and	CC	O	O
vascular	JJ	O	O
conductance	NN	O	O
are	VBP	O	O
associated	VBN	O	O
with	IN	O	O
the	DT	O	O
metabolic	JJ	O	O
syndrome	NN	O	O
,	,	O	O
functional	JJ	O	O
impairments	NNS	O	O
,	,	O	O
and	CC	O	O
osteoporosis	NN	O	O
.	.	O	O

We	PRP	O	O
tested	VBD	O	O
the	DT	O	O
hypothesis	NN	O	O
that	IN	O	O
a	DT	O	O
strength	NN	i	IPH
training	NN	i	IPH
program	NN	i	IPH
would	MD	O	O
increase	VB	O	O
basal	JJ	o	OPH
femoral	JJ	o	OPH
blood	NN	o	OPH
flow	NN	o	OPH
in	IN	O	O
aging	VBG	p	O
adults	NNS	p	O
.	.	p	O

Twenty-six	JJ	p	O
sedentary	JJ	p	O
but	CC	p	O
healthy	JJ	p	O
middle-aged	JJ	p	O
and	CC	p	O
older	JJR	p	O
subjects	NNS	p	O
were	VBD	O	O
randomly	RB	i	O
assigned	VBN	i	O
to	TO	i	O
either	CC	i	O
a	DT	i	O
whole	JJ	i	IPH
body	NN	i	IPH
strength	NN	i	IPH
training	VBG	i	IPH
intervention	NN	i	O
group	NN	i	O
(	(	i	O
52	CD	i	O
+/-	JJ	i	O
2	CD	i	O
yr	NN	i	O
,	,	i	O
3	CD	i	O
men	NNS	i	O
,	,	i	O
10	CD	i	O
women	NNS	i	O
)	)	i	O
who	WP	i	O
underwent	VBD	i	O
three	CD	i	O
supervised	VBN	i	O
resistance	NN	i	IPH
training	NN	i	IPH
sessions	NNS	i	O
per	IN	i	O
week	NN	i	O
for	IN	i	O
13	CD	i	O
wk	NN	i	O
or	CC	i	O
a	DT	i	O
control	NN	i	O
group	NN	i	O
(	(	i	O
53	CD	i	O
+/-	JJ	i	O
2	CD	i	O
yr	NN	i	O
,	,	i	O
4	CD	i	O
men	NNS	i	O
,	,	i	O
9	CD	i	O
women	NNS	i	O
)	)	i	O
who	WP	i	O
participated	VBD	i	O
in	IN	i	O
a	DT	i	O
supervised	JJ	i	O
stretching	NN	i	O
program	NN	i	O
.	.	i	O

At	IN	p	O
baseline	NN	p	O
,	,	p	O
there	EX	p	O
were	VBD	p	O
no	DT	p	O
significant	JJ	p	O
differences	NNS	p	O
in	IN	p	O
blood	NN	o	OPH
pressure	NN	o	OPH
,	,	o	O
cardiac	JJ	o	OPH
output	NN	o	OPH
,	,	o	O
basal	JJ	o	OPH
femoral	JJ	o	OPH
blood	NN	o	OPH
flow	NN	o	OPH
(	(	o	OPH
via	IN	o	OPH
Doppler	NNP	o	OPH
ultrasound	NN	o	OPH
)	)	o	OPH
,	,	o	O
vascular	JJ	o	OPH
conductance	NN	o	OPH
,	,	o	O
and	CC	o	O
vascular	JJ	o	OPH
resistance	NN	o	OPH
between	IN	p	O
the	DT	p	O
two	CD	p	O
groups	NNS	p	O
.	.	p	O

The	DT	O	O
strength	NN	i	IPH
training	VBG	i	IPH
group	NN	i	IPH
increased	VBD	O	O
maximal	JJ	o	OPH
strength	NN	o	OPH
in	IN	O	O
all	PDT	O	O
the	DT	O	O
major	JJ	O	O
muscle	NN	O	O
groups	NNS	O	O
tested	VBD	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

Whole	JJ	o	OPH
body	NN	o	OPH
lean	JJ	o	OPH
body	NN	o	OPH
mass	NN	o	OPH
increased	VBD	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
with	IN	O	O
strength	NN	O	O
training	NN	O	O
,	,	O	O
but	CC	O	O
leg	VBZ	o	OPH
fat-free	JJ	o	OPH
mass	NN	o	OPH
did	VBD	O	O
not	RB	O	O
.	.	O	O

Basal	NNP	o	OPH
femoral	JJ	o	OPH
blood	NN	o	OPH
flow	NN	o	OPH
and	CC	o	OPH
vascular	JJ	o	OPH
conductance	NN	o	OPH
increased	VBN	O	O
by	IN	O	O
55-60	CD	O	O
%	NN	O	O
after	IN	O	O
strength	NN	i	IPH
training	NN	i	IPH
(	(	O	O
both	DT	O	O
P	NNP	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

No	DT	O	O
such	JJ	O	O
changes	NNS	O	O
were	VBD	O	O
observed	VBN	O	O
in	IN	O	O
the	DT	O	O
control	NN	O	O
group	NN	O	O
.	.	O	O

In	IN	O	O
both	DT	O	O
groups	NNS	O	O
,	,	O	O
there	EX	O	O
were	VBD	O	O
no	DT	O	O
significant	JJ	O	O
changes	NNS	O	O
in	IN	O	O
brachial	JJ	o	OPH
blood	NN	o	OPH
pressure	NN	o	OPH
,	,	o	O
plasma	JJ	o	OPH
endothelin-1	NN	o	OPH
and	CC	o	OPH
angiotensin	NN	o	OPH
II	NNP	o	OPH
concentrations	NNS	o	OPH
,	,	o	O
femoral	JJ	o	OPH
artery	NN	o	OPH
wall	NN	o	OPH
thickness	NN	o	OPH
,	,	o	O
cardiac	JJ	o	OPH
output	NN	o	OPH
,	,	o	O
and	CC	o	O
systemic	JJ	o	OPH
vascular	JJ	o	OPH
resistance	NN	o	OPH
.	.	o	O

Our	PRP$	O	O
results	NNS	O	O
indicate	VBP	O	O
that	IN	O	O
short-term	JJ	i	IPH
strength	NN	i	IPH
training	NN	i	IPH
increases	NNS	O	O
basal	VBP	O	O
femoral	JJ	O	O
blood	NN	O	O
flow	NN	O	O
and	CC	O	O
vascular	JJ	O	O
conductance	NN	O	O
in	IN	O	O
healthy	JJ	p	O
middle-aged	JJ	p	O
and	CC	p	O
older	JJR	p	O
adults	NNS	p	O
.	.	p	O

Determinants	NNS	O	O
of	IN	O	O
serum	JJ	O	O
creatinine	NN	O	O
trajectory	NN	O	O
in	IN	O	O
acute	JJ	p	O
contrast	NN	p	O
nephropathy	NN	p	PC
.	.	p	O

The	DT	O	O
aim	NN	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
describe	VB	O	O
the	DT	O	O
trajectory	NN	O	O
of	IN	O	O
creatinine	NN	o	OPH
(	(	o	OPH
Cr	NNP	o	OPH
)	)	o	OPH
rise	NN	o	O
and	CC	O	O
its	PRP$	O	O
determinants	NNS	O	O
after	IN	p	O
exposure	NN	p	O
to	TO	p	O
radiocontrast	VB	p	PC
media	NNS	p	O
.	.	p	O

Included	VBN	O	O
were	VBD	O	O
98	CD	p	PSS
subjects	NNS	p	O
who	WP	p	O
underwent	VBP	p	O
cardiac	JJ	p	PC
catheterization	NN	p	PC
and	CC	O	O
were	VBD	O	O
randomized	VBN	O	O
to	TO	O	O
forced	VBN	O	O
diuresis	NN	i	IPM
with	IN	i	IPM
i.v	NN	i	IPM
.	.	i	IPM

crystalloid	NN	i	IPM
,	,	i	IPM
furosemide	RB	i	IPM
,	,	i	IPM
mannitol	NN	i	IPM
(	(	i	IPM
if	IN	i	IPM
pulmonary	JJ	i	IPM
capillary	JJ	i	IPM
wedge	NN	i	IPM
pressure	NN	i	IPM
was	VBD	i	IPM
<	JJ	i	IPM
20	CD	i	IPM
mmHg	NN	i	IPM
)	)	i	IPM
,	,	i	IPM
and	CC	i	O
low	JJ	i	IPM
dose	JJ	i	IPM
dopamine	NN	i	IPM
versus	NN	i	IPM
intravenous	JJ	i	IPM
crystalloid	NN	i	IPM
and	CC	i	O
matching	VBG	i	IC
placebos	NNS	i	IC
.	.	i	O

Baseline	NNP	O	O
and	CC	O	O
postcatheterization	NN	O	O
serum	NN	o	OPH
Cr	NNP	o	OPH
levels	NNS	o	OPH
were	VBD	O	O
analyzed	VBN	O	O
in	IN	O	O
a	DT	O	O
longitudinal	JJ	O	O
fashion	NN	O	O
,	,	O	O
allowing	VBG	O	O
for	IN	O	O
differences	NNS	O	O
in	IN	O	O
the	DT	O	O
time	NN	O	O
between	IN	O	O
blood	NN	O	O
draws	NNS	O	O
,	,	O	O
to	TO	O	O
determine	VB	O	O
the	DT	O	O
different	JJ	O	O
critical	JJ	O	O
trajectories	NNS	O	O
of	IN	O	O
serum	NN	O	O
Cr	NNP	O	O
.	.	O	O

The	DT	p	O
mean	JJ	o	OPH
age	NN	o	OPH
,	,	o	O
baseline	NN	o	OPH
serum	NN	o	OPH
Cr	NNP	o	OPH
,	,	o	O
and	CC	o	O
Cr	NNP	o	OPH
clearance	NN	o	OPH
(	(	o	OPH
CrCl	NNP	o	OPH
)	)	o	OPH
were	VBD	p	O
69.3	CD	p	PA
+/-	JJ	p	PA
10.8	CD	p	PA
years	NNS	p	PA
,	,	p	O
2.5	CD	p	O
+/-	JJ	p	O
0.9	CD	p	O
mg/dL	NN	p	O
,	,	p	O
and	CC	p	O
31.4	CD	p	O
+/-	JJ	p	O
12.1	CD	p	O
mL/min	NN	p	O
,	,	p	O
respectively	RB	p	O
.	.	p	O

The	DT	O	O
clinically	RB	o	OOt
driven	JJ	o	OOt
postprocedural	JJ	o	OOt
observation	NN	o	OOt
time	NN	o	OOt
was	VBD	O	O
5.5	CD	O	O
+/-	JJ	O	O
5.1	CD	O	O
days	NNS	O	O
(	(	O	O
range	VB	O	O
19	CD	O	O
hours	NNS	O	O
and	CC	O	O
one	CD	O	O
Cr	NNP	O	O
value	NN	O	O
to	TO	O	O
25.7	CD	O	O
days	NNS	O	O
and	CC	O	O
18	CD	O	O
values	NNS	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
mean	JJ	o	OPH
maximum	NN	o	OPH
Cr	NNP	o	OPH
was	VBD	O	O
3.3	CD	O	O
+/-	JJ	O	O
1.4	CD	O	O
,	,	O	O
range	NN	O	O
1.7-8.7	JJ	O	O
mg/dL	NN	O	O
)	)	O	O
.	.	O	O

Longitudinal	JJ	O	O
models	NNS	O	O
support	VBP	O	O
baseline	JJ	O	O
Cr	NNP	o	OPH
clearance	NN	o	OPH
predictions	NNS	O	O
for	IN	O	O
the	DT	O	O
change	NN	O	O
in	IN	O	O
Cr	NNP	O	O
at	IN	O	O
24	CD	O	O
hours	NNS	O	O
,	,	O	O
time	NN	O	O
as	IN	O	O
the	DT	O	O
determinant	NN	O	O
of	IN	O	O
Cr	NNP	O	O
trajectory	NN	O	O
,	,	O	O
and	CC	O	O
requisite	JJ	O	O
monitoring	NN	O	O
.	.	O	O

For	IN	O	O
any	DT	O	O
given	VBN	O	O
individual	NN	O	O
,	,	O	O
a	DT	O	O
rise	NN	O	O
in	IN	O	O
Cr	NNP	o	OPH
of	IN	O	O
<	NNP	O	O
or	CC	O	O
=	$	O	O
0.5	CD	O	O
mg/dL	NN	O	O
in	IN	O	O
the	DT	O	O
first	JJ	O	O
24	CD	O	O
hours	NNS	O	O
after	IN	O	O
contrast	NN	O	O
exposure	NN	O	O
predicted	VBD	O	O
a	DT	O	O
favorable	JJ	O	O
outcome	NN	O	O
.	.	O	O

Baseline	NNP	o	OPH
renal	JJ	o	OPH
function	NN	o	OPH
is	VBZ	O	O
the	DT	O	O
major	JJ	O	O
determinant	NN	O	O
of	IN	O	O
the	DT	O	O
rate	NN	O	O
of	IN	O	O
rise	NN	O	O
,	,	O	O
height	NN	O	O
,	,	O	O
and	CC	O	O
duration	NN	O	O
of	IN	O	O
Cr	NNP	O	O
trajectory	NN	O	O
after	IN	O	O
contrast	NN	O	O
exposure	NN	O	O
.	.	O	O

Length	NNP	O	O
of	IN	O	O
observation	NN	O	O
and	CC	O	O
frequency	NN	O	O
of	IN	O	O
laboratory	NN	O	O
measures	NNS	O	O
can	MD	O	O
be	VB	O	O
anticipated	VBN	O	O
from	IN	O	O
these	DT	O	O
models	NNS	O	O
.	.	O	O

[	JJ	O	O
Effect	NNP	O	O
of	IN	O	O
dopexamine	NN	i	IPM
in	IN	O	O
splanchnic	JJ	O	O
perfusion	NN	O	O
during	IN	O	O
surgery	NN	p	O
of	IN	p	O
the	DT	p	O
abdominal	JJ	p	O
aorta	NN	p	O
]	NNP	p	O
.	.	O	O

Abdominal	NNP	O	O
aortic	JJ	O	O
surgery	NN	O	O
has	VBZ	O	O
significant	JJ	O	O
effects	NNS	O	O
on	IN	O	O
cardiac	NN	O	O
and	CC	O	O
splanchnic	JJ	O	O
perfusion	NN	O	O
.	.	O	O

The	DT	O	O
purpose	NN	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
examine	VB	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
dopexamine	NN	O	O
,	,	O	O
an	DT	O	O
inodilator	JJ	O	O
drug	NN	O	O
,	,	O	O
on	IN	O	O
hemodynamic	JJ	O	O
and	CC	O	O
splanchnic	JJ	O	O
perfusion	NN	O	O
with	IN	O	O
measurement	NN	O	O
of	IN	O	O
gastric	JJ	O	O
intramucosal	NN	O	O
pH	NN	O	O
,	,	O	O
by	IN	O	O
the	DT	O	O
method	NN	O	O
of	IN	O	O
gastric	JJ	O	O
tonometry	NN	O	O
,	,	O	O
during	IN	O	O
abdominal	JJ	O	O
aneurysm	JJ	O	O
resection	NN	O	O
.	.	O	O

Twenty-five	JJ	p	O
patients	NNS	p	O
undergoing	VBG	p	O
excision	NN	p	O
of	IN	p	O
an	DT	p	O
aortic	JJ	p	O
abdominal	JJ	p	O
aneurysm	NN	p	O
were	VBD	O	O
randomly	RB	O	O
divided	VBN	O	O
into	IN	O	O
two	CD	O	O
groups	NNS	O	O
.	.	O	O

During	IN	O	O
aortic	JJ	O	O
cross-clamping	JJ	O	O
Group	NNP	O	O
II	NNP	O	O
patients	NNS	O	O
received	VBD	O	O
dopexamine	JJ	i	IPM
infusion	NN	O	O
,	,	O	O
at	IN	O	O
a	DT	O	O
dose	NN	O	O
of	IN	O	O
1	CD	O	O
microgram/kg/m	NN	O	O
,	,	O	O
and	CC	O	O
at	IN	O	O
a	DT	O	O
dose	NN	O	O
of	IN	O	O
0.5	CD	O	O
micrograms/kg/m	NN	O	O
from	IN	O	O
declamping	VBG	O	O
to	TO	O	O
the	DT	O	O
end	NN	O	O
of	IN	O	O
the	DT	O	O
surgery	NN	O	O
.	.	O	O

Whereas	NNP	O	O
Group	NNP	O	O
I	PRP	O	O
patients	NNS	O	O
did	VBD	i	IC
not	RB	i	IC
receive	VB	i	IC
a	DT	i	IC
dopexamine	JJ	i	IC
infusion	NN	i	IC
.	.	i	O

During	IN	O	O
aortic	JJ	O	O
cross-clamping	VBG	O	O
the	DT	O	O
intramucosal	NN	o	OPH
pH	VBZ	o	OPH
value	NN	o	OPH
decreased	VBN	O	O
in	IN	O	O
Group	NNP	O	O
I	PRP	O	O
patients	NNS	O	O
,	,	O	O
but	CC	O	O
did	VBD	O	O
not	RB	O	O
change	VB	O	O
in	IN	O	O
Group	NNP	O	O
II	NNP	O	O
patients	NNS	O	O
.	.	O	O

Heart	NNP	o	OPH
rate	NN	o	OPH
,	,	o	OPH
cardiac	JJ	o	OPH
index	NN	o	OPH
,	,	o	OPH
and	CC	o	OPH
mixed	JJ	o	OPH
venous	JJ	o	OPH
oxygen	NN	o	OPH
saturation	NN	o	OPH
increased	VBD	O	O
significantly	RB	O	O
during	IN	O	O
dopexamine	JJ	O	O
infusion	NN	O	O
,	,	O	O
whereas	JJ	O	O
systemic	JJ	o	OPH
vascular	NN	o	OPH
resistance	NN	o	OPH
was	VBD	O	O
reduced	VBN	O	O
.	.	O	O

During	IN	O	O
aortic	JJ	O	O
cross-clamping	JJ	O	O
dopexamine	NN	i	IPM
was	VBD	O	O
a	DT	O	O
useful	JJ	O	O
agent	NN	O	O
in	IN	O	O
improving	VBG	O	O
splanchnic	JJ	o	OPH
blood	NN	o	OPH
flow	NN	o	OPH
,	,	o	OPH
cardiac	JJ	o	OPH
index	NN	o	OPH
venous	JJ	o	OPH
saturation	NN	o	OPH
.	.	o	O

Also	RB	O	O
,	,	O	O
since	IN	O	O
the	DT	O	O
drug	NN	O	O
produces	VBZ	O	O
dose	RB	O	O
related	JJ	O	O
hemodynamic	JJ	O	O
changes	NNS	O	O
of	IN	O	O
rapid	JJ	O	O
onset	NN	O	O
and	CC	O	O
reversibility	NN	O	O
,	,	O	O
it	PRP	O	O
is	VBZ	O	O
possible	JJ	O	O
to	TO	O	O
interrupt	VB	O	O
the	DT	O	O
infusion	NN	O	O
before	IN	O	O
aortic	JJ	O	O
declamping	NN	O	O
to	TO	O	O
avoid	VB	O	O
the	DT	O	O
decrease	NN	O	O
in	IN	O	O
the	DT	O	O
intramucosal	NN	O	O
pH	VBZ	O	O
value	NN	O	O
.	.	O	O

Effect	NN	p	O
of	IN	p	O
resistance	NN	i	IPH
exercise	NN	i	IPH
contraction	NN	i	IPH
mode	NN	i	IPH
and	CC	p	O
protein	JJ	i	IPH
supplementation	NN	i	IPH
on	IN	p	O
members	NNS	p	O
of	IN	p	O
the	DT	p	O
STARS	NNP	p	O
signalling	VBG	p	O
pathway	RB	p	O
.	.	p	O

The	DT	O	O
striated	JJ	O	O
muscle	NN	O	O
activator	NN	O	O
of	IN	O	O
Rho	NNP	O	O
signalling	VBG	O	O
(	(	O	O
STARS	NNP	O	O
)	)	O	O
pathway	NN	O	O
is	VBZ	O	O
suggested	VBN	O	O
to	TO	O	O
provide	VB	O	O
a	DT	O	O
link	NN	O	O
between	IN	O	O
external	JJ	O	O
stress	NN	O	O
responses	NNS	O	O
and	CC	O	O
transcriptional	JJ	O	O
regulation	NN	O	O
in	IN	O	O
muscle	NN	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
the	DT	O	O
sensitivity	NN	O	O
of	IN	O	O
STARS	NNP	O	O
signalling	VBG	O	O
to	TO	O	O
different	JJ	O	O
mechanical	JJ	O	O
stresses	NNS	O	O
has	VBZ	O	O
not	RB	O	O
been	VBN	O	O
investigated	VBN	O	O
.	.	O	O

In	IN	O	O
a	DT	O	O
comparative	JJ	O	O
study	NN	O	O
,	,	O	O
we	PRP	O	O
examined	VBD	O	O
the	DT	O	O
regulation	NN	O	O
of	IN	O	O
the	DT	O	O
STARS	NNP	O	O
signalling	VBG	O	O
pathway	RB	O	O
in	IN	O	O
response	NN	O	O
to	TO	O	O
unilateral	JJ	O	O
resistance	NN	i	IPH
exercise	NN	i	IPH
performed	VBN	O	O
as	IN	O	O
either	DT	O	O
eccentric	JJ	i	IE
(	(	i	IPH
ECC	NNP	i	IPH
)	)	i	IPH
or	CC	i	IPH
concentric	JJ	i	IPH
(	(	i	IPH
CONC	NNP	i	IPH
)	)	i	IPH
contractions	NNS	i	IPH
as	RB	O	O
well	RB	O	O
as	IN	O	O
prolonged	JJ	i	IE
training	NN	i	IE
;	:	i	O
with	IN	p	O
and	CC	p	O
without	IN	p	O
whey	JJ	i	IPH
protein	NN	i	IPH
supplementation	NN	i	IPH
.	.	i	O

Skeletal	JJ	O	O
muscle	NN	O	O
STARS	NNP	O	O
,	,	O	O
myocardian-related	JJ	O	O
transcription	NN	O	O
factor-A	NN	O	O
(	(	O	O
MRTF-A	NNP	O	O
)	)	O	O
and	CC	O	O
serum	JJ	O	O
response	NN	O	O
factor	NN	O	O
(	(	O	O
SRF	NNP	O	O
)	)	O	O
mRNA	NN	O	O
and	CC	O	O
protein	NN	O	O
,	,	O	O
as	RB	O	O
well	RB	O	O
as	IN	O	O
muscle	NN	O	O
cross-sectional	JJ	O	O
area	NN	O	O
and	CC	O	O
maximal	JJ	O	O
voluntary	JJ	O	O
contraction	NN	O	O
,	,	O	O
were	VBD	O	O
measured	VBN	O	O
.	.	O	O

A	DT	O	O
single-bout	NN	O	O
of	IN	O	O
exercise	NN	i	IPH
produced	VBN	O	O
increases	NNS	O	O
in	IN	O	O
STARS	NNP	o	OPH
and	CC	o	OPH
SRF	NNP	o	OPH
mRNA	NN	o	OPH
and	CC	o	OPH
decreases	NNS	o	OPH
in	IN	o	OPH
MRTF-A	NNP	o	OPH
mRNA	NN	o	OPH
with	IN	o	OPH
both	DT	o	OPH
ECC	NNP	o	OPH
and	CC	o	OPH
CONC	NNP	o	OPH
exercise	NN	o	OPH
,	,	O	O
but	CC	O	O
with	IN	O	O
an	DT	O	O
enhanced	JJ	O	O
response	NN	O	O
occurring	VBG	O	O
following	VBG	O	O
ECC	NNP	i	IPH
exercise	NN	i	IPH
.	.	i	O

A	DT	O	O
31	CD	O	O
%	NN	O	O
increase	NN	O	O
in	IN	O	O
STARS	NNP	o	OPH
protein	NN	o	OPH
was	VBD	O	O
observed	VBN	O	O
exclusively	RB	O	O
after	IN	O	O
CONC	NNP	i	IPH
exercise	NN	i	IPH
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.001	CD	O	O
)	)	O	O
,	,	O	O
while	IN	O	O
pSRF	JJ	o	OPH
protein	NN	O	O
levels	NNS	O	O
increased	VBD	O	O
similarly	RB	O	O
by	IN	O	O
48	CD	O	O
%	NN	O	O
with	IN	O	O
both	DT	O	O
CONC	NNP	O	O
and	CC	O	O
ECC	NNP	O	O
exercise	NN	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.001	CD	O	O
)	)	O	O
.	.	O	O

Prolonged	VBN	O	O
ECC	NNP	O	O
and	CC	O	O
CONC	NNP	O	O
training	VBG	O	O
equally	RB	O	O
stimulated	VBN	O	O
muscle	NN	O	O
hypertrophy	NN	O	O
and	CC	O	O
produced	VBD	O	O
increases	NNS	O	O
in	IN	O	O
MRTF-A	NNP	o	OPH
protein	NN	o	OPH
of	IN	O	O
125	CD	O	O
%	NN	O	O
and	CC	O	O
99	CD	O	O
%	NN	O	O
,	,	O	O
respectively	RB	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.001	CD	O	O
)	)	O	O
.	.	O	O

No	UH	O	O
changes	NNS	O	O
occurred	VBD	O	O
for	IN	O	O
total	JJ	o	OPH
SRF	NNP	o	OPH
protein	NN	o	OPH
.	.	o	O

There	EX	O	O
was	VBD	O	O
no	DT	O	O
effect	NN	O	O
of	IN	O	O
whey	NN	o	OPH
protein	NN	o	OPH
supplementation	NN	o	OPH
.	.	o	OPH

These	DT	O	O
results	NNS	O	O
show	VBP	O	O
that	IN	O	O
resistance	NN	O	O
exercise	NN	O	O
provides	VBZ	O	O
an	DT	O	O
acute	JJ	o	OPH
stimulation	NN	o	OPH
of	IN	o	OPH
the	DT	o	OPH
STARS	NNP	o	OPH
pathway	NN	o	OPH
that	WDT	O	O
is	VBZ	O	O
contraction	JJ	O	O
mode	NN	O	O
dependent	NN	O	O
.	.	O	O

The	DT	O	O
responses	NNS	O	O
to	TO	O	O
acute	VB	i	IPH
exercise	NN	i	IPH
were	VBD	O	O
more	RBR	O	O
pronounced	JJ	O	O
than	IN	O	O
responses	NNS	O	O
to	TO	O	O
accumulated	JJ	i	IE
training	NN	i	IE
,	,	O	O
suggesting	VBG	O	O
that	IN	O	O
STARS	NNP	O	O
signalling	VBG	O	O
is	VBZ	O	O
primarily	RB	O	O
involved	VBN	O	O
in	IN	O	O
the	DT	O	O
initial	JJ	O	O
phase	NN	O	O
of	IN	O	O
exercise-induced	JJ	O	O
muscle	NN	O	O
adaptations	NNS	O	O
.	.	O	O

Autism-Spectrum	JJ	i	IOt
Quotient-Japanese	JJ	i	IOt
version	NN	O	O
and	CC	O	O
its	PRP$	O	O
short	JJ	O	O
forms	NNS	O	O
for	IN	O	O
screening	VBG	p	O
normally	RB	p	PC
intelligent	JJ	p	PC
persons	NNS	p	O
with	IN	p	O
pervasive	JJ	p	PC
developmental	NN	p	PC
disorders	NNS	p	PC
.	.	p	O

A	DT	O	O
Japanese	JJ	i	IOt
version	NN	i	IOt
of	IN	i	IOt
the	DT	i	IOt
Autism	NNP	i	IOt
Spectrum	NNP	i	IOt
Quotient	NNP	i	IOt
(	(	i	IOt
AQ	NNP	i	IOt
)	)	i	IOt
,	,	i	IOt
AQ-J	NNP	i	IOt
was	VBD	O	O
administered	VBN	O	O
to	TO	O	O
25	CD	p	PC
normally	RB	p	PC
intelligent	JJ	p	PC
high-functioning	JJ	p	PC
pervasive	JJ	p	PC
developmental	NN	p	PC
disorder	NN	p	PC
(	(	p	O
HPDD	NNP	p	PC
)	)	p	O
patients	NNS	p	O
(	(	p	O
mean	JJ	p	O
age	NN	p	O
,	,	p	O
24.2	CD	p	PA
years	NNS	p	PA
;	:	p	O
24	CD	p	PC
male	NN	p	PA
,	,	p	O
one	CD	p	PC
female	NN	p	PA
)	)	p	O
and	CC	p	O
215	CD	p	PC
controls	NNS	p	O
(	(	p	O
mean	JJ	p	O
age	NN	p	O
,	,	p	O
30.4	CD	p	PA
years	NNS	p	PA
;	:	p	O
86	CD	p	PC
male	NN	p	PA
,	,	p	O
129	CD	p	PC
female	NN	p	PA
)	)	p	O
randomly	RB	p	O
selected	VBN	p	O
from	IN	p	O
the	DT	p	O
general	JJ	p	O
population	NN	p	O
.	.	p	O

The	DT	O	O
AQ-J	NNP	i	IOt
had	VBD	O	O
satisfactory	JJ	o	OOt
internal	JJ	o	OOt
consistency	NN	o	OOt
reliability	NN	o	OOt
(	(	O	O
Cronbach	NNP	O	O
's	POS	O	O
alpha	NN	O	O
>	VBD	O	O
0.70	CD	O	O
in	IN	O	O
the	DT	O	O
two	CD	O	O
groups	NNS	O	O
)	)	O	O
,	,	O	O
test-retest	JJ	o	OOt
reliability	NN	o	OOt
,	,	o	O
and	CC	o	O
discriminant	JJ	o	OOt
validity	NN	o	OOt
[	NNP	O	O
i.e	NN	O	O
.	.	O	O

the	DT	O	O
AQ-J	NNP	O	O
score	NN	O	O
was	VBD	O	O
significantly	RB	O	O
higher	JJR	O	O
in	IN	O	O
the	DT	O	O
HPDD	NNP	O	O
(	(	O	O
mean	NN	O	O
,	,	O	O
29.6	CD	O	O
)	)	O	O
than	IN	O	O
controls	NNS	O	O
(	(	O	O
mean	NN	O	O
,	,	O	O
22.2	CD	O	O
)	)	O	O
]	NN	O	O
.	.	O	O

At	IN	O	O
a	DT	O	O
cut-off	NN	O	O
of	IN	O	O
26	CD	O	O
,	,	O	O
the	DT	O	O
AQ-J	NNP	o	OPH
had	VBD	O	O
satisfactory	JJ	o	OOt
sensitivity	NN	o	OOt
,	,	o	O
specificity	NN	o	OOt
,	,	o	O
and	CC	o	O
negative	JJ	o	OOt
predictive	JJ	o	OOt
value	NN	o	OOt
,	,	O	O
but	CC	O	O
it	PRP	O	O
had	VBD	O	O
low	JJ	o	OOt
positive	JJ	o	OOt
predictive	NN	o	OOt
value	NN	o	OOt
(	(	O	O
0.24	CD	O	O
)	)	O	O
possibly	RB	O	O
due	JJ	O	O
to	TO	O	O
the	DT	O	O
facts	NNS	O	O
that	IN	O	O
the	DT	O	O
25	CD	O	O
mild	JJ	O	O
HPDD	NNP	O	O
patients	NNS	O	O
scored	VBD	O	O
lower	JJR	O	O
and	CC	O	O
the	DT	O	O
controls	NNS	O	O
scored	VBD	O	O
higher	JJR	O	O
on	IN	O	O
the	DT	O	O
AQ-J	NNP	i	IOt
than	IN	O	O
British	NNP	O	O
counterparts	NNS	O	O
on	IN	O	O
the	DT	O	O
AQ	NNP	O	O
.	.	O	O

The	DT	O	O
AQ-J-21	NNP	o	OPH
(	(	o	OPH
consisting	VBG	o	OPH
of	IN	o	OPH
21	CD	o	OPH
items	NNS	o	OPH
significantly	RB	o	OPH
associated	VBN	o	OPH
with	IN	o	OPH
HPDD	NNP	o	OPH
diagnosis	NN	o	OPH
)	)	o	OPH
and	CC	O	O
the	DT	O	O
AQ-J-10	NNP	o	OPH
(	(	o	OPH
consisting	VBG	o	OPH
of	IN	o	OPH
10	CD	o	OPH
of	IN	o	OPH
the	DT	o	OPH
21	CD	o	OPH
items	NNS	o	OPH
with	IN	o	OPH
an	DT	o	OPH
effect	NN	o	OPH
size	NN	o	OPH
>	NNP	o	OPH
0.17	CD	o	OPH
)	)	o	OPH
had	VBD	O	O
higher	JJR	o	O
,	,	O	O
although	IN	O	O
not	RB	o	OPH
satisfactory	JJ	o	OPH
,	,	o	O
positive	JJ	o	OOt
predictive	JJ	o	OOt
values	NNS	o	OOt
of	IN	O	O
0.35	CD	O	O
and	CC	O	O
0.46	CD	O	O
at	IN	O	O
cut-offs	NNS	O	O
of	IN	O	O
12	CD	O	O
and	CC	O	O
7	CD	O	O
,	,	O	O
respectively	RB	O	O
,	,	O	O
than	IN	O	O
the	DT	O	O
AQ-J	NNP	i	IOt
.	.	i	IOt

The	DT	O	O
AQ-J	JJ	i	IOt
and	CC	O	O
two	CD	O	O
short	JJ	O	O
forms	NNS	O	O
are	VBP	O	O
useful	JJ	O	O
not	RB	O	O
to	TO	O	O
predict	VB	O	O
but	CC	O	O
to	TO	O	O
rule	VB	O	O
out	RP	O	O
mild	NN	o	OPH
HPDD	NNP	o	OPH
,	,	O	O
the	DT	O	O
most	RBS	O	O
difficult	JJ	O	O
part	NN	O	O
of	IN	O	O
HPDD	NNP	O	O
to	TO	O	O
be	VB	O	O
distinguished	VBN	O	O
from	IN	O	O
non-PDD	JJ	O	O
conditions	NNS	O	O
,	,	O	O
in	IN	O	O
persons	NNS	O	O
scoring	VBG	O	O
under	IN	O	O
the	DT	O	O
cut-offs	NNS	O	O
and	CC	O	O
to	TO	O	O
consider	VB	O	O
professionals	NNS	O	O
'	POS	O	O
examination	NN	O	O
of	IN	O	O
HPDD	NNP	O	O
in	IN	O	O
persons	NNS	O	O
scoring	VBG	O	O
over	IN	O	O
them	PRP	O	O
,	,	O	O
because	IN	O	O
their	PRP$	O	O
negative	JJ	O	O
predictive	JJ	O	O
values	NNS	O	O
were	VBD	O	O
satisfactory	JJ	O	O
.	.	O	O

The	DT	O	O
effects	NNS	O	O
of	IN	O	O
a	DT	O	O
24-h	JJ	O	O
psychological	JJ	i	IE
training	NN	i	IE
program	NN	i	IE
on	IN	O	O
attitudes	NNS	o	OME
,	,	o	OME
communication	NN	o	OME
skills	NNS	o	OME
and	CC	o	OME
occupational	JJ	o	OME
stress	NN	o	OME
in	IN	O	O
oncology	NN	O	O
:	:	O	O
a	DT	O	O
randomised	JJ	O	O
study	NN	O	O
.	.	O	O

The	DT	O	O
usefulness	NN	O	O
of	IN	O	O
psychological	JJ	i	IE
training	NN	i	IE
programs	NNS	i	IE
(	(	i	IE
P.T.P	NNP	i	IE
.	.	i	IE

)	)	i	IE
in	IN	O	O
health	NN	O	O
care	NN	O	O
settings	NNS	O	O
devoted	VBN	O	O
to	TO	O	O
cancer	NN	O	O
care	NN	O	O
is	VBZ	O	O
beginning	VBG	O	O
to	TO	O	O
be	VB	O	O
recognised	VBN	O	O
but	CC	O	O
their	PRP$	O	O
content	NN	O	O
,	,	O	O
form	NN	O	O
and	CC	O	O
effectiveness	VB	O	O
need	NN	O	O
further	JJ	O	O
investigation	NN	O	O
.	.	O	O

Seventy-two	JJ	p	PSS
oncology	NN	p	PC
nurses	NNS	p	PC
were	VBD	O	O
randomly	RB	O	O
assigned	VBN	O	O
to	TO	O	O
a	DT	O	O
24-h	JJ	i	IE
P.T.P	NNP	i	IE
.	.	i	IE

or	CC	i	IC
to	TO	i	IC
a	DT	i	IC
waiting	VBG	i	IC
list	NN	i	IC
period	NN	i	IC
.	.	i	O

Attitudes	NNS	o	OME
were	VBD	O	O
assessed	VBN	i	IE
by	IN	i	IE
a	DT	i	IE
semantic	JJ	o	OME
differential	NN	o	OME
questionnaire	NN	o	OME
,	,	o	O
occupational	JJ	o	OME
stress	NN	o	OME
was	VBD	i	IE
assessed	VBN	i	IE
by	IN	i	IE
the	DT	o	OME
Nursing	NNP	o	OME
Stress	NNP	o	OME
Scale	NNP	o	OME
and	CC	i	IE
communication	NN	o	OME
skills	NNS	o	OME
were	VBD	i	IE
assessed	VBN	i	IE
by	IN	i	IE
standardised	JJ	o	OME
videotaped	VBD	o	OME
role-playing	NN	o	OME
exercises	NNS	o	OME
.	.	o	OME

These	DT	O	O
were	VBD	O	O
used	VBN	O	O
to	TO	O	O
compare	VB	O	O
trained	JJ	O	O
(	(	O	O
T.S	NNP	O	O
.	.	O	O

)	)	O	O
and	CC	O	O
control	NN	O	O
subjects	NNS	O	O
(	(	O	O
C.S.	NNP	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
results	NNS	O	O
show	VBP	O	O
a	DT	O	O
significant	JJ	O	O
training	NN	O	O
effect	NN	O	O
on	IN	O	O
attitudes	NNS	o	OME
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.05	CD	O	O
)	)	O	O
,	,	O	O
especially	RB	O	O
on	IN	O	O
those	DT	O	O
related	VBN	O	O
to	TO	O	O
self	VB	o	OME
concept	NN	o	OME
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.004	CD	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
on	IN	O	O
the	DT	O	O
level	NN	o	OME
of	IN	o	OME
occupational	JJ	o	OME
stress	NN	o	OME
related	VBN	O	O
to	TO	O	O
inadequate	VB	O	O
preparation	NN	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.02	CD	O	O
)	)	O	O
.	.	O	O

Limited	VBN	O	O
changes	NNS	O	O
were	VBD	O	O
found	VBN	O	O
regarding	VBG	O	O
post-training	JJ	O	O
communication	NN	O	O
skills	NNS	O	O
.	.	O	O

T.S	NNP	O	O
.	.	O	O

were	VBD	O	O
significantly	RB	O	O
more	RBR	O	O
in	IN	O	O
control	NN	O	O
of	IN	O	O
the	DT	O	O
interview	NN	O	O
than	IN	O	O
C.S	NNP	O	O
.	.	O	O

(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.02	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
results	NNS	O	O
indicate	VBP	O	O
that	IN	O	O
24-h	JJ	O	O
P.T.P	NNP	i	IE
.	.	i	O

assessed	VBN	O	O
here	RB	O	O
are	VBP	O	O
effective	JJ	O	O
.	.	O	O

The	DT	O	O
data	NN	O	O
also	RB	O	O
demonstrate	VBP	O	O
the	DT	O	O
need	NN	O	O
to	TO	O	O
consolidate	VB	O	O
the	DT	O	O
skills	NNS	O	O
acquired	VBN	O	O
by	IN	O	O
regular	JJ	O	O
post-training	JJ	O	O
sessions	NNS	O	O
.	.	O	O

PROCLAIM	NN	O	O
:	:	O	O
pilot	NN	O	O
study	NN	O	O
to	TO	O	O
examine	VB	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
clopidogrel	NN	i	IPM
on	IN	O	O
inflammatory	JJ	O	O
markers	NNS	O	O
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
metabolic	JJ	p	O
syndrome	JJ	p	O
receiving	VBG	p	O
low-dose	JJ	p	O
aspirin	NN	i	IPM
.	.	i	IPM

Metabolic	NNP	O	O
syndrome	NN	O	O
is	VBZ	O	O
associated	VBN	O	O
with	IN	O	O
intravascular	JJ	O	O
inflammation	NN	O	O
,	,	O	O
as	IN	O	O
determined	VBN	O	O
by	IN	O	O
increased	JJ	O	O
levels	NNS	O	O
of	IN	O	O
inflammatory	NN	O	O
biomarkers	NNS	O	O
and	CC	O	O
an	DT	O	O
increased	VBN	O	O
risk	NN	O	O
of	IN	O	O
ischemic	JJ	O	O
atherothrombotic	JJ	O	O
events	NNS	O	O
.	.	O	O

Evidence	NN	O	O
suggests	VBZ	O	O
that	IN	O	O
atherothrombosis	NN	O	O
and	CC	O	O
intravascular	JJ	O	O
inflammation	NN	O	O
share	NN	O	O
predictive	JJ	O	O
biomarkers	NNS	O	O
,	,	O	O
including	VBG	O	O
high-sensitivity	JJ	O	O
C-reactive	JJ	O	O
protein	NN	O	O
,	,	O	O
CD40	NNP	O	O
ligand	NN	O	O
,	,	O	O
P-selectin	NNP	O	O
,	,	O	O
and	CC	O	O
N-terminal	JJ	O	O
pro-brain	JJ	O	O
natriuretic	JJ	O	O
peptide	NN	O	O
.	.	O	O

Patients	NNS	p	O
who	WP	p	O
had	VBD	p	O
metabolic	JJ	p	O
syndrome	NN	p	O
were	VBD	O	O
randomized	VBN	O	O
to	TO	O	O
receive	VB	O	O
clopidogrel	NN	i	IPM
75	CD	i	O
mg/day	JJ	i	O
plus	CC	i	O
aspirin	JJ	i	IPM
81	CD	i	O
mg/day	NN	i	O
(	(	i	O
n	JJ	i	O
=	NNP	i	O
89	CD	i	O
)	)	i	O
or	CC	i	O
placebo	JJ	i	IC
plus	CC	i	O
aspirin	JJ	i	IPM
81	CD	i	O
mg/day	NN	i	O
(	(	i	O
n	JJ	i	O
=	NNP	i	O
92	CD	i	O
)	)	i	O
for	IN	i	O
9	CD	i	O
weeks	NNS	i	O
to	TO	O	O
assess	VB	O	O
the	DT	O	O
efficacy	NN	O	O
of	IN	O	O
each	DT	O	O
treatment	NN	O	O
in	IN	O	O
suppression	NN	O	O
of	IN	O	O
inflammatory	JJ	O	O
markers	NNS	O	O
.	.	O	O

Change	NN	O	O
from	IN	O	O
baseline	NN	O	O
in	IN	O	O
the	DT	O	O
levels	NNS	O	O
of	IN	O	O
high-sensitivity	NN	o	OPH
C-reactive	JJ	o	OPH
protein	NN	o	OPH
,	,	o	O
CD40	NNP	o	OPH
ligand	NN	o	OPH
,	,	o	O
P-selectin	NNP	o	OPH
,	,	o	O
and	CC	o	O
N-terminal	JJ	o	OPH
pro-brain	JJ	o	OPH
natriuretic	JJ	o	OPH
peptide	NN	o	OPH
at	IN	O	O
6	CD	O	O
weeks	NNS	O	O
was	VBD	O	O
assessed	VBN	O	O
to	TO	O	O
evaluate	VB	O	O
each	DT	O	O
treatment	NN	O	O
.	.	O	O

There	EX	O	O
was	VBD	O	O
a	DT	O	O
significant	JJ	O	O
difference	NN	O	O
at	IN	O	O
Week	JJ	O	O
6	CD	O	O
in	IN	O	O
model-adjusted	JJ	o	OPH
CD40-ligand	NNP	o	OPH
levels	NNS	o	OPH
in	IN	O	O
favor	NN	O	O
of	IN	O	O
clopidogrel	NN	i	IPM
plus	CC	i	O
aspirin	JJ	i	IPM
compared	VBN	O	O
with	IN	O	O
placebo	NN	i	IC
plus	CC	i	O
aspirin	NN	i	IPM
in	IN	O	O
both	DT	O	O
the	DT	O	O
intent-to-treat	JJ	O	O
population	NN	O	O
(	(	O	O
difference	NN	O	O
between	IN	O	O
least-squares	NNS	O	O
means	NNS	O	O
=	VBP	O	O
-186.5	NNP	O	O
;	:	O	O
95	CD	O	O
%	NN	O	O
confidence	NN	O	O
interval	NN	O	O
,	,	O	O
-342.3	NN	O	O
to	TO	O	O
-30.8	VB	O	O
;	:	O	O
P	NNP	O	O
=	NNP	O	O
0.02	CD	O	O
)	)	O	O
and	CC	O	O
the	DT	O	O
per-protocol	JJ	O	O
population	NN	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

No	DT	O	O
significant	JJ	O	O
differences	NNS	O	O
were	VBD	O	O
observed	VBN	O	O
between	IN	O	O
the	DT	O	O
treatment	NN	O	O
arms	NNS	O	O
for	IN	O	O
high-sensitivity	JJ	o	OPH
C-reactive	JJ	o	OPH
protein	NN	o	OPH
,	,	o	O
P-selectin	NNP	o	OPH
,	,	o	O
and	CC	o	O
N-terminal	JJ	o	OPH
pro-brain	JJ	o	OPH
natriuretic	JJ	o	OPH
peptide	NN	o	OPH
.	.	o	O

There	EX	O	O
were	VBD	O	O
no	DT	O	O
deaths	NNS	o	OMO
or	CC	o	O
serious	JJ	o	OA
adverse	JJ	o	OA
events	NNS	o	OA
in	IN	O	O
either	DT	O	O
treatment	NN	O	O
arm	NN	O	O
.	.	O	O

Data	NNS	O	O
from	IN	O	O
this	DT	O	O
study	NN	O	O
suggest	VBP	O	O
that	IN	O	O
clopidogrel	NN	i	IPM
can	MD	O	O
decrease	VB	O	O
the	DT	O	O
expression	NN	o	OPH
of	IN	o	OPH
the	DT	o	OPH
CD40-ligand	NNP	o	OPH
biomarker	NN	o	OPH
.	.	o	O

Pharmacokinetics	NNS	O	O
and	CC	O	O
disposition	NN	O	O
of	IN	O	O
carvedilol	NN	i	IPM
in	IN	p	O
humans	NNS	p	O
.	.	p	O

Pharmacokinetics	NNS	o	OOt
of	IN	O	O
carvedilol	NN	i	IPM
(	(	O	O
C	NNP	O	O
)	)	O	O
have	VBP	O	O
been	VBN	O	O
studied	VBN	O	O
in	IN	O	O
healthy	JJ	p	O
volunteers	NNS	p	O
after	IN	p	O
a	DT	p	O
single	JJ	p	O
i.v	NN	p	O
.	.	p	O

and	CC	p	O
oral	JJ	p	O
administration	NN	p	O
,	,	O	O
and	CC	O	O
the	DT	O	O
metabolic	JJ	O	O
disposition	NN	O	O
after	IN	O	O
oral	JJ	O	O
administration	NN	O	O
of	IN	O	O
14C-labeled	JJ	i	IPM
drug	NN	i	IPM
.	.	i	IPM

C	NNP	O	O
demonstrates	VBZ	O	O
dose-linear	JJ	O	O
behavior	NN	O	O
.	.	O	O

The	DT	O	O
absolute	JJ	O	O
bioavailability	NN	O	O
reaches	VBZ	O	O
24	CD	O	O
%	NN	O	O
probably	RB	O	O
due	JJ	O	O
to	TO	O	O
a	DT	O	O
first-pass	JJ	O	O
effect	NN	O	O
.	.	O	O

After	IN	O	O
a	DT	O	O
50	CD	O	O
mg	JJ	O	O
oral	JJ	O	O
dose	NN	O	O
,	,	O	O
maximum	JJ	O	O
concentrations	NNS	O	O
of	IN	O	O
66	CD	O	O
micrograms/l	NNS	O	O
are	VBP	O	O
achieved	VBN	O	O
within	IN	O	O
1.2	CD	O	O
h.	JJ	O	O
C	NNP	O	O
is	VBZ	O	O
extensively	RB	O	O
distributed	VBN	O	O
to	TO	O	O
the	DT	O	O
tissues	NNS	O	O
(	(	O	O
Vz	NNP	O	O
=	VBZ	O	O
132	CD	O	O
l	NN	O	O
)	)	O	O
and	CC	O	O
eliminated	VBN	O	O
primarily	RB	O	O
by	IN	O	O
hepatic	JJ	O	O
metabolism	NN	O	O
(	(	O	O
total	JJ	O	O
clearance	NN	O	O
590	CD	O	O
ml/min	NN	O	O
,	,	O	O
renal	JJ	O	O
clearance	NN	O	O
4	CD	O	O
ml/min	NN	O	O
)	)	O	O
.	.	O	O

Because	IN	O	O
of	IN	O	O
the	DT	O	O
longer	RBR	O	O
half-life	NN	O	O
of	IN	O	O
6.4	CD	O	O
h	NN	O	O
after	IN	O	O
oral	JJ	O	O
administration	NN	O	O
in	IN	O	O
contrast	NN	O	O
to	TO	O	O
2.4	CD	O	O
h	NN	O	O
after	IN	O	O
i.v	NN	O	O
.	.	O	O

administration	NN	O	O
,	,	O	O
C	NNP	O	O
is	VBZ	O	O
assumed	VBN	O	O
to	TO	O	O
be	VB	O	O
absorption	JJ	O	O
dependent	JJ	O	O
since	IN	O	O
no	DT	O	O
sustained-release	JJ	O	O
formulation	NN	O	O
was	VBD	O	O
used	VBN	O	O
.	.	O	O

The	DT	O	O
half-life	NN	o	OPH
of	IN	O	O
radioactivity	NN	O	O
in	IN	O	O
plasma	NN	O	O
is	VBZ	O	O
39	CD	O	O
h	NN	O	O
;	:	O	O
16	CD	O	O
%	NN	O	O
of	IN	O	O
C	NNP	O	O
is	VBZ	O	O
excreted	VBN	O	O
in	IN	O	O
urine	NN	O	O
in	IN	O	O
the	DT	O	O
form	NN	O	O
of	IN	O	O
metabolites	NNS	O	O
and	CC	O	O
only	RB	O	O
0.3	CD	O	O
%	NN	O	O
unchanged	JJ	O	O
.	.	O	O

The	DT	O	O
urinary	JJ	O	O
metabolites	NNS	O	O
consist	VBP	O	O
of	IN	O	O
carvedilol	NN	O	O
glucuronide	NN	O	O
(	(	O	O
5.2	CD	O	O
%	NN	O	O
of	IN	O	O
the	DT	O	O
dose	NN	O	O
)	)	O	O
,	,	O	O
cleavage	JJ	O	O
products	NNS	O	O
of	IN	O	O
the	DT	O	O
beta-blocking	JJ	O	O
side	NN	O	O
chain	NN	O	O
(	(	O	O
2.1	CD	O	O
%	NN	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
ring-hydroxylated	JJ	O	O
forms	NNS	O	O
(	(	O	O
2.9	CD	O	O
%	NN	O	O
)	)	O	O
.	.	O	O

Sixty	NNP	O	O
percent	NN	O	O
of	IN	O	O
the	DT	O	O
dose	NN	O	O
is	VBZ	O	O
recovered	VBN	O	O
in	IN	O	O
the	DT	O	O
feces	NNS	O	O
.	.	O	O

A	DT	O	O
demethylated	JJ	O	O
product	NN	O	O
of	IN	O	O
C	NNP	O	O
exhibits	VBZ	O	O
only	RB	O	O
minor	JJ	O	O
beta-blocking	JJ	o	OPH
activity	NN	o	OPH
.	.	o	O

This	DT	O	O
metabolite	NN	o	OPH
is	VBZ	O	O
detected	VBN	O	O
in	IN	O	O
plasma	NN	O	O
in	IN	O	O
concentrations	NNS	O	O
ten	VBP	O	O
times	NNS	O	O
lower	JJR	O	O
than	IN	O	O
the	DT	O	O
parent	NN	O	O
compound	NN	O	O
.	.	O	O

Baseline	NNP	O	O
factors	NNS	O	O
predicting	VBG	O	O
placebo	NN	i	IC
response	NN	O	O
to	TO	O	O
treatment	NN	O	O
in	IN	O	O
children	NNS	p	O
and	CC	p	O
adolescents	NNS	p	O
with	IN	p	O
autism	NN	p	O
spectrum	NN	p	O
disorders	NNS	p	O
:	:	p	O
a	DT	O	O
multisite	JJ	O	O
randomized	JJ	O	O
clinical	JJ	O	O
trial	NN	O	O
.	.	O	O

IMPORTANCE	VBZ	O	O
The	DT	O	O
finding	NN	O	O
of	IN	O	O
factors	NNS	O	O
that	WDT	O	O
differentially	RB	O	O
predict	VBP	O	O
the	DT	O	O
likelihood	NN	O	O
of	IN	O	O
response	NN	O	O
to	TO	O	O
placebo	VB	O	O
over	IN	O	O
that	DT	O	O
of	IN	O	O
an	DT	O	O
active	JJ	O	O
drug	NN	O	O
could	MD	O	O
have	VB	O	O
a	DT	O	O
significant	JJ	O	O
impact	NN	O	O
on	IN	O	O
study	NN	O	O
design	NN	O	O
in	IN	O	O
this	DT	O	O
population	NN	O	O
.	.	O	O

OBJECTIVE	UH	O	O
To	TO	O	O
identify	VB	O	O
possible	JJ	O	O
nonspecific	NN	O	O
,	,	O	O
baseline	JJ	O	O
predictors	NNS	O	O
of	IN	O	O
response	NN	o	OOt
to	TO	o	OOt
intervention	NN	o	OOt
in	IN	O	O
a	DT	O	O
large	JJ	O	O
randomized	JJ	O	O
clinical	JJ	O	O
trial	NN	O	O
of	IN	O	O
children	NNS	p	O
and	CC	p	O
adolescents	NNS	p	O
with	IN	p	O
autism	NN	p	O
spectrum	NN	p	O
disorders	NNS	p	O
.	.	p	O

DESIGN	NNP	O	O
,	,	O	O
SETTING	NNP	O	O
,	,	O	O
AND	NNP	O	O
PARTICIPANTS	NNP	O	O
Randomized	NNP	O	O
clinical	JJ	O	O
trial	NN	O	O
of	IN	O	O
citalopram	NN	i	IPM
hydrobromide	NN	i	IPM
for	IN	O	O
children	NNS	p	O
and	CC	p	O
adolescents	NNS	p	O
with	IN	p	O
autism	NN	p	O
spectrum	NN	p	O
disorders	NNS	p	O
and	CC	p	O
prominent	JJ	p	O
repetitive	JJ	p	O
behavior	NN	p	O
.	.	p	O

Baseline	NNP	O	O
data	NN	O	O
at	IN	O	O
study	NN	O	O
entry	NN	O	O
were	VBD	O	O
examined	VBN	O	O
with	IN	O	O
respect	NN	O	O
to	TO	O	O
final	JJ	O	O
outcome	NN	O	O
to	TO	O	O
determine	VB	O	O
if	IN	O	O
response	NN	O	O
predictors	NNS	O	O
could	MD	O	O
be	VB	O	O
identified	VBN	O	O
.	.	O	O

A	DT	O	O
total	NN	O	O
of	IN	O	O
149	CD	p	O
children	NNS	p	O
and	CC	p	O
adolescents	NNS	p	O
5	CD	p	O
to	TO	p	O
17	CD	p	O
years	NNS	p	O
of	IN	p	O
age	NN	p	O
(	(	p	O
mean	JJ	p	O
[	NNP	p	O
SD	NNP	p	O
]	NNP	p	O
age	NN	p	O
,	,	p	O
9.4	CD	p	O
[	NN	p	O
3.1	CD	p	O
]	CD	p	O
years	NNS	p	O
)	)	p	O
from	IN	p	O
6	CD	p	O
academic	JJ	p	O
centers	NNS	p	O
were	VBD	O	O
randomly	RB	O	O
assigned	VBN	O	O
to	TO	O	O
citalopram	VB	i	IPM
(	(	O	O
n	JJ	O	O
=	NNP	O	O
73	CD	O	O
)	)	O	O
or	CC	O	O
placebo	NN	i	IC
(	(	O	O
n	JJ	O	O
=	NNP	O	O
76	CD	O	O
)	)	O	O
.	.	O	O

Participants	NNS	p	O
had	VBD	p	O
autistic	JJ	p	O
disorder	NN	p	O
,	,	p	O
Asperger	NNP	p	O
syndrome	NN	p	O
,	,	p	O
or	CC	p	O
pervasive	JJ	p	O
developmental	JJ	p	O
disorder	NN	p	O
,	,	p	O
not	RB	p	O
otherwise	RB	p	O
specified	VBN	p	O
;	:	p	O
had	VBD	p	O
illness	JJ	p	O
severity	NN	p	O
ratings	NNS	p	O
that	WDT	p	O
were	VBD	p	O
moderate	JJ	p	O
or	CC	p	O
more	JJR	p	O
than	IN	p	O
moderate	VB	p	O
on	IN	p	O
the	DT	p	O
Clinical	JJ	p	O
Global	NNP	p	O
Impression-Severity	NNP	p	O
scale	NN	p	O
;	:	p	O
and	CC	p	O
scored	VBD	p	O
moderate	JJ	p	O
or	CC	p	O
more	JJR	p	O
than	IN	p	O
moderate	VB	p	O
on	IN	p	O
compulsive	JJ	p	O
behaviors	NNS	p	O
measured	VBN	p	O
with	IN	p	O
the	DT	p	O
modified	JJ	p	O
Children	NNP	p	O
's	POS	p	O
Yale-Brown	JJ	p	O
Obsessive-Compulsive	JJ	p	O
Scale	NNP	p	O
.	.	p	O

INTERVENTIONS	NNP	O	O
Twelve	NNP	O	O
weeks	NNS	O	O
of	IN	O	O
treatment	NN	O	O
with	IN	O	O
citalopram	NN	i	IPM
(	(	O	O
10	CD	O	O
mg/5	RB	O	O
mL	NN	O	O
)	)	O	O
or	CC	O	O
placebo	NN	i	IC
.	.	i	O

The	DT	O	O
mean	NN	O	O
(	(	O	O
SD	NNP	O	O
)	)	O	O
maximum	VBD	O	O
dose	NN	O	O
of	IN	O	O
citalopram	NN	O	O
was	VBD	O	O
16.5	CD	O	O
(	(	O	O
6.5	CD	O	O
)	)	O	O
mg	NN	O	O
by	IN	O	O
mouth	JJ	O	O
daily	JJ	O	O
(	(	O	O
maximum	JJ	O	O
dose	NN	O	O
,	,	O	O
20	CD	O	O
mg/d	NN	O	O
)	)	O	O
.	.	O	O

MAIN	NNP	O	O
OUTCOMES	NNP	O	O
AND	NNP	O	O
MEASURES	NNP	O	O
A	NNP	O	O
positive	JJ	O	O
response	NN	O	O
was	VBD	O	O
defined	VBN	O	O
as	IN	O	O
having	VBG	O	O
a	DT	O	O
score	NN	O	O
of	IN	O	O
at	IN	O	O
least	JJS	O	O
much	JJ	O	O
improved	VBN	O	O
on	IN	O	O
the	DT	O	O
Clinical	JJ	o	OOt
Global	NNP	o	OOt
Impression-Improvement	NNP	o	OOt
scale	NN	o	OOt
at	IN	O	O
week	NN	O	O
12	CD	O	O
.	.	O	O

Baseline	NNP	O	O
measures	VBZ	O	O
included	VBN	O	O
demographic	JJ	O	O
(	(	O	O
sex	NN	O	O
,	,	O	O
age	NN	O	O
,	,	O	O
weight	NN	O	O
,	,	O	O
and	CC	O	O
pubertal	JJ	O	O
status	NN	O	O
)	)	O	O
,	,	O	O
clinical	JJ	O	O
,	,	O	O
and	CC	O	O
family	NN	O	O
measures	NNS	O	O
.	.	O	O

Clinical	JJ	O	O
variables	NNS	O	O
included	VBD	O	O
baseline	NN	O	O
illness	NN	O	O
severity	NN	O	O
ratings	NNS	O	O
(	(	o	OPH
the	DT	o	OPH
Aberrant	NNP	o	OPH
Behavior	NNP	o	OPH
Checklist	NNP	o	OPH
,	,	o	OPH
the	DT	o	OPH
Child	NNP	o	OPH
and	CC	o	OPH
Adolescent	NNP	o	OPH
Symptom	NNP	o	OPH
Inventory	NNP	o	OPH
,	,	o	OPH
the	DT	o	OPH
Vineland	NNP	o	OPH
Adaptive	NNP	o	OPH
Behavior	NNP	o	OPH
Scales	NNP	o	OPH
,	,	o	OPH
the	DT	o	OPH
Repetitive	JJ	o	OPH
Behavior	NNP	o	OPH
Scale-Revised	JJ	o	OPH
,	,	o	OPH
and	CC	o	OPH
the	DT	o	OPH
Children	NNP	o	OPH
's	POS	o	OPH
Yale-Brown	JJ	o	OPH
Obsessive-Compulsive	JJ	o	OPH
Scale	NNP	o	OPH
)	)	o	OPH
.	.	O	O

Family	JJ	O	O
measures	NNS	O	O
included	VBD	O	O
the	DT	O	O
Caregiver	NNP	o	OOt
Strain	NNP	o	OOt
Questionnaire	NNP	o	OOt
.	.	o	OPH

RESULTS	NNP	O	O
Several	JJ	O	O
baseline	JJ	O	O
predictors	NNS	O	O
of	IN	O	O
response	NN	O	O
were	VBD	O	O
identified	VBN	O	O
,	,	O	O
and	CC	O	O
a	DT	O	O
principal	JJ	O	O
component	NN	O	O
analysis	NN	O	O
yielded	VBD	O	O
3	CD	O	O
composite	JJ	O	O
measures	NNS	O	O
(	(	o	OME
disruptive	JJ	o	OME
behavior	NN	o	OME
,	,	o	OME
autism/mood	NN	o	OME
,	,	o	OME
and	CC	o	OME
caregiver	RB	o	OME
strain	NN	o	OME
)	)	o	OME
that	WDT	O	O
significantly	RB	O	O
predicted	VBD	O	O
response	NN	O	O
at	IN	O	O
week	NN	O	O
12	CD	O	O
.	.	O	O

Specifically	RB	O	O
,	,	O	O
participants	NNS	O	O
in	IN	O	O
the	DT	O	O
placebo	NN	O	O
group	NN	O	O
were	VBD	O	O
significantly	RB	O	O
less	RBR	O	O
likely	JJ	O	O
than	IN	O	O
participants	NNS	O	O
in	IN	O	O
the	DT	O	O
citalopram	NN	O	O
group	NN	O	O
to	TO	O	O
respond	VB	O	O
at	IN	O	O
week	NN	O	O
12	CD	O	O
if	IN	O	O
they	PRP	O	O
entered	VBD	O	O
the	DT	O	O
study	NN	O	O
more	RBR	O	O
symptomatic	JJ	O	O
on	IN	O	O
each	DT	O	O
of	IN	O	O
the	DT	O	O
3	CD	O	O
composite	JJ	O	O
measures	NNS	O	O
,	,	O	O
and	CC	O	O
they	PRP	O	O
were	VBD	O	O
at	IN	O	O
least	JJS	O	O
2	CD	O	O
times	NNS	O	O
less	RBR	O	O
likely	JJ	O	O
to	TO	O	O
be	VB	O	O
responders	NNS	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
AND	CC	O	O
RELEVANCE	NNP	O	O
This	DT	O	O
analysis	NN	O	O
suggests	VBZ	O	O
strategies	NNS	O	O
that	WDT	O	O
may	MD	O	O
be	VB	O	O
useful	JJ	O	O
in	IN	O	O
anticipating	VBG	O	O
and	CC	O	O
potentially	RB	O	O
mitigating	VBG	O	O
the	DT	O	O
nonspecific	JJ	O	O
response	NN	O	O
in	IN	O	O
randomized	JJ	O	O
clinical	JJ	O	O
trials	NNS	O	O
of	IN	O	O
children	NNS	p	O
and	CC	p	O
adolescents	NNS	p	O
with	IN	p	O
autism	NN	p	O
spectrum	NN	p	O
disorders	NNS	p	O
.	.	p	O

TRIAL	NNP	O	O
REGISTRATION	NNP	O	O
clinicaltrials.gov	NN	O	O
Identifier	NNP	O	O
:	:	O	O
NCT00086645	NN	O	O
.	.	O	O

The	DT	O	O
influence	NN	O	O
of	IN	O	O
sequential	JJ	O	O
annual	JJ	O	O
vaccination	NN	i	IPM
and	CC	i	O
of	IN	i	O
DHEA	NNP	i	IPM
administration	NN	i	IPM
on	IN	O	O
the	DT	O	O
efficacy	NN	O	O
of	IN	O	O
the	DT	O	O
immune	JJ	O	O
response	NN	O	O
to	TO	O	O
influenza	VB	p	PC
vaccine	NN	p	PC
in	IN	p	O
the	DT	p	O
elderly	JJ	p	PA
.	.	p	O

The	DT	O	O
present	JJ	O	O
study	NN	O	O
examined	VBD	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
repeated	VBN	O	O
vaccination	NN	i	IPM
and	CC	O	O
of	IN	O	O
dehydroepiandrosterone	NN	i	IPM
(	(	i	IPM
DHEA	NNP	i	IPM
)	)	i	IPM
treatment	NN	O	O
on	IN	O	O
the	DT	O	O
immune	JJ	O	O
response	NN	O	O
to	TO	O	O
influenza	VB	i	IPM
vaccine	NN	i	IPM
in	IN	p	O
elderly	JJ	p	O
subjects	NNS	p	O
.	.	p	O

Seventy-one	CD	p	PSS
elderly	JJ	p	PA
volunteers	NNS	p	O
,	,	p	O
aged	VBN	p	O
61-89	CD	p	PA
years	NNS	p	PA
,	,	O	O
enrolled	VBD	O	O
in	IN	O	O
a	DT	O	O
prospective	JJ	O	O
randomized	VBN	O	O
,	,	O	O
double-blind	JJ	O	O
study	NN	O	O
to	TO	O	O
receive	VB	O	O
either	DT	O	O
DHEA	NNP	i	IPM
(	(	O	O
50	CD	O	O
mg	NN	O	O
qd	NN	O	O
p.o	NN	O	O
.	.	O	O

for	IN	O	O
4	CD	O	O
consecutive	JJ	O	O
days	NNS	O	O
starting	VBG	O	O
2	CD	O	O
days	NNS	O	O
before	IN	O	O
immunization	NN	O	O
)	)	O	O
or	CC	O	O
placebo	NN	i	IC
.	.	i	IC

Antibody	NNP	O	O
response	NN	O	O
against	IN	O	O
the	DT	O	O
three	CD	O	O
strains	NNS	O	O
of	IN	O	O
vaccine	NN	O	O
was	VBD	O	O
measured	VBN	O	O
before	IN	O	O
and	CC	O	O
28	CD	O	O
days	NNS	O	O
after	IN	O	O
vaccination	NN	O	O
,	,	O	O
and	CC	O	O
compared	VBN	O	O
between	IN	O	O
previously	RB	O	O
vaccinated	VBN	O	O
and	CC	O	O
non-vaccinated	JJ	O	O
subjects	NNS	O	O
.	.	O	O

DHEA	NNP	i	IPM
treatment	NN	i	IPM
did	VBD	O	O
not	RB	O	O
enhance	VB	O	O
established	VBN	o	OPH
immunity	NN	o	OPH
.	.	o	OPH

A	DT	O	O
significant	JJ	O	O
decrease	NN	O	O
in	IN	O	O
attainment	NN	O	O
of	IN	O	O
protective	JJ	o	OOt
antibody	NN	o	OOt
titer	NN	o	OOt
(	(	O	O
titer	NN	O	O
of	IN	O	O
1:40	CD	O	O
or	CC	O	O
greater	JJR	O	O
)	)	O	O
against	IN	O	O
A/Texas	NNP	O	O
in	IN	O	O
subjects	NNS	O	O
with	IN	O	O
non-protective	JJ	O	O
baseline	NN	O	O
antibody	NN	O	O
titer	NN	O	O
was	VBD	O	O
recorded	VBN	O	O
following	VBG	O	O
DHEA	NNP	i	IPM
treatment	NN	i	IPM
compared	VBN	O	O
to	TO	O	O
placebo	VB	O	O
(	(	O	O
52	CD	O	O
vs.	FW	O	O
84	CD	O	O
%	NN	O	O
,	,	O	O
P	NNP	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

Post-immunization	NN	o	OOt
titers	NNS	o	OOt
against	IN	O	O
influenza	VBP	O	O
A	DT	O	O
strains	NNS	O	O
were	VBD	O	O
significantly	RB	O	O
higher	JJR	O	O
in	IN	O	O
those	DT	O	O
subjects	NNS	O	O
who	WP	O	O
were	VBD	O	O
never	RB	O	O
immunized	VBN	O	O
before	RB	O	O
.	.	O	O

Additionally	RB	O	O
,	,	O	O
post-vaccination	JJ	o	OOt
protective	JJ	o	OOt
titers	NNS	o	OOt
against	IN	O	O
the	DT	O	O
A/Johannesburg	NNP	O	O
strain	NN	O	O
were	VBD	O	O
more	RBR	O	O
prevalent	JJ	O	O
in	IN	O	O
those	DT	O	O
subjects	NNS	O	O
who	WP	O	O
were	VBD	O	O
never	RB	O	O
vaccinated	VBN	O	O
before	RB	O	O
.	.	O	O

The	DT	O	O
results	NNS	O	O
were	VBD	O	O
not	RB	O	O
the	DT	O	O
same	JJ	O	O
for	IN	O	O
anti-B/Harbin	JJ	O	O
antibodies-repeated	JJ	O	O
vaccination	NN	O	O
caused	VBD	O	O
a	DT	O	O
non-significant	JJ	O	O
increase	NN	O	O
in	IN	O	O
HI	NNP	O	O
titer	NN	O	O
in	IN	O	O
previously	RB	O	O
vaccinated	VBN	O	O
subjects	NNS	O	O
.	.	O	O

[	JJ	o	O
Metastatic	NNP	o	OPH
breast	NN	o	OPH
cancer	NN	o	OPH
:	:	o	O
a	DT	O	O
comparative	JJ	O	O
study	NN	O	O
of	IN	O	O
the	DT	O	O
efficacy	NN	O	O
of	IN	O	O
tamoxifen	NN	i	IPM
and	CC	O	O
the	DT	O	O
sequential	JJ	O	O
administration	NN	O	O
of	IN	O	O
tamoxifen	NN	i	IPM
and	CC	i	O
medroxyprogesterone	NN	i	IPM
acetate	NN	i	IPM
]	NNP	i	O
.	.	i	O

Seventy-nine	JJ	p	PSS
patients	NNS	p	O
with	IN	p	O
an	DT	p	O
histologically	RB	p	PC
proven	RB	p	PC
disseminated	VBN	p	PC
breast	NN	p	PC
cancer	NN	p	PC
,	,	p	O
never	RB	p	PC
treated	VBN	p	PC
before	IN	p	PC
with	IN	p	PC
additive	JJ	p	PC
hormonal	JJ	p	PC
therapy	NN	p	PC
,	,	p	O
entered	VBD	p	O
into	IN	p	O
a	DT	p	O
randomized	JJ	p	O
trial	NN	p	O
between	IN	p	O
june	NN	p	O
1981	CD	p	O
and	CC	p	O
december	VB	p	O
1982	CD	p	O
.	.	p	O

In	IN	O	O
the	DT	O	O
first	JJ	O	O
group	NN	O	O
44	CD	O	O
patients	NNS	O	O
were	VBD	O	O
given	VBN	O	O
continually	RB	O	O
a	DT	O	O
daily	JJ	O	O
dose	NN	O	O
of	IN	O	O
tamoxifen	NN	i	IPM
(	(	i	IPM
TAM	NNP	i	IPM
)	)	i	O
of	IN	O	O
20	CD	O	O
mg/m2	NN	O	O
.	.	O	O

In	IN	O	O
the	DT	O	O
2nd	CD	O	O
group	NN	O	O
35	CD	O	O
patients	NNS	O	O
were	VBD	O	O
given	VBN	O	O
a	DT	O	O
daily	JJ	O	O
dose	NN	O	O
of	IN	O	O
TAM	NNP	i	IPM
of	IN	O	O
20	CD	O	O
mg/m2	NN	O	O
for	IN	O	O
15	CD	O	O
days	NNS	O	O
and	CC	O	O
then	RB	O	O
an	DT	O	O
oral	JJ	O	O
daily	JJ	O	O
dose	NN	O	O
of	IN	O	O
medroxyprogesterone	NN	i	IPM
acetate	NN	i	IPM
of	IN	O	O
350	CD	O	O
mg/m2	NN	O	O
for	IN	O	O
the	DT	O	O
next	JJ	O	O
15	CD	O	O
days	NNS	O	O
.	.	O	O

In	IN	O	O
both	DT	O	O
groups	NNS	O	O
I	PRP	O	O
and	CC	O	O
II	NNP	O	O
,	,	O	O
the	DT	O	O
treatment	NN	O	O
was	VBD	O	O
stopped	VBN	O	O
at	IN	O	O
the	DT	O	O
first	JJ	O	O
manifestation	NN	O	O
of	IN	O	O
progression	NN	O	O
of	IN	O	O
the	DT	O	O
disease	NN	O	O
.	.	O	O

The	DT	O	O
hormonal	JJ	O	O
receptor	NN	O	O
status	NN	O	O
was	VBD	O	O
determined	VBN	O	O
in	IN	O	O
30	CD	O	O
patients	NNS	O	O
of	IN	O	O
the	DT	O	O
group	NN	O	O
I	PRP	O	O
and	CC	O	O
23	CD	O	O
patients	NNS	O	O
of	IN	O	O
the	DT	O	O
group	NN	O	O
II	NNP	O	O
.	.	O	O

An	DT	O	O
objective	JJ	O	O
response	NN	O	O
to	TO	O	O
treatment	NN	O	O
was	VBD	O	O
observed	VBN	O	O
in	IN	O	O
48	CD	O	O
per	IN	O	O
cent	NN	O	O
of	IN	O	O
the	DT	O	O
patients	NNS	O	O
of	IN	O	O
the	DT	O	O
group	NN	O	O
I	PRP	O	O
and	CC	O	O
60	CD	O	O
per	IN	O	O
cent	NN	O	O
of	IN	O	O
the	DT	O	O
group	NN	O	O
II	NNP	O	O
.	.	O	O

This	DT	O	O
difference	NN	O	O
is	VBZ	O	O
not	RB	O	O
significant	JJ	O	O
(	(	O	O
X2	NNP	O	O
=	NNP	O	O
1,05	CD	O	O
)	)	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
the	DT	O	O
mean	JJ	o	OPH
duration	NN	o	OOt
of	IN	o	OOt
therapeutic	JJ	o	OOt
response	NN	o	OOt
is	VBZ	O	O
significantly	RB	O	O
higher	RBR	O	O
in	IN	O	O
the	DT	O	O
group	NN	O	O
II	NNP	O	O
(	(	O	O
p	JJ	O	O
=	NNP	O	O
0,01	CD	O	O
)	)	O	O
.	.	O	O

[	RB	O	O
Comparative	NNP	O	O
study	NN	O	O
between	IN	O	O
5	CD	i	IPM
%	NN	i	IPM
prilocaine	NN	i	IPM
and	CC	O	O
2	CD	i	IPM
%	NN	i	IPM
mepivacaine	NN	i	IPM
by	IN	O	O
the	DT	O	O
subarachnoid	JJ	O	O
route	NN	O	O
in	IN	O	O
transurethral	JJ	p	O
resections	NNS	p	O
]	VBP	p	O
.	.	O	O

OBJECTIVE	NNP	O	O
To	TO	O	O
compare	VB	O	O
the	DT	O	O
duration	NN	o	OOt
of	IN	O	O
spinal	JJ	O	O
block	NN	O	O
with	IN	O	O
5	CD	i	IPM
%	NN	i	IPM
prilocaine	NN	i	IPM
and	CC	i	O
2	CD	i	IPM
%	NN	i	IPM
mepivacaine	NN	i	IPM
in	IN	O	O
short	JJ	p	O
procedures	NNS	p	O
for	IN	p	O
transurethral	JJ	p	O
resection	NN	p	O
and	CC	O	O
to	TO	O	O
assess	VB	o	OA
possible	JJ	o	OA
complications	NNS	o	OA
in	IN	O	O
the	DT	O	O
immediate	JJ	O	O
postoperative	JJ	O	O
period	NN	O	O
.	.	O	O

MATERIAL	NNP	O	O
AND	NNP	O	O
METHODS	NNP	O	O
Fifty-seven	NNP	p	PSS
patients	NNS	p	PC
scheduled	VBN	p	PC
for	IN	p	PC
transurethral	JJ	p	PC
resection	NN	p	PC
of	IN	p	PC
the	DT	p	PC
prostate	NN	p	PC
or	CC	p	PC
a	DT	p	PC
vesical	JJ	p	PC
tumor	NN	p	PC
.	.	p	PC

Patients	NNS	p	O
were	VBD	p	O
ASA	NNP	p	PC
I-III	NNP	p	PC
,	,	p	O
over	IN	p	PA
55	CD	p	PA
years	NNS	p	PA
of	IN	p	PA
age	NN	p	PA
and	CC	O	O
randomly	RB	O	O
assigned	VBN	O	O
to	TO	O	O
two	CD	i	IPM
groups	NNS	i	IPM
to	TO	i	IPM
receive	VB	i	IPM
5	CD	i	IPM
%	NN	i	IPM
prilocaine	NN	i	IPM
(	(	i	IPM
1	CD	i	IPM
mg/kg	NN	i	IPM
,	,	i	IPM
n	JJ	i	IPM
=	NNP	i	IPM
27	CD	i	IPM
)	)	i	IPM
or	CC	i	O
2	CD	i	IPM
%	NN	i	IPM
mepivacaine	NN	i	IPM
(	(	i	IPM
0.8	CD	i	IPM
mg/kg	NN	i	IPM
,	,	i	IPM
n	JJ	i	IPM
=	NNP	i	IPM
30	CD	i	IPM
)	)	i	IPM
.	.	O	O

We	PRP	i	IS
collected	VBD	i	IS
data	NNS	i	IS
on	IN	i	IS
anesthetic	JJ	o	OOt
technique	NN	o	OOt
,	,	o	OPH
levels	NNS	o	OOt
of	IN	o	OOt
extension	NN	o	OOt
of	IN	o	OOt
motor	NN	o	OOt
and	CC	o	OOt
sensory	JJ	o	OOt
blockades	NNS	o	OOt
,	,	o	OPH
duration	NN	o	OOt
of	IN	o	OOt
blockades	NNS	o	OOt
and	CC	o	OPH
complications	NNS	o	OPH
within	IN	o	OPH
the	DT	o	OPH
first	JJ	o	OPH
24	CD	o	OPH
hours	NNS	o	OPH
after	IN	i	IS
surgery	NN	i	IS
.	.	i	O

RESULTS	NNP	O	O
Demographic	NNP	O	O
data	NNS	O	O
,	,	O	O
ASA	NNP	O	O
classification	NN	O	O
and	CC	O	O
duration	NN	O	O
of	IN	O	O
surgery	NN	O	O
were	VBD	O	O
similar	JJ	O	O
in	IN	O	O
both	DT	O	O
groups	NNS	O	O
.	.	O	O

We	PRP	O	O
found	VBD	O	O
statistically	RB	O	O
significant	JJ	O	O
differences	NNS	O	O
(	(	O	O
p	JJ	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
in	IN	O	O
duration	NN	o	OOt
of	IN	o	OOt
sensory	JJ	o	OOt
blockade	NN	o	OOt
(	(	O	O
120.92	CD	O	O
+/-	JJ	O	O
36.21	CD	O	O
min	NN	O	O
with	IN	O	O
prilocaine	NN	i	IPM
and	CC	O	O
145.83	CD	O	O
+/-	JJ	O	O
35.81	CD	O	O
min	NN	O	O
with	IN	O	O
mepivacaine	NN	i	IPM
)	)	i	O
and	CC	O	O
in	IN	O	O
motor	NN	o	OOt
blockade	NN	o	OOt
(	(	O	O
106.29	CD	O	O
+/-	JJ	O	O
38.16	CD	O	O
min	NN	O	O
with	IN	O	O
prilocaine	NN	O	O
and	CC	O	O
133.16	CD	O	O
+/-	JJ	O	O
42.21	CD	O	O
min	NN	O	O
with	IN	O	O
mepivacaine	NN	O	O
)	)	O	O
.	.	O	O

Five	JJ	O	O
cases	NNS	O	O
of	IN	O	O
hypotension	NN	o	OA
and	CC	O	O
4	CD	O	O
of	IN	O	O
bradycardia	NN	o	OA
occurred	VBN	O	O
in	IN	O	O
each	DT	O	O
group	NN	O	O
and	CC	O	O
one	CD	O	O
patient	NN	O	O
in	IN	O	O
the	DT	O	O
mepivacaine	NN	O	O
group	NN	O	O
suffered	VBD	O	O
slight	JJ	O	O
postoperative	JJ	O	O
cephalea	NN	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
Both	NNP	O	O
local	JJ	O	O
anesthetics	NNS	O	O
offer	VBP	O	O
good	JJ	O	O
surgical	JJ	o	OOt
conditions	NNS	o	OOt
with	IN	O	O
hemodynamic	JJ	O	O
stability	NN	O	O
and	CC	O	O
few	JJ	O	O
complications	NNS	o	OA
.	.	o	O

The	DT	O	O
duration	NN	O	O
of	IN	O	O
sensory	NN	o	OOt
and	CC	o	OPH
motor	NN	o	OOt
blockade	NN	o	OOt
is	VBZ	O	O
shorter	JJR	O	O
with	IN	O	O
prilocaine	NN	O	O
than	IN	O	O
with	IN	O	O
mepivacaine	NN	O	O
,	,	O	O
making	VBG	O	O
prilocaine	NN	O	O
more	JJR	O	O
appropriate	JJ	O	O
for	IN	O	O
short	JJ	O	O
interventions	NNS	O	O
.	.	O	O

Granulocyte-macrophage	JJ	i	IPM
colony-stimulating	JJ	i	IPM
factor	NN	i	IPM
as	IN	O	O
immunomodulating	VBG	O	O
factor	NN	O	O
together	RB	O	O
with	IN	O	O
influenza	JJ	i	IPM
vaccination	NN	i	IPM
in	IN	O	O
stem	NN	p	PC
cell	NN	p	PC
transplant	NN	p	PC
patients	NNS	p	O
.	.	p	O

The	DT	O	O
effect	NN	O	O
of	IN	O	O
granulocyte-macrophage	JJ	i	IPH
colony-stimulating	JJ	i	IPH
factor	NN	i	IPH
(	(	i	IPH
GM-CSF	NNP	i	IPH
)	)	i	IPH
on	IN	O	O
the	DT	O	O
serological	JJ	o	OPH
response	NN	o	OPH
at	IN	O	O
influenza	JJ	i	IPM
vaccination	NN	i	IPM
was	VBD	O	O
studied	VBN	O	O
in	IN	O	O
117	CD	p	PSS
patients	NNS	p	O
who	WP	p	O
had	VBD	p	O
undergone	JJ	p	PC
stem	NN	p	PC
cell	NN	p	PC
transplantation	NN	p	PC
(	(	p	O
SCT	NNP	p	PC
)	)	p	O
.	.	p	O

The	DT	O	O
vaccine	NN	o	OPH
response	NN	o	OPH
was	VBD	O	O
evaluated	VBN	O	O
as	IN	O	O
significant	JJ	O	O
increases	NNS	O	O
in	IN	O	O
levels	NNS	o	OPH
of	IN	o	OPH
influenza	JJ	o	OPH
hemagglutination-inhibition	NN	o	OPH
(	(	o	OPH
HAI	NNP	o	OPH
)	)	o	OPH
antibodies	NNS	o	OPH
and	CC	O	O
of	IN	O	O
IgG	NNP	o	OPH
antibodies	NNS	o	OPH
measured	VBN	O	O
by	IN	O	O
enzyme-linked	JJ	O	O
immunosorbent	NN	O	O
assay	NN	O	O
(	(	O	O
ELISA	NNP	O	O
)	)	O	O
.	.	O	O

There	EX	O	O
was	VBD	O	O
no	DT	O	O
difference	NN	O	O
in	IN	O	O
antibody	NN	o	OPH
response	NN	o	OPH
to	TO	O	O
either	DT	O	O
influenza	VB	O	O
A	NNP	O	O
or	CC	O	O
B	NNP	O	O
in	IN	O	O
64	CD	O	O
patients	NNS	O	O
who	WP	O	O
received	VBD	O	O
GM-CSF	NNP	i	IPH
at	IN	O	O
vaccination	NN	O	O
,	,	O	O
compared	VBN	O	O
with	IN	O	O
the	DT	O	O
53	NNS	O	O
who	WP	O	O
did	VBD	O	O
not	RB	O	O
.	.	O	O

In	IN	O	O
the	DT	O	O
subgroup	NN	p	O
of	IN	p	O
allogeneic	JJ	p	PC
SCT	NNP	p	PC
patients	NNS	p	PC
,	,	O	O
HAI	NNP	O	O
showed	VBD	O	O
that	IN	O	O
the	DT	O	O
response	NN	o	O
rate	NN	o	O
to	TO	O	O
the	DT	O	O
influenza	NN	o	OOt
B	NNP	o	OOt
vaccine	NN	o	OOt
was	VBD	O	O
significantly	RB	O	O
higher	JJR	O	O
in	IN	O	O
the	DT	O	O
treatment	NN	O	O
group	NN	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
.05	NNP	O	O
)	)	O	O
.	.	O	O

ELISA	NN	o	OPH
showed	VBD	O	O
that	IN	O	O
autologous	JJ	p	PC
SCT	NNP	p	PC
patients	NNS	p	PC
with	IN	p	PC
breast	JJ	p	PC
cancer	NN	p	PC
who	WP	O	O
received	VBD	O	O
GM-CSF	NNP	O	O
had	VBD	O	O
a	DT	O	O
better	JJR	O	O
response	NN	o	O
to	TO	O	O
influenza	VB	o	OPH
A	NNP	o	OPH
(	(	O	O
P	NNP	O	O
<	NNP	O	O
.05	NNP	O	O
)	)	O	O
and	CC	O	O
B	NNP	o	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
.01	NNP	O	O
)	)	O	O
.	.	O	O

At	IN	O	O
early	JJ	O	O
vaccination	NN	O	O
,	,	O	O
4-12	JJ	O	O
months	NNS	O	O
after	IN	O	O
stem	NN	O	O
cell	NN	O	O
transplantation	NN	O	O
,	,	O	O
these	DT	O	O
responses	NNS	O	O
were	VBD	O	O
more	RBR	O	O
pronounced	JJ	O	O
.	.	O	O

GM-CSF	JJ	i	IPM
appears	VBZ	O	O
to	TO	O	O
improve	VB	O	O
the	DT	O	O
response	NN	o	OPH
to	TO	o	OPH
influenza	VB	o	OOt
vaccination	NN	o	OOt
in	IN	O	O
some	DT	O	O
groups	NNS	O	O
of	IN	O	O
SCT	NNP	p	PC
patients	NNS	p	PC
,	,	O	O
but	CC	O	O
only	RB	O	O
to	TO	O	O
a	DT	O	O
limited	JJ	O	O
extent	NN	O	O
.	.	O	O

Engagement	NN	i	IE
with	IN	i	IE
electronic	JJ	i	IE
screen	JJ	i	IE
media	NNS	i	IE
among	IN	O	O
students	NNS	p	O
with	IN	p	O
autism	NN	p	O
spectrum	NN	p	O
disorders	NNS	p	O
.	.	p	O

This	DT	O	O
study	NN	O	O
investigated	VBD	O	O
the	DT	O	O
relative	JJ	O	O
engagement	JJ	O	O
potential	NN	O	O
of	IN	O	O
four	CD	O	O
types	NNS	O	O
of	IN	O	O
electronic	JJ	i	IE
screen	JJ	i	IE
media	NNS	i	IE
(	(	i	IE
ESM	NNP	i	IE
)	)	i	IE
:	:	i	IE
animated	VBN	i	IE
video	NN	i	IE
,	,	i	IE
video	NN	i	IE
of	IN	i	IE
self	NN	i	IE
,	,	i	IE
video	NN	i	IE
of	IN	i	IE
a	DT	i	IE
familiar	JJ	i	IE
person	NN	i	IE
engaged	VBD	i	IE
with	IN	i	IE
an	DT	i	IE
immersive	JJ	i	IE
virtual	JJ	i	IE
reality	NN	i	IE
(	(	i	IE
VR	NNP	i	IE
)	)	i	IE
game	NN	i	IE
,	,	i	IE
and	CC	i	IE
immersion	NN	i	IE
of	IN	i	IE
self	NN	i	IE
in	IN	i	IE
the	DT	i	IE
VR	NNP	i	IE
game	NN	i	IE
.	.	i	IE

Forty-two	JJ	p	O
students	NNS	p	O
with	IN	p	O
autism	NN	p	O
,	,	p	O
varying	VBG	p	O
in	IN	p	O
age	NN	p	O
and	CC	p	O
expressive	JJ	p	O
communication	NN	p	O
ability	NN	p	O
,	,	p	O
were	VBD	p	O
randomly	RB	p	O
assigned	VBN	p	O
to	TO	p	O
the	DT	p	O
experimental	JJ	p	O
conditions	NNS	p	O
.	.	p	O

Gaze	NNP	o	OME
duration	NN	o	OME
and	CC	o	O
vocalization	NN	o	OME
served	VBD	O	O
as	IN	O	O
dependent	JJ	O	O
measures	NNS	O	O
of	IN	O	O
engagement	NN	O	O
.	.	O	O

The	DT	O	O
results	NNS	O	O
reveal	VBP	O	O
differential	JJ	O	O
responding	NN	O	O
across	IN	O	O
ESM	NNP	o	OPH
,	,	O	O
with	IN	O	O
some	DT	O	O
variation	NN	O	O
related	VBN	O	O
to	TO	O	O
the	DT	O	O
engagement	NN	O	O
metric	JJ	O	O
employed	VBN	O	O
.	.	O	O

Preferences	NNS	O	O
for	IN	O	O
seeing	VBG	o	OME
themselves	PRP	o	OME
on	IN	o	OME
the	DT	o	OME
screen	NN	o	OME
,	,	o	OME
as	RB	o	OME
well	RB	o	OME
as	IN	o	OME
for	IN	o	OME
viewing	VBG	o	OME
the	DT	o	OME
VR	NNP	o	OME
scenarios	NNS	o	OME
,	,	O	O
emerged	VBD	O	O
from	IN	O	O
the	DT	O	O
data	NNS	O	O
.	.	O	O

While	IN	O	O
the	DT	O	O
study	NN	O	O
did	VBD	O	O
not	RB	O	O
yield	VB	O	O
definitive	JJ	O	O
data	NNS	O	O
about	IN	O	O
the	DT	O	O
relative	JJ	O	O
engagement	JJ	O	O
potential	NN	O	O
of	IN	O	O
ESM	NNP	i	IE
alternatives	NNS	O	O
,	,	O	O
it	PRP	O	O
does	VBZ	O	O
provide	VB	O	O
a	DT	O	O
foundation	NN	O	O
for	IN	O	O
future	JJ	O	O
research	NN	O	O
,	,	O	O
including	VBG	O	O
guidance	NN	O	O
related	VBN	O	O
to	TO	O	O
participant	JJ	O	O
profiles	NNS	O	O
,	,	O	O
stimulus	NN	O	O
characteristics	NNS	O	O
,	,	O	O
and	CC	O	O
data	NNS	O	O
coding	NN	O	O
challenges	NNS	O	O
.	.	O	O

Long-stay	JJ	i	IPH
versus	NN	O	O
short-stay	JJ	i	IPH
hospital	NN	i	IPH
treatment	NN	i	IPH
of	IN	O	O
children	NNS	p	PA
suffering	VBG	p	O
from	IN	p	O
severe	JJ	p	PC
protein-energy	JJ	p	PC
malnutrition	NN	p	PC
.	.	p	O

OBJECTIVE	UH	O	O
To	TO	O	O
contrast	VB	O	O
early	JJ	i	IOt
discharge	NN	i	IOt
versus	NN	O	O
attempted	VBD	i	IOt
full	JJ	i	IOt
nutritional	JJ	i	IOt
rehabilitation	NN	i	IOt
in	IN	O	O
hospital	NN	p	O
of	IN	p	O
children	NNS	p	O
suffering	VBG	p	O
from	IN	p	O
severe	JJ	p	O
protein-energy	JJ	p	O
malnutrition	NN	p	O
(	(	p	O
PEM	NNP	p	PC
)	)	p	O
.	.	p	O

DESIGN	NNP	O	O
Field	NNP	O	O
experiment	NN	O	O
,	,	O	O
two-way	JJ	O	O
analysis	NN	O	O
of	IN	O	O
variance	NN	O	O
with	IN	O	O
one	CD	O	O
between	IN	O	O
group	NN	p	O
(	(	i	O
short-	JJ	i	IOt
versus	IN	i	O
long-stay	NN	i	IOt
)	)	i	O
and	CC	p	O
one	CD	p	O
repeated	VBN	p	O
measures	NNS	p	O
factor	NN	p	O
(	(	p	O
admission	NN	p	O
,	,	p	O
then	RB	p	O
12	CD	p	O
,	,	p	O
18	CD	p	O
,	,	p	O
24	CD	p	O
,	,	p	O
30	CD	p	O
and	CC	p	O
36	CD	p	O
months	NNS	p	O
post-admission	NN	p	O
)	)	p	O
.	.	O	O

Covariates	NNPS	O	O
introduced	VBD	O	O
.	.	O	O

SETTING	NNP	p	O
Primary	NNP	p	O
health	NN	p	O
care	NN	p	O
,	,	p	O
Kingston	NNP	p	O
,	,	p	O
Jamaica	NNP	p	O
.	.	p	O

SUBJECTS	NNP	p	O
n	JJ	p	O
=	NNP	p	O
81	CD	p	PSS
;	:	p	O
mean	JJ	p	O
age	NN	p	O
11	CD	p	PA
months	NNS	p	PA
;	:	p	O
79	CD	p	O
contribute	VBP	p	O
longitudinal	JJ	p	O
data	NNS	p	O
;	:	p	O
44	CD	p	O
every	DT	p	O
measurement	NN	p	O
.	.	p	O

INTERVENTIONS	NNP	O	O
When	WRB	O	O
concurrent	NN	O	O
illnesses	NNS	O	O
had	VBD	O	O
been	VBN	O	O
treated	VBN	O	O
and	CC	O	O
normal	JJ	O	O
feeding	VBG	O	O
re-established	JJ	O	O
(	(	O	O
weight	JJ	O	O
gain	NN	O	O
5	CD	O	O
g/kg.day-1	NN	O	O
)	)	O	O
,	,	O	O
subjects	NNS	O	O
were	VBD	O	O
randomly	RB	O	O
allocated	VBN	O	O
to	TO	O	O
short-stay	NN	i	IPH
(	(	i	IPH
SS	NNP	i	IPH
)	)	i	IPH
or	CC	i	O
long-stay	JJ	i	IPH
(	(	i	IPH
LS	NNP	i	IPH
)	)	i	IPH
group	NN	i	O
.	.	i	O

LS	NNP	i	IPH
retained	VBD	i	O
in	IN	i	O
hospital	NN	i	O
for	IN	i	O
full	JJ	i	O
nutritional	JJ	i	O
rehabilitation	NN	i	O
mean	VB	O	O
40	CD	O	O
days	NNS	O	O
)	)	O	O
.	.	O	O

SS	NNP	i	IPH
discharged	VBD	i	O
immediately	RB	i	O
(	(	O	O
mean	JJ	O	O
18	CD	O	O
days	NNS	O	O
)	)	O	O
for	IN	i	O
standard	JJ	i	O
Health	NNP	i	O
Service	NNP	i	O
care	NN	i	O
at	IN	i	O
home	NN	i	O
for	IN	O	O
6	CD	O	O
months	NNS	O	O
plus	CC	i	O
high-energy	JJ	i	O
supplement	NN	i	O
(	(	O	O
3.31	CD	O	O
MJ	NNP	O	O
with	IN	O	O
20.6	CD	O	O
g	NNS	O	O
protein	JJ	O	O
daily	JJ	O	O
)	)	O	O
for	IN	O	O
first	JJ	O	O
3	CD	O	O
months	NNS	O	O
.	.	O	O

After	IN	O	O
discharge	NN	O	O
LS	NNP	i	IPH
received	VBD	O	O
6	CD	O	O
months	NNS	O	O
home	NN	O	O
care	NN	O	O
,	,	O	O
but	CC	O	O
without	IN	O	O
supplementation	NN	O	O
.	.	O	O

RESULTS	NNP	O	O
Significant	NNP	O	O
advantages	VBZ	O	O
for	IN	O	O
LS	NNP	O	O
group	NN	O	O
on	IN	O	O
NCHS	NNP	o	OPH
weight	NN	o	OPH
&	CC	o	OPH
length	NN	o	OPH
for	IN	o	OPH
age	NN	o	OPH
at	IN	o	OPH
discharge	NN	o	OPH
,	,	O	O
and	CC	O	O
at	IN	O	O
12	CD	O	O
,	,	O	O
18	CD	O	O
,	,	O	O
24	CD	O	O
and	CC	O	O
for	IN	O	O
length	NN	O	O
also	RB	O	O
30	CD	O	O
months	NNS	O	O
(	(	O	O
P	NNP	O	O
<	VBZ	O	O
0.05	CD	O	O
to	TO	O	O
P	NNP	O	O
<	NNP	O	O
0.001	CD	O	O
)	)	O	O
.	.	O	O

Weight	NNP	o	OPH
advantage	NN	o	OPH
peaked	VBD	O	O
at	IN	O	O
12	CD	O	O
and	CC	O	O
18	CD	O	O
months	NNS	O	O
,	,	O	O
length	NN	O	O
later	RB	O	O
at	IN	O	O
18	CD	O	O
and	CC	O	O
24	CD	O	O
months	NNS	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
Contrary	NNP	O	O
to	TO	O	O
earlier	VB	O	O
reports	NNS	O	O
,	,	O	O
full	JJ	O	O
nutritional	JJ	O	O
rehabilitation	NN	O	O
can	MD	O	O
be	VB	O	O
achieved	VBN	O	O
in	IN	O	O
hospital	NN	O	O
for	IN	O	O
children	NNS	O	O
suffering	VBG	O	O
from	IN	O	O
PEM	NNP	O	O
.	.	O	O

Although	IN	O	O
in	IN	O	O
the	DT	O	O
long-term	JJ	O	O
both	DT	O	O
groups	NNS	O	O
move	VBP	O	O
towards	NNS	O	O
expected	VBN	O	O
levels	NNS	O	O
in	IN	O	O
their	PRP$	O	O
home	NN	O	O
community	NN	O	O
,	,	O	O
a	DT	O	O
significant	JJ	O	O
advantage	NN	O	O
maintained	VBD	O	O
for	IN	O	O
approximately	RB	O	O
2	CD	O	O
years	NNS	O	O
is	VBZ	O	O
developmentally	RB	O	O
advantageous	JJ	O	O
during	IN	O	O
the	DT	O	O
critical	JJ	O	O
time	NN	O	O
after	IN	O	O
weaning	VBG	O	O
.	.	O	O

Prevention	NN	O	O
of	IN	O	O
postoperative	JJ	O	O
hypocalcemia	NN	O	O
with	IN	O	O
routine	JJ	O	O
oral	JJ	O	O
calcium	NN	i	IPM
and	CC	O	O
vitamin	NN	i	IPM
D	NNP	i	IPM
supplements	NNS	i	IPM
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
differentiated	JJ	p	O
papillary	JJ	p	O
thyroid	NN	p	O
carcinoma	NN	p	O
undergoing	JJ	p	O
total	JJ	p	O
thyroidectomy	NN	p	O
plus	CC	p	O
central	JJ	p	O
neck	NN	p	O
dissection	NN	p	O
.	.	p	O

BACKGROUND	NNP	O	O
Routine	NNP	O	O
oral	JJ	i	IPM
calcium	NN	i	IPM
and	CC	i	O
vitamin	NN	i	IPM
D	NNP	i	IPM
supplementation	NN	i	IPM
may	MD	O	O
prevent	VB	O	O
hypocalcemic	JJ	O	O
crisis	NN	O	O
,	,	O	O
but	CC	O	O
its	PRP$	O	O
efficacy	NN	O	O
has	VBZ	O	O
not	RB	O	O
been	VBN	O	O
studied	VBN	O	O
in	IN	O	O
patients	NNS	p	O
undergoing	VBG	p	O
thyroidectomy	JJ	p	O
plus	JJ	p	O
central	JJ	p	O
neck	NN	p	O
dissection	NN	p	O
(	(	p	O
CND	NNP	p	O
)	)	p	O
.	.	p	O

The	DT	O	O
authors	NNS	O	O
therefore	VBP	O	O
prospectively	RB	O	O
evaluated	VBN	O	O
the	DT	O	O
clinical	JJ	O	O
usefulness	NN	O	O
of	IN	O	O
routine	JJ	O	O
oral	JJ	O	O
calcium	NN	O	O
and	CC	O	O
vitamin	NN	O	O
D	NNP	O	O
supplementation	NN	O	O
for	IN	O	O
prevention	NN	O	O
of	IN	O	O
hypocalcemia	NN	O	O
after	IN	O	O
total	JJ	O	O
thyroidectomy	NN	O	O
and	CC	O	O
CND	NNP	O	O
.	.	O	O

METHODS	NNP	O	O
Of	IN	O	O
197	CD	p	O
patients	NNS	p	O
with	IN	p	O
differentiated	JJ	p	O
papillary	JJ	p	O
thyroid	NN	p	O
carcinoma	NN	p	O
,	,	O	O
49	CD	O	O
underwent	JJ	O	O
total	JJ	O	O
thyroidectomy	NN	O	O
alone	RB	O	O
,	,	O	O
and	CC	O	O
148	CD	O	O
underwent	JJ	O	O
total	JJ	i	IPM
thyroidectomy	NN	i	IPM
plus	CC	i	IPM
CND	NNP	i	IPM
.	.	i	O

The	DT	O	O
latter	JJ	O	O
were	VBD	O	O
randomized	VBN	O	O
to	TO	O	O
oral	JJ	i	IPM
calcium	NN	i	IPM
(	(	O	O
3	CD	O	O
g/day	NN	O	O
)	)	O	O
plus	CC	O	O
vitamin	JJ	i	IPM
D	NNP	i	IPM
(	(	O	O
1	CD	O	O
mg/day	NN	O	O
)	)	O	O
(	(	O	O
Group	NNP	O	O
A	NNP	O	O
,	,	O	O
n=49	NN	O	O
)	)	O	O
,	,	O	O
calcium	NN	i	IPM
alone	RB	i	IPM
(	(	O	O
Group	NNP	O	O
B	NNP	O	O
,	,	O	O
n=49	NN	O	O
)	)	O	O
,	,	O	O
or	CC	O	O
no	DT	i	IPM
supplements	NNS	i	IPM
(	(	O	O
Group	NNP	O	O
C	NNP	O	O
,	,	O	O
n=50	RB	O	O
)	)	O	O
.	.	O	O

Hypocalcemic	NNP	o	OPH
symptoms	NNS	o	OPH
,	,	o	OPH
serum	JJ	o	OPH
calcium	NN	o	OPH
,	,	o	OPH
and	CC	o	OPH
parathyroid	VB	o	OPH
hormone	NN	o	OPH
(	(	o	OPH
PTH	NNP	o	OPH
)	)	o	OPH
levels	NNS	o	OPH
were	VBD	O	O
compared	VBN	O	O
among	IN	O	O
the	DT	O	O
groups	NNS	O	O
.	.	O	O

RESULTS	NNP	O	O
Group	NNP	O	O
C	NNP	O	O
had	VBD	O	O
significantly	RB	O	O
higher	JJR	O	O
incidences	NNS	O	O
of	IN	O	O
symptomatic	JJ	O	O
(	(	O	O
26.0	CD	O	O
%	NN	O	O
vs	JJ	O	O
6.1	CD	O	O
%	NN	O	O
;	:	O	O
P	NNP	O	O
<	NNP	O	O
.015	NNP	O	O
)	)	O	O
and	CC	O	O
laboratory	NN	O	O
(	(	O	O
44.0	CD	O	O
%	NN	O	O
vs	JJ	O	O
14.3	CD	O	O
%	NN	O	O
;	:	O	O
P	NNP	O	O
<	NNP	O	O
.015	NNP	O	O
)	)	O	O
hypocalcemia	NN	o	OPH
than	IN	O	O
the	DT	O	O
group	NN	O	O
without	IN	O	O
CND	NNP	O	O
.	.	O	O

The	DT	O	O
incidences	NNS	O	O
of	IN	O	O
symptomatic	JJ	o	OPH
and	CC	o	OPH
laboratory	JJ	o	OPH
hypocalcemia	NN	o	OPH
were	VBD	O	O
significantly	RB	O	O
decreased	VBN	O	O
in	IN	O	O
Groups	NNP	O	O
A	NNP	O	O
(	(	O	O
2.0	CD	O	O
%	NN	O	O
and	CC	O	O
8.2	CD	O	O
%	NN	O	O
,	,	O	O
respectively	RB	O	O
)	)	O	O
and	CC	O	O
B	NNP	O	O
(	(	O	O
12.2	CD	O	O
%	NN	O	O
and	CC	O	O
24.5	CD	O	O
%	NN	O	O
,	,	O	O
respectively	RB	O	O
)	)	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
.05	NNP	O	O
)	)	O	O
.	.	O	O

Serum	NNP	o	OPH
calcium	NN	o	OPH
levels	NNS	o	OPH
decreased	VBN	O	O
in	IN	O	O
most	JJS	O	O
patients	NNS	O	O
after	IN	O	O
surgery	NN	O	O
,	,	O	O
but	CC	O	O
recovered	VBD	O	O
earliest	JJS	O	O
in	IN	O	O
Group	NNP	O	O
A.	NNP	O	O
Hypercalcemia	NNP	O	O
and	CC	O	O
PTH	NNP	O	O
inhibition	NN	O	O
did	VBD	O	O
not	RB	O	O
occur	VB	O	O
in	IN	O	O
gs	NN	O	O
A	NNP	O	O
and	CC	O	O
B	NNP	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
Compared	NNP	O	O
with	IN	O	O
total	JJ	O	O
thyroidectomy	NN	O	O
alone	RB	O	O
,	,	O	O
CND	NNP	O	O
significantly	RB	O	O
increases	VBZ	O	O
the	DT	O	O
rate	NN	O	O
of	IN	O	O
postoperative	JJ	o	OPH
hypocalcemia	NN	o	OPH
,	,	O	O
which	WDT	O	O
can	MD	O	O
be	VB	O	O
prevented	VBN	O	O
by	IN	O	O
routine	JJ	O	O
postoperative	JJ	O	O
supplementation	NN	O	O
with	IN	O	O
oral	JJ	O	O
calcium	NN	O	O
and	CC	O	O
vitamin	NN	O	O
D	NNP	O	O
.	.	O	O

Comparison	NNP	O	O
of	IN	O	O
remifentanil	NN	i	IPM
with	IN	O	O
fentanyl	NN	i	IPM
for	IN	O	O
deep	JJ	o	OPH
sedation	NN	o	OPH
in	IN	O	O
oral	JJ	O	O
surgery	NN	O	O
.	.	O	O

PURPOSE	VB	O	O
The	DT	O	O
aim	NN	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
compare	VB	O	O
recovery	NN	O	O
for	IN	O	O
oral	JJ	p	PC
surgery	NN	p	PC
patients	NNS	p	PC
given	VBN	O	O
a	DT	O	O
deep	JJ	O	O
sedation	NN	O	O
regimen	NNS	O	O
of	IN	O	O
midazolam	NN	i	IPM
,	,	i	IPM
propofol	NN	i	IPM
,	,	O	O
and	CC	O	O
remifentanil	NN	i	IPM
with	IN	O	O
a	DT	O	O
standard	JJ	O	O
control	NN	O	O
of	IN	O	O
fentanyl	NN	O	O
in	IN	O	O
place	NN	O	O
of	IN	O	O
remifentanil	NN	O	O
.	.	O	O

MATERIALS	NNP	O	O
AND	CC	O	O
METHODS	NNP	O	O
This	DT	O	O
investigation	NN	O	O
was	VBD	O	O
designed	VBN	O	O
as	IN	O	O
a	DT	O	O
randomized	NN	O	O
,	,	O	O
prospective	JJ	O	O
,	,	O	O
single-blinded	JJ	O	O
controlled	VBD	O	O
study	NN	O	O
.	.	O	O

Group	NNP	O	O
1	CD	O	O
,	,	O	O
the	DT	O	O
control	NN	O	O
,	,	O	O
received	VBD	O	O
midazolam	JJ	i	IPM
0.03	CD	i	IPM
mg/kg	NN	i	IPM
,	,	i	IPM
fentanyl	VBP	i	IPM
1	CD	i	IPM
microg/kg	NN	i	IPM
,	,	i	IPM
and	CC	i	IPM
propofol	VB	i	IPM
initially	RB	i	IPM
at	IN	i	IPM
140	CD	i	IPM
microg/kg/min	NN	i	IPM
.	.	i	IPM

Group	NNP	O	O
2	CD	O	O
received	VBD	O	O
midazolam	RB	i	IPM
0.03	CD	i	IPM
mg/kg	NN	i	IPM
,	,	i	IPM
remifentanil	NN	i	IPM
:	:	i	IPM
propofol	NN	i	IPM
(	(	i	IPM
1:500	CD	i	IPM
)	)	i	IPM
given	VBN	i	IPM
at	IN	i	IPM
an	DT	i	IPM
initial	JJ	i	IPM
propofol	JJ	i	IPM
infusion	NN	i	IPM
rate	NN	i	IPM
of	IN	i	IPM
40	CD	i	IPM
microg/kg/min	NN	i	IPM
.	.	i	IPM

Outcome	NNP	O	O
measures	NNS	O	O
included	VBD	O	O
time	NN	o	OOt
to	TO	o	OOt
response	NN	o	OOt
to	TO	o	OOt
verbal	JJ	o	OOt
command	NN	o	OOt
,	,	o	O
Aldrete	NNP	o	OPH
score	VBD	o	OPH
=	JJ	o	OPH
9	CD	o	OPH
,	,	o	O
Postanesthesia	NNP	o	OOt
Discharge	NNP	o	OOt
Scoring	NNP	o	OOt
System	NNP	o	OOt
=	VBD	o	OPH
7	CD	o	OPH
,	,	o	O
and	CC	o	O
assessment	NN	o	OPH
by	IN	o	OPH
the	DT	o	OPH
Digit	NNP	o	OPH
Symbol	NNP	o	OPH
Substitution	NNP	o	OPH
Test	NNP	o	OPH
.	.	o	O

RESULTS	NNP	O	O
Forty-seven	JJ	p	O
subjects	NNS	p	O
were	VBD	p	O
entered	VBN	p	O
in	IN	p	O
the	DT	p	O
study	NN	p	O
.	.	p	O

Baseline	NNP	O	O
findings	NNS	O	O
were	VBD	O	O
homogenous	JJ	O	O
between	IN	O	O
the	DT	O	O
2	CD	O	O
groups	NNS	O	O
.	.	O	O

Subjects	NNS	O	O
in	IN	O	O
group	NN	O	O
2	CD	O	O
recovered	VBN	O	O
earlier	JJR	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
.005	NNP	O	O
)	)	O	O
and	CC	O	O
required	VBN	O	O
less	JJR	O	O
propofol	NN	i	IPM
for	IN	O	O
both	DT	O	O
the	DT	O	O
induction	NN	o	OPH
(	(	O	O
0.8	CD	O	O
+/-	JJ	O	O
0.4	CD	O	O
versus	NN	O	O
1.2	CD	O	O
+/-	JJ	O	O
0.6	CD	O	O
mg/kg	NN	O	O
;	:	O	O
mean	JJ	O	O
+/-	JJ	O	O
SD	NNP	O	O
,	,	O	O
P	NNP	O	O
<	NNP	O	O
.01	NNP	O	O
)	)	O	O
and	CC	O	O
maintenance	NN	o	OOt
of	IN	o	OOt
deep	JJ	o	OOt
sedation	NN	o	OOt
(	(	O	O
46	CD	O	O
+/-	JJ	O	O
9	CD	O	O
versus	NN	O	O
131	CD	O	O
+/-	JJ	O	O
17	CD	O	O
microg/kg/min	NN	O	O
;	:	O	O
P	NNP	O	O
<	NNP	O	O
.005	NNP	O	O
)	)	O	O
.	.	O	O

There	EX	O	O
were	VBD	O	O
minor	JJ	O	O
differences	NNS	O	O
in	IN	O	O
vital	JJ	O	O
signs	NNS	O	O
.	.	O	O

CONCLUSIONS	VB	O	O
This	DT	O	O
study	NN	O	O
demonstrated	VBD	O	O
that	IN	O	O
this	DT	O	O
remifentanil	JJ	O	O
regimen	NNS	O	O
provided	VBD	O	O
significantly	RB	O	O
more	RBR	O	O
rapid	JJ	o	OOt
recovery	NN	o	OOt
and	CC	O	O
used	VBD	O	O
significantly	RB	O	O
less	JJR	O	O
propofol	JJ	i	IPM
compared	VBN	O	O
with	IN	O	O
the	DT	O	O
fentanyl	JJ	i	IPM
regimen	NNS	O	O
.	.	O	O

[	JJ	O	O
Treatment	NNP	O	O
of	IN	O	O
autism	NN	p	PC
children	NNS	p	PC
:	:	p	PC
observation	NN	O	O
on	IN	O	O
efficacy	NN	o	O
of	IN	O	O
behavior	JJ	o	O
training	NN	o	O
with	IN	O	O
retention	NN	i	IPH
of	IN	i	IPH
needles	NNS	i	IPH
on	IN	i	IPH
head	NN	i	IPH
]	NN	i	IPH
.	.	O	O

OBJECTIVE	UH	O	O
To	TO	O	O
observe	VB	O	O
the	DT	O	O
effect	NN	O	O
difference	NN	O	O
of	IN	O	O
behavior	JJ	i	IE
training	NN	i	IE
with	IN	i	IE
head	NN	i	IE
needling	VBG	i	IE
retention	NN	i	IE
and	CC	i	IE
behavior	NN	i	IE
training	NN	i	IE
after	IN	i	IE
acupuncture	NN	i	IE
for	IN	O	O
autism	NN	p	O
children	NNS	p	O
.	.	p	O

METHODS	NNP	O	O
Sixty	NNP	p	O
qualified	VBD	p	O
autism	NN	p	O
children	NNS	p	O
were	VBD	O	O
divided	VBN	O	O
randomly	RB	O	O
into	IN	O	O
simultaneous	JJ	O	O
head	NN	i	IE
needling	VBG	i	IE
retention	NN	i	IE
and	CC	i	IE
behavior	JJ	i	IE
training	NN	i	IE
group	NN	i	IE
(	(	O	O
trial	NN	O	O
group	NN	O	O
)	)	O	O
and	CC	O	O
behavior	JJ	i	IE
training	NN	i	IE
after	IN	i	IE
acupuncture	NN	i	IE
treatment	NN	i	IE
group	NN	i	IE
(	(	O	O
control	VB	O	O
group	NN	O	O
)	)	O	O
with	IN	O	O
30	CD	O	O
case	NN	O	O
in	IN	O	O
each	DT	O	O
group	NN	O	O
.	.	O	O

Retention	NNP	i	IPH
needles	NNS	i	IPH
on	IN	O	O
the	DT	O	O
head	NN	O	O
with	IN	O	O
simultaneous	JJ	O	O
behavior	NN	O	O
training	NN	O	O
was	VBD	O	O
applied	VBN	O	O
for	IN	O	O
the	DT	O	O
trial	NN	O	O
group	NN	O	O
.	.	O	O

The	DT	O	O
main	JJ	O	O
acupoints	NNS	O	O
included	VBD	O	O
Sishen	NNP	O	O
Xue	NNP	O	O
,	,	O	O
Dingshen	NNP	O	O
Sanxue	NNP	O	O
(	(	O	O
3	CD	O	O
points	NNS	O	O
for	IN	O	O
mental	JJ	O	O
tranquilization	NN	O	O
)	)	O	O
,	,	O	O
Nao	NNP	O	O
Sanxue	NNP	O	O
(	(	O	O
3	CD	O	O
points	NNS	O	O
for	IN	O	O
the	DT	O	O
function	NN	O	O
of	IN	O	O
brain	NN	O	O
)	)	O	O
,	,	O	O
Shou	NNP	O	O
Zhisanxue	NNP	O	O
(	(	O	O
3	CD	O	O
points	NNS	O	O
for	IN	O	O
mental	JJ	O	O
activities	NNS	O	O
on	IN	O	O
hand	NN	O	O
)	)	O	O
and	CC	O	O
Zozhi	NNP	O	O
Sonxue	NNP	O	O
(	(	O	O
3	CD	O	O
points	NNS	O	O
for	IN	O	O
mental	JJ	O	O
activities	NNS	O	O
on	IN	O	O
foot	NN	O	O
)	)	O	O
.	.	O	O

Other	JJ	O	O
points	NNS	O	O
were	VBD	O	O
combined	VBN	O	O
according	VBG	O	O
to	TO	O	O
conditions	NNS	O	O
of	IN	O	O
patients	NNS	O	O
.	.	O	O

Needles	NNS	O	O
on	IN	O	O
the	DT	O	O
4	CD	O	O
extremities	NNS	O	O
were	VBD	O	O
withdrawn	VBN	O	O
first	RB	O	O
after	IN	O	O
30	CD	O	O
minutes	NNS	O	O
,	,	O	O
needles	NNS	O	O
on	IN	O	O
head	NN	O	O
were	VBD	O	O
remained	VBN	O	O
during	IN	O	O
behavior	JJ	i	IE
training	NN	i	IE
.	.	i	IE

While	IN	O	O
behavior	JJ	i	IE
training	NN	i	IE
was	VBD	O	O
applied	VBN	O	O
to	TO	O	O
the	DT	O	O
control	NN	O	O
group	NN	O	O
when	WRB	O	O
acupuncture	NN	O	O
treatment	NN	O	O
was	VBD	O	O
completely	RB	O	O
accomplished	VBN	O	O
.	.	O	O

Treatments	NNS	O	O
were	VBD	O	O
applied	VBN	O	O
once	RB	O	O
a	DT	O	O
day	NN	O	O
to	TO	O	O
both	DT	O	O
groups	NNS	O	O
.	.	O	O

And	CC	O	O
3	CD	O	O
months	NNS	O	O
was	VBD	O	O
taken	VBN	O	O
as	IN	O	O
one	CD	O	O
observation	NN	O	O
cycle	NN	O	O
.	.	O	O

Estimation	NN	O	O
was	VBD	O	O
made	VBN	O	O
on	IN	O	O
therapeutic	JJ	o	OME
effect	NN	o	OME
and	CC	O	O
developing	VBG	o	OME
level	NN	o	OME
of	IN	o	OME
autism	NN	o	OME
children	NNS	o	OME
with	IN	o	OME
CARS	NNP	o	OME
and	CC	o	OME
PEP	NNP	o	OME
.	.	o	O

RESULTS	VB	O	O
The	DT	O	O
total	JJ	o	OOt
effective	JJ	o	OOt
rate	NN	o	OOt
of	IN	O	O
the	DT	O	O
trial	NN	O	O
group	NN	O	O
was	VBD	O	O
83.3	CD	O	O
%	NN	O	O
(	(	O	O
25/30	CD	O	O
)	)	O	O
,	,	O	O
better	JJR	O	O
than	IN	O	O
66.7	CD	O	O
%	NN	O	O
(	(	O	O
20/30	CD	O	O
)	)	O	O
of	IN	O	O
the	DT	O	O
control	NN	O	O
group	NN	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
CARS	NNPS	o	OME
scores	NNS	o	OME
of	IN	O	O
both	DT	O	O
groups	NNS	O	O
declined	VBD	O	O
after	IN	O	O
the	DT	O	O
treatment	NN	O	O
.	.	O	O

And	CC	O	O
the	DT	O	O
score	NN	O	O
of	IN	O	O
trail	NN	O	O
group	NN	O	O
was	VBD	O	O
lower	JJR	O	O
than	IN	O	O
the	DT	O	O
control	NN	O	O
group	NN	O	O
(	(	O	O
all	DT	O	O
P	NNP	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

While	IN	O	O
the	DT	O	O
PEP	NNP	o	OME
scores	NNS	o	OME
of	IN	O	O
both	DT	O	O
groups	NNS	O	O
increased	VBD	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
score	NN	O	O
of	IN	O	O
trail	NN	O	O
group	NN	O	O
was	VBD	O	O
higher	JJR	O	O
than	IN	O	O
the	DT	O	O
control	NN	O	O
group	NN	O	O
(	(	O	O
all	DT	O	O
P	NNP	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
increasing	VBG	O	O
level	NN	O	O
of	IN	O	O
scores	NNS	o	OME
of	IN	o	OME
cognitive	JJ	o	OME
understanding	NN	o	OME
and	CC	o	OME
cognitive	JJ	o	OME
expression	NN	o	OME
were	VBD	O	O
all	DT	O	O
better	JJR	O	O
than	IN	O	O
the	DT	O	O
control	NN	O	O
group	NN	O	O
(	(	O	O
all	DT	O	O
P	NNP	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

CONCLUSION	VB	O	O
The	DT	O	O
effect	NN	O	O
of	IN	O	O
behavior	JJ	i	IE
training	NN	i	IE
with	IN	O	O
head	NN	O	O
needle	JJ	O	O
retention	NN	O	O
on	IN	O	O
autism	NN	p	O
children	NNS	p	O
is	VBZ	O	O
better	JJR	O	O
than	IN	O	O
behavior	JJ	i	O
training	NN	i	O
after	IN	i	O
acupuncture	NN	i	O
treatment	NN	O	O
,	,	O	O
especially	RB	O	O
in	IN	O	O
enhancing	VBG	o	OME
cognition	NN	o	OME
understanding	NN	o	OME
and	CC	o	OME
cognition	NN	o	OME
expression	NN	o	OME
.	.	o	OME

Noradrenergic	NNP	O	O
moderation	NN	o	OOt
of	IN	O	O
working	VBG	O	O
memory	NN	O	O
impairments	NNS	O	O
in	IN	O	O
adults	NNS	p	PA
with	IN	p	O
autism	NN	p	PC
spectrum	NN	p	PC
disorder	NN	p	PC
.	.	p	O

In	IN	O	O
addition	NN	O	O
to	TO	O	O
having	VBG	O	O
difficulties	NNS	O	O
with	IN	O	O
social	JJ	O	O
communications	NNS	O	O
,	,	O	O
individuals	NNS	p	O
with	IN	p	O
an	DT	p	O
autism	NN	p	PC
spectrum	NN	p	PC
disorder	NN	p	PC
(	(	p	PC
ASD	NNP	p	PC
)	)	p	PC
often	RB	O	O
also	RB	O	O
experience	JJ	O	O
impairment	NN	o	OME
in	IN	o	OME
higher-order	NN	o	OME
,	,	o	OME
executive	NN	o	OME
skills	NNS	o	OME
.	.	o	O

The	DT	O	O
present	JJ	O	O
study	NN	O	O
examined	VBD	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
pharmacological	JJ	O	O
modulation	NN	O	O
of	IN	O	O
the	DT	O	O
norepinephrine	NN	O	O
system	NN	O	O
on	IN	O	O
the	DT	O	O
severity	NN	O	O
of	IN	O	O
such	JJ	O	O
impairments	NNS	O	O
.	.	O	O

A	DT	O	O
sample	NN	O	O
of	IN	O	O
14	CD	p	PSS
high-functioning	JJ	p	O
adults	NNS	p	PA
with	IN	p	O
ASD	NNP	p	PC
and	CC	p	O
a	DT	p	O
demographically-matched	JJ	p	O
comparison	NN	p	O
group	NN	p	O
of	IN	p	O
13	CD	p	PSS
typically	RB	p	O
developing	VBG	p	O
individuals	NNS	p	O
participated	VBN	p	O
.	.	p	O

An	DT	O	O
AX	NNP	o	OME
continuous	JJ	o	OME
performance	NN	o	OME
test	NN	o	OME
(	(	o	OME
AX-CPT	NNP	o	OME
)	)	o	OME
was	VBD	O	O
used	VBN	O	O
to	TO	O	O
evaluate	VB	O	O
working	VBG	O	O
memory	NN	O	O
and	CC	O	O
inhibitory	NN	O	O
control	NN	O	O
.	.	O	O

AX-CPT	JJ	o	OME
performance	NN	o	OME
was	VBD	O	O
assessed	VBN	O	O
following	VBG	O	O
administration	NN	O	O
of	IN	O	O
a	DT	O	O
single	JJ	O	O
dose	NN	O	O
of	IN	O	O
propranolol	NN	i	IPM
(	(	i	IPM
a	DT	i	IPM
beta	NN	i	IPM
adrenergic	JJ	i	IPM
antagonist	NN	i	IPM
)	)	i	IPM
and	CC	i	O
following	VBG	i	O
placebo	NN	i	IC
(	(	O	O
sugar	NN	O	O
pill	NN	O	O
)	)	O	O
administration	NN	O	O
.	.	O	O

Individuals	NNS	p	O
with	IN	p	O
ASD	NNP	p	PC
performed	VBD	o	OME
more	RBR	O	O
poorly	RB	O	O
than	IN	O	O
non-ASD	JJ	O	O
individuals	NNS	O	O
in	IN	O	O
the	DT	O	O
working	JJ	O	O
memory	NN	O	O
condition	NN	O	O
(	(	O	O
BX	NNP	O	O
trials	NNS	O	O
)	)	O	O
.	.	O	O

Importantly	RB	O	O
,	,	O	O
administration	NN	O	O
of	IN	O	O
propranolol	NN	i	IPM
attenuated	VBN	o	OME
this	DT	o	OME
impairment	NN	o	OME
,	,	O	O
with	IN	O	O
the	DT	O	O
ASD	NNP	O	O
group	NN	O	O
performing	VBG	o	OME
significantly	RB	O	O
better	RBR	O	O
in	IN	O	O
the	DT	O	O
propranolol	NN	O	O
condition	NN	O	O
than	IN	O	O
the	DT	O	O
placebo	JJ	O	O
condition	NN	O	O
.	.	O	O

Working	VBG	o	OME
memory	NN	o	OME
performance	NN	o	OME
of	IN	O	O
the	DT	O	O
non-ASD	JJ	O	O
group	NN	O	O
was	VBD	O	O
unaffected	VBN	O	O
by	IN	O	O
propranolol/placebo	JJ	O	O
administration	NN	O	O
.	.	O	O

No	DT	O	O
group	NN	O	O
or	CC	O	O
medication	NN	O	O
effects	NNS	o	OOt
were	VBD	O	O
observed	VBN	O	O
for	IN	O	O
the	DT	O	O
inhibition	NN	o	OME
condition	NN	o	OME
(	(	O	O
AY	NNP	O	O
trials	NNS	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
present	JJ	O	O
findings	NNS	O	O
suggest	VBP	O	O
that	IN	O	O
norepinephrine	NN	O	O
may	MD	O	O
play	VB	O	O
a	DT	O	O
role	NN	O	O
in	IN	O	O
some	DT	O	O
,	,	O	O
but	CC	O	O
not	RB	O	O
necessarily	RB	O	O
all	RB	O	O
,	,	O	O
cognitive	JJ	o	OME
impairments	NNS	o	OME
associated	VBN	O	O
with	IN	O	O
ASD	NNP	O	O
.	.	O	O

Additional	NNP	O	O
research	NN	O	O
is	VBZ	O	O
needed	VBN	O	O
to	TO	O	O
fully	RB	O	O
understand	VB	O	O
whether	IN	O	O
this	DT	O	O
role	NN	O	O
is	VBZ	O	O
primarily	RB	O	O
causal	JJ	O	O
or	CC	O	O
compensatory	NN	O	O
in	IN	O	O
nature	NN	O	O
.	.	O	O

Skin	NNP	o	OPH
manifestations	NNS	o	OPH
of	IN	o	OPH
inhaled	JJ	o	OPH
corticosteroids	NNS	o	OPH
in	IN	O	O
COPD	NNP	p	PC
patients	NNS	p	PC
:	:	p	PC
results	NNS	O	O
from	IN	O	O
Lung	NNP	O	O
Health	NNP	O	O
Study	NNP	O	O
II	NNP	O	O
.	.	O	O

OBJECTIVE	NNP	O	O
To	TO	O	O
define	VB	O	O
the	DT	O	O
relationship	NN	O	O
between	IN	O	O
skin	NN	o	OA
bruising	NN	o	OA
(	(	o	OPH
as	RB	o	OPH
well	RB	o	OPH
as	IN	o	OPH
other	JJ	o	OPH
cutaneous	JJ	o	OA
manifestations	NNS	o	OA
)	)	o	OPH
and	CC	O	O
inhaled	VBN	O	O
corticosteroid	NN	i	IPM
(	(	i	IPM
ICS	NNP	i	IPM
)	)	i	IPM
therapy	NN	O	O
vs	NN	O	O
placebo	NN	O	O
in	IN	O	O
subjects	NNS	p	O
with	IN	p	O
COPD	NNP	p	O
who	WP	O	O
were	VBD	O	O
participating	VBG	O	O
in	IN	O	O
a	DT	O	O
clinical	JJ	O	O
trial	NN	O	O
.	.	O	O

To	TO	O	O
explore	VB	O	O
the	DT	O	O
relationship	NN	O	O
between	IN	O	O
easy	JJ	o	OPH
skin	NN	o	OPH
bruising	NN	o	OPH
and	CC	o	O
other	JJ	o	O
systemic	JJ	o	OPH
effects	NNS	o	OPH
of	IN	o	OPH
ICS	NNP	o	OPH
therapy	NN	o	OPH
,	,	O	O
including	VBG	O	O
adrenal	JJ	o	OA
suppression	NN	o	OA
and	CC	o	OPH
loss	NN	o	OA
of	IN	o	OA
bone	JJ	o	OA
mineral	JJ	o	OA
density	NN	o	OA
(	(	o	OA
BMD	NNP	o	OA
)	)	o	OPH
.	.	o	O

DESIGN	NNP	O	O
Double-blind	NNP	O	O
,	,	O	O
randomized	VBN	O	O
,	,	O	O
placebo-controlled	JJ	O	O
clinical	JJ	O	O
trial	NN	O	O
of	IN	O	O
triamcinolone	NN	i	IPM
acetonide	NN	i	IPM
(	(	O	O
1200	CD	O	O
microg	FW	O	O
daily	RB	O	O
)	)	O	O
vs	NN	O	O
placebo	NN	i	IC
in	IN	O	O
participants	NNS	p	O
with	IN	p	O
mild-to-moderate	JJ	p	O
COPD	NNP	p	O
.	.	p	O

SETTING	NNP	O	O
Lung	NNP	O	O
Health	NNP	O	O
Study	NNP	O	O
II	NNP	O	O
,	,	O	O
a	DT	O	O
clinical	JJ	O	O
trial	NN	O	O
to	TO	O	O
assess	VB	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
ICS	NNP	i	IPM
compared	VBN	O	O
to	TO	O	O
placebo	VB	i	O
in	IN	O	O
1,116	CD	p	O
participants	NNS	p	O
in	IN	p	O
10	CD	p	O
centers	NNS	p	O
over	IN	p	O
>	$	p	O
3.5	CD	p	O
to	TO	p	O
4.5	CD	p	O
years	NNS	p	O
.	.	p	O

PARTICIPANTS	VB	O	O
A	DT	p	O
total	NN	p	O
of	IN	p	O
1,116	CD	p	O
smokers	NNS	p	O
or	CC	p	O
recent	JJ	p	O
ex-smokers	NNS	p	O
with	IN	p	O
mild-to-moderate	JJ	p	O
COPD	NNP	p	O
(	(	p	O
age	NN	p	O
range	NN	p	O
,	,	p	O
40	CD	p	O
to	TO	p	O
69	CD	p	O
years	NNS	p	O
;	:	p	O
mean	JJ	p	O
age	NN	p	O
,	,	p	O
56.3	CD	p	O
years	NNS	p	O
;	:	p	O
37.2	CD	p	O
%	NN	p	O
female	NN	p	O
)	)	p	O
.	.	p	O

MEASUREMENTS	NNP	O	O
AND	CC	O	O
RESULTS	NNP	O	O
Every	NNP	O	O
6	CD	O	O
months	NNS	O	O
,	,	O	O
a	DT	O	O
structured	JJ	O	O
questionnaire	NN	O	O
was	VBD	O	O
administered	VBN	O	O
to	TO	O	O
elicit	VB	O	O
reports	NNS	O	O
of	IN	O	O
any	DT	O	O
bruising	NN	o	OA
and/or	NN	o	OA
skin	NN	o	OA
rashes	NNS	o	OA
,	,	o	OA
slow	JJ	o	OA
healing	NN	o	OA
of	IN	o	OA
cuts	NNS	o	OA
or	CC	o	OA
sores	NNS	o	OA
,	,	o	OPH
or	CC	o	OPH
other	JJ	o	OPH
skin	JJ	o	OA
changes	NNS	o	OA
.	.	o	OPH

Compliance	NN	O	O
with	IN	O	O
inhaler	NN	O	O
use	NN	O	O
was	VBD	O	O
assessed	VBN	O	O
by	IN	O	O
canister	NN	O	O
weighing	VBG	O	O
.	.	O	O

A	DT	O	O
significantly	RB	O	O
higher	JJR	O	O
proportion	NN	O	O
of	IN	O	O
ICS	NNP	i	IPM
than	IN	O	O
placebo	NN	i	O
participants	NNS	O	O
who	WP	O	O
complied	VBD	O	O
with	IN	O	O
using	VBG	O	O
their	PRP$	O	O
inhaler	NN	O	O
reported	VBD	O	O
easy	JJ	o	OA
bruising	NN	o	OA
(	(	O	O
11.2	CD	O	O
%	NN	O	O
vs	JJ	O	O
3.5	CD	O	O
%	NN	O	O
,	,	O	O
respectively	RB	O	O
)	)	O	O
and	CC	O	O
the	DT	O	O
slow	JJ	o	OA
healing	NN	o	OA
of	IN	o	OA
skin	NN	o	OA
cuts	NNS	o	OA
or	CC	o	OA
sores	NNS	o	OA
(	(	O	O
2.4	CD	O	O
%	NN	O	O
vs	JJ	O	O
0.5	CD	O	O
%	NN	O	O
,	,	O	O
respectively	RB	O	O
)	)	O	O
.	.	O	O

Older	JJR	p	O
men	NNS	p	O
in	IN	O	O
the	DT	O	O
ICS	NNP	i	IPM
group	NN	O	O
with	IN	O	O
good	JJ	O	O
inhaler	NN	O	O
compliance	NN	O	O
appeared	VBD	O	O
to	TO	O	O
be	VB	O	O
at	IN	O	O
the	DT	O	O
greatest	JJS	O	O
risk	NN	o	OA
of	IN	o	OA
bruising	VBG	o	OA
.	.	o	OPH

In	IN	O	O
those	DT	O	O
participants	NNS	O	O
undergoing	VBG	O	O
serial	JJ	O	O
measurements	NNS	O	O
of	IN	O	O
adrenal	JJ	O	O
function	NN	O	O
and	CC	O	O
BMD	NNP	O	O
,	,	O	O
no	DT	O	O
association	NN	O	O
was	VBD	O	O
noted	VBN	O	O
between	IN	O	O
skin	JJ	o	OA
bruising	NN	o	OA
and	CC	O	O
either	CC	O	O
the	DT	O	O
suppression	NN	o	OA
of	IN	o	OA
adrenal	JJ	o	OA
function	NN	o	OA
or	CC	o	O
the	DT	o	O
loss	NN	o	OA
of	IN	o	OA
BMD	NNP	o	OA
as	IN	O	O
systemic	JJ	O	O
complications	NNS	O	O
of	IN	O	O
ICS	NNP	O	O
use	NN	O	O
.	.	O	O

CONCLUSION	NNP	O	O
These	DT	O	O
findings	NNS	O	O
indicate	VBP	O	O
that	IN	O	O
moderate-to-high	JJ	O	O
doses	NNS	O	O
of	IN	O	O
ICSs	NNP	O	O
result	NN	O	O
in	IN	O	O
an	DT	O	O
increased	JJ	O	O
incidence	NN	O	O
of	IN	O	O
easy	JJ	o	OA
bruising	NN	o	OA
and	CC	o	O
impairment	NN	o	OA
in	IN	o	OA
skin	NN	o	OA
healing	NN	o	OA
in	IN	O	O
middle-aged	JJ	p	O
to	TO	p	O
elderly	JJ	p	O
persons	NNS	p	O
with	IN	p	O
COPD	NNP	p	O
.	.	p	O

No	DT	O	O
association	NN	O	O
was	VBD	O	O
noted	VBN	O	O
between	IN	O	O
skin	JJ	o	OA
bruising	NN	o	OA
and	CC	O	O
other	JJ	O	O
markers	NNS	O	O
of	IN	O	O
systemic	JJ	o	OA
toxicity	NN	o	OA
from	IN	O	O
the	DT	O	O
use	NN	O	O
of	IN	O	O
ICSs	NNP	i	O
.	.	O	O

Plasmakinetic	JJ	i	IS
prostate	NN	i	IS
resection	NN	i	IS
in	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
benign	JJ	O	O
prostate	JJ	O	O
hyperplasia	NN	O	O
:	:	O	O
results	NNS	O	O
of	IN	O	O
1-year	JJ	O	O
follow	VBP	O	O
up	RP	O	O
.	.	O	O

AIM	NNP	O	O
In	IN	O	O
our	PRP$	O	O
randomized	JJ	O	O
prospective	JJ	O	O
study	NN	O	O
,	,	O	O
we	PRP	O	O
aimed	VBD	O	O
to	TO	O	O
evaluate	VB	O	O
the	DT	O	O
efficiency	NN	O	O
of	IN	O	O
plasmakinetic	JJ	i	IS
resection	NN	i	IS
of	IN	i	IS
prostate	NN	i	IS
(	(	i	IS
PKRP	NNP	i	IS
)	)	i	IS
by	IN	O	O
comparing	VBG	O	O
the	DT	O	O
preoperative	NN	O	O
and	CC	O	O
postoperative	JJ	O	O
results	NNS	O	O
of	IN	O	O
the	DT	O	O
transurethral	JJ	i	IS
resection	NN	i	IS
of	IN	i	IS
prostate	NN	i	IS
(	(	O	O
TURP	NNP	O	O
)	)	O	O
and	CC	O	O
PKRP	NNP	O	O
techniques	NNS	O	O
which	WDT	O	O
we	PRP	O	O
administered	VBD	O	O
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
benign	JJ	p	O
prostate	NN	p	O
hyperplasia	NN	p	O
(	(	p	O
BPH	NNP	p	O
)	)	p	O
in	IN	p	O
our	PRP$	p	O
clinic	NN	p	O
.	.	p	O

METHODS	NNP	O	O
Of	IN	O	O
57	CD	p	O
patients	NNS	p	O
for	IN	p	O
whom	WP	p	O
we	PRP	p	O
thought	VBD	p	O
an	DT	p	O
operative	JJ	p	O
intervention	NN	p	O
was	VBD	p	O
necessary	JJ	p	O
,	,	O	O
30	CD	O	O
cases	NNS	O	O
in	IN	O	O
the	DT	O	O
first	JJ	O	O
group	NN	O	O
had	VBD	O	O
a	DT	O	O
TURP	NNP	i	IS
and	CC	O	O
24	CD	O	O
cases	NNS	O	O
in	IN	O	O
the	DT	O	O
second	JJ	O	O
group	NN	O	O
had	VBD	O	O
a	DT	O	O
PKRP	NNP	i	IS
.	.	i	O

International	NNP	o	OPH
prostate	JJ	o	OPH
symptom	NN	o	OPH
scores	NNS	o	OPH
(	(	o	OPH
I-PSS	NNP	o	OPH
)	)	o	OPH
,	,	o	O
uroflowmetry	UH	o	OPH
,	,	o	O
measurement	NN	o	OOt
of	IN	o	OOt
residual	JJ	o	OPH
urine	JJ	o	OPH
amount	NN	o	OPH
and	CC	o	OOt
ultrasonography	NN	o	OOt
were	VBD	O	O
performed	VBN	O	O
for	IN	O	O
each	DT	O	O
patient	NN	O	O
both	DT	O	O
preoperatively	RB	O	O
and	CC	O	O
postoperatively	RB	O	O
(	(	O	O
first	JJ	O	O
month	NN	O	O
and	CC	O	O
first	JJ	O	O
year	NN	O	O
)	)	O	O
.	.	O	O

Operation	NNP	o	OOt
times	NNS	o	OOt
,	,	o	O
urethral	JJ	o	OOt
catheterization	NN	o	OOt
times	NNS	o	OOt
,	,	o	O
preoperative	JJ	o	OPH
and	CC	o	OPH
postoperative	JJ	o	OPH
Hb	NNP	o	OPH
,	,	o	OOt
Htc	NNP	o	OPH
and	CC	o	OPH
serum	VB	o	OPH
Na	NNP	o	OPH
values	NNS	o	OPH
of	IN	O	O
the	DT	O	O
patients	NNS	O	O
were	VBD	O	O
compared	VBN	O	O
and	CC	O	O
the	DT	O	O
complications	NNS	O	O
of	IN	O	O
the	DT	O	O
groups	NNS	O	O
were	VBD	O	O
also	RB	O	O
compared	VBN	O	O
.	.	O	O

RESULTS	VB	O	O
On	IN	O	O
first	JJ	O	O
month	NN	O	O
and	CC	O	O
first	JJ	O	O
year	NN	O	O
follow	VBP	O	O
up	RP	O	O
between	IN	O	O
the	DT	O	O
groups	NNS	O	O
,	,	O	O
there	EX	O	O
was	VBD	O	O
no	DT	O	O
significant	JJ	O	O
statistical	JJ	o	O
difference	NN	o	O
in	IN	O	O
I-PSS	NNP	o	OPH
,	,	o	O
maximum	JJ	o	OPH
flow	NN	o	OPH
rate	NN	o	OPH
,	,	o	O
average	NN	o	OPH
flow	NN	o	OPH
,	,	o	O
residual	JJ	o	OPH
urine	NN	o	OPH
and	CC	o	OPH
size	NN	o	OPH
of	IN	o	OPH
the	DT	o	OPH
prostate	NN	o	OPH
.	.	o	O

The	DT	O	O
decrease	NN	O	O
in	IN	O	O
serum	NN	o	OPH
Na	NNP	o	OPH
level	NN	o	OPH
was	VBD	O	O
found	VBN	O	O
to	TO	O	O
be	VB	O	O
significantly	RB	O	O
higher	JJR	O	O
in	IN	O	O
the	DT	O	O
TURP	NNP	O	O
group	NN	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
operation	NN	o	OOt
times	NNS	o	OOt
were	VBD	O	O
not	RB	O	O
significantly	RB	O	O
different	JJ	O	O
between	IN	O	O
the	DT	O	O
groups	NNS	O	O
.	.	O	O

While	IN	O	O
the	DT	O	O
postoperative	JJ	o	OOt
catheterization	NN	o	OOt
time	NN	o	OOt
was	VBD	O	O
75.7	CD	O	O
h	NN	O	O
in	IN	O	O
TURP	NNP	O	O
group	NN	O	O
,	,	O	O
it	PRP	O	O
was	VBD	O	O
found	VBN	O	O
to	TO	O	O
be	VB	O	O
42	CD	O	O
h	NN	O	O
in	IN	O	O
PKRP	NNP	O	O
group	NN	O	O
and	CC	O	O
it	PRP	O	O
was	VBD	O	O
clear	JJ	O	O
that	IN	O	O
catheterization	NN	o	OOt
time	NN	o	OOt
was	VBD	O	O
significantly	RB	O	O
shorter	JJR	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0001	CD	O	O
)	)	O	O
.	.	O	O

CONCLUSION	VB	O	O
It	PRP	O	O
is	VBZ	O	O
obvious	JJ	O	O
that	IN	O	O
PKRP	NNP	i	IS
is	VBZ	O	O
as	RB	O	O
efficient	JJ	O	O
as	IN	O	O
TURP	NNP	O	O
and	CC	O	O
it	PRP	O	O
has	VBZ	O	O
a	DT	O	O
similar	JJ	O	O
morbidity	NN	O	O
.	.	O	O

In	IN	O	O
our	PRP$	O	O
opinion	NN	O	O
,	,	O	O
PKRP	NNP	i	IS
makes	VBZ	O	O
a	DT	O	O
promising	JJ	O	O
treatment	NN	O	O
for	IN	O	O
BPH	NNP	O	O
with	IN	O	O
its	PRP$	O	O
advantages	NNS	O	O
,	,	O	O
such	JJ	O	O
as	IN	O	O
early	JJ	O	O
removal	NN	O	O
of	IN	O	O
postoperative	JJ	O	O
urethral	JJ	O	O
catheter	NN	O	O
,	,	O	O
a	DT	O	O
shorter	JJR	O	O
hospital	NN	O	O
stay	NN	O	O
and	CC	O	O
the	DT	O	O
absence	NN	O	O
of	IN	O	O
TUR	NNP	O	O
syndrome	NN	O	O
risk	NN	O	O
.	.	O	O

Vaginal	JJ	i	IPH
electrical	JJ	i	IPH
stimulation	NN	i	IPH
of	IN	i	IPH
the	DT	i	IPH
pelvic	JJ	i	IPH
floor	NN	i	IPH
:	:	i	IPH
a	DT	O	O
randomized	JJ	O	O
feasibility	NN	O	O
study	NN	O	O
in	IN	O	O
urinary	JJ	p	O
incontinent	NN	p	O
elderly	JJ	p	O
women	NNS	p	O
.	.	p	O

BACKGROUND	NNP	O	O
To	TO	O	O
evaluate	VB	O	O
the	DT	O	O
effectiveness	NN	o	OOt
of	IN	O	O
intravaginal	JJ	i	IPH
electrical	JJ	i	IPH
stimulation	NN	i	IPH
(	(	i	IPH
ES	NNP	i	IPH
)	)	i	IPH
of	IN	O	O
the	DT	O	O
pelvic	JJ	O	O
floor	NN	O	O
for	IN	O	O
urinary	JJ	O	O
incontinence	NN	O	O
in	IN	O	O
elderly	JJ	p	O
women	NNS	p	O
,	,	O	O
and	CC	O	O
to	TO	O	O
determine	VB	O	O
whether	IN	O	O
ES	NNP	i	IPH
of	IN	i	IPH
the	DT	i	IPH
pelvic	JJ	i	IPH
floor	NN	i	IPH
is	VBZ	O	O
a	DT	O	O
preferable	JJ	O	O
treatment	NN	O	O
for	IN	O	O
urinary	JJ	p	O
incontinence	NN	p	O
in	IN	p	O
elderly	JJ	p	O
women	NNS	p	O
.	.	p	O

METHODS	NNP	O	O
Postmenopausal	NNP	p	O
women	NNS	p	O
(	(	p	O
age	NN	p	O
65	CD	p	O
years	NNS	p	O
or	CC	p	O
older	JJR	p	O
)	)	p	O
were	VBD	O	O
enrolled	VBN	O	O
in	IN	O	O
a	DT	O	O
randomized	JJ	O	O
clinical	JJ	O	O
trial	NN	O	O
and	CC	O	O
underwent	JJ	O	O
every-other-day	JJ	O	O
ES	NNP	i	IPH
of	IN	i	IPH
the	DT	i	IPH
pelvic	JJ	i	IPH
floor	NN	i	IPH
,	,	i	O
or	CC	i	O
a	DT	i	O
daily	JJ	i	IPH
Kegel	NNP	i	IPH
exercise	NN	i	IPH
(	(	i	IPH
KE	NNP	i	IPH
)	)	i	IPH
program	NN	i	O
.	.	i	O

Objective	NNP	O	O
outcome	NN	O	O
variables	NNS	O	O
were	VBD	O	O
:	:	O	O
(	(	o	O
1	CD	o	O
)	)	o	O
Urinary	JJ	o	OPH
leakage	NN	o	OPH
(	(	o	O
during	IN	o	O
a	DT	o	O
standardized	JJ	o	O
PAD	NNP	o	O
test	NN	o	O
)	)	o	O
,	,	o	O
(	(	o	O
2	CD	o	O
)	)	o	O
pelvic	NN	o	OPH
muscle	NN	o	OPH
strength	NN	o	OPH
(	(	o	O
measured	VBN	o	O
by	IN	o	O
a	DT	o	O
perineometer	NN	o	O
)	)	o	O
,	,	o	O
and	CC	o	O
(	(	o	O
3	CD	o	O
)	)	o	O
detrusor	NN	o	OPH
instability	NN	o	OPH
(	(	o	O
on	IN	o	O
ambulant	NN	o	OPH
urodynamic	JJ	o	OPH
registration	NN	o	OPH
)	)	o	O
.	.	o	O

Subjective	JJ	O	O
outcome	NN	O	O
variables	NNS	O	O
were	VBD	O	O
women	NNS	o	OME
's	POS	o	OME
subjective	JJ	o	OME
assessment	NN	o	OME
of	IN	o	OME
change	NN	o	OME
in	IN	o	OME
urinary	JJ	o	OME
symptoms	NNS	o	OME
based	VBN	o	OME
on	IN	o	OME
the	DT	o	OME
PRAFAB	NNP	o	OME
score	NN	o	OME
.	.	o	O

Twenty-four	JJ	p	O
women	NNS	p	O
treated	VBN	p	O
with	IN	p	O
ES	NNP	i	O
and	CC	p	O
11	CD	p	O
women	NNS	p	O
treated	VBN	p	O
with	IN	p	O
Kegel	NNP	i	O
exercises	NNS	i	O
completed	VBD	O	O
the	DT	O	O
8-week	JJ	O	O
study	NN	O	O
program	NN	O	O
.	.	O	O

The	DT	O	O
Chi-square	JJ	O	O
test	NN	O	O
was	VBD	O	O
used	VBN	O	O
for	IN	O	O
statistical	JJ	O	O
analysis	NN	O	O
.	.	O	O

RESULTS	NNP	O	O
No	NNP	O	O
significant	JJ	O	O
improvement	NN	O	O
in	IN	O	O
objective	JJ	O	O
outcome	NN	O	O
variables	NNS	O	O
was	VBD	O	O
observed	VBN	O	O
in	IN	O	O
the	DT	O	O
population	NN	O	O
treated	VBD	O	O
with	IN	O	O
ES	NNP	i	O
compared	VBN	O	O
with	IN	O	O
the	DT	O	O
population	NN	O	O
treated	VBD	O	O
with	IN	O	O
KE	NNP	i	O
(	(	O	O
with	IN	O	O
29.2	CD	O	O
%	NN	O	O
vs.	FW	O	O
36.4	CD	O	O
%	NN	O	O
of	IN	O	O
the	DT	O	O
women	NNS	O	O
showing	VBG	O	O
objective	JJ	O	O
improvement	NN	O	O
in	IN	O	O
measured	JJ	o	OPH
urinary	JJ	o	OPH
leakage	NN	o	OPH
)	)	o	O
.	.	O	O

Neither	CC	O	O
was	VBD	O	O
subjective	JJ	O	O
improvement	NN	O	O
significant	JJ	O	O
,	,	O	O
with	IN	O	O
29.2	CD	O	O
%	NN	O	O
vs.	FW	O	O
27.3	CD	O	O
%	NN	O	O
of	IN	O	O
the	DT	O	O
women	NNS	O	O
reporting	VBG	O	O
improvement	NN	O	O
in	IN	O	O
the	DT	O	O
amount	NN	o	O
of	IN	o	O
urinary	JJ	o	OPH
leakage	NN	o	OPH
.	.	o	O

CONCLUSIONS	NNP	O	O
Although	IN	O	O
the	DT	O	O
number	NN	O	O
of	IN	O	O
enrolled	JJ	O	O
women	NNS	O	O
was	VBD	O	O
very	RB	O	O
small	JJ	O	O
this	DT	O	O
study	NN	O	O
shows	VBZ	O	O
that	IN	O	O
:	:	O	O
1	CD	O	O
.	.	O	O

Treating	VBG	O	O
elderly	JJ	p	O
women	NNS	p	O
with	IN	O	O
vaginal	JJ	O	O
ES	NNP	O	O
of	IN	O	O
the	DT	O	O
pelvic	JJ	O	O
floor	NN	O	O
has	VBZ	O	O
a	DT	O	O
high	JJ	O	O
physical	JJ	O	O
and	CC	O	O
emotional	JJ	O	O
cost	NN	O	O
for	IN	O	O
the	DT	O	O
individual	NN	O	O
.	.	O	O

2	CD	O	O
.	.	O	O

The	DT	O	O
effectiveness	NN	o	OOt
of	IN	O	O
ES	NNP	i	O
of	IN	O	O
the	DT	O	O
pelvic	JJ	O	O
floor	NN	O	O
in	IN	O	O
urinary	JJ	O	O
incontinent	NN	O	O
elderly	JJ	O	O
women	NNS	O	O
is	VBZ	O	O
low	JJ	O	O
.	.	O	O

3	CD	O	O
.	.	O	O

There	EX	O	O
is	VBZ	O	O
no	DT	O	O
great	JJ	O	O
discrepancy	NN	O	O
between	IN	O	O
objective	JJ	O	O
amelioration	NN	O	O
(	(	O	O
PAD	NNP	O	O
test	NN	O	O
)	)	O	O
and	CC	O	O
subjective	JJ	O	O
amelioration	NN	O	O
(	(	O	O
PRAFAB	NNP	O	O
score/quantity	NN	O	O
of	IN	O	O
urinary	JJ	O	O
leakage	NN	O	O
)	)	O	O
,	,	O	O
if	IN	O	O
the	DT	O	O
objective	JJ	O	O
improvement	NN	O	O
is	VBZ	O	O
adequately	RB	O	O
defined	VBN	O	O
.	.	O	O

4	CD	O	O
.	.	O	O

It	PRP	O	O
is	VBZ	O	O
not	RB	O	O
reasonable	JJ	O	O
to	TO	O	O
advise	VB	O	O
elderly	JJ	O	O
women	NNS	O	O
with	IN	O	O
urinary	JJ	O	O
incontinence	NN	O	O
to	TO	O	O
undertake	VB	O	O
this	DT	O	O
treatment	NN	O	O
procedure	NN	O	O
.	.	O	O

The	DT	O	O
effectiveness	NN	O	O
of	IN	O	O
treatment	NN	O	O
does	VBZ	O	O
not	RB	O	O
compensate	VB	O	O
for	IN	O	O
the	DT	O	O
long-lasting	JJ	O	O
and	CC	O	O
intense	JJ	O	O
treatment	NN	O	O
protocol	NN	O	O
.	.	O	O

5	CD	O	O
.	.	O	O

We	PRP	O	O
terminated	VBD	O	O
this	DT	O	O
study	NN	O	O
because	IN	O	O
of	IN	O	O
the	DT	O	O
negative	JJ	O	O
outcome	NN	O	O
with	IN	O	O
ES	NNP	i	O
.	.	i	O

Tomato	NNP	i	IPM
paste	NN	i	IPM
rich	JJ	i	IPM
in	IN	i	IPM
lycopene	JJ	i	IPM
protects	NNS	O	O
against	IN	O	O
cutaneous	JJ	o	OPH
photodamage	NN	o	OPH
in	IN	O	O
humans	NNS	p	O
in	IN	p	O
vivo	NN	p	O
:	:	p	O
a	DT	O	O
randomized	NN	O	O
controlled	VBN	O	O
trial	NN	O	O
.	.	O	O

BACKGROUND	NNP	O	O
Previous	NNP	O	O
epidemiological	JJ	O	O
,	,	O	O
animal	JJ	O	O
and	CC	O	O
human	JJ	O	O
data	NNS	O	O
report	NN	O	O
that	IN	O	O
lycopene	NN	O	O
has	VBZ	O	O
a	DT	O	O
protective	JJ	O	O
effect	NN	O	O
against	IN	O	O
ultraviolet	NN	o	OPH
radiation	NN	o	OPH
(	(	o	OPH
UVR	NNP	o	OPH
)	)	o	OPH
-induced	VBD	o	OPH
erythema	NN	o	OPH
.	.	o	O

OBJECTIVES	IN	O	O
We	PRP	O	O
examined	VBD	O	O
whether	IN	O	O
tomato	NN	i	IPM
paste	NN	i	IPM
--	:	i	IPM
rich	JJ	i	IPM
in	IN	i	IPM
lycopene	NN	i	IPM
,	,	O	O
a	DT	O	O
powerful	JJ	O	O
antioxidant	NN	O	O
--	:	O	O
can	MD	O	O
protect	VB	O	O
human	JJ	O	O
skin	NN	O	O
against	IN	O	O
UVR-induced	JJ	O	O
effects	NNS	O	O
partially	RB	O	O
mediated	VBN	O	O
by	IN	O	O
oxidative	JJ	O	O
stress	NN	O	O
,	,	O	O
i.e	NN	O	O
.	.	O	O

erythema	NN	O	O
,	,	O	O
matrix	NN	O	O
changes	NNS	O	O
and	CC	O	O
mitochondrial	JJ	O	O
DNA	NNP	O	O
(	(	O	O
mtDNA	NN	O	O
)	)	O	O
damage	NN	O	O
.	.	O	O

METHODS	NNP	O	O
In	IN	O	O
a	DT	O	O
randomized	NN	O	O
controlled	VBN	O	O
study	NN	O	O
,	,	O	O
20	CD	p	PSS
healthy	JJ	p	O
women	NNS	p	PSE
(	(	p	O
median	JJ	p	PA
age	NN	p	PA
33	CD	p	PA
years	NNS	p	PA
,	,	p	O
range	VBP	p	PA
21-47	JJ	p	PA
;	:	p	O
phototype	JJ	p	O
I/II	NNP	p	O
)	)	p	O
ingested	VBD	O	O
55	CD	i	IPH
g	NN	i	IPH
tomato	NN	i	IPH
paste	NN	i	IPH
(	(	i	IPH
16	CD	i	IPH
mg	RB	i	IPH
lycopene	NN	i	IPH
)	)	i	IPH
in	IN	i	IPH
olive	JJ	i	IPH
oil	NN	i	IPH
,	,	i	IPH
or	CC	i	IPH
olive	JJ	i	IPH
oil	NN	i	IPH
alone	RB	i	IPH
,	,	i	IPH
daily	JJ	i	IPH
for	IN	i	IPH
12	CD	i	IPH
weeks	NNS	i	IPH
.	.	i	IPH

Pre-	NNP	O	O
and	CC	O	O
postsupplementation	NN	O	O
,	,	O	O
UVR	NNP	O	O
erythemal	JJ	o	OPH
sensitivity	NN	o	OPH
was	VBD	O	O
assessed	VBN	O	O
visually	RB	O	O
as	IN	O	O
the	DT	O	O
minimal	JJ	O	O
erythema	NN	O	O
dose	NN	O	O
(	(	O	O
MED	NNP	O	O
)	)	O	O
and	CC	O	O
quantified	VBN	O	O
with	IN	O	O
a	DT	O	O
reflectance	NN	O	O
instrument	NN	O	O
.	.	O	O

Biopsies	NNS	O	O
were	VBD	O	O
taken	VBN	O	O
from	IN	O	O
unexposed	JJ	O	O
and	CC	O	O
UVR-exposed	JJ	O	O
(	(	O	O
3	CD	O	O
?	.	O	O
MED	NNP	O	O
24	CD	O	O
h	NN	O	O
earlier	RBR	O	O
)	)	O	O
buttock	NN	O	O
skin	JJ	O	O
pre-	NN	O	O
and	CC	O	O
postsupplementation	NN	O	O
,	,	O	O
and	CC	O	O
analysed	VBD	O	O
immunohistochemically	RB	O	O
for	IN	O	O
procollagen	NN	O	O
(	(	O	O
pC	NN	O	O
)	)	O	O
I	PRP	O	O
,	,	O	O
fibrillin-1	JJ	O	O
and	CC	O	O
matrix	JJ	O	O
metalloproteinase	NN	O	O
(	(	O	O
MMP	NNP	O	O
)	)	O	O
-1	NN	O	O
,	,	O	O
and	CC	O	O
by	IN	O	O
quantitative	JJ	O	O
polymerase	NN	O	O
chain	NN	O	O
reaction	NN	O	O
for	IN	O	O
mtDNA	JJ	O	O
3895-bp	JJ	O	O
deletion	NN	O	O
.	.	O	O

RESULTS	VB	o	O
Mean	NNP	o	O
?	.	o	O
SD	NNP	o	O
erythemal	JJ	o	O
D	NNP	o	O
(	(	o	O
30	CD	o	O
)	)	o	O
was	VBD	o	O
significantly	RB	O	O
higher	JJR	O	O
following	VBG	O	O
tomato	JJ	O	O
paste	NN	O	O
vs.	FW	O	O
control	NN	O	O
(	(	O	O
baseline	NN	O	O
,	,	O	O
26?5	CD	O	O
?	.	O	O
7?5	CD	O	O
mJ	NN	O	O
cm	NN	O	O
(	(	O	O
-2	NNP	O	O
)	)	O	O
;	:	O	O
control	NN	O	O
,	,	O	O
23	CD	O	O
?	.	O	O
6?6	CD	O	O
mJ	NN	O	O
cm	NN	O	O
(	(	O	O
-2	NNP	O	O
)	)	O	O
;	:	O	O
tomato	CC	O	O
paste	NN	O	O
,	,	O	O
36?6	CD	O	O
?	.	O	O
14?7	CD	O	O
mJ	NN	O	O
cm	NN	O	O
(	(	O	O
-2	NNP	O	O
)	)	O	O
;	:	O	O
P	NNP	O	O
=	NNP	O	O
0?03	CD	O	O
)	)	O	O
,	,	O	O
while	IN	O	O
the	DT	O	O
MED	NNP	O	O
was	VBD	O	O
not	RB	O	O
significantly	RB	O	O
different	JJ	O	O
between	IN	O	O
groups	NNS	O	O
(	(	O	O
baseline	NN	O	O
,	,	O	O
35?1	CD	O	O
?	.	O	O
9?9	CD	O	O
mJ	NN	O	O
cm	NN	O	O
(	(	O	O
-2	NNP	O	O
)	)	O	O
;	:	O	O
control	NN	O	O
,	,	O	O
32?6	CD	O	O
?	.	O	O
9?6	CD	O	O
mJ	NN	O	O
cm	NN	O	O
(	(	O	O
-2	NNP	O	O
)	)	O	O
;	:	O	O
tomato	CC	O	O
paste	NN	O	O
,	,	O	O
42?2	CD	O	O
?	.	O	O
11?3	CD	O	O
mJ	NN	O	O
cm	NN	O	O
(	(	O	O
-2	NNP	O	O
)	)	O	O
)	)	O	O
.	.	O	O

Presupplementation	NN	O	O
,	,	O	O
UVR	NNP	O	O
induced	VBD	O	O
an	DT	O	O
increase	NN	O	O
in	IN	o	O
MMP-1	NNP	o	O
(	(	o	O
P	NNP	O	O
=	NNP	O	O
0?01	CD	O	O
)	)	O	O
and	CC	O	O
a	DT	O	O
reduction	NN	o	O
in	IN	o	O
fibrillin-1	NN	o	O
(	(	o	O
P	NNP	o	O
=	NNP	o	O
0?03	CD	O	O
)	)	O	O
.	.	O	O

Postsupplementation	NN	O	O
,	,	O	O
UVR-induced	JJ	o	O
MMP-1	NNP	o	O
was	VBD	o	O
reduced	VBN	O	O
in	IN	O	O
the	DT	O	O
tomato	NN	O	O
paste	NN	O	O
vs.	FW	O	O
control	NN	O	O
group	NN	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0?04	CD	O	O
)	)	O	O
,	,	O	O
while	IN	O	O
the	DT	O	O
UVR-induced	JJ	O	O
reduction	NN	O	O
in	IN	o	O
fibrillin-1	NN	o	O
was	VBD	o	O
similarly	RB	o	O
abrogated	VBN	O	O
in	IN	O	O
both	DT	O	O
groups	NNS	O	O
,	,	O	O
and	CC	O	O
an	DT	O	O
increase	NN	O	O
in	IN	O	O
pCI	JJ	O	O
deposition	NN	O	O
was	VBD	O	O
seen	VBN	O	O
following	VBG	O	O
tomato	JJ	O	O
paste	NN	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0?05	CD	O	O
)	)	O	O
.	.	o	O

mtDNA	JJ	o	O
3895-bp	JJ	o	O
deletion	NN	O	O
following	VBG	O	O
3	CD	O	O
?	.	O	O
MED	NNP	O	O
UVR	NNP	O	O
was	VBD	O	O
significantly	RB	O	O
reduced	VBN	O	O
postsupplementation	NN	O	O
with	IN	O	O
tomato	JJ	i	O
paste	NN	i	O
(	(	i	O
P	NNP	i	O
=	NNP	i	O
0?01	CD	i	O
)	)	O	O
.	.	O	O

CONCLUSIONS	NNP	i	O
Tomato	NNP	i	O
paste	NN	i	O
containing	VBG	O	O
lycopene	NNP	O	O
provides	VBZ	o	O
protection	NN	o	O
against	IN	o	O
acute	NN	o	O
and	CC	o	O
potentially	RB	o	O
longer-term	JJ	o	O
aspects	NNS	o	O
of	IN	o	O
photodamage	NN	o	O
.	.	o	O

Aerobic	NNP	i	IPH
exercise	NN	i	IPH
improves	VBZ	O	O
self-reported	JJ	o	OME
sleep	NN	o	OME
and	CC	o	O
quality	NN	o	OOt
of	IN	o	OOt
life	NN	o	OOt
in	IN	O	O
older	JJR	p	PA
adults	NNS	p	PA
with	IN	p	O
insomnia	NN	p	PC
.	.	p	O

OBJECTIVE	UH	O	O
To	TO	O	O
assess	VB	O	O
the	DT	O	O
efficacy	NN	o	OOt
of	IN	O	O
moderate	JJ	i	IPH
aerobic	JJ	i	IPH
physical	JJ	i	IPH
activity	NN	i	IPH
with	IN	O	O
sleep	JJ	O	O
hygiene	NN	O	O
education	NN	O	O
to	TO	O	O
improve	VB	o	OME
sleep	NN	o	OME
,	,	o	OME
mood	NN	o	OME
and	CC	o	O
quality	NN	o	OPH
of	IN	o	OPH
life	NN	o	OPH
in	IN	O	O
older	JJR	O	O
adults	NNS	O	O
with	IN	O	O
chronic	JJ	O	O
insomnia	NN	O	O
.	.	O	O

METHODS	NNP	O	O
Seventeen	NNP	p	O
sedentary	JJ	p	O
adults	NNS	p	O
aged	VBN	p	O
>	JJ	p	PA
or=55	CD	p	PA
years	NNS	p	PA
with	IN	p	O
insomnia	NN	p	O
(	(	p	O
mean	JJ	p	O
age	NN	p	O
61.6	CD	p	O
[	NN	p	O
SD?4.3	NNP	p	O
]	NNP	p	O
years	NNS	p	O
;	:	p	O
16	CD	p	O
female	NN	p	O
)	)	p	O
participated	VBD	p	O
in	IN	O	O
a	DT	O	O
randomized	NN	O	O
controlled	VBN	O	O
trial	NN	O	O
comparing	VBG	i	O
16	CD	i	O
weeks	NNS	i	O
of	IN	i	O
aerobic	JJ	i	O
physical	JJ	i	O
activity	NN	i	O
plus	CC	i	O
sleep	JJ	i	O
hygiene	NN	i	O
to	TO	i	O
non-physical	JJ	i	O
activity	NN	i	O
plus	CC	i	O
sleep	JJ	i	O
hygiene	NN	i	O
.	.	i	O

Eligibility	NNP	O	O
included	VBD	p	O
primary	JJ	p	O
insomnia	NN	p	O
for	IN	p	O
at	IN	p	O
least	JJS	p	O
3	CD	p	O
months	NNS	p	O
,	,	p	O
habitual	JJ	p	O
sleep	NN	p	O
duration	NN	p	O
<	POS	p	O
6.5h	CD	p	O
and	CC	p	O
a	DT	p	O
Pittsburgh	NNP	p	O
Sleep	NNP	p	O
Quality	NNP	p	O
Index	NNP	p	O
(	(	p	O
PSQI	NNP	p	O
)	)	p	O
score	VBD	p	O
>	JJ	p	O
5	CD	p	O
.	.	p	O

Outcomes	NNS	o	O
included	VBD	o	O
sleep	JJ	o	O
quality	NN	o	O
,	,	o	O
mood	NN	o	O
and	CC	o	O
quality	NN	o	O
of	IN	o	O
life	NN	o	O
questionnaires	NNS	o	O
(	(	o	O
PSQI	NNP	o	O
,	,	o	O
Epworth	NNP	o	O
Sleepiness	NNP	o	O
Scale	NNP	o	O
[	NNP	o	O
ESS	NNP	o	O
]	NNP	o	O
,	,	o	O
Short-form	NNP	o	O
36	CD	o	O
[	NNP	o	O
SF-36	NNP	o	O
]	NNP	o	O
,	,	o	O
Center	NNP	o	O
for	IN	o	O
Epidemiological	NNP	o	O
Studies	NNPS	o	O
Depression	NNP	o	O
Scale	NNP	o	O
[	NNP	o	O
CES-D	NNP	o	O
]	NNP	o	O
)	)	o	O
.	.	o	O

RESULTS	VB	O	O
The	DT	O	O
physical	JJ	O	O
activity	NN	O	O
group	NN	O	O
improved	VBD	O	O
in	IN	o	O
sleep	JJ	o	O
quality	NN	o	O
on	IN	o	O
the	DT	o	O
global	JJ	o	O
PSQI	NNP	o	O
(	(	O	O
p	JJ	O	O
<	NNP	O	O
.0001	NNP	O	O
)	)	O	O
,	,	O	O
sleep	JJ	o	O
latency	NN	o	O
(	(	O	O
p=.049	NN	O	O
)	)	O	O
,	,	O	O
sleep	JJ	o	O
duration	NN	o	O
(	(	O	O
p=.04	NN	O	O
)	)	O	O
,	,	O	O
daytime	JJ	o	O
dysfunction	NN	o	O
(	(	O	O
p=.027	NN	O	O
)	)	O	O
,	,	O	O
and	CC	o	O
sleep	JJ	o	O
efficiency	NN	o	O
(	(	O	O
p=.036	NN	O	O
)	)	O	O
PSQI	NNP	O	O
sub-scores	NNS	O	O
compared	VBN	O	O
to	TO	O	O
the	DT	O	O
control	NN	O	O
group	NN	O	O
.	.	O	O

The	DT	O	O
physical	JJ	O	O
activity	NN	O	O
group	NN	O	O
also	RB	O	O
had	VBD	O	O
reductions	NNS	O	O
in	IN	o	O
depressive	JJ	o	O
symptoms	NNS	o	O
(	(	O	O
p=.044	NN	O	O
)	)	O	O
,	,	O	O
daytime	JJ	o	O
sleepiness	NN	o	O
(	(	O	O
p=.02	NN	O	O
)	)	O	O
and	CC	o	O
improvements	NNS	o	O
in	IN	o	O
vitality	NN	o	O
(	(	O	O
p=.017	NN	O	O
)	)	O	O
compared	VBN	O	O
to	TO	O	O
baseline	VB	O	O
scores	NNS	O	O
.	.	O	O

CONCLUSION	NNP	O	O
Aerobic	NNP	O	O
physical	JJ	O	O
activity	NN	O	O
with	IN	O	O
sleep	JJ	O	O
hygiene	NN	O	O
education	NN	O	O
is	VBZ	O	O
an	DT	O	O
effective	JJ	O	O
treatment	NN	O	O
approach	NN	O	O
to	TO	O	O
improve	VB	o	O
sleep	JJ	o	O
quality	NN	o	O
,	,	o	O
mood	NN	o	O
and	CC	o	O
quality	NN	o	O
of	IN	o	O
life	NN	o	O
in	IN	p	O
older	JJR	p	PA
adults	NNS	p	PA
with	IN	p	O
chronic	JJ	p	O
insomnia	NN	p	O
.	.	p	O

Comparison	NNP	O	O
of	IN	O	O
indicators	NNS	O	O
for	IN	O	O
a	DT	O	O
primary	JJ	O	O
care	NN	O	O
medical	JJ	O	O
home	NN	O	O
between	IN	O	O
children	NNS	p	PA
with	IN	p	O
autism	NN	p	PC
or	CC	p	O
asthma	NN	p	PC
and	CC	p	O
other	JJ	p	O
special	JJ	p	PC
health	NN	p	PC
care	NN	p	PC
needs	NNS	p	PC
:	:	p	O
National	NNP	O	O
Survey	NNP	O	O
of	IN	O	O
Children	NNP	O	O
's	POS	O	O
Health	NNP	O	O
.	.	O	O

OBJECTIVE	NNP	O	O
To	TO	O	O
assess	VB	O	O
the	DT	O	O
extent	NN	O	O
to	TO	O	O
which	WDT	O	O
parents	NNS	i	O
of	IN	i	O
children	NNS	i	O
with	IN	i	O
autism	NN	i	O
compared	VBN	i	O
with	IN	i	O
parents	NNS	i	O
of	IN	i	O
children	NNS	i	O
with	IN	i	O
asthma	NN	i	O
or	CC	i	O
other	JJ	i	O
special	JJ	i	O
health	NN	i	O
care	NN	i	O
needs	VBZ	i	O
report	NN	O	O
receiving	VBG	O	O
primary	JJ	O	O
care	NN	O	O
for	IN	O	O
their	PRP$	O	O
child	NN	O	O
consistent	NN	O	O
with	IN	O	O
the	DT	O	O
American	JJ	O	O
Academy	NNP	O	O
of	IN	O	O
Pediatrics	NNP	O	O
medical	JJ	O	O
home	NN	O	O
model	NN	O	O
.	.	O	O

DESIGN	NNP	O	O
Population-based	JJ	O	O
cross-sectional	JJ	O	O
study	NN	O	O
.	.	O	O

SETTING	NNP	O	O
National	NNP	i	IE
Survey	NNP	i	IE
for	IN	i	IE
Children	NNP	i	IE
's	POS	i	IE
Health	NNP	i	IE
2003-2004	CD	i	IE
telephone	NN	i	IE
interview	NN	i	IE
.	.	i	O

PARTICIPANTS	NNP	O	O
Parents	NNPS	p	O
of	IN	p	O
495	CD	p	PSS
children	NNS	p	PA
with	IN	p	O
autism	NN	p	PC
,	,	p	O
parents	NNS	p	O
of	IN	p	O
6716	CD	p	PSS
children	NNS	p	PA
with	IN	p	O
asthma	NN	p	PC
,	,	p	O
and	CC	p	O
parents	NNS	p	O
of	IN	p	O
11,403	CD	p	PSS
children	NNS	p	O
with	IN	p	O
other	JJ	p	O
special	JJ	p	PC
health	NN	p	PC
care	NN	p	PC
needs	VBZ	p	PC
without	IN	p	O
asthma	NN	p	PC
.	.	p	O

Main	NNP	O	O
Exposures	NNPS	O	O
Autism	NNP	O	O
and	CC	O	O
other	JJ	O	O
special	JJ	O	O
health	NN	O	O
care	NN	O	O
needs	VBZ	O	O
including	VBG	O	O
asthma	NN	O	O
.	.	O	O

MAIN	NNP	O	O
OUTCOME	NNP	O	O
MEASURES	NNP	O	O
Medical	NNP	O	O
home	NN	O	O
score	NN	O	O
and	CC	O	O
components	NNS	O	O
of	IN	O	O
care	NN	O	O
,	,	O	O
as	IN	O	O
follows	VBZ	O	O
:	:	O	O
personal	JJ	O	O
provider	NN	O	O
and	CC	O	O
preventive	NN	O	O
;	:	O	O
family-centered	JJ	O	O
,	,	O	O
compassionate	NN	O	O
,	,	O	O
and	CC	O	O
culturally	RB	O	O
appropriate	JJ	O	O
;	:	O	O
accessible	JJ	O	O
;	:	O	O
comprehensive	JJ	O	O
;	:	O	O
and	CC	O	O
coordinated	VBD	O	O
.	.	O	O

RESULTS	VB	O	O
The	DT	O	O
odds	NNS	o	OME
of	IN	o	OME
parents	NNS	o	OME
reporting	VBG	o	OME
care	NN	o	OME
consistent	JJ	o	OME
with	IN	o	OME
that	DT	o	OME
in	IN	o	OME
a	DT	o	OME
medical	JJ	o	OME
home	NN	o	OME
were	VBD	O	O
less	RBR	o	OPH
likely	JJ	o	OPH
for	IN	o	OPH
children	NNS	o	OPH
with	IN	o	OPH
autism	NN	o	OPH
(	(	O	O
odds	NNS	O	O
ratio	NN	O	O
,	,	O	O
0.45	CD	O	O
;	:	O	O
95	CD	O	O
%	NN	O	O
confidence	NN	O	O
interval	NN	O	O
,	,	O	O
0.30-0.66	JJ	O	O
)	)	O	O
and	CC	O	O
more	RBR	O	O
likely	JJ	O	O
for	IN	O	O
children	NNS	O	O
with	IN	O	O
asthma	NN	O	O
(	(	O	O
odds	NNS	O	O
ratio	NN	O	O
,	,	O	O
1.17	CD	O	O
;	:	O	O
95	CD	O	O
%	NN	O	O
confidence	NN	O	O
interval	NN	O	O
,	,	O	O
1.06-1.30	JJ	O	O
)	)	O	O
compared	VBN	O	O
with	IN	O	O
children	NNS	O	O
with	IN	O	O
other	JJ	O	O
special	JJ	O	O
health	NN	O	O
care	NN	O	O
needs	NNS	O	O
(	(	O	O
1	CD	O	O
[	NN	O	O
reference	NN	O	O
]	NN	O	O
)	)	O	O
.	.	O	O

These	DT	O	O
differences	NNS	O	O
persisted	VBD	O	O
even	RB	O	O
after	IN	O	O
controlling	VBG	O	O
for	IN	O	O
condition	NN	O	O
severity	NN	O	O
,	,	O	O
personal	JJ	O	O
characteristics	NNS	O	O
,	,	O	O
and	CC	O	O
insurance	NN	O	O
status	NN	O	O
.	.	O	O

Specific	JJ	O	O
components	NNS	O	O
of	IN	O	O
a	DT	O	O
medical	JJ	O	O
home	NN	O	O
less	RBR	O	O
prevalent	JJ	O	O
among	IN	O	O
children	NNS	O	O
with	IN	O	O
autism	NN	O	O
than	IN	O	O
among	IN	O	O
children	NNS	O	O
with	IN	O	O
other	JJ	O	O
special	JJ	O	O
health	NN	O	O
care	NN	O	O
needs	VBZ	O	O
included	VBN	O	O
family-centered	JJ	O	O
,	,	O	O
comprehensive	JJ	O	O
,	,	O	O
and	CC	O	O
coordinated	VBD	O	O
care	NN	O	O
.	.	O	O

CONCLUSION	NNP	O	O
Although	IN	O	O
we	PRP	O	O
could	MD	O	O
not	RB	O	O
evaluate	VB	O	O
the	DT	O	O
reasons	NNS	O	O
why	WRB	O	O
,	,	O	O
a	DT	O	O
large	JJ	O	O
percentage	NN	O	O
of	IN	O	O
children	NNS	O	O
with	IN	O	O
autism	NN	O	O
do	VBP	O	O
not	RB	O	O
receive	VB	O	O
primary	JJ	o	OOt
care	NN	o	OOt
consistent	JJ	o	OOt
with	IN	o	OOt
that	DT	o	OOt
in	IN	o	OOt
a	DT	o	OOt
medical	JJ	o	OOt
home	NN	o	OOt
.	.	o	O

Trace	NNP	i	IPM
element	NN	i	IPM
supplementation	NN	i	IPM
after	IN	O	O
major	JJ	p	O
burns	NNS	p	O
modulates	VBZ	O	O
antioxidant	JJ	O	O
status	NN	O	O
and	CC	O	O
clinical	JJ	O	O
course	NN	O	O
by	IN	O	O
way	NN	O	O
of	IN	O	O
increased	JJ	O	O
tissue	NN	o	OPH
trace	NN	o	OPH
element	NN	o	OPH
concentrations	NNS	o	OPH
.	.	o	OPH

BACKGROUND	NNP	O	O
After	IN	O	O
major	JJ	p	O
burns	NNS	p	O
,	,	p	O
patients	NNS	p	O
can	MD	O	O
develop	VB	O	O
nutritional	JJ	p	O
deficiencies	NNS	p	O
including	VBG	p	O
trace	NN	o	OPH
element	NN	o	OPH
(	(	o	OPH
TE	NNP	o	OPH
)	)	o	OPH
deficiencies	NNS	p	O
.	.	p	O

Various	JJ	O	O
complications	NNS	O	O
,	,	O	O
such	JJ	O	O
as	IN	O	O
infections	NNS	O	O
and	CC	O	O
delayed	VBN	O	O
wound	NN	O	O
healing	NN	O	O
,	,	O	O
influence	VB	O	O
the	DT	O	O
clinical	JJ	O	O
course	NN	O	O
of	IN	O	O
such	JJ	O	O
patients	NNS	O	O
.	.	O	O

OBJECTIVES	IN	O	O
We	PRP	O	O
aimed	VBD	O	O
to	TO	O	O
investigate	VB	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
large	JJ	O	O
,	,	O	O
intravenous	JJ	O	O
doses	NNS	O	O
of	IN	O	O
TE	NNP	i	IPM
supplements	NNS	i	IPM
on	IN	O	O
circulating	NN	O	O
and	CC	O	O
cutaneous	JJ	O	O
TE	NNP	O	O
tissue	NN	O	O
concentrations	NNS	O	O
,	,	O	O
on	IN	O	O
antioxidant	JJ	o	O
status	NN	o	O
,	,	O	O
and	CC	O	O
on	IN	O	O
clinical	JJ	o	OPH
outcome	NN	o	OPH
after	IN	O	O
major	JJ	p	O
burns	NNS	p	O
.	.	p	O

DESIGN	NNP	O	O
This	DT	O	O
was	VBD	O	O
a	DT	O	O
prospective	JJ	O	O
,	,	O	O
randomized	VBN	O	O
,	,	O	O
placebo-controlled	JJ	i	IC
trial	NN	O	O
in	IN	O	O
21	CD	p	O
patients	NNS	p	O
aged	VBD	p	O
35	CD	p	O
+/-	JJ	p	O
11	CD	p	O
y	NN	p	O
(	(	p	O
x	JJ	p	O
+/-	NNP	p	O
SD	NNP	p	O
)	)	p	O
with	IN	p	O
burns	NNS	p	O
on	IN	p	O
45	CD	p	O
+/-	JJ	p	O
21	CD	p	O
%	NN	p	O
of	IN	p	O
their	PRP$	p	O
body	NN	p	O
surface	NN	p	O
area	NN	p	O
.	.	p	O

Intravenous	JJ	i	IPM
copper	NN	i	IPM
,	,	i	IPM
selenium	NN	i	IPM
,	,	i	IPM
and	CC	i	IPM
zinc	NN	i	IPM
(	(	i	IPM
TE	NNP	i	IPM
group	NN	i	IPM
)	)	i	IPM
or	CC	i	O
vehicle	NN	i	IPM
(	(	O	O
V	NNP	O	O
group	NN	O	O
)	)	O	O
was	VBD	O	O
given	VBN	O	O
with	IN	O	O
a	DT	O	O
saline	JJ	O	O
solution	NN	O	O
for	IN	O	O
14-21	JJ	O	O
d.	NN	O	O
Blood	NNP	O	O
and	CC	O	O
urine	JJ	O	O
samples	NNS	O	O
were	VBD	O	O
collected	VBN	O	O
until	IN	O	O
day	NN	O	O
20	CD	O	O
,	,	O	O
and	CC	O	O
skin	FW	O	O
biopsy	NN	O	O
specimens	NNS	O	O
were	VBD	O	O
collected	VBN	O	O
on	IN	O	O
days	NNS	O	O
3	CD	O	O
,	,	O	O
10	CD	O	O
,	,	O	O
and	CC	O	O
20	CD	O	O
.	.	O	O

RESULTS	VB	O	O
The	DT	O	O
age	NN	O	O
of	IN	O	O
the	DT	O	O
patients	NNS	O	O
and	CC	O	O
the	DT	O	O
severity	NN	O	O
of	IN	O	O
their	PRP$	O	O
burns	NNS	O	O
did	VBD	O	O
not	RB	O	O
differ	VB	O	O
significantly	RB	O	O
between	IN	O	O
the	DT	O	O
groups	NNS	O	O
.	.	O	O

Plasma	NNP	o	OPH
TE	NNP	o	OPH
concentrations	NNS	o	OPH
were	VBD	O	O
significantly	RB	O	O
higher	JJR	O	O
in	IN	O	O
the	DT	O	O
TE	NNP	O	O
group	NN	O	O
.	.	O	O

In	IN	O	O
burned	JJ	O	O
areas	NNS	O	O
,	,	O	O
skin	JJ	o	OPH
contents	NNS	o	OPH
of	IN	o	OPH
both	DT	o	OPH
selenium	NN	o	OPH
(	(	O	O
P=0.05	NNP	O	O
)	)	O	O
and	CC	O	O
zinc	NN	o	O
(	(	O	O
P=0.04	NNP	O	O
)	)	O	O
increased	VBD	O	O
significantly	RB	O	O
by	IN	O	O
day	NN	O	O
20	CD	O	O
.	.	O	O

Plasma	NNP	o	O
and	CC	o	O
tissue	NN	o	O
antioxidant	NN	o	O
status	NN	o	O
was	VBD	O	O
improved	VBN	O	O
by	IN	O	O
supplementation	NN	O	O
.	.	O	O

The	DT	O	O
number	NN	o	OPH
of	IN	o	OPH
infections	NNS	o	OPH
in	IN	O	O
the	DT	O	O
first	JJ	O	O
30	CD	O	O
d	NN	O	O
was	VBD	O	O
significantly	RB	O	O
lower	JJR	O	O
in	IN	O	O
the	DT	O	O
TE	NNP	O	O
group	NN	O	O
(	(	O	O
P=0.015	NNP	O	O
)	)	O	O
,	,	O	O
with	IN	O	O
a	DT	O	O
median	JJ	O	O
number	NN	O	O
of	IN	O	O
2	CD	O	O
versus	NN	O	O
4	CD	O	O
infections	NNS	O	O
per	IN	O	O
patient	NN	O	O
in	IN	O	O
the	DT	O	O
TE	NNP	O	O
and	CC	O	O
V	NNP	O	O
groups	NNS	O	O
,	,	O	O
respectively	RB	O	O
,	,	O	O
as	IN	O	O
a	DT	O	O
result	NN	O	O
of	IN	O	O
a	DT	O	O
reduction	NN	O	O
in	IN	O	O
pulmonary	JJ	o	O
infections	NNS	O	O
(	(	O	O
P=0.03	NNP	O	O
)	)	O	O
.	.	O	O

Wound	IN	o	O
healing	NN	o	O
was	VBD	O	O
improved	VBN	O	O
in	IN	O	O
the	DT	O	O
TE	NNP	O	O
group	NN	O	O
,	,	O	O
with	IN	O	O
lower	JJR	O	O
requirements	NNS	o	O
for	IN	o	O
regrafting	VBG	o	O
(	(	O	O
P=0.02	NNP	O	O
)	)	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
TE	NNP	i	IPM
supplementation	NN	O	O
was	VBD	O	O
associated	VBN	O	O
with	IN	O	O
higher	JJR	O	O
circulating	NN	o	O
plasma	NN	o	O
and	CC	o	O
skin	JJ	o	O
tissue	NN	o	O
contents	NNS	o	O
of	IN	o	O
selenium	NN	o	O
and	CC	o	O
zinc	NN	o	O
and	CC	O	O
improved	VBN	O	O
antioxidant	JJ	o	O
status	NN	o	O
.	.	o	O

These	DT	O	O
changes	NNS	O	O
were	VBD	O	O
associated	VBN	O	O
with	IN	O	O
improved	JJ	O	O
clinical	JJ	o	O
outcome	NN	o	O
,	,	o	O
including	VBG	o	O
fewer	JJR	o	O
pulmonary	JJ	o	O
infections	NNS	o	O
and	CC	o	O
better	JJR	o	O
wound	NN	o	O
healing	NN	o	O
.	.	o	O

Echocardiographic	JJ	O	O
evaluation	NN	O	O
of	IN	O	O
children	NNS	p	PA
with	IN	p	O
systemic	JJ	p	PC
ventricular	JJ	p	PC
dysfunction	NN	p	PC
treated	VBN	p	O
with	IN	p	O
carvedilol	NN	i	IPM
.	.	i	IPM

Echocardiography	NN	i	IPH
is	VBZ	O	O
used	VBN	O	O
to	TO	O	O
measure	VB	O	O
the	DT	O	O
therapeutic	JJ	O	O
effectiveness	NN	O	O
of	IN	O	O
heart	NN	O	O
failure	NN	O	O
therapy	NN	O	O
in	IN	O	O
adults	NNS	p	PA
and	CC	p	O
children	NNS	p	PA
.	.	p	O

The	DT	O	O
purposes	NNS	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
were	VBD	O	O
(	(	O	O
1	CD	O	O
)	)	O	O
to	TO	O	O
assess	VB	O	O
baseline	JJ	O	O
echocardiographic	JJ	O	O
predictors	NNS	O	O
of	IN	O	O
clinical	JJ	O	O
outcome	NN	O	O
,	,	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
to	TO	O	O
investigate	VB	O	O
changes	NNS	O	O
in	IN	O	O
echocardiographic	JJ	O	O
parameters	NNS	O	O
,	,	O	O
and	CC	O	O
(	(	O	O
3	CD	O	O
)	)	O	O
to	TO	O	O
compare	VB	O	O
these	DT	O	O
echocardiographic	JJ	O	O
changes	NNS	O	O
with	IN	O	O
changes	NNS	O	O
in	IN	O	O
plasma	NN	O	O
levels	NNS	O	O
of	IN	O	O
b-type	JJ	O	O
natriuretic	JJ	i	O
peptide	NN	i	O
(	(	O	O
BNP	NNP	O	O
)	)	O	O
in	IN	p	O
a	DT	p	O
population	NN	p	O
of	IN	p	O
children	NNS	p	PA
with	IN	p	O
systemic	JJ	p	PC
ventricular	JJ	p	PC
dysfunction	NN	p	PC
and	CC	p	O
symptomatic	JJ	p	O
heart	NN	p	O
failure	NN	p	O
treated	VBN	p	O
with	IN	p	O
carvedilol	NN	i	IPM
or	CC	i	O
placebo	NN	i	IC
.	.	i	O

All	DT	O	O
available	JJ	O	O
baseline	NN	O	O
and	CC	O	O
6-month	JJ	O	O
echocardiograms	NNS	O	O
from	IN	O	O
Pediatric	NNP	p	O
Carvedilol	NNP	p	O
Trial	NNP	p	O
(	(	p	O
PCT	NNP	p	O
)	)	p	O
participants	NNS	p	O
(	(	i	O
carvedilol	JJ	i	IPM
n	RB	p	O
=	JJ	p	O
161	CD	p	O
;	:	p	O
placebo	NN	i	IC
n	IN	p	O
=	$	p	O
55	CD	p	O
)	)	p	O
were	VBD	O	O
reviewed	VBN	O	O
.	.	O	O

Systolic	NNP	o	OPH
and	CC	O	O
diastolic	JJ	o	OPH
sphericity	NN	o	OPH
index	NN	o	OPH
(	(	O	O
SI	NNP	O	O
;	:	O	O
n	CC	O	O
=	VB	O	O
110	CD	O	O
)	)	O	O
,	,	O	O
TEI	NNP	O	O
index	NN	O	O
(	(	O	O
n	JJ	O	O
=	NNP	O	O
145	CD	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
systemic	JJ	O	O
ventricular	NN	O	O
dP/dt	NN	O	O
(	(	O	O
n	JJ	O	O
=	NNP	O	O
70	CD	O	O
)	)	O	O
were	VBD	O	O
measured	VBN	O	O
.	.	O	O

The	DT	O	O
PCT	NNP	O	O
composite	JJ	O	O
definition	NN	O	O
of	IN	O	O
clinical	JJ	O	O
outcome	NN	O	O
(	(	O	O
i.e.	FW	O	O
,	,	O	O
worsened	VBD	O	O
,	,	O	O
improved	VBN	O	O
,	,	O	O
or	CC	O	O
unchanged	JJ	O	O
)	)	O	O
was	VBD	O	O
used	VBN	O	O
.	.	O	O

For	IN	O	O
all	DT	O	O
patients	NNS	O	O
,	,	O	O
baseline	VBP	O	O
TEI	NNP	O	O
index	NN	O	O
was	VBD	O	O
a	DT	O	O
predictor	NN	O	O
of	IN	O	O
worsened	JJ	o	OPH
outcome	NN	o	OPH
.	.	o	O

Only	RB	O	O
children	NNS	p	O
treated	VBD	p	O
with	IN	p	O
carvedilol	NN	i	IPM
showed	VBD	O	O
a	DT	O	O
significant	JJ	O	O
decrease	NN	O	O
in	IN	O	O
systolic	JJ	o	OPH
SI	NNP	o	OPH
(	(	O	O
P	NNP	O	O
B	NNP	O	O
0.0001	CD	O	O
)	)	O	O
,	,	O	O
diastolic	JJ	o	OPH
SI	NNP	o	OPH
(	(	O	O
P	NNP	O	O
B	NNP	O	O
0.0001	CD	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
TEI	NNP	o	OPH
index	NN	o	OPH
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.02	CD	O	O
)	)	O	O
.	.	O	O

An	DT	O	O
inverse	JJ	O	O
correlation	NN	O	O
between	IN	O	O
changes	NNS	o	OPH
in	IN	o	OPH
BNP	NNP	o	OPH
and	CC	O	O
changes	NNS	o	OPH
in	IN	o	OPH
dP/dt	NN	o	OPH
(	(	O	O
r	JJ	O	O
=	NNP	O	O
-0.45	NNP	O	O
,	,	O	O
P	NNP	O	O
=	NNP	O	O
0.04	CD	O	O
)	)	O	O
was	VBD	O	O
found	VBN	O	O
only	RB	O	O
in	IN	O	O
the	DT	O	O
carvedilol	NN	i	IPM
group	NN	p	O
.	.	p	O

In	IN	O	O
conclusion	NN	O	O
,	,	O	O
TEI	NNP	O	O
index	NN	O	O
predicted	VBD	O	O
outcome	NN	O	O
in	IN	O	O
children	NNS	p	O
with	IN	O	O
systemic	JJ	o	O
ventricular	JJ	o	O
dysfunction	NN	o	O
and	CC	o	O
heart	NN	o	O
failure	NN	o	O
.	.	o	O

Carvedilol	NN	i	IPM
may	MD	O	O
have	VB	O	O
a	DT	O	O
beneficial	JJ	O	O
effect	NN	O	O
on	IN	O	O
reversal	NN	O	O
of	IN	O	O
left	JJ	O	O
ventricular	JJ	O	O
remodeling	NN	O	O
and	CC	O	O
global	JJ	O	O
ventricular	NN	O	O
function	NN	O	O
in	IN	O	O
pediatric	JJ	O	O
heart	NN	O	O
failure	NN	O	O
.	.	O	O

Effect	NN	O	O
of	IN	O	O
diltiazem	NN	i	IPM
on	IN	O	O
symptomatic	JJ	p	O
and	CC	p	O
asymptomatic	JJ	p	O
episodes	NNS	p	O
of	IN	p	O
ST	NNP	o	OME
segment	NN	o	OME
depression	NN	o	OME
occurring	VBG	p	O
during	IN	p	O
daily	JJ	p	O
life	NN	p	O
and	CC	p	O
during	IN	p	O
exercise	NN	p	O
.	.	p	O

BACKGROUND	NNP	O	O
Silent	NNP	O	O
myocardial	JJ	O	O
ischemia	NN	O	O
is	VBZ	O	O
an	DT	O	O
adverse	JJ	O	O
prognostic	JJ	O	O
marker	NN	O	O
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
coronary	JJ	p	PC
disease	NN	p	PC
;	:	p	O
however	RB	O	O
,	,	O	O
controlled	VBN	O	O
data	NNS	O	O
on	IN	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
treatment	NN	O	O
are	VBP	O	O
sparse	JJ	O	O
and	CC	O	O
contradictory	NN	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
relations	NNS	O	O
among	IN	O	O
the	DT	O	O
occurrence	NN	O	O
of	IN	O	O
ST	NNP	o	OME
segment	NN	o	OME
depression	NN	o	OME
,	,	O	O
drug	NN	O	O
efficacy	NN	O	O
,	,	O	O
and	CC	O	O
heart	NN	O	O
rate	NN	O	O
are	VBP	O	O
unclear	JJ	O	O
.	.	O	O

METHODS	NNP	O	O
AND	CC	O	O
RESULTS	NNP	O	O
Sixty	NNP	p	PSS
patients	NNS	p	O
with	IN	p	O
stable	JJ	p	O
coronary	JJ	p	O
artery	NN	p	O
disease	NN	p	O
,	,	p	O
a	DT	p	O
positive	JJ	p	O
treadmill	NN	p	O
exercise	NN	p	O
test	NN	p	O
and	CC	p	O
asymptomatic	JJ	p	O
ST	NNP	p	PC
segment	NN	p	PC
depression	NN	p	PC
on	IN	p	O
ambulatory	JJ	p	O
electrocardiographic	JJ	p	O
recording	VBG	p	O
were	VBD	p	O
assessed	VBN	p	O
in	IN	p	O
a	DT	p	O
multicenter	NN	p	O
,	,	p	O
double-blind	JJ	p	O
,	,	p	O
placebo-controlled	JJ	i	IC
,	,	p	O
cross-over	JJ	p	O
trial	NN	p	O
.	.	p	O

Treadmill	NNP	o	OOt
exercise	NN	o	OOt
tests	NNS	o	OOt
and	CC	O	O
72-hour	JJ	o	OOt
electrocardiographic	JJ	o	OOt
recordings	NNS	o	OOt
were	VBD	O	O
obtained	VBN	O	O
at	IN	O	O
the	DT	O	O
end	NN	O	O
of	IN	O	O
two	CD	O	O
2-week	JJ	O	O
treatment	NN	O	O
periods	NNS	O	O
with	IN	O	O
sustained-release	JJ	i	IPM
diltiazem	NN	i	IPM
180	CD	O	O
mg	NN	O	O
b.i.d	NN	O	O
.	.	O	O

or	CC	O	O
equivalent	JJ	O	O
placebo	NN	i	IC
.	.	i	IC

Episodes	NNS	o	OME
of	IN	o	OME
asymptomatic	JJ	o	OME
ST	NNP	o	OME
depression	NN	o	OME
decreased	VBN	O	O
by	IN	O	O
50	CD	O	O
%	NN	O	O
or	CC	O	O
more	JJR	O	O
in	IN	O	O
70	CD	O	O
%	NN	O	O
of	IN	O	O
the	DT	O	O
patients	NNS	O	O
from	IN	O	O
a	DT	O	O
median	JJ	O	O
number	NN	O	O
of	IN	O	O
4.5	CD	O	O
(	(	O	O
range	NN	O	O
,	,	O	O
0-19	NN	O	O
)	)	O	O
to	TO	O	O
1.5	CD	O	O
(	(	O	O
range	NN	O	O
,	,	O	O
0-13	NN	O	O
)	)	O	O
(	(	O	O
p	JJ	O	O
=	NNP	O	O
0.0001	CD	O	O
)	)	O	O
;	:	O	O
their	PRP$	O	O
cumulative	JJ	o	OPH
duration	NN	o	OPH
also	RB	O	O
decreased	VBD	O	O
from	IN	O	O
78.5	CD	O	O
(	(	O	O
range	NN	O	O
,	,	O	O
0-60	NN	O	O
)	)	O	O
to	TO	O	O
24.5	CD	O	O
(	(	O	O
range	NN	O	O
,	,	O	O
0-411	NN	O	O
)	)	O	O
minutes	NNS	O	O
(	(	O	O
p	JJ	O	O
=	NNP	O	O
0.001	CD	O	O
)	)	O	O
.	.	O	O

No	DT	O	O
circadian	JJ	o	OPH
variation	NN	o	OPH
was	VBD	O	O
found	VBN	O	O
in	IN	O	O
the	DT	O	O
efficacy	NN	O	O
of	IN	O	O
diltiazem	NN	i	IPM
.	.	i	IPM

The	DT	O	O
occurrence	NN	O	O
of	IN	O	O
ischemic	JJ	o	OPH
type	NN	o	OPH
ST	NNP	o	OPH
segment	NN	o	OPH
depression	NN	o	OPH
was	VBD	O	O
modulated	VBN	O	O
by	IN	O	O
changes	NNS	o	OPH
in	IN	o	OPH
heart	NN	o	OPH
rate	NN	o	OPH
rather	RB	O	O
than	IN	O	O
by	IN	O	O
absolute	JJ	O	O
heart	NN	O	O
rate	NN	O	O
.	.	O	O

Diltiazem	NNP	i	IPM
also	RB	O	O
improved	VBD	O	O
exercise	NN	o	OPH
test	NN	o	OPH
end	NN	o	OPH
points	NNS	o	OPH
but	CC	O	O
to	TO	O	O
a	DT	O	O
lesser	JJR	O	O
extent	NN	O	O
.	.	O	O

Time	NN	o	OPH
to	TO	o	OPH
ST	NNP	o	OPH
segment	NN	o	OPH
depression	NN	o	OPH
increased	VBD	O	O
to	TO	O	O
341	CD	O	O
+/-	JJ	O	O
148	CD	O	O
from	IN	O	O
296	CD	O	O
+/-	JJ	O	O
154	CD	O	O
seconds	NNS	O	O
(	(	O	O
p	JJ	O	O
=	NNP	O	O
0.005	CD	O	O
)	)	O	O
.	.	O	O

Although	IN	O	O
less	JJR	O	O
frequent	JJ	O	O
with	IN	O	O
diltiazem	JJ	i	IPM
administration	NN	O	O
(	(	O	O
45	CD	O	O
versus	NN	O	O
54	CD	O	O
patients	NNS	O	O
,	,	O	O
p	RB	O	O
less	JJR	O	O
than	IN	O	O
0.03	CD	O	O
)	)	O	O
,	,	O	O
exercise-induced	JJ	o	OPH
ST	NNP	o	OPH
depression	NN	o	OPH
was	VBD	O	O
more	RBR	O	O
often	RB	O	O
asymptomatic	JJ	O	O
(	(	O	O
98	CD	O	O
%	NN	O	O
versus	IN	O	O
72	CD	O	O
%	NN	O	O
of	IN	O	O
patients	NNS	O	O
,	,	O	O
p	RB	O	O
less	JJR	O	O
than	IN	O	O
0.0001	CD	O	O
)	)	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
Diltiazem	NNP	i	IPM
reduces	VBZ	O	O
the	DT	O	O
frequency	NN	O	O
and	CC	O	O
severity	NN	O	O
of	IN	O	O
ischemic	JJ	o	OME
type	NN	o	OME
ST	NNP	o	OME
depression	NN	o	OME
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
stable	JJ	p	O
coronary	JJ	p	O
artery	NN	p	O
disease	NN	p	O
.	.	p	O

Transthoracic	NNP	i	IPH
versus	NN	i	O
transesophageal	NN	i	IS
cardioversion	NN	i	IS
of	IN	i	IS
atrial	JJ	i	IS
fibrillation	NN	i	IS
under	IN	i	O
light	JJ	i	O
sedation	NN	i	O
:	:	i	O
a	DT	O	O
prospective	JJ	O	O
randomized	VBN	O	O
trial	NN	O	O
.	.	O	O

BACKGROUND	NNP	O	O
Electrical	JJ	p	O
cardioversion	NN	p	O
(	(	p	O
ECV	NNP	p	O
)	)	p	O
of	IN	p	O
atrial	JJ	p	O
fibrillation	NN	p	O
(	(	p	O
AF	NNP	p	O
)	)	p	O
is	VBZ	O	O
limited	VBN	O	O
by	IN	O	O
a	DT	O	O
5-10	JJ	O	O
%	NN	O	O
failure	NN	O	O
rate	NN	O	O
and	CC	O	O
by	IN	O	O
the	DT	O	O
expense	NN	O	O
arising	VBG	O	O
from	IN	O	O
a	DT	O	O
perceived	JJ	O	O
need	NN	O	O
for	IN	O	O
general	JJ	O	O
anesthesia	NN	O	O
.	.	O	O

A	DT	O	O
transesophageal	JJ	O	O
approach	NN	O	O
using	VBG	O	O
light	JJ	O	O
sedation	NN	O	O
has	VBZ	O	O
been	VBN	O	O
proposed	VBN	O	O
as	IN	O	O
a	DT	O	O
means	NN	O	O
of	IN	O	O
augmenting	VBG	O	O
the	DT	O	O
success	NN	O	O
rate	NN	O	O
and	CC	O	O
avoiding	VBG	O	O
the	DT	O	O
need	NN	O	O
for	IN	O	O
general	JJ	O	O
anesthesia	NN	O	O
.	.	O	O

We	PRP	O	O
hypothesized	VBD	O	O
that	IN	O	O
the	DT	O	O
high	JJ	O	O
rate	NN	O	O
of	IN	O	O
success	NN	O	O
and	CC	O	O
the	DT	O	O
lower	JJR	O	O
energy	NN	O	O
requirement	NN	O	O
associated	VBN	O	O
with	IN	O	O
biphasic	JJ	O	O
cardioversion	NN	O	O
might	MD	O	O
eliminate	VB	O	O
any	DT	O	O
advantage	NN	O	O
of	IN	O	O
the	DT	O	O
transesophageal	JJ	O	O
approach	NN	O	O
.	.	O	O

METHODS	NNP	O	O
We	PRP	O	O
randomly	VBP	O	O
assigned	VBD	O	O
60	CD	p	O
patients	NNS	p	O
attending	VBG	p	O
for	IN	p	O
ECV	NNP	i	O
of	IN	i	O
persistent	JJ	i	O
AF	NNP	i	O
to	TO	i	O
a	DT	i	O
transesophageal	NN	i	IS
or	CC	i	O
a	DT	i	O
transthoracic	JJ	i	IPH
approach	NN	i	IPH
.	.	i	O

Sedation	NN	O	O
of	IN	O	O
moderate	JJ	O	O
depth	NN	O	O
was	VBD	O	O
achieved	VBN	O	O
with	IN	O	O
intravenous	JJ	i	IPM
midazolam	NNS	i	IPM
.	.	i	O

The	DT	O	O
dose	NN	O	O
of	IN	O	O
midazolam	NN	O	O
was	VBD	O	O
titrated	VBN	O	O
in	IN	O	O
the	DT	O	O
same	JJ	O	O
manner	NN	O	O
in	IN	O	O
both	DT	O	O
groups	NNS	O	O
.	.	O	O

RESULTS	NNP	O	O
Sinus	NNP	o	OPH
rhythm	NN	o	OPH
was	VBD	O	O
restored	VBN	O	O
in	IN	O	O
29/30	CD	O	O
patients	NNS	O	O
(	(	O	O
97	CD	O	O
%	NN	O	O
)	)	O	O
in	IN	O	O
each	DT	O	O
group	NN	O	O
using	VBG	O	O
a	DT	O	O
similar	JJ	O	O
number	NN	O	O
of	IN	O	O
shocks	NNS	O	O
for	IN	O	O
both	DT	O	O
groups	NNS	O	O
(	(	O	O
1.3	CD	O	O
+/-	JJ	O	O
0.6	CD	O	O
transesophageal	NN	O	O
vs	NN	O	O
1.4	CD	O	O
+/-	JJ	O	O
0.7	CD	O	O
transthoracic	NN	O	O
,	,	O	O
P	NNP	O	O
=	NNP	O	O
NS	NNP	O	O
)	)	O	O
with	IN	O	O
a	DT	O	O
similar	JJ	O	O
procedure	NN	O	O
duration	NN	O	O
(	(	O	O
14.1	CD	O	O
+/-	JJ	O	O
8.2	CD	O	O
minutes	NNS	O	O
vs	JJ	O	O
13.8	CD	O	O
+/-	JJ	O	O
7.5	CD	O	O
minutes	NNS	O	O
,	,	O	O
P	NNP	O	O
=	NNP	O	O
NS	NNP	O	O
)	)	O	O
.	.	O	O

Both	DT	O	O
groups	NNS	O	O
received	VBD	O	O
similar	JJ	O	O
doses	NNS	O	O
of	IN	O	O
midazolam	NN	O	O
(	(	O	O
4.2	CD	O	O
+/-	JJ	O	O
2.7	CD	O	O
mg	NN	O	O
vs	NN	O	O
4.4	CD	O	O
+/-	JJ	O	O
2.8	CD	O	O
mg	NN	O	O
,	,	O	O
P	NNP	O	O
=	NNP	O	O
NS	NNP	O	O
)	)	O	O
and	CC	O	O
both	DT	O	O
reported	VBD	O	O
a	DT	O	O
similar	JJ	O	O
discomfort	NN	o	OPA
score	NN	o	OPA
in	IN	O	O
(	(	O	O
0.9	CD	O	O
+/-	JJ	O	O
1.3	CD	O	O
vs	JJ	O	O
1.1	CD	O	O
+/-	JJ	O	O
1.8	CD	O	O
,	,	O	O
P	NNP	O	O
=	NNP	O	O
NS	NNP	O	O
)	)	O	O
.	.	O	O

No	DT	O	O
complication	NN	o	OA
occurred	VBD	O	O
in	IN	O	O
either	DT	O	O
group	NN	O	O
.	.	O	O

CONCLUSION	NNP	O	O
AF	NNP	O	O
may	MD	O	O
be	VB	O	O
cardioverted	VBN	O	O
safely	RB	o	OOt
and	CC	o	OOt
effectively	RB	o	OOt
by	IN	O	O
either	CC	O	O
a	DT	O	O
transthoracic	NN	O	O
or	CC	O	O
a	DT	O	O
transesophageal	JJ	O	O
approach	NN	O	O
.	.	O	O

The	DT	O	O
use	NN	O	O
of	IN	O	O
sedation	NN	O	O
of	IN	O	O
moderate	JJ	O	O
depth	NN	O	O
renders	NNS	O	O
cardioversion	NN	O	O
by	IN	O	O
either	DT	O	O
approach	NN	O	O
acceptable	JJ	O	O
.	.	O	O

As	IN	O	O
transesophageal	NN	O	O
ECV	NNP	O	O
shows	VBZ	O	O
no	DT	O	O
clear	JJ	O	O
advantage	NN	O	O
,	,	O	O
transthoracic	JJ	O	O
cardioversion	NN	O	O
should	MD	O	O
remain	VB	O	O
the	DT	O	O
approach	NN	O	O
of	IN	O	O
first	JJ	O	O
choice	NN	O	O
.	.	O	O

Five-year	JJ	O	O
outcome	NN	O	O
of	IN	O	O
surgical	JJ	O	O
treatment	NN	O	O
of	IN	O	O
migraine	NN	o	OPA
headaches	NNS	o	OPA
.	.	o	OPH

BACKGROUND	NNP	O	O
This	DT	O	O
study	NN	O	O
was	VBD	O	O
designed	VBN	O	O
to	TO	O	O
assess	VB	O	O
the	DT	O	O
long-term	JJ	O	O
efficacy	NN	O	O
of	IN	O	O
surgical	JJ	O	O
deactivation	NN	O	O
of	IN	O	O
migraine	NN	o	OPH
headache	NN	o	OPH
trigger	NN	O	O
sites	NNS	O	O
.	.	O	O

METHODS	NNP	O	O
One	CD	p	PSS
hundred	VBD	p	PSS
twenty-five	JJ	p	PSS
volunteers	NNS	p	O
were	VBD	p	O
randomly	RB	p	O
assigned	VBN	p	O
to	TO	p	O
the	DT	p	O
treatment	NN	p	PSS
(	(	p	PSS
n	JJ	p	PSS
=	NNP	p	PSS
100	CD	p	PSS
)	)	p	PSS
or	CC	p	O
control	VB	p	PSS
group	NN	p	PSS
(	(	p	PSS
n	JJ	p	PSS
=	NNP	p	PSS
25	CD	p	PSS
)	)	p	PSS
after	IN	p	O
examination	NN	p	O
by	IN	p	O
the	DT	p	O
team	NN	p	O
neurologist	NN	p	O
to	TO	p	O
ensure	VB	p	O
a	DT	p	O
diagnosis	NN	p	O
of	IN	p	O
migraine	NN	o	OPA
headache	NN	o	OPA
.	.	o	O

Patients	NNS	O	O
were	VBD	O	O
asked	VBN	O	O
to	TO	O	O
complete	VB	O	O
the	DT	O	O
Medical	NNP	o	OPH
Outcomes	NNP	o	OPH
Study	NNP	o	OPH
36-Item	JJ	o	OPH
Short	NNP	o	OPH
Form	NNP	o	OPH
Health	NNP	o	OPH
Survey	NNP	o	OPH
,	,	o	O
Migraine-Specific	NNP	o	OOt
Quality	NNP	o	OOt
of	IN	o	OOt
Life	NNP	o	OOt
,	,	o	O
and	CC	o	O
Migraine	NNP	o	OPH
Disability	NNP	o	OPH
Assessment	NNP	o	OPH
questionnaires	VBZ	o	OPH
before	IN	O	O
treatment	NN	O	O
and	CC	O	O
at	IN	O	O
12-	JJ	O	O
and	CC	O	O
60-month	JJ	O	O
postoperative	JJ	O	O
follow-up	NN	O	O
.	.	O	O

The	DT	O	O
treatment	NN	O	O
group	NN	O	O
received	VBD	O	O
botulinum	RB	i	IPM
toxin	NN	i	IPM
to	TO	O	O
confirm	VB	O	O
the	DT	O	O
trigger	NN	O	O
sites	VBZ	O	O
;	:	O	O
controls	NNS	O	O
received	VBD	O	O
saline	JJ	i	IC
injections	NNS	i	IC
.	.	i	IC

Treated	VBN	O	O
patients	NNS	O	O
underwent	JJ	O	O
surgical	JJ	i	IPM
deactivation	NN	i	IPM
of	IN	O	O
trigger	NN	O	O
site	NN	O	O
(	(	O	O
s	JJ	O	O
)	)	O	O
.	.	O	O

Results	NNS	O	O
were	VBD	O	O
analyzed	VBN	O	O
at	IN	O	O
1	CD	O	O
year	NN	O	O
(	(	O	O
previously	RB	O	O
published	VBN	O	O
)	)	O	O
and	CC	O	O
5	CD	O	O
years	NNS	O	O
postoperatively	RB	O	O
(	(	O	O
the	DT	O	O
subject	NN	O	O
of	IN	O	O
this	DT	O	O
report	NN	O	O
)	)	O	O
.	.	O	O

RESULTS	JJ	O	O
Eighty-nine	NNP	O	O
of	IN	O	O
100	CD	p	PSS
patients	NNS	p	O
in	IN	p	O
the	DT	p	O
treatment	NN	p	O
group	NN	p	O
underwent	JJ	O	O
surgery	NN	O	O
,	,	O	O
and	CC	O	O
79	CD	O	O
were	VBD	O	O
followed	VBN	O	O
for	IN	O	O
5	CD	O	O
years	NNS	O	O
.	.	O	O

Ten	CD	O	O
patients	NNS	O	O
underwent	JJ	O	O
deactivation	NN	i	IE
of	IN	O	O
additional	JJ	O	O
(	(	O	O
different	JJ	O	O
)	)	O	O
trigger	NN	O	O
sites	NNS	O	O
during	IN	O	O
the	DT	O	O
follow-up	JJ	O	O
period	NN	O	O
and	CC	O	O
were	VBD	O	O
not	RB	O	O
included	VBN	O	O
in	IN	O	O
the	DT	O	O
data	NN	O	O
analysis	NN	O	O
.	.	O	O

The	DT	O	O
final	JJ	O	O
outcome	NN	O	O
with	IN	O	O
or	CC	O	O
without	IN	O	O
inclusion	NN	O	O
of	IN	O	O
these	DT	O	O
10	CD	O	O
patients	NNS	O	O
was	VBD	O	O
not	RB	O	O
statistically	RB	O	O
different	JJ	O	O
.	.	O	O

Sixty-one	NN	O	O
(	(	O	O
88	CD	O	O
percent	NN	O	O
)	)	O	O
of	IN	O	O
69	CD	O	O
patients	NNS	O	O
have	VBP	O	O
experienced	VBN	O	O
a	DT	O	O
positive	JJ	o	OPH
response	NN	o	OPH
to	TO	O	O
the	DT	O	O
surgery	NN	O	O
after	IN	O	O
5	CD	O	O
years	NNS	O	O
.	.	O	O

Twenty	NNP	O	O
(	(	O	O
29	CD	O	O
percent	NN	O	O
)	)	O	O
reported	VBD	O	O
complete	JJ	o	OOt
elimination	NN	o	OOt
of	IN	o	OOt
migraine	NN	o	OOt
headache	NN	o	OOt
,	,	O	O
41	CD	O	O
(	(	O	O
59	CD	O	O
percent	NN	O	O
)	)	O	O
noticed	VBD	O	O
a	DT	O	O
significant	JJ	O	O
decrease	NN	O	O
,	,	O	O
and	CC	O	O
eight	CD	O	O
(	(	O	O
12	CD	O	O
percent	NN	O	O
)	)	O	O
experienced	VBD	O	O
no	DT	O	O
significant	JJ	O	O
change	NN	O	O
.	.	O	O

When	WRB	O	O
compared	VBN	O	O
with	IN	O	O
the	DT	O	O
baseline	NN	O	O
values	NNS	O	O
,	,	O	O
all	DT	O	O
measured	VBD	O	O
variables	NNS	O	O
at	IN	O	O
60	CD	O	O
months	NNS	O	O
improved	VBN	O	O
significantly	RB	O	O
(	(	O	O
p	JJ	O	O
<	NNP	O	O
0.0001	CD	O	O
)	)	O	O
.	.	O	O

CONCLUSION	NNP	O	O
Based	VBD	O	O
on	IN	O	O
the	DT	O	O
5-year	JJ	O	O
follow-up	JJ	O	O
data	NNS	O	O
,	,	O	O
there	EX	O	O
is	VBZ	O	O
strong	JJ	O	O
evidence	NN	O	O
that	IN	O	O
surgical	JJ	O	O
manipulation	NN	O	O
of	IN	O	O
one	CD	O	O
or	CC	O	O
more	JJR	O	O
migraine	JJ	O	O
trigger	NN	O	O
sites	NNS	O	O
can	MD	O	O
successfully	RB	O	O
eliminate	VB	o	OOt
or	CC	o	OOt
reduce	VB	o	OOt
the	DT	o	OOt
frequency	NN	o	OOt
,	,	o	OOt
duration	NN	o	OOt
,	,	o	OOt
and	CC	o	OOt
intensity	NN	o	OOt
of	IN	o	OOt
migraine	NN	o	OOt
headache	NN	o	OOt
in	IN	O	O
a	DT	O	O
lasting	JJ	O	O
manner	NN	O	O
.	.	O	O

Comparison	NNP	O	O
of	IN	O	O
inhaled	JJ	i	IPM
albuterol	NN	i	IPM
powder	NN	i	IPM
and	CC	i	IPM
aerosol	NN	i	IPM
in	IN	O	O
asthma	NN	p	PC
.	.	p	O

In	IN	O	O
this	DT	O	O
multicenter	NN	O	O
,	,	O	O
randomized	VBN	O	O
,	,	O	O
double-blind	JJ	O	O
study	NN	O	O
comparing	VBG	O	O
the	DT	O	O
efficacy	NN	O	O
and	CC	O	O
safety	NN	O	O
of	IN	O	O
aerosolized	JJ	i	IPM
albuterol	NN	i	IPM
with	IN	i	IPM
the	DT	i	IPM
dry	JJ	i	IPM
powder	NN	i	IPM
formulation	NN	i	IPM
,	,	O	O
231	CD	p	PSS
patients	NNS	p	O
with	IN	p	O
chronic	JJ	p	PC
reversible	JJ	p	PC
obstructive	JJ	p	PC
airway	NN	p	PC
disease	NN	p	PC
were	VBD	O	O
randomly	RB	O	O
allocated	VBN	O	O
to	TO	O	O
receive	VB	O	O
either	DT	O	O
placebo	NN	i	IPM
albuterol	NN	i	IPM
aerosol	NN	i	IPM
followed	VBD	O	O
immediately	RB	O	O
by	IN	O	O
active	JJ	i	IPM
albuterol	NN	i	IPM
powder	NN	i	IPM
(	(	O	O
200	CD	O	O
micrograms	NNS	O	O
)	)	O	O
or	CC	O	O
active	JJ	i	IPM
albuterol	NN	i	IPM
aerosol	NN	i	IPM
(	(	O	O
two	CD	O	O
puffs	NNS	O	O
,	,	O	O
180	CD	O	O
micrograms	NNS	O	O
)	)	O	O
followed	VBD	O	O
immediately	RB	O	O
by	IN	O	O
placebo	NN	i	IPM
lactose	JJ	i	IPM
powder	NN	i	IPM
four	CD	O	O
times	NNS	O	O
a	DT	O	O
day	NN	O	O
for	IN	O	O
a	DT	O	O
period	NN	O	O
of	IN	O	O
12	CD	O	O
weeks	NNS	O	O
.	.	O	O

No	DT	O	O
statistically	RB	O	O
significant	JJ	O	O
differences	NNS	O	O
were	VBD	O	O
found	VBN	O	O
between	IN	O	O
the	DT	O	O
powder	NN	i	IPM
and	CC	O	O
aerosol	JJ	i	IPM
formulations	NNS	O	O
with	IN	O	O
respect	NN	O	O
to	TO	O	O
pulmonary	JJ	o	OPH
function	NN	o	OPH
,	,	o	O
length	NN	o	OPH
of	IN	o	OPH
time	NN	o	OPH
mean	JJ	o	OPH
FEV1	NNP	o	OPH
remained	VBD	O	O
greater	JJR	O	O
than	IN	O	O
or	CC	O	O
equal	JJ	O	O
to	TO	O	O
15	CD	O	O
%	NN	O	O
above	IN	O	O
baseline	NN	O	O
,	,	O	O
physicians	NNS	o	OPH
'	POS	o	OPH
assessments	NNS	o	OPH
of	IN	o	OPH
patients	NNS	o	OPH
'	POS	o	OPH
clinical	JJ	o	OPH
response	NN	o	OPH
,	,	O	O
or	CC	O	O
patients	NNS	o	OOt
'	POS	o	OOt
subjective	JJ	o	OOt
symptom	NN	o	OOt
scores	NNS	o	OOt
.	.	o	O

There	EX	O	O
were	VBD	O	O
also	RB	O	O
no	DT	O	O
significant	JJ	O	O
differences	NNS	O	O
between	IN	O	O
treatment	NN	O	O
groups	NNS	O	O
in	IN	O	O
cardiovascular	JJ	o	OPH
effects	NNS	o	OPH
,	,	o	O
laboratory	NN	o	OPH
values	NNS	o	OPH
,	,	o	O
or	CC	o	O
adverse	JJ	o	OA
events	NNS	o	OA
.	.	o	O

Among	IN	O	O
patients	NNS	O	O
who	WP	O	O
expressed	VBD	O	O
a	DT	O	O
preference	NN	o	OOt
for	IN	o	OOt
one	CD	o	OOt
of	IN	o	OOt
the	DT	o	OOt
delivery	NN	o	OOt
systems	NNS	o	OOt
,	,	O	O
half	NN	p	PSS
preferred	VBD	p	O
using	VBG	p	O
the	DT	p	O
powder	NN	p	O
.	.	p	O

Results	NNS	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
demonstrate	NN	O	O
that	IN	O	O
200	CD	O	O
micrograms	NNS	O	O
of	IN	O	O
albuterol	NN	i	IPM
powder	NN	i	IPM
is	VBZ	O	O
as	IN	O	O
safe	JJ	O	O
and	CC	O	O
effective	JJ	O	O
as	IN	O	O
180	CD	O	O
micrograms	NNS	O	O
of	IN	O	O
albuterol	NN	i	IPM
aerosol	NN	i	IPM
.	.	i	O

Teaching	VBG	O	O
picture-to-object	JJ	O	O
relations	NNS	O	O
in	IN	O	O
picture-based	JJ	O	O
requesting	NN	O	O
by	IN	O	O
children	NNS	p	PA
with	IN	p	O
autism	NN	p	PC
:	:	p	O
a	DT	O	O
comparison	NN	o	O
between	IN	O	O
error	NN	i	IE
prevention	NN	i	IE
and	CC	O	O
error	NN	i	IE
correction	NN	i	IE
teaching	NN	i	IE
procedures	NNS	i	IE
.	.	i	IE

BACKGROUND	NNP	O	O
Children	NNP	p	PA
who	WP	p	O
have	VBP	p	O
a	DT	p	O
combination	NN	p	O
of	IN	p	O
language	NN	p	PC
and	CC	p	PC
developmental	JJ	p	PC
disabilities	NNS	p	PC
with	IN	p	O
autism	NN	p	PC
often	RB	O	O
experience	JJ	O	O
major	JJ	O	O
difficulties	NNS	O	O
in	IN	O	O
learning	VBG	O	O
relations	NNS	O	O
between	IN	O	O
objects	NNS	O	O
and	CC	O	O
their	PRP$	O	O
graphic	JJ	O	O
representations	NNS	O	O
.	.	O	O

Therefore	RB	O	O
,	,	O	O
they	PRP	O	O
would	MD	O	O
benefit	VB	O	O
from	IN	O	O
teaching	VBG	i	IE
procedures	NNS	i	IE
that	WDT	O	O
minimize	VBP	O	O
their	PRP$	O	O
difficulties	NNS	O	O
in	IN	O	O
acquiring	VBG	O	O
these	DT	O	O
relations	NNS	O	O
.	.	O	O

This	DT	O	O
study	NN	O	O
compared	VBN	O	O
two	CD	O	O
teaching	NN	i	IE
procedures	NNS	i	IE
,	,	i	IE
an	DT	i	IE
error	NN	i	IE
prevention	NN	i	IE
procedure	NN	i	IE
and	CC	i	IE
an	DT	i	IE
error	NN	i	IE
correction	NN	i	IE
procedure	NN	i	IE
,	,	i	IE
for	IN	i	IE
teaching	VBG	i	IE
relations	NNS	i	IE
between	IN	i	IE
objects	NNS	i	IE
and	CC	i	IE
pictures	NNS	i	IE
.	.	i	IE

METHOD	JJ	O	O
Participants	NNS	p	O
were	VBD	p	O
two	CD	p	O
groups	NNS	p	O
of	IN	p	O
children	NNS	p	PA
with	IN	p	O
autism	NN	p	PC
,	,	p	O
aged	VBD	p	O
between	IN	p	O
3	CD	p	PA
and	CC	p	O
7	CD	p	PA
years	NNS	p	O
.	.	p	O

In	IN	O	O
the	DT	O	O
context	NN	O	O
of	IN	O	O
picture-to-object	JJ	O	O
requesting	NN	O	O
,	,	O	O
one	CD	O	O
group	NN	O	O
was	VBD	O	O
taught	VBN	O	O
using	VBG	O	O
an	DT	i	IE
error	NN	i	IE
correction	NN	i	IE
method	NN	i	IE
and	CC	O	O
the	DT	O	O
other	JJ	O	O
group	NN	O	O
with	IN	O	O
an	DT	i	IE
error	NN	i	IE
prevention	NN	i	IE
method	NN	i	IE
.	.	i	IE

The	DT	O	O
measures	NNS	O	O
for	IN	O	O
each	DT	O	O
child	NN	O	O
were	VBD	O	O
accuracy	NN	o	OOt
of	IN	o	OOt
correspondences	NNS	o	OOt
between	IN	o	OOt
taught	JJ	o	OOt
picture	NN	o	OOt
and	CC	o	OOt
object	JJ	o	OOt
pairs	NNS	o	OOt
and	CC	o	OOt
accuracy	NN	o	OOt
of	IN	o	OOt
delayed	JJ	o	OOt
correspondences	NNS	o	OOt
in	IN	o	OOt
learning	VBG	o	OOt
outcome	JJ	o	OOt
tests	NNS	o	OOt
with	IN	o	O
all	DT	o	O
combinations	NNS	o	O
of	IN	o	O
object	NN	o	O
and	CC	o	O
picture	NN	o	O
pairs	NNS	o	O
presented	VBN	o	O
to	TO	O	O
them	PRP	O	O
throughout	IN	O	O
the	DT	O	O
study	NN	O	O
.	.	O	O

RESULTS	NNP	O	O
The	DT	O	O
group	NN	O	O
receiving	VBG	O	O
the	DT	O	O
error	NN	O	O
prevention-based	JJ	i	IE
teaching	NN	i	IE
made	VBN	O	O
significantly	RB	O	O
fewer	JJR	O	O
errors	NNS	o	OOt
during	IN	O	O
the	DT	O	O
teaching	NN	O	O
phases	NNS	O	O
and	CC	O	O
in	IN	O	O
their	PRP$	O	O
learning	NN	O	O
outcome	NN	O	O
test	NN	O	O
for	IN	O	O
correspondences	NNS	O	O
between	IN	O	O
all	DT	O	O
combinations	NNS	O	O
of	IN	O	O
pictures	NNS	O	O
and	CC	O	O
objects	NNS	O	O
.	.	O	O

CONCLUSIONS	VB	O	O
The	DT	O	O
error	NN	O	O
prevention	NN	i	IE
teaching	NN	i	IE
procedure	NN	i	IE
would	MD	O	O
seem	VB	O	O
to	TO	O	O
provide	VB	O	O
a	DT	O	O
more	RBR	O	O
efficient	JJ	O	O
and	CC	O	O
ecologically	RB	O	O
valid	JJ	O	O
method	NN	O	O
than	IN	O	O
the	DT	O	O
error	NN	O	O
correction	NN	O	O
procedure	NN	O	O
for	IN	O	O
teaching	VBG	O	O
relations	NNS	O	O
between	IN	O	O
objects	NNS	O	O
and	CC	O	O
their	PRP$	O	O
graphic-based	JJ	O	O
referents	NNS	O	O
.	.	O	O

Improvements	NNS	O	O
in	IN	O	O
the	DT	O	O
methodology	NN	O	O
were	VBD	O	O
suggested	VBN	O	O
for	IN	O	O
providing	VBG	O	O
a	DT	O	O
stronger	JJR	O	O
basis	NN	O	O
for	IN	O	O
comparison	NN	O	O
between	IN	O	O
error	NN	O	O
correction	NN	O	O
and	CC	O	O
error	NN	O	O
prevention	NN	O	O
teaching	VBG	O	O
methods	NNS	O	O
.	.	O	O

Blood	NNP	o	OPH
pressure	NN	o	OPH
biofeedback	NN	i	IPS
treatment	NN	i	IPS
of	IN	O	O
white-coat	JJ	O	O
hypertension	NN	O	O
.	.	O	O

OBJECTIVE	CC	O	O
The	DT	O	O
objective	NN	O	O
of	IN	O	O
the	DT	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
compare	VB	O	O
blood	NN	o	OPH
pressure	NN	o	OPH
(	(	o	OPH
BP	NNP	o	OPH
)	)	o	OPH
biofeedback	NN	i	IPS
treatment	NN	i	IPS
(	(	i	IPS
BF	NNP	i	IPS
)	)	i	IPS
effects	NNS	O	O
between	IN	O	O
white-coat	JJ	O	O
hypertension	NN	O	O
and	CC	O	O
essential	JJ	O	O
hypertension	NN	O	O
.	.	O	O

METHODS	NNP	O	O
Fifteen	NNP	p	PSS
white-coat	JJ	p	PC
hypertensive	JJ	p	PC
out-patients	NNS	p	O
and	CC	p	O
23	CD	p	PSS
essential	JJ	p	PC
hypertensive	JJ	p	PC
out-patients	NNS	p	O
were	VBD	O	O
randomly	RB	O	O
assigned	VBN	O	O
to	TO	O	O
groups	NNS	O	O
A	NNP	O	O
or	CC	O	O
B	NNP	O	O
.	.	O	O

Subjects	NNS	O	O
in	IN	O	O
group	NN	O	O
A	NNP	O	O
underwent	NN	O	O
BF	NNP	i	IPS
once	RB	O	O
a	DT	O	O
week	NN	O	O
for	IN	O	O
a	DT	O	O
total	NN	O	O
of	IN	O	O
four	CD	O	O
sessions	NNS	O	O
.	.	O	O

Those	DT	O	O
in	IN	O	O
group	NN	i	O
B	NNP	i	O
visited	VBD	i	IOt
the	DT	i	IOt
clinic	NN	i	IOt
only	RB	i	O
to	TO	O	O
measure	VB	O	O
BP	NNP	o	OPH
and	CC	O	O
later	RB	O	O
underwent	VBD	O	O
the	DT	O	O
same	JJ	O	O
BF	NNP	i	IOt
.	.	i	O

RESULTS	NNP	O	O
In	IN	O	O
group	NN	O	O
A	NNP	O	O
,	,	O	O
BPs	NNP	o	OPH
of	IN	o	OPH
white-coat	JJ	o	OPH
hypertensives	NNS	o	OPH
and	CC	o	OPH
essential	JJ	o	OPH
hypertensives	NNS	o	OPH
were	VBD	O	O
significantly	RB	O	O
reduced	VBN	O	O
by	IN	O	O
22/11	CD	O	O
and	CC	O	O
14/8	CD	O	O
mmHg	NN	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

In	IN	O	O
group	NN	O	O
B	NNP	O	O
,	,	O	O
they	PRP	O	O
were	VBD	O	O
unchanged	JJ	O	O
during	IN	O	O
the	DT	O	O
same	JJ	O	O
period	NN	O	O
but	CC	O	O
later	RB	O	O
suppressed	VBN	O	O
by	IN	O	O
BF	NNP	i	IOt
.	.	i	O

Under	IN	O	O
BF	NNP	i	O
,	,	O	O
pulse	NN	o	OPH
and	CC	o	O
respiratory	NN	o	OPH
rates	NNS	o	OPH
were	VBD	O	O
significantly	RB	O	O
higher	JJR	O	O
,	,	O	O
and	CC	O	O
elevation	NN	o	OPH
of	IN	o	OPH
diastolic	JJ	o	OPH
BP	NNP	o	OPH
due	JJ	o	OPH
to	TO	o	OPH
mental	JJ	o	OPH
stress	NN	o	OPH
testing	NN	o	OPH
was	VBD	O	O
better	RBR	O	O
suppressed	VBN	O	O
in	IN	O	O
white-coat	NN	O	O
hypertensives	NNS	O	O
than	IN	O	O
in	IN	O	O
essential	JJ	O	O
hypertensives	NNS	O	O
.	.	O	O

CONCLUSION	VB	O	O
This	DT	O	O
treatment	NN	O	O
was	VBD	O	O
effective	JJ	O	O
in	IN	O	O
both	DT	O	O
types	NNS	O	O
of	IN	O	O
hypertension	NN	O	O
,	,	O	O
and	CC	O	O
pressor	NN	O	O
response	NN	O	O
to	TO	O	O
stress	VB	o	OPH
seems	VBZ	O	O
to	TO	O	O
be	VB	O	O
important	JJ	O	O
in	IN	O	O
the	DT	O	O
differentiated	JJ	O	O
BF	NNP	i	IOt
effect	NN	O	O
.	.	O	O

Measurement	NN	O	O
of	IN	O	O
health-related	JJ	o	OPH
quality	NN	o	OPH
of	IN	o	OPH
life	NN	o	OPH
in	IN	O	O
multiple	JJ	p	PC
myeloma	NN	p	PC
.	.	p	O

Nordic	NNP	O	O
Myeloma	NNP	O	O
Study	NNP	O	O
Group	NNP	O	O
.	.	O	O

When	WRB	O	O
a	DT	O	O
randomized	VBN	O	O
trial	NN	O	O
(	(	O	O
NMSG	NNP	O	O
4/90	CD	O	O
)	)	O	O
comparing	VBG	O	O
treatment	NN	O	O
with	IN	O	O
melphalan/prednisone	NN	i	IPM
to	TO	O	O
melphalan/	VB	i	IPM
prednisone	NN	i	IPM
+	NNP	i	IPM
interferon	VBZ	i	IPM
alpha-2b	NN	i	IPM
in	IN	O	O
newly	RB	p	O
diagnosed	VBN	p	O
multiple	JJ	p	PC
myeloma	NN	p	PC
was	VBD	O	O
initiated	VBN	O	O
in	IN	O	O
1990	CD	O	O
,	,	O	O
a	DT	O	O
quality-of-life	JJ	o	OOt
assessment	NN	o	OPH
was	VBD	O	O
integrated	VBN	O	O
into	IN	O	O
the	DT	O	O
study	NN	O	O
.	.	O	O

We	PRP	O	O
used	VBD	O	O
the	DT	O	O
questionnaire	NN	O	O
(	(	O	O
QLQ-C30	NNP	O	O
)	)	O	O
developed	VBN	O	O
by	IN	O	O
the	DT	O	O
European	JJ	O	O
Organization	NNP	O	O
of	IN	O	O
Research	NNP	O	O
and	CC	O	O
Treatment	NNP	O	O
of	IN	O	O
Cancer	NNP	O	O
(	(	O	O
EORTC	NNP	O	O
)	)	O	O
Study	NNP	O	O
Group	NNP	O	O
on	IN	O	O
Quality	NNP	o	OPH
of	IN	o	OPH
Life	NNP	o	OPH
.	.	o	O

The	DT	O	O
QLQ-C30	JJ	O	O
incorporates	NNS	O	O
five	CD	O	O
functional	JJ	O	O
scales	NNS	O	O
,	,	O	O
three	CD	O	O
symptom	NN	O	O
scales	NNS	O	O
,	,	O	O
a	DT	O	O
global	JJ	O	O
health	NN	O	O
and	CC	O	O
quality-of	JJ	o	OOt
life	NN	o	OOt
scale	NN	o	OOt
and	CC	O	O
some	DT	O	O
single	JJ	O	O
symptom	NN	O	O
measures	NNS	O	O
.	.	O	O

The	DT	O	O
questionnaire	NN	O	O
was	VBD	O	O
completed	VBN	O	O
prior	JJ	O	O
to	TO	O	O
treatment	NN	O	O
and	CC	O	O
after	IN	O	O
1	CD	O	O
,	,	O	O
6	CD	O	O
,	,	O	O
12	CD	O	O
,	,	O	O
24	CD	O	O
,	,	O	O
36	CD	O	O
and	CC	O	O
48	CD	O	O
months	NNS	O	O
.	.	O	O

524	CD	p	PSS
(	(	p	O
90.2	CD	p	O
%	NN	p	O
)	)	p	O
of	IN	p	O
581	CD	p	PSS
patients	NNS	p	O
enrolled	VBN	p	O
in	IN	p	O
the	DT	p	O
NMSG	NNP	p	O
4/90	CD	p	O
completed	VBD	p	O
the	DT	p	O
first	JJ	p	O
questionnaire	NN	p	O
,	,	p	O
and	CC	p	O
484	CD	p	PSS
(	(	p	O
83.3	CD	p	O
%	NN	p	O
)	)	p	O
completed	VBD	p	O
all	DT	p	O
questionnaires	NNS	p	O
given	VBN	p	O
to	TO	p	O
them	PRP	p	O
.	.	p	O

All	DT	O	O
but	CC	O	O
one	CD	O	O
of	IN	O	O
the	DT	O	O
scales	NNS	O	O
met	VBD	O	O
the	DT	O	O
minimum	JJ	O	O
criteria	NNS	O	O
of	IN	O	O
reliability	NN	O	O
(	(	O	O
Cronbach	NNP	O	O
's	POS	O	O
alpha	NN	O	O
>	NNP	O	O
/	NNP	O	O
0.70	CD	O	O
)	)	O	O
.	.	O	O

Validity	NNP	O	O
was	VBD	O	O
shown	VBN	O	O
by	IN	O	O
(	(	O	O
1	CD	O	O
)	)	O	O
the	DT	O	O
ability	NN	O	O
of	IN	O	O
the	DT	O	O
scales	NNS	O	O
to	TO	O	O
discriminate	VB	O	O
clearly	RB	O	O
between	IN	O	O
patients	NNS	O	O
differing	VBG	O	O
in	IN	O	O
clinical	JJ	O	O
status	NN	O	O
as	IN	O	O
defined	VBN	O	O
by	IN	O	O
pretreatment	NN	O	O
W.H.O	NNP	O	O
.	.	O	O

performance	NN	O	O
index	NN	O	O
and	CC	O	O
Durie	NNP	O	O
&	CC	O	O
Salmon	NNP	O	O
stage	NN	O	O
,	,	O	O
and	CC	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
the	DT	O	O
sensitivity	NN	O	O
to	TO	O	O
changes	NNS	O	O
in	IN	O	O
objective	JJ	O	O
disease	NN	O	O
status	NN	O	O
(	(	O	O
response	NN	O	O
and	CC	O	O
relapse	NN	O	O
)	)	O	O
.	.	O	O

This	DT	O	O
is	VBZ	O	O
the	DT	O	O
first	JJ	O	O
report	NN	O	O
of	IN	O	O
the	DT	O	O
measurement	NN	O	O
of	IN	O	O
health-related	JJ	o	OOt
quality	NN	o	OOt
of	IN	o	OOt
life	NN	o	OOt
in	IN	O	O
a	DT	O	O
prospective	JJ	O	O
clinical	JJ	O	O
trial	NN	O	O
in	IN	O	O
multiple	JJ	O	O
myeloma	NN	O	O
.	.	O	O

The	DT	o	O
results	NNS	o	O
demonstrate	VBP	o	O
that	IN	o	O
the	DT	o	O
QLQ-C30	NNP	o	OOt
is	VBZ	o	O
a	DT	o	O
reliable	JJ	o	O
and	CC	o	O
valid	JJ	o	O
instrument	NN	o	O
for	IN	o	O
the	DT	o	O
measurement	NN	o	O
of	IN	o	O
quality	NN	o	OOt
of	IN	o	OOt
life	NN	o	OOt
in	IN	o	O
these	DT	o	O
patients	NNS	o	O
.	.	o	O

The	DT	O	O
data	NN	O	O
will	MD	O	O
be	VB	O	O
used	VBN	O	O
for	IN	O	O
a	DT	O	O
cost-utility	JJ	O	O
analysis	NN	O	O
of	IN	O	O
the	DT	O	O
results	NNS	O	O
of	IN	O	O
the	DT	O	O
NMSG	NNP	O	O
4/90	CD	O	O
trial	NN	O	O
.	.	O	O

Early	JJ	O	O
treatment	NN	O	O
of	IN	O	O
cold	JJ	O	O
sores	NNS	O	O
with	IN	O	O
topical	JJ	O	O
ME-609	NNP	i	IPM
decreases	VBZ	O	O
the	DT	O	O
frequency	NN	o	OPH
of	IN	o	OPH
ulcerative	JJ	o	OPH
lesions	NNS	o	OPH
:	:	o	OPH
a	DT	O	O
randomized	JJ	O	O
,	,	O	O
double-blind	JJ	O	O
,	,	O	O
placebo-controlled	JJ	O	O
,	,	O	O
patient-initiated	JJ	O	O
clinical	JJ	O	O
trial	NN	O	O
.	.	O	O

BACKGROUND	NNP	O	O
Prior	NNP	O	O
pilot	NN	O	O
studies	NNS	O	O
support	VBP	O	O
the	DT	O	O
use	NN	O	O
of	IN	O	O
antiviral	JJ	O	O
medications	NNS	O	O
with	IN	O	O
topical	JJ	O	O
corticosteroids	NNS	O	O
for	IN	O	O
herpes	NNS	p	PC
simplex	JJ	p	PC
labialis	NN	p	PC
(	(	p	O
HSL	NNP	p	O
)	)	p	O
.	.	p	O

ME-609	NNP	i	IPM
(	(	i	IPM
Xerese	JJ	i	IPM
,	,	i	IPM
Xerclear	NNP	i	IPM
)	)	i	IPM
is	VBZ	O	O
a	DT	O	O
combination	NN	O	O
of	IN	O	O
5	CD	O	O
%	NN	O	O
acyclovir	NN	i	IPM
and	CC	O	O
1	CD	O	O
%	NN	O	O
hydrocortisone	NN	i	IPM
developed	VBD	O	O
for	IN	O	O
the	DT	O	O
topical	JJ	O	O
treatment	NN	O	O
of	IN	O	O
HSL	NNP	O	O
.	.	O	O

OBJECTIVES	NNP	O	O
The	DT	O	O
primary	NN	O	O
study	VBD	O	O
end	JJ	O	O
point	NN	O	O
was	VBD	O	O
the	DT	O	O
prevention	NN	O	O
of	IN	O	O
ulcerative	JJ	o	OPH
HSL	NNP	o	OPH
lesions	NNS	o	OPH
.	.	o	OPH

METHODS	NNP	O	O
In	IN	O	O
all	DT	O	O
,	,	O	O
2437	CD	p	PSS
patients	NNS	p	O
with	IN	p	O
a	DT	p	O
history	NN	p	PC
of	IN	p	PC
HSL	NNP	p	PC
were	VBD	O	O
randomized	VBN	i	IPM
to	TO	i	IPM
self-initiate	JJ	i	IPM
treatment	NN	i	IPM
with	IN	i	IPM
ME-609	NNP	i	IPM
,	,	i	O
5	CD	i	IPM
%	NN	i	IPM
acyclovir	NN	i	IPM
in	IN	i	IPM
ME-609	NNP	i	IPM
vehicle	NN	i	IPM
,	,	i	O
or	CC	i	O
ME-609	JJ	i	IPH
vehicle	NN	i	IPH
(	(	i	IPH
placebo	NN	i	IPH
)	)	i	IPH
at	IN	i	O
the	DT	i	O
earliest	JJS	i	O
sign	NN	i	O
of	IN	i	O
a	DT	i	O
cold	JJ	i	O
sore	NN	i	O
recurrence	NN	i	O
.	.	i	O

Cream	NNP	i	IPM
was	VBD	i	IPM
applied	VBN	i	IPM
5	CD	i	IPM
times/d	NN	i	IPM
for	IN	i	IPM
5	CD	i	IPM
days	NNS	i	IPM
.	.	i	O

A	DT	O	O
total	NN	O	O
of	IN	O	O
1443	CD	p	O
patients	NNS	p	O
experienced	VBD	p	O
a	DT	o	OPH
recurrence	NN	o	OPH
and	CC	O	O
initiated	JJ	O	O
treatment	NN	O	O
with	IN	O	O
ME-609	NNP	i	IPM
(	(	O	O
n	JJ	O	O
=	NNP	O	O
601	CD	O	O
)	)	O	O
,	,	O	O
acyclovir	FW	i	IPM
(	(	O	O
n	JJ	O	O
=	NNP	O	O
610	CD	O	O
)	)	O	O
,	,	O	O
or	CC	O	O
placebo	NN	i	IC
(	(	O	O
n	JJ	O	O
=	NNP	O	O
232	CD	O	O
)	)	O	O
.	.	O	O

RESULTS	NNP	O	O
Of	IN	O	O
patients	NNS	O	O
receiving	VBG	O	O
ME-609	NNP	O	O
,	,	O	O
42	CD	O	O
%	NN	O	O
did	VBD	O	O
not	RB	O	O
develop	VB	O	O
an	DT	O	O
ulcerative	JJ	o	OPH
lesion	NN	o	OPH
compared	VBN	O	O
with	IN	O	O
35	CD	p	O
%	NN	p	O
of	IN	p	O
patients	NNS	p	O
receiving	VBG	O	O
acyclovir	NN	i	IPM
in	IN	i	IPM
ME-609	NNP	i	IPM
vehicle	NN	i	IPM
(	(	O	O
P	NNP	O	O
=	NNP	O	O
.014	NNP	O	O
)	)	O	O
and	CC	O	O
26	CD	O	O
%	NN	O	O
of	IN	O	O
patients	NNS	O	O
receiving	VBG	O	O
placebo	NN	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
.0001	NNP	O	O
)	)	O	O
.	.	O	O

In	IN	O	O
patients	NNS	O	O
with	IN	O	O
ulcerative	JJ	O	O
lesions	NNS	O	O
,	,	O	O
healing	VBG	o	OOt
times	NNS	o	OOt
were	VBD	O	O
reduced	VBN	O	O
in	IN	O	O
the	DT	O	O
ME-609	NNP	O	O
and	CC	O	O
acyclovir	NN	O	O
groups	NNS	O	O
compared	VBN	O	O
with	IN	O	O
placebo	NN	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
.01	NNP	O	O
for	IN	O	O
both	DT	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
cumulative	JJ	o	OPH
lesion	NN	o	OPH
area	NN	o	OPH
for	IN	O	O
all	DT	O	O
lesions	NNS	O	O
was	VBD	O	O
reduced	VBN	O	O
50	CD	O	O
%	NN	O	O
in	IN	O	O
patients	NNS	O	O
receiving	VBG	O	O
ME-609	NNP	O	O
compared	VBN	O	O
with	IN	O	O
the	DT	O	O
placebo	NN	O	O
group	NN	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
.0001	NNP	O	O
)	)	O	O
.	.	O	O

There	EX	O	O
were	VBD	O	O
no	DT	O	O
differences	NNS	O	O
among	IN	O	O
groups	NNS	O	O
in	IN	O	O
the	DT	O	O
number	NN	O	O
of	IN	O	O
patients	NNS	O	O
with	IN	O	O
positive	JJ	O	O
herpes	NNS	O	O
simplex	JJ	O	O
virus	NN	O	O
cultures	NNS	O	O
.	.	O	O

The	DT	O	O
side-effect	JJ	o	OA
profile	NN	o	OA
was	VBD	O	O
similar	JJ	O	O
among	IN	O	O
treatments	NNS	O	O
.	.	O	O

LIMITATIONS	VB	O	O
The	DT	O	O
study	NN	O	O
did	VBD	O	O
not	RB	O	O
contain	VB	O	O
a	DT	O	O
group	NN	O	O
treated	VBD	O	O
with	IN	O	O
a	DT	O	O
topical	JJ	O	O
corticosteroid	NN	O	O
alone	RB	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
ME-609	NNP	O	O
prevented	VBD	O	O
progression	NN	O	O
of	IN	o	O
cold	JJ	o	OPH
sores	NNS	o	OPH
to	TO	o	O
ulcerative	JJ	o	OPH
lesions	NNS	o	OPH
and	CC	O	O
significantly	RB	O	O
reduced	VBD	O	O
the	DT	O	O
cumulative	JJ	o	OPH
lesion	NN	o	OPH
area	NN	o	OPH
compared	VBN	O	O
with	IN	O	O
acyclovir	NN	O	O
and	CC	O	O
placebo	NN	O	O
.	.	O	O

ME-609	NNP	O	O
treatment	NN	O	O
offers	NNS	O	O
additional	JJ	O	O
therapeutic	JJ	O	O
benefit	NN	O	O
compared	VBN	O	O
with	IN	O	O
therapy	NN	O	O
with	IN	O	O
topical	JJ	O	O
acyclovir	NN	O	O
alone	RB	O	O
.	.	O	O

Prevalence	NN	O	O
and	CC	O	O
treatment	NN	O	O
outcome	NN	O	O
of	IN	O	O
cervicitis	NN	o	OPH
of	IN	p	O
unknown	JJ	p	O
etiology	NN	p	O
.	.	p	O

BACKGROUND	NNP	O	O
Mucopurulent	NNP	O	O
cervicitis	NN	O	O
(	(	O	O
MPC	NNP	O	O
)	)	O	O
is	VBZ	O	O
a	DT	O	O
clinical	JJ	O	O
syndrome	NN	O	O
characterized	VBN	O	O
by	IN	O	O
mucopurulent	JJ	O	O
discharge	NN	O	O
from	IN	O	O
the	DT	O	O
cervix	NN	O	O
and	CC	O	O
other	JJ	O	O
signs	NNS	O	O
of	IN	O	O
inflammation	NN	O	O
.	.	O	O

This	DT	O	O
was	VBD	O	O
a	DT	O	O
phase	NN	O	O
III	NNP	O	O
,	,	O	O
multicenter	NN	O	O
study	NN	O	O
designed	VBN	O	O
to	TO	O	O
evaluate	VB	O	O
the	DT	O	O
effectiveness	NN	O	O
of	IN	O	O
placebo	NN	i	IC
versus	NN	O	O
empiric	JJ	i	IPM
antibiotic	JJ	i	IPM
treatment	NN	i	IPM
for	IN	O	O
clinical	JJ	O	O
cure	NN	O	O
of	IN	O	O
MPC	NNP	o	OPH
of	IN	O	O
unknown	JJ	O	O
etiology	NN	O	O
at	IN	O	O
2-month	JJ	O	O
follow-up	NN	O	O
.	.	O	O

Unfortunately	RB	O	O
,	,	O	O
enrollment	NN	O	O
was	VBD	O	O
terminated	VBN	O	O
because	IN	O	O
of	IN	O	O
low	JJ	O	O
accrual	NNS	O	O
of	IN	O	O
women	NNS	p	O
with	IN	p	O
cervicitis	NN	p	O
of	IN	p	O
unknown	JJ	p	O
etiology	NN	p	O
,	,	O	O
but	CC	O	O
important	JJ	O	O
prevalence	NN	O	O
and	CC	O	O
outcome	NN	O	O
data	NNS	O	O
were	VBD	O	O
obtained	VBN	O	O
.	.	O	O

METHODS	NNP	O	O
Five	CD	p	PSS
hundred	VBD	p	PSS
seventy-seven	JJ	p	PSS
women	NNS	p	O
were	VBD	p	O
screened	VBN	p	O
for	IN	p	O
MPC	NNP	p	PC
.	.	p	PC

Women	NNP	p	O
with	IN	p	O
MPC	NNP	p	O
were	VBD	O	O
randomized	VBN	O	O
to	TO	O	O
the	DT	O	O
treatment	NN	O	O
or	CC	O	O
placebo	NN	i	IC
arm	NN	O	O
of	IN	O	O
the	DT	O	O
study	NN	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
2	CD	O	O
arms	NNS	O	O
were	VBD	O	O
evaluated	VBN	O	O
based	VBN	O	O
on	IN	O	O
the	DT	O	O
etiology	NN	o	O
,	,	o	O
clinical	JJ	o	OOt
cure	NN	o	OOt
rates	NNS	o	OOt
,	,	o	O
adverse	JJ	o	OPH
events	NNS	o	OPH
(	(	o	OPH
AEs	NNP	o	OPH
)	)	o	OPH
,	,	o	O
and	CC	o	O
rates	NNS	o	OPH
of	IN	o	OPH
pelvic	JJ	o	OPH
inflammatory	JJ	o	OPH
disease	NN	o	OPH
.	.	o	O

RESULTS	NNP	O	O
One	CD	p	PSS
hundred	VBD	p	PSS
thirty-one	NN	p	PSS
(	(	p	O
23	CD	p	O
%	NN	p	O
[	CC	p	O
131/577	CD	p	O
]	NN	p	O
)	)	p	O
screened	VBD	p	O
women	NNS	p	O
were	VBD	O	O
found	VBN	O	O
to	TO	O	O
have	VB	O	O
MPC	NNP	O	O
.	.	O	O

Eighty-seven	NNP	p	PSS
were	VBD	p	O
enrolled	VBN	p	O
and	CC	O	O
randomized	VBN	O	O
.	.	O	O

After	IN	O	O
excluding	VBG	O	O
women	NNS	O	O
with	IN	O	O
sexually	RB	O	O
transmitted	VBN	O	O
infections	NNS	O	O
and	CC	O	O
other	JJ	O	O
exclusions	NNS	O	O
,	,	O	O
61	CD	O	O
%	NN	O	O
(	(	O	O
53/87	CD	O	O
)	)	O	O
had	VBD	O	O
cervicitis	NN	o	OPH
of	IN	O	O
unknown	JJ	O	O
etiology	NN	O	O
.	.	O	O

The	DT	O	O
overall	JJ	o	OOt
clinical	JJ	o	OOt
failure	NN	o	OOt
rate	NN	o	OOt
was	VBD	O	O
30	CD	O	O
%	NN	O	O
(	(	O	O
10/33	CD	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
clinical	JJ	o	OOt
cure	NN	o	OOt
rate	NN	o	OOt
was	VBD	O	O
only	RB	O	O
24	CD	O	O
%	NN	O	O
(	(	O	O
8/33	CD	O	O
)	)	O	O
.	.	O	O

Rates	NNS	O	O
were	VBD	O	O
not	RB	O	O
significantly	RB	O	O
different	JJ	O	O
between	IN	O	O
the	DT	O	O
arms	NNS	O	O
.	.	O	O

There	EX	O	O
were	VBD	O	O
24	CD	O	O
gastrointestinal	JJ	o	OPH
AEs	NNP	o	OPH
in	IN	O	O
the	DT	O	O
treatment	NN	O	O
arm	NN	O	O
compared	VBN	O	O
with	IN	O	O
1	CD	O	O
AE	NNP	O	O
in	IN	O	O
the	DT	O	O
placebo	NN	i	IC
arm	NN	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
More	JJR	O	O
than	IN	O	O
half	NN	O	O
of	IN	O	O
the	DT	O	O
cases	NNS	O	O
of	IN	O	O
MPC	NNP	O	O
were	VBD	O	O
of	IN	O	O
unknown	JJ	O	O
etiology	NN	O	O
.	.	O	O

Clinical	JJ	o	OOt
cure	NN	o	OOt
rates	NNS	o	OOt
for	IN	O	O
the	DT	O	O
placebo	NN	i	IC
and	CC	O	O
treatment	NN	O	O
arms	NNS	O	O
were	VBD	O	O
extremely	RB	O	O
low	JJ	O	O
,	,	O	O
with	IN	O	O
most	JJS	O	O
women	NNS	O	O
concluding	VBG	O	O
the	DT	O	O
study	NN	O	O
with	IN	O	O
a	DT	O	O
partial	JJ	O	O
response	NN	O	O
.	.	O	O

Gastrointestinal	JJ	o	OPH
AEs	NNP	o	OPH
were	VBD	O	O
higher	JJR	O	O
in	IN	O	O
the	DT	O	O
treatment	NN	O	O
arm	NN	O	O
.	.	O	O

Oral	JJ	O	O
bioavailability	NN	O	O
of	IN	O	O
moxifloxacin	NN	i	IPM
after	IN	p	PC
Roux-en-Y	NNP	i	IS
gastric	JJ	i	IS
bypass	NN	i	IS
surgery	NN	i	IS
.	.	i	O

OBJECTIVES	CC	O	O
Roux-en-Y	JJ	i	IS
gastric	JJ	i	IS
bypass	NN	i	IS
surgery	NN	i	IS
is	VBZ	O	O
the	DT	O	O
most	RBS	O	O
commonly	RB	O	O
performed	JJ	O	O
procedure	NN	O	O
for	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
morbid	NN	O	O
obesity	NN	O	O
.	.	O	O

This	DT	O	O
anatomical	JJ	O	O
alteration	NN	O	O
may	MD	O	O
affect	VB	O	O
the	DT	O	O
absorption	NN	O	O
and	CC	O	O
consequently	RB	O	O
the	DT	O	O
bioavailability	NN	O	O
of	IN	O	O
oral	JJ	O	O
drugs	NNS	O	O
.	.	O	O

This	DT	O	O
study	NN	O	O
aims	VBZ	O	O
to	TO	O	O
investigate	VB	O	O
the	DT	O	O
oral	JJ	o	O
bioavailability	NN	o	O
of	IN	O	O
moxifloxacin	NN	i	IPM
in	IN	O	O
12	CD	p	PC
healthy	JJ	p	PC
volunteers	NNS	p	PC
who	WP	p	PC
underwent	VBP	p	PC
gastric	JJ	i	IS
bypass	NN	i	IS
surgery	NN	i	IS
.	.	i	O

PATIENTS	NNP	O	O
AND	CC	O	O
METHODS	NNP	O	O
In	IN	O	O
this	DT	O	O
randomized	VBN	O	O
crossover	NN	O	O
study	NN	O	O
,	,	O	O
each	DT	O	O
subject	NN	O	O
received	VBD	O	O
two	CD	O	O
single	JJ	O	O
standard	NN	O	O
doses	NNS	O	O
of	IN	O	O
400	CD	i	IPM
mg	NN	i	IPM
of	IN	i	IPM
moxifloxacin	NN	i	IPM
orally	RB	i	IPM
or	CC	i	IPM
intravenously	RB	i	IPM
administered	VBN	O	O
on	IN	O	O
two	CD	O	O
occasions	NNS	O	O
separated	VBN	O	O
by	IN	O	O
a	DT	O	O
washout	JJ	O	O
period	NN	O	O
of	IN	O	O
1	CD	O	O
week	NN	O	O
.	.	O	O

Serial	JJ	O	O
venous	JJ	O	O
blood	NN	O	O
samples	NNS	O	O
were	VBD	O	O
drawn	VBN	O	O
up	RB	O	O
to	TO	O	O
72	CD	O	O
h	NN	O	O
after	IN	O	O
dosing	VBG	O	O
and	CC	O	O
moxifloxacin	JJ	o	OPH
plasma	NN	o	OPH
levels	NNS	o	OPH
were	VBD	O	O
measured	VBN	O	O
by	IN	O	O
a	DT	O	O
validated	JJ	O	O
HPLC	NNP	O	O
method	NN	O	O
with	IN	O	O
fluorescence	NN	O	O
detection	NN	O	O
.	.	O	O

[	CC	O	O
clinicaltrials.gov	JJ	O	O
database	NN	O	O
(	(	O	O
identifier	NN	O	O
:	:	O	O
NCT01130922	NNP	O	O
)	)	O	O
.	.	O	O

]	JJ	O	O
RESULTS	NNP	O	O
After	IN	O	O
oral	JJ	O	O
dosing	NN	O	O
,	,	O	O
moxifloxacin	FW	o	OPH
plasma	NN	o	OPH
concentrations	NNS	o	OPH
reached	VBD	O	O
a	DT	O	O
maximum	JJ	O	O
(	(	O	O
C	NNP	O	O
(	(	O	O
max	NN	O	O
)	)	O	O
)	)	O	O
of	IN	O	O
3.38	CD	O	O
?	.	O	O
1.41	CD	O	O
mg/L	NN	O	O
after	IN	O	O
1.75	CD	O	O
h	NN	O	O
(	(	O	O
0.75-4.00	JJ	O	O
)	)	O	O
.	.	O	O

After	IN	O	O
intravenous	JJ	O	O
dosing	NN	O	O
,	,	O	O
C	NNP	O	O
(	(	o	O
max	NN	o	O
)	)	o	O
and	CC	o	O
T	NNP	o	O
(	(	o	O
max	NN	o	O
)	)	o	O
were	VBD	O	O
4.53	CD	O	O
?	.	O	O
1.43	CD	O	O
mg/L	NN	O	O
and	CC	O	O
1.03	CD	O	O
h	NN	O	O
(	(	O	O
0.75-2.50	JJ	O	O
)	)	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

The	DT	o	O
mean	JJ	o	OOt
areas	NNS	o	OOt
under	IN	o	OOt
the	DT	o	OOt
plasma	JJ	o	OOt
concentration	NN	o	OOt
time	NN	o	OOt
curve	NN	o	OOt
extrapolated	VBD	o	O
to	TO	O	O
infinity	NN	O	O
(	(	O	O
AUC	NNP	O	O
(	(	O	O
?	.	O	O
)	)	O	O
)	)	O	O
were	VBD	O	O
46.2	CD	O	O
?	.	O	O
1.4	CD	O	O
mg	NN	O	O
?	.	O	O
h/L	NN	O	O
after	IN	O	O
oral	JJ	O	O
dosing	NN	O	O
and	CC	O	O
52.3	CD	O	O
?	.	O	O
1.3	CD	O	O
mg	NN	O	O
?	.	O	O
h/L	NN	O	O
after	IN	O	O
intravenous	JJ	O	O
dosing	NN	O	O
,	,	O	O
resulting	VBG	O	O
in	IN	O	O
a	DT	O	O
mean	JJ	o	O
oral	JJ	o	O
bioavailability	NN	o	O
of	IN	O	O
88.32	CD	O	O
%	NN	O	O
[	JJ	O	O
90	CD	O	O
%	NN	O	O
confidence	NN	O	O
interval	NN	O	O
(	(	O	O
CI	NNP	O	O
)	)	O	O
85.64	CD	O	O
%	NN	O	O
-91.08	CD	O	O
%	NN	O	O
]	NN	O	O
.	.	O	O

CONCLUSIONS	VB	O	O
This	DT	O	O
study	NN	O	O
confirms	VBZ	O	O
that	IN	O	O
exposure	NN	O	O
to	TO	O	O
moxifloxacin	VB	i	O
is	VBZ	O	O
equivalent	JJ	O	O
for	IN	O	O
oral	JJ	O	O
and	CC	O	O
intravenous	JJ	O	O
administration	NN	O	O
of	IN	O	O
400	CD	O	O
mg	NN	O	O
dosages	NNS	O	O
in	IN	p	O
healthy	JJ	p	O
volunteers	NNS	p	O
who	WP	p	O
underwent	VBP	p	O
gastric	JJ	p	O
bypass	NN	p	O
surgery	NN	p	O
.	.	p	O

But	CC	O	O
these	DT	O	O
exposures	NNS	O	O
were	VBD	O	O
more	JJR	O	O
than	IN	O	O
50	CD	O	O
%	NN	O	O
higher	JJR	O	O
than	IN	O	O
those	DT	O	O
described	VBN	O	O
for	IN	O	O
subjects	NNS	O	O
without	IN	O	O
gastric	JJ	O	O
bypass	NN	O	O
.	.	O	O

This	DT	O	O
may	MD	O	O
suggest	VB	O	O
a	DT	O	O
higher	JJR	O	O
enterohepatic	JJ	O	O
recirculation	NN	O	O
of	IN	O	O
moxifloxacin	NN	i	O
after	IN	p	O
gastric	JJ	p	O
bypass	NN	p	O
.	.	p	O

A	DT	O	O
phase	NN	O	O
II	NNP	O	O
randomized	VBD	O	O
trial	NN	O	O
comparing	VBG	O	O
radiotherapy	NN	i	IPH
with	IN	O	O
concurrent	JJ	O	O
weekly	JJ	O	O
cisplatin	NN	i	IPM
or	CC	O	O
weekly	JJ	O	O
paclitaxel	NN	i	IPM
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
advanced	JJ	p	PC
cervical	JJ	p	PC
cancer	NN	p	PC
.	.	p	O

PURPOSE/OBJECTIVE	VB	O	O
This	DT	O	O
is	VBZ	O	O
a	DT	O	O
prospective	JJ	O	O
comparison	NN	O	O
of	IN	O	O
weekly	JJ	O	O
cisplatin	NN	i	IPM
to	TO	O	O
weekly	VB	O	O
paclitaxel	NN	i	IPM
as	IN	O	O
concurrent	JJ	O	O
chemotherapy	NN	O	O
with	IN	O	O
standard	JJ	i	IPH
radiotherapy	NN	i	IPH
for	IN	O	O
locally	RB	O	O
advanced	JJ	p	PC
cervical	JJ	p	PC
carcinoma	NN	p	PC
.	.	p	O

MATERIALS/METHODS	NNP	O	O
Between	NNP	p	O
May	NNP	p	O
2000	CD	p	O
and	CC	p	O
May	NNP	p	O
2004	CD	p	O
,	,	p	O
31	CD	p	PSS
women	NNS	p	O
with	IN	p	O
FIGO	NNP	p	PC
stage	NN	p	PC
IB2-IVA	NNP	p	PC
cervical	JJ	p	PC
cancer	NN	p	PC
or	CC	p	PC
with	IN	p	PC
postsurgical	JJ	p	PC
pelvic	JJ	p	PC
recurrence	NN	p	PC
were	VBD	p	O
enrolled	VBN	p	O
into	IN	p	O
this	DT	p	O
phase	NN	p	O
II	NNP	p	O
study	NN	p	O
and	CC	O	O
randomized	VBN	O	O
to	TO	O	O
receive	VB	O	O
on	IN	O	O
a	DT	O	O
weekly	JJ	O	O
basis	NN	O	O
either	CC	O	O
40	CD	i	O
mg/m?	NN	i	O
Cisplatin	NNP	i	O
(	(	i	O
group	NN	i	O
I	PRP	i	O
;	:	i	O
16	CD	i	O
patients	NNS	i	O
)	)	i	O
or	CC	i	O
50	CD	i	O
mg/m?	NNS	i	O
paclitaxel	NN	i	O
(	(	i	O
group	NN	i	O
II	NNP	i	O
;	:	i	O
15	CD	i	O
patients	NNS	i	O
)	)	i	O
concurrently	RB	i	O
with	IN	i	O
radiotherapy	NN	i	O
.	.	i	O

Median	JJ	O	O
total	NN	O	O
dose	NN	O	O
to	TO	O	O
point	VB	O	O
A	NNP	O	O
was	VBD	O	O
74	CD	O	O
Gy	NNP	O	O
(	(	O	O
range	NN	O	O
:	:	O	O
66-92	JJ	O	O
Gy	NNP	O	O
)	)	O	O
for	IN	O	O
group	NN	O	O
I	PRP	O	O
and	CC	O	O
66	CD	O	O
Gy	NNP	O	O
(	(	O	O
range	NN	O	O
:	:	O	O
40-98	JJ	O	O
Gy	NNP	O	O
)	)	O	O
for	IN	O	O
group	NN	O	O
II	NNP	O	O
.	.	O	O

Median	JJ	O	O
follow-up	JJ	O	O
time	NN	O	O
was	VBD	O	O
46	CD	O	O
months	NNS	O	O
.	.	O	O

RESULTS	NNP	p	O
Patient	NNP	p	O
and	CC	p	O
tumor	NN	p	O
characteristics	NNS	p	O
were	VBD	p	O
similar	JJ	O	O
in	IN	O	O
both	DT	O	O
groups	NNS	O	O
.	.	O	O

The	DT	o	O
mean	JJ	o	O
number	NN	o	O
of	IN	o	O
chemotherapy	NN	o	O
cycles	NNS	o	O
was	VBD	o	O
also	RB	O	O
comparable	JJ	O	O
with	IN	O	O
87	CD	O	O
%	NN	O	O
and	CC	O	O
80	CD	O	O
%	NN	O	O
of	IN	O	O
patients	NNS	O	O
receiving	VBG	O	O
at	IN	O	O
least	JJS	O	O
4	CD	O	O
doses	NNS	O	O
in	IN	O	O
groups	NNS	O	O
I	PRP	O	O
and	CC	O	O
II	NNP	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

Seven	JJ	O	O
patients	NNS	O	O
(	(	O	O
44	CD	O	O
%	NN	O	O
)	)	O	O
of	IN	O	O
group	NN	O	O
I	PRP	O	O
and	CC	O	O
8	CD	O	O
patients	NNS	O	O
(	(	O	O
53	CD	O	O
%	NN	O	O
)	)	O	O
of	IN	O	O
group	NN	O	O
II	NNP	O	O
developed	VBD	o	O
tumor	NN	o	O
recurrence	NN	o	O
.	.	o	O

The	DT	o	O
Median	JJ	o	O
Survival	NNP	o	O
time	NN	o	O
was	VBD	o	O
not	RB	O	O
reached	VBN	O	O
for	IN	O	O
Group	NNP	O	O
I	PRP	O	O
and	CC	O	O
53	CD	O	O
months	NNS	O	O
for	IN	O	O
group	NN	O	O
II	NNP	O	O
.	.	O	O

The	DT	o	O
proportion	NN	o	O
of	IN	o	O
patients	NNS	o	O
surviving	VBG	o	O
at	IN	o	O
2	CD	O	O
and	CC	O	O
5	CD	O	O
years	NNS	O	O
was	VBD	O	O
78	CD	O	O
%	NN	O	O
and	CC	O	O
54	CD	O	O
%	NN	O	O
for	IN	O	O
group	NN	O	O
I	PRP	O	O
and	CC	O	O
73	CD	O	O
%	NN	O	O
and	CC	O	O
43	CD	O	O
%	NN	O	O
for	IN	O	O
group	NN	O	O
II	NNP	O	O
respectively	RB	O	O
.	.	O	O

CONCLUSIONS	VB	O	O
This	DT	O	O
small	JJ	O	O
prospective	JJ	O	O
study	NN	O	O
shows	NNS	O	O
that	WDT	O	O
weekly	VBP	i	O
paclitaxel	NN	i	O
does	VBZ	i	O
not	RB	O	O
provide	VB	O	O
any	DT	o	O
clinical	JJ	o	O
advantage	NN	o	O
over	IN	o	O
weekly	JJ	i	O
cisplatin	NN	i	O
for	IN	i	O
concurrent	JJ	i	O
chemoradiation	NN	i	O
for	IN	i	O
advanced	JJ	p	O
carcinoma	NN	p	O
of	IN	p	O
the	DT	p	O
cervix	NN	p	O
.	.	p	O

Hysteroscopic	NNP	i	IS
transcervical	JJ	i	IS
endometrial	JJ	i	IS
resection	NN	i	IS
versus	IN	O	O
thermal	JJ	i	IS
destruction	NN	i	IS
for	IN	O	O
menorrhagia	NN	O	O
:	:	O	O
a	DT	O	O
prospective	JJ	O	O
randomized	VBN	O	O
trial	NN	O	O
on	IN	O	O
satisfaction	NN	O	O
rate	NN	O	O
.	.	O	O

OBJECTIVE	IN	O	O
The	DT	O	O
purpose	NN	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
compare	VB	O	O
the	DT	O	O
satisfaction	NN	o	OOt
rate	NN	o	OOt
and	CC	o	O
the	DT	o	O
effectiveness	NN	o	OOt
of	IN	O	O
transcervical	JJ	i	IS
hysteroscopic	NN	i	IS
endometrial	JJ	i	IS
resection	NN	i	IS
and	CC	O	O
thermal	JJ	i	IS
destruction	NN	i	IS
of	IN	O	O
the	DT	O	O
endometrium	NN	O	O
in	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
menorrhagia	NN	p	PC
.	.	p	O

STUDY	NNP	O	O
DESIGN	NNP	O	O
A	NNP	O	O
prospective	JJ	O	O
randomized	VBN	O	O
trial	NN	O	O
with	IN	O	O
2	CD	O	O
years	NNS	O	O
of	IN	O	O
follow-up	NN	O	O
was	VBD	O	O
carried	VBN	O	O
out	RP	O	O
in	IN	O	O
the	DT	O	O
Department	NNP	p	O
of	IN	p	O
Gynecology	NNP	p	O
of	IN	p	O
the	DT	p	O
University	NNP	p	O
of	IN	p	O
Naples	NNP	p	O
.	.	p	O

Eighty-two	JJ	p	PSS
patients	NNS	p	O
who	WP	p	O
were	VBD	p	O
affected	VBN	p	O
by	IN	p	O
menorrhagia	NN	p	O
that	WDT	p	O
was	VBD	p	O
unresponsive	JJ	p	PC
to	TO	p	PC
medical	JJ	p	PC
treatment	NN	p	PC
were	VBD	O	O
respectively	RB	O	O
randomized	VBN	O	O
to	TO	O	O
transcervical	JJ	i	IS
hysteroscopic	NN	i	IS
endometrial	JJ	i	IS
resection	NN	i	IS
or	CC	i	O
to	TO	i	O
thermal	JJ	i	IS
destruction	NN	i	IS
of	IN	i	IS
the	DT	i	IS
endometrium	NN	i	IS
.	.	i	O

Satisfaction	NN	o	OOt
rate	NN	o	OOt
,	,	o	O
operative	JJ	o	OOt
time	NN	o	OOt
,	,	o	O
discharge	NN	o	OOt
time	NN	o	OOt
,	,	o	O
complication	NN	o	OA
rate	NN	o	OA
,	,	o	O
reintervention	NN	o	OOt
rate	NN	o	OOt
,	,	o	O
and	CC	o	O
resumption	NN	o	OOt
of	IN	o	OOt
normal	JJ	o	OOt
activity	NN	o	OOt
were	VBD	O	O
evaluated	VBN	O	O
in	IN	O	O
each	DT	O	O
group	NN	O	O
.	.	O	O

RESULTS	VB	O	O
The	DT	O	O
satisfaction	NN	o	OOt
rate	NN	o	OOt
was	VBD	O	O
significantly	RB	O	O
higher	JJR	O	O
in	IN	O	O
the	DT	O	O
thermal	JJ	i	IS
destruction	NN	i	IS
group	NN	O	O
.	.	O	O

Operative	JJ	o	OOt
time	NN	o	OOt
was	VBD	O	O
significantly	RB	O	O
shorter	JJR	O	O
in	IN	O	O
the	DT	O	O
thermal	JJ	O	O
destruction	NN	O	O
group	NN	O	O
(	(	O	O
24	CD	O	O
+/-	JJ	O	O
4	CD	O	O
minutes	NNS	O	O
vs	JJ	O	O
37	CD	O	O
+/-	JJ	O	O
6	CD	O	O
minutes	NNS	O	O
)	)	O	O
.	.	O	O

Intraoperative	JJ	o	OA
blood	NN	o	OA
loss	NN	o	OA
was	VBD	O	O
significantly	RB	O	O
lower	JJR	O	O
in	IN	O	O
the	DT	O	O
thermal	JJ	O	O
destruction	NN	O	O
group	NN	O	O
(	(	O	O
7.2	CD	O	O
+/-	JJ	O	O
2.8	CD	O	O
mL	NN	O	O
vs	NN	O	O
89	CD	O	O
+/-	JJ	O	O
38	CD	O	O
mL	NN	O	O
)	)	O	O
.	.	O	O

Reintervention	NN	o	OOt
rates	NNS	o	OOt
were	VBD	O	O
higher	JJR	O	O
in	IN	O	O
the	DT	O	O
transcervical	JJ	i	IS
hysteroscopic	NN	i	IS
endometrial	JJ	i	IS
resection	NN	i	IS
group	NN	O	O
,	,	O	O
although	IN	O	O
postoperative	JJ	O	O
pain	NN	O	O
was	VBD	O	O
not	RB	O	O
significantly	RB	O	O
different	JJ	O	O
between	IN	O	O
the	DT	O	O
two	CD	O	O
groups	NNS	O	O
.	.	O	O

Discharge	NNP	o	OOt
time	NN	o	OOt
,	,	o	O
complication	NN	o	OA
rate	NN	o	OA
,	,	o	O
and	CC	o	O
resumption	NN	o	OOt
of	IN	o	OOt
normal	JJ	o	OOt
activity	NN	o	OOt
were	VBD	O	O
not	RB	O	O
significantly	RB	O	O
different	JJ	O	O
between	IN	O	O
the	DT	O	O
two	CD	O	O
groups	NNS	O	O
.	.	O	O

CONCLUSION	NNP	O	O
Thermal	NNP	i	IS
destruction	NN	i	IS
of	IN	i	IS
the	DT	i	IS
endometrium	NN	i	IS
for	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
menorrhagia	NN	p	O
should	MD	O	O
be	VB	O	O
considered	VBN	O	O
an	DT	O	O
effective	JJ	O	O
therapeutic	JJ	O	O
option	NN	O	O
because	IN	O	O
of	IN	O	O
its	PRP$	O	O
acceptability	NN	o	OOt
among	IN	O	O
patients	NNS	O	O
,	,	O	O
shorter	RB	o	OOt
operative	JJ	o	OOt
time	NN	o	OOt
,	,	o	O
and	CC	o	O
lower	JJR	o	OOt
blood	NN	o	OOt
loss	NN	o	OOt
.	.	o	O

Validation	NN	O	O
of	IN	O	O
a	DT	O	O
novel	JJ	O	O
satisfaction	NN	i	IE
questionnaire	NN	i	IE
for	IN	O	O
patients	NNS	p	O
with	IN	p	O
rheumatoid	JJ	p	O
arthritis	NN	p	O
receiving	VBG	p	O
outpatient	JJ	p	O
clinical	JJ	p	O
nurse	NN	p	O
specialist	NN	p	O
care	NN	p	O
,	,	p	O
inpatient	NN	p	O
care	NN	p	O
,	,	p	O
or	CC	p	O
day	NN	p	O
patient	JJ	p	O
team	NN	p	O
care	NN	p	O
.	.	p	O

OBJECTIVES	NNP	O	O
To	TO	O	O
develop	VB	O	O
and	CC	O	O
validate	VB	O	O
a	DT	O	O
questionnaire	NN	O	O
for	IN	O	O
measuring	VBG	O	O
satisfaction	NN	o	OOt
with	IN	O	O
different	JJ	O	O
forms	NNS	O	O
of	IN	O	O
complex	JJ	O	O
multidisciplinary	JJ	O	O
care	NN	O	O
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
rheumatoid	JJ	p	O
arthritis	NN	p	O
(	(	p	O
RA	NNP	p	O
)	)	p	O
.	.	p	O

METHODS	PDT	O	O
The	DT	O	O
satisfaction	NN	o	OOt
questionnaire	NN	o	OOt
(	(	O	O
score	JJ	O	O
range	NN	O	O
0-100	NN	O	O
)	)	O	O
comprised	VBD	O	O
28	CD	O	O
items	NNS	O	O
covering	VBG	O	O
11	CD	O	O
domains	NNS	O	O
.	.	O	O

Together	RB	O	O
with	IN	O	O
a	DT	O	O
visual	JJ	o	OOt
analog	NN	o	OOt
scale	NN	o	OOt
(	(	o	OOt
VAS	NNP	o	OOt
,	,	o	OOt
range	VB	o	OOt
0-100	NNP	o	OOt
)	)	o	OOt
on	IN	o	O
overall	JJ	o	OOt
satisfaction	NN	o	OOt
,	,	O	O
the	DT	O	O
questionnaire	NN	i	IE
was	VBD	O	O
applied	VBN	O	O
in	IN	O	O
210	CD	p	PSS
RA	NNP	p	O
patients	NNS	p	O
who	WP	p	O
participated	VBD	p	O
in	IN	p	O
a	DT	p	O
randomized	JJ	p	O
trial	NN	p	O
comparing	VBG	O	O
3	CD	O	O
types	NNS	O	O
of	IN	O	O
multidisciplinary	JJ	O	O
care	NN	O	O
.	.	O	O

RESULTS	VB	O	O
The	DT	p	O
questionnaire	NN	p	O
was	VBD	p	O
returned	VBN	p	O
by	IN	p	O
174	CD	p	PSS
patients	NNS	p	PSS
(	(	p	PSS
83	CD	p	PSS
%	NN	p	PSS
)	)	p	PSS
.	.	p	O

The	DT	O	O
questionnaire	NN	o	OOt
and	CC	o	OOt
VAS	NNP	o	OOt
scores	NNS	o	OOt
in	IN	O	O
the	DT	O	O
total	JJ	O	O
group	NN	O	O
were	VBD	O	O
75	CD	O	O
(	(	O	O
SD	NNP	O	O
12	CD	O	O
)	)	O	O
and	CC	O	O
83	CD	O	O
(	(	O	O
SD	NNP	O	O
20	CD	O	O
)	)	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

Reliability	NNP	O	O
analysis	NN	O	O
showed	VBD	O	O
Cronbach	NNP	O	O
's	POS	O	O
alpha	NN	O	O
of	IN	O	O
the	DT	o	OOt
questionnaire	NN	o	OOt
was	VBD	O	O
0.91	CD	O	O
.	.	O	O

Spearman	NNP	O	O
's	POS	O	O
correlation	NN	O	O
coefficient	NN	O	O
between	IN	O	O
the	DT	O	O
satisfaction	NN	o	OOt
questionnaire	NN	o	OOt
score	NN	o	OOt
and	CC	o	OOt
VAS	NNP	o	OOt
score	NN	o	OOt
was	VBD	O	O
0.58	CD	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.01	CD	O	O
)	)	O	O
.	.	O	O

Mean	JJ	o	OOt
total	JJ	o	OOt
satisfaction	NN	o	OOt
questionnaire	NN	o	OOt
scores	NNS	o	OOt
were	VBD	O	O
72	CD	O	O
(	(	O	O
SD	NNP	O	O
9	CD	O	O
)	)	O	O
,	,	O	O
76	CD	O	O
(	(	O	O
SD	NNP	O	O
14	CD	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
78	CD	O	O
(	(	O	O
SD	NNP	O	O
11	CD	O	O
)	)	O	O
,	,	O	O
in	IN	O	O
the	DT	O	O
nurse	JJ	O	O
specialist	NN	O	O
,	,	O	O
inpatient	JJ	O	O
and	CC	O	O
day	NN	O	O
patient	NN	O	O
groups	NNS	O	O
,	,	O	O
respectively	RB	O	O
(	(	O	O
nurse	JJ	O	O
specialist	NN	O	O
versus	IN	O	O
day	NN	O	O
patient	NN	O	O
,	,	O	O
P	NNP	O	O
=	NNP	O	O
0.004	CD	O	O
)	)	O	O
.	.	O	O

Significant	JJ	O	O
differences	NNS	O	O
between	IN	O	O
nurse	JJ	O	O
specialist	NN	O	O
and	CC	O	O
day	NN	O	O
patients	NNS	O	O
were	VBD	O	O
seen	VBN	O	O
in	IN	O	O
the	DT	O	O
following	JJ	O	O
domains	NNS	O	O
:	:	O	O
waiting	VBG	o	OOt
time	NN	o	OOt
during	IN	o	OOt
the	DT	o	OOt
treatment	NN	o	OOt
,	,	o	OOt
autonomy	NN	o	OOt
,	,	o	OOt
coordination	NN	o	OOt
,	,	o	OOt
non-financial	JJ	o	OOt
access	NN	o	OOt
,	,	o	OOt
and	CC	o	OOt
quality	NN	o	OOt
of	IN	o	OOt
general	JJ	o	OOt
information	NN	o	OOt
(	(	O	O
all	DT	O	O
P	NNP	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

CONCLUSION	NNP	O	O
Overall	NNP	O	O
,	,	O	O
patients	NNS	O	O
were	VBD	O	O
highly	RB	O	O
satisfied	VBN	O	O
with	IN	O	O
the	DT	O	O
multidisciplinary	JJ	O	O
care	NN	O	O
they	PRP	O	O
received	VBD	O	O
.	.	O	O

Major	JJ	O	O
differences	NNS	O	O
regarding	VBG	O	O
the	DT	O	O
organization	NN	O	O
of	IN	O	O
care	NN	O	O
were	VBD	O	O
reflected	VBN	O	O
in	IN	O	O
the	DT	O	O
results	NNS	O	O
of	IN	O	O
the	DT	O	O
questionnaire	NN	O	O
scores	NNS	O	O
.	.	O	O

The	DT	O	O
satisfaction	NN	o	OOt
questionnaire	NN	o	OOt
appears	VBZ	O	O
to	TO	O	O
be	VB	O	O
a	DT	O	O
useful	JJ	O	O
instrument	NN	O	O
for	IN	O	O
measuring	VBG	O	O
satisfaction	NN	o	OOt
with	IN	O	O
complex	JJ	O	O
multidisciplinary	NN	O	O
care	NN	O	O
in	IN	O	O
RA	NNP	p	O
patients	NNS	p	O
.	.	p	O

[	JJ	O	O
Hemostatic	NNP	O	O
balance	NN	O	O
during	IN	O	O
treatment	NN	O	O
with	IN	O	O
the	DT	O	O
newest	JJS	O	O
contraceptives	NNS	O	O
]	RB	O	O
.	.	O	O

Thirty-four	CD	p	PSS
healthy	JJ	p	PC
young	JJ	p	PA
women	NNS	p	PA
were	VBD	O	O
allocated	VBN	i	O
to	TO	i	O
12	CD	i	O
consecutive	JJ	i	O
cycles	NNS	i	O
of	IN	i	O
treatment	NN	i	O
with	IN	i	O
monophasic	JJ	i	IPM
combinations	NNS	i	IPM
of	IN	i	IPM
:	:	i	IPM
20	CD	i	IPM
micrograms	NNS	i	IPM
ethinyl	VBP	i	IPM
estradiol	NN	i	IPM
and	CC	i	O
150	CD	i	IPM
micrograms	NNS	i	IPM
desogestrel	NN	i	IPM
(	(	i	O
n	JJ	i	O
=	NNP	i	O
15	CD	i	O
)	)	i	O
or	CC	i	O
30	CD	i	IPM
micrograms	NNS	i	IPM
ethinyl	VBP	i	IPM
estradiol	NN	i	IPM
and	CC	i	O
75	CD	i	IPM
micrograms	NNS	i	IPM
gestodene	NN	i	IPM
(	(	i	O
n	JJ	i	O
=	NNP	i	O
19	CD	i	O
)	)	i	O
.	.	O	O

In	IN	O	O
both	DT	O	O
groups	NNS	O	O
plasma	VBP	o	OPH
levels	NNS	o	OPH
of	IN	o	OPH
fibrinogen	NN	o	OPH
and	CC	o	OPH
factor	NN	o	OPH
VII	NNP	o	OPH
increased	VBD	O	O
while	IN	O	O
the	DT	O	O
capacity	NN	O	O
of	IN	O	O
coagulation	NN	O	O
inhibition	NN	O	O
was	VBD	O	O
affected	VBN	O	O
by	IN	O	O
increased	JJ	o	OPH
protein	NN	o	OPH
C	NNP	o	OPH
and	CC	o	OPH
decreased	VBN	o	OPH
protein	NN	o	OPH
S	NNP	o	OPH
levels	NNS	o	OPH
.	.	o	OPH

Increased	VBN	O	O
fibrinolytic	JJ	o	OPH
capacity	NN	o	OPH
was	VBD	O	O
indicated	VBN	O	O
by	IN	O	O
elevated	JJ	O	O
activity	NN	O	O
and	CC	O	O
reduced	JJ	O	O
antigen	NN	o	OPH
levels	NNS	o	OPH
of	IN	o	OPH
tissue	NN	o	OPH
plasminogen	NN	o	OPH
activator	NN	o	OPH
and	CC	O	O
reduced	JJ	O	O
activity	NN	O	O
and	CC	O	O
concentration	NN	o	OPH
of	IN	o	OPH
tissue	NN	o	OPH
plasminogen	NN	o	OPH
activator	NN	o	OPH
inhibitor	NN	o	OPH
.	.	o	OPH

The	DT	O	O
ratio	NN	o	OPH
between	IN	o	OPH
thrombin-antithrombin-III-complexes	NNS	o	OPH
and	CC	o	OPH
fibrin	JJ	o	OPH
degradation	NN	o	OPH
products	NNS	o	OPH
were	VBD	o	O
unchanged	JJ	o	O
signifying	VBG	O	O
no	DT	O	O
effect	NN	O	O
of	IN	O	O
hormonal	JJ	O	O
intake	NN	O	O
on	IN	O	O
the	DT	O	O
balance	NN	O	O
between	IN	O	O
thrombin	JJ	O	O
formation	NN	O	O
and	CC	O	O
fibrin	JJ	O	O
resolution	NN	O	O
.	.	O	O

In	IN	O	O
conclusion	NN	O	O
,	,	O	O
the	DT	O	O
dynamic	JJ	O	O
balance	NN	O	O
between	IN	O	O
generation	NN	O	O
and	CC	O	O
resolution	NN	O	O
of	IN	O	O
fibrin	NN	O	O
was	VBD	O	O
undisturbed	JJ	O	O
during	IN	O	O
treatment	NN	O	O
with	IN	O	O
both	DT	O	O
hormonal	JJ	O	O
compounds	NNS	O	O
and	CC	O	O
our	PRP$	O	O
findings	NNS	O	O
do	VBP	O	O
not	RB	O	O
provide	VB	O	O
evidence	NN	O	O
for	IN	O	O
increased	VBN	O	O
risk	NN	O	O
of	IN	O	O
thrombosis	NN	O	O
in	IN	O	O
normal	JJ	p	PC
women	NNS	p	PSE
.	.	p	O

Mediterranean	NNP	i	IOt
diet	NN	i	IOt
and	CC	i	O
high	JJ	i	IOt
dietary	JJ	i	IOt
acid	NN	i	IOt
load	NN	i	IOt
associated	VBN	O	O
with	IN	O	O
mixed	JJ	i	IOt
nuts	NNS	i	IOt
:	:	i	O
effect	NN	o	OPH
on	IN	O	O
bone	NN	o	OPH
metabolism	NN	o	OPH
in	IN	O	O
elderly	JJ	p	PA
subjects	NNS	p	O
.	.	p	O

OBJECTIVES	NNP	O	O
To	TO	O	O
analyze	VB	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
differing	VBG	O	O
diet	NN	O	O
on	IN	O	O
the	DT	O	O
acid	JJ	O	O
load	NN	O	O
content	NN	O	O
on	IN	O	O
bone	NN	o	OPH
metabolism	NN	o	OPH
.	.	o	O

DESIGN	NNP	O	O
Multicentric	NNP	O	O
,	,	O	O
randomized	VBD	O	O
,	,	O	O
single-blind	JJ	O	O
,	,	O	O
parallel-group	JJ	O	O
clinical	JJ	O	O
trial	NN	O	O
.	.	O	O

SETTING	NN	O	O
Outpatient	JJ	p	O
clinics	NNS	p	O
.	.	p	O

PARTICIPANTS	VB	O	O
Two	CD	p	PSS
hundred	CD	p	PSS
thirty-eight	JJ	p	PSS
elderly	JJ	p	PA
men	NNS	p	PC
and	CC	p	O
women	NNS	p	PC
aged	VBD	p	O
60	CD	p	PA
to	TO	p	PA
80	CD	p	PA
at	IN	p	O
high	JJ	p	O
risk	NN	p	O
for	IN	p	O
cardiovascular	JJ	p	PC
disease	NN	p	PC
were	VBD	O	O
randomly	RB	O	O
assigned	VBN	O	O
to	TO	O	O
three	CD	O	O
interventional	JJ	O	O
groups	NNS	O	O
:	:	O	O
a	DT	O	O
recommended	JJ	i	IC
low-fat	JJ	i	IOt
diet	NN	i	IOt
(	(	i	IC
control	VB	i	IC
diet	JJ	i	IC
group	NN	i	IC
)	)	i	IC
,	,	i	O
a	DT	i	O
Mediterranean	NNP	i	IOt
diet	NN	i	IOt
supplemented	VBD	i	IOt
with	IN	i	IOt
virgin	JJ	i	IOt
olive	JJ	i	IOt
oil	NN	i	IOt
,	,	i	IPH
or	CC	i	O
a	DT	i	O
Mediterranean	NNP	i	O
diet	NN	i	O
supplemented	VBD	i	O
with	IN	i	O
mixed	JJ	i	O
nuts	NNS	i	O
.	.	i	O

MEASUREMENTS	NNP	O	O
Main	NNP	O	O
outcomes	NNS	O	O
were	VBD	O	O
12-month	JJ	O	O
changes	NNS	O	O
from	IN	O	O
baseline	NN	O	O
in	IN	O	O
bone	NN	o	OPH
formation	NN	o	OPH
and	CC	o	OPH
resorption	NN	o	OPH
markers	NNS	o	OPH
and	CC	o	OPH
bone	NN	o	OPH
mass	NN	o	OPH
measured	VBD	o	OPH
according	VBG	O	O
to	TO	O	O
quantitative	JJ	O	O
ultrasound	JJ	O	O
scanning	NN	O	O
.	.	O	O

RESULTS	VB	O	O
The	DT	O	O
baseline	NN	O	O
data	NNS	O	O
on	IN	O	O
the	DT	O	O
anthropometric	NN	o	OPH
,	,	o	OPH
bone	NN	o	OPH
densitometry	NN	o	OPH
,	,	o	OPH
and	CC	o	OPH
biochemical	JJ	o	OPH
variables	NNS	o	OPH
did	VBD	O	O
not	RB	O	O
differ	VB	O	O
between	IN	O	O
the	DT	O	O
three	CD	p	O
groups	NNS	p	O
.	.	p	O

Dietary	NNP	o	OPH
potential	JJ	o	OPH
renal	JJ	o	OPH
acid	NN	o	OPH
load	NN	o	OPH
(	(	o	OPH
PRAL	NNP	o	OPH
)	)	o	OPH
and	CC	o	O
daily	JJ	o	OPH
net	NN	o	OPH
endogenous	JJ	o	OPH
acid	NN	o	OPH
production	NN	o	OPH
(	(	o	OPH
NEAP	NNP	o	OPH
)	)	o	OPH
at	IN	O	O
baseline	NN	O	O
did	VBD	O	O
not	RB	O	O
differ	VB	O	O
between	IN	O	O
groups	NNS	O	O
.	.	O	O

After	IN	O	O
intervention	NN	O	O
,	,	O	O
subjects	NNS	p	O
allocated	VBD	O	O
to	TO	O	O
the	DT	O	O
Mediterranean	NNP	i	IOt
diet	NN	i	IOt
with	IN	i	IOt
mixed	JJ	i	IOt
nuts	NNS	i	IOt
had	VBD	O	O
a	DT	O	O
significant	JJ	O	O
increase	NN	O	O
of	IN	O	O
PRAL	NNP	o	OPH
and	CC	o	O
NEAP	NNP	o	OPH
.	.	o	O

In	IN	O	O
comparison	NN	O	O
,	,	O	O
subjects	NNS	O	O
in	IN	O	O
the	DT	O	O
Mediterranean	NNP	i	IOt
diet	NN	i	IOt
with	IN	i	IOt
nuts	NNS	i	IOt
group	NN	p	O
had	VBD	O	O
higher	JJR	O	O
parathyroid	NN	o	OPH
hormone	NN	o	OPH
(	(	o	OPH
PTH	NNP	o	OPH
)	)	o	OPH
levels	NNS	o	OPH
(	(	O	O
2.63	CD	O	O
,	,	O	O
95	CD	O	O
%	NN	O	O
confidence	NN	O	O
interval	NN	O	O
(	(	O	O
CI	NNP	O	O
)	)	O	O
=-1.01-6.35	NN	O	O
,	,	O	O
P=.02	NNP	O	O
)	)	O	O
and	CC	O	O
a	DT	O	O
nonsignificantly	RB	O	O
higher	JJR	O	O
(	(	O	O
0.31	CD	O	O
,	,	O	O
95	CD	O	O
%	NN	O	O
CI=-0.13-0.74	NNP	O	O
,	,	O	O
P=.14	NNP	O	O
)	)	O	O
urine	VBP	o	OPH
free	JJ	o	OPH
deoxypyridoxine	NN	o	OPH
:	:	o	OPH
creatinine	NN	o	OPH
ratio	NN	o	OPH
,	,	O	O
a	DT	O	O
marker	NN	O	O
of	IN	O	O
bone	NN	O	O
resorption	NN	O	O
,	,	O	O
than	IN	O	O
the	DT	O	O
control	NN	O	O
group	NN	p	O
and	CC	O	O
the	DT	O	O
Mediterranean	NNP	O	O
diet	NN	O	O
with	IN	O	O
virgin	JJ	O	O
olive	JJ	O	O
oil	NN	O	O
group	NN	p	O
.	.	p	O

CONCLUSION	VB	O	O
A	DT	O	O
Mediterranean	NNP	i	IE
dietary	JJ	i	IE
pattern	NN	i	IE
associated	VBN	O	O
with	IN	O	O
a	DT	O	O
high	JJ	O	O
dietary	JJ	O	O
acid	NN	O	O
load	NN	O	O
derived	VBN	O	O
from	IN	O	O
consumption	NN	O	O
of	IN	O	O
mixed	JJ	O	O
nuts	NNS	O	O
does	VBZ	O	O
not	RB	O	O
seem	VB	O	O
to	TO	O	O
have	VB	O	O
a	DT	O	O
much	RB	O	O
greater	JJR	O	O
effect	NN	O	O
on	IN	O	O
bone	NN	o	OPH
metabolism	NN	o	OPH
biomarkers	NNS	o	OPH
,	,	O	O
with	IN	O	O
the	DT	O	O
exception	NN	O	O
of	IN	O	O
PTH	NNP	o	OPH
levels	NNS	o	OPH
,	,	O	O
than	IN	O	O
a	DT	O	O
Mediterranean	NNP	i	IOt
diet	NN	i	IOt
without	IN	i	IOt
mixed	JJ	i	IOt
nuts	NNS	i	IOt
or	CC	i	O
a	DT	i	O
control	NN	i	IC
diet	NN	i	IC
in	IN	O	O
elderly	JJ	p	PA
subjects	NNS	p	O
.	.	p	O

Angiotensin	NNP	O	O
converting	VBG	O	O
enzyme	JJ	O	O
inhibition	NN	O	O
does	VBZ	O	O
not	RB	O	O
affect	VB	O	O
the	DT	O	O
response	NN	O	O
to	TO	O	O
exogenous	JJ	O	O
angiotensin	NN	O	O
II	NNP	O	O
in	IN	O	O
the	DT	O	O
human	JJ	p	O
forearm	NN	p	O
.	.	p	O

Suppression	NN	O	O
of	IN	O	O
endogenous	JJ	O	O
levels	NNS	O	O
of	IN	O	O
angiotensin	NN	O	O
II	NNP	O	O
by	IN	O	O
angiotensin	NN	O	O
converting	VBG	O	O
enzyme	JJ	O	O
inhibition	NN	O	O
,	,	O	O
may	MD	O	O
result	VB	O	O
in	IN	O	O
up-regulation	NN	O	O
of	IN	O	O
vascular	JJ	O	O
AT1	NNP	O	O
receptors	NNS	O	O
.	.	O	O

We	PRP	O	O
have	VBP	O	O
evaluated	VBN	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
orally	RB	O	O
administered	VBN	O	O
enalapril	NN	i	IPM
on	IN	O	O
angiotensin	NN	O	O
II	NNP	O	O
induced	VBD	O	O
vasoconstriction	NN	O	O
in	IN	O	O
the	DT	O	O
human	JJ	p	O
forearm	NN	p	O
.	.	p	O

Subjects	VBZ	p	O
received	VBN	O	O
in	IN	O	O
random	JJ	O	O
order	NN	O	O
,	,	O	O
enalapril	NN	i	IPM
(	(	O	O
20	CD	O	O
mg	NN	O	O
)	)	O	O
or	CC	i	O
matched	VBN	i	O
placebo	JJ	i	IC
daily	JJ	O	O
for	IN	O	O
2	CD	O	O
weeks	NNS	O	O
.	.	O	O

Forearm	NNP	o	OPH
blood	NN	o	OPH
flow	NN	o	OPH
response	NN	O	O
to	TO	O	O
increasing	VBG	O	O
doses	NNS	O	O
of	IN	O	O
angiotensin	NN	O	O
II	NNP	O	O
was	VBD	O	O
measured	VBN	O	O
using	VBG	O	O
venous	JJ	O	O
occlusion	NN	O	O
plethysmography	NN	O	O
at	IN	O	O
the	DT	O	O
beginning	NN	O	O
of	IN	O	O
the	DT	O	O
study	NN	O	O
and	CC	O	O
at	IN	O	O
the	DT	O	O
end	NN	O	O
of	IN	O	O
each	DT	O	O
2	CD	O	O
week	NN	O	O
treatment	NN	O	O
period	NN	O	O
.	.	O	O

Treatment	NN	O	O
with	IN	O	O
enalapril	NN	O	O
significantly	RB	O	O
reduced	VBN	O	O
plasma	NN	o	OPH
angiotensin	NN	o	OPH
II	NNP	o	OPH
levels	NNS	o	OPH
and	CC	o	O
supine	VB	o	OPH
blood	NN	o	OPH
pressure	NN	o	OPH
compared	VBN	O	O
with	IN	O	O
placebo	NN	O	O
.	.	O	O

The	DT	O	O
percentage	NN	O	O
reductions	NNS	o	OPH
in	IN	o	OPH
forearm	NN	o	OPH
blood	NN	o	OPH
flow	NN	o	OPH
in	IN	O	O
the	DT	O	O
infused	JJ	O	O
arm	NN	O	O
,	,	O	O
in	IN	O	O
response	NN	O	O
to	TO	O	O
the	DT	O	O
maximum	JJ	O	O
dose	NN	O	O
of	IN	O	O
angiotensin	NN	O	O
II	NNP	O	O
(	(	O	O
50,000	CD	O	O
fmol	RB	O	O
min-1	NN	O	O
)	)	O	O
were	VBD	O	O
48.1	CD	O	O
+/-	JJ	O	O
3.6	CD	O	O
%	NN	O	O
at	IN	O	O
baseline	NN	O	O
,	,	O	O
57.5	CD	O	O
+/-	JJ	O	O
3.6	CD	O	O
%	NN	O	O
on	IN	O	O
placebo	NN	O	O
and	CC	O	O
54.5	CD	O	O
+/-	JJ	O	O
4.2	CD	O	O
%	NN	O	O
on	IN	O	O
enalapril	NN	O	O
.	.	O	O

The	DT	O	O
differences	NNS	O	O
were	VBD	O	O
not	RB	O	O
significantly	RB	O	O
different	JJ	O	O
.	.	O	O

This	DT	O	O
demonstrates	VBZ	O	O
that	IN	O	O
suppression	NN	O	O
of	IN	O	O
plasma	NN	O	O
angiotensin	NN	O	O
II	NNP	O	O
for	IN	O	O
a	DT	O	O
14	CD	O	O
day	NN	O	O
period	NN	O	O
does	VBZ	O	O
not	RB	O	O
enhance	VB	O	O
the	DT	O	O
response	NN	O	O
to	TO	O	O
exogenous	JJ	O	O
intra-arterial	JJ	O	O
angiotensin	NN	O	O
II	NNP	O	O
in	IN	O	O
the	DT	O	O
human	JJ	p	O
forearm	NN	p	O
of	IN	p	O
healthy	JJ	p	PC
salt	NN	p	PC
replete	JJ	p	PC
subjects	NNS	p	O
.	.	p	O

Improving	VBG	O	O
emotion	NN	o	OME
regulation	NN	o	OME
with	IN	O	O
CBT	NNP	i	IPM
in	IN	O	O
young	JJ	p	O
children	NNS	p	O
with	IN	p	O
high	JJ	p	O
functioning	VBG	p	O
autism	NN	p	O
spectrum	NN	p	O
disorders	NNS	p	O
:	:	p	O
a	DT	O	O
pilot	NN	O	O
study	NN	O	O
.	.	O	O

BACKGROUND	NNP	O	O
AND	CC	O	O
AIMS	NNP	O	O
This	DT	O	O
pilot	NN	O	O
study	NN	O	O
tested	VBD	O	O
the	DT	O	O
efficacy	NN	O	O
of	IN	O	O
a	DT	O	O
developmentally	RB	O	O
modified	VBN	O	O
CBT	NNP	i	O
for	IN	O	O
young	JJ	p	O
children	NNS	p	O
with	IN	p	O
Autism	NNP	p	O
Spectrum	NNP	p	O
Disorders	NNP	p	O
(	(	p	O
ASD	NNP	p	O
)	)	p	O
to	TO	O	O
teach	VB	O	O
emotion	NN	o	OME
regulation	NN	o	OME
strategies	NNS	O	O
for	IN	O	O
reducing	VBG	O	O
anger	NN	o	OME
and	CC	o	O
anxiety	NN	o	OME
,	,	O	O
commonly	RB	O	O
noted	VBD	O	O
problems	NNS	O	O
in	IN	O	O
this	DT	O	O
population	NN	O	O
.	.	O	O

METHOD	NNP	O	O
Eleven	NNP	p	O
5-7	JJ	p	O
year-old	JJ	p	O
children	NNS	p	O
participated	VBN	p	O
in	IN	O	O
a	DT	O	O
CBT-group	NNP	i	IPM
while	IN	O	O
parents	NNS	O	O
participated	VBN	i	IE
in	IN	i	IE
psychoeducation	NN	i	IE
.	.	i	O

Children	NNP	i	IC
were	VBD	i	IC
randomly	RB	i	IC
assigned	VBN	i	IC
to	TO	i	IC
an	DT	i	IC
experimental	JJ	i	IC
or	CC	i	IC
delayed-treatment	JJ	i	IC
control	NN	i	IC
group	NN	i	IC
.	.	i	O

RESULTS	CC	O	O
From	IN	O	O
pre-	JJ	O	O
to	TO	O	O
post-treatment	JJ	O	O
,	,	O	O
all	DT	O	O
children	NNS	O	O
had	VBD	O	O
less	RBR	O	O
parent	NN	p	O
reported	VBD	p	O
negativity/lability	NN	o	OME
,	,	O	O
better	JJR	O	O
parent	NN	O	O
reported	VBD	O	O
emotion	NN	o	OME
regulation	NN	o	OME
,	,	o	O
and	CC	o	O
shorter	JJR	o	OME
outbursts	NNS	o	OME
,	,	O	O
and	CC	O	O
also	RB	O	O
generated	VBD	o	OME
more	RBR	o	OME
coping	JJ	o	OME
strategies	NNS	o	OME
in	IN	O	O
response	NN	O	O
to	TO	O	O
vignettes	NNS	O	O
.	.	O	O

Parents	NNS	O	O
also	RB	O	O
reported	VBD	O	O
increases	NNS	O	O
in	IN	O	O
their	PRP$	O	O
own	JJ	O	O
confidence	NN	o	OME
and	CC	O	O
their	PRP$	O	O
child	NN	O	O
's	POS	O	O
ability	NN	o	OME
to	TO	o	OME
deal	VB	o	OME
with	IN	o	OME
anger	NN	o	OME
and	CC	o	OME
anxiety	NN	o	OME
.	.	o	O

CONCLUSIONS	VB	O	O
This	DT	O	O
study	NN	O	O
suggests	VBZ	O	O
that	IN	O	O
young	JJ	p	O
children	NNS	p	O
with	IN	p	O
high	JJ	p	O
functioning	VBG	p	O
ASD	NNP	p	O
may	MD	O	O
benefit	VB	O	O
from	IN	O	O
CBT	NNP	i	IPM
to	TO	O	O
improve	VB	O	O
regulation	NN	o	OME
of	IN	o	OME
anger	NN	o	OME
and	CC	o	OME
anxiety	NN	o	OME
,	,	O	O
and	CC	O	O
parent	NN	O	O
training	NN	O	O
may	MD	O	O
improve	VB	O	O
parental	JJ	o	OME
self-efficacy	NN	o	OME
.	.	o	O

Future	JJ	O	O
studies	NNS	O	O
are	VBP	O	O
needed	VBN	O	O
to	TO	O	O
make	VB	O	O
conclusions	NNS	O	O
about	IN	O	O
its	PRP$	O	O
efficacy	NN	O	O
.	.	O	O

Performance	NN	O	O
of	IN	O	O
a	DT	O	O
modified	VBN	i	O
starch	NN	i	O
hydrophilic	NN	i	O
matrix	NN	i	O
for	IN	i	O
the	DT	i	O
sustained	JJ	i	O
release	NN	i	O
of	IN	i	O
theophylline	NN	i	IPM
in	IN	O	O
healthy	JJ	p	O
volunteers	NNS	p	O
.	.	p	O

Two	CD	O	O
experimental	JJ	O	O
formulations	NNS	O	O
of	IN	O	O
theophylline	NN	i	IPM
with	IN	i	IPM
a	DT	i	IPM
hydrophilic	JJ	i	IPM
starch	NN	i	IPM
matrix	NN	i	IPM
were	VBD	O	O
evaluated	VBN	O	O
for	IN	O	O
their	PRP$	O	O
sustained-release	JJ	O	O
characteristics	NNS	O	O
after	IN	O	O
single	JJ	O	O
administration	NN	O	O
in	IN	O	O
healthy	JJ	p	O
human	JJ	p	O
volunteers	NNS	p	O
.	.	p	O

Theo-dur	NN	i	IPM
was	VBD	O	O
chosen	VBN	O	O
as	IN	O	O
a	DT	O	O
reference	NN	O	O
sustained-release	JJ	O	O
formulation	NN	O	O
.	.	O	O

In	IN	O	O
a	DT	O	O
first	JJ	O	O
study	NN	O	O
,	,	O	O
the	DT	O	O
extent	NN	O	O
of	IN	O	O
absorption	NN	O	O
was	VBD	O	O
similar	JJ	O	O
for	IN	O	O
a	DT	O	O
syrup	NN	O	O
,	,	O	O
for	IN	O	O
Theo-dur	NNP	i	IPM
,	,	O	O
and	CC	O	O
for	IN	O	O
the	DT	O	O
experimental	JJ	O	O
formulation	NN	O	O
of	IN	O	O
theophylline	NN	i	O
with	IN	i	O
70	CD	i	O
%	NN	i	O
drum-dried	JJ	i	O
corn	NN	i	O
starch	NN	i	O
as	IN	i	O
the	DT	i	O
sustained-release	JJ	i	O
agent	NN	i	O
(	(	i	O
DDCS-70	NNP	i	O
)	)	i	O
.	.	O	O

The	DT	O	O
maximal	JJ	o	OOt
plasma	NN	o	OOt
concentration	NN	o	OOt
(	(	o	OOt
Cmax	NNP	o	OOt
)	)	o	OOt
was	VBD	O	O
significantly	RB	O	O
lower	JJR	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
time	NN	o	OOt
to	TO	o	OOt
reach	VB	o	OOt
Cmax	NNP	o	OOt
as	RB	O	O
well	RB	O	O
as	IN	O	O
the	DT	O	O
time	NN	O	O
span	NN	O	O
during	IN	O	O
which	WDT	O	O
the	DT	O	O
plasma	NN	o	OOt
concentration	NN	o	OOt
was	VBD	O	O
at	IN	O	O
least	JJS	O	O
75	CD	O	O
%	NN	O	O
of	IN	O	O
the	DT	O	O
Cmax	NNP	O	O
were	VBD	O	O
significantly	RB	O	O
higher	JJR	O	O
for	IN	O	O
Theo-dur	NNP	O	O
than	IN	O	O
for	IN	O	O
the	DT	O	O
DDCS-70	NNP	O	O
formulation	NN	O	O
.	.	O	O

A	DT	O	O
sustained-release	JJ	O	O
profile	NN	O	O
,	,	O	O
as	IN	O	O
for	IN	O	O
Theo-dur	NNP	i	IPM
,	,	O	O
was	VBD	O	O
not	RB	O	O
reached	VBN	O	O
for	IN	O	O
DDCS-70	NNP	O	O
.	.	O	O

In	IN	O	O
a	DT	O	O
second	JJ	O	O
study	NN	O	O
the	DT	O	O
influence	NN	O	O
of	IN	O	O
the	DT	O	O
starch	NN	O	O
:	:	O	O
drug	NN	O	O
ratio	NN	O	O
on	IN	O	O
the	DT	O	O
bioavailability	NN	O	O
was	VBD	O	O
investigated	VBN	O	O
.	.	O	O

The	DT	O	O
decrease	NN	O	O
in	IN	O	O
starch	NN	O	O
content	NN	O	O
from	IN	O	O
70	CD	O	O
to	TO	O	O
50	CD	O	O
%	NN	O	O
of	IN	O	O
the	DT	O	O
formulation	NN	O	O
did	VBD	O	O
not	RB	O	O
improve	VB	O	O
the	DT	O	O
plasma	NN	o	OOt
concentration-time	JJ	o	OOt
profile	NN	O	O
towards	NNS	O	O
a	DT	O	O
sustained-release	JJ	O	O
profile	NN	O	O
.	.	O	O

The	DT	O	O
injured	JJ	p	PC
colon	NN	p	PC
:	:	p	O
therapeutic	JJ	O	O
considerations	NNS	O	O
.	.	O	O

A	DT	O	O
prospective	JJ	O	O
randomized	NN	O	O
study	NN	p	O
was	VBD	p	O
carried	VBN	p	O
out	RP	p	O
at	IN	p	O
the	DT	p	O
Detroit	NNP	p	O
General	NNP	p	O
Hospital	NNP	p	O
over	IN	p	O
a	DT	p	O
two	CD	p	O
year	NN	p	O
period	NN	p	O
to	TO	p	O
evaluate	VB	p	O
methods	NNS	p	O
of	IN	p	O
management	NN	p	O
in	IN	p	O
165	CD	p	PSS
patients	NNS	p	O
with	IN	p	O
colonic	JJ	i	IPH
injuries	NNS	i	IPH
.	.	i	O

Results	NNS	O	O
of	IN	O	O
the	DT	O	O
study	NN	O	O
show	NN	O	O
that	IN	O	O
primary	JJ	i	IPH
closure	NN	i	IPH
is	VBZ	O	O
a	DT	O	O
safe	JJ	o	OOt
and	CC	O	O
reiable	JJ	o	OOt
method	NN	O	O
of	IN	O	O
management	NN	O	O
when	WRB	O	O
rigid	JJ	O	O
criteria	NNS	O	O
are	VBP	O	O
incorporated	VBN	O	O
in	IN	O	O
an	DT	O	O
ongoing	JJ	O	O
protocol	NN	O	O
.	.	O	O

Moreover	RB	O	O
,	,	O	O
the	DT	O	O
technic	NN	O	O
of	IN	O	O
exteriorization	NN	i	IPH
is	VBZ	O	O
a	DT	O	O
safe	JJ	o	OOt
adjunct	NN	O	O
to	TO	O	O
management	NN	O	O
and	CC	O	O
is	VBZ	O	O
recommended	VBN	O	O
in	IN	O	O
any	DT	p	PC
patient	NN	p	PC
with	IN	p	PC
a	DT	p	PC
colonic	JJ	p	PC
injury	NN	p	PC
above	IN	p	PC
18	CD	p	PC
cm	NN	p	PC
in	IN	O	O
which	WDT	O	O
one	CD	O	O
suture	NN	O	O
line	NN	O	O
is	VBZ	O	O
required	VBN	O	O
and	CC	O	O
in	IN	O	O
which	WDT	O	O
the	DT	O	O
additional	JJ	O	O
operating	NN	O	O
time	NN	O	O
of	IN	O	O
twenty	NN	O	O
minutes	NNS	O	O
will	MD	O	O
not	RB	O	O
compromise	VB	O	O
the	DT	O	O
management	NN	O	O
of	IN	O	O
secondary	JJ	O	O
injuries	NNS	O	O
.	.	O	O

Patients	NNS	O	O
not	RB	O	O
fulfilling	VBG	O	O
these	DT	O	O
criteria	NNS	O	O
should	MD	O	O
have	VB	O	O
primary	JJ	o	OPH
colostomy	NN	o	OPH
.	.	o	OPH

These	DT	O	O
principles	NNS	O	O
make	VBP	O	O
it	PRP	O	O
possible	JJ	O	O
to	TO	O	O
reduce	VB	O	O
the	DT	O	O
need	NN	O	O
for	IN	O	O
primary	JJ	o	OPH
colostomy	NN	o	OPH
to	TO	O	O
approximately	RB	O	O
50	CD	O	O
per	IN	O	O
cent	NN	O	O
in	IN	O	O
a	DT	O	O
large	JJ	O	O
ongoing	VBG	O	O
group	NN	O	O
of	IN	O	O
patients	NNS	p	PC
with	IN	p	PC
colonic	JJ	p	PC
injury	NN	p	PC
.	.	p	O

A	DT	O	O
randomized	JJ	O	O
prospective	NN	O	O
controlled	VBN	O	O
trial	NN	O	O
of	IN	O	O
oral	JJ	O	O
ganciclovir	NN	i	IPM
versus	IN	O	O
oral	JJ	O	O
valacyclovir	NN	i	IPM
for	IN	O	O
prophylaxis	NN	O	O
of	IN	O	O
cytomegalovirus	NN	o	OPH
disease	NN	o	OPH
after	IN	O	O
renal	JJ	p	PC
transplantation	NN	p	PC
.	.	p	PC

Oral	NNP	O	O
ganciclovir	NN	i	IPM
and	CC	i	O
valacyclovir	NN	i	IPM
reduce	VB	O	O
the	DT	O	O
incidence	NN	O	O
of	IN	O	O
cytomegalovirus	NN	o	OPH
(	(	o	OPH
CMV	NNP	o	OPH
)	)	o	OPH
disease	NN	o	OPH
after	IN	p	O
renal	JJ	p	O
transplantation	NN	p	O
(	(	p	O
RTx	NNP	p	O
)	)	p	O
.	.	p	O

Our	PRP$	O	O
study	NN	O	O
was	VBD	O	O
designed	VBN	O	O
to	TO	O	O
compare	VB	O	O
the	DT	O	O
efficacy	NN	o	OOt
,	,	o	O
costs	NNS	o	OOt
,	,	o	O
and	CC	o	O
safety	NN	o	OOt
of	IN	O	O
oral	JJ	O	O
ganciclovir	NN	i	IPM
and	CC	i	O
valacyclovir	NN	i	IPM
in	IN	O	O
the	DT	O	O
prophylaxis	NN	O	O
of	IN	O	O
CMV	NNP	O	O
disease	NN	O	O
over	IN	O	O
the	DT	O	O
first	JJ	O	O
6	CD	O	O
months	NNS	O	O
after	IN	O	O
RTx	NNP	O	O
.	.	O	O

A	NNP	O	O
total	NN	p	O
of	IN	p	O
38	CD	p	O
patients	NNS	p	O
was	VBD	p	O
randomized	VBN	p	O
to	TO	p	O
3-month	JJ	p	O
treatment	NN	p	O
with	IN	p	O
either	DT	p	O
oral	JJ	i	IPM
ganciclovir	NN	i	IPM
(	(	p	O
1	CD	p	O
g	NN	p	O
t.i.d.	NN	p	O
,	,	O	O
n=14	RB	p	O
,	,	p	O
GAN	NNP	p	O
group	NN	p	O
)	)	p	O
or	CC	p	O
oral	JJ	i	IPM
valacyclovir	NN	i	IPM
(	(	p	O
2	CD	p	O
g	NN	p	O
q.i.d.	NN	p	O
,	,	O	O
n=12	RB	p	O
,	,	p	O
VAL	NNP	p	O
group	NN	p	O
)	)	p	O
.	.	O	O

A	DT	O	O
third	JJ	O	O
group	NN	O	O
(	(	O	O
C	NNP	O	O
,	,	O	O
n=12	NN	O	O
)	)	O	O
received	VBD	O	O
no	DT	i	IC
prophylaxis	NN	i	IC
.	.	i	O

The	DT	O	O
patients	NNS	O	O
were	VBD	O	O
monitored	VBN	O	O
by	IN	O	O
CMV-nested	JJ	O	O
PCR	NNP	O	O
in	IN	O	O
whole	JJ	O	O
blood	NN	O	O
.	.	O	O

No	DT	O	O
differences	NNS	O	O
were	VBD	O	O
found	VBN	O	O
between	IN	O	O
the	DT	O	O
groups	NNS	O	O
in	IN	O	O
their	PRP$	O	O
demographic	JJ	O	O
characteristics	NNS	O	O
,	,	O	O
immunosuppressive	JJ	O	O
protocols	NNS	O	O
,	,	O	O
or	CC	O	O
donor	NN	O	O
and	CC	O	O
recipient	NN	O	O
CMV	NNP	O	O
serology	NN	O	O
.	.	O	O

Thirty-six	CD	O	O
out	IN	O	O
of	IN	O	O
38	CD	O	O
(	(	O	O
94.7	CD	O	O
%	NN	O	O
)	)	O	O
recipients	NNS	O	O
were	VBD	O	O
CMV-seropositive	JJ	o	OPH
.	.	o	OPH

Over	IN	O	O
the	DT	O	O
6-month	JJ	O	O
post-RTx	JJ	O	O
period	NN	O	O
,	,	O	O
there	EX	O	O
were	VBD	O	O
13	CD	O	O
episodes	NNS	O	O
of	IN	O	O
CMV	NNP	o	OPH
disease	NN	O	O
in	IN	O	O
eight	CD	O	O
(	(	O	O
66.7	CD	O	O
%	NN	O	O
)	)	O	O
patients	NNS	O	O
of	IN	O	O
the	DT	O	O
C	NNP	O	O
group	NN	O	O
compared	VBN	O	O
with	IN	O	O
none	NN	O	O
in	IN	O	O
the	DT	O	O
GAN	NNP	O	O
and	CC	O	O
VAL	NNP	O	O
groups	NNS	O	O
(	(	O	O
P=0.0005	NNP	O	O
,	,	O	O
GAN	NNP	O	O
vs	NNP	O	O
C	NNP	O	O
;	:	O	O
P=0.001	NNP	O	O
,	,	O	O
VAL	NNP	O	O
vs	NNP	O	O
C	NNP	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
incidence	NN	o	OPH
of	IN	o	OPH
CMV	NNP	o	OPH
viremia	NN	o	OPH
was	VBD	O	O
30.8	CD	O	O
%	NN	O	O
,	,	O	O
50.0	CD	O	O
%	NN	O	O
,	,	O	O
and	CC	O	O
91.7	CD	O	O
%	NN	O	O
in	IN	O	O
the	DT	O	O
GAN	NNP	O	O
,	,	O	O
VAL	NNP	O	O
,	,	O	O
and	CC	O	O
C	NNP	O	O
groups	NNS	O	O
,	,	O	O
respectively	RB	O	O
(	(	O	O
P=0.004	NNP	O	O
,	,	O	O
GAN	NNP	O	O
vs	NNP	O	O
C	NNP	O	O
;	:	O	O
P=0.07	NNP	O	O
,	,	O	O
VAL	NNP	O	O
vs	NNP	O	O
C	NNP	O	O
;	:	O	O
P=NS	NNP	O	O
,	,	O	O
GAN	NNP	O	O
vs	NNP	O	O
VAL	NNP	O	O
)	)	O	O
.	.	O	O

Treatment	JJ	o	OOt
failure	NN	o	OOt
(	(	o	O
death	NN	o	OMO
,	,	o	O
graft	NN	o	OA
loss	NN	o	OA
,	,	o	O
CMV	NNP	o	OPH
disease	NN	o	OPH
,	,	o	O
or	CC	o	O
withdrawal	NN	o	OOt
from	IN	o	OOt
study	NN	o	OOt
)	)	o	O
occurred	VBD	O	O
in	IN	O	O
14.3	CD	O	O
%	NN	O	O
,	,	O	O
0	CD	O	O
%	NN	O	O
and	CC	O	O
66.7	CD	O	O
%	NN	O	O
in	IN	O	O
the	DT	O	O
GAN	NNP	O	O
,	,	O	O
VAL	NNP	O	O
,	,	O	O
and	CC	O	O
C	NNP	O	O
groups	NNS	O	O
,	,	O	O
respectively	RB	O	O
(	(	O	O
P=0.014	NNP	O	O
,	,	O	O
GAN	NNP	O	O
vs	NNP	O	O
C	NNP	O	O
;	:	O	O
P=0.001	NNP	O	O
,	,	O	O
VAL	NNP	O	O
vs	NNP	O	O
C	NNP	O	O
;	:	O	O
P=NS	NNP	O	O
,	,	O	O
GAN	NNP	O	O
vs	NNP	O	O
VAL	NNP	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
average	JJ	o	OOt
CMV-associated	JJ	o	OOt
costs	NNS	o	OOt
per	IN	o	OOt
patient	NN	o	OOt
(	(	O	O
in	IN	O	O
2001	CD	O	O
euros	NN	O	O
)	)	O	O
were	VBD	O	O
2,449+/-1,178	JJ	O	O
,	,	O	O
2,485+/-581	JJ	O	O
,	,	O	O
and	CC	O	O
4,259+/-4,616	JJ	O	O
in	IN	O	O
the	DT	O	O
GAN	NNP	O	O
,	,	O	O
VAL	NNP	O	O
,	,	O	O
and	CC	O	O
C	NNP	O	O
groups	NNS	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

Ganciclovir	NNP	O	O
and	CC	O	O
valacyclovir	NN	O	O
were	VBD	O	O
well	RB	o	OOt
tolerated	VBN	o	OOt
,	,	O	O
with	IN	O	O
ganciclovir	JJ	O	O
having	VBG	O	O
had	VBD	O	O
to	TO	O	O
be	VB	O	O
withdrawn	VBN	O	O
shortly	RB	O	O
in	IN	O	O
one	CD	O	O
patient	NN	O	O
only	RB	O	O
because	IN	O	O
of	IN	O	O
thrombocytopenia	NN	O	O
.	.	O	O

In	IN	O	O
conclusion	NN	O	O
,	,	O	O
oral	JJ	O	O
ganciclovir	NN	O	O
and	CC	O	O
valacyclovir	NN	O	O
are	VBP	O	O
equally	RB	o	OOt
safe	JJ	o	OOt
and	CC	o	OOt
effective	JJ	o	OOt
in	IN	O	O
the	DT	O	O
prophylaxis	NN	O	O
of	IN	O	O
CMV	NNP	O	O
disease	NN	O	O
after	IN	O	O
RTx	NNP	O	O
.	.	O	O

Both	DT	O	O
are	VBP	O	O
cost-effective	JJ	o	OOt
and	CC	O	O
help	VB	O	O
reduce	VB	O	O
CMV-associated	JJ	o	OOt
costs	NNS	o	OOt
by	IN	O	O
some	DT	O	O
40	CD	O	O
%	NN	O	O
compared	VBN	O	O
with	IN	O	O
patients	NNS	O	O
without	IN	O	O
prophylaxis	NN	O	O
.	.	O	O

A	DT	O	O
controlled	VBN	O	O
comparison	NN	O	O
between	IN	O	O
single	JJ	O	O
doses	NNS	O	O
of	IN	O	O
intravenous	JJ	i	IPM
and	CC	i	IPM
intramuscular	JJ	i	IPM
morphine	NN	i	IPM
with	IN	O	O
respect	NN	O	O
to	TO	O	O
analgesic	JJ	o	OOt
effects	NNS	o	OOt
and	CC	o	OOt
patient	JJ	o	OOt
safety	NN	o	OOt
.	.	o	OOt

UNLABELLED	VBN	O	O
BACKGROUND	NNP	O	O
AND	NNP	O	O
AIM	NNP	O	O
OF	NNP	O	O
INVESTIGATION	NNP	O	O
:	:	O	O
Intramuscular	NNP	O	O
(	(	O	O
IM	NNP	O	O
)	)	O	O
administration	NN	O	O
has	VBZ	O	O
been	VBN	O	O
considered	VBN	O	O
to	TO	O	O
be	VB	O	O
safer	JJR	O	O
than	IN	O	O
intravenous	JJ	O	O
(	(	O	O
IV	NNP	O	O
)	)	O	O
for	IN	O	O
opioids	NNS	i	IPM
on	IN	O	O
wards	NNS	O	O
,	,	O	O
but	CC	O	O
a	DT	O	O
comparative	JJ	O	O
knowledge	NN	O	O
of	IN	O	O
patient	JJ	o	OOt
safety	NN	o	OOt
and	CC	o	OOt
analgesic	JJ	o	OOt
potency	NN	o	OOt
following	VBG	O	O
a	DT	O	O
single	JJ	O	O
dose	NN	O	O
of	IN	O	O
IV	NNP	O	O
and	CC	O	O
IM	NNP	O	O
administration	NN	O	O
is	VBZ	O	O
lacking	VBG	O	O
.	.	O	O

This	DT	O	O
study	NN	O	O
was	VBD	O	O
carried	VBN	O	O
out	IN	O	O
to	TO	O	O
compare	VB	O	O
patient	JJ	o	OOt
safety	NN	o	OOt
and	CC	o	OOt
analgesic	JJ	o	OOt
efficacy	NN	o	OOt
of	IN	O	O
a	DT	O	O
single	JJ	O	O
and	CC	O	O
high	JJ	O	O
dose	NN	O	O
of	IN	O	O
morphine	NN	i	IPM
given	VBN	i	IPM
IM	NNP	i	IPM
or	CC	i	IPM
IV	NNP	i	IPM
for	IN	O	O
post-operative	JJ	p	O
pain	NN	p	O
management	NN	p	O
.	.	p	O

MATERIALS	NNP	O	O
AND	CC	O	O
METHODS	NNP	O	O
Thirty-eight	NNP	p	O
patients	NNS	p	O
with	IN	p	O
post-operative	JJ	p	O
pain	NN	p	O
following	VBG	p	O
hip	NN	i	IS
replacement	NN	i	IS
surgery	NN	i	IS
were	VBD	O	O
given	VBN	O	O
IM	NNP	i	IPM
or	CC	i	IPM
IV	NNP	i	IPM
morphine	VBP	i	IPM
10	CD	O	O
mg	NN	O	O
at	IN	O	O
a	DT	O	O
specified	JJ	O	O
pain	NN	O	O
level	NN	O	O
.	.	O	O

The	DT	O	O
study	NN	O	O
was	VBD	O	O
randomized	VBN	O	O
and	CC	O	O
double	JJ	O	O
blinded	VBN	O	O
.	.	O	O

Time	NN	o	OPH
to	TO	o	OPH
onset	VB	o	OPH
of	IN	o	OPH
analgesic	JJ	o	OPH
effect	NN	o	OPH
(	(	o	OPH
11-point	JJ	o	OPH
numeric	NN	o	OPH
rating	NN	o	OPH
scale	NN	o	OPH
)	)	o	OPH
,	,	o	OPH
respiratory	JJ	o	OPH
function	NN	o	OPH
(	(	o	OPH
p	NN	o	OPH
(	(	o	OPH
a	DT	o	OPH
)	)	o	OPH
CO2	NNP	o	OPH
,	,	o	OPH
p	NN	o	OPH
(	(	o	OPH
a	DT	o	OPH
)	)	o	OPH
O2	NNP	o	OPH
,	,	o	OPH
and	CC	o	OPH
respiratory	JJ	o	OPH
rate	NN	o	OPH
)	)	o	OPH
,	,	o	OPH
level	NN	o	OPH
of	IN	o	OPH
sedation	NN	o	OPH
(	(	o	OPH
5-point	JJ	o	OPH
verbal	NN	o	OPH
rating	NN	o	OPH
scale	NN	o	OPH
)	)	o	OPH
,	,	o	OPH
and	CC	o	OPH
hemodynamic	JJ	o	OPH
function	NN	o	OPH
were	VBD	O	O
recorded	VBN	O	O
.	.	O	O

RESULTS	NNP	O	O
In	IN	O	O
the	DT	O	O
IV	NNP	O	O
group	NN	O	O
there	EX	O	O
was	VBD	O	O
a	DT	O	O
slight	JJ	O	O
but	CC	O	O
significant	JJ	O	O
increase	NN	O	O
in	IN	O	O
p	NN	o	O
(	(	o	O
a	DT	o	O
)	)	o	O
CO2	NNP	o	O
after	IN	O	O
5	CD	O	O
,	,	O	O
10	CD	O	O
,	,	O	O
and	CC	O	O
15	CD	O	O
min	NNS	O	O
compared	VBN	O	O
with	IN	O	O
the	DT	O	O
IM	NNP	O	O
group	NN	O	O
(	(	O	O
5.2	CD	O	O
vs.	FW	O	O
4.8	CD	O	O
,	,	O	O
5.4	CD	O	O
,	,	O	O
vs.	FW	O	O
5.0	CD	O	O
and	CC	O	O
5.5	CD	O	O
vs.	FW	O	O
5.1	CD	O	O
kPa	NN	O	O
,	,	O	O
respectively	RB	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
IV	NNP	O	O
group	NN	O	O
had	VBD	O	O
a	DT	O	O
significantly	RB	O	O
faster	RBR	O	O
onset	NN	o	OPH
of	IN	o	OPH
analgesic	JJ	o	OPH
effect	NN	o	OPH
than	IN	O	O
the	DT	O	O
IM	NNP	O	O
group	NN	O	O
(	(	O	O
5	CD	O	O
vs.	FW	O	O
20	CD	O	O
min	NN	O	O
)	)	O	O
.	.	O	O

Between	$	O	O
5	CD	O	O
and	CC	O	O
25	CD	O	O
min	NN	O	O
after	IN	O	O
morphine	JJ	i	IPM
administration	NN	O	O
,	,	O	O
pain	NN	o	OPA
status	NN	o	OPA
in	IN	O	O
the	DT	O	O
IV	NNP	O	O
group	NN	O	O
was	VBD	O	O
significantly	RB	O	O
improved	VBN	O	O
compared	VBN	O	O
with	IN	O	O
the	DT	O	O
IM	NNP	O	O
group	NN	O	O
.	.	O	O

Patients	NNS	O	O
in	IN	O	O
the	DT	O	O
IV	NNP	O	O
group	NN	O	O
were	VBD	O	O
slightly	RB	O	O
more	RBR	O	O
sedated	JJ	o	OPH
than	IN	O	O
the	DT	O	O
IM	NNP	O	O
group	NN	O	O
5	CD	O	O
and	CC	O	O
10	CD	O	O
min	NN	O	O
after	IN	O	O
morphine	NN	O	O
.	.	O	O

CONCLUSION	VB	O	O
A	DT	O	O
10	CD	O	O
mg	NN	O	O
bolus	NN	O	O
dose	NN	O	O
of	IN	O	O
IV	NNP	O	O
morphine	NN	O	O
given	VBN	O	O
to	TO	O	O
patients	NNS	O	O
with	IN	O	O
moderate	JJ	O	O
pain	NN	O	O
after	IN	O	O
surgery	NN	i	IS
does	VBZ	O	O
not	RB	O	O
cause	VB	O	O
severe	JJ	o	OPH
respiratory	NN	o	OPH
depression	NN	o	OPH
,	,	O	O
but	CC	O	O
provides	VBZ	O	O
more	RBR	O	O
rapid	JJ	O	O
and	CC	O	O
better	RBR	O	O
initial	JJ	o	OPH
analgesia	NN	o	OPH
than	IN	O	O
10	CD	O	O
mg	NNS	O	O
given	VBN	O	O
IM	NNP	O	O
.	.	O	O

IV	NNP	O	O
morphine	VBD	i	IPM
even	RB	O	O
at	IN	O	O
a	DT	O	O
dose	NN	O	O
as	RB	O	O
high	JJ	O	O
as	IN	O	O
10	CD	O	O
mg	NN	O	O
IV	NNP	O	O
is	VBZ	O	O
well	RB	O	O
tolerated	VBN	o	OOt
if	IN	O	O
there	EX	O	O
is	VBZ	O	O
a	DT	O	O
certain	JJ	O	O
level	NN	O	O
of	IN	O	O
pain	NN	O	O
at	IN	O	O
its	PRP$	O	O
administration	NN	O	O
.	.	O	O

The	DT	O	O
safety	NN	O	O
of	IN	O	O
IV	NNP	O	O
morphine	NN	i	IPM
on	IN	O	O
the	DT	O	O
general	JJ	O	O
ward	NN	O	O
needs	VBZ	O	O
to	TO	O	O
be	VB	O	O
further	RB	O	O
explored	VBN	O	O
in	IN	O	O
adequately	RB	O	O
controlled	JJ	O	O
studies	NNS	O	O
.	.	O	O

Postoperative	JJ	o	OPA
pain	NN	o	OPA
control	NN	o	OPA
for	IN	O	O
outpatient	JJ	p	O
oral	JJ	p	PC
surgery	NN	p	PC
.	.	p	O

16	CD	p	PSS
healthy	JJ	p	PC
patients	NNS	p	O
requiring	VBG	p	PC
removal	NN	p	PC
of	IN	p	PC
bilateral	JJ	p	PC
symmetrically-impacted	JJ	p	PC
mandibular	JJ	p	PC
third	JJ	p	PC
molars	NNS	p	PC
participated	VBD	O	O
in	IN	O	O
a	DT	O	O
double-blind	NN	O	O
randomised	VBN	O	O
crossover	RB	O	O
trial	NN	O	O
to	TO	O	O
test	VB	O	O
the	DT	O	O
effectiveness	NN	o	OPA
of	IN	o	OPA
postoperative	JJ	o	OPA
pain	NN	o	OPA
control	NN	o	OPA
using	VBG	O	O
a	DT	O	O
long-acting	JJ	O	O
anti-inflammatory	JJ	O	O
agent	NN	O	O
(	(	i	O
diflunisal	NN	i	IPM
)	)	i	O
in	IN	O	O
combination	NN	O	O
with	IN	O	O
a	DT	O	O
long-acting	JJ	O	O
local	JJ	O	O
anaesthetic	JJ	O	O
agent	NN	O	O
(	(	i	IPM
bupivacaine	NN	i	IPM
)	)	i	IPM
.	.	O	O

Results	NNS	O	O
were	VBD	O	O
compared	VBN	O	O
to	TO	O	O
the	DT	O	O
more	RBR	O	O
traditional	JJ	O	O
method	NN	O	O
of	IN	O	O
using	VBG	O	O
an	DT	O	O
oral	JJ	O	O
analgesic	NN	O	O
with	IN	O	O
shorter	JJR	O	O
duration	NN	O	O
of	IN	O	O
action	NN	O	O
(	(	i	IPM
paracetamol	NN	i	IPM
with	IN	i	IPM
codeine	NN	i	IPM
)	)	i	IPM
with	IN	O	O
lignocaine	NN	i	IPM
as	IN	O	O
the	DT	O	O
local	JJ	O	O
anaesthetic	NN	O	O
.	.	O	O

Using	VBG	O	O
a	DT	O	O
visual	JJ	o	OPA
analogue	NN	o	OPA
pain	NN	o	OPA
scale	NN	o	OPA
,	,	O	O
patients	NNS	O	O
reported	VBD	O	O
that	IN	O	O
significantly	RB	O	O
reduced	VBN	O	O
pain	NN	o	OPA
was	VBD	O	O
experienced	VBN	O	O
over	IN	O	O
the	DT	O	O
first	JJ	O	O
4	CD	O	O
days	NNS	O	O
postoperatively	RB	O	O
with	IN	O	O
the	DT	O	O
diflunisal/bupivacaine	NN	i	IPM
treatment	NN	i	IPM
and	CC	O	O
patient	JJ	o	OPA
preference	NN	o	OPA
for	IN	O	O
this	DT	O	O
treatment	NN	O	O
was	VBD	O	O
highly	RB	O	O
significant	JJ	O	O
.	.	O	O

This	DT	O	O
report	NN	O	O
represents	VBZ	O	O
the	DT	O	O
first	JJ	O	O
such	JJ	O	O
study	NN	O	O
of	IN	O	O
diflunisal	NN	i	IPM
used	VBN	O	O
for	IN	O	O
an	DT	O	O
extended	JJ	O	O
course	NN	O	O
in	IN	O	O
oral	JJ	O	O
surgery	NN	O	O
with	IN	O	O
pain	NN	o	OPA
assessment	NN	O	O
over	IN	O	O
the	DT	O	O
same	JJ	O	O
period	NN	O	O
.	.	O	O

No	DT	O	O
significant	JJ	O	O
side-effects	NNS	o	OA
or	CC	o	OA
adverse	JJ	o	OA
reactions	NNS	o	OA
were	VBD	O	O
encountered	VBN	O	O
.	.	O	O

Comparative	JJ	O	O
efficacy	NN	O	O
and	CC	O	O
safety	NN	O	O
of	IN	O	O
calcium	NN	i	IPM
carbasalate	NN	i	IPM
plus	CC	i	O
metoclopramide	JJ	i	IPM
versus	NN	i	O
ergotamine	NN	i	IPM
tartrate	NN	i	IPM
plus	CC	i	O
caffeine	NN	i	IPM
in	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
acute	JJ	p	PC
migraine	NN	p	PC
attacks	NNS	p	PC
.	.	p	O

This	DT	O	O
randomized	JJ	O	O
,	,	O	O
double-blind	JJ	O	O
,	,	O	O
double-dummy	JJ	O	O
,	,	O	O
multicenter	NN	p	O
,	,	O	O
parallel-group	JJ	O	O
study	NN	O	O
aimed	VBN	O	O
at	IN	O	O
comparing	VBG	O	O
the	DT	O	O
efficacy	NN	O	O
and	CC	O	O
safety	NN	O	O
of	IN	O	O
calcium	NN	i	IPM
carbasalate	NN	i	IPM
(	(	i	IPM
equivalent	JJ	i	IPM
to	TO	i	IPM
900	CD	i	IPM
mg	NNS	i	IPM
aspirin	RB	i	IPM
)	)	i	IPM
plus	CC	i	O
metoclopramide	$	i	IPM
10	CD	i	IPM
mg	NN	i	IPM
(	(	i	IPM
CM	NNP	i	IPM
)	)	i	IPM
with	IN	i	O
ergotamine	JJ	i	IPM
tartrate	NN	i	IPM
1	CD	i	IPM
mg	NN	i	IPM
plus	CC	i	IPM
caffeine	JJ	i	IPM
100	CD	i	IPM
mg	NN	i	IPM
(	(	i	IPM
EC	NNP	i	IPM
)	)	i	IPM
administered	VBN	O	O
in	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
2	CD	O	O
acute	JJ	O	O
migraine	NN	O	O
attacks	NNS	O	O
.	.	O	O

A	DT	O	O
total	NN	O	O
of	IN	O	O
296	CD	p	PSS
patients	NNS	p	O
fulfilling	VBG	p	O
the	DT	p	O
International	NNP	p	O
Headache	NNP	p	O
Society	NNP	p	O
diagnostic	JJ	p	O
criteria	NNS	p	O
for	IN	p	O
migraine	NN	p	PC
were	VBD	p	O
enrolled	VBN	p	O
.	.	p	O

In	IN	O	O
total	JJ	O	O
,	,	O	O
one	CD	O	O
or	CC	O	O
two	CD	O	O
migraine	NN	O	O
attacks	NNS	O	O
were	VBD	O	O
treated	VBN	O	O
in	IN	O	O
268	CD	O	O
and	CC	O	O
235	CD	O	O
patients	NNS	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

The	DT	O	O
primary	JJ	O	O
endpoint	NN	O	O
for	IN	O	O
the	DT	O	O
first	JJ	O	O
treated	VBD	O	O
attack	NN	O	O
was	VBD	O	O
headache	NN	O	O
relief	NN	O	O
,	,	O	O
with	IN	O	O
intensity	NN	O	O
decreasing	VBG	O	O
from	IN	O	O
moderate	JJ	O	O
or	CC	O	O
severe	JJ	O	O
to	TO	O	O
mild	VB	O	O
or	CC	O	O
absent	VB	O	O
2	CD	O	O
h	NN	O	O
after	IN	O	O
drug	NN	O	O
intake	NN	O	O
.	.	O	O

Usual	JJ	O	O
secondary	JJ	O	O
efficacy	NN	O	O
endpoints	NNS	O	O
were	VBD	O	O
assessed	VBN	O	O
.	.	O	O

A	DT	O	O
superiority	NN	O	O
of	IN	O	O
CM	NNP	i	IPM
over	IN	O	O
EC	NNP	i	IPM
was	VBD	O	O
observed	VBN	O	O
for	IN	O	O
both	DT	O	O
treated	JJ	O	O
attacks	NNS	O	O
for	IN	O	O
the	DT	O	O
main	JJ	O	O
endpoint	NN	O	O
:	:	O	O
success	NN	O	O
in	IN	O	O
54	CD	O	O
versus	NN	O	O
36	CD	O	O
%	NN	O	O
,	,	O	O
p	NN	O	O
=	VBD	O	O
0.003	CD	O	O
for	IN	O	O
the	DT	O	O
first	JJ	O	O
attack	NN	O	O
and	CC	O	O
60	CD	O	O
versus	NN	O	O
44	CD	O	O
%	NN	O	O
,	,	O	O
p	NN	O	O
=	VBD	O	O
0.02	CD	O	O
for	IN	O	O
the	DT	O	O
second	JJ	O	O
attack	NN	O	O
.	.	O	O

CM	NNP	o	O
was	VBD	o	O
also	RB	o	O
significantly	RB	o	O
superior	JJ	o	O
to	TO	o	O
EC	NNP	o	O
during	IN	o	O
the	DT	o	O
first	JJ	o	O
attack	NN	o	O
for	IN	o	O
complete	JJ	o	OPH
headache	NN	o	OPH
relief	NN	o	OPH
(	(	o	O
20	CD	o	O
vs.	FW	o	O
8	CD	o	O
%	NN	o	O
,	,	o	O
p	NN	o	O
=	NNP	o	O
0.006	CD	o	O
)	)	o	O
,	,	o	O
nausea	NN	o	OA
(	(	o	O
42	CD	o	O
vs.	FW	o	O
63	CD	o	O
%	NN	o	O
,	,	o	O
p	NN	o	O
=	VBD	o	O
0	CD	o	O
.	.	o	O

007	CD	o	O
)	)	o	O
and	CC	o	O
willingness	NN	o	OME
to	TO	o	OME
take	VB	o	OME
the	DT	o	OME
drug	NN	o	OME
again	RB	o	OME
(	(	o	O
90	CD	o	O
vs.	FW	o	O
80	CD	o	O
%	NN	o	O
,	,	o	O
p	NN	o	O
=	NNP	o	O
0.043	CD	o	O
)	)	o	O
.	.	o	O

The	DT	o	O
global	JJ	o	OOt
efficacy	NN	o	OOt
evaluation	NN	o	OOt
,	,	o	OOt
rated	VBN	o	OOt
by	IN	o	OOt
the	DT	o	OOt
investigators	NNS	o	OOt
,	,	o	O
was	VBD	o	O
significantly	RB	o	O
more	RBR	o	O
favorable	JJ	o	O
to	TO	o	O
CM	NNP	o	O
for	IN	o	O
both	DT	o	O
attacks	NNS	o	O
(	(	o	O
p	VB	o	O
=	$	o	O
0.001	CD	o	O
for	IN	o	O
the	DT	o	O
first	JJ	o	O
attack	NN	o	O
and	CC	o	O
p	NN	o	O
=	VBP	o	O
0.02	CD	o	O
for	IN	o	O
the	DT	o	O
second	JJ	o	O
)	)	o	O
.	.	o	O

The	DT	o	OOt
patients	NNS	o	OOt
'	POS	o	OOt
evaluation	NN	o	OOt
was	VBD	o	OOt
significant	JJ	o	OOt
for	IN	o	OOt
the	DT	o	OOt
first	JJ	o	OOt
attack	NN	o	OOt
(	(	o	OOt
p	JJ	o	OOt
=	NNP	o	OOt
0.002	CD	o	OOt
)	)	o	OOt
.	.	o	O

The	DT	o	O
global	JJ	o	OA
incidence	NN	o	OA
of	IN	o	OA
adverse	JJ	o	OA
events	NNS	o	OA
was	VBD	o	O
45	CD	o	O
%	NN	o	O
higher	JJR	o	O
with	IN	o	O
EC	NNP	o	O
,	,	o	O
though	IN	o	O
not	RB	o	O
significant	JJ	o	O
(	(	o	O
32	CD	o	O
vs.	FW	o	O
22	CD	o	O
%	NN	o	O
,	,	o	O
p	NN	o	O
=	NNP	o	O
0.075	CD	o	O
)	)	o	O
.	.	o	O

They	PRP	o	O
were	VBD	o	O
most	RBS	o	O
often	RB	o	O
unspecific	JJ	o	O
and	CC	o	O
mild	JJ	o	O
to	TO	o	O
moderate	VB	o	O
in	IN	o	O
intensity	NN	o	O
.	.	o	O

Gastrointestinal	JJ	o	OA
side	NN	o	OA
effects	NNS	o	OA
were	VBD	o	O
significantly	RB	o	O
less	RBR	o	O
frequent	JJ	o	O
with	IN	o	O
CM	NNP	o	O
than	IN	o	O
EC	NNP	o	O
(	(	o	O
7	CD	o	O
vs.	FW	o	O
21	CD	o	O
%	NN	o	O
,	,	o	O
p	NN	o	O
=	NNP	o	O
0.001	CD	o	O
)	)	o	O
.	.	o	O

Thus	RB	o	OOt
,	,	o	OOt
CM	NNP	o	OOt
is	VBZ	o	OOt
more	RBR	o	OOt
effective	JJ	o	OOt
and	CC	o	OOt
has	VBZ	o	OOt
a	DT	o	OOt
better	JJR	o	OOt
gastrointestinal	JJ	o	OOt
safety	NN	o	OOt
than	IN	o	OOt
EC	NNP	o	OOt
in	IN	o	OOt
the	DT	o	OOt
acute	JJ	o	OOt
treatment	NN	o	OOt
of	IN	o	OOt
migraine	NN	o	OOt
attacks	NNS	o	OOt
.	.	o	O

Ropivacaine-clonidine	JJ	i	IPM
combination	NN	i	IPM
for	IN	O	O
caudal	NN	p	PC
blockade	NN	p	PC
in	IN	p	O
children	NNS	p	PA
.	.	p	O

BACKGROUND	NNP	O	O
Adding	NNP	O	O
clonidine	NN	i	IPM
to	TO	O	O
weak	JJ	i	IPM
ropivacaine	JJ	i	IPM
solutions	NNS	i	IPM
(	(	O	O
<	VB	O	O
0.2	CD	O	O
%	NN	O	O
)	)	O	O
could	MD	O	O
potentially	RB	O	O
enhance	VB	o	OOt
analgesia	NN	o	OOt
as	RB	O	O
well	RB	O	O
as	IN	O	O
further	JJ	O	O
reduce	VB	o	OPH
the	DT	o	OPH
risk	NN	o	OPH
for	IN	o	OPH
unwanted	JJ	o	OPH
motor	NN	o	OPH
blockade	NN	o	OPH
.	.	o	OPH

The	DT	O	O
aim	NN	O	O
of	IN	O	O
the	DT	O	O
present	JJ	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
compare	VB	O	O
the	DT	O	O
postoperative	JJ	O	O
pain-relieving	JJ	o	OPA
quality	NN	o	OPA
of	IN	O	O
a	DT	O	O
ropivacaine	JJ	i	IPM
0.1	CD	i	IPM
%	NN	i	IPM
-clonidine	JJ	i	IPM
mixture	NN	i	IPM
to	TO	O	O
that	DT	O	O
of	IN	O	O
plain	NN	i	IPM
ropivacaine	VBP	i	IPM
0.2	CD	O	O
%	NN	O	O
following	VBG	O	O
caudal	JJ	p	O
administration	NN	p	O
in	IN	p	O
children	NNS	p	O
.	.	p	O

METHODS	NNP	O	O
In	IN	O	O
a	DT	O	O
prospective	JJ	O	O
,	,	O	O
observer-blinded	JJ	O	O
fashion	NN	O	O
,	,	O	O
40	CD	p	PSS
ASA	NNP	p	O
1	CD	p	O
paediatric	JJ	p	PA
patients	NNS	p	PA
undergoing	VBG	p	O
subumbilical	JJ	p	PC
surgery	NN	p	PC
were	VBD	O	O
randomly	RB	i	O
allocated	VBN	i	O
to	TO	i	O
receive	VB	i	O
a	DT	i	O
caudal	JJ	i	O
injection	NN	i	O
of	IN	i	O
either	DT	i	O
plain	NN	i	IPM
ropivacaine	VBP	i	IPM
0.2	CD	i	IPM
%	NN	i	IPM
(	(	i	IPM
1	CD	i	IPM
ml/kg	NN	i	IPM
)	)	i	IPM
(	(	i	O
R0.2	NNP	i	O
)	)	i	O
or	CC	i	O
a	DT	i	O
mixture	NN	i	O
of	IN	i	O
ropivacaine	JJ	i	IPM
0.1	CD	i	IPM
%	NN	i	IPM
with	IN	i	O
clonidine	JJ	i	IPM
2	CD	i	IPM
microg/kg	NN	i	IPM
(	(	i	IPM
1	CD	i	IPM
ml/kg	NN	i	IPM
)	)	i	IPM
(	(	i	O
R0.1C	NNP	i	O
)	)	i	O
.	.	O	O

Objective	JJ	o	OPA
pain	NN	o	OPA
scale	NN	o	OPA
score	NN	o	OPA
and	CC	o	OPA
need	NN	o	OPA
for	IN	o	OPA
supplemental	JJ	o	OPA
analgesia	NN	o	OPA
were	VBD	i	O
used	VBN	i	O
to	TO	i	O
evaluate	VB	i	O
analgesia	NN	i	O
during	IN	i	O
the	DT	i	O
first	JJ	i	O
24	CD	i	O
h	NN	i	O
postoperatively	RB	i	O
.	.	i	O

Residual	JJ	o	OPH
postoperative	JJ	o	OPH
sedation	NN	o	OPH
was	VBD	i	O
also	RB	i	O
assessed	VBN	i	O
.	.	i	O

RESULTS	VB	O	O
A	DT	O	O
significantly	RB	O	O
higher	JJR	O	O
number	NN	O	O
of	IN	O	O
patients	NNS	O	O
in	IN	O	O
the	DT	O	O
R0.1C	NNP	O	O
group	NN	O	O
(	(	O	O
18/20	CD	O	O
)	)	O	O
could	MD	O	O
be	VB	O	O
managed	VBN	O	O
without	IN	O	O
supplemental	JJ	o	OPH
analgesia	NN	o	OPH
during	IN	O	O
the	DT	O	O
first	JJ	O	O
24	CD	O	O
h	NN	O	O
postoperatively	RB	O	O
compared	VBN	O	O
to	TO	O	O
the	DT	O	O
R0.2	NNP	O	O
group	NN	O	O
(	(	O	O
11/20	CD	O	O
)	)	O	O
(	(	O	O
P=0.034	NNP	O	O
)	)	O	O
.	.	O	O

Both	CC	O	O
the	DT	O	O
degree	NN	o	OPH
and	CC	o	OPH
the	DT	o	OPH
duration	NN	o	OPH
of	IN	o	OPH
postoperative	JJ	o	OPH
sedation	NN	o	OPH
was	VBD	O	O
similar	JJ	O	O
in	IN	O	O
both	DT	O	O
groups	NNS	O	O
.	.	O	O

No	DT	O	O
signs	NNS	O	O
of	IN	O	O
postoperative	JJ	o	OPH
motor	NN	o	OPH
blockade	NN	o	OPH
were	VBD	O	O
observed	VBN	O	O
.	.	O	O

CONCLUSIONS	VB	O	O
The	DT	O	O
combination	NN	O	O
of	IN	O	O
clonidine	NN	i	IPM
(	(	i	IPM
2	CD	i	IPM
microg/kg	NN	i	IPM
)	)	i	IPM
and	CC	i	IPM
ropivacaine	VB	i	IPM
0.1	CD	i	IPM
%	NN	i	IPM
is	VBZ	O	O
associated	VBN	O	O
with	IN	O	O
an	DT	O	O
improved	JJ	o	OOt
quality	NN	o	OOt
of	IN	o	OOt
postoperative	JJ	o	OOt
analgesia	NN	o	OOt
compared	VBN	O	O
to	TO	O	O
plain	VB	i	IPM
0.2	CD	i	IPM
%	NN	i	IPM
ropivacaine	NN	i	IPM
.	.	i	O

The	DT	O	O
improved	JJ	o	OOt
analgesic	JJ	o	OOt
quality	NN	o	OOt
of	IN	O	O
the	DT	O	O
clonidine-ropivacaine	JJ	O	O
mixture	NN	O	O
is	VBZ	O	O
achieved	VBN	O	O
without	IN	O	O
causing	VBG	O	O
any	DT	O	O
significant	JJ	O	O
degree	NN	O	O
of	IN	O	O
postoperative	JJ	O	O
sedation	NN	O	O
.	.	O	O

Peripheral	JJ	O	O
arterial	JJ	O	O
disease	NN	O	O
:	:	O	O
therapeutic	JJ	O	O
confidence	NN	O	O
of	IN	O	O
CT	NNP	i	IOt
versus	NNP	i	O
digital	JJ	i	IOt
subtraction	NN	i	IOt
angiography	NN	i	IOt
and	CC	O	O
effects	NNS	O	O
on	IN	O	O
additional	JJ	O	O
imaging	NN	O	O
recommendations	NNS	O	O
.	.	O	O

PURPOSE	NNP	O	O
To	TO	O	O
compare	VB	O	O
multi-detector	JJ	i	IOt
row	NN	i	IOt
computed	VBN	i	IOt
tomographic	JJ	i	IOt
(	(	i	IOt
CT	NNP	i	IOt
)	)	i	IOt
angiography	NN	i	IOt
and	CC	i	O
digital	JJ	i	IOt
subtraction	NN	i	IOt
angiography	NN	i	IOt
(	(	i	IOt
DSA	NNP	i	IOt
)	)	i	IOt
prior	RB	O	O
to	TO	O	O
revascularization	NN	i	IS
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
symptomatic	JJ	p	O
peripheral	JJ	p	O
arterial	JJ	p	O
disease	NN	p	O
for	IN	O	O
the	DT	O	O
purpose	NN	O	O
of	IN	O	O
assessing	VBG	O	O
recommendations	NNS	O	O
for	IN	O	O
additional	JJ	O	O
imaging	NN	O	O
and	CC	O	O
physician	JJ	O	O
confidence	NN	O	O
ratings	NNS	O	O
for	IN	O	O
chosen	NN	O	O
therapy	NN	O	O
.	.	O	O

MATERIALS	NNP	O	O
AND	CC	O	O
METHODS	NNP	O	O
In	IN	O	O
a	DT	O	O
randomized	NN	O	O
controlled	VBN	O	O
trial	NN	O	O
,	,	O	O
73	CD	p	O
patients	NNS	p	O
were	VBD	p	O
assigned	VBN	p	O
to	TO	p	O
CT	NNP	i	IOt
angiography	NN	i	IOt
,	,	p	O
and	CC	p	O
72	CD	p	O
were	VBD	p	O
assigned	VBN	p	O
to	TO	p	O
DSA	NNP	i	IPH
.	.	i	O

Physician	JJ	o	OME
confidence	NN	o	OME
in	IN	o	OME
the	DT	o	OME
treatment	NN	o	OME
decision	NN	o	OME
was	VBD	O	O
measured	VBN	O	O
as	IN	O	O
a	DT	O	O
continuous	JJ	O	O
outcome	NN	O	O
on	IN	O	O
a	DT	O	O
scale	NN	O	O
of	IN	O	O
0-10	NNP	O	O
(	(	O	O
uncertain	JJ	O	O
to	TO	O	O
certain	JJ	O	O
)	)	O	O
and	CC	O	O
as	IN	O	O
a	DT	O	O
dichotomous	JJ	o	O
outcome	NN	o	O
(	(	O	O
further	JJ	O	O
imaging	NN	O	O
recommended	VBD	O	O
,	,	O	O
yes	UH	O	O
or	CC	O	O
no	DT	O	O
)	)	O	O
.	.	O	O

Mean	JJ	o	OME
confidence	NN	o	OME
scores	NNS	o	OME
and	CC	O	O
additional	JJ	o	OOt
imaging	NN	o	OOt
recommendations	NNS	o	OOt
were	VBD	O	O
compared	VBN	O	O
between	IN	O	O
CT	NNP	i	IOt
and	CC	i	O
DSA	NNP	i	IOt
groups	NNS	O	O
in	IN	O	O
an	DT	O	O
intention-to-diagnose-and-treat	JJ	O	O
analysis	NN	O	O
.	.	O	O

To	TO	O	O
detect	VB	O	O
trends	NNS	O	O
in	IN	O	O
confidence	NN	O	O
,	,	O	O
confidence	NN	O	O
scores	NNS	O	O
were	VBD	O	O
plotted	VBN	O	O
over	IN	O	O
time	NN	O	O
,	,	O	O
and	CC	O	O
multiple	JJ	O	O
linear	JJ	O	O
regression	NN	O	O
analysis	NN	O	O
was	VBD	O	O
performed	VBN	O	O
.	.	O	O

To	TO	O	O
detect	VB	O	O
trends	NNS	O	O
in	IN	O	O
additional	JJ	o	OOt
imaging	NN	o	OOt
recommendations	NNS	o	OOt
,	,	O	O
logistic	JJ	O	O
regression	NN	O	O
analysis	NN	O	O
was	VBD	O	O
used	VBN	O	O
.	.	O	O

Data	NNS	O	O
from	IN	O	O
eligible	JJ	O	O
nonrandomized	JJ	O	O
patients	NNS	O	O
were	VBD	O	O
analyzed	VBN	O	O
separately	RB	O	O
.	.	O	O

RESULTS	NNP	O	O
No	NNP	o	O
statistically	RB	o	O
significant	JJ	o	O
difference	NN	o	O
in	IN	O	O
baseline	NN	O	O
characteristics	NNS	O	O
between	IN	O	O
randomized	VBN	O	O
groups	NNS	O	O
was	VBD	O	O
found	VBN	O	O
.	.	O	O

CT	NNP	i	IOt
had	VBD	O	O
a	DT	O	O
lower	JJR	o	OME
confidence	NN	o	OME
score	JJR	o	OME
than	IN	O	O
did	VBD	O	O
DSA	NNP	i	IOt
(	(	O	O
7.2	CD	O	O
vs	NN	O	O
8.2	CD	O	O
,	,	O	O
P	NNP	O	O
<	NNP	O	O
.001	NNP	O	O
)	)	O	O
.	.	O	O

Further	JJ	O	O
imaging	NN	O	O
was	VBD	O	O
recommended	VBN	O	O
more	RBR	O	O
often	RB	O	O
after	IN	O	O
CT	NNP	i	IOt
(	(	O	O
25	CD	O	O
of	IN	O	O
71	CD	O	O
patients	NNS	O	O
,	,	O	O
35	CD	O	O
%	NN	O	O
)	)	O	O
than	IN	O	O
after	IN	O	O
DSA	NNP	i	IOt
(	(	O	O
nine	CD	O	O
of	IN	O	O
66	CD	O	O
patients	NNS	O	O
,	,	O	O
14	CD	O	O
%	NN	O	O
;	:	O	O
P	NNP	O	O
=	NNP	O	O
.003	NNP	O	O
)	)	O	O
.	.	O	O

Analysis	NN	O	O
of	IN	O	O
trends	NNS	O	O
demonstrated	VBN	O	O
increasing	VBG	O	O
(	(	O	O
but	CC	O	O
not	RB	O	O
statistically	RB	O	O
significant	JJ	O	O
)	)	O	O
confidence	NN	o	OME
in	IN	O	O
CT	NNP	i	IOt
and	CC	O	O
stable	JJ	O	O
confidence	NN	o	OME
in	IN	O	O
DSA	NNP	i	IOt
.	.	i	O

No	NNP	o	OOt
significant	JJ	o	OOt
difference	NN	o	OOt
was	VBD	O	O
found	VBN	O	O
in	IN	O	O
baseline	NN	O	O
characteristics	NNS	O	O
between	IN	O	O
randomized	VBN	O	O
and	CC	O	O
nonrandomized	JJ	O	O
patients	NNS	O	O
.	.	O	O

Among	IN	O	O
nonrandomized	JJ	O	O
patients	NNS	O	O
,	,	O	O
no	DT	O	O
significant	JJ	O	O
difference	NN	O	O
in	IN	O	O
mean	JJ	o	OME
confidence	NN	o	OME
score	NN	o	OME
(	(	O	O
8.2	CD	O	O
vs	NN	O	O
8.3	CD	O	O
,	,	O	O
P	NNP	O	O
=	NNP	O	O
.26	NNP	O	O
)	)	O	O
was	VBD	O	O
found	VBN	O	O
between	IN	O	O
CT	NNP	i	IOt
(	(	O	O
n	JJ	O	O
=	NNP	O	O
24	CD	O	O
)	)	O	O
and	CC	O	O
DSA	NNP	i	IOt
(	(	O	O
n	JJ	O	O
=	NNP	O	O
26	CD	O	O
)	)	O	O
.	.	O	O

CONCLUSION	NN	O	O
With	IN	O	O
CT	NNP	i	IOt
angiography	NN	i	IOt
,	,	O	O
physician	JJ	O	O
confidence	NN	O	O
decreases	NNS	O	O
with	IN	O	O
an	DT	O	O
associated	JJ	O	O
increase	NN	O	O
in	IN	O	O
additional	JJ	O	O
imaging	NN	O	O
prior	RB	O	O
to	TO	O	O
revascularization	NN	O	O
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
symptomatic	JJ	p	O
peripheral	JJ	p	O
arterial	JJ	p	O
disease	NN	p	O
.	.	p	O

Given	VBN	O	O
that	IN	O	O
CT	NNP	i	IOt
is	VBZ	O	O
less	RBR	O	O
invasive	JJ	O	O
than	IN	O	O
DSA	NNP	i	IOt
,	,	O	O
results	NNS	O	O
suggest	VBP	O	O
that	IN	O	O
CT	NNP	i	IOt
may	MD	O	O
replace	VB	O	O
DSA	NNP	i	IOt
in	IN	O	O
selected	VBN	O	O
cases	NNS	O	O
.	.	O	O

Adult	NNP	p	PA
height	NN	p	O
in	IN	p	O
short	JJ	p	O
children	NNS	p	PA
born	VBN	p	O
SGA	NNP	p	PC
treated	VBD	p	O
with	IN	p	O
growth	NN	i	IPM
hormone	NN	i	IPM
and	CC	i	O
gonadotropin	NN	i	IPM
releasing	VBG	i	IPM
hormone	NN	i	IPM
analog	NN	i	IPM
:	:	i	O
results	NNS	O	O
of	IN	O	O
a	DT	O	O
randomized	JJ	O	O
,	,	O	O
dose-response	JJ	O	O
GH	NNP	i	IPM
trial	NN	O	O
.	.	O	O

CONTEXT	NNP	O	O
GH	NNP	i	IPM
treatment	NN	i	O
is	VBZ	O	O
effective	JJ	O	O
in	IN	O	O
improving	VBG	O	O
height	NN	O	O
in	IN	O	O
short	JJ	p	PC
children	NNS	p	PC
born	VBP	p	PC
small	JJ	p	PC
for	IN	p	PC
gestational	JJ	p	PC
age	NN	p	PC
(	(	p	PC
SGA	NNP	p	PC
)	)	p	PC
.	.	p	O

GH	NNP	i	O
is	VBZ	O	O
thought	VBN	O	O
to	TO	O	O
have	VB	O	O
limited	VBN	O	O
effect	NN	O	O
when	WRB	O	O
started	VBD	O	O
during	IN	O	O
adolescence	NN	O	O
.	.	O	O

OBJECTIVE	CC	O	O
The	DT	O	O
aim	NN	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
investigate	VB	O	O
GH	NNP	i	IPM
treatment	NN	i	O
efficacy	NN	o	OOt
in	IN	O	O
short	JJ	O	O
SGA	NNP	O	O
children	NNS	O	O
when	WRB	O	O
treatment	NN	O	O
was	VBD	O	O
started	VBN	O	O
during	IN	O	O
adolescence	NN	O	O
;	:	O	O
to	TO	O	O
assess	VB	O	O
whether	IN	O	O
GH	NNP	i	IPM
2	CD	i	O
mg/m	NN	i	O
(	(	i	O
2	CD	i	O
)	)	i	O
?	.	O	O
d	NN	O	O
during	IN	O	O
puberty	JJ	O	O
improves	NNS	o	O
adult	VBP	o	O
height	NN	o	O
(	(	o	O
AH	NNP	o	O
)	)	o	O
compared	VBN	O	O
with	IN	O	O
1	CD	O	O
mg/m	NNS	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
?	.	O	O
d	NN	O	O
;	:	O	O
and	CC	O	O
to	TO	O	O
assess	VB	O	O
whether	IN	O	O
an	DT	O	O
additional	JJ	O	O
2-yr	JJ	O	O
postponement	NN	O	O
of	IN	O	O
puberty	NN	O	O
by	IN	O	O
GnRH	NNP	i	O
analog	NN	i	O
(	(	i	O
GnRHa	NNP	i	O
)	)	i	O
improves	VBZ	i	O
AH	NNP	O	O
in	IN	O	O
children	NNS	O	O
who	WP	O	O
are	VBP	O	O
short	JJ	O	O
at	IN	O	O
the	DT	O	O
start	NN	O	O
of	IN	O	O
puberty	NN	O	O
(	(	O	O
<	JJ	O	O
140	CD	O	O
cm	NN	O	O
)	)	O	O
,	,	O	O
with	IN	O	O
a	DT	O	O
poor	JJ	O	O
AH	NNP	O	O
expectation	NN	p	O
.	.	p	O

PATIENTS	NNP	O	O
AND	CC	O	O
DESIGN	NNP	O	O
In	IN	O	O
this	DT	O	O
longitudinal	JJ	O	O
,	,	O	O
randomized	VBN	O	O
,	,	O	O
dose-response	JJ	O	O
GH	NNP	O	O
trial	NN	O	O
,	,	O	O
we	PRP	O	O
included	VBD	p	O
121	CD	p	O
short	JJ	p	O
SGA	NNP	p	O
children	NNS	p	O
(	(	p	O
60	CD	p	O
boys	NNS	p	O
)	)	p	O
at	IN	p	O
least	JJS	p	O
8	CD	p	O
yr	NN	p	O
of	IN	p	O
age	NN	p	O
.	.	p	O

We	PRP	O	O
performed	VBD	p	O
intention-to-treat	JJ	p	O
analyses	NNS	p	O
on	IN	p	O
all	DT	p	O
children	NNS	p	O
and	CC	p	O
uncensored	JJ	p	O
case	NN	p	O
analyses	VBZ	p	O
on	IN	p	O
84	CD	p	O
children	NNS	p	O
who	WP	p	O
reached	VBD	p	O
AH	NNP	p	O
.	.	p	O

Besides	NNP	O	O
,	,	O	O
we	PRP	O	O
evaluated	VBD	o	O
growth	NN	o	O
during	IN	o	O
2	CD	O	O
yr	NNS	O	O
of	IN	O	O
combined	JJ	i	O
GH/GnRHa	NNP	i	O
and	CC	i	O
subsequent	JJ	i	O
GH	NNP	i	O
treatment	NN	i	O
until	IN	i	O
AH	NNP	O	O
in	IN	O	O
a	DT	O	O
subgroup	NN	O	O
of	IN	O	O
40	CD	O	O
pubertal	JJ	O	O
children	NNS	O	O
with	IN	O	O
a	DT	O	O
height	NN	O	O
of	IN	O	O
less	JJR	O	O
than	IN	O	O
140	CD	O	O
cm	NN	O	O
at	IN	O	O
the	DT	O	O
start	NN	O	O
.	.	O	O

RESULTS	NNP	p	O
Short	NNP	p	O
SGA	NNP	p	O
children	NNS	p	O
started	VBD	p	O
treatment	NN	O	O
at	IN	O	O
a	DT	O	O
median	JJ	O	O
age	NN	O	O
of	IN	O	O
11.2	CD	O	O
yr	NNS	O	O
,	,	O	O
when	WRB	O	O
46	CD	O	O
%	NN	O	O
had	VBD	O	O
already	RB	O	O
started	VBN	O	O
puberty	NN	o	O
.	.	o	O

Median	JJ	o	O
height	NN	o	O
increased	VBD	o	O
from	IN	O	O
-2.9	NN	O	O
at	IN	O	O
start	NN	O	O
to	TO	O	O
-1.7	VB	O	O
sd	NN	O	O
score	NN	O	O
(	(	O	O
SDS	NNP	O	O
)	)	O	O
at	IN	O	O
AH	NNP	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.001	CD	i	O
)	)	i	O
.	.	i	O

Treatment	NN	i	O
with	IN	i	O
GH	NNP	i	O
2	CD	i	O
vs.	FW	O	O
1	CD	O	O
mg/m	NN	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
?	.	O	O
d	NN	O	O
during	IN	O	O
puberty	NN	O	O
resulted	VBD	O	O
in	IN	O	O
significantly	RB	O	O
better	JJR	o	O
AH	NNP	o	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.001	CD	O	O
)	)	O	O
,	,	O	O
also	RB	O	O
after	IN	O	O
correction	NN	O	O
for	IN	O	O
gender	NN	O	O
,	,	O	O
age	NN	O	O
at	IN	O	O
start	NN	O	O
,	,	O	O
height	VBD	O	O
SDS	NNP	O	O
at	IN	O	O
start	NN	O	O
,	,	O	O
treatment	NN	O	O
years	NNS	O	O
before	IN	O	O
puberty	NN	O	O
,	,	O	O
and	CC	O	O
target	VB	O	O
height	JJ	O	O
SDS	NNP	O	O
.	.	o	O

AH	NNP	o	O
was	VBD	O	O
similar	JJ	O	O
in	IN	O	O
children	NNS	O	O
who	WP	O	O
started	VBD	O	O
puberty	NN	O	O
at	IN	O	O
less	JJR	O	O
than	IN	O	O
140	CD	O	O
cm	NN	O	O
and	CC	O	O
received	VBD	i	O
GH/GnRHa	NNP	i	O
,	,	i	O
compared	VBN	i	O
with	IN	O	O
children	NNS	O	O
who	WP	O	O
started	VBD	O	O
puberty	NN	O	O
greater	JJR	O	O
than	IN	O	O
140	CD	O	O
cm	NN	O	O
and	CC	O	O
received	VBD	i	O
GH	NNP	i	O
only	RB	i	O
(	(	i	O
P	NNP	i	O
=	NNP	O	O
0.795	CD	O	O
)	)	O	O
.	.	O	O

CONCLUSION	NN	O	O
When	WRB	O	O
started	VBN	O	O
in	IN	O	O
adolescence	NN	i	O
,	,	i	O
GH	NNP	i	O
treatment	NN	i	O
significantly	RB	i	O
improves	VBZ	o	O
AH	NNP	o	O
in	IN	O	O
short	JJ	p	O
SGA	NNP	p	O
children	NNS	p	O
,	,	p	O
particularly	RB	p	O
with	IN	i	O
GH	NNP	i	O
2	CD	p	O
mg/m	NN	p	O
(	(	p	O
2	CD	p	O
)	)	p	O
?	.	p	O
d	NN	p	O
during	IN	p	O
puberty	NN	p	O
.	.	p	O

When	WRB	p	O
SGA	NNP	O	O
children	NNS	O	O
are	VBP	O	O
short	JJ	O	O
at	IN	O	O
the	DT	O	O
start	NN	O	O
of	IN	O	O
puberty	NN	O	O
,	,	O	O
they	PRP	O	O
can	MD	O	O
benefit	VB	O	O
from	IN	O	O
combined	JJ	i	O
GH/GnRHa	NNP	i	O
treatment	NN	i	O
.	.	i	O

The	DT	O	O
11-beta-hydroxysteroid	JJ	O	O
dehydrogenase	NN	O	O
type	NN	O	O
1	CD	O	O
inhibitor	NN	O	O
INCB13739	NNP	i	IPM
improves	VBZ	O	O
hyperglycemia	NN	o	OPH
in	IN	p	O
patients	NNS	p	O
with	IN	p	O
type	JJ	p	O
2	CD	p	O
diabetes	NNS	p	O
inadequately	RB	p	O
controlled	VBN	p	O
by	IN	p	O
metformin	NN	p	O
monotherapy	NN	p	O
.	.	p	O

OBJECTIVE	CC	O	O
11-Beta-hydroxysteroid	JJ	O	O
dehydrogenase	NN	O	O
type	NN	O	O
1	CD	O	O
(	(	O	O
11betaHSD1	CD	O	O
)	)	O	O
converts	NNS	O	O
inactive	JJ	O	O
cortisone	NN	O	O
into	IN	O	O
active	JJ	O	O
cortisol	NN	O	O
,	,	O	O
thereby	RB	O	O
amplifying	VBG	O	O
intracellular	JJ	O	O
glucocorticoid	JJ	O	O
action	NN	O	O
.	.	O	O

The	DT	O	O
efficacy	NN	o	OOt
and	CC	o	OOt
safety	NN	o	OOt
of	IN	O	O
the	DT	O	O
11betaHSD1	CD	O	O
inhibitor	NN	O	O
INCB13739	NNP	O	O
were	VBD	O	O
assessed	VBN	O	O
when	WRB	O	O
added	VBN	O	O
to	TO	O	O
ongoing	VBG	O	O
metformin	NN	O	O
monotherapy	NN	O	O
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
type	JJ	p	O
2	CD	p	O
diabetes	NNS	p	O
exhibiting	VBG	p	O
inadequate	JJ	p	O
glycemic	NNS	p	O
control	NN	p	O
(	(	p	O
A1C	NNP	p	O
7-11	CD	p	O
%	NN	p	O
)	)	p	O
.	.	p	O

RESEARCH	NNP	O	O
DESIGN	NNP	O	O
AND	NNP	O	O
METHODS	NNP	O	O
This	DT	O	O
double-blind	JJ	O	O
placebo-controlled	JJ	i	IC
paralleled	VBN	O	O
study	NN	O	O
randomized	VBD	O	O
302	CD	p	O
patients	NNS	p	O
with	IN	p	O
type	JJ	p	O
2	CD	p	O
diabetes	NNS	p	O
(	(	p	O
mean	JJ	p	O
A1C	NNP	p	O
8.3	CD	p	O
%	NN	p	O
)	)	p	O
on	IN	p	O
metformin	NN	i	IPM
monotherapy	NN	i	IPM
(	(	p	O
mean	JJ	p	O
1.5	CD	p	O
g/day	NN	p	O
)	)	p	O
to	TO	O	O
receive	VB	O	O
one	CD	O	O
of	IN	O	O
five	CD	O	O
INCB13739	NNP	i	IPM
doses	NNS	i	IPM
or	CC	i	O
placebo	NN	i	IC
once	RB	O	O
daily	JJ	O	O
for	IN	O	O
12	CD	O	O
weeks	NNS	O	O
.	.	O	O

The	DT	O	O
primary	JJ	O	O
end	NN	O	O
point	NN	O	O
was	VBD	O	O
the	DT	O	O
change	NN	o	OPH
in	IN	o	OPH
A1C	NNP	o	OPH
at	IN	o	OPH
study	JJ	o	OPH
end	NN	o	OPH
.	.	o	O

Other	JJ	O	O
end	NN	O	O
points	NNS	O	O
included	VBD	O	O
changes	NNS	o	OPH
in	IN	o	OPH
fasting	VBG	o	OPH
glucose	NN	o	OPH
,	,	o	O
lipids	NNS	o	OPH
,	,	o	O
weight	NN	o	OPH
,	,	o	O
adverse	JJ	o	OA
events	NNS	o	OA
,	,	o	O
and	CC	o	O
safety	NN	o	OOt
.	.	o	O

RESULTS	NNP	O	O
After	IN	O	O
12	CD	O	O
weeks	NNS	O	O
,	,	O	O
200	CD	O	O
mg	NN	O	O
of	IN	O	O
INCB13739	NNP	O	O
resulted	VBD	O	O
in	IN	O	O
significant	JJ	O	O
reductions	NNS	O	O
in	IN	O	O
A1C	NNP	o	O
(	(	O	O
-0.6	NNP	O	O
%	NN	O	O
)	)	O	O
,	,	O	O
fasting	VBG	o	OPH
plasma	NN	o	OPH
glucose	NN	o	OPH
(	(	O	O
-24	NNP	O	O
mg/dl	NN	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
homeostasis	NN	o	OPH
model	NN	o	OPH
assessment-insulin	JJ	o	OPH
resistance	NN	o	OPH
(	(	O	O
HOMA-IR	NNP	O	O
)	)	O	O
(	(	O	O
-24	CD	O	O
%	NN	O	O
)	)	O	O
compared	VBN	O	O
with	IN	O	O
placebo	NN	O	O
.	.	O	O

Total	JJ	o	OPH
cholesterol	NN	o	OPH
,	,	o	O
LDL	NNP	o	OPH
cholesterol	NN	o	OPH
,	,	o	O
and	CC	o	O
triglycerides	NNS	o	OPH
were	VBD	O	O
all	DT	O	O
significantly	RB	O	O
decreased	VBN	O	O
in	IN	O	O
hyperlipidemic	JJ	O	O
patients	NNS	O	O
.	.	O	O

Body	NNP	o	OPH
weight	VBD	o	OPH
decreased	JJ	O	O
relative	NN	O	O
to	TO	O	O
placebo	VB	O	O
after	IN	O	O
INCB13739	NNP	O	O
therapy	NN	O	O
.	.	O	O

A	DT	O	O
reversible	JJ	O	O
dose-dependent	JJ	O	O
elevation	NN	O	O
in	IN	O	O
adrenocorticotrophic	JJ	o	OPH
hormone	NN	o	OPH
,	,	O	O
generally	RB	O	O
within	IN	O	O
the	DT	O	O
normal	JJ	O	O
reference	NN	O	O
range	NN	O	O
,	,	O	O
was	VBD	O	O
observed	VBN	O	O
.	.	O	O

Basal	NNP	o	OPH
cortisol	JJ	o	OPH
homeostasis	NN	o	OPH
,	,	o	O
testosterone	NN	o	OPH
in	IN	o	OPH
men	NNS	o	OPH
,	,	o	O
and	CC	o	O
free	JJ	o	OPH
androgen	NN	o	OPH
index	NN	o	OPH
in	IN	o	OPH
women	NNS	o	OPH
were	VBD	O	O
unchanged	JJ	O	O
by	IN	O	O
INCB13739	NNP	O	O
.	.	O	O

Adverse	JJ	O	O
events	NNS	O	O
were	VBD	O	O
similar	JJ	O	O
across	IN	O	O
all	DT	O	O
treatment	NN	O	O
groups	NNS	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
INCB13739	NNP	O	O
added	VBD	O	O
to	TO	O	O
ongoing	VBG	O	O
metformin	NN	O	O
therapy	NN	O	O
was	VBD	O	O
efficacious	JJ	o	OOt
and	CC	O	O
well	RB	O	O
tolerated	VBN	o	OOt
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
type	JJ	p	O
2	CD	p	O
diabetes	NNS	p	O
who	WP	p	O
had	VBD	p	O
inadequate	JJ	p	O
glycemic	NNS	p	O
control	NN	p	O
with	IN	p	O
metformin	NN	p	O
alone	RB	p	O
.	.	p	O

11BetaHSD1	CD	O	O
inhibition	NN	O	O
offers	NNS	O	O
a	DT	O	O
new	JJ	O	O
potential	JJ	O	O
approach	NN	O	O
to	TO	O	O
control	VB	O	O
glucose	JJ	o	OPH
and	CC	o	OPH
cardiovascular	JJ	o	OPH
risk	NN	o	OPH
factors	NNS	o	OPH
in	IN	O	O
type	NN	p	O
2	CD	p	O
diabetes	NNS	p	O
.	.	p	O

Avatar	NNP	O	O
assistant	NN	O	O
:	:	O	O
improving	VBG	O	O
social	JJ	o	OME
skills	NNS	o	OME
in	IN	O	O
students	NNS	p	PC
with	IN	p	PC
an	DT	p	PC
ASD	NNP	p	PC
through	IN	O	O
a	DT	O	O
computer-based	JJ	i	IE
intervention	NN	i	IE
.	.	i	O

This	DT	O	O
study	NN	O	O
assessed	VBD	O	O
the	DT	O	O
efficacy	NN	o	OOt
of	IN	O	O
FaceSay	NNP	i	IE
,	,	i	IE
a	DT	i	IE
computer-based	JJ	i	IE
social	JJ	o	OME
skills	NNS	o	OME
training	VBG	i	IE
program	NN	i	IE
for	IN	O	O
children	NNS	p	O
with	IN	p	O
Autism	NNP	p	O
Spectrum	NNP	p	O
Disorders	NNP	p	O
(	(	p	O
ASD	NNP	p	O
)	)	p	O
.	.	p	O

This	DT	O	O
randomized	VBD	O	O
controlled	VBN	O	O
study	NN	p	O
(	(	p	O
N	NNP	p	O
=	NNP	p	O
49	CD	p	O
)	)	p	O
indicates	VBZ	p	O
that	IN	O	O
providing	VBG	p	O
children	NNS	p	O
with	IN	p	O
low-functioning	JJ	p	O
autism	NN	p	O
(	(	p	O
LFA	NNP	p	O
)	)	p	O
and	CC	p	O
high	JJ	p	O
functioning	NN	p	O
autism	NN	p	O
(	(	p	O
HFA	NNP	p	O
)	)	p	O
opportunities	VBZ	p	O
to	TO	O	O
practice	NN	O	O
attending	VBG	O	O
to	TO	O	O
eye	NN	O	O
gaze	NN	O	O
,	,	O	O
discriminating	VBG	O	O
facial	JJ	O	O
expressions	NNS	O	O
and	CC	O	O
recognizing	VBG	O	O
faces	VBZ	O	O
and	CC	O	O
emotions	NNS	O	O
in	IN	O	O
FaceSay	NNP	O	O
's	POS	O	O
structured	JJ	O	O
environment	NN	O	O
with	IN	O	O
interactive	JJ	O	O
,	,	O	O
realistic	JJ	O	O
avatar	NN	O	O
assistants	NNS	O	O
improved	VBD	O	O
their	PRP$	o	O
social	JJ	o	O
skills	NNS	o	O
abilities	NNS	o	O
.	.	o	O

The	DT	O	O
children	NNS	O	O
with	IN	O	O
LFA	NNP	O	O
demonstrated	VBD	O	O
improvements	NNS	O	O
in	IN	O	O
two	CD	O	O
areas	NNS	O	O
of	IN	O	O
the	DT	O	O
intervention	NN	o	O
:	:	o	O
emotion	NN	o	O
recognition	NN	o	O
and	CC	o	O
social	JJ	o	O
interactions	NNS	o	O
.	.	o	O

The	DT	O	O
children	NNS	O	O
with	IN	O	O
HFA	NNP	O	O
demonstrated	VBD	O	O
improvements	NNS	O	O
in	IN	O	O
all	DT	O	O
three	CD	O	O
areas	NNS	o	O
:	:	o	O
facial	JJ	o	O
recognition	NN	o	O
,	,	o	O
emotion	NN	o	O
recognition	NN	o	O
,	,	o	O
and	CC	o	O
social	JJ	o	O
interactions	NNS	o	O
.	.	o	O

These	DT	O	O
findings	NNS	O	O
,	,	O	O
particularly	RB	O	O
the	DT	O	O
measured	JJ	O	O
improvements	NNS	O	O
to	TO	O	O
social	JJ	o	O
interactions	NNS	o	O
in	IN	o	O
a	DT	O	O
natural	JJ	O	O
environment	NN	O	O
,	,	O	O
are	VBP	O	O
encouraging	VBG	O	O
.	.	O	O

The	DT	O	O
effects	NNS	O	O
of	IN	O	O
physical	JJ	i	IPS
and	CC	i	IPS
emotional	JJ	i	IPS
status	NN	i	IPS
on	IN	O	O
adherence	NN	O	O
to	TO	O	O
a	DT	O	O
low-fat	JJ	i	IOt
dietary	JJ	i	IOt
pattern	NN	i	IOt
in	IN	O	O
the	DT	O	O
Women	NNP	O	O
's	POS	O	O
Health	NNP	O	O
Initiative	NNP	O	O
.	.	O	O

OBJECTIVE	NNP	O	O
To	TO	O	O
examine	VB	O	O
whether	IN	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
physical	JJ	O	O
and	CC	O	O
emotional	JJ	O	O
status	NN	O	O
on	IN	O	O
adherance	NN	O	O
to	TO	O	O
a	DT	O	O
low-fat	JJ	i	IE
(	(	i	IE
20	CD	i	IE
%	NN	i	IE
energy	NN	i	IE
)	)	i	IE
dietary	JJ	i	IE
pattern	NN	i	IE
are	VBP	O	O
mediated	VBN	O	O
by	IN	O	O
participation	NN	O	O
in	IN	O	O
an	DT	O	O
intervention	NN	i	IE
program	NN	i	IE
(	(	i	IE
attending	VBG	i	IE
sessions	NNS	i	IE
and	CC	i	IE
self-monitoring	NN	i	IE
)	)	i	IE
.	.	i	IE

DESIGN	VB	O	O
The	DT	O	O
Baron	NNP	O	O
and	CC	O	O
Kenny	NNP	O	O
mediator	NN	O	O
model	NN	O	O
,	,	O	O
a	DT	O	O
series	NN	O	O
of	IN	O	O
4	CD	O	O
regression	NN	O	O
analyses	NNS	O	O
,	,	O	O
was	VBD	O	O
used	VBN	O	O
to	TO	O	O
evaluate	VB	O	O
whether	IN	O	O
:	:	O	O
a	DT	O	O
)	)	O	O
physical	JJ	O	O
and	CC	O	O
emotional	JJ	O	O
status	NN	O	O
predicted	VBD	O	O
program	NN	O	O
participation	NN	O	O
,	,	O	O
b	NN	O	O
)	)	O	O
program	NN	O	O
participation	NN	O	O
predicted	VBD	O	O
dietary	JJ	O	O
adherence	NN	O	O
,	,	O	O
c	NN	O	O
)	)	O	O
physical	JJ	O	O
and	CC	O	O
emotional	JJ	O	O
status	NN	O	O
factors	NNS	O	O
predicted	VBD	O	O
dietary	JJ	i	IOt
adherence	NN	i	IOt
,	,	O	O
and	CC	O	O
,	,	O	O
ultimately	RB	O	O
d	NN	O	O
)	)	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
physical	JJ	O	O
and	CC	O	O
emotional	JJ	O	O
status	NN	O	O
on	IN	O	O
dietary	JJ	O	O
adherence	NN	O	O
were	VBD	O	O
mediated	VBN	O	O
by	IN	O	O
program	NN	O	O
participation	NN	O	O
.	.	O	O

SUBJECTS/SETTING	NNP	O	O
Data	NNP	p	O
from	IN	p	O
13,277	CD	p	PSS
postmenopausal	JJ	p	PC
women	NNS	p	PSE
randomly	RB	p	O
assigned	VBN	p	O
to	TO	p	O
the	DT	p	O
low-fat	JJ	i	IE
intervention	NN	i	IE
arm	NN	p	O
of	IN	p	O
the	DT	p	O
Women	NNP	p	O
's	POS	p	O
Health	NNP	p	O
Initiative	NNP	p	O
Dietary	NNP	p	O
Modification	NNP	p	O
Trial	NNP	p	O
.	.	p	O

INTERVENTION	NNP	O	O
The	DT	O	O
nutrition	NN	O	O
goals	NNS	O	O
for	IN	O	O
women	NNS	O	O
randomly	RB	O	O
assigned	VBN	O	O
to	TO	O	O
the	DT	O	O
low-fat	JJ	i	IE
intervention	NN	i	IE
were	VBD	O	O
to	TO	O	O
reduce	VB	i	IE
total	JJ	i	IE
fat	JJ	i	IE
intake	NN	i	IE
to	TO	i	IE
20	CD	i	IE
%	NN	i	IE
or	CC	i	IE
less	JJR	i	IE
of	IN	i	IE
energy	NN	i	IE
from	IN	i	IE
fat	JJ	i	IE
and	CC	i	IE
to	TO	i	IE
consume	VB	i	IE
5	CD	i	IE
or	CC	i	IE
more	JJR	i	IE
fruit/vegetable	JJ	i	IE
servings	NNS	i	IE
daily	RB	i	IE
and	CC	i	IE
6	CD	i	IE
or	CC	i	IE
more	JJR	i	IE
grain	JJ	i	IE
servings	NNS	i	IE
daily	RB	i	IE
.	.	i	IE

MAIN	NNP	O	O
OUTCOME	NNP	O	O
MEASURES	NNP	O	O
Year	NNP	o	OME
1	CD	o	OME
program	NN	o	OME
participation	NN	o	OME
(	(	o	OME
degree	NN	o	OME
of	IN	o	OME
attending	VBG	o	OME
group	NN	o	OME
sessions	NNS	o	OME
and	CC	o	OME
submitting	VBG	o	OME
fat	JJ	o	OME
scores	NNS	o	OME
)	)	o	OME
and	CC	p	O
adherence	NN	o	OME
to	TO	o	OME
the	DT	o	OME
low-fat	JJ	o	OME
dietary	JJ	o	OME
pattern	NN	o	OME
(	(	o	OME
percent	JJ	o	OME
energy	NN	o	OME
from	IN	o	OME
fat	NN	o	OME
)	)	o	OME
as	IN	O	O
predicted	VBN	O	O
by	IN	O	O
baseline	JJ	O	O
physical	JJ	O	O
and	CC	O	O
emotional	JJ	O	O
status	NN	O	O
(	(	O	O
eight	CD	O	O
SF-36	NNP	O	O
Health	NNP	O	O
Survey	NNP	O	O
subscales	VBZ	O	O
)	)	O	O
.	.	O	O

RESULTS	NNP	O	O
Participating	VBG	O	O
in	IN	O	O
the	DT	O	O
dietary	JJ	i	IE
intervention	NN	i	IE
program	NN	i	IE
reduced	VBN	O	O
(	(	O	O
mediated	VBN	O	O
)	)	O	O
the	DT	O	O
negative	JJ	O	O
effect	NN	o	OME
of	IN	o	OME
poorer	JJR	o	OME
mental	JJ	o	OME
health	NN	o	OME
on	IN	O	O
dietary	JJ	o	OME
adherence	NN	o	OME
by	IN	O	O
15	CD	O	O
%	NN	O	O
.	.	O	O

Additional	JJ	O	O
findings	NNS	O	O
included	VBD	O	O
that	IN	O	O
a	DT	O	O
10	CD	O	O
%	NN	O	O
increase	NN	O	O
in	IN	O	O
physical	JJ	o	OPH
functioning	NN	o	OPH
increased	VBD	O	O
session	NN	o	OME
attendance	NN	o	OME
by	IN	O	O
0.4	CD	O	O
%	NN	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
.001	NNP	O	O
)	)	O	O
and	CC	O	O
a	DT	O	O
10	CD	O	O
%	NN	O	O
increase	NN	O	O
in	IN	O	O
mental	JJ	o	OME
health	NN	o	OME
predicted	VBD	O	O
a	DT	O	O
decrease	NN	O	O
in	IN	O	O
percent	NN	O	O
energy	NN	o	O
from	IN	o	O
fat	NN	o	O
of	IN	O	O
0.3	CD	O	O
%	NN	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
.001	NNP	O	O
)	)	O	O
.	.	O	O

Program	NNP	O	O
participation	NN	O	O
had	VBD	O	O
a	DT	O	O
marked	JJ	O	O
effect	NN	O	O
on	IN	O	O
dietary	JJ	o	OME
adherence	NN	o	OME
:	:	o	O
a	DT	O	O
10	CD	O	O
%	NN	O	O
increase	NN	O	O
in	IN	O	O
session	NN	o	OME
attendance	NN	o	OME
predicted	VBD	O	O
a	DT	O	O
1.2	CD	O	O
%	NN	O	O
decrease	NN	O	O
in	IN	O	O
percent	NN	o	O
energy	NN	o	O
from	IN	o	O
fat	JJ	o	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
.001	NNP	O	O
)	)	O	O
.	.	O	O

APPLICATIONS/CONCLUSIONS	NNP	O	O
Understanding	NNP	O	O
and	CC	O	O
using	VBG	O	O
instruments	NNS	O	O
to	TO	O	O
assess	VB	O	O
the	DT	O	O
physical	JJ	O	O
and	CC	O	O
emotional	JJ	O	O
status	NN	O	O
of	IN	O	O
a	DT	O	O
target	NN	O	O
population	NN	O	O
will	MD	O	O
help	VB	O	O
dietetic	JJ	O	O
professionals	NNS	O	O
promote	VBP	O	O
healthful	JJ	O	O
dietary	JJ	O	O
change	NN	O	O
and	CC	O	O
maintenance	NN	O	O
.	.	O	O

Effects	NNS	O	O
of	IN	O	O
creatine	JJ	i	IPM
supplementation	NN	i	IPM
on	IN	O	O
repetitive	JJ	O	O
sprint	NN	O	O
performance	NN	O	O
and	CC	O	O
body	NN	O	O
composition	NN	O	O
in	IN	O	O
competitive	JJ	p	O
swimmers	NNS	p	O
.	.	p	O

In	IN	O	O
a	DT	O	O
double-blind	NN	O	O
and	CC	O	O
randomized	JJ	O	O
manner	NN	O	O
,	,	O	O
18	CD	p	O
male	NN	p	O
and	CC	p	O
female	JJ	p	O
junior	JJ	p	O
competitive	JJ	p	O
swimmers	NNS	p	O
supplemented	VBD	O	O
their	PRP$	O	O
diets	NNS	O	O
with	IN	O	O
21	CD	O	O
g.day-1	NN	O	O
of	IN	O	O
creatine	NN	i	IPM
monohydrate	NN	i	IPM
(	(	i	IPM
Cr	NNP	i	IPM
)	)	i	IPM
or	CC	O	O
a	DT	O	O
maltodextrin	JJ	i	IPM
placebo	NN	i	IPM
(	(	i	IPM
P	NNP	i	IPM
)	)	i	IPM
for	IN	O	O
9	CD	p	O
days	NNS	p	O
during	IN	p	O
training	NN	p	O
.	.	p	O

Prior	NNP	O	O
to	TO	O	O
and	CC	O	O
following	VBG	O	O
supplementation	NN	O	O
,	,	O	O
subjects	NNS	O	O
performed	VBD	O	O
three	CD	O	O
100-m	JJ	O	O
freestyle	JJ	O	O
sprint	NN	O	O
swims	NNS	O	O
(	(	O	O
long	JJ	O	O
course	NN	O	O
)	)	O	O
with	IN	O	O
60	CD	O	O
s	JJ	O	O
rest/recovery	NN	O	O
between	IN	O	O
heats	NNS	O	O
.	.	O	O

In	IN	O	O
addition	NN	O	O
,	,	O	O
subjects	NNS	O	O
performed	VBD	O	O
three	CD	O	O
20-s	JJ	O	O
arm	NN	O	O
ergometer	NN	O	O
maximal-effort	JJ	O	O
sprint	NN	O	O
tests	NNS	O	O
in	IN	O	O
the	DT	O	O
prone	NN	O	O
position	NN	O	O
with	IN	O	O
60	CD	O	O
s	JJ	O	O
rest/recovery	NN	O	O
between	IN	O	O
sprint	NN	O	O
tests	NNS	O	O
.	.	O	O

Significant	JJ	O	O
differences	NNS	O	O
were	VBD	O	O
observed	VBN	O	O
among	IN	O	O
swim	JJ	o	OOt
times	NNS	o	OOt
,	,	O	O
with	IN	O	O
Cr	NNP	O	O
subjects	NNS	O	O
swimming	VBG	O	O
significantly	RB	O	O
faster	RBR	O	O
than	IN	O	O
P	NNP	O	O
subjects	NNS	O	O
following	VBG	O	O
supplementation	NN	O	O
in	IN	O	O
Heat	NNP	O	O
1	CD	O	O
and	CC	O	O
significantly	RB	O	O
decreasing	VBG	O	O
swim	JJ	o	OOt
time	NN	o	OOt
in	IN	O	O
the	DT	O	O
second	JJ	O	O
100-m	JJ	O	O
sprint	NN	O	O
.	.	O	O

There	EX	O	O
was	VBD	O	O
also	RB	O	O
some	DT	O	O
evidence	NN	O	O
that	IN	O	O
cumulative	JJ	o	OOt
time	NN	o	OOt
to	TO	o	OOt
perform	VB	o	OOt
the	DT	o	OOt
three	CD	o	OOt
100-m	JJ	o	OOt
swims	NNS	o	OOt
was	VBD	O	O
decreased	VBN	O	O
in	IN	O	O
the	DT	O	O
Cr	NNP	O	O
group	NN	O	O
.	.	O	O

Results	NNP	O	O
indicate	VBP	O	O
that	IN	O	O
9	CD	O	O
days	NNS	O	O
of	IN	O	O
Cr	NNP	i	IPM
supplementation	NN	O	O
during	IN	O	O
swim	JJ	O	O
training	NN	O	O
may	MD	O	O
provide	VB	O	O
some	DT	O	O
ergogenic	JJ	O	O
value	NN	O	O
to	TO	O	O
competitive	JJ	O	O
junior	JJ	O	O
swimmers	NNS	O	O
during	IN	O	O
repetitive	JJ	O	O
sprint	NN	O	O
performance	NN	O	O
.	.	O	O

[	JJ	O	O
Myocardial	NNP	O	O
ischemia	NN	O	O
with	IN	O	O
stable	JJ	O	O
angina	JJ	O	O
pectoris	NN	O	O
:	:	O	O
clinico-ergometric	JJ	O	O
evaluation	NN	O	O
after	IN	O	O
the	DT	O	O
use	NN	O	O
of	IN	O	O
diltiazem	NN	i	IPM
]	NN	i	IPM
.	.	O	O

PURPOSE	NNP	O	O
To	TO	O	O
evaluate	VB	O	O
the	DT	O	O
efficacy	NN	O	O
of	IN	O	O
diltiazem	JJ	i	IPM
versus	NN	O	O
placebo	NN	i	IC
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
stable	JJ	p	PC
angina	NN	p	PC
.	.	p	O

METHODS	NNP	O	O
Eight-seven	JJ	p	PSS
angina	NNS	p	O
pectoris	JJ	p	O
patients	NNS	p	O
,	,	p	O
mean	JJ	p	PA
age	NN	p	PA
of	IN	p	PA
57	CD	p	PA
+/-	JJ	p	PA
9	CD	p	PA
,	,	p	O
82	CD	p	O
white	JJ	p	O
and	CC	p	O
79	CD	p	PSE
male	NN	p	PSE
were	VBD	O	O
evaluated	VBN	O	O
in	IN	O	O
a	DT	O	O
randomized	JJ	O	O
,	,	O	O
double-blind	JJ	O	O
trial	NN	O	O
of	IN	O	O
two	CD	O	O
groups	NNS	O	O
of	IN	O	O
patients	NNS	O	O
diltiazem	JJ	i	IPM
and	CC	i	O
placebo	NN	i	IC
,	,	O	O
3	CD	O	O
to	TO	O	O
4	CD	O	O
tablets	NNS	O	O
a	DT	O	O
day	NN	O	O
(	(	i	O
diltiazem	JJ	i	IPM
180	CD	O	O
to	TO	O	O
240	CD	O	O
mg	NNS	O	O
daily	RB	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
patients	NNS	O	O
were	VBD	O	O
evaluated	VBN	O	O
after	IN	O	O
laboratory	NN	O	O
tests	NNS	O	O
and	CC	O	O
clinical-ergometric	JJ	O	O
examinations	NNS	O	O
.	.	O	O

A	DT	O	O
coronary	JJ	O	O
arteriography	NN	O	O
was	VBD	O	O
performed	VBN	O	O
on	IN	O	O
study	NN	O	O
entry	NN	O	O
.	.	O	O

RESULTS	VB	O	O
The	DT	O	O
average	NN	o	OPH
of	IN	o	OPH
anginal	JJ	o	OPH
attacks	NNS	o	OPH
,	,	o	OOt
number	NN	o	OOt
of	IN	o	OOt
weekly	JJ	o	OOt
sublingual	JJ	o	OOt
nitrate	NN	o	OOt
,	,	o	OOt
heart	NN	o	OPH
rate	NN	o	OPH
,	,	o	OOt
systolic	JJ	o	OPH
and	CC	o	OPH
diastolic	JJ	o	OPH
pressure	NN	o	OPH
at	IN	o	OPH
rest	NN	o	OPH
and	CC	o	OPH
at	IN	o	OPH
the	DT	o	OPH
end	NN	o	OPH
of	IN	o	OPH
diltiazem	JJ	o	OPH
period	NN	o	OPH
were	VBD	O	O
significantly	RB	O	O
lower	JJR	O	O
(	(	O	O
p	JJ	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
regarding	VBG	O	O
same	JJ	O	O
periods	NNS	O	O
on	IN	O	O
placebo	NN	i	IC
.	.	i	O

The	DT	O	O
percentage	NN	O	O
of	IN	O	O
depression	NN	o	OPH
for	IN	o	OPH
ST-segment	NNP	o	OPH
was	VBD	O	O
lower	JJR	O	O
for	IN	O	O
diltiazem	NN	i	IPM
when	WRB	O	O
compared	VBN	O	O
with	IN	O	O
placebo	NN	i	IC
(	(	O	O
p	JJ	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
and	CC	O	O
the	DT	O	O
percentage	NN	O	O
of	IN	O	O
patients	NNS	O	O
that	WDT	O	O
reach	VBP	O	O
higher	JJR	O	O
stages	NNS	O	O
in	IN	O	O
the	DT	O	O
ergometric	JJ	O	O
test	NN	O	O
was	VBD	O	O
significantly	RB	O	O
better	JJR	O	O
for	IN	O	O
diltiazem	NN	i	IPM
.	.	i	O

Heart	NNP	o	OPH
rate	NN	o	OPH
and	CC	o	OOt
systolic	JJ	o	OPH
plus	CC	o	OPH
diastolic	JJ	o	OPH
pressures	NNS	o	OPH
after	IN	O	O
exercise	NN	O	O
did	VBD	O	O
not	RB	O	O
differ	VB	O	O
in	IN	O	O
both	DT	O	O
groups	NNS	O	O
.	.	O	O

CONCLUSION	NNP	O	O
Diltiazem	NNP	i	IPM
reduced	VBD	O	O
the	DT	O	O
clinical	JJ	O	O
and	CC	O	O
electrocardiographical	JJ	O	O
aspects	NNS	O	O
and	CC	O	O
raises	VBZ	O	O
the	DT	O	O
effort	NN	O	O
tolerance	NN	O	O
during	IN	O	O
the	DT	O	O
ergometric	JJ	O	O
test	NN	O	O
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
stable	JJ	p	O
angina	NN	p	O
.	.	p	O

Direct	JJ	i	IPH
trocar	NN	i	IPH
insertion	NN	i	IPH
vs.	FW	i	O
Verres	NNP	i	IPH
needle	FW	i	IPH
use	NN	i	IPH
for	IN	O	O
laparoscopic	JJ	p	PC
sterilization	NN	p	PC
.	.	p	O

A	DT	O	O
randomized	JJ	p	O
,	,	p	O
prospective	JJ	p	O
trial	NN	p	O
was	VBD	p	O
designed	VBN	p	O
to	TO	p	O
compare	VB	p	O
direct	JJ	i	IPH
trocar	NN	i	IPH
insertion	NN	i	IPH
with	IN	i	O
prior	JJ	i	O
peritoneal	JJ	i	O
insufflation	NN	i	O
with	IN	i	O
a	DT	i	O
Verres	NNP	i	IPH
needle	NN	i	IPH
for	IN	i	O
laparoscopic	NN	i	O
tubal	JJ	i	O
sterilization	NN	i	O
.	.	i	O

Direct	JJ	i	IPH
trocar	NN	i	IPH
insertion	NN	i	IPH
resulted	VBD	O	O
in	IN	O	O
fewer	JJR	O	O
instrument	NN	o	OOt
insertions	NNS	o	OOt
(	(	O	O
21.8	CD	O	O
%	NN	O	O
vs.	FW	O	O
7.8	CD	O	O
%	NN	O	O
)	)	O	O
and	CC	O	O
use	NN	O	O
of	IN	O	O
smaller	JJR	o	OOt
volumes	NNS	o	OOt
of	IN	o	OOt
CO2	NNP	o	OOt
(	(	O	O
2.67	CD	O	O
vs.	FW	O	O
2.32	CD	O	O
L	NNP	O	O
)	)	O	O
.	.	O	O

Direct	JJ	i	IPH
trocar	NN	i	IPH
use	NN	O	O
resulted	VBD	O	O
in	IN	O	O
a	DT	O	O
decrease	NN	O	O
in	IN	O	O
operating	NN	o	OOt
time	NN	o	OOt
from	IN	O	O
9	CD	O	O
minutes	NNS	O	O
,	,	O	O
40	CD	O	O
seconds	NNS	O	O
in	IN	O	O
the	DT	O	O
needle	JJ	p	O
group	NN	p	O
to	TO	O	O
7	CD	O	O
minutes	NNS	O	O
,	,	O	O
30	CD	O	O
seconds	NNS	O	O
in	IN	O	O
the	DT	O	O
trocar	NN	p	O
group	NN	p	O
.	.	p	O

Minor	NNP	o	OA
omental	JJ	o	OA
injuries	NNS	o	OA
occurred	VBD	O	O
in	IN	O	O
a	DT	O	O
small	JJ	O	O
percentage	NN	O	O
of	IN	O	O
each	DT	O	O
group	NN	O	O
,	,	O	O
while	IN	O	O
serious	JJ	O	O
complications	NNS	O	O
occurred	VBD	O	O
once	RB	O	O
in	IN	O	O
each	DT	O	O
group	NN	O	O
.	.	O	O

Toxicity	NN	o	OOt
and	CC	o	OOt
efficacy	NN	o	OOt
of	IN	O	O
6-thioguanine	JJ	i	IPM
versus	NN	i	O
6-mercaptopurine	JJ	i	IPM
in	IN	O	O
childhood	NN	p	PA
lymphoblastic	JJ	p	PC
leukaemia	NN	p	PC
:	:	p	O
a	DT	O	O
randomised	JJ	O	O
trial	NN	O	O
.	.	O	O

BACKGROUND	NNP	O	O
6-mercaptopurine	JJ	i	IPM
has	VBZ	O	O
been	VBN	O	O
a	DT	O	O
standard	JJ	O	O
component	NN	O	O
of	IN	O	O
long-term	JJ	O	O
continuing	VBG	O	O
treatment	NN	O	O
for	IN	O	O
childhood	NN	p	PA
lymphoblastic	JJ	p	PC
leukaemia	NN	p	PC
,	,	O	O
whereas	JJ	O	O
6-thioguanine	NN	i	IPM
has	VBZ	O	O
been	VBN	O	O
mainly	RB	O	O
used	VBN	O	O
for	IN	O	O
intensification	NN	O	O
courses	NNS	O	O
.	.	O	O

Since	IN	O	O
preliminary	JJ	O	O
data	NNS	O	O
have	VBP	O	O
shown	VBN	O	O
that	IN	O	O
6-thioguanine	JJ	i	IPM
is	VBZ	O	O
more	RBR	O	O
effective	JJ	O	O
than	IN	O	O
6-mercaptopurine	JJ	i	IPM
,	,	O	O
we	PRP	O	O
compared	VBN	O	O
the	DT	O	O
efficacy	NN	o	OOt
and	CC	o	OOt
toxicity	NN	o	OOt
of	IN	O	O
the	DT	O	O
two	CD	O	O
drugs	NNS	O	O
for	IN	O	O
childhood	NN	p	O
lymphoblastic	JJ	p	O
leukaemia	NN	p	O
.	.	p	O

METHODS	NNP	O	O
Consecutive	JJ	p	O
children	NNS	p	PA
with	IN	p	O
lymphoblastic	JJ	p	PC
leukaemia	NN	p	O
diagnosed	VBN	p	O
in	IN	p	O
the	DT	p	O
UK	NNP	p	O
and	CC	p	O
Ireland	NNP	p	O
between	IN	p	O
April	NNP	p	O
,	,	p	O
1997	CD	p	O
,	,	p	O
and	CC	p	O
June	NNP	p	O
,	,	p	O
2002	CD	p	O
,	,	O	O
were	VBD	O	O
randomly	RB	O	O
assigned	VBN	O	O
either	CC	O	O
6-thioguanine	JJ	i	IPM
(	(	i	O
750	CD	i	O
patients	NNS	O	O
)	)	O	O
or	CC	O	O
6-mercaptopurine	JJ	i	IPM
(	(	O	O
748	CD	O	O
patients	NNS	O	O
)	)	O	O
during	IN	O	O
interim	JJ	O	O
maintenance	NN	O	O
and	CC	O	O
continuing	VBG	O	O
therapy	NN	O	O
.	.	O	O

All	DT	O	O
patients	NNS	O	O
received	VBD	O	O
6-thioguanine	JJ	i	IPM
during	IN	O	O
intensification	NN	O	O
courses	NNS	O	O
.	.	O	O

We	PRP	O	O
analysed	VBD	O	O
event-free	JJ	o	OMO
and	CC	o	OMO
overall	JJ	o	OMO
survival	NN	o	OMO
on	IN	O	O
an	DT	O	O
intention-to-treat	JJ	O	O
basis	NN	O	O
.	.	O	O

We	PRP	O	O
obtained	VBD	O	O
toxicity	NN	o	OA
data	NNS	O	O
using	VBG	O	O
an	DT	O	O
adverse-event	JJ	O	O
reporting	NN	O	O
system	NN	O	O
,	,	O	O
with	IN	O	O
follow-up	JJ	O	O
questionnaires	NNS	O	O
to	TO	O	O
seek	VB	O	O
detailed	JJ	O	O
information	NN	O	O
for	IN	O	O
specific	JJ	O	O
toxicities	NNS	O	O
.	.	O	O

This	DT	O	O
trial	NN	O	O
is	VBZ	O	O
registered	VBN	O	O
with	IN	O	O
the	DT	O	O
International	NNP	O	O
Standard	NNP	O	O
Randomised	VBD	O	O
Controlled	NNP	O	O
Number	NNP	O	O
26727615	CD	O	O
with	IN	O	O
the	DT	O	O
name	NN	O	O
ALL97	NNP	O	O
.	.	O	O

FINDINGS	NNP	O	O
After	IN	O	O
a	DT	O	O
median	JJ	O	O
follow	NN	O	O
up	IN	O	O
of	IN	O	O
6	CD	O	O
years	NNS	O	O
,	,	O	O
there	EX	O	O
was	VBD	O	O
no	DT	O	O
difference	NN	O	O
in	IN	O	O
event-free	JJ	o	OMO
or	CC	o	OMO
overall	JJ	o	OMO
survival	NN	o	OMO
between	IN	O	O
the	DT	O	O
two	CD	O	O
treatment	NN	O	O
groups	NNS	O	O
.	.	O	O

Although	IN	O	O
6-thioguanine	JJ	i	IPM
conferred	VBD	O	O
a	DT	O	O
significantly	RB	O	O
lower	JJR	O	O
risk	NN	O	O
of	IN	O	O
isolated	JJ	O	O
CNS	NNP	o	OPH
relapse	NN	o	OPH
than	IN	O	O
did	VBD	O	O
6-mercaptopurine	JJ	i	IPM
(	(	O	O
odds	NNS	O	O
ratio	VBP	O	O
[	CD	O	O
OR	NNP	O	O
]	$	O	O
0.53	CD	O	O
,	,	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
0.30-0.92	CD	O	O
,	,	O	O
p=0.02	NN	O	O
)	)	O	O
,	,	O	O
the	DT	O	O
benefit	NN	O	O
was	VBD	O	O
offset	VBN	O	O
by	IN	O	O
an	DT	O	O
increased	VBN	O	O
risk	NN	o	OMO
of	IN	o	OMO
death	NN	o	OMO
in	IN	O	O
remission	NN	O	O
(	(	O	O
2.22	CD	O	O
,	,	O	O
1.20-4.14	CD	O	O
,	,	O	O
p=0.01	NN	O	O
)	)	O	O
,	,	O	O
mainly	RB	O	O
due	JJ	O	O
to	TO	O	O
infections	NNS	O	O
during	IN	O	O
continuing	VBG	O	O
therapy	NN	O	O
.	.	O	O

Additionally	RB	O	O
,	,	O	O
95	CD	O	O
patients	NNS	O	O
developed	VBD	O	O
veno-occlusive	JJ	o	OA
disease	NN	o	OA
of	IN	o	OA
the	DT	o	OA
liver	NN	o	OA
.	.	o	O

Of	IN	O	O
these	DT	O	O
,	,	O	O
82	CD	O	O
were	VBD	O	O
randomly	RB	O	O
assigned	VBN	O	O
6-thioguanine	JJ	i	IPM
,	,	O	O
representing	VBG	O	O
11	CD	O	O
%	NN	O	O
of	IN	O	O
all	DT	O	O
6-thioguanine	JJ	i	IPM
recipients	NNS	O	O
.	.	O	O

On	IN	O	O
long-term	JJ	O	O
follow-up	NN	O	O
,	,	O	O
about	RB	O	O
5	CD	O	O
%	NN	O	O
of	IN	O	O
6-thioguanine	JJ	i	IPM
recipients	NNS	O	O
have	VBP	O	O
evidence	NN	O	O
of	IN	O	O
non-cirrhotic	JJ	o	OPH
portal	JJ	o	OPH
hypertension	NN	o	OPH
due	JJ	O	O
to	TO	O	O
periportal	JJ	O	O
liver	JJ	O	O
fibrosis	NN	O	O
or	CC	O	O
nodular	JJ	O	O
regenerative	JJ	O	O
hyperplasia	NN	O	O
.	.	O	O

INTERPRETATION	NNP	O	O
Compared	VBD	O	O
with	IN	O	O
6-mercaptopurine	JJ	i	IPM
,	,	i	O
6-thioguanine	JJ	i	IPM
causes	NNS	O	O
excess	JJ	O	O
toxicity	NN	o	OA
without	IN	O	O
an	DT	O	O
overall	JJ	o	OOt
benefit	NN	o	OOt
.	.	o	O

6-mercaptopurine	JJ	i	IPM
should	MD	O	O
remain	VB	O	O
the	DT	O	O
thiopurine	NN	O	O
of	IN	O	O
choice	NN	O	O
for	IN	O	O
continuing	VBG	O	O
therapy	NN	O	O
of	IN	O	O
childhood	NN	O	O
lymphoblastic	JJ	O	O
leukaemia	NN	O	O
.	.	O	O

Effect	NN	O	O
of	IN	O	O
gravity	NN	O	O
on	IN	O	O
robot-assisted	JJ	i	IPH
motor	NN	i	IPH
training	NN	i	IPH
after	IN	p	O
chronic	JJ	o	OPH
stroke	NN	o	OPH
:	:	o	O
a	DT	O	O
randomized	JJ	O	O
trial	NN	O	O
.	.	O	O

OBJECTIVES	UH	O	O
To	TO	O	O
determine	VB	O	O
the	DT	O	O
efficacy	NN	O	O
of	IN	O	O
2	CD	O	O
distinct	JJ	O	O
6-week	JJ	O	O
robot-assisted	JJ	i	IPH
reaching	NN	i	IPH
programs	NNS	i	IPH
compared	VBN	O	O
with	IN	O	O
an	DT	O	O
intensive	JJ	O	O
conventional	JJ	i	IPH
arm	NN	i	IPH
exercise	NN	i	IPH
program	NN	i	IPH
(	(	O	O
ICAE	NNP	O	O
)	)	O	O
for	IN	O	O
chronic	NN	o	OPH
,	,	o	OPH
stroke-related	JJ	o	OPH
upper-extremity	NN	o	OPH
(	(	o	OPH
UE	NNP	o	OPH
)	)	o	OPH
impairment	NN	O	O
.	.	O	O

To	TO	O	O
examine	VB	O	O
whether	IN	O	O
the	DT	O	O
addition	NN	O	O
of	IN	O	O
robot-assisted	JJ	i	IPH
training	VBG	i	IPH
out	IN	p	O
of	IN	p	O
the	DT	p	O
horizontal	JJ	p	O
plane	NN	p	O
leads	VBZ	O	O
to	TO	O	O
improved	VBN	O	O
outcomes	NNS	O	O
.	.	O	O

DESIGN	NNP	O	O
Randomized	NNP	O	O
controlled	VBD	O	O
trial	NN	O	O
,	,	O	O
single-blinded	JJ	O	O
,	,	O	O
with	IN	O	O
12-week	JJ	O	O
follow-up	NN	O	O
.	.	O	O

SETTING	NNP	O	O
Research	NNP	O	O
setting	VBG	O	O
in	IN	O	O
a	DT	O	O
large	JJ	O	O
medical	JJ	O	O
center	NN	O	O
.	.	O	O

PARTICIPANTS	NNP	O	O
Adults	NNP	p	PA
(	(	p	O
N=62	NNP	p	PSS
)	)	p	O
with	IN	p	O
chronic	JJ	p	PC
,	,	p	PC
stroke-related	JJ	p	PC
arm	NN	p	PC
weakness	NN	p	PC
stratified	VBN	p	O
by	IN	p	O
impairment	JJ	p	O
severity	NN	p	O
using	VBG	p	O
baseline	JJ	p	O
UE	NNP	p	O
motor	NN	p	O
assessments	NNS	p	O
.	.	p	O

INTERVENTIONS	NNP	O	O
Sixty	NNP	O	O
minutes	NNS	O	O
,	,	O	O
3	CD	O	O
times	NNS	O	O
a	DT	O	O
week	NN	O	O
for	IN	O	O
6	CD	O	O
weeks	NNS	O	O
of	IN	O	O
robot-assisted	JJ	i	IPH
planar	NN	i	IPH
reaching	NN	i	IPH
(	(	i	IPH
gravity	NN	i	IPH
compensated	VBN	i	IPH
)	)	i	IPH
,	,	i	O
combined	VBN	i	IPH
planar	NN	i	IPH
with	IN	i	IPH
vertical	JJ	i	IPH
robot-assisted	JJ	i	IPH
reaching	NN	i	IPH
,	,	O	O
or	CC	O	O
intensive	JJ	i	IPH
conventional	JJ	i	IPH
arm	NN	i	IPH
exercise	NN	i	IPH
program	NN	i	IPH
.	.	i	O

MAIN	NNP	O	O
OUTCOME	NNP	O	O
MEASURE	NNP	O	O
UE	NNP	o	OPH
Fugl-Meyer	NNP	o	OPH
Assessment	NNP	o	OPH
(	(	o	OPH
FMA	NNP	o	OPH
)	)	o	OPH
mean	VBP	o	OPH
change	NN	o	OPH
from	IN	O	O
baseline	NN	O	O
to	TO	O	O
final	JJ	O	O
training	NN	O	O
.	.	O	O

RESULTS	NNP	O	O
All	DT	O	O
groups	NNS	O	O
showed	VBD	O	O
modest	JJ	o	OOt
gains	NNS	o	OOt
in	IN	o	OOt
the	DT	o	OOt
FMA	NNP	o	OPH
from	IN	O	O
baseline	NN	O	O
to	TO	O	O
final	JJ	O	O
with	IN	O	O
no	DT	O	O
significant	JJ	O	O
between	IN	O	O
group	NN	O	O
differences	NNS	O	O
.	.	O	O

Most	JJS	O	O
change	NN	O	O
occurred	VBD	O	O
in	IN	O	O
the	DT	O	O
planar	NN	O	O
robot	NN	O	O
group	NN	O	O
(	(	O	O
mean	JJ	O	O
change	NN	O	O
?	.	O	O
SD	NNP	O	O
,	,	O	O
2.94	CD	O	O
?	.	O	O
0.77	CD	O	O
;	:	O	O
95	CD	O	O
%	NN	O	O
confidence	NN	O	O
interval	NN	O	O
[	NNP	O	O
CI	NNP	O	O
]	NNP	O	O
,	,	O	O
1.40-4.47	JJ	p	O
)	)	p	O
.	.	p	O

Participants	NNS	p	O
with	IN	p	O
greater	JJR	o	O
motor	NN	o	O
impairment	NN	o	O
(	(	o	O
n=41	JJ	p	O
)	)	p	O
demonstrated	VBD	p	O
a	DT	O	O
larger	JJR	O	O
difference	NN	O	O
in	IN	O	O
response	NN	o	O
(	(	o	O
mean	JJ	O	O
change	NN	O	O
?	.	O	O
SD	NNP	O	O
,	,	O	O
2.29	CD	O	O
?	.	O	O
0.72	CD	O	O
;	:	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
,	,	O	O
0.85-3.72	NNP	O	O
)	)	O	O
for	IN	O	O
planar	JJ	O	O
robot-assisted	JJ	O	O
exercise	NN	O	O
compared	VBN	O	O
with	IN	O	O
the	DT	O	O
intensive	JJ	O	O
conventional	JJ	O	O
arm	NN	O	O
exercise	NN	O	O
program	NN	O	O
(	(	O	O
mean	JJ	O	O
change	NN	O	O
?	.	O	O
SD	NNP	O	O
,	,	O	O
0.43	CD	O	O
?	.	O	O
0.72	CD	O	O
;	:	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
,	,	O	O
-1.00	NNP	O	O
to	TO	O	O
1.86	CD	O	O
)	)	O	O
.	.	O	O

CONCLUSIONS	NNP	o	O
Chronic	NNP	o	O
UE	NNP	o	O
deficits	NNS	o	O
because	IN	O	O
of	IN	O	O
stroke	NN	O	O
are	VBP	o	O
responsive	JJ	o	O
to	TO	O	O
intensive	JJ	O	O
motor	NN	O	O
task	NN	O	O
training	NN	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
training	VBG	O	O
outside	IN	O	O
the	DT	O	O
horizontal	JJ	O	O
plane	NN	O	O
in	IN	O	O
a	DT	O	O
gravity	NN	O	O
present	JJ	O	O
environment	NN	O	O
using	VBG	O	O
a	DT	O	O
combination	NN	O	O
of	IN	O	O
vertical	JJ	O	O
with	IN	O	O
planar	JJ	O	O
robots	NNS	O	O
was	VBD	o	O
not	RB	o	O
superior	JJ	o	O
to	TO	o	O
training	VBG	o	O
with	IN	O	O
the	DT	O	O
planar	NN	O	O
robot	NN	O	O
alone	RB	O	O
.	.	O	O

A	DT	O	O
randomized	JJ	O	O
phase	NN	O	O
II	NNP	O	O
trial	NN	O	O
of	IN	O	O
5-fluorouracil	JJ	i	IPM
,	,	O	O
with	IN	O	O
or	CC	O	O
without	IN	O	O
human	JJ	i	IPM
interferon-beta	NN	i	IPM
,	,	O	O
for	IN	O	O
advanced	JJ	p	PC
colorectal	JJ	p	PC
cancer	NN	p	PC
.	.	p	O

This	DT	O	O
study	NN	O	O
compared	VBN	O	O
the	DT	O	O
efficacy	NN	o	OOt
and	CC	o	OOt
safety	NN	o	OOt
of	IN	O	O
5-fluorouracil	JJ	i	IPM
(	(	i	IPM
5-FU	JJ	i	IPM
)	)	i	IPM
monotherapy	NN	i	IPM
to	TO	O	O
that	DT	O	O
of	IN	O	O
5-FU	JJ	i	IPM
combined	VBN	i	IPM
with	IN	i	IPM
natural	JJ	i	IPM
human	JJ	i	IPM
interferon-beta	NN	i	IPM
(	(	i	IPM
IFN-beta	NNP	i	IPM
)	)	i	IPM
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
unresectable	JJ	p	O
,	,	p	O
advanced	JJ	p	PC
colorectal	JJ	p	PC
carcinoma	NN	p	PC
.	.	p	O

Forty-nine	JJ	p	PSS
chemotherapy-naive	JJ	p	PC
patients	NNS	p	O
were	VBD	p	O
randomized	VBN	p	O
to	TO	O	O
5-FU	JJ	O	O
alone	RB	O	O
or	CC	O	O
to	TO	O	O
the	DT	O	O
combination	NN	O	O
.	.	O	O

All	DT	O	O
patients	NNS	O	O
received	VBD	O	O
750	CD	O	O
mg	NNS	O	O
m	NN	O	O
(	(	O	O
-2	JJ	O	O
)	)	O	O
day	NN	O	O
(	(	O	O
-1	JJ	O	O
)	)	O	O
5-FU	NN	O	O
for	IN	O	O
5	CD	O	O
days	NNS	O	O
by	IN	O	O
continuous	JJ	O	O
intravenous	JJ	O	O
(	(	O	O
i.v	JJ	O	O
.	.	O	O

)	)	O	O
infusion	NN	O	O
,	,	O	O
followed	VBD	O	O
after	IN	O	O
day	NN	O	O
15	CD	O	O
by	IN	O	O
a	DT	O	O
weekly	JJ	O	O
i.v	NN	O	O
.	.	O	O

bolus	NN	O	O
of	IN	O	O
750	CD	O	O
mg	NNS	O	O
m	NN	O	O
(	(	O	O
-2	NNP	O	O
)	)	O	O
.	.	O	O

IFN-beta	NNP	i	IPM
was	VBD	O	O
injected	VBN	O	O
intramuscularly	RB	O	O
three	CD	O	O
times	NNS	O	O
weekly	RB	O	O
at	IN	O	O
9	CD	O	O
M	NNP	O	O
IU	NNP	O	O
.	.	O	O

Treatment	NNP	O	O
continued	VBD	O	O
for	IN	O	O
52	CD	O	O
weeks	NNS	O	O
,	,	O	O
or	CC	O	O
until	IN	O	O
disease	JJ	o	OPH
progression	NN	o	OPH
or	CC	O	O
intolerable	JJ	o	OA
toxicity	NN	o	OA
.	.	o	O

Clinical	JJ	O	O
endpoints	NNS	O	O
were	VBD	O	O
tumor	JJ	o	OPH
response	NN	o	OPH
,	,	o	O
time	NN	o	OPH
to	TO	o	OPH
progression	NN	o	OPH
,	,	o	O
survival	NN	o	OPH
and	CC	o	OPH
toxicity	NN	o	OPH
.	.	o	O

The	DT	O	O
addition	NN	O	O
of	IN	O	O
IFN-3	NNP	i	IPM
to	TO	i	IPM
5-FU	CD	i	IPM
significantly	RB	O	O
improved	VBN	o	OPH
response	NN	o	OPH
rate	NN	o	OPH
(	(	O	O
33.3	CD	O	O
%	NN	O	O
vs	JJ	O	O
4.5	CD	O	O
%	NN	O	O
for	IN	O	O
evaluable	JJ	O	O
patients	NNS	O	O
;	:	O	O
P	NNP	O	O
=	NNP	O	O
0.021	CD	O	O
)	)	O	O
,	,	O	O
time	NN	o	OPH
to	TO	o	OPH
progression	NN	o	OPH
(	(	O	O
median	JJ	O	O
7.2	CD	O	O
vs	JJ	O	O
4.2	CD	O	O
months	NNS	O	O
;	:	O	O
P	NNP	O	O
=	NNP	O	O
0.0435	CD	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
survival	JJ	o	OMO
time	NN	o	OMO
(	(	O	O
median	JJ	O	O
15.9	CD	O	O
vs	JJ	O	O
7.2	CD	O	O
months	NNS	O	O
;	:	O	O
P	NNP	O	O
=	NNP	O	O
0.038	CD	O	O
)	)	O	O
without	IN	O	O
significantly	RB	O	O
increasing	VBG	O	O
toxicity	NN	o	OPH
compared	VBN	O	O
to	TO	O	O
5-FU	JJ	O	O
alone	RB	O	O
.	.	O	O

Cumulative	JJ	o	OPH
5-FU	JJ	o	OPH
dose	NN	o	OPH
was	VBD	O	O
higher	JJR	O	O
with	IN	O	O
combined	JJ	O	O
therapy	NN	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.001	CD	O	O
)	)	O	O
:	:	O	O
more	JJR	O	O
patients	NNS	O	O
receiving	VBG	O	O
monotherapy	JJ	O	O
discontinued	VBN	O	O
treatment	NN	O	O
because	IN	O	O
of	IN	O	O
disease	NN	o	OPH
progression	NN	o	OPH
.	.	o	O

Fever	NNP	o	OPH
was	VBD	O	O
more	RBR	O	O
frequent	JJ	O	O
with	IN	O	O
combined	JJ	O	O
therapy	NN	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.008	CD	O	O
)	)	O	O
;	:	O	O
there	EX	O	O
were	VBD	O	O
no	DT	O	O
other	JJ	O	O
differences	NNS	O	O
in	IN	O	O
toxicity	NN	o	OA
.	.	o	O

The	DT	O	O
only	JJ	O	O
grade	NN	o	OA
IV	NNP	o	OA
toxicity	NN	o	OA
observed	VBD	O	O
was	VBD	O	O
neutropenia	JJ	O	O
(	(	O	O
two	CD	O	O
patients	NNS	O	O
per	IN	O	O
group	NN	O	O
)	)	O	O
.	.	O	O

A	DT	O	O
randomized	JJ	O	O
phase	NN	O	O
III	NNP	O	O
trial	NN	O	O
has	VBZ	O	O
been	VBN	O	O
initiated	VBN	O	O
to	TO	O	O
confirm	VB	O	O
the	DT	O	O
synergy	NN	O	O
between	IN	O	O
5-FU	JJ	i	IPM
and	CC	O	O
IFN-beta	NNP	i	IPM
.	.	i	O

Cryotherapy	NN	O	O
does	VBZ	O	O
not	RB	O	O
affect	VB	O	O
peroneal	JJ	O	O
reaction	NN	O	O
following	VBG	O	O
sudden	JJ	O	O
inversion	NN	O	O
.	.	O	O

CONTEXT	NNP	O	O
If	IN	O	O
ankle	JJ	O	O
joint	NN	O	O
cryotherapy	NN	O	O
impairs	VBZ	O	O
the	DT	O	O
ability	NN	O	O
of	IN	O	O
the	DT	O	O
ankle	JJ	O	O
musculature	NN	O	O
to	TO	O	O
counteract	VB	O	O
potentially	RB	O	O
injurious	JJ	O	O
forces	NNS	O	O
,	,	O	O
the	DT	O	O
ankle	NN	O	O
is	VBZ	O	O
left	VBN	O	O
vulnerable	JJ	O	O
to	TO	O	O
injury	VB	O	O
.	.	O	O

OBJECTIVE	NNP	O	O
To	TO	O	O
compare	VB	O	O
peroneal	JJ	O	O
reaction	NN	O	O
to	TO	O	O
sudden	JJ	O	O
inversion	NN	O	O
following	VBG	O	O
ankle	JJ	O	O
joint	JJ	O	O
cryotherapy	NN	O	O
.	.	O	O

DESIGN	NNP	O	O
Repeated	VBD	O	O
measures	NNS	O	O
design	NN	O	O
with	IN	O	O
independent	JJ	O	O
variables	NNS	O	O
,	,	O	O
treatment	NN	O	O
(	(	i	O
cryotherapy	NN	i	IPH
and	CC	i	O
control	NN	i	IC
)	)	i	O
,	,	O	O
and	CC	O	O
time	NN	O	O
(	(	O	O
baseline	NN	O	O
,	,	O	O
immediately	RB	O	O
post	NN	O	O
treatment	NN	O	O
,	,	O	O
15	CD	O	O
minutes	NNS	O	O
post	RB	O	O
treatment	NN	O	O
,	,	O	O
and	CC	O	O
30	CD	O	O
minutes	NNS	O	O
post	RB	O	O
treatment	NN	O	O
)	)	O	O
.	.	O	O

SETTING	NNP	O	O
University	NNP	p	O
research	NN	p	O
laboratory	NN	p	O
.	.	p	O

PATIENTS	CC	O	O
OR	CC	O	O
OTHER	NNP	O	O
PARTICIPANTS	NNP	O	O
Twenty-seven	NNP	p	PSS
healthy	JJ	p	PC
volunteers	NNS	p	O
.	.	p	O

INTERVENTION	NNP	O	O
(	(	O	O
S	NNP	O	O
)	)	O	O
An	DT	O	O
ice	NN	O	O
bag	NN	O	O
was	VBD	O	O
secured	VBN	O	O
to	TO	O	O
the	DT	O	O
lateral	JJ	O	O
ankle	NN	O	O
joint	NN	O	O
for	IN	O	O
20	CD	O	O
minutes	NNS	O	O
.	.	O	O

MAIN	NNP	O	O
OUTCOME	NNP	O	O
MEASURES	NNP	O	O
The	DT	O	O
onset	NN	o	OPH
and	CC	o	OPH
average	JJ	o	OPH
root	NN	o	OPH
mean	JJ	o	OPH
square	JJ	o	OPH
amplitude	NN	o	OPH
of	IN	o	OPH
EMG	NNP	o	OPH
activity	NN	o	OPH
in	IN	o	OPH
the	DT	o	OPH
peroneal	NN	o	OPH
muscles	NNS	o	OPH
was	VBD	o	OPH
calculated	VBN	o	O
following	VBG	o	O
the	DT	o	O
release	NN	o	OOt
of	IN	o	OOt
a	DT	o	OOt
trap	NN	o	OOt
door	NN	o	OOt
mechanism	NN	o	OOt
causing	VBG	o	OOt
inversion	NN	o	OOt
.	.	o	O

RESULTS	NNP	O	O
There	EX	O	O
was	VBD	O	O
no	DT	O	O
statistically	RB	O	O
significant	JJ	O	O
change	NN	O	O
from	IN	O	O
baseline	NN	O	O
for	IN	O	O
peroneal	JJ	o	OPH
reaction	NN	o	OPH
time	NN	o	OPH
or	CC	o	OPH
average	JJ	o	OPH
peroneal	JJ	o	OPH
muscle	NN	o	OPH
activity	NN	o	OPH
at	IN	O	O
any	DT	O	O
post	NN	O	O
treatment	NN	O	O
time	NN	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
Cryotherapy	NNP	O	O
does	VBZ	O	O
not	RB	O	O
affect	VB	O	O
peroneal	JJ	O	O
muscle	NN	O	O
reaction	NN	O	O
following	VBG	O	O
sudden	JJ	O	O
inversion	NN	O	O
perturbation	NN	O	O
.	.	O	O

A	DT	O	O
controlled	JJ	O	O
trial	NN	O	O
of	IN	O	O
extended	JJ	i	IS
radical	JJ	i	IS
versus	NN	O	O
radical	JJ	i	IS
mastectomy	NN	i	IS
.	.	i	O

Ten-year	JJ	O	O
results	NNS	O	O
.	.	O	O

In	IN	O	O
view	NN	O	O
of	IN	O	O
increasing	VBG	O	O
debate	NN	O	O
over	IN	O	O
possible	JJ	O	O
benefit	NN	O	O
of	IN	O	O
more	JJR	O	O
complete	JJ	O	O
surgery	NN	O	O
compared	VBN	O	O
to	TO	O	O
conservative	JJ	O	O
procedures	NNS	O	O
,	,	O	O
a	DT	O	O
randomized	VBN	O	O
controlled	VBN	O	O
trial	NN	O	O
contrasting	VBG	O	O
the	DT	O	O
then	RB	O	O
standard	NN	i	IS
Halsted	NNP	i	IS
radical	NN	i	IS
(	(	i	IS
RDL	NNP	i	IS
)	)	i	IS
operation	NN	i	IS
with	IN	O	O
the	DT	O	O
more	RBR	O	O
complete	JJ	i	IS
extended	JJ	i	IS
radical	NN	i	IS
(	(	i	IS
EXT	NNP	i	IS
)	)	i	IS
mastectomy	NN	i	IS
was	VBD	O	O
initiated	VBN	O	O
in	IN	O	O
1973	CD	O	O
.	.	O	O

Between	IN	p	O
November	NNP	p	O
1973	CD	p	O
and	CC	p	O
July	NNP	p	O
1982	CD	p	O
,	,	p	O
123	CD	p	PSS
women	NNS	p	PSE
younger	JJR	p	PA
than	IN	p	PA
70	CD	p	PA
years	NNS	p	PA
of	IN	p	PA
age	NN	p	PA
and	CC	p	O
at	IN	p	O
clinical	JJ	p	PC
Stages	NNP	p	PC
I	PRP	p	PC
and	CC	p	PC
II	NNP	p	PC
were	VBD	p	O
enrolled	VBN	p	O
.	.	p	O

Of	IN	O	O
the	DT	O	O
total	JJ	O	O
series	NN	O	O
,	,	O	O
112	CD	p	PSS
were	VBD	p	O
treated	VBN	p	O
by	IN	p	O
the	DT	p	O
same	JJ	p	O
surgeon	NN	p	O
and	CC	p	O
confirmed	VBD	p	O
pathologically	RB	p	O
as	IN	p	O
having	VBG	p	O
invasive	JJ	p	PC
mammary	JJ	p	PC
carcinoma	NN	p	PC
.	.	p	O

In	IN	O	O
this	DT	O	O
more	RBR	O	O
homogeneous	JJ	O	O
subgroup	NN	O	O
,	,	O	O
the	DT	O	O
10-year	JJ	o	OMO
survival	NN	o	OMO
rates	NNS	o	OMO
(	(	O	O
and	CC	O	O
standard	JJ	O	O
errors	NNS	O	O
)	)	O	O
were	VBD	O	O
for	IN	O	O
RDL	NNP	O	O
,	,	O	O
60	CD	O	O
%	NN	O	O
(	(	O	O
+/-	JJ	O	O
7	CD	O	O
%	NN	O	O
)	)	O	O
and	CC	O	O
for	IN	O	O
EXT	NNP	O	O
,	,	O	O
74	CD	O	O
%	NN	O	O
(	(	O	O
+/-	JJ	O	O
6	CD	O	O
%	NN	O	O
)	)	O	O
(	(	O	O
P	NNP	O	O
value	NN	O	O
for	IN	O	O
comparison	NN	O	O
of	IN	O	O
survival	JJ	O	O
curves	NNS	O	O
=	VBP	O	O
0.13	CD	O	O
)	)	O	O
.	.	O	O

In	IN	O	O
patients	NNS	O	O
from	IN	O	O
this	DT	O	O
subgroup	NN	O	O
with	IN	O	O
central-medial	JJ	O	O
tumors	NNS	O	O
,	,	O	O
comprising	VBG	O	O
62	CD	O	O
%	NN	O	O
of	IN	O	O
the	DT	O	O
total	NN	O	O
,	,	O	O
survival	NN	o	OMO
after	IN	O	O
RDL	NNP	O	O
at	IN	O	O
10	CD	O	O
years	NNS	O	O
was	VBD	O	O
60	CD	O	O
%	NN	O	O
(	(	O	O
+/-	JJ	O	O
8	CD	O	O
%	NN	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
after	IN	O	O
EXT	NNP	O	O
86	CD	O	O
%	NN	O	O
(	(	O	O
+/-	JJ	O	O
6	CD	O	O
%	NN	O	O
)	)	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.025	CD	O	O
)	)	O	O
.	.	O	O

In	IN	O	O
the	DT	O	O
remaining	VBG	O	O
patients	NNS	p	O
with	IN	p	O
lateral	JJ	p	PC
tumors	NNS	p	PC
,	,	O	O
survival	JJ	o	OMO
rates	NNS	o	OMO
were	VBD	O	O
unaffected	VBN	O	O
by	IN	O	O
treatment	NN	O	O
:	:	O	O
58	CD	O	O
%	NN	O	O
(	(	O	O
+/-	JJ	O	O
13	CD	O	O
%	NN	O	O
)	)	O	O
and	CC	O	O
56	CD	O	O
%	NN	O	O
(	(	O	O
+/-	JJ	O	O
11	CD	O	O
%	NN	O	O
)	)	O	O
,	,	O	O
respectively	RB	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.62	CD	O	O
)	)	O	O
.	.	O	O

Comparison	NNP	O	O
of	IN	O	O
a	DT	O	O
nonrandomized	JJ	O	O
series	NN	O	O
of	IN	O	O
266	CD	O	O
RDL	NNP	O	O
and	CC	O	O
124	CD	O	O
EXT	NNP	O	O
patients	NNS	p	O
treated	VBD	p	O
between	IN	p	O
1960	CD	p	O
and	CC	p	O
1978	CD	p	O
found	VBD	O	O
differences	NNS	O	O
consistent	JJ	O	O
with	IN	O	O
those	DT	O	O
of	IN	O	O
the	DT	O	O
randomized	VBN	O	O
study	NN	O	O
,	,	O	O
although	IN	O	O
not	RB	O	O
statistically	RB	O	O
significant	JJ	O	O
.	.	O	O

A	DT	O	O
sensory	JJ	i	IPS
integration	NN	i	IPS
therapy	NN	i	IPS
program	NN	i	IPS
on	IN	O	O
sensory	JJ	p	PC
problems	NNS	p	PC
for	IN	p	O
children	NNS	p	O
with	IN	p	O
autism	NN	p	PC
.	.	p	O

The	DT	O	O
study	NN	O	O
was	VBD	O	O
planned	VBN	O	O
to	TO	O	O
investigate	VB	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
a	DT	O	O
sensory	JJ	i	IPS
integration	NN	i	IPS
therapy	NN	i	IPS
program	NN	i	IPS
on	IN	O	O
sensory	JJ	o	OOt
problems	NNS	o	OOt
of	IN	O	O
children	NNS	p	O
with	IN	p	O
autism	NN	p	PC
.	.	p	O

This	DT	O	O
study	NN	O	O
was	VBD	O	O
conducted	VBN	O	O
at	IN	O	O
the	DT	O	O
Trakya	NNP	p	O
University	NNP	p	O
Training	NNP	p	O
and	CC	p	O
Research	NNP	p	O
Center	NNP	p	O
for	IN	p	O
Mentally	NNP	p	O
and	CC	p	O
Physically	NNP	p	O
Handicapped	NNP	p	O
Children	NNP	p	O
in	IN	p	O
Turkey	NNP	p	O
.	.	p	O

The	DT	O	O
children	NNS	O	O
were	VBD	O	O
separated	VBN	O	O
into	IN	O	O
two	CD	O	O
groups	NNS	O	O
,	,	O	O
each	DT	O	O
comprising	VBG	p	O
15	CD	p	PSS
children	NNS	p	O
between	IN	p	O
7	CD	p	O
and	CC	p	O
11	CD	p	O
years	NNS	p	O
of	IN	p	O
age	NN	p	O
with	IN	p	O
autism	NN	p	PC
,	,	p	O
according	VBG	p	O
to	TO	p	O
DSM-IV	NNP	p	O
criteria	NNS	p	O
.	.	p	O

The	DT	O	O
children	NNS	O	O
in	IN	O	O
each	DT	O	O
group	NN	O	O
were	VBD	O	O
assessed	VBN	O	O
initially	RB	O	O
on	IN	O	O
a	DT	O	O
checklist	NN	O	O
,	,	O	O
Sensory	NNP	O	O
Evaluation	NNP	O	O
Form	NNP	O	O
for	IN	O	O
Children	NNP	O	O
with	IN	O	O
Autism	NNP	O	O
,	,	O	O
developed	VBD	O	O
to	TO	O	O
evaluate	VB	O	O
sensory	JJ	o	OME
characteristics	NNS	o	OME
of	IN	O	O
children	NNS	O	O
with	IN	O	O
autism	NN	O	O
,	,	O	O
and	CC	O	O
at	IN	O	O
the	DT	O	O
end	NN	O	O
of	IN	O	O
the	DT	O	O
study	NN	O	O
,	,	O	O
participants	NNS	O	O
were	VBD	O	O
assessed	VBN	O	O
again	RB	O	O
on	IN	O	O
the	DT	O	O
checklist	NN	O	O
.	.	O	O

Statistically	NNP	O	O
significant	JJ	O	O
differences	NNS	O	O
between	IN	O	O
groups	NNS	O	O
indicated	VBD	O	O
that	IN	O	O
the	DT	O	O
sensory	JJ	i	IPS
integration	NN	i	IPS
therapy	NN	i	IPS
program	NN	i	IPS
positively	RB	O	O
affected	VBD	O	O
treated	JJ	O	O
children	NNS	O	O
.	.	O	O

Comparison	NNP	O	O
between	IN	O	O
intermittent	JJ	i	IPH
mandatory	JJ	i	IPH
ventilation	NN	i	IPH
and	CC	O	O
synchronized	JJ	i	IPH
intermittent	NN	i	IPH
mandatory	JJ	i	IPH
ventilation	NN	i	IPH
with	IN	O	O
pressure	NN	i	IPH
support	NN	i	IPH
in	IN	p	O
children	NNS	p	PA
.	.	p	O

OBJECTIVE	NN	O	O
To	TO	O	O
compare	VB	O	O
intermittent	JJ	i	IPH
mandatory	JJ	i	IPH
ventilation	NN	i	IPH
(	(	i	IPH
IMV	NNP	i	IPH
)	)	i	IPH
with	IN	O	O
synchronized	JJ	i	IPH
intermittent	JJ	i	IPH
mandatory	NN	i	IPH
ventilation	NN	i	IPH
plus	CC	i	IPH
pressure	NN	i	IPH
support	NN	i	IPH
(	(	i	IPH
SIMV+PS	NNP	i	IPH
)	)	i	IPH
in	IN	O	O
terms	NNS	O	O
of	IN	O	O
time	NN	o	OPH
on	IN	o	OPH
mechanical	JJ	o	OPH
ventilation	NN	o	OPH
,	,	o	OOt
duration	NN	o	OOt
of	IN	o	OOt
weaning	VBG	o	OOt
and	CC	o	OOt
length	NN	o	OOt
of	IN	o	OOt
stay	NN	o	OOt
in	IN	o	OOt
a	DT	o	OOt
pediatric	JJ	o	OOt
intensive	JJ	o	OOt
care	NN	o	OOt
unit	NN	o	OOt
(	(	p	O
PICU	NNP	p	O
)	)	p	O
.	.	p	O

METHODS	NNP	O	O
This	DT	O	O
was	VBD	O	O
a	DT	O	O
randomized	JJ	O	O
clinical	JJ	O	O
trial	NN	O	O
that	WDT	O	O
enrolled	VBD	p	O
children	NNS	p	PA
aged	VBN	p	O
28	CD	p	PA
days	NNS	p	PA
to	TO	p	PA
4	CD	p	PA
years	NNS	p	PA
who	WP	p	O
were	VBD	p	O
admitted	VBN	p	O
to	TO	p	O
a	DT	p	O
PICU	NNP	p	O
between	IN	p	O
October	NNP	p	O
of	IN	p	O
2005	CD	p	O
and	CC	p	O
June	NNP	p	O
of	IN	p	O
2007	CD	p	O
and	CC	p	O
put	VB	p	O
on	IN	p	O
mechanical	JJ	i	IPH
ventilation	NN	i	IPH
(	(	i	IPH
MV	NNP	i	IPH
)	)	i	IPH
for	IN	p	O
more	JJR	p	O
than	IN	p	O
48	CD	p	O
hours	NNS	p	O
.	.	p	O

These	DT	O	O
patients	NNS	O	O
were	VBD	O	O
allocated	VBN	O	O
to	TO	O	O
one	CD	O	O
of	IN	O	O
two	CD	O	O
groups	NNS	O	O
by	IN	O	O
drawing	VBG	O	O
lots	NNS	O	O
:	:	O	O
IMV	NNP	i	IPH
group	NN	O	O
(	(	i	IPH
IMVG	NNP	i	IPH
;	:	i	O
n	CC	O	O
=	VB	O	O
35	CD	O	O
)	)	O	O
and	CC	O	O
SIMV+PS	NNP	i	IPH
group	NN	O	O
(	(	i	O
SIMVG	NNP	i	IPH
;	:	i	O
n	CC	O	O
=	VB	O	O
35	CD	O	O
)	)	O	O
.	.	O	O

Children	NNP	p	PA
were	VBD	p	O
excluded	VBN	p	O
if	IN	p	O
they	PRP	p	O
had	VBD	p	O
undergone	JJ	p	O
tracheotomy	NN	p	O
or	CC	p	O
had	VBD	p	O
chronic	JJ	p	PC
respiratory	NN	p	PC
diseases	NNS	p	PC
.	.	p	PC

Data	NNS	O	O
on	IN	O	O
oxygenation	NN	o	OPH
and	CC	o	OOt
ventilation	NN	o	OPH
were	VBD	O	O
recorded	VBN	O	O
at	IN	O	O
admission	NN	O	O
and	CC	O	O
at	IN	O	O
the	DT	O	O
start	NN	O	O
of	IN	O	O
weaning	VBG	O	O
.	.	O	O

RESULTS	CC	O	O
There	EX	O	O
were	VBD	O	O
no	DT	O	O
statistical	JJ	O	O
differences	NNS	O	O
between	IN	O	O
the	DT	O	O
groups	NNS	O	O
in	IN	O	O
terms	NNS	O	O
of	IN	O	O
age	NN	o	OOt
,	,	o	OOt
sex	NN	o	OOt
,	,	o	OOt
indication	NN	o	OOt
for	IN	o	OOt
MV	NNP	o	OOt
,	,	o	OOt
PRISM	NNP	o	OOt
score	NN	o	OOt
,	,	o	OOt
Comfort	NNP	o	OOt
scale	NN	o	OOt
,	,	o	OOt
use	NN	o	OOt
of	IN	o	OOt
sedatives	NNS	o	OOt
or	CC	o	OOt
ventilation	NN	o	OOt
and	CC	o	OOt
oxygenation	NN	o	OOt
parameters	NNS	o	OOt
.	.	o	OOt

The	DT	O	O
median	JJ	o	OOt
time	NN	o	OOt
on	IN	o	OOt
MV	NNP	o	OOt
was	VBD	O	O
5	CD	O	O
days	NNS	O	O
for	IN	O	O
both	DT	O	O
groups	NNS	O	O
(	(	O	O
p	JJ	O	O
=	NNP	O	O
0.120	CD	O	O
)	)	O	O
.	.	O	O

There	EX	O	O
were	VBD	O	O
also	RB	O	O
no	DT	O	O
statistical	JJ	O	O
differences	NNS	O	O
between	IN	O	O
the	DT	O	O
two	CD	O	O
groups	NNS	O	O
for	IN	O	O
duration	NN	o	OOt
of	IN	o	OOt
weaning	VBG	o	OOt
[	JJ	i	O
IMVG	NNP	i	IPH
:	:	i	O
1	CD	O	O
day	NN	O	O
(	(	O	O
1-6	JJ	O	O
)	)	O	O
vs.	FW	O	O
SIMVG	NNP	i	IPH
:	:	i	O
1	CD	O	O
day	NN	O	O
(	(	O	O
1-6	JJ	O	O
)	)	O	O
;	:	O	O
p	CC	O	O
=	$	O	O
0.262	CD	O	O
]	NN	O	O
or	CC	O	O
length	NN	o	OOt
of	IN	o	OOt
hospital	NN	o	OOt
stay	NN	o	OOt
[	JJ	i	O
IMVG	NNP	i	IPH
:	:	i	O
8	CD	O	O
days	NNS	O	O
(	(	O	O
2-22	JJ	O	O
)	)	O	O
vs.	FW	O	O
SIMVG	NNP	i	IPH
:	:	i	O
6	CD	O	O
days	NNS	O	O
(	(	O	O
3-20	JJ	O	O
)	)	O	O
;	:	O	O
p	CC	O	O
=	$	O	O
0.113	CD	O	O
]	NNP	O	O
.	.	O	O

CONCLUSION	NNP	O	O
Among	IN	O	O
the	DT	O	O
children	NNS	p	PA
studied	VBN	p	O
here	RB	p	O
,	,	O	O
there	EX	O	O
was	VBD	O	O
no	DT	O	O
statistically	RB	O	O
significant	JJ	O	O
difference	NN	O	O
between	IN	O	O
IMV	NNP	i	IPH
and	CC	O	O
SIMV+PS	NNP	i	IPH
in	IN	O	O
terms	NNS	O	O
of	IN	O	O
time	NN	O	O
on	IN	O	O
MV	NNP	o	OOt
,	,	o	OOt
duration	NN	o	OOt
of	IN	o	OOt
weaning	VBG	o	OOt
or	CC	o	OOt
time	NN	o	OOt
spent	VBN	o	OOt
in	IN	o	OOt
the	DT	o	OOt
PICU	NNP	o	OOt
.	.	o	OOt

ClinicalTrials.govID	NN	O	O
:	:	O	O
NCT00549809	NNP	O	O
.	.	O	O

Double-blind	NNP	O	O
,	,	O	O
placebo-controlled	JJ	O	O
trial	NN	O	O
of	IN	O	O
risperidone	NN	i	IPM
plus	CC	i	IPM
topiramate	NN	i	IPM
in	IN	O	O
children	NNS	p	PA
with	IN	p	O
autistic	JJ	p	PC
disorder	NN	p	PC
.	.	p	O

BACKGROUND	NNP	O	O
Autism	NNP	O	O
is	VBZ	O	O
a	DT	O	O
complex	JJ	O	O
neurodevelopmental	JJ	O	O
disorder	NN	O	O
that	WDT	O	O
forms	VBZ	O	O
part	NN	O	O
of	IN	O	O
a	DT	O	O
spectrum	NN	O	O
of	IN	O	O
related	JJ	O	O
disorders	NNS	O	O
referred	VBD	O	O
to	TO	O	O
as	IN	O	O
Autism	NNP	O	O
Spectrum	NNP	O	O
Disorders	NNP	O	O
.	.	O	O

The	DT	O	O
present	JJ	O	O
study	NN	O	O
assessed	VBD	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
topiramate	NN	i	IPM
plus	CC	i	IPM
risperidone	NN	i	IPM
in	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
autistic	JJ	p	PC
disorder	NN	p	PC
.	.	p	O

METHOD	NNP	O	O
Forty	NNP	p	PSS
children	NNS	p	O
between	IN	p	O
the	DT	p	O
ages	NNS	p	PA
of	IN	p	PA
4	CD	p	PA
and	CC	p	PA
12	CD	p	PA
years	NNS	p	PA
with	IN	p	O
a	DT	p	O
DSM	NNP	p	PC
IV	NNP	p	PC
clinical	JJ	p	PC
diagnosis	NN	p	PC
of	IN	p	PC
autism	NN	p	PC
who	WP	p	O
were	VBD	p	O
outpatients	NNS	p	O
from	IN	p	O
a	DT	p	O
specialty	NN	p	O
clinic	NN	p	O
for	IN	p	O
children	NNS	p	O
were	VBD	p	O
recruited	VBN	p	O
.	.	p	O

The	DT	O	O
children	NNS	p	O
presented	VBN	O	O
with	IN	O	O
a	DT	O	O
chief	JJ	O	O
complaint	NN	O	O
of	IN	O	O
severely	RB	p	PC
disruptive	JJ	p	PC
symptoms	NNS	p	PC
related	VBN	p	O
to	TO	p	O
autistic	JJ	p	PC
disorder	NN	p	PC
.	.	p	O

Patients	NNS	O	O
were	VBD	O	O
randomly	RB	O	O
allocated	VBN	O	O
to	TO	O	O
topiramate+risperidone	VB	i	IPM
(	(	i	O
Group	NNP	i	O
A	NNP	i	O
)	)	i	O
or	CC	i	O
placebo+risperidone	NN	i	IPM
(	(	i	O
Group	NNP	i	O
B	NNP	i	O
)	)	i	O
for	IN	O	O
an	DT	O	O
8-week	JJ	O	O
,	,	O	O
double-blind	JJ	O	O
,	,	O	O
placebo-controlled	JJ	O	O
study	NN	O	O
.	.	O	O

The	DT	O	O
dose	NN	O	O
of	IN	O	O
risperidone	NN	i	IPM
was	VBD	O	O
titrated	VBN	O	O
up	RB	O	O
to	TO	O	O
2	CD	O	O
mg/day	NN	O	O
for	IN	O	O
children	NNS	O	O
between	IN	O	O
10	CD	O	O
and	CC	O	O
40	CD	O	O
kg	NN	O	O
and	CC	O	O
3	CD	O	O
mg/day	NN	O	O
for	IN	O	O
children	NNS	O	O
weighting	VBG	O	O
above	IN	O	O
40	CD	O	O
kg	NN	O	O
.	.	O	O

The	DT	O	O
dose	NN	O	O
of	IN	O	O
topiramate	NN	i	IPM
was	VBD	O	O
titrated	VBN	O	O
up	RB	O	O
to	TO	O	O
200	CD	O	O
mg/day	NN	O	O
depending	VBG	O	O
on	IN	O	O
weight	NN	O	O
(	(	O	O
100	CD	O	O
mg/day	NN	O	O
for	IN	O	O
<	$	O	O
30	CD	O	O
kg	NN	O	O
and	CC	O	O
200	CD	O	O
mg/day	NN	O	O
for	IN	O	O
>	$	O	O
30	CD	O	O
kg	NN	O	O
)	)	O	O
.	.	O	O

Patients	NNS	O	O
were	VBD	O	O
assessed	VBN	O	O
at	IN	O	O
baseline	NN	O	O
and	CC	O	O
after	IN	O	O
2	CD	O	O
,	,	O	O
4	CD	O	O
,	,	O	O
6	CD	O	O
and	CC	O	O
8	CD	O	O
weeks	NNS	O	O
after	IN	O	O
starting	VBG	O	O
medication	NN	O	O
.	.	O	O

Measure	NN	O	O
of	IN	O	O
outcome	NN	O	O
was	VBD	O	O
the	DT	O	O
Aberrant	NNP	o	OOt
Behavior	NNP	o	OOt
Checklist-Community	NNP	o	OOt
(	(	o	OOt
ABC-C	NNP	o	OOt
)	)	o	OOt
Rating	VBG	o	OOt
Scale	NNP	o	OOt
.	.	o	O

RESULTS	NNP	O	O
Difference	NNP	O	O
between	IN	O	O
the	DT	O	O
two	CD	O	O
protocols	NNS	O	O
was	VBD	O	O
significant	JJ	O	O
as	IN	O	O
the	DT	O	O
group	NN	O	O
that	WDT	O	O
received	VBD	O	O
topiramate	NN	i	IPM
had	VBD	O	O
a	DT	O	O
greater	JJR	O	O
reduction	NN	o	OOt
in	IN	o	OOt
ABC-C	NNP	o	OOt
subscale	NN	o	OOt
scores	NNS	o	OOt
for	IN	o	OOt
irritability	NN	o	OOt
,	,	o	O
stereotypic	JJ	o	OPH
behavior	NN	o	OPH
and	CC	o	O
hyperactivity/noncompliance	NN	o	OME
.	.	o	O

CONCLUSION	VB	O	O
The	DT	O	O
results	NNS	O	O
suggest	VBP	O	O
that	IN	O	O
the	DT	O	O
combination	NN	O	O
of	IN	O	O
topiramate	NN	i	IPM
with	IN	O	O
risperidone	NN	O	O
may	MD	O	O
be	VB	O	O
superior	JJ	O	O
to	TO	O	O
risperidone	VB	O	O
monotherapy	NN	O	O
for	IN	O	O
children	NNS	p	PA
with	IN	p	O
autistic	JJ	p	PC
disorder	NN	p	PC
.	.	p	O

However	RB	O	O
the	DT	O	O
results	NNS	O	O
need	VBP	O	O
to	TO	O	O
be	VB	O	O
further	RB	O	O
confirmed	VBN	O	O
by	IN	O	O
a	DT	O	O
larger	JJR	O	O
randomized	VBN	O	O
controlled	VBN	O	O
trial	NN	O	O
.	.	O	O

In-season	JJ	O	O
effect	NN	O	O
of	IN	O	O
short-term	JJ	i	IOt
sprint	NN	i	IOt
and	CC	i	IE
power	NN	i	IOt
training	NN	i	IOt
programs	NNS	i	IOt
on	IN	O	O
elite	JJ	p	O
junior	JJ	p	O
soccer	NN	p	O
players	NNS	p	O
.	.	p	O

The	DT	O	O
aim	NN	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
examine	VB	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
2	CD	O	O
in-season	JJ	O	O
short-term	JJ	i	IOt
sprint	NN	i	IOt
and	CC	i	IE
power	NN	i	IOt
training	NN	i	IOt
protocols	NNS	i	IOt
on	IN	O	O
vertical	JJ	O	O
countermovement	NN	O	O
jump	NN	O	O
height	NN	O	O
(	(	O	O
with	IN	O	O
or	CC	O	O
without	IN	O	O
arms	NNS	O	O
)	)	O	O
,	,	O	O
sprint	NN	O	O
(	(	O	O
Sprint-15m	NNP	O	O
)	)	O	O
speed	NN	O	O
,	,	O	O
and	CC	O	O
agility	NN	O	O
(	(	O	O
Agility-15m	NNP	O	O
)	)	O	O
speed	NN	O	O
in	IN	O	O
male	JJ	p	PSE
elite	JJ	p	O
junior	JJ	p	O
soccer	NN	p	O
players	NNS	p	O
.	.	p	O

Twenty	NNP	p	O
highly	RB	p	O
trained	VBD	p	O
soccer	NN	p	O
players	NNS	p	O
(	(	p	O
age	NN	p	O
18.3	CD	p	PA
+/-	JJ	p	PA
0.6	CD	p	PA
years	NNS	p	PA
,	,	p	O
height	VBD	p	O
177	CD	p	O
+/-	JJ	p	O
4	CD	p	O
cm	NN	p	O
,	,	p	O
body	NN	p	O
mass	VBD	p	O
71.4	CD	p	O
+/-	JJ	p	O
6.9	CD	p	O
kg	NN	p	O
,	,	p	O
sum	NN	p	O
skinfolds	NNS	p	O
48.1	CD	p	O
+/-	JJ	p	O
11.4	CD	p	O
mm	NN	p	O
)	)	p	O
,	,	p	O
members	NNS	p	O
of	IN	p	O
a	DT	p	O
professional	JJ	p	O
soccer	NN	p	O
academy	NN	p	O
,	,	O	O
were	VBD	O	O
randomly	RB	O	O
allocated	VBN	O	O
to	TO	O	O
either	VB	O	O
a	DT	O	O
CONTRAST	NNP	O	O
(	(	O	O
n	JJ	O	O
=	NNP	O	O
10	CD	O	O
)	)	O	O
or	CC	O	O
SPRINT	NNP	O	O
(	(	O	O
n	JJ	O	O
=	NNP	O	O
10	CD	O	O
)	)	O	O
group	NN	O	O
.	.	O	O

The	DT	i	IE
training	NN	i	IE
intervention	NN	i	IE
consisted	VBD	O	O
of	IN	O	O
6	CD	i	IE
supervised	JJ	i	IE
training	NN	i	IE
sessions	NNS	i	IE
over	IN	O	O
7	CD	O	O
weeks	NNS	O	O
,	,	O	O
targeting	VBG	O	O
the	DT	O	O
improvement	NN	O	O
of	IN	O	O
the	DT	O	O
players	NNS	O	O
'	POS	O	O
speed	NN	o	OME
and	CC	o	OME
power	NN	o	OME
.	.	o	OPH

CONTRAST	NNP	O	O
protocol	NN	O	O
consisted	VBD	O	O
of	IN	O	O
alternating	VBG	O	O
heavy-light	JJ	O	O
resistance	NN	O	O
(	(	O	O
15-50	CD	O	O
%	NN	O	O
body	NN	O	O
mass	NN	O	O
)	)	O	O
with	IN	O	O
soccer-specific	JJ	O	O
drills	NNS	O	O
(	(	O	O
small-sided	JJ	O	O
games	NNS	O	O
or	CC	O	O
technical	JJ	O	O
skills	NNS	O	O
)	)	O	O
.	.	O	O

SPRINT	NNP	i	IOt
training	NN	i	IOt
protocol	NN	i	IOt
used	VBN	O	O
line	NN	O	O
30-m	JJ	O	O
sprints	NNS	O	O
(	(	O	O
2-4	JJ	O	O
sets	NNS	O	O
of	IN	O	O
4	CD	O	O
x	JJ	O	O
30	CD	O	O
m	NN	O	O
with	IN	O	O
180	CD	O	O
and	CC	O	O
90	CD	O	O
seconds	NNS	O	O
of	IN	O	O
recovery	NN	O	O
,	,	O	O
respectively	RB	O	O
)	)	O	O
.	.	O	O

At	IN	O	O
baseline	JJ	O	O
no	DT	O	O
difference	NN	O	O
between	IN	O	O
physical	JJ	o	OPH
test	NN	o	OPH
performance	NN	o	OPH
was	VBD	O	O
evident	JJ	O	O
between	IN	O	O
the	DT	O	O
2	CD	O	O
groups	NNS	O	O
(	(	O	O
p	JJ	O	O
>	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

No	DT	O	O
time	NN	O	O
x	VBZ	O	O
training	VBG	O	O
group	NN	O	O
effect	NN	O	O
was	VBD	O	O
found	VBN	O	O
for	IN	O	O
any	DT	O	O
of	IN	O	O
the	DT	O	O
vertical	JJ	o	OOt
jump	NN	o	OOt
and	CC	o	OOt
Agility-15m	JJ	o	OOt
variables	NNS	o	OOt
(	(	o	OPH
p	JJ	o	OPH
>	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

A	DT	O	O
time	NN	O	O
x	JJ	O	O
training	VBG	O	O
group	NN	O	O
effect	NN	O	O
was	VBD	O	O
found	VBN	O	O
for	IN	O	O
Sprint-15m	JJ	O	O
performance	NN	O	O
with	IN	O	O
the	DT	O	O
CONTRAST	NNP	O	O
group	NN	O	O
showing	VBG	O	O
significantly	RB	O	O
better	JJR	O	O
scores	NNS	O	O
than	IN	O	O
the	DT	O	O
SPRINT	NNP	O	O
group	NN	O	O
(	(	O	O
7.23	CD	O	O
+/-	JJ	O	O
0.18	CD	O	O
vs.	FW	O	O
7.09	CD	O	O
+/-	JJ	O	O
0.20	CD	O	O
m.s	NN	O	O
,	,	O	O
p	NN	O	O
<	NNP	O	O
0.01	CD	O	O
)	)	O	O
.	.	O	O

In	IN	O	O
light	NN	O	O
of	IN	O	O
these	DT	O	O
findings	NNS	O	O
CONTRAST	NNP	i	IE
training	NN	i	IE
should	MD	O	O
be	VB	O	O
preferred	VBN	O	O
to	TO	O	O
line	NN	O	O
sprint	NN	O	O
training	NN	O	O
in	IN	O	O
the	DT	O	O
short	JJ	O	O
term	NN	O	O
in	IN	O	O
young	JJ	p	O
elite	JJ	p	O
soccer	NN	p	O
players	NNS	p	O
when	WRB	O	O
the	DT	O	O
aim	NN	O	O
is	VBZ	O	O
to	TO	O	O
improve	VB	O	O
soccer-specific	JJ	o	OME
sprint	NN	o	OME
performance	NN	o	OME
(	(	o	OPH
15	CD	o	OPH
m	NN	o	OPH
)	)	o	OPH
during	IN	O	O
the	DT	O	O
competitive	JJ	O	O
season	NN	O	O
.	.	O	O

A	DT	O	O
program	NN	O	O
of	IN	O	O
screening	VBG	O	O
and	CC	O	O
prompting	VBG	O	O
improves	NNS	O	O
short-term	JJ	O	O
physician	JJ	O	O
counseling	NN	O	O
of	IN	O	O
dependent	NN	p	O
and	CC	p	O
nondependent	JJ	p	O
harmful	JJ	p	O
drinkers	NNS	p	O
.	.	p	O

BACKGROUND	NNP	O	O
Physicians	NNPS	O	O
in	IN	O	O
the	DT	O	O
general	JJ	O	O
medical	JJ	O	O
setting	VBG	O	O
commonly	RB	O	O
encounter	RB	O	O
but	CC	O	O
rarely	RB	O	O
counsel	NN	O	O
patients	NNS	p	O
with	IN	p	O
dependent	JJ	p	O
or	CC	p	O
harmful	JJ	p	O
drinking	NN	p	O
behaviors	NNS	p	O
.	.	p	O

We	PRP	O	O
tested	VBD	O	O
whether	IN	O	O
providing	VBG	O	O
physicians	NNS	O	O
with	IN	O	O
their	PRP$	O	O
patients	NNS	O	O
'	POS	O	O
results	NNS	O	O
on	IN	O	O
the	DT	O	O
alcohol	NN	O	O
module	NN	O	O
of	IN	O	O
the	DT	O	O
Diagnostic	NNP	O	O
Interview	NNP	O	O
Schedule	NNP	O	O
and	CC	O	O
counseling	VBG	O	O
directives	NNS	O	O
would	MD	O	O
prompt	VB	O	O
them	PRP	O	O
to	TO	O	O
counsel	NN	O	O
these	DT	O	O
patients	NNS	O	O
.	.	O	O

METHODS	NNP	O	O
We	PRP	O	O
randomly	VBP	O	O
assigned	VBN	O	O
83	CD	p	O
first-	JJ	p	O
,	,	p	O
second-	JJ	p	O
,	,	p	O
and	CC	p	O
third-year	JJ	p	O
medical	JJ	p	O
residents	NNS	p	O
to	TO	p	O
receive	VB	i	IE
or	CC	i	IE
not	RB	i	IE
to	TO	i	IE
receive	VB	i	IE
diagnostic	JJ	i	IE
information	NN	i	IE
and	CC	i	IE
counseling	VBG	i	IE
directives	NNS	i	IE
on	IN	i	IE
214	CD	p	O
patients	NNS	p	O
who	WP	p	O
reported	VBD	p	O
at	IN	p	O
least	JJS	p	O
one	CD	p	O
symptom	NN	p	O
of	IN	p	O
alcohol	NN	p	O
impairment	NN	p	O
as	IN	p	O
defined	VBN	p	O
in	IN	p	O
the	DT	p	O
Diagnostic	NNP	p	O
and	CC	p	O
Statistical	NNP	p	O
Manual	NNP	p	O
of	IN	p	O
Mental	NNP	p	O
Disorders	NNP	p	O
,	,	p	O
Third	NNP	p	O
Edition	NNP	p	O
.	.	p	O

Using	VBG	O	O
binary	JJ	i	IE
logistic	JJ	i	IE
regression	NN	i	IE
,	,	O	O
we	PRP	O	O
examined	VBD	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
specific	JJ	O	O
covariables	NNS	O	O
on	IN	O	O
rates	NNS	O	O
of	IN	O	O
physician	JJ	O	O
counseling	NN	O	O
.	.	O	O

These	DT	O	O
variables	NNS	O	O
included	VBD	O	O
physician	JJ	O	O
information	NN	O	O
status	NN	O	O
,	,	O	O
patient	JJ	O	O
gender	NN	O	O
,	,	O	O
and	CC	O	O
drinking	VBG	O	O
disorder	NN	O	O
severity	NN	O	O
and	CC	O	O
recency	NN	O	O
.	.	O	O

We	PRP	O	O
also	RB	O	O
examined	VBD	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
physician	JJ	O	O
prompting	VBG	O	O
on	IN	O	O
counseling	NN	O	O
of	IN	O	O
female	JJ	p	O
patients	NNS	p	O
,	,	p	O
patients	NNS	p	O
with	IN	p	O
inactive	JJ	p	O
disorders	NNS	p	O
,	,	p	O
and	CC	p	O
nondependent	NN	p	O
but	CC	p	O
harmful	JJ	p	O
drinkers	NNS	p	O
.	.	p	O

We	PRP	O	O
determined	VBD	O	O
counseling	VBG	O	O
by	IN	O	O
post-visit	JJ	O	O
patient	JJ	O	O
interviews	NNS	O	O
.	.	O	O

RESULTS	NNP	O	O
Physician	JJ	o	OME
prompting	NN	o	OME
,	,	o	O
dependent	JJ	o	OME
drinking	NN	o	OME
,	,	o	O
and	CC	o	O
recent	JJ	o	OME
disorder	NN	o	OME
activity	NN	o	OME
were	VBD	O	O
significant	JJ	O	O
correlates	NNS	O	O
of	IN	O	O
physician	JJ	O	O
counseling	NN	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
.05	NNP	O	O
)	)	O	O
,	,	O	O
while	IN	O	O
male	JJ	O	O
gender	NN	O	O
was	VBD	O	O
a	DT	O	O
marginally	RB	O	O
significant	JJ	O	O
correlate	NN	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
.08	NNP	O	O
)	)	O	O
.	.	O	O

Informed	VBN	O	O
physicians	NNS	O	O
counseled	VBD	O	O
female	JJ	O	O
patients	NNS	O	O
,	,	O	O
harmful	JJ	O	O
but	CC	O	O
nondependent	JJ	O	O
drinkers	NNS	O	O
,	,	O	O
and	CC	O	O
patients	NNS	O	O
with	IN	O	O
inactive	JJ	O	O
disorders	NNS	O	O
more	RBR	O	O
often	RB	O	O
than	IN	O	O
their	PRP$	O	O
uninformed	JJ	O	O
colleagues	NNS	O	O
,	,	O	O
although	IN	O	O
only	RB	O	O
the	DT	O	O
last	JJ	O	O
variable	JJ	O	O
achieved	VBD	O	O
statistical	JJ	O	O
significance	NN	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
Providing	VBG	O	O
physicians	NNS	O	O
with	IN	O	O
the	DT	O	O
results	NNS	O	O
of	IN	O	O
the	DT	O	O
Diagnostic	NNP	O	O
Interview	NNP	O	O
Schedule	NNP	O	O
and	CC	O	O
counseling	VBG	O	O
directives	NNS	O	O
resulted	VBD	O	O
in	IN	O	O
short-term	JJ	O	O
improvement	NN	O	O
in	IN	O	O
their	PRP$	O	O
rates	NNS	O	O
of	IN	O	O
counseling	VBG	O	O
patients	NNS	O	O
with	IN	O	O
a	DT	O	O
history	NN	O	O
of	IN	O	O
dependent	NN	O	O
or	CC	O	O
nondependent	NN	O	O
but	CC	O	O
harmful	JJ	O	O
drinking	NN	O	O
.	.	O	O

Further	NNP	O	O
research	NN	O	O
is	VBZ	O	O
necessary	JJ	O	O
to	TO	O	O
determine	VB	O	O
long-term	JJ	O	O
gains	NNS	O	O
in	IN	O	O
rates	NNS	O	O
of	IN	O	O
physician	JJ	i	IE
counseling	NN	i	IE
and	CC	i	IE
improvements	NNS	i	IE
in	IN	O	O
the	DT	O	O
course	NN	O	O
of	IN	O	O
these	DT	O	O
patients	NNS	O	O
.	.	O	O

Antihistamines	NNS	i	IPM
do	VBP	O	O
not	RB	O	O
inhibit	VB	O	O
the	DT	O	O
wheal	NN	O	O
induced	VBN	O	O
by	IN	O	O
the	DT	O	O
intradermal	JJ	O	O
injection	NN	O	O
of	IN	O	O
autologous	JJ	O	O
serum	NN	O	O
in	IN	O	O
resistant	JJ	O	O
chronic	JJ	O	O
idiopathic	JJ	O	O
urticaria	NN	O	O
.	.	O	O

Some	DT	O	O
patients	NNS	p	O
with	IN	p	O
chronic	JJ	p	O
idiopathic	JJ	p	O
urticaria	NN	p	O
(	(	p	O
CIU	NNP	p	O
)	)	p	O
are	VBP	O	O
resistant	JJ	O	O
to	TO	O	O
conventional	JJ	O	O
doses	NNS	O	O
of	IN	O	O
antihistamines	NNS	i	IPM
(	(	i	IPM
AHs	NNP	i	IPM
)	)	i	IPM
.	.	i	O

This	DT	O	O
study	NN	O	O
was	VBD	O	O
designed	VBN	O	O
to	TO	O	O
check	VB	O	O
whether	IN	O	O
the	DT	O	O
skin	JJ	o	OPH
wheal	NN	o	OPH
and	CC	o	OA
flare	JJ	o	OPH
reaction	NN	o	OPH
produced	VBN	O	O
by	IN	O	O
the	DT	O	O
intradermal	JJ	O	O
injection	NN	O	O
of	IN	O	O
autologous	JJ	i	IPM
serum	NN	i	IPM
(	(	i	IPM
AS	IN	i	IPM
)	)	i	IPM
and	CC	O	O
by	IN	O	O
histamine	NN	i	IPM
differs	NNS	O	O
in	IN	O	O
AH-resistant	NNP	p	O
and	CC	p	O
AH	NNP	p	O
responder	VBP	p	O
CIU	NNP	p	O
patients	NNS	p	O
.	.	p	O

CIU	NNP	p	O
patients	NNS	p	O
with	IN	p	O
treatment	NN	p	O
failure	NN	p	O
under	IN	p	O
fexofenadine	NN	i	IPM
at	IN	p	O
180	CD	p	O
mg	NN	p	O
q.d	NN	p	O
.	.	p	O

increased	VBD	i	O
their	PRP$	i	O
daily	JJ	i	O
dose	NN	i	O
of	IN	O	O
AH	NNP	O	O
to	TO	O	O
4	CD	O	O
tablets	NNS	O	O
daily	RB	O	O
.	.	O	O

Those	DT	p	O
with	IN	p	O
significant	JJ	p	O
improvement	NN	p	O
of	IN	p	O
urticaria	JJ	p	O
activity	NN	p	O
score	NN	p	O
under	IN	p	O
fexofenadine	NN	i	IPM
at	IN	p	O
180	CD	p	O
mg	NNS	p	O
were	VBD	O	O
included	VBN	O	O
in	IN	O	O
the	DT	O	O
CIU	NNP	O	O
group	NN	O	O
.	.	O	O

Subjects	VBZ	O	O
with	IN	O	O
treatment	NN	O	O
failure	NN	O	O
despite	IN	O	O
a	DT	O	O
full	JJ	O	O
8-week	JJ	O	O
fourfold	JJ	O	O
fexofenadine	NN	i	IPM
treatment	NN	O	O
were	VBD	O	O
included	VBN	O	O
in	IN	O	O
the	DT	O	O
resistant	JJ	O	O
CIU	NNP	O	O
(	(	O	O
R-CIU	NNP	O	O
group	NN	O	O
)	)	O	O
.	.	O	O

The	DT	p	O
control	NN	p	O
group	NN	p	O
consisted	VBD	p	O
of	IN	p	O
sex-	JJ	p	O
and	CC	p	O
age-matched	JJ	p	O
patents	NNS	p	O
with	IN	p	O
allergic	JJ	p	O
rhinitis	NN	p	O
.	.	p	O

The	DT	O	O
AS	NNP	O	O
skin	JJ	O	O
test	NN	O	O
and	CC	O	O
intradermal	JJ	O	O
histamine-induced	JJ	i	IPM
wheal	NN	O	O
and	CC	O	O
flare	JJ	O	O
reaction	NN	O	O
were	VBD	O	O
performed	VBN	O	O
at	IN	O	O
baseline	NN	O	O
(	(	O	O
without	IN	O	O
AH	NNP	O	O
)	)	O	O
,	,	O	O
after	IN	O	O
8	CD	O	O
and	CC	O	O
16	CD	O	O
weeks	NNS	O	O
(	(	O	O
under	IN	O	O
AH	NNP	O	O
treatment	NN	O	O
)	)	O	O
.	.	O	O

Forty-six	JJ	p	O
subjects	NNS	p	O
were	VBD	p	O
included	VBN	p	O
in	IN	p	O
the	DT	p	O
CIU	NNP	p	O
group	NN	p	O
,	,	p	O
21	CD	p	O
were	VBD	p	O
in	IN	p	O
the	DT	p	O
R-CIU	NNP	p	O
group	NN	p	O
,	,	p	O
and	CC	p	O
44	CD	p	O
were	VBD	p	O
in	IN	p	O
the	DT	p	O
control	NN	p	O
group	NN	p	O
.	.	p	O

Under	IN	O	O
AH	NNP	O	O
therapy	NN	O	O
,	,	O	O
the	DT	O	O
skin	JJ	o	OA
reaction	NN	o	OA
to	TO	o	OA
intradermal	VB	o	OA
histamine	JJ	o	OA
injection	NN	o	OA
was	VBD	O	O
significantly	RB	O	O
diminished	VBN	O	O
in	IN	O	O
all	DT	O	O
study	NN	O	O
groups	NNS	O	O
.	.	O	O

In	IN	O	O
the	DT	O	O
R-CIU	NNP	O	O
group	NN	O	O
,	,	O	O
fexofenadine	NN	i	IPM
at	IN	O	O
180	CD	O	O
mg	NNS	O	O
did	VBD	O	O
not	RB	O	O
suppress	VB	O	O
AS-induced	NNP	o	OPH
wheal	JJ	o	OPH
reaction	NN	o	OPH
(	(	O	O
5.96	CD	O	O
?	.	O	O
2.25	CD	O	O
mm	NN	O	O
;	:	O	O
p	CC	O	O
=	VB	O	O
0.85	CD	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
with	IN	O	O
a	DT	O	O
fourfold	JJ	i	O
AH	NNP	i	O
dose	VB	O	O
some	DT	o	O
reduction	NN	o	O
of	IN	o	O
AS-induced	NNP	o	O
wheal	NN	o	O
(	(	O	O
3.79	CD	O	O
?	.	O	O
1.74	CD	O	O
mm	NN	O	O
;	:	O	O
p	CC	O	O
=	VB	O	O
0.008	CD	O	O
)	)	O	O
was	VBD	O	O
observed	VBN	O	O
but	CC	O	O
remained	VBD	O	O
larger	JJR	O	O
than	IN	O	O
in	IN	O	O
the	DT	O	O
CIU	NNP	O	O
(	(	O	O
2.31	CD	O	O
?	.	O	O
1.12	CD	O	O
;	:	O	O
p	NN	O	O
=	VBZ	O	O
0.006	CD	O	O
)	)	O	O
and	CC	O	O
control	NN	O	O
groups	NNS	O	O
(	(	O	O
2.52	CD	O	O
?	.	O	O
1.36	CD	O	O
;	:	O	O
p	NN	O	O
=	VBZ	O	O
0.037	CD	i	O
)	)	i	O
.	.	i	O

AHs	NNP	i	O
do	VBP	O	O
not	RB	O	O
inhibit	VB	O	O
the	DT	O	O
wheal	NN	O	O
induced	VBN	O	O
by	IN	O	O
the	DT	O	O
intradermal	JJ	O	O
injection	NN	O	O
of	IN	O	O
AS	NNP	O	O
in	IN	O	O
R-CIU	NNP	O	O
.	.	O	O

Plasma	NNP	O	O
pH	NN	O	O
does	VBZ	O	O
not	RB	O	O
influence	VB	O	O
the	DT	O	O
cerebral	JJ	p	O
metabolic	JJ	p	O
ratio	NN	p	O
during	IN	p	O
maximal	JJ	p	O
whole	JJ	p	O
body	NN	p	O
exercise	NN	p	O
.	.	p	O

Exercise	NN	O	O
lowers	VBZ	O	O
the	DT	O	O
cerebral	JJ	O	O
metabolic	JJ	O	O
ratio	NN	O	O
of	IN	O	O
O2	NNP	O	O
to	TO	O	O
carbohydrate	VB	O	O
(	(	O	O
glucose+1/2	JJ	O	O
lactate	NN	O	O
)	)	O	O
and	CC	O	O
metabolic	JJ	O	O
acidosis	NN	O	O
appears	VBZ	O	O
to	TO	O	O
promote	VB	o	OOt
cerebral	JJ	o	OOt
lactate	JJ	o	OOt
uptake	NN	o	OOt
.	.	o	O

However	RB	O	O
,	,	O	O
the	DT	O	O
influence	NN	O	O
of	IN	O	O
pH	NN	O	O
on	IN	O	O
cerebral	JJ	O	O
lactate	JJ	O	O
uptake	NN	O	O
and	CC	O	O
,	,	O	O
in	IN	O	O
turn	NN	O	O
,	,	O	O
on	IN	O	O
the	DT	O	O
cerebral	JJ	O	O
metabolic	JJ	O	O
ratio	NN	O	O
during	IN	O	O
exercise	NN	O	O
is	VBZ	O	O
not	RB	O	O
known	VBN	O	O
.	.	O	O

Sodium	NN	i	IPM
bicarbonate	NN	i	IPM
(	(	i	O
Bicarb	NNP	i	O
,	,	i	O
1	CD	i	O
M	NNP	i	O
;	:	i	O
350-500	CD	i	O
ml	NN	i	O
)	)	i	O
or	CC	i	O
an	DT	i	O
equal	JJ	i	O
volume	NN	i	O
of	IN	i	O
normal	JJ	i	IPM
saline	NN	i	IPM
(	(	i	O
Sal	NNP	i	O
)	)	i	O
was	VBD	i	O
infused	VBN	i	O
intravenously	RB	i	O
at	IN	i	O
a	DT	i	O
constant	JJ	i	O
rate	NN	i	O
during	IN	i	O
a	DT	i	O
'2000	CD	i	O
m	NN	i	O
'	''	i	O
maximal	JJ	i	O
ergometer	NN	i	IPM
row	NN	i	IPM
in	IN	O	O
six	CD	p	O
male	JJ	p	O
oarsmen	NNS	p	O
(	(	p	O
23?2	CD	p	O
years	NNS	p	O
;	:	p	O
mean?S.D.	NN	p	O
)	)	p	O
.	.	p	O

During	IN	O	O
the	DT	O	O
Sal	NNP	O	O
trial	NN	o	O
,	,	o	O
pH	NN	o	O
decreased	VBD	o	O
from	IN	O	O
7.41?0.01	CD	O	O
at	IN	O	O
rest	NN	O	O
to	TO	O	O
7.02?0.02	CD	O	O
but	CC	O	O
only	RB	O	O
to	TO	O	O
7.36?0.02	CD	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
during	IN	O	O
the	DT	O	O
Bicarb	NNP	O	O
trial	NN	O	O
.	.	o	O

Arterial	JJ	o	O
lactate	NN	o	O
increased	VBD	o	O
to	TO	O	O
21.4?0.8	CD	O	O
and	CC	O	O
32.7?2.3	CD	O	O
mM	NN	O	O
during	IN	O	O
the	DT	O	O
Sal	NNP	O	O
and	CC	O	O
Bicarb	NNP	O	O
trials	NNS	O	O
,	,	O	O
respectively	RB	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

Also	RB	O	O
,	,	O	O
the	DT	o	O
arterial-jugular	JJ	o	O
venous	JJ	o	O
lactate	NN	o	O
difference	NN	o	O
increased	VBD	O	O
from-0.03?0.01	JJ	O	O
mM	NN	O	O
at	IN	O	O
rest	NN	O	O
to	TO	O	O
3.2?0.9	CD	O	O
mM	NN	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
and	CC	O	O
3.4?1.4	CD	O	O
mM	NN	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
following	VBG	O	O
the	DT	O	O
Sal	NNP	O	O
and	CC	O	O
Bicarb	NNP	O	O
trials	NNS	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

Accordingly	RB	o	O
,	,	o	O
the	DT	o	O
cerebral	JJ	o	OPH
metabolic	NN	o	OPH
ratio	NN	o	OPH
decreased	VBD	o	O
equally	RB	O	O
during	IN	O	O
the	DT	O	O
Sal	NNP	O	O
and	CC	O	O
Bicarb	NNP	O	O
trials	NNS	O	O
:	:	O	O
from	IN	O	O
5.8?0.6	CD	O	O
at	IN	O	O
rest	NN	O	O
to	TO	O	O
1.7?0.1	CD	O	O
and	CC	O	O
1.8?0.2	CD	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

The	DT	o	O
enlarged	JJ	o	O
blood-buffering	NN	o	O
capacity	NN	o	O
after	IN	o	O
infusion	NN	i	O
of	IN	i	O
Bicarb	NNP	i	O
eliminated	VBD	o	O
metabolic	JJ	o	O
acidosis	NN	o	O
during	IN	o	O
maximal	JJ	O	O
exercise	NN	O	O
but	CC	O	O
that	DT	O	O
did	VBD	O	O
not	RB	O	O
affect	VB	O	O
the	DT	o	O
cerebral	JJ	o	O
lactate	NN	o	O
uptake	NN	o	O
and	CC	o	O
,	,	o	O
therefore	RB	O	O
,	,	O	O
the	DT	O	O
decrease	NN	O	O
in	IN	O	O
the	DT	o	O
cerebral	JJ	o	O
metabolic	NN	o	O
ratio	NN	o	O
.	.	o	O

Incidence	NN	O	O
and	CC	O	O
clinical	JJ	O	O
significance	NN	O	O
of	IN	O	O
false-negative	JJ	p	PC
sextant	JJ	p	PC
prostate	NN	p	PC
biopsies	NNS	p	PC
.	.	p	PC

PURPOSE	NNP	O	O
Since	IN	O	O
most	JJS	O	O
patients	NNS	O	O
do	VBP	O	O
not	RB	O	O
undergo	VB	O	O
repeat	NN	O	O
sextant	JJ	O	O
prostate	NN	O	O
biopsies	NNS	O	O
after	IN	O	O
a	DT	O	O
biopsy	NN	O	O
is	VBZ	O	O
positive	JJ	O	O
for	IN	O	O
prostate	NN	O	O
cancer	NN	O	O
,	,	O	O
the	DT	O	O
true	JJ	O	O
incidence	NN	O	O
of	IN	O	O
false-negative	JJ	O	O
biopsies	NNS	O	O
is	VBZ	O	O
not	RB	O	O
well	RB	O	O
defined	VBN	O	O
.	.	O	O

We	PRP	O	O
assess	VBP	O	O
the	DT	O	O
incidence	NN	O	O
and	CC	O	O
clinical	JJ	O	O
significance	NN	O	O
of	IN	O	O
false-negative	JJ	p	O
sextant	JJ	p	O
prostate	NN	p	O
biopsies	NNS	p	O
in	IN	p	O
patients	NNS	p	O
undergoing	VBG	p	O
radical	JJ	i	IS
prostatectomy	NN	i	IS
.	.	i	O

MATERIALS	NNP	O	O
AND	NNP	O	O
METHODS	NNP	O	O
A	NNP	p	O
total	NN	p	O
of	IN	p	O
118	CD	p	O
patients	NNS	p	O
with	IN	p	O
biopsy	NN	p	O
proved	VBN	p	O
prostate	JJ	p	O
cancer	NN	p	O
underwent	JJ	O	O
repeat	NN	i	IS
sextant	JJ	i	IS
prostate	NN	i	IS
biopsy	NN	i	IS
before	IN	O	O
enrollment	NN	O	O
in	IN	O	O
a	DT	O	O
prospective	JJ	O	O
randomized	VBN	O	O
trial	NN	O	O
of	IN	O	O
radical	JJ	i	IS
prostatectomy	NN	i	IS
with	IN	i	O
or	CC	i	O
without	IN	i	O
neoadjuvant	JJ	i	IPH
hormonal	JJ	i	IPH
therapy	NN	i	IPH
.	.	i	O

Clinical	JJ	O	O
parameters	NNS	O	O
were	VBD	O	O
assessed	VBN	O	O
to	TO	O	O
determine	VB	O	O
potential	JJ	O	O
sources	NNS	O	O
of	IN	O	O
bias	NN	O	O
.	.	O	O

Pathological	JJ	O	O
parameters	NNS	O	O
and	CC	O	O
prostate	NN	o	OA
specific	JJ	o	OA
antigen	NN	o	OA
relapse-free	JJ	o	OA
survival	NN	o	OA
rates	NNS	o	OA
were	VBD	O	O
compared	VBN	O	O
to	TO	O	O
determine	VB	O	O
the	DT	O	O
clinical	JJ	O	O
significance	NN	O	O
of	IN	O	O
false-negative	JJ	O	O
biopsies	NNS	O	O
.	.	O	O

RESULTS	NNP	O	O
Of	IN	O	O
the	DT	O	O
118	CD	p	O
patients	NNS	p	O
27	CD	O	O
(	(	O	O
23	CD	O	O
%	NN	O	O
)	)	O	O
had	VBD	O	O
a	DT	O	O
negative	JJ	O	O
repeat	NN	O	O
sextant	JJ	O	O
biopsy	NN	O	O
.	.	O	O

Except	IN	O	O
for	IN	O	O
initial	JJ	O	O
clinical	JJ	O	O
stage	NN	O	O
,	,	O	O
no	DT	O	O
differences	NNS	O	O
were	VBD	O	O
noted	VBN	O	O
in	IN	O	O
the	DT	O	O
clinical	JJ	o	OPH
or	CC	o	OPH
pathological	JJ	o	OPH
parameters	NNS	o	OPH
,	,	O	O
or	CC	O	O
prostate	VB	o	OPH
specific	JJ	o	OPH
antigen	NN	o	OPH
relapse	NN	o	OPH
rates	NNS	o	OPH
in	IN	O	O
patients	NNS	O	O
with	IN	O	O
negative	JJ	O	O
versus	NN	O	O
positive	JJ	O	O
repeat	NN	O	O
biopsies	NNS	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
Our	PRP$	O	O
findings	NNS	O	O
suggest	VBP	O	O
that	IN	O	O
this	DT	O	O
23	CD	O	O
%	NN	O	O
incidence	NN	O	O
of	IN	O	O
false-negative	JJ	O	O
biopsies	NNS	O	O
represents	VBZ	O	O
significant	JJ	O	O
cancer	NN	O	O
.	.	O	O

This	DT	O	O
relatively	RB	O	O
high	JJ	O	O
incidence	NN	O	O
is	VBZ	O	O
important	JJ	O	O
to	TO	O	O
consider	VB	O	O
in	IN	O	O
treatment	NN	O	O
modalities	NNS	O	O
in	IN	O	O
which	WDT	O	O
prostate	VBP	O	O
biopsy	NN	O	O
may	MD	O	O
be	VB	O	O
performed	VBN	O	O
to	TO	O	O
determine	VB	O	O
response	NN	O	O
to	TO	O	O
therapy	NN	O	O
.	.	O	O

Efficacy	NN	o	OOt
of	IN	O	O
chlorhexidine	NN	i	IPM
gluconate	NN	i	IPM
use	NN	O	O
in	IN	O	O
the	DT	O	O
prevention	NN	O	O
of	IN	O	O
perirectal	JJ	O	O
infections	NNS	O	O
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
acute	JJ	p	PC
leukemia	NN	p	PC
.	.	p	O

The	DT	O	O
frequency	NN	O	O
of	IN	O	O
rectal	JJ	o	OPH
infections	NNS	o	OPH
is	VBZ	O	O
increased	VBN	O	O
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
acute	JJ	p	PC
leukemia	NN	p	PC
.	.	p	O

Complications	NNS	O	O
associated	VBN	O	O
with	IN	O	O
rectal	JJ	O	O
lesions	NNS	O	O
may	MD	O	O
be	VB	O	O
severe	JJ	O	O
enough	RB	O	O
to	TO	O	O
cause	VB	O	O
life-threatening	JJ	O	O
septicemia	NN	O	O
.	.	O	O

Clinical	JJ	O	O
research	NN	O	O
evaluating	VBG	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
preventive	JJ	O	O
perirectal	NN	O	O
skin	NN	O	O
care	NN	O	O
is	VBZ	O	O
scarce	JJ	O	O
.	.	O	O

This	DT	O	O
study	NN	O	O
's	POS	O	O
purpose	NN	O	O
was	VBD	O	O
to	TO	O	O
determine	VB	O	O
whether	IN	O	O
using	VBG	O	O
chlorhexidine	JJ	i	IPM
gluconate	NN	i	IPM
(	(	i	IPM
CHG	NNP	i	IPM
)	)	i	IPM
in	IN	O	O
a	DT	O	O
prophylactic	JJ	O	O
perirectal	JJ	O	O
skin-care	JJ	O	O
regimen	NNS	O	O
decreases	VBZ	O	O
perirectal	JJ	O	O
infections	NNS	O	O
and	CC	O	O
whether	IN	O	O
it	PRP	O	O
produces	VBZ	O	O
more	JJR	O	O
skin	JJ	O	O
irritation	NN	O	O
than	IN	O	O
a	DT	O	O
nonmedicated	JJ	O	O
skin	NN	O	O
cleanser	NN	O	O
.	.	O	O

The	DT	O	O
sample	NN	p	O
consisted	VBD	p	O
of	IN	p	O
40	CD	p	PSS
patients	NNS	p	O
,	,	O	O
16	CD	O	O
of	IN	O	O
whom	WP	O	O
were	VBD	O	O
randomized	VBN	O	O
to	TO	O	O
use	VB	O	O
chlorhexidine	NN	i	IPM
and	CC	O	O
24	CD	O	O
of	IN	O	O
whom	WP	O	O
were	VBD	O	O
randomized	VBN	O	O
to	TO	O	O
use	VB	O	O
nonmedicated	JJ	i	IPH
skin	NN	i	IPH
cleanser	NN	i	IPH
.	.	i	O

Chi-square	JJ	O	O
and	CC	O	O
t-tests	NNS	O	O
were	VBD	O	O
used	VBN	O	O
to	TO	O	O
analyze	VB	O	O
the	DT	O	O
incidence	NN	O	O
of	IN	O	O
skin	JJ	o	OPH
breakdown	NN	o	OPH
and	CC	O	O
rectal	JJ	o	OPH
infections	NNS	o	OPH
;	:	o	OPH
the	DT	O	O
correlation	NN	O	O
between	IN	O	O
the	DT	O	O
two	CD	O	O
factors	NNS	O	O
;	:	O	O
a	DT	O	O
positive	JJ	O	O
history	NN	O	O
of	IN	O	O
rectal	JJ	O	O
infections	NNS	O	O
,	,	O	O
fissures	NNS	O	O
,	,	O	O
or	CC	O	O
hemorrhoids	NNS	O	O
;	:	O	O
presence	NN	O	O
of	IN	O	O
hemorrhoids	NNS	O	O
;	:	O	O
severity	NN	O	O
of	IN	O	O
diarrhea	NN	O	O
;	:	O	O
and	CC	O	O
duration	NN	O	O
and	CC	O	O
severity	NN	O	O
of	IN	O	O
granulocytopenia	NN	O	O
.	.	O	O

A	DT	O	O
positive	JJ	O	O
relationship	NN	O	O
was	VBD	O	O
found	VBN	O	O
between	IN	O	O
the	DT	O	O
severity	NN	o	OPH
of	IN	o	OPH
granulocytopenia	NN	o	OPH
and	CC	O	O
the	DT	O	O
incidence	NN	o	OPH
of	IN	o	OPH
rectal	JJ	o	OPH
infections	NNS	o	OPH
(	(	O	O
p	JJ	O	O
=	NNP	O	O
0.02	CD	O	O
)	)	O	O
.	.	O	O

No	DT	O	O
significant	JJ	O	O
difference	NN	O	O
was	VBD	O	O
seen	VBN	O	O
in	IN	O	O
the	DT	O	O
occurrence	NN	o	OPH
of	IN	o	OPH
perirectal	JJ	o	OPH
infections	NNS	o	OPH
(	(	O	O
p	JJ	O	O
=	NNP	O	O
0.35	CD	O	O
)	)	O	O
or	CC	O	O
skin	JJ	o	OPH
breakdown	NN	o	OPH
(	(	O	O
p	JJ	O	O
=	NNP	O	O
0.18	CD	O	O
)	)	O	O
between	IN	O	O
the	DT	O	O
two	CD	O	O
groups	NNS	O	O
.	.	O	O

The	DT	O	O
data	NN	O	O
suggest	NN	O	O
that	IN	O	O
CHG	NNP	O	O
does	VBZ	O	O
not	RB	O	O
offer	VB	O	O
increased	JJ	O	O
protection	NN	O	O
against	IN	O	O
perirectal	JJ	O	O
infections	NNS	O	O
in	IN	O	O
patients	NNS	O	O
undergoing	VBG	O	O
intensive	JJ	O	O
chemotherapy	NN	O	O
,	,	O	O
nor	CC	O	O
is	VBZ	O	O
it	PRP	O	O
more	RBR	O	O
irritating	JJ	O	O
than	IN	O	O
a	DT	O	O
nonmedicated	JJ	O	O
skin	NN	O	O
cleanser	NN	O	O
.	.	O	O

Further	JJ	O	O
studies	NNS	O	O
are	VBP	O	O
needed	VBN	O	O
to	TO	O	O
examine	VB	O	O
the	DT	O	O
efficacy	NN	O	O
of	IN	O	O
hygienic	JJ	O	O
measures	NNS	O	O
such	JJ	O	O
as	IN	O	O
using	VBG	O	O
skin	JJ	O	O
disinfectants	NNS	O	O
to	TO	O	O
prevent	VB	O	O
infections	NNS	O	O
in	IN	O	O
patients	NNS	O	O
who	WP	O	O
are	VBP	O	O
immunocompromised	VBN	O	O
.	.	O	O

Pharmacokinetics	NNS	O	O
and	CC	O	O
follicular	JJ	O	O
dynamics	NNS	O	O
of	IN	O	O
corifollitropin	NN	i	IPM
alfa	NN	i	IPM
versus	NN	i	O
recombinant	JJ	i	IPM
FSH	NNP	i	IPM
during	IN	O	O
ovarian	JJ	p	O
stimulation	NN	p	O
for	IN	p	O
IVF	NNP	p	O
.	.	p	O

A	NNP	O	O
single	JJ	O	O
injection	NN	O	O
of	IN	O	O
corifollitropin	NN	i	IPM
alfa	NN	i	IPM
can	MD	O	O
replace	VB	O	O
seven	CD	O	O
daily	JJ	O	O
injections	NNS	O	O
of	IN	O	O
recombinant	JJ	i	IPM
FSH	NNP	i	IPM
(	(	i	IPM
rFSH	NN	i	IPM
)	)	i	IPM
using	VBG	O	O
a	DT	O	O
gonadotrophin-releasing	JJ	O	O
hormone	NN	O	O
antagonist	NN	O	O
protocol	NN	O	O
in	IN	O	O
ovarian	JJ	O	O
stimulation	NN	O	O
prior	RB	p	O
to	TO	p	O
IVF	NNP	p	O
or	CC	O	O
intracytoplasmic	JJ	O	O
sperm	JJ	O	O
injection	NN	O	O
.	.	O	O

This	DT	O	O
double-blind	JJ	O	O
randomized	NN	O	O
controlled	VBD	O	O
trial	NN	O	O
assessed	VBD	O	O
the	DT	O	O
pharmacokinetics	NNS	O	O
and	CC	O	O
pharmacodynamics	NNS	O	O
of	IN	O	O
150?g	CD	i	O
corifollitropin	NN	i	O
alfa	NN	i	O
versus	IN	i	O
daily	JJ	i	O
200IU	CD	i	O
rFSH	NN	i	O
in	IN	p	O
1509	CD	p	O
patients	NNS	p	O
.	.	p	O

Comparative	JJ	O	O
analyses	NNS	O	O
were	VBD	O	O
performed	VBN	O	O
on	IN	o	O
serum	JJ	o	O
concentrations	NNS	o	O
of	IN	o	O
FSH	NNP	o	O
immunoreactivity	NN	o	O
(	(	O	O
pharmacokinetics	NNS	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
the	DT	o	O
number	NN	o	O
and	CC	o	O
size	NN	o	O
of	IN	o	O
growing	VBG	o	O
follicles	NNS	o	O
,	,	o	O
and	CC	o	O
inhibin	NN	o	O
B	NNP	o	O
and	CC	o	O
oestradiol	JJ	o	O
concentrations	NNS	o	O
as	IN	O	O
biomarkers	NNS	O	O
of	IN	O	O
ovarian	JJ	O	O
response	NN	O	O
(	(	O	O
pharmacodynamics	NNS	O	O
)	)	O	O
.	.	O	O

The	DT	o	O
rate	NN	o	O
of	IN	o	O
follicular	JJ	o	O
development	NN	o	O
was	VBD	O	O
similar	JJ	O	O
in	IN	O	O
both	DT	O	O
treatment	NN	O	O
groups	NNS	O	O
.	.	O	O

By	IN	O	O
stimulation	NN	O	O
day	NN	O	O
8	CD	O	O
,	,	O	O
33	CD	O	O
%	NN	O	O
of	IN	O	O
patients	NNS	O	O
treated	VBN	O	O
with	IN	O	O
corifollitropin	NN	O	O
alfa	NN	O	O
reached	VBD	O	O
the	DT	O	O
criterion	NN	O	O
for	IN	O	O
human	JJ	O	O
chorionic	NN	O	O
gonadotrophin	NN	O	O
(	(	O	O
HCG	NNP	O	O
)	)	O	O
injection	NN	O	O
.	.	O	O

The	DT	o	O
number	NN	o	O
of	IN	o	O
follicles	NNS	o	O
?11mm	NNP	o	O
was	VBD	o	O
slightly	RB	O	O
higher	JJR	O	O
after	IN	i	O
corifollitropin	NN	i	O
alfa	NN	i	O
compared	VBN	i	O
with	IN	O	O
daily	JJ	O	O
rFSH	NN	O	O
at	IN	O	O
stimulation	NN	O	O
day	NN	O	O
8	CD	O	O
(	(	O	O
difference	NN	O	O
,	,	O	O
1.2	CD	O	O
;	:	O	O
95	CD	O	O
%	NN	O	O
confidence	NN	O	O
interval	NN	O	O
(	(	O	O
CI	NNP	O	O
)	)	O	O
0.5-1.8	NN	O	O
;	:	O	O
P	NNP	O	O
<	NNP	O	O
0.01	CD	O	O
)	)	O	O
and	CC	O	O
on	IN	O	O
the	DT	O	O
day	NN	O	O
of	IN	O	O
HCG	NNP	O	O
injection	NN	O	O
(	(	O	O
difference	NN	O	O
,	,	O	O
2.1	CD	O	O
;	:	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
1.4-2.8	CD	O	O
;	:	O	O
P	NNP	O	O
<	NNP	O	O
0.01	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
rise	NN	o	O
of	IN	o	O
inhibin	NN	o	O
B	NNP	o	O
and	CC	o	O
oestradiol	JJ	o	O
concentrations	NNS	o	O
was	VBD	o	O
similar	JJ	O	O
in	IN	O	O
both	DT	O	O
treatment	NN	O	O
groups	NNS	O	O
.	.	O	O

Although	IN	O	O
the	DT	O	O
pharmacokinetics	NNS	O	O
of	IN	O	O
corifollitropin	NN	i	O
alfa	NN	i	O
and	CC	i	O
rFSH	NN	i	O
are	VBP	i	O
quite	RB	O	O
different	JJ	O	O
their	PRP$	O	O
pharmacodynamic	JJ	O	O
profiles	NNS	O	O
at	IN	O	O
the	DT	O	O
dosages	NNS	O	O
used	VBN	O	O
are	VBP	O	O
similar	JJ	O	O
.	.	O	O

A	DT	O	O
single	JJ	O	O
injection	NN	O	O
of	IN	O	O
corifollitropin	NN	i	O
alfa	NN	i	O
can	MD	i	O
replace	VB	O	O
seven	CD	O	O
daily	JJ	O	O
injections	NNS	O	O
of	IN	O	O
recombinant	JJ	i	O
FSH	NNP	i	O
(	(	i	O
rFSH	NN	i	O
)	)	i	O
using	VBG	i	O
a	DT	O	O
gonadotrophin-releasing	JJ	O	O
hormone	NN	O	O
antagonist	NN	O	O
protocol	NN	O	O
in	IN	O	O
ovarian	JJ	O	O
stimulation	NN	O	O
prior	RB	O	O
to	TO	O	O
IVF	NNP	O	O
or	CC	O	O
intracytoplasmic	JJ	O	O
sperm	JJ	O	O
injection	NN	O	O
.	.	O	O

The	DT	O	O
objective	NN	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
compare	VB	O	O
the	DT	O	O
pharmacokinetics	NNS	O	O
and	CC	O	O
pharmacodynamics	NNS	O	O
of	IN	O	O
corifollitropin	NN	i	O
alfa	JJ	i	O
versus	JJ	i	O
daily	JJ	i	O
rFSH	NN	i	O
.	.	i	O

A	DT	i	O
total	NN	O	O
of	IN	O	O
1509	CD	p	O
patients	NNS	p	O
were	VBD	p	O
randomized	VBN	O	O
in	IN	O	O
a	DT	O	O
double-blind	NN	O	O
,	,	O	O
controlled	VBN	O	O
trial	NN	O	O
to	TO	O	O
either	VB	O	O
a	DT	O	O
single	JJ	O	O
injection	NN	O	O
of	IN	O	O
150?g	CD	i	O
corifollitropin	NN	i	O
alfa	NN	i	O
or	CC	i	O
to	TO	O	O
daily	JJ	O	O
injections	NNS	O	O
of	IN	O	O
200IU	CD	i	O
rFSH	NN	i	O
for	IN	i	O
the	DT	O	O
first	JJ	O	O
7	CD	O	O
days	NNS	O	O
of	IN	O	O
ovarian	JJ	O	O
stimulation	NN	o	O
.	.	o	O

Serum	NNP	o	O
levels	NNS	o	O
of	IN	o	O
FSH	NNP	o	O
immunoreactivity	NN	o	O
were	VBD	o	O
analysed	VBN	O	O
(	(	O	O
pharmacokinetic	JJ	O	O
analysis	NN	O	O
)	)	O	O
,	,	O	O
together	RB	O	O
with	IN	O	O
the	DT	O	O
number	NN	o	O
and	CC	o	O
size	NN	o	O
of	IN	o	O
growing	VBG	o	O
follicles	NNS	o	O
and	CC	o	O
serum	NN	o	O
inhibin	NN	o	O
B	NNP	o	O
and	CC	o	O
oestradiol	JJ	o	O
concentrations	NNS	o	O
as	IN	o	O
biomarkers	NNS	O	O
of	IN	O	O
the	DT	O	O
ovarian	JJ	O	O
response	NN	O	O
(	(	O	O
pharmacodynamic	JJ	O	O
analysis	NN	o	O
)	)	o	O
.	.	o	O

Serum	NNP	o	O
FSH	NNP	o	O
immunoreactivity	NN	o	O
levels	NNS	o	O
were	VBD	o	O
higher	JJR	O	O
up	RB	O	O
to	TO	O	O
stimulation	VB	O	O
day	NN	O	O
5	CD	O	O
for	IN	O	O
corifollitropin	NN	i	O
alfa	NN	i	O
compared	VBN	i	O
with	IN	O	O
the	DT	O	O
daily	JJ	i	O
rFSH	NN	i	O
regimen	NNS	i	O
but	CC	O	O
were	VBD	O	O
similar	JJ	O	O
from	IN	O	O
day	NN	O	O
8	CD	O	O
onwards	NNS	O	O
,	,	O	O
when	WRB	O	O
patients	NNS	O	O
started	VBD	O	O
rFSH	RB	O	O
if	IN	O	O
the	DT	O	O
criteria	NN	O	O
for	IN	O	O
human	JJ	O	O
chorionic	NN	O	O
gonadotrophin	NN	O	O
were	VBD	O	O
not	RB	O	O
yet	RB	O	O
reached	VBN	i	O
.	.	i	O

Corifollitropin	NNP	i	O
alfa	JJ	i	O
treatment	NN	i	O
resulted	VBD	O	O
in	IN	O	O
a	DT	O	O
similar	JJ	o	O
growth	NN	o	O
rate	NN	o	O
of	IN	o	O
follicles	NNS	o	O
though	IN	o	O
a	DT	O	O
slightly	RB	o	O
higher	JJR	o	O
number	NN	o	O
of	IN	o	O
follicles	NNS	o	O
were	VBD	o	O
recruited	VBN	O	O
compared	VBN	O	O
with	IN	O	O
daily	JJ	O	O
rFSH	NN	O	O
.	.	O	O

It	PRP	O	O
is	VBZ	O	O
concluded	VBN	O	O
that	IN	O	O
the	DT	O	O
pharmacokinetics	NNS	i	O
of	IN	i	O
corifollitropin	NN	i	IPM
alfa	NN	i	IPM
and	CC	i	O
rFSH	NN	i	IPM
are	VBP	i	O
quite	RB	O	O
different	JJ	O	O
but	CC	O	O
their	PRP$	O	O
induced	JJ	o	O
pharmacodynamic	JJ	o	O
effects	NNS	o	O
at	IN	o	O
the	DT	O	O
dosages	NNS	O	O
used	VBN	O	O
are	VBP	O	O
similar	JJ	O	O
.	.	O	O

Use	NNP	o	OOt
and	CC	o	OOt
limitations	NNS	o	OOt
of	IN	O	O
Holter	NNP	i	IPH
electrocardiography	NN	i	IPH
in	IN	O	O
assessing	VBG	O	O
drug	NN	p	O
therapy	NN	p	O
of	IN	p	O
myocardial	JJ	p	PC
ischemia	NN	p	PC
during	IN	p	O
the	DT	p	O
peri-PTCA	JJ	p	PC
period	NN	p	O
.	.	p	O

Incidence	NN	O	O
and	CC	O	O
pattern	NN	O	O
of	IN	O	O
myocardial	JJ	O	O
ischemia	NN	O	O
during	IN	O	O
the	DT	O	O
peri-PTCA	JJ	p	PC
(	(	p	O
percutaneous	JJ	p	PC
transluminal	JJ	p	PC
coronary	JJ	p	PC
angioplasty	NN	p	PC
)	)	p	O
period	NN	O	O
and	CC	O	O
the	DT	O	O
possible	JJ	O	O
role	NN	O	O
of	IN	O	O
continuous	JJ	i	IPM
intravenous	JJ	i	IPM
isosorbide	NN	i	IPM
dinitrate	NN	i	IPM
in	IN	O	O
its	PRP$	O	O
prevention	NN	O	O
were	VBD	O	O
examined	VBN	O	O
prospectively	RB	O	O
in	IN	O	O
30	CD	p	PSS
patients	NNS	p	O
.	.	p	O

Holter	NNP	o	O
electrocardiographic	JJ	o	O
monitoring	NN	o	O
was	VBD	O	O
performed	VBN	O	O
for	IN	O	O
21	CD	O	O
+/-	JJ	O	O
3	CD	O	O
h	NN	O	O
before	IN	O	O
PTCA	NNP	O	O
and	CC	O	O
continued	VBN	O	O
during	IN	O	O
and	CC	O	O
for	IN	O	O
41	CD	O	O
+/-	JJ	O	O
8	CD	O	O
h	NN	O	O
after	IN	O	O
the	DT	O	O
procedure	NN	O	O
.	.	O	O

Before	IN	O	O
PTCA	NNP	O	O
,	,	O	O
19	CD	O	O
ischemic	JJ	O	O
episodes	NNS	O	O
were	VBD	O	O
present	JJ	O	O
in	IN	O	O
10	CD	O	O
(	(	O	O
33	CD	O	O
%	NN	O	O
)	)	O	O
of	IN	O	O
30	CD	p	PSS
patients	NNS	p	O
.	.	p	O

PTCA	NNP	O	O
produced	VBD	O	O
an	DT	O	O
abrupt	JJ	O	O
decrease	NN	O	O
in	IN	O	O
number	NN	O	O
(	(	O	O
p	JJ	O	O
=	NNP	O	O
0.015	CD	O	O
)	)	O	O
and	CC	O	O
duration	NN	O	O
(	(	O	O
p	JJ	O	O
=	NNP	O	O
0.03	CD	O	O
)	)	O	O
of	IN	O	O
spontaneous	JJ	o	OPH
ischemic	JJ	o	OPH
episodes	NNS	o	OPH
.	.	o	OPH

The	DT	O	O
rarity	NN	O	O
of	IN	O	O
recurrent	JJ	o	OPH
myocardial	JJ	o	OPH
ischemic	JJ	o	OPH
events	NNS	o	OPH
by	IN	O	O
Holter	NNP	i	IPH
monitoring	NN	i	IPH
after	IN	O	O
PTCA	NNP	O	O
negated	VBD	O	O
any	DT	O	O
attempt	NN	O	O
at	IN	O	O
assessing	VBG	O	O
the	DT	O	O
efficacy	NN	O	O
of	IN	O	O
intravenous	JJ	O	O
isosorbide	JJ	i	IPM
dinitrate	NN	i	IPM
in	IN	O	O
their	PRP$	O	O
prevention	NN	O	O
.	.	O	O

Holter	NNP	i	IPH
monitoring	NN	i	IPH
could	MD	O	O
not	RB	O	O
be	VB	O	O
used	VBN	O	O
as	IN	O	O
an	DT	O	O
early	JJ	O	O
predictor	NN	O	O
of	IN	O	O
late	JJ	O	O
coronary	JJ	O	O
restenosis	NN	O	O
.	.	O	O

14	CD	O	O
day	NN	O	O
endoscopy	NN	O	O
study	NN	O	O
comparing	VBG	O	O
risedronate	NN	i	IPM
and	CC	O	O
alendronate	NN	i	IPM
in	IN	O	O
postmenopausal	JJ	p	PC
women	NNS	p	PSE
stratified	VBN	p	O
by	IN	p	O
Helicobacter	NNP	p	PC
pylori	NN	p	PC
status	NN	p	O
.	.	p	O

OBJECTIVE	NNP	O	O
Bisphosphonates	NNPS	i	IPM
are	VBP	O	O
effective	JJ	O	O
treatment	NN	O	O
for	IN	O	O
osteoporosis	NN	O	O
but	CC	O	O
have	VBP	O	O
been	VBN	O	O
associated	VBN	O	O
with	IN	O	O
gastrointestinal	JJ	O	O
(	(	O	O
GI	NNP	O	O
)	)	O	O
mucosal	NN	O	O
injury	NN	O	O
.	.	O	O

This	DT	O	O
study	NN	O	O
compared	VBN	O	O
the	DT	O	O
incidence	NN	O	O
of	IN	O	O
gastric	JJ	O	O
ulcers	NNS	O	O
after	IN	O	O
treatment	NN	O	O
with	IN	O	O
risedronate	NN	i	IPM
,	,	i	IPM
a	DT	i	IPM
pyridinyl	NN	i	IPM
bisphosphonate	NN	i	IPM
,	,	i	O
or	CC	i	O
alendronate	NN	i	IPM
,	,	i	IPM
a	DT	i	IPM
primary	JJ	i	IPM
amino	NN	i	IPM
bisphosphonate	NN	i	IPM
,	,	O	O
in	IN	O	O
healthy	JJ	p	PC
postmenopausal	NN	p	PC
women	NNS	p	PSE
stratified	VBN	p	O
by	IN	p	O
Helicobacter	NNP	p	PC
pylori	NN	p	PC
status	NN	p	O
.	.	p	O

METHODS	NNP	O	O
Subjects	NNPS	O	O
were	VBD	O	O
randomized	VBN	O	O
to	TO	O	O
receive	VB	O	O
risedronate	NN	i	IPM
5	CD	O	O
mg	NN	O	O
(	(	O	O
n	JJ	O	O
=	NNP	O	O
318	CD	O	O
)	)	O	O
or	CC	O	O
alendronate	$	i	IPM
10	CD	O	O
mg	NN	O	O
(	(	O	O
n	JJ	O	O
=	NNP	O	O
317	CD	O	O
)	)	O	O
daily	RB	O	O
for	IN	O	O
14	CD	O	O
days	NNS	O	O
.	.	O	O

Endoscopy	NNP	i	IS
and	CC	O	O
evaluator-blind	JJ	O	O
assessments	NNS	O	O
of	IN	O	O
the	DT	O	O
esophageal	NN	O	O
,	,	O	O
gastric	NN	O	O
,	,	O	O
and	CC	O	O
duodenal	JJ	O	O
mucosa	NN	O	O
were	VBD	O	O
performed	VBN	O	O
at	IN	O	O
baseline	NN	O	O
and	CC	O	O
on	IN	O	O
Days	NNP	O	O
8	CD	O	O
and	CC	O	O
15	CD	O	O
.	.	O	O

RESULTS	NNP	O	O
Overall	NNP	O	O
,	,	O	O
gastric	JJ	o	OPH
ulcers	NNS	o	OPH
>	VBP	O	O
or	CC	O	O
=	VBP	O	O
3	CD	O	O
mm	NNS	O	O
were	VBD	O	O
observed	VBN	O	O
in	IN	O	O
18	CD	O	O
(	(	O	O
6.0	CD	O	O
%	NN	O	O
)	)	O	O
of	IN	O	O
300	CD	O	O
evaluable	JJ	O	O
subjects	NNS	O	O
in	IN	O	O
the	DT	O	O
risedronate	NN	i	IPM
group	NN	O	O
and	CC	O	O
36	CD	O	O
(	(	O	O
12.1	CD	O	O
%	NN	O	O
)	)	O	O
of	IN	O	O
297	CD	O	O
in	IN	O	O
the	DT	O	O
alendronate	NN	O	O
group	NN	O	O
during	IN	O	O
treatment	NN	O	O
(	(	O	O
p	JJ	O	O
=	NNP	O	O
0.013	CD	O	O
)	)	O	O
.	.	O	O

On	IN	O	O
Day	NNP	O	O
8	CD	O	O
,	,	O	O
the	DT	O	O
incidences	NNS	o	OPH
of	IN	o	OPH
gastric	JJ	o	OPH
ulcers	NNS	o	OPH
in	IN	O	O
the	DT	O	O
risedronate	NN	i	IPM
and	CC	O	O
alendronate	NN	i	IPM
groups	NNS	O	O
were	VBD	O	O
3.6	CD	O	O
%	NN	O	O
and	CC	O	O
6.6	CD	O	O
%	NN	O	O
,	,	O	O
respectively	RB	O	O
(	(	O	O
p	JJ	O	O
=	NNP	O	O
0.133	CD	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
on	IN	O	O
Day	NNP	O	O
15	CD	O	O
,	,	O	O
they	PRP	O	O
were	VBD	O	O
3.3	CD	O	O
%	NN	O	O
and	CC	O	O
8.7	CD	O	O
%	NN	O	O
(	(	O	O
p	JJ	O	O
=	NNP	O	O
0.008	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
incidence	NN	o	OPH
of	IN	o	OPH
gastric	JJ	o	OPH
ulcers	NNS	o	OPH
was	VBD	O	O
not	RB	O	O
affected	VBN	O	O
by	IN	O	O
H.	NNP	O	O
pylori	NN	O	O
status	NN	O	O
.	.	O	O

Mean	NNP	o	OOt
gastric	JJ	o	OOt
endoscopy	NN	o	OOt
scores	NNS	o	OOt
at	IN	O	O
Days	NNP	O	O
8	CD	O	O
and	CC	O	O
15	CD	O	O
were	VBD	O	O
significantly	RB	O	O
lower	JJR	O	O
in	IN	O	O
the	DT	O	O
risedronate	NN	i	IPM
group	NN	O	O
than	IN	O	O
in	IN	O	O
the	DT	O	O
alendronate	NN	i	IPM
group	NN	O	O
(	(	O	O
p	JJ	O	O
<	NNP	O	O
0.001	CD	O	O
)	)	O	O
.	.	O	O

Mean	JJ	o	OOt
esophageal	NN	o	OOt
and	CC	o	OOt
duodenal	JJ	o	OOt
endoscopy	NN	o	OOt
scores	NNS	o	OOt
were	VBD	O	O
similar	JJ	O	O
in	IN	O	O
the	DT	O	O
2	CD	O	O
groups	NNS	O	O
at	IN	O	O
Days	NNP	O	O
8	CD	O	O
and	CC	O	O
15	CD	O	O
.	.	O	O

When	WRB	O	O
the	DT	O	O
treatment	NN	O	O
groups	NNS	O	O
were	VBD	O	O
combined	VBN	O	O
,	,	O	O
gastric	JJ	o	OOt
endoscopy	NN	o	OOt
scores	NNS	o	OOt
were	VBD	O	O
significantly	RB	O	O
higher	JJR	O	O
among	IN	O	O
H.	NNP	O	O
pylori	FW	O	O
negative	JJ	O	O
than	IN	O	O
H.	NNP	O	O
pylori	FW	O	O
positive	JJ	O	O
subjects	NNS	O	O
at	IN	O	O
Days	NNP	O	O
8	CD	O	O
and	CC	O	O
15	CD	O	O
(	(	O	O
p	NN	O	O
<	RB	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

Upper	NNP	o	OA
GI	NNP	o	OA
adverse	JJ	o	OA
events	NNS	o	OA
were	VBD	O	O
reported	VBN	O	O
by	IN	O	O
18	CD	O	O
(	(	O	O
5.7	CD	O	O
%	NN	O	O
)	)	O	O
subjects	VBZ	O	O
in	IN	O	O
the	DT	O	O
risedronate	NN	i	IPM
group	NN	O	O
(	(	O	O
19	CD	O	O
events	NNS	O	O
)	)	O	O
and	CC	O	O
28	CD	O	O
(	(	O	O
8.8	CD	O	O
%	NN	O	O
)	)	O	O
subjects	VBZ	O	O
in	IN	O	O
the	DT	O	O
alendronate	NN	i	IPM
group	NN	O	O
(	(	O	O
32	CD	O	O
events	NNS	O	O
)	)	O	O
.	.	O	O

Symptoms	NNS	O	O
did	VBD	O	O
not	RB	O	O
predict	VB	O	O
the	DT	O	O
presence	NN	O	O
of	IN	O	O
mucosal	JJ	O	O
damage	NN	O	O
.	.	O	O

CONCLUSION	NNP	O	O
Risedronate	NNP	i	IPM
was	VBD	O	O
associated	VBN	O	O
with	IN	O	O
a	DT	O	O
significantly	RB	O	O
lower	JJR	O	O
incidence	NN	O	O
of	IN	O	O
gastric	JJ	O	O
ulcers	NNS	O	O
than	IN	O	O
alendronate	NN	i	IPM
.	.	i	O

H.	NNP	O	O
pylori	JJ	O	O
infection	NN	O	O
did	VBD	O	O
not	RB	O	O
increase	VB	O	O
the	DT	O	O
incidence	NN	O	O
of	IN	O	O
bisphosphonate	NN	O	O
related	VBN	O	O
gastric	JJ	O	O
ulcers	NNS	O	O
.	.	O	O

The	DT	O	O
findings	NNS	O	O
from	IN	O	O
this	DT	O	O
14	CD	O	O
day	NN	O	O
study	NN	O	O
in	IN	O	O
healthy	JJ	O	O
volunteers	NNS	O	O
support	VBP	O	O
the	DT	O	O
hypothesis	NN	O	O
that	WDT	O	O
bisphosphonates	VBZ	O	O
may	MD	O	O
differ	VB	O	O
from	IN	O	O
one	CD	O	O
another	DT	O	O
in	IN	O	O
their	PRP$	O	O
potential	JJ	O	O
to	TO	O	O
produce	VB	O	O
upper	JJ	O	O
GI	NNP	O	O
mucosal	NN	O	O
damage	NN	O	O
.	.	O	O

Prophylactic	JJ	i	IPM
lidocaine	NN	i	IPM
in	IN	O	O
the	DT	O	O
early	JJ	O	O
phase	NN	O	O
of	IN	O	O
suspected	JJ	O	O
myocardial	JJ	O	O
infarction	NN	O	O
.	.	O	O

Four	CD	p	PSS
hundred	VBD	p	PSS
two	CD	p	PSS
patients	NNS	p	O
with	IN	p	O
suspected	JJ	p	PC
myocardial	JJ	p	PC
infarction	NN	p	PC
seen	VBN	p	O
within	IN	p	O
6	CD	p	O
hours	NNS	p	O
of	IN	p	O
the	DT	p	O
onset	NN	p	O
of	IN	p	O
symptoms	NNS	p	O
entered	VBD	O	O
a	DT	O	O
double-blind	JJ	O	O
randomized	JJ	O	O
trial	NN	O	O
of	IN	O	O
lidocaine	NN	i	IPM
vs	NN	i	O
placebo	NN	i	IC
.	.	i	O

During	IN	O	O
the	DT	O	O
1	CD	O	O
hour	NN	O	O
after	IN	O	O
administration	NN	O	O
of	IN	O	O
the	DT	O	O
drug	NN	O	O
the	DT	O	O
incidence	NN	o	OPH
of	IN	o	OPH
ventricular	JJ	o	OPH
fibrillation	NN	o	OPH
or	CC	o	O
sustained	VBN	o	OPH
ventricular	JJ	o	OPH
tachycardia	NN	o	OPH
among	IN	O	O
the	DT	O	O
204	CD	p	PSS
patients	NNS	p	O
with	IN	p	O
acute	JJ	p	PC
myocardial	JJ	p	PC
infarction	NN	p	PC
was	VBD	O	O
low	JJ	O	O
,	,	O	O
1.5	CD	O	O
%	NN	O	O
.	.	O	O

Lidocaine	NNP	i	IPM
,	,	O	O
given	VBN	O	O
in	IN	O	O
a	DT	O	O
300	CD	O	O
mg	NN	O	O
dose	VBD	O	O
intramuscularly	RB	O	O
followed	VBN	O	O
by	IN	O	O
100	CD	O	O
mg	NN	O	O
intravenously	RB	O	O
,	,	O	O
did	VBD	O	O
not	RB	O	O
prevent	VB	O	O
sustained	JJ	o	OPH
ventricular	JJ	o	OPH
tachycardia	NN	o	OPH
,	,	O	O
although	IN	O	O
there	EX	O	O
was	VBD	O	O
a	DT	O	O
significant	JJ	O	O
reduction	NN	O	O
in	IN	O	O
the	DT	O	O
number	NN	o	OPH
of	IN	o	OPH
patients	NNS	o	OPH
with	IN	o	OPH
warning	VBG	o	OPH
arrhythmias	NNS	o	OPH
between	IN	O	O
15	CD	O	O
and	CC	O	O
45	CD	O	O
minutes	NNS	O	O
after	IN	O	O
the	DT	O	O
administration	NN	O	O
of	IN	O	O
lidocaine	NN	i	IPM
(	(	O	O
p	NN	O	O
less	JJR	O	O
than	IN	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
average	JJ	o	OPH
plasma	JJ	o	OPH
lidocaine	JJ	o	OPH
level	NN	o	OPH
10	CD	O	O
minutes	NNS	o	OOt
after	IN	o	OOt
administration	NN	O	O
for	IN	O	O
patients	NNS	O	O
without	IN	O	O
a	DT	O	O
myocardial	JJ	O	O
infarction	NN	O	O
was	VBD	O	O
significantly	RB	O	O
higher	JJR	O	O
than	IN	O	O
that	DT	O	O
for	IN	O	O
patients	NNS	O	O
with	IN	O	O
an	DT	O	O
acute	JJ	O	O
infarction	NN	O	O
.	.	O	O

The	DT	O	O
mean	JJ	o	OPH
plasma	NN	o	OPH
lidocaine	JJ	o	OPH
level	NN	o	OPH
of	IN	O	O
patients	NNS	O	O
on	IN	O	O
beta-blocking	JJ	O	O
agents	NNS	O	O
was	VBD	O	O
no	DT	O	O
different	JJ	O	O
from	IN	O	O
that	DT	O	O
in	IN	O	O
patients	NNS	O	O
not	RB	O	O
on	IN	O	O
beta	NN	O	O
blocking	VBG	O	O
agents	NNS	O	O
.	.	O	O

During	IN	O	O
the	DT	O	O
1-hour	JJ	O	O
study	NN	O	O
period	NN	O	O
,	,	O	O
the	DT	O	O
incidence	NN	o	OA
of	IN	o	OA
central	JJ	o	OA
nervous	JJ	o	OA
system	NN	o	OA
side	NN	o	OA
effects	NNS	o	OA
was	VBD	O	O
significantly	RB	O	O
greater	JJR	O	O
in	IN	O	O
the	DT	O	O
lidocaine	NN	O	O
group	NN	O	O
,	,	O	O
hypotension	NN	o	OPH
occurred	VBD	O	O
in	IN	O	O
11	CD	O	O
patients	NNS	O	O
,	,	O	O
nine	CD	O	O
of	IN	O	O
whom	WP	O	O
had	VBD	O	O
received	VBN	O	O
lidocaine	NN	O	O
,	,	O	O
and	CC	O	O
four	CD	p	O
patients	NNS	p	O
died	VBD	o	OMO
from	IN	O	O
asystole	NN	O	O
,	,	O	O
three	CD	O	O
of	IN	O	O
whom	WP	O	O
had	VBD	O	O
had	VBN	O	O
lidocaine	NN	i	IPM
.	.	i	O

We	PRP	O	O
can	MD	O	O
not	RB	O	O
advocate	VB	O	O
the	DT	O	O
administration	NN	O	O
of	IN	O	O
lidocaine	JJ	i	IPM
prophylactically	RB	O	O
in	IN	O	O
the	DT	O	O
early	JJ	O	O
hours	NNS	O	O
of	IN	O	O
suspected	JJ	O	O
myocardial	JJ	O	O
infarction	NN	O	O
.	.	O	O

Intravenous	JJ	O	O
platelet	NN	O	O
blockade	NN	O	O
with	IN	O	O
cangrelor	NN	i	IPM
during	IN	O	O
PCI	NNP	p	O
.	.	p	O

BACKGROUND	NNP	O	O
Intravenous	NNP	O	O
cangrelor	NN	i	IPM
,	,	O	O
a	DT	O	O
rapid-acting	NN	O	O
,	,	O	O
reversible	JJ	O	O
adenosine	NN	O	O
diphosphate	NN	O	O
(	(	O	O
ADP	NNP	O	O
)	)	O	O
receptor	NN	O	O
antagonist	NN	O	O
,	,	O	O
might	MD	O	O
reduce	VB	O	O
ischemic	JJ	O	O
events	NNS	O	O
during	IN	O	O
percutaneous	JJ	p	O
coronary	JJ	p	O
intervention	NN	p	O
(	(	p	O
PCI	NNP	p	O
)	)	p	O
.	.	p	O

METHODS	NNP	O	O
In	IN	O	O
this	DT	O	O
double-blind	NN	O	O
,	,	O	O
placebo-controlled	JJ	O	O
study	NN	O	O
,	,	O	O
we	PRP	O	O
randomly	VBP	O	O
assigned	JJ	O	O
5362	CD	p	PSS
patients	NNS	p	O
who	WP	p	O
had	VBD	p	O
not	RB	p	O
been	VBN	p	O
treated	VBN	p	O
with	IN	p	O
clopidogrel	NN	p	O
to	TO	p	O
receive	VB	p	O
either	DT	p	O
cangrelor	NN	i	IPM
or	CC	i	O
placebo	NN	i	IC
at	IN	p	O
the	DT	p	O
time	NN	p	O
of	IN	p	O
PCI	NNP	p	O
,	,	p	O
followed	VBN	p	O
by	IN	p	O
600	CD	i	O
mg	NNS	i	O
of	IN	i	O
clopidogrel	NN	i	IPM
.	.	i	O

The	DT	O	O
primary	JJ	O	O
end	NN	O	O
point	NN	O	O
was	VBD	O	O
a	DT	O	O
composite	JJ	o	OMO
of	IN	o	OMO
death	NN	o	OMO
,	,	o	OPH
myocardial	JJ	o	OPH
infarction	NN	o	OPH
,	,	o	OPH
or	CC	o	OPH
ischemia-driven	JJ	o	OPH
revascularization	NN	o	OPH
at	IN	o	OPH
48	CD	o	OPH
hours	NNS	o	OPH
.	.	o	OPH

Enrollment	NN	O	O
was	VBD	O	O
stopped	VBN	O	O
when	WRB	O	O
an	DT	O	O
interim	JJ	O	O
analysis	NN	O	O
concluded	VBD	O	O
that	IN	O	O
the	DT	O	O
trial	NN	O	O
would	MD	O	O
be	VB	O	O
unlikely	JJ	O	O
to	TO	O	O
show	VB	O	O
superiority	NN	O	O
for	IN	O	O
the	DT	O	O
primary	JJ	O	O
end	NN	O	O
point	NN	O	O
.	.	O	O

RESULTS	VB	O	O
The	DT	O	O
primary	JJ	o	OPH
end	NN	o	OPH
point	NN	o	OPH
occurred	VBD	p	O
in	IN	p	O
185	CD	p	O
of	IN	p	O
2654	CD	p	PSS
patients	NNS	p	O
receiving	VBG	p	O
cangrelor	NN	i	IPM
(	(	p	O
7.0	CD	p	O
%	NN	p	O
)	)	p	O
and	CC	p	O
in	IN	p	O
210	CD	p	O
of	IN	p	O
2641	CD	p	PSS
patients	NNS	p	O
receiving	VBG	p	O
placebo	NN	i	IC
(	(	p	O
8.0	CD	p	O
%	NN	p	O
)	)	p	O
(	(	O	O
odds	NNS	O	O
ratio	NN	O	O
in	IN	O	O
the	DT	O	O
cangrelor	NN	O	O
group	NN	O	O
,	,	O	O
0.87	CD	O	O
;	:	O	O
95	CD	O	O
%	NN	O	O
confidence	NN	O	O
interval	NN	O	O
[	NNP	O	O
CI	NNP	O	O
]	NNP	O	O
,	,	O	O
0.71	CD	O	O
to	TO	O	O
1.07	CD	O	O
;	:	O	O
P=0.17	NNP	O	O
)	)	O	O
(	(	O	O
modified	VBN	O	O
intention-to-treat	NN	O	O
population	NN	O	O
adjusted	VBN	O	O
for	IN	O	O
missing	VBG	O	O
data	NNS	O	O
)	)	O	O
.	.	O	O

In	IN	O	O
the	DT	O	O
cangrelor	NN	i	IPM
group	NN	O	O
,	,	O	O
as	IN	O	O
compared	VBN	O	O
with	IN	O	O
the	DT	O	O
placebo	NN	O	O
group	NN	O	O
,	,	O	O
two	CD	O	O
prespecified	VBD	O	O
secondary	JJ	O	O
end	NN	O	O
points	NNS	O	O
were	VBD	O	O
significantly	RB	O	O
reduced	VBN	O	O
at	IN	O	O
48	CD	O	O
hours	NNS	O	O
:	:	O	O
the	DT	O	O
rate	NN	o	OPH
of	IN	o	OPH
stent	JJ	o	OPH
thrombosis	NN	o	OPH
,	,	O	O
from	IN	O	O
0.6	CD	O	O
%	NN	O	O
to	TO	O	O
0.2	CD	O	O
%	NN	O	O
(	(	O	O
odds	JJ	O	O
ratio	NN	O	O
,	,	O	O
0.31	CD	O	O
;	:	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
,	,	O	O
0.11	CD	O	O
to	TO	O	O
0.85	CD	O	O
;	:	O	O
P=0.02	NNP	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
rate	NN	o	OMO
of	IN	o	OMO
death	NN	o	OMO
from	IN	o	OMO
any	DT	o	OMO
cause	NN	o	OMO
,	,	O	O
from	IN	O	O
0.7	CD	O	O
%	NN	O	O
to	TO	O	O
0.2	CD	O	O
%	NN	O	O
(	(	O	O
odds	JJ	O	O
ratio	NN	O	O
,	,	O	O
0.33	CD	O	O
;	:	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
,	,	O	O
0.13	CD	O	O
to	TO	O	O
0.83	CD	O	O
;	:	O	O
P=0.02	NNP	O	O
)	)	O	O
.	.	O	O

There	EX	O	O
was	VBD	O	O
no	DT	O	O
significant	JJ	O	O
difference	NN	O	O
in	IN	O	O
the	DT	O	O
rate	NN	o	OPH
of	IN	o	OPH
blood	NN	o	OPH
transfusion	NN	o	OPH
(	(	O	O
1.0	CD	O	O
%	NN	O	O
in	IN	O	O
the	DT	O	O
cangrelor	NN	i	IPM
group	NN	O	O
and	CC	O	O
0.6	CD	O	O
%	NN	O	O
in	IN	O	O
the	DT	O	O
placebo	NN	i	IC
group	NN	O	O
,	,	O	O
P=0.13	NNP	O	O
)	)	O	O
,	,	O	O
though	IN	O	O
major	JJ	o	OPH
bleeding	VBG	o	OPH
on	IN	O	O
one	CD	O	O
scale	NN	O	O
was	VBD	O	O
increased	VBN	O	O
in	IN	O	O
the	DT	O	O
cangrelor	NN	O	O
group	NN	O	O
,	,	O	O
from	IN	O	O
3.5	CD	O	O
%	NN	O	O
to	TO	O	O
5.5	CD	O	O
%	NN	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.001	CD	O	O
)	)	O	O
,	,	O	O
because	IN	O	O
of	IN	O	O
more	JJR	O	O
groin	JJ	o	OPH
hematomas	NN	o	OPH
.	.	o	OPH

CONCLUSIONS	VB	O	O
The	DT	O	O
use	NN	O	O
of	IN	O	O
periprocedural	JJ	O	O
cangrelor	NN	i	IPM
during	IN	O	O
PCI	NNP	O	O
was	VBD	O	O
not	RB	O	O
superior	JJ	O	O
to	TO	O	O
placebo	VB	O	O
in	IN	O	O
reducing	VBG	O	O
the	DT	O	O
primary	JJ	O	O
end	NN	O	O
point	NN	O	O
.	.	O	O

The	DT	O	O
prespecified	JJ	O	O
secondary	JJ	O	O
end	NN	O	O
points	NNS	O	O
of	IN	O	O
stent	JJ	O	O
thrombosis	NN	O	O
and	CC	O	O
death	NN	O	O
were	VBD	O	O
lower	JJR	O	O
in	IN	O	O
the	DT	O	O
cangrelor	NN	i	IPM
group	NN	O	O
,	,	O	O
with	IN	O	O
no	DT	O	O
significant	JJ	O	O
increase	NN	O	O
in	IN	O	O
the	DT	O	O
rate	NN	O	O
of	IN	O	O
transfusion	NN	O	O
.	.	O	O

Further	NNP	O	O
study	NN	O	O
of	IN	O	O
intravenous	JJ	O	O
ADP	NNP	i	IPM
blockade	NN	i	IPM
with	IN	i	IPM
cangrelor	NN	i	IPM
may	MD	O	O
be	VB	O	O
warranted	VBN	O	O
.	.	O	O

(	(	O	O
ClinicalTrials.gov	NNP	O	O
number	NN	O	O
,	,	O	O
NCT00385138	NNP	O	O
.	.	O	O

)	)	O	O
Randomized	NNP	O	O
comparison	NN	O	O
of	IN	O	O
two	CD	i	O
communication	NN	i	O
interventions	NNS	i	O
for	IN	O	O
preschoolers	NNS	p	PA
with	IN	p	O
autism	NN	p	PC
spectrum	NN	p	PC
disorders	NNS	p	PC
.	.	p	O

This	DT	O	O
randomized	JJ	O	O
group	NN	O	O
experiment	NN	O	O
compared	VBN	O	O
the	DT	O	O
efficacy	NN	O	O
of	IN	O	O
2	CD	i	IE
communication	NN	i	IE
interventions	NNS	i	IE
(	(	i	IE
Responsive	JJ	i	IE
Education	NN	i	IE
and	CC	i	IE
Prelinguistic	NNP	i	IE
Milieu	NNP	i	IE
Teaching	NNP	i	IE
[	NNP	i	IE
RPMT	NNP	i	IE
]	NNP	i	IE
and	CC	i	IE
the	DT	i	IE
Picture	NNP	i	IE
Exchange	NNP	i	IE
Communication	NNP	i	IE
System	NNP	i	IE
[	NNP	i	IE
PECS	NNP	i	IE
]	NNP	i	IE
)	)	i	O
in	IN	O	O
36	CD	p	PSS
preschoolers	NNS	p	O
with	IN	p	O
autism	NN	p	PC
spectrum	NN	p	PC
disorders	NNS	p	PC
.	.	p	PC

Each	DT	O	O
treatment	NN	O	O
was	VBD	O	O
delivered	VBN	O	O
3	CD	O	O
times	NNS	O	O
per	IN	O	O
week	NN	O	O
,	,	O	O
in	IN	O	O
20-min	JJ	O	O
sessions	NNS	O	O
,	,	O	O
for	IN	O	O
6	CD	O	O
months	NNS	O	O
.	.	O	O

The	DT	O	O
results	NNS	O	O
revealed	VBD	O	O
that	IN	O	O
the	DT	O	O
RPMT	NNP	i	IE
facilitated	VBD	O	O
the	DT	O	O
frequency	NN	o	OME
of	IN	o	OME
generalized	JJ	o	OME
turn	NN	o	OME
taking	VBG	o	OME
and	CC	o	O
generalized	VBN	o	OME
initiating	NN	o	OME
joint	JJ	o	OME
attention	NN	o	OME
more	RBR	O	O
than	IN	O	O
did	VBD	O	O
the	DT	O	O
PECS	NNP	O	O
.	.	O	O

The	DT	O	O
latter	JJ	O	O
effect	NN	O	O
occurred	VBD	O	O
only	RB	O	O
for	IN	O	O
children	NNS	O	O
who	WP	O	O
began	VBD	O	O
treatment	NN	O	O
with	IN	O	O
at	IN	O	O
least	JJS	O	O
some	DT	O	O
initiating	VBG	o	OME
joint	JJ	o	OME
attention	NN	o	OME
.	.	o	O

In	IN	O	O
contrast	NN	O	O
,	,	O	O
the	DT	O	O
PECS	NNP	i	IPM
facilitated	VBD	O	O
generalized	JJ	o	OME
requests	NNS	o	OME
more	RBR	O	O
than	IN	O	O
the	DT	O	O
RPMT	NNP	O	O
in	IN	O	O
children	NNS	O	O
with	IN	O	O
very	RB	O	O
little	JJ	O	O
initiating	VBG	o	OME
joint	JJ	o	OME
attention	NN	o	OME
prior	RB	O	O
to	TO	O	O
treatment	NN	O	O
.	.	O	O

These	DT	O	O
effect	NN	o	OOt
sizes	NNS	o	OOt
were	VBD	O	O
large	JJ	o	OOt
.	.	o	O

Remifentanil	NNP	O	O
with	IN	O	O
morphine	JJ	O	O
transitional	JJ	O	O
analgesia	NN	O	O
shortens	VBZ	O	O
neurological	JJ	o	OPH
recovery	NN	o	OPH
compared	VBN	O	O
to	TO	O	O
fentanyl	VB	O	O
for	IN	O	O
supratentorial	JJ	O	O
craniotomy	NN	O	O
.	.	O	O

PURPOSE	NNP	O	O
To	TO	O	O
compare	VB	O	O
the	DT	O	O
recovery	NN	o	OPH
profiles	NNS	o	OPH
,	,	o	O
efficacy	NN	o	OOt
and	CC	o	O
safety	NN	o	OOt
of	IN	O	O
remifentanil	NN	O	O
and	CC	O	O
morphine	NN	O	O
for	IN	O	O
transitional	JJ	O	O
analgesia	NN	O	O
with	IN	O	O
fentanyl	NN	O	O
in	IN	O	O
patients	NNS	p	O
undergoing	VBG	p	O
elective	JJ	p	PC
craniotomy	NN	p	PC
for	IN	p	O
supratentorial	JJ	p	PC
mass	NN	p	PC
lesions	NNS	p	PC
.	.	p	O

METHODS	NNP	O	O
Ninety-one	JJ	p	PSS
patients	NNS	p	O
were	VBD	O	O
enrolled	VBN	O	O
in	IN	O	O
this	DT	O	O
prospective	JJ	O	O
,	,	O	O
randomized	VBN	O	O
,	,	O	O
multicentre	FW	O	O
study	NN	O	O
.	.	O	O

Anesthesia	NNP	i	IPM
was	VBD	i	O
induced	VBN	i	O
with	IN	i	O
thiopental	JJ	i	O
and	CC	i	O
remifentanil	NN	i	IPM
(	(	i	IPM
1.0	CD	i	IPM
micro	NN	i	IPM
g	NN	i	IPM
x	NNP	i	IPM
kg	NN	i	IPM
(	(	i	IPM
-1	NNP	i	IPM
)	)	i	IPM
bolus	NN	i	IPM
and	CC	i	O
a	DT	i	O
1	CD	i	IPM
micro	NN	i	IPM
g	NN	i	IPM
x	NNP	i	IPM
kg	NN	i	IPM
(	(	i	IPM
-1	NNP	i	IPM
)	)	i	IPM
x	VBP	i	IPM
min	NN	i	IPM
(	(	i	IPM
-1	NNP	i	IPM
)	)	i	IPM
infusion	NN	i	IPM
)	)	i	IPM
or	CC	i	O
fentanyl	NN	i	IPM
(	(	i	IPM
1	CD	i	IPM
micro	NN	i	IPM
g	NN	i	IPM
x	NNP	i	IPM
kg	NN	i	IPM
(	(	i	IPM
-1	NNP	i	IPM
)	)	i	IPM
bolus	NN	i	IPM
and	CC	i	O
a	DT	i	O
1.0	CD	i	IPM
micro	NN	i	IPM
g	NN	i	IPM
x	NNP	i	IPM
kg	NN	i	IPM
(	(	i	IPM
-1	NNP	i	IPM
)	)	i	IPM
x	VBP	i	IPM
min	NN	i	IPM
(	(	i	IPM
-1	NNP	i	IPM
)	)	i	IPM
infusion	NN	i	IPM
)	)	i	O
.	.	i	O

The	DT	i	O
opioid	JJ	i	IPM
infusion	NN	i	IPM
continued	VBD	i	O
until	IN	i	O
the	DT	i	O
level	NN	i	O
of	IN	i	O
anesthesia	NN	i	IPM
was	VBD	i	O
deemed	VBN	i	O
appropriate	JJ	i	O
for	IN	i	O
intubation	NN	i	O
.	.	i	O

Anesthesia	NNP	i	IPM
was	VBD	i	O
maintained	VBN	i	O
with	IN	i	O
N	NNP	i	O
(	(	i	O
2	CD	i	O
)	)	i	O
O/O	NNP	i	O
(	(	i	O
2	CD	i	O
)	)	i	O
,	,	i	O
isoflurane	$	i	IPM
0.5	CD	i	IPM
MAC	NNP	i	IPM
and	CC	i	O
remifentanil	VB	i	IPM
0.2	CD	i	IPM
micro	NN	i	IPM
g	NN	i	IPM
x	NNP	i	IPM
kg	NN	i	IPM
(	(	i	IPM
-1	NNP	i	IPM
)	)	i	IPM
x	VBP	i	IPM
min	NN	i	IPM
(	(	i	IPM
-1	JJ	i	IPM
)	)	i	IPM
or	CC	i	O
fentanyl	$	i	IPM
0.04	CD	i	IPM
micro	NN	i	IPM
g	NN	i	IPM
x	NNP	i	IPM
kg	NN	i	IPM
(	(	i	IPM
-1	NNP	i	IPM
)	)	i	IPM
x	VBP	i	IPM
min	NN	i	IPM
(	(	i	IPM
-1	NNP	i	IPM
)	)	i	IPM
.	.	i	O

At	IN	i	IPH
bone	NN	i	IPH
flap	NN	i	IPH
replacement	NN	i	IPH
,	,	i	O
either	DT	i	IPM
morphine	NN	i	IPM
0.08	CD	i	IPM
mg	NN	i	IPM
x	NN	i	O
kg	NN	i	O
(	(	i	O
-1	NN	i	O
)	)	i	O
(	(	i	O
remifentanil	JJ	i	IPM
group	NN	i	IPM
)	)	i	IPM
or	CC	i	O
saline	NN	i	IPM
(	(	i	O
fentanyl	JJ	i	O
group	NN	i	O
)	)	i	O
was	VBD	i	O
given	VBN	i	O
.	.	i	O

RESULTS	NNP	O	O
Systolic	NNP	o	OPH
blood	NN	o	OPH
pressure	NN	o	OPH
was	VBD	O	O
greater	JJR	O	O
in	IN	O	O
those	DT	O	O
receiving	VBG	O	O
fentanyl	NN	O	O
during	IN	O	O
induction	NN	O	O
(	(	O	O
145.6	CD	O	O
+/-17.5	JJ	O	O
mmHg	NN	O	O
vs	NN	O	O
128.8	CD	O	O
+/-18.3	JJ	O	O
mmHg	NN	O	O
;	:	O	O
P	NNP	O	O
=	NNP	O	O
0.006	CD	O	O
)	)	O	O
and	CC	O	O
intubation	NN	O	O
(	(	O	O
126.9	CD	O	O
+/-17.1	JJ	O	O
vs	NN	O	O
110.9	CD	O	O
+/-16.5	JJ	O	O
mmHg	NN	O	O
;	:	O	O
P	NNP	O	O
<	NNP	O	O
0.001	CD	O	O
)	)	O	O
.	.	O	O

Median	JJ	o	OPH
time	NN	o	OPH
to	TO	o	OPH
tracheal	VB	o	OPH
extubation	NN	o	OPH
was	VBD	O	O
similar	JJ	O	O
but	CC	O	O
less	RBR	O	O
variable	JJ	O	O
in	IN	O	O
the	DT	O	O
remifentanil	NN	O	O
group	NN	O	O
(	(	O	O
remifentanil	JJ	O	O
=	$	O	O
8	CD	O	O
min	NN	O	O
:	:	O	O
range	NN	O	O
=	VBZ	O	O
2-44	JJ	O	O
min	NN	O	O
;	:	O	O
fentanyl	CC	O	O
=	$	O	O
8	CD	O	O
min	NN	O	O
:	:	O	O
range	NN	O	O
=	VBZ	O	O
1-732	JJ	O	O
min	NN	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
fentanyl	JJ	O	O
patients	NNS	O	O
required	VBD	O	O
a	DT	O	O
longer	JJR	O	O
time	NN	o	OPH
to	TO	o	OPH
achieve	VB	o	OPH
the	DT	o	OPH
first	JJ	o	OPH
normal	JJ	o	OPH
neurological	JJ	o	OPH
score	NN	o	OPH
(	(	O	O
fentanyl	JJ	O	O
=	$	O	O
38.0	CD	O	O
min	NN	O	O
;	:	O	O
remifentanil	CC	O	O
=	$	O	O
26.0	CD	O	O
min	NN	O	O
;	:	O	O
P	NNP	O	O
=	NNP	O	O
0.035	CD	O	O
)	)	O	O
.	.	O	O

Both	CC	O	O
the	DT	O	O
anesthesiologists	NNS	O	O
and	CC	O	O
the	DT	O	O
recovery	NN	O	O
room	NN	O	O
nurses	NNS	O	O
rated	VBD	O	O
remifentanil	JJ	O	O
better	RBR	O	O
with	IN	O	O
respect	NN	O	O
to	TO	O	O
level	NN	o	OME
of	IN	o	OME
consciousness	NN	o	OME
.	.	o	O

Analgesics	NNS	o	OPA
were	VBD	O	O
required	VBN	O	O
earlier	RBR	O	O
in	IN	O	O
patients	NNS	O	O
receiving	VBG	O	O
remifentanil	NN	O	O
;	:	O	O
median	JJ	O	O
time	NN	O	O
0.5	CD	O	O
vs	NN	O	O
1.08	CD	O	O
hr	NN	O	O
,	,	O	O
P	NNP	O	O
<	VBZ	O	O
0.001	CD	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
Remifentanil	NNP	O	O
is	VBZ	O	O
a	DT	O	O
suitable	JJ	O	O
alternative	NN	O	O
to	TO	O	O
fentanyl	VB	O	O
in	IN	O	O
supratentorial	JJ	O	O
craniotomy	NN	O	O
.	.	O	O

Time	NN	o	OPH
to	TO	o	OPH
preoperative	VB	o	OPH
neurological	JJ	o	OPH
recovery	NN	o	OPH
is	VBZ	O	O
faster	RBR	O	O
and	CC	O	O
morphine	VB	O	O
provides	VBZ	O	O
some	DT	O	O
transitional	JJ	o	OPA
analgesia	NN	o	OPA
without	IN	O	O
compromising	VBG	O	O
the	DT	O	O
quality	NN	o	OOt
of	IN	o	OOt
recovery	NN	o	OOt
.	.	o	O

Effect	NN	O	O
of	IN	O	O
delayed	JJ	i	IS
cord	NN	i	IS
clamping	VBG	i	IS
on	IN	O	O
iron	NN	o	OPH
stores	NNS	o	OPH
in	IN	O	O
infants	NNS	p	PA
born	VBN	p	O
to	TO	p	O
anemic	JJ	p	PC
mothers	NNS	p	O
:	:	p	O
a	DT	O	O
randomized	NN	O	O
controlled	VBN	O	O
trial	NN	O	O
.	.	O	O

OBJECTIVE	UH	O	O
To	TO	O	O
study	VB	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
cord	NN	O	O
clamping	VBG	O	O
on	IN	O	O
iron	NN	O	O
stores	NNS	O	O
of	IN	O	O
infants	NNS	p	O
born	VBN	p	O
to	TO	p	O
anemic	VB	p	O
mothers	NNS	p	O
at	IN	p	O
3	CD	p	O
months	NNS	p	O
of	IN	p	O
age	NN	p	O
.	.	p	O

DESIGN	NNP	O	O
Randomized	NNP	O	O
controlled	VBD	O	O
trial	NN	O	O
.	.	O	O

SETTING	NN	O	O
Teaching	NNP	p	O
hospital	NN	p	O
.	.	p	O

METHODS	NNP	O	O
Infants	NNPS	p	O
born	VBN	p	O
to	TO	p	O
mothers	NNS	p	O
with	IN	p	O
hemoglobin	NN	p	O
(	(	p	O
Hb	NNP	p	O
)	)	p	O
<	VBD	p	O
100	CD	p	O
g/L	NNS	p	O
were	VBD	O	O
randomized	VBN	O	O
at	IN	O	O
delivery	NN	O	O
to	TO	O	O
either	DT	O	O
immediate	JJ	i	IS
cord	NN	i	IS
clamping	NN	i	IS
(	(	O	O
early	JJ	O	O
group	NN	O	O
)	)	O	O
or	CC	O	O
cord	NN	i	IS
clamping	VBG	i	IS
delayed	VBN	i	IS
till	JJ	i	IS
descent	NN	i	IS
of	IN	i	IS
placenta	NN	i	IS
into	IN	i	IS
vagina	NN	i	IS
(	(	O	O
delayed	VBN	O	O
group	NN	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
outcome	NN	O	O
measures	NNS	O	O
were	VBD	O	O
infant	NN	o	OPH
's	POS	o	OPH
hemoglobin	NN	o	OPH
and	CC	o	OPH
serum	NN	o	OPH
ferritin	VBP	o	OPH
3	CD	o	OPH
months	NNS	o	OPH
after	IN	o	OPH
delivery	NN	o	OPH
.	.	o	O

RESULTS	CC	O	O
There	EX	O	O
were	VBD	O	O
102	CD	p	O
neonates	NNS	p	O
randomized	VBN	O	O
to	TO	O	O
early	JJ	O	O
(	(	O	O
n	JJ	O	O
=	NNP	O	O
43	CD	O	O
)	)	O	O
or	CC	O	O
delayed	VBN	O	O
cord	NN	O	O
clamping	NN	O	O
(	(	O	O
n	JJ	O	O
=	NNP	O	O
59	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
groups	NNS	O	O
were	VBD	O	O
comparable	JJ	O	O
for	IN	O	O
maternal	JJ	O	O
age	NN	O	O
,	,	O	O
parity	NN	O	O
,	,	O	O
weight	NN	O	O
and	CC	O	O
supplemental	JJ	O	O
iron	NN	O	O
intake	NN	O	O
,	,	O	O
infant	JJ	O	O
s	NN	O	O
birth	NN	O	O
weight	NN	O	O
,	,	O	O
gestation	NN	O	O
and	CC	O	O
sex	NN	O	O
.	.	O	O

The	DT	O	O
mean	JJ	o	OPH
infant	NN	o	OPH
ferritin	NN	o	OPH
and	CC	o	OPH
Hb	NNP	o	OPH
at	IN	o	OPH
3	CD	o	OPH
months	NNS	o	OPH
were	VBD	O	O
significantly	RB	O	O
higher	JJR	O	O
in	IN	O	O
the	DT	O	O
delayed	JJ	i	IS
clamping	NN	i	IS
group	NN	O	O
(	(	O	O
118.4	CD	O	O
microg/L	NN	O	O
and	CC	O	O
99	CD	O	O
g/L	NN	O	O
)	)	O	O
than	IN	O	O
in	IN	O	O
the	DT	O	O
early	JJ	i	IS
clamping	NN	i	IS
group	NN	O	O
(	(	O	O
73	CD	O	O
microg/L	NN	O	O
and	CC	O	O
88	CD	O	O
g/L	NN	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
mean	JJ	O	O
decrease	NN	O	O
in	IN	O	O
Hb	NNP	o	OPH
(	(	O	O
g/L	NN	O	O
)	)	O	O
at	IN	O	O
3	CD	O	O
months	NNS	O	O
adjusted	VBN	O	O
for	IN	O	O
co-variates	NNS	O	O
was	VBD	O	O
significantly	RB	O	O
less	RBR	O	O
in	IN	O	O
the	DT	O	O
delayed	JJ	i	IS
clamping	NN	i	IS
group	NN	O	O
compared	VBN	O	O
to	TO	O	O
the	DT	O	O
early	JJ	i	IS
clamping	NN	i	IS
group	NN	O	O
(	(	O	O
-1.09	NNP	O	O
,	,	O	O
95	CD	O	O
%	NN	O	O
CI-1.58	NNP	O	O
to	TO	O	O
-0.62	VB	O	O
,	,	O	O
p	VB	O	O
>	NNP	O	O
0.001	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
odds	NNS	O	O
for	IN	O	O
anemia	NN	o	OPH
(	(	O	O
<	JJ	O	O
100	CD	O	O
g/L	NN	O	O
)	)	O	O
at	IN	O	O
3	CD	O	O
months	NNS	O	O
was	VBD	O	O
7.7	CD	O	O
(	(	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
1.84-34.9	CD	O	O
)	)	O	O
times	NNS	O	O
higher	RBR	O	O
in	IN	O	O
the	DT	O	O
early	JJ	O	O
compared	VBN	O	O
to	TO	O	O
the	DT	O	O
delayed	JJ	i	IS
clamping	NN	i	IS
group	NN	O	O
.	.	O	O

CONCLUSION	NNP	O	O
Iron	NNP	o	OPH
stores	NNS	o	OPH
and	CC	o	O
Hb	NNP	o	OPH
in	IN	O	O
infancy	NN	O	O
can	MD	O	O
be	VB	O	O
improved	VBN	O	O
in	IN	O	O
neonates	NNS	p	O
born	VBN	p	O
to	TO	p	O
anemic	VB	p	O
mothers	NNS	p	O
by	IN	O	O
delaying	VBG	i	IS
cord	NN	i	IS
clamping	NN	i	IS
at	IN	O	O
birth	NN	O	O
.	.	O	O

Comparison	NNP	O	O
of	IN	O	O
yoga	NNP	i	IPH
versus	NN	i	IPH
stretching	VBG	i	IPH
for	IN	O	O
chronic	JJ	o	OPA
low	JJ	o	OPA
back	RB	o	OPA
pain	NN	o	OPA
:	:	o	O
protocol	NN	O	O
for	IN	O	O
the	DT	O	O
Yoga	NNP	O	O
Exercise	NNP	O	O
Self-care	NNP	O	O
(	(	O	O
YES	NNP	O	O
)	)	O	O
trial	NN	O	O
.	.	O	O

BACKGROUND	NNP	O	O
Back	NNP	o	OPA
pain	NN	o	OPA
,	,	O	O
one	CD	O	O
of	IN	O	O
the	DT	O	O
most	RBS	O	O
prevalent	JJ	O	O
conditions	NNS	O	O
afflicting	VBG	O	O
American	JJ	O	O
adults	NNS	O	O
,	,	O	O
is	VBZ	O	O
the	DT	O	O
leading	VBG	O	O
reason	NN	O	O
for	IN	O	O
using	VBG	O	O
complementary	JJ	i	IPH
and	CC	i	IPH
alternative	JJ	i	IPH
medicine	NN	i	IPH
(	(	i	IPH
CAM	NNP	i	IPH
)	)	i	IPH
therapies	NNS	i	IPH
.	.	i	O

Yoga	NNP	i	IPH
is	VBZ	O	O
an	DT	O	O
increasingly	RB	O	O
popular	JJ	O	O
mind-body	NN	O	O
CAM	NNP	O	O
therapy	NN	O	O
often	RB	O	O
used	VBN	O	O
for	IN	O	O
relieving	VBG	o	OPA
back	RB	o	OPA
pain	NN	o	OPA
and	CC	O	O
several	JJ	O	O
small	JJ	O	O
studies	NNS	O	O
have	VBP	O	O
found	VBN	O	O
yoga	RB	O	O
effective	JJ	O	O
for	IN	O	O
this	DT	O	O
condition	NN	O	O
.	.	O	O

This	DT	O	O
study	NN	O	O
will	MD	O	O
assess	VB	O	O
whether	IN	O	O
yoga	NN	i	IPH
is	VBZ	O	O
effective	JJ	O	O
for	IN	O	O
treating	VBG	O	O
chronic	JJ	o	OPA
low	JJ	o	OPA
back	RB	o	OPA
pain	NN	o	OPA
compared	VBN	O	O
with	IN	O	O
self	PRP	i	IE
care	NN	i	IE
and	CC	i	O
exercise	NN	i	IPH
and	CC	O	O
will	MD	O	O
explore	VB	O	O
the	DT	O	O
mechanisms	NNS	O	O
responsible	JJ	O	O
for	IN	O	O
any	DT	O	O
observed	JJ	O	O
benefits	NNS	O	O
.	.	O	O

METHODS/DESIGN	NNP	O	O
A	NNP	p	O
total	NN	p	O
of	IN	p	O
210	CD	p	PC
participants	NNS	p	O
with	IN	p	O
low	JJ	p	PC
back	RB	p	PC
pain	NN	p	PC
lasting	NN	p	O
at	IN	p	O
least	JJS	p	O
3	CD	p	O
months	NNS	p	O
will	MD	p	O
be	VB	p	O
recruited	VBN	p	O
from	IN	p	O
primary	JJ	p	O
care	NN	p	O
clinics	NNS	p	O
of	IN	p	O
a	DT	p	O
large	JJ	p	O
healthcare	NN	p	O
system	NN	p	O
based	VBN	p	O
in	IN	p	O
Seattle	NNP	p	O
.	.	p	O

They	PRP	O	O
will	MD	O	O
be	VB	O	O
randomized	VBN	O	O
in	IN	O	O
a	DT	O	O
2:2:1	CD	O	O
ratio	NN	O	O
to	TO	O	O
receive	VB	O	O
12	CD	i	IPH
weekly	JJ	i	IPH
yoga	NN	i	IPH
classes	NNS	i	IPH
,	,	i	IPH
12	CD	i	IPH
weekly	JJ	i	IPH
conventional	JJ	i	IPH
therapeutic	JJ	i	IPH
exercise	NN	i	IPH
classes	NNS	i	IPH
of	IN	i	IPH
comparable	JJ	i	IPH
physical	JJ	i	IPH
exertion	NN	i	IPH
,	,	i	IPH
or	CC	i	IPH
a	DT	i	IPH
self-care	JJ	i	IOt
book	NN	i	IOt
.	.	i	O

Interviewers	NNS	O	O
masked	VBD	O	O
to	TO	O	O
participants	NNS	O	O
'	POS	O	O
treatment	NN	O	O
group	NN	O	O
will	MD	O	O
assess	VB	O	O
outcomes	NNS	O	O
at	IN	O	O
baseline	NN	O	O
and	CC	O	O
6	CD	O	O
,	,	O	O
12	CD	O	O
and	CC	O	O
26	CD	O	O
weeks	NNS	O	O
after	IN	O	O
randomization	NN	O	O
.	.	O	O

Primary	JJ	O	O
outcomes	NNS	O	O
will	MD	O	O
be	VB	O	O
back-related	JJ	o	OPH
dysfunction	NN	o	OPH
and	CC	o	OPH
symptom	NN	o	OPH
bothersomeness	NN	o	OPH
.	.	o	OPH

In	IN	O	O
addition	NN	O	O
,	,	O	O
data	NNS	O	O
will	MD	O	O
be	VB	O	O
collected	VBN	O	O
on	IN	O	O
physical	JJ	o	OPH
measurements	NNS	o	OPH
(	(	o	O
e.g.	NN	o	O
,	,	O	O
flexion	NN	o	OPH
)	)	o	O
at	IN	O	O
baseline	NN	O	O
and	CC	O	O
12	CD	O	O
weeks	NNS	O	O
and	CC	O	O
saliva	NN	O	O
samples	NNS	O	O
will	MD	O	O
be	VB	O	O
obtained	VBN	O	O
at	IN	O	O
baseline	NN	O	O
,	,	O	O
6	CD	O	O
and	CC	O	O
12	CD	O	O
weeks	NNS	O	O
.	.	O	O

Information	NN	O	O
will	MD	O	O
be	VB	O	O
collected	VBN	O	O
on	IN	O	O
specific	JJ	O	O
physical	JJ	O	O
,	,	O	O
psychological	JJ	O	O
,	,	O	O
and	CC	O	O
physiological	JJ	O	O
factors	NNS	O	O
to	TO	O	O
allow	VB	O	O
exploration	NN	O	O
of	IN	O	O
possible	JJ	O	O
mechanisms	NNS	O	O
of	IN	O	O
action	NN	O	O
through	IN	O	O
which	WDT	O	O
yoga	NN	i	IPH
could	MD	O	O
relieve	VB	o	OPA
back	RB	o	OPA
pain	NN	o	OPA
and	CC	o	OPA
dysfunction	NN	o	OPA
.	.	o	OPA

The	DT	O	O
effectiveness	NN	O	O
of	IN	O	O
yoga	NN	i	IPH
will	MD	O	O
be	VB	O	O
assessed	VBN	O	O
using	VBG	O	O
analysis	NN	O	O
of	IN	O	O
covariance	NN	O	O
(	(	O	O
using	VBG	O	O
general	JJ	O	O
estimating	VBG	O	O
equations	NNS	O	O
-	:	O	O
GEE	NNP	O	O
)	)	O	O
within	IN	O	O
an	DT	O	O
intention-to-treat	JJ	O	O
context	NN	O	O
.	.	O	O

If	IN	O	O
yoga	NN	i	IPH
is	VBZ	O	O
found	VBN	O	O
effective	JJ	O	O
,	,	O	O
further	JJ	O	O
analyses	NNS	O	O
will	MD	O	O
explore	VB	O	O
whether	IN	O	O
yoga	NN	O	O
's	POS	O	O
benefits	NNS	O	O
are	VBP	O	O
attributable	JJ	O	O
to	TO	O	O
physical	JJ	O	O
,	,	O	O
psychological	JJ	O	O
and/or	NN	O	O
physiological	JJ	O	O
factors	NNS	O	O
.	.	O	O

CONCLUSIONS	VB	O	O
This	DT	O	O
study	NN	O	O
will	MD	O	O
provide	VB	O	O
the	DT	O	O
clearest	JJS	O	O
evidence	NN	O	O
to	TO	O	O
date	NN	O	O
about	IN	O	O
the	DT	O	O
value	NN	O	O
of	IN	O	O
yoga	NN	i	IPH
as	IN	O	O
a	DT	O	O
therapeutic	JJ	O	O
option	NN	O	O
for	IN	O	O
treating	VBG	O	O
chronic	JJ	o	OPA
back	RB	o	OPA
pain	NN	o	OPA
,	,	O	O
and	CC	O	O
if	IN	O	O
the	DT	O	O
results	NNS	O	O
are	VBP	O	O
positive	JJ	O	O
,	,	O	O
will	MD	O	O
help	VB	O	O
focus	VB	O	O
future	JJ	O	O
,	,	O	O
more	RBR	O	O
in-depth	JJ	O	O
,	,	O	O
research	NN	O	O
on	IN	O	O
the	DT	O	O
most	RBS	O	O
promising	JJ	O	O
potential	JJ	O	O
mechanisms	NN	O	O
of	IN	O	O
action	NN	O	O
identified	VBN	O	O
by	IN	O	O
this	DT	O	O
study	NN	O	O
.	.	O	O

Efficacy	NN	o	OOt
of	IN	O	O
dose-intensified	JJ	O	O
MEC	NNP	i	IPM
(	(	i	O
methotrexate	NN	i	IPM
,	,	i	O
epirubicin	NN	i	IPM
and	CC	i	O
cisplatin	NN	i	IPM
)	)	i	O
chemotherapy	NN	O	O
for	IN	O	O
advanced	JJ	p	PC
urothelial	JJ	p	PC
carcinoma	NN	p	PC
:	:	p	O
a	DT	O	O
prospective	JJ	O	O
randomized	VBN	O	O
trial	NN	O	O
comparing	VBG	O	O
MEC	NNP	i	IPM
and	CC	O	O
M-VAC	NNP	i	IPM
(	(	i	O
methotrexate	NN	i	IPM
,	,	i	O
vinblastine	NN	i	IPM
,	,	i	O
doxorubicin	NN	i	IPM
and	CC	i	O
cisplatin	NN	i	IPM
)	)	i	O
.	.	O	O

Japanese	JJ	p	O
Urothelial	JJ	p	PC
Cancer	NNP	p	PC
Research	NNP	p	O
Group	NNP	p	O
.	.	p	O

BACKGROUND	NNP	O	O
To	TO	O	O
evaluate	VB	O	O
the	DT	O	O
antitumor	NN	o	OOt
activity	NN	o	OOt
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
T3b	NNP	p	PC
,	,	p	PC
T4	NNP	p	PC
or	CC	p	PC
metastatic	JJ	p	PC
urothelial	JJ	p	PC
carcinoma	NN	p	PC
treated	VBN	p	O
with	IN	p	O
MEC	NNP	i	IPM
or	CC	p	O
M-VAC	NNP	i	IPM
chemotherapy	NN	p	O
,	,	O	O
by	IN	O	O
performing	VBG	O	O
a	DT	O	O
multi-center	JJ	O	O
randomized	JJ	O	O
prospective	JJ	O	O
study	NN	O	O
.	.	O	O

METHODS	NNP	O	O
From	IN	p	O
1991	CD	p	O
to	TO	p	O
1995	CD	p	O
,	,	p	O
89	CD	p	PSS
patients	NNS	p	O
with	IN	p	O
T3b	NNP	p	PC
,	,	p	PC
T4	NNP	p	PC
or	CC	p	PC
metastatic	JJ	p	PC
urothelial	JJ	p	PC
carcinoma	NN	p	PC
were	VBD	O	O
randomly	RB	O	O
allocated	VBN	O	O
to	TO	O	O
a	DT	O	O
methotrexate	NN	i	IPM
,	,	i	O
epirubicin	NN	i	IPM
and	CC	i	O
cisplatin	NN	i	IPM
chemotherapy	NN	i	O
group	NN	i	O
(	(	i	O
arm	JJ	i	O
1	CD	i	O
:	:	i	O
S-MEC	JJ	i	O
therapy	NN	i	O
;	:	i	O
n	CC	i	O
=	VB	i	O
29	CD	i	O
)	)	i	O
,	,	i	O
a	DT	i	O
dose-intensified	JJ	i	O
MEC	NNP	i	IPM
therapy	NN	i	IPM
combined	VBN	i	O
with	IN	i	O
G-CSF	NNP	i	IPM
group	NN	i	O
(	(	i	O
arm	JJ	i	O
2	CD	i	O
:	:	i	O
I-MEC	JJ	i	O
therapy	NN	i	O
;	:	i	O
n	CC	i	O
=	VB	i	O
30	CD	i	O
)	)	i	O
or	CC	i	O
a	DT	i	O
methotrexate	NN	i	IPM
,	,	i	O
vinblastine	NN	i	IPM
,	,	i	O
doxorubicin	NN	i	IPM
and	CC	i	O
cisplatin	NN	i	IPM
chemotherapy	NN	i	O
(	(	i	O
arm	JJ	i	O
3	CD	i	O
:	:	i	O
M-VAC	JJ	i	IPM
therapy	NN	i	IPM
;	:	i	O
n	CC	i	O
=	VB	i	O
30	CD	i	O
)	)	i	O
.	.	i	O

At	IN	O	O
the	DT	O	O
registration	NN	O	O
center	NN	O	O
,	,	O	O
the	DT	O	O
patients	NNS	O	O
were	VBD	O	O
stratified	VBN	O	O
into	IN	O	O
previously	RB	O	O
untreated	JJ	O	O
patients	NNS	O	O
and	CC	O	O
patients	NNS	O	O
with	IN	O	O
recurrence	NN	O	O
after	IN	O	O
radical	JJ	O	O
operation	NN	O	O
and	CC	O	O
then	RB	O	O
randomly	RB	O	O
allocated	VBN	O	O
to	TO	O	O
the	DT	O	O
treatment	NN	O	O
groups	NNS	O	O
.	.	O	O

In	IN	O	O
each	DT	O	O
arm	NN	O	O
,	,	O	O
two	CD	O	O
or	CC	O	O
more	JJR	O	O
courses	NNS	O	O
of	IN	O	O
chemotherapy	NN	O	O
(	(	O	O
4-week	JJ	O	O
cycles	NNS	O	O
)	)	O	O
were	VBD	O	O
performed	VBN	O	O
.	.	O	O

RESULTS	NNP	O	O
Of	IN	O	O
the	DT	O	O
88	CD	O	O
eligible	JJ	O	O
patients	NNS	O	O
,	,	O	O
four	CD	O	O
treated	VBN	O	O
with	IN	O	O
S-MEC	NNP	i	IPM
therapy	NN	i	IPM
and	CC	O	O
two	CD	O	O
treated	VBN	O	O
with	IN	O	O
I-MEC	NNP	i	IPM
therapy	NN	O	O
showed	VBD	O	O
CR	NNP	O	O
.	.	O	O

The	DT	O	O
response	NN	o	OOt
rates	NNS	o	OOt
(	(	o	O
CR	NNP	o	O
+	NNP	o	O
PR	NNP	o	O
)	)	o	O
were	VBD	O	O
52	CD	O	O
%	NN	O	O
(	(	O	O
15/29	CD	O	O
)	)	O	O
with	IN	O	O
S-MEC	NNP	i	IPM
therapy	NN	i	IPM
,	,	O	O
76	CD	O	O
%	NN	O	O
(	(	O	O
22/29	CD	O	O
)	)	O	O
with	IN	O	O
I-MEC	NNP	i	IPM
therapy	NN	O	O
and	CC	O	O
47	CD	O	O
%	NN	O	O
(	(	O	O
14/30	CD	O	O
)	)	O	O
with	IN	O	O
M-VAC	NNP	i	IPM
therapy	NN	O	O
.	.	O	O

The	DT	O	O
response	NN	o	OOt
rate	NN	o	OOt
with	IN	o	OOt
I-MEC	NNP	o	OOt
therapy	NN	o	OOt
was	VBD	O	O
significantly	RB	O	O
higher	JJR	O	O
than	IN	O	O
that	DT	O	O
with	IN	O	O
M-VAC	NNP	i	IPM
therapy	NN	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.02	CD	O	O
)	)	O	O
.	.	O	O

Although	IN	O	O
the	DT	O	O
incidence	NN	O	O
of	IN	O	O
leukopenia	NN	O	O
was	VBD	O	O
low	JJ	O	O
with	IN	O	O
I-MEC	NNP	o	OOt
therapy	NN	o	OOt
,	,	O	O
the	DT	O	O
incidence	NN	O	O
of	IN	O	O
thrombocytopenia	NN	o	OPH
was	VBD	O	O
high	JJ	O	O
with	IN	O	O
this	DT	O	O
therapy	NN	O	O
.	.	O	O

CONCLUSION	NNP	O	O
MEC	NNP	i	IPM
therapy	NN	i	IPM
used	VBN	O	O
in	IN	O	O
this	DT	O	O
study	NN	O	O
is	VBZ	O	O
promising	VBG	O	O
in	IN	O	O
terms	NNS	O	O
of	IN	O	O
the	DT	O	O
antitumor	NN	o	OOt
effects	NNS	o	OOt
.	.	o	OOt

Milk	NNP	O	O
protein	NN	O	O
quantity	NN	O	O
and	CC	O	O
quality	NN	O	O
in	IN	O	O
low-birth-weight	JJ	p	PC
infants	NNS	p	PA
.	.	p	O

IV	NNP	O	O
.	.	O	O

Effects	NNS	O	O
on	IN	O	O
tyrosine	NN	o	OPH
and	CC	O	O
phenylalanine	NN	o	OPH
in	IN	o	O
plasma	NN	o	O
and	CC	o	O
urine	NN	o	O
.	.	o	O

Well	UH	O	O
,	,	O	O
appropriate-for-gestational	JJ	p	PA
age	NN	p	PA
,	,	p	O
low-birth-weight	JJ	p	PC
infants	NNS	p	PA
were	VBD	O	O
divided	VBN	O	O
into	IN	O	O
three	CD	O	O
gestational	JJ	O	O
age	NN	O	O
groups	NNS	O	O
and	CC	O	O
assigned	VBD	O	O
randomly	RB	O	O
within	IN	O	O
each	DT	O	O
age	NN	O	O
group	NN	O	O
to	TO	O	O
one	CD	O	O
of	IN	O	O
five	CD	O	O
feeding	VBG	O	O
regimens	NNS	O	O
:	:	O	O
pooled	VBN	i	IPM
human	JJ	i	IPM
milk	NN	i	IPM
(	(	i	IPM
BM	NNP	i	IPM
)	)	i	IPM
;	:	i	IPM
formula	$	i	IPM
1	CD	i	IPM
(	(	i	IPM
F1	NNP	i	IPM
)	)	i	IPM
=	VBD	i	IPM
1.5	CD	i	IPM
gm/dl	NN	i	IPM
protein	NN	i	IPM
,	,	i	IPM
60	CD	i	IPM
parts	NNS	i	IPM
bovine	NN	i	IPM
whey	NN	i	IPM
proteins	NNS	i	IPM
:	:	i	IPM
40	CD	i	IPM
parts	NNS	i	IPM
bovine	NN	i	IPM
caseins	NNS	i	IPM
;	:	i	IPM
F2	NNP	i	IPM
=	VBD	i	IPM
3.0	CD	i	IPM
gm/dl	NN	i	IPM
,	,	i	IPM
60:40	CD	i	IPM
;	:	i	IPM
F3	NNP	i	IPM
=	VBD	i	IPM
1.5	CD	i	IPM
gm/dl	NN	i	IPM
,	,	i	IPM
18:82	CD	i	IPM
;	:	i	IPM
F4	NNP	i	IPM
=	VBD	i	IPM
3.0	CD	i	IPM
gm/dl	NN	i	IPM
,	,	O	O
18:82	CD	O	O
.	.	O	O

Plasma	NNP	o	O
and	CC	o	O
urine	JJ	o	O
concentrations	NNS	o	O
of	IN	o	O
tyrosine	NN	o	OPH
and	CC	o	O
phenylalanine	NN	o	OPH
were	VBD	O	O
far	RB	O	O
higher	JJR	o	O
in	IN	O	O
the	DT	O	O
infants	NNS	O	O
fed	VBP	O	O
F1	NNP	O	O
to	TO	O	O
F4	NNP	O	O
,	,	O	O
especially	RB	O	O
F2	NNP	O	O
and	CC	O	O
F4	NNP	O	O
,	,	O	O
than	IN	O	O
in	IN	O	O
the	DT	O	O
infants	NNS	O	O
fed	VBN	O	O
BM	NNP	O	O
.	.	O	O

These	DT	O	O
findings	NNS	O	O
offer	VBP	O	O
further	JJ	O	O
evidence	NN	O	O
for	IN	O	O
the	DT	O	O
limited	JJ	O	O
capacity	NN	O	O
of	IN	O	O
the	DT	O	O
low-birth-weight	JJ	O	O
infant	NN	O	O
to	TO	O	O
catabolize	VB	o	OPH
tyrosine	NN	o	OPH
.	.	o	O

Infants	NNS	O	O
fed	VBD	O	O
F3	NNP	O	O
had	VBD	O	O
significantly	RB	o	O
higher	JJR	o	O
plasma	JJ	o	OPH
tyrosine	NN	o	OPH
concentrations	NNS	o	OPH
than	IN	O	O
infants	NNS	O	O
fed	VBN	O	O
F1	NNP	O	O
,	,	O	O
and	CC	O	O
those	DT	O	O
fed	VBN	O	O
F4	NNP	O	O
had	VBD	O	O
higher	JJR	O	O
concentrations	NNS	O	O
than	IN	O	O
those	DT	O	O
fed	JJ	O	O
F2	NNP	O	O
.	.	O	O

Thus	NNP	O	O
,	,	O	O
increased	VBD	o	O
plasma	JJ	o	OPH
tyrosine	NN	o	OPH
concentrations	NNS	o	OPH
in	IN	O	O
low-birth-weight	JJ	O	O
infants	NNS	O	O
are	VBP	O	O
related	VBN	O	O
directly	RB	O	O
both	DT	O	O
to	TO	O	O
the	DT	O	O
quantity	NN	O	O
and	CC	O	O
to	TO	O	O
the	DT	O	O
quality	NN	O	O
of	IN	O	O
the	DT	O	O
protein	NN	O	O
in	IN	O	O
their	PRP$	O	O
diets	NNS	O	O
.	.	O	O

High-pressure	NN	i	IPH
,	,	i	IPH
rapid-inflation	NN	i	IPH
pneumatic	JJ	i	IPH
compression	NN	i	IPH
improves	VBZ	O	O
venous	JJ	O	O
hemodynamics	NNS	O	O
in	IN	O	O
healthy	JJ	p	O
volunteers	NNS	p	O
and	CC	p	O
patients	NNS	p	O
who	WP	p	O
are	VBP	p	O
post-thrombotic	JJ	p	O
.	.	p	O

PURPOSE	NNP	O	O
Deep	NNP	p	O
vein	NN	p	O
thrombosis	NN	p	O
(	(	p	O
DVT	NNP	p	O
)	)	p	O
is	VBZ	O	O
a	DT	O	O
preventable	JJ	O	O
cause	NN	O	O
of	IN	O	O
morbidity	NN	p	O
and	CC	p	O
mortality	NN	p	O
in	IN	p	O
patients	NNS	p	O
who	WP	p	O
are	VBP	p	O
hospitalized	VBN	p	O
.	.	p	O

An	DT	O	O
important	JJ	O	O
part	NN	O	O
of	IN	O	O
the	DT	O	O
mechanism	NN	O	O
of	IN	O	O
DVT	NNP	O	O
prophylaxis	NN	O	O
with	IN	O	O
intermittent	JJ	O	O
pneumatic	JJ	O	O
compression	NN	O	O
(	(	O	O
IPC	NNP	O	O
)	)	O	O
is	VBZ	O	O
reduced	VBN	O	O
venous	JJ	O	O
stasis	NN	O	O
with	IN	O	O
increased	JJ	O	O
velocity	NN	O	O
of	IN	O	O
venous	JJ	O	O
return	NN	O	O
.	.	O	O

The	DT	O	O
conventional	JJ	O	O
methods	NNS	O	O
of	IN	O	O
IPC	NNP	O	O
use	NN	O	O
low	JJ	O	O
pressure	NN	O	O
and	CC	O	O
slow	JJ	O	O
inflation	NN	O	O
of	IN	O	O
the	DT	O	O
air	NN	O	O
bladder	NN	O	O
on	IN	O	O
the	DT	O	O
leg	NN	O	O
to	TO	O	O
augment	VB	O	O
venous	JJ	O	O
return	NN	O	O
.	.	O	O

Recently	RB	O	O
,	,	O	O
compression	NN	O	O
devices	NNS	O	O
have	VBP	O	O
been	VBN	O	O
designed	VBN	O	O
that	IN	O	O
produce	VBP	O	O
high	JJ	O	O
pressure	NN	O	O
and	CC	O	O
rapid	JJ	O	O
inflation	NN	O	O
of	IN	O	O
air	NN	O	O
cuffs	NNS	O	O
on	IN	O	O
the	DT	O	O
plantar	NN	O	O
plexus	NN	O	O
of	IN	O	O
the	DT	O	O
foot	NN	O	O
and	CC	O	O
the	DT	O	O
calf	NN	O	O
.	.	O	O

The	DT	O	O
purpose	NN	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
is	VBZ	O	O
to	TO	O	O
evaluate	VB	O	O
the	DT	O	O
venous	JJ	O	O
velocity	NN	O	O
response	NN	O	O
to	TO	O	O
high-pressure	NN	O	O
,	,	O	O
rapid-inflation	NN	O	O
compression	NN	O	O
devices	NNS	O	O
versus	VBP	O	O
standard	JJ	O	O
,	,	O	O
low-pressure	JJ	O	O
,	,	O	O
slow-inflation	JJ	O	O
compression	NN	O	O
devices	NNS	O	O
in	IN	O	O
healthy	JJ	p	O
volunteers	NNS	p	O
and	CC	p	O
patients	NNS	p	O
with	IN	p	O
severe	JJ	p	O
post-thrombotic	JJ	p	O
venous	JJ	p	O
disease	NN	p	O
.	.	p	O

METHOD	NNP	O	O
Twenty-two	NNP	p	O
lower	JJR	p	O
extremities	NNS	p	O
from	IN	p	O
healthy	JJ	p	O
volunteers	NNS	p	O
and	CC	p	O
11	CD	p	O
lower	JJR	p	O
extremities	NNS	p	O
from	IN	p	O
patients	NNS	p	O
with	IN	p	O
class	NN	p	O
4	CD	p	O
to	TO	p	O
class	NN	p	O
6	CD	p	O
post-thrombotic	JJ	p	O
chronic	JJ	p	O
venous	JJ	p	O
insufficiency	NN	p	O
were	VBD	p	O
studied	VBN	p	O
.	.	p	O

With	IN	O	O
duplex	JJ	i	IPH
ultrasound	NN	i	IPH
scanning	NN	i	IPH
(	(	O	O
ATL-Ultramark	NNP	O	O
9	CD	O	O
,	,	O	O
Advanced	NNP	O	O
Tech	NNP	O	O
Laboratory	NNP	O	O
,	,	O	O
Bothell	NNP	O	O
,	,	O	O
Wash	NNP	O	O
)	)	O	O
,	,	O	O
acute	JJ	O	O
DVT	NNP	O	O
was	VBD	O	O
excluded	VBN	O	O
before	IN	O	O
subject	JJ	O	O
evaluation	NN	O	O
.	.	O	O

Venous	JJ	O	O
velocities	NNS	O	O
were	VBD	O	O
monitored	VBN	O	O
after	IN	O	O
the	DT	O	O
application	NN	O	O
of	IN	O	O
each	DT	O	O
of	IN	O	O
five	CD	O	O
IPC	NNP	O	O
devices	NNS	O	O
,	,	O	O
with	IN	O	O
all	PDT	O	O
the	DT	O	O
patients	NNS	O	O
in	IN	O	O
the	DT	O	O
supine	JJ	O	O
position	NN	O	O
.	.	O	O

Three	CD	i	IPH
high-pressure	NN	i	IPH
,	,	i	IPH
rapid-compression	NN	i	IPH
devices	NNS	i	IPH
and	CC	i	IPH
two	CD	i	IPH
standard	NN	i	IPH
,	,	i	IPH
low-pressure	JJ	i	IPH
,	,	i	O
slow-inflation	JJ	i	IPH
compression	NN	i	IPH
devices	NNS	i	IPH
were	VBD	O	O
applied	VBN	O	O
in	IN	O	O
a	DT	O	O
random	JJ	O	O
sequence	NN	O	O
.	.	O	O

Maximal	NNP	O	O
venous	JJ	O	O
velocities	NNS	O	O
were	VBD	O	O
obtained	VBN	O	O
at	IN	O	O
the	DT	O	O
common	JJ	O	O
femoral	JJ	O	O
vein	NN	O	O
and	CC	O	O
the	DT	O	O
popliteal	NN	O	O
vein	NN	O	O
for	IN	O	O
all	PDT	O	O
the	DT	O	O
devices	NNS	O	O
and	CC	O	O
were	VBD	O	O
recorded	VBN	O	O
as	IN	O	O
the	DT	O	O
mean	JJ	O	O
peak	JJ	O	O
velocity	NN	O	O
of	IN	O	O
three	CD	O	O
compression	NN	O	O
cycles	NNS	O	O
and	CC	O	O
compared	VBN	O	O
with	IN	O	O
baseline	NN	O	O
velocities	NNS	O	O
.	.	O	O

RESULTS	VB	O	O
The	DT	O	O
baseline	NN	O	O
venous	JJ	O	O
velocities	NNS	O	O
were	VBD	O	O
higher	JJR	O	O
in	IN	O	O
the	DT	O	O
femoral	JJ	O	O
veins	NNS	O	O
than	IN	O	O
in	IN	O	O
the	DT	O	O
popliteal	NN	O	O
veins	NNS	O	O
in	IN	O	O
both	DT	O	O
the	DT	O	O
volunteers	NNS	O	O
and	CC	O	O
the	DT	O	O
post-thrombotic	JJ	O	O
subjects	NNS	O	O
.	.	O	O

Standard	NNP	o	OPH
and	CC	o	OPH
high-pressure	NN	o	OPH
,	,	o	O
rapid-inflation	NN	o	OPH
compression	NN	o	OPH
significantly	RB	O	O
increased	VBD	O	O
the	DT	O	O
popliteal	NN	o	OPH
and	CC	o	OPH
femoral	JJ	o	OPH
vein	NN	o	OPH
velocities	NNS	o	OPH
in	IN	O	O
healthy	JJ	O	O
and	CC	O	O
post-thrombotic	JJ	O	O
subjects	NNS	O	O
.	.	O	O

High-pressure	NN	O	O
,	,	O	O
rapid-inflation	NN	O	O
compression	NN	O	O
produced	VBD	O	O
significantly	RB	O	O
higher	JJR	O	O
maximal	JJ	o	OPH
venous	JJ	o	OPH
velocities	NNS	o	OPH
in	IN	o	O
the	DT	o	O
popliteal	NN	o	OPH
and	CC	o	OPH
femoral	JJ	o	OPH
veins	NNS	o	OPH
in	IN	O	O
both	DT	O	O
healthy	JJ	O	O
volunteers	NNS	O	O
and	CC	O	O
patients	NNS	O	O
who	WP	O	O
were	VBD	O	O
post-thrombotic	JJ	O	O
as	IN	O	O
compared	VBN	O	O
with	IN	O	O
standard	JJ	O	O
compression	NN	O	O
.	.	O	O

Compared	VBN	O	O
with	IN	O	O
the	DT	O	O
healthy	JJ	O	O
volunteers	NNS	O	O
,	,	O	O
the	DT	O	O
patients	NNS	O	O
who	WP	O	O
were	VBD	O	O
post-thrombotic	JJ	O	O
had	VBD	O	O
a	DT	O	O
significantly	RB	O	O
attenuated	VBN	O	O
velocity	NN	o	OPH
response	NN	o	OPH
at	IN	O	O
both	DT	O	O
the	DT	O	O
popliteal	NN	O	O
and	CC	O	O
the	DT	O	O
femoral	JJ	O	O
vein	NN	O	O
levels	NNS	O	O
.	.	O	O

CONCLUSION	NNP	O	O
High-pressure	NNP	O	O
,	,	O	O
rapid-inflation	NN	O	O
pneumatic	JJ	O	O
compression	NN	O	O
increases	NNS	O	O
popliteal	NN	o	OPH
and	CC	o	OPH
femoral	JJ	o	OPH
vein	NN	o	OPH
velocity	NN	o	OPH
as	IN	O	O
compared	VBN	O	O
with	IN	O	O
standard	JJ	O	O
,	,	O	O
low-pressure	JJ	O	O
,	,	O	O
slow-inflation	JJ	O	O
pneumatic	JJ	O	O
compression	NN	O	O
.	.	O	O

Patients	NNS	p	O
with	IN	p	O
post-thrombotic	JJ	p	O
venous	JJ	p	O
disease	NN	p	O
have	VBP	O	O
a	DT	O	O
compromised	JJ	O	O
hemodynamic	JJ	O	O
response	NN	O	O
to	TO	O	O
all	DT	O	O
IPC	NNP	O	O
devices	NNS	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
an	DT	O	O
increased	VBN	O	O
velocity	NN	O	O
response	NN	O	O
to	TO	O	O
the	DT	O	O
high-pressure	NN	O	O
,	,	O	O
rapid-inflation	NN	O	O
compression	NN	O	O
device	NN	O	O
is	VBZ	O	O
preserved	VBN	O	O
.	.	O	O

High-pressure	NN	O	O
,	,	O	O
rapid-inflation	NN	O	O
pneumatic	JJ	O	O
compression	NN	O	O
may	MD	O	O
offer	VB	O	O
additional	JJ	O	O
protection	NN	O	O
from	IN	O	O
thrombotic	JJ	O	O
complications	NNS	O	O
on	IN	O	O
the	DT	O	O
basis	NN	O	O
of	IN	O	O
an	DT	O	O
improved	JJ	O	O
hemodynamic	JJ	o	OPH
response	NN	o	OPH
,	,	O	O
both	DT	O	O
in	IN	O	O
healthy	JJ	p	O
volunteers	NNS	p	O
and	CC	p	O
in	IN	p	O
patients	NNS	p	O
who	WP	p	O
were	VBD	p	O
post-thrombotic	JJ	p	O
.	.	p	O

Acute	JJ	O	O
effects	NNS	O	O
of	IN	O	O
caffeine	JJ	i	IPM
ingestion	NN	i	IPM
on	IN	O	O
signal-averaged	JJ	o	OPH
electrocardiograms	NNS	o	OPH
.	.	o	OPH

BACKGROUND	NNP	O	O
Although	IN	O	O
moderate	JJ	O	O
caffeine	NN	O	O
ingestion	NN	O	O
has	VBZ	O	O
not	RB	O	O
been	VBN	O	O
shown	VBN	O	O
to	TO	O	O
be	VB	O	O
arrhythmogenic	JJ	O	O
,	,	O	O
caffeine	JJ	O	O
toxicity	NN	O	O
can	MD	O	O
cause	VB	O	O
severe	JJ	O	O
cardiac	JJ	O	O
arrhythmias	NN	O	O
,	,	O	O
including	VBG	O	O
atrial	JJ	O	O
fibrillation	NN	O	O
and	CC	O	O
ventricular	JJ	O	O
tachycardia	NN	O	O
.	.	O	O

Atrial	JJ	O	O
fibrillation	NN	O	O
and	CC	O	O
ventricular	JJ	O	O
tachycardia	NN	O	O
have	VBP	O	O
been	VBN	O	O
associated	VBN	O	O
with	IN	O	O
prolongation	NN	o	OPH
of	IN	o	OPH
P-wave	NNP	o	OPH
and	CC	o	OPH
QRS	NNP	o	OPH
complex	JJ	o	OPH
durations	NNS	o	OPH
on	IN	o	OPH
signal-averaged	JJ	o	OPH
electrocardiograms	NNS	o	OPH
.	.	o	OPH

This	DT	O	O
study	NN	O	O
investigated	VBD	O	O
acute	JJ	O	O
effects	NNS	O	O
of	IN	O	O
caffeine	JJ	O	O
ingestion	NN	O	O
on	IN	O	O
signal-averaged	JJ	o	OPH
P-wave	NNP	o	OPH
and	CC	o	OPH
QRS	NNP	o	OPH
complexes	NNS	o	OPH
.	.	o	O

METHODS	NNP	O	O
AND	CC	O	O
RESULTS	NNP	O	O
Signal-averaged	JJ	o	O
electrocardiograms	NNS	o	O
were	VBD	O	O
obtained	VBN	O	O
from	IN	O	O
12	CD	p	O
normal	JJ	p	O
subjects	NNS	p	O
(	(	p	O
6	CD	p	O
men	NNS	p	O
,	,	p	O
6	CD	p	O
women	NNS	p	O
;	:	p	O
ages	VBZ	p	O
21	CD	p	O
to	TO	p	O
26	CD	p	O
years	NNS	p	O
)	)	p	O
before	IN	p	O
and	CC	p	O
after	IN	p	O
ingestion	NN	p	O
of	IN	p	O
caffeine	NN	i	IPM
(	(	O	O
5	CD	O	O
mg/kg	NN	O	O
body	NN	O	O
weight	NN	O	O
)	)	O	O
or	CC	O	O
placebo	NN	i	IC
in	IN	O	O
a	DT	O	O
randomized	JJ	O	O
,	,	O	O
double-blind	JJ	O	O
,	,	O	O
crossover	JJ	O	O
fashion	NN	O	O
.	.	O	O

Electrocardiograms	NNP	O	O
for	IN	O	O
signal	JJ	O	O
averaging	NN	O	O
were	VBD	O	O
recorded	VBN	O	O
from	IN	O	O
electrodes	NNS	O	O
left	VBN	O	O
in	IN	O	O
a	DT	O	O
constant	JJ	O	O
location	NN	O	O
.	.	O	O

After	IN	O	O
bandpass	NN	O	O
filtering	NN	O	O
(	(	O	O
30	CD	O	O
to	TO	O	O
300	CD	O	O
Hz	NNP	O	O
)	)	O	O
and	CC	O	O
amplification	NN	O	O
,	,	O	O
signals	NNS	O	O
were	VBD	O	O
sampled	VBN	O	O
over	IN	O	O
7.2	CD	O	O
minutes	NNS	O	O
at	IN	O	O
2000	CD	O	O
Hz	NNP	O	O
.	.	O	O

Signal-averaged	JJ	o	OPH
P-wave	NNP	o	OPH
and	CC	o	OPH
QRS	NNP	o	OPH
complex	JJ	o	OPH
durations	NNS	o	OPH
did	VBD	O	O
not	RB	O	O
significantly	RB	O	O
change	VBP	O	O
after	IN	O	O
placebo	NN	O	O
ingestion	NN	O	O
.	.	O	O

After	IN	O	O
caffeine	JJ	O	O
ingestion	NN	O	O
QRS	NNP	o	OPH
duration	NN	o	OPH
prolonged	VBD	O	O
in	IN	O	O
9	CD	O	O
of	IN	O	O
11	CD	O	O
subjects	NNS	O	O
at	IN	O	O
90	CD	O	O
minutes	NNS	O	O
(	(	O	O
mean	JJ	O	O
+/-	JJ	O	O
SEM	NNP	O	O
=	NNP	O	O
0.8+/-0.3	JJ	O	O
ms	NN	O	O
,	,	O	O
P	NNP	O	O
<	NNP	O	O
.02	NNP	O	O
)	)	O	O
and	CC	O	O
in	IN	O	O
8	CD	O	O
of	IN	O	O
9	CD	O	O
after	IN	O	O
3	CD	O	O
hours	NNS	O	O
(	(	O	O
1.1+/-0.2	JJ	O	O
ms	NN	O	O
,	,	O	O
P	NNP	O	O
<	NNP	O	O
.001	NNP	O	O
)	)	O	O
.	.	O	O

No	DT	O	O
significant	JJ	O	O
change	NN	O	O
in	IN	O	O
P-wave	NNP	o	OPH
duration	NN	o	OPH
or	CC	o	OPH
heart	NN	o	OPH
rate	NN	o	OPH
was	VBD	O	O
found	VBN	O	O
after	IN	O	O
caffeine	JJ	O	O
ingestion	NN	O	O
at	IN	O	O
any	DT	O	O
test	NN	O	O
interval	NN	O	O
.	.	O	O

Average	JJ	o	OPH
caffeine	JJ	o	OPH
level	NN	o	OPH
in	IN	o	OPH
saliva	JJ	o	OPH
90	CD	O	O
minutes	NNS	O	O
after	IN	O	O
ingestion	NN	O	O
was	VBD	O	O
6.6+/-1.6	JJ	O	O
(	(	O	O
SD	NNP	O	O
)	)	O	O
microg/dL	NN	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
Although	IN	O	O
probably	RB	O	O
not	RB	O	O
arrhythmogenic	JJ	O	O
in	IN	O	O
normal	JJ	p	O
subjects	NNS	p	O
,	,	O	O
moderate	JJ	O	O
caffeine	NN	O	O
ingestion	NN	O	O
does	VBZ	O	O
produce	VB	O	O
a	DT	O	O
small	JJ	O	O
but	CC	O	O
statistically	RB	O	O
significant	JJ	O	O
prolongation	NN	O	O
of	IN	O	O
signal-averaged	JJ	o	OPH
QRS	NNP	o	OPH
complexes	NNS	o	OPH
.	.	o	O

Further	JJ	O	O
prolongation	NN	O	O
caused	VBN	O	O
by	IN	O	O
excessive	JJ	O	O
caffeine	NNS	O	O
intake	VBP	O	O
may	MD	O	O
be	VB	O	O
a	DT	O	O
factor	NN	O	O
in	IN	O	O
the	DT	O	O
genesis	NN	O	O
of	IN	O	O
arrhythmias	NNS	O	O
associated	VBN	O	O
with	IN	O	O
caffeine	JJ	O	O
toxicity	NN	O	O
.	.	O	O

Working	VBG	O	O
well	RB	O	O
with	IN	O	O
a	DT	O	O
disability	NN	p	O
:	:	p	O
health	NN	i	IE
promotion	NN	i	IE
as	IN	O	O
a	DT	O	O
means	NN	O	O
to	TO	O	O
employment	NN	O	O
.	.	O	O

PURPOSE/OBJECTIVE	VB	O	O
The	DT	O	O
purpose	NN	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
test	VB	O	O
the	DT	O	O
utility	NN	O	O
of	IN	O	O
the	DT	O	O
Working	NNP	i	IE
Well	NNP	i	IE
with	IN	i	IE
a	DT	i	IE
Disability	NNP	i	IE
health-promotion	NN	i	IE
program	NN	i	IE
with	IN	O	O
vocational	JJ	i	IE
rehabilitation	NN	i	IE
(	(	p	O
VR	NNP	p	O
)	)	p	O
clients	NNS	p	O
.	.	p	O

Health-promotion	NN	i	IE
interventions	NNS	i	IE
have	VBP	O	O
been	VBN	O	O
shown	VBN	O	O
to	TO	O	O
reduce	VB	O	O
limitation	NN	O	O
from	IN	O	O
secondary	JJ	O	O
conditions	NNS	O	O
,	,	O	O
which	WDT	O	O
can	MD	O	O
be	VB	O	O
a	DT	O	O
significant	JJ	O	O
barrier	NN	O	O
to	TO	O	O
labor	NN	O	O
force	NN	O	O
participation	NN	O	O
among	IN	O	O
people	NNS	p	O
with	IN	p	O
disabilities	NNS	p	O
.	.	p	O

The	DT	O	O
state	NN	O	O
and	CC	O	O
federal	JJ	O	O
VR	NNP	O	O
system	NN	O	O
represents	VBZ	O	O
a	DT	O	O
potential	JJ	O	O
access	NN	O	O
point	NN	O	O
for	IN	O	O
delivery	NN	O	O
of	IN	O	O
health-promotion	NN	O	O
activities	NNS	O	O
.	.	O	O

RESEARCH	NNP	O	O
METHOD/DESIGN	NNP	O	O
A	NNP	p	O
total	NN	p	O
of	IN	p	O
297	CD	p	O
VR	NNP	p	O
clients	NNS	p	O
participated	VBD	p	O
in	IN	p	O
a	DT	p	O
randomized	JJ	p	O
trial	NN	p	O
of	IN	O	O
the	DT	O	O
Working	NNP	i	IE
Well	NNP	i	IE
health	NN	i	IE
promotion	NN	i	IE
program	NN	i	IE
.	.	i	O

Control	NNP	O	O
and	CC	O	O
intervention	NN	O	O
participants	NNS	O	O
provided	VBD	O	O
baseline	NN	O	O
and	CC	O	O
four	CD	O	O
waves	NNS	O	O
of	IN	O	O
quarterly	JJ	O	O
follow-up	JJ	O	O
data	NNS	O	O
.	.	O	O

Data	NNS	O	O
were	VBD	O	O
analyzed	VBN	O	O
with	IN	O	O
repeated-measures	NNS	O	O
ANOVA	NNP	O	O
.	.	O	O

RESULTS	NNP	O	O
Intervention-group	JJ	i	IE
participants	NNS	O	O
who	WP	O	O
attended	VBD	O	O
over	IN	O	O
half	NN	O	O
of	IN	O	O
the	DT	O	O
Working	NNP	i	IE
Well	NNP	i	IE
sessions	NNS	O	O
reported	VBD	O	O
significantly	RB	O	O
lower	JJR	O	O
rates	NNS	o	OME
of	IN	o	OME
limitation	NN	o	OME
from	IN	o	OME
secondary	JJ	o	OME
conditions	NNS	o	OME
over	IN	O	O
the	DT	O	O
1-year	JJ	O	O
study	NN	O	O
span	NN	O	O
,	,	O	O
F	NNP	O	O
(	(	O	O
1	CD	O	O
,	,	O	O
124	CD	O	O
)	)	O	O
=	NN	O	O
4.11	CD	O	O
,	,	O	O
p	NN	O	O
=	NNP	O	O
.004	NNP	O	O
.	.	O	O

Control-group	NN	i	IC
participants	NNS	O	O
also	RB	O	O
experienced	VBD	O	O
significantly	RB	O	O
lower	JJR	o	OME
rates	NNS	o	OME
of	IN	o	OME
limitation	NN	o	OME
,	,	O	O
but	CC	O	O
pre-	JJ	o	O
to	TO	o	O
postdifferences	NNS	o	O
were	VBD	O	O
less	RBR	O	O
dramatic	JJ	O	O
,	,	O	O
F	NNP	O	O
(	(	O	O
1	CD	O	O
,	,	O	O
308	CD	O	O
)	)	O	O
=	NN	O	O
4.19	CD	O	O
,	,	O	O
p	NN	O	O
=	NNP	O	O
.006	NNP	O	O
.	.	O	O

CONCLUSIONS/IMPLICATIONS	NNP	O	O
Overall	NNP	O	O
,	,	O	O
health	NN	O	O
data	NNS	O	O
indicated	VBD	O	O
that	IN	O	O
the	DT	O	O
Working	NNP	i	IE
Well	NNP	i	IE
program	NN	i	IE
may	MD	O	O
be	VB	O	O
particularly	RB	O	O
helpful	JJ	o	O
to	TO	O	O
VR	NNP	p	O
clients	NNS	p	O
with	IN	p	O
higher	JJR	p	O
rates	NNS	p	O
of	IN	p	O
secondary	JJ	p	O
health	NN	p	O
conditions	NNS	p	O
and	CC	O	O
may	MD	O	O
represent	VB	O	O
one	CD	O	O
strategy	NN	O	O
for	IN	O	O
overcoming	VBG	o	OOt
barriers	NNS	o	OOt
to	TO	o	OOt
employment	NN	o	OOt
.	.	o	O

The	DT	O	O
effect	NN	O	O
of	IN	O	O
metronidazole	NN	i	IPM
on	IN	O	O
the	DT	O	O
incidence	NN	o	OPH
of	IN	o	OPH
postoperative	JJ	o	OPH
wound	NN	o	OPH
infection	NN	o	OPH
in	IN	p	O
elective	JJ	p	O
colon	NN	p	O
surgery	NN	p	O
.	.	p	O

A	DT	O	O
prospective	JJ	O	O
randomized	VBN	O	O
clinical	JJ	O	O
trial	NN	O	O
assessing	VBG	O	O
the	DT	O	O
relative	JJ	O	O
effectiveness	NN	O	O
of	IN	O	O
erythromycin-neomycin	JJ	i	IPM
and	CC	i	O
metronidazole-neomycin	JJ	i	IPM
as	IN	O	O
a	DT	O	O
preoperative	JJ	O	O
bowel	NN	O	O
preparation	NN	O	O
was	VBD	O	O
carried	VBN	O	O
out	RP	O	O
.	.	O	O

Bacteriologic	NNP	O	O
studies	NNS	O	O
of	IN	O	O
feces	NNS	O	O
and	CC	O	O
colon	NN	O	O
content	NN	O	O
revealed	VBD	O	O
no	DT	O	O
significant	JJ	O	O
difference	NN	O	O
in	IN	O	O
the	DT	O	O
reduction	NN	o	OPH
of	IN	o	OPH
aerobic	JJ	o	OPH
bacteria	NNS	o	OPH
between	IN	O	O
the	DT	O	O
two	CD	O	O
groups	NNS	O	O
.	.	O	O

There	EX	O	O
was	VBD	O	O
,	,	O	O
however	RB	O	O
,	,	O	O
a	DT	O	O
significantly	RB	O	O
greater	JJR	O	O
reduction	NN	o	O
in	IN	O	O
anaerobic	JJ	o	O
bacteria	NNS	o	O
in	IN	O	O
the	DT	O	O
feces	NNS	O	O
and	CC	O	O
colon	NN	O	O
contents	NNS	O	O
of	IN	O	O
patients	NNS	O	O
receiving	VBG	O	O
metronidazole	NN	O	O
.	.	O	O

Wound	IN	o	OPH
infection	NN	o	OPH
rate	NN	o	OPH
was	VBD	O	O
25	CD	O	O
%	NN	O	O
in	IN	O	O
the	DT	O	O
erythromycin	NN	O	O
group	NN	O	O
,	,	O	O
and	CC	O	O
organisms	NNS	O	O
recovered	VBN	O	O
from	IN	O	O
the	DT	O	O
wound	NN	O	O
in	IN	O	O
all	DT	O	O
cases	NNS	O	O
were	VBD	O	O
fecal	JJ	O	O
in	IN	O	O
nature	NN	O	O
.	.	O	O

Two	CD	O	O
wound	IN	o	O
infections	NNS	o	O
occurred	VBD	O	O
in	IN	O	O
the	DT	O	O
metronidazole	NN	O	O
group	NN	O	O
(	(	O	O
5	CD	O	O
%	NN	O	O
)	)	O	O
and	CC	O	O
in	IN	O	O
both	DT	O	O
cases	NNS	O	O
the	DT	O	O
organisms	NNS	O	O
recovered	VBN	O	O
were	VBD	O	O
staphylococci	NNS	o	OPH
of	IN	o	OPH
presumed	JJ	o	OPH
skin	JJ	o	OPH
origin	NN	o	OPH
.	.	o	OPH

These	DT	O	O
studies	NNS	O	O
suggest	VBP	O	O
that	IN	O	O
anaerobic	JJ	O	O
bacteria	NNS	O	O
are	VBP	O	O
the	DT	O	O
major	JJ	O	O
contributors	NNS	O	O
to	TO	O	O
wound	VB	o	O
infection	NN	o	O
after	IN	O	O
colon	NN	O	O
surgery	NN	O	O
and	CC	O	O
that	IN	O	O
their	PRP$	O	O
specific	JJ	O	O
reduction	NN	O	O
is	VBZ	O	O
associated	VBN	O	O
with	IN	O	O
a	DT	O	O
lower	JJR	O	O
incidence	NN	O	O
of	IN	O	O
wound	JJ	o	O
infection	NN	o	O
.	.	o	O

Effect	NN	O	O
of	IN	O	O
chelation	NN	i	IPM
therapy	NN	i	IPM
on	IN	O	O
progressive	JJ	O	O
diabetic	JJ	O	O
nephropathy	NN	O	O
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
type	JJ	p	PC
2	CD	p	PC
diabetes	NNS	p	PC
and	CC	p	O
high-normal	JJ	p	PC
body	NN	p	PC
lead	JJ	p	PC
burdens	NNS	p	PC
.	.	p	O

BACKGROUND	VB	O	O
A	DT	O	O
previous	JJ	O	O
study	NN	O	O
in	IN	O	O
type	NN	p	PC
2	CD	p	PC
diabetic	JJ	p	PC
patients	NNS	p	O
with	IN	O	O
high-normal	JJ	O	O
body	NN	O	O
lead	NN	O	O
burdens	VBZ	O	O
showed	VBD	O	O
that	IN	O	O
EDTA	NNP	i	IPM
chelation	NN	i	IPM
therapy	NN	i	IPM
for	IN	O	O
3	CD	O	O
months	NNS	O	O
slows	VBZ	O	O
progressive	JJ	O	O
diabetic	JJ	O	O
nephropathy	NN	O	O
during	IN	O	O
a	DT	O	O
12-month	JJ	O	O
follow-up	NN	O	O
.	.	O	O

The	DT	O	O
effect	NN	O	O
of	IN	O	O
a	DT	O	O
longer	JJR	O	O
course	NN	O	O
of	IN	O	O
therapy	NN	O	O
on	IN	O	O
kidney	NN	O	O
function	NN	O	O
decrease	NN	O	O
over	IN	O	O
a	DT	O	O
longer	JJR	O	O
follow-up	NN	O	O
is	VBZ	O	O
not	RB	O	O
known	VBN	O	O
.	.	O	O

STUDY	NNP	O	O
DESIGN	NNP	O	O
A	NNP	O	O
12-month	JJ	O	O
run-in	JJ	O	O
phase	NN	O	O
,	,	O	O
then	RB	O	O
a	DT	O	O
randomized	VBN	O	O
single-blind	NN	O	O
study	NN	O	O
with	IN	O	O
a	DT	O	O
27-month	JJ	O	O
intervention	NN	O	O
.	.	O	O

SETTING	NNP	O	O
&	CC	O	O
PARTICIPANTS	NNP	O	O
University	NNP	p	O
medical	JJ	p	O
center	NN	p	O
;	:	p	O
50	CD	p	O
patients	NNS	p	O
(	(	p	O
serum	JJ	p	O
creatinine	NN	p	O
,	,	p	O
1.5-3.9	JJ	p	O
mg/dL	NN	p	O
)	)	p	O
with	IN	p	O
high-normal	JJ	p	O
body	NN	p	O
lead	JJ	p	O
burden	NN	p	O
(	(	p	O
?80-	JJ	p	O
<	NN	p	O
600	CD	p	O
?g	NN	p	O
)	)	p	O
were	VBD	p	O
randomly	RB	O	O
assigned	VBN	O	O
to	TO	O	O
the	DT	O	O
treatment	NN	i	O
and	CC	i	O
control	NN	i	O
groups	NNS	i	O
.	.	i	O

INTERVENTION	NNP	i	O
The	DT	O	O
treatment	NN	O	O
group	NN	O	O
received	VBD	O	O
weekly	JJ	i	O
chelation	NN	i	O
therapy	NN	i	O
for	IN	i	O
3	CD	O	O
months	NNS	O	O
to	TO	O	O
reduce	VB	O	O
their	PRP$	O	O
body	NN	O	O
lead	JJ	O	O
burden	NN	O	O
to	TO	O	O
<	VB	O	O
60	CD	O	O
?g	NNS	O	O
and	CC	O	O
then	RB	O	O
as	IN	O	O
needed	VBN	O	O
for	IN	O	O
24	CD	O	O
months	NNS	O	O
to	TO	O	O
maintain	VB	O	O
this	DT	O	O
level	NN	O	O
.	.	O	O

The	DT	O	O
control	NN	O	O
group	NN	O	O
received	VBD	i	O
placebo	NN	i	O
for	IN	i	O
3	CD	O	O
months	NNS	O	O
and	CC	O	O
then	RB	O	O
weekly	VB	O	O
for	IN	O	O
5	CD	O	O
weeks	NNS	O	O
at	IN	O	O
6-month	JJ	O	O
intervals	NNS	O	O
for	IN	O	O
24	CD	O	O
months	NNS	O	O
.	.	O	O

OUTCOMES	IN	o	O
The	DT	o	O
primary	JJ	o	O
end	NN	o	O
point	NN	o	O
was	VBD	o	O
change	NN	o	O
in	IN	o	O
estimated	VBN	o	O
glomerular	JJ	o	O
filtration	NN	o	O
rate	NN	o	O
(	(	o	O
eGFR	NN	o	O
)	)	o	O
over	IN	o	O
time	NN	o	O
.	.	o	O

A	DT	o	O
secondary	JJ	O	O
end	NN	O	O
point	NN	O	O
was	VBD	O	O
a	DT	o	O
2-fold	JJ	o	O
increase	NN	o	O
in	IN	o	O
baseline	JJ	o	O
serum	NN	o	O
creatinine	NN	o	O
level	NN	o	O
or	CC	o	O
the	DT	o	O
requirement	NN	o	O
for	IN	o	O
renal	JJ	o	O
replacement	NN	o	O
therapy	NN	o	O
.	.	o	O

MEASUREMENTS	NNP	o	O
Body	NNP	O	O
lead	JJ	O	O
burdens	NNS	O	O
were	VBD	O	O
assessed	VBN	O	O
by	IN	O	O
EDTA	NNP	O	O
mobilization	NN	O	O
tests	NNS	O	O
and	CC	O	O
eGFR	NN	O	O
was	VBD	O	O
calculated	VBN	O	O
using	VBG	O	O
the	DT	O	O
equation	NN	O	O
for	IN	O	O
Chinese	JJ	p	O
patients	NNS	p	O
with	IN	p	O
type	JJ	p	O
2	CD	p	O
diabetes	NNS	p	O
.	.	p	O

RESULTS	NNP	o	O
Mean	NNP	o	O
baseline	NN	o	O
eGFRs	NN	o	O
in	IN	o	O
the	DT	O	O
treatment	NN	O	O
and	CC	O	O
control	NN	O	O
groups	NNS	O	O
were	VBD	O	O
similar	JJ	O	O
.	.	O	O

After	IN	O	O
3	CD	O	O
months	NNS	O	O
of	IN	O	O
chelation	NN	O	O
therapy	NN	O	O
,	,	O	O
the	DT	O	O
change	NN	o	O
in	IN	o	O
eGFR	NN	o	O
in	IN	o	O
the	DT	O	O
treatment	NN	O	O
group	NN	O	O
(	(	O	O
+1.0	NNP	O	O
?	.	O	O
4.8	CD	O	O
mL/min/1.73	NN	O	O
m	NN	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
)	)	O	O
differed	VBN	O	O
significantly	RB	O	O
from	IN	O	O
that	DT	O	O
in	IN	O	O
the	DT	O	O
control	NN	O	O
group	NN	O	O
(	(	O	O
-1.5	NNP	O	O
?	.	O	O
4.8	CD	O	O
mL/min/1.73	NN	O	O
m	NN	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
;	:	O	O
P	NNP	O	O
=	NNP	O	O
0.04	CD	O	O
)	)	O	O
.	.	O	O

In	IN	O	O
the	DT	O	O
subsequent	JJ	O	O
24-month	JJ	O	O
intervention	NN	O	O
,	,	O	O
the	DT	O	O
yearly	JJ	O	O
rate	NN	o	O
of	IN	o	O
decrease	NN	o	O
in	IN	o	O
eGFR	NN	o	O
(	(	O	O
5.6	CD	O	O
?	.	O	O
5.0	CD	O	O
mL/min/1.73	NN	O	O
m	NN	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
per	IN	O	O
year	NN	O	O
)	)	O	O
in	IN	O	O
the	DT	O	O
treatment	NN	O	O
group	NN	O	O
was	VBD	O	O
slower	JJR	O	O
than	IN	O	O
that	DT	O	O
(	(	O	O
9.2	CD	O	O
?	.	O	O
3.6	CD	O	O
mL/min/1.73	NN	O	O
m	NN	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
per	IN	O	O
year	NN	O	O
;	:	O	O
P	NNP	O	O
=	NNP	O	O
0.04	CD	O	O
)	)	O	O
in	IN	O	O
the	DT	O	O
control	NN	O	O
group	NN	p	O
.	.	p	O

17	CD	p	O
(	(	p	O
68	CD	p	O
%	NN	p	O
)	)	O	O
control-group	NN	p	O
patients	NNS	p	O
and	CC	p	O
9	CD	p	O
(	(	p	O
36	CD	p	O
%	NN	p	O
)	)	p	O
treatment-group	NN	p	O
patients	NNS	p	O
achieved	VBD	p	O
the	DT	O	O
secondary	JJ	O	O
end	NN	O	O
point	NN	O	O
.	.	O	O

LIMITATIONS	NNP	O	O
Small	NNP	O	O
sample	NN	O	O
size	NN	O	O
,	,	O	O
not	RB	O	O
double	JJ	O	O
blind	NN	O	O
.	.	O	O

CONCLUSIONS	VB	O	O
A	DT	O	O
27-month	JJ	O	O
course	NN	O	O
of	IN	O	O
EDTA	NNP	O	O
chelation	NN	O	O
therapy	NN	O	O
retards	VBZ	O	O
the	DT	O	O
progression	NN	O	O
of	IN	O	O
diabetic	JJ	O	O
nephropathy	NN	p	O
in	IN	p	O
type	NN	p	O
2	CD	p	O
diabetic	JJ	p	O
patients	NNS	p	O
with	IN	p	O
high-normal	JJ	p	O
body	NN	p	O
lead	JJ	p	O
burdens	NNS	p	O
.	.	O	O

Prognostic	JJ	O	O
factor	NN	O	O
analysis	NN	O	O
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
advanced	JJ	p	PC
prostate	NN	p	PC
cancer	NN	p	PC
treated	VBN	p	O
by	IN	p	O
castration	NN	i	IS
plus	CC	i	O
anandron	NN	i	IPM
or	CC	i	O
placebo	NN	i	IC
:	:	i	O
a	DT	O	O
final	JJ	O	O
update	NN	O	O
.	.	O	O

PURPOSE	NNP	O	O
Different	NNP	O	O
outcome	NN	O	O
results	NNS	O	O
have	VBP	O	O
been	VBN	O	O
published	VBN	O	O
in	IN	O	O
trials	NNS	O	O
comparing	VBG	O	O
maximal	JJ	O	O
androgen	NN	O	O
blockade	NN	O	O
(	(	O	O
MAB	NNP	O	O
)	)	O	O
with	IN	O	O
chemical	NN	i	IS
or	CC	i	IS
surgical	JJ	i	IS
castration	NN	i	IS
alone	RB	i	IS
.	.	i	O

The	DT	O	O
conflicting	NN	O	O
results	NNS	O	O
could	MD	O	O
be	VB	O	O
explained	VBN	O	O
by	IN	O	O
the	DT	O	O
fact	NN	O	O
that	IN	O	O
patients	NNS	O	O
were	VBD	O	O
included	VBN	O	O
with	IN	O	O
different	JJ	O	O
prognostic	JJ	O	O
factors	NNS	O	O
.	.	O	O

In	IN	O	O
this	DT	O	O
new	JJ	O	O
analysis	NN	O	O
of	IN	O	O
the	DT	O	O
Anandron	NNP	O	O
European	NNP	O	O
Study	NNP	O	O
,	,	O	O
independent	JJ	O	O
prognostic	JJ	O	O
factors	NNS	O	O
have	VBP	O	O
been	VBN	O	O
evaluated	VBN	O	O
in	IN	O	O
order	NN	O	O
to	TO	O	O
identify	VB	O	O
those	DT	O	O
which	WDT	O	O
could	MD	O	O
influence	VB	O	O
the	DT	O	O
study	NN	O	O
outcome	NN	O	O
and	CC	O	O
the	DT	O	O
impact	NN	O	O
of	IN	O	O
the	DT	O	O
treatment	NN	O	O
.	.	O	O

MATERIAL	NNP	O	O
AND	NNP	O	O
METHODS	NNP	O	O
399	CD	p	PSS
out	IN	p	O
of	IN	p	O
457	CD	p	PSS
patients	NNS	p	O
recruited	VBN	p	O
in	IN	p	O
this	DT	p	O
study	NN	p	O
were	VBD	p	O
divided	VBN	p	O
in	IN	p	O
a	DT	p	O
good	JJ	p	O
or	CC	p	O
poor	JJ	p	O
prognostic	JJ	p	O
group	NN	p	O
depending	VBG	p	O
on	IN	p	O
the	DT	p	O
presence	NN	p	O
of	IN	p	O
two	CD	p	O
or	CC	p	O
more	JJR	p	O
poor	JJ	p	O
prognostic	JJ	p	O
factors	NNS	p	O
,	,	p	O
these	DT	p	O
were	VBD	p	O
pain	NN	p	O
requiring	VBG	p	O
treatment	NN	p	O
,	,	p	O
>	VBZ	p	O
5	CD	p	O
bone	NN	p	O
metastases	NNS	p	O
,	,	p	O
hydronephrosis	NN	p	O
,	,	p	O
and	CC	p	O
alkaline	JJ	p	O
phosphatase	NN	p	O
>	VBD	p	O
2	CD	p	O
ULN	NNP	p	O
.	.	p	O

RESULTS	NNP	O	O
When	WRB	O	O
expressed	VBN	O	O
as	IN	O	O
a	DT	O	O
percentage	NN	O	O
,	,	O	O
the	DT	O	O
improvement	NN	o	OPH
in	IN	o	OPH
time	NN	o	OPH
to	TO	o	OPH
progression	NN	o	OPH
,	,	o	OPH
overall	JJ	o	OMO
and	CC	o	OMO
cancer	NN	o	OMO
specific	JJ	o	OMO
survival	NN	o	OMO
in	IN	O	O
the	DT	O	O
Anandron	NNP	i	IPM
treated	VBD	O	O
patients	NNS	O	O
was	VBD	O	O
identical	JJ	O	O
in	IN	O	O
both	DT	O	O
groups	NNS	O	O
.	.	O	O

In	IN	O	O
absolute	JJ	O	O
terms	NNS	O	O
this	DT	O	O
improvement	NN	O	O
,	,	O	O
however	RB	O	O
,	,	O	O
was	VBD	O	O
greater	JJR	O	O
in	IN	O	O
the	DT	O	O
good	JJ	O	O
prognostic	JJ	O	O
group	NN	O	O
.	.	O	O

CONCLUSION	NNP	O	O
In	IN	O	O
comparison	NN	O	O
with	IN	O	O
surgical	JJ	i	IS
castration	NN	i	IS
MAB	NNP	i	IPM
using	VBG	i	IPM
Anandron	NNP	i	IPM
,	,	O	O
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
metastatic	JJ	p	PC
prostate	NN	p	PC
cancer	NN	p	PC
improves	VBZ	O	O
the	DT	O	O
time	NN	O	O
to	TO	O	O
objective	VB	o	OPH
progression	NN	o	OPH
,	,	o	OPH
overall	JJ	o	OMO
and	CC	o	OMO
cancer	NN	o	OMO
specific	JJ	o	OMO
survival	NN	o	OMO
,	,	O	O
irrespective	NN	O	O
of	IN	O	O
certain	JJ	O	O
poor	JJ	O	O
prognostic	JJ	O	O
factors	NNS	O	O
.	.	O	O

Instant	JJ	i	O
Recess?	NNP	i	O
:	:	i	O
a	DT	O	O
practical	JJ	O	O
tool	NN	O	O
for	IN	O	O
increasing	VBG	o	O
physical	JJ	o	O
activity	NN	o	O
during	IN	O	O
the	DT	O	O
school	NN	O	O
day	NN	O	O
.	.	O	O

BACKGROUND	NNP	O	O
An	DT	O	O
increased	JJ	O	O
prevalence	NN	O	O
of	IN	p	O
overweight/obesity	NN	p	O
among	IN	p	O
children	NNS	p	O
has	VBZ	O	O
led	VBN	O	O
to	TO	O	O
school	NN	O	O
district	NN	O	O
level	NN	O	O
policies	NNS	O	O
to	TO	O	O
increase	VB	o	O
physical	JJ	o	O
activity	NN	o	O
(	(	o	O
PA	NNP	o	O
)	)	o	O
among	IN	p	O
elementary	JJ	p	O
school	NN	p	O
students	NNS	p	O
.	.	p	O

Interventions	NNS	O	O
are	VBP	O	O
needed	VBN	O	O
that	IN	O	O
increase	NN	O	O
activity	NN	O	O
levels	NNS	O	O
without	IN	O	O
sacrificing	VBG	O	O
time	NN	O	O
spent	VBN	O	O
in	IN	O	O
academics	NNS	O	O
.	.	O	O

OBJECTIVES	IN	O	O
We	PRP	O	O
evaluated	VBD	O	O
a	DT	O	O
policy	NN	i	O
implementation	NN	i	O
intervention	NN	i	O
for	IN	O	O
to	TO	O	O
increase	VB	O	O
in-school	JJ	i	O
PA	NNP	i	O
in	IN	p	O
elementary	JJ	p	O
schools	NNS	p	O
in	IN	p	O
Forsyth	NNP	p	O
County	NNP	p	O
,	,	p	O
North	NNP	p	O
Carolina	NNP	p	O
,	,	p	O
in	IN	O	O
a	DT	O	O
randomized	JJ	O	O
study	NN	O	O
with	IN	O	O
a	DT	O	O
delayed	JJ	O	O
intervention	NN	O	O
control	NN	O	O
group	NN	O	O
.	.	O	O

METHODS	NNP	p	O
The	DT	p	O
study	NN	p	O
included	VBD	p	O
third-	JJ	p	O
through	IN	p	O
fifth-grade	JJ	p	O
classrooms	NNS	p	O
in	IN	p	O
eight	CD	p	O
elementary	JJ	p	O
schools	NNS	p	O
.	.	p	O

Instant	NNP	i	O
Recess?	NNP	i	O
was	VBD	i	O
used	VBN	O	O
to	TO	O	O
introduce	VB	O	O
10-minute	JJ	i	O
PA	NNP	i	O
breaks	NNS	i	O
in	IN	i	O
classrooms	NNS	O	O
on	IN	O	O
schedules	NNS	O	O
determined	VBN	O	O
by	IN	O	O
teachers	NNS	O	O
.	.	O	O

Direct	JJ	O	O
observation	NN	O	O
was	VBD	O	O
used	VBN	O	O
to	TO	O	O
measure	VB	o	O
activity	NN	o	O
levels	NNS	o	O
,	,	o	O
other	JJ	o	O
student	NN	o	O
behaviors	NNS	o	O
,	,	o	O
and	CC	o	O
teacher	NN	o	O
behaviors	NNS	o	O
related	VBN	o	O
to	TO	O	O
PA	NNP	O	O
in	IN	O	O
the	DT	O	O
classrooms	NNS	O	O
.	.	O	O

RESULTS	NNP	O	O
Twenty-eight	JJ	O	O
visits	NNS	O	O
to	TO	O	O
schools	NNS	O	O
were	VBD	O	O
made	VBN	O	O
during	IN	O	O
the	DT	O	O
spring	NN	O	O
and	CC	O	O
fall	NN	O	O
semesters	NNS	O	O
of	IN	O	O
2009	CD	O	O
.	.	O	O

At	IN	O	O
baseline	JJ	O	O
11	CD	O	O
%	NN	O	O
to	TO	O	O
44	CD	O	O
%	NN	O	O
of	IN	O	O
intervention	NN	O	O
and	CC	O	O
control	NN	O	O
schools	NNS	O	O
were	VBD	O	O
engaged	VBN	O	O
in	IN	O	O
classroom-based	JJ	i	O
PA.	NNP	o	O
PA	NNP	o	O
increased	VBD	o	O
from	IN	O	O
baseline	NN	O	O
to	TO	O	O
spring	VB	O	O
follow-up	NN	O	O
in	IN	O	O
intervention	NN	O	O
schools	NNS	O	O
and	CC	O	O
was	VBD	O	O
maintained	VBN	O	O
the	DT	O	O
following	VBG	O	O
fall	NN	O	O
.	.	O	O

Control	NNP	O	O
schools	NNS	O	O
decreased	VBD	o	O
PA	NNP	o	O
from	IN	o	O
baseline	NN	O	O
to	TO	O	O
spring	NN	O	O
and	CC	O	O
increased	VBD	o	O
PA	NNP	o	O
once	RB	o	O
they	PRP	O	O
began	VBD	O	O
the	DT	O	O
intervention	NN	O	O
.	.	O	O

Students	NNS	O	O
in	IN	O	O
classrooms	NNS	O	O
engaged	VBN	O	O
in	IN	O	O
Instant	NNP	O	O
Recess	NNP	O	O
exhibited	VBD	o	O
statistically	RB	o	O
significant	JJ	o	O
increases	NNS	o	O
in	IN	o	O
light	NN	o	O
(	(	o	O
51	CD	o	O
%	NN	o	O
)	)	o	O
and	CC	o	O
moderate-intensity	NN	o	O
(	(	o	O
16	CD	o	O
%	NN	o	O
)	)	o	O
PA	NNP	o	O
and	CC	o	O
increases	NNS	o	O
in	IN	o	O
time	NN	o	O
spent	VBN	o	O
in	IN	o	O
on-task	JJ	o	O
behavior	NN	o	O
(	(	o	O
11	CD	O	O
%	NN	O	O
)	)	O	O
.	.	O	O

Control	NNP	O	O
schools	NNS	O	O
experienced	VBD	O	O
similar	JJ	O	O
benefits	NNS	O	O
after	IN	O	O
they	PRP	O	O
began	VBD	O	O
implementing	VBG	O	O
Instant	NNP	O	O
Recess	NNP	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
Instant	NNP	O	O
Recess	NNP	O	O
is	VBZ	O	O
useful	JJ	O	O
for	IN	o	O
increasing	VBG	o	O
PA	NNP	o	O
and	CC	o	O
improving	VBG	o	O
behavior	NN	o	O
among	IN	o	O
elementary	JJ	p	O
school	NN	p	O
children	NNS	p	O
.	.	p	O

Additional	NNP	O	O
research	NN	O	O
may	MD	O	O
be	VB	O	O
needed	VBN	O	O
to	TO	O	O
understand	VB	O	O
how	WRB	O	O
to	TO	O	O
create	VB	O	O
policies	NNS	O	O
supporting	VBG	O	O
classroom	NN	O	O
activity	NN	O	O
breaks	NNS	O	O
and	CC	O	O
how	WRB	O	O
to	TO	O	O
assess	VB	O	O
policy	NN	O	O
adherence	NN	O	O
.	.	O	O

The	DT	O	O
effects	NNS	O	O
of	IN	O	O
haloperidol	NN	i	IPM
on	IN	O	O
discrimination	NN	o	OME
learning	NN	o	OME
and	CC	o	OME
behavioral	JJ	o	OME
symptoms	NNS	o	OME
in	IN	O	O
autistic	JJ	p	PC
children	NNS	p	O
.	.	p	O

This	DT	O	O
double-blind	JJ	O	O
and	CC	O	O
placebo-controlled	JJ	i	IC
clinical	JJ	O	O
trial	NN	O	O
in	IN	O	O
autistic	JJ	p	O
children	NNS	p	O
had	VBD	O	O
three	CD	O	O
objectives	NNS	O	O
:	:	O	O
(	(	O	O
a	DT	O	O
)	)	O	O
to	TO	O	O
replicate	VB	O	O
earlier	JJR	O	O
findings	NNS	O	O
that	IN	O	O
haloperidol	JJ	i	IPM
administration	NN	O	O
is	VBZ	O	O
associated	VBN	O	O
with	IN	O	O
a	DT	O	O
significant	JJ	O	O
reduction	NN	O	O
of	IN	O	O
behavioral	JJ	o	OME
symptoms	NNS	o	OME
;	:	o	O
(	(	O	O
b	NN	O	O
)	)	O	O
to	TO	O	O
further	JJ	O	O
assess	NN	O	O
its	PRP$	O	O
safety	NN	o	OOt
when	WRB	O	O
given	VBN	O	O
on	IN	O	O
a	DT	O	O
short-term	JJ	O	O
basis	NN	O	O
;	:	O	O
and	CC	O	O
(	(	O	O
c	NN	O	O
)	)	O	O
to	TO	O	O
assess	VB	O	O
whether	IN	O	O
it	PRP	O	O
has	VBZ	O	O
an	DT	O	O
effect	NN	o	OME
on	IN	o	OME
discrimination	NN	o	OME
learning	NN	o	OME
.	.	o	O

Forty-five	JJ	p	PSS
children	NNS	p	O
,	,	p	O
2.02	CD	p	PA
to	TO	p	PA
7.58	CD	p	PA
years	NNS	p	O
old	JJ	p	O
(	(	p	O
M	NNP	p	PA
=	NNP	p	PA
4.49	CD	p	PA
)	)	p	O
,	,	O	O
completed	VBD	O	O
this	DT	O	O
crossover	NN	O	O
design	NN	O	O
,	,	O	O
with	IN	O	O
random	JJ	O	O
assignment	NN	O	O
to	TO	O	O
treatment	NN	O	O
sequences	NNS	O	O
.	.	O	O

Haloperidol	NNP	i	IPM
was	VBD	O	O
shown	VBN	O	O
to	TO	O	O
be	VB	O	O
a	DT	O	O
powerful	JJ	O	O
therapeutic	JJ	O	O
agent	NN	O	O
when	WRB	O	O
administered	VBN	O	O
for	IN	O	O
4	CD	O	O
weeks	NNS	O	O
and	CC	O	O
free	JJ	O	O
of	IN	O	O
side	JJ	o	OA
effects	NNS	o	OA
;	:	o	O
at	IN	O	O
doses	NNS	O	O
ranging	VBG	O	O
from	IN	O	O
0.25	CD	O	O
to	TO	O	O
4.0	CD	O	O
mg/day	NN	O	O
(	(	O	O
M	NNP	O	O
=	NNP	O	O
0.844	CD	O	O
)	)	O	O
,	,	O	O
there	EX	O	O
was	VBD	O	O
a	DT	O	O
clinically	RB	O	O
and	CC	O	O
statistically	RB	O	O
significant	JJ	O	O
reduction	NN	O	O
of	IN	O	O
a	DT	O	O
variety	NN	o	OME
of	IN	o	OME
symptoms	NNS	o	OME
.	.	o	O

Under	IN	O	O
the	DT	O	O
given	VBN	O	O
conditions	NNS	O	O
,	,	O	O
the	DT	O	O
children	NNS	O	O
failed	VBD	O	O
to	TO	O	O
learn	VB	O	O
on	IN	O	O
either	DT	O	O
haloperidol	NN	i	IPM
or	CC	O	O
placebo	NN	i	O
.	.	i	O

A	DT	O	O
controlled	JJ	O	O
trial	NN	O	O
of	IN	O	O
trimethoprim-sulfamethoxazole	JJ	i	IPM
or	CC	i	O
aerosolized	JJ	i	IPM
pentamidine	NN	i	IPM
for	IN	O	O
secondary	JJ	O	O
prophylaxis	NN	O	O
of	IN	O	O
Pneumocystis	NNP	O	O
carinii	NN	O	O
pneumonia	NN	O	O
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
the	DT	p	O
acquired	JJ	p	PC
immunodeficiency	NN	p	PC
syndrome	NN	p	PC
.	.	p	O

AIDS	NNP	O	O
Clinical	JJ	O	O
Trials	NNP	O	O
Group	NNP	O	O
Protocol	NNP	O	O
021	CD	O	O
.	.	O	O

BACKGROUND	NNP	O	O
Pneumocystis	NNP	O	O
carinii	NN	O	O
pneumonia	NN	O	O
(	(	O	O
PCP	NNP	O	O
)	)	O	O
continues	VBZ	O	O
to	TO	O	O
be	VB	O	O
the	DT	O	O
most	RBS	O	O
common	JJ	O	O
index	NN	O	O
diagnosis	NN	O	O
in	IN	O	O
the	DT	O	O
acquired	JJ	O	O
immunodeficiency	NN	O	O
syndrome	NN	O	O
(	(	O	O
AIDS	NNP	O	O
)	)	O	O
,	,	O	O
but	CC	O	O
it	PRP	O	O
is	VBZ	O	O
not	RB	O	O
clear	JJ	O	O
which	WDT	O	O
of	IN	O	O
several	JJ	O	O
available	JJ	O	O
agents	NNS	O	O
is	VBZ	O	O
the	DT	O	O
most	RBS	O	O
effective	JJ	O	O
in	IN	O	O
preventing	VBG	o	OPH
a	DT	o	OPH
recurrence	NN	o	OPH
of	IN	o	OPH
PCP	NNP	o	OPH
.	.	o	O

METHODS	NNP	O	O
We	PRP	O	O
conducted	VBD	O	O
a	DT	O	O
comparative	JJ	O	O
,	,	O	O
open-label	JJ	O	O
trial	NN	O	O
in	IN	O	O
310	CD	p	PSS
adults	NNS	p	PA
with	IN	p	O
AIDS	NNP	p	PC
who	WP	p	O
had	VBD	p	O
recently	RB	p	O
recovered	VBN	p	O
from	IN	p	O
an	DT	p	O
initial	JJ	p	O
episode	NN	p	O
of	IN	p	O
PCP	NNP	p	PC
and	CC	p	O
had	VBD	p	O
no	DT	p	O
treatment-limiting	JJ	p	O
toxic	NN	p	O
effects	NNS	p	O
of	IN	p	O
trimethoprim-sulfamethoxazole	JJ	i	IPM
or	CC	i	O
pentamidine	NN	i	IPM
.	.	i	O

All	PDT	O	O
the	DT	O	O
patients	NNS	O	O
were	VBD	O	O
treated	VBN	i	O
with	IN	i	O
zidovudine	NN	i	IPM
and	CC	O	O
were	VBD	O	O
randomly	RB	O	O
assigned	VBN	O	O
to	TO	O	O
receive	VB	i	O
either	RB	i	O
800	CD	i	IPM
mg	NN	i	IPM
of	IN	i	IPM
sulfamethoxazole	NN	i	IPM
and	CC	i	IPM
160	CD	i	IPM
mg	NN	i	IPM
of	IN	i	IPM
trimethoprim	JJ	i	IPM
once	JJ	i	O
daily	JJ	i	O
or	CC	i	O
300	CD	i	IPM
mg	NN	i	IPM
of	IN	i	IPM
aerosolized	JJ	i	IPM
pentamidine	NN	i	IPM
administered	VBN	i	O
every	DT	i	O
four	CD	i	O
weeks	NNS	i	O
by	IN	i	O
jet	NN	i	IPM
nebulizer	NN	i	IPM
.	.	i	O

The	DT	O	O
participants	NNS	O	O
were	VBD	O	O
followed	VBN	O	O
for	IN	O	O
a	DT	O	O
median	NN	O	O
of	IN	O	O
17.4	CD	O	O
months	NNS	O	O
.	.	O	O

RESULTS	NNP	O	O
In	IN	O	O
the	DT	O	O
trimethoprim-sulfamethoxazole	JJ	i	IPM
group	NN	O	O
(	(	O	O
n	JJ	O	O
=	NNP	O	O
154	CD	O	O
)	)	O	O
there	EX	O	O
were	VBD	O	O
14	CD	O	O
recurrences	NNS	o	OPH
of	IN	o	OPH
PCP	NNP	o	OPH
,	,	O	O
as	IN	O	O
compared	VBN	O	O
with	IN	O	O
36	CD	O	O
recurrences	NNS	O	O
(	(	O	O
including	VBG	O	O
1	CD	O	O
extrapulmonary	JJ	O	O
recurrence	NN	O	O
)	)	O	O
in	IN	O	O
the	DT	O	O
aerosolized-pentamidine	JJ	O	O
group	NN	O	O
(	(	O	O
n	JJ	O	O
=	NNP	O	O
156	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
estimated	JJ	O	O
recurrence	NN	o	OPH
rates	NNS	o	OPH
at	IN	O	O
18	CD	O	O
months	NNS	O	O
were	VBD	O	O
11.4	CD	O	O
percent	NN	O	O
with	IN	O	O
trimethoprim-sulfamethoxazole	JJ	i	IPM
and	CC	O	O
27.6	CD	O	O
percent	NN	O	O
with	IN	O	O
pentamidine	NN	i	IPM
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.001	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
risk	NN	O	O
of	IN	O	O
a	DT	O	O
recurrence	NN	o	OPH
(	(	O	O
adjusted	VBN	O	O
for	IN	O	O
initial	JJ	O	O
CD4	NNP	O	O
cell	NN	O	O
count	NN	O	O
)	)	O	O
was	VBD	O	O
3.25	CD	O	O
times	NNS	O	O
higher	RBR	O	O
in	IN	O	O
the	DT	O	O
pentamidine	NN	i	IPM
group	NN	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.001	CD	O	O
,	,	O	O
95	CD	O	O
percent	NN	O	O
confidence	NN	O	O
interval	NN	O	O
,	,	O	O
1.72	CD	O	O
to	TO	O	O
6.16	CD	O	O
)	)	O	O
.	.	O	O

There	EX	O	O
were	VBD	O	O
no	DT	O	O
significant	JJ	O	O
differences	NNS	O	O
between	IN	O	O
the	DT	O	O
groups	NNS	O	O
in	IN	O	O
survival	NN	o	OMO
or	CC	o	O
in	IN	o	O
hematologic	JJ	o	OA
or	CC	o	OA
hepatic	JJ	o	OA
toxicity	NN	o	OA
.	.	o	OA

Crossovers	NNS	O	O
from	IN	O	O
trimethoprim-sulfamethoxazole	JJ	i	IPM
to	TO	O	O
aerosolized	JJ	O	O
pentamidine	NN	i	IPM
were	VBD	O	O
more	JJR	O	O
common	JJ	O	O
than	IN	O	O
the	DT	O	O
reverse	NN	O	O
(	(	O	O
27	CD	O	O
vs.	FW	O	O
4	CD	O	O
percent	NN	O	O
)	)	O	O
,	,	O	O
partly	RB	O	O
because	IN	O	O
of	IN	O	O
the	DT	O	O
study	NN	O	O
protocols	NNS	O	O
for	IN	O	O
the	DT	O	O
management	NN	O	O
of	IN	O	O
leukopenia	NN	O	O
.	.	O	O

There	EX	O	O
were	VBD	O	O
19	CD	O	O
serious	JJ	O	O
bacterial	JJ	o	OPH
infections	NNS	o	OPH
in	IN	O	O
the	DT	O	O
trimethoprim-sulfamethoxazole	JJ	O	O
group	NN	O	O
and	CC	O	O
38	CD	O	O
in	IN	O	O
the	DT	O	O
pentamidine	NN	O	O
group	NN	O	O
.	.	O	O

The	DT	O	O
time	NN	o	OPH
to	TO	o	OPH
a	DT	o	OPH
first	JJ	o	OPH
bacterial	JJ	o	OPH
infection	NN	o	OPH
was	VBD	O	O
significantly	RB	O	O
greater	JJR	O	O
for	IN	O	O
those	DT	O	O
assigned	VBN	O	O
to	TO	O	O
trimethoprim-sulfamethoxazole	JJ	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.017	CD	O	O
)	)	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
In	IN	O	O
patients	NNS	p	O
with	IN	p	O
AIDS	NNP	p	PC
who	WP	p	O
are	VBP	p	O
receiving	VBG	p	O
zidovudine	NN	i	IPM
,	,	i	O
trimethoprim-sulfamethoxazole	JJ	i	IPM
is	VBZ	O	O
more	RBR	O	O
effective	JJ	O	O
than	IN	O	O
aerosolized	JJ	i	IPM
pentamidine	NN	i	IPM
in	IN	O	O
conventional	JJ	O	O
doses	NNS	O	O
for	IN	O	O
the	DT	O	O
prevention	NN	o	OPH
of	IN	o	OPH
recurrent	NN	o	OPH
pneumocystis	NN	o	OPH
infection	NN	o	OPH
.	.	o	O

Effects	NNS	O	O
of	IN	O	O
large	JJ	O	O
doses	NNS	O	O
of	IN	O	O
arachidonic	JJ	i	O
acid	NN	i	O
added	VBD	O	O
to	TO	O	O
docosahexaenoic	VB	i	O
acid	NN	i	O
on	IN	O	O
social	JJ	p	PC
impairment	NN	p	PC
in	IN	p	PC
individuals	NNS	p	PC
with	IN	p	PC
autism	NN	p	PC
spectrum	NN	p	PC
disorders	NNS	p	PC
:	:	p	PC
a	DT	O	O
double-blind	NN	O	O
,	,	O	O
placebo-controlled	JJ	i	IC
,	,	O	O
randomized	JJ	O	O
trial	NN	O	O
.	.	O	O

Autism	NNP	O	O
spectrum	NN	O	O
disorders	NNS	O	O
are	VBP	O	O
a	DT	O	O
neurodevelopmental	JJ	O	O
disorders	NNS	O	O
with	IN	O	O
reduced	JJ	O	O
cortical	JJ	O	O
functional	JJ	O	O
connectivity	NN	O	O
relating	VBG	O	O
to	TO	O	O
social	JJ	O	O
cognition	NN	O	O
.	.	O	O

Polyunsaturated	VBN	i	IPM
fatty	JJ	i	IPM
acids	NNS	i	IPM
arachidonic	JJ	i	IPM
acid	NN	i	IPM
(	(	i	IPM
ARA	NNP	i	IPM
)	)	i	IPM
and	CC	O	O
docosahexaenoic	JJ	i	IPM
acid	NN	i	IPM
(	(	i	IPM
DHA	NNP	i	IPM
)	)	i	IPM
may	MD	O	O
have	VB	O	O
key	JJ	O	O
role	NN	O	O
in	IN	O	O
brain	NN	O	O
network	NN	O	O
maturation	NN	O	O
.	.	O	O

In	IN	O	O
particularly	RB	O	O
,	,	O	O
ARA	NNP	i	IPM
is	VBZ	O	O
important	JJ	O	O
in	IN	O	O
signal	JJ	O	O
transduction	NN	O	O
related	VBN	O	O
to	TO	O	O
neuronal	JJ	O	O
maturation	NN	O	O
.	.	O	O

Supplementation	NN	O	O
with	IN	O	O
larger	JJR	O	O
ARA	NNP	i	IPM
doses	VBZ	i	IPM
added	VBN	i	IPM
to	TO	i	IPM
DHA	NNP	i	IPM
may	MD	O	O
therefore	VB	O	O
mitigate	VB	O	O
social	JJ	O	O
impairment	NN	O	O
.	.	O	O

In	IN	O	O
a	DT	O	O
16-week	JJ	O	O
,	,	O	O
double-blind	JJ	O	O
,	,	O	O
randomized	VBN	O	O
,	,	O	O
placebo-controlled	JJ	i	IC
trial	NN	O	O
,	,	O	O
we	PRP	O	O
evaluated	VBD	O	O
the	DT	O	O
efficacy	NN	O	O
of	IN	O	O
supplementation	NN	O	O
with	IN	O	O
large	JJ	O	O
doses	NNS	O	O
of	IN	O	O
ARA	NNP	i	IPM
added	VBD	i	IPM
to	TO	i	IPM
DHA	NNP	i	IPM
(	(	i	O
n	JJ	i	O
=	NNP	i	O
7	CD	i	O
)	)	i	O
or	CC	p	O
placebo	NN	i	IC
(	(	i	O
n	JJ	i	O
=	NNP	i	O
6	CD	i	O
)	)	i	O
in	IN	p	O
13	CD	p	O
participants	NNS	p	O
(	(	p	O
mean	JJ	p	O
age	NN	p	O
,	,	p	O
14.6	CD	p	O
[	NN	p	O
SD	NNP	p	O
,	,	p	O
5.9	CD	p	O
]	CD	p	O
years	NNS	p	O
)	)	p	O
.	.	p	O

To	TO	O	O
examine	VB	O	O
underlying	JJ	O	O
mechanisms	NNS	O	O
underlying	VBG	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
our	PRP$	O	O
supplementation	NN	O	O
regimen	NNS	O	O
,	,	O	O
we	PRP	O	O
examined	VBD	O	O
plasma	JJ	o	OPH
levels	NNS	o	OPH
of	IN	o	OPH
antioxidants	NNS	o	OPH
transferrin	JJ	o	OPH
and	CC	o	OPH
superoxide	JJ	o	OPH
dismutase	NN	o	OPH
,	,	O	O
which	WDT	O	O
are	VBP	O	O
useful	JJ	O	O
markers	NNS	O	O
of	IN	O	O
signal	JJ	O	O
transduction	NN	O	O
.	.	O	O

The	DT	O	O
outcome	NN	O	O
measures	NNS	O	O
were	VBD	O	O
the	DT	O	O
Social	NNP	o	OME
Responsiveness	NNP	o	OME
Scale	NNP	o	OME
and	CC	o	OME
the	DT	o	OME
Aberrant	NNP	o	OME
Behavior	NNP	o	OME
Checklist-Community	NNP	o	OME
.	.	o	O

Repeated-measures	JJ	O	O
analysis	NN	O	O
of	IN	O	O
variance	NN	O	O
revealed	VBD	O	O
that	IN	O	O
our	PRP$	O	O
supplementation	NN	O	O
regimen	NNS	O	O
significantly	RB	O	O
improved	VBN	O	O
Aberrant	NNP	o	OME
Behavior	NNP	o	OME
Checklist-Community-measured	NNP	o	OME
social	JJ	o	OME
withdrawal	NN	o	OME
and	CC	O	O
Social	NNP	o	OME
Responsiveness	NNP	o	OME
Scale-measured	JJ	o	OME
communication	NN	o	OME
.	.	o	O

Treatment	NNP	O	O
effect	NN	O	O
sizes	NNS	O	O
were	VBD	O	O
more	RBR	O	O
favorable	JJ	O	O
for	IN	O	O
the	DT	O	O
treatment	NN	O	O
group	NN	O	O
compared	VBN	O	O
with	IN	O	O
the	DT	O	O
placebo	NN	i	IC
group	NN	O	O
(	(	O	O
communication	NN	O	O
:	:	O	O
treatment	NN	O	O
groups	NNS	O	O
,	,	O	O
0.87	CD	O	O
vs	NN	O	O
,	,	O	O
placebo	NN	i	IC
,	,	O	O
0.44	CD	O	O
;	:	O	O
social	JJ	O	O
withdrawal	NN	O	O
:	:	O	O
treatment	NN	O	O
groups	NNS	O	O
,	,	O	O
0.88	CD	O	O
,	,	O	O
vs	NN	O	O
placebo	NN	i	IC
,	,	O	O
0.54	CD	O	O
)	)	O	O
.	.	O	O

There	EX	O	O
was	VBD	O	O
a	DT	O	O
significant	JJ	O	O
difference	NN	O	O
in	IN	O	O
the	DT	O	O
change	NN	o	OPH
in	IN	o	OPH
plasma	NN	o	OPH
transferrin	NN	o	OPH
levels	NNS	o	OPH
and	CC	O	O
a	DT	O	O
trend	NN	O	O
toward	IN	O	O
a	DT	O	O
significant	JJ	O	O
difference	NN	O	O
in	IN	O	O
the	DT	O	O
change	NN	O	O
in	IN	O	O
plasma	JJ	o	OPH
superoxide	JJ	o	OPH
dismutase	NN	o	OPH
levels	NNS	o	OPH
between	IN	O	O
the	DT	O	O
2	CD	O	O
groups	NNS	O	O
.	.	O	O

This	DT	O	O
preliminary	JJ	O	O
study	NN	O	O
suggests	VBZ	O	O
that	IN	O	O
supplementation	NN	O	O
with	IN	O	O
larger	JJR	O	O
ARA	NNP	i	IPM
doses	VBZ	i	IPM
added	VBN	i	IPM
to	TO	i	IPM
DHA	NNP	i	IPM
improves	NNS	O	O
impaired	VBD	O	O
social	JJ	o	OPH
interaction	NN	o	OPH
in	IN	O	O
individuals	NNS	p	O
with	IN	p	O
autism	NN	p	O
spectrum	NN	p	O
disorder	NN	p	O
by	IN	O	O
up-regulating	JJ	O	O
signal	JJ	O	O
transduction	NN	O	O
.	.	O	O

Effect	NN	O	O
of	IN	O	O
clinical	JJ	i	IE
pharmacy	NN	i	IE
services	NNS	i	IE
on	IN	O	O
the	DT	O	O
blood	NN	o	OPH
pressure	NN	o	OPH
of	IN	O	O
African-American	JJ	p	O
renal	JJ	p	PC
transplant	NN	p	PC
patients	NNS	p	O
.	.	p	O

OBJECTIVE	IN	O	O
The	DT	O	O
objective	NN	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
determine	VB	O	O
if	IN	O	O
African-American	JJ	p	O
renal	JJ	p	O
transplant	NN	p	O
patients	NNS	p	O
who	WP	O	O
received	VBD	O	O
direct	JJ	O	O
patient	NN	O	O
care	NN	O	O
from	IN	O	O
a	DT	O	O
clinical	JJ	i	IE
pharmacist	NN	i	IE
had	VBD	O	O
better	RBR	O	O
blood	NN	o	OPH
pressure	NN	o	OPH
control	NN	o	OPH
compared	VBN	O	O
to	TO	O	O
African-American	JJ	p	O
renal	JJ	p	O
transplant	NN	p	O
patients	NNS	p	O
who	WP	p	O
did	VBD	p	O
not	RB	p	O
have	VB	p	O
clinical	JJ	p	O
pharmacy	NN	p	O
services	NNS	p	O
.	.	p	O

METHODS	NNP	O	O
Renal	NNP	p	PSS
transplant	NN	p	PSS
patients	NNS	p	PSS
were	VBD	O	O
prospectively	RB	O	O
randomized	VBN	O	O
into	IN	O	O
an	DT	O	O
intervention	NN	O	O
group	NN	O	O
or	CC	O	O
a	DT	O	O
control	NN	O	O
group	NN	O	O
.	.	O	O

Patients	NNS	O	O
in	IN	O	O
the	DT	O	O
intervention	NN	O	O
group	NN	O	O
received	VBD	i	IE
clinical	JJ	i	IE
pharmacy	NN	i	IE
services	NNS	i	IE
that	WDT	i	IE
included	VBD	i	IE
a	DT	i	IE
clinical	JJ	i	IE
pharmacist	NN	i	IE
performing	VBG	i	IE
patient	JJ	i	IE
medication	NN	i	IE
reviews	NNS	i	IE
,	,	i	IE
with	IN	i	IE
emphasis	NN	i	IE
on	IN	i	IE
preventing	VBG	i	IE
or	CC	i	IE
resolving	VBG	i	IE
medication-related	JJ	i	IE
problems	NNS	i	IE
and	CC	i	IE
providing	VBG	i	IE
medication	NN	i	IE
recommendations	NNS	i	IE
.	.	i	IE

Patients	NNS	O	O
in	IN	O	O
the	DT	O	O
control	NN	O	O
group	NN	O	O
received	VBD	i	IE
routine	JJ	i	IC
clinic	NN	i	IC
services	NNS	i	IC
,	,	i	IE
but	CC	i	IE
had	VBD	i	IE
no	DT	i	IC
clinical	JJ	i	IC
pharmacist	NN	i	IC
interaction	NN	i	IC
.	.	i	IE

Analysis	NN	O	O
was	VBD	O	O
performed	VBN	O	O
to	TO	O	O
detect	VB	O	O
differences	NNS	O	O
between	IN	O	O
the	DT	O	O
intervention	NN	O	O
and	CC	O	O
control	NN	O	O
groups	NNS	O	O
in	IN	O	O
baseline	NN	o	OPH
and	CC	o	OPH
quarterly	JJ	o	OPH
systolic	JJ	o	OPH
blood	NN	o	OPH
pressure	NN	o	OPH
(	(	o	OPH
SBP	NNP	o	OPH
)	)	o	OPH
and	CC	o	O
diastolic	JJ	o	OPH
blood	NN	o	OPH
pressure	NN	o	OPH
(	(	o	OPH
DBP	NNP	o	OPH
)	)	o	OPH
for	IN	O	O
one	CD	O	O
year	NN	O	O
post-study	NN	O	O
enrollment	NN	O	O
.	.	O	O

RESULTS	CC	O	O
There	EX	O	O
were	VBD	O	O
no	DT	O	O
differences	NNS	O	O
between	IN	O	O
the	DT	O	O
intervention	NN	O	O
(	(	p	O
N	NNP	p	O
=	NNP	p	O
13	CD	p	PSS
)	)	p	O
and	CC	O	O
control	NN	O	O
(	(	p	O
N	NNP	p	O
=	NNP	p	O
10	CD	p	PSS
)	)	p	O
groups	NNS	O	O
in	IN	O	O
baseline	NN	O	O
blood	NN	o	OPH
pressures	NNS	o	OPH
or	CC	O	O
in	IN	O	O
the	DT	O	O
percentage	NN	O	O
of	IN	O	O
hypertensive	JJ	O	O
patients	NNS	O	O
.	.	O	O

Significant	JJ	O	O
differences	NNS	O	O
in	IN	O	O
the	DT	O	O
change	NN	O	O
in	IN	O	O
SBP	NNP	o	OPH
and	CC	o	O
DBP	NNP	o	OPH
from	IN	O	O
baseline	NN	O	O
between	IN	O	O
the	DT	O	O
intervention	NN	O	O
and	CC	O	O
control	NN	O	O
groups	NNS	O	O
were	VBD	O	O
observed	VBN	O	O
at	IN	O	O
the	DT	O	O
second	JJ	O	O
,	,	O	O
third	JJ	O	O
,	,	O	O
and	CC	O	O
fourth	JJ	O	O
quarters	NNS	O	O
of	IN	O	O
the	DT	O	O
study	NN	O	O
,	,	O	O
favoring	VBG	O	O
the	DT	O	O
intervention	NN	O	O
group	NN	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
.01	NNP	O	O
)	)	O	O
.	.	O	O

Mean	NNP	o	OPH
SBP	NNP	o	OPH
was	VBD	O	O
significantly	RB	O	O
lower	JJR	O	O
in	IN	O	O
the	DT	O	O
intervention	NN	O	O
group	NN	O	O
at	IN	O	O
the	DT	O	O
second	JJ	O	O
(	(	O	O
137.8	CD	O	O
+/-	JJ	O	O
15.0	CD	O	O
vs	JJ	O	O
168.9	CD	O	O
+/-	JJ	O	O
15.3	CD	O	O
)	)	O	O
,	,	O	O
third	JJ	O	O
(	(	O	O
135.9	CD	O	O
+/-	JJ	O	O
11.7	CD	O	O
vs	JJ	O	O
164.6	CD	O	O
+/-	JJ	O	O
20.1	CD	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
fourth	JJ	O	O
(	(	O	O
145.3	CD	O	O
+/-	JJ	O	O
16.8	CD	O	O
vs	JJ	O	O
175.8	CD	O	O
+/-	JJ	O	O
33.9	CD	O	O
)	)	O	O
quarters	NNS	O	O
of	IN	O	O
the	DT	O	O
study	NN	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
.05	NNP	O	O
)	)	O	O
.	.	O	O

Mean	NNP	o	OPH
DBP	NNP	o	OPH
was	VBD	O	O
significantly	RB	O	O
lower	JJR	O	O
in	IN	O	O
the	DT	O	O
intervention	NN	O	O
group	NN	O	O
at	IN	O	O
the	DT	O	O
second	JJ	O	O
(	(	O	O
76.0	CD	O	O
+/-	JJ	O	O
11.8	CD	O	O
vs	JJ	O	O
84.9	CD	O	O
+/-	JJ	O	O
6.1	CD	O	O
)	)	O	O
and	CC	O	O
fourth	JJ	O	O
(	(	O	O
77.0	CD	O	O
+/-	JJ	O	O
10.2	CD	O	O
vs	JJ	O	O
91.8	CD	O	O
+/-	JJ	O	O
12.0	CD	O	O
)	)	O	O
quarters	NNS	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
.05	NNP	O	O
)	)	O	O
.	.	O	O

CONCLUSION	NNP	O	O
Direct	NNP	O	O
patient	NN	O	O
care	NN	O	O
services	NNS	O	O
provided	VBN	O	O
by	IN	O	O
a	DT	O	O
clinical	JJ	O	O
pharmacist	NN	O	O
,	,	O	O
in	IN	O	O
addition	NN	O	O
to	TO	O	O
routine	VB	O	O
clinical	JJ	O	O
services	NNS	O	O
,	,	O	O
have	VBP	O	O
a	DT	O	O
positive	JJ	O	O
effect	NN	O	O
on	IN	O	O
the	DT	O	O
blood	NN	o	OPH
pressure	NN	o	OPH
of	IN	O	O
African-American	JJ	p	O
renal	JJ	p	O
transplant	NN	p	O
patients	NNS	p	O
.	.	p	O

A	DT	O	O
multidisciplinary	JJ	O	O
team	NN	O	O
that	WDT	O	O
includes	VBZ	O	O
a	DT	O	O
clinical	JJ	O	O
pharmacist	NN	O	O
is	VBZ	O	O
beneficial	JJ	O	O
to	TO	O	O
patient	VB	O	O
care	NN	O	O
.	.	O	O

Granulocyte-colony	JJ	i	IPM
stimulating	NN	i	IPM
factor	NN	i	IPM
for	IN	O	O
mobilizing	VBG	O	O
bone	NN	O	O
marrow	NN	O	O
stem	NN	O	O
cells	NNS	O	O
in	IN	O	O
subacute	JJ	O	O
stroke	NN	O	O
:	:	O	O
the	DT	O	O
stem	NN	i	IPH
cell	VBP	i	IPH
trial	NN	O	O
of	IN	O	O
recovery	NN	p	O
enhancement	NN	p	O
after	IN	p	O
stroke	VBD	p	PC
2	CD	p	O
randomized	VBN	O	O
controlled	VBN	O	O
trial	NN	O	O
.	.	O	O

BACKGROUND	NNP	O	O
AND	CC	O	O
PURPOSE	NNP	O	O
Granulocyte-colony	NNP	i	IPM
stimulating	VBG	i	IPM
factor	NN	i	IPM
(	(	i	IPM
G-CSF	NNP	i	IPM
)	)	i	IPM
is	VBZ	O	O
neuroprotective	JJ	O	O
in	IN	O	O
experimental	JJ	O	O
stroke	NN	O	O
and	CC	O	O
mobilizes	VBZ	O	O
CD34	NNP	O	O
(	(	O	O
+	NNP	O	O
)	)	O	O
peripheral	JJ	O	O
blood	NN	O	O
stem	NN	O	O
cells	NNS	O	O
into	IN	O	O
the	DT	O	O
circulation	NN	O	O
.	.	O	O

We	PRP	O	O
assessed	VBD	O	O
the	DT	O	O
safety	NN	O	O
of	IN	O	O
G-CSF	NNP	i	IPM
in	IN	O	O
recent	JJ	O	O
stroke	NN	O	O
in	IN	O	O
a	DT	O	O
phase	NN	O	O
IIb	NNP	O	O
single-center	NN	O	O
randomized	NN	O	O
,	,	O	O
controlled	VBN	O	O
trial	NN	O	O
.	.	O	O

METHODS	NNP	O	O
G-CSF	NNP	i	O
(	(	i	O
10	CD	i	O
?g/kg	NN	i	O
)	)	i	O
or	CC	i	O
placebo	NN	i	O
(	(	O	O
ratio	VB	O	O
2:1	CD	O	O
)	)	O	O
was	VBD	O	O
given	VBN	i	O
SC	NNP	i	O
for	IN	O	O
5	CD	O	O
days	NNS	O	O
to	TO	p	O
60	CD	p	O
patients	NNS	p	O
3	CD	p	O
to	TO	p	O
30	CD	p	O
days	NNS	p	O
after	IN	p	O
ischemic	JJ	p	O
or	CC	p	O
hemorrhagic	JJ	p	O
stroke	NN	p	O
.	.	p	O

The	DT	O	O
primary	JJ	O	O
outcome	NN	O	O
was	VBD	O	O
the	DT	o	O
frequency	NN	o	O
of	IN	o	O
serious	JJ	o	O
adverse	JJ	o	O
events	NNS	o	O
.	.	o	O

Peripheral	NNP	o	O
blood	NN	o	O
counts	NNS	o	O
,	,	o	O
CD34	NNP	o	O
(	(	o	O
+	NNP	o	O
)	)	o	O
count	NN	o	O
,	,	o	O
and	CC	o	O
functional	JJ	o	O
outcome	NN	o	O
were	VBD	O	O
measured	VBN	O	O
.	.	O	O

MRI	NNP	O	O
assessed	VBD	o	O
lesion	NN	o	O
volume	NN	o	O
,	,	o	O
atrophy	NN	o	O
,	,	o	O
and	CC	o	O
the	DT	o	O
presence	NN	o	O
of	IN	o	O
iron-labeled	JJ	o	O
CD34	NNP	o	O
(	(	o	O
+	NNP	o	O
)	)	o	O
cells	NNS	o	O
reinjected	VBN	O	O
on	IN	O	O
day	NN	O	O
6	CD	O	O
.	.	O	O

RESULTS	NNP	p	O
Sixty	NNP	p	O
patients	NNS	p	O
were	VBD	p	O
recruited	VBN	p	O
at	IN	o	O
mean	NN	o	O
of	IN	o	O
8	CD	o	O
days	NNS	o	O
(	(	p	O
SD	NNP	p	O
?	.	p	O
5	CD	p	O
)	)	p	O
post	NN	p	O
ictus	NN	p	O
,	,	p	O
with	IN	p	O
mean	JJ	p	O
age	NN	p	O
71	CD	p	O
years	NNS	p	O
(	(	p	O
?	.	p	O
12	CD	p	O
years	NNS	p	O
)	)	p	O
and	CC	p	O
53	CD	p	O
%	NN	p	O
men	NNS	p	O
.	.	p	O

The	DT	p	O
groups	NNS	O	O
were	VBD	O	O
well	RB	O	O
matched	VBN	O	O
for	IN	O	O
baseline	JJ	O	O
minimization/prognostic	JJ	O	O
factors	NNS	O	O
.	.	O	O

There	EX	O	O
were	VBD	p	O
no	DT	p	O
significant	JJ	p	O
differences	NNS	p	O
between	IN	p	O
groups	NNS	p	O
in	IN	p	O
the	DT	O	O
number	NN	O	O
of	IN	O	O
participants	NNS	O	O
with	IN	o	O
serious	JJ	o	O
adverse	JJ	o	O
events	NNS	o	O
:	:	o	O
G-CSF	JJ	o	O
15	CD	o	O
(	(	O	O
37.5	CD	O	O
%	NN	O	O
)	)	O	O
of	IN	O	O
40	CD	O	O
versus	NN	i	O
placebo	NN	i	IC
7	CD	i	O
(	(	O	O
35	CD	O	O
%	NN	O	O
)	)	O	O
of	IN	O	O
20	CD	O	O
,	,	O	O
death	NN	o	O
or	CC	o	O
dependency	NN	o	O
(	(	o	O
modified	JJ	o	O
Rankin	NNP	O	O
Score	NN	O	O
:	:	O	O
G-CSF	JJ	O	O
3.3	CD	O	O
?	.	O	O
1.3	CD	O	O
,	,	O	O
placebo	NN	i	O
3.0	CD	i	O
?	.	O	O
1.3	CD	O	O
)	)	O	O
at	IN	O	O
90	CD	O	O
days	NNS	O	O
,	,	O	O
or	CC	O	O
the	DT	o	O
number	NN	o	O
of	IN	o	O
injections	NNS	o	O
received	VBN	o	O
.	.	o	O

G-CSF	NNP	o	O
increased	VBD	o	O
CD34	NNP	o	O
(	(	o	O
+	NNP	o	O
)	)	o	O
and	CC	o	O
total	JJ	o	O
white	JJ	o	O
cell	NN	o	O
counts	NNS	o	O
of	IN	o	O
9.5-	CD	o	O
and	CC	O	O
4.2-fold	JJ	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

There	EX	O	O
was	VBD	O	O
a	DT	O	O
trend	NN	O	O
toward	IN	O	O
reduction	NN	o	O
in	IN	o	O
MRI	NNP	o	O
ischemic	JJ	o	O
lesion	NN	o	O
volume	NN	o	O
with	IN	o	O
respect	NN	O	O
to	TO	O	O
change	VB	O	O
from	IN	O	O
baseline	NN	i	O
in	IN	i	O
G-CSF-treated	JJ	i	O
patients	NNS	i	O
(	(	p	O
P=0.06	NNP	p	O
)	)	O	O
.	.	O	O

In	IN	O	O
1	CD	O	O
participant	NN	O	O
,	,	O	O
there	EX	O	O
was	VBD	O	O
suggestion	NN	O	O
that	IN	O	O
labeled	VBD	o	O
CD34	NNP	o	O
(	(	o	O
+	NNP	o	O
)	)	o	O
cells	NNS	o	O
had	VBD	o	O
migrated	VBN	O	O
to	TO	O	O
the	DT	O	O
ischemic	JJ	O	O
lesion	NN	O	O
.	.	O	O

CONCLUSIONS	VB	O	O
This	DT	O	O
randomized	VBN	O	O
,	,	O	O
double-blind	JJ	O	O
,	,	O	O
placebo-controlled	JJ	O	O
trial	NN	O	O
suggests	VBZ	O	O
that	IN	O	O
G-CSF	NNP	i	O
is	VBZ	i	O
safe	JJ	i	O
when	WRB	O	O
administered	VBN	O	O
subacutely	RB	O	O
.	.	O	O

It	PRP	O	O
is	VBZ	O	O
feasible	JJ	O	O
to	TO	O	O
label	VB	O	O
and	CC	O	O
readminister	VB	O	O
iron-labeled	JJ	O	O
CD34	NNP	O	O
(	(	O	O
+	NNP	O	O
)	)	O	O
cells	NNS	O	O
in	IN	p	O
patients	NNS	p	O
with	IN	p	O
ischemic	JJ	p	O
stroke	NN	p	O
.	.	p	O

CLINICAL	NNP	p	O
TRIAL	NNP	O	O
REGISTRATION	NNP	O	O
URL	NNP	O	O
:	:	O	O
www.controlled-trials.com	NN	O	O
.	.	O	O

Unique	NNP	O	O
identifier	NN	O	O
:	:	O	O
ISRCTN63336619	NNP	O	O
.	.	O	O

Effect	NN	O	O
of	IN	O	O
device-guided	JJ	i	IE
breathing	NN	i	IE
exercises	NNS	i	IE
on	IN	O	O
blood	NN	o	OPH
pressure	NN	o	OPH
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
hypertension	NN	p	PC
:	:	p	O
a	DT	O	O
randomized	NN	O	O
controlled	VBN	O	O
trial	NN	O	O
.	.	O	O

OBJECTIVE	NNP	O	O
Hypertension	NNP	O	O
is	VBZ	O	O
a	DT	O	O
chronic	JJ	O	O
disorder	NN	O	O
with	IN	O	O
a	DT	O	O
high	JJ	O	O
prevalence	NN	O	O
worldwide	NN	O	O
.	.	O	O

Despite	IN	O	O
considerable	JJ	O	O
efforts	NNS	O	O
,	,	O	O
it	PRP	O	O
is	VBZ	O	O
sometimes	RB	O	O
hard	JJ	O	O
to	TO	O	O
reach	VB	O	O
treatment	NN	O	O
goals	NNS	O	O
for	IN	O	O
blood	NN	o	OPH
pressure	NN	o	OPH
(	(	o	OPH
BP	NNP	o	OPH
)	)	o	OPH
with	IN	O	O
classical	JJ	O	O
treatment	NN	O	O
options	NNS	O	O
.	.	O	O

Reducing	VBG	O	O
breathing	VBG	O	O
frequency	NN	O	O
has	VBZ	O	O
been	VBN	O	O
advocated	VBN	O	O
as	IN	O	O
a	DT	O	O
method	NN	O	O
to	TO	O	O
reduce	VB	O	O
BP	NNP	o	OPH
.	.	o	O

METHODS	NNP	O	O
A	NNP	O	O
randomized	JJ	O	O
,	,	O	O
single-blind	JJ	O	O
,	,	O	O
controlled	VBD	O	O
trial	NN	O	O
was	VBD	O	O
conducted	VBN	O	O
in	IN	O	O
30	CD	p	PSS
non-diabetic	JJ	p	PC
patients	NNS	p	PC
with	IN	p	PC
hypertension	NN	p	PC
over	IN	O	O
a	DT	O	O
period	NN	O	O
of	IN	O	O
9	CD	O	O
weeks	NNS	O	O
to	TO	O	O
evaluate	VB	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
a	DT	O	O
device	NN	i	IE
that	WDT	i	IE
helps	VBZ	i	IE
to	TO	i	IE
slow	VB	o	OPH
breathing	NN	o	OPH
(	(	i	IE
Resperate	NNP	i	IE
)	)	i	IE
on	IN	O	O
BP	NNP	o	OPH
and	CC	o	O
quality	NN	o	OPH
of	IN	o	OPH
life	NN	o	OPH
(	(	o	OPH
QoL	NNP	o	OPH
)	)	o	OPH
.	.	o	O

The	DT	O	O
control	NN	O	O
group	NN	O	O
listened	VBD	i	IE
to	TO	i	IE
music	NN	i	IE
and	CC	i	IE
used	VBN	i	IE
no	DT	i	IE
other	JJ	i	IE
therapeutic	JJ	i	IE
device	NN	i	IE
.	.	i	O

RESULTS	NNP	O	O
There	EX	O	O
was	VBD	O	O
no	DT	O	O
significant	JJ	O	O
difference	NN	O	O
in	IN	O	O
change	NN	O	O
in	IN	O	O
BP	NNP	o	OPH
between	IN	O	O
intervention	NN	O	O
and	CC	O	O
control	NN	O	O
;	:	O	O
BP	NNP	o	OPH
-4.2	NNP	O	O
mmHg	NN	O	O
(	(	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
-12.4	NNP	O	O
to	TO	O	O
3.9	CD	O	O
)	)	O	O
/-2.6	NN	O	O
mmHg	NN	O	O
(	(	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
-8.4	NNP	O	O
to	TO	O	O
3.3	CD	O	O
)	)	O	O
.	.	O	O

This	DT	O	O
result	NN	O	O
did	VBD	O	O
not	RB	O	O
alter	VB	O	O
in	IN	O	O
post	NN	O	O
hoc	NN	O	O
analyses	NNS	O	O
,	,	O	O
when	WRB	O	O
patients	NNS	O	O
not	RB	O	O
achieving	VBG	O	O
target	NN	o	OPH
breathing	NN	o	OPH
frequency	NN	o	OPH
(	(	O	O
<	JJ	O	O
10	CD	O	O
breaths/min	NN	O	O
)	)	O	O
or	CC	O	O
non-compliant	JJ	O	O
patients	NNS	O	O
were	VBD	O	O
excluded	VBN	O	O
.	.	O	O

QoL	NNP	o	OPH
did	VBD	O	O
not	RB	O	O
change	VB	O	O
over	IN	O	O
time	NN	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
We	PRP	O	O
found	VBD	O	O
no	DT	O	O
effect	NN	O	O
of	IN	O	O
the	DT	O	O
Resperate	NNP	O	O
on	IN	O	O
BP	NNP	o	OPH
or	CC	O	O
QoL	NNP	o	OPH
compared	VBN	O	O
with	IN	O	O
the	DT	O	O
control	NN	O	O
group	NN	O	O
.	.	O	O

We	PRP	O	O
conclude	VBP	O	O
that	IN	O	O
,	,	O	O
at	IN	O	O
this	DT	O	O
moment	NN	O	O
,	,	O	O
this	DT	O	O
device	NN	O	O
has	VBZ	O	O
no	DT	O	O
added	VBN	O	O
value	NN	O	O
in	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
hypertension	NN	O	O
.	.	O	O

Management	NN	O	O
of	IN	O	O
unstable	JJ	p	PC
angina	NN	p	PC
at	IN	p	O
rest	NN	p	O
by	IN	O	O
verapamil	NN	i	IPM
.	.	i	O

A	DT	O	O
double-blind	JJ	O	O
cross-over	NN	O	O
study	NN	O	O
in	IN	O	O
coronary	JJ	O	O
care	NN	O	O
unit	NN	O	O
.	.	O	O

A	NNP	O	O
therapeutic	JJ	O	O
trial	NN	O	O
with	IN	O	O
verapamil	NN	i	IPM
,	,	O	O
a	DT	O	O
calcium-antagonist	JJ	i	IPM
drug	NN	i	IPM
,	,	O	O
was	VBD	O	O
performed	VBN	O	O
in	IN	O	O
12	CD	p	PSS
patients	NNS	p	PSS
admitted	VBN	p	O
to	TO	p	O
our	PRP$	p	O
coronary	JJ	p	O
care	NN	p	O
unit	NN	p	O
because	IN	p	O
of	IN	p	O
frequent	JJ	p	O
daily	JJ	p	O
attacks	NNS	p	O
of	IN	p	O
angina	NN	p	PC
at	IN	p	O
rest	NN	p	O
attributed	VBN	p	O
to	TO	p	O
coronary	JJ	p	PC
vasospasm	NN	p	PC
.	.	p	O

After	IN	O	O
a	DT	O	O
48-hour	JJ	O	O
run-in	JJ	O	O
period	NN	O	O
,	,	O	O
oral	JJ	i	IPM
verapamil	NN	i	IPM
480	CD	i	IPM
mg/day	NN	i	IPM
and	CC	i	O
placebo	NN	i	IC
were	VBD	O	O
administered	VBN	O	O
alternately	RB	O	O
during	IN	O	O
4	CD	O	O
randomised	VBD	O	O
48-hour	CD	O	O
periods	NNS	O	O
.	.	O	O

Transient	NNP	o	OPH
ischaemic	JJ	o	OPH
attacks	NNS	o	OPH
with	IN	o	OPH
ST	NNP	o	OPH
segment	NN	o	OPH
elevation	NN	o	OPH
or	CC	o	OPH
depression	NN	o	OPH
,	,	o	OPH
with	IN	o	OPH
or	CC	o	OPH
without	IN	o	OPH
pain	NN	o	OPH
,	,	O	O
were	VBD	O	O
documented	VBN	O	O
by	IN	O	O
continuous	JJ	o	OOt
electrocardiographic	JJ	o	OOt
monitoring	NN	o	OOt
.	.	o	O

The	DT	O	O
number	NN	o	OPH
of	IN	o	OPH
attacks	NNS	o	OPH
during	IN	O	O
the	DT	O	O
run-in	JJ	O	O
and	CC	O	O
2	CD	O	O
placebo	NN	i	IC
periods	NNS	O	O
were	VBD	O	O
128	CD	O	O
,	,	O	O
123	CD	O	O
,	,	O	O
and	CC	O	O
130	CD	O	O
,	,	O	O
respectively	RB	O	O
,	,	O	O
and	CC	O	O
31	CD	O	O
and	CC	O	O
23	CD	O	O
during	IN	O	O
the	DT	O	O
2	CD	O	O
treatment	NN	O	O
periods	NNS	O	O
(	(	O	O
P	NNP	O	O
less	JJR	O	O
than	IN	O	O
0.006	CD	O	O
and	CC	O	O
P	NNP	O	O
less	JJR	O	O
than	IN	O	O
0.003	CD	O	O
)	)	O	O
.	.	O	O

This	DT	O	O
drug	NN	O	O
therefore	RB	O	O
appears	VBZ	O	O
to	TO	O	O
be	VB	O	O
effective	JJ	O	O
in	IN	O	O
the	DT	O	O
management	NN	O	O
of	IN	O	O
patients	NNS	p	O
with	IN	p	O
frequent	JJ	p	O
attacks	NNS	o	OPH
of	IN	o	OPH
angina	NN	o	OPH
at	IN	o	OPH
rest	NN	o	OPH
.	.	o	O

Rate-modulated	JJ	O	O
cardiac	NN	O	O
pacing	NN	O	O
based	VBN	O	O
on	IN	O	O
transthoracic	JJ	O	O
impedance	NN	O	O
measurements	NNS	O	O
of	IN	O	O
minute	JJ	O	O
ventilation	NN	O	O
:	:	O	O
correlation	NN	O	O
with	IN	O	O
exercise	NN	O	O
gas	NN	O	O
exchange	NN	O	O
.	.	O	O

The	DT	O	O
relation	NN	O	O
of	IN	O	O
pacing	VBG	O	O
rate	NN	O	O
to	TO	O	O
physiologic	VB	O	O
variables	NNS	O	O
of	IN	O	O
metabolic	JJ	O	O
demand	NN	O	O
was	VBD	O	O
examined	VBN	O	O
in	IN	O	O
10	CD	p	PSS
consecutive	JJ	p	O
patients	NNS	p	O
with	IN	p	O
a	DT	p	O
minute	NN	p	O
ventilation-sensing	NN	p	O
,	,	p	O
rate-modulating	JJ	p	O
ventricular	JJ	p	O
pacemaker	NN	p	O
implanted	VBN	p	O
for	IN	p	O
complete	JJ	p	O
heart	NN	p	O
block	NN	p	O
.	.	p	O

All	DT	p	O
patients	NNS	p	O
had	VBD	p	O
paroxysmal	JJ	p	PC
(	(	p	O
seven	CD	p	PSS
patients	NNS	p	O
)	)	p	O
or	CC	p	O
chronic	JJ	p	O
(	(	p	O
three	CD	p	PSS
patients	NNS	p	O
)	)	p	O
atrial	JJ	p	PC
fibrillation	NN	p	PC
and	CC	p	O
were	VBD	p	O
referred	VBN	p	O
for	IN	p	O
catheter	JJR	i	IS
ablation	NN	i	IS
of	IN	i	IS
the	DT	i	IS
atrioventricular	JJ	i	IS
junction	NN	i	IS
.	.	i	O

Treadmill	NNP	i	IPH
exercise	NN	i	IPH
testing	VBG	i	IPH
with	IN	O	O
measurement	NN	O	O
of	IN	O	O
expired	NNP	o	OPH
gas	NN	o	OPH
exchange	NN	o	OPH
and	CC	o	OPH
respiratory	NN	o	OPH
flow	NN	o	OPH
was	VBD	O	O
performed	VBN	O	O
before	IN	O	O
ablation	NN	O	O
and	CC	O	O
4	CD	O	O
weeks	NNS	O	O
after	IN	O	O
pacemaker	NN	O	O
implantation	NN	O	O
,	,	O	O
with	IN	O	O
the	DT	O	O
pacemaker	NN	O	O
programmed	VBD	O	O
to	TO	O	O
both	DT	O	O
the	DT	O	O
fixed-rate	JJ	O	O
VVI	NNP	O	O
and	CC	O	O
rate-modulating	JJ	O	O
minute	NN	O	O
ventilation	NN	O	O
VVIR	NNP	O	O
pacing	VBG	O	O
modes	NNS	O	O
in	IN	O	O
random	JJ	O	O
sequence	NN	O	O
.	.	O	O

The	DT	O	O
relation	NN	o	OPH
of	IN	o	OPH
pacing	VBG	o	OPH
rate	NN	o	OPH
to	TO	o	OPH
oxygen	VB	o	OPH
consumption	NN	o	OPH
(	(	o	OPH
VO2	NNP	o	OPH
)	)	o	OPH
,	,	o	O
expired	VBD	o	OPH
carbon	NN	o	OPH
dioxide	NN	o	OPH
concentration	NN	o	OPH
(	(	o	OPH
VCO2	NNP	o	OPH
)	)	o	OPH
,	,	o	O
respiratory	JJ	o	OPH
quotient	NN	o	OPH
,	,	o	O
tidal	JJ	o	OPH
volume	NN	o	OPH
,	,	o	O
respiratory	NN	o	OPH
rate	NN	o	OPH
and	CC	o	OPH
minute	NN	o	OPH
ventilation	NN	o	OPH
was	VBD	O	O
determined	VBN	O	O
during	IN	O	O
exercise	NN	O	O
in	IN	O	O
the	DT	O	O
rate-modulating	JJ	O	O
minute	NN	O	O
ventilation	NN	O	O
pacing	VBG	O	O
mode	NN	O	O
.	.	O	O

Pacing	VBG	o	OPH
rate	NN	o	OPH
was	VBD	O	O
highly	RB	O	O
correlated	VBN	O	O
with	IN	O	O
minute	JJ	o	OOt
ventilation	NN	o	OOt
(	(	O	O
r	JJ	O	O
=	NNP	O	O
0.89	CD	O	O
)	)	O	O
,	,	O	O
respiratory	JJ	o	OPH
quotient	NN	o	OPH
(	(	O	O
r	JJ	O	O
=	NNP	O	O
0.89	CD	O	O
)	)	O	O
,	,	O	O
VCO2	NNP	o	OPH
(	(	O	O
r	VB	O	O
=	RB	O	O
0.87	CD	O	O
)	)	O	O
,	,	O	O
tidal	JJ	o	OPH
volume	NN	o	OPH
(	(	O	O
r	JJ	O	O
=	NNP	O	O
0.87	CD	O	O
)	)	O	O
,	,	O	O
VO2	NNP	o	OPH
(	(	O	O
r	VB	O	O
=	RB	O	O
0.84	CD	O	O
)	)	O	O
and	CC	O	O
respiratory	JJ	o	OPH
rate	NN	o	OPH
(	(	O	O
r	NN	O	O
=	RB	O	O
0.84	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
mean	JJ	o	OPH
exercise	NN	o	OPH
duration	NN	o	OPH
increased	VBD	O	O
from	IN	O	O
8.3	CD	O	O
+/-	JJ	O	O
2.8	CD	O	O
min	NN	O	O
in	IN	O	O
the	DT	O	O
fixed	JJ	O	O
rate	NN	O	O
pacing	VBG	O	O
mode	NN	O	O
to	TO	O	O
10.2	CD	O	O
+/-	JJ	O	O
3.4	CD	O	O
min	NN	O	O
in	IN	O	O
the	DT	O	O
rate-modulating	NN	O	O
,	,	O	O
minute	NN	O	O
ventilation	NN	O	O
mode	NN	O	O
(	(	O	O
p	JJ	O	O
=	NNP	O	O
0.0001	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
maximal	JJ	o	OPH
VO2	NNP	o	OPH
increased	VBD	O	O
from	IN	O	O
13.4	CD	O	O
+/-	JJ	O	O
3.4	CD	O	O
to	TO	O	O
16.3	CD	O	O
+/-	JJ	O	O
4.1	CD	O	O
cc/kg	NN	O	O
per	IN	O	O
min	NN	O	O
(	(	O	O
p	JJ	O	O
=	NNP	O	O
0.0004	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
maximal	JJ	O	O
heart	NN	O	O
rate	NN	O	O
achieved	VBN	O	O
in	IN	O	O
the	DT	O	O
minute	NN	O	O
ventilation	NN	O	O
pacing	VBG	O	O
mode	NN	O	O
was	VBD	O	O
136	CD	O	O
+/-	JJ	O	O
9.7	CD	O	O
beats/min	NN	O	O
,	,	O	O
similar	JJ	O	O
to	TO	O	O
that	DT	O	O
observed	VBN	O	O
in	IN	O	O
the	DT	O	O
patient	NN	O	O
's	POS	O	O
intrinsic	JJ	O	O
cardiac	JJ	O	O
rhythm	NN	O	O
before	IN	O	O
ablation	NN	O	O
(	(	O	O
134.9	CD	O	O
+/-	JJ	O	O
30.1	CD	O	O
beats/min	NN	O	O
,	,	O	O
p	NN	O	O
=	NNP	O	O
NS	NNP	O	O
)	)	O	O
.	.	O	O

(	(	O	O
ABSTRACT	NNP	O	O
TRUNCATED	NNP	O	O
AT	NNP	O	O
250	CD	O	O
WORDS	NNP	O	O
)	)	O	O
Supporting	VBG	O	O
families	NNS	p	O
in	IN	p	O
challenging	VBG	p	O
contexts	NN	p	O
:	:	p	O
the	DT	O	O
CAPEDP	NNP	O	O
project	NN	O	O
.	.	O	O

Although	IN	O	O
France	NNP	p	O
has	VBZ	O	O
one	CD	O	O
of	IN	O	O
the	DT	O	O
most	RBS	O	O
generous	JJ	O	O
health	NN	O	O
and	CC	O	O
social	JJ	O	O
care	NN	O	O
systems	NNS	O	O
for	IN	O	O
infant	NN	O	O
and	CC	O	O
maternal	JJ	O	O
well-being	NN	O	O
in	IN	O	O
the	DT	O	O
Western	JJ	O	O
world	NN	O	O
,	,	O	O
professionals	NNS	O	O
have	VBP	O	O
been	VBN	O	O
increasingly	RB	O	O
concerned	VBN	O	O
by	IN	O	O
the	DT	O	O
rising	VBG	O	O
number	NN	O	O
of	IN	O	O
children	NNS	p	O
being	VBG	p	O
referred	VBN	p	O
for	IN	p	O
mental	JJ	p	O
health	NN	p	O
problems	NNS	p	O
.	.	p	O

The	DT	O	O
present	JJ	O	O
article	NN	O	O
describes	VBZ	O	O
the	DT	O	O
first	JJ	O	O
home-visiting	JJ	i	IE
program	NN	i	IE
in	IN	O	O
France	NNP	O	O
to	TO	O	O
specifically	RB	O	O
target	VB	O	O
mental	JJ	O	O
health	NN	O	O
questions	NNS	O	O
in	IN	O	O
families	NNS	p	O
living	VBG	p	O
in	IN	p	O
vulnerable	JJ	p	O
contexts	NN	p	O
.	.	p	O

The	DT	O	O
CAPEDP	NNP	O	O
project	NN	O	O
,	,	O	O
involving	VBG	O	O
440	CD	p	O
women	NNS	p	O
and	CC	p	O
their	PRP$	p	O
families	NNS	p	O
,	,	p	O
took	VBD	p	O
place	NN	p	O
in	IN	p	O
Paris	NNP	p	O
and	CC	p	O
its	PRP$	p	O
inner	JJ	p	O
suburbs	NNS	p	O
from	IN	p	O
2006	CD	p	O
to	TO	p	O
2011	CD	p	O
.	.	p	O

To	TO	p	O
be	VB	p	O
eligible	JJ	p	O
for	IN	p	O
inclusion	NN	p	O
,	,	p	O
women	NNS	p	O
had	VBD	p	O
to	TO	p	O
be	VB	p	O
(	(	p	O
i	NN	p	O
)	)	p	O
under	IN	p	O
26	CD	p	O
years	NNS	p	O
old	JJ	p	O
,	,	p	O
(	(	p	O
ii	NN	p	O
)	)	p	O
less	JJR	p	O
that	IN	p	O
27	CD	p	O
weeks	NNS	p	O
pregnant	JJ	p	O
,	,	p	O
(	(	p	O
iii	NN	p	O
)	)	p	O
sufficiently	RB	p	O
fluent	VBN	p	O
in	IN	p	O
French	JJ	p	O
to	TO	p	O
give	VB	p	O
truly	NN	p	O
informed	JJ	p	O
consent	NN	p	O
to	TO	p	O
participate	VB	p	O
in	IN	p	O
the	DT	p	O
study	NN	p	O
and	CC	p	O
benefit	NN	p	O
from	IN	p	O
the	DT	p	O
intervention	NN	p	O
and	CC	p	O
(	(	p	O
iv	NN	p	O
)	)	p	O
presenting	VBG	p	O
with	IN	p	O
one	CD	p	O
or	CC	p	O
more	JJR	p	O
of	IN	p	O
the	DT	p	O
following	JJ	p	O
social	JJ	p	O
vulnerability	NN	p	O
factors	NNS	p	O
:	:	p	O
low	JJ	p	O
income	NN	p	O
,	,	p	O
low	JJ	p	O
educational	JJ	p	O
level	NN	p	O
,	,	p	O
and/or	RB	p	O
intending	VBG	p	O
to	TO	p	O
bring	VB	p	O
up	RP	p	O
the	DT	p	O
child	NN	p	O
without	IN	p	O
the	DT	p	O
child	NN	p	O
's	POS	p	O
father	NN	p	O
.	.	p	O

The	DT	i	IE
intervention	NN	i	IE
consisted	VBD	i	IE
of	IN	i	IE
44	CD	i	IE
home	NN	i	IE
visits	NNS	i	IE
from	IN	i	IE
the	DT	i	IE
third	JJ	i	IE
trimester	NN	i	IE
of	IN	i	IE
pregnancy	NN	i	IE
through	IN	i	IE
to	TO	i	IE
the	DT	i	IE
child	NN	i	IE
's	POS	i	IE
second	JJ	i	IE
birthday	NN	i	IE
.	.	i	O

The	DT	O	O
aim	NN	O	O
of	IN	O	O
the	DT	O	O
intervention	NN	O	O
was	VBD	O	O
to	TO	O	O
promote	VB	O	O
infant	JJ	o	OME
mental	JJ	o	OME
health	NN	o	OME
and	CC	O	O
reduce	VB	O	O
the	DT	O	O
incidence	NN	o	OME
of	IN	o	OME
infant	JJ	o	OME
mental	JJ	o	OME
health	NN	o	OME
problems	NNS	o	OME
at	IN	O	O
the	DT	O	O
age	NN	O	O
of	IN	O	O
two	CD	O	O
years	NNS	O	O
.	.	O	O

The	DT	O	O
intervention	NN	O	O
paid	VBD	O	O
particular	JJ	O	O
attention	NN	O	O
to	TO	O	O
postnatal	JJ	O	O
maternal	JJ	O	O
depression	NN	O	O
and	CC	O	O
promoting	VBG	O	O
parenting	VBG	O	O
skills	NNS	O	O
and	CC	O	O
attachment	JJ	O	O
security	NN	O	O
,	,	O	O
particularly	RB	O	O
through	IN	O	O
the	DT	O	O
use	NN	i	IE
of	IN	i	IE
video	NN	i	IE
during	IN	i	IE
home-visits	NNS	i	IE
.	.	i	O

A	DT	O	O
major	JJ	O	O
issue	NN	O	O
was	VBD	O	O
that	IN	O	O
of	IN	O	O
adapting	VBG	O	O
international	JJ	O	O
best	JJS	O	O
practice	NN	O	O
recommendations	NNS	O	O
with	IN	O	O
regard	NN	O	O
to	TO	O	O
home-visiting	JJ	O	O
programs	NNS	O	O
to	TO	O	O
the	DT	O	O
particularities	NNS	O	O
of	IN	O	O
the	DT	O	O
existing	VBG	O	O
French	JJ	O	O
social	JJ	O	O
and	CC	O	O
health	NN	O	O
care	NN	O	O
system	NN	O	O
.	.	O	O

An	DT	O	O
original	JJ	O	O
aspect	NN	O	O
of	IN	O	O
the	DT	O	O
intervention	NN	O	O
was	VBD	O	O
to	TO	O	O
use	VB	O	O
trained	JJ	O	O
clinical	JJ	O	O
psychologists	NNS	O	O
to	TO	O	O
conduct	VB	O	O
all	DT	O	O
home	NN	O	O
visits	NNS	O	O
.	.	O	O

The	DT	O	O
Social	NNP	i	IE
Communication	NNP	i	IE
Assessment	NNP	i	IE
for	IN	i	IE
Toddlers	NNP	i	IE
with	IN	i	IE
Autism	NNP	i	IE
(	(	i	IE
SCATA	NNP	i	IE
)	)	i	IE
:	:	i	O
an	DT	O	O
instrument	NN	O	O
to	TO	O	O
measure	VB	O	O
the	DT	O	O
frequency	NN	o	OOt
,	,	O	O
form	NN	O	O
and	CC	O	O
function	NN	o	OME
of	IN	o	OME
communication	NN	o	OME
in	IN	O	O
toddlers	NNS	p	O
with	IN	p	O
autism	NN	p	O
spectrum	NN	p	O
disorder	NN	p	O
.	.	p	O

The	DT	O	O
Social	NNP	i	IE
Communication	NNP	i	IE
Assessment	NNP	i	IE
for	IN	i	IE
Toddlers	NNP	i	IE
with	IN	i	IE
Autism	NNP	i	IE
(	(	i	IE
SCATA	NNP	i	IE
)	)	i	IE
was	VBD	O	O
designed	VBN	O	O
to	TO	O	O
measure	VB	O	O
non-verbal	JJ	o	OME
communication	NN	o	OME
,	,	o	OME
including	VBG	o	OME
early	JJ	o	OME
and	CC	o	OME
atypical	JJ	o	OME
communication	NN	o	OME
,	,	O	O
in	IN	O	O
young	JJ	p	O
children	NNS	p	O
with	IN	p	O
autism	NN	p	O
spectrum	NN	p	O
disorder	NN	p	O
.	.	p	O

Each	DT	O	O
communicative	JJ	O	O
act	NN	O	O
is	VBZ	O	O
scored	VBN	O	O
according	VBG	O	O
to	TO	O	O
its	PRP$	O	O
form	NN	O	O
,	,	O	O
function	NN	O	O
,	,	O	O
role	NN	O	O
and	CC	O	O
complexity	NN	O	O
.	.	O	O

The	DT	O	O
SCATA	NNP	i	IE
was	VBD	O	O
used	VBN	O	O
to	TO	O	O
measure	VB	O	O
communicative	JJ	O	O
ability	NN	O	O
longitudinally	RB	O	O
in	IN	O	O
two	CD	O	O
samples	NNS	O	O
of	IN	O	O
toddlers	NNS	p	O
with	IN	p	O
autism	NN	p	O
spectrum	NN	p	O
disorder	NN	p	O
.	.	p	O

Overall	JJ	o	OME
frequency	NN	o	OME
of	IN	o	OME
non-verbal	JJ	o	OME
communicative	JJ	o	OME
acts	NNS	o	OME
did	VBD	O	O
not	RB	O	O
change	NN	O	O
between	IN	O	O
the	DT	O	O
two	CD	O	O
assessments	NNS	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
the	DT	O	O
form	NN	o	OME
and	CC	o	OME
complexity	NN	o	OME
,	,	o	OME
the	DT	o	OME
function	NN	o	OME
and	CC	o	OME
the	DT	o	OME
role	NN	o	OME
the	DT	O	O
child	NN	O	O
took	VBD	O	O
in	IN	O	O
the	DT	O	O
interaction	NN	O	O
did	VBD	O	O
change	VB	O	O
with	IN	O	O
time	NN	O	O
.	.	O	O

Both	DT	O	O
frequency	NN	o	OME
and	CC	o	OME
function	NN	o	OME
of	IN	o	OME
communicative	JJ	o	OME
acts	NNS	o	OME
in	IN	O	O
toddlerhood	NN	O	O
were	VBD	O	O
positively	RB	O	O
associated	VBN	O	O
with	IN	O	O
later	JJ	o	OME
language	NN	o	OME
ability	NN	o	OME
:	:	o	OME
social	JJ	o	OME
acts	NNS	o	OME
,	,	o	OME
comments	NNS	o	OME
and	CC	o	OME
initiations	NNS	o	OME
showed	VBD	O	O
greater	JJR	O	O
predictive	JJ	O	O
association	NN	O	O
than	IN	O	O
requests	NNS	O	O
and	CC	O	O
responses	NNS	O	O
.	.	O	O

[	JJ	O	O
Comparative	NNP	O	O
effects	NNS	O	O
of	IN	O	O
nebivolol	NN	i	IPM
and	CC	i	O
valsartan	NN	i	IPM
on	IN	O	O
atrial	JJ	o	OPH
electromechanical	JJ	o	OPH
coupling	NN	o	OPH
in	IN	O	O
newly	RB	p	PC
diagnosed	VBN	p	PC
stage	NN	p	PC
1	CD	p	PC
hypertensive	JJ	p	PC
patients	NNS	p	PC
]	VBP	p	PC
.	.	O	O

OBJECTIVES	NNP	O	O
Hypertension	NNP	O	O
is	VBZ	O	O
an	DT	O	O
important	JJ	O	O
cardiovascular	NN	O	O
risk	NN	O	O
factor	NN	O	O
for	IN	O	O
the	DT	O	O
development	NN	O	O
of	IN	O	O
atrial	JJ	o	OPH
fibrillation	NN	o	OPH
(	(	o	OPH
AF	NNP	o	OPH
)	)	o	OPH
.	.	o	OPH

Increased	VBN	O	O
atrial	JJ	O	O
electromechanical	JJ	O	O
coupling	NN	O	O
time	NN	O	O
interval	NN	O	O
measured	VBN	O	O
by	IN	O	O
tissue	NN	O	O
Doppler	NNP	O	O
is	VBZ	O	O
accepted	VBN	O	O
as	IN	O	O
an	DT	O	O
important	JJ	O	O
factor	NN	O	O
for	IN	O	O
prediction	NN	O	O
of	IN	O	O
AF	NNP	o	OPH
development	NN	o	OPH
in	IN	O	O
hypertensive	JJ	p	PC
patients	NNS	p	PC
.	.	p	PC

The	DT	O	O
aim	NN	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
compare	VB	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
valsartan	NN	i	IPM
,	,	O	O
an	DT	O	O
angiotensin	NN	O	O
receptor	NN	O	O
blocker	NN	O	O
,	,	O	O
and	CC	O	O
nebivolol	RB	i	IPM
,	,	O	O
a	DT	O	O
beta-blocker	NN	O	O
,	,	O	O
on	IN	O	O
atrial	JJ	O	O
electromechanical	JJ	O	O
coupling	NN	O	O
in	IN	O	O
newly	RB	p	PC
diagnosed	VBN	p	PC
stage	NN	p	PC
1	CD	p	PC
hypertensive	JJ	p	PC
patients	NNS	p	PC
.	.	p	PC

STUDY	NNP	O	O
DESIGN	NNP	O	O
The	DT	O	O
study	NN	O	O
included	VBD	O	O
60	CD	p	PC
newly	RB	p	PC
diagnosed	VBN	p	PC
stage	NN	p	PC
1	CD	p	PC
hypertensive	JJ	p	PC
patients	NNS	p	PC
with	IN	p	PC
no	DT	p	PC
other	JJ	p	PC
systemic	JJ	p	PC
disease	NN	p	PC
.	.	p	PC

The	DT	O	O
patients	NNS	O	O
were	VBD	O	O
randomized	VBN	O	O
to	TO	O	O
receive	VB	O	O
nebivolol	JJ	i	IPM
5	CD	i	IPM
mg	NN	i	IPM
(	(	O	O
30	CD	O	O
patients	NNS	O	O
;	:	O	O
21	CD	O	O
women	NNS	O	O
,	,	O	O
9	CD	O	O
men	NNS	O	O
;	:	O	O
mean	JJ	O	O
age	NN	O	O
48.4	CD	O	O
?	.	O	O
11.4	CD	O	O
years	NNS	O	O
)	)	O	O
and	CC	i	O
valsartan	$	i	O
160	CD	i	O
mg	NN	i	O
(	(	O	O
30	CD	O	O
patients	NNS	O	O
;	:	O	O
21	CD	O	O
women	NNS	O	O
,	,	O	O
9	CD	O	O
men	NNS	O	O
;	:	O	O
mean	JJ	O	O
age	NN	O	O
49.8	CD	O	O
?	.	O	O
11.3	CD	O	O
years	NNS	O	O
)	)	O	O
.	.	O	O

All	PDT	O	O
the	DT	O	O
patients	NNS	O	O
underwent	JJ	O	O
tissue	NN	O	O
Doppler	NNP	O	O
echocardiographic	JJ	O	O
examination	NN	O	O
before	IN	O	O
and	CC	O	O
three	CD	O	O
months	NNS	O	O
after	IN	O	O
treatment	NN	O	O
to	TO	O	O
compare	VB	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
the	DT	O	O
two	CD	O	O
drugs	NNS	O	O
on	IN	O	O
atrial	JJ	o	O
electromechanical	JJ	o	O
coupling	NN	o	O
.	.	o	O

RESULTS	NNP	o	O
Baseline	NNP	o	O
blood	NN	o	O
pressures	NNS	o	O
,	,	o	O
electrocardiographic	JJ	o	O
and	CC	o	O
echocardiographic	JJ	o	O
findings	NNS	o	O
,	,	o	O
and	CC	o	O
atrial	JJ	o	O
electromechanical	JJ	o	O
coupling	NN	o	O
were	VBD	o	O
similar	JJ	O	O
in	IN	O	O
both	DT	O	O
groups	NNS	O	O
(	(	O	O
p	JJ	O	O
>	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

Both	DT	O	O
drugs	NNS	O	O
significantly	RB	O	O
reduced	VBD	o	O
blood	NN	o	O
pressure	NN	o	O
after	IN	o	O
treatment	NN	O	O
,	,	O	O
with	IN	O	O
similar	JJ	O	O
efficacy	NN	O	O
(	(	O	O
p	JJ	O	O
>	NNP	o	O
0.05	CD	o	O
)	)	o	O
.	.	o	O

Atrial	JJ	o	O
electromechanical	JJ	o	O
coupling	NN	o	O
time	NN	o	O
intervals	NNS	o	O
showed	VBD	o	O
significant	JJ	O	O
decreases	NNS	O	O
in	IN	O	O
both	DT	O	O
groups	NNS	O	O
.	.	O	O

CONCLUSION	NNP	o	O
Prolonged	VBD	o	O
interatrial	JJ	o	O
electromechanical	JJ	o	O
time	NN	o	O
intervals	NNS	o	O
in	IN	o	O
hypertensives	NNS	O	O
are	VBP	O	O
improved	VBN	O	O
with	IN	O	O
antihypertensive	JJ	O	O
treatment	NN	O	O
.	.	O	O

Beta-carotene	NNP	i	IPM
in	IN	O	O
HIV	NNP	p	PC
infection	NN	p	PC
.	.	p	PC

beta-Carotene	NN	i	IPM
has	VBZ	O	O
been	VBN	O	O
reported	VBN	O	O
to	TO	O	O
have	VB	O	O
an	DT	O	O
immunostimulatory	JJ	O	O
effect	NN	O	O
.	.	O	O

Recent	JJ	O	O
studies	NNS	O	O
suggest	VBP	O	O
that	IN	O	O
beta-carotene	JJ	i	IPM
supplementation	NN	i	IPM
can	MD	O	O
increase	VB	O	O
CD4	NNP	o	OPH
counts	NNS	o	OPH
in	IN	O	O
HIV-infected	JJ	p	PC
patients	NNS	p	O
.	.	p	O

Our	PRP$	O	O
double-blind	JJ	O	O
,	,	O	O
placebo-controlled	JJ	i	IC
clinical	JJ	O	O
trial	NN	O	O
was	VBD	O	O
designed	VBN	O	O
to	TO	O	O
test	VB	O	O
the	DT	O	O
efficacy	NN	O	O
of	IN	O	O
beta-carotene	NN	i	IPM
in	IN	O	O
raising	VBG	O	O
CD4	NNP	O	O
counts	NNS	O	O
in	IN	O	O
HIV-infected	JJ	p	PC
patients	NNS	p	O
.	.	p	O

Twenty-one	CD	p	PSS
HIV-seropositive	JJ	p	PC
patients	NNS	p	O
were	VBD	O	O
randomized	VBN	O	O
to	TO	O	O
receive	VB	O	O
either	DT	O	O
beta-carotene	NN	i	IPM
,	,	i	IPM
180	CD	i	IPM
mg/day	NN	i	IPM
or	CC	i	O
placebo	NN	i	IC
for	IN	O	O
4	CD	O	O
weeks	NNS	O	O
,	,	O	O
and	CC	O	O
then	RB	O	O
crossed	VBD	O	O
over	IN	O	O
to	TO	O	O
receive	VB	O	O
the	DT	O	O
alternative	JJ	O	O
treatment	NN	O	O
for	IN	O	O
the	DT	O	O
following	JJ	O	O
4	CD	O	O
weeks	NNS	O	O
.	.	O	O

beta-Carotene	NN	O	O
resulted	VBD	O	O
in	IN	O	O
a	DT	O	O
statistically	RB	O	O
significant	JJ	O	O
increase	NN	O	O
in	IN	O	O
total	JJ	o	OPH
WBC	NNP	o	OPH
count	NN	o	OPH
(	(	O	O
p	JJ	O	O
=	NNP	O	O
0.01	CD	O	O
)	)	O	O
,	,	O	O
%	NN	o	O
change	NN	o	O
in	IN	o	O
CD4	NNP	o	OPH
count	NN	o	OPH
(	(	O	O
p	JJ	O	O
=	NNP	O	O
0.02	CD	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
%	NN	o	O
change	NN	o	O
in	IN	o	O
CD4/CD8	NNP	o	OPH
ratios	NNS	o	OPH
(	(	O	O
p	JJ	O	O
=	NNP	O	O
0.02	CD	O	O
)	)	O	O
compared	VBN	O	O
to	TO	O	O
placebo	VB	O	O
.	.	O	O

The	DT	O	O
absolute	JJ	o	O
CD4	NNP	o	OPH
count	NN	o	OPH
,	,	o	O
absolute	JJ	o	O
CD4/CD8	NNP	o	OPH
ratio	NN	o	OPH
,	,	o	O
and	CC	o	O
total	JJ	o	O
and	CC	o	O
B-lymphocytes	NNP	o	O
all	DT	O	O
increased	VBN	O	O
on	IN	O	O
carotene	NN	O	O
and	CC	O	O
fell	VBD	O	O
during	IN	O	O
placebo	NN	O	O
,	,	O	O
but	CC	O	O
these	DT	O	O
differences	NNS	O	O
did	VBD	O	O
not	RB	O	O
reach	VB	O	O
statistical	JJ	O	O
significance	NN	O	O
.	.	O	O

No	DT	O	O
toxicity	NN	o	OPH
was	VBD	O	O
observed	VBN	O	O
on	IN	O	O
either	DT	O	O
treatment	NN	O	O
.	.	O	O

beta-Carotene	JJ	O	O
appears	VBZ	O	O
to	TO	O	O
have	VB	O	O
an	DT	O	O
immunostimulatory	JJ	o	OOt
effect	NN	o	OOt
in	IN	O	O
HIV-infected	JJ	p	PC
patients	NNS	p	O
.	.	p	O

Further	JJ	O	O
studies	NNS	O	O
are	VBP	O	O
needed	VBN	O	O
to	TO	O	O
demonstrate	VB	O	O
whether	IN	O	O
beta-carotene	NN	O	O
has	VBZ	O	O
a	DT	O	O
role	NN	O	O
as	IN	O	O
adjunct	JJ	O	O
therapy	NN	O	O
in	IN	O	O
treatment	NN	O	O
of	IN	O	O
HIV-infected	JJ	o	OPH
patients	NNS	o	OPH
.	.	o	O

Randomized	NNP	O	O
comparison	NN	O	O
of	IN	O	O
the	DT	O	O
efficacy	NN	o	OOt
and	CC	o	OOt
safety	NN	o	OOt
of	IN	O	O
zotarolimus-eluting	JJ	i	IPM
stents	NNS	i	IPM
vs.	IN	O	O
sirolimus-eluting	JJ	i	IPM
stents	NNS	i	IPM
for	IN	O	O
percutaneous	JJ	p	O
coronary	JJ	p	O
intervention	NN	p	O
in	IN	p	O
chronic	JJ	p	O
total	JJ	p	O
occlusion	NN	p	O
--	:	p	O
CAtholic	NNP	p	O
Total	NNP	p	O
Occlusion	NNP	p	O
Study	NNP	p	O
(	(	p	O
CATOS	NNP	p	O
)	)	p	O
trial	NN	p	O
.	.	p	O

BACKGROUND	NNP	O	O
Limited	NNP	O	O
data	NNS	O	O
are	VBP	O	O
available	JJ	O	O
regarding	VBG	O	O
the	DT	O	O
direct	JJ	O	O
comparison	NN	O	O
of	IN	O	O
angiographic	JJ	O	O
and	CC	O	O
clinical	JJ	O	O
outcomes	NNS	O	O
after	IN	O	O
percutaneous	JJ	O	O
coronary	JJ	O	O
intervention	NN	O	O
(	(	O	O
PCI	NNP	O	O
)	)	O	O
with	IN	O	O
drug-eluting	JJ	i	IPM
stents	NNS	i	IPM
(	(	O	O
DESs	NNP	O	O
)	)	O	O
for	IN	O	O
chronic	JJ	p	O
total	JJ	p	O
occlusion	NN	p	O
(	(	p	O
CTO	NNP	p	O
)	)	p	O
.	.	p	O

METHODS	NNP	O	O
AND	NNP	O	O
RESULTS	NNP	O	O
A	NNP	O	O
prospective	JJ	O	O
,	,	O	O
randomized	VBN	O	O
,	,	O	O
multicenter	RBR	O	O
trial	NN	O	O
was	VBD	O	O
conducted	VBN	O	O
to	TO	O	O
evaluate	VB	O	O
the	DT	O	O
non-inferiority	NN	O	O
of	IN	O	O
a	DT	O	O
zotarolimus-eluting	JJ	i	IPH
stent	NN	i	IPH
(	(	i	O
ZES	NNP	i	O
;	:	i	O
Endeavor	NNP	i	O
Sprint?	NNP	i	O
,	,	i	O
n=80	RB	O	O
)	)	O	O
to	TO	O	O
a	DT	O	O
sirolimus-eluting	JJ	i	IPH
stent	NN	i	IPH
(	(	i	O
SES	NNP	i	O
;	:	i	O
Cypher?	NNP	i	O
,	,	i	O
n=80	NN	O	O
)	)	O	O
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
CTO	NNP	p	O
lesion	NN	p	O
with	IN	p	O
a	DT	p	O
reference	NN	p	O
vessel	NN	p	O
diameter	NN	p	O
?	.	p	O
2.5mm	CD	p	O
.	.	p	O

The	DT	p	O
primary	JJ	O	O
endpoint	NN	O	O
was	VBD	O	O
in-segment	JJ	o	OPH
binary	JJ	o	OPH
restenosis	NN	o	OPH
rate	NN	o	OPH
at	IN	o	O
9-month	JJ	O	O
angiographic	JJ	O	O
follow-up	NN	O	O
.	.	O	O

Key	NNP	O	O
secondary	JJ	O	O
endpoints	NNS	O	O
included	VBD	o	O
target	NN	o	OPH
vessel	NN	o	OPH
failure	NN	o	OPH
(	(	o	OPH
TVF	NNP	o	OPH
;	:	o	OPH
including	VBG	o	OPH
cardiac	JJ	o	OPH
death	NN	o	OPH
,	,	o	OPH
myocardial	JJ	o	OPH
infarction	NN	o	OPH
,	,	o	OPH
and	CC	o	OPH
target	VB	o	OPH
vessel	JJ	o	OPH
revascularization	NN	o	OPH
)	)	o	OPH
and	CC	o	O
Academic	NNP	o	OPH
Research	NNP	o	OPH
Consortium-defined	NNP	o	OPH
definite/probable	JJ	o	OPH
stent	NN	o	OPH
thrombosis	NN	o	OPH
(	(	o	OPH
ST	NNP	o	OPH
)	)	o	OPH
within	IN	o	O
12	CD	O	O
months	NNS	O	O
.	.	O	O

The	DT	O	O
ZES	NNP	O	O
was	VBD	O	O
non-inferior	JJ	O	O
to	TO	O	O
the	DT	O	O
SES	NNP	O	O
with	IN	O	O
respect	NN	O	O
to	TO	O	O
the	DT	O	O
primary	JJ	O	O
endpoint	NN	o	O
,	,	o	O
which	WDT	o	O
occurred	VBD	O	O
in	IN	O	O
14.1	CD	O	O
%	NN	O	O
(	(	O	O
95	CD	O	O
%	NN	O	O
confidence	NN	O	O
interval	NN	O	O
[	NNP	O	O
CI	NNP	O	O
]	NN	O	O
:	:	O	O
6.0-22.2	JJ	O	O
)	)	O	O
and	CC	O	O
in	IN	O	O
13.7	CD	O	O
%	NN	O	O
(	(	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
:	:	O	O
5.8-21.6	JJ	O	O
)	)	O	O
of	IN	O	O
patients	NNS	O	O
,	,	O	O
respectively	RB	O	O
(	(	O	O
non-inferiority	JJ	O	O
margin	NN	O	O
,	,	O	O
15.0	CD	O	O
%	NN	O	O
;	:	O	O
P	NNP	O	O
for	IN	O	O
non-inferiority	JJ	O	O
<	NNP	O	O
0.001	CD	O	O
)	)	O	O
.	.	O	O

There	EX	O	O
were	VBD	O	O
no	DT	O	O
significant	JJ	O	O
between-group	JJ	O	O
differences	NNS	O	O
in	IN	O	O
the	DT	O	O
rate	NN	o	O
of	IN	o	O
TVF	NNP	o	O
(	(	O	O
10.0	CD	O	O
%	NN	O	O
vs.	FW	O	O
17.5	CD	O	O
%	NN	O	O
;	:	O	O
P=0.168	NNP	O	O
)	)	O	O
nor	CC	O	O
in	IN	O	O
the	DT	O	O
rate	NN	O	O
of	IN	O	O
ST	NNP	O	O
(	(	O	O
0.0	CD	O	O
%	NN	O	O
vs.	FW	O	O
1.3	CD	O	O
%	NN	O	O
;	:	O	O
P=0.316	NNP	O	O
)	)	O	O
during	IN	O	O
the	DT	O	O
12-month	JJ	O	O
clinical	JJ	O	O
follow-up	NN	O	O
.	.	O	O

CONCLUSIONS	VB	O	O
The	DT	O	O
effectiveness	NN	O	O
and	CC	O	O
safety	NN	O	O
of	IN	O	O
ZES	NNP	O	O
are	VBP	O	O
similar	JJ	O	O
to	TO	O	O
those	DT	O	O
of	IN	O	O
SES	NNP	O	O
and	CC	O	O
therefore	VB	O	O
it	PRP	O	O
is	VBZ	O	O
a	DT	O	O
good	JJ	O	O
treatment	NN	O	O
option	NN	p	O
in	IN	p	O
patients	NNS	p	O
undergoing	VBG	p	O
PCI	NNP	p	O
for	IN	p	O
CTO	NNP	p	O
with	IN	p	O
DESs	NNP	p	O
.	.	p	O

Improved	VBN	O	O
fibrinolysis	NN	O	O
after	IN	O	O
1-year	JJ	O	O
treatment	NN	O	O
with	IN	O	O
HMG	NNP	i	IPM
CoA	NNP	i	IPM
reductase	NN	i	IPM
inhibitors	NNS	i	IPM
in	IN	O	O
patients	NNS	p	PC
with	IN	p	PC
coronary	JJ	p	PC
heart	NN	p	PC
disease	NN	p	PC
.	.	p	O

The	DT	O	O
study	NN	O	O
was	VBD	O	O
aimed	VBN	O	O
to	TO	O	O
investigate	VB	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
two	CD	O	O
different	JJ	O	O
statins	NNS	i	IPM
on	IN	O	O
the	DT	O	O
levels	NNS	O	O
of	IN	O	O
haemostatic	JJ	O	O
variables	NNS	O	O
reflecting	VBG	O	O
procoagulant	NN	O	O
and	CC	O	O
fibrinolytic	JJ	O	O
activity	NN	O	O
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
coronary	JJ	p	O
heart	NN	p	O
disease	NN	p	O
(	(	p	O
CHD	NNP	p	O
)	)	p	O
,	,	O	O
with	IN	O	O
the	DT	O	O
hypothesis	NN	O	O
that	WDT	O	O
statins	VBZ	i	IPM
might	MD	O	O
beneficially	RB	O	O
modify	VB	O	O
these	DT	O	O
levels	NNS	O	O
.	.	O	O

Fifty-eight	JJ	p	PSS
patients	NNS	p	PSS
were	VBD	O	O
randomized	VBN	O	O
to	TO	O	O
treatment	NN	O	O
with	IN	O	O
atorvastatin	NN	i	IPM
(	(	O	O
n=28	JJ	O	O
)	)	O	O
or	CC	O	O
simvastatin	NN	i	IPM
(	(	O	O
n=30	JJ	O	O
)	)	O	O
for	IN	O	O
1	CD	O	O
year	NN	O	O
.	.	O	O

The	DT	O	O
starting	VBG	O	O
dose	NN	O	O
in	IN	O	O
both	DT	O	O
groups	NNS	O	O
was	VBD	O	O
20	CD	O	O
mg/day	NN	O	O
.	.	O	O

Fasting	VBG	o	OOt
blood	NN	o	OOt
samples	NNS	o	OOt
were	VBD	O	O
collected	VBN	O	O
before	IN	O	O
and	CC	O	O
after	IN	O	O
12-month	JJ	O	O
treatment	NN	O	O
for	IN	O	O
determinations	NNS	O	O
of	IN	O	O
fibrinogen	NN	o	OPH
,	,	o	O
prothrombin	JJ	o	OPH
fragment	NN	o	OPH
1+2	CD	o	OPH
(	(	o	OPH
F1+2	NNP	o	OPH
)	)	o	OPH
,	,	o	OPH
plasma	JJ	o	OPH
D-dimer	NNP	o	OPH
,	,	o	O
soluble	JJ	o	OPH
tissue	NN	o	OPH
factor	NN	o	OPH
,	,	o	O
tissue	NN	o	OPH
plasminogen	NN	o	OPH
activator	NN	o	OPH
(	(	o	OPH
tPA	NN	o	OPH
)	)	o	OPH
antigen	NN	o	OPH
,	,	o	O
tPA	NN	o	OPH
activity	NN	o	OPH
,	,	o	O
plasminogen	NN	o	OPH
activator	NN	o	OPH
inhibitor	JJ	o	OPH
type-1	JJ	o	OPH
activity	NN	o	OPH
(	(	o	OPH
PAI-1	NNP	o	OPH
activity	NN	o	OPH
)	)	o	OPH
and	CC	o	O
serum	JJ	o	OPH
D-dimer	NNP	o	OPH
as	IN	o	OPH
a	DT	o	OPH
global	JJ	o	OPH
test	NN	o	OPH
of	IN	o	OPH
fibrinolytic	JJ	o	OPH
activity	NN	o	OPH
.	.	o	O

In	IN	O	O
the	DT	O	O
total	JJ	O	O
population	NN	O	O
,	,	O	O
improved	VBN	o	OPH
fibrinolytic	JJ	o	OPH
activity	NN	o	OPH
was	VBD	O	O
observed	VBN	O	O
after	IN	O	O
1	CD	O	O
year	NN	O	O
with	IN	O	O
increased	JJ	o	O
levels	NNS	o	O
of	IN	O	O
serum	NN	o	OPH
D-dimer	NNP	o	OPH
(	(	O	O
P=.001	NNP	O	O
)	)	O	O
and	CC	O	O
tPA	JJ	o	OPH
activity	NN	o	OPH
(	(	O	O
P=.024	NNP	O	O
)	)	O	O
and	CC	O	O
a	DT	O	O
reduction	NN	o	OPH
in	IN	o	OPH
tPA	NN	o	OPH
antigen	NN	o	OPH
(	(	O	O
P=.048	NNP	O	O
)	)	O	O
.	.	O	O

No	DT	O	O
statistically	RB	O	O
significant	JJ	O	O
changes	NNS	O	O
were	VBD	O	O
observed	VBN	O	O
in	IN	O	O
any	DT	O	O
of	IN	O	O
the	DT	O	O
measured	JJ	O	O
coagulation	NN	O	O
variables	NNS	O	O
.	.	O	O

Separately	RB	O	O
examined	VBD	O	O
,	,	O	O
an	DT	O	O
improved	JJ	O	O
fibrinolytic	JJ	O	O
profile	NN	O	O
was	VBD	O	O
seen	VBN	O	O
in	IN	O	O
the	DT	O	O
atorvastatin	NN	i	IPM
group	NN	O	O
with	IN	O	O
a	DT	O	O
significant	JJ	o	O
increase	NN	o	OPH
in	IN	o	OPH
serum	JJ	o	OPH
D-dimer	NNP	o	OPH
(	(	O	O
P=.005	NNP	O	O
)	)	O	O
,	,	O	O
a	DT	O	O
borderline	JJ	o	O
increase	NN	o	OPH
in	IN	o	OPH
tPA	JJ	o	OPH
activity	NN	o	OPH
(	(	O	O
P=.083	NNP	O	O
)	)	O	O
and	CC	O	O
a	DT	O	O
borderline	NN	o	O
reduction	NN	o	OPH
in	IN	o	OPH
tPA	NN	o	OPH
antigen	NN	o	OPH
(	(	O	O
P=.069	NNP	O	O
)	)	O	O
.	.	O	O

Within	IN	O	O
the	DT	O	O
simvastatin	NN	i	IPM
group	NN	O	O
,	,	O	O
a	DT	O	O
reduction	NN	o	OPH
in	IN	o	OPH
prothrombin	NN	o	OPH
F1+2	NNP	o	OPH
was	VBD	O	O
observed	VBN	O	O
(	(	O	O
P=.038	NNP	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
differences	NNS	O	O
in	IN	O	O
changes	NNS	O	O
between	IN	O	O
the	DT	O	O
groups	NNS	O	O
were	VBD	O	O
statistically	RB	O	O
significant	JJ	O	O
only	RB	O	O
for	IN	O	O
global	JJ	o	OPH
fibrinolysis	NN	o	OPH
(	(	O	O
serum	JJ	O	O
D-dimer	NNP	O	O
,	,	O	O
P=.046	NNP	O	O
)	)	O	O
.	.	O	O

In	IN	O	O
conclusion	NN	O	O
,	,	O	O
an	DT	O	O
improved	JJ	O	O
fibrinolytic	JJ	o	OPH
profile	NN	o	OPH
was	VBD	O	O
observed	VBN	O	O
after	IN	O	O
statin	NN	i	IPM
treatment	NN	O	O
,	,	O	O
most	RBS	O	O
pronounced	JJ	O	O
with	IN	O	O
atorvastatin	NN	i	IPM
.	.	i	O

The	DT	O	O
results	NNS	O	O
indicate	VBP	O	O
that	IN	O	O
the	DT	O	O
drugs	NNS	O	O
promote	VBP	O	O
a	DT	O	O
profibrinolytic	JJ	O	O
profile	NN	O	O
,	,	O	O
and	CC	O	O
may	MD	O	O
in	IN	O	O
part	NN	O	O
explain	VBP	O	O
the	DT	O	O
benefit	NN	O	O
of	IN	O	O
statin	NN	i	IPM
treatment	NN	O	O
rendered	VBN	O	O
in	IN	O	O
the	DT	O	O
prevention	NN	O	O
of	IN	O	O
CHD	NNP	O	O
.	.	O	O

Predictors	NNS	O	O
of	IN	O	O
recruited	JJ	O	O
melanoma	NN	p	PC
families	NNS	p	O
into	IN	O	O
a	DT	O	O
behavioral	JJ	i	IE
intervention	NN	i	IE
project	NN	i	IE
.	.	i	O

BACKGROUND	NNP	O	O
Examination	NNP	O	O
of	IN	O	O
families	NNS	p	O
represents	VBZ	O	O
an	DT	O	O
important	JJ	O	O
priority	NN	O	O
in	IN	O	O
health	NN	O	O
research	NN	O	O
.	.	O	O

In	IN	O	O
this	DT	O	O
paper	NN	O	O
we	PRP	O	O
report	VBP	o	OOt
on	IN	O	O
individual	JJ	o	OME
and	CC	o	OME
family-level	JJ	o	OME
factors	NNS	o	OME
associated	VBN	O	O
with	IN	O	O
enrollment	NN	O	O
in	IN	O	O
a	DT	O	O
cancer	NN	O	O
prevention	NN	O	O
research	NN	O	O
project	NN	O	O
.	.	O	O

We	PRP	O	O
approached	VBD	O	O
families	NNS	p	O
affected	VBN	p	O
by	IN	p	O
melanoma	NN	p	PC
for	IN	O	O
possible	JJ	O	O
participation	NN	O	O
in	IN	O	O
a	DT	O	O
randomized	NN	O	O
controlled	VBN	O	O
trial	NN	O	O
of	IN	O	O
a	DT	O	O
web-based	JJ	i	IE
communication	NN	i	IE
and	CC	i	IE
support	NN	i	IE
intervention	NN	i	IE
.	.	i	O

METHODS	NNP	O	O
We	PRP	O	O
recruited	VBD	O	O
three	CD	p	PSS
family	NN	p	PSS
members	NNS	p	PSS
per	IN	p	PSS
family	NN	p	PSS
for	IN	p	O
assessment	NN	p	O
-	:	p	O
the	DT	p	O
melanoma	NN	p	O
case	NN	p	O
,	,	p	O
a	DT	p	O
first-degree	JJ	p	O
relative	NN	p	O
(	(	p	O
FDR	NNP	p	O
)	)	p	O
,	,	p	O
and	CC	p	O
a	DT	p	O
relative	NN	p	O
who	WP	p	O
is	VBZ	p	O
a	DT	p	O
parent	NN	p	O
of	IN	p	O
a	DT	p	O
child	JJ	p	O
age	NN	p	O
18	CD	p	PA
or	CC	p	PA
younger	JJR	p	PA
.	.	p	O

Recruitment	NNP	O	O
involved	VBD	O	O
three	CD	O	O
steps	NNS	O	O
:	:	O	O
requesting	VBG	O	O
the	DT	O	O
physician	NN	O	O
's	POS	O	O
consent	NN	O	O
to	TO	O	O
approach	VB	O	O
the	DT	O	O
melanoma	NN	O	O
case	NN	O	O
,	,	O	O
approaching	VBG	O	O
the	DT	O	O
case	NN	O	O
to	TO	O	O
request	VB	O	O
their	PRP$	O	O
participation	NN	O	O
and	CC	O	O
family	NN	O	O
contact	NN	O	O
information	NN	O	O
,	,	O	O
and	CC	O	O
they	PRP	O	O
approaching	VBG	O	O
the	DT	O	O
FDRs	NNP	O	O
and	CC	O	O
parents	NNS	O	O
.	.	O	O

RESULTS	NNP	O	O
Of	IN	O	O
the	DT	O	O
1380	CD	p	PSS
families	NNS	p	O
approached	VBD	p	O
,	,	p	O
313	CD	p	PSS
were	VBD	p	O
enrolled	VBN	p	O
,	,	p	O
263	CD	p	O
were	VBD	p	O
excluded	VBN	p	O
because	IN	p	O
we	PRP	p	O
could	MD	p	O
not	RB	p	O
find	VB	p	O
or	CC	p	O
contact	VB	p	O
a	DT	p	O
family	NN	p	O
member	NN	p	O
(	(	p	O
FDR	CD	p	O
or	CC	p	O
parent	NN	p	O
)	)	p	O
,	,	p	O
331	CD	p	O
did	VBD	p	O
not	RB	p	O
have	VB	p	O
eligible	JJ	p	O
family	NN	p	O
members	NNS	p	O
,	,	p	O
and	CC	p	O
473	CD	p	O
refused	VBD	p	O
.	.	p	O

The	DT	O	O
most	RBS	O	O
frequently	RB	o	O
noted	VBD	O	O
reason	NN	O	O
for	IN	O	O
refusal	NN	o	OOt
was	VBD	O	O
being	VBG	O	O
too	RB	O	O
busy	JJ	O	O
or	CC	O	O
having	VBG	O	O
no	DT	O	O
time	NN	O	O
.	.	O	O

The	DT	O	O
primary	JJ	O	O
predictors	NNS	O	O
of	IN	O	O
participation	NN	o	O
for	IN	O	O
cases	NNS	O	O
(	(	O	O
OR=1.6	NNP	O	O
;	:	O	O
CI=1.01-2.51	NNP	O	O
)	)	O	O
and	CC	O	O
FDRs	NNP	O	O
(	(	O	O
OR=2.15	NNP	O	O
;	:	O	O
CI=1.11-4.13	NNP	O	O
)	)	O	O
included	VBD	O	O
higher	JJR	o	OME
educational	JJ	o	OME
attainment	NN	o	OME
.	.	o	OME

FDRs	NNP	O	O
were	VBD	O	O
more	RBR	O	O
likely	JJ	O	O
to	TO	O	O
enroll	VB	o	O
if	IN	O	O
they	PRP	O	O
were	VBD	O	O
female	JJ	o	O
(	(	O	O
OR=1.77	NNP	O	O
;	:	O	O
CI=1.1-.85	NNP	O	O
)	)	O	O
and	CC	O	O
parents	NNS	O	O
were	VBD	O	O
more	RBR	O	O
likely	JJ	O	O
to	TO	O	O
enroll	VB	o	O
if	IN	O	O
the	DT	O	O
case	NN	O	O
had	VBD	O	O
been	VBN	O	O
diagnosed	VBN	o	OPH
more	RBR	o	OPH
recently	RB	o	OPH
(	(	O	O
OR=3.3	NNP	O	O
;	:	O	O
CI=1.9-5.93	NNP	O	O
)	)	O	O
,	,	O	O
if	IN	O	O
the	DT	O	O
parent	NN	o	OOt
was	VBD	o	OOt
partnered	VBN	o	OOt
(	(	O	O
OR=4.37	NNP	O	O
;	:	O	O
CI=1.86-10.26	NNP	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
if	IN	O	O
the	DT	O	O
parent	NN	o	OME
lived	VBD	o	OME
in	IN	o	OME
the	DT	o	OME
same	JJ	o	OME
city	NN	o	OME
as	IN	o	OME
the	DT	o	OME
case	NN	o	OME
(	(	O	O
OR=2.88	NNP	O	O
;	:	O	O
CI=1.08-7.68	NNP	O	O
)	)	O	O
.	.	O	O

CONCLUSIONS	VB	O	O
The	DT	O	O
results	NNS	O	O
can	MD	O	O
provide	VB	O	O
information	NN	O	O
on	IN	O	O
potential	JJ	O	O
directions	NNS	O	O
for	IN	O	O
future	JJ	O	O
family	NN	O	O
recruitment	NN	O	O
.	.	O	O

The	DT	O	O
effects	NNS	O	O
of	IN	O	O
a	DT	O	O
multi-component	JJ	O	O
higher-functioning	JJ	p	PC
autism	NN	p	PC
anti-stigma	JJ	O	O
program	NN	O	O
on	IN	O	O
adolescent	JJ	p	PC
boys	NNS	p	PC
.	.	p	PC

A	DT	O	O
six-session	JJ	O	O
higher-functioning	JJ	p	PC
autism	NN	p	PC
anti-stigma	JJ	O	O
program	NN	O	O
incorporating	NN	O	O
descriptive	NN	O	O
,	,	O	O
explanatory	NN	O	O
and	CC	O	O
directive	JJ	O	O
information	NN	O	O
was	VBD	O	O
delivered	VBN	O	O
to	TO	O	O
adolescent	VB	p	PC
boys	NNS	p	PC
and	CC	O	O
the	DT	O	O
impact	NN	O	O
upon	IN	O	O
knowledge	NN	o	OME
,	,	o	OME
attitudes	NNS	o	OME
and	CC	o	OME
behavioural	JJ	o	OME
intentions	NNS	o	OME
towards	NNS	O	O
peers	NNS	O	O
with	IN	O	O
autism	NN	O	O
was	VBD	O	O
evaluated	VBN	O	O
.	.	O	O

Participants	NNS	p	O
were	VBD	p	O
seventh-	JJ	p	O
,	,	p	O
eighth-	JJ	p	O
and	CC	p	O
ninth-grade	JJ	p	O
students	NNS	p	O
(	(	p	O
N	NNP	p	O
=	NNP	p	O
395	CD	p	O
)	)	p	O
from	IN	p	O
regular	JJ	p	O
classes	NNS	p	O
in	IN	p	O
a	DT	p	O
mainstream	JJ	p	O
school	NN	p	O
.	.	p	O

Two-eighth-grade	JJ	p	O
classes	NNS	p	O
were	VBD	i	O
randomly	RB	i	O
allocated	VBN	i	O
to	TO	i	O
the	DT	i	O
intervention	NN	i	O
condition	NN	i	O
and	CC	i	O
all	DT	i	O
remaining	VBG	i	O
students	NNS	i	O
were	VBD	i	O
either	RB	i	O
allocated	VBN	i	O
to	TO	i	O
the	DT	i	O
no-intervention	JJ	i	O
peer	NN	i	O
or	CC	i	O
no-intervention	JJ	i	O
non-peer	JJ	i	O
condition	NN	i	O
.	.	i	O

The	DT	O	O
anti-stigma	JJ	O	O
program	NN	O	O
improved	VBD	O	O
the	DT	o	O
knowledge	NN	o	O
and	CC	o	O
attitudes	NNS	o	O
,	,	o	O
but	CC	O	O
not	RB	O	O
the	DT	o	O
behavioural	JJ	o	O
intentions	NNS	o	O
of	IN	o	O
participants	NNS	O	O
towards	VBP	O	O
their	PRP$	O	O
peers	NNS	O	O
with	IN	O	O
autism	NN	o	O
.	.	o	O

Knowledge	NNP	o	O
and	CC	o	O
attitudinal	JJ	o	O
changes	NNS	o	O
were	VBD	o	O
maintained	VBN	O	O
at	IN	O	O
follow-up	NN	O	O
.	.	O	O

There	EX	O	O
were	VBD	O	O
no	DT	O	O
spill-over	JJ	o	O
effects	NNS	o	O
of	IN	o	O
the	DT	O	O
program	NN	O	O
to	TO	O	O
non-targeted	JJ	O	O
students	NNS	O	O
.	.	O	O

These	DT	O	O
results	NNS	O	O
provide	VBP	O	O
some	DT	O	O
preliminary	JJ	O	O
evidence	NN	O	O
for	IN	O	O
the	DT	O	O
effectiveness	NN	O	O
of	IN	O	O
multi-session	NN	O	O
anti-stigma	JJ	O	O
programs	NNS	O	O
incorporating	VBG	O	O
combined	VBN	O	O
information	NN	O	O
for	IN	p	O
adolescent	NN	p	O
students	NNS	p	O
in	IN	p	O
inclusive	JJ	p	O
educational	JJ	p	O
environments	NNS	p	O
.	.	p	O

Take	VB	O	O
a	DT	O	O
walk	NN	O	O
in	IN	O	O
the	DT	O	O
park	NN	O	O
?	.	O	O
A	DT	O	O
cross-over	NN	O	O
pilot	NN	O	O
trial	NN	O	O
comparing	VBG	O	O
brisk	JJ	i	IPH
walking	VBG	i	IPH
in	IN	i	IPH
two	CD	i	IPH
different	JJ	i	IPH
environments	NNS	i	IPH
:	:	i	IPH
park	NN	O	O
and	CC	O	O
urban	JJ	O	O
.	.	O	O

OBJECTIVE	CC	O	O
The	DT	O	O
objective	NN	O	O
of	IN	O	O
the	DT	O	O
present	JJ	O	O
study	NN	O	O
is	VBZ	O	O
to	TO	O	O
investigate	VB	O	O
whether	IN	O	O
differences	NNS	O	O
exist	VBP	O	O
between	IN	O	O
a	DT	O	O
30	CD	i	IPH
minute	NN	i	IPH
brisk	NN	i	IPH
walk	VBP	i	IPH
taken	VBN	O	O
in	IN	O	O
two	CD	O	O
different	JJ	O	O
environments	NNS	O	O
in	IN	O	O
order	NN	O	O
to	TO	O	O
determine	VB	O	O
which	WDT	O	O
environment	NN	O	O
best	JJS	O	O
facilitates	NNS	O	O
current	JJ	O	O
physical	JJ	O	O
activity	NN	O	O
guidelines	NNS	O	O
:	:	O	O
park	NN	O	O
or	CC	O	O
urban	JJ	O	O
.	.	O	O

METHODS	NNP	O	O
In	IN	O	O
this	DT	O	O
randomised	JJ	O	O
cross-over	NN	O	O
pilot	NN	O	O
study	NN	O	O
,	,	O	O
participants	NNS	p	O
performed	VBD	p	O
a	DT	p	O
self-timed	JJ	i	IPH
30	CD	i	IPH
minute	NN	i	IPH
brisk	NN	i	IPH
walk	VBP	i	IPH
in	IN	i	IPH
two	CD	i	IPH
different	JJ	i	IPH
environments	NNS	i	IPH
,	,	i	IPH
park	NN	i	IPH
and	CC	i	IPH
urban	JJ	i	IPH
,	,	O	O
in	IN	O	O
Glasgow	NNP	O	O
,	,	O	O
Scotland	NNP	O	O
(	(	O	O
October	NNP	O	O
2009	CD	O	O
to	TO	O	O
January	NNP	O	O
2010	CD	O	O
)	)	O	O
.	.	O	O

Cadence	NN	o	OPH
,	,	O	O
recorded	VBD	O	O
using	VBG	O	O
the	DT	O	O
activPAL?	NN	O	O
activity	NN	O	O
monitor	NN	O	O
,	,	O	O
was	VBD	O	O
used	VBN	O	O
to	TO	O	O
measure	VB	O	O
intensity	NN	O	O
.	.	O	O

Outcome	CC	O	O
measures	NNS	O	O
were	VBD	o	O
:	:	o	O
mean	JJ	o	O
cadence	NN	o	O
;	:	o	O
moderate-to-vigorous	JJ	o	O
physical	JJ	o	O
activity	NN	o	O
time	NN	o	O
accumulated	VBN	o	O
in	IN	o	O
bouts	NNS	o	O
lasting	VBG	o	O
?	.	o	O
10	CD	o	O
min	NN	o	O
;	:	o	O
number	NN	o	O
of	IN	o	O
walking	VBG	o	O
breaks	NNS	o	O
;	:	o	O
and	CC	o	O
duration	NN	o	O
.	.	o	O

RESULTS	VB	o	O
A	DT	O	O
convenience	NN	O	O
sample	NN	p	O
of	IN	p	O
40	CD	p	O
healthy	JJ	p	O
adults	NNS	p	O
was	VBD	p	O
recruited	VBN	p	O
:	:	p	O
16	CD	p	O
males	NNS	p	O
,	,	p	O
24	CD	p	O
females	NNS	p	O
,	,	p	O
mean	JJ	p	O
age	NN	p	O
22.9	CD	p	O
(	(	p	O
5.5	CD	p	O
)	)	p	O
years	NNS	p	O
.	.	p	O

The	DT	p	O
mean	JJ	o	O
cadence	NN	o	O
for	IN	o	O
the	DT	o	O
whole	JJ	o	O
walk	NN	o	O
was	VBD	o	O
higher	RBR	O	O
in	IN	O	O
the	DT	O	O
park	NN	O	O
:	:	O	O
119.3	CD	O	O
(	(	O	O
8.3	CD	O	O
)	)	O	O
vs.	FW	O	O
110.9	CD	O	O
(	(	O	O
8.9	CD	O	O
)	)	O	O
steps/min	NN	p	O
.	.	p	O

Participants	NNS	p	O
accumulated	VBD	p	O
more	RBR	O	O
moderate-to-vigorous	JJ	o	O
physical	JJ	o	O
activity	NN	o	O
in	IN	o	O
?	.	o	O
10	CD	o	O
minute	NN	o	O
bouts	NNS	o	O
during	IN	O	O
park	JJ	O	O
walks	NNS	O	O
:	:	O	O
25.5	CD	O	O
(	(	O	O
9.6	CD	O	O
)	)	O	O
[	NN	O	O
median	JJ	O	O
(	(	O	O
interquartile	JJ	O	O
range	NN	O	O
)	)	O	O
]	VBZ	O	O
vs.	FW	O	O
14.0	CD	O	O
(	(	O	O
20.3	CD	O	O
)	)	O	O
min	NN	O	O
.	.	O	O

There	EX	O	O
was	VBD	O	O
no	DT	O	O
difference	NN	o	O
in	IN	o	O
self-timed	JJ	o	O
duration	NN	o	O
between	IN	o	O
locations	NNS	O	O
.	.	O	O

CONCLUSION	NNP	O	O
Participants	NNPS	O	O
accumulated	VBD	o	O
more	RBR	o	O
moderate-to-vigorous	JJ	o	O
physical	JJ	o	O
activity	NN	o	O
in	IN	o	O
bouts	NNS	o	O
?	.	O	O
10	CD	O	O
min	NN	O	O
in	IN	O	O
duration	NN	O	O
on	IN	O	O
park	NN	O	O
walks	NNS	O	O
due	JJ	O	O
to	TO	O	O
the	DT	O	O
lack	NN	O	O
of	IN	O	O
interruptions	NNS	O	O
in	IN	O	O
walking	VBG	O	O
.	.	O	O

Hence	NNP	O	O
the	DT	O	O
park	NN	O	O
environment	NN	O	O
better	RBR	O	O
facilitated	VBD	O	O
the	DT	O	O
achievement	NN	O	O
of	IN	O	O
current	JJ	O	O
physical	JJ	O	O
activity	NN	O	O
guidelines	NNS	O	O
.	.	O	O

Further	JJ	O	O
research	NN	O	O
involving	VBG	O	O
a	DT	O	O
larger	JJR	O	O
,	,	O	O
more	RBR	O	O
heterogeneous	JJ	O	O
sample	NN	O	O
is	VBZ	O	O
recommended	VBN	O	O
.	.	O	O

Predicting	VBG	O	O
completion	NN	O	O
of	IN	O	O
treatment	NN	O	O
among	IN	O	O
foreign-born	JJ	p	PC
adolescents	NNS	p	PA
treated	VBN	p	O
for	IN	p	O
latent	JJ	p	PC
tuberculosis	NN	p	PC
infection	NN	p	PC
in	IN	p	O
Los	NNP	p	O
Angeles	NNP	p	O
.	.	p	O

SETTING	NNP	O	O
Two	CD	p	O
health	NN	p	O
clinics	NNS	p	O
in	IN	p	O
Los	NNP	p	O
Angeles	NNP	p	O
County	NNP	p	O
,	,	p	O
California	NNP	p	O
.	.	p	O

OBJECTIVE	NNP	O	O
To	TO	O	O
identify	VB	O	O
factors	NNS	O	O
associated	VBN	O	O
with	IN	O	O
completion	NN	O	O
of	IN	O	O
care	NN	O	O
among	IN	O	O
foreign-born	JJ	p	PC
adolescents	NNS	p	PA
treated	VBN	p	O
for	IN	p	O
latent	JJ	p	PC
tuberculosis	NN	p	PC
infection	NN	p	PC
(	(	p	PC
LTBI	NNP	p	PC
)	)	p	PC
.	.	p	O

DESIGN	VB	O	O
A	DT	p	O
total	NN	p	O
of	IN	p	O
766	CD	p	PSS
low-income	JJ	p	PC
adolescents	NNS	p	PA
(	(	p	O
79	CD	p	O
%	NN	p	O
participation	NN	p	O
rate	NN	p	O
)	)	p	O
,	,	p	O
including	VBG	p	O
610	CD	p	PSS
foreign-born	JJ	p	PC
,	,	p	O
were	VBD	p	O
recruited	VBN	p	O
.	.	p	O

In	IN	O	O
prospective	JJ	O	O
face-to-face	NN	i	IE
interviews	NNS	i	IE
,	,	O	O
data	NNS	O	O
were	VBD	O	O
obtained	VBN	O	O
on	IN	O	O
socio-demographic	JJ	O	O
and	CC	O	O
lifestyle	JJ	O	O
characteristics	NNS	O	O
,	,	O	O
psychosocial	JJ	O	O
factors	NNS	O	O
and	CC	O	O
clinic-related	JJ	O	O
variables	NNS	O	O
.	.	O	O

Medical	JJ	i	IE
chart	NN	i	IE
data	NNS	i	IE
were	VBD	i	IE
abstracted	VBN	i	IE
regarding	VBG	O	O
clinic	JJ	O	O
appointment	NN	O	O
keeping	VBG	O	O
and	CC	O	O
completion	NN	O	O
of	IN	O	O
treatment	NN	O	O
.	.	O	O

Univariate	NNP	i	IPH
and	CC	i	IPH
multivariate	VB	i	IPH
logistic	JJ	i	IPH
regression	NN	i	IPH
analyses	NNS	i	IPH
were	VBD	O	O
performed	VBN	O	O
to	TO	O	O
identify	VB	O	O
factors	NNS	O	O
associated	VBN	O	O
with	IN	O	O
completion	NN	O	O
of	IN	O	O
care	NN	O	O
.	.	O	O

RESULTS	NNP	O	O
Foreign-born	JJ	p	PC
adolescents	NNS	p	PA
were	VBD	O	O
more	RBR	O	O
likely	JJ	O	O
to	TO	O	O
complete	VB	o	OPH
care	NN	o	OPH
than	IN	O	O
US-born	JJ	O	O
adolescents	NNS	O	O
,	,	O	O
with	IN	O	O
82	CD	O	O
%	NN	O	O
completion	NN	O	O
of	IN	O	O
care	NN	O	O
rate	NN	O	O
.	.	O	O

In	IN	O	O
logistic	JJ	O	O
regression	NN	O	O
analyses	NNS	O	O
after	IN	O	O
controlling	VBG	O	O
for	IN	O	O
age	NN	O	O
,	,	O	O
medication	NN	o	OME
taking	VBG	o	OME
behavior	NN	o	OME
(	(	O	O
OR	CC	O	O
1.26	CD	O	O
,	,	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
1.15-1.39	CD	O	O
)	)	O	O
,	,	O	O
living	VBG	o	OME
with	IN	o	OME
both	DT	o	OME
parents	NNS	o	OME
(	(	O	O
OR	NNP	O	O
1.74	CD	O	O
,	,	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
1.02-2.97	CD	O	O
)	)	O	O
,	,	O	O
sexual	JJ	o	OME
intercourse	NN	o	OME
(	(	O	O
OR	CC	O	O
0.66	CD	O	O
,	,	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
0.36-1.19	NN	O	O
)	)	O	O
and	CC	O	O
speaking	VBG	o	OME
mostly	RB	o	OME
or	CC	o	OME
only	RB	o	OME
English	JJ	o	OME
with	IN	o	OME
parents	NNS	o	OME
(	(	O	O
OR	NNP	O	O
0.39	CD	O	O
,	,	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
0.15-1.03	NN	O	O
)	)	O	O
were	VBD	O	O
independently	RB	O	O
associated	VBN	O	O
with	IN	O	O
completion	NN	O	O
of	IN	O	O
care	NN	O	O
.	.	O	O

CONCLUSION	NNP	O	O
These	DT	O	O
findings	NNS	O	O
contribute	VBP	O	O
to	TO	O	O
our	PRP$	O	O
understanding	NN	O	O
of	IN	O	O
the	DT	O	O
factors	NNS	O	O
that	WDT	O	O
may	MD	O	O
explain	VB	O	O
why	WRB	O	O
some	DT	O	O
adolescents	NNS	O	O
complete	JJ	O	O
care	NN	O	O
whereas	IN	O	O
others	NNS	O	O
do	VBP	O	O
not	RB	O	O
.	.	O	O

They	PRP	O	O
provide	VBP	O	O
supportive	JJ	O	O
evidence	NN	O	O
that	WDT	O	O
tailored	VBD	O	O
intervention	NN	O	O
programs	NNS	O	O
should	MD	O	O
be	VB	O	O
developed	VBN	O	O
to	TO	O	O
support	VB	O	O
the	DT	O	O
screening	NN	O	O
and	CC	O	O
completion	NN	O	O
of	IN	O	O
treatment	NN	O	O
of	IN	O	O
foreign-born	JJ	p	PC
adolescents	NNS	p	PA
.	.	p	O

Accumulated	VBN	i	IPH
brisk	JJ	i	IPH
walking	NN	i	IPH
reduces	NNS	O	O
arterial	JJ	O	O
stiffness	NN	O	O
in	IN	p	O
overweight	JJ	p	O
adults	NNS	p	O
:	:	p	O
evidence	NN	O	O
from	IN	O	O
a	DT	O	O
randomized	VBN	O	O
control	NN	O	O
trial	NN	O	O
.	.	O	O

Arterial	JJ	O	O
stiffness	NN	O	O
is	VBZ	O	O
a	DT	O	O
major	JJ	O	O
contributor	NN	O	O
to	TO	O	O
the	DT	O	O
development	NN	O	O
of	IN	O	O
atherosclerosis	NN	O	O
and	CC	O	O
consequently	RB	O	O
cardiovascular	JJ	O	O
disease	NN	O	O
.	.	O	O

This	DT	O	O
study	NN	O	O
aimed	VBD	O	O
to	TO	O	O
examine	VB	O	O
whether	IN	O	O
6	CD	O	O
months	NNS	O	O
of	IN	O	O
accumulated	VBN	O	O
(	(	O	O
3	CD	O	O
?	.	O	O
10	CD	O	O
minutes	NNS	O	O
,	,	O	O
5	CD	O	O
days/week	NN	i	O
)	)	i	O
brisk	NN	i	O
walking	NN	i	O
was	VBD	O	O
sufficient	JJ	O	O
to	TO	O	O
reduce	VB	O	O
arterial	JJ	O	O
stiffness	NN	p	O
in	IN	p	O
sedentary	JJ	p	O
,	,	p	O
overweight	JJ	p	O
individuals	NNS	p	O
.	.	p	O

Seventy-seven	JJ	p	O
individuals	NNS	p	O
(	(	p	O
19	CD	p	O
men	NNS	p	O
,	,	p	O
58	CD	p	O
women	NNS	p	O
;	:	p	O
age	NN	p	O
,	,	p	O
30-55	CD	p	O
years	NNS	p	O
)	)	p	O
were	VBD	O	O
randomly	RB	O	O
allocated	VBN	O	O
to	TO	O	O
one	CD	O	O
of	IN	O	O
three	CD	O	O
groups	NNS	p	O
;	:	p	O
two	CD	p	O
groups	NNS	p	O
completed	VBD	i	O
30	CD	i	O
minutes	NNS	i	O
of	IN	i	O
accumulated	JJ	i	O
walking	VBG	i	O
with	IN	i	O
either	DT	i	O
monthly	JJ	i	O
or	CC	i	O
weekly	JJ	i	O
telephone	NN	i	O
support	NN	i	O
;	:	i	O
the	DT	p	O
third	JJ	i	O
group	NN	i	O
(	(	i	O
control	NN	i	O
)	)	i	O
performed	VBD	i	O
stretching	VBG	i	O
exercises	NNS	i	O
.	.	i	O

The	DT	p	O
walking	VBG	p	O
groups	NNS	p	O
were	VBD	O	O
combined	VBN	O	O
and	CC	O	O
telephone	NN	O	O
support	NN	O	O
included	VBD	O	O
as	IN	O	O
a	DT	O	O
covariate	NN	O	O
.	.	O	O

Anthropometry	NNP	o	O
,	,	o	O
blood	NN	o	O
pressure	NN	o	O
(	(	o	O
BP	NNP	o	O
)	)	o	O
,	,	o	O
blood	NN	o	O
lipids	NNS	o	O
,	,	o	O
pulse	RB	o	O
wave	VBP	o	O
velocity	NN	o	O
(	(	o	O
PWV	NNP	o	O
)	)	o	O
,	,	o	O
and	CC	o	O
NOx	NNP	o	O
(	(	o	O
surrogate	JJ	o	O
marker	NN	o	O
for	IN	o	O
nitric	JJ	o	O
oxide	NN	o	O
)	)	o	O
were	VBD	O	O
measured	VBN	O	O
at	IN	O	O
baseline	NN	O	O
,	,	O	O
post-intervention	NN	O	O
and	CC	O	O
4	CD	O	O
months	NNS	O	O
post-intervention	NN	O	O
.	.	O	O

No	CC	O	O
changes	NNS	O	O
were	VBD	O	O
observed	VBN	O	O
for	IN	o	O
anthropometry	NN	o	O
,	,	o	O
BP	NNP	o	O
,	,	o	O
or	CC	o	O
lipids	NNS	o	O
.	.	o	O

However	RB	O	O
,	,	O	O
at	IN	O	O
the	DT	O	O
end	NN	O	O
of	IN	O	O
the	DT	O	O
intervention	NN	O	O
,	,	O	O
there	EX	O	O
was	VBD	O	O
a	DT	O	O
decrease	NN	O	O
in	IN	o	O
PWV	NNP	o	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
.001	NNP	O	O
)	)	O	O
accompanied	VBN	O	O
by	IN	O	O
an	DT	O	O
increase	NN	O	O
in	IN	o	O
NOx	NNP	o	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
.001	NNP	O	O
)	)	O	O
,	,	O	O
with	IN	O	O
changes	NNS	O	O
maintained	VBD	O	O
4	CD	O	O
months	NNS	O	O
post-intervention	NN	O	O
.	.	O	O

A	NNP	O	O
strong	JJ	O	O
negative	JJ	O	O
correlation	NN	O	O
between	IN	o	O
PWV	NNP	o	O
and	CC	o	O
NOx	NNP	o	O
was	VBD	O	O
also	RB	O	O
observed	VBN	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
.001	NNP	O	O
;	:	O	O
r	NN	O	O
=	NNP	O	O
-0.65	NNP	O	O
)	)	O	O
.	.	O	O

A	DT	O	O
lifestyle	JJ	O	O
approach	NN	O	O
to	TO	O	O
meeting	VBG	O	O
current	JJ	i	O
physical	JJ	i	O
activity	NN	i	O
guidelines	NNS	O	O
results	NNS	O	O
in	IN	O	O
favorable	JJ	O	O
alterations	NNS	O	O
in	IN	O	O
arterial	JJ	O	O
function	NN	O	O
in	IN	p	O
overweight	JJ	p	O
individuals	NNS	p	O
.	.	p	O

Households	NNS	p	O
with	IN	p	O
young	JJ	p	PA
children	NNS	p	PA
and	CC	p	O
use	NN	p	O
of	IN	p	O
freely	RB	p	O
distributed	VBN	p	O
bednets	NNS	i	IOt
in	IN	p	O
rural	JJ	p	O
Madagascar	NNP	p	O
.	.	p	O

BACKGROUND	NNP	O	O
Malaria	NNP	O	O
infections	NNS	O	O
are	VBP	O	O
the	DT	O	O
leading	VBG	O	O
cause	NN	O	O
of	IN	O	O
death	NN	O	O
for	IN	O	O
children	NNS	p	PA
in	IN	p	O
Madagascar	NNP	p	O
.	.	p	O

Insecticide-treated	JJ	i	IOt
bednets	NNS	i	IOt
offer	VBP	O	O
effective	JJ	O	O
prevention	NN	O	O
,	,	O	O
but	CC	O	O
it	PRP	O	O
is	VBZ	O	O
unclear	JJ	O	O
how	WRB	O	O
well	RB	O	O
free	JJ	i	IE
bednet	NN	i	IE
distribution	NN	i	IE
programs	NNS	i	IE
reach	VBP	O	O
young	JJ	p	PA
children	NNS	p	PA
.	.	p	O

METHODS	NNP	O	O
We	PRP	O	O
conducted	VBD	O	O
a	DT	O	O
secondary	JJ	O	O
analysis	NN	O	O
of	IN	O	O
a	DT	O	O
free	JJ	i	IOt
bednet	NN	i	IOt
distribution	NN	i	IOt
program	NN	i	IOt
in	IN	p	O
Madagascar	NNP	p	O
from	IN	p	O
2007-2008	JJ	p	O
.	.	p	O

Interviews	NNS	i	IE
were	VBD	O	O
performed	VBN	O	O
at	IN	O	O
baseline	NN	O	O
and	CC	O	O
6	CD	O	O
months	NNS	O	O
.	.	O	O

Principal	JJ	O	O
components	NNS	O	O
analysis	NN	O	O
was	VBD	O	O
used	VBN	O	O
to	TO	O	O
construct	VB	O	O
a	DT	O	O
wealth	NN	O	O
and	CC	O	O
malaria	NNS	O	O
knowledge	VBP	O	O
index	NN	O	O
.	.	O	O

Coverage	NNP	O	O
efficiency	NN	O	O
was	VBD	O	O
calculated	VBN	O	O
as	IN	O	O
coverage	NN	i	IOt
of	IN	i	IOt
children	NNS	i	IOt
per	IN	i	IOt
bednet	NN	i	IOt
owned	VBN	i	IOt
.	.	i	O

Univariable	JJ	O	O
and	CC	O	O
multivariable	JJ	O	O
regressions	NNS	O	O
were	VBD	O	O
used	VBN	O	O
to	TO	O	O
determine	VB	O	O
predictors	NNS	O	O
of	IN	O	O
bednet	NN	i	IOt
use	NN	O	O
.	.	O	O

RESULTS	NNP	O	O
Bednet	NNP	o	OOt
use	NN	o	OOt
,	,	O	O
among	IN	O	O
the	DT	O	O
560	CD	p	PSS
households	NNS	p	O
in	IN	p	O
the	DT	p	O
study	NN	p	O
,	,	O	O
increased	VBD	O	O
from	IN	O	O
6	CD	O	O
to	TO	O	O
91	CD	O	O
%	NN	O	O
after	IN	O	O
6	CD	O	O
months	NNS	O	O
.	.	O	O

Coverage	NNP	o	OOt
efficiency	NN	o	OOt
increased	VBD	O	O
from	IN	O	O
1.29	CD	O	O
to	TO	O	O
1.56	CD	O	O
children	NNS	O	O
covered	VBN	O	O
per	IN	O	O
bednet	NN	O	O
owned	VBN	O	O
.	.	O	O

In	IN	O	O
multivariable	JJ	O	O
analysis	NN	O	O
,	,	O	O
having	VBG	O	O
a	DT	O	O
child	NN	p	O
under	IN	p	PA
5	CD	p	PA
years	NNS	p	PA
of	IN	p	O
age	NN	p	O
was	VBD	O	O
the	DT	O	O
only	JJ	O	O
variable	NN	O	O
associated	VBN	O	O
with	IN	O	O
bednet	NN	O	O
use	NN	O	O
(	(	O	O
OR	CC	O	O
9.10	CD	O	O
;	:	O	O
p=0.001	NN	O	O
)	)	O	O
,	,	O	O
yielding	VBG	O	O
a	DT	O	O
99	CD	O	O
%	NN	O	O
likelihood	NN	O	O
of	IN	O	O
using	VBG	O	O
a	DT	O	O
bednet	NN	O	O
(	(	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
96.4	CD	O	O
to	TO	O	O
99.9	CD	O	O
%	NN	O	O
)	)	O	O
versus	VBZ	O	O
82	CD	O	O
%	NN	O	O
(	(	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
72.2	CD	O	O
to	TO	O	O
88.4	CD	O	O
%	NN	O	O
)	)	O	O
in	IN	O	O
households	NNS	O	O
without	IN	O	O
young	JJ	O	O
children	NNS	O	O
.	.	O	O

CONCLUSION	VB	O	O
This	DT	O	O
free	JJ	i	IOt
bednet	NN	i	IOt
distribution	NN	i	IOt
program	NN	i	IOt
achieved	VBN	O	O
high	JJ	O	O
levels	NNS	O	O
of	IN	O	O
adherence	NN	O	O
after	IN	O	O
6	CD	O	O
months	NNS	O	O
.	.	O	O

Household	NNP	O	O
presence	NN	O	O
of	IN	O	O
children	NNS	p	O
was	VBD	O	O
associated	VBN	O	O
with	IN	O	O
bednet	NN	O	O
use	NN	O	O
,	,	O	O
but	CC	O	O
not	RB	O	O
household	JJ	O	O
income	NN	O	O
or	CC	O	O
education	NN	O	O
,	,	O	O
suggesting	VBG	O	O
that	IN	O	O
distribution	NN	O	O
to	TO	O	O
priority	NN	O	O
groups	NNS	O	O
may	MD	O	O
help	VB	O	O
overcome	VB	O	O
traditional	JJ	O	O
barriers	NNS	O	O
to	TO	O	O
adoption	NN	O	O
in	IN	O	O
some	DT	O	O
settings	NNS	O	O
.	.	O	O

Safety	NN	o	OOt
and	CC	O	O
efficacy	NN	o	OOt
of	IN	O	O
a	DT	O	O
low	JJ	O	O
molecular	JJ	O	O
weight	NN	O	O
heparin	NN	O	O
(	(	O	O
Logiparin	NNP	O	O
)	)	O	O
versus	NN	O	O
dextran	NN	O	O
as	IN	O	O
prophylaxis	NN	O	O
against	IN	O	O
thrombosis	NN	o	O
after	IN	O	O
total	JJ	p	PC
hip	NN	p	PC
replacement	NN	p	PC
.	.	p	O

In	IN	O	O
order	NN	O	O
to	TO	O	O
study	VB	O	O
the	DT	O	O
plasma	NN	O	O
levels	NNS	O	O
of	IN	O	O
factor	NN	O	O
XaI	NNP	O	O
and	CC	O	O
IIaI	NNP	O	O
activity	NN	O	O
an	DT	O	O
enzymatically	RB	i	IPM
depolymerized	VBN	i	IPM
low	JJ	i	IPM
molecular	JJ	i	IPM
weight	NN	i	IPM
heparin	NN	i	IPM
(	(	i	IPM
LMW-heparin	NNP	i	IPM
;	:	i	IPM
Logiparin	NNP	i	IPM
)	)	i	IPM
was	VBD	O	O
given	VBN	O	O
s.c.	NN	O	O
in	IN	O	O
a	DT	O	O
dose	NN	O	O
of	IN	O	O
35	CD	O	O
XaI	NNP	O	O
mu/kg	NN	O	O
b.w	NN	O	O
.	.	O	O

once	RB	O	O
daily	JJ	O	O
for	IN	O	O
7	CD	O	O
days	NNS	O	O
to	TO	O	O
10	CD	p	PSS
patients	NNS	p	O
undergoing	JJ	p	O
total	JJ	p	O
hip	NN	p	O
replacement	NN	p	O
(	(	p	O
THR	NNP	p	PC
)	)	p	O
in	IN	O	O
a	DT	O	O
pilot	NN	O	O
study	NN	O	O
.	.	O	O

The	DT	O	O
XaI	NN	O	O
activity	NN	O	O
was	VBD	O	O
less	JJR	O	O
than	IN	O	O
or	CC	O	O
equal	JJ	O	O
to	TO	O	O
0.24	CD	O	O
XaI	NNP	O	O
units/ml	NN	O	O
and	CC	O	O
the	DT	O	O
IIaI	NNP	O	O
activity	NN	O	O
less	JJR	O	O
than	IN	O	O
or	CC	O	O
equal	JJ	O	O
to	TO	O	O
0.043	CD	O	O
IIaI	NNP	O	O
mu/ml	NN	O	O
.	.	O	O

No	DT	O	O
accumulation	NN	O	O
of	IN	O	O
the	DT	O	O
activities	NNS	O	O
were	VBD	O	O
seen	VBN	O	O
.	.	O	O

No	DT	O	O
phlebographically	RB	o	OPH
verified	VBN	o	OPH
thrombi	NN	o	OPH
or	CC	O	O
any	DT	O	O
bleeding	JJ	o	OPH
complications	NNS	o	OPH
were	VBD	O	O
registered	VBN	O	O
.	.	O	O

From	IN	O	O
this	DT	O	O
study	NN	O	O
it	PRP	O	O
was	VBD	O	O
concluded	VBN	O	O
that	IN	O	O
the	DT	O	O
given	VBN	O	O
dose	NN	O	O
of	IN	O	O
Logiparin	NNP	O	O
was	VBD	O	O
safe	JJ	O	O
with	IN	O	O
regard	NN	O	O
to	TO	O	O
bleeding	VBG	O	O
complications	NNS	O	O
.	.	O	O

Based	VBN	O	O
on	IN	O	O
these	DT	O	O
data	NNS	O	O
,	,	O	O
an	DT	O	O
open	JJ	O	O
,	,	O	O
randomized	VBD	O	O
controlled	VBN	O	O
trial	NN	O	O
was	VBD	O	O
started	VBN	O	O
.	.	O	O

In	IN	O	O
this	DT	O	O
main	JJ	O	O
study	NN	O	O
the	DT	O	O
thromboprophylactic	JJ	o	OPH
effect	NN	o	OPH
of	IN	O	O
the	DT	O	O
LMW-heparin	NNP	O	O
(	(	O	O
Logiparin	NNP	O	O
)	)	O	O
in	IN	O	O
a	DT	O	O
dose	NN	O	O
of	IN	O	O
35	CD	O	O
XaI	NNP	O	O
mu/kg	NN	O	O
b.w	NN	O	O
.	.	O	O

once	RB	O	O
daily	JJ	O	O
was	VBD	O	O
compared	VBN	O	O
with	IN	O	O
that	DT	O	O
of	IN	O	O
dextran	NN	O	O
70	CD	O	O
in	IN	O	O
patients	NNS	p	O
undergoing	JJ	p	PC
THR	NNP	p	PC
.	.	p	O

100	CD	p	PSS
patients	NNS	p	O
were	VBD	p	O
randomized	VBN	p	O
.	.	p	O

The	DT	O	O
over-all	JJ	o	OOt
thrombosis	NN	o	OOt
rate	NN	o	OOt
was	VBD	O	O
28	CD	O	O
%	NN	O	O
in	IN	O	O
patients	NNS	O	O
treated	VBN	O	O
with	IN	O	O
LMW-heparin	NNP	O	O
and	CC	O	O
39	CD	O	O
%	NN	O	O
in	IN	O	O
those	DT	O	O
given	VBN	O	O
dextran	NN	O	O
,	,	O	O
a	DT	O	O
non-significant	JJ	O	O
difference	NN	O	O
.	.	O	O

No	UH	O	O
bleeding	VBG	o	OA
complications	NNS	o	OA
,	,	o	O
deaths	NNS	o	OMO
or	CC	o	O
pulmonary	JJ	o	OPH
embolism	NN	o	OPH
were	VBD	O	O
recorded	VBN	O	O
in	IN	O	O
either	DT	O	O
group	NN	O	O
.	.	O	O

Peroperative	JJ	o	OPH
blood	NN	o	OPH
loss	NN	o	OPH
and	CC	o	OPH
transfusion	NN	o	OPH
requirements	NNS	o	OPH
were	VBD	O	O
similar	JJ	O	O
in	IN	O	O
the	DT	O	O
two	CD	O	O
groups	NNS	O	O
.	.	O	O

In	IN	O	O
conclusion	NN	O	O
,	,	O	O
the	DT	O	O
investigated	JJ	O	O
LMW-heparin	NNP	O	O
(	(	O	O
Logiparin	NNP	O	O
)	)	O	O
is	VBZ	O	O
safe	JJ	O	O
and	CC	O	O
effective	JJ	O	O
in	IN	O	O
preventing	VBG	O	O
postoperative	JJ	O	O
thromboembolism	NN	O	O
in	IN	O	O
patients	NNS	p	O
undergoing	JJ	p	O
total	JJ	p	O
hip	NN	p	O
replacement	NN	p	O
,	,	O	O
but	CC	O	O
the	DT	O	O
dosage	NN	O	O
can	MD	O	O
probably	RB	O	O
be	VB	O	O
optimized	VBN	O	O
.	.	O	O

Efficacy	NN	o	OOt
and	CC	o	OOt
safety	NN	o	OOt
of	IN	O	O
sildenafil	NN	i	IPM
in	IN	O	O
Asian	JJ	p	O
males	NNS	p	O
with	IN	p	O
erectile	JJ	p	PC
dysfunction	NN	p	PC
and	CC	p	O
cardiovascular	JJ	p	PC
risk	NN	p	PC
.	.	p	O

OBJECTIVE	NNP	O	O
Assess	NNP	O	O
the	DT	O	O
effectiveness	NN	O	O
of	IN	O	O
sildenafil	NN	i	IPM
in	IN	O	O
Asian	JJ	p	O
males	NNS	p	O
with	IN	p	O
erectile	JJ	p	PC
dysfunction	NN	p	PC
(	(	p	O
ED	NNP	p	PC
)	)	p	O
and	CC	p	O
one	CD	p	O
or	CC	p	O
more	JJR	p	O
of	IN	p	O
the	DT	p	O
co-morbidities	NNS	p	O
,	,	p	O
mild-to-moderate	JJ	p	O
hypertension	NN	p	PC
,	,	p	O
dyslipidemia	NN	p	PC
,	,	p	O
and	CC	p	O
diabetes	NNS	p	PC
.	.	p	O

MATERIAL	NNP	O	O
AND	NNP	O	O
METHOD	NNP	O	O
A	NNP	O	O
six-week	JJ	O	O
,	,	O	O
double-blind	JJ	O	O
,	,	O	O
randomized	VBN	O	O
,	,	O	O
placebo-controlled	JJ	i	IC
,	,	O	O
multicenter	NN	O	O
study	NN	O	O
was	VBD	O	O
carried	VBN	O	O
out	RP	O	O
in	IN	O	O
Thailand	NNP	O	O
,	,	O	O
Malaysia	NNP	O	O
and	CC	O	O
Singapore	NNP	O	O
.	.	O	O

One	CD	p	PSS
hundred	CD	p	PSS
and	CC	p	PSS
fifty	VB	p	PSS
five	CD	p	PSS
male	JJ	p	PSS
subjects	NNS	p	O
were	VBD	O	O
randomized	VBN	O	O
(	(	O	O
2:1	CD	O	O
)	)	O	O
to	TO	O	O
sildenafil	VB	i	IPM
(	(	O	O
n	JJ	O	O
=	NNP	O	O
104	CD	O	O
)	)	O	O
or	CC	O	O
placebo	NN	i	IC
(	(	O	O
n	JJ	O	O
=	NNP	O	O
51	CD	O	O
)	)	O	O
.	.	O	O

Sildenafil	NNP	i	IPM
was	VBD	O	O
started	VBN	O	O
at	IN	O	O
50	CD	O	O
mg	NN	O	O
and	CC	O	O
increased	VBD	O	O
(	(	O	O
100	CD	O	O
mg	NN	O	O
)	)	O	O
or	CC	O	O
decreased	VBN	O	O
(	(	O	O
25	CD	O	O
mg	NN	O	O
)	)	O	O
at	IN	O	O
week	NN	O	O
2	CD	O	O
if	IN	O	O
necessary	JJ	O	O
.	.	O	O

RESULTS	VB	O	O
On	IN	O	O
the	DT	O	O
primary	JJ	O	O
efficacy	NN	O	O
endpoint	NN	O	O
,	,	O	O
sildenafil-treated	JJ	i	IPM
subjects	NNS	O	O
had	VBD	O	O
significantly	RB	O	O
better	JJR	O	O
scores	NNS	o	O
on	IN	O	O
the	DT	O	O
International	NNP	o	OPH
Index	NNP	o	OPH
of	IN	o	OPH
Erectile	NNP	o	OPH
Function	NNP	o	OPH
(	(	o	OPH
IIEF	NNP	o	OPH
)	)	o	OPH
questions	NNS	o	OPH
3	CD	o	OPH
and	CC	o	OPH
4	CD	o	OPH
than	IN	O	O
placebo	NN	O	O
(	(	O	O
p	JJ	O	O
<	NN	O	O
0.001	CD	O	O
,	,	O	O
both	DT	O	O
questions	NNS	O	O
)	)	O	O
.	.	O	O

When	WRB	O	O
accumulated	VBN	O	O
into	IN	O	O
IIEF	NNP	O	O
domains	NNS	O	O
,	,	O	O
all	DT	O	O
five	CD	O	O
domains	NNS	O	O
were	VBD	O	O
significant	JJ	O	O
in	IN	O	O
favor	NN	O	O
of	IN	O	O
sildenafil	NN	O	O
.	.	O	O

In	IN	O	O
addition	NN	O	O
,	,	O	O
sildenafil-treated	JJ	i	IPM
subjects	NNS	O	O
were	VBD	O	O
more	RBR	O	O
satisfied	JJ	o	O
with	IN	O	O
treatment	NN	O	O
and	CC	O	O
had	VBD	O	O
a	DT	O	O
higher	JJR	O	O
intercourse	JJ	o	OPH
success	NN	o	OPH
rate	NN	o	OPH
.	.	o	O

The	DT	O	O
majority	NN	O	O
of	IN	O	O
adverse	JJ	O	O
events	NNS	O	O
were	VBD	O	O
mild	VBN	O	O
in	IN	O	O
severity	NN	o	O
;	:	o	O
the	DT	O	O
most	RBS	O	O
commonly	RB	O	O
reported	VBD	O	O
treatment-related	JJ	O	O
events	NNS	O	O
were	VBD	O	O
dizziness	NN	o	OA
(	(	O	O
7.7	CD	O	O
%	NN	O	O
)	)	O	O
and	CC	O	O
tinnitus	NN	o	OA
(	(	O	O
2.9	CD	O	O
%	NN	O	O
)	)	O	O
.	.	O	O

CONCLUSION	NNP	O	O
Sildenafil	NNP	O	O
(	(	O	O
25	CD	O	O
,	,	O	O
50	CD	O	O
,	,	O	O
and	CC	O	O
100	CD	O	O
mg	NN	O	O
)	)	O	O
was	VBD	O	O
found	VBN	O	O
to	TO	O	O
be	VB	O	O
an	DT	O	O
effective	JJ	O	O
,	,	O	O
safe	JJ	O	O
,	,	O	O
and	CC	O	O
well-tolerated	JJ	O	O
treatment	NN	O	O
for	IN	O	O
ED	NNP	O	O
in	IN	O	O
the	DT	O	O
present	JJ	O	O
study	NN	O	O
population	NN	O	O
of	IN	O	O
Thai	NNP	O	O
,	,	O	O
Malaysian	NNP	O	O
,	,	O	O
and	CC	O	O
Singaporean	NNP	O	O
males	NNS	O	O
who	WP	O	O
also	RB	O	O
had	VBD	O	O
increased	VBN	O	O
cardiovascular	JJ	O	O
risk	NN	O	O
T	NNP	O	O
lymphocyte	JJ	O	O
subsets	NNS	O	O
and	CC	O	O
NK	NNP	O	O
cell	VBP	O	O
cytotoxicity	NN	O	O
in	IN	O	O
chronic	JJ	p	O
hemodialysis	NN	p	PC
patients	NNS	p	O
.	.	p	O

The	DT	O	O
effect	NN	O	O
of	IN	O	O
recombinant	JJ	i	IPM
human	JJ	i	IPM
erythropoietin	NN	i	IPM
(	(	i	IPM
rHu-EPO	JJ	i	IPM
)	)	i	IPM
treatment	NN	i	O
.	.	i	O

We	PRP	O	O
investigated	VBD	O	O
subpopulations	NNS	O	O
of	IN	O	O
T	NNP	o	OPH
lymphocytes	NNS	o	OPH
,	,	o	O
NK	NNP	o	OPH
cell	NN	o	OPH
number	NN	o	OPH
and	CC	o	O
cytotoxic	JJ	o	OOt
activity	NN	o	OOt
in	IN	O	O
14	CD	p	PSS
chronic	JJ	p	PC
uremic	JJ	p	PC
patients	NNS	p	PC
on	IN	p	PC
regular	JJ	i	IC
hemodialysis	NN	i	IC
treatment	NN	i	IC
.	.	i	O

We	PRP	O	O
observed	VBD	O	O
a	DT	O	O
significantly	RB	O	O
decreased	VBN	O	O
absolute	NN	o	OPH
lymphocyte	NN	o	OPH
number	NN	o	OPH
and	CC	o	O
percentage	NN	o	OPH
of	IN	o	OPH
CD3	NNP	o	OPH
cells	NNS	o	OPH
.	.	o	O

Relative	JJ	O	O
numbers	NNS	O	O
of	IN	O	O
CD16	NNP	o	OPH
cells	NNS	o	OPH
were	VBD	O	O
significantly	RB	O	O
elevated	VBN	O	O
,	,	O	O
but	CC	O	O
NK	NNP	o	OPH
cell	VBP	o	OPH
cytotoxic	JJ	o	OPH
activity	NN	o	OPH
was	VBD	O	O
within	IN	O	O
a	DT	O	O
normal	JJ	O	O
range	NN	O	O
.	.	O	O

Nine	JJ	p	PSS
patients	NNS	p	O
with	IN	p	O
chronic	JJ	p	PC
renal	JJ	p	PC
anemia	NN	p	PC
on	IN	p	PC
maintenance	NN	p	PC
hemodialysis	NN	p	PC
were	VBD	O	O
enrolled	VBN	O	O
in	IN	O	O
rHu-EPO	JJ	i	IPM
treatment	NN	O	O
trial	NN	O	O
.	.	O	O

The	DT	O	O
treatment	NN	O	O
was	VBD	O	O
continued	VBN	O	O
till	IN	O	O
the	DT	O	O
hematocrit	NN	o	OPH
level	NN	o	OPH
reached	VBD	O	O
30	CD	O	O
%	NN	O	O
.	.	O	O

Each	DT	O	O
of	IN	O	O
the	DT	O	O
patients	NNS	p	O
had	VBD	p	O
corrected	VBN	O	O
anemia	NN	o	OPH
and	CC	O	O
well-being	NN	O	O
.	.	O	O

After	IN	O	O
12	CD	O	O
weeks	NNS	O	O
of	IN	O	O
the	DT	O	O
treatment	NN	O	O
we	PRP	O	O
observed	VBD	O	O
in	IN	O	O
these	DT	O	O
patients	NNS	O	O
decreases	NNS	O	O
in	IN	O	O
CD3	NNP	o	OPH
,	,	o	OPH
CD4	NNP	o	OPH
,	,	o	OPH
CD8	NNP	o	OPH
and	CC	o	OPH
CD16	NNP	o	OPH
cell	NN	o	OPH
numbers	NNS	o	OPH
and	CC	O	O
elevation	NN	O	O
of	IN	O	O
CD4/CD8	NNP	o	OPH
ratio	NN	o	OPH
.	.	o	O

Cytotoxic	NNP	o	OPH
activity	NN	o	OPH
of	IN	o	OPH
NK	NNP	o	OPH
cells	NNS	o	OPH
did	VBD	O	O
not	RB	O	O
change	VB	O	O
significantly	RB	O	O
.	.	O	O

Presented	VBN	O	O
results	NNS	O	O
indicate	VBP	O	O
that	IN	O	O
chronic	JJ	p	O
hemodialysis	NN	p	O
patients	NNS	p	O
have	VBP	O	O
significantly	RB	O	O
diminished	VBN	O	O
lymphocyte	JJ	o	OPH
number	NN	o	OPH
.	.	o	O

rHu	JJ	i	IPM
EPO	NNP	i	IPM
treatment	NN	O	O
affects	VBZ	O	O
the	DT	O	O
T	NNP	O	O
lymphocyte	NN	O	O
subsets	NNS	O	O
inducing	VBG	O	O
a	DT	O	O
deep	JJ	O	O
decrease	NN	O	O
of	IN	O	O
CD8	NNP	o	OPH
and	CC	o	OPH
CD16	NNP	o	OPH
cell	NN	o	OPH
percentage	NN	o	OPH
leading	VBG	O	O
to	TO	O	O
normalisation	NN	O	O
of	IN	O	O
the	DT	O	O
CD4/CD8	NNP	o	OPH
ratio	NN	o	OPH
.	.	o	O

Mechanical	JJ	o	OPH
efficiency	NN	o	OPH
and	CC	o	O
propulsion	NN	o	OPH
technique	NN	o	OPH
after	IN	O	O
7	CD	O	O
weeks	NNS	O	O
of	IN	O	O
low-intensity	JJ	O	O
wheelchair	NN	O	O
training	NN	O	O
.	.	O	O

BACKGROUND	NNP	O	O
To	TO	O	O
evaluate	VB	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
a	DT	O	O
7-week	JJ	O	O
low-intensity	NN	O	O
hand	NN	O	O
rim	VBZ	O	O
wheelchair	JJ	O	O
training	VBG	O	O
on	IN	O	O
the	DT	O	O
submaximal	JJ	O	O
metabolic	NN	O	O
cost	NN	O	O
,	,	O	O
mechanical	JJ	o	OPH
efficiency	NN	o	OPH
and	CC	O	O
propulsion	NN	O	O
technique	NN	O	O
in	IN	O	O
able-bodied	JJ	p	O
participants	NNS	p	O
.	.	p	O

METHODS	JJ	O	O
Participants	NNS	p	O
were	VBD	O	O
randomly	RB	O	O
divided	VBN	O	O
over	RP	O	O
an	DT	O	O
experimental	JJ	O	O
group	NN	O	O
(	(	p	O
n=14	CC	p	O
)	)	p	O
and	CC	p	O
a	DT	p	O
control	NN	p	O
group	NN	p	O
(	(	p	O
n=7	RB	p	O
)	)	p	O
.	.	p	O

The	DT	O	O
experimental	JJ	O	O
group	NN	O	O
received	VBD	i	O
7	CD	i	O
weeks	NNS	i	O
wheelchair	JJ	i	IPH
training	NN	i	IPH
(	(	i	O
3	CD	i	O
week	NN	i	O
(	(	i	O
-1	NN	i	O
)	)	i	O
,	,	i	O
70	CD	i	O
min	NN	i	O
)	)	i	O
at	IN	i	O
a	DT	i	O
low	JJ	i	O
intensity	NN	i	O
(	(	i	O
30	CD	i	O
%	NN	i	O
of	IN	i	O
the	DT	i	O
heart	NN	i	O
rate	NN	i	O
reserve	NN	i	O
)	)	i	O
,	,	i	O
whereas	IN	i	O
the	DT	i	O
control	NN	i	IE
group	NN	i	O
did	VBD	i	IE
not	RB	i	IE
receive	VB	i	IE
training	NN	i	IE
.	.	i	O

During	IN	i	O
pre-	JJ	i	O
and	CC	i	O
post-tests	NNS	i	O
,	,	i	O
submaximal	JJ	i	O
exercise	NN	i	O
was	VBD	i	O
performed	VBN	i	O
on	IN	i	O
a	DT	i	O
stationary	JJ	i	O
wheelchair	NN	i	IPH
ergometer	NN	i	O
at	IN	i	O
fixed	JJ	i	O
levels	NNS	i	O
of	IN	i	O
power	NN	i	O
output	NN	i	O
.	.	i	O

Mechanical	JJ	o	OPH
efficiency	NN	o	OPH
,	,	o	O
oxygen	NN	o	OPH
uptake	NN	o	OPH
,	,	o	O
heart	NN	o	OPH
rate	NN	o	OPH
,	,	o	O
timing	VBG	o	OOt
parameters	NNS	o	OOt
and	CC	o	O
stroke	NN	o	OPH
angles	NNS	o	OPH
were	VBD	i	O
measured	VBN	i	O
.	.	i	O

Video	NNP	O	O
recordings	NNS	O	O
were	VBD	O	O
made	VBN	O	O
to	TO	O	O
determine	VB	O	O
the	DT	O	O
stroke	NN	o	OPH
pattern	NN	o	OPH
.	.	o	O

FINDINGS	NNP	O	O
Mechanical	NNP	o	OPH
efficiency	NN	o	OPH
increased	VBD	o	O
and	CC	o	O
metabolic	JJ	o	OPH
cost	NN	o	OPH
decreased	VBN	o	O
significantly	RB	O	O
in	IN	O	O
the	DT	O	O
experimental	JJ	O	O
group	NN	O	O
compared	VBN	O	O
to	TO	O	O
the	DT	O	O
control	NN	O	O
group	NN	O	O
.	.	O	O

Push	NNP	o	OOt
time	NN	o	OOt
increased	VBD	O	O
and	CC	O	O
cycle	NN	o	OOt
frequency	NN	o	OOt
decreased	VBD	O	O
as	IN	O	O
a	DT	O	O
result	NN	O	O
of	IN	O	O
training	NN	O	O
.	.	O	O

The	DT	O	O
stroke	NN	o	OPH
angle	NN	o	OPH
increased	VBD	O	O
in	IN	O	O
the	DT	O	O
experimental	JJ	O	O
group	NN	O	O
during	IN	O	O
the	DT	O	O
training	NN	O	O
period	NN	O	O
.	.	O	O

The	DT	O	O
experimental	JJ	O	O
group	NN	O	O
preferred	VBD	O	O
double-looping	NN	O	O
over	IN	O	O
propulsion	NN	O	O
,	,	O	O
while	IN	O	O
the	DT	O	O
control	NN	O	O
group	NN	O	O
mainly	RB	O	O
used	VBD	O	O
single-looping	NN	o	OOt
over	IN	o	OOt
propulsion	NN	o	OOt
patterns	NNS	O	O
during	IN	O	O
the	DT	O	O
post-test	JJ	O	O
.	.	O	O

INTERPRETATION	VB	O	O
A	DT	O	O
low-intensity	NN	O	O
,	,	O	O
7-week	JJ	O	O
training	NN	O	O
protocol	NN	O	O
has	VBZ	O	O
a	DT	O	O
beneficial	JJ	O	O
effect	NN	O	O
on	IN	O	O
the	DT	O	O
mechanical	JJ	o	OPH
efficiency	NN	o	OPH
and	CC	o	O
metabolic	JJ	o	OPH
cost	NN	o	OPH
of	IN	O	O
wheelchair	NN	O	O
propulsion	NN	O	O
in	IN	O	O
able-bodied	JJ	p	O
participants	NNS	p	O
.	.	p	O

The	DT	O	O
improved	JJ	O	O
mechanical	JJ	O	O
efficiency	NN	O	O
seems	VBZ	O	O
to	TO	O	O
be	VB	O	O
the	DT	O	O
result	NN	O	O
of	IN	O	O
changes	NNS	O	O
in	IN	O	O
propulsion	NN	O	O
technique	NN	O	O
that	WDT	O	O
were	VBD	O	O
found	VBN	O	O
.	.	O	O

Randomized	VBN	O	O
trial	NN	O	O
of	IN	O	O
daily	JJ	O	O
versus	FW	O	O
weekly	JJ	O	O
administration	NN	O	O
of	IN	O	O
2-chlorodeoxyadenosine	JJ	i	IPM
in	IN	O	O
patients	NNS	p	PC
with	IN	p	PC
hairy	JJ	p	PC
cell	NN	p	PC
leukemia	NN	p	PC
:	:	p	PC
a	DT	p	PC
multicenter	NN	p	PC
phase	NN	p	PC
III	NNP	p	PC
trial	NN	p	PC
(	(	p	PC
SAKK	NNP	p	PC
32/98	CD	p	PC
)	)	p	PC
.	.	p	PC

Daily	JJ	O	O
administration	NN	O	O
of	IN	O	O
2-chlorodeoxyadenosine	JJ	i	IPM
(	(	i	IPM
Cladribine	NNP	i	IPM
,	,	i	IPM
CDA	NNP	i	IPM
)	)	i	IPM
is	VBZ	O	O
a	DT	O	O
standard	JJ	O	O
treatment	NN	O	O
for	IN	O	O
hairy	NN	O	O
cell	NN	O	O
leukemia	NN	O	O
,	,	O	O
but	CC	O	O
may	MD	O	O
cause	VB	O	O
severe	JJ	O	O
neutropenia	NN	o	OPH
and	CC	o	OPH
neutropenic	JJ	o	OPH
fever	NN	o	OPH
.	.	o	O

This	DT	O	O
trial	NN	O	O
compared	VBN	O	O
toxicity	NN	O	O
and	CC	O	O
efficacy	NN	O	O
of	IN	O	O
weekly	JJ	O	O
versus	NN	O	O
daily	RB	O	O
CDA	NNP	i	IPM
administration	NN	O	O
.	.	O	O

One	CD	p	O
hundred	VBD	p	O
patients	NNS	p	O
were	VBD	O	O
randomized	VBN	O	O
to	TO	O	O
receive	VB	O	O
standard	NN	O	O
(	(	i	O
CDA	NNP	i	IPM
0.14	CD	O	O
mg/kg/day	JJ	O	O
day	NN	O	O
1-5	JJ	O	O
[	NNP	O	O
Arm	NNP	O	O
A	NNP	O	O
]	NN	O	O
)	)	O	O
or	CC	O	O
experimental	JJ	O	O
treatment	NN	O	O
(	(	i	O
CDA	NNP	i	IPM
0.14	CD	O	O
mg/kg/day	NN	O	O
once	RB	O	O
weekly	JJ	O	O
for	IN	O	O
5	CD	O	O
weeks	NNS	O	O
[	JJ	O	O
Arm	NNP	O	O
B	NNP	O	O
]	NN	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
primary	JJ	O	O
endpoint	NN	O	O
was	VBD	O	O
average	JJ	o	OPH
leukocyte	JJ	o	OPH
count	NN	o	OPH
within	IN	O	O
6	CD	O	O
weeks	NNS	O	O
from	IN	O	O
randomization	NN	O	O
.	.	O	O

Secondary	JJ	O	O
endpoints	NNS	O	O
included	VBD	O	O
response	NN	o	OPH
rates	NNS	o	OPH
,	,	o	O
other	JJ	o	OPH
acute	JJ	o	OA
hematotoxicity	NN	o	OA
,	,	o	O
acute	JJ	o	OA
infection	NN	o	OA
rate	NN	o	OA
,	,	o	O
hospital	NN	o	OOt
admission	NN	o	OOt
,	,	o	O
remission	NN	o	OOt
duration	NN	o	OOt
,	,	o	O
event-free	JJ	o	OMO
,	,	o	OMO
and	CC	o	OMO
overall	JJ	o	OMO
survival	NN	o	OMO
.	.	o	O

There	EX	O	O
was	VBD	O	O
no	DT	O	O
significant	JJ	O	O
difference	NN	O	O
in	IN	O	O
average	JJ	o	O
leukocyte	JJ	o	OPH
count	NN	o	OPH
.	.	o	O

Response	JJ	o	OPH
rate	NN	o	OPH
(	(	O	O
complete	JJ	O	O
+	NNP	O	O
partial	JJ	O	O
remission	NN	O	O
)	)	O	O
at	IN	O	O
week	NN	O	O
10	CD	O	O
was	VBD	O	O
78	CD	O	O
%	NN	O	O
(	(	O	O
95	CD	O	O
%	NN	O	O
confidence	NN	O	O
interval	NN	O	O
(	(	O	O
CI	NNP	O	O
)	)	O	O
64-88	CD	O	O
%	NN	O	O
)	)	O	O
in	IN	O	O
Arm	NNP	O	O
A	NNP	O	O
and	CC	O	O
68	CD	O	O
%	NN	O	O
(	(	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
54-80	CD	O	O
%	NN	O	O
)	)	O	O
in	IN	O	O
Arm	NNP	O	O
B	NNP	O	O
(	(	O	O
p	JJ	O	O
=	NNP	O	O
0.13	CD	O	O
)	)	O	O
.	.	O	O

Best	JJS	O	O
response	NN	o	OPH
rates	NNS	o	OPH
during	IN	O	O
follow-up	JJ	O	O
were	VBD	O	O
identical	JJ	O	O
(	(	O	O
86	CD	O	O
%	NN	O	O
)	)	O	O
in	IN	O	O
both	DT	O	O
arms	NNS	O	O
.	.	O	O

No	DT	O	O
significant	JJ	O	O
difference	NN	O	O
was	VBD	O	O
found	VBN	O	O
in	IN	O	O
the	DT	O	O
rate	NN	O	O
of	IN	O	O
grade	NN	o	OPH
3+4	CD	o	OPH
leukocytopenia	NN	o	OPH
(	(	O	O
94	CD	O	O
%	NN	O	O
vs	NN	O	O
.	.	O	O

84	CD	O	O
%	NN	O	O
)	)	O	O
,	,	O	O
grade	VBD	o	OPH
3+4	CD	o	OPH
neutropenia	NN	o	OPH
(	(	O	O
90	CD	O	O
%	NN	O	O
vs	NN	O	O
.	.	O	O

80	CD	O	O
%	NN	O	O
)	)	O	O
,	,	O	O
acute	JJ	o	OPH
infection	NN	o	OPH
(	(	O	O
44	CD	O	O
%	NN	O	O
vs	NN	O	O
.	.	O	O

40	CD	O	O
%	NN	O	O
)	)	O	O
,	,	O	O
hospitalization	NN	o	OOt
(	(	O	O
38	CD	O	O
%	NN	O	O
vs	NN	O	O
.	.	O	O

34	CD	O	O
%	NN	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
erythrocyte	JJ	o	OPH
support	NN	o	OPH
(	(	O	O
22	CD	O	O
%	NN	O	O
vs	NN	O	O
.	.	O	O

30	CD	O	O
%	NN	O	O
)	)	O	O
within	IN	O	O
10	CD	O	O
weeks	NNS	O	O
.	.	O	O

Overall	JJ	O	O
,	,	O	O
these	DT	O	O
findings	NNS	O	O
indicate	VBP	O	O
that	IN	O	O
there	EX	O	O
are	VBP	O	O
no	DT	O	O
apparent	JJ	O	O
advantages	NNS	O	O
in	IN	O	O
toxicity	NN	o	OOt
and	CC	o	OOt
efficacy	NN	o	OOt
by	IN	O	O
giving	VBG	O	O
CDA	NNP	i	IPM
weekly	RB	O	O
rather	RB	O	O
than	IN	O	O
daily	RB	O	O
.	.	O	O

Immunologic	NNP	O	O
and	CC	O	O
hemodynamic	JJ	O	O
effects	NNS	O	O
of	IN	O	O
low-dose	JJ	i	IPM
hydrocortisone	NN	i	IPM
in	IN	O	O
septic	JJ	p	PC
shock	NN	p	PC
:	:	p	PC
a	DT	O	O
double-blind	NN	O	O
,	,	O	O
randomized	VBN	O	O
,	,	O	O
placebo-controlled	JJ	i	IC
,	,	O	O
crossover	NN	O	O
study	NN	O	O
.	.	O	O

Within	IN	O	O
the	DT	O	O
last	JJ	O	O
few	JJ	O	O
years	NNS	O	O
,	,	O	O
increasing	VBG	O	O
evidence	NN	O	O
of	IN	O	O
relative	JJ	O	O
adrenal	JJ	p	PC
insufficiency	NN	p	PC
in	IN	p	O
septic	JJ	p	PC
shock	NN	p	PC
evoked	VBD	O	O
a	DT	O	O
reassessment	NN	O	O
of	IN	O	O
hydrocortisone	NN	i	IPM
therapy	NN	i	O
.	.	i	O

To	TO	O	O
evaluate	VB	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
hydrocortisone	NN	i	IPM
on	IN	O	O
the	DT	O	O
balance	NN	O	O
between	IN	O	O
proinflammatory	NN	O	O
and	CC	O	O
antiinflammation	NN	O	O
,	,	O	O
40	CD	p	PSS
patients	NNS	p	O
with	IN	p	O
septic	JJ	p	PC
shock	NN	p	PC
were	VBD	O	O
randomized	VBN	O	O
in	IN	O	O
a	DT	O	O
double-blind	JJ	O	O
crossover	NN	O	O
study	NN	O	O
to	TO	O	O
receive	VB	O	O
either	CC	O	O
the	DT	O	O
first	JJ	O	O
100	CD	O	O
mg	NN	O	O
of	IN	O	O
hydrocortisone	NN	i	IPM
as	IN	O	O
a	DT	O	O
loading	NN	O	O
dose	NN	O	O
and	CC	O	O
10	CD	O	O
mg	NNS	O	O
per	IN	O	O
hour	NN	O	O
until	IN	O	O
Day	NNP	O	O
3	CD	O	O
(	(	O	O
n	JJ	O	O
=	NNP	O	O
20	CD	O	O
)	)	O	O
or	CC	O	O
placebo	NN	i	IC
(	(	O	O
n	JJ	O	O
=	NNP	O	O
20	CD	O	O
)	)	O	O
,	,	O	O
followed	VBN	O	O
by	IN	O	O
the	DT	O	O
opposite	JJ	O	O
medication	NN	O	O
until	IN	O	O
Day	NNP	O	O
6	CD	O	O
.	.	O	O

Hydrocortisone	CD	i	IPM
infusion	NN	O	O
induced	VBD	O	O
an	DT	O	O
increase	NN	O	O
of	IN	O	O
mean	JJ	o	OPH
arterial	JJ	o	OPH
pressure	NN	o	OPH
,	,	o	OPH
systemic	JJ	o	OPH
vascular	NN	o	OPH
resistance	NN	o	OPH
,	,	O	O
and	CC	O	O
a	DT	O	O
decline	NN	O	O
of	IN	O	O
heart	NN	o	OPH
rate	NN	o	OPH
,	,	o	O
cardiac	JJ	o	OPH
index	NN	o	OPH
,	,	o	O
and	CC	o	O
norepinephrine	JJ	o	OOt
requirement	NN	o	OOt
.	.	o	O

A	DT	O	O
reduction	NN	O	O
of	IN	O	O
plasma	NN	o	OPH
nitrite/nitrate	NN	o	OPH
indicated	VBD	O	O
inhibition	NN	O	O
of	IN	O	O
nitric	JJ	o	OPH
oxide	JJ	o	OPH
formation	NN	o	OPH
and	CC	O	O
correlated	VBN	O	O
with	IN	O	O
a	DT	O	O
reduction	NN	o	OPH
of	IN	o	OPH
vasopressor	NN	o	OPH
support	NN	o	OPH
.	.	o	OPH

The	DT	O	O
inflammatory	JJ	o	OPH
response	NN	o	OPH
(	(	o	OPH
interleukin-6	JJ	o	OPH
and	CC	o	OPH
interleukin-8	JJ	o	OPH
)	)	o	OPH
,	,	o	OPH
endothelial	JJ	o	OPH
(	(	o	OPH
soluble	JJ	o	OPH
E-selectin	NN	o	OPH
)	)	o	OPH
and	CC	o	OPH
neutrophil	JJ	o	OPH
activation	NN	o	OPH
(	(	o	OPH
expression	NN	o	OPH
of	IN	o	OPH
CD11b	NNP	o	OPH
,	,	o	OPH
CD64	NNP	o	OPH
)	)	o	OPH
,	,	o	OPH
and	CC	o	OPH
antiinflammatory	JJ	o	OPH
response	NN	o	OPH
(	(	o	OPH
soluble	JJ	o	OPH
tumor	NN	o	OPH
necrosis	NN	o	OPH
factor	NN	o	OPH
receptors	NNS	o	OPH
I	PRP	o	OPH
and	CC	o	OPH
II	NNP	o	OPH
and	CC	o	OPH
interleukin-10	JJ	o	OPH
)	)	o	OPH
were	VBD	O	O
attenuated	VBN	O	O
.	.	O	O

In	IN	O	O
peripheral	JJ	O	O
blood	NN	O	O
monocytes	NNS	O	O
,	,	O	O
human	JJ	o	OPH
leukocyte	VBD	o	OPH
antigen-DR	JJ	o	OPH
expression	NN	o	OPH
was	VBD	O	O
only	RB	O	O
slightly	RB	O	O
depressed	VBN	O	O
,	,	O	O
whereas	NNS	O	O
in	IN	o	OPH
vitro	JJ	o	OPH
phagocytosis	NN	o	OPH
and	CC	o	OPH
the	DT	o	OPH
monocyte-activating	JJ	o	OPH
cytokine	JJ	o	OPH
interleukin-12	NN	o	OPH
increased	VBD	O	O
.	.	O	O

Hydrocortisone	NNP	i	IPM
withdrawal	NN	O	O
induced	VBD	O	O
hemodynamic	JJ	o	OA
and	CC	o	OA
immunologic	JJ	o	OA
rebound	NN	o	OA
effects	NNS	o	OA
.	.	o	OA

In	IN	O	O
conclusion	NN	O	O
,	,	O	O
hydrocortisone	NN	i	IPM
therapy	NN	i	O
restored	VBD	O	O
hemodynamic	JJ	o	OPH
stability	NN	o	OPH
and	CC	O	O
differentially	RB	O	O
modulated	VBD	O	O
the	DT	O	O
immunologic	JJ	o	OPH
response	NN	o	OPH
to	TO	o	OPH
stress	VB	o	OPH
in	IN	O	O
a	DT	O	O
way	NN	O	O
of	IN	O	O
antiinflammation	NN	O	O
rather	RB	O	O
than	IN	O	O
immunosuppression	NN	O	O
.	.	O	O

Effectiveness	NN	O	O
of	IN	O	O
Dader	NNP	i	IE
Method	NNP	i	IE
for	IN	O	O
pharmaceutical	JJ	O	O
care	NN	O	O
on	IN	O	O
control	NN	o	OPH
of	IN	o	OPH
blood	NN	o	OPH
pressure	NN	o	OPH
and	CC	o	O
total	JJ	o	OPH
cholesterol	NN	o	OPH
in	IN	O	O
outpatients	NNS	p	O
with	IN	p	O
cardiovascular	JJ	p	PC
disease	NN	p	PC
or	CC	p	O
cardiovascular	JJ	p	PC
risk	NN	p	PC
:	:	p	O
EMDADER-CV	JJ	O	O
randomized	NNS	O	O
controlled	VBN	O	O
trial	NN	O	O
.	.	O	O

BACKGROUND	NNP	O	O
Although	IN	O	O
some	DT	O	O
studies	NNS	O	O
have	VBP	O	O
demonstrated	VBN	O	O
that	IN	O	O
pharmacist	JJ	i	IE
intervention	NN	i	IE
can	MD	O	O
improve	VB	O	O
drug	NN	O	O
therapy	NN	O	O
among	IN	O	O
patients	NNS	p	O
with	IN	p	O
cardiovascular	JJ	p	PC
disease	NN	p	PC
(	(	p	O
CVD	NNP	p	PC
)	)	p	O
,	,	O	O
more	JJR	O	O
evidence	NN	O	O
derived	VBN	O	O
from	IN	O	O
randomized	VBN	O	O
controlled	VBN	O	O
trials	NNS	O	O
(	(	O	O
RCTs	NNP	O	O
)	)	O	O
is	VBZ	O	O
needed	VBN	O	O
,	,	O	O
including	VBG	O	O
assessment	NN	O	O
of	IN	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
community	NN	i	IE
pharmacist	NN	i	IE
interventions	NNS	i	IE
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
CVD	NNP	p	PC
.	.	p	O

OBJECTIVE	NNP	O	O
To	TO	O	O
assess	VB	O	O
the	DT	O	O
effectiveness	NN	O	O
of	IN	O	O
the	DT	O	O
Dader	NNP	i	IE
Method	NNP	i	IE
for	IN	i	IE
pharmaceutical	JJ	i	IE
care	NN	i	IE
on	IN	O	O
achieving	VBG	O	O
therapeutic	JJ	O	O
goals	NNS	O	O
for	IN	O	O
blood	NN	o	OPH
pressure	NN	o	OPH
(	(	o	OPH
BP	NNP	o	OPH
)	)	o	OPH
,	,	o	O
total	JJ	o	OPH
cholesterol	NN	o	OPH
(	(	o	OPH
TC	NNP	o	OPH
)	)	o	OPH
,	,	O	O
and	CC	O	O
both	DT	o	OPH
BP	NNP	o	OPH
and	CC	o	O
TC	NNP	o	OPH
(	(	o	OPH
BP/TC	NNP	o	OPH
)	)	o	OPH
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
CVD	NNP	p	O
and/or	VBP	p	O
high	JJ	p	PC
or	CC	p	PC
intermediate	JJ	p	PC
cardiovascular	NN	p	PC
(	(	p	PC
CV	NNP	p	PC
)	)	p	PC
risk	NN	p	PC
attending	VBG	p	O
community	NN	p	O
pharmacies	NNS	p	O
in	IN	p	O
Spain	NNP	p	O
.	.	p	O

METHODS	NNP	O	O
Patients	NNPS	p	O
aged	VBD	p	O
25	CD	p	PA
to	TO	p	PA
74	CD	p	PA
years	NNS	p	O
attending	VBG	p	O
community	NN	p	O
pharmacies	NNS	p	O
with	IN	p	O
a	DT	p	O
prescription	NN	p	O
for	IN	p	O
at	IN	p	O
least	JJS	p	O
1	CD	p	O
drug	NN	p	O
indicated	VBN	p	O
for	IN	p	O
CVD	NNP	p	O
or	CC	p	O
CV	NNP	p	PC
risk	NN	p	O
factors	NNS	p	O
were	VBD	O	O
randomized	VBN	O	O
to	TO	O	O
2	CD	O	O
groups	NNS	O	O
:	:	O	O
an	DT	O	O
intervention	NN	i	IE
group	NN	i	IE
that	WDT	i	IE
received	VBD	i	IE
pharmaceutical	JJ	i	IE
care	NN	i	IE
,	,	i	IE
which	WDT	i	IE
was	VBD	i	IE
provided	VBN	i	IE
by	IN	i	IE
specially	RB	i	IE
trained	JJ	i	IE
pharmacists	NNS	i	IE
working	VBG	i	IE
in	IN	i	IE
collaboration	NN	i	IE
with	IN	i	IE
physicians	NNS	i	IE
,	,	O	O
and	CC	O	O
a	DT	O	O
control	NN	i	IE
group	NN	i	IE
that	WDT	i	IE
received	VBD	i	IE
usual	JJ	i	IE
care	NN	i	IE
(	(	i	IE
routine	JJ	i	IE
dispensing	VBG	i	IE
counseling	NN	i	IE
)	)	i	IE
and	CC	i	IE
verbal	JJ	i	IE
and	CC	i	IE
written	VBN	i	IE
counseling	VBG	i	IE
regarding	VBG	i	IE
CVD	NNP	i	IE
prevention	NN	i	IE
.	.	i	O

Patients	NNS	p	O
were	VBD	p	O
recruited	VBN	p	O
from	IN	p	O
December	NNP	p	O
2005	CD	p	O
to	TO	p	O
September	NNP	p	O
2006	CD	p	O
,	,	O	O
and	CC	O	O
both	DT	O	O
groups	NNS	O	O
were	VBD	O	O
followed	VBN	O	O
for	IN	O	O
8	CD	O	O
months	NNS	O	O
.	.	O	O

Study	NNP	O	O
outcomes	NNS	O	O
were	VBD	O	O
assessed	VBN	O	O
at	IN	O	O
baseline	NN	O	O
and	CC	O	O
at	IN	O	O
16	CD	O	O
and	CC	O	O
32	CD	O	O
weeks	NNS	O	O
after	IN	O	O
randomization	NN	O	O
.	.	O	O

The	DT	O	O
primary	JJ	O	O
outcome	NN	O	O
measures	NNS	O	O
were	VBD	O	O
the	DT	O	O
proportions	NNS	o	OPH
of	IN	o	OPH
patients	NNS	o	OPH
achieving	VBG	o	OPH
BP	NNP	o	OPH
,	,	o	O
TC	NNP	o	OPH
,	,	o	O
and	CC	o	O
BP/TC	NNP	o	OPH
therapeutic	JJ	o	OPH
goals	NNS	o	OPH
(	(	O	O
BP	NNP	O	O
lower	JJR	O	O
than	IN	O	O
140/90	CD	O	O
mm	NNS	O	O
Hg	NNP	O	O
for	IN	O	O
patients	NNS	O	O
with	IN	O	O
uncomplicated	JJ	O	O
hypertension	NN	O	O
and	CC	O	O
lower	JJR	O	O
than	IN	O	O
130/80	CD	O	O
mm	NNS	O	O
Hg	NNP	O	O
for	IN	O	O
patients	NNS	O	O
with	IN	O	O
diabetes	NNS	O	O
,	,	O	O
chronic	JJ	O	O
kidney	NN	O	O
disease	NN	O	O
,	,	O	O
or	CC	O	O
history	NN	O	O
of	IN	O	O
myocardial	JJ	O	O
infarction	NN	O	O
or	CC	O	O
stroke	NN	O	O
;	:	O	O
TC	NNP	O	O
lower	JJR	O	O
than	IN	O	O
200	CD	O	O
mg	NNS	O	O
per	IN	O	O
dL	NN	O	O
for	IN	O	O
patients	NNS	O	O
without	IN	O	O
CVD	NNP	O	O
and	CC	O	O
lower	JJR	O	O
than	IN	O	O
175	CD	O	O
mg	NNS	O	O
per	IN	O	O
dL	NN	O	O
for	IN	O	O
patients	NNS	O	O
with	IN	O	O
CVD	NNP	O	O
)	)	O	O
.	.	O	O

Secondary	JJ	O	O
outcomes	NNS	O	O
were	VBD	O	O
mean	JJ	o	OPH
BP	NNP	o	OPH
and	CC	o	O
TC	NNP	o	OPH
values	NNS	o	OPH
.	.	o	O

BP	NNP	o	OPH
was	VBD	o	O
assessed	VBN	o	O
manually	RB	o	O
by	IN	O	O
the	DT	O	O
pharmacist	NN	O	O
after	IN	O	O
a	DT	O	O
10-minute	JJ	O	O
rest	NN	O	O
in	IN	O	O
the	DT	O	O
supine	JJ	O	O
position	NN	O	O
.	.	O	O

This	DT	O	O
measurement	NN	O	O
was	VBD	O	O
performed	VBN	O	O
twice	RB	O	O
for	IN	O	O
every	DT	O	O
participant	NN	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
average	NN	O	O
of	IN	O	O
the	DT	O	O
2	CD	O	O
measurements	NNS	O	O
was	VBD	O	O
calculated	VBN	O	O
.	.	O	O

TC	NNP	o	OPH
was	VBD	O	O
measured	VBN	O	O
by	IN	O	O
the	DT	O	O
pharmacist	NN	O	O
during	IN	O	O
the	DT	O	O
study	NN	O	O
visit	NN	O	O
using	VBG	O	O
the	DT	O	O
enzymatic	JJ	o	O
dry	JJ	o	O
method	NN	o	O
.	.	o	O

Statistical	JJ	O	O
analyses	NNS	O	O
were	VBD	O	O
performed	VBN	O	O
using	VBG	O	O
2-tailed	JJ	O	O
McNemar	NNP	O	O
tests	NNS	O	O
,	,	O	O
Pearson	NNP	O	O
chi-square	NN	O	O
tests	NNS	O	O
,	,	O	O
and	CC	O	O
Student	NNP	O	O
's	POS	O	O
t-tests	NNS	O	O
;	:	O	O
P	NNP	O	O
<	VBD	O	O
0.05	CD	O	O
was	VBD	O	O
considered	VBN	O	O
statistically	RB	O	O
significant	JJ	O	O
.	.	O	O

RESULTS	VB	O	O
714	CD	p	PSS
patients	NNS	p	O
were	VBD	O	O
included	VBN	O	O
in	IN	O	O
the	DT	O	O
study	NN	O	O
(	(	O	O
356	CD	O	O
intervention	NN	i	O
,	,	O	O
358	CD	O	O
control	NN	i	O
)	)	i	O
,	,	O	O
and	CC	O	O
the	DT	O	O
mean	JJ	p	O
[	NNP	p	O
SD	NNP	p	O
]	NNP	p	O
age	NN	p	O
was	VBD	p	O
62.8	CD	p	PA
[	JJ	p	O
8.1	CD	p	O
]	JJ	p	O
years	NNS	p	O
.	.	p	O

The	DT	O	O
2	CD	O	O
groups	NNS	O	O
were	VBD	O	O
similar	JJ	O	O
at	IN	O	O
baseline	NN	O	O
in	IN	O	O
clinical	JJ	O	O
and	CC	O	O
demographic	JJ	O	O
characteristics	NNS	O	O
,	,	O	O
including	VBG	O	O
the	DT	O	O
proportion	NN	O	O
of	IN	O	O
patients	NNS	O	O
at	IN	O	O
therapeutic	JJ	O	O
goals	NNS	o	O
for	IN	o	O
BP	NNP	o	OPH
,	,	o	O
TC	NNP	o	OPH
,	,	o	O
and	CC	o	O
BP/TC	NNP	o	OPH
.	.	o	O

After	IN	O	O
8	CD	O	O
months	NNS	O	O
of	IN	O	O
follow-up	NN	O	O
,	,	O	O
there	EX	O	O
were	VBD	O	O
statistically	RB	O	O
significant	JJ	O	O
differences	NNS	O	O
in	IN	O	O
favor	NN	O	O
of	IN	O	O
pharmaceutical	JJ	O	O
care	NN	O	O
in	IN	O	O
the	DT	O	O
proportions	NNS	O	O
of	IN	O	O
patients	NNS	O	O
who	WP	O	O
achieved	VBD	O	O
therapeutic	JJ	O	O
goals	NNS	o	O
for	IN	o	O
BP	NNP	o	OPH
(	(	O	O
52.5	CD	O	O
%	NN	O	O
vs.	FW	O	O
43.0	CD	O	O
%	NN	O	O
,	,	O	O
P=0.017	NNP	O	O
)	)	O	O
,	,	O	O
TC	NNP	o	OPH
(	(	O	O
56.5	CD	O	O
%	NN	O	O
vs.	FW	O	O
44.1	CD	O	O
%	NN	O	O
,	,	O	O
P=0.001	NNP	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
BP/TC	NNP	o	OPH
(	(	O	O
37.1	CD	O	O
%	NN	O	O
vs.	FW	O	O
21.8	CD	O	O
%	NN	O	O
,	,	O	O
P	NNP	O	O
<	NNP	O	O
0.001	CD	O	O
)	)	O	O
.	.	O	O

CONCLUSION	NNP	O	O
Compared	NNP	O	O
with	IN	O	O
usual	JJ	i	O
care	NN	i	O
plus	CC	i	O
written	VBN	i	O
education	NN	i	O
,	,	i	O
pharmaceutical	JJ	i	O
care	NN	i	O
focused	VBN	i	O
on	IN	i	O
patient	JJ	i	O
evaluation	NN	i	O
and	CC	i	O
follow-up	NN	i	O
in	IN	i	O
collaboration	NN	i	O
with	IN	i	O
physicians	NNS	i	O
improved	VBN	O	O
the	DT	O	O
achievement	NN	O	O
of	IN	O	O
BP	NNP	o	OPH
,	,	o	O
TC	NNP	o	OPH
,	,	o	O
and	CC	o	O
BP/TC	NNP	o	OPH
treatment	NN	O	O
goals	NNS	O	O
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
CVD	NNP	p	O
and/or	VBP	p	O
high	JJ	p	O
or	CC	p	O
intermediate	JJ	p	O
CV	NNP	p	O
risk	NN	p	O
attending	VBG	p	O
community	NN	p	O
pharmacies	NNS	p	O
in	IN	p	O
Spain	NNP	p	O
.	.	p	O

The	DT	O	O
lunar	JJ	i	IS
stent	NN	i	IS
characteristics	NNS	O	O
and	CC	O	O
clinical	JJ	O	O
results	NNS	O	O
.	.	O	O

One	CD	O	O
of	IN	O	O
the	DT	O	O
frequent	JJ	O	O
long-term	JJ	O	O
complications	NNS	O	O
after	IN	O	O
stent	JJ	i	IS
implantation	NN	i	IS
is	VBZ	O	O
restenosis	JJ	O	O
due	JJ	O	O
to	TO	O	O
the	DT	O	O
building	NN	O	O
up	IN	O	O
of	IN	O	O
a	DT	O	O
neointima	NN	O	O
within	IN	O	O
the	DT	O	O
artery	NN	O	O
,	,	O	O
as	RB	O	O
well	RB	O	O
as	IN	O	O
endovascular	JJ	O	O
hyperplasia	NN	O	O
(	(	O	O
tissue	VB	O	O
growth	NN	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
interesting	JJ	O	O
feature	NN	O	O
of	IN	O	O
the	DT	O	O
Lunar	NNP	i	IS
stent	NN	i	IS
from	IN	i	IS
Inflow	NNP	i	IS
Dynamics	NNP	i	IS
is	VBZ	O	O
that	IN	O	O
it	PRP	O	O
is	VBZ	O	O
coated	VBN	O	O
with	IN	O	O
a	DT	O	O
layer	NN	O	O
of	IN	O	O
iridium	NN	O	O
oxide	NN	O	O
.	.	O	O

The	DT	O	O
iridium	NN	i	IPM
oxide	IN	i	IPM
coating	NN	O	O
is	VBZ	O	O
believed	VBN	O	O
to	TO	O	O
reduce	VB	O	O
restenosis	NN	o	OPH
by	IN	O	O
decreasing	VBG	O	O
the	DT	O	O
inflammatory	JJ	o	OPH
response	NN	o	OPH
to	TO	O	O
the	DT	O	O
stent	NN	O	O
via	IN	O	O
its	PRP$	O	O
antioxidant	JJ	O	O
action	NN	O	O
.	.	O	O

The	DT	O	O
MOONLIGHT	NNP	p	O
(	(	p	O
Multicenter	NNP	p	O
Objective	NNP	p	O
ObservatioNal	NNP	p	O
Lunar	NNP	i	IPM
Iridiumoxide	NNP	i	IPM
intimal	JJ	p	O
GrowtH	NNP	p	O
Trial	NNP	p	O
)	)	p	O
study	NN	p	O
was	VBD	O	O
carried	VBN	O	O
out	IN	O	O
to	TO	O	O
evaluate	VB	O	O
the	DT	O	O
immediate	JJ	O	O
outcome	NN	O	O
and	CC	O	O
long-term	JJ	O	O
angiographic	JJ	O	O
success	NN	O	O
after	IN	O	O
implantation	NN	i	IS
of	IN	i	IS
Lunar	NNP	i	IS
stents	NNS	i	IS
.	.	i	O

Between	IN	p	O
March	NNP	p	O
2001	CD	p	O
and	CC	p	O
November	NNP	p	O
2001	CD	p	O
,	,	p	O
87	CD	p	PSS
patients	NNS	p	O
with	IN	p	O
99	CD	p	O
lesions	NNS	p	PC
were	VBD	p	O
enrolled	VBN	p	O
in	IN	p	O
this	DT	p	O
study	NN	p	O
and	CC	O	O
were	VBD	O	O
treated	VBN	O	O
with	IN	O	O
12	CD	O	O
and	CC	O	O
16	CD	O	O
mm	NNS	O	O
long	JJ	O	O
iridium-oxide	JJ	i	IPM
coated	VBN	i	IS
Lunar	NNP	i	IS
stents	NNS	i	IS
.	.	i	O

Delivery	NN	O	O
of	IN	O	O
the	DT	O	O
Lunar	NNP	i	IS
stent	NN	i	IS
was	VBD	O	O
successful	JJ	O	O
in	IN	O	O
most	JJS	O	O
lesions	NNS	O	O
and	CC	O	O
the	DT	O	O
optimal	JJ	O	O
radiopacity	NN	O	O
facilitated	VBN	O	O
optimal	JJ	O	O
stent	NN	o	OPH
positioning	VBG	o	OPH
with	IN	O	O
optimal	JJ	O	O
immediate	JJ	O	O
clinical	JJ	O	O
and	CC	O	O
angiographic	JJ	O	O
results	NNS	O	O
is	VBZ	O	O
an	DT	O	O
unselected	JJ	O	O
patient	NN	O	O
and	CC	O	O
lesion	NN	O	O
population	NN	O	O
.	.	O	O

Preliminary	JJ	O	O
clinical	JJ	O	O
and	CC	O	O
angiographic	JJ	O	O
follow-up	JJ	O	O
show	NN	O	O
a	DT	O	O
low	JJ	O	O
rate	NN	o	OPH
of	IN	o	OPH
cardiac	JJ	o	OPH
events	NNS	o	OPH
at	IN	O	O
6	CD	O	O
months	NNS	O	O
(	(	O	O
16.1	CD	O	O
%	NN	O	O
MACE	NNP	O	O
)	)	O	O
and	CC	O	O
a	DT	O	O
moderate	JJ	O	O
hyperplastic	JJ	o	OPH
response	NN	o	OPH
.	.	o	OPH

Enhancing	VBG	O	O
the	DT	O	O
self-esteem	NN	o	OME
of	IN	O	O
inpatient	JJ	p	PC
alcoholics	NNS	p	PC
.	.	p	O

This	DT	O	O
study	NN	O	O
examined	VBD	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
pairing	VBG	O	O
inpatient	JJ	p	O
alcoholics	NNS	p	O
with	IN	p	O
nursing	NN	i	IOt
home	NN	i	IOt
residents	NNS	i	IOt
(	(	i	IOt
NHRs	NNP	i	IOt
)	)	i	IOt
on	IN	O	O
the	DT	O	O
alcoholics	NNS	o	OME
'	POS	o	OME
self-esteem	NN	o	OME
.	.	o	O

In	IN	O	O
this	DT	O	O
PALS	NNP	O	O
program	NN	O	O
,	,	O	O
the	DT	O	O
alcoholic	JJ	O	O
inpatients	NNS	O	O
assumed	VBD	O	O
a	DT	O	O
helping-companion	NN	O	O
relationship	NN	O	O
with	IN	O	O
the	DT	O	O
NHRs	NNP	O	O
for	IN	O	O
2	CD	O	O
hr	NNS	O	O
per	IN	O	O
day	NN	O	O
during	IN	O	O
their	PRP$	O	O
last	JJ	O	O
2	CD	O	O
weeks	NNS	O	O
of	IN	O	O
treatment	NN	O	O
.	.	O	O

Fifty	NNP	p	O
alcoholic	JJ	p	O
inpatients	NNS	p	PC
were	VBD	p	PC
randomly	RB	p	PC
assigned	VBN	p	PC
to	TO	p	PC
the	DT	p	PC
PALS	NNP	i	IPS
program	NN	i	IPS
(	(	p	PC
n	JJ	p	PC
=	NNP	p	PC
25	CD	p	PC
)	)	p	PC
or	CC	p	PC
to	TO	p	PC
the	DT	p	PC
library	NN	i	IPS
for	IN	i	IPS
free	JJ	i	IPS
reading	NN	i	IPS
time	NN	i	IPS
(	(	p	PC
n	JJ	p	PC
=	NNP	p	PC
25	CD	p	PC
)	)	p	PC
.	.	p	O

The	DT	O	O
Tennessee	NNP	o	OME
Self-Concept	NNP	o	OME
Scale	NNP	o	OME
(	(	o	OME
TSCS	NNP	o	OME
)	)	o	OME
was	VBD	O	O
administered	VBN	O	O
to	TO	O	O
all	DT	O	O
subjects	NNS	O	O
in	IN	O	O
both	DT	O	O
groups	NNS	O	O
before	IN	O	O
and	CC	O	O
after	IN	O	O
the	DT	O	O
interventions	NNS	O	O
.	.	O	O

Of	IN	O	O
the	DT	O	O
nine	CD	O	O
TSCS	NNP	o	OME
scales	NNS	o	OME
,	,	O	O
the	DT	O	O
improvement	NN	O	O
on	IN	O	O
the	DT	O	O
Moral-Ethical	JJ	o	OME
scale	NN	o	OME
was	VBD	O	O
significantly	RB	O	O
greater	JJR	O	O
in	IN	O	O
the	DT	O	O
PALS	NNP	O	O
group	NN	O	O
.	.	O	O

Because	IN	O	O
the	DT	O	O
alcoholic	JJ	O	O
inpatients	NNS	O	O
in	IN	O	O
the	DT	O	O
PALS	NNP	O	O
group	NN	O	O
engaged	VBD	O	O
in	IN	O	O
altruistic	JJ	o	OME
(	(	o	OME
moral	JJ	o	OME
)	)	o	OME
behavior	NN	o	OME
,	,	O	O
this	DT	O	O
study	NN	O	O
provides	VBZ	O	O
a	DT	O	O
logical	JJ	O	O
link	NN	O	O
between	IN	O	O
the	DT	O	O
intervention	NN	O	O
and	CC	O	O
the	DT	O	O
outcome	NN	O	O
,	,	O	O
which	WDT	O	O
has	VBZ	O	O
been	VBN	O	O
a	DT	O	O
prevalent	JJ	O	O
weakness	NN	O	O
in	IN	O	O
previous	JJ	O	O
studies	NNS	O	O
of	IN	O	O
self-esteem	NN	O	O
in	IN	O	O
alcoholics	NNS	O	O
.	.	O	O

Is	VBZ	O	O
periprostatic	JJ	O	O
local	JJ	O	O
anesthesia	NN	i	IPH
for	IN	O	O
transrectal	JJ	p	PC
ultrasound	NN	p	PC
guided	VBD	p	PC
prostate	NN	p	PC
biopsy	NN	p	PC
associated	VBN	O	O
with	IN	O	O
increased	JJ	O	O
infectious	JJ	o	OA
or	CC	o	OA
hemorrhagic	JJ	o	OA
complications	NNS	o	OA
?	.	O	O
A	DT	O	O
prospective	JJ	O	O
randomized	VBN	O	O
trial	NN	O	O
.	.	O	O

PURPOSE	NNP	O	O
Periprostatic	NNP	O	O
local	JJ	O	O
anesthesia	NN	O	O
for	IN	O	O
prostate	NN	O	O
biopsy	NN	O	O
requires	VBZ	O	O
2	CD	O	O
or	CC	O	O
more	JJR	O	O
extra	JJ	O	O
needle	JJ	O	O
punctures	NNS	O	O
and	CC	O	O
injection	NN	O	O
of	IN	O	O
the	DT	O	O
local	JJ	O	O
anesthetic	NN	O	O
through	IN	O	O
the	DT	O	O
highly	RB	O	O
colonized	JJ	O	O
rectum	NN	O	O
.	.	O	O

To	TO	O	O
our	PRP$	O	O
knowledge	NN	O	O
we	PRP	O	O
report	VBP	O	O
the	DT	O	O
first	JJ	O	O
prospective	JJ	O	O
randomized	VBN	O	O
trial	NN	O	O
to	TO	O	O
assess	VB	O	O
the	DT	O	O
infectious	JJ	o	OA
or	CC	o	OA
hemorrhagic	JJ	o	OA
complications	NNS	o	OA
associated	VBN	O	O
with	IN	O	O
this	DT	O	O
method	NN	O	O
.	.	O	O

MATERIALS	NNP	O	O
AND	NNP	O	O
METHODS	NNP	O	O
A	NNP	O	O
total	NN	O	O
of	IN	O	O
100	CD	p	PSS
consecutive	JJ	p	O
patients	NNS	p	O
with	IN	p	O
sterile	JJ	p	PC
urine	JJ	p	PC
cultures	NNS	p	PC
underwent	JJ	p	O
transrectal	JJ	i	IS
ultrasound	NN	i	IS
guided	VBD	i	IS
prostate	NN	i	IS
biopsy	NN	i	IS
.	.	i	O

They	PRP	O	O
were	VBD	O	O
randomized	VBN	O	O
to	TO	O	O
receive	VB	O	O
a	DT	O	O
periprostatic	JJ	i	IPH
nerve	NN	i	IPH
block	NN	i	IPH
or	CC	i	O
no	DT	i	IPH
anesthesia	NN	i	IPH
.	.	i	O

Patients	NNS	i	O
were	VBD	i	O
evaluated	VBN	i	O
for	IN	i	O
the	DT	i	O
amount	NN	o	OPH
of	IN	o	OPH
rectal	NN	o	OPH
and	CC	o	OPH
urethral	JJ	o	OPH
bleeding	NN	o	OPH
,	,	i	O
and	CC	i	O
symptoms	NNS	i	IPH
and	CC	i	IPH
signs	NNS	i	IPH
of	IN	i	IPH
infection	NN	o	OA
after	IN	o	OA
biopsy	NN	o	OA
.	.	o	OPH

RESULTS	VB	O	O
The	DT	O	O
amount	NN	o	OPH
of	IN	o	OPH
urethral	JJ	o	OPH
bleeding	NN	o	OPH
was	VBD	O	O
slight	JJ	O	O
and	CC	O	O
similar	JJ	O	O
in	IN	O	O
the	DT	O	O
2	CD	O	O
groups	NNS	O	O
.	.	O	O

Rectal	JJ	o	OPH
bleeding	NN	o	OPH
was	VBD	O	O
significantly	RB	O	O
less	RBR	O	O
in	IN	O	O
the	DT	O	O
patients	NNS	O	O
who	WP	O	O
received	VBD	O	O
anesthesia	NN	O	O
.	.	O	O

High	JJ	o	OPH
fever	NN	o	OPH
(	(	O	O
greater	JJR	O	O
than	IN	O	O
37.8C	CD	O	O
)	)	O	O
was	VBD	O	O
more	RBR	O	O
frequent	JJ	O	O
in	IN	O	O
the	DT	O	O
nerve	NN	O	O
block	NN	O	O
group	NN	O	O
and	CC	O	O
2	CD	O	O
patients	NNS	O	O
in	IN	O	O
this	DT	O	O
group	NN	O	O
required	VBD	O	O
rehospitalization	NN	O	O
.	.	O	O

Bacteriuria	NNP	o	OPH
in	IN	o	OPH
post-biopsy	JJ	o	OPH
urine	JJ	o	OPH
cultures	NNS	o	OPH
was	VBD	O	O
significantly	RB	O	O
more	JJR	O	O
common	JJ	O	O
in	IN	O	O
the	DT	O	O
anesthesia	NN	O	O
group	NN	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
Our	PRP$	O	O
results	NNS	O	O
suggest	VBP	O	O
that	IN	O	O
periprostatic	JJ	O	O
local	JJ	O	O
anesthesia	NN	i	IPH
for	IN	O	O
prostate	JJ	O	O
biopsy	NN	O	O
does	VBZ	O	O
not	RB	O	O
increase	VB	O	O
the	DT	O	O
risk	NN	O	O
of	IN	O	O
urethral	JJ	o	OPH
bleeding	NN	o	OPH
.	.	o	O

It	PRP	O	O
is	VBZ	O	O
associated	VBN	O	O
with	IN	O	O
a	DT	O	O
decreased	JJ	O	O
incidence	NN	O	O
of	IN	O	O
rectal	JJ	o	OPH
bleeding	NN	o	OPH
,	,	O	O
presumably	RB	O	O
due	JJ	O	O
to	TO	O	O
decreased	JJ	O	O
patient	NN	O	O
discomfort	NN	O	O
.	.	O	O

The	DT	O	O
incidence	NN	O	O
of	IN	O	O
bacteriuria	NN	o	OPH
was	VBD	O	O
significantly	RB	O	O
higher	JJR	O	O
in	IN	O	O
the	DT	O	O
anesthesia	NN	O	O
group	NN	O	O
.	.	O	O

High	NNP	o	OA
fever	NN	o	OA
and	CC	o	OA
hospitalization	NN	o	OA
due	JJ	O	O
to	TO	O	O
infectious	JJ	O	O
complications	NNS	O	O
were	VBD	O	O
also	RB	O	O
more	RBR	O	O
common	JJ	O	O
in	IN	O	O
the	DT	O	O
local	JJ	O	O
anesthesia	NN	O	O
group	NN	O	O
,	,	O	O
although	IN	O	O
not	RB	O	O
statistically	RB	O	O
significant	JJ	O	O
.	.	O	O

Prospective	JJ	O	O
randomized	JJ	O	O
trials	NNS	O	O
seem	VBP	O	O
warranted	VBN	O	O
to	TO	O	O
determine	VB	O	O
the	DT	O	O
optimum	JJ	O	O
antibiotic	JJ	O	O
prophylaxis	NN	O	O
regimen	NNS	O	O
in	IN	O	O
patients	NNS	O	O
undergoing	VBG	O	O
biopsy	NN	O	O
with	IN	O	O
a	DT	O	O
periprostatic	JJ	O	O
nerve	NN	O	O
block	NN	O	O
.	.	O	O

A	DT	O	O
comparison	NN	O	O
of	IN	O	O
single-dose	JJ	O	O
cefixime	NN	i	IPM
with	IN	O	O
ceftriaxone	NN	i	IPM
as	IN	O	O
treatment	NN	O	O
for	IN	O	O
uncomplicated	JJ	o	OPH
gonorrhea	NN	o	OPH
.	.	o	O

The	DT	O	O
Gonorrhea	NNP	O	O
Treatment	NNP	O	O
Study	NNP	O	O
Group	NNP	O	O
.	.	O	O

BACKGROUND	NNP	O	O
Because	IN	O	O
of	IN	O	O
the	DT	O	O
widespread	JJ	O	O
existence	NN	O	O
of	IN	O	O
Neisseria	NNP	O	O
gonorrhoeae	NN	O	O
resistant	NN	O	O
to	TO	O	O
penicillin	VB	O	O
or	CC	O	O
tetracycline	VB	O	O
,	,	O	O
ceftriaxone	NN	O	O
is	VBZ	O	O
now	RB	O	O
recommended	VBN	O	O
for	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
gonorrhea	NN	o	OPH
.	.	o	O

There	EX	O	O
is	VBZ	O	O
,	,	O	O
however	RB	O	O
,	,	O	O
a	DT	O	O
need	NN	O	O
for	IN	O	O
effective	JJ	O	O
antibiotics	NNS	O	O
that	WDT	O	O
can	MD	O	O
be	VB	O	O
administered	VBN	O	O
orally	RB	O	O
as	IN	O	O
an	DT	O	O
alternative	NN	O	O
to	TO	O	O
ceftriaxone	NN	i	IPM
,	,	O	O
which	WDT	O	O
requires	VBZ	O	O
intramuscular	JJ	O	O
administration	NN	O	O
.	.	O	O

Cefixime	NNP	O	O
is	VBZ	O	O
an	DT	O	O
orally	RB	O	O
absorbed	JJ	O	O
cephalosporin	NN	O	O
that	WDT	O	O
is	VBZ	O	O
active	JJ	O	O
against	IN	O	O
resistant	JJ	O	O
gonococci	NN	O	O
and	CC	O	O
has	VBZ	O	O
pharmacokinetic	JJ	O	O
activity	NN	O	O
suitable	JJ	O	O
for	IN	O	O
single-dose	JJ	O	O
administration	NN	O	O
.	.	O	O

METHODS	NNP	O	O
AND	CC	O	O
RESULTS	NNP	O	O
In	IN	O	O
a	DT	O	O
randomized	JJ	O	O
,	,	O	O
unblinded	JJ	p	O
multicenter	NN	p	O
study	NN	p	O
of	IN	p	O
209	CD	p	PSS
men	NNS	p	O
and	CC	p	O
124	CD	p	PSS
women	NNS	p	O
with	IN	p	O
uncomplicated	JJ	p	O
gonorrhea	NN	p	PC
,	,	O	O
we	PRP	O	O
compared	VBN	O	O
three	CD	O	O
single-dose	JJ	O	O
treatment	NN	O	O
regimens	NNS	O	O
:	:	O	O
400	CD	i	IPM
mg	NN	i	IPM
or	CC	i	IPM
800	CD	i	IPM
mg	NN	i	IPM
of	IN	i	IPM
cefixime	NN	i	IPM
,	,	i	O
administered	VBN	i	IE
orally	RB	i	IE
,	,	i	O
and	CC	i	O
250	CD	i	IPM
mg	NN	i	IPM
of	IN	i	IPM
ceftriaxone	NN	i	IPM
administered	VBN	O	O
intramuscularly	RB	O	O
.	.	O	O

The	DT	O	O
overall	JJ	o	OOt
cure	NN	o	OOt
rates	NNS	o	OOt
were	VBD	O	O
96	CD	O	O
percent	NN	O	O
for	IN	O	O
the	DT	O	O
400-mg	JJ	O	O
dose	NN	O	O
of	IN	O	O
cefixime	NN	i	IPM
(	(	O	O
89	CD	O	O
of	IN	O	O
93	CD	O	O
patients	NNS	O	O
)	)	O	O
(	(	O	O
95	CD	O	O
percent	NN	O	O
confidence	NN	O	O
interval	NN	O	O
,	,	O	O
93.5	CD	O	O
percent	NN	O	O
to	TO	O	O
97.8	CD	O	O
percent	NN	O	O
)	)	O	O
;	:	O	O
98	CD	O	O
percent	NN	O	O
for	IN	O	O
the	DT	O	O
800-mg	JJ	O	O
dose	NN	O	O
of	IN	O	O
cefixime	NN	i	IPM
(	(	O	O
86	CD	O	O
of	IN	O	O
88	CD	O	O
patients	NNS	O	O
)	)	O	O
(	(	O	O
95	CD	O	O
percent	NN	O	O
confidence	NN	O	O
interval	NN	O	O
,	,	O	O
94.6	CD	O	O
percent	NN	O	O
to	TO	O	O
100	CD	O	O
percent	NN	O	O
)	)	O	O
;	:	O	O
and	CC	O	O
98	CD	O	O
percent	NN	O	O
for	IN	O	O
ceftriaxone	NN	i	IPM
(	(	O	O
92	CD	O	O
of	IN	O	O
94	CD	O	O
patients	NNS	O	O
)	)	O	O
(	(	O	O
95	CD	O	O
percent	NN	O	O
confidence	NN	O	O
interval	NN	O	O
,	,	O	O
94.9	CD	O	O
to	TO	O	O
100	CD	O	O
percent	NN	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
cure	NN	o	OOt
rates	NNS	o	OOt
were	VBD	O	O
similar	JJ	O	O
in	IN	O	O
men	NNS	O	O
and	CC	O	O
women	NNS	O	O
,	,	O	O
and	CC	O	O
pharyngeal	JJ	o	OPH
infection	NN	o	OPH
was	VBD	O	O
eradicated	VBN	O	O
in	IN	O	O
20	CD	O	O
of	IN	O	O
22	CD	O	O
patients	NNS	O	O
(	(	O	O
91	CD	O	O
percent	NN	O	O
)	)	O	O
.	.	O	O

Thirty-nine	JJ	O	O
percent	NN	O	O
of	IN	O	O
303	CD	O	O
pretreatment	JJ	O	O
gonococcal	JJ	O	O
isolates	NNS	O	O
had	VBD	O	O
one	CD	O	O
or	CC	O	O
more	JJR	O	O
types	NNS	O	O
of	IN	O	O
antimicrobial	JJ	O	O
resistance	NN	O	O
;	:	O	O
the	DT	O	O
efficacy	NN	o	OOt
of	IN	O	O
all	DT	O	O
three	CD	O	O
regimens	NNS	O	O
was	VBD	O	O
independent	JJ	O	O
of	IN	O	O
the	DT	O	O
resistance	NN	O	O
pattern	NN	O	O
.	.	O	O

Chlamydia	NNP	o	OPH
trachomatis	NN	o	OPH
infection	NN	o	OPH
persisted	VBN	O	O
in	IN	O	O
at	IN	O	O
least	JJS	O	O
half	PDT	O	O
the	DT	O	O
patients	NNS	O	O
infected	VBN	O	O
in	IN	O	O
each	DT	O	O
treatment	NN	O	O
group	NN	O	O
.	.	O	O

All	DT	O	O
three	CD	O	O
regimens	NNS	O	O
were	VBD	O	O
well	RB	O	O
tolerated	VBN	o	OOt
.	.	o	O

CONCLUSIONS	NNP	O	O
In	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
uncomplicated	JJ	o	OPH
gonorrhea	NN	o	OPH
,	,	O	O
a	DT	O	O
single	JJ	O	O
dose	NN	O	O
of	IN	O	O
cefixime	NN	i	IPM
(	(	O	O
400	CD	O	O
or	CC	O	O
800	CD	O	O
mg	NN	O	O
)	)	O	O
given	VBN	O	O
orally	RB	O	O
appears	VBZ	O	O
to	TO	O	O
be	VB	O	O
as	RB	O	O
effective	JJ	o	OOt
as	IN	O	O
the	DT	O	O
currently	RB	O	O
recommended	VBN	O	O
regimen	NNS	O	O
of	IN	O	O
ceftriaxone	NN	i	IPM
(	(	O	O
250	CD	O	O
mg	NN	O	O
given	VBN	O	O
intramuscularly	RB	O	O
)	)	O	O
.	.	O	O

[	JJ	O	O
Effects	NNS	O	O
of	IN	O	O
transcutaneous	JJ	i	IPH
electrical	JJ	i	IPH
stimulation	NN	i	IPH
of	IN	i	IPH
auricular	JJ	i	IPH
Shenmen	NNP	i	IPH
point	NN	i	IPH
on	IN	O	O
postoperative	JJ	O	O
nausea	NN	O	O
and	CC	O	O
vomiting	NN	O	O
and	CC	O	O
patient-controlled	JJ	O	O
epidural	JJ	O	O
analgesia	NN	O	O
in	IN	O	O
cesarean	JJ	p	O
section	NN	p	O
]	NNP	p	O
.	.	O	O

OBJECTIVE	NNP	O	O
To	TO	O	O
investigate	VB	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
transcutaneous	JJ	O	O
electrical	JJ	O	O
stimulation	NN	O	O
of	IN	O	O
auricular	JJ	O	O
Shenmen	NNP	O	O
point	NN	O	O
on	IN	O	O
postoperative	JJ	O	O
nausea	NN	O	O
and	CC	O	O
vomiting	NN	O	O
and	CC	O	O
patient-controlled	JJ	O	O
epidural	JJ	O	O
analgesia	NN	O	O
in	IN	O	O
cesarean	JJ	O	O
section	NN	O	O
.	.	O	O

METHODS	NNP	O	O
After	IN	O	O
IRB	NNP	O	O
approval	NN	O	O
and	CC	O	O
informed	JJ	O	O
consent	NN	O	O
,	,	O	O
one	CD	p	O
hundred	CD	p	O
and	CC	p	O
eighty	VB	p	O
singleton	NN	p	O
primiparas	IN	p	O
undergoing	VBG	p	O
elective	JJ	p	O
cesarean	JJ	p	O
section	NN	p	O
,	,	p	O
in	IN	p	O
Qingdao	NNP	p	O
Municipal	NNP	p	O
Hospital	NNP	p	O
,	,	p	O
and	CC	p	O
Qingdao	NNP	p	O
Hiser	NNP	p	O
Medical	NNP	p	O
Center	NNP	p	O
,	,	p	O
from	IN	p	O
November	NNP	p	O
2011	CD	p	O
to	TO	p	O
March	NNP	p	O
2012	CD	p	O
,	,	p	O
were	VBD	p	O
randomly	RB	p	O
assigned	VBN	p	O
to	TO	O	O
three	CD	O	O
groups	NNS	O	O
:	:	O	O
transcutaneous	JJ	i	IPH
electrical	JJ	i	IPH
stimulation	NN	i	IPH
of	IN	i	IPH
auricular	JJ	i	IPH
Shenmen	NNP	i	IPH
point	NN	i	IPH
group	NN	i	IPH
(	(	O	O
group	NN	O	O
A	NNP	O	O
,	,	O	O
n	JJ	O	O
=	NNP	O	O
60	CD	O	O
)	)	O	O
,	,	O	O
transcutaneous	JJ	i	IPH
electrical	JJ	i	IPH
stimulation	NN	i	IPH
of	IN	i	IPH
auricular	JJ	i	IPH
Eye	NNP	i	IPH
point	NN	i	IPH
group	NN	i	IPH
(	(	O	O
group	NN	O	O
B	NNP	O	O
,	,	O	O
n	JJ	O	O
=	NNP	O	O
60	CD	O	O
)	)	O	O
and	CC	O	O
control	NN	i	IC
group	NN	i	IC
(	(	O	O
group	NN	O	O
C	NNP	O	O
,	,	O	O
n	JJ	O	O
=	NNP	O	O
60	CD	O	O
)	)	O	O
.	.	O	O

Women	NNP	O	O
of	IN	O	O
group	NN	O	O
A	NNP	O	O
received	VBD	O	O
transcutaneous	JJ	i	IPH
electrical	JJ	i	IPH
stimulation	NN	i	IPH
of	IN	O	O
auricular	JJ	O	O
Shenmen	NNP	O	O
point	NN	O	O
(	(	O	O
frequency	NN	O	O
1.5	CD	O	O
HZ	NNP	O	O
)	)	O	O
at	IN	O	O
the	DT	O	O
time	NN	O	O
of	IN	O	O
preoperation	NN	O	O
,	,	O	O
4	CD	O	O
,	,	O	O
10	CD	O	O
and	CC	O	O
22	CD	O	O
hours	NNS	O	O
of	IN	O	O
postoperation	NN	O	O
for	IN	O	O
30	CD	O	O
minutes	NNS	O	O
.	.	O	O

The	DT	O	O
strength	NN	O	O
was	VBD	O	O
controlled	VBN	O	O
by	IN	O	O
themselves	PRP	O	O
.	.	O	O

Women	NNP	O	O
of	IN	O	O
group	NN	O	O
B	NNP	O	O
received	VBD	O	O
stimulation	NN	O	O
of	IN	O	O
auricular	JJ	O	O
Eye	NNP	O	O
point	NN	O	O
as	IN	O	O
group	NN	O	O
A	NNP	O	O
.	.	O	O

Women	NNP	O	O
of	IN	O	O
group	NN	O	O
C	NNP	O	O
received	VBD	O	O
pressurization	NN	i	O
and	CC	i	O
connected	VBN	i	O
line	NN	i	O
were	VBD	i	O
the	DT	i	O
same	JJ	i	O
with	IN	i	O
group	NN	i	O
A	NNP	i	O
,	,	i	O
but	CC	i	O
without	IN	i	O
electrical	JJ	i	IC
stimulation	NN	i	IC
.	.	i	O

The	DT	O	O
following	JJ	O	O
indexes	NNS	O	O
was	VBD	O	O
observed	VBN	O	O
:	:	O	O
the	DT	O	O
incidence	NN	O	O
of	IN	O	O
postoperative	JJ	O	O
nausea	NN	O	O
and	CC	O	O
vomiting	NN	O	O
(	(	O	O
PONV	NNP	O	O
)	)	O	O
for	IN	O	O
48	CD	O	O
hours	NNS	O	O
;	:	O	O
the	DT	O	O
rate	NN	O	O
of	IN	O	O
metoclopramide	NN	O	O
;	:	O	O
the	DT	o	O
visual	JJ	o	OPA
analogue	NN	o	OPA
scale	NN	o	OPA
(	(	o	OPA
VAS	NNP	o	OPA
)	)	o	OPA
score	NN	o	OPA
of	IN	o	OPA
rest	NN	o	OPA
pain	NN	o	OPA
,	,	o	OPA
uterine	JJ	o	OPA
contration	NN	o	OPA
pain	NN	o	OPA
and	CC	o	OPA
dynamic	JJ	o	OPA
pain	NN	o	OPA
at	IN	o	O
the	DT	o	O
time	NN	o	O
of	IN	o	O
postoperation	NN	o	O
for	IN	o	O
6	CD	o	O
,	,	o	O
12	CD	o	O
,	,	o	O
24	CD	o	O
and	CC	o	O
48	CD	o	O
hours	NNS	o	O
(	(	o	O
T	NNP	o	O
(	(	o	O
1	CD	o	O
)	)	o	O
-T	NN	o	O
(	(	o	O
4	CD	o	O
)	)	o	O
)	)	o	O
;	:	o	O
the	DT	o	O
total	JJ	o	O
number	NN	o	O
and	CC	o	O
effective	JJ	o	O
compressions	NNS	o	O
number	NN	o	O
of	IN	o	O
patient-controlled	JJ	o	OPH
epidural	JJ	o	OPH
analgesia	NN	o	OPH
(	(	o	OPH
PCEA	NNP	o	OPH
)	)	o	OPH
;	:	o	O
the	DT	o	O
dose	NN	o	OOt
of	IN	o	OOt
analgesia	JJ	o	OOt
mixture	NN	o	OOt
;	:	o	O
the	DT	o	O
anal	JJ	o	OPH
exhaust	JJ	o	OPH
time	NN	o	OPH
;	:	o	O
the	DT	o	O
volume	NN	o	OPH
of	IN	o	OPH
postoperative	JJ	o	OPH
bleeding	NN	o	OPH
for	IN	o	OPH
6	CD	o	OPH
hours	NNS	o	OPH
of	IN	o	OPH
postoperation	NN	o	OPH
and	CC	o	O
the	DT	o	O
other	JJ	o	OA
side	NN	o	OA
effects	NNS	o	OA
.	.	o	O

RESULTS	NNP	O	O
Compared	NNP	O	O
with	IN	O	O
group	NN	O	O
B	NNP	O	O
and	CC	O	O
group	NN	O	O
C	NNP	O	O
,	,	O	O
the	DT	O	O
incidence	NN	o	OPH
of	IN	o	OPH
PONV	NNP	o	OPH
,	,	o	O
the	DT	o	O
rate	NN	o	OOt
of	IN	o	OOt
metoclopramide	NN	o	OOt
,	,	o	O
the	DT	o	O
VAS	NNP	o	OPH
score	NN	o	OPH
at	IN	O	O
the	DT	O	O
time	NN	O	O
T	NNP	O	O
(	(	O	O
1	CD	O	O
)	)	O	O
-T	NN	O	O
(	(	O	O
4	CD	O	O
)	)	O	O
,	,	O	O
the	DT	O	O
total	JJ	o	OPH
number	NN	o	OPH
and	CC	o	OPH
effective	JJ	o	OPH
compressions	NNS	o	OPH
number	NN	o	OPH
of	IN	o	OPH
PCEA	NNP	o	OPH
,	,	o	O
the	DT	o	O
ratio	NN	o	OPH
of	IN	o	OPH
the	DT	o	OPH
total	JJ	o	OPH
number	NN	o	OPH
with	IN	o	OPH
effective	JJ	o	OPH
compressions	NNS	o	OPH
number	NN	o	OPH
and	CC	o	O
the	DT	o	O
dose	NN	o	OPH
of	IN	o	OPH
analgesia	JJ	o	OPH
mixture	NN	o	OPH
were	VBD	O	O
decreased	VBN	O	O
in	IN	O	O
group	NN	O	O
A	NNP	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
,	,	O	O
but	CC	O	O
no	DT	O	O
difference	NN	O	O
compared	VBN	O	O
group	NN	O	O
B	NNP	O	O
with	IN	O	O
group	NN	O	O
C	NNP	O	O
(	(	O	O
P	NNP	O	O
>	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
anal	JJ	o	OPH
exhaust	NN	o	OPH
time	NN	o	OPH
and	CC	o	O
the	DT	o	OA
volume	NN	o	OPH
of	IN	o	OPH
postoperative	JJ	o	OPH
bleeding	NN	o	OPH
for	IN	O	O
6	CD	O	O
hours	NNS	O	O
of	IN	O	O
postoperation	NN	O	O
were	VBD	O	O
no	DT	O	O
difference	NN	O	O
in	IN	O	O
the	DT	O	O
three	CD	O	O
groups	NNS	O	O
(	(	O	O
P	NNP	O	O
>	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

No	UH	O	O
other	JJ	O	O
side	NN	o	OA
effects	NNS	o	OA
were	VBD	O	O
observed	VBN	O	O
.	.	O	O

CONCLUSION	NNP	O	O
Transcutaneous	NNP	O	O
electrical	JJ	O	O
stimulation	NN	O	O
of	IN	O	O
auricular	JJ	O	O
Shenmen	NNS	O	O
point	NN	O	O
can	MD	O	O
reduce	VB	O	O
the	DT	O	O
incidence	NN	o	OPH
of	IN	o	OPH
PONV	NNP	o	OPH
and	CC	o	O
improves	VBZ	o	O
analgesia	JJ	o	OPA
effect	NN	o	OPA
of	IN	o	OPA
PCEA	NNP	o	OPA
in	IN	o	O
postoperation	NN	o	O
of	IN	o	O
cesarean	JJ	o	O
section	NN	o	O
.	.	o	O

Randomized	VBN	O	O
controlled	VBD	O	O
trial	NN	O	O
to	TO	O	O
compare	VB	O	O
the	DT	O	O
dose	NN	O	O
of	IN	O	O
adjuvant	JJ	i	IPM
chemotherapy	NN	i	IPM
after	IN	O	O
curative	JJ	i	IS
resection	NN	i	IS
of	IN	O	O
hepatocellular	JJ	p	PC
carcinoma	NN	p	PC
.	.	p	O

BACKGROUND	NNP	O	O
AND	NNP	O	O
AIM	NNP	O	O
Adjuvant	NNP	i	IPM
locoregional	JJ	i	IPM
chemotherapy	NN	i	IPM
has	VBZ	O	O
been	VBN	O	O
shown	VBN	O	O
to	TO	O	O
be	VB	O	O
useful	JJ	O	O
to	TO	O	O
prevent	VB	O	O
recurrence	NN	O	O
after	IN	O	O
curative	JJ	O	O
resection	NN	O	O
of	IN	O	O
hepatocellular	JJ	O	O
carcinoma	NN	O	O
(	(	O	O
HCC	NNP	O	O
)	)	O	O
in	IN	O	O
some	DT	O	O
retrospective	JJ	O	O
studies	NNS	O	O
.	.	O	O

Our	PRP$	O	O
aim	NN	O	O
was	VBD	O	O
to	TO	O	O
compare	VB	O	O
the	DT	O	O
dose	JJ	O	O
effect	NN	O	O
in	IN	O	O
the	DT	O	O
prevention	NN	O	O
of	IN	O	O
tumor	NN	O	O
recurrence	NN	O	O
.	.	O	O

METHODS	NNP	O	O
A	NNP	O	O
prospective	JJ	O	O
randomized	VBN	O	O
controlled	JJ	O	O
trial	NN	O	O
was	VBD	O	O
conducted	VBN	O	O
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
curative	JJ	p	O
resection	NN	p	O
of	IN	p	O
HCC	NNP	p	PC
;	:	p	O
they	PRP	O	O
were	VBD	O	O
given	VBN	O	O
either	DT	O	O
one	CD	O	O
intra-arterial	JJ	O	O
dose	NN	O	O
of	IN	O	O
cisplatin/lipiodol	NN	i	IPM
,	,	O	O
or	CC	O	O
received	VBD	O	O
four	CD	O	O
doses	NNS	O	O
,	,	O	O
once	RB	O	O
every	DT	O	O
3	CD	O	O
months	NNS	O	O
.	.	O	O

The	DT	O	O
rates	NNS	o	OPH
of	IN	o	OPH
recurrence	NN	o	OPH
,	,	o	O
disease-free	JJ	o	OMO
and	CC	o	O
overall	JJ	o	OMO
survival	NN	o	OMO
were	VBD	O	O
compared	VBN	O	O
.	.	O	O

RESULTS	NNP	O	O
During	IN	O	O
a	DT	O	O
median	JJ	O	O
follow	NN	O	O
up	IN	O	O
of	IN	O	O
818	CD	p	O
days	NNS	p	O
,	,	p	O
21	CD	p	PSS
patients	NNS	p	O
received	VBD	p	O
one	CD	p	O
dose	NN	p	O
and	CC	p	O
19	CD	p	PSS
received	VBD	p	O
four	CD	p	O
doses	NNS	p	O
,	,	p	O
with	IN	p	O
10	CD	p	O
(	(	p	O
47.6	CD	p	O
%	NN	p	O
)	)	p	O
and	CC	p	O
eight	CD	p	O
(	(	p	O
42.1	CD	p	O
%	NN	p	O
)	)	p	O
recurrences	NNS	p	O
,	,	p	O
respectively	RB	p	O
.	.	p	O

The	DT	O	O
1-year	JJ	o	OMO
,	,	o	OMO
2-year	JJ	o	OMO
and	CC	o	OMO
3-year	JJ	o	OMO
disease-free	JJ	o	OMO
survival	NN	o	OMO
rates	NNS	o	OMO
were	VBD	O	O
71	CD	O	O
%	NN	O	O
,	,	O	O
54	CD	O	O
%	NN	O	O
and	CC	O	O
44	CD	O	O
%	NN	O	O
for	IN	O	O
the	DT	O	O
one-dose	JJ	O	O
group	NN	O	O
and	CC	O	O
74	CD	O	O
%	NN	O	O
,	,	O	O
60	CD	O	O
%	NN	O	O
and	CC	O	O
40	CD	O	O
%	NN	O	O
for	IN	O	O
the	DT	O	O
four-dose	JJ	O	O
group	NN	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.78	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
respective	JJ	o	O
overall	JJ	o	OMO
survival	NN	o	OMO
rates	NNS	o	OMO
were	VBD	O	O
85	CD	O	O
%	NN	O	O
,	,	O	O
74	CD	O	O
%	NN	O	O
,	,	O	O
55	CD	O	O
%	NN	O	O
and	CC	O	O
84	CD	O	O
%	NN	O	O
,	,	O	O
71	CD	O	O
%	NN	O	O
,	,	O	O
40	CD	O	O
%	NN	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.64	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
only	JJ	O	O
prognostic	JJ	O	O
factor	NN	O	O
was	VBD	O	O
presence	NN	o	OPH
of	IN	o	OPH
vascular	JJ	o	OPH
permeation	NN	o	OPH
.	.	o	O

The	DT	O	O
side-effects	NNS	o	OA
were	VBD	O	O
mild	JJ	o	O
and	CC	o	O
tolerable	JJ	o	O
.	.	o	O

CONCLUSIONS	NNP	O	O
There	EX	O	O
is	VBZ	O	O
no	DT	O	O
significant	JJ	O	O
difference	NN	O	O
in	IN	O	O
the	DT	O	O
survival	NN	o	OMO
rates	NNS	o	OMO
between	IN	O	O
the	DT	O	O
two	CD	p	O
groups	NNS	p	O
.	.	p	O

Adjuvant	NNP	i	IPM
chemotherapy	NN	i	IPM
may	MD	O	O
not	RB	O	O
be	VB	O	O
useful	JJ	O	O
.	.	O	O

The	DT	O	O
efficacy	NN	O	O
of	IN	O	O
audiotapes	NNS	i	IE
in	IN	O	O
promoting	VBG	o	OME
psychological	JJ	o	OME
well-being	NN	o	OME
in	IN	O	O
cancer	NN	p	O
patients	NNS	p	O
:	:	p	O
a	DT	O	O
randomised	JJ	O	O
,	,	O	O
controlled	JJ	O	O
trial	NN	O	O
.	.	O	O

Open	VB	O	O
or	CC	O	O
uncontrolled	JJ	O	O
studies	NNS	O	O
have	VBP	O	O
suggested	VBN	O	O
that	IN	O	O
providing	VBG	O	O
cancer	NN	p	O
patients	NNS	p	O
with	IN	O	O
audiotapes	NNS	i	IE
of	IN	O	O
their	PRP$	O	O
clinical	JJ	O	O
interviews	NNS	O	O
can	MD	O	O
improve	VB	O	O
information	NN	o	OME
recall	NN	o	OME
and	CC	O	O
reduce	VB	O	O
psychological	JJ	o	OME
distress	NN	o	OME
.	.	o	O

We	PRP	O	O
tested	VBD	O	O
these	DT	O	O
hypotheses	NNS	O	O
in	IN	O	O
a	DT	O	O
'clinician-blind	JJ	O	O
'	''	O	O
,	,	O	O
prospective	JJ	O	O
,	,	O	O
randomised	VBD	O	O
controlled	VBN	O	O
trial	NN	O	O
.	.	O	O

A	DT	p	O
total	NN	p	O
of	IN	p	O
117	CD	p	O
patients	NNS	p	O
newly	RB	p	O
referred	VBN	p	O
to	TO	p	O
a	DT	p	O
medical	JJ	p	O
oncology	NN	p	O
clinic	NN	p	O
who	WP	p	O
were	VBD	p	O
to	TO	p	O
be	VB	p	O
given	VBN	p	O
'bad	CD	p	O
news	NN	p	O
'	POS	p	O
had	VBD	O	O
their	PRP$	O	O
consultations	NNS	O	O
audiotaped	VBN	i	IE
.	.	i	O

Blind	NNP	O	O
to	TO	O	O
the	DT	O	O
clinician	JJ	O	O
,	,	O	O
patients	NNS	O	O
were	VBD	O	O
randomly	RB	O	O
allocated	VBN	O	O
to	TO	O	O
receive	VB	O	O
a	DT	O	O
copy	NN	i	IE
of	IN	i	IE
the	DT	i	IE
tape	NN	i	IE
to	TO	i	IE
play	VB	i	IE
at	IN	i	IE
home	NN	i	IE
or	CC	i	IE
not	RB	i	IE
(	(	i	IE
control	VB	i	IE
group	NN	i	IE
)	)	i	IE
.	.	i	O

At	IN	O	O
6	CD	O	O
months	NNS	O	O
follow-up	JJ	O	O
,	,	O	O
tape	NN	O	O
group	NN	O	O
patients	NNS	O	O
reported	VBD	O	O
positive	JJ	o	OME
attitudes	NNS	o	OME
to	TO	O	O
the	DT	O	O
audiotape	NN	i	IE
and	CC	O	O
were	VBD	O	O
shown	VBN	O	O
to	TO	O	O
recall	VB	o	OME
significantly	RB	o	OME
more	JJR	o	OME
information	NN	o	OME
about	IN	o	OME
their	PRP$	o	OME
illness	NN	o	OME
than	IN	O	O
did	VBD	O	O
controls	NNS	O	O
.	.	O	O

Overall	JJ	O	O
improvement	NN	O	O
in	IN	O	O
psychological	JJ	o	OME
distress	NN	o	OME
at	IN	O	O
1	CD	O	O
and	CC	O	O
6	CD	O	O
months	NNS	O	O
follow-up	RB	O	O
,	,	O	O
as	IN	O	O
measured	VBN	O	O
with	IN	O	O
the	DT	O	O
30-item	JJ	o	OME
General	NNP	o	OME
Health	NNP	o	OME
Questionnaire	NNP	o	OME
and	CC	o	OME
the	DT	o	OME
Hospital	NNP	o	OME
Anxiety	NNP	o	OME
and	CC	o	OME
Depression	NNP	o	OME
Scale	NNP	o	OME
was	VBD	O	O
no	DT	O	O
different	JJ	O	O
in	IN	O	O
the	DT	O	O
two	CD	O	O
groups	NNS	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
a	DT	O	O
second-order	JJ	O	O
interaction	NN	O	O
suggested	VBD	O	O
that	IN	O	O
poor-prognosis	NN	O	O
patients	NNS	O	O
were	VBD	O	O
disadvantaged	VBN	O	O
specifically	RB	O	O
by	IN	O	O
access	NN	O	O
to	TO	O	O
the	DT	O	O
audiotape	NN	O	O
,	,	O	O
with	IN	O	O
less	JJR	O	O
improvement	NN	O	O
in	IN	O	O
psychological	JJ	o	OME
distress	NN	o	OME
at	IN	O	O
6	CD	O	O
months	NNS	O	O
follow-up	JJ	O	O
than	IN	O	O
non-tape	JJ	O	O
controls	NNS	O	O
.	.	O	O

Patient	JJ	O	O
access	NN	O	O
to	TO	O	O
audiotapes	NNS	i	IE
of	IN	O	O
clinical	JJ	O	O
interviews	NNS	O	O
promotes	VBZ	O	O
factual	JJ	o	OME
retention	NN	o	OME
but	CC	O	O
does	VBZ	O	O
not	RB	O	O
reliably	RB	O	O
reduce	VB	O	O
psychological	JJ	o	OME
distress	NN	o	OME
and	CC	O	O
may	MD	O	O
be	VB	O	O
actively	RB	O	O
unhelpful	JJ	O	O
in	IN	O	O
some	DT	O	O
subgroups	NNS	O	O
of	IN	O	O
patients	NNS	O	O
.	.	O	O

The	DT	O	O
cost-effectiveness	NN	o	OOt
of	IN	O	O
parasitologic	JJ	O	O
diagnosis	NN	O	O
for	IN	O	O
malaria-suspected	JJ	p	O
patients	NNS	p	O
in	IN	O	O
an	DT	O	O
era	NN	O	O
of	IN	O	O
combination	NN	O	O
therapy	NN	O	O
.	.	O	O

The	DT	O	O
introduction	NN	O	O
of	IN	O	O
artemisinin-based	JJ	i	IPM
combination	NN	i	IPM
therapy	NN	i	IPM
in	IN	O	O
sub-Saharan	NN	p	O
Africa	NNP	p	O
has	VBZ	O	O
prompted	VBN	O	O
calls	NNS	O	O
for	IN	O	O
increased	VBN	O	O
use	NN	O	O
of	IN	O	O
parasitologic	JJ	O	O
diagnosis	NN	O	O
for	IN	O	O
malaria	NN	O	O
.	.	O	O

We	PRP	O	O
evaluated	VBD	O	O
the	DT	O	O
cost-effectiveness	NN	o	OOt
of	IN	O	O
rapid	JJ	i	IPH
diagnostic	JJ	i	IPH
tests	NNS	i	IPH
(	(	i	IPH
RDTs	NNP	i	IPH
)	)	i	IPH
in	IN	O	O
comparison	NN	O	O
to	TO	O	O
microscopy	VB	i	IOt
in	IN	O	O
guiding	VBG	O	O
treatment	NN	O	O
of	IN	O	O
non-severe	JJ	O	O
febrile	JJ	O	O
illness	NN	O	O
at	IN	O	O
varying	VBG	O	O
levels	NNS	O	O
of	IN	O	O
malaria	NN	O	O
endemicity	NN	O	O
using	VBG	O	O
data	NNS	O	O
on	IN	O	O
test	NN	O	O
accuracy	NN	O	O
and	CC	O	O
costs	NNS	o	OOt
collected	VBN	O	O
as	IN	O	O
part	NN	O	O
of	IN	O	O
a	DT	O	O
Tanzanian	JJ	p	O
trial	NN	p	O
.	.	p	O

If	IN	O	O
prescribers	NNS	O	O
complied	VBD	O	O
with	IN	O	O
current	JJ	O	O
guidelines	NNS	O	O
,	,	O	O
microscopy	NN	O	O
would	MD	O	O
give	VB	O	O
rise	NN	O	O
to	TO	O	O
lower	JJR	O	O
average	NN	O	O
costs	NNS	o	OOt
per	IN	O	O
patient	NN	O	O
correctly	RB	O	O
treated	VBD	O	O
than	IN	O	O
RDTs	NNP	i	O
in	IN	O	O
areas	NNS	O	O
of	IN	O	O
both	DT	O	O
high	JJ	O	O
and	CC	O	O
low	JJ	O	O
transmission	NN	O	O
.	.	O	O

RDT	NNP	O	O
introduction	NN	O	O
would	MD	O	O
result	VB	O	O
in	IN	O	O
an	DT	O	O
additional	JJ	O	O
2.3	CD	O	O
%	NN	O	O
and	CC	O	O
9.4	CD	o	O
%	NN	o	O
of	IN	o	O
patients	NNS	o	OOt
correctly	RB	o	OOt
treated	VBN	o	OOt
,	,	O	O
at	IN	O	O
an	DT	O	O
incremental	JJ	o	OOt
cost	NN	o	OOt
of	IN	O	O
$	$	O	O
25	CD	O	O
and	CC	O	O
$	$	O	O
7	CD	O	O
in	IN	O	O
the	DT	O	O
low	JJ	O	O
and	CC	O	O
high	JJ	O	O
transmission	NN	O	O
settings	NNS	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

Cost-effectiveness	NNP	o	OOt
would	MD	O	O
be	VB	O	O
worse	JJR	O	O
if	IN	O	O
prescribers	NNS	O	O
do	VBP	O	O
not	RB	O	O
comply	VB	O	O
with	IN	O	O
test	NN	O	O
results	NNS	O	O
.	.	O	O

The	DT	O	O
cost	NN	O	O
of	IN	O	O
this	DT	O	O
additional	JJ	O	O
benefit	NN	O	O
may	MD	O	O
be	VB	O	O
higher	JJR	O	O
than	IN	O	O
many	JJ	O	O
countries	NNS	O	O
can	MD	O	O
afford	VB	O	O
without	IN	O	O
external	JJ	O	O
assistance	NN	O	O
or	CC	O	O
lower	JJR	O	O
RDT	NNP	O	O
prices	NNS	O	O
.	.	O	O

Effects	NNS	O	O
of	IN	O	O
hydraulic	JJ	O	O
circuit	NN	O	O
training	NN	O	O
on	IN	O	O
cardiovascular	JJ	p	PC
function	NN	p	PC
.	.	p	O

The	DT	O	O
effect	NN	O	O
of	IN	O	O
hydraulic	JJ	O	O
circuit	NN	O	O
training	NN	O	O
(	(	O	O
HCT	NNP	O	O
)	)	O	O
on	IN	O	O
cardiovascular	NN	o	OPH
(	(	o	OPH
CV	NNP	o	OPH
)	)	o	OPH
function	NN	o	OPH
was	VBD	O	O
assessed	VBN	O	O
in	IN	O	O
32	CD	p	PSS
healthy	JJ	p	O
middle-aged	JJ	p	O
males	NNS	p	PSE
(	(	p	O
X	JJ	p	O
age	NN	p	O
=	VBD	p	O
42.2	CD	p	PA
+/-	JJ	p	PA
2.1	CD	p	PA
yr	NN	p	PA
)	)	p	O
.	.	p	O

Maximal	NNP	o	OPH
aerobic	JJ	o	OPH
power	NN	o	OPH
(	(	o	OPH
VO2max	NNP	o	OPH
)	)	o	OPH
,	,	o	O
with	IN	o	O
simultaneous	JJ	o	OPH
measurement	NN	o	OPH
of	IN	o	OPH
stroke	NN	o	OPH
volume	NN	o	OPH
(	(	o	OPH
SV	NNP	o	OPH
)	)	o	OPH
and	CC	o	O
cardiac	JJ	o	OPH
output	NN	o	OPH
(	(	o	OPH
CO	NNP	o	OPH
)	)	o	OPH
,	,	o	O
by	IN	o	O
impedance	NN	o	OOt
cardiography	NN	o	OOt
,	,	O	O
was	VBD	O	O
assessed	VBN	O	O
pre-	JJ	O	O
and	CC	O	O
post-training	JJ	O	O
.	.	O	O

Subjects	NNS	O	O
were	VBD	O	O
randomly	RB	O	O
assigned	VBN	O	O
to	TO	O	O
a	DT	O	O
nonexercising	JJ	i	IC
control	NN	i	IC
group	NN	i	IC
,	,	i	IC
a	DT	i	IPH
cycle	NN	i	IPH
training	NN	i	IPH
group	NN	i	IPH
(	(	i	IPH
cycle	NN	i	IPH
)	)	i	IPH
,	,	i	IC
or	CC	i	IPH
one	CD	i	IPH
of	IN	i	IPH
the	DT	i	IPH
two	CD	i	IPH
HCT	NNP	i	IPH
groups	NNS	i	IPH
.	.	i	O

Training	VBG	i	IE
groups	NNS	i	IE
participated	VBN	i	IE
in	IN	i	IE
a	DT	i	IE
9	CD	i	IE
wk	NN	i	IE
program	NN	i	IE
,	,	i	IE
3	CD	i	IE
d.wk-1	NN	i	IE
.	.	i	O

Subjects	NNS	i	IPH
assigned	VBD	i	IPH
to	TO	i	IPH
HCT	NNP	i	IPH
exercised	VBN	i	IPH
on	IN	i	IPH
a	DT	i	IPH
9	CD	i	IPH
station	NN	i	IPH
circuit	NN	i	IPH
,	,	i	IPH
completing	VBG	i	IPH
3	CD	i	IPH
circuits.d-1	JJ	i	IPH
.	.	i	O

Each	DT	O	O
circuit	NN	O	O
consisted	VBD	O	O
of	IN	O	O
three	CD	O	O
20	CD	O	O
s	JJ	O	O
work	NN	O	O
intervals	NNS	O	O
at	IN	O	O
each	DT	O	O
station	NN	O	O
with	IN	O	O
a	DT	O	O
1:1	CD	O	O
work	NN	O	O
:	:	O	O
rest	NN	O	O
ratio	NN	O	O
.	.	O	O

One	CD	O	O
HCT	NNP	O	O
group	NN	O	O
(	(	O	O
HCTmax	NNP	O	O
)	)	O	O
completed	VBD	O	O
the	DT	O	O
maximal	JJ	O	O
repetitions	NNS	O	O
possible	JJ	O	O
(	(	O	O
RM	NNP	O	O
)	)	O	O
during	IN	O	O
each	DT	O	O
work	NN	O	O
interval	NN	O	O
.	.	O	O

The	DT	O	O
other	JJ	O	O
HCT	NNP	O	O
group	NN	O	O
(	(	O	O
HCTsub	NNP	O	O
)	)	O	O
exercised	VBD	O	O
at	IN	O	O
70-85	CD	O	O
%	NN	O	O
of	IN	O	O
RM	NNP	O	O
.	.	O	O

Following	VBG	O	O
training	NN	O	O
VO2max	NNP	o	OPH
(	(	o	OPH
ml.kg-1	JJ	o	OPH
min-1	NN	o	OPH
)	)	o	OPH
was	VBD	O	O
significantly	RB	O	O
increased	VBN	O	O
in	IN	O	O
all	DT	O	O
training	NN	O	O
groups	NNS	O	O
(	(	O	O
18.0	CD	O	O
,	,	O	O
12.5	CD	O	O
,	,	O	O
and	CC	O	O
11.3	CD	O	O
%	NN	O	O
for	IN	O	O
cycle	NN	O	O
,	,	O	O
HCTsub	NNP	O	O
,	,	O	O
and	CC	O	O
HCTmax	NNP	o	OPH
groups	NNS	o	OPH
,	,	O	O
respectively	RB	O	O
;	:	O	O
P	NNP	O	O
less	JJR	O	O
than	IN	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
increase	NN	O	O
in	IN	O	O
VO2max	NNP	o	OPH
observed	VBD	O	O
in	IN	O	O
the	DT	O	O
cycle	NN	O	O
group	NN	O	O
was	VBD	O	O
significantly	RB	O	O
greater	JJR	O	O
than	IN	O	O
that	DT	O	O
recorded	VBN	O	O
by	IN	O	O
the	DT	O	O
two	CD	O	O
HCT	NNP	O	O
groups	NNS	O	O
(	(	O	O
P	NNP	O	O
less	JJR	O	O
than	IN	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

For	IN	O	O
all	DT	O	O
three	CD	O	O
training	VBG	O	O
groups	NNS	O	O
,	,	O	O
the	DT	O	O
increase	NN	O	O
in	IN	O	O
VO2max	NNP	o	OPH
was	VBD	O	O
associated	VBN	O	O
with	IN	O	O
increases	NNS	O	O
in	IN	O	O
SVmax	NNP	o	OPH
and	CC	o	O
COmax	NNP	o	OPH
(	(	O	O
P	NNP	O	O
less	JJR	O	O
than	IN	O	O
0.05	CD	O	O
for	IN	O	O
both	DT	O	O
)	)	O	O
.	.	O	O

These	DT	O	O
findings	NNS	O	O
suggest	VBP	O	O
that	IN	O	O
both	DT	O	O
maximal	JJ	O	O
and	CC	O	O
submaximal	JJ	O	O
HCT	NNP	O	O
programs	NNS	O	O
can	MD	O	O
elicit	VB	O	O
improvements	NNS	O	O
in	IN	O	O
cardiovascular	JJ	o	OPH
fitness	NN	o	OPH
.	.	o	O

Randomized	VBN	O	O
,	,	O	O
controlled	VBD	O	O
study	NN	O	O
of	IN	O	O
various	JJ	O	O
agents	NNS	O	O
for	IN	O	O
endoscopic	NN	O	O
injection	NN	O	O
sclerotherapy	NN	O	O
of	IN	O	O
bleeding	VBG	O	O
canine	NN	O	O
gastric	JJ	O	O
varices	NNS	O	O
.	.	O	O

The	DT	O	O
purpose	NN	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
compare	VB	O	O
the	DT	O	O
relative	JJ	o	OOt
efficacy	NN	o	OOt
and	CC	o	OOt
technical	JJ	o	OOt
ease	NN	o	OOt
of	IN	o	OOt
use	NN	o	OOt
of	IN	O	O
eight	CD	O	O
different	JJ	O	O
agents	NNS	O	O
for	IN	O	O
endoscopic	JJ	O	O
hemostasis	NN	O	O
and	CC	O	O
obliteration	NN	O	O
of	IN	O	O
bleeding	VBG	O	O
gastric	JJ	O	O
varices	NNS	O	O
in	IN	O	O
a	DT	O	O
canine	NN	O	O
model	NN	O	O
,	,	O	O
as	IN	O	O
no	DT	O	O
comparative	JJ	O	O
data	NNS	O	O
are	VBP	O	O
available	JJ	O	O
on	IN	O	O
gastric	JJ	O	O
variceal	NN	O	O
sclerotherapy	NN	O	O
.	.	O	O

Large	JJ	O	O
bleeding	VBG	O	O
gastric	JJ	O	O
varices	NNS	O	O
in	IN	O	O
20	CD	p	PSS
heparinized	JJ	p	PC
dogs	NNS	p	O
were	VBD	O	O
randomized	VBN	i	O
to	TO	i	O
endoscopic	VB	i	O
injection	NN	i	O
treatment	NN	i	O
with	IN	i	O
one	CD	i	O
of	IN	i	O
the	DT	i	O
following	JJ	i	O
agents	NNS	i	O
:	:	i	O
cyanoacrylate	NN	i	IPM
;	:	i	O
a	DT	i	IPM
1:1:1	CD	i	IPM
mixture	NN	i	IPM
of	IN	i	IPM
sodium	NN	i	IPM
tetradecyl	NN	i	IPM
sulfate	VBP	i	IPM
3	CD	i	IPM
%	NN	i	IPM
,	,	i	IPM
ethanol	RB	i	IPM
98	CD	i	IPM
%	NN	i	IPM
,	,	i	IPM
and	CC	i	IPM
normal	JJ	i	IPM
saline	JJ	i	IPM
solution	NN	i	IPM
;	:	i	O
ethanolamine	VB	i	IPM
oleate	VBP	i	IPM
5	CD	i	IPM
%	NN	i	IPM
;	:	i	O
sodium	NN	i	IPM
morrhuate	VBP	i	IPM
5	CD	i	IPM
%	NN	i	IPM
;	:	i	IPM
sodium	NN	i	IPM
tetradecyl	NN	i	IPM
sulfate	VBP	i	IPM
1.5	CD	i	IPM
%	NN	i	IPM
;	:	i	IPM
polidocanol	CC	i	IPM
1	CD	i	IPM
%	NN	i	IPM
;	:	i	O
normal	JJ	i	IPM
saline	JJ	i	IPM
solution	NN	i	IPM
with	IN	i	IPM
epinephrine	JJ	i	IPM
1:10,000	CD	i	IPM
;	:	i	O
or	CC	i	O
normal	JJ	i	IC
saline	JJ	i	IC
solution	NN	i	IC
(	(	i	IC
control	NN	i	IC
)	)	i	IC
.	.	i	IC

The	DT	O	O
number	NN	O	O
and	CC	O	O
volume	NN	O	O
of	IN	O	O
injections	NNS	O	O
and	CC	O	O
the	DT	O	O
time	NN	O	O
required	VBN	O	O
to	TO	O	O
achieve	VB	O	O
complete	JJ	O	O
hemostasis	NN	O	O
were	VBD	O	O
evaluated	VBN	O	O
;	:	O	O
follow-up	JJ	O	O
endoscopy	NN	O	O
was	VBD	O	O
performed	VBN	O	O
at	IN	O	O
1	CD	O	O
month	NN	O	O
to	TO	O	O
assess	VB	O	O
gastric	JJ	O	O
variceal	NN	O	O
obliteration	NN	O	O
.	.	O	O

Cyanoacrylate	NNP	O	O
was	VBD	O	O
the	DT	O	O
best	JJS	O	O
agent	NN	O	O
overall	JJ	O	O
in	IN	O	O
terms	NNS	O	O
of	IN	O	O
immediate	JJ	o	OOt
efficacy	NN	o	OOt
,	,	o	O
low	JJ	o	OPH
volume	NN	o	OPH
requirement	NN	o	OPH
,	,	o	O
time	NN	o	OOt
required	VBN	o	OOt
for	IN	o	OOt
initial	JJ	o	OOt
hemostasis	NN	o	OOt
,	,	o	O
and	CC	o	O
reduction	NN	o	OPH
of	IN	o	OPH
gastric	JJ	o	OPH
variceal	NN	o	OPH
size	NN	o	OPH
.	.	o	O

Cyanoacrylate	NNP	o	OOt
,	,	o	O
tetradecyl	NN	o	OOt
sulfate	NN	o	OOt
,	,	o	O
and	CC	o	O
polidocanol	NN	o	OOt
were	VBD	O	O
the	DT	O	O
most	RBS	O	O
effective	JJ	O	O
agents	NNS	O	O
for	IN	O	O
reducing	VBG	O	O
gastric	JJ	O	O
variceal	NN	O	O
size	NN	O	O
.	.	O	O

Epinephrine	NNP	O	O
was	VBD	O	O
effective	JJ	O	O
for	IN	O	O
controlling	VBG	O	O
induced	JJ	o	OPH
or	CC	o	OPH
secondary	JJ	o	OPH
bleeding	NN	o	OPH
caused	VBN	O	O
by	IN	O	O
puncture	NN	O	O
of	IN	O	O
the	DT	O	O
gastric	JJ	O	O
varices	NNS	O	O
with	IN	O	O
the	DT	O	O
sclerotherapy	NN	O	O
needle	NN	O	O
during	IN	O	O
intravariceal	JJ	O	O
injections	NNS	O	O
.	.	O	O

Ongoing	VBG	O	O
studies	NNS	O	O
are	VBP	O	O
evaluating	VBG	O	O
combinations	NNS	O	O
of	IN	O	O
agents	NNS	O	O
with	IN	O	O
different	JJ	O	O
mechanisms	NNS	O	O
of	IN	O	O
action	NN	O	O
,	,	O	O
such	JJ	O	O
as	IN	O	O
epinephrine	NN	O	O
(	(	O	O
for	IN	O	O
vasoconstriction	NN	O	O
to	TO	O	O
minimize	VB	O	O
secondary	JJ	O	O
bleeding	NN	O	O
)	)	O	O
plus	CC	O	O
alcohol	NN	O	O
,	,	O	O
and/or	JJ	O	O
tetradecyl	NN	O	O
sulfate	NN	O	O
(	(	O	O
for	IN	O	O
variceal	NN	O	O
thrombosis	NN	O	O
and	CC	O	O
sclerosis	NN	O	O
)	)	O	O
.	.	O	O

(	(	O	O
ABSTRACT	NNP	O	O
TRUNCATED	NNP	O	O
AT	NNP	O	O
250	CD	O	O
WORDS	NNP	O	O
)	)	O	O
Sodium	NN	i	IPM
bicarbonate	NN	i	IPM
,	,	i	O
N-acetylcysteine	NNP	i	IPM
,	,	i	O
and	CC	i	O
saline	NN	i	IC
for	IN	O	O
prevention	NN	O	O
of	IN	O	O
radiocontrast-induced	JJ	o	OA
nephropathy	NN	o	OA
.	.	o	O

A	DT	O	O
comparison	NN	O	O
of	IN	O	O
3	CD	O	O
regimens	NNS	O	O
for	IN	O	O
protecting	VBG	O	O
contrast-induced	JJ	O	O
nephropathy	JJ	O	O
in	IN	O	O
patients	NNS	p	O
undergoing	VBG	p	O
coronary	JJ	i	IS
procedures	NNS	i	IS
.	.	i	IS

A	DT	O	O
single-center	JJ	p	O
prospective	NN	O	O
controlled	VBN	O	O
trial	NN	O	O
.	.	O	O

BACKGROUND	NNP	O	O
Several	NNP	O	O
protective	JJ	O	O
therapies	NNS	O	O
have	VBP	O	O
been	VBN	O	O
developed	VBN	O	O
to	TO	O	O
prevent	VB	O	O
contrast-induced	JJ	o	OA
nephropathy	JJ	o	OA
(	(	o	OA
CIN	NNP	o	OA
)	)	o	OA
.	.	o	OA

We	PRP	O	O
aimed	VBD	O	O
to	TO	O	O
investigate	VB	O	O
the	DT	O	O
efficacy	NN	O	O
of	IN	O	O
sodium	NN	i	IPM
bicarbonate	NN	i	IPM
by	IN	O	O
comparing	VBG	O	O
2	CD	O	O
other	JJ	O	O
regimens	NNS	O	O
,	,	O	O
including	VBG	O	O
combination	NN	i	O
of	IN	i	O
N-acetylcysteine	NNP	i	IS
(	(	i	IS
NAC	NNP	i	IS
)	)	i	IS
plus	CC	i	O
sodium	JJ	i	IPM
chloride	NN	i	IPM
and	CC	i	O
sodium	NN	i	IPM
chloride	NN	i	IPM
alone	RB	i	O
,	,	O	O
to	TO	O	O
prevent	VB	O	O
CIN	NNP	O	O
in	IN	O	O
patients	NNS	p	PC
undergoing	VBG	p	PC
cardiovascular	JJ	p	PC
procedures	NNS	p	PC
.	.	p	PC

METHODS	NNP	O	O
We	PRP	p	O
prospectively	RB	p	O
enrolled	VBD	p	O
264	CD	p	O
patients	NNS	p	O
who	WP	p	O
were	VBD	p	O
scheduled	VBN	p	O
for	IN	p	O
cardiovascular	JJ	p	O
procedures	NNS	p	O
and	CC	p	O
had	VBD	p	O
a	DT	p	O
baseline	JJ	p	O
creatinine	NN	p	O
level	NN	p	O
>	VBD	p	O
1.2	CD	p	O
mg/dL	NN	p	O
.	.	p	O

The	DT	O	O
patients	NNS	O	O
were	VBD	O	O
assigned	VBN	O	O
1	CD	O	O
of	IN	O	O
3	CD	O	O
prophylactic	JJ	O	O
regimens	NNS	O	O
:	:	O	O
infusion	NN	i	O
of	IN	i	O
sodium	NN	i	IPM
bicarbonate	NN	i	IPM
,	,	i	O
sodium	NN	i	IPM
chloride	NN	i	IPM
,	,	i	O
sodium	NN	i	IPM
chloride	NN	i	IPM
plus	CC	i	O
oral	JJ	i	O
NAC	NNP	i	IPM
(	(	O	O
600	CD	O	O
mg	RB	O	O
bid	NN	O	O
)	)	O	O
.	.	O	O

Contrast-induced	JJ	o	OA
nephropathy	NN	o	OA
was	VBD	O	O
defined	VBN	O	O
as	IN	O	O
an	DT	O	O
increase	NN	o	OA
in	IN	o	OA
serum	JJ	o	OA
creatinine	NN	o	OA
level	NN	o	OA
>	VBD	o	OA
25	CD	o	OA
%	NN	o	OA
or	CC	O	O
0.5	CD	O	O
mg/dL	NNS	O	O
after	IN	O	O
48	CD	O	O
hours	NNS	O	O
.	.	O	O

RESULTS	VB	O	O
There	EX	O	O
were	VBD	O	O
no	DT	O	O
significant	JJ	O	O
differences	NNS	O	O
among	IN	O	O
groups	NNS	O	O
regarding	VBG	O	O
baseline	NN	O	O
demographic	JJ	o	O
properties	NNS	o	O
and	CC	O	O
nephropathy	JJ	o	O
risk	NN	o	O
factors	NNS	o	O
.	.	o	O

The	DT	O	O
change	NN	o	OA
in	IN	o	OA
creatinine	JJ	o	OA
clearance	NN	o	OA
was	VBD	O	O
significantly	RB	O	O
better	RBR	O	O
in	IN	O	O
the	DT	O	O
sodium	NN	i	IPM
bicarbonate	NN	i	IPM
group	NN	O	O
than	IN	O	O
other	JJ	O	O
2	CD	O	O
groups	NNS	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
.007	NNP	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
incidence	NN	o	OA
of	IN	o	OA
CIN	NNP	o	OA
was	VBD	O	O
significantly	RB	O	O
lower	JJR	O	O
in	IN	O	O
the	DT	O	O
sodium	NN	i	IPM
bicarbonate	NN	i	IPM
group	NN	O	O
(	(	O	O
4.5	CD	O	O
%	NN	O	O
)	)	O	O
compared	VBN	O	O
with	IN	O	O
sodium	JJ	i	IPM
chloride	NN	i	IPM
alone	RB	i	O
(	(	O	O
13.6	CD	O	O
%	NN	O	O
,	,	O	O
P	NNP	O	O
=	NNP	O	O
.036	NNP	O	O
)	)	O	O
and	CC	O	O
tended	VBD	O	O
to	TO	O	O
be	VB	O	O
lower	JJR	O	O
than	IN	O	O
in	IN	O	O
the	DT	O	O
combination	NN	i	O
group	NN	O	O
(	(	O	O
12.5	CD	O	O
%	NN	O	O
,	,	O	O
P	NNP	O	O
=	NNP	O	O
.059	NNP	O	O
)	)	O	O
.	.	O	O

After	IN	O	O
adjusting	VBG	O	O
the	DT	O	O
Mehran	NNP	o	OA
nephropathy	NN	o	OA
risk	NN	o	OA
score	NN	o	OA
,	,	O	O
the	DT	O	O
risk	NN	o	OA
of	IN	o	OA
CIN	NNP	o	OA
significantly	RB	O	O
reduced	VBD	O	O
with	IN	O	O
sodium	NN	i	IPM
bicarbonate	NN	i	IPM
compared	VBN	O	O
with	IN	O	O
sodium	JJ	i	IPM
chloride	NN	i	IPM
alone	RB	O	O
(	(	O	O
adjusted	VBN	O	O
risk	NN	O	O
ratio	NN	O	O
0.29	CD	O	O
,	,	O	O
P	NNP	O	O
=	NNP	O	O
.043	NNP	O	O
)	)	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
Hydration	NNP	O	O
with	IN	O	O
sodium	JJ	i	IPM
bicarbonate	NN	i	IPM
provides	VBZ	O	O
better	JJR	O	O
protection	NN	o	O
against	IN	O	O
CIN	NNP	o	OA
than	IN	O	O
the	DT	O	O
sodium	NN	i	IPM
chloride	JJ	i	IPM
infusion	NN	i	IPM
does	VBZ	O	O
alone	RB	O	O
.	.	O	O

Combination	NNP	i	O
therapy	NN	i	O
of	IN	i	O
NAC	NNP	i	IPM
plus	CC	i	IPM
sodium	JJ	i	IPM
chloride	NN	i	IPM
did	VBD	O	O
not	RB	O	O
offer	VB	O	O
additional	JJ	O	O
benefit	NN	O	O
over	IN	O	O
hydration	NN	O	O
with	IN	O	O
sodium	JJ	i	IPM
chloride	NN	i	IPM
alone	RB	i	O
.	.	i	O

Histamine	NNP	p	PC
intolerance-like	NN	p	PC
symptoms	NNS	p	PC
in	IN	p	O
healthy	JJ	p	PC
volunteers	NNS	p	O
after	IN	O	O
oral	JJ	O	O
provocation	NN	O	O
with	IN	O	O
liquid	JJ	O	O
histamine	NN	O	O
.	.	O	O

Histamine	NNP	O	O
in	IN	O	O
food	NN	O	O
at	IN	O	O
non-toxic	JJ	O	O
doses	NNS	O	O
has	VBZ	O	O
been	VBN	O	O
proposed	VBN	O	O
to	TO	O	O
be	VB	O	O
a	DT	O	O
major	JJ	O	O
cause	NN	O	O
of	IN	O	O
food	NN	O	O
intolerance	NN	O	O
causing	NN	O	O
symptoms	NNS	O	O
like	IN	O	O
diarrhea	NN	O	O
,	,	O	O
hypotension	NN	O	O
,	,	O	O
headache	NN	O	O
,	,	O	O
pruritus	NN	O	O
and	CC	O	O
flush	NN	O	O
(	(	O	O
histamine	JJ	O	O
intolerance	NN	O	O
)	)	O	O
.	.	O	O

Histamine-rich	JJ	O	O
foods	NNS	O	O
such	JJ	O	O
as	IN	O	O
cheese	NN	O	O
,	,	O	O
sausages	NNS	O	O
,	,	O	O
sauerkraut	NN	O	O
,	,	O	O
tuna	NN	O	O
,	,	O	O
tomatoes	NNS	O	O
,	,	O	O
and	CC	O	O
alcoholic	JJ	O	O
beverages	NNS	O	O
may	MD	O	O
contain	VB	O	O
histamine	VB	O	O
up	IN	O	O
to	TO	O	O
500	CD	O	O
mg/kg	NNS	O	O
.	.	O	O

We	PRP	O	O
conducted	VBD	O	O
a	DT	O	O
randomized	VBN	O	O
,	,	O	O
double-blind	JJ	O	O
,	,	O	O
placebo-controlled	JJ	i	IC
cross-over	NN	O	O
study	NN	O	O
in	IN	O	O
10	CD	p	PSS
healthy	JJ	p	O
females	NNS	p	PSE
(	(	p	O
age	NN	p	O
range	NN	p	O
22-36	CD	p	PA
years	NNS	p	PA
,	,	p	O
mean	JJ	p	O
29.1	CD	p	O
+/-	JJ	p	O
5.4	CD	p	O
)	)	p	O
who	WP	p	O
were	VBD	p	O
hospitalized	VBN	p	O
and	CC	p	O
challenged	VBN	p	O
on	IN	p	O
two	CD	p	O
consecutive	JJ	p	O
days	NNS	p	O
with	IN	p	O
placebo	NN	i	IC
(	(	i	IC
peppermint	JJ	i	IC
tea	NN	i	IC
)	)	i	IC
or	CC	i	O
75	CD	i	O
mg	NN	i	O
of	IN	i	O
pure	JJ	i	O
histamine	NN	i	IPM
(	(	p	O
equaling	VBG	p	O
124	CD	p	O
mg	JJ	p	O
histamine	NN	p	O
dihydrochloride	NN	p	O
,	,	p	O
dissolved	VBN	p	O
in	IN	p	O
peppermint	NN	p	O
tea	NN	p	O
)	)	p	O
.	.	p	O

Objective	JJ	O	O
parameters	NNS	O	O
(	(	O	O
heart	NN	O	O
rate	NN	O	O
,	,	O	O
blood	NN	O	O
pressure	NN	O	O
,	,	O	O
skin	JJ	O	O
temperature	NN	O	O
,	,	O	O
peak	VB	O	O
flow	NN	O	O
)	)	O	O
as	RB	O	O
well	RB	O	O
as	IN	O	O
a	DT	O	O
total	JJ	O	O
clinical	JJ	O	O
symptom	NN	O	O
score	NN	O	O
using	VBG	O	O
a	DT	O	O
standardized	VBN	O	O
protocol	NN	O	O
were	VBD	O	O
recorded	VBN	O	O
at	IN	O	O
baseline	NN	O	O
,	,	O	O
10	CD	O	O
,	,	O	O
20	CD	O	O
,	,	O	O
40	CD	O	O
,	,	O	O
80	CD	O	O
minutes	NNS	O	O
,	,	O	O
and	CC	O	O
24	CD	O	O
hours	NNS	O	O
.	.	O	O

The	DT	O	O
subjects	NNS	O	O
received	VBD	O	O
a	DT	O	O
histamine-free	JJ	i	IPM
diet	NN	i	IPM
also	RB	O	O
low	JJ	O	O
in	IN	O	O
allergen	NN	O	O
24	CD	O	O
hours	NNS	O	O
before	IN	O	O
hospitalization	NN	O	O
and	CC	O	O
over	IN	O	O
the	DT	O	O
whole	JJ	O	O
observation	NN	O	O
period	NN	O	O
.	.	O	O

Blood	NN	O	O
samples	NNS	O	O
were	VBD	O	O
drawn	VBN	O	O
at	IN	O	O
baseline	NN	O	O
,	,	O	O
10	CD	O	O
,	,	O	O
20	CD	O	O
,	,	O	O
40	CD	O	O
,	,	O	O
and	CC	O	O
80	CD	O	O
minutes	NNS	O	O
,	,	O	O
and	CC	O	O
histamine	NN	O	O
and	CC	O	O
the	DT	O	O
histamine-degrading	JJ	O	O
enzyme	NN	O	O
diamine	NN	O	O
oxidase	NN	O	O
(	(	O	O
DAO	NNP	O	O
)	)	O	O
were	VBD	O	O
determined	VBN	O	O
.	.	O	O

After	IN	O	O
histamine	JJ	O	O
challenge	NN	O	O
,	,	O	O
5	CD	O	O
of	IN	O	O
10	CD	O	O
subjects	NNS	O	O
showed	VBD	O	O
no	DT	o	OPH
reaction	NN	o	OPH
.	.	o	O

One	CD	O	O
individual	NN	O	O
experienced	VBD	O	O
tachycardia	NN	o	OPH
,	,	o	O
mild	JJ	o	OPH
hypotension	NN	o	OPH
after	IN	o	OPH
20	CD	o	OPH
minutes	NNS	o	OPH
,	,	o	O
sneezing	VBG	o	OPH
,	,	o	O
itching	NN	o	OPH
of	IN	o	OPH
the	DT	o	OPH
nose	NN	o	OPH
,	,	o	O
and	CC	o	O
rhinorrhea	NN	o	OPH
after	IN	o	OPH
60	CD	o	OPH
minutes	NNS	o	OPH
.	.	o	O

Four	CD	O	O
subjects	NNS	O	O
experienced	VBD	O	O
delayed	JJ	O	O
symptoms	NNS	O	O
like	IN	O	O
diarrhea	NN	o	OPH
(	(	o	OPH
4x	CD	o	OPH
)	)	o	OPH
,	,	o	O
flatulence	NN	o	OPH
(	(	o	OPH
3x	CD	o	OPH
)	)	o	OPH
,	,	o	O
headache	NN	o	OPH
(	(	o	OPH
3x	CD	o	OPH
)	)	o	OPH
,	,	o	O
pruritus	NN	o	OPH
(	(	o	OPH
2x	CD	o	OPH
)	)	o	OPH
and	CC	o	O
ocular	JJ	o	OPH
symptoms	NNS	o	OPH
(	(	O	O
1x	CD	O	O
)	)	O	O
starting	VBG	O	O
3	CD	O	O
to	TO	O	O
24	CD	O	O
hours	NNS	O	O
after	IN	O	O
provocation	NN	O	O
.	.	O	O

No	DT	O	O
subject	NN	O	O
reacted	VBD	O	O
to	TO	O	O
placebo	VB	O	O
.	.	O	O

No	DT	O	O
changes	NNS	O	O
were	VBD	O	O
observed	VBN	O	O
in	IN	O	O
histamine	NN	o	OPH
and	CC	o	OPH
DAO	NNP	o	OPH
levels	NNS	o	OPH
within	IN	O	O
the	DT	O	O
first	JJ	O	O
80	CD	O	O
minutes	NNS	O	O
in	IN	O	O
non-reactors	NNS	O	O
as	RB	O	O
well	RB	O	O
as	IN	O	O
reactors	NNS	O	O
.	.	O	O

There	EX	O	O
was	VBD	O	O
no	DT	O	O
difference	NN	O	O
in	IN	O	O
challenge	NN	O	O
with	IN	O	O
histamine	JJ	O	O
versus	NN	O	O
challenge	NN	O	O
with	IN	O	O
placebo	NN	O	O
.	.	O	O

We	PRP	O	O
conclude	VBP	O	O
that	IN	O	O
75	CD	O	O
mg	NN	O	O
of	IN	O	O
pure	NN	O	O
liquid	JJ	O	O
oral	JJ	O	O
histamine	NN	O	O
--	:	O	O
a	DT	O	O
dose	JJ	O	O
found	VBN	O	O
in	IN	O	O
normal	JJ	O	O
meals	NNS	O	O
--	:	O	O
can	MD	O	O
provoke	VB	O	O
immediate	JJ	O	O
as	RB	O	O
well	RB	O	O
as	IN	O	O
delayed	VBN	O	O
symptoms	NNS	O	O
in	IN	O	O
50	CD	O	O
%	NN	O	O
of	IN	O	O
healthy	JJ	p	O
females	NNS	p	PSE
without	IN	p	O
a	DT	p	O
history	NN	p	O
of	IN	p	O
food	NN	p	O
intolerance	NN	p	O
.	.	p	O

The	DT	O	O
NORwegian	JJ	O	O
study	NN	O	O
on	IN	O	O
DIstrict	NNP	O	O
treatment	NN	O	O
of	IN	O	O
ST-elevation	NNP	p	O
myocardial	JJ	p	O
infarction	NN	p	O
(	(	O	O
NORDISTEMI	NNP	O	O
)	)	O	O
.	.	O	O

OBJECTIVES	NNP	O	O
Thrombolysis	NNP	O	O
is	VBZ	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
choice	NN	O	O
for	IN	O	O
patients	NNS	p	O
with	IN	p	O
ST-elevation	NNP	p	O
myocardial	JJ	p	O
infarction	NN	p	O
(	(	p	O
STEMI	NNP	p	O
)	)	p	O
living	NN	p	O
in	IN	p	O
rural	JJ	p	O
areas	NNS	p	O
with	IN	p	O
long	JJ	p	O
transfer	NN	p	O
delays	NNS	p	O
to	TO	p	O
percutaneous	JJ	p	O
coronary	JJ	p	O
intervention	NN	p	O
(	(	p	O
PCI	NNP	p	O
)	)	p	O
.	.	p	O

This	DT	O	O
trial	NN	O	O
compares	VBZ	O	O
two	CD	O	O
different	JJ	O	O
strategies	NNS	O	O
following	VBG	O	O
thrombolysis	NN	O	O
:	:	O	O
to	TO	O	O
transfer	VB	O	O
all	DT	O	O
patients	NNS	O	O
for	IN	O	O
immediate	JJ	O	O
coronary	JJ	O	O
angiography	NN	O	O
and	CC	O	O
intervention	NN	O	O
,	,	O	O
or	CC	O	O
to	TO	O	O
manage	VB	O	O
the	DT	O	O
patients	NNS	O	O
more	RBR	O	O
conservatively	RB	O	O
.	.	O	O

DESIGN	VB	O	O
The	DT	p	O
NORwegian	JJ	p	O
study	NN	p	O
on	IN	p	O
DIstrict	NNP	p	O
treatment	NN	p	O
of	IN	p	O
STEMI	NNP	p	O
(	(	p	O
NORDISTEMI	NNP	p	O
)	)	p	O
is	VBZ	O	O
an	DT	O	O
open	JJ	O	O
,	,	O	O
prospective	JJ	O	O
,	,	O	O
randomized	VBD	i	O
controlled	VBN	i	O
trial	NN	i	O
in	IN	i	O
patients	NNS	i	O
with	IN	i	O
STEMI	NNP	i	O
of	IN	i	O
less	JJR	i	O
than	IN	i	O
6	CD	i	O
hours	NNS	i	O
of	IN	i	O
duration	NN	i	O
and	CC	i	O
more	JJR	i	O
than	IN	i	O
90	CD	i	O
minutes	NNS	i	O
expected	VBD	i	O
time	NN	i	O
delay	NN	i	O
to	TO	i	O
PCI	NNP	i	IS
.	.	i	O

A	NNP	p	O
total	NN	p	O
of	IN	p	O
266	CD	p	O
patients	NNS	p	O
will	MD	O	O
receive	VB	i	IPH
full-dose	JJ	i	IPM
thrombolysis	NN	i	IPM
,	,	i	O
preferably	RB	i	O
pre-hospital	JJ	i	O
,	,	i	O
and	CC	i	O
then	RB	i	O
be	VB	i	O
randomized	VBN	i	O
to	TO	i	O
either	DT	i	O
strategy	NN	i	O
.	.	i	O

Our	PRP$	O	O
primary	JJ	O	O
endpoint	NN	O	O
is	VBZ	O	O
the	DT	O	O
one	CD	O	O
year	NN	O	O
combined	VBN	o	OMO
incidence	NN	o	OMO
of	IN	o	OMO
death	NN	o	OMO
,	,	o	O
reinfarction	NN	o	OPH
,	,	o	O
stroke	VBD	o	OPH
or	CC	o	O
new	JJ	o	OPH
myocardial	JJ	o	OPH
ischaemia	NN	o	OPH
.	.	o	O

The	DT	O	O
study	NN	O	O
is	VBZ	O	O
registered	VBN	O	O
with	IN	O	O
ClinicalTrials.gov	NNP	O	O
,	,	O	O
number	NN	O	O
NCT00161005	NNP	O	O
.	.	O	O

RESULTS	VBN	O	O
By	IN	O	O
April	NNP	p	O
2006	CD	p	O
,	,	p	O
109	CD	p	O
patients	NNS	p	O
have	VBP	O	O
been	VBN	O	O
randomized	VBN	O	O
.	.	O	O

Thrombolysis	NN	O	O
has	VBZ	O	O
been	VBN	O	O
given	VBN	O	O
pre-hospital	JJ	O	O
to	TO	O	O
52	CD	O	O
%	NN	O	O
of	IN	O	O
patients	NNS	O	O
.	.	O	O

The	DT	O	O
median	JJ	O	O
transport	NN	O	O
distance	NN	O	O
from	IN	O	O
first	JJ	O	O
medical	JJ	O	O
contact	NN	O	O
to	TO	O	O
catheterization	NN	O	O
laboratory	NN	O	O
was	VBD	O	O
155	CD	O	O
km	NN	O	O
(	(	O	O
range	JJ	O	O
90-396	CD	O	O
km	NN	O	O
)	)	O	O
.	.	O	O

Results	NNS	O	O
of	IN	O	O
the	DT	O	O
study	NN	O	O
are	VBP	O	O
expected	VBN	O	O
in	IN	O	O
2008	CD	O	O
.	.	O	O

Bradykinin-induced	JJ	O	O
cough	NN	O	O
reflex	NN	O	O
markedly	RB	O	O
increases	VBZ	O	O
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
cough	NN	p	PC
associated	VBN	p	O
with	IN	p	O
captopril	NN	p	O
and	CC	p	O
enalapril	NN	p	O
.	.	p	O

We	PRP	O	O
studied	VBD	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
angiotensin	NN	i	IPM
converting	VBG	i	IPM
enzyme	NN	i	IPM
(	(	i	IPM
ACE	NNP	i	IPM
)	)	i	IPM
inhibitors	NNS	i	IPM
on	IN	O	O
cough	NN	o	OA
responses	NNS	o	OA
to	TO	i	IPM
bradykinin	VB	i	IPM
(	(	i	IPM
BK	NNP	i	IPM
)	)	i	IPM
,	,	i	O
substance	NN	i	IPM
P	NNP	i	IPM
(	(	i	IPM
SP	NNP	i	IPM
)	)	i	IPM
and	CC	i	O
citric	JJ	i	IPM
acid	NN	i	IPM
in	IN	O	O
a	DT	O	O
double	JJ	O	O
blind	NN	O	O
,	,	O	O
random	NN	O	O
study	NN	O	O
on	IN	O	O
10	CD	p	PSS
hypertensive	JJ	p	PC
patients	NNS	p	O
receiving	VBG	p	O
ACE	NNP	i	IPM
inhibitors	NNS	i	IPM
.	.	i	O

Of	IN	p	O
these	DT	p	O
patients	NNS	p	O
,	,	p	O
five	CD	p	PSS
had	VBD	p	O
reported	VBN	p	O
cough	NN	p	PC
with	IN	p	O
ACE	NNP	i	IPM
inhibitors	NNS	i	IPM
.	.	i	O

Cough	NNP	O	O
responses	VBZ	O	O
to	TO	O	O
citric	VB	O	O
acid	NN	O	O
were	VBD	O	O
similar	JJ	O	O
between	IN	O	O
patients	NNS	O	O
with	IN	O	O
and	CC	O	O
without	IN	O	O
cough	NN	O	O
,	,	O	O
and	CC	O	O
SP	NNP	O	O
up	RB	O	O
to	TO	O	O
10	CD	O	O
(	(	O	O
-5	NN	O	O
)	)	O	O
M	NNP	O	O
did	VBD	O	O
not	RB	O	O
cause	VB	O	O
cough	NN	O	O
in	IN	O	O
any	DT	O	O
of	IN	O	O
the	DT	O	O
subjects	NNS	O	O
.	.	O	O

BK	NNP	i	IPM
caused	VBD	p	O
cough	NN	o	OA
at	IN	p	O
13.4	CD	p	O
+/-	JJ	p	O
1.2	CD	p	O
(	(	p	O
-log	NNP	p	O
M	NNP	p	O
)	)	p	O
in	IN	p	O
5	CD	p	PSS
patients	NNS	p	O
with	IN	p	O
cough	NN	p	O
associated	VBN	p	O
with	IN	p	O
ACE	NNP	i	IPM
inhibitors	NNS	i	IPM
,	,	p	O
but	CC	p	O
it	PRP	p	O
did	VBD	p	O
not	RB	p	O
cause	VB	p	O
cough	NN	o	OA
at	IN	p	O
concentrations	NNS	p	O
up	RB	p	O
to	TO	p	O
10	CD	p	O
(	(	p	O
-5	NN	p	O
)	)	p	O
M	NNP	p	O
in	IN	p	O
other	JJ	p	O
5	CD	p	PSS
patients	NNS	p	O
.	.	p	O

One	CD	O	O
month	NN	O	O
after	IN	O	O
the	DT	O	O
withdrawal	NN	O	O
of	IN	O	O
ACE	NNP	O	O
inhibitors	NNS	O	O
,	,	O	O
5	CD	p	PSS
patients	NNS	p	O
were	VBD	p	O
free	JJ	p	O
from	IN	p	O
cough	NN	o	OPH
symptoms	NNS	o	OPH
,	,	p	O
and	CC	p	O
BK	NNP	p	O
did	VBD	p	O
not	RB	p	O
cause	VB	p	O
cough	NN	o	OPH
up	RB	p	O
to	TO	p	O
10	CD	p	O
(	(	p	O
-5	NN	p	O
)	)	p	O
M	NNP	p	O
in	IN	p	O
these	DT	p	O
patients	NNS	p	O
,	,	p	O
except	IN	p	O
for	IN	p	O
one	CD	p	O
who	WP	p	O
coughed	VBD	p	O
at	IN	p	O
10	CD	p	O
(	(	p	O
-9	NN	p	O
)	)	p	O
M	NNP	p	O
,	,	O	O
without	IN	O	O
changes	NNS	O	O
in	IN	O	O
responses	NNS	O	O
to	TO	O	O
citric	VB	O	O
acid	NN	O	O
.	.	O	O

BK	NNP	O	O
caused	VBD	O	O
cough	NN	o	OPH
at	IN	O	O
14.3	CD	O	O
+/-	JJ	O	O
0.7	CD	O	O
(	(	O	O
-log	NNP	O	O
M	NNP	O	O
)	)	O	O
although	IN	O	O
BK1-7	NNP	O	O
,	,	O	O
a	DT	O	O
major	JJ	O	O
metabolite	NN	O	O
of	IN	O	O
BK	NNP	O	O
by	IN	O	O
ACE	NNP	O	O
,	,	O	O
caused	VBD	O	O
cough	NN	o	OPH
at	IN	O	O
5.7	CD	O	O
+/-	JJ	O	O
0.7	CD	O	O
(	(	O	O
-log	NNP	O	O
M	NNP	O	O
)	)	O	O
in	IN	O	O
another	DT	O	O
3	CD	O	O
patients	NNS	O	O
with	IN	O	O
cough	NN	O	O
associated	VBN	O	O
with	IN	O	O
ACE	NNP	O	O
inhibitor	NN	O	O
.	.	O	O

These	DT	O	O
results	NNS	O	O
suggest	VBP	O	O
that	IN	O	O
impaired	JJ	O	O
metabolism	NN	O	O
of	IN	O	O
BK	NNP	O	O
induced	VBN	O	O
by	IN	O	O
ACE	NNP	O	O
inhibitors	NNS	O	O
may	MD	O	O
relate	VB	O	O
to	TO	O	O
the	DT	O	O
manifestation	NN	O	O
of	IN	O	O
cough	NN	O	O
in	IN	O	O
hypertensive	JJ	p	O
patients	NNS	p	O
receiving	VBG	p	O
ACE	NNP	p	O
inhibitors	NNS	p	O
.	.	p	O

Improved	VBN	o	OOt
intraoperative	JJ	o	OOt
management	NN	o	OOt
of	IN	O	O
anastomotic	JJ	o	OPH
bleeding	NN	o	OPH
during	IN	p	O
aortic	JJ	p	O
reconstruction	NN	p	O
:	:	p	O
results	NNS	O	O
of	IN	O	O
a	DT	O	O
randomized	VBN	O	O
controlled	VBN	O	O
trial	NN	O	O
.	.	O	O

In	IN	O	O
a	DT	O	O
randomized	NN	O	O
controlled	VBN	O	O
trial	NN	O	O
,	,	O	O
the	DT	O	O
effectiveness	NN	o	OOt
of	IN	O	O
a	DT	O	O
polymeric	JJ	i	IS
surgical	JJ	i	IS
sealant	NN	i	IS
(	(	i	IS
CoSeal	NNP	i	IS
)	)	i	IS
was	VBD	O	O
compared	VBN	i	O
to	TO	i	O
Gelfoam/thrombin	NNP	i	IS
for	IN	i	O
managing	VBG	i	O
anastomotic	JJ	o	OPH
bleeding	NN	o	OPH
after	IN	i	O
implantation	NN	i	IPH
of	IN	i	IS
Dacron	NNP	i	IS
grafts	NNS	i	IS
during	IN	i	IS
aortic	JJ	i	IS
reconstruction	NN	i	IS
for	IN	i	IS
nonruptured	JJ	i	IS
aneurysms	NNS	i	IS
.	.	i	O

Each	DT	i	IS
treatment	NN	i	IS
was	VBD	i	IS
directly	RB	i	IS
applied	VBN	i	IS
to	TO	i	IS
the	DT	i	IS
suture	NN	i	IS
line	NN	i	IS
after	IN	i	IS
confirmation	NN	i	IS
of	IN	i	IS
anastomotic	JJ	i	IS
bleeding	NN	i	IS
.	.	i	IS

The	DT	O	O
proportion	NN	O	O
of	IN	O	O
suture	NN	O	O
line	NN	O	O
sites	VBZ	O	O
that	IN	O	O
achieved	VBD	O	O
immediate	JJ	o	OOt
sealing	NN	o	OOt
and	CC	O	O
the	DT	O	O
proportion	NN	O	O
sealed	VBD	O	O
within	IN	O	O
5	CD	O	O
minutes	NNS	O	O
were	VBD	O	O
determined	VBN	O	O
among	IN	O	O
37	CD	p	PSS
experimental	JJ	p	O
(	(	p	O
59	CD	p	O
sites	NNS	p	O
)	)	p	O
and	CC	p	O
17	CD	p	PSS
control	NN	p	O
subjects	NNS	p	O
(	(	p	O
27	CD	p	O
sites	NNS	p	O
)	)	p	O
.	.	p	O

A	DT	O	O
significantly	RB	O	O
greater	JJR	O	O
proportion	NN	O	O
of	IN	O	O
bleeding	VBG	O	O
suture	NN	O	O
line	NN	O	O
sites	NNS	O	O
treated	VBD	O	O
with	IN	O	O
the	DT	O	O
polymeric	JJ	i	IS
sealant	NN	i	IS
achieved	VBN	O	O
immediate	JJ	o	OOt
sealing	NN	o	OOt
following	VBG	O	O
reestablishment	NN	O	O
of	IN	O	O
blood	NN	O	O
flow	NN	O	O
compared	VBN	O	O
with	IN	O	O
control-treated	JJ	O	O
sites	NNS	O	O
[	VBP	O	O
48	CD	O	O
of	IN	O	O
59	CD	O	O
(	(	O	O
81	CD	O	O
%	NN	O	O
)	)	O	O
vs	VBZ	O	O
10	CD	O	O
of	IN	O	O
27	CD	O	O
(	(	O	O
37	CD	O	O
%	NN	O	O
)	)	O	O
;	:	O	O
P	NNP	O	O
=	VBD	O	O
0.002	CD	O	O
]	NN	O	O
.	.	O	O

The	DT	O	O
difference	NN	O	O
between	IN	O	O
treatment	NN	O	O
groups	NNS	O	O
was	VBD	O	O
maintained	VBN	O	O
after	IN	O	O
5	CD	O	O
minutes	NNS	O	O
with	IN	O	O
approximately	RB	O	O
85	CD	O	O
per	IN	O	O
cent	NN	O	O
(	(	O	O
50	CD	O	O
of	IN	O	O
59	CD	O	O
)	)	O	O
of	IN	O	O
CoSeal	NNP	i	IS
sites	NNS	O	O
compared	VBN	O	O
to	TO	O	O
just	RB	O	O
over	IN	O	O
one-half	JJ	O	O
(	(	O	O
14	CD	O	O
of	IN	O	O
27	CD	O	O
)	)	O	O
of	IN	O	O
control	NN	O	O
sites	VBZ	O	O
demonstrating	VBG	O	O
ultimate	JJ	o	OPH
sealing	NN	o	OPH
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.01	CD	O	O
)	)	O	O
.	.	O	O

There	EX	O	O
were	VBD	O	O
no	DT	O	O
adverse	JJ	O	O
events	NNS	O	O
related	VBN	O	O
to	TO	O	O
the	DT	O	O
use	NN	O	O
of	IN	O	O
the	DT	O	O
polymeric	JJ	i	IS
sealant	NN	i	IS
in	IN	O	O
this	DT	O	O
study	NN	O	O
.	.	O	O

These	DT	O	O
results	NNS	O	O
support	VBP	O	O
the	DT	O	O
use	NN	O	O
of	IN	O	O
this	DT	O	O
novel	JJ	O	O
sealant	NN	O	O
for	IN	O	O
the	DT	O	O
intraoperative	JJ	p	O
management	NN	p	O
of	IN	p	O
anastomotic	JJ	p	PC
bleeding	NN	p	PC
during	IN	p	O
aortic	JJ	p	O
reconstruction	NN	p	O
procedures	NNS	p	O
.	.	p	O

Exposure	NN	i	O
to	TO	i	O
the	DT	i	O
self-face	NN	i	IPH
facilitates	VBZ	i	IPH
identification	NN	o	OME
of	IN	o	OME
dynamic	JJ	o	OME
facial	JJ	o	OME
expressions	NNS	o	OME
:	:	o	OOt
influences	NNS	O	O
on	IN	O	O
individual	JJ	O	O
differences	NNS	O	O
.	.	O	O

A	DT	O	O
growing	VBG	O	O
literature	NN	O	O
suggests	VBZ	O	O
that	IN	O	O
the	DT	O	O
self-face	NN	i	IPH
is	VBZ	O	O
involved	VBN	O	O
in	IN	O	O
processing	VBG	o	OME
the	DT	o	OME
facial	JJ	o	OME
expressions	NNS	o	OME
of	IN	O	O
others	NNS	O	O
.	.	O	O

The	DT	O	O
authors	NNS	O	O
experimentally	RB	O	O
activated	VBD	O	O
self-face	JJ	i	IPH
representations	NNS	i	IPH
to	TO	O	O
assess	VB	O	O
its	PRP$	O	O
effects	NNS	O	O
on	IN	O	O
the	DT	O	O
recognition	NN	o	OME
of	IN	o	OME
dynamically	RB	o	OME
emerging	VBG	o	OME
facial	JJ	o	OME
expressions	NNS	o	OME
of	IN	o	OME
others	NNS	o	OME
.	.	o	O

They	PRP	O	O
exposed	VBD	O	O
participants	NNS	p	O
to	TO	O	O
videos	NNS	O	O
of	IN	O	O
either	DT	O	O
their	PRP$	O	O
own	JJ	O	O
faces	VBZ	O	O
(	(	i	O
self-face	JJ	i	IPH
prime	NN	i	IPH
)	)	i	IPH
or	CC	i	IPH
faces	VBZ	i	IPH
of	IN	i	IPH
others	NNS	i	IPH
(	(	i	IPH
nonself-face	JJ	i	IPH
prime	NN	i	IPH
)	)	i	O
prior	RB	O	O
to	TO	O	O
a	DT	O	O
facial	JJ	O	O
expression	NN	O	O
judgment	NN	O	O
task	NN	O	O
.	.	O	O

Their	PRP$	O	O
results	NNS	O	O
show	VBP	O	O
that	IN	O	O
experimentally	RB	O	O
activating	VBG	O	O
self-face	JJ	O	O
representations	NNS	O	O
results	NNS	O	O
in	IN	O	O
earlier	JJR	O	O
recognition	NN	o	OME
of	IN	o	OME
dynamically	RB	o	OME
emerging	VBG	o	OME
facial	JJ	o	OME
expression	NN	o	OME
.	.	o	O

As	IN	O	O
a	DT	O	O
group	NN	O	O
,	,	O	O
participants	NNS	p	O
in	IN	p	O
the	DT	p	O
self-face	JJ	p	O
prime	JJ	p	O
condition	NN	p	O
recognized	VBD	o	OME
expressions	NNS	o	OME
earlier	RBR	O	O
(	(	O	O
when	WRB	O	O
less	RBR	O	O
affective	JJ	O	O
perceptual	JJ	O	O
information	NN	O	O
was	VBD	O	O
available	JJ	O	O
)	)	O	O
compared	VBN	O	O
to	TO	O	O
participants	NNS	O	O
in	IN	O	O
the	DT	O	O
nonself-face	JJ	O	O
prime	JJ	O	O
condition	NN	O	O
.	.	O	O

There	EX	O	O
were	VBD	O	O
individual	JJ	O	O
differences	NNS	O	O
in	IN	O	O
performance	NN	O	O
,	,	O	O
such	JJ	O	O
that	IN	O	O
poorer	JJR	O	O
expression	NN	o	OME
identification	NN	o	OME
was	VBD	O	O
associated	VBN	O	O
with	IN	O	O
higher	JJR	p	O
autism	NN	p	PC
traits	NNS	p	O
(	(	O	O
in	IN	O	O
this	DT	O	O
neurocognitively	RB	p	PC
healthy	JJ	p	PC
sample	NN	p	PC
)	)	p	O
.	.	O	O

However	RB	O	O
,	,	O	O
when	WRB	O	O
randomized	VBN	O	O
into	IN	O	O
the	DT	O	O
self-face	JJ	O	O
prime	JJ	O	O
condition	NN	O	O
,	,	O	O
participants	NNS	p	O
with	IN	p	O
high	JJ	p	PC
autism	NN	p	PC
traits	NNS	p	PC
performed	VBN	p	O
as	RB	p	O
well	RB	p	O
as	IN	p	O
those	DT	p	O
with	IN	p	O
low	JJ	p	PC
autism	NN	p	PC
traits	NNS	p	PC
.	.	p	O

Taken	VB	O	O
together	RB	O	O
,	,	O	O
these	DT	O	O
data	NNS	O	O
suggest	VBP	O	O
that	IN	O	O
the	DT	O	O
ability	NN	o	OME
to	TO	o	OME
recognize	VB	o	OME
facial	JJ	o	OME
expressions	NNS	o	OME
in	IN	O	O
others	NNS	O	O
is	VBZ	O	O
linked	VBN	O	O
with	IN	O	O
the	DT	O	O
internal	JJ	O	O
representations	NNS	O	O
of	IN	O	O
our	PRP$	O	O
own	JJ	O	O
faces	VBZ	O	O
.	.	O	O

Successful	JJ	O	O
treatment	NN	O	O
of	IN	O	O
blepharitis	NN	p	PC
with	IN	O	O
bibrocathol	NN	i	O
(	(	i	O
Posiformin?	NNP	i	O
2	CD	i	O
%	NN	i	O
)	)	i	O
.	.	i	O

BACKGROUND	NNP	i	O
Bibrocathol	NNP	i	O
is	VBZ	O	O
a	DT	O	O
well-established	JJ	i	O
antiseptic	JJ	i	O
drug	NN	i	O
for	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	p	O
acute	NN	p	O
eyelid	JJ	p	O
diseases	NNS	p	O
like	IN	p	O
blepharitis	NN	p	O
.	.	p	O

Despite	IN	O	O
its	PRP$	O	O
frequent	JJ	O	O
use	NN	O	O
in	IN	O	O
clinical	JJ	O	O
practice	NN	O	O
,	,	O	O
no	DT	O	O
controlled	JJ	O	O
clinical	JJ	O	O
trial	NN	O	O
on	IN	O	O
the	DT	o	O
efficacy	NN	o	O
of	IN	i	O
bibrocathol	$	i	O
2	CD	i	O
%	NN	i	O
eye	NN	O	O
ointment	NN	O	O
has	VBZ	O	O
been	VBN	O	O
performed	VBN	O	O
until	IN	O	O
now	RB	O	O
.	.	O	O

The	DT	O	O
aim	NN	O	O
of	IN	O	O
the	DT	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
investigate	VB	o	O
efficacy	NN	o	O
,	,	o	O
safety	NN	o	O
and	CC	o	O
tolerability	NN	o	O
of	IN	i	O
bibrocathol	NN	i	O
(	(	i	O
Posiformin?	NNP	i	O
2	CD	i	O
%	NN	O	O
)	)	O	O
eye	NN	O	O
ointment	NN	O	O
in	IN	O	O
patients	NNS	p	O
diagnosed	VBN	p	O
with	IN	p	O
blepharitis	NN	p	O
.	.	p	O

METHODS	NNP	p	O
In	IN	O	O
this	DT	p	O
multi-center	NN	p	O
,	,	p	O
randomized	VBN	p	O
,	,	O	O
double-masked	JJ	i	O
,	,	i	O
placebo-controlled	JJ	i	O
parallel-group	NN	i	O
comparison	NN	O	O
,	,	O	O
the	DT	O	O
change	NN	O	O
of	IN	O	O
signs	NNS	O	O
and	CC	O	O
symptoms	NNS	O	O
(	(	O	O
sum	VB	O	O
score	NN	O	O
)	)	O	O
of	IN	O	O
blepharitis	NN	O	O
in	IN	O	O
197	CD	p	O
patients	NNS	p	O
(	(	p	O
ITT	NNP	p	O
(	(	p	O
intention-to-treat-group	JJ	p	O
)	)	p	O
;	:	p	O
mean	JJ	p	O
age	NN	p	O
56	CD	p	O
?	.	p	O
18	CD	p	O
years	NNS	p	O
,	,	p	O
56	CD	p	O
%	NN	p	O
female	NN	p	O
,	,	p	O
active	JJ	p	O
drug	NN	p	O
:	:	p	O
vehicle	NN	p	O
=	IN	p	O
97:100	CD	p	O
)	)	p	O
over	IN	p	O
2	CD	p	O
weeks	NNS	p	O
treatment	NN	O	O
with	IN	O	O
bibrocathol	JJ	i	O
2	CD	i	O
%	NN	i	O
eye	NN	i	O
ointment	NN	i	O
was	VBD	i	O
evaluated	VBN	O	O
.	.	O	O

RESULTS	JJ	O	O
Patients	NNPS	O	O
receiving	VBG	i	O
bibrocathol	RB	i	O
2	CD	i	O
%	NN	i	O
showed	VBD	o	O
greater	JJR	o	O
improvement	NN	o	O
in	IN	o	O
the	DT	o	O
sum	NN	o	O
score	NN	o	O
than	IN	O	O
the	DT	i	O
placebo	NN	i	O
patients	NNS	O	O
(	(	O	O
p	JJ	O	O
<	NN	O	O
0.0001	CD	O	O
,	,	O	O
Cohen	NNP	O	O
's	POS	O	O
effect	NN	O	O
size	NN	O	O
d	NN	O	O
=	NNP	O	O
0.73	CD	O	O
)	)	O	O
.	.	O	O

Also	RB	O	O
,	,	O	O
the	DT	O	O
results	NNS	O	O
from	IN	O	O
further	JJ	O	O
efficacy	NN	o	O
assessments	NNS	o	O
improvement	NN	O	O
of	IN	o	O
single	JJ	o	O
symptoms	NNS	o	O
and	CC	o	O
ocular	JJ	o	O
discomfort	NN	o	O
measured	VBN	o	O
by	IN	O	O
a	DT	O	O
VAS	NNP	o	O
(	(	o	O
visual	JJ	o	O
analogue	NN	o	O
scale	NN	o	O
)	)	o	O
supported	VBD	O	O
treatment	NN	O	O
with	IN	O	O
bibrocathol	NN	i	O
.	.	i	O

Patients	NNS	i	O
and	CC	O	O
investigators	NNS	O	O
provided	VBD	o	O
favorable	JJ	o	O
tolerability	NN	o	OOt
ratings	NNS	o	O
preferring	VBG	o	O
bibrocathol	NN	i	O
over	IN	i	O
placebo	NN	i	O
.	.	O	O

No	DT	o	O
safety	NN	o	O
issues	NNS	o	O
were	VBD	o	O
observed	VBN	o	O
with	IN	O	O
regard	NN	O	O
to	TO	o	O
intraocular	JJ	o	O
pressure	NN	o	O
,	,	o	O
visual	JJ	o	O
acuity	NN	o	O
,	,	o	O
or	CC	o	O
occurrence	NN	o	O
of	IN	o	O
adverse	JJ	o	O
events	NNS	o	O
.	.	o	O

CONCLUSIONS	NNP	o	O
Blepharitis	NNP	O	O
therapy	NN	O	O
with	IN	O	O
the	DT	i	O
antiseptic	JJ	i	O
bibrocathol	NN	i	O
2	CD	i	O
%	NN	i	O
in	IN	i	O
this	DT	i	O
trial	NN	O	O
was	VBD	O	O
highly	RB	O	O
efficacious	JJ	O	O
and	CC	O	O
safe	JJ	O	O
.	.	O	O

A	DT	O	O
randomized	JJ	O	O
,	,	O	O
double-blind	JJ	O	O
,	,	O	O
vehicle-controlled	JJ	O	O
study	NN	O	O
to	TO	O	O
assess	VB	O	O
5	CD	O	O
%	NN	O	O
imiquimod	JJ	i	IPM
cream	NN	i	IPM
for	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	p	O
multiple	JJ	o	OPH
actinic	JJ	o	OPH
keratoses	NNS	o	OPH
.	.	o	O

BACKGROUND	NNP	O	O
Actinic	NNP	o	OPH
keratoses	NNS	o	OPH
(	(	o	OPH
AKs	NNP	o	OPH
)	)	o	OPH
are	VBP	O	O
precancerous	JJ	O	O
epidermal	JJ	O	O
lesions	NNS	O	O
found	VBD	O	O
most	JJS	O	O
frequently	RB	O	O
on	IN	O	O
areas	NNS	O	O
of	IN	O	O
the	DT	O	O
skin	NN	O	O
exposed	VBD	O	O
to	TO	O	O
the	DT	O	O
sun	NN	O	O
.	.	O	O

Several	JJ	O	O
case	NN	O	O
studies	NNS	O	O
published	VBN	O	O
recently	RB	O	O
have	VBP	O	O
indicated	VBN	O	O
that	IN	O	O
5	CD	O	O
%	NN	O	O
imiquimod	JJ	i	O
cream	NN	O	O
,	,	O	O
currently	RB	O	O
licensed	VBN	O	O
for	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
genital	JJ	O	O
warts	NNS	O	O
,	,	O	O
may	MD	O	O
be	VB	O	O
an	DT	O	O
effective	JJ	O	O
treatment	NN	O	O
for	IN	O	O
AK	NNP	O	O
.	.	O	O

OBJECTIVE	NNP	O	O
To	TO	O	O
assess	VB	O	O
the	DT	O	O
efficacy	NN	O	O
and	CC	O	O
safety	NN	O	O
of	IN	O	O
imiquimod	NN	O	O
for	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
AK	NNP	o	OPH
.	.	o	O

DESIGN	NNP	O	O
Patients	NNPS	O	O
in	IN	O	O
this	DT	O	O
randomized	JJ	O	O
,	,	O	O
double-blind	JJ	O	O
,	,	O	O
vehicle-controlled	JJ	O	O
study	NN	O	O
applied	VBD	O	O
5	CD	i	O
%	NN	i	O
imiquimod	JJ	i	IPM
cream	NN	i	IPM
or	CC	i	O
vehicle	NN	i	O
to	TO	i	O
AK	NNP	o	OPH
lesions	NNS	o	OPH
3	CD	i	O
times	NNS	i	O
per	IN	i	O
week	NN	i	O
for	IN	i	O
a	DT	i	O
maximum	NN	i	O
of	IN	i	O
12	CD	i	O
weeks	NNS	i	O
or	CC	i	O
until	IN	i	O
lesions	NNS	i	O
had	VBD	i	O
resolved	VBN	i	O
.	.	i	O

In	IN	O	O
the	DT	O	O
event	NN	O	O
of	IN	O	O
an	DT	O	O
adverse	JJ	O	O
reaction	NN	O	O
,	,	O	O
application	NN	O	O
of	IN	O	O
imiquimod	NN	i	IPM
was	VBD	O	O
reduced	VBN	O	O
to	TO	O	O
1	CD	O	O
or	CC	O	O
2	CD	O	O
times	NNS	O	O
per	IN	O	O
week	NN	O	O
.	.	O	O

Rest	JJS	O	O
periods	NNS	O	O
were	VBD	O	O
also	RB	O	O
allowed	VBN	O	O
if	IN	O	O
necessary	JJ	O	O
.	.	O	O

SETTING	VB	O	O
A	DT	p	O
specialized	JJ	p	O
outpatient	NN	p	O
dermatology	NN	p	O
clinic	NN	p	O
within	IN	p	O
a	DT	p	O
state-funded	JJ	p	O
hospital	NN	p	O
in	IN	p	O
Germany	NNP	p	O
.	.	p	O

PATIENTS	VB	p	O
The	DT	p	O
study	NN	p	O
population	NN	p	O
was	VBD	p	O
aged	VBN	p	O
45	CD	p	PA
to	TO	p	PA
85	CD	p	PA
years	NNS	p	O
.	.	p	O

Of	IN	p	O
52	CD	p	PSS
patients	NNS	p	O
screened	VBD	p	O
,	,	p	O
36	CD	p	O
men	NNS	p	PSE
and	CC	p	PSE
women	NNS	p	PSE
with	IN	p	O
AK	NNP	p	O
confirmed	VBN	p	O
by	IN	p	O
histological	JJ	p	O
diagnosis	NN	p	O
were	VBD	p	O
enrolled	VBN	p	O
.	.	p	O

Patients	NNS	p	O
were	VBD	p	O
excluded	VBN	p	O
from	IN	p	O
the	DT	p	O
study	NN	p	O
if	IN	p	O
they	PRP	p	O
did	VBD	p	O
not	RB	p	O
have	VB	p	O
a	DT	p	O
histological	JJ	p	O
diagnosis	NN	p	O
for	IN	p	O
AK	NNP	p	O
,	,	p	O
if	IN	p	O
they	PRP	p	O
were	VBD	p	O
older	JJR	p	O
than	IN	p	O
85	CD	p	O
years	NNS	p	O
,	,	p	O
or	CC	p	O
if	IN	p	O
they	PRP	p	O
did	VBD	p	O
not	RB	p	O
comply	VB	p	O
with	IN	p	O
the	DT	p	O
protocol	NN	p	O
.	.	p	O

All	DT	p	O
patients	NNS	p	O
had	VBD	p	O
responded	VBN	p	O
to	TO	p	O
a	DT	p	O
notice	NN	p	O
asking	VBG	p	O
for	IN	p	O
volunteers	NNS	p	O
.	.	p	O

MAIN	NNP	O	O
OUTCOME	NNP	O	O
MEASURES	NNP	O	O
The	DT	O	O
number	NN	o	OPH
and	CC	o	OPH
appearance	NN	o	OPH
of	IN	o	OPH
lesions	NNS	o	OPH
were	VBD	O	O
evaluated	VBN	O	O
before	RB	O	O
,	,	O	O
during	IN	O	O
,	,	O	O
and	CC	O	O
after	IN	O	O
treatment	NN	O	O
.	.	O	O

All	DT	O	O
adverse	JJ	o	OA
effects	NNS	o	OA
were	VBD	O	O
recorded	VBN	O	O
.	.	O	O

RESULTS	NNP	O	O
Lesions	NNP	O	O
treated	VBD	O	O
with	IN	O	O
5	CD	O	O
%	NN	O	O
imiquimod	JJ	i	IPM
cream	NN	i	IPM
were	VBD	O	O
clinically	RB	o	OPH
cleared	VBN	o	OPH
in	IN	O	O
21	CD	O	O
(	(	O	O
84	CD	O	O
%	NN	O	O
)	)	O	O
of	IN	O	O
25	CD	O	O
patients	NNS	O	O
and	CC	O	O
partially	RB	o	OPH
cleared	VBN	o	OPH
in	IN	O	O
2	CD	O	O
(	(	O	O
8	CD	O	O
%	NN	O	O
)	)	O	O
.	.	O	O

Clearance	NN	o	OPH
was	VBD	O	O
histologically	RB	O	O
confirmed	VBN	O	O
2	CD	O	O
weeks	NNS	O	O
after	IN	O	O
the	DT	O	O
last	JJ	O	O
application	NN	O	O
of	IN	O	O
imiquimod	NN	i	IPM
in	IN	O	O
all	DT	O	O
patients	NNS	O	O
clinically	RB	O	O
diagnosed	VBN	O	O
as	IN	O	O
lesion	NN	O	O
free	NN	O	O
.	.	O	O

Only	RB	O	O
10	CD	O	O
%	NN	O	O
of	IN	O	O
patients	NNS	O	O
treated	VBN	O	O
with	IN	O	O
imiquimod	NN	i	O
were	VBD	O	O
clinically	RB	O	O
diagnosed	VBN	O	O
with	IN	O	O
recurrence	NN	O	O
1	CD	O	O
year	NN	O	O
after	IN	O	O
treatment	NN	O	O
.	.	O	O

No	DT	O	O
reduction	NN	o	OPH
in	IN	o	OPH
the	DT	o	OPH
size	NN	o	OPH
or	CC	o	OPH
number	NN	o	OPH
of	IN	o	OPH
AK	NNP	o	OPH
lesions	NNS	o	OPH
was	VBD	O	O
observed	VBN	O	O
in	IN	O	O
vehicle-treated	JJ	O	O
patients	NNS	O	O
.	.	O	O

Adverse	JJ	O	O
effects	NNS	O	O
reported	VBN	O	O
by	IN	p	O
patients	NNS	p	O
treated	VBN	p	O
with	IN	p	O
imiquimod	NN	i	IPM
included	VBD	O	O
erythema	NN	o	OA
,	,	o	O
edema	NN	o	OA
,	,	o	O
induration	NN	o	OA
,	,	o	O
vesicles	NNS	o	OA
,	,	o	O
erosion	NN	o	OA
,	,	o	O
ulceration	NN	o	OA
,	,	o	O
excoriation	NN	o	OA
,	,	o	O
and	CC	o	O
scabbing	VBG	o	OA
.	.	o	O

However	RB	O	O
,	,	O	O
imiquimod	NN	i	IPM
was	VBD	O	O
well	RB	O	O
tolerated	VBN	o	OOt
since	IN	O	O
all	DT	O	O
patients	NNS	O	O
completed	VBD	O	O
the	DT	O	O
12-week	JJ	O	O
treatment	NN	O	O
.	.	O	O

Only	RB	O	O
a	DT	O	O
few	JJ	O	O
,	,	O	O
mild	JJ	O	O
adverse	JJ	O	O
reactions	NNS	O	O
to	TO	O	O
the	DT	O	O
vehicle	NN	O	O
cream	NN	O	O
were	VBD	O	O
reported	VBN	O	O
.	.	O	O

CONCLUSION	NNP	O	O
Application	NNP	O	O
of	IN	O	O
5	CD	O	O
%	NN	O	O
imiquimod	JJ	i	IPM
cream	NN	i	IPM
for	IN	O	O
12	CD	O	O
weeks	NNS	O	O
is	VBZ	O	O
an	DT	O	O
effective	JJ	O	O
and	CC	O	O
well-tolerated	JJ	O	O
treatment	NN	O	O
for	IN	O	O
AK	NNP	o	OPH
.	.	o	O

Analysis	NN	O	O
of	IN	O	O
face	NN	i	IOt
gaze	NN	i	IOt
in	IN	O	O
autism	NN	p	O
using	VBG	O	O
Bubbles	NNP	O	O
.	.	O	O

One	CD	O	O
of	IN	O	O
the	DT	O	O
components	NNS	O	O
of	IN	O	O
abnormal	JJ	O	O
social	JJ	O	O
functioning	NN	O	O
in	IN	O	O
autism	NN	p	O
is	VBZ	O	O
an	DT	O	O
impaired	JJ	O	O
ability	NN	O	O
to	TO	O	O
direct	VB	O	O
eye	NN	O	O
gaze	NN	O	O
onto	IN	O	O
other	JJ	O	O
people	NNS	O	O
's	POS	O	O
faces	VBZ	O	O
in	IN	O	O
social	JJ	O	O
situations	NNS	O	O
.	.	O	O

Here	RB	O	O
,	,	O	O
we	PRP	O	O
investigated	VBD	O	O
the	DT	O	O
relationship	NN	O	O
between	IN	O	O
gaze	NN	o	OME
onto	IN	o	OME
the	DT	o	OME
eye	NN	o	OME
and	CC	o	OME
mouth	JJ	o	OME
regions	NNS	o	OME
of	IN	o	OME
faces	VBZ	o	OME
,	,	O	O
and	CC	O	O
the	DT	O	O
visual	JJ	O	O
information	NN	O	O
that	WDT	O	O
was	VBD	O	O
present	JJ	O	O
within	IN	O	O
those	DT	O	O
regions	NNS	O	O
.	.	O	O

We	PRP	O	O
used	VBD	O	O
the	DT	O	O
Bubbles	NNP	i	IOt
method	NN	i	IOt
to	TO	O	O
vary	VB	O	O
the	DT	O	O
facial	JJ	O	O
information	NN	O	O
available	JJ	O	O
on	IN	O	O
any	DT	O	O
given	VBN	O	O
trial	NN	O	O
by	IN	O	O
revealing	VBG	O	O
only	RB	O	O
small	JJ	O	O
parts	NNS	O	O
of	IN	O	O
the	DT	O	O
face	NN	O	O
,	,	O	O
and	CC	O	O
measured	VBD	O	O
the	DT	O	O
eye	NN	o	OME
movements	NNS	o	OME
made	VBN	O	O
as	IN	O	O
participants	NNS	O	O
viewed	IN	O	O
these	DT	O	O
stimuli	NNS	O	O
.	.	O	O

Compared	VBN	p	O
to	TO	p	O
ten	VB	p	O
IQ-	NNP	p	O
and	CC	p	O
age-matched	JJ	p	O
healthy	JJ	p	O
controls	NNS	p	O
,	,	p	O
eight	CD	p	O
participants	NNS	p	O
with	IN	p	O
autism	NN	p	O
showed	VBD	O	O
less	JJR	O	O
fixation	JJ	o	OME
specificity	NN	o	OME
to	TO	O	O
the	DT	O	O
eyes	NNS	O	O
and	CC	O	O
mouth	NN	O	O
,	,	O	O
a	DT	O	O
greater	JJR	O	O
tendency	NN	O	O
to	TO	O	O
saccade	VB	O	O
away	RB	O	O
from	IN	O	O
the	DT	O	O
eyes	NNS	O	O
when	WRB	O	O
information	NN	O	O
was	VBD	O	O
present	JJ	O	O
in	IN	O	O
those	DT	O	O
regions	NNS	O	O
,	,	O	O
and	CC	O	O
abnormal	JJ	O	O
directionality	NN	O	O
of	IN	O	O
saccades	NNS	O	O
.	.	O	O

The	DT	O	O
findings	NNS	O	O
provide	VBP	O	O
novel	JJ	O	O
detail	NN	O	O
to	TO	O	O
the	DT	O	O
abnormal	JJ	O	O
way	NN	O	O
in	IN	O	O
which	WDT	O	O
people	NNS	O	O
with	IN	O	O
autism	NN	O	O
look	NN	O	O
at	IN	O	O
faces	VBZ	O	O
,	,	O	O
an	DT	O	O
impairment	NN	O	O
that	WDT	O	O
likely	JJ	O	O
influences	VBZ	O	O
all	DT	O	O
subsequent	JJ	O	O
face	NN	O	O
processing	NN	O	O
.	.	O	O

Oral	JJ	i	IPM
sildenafil	NN	i	IPM
to	TO	O	O
control	VB	O	O
pulmonary	JJ	o	OPH
hypertension	NN	o	OPH
after	IN	p	O
congenital	JJ	p	O
heart	NN	p	O
surgery	NN	p	O
.	.	p	O

This	DT	O	O
study	NN	O	O
investigates	VBZ	O	O
the	DT	O	O
role	NN	O	O
of	IN	O	O
oral	JJ	O	O
sildenafil	NN	i	IPM
in	IN	O	O
decreasing	VBG	O	O
pulmonary	JJ	o	OPH
pressure	NN	o	OPH
after	IN	p	O
congenital	JJ	i	IS
heart	NN	i	IS
surgery	NN	i	IS
.	.	i	IS

Between	NNP	p	O
September	NNP	p	O
2002	CD	p	O
and	CC	p	O
September	NNP	p	O
2004	CD	p	O
,	,	p	O
among	IN	p	O
a	DT	p	O
group	NN	p	O
of	IN	p	O
postoperative	JJ	p	O
children	NNS	p	O
with	IN	p	O
large	JJ	p	O
septal	JJ	p	O
defects	NNS	p	O
,	,	p	O
moderate	VBP	p	O
to	TO	p	O
severe	VB	p	O
pulmonary	JJ	p	O
hypertension	NN	p	O
[	NNP	p	O
pulmonary	JJ	p	O
artery	NN	p	O
(	(	p	O
PA	NNP	p	O
)	)	p	O
to	TO	p	O
aortic	JJ	p	O
(	(	p	O
Ao	NNP	p	O
)	)	p	O
pressure	NN	p	O
ratio	NN	p	O
of	IN	p	O
0.76	CD	p	O
+/-	JJ	p	O
0.17	CD	p	O
]	NN	p	O
and	CC	p	O
systemic	JJ	p	O
desaturation	NN	p	O
(	(	p	O
Ao	NNP	p	O
Sat	NNP	p	O
=	VBD	p	O
0.89	CD	p	O
+/-	JJ	p	O
0.11	CD	p	O
)	)	p	O
,	,	p	O
oral	JJ	i	IPM
sildenafil	NN	i	IPM
(	(	p	O
0.3	CD	p	O
mg	NN	p	O
x	NN	p	O
kg	NN	p	O
(	(	p	O
-1	NNP	p	O
)	)	p	O
,	,	p	O
every	DT	p	O
3	CD	p	O
hours	NNS	p	O
)	)	p	O
was	VBD	p	O
administered	VBN	p	O
for	IN	p	O
a	DT	p	O
period	NN	p	O
of	IN	p	O
24-48	JJ	p	O
hours	NNS	p	O
(	(	i	O
sildenafil	JJ	i	IPM
group	NN	p	O
)	)	p	O
.	.	p	O

These	DT	O	O
patients	NNS	p	O
were	VBD	O	O
compared	VBN	O	O
to	TO	O	O
a	DT	O	O
group	NN	O	O
of	IN	O	O
22	CD	p	O
children	NNS	p	O
with	IN	p	O
similar	JJ	p	O
pathologies	NNS	p	O
who	WP	p	O
did	VBD	p	O
not	RB	p	O
receive	VB	p	O
sildenafil	NN	i	IPM
(	(	i	O
control	VB	i	O
group	NN	p	O
)	)	p	O
.	.	p	O

Postoperative	JJ	o	OPH
PA	NNP	o	OPH
pressure	NN	o	OPH
(	(	O	O
28.61	CD	O	O
+/-	JJ	O	O
7.80	CD	O	O
vs	JJ	O	O
39.40	CD	O	O
+/-	JJ	O	O
10.80	CD	O	O
mm	NN	O	O
Hg	NNP	O	O
)	)	O	O
and	CC	O	O
PA/Ao	NNP	o	OPH
pressure	NN	o	OPH
(	(	O	O
0.28	CD	O	O
+/-	JJ	O	O
0.08	CD	O	O
vs	JJ	O	O
0.41	CD	O	O
+/-	JJ	O	O
0.11	CD	O	O
)	)	O	O
were	VBD	O	O
significantly	RB	O	O
lower	JJR	O	O
in	IN	O	O
the	DT	O	O
sildenafil	NN	i	IPM
group	NN	O	O
(	(	O	O
p	JJ	O	O
=	NN	O	O
0.001	CD	O	O
and	CC	O	O
0.001	CD	O	O
respectively	RB	O	O
)	)	O	O
.	.	O	O

Pulmonary	JJ	o	OPH
hypertensive	JJ	o	OPH
crisis	NN	o	OPH
was	VBD	O	O
detected	VBN	O	O
in	IN	O	O
4	CD	O	O
patients	NNS	O	O
in	IN	O	O
the	DT	O	O
control	NN	O	O
group	NN	O	O
,	,	O	O
but	CC	O	O
none	NN	O	O
in	IN	O	O
the	DT	O	O
sildenafil	NN	i	IPM
group	NN	O	O
(	(	O	O
p	JJ	O	O
=	NNP	O	O
0.02	CD	O	O
)	)	O	O
.	.	O	O

There	EX	O	O
was	VBD	O	O
no	DT	O	O
significant	JJ	O	O
rise	NN	O	O
in	IN	O	O
PA	NNP	o	O
pressure	NN	o	O
following	VBG	O	O
discontinuation	NN	O	O
of	IN	O	O
the	DT	O	O
drug	NN	O	O
(	(	O	O
26.30	CD	O	O
+/-	JJ	O	O
6.66	CD	O	O
vs	JJ	O	O
28.49	CD	O	O
+/-	JJ	O	O
10.93	CD	O	O
mm	NN	O	O
Hg	NNP	O	O
,	,	O	O
p	NN	O	O
=	NNP	O	O
0.366	CD	O	O
)	)	O	O
.	.	O	O

No	DT	O	O
significant	JJ	o	O
complications	NNS	o	OPH
were	VBD	O	O
noticed	VBN	O	O
regarding	VBG	O	O
sildenafil	NN	i	IPM
use	NN	O	O
.	.	O	O

Low	JJ	O	O
doses	NNS	O	O
of	IN	O	O
oral	JJ	O	O
sildenafil	NN	i	IPM
appear	VBP	O	O
to	TO	O	O
be	VB	O	O
effective	JJ	O	O
and	CC	O	O
safe	JJ	O	O
to	TO	O	O
control	VB	O	O
postoperative	JJ	O	O
PA	NNP	O	O
pressure	NN	O	O
in	IN	O	O
children	NNS	O	O
.	.	O	O

Absence	NN	O	O
of	IN	O	O
rebound	NN	O	O
pulmonary	JJ	o	OPH
hypertension	NN	o	OPH
,	,	O	O
availability	NN	O	O
,	,	O	O
and	CC	O	O
low	JJ	O	O
cost	NN	O	O
of	IN	O	O
the	DT	O	O
drug	NN	O	O
are	VBP	O	O
considered	VBN	O	O
as	IN	O	O
its	PRP$	O	O
major	JJ	O	O
advantages	NNS	O	O
.	.	O	O

Bioequivalence	NNP	O	O
evaluation	NN	O	O
of	IN	O	O
a	DT	O	O
fixed	VBN	i	O
dose	JJ	i	O
combination	NN	i	O
lamivudine	NN	i	IPM
+	NNP	i	IPM
stavudine	NN	i	IPM
tablet	NN	O	O
with	IN	O	O
concurrent	JJ	O	O
administration	NN	O	O
of	IN	O	O
lamivudine	JJ	i	IPM
tablet	NN	O	O
and	CC	O	O
stavudine	NN	i	IPM
capsule	NN	O	O
in	IN	O	O
healthy	JJ	p	O
volunteers	NNS	p	O
.	.	p	O

The	DT	O	O
study	NN	O	O
was	VBD	O	O
designed	VBN	O	O
to	TO	O	O
compare	VB	O	O
the	DT	O	O
rate	NN	o	OPH
and	CC	o	OPH
extent	NN	o	OPH
of	IN	o	OPH
absorption	NN	o	OPH
of	IN	O	O
a	DT	O	O
fixed	VBN	O	O
dose	JJ	O	O
combination	NN	O	O
tablet	NN	O	O
of	IN	O	O
lamivudine	NN	i	IPM
(	(	i	IPM
CAS	NNP	i	IPM
134678-17-4	CD	i	IPM
)	)	i	IPM
and	CC	i	O
stavudine	NN	i	IPM
(	(	i	IPM
CAS	NNP	i	IPM
3056-17-5	CD	i	IPM
)	)	i	IPM
with	IN	O	O
the	DT	O	O
concurrent	JJ	O	O
administration	NN	O	O
of	IN	O	O
lamivudine	JJ	i	IPM
tablet	NN	i	IPM
and	CC	i	O
stavudine	NN	i	IPM
capsule	NN	i	IPM
in	IN	O	O
24	CD	p	PSS
healthy	JJ	p	O
volunteers	NNS	p	O
under	IN	p	PC
fasting	VBG	p	PC
conditions	NNS	p	O
.	.	p	O

The	DT	O	O
volunteers	NNS	O	O
were	VBD	O	O
randomly	RB	O	O
assigned	VBN	O	O
to	TO	O	O
the	DT	O	O
test	NN	O	O
or	CC	O	O
reference	NN	O	O
treatment	NN	O	O
,	,	O	O
with	IN	O	O
the	DT	O	O
two	CD	O	O
treatment	NN	O	O
periods	NNS	O	O
separated	VBN	O	O
by	IN	O	O
a	DT	O	O
washout	JJ	O	O
period	NN	O	O
of	IN	O	O
at	IN	O	O
least	JJS	O	O
7	CD	O	O
days	NNS	O	O
.	.	O	O

Plasma	NNP	o	OPH
samples	NNS	o	OPH
were	VBD	O	O
analyzed	VBN	O	O
for	IN	O	O
both	DT	O	O
analytes	NNS	O	O
lamivudine	VBP	i	IPM
and	CC	O	O
stavudine	VBP	i	IPM
by	IN	O	O
a	DT	O	O
validated	JJ	O	O
analytical	JJ	O	O
method	NN	O	O
.	.	O	O

Since	IN	O	O
the	DT	O	O
90	CD	O	O
%	NN	O	O
confidence	NN	O	O
intervals	NNS	O	O
for	IN	O	O
the	DT	O	O
test/reference	NN	o	OPH
mean	JJ	O	O
ratio	NN	O	O
of	IN	O	O
the	DT	O	O
In-transformed	NNP	O	O
pharmacokinetic	JJ	O	O
variables	NNS	O	O
C	NNP	o	OPH
(	(	o	OPH
max	NN	o	OPH
)	)	o	OPH
AUC	NNP	o	OPH
(	(	o	OPH
0-t	JJ	o	OPH
)	)	o	OPH
and	CC	o	OPH
AUC	NNP	o	OPH
(	(	o	OPH
0-infinity	NN	o	OPH
)	)	o	OPH
were	VBD	O	O
clearly	RB	O	O
within	IN	O	O
the	DT	O	O
conventional	JJ	O	O
bioequivalence	NN	O	O
range	NN	O	O
of	IN	O	O
80	CD	O	O
%	NN	O	O
to	TO	O	O
125	CD	O	O
%	NN	O	O
,	,	O	O
the	DT	O	O
two	CD	O	O
treatments	NNS	O	O
were	VBD	O	O
considered	VBN	O	O
bioequivalent	NN	O	O
.	.	O	O

The	DT	O	O
safety	NN	o	OOt
profiles	NNS	o	OOt
of	IN	O	O
both	DT	O	O
the	DT	O	O
test	NN	O	O
and	CC	O	O
reference	NN	O	O
formulations	NNS	O	O
were	VBD	O	O
comparable	JJ	O	O
.	.	O	O

Effectiveness	NN	O	O
of	IN	O	O
initiating	VBG	O	O
treatment	NN	O	O
with	IN	O	O
valsartan/hydrochlorothiazide	NN	i	IPM
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
stage-1	JJ	p	O
or	CC	p	O
stage-2	JJ	p	O
hypertension	NN	p	PC
.	.	p	O

This	DT	O	O
prospective	JJ	O	O
,	,	O	O
6-week	JJ	O	O
,	,	O	O
multicenter	NN	O	O
,	,	O	O
double-blind	NN	O	O
study	NN	O	O
examined	VBD	O	O
the	DT	O	O
benefits	NNS	O	O
of	IN	O	O
initiating	VBG	O	O
treatment	NN	O	O
with	IN	O	O
combination	NN	O	O
valsartan/hydrochlorothiazide	NN	i	IPM
(	(	i	IPM
HCTZ	NNP	i	IPM
)	)	i	IPM
compared	VBN	O	O
with	IN	O	O
initial	JJ	O	O
valsartan	NNS	O	O
monotherapy	NN	O	O
for	IN	O	O
648	CD	p	PC
patients	NNS	p	O
with	IN	p	O
stage-1	JJ	p	O
or	CC	p	O
stage-2	JJ	p	O
hypertension	NN	p	O
(	(	p	O
age=52.6+/-10	JJ	p	PA
years	NNS	p	PA
;	:	p	O
54	CD	p	O
%	NN	p	O
male	NN	p	PA
;	:	p	O
baseline	VB	p	O
blood	NN	p	O
pressure	NN	p	O
(	(	p	O
BP	NNP	p	O
)	)	p	O
=161/98	VBP	p	O
mm	JJ	p	O
Hg	NNP	p	O
,	,	p	O
32	CD	p	O
%	NN	p	O
stage	NN	p	O
1	CD	p	O
)	)	p	O
.	.	p	O

Patients	NNS	O	O
were	VBD	O	O
randomized	VBN	O	O
to	TO	O	O
valsartan	VB	i	IPM
80	CD	i	IPM
mg	NN	i	IPM
(	(	i	IPM
V-low	NNP	i	IPM
)	)	i	IPM
,	,	i	O
valsartan	$	i	IPM
160	CD	i	IPM
mg	NN	i	IPM
(	(	i	IPM
V-high	NNP	i	IPM
)	)	i	IPM
or	CC	i	O
valsartan/HCTZ	$	i	IPM
160/12.5	CD	i	IPM
mg	NN	i	IPM
(	(	i	IPM
V/HCTZ	NNP	i	IPM
)	)	i	IPM
,	,	i	O
and	CC	i	O
electively	RB	i	O
titrated	VBN	i	O
after	IN	i	O
weeks	NNS	i	O
2	CD	i	O
and	CC	i	O
4	CD	i	O
to	TO	i	O
the	DT	i	O
next	JJ	i	O
dosage	NN	i	O
level	NN	i	O
(	(	i	O
maximum	JJ	i	IPM
dose	NN	i	IPM
valsartan/HCTZ	NN	i	IPM
160/25	CD	i	IPM
mg	NN	i	IPM
)	)	i	O
if	IN	i	O
BP	NNP	i	IPM
remained	VBD	i	IPM
>	JJ	i	IPM
140/90	CD	i	IPM
mm	NN	i	IPM
Hg	NNP	i	IPM
.	.	i	O

At	IN	O	O
end	NN	O	O
of	IN	O	O
the	DT	O	O
study	NN	O	O
,	,	O	O
patients	NNS	O	O
initiated	VBN	O	O
with	IN	O	O
V/HCTZ	NNP	i	IPM
required	VBD	O	O
less	JJR	o	OOt
titration	JJ	o	OOt
steps	NNS	o	OOt
compared	VBN	O	O
with	IN	O	O
the	DT	O	O
initial	JJ	O	O
valsartan	NN	O	O
monotherapy	NN	O	O
groups	NNS	O	O
(	(	O	O
63	CD	O	O
vs	RB	O	O
86	CD	O	O
%	NN	O	O
required	VBN	O	O
titration	NN	O	O
by	IN	O	O
study	JJ	O	O
end	NN	O	O
,	,	O	O
respectively	RB	O	O
)	)	O	O
and	CC	O	O
reached	VBD	O	O
the	DT	O	O
target	NN	O	O
BP	NNP	o	OPH
goal	NN	o	OPH
of	IN	O	O
<	$	O	O
140/90	CD	O	O
mm	NN	O	O
Hg	NNP	O	O
in	IN	O	O
a	DT	O	O
shorter	JJ	O	O
period	NN	O	O
of	IN	O	O
time	NN	O	O
(	(	O	O
2.8	CD	O	O
weeks	NNS	O	O
)	)	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.0001	CD	O	O
)	)	O	O
vs	NN	O	O
V-low	NNP	O	O
(	(	O	O
4.3	CD	O	O
weeks	NNS	O	O
)	)	O	O
and	CC	O	O
V-high	NNP	O	O
(	(	O	O
3.9	CD	O	O
weeks	NNS	O	O
)	)	O	O
.	.	O	O

Initial	JJ	O	O
combination	NN	O	O
therapy	NN	O	O
was	VBD	O	O
also	RB	O	O
associated	VBN	O	O
with	IN	O	O
higher	JJR	O	O
BP	NNP	o	OPH
control	NN	o	OPH
rates	NNS	o	OPH
and	CC	O	O
greater	JJR	O	O
reductions	NNS	o	OOt
in	IN	o	OOt
both	DT	o	OOt
systolic	JJ	o	OOt
and	CC	o	OOt
diastolic	JJ	o	OOt
BP	NNP	o	OOt
from	IN	O	O
baseline	NN	O	O
(	(	O	O
63	CD	O	O
%	NN	O	O
,	,	O	O
-27.7+/-13/-15.1+/-8	NNP	O	O
mm	NNP	O	O
Hg	NNP	O	O
)	)	O	O
compared	VBN	O	O
with	IN	O	O
V-low	NNP	O	O
(	(	O	O
46	CD	O	O
%	NN	O	O
,	,	O	O
-21.2+/-13/-11.4+/-8	NNP	O	O
mm	NNP	O	O
Hg	NNP	O	O
,	,	O	O
P	NNP	O	O
<	NNP	O	O
0.0001	CD	O	O
)	)	O	O
or	CC	O	O
V-high	NNP	O	O
(	(	O	O
51	CD	O	O
%	NN	O	O
,	,	O	O
-24.0+/-13/-12.0+/-10	NNP	O	O
mm	NNP	O	O
Hg	NNP	O	O
,	,	O	O
P	NNP	O	O
<	NNP	O	O
0.01	CD	O	O
)	)	O	O
.	.	O	O

Overall	JJ	O	O
and	CC	O	O
drug-related	JJ	o	OA
AEs	NNP	o	OA
were	VBD	O	O
mild	JJ	O	O
to	TO	O	O
moderate	VB	O	O
and	CC	O	O
were	VBD	O	O
similar	JJ	O	O
between	IN	O	O
V/HCTZ	NNP	i	IPM
(	(	O	O
53.1	CD	O	O
and	CC	O	O
14.1	CD	O	O
%	NN	O	O
,	,	O	O
respectively	RB	O	O
)	)	O	O
and	CC	O	O
the	DT	O	O
two	CD	O	O
monotherapy	NN	O	O
groups	NNS	O	O
,	,	O	O
V-low	NNP	O	O
(	(	O	O
50.5	CD	O	O
and	CC	O	O
13.8	CD	O	O
%	NN	O	O
)	)	O	O
and	CC	O	O
V-high	NNP	O	O
(	(	O	O
50.7	CD	O	O
and	CC	O	O
11.8	CD	O	O
%	NN	O	O
)	)	O	O
.	.	O	O

In	IN	O	O
conclusion	NN	O	O
,	,	O	O
initiating	VBG	O	O
therapy	NN	O	O
with	IN	O	O
a	DT	O	O
combination	NN	O	O
of	IN	O	O
valsartan	NN	i	IPM
and	CC	O	O
low-dose	JJ	O	O
HCTZ	NNP	i	IPM
results	NNS	O	O
in	IN	O	O
early	JJ	o	OOt
,	,	o	OOt
improved	JJ	o	OOt
BP	NNP	o	OPH
efficacy	NN	o	OPH
with	IN	O	O
similar	JJ	O	O
tolerability	NN	o	OOt
as	IN	O	O
compared	VBN	O	O
with	IN	O	O
starting	VBG	O	O
treatment	NN	O	O
with	IN	O	O
a	DT	O	O
low	JJ	O	O
or	CC	O	O
higher	JJR	O	O
dose	NN	O	O
of	IN	O	O
valsartan	NN	i	IPM
for	IN	O	O
patients	NNS	p	O
with	IN	p	O
stage-1	JJ	p	O
and	CC	p	O
stage-2	JJ	p	O
hypertension	NN	p	O
.	.	p	O

Impact	NN	O	O
of	IN	O	O
vitamin	NN	i	IPM
D	NNP	i	IPM
supplementation	NN	i	IPM
on	IN	O	O
inflammatory	JJ	o	OPH
markers	NNS	o	OPH
in	IN	O	O
African	JJ	p	O
Americans	NNPS	p	O
:	:	p	O
results	NNS	O	O
of	IN	O	O
a	DT	O	O
four-arm	JJ	O	O
,	,	O	O
randomized	VBN	O	O
,	,	O	O
placebo-controlled	JJ	O	O
trial	NN	O	O
.	.	O	O

African	JJ	p	O
Americans	NNPS	p	O
have	VBP	p	O
a	DT	p	O
disproportionate	JJ	p	O
burden	NN	p	O
of	IN	p	O
inflammation-associated	JJ	p	O
chronic	JJ	p	O
diseases	NNS	p	O
such	JJ	O	O
as	IN	O	O
cancer	NN	O	O
and	CC	O	O
lower	JJR	O	O
circulating	NN	O	O
levels	NNS	O	O
of	IN	O	O
25-hydroxyvitamin	JJ	O	O
D	NNP	O	O
[	NN	O	O
25	CD	O	O
(	(	O	O
OH	NNP	O	O
)	)	O	O
D	NNP	O	O
]	NNP	O	O
.	.	O	O

The	DT	O	O
effect	NN	O	O
of	IN	O	O
vitamin	NN	i	IPM
D3	NNP	i	IPM
(	(	i	IPM
cholecalciferol	NN	i	IPM
)	)	i	IPM
supplementation	NN	i	IPM
on	IN	O	O
inflammatory	JJ	o	OPH
markers	NNS	o	OPH
is	VBZ	O	O
uncertain	JJ	O	O
.	.	O	O

We	PRP	O	O
conducted	VBD	O	O
a	DT	O	O
randomized	VBN	O	O
,	,	O	O
double-blind	JJ	O	O
,	,	O	O
placebo-controlled	JJ	O	O
trial	NN	O	O
of	IN	O	O
supplemental	JJ	i	IPM
oral	JJ	i	IPM
vitamin	NN	i	IPM
D	NNP	i	IPM
(	(	i	O
placebo	NN	i	O
,	,	O	O
1,000	CD	O	O
,	,	O	O
2,000	CD	O	O
,	,	O	O
or	CC	O	O
4,000	CD	O	O
IU/day	NN	O	O
of	IN	O	O
vitamin	NN	O	O
D3	NNP	O	O
orally	RB	O	O
for	IN	O	O
3	CD	O	O
months	NNS	O	O
)	)	O	O
in	IN	O	O
328	CD	p	O
African	JJ	p	O
Americans	NNPS	p	O
(	(	p	O
median	JJ	p	O
age	NN	p	O
,	,	p	O
51	CD	p	O
years	NNS	p	O
)	)	p	O
of	IN	p	O
public	JJ	p	O
housing	NN	p	O
communities	NNS	p	O
in	IN	p	O
Boston	NNP	p	O
,	,	p	O
MA	NNP	p	O
,	,	p	O
who	WP	p	O
were	VBD	p	O
enrolled	VBN	p	O
over	RP	p	O
three	CD	p	O
consecutive	JJ	p	O
winter	NN	p	O
periods	NNS	p	O
(	(	p	O
2007-2010	JJ	p	O
)	)	p	O
.	.	p	O

Change	NN	O	O
from	IN	O	O
0	CD	O	O
to	TO	O	O
3	CD	O	O
months	NNS	O	O
of	IN	O	O
plasma	NN	o	OPH
levels	NNS	o	OPH
of	IN	o	OPH
25	CD	o	OPH
(	(	o	OPH
OH	NNP	o	OPH
)	)	o	OPH
D	NNP	o	OPH
,	,	o	O
high-sensitivity	JJ	o	OPH
C-reactive	JJ	o	OPH
protein	NN	o	OPH
(	(	o	OPH
CRP	NNP	o	OPH
)	)	o	OPH
,	,	o	OPH
interleukin	FW	o	OPH
(	(	o	OPH
IL	NNP	o	OPH
)	)	o	OPH
-6	NN	o	OPH
,	,	o	O
IL-10	NNP	o	OPH
,	,	o	O
and	CC	o	O
soluble	JJ	o	O
TNF-?	NNP	o	O
receptor	NN	o	O
type	NN	o	O
2	CD	o	O
(	(	o	O
sTNF-R2	NN	o	O
)	)	o	O
in	IN	O	O
292	CD	O	O
(	(	O	O
89	CD	O	O
%	NN	O	O
)	)	O	O
participants	NNS	O	O
were	VBD	O	O
measured	VBN	O	O
.	.	O	O

Overall	NNP	O	O
,	,	O	O
no	DT	O	O
statistically	RB	O	O
significant	JJ	O	O
changes	NNS	O	O
in	IN	o	O
CRP	NNP	o	OPH
,	,	o	O
IL-6	NNP	o	OPH
,	,	o	OPH
IL-10	NNP	o	OPH
,	,	o	O
and	CC	o	O
sTNF-R2	NNS	o	OPH
were	VBD	O	O
observed	VBN	O	O
after	IN	O	O
the	DT	O	O
vitamin	NN	O	O
D	NNP	O	O
supplementation	NN	O	O
period	NN	O	O
.	.	O	O

Baseline	NNP	o	O
CRP	NNP	o	O
was	VBD	O	O
significantly	RB	O	O
inversely	RB	O	O
associated	VBN	O	O
with	IN	O	O
the	DT	o	O
baseline	NN	o	OPH
25	CD	o	OPH
(	(	o	OPH
OH	NNP	o	OPH
)	)	o	OPH
D	NNP	o	OPH
level	NN	o	OPH
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.001	CD	O	O
)	)	O	O
in	IN	O	O
unadjusted	JJ	O	O
and	CC	O	O
adjusted	JJ	O	O
models	NNS	O	O
.	.	O	O

An	DT	O	O
interaction	NN	O	O
between	IN	O	O
baseline	NN	o	O
25	CD	o	O
(	(	o	O
OH	NNP	o	O
)	)	o	O
D	NNP	o	O
and	CC	o	O
vitamin	NNP	o	O
D	NNP	o	O
supplementation	NN	o	O
was	VBD	O	O
observed	VBN	O	O
for	IN	O	O
outcome	JJ	O	O
change	NN	O	O
in	IN	o	O
log	NN	o	O
CRP	NNP	o	O
(	(	O	O
month	NN	O	O
3-month	RB	O	O
0	CD	O	O
;	:	O	O
P	NNP	O	O
for	IN	O	O
interaction	NN	O	O
=	NNP	O	O
0.04	CD	O	O
)	)	O	O
.	.	O	O

Within	IN	O	O
an	DT	O	O
unselected	JJ	O	O
population	NN	O	O
of	IN	O	O
African	JJ	O	O
Americans	NNPS	O	O
,	,	O	O
short-term	JJ	i	O
exposure	NN	i	O
to	TO	i	O
vitamin	VB	i	O
D	NNP	i	O
supplementation	NN	i	O
produced	VBD	O	O
no	DT	O	O
change	NN	O	O
in	IN	o	O
circulating	VBG	o	O
inflammatory	JJ	o	O
markers	NNS	o	O
.	.	o	O

This	DT	O	O
study	NN	O	O
confirms	VBZ	O	O
the	DT	O	O
strong	JJ	O	O
independent	JJ	O	O
association	NN	O	O
of	IN	o	O
CRP	NNP	o	O
with	IN	o	O
25	CD	o	O
(	(	o	O
OH	NNP	o	O
)	)	o	O
D	NNP	o	O
status	NN	O	O
even	RB	O	O
after	IN	O	O
adjusting	VBG	O	O
for	IN	O	O
body	NN	O	O
mass	NN	O	O
index	NN	O	O
.	.	O	O

Future	JJ	O	O
studies	NNS	O	O
of	IN	O	O
longer	JJR	O	O
supplemental	JJ	O	O
vitamin	NN	O	O
D3	NNP	O	O
duration	NN	O	O
are	VBP	O	O
necessary	JJ	O	O
to	TO	O	O
examine	VB	O	O
the	DT	O	O
complex	JJ	O	O
influence	NN	O	O
of	IN	O	O
vitamin	NN	O	O
D3	NNP	O	O
on	IN	O	O
CRP	NNP	O	O
and	CC	O	O
other	JJ	O	O
chronic	JJ	O	O
inflammatory	NN	O	O
cytokines	NNS	O	O
for	IN	O	O
possible	JJ	O	O
reduction	NN	O	O
of	IN	p	O
cancer	NN	p	O
health	NN	p	O
disparities	NNS	p	O
in	IN	p	O
African	JJ	p	O
Americans	NNPS	p	O
.	.	p	O

Mouth	NNP	O	O
closing	NN	O	O
device	NN	O	O
(	(	O	O
chinstrap	NN	O	O
)	)	O	O
reduces	VBZ	O	O
mouth	JJ	o	OPH
leak	NN	o	OPH
during	IN	O	O
nasal	JJ	p	O
CPAP	NNP	p	O
.	.	p	O

BACKGROUND	NNP	O	O
AND	CC	O	O
PURPOSE	NNP	O	O
Mouth	NNP	O	O
leak	VBP	O	O
occasionally	RB	O	O
complicates	VBZ	O	O
continuous	JJ	O	O
positive	JJ	O	O
airway	NN	O	O
pressure	NN	O	O
(	(	p	O
CPAP	NNP	p	O
)	)	p	O
therapy	NN	p	O
,	,	O	O
which	WDT	O	O
leads	VBZ	O	O
to	TO	O	O
discomfort	VB	O	O
.	.	O	O

While	IN	O	O
a	DT	O	O
chinstrap	NN	O	O
prevents	VBZ	O	O
the	DT	O	O
mouth	NN	O	O
from	IN	O	O
opening	VBG	O	O
during	IN	O	O
sleep	NN	O	O
,	,	O	O
its	PRP$	O	O
efficacy	NN	O	O
in	IN	O	O
diminishing	VBG	O	O
mouth	NN	O	O
leak	NN	O	O
has	VBZ	O	O
not	RB	O	O
been	VBN	O	O
studied	VBN	O	O
.	.	O	O

PATIENTS	NNP	O	O
AND	CC	O	O
METHODS	NNP	O	O
Fifteen	NNP	p	O
patients	NNS	p	O
with	IN	p	O
mouth	JJ	p	O
leak	JJ	p	O
complaining	NN	p	O
of	IN	p	O
mouth	NN	p	O
dryness	NN	p	O
and	CC	p	O
nasal	JJ	p	O
obstruction	NN	p	O
underwent	JJ	O	O
two	CD	i	IPH
consecutive	JJ	i	IPH
overnight	JJ	i	IPH
polysomnographies	NNS	i	IPH
,	,	i	O
one	CD	i	O
with	IN	i	O
a	DT	i	O
chinstrap	NN	i	IPH
,	,	i	O
in	IN	i	O
random	JJ	i	O
order	NN	i	O
.	.	i	O

Cephalometry	NN	o	OPH
with	IN	i	IPH
and	CC	i	IPH
without	IN	i	IPH
a	DT	i	IPH
chinstrap	NN	i	IPH
was	VBD	O	O
randomly	RB	O	O
performed	VBN	O	O
on	IN	O	O
six	CD	p	O
patients	NNS	p	O
.	.	p	O

RESULTS	NNP	O	O
With	IN	O	O
the	DT	O	O
chinstrap	NN	O	O
,	,	O	O
both	DT	O	O
mouth	FW	o	OPH
leak	NN	o	OPH
and	CC	o	O
the	DT	o	OOt
arousal	NN	o	OOt
index	NN	o	OOt
decreased	VBD	O	O
significantly	RB	O	O
,	,	O	O
from	IN	O	O
(	(	O	O
mean+/-SD	JJ	O	O
)	)	O	O
42.9+/-23.5	CD	O	O
to	TO	O	O
23.8+/-13.3	CD	O	O
%	NN	O	O
of	IN	O	O
total	JJ	o	OPH
sleep	JJ	o	OPH
time	NN	o	OPH
(	(	O	O
TST	NNP	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
from	IN	O	O
33.4+/-18.6	JJ	O	O
to	TO	O	O
23.6+/-9.3/sleep	JJ	O	O
hour	NN	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
snoring	VBG	o	OPH
time	NN	o	OPH
showed	VBD	O	O
a	DT	O	O
concomitant	JJ	O	O
increase	NN	O	O
from	IN	O	O
6.7+/-14.3	JJ	O	O
to	TO	O	O
24.0+/-13.2	CD	O	O
%	NN	O	O
of	IN	O	O
TST	NNP	O	O
.	.	O	O

The	DT	O	O
arousal	JJ	o	OPH
index	NN	o	OPH
was	VBD	O	O
significantly	RB	O	O
higher	JJR	O	O
during	IN	O	O
leak	JJR	O	O
periods	NNS	O	O
,	,	O	O
and	CC	O	O
its	PRP$	O	O
changes	NNS	O	O
correlated	VBN	O	O
positively	RB	O	O
with	IN	O	O
changes	NNS	O	O
in	IN	O	O
mouth	NN	o	OPH
leak	NN	o	OPH
.	.	o	O

Cephalometric	JJ	o	OPH
measures	NNS	o	OPH
showed	VBD	O	O
a	DT	O	O
significant	JJ	O	O
decrease	NN	O	O
in	IN	O	O
anterior	JJ	o	OPH
lower	JJR	o	OPH
facial	JJ	o	OPH
height	NN	o	OPH
.	.	o	O

CONCLUSIONS	VB	O	O
The	DT	O	O
chinstrap	NN	O	O
,	,	O	O
by	IN	O	O
closing	VBG	O	O
the	DT	O	O
mouth	NN	O	O
during	IN	O	O
CPAP	NNP	O	O
,	,	O	O
reduces	VBZ	O	O
mouth	JJ	O	O
leak	NN	O	O
and	CC	O	O
therefore	RB	O	O
the	DT	O	O
arousal	NN	O	O
index	NN	O	O
in	IN	O	O
most	JJS	O	O
patients	NNS	O	O
.	.	O	O

Nevertheless	NNP	O	O
,	,	O	O
the	DT	O	O
indices	NNS	O	O
remained	VBD	O	O
unacceptably	RB	O	O
high	JJ	O	O
.	.	O	O

The	DT	O	O
chinstrap	NN	O	O
may	MD	O	O
also	RB	O	O
increase	VB	O	O
snoring	NN	O	O
and	CC	O	O
,	,	O	O
in	IN	O	O
rare	JJ	O	O
cases	NNS	O	O
,	,	O	O
can	MD	O	O
worsen	VB	O	O
the	DT	O	O
respiratory	NN	O	O
disturbance	NN	O	O
index	NN	O	O
.	.	O	O

Consideration	NN	O	O
of	IN	O	O
these	DT	O	O
potential	JJ	O	O
effects	NNS	O	O
is	VBZ	O	O
important	JJ	O	O
before	IN	O	O
instituting	VBG	O	O
regular	JJ	O	O
home	NN	O	O
use	NN	O	O
of	IN	O	O
the	DT	O	O
chinstrap	NN	O	O
.	.	O	O

Stepping	VBG	i	IE
Stones	NNP	i	IE
Triple	NNP	i	IE
P	NNP	i	IE
:	:	i	IE
an	DT	O	O
RCT	NNP	O	O
of	IN	O	O
a	DT	O	O
parenting	VBG	i	IE
program	NN	i	IE
with	IN	O	O
parents	NNS	p	PC
of	IN	p	PC
a	DT	p	PC
child	NN	p	PC
diagnosed	VBN	p	PC
with	IN	p	PC
an	DT	p	PC
autism	NN	p	PC
spectrum	NN	p	PC
disorder	NN	p	PC
.	.	p	PC

Whilst	IN	O	O
the	DT	O	O
Triple	NNP	i	IE
P	NNP	i	IE
Positive	NNP	i	IE
Parenting	NNP	i	IE
Program	NNP	i	IE
has	VBZ	O	O
a	DT	O	O
large	JJ	O	O
evidence	NN	O	O
base	NN	O	O
(	(	O	O
Sanders	NNP	O	O
,	,	O	O
Clinical	NNP	O	O
Child	NNP	O	O
and	CC	O	O
Family	NNP	O	O
Psychology	NNP	O	O
Review	NNP	O	O
2:71-90	CD	O	O
,	,	O	O
1999	CD	O	O
;	:	O	O
Sanders	NNP	O	O
,	,	O	O
Journal	NNP	O	O
of	IN	O	O
Consulting	NNP	O	O
and	CC	O	O
Clinical	NNP	O	O
Psychology	NNP	O	O
68:624-640	CD	O	O
,	,	O	O
2000	CD	O	O
)	)	O	O
and	CC	O	O
preliminary	JJ	O	O
evidence	NN	O	O
indicates	VBZ	O	O
that	IN	O	O
Stepping	VBG	i	IE
Stones	NNP	i	IE
Triple	NNP	i	IE
P	NNP	i	IE
is	VBZ	O	O
also	RB	O	O
efficacious	JJ	O	O
(	(	O	O
Roberts	NNP	O	O
,	,	O	O
Journal	NNP	O	O
of	IN	O	O
Clinical	NNP	O	O
Child	NNP	O	O
and	CC	O	O
Adolescent	NNP	O	O
Psychology	NNP	O	O
,	,	O	O
35	CD	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
:180-193	NN	O	O
,	,	O	O
2006	CD	O	O
)	)	O	O
,	,	O	O
to	TO	O	O
date	NN	O	O
Stepping	NNP	i	IE
Stones	NNP	i	IE
has	VBZ	O	O
not	RB	O	O
been	VBN	O	O
evaluated	VBN	O	O
with	IN	O	O
the	DT	O	O
ASD	NNP	O	O
population	NN	O	O
.	.	O	O

Fifty-nine	JJ	p	O
families	NNS	p	O
with	IN	p	O
a	DT	p	O
child	NN	p	O
with	IN	p	O
ASD	NNP	p	O
aged	VBD	p	O
between	IN	p	O
2	CD	p	O
and	CC	p	O
9	CD	p	O
participated	VBN	p	O
in	IN	O	O
this	DT	O	O
randomized	VBN	O	O
controlled	VBD	O	O
trial	NN	O	O
.	.	O	O

The	DT	O	O
results	NNS	O	O
demonstrate	VBP	O	O
significant	JJ	O	O
improvements	NNS	O	O
in	IN	O	O
parental	JJ	o	OME
reports	NNS	o	OME
of	IN	o	OME
child	JJ	o	OME
behaviour	NN	o	OME
and	CC	o	OME
parenting	NN	o	OME
styles	NNS	o	OME
with	IN	o	OME
the	DT	o	OME
treatment	NN	o	OME
effects	NNS	o	OME
for	IN	o	OME
child	NN	o	OME
behaviour	NN	o	OME
,	,	o	OME
parental	NN	o	OME
over	IN	o	OME
reactivity	NN	o	OME
and	CC	o	OME
parental	JJ	o	OME
verbosity	NN	o	OME
being	VBG	O	O
maintained	VBN	O	O
at	IN	O	O
follow-up	JJ	O	O
6	CD	O	O
months	NNS	O	O
later	RB	O	O
.	.	O	O

Further	RBR	O	O
,	,	O	O
the	DT	O	O
results	NNS	O	O
suggest	VBP	O	O
significant	JJ	O	O
improvements	NNS	O	O
in	IN	O	O
parental	JJ	o	OME
satisfaction	NN	o	OME
and	CC	o	OME
conflict	NN	o	OME
about	RB	o	OME
parenting	VBG	o	OME
as	RB	O	O
well	RB	O	O
as	IN	O	O
a	DT	O	O
sleeper	JJ	o	OME
effect	NN	o	OME
for	IN	o	OME
parental	JJ	o	OME
efficacy	NN	o	OME
.	.	o	O

The	DT	O	O
results	NNS	O	O
indicate	VBP	O	O
that	IN	O	O
Stepping	VBG	i	IE
Stones	NNP	i	IE
Triple	NNP	i	IE
P	NNP	i	IE
is	VBZ	O	O
a	DT	O	O
promising	JJ	O	O
intervention	NN	O	O
for	IN	O	O
parents	NNS	p	O
of	IN	p	O
children	NNS	p	O
with	IN	p	O
ASD	NNP	p	O
.	.	p	O

Limitations	NNS	O	O
and	CC	O	O
future	JJ	O	O
research	NN	O	O
are	VBP	O	O
also	RB	O	O
addressed	VBN	O	O
.	.	O	O

Different	NNP	i	IPM
aprotinin	NN	i	IPM
applications	NNS	i	IPM
influencing	VBG	O	O
hemostatic	JJ	O	O
changes	NNS	O	O
in	IN	O	O
orthotopic	NN	p	O
liver	NN	p	O
transplantation	NN	p	O
.	.	p	O

The	DT	O	O
effect	NN	O	O
of	IN	O	O
different	JJ	O	O
aprotinin	NN	i	IPM
applications	NNS	i	IPM
on	IN	O	O
hemostatic	JJ	O	O
changes	NNS	O	O
and	CC	O	O
blood	NN	O	O
product	NN	O	O
requirements	NNS	O	O
in	IN	O	O
orthotopic	JJ	p	O
liver	NN	p	O
transplantation	NN	p	O
was	VBD	O	O
investigated	VBN	O	O
in	IN	O	O
a	DT	O	O
prospective	JJ	O	O
,	,	O	O
open	JJ	O	O
,	,	O	O
and	CC	O	O
randomized	VBD	O	O
study	NN	O	O
.	.	O	O

From	IN	p	O
November	NNP	p	O
1989	CD	p	O
to	TO	p	O
June	NNP	p	O
1990	CD	p	O
,	,	p	O
13	CD	p	PC
patients	NNS	p	O
received	VBD	O	O
aprotinin	RB	i	IPM
as	IN	O	O
a	DT	O	O
bolus	NN	i	IPM
of	IN	i	IPM
0.5	CD	i	IPM
Mill	NNP	i	IPM
.	.	i	O

Kallikrein	NNP	O	O
inactivator	JJ	O	O
units	NNS	O	O
(	(	O	O
KIU	NNP	O	O
)	)	O	O
on	IN	O	O
three	CD	O	O
occasions	NNS	O	O
in	IN	O	O
the	DT	O	O
course	NN	O	O
of	IN	O	O
an	DT	O	O
OLT	NNP	O	O
,	,	O	O
whereas	RB	O	O
10	CD	O	O
other	JJ	O	O
patients	NNS	O	O
were	VBD	O	O
treated	VBN	O	O
with	IN	O	O
continuous	JJ	i	IPM
aprotinin	JJ	i	IPM
infusion	NN	i	IPM
of	IN	i	IPM
0.1-0.4	JJ	i	IPM
Mill	NNP	i	IPM
.	.	i	IPM

KIU/hr	NNP	O	O
.	.	O	O

Before	IN	O	O
and	CC	O	O
after	IN	O	O
reperfusion	NN	O	O
of	IN	O	O
the	DT	O	O
graft	NN	o	OPH
liver	NN	o	OPH
,	,	o	OPH
signs	NNS	o	OPH
of	IN	o	OPH
hyperfibrinolysis	NN	o	OPH
,	,	O	O
measured	VBN	O	O
by	IN	O	O
thrombelastography	NN	O	O
,	,	O	O
were	VBD	O	O
significantly	RB	O	O
lower	JJR	O	O
in	IN	O	O
the	DT	O	O
infusion	NN	O	O
group	NN	O	O
.	.	O	O

Tissue-type	JJ	o	OPH
plasminogen	NN	o	OPH
activator	NN	o	OPH
(	(	o	OPH
t-PA	JJ	o	OPH
)	)	o	OPH
activity	NN	o	OPH
increased	VBD	O	O
during	IN	O	O
the	DT	O	O
anhepatic	JJ	O	O
phase	NN	O	O
but	CC	O	O
to	TO	O	O
a	DT	O	O
significantly	RB	O	O
lesser	JJR	O	O
extent	NN	O	O
in	IN	O	O
the	DT	O	O
infusion	NN	O	O
group	NN	O	O
.	.	O	O

Blood	NNP	o	OPH
product	NN	o	OPH
requirements	NNS	o	OPH
during	IN	O	O
OLT	NNP	O	O
were	VBD	O	O
tendentiously	RB	O	O
higher	JJR	O	O
in	IN	O	O
the	DT	O	O
bolus	NN	O	O
group	NN	O	O
but	CC	O	O
not	RB	O	O
significantly	RB	O	O
so	RB	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
the	DT	O	O
use	NN	O	O
of	IN	O	O
packed	JJ	o	OPH
red	JJ	o	OPH
blood	NN	o	OPH
cells	NNS	o	OPH
was	VBD	O	O
significantly	RB	O	O
lower	JJR	O	O
in	IN	O	O
the	DT	O	O
postoperative	JJ	O	O
period	NN	O	O
,	,	O	O
whereas	IN	O	O
there	EX	O	O
was	VBD	O	O
no	DT	O	O
significant	JJ	O	O
difference	NN	O	O
in	IN	O	O
fresh	JJ	O	O
frozen	NN	O	O
plasma	NN	o	OOt
requirements	NNS	o	OOt
between	IN	O	O
the	DT	O	O
two	CD	O	O
groups	NNS	O	O
.	.	O	O

All	DT	O	O
23	CD	p	PSS
patients	NNS	p	O
have	VBP	O	O
survived	VBN	o	OMO
,	,	O	O
and	CC	O	O
only	RB	O	O
one	CD	O	O
woman	NN	O	O
of	IN	O	O
each	DT	O	O
group	NN	O	O
required	VBN	O	O
retransplantation	NN	o	OPH
due	JJ	O	O
to	TO	O	O
severe	VB	O	O
host-versus-graft	JJ	o	OPH
reactions	NNS	o	OPH
.	.	o	OPH

Furthermore	RB	O	O
,	,	O	O
we	PRP	O	O
investigated	VBD	O	O
the	DT	O	O
perfusate	NN	O	O
of	IN	O	O
the	DT	O	O
graft	NN	O	O
liver	NN	O	O
in	IN	O	O
both	DT	O	O
groups	NNS	O	O
and	CC	O	O
detected	JJ	O	O
signs	NNS	O	O
of	IN	O	O
a	DT	O	O
decreased	JJ	O	O
t-PA	JJ	o	OPH
release	NN	o	OPH
in	IN	O	O
the	DT	O	O
infusion	NN	O	O
group	NN	O	O
.	.	O	O

Our	PRP$	O	O
results	NNS	O	O
demonstrate	VBP	O	O
an	DT	O	O
advantage	NN	O	O
of	IN	O	O
aprotinin	NN	i	IPM
given	VBN	O	O
as	IN	O	O
continuous	JJ	O	O
infusion	NN	O	O
over	IN	O	O
bolus	JJ	O	O
application	NN	O	O
in	IN	O	O
OLT	NNP	O	O
.	.	O	O

The	DT	O	O
peroxisome	JJ	O	O
proliferator-activated	JJ	O	O
receptor-gamma	JJ	O	O
agonist	NN	O	O
pioglitazone	NN	i	IPM
increases	VBZ	O	O
number	NN	o	OPH
and	CC	o	OPH
function	NN	o	OPH
of	IN	o	OPH
endothelial	JJ	o	OPH
progenitor	NN	o	OPH
cells	NNS	o	OPH
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
coronary	JJ	p	O
artery	NN	p	O
disease	NN	p	O
and	CC	p	O
normal	JJ	p	O
glucose	JJ	p	O
tolerance	NN	p	O
.	.	p	O

OBJECTIVE	CC	O	O
Peroxisome	JJ	O	O
proliferator-activated	JJ	O	O
receptor-gamma	NN	O	O
(	(	O	O
PPAR	NNP	O	O
gamma	NN	O	O
)	)	O	O
agonists	VBZ	O	O
(	(	i	O
thiazolidinediones	NNS	i	IPM
[	NNP	i	IPM
TZDs	NNP	i	IPM
]	NNP	i	O
)	)	i	O
are	VBP	O	O
used	VBN	O	O
for	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
diabetes	NNS	O	O
.	.	O	O

Bone	CD	O	O
marrow-derived	JJ	O	O
endothelial	JJ	O	O
progenitor	NN	O	O
cells	NNS	O	O
(	(	O	O
EPCs	NNP	O	O
)	)	O	O
improve	VB	O	O
vascular	JJ	o	OPH
function	NN	o	OPH
and	CC	O	O
predict	NN	O	O
cardiovascular	NN	o	OPH
risk	NN	o	OPH
.	.	o	OPH

The	DT	O	O
effect	NN	O	O
of	IN	O	O
pioglitazone	NN	i	IPM
therapy	NN	O	O
on	IN	O	O
EPCs	NNP	O	O
was	VBD	O	O
examined	VBN	O	O
.	.	O	O

RESEARCH	NNP	O	O
DESIGN	NNP	O	O
AND	NNP	O	O
METHODS	NNP	O	O
AND	NNP	O	O
RESULTS	NNP	O	O
We	PRP	O	O
performed	VBD	O	O
a	DT	O	O
prospective	JJ	O	O
,	,	O	O
randomized	VBN	O	O
,	,	O	O
double-blind	JJ	O	O
study	NN	O	O
on	IN	O	O
patients	NNS	p	O
with	IN	p	O
documented	JJ	p	O
stable	JJ	p	O
coronary	JJ	p	O
artery	NN	p	O
disease	NN	p	O
and	CC	p	O
normal	JJ	p	O
glucose	JJ	p	O
tolerance	NN	p	O
.	.	p	O

Of	IN	O	O
54	CD	p	O
patients	NNS	p	O
with	IN	p	O
normal	JJ	p	O
fasting	VBG	p	O
glucose	JJ	p	O
levels	NNS	p	O
,	,	p	O
18	CD	p	O
showed	VBD	p	O
impaired	JJ	p	O
glucose	JJ	p	O
tolerance	NN	p	O
and	CC	p	O
36	CD	p	O
patients	NNS	p	O
with	IN	p	O
normal	JJ	p	O
glucose	JJ	p	O
tolerance	NN	p	O
were	VBD	p	O
randomized	VBN	p	O
to	TO	O	O
30-day	JJ	O	O
treatment	NN	O	O
with	IN	O	O
pioglitazone	NN	i	IPM
(	(	O	O
45	CD	O	O
mg	NN	O	O
)	)	O	O
or	CC	i	O
placebo	NN	i	O
in	IN	i	O
addition	NN	i	O
to	TO	i	O
optimal	VB	i	O
medical	JJ	i	O
therapy	NN	i	O
.	.	i	O

All	DT	O	O
patients	NNS	O	O
in	IN	O	O
the	DT	O	O
TZD	NNP	i	IPM
group	NN	O	O
showed	VBD	O	O
an	DT	O	O
increase	NN	O	O
of	IN	O	O
adiponectin	JJ	o	OPH
levels	NNS	o	OPH
as	IN	O	O
an	DT	O	O
indicator	NN	O	O
of	IN	O	O
compliance	NN	O	O
(	(	O	O
11.4	CD	O	O
+/-	JJ	O	O
1.1	CD	O	O
to	TO	O	O
36.8	CD	O	O
+/-	JJ	O	O
2.1	CD	O	O
microg/ml	NN	O	O
;	:	O	O
P	NNP	O	O
<	NNP	O	O
0.001	CD	O	O
)	)	O	O
.	.	O	O

TZD	NNP	i	IPM
,	,	O	O
but	CC	O	O
not	RB	O	O
placebo	VB	i	O
,	,	O	O
decreased	VBN	O	O
mean	JJ	o	OPH
high-sensitivity	NN	o	OPH
C-reactive	JJ	o	OPH
protein	NN	o	OPH
to	TO	O	O
43	CD	O	O
+/-	JJ	O	O
19	CD	O	O
%	NN	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

Pioglitazone	NN	O	O
increased	VBD	O	O
CD34	NNP	o	OPH
(	(	o	OPH
+	NNP	o	OPH
)	)	o	OPH
/kinase	NN	o	OPH
insert	JJ	o	OPH
domain	NN	o	OPH
receptor	NN	o	OPH
(	(	o	OPH
+	NNP	o	OPH
)	)	o	OPH
EPCs	NNP	o	OPH
to	TO	O	O
142	CD	O	O
+/-	JJ	O	O
9	CD	O	O
%	NN	O	O
and	CC	O	O
cultured	VBD	o	OPH
1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine-labeled	JJ	o	OPH
acetylated	JJ	o	OPH
LDL	NNP	o	OPH
(	(	o	OPH
+	NNP	o	OPH
)	)	o	OPH
/lectin	NN	o	OPH
(	(	o	OPH
+	NNP	o	OPH
)	)	o	OPH
EPCs	NNP	o	OPH
to	TO	O	O
180	CD	O	O
+/-	JJ	O	O
3	CD	O	O
%	NN	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

EPC	JJ	o	OPH
numbers	NNS	o	OPH
were	VBD	O	O
not	RB	O	O
changed	VBN	O	O
in	IN	O	O
the	DT	O	O
placebo	NN	O	O
group	NN	O	O
.	.	O	O

TZD	NNP	O	O
increased	VBD	O	O
the	DT	O	O
SDF-1-induced	NNP	o	OPH
migratory	NN	o	OPH
capacity	NN	o	OPH
to	TO	O	O
146	CD	O	O
+/-	JJ	O	O
9	CD	O	O
%	NN	O	O
per	IN	O	O
EPC	NNP	O	O
number	NN	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
and	CC	O	O
upregulated	VBD	O	O
the	DT	O	O
clonogenic	JJ	o	OPH
potential	NN	o	OPH
of	IN	o	OPH
EPCs	NNP	o	OPH
,	,	O	O
increasing	VBG	O	O
the	DT	o	OPH
colony-forming	JJ	o	OPH
units	NNS	o	OPH
to	TO	O	O
172	CD	O	O
+/-	JJ	O	O
12	CD	O	O
%	NN	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.001	CD	O	O
)	)	O	O
.	.	O	O

In	IN	O	O
cultured	JJ	O	O
human	JJ	O	O
EPCs	NNP	O	O
,	,	O	O
TZD	NNP	i	IPM
increased	VBD	O	O
EPC	NNP	o	OPH
numbers	NNS	o	OPH
and	CC	o	OPH
migration	NN	o	OPH
and	CC	o	OPH
reduced	JJ	o	OPH
NADPH-oxidase	NNP	o	OPH
activity	NN	o	OPH
.	.	o	OPH

The	DT	O	O
TZD	NNP	i	IPM
effect	NN	O	O
was	VBD	O	O
reversed	VBN	O	O
by	IN	O	O
the	DT	O	O
PPAR	NNP	O	O
gamma	NN	O	O
antagonist	NN	O	O
GW9662	NNP	O	O
and	CC	O	O
mimicked	VBN	O	O
by	IN	O	O
treatment	NN	O	O
with	IN	O	O
adiponectin	NN	O	O
.	.	O	O

CONCLUSIONS	VB	O	O
The	DT	O	O
PPAR	NNP	O	O
gamma	NN	O	O
agonist	NN	O	O
pioglitazone	NN	i	IPM
increases	VBZ	O	O
the	DT	O	O
number	NN	o	OPH
and	CC	o	OPH
function	NN	o	OPH
of	IN	o	OPH
EPCs	NNP	o	OPH
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
coronary	JJ	p	O
artery	NN	p	O
disease	NN	p	O
.	.	p	O

The	DT	O	O
effect	NN	O	O
represents	VBZ	O	O
a	DT	O	O
potential	JJ	O	O
regenerative	NN	O	O
mechanism	NN	O	O
in	IN	O	O
atherosclerosis	NN	O	O
and	CC	O	O
is	VBZ	O	O
observed	VBN	O	O
in	IN	O	O
normoglycemic	JJ	p	O
individuals	NNS	p	O
with	IN	p	O
stable	JJ	p	O
coronary	JJ	p	O
artery	NN	p	O
disease	NN	p	O
.	.	p	O

The	DT	O	O
effect	NN	O	O
of	IN	O	O
Naftidrofuryl	NNP	i	IPM
on	IN	O	O
ethanol-induced	JJ	O	O
liver	NN	O	O
damage	NN	O	O
in	IN	O	O
chronic	JJ	p	PC
alcoholic	JJ	p	PC
patients	NNS	p	O
.	.	p	O

A	DT	O	O
prospective	JJ	O	O
double-blind	JJ	O	O
placebo-controlled	JJ	i	IC
trial	NN	O	O
of	IN	O	O
intramuscular	JJ	O	O
Naftidrofuryl	NNP	i	IPM
was	VBD	O	O
carried	VBN	O	O
out	RP	O	O
on	IN	O	O
32	CD	p	PSS
randomly	RB	p	O
selected	VBN	p	O
hospitalized	VBN	p	O
male	JJ	p	PSE
alcoholic	JJ	p	PC
patients	NNS	p	O
with	IN	p	O
clinical	JJ	p	O
,	,	p	O
biochemical	JJ	p	O
and	CC	p	O
histological	JJ	p	O
evidence	NN	p	O
of	IN	p	O
hepatic	JJ	p	PC
damage	NN	p	PC
.	.	p	O

Seventeen	JJ	O	O
patients	NNS	O	O
received	VBD	O	O
the	DT	O	O
drug	NN	O	O
(	(	O	O
40	CD	O	O
mg	NN	O	O
in	IN	O	O
5	CD	O	O
ml	NN	O	O
i.m	NN	O	O
.	.	O	O

three	CD	O	O
times	NNS	O	O
daily	RB	O	O
for	IN	O	O
6	CD	O	O
days	NNS	O	O
)	)	O	O
and	CC	O	O
15	CD	O	O
patients	NNS	O	O
received	VBD	O	O
a	DT	O	O
placebo	NN	i	IPM
(	(	O	O
5	CD	O	O
ml	NN	O	O
in	IN	O	O
normal	JJ	O	O
saline	JJ	O	O
i.m	NN	O	O
.	.	O	O

three	CD	O	O
times	NNS	O	O
daily	RB	O	O
for	IN	O	O
6	CD	O	O
days	NNS	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
drug	NN	O	O
was	VBD	O	O
well	RB	O	O
tolerated	VBN	O	O
and	CC	O	O
there	EX	O	O
were	VBD	O	O
no	DT	O	O
adverse	JJ	o	OA
side-effects	NNS	o	OA
.	.	o	OA

Naftidrofuryl	NNP	i	O
significantly	RB	O	O
improved	VBD	O	O
the	DT	O	O
physiological	JJ	o	OPH
function	NN	o	OPH
of	IN	o	OPH
the	DT	o	OPH
liver	NN	o	OPH
cells	NNS	o	OPH
as	IN	o	OPH
reflected	VBN	o	OPH
by	IN	o	OPH
indocyanine	NN	o	OPH
green	NN	o	OPH
(	(	o	OPH
ICG	NNP	o	OPH
)	)	o	OPH
clearance	NN	o	OPH
by	IN	O	O
the	DT	O	O
liver	NN	O	O
(	(	O	O
t	JJ	O	O
=	VBZ	O	O
2.61	CD	O	O
;	:	O	O
p	NN	O	O
less	JJR	O	O
than	IN	O	O
or	CC	O	O
equal	JJ	O	O
to	TO	O	O
0.02	CD	O	O
)	)	O	O
and	CC	O	O
also	RB	O	O
caused	VBD	O	O
a	DT	O	O
larger	JJR	O	O
fall	NN	O	O
in	IN	O	O
raised	VBN	O	O
serum	NN	o	OPH
levels	NNS	o	OPH
of	IN	o	OPH
gamma	NN	o	OPH
glutamyl	NN	o	OPH
transpeptidase	NN	o	OPH
(	(	o	OPH
GGT	NNP	o	OPH
)	)	o	OPH
than	IN	O	O
did	VBD	O	O
the	DT	O	O
placebo	NN	i	O
injections	NNS	O	O
.	.	O	O

Overall	JJ	O	O
clinical	JJ	o	OPH
improvement	NN	o	OPH
(	(	o	OPH
e.g	NN	o	OPH
.	.	o	OPH

appetite	NN	o	OPH
,	,	o	OPH
body	NN	o	OPH
weight	NN	o	OPH
,	,	o	OPH
reduced	VBD	o	OPH
liver	JJ	o	OPH
size	NN	o	OPH
,	,	o	OPH
general	JJ	o	OPH
sense	NN	o	OPH
of	IN	o	OPH
well-being	NN	o	OPH
)	)	o	OPH
was	VBD	O	O
more	RBR	O	O
clearly	RB	O	O
evident	JJ	O	O
in	IN	O	O
patients	NNS	O	O
of	IN	O	O
the	DT	O	O
treated	VBN	O	O
group	NN	O	O
than	IN	O	O
in	IN	O	O
those	DT	O	O
of	IN	O	O
the	DT	O	O
placebo	NN	i	O
group	NN	O	O
.	.	O	O

Naftidrofuryl	NNP	i	IPM
,	,	O	O
therefore	RB	O	O
,	,	O	O
appears	VBZ	O	O
to	TO	O	O
be	VB	O	O
of	IN	O	O
benefit	NN	O	O
in	IN	O	O
ethanol-induced	JJ	p	PC
liver	NN	p	PC
damage	NN	p	PC
and	CC	O	O
more	RBR	O	O
extensive	JJ	O	O
long-term	JJ	O	O
trials	NNS	O	O
are	VBP	O	O
suggested	VBN	O	O
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
alcoholic	JJ	p	PC
liver	NN	p	PC
disease	NN	p	PC
(	(	p	PC
ALD	NNP	p	PC
)	)	p	PC
.	.	p	O

?-Blockers	NNS	O	O
in	IN	p	O
patients	NNS	p	O
with	IN	p	O
intermittent	JJ	p	O
claudication	NN	p	O
and	CC	p	O
arterial	JJ	p	O
hypertension	NN	p	O
:	:	p	O
results	NNS	O	O
from	IN	O	O
the	DT	O	O
nebivolol	NN	O	O
or	CC	O	O
metoprolol	NN	O	O
in	IN	O	O
arterial	JJ	O	O
occlusive	JJ	O	O
disease	NN	O	O
trial	NN	O	O
.	.	O	O

The	DT	O	O
use	NN	O	O
of	IN	O	O
?-receptor	NN	O	O
blockers	NNS	O	O
in	IN	O	O
peripheral	JJ	O	O
arterial	JJ	O	O
disease	NN	O	O
is	VBZ	O	O
controversial	JJ	O	O
for	IN	O	O
their	PRP$	O	O
impact	NN	O	O
on	IN	O	O
vasomotor	NN	O	O
tone	NN	O	O
.	.	O	O

The	DT	O	O
?-blocker	NN	O	O
nebivolol	NN	O	O
possesses	VBZ	O	O
vasodilating	VBG	O	O
,	,	O	O
endothelium-dependent	JJ	O	O
,	,	O	O
NO-releasing	JJ	O	O
properties	NNS	O	O
that	WDT	O	O
might	MD	O	O
be	VB	O	O
beneficial	JJ	O	O
in	IN	O	O
peripheral	JJ	O	O
arterial	JJ	O	O
disease	NN	O	O
.	.	O	O

The	DT	O	O
aim	NN	O	O
of	IN	O	O
the	DT	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
evaluate	VB	O	O
the	DT	O	O
effects	NNS	o	OOt
and	CC	o	OOt
tolerability	NN	o	OOt
of	IN	o	O
nebivolol	NN	i	O
in	IN	i	O
comparison	NN	O	O
with	IN	i	O
metoprolol	NN	i	O
in	IN	i	O
these	DT	O	O
patients	NNS	p	O
.	.	p	O

A	DT	p	O
total	NN	p	O
of	IN	p	O
128	CD	p	O
patients	NNS	p	O
with	IN	p	O
intermittent	JJ	p	O
claudication	NN	p	O
and	CC	p	O
essential	JJ	p	O
hypertension	NN	p	O
were	VBD	p	O
included	VBN	O	O
and	CC	O	O
double-blind	JJ	O	O
randomized	VBN	O	O
to	TO	O	O
receive	VB	i	O
5	CD	i	O
mg	NN	i	O
of	IN	i	O
nebivolol	NN	i	O
(	(	i	O
N=65	NNP	i	O
)	)	O	O
or	CC	O	O
95	CD	i	O
mg	NN	i	O
of	IN	i	O
metoprolol	NN	i	O
(	(	i	O
N=63	NNP	i	O
)	)	O	O
once	RB	O	O
daily	JJ	O	O
.	.	O	O

End	NN	O	O
points	NNS	O	O
were	VBD	O	O
changes	NNS	O	O
in	IN	O	O
ankle-brachial	JJ	o	O
index	NN	o	O
,	,	o	O
initial	JJ	o	O
and	CC	o	O
absolute	JJ	o	O
claudication	NN	o	O
distance	NN	o	O
,	,	o	O
endothelial	JJ	o	O
function	NN	o	O
assessed	VBN	o	O
by	IN	o	O
flow-mediated	JJ	o	O
dilatation	NN	o	O
of	IN	o	O
the	DT	o	O
brachial	JJ	o	O
artery	NN	o	O
,	,	o	O
blood	NN	o	OPH
pressure	NN	o	OPH
,	,	o	O
and	CC	o	O
quality	NN	o	OOt
of	IN	o	OOt
life	NN	o	OOt
using	VBG	o	OOt
the	DT	o	OOt
claudication	NN	o	OOt
scale	NN	o	OOt
questionnaire	NN	o	OOt
.	.	o	O

End	NN	o	O
point	NN	O	O
analysis	NN	O	O
was	VBD	O	O
possible	JJ	O	O
in	IN	O	O
109	CD	O	O
patients	NNS	O	O
(	(	O	O
85.2	CD	O	O
%	NN	O	O
)	)	O	O
.	.	O	O

After	IN	O	O
the	DT	O	O
48-week	JJ	O	O
treatment	NN	O	O
period	NN	o	O
,	,	o	O
ankle-brachial	JJ	o	O
index	NN	o	O
and	CC	o	O
absolute	JJ	o	O
claudication	NN	o	O
distance	NN	o	O
improved	VBD	o	O
significantly	RB	O	O
in	IN	O	O
both	DT	O	O
patient	JJ	O	O
groups	NNS	O	O
(	(	O	O
P	NNP	O	O
<	VBZ	O	O
0.05	CD	O	O
for	IN	O	O
both	DT	O	O
)	)	O	O
,	,	O	O
with	IN	O	O
no	DT	O	O
difference	NN	O	O
across	IN	O	O
treatments	NNS	O	O
.	.	O	O

A	DT	O	O
significant	JJ	O	O
increase	NN	O	O
of	IN	O	O
initial	JJ	o	O
claudication	NN	o	O
distance	NN	o	O
was	VBD	o	O
found	VBN	O	O
in	IN	O	O
the	DT	O	O
nebivolol	JJ	O	O
group	NN	O	O
.	.	O	O

Adjusted	VBN	O	O
mean	JJ	O	O
change	NN	O	O
of	IN	O	O
initial	JJ	o	O
claudication	NN	o	O
distance	NN	o	O
was	VBD	o	O
33.9	CD	O	O
%	NN	O	O
after	IN	O	O
nebivolol	NN	O	O
(	(	O	O
P=0.003	NNP	O	O
)	)	O	O
and	CC	O	O
16.6	CD	O	O
%	NN	O	O
after	IN	O	O
metoprolol	NN	O	O
(	(	O	O
P=0.12	NNP	O	O
)	)	O	O
treatment	NN	o	O
.	.	o	O

Quality	NN	o	O
of	IN	o	O
life	NN	o	O
was	VBD	o	O
not	RB	O	O
influenced	VBN	O	O
by	IN	O	O
either	DT	O	O
treatment	NN	O	O
,	,	O	O
and	CC	O	O
there	EX	O	O
was	VBD	O	O
no	DT	O	O
relevant	JJ	O	O
change	NN	O	O
in	IN	O	O
flow-mediated	JJ	o	O
dilatation	NN	o	O
in	IN	o	O
patients	NNS	O	O
treated	VBN	O	O
with	IN	O	O
nebivolol	NN	O	O
or	CC	O	O
metoprolol	NN	O	O
(	(	O	O
P=0.16	NNP	O	O
)	)	O	O
.	.	O	O

Both	DT	O	O
drugs	NNS	O	O
were	VBD	O	O
equally	RB	O	O
effective	JJ	O	O
in	IN	O	O
lowering	VBG	o	O
blood	NN	o	O
pressure	NN	o	O
.	.	o	O

In	IN	o	O
conclusion	NN	O	O
,	,	O	O
?-blocker	JJ	O	O
therapy	NN	O	O
was	VBD	O	O
well	RB	O	O
tolerated	VBN	p	O
in	IN	p	O
patients	NNS	p	O
with	IN	p	O
intermittent	JJ	p	O
claudication	NN	p	O
and	CC	p	O
arterial	JJ	p	O
hypertension	NN	p	O
during	IN	p	O
a	DT	O	O
treatment	NN	O	O
period	NN	O	O
of	IN	O	O
?1	JJ	O	O
year	NN	O	O
.	.	O	O

In	IN	O	O
the	DT	O	O
direct	JJ	O	O
comparison	NN	O	O
,	,	O	O
there	EX	O	O
was	VBD	O	O
no	DT	O	O
significant	JJ	O	O
difference	NN	O	O
between	IN	O	O
nebivolol	NNS	O	O
and	CC	O	O
metoprolol	NN	O	O
.	.	O	O

Preliminary	JJ	O	O
findings	NNS	O	O
of	IN	O	O
the	DT	O	O
minimally-invasive	JJ	i	IS
surgery	NN	i	IS
plus	CC	i	IS
rtPA	NN	i	IS
for	IN	O	O
intracerebral	JJ	o	OPH
hemorrhage	NN	o	OPH
evacuation	NN	o	OPH
(	(	p	O
MISTIE	NNP	p	O
)	)	p	O
clinical	JJ	O	O
trial	NN	O	O
.	.	O	O

INTRODUCTION	NNP	O	O
Compared	VBD	O	O
to	TO	O	O
ischemic	VB	O	O
stroke	NN	O	O
,	,	O	O
intracerebral	JJ	O	O
hemorrhage	NN	O	O
(	(	O	O
ICH	NNP	O	O
)	)	O	O
is	VBZ	O	O
easily	RB	O	O
and	CC	O	O
rapidly	RB	O	O
identified	VBN	O	O
,	,	O	O
occurs	VBZ	O	O
in	IN	O	O
younger	JJR	p	PA
patients	NNS	p	O
,	,	p	O
and	CC	p	O
produces	VBZ	p	O
relatively	RB	p	O
small	JJ	p	O
initial	JJ	p	O
injury	NN	p	O
to	TO	p	O
cerebral	JJ	p	O
tissues	NNS	p	O
--	:	p	O
all	DT	p	O
factors	NNS	p	O
suggesting	VBG	p	O
that	IN	p	O
interventional	JJ	p	O
amelioration	NN	p	O
is	VBZ	p	O
possible	JJ	p	O
.	.	p	O

Investigations	NNS	O	O
from	IN	O	O
the	DT	O	O
last	JJ	O	O
decade	NN	O	O
established	VBD	O	O
that	IN	O	O
extent	NN	O	O
of	IN	O	O
ICH-mediated	NNP	O	O
brain	NN	O	O
injury	NN	O	O
relates	VBZ	O	O
directly	RB	O	O
to	TO	O	O
blood	VB	O	O
clot	NN	O	O
volume	NN	O	O
and	CC	O	O
duration	NN	O	O
of	IN	O	O
blood	NN	O	O
exposure	NN	O	O
to	TO	O	O
brain	NN	O	O
tissue	NN	O	O
.	.	O	O

Using	VBG	O	O
minimally-invasive	JJ	i	IS
surgery	NN	i	IS
plus	CC	i	IS
recombinant	JJ	i	IS
tissue	NN	i	IS
plasminogen	NN	i	IS
activator	NN	i	IS
(	(	i	IS
rtPA	NN	i	IS
)	)	i	IS
,	,	O	O
MISTIE	NNP	O	O
investigators	NNS	O	O
explored	VBD	O	O
aggressive	JJ	O	O
avenues	NNS	O	O
to	TO	O	O
treat	VB	O	O
ICH	NNP	O	O
.	.	O	O

METHODS	NNP	O	O
We	PRP	O	O
investigated	VBD	O	O
the	DT	O	O
difference	NN	O	O
between	IN	O	O
surgical	JJ	i	IS
intervention	NN	i	IS
plus	CC	i	IS
rtPA	NN	i	IS
and	CC	i	O
standard	JJ	i	O
medical	JJ	i	O
management	NN	i	O
for	IN	i	O
ICH	NNP	O	O
.	.	O	O

Subjects	NNS	p	O
in	IN	p	O
both	DT	p	O
groups	NNS	p	O
were	VBD	O	O
medically	RB	p	O
managed	VBN	p	O
according	VBG	p	O
to	TO	p	O
standard	JJ	p	O
ICU	NNP	p	O
protocols	NNS	p	O
.	.	p	O

Subjects	NNS	O	O
randomized	VBD	O	O
to	TO	O	O
surgery	VB	O	O
underwent	JJ	O	O
stereotactic	JJ	i	IS
catheter	NN	i	IS
placement	NN	i	IS
and	CC	i	IS
clot	NN	i	IS
aspiration	NN	i	IS
.	.	i	O

Injections	NNS	i	IPM
of	IN	i	IPM
rtPA	NN	i	IPM
were	VBD	O	O
then	RB	O	O
given	VBN	O	O
through	IN	O	O
hematoma	NN	O	O
catheter	NN	O	O
every	DT	O	O
8	CD	O	O
h	NN	O	O
,	,	O	O
up	RB	O	O
to	TO	O	O
9	CD	O	O
doses	NNS	O	O
,	,	O	O
or	CC	O	O
until	IN	O	O
a	DT	O	O
clot-reduction	JJ	O	O
endpoint	NN	O	O
.	.	O	O

After	IN	O	O
each	DT	O	O
injection	NN	O	O
the	DT	O	O
system	NN	O	O
was	VBD	O	O
flushed	VBN	O	O
with	IN	O	O
sterile	JJ	i	IPM
saline	NN	i	IPM
and	CC	O	O
closed	VBD	O	O
for	IN	O	O
60	CD	O	O
min	NN	O	O
before	IN	O	O
opening	VBG	O	O
to	TO	O	O
spontaneous	JJ	O	O
drainage	NN	O	O
.	.	O	O

RESULTS	JJ	O	O
Average	JJ	o	OPH
aspiration	NN	o	OPH
of	IN	o	OPH
clots	NNS	o	OPH
for	IN	O	O
all	DT	O	O
patients	NNS	O	O
randomized	VBN	O	O
to	TO	O	O
surgery	VB	O	O
plus	CC	O	O
rtPA	VB	O	O
was	VBD	O	O
20	CD	O	O
%	NN	O	O
of	IN	O	O
mean	JJ	O	O
initial	JJ	O	O
clot	NN	O	O
size	NN	O	O
.	.	O	O

After	IN	O	O
acute	JJ	O	O
treatment	NN	O	O
phase	NN	O	O
(	(	O	O
aspiration	NN	O	O
plus	CC	O	O
rtPA	NN	O	O
)	)	O	O
,	,	O	O
clot	NN	o	OPH
was	VBD	o	O
reduced	VBN	o	O
an	DT	O	O
average	NN	O	O
of	IN	O	O
46	CD	O	O
%	NN	O	O
.	.	O	O

Recorded	VBN	O	O
adverse	JJ	O	O
events	NNS	O	O
were	VBD	O	O
within	IN	O	O
safety	NN	O	O
limits	NNS	O	O
,	,	O	O
including	VBG	O	O
30-day	JJ	o	OMO
mortality	NN	o	OMO
,	,	O	O
8	CD	O	O
%	NN	O	O
;	:	O	O
symptomatic	JJ	o	OPH
re-bleeding	NN	o	OPH
,	,	O	O
8	CD	O	O
%	NN	O	O
;	:	O	O
and	CC	O	O
bacterial	JJ	o	OPH
ventriculitis	NN	o	OPH
,	,	O	O
0	CD	O	O
%	NN	O	O
.	.	O	O

Patients	NNS	O	O
randomized	VBD	O	O
to	TO	O	O
medical	JJ	O	O
management	NN	O	O
showed	VBD	O	O
4	CD	O	O
%	NN	O	O
clot	NN	o	OPH
resolution	NN	o	OPH
in	IN	O	O
a	DT	O	O
similar	JJ	O	O
time	NN	O	O
window	NN	O	O
.	.	O	O

Preliminary	JJ	O	O
analysis	NN	O	O
indicates	VBZ	O	O
that	IN	O	O
clot	NN	o	OPH
resolution	NN	o	OPH
rates	NNS	o	OPH
are	VBP	O	O
greatly	RB	O	O
dependent	JJ	O	O
on	IN	O	O
catheter	NN	O	O
placement	NN	O	O
.	.	O	O

Location	NN	O	O
of	IN	O	O
ICH	NNP	O	O
also	RB	O	O
affects	VBZ	O	O
efficacy	NN	O	O
of	IN	O	O
aggressive	JJ	O	O
treatment	NN	O	O
of	IN	O	O
ICH	NNP	O	O
.	.	O	O

CONCLUSION	NNP	O	O
There	EX	O	O
is	VBZ	O	O
tentative	JJ	O	O
indication	NN	O	O
that	IN	O	O
minimally-invasive	JJ	O	O
surgery	NN	O	O
plus	CC	O	O
rtPA	NN	O	O
shows	NNS	O	O
greater	JJR	o	OPH
clot	NN	o	OPH
resolution	NN	o	OPH
than	IN	O	O
traditional	JJ	O	O
medical	JJ	O	O
management	NN	O	O
.	.	O	O

Efficacy	NN	o	OOt
and	CC	o	OOt
safety	NN	o	OOt
of	IN	O	O
bexarotene	NN	i	IPM
combined	VBN	i	IPM
with	IN	i	IPM
psoralen-ultraviolet	NN	i	IPH
A	NNP	i	IPH
(	(	i	IPM
PUVA	NNP	i	IPM
)	)	i	IPM
compared	VBN	i	O
with	IN	i	O
PUVA	NNP	i	IPH
treatment	NN	i	IPH
alone	RB	i	IPH
in	IN	O	O
stage	JJ	O	O
IB-IIA	JJ	O	O
mycosis	NN	O	O
fungoides	NNS	O	O
:	:	O	O
final	JJ	O	O
results	NNS	O	O
from	IN	O	O
the	DT	O	O
EORTC	NNP	O	O
Cutaneous	NNP	p	PC
Lymphoma	NNP	p	PC
Task	NNP	p	O
Force	NNP	p	O
phase	NN	p	O
III	NNP	p	O
randomized	VBD	p	O
clinical	JJ	p	O
trial	NN	p	O
(	(	O	O
NCT00056056	NNP	O	O
)	)	O	O
.	.	O	O

BACKGROUND	NNP	O	O
Psoralen	NNP	i	IPH
plus	CC	i	IPH
ultraviolet	VB	i	IPH
A	NNP	i	IPH
(	(	i	IPH
PUVA	NNP	i	IPH
)	)	i	IPH
is	VBZ	O	O
the	DT	O	O
standard	JJ	O	O
treatment	NN	O	O
for	IN	O	O
early	JJ	p	O
stages	NNS	p	O
of	IN	p	O
mycosis	NN	p	PC
fungoides	NNS	p	PC
.	.	p	O

There	EX	O	O
have	VBP	O	O
been	VBN	O	O
no	DT	O	O
adequate	JJ	O	O
randomized	VBN	O	O
controlled	JJ	O	O
trials	NNS	O	O
with	IN	O	O
sufficient	JJ	O	O
power	NN	O	O
comparing	VBG	O	O
this	DT	O	O
modality	NN	O	O
with	IN	O	O
other	JJ	O	O
therapies	NNS	O	O
.	.	O	O

OBJECTIVE	NNP	O	O
To	TO	O	O
assess	VB	O	O
disease	NN	o	OPH
response	NN	o	OPH
and	CC	O	O
to	TO	O	O
compare	VB	O	O
the	DT	O	O
response	NN	o	OPH
rates	NNS	o	OPH
of	IN	O	O
patients	NNS	p	O
treated	VBN	p	O
with	IN	p	O
PUVA	NNP	i	IPH
alone	RB	i	IPH
or	CC	p	O
PUVA	NNP	i	IPM
and	CC	i	IPM
bexarotene	NN	i	IPM
.	.	i	O

METHODS	NNP	O	O
EORTC	NNP	O	O
21011	CD	O	O
(	(	O	O
NCT	NNP	O	O
00056056	CD	O	O
)	)	O	O
was	VBD	O	O
a	DT	O	O
randomized	JJ	O	O
phase	NN	O	O
III	NNP	O	O
study	NN	O	O
comparing	VBG	O	O
combined	VBN	i	O
bexarotene	NN	i	O
(	(	i	O
Targretin	NNP	i	O
(	(	i	O
?	.	i	O
)	)	i	O
)	)	i	O
and	CC	i	O
PUVA	NNP	i	O
vs.	FW	i	O
PUVA	NNP	i	O
alone	RB	i	O
in	IN	p	O
patients	NNS	p	O
with	IN	p	O
stage	NN	p	O
IB	NNP	p	O
and	CC	p	O
IIA	NNP	p	O
mycosis	NN	p	O
fungoides	NNS	p	O
(	(	p	O
MF	NNP	p	O
)	)	p	O
.	.	p	O

The	DT	O	O
primary	JJ	O	O
endpoint	NN	O	O
was	VBD	O	O
the	DT	o	O
overall	JJ	o	O
response	NN	o	O
rate	NN	o	O
[	NNP	o	O
complete	JJ	o	O
clinical	JJ	o	O
response	NN	o	O
(	(	o	O
CCR	NNP	o	O
)	)	o	O
plus	CC	o	O
partial	JJ	o	O
response	NN	o	O
(	(	o	O
PR	NNP	o	O
)	)	o	O
]	NN	o	O
.	.	o	O

RESULTS	VB	O	O
The	DT	O	O
study	NN	O	O
was	VBD	O	O
prematurely	RB	O	O
closed	VBN	O	O
due	JJ	O	O
to	TO	O	O
low	JJ	O	O
accrual	JJ	O	O
after	IN	p	O
93	CD	p	O
of	IN	p	O
145	CD	p	O
required	JJ	p	O
patients	NNS	p	O
(	(	O	O
65	CD	O	O
%	NN	O	O
)	)	O	O
were	VBD	O	O
randomized	VBN	O	O
.	.	O	O

Of	IN	O	O
the	DT	p	O
93	CD	p	O
randomized	JJ	p	O
patients	NNS	p	O
,	,	p	O
87	CD	p	O
started	VBD	p	O
treatment	NN	p	O
,	,	p	O
41	CD	p	O
received	VBD	i	O
PUVA	NNP	i	O
and	CC	p	O
46	CD	p	O
received	VBD	i	O
PUVA	NNP	i	O
+	NNP	i	O
bexarotene	NN	i	O
.	.	i	O

Total	JJ	o	O
UVA	NNP	o	O
doses	NNS	o	O
received	VBD	O	O
were	VBD	O	O
107	CD	O	O
J	NNP	O	O
cm	NN	O	O
(	(	O	O
-2	NN	O	O
)	)	O	O
(	(	O	O
range	VB	O	O
1?4-489?9	CD	O	O
)	)	O	O
in	IN	O	O
the	DT	O	O
PUVA	NNP	i	O
arm	NN	i	O
vs.	FW	O	O
101?7	CD	O	O
J	NNP	O	O
cm	NN	O	O
(	(	O	O
-2	NN	O	O
)	)	O	O
(	(	O	O
0?2-529?9	JJ	O	O
)	)	O	O
in	IN	O	O
the	DT	O	O
combination	NN	O	O
arm	NN	O	O
.	.	O	O

The	DT	o	O
safety	NN	o	O
profile	NN	o	O
was	VBD	o	O
acceptable	JJ	o	O
with	IN	O	O
few	JJ	o	O
grade	JJ	o	O
3-4	JJ	o	O
toxicities	NNS	o	O
observed	VBN	o	O
in	IN	O	O
either	DT	O	O
arm	NN	O	O
.	.	O	O

More	JJR	O	O
drop-outs	NNS	o	O
due	JJ	o	O
to	TO	o	O
toxicity	NN	o	O
were	VBD	o	O
observed	VBN	O	O
in	IN	O	O
the	DT	O	O
combination	NN	O	O
arm	NN	O	O
compared	VBN	O	O
with	IN	O	O
the	DT	i	O
PUVA-alone	JJ	i	O
arm	NN	i	O
.	.	i	O

The	DT	O	O
best	JJS	o	O
overall	JJ	o	O
response	NN	o	O
(	(	o	O
CCR	NNP	o	O
+	NNP	o	O
PR	NNP	o	O
)	)	o	O
rate	NN	o	O
was	VBD	O	O
71	CD	O	O
%	NN	O	O
for	IN	i	O
PUVA	NNP	i	O
alone	RB	i	O
and	CC	O	O
77	CD	O	O
%	NN	O	O
for	IN	O	O
the	DT	O	O
combination	NN	O	O
arm	NN	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0?57	CD	O	O
)	)	O	O
.	.	O	O

The	DT	o	O
median	JJ	o	O
duration	NN	o	O
of	IN	o	O
response	NN	o	O
was	VBD	o	O
9?7	CD	o	O
months	NNS	O	O
for	IN	i	O
PUVA	NNP	i	O
vs.	FW	i	O
5?8	CD	O	O
months	NNS	O	O
for	IN	O	O
the	DT	O	O
combination	NN	O	O
arm	NN	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0?33	CD	O	O
)	)	O	O
.	.	O	O

CCR	NNP	o	O
was	VBD	o	O
seen	VBN	O	O
in	IN	O	O
25	CD	O	O
patients	NNS	O	O
of	IN	O	O
whom	WP	O	O
10	CD	O	O
received	VBD	i	O
PUVA	NNP	i	O
alone	RB	i	O
(	(	o	O
CCR	NNP	o	O
22	CD	o	O
%	NN	o	O
)	)	o	O
and	CC	O	O
15	CD	O	O
received	VBN	i	O
combination	NN	o	O
therapy	NN	o	O
(	(	o	O
CCR	NNP	o	O
31	CD	o	O
%	NN	o	O
)	)	o	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0?45	CD	O	O
)	)	O	O
.	.	o	O

CCR	NNP	o	O
was	VBD	o	O
sustained	VBN	o	O
in	IN	O	O
25	CD	O	O
%	NN	O	O
of	IN	O	O
patients	NNS	O	O
regardless	RB	O	O
of	IN	O	O
therapy	NN	O	O
.	.	O	O

There	EX	O	O
was	VBD	O	O
a	DT	O	O
trend	NN	O	O
towards	VBZ	O	O
fewer	JJR	i	O
PUVA	NNP	i	O
sessions	NNS	o	O
needed	VBD	o	O
to	TO	o	O
achieve	VB	o	O
CCR	NNP	o	O
in	IN	o	O
the	DT	o	O
combination	NN	O	O
arm	NN	O	O
(	(	O	O
median	JJ	O	O
22	CD	O	O
)	)	O	O
compared	VBN	O	O
with	IN	i	O
the	DT	i	O
PUVA	NNP	i	O
arm	NN	i	O
(	(	O	O
median	JJ	O	O
27?5	CD	O	O
)	)	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0?11	CD	O	O
)	)	O	O
.	.	O	O

Similarly	RB	O	O
,	,	O	O
a	DT	O	O
trend	NN	O	O
towards	NNS	O	O
lower	JJR	O	O
UVA	NNP	i	O
dose	NN	o	O
required	VBN	o	O
to	TO	o	O
achieve	VB	o	O
CCR	NNP	o	O
in	IN	O	O
the	DT	O	O
combination	NN	O	O
arm	NN	O	O
(	(	O	O
median	JJ	O	O
55?8	CD	O	O
J	NNP	O	O
cm	NN	O	O
(	(	O	O
-2	NNP	O	O
)	)	O	O
)	)	O	O
compared	VBN	O	O
with	IN	O	O
the	DT	i	O
PUVA	NNP	i	O
arm	NN	O	O
alone	RB	O	O
(	(	O	O
median	JJ	O	O
117?5	CD	O	O
J	NNP	O	O
cm	NN	O	O
(	(	O	O
-2	NNP	O	O
)	)	O	O
)	)	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0?5	CD	O	O
)	)	O	O
was	VBD	O	O
observed	VBN	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
No	NNP	O	O
significant	JJ	O	O
difference	NN	o	O
in	IN	o	O
response	NN	o	O
rate	NN	o	O
or	CC	o	O
response	NN	o	O
duration	NN	o	O
was	VBD	o	O
observed	VBN	o	O
in	IN	O	O
this	DT	O	O
study	NN	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
there	EX	O	O
was	VBD	O	O
a	DT	O	O
trend	NN	O	O
towards	VBZ	O	O
fewer	JJR	o	O
PUVA	NNP	o	O
sessions	NNS	o	O
and	CC	o	O
lower	JJR	o	O
UVA	NNP	o	O
dose	NN	o	O
required	VBN	o	O
to	TO	o	O
achieve	VB	o	O
CCR	NNP	o	O
in	IN	O	O
the	DT	O	O
combination	NN	O	O
arm	NN	O	O
(	(	i	O
PUVA	NNP	i	O
+	NNP	i	O
bexarotene	NN	i	O
)	)	i	O
but	CC	i	O
this	DT	O	O
did	VBD	O	O
not	RB	O	O
achieve	VB	O	O
statistical	JJ	O	O
significance	NN	O	O
due	JJ	O	O
to	TO	O	O
insufficient	JJ	O	O
power	NN	O	O
.	.	O	O

The	DT	O	O
effect	NN	O	O
of	IN	O	O
random	JJ	i	IPH
modulation	NN	i	IPH
of	IN	i	IPH
functional	JJ	i	IPH
electrical	JJ	i	IPH
stimulation	NN	i	IPH
parameters	NNS	i	IPH
on	IN	O	O
muscle	NN	p	PC
fatigue	NN	p	PC
.	.	p	O

Muscle	NNP	O	O
contractions	NNS	O	O
induced	VBN	O	O
by	IN	O	O
functional	JJ	i	IPH
electrical	JJ	i	IPH
stimulation	NN	i	IPH
(	(	O	O
FES	NNP	O	O
)	)	O	O
tend	VBP	O	O
to	TO	O	O
result	VB	O	O
in	IN	O	O
rapid	JJ	o	OPH
muscle	NN	o	OPH
fatigue	NN	o	OPH
,	,	O	O
which	WDT	O	O
greatly	RB	O	O
limits	VBZ	O	O
activities	NNS	O	O
such	JJ	O	O
as	IN	O	O
FES-assisted	JJ	O	O
standing	NN	O	O
and	CC	O	O
walking	NN	O	O
.	.	O	O

It	PRP	O	O
was	VBD	O	O
hypothesized	VBN	O	O
that	IN	O	O
muscle	NN	o	OPH
fatigue	NN	o	OPH
caused	VBN	O	O
by	IN	O	O
FES	NNP	O	O
could	MD	O	O
be	VB	O	O
reduced	VBN	O	O
by	IN	O	O
randomly	RB	O	O
modulating	VBG	O	O
parameters	NNS	O	O
of	IN	O	O
the	DT	O	O
electrical	JJ	O	O
stimulus	NN	O	O
.	.	O	O

Seven	NNP	p	PSS
paraplegic	JJ	p	O
subjects	NNS	p	O
participated	VBN	p	O
in	IN	O	O
this	DT	O	O
study	NN	O	O
.	.	O	O

While	IN	O	O
subjects	NNS	O	O
were	VBD	O	O
seated	VBN	O	O
,	,	O	O
FES	NNP	O	O
was	VBD	O	O
applied	VBN	O	O
to	TO	O	O
quadriceps	NNS	O	O
and	CC	O	O
tibialis	JJ	O	O
anterior	JJ	O	O
muscles	NNS	O	O
bilaterally	RB	O	O
using	VBG	O	O
surface	NN	O	O
electrodes	NNS	O	O
.	.	O	O

The	DT	O	O
isometric	JJ	o	OPH
force	NN	o	OPH
was	VBD	O	O
measured	VBN	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
time	NN	O	O
for	IN	O	O
the	DT	O	O
force	NN	O	O
to	TO	O	O
drop	VB	O	O
by	IN	O	O
3	CD	O	O
dB	NN	O	O
(	(	O	O
fatigue	JJ	O	O
time	NN	O	O
)	)	O	O
and	CC	O	O
the	DT	O	O
normalized	JJ	O	O
force-time	JJ	o	OPH
integral	JJ	o	OPH
(	(	o	OPH
FTI	NNP	o	OPH
)	)	o	OPH
were	VBD	O	O
determined	VBN	O	O
.	.	O	O

Four	CD	O	O
different	JJ	O	O
modes	NNS	O	O
of	IN	O	O
FES	NNP	O	O
were	VBD	O	O
applied	VBN	O	O
in	IN	O	O
random	JJ	O	O
order	NN	O	O
:	:	O	O
constant	JJ	O	O
stimulation	NN	O	O
,	,	O	O
randomized	VBN	O	O
frequency	NN	O	O
(	(	O	O
mean	JJ	O	O
40	CD	O	O
Hz	NNP	O	O
)	)	O	O
,	,	O	O
randomized	VBN	O	O
current	JJ	O	O
amplitude	NN	O	O
,	,	O	O
and	CC	O	O
randomized	VBD	O	O
pulsewidth	NN	O	O
(	(	O	O
mean	JJ	O	O
250	CD	O	O
micros	NN	O	O
)	)	O	O
.	.	O	O

In	IN	O	O
randomized	JJ	O	O
trials	NNS	O	O
,	,	O	O
stimulation	NN	O	O
parameters	NNS	O	O
were	VBD	O	O
stochastically	RB	O	O
modulated	VBN	O	O
every	DT	O	O
100	CD	O	O
ms	NN	O	O
in	IN	O	O
a	DT	O	O
range	NN	O	O
of	IN	O	O
+/-15	NNP	O	O
%	NN	O	O
using	VBG	O	O
a	DT	O	O
uniform	JJ	O	O
probability	NN	O	O
distribution	NN	O	O
.	.	O	O

There	EX	O	O
was	VBD	O	O
no	DT	O	O
significant	JJ	O	O
difference	NN	O	O
between	IN	O	O
the	DT	O	O
fatigue	NN	o	OPH
time	NN	o	OPH
measurements	NNS	o	OPH
for	IN	O	O
the	DT	O	O
four	CD	O	O
modes	NNS	O	O
of	IN	O	O
stimulation	NN	O	O
.	.	O	O

There	EX	O	O
was	VBD	O	O
also	RB	O	O
no	DT	O	O
significant	JJ	O	O
difference	NN	O	O
in	IN	O	O
the	DT	O	O
FTI	NNP	o	OPH
measurements	NNS	o	OPH
.	.	o	O

Therefore	RB	O	O
,	,	O	O
our	PRP$	O	O
particular	JJ	O	O
method	NN	O	O
of	IN	O	O
stochastic	JJ	O	O
modulation	NN	O	O
of	IN	O	O
the	DT	O	O
stimulation	NN	O	O
parameters	NNS	O	O
,	,	O	O
which	WDT	O	O
involved	VBD	O	O
moderate	JJ	O	O
(	(	O	O
15	CD	O	O
%	NN	O	O
)	)	O	O
variations	NNS	O	O
updated	VBN	O	O
every	DT	O	O
100	CD	O	O
ms	NN	O	O
and	CC	O	O
centered	VBD	O	O
around	IN	O	O
40	CD	O	O
Hz	NNP	O	O
,	,	O	O
appeared	VBD	O	O
to	TO	O	O
have	VB	O	O
no	DT	O	O
effect	NN	O	O
on	IN	O	O
muscle	NN	o	OPH
fatigue	NN	o	OPH
.	.	o	O

There	EX	O	O
was	VBD	O	O
a	DT	O	O
strong	JJ	O	O
correlation	NN	O	O
between	IN	O	O
maximum	JJ	O	O
force	NN	O	O
measurements	NNS	O	O
and	CC	O	O
stimulation	NN	O	O
order	NN	O	O
,	,	O	O
which	WDT	O	O
was	VBD	O	O
not	RB	O	O
apparent	JJ	O	O
in	IN	O	O
the	DT	O	O
fatigue	JJ	o	OPH
time	NN	o	OPH
or	CC	o	O
FTI	NNP	o	OPH
measurements	NNS	o	OPH
.	.	o	O

It	PRP	O	O
was	VBD	O	O
concluded	VBN	O	O
that	IN	O	O
a	DT	O	O
10-min	JJ	O	O
rest	NN	O	O
period	NN	O	O
between	IN	O	O
stimulation	NN	O	O
trials	NNS	O	O
was	VBD	O	O
insufficient	JJ	O	O
to	TO	O	O
allow	VB	O	O
full	JJ	O	O
recovery	NN	o	OPH
of	IN	o	OPH
muscle	NN	o	OPH
strength	NN	o	OPH
.	.	o	O

The	DT	O	O
evaluation	NN	O	O
of	IN	O	O
pulmonary	JJ	O	O
hypertension	NN	O	O
using	VBG	O	O
right	JJ	i	IPH
ventricular	JJ	i	IPH
myocardial	JJ	i	IPH
isovolumic	JJ	i	IPH
relaxation	NN	i	IPH
time	NN	i	IPH
.	.	i	O

Right	JJ	O	O
ventricular	NN	O	O
(	(	O	O
RV	NNP	O	O
)	)	O	O
blood	VBD	O	O
pool-derived	JJ	O	O
isovolumic	JJ	O	O
relaxation	NN	O	O
time	NN	O	O
(	(	O	O
IVRT	NNP	O	O
)	)	O	O
correlates	VBZ	O	O
well	RB	O	O
with	IN	O	O
systolic	JJ	O	O
pulmonary	JJ	O	O
arterial	JJ	O	O
pressure	NN	O	O
(	(	O	O
PAP	NNP	O	O
)	)	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
because	IN	O	O
of	IN	O	O
complex	JJ	O	O
parameter	NN	O	O
derivation	NN	O	O
,	,	O	O
the	DT	O	O
method	NN	O	O
is	VBZ	O	O
rarely	RB	O	O
used	VBN	O	O
.	.	O	O

The	DT	O	O
aim	NN	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
validate	VB	O	O
the	DT	O	O
measurement	NN	O	O
of	IN	O	O
myocardial	JJ	O	O
velocity	NN	O	O
imaging-derived	JJ	O	O
RV	NNP	i	IPH
IVRT	NNP	i	IPH
(	(	i	IPH
IVRT	NNP	i	IPH
'	POS	i	IPH
)	)	i	IPH
against	IN	O	O
invasively	RB	i	IS
measured	VBN	i	IS
PAP	NNP	i	IS
.	.	i	IS

Transthoracic	NNP	i	IPH
echocardiography	NN	i	IPH
with	IN	i	IPH
myocardial	JJ	i	IPH
velocity	NN	i	IPH
imaging	NN	i	IPH
and	CC	i	IPH
right	JJ	i	IS
heart	NN	i	IS
catheterization	NN	i	IS
were	VBD	O	O
performed	VBN	O	O
in	IN	O	O
33	CD	p	PSS
patients	NNS	p	O
with	IN	p	O
pulmonary	JJ	p	PC
hypertension	NN	p	PC
.	.	p	O

Blood	NNP	o	OPH
pool	NN	o	OPH
IVRT	NNP	o	OPH
and	CC	o	OPH
myocardial	JJ	o	OPH
IVRTs	NNP	o	OPH
for	IN	o	OPH
the	DT	o	OPH
tricuspid	JJ	o	OPH
valve	NN	o	OPH
annulus	NN	o	OPH
ring	NN	o	OPH
,	,	o	OPH
basal	NN	o	OPH
and	CC	o	OPH
apical	JJ	o	OPH
RV	NNP	o	OPH
free	JJ	o	OPH
wall	NN	o	OPH
segments	NNS	o	OPH
were	VBD	O	O
measured	VBN	O	O
and	CC	O	O
compared	VBN	O	O
with	IN	O	O
data	NNS	O	O
from	IN	O	O
33	CD	p	PSS
age-	JJ	p	O
and	CC	p	O
sex-matched	JJ	p	O
control	NN	p	O
subjects	NNS	p	O
.	.	p	O

Measured	VBN	o	OPH
IVRTs	NNP	o	OPH
were	VBD	O	O
significantly	RB	o	O
longer	RBR	o	O
in	IN	O	O
patients	NNS	O	O
with	IN	O	O
pulmonary	JJ	O	O
hypertension	NN	O	O
than	IN	O	O
in	IN	O	O
control	NN	O	O
subjects	NNS	O	O
.	.	O	O

The	DT	O	O
strongest	JJS	O	O
correlation	NN	O	O
(	(	O	O
R	NNP	O	O
=	NNP	O	O
0.74	CD	O	O
,	,	O	O
P	NNP	O	O
<	NNP	O	O
.0001	NNP	O	O
)	)	O	O
was	VBD	O	O
found	VBN	O	O
between	IN	O	O
systolic	JJ	o	OPH
PAP	NNP	o	OPH
and	CC	o	OPH
the	DT	o	OPH
heart	NN	o	OPH
rate-corrected	JJ	o	OPH
IVRT	NNP	o	OPH
'	POS	o	OPH
derived	VBN	O	O
from	IN	O	O
the	DT	O	O
basal	NN	O	O
RV	NNP	O	O
free	JJ	O	O
wall	NN	O	O
segment	NN	O	O
.	.	O	O

The	DT	O	O
basal	NN	o	OPH
segment	NN	o	OPH
IVRT	NNP	o	OPH
'	POS	o	OPH
corrected	VBN	O	O
for	IN	O	O
heart	NN	o	OPH
rate	NN	o	OPH
correlates	NNS	O	O
well	RB	O	O
with	IN	O	O
the	DT	O	O
invasive	JJ	O	O
PAP	NNP	O	O
measurement	NN	O	O
and	CC	O	O
,	,	O	O
therefore	RB	O	O
,	,	O	O
can	MD	O	O
be	VB	O	O
used	VBN	O	O
to	TO	O	O
predict	VB	O	O
systolic	JJ	o	OPH
PAP	NNP	o	OPH
.	.	o	O

It	PRP	O	O
can	MD	O	O
even	RB	O	O
be	VB	O	O
considered	VBN	O	O
as	IN	O	O
an	DT	O	O
alternative	NN	O	O
to	TO	O	O
tricuspid	VB	O	O
regurgitation-derived	JJ	O	O
PAP	NNP	O	O
systolic	NN	O	O
when	WRB	O	O
tricuspid	JJ	O	O
regurgitation	NN	O	O
is	VBZ	O	O
nonrecordable	JJ	O	O
.	.	O	O

A	DT	O	O
proposed	VBN	O	O
method	NN	O	O
to	TO	O	O
derive	VB	O	O
systolic	JJ	O	O
PAP	NNP	O	O
should	MD	O	O
be	VB	O	O
used	VBN	O	O
while	IN	O	O
screening	VBG	O	O
the	DT	O	O
patients	NNS	O	O
at	IN	O	O
risk	NN	O	O
for	IN	O	O
pulmonary	JJ	O	O
hypertension	NN	O	O
,	,	O	O
monitoring	VBG	O	O
the	DT	O	O
disease	NN	O	O
progression	NN	O	O
and	CC	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
treatment	NN	O	O
.	.	O	O

Treatment	NN	O	O
of	IN	O	O
vasculogenic	JJ	p	PC
sexual	JJ	p	PC
dysfunction	NN	p	PC
with	IN	O	O
pentoxifylline	NN	i	IPM
.	.	i	IPM

OBJECTIVE	UH	O	O
To	TO	O	O
evaluate	VB	O	O
the	DT	O	O
use	NN	O	O
of	IN	O	O
pentoxifylline	NN	i	IPM
to	TO	O	O
treat	VB	O	O
impotence	NN	O	O
in	IN	O	O
men	NNS	p	O
with	IN	p	O
mild	NN	p	O
to	TO	p	O
moderate	VB	p	O
penile	IN	p	O
vascular	JJ	p	O
insufficiency	NN	p	O
.	.	p	O

DESIGN	NNP	O	O
Double-blind	NNP	O	O
randomized	VBD	O	O
clinical	JJ	O	O
trial	NN	O	O
.	.	O	O

SETTING	NN	O	O
Sexual	JJ	p	O
Dysfunction	NNP	p	O
Clinic	NNP	p	O
at	IN	p	O
VA	NNP	p	O
Medical	NNP	p	O
Center	NNP	p	O
,	,	p	O
Sepulveda	NNP	p	O
,	,	p	O
CA	NNP	p	O
.	.	p	O

PARTICIPANTS	NNP	O	O
Convenience	NNP	p	O
sample	NN	p	O
of	IN	p	O
couples	NNS	p	O
.	.	p	O

INTERVENTION	NNP	O	O
Twelve	NNP	O	O
weeks	NNS	O	O
of	IN	O	O
treatment	NN	O	O
with	IN	O	O
placebo	NN	i	IC
or	CC	i	O
400	CD	i	IPM
mg	JJ	i	IPM
tid	NN	i	IPM
of	IN	i	IPM
pentoxifylline	NN	i	IPM
.	.	i	O

MEASUREMENTS	NNP	O	O
(	(	O	O
1	CD	O	O
)	)	O	O
Report	NN	o	OME
of	IN	o	OME
patient	JJ	o	OME
verified	VBN	o	OME
by	IN	o	OME
partner	NN	o	OME
as	IN	o	OME
to	TO	o	OME
number	NN	o	OME
of	IN	o	OME
coital	JJ	o	OME
episodes	NNS	o	OME
per	IN	o	OME
month	NN	o	OME
;	:	o	O
(	(	O	O
2	CD	O	O
)	)	O	O
penile-brachial	JJ	o	OPH
pressure	NN	o	OPH
index	NN	o	OPH
determinations	NNS	o	OPH
.	.	o	O

RESULTS	NNP	O	O
Pentoxifylline	NNP	i	IPM
therapy	VBZ	i	IPM
regularly	RB	O	O
increased	VBN	O	O
the	DT	O	O
PBPI	NNP	o	OME
in	IN	O	O
impotent	JJ	p	O
men	NNS	p	O
in	IN	O	O
comparison	NN	O	O
with	IN	O	O
the	DT	O	O
placebo	NN	O	O
,	,	O	O
frequently	RB	O	O
into	IN	O	O
the	DT	O	O
normal	JJ	O	O
range	NN	O	O
.	.	O	O

Pentoxifylline	NNP	O	O
therapy	NN	O	O
was	VBD	O	O
particularly	RB	O	O
useful	JJ	O	O
in	IN	O	O
restoring	VBG	o	OME
the	DT	o	OME
PBPI	NNP	o	OME
in	IN	O	O
men	NNS	p	O
with	IN	p	O
the	DT	p	O
pelvic	JJ	p	O
steal	JJ	p	O
syndrome	NN	p	O
;	:	p	O
six	CD	O	O
of	IN	O	O
seven	CD	O	O
such	JJ	O	O
subjects	NNS	O	O
improved	VBN	O	O
into	IN	O	O
the	DT	O	O
normal	JJ	O	O
range	NN	O	O
.	.	O	O

During	IN	O	O
the	DT	O	O
pentoxifylline	JJ	O	O
treatment	NN	O	O
period	NN	O	O
,	,	O	O
in	IN	O	O
contrast	NN	O	O
with	IN	O	O
the	DT	O	O
control	NN	O	O
period	NN	O	O
,	,	O	O
nine	CD	O	O
men	NNS	O	O
were	VBD	O	O
able	JJ	O	O
to	TO	O	O
reestablish	VB	o	OME
coital	JJ	o	OME
function	NN	o	OME
and	CC	O	O
three	CD	O	O
had	VBD	O	O
no	DT	O	O
improvement	NN	O	O
.	.	O	O

Six	NNP	O	O
couples	NNS	O	O
did	VBD	O	O
not	RB	O	O
attempt	VB	o	OME
intercourse	JJ	o	OME
despite	IN	O	O
a	DT	O	O
professed	JJ	O	O
interest	NN	O	O
in	IN	O	O
sexual	JJ	o	OME
activity	NN	o	OME
;	:	o	O
however	RB	O	O
five	CD	O	O
out	IN	O	O
of	IN	O	O
the	DT	O	O
six	CD	O	O
men	NNS	O	O
experienced	VBD	O	O
erections	NNS	o	OME
during	IN	o	OME
episodes	NNS	o	OME
of	IN	o	OME
fantasy	NN	o	OME
or	CC	o	OME
attempts	NNS	o	OME
at	IN	o	OME
masturbation	NN	o	OME
during	IN	O	O
treatment	NN	O	O
.	.	O	O

There	EX	O	O
were	VBD	O	O
no	DT	O	O
complications	NNS	o	OA
of	IN	O	O
therapy	NN	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
These	DT	O	O
promising	VBG	O	O
preliminary	JJ	O	O
results	NNS	O	O
suggest	VBP	O	O
a	DT	O	O
well	RB	O	O
tolerated	JJ	O	O
alternative	JJ	O	O
therapy	NN	O	O
for	IN	O	O
erectile	JJ	p	O
dysfunction	NN	p	O
in	IN	p	O
patients	NNS	p	O
with	IN	p	O
mild	JJ	p	O
to	TO	p	O
moderate	VB	p	O
penile	IN	p	O
vascular	JJ	p	O
disease	NN	p	O
.	.	p	O

Removal	NN	O	O
of	IN	O	O
inflammatory	JJ	O	O
cytokines	NNS	O	O
and	CC	O	O
endotoxin	NN	O	O
by	IN	O	O
veno-venous	JJ	i	IPH
continuous	JJ	i	IPH
renal	JJ	i	IPH
replacement	NN	i	IPH
therapy	NN	i	IPH
for	IN	O	O
burned	JJ	p	PC
patients	NNS	p	PC
with	IN	p	O
sepsis	NN	p	PC
.	.	p	O

OBJECTIVE	UH	O	O
To	TO	O	O
evaluate	VB	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
veno-venous	JJ	i	IPH
continuous	JJ	i	IPH
renal	JJ	i	IPH
replacement	NN	i	IPH
therapy	NN	i	IPH
(	(	i	IPH
CRRT	NNP	i	IPH
)	)	i	IPH
on	IN	O	O
the	DT	O	O
plasma	NN	O	O
levels	NNS	O	O
of	IN	O	O
endotoxin	NN	O	O
and	CC	O	O
cytokines	NNS	O	O
in	IN	O	O
severely	RB	p	PC
burned	VBN	p	PC
patients	NNS	p	PC
with	IN	p	O
sepsis	NN	p	PC
.	.	p	O

METHODS	NNP	O	O
Twenty	NNP	p	PSS
adult	NN	p	O
severely	RB	p	PC
burned	VBD	p	PC
patients	NNS	p	PC
with	IN	p	PC
sepsis	NN	p	PC
were	VBD	p	O
studied	VBN	p	O
.	.	p	O

For	IN	O	O
the	DT	O	O
diagnosis	NN	O	O
of	IN	O	O
sepsis	NN	O	O
,	,	O	O
patients	NNS	O	O
were	VBD	O	O
randomly	RB	O	O
divided	VBN	O	O
into	IN	O	O
CRRT	NNP	i	IPH
(	(	O	O
n=10	NN	O	O
)	)	O	O
and	CC	O	O
Control	NNP	i	IC
(	(	O	O
n=10	RB	O	O
)	)	O	O
.	.	O	O

Both	DT	O	O
groups	NNS	O	O
received	VBD	O	O
conventional	JJ	i	IPH
therapy	NN	i	IPH
after	IN	O	O
admission	NN	O	O
.	.	O	O

Veno-venous	JJ	i	IPH
CRRT	NNP	i	IPH
was	VBD	O	O
administered	VBN	O	O
to	TO	O	O
10	CD	O	O
patients	NNS	O	O
in	IN	O	O
the	DT	O	O
CRRT	NNP	O	O
group	NN	O	O
whenever	WDT	O	O
patients	NNS	O	O
were	VBD	O	O
determined	VBN	O	O
to	TO	O	O
be	VB	O	O
septic	JJ	O	O
.	.	O	O

The	DT	O	O
plasma	JJ	O	O
level	NN	O	O
of	IN	O	O
endotoxin	NN	O	O
,	,	O	O
TNF-alpha	NNP	O	O
,	,	O	O
IL-1	NNP	O	O
beta	NN	O	O
,	,	O	O
IL-6	NNP	O	O
and	CC	O	O
IL-8	NNP	O	O
were	VBD	O	O
measured	VBN	O	O
at	IN	O	O
0	CD	O	O
,	,	O	O
1	CD	O	O
,	,	O	O
2	CD	O	O
,	,	O	O
6	CD	O	O
,	,	O	O
12	CD	O	O
,	,	O	O
36	CD	O	O
and	CC	O	O
60	CD	O	O
h	NN	O	O
after	IN	O	O
CRRT	NNP	O	O
initiation	NN	O	O
,	,	O	O
and	CC	O	O
at	IN	O	O
0	CD	O	O
,	,	O	O
12	CD	O	O
,	,	O	O
36	CD	O	O
and	CC	O	O
60	CD	O	O
h	NN	O	O
after	IN	O	O
the	DT	O	O
patients	NNS	O	O
were	VBD	O	O
diagnosed	VBN	O	O
as	IN	O	O
having	VBG	O	O
sepsis	NN	O	O
in	IN	O	O
the	DT	O	O
Control	NNP	O	O
group	NN	O	O
.	.	O	O

MAIN	NNP	O	O
RESULTS	NNP	O	O
Plasma	NNP	o	OPH
level	NN	o	OPH
of	IN	o	OPH
endotoxin	NN	o	OPH
and	CC	o	O
all	PDT	o	OPH
the	DT	o	OPH
cytokines	NNS	o	OPH
after	IN	o	OPH
CRRT	NNP	o	OPH
initiation	NN	o	OPH
were	VBD	O	O
significantly	RB	O	O
lower	JJR	O	O
than	IN	O	O
those	DT	O	O
before	IN	O	O
the	DT	O	O
treatment	NN	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.01	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
serial	JJ	o	OPH
change	NN	o	OPH
of	IN	o	OPH
endotoxin	NN	o	OPH
,	,	o	OPH
IL-1	NNP	o	OPH
beta	NN	o	OPH
,	,	o	OPH
IL-6	NNP	o	OPH
and	CC	o	OPH
IL-8	NNP	o	OPH
was	VBD	O	O
significantly	RB	O	O
lower	JJR	O	O
at	IN	O	O
12	CD	O	O
,	,	O	O
36	CD	O	O
and	CC	O	O
60	CD	O	O
h	NN	O	O
after	IN	O	O
treatment	NN	O	O
compared	VBN	O	O
with	IN	O	O
Control	NNP	O	O
groups	NNS	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.01	CD	O	O
)	)	O	O
.	.	O	O

A	DT	O	O
significant	JJ	O	O
decrease	NN	O	O
in	IN	O	O
plasma	JJ	o	OPH
TNF-alpha	JJ	o	OPH
levels	NNS	o	OPH
was	VBD	O	O
seen	VBN	O	O
at	IN	O	O
36	CD	O	O
and	CC	O	O
60	CD	O	O
h	NN	O	O
after	IN	O	O
treatment	NN	O	O
compared	VBN	O	O
with	IN	O	O
Control	NNP	O	O
groups	NNS	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.01	CD	O	O
)	)	O	O
.	.	O	O

CONCLUSION	NNP	O	O
Plasma	NNP	O	O
endotoxin	NN	O	O
and	CC	O	O
cytokines	NNS	O	O
(	(	O	O
TNF-alpha	NNP	O	O
,	,	O	O
IL-1	NNP	O	O
beta	NN	O	O
,	,	O	O
IL-6	NNP	O	O
and	CC	O	O
IL-8	NNP	O	O
)	)	O	O
can	MD	O	O
be	VB	O	O
removed	VBN	O	O
effectively	RB	O	O
with	IN	O	O
CRRT	NNP	i	O
in	IN	O	O
severely	RB	O	O
burned	VBN	O	O
patients	NNS	O	O
with	IN	O	O
sepsis	NN	O	O
.	.	O	O

Predictors	NNS	O	O
of	IN	O	O
survival	NN	O	O
and	CC	O	O
eradication	NN	O	O
of	IN	O	O
Mycobacterium	NNP	O	O
avium	NN	O	O
complex	NN	O	O
bacteremia	NN	O	O
(	(	O	O
MAC	NNP	O	O
)	)	O	O
in	IN	p	O
AIDS	NNP	p	PC
patients	NNS	p	O
in	IN	p	O
the	DT	p	O
Canadian	NNP	p	O
randomized	VBD	p	O
MAC	NNP	p	O
treatment	NN	p	O
trial	NN	p	O
.	.	p	O

Canadian	JJ	O	O
HIV	NNP	O	O
Trials	NNP	O	O
Network	NNP	O	O
Protocol	NNP	O	O
010	CD	O	O
Study	NNP	O	O
Group	NNP	O	O
.	.	O	O

OBJECTIVE	NNP	O	O
To	TO	O	O
assess	VB	O	O
the	DT	O	O
importance	NN	O	O
of	IN	O	O
baseline	NN	O	O
characteristics	NNS	O	O
including	VBG	O	O
medical	JJ	o	OPH
history	NN	o	OPH
,	,	o	O
indicators	NNS	o	OPH
of	IN	o	OPH
current	JJ	o	OPH
disease	NN	o	OPH
status	NN	o	OPH
,	,	o	O
therapeutic	JJ	o	OPH
drug	NN	o	OPH
use	NN	o	OPH
,	,	o	O
in	IN	o	OPH
vitro	JJ	o	OPH
drug	NN	o	OPH
susceptibility	NN	o	OPH
,	,	o	O
immune	JJ	o	OPH
status	NN	o	OPH
and	CC	o	O
mycobacterial	JJ	o	OPH
load	NN	o	OPH
on	IN	o	O
bacteriologic	JJ	o	OPH
response	NN	o	OPH
and	CC	O	O
survival	NN	o	OMO
in	IN	O	O
HIV-positive	JJ	p	PC
patients	NNS	p	O
with	IN	p	O
Mycobacterium	NNP	p	PC
avium	NN	p	PC
complex	NN	p	PC
(	(	p	PC
MAC	NNP	p	PC
)	)	p	PC
bacteremia	NN	p	PC
.	.	p	O

DESIGN	NNP	O	O
An	DT	O	O
observational	JJ	O	O
substudy	NN	O	O
of	IN	O	O
an	DT	O	O
open-label	JJ	O	O
randomized	NN	O	O
controlled	VBD	O	O
trial	NN	O	O
of	IN	O	O
two	CD	i	O
alternative	JJ	i	O
therapeutic	JJ	i	IPM
regimens	NNS	i	IPM
for	IN	i	O
MAC	NNP	i	O
.	.	i	O

SETTING	NNP	O	O
Twenty-four	JJ	p	PSS
hospital-based	JJ	p	O
HIV	NNP	p	O
clinics	NNS	p	O
in	IN	p	O
16	CD	p	O
Canadian	JJ	p	O
cities	NNS	p	O
.	.	p	O

MAIN	NNP	O	O
OUTCOME	NNP	O	O
MEASURES	NNP	O	O
The	DT	O	O
main	JJ	O	O
outcome	NN	O	O
measures	NNS	O	O
were	VBD	O	O
survival	JJ	o	OMO
and	CC	o	OPH
bacteriologic	JJ	o	OPH
response	NN	o	OPH
,	,	o	O
defined	VBN	o	OPH
by	IN	o	OPH
consecutive	JJ	o	OPH
negative	JJ	o	OPH
blood	NN	o	OPH
cultures	NNS	o	OPH
for	IN	o	OPH
MAC	NNP	o	OPH
at	IN	O	O
least	JJS	O	O
2	CD	O	O
weeks	NNS	O	O
apart	RB	O	O
within	IN	O	O
16	CD	O	O
weeks	NNS	O	O
of	IN	O	O
study	NN	O	O
entry	NN	O	O
.	.	O	O

RESULTS	NNP	O	O
Prior	NNP	O	O
AIDS	NNP	O	O
diagnosis	NN	O	O
,	,	O	O
low	JJ	O	O
Karnofsky	NNP	O	O
score	NN	O	O
,	,	O	O
active	JJ	O	O
unstable	JJ	O	O
AIDS-related	JJ	O	O
conditions	NNS	O	O
,	,	O	O
absence	NN	O	O
of	IN	O	O
antiretroviral	JJ	O	O
therapy	NN	O	O
and	CC	O	O
absence	NN	O	O
of	IN	O	O
Pneumocystis	NNP	O	O
carinii	NN	O	O
pneumonia	NN	O	O
prophylaxis	NN	O	O
were	VBD	O	O
associated	VBN	O	O
with	IN	O	O
shorter	JJR	O	O
survival	NN	o	OMO
by	IN	O	O
univariate	JJ	O	O
regression	NN	O	O
using	VBG	O	O
the	DT	O	O
proportional	JJ	O	O
hazards	NNS	O	O
model	NN	O	O
.	.	O	O

On	IN	O	O
multivariate	NN	O	O
analysis	NN	O	O
,	,	O	O
antiretroviral	JJ	O	O
therapy	NN	O	O
was	VBD	O	O
not	RB	O	O
an	DT	O	O
independent	JJ	O	O
predictor	NN	O	O
of	IN	O	O
mortality	NN	o	OMO
,	,	O	O
and	CC	O	O
previous	JJ	O	O
rifabutin	NN	O	O
prophylaxis	NN	O	O
was	VBD	O	O
independently	RB	O	O
associated	VBN	O	O
with	IN	O	O
poor	JJ	O	O
survival	NN	O	O
outcomes	NNS	O	O
,	,	O	O
a	DT	O	O
result	NN	O	O
consistent	JJ	O	O
across	IN	O	O
study	NN	O	O
treatment	NN	O	O
.	.	O	O

Using	VBG	O	O
a	DT	O	O
logistic	JJ	O	O
regression	NN	O	O
model	NN	O	O
,	,	O	O
baseline	JJ	o	OPH
quantitative	JJ	o	OPH
mycobacterial	JJ	o	OPH
load	NN	o	OPH
[	NNP	O	O
relative	JJ	O	O
odds	NNS	O	O
of	IN	O	O
clearing	NN	O	O
,	,	O	O
1.97	CD	O	O
for	IN	O	O
a	DT	O	O
decrease	NN	O	O
of	IN	O	O
1	CD	O	O
log10	JJ	O	O
colony	NN	O	O
forming	VBG	O	O
count	NN	O	O
;	:	O	O
95	CD	O	O
%	NN	O	O
confidence	NN	O	O
interval	NN	O	O
(	(	O	O
CI	NNP	O	O
)	)	O	O
,	,	O	O
1.36-2.87	JJ	O	O
;	:	O	O
P	NNP	O	O
<	VBD	O	O
0.001	CD	O	O
]	NN	O	O
and	CC	O	O
Karnofsky	NNP	o	OPH
score	NN	o	OPH
were	VBD	O	O
the	DT	O	O
only	JJ	O	O
statistically	RB	O	O
significant	JJ	O	O
univariate	JJ	O	O
predictors	NNS	O	O
of	IN	O	O
clearance	NN	O	O
,	,	O	O
although	IN	O	O
previous	JJ	O	O
prophylaxis	NN	O	O
with	IN	O	O
rifabutin	NN	O	O
was	VBD	O	O
also	RB	O	O
a	DT	O	O
significant	JJ	O	O
predictor	NN	O	O
in	IN	O	O
a	DT	O	O
multivariate	NN	o	O
model	NN	o	O
(	(	O	O
relative	JJ	O	O
odds	NNS	O	O
of	IN	O	O
clearing	NN	O	O
,	,	O	O
0.39	CD	O	O
;	:	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
,	,	O	O
0.17-0.88	NNP	O	O
;	:	O	O
P	NNP	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

CONCLUSIONS	VB	O	O
This	DT	O	O
study	NN	O	O
indicates	VBZ	O	O
that	IN	O	O
although	IN	O	O
the	DT	O	O
level	NN	O	O
of	IN	O	O
MAC	NNP	O	O
bacteremia	NN	O	O
is	VBZ	O	O
an	DT	O	O
important	JJ	O	O
predictor	NN	O	O
of	IN	O	O
clearance	NN	O	O
,	,	O	O
it	PRP	O	O
is	VBZ	O	O
not	RB	O	O
associated	VBN	O	O
with	IN	O	O
survival	NN	O	O
.	.	O	O

The	DT	O	O
effect	NN	O	O
of	IN	O	O
the	DT	O	O
PostureJac	NNP	i	IPH
on	IN	O	O
deep	JJ	o	OPH
cervical	JJ	o	OPH
flexor	NN	o	OPH
endurance	NN	o	OPH
:	:	o	OPH
implications	NNS	O	O
in	IN	O	O
the	DT	O	O
management	NN	O	O
of	IN	O	O
cervicogenic	JJ	o	OPH
headache	NN	o	OPH
and	CC	O	O
mechanical	JJ	o	OPH
neck	NN	o	OPH
pain	NN	o	OPH
.	.	o	O

The	DT	O	O
convergence	NN	O	O
of	IN	O	O
cervical	JJ	O	O
and	CC	O	O
trigeminal	JJ	O	O
afferents	NNS	O	O
on	IN	O	O
second-order	JJ	O	O
neurons	NNS	O	O
in	IN	O	O
the	DT	O	O
trigeminocervical	JJ	O	O
nucleus	NN	O	O
may	MD	O	O
refer	VB	O	O
pain	NN	O	O
from	IN	O	O
the	DT	O	O
upper	JJ	O	O
cervical	JJ	O	O
spine	NN	O	O
into	IN	O	O
the	DT	O	O
head	NN	O	O
and	CC	O	O
face	NN	O	O
.	.	O	O

Furthermore	RB	O	O
,	,	O	O
bi-directional	JJ	O	O
interactions	NNS	O	O
between	IN	O	O
trigeminal	JJ	O	O
and	CC	O	O
upper	JJ	O	O
cervical	JJ	O	O
afferents	NNS	O	O
may	MD	O	O
also	RB	O	O
explain	VB	O	O
neck	NN	O	O
symptoms	NNS	O	O
of	IN	O	O
trigeminal	JJ	O	O
origin	NN	O	O
(	(	O	O
e.g.	JJ	O	O
,	,	O	O
migraine	NN	O	O
)	)	O	O
.	.	O	O

It	PRP	O	O
is	VBZ	O	O
known	VBN	O	O
that	IN	O	O
cervicogenic	JJ	O	O
headache	NN	O	O
sufferers	NNS	O	O
present	JJ	O	O
with	IN	O	O
several	JJ	O	O
musculoskeletal	JJ	O	O
changes	NNS	O	O
including	VBG	O	O
poor	JJ	O	O
endurance	NN	O	O
of	IN	O	O
the	DT	O	O
deep	JJ	O	O
cervical	JJ	O	O
flexor	NN	O	O
muscles	NNS	O	O
.	.	O	O

These	DT	O	O
intrinsic	JJ	O	O
muscles	NNS	O	O
of	IN	O	O
the	DT	O	O
neck	NN	O	O
contribute	NN	O	O
to	TO	O	O
stabilization	NN	O	O
and	CC	O	O
protection	NN	O	O
of	IN	O	O
the	DT	O	O
cervical	JJ	O	O
spine	NN	O	O
and	CC	O	O
are	VBP	O	O
critical	JJ	O	O
for	IN	O	O
the	DT	O	O
control	NN	O	O
of	IN	O	O
both	DT	O	O
intervertebral	JJ	O	O
motion	NN	O	O
and	CC	O	O
the	DT	O	O
cervical	JJ	O	O
lordosis	NN	O	O
.	.	O	O

The	DT	O	O
purpose	NN	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
determine	VB	O	O
whether	IN	O	O
the	DT	O	O
use	NN	O	O
of	IN	O	O
the	DT	O	O
PostureJac	NNP	i	IPH
(	(	O	O
SomatoCentric	NNP	O	O
Systems	NNP	O	O
,	,	O	O
Inc.	NNP	O	O
,	,	O	O
Toronto	NNP	O	O
,	,	O	O
Ontario	NNP	O	O
,	,	O	O
Canada	NNP	O	O
)	)	O	O
,	,	O	O
a	DT	O	O
posture	NN	O	O
support	NN	O	O
and	CC	O	O
exercise	NN	O	O
jacket	NN	O	O
,	,	O	O
was	VBD	O	O
effective	JJ	O	O
in	IN	O	O
enhancing	VBG	O	O
deep	JJ	o	OPH
cervical	JJ	o	OPH
muscle	NN	o	OPH
endurance	NN	o	OPH
.	.	o	O

Forty-five	JJ	p	PSS
(	(	p	O
45	CD	p	PSS
)	)	p	O
female	NN	p	PSE
subjects	NNS	p	O
,	,	p	O
between	IN	p	O
the	DT	p	O
ages	NNS	p	O
of	IN	p	O
18	CD	p	PA
and	CC	p	PA
40	CD	p	PA
years	NNS	p	PA
,	,	O	O
were	VBD	O	O
randomly	RB	O	O
assigned	VBN	O	O
to	TO	O	O
three	CD	O	O
groups	NNS	O	O
consisting	VBG	O	O
of	IN	O	O
the	DT	O	O
no-treatment	JJ	i	IC
control	NN	i	IC
,	,	p	O
the	DT	p	O
treatment-control	NN	i	IC
(	(	i	IC
table	JJ	i	IC
stabilization	NN	i	IC
)	)	i	IC
,	,	i	O
and	CC	i	O
the	DT	i	O
experimental	JJ	i	IPH
(	(	i	IPH
PostureJac	NNP	i	IPH
)	)	i	IPH
group	NN	i	O
.	.	i	O

The	DT	O	O
outcome	JJ	O	O
measure	NN	O	O
of	IN	O	O
deep	JJ	o	OPH
cervical	JJ	o	OPH
flexor	NN	o	OPH
muscle	NN	o	OPH
endurance	NN	o	OPH
was	VBD	O	O
based	VBN	O	O
on	IN	O	O
the	DT	O	O
Flexor	NNP	o	OPH
Endurance	NNP	o	OPH
Test	NNP	o	OPH
and	CC	O	O
was	VBD	O	O
recorded	VBN	O	O
in	IN	O	O
seconds	NNS	O	O
.	.	O	O

The	DT	O	O
results	NNS	O	O
indicated	VBD	O	O
that	IN	O	O
the	DT	O	O
PostureJac	NNP	i	O
group	NN	p	O
was	VBD	O	O
superior	JJ	O	O
to	TO	O	O
the	DT	O	O
no-treatment	JJ	p	O
control	NN	p	O
(	(	p	O
p=.001	NN	p	O
)	)	p	O
and	CC	p	O
the	DT	p	O
treatment-control	NN	p	O
(	(	p	O
p=.004	NN	p	O
)	)	p	O
groups	NNS	p	O
in	IN	O	O
terms	NNS	O	O
of	IN	O	O
increasing	VBG	O	O
endurance	NN	o	OPH
of	IN	o	OPH
the	DT	o	OPH
deep	JJ	o	OPH
cervical	JJ	o	OPH
flexors	NNS	o	OPH
.	.	o	O

Consequently	RB	O	O
,	,	O	O
the	DT	O	O
PostureJac	NNP	i	O
may	MD	O	O
be	VB	O	O
a	DT	O	O
useful	JJ	O	O
therapeutic	JJ	O	O
tool	NN	O	O
in	IN	O	O
the	DT	O	O
management	NN	O	O
of	IN	O	O
cervicogenic	JJ	o	OPH
headache	NN	o	OPH
and	CC	o	O
mechanical	JJ	o	OPH
neck	NN	o	OPH
pain	NN	o	OPH
.	.	o	O

The	DT	O	O
effect	NN	o	OOt
of	IN	O	O
quality	NN	O	O
and	CC	O	O
amount	NN	O	O
of	IN	O	O
dietary	JJ	O	O
fat	NN	O	O
on	IN	O	O
the	DT	O	O
susceptibility	NN	o	OPH
of	IN	o	OPH
low	JJ	o	OPH
density	NN	o	OPH
lipoprotein	NN	o	OPH
to	TO	o	OPH
oxidation	NN	o	OPH
in	IN	p	O
subjects	NNS	p	O
with	IN	p	O
impaired	JJ	p	PC
glucose	JJ	p	PC
tolerance	NN	p	PC
.	.	p	O

OBJECTIVES	IN	O	O
We	PRP	O	O
examined	VBD	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
a	DT	O	O
high	JJ	i	IPM
fat	NN	i	IPM
diet	JJ	i	IPM
rich	JJ	i	IPM
in	IN	i	IPM
monounsaturated	JJ	i	IPM
fat	NN	i	IPM
(	(	i	IPM
MUFA-diet	NNP	i	IPM
)	)	i	IPM
and	CC	O	O
a	DT	O	O
moderate	JJ	i	IPM
fat	NN	i	IPM
diet	JJ	i	IPM
rich	JJ	i	IPM
in	IN	i	IPM
polyunsaturated	JJ	i	IPM
fat	NN	i	IPM
(	(	i	IPM
PUFA-diet	NNP	i	IPM
)	)	i	IPM
on	IN	O	O
the	DT	O	O
susceptibility	NN	o	OPH
of	IN	o	OPH
LDL	NNP	o	OPH
to	TO	o	OPH
oxidation	NN	o	OPH
.	.	o	O

SUBJECTS	NNP	O	O
29	CD	p	PSS
subjects	NNS	p	O
with	IN	p	O
impaired	JJ	p	O
glucose	JJ	p	O
tolerance	NN	p	O
.	.	p	O

METHODS	NNP	O	O
After	IN	O	O
consuming	VBG	O	O
a	DT	O	O
run-in	JJ	O	O
diet	JJ	O	O
[	FW	O	O
37	CD	O	O
%	NN	O	O
of	IN	O	O
energy	NN	O	O
(	(	O	O
E	NNP	O	O
%	NN	O	O
)	)	O	O
fat	NN	O	O
,	,	O	O
18	CD	O	O
E	NNP	O	O
%	NN	O	O
saturated	VBD	O	O
fat	JJ	O	O
]	NN	O	O
for	IN	O	O
three	CD	O	O
weeks	NNS	O	O
,	,	O	O
subjects	NNS	O	O
were	VBD	O	O
randomly	RB	O	O
assigned	VBN	O	O
either	RB	O	O
to	TO	O	O
a	DT	O	O
MUFA-diet	JJ	O	O
(	(	O	O
40	CD	O	O
E	NNP	O	O
%	NN	O	O
fat	NN	O	O
,	,	O	O
19	CD	O	O
E	NNP	O	O
%	NN	O	O
monounsaturated	VBD	O	O
fatty	JJ	O	O
acids	NNS	O	O
)	)	O	O
or	CC	O	O
a	DT	O	O
PUFA-diet	JJ	O	O
(	(	O	O
34	CD	O	O
E	NNP	O	O
%	NN	O	O
fat	NN	O	O
,	,	O	O
10	CD	O	O
E	NNP	O	O
%	NN	O	O
polyunsaturated	VBD	O	O
fat	NN	O	O
)	)	O	O
for	IN	O	O
eight	CD	O	O
weeks	NNS	O	O
.	.	O	O

The	DT	O	O
susceptibility	NN	o	OPH
of	IN	o	OPH
LDL	NNP	o	OPH
to	TO	o	OPH
oxidation	NN	o	OPH
was	VBD	O	O
measured	VBN	O	O
by	IN	O	O
challenging	VBG	O	O
LDL	NNP	O	O
with	IN	O	O
hemin	NN	O	O
and	CC	O	O
H2O2	NNP	O	O
and	CC	O	O
measuring	VBG	O	O
the	DT	O	O
time	NN	o	OOt
for	IN	o	OOt
the	DT	o	OOt
reaction	NN	o	OOt
to	TO	o	OOt
reach	VB	o	OOt
maximum	JJ	o	OOt
velocity	NN	o	OOt
.	.	o	O

Results	NNS	O	O
are	VBP	O	O
expressed	VBN	O	O
as	IN	O	O
lag	NN	o	OOt
time	NN	o	OOt
to	TO	o	OOt
oxidation	NN	o	OOt
in	IN	O	O
minutes	NNS	O	O
.	.	O	O

RESULTS	NNP	O	O
In	IN	O	O
the	DT	O	O
PUFA-diet	JJ	O	O
group	NN	O	O
(	(	O	O
n	JJ	O	O
=	NNP	O	O
15	CD	O	O
)	)	O	O
lag	NN	o	OOt
time	NN	o	OOt
tended	VBD	O	O
to	TO	O	O
decrease	VB	O	O
during	IN	O	O
the	DT	O	O
experimental	JJ	O	O
diet	NN	O	O
(	(	O	O
97	CD	O	O
+/-	JJ	O	O
28	CD	O	O
vs	JJ	O	O
90	CD	O	O
+/-	JJ	O	O
25	CD	O	O
min	NN	O	O
,	,	O	O
mean	JJ	O	O
+/-	JJ	O	O
s.d.	NN	O	O
,	,	O	O
P	NNP	O	O
=	NNP	O	O
0.073	CD	O	O
)	)	O	O
,	,	O	O
whereas	RB	O	O
in	IN	O	O
the	DT	O	O
MUFA-diet	JJ	O	O
group	NN	O	O
(	(	O	O
n	JJ	O	O
=	NNP	O	O
14	CD	O	O
)	)	O	O
there	EX	O	O
was	VBD	O	O
no	DT	O	O
significant	JJ	O	O
change	NN	O	O
(	(	O	O
lag	JJ	O	O
time	NN	O	O
96	CD	O	O
+/-	JJ	O	O
24	CD	O	O
vs	JJ	O	O
100	CD	O	O
+/-	JJ	O	O
16	CD	O	O
min	NN	O	O
,	,	O	O
P	NNP	O	O
=	NNP	O	O
0.408	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
mean	JJ	o	OOt
change	NN	o	OOt
in	IN	o	OOt
lag	NN	o	OOt
time	NN	o	OOt
was	VBD	O	O
-7	JJ	O	O
+/-	JJ	O	O
14	CD	O	O
min	NN	O	O
(	(	O	O
-7.2	CD	O	O
%	NN	O	O
)	)	O	O
in	IN	O	O
the	DT	O	O
PUFA-diet	JJ	O	O
group	NN	O	O
and	CC	O	O
+4	VBZ	O	O
+/-	JJ	O	O
16	CD	O	O
min	NN	O	O
(	(	O	O
+4.0	CD	O	O
%	NN	O	O
)	)	O	O
in	IN	O	O
the	DT	O	O
MUFA-diet	JJ	O	O
group	NN	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.029	CD	O	O
,	,	O	O
PUFA-diet	JJ	O	O
group	NN	O	O
vs	VBD	O	O
MUFA-diet	NNP	O	O
group	NN	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
alpha-tocopherol	JJ	o	OPH
concentration	NN	o	OPH
in	IN	o	OPH
LDL	NNP	o	OPH
increased	VBD	O	O
significantly	RB	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.01	CD	O	O
)	)	O	O
in	IN	O	O
both	DT	O	O
diet	JJ	O	O
groups	NNS	O	O
relative	VBP	O	O
to	TO	O	O
the	DT	O	O
run-in	JJ	O	O
diet	JJ	O	O
period	NN	O	O
,	,	O	O
but	CC	O	O
LDL	NNP	o	OPH
particle	VBD	o	OPH
score	RB	o	OPH
did	VBD	O	O
not	RB	O	O
change	VB	O	O
in	IN	O	O
either	DT	O	O
of	IN	O	O
the	DT	O	O
diet	JJ	O	O
groups	NNS	O	O
during	IN	O	O
the	DT	O	O
dietary	JJ	O	O
intervention	NN	O	O
.	.	O	O

In	IN	O	O
subjects	NNS	p	O
with	IN	p	O
impaired	JJ	p	O
glucose	JJ	p	O
tolerance	NN	p	O
a	DT	O	O
PUFA-rich	JJ	i	IPM
diet	NN	O	O
with	IN	O	O
a	DT	O	O
moderate	JJ	O	O
amount	NN	O	O
of	IN	O	O
fat	NN	O	O
tended	VBN	O	O
to	TO	O	O
increase	VB	O	O
the	DT	O	O
susceptibility	NN	o	OPH
of	IN	o	OPH
LDL	NNP	o	OPH
to	TO	o	OPH
oxidation	NN	o	OPH
as	IN	O	O
compared	VBN	O	O
to	TO	O	O
a	DT	O	O
higher	JJR	O	O
fat	JJ	O	O
diet	JJ	O	O
rich	NN	O	O
in	IN	O	O
MUFA	NNP	i	IPM
.	.	i	O

Furthermore	NNP	O	O
,	,	O	O
the	DT	O	O
negative	JJ	O	O
mean	NN	O	O
change	NN	O	O
in	IN	O	O
lag	NN	o	OOt
time	NN	o	OOt
to	TO	o	OOt
oxidation	NN	o	OOt
found	VBN	O	O
in	IN	O	O
the	DT	O	O
PUFA-diet	JJ	O	O
group	NN	O	O
differed	VBD	O	O
significantly	RB	O	O
from	IN	O	O
the	DT	O	O
slightly	RB	O	O
positive	JJ	O	O
mean	NN	O	O
change	NN	O	O
found	VBD	O	O
in	IN	O	O
the	DT	O	O
MUFA-diet	JJ	O	O
group	NN	O	O
.	.	O	O

A	DT	O	O
clinical	JJ	O	O
evaluation	NN	O	O
of	IN	O	O
a	DT	O	O
blood	NN	i	IPH
conservation	NN	i	IPH
device	NN	i	IPH
in	IN	O	O
medical	JJ	p	PC
intensive	JJ	p	PC
care	NN	p	PC
unit	NN	p	PC
patients	NNS	p	PC
.	.	p	PC

OBJECTIVES	NNP	O	O
This	DT	O	O
study	NN	O	O
was	VBD	O	O
designed	VBN	O	O
to	TO	O	O
a	DT	O	O
)	)	O	O
document	NN	O	O
the	DT	O	O
efficacy	NN	O	O
of	IN	O	O
a	DT	O	O
device	NN	O	O
intended	VBN	O	O
to	TO	O	O
conserve	VB	O	O
blood	NN	O	O
in	IN	O	O
critically	RB	p	O
ill	JJ	p	O
patients	NNS	p	O
;	:	p	O
b	NN	O	O
)	)	O	O
determine	VBZ	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
this	DT	O	O
blood	NN	O	O
conservation	NN	O	O
on	IN	O	O
hemoglobin	JJ	o	OPH
concentration	NN	o	OPH
and	CC	O	O
the	DT	O	O
need	NN	o	OPH
for	IN	o	OPH
blood	NN	o	OPH
transfusions	NNS	o	OPH
;	:	o	O
c	NNS	O	O
)	)	O	O
determine	VBP	O	O
if	IN	O	O
the	DT	O	O
blood	NN	O	O
conservation	NN	O	O
device	NN	O	O
resulted	VBD	O	O
in	IN	O	O
interference	NN	O	O
with	IN	O	O
arterial	JJ	O	O
pressure	NN	O	O
waveforms	NNS	O	O
;	:	O	O
d	NN	O	O
)	)	O	O
determine	NN	O	O
if	IN	O	O
use	NN	O	O
of	IN	O	O
the	DT	O	O
blood	NN	O	O
conservation	NN	O	O
device	NN	O	O
resulted	VBD	O	O
in	IN	O	O
a	DT	O	O
difference	NN	O	O
in	IN	O	O
the	DT	O	O
number	NN	O	O
of	IN	O	O
accidental	JJ	O	O
needle	JJ	O	O
punctures	NNS	O	O
suffered	VBN	O	O
by	IN	O	O
healthcare	JJ	O	O
workers	NNS	O	O
.	.	O	O

DESIGN	NNP	O	O
Prospective	NNP	O	O
,	,	O	O
randomized	VBD	O	O
,	,	O	O
controlled	VBD	O	O
trial	NN	O	O
.	.	O	O

A	DT	O	O
clinical	JJ	O	O
trial	NN	O	O
using	VBG	O	O
prospective	JJ	O	O
,	,	O	O
random	JJ	O	O
allocation	NN	O	O
of	IN	O	O
consecutive	JJ	O	O
eligible	JJ	O	O
patients	NNS	O	O
.	.	O	O

SETTING	VBG	O	O
The	DT	p	O
medical	JJ	p	O
intensive	JJ	p	O
care	NN	p	O
unit	NN	p	O
(	(	p	O
ICU	NNP	p	O
)	)	p	O
of	IN	p	O
a	DT	p	O
university	NN	p	O
hospital	NN	p	O
located	VBN	p	O
in	IN	p	O
a	DT	p	O
large	JJ	p	O
metropolitan	JJ	p	O
area	NN	p	O
.	.	p	O

PATIENTS	VB	O	O
A	DT	p	O
total	NN	p	O
of	IN	p	O
100	CD	p	O
patients	NNS	p	O
who	WP	p	O
were	VBD	p	O
admitted	VBN	p	O
to	TO	p	O
the	DT	p	O
medical	JJ	p	O
ICU	NNP	p	O
,	,	p	O
required	VBD	p	O
arterial	JJ	p	O
line	NN	p	O
monitoring	NN	p	O
for	IN	p	O
clinical	JJ	p	O
purposes	NNS	p	O
,	,	p	O
and	CC	p	O
were	VBD	p	O
managed	VBN	p	O
by	IN	p	O
the	DT	p	O
ICU	NNP	p	O
medical	JJ	p	O
service	NN	p	O
.	.	p	O

Exclusion	NNP	p	O
criteria	NNS	p	O
included	VBD	p	O
active	JJ	p	O
bleeding	NN	p	O
or	CC	p	O
chronic	JJ	p	O
renal	JJ	p	O
failure	NN	p	O
at	IN	p	O
the	DT	p	O
time	NN	p	O
of	IN	p	O
ICU	NNP	p	O
admission	NN	p	O
.	.	p	O

INTERVENTIONS	JJ	O	O
Patients	NNPS	O	O
in	IN	O	O
the	DT	O	O
experimental	JJ	O	O
group	NN	O	O
had	VBD	O	O
a	DT	O	O
blood	NN	i	IPH
conservation	NN	i	IPH
device	NN	i	IPH
incorporated	VBN	i	IPH
into	IN	i	IPH
the	DT	i	IPH
arterial	JJ	i	IPH
pressure	NN	i	IPH
monitoring	NN	i	IPH
system	NN	i	IPH
,	,	O	O
while	IN	O	O
patients	NNS	O	O
in	IN	O	O
the	DT	O	O
control	NN	i	IC
group	NN	i	IC
received	VBD	i	IC
a	DT	i	IC
conventional	JJ	i	IC
arterial	JJ	i	IC
pressure	NN	i	IC
monitoring	NN	i	IC
system	NN	i	IC
.	.	i	IC

MEASUREMENTS	NNP	O	O
AND	CC	O	O
MAIN	NNP	O	O
RESULTS	NNP	O	O
Data	NNP	O	O
gathered	VBD	O	O
included	VBN	O	O
:	:	O	O
age	NN	O	O
;	:	O	O
gender	NN	O	O
;	:	O	O
ICU	NNP	O	O
discharge	NN	O	O
status	NN	O	O
;	:	O	O
the	DT	O	O
duration	NN	o	OOt
of	IN	o	OOt
ICU	NNP	o	OOt
stay	NN	o	OOt
;	:	o	OOt
time	NN	o	OOt
in	IN	o	OOt
the	DT	o	OOt
study	NN	o	OOt
;	:	o	OOt
volume	NN	o	OOt
of	IN	o	OOt
all	DT	o	OOt
blood	NN	o	OOt
drawn	NN	o	OOt
,	,	o	OOt
discarded	VBD	o	OOt
,	,	o	OOt
or	CC	o	OOt
lost	VBN	o	OOt
due	JJ	o	OOt
to	TO	o	OOt
leakage	VB	o	OOt
;	:	o	OOt
hemoglobin	JJ	o	OPH
concentrations	NNS	o	OPH
;	:	o	O
blood	NN	o	OPH
transfusions	NNS	o	OPH
;	:	o	O
and	CC	o	O
accidental	JJ	o	OME
needle	JJ	o	OME
injuries	NNS	o	OME
.	.	o	O

Arterial	JJ	o	OPH
pressure	NN	o	OPH
waveforms	NNS	o	OPH
were	VBD	O	O
recorded	VBN	O	O
and	CC	O	O
inspected	VBN	O	O
for	IN	O	O
dampening	VBG	O	O
or	CC	O	O
other	JJ	O	O
deformation	NN	O	O
.	.	O	O

Mean	NNP	o	OPH
hemoglobin	JJ	o	OPH
concentrations	NNS	o	OPH
were	VBD	O	O
compared	VBN	O	O
on	IN	O	O
ICU	NNP	O	O
admission	NN	O	O
and	CC	O	O
at	IN	O	O
12-hr	JJ	O	O
intervals	NNS	O	O
.	.	O	O

Demographic	NNP	O	O
and	CC	O	O
clinical	JJ	O	O
characteristics	NNS	O	O
of	IN	O	O
the	DT	O	O
two	CD	O	O
groups	NNS	O	O
were	VBD	O	O
not	RB	O	O
significantly	RB	O	O
different	JJ	O	O
.	.	O	O

The	DT	O	O
volume	NN	o	OOt
of	IN	o	OOt
blood	NN	o	OOt
drawn	NN	o	OOt
and	CC	o	OOt
discarded	VBD	o	OOt
from	IN	o	OOt
arterial	JJ	o	OOt
catheters	NNS	o	OOt
was	VBD	O	O
significantly	RB	O	O
lower	JJR	O	O
in	IN	O	O
the	DT	O	O
blood	NN	O	O
conservation	NN	O	O
group	NN	O	O
(	(	O	O
blood	NN	O	O
conservation	NN	O	O
device	NN	O	O
:	:	O	O
5.7	CD	O	O
+/-	JJ	O	O
7.5	CD	O	O
mL	NN	O	O
;	:	O	O
control	NN	O	O
:	:	O	O
96.4	CD	O	O
+/-	JJ	O	O
88.5	CD	O	O
mL	NN	O	O
;	:	O	O
p	CC	O	O
<	NNP	O	O
.0001	NNP	O	O
)	)	O	O
,	,	O	O
as	IN	O	O
was	VBD	O	O
the	DT	O	O
total	JJ	o	OOt
volume	NN	o	OOt
of	IN	o	OOt
blood	NN	o	OOt
discarded	VBN	o	OOt
(	(	O	O
blood	NN	O	O
conservation	NN	O	O
device	NN	O	O
:	:	O	O
19.4	CD	O	O
+/-	JJ	O	O
47.4	CD	O	O
mL	NN	O	O
;	:	O	O
control	NN	O	O
:	:	O	O
103.5	CD	O	O
+/-	JJ	O	O
99.9	CD	O	O
mL	NN	O	O
;	:	O	O
p	CC	O	O
<	NNP	O	O
.0001	NNP	O	O
)	)	O	O
.	.	O	O

Mean	NNP	o	OPH
hemoglobin	JJ	o	OPH
concentration	NN	o	OPH
on	IN	O	O
admission	NN	O	O
was	VBD	O	O
similar	JJ	O	O
in	IN	O	O
the	DT	O	O
two	CD	O	O
groups	NNS	O	O
(	(	O	O
blood	NN	O	O
conservation	NN	O	O
device	NN	O	O
group	NN	O	O
:	:	O	O
11.8	CD	O	O
+/-	JJ	O	O
2.5	CD	O	O
g/dL	NN	O	O
;	:	O	O
control	NN	O	O
group	NN	O	O
:	:	O	O
12.6	CD	O	O
+/-	JJ	O	O
2.3	CD	O	O
g/dL	NN	O	O
)	)	O	O
.	.	O	O

In	IN	O	O
both	DT	O	O
groups	NNS	O	O
,	,	O	O
the	DT	O	O
mean	JJ	o	OPH
hemoglobin	NN	o	OPH
concentration	NN	o	OPH
declined	VBD	O	O
most	JJS	O	O
rapidly	RB	O	O
in	IN	O	O
the	DT	O	O
first	JJ	O	O
24	CD	O	O
hrs	NN	O	O
of	IN	O	O
ICU	NNP	O	O
care	NN	O	O
and	CC	O	O
,	,	O	O
thereafter	RB	O	O
,	,	O	O
declined	VBD	O	O
more	RBR	O	O
slowly	RB	O	O
.	.	O	O

Although	IN	O	O
the	DT	O	O
mean	JJ	o	OPH
hemoglobin	NN	o	OPH
concentration	NN	o	OPH
was	VBD	O	O
higher	RBR	O	O
in	IN	O	O
the	DT	O	O
blood	NN	O	O
conservation	NN	O	O
group	NN	O	O
after	IN	O	O
6	CD	O	O
days	NNS	O	O
,	,	O	O
statistical	JJ	O	O
significance	NN	O	O
was	VBD	O	O
not	RB	O	O
reached	VBN	O	O
until	IN	O	O
9.5	CD	O	O
days	NNS	O	O
of	IN	O	O
ICU	NNP	O	O
care	NN	O	O
.	.	O	O

The	DT	O	O
mean	JJ	o	OPH
change	NN	o	OPH
in	IN	o	OPH
hemoglobin	JJ	o	OPH
concentration	NN	o	OPH
(	(	O	O
overall	JJ	O	O
:	:	O	O
1.2	CD	O	O
+/-	JJ	O	O
2.2	CD	O	O
g/dL	NN	O	O
)	)	O	O
during	IN	O	O
the	DT	O	O
study	NN	O	O
represents	VBZ	O	O
a	DT	O	O
statistically	RB	O	O
significant	JJ	O	O
(	(	O	O
p	JJ	O	O
<	NNP	O	O
.0001	NNP	O	O
)	)	O	O
decrease	NN	O	O
of	IN	O	O
9.7	CD	O	O
%	NN	O	O
.	.	O	O

Hemoglobin	NNP	o	OPH
concentration	NN	o	OPH
during	IN	O	O
the	DT	O	O
study	NN	O	O
decreased	VBN	O	O
by	IN	O	O
1.4	CD	O	O
+/-	JJ	O	O
2.2	CD	O	O
g/dL	NN	O	O
in	IN	O	O
the	DT	O	O
control	NN	O	O
group	NN	O	O
and	CC	O	O
1.0	CD	O	O
+/-	JJ	O	O
2.3	CD	O	O
g/dL	NN	O	O
in	IN	O	O
the	DT	O	O
blood	NN	O	O
conservation	NN	O	O
group	NN	O	O
(	(	O	O
p	JJ	O	O
=	NNP	O	O
nonsignificant	NN	O	O
)	)	O	O
.	.	O	O

Univariate	NNP	o	OPH
and	CC	o	OPH
multiple	JJ	o	OPH
regression	NN	o	OPH
analysis	NN	o	OPH
demonstrated	VBD	O	O
discarded	JJ	O	O
blood	NN	o	OPH
volume	NN	o	OPH
to	TO	O	O
be	VB	O	O
a	DT	O	O
significant	JJ	O	O
and	CC	O	O
independent	JJ	O	O
predictor	NN	O	O
of	IN	O	O
the	DT	O	O
decline	NN	O	O
in	IN	O	O
hemoglobin	JJ	O	O
concentration	NN	O	O
.	.	O	O

Transfusion	NN	o	OPH
requirements	NNS	o	OPH
were	VBD	O	O
similar	JJ	O	O
in	IN	O	O
both	DT	O	O
groups	NNS	O	O
.	.	O	O

The	DT	O	O
blood	NN	i	IPH
conservation	NN	i	IPH
system	NN	i	IPH
did	VBD	O	O
not	RB	O	O
alter	VB	O	O
or	CC	O	O
interfere	VB	O	O
with	IN	O	O
pressure	NN	o	OPH
waveforms	NNS	o	OPH
.	.	o	O

There	EX	O	O
were	VBD	O	O
no	DT	O	O
accidental	JJ	o	OME
needle	JJ	o	OME
injuries	NNS	o	OME
noted	VBD	O	O
.	.	O	O

CONCLUSIONS	VB	O	O
The	DT	O	O
conservation	NN	O	O
of	IN	O	O
blood	NN	O	O
in	IN	O	O
critically	RB	p	O
ill	JJ	p	O
patients	NNS	p	O
must	MD	O	O
be	VB	O	O
a	DT	O	O
high-priority	JJ	O	O
concern	NN	O	O
of	IN	O	O
all	DT	O	O
healthcare	JJ	O	O
workers	NNS	O	O
.	.	O	O

Our	PRP$	O	O
data	NNS	O	O
indicate	VBP	O	O
that	IN	O	O
the	DT	O	O
blood	NN	O	O
conservation	NN	O	O
system	NN	O	O
eliminates	VBZ	O	O
a	DT	O	O
significant	JJ	O	O
factor	NN	O	O
in	IN	O	O
the	DT	O	O
decline	NN	O	O
in	IN	O	O
hemoglobin	JJ	o	OPH
concentration	NN	o	OPH
.	.	o	O

With	IN	O	O
devices	NNS	O	O
as	IN	O	O
described	NN	O	O
here	RB	O	O
,	,	O	O
there	EX	O	O
is	VBZ	O	O
no	DT	O	O
reason	NN	O	O
to	TO	O	O
continue	VB	O	O
the	DT	O	O
practice	NN	O	O
of	IN	O	O
wasting	VBG	O	O
the	DT	O	O
blood	NN	O	O
of	IN	O	O
critically	RB	p	O
ill	JJ	p	O
patients	NNS	p	O
in	IN	O	O
order	NN	O	O
to	TO	O	O
prevent	VB	O	O
preanalytic	JJ	O	O
error	NN	O	O
.	.	O	O

Metabolic	JJ	O	O
responses	NNS	O	O
to	TO	O	O
oral	JJ	i	IS
surgery	NN	i	IS
under	IN	O	O
local	JJ	i	IPM
anesthesia	NN	i	IPM
and	CC	O	O
sedation	NN	O	O
with	IN	O	O
intravenous	JJ	O	O
midazolam	NNS	i	IPM
:	:	i	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
two	CD	O	O
different	JJ	O	O
local	JJ	i	IPM
anesthetics	NNS	i	IPM
.	.	i	O

The	DT	O	O
effects	NNS	O	O
of	IN	O	O
epinephrine-free	JJ	i	IPM
and	CC	i	IPM
epinephrine-containing	JJ	i	IPM
local	JJ	i	IPM
anesthetic	JJ	i	IPM
solutions	NNS	O	O
on	IN	O	O
plasma	NN	o	OPH
potassium	NN	o	OPH
and	CC	o	OPH
blood	NN	o	OPH
glucose	JJ	o	OPH
concentrations	NNS	o	OPH
were	VBD	O	O
investigated	VBN	O	O
in	IN	O	O
20	CD	p	PSS
patients	NNS	p	O
undergoing	JJ	p	O
oral	JJ	p	PC
surgery	NN	p	PC
with	IN	p	O
intravenous	JJ	p	O
midazolam	NNS	i	IPM
sedation	NN	p	PC
.	.	p	O

Ten	CD	O	O
patients	NNS	O	O
were	VBD	O	O
randomly	RB	O	O
assigned	VBN	O	O
to	TO	O	O
receive	VB	O	O
4.4	CD	i	IPM
mL	NN	i	IPM
of	IN	i	IPM
2	CD	i	IPM
%	NN	i	IPM
lidocaine	NN	i	IPM
with	IN	i	IPM
1:80,000	CD	i	IPM
epinephrine	NN	i	IPM
as	IN	i	IPM
a	DT	i	IPM
local	JJ	i	IPM
anesthetic	NN	i	IPM
and	CC	i	O
10	CD	i	O
were	VBD	i	O
given	VBN	i	O
4.4	CD	i	IPM
mL	NN	i	IPM
of	IN	i	IPM
3	CD	i	IPM
%	NN	i	IPM
prilocaine	NN	i	IPM
with	IN	i	IPM
0.03	CD	i	IPM
IU/mL	NNP	i	IPM
felypressin	NN	i	IPM
.	.	i	O

There	EX	O	O
were	VBD	O	O
significant	JJ	O	O
changes	NNS	O	O
from	IN	O	O
baseline	NN	O	O
potassium	NN	o	OPH
and	CC	o	OPH
glucose	JJ	o	OPH
concentrations	NNS	o	OPH
both	DT	O	O
within	IN	O	O
and	CC	O	O
between	IN	O	O
treatments	NNS	O	O
in	IN	O	O
the	DT	O	O
early	JJ	O	O
postinjection	NN	O	O
period	NN	O	O
.	.	O	O

The	DT	O	O
epinephrine-containing	JJ	O	O
local	JJ	O	O
anesthetic	NN	O	O
significantly	RB	O	O
reduced	VBD	O	O
the	DT	O	O
plasma	NN	o	OPH
potassium	NN	o	OPH
concentration	NN	o	OPH
10	CD	o	OPH
min	NN	o	OPH
after	IN	o	OPH
injection	NN	o	OPH
,	,	O	O
by	IN	O	O
0.16	CD	O	O
+/-	JJ	O	O
0.20	CD	O	O
mmol/L	NN	O	O
(	(	O	O
mean	JJ	O	O
+/-	NNP	O	O
SD	NNP	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
increased	VBD	O	O
the	DT	O	O
blood	NN	o	OPH
glucose	JJ	o	OPH
concentration	NN	o	OPH
at	IN	O	O
10	CD	O	O
,	,	O	O
20	CD	O	O
,	,	O	O
and	CC	O	O
30	CD	O	O
min	NN	O	O
(	(	O	O
by	IN	O	O
0.46	CD	O	O
+/-	JJ	O	O
0.37	CD	O	O
,	,	O	O
0.63	CD	O	O
+/-	JJ	O	O
0.45	CD	O	O
,	,	O	O
and	CC	O	O
0.56	CD	O	O
+/-	JJ	O	O
0.28	CD	O	O
mmol/L	NN	O	O
,	,	O	O
respectively	RB	O	O
)	)	O	O
.	.	O	O

Conversely	RB	O	O
,	,	O	O
plasma	JJ	o	OPH
potassium	NN	o	OPH
increased	VBD	O	O
and	CC	O	O
blood	NN	o	OPH
glucose	NN	o	OPH
decreased	VBD	O	O
10	CD	O	O
,	,	O	O
20	CD	O	O
,	,	O	O
and	CC	O	O
30	CD	O	O
min	NN	O	O
following	VBG	O	O
the	DT	O	O
administration	NN	O	O
of	IN	O	O
the	DT	O	O
epinephrine-free	JJ	i	IPM
solution	NN	i	IPM
.	.	i	O

At	IN	O	O
30	CD	o	OPH
min	NN	o	OPH
potassium	NN	o	OPH
was	VBD	O	O
increased	VBN	O	O
by	IN	O	O
0.24	CD	O	O
+/-	JJ	O	O
0.16	CD	O	O
mmol/L	NN	O	O
,	,	O	O
and	CC	O	O
glucose	NN	o	OPH
was	VBD	O	O
decreased	VBN	O	O
by	IN	O	O
0.23	CD	O	O
+/-	JJ	O	O
0.16	CD	O	O
mmol/L	NN	O	O
.	.	O	O

It	PRP	O	O
is	VBZ	O	O
concluded	VBN	O	O
that	IN	O	O
epinephrine-free	JJ	i	IPM
and	CC	O	O
epinephrine-containing	JJ	i	IPM
local	JJ	i	IPM
anesthetics	NNS	i	IPM
differ	VBP	O	O
in	IN	O	O
their	PRP$	O	O
metabolic	JJ	O	O
effects	NNS	O	O
during	IN	O	O
oral	JJ	O	O
surgery	NN	O	O
with	IN	O	O
midazolam	JJ	i	IPM
sedation	NN	i	IPM
.	.	i	O

Active	JJ	o	O
warming	NN	o	O
,	,	o	O
not	RB	o	O
passive	JJ	o	O
heat	NN	o	O
retention	NN	o	O
,	,	O	O
maintains	VBZ	O	O
normothermia	JJ	o	OPH
during	IN	O	O
combined	JJ	O	O
epidural-general	JJ	O	O
anesthesia	NN	O	O
for	IN	O	O
hip	NN	p	O
and	CC	p	O
knee	NN	p	O
arthroplasty	NN	p	PC
.	.	p	O

STUDY	NNP	O	O
OBJECTIVE	NNP	O	O
to	TO	O	O
compare	VB	O	O
passive	JJ	O	O
heat	NN	O	O
retention	NN	O	O
by	IN	O	O
low-flow	JJ	O	O
anesthesia	NN	O	O
,	,	O	O
alone	RB	O	O
and	CC	O	O
with	IN	O	O
additional	JJ	O	O
thermal	JJ	O	O
insulation	NN	O	O
by	IN	O	O
reflective	JJ	O	O
blankets	NNS	O	O
,	,	O	O
with	IN	O	O
forced-air	JJ	O	O
warming	VBG	O	O
preventing	VBG	O	O
intraoperative	JJ	O	O
hypothermia	NN	O	O
during	IN	O	O
combined	JJ	O	O
epidural-general	JJ	O	O
anesthesia	NN	O	O
.	.	O	O

DESIGN	NNP	O	O
Randomized	NNP	O	O
,	,	O	O
controlled	VBD	O	O
study	NN	O	O
.	.	O	O

SETTING	NNP	O	O
Inpatient	NNP	p	O
anesthesia	NN	p	O
at	IN	p	O
a	DT	p	O
university	NN	p	O
department	NN	p	O
of	IN	p	O
orthopedic	JJ	p	O
surgery	NN	p	O
.	.	p	O

PATIENTS	CC	p	O
30	CD	p	PSS
ASA	NNP	p	O
physical	JJ	p	O
status	NN	p	O
I	PRP	p	PSS
and	CC	p	O
II	NNP	p	PSS
patients	NNS	p	O
,	,	p	O
who	WP	p	O
were	VBD	p	O
scheduled	VBN	p	O
for	IN	p	O
elective	JJ	p	O
hip	NN	p	O
or	CC	p	O
knee	VB	p	O
arthroplasty	JJ	p	O
and	CC	p	O
were	VBD	p	O
free	JJ	p	O
from	IN	p	O
systemic	JJ	p	PC
disease	NN	p	PC
.	.	p	PC

INTERVENTIONS	JJ	O	O
Patients	NNPS	O	O
received	VBD	O	O
epidural	JJ	O	O
block	NN	O	O
up	RB	O	O
to	TO	O	O
T10	NNP	O	O
by	IN	O	O
alkalinized	JJ	i	IPM
lidocaine	JJ	i	IPM
2	CD	i	IPM
%	NN	i	IPM
,	,	O	O
and	CC	O	O
then	RB	O	O
were	VBD	O	O
administered	VBN	O	O
standard	JJ	i	O
general	JJ	i	O
anesthesia	NN	i	O
by	IN	i	O
means	NNS	i	O
of	IN	i	O
low-flow	JJ	i	IPH
rebreathing	NN	i	IPH
system	NN	i	IPH
(	(	O	O
fresh	JJ	O	O
gas	NN	O	O
flow	NN	O	O
=	VBD	O	O
1	CD	O	O
L/min	NNP	O	O
)	)	O	O
.	.	O	O

All	DT	O	O
procedures	NNS	O	O
started	VBD	O	O
between	IN	O	O
8	CD	O	O
and	CC	O	O
10	CD	O	O
AM	NNP	O	O
,	,	O	O
and	CC	O	O
operating	NN	O	O
room	NN	O	O
(	(	O	O
OR	NNP	O	O
)	)	O	O
temperature	NN	O	O
was	VBD	O	O
maintained	VBN	O	O
between	IN	O	O
21	CD	O	O
degrees	NNS	O	O
and	CC	O	O
23	CD	O	O
degrees	NNS	O	O
C	NNP	O	O
,	,	O	O
with	IN	O	O
relative	JJ	O	O
humidity	NN	O	O
ranging	VBG	O	O
between	IN	O	O
40	CD	O	O
%	NN	O	O
and	CC	O	O
45	CD	O	O
%	NN	O	O
.	.	O	O

For	IN	O	O
heat	NN	O	O
retention	NN	O	O
or	CC	O	O
warming	VBG	O	O
therapy	NN	O	O
,	,	O	O
patients	NNS	O	O
received	VBD	O	O
either	RB	O	O
low-flow	JJ	i	IPH
anesthesia	NN	i	IPH
only	RB	i	IPH
(	(	O	O
control	NN	O	O
,	,	O	O
n	JJ	O	O
=	NNP	O	O
10	CD	O	O
)	)	O	O
,	,	O	O
low-flow	JJ	i	IPH
anesthesia	NN	i	IPH
with	IN	i	IPH
additional	JJ	i	IPH
reflective	JJ	i	IPH
blankets	NNS	i	IPH
(	(	O	O
blanket	NN	O	O
,	,	O	O
n	JJ	O	O
=	NNP	O	O
10	CD	O	O
)	)	O	O
,	,	O	O
or	CC	O	O
low-flow	JJ	i	IPH
anesthesia	NN	i	IPH
with	IN	i	IPH
active	JJ	i	IPH
forced-air	JJ	i	IPH
warming	NN	i	IPH
(	(	O	O
forced-air	JJ	O	O
,	,	O	O
n	JJ	O	O
=	NNP	O	O
10	CD	O	O
)	)	O	O
.	.	O	O

Tympanic	JJ	o	OPH
temperature	NN	o	OPH
was	VBD	O	O
measured	VBN	O	O
at	IN	O	O
OR	NNP	O	O
arrival	NN	O	O
(	(	O	O
baseline	NN	O	O
)	)	O	O
;	:	O	O
immediately	RB	O	O
following	VBG	O	O
general	JJ	O	O
anesthesia	JJ	O	O
induction	NN	O	O
;	:	O	O
30	CD	O	O
,	,	O	O
60	CD	O	O
,	,	O	O
90	CD	O	O
,	,	O	O
and	CC	O	O
120	CD	O	O
minutes	NNS	O	O
from	IN	O	O
general	JJ	O	O
anesthesia	NN	O	O
induction	NN	O	O
;	:	O	O
and	CC	O	O
at	IN	O	O
the	DT	O	O
end	NN	O	O
of	IN	O	O
surgery	NN	O	O
.	.	O	O

MEASUREMENTS	NNP	O	O
AND	CC	O	O
MAIN	NNP	O	O
RESULTS	NNP	O	O
Duration	NNP	o	OPH
of	IN	o	OPH
anesthesia	NN	o	OPH
,	,	o	OPH
invasiveness	NN	o	OPH
of	IN	o	OPH
surgery	NN	o	OPH
,	,	o	OPH
and	CC	o	OPH
baseline	NN	o	OPH
core	NN	o	OPH
temperature	NN	o	OPH
were	VBD	O	O
similar	JJ	O	O
in	IN	O	O
the	DT	O	O
three	CD	O	O
groups	NNS	O	O
.	.	O	O

Core	NNP	o	OPH
temperature	NN	o	OPH
decreased	VBN	O	O
in	IN	O	O
all	PDT	O	O
the	DT	O	O
three	CD	O	O
groups	NNS	O	O
30	CD	O	O
minutes	NNS	O	O
after	IN	O	O
general	JJ	O	O
anesthesia	NN	O	O
induction	NN	O	O
compared	VBN	O	O
with	IN	O	O
baseline	NN	O	O
(	(	O	O
p	JJ	O	O
<	NNP	O	O
0.01	CD	O	O
)	)	O	O
;	:	O	O
afterwards	NNS	O	O
,	,	O	O
it	PRP	O	O
progressively	RB	O	O
decreased	VBD	O	O
in	IN	O	O
the	DT	O	O
control	NN	O	O
and	CC	O	O
blankets	NNS	O	O
groups	NNS	O	O
(	(	O	O
p	JJ	O	O
=	NNP	O	O
0.004	CD	O	O
)	)	O	O
,	,	O	O
with	IN	O	O
a	DT	O	O
reduction	NN	o	OPH
from	IN	o	OPH
baseline	NN	o	OPH
values	NNS	o	OPH
measured	VBN	O	O
at	IN	O	O
the	DT	O	O
end	NN	O	O
of	IN	O	O
surgery	NN	O	O
of	IN	O	O
2.0	CD	O	O
degrees	NNS	O	O
C	NNP	O	O
and	CC	O	O
1.6	CD	O	O
degrees	NNS	O	O
C	NNP	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

In	IN	O	O
the	DT	O	O
forced-air	JJ	O	O
group	NN	O	O
,	,	O	O
after	IN	O	O
the	DT	O	O
initial	JJ	O	O
significant	JJ	O	O
decrease	NN	O	O
(	(	O	O
p	JJ	O	O
=	$	O	O
0.01	CD	O	O
vs.	FW	O	O
baseline	NN	O	O
)	)	O	O
,	,	O	O
core	JJ	o	OPH
temperature	NN	o	OPH
progressively	RB	O	O
increased	VBD	O	O
to	TO	O	O
35.8	CD	O	O
+/-	JJ	O	O
0.6	CD	O	O
degrees	NNS	O	O
C	NNP	O	O
,	,	O	O
which	WDT	O	O
was	VBD	O	O
similar	JJ	O	O
to	TO	O	O
preoperative	VB	O	O
values	NNS	O	O
and	CC	O	O
significantly	RB	O	O
higher	JJR	O	O
than	IN	O	O
either	CC	O	O
the	DT	O	O
control	NN	O	O
or	CC	O	O
blankets	NNS	O	O
groups	NNS	O	O
(	(	O	O
p	JJ	O	O
=	NNP	O	O
0.004	CD	O	O
)	)	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
During	IN	O	O
combined	VBN	O	O
epidural-general	JJ	O	O
anesthesia	NN	O	O
for	IN	O	O
elective	JJ	p	O
hip	NN	p	O
and	CC	p	O
knee	NN	p	O
arthroplasty	NN	p	O
,	,	O	O
passive	JJ	O	O
heat	NN	O	O
retention	NN	O	O
by	IN	O	O
means	NNS	O	O
of	IN	O	O
low-flow	JJ	i	IPH
anesthesia	NN	i	IPH
alone	RB	i	IPH
and	CC	i	IPH
in	IN	i	IPH
combination	NN	i	IPH
with	IN	i	IPH
reflective	JJ	i	IPH
blankets	NNS	i	IPH
is	VBZ	O	O
ineffective	JJ	O	O
in	IN	O	O
maintaining	VBG	o	OPH
intraoperative	JJ	o	OPH
normothermia	NN	o	OPH
and	CC	O	O
definitely	RB	O	O
inferior	JJ	O	O
to	TO	O	O
active	JJ	O	O
forced-air	JJ	O	O
warning	NN	O	O
.	.	O	O

[	JJ	o	OPH
Acute	NNP	o	OPH
cardiovascular	NN	o	OPH
and	CC	o	OPH
metabolic	JJ	o	OPH
changes	NNS	o	OPH
in	IN	O	O
interval	NN	O	O
and	CC	O	O
endurance	NN	i	IPH
training	NN	i	IPH
in	IN	O	O
selected	VBN	p	PC
patients	NNS	p	PC
following	VBG	p	PC
aortocoronary	JJ	p	PC
bypass	NN	p	PC
operation	NN	p	PC
]	NNP	p	O
.	.	O	O

UNLABELLED	VB	O	O
This	DT	O	O
study	NN	O	O
compared	VBN	O	O
the	DT	O	O
acute	NN	o	OPH
changes	NNS	o	OPH
of	IN	o	OPH
cardiovascular	NN	o	OPH
and	CC	o	OPH
metabolic	JJ	o	OPH
reactions	NNS	o	OPH
during	IN	O	O
interval	NN	i	IPH
and	CC	i	IPH
continuous	JJ	i	IPH
training	NN	i	IPH
after	IN	O	O
coronary	JJ	O	O
bypass	NN	O	O
surgery	NN	O	O
.	.	O	O

Two	CD	p	O
groups	NNS	p	O
of	IN	p	O
9	CD	p	PSS
male	JJ	p	PSE
patients	NNS	p	O
(	(	p	O
age	NN	p	PA
:	:	p	PA
59	CD	p	PA
+/-	JJ	p	PA
4	CD	p	PA
and	CC	p	PA
56	CD	p	PA
+/-	JJ	p	PA
6	CD	p	PA
years	NNS	p	PA
,	,	p	PA
resp	NN	p	PA
.	.	p	O

)	)	p	O
each	DT	i	IPH
trained	VBN	i	IPH
on	IN	i	IPH
bicycle	NN	i	IPH
ergometer	JJ	i	IPH
start	NN	i	IPH
on	IN	i	IPH
post-operative	JJ	i	IPH
days	NNS	i	IPH
24	CD	i	IPH
and	CC	i	IPH
26	CD	i	IPH
,	,	i	IPH
resp	NN	i	IPH
.	.	i	O

In	IN	O	O
both	DT	O	O
training	NN	O	O
groups	NNS	O	O
training	VBG	o	OPH
heart	NN	o	OPH
rate	NN	o	OPH
was	VBD	O	O
set	VBN	O	O
at	IN	O	O
86	CD	O	O
%	NN	O	O
of	IN	O	O
individual	JJ	O	O
maximum	JJ	O	O
heart	NN	O	O
rate	NN	O	O
.	.	O	O

In	IN	i	IPH
the	DT	i	IPH
last	JJ	i	IPH
week	NN	i	IPH
of	IN	i	IPH
training	VBG	i	IPH
the	DT	i	IPH
exercise	NN	i	IPH
intensity	NN	i	IPH
in	IN	i	IPH
the	DT	i	IPH
group	NN	i	IPH
of	IN	i	IPH
patients	NNS	i	IPH
who	WP	i	IPH
were	VBD	i	IPH
trained	VBN	i	IPH
by	IN	i	IPH
the	DT	i	IPH
continuous	JJ	i	IPH
method	NN	i	IPH
was	VBD	i	IPH
at	IN	i	IPH
83	CD	i	IPH
watts	NN	i	IPH
,	,	i	IPH
and	CC	i	IPH
at	IN	i	IPH
20:121	CD	i	IPH
watts	NN	i	IPH
in	IN	i	IPH
the	DT	i	IPH
group	NN	i	IPH
of	IN	i	IPH
patients	NNS	i	IPH
who	WP	i	IPH
were	VBD	i	IPH
trained	VBN	i	IPH
by	IN	i	IPH
interval	JJ	i	IPH
method	NN	i	IPH
(	(	i	IPH
rest	NN	i	IPH
:	:	i	IPH
work	NN	i	IPH
each	DT	i	IPH
1:1	CD	i	IPH
min	NN	i	IPH
)	)	i	IPH
.	.	i	O

At	IN	O	O
this	DT	O	O
exercise	NN	O	O
training	NN	O	O
that	WDT	O	O
lasted	VBD	O	O
for	IN	O	O
20	CD	O	O
min	PDT	O	O
the	DT	O	O
acute	JJ	o	OPH
response	NN	o	OPH
of	IN	o	OPH
heart	NN	o	OPH
rate	NN	o	OPH
,	,	o	O
blood	NN	o	OPH
pressure	NN	o	OPH
,	,	o	O
rate-pressure	JJ	o	OPH
product	NN	o	OPH
,	,	o	O
glucose	JJ	o	OPH
,	,	o	O
lactate	JJ	o	OPH
and	CC	o	O
catecholamines	NNS	o	OPH
was	VBD	O	O
measured	VBN	O	O
.	.	O	O

RESULTS	NNP	O	O
In	IN	O	O
both	DT	O	O
methods	NNS	O	O
there	EX	O	O
were	VBD	O	O
no	DT	o	O
significant	JJ	o	O
differences	NNS	o	O
in	IN	o	O
systolic	JJ	o	OOt
and	CC	o	OOt
diastolic	JJ	o	OOt
pressure	NN	o	OOt
,	,	o	O
rate-pressure	JJ	o	OOt
product	NN	o	OOt
,	,	o	O
in	IN	o	O
glucose	NN	o	OOt
or	CC	o	O
catecholamine	NN	o	OOt
levels	NNS	o	O
.	.	o	O

However	RB	O	O
,	,	O	O
there	EX	O	O
was	VBD	O	O
a	DT	O	O
significantly	RB	O	O
higher	JJR	O	O
rate	NN	o	OPH
of	IN	o	OPH
lactate	NN	o	OPH
in	IN	O	O
the	DT	O	O
second	JJ	O	O
10	CD	O	O
min	NN	O	O
of	IN	O	O
the	DT	O	O
interval	JJ	O	O
training	NN	O	O
.	.	O	O

And	CC	O	O
,	,	O	O
in	IN	O	O
spite	NN	O	O
of	IN	O	O
higher	JJR	O	O
peripheral	JJ	O	O
exercise	NN	O	O
intensity	NN	O	O
by	IN	O	O
interval	JJ	O	O
training	NN	O	O
,	,	O	O
there	EX	O	O
was	VBD	O	O
no	DT	O	O
higher	JJR	O	O
cardiac	NN	o	OPH
work	NN	o	OPH
than	IN	O	O
by	IN	O	O
the	DT	O	O
continuous	JJ	O	O
training	NN	O	O
.	.	O	O

These	DT	O	O
findings	NNS	O	O
suggest	VBP	O	O
that	IN	O	O
interval	JJ	O	O
training	NN	O	O
strains	VBZ	O	O
the	DT	O	O
oxidative	JJ	O	O
capacity	NN	O	O
of	IN	O	O
the	DT	O	O
trained	JJ	O	O
muscles	NNS	O	O
in	IN	O	O
a	DT	O	O
more	RBR	O	O
intensive	JJ	O	O
and	CC	O	O
direct	JJ	O	O
way	NN	O	O
than	IN	O	O
does	VBZ	O	O
continuous	JJ	O	O
training	NN	O	O
.	.	O	O

Children	NNP	O	O
's	POS	O	O
Yale-Brown	JJ	O	O
Obsessive	NNP	O	O
Compulsive	NNP	O	O
Scale	NNP	O	O
modified	VBD	O	O
for	IN	O	O
pervasive	JJ	O	O
developmental	NN	O	O
disorders	NNS	O	O
.	.	O	O

OBJECTIVE	NNP	O	O
To	TO	O	O
examine	VB	O	O
the	DT	O	O
psychometric	JJ	O	O
properties	NNS	O	O
of	IN	O	O
the	DT	O	O
Children	NNP	i	IPS
's	POS	i	IPS
Yale-Brown	JJ	i	IPS
Obsessive	NNP	i	IPS
Compulsive	NNP	i	IPS
Scales	NNP	i	IPS
(	(	i	IPS
CYBOCS	NNP	i	IPS
)	)	i	IPS
modified	VBD	i	IPS
for	IN	i	IPS
pervasive	JJ	i	IPS
developmental	NN	i	IPS
disorders	NNS	i	IPS
(	(	i	IPS
PDDs	NNP	i	IPS
)	)	i	IPS
.	.	i	O

METHOD	NNP	O	O
Raters	NNPS	O	O
from	IN	O	O
five	CD	O	O
Research	NNP	O	O
Units	NNS	O	O
on	IN	O	O
Pediatric	NNP	O	O
Psychopharmacology	NNP	O	O
(	(	O	O
RUPP	NNP	O	O
)	)	O	O
Autism	NNP	O	O
Network	NNP	O	O
were	VBD	O	O
trained	VBN	O	O
to	TO	O	O
reliability	NN	O	O
.	.	O	O

The	DT	O	O
modified	JJ	O	O
scale	NN	O	O
(	(	i	IPS
CYBOCS-PDD	NNP	i	IPS
)	)	i	IPS
,	,	O	O
which	WDT	O	O
contains	VBZ	O	O
only	RB	O	O
the	DT	O	O
five	CD	i	IE
Compulsion	NNP	i	IE
severity	NN	i	IE
items	NNS	i	IE
(	(	O	O
range	VB	O	O
0-20	NN	O	O
)	)	O	O
,	,	O	O
was	VBD	O	O
administered	VBN	p	O
to	TO	p	O
172	CD	p	O
medication-free	JJ	p	O
children	NNS	p	O
(	(	p	O
mean	JJ	p	O
8.2	CD	p	O
+/-	JJ	p	O
2.6	CD	p	O
years	NNS	p	O
)	)	p	O
with	IN	p	O
PDD	NNP	p	O
(	(	p	O
autistic	JJ	p	O
disorder	NN	p	O
,	,	p	O
n	JJ	p	O
=	VBP	p	O
152	CD	p	O
;	:	p	O
Asperger	NNP	p	O
's	POS	p	O
disorder	NN	p	O
,	,	p	O
n	JJ	p	O
=	VBP	p	O
6	CD	p	O
;	:	p	O
PDD	NNP	p	O
not	RB	p	O
otherwise	RB	p	O
specified	VBN	p	O
,	,	p	O
n	JJ	p	O
=	NNP	p	O
14	CD	p	O
)	)	p	O
participating	NN	p	O
in	IN	p	O
RUPP	NNP	p	O
clinical	JJ	p	O
trials	NNS	p	O
.	.	p	O

Reliability	NNP	o	OME
was	VBD	O	O
assessed	VBN	O	O
by	IN	O	O
intraclass	NN	O	O
correlation	NN	O	O
coefficient	NN	O	O
(	(	O	O
ICC	NNP	O	O
)	)	O	O
and	CC	O	O
internal	JJ	O	O
consistency	NN	O	O
by	IN	O	O
Cronbach	NNP	O	O
's	POS	O	O
alpha	JJ	O	O
coefficient	NN	O	O
.	.	O	O

Correlations	NNS	O	O
with	IN	O	O
ratings	NNS	O	O
of	IN	O	O
repetitive	JJ	O	O
behavior	NN	O	O
and	CC	O	O
disruptive	JJ	O	O
behavior	NN	O	O
were	VBD	O	O
examined	VBN	O	O
for	IN	O	O
validity	NN	O	O
.	.	O	O

RESULTS	NNP	O	O
Eleven	NNP	O	O
raters	NNS	O	O
showed	VBD	O	O
excellent	JJ	O	O
reliability	NN	o	OME
(	(	O	O
ICC	NNP	O	O
=	NNP	O	O
0.97	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
mean	JJ	o	OME
CYBOCS	NNP	o	OME
score	NN	o	OME
was	VBD	O	O
14.4	CD	O	O
(	(	O	O
+/-	JJ	O	O
3.86	CD	O	O
)	)	O	O
with	IN	O	O
excellent	JJ	O	O
internal	JJ	o	OOt
consistency	NN	o	OOt
(	(	O	O
alpha	JJ	O	O
=	NNP	O	O
.85	NNP	O	O
)	)	O	O
.	.	O	O

Correlations	NNS	O	O
with	IN	O	O
other	JJ	O	O
measures	NNS	O	O
of	IN	O	O
repetitive	JJ	O	O
behavior	NN	O	O
ranged	VBD	O	O
from	IN	O	O
r	NN	O	O
=	$	O	O
0.11	CD	O	O
to	TO	O	O
r	VB	O	O
=	JJ	O	O
0.28	CD	O	O
and	CC	O	O
were	VBD	O	O
similar	JJ	O	O
to	TO	O	O
correlations	NNS	O	O
with	IN	O	O
measures	NNS	o	OME
of	IN	o	OME
irritability	NN	o	OME
(	(	O	O
r	JJ	O	O
=	NNP	O	O
0.24	CD	O	O
)	)	O	O
and	CC	O	O
hyperactivity	NN	o	OME
(	(	O	O
r	JJ	O	O
=	NNP	O	O
0.25	CD	O	O
)	)	O	O
.	.	O	O

Children	NNP	p	O
with	IN	p	O
higher	JJR	p	O
scores	NNS	p	O
on	IN	O	O
the	DT	O	O
CYBOCS-PDD	NNP	O	O
had	VBD	O	O
higher	JJR	O	O
levels	NNS	O	O
of	IN	O	O
maladaptive	JJ	o	OME
behaviors	NNS	o	OME
and	CC	o	O
lower	JJR	o	OME
adaptive	JJ	o	OME
functioning	NN	o	OME
.	.	o	O

CONCLUSIONS	VB	O	O
The	DT	O	O
five-item	JJ	O	O
CYBOCS-PDD	NNP	O	O
is	VBZ	O	O
reliable	JJ	O	O
,	,	O	O
distinct	JJ	O	O
from	IN	O	O
other	JJ	O	O
measures	NNS	O	O
of	IN	O	O
repetitive	JJ	O	O
behavior	NN	O	O
,	,	O	O
and	CC	O	O
sensitive	JJ	O	O
to	TO	O	O
change	VB	O	O
.	.	O	O

Response	NN	O	O
of	IN	O	O
pre-core	NN	p	O
mutant	NN	p	O
chronic	JJ	p	O
hepatitis	NN	p	O
B	NNP	p	O
infection	NN	p	O
to	TO	O	O
lamivudine	VB	i	IPM
.	.	i	O

The	DT	O	O
proportion	NN	O	O
of	IN	O	O
chronic	JJ	O	O
liver	NN	O	O
disease	NN	O	O
associated	VBN	O	O
with	IN	O	O
the	DT	O	O
pre-core	JJ	p	O
mutant	NN	p	O
of	IN	p	O
hepatitis	NN	p	O
B	NNP	p	O
virus	NN	p	O
(	(	p	O
HBV	NNP	p	O
)	)	p	O
infection	NN	p	O
is	VBZ	O	O
increasing	VBG	O	O
,	,	O	O
particularly	RB	O	O
in	IN	O	O
Mediterranean	NNP	p	O
Europe	NNP	p	O
and	CC	p	O
in	IN	p	O
Asia	NNP	p	O
.	.	p	O

The	DT	O	O
pre-core	JJ	p	O
mutant	NN	p	O
HBV	NNP	p	O
is	VBZ	O	O
unable	JJ	O	O
to	TO	O	O
produce	VB	O	O
hepatitis	NN	O	O
B	NNP	O	O
e	NN	O	O
antigen	NN	O	O
(	(	O	O
HBeAg	NNP	O	O
)	)	O	O
,	,	O	O
so	RB	O	O
that	IN	O	O
patients	NNS	p	O
with	IN	p	O
this	DT	p	O
variant	NN	p	O
do	VBP	O	O
not	RB	O	O
present	VB	O	O
with	IN	O	O
HBV	NNP	O	O
characterised	VBN	O	O
by	IN	O	O
HBeAg	NNP	o	OPH
in	IN	o	OPH
the	DT	o	OPH
serum	NN	o	OPH
.	.	o	OPH

Pre-core	NN	O	O
mutant	JJ	O	O
chronic	JJ	O	O
hepatitis	NN	O	O
B	NNP	O	O
infection	NN	O	O
usually	RB	O	O
proceeds	VBZ	O	O
to	TO	O	O
serious	JJ	O	O
liver	JJ	O	O
disease	NN	O	O
.	.	O	O

Wild-type	JJ	O	O
HBV	NNP	O	O
infection	NN	O	O
may	MD	O	O
be	VB	O	O
mild	JJ	O	O
and	CC	O	O
respond	NN	O	O
relatively	RB	O	O
well	RB	O	O
to	TO	O	O
interferon	VB	O	O
(	(	O	O
IFN	NNP	O	O
)	)	O	O
alpha	NN	O	O
therapy	NN	O	O
,	,	O	O
but	CC	O	O
IFN	NNP	O	O
alpha	NN	O	O
is	VBZ	O	O
not	RB	O	O
an	DT	O	O
effective	JJ	O	O
therapeutic	JJ	O	O
option	NN	O	O
in	IN	O	O
pre-core	NN	O	O
mutant	NN	O	O
hepatitis	NN	O	O
B	NNP	O	O
infection	NN	O	O
and	CC	O	O
new	JJ	O	O
therapeutic	JJ	O	O
options	NNS	O	O
are	VBP	O	O
needed	VBN	O	O
.	.	O	O

Clinical	JJ	O	O
data	NNS	O	O
show	VBP	O	O
that	IN	O	O
lamivudine	NN	i	IPM
is	VBZ	O	O
an	DT	O	O
effective	JJ	o	OOt
treatment	NN	O	O
for	IN	O	O
patients	NNS	p	PC
with	IN	p	PC
pre-core	JJ	p	PC
mutant	NN	p	PC
hepatitis	NN	p	PC
B	NNP	p	PC
.	.	p	O

There	EX	O	O
is	VBZ	O	O
profound	JJ	O	O
suppression	NN	O	O
of	IN	O	O
HBV	NNP	o	OPH
replication	NN	o	OPH
and	CC	O	O
improvement	NN	O	O
in	IN	O	O
indicators	NNS	o	OPH
of	IN	o	OPH
liver	JJ	o	OPH
disease	NN	o	OPH
in	IN	O	O
most	JJS	O	O
patients	NNS	O	O
.	.	O	O

In	IN	O	O
conclusion	NN	O	O
,	,	O	O
lamivudine	NN	i	IPM
is	VBZ	O	O
suitable	JJ	O	O
for	IN	O	O
treatment	NN	O	O
of	IN	O	O
a	DT	O	O
wide	JJ	O	O
range	NN	O	O
of	IN	O	O
patients	NNS	p	PC
with	IN	p	PC
chronic	JJ	p	PC
hepatitis	NN	p	PC
B	NNP	p	PC
,	,	p	PC
including	VBG	p	PC
those	DT	p	PC
with	IN	p	PC
pre-core	JJ	p	PC
mutant	JJ	p	PC
HBV	NNP	p	PC
infection	NN	p	PC
.	.	p	O

Evolution	NN	O	O
of	IN	O	O
coronary	JJ	O	O
stenoses	NNS	O	O
is	VBZ	O	O
related	VBN	O	O
to	TO	O	O
baseline	VB	O	O
severity	NN	O	O
--	:	O	O
a	DT	O	O
prospective	JJ	O	O
quantitative	JJ	O	O
angiographic	JJ	O	O
analysis	NN	O	O
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
moderate	JJ	p	PC
coronary	JJ	p	PC
disease	NN	p	PC
.	.	p	O

INTACT	JJ	O	O
Investigators	NNPS	O	O
.	.	O	O

International	NNP	O	O
Nifedipine	NNP	O	O
Trial	NNP	O	O
on	IN	O	O
Antiatherosclerotic	NNP	O	O
Therapy	NNP	O	O
.	.	O	O

A	DT	O	O
correlation	NN	O	O
of	IN	O	O
the	DT	O	O
angiographic	JJ	O	O
evolution	NN	O	O
of	IN	O	O
coronary	JJ	O	O
stenoses	NNS	O	O
(	(	O	O
stenosis	NN	O	O
diameter	NN	O	O
>	NN	O	O
or	CC	O	O
=	VB	O	O
20	CD	O	O
%	NN	O	O
)	)	O	O
with	IN	O	O
morphological	JJ	O	O
stenosis	NN	O	O
parameters	NNS	O	O
at	IN	O	O
baseline	NN	O	O
could	MD	O	O
help	VB	O	O
to	TO	O	O
identify	VB	o	OPH
the	DT	o	OPH
risk	NN	o	OPH
of	IN	o	OPH
progressive	JJ	o	OPH
stenoses	NNS	o	OPH
.	.	o	OPH

Therefore	RB	O	O
,	,	O	O
the	DT	O	O
data	NN	O	O
of	IN	O	O
the	DT	O	O
prospective	JJ	O	O
INTACT	NNP	O	O
study	NN	O	O
(	(	O	O
International	NNP	O	O
Nifedipine	NNP	O	O
Trial	NNP	O	O
on	IN	O	O
Antiatherosclerotic	NNP	O	O
Therapy	NNP	O	O
)	)	O	O
were	VBD	O	O
reviewed	VBN	O	O
.	.	O	O

In	IN	O	O
348	CD	p	PSS
patients	NNS	p	O
with	IN	p	O
moderate	JJ	p	PC
coronary	JJ	p	PC
artery	NN	p	PC
disease	NN	p	PC
,	,	p	O
standardized	VBD	i	IPH
coronary	JJ	i	IPH
angiograms	NNS	i	IPH
were	VBD	p	O
taken	VBN	p	O
3	CD	p	O
years	NNS	p	O
apart	RB	p	O
and	CC	O	O
were	VBD	O	O
quantitatively	RB	O	O
analysed	VBN	O	O
.	.	O	O

Changes	NNS	O	O
in	IN	O	O
the	DT	O	O
minimal	JJ	o	OPH
diameter	NN	o	OPH
of	IN	O	O
the	DT	O	O
1063	CD	O	O
preexisting	VBG	O	O
coronary	JJ	O	O
stenoses	NNS	O	O
compared	VBN	O	O
between	IN	O	O
both	DT	O	O
angiograms	NNS	O	O
were	VBD	O	O
set	VBN	O	O
in	IN	O	O
relation	NN	O	O
to	TO	O	O
a	DT	O	O
number	NN	o	OPH
of	IN	o	OPH
conventional	JJ	o	OPH
stenosis	NN	o	OPH
parameters	NNS	o	OPH
at	IN	O	O
baseline	NN	O	O
.	.	O	O

Regression	NNP	O	O
analysis	NN	O	O
demonstrated	VBD	O	O
a	DT	O	O
significant	JJ	O	O
correlation	NN	o	OOt
of	IN	O	O
the	DT	O	O
changes	NNS	o	OPH
in	IN	o	OPH
minimal	JJ	o	OPH
diameter	NN	o	OPH
with	IN	O	O
baseline	NN	o	OPH
%	NN	o	OPH
diameter	NN	o	OPH
stenosis	NN	o	OPH
(	(	O	O
r	JJ	O	O
=	VBZ	O	O
0.30	CD	O	O
;	:	O	O
P	NNP	O	O
<	NNP	O	O
0.001	CD	O	O
)	)	O	O
,	,	O	O
minimal	JJ	o	OPH
diameter	NN	o	OPH
(	(	O	O
r	JJ	O	O
=	NNP	O	O
-0.28	NNP	O	O
;	:	O	O
P	NNP	O	O
<	NNP	O	O
0.001	CD	O	O
)	)	O	O
and	CC	O	O
reference	NN	o	OPH
diameter	NN	o	OPH
of	IN	o	OPH
stenoses	NNS	o	OPH
(	(	O	O
r	NN	O	O
=	NNP	O	O
-0.14	NNP	O	O
;	:	O	O
P	NNP	O	O
<	NNP	O	O
0.001	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
changes	NNS	o	OOt
were	VBD	o	OOt
not	RB	o	OOt
correlated	VBN	o	OOt
with	IN	O	O
stenosis	NN	o	OPH
length	NN	o	OPH
and	CC	o	OPH
plaque	JJ	o	OPH
area	NN	o	OPH
.	.	o	OPH

The	DT	O	O
baseline	NN	O	O
parameters	NNS	O	O
of	IN	O	O
22	CD	O	O
preexisting	VBG	O	O
stenoses	NNS	O	O
progressing	VBG	o	OPH
to	TO	o	OPH
occlusions	NNS	o	OPH
differed	VBN	O	O
from	IN	O	O
those	DT	O	O
remaining	VBG	o	OPH
patent	NN	o	OPH
only	RB	O	O
with	IN	O	O
regard	NN	O	O
to	TO	O	O
the	DT	O	O
%	NN	o	OPH
diameter	NN	o	OPH
stenosis	NN	o	OPH
(	(	O	O
43	CD	O	O
+/-	JJ	O	O
9	CD	O	O
%	NN	O	O
vs	JJ	O	O
39	CD	O	O
+/-	JJ	O	O
11	CD	O	O
%	NN	O	O
;	:	O	O
P	NNP	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

Additional	JJ	O	O
progression	NN	o	OPH
of	IN	o	OPH
coronary	JJ	o	OPH
disease	NN	o	OPH
became	VBD	O	O
manifest	JJS	O	O
through	IN	O	O
development	NN	O	O
of	IN	O	O
228	CD	O	O
stenoses	NNS	o	OPH
and	CC	O	O
19	CD	O	O
occlusions	NNS	o	OPH
at	IN	O	O
arterial	JJ	O	O
sites	NNS	O	O
free	VBP	O	O
from	IN	O	O
definitive	JJ	O	O
stenoses	NNS	O	O
in	IN	O	O
the	DT	O	O
baseline	NN	O	O
angiograms	NN	O	O
.	.	O	O

Thus	RB	O	O
,	,	O	O
progression	NN	o	OPH
of	IN	o	OPH
atherosclerosis	NN	o	OPH
predominantly	RB	o	OPH
occurred	VBD	o	OPH
in	IN	O	O
mild	NN	O	O
preexisting	VBG	O	O
coronary	JJ	O	O
stenoses	NNS	O	O
and	CC	O	O
developed	VBN	O	O
at	IN	O	O
previously	RB	O	O
angiographically	RB	O	O
normal	JJ	O	O
sites	NNS	O	O
.	.	O	O

Since	IN	O	O
the	DT	O	O
conventional	JJ	O	O
angiographic	JJ	O	O
parameters	NNS	O	O
analysed	VBN	O	O
in	IN	O	O
this	DT	O	O
study	NN	O	O
failed	VBD	O	O
to	TO	O	O
identify	VB	O	O
individual	JJ	O	O
arterial	JJ	O	O
sites	NNS	O	O
with	IN	O	O
an	DT	O	O
increased	VBN	O	O
risk	NN	O	O
for	IN	O	O
progression	NN	O	O
,	,	O	O
definition	NN	O	O
of	IN	O	O
new	JJ	O	O
angiographic	JJ	O	O
parameters	NNS	O	O
or	CC	O	O
application	NN	O	O
of	IN	O	O
new	JJ	O	O
techniques	NNS	O	O
seem	VBP	O	O
mandatory	JJ	O	O
to	TO	O	O
this	DT	O	O
end	NN	O	O
.	.	O	O

Uvulopalatopharyngoplasty	NNP	i	IS
versus	NN	O	O
laser	NN	i	IPH
assisted	VBD	i	IPH
uvulopalatoplasty	JJ	i	IPH
for	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
snoring	NN	p	O
:	:	p	O
an	DT	O	O
objective	NN	O	O
randomised	VBD	O	O
clinical	JJ	O	O
trial	NN	O	O
.	.	O	O

This	DT	O	O
study	NN	O	O
was	VBD	O	O
designed	VBN	O	O
to	TO	O	O
evaluate	VB	O	O
objectively	RB	O	O
the	DT	O	O
clinical	JJ	O	O
effectiveness	NN	O	O
of	IN	O	O
surgery	NN	O	O
for	IN	O	O
snoring	VBG	O	O
and	CC	O	O
to	TO	O	O
compare	VB	O	O
the	DT	O	O
results	NNS	O	O
of	IN	O	O
conventional	JJ	i	IPH
uvulopalatopharyngoplasty	JJ	i	IPH
(	(	i	IPH
UPPP	NNP	i	IPH
)	)	i	IPH
and	CC	O	O
laser	$	i	IPH
assisted	VBN	i	IPH
uvulopalatoplasty	JJ	i	IPH
(	(	i	IPH
LAUP	NNP	i	IPH
)	)	i	IPH
in	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
snoring	VBG	O	O
.	.	O	O

Patients	NNS	p	O
who	WP	p	O
had	VBD	p	O
been	VBN	p	O
referred	VBN	p	O
for	IN	p	O
investigation	NN	p	O
and	CC	p	O
treatment	NN	p	O
of	IN	p	O
their	PRP$	p	O
snoring	NN	p	PC
were	VBD	p	O
randomly	RB	p	O
allocated	VBN	p	O
to	TO	p	O
receive	VB	p	O
either	DT	p	O
UPPP	NNP	i	IPH
or	CC	i	O
LAUP	NNP	i	IPH
.	.	i	O

Forty-seven	JJ	p	PSS
patients	NNS	p	O
with	IN	p	O
confirmed	JJ	p	PC
palatal	JJ	p	PC
flutter	NN	p	PC
had	VBD	p	PC
surgery	NN	p	PC
and	CC	p	O
all	DT	p	O
of	IN	p	O
them	PRP	p	O
had	VBD	p	O
a	DT	p	O
preoperative	JJ	p	O
and	CC	p	O
postoperative	JJ	p	O
objective	JJ	p	O
assessment	NN	p	O
of	IN	p	O
their	PRP$	p	O
snoring	NN	o	OPH
loudness	NN	o	OPH
and	CC	o	O
duration	NN	o	OOt
in	IN	o	OOt
the	DT	o	OOt
home	NN	o	OOt
.	.	o	O

The	DT	O	O
recording	NN	O	O
device	NN	O	O
(	(	O	O
Snore	NNP	O	O
Box	NNP	O	O
)	)	O	O
is	VBZ	O	O
simple	JJ	O	O
for	IN	O	O
the	DT	O	O
patient	NN	O	O
to	TO	O	O
operate	VB	O	O
,	,	O	O
portable	JJ	O	O
with	IN	O	O
a	DT	O	O
built	VBN	O	O
in	IN	O	O
microphone	NN	O	O
,	,	O	O
and	CC	O	O
able	JJ	O	O
to	TO	O	O
produce	VB	O	O
objective	JJ	O	O
results	NNS	O	O
,	,	O	O
which	WDT	O	O
can	MD	O	O
be	VB	O	O
automatically	RB	O	O
analysed	VBN	O	O
.	.	O	O

Of	IN	O	O
the	DT	O	O
38	CD	O	O
patients	NNS	O	O
,	,	O	O
who	WP	O	O
had	VBD	O	O
technically	RB	O	O
valid	JJ	O	O
recordings	NNS	O	O
,	,	O	O
22	CD	O	O
underwent	JJ	O	O
LAUP	NNP	i	IPH
and	CC	O	O
16	CD	O	O
UPPP	NNP	i	IPH
.	.	i	O

Overall	VB	O	O
the	DT	O	O
mean	NN	o	OPH
postoperative	NN	o	OPH
Snore	NNP	o	OPH
Index	NNP	o	OPH
(	(	o	OPH
SI	NNP	o	OPH
)	)	o	OPH
was	VBD	O	O
less	JJR	O	O
than	IN	O	O
the	DT	O	O
preoperative	JJ	O	O
SI	NNP	o	OPH
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.0001	CD	O	O
)	)	O	O
,	,	O	O
the	DT	O	O
average	JJ	O	O
difference	NN	O	O
being	VBG	O	O
78.2	CD	O	O
snores/h	NN	O	O
.	.	O	O

There	EX	O	O
was	VBD	O	O
no	DT	O	O
significant	JJ	O	O
difference	NN	O	O
between	IN	O	O
the	DT	O	O
LAUP	NNP	i	IPH
and	CC	O	O
UPPP	NNP	i	IPH
regarding	VBG	O	O
the	DT	O	O
fall	NN	o	OPH
in	IN	o	OPH
the	DT	o	OPH
SI	NNP	o	OPH
.	.	o	O

This	DT	O	O
study	NN	O	O
is	VBZ	O	O
the	DT	O	O
first	JJ	O	O
objective	JJ	O	O
comparative	NN	O	O
study	NN	O	O
to	TO	O	O
demonstrate	VB	O	O
the	DT	O	O
effectiveness	NN	o	OOt
of	IN	o	OOt
snoring	VBG	o	OOt
surgery	NN	o	OOt
.	.	o	O

Efficacy	NN	O	O
of	IN	O	O
a	DT	O	O
family	NN	i	IE
practice-based	JJ	i	IE
lifestyle	JJ	i	IE
intervention	NN	i	IE
program	NN	i	IE
to	TO	O	O
increase	VB	O	O
physical	JJ	o	OOt
activity	NN	o	OOt
and	CC	O	O
reduce	VB	O	O
clinical	JJ	O	O
and	CC	O	O
physiological	JJ	O	O
markers	NNS	O	O
of	IN	O	O
vascular	JJ	O	O
health	NN	O	O
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
high	JJ	p	PC
normal	JJ	p	PC
blood	NN	p	PC
pressure	NN	p	PC
and/or	RB	p	O
high	JJ	p	PC
normal	JJ	p	PC
blood	NN	p	PC
glucose	NN	p	PC
(	(	p	PC
SNAC	NNP	p	PC
)	)	p	PC
:	:	p	O
study	NN	O	O
protocol	NN	O	O
for	IN	O	O
a	DT	O	O
randomized	VBN	O	O
controlled	VBN	O	O
trial	NN	O	O
.	.	O	O

BACKGROUND	NNP	O	O
Previous	JJ	O	O
interventions	NNS	O	O
to	TO	O	O
increase	VB	O	O
physical	JJ	o	OPH
activity	NN	o	OPH
and	CC	O	O
reduce	VB	O	O
cardiovascular	JJ	O	O
risk	NN	O	O
factors	NNS	O	O
have	VBP	O	O
been	VBN	O	O
targeted	VBN	O	O
at	IN	O	O
individuals	NNS	O	O
with	IN	O	O
established	VBN	O	O
disease	NN	O	O
;	:	O	O
less	CC	O	O
attention	NN	O	O
has	VBZ	O	O
been	VBN	O	O
given	VBN	O	O
to	TO	O	O
intervention	VB	O	O
among	IN	O	O
individuals	NNS	p	O
with	IN	p	O
high	JJ	p	PC
risk	NN	p	PC
for	IN	p	PC
disease	NN	p	PC
nor	CC	O	O
has	VBZ	O	O
there	RB	O	O
been	VBN	O	O
determination	NN	O	O
of	IN	O	O
the	DT	O	O
influence	NN	O	O
of	IN	O	O
setting	VBG	O	O
in	IN	O	O
which	WDT	O	O
the	DT	O	O
intervention	NN	O	O
is	VBZ	O	O
provided	VBN	O	O
.	.	O	O

In	IN	O	O
particular	JJ	O	O
,	,	O	O
family	NN	O	O
practice	NN	O	O
represents	VBZ	O	O
an	DT	O	O
ideal	JJ	O	O
setting	NN	O	O
for	IN	O	O
the	DT	O	O
provision	NN	O	O
and	CC	O	O
long-term	JJ	O	O
maintenance	NN	O	O
of	IN	O	O
lifestyle	JJ	O	O
interventions	NNS	O	O
for	IN	O	O
patients	NNS	p	O
at	IN	p	O
risk	NN	p	O
(	(	p	O
ie	JJ	p	O
high-normal	JJ	p	PC
blood	NN	p	PC
pressure	NN	p	PC
or	CC	p	PC
impaired	JJ	p	PC
glucose	JJ	p	PC
tolerance	NN	p	PC
)	)	p	O
.	.	p	O

METHODS/DESIGN	PDT	O	O
The	DT	O	O
Staged	NNP	p	O
Nutrition	NNP	p	O
and	CC	p	O
Activity	NNP	p	O
Counseling	NNP	p	O
(	(	p	O
SNAC	NNP	p	O
)	)	p	O
study	NN	p	O
is	VBZ	O	O
a	DT	O	O
randomized	JJ	O	O
clustered	JJ	O	O
design	NN	O	O
clinical	JJ	O	O
trial	NN	O	O
that	WDT	O	O
will	MD	O	O
investigate	VB	O	O
the	DT	O	O
effectiveness	NN	O	O
and	CC	O	O
efficacy	NN	O	O
of	IN	O	O
a	DT	O	O
multi-component	JJ	i	IE
lifestyle	JJ	i	IE
intervention	NN	i	IE
on	IN	O	O
cardiovascular	JJ	p	O
disease	NN	p	O
risk	NN	p	O
factors	NNS	p	O
and	CC	p	O
vascular	JJ	p	O
function	NN	p	O
in	IN	p	O
patients	NNS	p	O
at	IN	p	O
risk	NN	p	O
in	IN	p	O
primary	JJ	p	O
care	NN	p	O
.	.	p	O

Patients	NNS	O	O
will	MD	O	O
be	VB	O	O
randomized	VBN	O	O
by	IN	O	O
practice	NN	O	O
to	TO	O	O
either	VB	O	O
a	DT	O	O
standard	NN	i	IE
of	IN	i	IE
care	NN	i	IE
lifestyle	JJ	i	IE
intervention	NN	i	IE
or	CC	O	O
a	DT	O	O
behaviourally-based	JJ	i	IE
,	,	i	IE
matched	VBD	i	IE
prescriptive	JJ	i	IE
physical	JJ	i	IE
activity	NN	i	IE
and	CC	i	IE
diet	JJ	i	IE
change	NN	i	IE
program	NN	i	IE
.	.	i	O

The	DT	O	O
primary	JJ	O	O
goal	NN	O	O
is	VBZ	O	O
to	TO	O	O
increase	VB	O	O
physical	JJ	o	OOt
activity	NN	o	OOt
and	CC	O	O
improve	VB	O	O
dietary	JJ	o	OME
intake	NN	o	OME
according	VBG	O	O
to	TO	O	O
Canada	NNP	o	O
's	POS	o	O
Guides	NNP	o	O
to	TO	o	O
Physical	NNP	o	OME
Activity	NNP	o	OME
Healthy	NNP	o	OME
Eating	NNP	o	OME
over	IN	O	O
24	CD	O	O
months	NNS	O	O
.	.	O	O

The	DT	O	O
primary	JJ	O	O
intention	NN	O	O
to	TO	O	O
treat	VB	O	O
analysis	NN	O	O
will	MD	O	O
compare	VB	O	O
behavioral	JJ	O	O
,	,	O	O
physiological	JJ	O	O
and	CC	O	O
metabolic	JJ	O	O
outcomes	NNS	O	O
at	IN	O	O
6	CD	O	O
,	,	O	O
12	CD	O	O
and	CC	O	O
24	CD	O	O
months	NNS	O	O
post-randomization	JJ	O	O
including	VBG	O	O
estimation	NN	O	O
of	IN	O	O
incident	JJ	O	O
hypertension	NN	o	OPH
and/or	NN	O	O
diabetes	VBZ	o	OPH
.	.	o	O

DISCUSSION	VB	O	O
The	DT	O	O
design	NN	O	O
features	NNS	O	O
of	IN	O	O
our	PRP$	O	O
trial	NN	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
practical	JJ	O	O
problems	NNS	O	O
(	(	O	O
and	CC	O	O
solutions	NNS	O	O
)	)	O	O
associated	VBN	O	O
with	IN	O	O
implementing	VBG	O	O
these	DT	O	O
design	NN	O	O
features	NNS	O	O
,	,	O	O
particularly	RB	O	O
those	DT	O	O
that	IN	O	O
result	NN	O	O
in	IN	O	O
potential	JJ	O	O
delay	NN	O	O
between	IN	O	O
recruitment	NN	O	O
,	,	O	O
baseline	NN	O	O
data	NNS	O	O
collection	NN	O	O
,	,	O	O
randomization	NN	O	O
,	,	O	O
intervention	NN	O	O
,	,	O	O
and	CC	O	O
assessment	NN	O	O
will	MD	O	O
be	VB	O	O
discussed	VBN	O	O
.	.	O	O

Results	NNS	O	O
of	IN	O	O
the	DT	O	O
SNAC	NNP	O	O
trial	NN	O	O
will	MD	O	O
provide	VB	O	O
scientific	JJ	O	O
rationale	NN	O	O
for	IN	O	O
the	DT	O	O
implementation	NN	O	O
of	IN	O	O
this	DT	O	O
lifestyle	JJ	O	O
intervention	NN	O	O
in	IN	O	O
primary	JJ	O	O
care	NN	O	O
.	.	O	O

TRIAL	NNP	O	O
REGISTRATION	NNP	O	O
ISRCTN	NNP	O	O
:	:	O	O
ISRCTN:42921300	NNP	O	O
.	.	O	O

Short-term	JJ	O	O
studies	NNS	O	O
on	IN	O	O
the	DT	O	O
use	NN	O	O
of	IN	O	O
glycerol	NN	i	IPM
as	IN	O	O
an	DT	O	O
osmotic	JJ	O	O
agent	NN	O	O
in	IN	O	O
continuous	JJ	p	PC
ambulatory	JJ	p	PC
peritoneal	JJ	p	PC
dialysis	NN	p	PC
(	(	p	O
CAPD	NNP	p	PC
)	)	p	O
.	.	p	O

The	DT	O	O
use	NN	O	O
of	IN	O	O
glycerol	NN	i	IPM
as	IN	O	O
an	DT	O	O
osmotic	JJ	O	O
agent	NN	O	O
in	IN	O	O
two	CD	O	O
different	JJ	O	O
concentrations	NNS	O	O
(	(	O	O
92	CD	O	O
mmol/l	NN	O	O
and	CC	O	O
272	CD	O	O
mmol/l	NN	O	O
)	)	O	O
in	IN	O	O
peritoneal	JJ	O	O
dialysis	NN	O	O
fluid	NN	O	O
was	VBD	O	O
investigated	VBN	O	O
over	IN	O	O
3	CD	O	O
days	NNS	O	O
in	IN	p	O
six	CD	p	PSS
patients	NNS	p	O
on	IN	p	O
continuous	JJ	p	PC
ambulatory	JJ	p	PC
peritoneal	JJ	p	PC
dialysis	NN	p	PC
and	CC	O	O
compared	VBN	O	O
with	IN	O	O
two	CD	O	O
concentrations	NNS	O	O
of	IN	O	O
glucose	NN	i	IC
(	(	O	O
76	CD	O	O
mmol/l	NN	O	O
and	CC	O	O
215	CD	O	O
mmol/l	NN	O	O
)	)	O	O
in	IN	O	O
the	DT	O	O
same	JJ	O	O
patients	NNS	O	O
.	.	O	O

The	DT	O	O
calorific	JJ	o	OPH
value	NN	o	OPH
of	IN	O	O
the	DT	O	O
absorbed	JJ	O	O
osmotic	JJ	O	O
agent	NN	O	O
was	VBD	O	O
lower	JJR	O	O
,	,	O	O
by	IN	O	O
19	CD	O	O
%	NN	O	O
with	IN	O	O
isotonic	JJ	O	O
and	CC	O	O
22	CD	O	O
%	NN	O	O
with	IN	O	O
hypertonic	JJ	O	O
solutions	NNS	O	O
,	,	O	O
when	WRB	O	O
glycerol	NN	i	IPM
was	VBD	O	O
used	VBN	O	O
in	IN	O	O
place	NN	O	O
of	IN	O	O
glucose	NN	i	IC
.	.	i	O

However	RB	O	O
,	,	O	O
glycerol	NN	O	O
provided	VBD	O	O
significantly	RB	O	O
lower	JJR	O	O
total	JJ	o	OPH
ultrafiltration	NN	o	OPH
than	IN	O	O
glucose	NN	O	O
at	IN	O	O
each	DT	O	O
concentration	NN	O	O
,	,	O	O
despite	IN	O	O
a	DT	O	O
higher	JJR	O	O
initial	JJ	O	O
osmotic	JJ	O	O
pressure	NN	O	O
of	IN	O	O
the	DT	O	O
glycerol-based	JJ	O	O
solutions	NNS	O	O
.	.	O	O

Thus	RB	O	O
,	,	O	O
the	DT	O	O
higher	JJR	O	O
concentration	NN	O	O
of	IN	O	O
glycerol	NN	O	O
required	VBN	O	O
to	TO	O	O
provide	VB	O	O
equal	JJ	o	OPH
ultrafiltration	NN	o	OPH
may	MD	O	O
offset	VB	O	O
any	DT	O	O
calorific	JJ	O	O
advantage	NN	O	O
.	.	O	O

Equilibration	NN	o	OPH
of	IN	o	OPH
creatinine	NN	o	OPH
and	CC	o	OPH
urea	NN	o	OPH
was	VBD	O	O
slower	JJR	O	O
and	CC	O	O
creatinine	JJ	o	OPH
clearance	NN	o	OPH
lower	RBR	O	O
with	IN	O	O
glycerol	NN	i	IPM
.	.	i	O

Solutions	NNS	O	O
containing	VBG	O	O
glycerol	NN	i	IPM
were	VBD	O	O
initially	RB	O	O
less	JJR	O	O
acid	JJ	O	O
(	(	O	O
pH	JJ	O	O
6.5	CD	O	O
)	)	O	O
than	IN	O	O
those	DT	O	O
containing	VBG	O	O
glucose	NN	O	O
(	(	O	O
pH	JJ	O	O
5.1	CD	O	O
)	)	O	O
.	.	O	O

Blood	NNP	o	OPH
glycerol	NN	o	OPH
levels	NNS	o	OPH
,	,	O	O
which	WDT	O	O
were	VBD	O	O
in	IN	O	O
the	DT	O	O
physiological	JJ	O	O
range	NN	O	O
with	IN	O	O
glucose	NN	O	O
as	IN	O	O
the	DT	O	O
osmotic	JJ	O	O
agent	NN	O	O
,	,	O	O
reached	VBD	O	O
a	DT	O	O
peak	JJ	O	O
80-fold	JJ	O	O
greater	JJR	O	O
at	IN	O	O
4.3	CD	O	O
+/-	JJ	O	O
0.8	CD	O	O
mmol/l	NN	O	O
during	IN	O	O
dialysis	NN	O	O
with	IN	O	O
fluid	NN	O	O
containing	VBG	O	O
glycerol	NN	i	IPM
at	IN	O	O
272	CD	O	O
mmol/l	NN	O	O
and	CC	O	O
eightfold	VB	O	O
higher	JJR	O	O
at	IN	O	O
0.42	CD	O	O
+/-	JJ	O	O
0.09	CD	O	O
mmol/l	NN	O	O
with	IN	O	O
glycerol	NN	i	IPM
at	IN	O	O
92	CD	O	O
mmol/l	NN	O	O
.	.	O	O

There	EX	O	O
was	VBD	O	O
no	DT	O	O
evidence	NN	O	O
of	IN	O	O
haemolysis	NN	o	OA
or	CC	O	O
other	JJ	O	O
toxic	JJ	o	OA
effect	NN	o	OA
despite	IN	O	O
these	DT	O	O
levels	NNS	O	O
.	.	O	O

The	DT	O	O
rise	NN	O	O
in	IN	O	O
blood	NN	o	O
glucose	NN	o	O
and	CC	o	O
insulin	NN	o	O
noted	VBD	O	O
during	IN	O	O
the	DT	O	O
use	NN	O	O
of	IN	O	O
glucose-based	JJ	O	O
solutions	NNS	O	O
was	VBD	O	O
not	RB	O	O
found	VBN	O	O
with	IN	O	O
glycerol	NN	i	IPM
.	.	i	O

Circulating	NNP	o	OPH
levels	NNS	o	OPH
of	IN	o	OPH
lactate	NN	o	OPH
,	,	o	O
pyruvate	NN	o	OPH
,	,	o	O
alanine	NN	o	OPH
,	,	o	O
non-esterified	JJ	o	OPH
fatty	JJ	o	OPH
acids	NNS	o	OPH
and	CC	o	O
the	DT	o	O
ketone	NN	o	O
bodies	NNS	o	O
were	VBD	O	O
similar	JJ	O	O
with	IN	O	O
the	DT	O	O
two	CD	O	O
agents	NNS	O	O
.	.	O	O

Although	IN	O	O
these	DT	O	O
short-term	JJ	O	O
studies	NNS	O	O
have	VBP	O	O
shown	VBN	O	O
no	DT	O	O
conclusive	JJ	O	O
advantage	NN	O	O
of	IN	O	O
glycerol	NN	i	IPM
over	IN	O	O
glucose	JJ	i	IC
,	,	O	O
long-term	JJ	O	O
effects	NNS	O	O
of	IN	O	O
glycerol	NN	i	IPM
,	,	O	O
particularly	RB	O	O
on	IN	O	O
circulating	VBG	o	OPH
lipid	JJ	o	OPH
levels	NNS	o	OPH
,	,	O	O
will	MD	O	O
determine	VB	O	O
its	PRP$	O	O
future	JJ	O	O
role	NN	O	O
as	IN	O	O
an	DT	O	O
osmotic	JJ	O	O
agent	NN	O	O
in	IN	O	O
continuous	JJ	O	O
ambulatory	JJ	p	PC
peritoneal	JJ	p	PC
dialysis	NN	p	PC
.	.	p	O

Twice-a-day	JJ	O	O
versus	NN	O	O
four-times-a-day	JJ	O	O
ofloxacin	JJ	O	O
treatment	NN	O	O
of	IN	O	O
external	JJ	O	O
ocular	JJ	O	O
infection	NN	O	O
.	.	O	O

PURPOSE	VB	O	O
The	DT	O	O
purpose	NN	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
compare	VB	O	O
the	DT	O	O
efficacies	NNS	o	OOt
of	IN	O	O
0.3	CD	O	O
%	NN	O	O
ofloxacin	JJ	O	O
eyedrops	NNS	O	O
,	,	O	O
when	WRB	O	O
given	VBN	O	O
twice-a-day	JJ	O	O
(	(	O	O
BID	NNP	O	O
)	)	O	O
versus	IN	O	O
four-times-a-day	JJ	O	O
(	(	O	O
QID	NNP	O	O
)	)	O	O
,	,	O	O
for	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
external	JJ	O	O
ocular	JJ	O	O
disease	NN	O	O
.	.	O	O

METHOD	NNP	O	O
Fifty	NNP	p	PSS
patients	NNS	p	O
with	IN	p	O
blepharitis	NN	p	PC
,	,	p	O
conjuctivitis	NN	p	PC
,	,	p	O
or	CC	p	O
blepharoconjunctivitis	NN	p	PC
were	VBD	O	O
randomly	RB	O	O
assigned	VBN	O	O
to	TO	O	O
treatment	NN	i	O
with	IN	i	O
0.3	CD	i	IPM
%	NN	i	IPM
ofloxacin	JJ	i	IPM
eyedrops	NNS	i	IPM
,	,	i	IPM
BID	NNP	i	IPM
or	CC	i	IPM
QID	NNP	i	IPM
,	,	i	IPM
for	IN	i	IPM
10	CD	i	IPM
days	NNS	i	IPM
.	.	i	O

Signs	NNP	O	O
,	,	O	O
symptoms	NNS	O	O
,	,	O	O
and	CC	O	O
cultures	NNS	O	O
were	VBD	O	O
evaluated	VBN	O	O
at	IN	O	O
the	DT	O	O
beginning	NN	O	O
and	CC	O	O
at	IN	O	O
the	DT	O	O
end	NN	O	O
of	IN	O	O
the	DT	O	O
study	NN	O	O
.	.	O	O

RESULTS	VB	O	O
The	DT	O	O
clinical	JJ	O	O
outcome	NN	O	O
was	VBD	O	O
virtually	RB	O	O
identical	JJ	O	O
in	IN	O	O
the	DT	O	O
two	CD	O	O
groups	NNS	O	O
.	.	O	O

There	EX	O	O
was	VBD	O	O
a	DT	O	O
significant	JJ	O	O
decrease	NN	O	O
in	IN	O	O
clinical	JJ	o	OOt
scores	NNS	o	OOt
in	IN	O	O
the	DT	O	O
BID	NNP	O	O
and	CC	O	O
QID	NNP	O	O
groups	NNS	O	O
by	IN	O	O
days	NNS	O	O
3	CD	O	O
to	TO	O	O
5	CD	O	O
(	(	O	O
2.6-3.0	JJ	O	O
points	NNS	O	O
)	)	O	O
and	CC	O	O
a	DT	O	O
further	JJ	O	O
decrease	NN	O	O
by	IN	O	O
day	NN	O	O
11	CD	O	O
(	(	O	O
4.3-5.0	JJ	O	O
points	NNS	O	O
)	)	O	O
.	.	O	O

There	EX	O	O
was	VBD	O	O
no	DT	O	O
significant	JJ	O	O
difference	NN	O	O
between	IN	O	O
the	DT	O	O
two	CD	O	O
groups	NNS	O	O
at	IN	O	O
any	DT	O	O
time	NN	O	O
interval	NN	O	O
.	.	O	O

Microbiologic	NNP	O	O
studies	NNS	O	O
showed	VBD	O	O
a	DT	O	O
reduction	NN	O	O
in	IN	O	O
colony-forming	JJ	o	OPH
units	NNS	o	OPH
in	IN	O	O
87	CD	O	O
%	NN	O	O
of	IN	O	O
the	DT	O	O
BID	NNP	O	O
group	NN	O	O
and	CC	O	O
in	IN	O	O
80	CD	O	O
%	NN	O	O
of	IN	O	O
the	DT	O	O
QID	NNP	O	O
group	NN	O	O
.	.	O	O

CONCLUSION	NNP	O	O
The	DT	O	O
treatment	NN	O	O
of	IN	O	O
external	JJ	o	OPH
ocular	JJ	o	OPH
disease	NN	o	OPH
with	IN	O	O
0.3	CD	O	O
%	NN	O	O
ofloxacin	JJ	o	OOt
eyedrops	NN	o	OOt
was	VBD	o	OOt
equally	RB	o	OOt
effective	JJ	o	OOt
when	WRB	o	OOt
given	VBN	o	OOt
BID	NNP	o	OOt
or	CC	o	OOt
QID	NNP	o	OOt
.	.	o	O

An	DT	O	O
open	JJ	O	O
multicenter	NN	O	O
efficacy	NN	o	OOt
and	CC	o	OOt
safety	NN	o	OOt
evaluation	NN	o	OOt
of	IN	O	O
amlodipine	NN	i	IPM
in	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
symptomatic	JJ	p	O
myocardial	JJ	p	O
ischemia	NN	p	O
.	.	p	O

The	DT	O	O
efficacy	NN	o	OOt
and	CC	o	OOt
safety	NN	o	OOt
of	IN	O	O
amlodipine	NN	i	IPM
(	(	O	O
5-10	JJ	O	O
mg	NN	O	O
)	)	O	O
once	RB	O	O
daily	JJ	O	O
were	VBD	O	O
studied	VBN	O	O
in	IN	O	O
an	DT	p	O
open	JJ	p	O
study	NN	p	O
in	IN	p	O
patients	NNS	p	O
with	IN	p	O
symptomatic	JJ	p	O
myocardial	JJ	p	O
ischemia	NN	p	O
.	.	p	O

The	DT	O	O
study	NN	O	O
is	VBZ	O	O
ongoing	VBG	O	O
and	CC	O	O
this	DT	O	O
report	NN	O	O
is	VBZ	O	O
based	VBN	O	O
on	IN	O	O
an	DT	O	O
interim	JJ	O	O
analysis	NN	O	O
of	IN	O	O
data	NNS	p	O
from	IN	p	O
78	CD	p	O
patients	NNS	p	O
.	.	p	O

A	DT	O	O
2-week	JJ	O	O
baseline	NN	O	O
period	NN	O	O
in	IN	O	O
which	WDT	O	O
patients	NNS	O	O
maintained	VBD	O	O
their	PRP$	O	O
current	JJ	i	O
antianginal	JJ	i	IC
therapy	NN	i	IC
was	VBD	O	O
followed	VBN	O	O
by	IN	O	O
a	DT	O	O
10-week	JJ	O	O
treatment	NN	O	O
period	NN	O	O
with	IN	O	O
5-10	JJ	O	O
mg	NN	O	O
of	IN	O	O
amlodipine/day	NN	i	IPM
.	.	O	O

Both	CC	O	O
the	DT	O	O
median	JJ	o	OPH
number	NN	o	OPH
of	IN	o	OPH
angina	JJ	o	OPH
attacks	NNS	o	OPH
per	IN	o	OPH
week	NN	o	OPH
and	CC	o	OPH
the	DT	o	OPH
median	JJ	o	OPH
number	NN	o	OPH
of	IN	o	OPH
nitroglycerin	NN	o	OPH
(	(	o	OPH
NTG	NNP	o	OPH
)	)	o	OPH
tablets	NNS	o	OPH
consumed/week	VBP	o	OPH
were	VBD	O	O
significantly	RB	O	O
reduced	VBN	O	O
after	IN	O	O
amlodipine	NN	i	IPM
(	(	O	O
mean	JJ	O	O
daily	RB	O	O
dose	NN	O	O
of	IN	O	O
8.6	CD	O	O
mg	NNS	O	O
)	)	O	O
when	WRB	O	O
compared	VBN	O	O
with	IN	O	O
baseline	NN	O	O
(	(	O	O
p	JJ	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

A	DT	O	O
total	NN	O	O
of	IN	O	O
98.4	CD	O	O
%	NN	O	O
of	IN	O	O
patients	NNS	O	O
(	(	O	O
63/64	CD	O	O
)	)	O	O
experienced	VBD	O	O
a	DT	O	O
reduction	NN	O	O
in	IN	O	O
the	DT	O	O
frequency	NN	o	OPH
of	IN	o	OPH
angina	JJ	o	OPH
attacks/week	NN	o	OPH
and	CC	O	O
91	CD	O	O
%	NN	O	O
of	IN	O	O
patients	NNS	O	O
(	(	O	O
58/64	CD	O	O
)	)	O	O
had	VBD	O	O
angina	VBN	o	OPH
attacks	NNS	o	OPH
reduced	VBD	O	O
to	TO	O	O
<	VB	O	O
or	CC	O	O
=	VB	O	O
2/week	CD	O	O
.	.	O	O

In	IN	O	O
self-assessments	NNS	o	O
,	,	O	O
95	CD	O	O
%	NN	O	O
of	IN	O	O
patients	NNS	O	O
(	(	O	O
55/58	CD	O	O
)	)	O	O
reported	VBD	O	O
improved	JJ	O	O
angina	NNS	o	OPH
control	NN	o	OPH
and	CC	O	O
91	CD	O	O
%	NN	O	O
(	(	O	O
53/58	CD	O	O
)	)	O	O
felt	VBD	O	O
their	PRP$	O	O
ability	NN	o	OPH
to	TO	o	OPH
perform	VB	o	OPH
usual	JJ	o	OPH
activities	NNS	o	OPH
had	VBD	O	O
improved	VBN	O	O
.	.	O	O

Twenty-seven	JJ	O	O
patients	NNS	O	O
experienced	JJ	O	O
adverse	JJ	o	OA
events	NNS	o	OA
reported	VBN	O	O
as	IN	O	O
drug	NN	O	O
related	VBN	O	O
.	.	O	O

The	DT	O	O
most	RBS	O	O
common	JJ	O	O
adverse	JJ	o	OA
event	NN	o	OA
noted	VBD	O	O
was	VBD	O	O
edema	RB	o	OA
.	.	o	O

Amlodipine	NNP	i	IPM
once	RB	O	O
daily	RB	O	O
significantly	RB	O	O
reduced	VBN	O	O
the	DT	O	O
incidence	NN	o	OPH
of	IN	o	OPH
angina	NN	o	OPH
attacks	NNS	o	OPH
and	CC	O	O
the	DT	O	O
concomitant	JJ	O	O
need	NN	o	OPH
of	IN	o	OPH
nitroglycerin	NN	o	OPH
for	IN	O	O
relief	NN	O	O
of	IN	O	O
symptoms	NNS	O	O
and	CC	O	O
thus	RB	O	O
improved	VBN	O	O
the	DT	O	O
patients	NNS	O	O
'	POS	O	O
ability	NN	O	O
to	TO	O	O
perform	VB	O	O
daily	JJ	O	O
activities	NNS	O	O
.	.	O	O

Most	JJS	O	O
adverse	JJ	O	O
events	NNS	O	O
reported	VBN	O	O
were	VBD	O	O
mild	JJ	O	O
or	CC	O	O
moderate	JJ	O	O
and	CC	O	O
the	DT	O	O
incidence	NN	O	O
is	VBZ	O	O
as	RB	O	O
would	MD	O	O
be	VB	O	O
expected	VBN	O	O
in	IN	O	O
this	DT	O	O
patient	JJ	O	O
population	NN	O	O
.	.	O	O

The	DT	O	O
effects	NNS	O	O
of	IN	O	O
the	DT	O	O
angiotensin-converting	JJ	i	IPM
enzyme	NN	i	IPM
inhibitor	NN	i	IPM
imidapril	NN	i	IPM
on	IN	O	O
plasma	NN	O	O
plasminogen	NN	O	O
activator	NN	O	O
inhibitor	NN	O	O
activity	NN	O	O
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
acute	JJ	p	PC
myocardial	JJ	p	PC
infarction	NN	p	PC
.	.	p	O

This	DT	O	O
study	NN	O	O
sought	VBD	O	O
to	TO	O	O
determine	VB	O	O
whether	IN	O	O
early	JJ	O	O
treatment	NN	O	O
with	IN	O	O
angiotensin-converting	JJ	i	IPM
enzyme	NN	i	IPM
(	(	i	IPM
ACE	NNP	i	IPM
)	)	i	IPM
inhibitors	NNS	i	IPM
in	IN	O	O
patients	NNS	O	O
with	IN	O	O
acute	JJ	O	O
myocardial	JJ	O	O
infarction	NN	O	O
(	(	O	O
AMI	NNP	O	O
)	)	O	O
is	VBZ	O	O
useful	JJ	O	O
for	IN	O	O
the	DT	O	O
improvement	NN	O	O
of	IN	O	O
fibrinolytic	JJ	o	OPH
function	NN	o	OPH
,	,	O	O
as	RB	O	O
well	RB	O	O
as	IN	O	O
left	VBN	o	OPH
ventricular	JJ	o	OPH
function	NN	o	OPH
.	.	o	O

This	DT	O	O
study	NN	O	O
was	VBD	O	O
designed	VBN	O	O
to	TO	O	O
examine	VB	O	O
the	DT	O	O
levels	NNS	O	O
of	IN	O	O
plasma	NN	o	OPH
plasminogen	NN	o	OPH
activator	NN	o	OPH
inhibitor	NN	o	OPH
(	(	o	OPH
PAI	NNP	o	OPH
)	)	o	OPH
activity	NN	o	OPH
and	CC	O	O
serum	JJ	o	OPH
ACE	NNP	o	OPH
activity	NN	o	OPH
during	IN	O	O
the	DT	O	O
course	NN	O	O
of	IN	O	O
2	CD	O	O
weeks	NNS	O	O
in	IN	O	O
40	CD	p	PSS
patients	NNS	p	O
with	IN	p	O
AMI	NNP	p	PC
within	IN	p	O
12	CD	p	O
hours	NNS	p	O
after	IN	p	O
the	DT	p	O
onset	NN	p	O
of	IN	p	O
the	DT	p	O
symptom	NN	p	O
and	CC	p	O
who	WP	p	O
randomly	VBP	p	O
received	VBN	p	O
early	JJ	p	O
treatment	NN	p	O
with	IN	p	O
either	CC	p	O
the	DT	p	O
ACE	NNP	i	IPM
inhibitor	NN	i	IPM
imidapril	NN	i	IPM
or	CC	i	O
a	DT	i	O
placebo	NN	i	IC
(	(	p	O
20	CD	p	PSS
patients	NNS	p	O
in	IN	p	O
the	DT	p	O
imidapril	NN	p	O
group	NN	p	O
and	CC	p	O
20	CD	p	PSS
in	IN	p	O
the	DT	p	O
placebo	NN	p	O
group	NN	p	O
)	)	p	O
.	.	p	O

The	DT	O	O
levels	NNS	o	OPH
of	IN	o	OPH
serum	JJ	o	OPH
ACE	NNP	o	OPH
activity	NN	o	OPH
in	IN	O	O
the	DT	O	O
imidapril	NN	i	IPM
group	NN	O	O
decreased	VBD	O	O
significantly	RB	O	O
(	(	O	O
p	JJ	O	O
<	NNP	O	O
0.01	CD	O	O
)	)	O	O
8	CD	O	O
hours	NNS	O	O
after	IN	O	O
the	DT	O	O
administration	NN	O	O
of	IN	O	O
imidapril	NN	i	IPM
,	,	O	O
and	CC	O	O
the	DT	O	O
levels	NNS	O	O
24	CD	O	O
hours	NNS	O	O
after	IN	O	O
administration	NN	O	O
were	VBD	O	O
significantly	RB	O	O
lower	JJR	O	O
than	IN	O	O
those	DT	O	O
in	IN	O	O
the	DT	O	O
placebo	NN	i	IC
group	NN	O	O
(	(	O	O
3.6	CD	O	O
+/-	JJ	O	O
0.6	CD	O	O
IU/L	NNP	O	O
vs	VBD	O	O
7.4	CD	O	O
+/-	JJ	O	O
0.8	CD	O	O
IU/L	NNP	O	O
;	:	O	O
p	VBZ	O	O
<	$	O	O
0.001	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
plasma	JJ	o	OPH
PAI	NNP	o	OPH
activity	NN	o	OPH
increased	VBD	O	O
gradually	RB	O	O
to	TO	O	O
peak	VB	O	O
levels	NNS	O	O
16	CD	O	O
hours	NNS	O	O
after	IN	O	O
the	DT	O	O
administration	NN	O	O
of	IN	O	O
imidapril	NN	O	O
and	CC	O	O
placebo	NN	O	O
.	.	O	O

The	DT	O	O
levels	NNS	O	O
in	IN	O	O
the	DT	O	O
placebo	NN	O	O
group	NN	O	O
decreased	VBD	O	O
gradually	RB	O	O
but	CC	O	O
remained	VBD	O	O
high	JJ	O	O
during	IN	O	O
the	DT	O	O
study	NN	O	O
period	NN	O	O
.	.	O	O

On	IN	O	O
the	DT	O	O
other	JJ	O	O
hand	NN	O	O
,	,	O	O
the	DT	O	O
levels	NNS	o	OPH
of	IN	o	OPH
PAI	NNP	o	OPH
activity	NN	o	OPH
in	IN	O	O
the	DT	O	O
imidapril	NN	i	IPM
group	NN	O	O
decreased	VBD	O	O
rapidly	RB	O	O
and	CC	O	O
those	DT	O	O
48	CD	O	O
hours	NNS	O	O
after	IN	O	O
administration	NN	O	O
were	VBD	O	O
significantly	RB	O	O
lower	JJR	O	O
than	IN	O	O
those	DT	O	O
in	IN	O	O
the	DT	O	O
placebo	NN	i	IC
group	NN	O	O
(	(	O	O
7.9	CD	O	O
+/-	JJ	O	O
1.9	CD	O	O
IU/ml	NNP	O	O
vs	VBD	O	O
18.4	CD	O	O
+/-	JJ	O	O
3.5	CD	O	O
IU/ml	NNP	O	O
;	:	O	O
p	VBZ	O	O
<	$	O	O
0.01	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
levels	NNS	o	OPH
of	IN	o	OPH
left	JJ	o	OPH
ventricular	JJ	o	OPH
ejection	NN	o	OPH
fraction	NN	o	OPH
about	IN	O	O
2	CD	O	O
weeks	NNS	O	O
after	IN	O	O
admission	NN	O	O
were	VBD	O	O
significantly	RB	O	O
higher	JJR	O	O
in	IN	O	O
the	DT	O	O
imidapril	NN	O	O
group	NN	O	O
than	IN	O	O
in	IN	O	O
the	DT	O	O
placebo	NN	i	IC
group	NN	O	O
(	(	O	O
65.9	CD	O	O
%	NN	O	O
+/-	JJ	O	O
2.5	CD	O	O
%	NN	O	O
vs	JJ	O	O
49.1	CD	O	O
%	NN	O	O
+/-	JJ	O	O
4.4	CD	O	O
%	NN	O	O
;	:	O	O
p	CC	O	O
<	VB	O	O
0.01	CD	O	O
)	)	O	O
.	.	O	O

This	DT	O	O
study	NN	O	O
showed	VBD	O	O
that	IN	O	O
imidapril	NN	i	IPM
,	,	O	O
an	DT	O	O
ACE	NNP	O	O
inhibitor	NN	O	O
,	,	O	O
might	MD	O	O
be	VB	O	O
useful	JJ	O	O
for	IN	O	O
the	DT	O	O
improvement	NN	O	O
of	IN	O	O
fibrinolytic	JJ	o	OPH
function	NN	o	OPH
and	CC	O	O
left	VBD	o	OPH
ventricular	JJ	o	OPH
function	NN	o	OPH
in	IN	O	O
the	DT	O	O
acute	JJ	O	O
phase	NN	O	O
of	IN	O	O
myocardial	JJ	O	O
infarction	NN	O	O
.	.	O	O

Gonadotropin-releasing	VBG	i	IPM
hormone	NN	i	IPM
agonist	NN	O	O
in	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
premenstrual	JJ	O	O
symptoms	NNS	O	O
with	IN	O	O
and	CC	O	O
without	IN	O	O
ongoing	VBG	O	O
dysphoria	NN	O	O
:	:	O	O
a	DT	O	O
controlled	VBN	O	O
study	NN	O	O
.	.	O	O

Gonadotropin-releasing	VBG	i	IPM
hormone	NN	i	IPM
(	(	i	IPM
GnRH	NNP	i	IPM
)	)	i	IPM
agonists	NNS	i	IPM
have	VBP	O	O
been	VBN	O	O
shown	VBN	O	O
to	TO	O	O
reduce	VB	O	O
symptoms	NNS	o	OPH
of	IN	o	OPH
premenstrual	JJ	o	OPH
syndrome	NN	o	OPH
(	(	o	OPH
PMS	NNP	o	OPH
)	)	o	OPH
.	.	o	OPH

This	DT	O	O
randomized	JJ	O	O
,	,	O	O
placebo-controlled	JJ	O	O
study	NN	O	O
examined	VBD	O	O
the	DT	O	O
efficacy	NN	O	O
of	IN	O	O
the	DT	O	O
GnRH	NNP	i	IPM
agonist	NN	i	IPM
,	,	O	O
leuprolide	JJ	O	O
acetate	NN	O	O
depot	NN	O	O
,	,	O	O
in	IN	O	O
a	DT	O	O
clearly	RB	p	O
defined	VBN	p	O
PMS	NNP	p	PC
sample	JJ	p	O
versus	NNS	p	O
women	NNS	p	PC
with	IN	p	O
premenstrual	JJ	p	PC
symptoms	NNS	p	O
in	IN	p	O
combination	NN	p	O
with	IN	p	O
dysphoric	NN	p	PC
symptoms	NNS	p	O
throughout	IN	p	O
the	DT	p	O
cycle	NN	p	O
,	,	p	O
termed	VBD	p	O
the	DT	p	O
premenstrual	JJ	p	O
exacerbation	NN	p	O
(	(	p	O
PME	NNP	p	O
)	)	p	O
group	NN	p	O
.	.	p	O

Evaluation	NN	O	O
included	VBD	O	O
the	DT	O	O
Structured	NNP	o	OOt
Clinical	NNP	o	OOt
Interview	NNP	o	OOt
for	IN	o	OOt
DSM-III-R	NNP	o	OOt
,	,	O	O
administered	VBN	O	O
in	IN	O	O
the	DT	O	O
follicular	JJ	O	O
phase	NN	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
subject	NN	o	OOt
Penn	NNP	o	OOt
Dally	NNP	o	OOt
Symptoms	NNP	o	OOt
Report	NNP	o	OOt
(	(	o	OOt
DSR	NNP	o	OOt
)	)	o	OOt
maintained	VBD	O	O
throughout	IN	O	O
the	DT	O	O
study	NN	O	O
.	.	O	O

Thirty-three	NNP	p	PSS
eligible	JJ	p	O
women	NNS	p	PSE
were	VBD	O	O
randomized	VBN	O	O
to	TO	O	O
double-blind	VB	O	O
treatment	NN	O	O
and	CC	O	O
administered	VBD	O	O
3.75	CD	i	IPM
mg	NN	i	IPM
of	IN	i	IPM
depot	NN	i	IPM
leuprolide	NN	i	IPM
or	CC	i	O
a	DT	i	O
placebo	NN	i	IC
once	RB	O	O
a	DT	O	O
month	NN	O	O
for	IN	O	O
3	CD	O	O
months	NNS	O	O
.	.	O	O

The	DT	O	O
subjects	NNS	O	O
were	VBD	O	O
seen	VBN	O	O
for	IN	O	O
efficacy	NN	o	OOt
evaluations	NNS	O	O
at	IN	O	O
the	DT	O	O
end	NN	O	O
of	IN	O	O
each	DT	O	O
cycle	NN	O	O
.	.	O	O

Outcome	CC	O	O
measures	NNS	O	O
were	VBD	O	O
the	DT	O	O
DSRs	NNP	o	OOt
and	CC	o	OPH
the	DT	o	OPH
17-item	JJ	o	OOt
Hamilton	NNP	o	OOt
Depression	NNP	o	OOt
Rating	NNP	o	OOt
Scale	NNP	o	OOt
(	(	o	OOt
HAM-D17	NNP	o	OOt
)	)	o	OOt
.	.	o	OPH

The	DT	O	O
PMS	NNP	O	O
leuprolide	JJ	i	IPM
subjects	NNS	O	O
improved	VBN	O	O
significantly	RB	O	O
compared	VBN	O	O
with	IN	O	O
the	DT	O	O
PMS	NNP	O	O
placebo	NN	O	O
and	CC	O	O
PME	NNP	O	O
leuprolide	RB	O	O
groups	NNS	O	O
.	.	O	O

The	DT	O	O
PME	NNP	O	O
leuprolide	NN	i	IPM
group	NN	O	O
,	,	O	O
who	WP	O	O
had	VBD	O	O
dysphoric	NN	o	OME
symptoms	NNS	o	OME
throughout	IN	O	O
the	DT	O	O
cycle	NN	O	O
,	,	O	O
did	VBD	O	O
not	RB	O	O
improve	VB	O	O
.	.	O	O

Depression	NNP	o	OME
symptoms	NNS	o	OME
were	VBD	O	O
at	IN	O	O
clinical	JJ	O	O
levels	NNS	O	O
premenstrually	RB	O	O
in	IN	O	O
the	DT	O	O
PMS	NNP	O	O
and	CC	O	O
PME	NNP	O	O
groups	NNS	O	O
;	:	O	O
following	VBG	O	O
treatment	NN	O	O
they	PRP	O	O
remitted	VBD	O	O
in	IN	O	O
the	DT	O	O
PMS	NNP	O	O
group	NN	O	O
but	CC	O	O
not	RB	O	O
in	IN	O	O
the	DT	O	O
PME	NNP	O	O
leuprolide	JJ	i	IPM
subjects	NNS	O	O
.	.	O	O

Efficacy	NN	O	O
did	VBD	O	O
not	RB	O	O
occur	VB	O	O
until	IN	O	O
after	IN	O	O
several	JJ	O	O
months	NNS	O	O
of	IN	O	O
leuprolide	JJ	i	IPM
treatment	NN	O	O
,	,	O	O
but	CC	O	O
there	EX	O	O
was	VBD	O	O
no	DT	O	O
evidence	NN	O	O
that	IN	O	O
PMS	NNP	o	OPH
symptoms	NNS	o	OPH
worsened	VBD	O	O
with	IN	O	O
the	DT	O	O
onset	NN	O	O
of	IN	O	O
treatment	NN	O	O
.	.	O	O

These	DT	O	O
results	NNS	O	O
replicate	VBP	O	O
the	DT	O	O
findings	NNS	O	O
in	IN	O	O
our	PRP$	O	O
preliminary	JJ	O	O
open-label	NN	O	O
study	NN	O	O
.	.	O	O

Leuprolide	NNP	i	IPM
reduced	VBD	O	O
PMS	NNP	o	OPH
symptoms	NNS	o	OPH
to	TO	O	O
minimal	JJ	O	O
levels	NNS	O	O
where	WRB	O	O
symptoms	NNS	O	O
were	VBD	O	O
limited	VBN	O	O
to	TO	O	O
the	DT	O	O
luteal	JJ	O	O
phase	NN	O	O
.	.	O	O

Leuprolide	NNP	i	IPM
was	VBD	O	O
not	RB	O	O
effective	JJ	O	O
for	IN	O	O
women	NNS	O	O
with	IN	O	O
ongoing	VBG	O	O
dysphoric	NN	O	O
symptoms	NNS	O	O
,	,	O	O
suggesting	VBG	O	O
that	IN	O	O
premenstrual	JJ	O	O
depression	NN	O	O
may	MD	O	O
have	VB	O	O
mechanisms	NNS	O	O
different	JJ	O	O
from	IN	O	O
those	DT	O	O
of	IN	O	O
other	JJ	O	O
dysphoric	JJ	O	O
mood	NN	O	O
disorders	NNS	O	O
.	.	O	O

Influence	NN	O	O
of	IN	O	O
special-effect	JJ	i	IPH
contact	NN	i	IPH
lenses	NNS	i	IPH
(	(	i	IPH
Crazy	NNP	i	IPH
Lenses	NNP	i	IPH
)	)	i	IPH
on	IN	O	O
visual	JJ	o	OPH
function	NN	o	OPH
.	.	o	O

PURPOSE	NNP	O	O
Special-effect	JJ	i	IPH
contact	NN	i	IPH
lenses	NNS	i	IPH
(	(	O	O
opaque	NN	O	O
,	,	O	O
tinted	VBD	O	O
soft	JJ	O	O
contact	NN	O	O
lenses	VBZ	O	O
that	IN	O	O
incorporate	JJ	O	O
decorative	JJ	O	O
images	NNS	O	O
such	JJ	O	O
as	IN	O	O
cateyes	NNS	O	O
,	,	O	O
stars	NNS	O	O
,	,	O	O
or	CC	O	O
hearts	NNS	O	O
to	TO	O	O
alter	VB	O	O
eye	NN	O	O
color	NN	O	O
and	CC	O	O
structure	NN	O	O
)	)	O	O
have	VBP	O	O
become	VBN	O	O
increasingly	RB	O	O
popular	JJ	O	O
.	.	O	O

The	DT	O	O
purpose	NN	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
investigate	VB	O	O
whether	IN	O	O
such	JJ	O	O
lenses	NNS	O	O
impair	VBP	O	O
visual	JJ	o	OPH
function	NN	o	OPH
.	.	o	O

METHODS	NNP	O	O
A	DT	i	IPH
clear	JJ	i	IPH
soft	JJ	i	IPH
contact	NN	i	IPH
lens	NNS	i	IPH
and	CC	i	O
a	DT	i	IPH
special-effect	JJ	i	IPH
soft	JJ	i	IPH
contact	NN	i	IPH
lens	NNS	i	IPH
(	(	i	IPH
Crazy	NNP	i	IPH
lens	VBZ	i	IPH
,	,	i	IPH
)	)	i	IPH
were	VBD	O	O
fit	JJ	O	O
in	IN	O	O
changing	VBG	O	O
sequence	NN	O	O
in	IN	O	O
nine	CD	p	PSS
healthy	JJ	p	PC
subjects	NNS	p	O
.	.	p	O

The	DT	O	O
parameters	NNS	O	O
studied	VBD	O	O
included	VBN	O	O
:	:	O	O
visual	JJ	o	OPH
acuity	NN	o	OPH
,	,	o	O
contrast	NN	o	OPH
sensitivity	NN	o	OPH
(	(	o	OPH
with	IN	o	OPH
and	CC	o	OPH
without	IN	o	OPH
glare	NN	o	OPH
)	)	o	OPH
,	,	o	O
visual	JJ	o	OPH
field	NN	o	OPH
,	,	o	O
and	CC	o	O
mesopic	NN	o	OPH
vision	NN	o	OPH
(	(	o	OPH
with	IN	o	OPH
and	CC	o	OPH
without	IN	o	OPH
glare	NN	o	OPH
)	)	o	OPH
.	.	o	O

RESULTS	VB	O	O
The	DT	O	O
following	JJ	O	O
parameters	NNS	O	O
displayed	VBD	O	O
a	DT	O	O
statistically	RB	O	O
significant	JJ	O	O
difference	NN	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

Visual	JJ	o	OPH
acuity	NN	o	OPH
was	VBD	O	O
decreased	VBN	O	O
to	TO	O	O
0.9	CD	O	O
+/-	JJ	O	O
0.23	CD	O	O
in	IN	O	O
the	DT	O	O
Crazy	NNP	O	O
lens	VBZ	O	O
group	NN	O	O
as	IN	O	O
compared	VBN	O	O
with	IN	O	O
1.2	CD	O	O
+/-	JJ	O	O
0.13	CD	O	O
in	IN	O	O
the	DT	O	O
clear	JJ	i	IPH
lens	NNS	i	IPH
group	NN	O	O
.	.	O	O

Goldmann	NNP	o	OPH
visual	JJ	o	OPH
field	NN	o	OPH
displayed	VBD	O	O
a	DT	O	O
significant	JJ	O	O
constriction	NN	o	OPH
of	IN	o	OPH
the	DT	o	OPH
isopters	NNS	o	OPH
:	:	o	O
III/4	NNP	O	O
,	,	O	O
I/4	NNP	O	O
,	,	O	O
and	CC	O	O
I/3	NNP	O	O
.	.	O	O

Mesopic	NNP	o	OPH
vision	NN	o	OPH
without	IN	o	OPH
glare	NN	o	OPH
was	VBD	O	O
reduced	VBN	O	O
from	IN	O	O
1:2.5	CD	O	O
to	TO	O	O
1:7.4	CD	O	O
.	.	O	O

Contrast	NNP	o	OPH
sensitivity	NN	o	OPH
was	VBD	O	O
significantly	RB	O	O
reduced	VBN	O	O
in	IN	O	O
a	DT	O	O
photopic	JJ	O	O
condition	NN	O	O
with	IN	O	O
and	CC	O	O
without	IN	O	O
glare	NN	O	O
and	CC	O	O
in	IN	O	O
a	DT	O	O
scotopic	JJ	O	O
condition	NN	O	O
without	IN	O	O
glare	NN	O	O
.	.	O	O

Furthermore	RB	O	O
,	,	O	O
the	DT	O	O
special-effect	JJ	i	IPH
lenses	NNS	i	IPH
were	VBD	O	O
associated	VBN	O	O
with	IN	O	O
a	DT	O	O
decrease	NN	O	O
in	IN	O	O
lens	NNS	o	OPH
wearing	VBG	o	OPH
comfort	NN	o	OPH
.	.	o	O

CONCLUSIONS	NNP	O	O
Special-effect	JJ	i	IPH
contact	NN	i	IPH
lenses	NNS	i	IPH
were	VBD	O	O
associated	VBN	O	O
with	IN	O	O
a	DT	O	O
reduction	NN	O	O
of	IN	O	O
many	JJ	O	O
visual	JJ	o	OPH
functions	NNS	o	OPH
,	,	O	O
including	VBG	O	O
visual	JJ	o	OPH
acuity	NN	o	OPH
and	CC	o	O
contrast	NN	o	OPH
sensitivity	NN	o	OPH
.	.	o	O

For	IN	O	O
some	DT	O	O
wearers	NNS	p	O
this	DT	O	O
may	MD	O	O
interfere	VB	O	O
with	IN	O	O
activities	NNS	O	O
where	WRB	O	O
excellent	JJ	O	O
vision	NN	O	O
is	VBZ	O	O
crucial	JJ	O	O
,	,	O	O
such	JJ	O	O
as	IN	O	O
driving	VBG	O	O
a	DT	O	O
car	NN	O	O
.	.	O	O

Response	NNP	O	O
prediction	NN	O	O
in	IN	O	O
metastasised	JJ	O	O
colorectal	NN	O	O
cancer	NN	O	O
using	VBG	O	O
intratumoural	JJ	O	O
thymidylate	JJ	O	O
synthase	NN	O	O
:	:	O	O
results	NNS	O	O
of	IN	O	O
a	DT	O	O
randomised	JJ	O	O
multicentre	NN	O	O
trial	NN	O	O
.	.	O	O

BACKGROUND	NNP	O	O
Molecular	NNP	O	O
markers	NNS	O	O
to	TO	O	O
predict	VB	O	O
response	NN	O	O
to	TO	O	O
5-fluorouracil	JJ	i	IPM
(	(	i	IPM
FU	NNP	i	IPM
)	)	i	IPM
-based	VBD	i	IPM
treatment	NN	O	O
of	IN	O	O
recurrent	NN	p	O
or	CC	p	O
metastasised	VBN	p	O
colorectal	JJ	p	O
cancer	NN	p	O
(	(	p	O
mCRC	NN	p	O
)	)	p	O
are	VBP	O	O
not	RB	O	O
established	VBN	O	O
.	.	O	O

The	DT	O	O
aim	NN	O	O
of	IN	O	O
this	DT	O	O
trial	NN	O	O
was	VBD	O	O
to	TO	O	O
determine	VB	O	O
the	DT	O	O
value	NN	O	O
of	IN	O	O
thymidylate	JJ	O	O
synthase	NN	O	O
(	(	O	O
TS	NNP	O	O
)	)	O	O
,	,	O	O
a	DT	O	O
key	JJ	O	O
enzyme	NN	O	O
of	IN	O	O
DNA	NNP	O	O
synthesis	NN	O	O
and	CC	O	O
target	NN	O	O
of	IN	O	O
5-FU	JJ	O	O
,	,	O	O
to	TO	O	O
predict	VB	o	OPH
response	NN	o	OPH
to	TO	O	O
chemotherapy	NN	O	O
of	IN	O	O
mCRC	NN	O	O
.	.	O	O

METHODS	NNP	O	O
Tumour	NNP	p	O
tissue	NN	p	O
was	VBD	p	O
obtained	VBN	p	O
from	IN	p	O
168	CD	p	O
patients	NNS	p	O
with	IN	p	O
mCRC	NN	p	O
for	IN	p	O
relative	JJ	p	O
thymidylate	NN	o	OPH
synthase	NN	o	OPH
(	(	o	OPH
TS	NNP	o	OPH
)	)	o	OPH
mRNA	NN	p	O
quantitation	NN	p	O
.	.	p	O

Patients	NNS	O	O
were	VBD	O	O
randomised	VBN	O	O
to	TO	O	O
receive	VB	O	O
either	DT	O	O
5-FU/folinic	JJ	i	IPM
acid	NN	i	IPM
(	(	i	IPM
FA	NNP	i	IPM
,	,	i	IPM
FUFA	NNP	i	IPM
)	)	i	IPM
alone	RB	i	IPM
or	CC	i	IPM
in	IN	i	IPM
combination	NN	i	IPM
with	IN	i	IPM
irinotecan	JJ	i	IPM
5-fluorouracil/folinic	JJ	i	IPM
acid	NN	i	IPM
and	CC	i	IPM
irinotecan	JJ	i	IPM
(	(	i	IPM
FOLFIRI	NNP	i	IPM
)	)	i	IPM
stratified	VBN	i	IPM
by	IN	i	IPM
TS	NNP	i	IPM
(	(	i	IPM
low	JJ	i	IPM
versus	RB	i	IPM
high	JJ	i	IPM
)	)	i	IPM
.	.	O	O

Primary	JJ	O	O
end-point	NN	O	O
was	VBD	O	O
overall	JJ	o	OPH
response	NN	o	OPH
to	TO	o	OPH
first-line	JJ	o	OPH
treatment	NN	o	OPH
among	IN	O	O
TS	NNP	O	O
high	JJ	O	O
patients	NNS	O	O
.	.	O	O

All	DT	O	O
parties	NNS	O	O
,	,	O	O
except	IN	O	O
for	IN	O	O
the	DT	O	O
randomisation	NN	O	O
centre	NN	O	O
,	,	O	O
were	VBD	O	O
blinded	VBN	O	O
for	IN	O	O
TS	NNP	O	O
status	NN	O	O
.	.	O	O

RESULTS	NNP	O	O
Biopsies	NNP	O	O
(	(	O	O
n=168	RB	O	O
)	)	O	O
were	VBD	O	O
taken	VBN	O	O
without	IN	O	O
complications	NNS	O	O
.	.	O	O

TS	NN	o	OPH
levels	NNS	o	OPH
were	VBD	O	O
available	JJ	O	O
for	IN	O	O
147	CD	O	O
patients	NNS	O	O
(	(	O	O
87.5	CD	O	O
%	NN	O	O
)	)	O	O
.	.	O	O

Analysing	VBG	O	O
response	NN	o	OPH
to	TO	o	OPH
FUFA	NNP	o	OPH
and	CC	o	OPH
FOLFIRI	NNP	o	OPH
in	IN	O	O
the	DT	O	O
per	NN	O	O
protocol	NN	O	O
set	VBN	O	O
(	(	O	O
n=119	NN	O	O
)	)	O	O
after	IN	O	O
un-blinding	JJ	O	O
TS	NNP	O	O
in	IN	O	O
the	DT	O	O
data	NN	O	O
base	NN	O	O
revealed	VBD	O	O
a	DT	O	O
trend	NN	O	O
to	TO	O	O
better	JJR	O	O
overall	JJ	O	O
response	NN	O	O
to	TO	O	O
FOLFIRI	NNP	O	O
(	(	O	O
9/19	CD	O	O
,	,	O	O
47	CD	O	O
%	NN	O	O
)	)	O	O
in	IN	O	O
TS	NNP	O	O
high	JJ	O	O
compared	VBN	O	O
to	TO	O	O
FUFA	NNP	O	O
(	(	O	O
5/23	CD	O	O
,	,	O	O
22	CD	O	O
%	NN	O	O
,	,	O	O
p=0.077	NN	O	O
)	)	O	O
.	.	O	O

In	IN	O	O
patients	NNS	O	O
with	IN	O	O
biopsies	NNS	O	O
taken	VBN	O	O
from	IN	O	O
liver	JJ	O	O
lesions	NNS	O	O
(	(	O	O
n=91	NN	O	O
)	)	O	O
overall	JJ	O	O
response	NN	O	O
to	TO	O	O
FOLFIRI	NNP	O	O
and	CC	O	O
FUFA	NNP	O	O
in	IN	O	O
TS	NNP	O	O
high	NN	O	O
was	VBD	O	O
53	CD	O	O
%	NN	O	O
(	(	O	O
9/17	CD	O	O
)	)	O	O
and	CC	O	O
18	CD	O	O
%	NN	O	O
(	(	O	O
3/17	CD	O	O
)	)	O	O
,	,	O	O
respectively	RB	O	O
(	(	O	O
p=0.035	NN	O	O
)	)	O	O
.	.	O	O

In	IN	O	O
patients	NNS	O	O
with	IN	O	O
low	JJ	O	O
TS	NNP	O	O
,	,	O	O
no	DT	O	O
remarkable	JJ	O	O
difference	NN	O	O
in	IN	O	O
overall	JJ	O	O
response	NN	O	O
to	TO	O	O
FOLFIRI	NNP	O	O
and	CC	O	O
FUFA	NNP	O	O
was	VBD	O	O
observed	VBN	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
Taking	VBG	O	O
a	DT	O	O
pre-treatment	JJ	O	O
biopsy	NN	O	O
is	VBZ	O	O
a	DT	O	O
safe	JJ	O	O
and	CC	O	O
feasible	JJ	O	O
procedure	NN	O	O
in	IN	O	O
mCRC	NN	O	O
.	.	O	O

After	IN	O	O
validation	NN	O	O
of	IN	O	O
our	PRP$	O	O
data	NNS	O	O
in	IN	O	O
a	DT	O	O
larger	JJR	O	O
group	NN	O	O
TS	NNP	O	O
determination	NN	O	O
may	MD	O	O
have	VB	O	O
the	DT	O	O
potential	NN	O	O
to	TO	O	O
better	JJR	O	O
help	NN	O	O
direct	VB	O	O
systemic	JJ	O	O
treatment	NN	O	O
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
primarily	RB	p	O
non-resectable	JJ	p	O
mCRC	NN	p	O
.	.	p	O

[	JJ	i	O
Intra-arterial	JJ	i	IPM
(	(	i	IPM
5-FU/FA	JJ	i	IPM
and	CC	i	IPH
FUDR	NNP	i	IPM
)	)	i	IPH
versus	VBP	i	O
systemic	JJ	i	IPM
chemotherapy	NN	i	IPM
(	(	i	IPM
5-FU/FA	JJ	i	IPM
)	)	i	IPM
of	IN	O	O
non-resectable	JJ	o	OPH
colorectal	JJ	o	OPH
liver	NN	o	OPH
metastases	NNS	o	OPH
]	VBP	o	O
.	.	O	O

The	DT	O	O
relative	JJ	o	OOt
efficacy	NN	o	OOt
of	IN	O	O
HAI	NNP	i	IPM
FUDR	NNP	i	IPM
,	,	i	IPH
HAI	NNP	i	IPM
5-FU/FA	CD	i	IPM
,	,	i	IPH
and	CC	i	IPH
i.v	NN	i	IPH
.	.	i	IPH

5-FU/FA	JJ	i	O
chemotherapy	NN	i	O
for	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
unresectable	JJ	p	O
colorectal	JJ	p	O
liver	NN	p	O
metastases	NNS	p	O
was	VBD	O	O
compared	VBN	O	O
in	IN	O	O
a	DT	O	O
prospective	JJ	O	O
randomized	VBN	O	O
clinical	JJ	O	O
trial	NN	O	O
.	.	O	O

The	DT	O	O
response	NN	o	OOt
rate	NN	o	OOt
after	IN	O	O
HAI	NNP	i	IPM
treatment	NN	O	O
was	VBD	O	O
significantly	RB	O	O
higher	JJR	O	O
as	IN	O	O
compared	VBN	O	O
to	TO	O	O
i.v	VB	O	O
.	.	O	O

treatment	NN	O	O
with	IN	O	O
no	DT	O	O
statistical	JJ	O	O
benefit	NN	O	O
regarding	VBG	O	O
survival	NN	o	OMO
and	CC	o	OPH
time	NN	o	OPH
to	TO	o	OPH
progression	NN	o	OPH
.	.	o	O

HAI	NNP	i	IPM
FUDR	NNP	i	IPM
treatment	NN	O	O
was	VBD	O	O
inferior	JJ	o	OOt
as	IN	O	O
compared	VBN	O	O
to	TO	O	O
HAI	NNP	i	IPM
or	CC	O	O
i.v	NN	O	O
.	.	O	O

5-FU/FA	JJ	i	IPM
.	.	i	IPM

i.v	NN	O	O
.	.	O	O

5-FU/FA-therapy	NN	i	IPM
is	VBZ	O	O
therefore	IN	O	O
the	DT	O	O
method	NN	O	O
of	IN	O	O
choice	NN	O	O
outside	IN	O	O
clinical	JJ	O	O
trials	NNS	O	O
.	.	O	O

Use	NNP	O	O
of	IN	O	O
high-dose	JJ	O	O
cytarabine	NN	i	IPM
to	TO	O	O
enhance	VB	O	O
cisplatin	JJ	i	IPM
cytotoxicity-effects	NNS	o	OA
on	IN	O	O
the	DT	O	O
response	NN	O	O
and	CC	O	O
overall	JJ	O	O
survival	NN	o	OMO
rates	NNS	o	OMO
of	IN	O	O
advanced	JJ	p	PC
head	NN	p	PC
and	CC	p	PC
neck	NN	p	PC
cancer	NN	p	PC
patients	NNS	p	PC
.	.	p	PC

UNLABELLED	IN	O	O
It	PRP	O	O
has	VBZ	O	O
been	VBN	O	O
reported	VBN	O	O
that	IN	O	O
cytarabine	NN	i	IPM
,	,	O	O
acting	VBG	O	O
by	IN	O	O
at	IN	O	O
least	JJS	O	O
two	CD	O	O
different	JJ	O	O
mechanisms	NNS	O	O
,	,	O	O
enhances	VBZ	O	O
the	DT	O	O
cytotoxic	JJ	O	O
effect	NN	O	O
of	IN	O	O
cisplatin	NN	i	IPM
in	IN	O	O
in	IN	O	O
vitro	JJ	O	O
systems	NNS	O	O
.	.	O	O

The	DT	O	O
aim	NN	O	O
of	IN	O	O
this	DT	O	O
open	JJ	O	O
,	,	O	O
prospective	JJ	O	O
,	,	O	O
randomised	VBD	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
estimate	VB	O	O
the	DT	O	O
eventual	JJ	O	O
benefits	NNS	O	O
from	IN	O	O
the	DT	O	O
inclusion	NN	O	O
of	IN	O	O
high-dose	JJ	O	O
cytarabine	NN	i	IPM
in	IN	O	O
the	DT	O	O
cisplatin-5-fluorouracil	NN	i	IPM
(	(	i	IPM
5-FU	JJ	i	IPM
)	)	i	IPM
regimen	NNS	O	O
as	IN	O	O
first-line	JJ	p	O
treatment	NN	p	O
of	IN	p	O
patients	NNS	p	O
with	IN	p	O
advanced	JJ	p	O
head	NN	p	O
and	CC	p	O
neck	NN	p	O
cancer	NN	p	O
.	.	p	O

The	DT	O	O
study	NN	O	O
recruited	VBD	O	O
successive	JJ	p	O
patients	NNS	p	O
with	IN	p	O
unresectable	JJ	p	O
grade	NN	p	O
I/II	NNP	p	O
head	NN	p	O
and	CC	p	O
neck	NN	p	O
cancer	NN	p	O
who	WP	p	O
were	VBD	p	O
not	RB	p	O
suitable	JJ	p	O
for	IN	p	O
irradiation	NN	i	IPH
treatment	NN	i	IPH
(	(	p	O
T	NNP	p	O
any	DT	p	O
N3	NNP	p	O
or	CC	p	O
T4	NNP	p	O
N2C	NNP	p	O
)	)	p	O
,	,	p	O
metastatic	JJ	p	O
or	CC	p	O
previously	RB	p	O
irradiated	VBN	p	O
.	.	p	O

All	DT	O	O
patients	NNS	O	O
gave	VBD	O	O
their	PRP$	O	O
informed	JJ	O	O
consent	NN	O	O
.	.	O	O

A	DT	O	O
joint	JJ	O	O
ear	NN	O	O
,	,	O	O
nose	JJ	O	O
and	CC	O	O
throat	NN	O	O
(	(	O	O
ENT	NNP	O	O
)	)	O	O
oncological	JJ	O	O
committee	NN	O	O
performed	VBD	O	O
the	DT	O	O
selection	NN	O	O
.	.	O	O

A	DT	p	PC
total	NN	p	PC
of	IN	p	PC
170	CD	p	PC
patients	NNS	p	PC
were	VBD	p	PC
included	VBN	p	PC
in	IN	p	PC
the	DT	p	PC
study	NN	p	PC
.	.	p	PC

Patients	NNS	O	O
randomised	VBD	O	O
to	TO	O	O
arm	VB	O	O
A	NNP	O	O
were	VBD	O	O
given	VBN	O	O
1000	CD	i	IPM
mg/m	NN	i	IPM
(	(	i	IPM
2	CD	i	IPM
)	)	i	IPM
cytarabine	NN	i	IPM
on	IN	O	O
day	NN	O	O
1	CD	O	O
preceding	NN	O	O
for	IN	O	O
6	CD	O	O
h	NN	O	O
cisplatin	NN	i	IPM
infusion	NN	i	IPM
,	,	O	O
30	CD	O	O
mg/m	NN	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
/24	NN	O	O
h	NN	O	O
cisplatin	NN	i	IPM
intravenous	JJ	O	O
(	(	O	O
i.v	JJ	O	O
.	.	O	O

)	)	O	O
bolus	JJ	O	O
days	NNS	O	O
1-4	CD	O	O
and	CC	O	O
1000	CD	O	O
mg/m	NN	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
/24	NN	O	O
h	JJ	O	O
5-FU	JJ	O	O
in	IN	O	O
a	DT	O	O
4-h	JJ	O	O
infusion	NN	O	O
on	IN	O	O
days	NNS	O	O
1-4	JJ	O	O
.	.	O	O

Patients	NNS	O	O
in	IN	O	O
arm	NN	O	O
B	NNP	O	O
were	VBD	O	O
given	VBN	O	O
cisplatin	NNS	i	IPM
and	CC	i	IPM
5-FU	JJ	i	IPM
in	IN	O	O
the	DT	O	O
same	JJ	O	O
dosage	NN	O	O
and	CC	O	O
schedule	NN	O	O
as	IN	O	O
in	IN	O	O
arm	NN	O	O
A	NNP	O	O
.	.	O	O

Additional	NNP	O	O
irradiation+/-surgery	NN	i	IS
was	VBD	O	O
performed	VBN	O	O
if	IN	O	O
and	CC	O	O
when	WRB	O	O
feasible	JJ	O	O
.	.	O	O

Patients	NNS	O	O
in	IN	O	O
both	DT	O	O
arms	NNS	O	O
were	VBD	O	O
well	RB	O	O
balanced	VBN	O	O
with	IN	O	O
regard	NN	O	O
to	TO	O	O
clinical	JJ	O	O
variables	NNS	O	O
.	.	O	O

The	DT	O	O
following	JJ	O	O
results	NNS	O	O
were	VBD	O	O
obtained	VBN	O	O
:	:	O	O
Arm	NN	O	O
A	NN	O	O
:	:	O	O
84	CD	O	O
patients	NNS	O	O
were	VBD	O	O
included	VBN	O	O
,	,	O	O
74	CD	O	O
were	VBD	O	O
evaluable	JJ	O	O
for	IN	O	O
activity	NN	O	O
;	:	O	O
RESPONSE	NNP	O	O
complete	JJ	o	OPH
response	NN	o	OPH
(	(	o	OPH
CR	NNP	o	OPH
)	)	o	OPH
8	CD	O	O
(	(	O	O
11	CD	O	O
%	NN	O	O
)	)	O	O
,	,	O	O
partial	JJ	o	OPH
response	NN	o	OPH
(	(	o	OPH
PR	NNP	o	OPH
)	)	o	OPH
40	CD	O	O
(	(	O	O
54	CD	O	O
%	NN	O	O
)	)	O	O
,	,	O	O
stable	JJ	o	OPH
disease	NN	o	OPH
(	(	o	OPH
SD	NNP	o	OPH
)	)	o	OPH
11	CD	O	O
(	(	O	O
15	CD	O	O
%	NN	O	O
)	)	O	O
,	,	O	O
progressive	JJ	o	OPH
disease	NN	o	OPH
(	(	O	O
PD	NNP	O	O
)	)	O	O
15	CD	O	O
(	(	O	O
20	CD	O	O
%	NN	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
overall	JJ	o	OPH
response	NN	o	OPH
rate	NN	o	OPH
(	(	o	OPH
RR	NNP	o	OPH
)	)	o	OPH
based	VBN	O	O
on	IN	O	O
the	DT	O	O
evaluable	JJ	O	O
patients	NNS	O	O
was	VBD	O	O
48/74	CD	O	O
(	(	O	O
65	CD	O	O
%	NN	O	O
,	,	O	O
95	CD	O	O
%	NN	O	O
confidence	NN	O	O
interval	NN	O	O
(	(	O	O
CI	NNP	O	O
)	)	O	O
54-75	CD	O	O
%	NN	O	O
)	)	O	O
;	:	O	O
The	DT	O	O
RR	NNP	o	OPH
based	VBN	o	OPH
on	IN	o	OPH
an	DT	o	OPH
intent-to-treat	JJ	o	OPH
analysis	NN	o	OPH
was	VBD	O	O
57	CD	O	O
%	NN	O	O
,	,	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
47-67	CD	O	O
%	NN	O	O
;	:	O	O
Median	JJ	o	OMO
survival	NN	o	OMO
was	VBD	O	O
13	CD	O	O
months	NNS	O	O
;	:	O	O
There	EX	O	O
were	VBD	O	O
50	CD	O	O
episodes	NNS	O	O
of	IN	O	O
granulocytopenia	NN	o	OPH
grade	NN	o	OPH
IV	NNP	o	OPH
and	CC	O	O
15	CD	O	O
of	IN	O	O
febrile	JJ	o	OPH
neutropenia	NNS	o	OPH
per	IN	O	O
316	CD	O	O
cycles	NNS	O	O
.	.	O	O

Arm	NN	O	O
B	NN	O	O
:	:	O	O
86	CD	O	O
patients	NNS	O	O
were	VBD	O	O
included	VBN	O	O
,	,	O	O
80	CD	O	O
were	VBD	O	O
evaluable	JJ	O	O
for	IN	O	O
activity	NN	O	O
;	:	O	O
RESPONSE	NNP	O	O
CR	NNP	o	OPH
7	CD	O	O
(	(	O	O
9	CD	O	O
%	NN	O	O
)	)	O	O
,	,	O	O
PR	NNP	o	OPH
29	CD	O	O
(	(	O	O
36	CD	O	O
%	NN	O	O
)	)	O	O
,	,	O	O
SD	NNP	o	OPH
10	CD	O	O
(	(	O	O
12.5	CD	O	O
%	NN	O	O
)	)	O	O
,	,	O	O
PD	NNP	o	OPH
34	CD	O	O
(	(	O	O
42.5	CD	O	O
%	NN	O	O
)	)	O	O
;	:	O	O
The	DT	O	O
overall	JJ	o	OPH
RR	NNP	o	OPH
based	VBN	O	O
on	IN	O	O
the	DT	O	O
evaluable	JJ	O	O
patients	NNS	O	O
was	VBD	O	O
36/80	CD	O	O
(	(	O	O
45	CD	O	O
%	NN	O	O
,	,	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
35-56	CD	O	O
%	NN	O	O
)	)	O	O
;	:	O	O
The	DT	O	O
RR	NNP	o	O
based	VBN	o	O
on	IN	o	O
an	DT	o	O
intent-to-treat	JJ	o	O
analysis	NN	o	O
was	VBD	O	O
42	CD	O	O
%	NN	O	O
,	,	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
32-52	CD	O	O
%	NN	O	O
;	:	O	O
Median	JJ	o	O
survival	NN	o	O
was	VBD	O	O
8	CD	O	O
months	NNS	O	O
;	:	O	O
There	EX	O	O
were	VBD	O	O
14	CD	O	O
episodes	NNS	O	O
of	IN	O	O
granulocytopenia	NN	O	O
grade	NN	O	O
IV	NNP	O	O
and	CC	O	O
7	CD	O	O
febrile	NN	O	O
neutropenias	NNS	O	O
per	IN	O	O
324	CD	O	O
cycles	NNS	O	O
.	.	O	O

The	DT	O	O
RR	NNP	o	OPH
was	VBD	o	OPH
significantly	RB	o	OPH
higher	JJR	o	OPH
in	IN	O	O
arm	NN	O	O
A	NNP	O	O
(	(	O	O
P=0.013	NNP	O	O
)	)	O	O
,	,	O	O
power	NN	O	O
(	(	O	O
one-sided	JJ	O	O
)	)	O	O
80	CD	O	O
%	NN	O	O
.	.	O	O

The	DT	O	O
proportion	NN	O	O
of	IN	O	O
patients	NNS	O	O
from	IN	O	O
the	DT	O	O
appropriate	JJ	O	O
subset	NN	O	O
who	WP	O	O
achieved	VBD	O	O
a	DT	O	O
clinical	JJ	o	O
response	NN	o	O
making	VBG	o	O
additional	JJ	o	O
treatment	NN	o	O
feasible	NN	o	O
was	VBD	O	O
higher	RBR	o	O
in	IN	O	O
arm	NN	O	O
A	NNP	O	O
(	(	O	O
P=0.00015	NNP	O	O
)	)	O	O
,	,	O	O
as	RB	O	O
well	RB	O	O
as	IN	O	O
the	DT	O	O
proportion	NN	o	OOt
of	IN	o	OOt
patients	NNS	o	OOt
with	IN	o	OOt
a	DT	o	OOt
performance	NN	o	OOt
status	NN	o	OOt
2+3	CD	o	OOt
achieving	VBG	o	OOt
a	DT	o	OOt
response	NN	o	OOt
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.0001	CD	O	O
)	)	O	O
.	.	O	O

Using	VBG	O	O
the	DT	O	O
Log-rank	JJ	O	O
test	NN	O	O
,	,	O	O
patients	NNS	O	O
from	IN	O	O
arm	NN	O	O
A	NNP	O	O
achieved	VBD	O	O
a	DT	O	O
significantly	RB	o	O
longer	RBR	o	O
survival	JJ	o	OMO
(	(	O	O
P=0.009	NNP	O	O
)	)	O	O
,	,	O	O
with	IN	O	O
the	DT	O	O
probability	NN	O	O
of	IN	O	O
survival	NN	o	OMO
at	IN	o	OMO
12	CD	o	OMO
months	NNS	o	OMO
of	IN	O	O
0.58	CD	O	O
for	IN	O	O
patients	NNS	O	O
in	IN	O	O
arm	NN	O	O
A	NN	O	O
and	CC	O	O
0.28	CD	O	O
for	IN	O	O
patients	NNS	O	O
in	IN	O	O
arm	NN	O	O
B.	NNP	O	O
Grade	NNP	o	OPH
IV	NNP	o	OPH
granulocytopenia	NN	o	OPH
and	CC	o	OPH
thrombocytopenia	NN	o	OPH
were	VBD	O	O
more	RBR	o	O
frequent	JJ	o	O
in	IN	O	O
arm	NN	O	O
A	NN	O	O
.	.	O	O

Due	JJ	O	O
to	TO	O	O
its	PRP$	O	O
haematological	JJ	o	OA
side-effects	NNS	o	OA
,	,	O	O
cytarabine	NN	i	IPM
might	MD	O	O
not	RB	O	O
be	VB	O	O
the	DT	O	O
ideal	JJ	O	O
drug	NN	O	O
to	TO	O	O
modulate	VB	O	O
the	DT	O	O
cytotoxicity	NN	o	OA
of	IN	O	O
cisplatin	NN	i	IPM
.	.	i	O

However	RB	O	O
,	,	O	O
other	JJ	O	O
modulators	NNS	O	O
of	IN	O	O
its	PRP$	O	O
activity	NN	O	O
could	MD	O	O
be	VB	O	O
of	IN	O	O
interest	NN	O	O
for	IN	O	O
further	JJ	O	O
studies	NNS	O	O
in	IN	O	O
head	NN	p	O
and	CC	p	O
neck	NN	p	O
cancer	NN	p	O
patients	NNS	p	O
.	.	p	O

Eberconazole	JJ	i	IPM
1	CD	O	O
%	NN	O	O
cream	NN	O	O
is	VBZ	O	O
an	DT	O	O
effective	JJ	o	OOt
and	CC	o	OOt
safe	JJ	o	OOt
alternative	NN	O	O
for	IN	O	O
dermatophytosis	NN	O	O
treatment	NN	O	O
:	:	O	O
multicenter	NN	O	O
,	,	O	O
randomized	VBN	O	O
,	,	O	O
double-blind	JJ	O	O
,	,	O	O
comparative	JJ	O	O
trial	NN	O	O
with	IN	O	O
miconazole	JJ	i	IPM
2	CD	O	O
%	NN	O	O
cream	NN	O	O
.	.	O	O

BACKGROUND	NNP	O	O
Eberconazole	NNP	i	IPM
is	VBZ	O	O
a	DT	O	O
topical	JJ	O	O
,	,	O	O
broad-spectrum	JJ	O	O
imidazole	NN	O	O
derivative	NN	O	O
,	,	O	O
effective	JJ	O	O
in	IN	O	O
dermatophytoses	NNS	O	O
,	,	O	O
candidiasis	NN	O	O
,	,	O	O
and	CC	O	O
pityriasis	NN	O	O
treatment	NN	O	O
.	.	O	O

In	IN	O	O
previous	JJ	O	O
trials	NNS	O	O
,	,	O	O
it	PRP	O	O
showed	VBD	O	O
a	DT	O	O
higher	JJR	O	O
efficacy	NN	O	O
than	IN	O	O
clotrimazole	NN	O	O
in	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
dermatophytoses	NNS	O	O
.	.	O	O

The	DT	O	O
purpose	NN	O	O
of	IN	O	O
this	DT	O	O
trial	NN	O	O
was	VBD	O	O
to	TO	O	O
evaluate	VB	O	O
the	DT	O	O
efficacy	NN	O	O
of	IN	O	O
eberconazole	JJ	i	IPM
1	CD	O	O
%	NN	O	O
cream	NN	O	O
compared	VBN	O	O
with	IN	O	O
miconazole	JJ	i	IPM
2	CD	O	O
%	NN	O	O
cream	NN	O	O
in	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
dermatophytoses	NNS	O	O
.	.	O	O

METHODS	NNP	O	O
A	NNP	O	O
multicenter	NN	O	O
,	,	O	O
double-blind	NN	O	O
,	,	O	O
randomized	VBN	O	O
trial	NN	O	O
was	VBD	O	O
performed	VBN	O	O
in	IN	O	O
653	CD	p	O
patients	NNS	p	O
with	IN	p	O
dermatophytoses	NNS	p	O
,	,	O	O
randomized	VBN	O	O
to	TO	O	O
eberconazole	VB	i	IPM
1	CD	O	O
%	NN	O	O
cream	NN	O	O
every	DT	O	O
12	CD	O	O
h	NN	O	O
or	CC	O	O
miconazole	VB	i	IPM
2	CD	O	O
%	NN	O	O
cream	NN	O	O
every	DT	O	O
12	CD	O	O
h	NN	O	O
for	IN	O	O
4	CD	O	O
weeks	NNS	O	O
.	.	O	O

Treatment	NNP	o	OOt
efficacy	NN	o	OOt
was	VBD	O	O
assessed	VBN	O	O
on	IN	O	O
the	DT	O	O
basis	NN	O	O
of	IN	O	O
the	DT	O	O
percentage	NN	O	O
of	IN	O	O
effective	JJ	O	O
response	NN	O	O
after	IN	O	O
4	CD	O	O
weeks	NNS	O	O
through	IN	O	O
mycologic	NN	O	O
and	CC	O	O
clinical	JJ	O	O
assessment	NN	O	O
.	.	O	O

RESULTS	NNP	O	O
Of	IN	O	O
the	DT	O	O
653	CD	p	O
patients	NNS	p	O
included	VBN	p	O
in	IN	p	O
the	DT	p	O
trial	NN	p	O
,	,	O	O
360	CD	O	O
produced	VBD	O	O
positive	JJ	O	O
baseline	NN	O	O
mycologic	NN	O	O
cultures	NNS	O	O
and	CC	O	O
were	VBD	O	O
included	VBN	O	O
in	IN	O	O
the	DT	O	O
efficacy	NN	O	O
assessment	NN	O	O
.	.	O	O

Clinical	JJ	O	O
efficacy	NN	O	O
was	VBD	O	O
shown	VBN	O	O
in	IN	O	O
76.1	CD	O	O
%	NN	O	O
of	IN	O	O
patients	NNS	O	O
receiving	VBG	O	O
eberconazole	JJ	O	O
and	CC	O	O
in	IN	O	O
75.0	CD	O	O
%	NN	O	O
of	IN	O	O
patients	NNS	O	O
receiving	VBG	O	O
miconazole	NN	O	O
.	.	O	O

The	DT	O	O
incidence	NN	O	O
of	IN	O	O
adverse	JJ	o	OA
events	NNS	o	OA
related	VBN	O	O
to	TO	O	O
treatment	NN	O	O
was	VBD	O	O
0.91	CD	O	O
%	NN	O	O
for	IN	O	O
eberconazole	NN	O	O
and	CC	O	O
0.92	CD	O	O
%	NN	O	O
for	IN	O	O
miconazole	NN	O	O
,	,	O	O
none	NN	O	O
being	VBG	O	O
serious	JJ	O	O
,	,	O	O
and	CC	O	O
all	DT	O	O
being	VBG	O	O
local	JJ	O	O
and	CC	O	O
transient	NN	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
Eberconazole	NNP	O	O
1	CD	O	O
%	NN	O	O
cream	NN	O	O
is	VBZ	O	O
an	DT	O	O
effective	JJ	O	O
treatment	NN	O	O
for	IN	O	O
fungal	JJ	O	O
infections	NNS	O	O
produced	VBN	O	O
by	IN	O	O
dermatophytes	NNS	O	O
,	,	O	O
with	IN	O	O
a	DT	O	O
good	JJ	O	O
safety	NN	o	OOt
and	CC	o	OOt
tolerability	NN	o	OOt
profile	NN	O	O
,	,	O	O
and	CC	O	O
can	MD	O	O
be	VB	O	O
considered	VBN	O	O
a	DT	O	O
good	JJ	O	O
alternative	NN	O	O
for	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
dermatophytoses	NNS	O	O
.	.	O	O

Effects	NNS	O	O
of	IN	O	O
Thai	NNP	O	O
traditional	JJ	O	O
massage	NN	O	O
on	IN	O	O
autistic	JJ	p	PC
children	NNS	p	PA
's	POS	p	PA
behavior	NN	p	O
.	.	p	O

OBJECTIVES	CC	O	O
The	DT	O	O
objective	NN	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
access	NN	O	O
whether	IN	O	O
there	EX	O	O
were	VBD	O	O
any	DT	O	O
therapeutic	JJ	O	O
effects	NNS	O	O
of	IN	O	O
Thai	NNP	i	IE
Traditional	NNP	i	IE
Massage	NNP	i	IE
(	(	i	IE
TTM	NNP	i	IE
)	)	i	IE
on	IN	O	O
major	JJ	O	O
behavioral	JJ	p	O
and	CC	p	O
emotional	JJ	p	O
disturbances	NNS	p	O
in	IN	p	O
Thai	NNP	p	O
autistic	JJ	p	O
children	NNS	p	O
.	.	p	O

DESIGN	NN	O	O
This	DT	O	O
was	VBD	O	O
a	DT	O	O
randomized	VBN	O	O
controlled	VBN	O	O
trial	NN	O	O
study	NN	O	O
.	.	O	O

SETTINGS/LOCATION	NNP	O	O
The	DT	p	O
study	NN	p	O
was	VBD	p	O
conducted	VBN	p	O
at	IN	p	O
the	DT	p	O
Rehabilitation	NNP	p	O
Centre	NNP	p	O
of	IN	p	O
the	DT	p	O
Thai	NNP	p	O
Red	NNP	p	O
Cross	NNP	p	O
Society	NNP	p	O
.	.	p	O

SUBJECTS	NNP	O	O
A	NNP	p	O
total	NN	p	O
of	IN	p	O
60	CD	p	PSS
autistic	JJ	p	PC
children	NNS	p	O
between	IN	p	O
the	DT	p	O
ages	NNS	p	O
of	IN	p	O
3	CD	p	PA
and	CC	p	PA
10	CD	p	PA
completed	VBD	p	O
this	DT	p	O
study	NN	p	O
.	.	p	O

INTERVENTIONS	NNP	O	O
Standard	NNP	i	IE
sensory	JJ	i	IE
integration	NN	i	IE
therapy	NN	i	IE
(	(	i	IE
SI	NNP	i	IE
)	)	i	IE
was	VBD	O	O
compared	VBN	O	O
to	TO	O	O
the	DT	O	O
SI	NNP	O	O
with	IN	O	O
TTM	NNP	i	IE
treatments	NNS	O	O
.	.	O	O

OUTCOME	NNP	O	O
MEASURES	NNP	O	O
Parents	NNP	O	O
and	CC	O	O
teachers	NNS	O	O
assessed	VBD	O	O
major	JJ	o	OME
behavior	NN	o	OME
disturbances	NNS	o	OME
using	VBG	O	O
the	DT	O	O
Conners	NNPS	o	OME
'	POS	o	OME
Rating	VBG	o	OME
Scales	NNS	o	OME
at	IN	O	O
0	CD	O	O
and	CC	O	O
8	CD	O	O
weeks	NNS	O	O
.	.	O	O

Sleep	JJ	o	OME
Diary	NNP	o	OME
(	(	o	OME
SD	NNP	o	OME
)	)	o	OME
,	,	O	O
recorded	VBN	O	O
by	IN	O	O
the	DT	O	O
parents	NNS	O	O
,	,	O	O
assessed	VBD	O	O
the	DT	O	O
patient	NN	O	O
's	POS	O	O
sleeping	NN	O	O
patterns	NNS	O	O
every	DT	O	O
week	NN	O	O
.	.	O	O

RESULTS	NNP	O	O
Sixty	NNP	p	PSS
(	(	p	PSS
60	CD	p	PSS
)	)	p	PSS
autistic	JJ	p	O
children	NNS	p	O
,	,	p	O
mean	JJ	p	O
age	NN	p	O
4.67	CD	p	PA
+/-	JJ	p	PA
1.82	CD	p	PA
,	,	p	O
were	VBD	p	O
recruited	VBN	p	O
.	.	p	O

No	DT	O	O
statistical	JJ	O	O
differences	NNS	O	O
were	VBD	O	O
seen	VBN	O	O
in	IN	O	O
the	DT	O	O
demographic	JJ	O	O
and	CC	O	O
baseline	JJ	O	O
data	NN	O	O
among	IN	O	O
both	DT	O	O
groups	NNS	O	O
.	.	O	O

From	IN	O	O
both	CC	O	O
the	DT	O	O
Conners	NNPS	o	OME
'	POS	o	OME
Teacher	NNP	o	OME
Questionnaire	NNP	o	OME
and	CC	o	O
SD	NNP	o	OME
,	,	O	O
statistical	JJ	O	O
improvement	NN	O	O
was	VBD	O	O
detected	VBN	O	O
for	IN	O	O
conduct	NN	o	OME
problem	NN	o	OME
,	,	o	OME
hyperactivity	NN	o	OME
,	,	o	OME
inattention-passivity	NN	o	OME
,	,	o	OME
hyperactivity	NN	o	OME
index	NN	o	OME
,	,	o	OME
and	CC	o	OME
sleeping	VBG	o	OME
behavior	NN	o	OME
.	.	o	O

However	RB	O	O
,	,	O	O
results	NNS	O	O
from	IN	O	O
the	DT	O	O
Conners	NNP	o	OME
'	POS	o	OME
Parent	NNP	o	OME
Questionnaire	NNP	o	OME
revealed	VBD	O	O
an	DT	O	O
improvement	NN	O	O
only	RB	O	O
for	IN	O	O
anxiety	NN	o	OPH
(	(	O	O
p	JJ	O	O
=	NNP	O	O
0.04	CD	O	O
)	)	O	O
in	IN	O	O
the	DT	O	O
massage	NN	O	O
group	NN	O	O
,	,	O	O
whereas	IN	O	O
when	WRB	O	O
both	DT	O	O
groups	NNS	O	O
were	VBD	O	O
compared	VBN	O	O
,	,	O	O
a	DT	O	O
significant	JJ	O	O
improvement	NN	O	O
in	IN	O	O
conduct	NN	o	OME
problem	NN	o	OME
(	(	O	O
p	JJ	O	O
=	NNP	O	O
0.03	CD	O	O
)	)	O	O
and	CC	O	O
anxiety	NN	o	OPH
(	(	O	O
p	JJ	O	O
=	NNP	O	O
0.01	CD	O	O
)	)	O	O
was	VBD	O	O
found	VBN	O	O
.	.	O	O

Results	NNS	O	O
indicated	VBD	O	O
that	IN	O	O
TTM	NNP	O	O
may	MD	O	O
have	VB	O	O
a	DT	O	O
positive	JJ	O	O
effect	NN	O	O
in	IN	O	O
improving	VBG	O	O
stereotypical	JJ	o	OME
behaviors	NNS	o	OME
in	IN	O	O
autistic	JJ	O	O
children	NNS	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
Over	IN	O	O
a	DT	O	O
period	NN	O	O
of	IN	O	O
8	CD	O	O
weeks	NNS	O	O
,	,	O	O
our	PRP$	O	O
findings	NNS	O	O
suggested	VBD	O	O
that	IN	O	O
TTM	NNP	O	O
could	MD	O	O
be	VB	O	O
used	VBN	O	O
as	IN	O	O
a	DT	O	O
complementary	JJ	O	O
therapy	NN	O	O
for	IN	O	O
autistic	JJ	O	O
children	NNS	O	O
in	IN	O	O
Thailand	NNP	p	O
.	.	p	O

Effects	NNS	O	O
of	IN	O	O
exposure	NN	O	O
to	TO	O	O
thin-ideal	JJ	O	O
media	NNS	O	O
images	NNS	O	O
on	IN	O	O
body	NN	o	OME
dissatisfaction	NN	o	OME
:	:	o	O
testing	VBG	O	O
the	DT	O	O
inclusion	NN	O	O
of	IN	O	O
a	DT	O	O
disclaimer	NN	i	IE
versus	NN	i	O
warning	VBG	i	IE
label	NN	i	IE
.	.	i	O

The	DT	O	O
current	JJ	O	O
study	NN	O	O
was	VBD	O	O
designed	VBN	O	O
to	TO	O	O
determine	VB	O	O
whether	IN	O	O
the	DT	O	O
inclusion	NN	O	O
of	IN	O	O
a	DT	O	O
disclaimer	NN	O	O
(	(	O	O
i.e.	FW	O	O
,	,	O	O
Retouched	NNP	O	O
photograph	NN	O	O
aimed	VBN	O	O
at	IN	O	O
changing	VBG	O	O
a	DT	O	O
person	NN	O	O
's	POS	O	O
physical	JJ	O	O
appearance	NN	O	O
.	.	O	O

)	)	O	O
or	CC	O	O
warning	VBG	O	O
(	(	O	O
i.e.	FW	O	O
,	,	O	O
Warning	VBG	O	O
:	:	O	O
Trying	NN	O	O
to	TO	O	O
look	VB	O	O
as	RB	O	O
thin	JJ	O	O
as	IN	O	O
this	DT	O	O
model	NN	O	O
may	MD	O	O
be	VB	O	O
dangerous	JJ	O	O
to	TO	O	O
your	PRP$	O	O
health	NN	O	O
.	.	O	O

)	)	O	O
added	VBD	O	O
to	TO	O	O
images	NNS	O	O
of	IN	O	O
thin/attractive	JJ	O	O
models	NNS	O	O
would	MD	O	O
affect	VB	O	O
body	NN	o	OME
dissatisfaction	NN	o	OME
and	CC	O	O
intent	NN	O	O
to	TO	O	O
diet	VB	O	O
in	IN	O	O
female	JJ	p	PSE
undergraduate	JJ	p	PSE
students	NNS	p	PSE
(	(	p	PSE
n=342	NN	p	PSE
)	)	p	PSE
.	.	p	PSE

Participants	NNS	O	O
were	VBD	O	O
randomly	RB	O	O
assigned	VBN	O	O
to	TO	O	O
one	CD	O	O
of	IN	O	O
four	CD	O	O
groups	NNS	i	O
:	:	i	O
(	(	i	O
a	DT	i	O
)	)	i	O
disclaimer	NN	i	IE
,	,	i	O
(	(	i	O
b	NN	i	O
)	)	i	O
warning	NN	i	IE
,	,	i	O
(	(	i	O
c	NN	i	O
)	)	i	O
model	NN	i	IC
control	NN	i	IC
,	,	i	O
or	CC	i	O
(	(	i	O
d	NN	i	O
)	)	i	O
car	NN	i	IC
control	NN	i	IC
.	.	i	O

Results	NNP	O	O
revealed	VBD	O	O
a	DT	O	O
significant	JJ	O	O
interaction	NN	O	O
between	IN	O	O
group	NN	O	O
and	CC	O	O
time	NN	O	O
,	,	O	O
whereby	WRB	O	O
only	RB	O	O
the	DT	O	O
car	NN	O	O
control	NN	O	O
group	NN	O	O
reported	VBD	O	O
a	DT	O	O
significant	JJ	O	O
change	NN	O	O
(	(	O	O
i.e.	FW	O	O
,	,	O	O
decrease	NN	O	O
)	)	O	O
in	IN	O	O
body	NN	o	OME
dissatisfaction	NN	o	OME
over	IN	O	O
time	NN	O	O
.	.	O	O

Groups	NNP	O	O
did	VBD	O	O
not	RB	O	O
differ	VB	O	O
on	IN	O	O
intent	NN	O	O
to	TO	O	O
diet	VB	o	OME
measured	VBN	O	O
at	IN	O	O
post-exposure	NN	O	O
.	.	O	O

The	DT	O	O
results	NNS	O	O
largely	RB	O	O
replicate	VBP	O	O
other	JJ	O	O
findings	NNS	O	O
in	IN	O	O
this	DT	O	O
area	NN	O	O
and	CC	O	O
call	VB	O	O
into	IN	O	O
question	NN	O	O
advocacy	NN	O	O
efforts	NNS	O	O
to	TO	O	O
label	VB	O	O
media	NNS	O	O
images	NNS	O	O
as	IN	O	O
a	DT	O	O
strategy	NN	O	O
to	TO	O	O
decrease	VB	O	O
women	NNS	p	PSE
's	POS	p	PSE
identification	NN	O	O
with	IN	O	O
the	DT	O	O
stimuli	NNS	O	O
.	.	O	O

[	JJ	O	O
Effects	NNS	O	O
of	IN	O	O
an	DT	O	O
intensive	JJ	i	O
therapy	NN	i	O
program	NN	i	O
for	IN	O	O
behaviorally	RB	p	PC
disordered	VBN	p	PC
mentally	RB	p	PC
handicapped	JJ	p	PC
patients	NNS	p	O
on	IN	p	O
staff	NN	p	O
personnel	NNS	p	O
in	IN	p	O
residential	JJ	p	O
care	NN	p	O
]	NNP	p	O
.	.	O	O

This	DT	O	O
study	NN	O	O
evaluates	VBZ	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
an	DT	O	O
intensive	JJ	i	IPS
therapy	NN	i	IPS
program	NN	i	IPS
designed	VBN	O	O
for	IN	O	O
mentally	RB	p	PC
handicapped	JJ	p	PC
persons	NNS	p	O
with	IN	p	O
severely	RB	p	O
disturbed	VBN	p	O
or	CC	p	O
autistic	JJ	p	PC
behavior	NN	p	PC
on	IN	p	O
their	PRP$	p	O
staff	NN	p	O
personal	JJ	p	O
which	WDT	p	O
had	VBD	p	O
an	DT	p	O
active	JJ	p	O
role	NN	p	O
in	IN	p	O
the	DT	p	O
program	NN	p	O
.	.	p	O

The	DT	O	O
staff	NN	O	O
members	NNS	O	O
rated	VBD	O	O
their	PRP$	O	O
professional	JJ	O	O
competence	NN	O	O
,	,	O	O
quality	NN	O	O
of	IN	O	O
interaction	NN	O	O
with	IN	O	O
the	DT	O	O
client	NN	O	O
,	,	O	O
team	JJ	O	O
culture	NN	O	O
and	CC	O	O
work	NN	O	O
satisfaction	NN	O	O
before	IN	O	O
and	CC	O	O
after	IN	O	O
being	VBG	O	O
engaged	VBN	O	O
in	IN	O	O
the	DT	O	O
program	NN	O	O
,	,	O	O
with	IN	O	O
additional	JJ	O	O
ratings	NNS	O	O
of	IN	O	O
their	PRP$	O	O
personal	JJ	O	O
aims	NNS	O	O
at	IN	O	O
the	DT	O	O
beginning	NN	O	O
of	IN	O	O
the	DT	O	O
program	NN	O	O
.	.	O	O

Three	NNP	O	O
sets	NNS	O	O
of	IN	O	O
data	NNS	O	O
were	VBD	O	O
obtained	VBN	O	O
with	IN	O	O
the	DT	O	O
program	NN	O	O
being	VBG	O	O
conducted	VBN	O	O
three	CD	O	O
times	NNS	O	O
in	IN	O	O
a	DT	O	O
row	NN	O	O
.	.	O	O

The	DT	O	O
testings	NNS	O	O
of	IN	O	O
the	DT	O	O
related	VBN	O	O
as	RB	O	O
well	RB	O	O
as	IN	O	O
the	DT	O	O
independent	JJ	O	O
samples	NNS	O	O
show	VBP	O	O
differentiated	JJ	O	O
program	NN	O	O
effects	NNS	O	O
.	.	O	O

The	DT	O	O
main	JJ	O	O
effect	NN	O	O
is	VBZ	O	O
an	DT	O	O
increase	NN	O	O
of	IN	O	O
the	DT	O	O
professional	JJ	o	OOt
competence	NN	o	OOt
and	CC	o	OOt
quality	NN	o	OOt
of	IN	o	OOt
interaction	NN	o	OOt
,	,	O	O
especially	RB	O	O
by	IN	O	O
the	DT	O	O
qualified	JJ	O	O
staff	NN	O	O
members	NNS	O	O
.	.	O	O

Trainees	NNP	O	O
put	VBD	O	O
emphasis	NN	O	O
on	IN	O	O
the	DT	O	O
development	NN	O	O
of	IN	O	O
their	PRP$	O	O
personal	JJ	O	O
relationship	NN	O	O
with	IN	O	O
the	DT	O	O
client	NN	O	O
.	.	O	O

The	DT	O	O
results	NNS	O	O
are	VBP	O	O
discussed	VBN	O	O
in	IN	O	O
terms	NNS	O	O
of	IN	O	O
the	DT	O	O
impact	NN	O	O
of	IN	O	O
learning	VBG	O	O
processes	NNS	O	O
specific	JJ	O	O
to	TO	O	O
the	DT	O	O
roles	NNS	O	O
of	IN	O	O
the	DT	O	O
staff	NN	O	O
members	NNS	O	O
and	CC	O	O
motivational	JJ	O	O
factors	NNS	O	O
on	IN	O	O
learning	NN	O	O
and	CC	O	O
therapy	NN	O	O
outcome	NN	O	O
,	,	O	O
along	IN	O	O
with	IN	O	O
institutional	JJ	O	O
conditions	NNS	O	O
influencing	VBG	O	O
successful	JJ	O	O
learning	NN	O	O
.	.	O	O

Thus	VB	O	O
the	DT	O	O
program	NN	O	O
facilitates	VBZ	O	O
the	DT	O	O
professional	JJ	O	O
and	CC	O	O
interpersonal	JJ	O	O
learning	NN	O	O
process	NN	O	O
of	IN	O	O
staff	NN	O	O
members	NNS	O	O
in	IN	O	O
a	DT	O	O
specific	JJ	O	O
way	NN	O	O
with	IN	O	O
success	NN	O	O
as	RB	O	O
well	RB	O	O
as	IN	O	O
with	IN	O	O
limitations	NNS	O	O
.	.	O	O

Relaxation	NN	i	IE
and	CC	i	IE
imagery	NN	i	IE
and	CC	i	IE
cognitive-behavioral	JJ	i	IE
training	NN	i	IE
reduce	VB	O	O
pain	NN	o	OPA
during	IN	O	O
cancer	NN	O	O
treatment	NN	O	O
:	:	O	O
a	DT	O	O
controlled	JJ	O	O
clinical	JJ	O	O
trial	NN	O	O
.	.	O	O

Few	NNP	O	O
controlled	VBD	O	O
clinical	JJ	O	O
trials	NNS	O	O
of	IN	O	O
psychological	JJ	O	O
interventions	NNS	O	O
for	IN	O	O
cancer	NN	o	OPA
pain	NN	o	OPA
relief	NN	o	OPA
exist	NN	O	O
in	IN	O	O
spite	NN	O	O
of	IN	O	O
frequent	JJ	O	O
support	NN	O	O
for	IN	O	O
their	PRP$	O	O
importance	NN	O	O
as	IN	O	O
adjuncts	NNS	O	O
to	TO	O	O
medical	JJ	O	O
treatment	NN	O	O
.	.	O	O

This	DT	O	O
study	NN	O	O
compared	VBN	O	O
oral	JJ	O	O
mucositis	NN	O	O
pain	NN	O	O
levels	NNS	O	O
in	IN	O	O
4	CD	p	O
groups	NNS	p	O
of	IN	p	O
cancer	NN	p	O
patients	NNS	p	O
receiving	VBG	p	O
bone	NN	p	O
marrow	NN	p	O
transplants	NNS	p	O
(	(	p	O
BMT	NNP	p	O
)	)	p	O
:	:	p	O
(	(	p	O
1	CD	p	O
)	)	p	O
treatment	NN	i	IC
as	IN	i	IC
usual	JJ	i	IC
control	NN	i	IC
,	,	i	O
(	(	i	O
2	CD	i	O
)	)	i	O
therapist	NN	i	IE
support	NN	i	IE
,	,	i	IE
(	(	i	IE
3	CD	i	IE
)	)	i	IE
relaxation	NN	i	IE
and	CC	i	IE
imagery	NN	i	IE
training	NN	i	IE
,	,	i	IE
and	CC	i	IE
(	(	i	IE
4	CD	i	IE
)	)	i	IE
training	NN	i	IE
in	IN	i	IE
a	DT	i	IE
package	NN	i	IE
of	IN	i	IE
cognitive-behavioral	JJ	i	IE
coping	NN	i	IE
skills	NNS	i	IE
which	WDT	i	IE
included	VBD	i	IE
relaxation	NN	i	IE
and	CC	i	IE
imagery	NN	i	IE
.	.	i	O

A	DT	O	O
total	NN	O	O
of	IN	O	O
94	CD	p	O
patients	NNS	p	O
completed	VBD	p	O
the	DT	p	O
study	NN	p	O
which	WDT	p	O
involved	VBD	p	O
two	CD	p	O
training	NN	p	O
sessions	NNS	p	O
prior	RB	p	O
to	TO	p	O
treatment	NN	p	O
and	CC	p	O
twice	RB	p	O
a	DT	p	O
week	NN	p	O
'booster	POS	p	O
'	POS	p	O
sessions	NNS	p	O
during	IN	p	O
the	DT	p	O
first	JJ	p	O
5	CD	p	O
weeks	NNS	p	O
of	IN	p	O
treatment	NN	p	O
.	.	p	O

Results	NNS	O	O
confirmed	VBD	O	O
our	PRP$	O	O
hypothesis	NN	O	O
that	IN	O	O
patients	NNS	O	O
who	WP	O	O
received	VBD	O	O
either	DT	O	O
relaxation	NN	O	O
and	CC	O	O
imagery	VB	O	O
alone	RB	O	O
or	CC	O	O
patients	NNS	O	O
who	WP	O	O
received	VBD	O	O
the	DT	O	O
package	NN	O	O
of	IN	O	O
cognitive-behavioral	JJ	O	O
coping	NN	O	O
skills	NNS	O	O
would	MD	O	O
report	VB	O	O
less	JJR	O	O
pain	NN	o	OPA
than	IN	O	O
patients	NNS	O	O
in	IN	O	O
the	DT	O	O
other	JJ	O	O
2	CD	O	O
groups	NNS	O	O
.	.	O	O

The	DT	O	O
hypothesis	NN	O	O
that	IN	O	O
the	DT	O	O
cognitive-behavioral	JJ	O	O
skills	NNS	O	O
package	NN	O	O
would	MD	O	O
have	VB	O	O
an	DT	O	O
additive	JJ	O	O
effect	NN	O	O
beyond	IN	O	O
relaxation	NN	O	O
and	CC	O	O
imagery	NN	O	O
alone	RB	O	O
was	VBD	O	O
not	RB	O	O
confirmed	VBN	O	O
.	.	O	O

Average	JJ	o	OPA
visual	JJ	o	OPA
analogue	NN	o	OPA
scale	NN	o	OPA
(	(	o	OPA
VAS	NNP	o	OPA
)	)	o	OPA
report	NN	o	OPA
of	IN	o	OPA
pain	NN	o	OPA
within	IN	O	O
the	DT	O	O
therapist	JJ	O	O
support	NN	O	O
group	NN	O	O
was	VBD	O	O
not	RB	O	O
significantly	RB	O	O
lower	JJR	O	O
than	IN	O	O
the	DT	O	O
control	NN	O	O
group	NN	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.103	CD	O	O
)	)	O	O
nor	CC	O	O
significantly	RB	O	O
higher	JJR	O	O
than	IN	O	O
the	DT	O	O
training	NN	O	O
groups	NNS	O	O
.	.	O	O

Patient	JJ	O	O
reports	NNS	O	O
of	IN	O	O
relative	JJ	O	O
helpfulness	NN	O	O
of	IN	O	O
the	DT	O	O
interventions	NNS	O	O
for	IN	O	O
managing	VBG	O	O
pain	NN	o	OPA
and	CC	o	O
nausea	NN	o	OPA
matched	VBD	O	O
the	DT	O	O
results	NNS	O	O
of	IN	O	O
VAS	NNP	O	O
reports	NNS	O	O
.	.	O	O

From	IN	O	O
these	DT	O	O
results	NNS	O	O
,	,	O	O
we	PRP	O	O
conclude	VBP	O	O
that	DT	O	O
relaxation	NN	O	O
and	CC	O	O
imagery	NN	O	O
training	NN	O	O
reduces	NNS	O	O
cancer	NN	o	OPA
treatment-related	JJ	o	OPA
pain	NN	o	OPA
;	:	o	O
adding	VBG	O	O
cognitive-behavioral	JJ	O	O
skills	NNS	O	O
to	TO	O	O
the	DT	O	O
relaxation	NN	O	O
with	IN	O	O
imagery	NN	O	O
does	VBZ	O	O
not	RB	O	O
,	,	O	O
on	IN	O	O
average	NN	O	O
,	,	O	O
further	JJ	O	O
improve	VB	O	O
pain	NN	o	OPA
relief	NN	o	OPA
.	.	o	O

Comparison	NNP	O	O
of	IN	O	O
chemotherapy	NN	i	IPM
with	IN	i	O
chemohormonal	JJ	i	IPM
therapy	NN	i	IPM
as	IN	O	O
first-line	JJ	O	O
therapy	NN	O	O
for	IN	O	O
metastatic	JJ	p	PC
,	,	p	PC
hormone-sensitive	JJ	p	PC
breast	NN	p	PC
cancer	NN	p	PC
:	:	p	O
An	DT	p	O
Eastern	JJ	p	O
Cooperative	NNP	p	O
Oncology	NNP	p	O
Group	NNP	p	O
study	NN	p	O
.	.	p	O

PURPOSE	NNP	O	O
Although	IN	O	O
hormonal	JJ	O	O
therapy	NN	O	O
represents	VBZ	O	O
standard	JJ	O	O
therapy	NN	O	O
for	IN	O	O
metastatic	JJ	O	O
hormone-sensitive	JJ	O	O
disease	NN	O	O
,	,	O	O
many	JJ	O	O
patients	NNS	O	O
receive	VBP	O	O
initial	JJ	O	O
chemotherapy	NN	i	IPM
because	IN	O	O
of	IN	O	O
the	DT	O	O
location	NN	O	O
,	,	O	O
bulk	NN	O	O
,	,	O	O
or	CC	O	O
aggressiveness	NN	O	O
of	IN	O	O
their	PRP$	O	O
disease	NN	O	O
.	.	O	O

It	PRP	O	O
is	VBZ	O	O
uncertain	JJ	O	O
whether	IN	O	O
simultaneous	JJ	i	IPM
hormonal	JJ	i	IPM
therapy	NN	i	IPM
provides	VBZ	O	O
additional	JJ	O	O
benefit	NN	O	O
compared	VBN	O	O
with	IN	O	O
chemotherapy	NN	O	O
alone	RB	O	O
.	.	O	O

Eastern	JJ	O	O
Cooperative	NNP	O	O
Oncology	NNP	O	O
Group	NNP	O	O
trial	NN	O	O
E3186	NNP	O	O
was	VBD	O	O
initiated	VBN	O	O
to	TO	O	O
explore	VB	O	O
this	DT	O	O
question	NN	O	O
.	.	O	O

PATIENTS	NN	O	O
AND	CC	O	O
METHODS	NNP	O	O
Between	NNP	p	O
January	NNP	p	O
1988	CD	p	O
and	CC	p	O
December	NNP	p	O
1992	CD	p	O
,	,	p	O
231	CD	p	PSS
patients	NNS	p	O
with	IN	p	O
estrogen	JJ	p	O
receptor	NN	p	O
(	(	p	O
ER	NNP	p	O
)	)	p	O
-positive	CD	p	O
or	CC	p	O
ER-unknown	JJ	p	O
metastatic	JJ	p	O
breast	NN	p	O
cancer	NN	p	O
were	VBD	O	O
randomized	VBN	O	O
to	TO	O	O
receive	VB	O	O
either	DT	O	O
chemotherapy	NN	i	O
(	(	i	O
cyclophosphamide	NN	i	O
,	,	i	O
doxorubicin	NN	i	O
,	,	i	O
and	CC	i	O
fluorouracil	RB	i	O
?CAF	NNP	i	O
)	)	i	O
or	CC	i	O
chemohormonal	JJ	i	O
therapy	NN	i	O
(	(	i	O
CAF	NNP	i	O
plus	CC	i	O
tamoxifen	NN	i	O
and	CC	i	O
Halotestin	NNP	i	O
?fluoxymesterone	NN	i	O
;	:	i	O
Pharmacia-Upjohn	NNP	i	O
,	,	i	O
Kalamazoo	NNP	i	O
,	,	i	O
MI	NNP	i	O
?CAFTH	NNP	i	O
)	)	i	O
as	IN	i	O
front-line	JJ	i	O
therapy	NN	i	O
for	IN	i	O
metastatic	JJ	O	O
breast	NN	O	O
cancer	NN	O	O
.	.	O	O

Patients	NNS	O	O
who	WP	O	O
experienced	VBD	O	O
a	DT	O	O
complete	JJ	O	O
response	NN	O	O
to	TO	O	O
induction	NN	O	O
therapy	NN	O	O
either	CC	O	O
received	VBD	O	O
or	CC	O	O
did	VBD	O	O
not	RB	O	O
receive	JJ	O	O
maintenance	NN	O	O
cyclophosphamide	NN	O	O
,	,	O	O
methotrexate	NN	O	O
,	,	O	O
fluorouracil	NN	O	O
,	,	O	O
prednisone	NN	O	O
,	,	O	O
and	CC	O	O
TH	NNP	O	O
as	IN	O	O
a	DT	O	O
secondary	JJ	O	O
randomization	NN	O	O
.	.	O	O

RESULTS	VB	O	O
The	DT	O	O
response	NN	o	O
rates	NNS	o	O
(	(	o	O
complete	JJ	o	O
response	NN	o	O
and	CC	o	O
partial	JJ	o	O
response	NN	o	O
)	)	o	O
of	IN	o	O
patients	NNS	O	O
who	WP	O	O
received	VBD	O	O
CAF	NNP	O	O
and	CC	O	O
CAFTH	NNP	O	O
were	VBD	O	O
similar	JJ	O	O
(	(	O	O
69.2	CD	O	O
%	NN	O	O
v	JJ	O	O
68.9	CD	O	O
%	NN	O	O
,	,	O	O
respectively	RB	O	O
;	:	O	O
P	NNP	O	O
=.99	NNP	o	O
)	)	o	O
.	.	o	O

Time	NN	o	O
to	TO	o	O
treatment	NN	o	O
failure	NN	o	O
(	(	o	O
TTF	NNP	o	O
)	)	o	O
was	VBD	o	O
slightly	RB	O	O
longer	JJR	O	O
for	IN	O	O
patients	NNS	O	O
who	WP	O	O
received	VBD	O	O
chemohormonal	JJ	O	O
therapy	NN	O	O
compared	VBN	O	O
with	IN	O	O
chemotherapy	NN	O	O
alone	RB	O	O
patients	NNS	O	O
(	(	O	O
13.4	CD	O	O
months	NNS	O	O
v	RB	O	O
10.3	CD	O	O
months	NNS	O	O
,	,	O	O
respectively	RB	O	O
;	:	O	O
P	NNP	O	O
=.087	NNP	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
TTF	NNP	o	O
was	VBD	o	O
significantly	RB	O	O
longer	RBR	O	O
in	IN	O	O
ER-positive	JJ	O	O
compared	VBN	O	O
with	IN	O	O
ER-negative	JJ	O	O
patients	NNS	O	O
(	(	O	O
17.4	CD	O	O
months	NNS	O	O
v	RB	O	O
10.3	CD	O	O
months	NNS	O	O
,	,	O	O
respectively	RB	O	O
;	:	O	O
P	NNP	O	O
=.048	NNP	O	O
)	)	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
ER	NNP	O	O
status	NN	O	O
had	VBD	O	O
no	DT	O	O
effect	NN	O	O
on	IN	O	O
overall	JJ	o	O
survival	NN	o	O
(	(	o	O
30.0	CD	o	O
months	NNS	O	O
for	IN	O	O
CAF	NNP	O	O
v	FW	O	O
29.3	CD	O	O
months	NNS	O	O
for	IN	O	O
CAFTH	NNP	O	O
)	)	O	O
.	.	O	O

CONCLUSION	NNP	O	O
In	IN	O	O
patients	NNS	O	O
with	IN	O	O
potentially	RB	O	O
hormone-sensitive	JJ	O	O
metastatic	JJ	O	O
breast	NN	O	O
cancer	NN	i	O
,	,	i	O
chemohormonal	JJ	i	O
therapy	NN	i	O
prolongs	NNS	i	O
TTF	NNP	O	O
for	IN	O	O
ER-positive	JJ	O	O
patients	NNS	O	O
without	IN	O	O
improving	VBG	O	O
overall	JJ	O	O
survival	NN	O	O
.	.	O	O

Digestive	JJ	i	IPM
enzyme	NN	i	IPM
supplementation	NN	i	IPM
for	IN	O	O
autism	NN	p	PC
spectrum	NN	p	PC
disorders	NNS	p	PC
:	:	p	O
a	DT	O	O
double-blind	JJ	O	O
randomized	NN	O	O
controlled	VBD	O	O
trial	NN	O	O
.	.	O	O

To	TO	O	O
examine	VB	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
a	DT	O	O
digestive	JJ	i	IPM
enzyme	NN	i	IPM
supplement	NN	i	IPM
in	IN	O	O
improving	VBG	O	O
expressive	JJ	o	OME
language	NN	o	OME
,	,	o	O
behaviour	NN	o	OME
and	CC	o	O
other	JJ	o	OME
symptoms	NNS	o	OME
in	IN	O	O
children	NNS	p	O
with	IN	p	O
Autism	NNP	p	PC
Spectrum	NNP	p	PC
Disorder	NNP	p	PC
.	.	p	PC

Randomized	VBN	O	O
,	,	O	O
double-blind	JJ	O	O
placebo-controlled	JJ	i	IC
trial	NN	O	O
using	VBG	O	O
crossover	NN	O	O
design	NN	O	O
over	IN	O	O
6	CD	O	O
months	NNS	O	O
for	IN	O	O
43	CD	p	PSS
children	NNS	p	O
,	,	p	O
aged	VBN	p	O
3-8	CD	p	O
years	NNS	p	O
.	.	p	O

Outcome	NNP	O	O
measurement	NN	O	O
tools	NNS	O	O
included	VBD	O	O
monthly	JJ	O	O
Global	NNP	o	OOt
Behaviour	NNP	o	OOt
Rating	NNP	o	OOt
Scales	NNP	o	OOt
,	,	o	O
Additional	NNP	o	OPH
Rating	NNP	o	OPH
Scales	NNP	o	OPH
of	IN	o	OPH
other	JJ	o	OPH
symptoms	NNS	o	OPH
by	IN	o	OPH
parents	NNS	o	OPH
and	CC	o	OPH
therapists	NNS	o	OPH
,	,	O	O
and	CC	O	O
monthly	JJ	o	OOt
completion	NN	o	OOt
of	IN	o	OOt
the	DT	o	OOt
Rescorla	NNP	o	OOt
Language	NNP	o	OOt
Development	NNP	o	OOt
Survey	NNP	o	OOt
.	.	o	O

Compared	VBN	O	O
with	IN	O	O
placebo	NN	i	IC
,	,	O	O
treatment	NN	O	O
with	IN	O	O
enzyme	NN	i	IPM
was	VBD	O	O
not	RB	O	O
associated	VBN	O	O
with	IN	O	O
clinically	RB	O	O
significant	JJ	o	OPH
improvement	NN	o	OPH
in	IN	o	OPH
behaviour	NN	o	OPH
,	,	o	O
food	NN	o	OPH
variety	NN	o	OPH
,	,	o	O
gastrointestinal	JJ	o	OPH
symptoms	NNS	o	OPH
,	,	o	O
sleep	JJ	o	OPH
quality	NN	o	OPH
,	,	o	O
engagement	NN	o	OOt
with	IN	o	OOt
therapist	NN	o	OOt
,	,	o	O
or	CC	o	O
the	DT	o	OOt
Language	NNP	o	OOt
Development	NNP	o	OOt
Survey	NNP	o	OOt
Vocabulary	NNP	o	OOt
or	CC	o	OOt
Sentence	NNP	o	OOt
Complexity	NNP	o	OOt
Scores	NNP	o	OOt
.	.	o	O

A	NNP	O	O
small	JJ	O	O
statistically	RB	O	O
significant	JJ	o	OOt
improvement	NN	o	OOt
on	IN	O	O
enzyme	NN	O	O
therapy	NN	O	O
was	VBD	O	O
seen	VBN	O	O
for	IN	O	O
the	DT	O	O
food	NN	O	O
variety	NN	O	O
scores	NNS	O	O
.	.	O	O

No	DT	O	O
clinically	RB	O	O
significant	JJ	O	O
effect	NN	O	O
improvement	NN	O	O
of	IN	O	O
autism	NN	o	OPH
symptoms	NNS	o	OPH
with	IN	O	O
enzyme	NN	O	O
use	NN	O	O
was	VBD	O	O
shown	VBN	O	O
with	IN	O	O
this	DT	O	O
trial	NN	O	O
,	,	O	O
however	RB	O	O
,	,	O	O
possible	JJ	O	O
effects	NNS	O	O
on	IN	O	O
improvement	NN	o	OME
in	IN	o	OME
food	NN	o	OME
variety	NN	o	OME
warrants	NNS	O	O
further	RBR	O	O
detailed	JJ	O	O
investigation	NN	O	O
.	.	O	O

The	DT	O	O
adrenocorticotrophic	JJ	i	IPM
hormone	NN	i	IPM
(	(	i	IPM
4-9	JJ	i	IPM
)	)	i	IPM
analog	NN	i	IPM
ORG	IN	i	IPM
2766	CD	i	IPM
benefits	NNS	O	O
autistic	JJ	p	O
children	NNS	p	O
:	:	p	O
report	NN	O	O
on	IN	O	O
a	DT	O	O
second	JJ	O	O
controlled	JJ	O	O
clinical	JJ	O	O
trial	NN	O	O
.	.	O	O

In	IN	O	O
a	DT	O	O
second	JJ	O	O
controlled	VBN	O	O
crossover	NN	O	O
trial	NN	O	O
,	,	O	O
20	CD	p	O
autistic	JJ	p	O
children	NNS	p	O
received	VBD	p	O
40	CD	i	IPM
mg/day	NN	i	IPM
of	IN	i	IPM
the	DT	i	IPM
neuropeptide	NN	i	IPM
ORG	NNP	i	IPM
2766	CD	i	IPM
,	,	i	IPM
a	DT	i	IPM
synthetic	JJ	i	IPM
analog	NN	i	IPM
of	IN	i	IPM
ACTH	NNP	i	IPM
(	(	i	IPM
4-9	JJ	i	IPM
)	)	i	IPM
,	,	p	O
for	IN	p	O
8	CD	p	O
weeks	NNS	p	O
.	.	p	O

Parents	NNS	o	OOt
'	POS	o	OOt
checklist	NN	o	OOt
ratings	NNS	o	OOt
(	(	o	OOt
ABC	NNP	o	OOt
)	)	o	OOt
as	RB	O	O
well	RB	O	O
as	IN	O	O
clinicians	NNS	o	OOt
'	POS	o	OOt
ratings	NNS	o	OOt
(	(	o	OOt
CGI	NNP	o	OOt
)	)	o	OOt
pointed	VBD	O	O
to	TO	O	O
significant	JJ	O	O
improvements	NNS	O	O
after	IN	O	O
the	DT	O	O
course	NN	O	O
of	IN	O	O
treatment	NN	O	O
;	:	O	O
improvements	NNS	O	O
were	VBD	O	O
clearest	VBN	O	O
on	IN	O	O
the	DT	O	O
ABC	NNP	o	OOt
social	JJ	o	OOt
withdrawal	NN	o	OOt
subscale	NN	o	OOt
.	.	o	OOt

The	DT	O	O
analysis	NN	O	O
of	IN	O	O
individual	JJ	O	O
target	NN	O	O
symptoms	NNS	O	O
and	CC	O	O
the	DT	O	O
parents	NNS	O	O
'	POS	O	O
treatment	NN	O	O
preferences	NNS	O	O
substantiated	VBD	O	O
the	DT	O	O
beneficial	JJ	O	O
effects	NNS	O	O
of	IN	O	O
ORG	NNP	i	IPM
2766	CD	i	IPM
.	.	i	IPM

In	IN	O	O
an	DT	O	O
ethologically	RB	O	O
analyzed	JJ	O	O
playroom	NN	O	O
session	NN	O	O
,	,	O	O
ORG	NNP	O	O
2766	CD	O	O
treatment	NN	O	O
was	VBD	O	O
associated	VBN	O	O
with	IN	O	O
an	DT	O	O
improvement	NN	O	O
in	IN	O	O
the	DT	O	O
children	NNS	o	OME
's	POS	o	OME
play	NN	o	OME
behavior	NN	o	OME
and	CC	O	O
a	DT	O	O
significant	JJ	O	O
increase	NN	O	O
in	IN	O	O
the	DT	O	O
social	JJ	o	OME
interaction	NN	o	OME
between	IN	o	OME
child	NN	o	OME
and	CC	o	OME
experimenter	NN	o	OME
.	.	o	OME

Gaze	NNP	o	OME
coordination	NN	o	OME
between	IN	O	O
child	NN	O	O
and	CC	O	O
experimenter	NN	O	O
also	RB	O	O
was	VBD	O	O
improved	VBN	O	O
.	.	O	O

Disopyramide-pyridostigmine	JJ	i	IPM
interaction	NN	O	O
:	:	O	O
selective	JJ	O	O
reversal	NN	O	O
of	IN	O	O
anticholinergic	NN	O	O
symptoms	NNS	O	O
with	IN	O	O
preservation	NN	O	O
of	IN	O	O
antiarrhythmic	JJ	O	O
effect	NN	O	O
.	.	O	O

This	DT	O	O
double-blind	NN	O	O
,	,	O	O
randomized	VBN	O	O
,	,	O	O
placebo	FW	i	IC
crossover	NN	O	O
study	NN	O	O
was	VBD	O	O
used	VBN	O	O
to	TO	O	O
evaluate	VB	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
a	DT	O	O
cholinesterase	NN	i	IPM
inhibitor	NN	i	IPM
--	:	i	IPM
slow-release	JJ	i	IPM
pyridostigmine	NN	i	IPM
(	(	O	O
180	CD	O	O
mg	NNS	O	O
orally	RB	O	O
every	DT	O	O
12	CD	O	O
hours	NNS	O	O
)	)	O	O
--	:	O	O
on	IN	O	O
the	DT	O	O
anticholinergic	NN	o	OPH
and	CC	o	OPH
antiarrhythmic	JJ	o	OPH
properties	NNS	o	OPH
of	IN	O	O
disopyramide	NN	i	IPM
.	.	i	O

Quantitative	JJ	O	O
side	NN	O	O
effects	NNS	O	O
questionnaire	VBP	O	O
scores	NNS	O	O
were	VBD	O	O
used	VBN	O	O
to	TO	O	O
guide	VB	O	O
disopyramide	JJ	i	IPM
administration	NN	O	O
in	IN	O	O
20	CD	p	PSS
men	NNS	p	PSE
with	IN	p	O
ventricular	JJ	p	PC
tachycardia	NN	p	PC
.	.	p	O

Disopyramide	NNP	i	IPM
was	VBD	O	O
given	VBN	O	O
to	TO	O	O
each	DT	O	O
patient	NN	p	O
both	DT	p	O
with	IN	p	O
placebo	NN	i	IC
and	CC	p	O
with	IN	p	O
active	JJ	p	PC
pyridostigmine	NN	i	IPM
.	.	i	O

The	DT	O	O
maximal	JJ	O	O
administered	VBD	O	O
dose	NN	O	O
for	IN	O	O
each	DT	O	O
regimen	NN	O	O
was	VBD	O	O
used	VBN	O	O
in	IN	O	O
conjunction	NN	O	O
with	IN	O	O
corresponding	JJ	O	O
questionnaire	NN	O	O
scores	NNS	O	O
to	TO	O	O
calculate	VB	O	O
an	DT	O	O
index	NN	O	O
or	CC	O	O
estimate	NN	O	O
of	IN	O	O
the	DT	O	O
maximal	JJ	o	OOt
tolerable	JJ	o	OOt
dose	NN	o	OOt
of	IN	O	O
disopyramide	NN	i	IPM
.	.	i	O

Additional	JJ	O	O
evaluations	NNS	O	O
performed	VBN	O	O
at	IN	O	O
baseline	NN	O	O
and	CC	O	O
at	IN	O	O
each	DT	O	O
maximal	NN	O	O
administered	VBD	O	O
dose	JJ	O	O
regimen	NNS	O	O
included	VBD	O	O
tear	JJ	o	OPH
and	CC	o	OPH
saliva	JJ	o	OPH
quantitation	NN	o	OPH
,	,	o	OPH
24	CD	o	OPH
hour	NN	o	OPH
electrocardiogram	NN	o	OPH
(	(	o	OPH
ECG	NNP	o	OPH
)	)	o	OPH
,	,	o	OPH
exercise	VBP	o	OPH
testing	VBG	o	OPH
and	CC	o	OPH
programmed	VBD	o	OPH
ventricular	JJ	o	OPH
stimulation	NN	o	OPH
.	.	o	OPH

Results	NNS	O	O
showed	VBD	O	O
that	IN	O	O
the	DT	O	O
maximal	NN	O	O
administered	VBD	O	O
dose	NN	O	O
of	IN	O	O
disopyramide	NN	i	IPM
was	VBD	O	O
greater	JJR	O	O
with	IN	O	O
active	JJ	O	O
pyridostigmine	NN	i	IPM
than	IN	O	O
with	IN	O	O
placebo	NN	O	O
:	:	O	O
295	CD	O	O
+/-	JJ	O	O
75	CD	O	O
versus	NN	O	O
245	CD	O	O
+/-	JJ	O	O
100	CD	O	O
mg	NN	O	O
every	DT	O	O
6	CD	O	O
hours	NNS	O	O
(	(	O	O
p	NN	O	O
less	JJR	O	O
than	IN	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
calculated	JJ	O	O
maximal	NN	o	OOt
tolerable	JJ	o	OOt
dose	NN	o	OOt
was	VBD	O	O
substantially	RB	O	O
greater	JJR	O	O
in	IN	O	O
the	DT	O	O
presence	NN	O	O
of	IN	O	O
pyridostigmine	NN	i	IPM
:	:	i	O
355	CD	O	O
+/-	JJ	O	O
90	CD	O	O
versus	NN	O	O
260	CD	O	O
+/-	JJ	O	O
115	CD	O	O
mg	NN	O	O
every	DT	O	O
6	CD	O	O
hours	NNS	O	O
(	(	O	O
p	NN	O	O
less	JJR	O	O
than	IN	O	O
0.001	CD	O	O
)	)	O	O
.	.	O	O

Maximal	JJ	o	OA
side	NN	o	OA
effects	NNS	o	OA
questionnaire	NN	o	OA
scores	NNS	o	OA
also	RB	O	O
reflected	VBD	O	O
decreased	JJ	O	O
anticholinergic	JJ	o	OPH
activity	NN	o	OPH
in	IN	O	O
the	DT	O	O
presence	NN	O	O
of	IN	O	O
pyridostigmine	NN	i	IPM
compared	VBN	O	O
with	IN	O	O
placebo	NN	i	IC
:	:	i	O
101.9	CD	O	O
+/-	JJ	O	O
2.2	CD	O	O
versus	NN	O	O
104.6	CD	O	O
+/-	JJ	O	O
2.8	CD	O	O
,	,	O	O
respectively	RB	O	O
(	(	O	O
p	NN	O	O
less	JJR	O	O
than	IN	O	O
0.005	CD	O	O
)	)	O	O
.	.	O	O

Baseline	NNP	O	O
tear	NN	O	O
and	CC	O	O
saliva	JJ	O	O
production	NN	O	O
was	VBD	O	O
significantly	RB	O	O
reduced	VBN	O	O
during	IN	O	O
disopyramide	JJ	O	O
therapy	NN	O	O
,	,	O	O
but	CC	O	O
was	VBD	O	O
restored	VBN	O	O
toward	IN	O	O
normal	JJ	O	O
by	IN	O	O
the	DT	O	O
addition	NN	O	O
of	IN	O	O
pyridostigmine	NN	O	O
.	.	O	O

(	(	O	O
ABSTRACT	NNP	O	O
TRUNCATED	NNP	O	O
AT	NNP	O	O
250	CD	O	O
WORDS	NNP	O	O
)	)	O	O
MF101	NNP	i	IPM
,	,	i	IPM
a	DT	i	IPM
selective	JJ	i	IPM
estrogen	NN	i	IPM
receptor	NN	i	IPM
beta	NN	O	O
modulator	NN	O	O
for	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
menopausal	NN	O	O
hot	JJ	O	O
flushes	NNS	O	O
:	:	O	O
a	DT	O	O
phase	NN	O	O
II	NNP	O	O
clinical	JJ	O	O
trial	NN	O	O
.	.	O	O

OBJECTIVE	NN	O	O
To	TO	O	O
determine	VB	O	O
the	DT	O	O
optimal	JJ	O	O
dose	NN	O	O
,	,	O	O
safety	NN	O	O
,	,	O	O
and	CC	O	O
efficacy	NN	O	O
of	IN	O	O
an	DT	O	O
estrogen	NN	i	IPM
receptor	NN	i	IPM
beta	NN	i	IPM
selective	JJ	i	IPM
Chinese	NNP	i	IPM
herbal	NN	i	IPM
extract	NN	i	IPM
,	,	i	O
menopausal	JJ	i	IPM
formula	NN	i	IPM
101	CD	i	IPM
(	(	O	O
MF101	NNP	O	O
)	)	O	O
,	,	O	O
for	IN	O	O
treating	VBG	O	O
hot	JJ	O	O
flushes	NNS	O	O
.	.	O	O

METHODS	NNP	O	O
A	NNP	O	O
randomized	NN	p	O
,	,	p	O
blinded	VBD	p	O
trial	NN	p	O
in	IN	p	O
217	CD	p	PSS
postmenopausal	JJ	p	PC
women	NNS	p	PSE
with	IN	p	O
hot	JJ	p	PC
flushes	NNS	p	PC
randomized	VBD	p	O
to	TO	p	O
5	CD	p	O
or	CC	p	O
10	CD	p	O
g/day	NN	p	O
of	IN	p	O
MF101	NNP	i	IPM
or	CC	i	O
placebo	NN	i	IC
for	IN	p	O
12	CD	p	O
weeks	NNS	p	O
.	.	p	O

RESULTS	VB	O	O
The	DT	O	O
effects	NNS	O	O
of	IN	O	O
5	CD	O	O
g/day	NN	O	O
of	IN	O	O
MF101	NNP	O	O
did	VBD	O	O
not	RB	O	O
differ	VB	O	O
from	IN	O	O
those	DT	O	O
of	IN	O	O
placebo	NN	i	IC
.	.	i	O

After	IN	O	O
12	CD	O	O
weeks	NNS	O	O
,	,	O	O
the	DT	O	O
mean	JJ	o	OOt
percent	NN	o	OOt
decrease	NN	o	OOt
in	IN	o	OOt
frequency	NN	o	OOt
of	IN	o	OOt
hot	JJ	o	OOt
flushes	NNS	o	OOt
in	IN	O	O
the	DT	O	O
10	CD	O	O
g/day	NN	O	O
group	NN	O	O
was	VBD	O	O
12.9	CD	O	O
%	NN	O	O
greater	JJR	O	O
than	IN	O	O
that	DT	O	O
in	IN	O	O
the	DT	O	O
placebo	NN	i	IC
group	NN	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.15	CD	O	O
)	)	O	O
,	,	O	O
the	DT	O	O
median	JJ	O	O
percent	NN	O	O
decrease	NN	O	O
was	VBD	O	O
11.7	CD	O	O
%	NN	O	O
greater	JJR	O	O
than	IN	O	O
that	DT	O	O
in	IN	O	O
the	DT	O	O
placebo	NN	O	O
group	NN	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.05	CD	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
proportion	NN	o	OOt
of	IN	o	OOt
women	NNS	o	OOt
with	IN	o	OOt
at	IN	o	OOt
least	JJS	o	OOt
a	DT	o	OOt
50	CD	o	OOt
%	NN	o	OOt
reduction	NN	o	OOt
in	IN	o	OOt
hot	JJ	o	OOt
flushes	NNS	o	OOt
was	VBD	O	O
16.2	CD	O	O
%	NN	O	O
greater	JJR	O	O
than	IN	O	O
that	DT	O	O
in	IN	O	O
the	DT	O	O
placebo	NN	O	O
group	NN	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.03	CD	O	O
)	)	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
Treatment	NNP	O	O
with	IN	O	O
10	CD	O	O
g/day	NN	O	O
of	IN	O	O
MF101	NNP	i	IPM
reduces	VBZ	O	O
the	DT	O	O
frequency	NN	O	O
of	IN	O	O
hot	JJ	O	O
flushes	NNS	O	O
.	.	O	O

Trials	NNS	O	O
with	IN	O	O
higher	JJR	O	O
doses	NNS	O	O
are	VBP	O	O
planned	VBN	O	O
.	.	O	O

Sustained	VBN	O	O
oral	JJ	o	OPH
health	NN	o	OPH
improvement	NN	o	OPH
and	CC	O	O
use	NN	O	O
of	IN	O	O
toothbrushes	NNS	i	IPH
and	CC	i	IPH
dentifrice	NN	i	IPH
by	IN	O	O
previous	JJ	p	O
users	NNS	p	O
of	IN	p	O
traditional	JJ	p	O
materials	NNS	p	O
in	IN	p	O
a	DT	p	O
rural	JJ	p	O
population	NN	p	O
in	IN	p	O
Andhra	NNP	p	O
Pradesh	NNP	p	O
,	,	p	O
India	NNP	p	O
.	.	p	O

AIM	NNP	O	O
To	TO	O	O
follow-up	NN	O	O
,	,	O	O
one	CD	O	O
year	NN	O	O
later	RB	O	O
,	,	O	O
a	DT	O	O
double-blind	NN	O	O
,	,	O	O
randomised	VBN	O	O
study	NN	O	O
,	,	O	O
which	WDT	O	O
investigated	VBD	O	O
the	DT	O	O
effect	NN	o	OOt
of	IN	O	O
regular	JJ	i	IPH
brushing	NN	i	IPH
with	IN	i	IPH
dentifrices	NNS	i	IPH
on	IN	O	O
the	DT	O	O
oral	JJ	p	PC
health	NN	p	PC
of	IN	p	O
an	DT	p	O
economically	RB	p	O
disadvantaged	JJ	p	O
rural	JJ	p	O
population	NN	p	O
in	IN	p	O
Andhra	NNP	p	O
Pradesh	NNP	p	O
,	,	p	O
India	NNP	p	O
who	WP	p	O
were	VBD	p	O
primarily	RB	p	O
users	NNS	p	O
of	IN	p	O
traditional	JJ	p	O
materials	NNS	p	O
.	.	p	O

SUBJECTS	NNP	O	O
150	CD	p	PSS
of	IN	p	O
the	DT	p	O
original	JJ	p	O
study	NN	p	O
population	NN	p	O
.	.	p	O

METHOD	NNP	O	O
Examination	NNP	O	O
to	TO	O	O
determine	VB	O	O
whether	IN	O	O
the	DT	O	O
improvements	NNS	o	OPH
in	IN	o	OPH
oral	JJ	o	OPH
health	NN	o	OPH
status	NN	o	OPH
and	CC	o	OPH
oral	JJ	o	OPH
health	NN	o	OPH
behaviour	NN	o	OPH
(	(	O	O
use	NN	O	O
of	IN	O	O
toothbrush	NN	i	IPH
and	CC	i	IPH
dentifrice	NN	i	IPH
)	)	i	O
,	,	O	O
being	VBG	O	O
unsupported	JJ	O	O
,	,	O	O
had	VBD	O	O
been	VBN	O	O
sustained	VBN	O	O
since	IN	O	O
completion	NN	O	O
of	IN	O	O
the	DT	O	O
original	JJ	O	O
study	NN	O	O
.	.	O	O

RESULTS	NNP	O	O
Data	NNP	O	O
analysis	NN	O	O
showed	VBD	O	O
sustained	VBN	O	O
,	,	O	O
statistically	RB	o	O
significant	JJ	o	O
improvements	NNS	o	O
in	IN	o	O
gingival	JJ	o	OPH
health	NN	o	OPH
as	IN	o	OPH
measured	VBN	o	OPH
by	IN	o	OPH
gingival	NN	o	OPH
bleeding	NN	o	OPH
and	CC	o	OPH
plaque	NN	o	OPH
indices	NNS	o	OPH
(	(	o	OPH
GBI	NNP	o	OPH
and	CC	o	OPH
PI	NNP	o	OPH
)	)	o	OPH
comparing	VBG	O	O
users	NNS	O	O
and	CC	O	O
non-users	NNS	O	O
of	IN	O	O
toothbrushes	NNS	O	O
and	CC	O	O
dentifrice	NN	O	O
in	IN	O	O
the	DT	O	O
original	JJ	O	O
study	NN	O	O
(	(	O	O
PI	NNP	O	O
:	:	O	O
p	NN	O	O
=	VBZ	O	O
0.04	CD	O	O
;	:	O	O
GBI	NNP	O	O
:	:	O	O
p	NN	O	O
=	VBZ	O	O
0.03	CD	O	O
)	)	O	O
and	CC	O	O
sustained	VBN	o	OOt
use	NN	o	OOt
of	IN	o	OOt
toothbrushes	NNS	o	OOt
and	CC	o	OOt
dentifrice	NN	o	OOt
by	IN	O	O
60	CD	O	O
%	NN	O	O
of	IN	O	O
the	DT	O	O
subjects	NNS	O	O
at	IN	O	O
follow-up	JJ	O	O
one	CD	O	O
year	NN	O	O
later	RB	O	O
.	.	O	O

CONCLUSIONS	VB	O	O
This	DT	O	O
study	NN	O	O
shows	VBZ	O	O
a	DT	O	O
beneficial	JJ	o	OPH
effect	NN	o	OPH
on	IN	o	OPH
oral	JJ	o	OPH
hygiene	NN	o	OPH
indices	NNS	O	O
following	VBG	O	O
the	DT	O	O
introduction	NN	i	IPH
of	IN	i	IPH
toothbrushes	NNS	i	IPH
and	CC	i	IPH
dentifrices	NNS	i	IPH
to	TO	O	O
a	DT	O	O
community	NN	O	O
using	VBG	O	O
traditional	JJ	O	O
oral	JJ	O	O
hygiene	NN	O	O
materials	NNS	O	O
and	CC	O	O
sustainability	NN	O	O
of	IN	O	O
use	NN	O	O
of	IN	O	O
these	DT	O	O
materials	NNS	O	O
with	IN	O	O
motivation	NN	O	O
and	CC	O	O
support	NN	O	O
.	.	O	O

It	PRP	O	O
may	MD	O	O
therefore	RB	O	O
be	VB	O	O
concluded	VBN	O	O
that	IN	O	O
it	PRP	O	O
is	VBZ	O	O
feasible	JJ	O	O
to	TO	O	O
achieve	VB	O	O
significant	JJ	O	O
use	NN	O	O
of	IN	O	O
conventional	JJ	O	O
toothbrushes	NNS	O	O
and	CC	O	O
toothpastes	NNS	O	O
,	,	O	O
with	IN	O	O
consequent	JJ	O	O
major	JJ	O	O
and	CC	O	O
sustained	JJ	O	O
improvements	NNS	O	O
in	IN	O	O
plaque	NN	O	O
control	NN	O	O
and	CC	O	O
gingival	JJ	O	O
health	NN	O	O
in	IN	O	O
a	DT	O	O
disadvantaged	JJ	O	O
population	NN	O	O
hitherto	NN	O	O
often	RB	O	O
considered	VBN	O	O
as	IN	O	O
not	RB	O	O
amenable	JJ	O	O
to	TO	O	O
conventional	JJ	O	O
oral	JJ	O	O
hygiene	NN	O	O
for	IN	O	O
cultural	JJ	O	O
or	CC	O	O
economic	JJ	O	O
reasons	NNS	O	O
.	.	O	O

Effect	NN	O	O
of	IN	O	O
systemic	JJ	O	O
nitric	JJ	i	IPM
oxide	IN	i	IPM
synthase	JJ	i	IPM
inhibition	NN	O	O
on	IN	O	O
postexercise	NN	p	PC
hypotension	NN	p	PC
in	IN	p	O
humans	NNS	p	O
.	.	p	O

An	DT	O	O
acute	JJ	O	O
bout	NN	O	O
of	IN	O	O
aerobic	JJ	O	O
exercise	NN	O	O
results	NNS	O	O
in	IN	O	O
a	DT	O	O
reduced	JJ	O	O
blood	NN	o	OPH
pressure	NN	o	OPH
that	WDT	O	O
lasts	VBZ	O	O
several	JJ	O	O
hours	NNS	O	O
.	.	O	O

Animal	NNP	O	O
studies	NNS	O	O
suggest	VBP	O	O
this	DT	O	O
response	NN	O	O
is	VBZ	O	O
mediated	VBN	O	O
by	IN	O	O
increased	JJ	O	O
production	NN	O	O
of	IN	O	O
nitric	JJ	O	O
oxide	NN	O	O
.	.	O	O

We	PRP	O	O
tested	VBD	O	O
the	DT	O	O
extent	NN	O	O
to	TO	O	O
which	WDT	O	O
systemic	JJ	O	O
nitric	JJ	O	O
oxide	IN	O	O
synthase	JJ	O	O
inhibition	NN	O	O
[	NNP	O	O
N	NNP	O	O
(	(	O	O
G	NNP	O	O
)	)	O	O
-monomethyl-L-arginine	NN	O	O
(	(	O	O
L-NMMA	NNP	O	O
)	)	O	O
]	NN	O	O
can	MD	O	O
reverse	VB	O	O
the	DT	O	O
drop	NN	O	O
in	IN	O	O
blood	NN	o	OPH
pressure	NN	o	OPH
that	WDT	p	O
occurs	VBZ	p	O
after	IN	p	O
exercise	NN	p	O
in	IN	p	O
humans	NNS	p	O
.	.	p	O

Eight	NNP	p	PSS
healthy	JJ	p	O
subjects	NNS	p	O
underwent	JJ	O	O
parallel	JJ	O	O
experiments	NNS	O	O
on	IN	O	O
2	CD	O	O
separate	JJ	O	O
days	NNS	O	O
.	.	O	O

The	DT	O	O
order	NN	O	O
of	IN	O	O
the	DT	O	O
experiments	NNS	O	O
was	VBD	O	O
randomized	VBN	O	O
between	IN	O	O
sham	NN	O	O
(	(	i	O
60	CD	i	O
min	NN	i	O
of	IN	i	O
seated	JJ	i	IPH
upright	JJ	i	IPH
rest	NN	i	IPH
)	)	i	O
and	CC	O	O
exercise	NN	O	O
(	(	i	O
60	CD	i	IPH
min	NN	i	IPH
of	IN	i	IPH
upright	JJ	i	IPH
cycling	NN	i	IPH
at	IN	i	O
60	CD	i	O
%	NN	i	O
peak	NN	i	O
aerobic	JJ	i	O
capacity	NN	i	O
)	)	i	O
.	.	O	O

After	IN	O	O
both	DT	O	O
sham	NN	O	O
and	CC	O	O
exercise	NN	O	O
,	,	O	O
subjects	VBZ	O	O
received	VBN	O	O
,	,	O	O
in	IN	O	O
sequence	NN	O	O
,	,	O	O
systemic	JJ	O	O
alpha-adrenergic	JJ	O	O
blockade	NN	O	O
(	(	O	O
phentolamine	NN	O	O
)	)	O	O
and	CC	O	O
L-NMMA	NNP	O	O
.	.	O	O

Phentolamine	NNP	O	O
was	VBD	O	O
given	VBN	O	O
first	RB	O	O
to	TO	O	O
isolate	VB	O	O
the	DT	O	O
contribution	NN	O	O
of	IN	O	O
nitric	JJ	O	O
oxide	NN	O	O
to	TO	O	O
postexercise	VB	O	O
hypotension	NN	O	O
by	IN	O	O
preventing	VBG	O	O
reflex	JJ	O	O
changes	NNS	O	O
in	IN	O	O
sympathetic	JJ	O	O
tone	NN	O	O
that	WDT	O	O
result	NN	O	O
from	IN	O	O
systemic	JJ	O	O
nitric	JJ	O	O
oxide	IN	O	O
synthase	JJ	O	O
inhibition	NN	O	O
and	CC	O	O
to	TO	O	O
control	VB	O	O
for	IN	O	O
alterations	NNS	O	O
in	IN	O	O
resting	VBG	O	O
sympathetic	JJ	O	O
activity	NN	O	O
after	IN	O	O
exercise	NN	O	O
.	.	O	O

During	IN	O	O
each	DT	O	O
condition	NN	O	O
,	,	O	O
systemic	JJ	o	OPH
and	CC	o	OPH
regional	JJ	o	OPH
hemodynamics	NNS	o	OPH
were	VBD	O	O
measured	VBN	O	O
.	.	O	O

Throughout	IN	O	O
the	DT	O	O
study	NN	O	O
,	,	O	O
arterial	JJ	o	OPH
pressure	NN	o	OPH
and	CC	o	OPH
vascular	JJ	o	OPH
resistances	NNS	o	OPH
remained	VBD	O	O
lower	JJR	O	O
postexercise	NN	O	O
vs.	FW	O	O
postsham	NN	O	O
despite	IN	O	O
nitric	JJ	o	OME
oxide	JJ	o	OME
synthase	NN	o	OME
inhibition	NN	O	O
(	(	O	O
e.g.	JJ	O	O
,	,	O	O
mean	JJ	o	OOt
arterial	JJ	o	OOt
pressure	NN	o	OOt
after	IN	o	OOt
L-NMMA	NNP	o	OOt
was	VBD	O	O
108.0+/-2.4	JJ	O	O
mmHg	NN	O	O
postsham	NN	O	O
vs.	FW	O	O
102.1+/-3.3	JJ	O	O
mmHg	NN	O	O
postexercise	NN	O	O
;	:	O	O
P	NNP	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

Thus	VB	O	O
it	PRP	O	O
does	VBZ	O	O
not	RB	O	O
appear	VB	O	O
that	IN	O	O
postexercise	NN	o	OPH
hypotension	NN	o	OPH
is	VBZ	O	O
dependent	JJ	O	O
on	IN	O	O
increased	JJ	O	O
production	NN	o	OME
of	IN	o	OME
nitric	JJ	o	OME
oxide	NN	o	OME
in	IN	O	O
humans	NNS	p	O
.	.	p	O

Biomarkers	NNS	O	O
of	IN	O	O
dietary	JJ	i	IPH
exposure	NN	i	IPH
are	VBP	O	O
associated	VBN	O	O
with	IN	O	O
lower	JJR	O	O
risk	NN	O	O
of	IN	O	O
breast	NN	p	PC
fibroadenomas	NN	p	PC
in	IN	p	PC
Chinese	JJ	p	PC
women	NNS	p	PC
.	.	p	PC

Fibroadenomas	NNP	O	O
are	VBP	O	O
the	DT	O	O
most	RBS	O	O
common	JJ	O	O
benign	NN	O	O
breast	JJ	O	O
condition	NN	O	O
among	IN	O	O
women	NNS	O	O
and	CC	O	O
account	NN	O	O
for	IN	O	O
up	IN	O	O
to	TO	O	O
50	CD	O	O
%	NN	O	O
of	IN	O	O
all	DT	O	O
breast	NN	O	O
biopsies	NNS	O	O
being	VBG	O	O
performed	VBN	O	O
.	.	O	O

Although	IN	O	O
considered	VBN	O	O
a	DT	O	O
benign	JJ	O	O
condition	NN	O	O
,	,	O	O
fibroadenomas	JJ	O	O
utilize	VBP	O	O
substantial	JJ	O	O
resources	NNS	O	O
for	IN	O	O
management	NN	O	O
and	CC	O	O
treatment	NN	O	O
to	TO	O	O
rule	VB	O	O
out	RP	O	O
potential	JJ	O	O
malignancies	NNS	O	O
.	.	O	O

Dietary	JJ	i	IPH
factors	NNS	i	IPH
may	MD	O	O
influence	VB	O	O
benign	JJ	O	O
fibrocystic	JJ	O	O
breast	NN	O	O
conditions	NNS	O	O
,	,	O	O
but	CC	O	O
little	JJ	O	O
is	VBZ	O	O
known	VBN	O	O
of	IN	O	O
their	PRP$	O	O
association	NN	O	O
with	IN	O	O
fibroadenomas	NN	O	O
.	.	O	O

We	PRP	O	O
examined	VBD	O	O
possible	JJ	O	O
associations	NNS	O	O
between	IN	O	O
a	DT	O	O
broad	JJ	O	O
spectrum	NN	O	O
of	IN	O	O
circulating	VBG	O	O
biomarkers	NNS	o	OPH
of	IN	o	OPH
dietary	JJ	o	OPH
intake	NN	o	OPH
and	CC	O	O
risk	NN	O	O
of	IN	O	O
fibroadenomas	NN	O	O
.	.	O	O

Participants	NNS	p	O
were	VBD	p	O
women	NNS	p	O
in	IN	p	O
a	DT	p	O
breast	NN	i	IE
self-examination	NN	i	IE
trial	NN	p	O
in	IN	p	O
Shanghai	NNP	p	O
,	,	p	O
China	NNP	p	O
who	WP	p	O
were	VBD	p	O
diagnosed	VBN	p	O
with	IN	p	O
fibroadenomas	NN	p	O
(	(	p	O
n	JJ	p	O
=	NNP	p	O
258	CD	p	O
)	)	p	O
and	CC	p	O
1035	CD	p	O
controls	NNS	p	O
.	.	p	O

Conditional	NNP	o	OPH
logistic	JJ	o	OPH
regression	NN	o	OPH
was	VBD	O	O
used	VBN	O	O
to	TO	O	O
estimate	VB	o	OPH
adjusted	VBN	o	OPH
odds	NNS	o	OPH
ratios	NNS	o	OPH
(	(	o	OPH
OR	NNP	o	OPH
)	)	o	OPH
and	CC	O	O
95	CD	o	O
%	NN	o	O
CI	NNP	o	O
.	.	o	O

Isoflavone	NNP	o	OPH
concentrations	NNS	o	OPH
were	VBD	O	O
inversely	RB	O	O
associated	VBN	O	O
with	IN	O	O
risk	NN	o	OPH
of	IN	o	OPH
fibroadenomas	NN	o	OPH
.	.	o	O

Adjusted	VBN	o	OPH
OR	NNP	o	OPH
(	(	o	OPH
95	CD	o	OPH
%	NN	o	OPH
CI	NNP	o	OPH
)	)	o	OPH
for	IN	O	O
the	DT	O	O
highest	JJS	O	O
versus	NN	O	O
the	DT	O	O
lowest	JJS	O	O
quartile	NN	O	O
of	IN	O	O
plasma	JJ	O	O
concentration	NN	O	O
were	VBD	O	O
0.36	CD	O	O
(	(	O	O
0.16-0.79	CD	O	O
;	:	O	O
P-trend	NNP	O	O
<	NNP	O	O
0.001	CD	O	O
)	)	O	O
for	IN	O	O
daidzein	NN	i	IPM
and	CC	O	O
0.39	CD	O	O
(	(	O	O
0.19-0.84	CD	O	O
;	:	O	O
P-trend	NNP	O	O
=	NNP	O	O
0.010	CD	O	O
)	)	O	O
for	IN	O	O
genistein	NN	i	IPM
.	.	i	O

We	PRP	O	O
also	RB	O	O
observed	VBD	O	O
inverse	JJ	o	OPH
associations	NNS	o	OPH
between	IN	O	O
higher	JJR	O	O
percentages	NNS	o	OPH
of	IN	o	OPH
the	DT	o	OPH
RBC	NNP	o	OPH
(	(	o	OPH
n-3	JJ	o	OPH
)	)	o	OPH
fatty	JJ	o	OPH
acids	NNS	o	OPH
,	,	o	OPH
eicosapentaenoic	JJ	o	OPH
acid	NN	o	OPH
(	(	o	OPH
EPA	NNP	o	OPH
)	)	o	OPH
(	(	O	O
[	$	O	O
0.38	CD	O	O
(	(	O	O
0.19-0.77	JJ	O	O
)	)	O	O
;	:	O	O
P-trend	JJ	O	O
=	NN	O	O
0.007	CD	O	O
]	NN	O	O
and	CC	O	O
docosapentaenoic	NN	o	OPH
acid	NN	o	OPH
(	(	o	OPH
DPA	NNP	o	OPH
)	)	o	OPH
[	VBZ	O	O
0.32	CD	O	O
(	(	O	O
0.15-0.70	JJ	O	O
)	)	O	O
;	:	O	O
P-trend	JJ	O	O
=	NN	O	O
0.024	CD	O	O
]	NN	O	O
,	,	O	O
and	CC	O	O
fibroadenoma	NN	O	O
risk	NN	O	O
.	.	O	O

Circulating	VBG	O	O
concentrations	NNS	O	O
of	IN	O	O
carotenoids	NNS	o	OPH
,	,	o	OPH
vitamin	FW	o	OPH
C	NNP	o	OPH
,	,	o	OPH
retinol	NN	o	OPH
,	,	o	OPH
and	CC	o	OPH
ferritin	NNS	o	OPH
were	VBD	O	O
not	RB	O	O
associated	VBN	O	O
with	IN	O	O
fibroadenoma	NN	O	O
risk	NN	O	O
.	.	O	O

The	DT	O	O
inverse	JJ	o	OPH
associations	NNS	o	OPH
between	IN	O	O
plasma	NN	o	OPH
isoflavone	NN	o	OPH
concentrations	NNS	o	OPH
and	CC	O	O
RBC	NNP	o	OPH
EPA	NNP	o	OPH
and	CC	o	OPH
DPA	NNP	o	OPH
and	CC	O	O
fibroadenoma	NN	o	OPH
risk	NN	o	OPH
suggest	VBP	O	O
that	IN	O	O
higher	JJR	O	O
intakes	NNS	O	O
of	IN	O	O
soy	JJ	i	IPM
foods	NNS	i	IPM
and	CC	i	IPM
fatty	JJ	i	IPM
fish	NN	i	IPM
may	MD	O	O
lower	VB	O	O
the	DT	O	O
risk	NN	o	OPH
of	IN	o	OPH
fibroadenomas	NN	o	OPH
.	.	o	OPH

Comparison	NNP	O	O
of	IN	O	O
the	DT	O	O
effectiveness	NN	o	OOt
of	IN	O	O
oral	JJ	O	O
diazepam	NN	i	IPM
and	CC	i	IPM
midazolam	NN	i	IPM
for	IN	O	O
the	DT	O	O
sedation	NN	o	OPH
of	IN	p	O
autistic	JJ	p	PC
patients	NNS	p	PC
during	IN	p	O
dental	JJ	p	PC
treatment	NN	p	PC
.	.	p	O

PURPOSE	VB	O	O
This	DT	O	O
study	NN	O	O
was	VBD	O	O
undertaken	VBN	O	O
to	TO	O	O
compare	VB	O	O
the	DT	O	O
effectiveness	NN	o	OOt
of	IN	O	O
oral	JJ	O	O
diazepam	NN	i	IPM
and	CC	i	IPM
midazolam	NN	i	IPM
in	IN	O	O
sedating	VBG	p	O
autistic	JJ	p	O
patients	NNS	p	O
during	IN	p	O
dental	JJ	p	O
treatment	NN	p	O
.	.	p	O

METHODS	NNP	O	O
The	DT	O	O
treatment	NN	O	O
regimen	NNS	O	O
consisted	VBD	O	O
of	IN	O	O
nitrous	JJ	i	IPM
oxide/oxygen	NN	i	IPM
inhalation	NN	i	IPM
in	IN	O	O
conjunction	NN	O	O
with	IN	O	O
oral	JJ	i	IPM
administration	NN	i	IPM
of	IN	i	IPM
either	DT	i	IPM
diazepam	NN	i	IPM
0.3	CD	i	IPM
mg/kg	NN	i	IPM
or	CC	i	IPM
midazolam	VB	i	IPM
0.5	CD	i	IPM
mg/kg	NN	i	IPM
in	IN	O	O
a	DT	O	O
cross-over	JJ	O	O
design	NN	O	O
study	NN	O	O
of	IN	O	O
13	CD	p	O
subjects	NNS	p	O
aged	VBD	p	O
5.8	CD	p	PA
to	TO	p	PA
14.7	CD	p	PA
years	NNS	p	PA
.	.	p	O

A	DT	O	O
drug	NN	O	O
was	VBD	O	O
classified	VBN	O	O
as	IN	O	O
being	VBG	O	O
effective	JJ	o	OOt
when	WRB	O	O
over	RB	O	O
70	CD	O	O
%	NN	O	O
of	IN	O	O
the	DT	O	O
patients	NNS	O	O
taking	VBG	O	O
the	DT	O	O
drug	NN	O	O
were	VBD	O	O
judged	VBN	O	O
as	IN	O	O
success	NN	O	O
in	IN	O	O
all	DT	O	O
3	CD	O	O
behavioral	JJ	O	O
criteria	NNS	O	O
:	:	O	O
(	(	O	O
1	CD	O	O
)	)	O	O
sleeping	NN	O	O
;	:	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
body	NN	O	O
movement	NN	O	O
;	:	O	O
and	CC	O	O
(	(	O	O
3	CD	O	O
)	)	O	O
crying	NN	O	O
behaviors	NNS	O	O
.	.	O	O

The	DT	O	O
study	NN	O	O
was	VBD	O	O
observed	VBN	O	O
by	IN	O	O
an	DT	O	O
independent	JJ	O	O
clinician	NN	O	O
with	IN	O	O
an	DT	O	O
intraexaminer	NN	O	O
reliability	NN	O	O
of	IN	O	O
88	CD	O	O
%	NN	O	O
.	.	O	O

RESULTS	NNP	O	O
For	IN	O	O
sleeping	VBG	o	OME
behavior	NN	o	OME
,	,	O	O
midazolam	NN	O	O
was	VBD	O	O
found	VBN	O	O
to	TO	O	O
be	VB	O	O
significantly	RB	o	OOt
more	RBR	o	OOt
effective	JJ	o	OOt
than	IN	O	O
diazepam	RB	O	O
as	IN	O	O
the	DT	O	O
duration	NN	O	O
of	IN	O	O
stimulation	NN	O	O
increased	VBN	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
.05	NNP	O	O
)	)	O	O
.	.	O	O

For	IN	O	O
the	DT	O	O
movement	NN	o	OME
and	CC	o	OME
crying	NN	o	OME
behaviors	NNS	o	OME
,	,	O	O
midazolam	NN	O	O
also	RB	O	O
proved	VBD	O	O
to	TO	O	O
be	VB	O	O
significantly	RB	o	OOt
more	RBR	o	OOt
effective	JJ	o	OOt
from	IN	O	O
the	DT	O	O
start	NN	O	O
of	IN	O	O
treatment	NN	O	O
through	IN	O	O
the	DT	O	O
35-	JJ	O	O
and	CC	O	O
40-min	JJ	O	O
markers	NNS	O	O
,	,	O	O
respectively	RB	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
.05	NNP	O	O
)	)	O	O
.	.	O	O

For	IN	O	O
the	DT	O	O
remainder	NN	o	O
of	IN	o	O
treatment	NN	o	O
,	,	O	O
however	RB	O	O
,	,	O	O
there	EX	O	O
was	VBD	O	O
no	DT	o	O
statistically	RB	o	O
significant	JJ	o	O
difference	NN	o	O
in	IN	O	O
these	DT	O	O
behaviors	NNS	O	O
between	IN	O	O
the	DT	O	O
trials	NNS	O	O
(	(	O	O
P	NNP	O	O
>	NNP	O	O
.05	NNP	O	O
)	)	O	O
.	.	O	O

Diazepam	NNP	O	O
and	CC	O	O
midazolam	NNS	O	O
were	VBD	O	O
rated	VBN	O	O
as	IN	O	O
77	CD	O	O
%	NN	O	O
and	CC	O	O
100	CD	O	O
%	NN	O	O
successful	JJ	o	OOt
,	,	O	O
according	VBG	O	O
to	TO	O	O
the	DT	O	O
overall	JJ	O	O
behavior	NN	o	OME
evaluation	NN	o	OME
criteria	NNS	O	O
(	(	O	O
P=.02	NNP	O	O
)	)	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
Both	NNP	O	O
diazepam	NN	O	O
and	CC	O	O
midazolam	NN	O	O
were	VBD	O	O
shown	VBN	O	O
to	TO	O	O
be	VB	O	O
effective	JJ	o	OOt
sedative	JJ	O	O
agents	NNS	O	O
,	,	O	O
successfully	RB	O	O
and	CC	O	O
safely	RB	O	O
used	VBN	O	O
to	TO	O	O
sedate	VB	O	O
autistic	JJ	p	O
patients	NNS	p	O
for	IN	O	O
dental	JJ	O	O
treatment	NN	O	O
.	.	O	O

Midazolam	NNP	O	O
was	VBD	O	O
significantly	RB	O	O
more	RBR	O	O
effective	JJ	O	O
than	IN	O	O
diazepam	NN	O	O
in	IN	O	O
those	DT	O	O
portions	NNS	O	O
of	IN	O	O
the	DT	O	O
procedure	NN	O	O
with	IN	O	O
increased	JJ	O	O
stimulation	NN	O	O
.	.	O	O

[	RB	O	O
Clinical	NNP	O	O
study	NN	O	O
on	IN	O	O
dan	NN	i	IPM
shao	NN	i	IPM
tang	NN	i	IPM
in	IN	O	O
treating	VBG	O	O
IgA	NNP	O	O
nephropathy	NN	O	O
of	IN	O	O
deficiency	NN	O	O
of	IN	O	O
yin	NN	O	O
with	IN	O	O
damp-heat	JJ	O	O
symptom	NN	O	O
]	NNP	O	O
.	.	O	O

OBJECTIVE	NNP	O	O
To	TO	O	O
explore	VB	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
Dan	NNP	i	IPM
Shao	NNP	i	IPM
Tang	NNP	i	IPM
(	(	i	IPM
DST	NNP	i	IPM
)	)	i	IPM
in	IN	O	O
treating	VBG	O	O
IgA	NNP	O	O
nephropathy	NN	O	O
(	(	O	O
IgAN	NNP	O	O
)	)	O	O
of	IN	O	O
deficiency	NN	O	O
of	IN	O	O
Yin	NNP	O	O
with	IN	O	O
damp-heat	JJ	O	O
symptom	NN	O	O
.	.	O	O

METHODS	NNP	O	O
90	CD	p	PSS
patients	NNS	p	O
with	IN	p	O
IgAN	NNP	p	PC
of	IN	p	PC
deficiency	NN	p	PC
of	IN	p	PC
Yin	NNP	p	PC
with	IN	p	O
damp-heat	JJ	p	PC
symptom	NN	p	PC
were	VBD	O	O
randomly	RB	O	O
divided	VBN	O	O
into	IN	O	O
two	CD	O	O
groups	NNS	O	O
.	.	O	O

50	CD	O	O
patients	NNS	O	O
in	IN	O	O
treatment	NN	O	O
group	NN	O	O
were	VBD	O	O
treated	VBN	O	O
with	IN	O	O
DST	NNP	i	IPM
and	CC	i	O
western	JJ	i	IPM
medicine	NN	i	IPM
and	CC	O	O
40	CD	O	O
patients	NNS	O	O
in	IN	O	O
control	NN	O	O
group	NN	O	O
were	VBD	O	O
treated	VBN	O	O
only	RB	i	O
with	IN	i	IPM
western	JJ	i	IPM
medicine	NN	i	IPM
.	.	i	O

The	DT	O	O
effects	NNS	O	O
and	CC	O	O
changes	NNS	O	O
of	IN	O	O
the	DT	O	O
indexes	NNS	O	O
including	VBG	O	O
renal	JJ	o	OPH
function	NN	o	OPH
,	,	o	OPH
hematuria	NN	o	OPH
,	,	o	OPH
proteinuria	NN	o	OPH
,	,	o	OPH
blood	NN	o	OPH
IgA	NNP	o	OPH
before	IN	O	O
and	CC	O	O
after	IN	O	O
treatment	NN	O	O
were	VBD	O	O
observed	VBN	O	O
.	.	O	O

RESULTS	NNP	O	O
After	IN	O	O
six	CD	O	O
months	NNS	O	O
treatment	NN	O	O
,	,	O	O
the	DT	O	O
general	JJ	o	OOt
effective	JJ	o	OOt
rate	NN	o	OOt
in	IN	O	O
treatment	NN	O	O
group	NN	O	O
was	VBD	O	O
70.00	CD	O	O
%	NN	O	O
,	,	O	O
which	WDT	O	O
was	VBD	O	O
markedly	RB	O	O
higher	JJR	O	O
than	IN	O	O
that	DT	O	O
in	IN	O	O
control	NN	O	O
group	NN	O	O
(	(	O	O
37.50	CD	O	O
%	NN	O	O
,	,	O	O
P	NNP	O	O
<	NNP	O	O
0.01	CD	O	O
)	)	O	O
.	.	O	O

Treatment	NNP	O	O
group	NN	O	O
is	VBZ	O	O
obviously	RB	O	O
better	JJR	O	O
than	IN	O	O
control	NN	O	O
group	NN	O	O
on	IN	O	O
decreasing	VBG	o	OPH
hematuria	NN	o	OPH
,	,	o	OPH
proteinuria	NN	o	OPH
,	,	o	OPH
blood	NN	o	OPH
IgA	NNP	o	OPH
and	CC	o	OPH
improving	VBG	o	OPH
renal	JJ	o	OPH
function	NN	o	OPH
(	(	o	OPH
P	NNP	o	OPH
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

CONCLUSION	NNP	O	O
DST	NNP	i	IPM
is	VBZ	O	O
effective	JJ	O	O
on	IN	O	O
IgAN	NNP	O	O
of	IN	O	O
deficiency	NN	O	O
of	IN	O	O
Yin	NNP	O	O
with	IN	O	O
damp-heat	JJ	O	O
symptom	NN	O	O
.	.	O	O

International	NNP	p	O
Czech	NNP	i	IOt
and	CC	i	IOt
Slovak	NNP	i	IOt
cooperation	NN	i	IOt
in	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
patients	NNS	p	O
with	IN	p	O
differentiated	JJ	p	PC
thyroid	NN	p	PC
cancer	NN	p	PC
.	.	p	O

BACKGROUND	IN	O	O
The	DT	O	O
aim	NN	O	O
of	IN	O	O
this	DT	O	O
paper	NN	O	O
is	VBZ	O	O
to	TO	O	O
present	VB	O	O
our	PRP$	O	O
experience	NN	O	O
concerning	VBG	O	O
cooperation	NN	O	O
in	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
Slovak	NNP	p	O
patients	NNS	p	O
with	IN	p	O
differentiated	JJ	p	O
thyroid	NN	p	O
cancer	NN	p	O
in	IN	p	O
Slovak	NNP	p	O
and	CC	p	O
Czech	NNP	p	O
hospitals	NNS	p	O
.	.	p	O

The	DT	O	O
objectives	NNS	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
were	VBD	O	O
to	TO	O	O
demonstrate	VB	O	O
the	DT	O	O
means	NNS	o	OME
of	IN	o	OME
this	DT	o	OME
cooperation	NN	o	OME
and	CC	O	O
the	DT	O	O
results	NNS	o	OOt
of	IN	O	O
therapy	NN	O	O
.	.	O	O

MATERIAL	NNP	O	O
AND	CC	O	O
METHODS	NNP	O	O
From	NNP	p	O
September	NNP	p	O
1991	CD	p	O
to	TO	p	O
October	NNP	p	O
2005	CD	p	O
in	IN	p	O
the	DT	p	O
Department	NNP	p	O
of	IN	p	O
Nuclear	NNP	p	O
Medicine	NNP	p	O
in	IN	p	O
Ostrava	NNP	p	O
357	CD	p	PSS
patients	NNS	p	O
from	IN	p	O
the	DT	p	O
Slovak	NNP	p	O
Republic	NNP	p	O
with	IN	p	O
differentiated	VBN	p	PC
thyroid	NN	p	PC
cancers	NNS	p	PC
(	(	p	O
follicular	JJ	p	PC
and	CC	p	PC
papillary	JJ	p	PC
)	)	p	O
underwent	NN	p	O
complex	JJ	i	IPH
therapy	NN	i	IPH
.	.	i	O

They	PRP	p	O
were	VBD	p	O
diagnosed	VBN	p	O
and	CC	p	O
operated	VBN	p	O
due	JJ	p	O
to	TO	p	O
the	DT	p	O
cancer	NN	p	O
(	(	p	O
near-total	JJ	p	PC
thyroidectomy	NN	p	PC
and	CC	p	O
removal	NN	p	PC
of	IN	p	PC
lymph	JJ	p	PC
node	JJ	p	PC
metastases	NNS	p	PC
)	)	p	O
in	IN	p	O
Slovak	NNP	p	O
hospitals	NNS	p	O
.	.	p	O

Then	RB	p	O
they	PRP	p	O
were	VBD	p	O
sent	VBN	p	O
to	TO	p	O
the	DT	p	O
Department	NNP	p	O
of	IN	p	O
Nuclear	NNP	p	O
Medicine	NNP	p	O
in	IN	p	O
Ostrava	NNP	p	O
in	IN	p	O
the	DT	p	O
Czech	NNP	p	O
Republic	NNP	p	O
.	.	p	O

In	IN	O	O
this	DT	O	O
department	NN	O	O
a	DT	O	O
radioiodine	JJ	i	IPM
ablation	NN	O	O
of	IN	O	O
thyroid	JJ	O	O
remnants	NNS	O	O
,	,	O	O
by	IN	O	O
means	NNS	O	O
of	IN	O	O
the	DT	O	O
treatment	NN	i	O
amount	NN	O	O
of	IN	O	O
radioiodine	NN	i	IPM
of	IN	O	O
a	DT	O	O
standard	JJ	O	O
activity	NN	O	O
of	IN	O	O
3.7	CD	O	O
GBq	NNP	O	O
,	,	O	O
was	VBD	O	O
performed	VBN	O	O
,	,	O	O
and	CC	O	O
then	RB	O	O
a	DT	O	O
suppression	NN	O	O
and	CC	O	O
substitution	NN	i	O
therapy	NN	i	O
of	IN	O	O
thyroid	JJ	O	O
hormones	NNS	O	O
was	VBD	O	O
started	VBN	O	O
.	.	O	O

After	IN	O	O
3-6	JJ	O	O
months	NNS	O	O
some	DT	O	O
patients	NNS	O	O
were	VBD	O	O
examined	VBN	O	O
by	IN	O	O
means	NNS	O	O
of	IN	O	O
diagnostic	JJ	o	OOt
whole	JJ	o	OOt
body	NN	o	OOt
scintigraphy	NN	o	OOt
after	IN	O	O
application	NN	O	O
of	IN	O	O
300	CD	O	O
MBq	NNP	O	O
131I	CD	O	O
.	.	O	O

Some	DT	O	O
patients	NNS	O	O
were	VBD	O	O
treated	VBN	O	O
by	IN	O	O
means	NNS	O	O
of	IN	O	O
a	DT	O	O
standard	JJ	O	O
activity	NN	O	O
of	IN	O	O
7.4	CD	O	O
GBq	NNP	O	O
131I	CD	O	O
and	CC	O	O
after	IN	O	O
5	CD	O	O
days	NNS	O	O
whole	JJ	O	O
body	NN	O	O
scintigraphy	NN	O	O
(	(	O	O
WBS	NNP	O	O
)	)	O	O
was	VBD	O	O
performed	VBN	O	O
.	.	O	O

In	IN	O	O
both	DT	O	O
of	IN	O	O
these	DT	O	O
groups	NNS	O	O
of	IN	O	O
patients	NNS	O	O
the	DT	O	O
diagnostic	JJ	O	O
or	CC	O	O
therapeutic	JJ	O	O
radioiodine	NN	i	IPM
application	NN	O	O
was	VBD	O	O
done	VBN	O	O
after	IN	O	O
withdrawal	NN	O	O
of	IN	O	O
thyroid	JJ	O	O
hormone	NN	O	O
treatment	NN	O	O
.	.	O	O

If	IN	O	O
thyroglobulin	JJ	o	OPH
levels	NNS	o	OPH
were	VBD	O	O
low	JJ	O	O
and	CC	O	O
WBSs	NNP	o	OPH
were	VBD	O	O
negative	JJ	O	O
,	,	O	O
patients	NNS	O	O
were	VBD	O	O
followed	VBN	O	O
up	RP	O	O
in	IN	O	O
the	DT	O	O
Department	NNP	O	O
of	IN	O	O
Nuclear	NNP	O	O
Medicine	NNP	O	O
in	IN	O	O
Martin	NNP	O	O
.	.	O	O

Patients	NNS	O	O
with	IN	O	O
radioiodine	NN	O	O
accumulated	VBN	O	O
metastases	NNS	O	O
were	VBD	O	O
again	RB	O	O
treated	VBN	O	O
with	IN	O	O
radioiodine	NN	i	IPM
in	IN	O	O
Ostrava	NNP	O	O
.	.	O	O

If	IN	O	O
indicated	VBN	O	O
,	,	O	O
external	JJ	O	O
radiation	NN	i	IPH
therapy	NN	i	IPH
targeted	VBN	O	O
on	IN	O	O
the	DT	O	O
neck	NN	O	O
and	CC	O	O
upper	JJ	O	O
mediastinum	NN	O	O
was	VBD	O	O
performed	VBN	O	O
in	IN	O	O
the	DT	O	O
Slovak	NNP	p	O
Republic	NNP	p	O
,	,	p	O
in	IN	p	O
the	DT	p	O
University	NNP	p	O
Hospital	NNP	p	O
in	IN	p	O
Martin	NNP	p	O
.	.	p	O

Newly	RB	O	O
formed	VBN	O	O
lymph	JJ	O	O
node	NN	O	O
metastases	NNS	O	O
were	VBD	O	O
surgically	RB	O	O
treated	VBN	O	O
in	IN	O	O
Slovakia	NNP	O	O
,	,	O	O
too	RB	O	O
.	.	O	O

Generally	RB	O	O
we	PRP	O	O
have	VBP	O	O
very	RB	O	O
good	JJ	o	OOt
treatment	NN	o	OOt
results	NNS	o	OOt
.	.	o	O

Also	RB	O	O
,	,	O	O
economically	RB	O	O
our	PRP$	O	O
partnership	NN	O	O
is	VBZ	O	O
cost	VBN	o	OOt
effective	JJ	o	OOt
.	.	o	O

Our	PRP$	O	O
collaboration	NN	O	O
also	RB	O	O
successfully	RB	O	O
continues	VBZ	O	O
after	IN	O	O
entrance	NN	O	O
of	IN	O	O
the	DT	O	O
Slovak	NNP	O	O
Republic	NNP	O	O
and	CC	O	O
the	DT	O	O
Czech	NNP	O	O
Republic	NNP	O	O
to	TO	O	O
the	DT	O	O
European	NNP	O	O
Union	NNP	O	O
in	IN	O	O
2004	CD	O	O
.	.	O	O

CONCLUSIONS	VB	O	O
The	DT	O	O
results	NNS	O	O
of	IN	O	O
this	DT	O	O
multi-centre	JJ	O	O
study	NN	O	O
show	NN	O	O
that	IN	O	O
international	JJ	O	O
Czech	NNP	O	O
and	CC	O	O
Slovak	NNP	O	O
cooperation	NN	i	IOt
in	IN	O	O
the	DT	O	O
complex	JJ	O	O
therapy	NN	O	O
of	IN	O	O
patients	NNS	O	O
with	IN	O	O
differentiated	JJ	O	O
thyroid	NN	O	O
cancers	NNS	O	O
is	VBZ	O	O
successful	JJ	O	O
,	,	O	O
with	IN	O	O
high	JJ	O	O
efficacy	NN	O	O
.	.	O	O

The	DT	O	O
treatment	NN	O	O
results	NNS	O	O
were	VBD	O	O
very	RB	O	O
similar	JJ	O	O
to	TO	O	O
therapeutic	JJ	O	O
results	NNS	O	O
in	IN	O	O
our	PRP$	O	O
patients	NNS	O	O
from	IN	O	O
the	DT	O	O
Czech	NNP	O	O
Republic	NNP	O	O
.	.	O	O

[	JJ	O	O
Carbohydrate	NNP	O	O
substitutes	NNS	O	O
:	:	O	O
comparative	JJ	O	O
study	NN	O	O
of	IN	O	O
intestinal	JJ	p	O
absorption	NN	p	O
of	IN	p	O
fructose	NN	i	IPM
,	,	i	O
sorbitol	NN	i	IPM
and	CC	i	O
xylitol	NNP	i	IPM
]	NNP	i	O
.	.	O	O

BACKGROUND	NNP	O	O
The	DT	O	O
carbohydrate	NN	O	O
substitutes	NNS	O	O
fructose	VBP	i	IPM
,	,	i	O
sorbitol	JJ	i	IPM
and	CC	i	O
xylitol	NNS	i	IPM
are	VBP	O	O
gaining	VBG	O	O
more	JJR	O	O
and	CC	O	O
more	JJR	O	O
importance	NN	O	O
in	IN	O	O
the	DT	O	O
production	NN	O	O
of	IN	O	O
dietary	JJ	O	O
food	NN	O	O
.	.	O	O

But	CC	O	O
they	PRP	O	O
can	MD	O	O
provoke	VB	O	O
gastrointestinal	JJ	O	O
side-effects	NNS	O	O
.	.	O	O

In	IN	O	O
a	DT	O	O
randomized	JJ	O	O
double	JJ	O	O
blind	NN	O	O
study	VBD	O	O
the	DT	O	O
rate	NN	O	O
of	IN	O	O
malabsorption	NN	O	O
of	IN	O	O
these	DT	O	O
sugars	NNS	O	O
was	VBD	O	O
compared	VBN	O	O
and	CC	O	O
the	DT	O	O
concomitant	NN	O	O
symptoms	NNS	O	O
were	VBD	O	O
recorded	VBN	O	O
.	.	O	O

SUBJECTS	NNP	O	O
AND	NNP	O	O
METHODS	NNP	O	O
25	CD	p	PSS
healthy	JJ	p	O
controls	NNS	p	O
received	VBD	O	O
25	CD	i	IPM
g	NN	i	IPM
of	IN	i	IPM
each	DT	i	IPM
sugar	NN	i	IPM
within	IN	O	O
3	CD	O	O
consecutive	JJ	O	O
days	NNS	O	O
.	.	O	O

The	DT	O	O
intestinal	JJ	o	OPH
absorption	NN	o	OPH
was	VBD	o	OPH
determined	VBN	o	OPH
by	IN	o	OPH
H2-exhalation	NNP	o	OPH
tests	NNS	o	OPH
and	CC	O	O
the	DT	O	O
clinical	JJ	o	OPH
symptoms	NNS	o	OPH
were	VBD	O	O
recorded	VBN	O	O
.	.	O	O

RESULTS	VB	O	O
The	DT	O	O
rate	NN	o	OPH
of	IN	o	OPH
malabsorption	NN	o	OPH
was	VBD	O	O
84	CD	O	O
%	NN	O	O
for	IN	O	O
sorbitol	NN	i	IPM
,	,	O	O
36	CD	O	O
%	NN	O	O
for	IN	O	O
fructose	JJ	i	IPM
and	CC	O	O
12	CD	O	O
%	NN	O	O
for	IN	O	O
xylitol	NNP	i	IPM
(	(	O	O
p	JJ	O	O
<	VBP	O	O
0.01	CD	O	O
for	IN	O	O
sorbitol	NN	i	IPM
versus	NN	i	O
fructose	NN	i	IPM
and	CC	i	O
xylitol	NN	i	IPM
)	)	i	O
.	.	O	O

57	CD	O	O
%	NN	O	O
of	IN	O	O
the	DT	O	O
participants	NNS	O	O
with	IN	O	O
pathological	JJ	O	O
H2-test	NNP	O	O
after	IN	O	O
sorbitol	NN	i	IPM
and	CC	O	O
56	CD	O	O
%	NN	O	O
after	IN	O	O
fructose	JJ	i	IPM
reported	VBD	O	O
symptoms	NNS	O	O
,	,	O	O
while	IN	O	O
all	DT	O	O
of	IN	O	O
the	DT	O	O
3	CD	O	O
malabsorbers	NNS	O	O
of	IN	O	O
xylitol	NN	i	IPM
were	VBD	O	O
symptomatic	JJ	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
There	EX	O	O
is	VBZ	O	O
an	DT	O	O
advantage	NN	O	O
to	TO	O	O
administering	VBG	O	O
xylitol	NN	i	IPM
and	CC	O	O
fructose	JJ	i	IPM
with	IN	O	O
regard	NN	O	O
to	TO	O	O
the	DT	O	O
intestinal	JJ	o	OPH
absorption	NN	o	OPH
and	CC	O	O
concomitant	NN	O	O
symptoms	NNS	O	O
as	IN	O	O
compared	VBN	O	O
with	IN	O	O
sorbitol	NN	i	IPM
.	.	i	O

H2-exhalation	NN	O	O
tests	NNS	O	O
appear	VBP	O	O
to	TO	O	O
be	VB	O	O
a	DT	O	O
reliable	JJ	O	O
diagnostic	JJ	O	O
tool	NN	O	O
to	TO	O	O
detect	VB	O	O
carbohydrate	JJ	o	OPH
malabsorption	NN	o	OPH
and	CC	O	O
should	MD	O	O
find	VB	O	O
broader	JJR	O	O
application	NN	O	O
in	IN	O	O
patients	NNS	O	O
suffering	VBG	O	O
from	IN	O	O
non-specific	JJ	O	O
abdominal	JJ	O	O
complaints	NNS	O	O
.	.	O	O

Dietary	NNP	O	O
patterns	NNS	O	O
differ	VBP	O	O
between	IN	O	O
urban	JJ	p	O
and	CC	p	O
rural	JJ	p	O
older	JJR	p	O
,	,	p	O
long-term	JJ	p	PC
survivors	NNS	p	PC
of	IN	p	PC
breast	NN	p	PC
,	,	p	PC
prostate	NN	p	PC
,	,	p	PC
and	CC	p	PC
colorectal	JJ	p	PC
cancer	NN	p	PC
and	CC	O	O
are	VBP	O	O
associated	VBN	O	O
with	IN	O	O
body	NN	O	O
mass	NN	O	O
index	NN	O	O
.	.	O	O

BACKGROUND	NNP	O	O
Older	NNP	p	O
adult	NN	p	O
cancer	NN	p	O
survivors	NNS	p	O
are	VBP	O	O
at	IN	O	O
greater	JJR	O	O
risk	NN	O	O
of	IN	O	O
cancer	NN	o	OPH
recurrence	NN	o	OPH
and	CC	O	O
other	JJ	O	O
comorbidities	NNS	o	OPH
that	WDT	O	O
can	MD	O	O
be	VB	O	O
prevented	VBN	O	O
through	IN	O	O
improved	VBN	O	O
diet	JJ	O	O
and	CC	O	O
weight	JJ	O	O
management	NN	O	O
.	.	O	O

The	DT	O	O
tertiary	JJ	O	O
prevention	NN	O	O
needs	NNS	O	O
of	IN	O	O
rural-dwelling	JJ	O	O
survivors	NNS	O	O
can	MD	O	O
be	VB	O	O
even	RB	O	O
greater	JJR	O	O
,	,	O	O
yet	RB	O	O
little	JJ	O	O
is	VBZ	O	O
known	VBN	O	O
about	IN	O	O
rural	JJ	O	O
and	CC	O	O
urban	JJ	O	O
differences	NNS	O	O
in	IN	O	O
lifestyle	JJ	O	O
factors	NNS	O	O
among	IN	O	O
this	DT	O	O
high-risk	JJ	O	O
population	NN	O	O
.	.	O	O

OBJECTIVES	NNP	O	O
To	TO	O	O
compare	VB	i	IE
dietary	JJ	i	IE
patterns	NNS	i	IE
of	IN	O	O
urban	JJ	p	O
and	CC	p	O
rural	JJ	p	O
cancer	NN	p	O
survivors	NNS	p	O
and	CC	O	O
to	TO	O	O
examine	VB	O	O
associations	NNS	O	O
of	IN	O	O
dietary	JJ	o	OOt
patterns	NNS	o	OOt
with	IN	O	O
body	NN	o	OPH
mass	NN	o	OPH
index	NN	o	OPH
(	(	o	OPH
BMI	NNP	o	OPH
)	)	o	OPH
.	.	o	OPH

DESIGN	VB	O	O
A	DT	O	O
secondary	JJ	O	O
analysis	NN	O	O
was	VBD	O	O
performed	VBN	O	O
of	IN	O	O
baseline	NN	O	O
data	NNS	O	O
from	IN	O	O
the	DT	O	O
Reach	NNP	o	OPH
Out	NNP	o	OPH
to	TO	o	OPH
Enhance	VB	o	OPH
Wellness	NNP	o	OPH
(	(	O	O
RENEW	NNP	O	O
)	)	O	O
trial	NN	O	O
,	,	O	O
a	DT	O	O
diet	JJ	i	IE
and	CC	i	IE
exercise	JJ	i	IE
intervention	NN	i	IE
among	IN	O	O
overweight	JJ	O	O
,	,	O	O
long-term	JJ	O	O
(	(	O	O
?5	CD	O	O
years	NNS	O	O
)	)	O	O
,	,	O	O
older	JJR	O	O
survivors	NNS	O	O
of	IN	O	O
colorectal	NN	O	O
,	,	O	O
breast	NN	O	O
,	,	O	O
and	CC	O	O
prostate	NN	O	O
cancer	NN	p	O
.	.	p	O

Survivors	NNS	p	O
in	IN	p	O
the	DT	p	O
present	JJ	p	O
analysis	NN	p	O
(	(	p	O
n=729	JJ	p	O
)	)	p	O
underwent	JJ	i	O
two	CD	i	O
45-	JJ	i	O
to	TO	i	O
60-minute	JJ	i	O
telephone	NN	i	O
surveys	NNS	i	O
,	,	i	O
which	WDT	i	O
included	VBD	i	O
two	CD	i	O
24-hour	JJ	i	O
dietary	JJ	i	O
recalls	NNS	i	O
.	.	i	O

Principal	JJ	i	O
components	NNS	i	O
analysis	NN	i	O
and	CC	i	O
multivariable	JJ	i	O
general	JJ	i	O
linear	JJ	i	O
models	NNS	i	O
were	VBD	i	O
used	VBN	O	O
to	TO	O	O
derive	VB	o	O
dietary	JJ	o	O
patterns	NNS	o	O
and	CC	o	O
to	TO	O	O
evaluate	VB	O	O
associations	NNS	O	O
between	IN	o	O
dietary	JJ	o	O
patterns	NNS	o	O
and	CC	o	O
BMI	NNP	o	O
,	,	o	O
respectively	RB	O	O
.	.	O	O

RESULTS	VB	O	O
Principal	JJ	O	O
components	NNS	O	O
analysis	NN	O	O
identified	VBD	O	O
three	CD	o	O
primary	JJ	o	O
dietary	JJ	o	O
patterns	NNS	o	O
among	IN	o	O
rural	JJ	O	O
dwellers	NNS	O	O
(	(	O	O
high	JJ	O	O
sweets	NNS	O	O
and	CC	O	O
starches	NNS	O	O
,	,	O	O
high	JJ	O	O
reduced-fat	NN	O	O
dairy	NN	O	O
,	,	O	O
cereal	NN	O	O
,	,	O	O
nuts	NNS	O	O
,	,	O	O
and	CC	O	O
fruits	NNS	O	O
,	,	O	O
and	CC	O	O
mixed	JJ	O	O
)	)	O	O
and	CC	O	O
three	CD	O	O
among	IN	O	O
urban	JJ	O	O
dwellers	NNS	O	O
(	(	O	O
high	JJ	O	O
fruits	NNS	O	O
and	CC	O	O
vegetables	NNS	O	O
,	,	O	O
high	JJ	O	O
meat	NN	O	O
and	CC	O	O
refined	VBD	O	O
grains	NNS	O	O
,	,	O	O
and	CC	O	O
high	JJ	O	O
sugar-sweetened	JJ	O	O
beverages	NNS	O	O
)	)	O	O
.	.	O	O

Among	IN	p	O
rural	JJ	p	O
survivors	NNS	p	O
,	,	p	O
greater	JJR	O	O
adherence	NN	O	O
to	TO	O	O
the	DT	O	O
high	JJ	O	O
reduced-fat	NN	O	O
dairy	NN	O	O
,	,	O	O
cereal	NN	O	O
,	,	O	O
nuts	NNS	O	O
,	,	O	O
and	CC	O	O
fruits	NNS	O	O
pattern	NN	O	O
was	VBD	O	O
positively	RB	O	O
associated	VBN	O	O
with	IN	O	O
lower	JJR	o	O
BMI	NNP	o	O
(	(	o	O
P	NNP	O	O
trend	NN	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
,	,	O	O
whereas	IN	O	O
higher	JJR	O	O
scores	NNS	O	O
on	IN	O	O
the	DT	O	O
mixed	JJ	O	O
pattern	NN	O	O
was	VBD	O	O
associated	VBN	O	O
with	IN	O	O
greater	JJR	o	O
BMI	NNP	o	O
(	(	o	O
P	NNP	O	O
trend	NN	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

Greater	NNP	O	O
adherence	NN	O	O
to	TO	O	O
the	DT	O	O
high	JJ	O	O
fruits	NNS	O	O
and	CC	O	O
vegetables	NNS	O	O
pattern	VBP	O	O
among	IN	O	O
urban	JJ	O	O
survivors	NNS	O	O
was	VBD	O	O
inversely	RB	O	O
associated	VBN	O	O
with	IN	o	O
BMI	NNP	o	O
(	(	o	O
P	NNP	O	O
trend	NN	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
Urban	NNP	O	O
and	CC	O	O
rural	JJ	O	O
differences	NNS	O	O
in	IN	O	O
dietary	JJ	O	O
intake	NN	O	O
behavior	NN	O	O
should	MD	O	O
be	VB	O	O
considered	VBN	O	O
in	IN	O	O
designing	VBG	O	O
public	JJ	O	O
health	NN	O	O
interventions	NNS	O	O
among	IN	O	O
the	DT	o	O
increasing	VBG	o	O
population	NN	o	O
of	IN	o	O
older	JJR	O	O
cancer	NN	O	O
survivors	NNS	O	O
.	.	O	O

In	IN	O	O
addition	NN	O	O
,	,	O	O
targeting	VBG	O	O
overall	JJ	O	O
dietary	JJ	O	O
patterns	NNS	O	O
might	MD	O	O
be	VB	O	O
one	CD	O	O
approach	NN	O	O
to	TO	O	O
help	VB	O	O
reduce	VB	O	O
the	DT	O	O
burden	NN	O	O
of	IN	O	O
obesity	NN	O	O
among	IN	O	O
this	DT	O	O
population	NN	O	O
.	.	O	O

Cardiovascular	JJ	O	O
effects	NNS	O	O
of	IN	O	O
tamoxifen	NN	i	IPM
in	IN	O	O
women	NNS	p	O
with	IN	p	O
and	CC	p	O
without	IN	p	O
heart	NN	p	O
disease	NN	p	O
:	:	p	O
breast	NN	O	O
cancer	NN	O	O
prevention	NN	O	O
trial	NN	O	O
.	.	O	O

National	NNP	O	O
Surgical	NNP	O	O
Adjuvant	NNP	O	O
Breast	NNP	O	O
and	CC	O	O
Bowel	NNP	O	O
Project	NNP	O	O
Breast	NNP	O	O
Cancer	NNP	O	O
Prevention	NNP	O	O
Trial	NNP	O	O
Investigators	NNP	O	O
.	.	O	O

BACKGROUND	NNP	O	O
The	DT	O	O
overall	JJ	O	O
effect	NN	O	O
of	IN	O	O
prophylactic	JJ	O	O
tamoxifen	NN	O	O
in	IN	O	O
women	NNS	O	O
depends	NNS	O	O
on	IN	O	O
the	DT	O	O
balance	NN	O	O
between	IN	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
the	DT	O	O
drug	NN	O	O
,	,	O	O
which	WDT	O	O
include	VBP	O	O
preventing	VBG	o	OPH
breast	NN	o	OPH
cancer	NN	o	OPH
and	CC	O	O
altering	VBG	O	O
cardiovascular	JJ	o	OPH
risk	NN	o	OPH
.	.	o	O

In	IN	O	O
a	DT	O	O
recent	JJ	O	O
clinical	JJ	O	O
trial	NN	O	O
,	,	O	O
postmenopausal	JJ	O	O
estrogen-progestin	JJ	O	O
therapy	NN	O	O
was	VBD	O	O
shown	VBN	O	O
to	TO	O	O
increase	VB	O	O
the	DT	O	O
risk	NN	O	O
of	IN	O	O
early	JJ	o	OPH
cardiovascular	JJ	o	OPH
events	NNS	o	OPH
among	IN	O	O
women	NNS	p	O
with	IN	p	O
a	DT	p	O
history	NN	p	O
of	IN	p	O
coronary	JJ	p	O
heart	NN	p	O
disease	NN	p	O
(	(	p	O
CHD	NNP	p	O
)	)	p	O
.	.	p	O

The	DT	O	O
cardiovascular	JJ	o	OA
effects	NNS	o	OA
of	IN	O	O
tamoxifen	NN	O	O
in	IN	O	O
women	NNS	p	O
with	IN	p	O
and	CC	p	O
without	IN	p	O
CHD	NNP	p	O
are	VBP	O	O
not	RB	O	O
known	VBN	O	O
.	.	O	O

The	DT	O	O
National	NNP	O	O
Surgical	NNP	O	O
Adjuvant	NNP	O	O
Breast	NNP	O	O
and	CC	O	O
Bowel	NNP	O	O
Project	NNP	O	O
Breast	NNP	O	O
Cancer	NNP	O	O
Prevention	NNP	O	O
Trial	NNP	O	O
(	(	O	O
BCPT	NNP	O	O
)	)	O	O
is	VBZ	O	O
the	DT	O	O
only	JJ	O	O
clinical	JJ	O	O
trial	NN	O	O
that	WDT	O	O
provides	VBZ	O	O
data	NNS	O	O
to	TO	O	O
assess	VB	O	O
the	DT	O	O
cardiovascular	JJ	o	OA
effects	NNS	o	OA
of	IN	O	O
tamoxifen	NN	O	O
in	IN	O	O
women	NNS	O	O
with	IN	O	O
and	CC	O	O
without	IN	O	O
CHD	NNP	O	O
.	.	O	O

METHODS	NNP	O	O
A	NNP	O	O
total	NN	O	O
of	IN	O	O
13	CD	p	O
388	CD	p	O
women	NNS	p	O
at	IN	p	O
increased	VBN	p	O
risk	NN	p	O
for	IN	p	O
breast	NN	p	O
cancer	NN	p	O
were	VBD	O	O
randomly	RB	O	O
assigned	VBN	O	O
in	IN	O	O
the	DT	O	O
BCPT	NNP	O	O
to	TO	O	O
receive	VB	O	O
either	DT	O	O
tamoxifen	NN	i	IPM
(	(	i	IPM
20	CD	i	IPM
mg/day	NN	i	IPM
)	)	i	IPM
or	CC	i	O
placebo	NN	i	IC
.	.	i	O

Cardiovascular	JJ	p	O
follow-up	NN	p	O
was	VBD	p	O
available	JJ	p	O
for	IN	p	O
13	CD	p	O
194	CD	p	O
women	NNS	p	O
,	,	p	O
1048	CD	p	O
of	IN	p	O
whom	WP	p	O
had	VBD	p	O
prior	RB	p	O
clinical	JJ	p	O
CHD	NNP	p	O
.	.	p	O

Fatal	NNP	o	OPH
and	CC	o	OPH
nonfatal	JJ	o	OPH
myocardial	JJ	o	OPH
infarction	NN	o	OPH
,	,	o	O
unstable	JJ	o	OPH
angina	NN	o	OPH
,	,	o	OPH
and	CC	o	OPH
severe	JJ	o	OPH
angina	NN	o	OPH
were	VBD	O	O
tabulated	VBN	O	O
(	(	O	O
mean	JJ	O	O
follow-up	NN	O	O
:	:	O	O
49	CD	O	O
months	NNS	O	O
)	)	O	O
.	.	O	O

All	DT	O	O
statistical	JJ	O	O
tests	NNS	O	O
were	VBD	O	O
two-sided	JJ	O	O
.	.	O	O

RESULTS	NNP	O	O
Cardiovascular	JJ	o	OOt
event	NN	o	OOt
rates	NNS	o	OOt
were	VBD	O	O
not	RB	O	O
statistically	RB	O	O
significantly	RB	O	O
different	JJ	O	O
between	IN	O	O
women	NNS	O	O
assigned	VBN	O	O
to	TO	O	O
receive	VB	O	O
tamoxifen	NN	O	O
and	CC	O	O
those	DT	O	O
assigned	VBN	O	O
to	TO	O	O
receive	VB	O	O
placebo	NN	O	O
,	,	O	O
independent	JJ	O	O
of	IN	O	O
pre-existing	JJ	O	O
CHD	NNP	O	O
.	.	O	O

Among	IN	O	O
women	NNS	O	O
without	IN	O	O
CHD	NNP	O	O
(	(	O	O
6074	CD	O	O
on	IN	O	O
tamoxifen	NN	O	O
versus	NN	O	O
6072	CD	O	O
on	IN	O	O
placebo	NN	O	O
)	)	O	O
,	,	O	O
risk	JJ	O	O
ratios	NNS	O	O
(	(	O	O
95	CD	O	O
%	NN	O	O
confidence	NN	O	O
intervals	NNS	O	O
[	VBP	O	O
CIs	NNP	O	O
]	NNP	O	O
)	)	O	O
for	IN	O	O
tamoxifen	NN	O	O
users	NNS	O	O
were	VBD	O	O
1.75	CD	O	O
(	(	O	O
0.44	CD	O	O
to	TO	O	O
8.13	CD	O	O
)	)	O	O
for	IN	O	O
fatal	JJ	o	OPH
myocardial	JJ	o	OPH
infarction	NN	o	OPH
,	,	O	O
1.11	CD	O	O
(	(	O	O
0.55	CD	O	O
to	TO	O	O
2.28	CD	O	O
)	)	O	O
for	IN	O	O
nonfatal	JJ	o	OPH
myocardial	JJ	o	OPH
infarction	NN	o	OPH
,	,	O	O
0.69	CD	O	O
(	(	O	O
0.29	CD	O	O
to	TO	O	O
1.57	CD	O	O
)	)	O	O
for	IN	O	O
unstable	JJ	o	OPH
angina	NN	o	OPH
,	,	O	O
and	CC	O	O
0.83	CD	O	O
(	(	O	O
0.32	CD	O	O
to	TO	O	O
2.10	CD	O	O
)	)	O	O
for	IN	O	O
severe	JJ	o	OPH
angina	NN	o	OPH
.	.	o	O

In	IN	O	O
women	NNS	O	O
with	IN	O	O
CHD	NNP	O	O
(	(	O	O
516	CD	O	O
on	IN	O	O
tamoxifen	NNS	O	O
versus	$	O	O
532	CD	O	O
on	IN	O	O
placebo	NN	O	O
)	)	O	O
,	,	O	O
risk	JJ	o	OOt
ratios	NNS	o	OOt
(	(	O	O
95	CD	O	O
%	NN	O	O
CIs	NNP	O	O
)	)	O	O
for	IN	O	O
tamoxifen	NN	O	O
users	NNS	O	O
were	VBD	O	O
0.00	CD	O	O
(	(	O	O
0	CD	O	O
to	TO	O	O
1.58	CD	O	O
)	)	O	O
for	IN	O	O
fatal	JJ	o	OPH
myocardial	JJ	o	OPH
infarction	NN	o	OPH
,	,	O	O
1.25	CD	O	O
(	(	O	O
0.32	CD	O	O
to	TO	O	O
5.18	CD	O	O
)	)	O	O
for	IN	O	O
nonfatal	JJ	o	OPH
myocardial	JJ	o	OPH
infarction	NN	o	OPH
,	,	O	O
2.26	CD	O	O
(	(	O	O
0.87	CD	O	O
to	TO	O	O
6.55	CD	O	O
)	)	O	O
for	IN	O	O
unstable	JJ	o	OPH
angina	NN	o	OPH
,	,	O	O
and	CC	O	O
1.39	CD	O	O
(	(	O	O
0.23	CD	O	O
to	TO	O	O
9.47	CD	O	O
)	)	O	O
for	IN	O	O
severe	JJ	o	OPH
angina	NN	o	OPH
.	.	o	O

There	EX	O	O
was	VBD	O	O
no	DT	O	O
evidence	NN	O	O
that	IN	O	O
the	DT	O	O
lack	NN	O	O
of	IN	O	O
association	NN	O	O
between	IN	O	O
tamoxifen	NN	O	O
and	CC	O	O
cardiovascular	JJ	o	OPH
events	NNS	o	OPH
was	VBD	O	O
related	VBN	O	O
to	TO	O	O
an	DT	O	O
early	JJ	O	O
increase	NN	o	OPH
in	IN	o	OPH
risk	NN	o	OPH
that	WDT	O	O
may	MD	O	O
have	VB	O	O
been	VBN	O	O
offset	VBN	O	O
by	IN	O	O
a	DT	O	O
late	JJ	O	O
decrease	NN	O	O
in	IN	O	O
risk	NN	O	O
.	.	O	O

CONCLUSION	NN	O	O
When	WRB	O	O
used	VBN	O	O
for	IN	O	O
breast	NN	O	O
cancer	NN	O	O
prevention	NN	O	O
in	IN	O	O
women	NNS	p	O
with	IN	p	O
or	CC	p	O
without	IN	p	O
heart	NN	p	O
disease	NN	p	O
,	,	O	O
tamoxifen	NN	O	O
is	VBZ	O	O
not	RB	O	O
associated	VBN	O	O
with	IN	O	O
beneficial	JJ	O	O
or	CC	O	O
adverse	JJ	O	O
cardiovascular	JJ	o	OA
effects	NNS	o	OA
.	.	o	O

Low-dose	JJ	O	O
,	,	O	O
vaginally	RB	O	O
administered	VBN	O	O
estrogens	NNS	i	IPM
may	MD	O	O
enhance	VB	O	O
local	JJ	O	O
benefits	NNS	O	O
of	IN	O	O
systemic	JJ	O	O
therapy	NN	O	O
in	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
urogenital	JJ	p	PC
atrophy	NN	p	PC
in	IN	p	O
postmenopausal	JJ	p	PC
women	NNS	p	PSS
on	IN	p	PC
hormone	NN	p	PC
therapy	NN	p	PC
.	.	p	O

BACKGROUND	NNP	O	O
When	WRB	O	O
genital	JJ	O	O
atrophy	NN	O	O
exists	NNS	O	O
,	,	O	O
systemic	JJ	i	IPH
hormone	NN	i	IPH
therapy	NN	i	IPH
(	(	i	IPH
HT	NNP	i	IPH
)	)	i	IPH
has	VBZ	O	O
a	DT	O	O
timing	NN	O	O
until	IN	O	O
to	TO	O	O
induce	VB	O	O
vaginal	JJ	O	O
proliferation	NN	O	O
and	CC	O	O
symptomatic	JJ	O	O
relieve	NN	O	O
.	.	O	O

Thus	RB	O	O
,	,	O	O
in	IN	O	O
order	NN	O	O
to	TO	O	O
obtain	VB	O	O
a	DT	O	O
prompt	JJ	O	O
improvement	NN	O	O
,	,	O	O
the	DT	O	O
association	NN	O	O
of	IN	O	O
local	JJ	O	O
therapy	NN	O	O
acting	VBG	O	O
on	IN	O	O
the	DT	O	O
genital	JJ	O	O
epithelium	NN	O	O
to	TO	O	O
the	DT	O	O
systemic	JJ	O	O
treatment	NN	O	O
should	MD	O	O
be	VB	O	O
considered	VBN	O	O
.	.	O	O

OBJECTIVE	UH	O	O
To	TO	O	O
evaluate	VB	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
a	DT	O	O
combined	JJ	O	O
therapy	NN	O	O
consisting	NN	O	O
of	IN	O	O
vaginal	JJ	O	O
estriol	NN	O	O
with	IN	O	O
transdermal	JJ	O	O
17-beta-estradiol	JJ	O	O
(	(	O	O
50	CD	O	O
microg/day	NN	O	O
)	)	O	O
plus	CC	O	O
medroxyprogesterone	JJ	O	O
acetate	NN	O	O
(	(	O	O
5	CD	O	O
mg/day	NN	O	O
)	)	O	O
per	IN	O	O
os	NN	O	O
in	IN	O	O
shortening	VBG	O	O
the	DT	O	O
period	NN	O	O
of	IN	O	O
uro-genital	JJ	O	O
symptoms	NNS	O	O
.	.	O	O

SUBJECTS	NNP	O	O
AND	NNP	O	O
METHODS	NNP	O	O
In	IN	O	O
a	DT	O	O
randomized	JJ	O	O
,	,	O	O
double	JJ	O	O
blind	NN	O	O
,	,	O	O
controlled	VBN	O	O
with	IN	O	O
placebo	NN	i	IC
study	NN	O	O
,	,	O	O
27	CD	p	PSS
women	NNS	p	PSS
with	IN	p	O
climacteric	JJ	p	PC
symptoms	NNS	p	PC
and	CC	p	O
atrophic	JJ	p	PC
vaginitis	NN	p	PC
were	VBD	O	O
treated	VBN	O	O
for	IN	O	O
4	CD	O	O
months	NNS	O	O
with	IN	O	O
HT	NNP	i	IPM
plus	CC	i	IPM
vaginal	JJ	i	IPM
estriol	NN	i	IPM
0.5	CD	i	IPM
mg/day	NN	i	IPM
(	(	O	O
group	NN	O	O
E	NNP	O	O
)	)	O	O
or	CC	O	O
placebo	NN	i	IC
(	(	O	O
group	NN	O	O
P	NNP	O	O
)	)	O	O
.	.	O	O

Patients	NNS	O	O
use	VBP	O	O
the	DT	O	O
local	JJ	O	O
medication	NN	O	O
daily	RB	O	O
for	IN	O	O
the	DT	O	O
first	JJ	O	O
3	CD	O	O
weeks	NNS	O	O
and	CC	O	O
twice-weekly	JJ	O	O
thereafter	NN	O	O
.	.	O	O

Before	IN	O	O
entering	VBG	O	O
in	IN	O	O
the	DT	O	O
study	NN	O	O
,	,	O	O
patients	NNS	O	O
were	VBD	O	O
asked	VBN	O	O
about	IN	O	O
HT	NNP	O	O
and	CC	O	O
selected	VBN	O	O
for	IN	O	O
inclusion	NN	O	O
.	.	O	O

In	IN	O	O
the	DT	O	O
first	JJ	O	O
visit	NN	O	O
,	,	O	O
electible	JJ	O	O
patients	NNS	O	O
after	IN	O	O
written	VBN	O	O
informed	JJ	O	O
consent	NN	O	O
were	VBD	O	O
randomized	VBN	O	O
to	TO	O	O
receive	VB	p	O
HT	NNP	i	IPM
plus	CC	i	IPM
local	JJ	i	IPM
estriol	NN	i	IPM
or	CC	p	O
placebo	NN	i	IC
.	.	i	O

All	PDT	O	O
the	DT	O	O
subjects	NNS	O	O
had	VBD	O	O
baseline	NN	O	O
studies	NNS	O	O
,	,	O	O
including	VBG	O	O
medical	JJ	O	O
history	NN	O	O
,	,	O	O
physical	JJ	O	O
examination	NN	O	O
,	,	O	O
blood	NN	O	O
and	CC	O	O
urine	JJ	O	O
analysis	NN	O	O
.	.	O	O

In	IN	O	O
order	NN	O	O
to	TO	O	O
evaluate	VB	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
local	JJ	O	O
treatment	NN	O	O
on	IN	O	O
urinary	JJ	O	O
and	CC	O	O
genital	JJ	O	O
symptoms	NNS	O	O
,	,	O	O
a	DT	O	O
score	NN	O	O
for	IN	O	O
genital	NN	O	O
,	,	O	O
urinary	JJ	O	O
and	CC	O	O
colposcopic	JJ	O	O
complaints	NNS	O	O
(	(	O	O
0	CD	O	O
minimum-100	JJ	O	O
maximum	NN	O	O
)	)	O	O
was	VBD	O	O
developed	VBN	O	O
.	.	O	O

This	DT	O	O
score	NN	O	O
and	CC	O	O
Blatt-Kuperman	NNP	O	O
were	VBD	O	O
recorded	VBN	O	O
and	CC	O	O
performed	VBN	O	O
in	IN	O	O
every	DT	O	O
control	NN	O	O
.	.	O	O

RESULTS	CC	O	O
There	EX	O	O
were	VBD	O	O
no	DT	o	OOt
differences	NNS	o	OOt
on	IN	o	OOt
climacteric	NN	o	OOt
symptoms	NNS	o	OOt
relief	NN	o	OOt
between	IN	o	OOt
the	DT	o	OOt
two	CD	o	OOt
groups	NNS	o	OOt
.	.	o	O

Additionally	RB	O	O
,	,	O	O
the	DT	O	O
improvement	NN	o	OOt
in	IN	o	OOt
urinary	JJ	o	OOt
symptoms	NNS	o	OOt
at	IN	o	OOt
the	DT	o	OOt
end	NN	o	OOt
of	IN	o	OOt
the	DT	o	OOt
study	NN	o	OOt
was	VBD	o	O
similar	JJ	o	O
for	IN	o	O
both	DT	o	O
groups	NNS	o	O
(	(	O	O
from	IN	O	O
16.5	CD	O	O
+/-	JJ	O	O
6.1	CD	O	O
to	TO	O	O
8.5	CD	O	O
+/-	JJ	O	O
2.4	CD	O	O
for	IN	O	O
E	NNP	O	O
group	NN	O	O
and	CC	O	O
from	IN	O	O
15.8	CD	O	O
+/-	JJ	O	O
7.8	CD	O	O
to	TO	O	O
8.8	CD	O	O
+/-	JJ	O	O
2.7	CD	O	O
for	IN	O	O
P	NNP	O	O
group	NN	O	O
;	:	O	O
P	NNP	O	O
<	VBD	O	O
0.01	CD	O	O
versus	NN	O	O
basal	NN	O	O
)	)	O	O
;	:	O	O
however	RB	O	O
,	,	O	O
those	DT	O	O
women	NNS	o	O
in	IN	o	O
group	NN	o	O
E	NNP	o	O
reached	VBD	o	O
significant	JJ	o	OOt
improvement	NN	o	OOt
on	IN	o	OOt
urinary	JJ	o	OOt
complaints	NNS	o	OOt
since	IN	o	O
the	DT	o	O
first	JJ	o	O
month	NN	o	O
of	IN	o	O
treatment	NN	o	O
.	.	o	O

Additionally	RB	O	O
,	,	O	O
a	DT	O	O
significant	JJ	o	O
difference	NN	o	O
between	IN	o	O
E	NNP	o	O
and	CC	o	O
P	NNP	o	O
was	VBD	o	O
observed	VBN	o	O
at	IN	o	O
months	NNS	o	O
2	CD	o	O
and	CC	o	O
3	CD	o	O
,	,	o	O
although	IN	o	O
no	DT	o	O
differences	NNS	o	O
were	VBD	o	O
detected	VBN	o	O
at	IN	o	O
the	DT	o	O
end	NN	o	O
of	IN	o	O
the	DT	o	O
study	NN	o	O
.	.	o	O

Papanicolaou	NNP	o	O
smear	JJ	o	O
showed	VBD	o	O
reactive	JJ	o	OOt
or	CC	o	O
reparative	JJ	o	OOt
changes	NNS	o	OOt
and	CC	o	O
karyopyknotic	JJ	o	OOt
index	NN	o	OOt
exhibited	VBD	o	OOt
a	DT	o	OOt
significant	JJ	o	OOt
increase	NN	o	OOt
in	IN	o	OOt
superficial	JJ	o	OPH
cells	NNS	o	OPH
in	IN	o	OOt
both	DT	o	OOt
groups	NNS	o	OOt
and	CC	o	OOt
at	IN	o	OOt
the	DT	o	OOt
end	NN	o	OOt
of	IN	o	OOt
the	DT	o	OOt
study	NN	o	OOt
.	.	o	O

CONCLUSIONS	NNP	O	O
Adding	NNP	O	O
vaginal	JJ	O	O
estriol	NN	O	O
to	TO	O	O
HRT	NNP	O	O
may	MD	O	O
shorten	VB	O	O
the	DT	O	O
latency	NN	O	O
period	NN	O	O
for	IN	O	O
urinary	JJ	O	O
symptoms	NNS	O	O
.	.	O	O

Blind	NNP	i	IS
versus	NN	i	IS
open	JJ	i	IS
approach	NN	i	IS
to	TO	i	IS
laparoscopic	VB	i	IS
cholecystectomy	NN	i	IS
:	:	i	IS
a	DT	O	O
randomized	JJ	O	O
study	NN	O	O
.	.	O	O

Intraabdominal	NNP	O	O
structures	NNS	O	O
may	MD	O	O
be	VB	O	O
damaged	VBN	O	O
during	IN	O	O
blind	JJ	O	O
introduction	NN	O	O
of	IN	O	O
the	DT	O	O
first	JJ	O	O
trocar	NN	O	O
for	IN	O	O
laparoscopic	JJ	i	IS
operations	NNS	O	O
.	.	O	O

In	IN	O	O
this	DT	O	O
study	NN	O	O
,	,	O	O
150	CD	p	PSS
patients	NNS	p	O
with	IN	p	O
gallbladder	JJ	p	PC
lithiasis	NN	p	PC
who	WP	p	O
underwent	JJ	p	O
laparoscopy	NN	p	PC
were	VBD	O	O
randomly	RB	O	O
assigned	VBN	O	O
to	TO	O	O
two	CD	O	O
groups	NNS	O	O
,	,	O	O
a	DT	O	O
blind	NN	O	O
(	(	O	O
V	NNP	O	O
group	NN	O	O
)	)	O	O
or	CC	O	O
an	DT	O	O
open	JJ	O	O
(	(	O	O
H	NNP	O	O
group	NN	O	O
)	)	O	O
,	,	O	O
in	IN	O	O
order	NN	O	O
to	TO	O	O
compare	VB	O	O
the	DT	O	O
results	NNS	O	O
and	CC	O	O
the	DT	O	O
rate	NN	o	OA
of	IN	o	OA
complications	NNS	o	OA
.	.	o	O

No	DT	O	O
mortality	NN	o	OMO
was	VBD	O	O
observed	VBN	O	O
.	.	O	O

Major	JJ	o	OA
complications	NNS	o	OA
occurred	VBD	O	O
in	IN	O	O
3/75	CD	O	O
(	(	O	O
4	CD	O	O
%	NN	O	O
)	)	O	O
patients	NNS	O	O
of	IN	O	O
the	DT	O	O
V	NNP	O	O
group	NN	O	O
and	CC	O	O
in	IN	O	O
1/75	CD	O	O
(	(	O	O
1.3	CD	O	O
%	NN	O	O
)	)	O	O
patient	NN	O	O
of	IN	O	O
the	DT	O	O
H	NNP	O	O
group	NN	O	O
(	(	O	O
p	JJ	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

Minor	JJ	o	OA
complications	NNS	o	OA
occurred	VBD	O	O
in	IN	O	O
5/75	CD	O	O
(	(	O	O
6.7	CD	O	O
%	NN	O	O
)	)	O	O
patients	NNS	O	O
of	IN	O	O
either	DT	O	O
group	NN	O	O
.	.	O	O

The	DT	O	O
achievement	NN	o	OPH
of	IN	o	OPH
pneumoperitoneum	NN	o	OPH
required	VBN	O	O
4.5+/-0.4	JJ	O	O
min	NN	O	O
in	IN	O	O
the	DT	O	O
V	NNP	O	O
group	NN	O	O
and	CC	O	O
3.2+/-0.2	JJ	O	O
min	NN	O	O
in	IN	O	O
the	DT	O	O
H	NNP	O	O
group	NN	O	O
(	(	O	O
p	JJ	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
open	JJ	i	IS
laparoscopic	NN	i	IS
technique	NN	i	IS
is	VBZ	O	O
safer	JJR	O	O
and	CC	O	O
faster	RBR	O	O
than	IN	O	O
the	DT	O	O
blind	JJ	i	IPH
approach	NN	i	IPH
;	:	i	O
therefore	RB	O	O
,	,	O	O
it	PRP	O	O
is	VBZ	O	O
proposed	VBN	O	O
that	IN	O	O
this	DT	O	O
approach	NN	O	O
be	VB	O	O
routinely	RB	O	O
used	VBN	O	O
in	IN	O	O
all	DT	O	O
laparoscopic	NN	O	O
procedures	NNS	O	O
.	.	O	O

Timing	VBG	O	O
for	IN	O	O
delivering	VBG	O	O
individualized	JJ	i	IE
patient	JJ	i	IE
education	NN	i	IE
intervention	NN	i	IE
to	TO	O	O
Coronary	NNP	p	PC
Artery	NNP	p	PC
Bypass	NNP	p	PC
Graft	NNP	p	PC
patients	NNS	p	O
:	:	p	O
An	DT	O	O
RCT	NNP	O	O
.	.	O	O

BACKGROUND	NNP	O	O
The	DT	O	O
primary	JJ	O	O
focus	NN	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
is	VBZ	O	O
on	IN	O	O
the	DT	O	O
timing	NN	O	O
of	IN	O	O
the	DT	O	O
delivery	NN	O	O
of	IN	O	O
education	NN	O	O
to	TO	O	O
patients	NNS	p	O
who	WP	p	O
had	VBD	p	O
CABG	NNP	i	IS
surgery	NN	i	IS
.	.	i	IS

AIM	NNP	O	O
To	TO	O	O
determine	VB	O	O
the	DT	O	O
efficacy	NN	O	O
of	IN	O	O
an	DT	O	O
individualized	JJ	i	IE
telephone	NN	i	IE
patient	JJ	i	IE
education	NN	i	IE
intervention	NN	i	IE
,	,	O	O
delivered	VBN	O	O
at	IN	O	O
two	CD	O	O
different	JJ	O	O
points	NNS	O	O
in	IN	O	O
time	NN	O	O
(	(	O	O
1-2	JJ	O	O
days	NNS	O	O
pre-discharge	JJ	O	O
versus	JJ	O	O
1-2	JJ	O	O
days	NNS	O	O
post-discharge	NN	O	O
)	)	O	O
in	IN	O	O
enhancing	VBG	O	O
the	DT	O	O
CABG	NNP	p	PC
patient	NN	p	O
's	POS	p	O
knowledge	NN	O	O
of	IN	O	O
self-care	JJ	O	O
behaviours	NNS	O	O
,	,	O	O
performance	NN	O	O
of	IN	O	O
self-care	JJ	O	O
behaviours	NNS	O	O
,	,	O	O
and	CC	O	O
symptom	JJ	O	O
frequency	NN	O	O
.	.	O	O

METHOD	NNP	O	O
A	NNP	O	O
randomized	VBD	O	O
clinical	JJ	O	O
trial	NN	O	O
that	WDT	O	O
included	VBD	O	O
a	DT	O	O
convenience	NN	p	O
sample	NN	p	O
of	IN	p	O
first	JJ	p	O
time	NN	p	O
CABG	NNP	p	PC
patients	NNS	p	O
.	.	p	O

Individuals	NNS	O	O
who	WP	O	O
received	VBD	O	O
education	NN	i	IE
pre-discharge	NN	i	IE
were	VBD	O	O
compared	VBN	O	O
to	TO	O	O
individuals	NNS	p	O
who	WP	p	O
received	VBD	p	O
education	NN	p	O
post-discharge	NN	p	O
on	IN	p	O
the	DT	p	O
outcomes	NNS	p	O
.	.	p	O

RESULTS	NNP	O	O
Results	NNP	O	O
indicated	VBD	O	O
no	DT	O	O
statistically	RB	O	O
significant	JJ	O	O
difference	NN	O	O
in	IN	O	O
outcomes	NNS	o	OOt
between	IN	o	OOt
the	DT	o	OOt
two	CD	o	OOt
time	NN	o	OOt
points	NNS	o	OOt
.	.	o	OOt

As	NNP	O	O
well	RB	O	O
,	,	O	O
anxiety	NN	o	OME
levels	NNS	o	OME
were	VBD	O	O
found	VBN	O	O
to	TO	O	O
be	VB	O	O
significantly	RB	O	O
higher	JJR	O	O
in	IN	O	O
the	DT	O	O
pre-discharge	NN	O	O
group	NN	O	O
than	IN	O	O
the	DT	O	O
post-discharge	JJ	O	O
group	NN	O	O
.	.	O	O

CONCLUSIONS	VB	O	O
The	DT	O	O
individualized	JJ	O	O
nature	NN	O	O
of	IN	O	O
the	DT	O	O
educational	JJ	i	IE
intervention	NN	i	IE
may	MD	O	O
have	VB	O	O
accounted	VBN	O	O
for	IN	O	O
non-significant	JJ	O	O
findings	NNS	O	O
reported	VBN	O	O
in	IN	O	O
outcomes	NNS	O	O
between	IN	O	O
the	DT	O	O
two	CD	O	O
time	NN	O	O
points	NNS	O	O
.	.	O	O

PRACTICE	NNP	O	O
IMPLICATIONS	NNP	O	O
Nurses	NNP	O	O
may	MD	O	O
consider	VB	O	O
assessing	VBG	O	O
anxiety	NN	o	OME
levels	NNS	o	OME
prior	RB	O	O
to	TO	O	O
delivery	NN	O	O
of	IN	O	O
educational	JJ	O	O
interventions	NNS	O	O
,	,	O	O
implement	JJ	O	O
interventions	NNS	O	O
aimed	VBN	O	O
at	IN	O	O
reducing	VBG	O	O
anxiety	NN	O	O
levels	NNS	O	O
,	,	O	O
and	CC	O	O
provide	VB	O	O
individualized	JJ	O	O
teaching	NN	O	O
.	.	O	O

Control	NN	O	O
of	IN	O	O
perioperative	JJ	O	O
hypertension	NN	o	OPH
during	IN	O	O
coronary	JJ	i	IS
artery	NN	i	IS
surgery	NN	i	IS
.	.	i	O

A	DT	O	O
randomised	JJ	O	O
double-blind	NN	O	O
study	NN	O	O
comparing	VBG	O	O
isosorbide	JJ	i	IPM
dinitrate	NN	i	IPM
and	CC	i	O
nitroglycerin	NN	i	IPM
.	.	i	O

A	DT	O	O
reduction	NN	O	O
in	IN	O	O
the	DT	O	O
causes	NNS	O	O
of	IN	O	O
myocardial	JJ	o	OPH
ischaemia	NN	o	OPH
remains	VBZ	O	O
of	IN	O	O
prime	JJ	O	O
importance	NN	O	O
during	IN	O	O
coronary	JJ	O	O
artery	NN	O	O
surgery	NN	O	O
.	.	O	O

Hypertension	NN	o	OPH
with	IN	O	O
the	DT	O	O
ensuing	VBG	O	O
increase	NN	O	O
in	IN	O	O
myocardial	JJ	o	OPH
oxygen	NN	o	OPH
demand	NN	o	OPH
is	VBZ	O	O
a	DT	O	O
major	JJ	O	O
factor	NN	O	O
in	IN	O	O
the	DT	O	O
aetiology	NN	O	O
of	IN	O	O
perioperative	JJ	O	O
myocardial	JJ	o	OPH
ischaemia	NN	o	OPH
.	.	o	O

Nitroglycerin	NNP	i	IPM
(	(	i	IPM
NTG	NNP	i	IPM
)	)	i	IPM
has	VBZ	O	O
long	RB	O	O
been	VBN	O	O
used	VBN	O	O
beneficially	RB	O	O
to	TO	O	O
reduce	VB	O	O
myocardial	JJ	o	OPH
oxygen	NN	o	OPH
demand	NN	o	OPH
by	IN	O	O
its	PRP$	O	O
effects	NNS	O	O
on	IN	O	O
the	DT	O	O
systemic	JJ	O	O
and	CC	O	O
peripheral	JJ	O	O
vascular	JJ	O	O
resistances	NNS	O	O
.	.	O	O

An	DT	O	O
alternative	JJ	O	O
nitrate	NN	i	IPM
,	,	i	O
isosorbide	JJ	i	IPM
dinitrate	NN	i	IPM
(	(	i	IPM
ISDN	NNP	i	IPM
)	)	i	IPM
is	VBZ	O	O
now	RB	O	O
available	JJ	O	O
as	IN	O	O
an	DT	O	O
intravenous	JJ	O	O
preparation	NN	O	O
,	,	O	O
and	CC	O	O
may	MD	O	O
offer	VB	O	O
technical	JJ	O	O
advantages	NNS	O	O
,	,	O	O
both	DT	O	O
due	JJ	O	O
to	TO	O	O
its	PRP$	O	O
stability	NN	O	O
in	IN	O	O
solution	NN	O	O
and	CC	O	O
also	RB	O	O
its	PRP$	O	O
longer	NN	O	O
in	IN	O	O
vivo	JJ	O	O
half-life	NN	O	O
.	.	O	O

We	PRP	O	O
designed	VBD	O	O
and	CC	O	O
carried	VBD	O	O
out	RP	O	O
a	DT	O	O
multi-centre	JJ	O	O
study	NN	O	O
to	TO	O	O
compare	VB	O	O
and	CC	O	O
evaluate	VB	O	O
the	DT	O	O
efficacy	NN	o	OOt
of	IN	o	OOt
ISDN	NNP	o	OOt
and	CC	o	OOt
NTG	NNP	o	OOt
in	IN	O	O
the	DT	O	O
management	NN	O	O
of	IN	O	O
perioperative	JJ	O	O
hypertension	NN	O	O
in	IN	O	O
85	CD	p	O
patients	NNS	p	O
undergoing	JJ	p	O
elective	JJ	i	IS
coronary	JJ	i	IS
artery	NN	i	IS
surgery	NN	i	IS
.	.	i	O

A	DT	p	O
total	NN	p	O
of	IN	p	O
288	CD	p	O
events	NNS	p	O
in	IN	p	O
which	WDT	p	O
the	DT	p	O
systolic	NN	o	OPH
blood	NN	o	OPH
pressure	NN	o	OPH
(	(	o	OPH
SBP	NNP	o	OPH
)	)	o	OPH
exceeded	VBD	p	O
a	DT	p	O
predetermined	JJ	p	O
trigger	NN	p	O
value	NN	p	O
were	VBD	p	O
observed	VBN	p	O
.	.	p	O

ISDN	NNP	i	IPM
was	VBD	O	O
successful	JJ	o	OOt
in	IN	O	O
treating	VBG	O	O
hypertension	NN	o	OPH
in	IN	O	O
63	CD	O	O
%	NN	O	O
of	IN	O	O
the	DT	O	O
events	NNS	O	O
,	,	O	O
whereas	NNS	O	O
NTG	NNP	i	IPM
had	VBD	O	O
an	DT	O	O
83	CD	O	O
%	NN	O	O
success	NN	O	O
.	.	O	O

The	DT	O	O
SBP	NNP	o	OPH
was	VBD	O	O
significantly	RB	O	O
lowered	VBN	O	O
after	IN	O	O
treatment	NN	O	O
with	IN	O	O
either	DT	O	O
ISDN	NNP	i	IPM
,	,	O	O
155	CD	O	O
mmHg	NN	O	O
to	TO	O	O
138	CD	O	O
mmHg	NN	O	O
,	,	O	O
or	CC	O	O
NTG	NNP	O	O
,	,	O	O
160	CD	O	O
mmHg	NN	O	O
to	TO	O	O
130	CD	O	O
mmHg	NN	O	O
.	.	O	O

The	DT	O	O
mean	JJ	o	OOt
successful	JJ	o	OOt
dose	NN	o	OOt
rate	NN	o	OOt
for	IN	O	O
ISDN	NNP	i	IPM
was	VBD	O	O
6.5	CD	O	O
micrograms	JJ	O	O
kg-1	JJ	O	O
min-1	NN	O	O
,	,	O	O
whereas	NNS	O	O
for	IN	O	O
NTG	NNP	i	IPM
this	DT	O	O
was	VBD	O	O
3.8	CD	O	O
micrograms	JJ	O	O
kg-1	JJ	O	O
min-1	NN	O	O
.	.	O	O

In	IN	O	O
the	DT	O	O
ISDN	NNP	i	IPM
group	NN	O	O
less	JJR	O	O
events	NNS	o	OPH
took	VBD	O	O
place	NN	O	O
possibly	RB	O	O
due	JJ	O	O
to	TO	O	O
the	DT	O	O
longer	JJR	O	O
duration	NN	O	O
of	IN	O	O
this	DT	O	O
drug	NN	O	O
.	.	O	O

In	IN	O	O
many	JJ	O	O
previous	JJ	O	O
studies	NNS	O	O
NTG	NNP	i	IPM
has	VBZ	O	O
been	VBN	O	O
found	VBN	O	O
to	TO	O	O
be	VB	O	O
effective	JJ	O	O
in	IN	O	O
controlling	VBG	O	O
hypertension	NN	o	OPH
;	:	o	O
ISDN	NNP	i	IPM
offers	NNS	O	O
and	CC	O	O
alternative	JJ	O	O
approach	NN	O	O
in	IN	O	O
reducing	VBG	o	OPH
hypertension	NN	o	OPH
.	.	o	O

Use	NNP	O	O
of	IN	O	O
an	DT	O	O
inspiratory	JJ	i	IPH
impedance	NN	i	IPH
threshold	JJ	i	IPH
device	NN	i	IPH
on	IN	i	IPH
a	DT	i	IPH
facemask	NN	i	IPH
and	CC	i	IPH
endotracheal	VB	i	IPH
tube	NN	i	IPH
to	TO	O	O
reduce	VB	O	O
intrathoracic	JJ	o	OPH
pressures	NNS	o	OPH
during	IN	O	O
the	DT	O	O
decompression	NN	O	O
phase	NN	O	O
of	IN	O	O
active	JJ	p	O
compression-decompression	NN	o	OPH
cardiopulmonary	JJ	o	OPH
resuscitation	NN	o	OPH
.	.	o	O

INTRODUCTION	NNP	O	O
Use	NNP	O	O
of	IN	O	O
an	DT	O	O
inspiratory	JJ	i	IPH
impedance	NN	i	IPH
threshold	NN	i	IPH
device	NN	i	IPH
(	(	i	IPH
ITD	NNP	i	IPH
)	)	i	IPH
significantly	RB	O	O
increases	VBZ	O	O
coronary	JJ	O	O
perfusion	NN	O	O
pressures	NNS	O	O
and	CC	O	O
survival	NN	O	O
in	IN	O	O
patients	NNS	p	O
ventilated	VBN	p	O
with	IN	p	O
an	DT	p	O
endotracheal	JJ	i	IPH
tube	NN	i	IPH
(	(	i	IPH
ETT	NNP	i	IPH
)	)	i	IPH
during	IN	p	O
active	JJ	i	IPH
compression-decompression	NN	i	IPH
cardiopulmonary	JJ	i	IPH
resuscitation	NN	i	IPH
.	.	i	O

We	PRP	O	O
tested	VBD	O	O
the	DT	O	O
hypothesis	NN	O	O
that	IN	O	O
the	DT	O	O
ITD	NNP	i	IPH
could	MD	O	O
lower	VB	O	O
intratracheal	NN	O	O
pressures	NNS	O	O
when	WRB	O	O
attached	VBN	O	O
to	TO	O	O
either	VB	O	O
a	DT	O	O
facemask	NN	i	IPH
or	CC	i	IPH
ETT	NNP	i	IPH
.	.	i	O

METHODS	NNP	O	O
An	DT	i	O
active	JJ	i	IPH
and	CC	i	IPH
sham	JJ	i	IPH
ITD	NNP	i	IPH
were	VBD	O	O
randomly	RB	O	O
applied	VBN	O	O
first	RB	O	O
to	TO	O	O
a	DT	O	O
facemask	NN	i	IPH
and	CC	O	O
then	RB	O	O
to	TO	O	O
an	DT	O	O
ETT	NNP	i	IPH
during	IN	O	O
active	JJ	i	IPH
compression-decompression	NN	i	IPH
cardiopulmonary	JJ	i	IPH
resuscitation	NN	i	IPH
in	IN	p	O
13	CD	p	O
out-of-hospital	JJ	p	O
cardiac	JJ	p	O
arrest	NN	p	O
patients	NNS	p	O
in	IN	O	O
a	DT	O	O
randomized	JJ	O	O
,	,	O	O
double-blinded	JJ	O	O
,	,	O	O
prospective	JJ	O	O
clinical	JJ	O	O
trial	NN	O	O
.	.	O	O

The	DT	O	O
compression-to-bag-valve	JJ	O	O
ventilation	NN	O	O
ratio	NN	O	O
was	VBD	O	O
15:2	CD	O	O
.	.	O	O

Airway	NN	O	O
pressures	NNS	O	O
(	(	O	O
surrogate	NN	O	O
for	IN	O	O
intrathoracic	JJ	O	O
pressure	NN	O	O
)	)	O	O
were	VBD	O	O
measured	VBN	O	O
with	IN	O	O
a	DT	O	O
pressure	NN	O	O
transducer	NN	O	O
.	.	O	O

A	DT	i	O
sham	NN	i	IPH
and	CC	i	IPH
an	DT	i	IPH
active	JJ	i	IPH
ITD	NNP	i	IPH
were	VBD	O	O
used	VBN	O	O
for	IN	O	O
1	CD	O	O
min	NNS	O	O
each	DT	O	O
in	IN	O	O
a	DT	O	O
randomized	JJ	O	O
order	NN	O	O
,	,	O	O
first	RB	O	O
on	IN	O	O
a	DT	O	O
facemask	NN	i	IPH
and	CC	O	O
then	RB	O	O
on	IN	O	O
an	DT	O	O
ETT	NNP	i	IPH
.	.	i	O

Statistical	JJ	O	O
analyses	NNS	O	O
were	VBD	O	O
made	VBN	O	O
using	VBG	O	O
Friedman	NNP	O	O
's	POS	O	O
and	CC	O	O
Wilcoxon	NNP	O	O
's	POS	O	O
rank-sum	JJ	O	O
tests	NNS	O	O
.	.	O	O

RESULTS	NNP	O	O
For	IN	O	O
the	DT	O	O
primary	JJ	O	O
end	NN	O	O
point	NN	O	O
,	,	O	O
mean	JJ	o	OPH
+/-	JJ	o	OPH
sd	NN	o	OPH
maximum	JJ	o	OPH
negative	JJ	o	OPH
intrathoracic	NN	o	OPH
pressures	NNS	o	OPH
(	(	O	O
mm	VB	O	O
Hg	NNP	O	O
)	)	O	O
during	IN	O	O
the	DT	O	O
decompression	NN	o	OPH
phase	NN	o	OPH
of	IN	o	OPH
cardiopulmonary	JJ	o	OPH
resuscitation	NN	o	OPH
were	VBD	O	O
-1.0	JJ	O	O
+/-	JJ	O	O
0.73	CD	O	O
mm	NN	O	O
Hg	NNP	O	O
with	IN	O	O
a	DT	O	O
sham	NN	i	IPH
vs.	FW	O	O
-4.6	NNP	O	O
+/-	JJ	O	O
3.7	CD	O	O
mm	NN	O	O
Hg	NNP	O	O
with	IN	O	O
an	DT	O	O
active	JJ	i	IPH
ITD	NN	i	IPH
on	IN	O	O
the	DT	O	O
facemask	NN	O	O
(	(	O	O
p	JJ	O	O
=	NNP	O	O
.003	NNP	O	O
)	)	O	O
and	CC	O	O
-1.3	JJ	O	O
+/-	JJ	O	O
1.3	CD	O	O
mm	NN	O	O
Hg	NNP	O	O
with	IN	O	O
a	DT	O	O
sham	NN	O	O
ITD	NNP	O	O
vs.	IN	O	O
-7.3	NNP	O	O
+/-	JJ	O	O
4.5	CD	O	O
mm	NN	O	O
Hg	NNP	O	O
with	IN	O	O
an	DT	O	O
active	JJ	O	O
ITD	NNP	O	O
on	IN	O	O
an	DT	O	O
ETT	NNP	O	O
(	(	O	O
p	JJ	O	O
=	NNP	O	O
.0009	NNP	O	O
)	)	O	O
.	.	O	O

Decompression	NNP	o	OPH
phase	NN	o	OPH
airway	NN	o	OPH
pressures	NNS	o	OPH
with	IN	O	O
the	DT	O	O
facemask	NN	i	IPH
and	CC	i	IPH
ETT	NNP	i	IPH
were	VBD	O	O
not	RB	O	O
statistically	RB	O	O
different	JJ	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
Use	NNP	O	O
of	IN	O	O
an	DT	O	O
active	JJ	i	IPH
ITD	NNP	i	IPH
attached	VBD	i	IPH
to	TO	i	IPH
a	DT	i	IPH
facemask	NN	i	IPH
or	CC	i	IPH
an	DT	i	IPH
ETT	NNP	i	IPH
resulted	VBD	O	O
in	IN	O	O
a	DT	O	O
significantly	RB	O	O
lower	JJR	O	O
negative	JJ	o	OPH
intratracheal	JJ	o	OPH
pressure	NN	o	OPH
during	IN	O	O
the	DT	O	O
decompression	NN	O	O
phase	NN	O	O
of	IN	O	O
active	JJ	O	O
compression-decompression	NN	O	O
cardiopulmonary	JJ	O	O
resuscitation	NN	O	O
when	WRB	O	O
compared	VBN	O	O
with	IN	O	O
controls	NNS	O	O
.	.	O	O

Airway	NNP	O	O
pressures	VBZ	O	O
with	IN	O	O
an	DT	O	O
ITD	NNP	i	IPH
on	IN	O	O
either	CC	O	O
a	DT	i	O
facemask	NN	i	IPH
or	CC	O	O
ETT	NNP	i	IPH
were	VBD	O	O
similar	JJ	O	O
.	.	O	O

The	DT	O	O
ITD-facemask	JJ	i	IPH
combination	NN	i	IPH
was	VBD	O	O
practical	JJ	O	O
and	CC	O	O
enables	VBZ	O	O
rapid	JJ	O	O
deployment	NN	O	O
of	IN	O	O
this	DT	O	O
life-saving	JJ	O	O
technology	NN	O	O
.	.	O	O

Effect	NN	O	O
of	IN	O	O
m-chlorophenylpiperazine	NN	i	IPM
on	IN	O	O
plasma	NN	o	O
homovanillic	JJ	o	O
acid	NN	o	O
concentrations	NNS	o	O
in	IN	O	O
healthy	JJ	p	PC
subjects	NNS	p	PC
.	.	p	O

In	IN	O	O
view	NN	O	O
of	IN	O	O
the	DT	O	O
abundant	JJ	O	O
anatomical	JJ	O	O
and	CC	O	O
functional	JJ	O	O
interactions	NNS	O	O
between	IN	O	O
serotonin	NN	O	O
and	CC	O	O
dopamine	NN	O	O
systems	NNS	O	O
,	,	O	O
this	DT	O	O
study	NN	O	O
examined	VBD	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
the	DT	O	O
serotonin	JJ	O	O
agonist	NN	O	O
,	,	O	O
m-chlorophenylpiperazine	NN	i	IPM
(	(	i	IPM
mCPP	NN	i	IPM
)	)	i	IPM
on	IN	O	O
plasma	NN	o	O
concentrations	NNS	o	O
of	IN	o	O
the	DT	o	O
dopamine	NN	o	O
metabolite	NN	o	O
,	,	o	O
homovanillic	JJ	o	O
acid	NN	o	O
.	.	o	O

Plasma	NNP	O	O
prolactin	NN	O	O
levels	NNS	O	O
,	,	O	O
body	NN	O	O
temperature	NN	O	O
,	,	O	O
and	CC	O	O
mCPP	RB	o	OA
blood	NN	O	O
level	NN	O	O
were	VBD	O	O
also	RB	O	O
measured	VBN	O	O
.	.	O	O

mCPP	NN	i	IPM
(	(	O	O
0.35	CD	O	O
mg/kg	NN	O	O
)	)	O	O
and	CC	O	O
placebo	$	i	IC
were	VBD	O	O
administered	VBN	O	O
orally	RB	O	O
to	TO	O	O
10	CD	p	O
healthy	JJ	p	O
men	NNS	p	O
in	IN	O	O
a	DT	O	O
randomized	JJ	O	O
double-blind	NN	O	O
design	NN	O	O
.	.	O	O

Variables	NNS	O	O
were	VBD	O	O
measured	VBN	O	O
for	IN	O	O
210	CD	O	O
min	NNS	O	O
after	IN	O	O
administration	NN	O	O
of	IN	O	O
capsules	NNS	O	O
.	.	O	O

mCPP	NNS	o	OPH
raised	VBD	o	OPH
prolactin	NN	o	OPH
and	CC	o	OPH
temperature	NN	o	OPH
as	IN	o	OPH
compared	VBN	o	OPH
to	TO	o	OPH
placebo	VB	o	OPH
,	,	O	O
but	CC	O	O
did	VBD	O	O
not	RB	O	O
affect	VB	O	O
plasma	NN	o	OPH
homovanillic	JJ	o	OPH
acid	JJ	o	OPH
concentrations	NNS	o	OPH
.	.	o	OPH

Results	VB	O	O
suggest	JJS	O	O
that	IN	O	O
mCPP	NN	o	OPH
does	VBZ	o	OPH
not	RB	o	OPH
alter	VB	o	OPH
dopamine	NN	o	OPH
function	NN	o	OPH
.	.	o	OPH

A	DT	O	O
double-blind	JJ	O	O
placebo	NN	i	IC
controlled	VBD	O	O
trial	NN	O	O
of	IN	O	O
piracetam	NN	i	IPM
added	VBN	O	O
to	TO	O	O
risperidone	VB	i	IPM
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
autistic	JJ	p	PC
disorder	NN	p	PC
.	.	p	O

It	PRP	O	O
has	VBZ	O	O
been	VBN	O	O
reported	VBN	O	O
that	IN	O	O
autism	NN	O	O
is	VBZ	O	O
a	DT	O	O
hypoglutamatergic	JJ	O	O
disorder	NN	O	O
.	.	O	O

Therefore	RB	O	O
,	,	O	O
it	PRP	O	O
was	VBD	O	O
of	IN	O	O
interest	NN	O	O
to	TO	O	O
assess	VB	O	O
the	DT	O	O
efficacy	NN	o	OOt
of	IN	O	O
piracetam	NN	i	IPM
,	,	O	O
a	DT	O	O
positive	JJ	O	O
modulator	NN	O	O
of	IN	O	O
AMPA-sensitive	JJ	O	O
glutamate	NN	O	O
receptors	NNS	O	O
in	IN	O	O
autistic	JJ	O	O
disorder	NN	O	O
.	.	O	O

About	IN	p	O
40	CD	p	PSS
children	NNS	p	PA
between	IN	p	O
the	DT	p	O
ages	NNS	p	O
three	CD	p	PA
and	CC	p	PA
11	CD	p	PA
years	NNS	p	PA
(	(	p	O
inclusive	JJ	p	O
)	)	p	O
with	IN	p	O
a	DT	p	O
DSM	NNP	p	O
IV	NNP	p	O
clinical	JJ	p	O
diagnosis	NN	p	O
of	IN	p	O
autism	NN	p	PC
and	CC	p	O
who	WP	p	O
were	VBD	p	O
outpatients	NNS	p	O
from	IN	p	O
a	DT	p	O
specialty	NN	p	O
clinic	NN	p	O
for	IN	p	O
children	NNS	p	O
were	VBD	p	O
recruited	VBN	p	O
.	.	p	O

The	DT	O	O
children	NNS	p	PA
presented	VBN	p	O
with	IN	p	O
a	DT	p	O
chief	JJ	p	O
complaint	NN	p	O
of	IN	p	O
severely	RB	p	O
disruptive	JJ	p	O
symptoms	NNS	p	O
related	VBN	p	O
to	TO	p	O
autistic	JJ	p	PC
disorder	NN	p	PC
.	.	p	O

Patients	NNS	O	O
were	VBD	O	O
randomly	RB	O	O
allocated	VBN	O	O
to	TO	O	O
piracetam	VB	i	IPM
+	NNP	i	O
risperidone	NN	i	IPM
(	(	i	O
Group	NNP	i	O
A	NNP	i	O
)	)	i	O
or	CC	i	O
placebo	JJ	i	IC
+	NN	i	O
risperidone	NN	i	IPM
(	(	O	O
Group	NNP	O	O
B	NNP	O	O
)	)	O	O
for	IN	O	O
a	DT	O	O
10-week	JJ	O	O
,	,	O	O
double-blind	JJ	O	O
,	,	O	O
placebo-controlled	JJ	O	O
study	NN	O	O
.	.	O	O

The	DT	O	O
dose	NN	O	O
of	IN	O	O
risperidone	NN	i	IPM
was	VBD	O	O
titrated	VBN	O	O
up	RB	O	O
to	TO	O	O
2	CD	O	O
mg/day	NN	O	O
for	IN	O	O
children	NNS	O	O
between	IN	O	O
10	CD	O	O
and	CC	O	O
40	CD	O	O
kg	NN	O	O
and	CC	O	O
3	CD	O	O
mg/day	NN	O	O
for	IN	O	O
children	NNS	O	O
weighting	VBG	O	O
above	IN	O	O
40	CD	O	O
kg	NN	O	O
.	.	O	O

The	DT	O	O
dose	NN	O	O
of	IN	O	O
piracetam	NN	i	IPM
was	VBD	O	O
titrated	VBN	O	O
up	RB	O	O
to	TO	O	O
800	CD	O	O
mg/day	NN	O	O
.	.	O	O

Patients	NNS	O	O
were	VBD	O	O
assessed	VBN	O	O
at	IN	O	O
baseline	NN	O	O
and	CC	O	O
after	IN	O	O
2	CD	O	O
,	,	O	O
4	CD	O	O
,	,	O	O
6	CD	O	O
,	,	O	O
8	CD	O	O
and	CC	O	O
10	CD	O	O
weeks	NNS	O	O
of	IN	O	O
starting	VBG	O	O
medication	NN	O	O
.	.	O	O

The	DT	O	O
measure	NN	O	O
of	IN	O	O
the	DT	O	O
outcome	NN	O	O
was	VBD	O	O
the	DT	O	O
Aberrant	NNP	o	OOt
Behavior	NNP	o	OOt
Checklist-Community	NNP	o	OOt
(	(	o	OOt
ABC-C	NNP	o	OOt
)	)	o	OOt
Rating	VBG	o	OOt
Scale	NNP	o	OOt
(	(	o	OPH
total	JJ	o	OPH
score	NN	o	OPH
)	)	o	OPH
.	.	o	O

The	DT	O	O
ABC-C	JJ	o	OOt
Rating	NNP	o	OOt
Scale	NNP	o	OOt
scores	VBZ	o	OOt
improved	VBN	O	O
with	IN	O	O
piracetam	NN	O	O
.	.	O	O

The	DT	O	O
difference	NN	O	O
between	IN	O	O
the	DT	O	O
two	CD	O	O
protocols	NNS	O	O
was	VBD	O	O
significant	JJ	O	O
as	IN	O	O
indicated	VBN	O	O
by	IN	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
group	NN	O	O
,	,	O	O
the	DT	O	O
between	IN	O	O
subjects	NNS	O	O
factor	NN	O	O
(	(	O	O
F	NNP	O	O
=	NNP	O	O
5.85	CD	O	O
,	,	O	O
d.f	NN	O	O
.	.	O	O

=	CC	O	O
1	CD	O	O
,	,	O	O
P	NNP	O	O
=	NNP	O	O
0.02	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
changes	NNS	O	O
at	IN	O	O
the	DT	O	O
endpoint	NN	O	O
compared	VBN	O	O
with	IN	O	O
baseline	NN	O	O
were	VBD	O	O
:	:	O	O
-11.90	JJ	O	O
+/-	JJ	O	O
3.79	CD	O	O
(	(	O	O
mean	JJ	O	O
+/-	NNP	O	O
SD	NNP	O	O
)	)	O	O
and	CC	O	O
-5.15	JJ	O	O
+/-	JJ	O	O
3.04	CD	O	O
for	IN	O	O
group	NN	O	O
A	NNP	O	O
and	CC	O	O
B	NNP	O	O
respectively	RB	O	O
.	.	O	O

A	DT	O	O
significant	JJ	O	O
difference	NN	O	O
was	VBD	O	O
observed	VBN	O	O
on	IN	O	O
the	DT	O	O
change	NN	O	O
in	IN	O	O
scores	NNS	o	OOt
in	IN	o	OOt
the	DT	o	OOt
ABC-C	NNP	o	OOt
Rating	NNP	o	OOt
Scale	NNP	o	OOt
in	IN	O	O
week	NN	O	O
10	CD	O	O
compared	VBN	O	O
with	IN	O	O
baseline	NN	O	O
in	IN	O	O
the	DT	O	O
two	CD	O	O
groups	NNS	O	O
(	(	O	O
t	JJ	O	O
=	NN	O	O
6.017	CD	O	O
,	,	O	O
d.f	NN	O	O
.	.	O	O

=	CC	O	O
38	CD	O	O
,	,	O	O
P	NNP	O	O
<	NNP	O	O
0.0001	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
results	NNS	O	O
suggest	VBP	O	O
that	IN	O	O
a	DT	O	O
combination	NN	O	O
of	IN	O	O
atypical	JJ	O	O
antipsychotic	JJ	O	O
medications	NNS	O	O
and	CC	O	O
a	DT	O	O
glutamate	JJ	O	O
agent	NN	O	O
such	JJ	O	O
as	IN	O	O
piracetam	NNS	O	O
,	,	O	O
might	MD	O	O
have	VB	O	O
increase	VBN	O	O
synergistic	JJ	O	O
effects	NNS	O	O
in	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
autism	NN	O	O
.	.	O	O

Simulating	VBG	O	O
a	DT	O	O
memory	NN	O	O
impairment	NN	O	O
:	:	O	O
can	MD	O	O
amnesics	VB	p	PC
implicitly	RB	O	O
outperform	JJ	O	O
simulators	NNS	O	O
?	.	O	O
OBJECTIVES	IN	O	O
The	DT	O	O
purpose	NN	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
examine	VB	O	O
the	DT	O	O
effectiveness	NN	o	OOt
of	IN	O	O
a	DT	O	O
variety	NN	O	O
of	IN	O	O
tests	NNS	O	O
in	IN	O	O
differentiating	VBG	O	O
simulating	VBG	o	OME
test	NN	o	OME
performances	NNS	o	OME
from	IN	O	O
genuine	JJ	O	O
memory-impaired	JJ	o	OME
and	CC	O	O
normal	JJ	O	O
(	(	O	O
control	NN	O	O
)	)	O	O
test	NN	O	O
performances	NNS	O	O
.	.	O	O

DESIGN	VB	O	O
A	DT	i	O
simulation	NN	i	IE
design	NN	i	IE
was	VBD	O	O
implemented	VBN	O	O
,	,	O	O
based	VBN	O	O
on	IN	O	O
an	DT	O	O
analogue	NN	O	O
design	NN	O	O
in	IN	O	O
which	WDT	O	O
normal	JJ	O	O
participants	NNS	O	O
were	VBD	O	O
given	VBN	O	O
experimental	JJ	O	O
instructions	NNS	O	O
to	TO	O	O
feign	VB	O	O
a	DT	O	O
mental	JJ	O	O
impairment	NN	O	O
and	CC	O	O
are	VBP	O	O
compared	VBN	O	O
to	TO	O	O
(	(	O	O
a	DT	O	O
)	)	O	O
other	JJ	O	O
normal	JJ	O	O
participants	NNS	O	O
with	IN	O	O
instructions	NNS	O	O
to	TO	O	O
perform	VB	O	O
honestly	RB	O	O
,	,	O	O
and	CC	O	O
(	(	O	O
b	NN	O	O
)	)	O	O
a	DT	O	O
comparison	NN	O	O
group	NN	O	O
,	,	O	O
for	IN	O	O
example	NN	O	O
,	,	O	O
acquired	VBD	p	PC
brain-injured	JJ	p	PC
persons	NNS	p	O
,	,	O	O
with	IN	O	O
similar	JJ	O	O
instructions	NNS	O	O
.	.	O	O

METHOD	NNP	O	O
Forty	NNP	p	PSS
individuals	NNS	p	O
comprised	VBD	p	O
the	DT	p	O
simulating	NN	p	O
and	CC	p	O
control	NN	p	O
group	NN	p	O
and	CC	O	O
all	DT	O	O
participants	NNS	O	O
were	VBD	O	O
randomly	RB	i	O
assigned	VBN	i	IE
to	TO	i	IE
the	DT	i	IE
simulating	NN	i	IE
and	CC	i	O
control	NN	i	IC
groups	NNS	i	IC
.	.	i	O

Twenty	CD	p	PSS
memory-impaired	JJ	p	PC
patients	NNS	p	O
,	,	p	O
all	DT	p	O
of	IN	p	O
whom	WP	p	O
had	VBD	p	O
been	VBN	p	O
diagnosed	VBN	p	O
as	IN	p	O
suffering	VBG	p	O
from	IN	p	O
a	DT	p	O
memory	NN	p	PC
impairment	NN	p	PC
following	VBG	p	O
acquired	VBD	p	PC
brain	NN	p	PC
damage	NN	p	PC
,	,	p	PC
participated	VBD	p	O
as	IN	p	O
the	DT	p	O
memory-impaired	JJ	p	O
control	NN	p	O
group	NN	p	O
.	.	p	O

The	DT	i	O
simulation	NN	i	O
group	NN	i	O
was	VBD	i	O
directed	VBN	i	IE
to	TO	i	IE
imitate	VB	i	IE
a	DT	i	IE
person	NN	i	IE
with	IN	i	IE
a	DT	i	IE
memory	NN	i	IE
impairment	NN	i	IE
.	.	i	O

The	DT	O	O
primary	JJ	o	O
outcome	JJ	o	O
measure	NN	o	O
involved	VBN	O	O
identifying	VBG	o	OME
those	DT	o	OME
tests	NNS	o	OME
,	,	o	OME
if	IN	o	OME
any	DT	o	OME
,	,	o	OME
where	WRB	o	OME
simulators	NNS	o	OME
were	VBD	o	OME
significantly	RB	o	OME
different	JJ	o	OME
from	IN	o	OME
normal	JJ	o	OME
and	CC	o	OME
memory-impaired	JJ	o	OME
participants	NNS	o	OME
.	.	o	OME

RESULTS	VB	O	O
On	IN	O	O
5	CD	O	O
of	IN	O	O
the	DT	O	O
15	CD	O	O
tasks	NNS	O	O
administered	VBN	O	O
,	,	O	O
simulators	NNS	o	OME
performed	VBD	o	OME
significantly	RB	o	OME
differently	RB	o	OME
from	IN	o	OME
normal	JJ	o	OME
and	CC	o	OME
memory-impaired	JJ	o	OME
participants	NNS	o	OME
.	.	o	OME

Of	IN	O	O
these	DT	O	O
5	CD	O	O
tasks	NNS	O	O
,	,	O	O
the	DT	O	O
coin-in-the-hand	NN	O	O
,	,	O	O
when	WRB	O	O
administered	VBN	O	O
in	IN	O	O
conjunction	NN	O	O
with	IN	O	O
the	DT	O	O
autobiographical	JJ	O	O
interview	NN	O	O
,	,	O	O
identified	VBD	O	O
95	CD	O	O
per	IN	O	O
cent	NN	O	O
of	IN	O	O
the	DT	O	O
simulators	NNS	O	O
without	IN	O	O
misclassifying	VBG	O	O
any	DT	O	O
of	IN	O	O
the	DT	O	O
memory-impaired	JJ	O	O
or	CC	O	O
normal	JJ	O	O
participants	NNS	O	O
.	.	O	O

CONCLUSION	VB	O	O
It	PRP	O	O
is	VBZ	O	O
suggested	VBN	O	O
that	IN	O	O
these	DT	O	O
two	CD	O	O
tests	NNS	O	O
,	,	O	O
when	WRB	O	O
administered	VBN	O	O
jointly	RB	O	O
,	,	O	O
might	MD	O	O
be	VB	O	O
of	IN	O	O
use	NN	O	O
in	IN	O	O
clinical	JJ	O	O
settings	NNS	O	O
to	TO	O	O
assist	VB	O	O
in	IN	O	O
the	DT	O	O
detection	NN	O	O
of	IN	O	O
malingerers	NNS	O	O
.	.	O	O

Chemoradiation	NN	O	O
comparing	VBG	O	O
cisplatin	JJ	i	IPM
versus	NN	O	O
carboplatin	NN	i	IPM
in	IN	O	O
locally	RB	p	O
advanced	JJ	p	PC
nasopharyngeal	JJ	p	PC
cancer	NN	p	PC
:	:	p	O
randomised	VBN	O	O
,	,	O	O
non-inferiority	NN	O	O
,	,	O	O
open	JJ	O	O
trial	NN	O	O
.	.	O	O

PURPOSE	VB	O	O
This	DT	O	O
single	JJ	p	O
centre	NN	p	O
,	,	O	O
open	JJ	O	O
labelled	VBD	O	O
,	,	O	O
randomised	VBD	O	O
non-inferiority	JJ	O	O
trial	NN	O	O
compared	VBN	O	O
concurrent	JJ	O	O
chemoradiotherapy	NN	i	IPM
with	IN	i	IPM
carboplatin	JJ	i	IPM
versus	JJ	O	O
standard	NN	i	IPM
concurrent	NN	i	IPM
chemoradiotherapy	NN	i	IPM
with	IN	i	IPM
cisplatin	NN	i	IPM
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
locoregionally	RB	p	PC
advanced	JJ	p	PC
nasopharyngeal	JJ	p	PC
cancer	NN	p	PC
(	(	O	O
NPC	NNP	O	O
)	)	O	O
.	.	O	O

PATIENTS	NNP	O	O
AND	CC	O	O
METHODS	NNP	O	O
From	NNP	p	O
August	NNP	p	O
1999	CD	p	O
to	TO	p	O
December	NNP	p	O
2004	CD	p	O
,	,	p	O
206	CD	p	PSS
patients	NNS	p	O
with	IN	p	O
locally	RB	p	O
advanced	JJ	p	O
NPC	NNP	p	O
were	VBD	p	O
randomised	VBN	p	O
with	IN	p	O
101	CD	i	O
to	TO	i	O
cisplatin	VB	i	IPM
arm	NN	i	O
and	CC	i	O
105	CD	i	O
to	TO	i	O
carboplatin	VB	i	IPM
arm	NN	p	O
.	.	p	O

Planned	VBD	i	IPM
radiotherapy	NN	i	IPM
was	VBD	O	O
the	DT	O	O
same	JJ	O	O
in	IN	O	O
both	DT	O	O
groups	NNS	O	O
.	.	O	O

All	PDT	O	O
the	DT	O	O
patients	NNS	O	O
were	VBD	O	O
evaluated	VBN	O	O
for	IN	O	O
toxicity	NN	o	OPH
and	CC	o	O
survival	NN	o	OMO
according	VBG	O	O
to	TO	O	O
the	DT	O	O
as-treated	JJ	O	O
principle	NN	O	O
.	.	O	O

RESULTS	NNP	O	O
With	IN	O	O
a	DT	O	O
median	JJ	O	O
follow-up	NN	O	O
of	IN	O	O
26.3	CD	O	O
months	NNS	O	O
(	(	O	O
range	VB	O	O
3-74.6	JJ	O	O
months	NNS	O	O
)	)	O	O
,	,	O	O
59	CD	O	O
%	NN	O	O
of	IN	O	O
patients	NNS	O	O
in	IN	O	O
the	DT	O	O
cisplatin	NN	O	O
arm	NN	O	O
completed	VBD	O	O
the	DT	O	O
planned	VBN	O	O
concurrent	NN	O	O
chemoradiation	NN	O	O
treatment	NN	O	O
,	,	O	O
compared	VBN	O	O
to	TO	O	O
73	CD	O	O
%	NN	O	O
in	IN	O	O
the	DT	O	O
carboplatin	NN	O	O
arm	NN	O	O
.	.	O	O

Forty-two	JJ	O	O
percent	NN	O	O
of	IN	O	O
cisplatin	NN	O	O
patients	NNS	O	O
completed	VBD	O	O
the	DT	O	O
3	CD	o	OME
cycles	NNS	o	OME
of	IN	o	OME
adjuvant	JJ	o	OME
therapy	NN	o	OME
compared	VBN	O	O
to	TO	O	O
70	CD	O	O
%	NN	O	O
in	IN	O	O
the	DT	O	O
carboplatin	NN	O	O
group	NN	O	O
.	.	O	O

There	EX	O	O
were	VBD	O	O
more	JJR	O	O
renal	JJ	o	OPH
toxicity	NN	o	OPH
,	,	o	O
leucopenia	NN	o	OPH
,	,	o	O
and	CC	o	O
anaemia	NN	o	OPH
in	IN	O	O
the	DT	O	O
cisplatin	NN	O	O
group	NN	O	O
,	,	O	O
and	CC	O	O
more	JJR	O	O
thrombocytopenia	NN	o	OPH
in	IN	O	O
the	DT	O	O
carboplatin	NN	O	O
arm	NN	O	O
.	.	O	O

The	DT	O	O
3	CD	o	OMO
year	NN	o	OMO
disease	NN	o	OMO
free	JJ	o	OMO
survival	NN	o	OMO
rates	NNS	o	OMO
were	VBD	O	O
63.4	CD	O	O
%	NN	O	O
for	IN	O	O
the	DT	O	O
cisplatin	NN	O	O
group	NN	O	O
and	CC	O	O
60.9	CD	O	O
%	NN	O	O
for	IN	O	O
the	DT	O	O
carboplatin	NN	O	O
group	NN	O	O
(	(	O	O
p=0.9613	NN	O	O
)	)	O	O
(	(	O	O
HR	$	O	O
0.70	CD	O	O
,	,	O	O
95	CD	O	O
%	NN	O	O
confidence	NN	O	O
interval	NN	O	O
(	(	O	O
CI	NNP	O	O
)	)	O	O
:	:	O	O
0.50-0.98	JJ	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
3	CD	o	OMO
year	NN	o	OMO
overall	JJ	o	OMO
survival	NN	o	OMO
rates	NNS	o	OMO
were	VBD	O	O
77.7	CD	O	O
%	NN	O	O
and	CC	O	O
79.2	CD	O	O
%	NN	O	O
for	IN	O	O
cisplatin	NN	O	O
and	CC	O	O
carboplatin	NN	O	O
groups	NNS	O	O
,	,	O	O
respectively	RB	O	O
(	(	O	O
p=0.9884	NN	O	O
)	)	O	O
(	(	O	O
HR	$	O	O
0.83	CD	O	O
,	,	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
:	:	O	O
0.63-1.010	NN	O	O
)	)	O	O
.	.	O	O

CONCLUSION	NNP	O	O
We	PRP	O	O
concluded	VBD	O	O
that	IN	O	O
the	DT	O	O
tolerability	NN	o	OOt
of	IN	o	OOt
carboplatin	NN	o	OOt
based	VBN	o	OOt
regimen	NNS	o	OOt
is	VBZ	O	O
better	JJR	O	O
than	IN	O	O
that	DT	O	O
of	IN	O	O
the	DT	O	O
cisplatin	NN	i	IPM
regimen	NN	O	O
.	.	O	O

Moreover	RB	O	O
,	,	O	O
the	DT	O	O
treatment	NN	O	O
efficacy	NN	O	O
of	IN	O	O
carboplatin	NN	O	O
arm	NN	O	O
is	VBZ	O	O
not	RB	O	O
different	JJ	O	O
from	IN	O	O
the	DT	O	O
standard	JJ	O	O
regimen	NNS	O	O
in	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
locoregional	JJ	p	PC
advanced	JJ	p	PC
stage	NN	p	PC
NPC	NNP	p	PC
.	.	p	O

[	NNS	p	PC
Localised	VBN	p	PC
prostate	JJ	p	PC
cancer	NN	p	PC
:	:	p	PC
the	DT	O	O
PREFERE	NNP	O	O
trial	NN	O	O
]	NNP	O	O
.	.	O	O

Prostate	NNP	O	O
cancer	NN	O	O
is	VBZ	O	O
the	DT	O	O
most	RBS	O	O
common	JJ	O	O
carcinoma	NN	p	PC
of	IN	p	O
the	DT	p	O
elderly	JJ	p	O
man	NN	p	O
and	CC	O	O
holds	VBZ	O	O
the	DT	O	O
third	JJ	O	O
place	NN	O	O
in	IN	O	O
the	DT	O	O
ranking	NN	O	O
of	IN	O	O
cancer-specific	JJ	o	OMO
mortality	NN	o	OMO
.	.	o	O

However	RB	O	O
,	,	O	O
mortality	NN	o	OMO
rates	NNS	o	OMO
of	IN	O	O
3	CD	O	O
%	NN	O	O
are	VBP	O	O
low	JJ	O	O
,	,	O	O
and	CC	O	O
half	NN	O	O
of	IN	O	O
the	DT	O	O
patients	NNS	O	O
will	MD	O	O
die	VB	O	O
from	IN	O	O
intercurrent	JJ	O	O
disease	NN	O	O
.	.	O	O

Due	NNP	O	O
to	TO	O	O
the	DT	O	O
significantly	RB	O	O
improved	VBN	O	O
diagnostic	JJ	O	O
methods	NNS	O	O
and	CC	O	O
the	DT	O	O
increasing	VBG	O	O
use	NN	O	O
of	IN	O	O
PSA	NNP	O	O
screening	NN	O	O
,	,	O	O
there	EX	O	O
has	VBZ	O	O
been	VBN	O	O
a	DT	O	O
stage	NN	O	O
migration	NN	O	O
towards	NNS	O	O
early	RB	O	O
tumour	VBP	O	O
stages	NNS	O	O
that	WDT	O	O
are	VBP	O	O
prognostically	RB	O	O
heterogeneous	JJ	O	O
and	CC	O	O
require	NN	O	O
differentiated	VBN	O	O
treatment	NN	O	O
.	.	O	O

Based	VBN	O	O
on	IN	O	O
the	DT	O	O
discussions	NNS	O	O
of	IN	O	O
the	DT	O	O
Joint	NNP	O	O
Federal	NNP	O	O
Committee	NNP	O	O
(	(	O	O
G-BA	NNP	O	O
)	)	O	O
and	CC	O	O
the	DT	O	O
conceptual	JJ	O	O
work	NN	O	O
of	IN	O	O
the	DT	O	O
MDS	NNP	O	O
,	,	O	O
the	DT	O	O
Competence	NNP	O	O
Centre	NNP	O	O
Oncology	NNP	O	O
of	IN	O	O
the	DT	O	O
MDK	NNP	O	O
,	,	O	O
the	DT	O	O
IQWIG	NNP	O	O
and	CC	O	O
the	DT	O	O
National	NNP	O	O
Association	NNP	O	O
of	IN	O	O
Statutory	NNP	O	O
Health	NNP	O	O
Insurance	NNP	O	O
Funds	NNP	O	O
(	(	O	O
GKV-Spitzenverband	NNP	O	O
)	)	O	O
,	,	O	O
a	DT	O	O
prospective	JJ	O	O
randomised	VBN	O	O
multicentre	JJ	O	O
trial	NN	O	O
was	VBD	O	O
developed	VBN	O	O
comparing	VBG	O	O
the	DT	O	O
four	CD	O	O
treatments	NNS	O	O
actually	RB	O	O
recommended	VBN	O	O
by	IN	O	O
the	DT	O	O
German	JJ	O	O
and	CC	O	O
European	JJ	O	O
guidelines	NNS	O	O
for	IN	O	O
localised	JJ	O	O
prostate	NN	O	O
cancer	NN	O	O
(	(	o	O
radical	JJ	o	OOt
prostatectomy	NN	o	OOt
,	,	o	O
percutaneous	JJ	o	OOt
radiotherapy	NN	o	OOt
and	CC	o	O
permanent	JJ	o	OOt
seed	NN	o	OOt
implantation	NN	o	OOt
and	CC	o	O
active	JJ	o	OOt
surveillance	NN	o	OOt
)	)	o	O
allowing	VBG	O	O
a	DT	O	O
rejection	NN	O	O
of	IN	O	O
one	CD	O	O
or	CC	O	O
two	CD	O	O
treatment	NN	O	O
options	NNS	O	O
.	.	O	O

The	DT	O	O
trial	NN	O	O
is	VBZ	O	O
expected	VBN	O	O
to	TO	O	O
start	VB	O	O
at	IN	O	O
the	DT	O	O
beginning	NN	O	O
of	IN	O	O
next	JJ	O	O
year	NN	O	O
.	.	O	O

Randomized	VBN	O	O
trial	NN	O	O
of	IN	O	O
combination	NN	O	O
chemotherapy	NN	i	IPH
in	IN	O	O
hormone-resistant	JJ	p	O
metastatic	JJ	p	O
prostate	NN	p	O
carcinoma	NN	p	O
.	.	p	O

A	DT	O	O
prospective	JJ	O	O
randomized	NN	O	O
study	NN	O	O
was	VBD	O	O
conducted	VBN	O	O
in	IN	O	O
51	CD	p	O
patients	NNS	p	O
with	IN	p	O
stage	JJ	p	O
D	NNP	p	O
hormone-resistant	JJ	p	O
prostatic	JJ	p	O
carcinoma	NN	p	O
,	,	O	O
comparing	VBG	O	O
a	DT	O	O
combination	NN	O	O
of	IN	O	O
doxorubicin	NN	i	IPM
and	CC	i	O
lomustine	NN	i	IPM
(	(	O	O
DC	NNP	O	O
)	)	O	O
with	IN	O	O
cyclophosphamide	NN	i	IPM
and	CC	i	IPM
5-FU	JJ	i	IPM
(	(	i	IPM
CF	NNP	i	IPM
)	)	i	IPM
.	.	i	O

Patients	NNS	O	O
were	VBD	O	O
assessed	VBN	O	O
objectively	RB	O	O
(	(	O	O
employing	VBG	O	O
National	NNP	O	O
Prostate	NNP	O	O
Cancer	NNP	O	O
Project	NNP	O	O
criteria	NNS	O	O
)	)	O	O
and	CC	O	O
subjectively	RB	O	O
(	(	O	O
using	VBG	O	O
a	DT	O	O
numerical	JJ	O	O
scoring	NN	O	O
scheme	NN	O	O
)	)	O	O
.	.	O	O

Each	DT	O	O
regimen	NN	O	O
was	VBD	O	O
well	RB	O	O
tolerated	VBN	o	OOt
with	IN	O	O
acceptable	JJ	O	O
levels	NNS	o	OPH
of	IN	o	OPH
myelosuppression	NN	o	OPH
.	.	o	O

The	DT	O	O
objective	JJ	o	OOt
partial	JJ	o	OOt
response	NN	o	OOt
rate	NN	o	OOt
was	VBD	O	O
57	CD	O	O
%	NN	O	O
for	IN	O	O
DC	NNP	O	O
and	CC	O	O
8	CD	O	O
%	NN	O	O
for	IN	O	O
CF	NNP	O	O
.	.	O	O

Objective	NNP	o	OPH
stabilization	NN	o	OPH
occurred	VBD	O	O
,	,	O	O
respectively	RB	O	O
,	,	O	O
in	IN	O	O
14	CD	O	O
%	NN	O	O
and	CC	O	O
44	CD	O	O
%	NN	O	O
of	IN	O	O
the	DT	O	O
patients	NNS	O	O
.	.	O	O

Similarly	RB	O	O
,	,	O	O
DC	NNP	O	O
demonstrated	VBD	O	O
a	DT	O	O
significantly	RB	O	O
superior	JJ	O	O
subjective	JJ	o	OOt
response	NN	o	OOt
rate	NN	o	OOt
(	(	o	OOt
partial	JJ	o	OOt
plus	CC	o	OOt
complete	JJ	o	OOt
)	)	o	OOt
of	IN	O	O
82	CD	O	O
%	NN	O	O
,	,	O	O
compared	VBN	O	O
to	TO	O	O
48	CD	O	O
%	NN	O	O
for	IN	O	O
CF	NNP	i	IPM
.	.	i	O

Patients	NNS	O	O
with	IN	O	O
poor	JJ	p	O
initial	JJ	p	O
performance	NN	p	O
status	NN	p	O
or	CC	p	O
liver	VB	p	O
involvement	NN	p	O
had	VBD	O	O
significantly	RB	O	O
lower	JJR	O	O
response	NN	o	OOt
rates	NNS	o	OOt
and	CC	O	O
reduced	JJ	O	O
survival	NN	o	OMO
.	.	o	O

Overall	JJ	O	O
,	,	O	O
there	EX	o	O
was	VBD	o	O
no	DT	o	OOt
significant	JJ	o	OOt
difference	NN	o	OOt
in	IN	o	OOt
survival	NN	o	OMO
between	IN	o	OOt
the	DT	o	OOt
two	CD	o	OOt
arms	NNS	o	OOt
,	,	o	O
reflecting	VBG	o	O
the	DT	o	O
similarity	NN	o	OPH
between	IN	o	OPH
DC	NNP	o	OPH
and	CC	o	OPH
CF	NNP	o	OPH
in	IN	o	OPH
total	JJ	o	OPH
objective	JJ	o	OPH
response	NN	o	OPH
rate	NN	o	OPH
(	(	o	O
partial	JJ	o	O
response	NN	o	O
plus	CC	o	O
stable	JJ	o	O
disease	NN	o	O
)	)	o	O
.	.	o	O

DC	NNP	i	IPM
provided	VBD	O	O
superior	JJ	O	O
palliation	NN	o	OPH
and	CC	O	O
was	VBD	O	O
well	RB	O	O
tolerated	VBN	o	OOt
by	IN	O	O
an	DT	O	O
essentially	RB	p	O
geriatric	JJ	p	O
population	NN	p	O
.	.	p	O

Improved	VBN	O	O
frontoparietal	JJ	o	OPH
white	JJ	o	OPH
matter	NN	o	OPH
integrity	NN	o	OPH
in	IN	O	O
overweight	JJ	p	PC
children	NNS	p	O
is	VBZ	O	O
associated	VBN	O	O
with	IN	O	O
attendance	NN	O	O
at	IN	O	O
an	DT	O	O
after-school	JJ	i	IE
exercise	NN	i	IE
program	NN	i	IE
.	.	i	O

Aerobic	NNP	O	O
fitness	NN	O	O
is	VBZ	O	O
associated	VBN	O	O
with	IN	O	O
white	JJ	o	OPH
matter	NN	o	OPH
integrity	NN	o	OPH
(	(	o	OPH
WMI	NNP	o	OPH
)	)	o	OPH
in	IN	O	O
adults	NNS	O	O
as	IN	O	O
measured	VBN	O	O
by	IN	O	O
diffusion	NN	o	OPH
tensor	NN	o	OPH
imaging	NN	o	OPH
(	(	o	OPH
DTI	NNP	o	OPH
)	)	o	OPH
.	.	O	O

This	DT	O	O
study	NN	O	O
examined	VBD	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
an	DT	O	O
8-month	JJ	O	O
exercise	NN	i	IPH
intervention	NN	i	IPH
on	IN	O	O
WMI	NNP	o	OPH
in	IN	O	O
children	NNS	p	PA
.	.	p	O

Participants	NNS	O	O
were	VBD	O	O
18	CD	p	O
sedentary	JJ	p	O
,	,	p	O
overweight	JJ	p	O
(	(	p	O
BMI?85th	NNP	p	O
percentile	NN	p	O
)	)	p	O
8-	CD	p	O
to	TO	p	O
11-year-old	JJ	p	O
children	NNS	p	O
(	(	p	O
94	CD	p	O
%	NN	p	O
Black	NNP	p	O
)	)	p	O
,	,	p	O
randomly	RB	O	O
assigned	VBN	O	O
to	TO	O	O
either	DT	O	O
an	DT	O	O
aerobic	JJ	O	O
exercise	NN	O	O
(	(	O	O
n=10	JJ	O	O
)	)	O	O
or	CC	O	O
sedentary	JJ	O	O
attention	NN	O	O
control	NN	O	O
group	NN	O	O
(	(	O	O
n=8	RB	O	O
)	)	O	O
.	.	O	O

Each	DT	O	O
group	NN	O	O
was	VBD	O	O
offered	VBN	O	O
an	DT	O	O
instructor-led	JJ	i	O
after-school	JJ	i	O
program	NN	i	O
every	DT	i	O
school	NN	O	O
day	NN	O	O
for	IN	O	O
approximately	RB	O	O
8	CD	O	O
months	NNS	O	O
.	.	O	O

Before	IN	O	O
and	CC	O	O
after	IN	O	O
the	DT	O	O
program	NN	O	O
,	,	O	O
all	DT	O	O
subjects	NNS	O	O
participated	VBN	O	O
in	IN	O	O
DTI	NNP	o	O
scans	NNS	o	O
.	.	o	O

Tractography	NN	i	O
was	VBD	i	O
conducted	VBN	O	O
to	TO	O	O
isolate	VB	O	O
the	DT	O	O
superior	JJ	O	O
longitudinal	JJ	O	O
fasciculus	NN	O	O
and	CC	O	O
investigate	VB	O	O
whether	IN	O	O
the	DT	O	O
exercise	NN	O	O
intervention	NN	O	O
affected	VBD	o	O
WMI	NNP	o	O
in	IN	o	O
this	DT	O	O
region	NN	O	O
.	.	O	O

There	EX	O	O
was	VBD	O	O
no	DT	O	O
group	NN	O	O
by	IN	O	O
time	NN	o	O
interaction	NN	o	O
for	IN	o	O
WMI	NNP	o	O
in	IN	o	O
the	DT	O	O
superior	JJ	O	O
longitudinal	JJ	O	O
fasciculus	NN	O	O
.	.	O	O

There	EX	O	O
was	VBD	O	O
a	DT	O	O
group	NN	o	O
by	IN	o	O
time	NN	o	O
by	IN	o	O
attendance	NN	o	O
interaction	NN	o	O
,	,	o	O
however	RB	O	O
,	,	O	O
such	JJ	O	O
that	IN	O	O
higher	JJR	o	O
attendance	NN	o	O
at	IN	o	O
the	DT	i	O
exercise	NN	i	O
intervention	NN	i	O
,	,	i	O
but	CC	O	O
not	RB	O	O
the	DT	i	O
control	NN	i	O
intervention	NN	i	O
,	,	i	O
was	VBD	O	O
associated	VBN	O	O
with	IN	o	O
increased	JJ	o	O
WMI	NNP	o	O
.	.	o	O

Heart	NNP	o	O
rate	NN	o	O
and	CC	o	O
the	DT	o	O
total	JJ	o	O
dose	NN	o	O
of	IN	o	O
exercise	NN	o	O
correlated	VBN	o	O
with	IN	o	O
WMI	NNP	o	O
changes	NNS	o	O
in	IN	o	O
the	DT	O	O
exercise	NN	O	O
group	NN	O	O
.	.	O	O

In	IN	O	O
the	DT	O	O
overall	JJ	O	O
sample	NN	O	O
,	,	O	O
increased	VBD	o	O
WMI	NNP	o	O
was	VBD	o	O
associated	VBN	O	O
with	IN	o	O
improved	JJ	o	O
scores	NNS	o	O
on	IN	o	O
a	DT	o	O
measure	NN	o	O
of	IN	o	O
attention	NN	o	O
and	CC	o	O
improved	VBN	o	O
teacher	JJ	o	O
ratings	NNS	o	O
of	IN	o	O
executive	NN	o	O
function	NN	o	O
.	.	o	O

This	DT	O	O
study	NN	O	O
indicates	VBZ	O	O
that	IN	O	O
participating	VBG	O	O
in	IN	O	O
an	DT	O	O
exercise	NN	i	O
intervention	NN	o	O
improves	VBZ	o	O
WMI	NNP	o	O
in	IN	o	O
children	NNS	O	O
as	IN	O	O
compared	VBN	O	O
to	TO	O	O
a	DT	O	O
sedentary	JJ	O	O
after-school	JJ	O	O
program	NN	O	O
.	.	O	O

Caregiver-mediated	JJ	O	O
intervention	NN	i	IE
for	IN	O	O
low-resourced	JJ	p	O
preschoolers	NNS	p	PA
with	IN	p	O
autism	NN	p	PC
:	:	p	O
an	DT	O	O
RCT	NNP	O	O
.	.	O	O

OBJECTIVES	NNP	O	O
To	TO	O	O
compare	VB	O	O
2	CD	O	O
short-term	JJ	O	O
,	,	O	O
community	NN	i	IE
caregiver	RB	i	IE
training	NN	i	IE
interventions	NNS	i	IE
for	IN	O	O
preschool-aged	JJ	p	PA
children	NNS	p	PA
with	IN	p	O
Autism	NNP	p	PC
Spectrum	NNP	p	PC
Disorder	NNP	p	PC
who	WP	p	O
had	VBD	p	O
low	JJ	p	O
resources	NNS	p	O
.	.	p	O

Low	NNP	O	O
resource	NN	O	O
was	VBD	O	O
defined	VBN	O	O
by	IN	O	O
the	DT	O	O
US	NNP	O	O
Department	NNP	O	O
of	IN	O	O
Housing	NNP	O	O
and	CC	O	O
Urban	NNP	O	O
Development	NNP	O	O
low-income	JJ	O	O
index	NN	O	O
or	CC	O	O
1	CD	O	O
indicator	NN	o	O
,	,	O	O
(	(	O	O
e.g.	UH	O	O
,	,	O	O
Medicaid	NNP	O	O
eligibility	NN	O	O
)	)	O	O
.	.	O	O

Child	NNP	O	O
outcomes	NNS	O	O
focused	VBD	O	O
on	IN	O	O
joint	JJ	O	O
engagement	NN	o	OME
,	,	O	O
joint	JJ	O	O
attention	NN	O	O
,	,	O	O
and	CC	O	O
play	NN	O	O
.	.	O	O

METHODS	NNP	O	O
Participants	NNP	p	O
included	VBD	p	O
112	CD	p	PSS
families	NNS	p	O
of	IN	p	O
a	DT	p	O
child	NN	p	PA
who	WP	p	O
had	VBD	p	O
Autism	NNP	p	PC
Spectrum	NNP	p	PC
Disorder	NNP	p	PC
who	WP	p	O
met	VBD	p	O
criteria	NNS	p	O
for	IN	p	O
being	VBG	p	O
low-resourced	JJ	p	O
and	CC	p	O
who	WP	p	O
were	VBD	p	O
randomly	RB	p	O
assigned	VBN	p	O
to	TO	p	O
1	CD	p	O
of	IN	p	O
2	CD	i	IE
3-month	JJ	i	IE
interventions	NNS	i	IE
,	,	i	O
group	NN	i	IE
caregiver	NN	o	O
education	NN	i	IE
or	CC	i	IE
individualized	VBN	i	IE
caregiver-mediated	JJ	i	IE
intervention	NN	i	IE
(	(	i	IE
CMM	NNP	i	IE
)	)	i	IE
.	.	i	O

Children	NNP	O	O
were	VBD	O	O
assessed	VBN	O	O
for	IN	O	O
social	JJ	O	O
communication	NN	O	O
skills	NNS	O	O
pre-	JJ	o	OPH
and	CC	o	OPH
post-treatment	JJ	o	OPH
,	,	O	O
and	CC	O	O
followed	VBD	O	O
up	RB	O	O
at	IN	O	O
3	CD	O	O
months	NNS	O	O
.	.	O	O

RESULTS	NNP	O	O
All	NNP	O	O
children	NNS	O	O
improved	VBN	O	O
in	IN	O	O
joint	JJ	o	OME
engagement	NN	o	OME
and	CC	o	O
initiating	VBG	o	OME
joint	JJ	o	OME
attention	NN	o	OME
,	,	O	O
with	IN	O	O
significantly	RB	O	O
greater	JJR	O	O
improvement	NN	O	O
by	IN	O	O
the	DT	O	O
CMM	NNP	i	IE
group	NN	O	O
.	.	O	O

Outcomes	CC	O	O
on	IN	O	O
play	NN	o	OME
skills	NNS	o	OME
were	VBD	O	O
mixed	JJ	O	O
,	,	O	O
with	IN	O	O
improvement	NN	O	O
of	IN	O	O
symbolic	JJ	o	OME
play	NN	o	OME
for	IN	O	O
the	DT	O	O
CMM	NNP	O	O
group	NN	O	O
and	CC	O	O
no	DT	O	O
change	NN	O	O
in	IN	O	O
functional	JJ	o	OME
play	NN	o	OME
skills	NNS	o	OME
.	.	o	O

Joint	JJ	O	O
engagement	NN	O	O
maintained	VBD	O	O
over	IN	O	O
time	NN	O	O
for	IN	O	O
the	DT	O	O
CMM	NNP	i	IE
group	NN	O	O
,	,	O	O
and	CC	O	O
initiating	VBG	O	O
joint	JJ	O	O
attention	NN	O	O
maintained	VBD	O	O
for	IN	O	O
both	DT	O	O
groups	NNS	O	O
over	IN	O	O
time	NN	O	O
.	.	O	O

CONCLUSIONS	VB	O	O
This	DT	O	O
study	NN	O	O
is	VBZ	O	O
among	IN	O	O
the	DT	O	O
first	JJ	O	O
randomized	JJ	O	O
trials	NNS	O	O
comparing	VBG	O	O
2	CD	O	O
active	JJ	O	O
interventions	NNS	O	O
with	IN	O	O
a	DT	O	O
large	JJ	O	O
sample	NN	O	O
of	IN	O	O
low-resourced	JJ	p	O
families	NNS	p	O
.	.	p	O

Results	NNP	O	O
suggest	JJ	O	O
improvements	NNS	O	O
in	IN	O	O
core	NN	O	O
autism	NN	O	O
deficits	NNS	O	O
of	IN	O	O
joint	JJ	O	O
engagement	NN	O	O
,	,	O	O
joint	JJ	o	OME
attention	NN	o	OME
,	,	O	O
and	CC	O	O
symbolic	JJ	O	O
play	NN	O	O
with	IN	O	O
relatively	RB	O	O
brief	JJ	O	O
,	,	O	O
caregiver-mediated	JJ	o	O
interventions	NNS	O	O
,	,	O	O
but	CC	O	O
additional	JJ	O	O
support	NN	O	O
is	VBZ	O	O
necessary	JJ	O	O
to	TO	O	O
maintain	VB	O	O
and	CC	O	O
generalize	VB	O	O
these	DT	O	O
gains	NNS	O	O
over	IN	O	O
time	NN	O	O
.	.	O	O

Assessment	NN	O	O
of	IN	O	O
therapeutic	JJ	o	OOt
response	NN	O	O
of	IN	O	O
Plasmodium	NNP	O	O
falciparum	NN	O	O
to	TO	O	O
chloroquine	VB	i	IPM
and	CC	O	O
sulfadoxine-pyrimethamine	VB	i	IPM
in	IN	O	O
an	DT	O	O
area	NN	p	O
of	IN	p	O
low	JJ	p	PC
malaria	NNS	p	PC
transmission	NN	p	O
in	IN	p	O
Colombia	NNP	p	O
.	.	p	O

Although	IN	O	O
chloroquine	NN	i	IPM
(	(	O	O
CQ	NNP	O	O
)	)	O	O
resistance	NN	O	O
was	VBD	O	O
first	RB	O	O
reported	VBN	O	O
in	IN	O	O
Colombia	NNP	O	O
in	IN	O	O
1961	CD	O	O
and	CC	O	O
sulfadoxine-pyrimethamine	JJ	i	IPM
(	(	O	O
SP	NNP	O	O
)	)	O	O
resistance	NN	O	O
in	IN	O	O
1981	CD	O	O
,	,	O	O
the	DT	O	O
frequency	NN	O	O
of	IN	O	O
treatment	NN	O	O
failures	NNS	O	O
to	TO	O	O
these	DT	O	O
drugs	NNS	O	O
in	IN	O	O
Colombia	NNP	O	O
is	VBZ	O	O
unclear	JJ	O	O
.	.	O	O

A	DT	O	O
modified	JJ	O	O
World	NNP	O	O
Health	NNP	O	O
Organization	NNP	O	O
14-day	JJ	O	O
in	IN	O	O
vivo	JJ	O	O
drug	NN	O	O
efficacy	NN	O	O
test	NN	O	O
for	IN	O	O
uncomplicated	JJ	O	O
Plasmodium	NNP	O	O
falciparum	NN	O	O
malaria	NN	O	O
in	IN	O	O
areas	NNS	O	O
with	IN	O	O
intense	JJ	O	O
malaria	NNS	O	O
transmission	NN	O	O
was	VBD	O	O
adapted	VBN	O	O
to	TO	O	O
reflect	VB	O	O
the	DT	O	O
clinical	JJ	O	O
and	CC	O	O
epidemiologic	JJ	O	O
features	NNS	O	O
of	IN	O	O
a	DT	O	O
low-intensity	JJ	O	O
malaria	NN	O	O
transmission	NN	O	O
area	NN	O	O
in	IN	O	O
the	DT	O	O
Pacific	NNP	O	O
Coast	NNP	O	O
Region	NNP	O	O
of	IN	O	O
Colombia	NNP	O	O
.	.	O	O

Patients	NNPS	p	O
>	JJ	p	PA
or	CC	p	PA
=1	JJ	p	PA
year	NN	p	PA
of	IN	p	PA
age	NN	p	PA
with	IN	p	O
a	DT	p	O
parasite	JJ	p	O
density	NN	p	O
>	NN	p	O
or	CC	p	O
=1,000	CD	p	O
asexual	JJ	p	O
parasites	NNS	p	O
per	IN	p	O
microliter	NN	p	O
were	VBD	p	O
enrolled	VBN	p	O
in	IN	p	O
this	DT	p	O
study	NN	p	O
.	.	p	O

Forty-four	CD	p	PSS
percent	NN	p	O
(	(	p	O
24	CD	p	O
of	IN	p	O
54	CD	p	O
)	)	p	O
of	IN	p	O
the	DT	p	O
CQ-treated	JJ	i	IPM
patients	NNS	p	O
were	VBD	p	O
therapeutic	JJ	o	OOt
failures	NNS	o	OOt
,	,	p	O
including	VBG	p	O
7	CD	p	O
early	JJ	o	OOt
treatment	NN	o	OOt
failures	NNS	o	OOt
(	(	o	OOt
ETFs	NNP	o	OOt
)	)	o	OPH
and	CC	p	O
17	CD	p	O
late	JJ	o	OOt
treatment	NN	o	OOt
failures	NNS	o	OOt
(	(	o	OPH
LTFs	NNP	o	OPH
)	)	o	OPH
.	.	o	OPH

Four	CD	p	O
(	(	p	O
6	CD	p	O
%	NN	p	O
)	)	p	O
of	IN	p	O
67	CD	p	O
SP-treated	JJ	O	O
patients	NNS	O	O
were	VBD	O	O
therapeutic	JJ	o	OOt
failures	NNS	o	OOt
(	(	O	O
2	CD	O	O
ETFs	NNP	O	O
and	CC	O	O
2	CD	O	O
LTFs	NNP	O	O
)	)	O	O
.	.	O	O

Therapeutic	JJ	o	OOt
failure	NN	o	OOt
in	IN	O	O
the	DT	O	O
CQ-treated	JJ	i	IPM
group	NN	O	O
was	VBD	O	O
associated	VBN	O	O
with	IN	O	O
an	DT	O	O
age	NN	O	O
<	VBD	O	O
15	CD	O	O
years	NNS	O	O
old	JJ	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.01	CD	O	O
)	)	O	O
,	,	O	O
but	CC	O	O
was	VBD	O	O
not	RB	O	O
associated	VBN	O	O
with	IN	O	O
initial	JJ	O	O
parasite	JJ	O	O
density	NN	O	O
,	,	O	O
the	DT	O	O
presence	NN	O	O
of	IN	O	O
CQ	NNP	i	IPM
or	CC	O	O
sulfa-containing	JJ	O	O
drugs	NNS	O	O
in	IN	O	O
urine	NN	O	O
,	,	O	O
or	CC	O	O
a	DT	O	O
history	NN	O	O
of	IN	O	O
malaria	NN	O	O
.	.	O	O

The	DT	O	O
high	JJ	O	O
level	NN	O	O
of	IN	O	O
therapeutic	JJ	o	OOt
failures	NNS	o	OOt
to	TO	O	O
CQ	NNP	i	IPM
detected	VBN	O	O
in	IN	O	O
this	DT	O	O
study	NN	O	O
underscores	VBZ	O	O
the	DT	O	O
need	NN	O	O
and	CC	O	O
importance	NN	O	O
of	IN	O	O
drug	NN	O	O
efficacy	NN	o	OOt
evaluation	NN	O	O
in	IN	O	O
the	DT	O	O
development	NN	O	O
of	IN	O	O
a	DT	O	O
rational	JJ	O	O
national	JJ	O	O
antimalarial	JJ	O	O
drug	NN	O	O
policy	NN	O	O
.	.	O	O

The	DT	O	O
relatively	RB	O	O
low	JJ	O	O
level	NN	O	O
of	IN	O	O
therapeutic	JJ	o	OOt
failures	NNS	o	OOt
to	TO	O	O
SP	NNP	O	O
compared	VBN	O	O
with	IN	O	O
other	JJ	O	O
South	JJ	O	O
American	JJ	O	O
countries	NNS	O	O
raises	VBZ	O	O
further	JJ	O	O
questions	NNS	O	O
regarding	VBG	O	O
factors	NNS	O	O
that	WDT	O	O
might	MD	O	O
have	VB	O	O
prevented	VBN	O	O
the	DT	O	O
rapid	JJ	O	O
development	NN	O	O
of	IN	O	O
in	IN	O	O
vivo	NN	O	O
resistance	NN	O	O
to	TO	O	O
this	DT	O	O
drug	NN	O	O
combination	NN	O	O
.	.	O	O

Effects	NNS	O	O
of	IN	O	O
extended	JJ	O	O
release	NN	O	O
methylphenidate	NN	i	IPM
treatment	NN	i	IPM
on	IN	O	O
ratings	NNS	o	OME
of	IN	o	OME
attention-deficit/hyperactivity	NN	o	OME
disorder	NN	o	OME
(	(	o	OME
ADHD	NNP	o	OME
)	)	o	OME
and	CC	o	O
associated	VBN	o	OME
behavior	NN	o	OME
in	IN	O	O
children	NNS	p	PA
with	IN	p	O
autism	NN	p	PC
spectrum	NN	p	PC
disorders	NNS	p	PC
and	CC	p	PC
ADHD	NNP	p	PC
symptoms	NNS	p	PC
.	.	p	O

OBJECTIVE	IN	O	O
The	DT	O	O
purpose	NN	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
examine	VB	O	O
the	DT	O	O
behavioral	JJ	o	OME
effects	NNS	o	OME
of	IN	O	O
four	CD	O	O
doses	NNS	O	O
of	IN	O	O
psychostimulant	JJ	i	O
medication	NN	i	O
,	,	i	O
combining	VBG	i	O
extended-release	JJ	i	IPM
methylphenidate	NN	i	IPM
(	(	i	IPM
MPH	NNP	i	IPM
)	)	i	IPM
in	IN	i	IPM
the	DT	i	IPM
morning	NN	i	IPM
with	IN	i	O
immediate-release	JJ	i	IPM
MPH	NNP	i	IPM
in	IN	i	IPM
the	DT	i	IPM
afternoon	NN	i	IPM
.	.	i	O

METHOD	NNP	O	O
The	DT	O	O
sample	NN	O	O
comprised	VBD	O	O
24	CD	p	PSS
children	NNS	p	PA
(	(	p	O
19	CD	p	PSS
boys	NNS	p	PSE
;	:	p	O
5	CD	p	PSS
girls	NNS	p	PSE
)	)	p	O
who	WP	p	O
met	VBD	p	O
American	NNP	p	O
Psychiatric	NNP	p	O
Association	NNP	p	O
,	,	p	O
Diagnostic	NNP	p	O
and	CC	p	O
Statistical	NNP	p	O
Manual	NNP	p	O
of	IN	p	O
Mental	NNP	p	O
Disorders	NNP	p	O
,	,	p	O
4th	CD	p	O
ed	NN	p	O
.	.	p	O

(	(	O	O
DSM-IV-TR	NNP	O	O
)	)	O	O
criteria	NN	O	O
for	IN	O	O
an	DT	O	O
autism	NN	O	O
spectrum	NN	O	O
disorder	NN	O	O
(	(	O	O
ASD	NNP	O	O
)	)	O	O
on	IN	O	O
the	DT	O	O
Autism	NNP	O	O
Diagnostic	NNP	O	O
Interview-Revised	JJ	O	O
(	(	O	O
ADI-R	NNP	O	O
)	)	O	O
and	CC	O	O
the	DT	O	O
Autism	NNP	O	O
Diagnostic	NNP	O	O
Observation	NNP	O	O
Schedule	NNP	O	O
(	(	O	O
ADOS	NNP	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
had	VBD	O	O
significant	JJ	O	O
symptoms	NNS	O	O
of	IN	O	O
attention-deficit/hyperactivity	NN	O	O
disorder	NN	O	O
(	(	O	O
ADHD	NNP	O	O
)	)	O	O
.	.	O	O

This	DT	O	O
sample	NN	O	O
consisted	VBD	O	O
of	IN	O	O
elementary	JJ	p	PA
school-age	NN	p	PA
,	,	p	PA
community-based	JJ	p	PA
children	NNS	p	PA
(	(	p	O
mean	JJ	p	O
chronological	JJ	p	O
age=8.8	NN	p	PA
years	NNS	p	PA
,	,	p	O
SD=1.7	NNP	p	O
;	:	p	O
mean	JJ	p	O
intelligence	NN	p	O
quotient	NN	p	O
[	NNP	p	O
IQ	NNP	p	O
]	NNP	p	O
=85	NNP	p	O
;	:	p	O
SD=16.8	NNP	p	O
)	)	p	O
.	.	p	O

Effects	NNS	O	O
of	IN	O	O
four	CD	O	O
dose	NN	O	O
levels	NNS	O	O
of	IN	O	O
MPH	NNP	i	IPM
on	IN	O	O
parent	NN	o	OOt
and	CC	o	OOt
teacher	RB	o	OOt
behavioral	JJ	o	OOt
ratings	NNS	o	OOt
were	VBD	O	O
investigated	VBN	O	O
using	VBG	O	O
a	DT	O	O
within-subject	JJ	O	O
,	,	O	O
crossover	NN	O	O
,	,	O	O
placebo-controlled	JJ	O	O
design	NN	O	O
.	.	O	O

RESULTS	NNP	O	O
MPH	NNP	i	IPM
treatment	NN	O	O
was	VBD	O	O
associated	VBN	O	O
with	IN	O	O
significant	JJ	O	O
declines	NNS	O	O
in	IN	O	O
hyperactive	JJ	o	OME
and	CC	o	OME
impulsive	JJ	o	OME
behavior	NN	o	OME
at	IN	o	OME
both	DT	o	OME
home	NN	o	OME
and	CC	o	OME
school	NN	o	OME
.	.	o	O

Parents	NNS	O	O
noted	VBD	O	O
significant	JJ	O	O
declines	NNS	O	O
in	IN	O	O
inattentive	JJ	o	OME
and	CC	o	OME
oppositional	JJ	o	OME
behavior	NN	o	OME
,	,	O	O
and	CC	O	O
improvements	NNS	O	O
in	IN	O	O
social	JJ	o	OME
skills	NNS	o	OME
.	.	o	O

No	DT	O	O
exacerbation	NN	o	OME
of	IN	o	OME
stereotypies	NNS	o	OME
was	VBD	O	O
noted	VBN	O	O
,	,	O	O
and	CC	O	O
side	JJ	o	OA
effects	NNS	o	OA
were	VBD	O	O
similar	JJ	O	O
to	TO	O	O
those	DT	O	O
seen	VBN	O	O
in	IN	O	O
typically	RB	O	O
developing	VBG	O	O
children	NNS	O	O
with	IN	O	O
ADHD	NNP	O	O
.	.	O	O

Dose	NNP	O	O
response	NN	O	O
was	VBD	O	O
primarily	RB	O	O
linear	JJ	O	O
in	IN	O	O
the	DT	O	O
dose	JJ	O	O
range	NN	O	O
studied	VBN	O	O
.	.	O	O

CONCLUSIONS	VB	O	O
The	DT	O	O
results	NNS	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
suggest	VBP	O	O
that	IN	O	O
MPH	NNP	O	O
formulations	NNS	O	O
are	VBP	O	O
efficacious	JJ	o	OOt
and	CC	o	OOt
well-tolerated	JJ	o	OOt
for	IN	O	O
children	NNS	p	PA
with	IN	p	O
ASD	NNP	p	PC
and	CC	p	O
significant	JJ	p	PC
ADHD	NNP	p	PC
symptoms	NNS	p	PC
.	.	p	O

Effect	NN	O	O
of	IN	O	O
total	JJ	i	IPM
androgen	NN	i	IPM
ablation	NN	i	IPM
on	IN	O	O
pathologic	JJ	o	OPH
stage	NN	o	OPH
and	CC	o	OPH
resection	NN	o	OPH
limit	NN	o	OPH
status	NN	o	OPH
of	IN	o	OPH
prostate	NN	o	OPH
cancer	NN	o	OPH
.	.	o	O

Initial	JJ	O	O
results	NNS	O	O
of	IN	O	O
the	DT	O	O
Italian	JJ	p	O
PROSIT	NNP	p	O
study	NN	p	O
.	.	p	O

The	DT	O	O
likelihood	NN	O	O
of	IN	O	O
finding	VBG	O	O
organ-confined	JJ	O	O
untreated	JJ	O	O
prostate	NN	O	O
cancer	NN	O	O
(	(	O	O
PCa	NNP	O	O
)	)	O	O
by	IN	O	O
pathological	JJ	O	O
examination	NN	O	O
at	IN	O	O
the	DT	O	O
time	NN	O	O
of	IN	O	O
radical	JJ	i	IS
prostatectomy	NN	i	IS
(	(	i	IS
RP	NNP	i	IS
)	)	i	IS
is	VBZ	O	O
only	RB	O	O
50	CD	O	O
%	NN	O	O
in	IN	O	O
patients	NNS	O	O
with	IN	O	O
clinically	RB	O	O
organ-confined	JJ	O	O
disease	NN	O	O
.	.	O	O

In	IN	O	O
addition	NN	O	O
,	,	O	O
tumour	NN	O	O
is	VBZ	O	O
present	JJ	O	O
at	IN	O	O
the	DT	O	O
resection	NN	O	O
margin	NN	O	O
in	IN	O	O
approximately	RB	O	O
30	CD	O	O
%	NN	O	O
of	IN	O	O
clinical	JJ	O	O
T2	NNP	O	O
(	(	O	O
clinical	JJ	O	O
stage	NN	O	O
B	NNP	O	O
)	)	O	O
cases	NNS	O	O
.	.	O	O

The	DT	O	O
issue	NN	O	O
of	IN	O	O
clinical	JJ	O	O
understaging	NN	O	O
and	CC	O	O
of	IN	O	O
resection	NN	O	O
limit	NN	O	O
positivity	NN	O	O
have	VBP	O	O
led	VBN	O	O
to	TO	O	O
the	DT	O	O
development	NN	O	O
of	IN	O	O
novel	JJ	O	O
management	NN	O	O
practices	NNS	O	O
,	,	O	O
including	VBG	O	O
neoadjuvant	JJ	i	IPM
hormonal	JJ	i	IPM
therapy	NN	i	IPM
(	(	i	IPM
NHT	NNP	i	IPM
)	)	i	IPM
.	.	i	O

The	DT	O	O
optimal	JJ	O	O
duration	NN	O	O
of	IN	O	O
NHT	NNP	O	O
is	VBZ	O	O
unknown	JJ	O	O
.	.	O	O

We	PRP	O	O
undertook	VBD	O	O
the	DT	O	O
present	JJ	O	O
analysis	NN	O	O
to	TO	O	O
evaluate	VB	O	O
the	DT	O	O
effect	NN	o	OPH
of	IN	o	OPH
NHT	NNP	o	OPH
on	IN	o	OPH
pathologic	JJ	o	OPH
stage	NN	o	OPH
of	IN	o	OPH
PCa	NNP	o	OPH
and	CC	o	OPH
resection	NN	o	OPH
limit	NN	o	OPH
status	NN	o	OPH
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
prostate	JJ	p	O
cancer	NN	p	O
and	CC	p	O
treated	VBN	p	O
with	IN	p	O
total	JJ	i	IPM
androgen	NN	i	IPM
ablation	NN	i	IPM
either	DT	p	O
for	IN	p	O
three	CD	p	O
or	CC	p	O
six	CD	p	O
months	NNS	p	O
before	IN	p	O
RP	NNP	p	O
.	.	p	O

Between	NNP	p	O
January	NNP	p	O
1996	CD	p	O
and	CC	p	O
February	NNP	p	O
1998	CD	p	O
,	,	p	O
259	CD	p	O
men	NNS	p	PSE
with	IN	p	O
prostate	NN	p	PC
cancer	NN	p	PC
underwent	JJ	p	O
radical	JJ	i	IS
retropubic	NN	i	IS
prostatectomy	NN	i	IS
and	CC	i	IS
bilateral	JJ	i	IS
pelvic	JJ	i	IS
node	NN	i	IS
dissection	NN	i	IS
in	IN	p	O
the	DT	p	O
26	CD	p	O
centres	NNS	p	O
participating	VBG	p	O
in	IN	p	O
the	DT	p	O
Italian	JJ	p	O
randomised	VBD	p	O
prospective	JJ	p	O
PROSIT	NNP	p	O
study	NN	p	O
.	.	p	O

Whole	NNP	O	O
mount	NN	O	O
sectioning	NN	O	O
of	IN	O	O
the	DT	O	O
complete	JJ	O	O
RP	NNP	O	O
specimens	NNS	O	O
was	VBD	O	O
adopted	VBN	O	O
in	IN	O	O
each	DT	O	O
centre	NN	O	O
for	IN	O	O
accurately	RB	O	O
evaluating	VBG	O	O
the	DT	O	O
pathologic	JJ	o	OPH
stage	NN	o	OPH
and	CC	o	OPH
resection	NN	o	OPH
limit	NN	o	OPH
status	NN	o	OPH
.	.	o	O

By	IN	O	O
February	NNP	O	O
1998	CD	O	O
,	,	O	O
haematoxylin	NN	O	O
and	CC	O	O
eosin	NN	O	O
stained	VBD	O	O
sections	NNS	O	O
from	IN	O	O
155	CD	O	O
RP	NNP	O	O
specimens	NNS	O	O
had	VBD	O	O
been	VBN	O	O
received	VBN	O	O
and	CC	O	O
evaluated	VBN	O	O
by	IN	O	O
the	DT	O	O
reviewing	VBG	O	O
pathologist	NN	O	O
(	(	O	O
RM	NNP	O	O
)	)	O	O
.	.	O	O

64	CD	O	O
cases	NNS	O	O
had	VBD	O	O
not	RB	O	O
been	VBN	O	O
treated	VBN	O	O
with	IN	O	O
total	JJ	i	IPM
androgen	NN	i	IPM
ablation	NN	i	IPM
(	(	O	O
e.g	JJ	O	O
.	.	O	O

NHT	NNP	i	IPM
)	)	i	O
before	IN	O	O
RP	NNP	O	O
was	VBD	O	O
performed	VBN	O	O
,	,	O	O
whereas	JJ	O	O
58	CD	O	O
and	CC	O	O
33	CD	O	O
had	VBD	O	O
been	VBN	O	O
treated	VBN	O	O
for	IN	O	O
three	CD	O	O
and	CC	O	O
six	CD	O	O
months	NNS	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

114	CD	p	O
patients	NNS	p	O
were	VBD	O	O
clinical	JJ	O	O
stage	NN	O	O
B	NNP	O	O
whereas	IN	O	O
41	CD	O	O
were	VBD	O	O
clinical	JJ	O	O
stage	NN	O	O
C.	NNP	O	O
After	IN	O	O
three	CD	O	O
months	NNS	O	O
of	IN	O	O
total	JJ	i	IPM
androgen	NN	i	IPM
ablation	NN	i	IPM
,	,	O	O
pathological	JJ	o	OPH
stage	NN	o	OPH
B	NNP	o	OPH
was	VBD	O	O
more	RBR	O	O
prevalent	JJ	O	O
among	IN	O	O
patients	NNS	O	O
with	IN	O	O
clinical	JJ	O	O
B	NNP	O	O
tumours	NN	O	O
,	,	O	O
compared	VBN	O	O
with	IN	O	O
untreated	JJ	O	O
patients	NNS	O	O
(	(	O	O
57	CD	O	O
%	NN	O	O
in	IN	O	O
treated	JJ	O	O
patients	NNS	O	O
vs.	FW	O	O
36	CD	O	O
%	NN	O	O
in	IN	O	O
untreated	JJ	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
percentage	NN	o	OPH
of	IN	o	OPH
cancers	NNS	o	OPH
with	IN	o	OPH
negative	JJ	o	OPH
margins	NNS	o	OPH
was	VBD	O	O
statistically	RB	O	O
significantly	RB	O	O
greater	JJR	O	O
in	IN	O	O
patients	NNS	O	O
treated	VBN	O	O
with	IN	O	O
neoadjuvant	JJ	i	IPM
therapy	NN	i	IPM
than	IN	O	O
those	DT	O	O
treated	VBN	O	O
with	IN	O	O
immediate	JJ	i	IPM
surgery	NN	i	IPM
alone	RB	i	IPM
(	(	O	O
69	CD	O	O
%	NN	O	O
vs.	FW	O	O
42	CD	O	O
%	NN	O	O
,	,	O	O
respectively	RB	O	O
)	)	O	O
.	.	O	O

After	IN	O	O
six	CD	O	O
months	NNS	O	O
of	IN	O	O
NHT	NNP	O	O
therapy	VBP	O	O
the	DT	O	O
proportion	NN	o	OPH
of	IN	o	OPH
patients	NNS	o	OPH
with	IN	o	OPH
pathological	JJ	o	OPH
stage	NN	o	OPH
B	NNP	o	OPH
(	(	O	O
67	CD	O	O
%	NN	O	O
vs.	FW	O	O
36	CD	O	O
%	NN	O	O
,	,	O	O
respectively	RB	O	O
)	)	O	O
and	CC	O	O
negative	JJ	o	OPH
margins	NNS	o	OPH
was	VBD	O	O
greater	JJR	O	O
than	IN	O	O
after	IN	O	O
3	CD	O	O
months	NNS	O	O
(	(	O	O
92	CD	O	O
%	NN	O	O
vs.	FW	O	O
42	CD	O	O
%	NN	O	O
,	,	O	O
respectively	RB	O	O
)	)	O	O
.	.	O	O

For	IN	O	O
clinical	JJ	O	O
C	NNP	O	O
tumours	NN	O	O
,	,	O	O
the	DT	O	O
prevalence	NN	O	O
of	IN	O	O
pathological	JJ	o	OPH
stage	NN	o	OPH
B	NNP	o	OPH
and	CC	o	OPH
negative	JJ	o	OPH
margins	NNS	o	OPH
in	IN	O	O
the	DT	O	O
patients	NNS	O	O
treated	VBD	O	O
for	IN	O	O
either	DT	O	O
3	CD	O	O
or	CC	O	O
6	CD	O	O
months	NNS	O	O
was	VBD	O	O
not	RB	O	O
as	RB	O	O
high	JJ	O	O
as	IN	O	O
in	IN	O	O
the	DT	O	O
clinical	JJ	O	O
B	NNP	O	O
tumours	NN	O	O
,	,	O	O
when	WRB	O	O
compared	VBN	O	O
with	IN	O	O
the	DT	O	O
untreated	JJ	O	O
group	NN	O	O
(	(	O	O
pathological	JJ	O	O
stage	NN	O	O
B	NNP	O	O
:	:	O	O
31	CD	O	O
%	NN	O	O
and	CC	O	O
33	CD	O	O
%	NN	O	O
vs.	FW	O	O
6	CD	O	O
%	NN	O	O
in	IN	O	O
the	DT	O	O
clinical	JJ	O	O
C	NNP	O	O
cases	NNS	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

Negative	JJ	O	O
margins	NNS	O	O
:	:	O	O
56	CD	O	O
%	NN	O	O
and	CC	O	O
67	CD	O	O
%	NN	O	O
vs.	FW	O	O
31	CD	O	O
%	NN	O	O
,	,	O	O
respectively	RB	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
initial	JJ	O	O
results	NNS	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
suggest	VBP	O	O
that	IN	O	O
total	JJ	i	IPM
androgen	NN	i	IPM
ablation	NN	i	IPM
before	IN	i	O
RP	NNP	i	IS
is	VBZ	O	O
beneficial	JJ	O	O
in	IN	O	O
men	NNS	O	O
with	IN	O	O
clinical	JJ	O	O
stage	NN	O	O
B	NNP	O	O
because	IN	O	O
of	IN	O	O
the	DT	O	O
significant	JJ	O	O
pathological	JJ	o	OPH
downstaging	NN	o	OPH
and	CC	O	O
decrease	NN	O	O
in	IN	O	O
the	DT	O	O
number	NN	O	O
of	IN	O	O
positive	JJ	o	OPH
margins	NNS	o	OPH
in	IN	o	OPH
the	DT	o	OPH
RP	NNP	o	OPH
specimens	NNS	o	OPH
.	.	o	O

These	DT	O	O
two	CD	O	O
effects	NNS	O	O
are	VBP	O	O
more	RBR	O	O
pronounced	JJ	O	O
after	IN	O	O
six	CD	O	O
months	NNS	O	O
of	IN	O	O
NHT	NNP	i	IPM
than	IN	O	O
after	IN	O	O
three	CD	O	O
months	NNS	O	O
of	IN	O	O
therapy	NN	O	O
.	.	O	O

The	DT	O	O
same	JJ	O	O
degree	NN	O	O
of	IN	O	O
beneficial	JJ	o	OOt
effects	NNS	o	OOt
are	VBP	O	O
not	RB	O	O
observed	VBN	O	O
in	IN	O	O
clinical	JJ	O	O
C	NNP	O	O
tumours	NN	O	O
.	.	O	O

Serum	NNP	o	OPH
bactericidal	NN	o	OPH
activities	NNS	o	OPH
and	CC	o	OPH
comparative	JJ	o	OOt
pharmacokinetics	NNS	o	OOt
of	IN	O	O
meropenem	NN	O	O
and	CC	O	O
imipenem-cilastatin	NN	O	O
.	.	O	O

The	DT	O	O
pharmacokinetics	NNS	o	OOt
and	CC	o	OPH
serum	NN	o	OPH
bactericidal	NN	o	OPH
activities	NNS	o	OPH
(	(	o	OPH
SBAs	NNP	o	OPH
)	)	o	OPH
of	IN	O	O
imipenem	NN	i	IPM
and	CC	O	O
meropenem	NN	i	IPM
were	VBD	O	O
investigated	VBN	O	O
in	IN	O	O
a	DT	O	O
randomized	VBN	O	O
crossover	NN	O	O
study	NN	O	O
.	.	O	O

Twelve	NNP	p	O
healthy	JJ	p	O
male	NN	p	O
volunteers	NNS	p	O
received	VBD	O	O
a	DT	O	O
constant	JJ	i	O
30-min	JJ	i	O
infusion	NN	i	O
of	IN	i	O
either	CC	i	O
1	CD	i	O
g	NN	i	O
of	IN	i	O
imipenem	JJ	i	IPM
plus	CC	i	IPM
1	CD	i	IPM
g	NN	i	IPM
of	IN	i	IPM
cilastatin	NN	i	IPM
or	CC	i	O
1	CD	i	IPM
g	NN	i	IPM
of	IN	i	IPM
meropenem	NN	i	IPM
.	.	i	O

The	DT	O	O
concentrations	NNS	o	OPH
of	IN	o	OPH
the	DT	o	OPH
drugs	NNS	o	OPH
in	IN	o	OPH
serum	NN	o	OPH
and	CC	o	OPH
urine	NN	o	OPH
were	VBD	O	O
determined	VBN	i	O
by	IN	i	O
bioassay	NN	o	OOt
and	CC	o	OOt
high-pressure	NN	o	OOt
liquid	NN	o	OOt
chromatography	NN	o	OOt
.	.	o	OOt

Pharmacokinetic	JJ	O	O
parameters	NNS	O	O
were	VBD	O	O
based	VBN	O	O
on	IN	O	O
an	DT	O	O
open	JJ	O	O
two-compartment	JJ	i	IPH
model	NN	i	IPH
and	CC	i	O
a	DT	i	O
noncompartmental	JJ	i	IPH
technique	NN	i	IPH
.	.	i	O

At	IN	O	O
the	DT	O	O
end	NN	O	O
of	IN	O	O
infusion	NN	O	O
,	,	O	O
the	DT	O	O
mean	JJ	o	OPH
concentrations	NNS	o	OPH
of	IN	o	OPH
imipenem	NN	o	OPH
and	CC	o	OPH
meropenem	NN	o	OPH
measured	VBN	o	OPH
in	IN	o	OPH
serum	NN	o	OPH
were	VBD	O	O
61.2	CD	O	O
+/-	JJ	O	O
9.8	CD	O	O
and	CC	O	O
51.6	CD	O	O
+/-	JJ	O	O
6.5	CD	O	O
mg/liter	NN	O	O
,	,	O	O
respectively	RB	O	O
;	:	O	O
urinary	JJ	o	OPH
recoveries	NNS	o	OPH
were	VBD	O	O
48.6	CD	O	O
%	NN	O	O
+/-	JJ	O	O
8.2	CD	O	O
%	NN	O	O
and	CC	O	O
60.0	CD	O	O
%	NN	O	O
+/-	JJ	O	O
6.5	CD	O	O
%	NN	O	O
of	IN	O	O
the	DT	O	O
dose	NN	O	O
in	IN	O	O
12	CD	O	O
h	NN	O	O
,	,	O	O
respectively	RB	O	O
;	:	O	O
and	CC	O	O
the	DT	O	O
areas	NNS	o	OPH
under	IN	o	OPH
the	DT	o	OPH
concentration-time	JJ	o	OPH
curve	NN	o	OPH
from	IN	O	O
time	NN	O	O
zero	CD	O	O
to	TO	O	O
infinity	NN	O	O
were	VBD	O	O
96.1	CD	O	O
+/-	JJ	O	O
14.4	CD	O	O
and	CC	O	O
70.5	CD	O	O
+/-	JJ	O	O
10.3	CD	O	O
mg.h/liter	NN	O	O
,	,	O	O
respectively	RB	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
or	CC	O	O
=	VB	O	O
0.02	CD	O	O
)	)	O	O
.	.	O	O

Imipenem	NNP	O	O
had	VBD	O	O
a	DT	O	O
mean	JJ	O	O
half-life	NN	O	O
of	IN	O	O
66.7	CD	O	O
+/-	JJ	O	O
10.4	CD	O	O
min	NN	O	O
;	:	O	O
that	IN	O	O
of	IN	O	O
meropenem	NN	O	O
was	VBD	O	O
64.4	CD	O	O
+/-	JJ	O	O
6.9	CD	O	O
min	NN	O	O
.	.	O	O

The	DT	O	O
volumes	NNS	O	O
of	IN	O	O
distribution	NN	O	O
at	IN	O	O
steady	JJ	O	O
state	NN	O	O
of	IN	O	O
imipenem	NN	O	O
and	CC	O	O
meropenem	NN	O	O
were	VBD	O	O
15.3	CD	O	O
+/-	JJ	O	O
3.3	CD	O	O
and	CC	O	O
18.6	CD	O	O
+/-	JJ	O	O
3.0	CD	O	O
liters/70	NN	O	O
kg	NN	O	O
,	,	O	O
respectively	RB	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
mean	JJ	O	O
renal	JJ	O	O
clearances	NNS	O	O
per	IN	O	O
1.73	CD	O	O
m2	NNS	O	O
were	VBD	O	O
85.6	CD	O	O
+/-	JJ	O	O
17.6	CD	O	O
and	CC	O	O
144.6	CD	O	O
+/-	JJ	O	O
26.0	CD	O	O
ml/min	NN	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

Both	DT	p	O
antibiotics	NNS	p	O
were	VBD	p	O
well	RB	p	O
tolerated	VBN	p	O
in	IN	p	O
this	DT	p	O
single-dose	JJ	p	O
administration	NN	p	O
study	NN	p	O
.	.	p	O

The	DT	O	O
SBAs	NNP	o	OPH
were	VBD	O	O
measured	VBN	O	O
by	IN	O	O
the	DT	O	O
microdilution	NN	o	OOt
method	NN	o	OOt
of	IN	o	OOt
Reller	NNP	o	OOt
and	CC	o	OOt
Stratton	NNP	o	OOt
(	(	O	O
L.	NNP	O	O
B.	NNP	O	O
Reller	NNP	O	O
and	CC	O	O
C.	NNP	O	O
W.	NNP	O	O
Stratton	NNP	O	O
,	,	O	O
J.	NNP	O	O
Infect	NNP	O	O
.	.	O	O

Dis	NNP	O	O
.	.	O	O

136:196-204	CD	O	O
,	,	O	O
1977	CD	O	O
)	)	O	O
against	IN	O	O
40	CD	O	O
clinically	RB	O	O
isolated	JJ	O	O
strains	NNS	O	O
.	.	O	O

Mean	NNP	o	OPH
reciprocal	JJ	o	OPH
bactericidal	NN	o	OPH
titers	NNS	o	OPH
were	VBD	O	O
measured	VBN	O	O
1	CD	O	O
and	CC	O	O
6	CD	O	O
h	NN	O	O
after	IN	O	O
administration	NN	O	O
.	.	O	O

After	IN	O	O
1	CD	O	O
and	CC	O	O
6	CD	O	O
h	NN	O	O
the	DT	O	O
median	JJ	O	O
SBAs	NNP	o	OPH
for	IN	O	O
imipenem	NN	O	O
and	CC	O	O
meropenem	NN	O	O
,	,	O	O
were	VBD	O	O
409	CD	O	O
and	CC	O	O
34.9	CD	O	O
and	CC	O	O
97.9	CD	O	O
and	CC	O	O
5.8	CD	O	O
,	,	O	O
respectively	RB	O	O
,	,	O	O
against	IN	O	O
Staphylococcus	NNP	O	O
aureus	NN	O	O
,	,	O	O
19.9	CD	O	O
and	CC	O	O
4.4	CD	O	O
and	CC	O	O
19.4	CD	O	O
and	CC	O	O
4.8	CD	O	O
,	,	O	O
respectively	RB	O	O
,	,	O	O
against	IN	O	O
Pseudomonas	NNP	O	O
aeruginosa	NN	O	O
,	,	O	O
34.3	CD	O	O
and	CC	O	O
2.2	CD	O	O
and	CC	O	O
232	CD	O	O
and	CC	O	O
15.5	CD	O	O
,	,	O	O
respectively	RB	O	O
,	,	O	O
against	IN	O	O
Enterobacter	NNP	O	O
cloacae	NN	O	O
,	,	O	O
and	CC	O	O
13.4	CD	O	O
and	CC	O	O
2.25	CD	O	O
and	CC	O	O
90.7	CD	O	O
and	CC	O	O
7.9	CD	O	O
,	,	O	O
respectively	RB	O	O
,	,	O	O
against	IN	O	O
Proteus	NNP	O	O
mirabilis	NN	O	O
.	.	O	O

Both	DT	p	O
drugs	NNS	p	O
had	VBD	p	O
rather	RB	p	O
short	JJ	p	O
biological	JJ	p	O
elimination	NN	p	O
half-lives	NNS	o	OOt
and	CC	p	O
a	DT	p	O
predominantly	RB	p	O
renal	JJ	p	O
route	NN	p	O
of	IN	p	O
elimination	NN	p	O
.	.	p	O

Both	DT	O	O
carbapenems	NNS	O	O
revealed	VBD	O	O
high	JJ	O	O
SBAs	NNP	o	OPH
against	IN	o	OPH
clinically	RB	o	OPH
important	JJ	o	OPH
pathogens	NNS	o	OPH
at	IN	O	O
1	CD	O	O
h	NN	O	O
;	:	O	O
meropenem	NN	O	O
had	VBD	O	O
a	DT	O	O
higher	JJR	O	O
SBA	NNP	o	OPH
against	IN	O	O
E.	NNP	O	O
cloacae	NN	O	O
and	CC	O	O
P.	NNP	O	O
mirabilis	NN	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
SBA	NNP	o	OPH
of	IN	O	O
imipenem	NN	O	O
against	IN	O	O
S.	NNP	O	O
aureus	NN	O	O
was	VBD	O	O
greater	JJR	O	O
than	IN	O	O
the	DT	O	O
SBA	NNP	O	O
of	IN	O	O
meropenem	NN	O	O
.	.	O	O

Effectiveness	NN	o	OOt
of	IN	O	O
the	DT	O	O
school	NN	i	IE
dental	JJ	i	IE
screening	VBG	i	IE
programme	NN	i	IE
in	IN	O	O
stimulating	VBG	o	OOt
dental	JJ	o	OOt
attendance	NN	o	OOt
for	IN	O	O
children	NNS	p	PA
in	IN	p	O
need	NN	p	O
of	IN	p	O
treatment	NN	p	O
in	IN	p	O
Northern	NNP	p	O
Ireland	NNP	p	O
.	.	p	O

UNLABELLED	IN	O	O
The	DT	O	O
school	NN	i	O
dental	JJ	i	O
screening	NN	i	O
programme	NN	i	O
has	VBZ	O	O
been	VBN	O	O
in	IN	O	O
existence	NN	O	O
from	IN	O	O
the	DT	O	O
beginning	NN	O	O
of	IN	O	O
the	DT	O	O
20th	JJ	O	O
century	NN	O	O
yet	RB	O	O
its	PRP$	O	O
value	NN	O	O
in	IN	O	O
encouraging	JJ	O	O
attendance	NN	O	O
among	IN	O	O
children	NNS	p	O
with	IN	p	O
a	DT	p	O
dental	JJ	p	PC
health	NN	p	PC
need	NN	p	O
is	VBZ	O	O
not	RB	O	O
fully	RB	O	O
established	VBN	O	O
.	.	O	O

OBJECTIVE	NNP	O	O
To	TO	O	O
evaluate	VB	O	O
the	DT	O	O
effectiveness	NN	O	O
of	IN	O	O
school	NN	i	IE
dental	JJ	i	IE
screening	NN	i	IE
in	IN	O	O
promoting	VBG	O	O
dental	JJ	o	OOt
attendance	NN	o	OOt
among	IN	O	O
children	NNS	p	PA
with	IN	p	O
a	DT	p	O
treatment	NN	p	O
need	NN	p	O
and	CC	O	O
to	TO	O	O
examine	VB	O	O
the	DT	O	O
relative	JJ	O	O
importance	NN	O	O
of	IN	O	O
screening	NN	O	O
,	,	O	O
social	JJ	O	O
class	NN	O	O
and	CC	O	O
other	JJ	O	O
factors	NNS	O	O
in	IN	O	O
dental	JJ	o	OOt
attendance	NN	o	OOt
.	.	o	O

METHODS	NNP	O	O
Sixty-four	JJ	p	PSS
participating	NN	p	O
schools	NNS	p	O
were	VBD	O	O
assigned	VBN	O	O
to	TO	O	O
study	VB	O	O
and	CC	O	O
control	VB	O	O
groups	NNS	O	O
using	VBG	O	O
a	DT	O	O
stratified	JJ	O	O
,	,	O	O
blocked	JJ	O	O
randomisation	NN	O	O
technique	NN	O	O
.	.	O	O

The	DT	O	O
study	NN	O	O
group	NN	O	O
children	NNS	O	O
received	VBD	O	O
the	DT	O	O
standard	JJ	i	IE
school	NN	i	IE
dental	JJ	i	IE
screening	NN	i	IE
and	CC	O	O
the	DT	O	O
dental	JJ	o	OOt
attendance	NN	o	OOt
of	IN	O	O
those	DT	O	O
with	IN	O	O
a	DT	O	O
positive	JJ	O	O
screening	NN	o	O
result	NN	o	O
was	VBD	O	O
assessed	VBN	O	O
after	IN	O	O
2	CD	O	O
months	NNS	O	O
by	IN	O	O
means	NNS	O	O
of	IN	O	O
a	DT	O	O
questionnaire	NN	O	O
issued	VBN	O	O
to	TO	O	O
the	DT	O	O
children	NNS	O	O
's	POS	O	O
parents	NNS	O	O
.	.	O	O

The	DT	O	O
control	NN	O	O
group	NN	i	IE
children	NNS	i	IE
were	VBD	i	IE
not	RB	i	IE
,	,	i	IE
at	IN	i	IE
this	DT	i	IE
stage	NN	i	IE
,	,	i	IE
screened	VBD	i	IE
,	,	O	O
yet	CC	O	O
their	PRP$	O	O
parents	NNS	O	O
received	VBD	O	O
the	DT	O	O
same	JJ	i	O
questionnaire	NN	i	O
assessing	VBG	i	O
dental	JJ	o	OOt
attendance	NN	o	OOt
over	IN	i	O
the	DT	i	O
2-month	JJ	i	O
period	NN	i	O
.	.	i	O

However	RB	O	O
,	,	O	O
only	RB	O	O
questionnaires	VBZ	O	O
from	IN	O	O
control	NN	i	O
group	NN	O	O
children	NNS	O	O
who	WP	O	O
had	VBD	O	O
a	DT	O	O
positive	JJ	O	O
result	NN	O	O
at	IN	O	O
a	DT	O	O
subsequent	JJ	O	O
screening	NN	O	O
were	VBD	O	O
retained	VBN	O	O
for	IN	O	O
analysis	NN	O	O
.	.	O	O

RESULTS	VB	O	O
A	DT	p	O
total	NN	p	O
of	IN	p	O
2,321	CD	p	PSS
children	NNS	p	PSS
were	VBD	p	O
screened	VBN	p	O
,	,	p	O
with	IN	p	O
980	CD	p	PSS
having	VBG	p	O
a	DT	p	O
positive	JJ	p	O
result	NN	p	O
.	.	p	O

The	DT	O	O
mean	JJ	O	O
dmft	NN	O	O
of	IN	O	O
those	DT	O	O
screening	VBG	O	O
positive	JJ	O	O
was	VBD	O	O
4.85	CD	O	O
.	.	O	O

In	IN	O	O
all	DT	O	O
,	,	O	O
664	CD	p	PSS
completed	VBN	p	O
questionnaires	NNS	p	O
were	VBD	O	O
returned	VBN	O	O
,	,	O	O
giving	VBG	O	O
a	DT	O	O
response	NN	O	O
rate	NN	O	O
of	IN	O	O
67.8	CD	O	O
%	NN	O	O
.	.	O	O

Dental	JJ	o	OOt
attendance	NN	o	OOt
was	VBD	O	O
reported	VBN	O	O
among	IN	O	O
45.5	CD	O	O
%	NN	O	O
of	IN	O	O
the	DT	O	O
study	NN	O	O
group	NN	O	O
(	(	O	O
n=352	NN	O	O
)	)	O	O
in	IN	O	O
the	DT	O	O
2	CD	O	O
months	NNS	O	O
following	VBG	O	O
screening	NN	O	O
.	.	O	O

In	IN	O	O
the	DT	O	O
same	JJ	O	O
period	NN	O	O
,	,	O	O
27.6	CD	O	O
%	NN	O	O
of	IN	O	O
the	DT	O	O
control	NN	O	O
group	NN	O	O
(	(	O	O
n=312	RB	O	O
)	)	O	O
claimed	VBD	O	O
attendance	NN	O	O
.	.	O	O

The	DT	O	O
effect	NN	O	O
was	VBD	O	O
found	VBN	O	O
to	TO	O	O
be	VB	O	O
significant	JJ	O	O
among	IN	O	O
the	DT	O	O
high	JJ	O	O
employed	VBN	O	O
group	NN	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.01	CD	O	O
)	)	O	O
and	CC	O	O
the	DT	O	O
unemployed	JJ	O	O
group	NN	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

CONCLUSION	NNP	O	O
School	NNP	O	O
dental	JJ	O	O
screening	NN	O	O
was	VBD	O	O
capable	JJ	O	O
of	IN	O	O
stimulating	VBG	O	O
dental	JJ	o	OOt
attendance	NN	o	OOt
.	.	o	O

The	DT	O	O
strong	JJ	O	O
effect	NN	O	O
among	IN	O	O
the	DT	O	O
lowest	JJS	O	O
socio-economic	JJ	O	O
group	NN	O	O
shows	VBZ	O	O
that	IN	O	O
school	NN	O	O
dental	JJ	O	O
screening	NN	O	O
may	MD	O	O
be	VB	O	O
used	VBN	O	O
to	TO	O	O
decrease	VB	O	O
dental	JJ	o	OOt
health	NN	o	OOt
inequalities	NNS	o	OOt
.	.	o	O

[	NN	O	O
Study	NNP	O	O
on	IN	O	O
safety	NN	O	O
and	CC	O	O
immunogenicity	NN	O	O
of	IN	O	O
oral	JJ	i	IPM
poliomyelitis	NN	i	IPM
attenuated	VBD	i	IPM
live	JJ	i	IPM
vaccine	NN	i	IPM
(	(	O	O
human	JJ	O	O
diploid	NN	O	O
cell	NN	O	O
)	)	O	O
]	NN	O	O
.	.	O	O

OBJECTIVE	UH	O	O
To	TO	O	O
evaluate	VB	O	O
the	DT	O	O
safety	NN	o	OOt
and	CC	O	O
Immunogenicity	NNP	o	OPH
of	IN	O	O
the	DT	O	O
Poliomyelitis	NNP	i	IPM
vaccine	NN	i	IPM
(	(	O	O
Human	NNP	O	O
Diploid	NNP	O	O
Cell	NNP	O	O
)	)	O	O
in	IN	O	O
>	NN	O	O
or	CC	O	O
=2	VB	p	O
month-old	JJ	p	O
children	NNS	p	O
.	.	p	O

METHODS	NNP	O	O
A	NNP	O	O
random	NN	O	O
,	,	O	O
blind	NN	O	O
and	CC	O	O
control	NN	O	O
trial	NN	O	O
,	,	O	O
1200	CD	p	PSS
healthy	JJ	p	O
children	NNS	p	PA
of	IN	p	O
2-5	JJ	p	PA
months	NNS	p	PA
old	JJ	p	PA
in	IN	p	O
Jiangsu	NNP	p	O
province	NN	p	O
were	VBD	p	O
administered	VBN	p	O
OPV	NNP	i	IPM
(	(	i	IPM
HDC	NNP	i	IPM
)	)	i	IPM
vaccine	NN	i	IPM
and	CC	i	O
control	NN	i	IPM
vaccines	NNS	i	IPM
.	.	i	O

The	DT	O	O
antibody	NN	O	O
was	VBD	O	O
tested	VBN	O	O
by	IN	O	O
neutralization	NN	O	O
test	NN	O	O
.	.	O	O

RESULTS	NNP	O	O
After	IN	O	O
3	CD	O	O
doses	NNS	O	O
of	IN	O	O
the	DT	O	O
OPV	NNP	i	IPM
(	(	i	IPM
HDC	NNP	i	IPM
)	)	i	IPM
vaccine	NN	i	IPM
,	,	O	O
the	DT	O	O
systemic	JJ	o	OPH
reactions	NNS	o	OPH
were	VBD	O	O
mild	JJ	O	O
.	.	O	O

After	IN	O	O
1	CD	O	O
month	NN	O	O
of	IN	O	O
vaccination	NN	O	O
with	IN	O	O
3	CD	O	O
doses	NNS	O	O
of	IN	O	O
the	DT	O	O
OPV	NNP	i	IPM
(	(	i	IPM
HDC	NNP	i	IPM
)	)	i	IPM
vaccine	NN	i	IPM
,	,	O	O
the	DT	O	O
immune	JJ	o	OPH
success	NN	o	OPH
rates	NNS	o	OPH
of	IN	o	OPH
I	PRP	o	OPH
,	,	o	OPH
II	NNP	o	OPH
,	,	o	OPH
III	NNP	o	OPH
type	NN	o	OPH
were	VBD	O	O
98.28	CD	O	O
%	NN	O	O
,	,	O	O
99.45	CD	O	O
%	NN	O	O
,	,	O	O
and	CC	O	O
95.71	CD	O	O
%	NN	O	O
respectively	RB	O	O
,	,	O	O
the	DT	O	O
GMTs	NNP	o	OPH
of	IN	o	OPH
I	PRP	o	OPH
,	,	o	OPH
II	NNP	o	OPH
,	,	o	OPH
III	NNP	o	OPH
type	NN	o	OPH
in	IN	O	O
susceptible	JJ	O	O
children	NNS	O	O
were	VBD	O	O
1:1243.72	CD	O	O
,	,	O	O
1:234.38	CD	O	O
and	CC	O	O
1:273.10	CD	O	O
respectively	RB	O	O
.	.	O	O

CONCLUSIONS	VB	O	O
The	DT	O	O
OPV	NNP	i	IPM
(	(	i	IPM
HDC	NNP	i	IPM
)	)	i	IPM
vaccine	NN	i	IPM
was	VBD	O	O
safe	JJ	O	O
and	CC	O	O
immunogenicity	NN	O	O
for	IN	O	O
the	DT	p	O
children	NNS	p	O
>	VBP	p	O
or	CC	p	O
=2	JJ	p	O
months	NNS	p	O
old	JJ	p	O
.	.	p	O

Use	NNP	i	IE
of	IN	i	IE
an	DT	i	IE
Internet	NNP	i	IE
portal	NN	i	IE
to	TO	O	O
improve	VB	O	O
community-based	JJ	p	O
pediatric	JJ	p	PA
ADHD	NNP	p	PC
care	NN	p	O
:	:	p	O
a	DT	O	O
cluster	NN	O	O
randomized	VBN	O	O
trial	NN	O	O
.	.	O	O

OBJECTIVE	NN	O	O
To	TO	O	O
determine	VB	O	O
the	DT	O	O
effectiveness	NN	O	O
of	IN	O	O
a	DT	O	O
quality	NN	i	IE
improvement	NN	i	IE
program	NN	i	IE
to	TO	O	O
improve	VB	O	O
pediatricians	NNS	p	O
'	POS	p	O
adherence	NN	O	O
to	TO	O	O
existing	VBG	O	O
,	,	O	O
evidence-based	JJ	O	O
,	,	O	O
attention-deficit/hyperactivity	JJ	O	O
disorder	NN	O	O
(	(	O	O
ADHD	NNP	O	O
)	)	O	O
practice	NN	O	O
guidelines	NNS	O	O
.	.	O	O

METHODS	NNP	O	O
Forty-nine	JJ	p	PSS
community-based	JJ	p	O
pediatricians	NNS	p	O
at	IN	p	O
8	CD	p	O
practices	NNS	p	O
participated	VBN	p	O
in	IN	p	O
a	DT	p	O
cluster-randomized	JJ	p	O
trial	NN	p	O
.	.	p	O

Practices	NNS	O	O
were	VBD	O	O
matched	VBN	O	O
according	VBG	O	O
to	TO	O	O
the	DT	O	O
numbers	NNS	p	O
of	IN	p	O
pediatricians	NNS	p	O
and	CC	p	O
the	DT	p	O
proportions	NNS	p	O
of	IN	p	O
patients	NNS	p	O
receiving	VBG	p	O
Medicaid	NNP	p	O
.	.	p	O

The	DT	O	O
medical	JJ	O	O
charts	NNS	O	O
for	IN	O	O
a	DT	O	O
random	JJ	O	O
sample	NN	O	O
of	IN	O	O
patients	NNS	O	O
with	IN	O	O
ADHD	NNP	O	O
for	IN	O	O
each	DT	O	O
of	IN	O	O
the	DT	O	O
participating	VBG	O	O
pediatricians	NNS	O	O
were	VBD	O	O
examined	VBN	O	O
at	IN	O	O
baseline	NN	O	O
and	CC	O	O
6	CD	O	O
months	NNS	O	O
.	.	O	O

All	DT	O	O
practices	NNS	O	O
participated	VBN	O	O
in	IN	O	O
4	CD	O	O
sessions	NNS	O	O
of	IN	O	O
training	NN	i	IE
,	,	i	IE
including	VBG	i	IE
didactic	JJ	i	IE
lectures	NNS	i	IE
and	CC	i	IE
office	NN	i	IE
flow	NN	i	IE
modification	NN	i	IE
workshops	NNS	i	IE
.	.	i	IE

Practices	NNS	O	O
were	VBD	O	O
then	RB	O	O
given	VBN	O	O
access	NN	O	O
to	TO	O	O
an	DT	O	O
ADHD	NNP	i	IE
Internet	NNP	i	IE
portal	NN	i	IE
that	WDT	O	O
allowed	VBD	O	O
parents	NNS	O	O
,	,	O	O
teachers	NNS	O	O
,	,	O	O
and	CC	O	O
pediatricians	NNS	O	O
to	TO	O	O
input	VB	O	O
information	NN	O	O
(	(	O	O
eg	NN	O	O
,	,	O	O
rating	NN	O	O
scales	NNS	O	O
)	)	O	O
about	IN	O	O
patients	NNS	O	O
,	,	O	O
after	IN	O	O
which	WDT	O	O
information	NN	O	O
was	VBD	O	O
scored	VBN	O	O
,	,	O	O
interpreted	VBN	O	O
,	,	O	O
and	CC	O	O
formatted	VBN	O	O
in	IN	O	O
a	DT	O	O
report	NN	O	O
style	NN	O	O
that	WDT	O	O
was	VBD	O	O
helpful	JJ	O	O
for	IN	O	O
assessment	NN	O	O
and	CC	O	O
treatment	NN	O	O
of	IN	O	O
patients	NNS	O	O
with	IN	O	O
ADHD	NNP	O	O
.	.	O	O

Physicians	NNPS	O	O
evaluated	VBD	O	O
their	PRP$	O	O
practice	NN	o	OME
behaviors	NNS	o	OME
quarterly	RB	O	O
and	CC	O	O
addressed	VBD	O	O
underperforming	JJ	o	OME
areas	NNS	o	OME
.	.	o	OME

RESULTS	NNP	O	O
Pediatricians	NNPS	O	O
in	IN	O	O
the	DT	O	O
intervention	NN	O	O
group	NN	O	O
,	,	O	O
compared	VBN	O	O
with	IN	O	O
those	DT	O	O
in	IN	O	O
the	DT	O	O
control	NN	i	IC
group	NN	O	O
,	,	O	O
demonstrated	VBD	O	O
significantly	RB	O	O
higher	JJR	O	O
rates	NNS	O	O
of	IN	O	O
many	JJ	O	O
American	JJ	O	O
Academy	NNP	O	O
of	IN	O	O
Pediatrics-recommended	NNP	O	O
ADHD	NNP	O	O
care	NN	O	O
practices	NNS	O	O
,	,	O	O
including	VBG	O	O
collection	NN	o	OME
of	IN	o	OME
parent	NN	o	OME
(	(	O	O
Cohen	NNP	O	O
's	POS	O	O
d	NN	O	O
=	VBZ	O	O
0.69	CD	O	O
)	)	O	O
and	CC	O	O
teacher	$	o	OME
(	(	O	O
d	JJ	O	O
=	NNP	O	O
0.68	CD	O	O
)	)	O	O
rating	NN	o	OME
scales	NNS	o	OME
for	IN	O	O
assessment	NN	O	O
of	IN	O	O
children	NNS	O	O
with	IN	O	O
ADHD	NNP	O	O
,	,	O	O
use	NN	O	O
of	IN	O	O
Diagnostic	NNP	O	O
and	CC	O	O
Statistical	NNP	o	OME
Manual	NNP	o	OME
of	IN	o	OME
Mental	NNP	o	OME
Disorders	NNP	o	OME
,	,	O	O
Fourth	NNP	O	O
Edition	NNP	O	O
,	,	O	O
criteria	NNS	O	O
(	(	O	O
d	VB	O	O
=	RB	O	O
0.85	CD	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
use	NN	O	O
of	IN	O	O
teacher	NN	o	OME
rating	NN	o	OME
scales	NNS	o	OME
to	TO	O	O
monitor	VB	O	O
treatment	NN	O	O
responses	NNS	O	O
(	(	O	O
d	VB	O	O
=	RB	O	O
1.01	CD	O	O
)	)	O	O
.	.	O	O

CONCLUSION	VB	O	O
A	DT	i	IE
quality	NN	i	IE
improvement	NN	i	IE
intervention	NN	i	IE
that	WDT	O	O
can	MD	O	O
be	VB	O	O
widely	RB	O	O
disseminated	VBN	O	O
by	IN	O	O
using	VBG	O	O
Internet-based	JJ	i	IE
information	NN	i	IE
technology	NN	i	IE
significantly	RB	O	O
improved	VBD	O	O
the	DT	O	O
quality	NN	O	O
of	IN	O	O
ADHD	NNP	O	O
care	NN	O	O
in	IN	O	O
community-based	JJ	p	O
pediatric	JJ	p	O
settings	NNS	p	O
.	.	p	O

Lack	NN	O	O
of	IN	O	O
effect	NN	O	O
of	IN	O	O
warfarin	NN	i	IPM
on	IN	O	O
the	DT	O	O
restenosis	NN	o	OPH
rate	NN	o	OPH
or	CC	O	O
on	IN	p	O
clinical	JJ	p	O
outcome	NN	p	O
after	IN	p	O
balloon	NN	p	O
coronary	JJ	p	O
angioplasty	NN	p	O
.	.	p	O

Between	NNP	p	O
September	NNP	p	O
1985	CD	p	O
and	CC	p	O
April	NNP	p	O
1987	CD	p	O
,	,	p	O
110	CD	p	O
consecutive	JJ	p	O
patients	NNS	p	O
who	WP	p	O
had	VBD	p	O
successful	JJ	p	O
coronary	JJ	p	O
angioplasty	NN	p	O
were	VBD	O	O
included	VBN	O	O
in	IN	O	O
a	DT	O	O
randomised	JJ	O	O
prospective	NN	O	O
controlled	VBN	O	O
evaluation	NN	O	O
of	IN	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
warfarin	NN	i	IPM
on	IN	O	O
restenosis	NN	O	O
.	.	O	O

The	DT	O	O
warfarin	NN	i	IPM
(	(	O	O
n	JJ	O	O
=	NNP	O	O
56	CD	O	O
)	)	O	O
and	CC	O	O
the	DT	O	O
control	NN	i	IC
(	(	O	O
n	JJ	O	O
=	NNP	O	O
54	CD	O	O
)	)	O	O
groups	NNS	O	O
were	VBD	O	O
not	RB	O	O
different	JJ	O	O
in	IN	O	O
terms	NNS	O	O
of	IN	O	O
age	NN	O	O
,	,	O	O
sex	NN	O	O
,	,	O	O
previous	JJ	O	O
coronary	JJ	O	O
bypass	NN	O	O
surgery	NN	O	O
or	CC	O	O
coronary	JJ	O	O
balloon	NN	O	O
angioplasty	NN	O	O
,	,	O	O
severity	NN	O	O
of	IN	O	O
symptoms	NNS	O	O
,	,	O	O
and	CC	O	O
frequency	NN	O	O
of	IN	O	O
multivessel	JJ	O	O
disease	NN	O	O
or	CC	O	O
of	IN	O	O
total	JJ	O	O
coronary	JJ	O	O
occlusions	NNS	O	O
.	.	O	O

Warfarin	NNP	i	IPM
was	VBD	O	O
started	VBN	O	O
on	IN	O	O
the	DT	O	O
day	NN	O	O
of	IN	O	O
the	DT	O	O
procedure	NN	O	O
and	CC	O	O
the	DT	O	O
dosage	NN	O	O
was	VBD	O	O
adjusted	VBN	O	O
to	TO	O	O
maintain	VB	O	O
the	DT	O	O
thromboplastin	JJ	O	O
international	JJ	O	O
normalised	VBN	O	O
ratio	NN	O	O
greater	JJR	O	O
than	IN	O	O
or	CC	O	O
equal	JJ	O	O
to	TO	O	O
2.5	CD	O	O
.	.	O	O

One	CD	O	O
hundred	CD	O	O
and	CC	O	O
five	CD	O	O
(	(	O	O
96	CD	O	O
%	NN	O	O
)	)	O	O
of	IN	O	O
the	DT	O	O
patients	NNS	O	O
were	VBD	O	O
given	VBN	O	O
verapamil	NNS	i	IPM
and	CC	O	O
other	JJ	i	IPM
antianginal	JJ	i	IPM
drugs	NNS	i	IPM
were	VBD	O	O
prescribed	VBN	O	O
as	IN	O	O
needed	VBN	O	O
.	.	O	O

Low	JJ	i	IPM
molecular	JJ	i	IPM
weight	NN	i	IPM
dextran	NN	i	IPM
and	CC	i	IPM
heparin	NN	i	IPM
were	VBD	O	O
given	VBN	O	O
during	IN	O	O
the	DT	O	O
procedure	NN	O	O
and	CC	O	O
heparin	NN	i	IPM
was	VBD	O	O
continued	VBN	O	O
for	IN	O	O
24	CD	O	O
hours	NNS	O	O
in	IN	O	O
all	DT	O	O
patients	NNS	O	O
.	.	O	O

One	CD	p	O
hundred	CD	p	O
and	CC	p	O
eight	CD	p	O
(	(	p	O
98	CD	p	O
%	NN	p	O
)	)	p	O
of	IN	p	O
patients	NNS	p	O
were	VBD	p	O
followed	VBN	p	O
up	RP	p	O
clinically	RB	p	O
after	IN	p	O
a	DT	p	O
median	NN	p	O
of	IN	p	O
five	CD	p	O
months	NNS	p	O
(	(	p	O
range	VB	p	O
1-20	CD	p	O
)	)	p	O
.	.	p	O

Eighty	NNP	p	O
five	CD	p	O
(	(	p	O
77	CD	p	O
%	NN	p	O
)	)	p	O
had	VBD	p	O
follow	VBN	p	O
up	RP	p	O
angiography	NN	p	O
at	IN	p	O
five	CD	p	O
months	NNS	p	O
.	.	p	O

In	IN	O	O
the	DT	O	O
warfarin	NN	i	IPM
group	NN	O	O
symptoms	NNS	o	OPH
improved	VBN	o	OOt
in	IN	O	O
46	CD	O	O
(	(	O	O
85	CD	O	O
%	NN	O	O
)	)	O	O
patients	NNS	O	O
by	IN	O	O
at	IN	O	O
least	JJS	O	O
1	CD	O	O
angina	JJ	O	O
class	NN	O	O
and	CC	O	O
31	CD	O	O
(	(	O	O
57	CD	O	O
%	NN	O	O
)	)	O	O
were	VBD	O	O
symptom	JJ	o	OOt
free	JJ	o	OOt
;	:	o	O
the	DT	O	O
exercise	NN	O	O
test	NN	O	O
remained	VBD	O	O
positive	JJ	O	O
in	IN	O	O
20	CD	O	O
(	(	O	O
36	CD	O	O
%	NN	O	O
)	)	O	O
patients	NNS	O	O
and	CC	O	O
the	DT	O	O
angiographic	JJ	o	OPH
restenosis	NN	o	OPH
rate	NN	o	OPH
was	VBD	O	O
25	CD	O	O
%	NN	O	O
per	IN	O	O
lesion	NN	O	O
and	CC	O	O
29	CD	O	O
%	NN	O	O
per	IN	O	O
patient	NN	O	O
.	.	O	O

There	EX	O	O
were	VBD	O	O
no	DT	O	O
major	JJ	o	OA
bleeding	NN	o	OA
complications	NNS	o	OA
.	.	o	O

In	IN	O	O
the	DT	O	O
control	NN	i	O
group	NN	O	O
46	CD	O	O
(	(	O	O
85	CD	O	O
%	NN	O	O
)	)	O	O
patients	NNS	O	O
were	VBD	O	O
improved	VBN	O	O
by	IN	O	O
at	IN	O	O
least	JJS	O	O
1	CD	O	O
angina	JJ	O	O
class	NN	O	O
and	CC	O	O
31	CD	O	O
(	(	O	O
57	CD	O	O
%	NN	O	O
)	)	O	O
were	VBD	O	O
symptom	JJ	O	O
free	JJ	O	O
;	:	O	O
the	DT	O	O
exercise	NN	o	OOt
test	NN	o	OOt
was	VBD	O	O
positive	JJ	O	O
in	IN	O	O
11	CD	O	O
(	(	O	O
21	CD	O	O
%	NN	O	O
)	)	O	O
patients	NNS	O	O
and	CC	O	O
the	DT	O	O
angiographic	JJ	o	OPH
restenosis	NN	o	OPH
rate	NN	o	OPH
was	VBD	O	O
33	CD	O	O
%	NN	O	O
per	IN	O	O
lesion	NN	O	O
and	CC	O	O
37	CD	O	O
%	NN	O	O
per	IN	O	O
patient	NN	O	O
.	.	O	O

Although	IN	O	O
the	DT	O	O
incidence	NN	O	O
of	IN	O	O
angiographic	JJ	O	O
restenosis	NN	O	O
tended	VBD	O	O
to	TO	O	O
be	VB	O	O
lower	JJR	O	O
with	IN	O	O
warfarin	NN	i	IPM
,	,	O	O
none	NN	O	O
of	IN	O	O
these	DT	O	O
differences	NNS	O	O
was	VBD	O	O
significant	JJ	O	O
.	.	O	O

These	DT	O	O
data	NNS	O	O
suggest	VBP	O	O
that	IN	O	O
the	DT	O	O
combination	NN	O	O
of	IN	O	O
verapamil	NN	i	IPM
and	CC	O	O
warfarin	NN	i	IPM
,	,	O	O
in	IN	O	O
the	DT	O	O
absence	NN	O	O
of	IN	O	O
aspirin	NN	i	IPM
,	,	O	O
is	VBZ	O	O
not	RB	O	O
significantly	RB	O	O
better	JJR	O	O
than	IN	O	O
verapamil	NN	O	O
alone	RB	O	O
in	IN	O	O
preventing	VBG	O	O
symptom	JJ	O	O
recurrence	NN	O	O
or	CC	O	O
angiographic	JJ	o	OPH
restenosis	NN	o	OPH
after	IN	O	O
coronary	JJ	O	O
angioplasty	NN	O	O
.	.	O	O

Evaluation	NN	O	O
of	IN	O	O
a	DT	O	O
new	JJ	i	IE
computer	NN	i	IE
intervention	NN	i	IE
to	TO	O	O
teach	VB	O	O
people	NNS	p	O
with	IN	p	O
autism	NN	p	PC
or	CC	p	O
Asperger	NNP	p	PC
syndrome	VBP	p	PC
to	TO	O	O
recognize	VB	O	O
and	CC	O	O
predict	VB	O	O
emotions	NNS	O	O
in	IN	O	O
others	NNS	O	O
.	.	O	O

This	DT	O	O
randomized	VBD	O	O
controlled	JJ	O	O
trial	NN	O	O
looked	VBD	O	O
at	IN	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
a	DT	O	O
new	JJ	i	IE
computer	NN	i	IE
program	NN	i	IE
designed	VBN	O	O
to	TO	O	O
teach	VB	O	O
people	NNS	p	O
with	IN	p	O
autistic	JJ	p	PC
spectrum	NN	p	PC
disorders	NNS	p	PC
to	TO	O	O
better	JJR	O	O
recognize	VB	O	O
and	CC	O	O
predict	VBP	O	O
emotional	JJ	O	O
responses	NNS	O	O
in	IN	O	O
others	NNS	O	O
.	.	O	O

Two	CD	p	O
groups	NNS	p	O
of	IN	p	O
11	CD	p	PSS
children	NNS	p	PA
(	(	p	O
age	NN	p	PA
12-18	CD	p	PA
)	)	p	O
with	IN	p	O
autism	NN	p	O
or	CC	p	O
Asperger	NNP	p	O
syndrome	VBP	p	O
at	IN	p	O
two	CD	p	O
special	JJ	p	O
schools	NNS	p	O
participated	VBD	p	O
:	:	p	O
one	CD	i	IE
group	NN	i	IE
used	VBD	i	IE
the	DT	i	IE
computer	NN	i	IE
program	NN	i	IE
for	IN	i	IE
10	CD	i	IE
half-hour	JJ	i	IE
sessions	NNS	i	IE
over	IN	i	IE
2	CD	i	IE
weeks	NNS	i	IE
.	.	i	O

Within-program	NNP	O	O
data	NN	O	O
showed	VBD	O	O
a	DT	O	O
significant	JJ	O	O
reduction	NN	O	O
in	IN	O	O
errors	NNS	O	O
made	VBN	O	O
from	IN	O	O
first	JJ	O	O
to	TO	O	O
last	JJ	O	O
use	NN	O	O
.	.	O	O

Students	NNS	O	O
were	VBD	O	O
assessed	VBN	O	O
pre-	JJ	O	O
and	CC	O	O
post-intervention	NN	O	O
using	VBG	O	O
facial	JJ	o	OME
expression	NN	o	OME
photographs	NN	o	OME
,	,	o	OOt
cartoons	NNS	o	OME
depicting	VBG	o	OME
emotion-laden	JJ	o	OME
situations	NNS	o	OME
,	,	o	OOt
and	CC	o	OOt
non-literal	JJ	o	OME
stories	NNS	o	OME
.	.	o	O

Scores	NNS	O	O
were	VBD	O	O
not	RB	O	O
related	VBN	O	O
to	TO	O	O
age	NN	O	O
or	CC	O	O
verbal	JJ	O	O
ability	NN	O	O
.	.	O	O

The	DT	O	O
experimental	JJ	O	O
group	NN	O	O
made	VBD	O	O
gains	NNS	O	O
relative	JJ	O	O
to	TO	O	O
the	DT	O	O
control	NN	O	O
group	NN	O	O
on	IN	O	O
all	DT	O	O
three	CD	O	O
measures	NNS	O	O
.	.	O	O

Gains	NNP	O	O
correlated	VBD	O	O
significantly	RB	O	O
with	IN	O	O
the	DT	O	O
number	NN	O	O
of	IN	O	O
times	NNS	O	O
the	DT	O	O
computer	NN	i	IE
program	NN	i	IE
was	VBD	O	O
used	VBN	O	O
and	CC	O	O
results	NNS	O	O
suggest	VBP	O	O
positive	JJ	O	O
effects	NNS	O	O
.	.	O	O

Further	NNP	O	O
research	NN	O	O
could	MD	O	O
assess	VB	O	O
whether	IN	O	O
these	DT	O	O
gains	NNS	O	O
generalized	VBD	O	O
into	IN	O	O
real	JJ	O	O
life	NN	O	O
or	CC	O	O
improved	VBN	O	O
performance	NN	O	O
on	IN	O	O
theory	NN	O	O
of	IN	O	O
mind	NN	O	O
measures	NNS	O	O
.	.	O	O

Risperidone	NN	i	IPM
in	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
negative	JJ	o	OME
symptoms	NNS	o	OME
of	IN	O	O
schizophrenia	NN	p	O
:	:	p	O
a	DT	O	O
meta-analysis	NN	O	O
.	.	O	O

Risperidone	NN	i	IPM
has	VBZ	O	O
antiserotonergic	VBN	O	O
and	CC	O	O
antidopaminergic	JJ	O	O
properties	NNS	O	O
that	WDT	O	O
may	MD	O	O
make	VB	O	O
it	PRP	O	O
more	RBR	O	O
effective	JJ	O	O
than	IN	O	O
conventional	JJ	O	O
antipsychotic	JJ	O	O
agents	NNS	O	O
in	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
the	DT	O	O
negative	JJ	o	OME
symptoms	NNS	o	OME
of	IN	O	O
schizophrenia	NN	p	O
.	.	p	O

Clinical	JJ	O	O
trials	NNS	O	O
in	IN	O	O
chronic	JJ	p	O
schizophrenic	JJ	p	O
patients	NNS	p	O
have	VBP	O	O
shown	VBN	O	O
trends	NNS	O	O
in	IN	O	O
favor	NN	O	O
of	IN	O	O
risperidone	NN	i	IPM
in	IN	O	O
the	DT	O	O
control	NN	O	O
of	IN	O	O
negative	JJ	o	OME
symptoms	NNS	o	OME
compared	VBN	O	O
with	IN	O	O
haloperidol	NN	i	IPM
,	,	i	O
perphenazine	NN	i	IPM
or	CC	i	O
zuclopenthixol	NN	i	IPM
,	,	O	O
but	CC	O	O
the	DT	O	O
differences	NNS	O	O
were	VBD	O	O
not	RB	O	O
consistently	RB	O	O
statistically	RB	O	O
significant	JJ	O	O
.	.	O	O

A	DT	O	O
meta-analysis	NN	O	O
of	IN	O	O
the	DT	O	O
pooled	JJ	O	O
results	NNS	O	O
from	IN	O	O
six	CD	p	O
double-blind	JJ	p	O
trials	NNS	p	O
showed	VBD	O	O
that	IN	O	O
risperidone	NN	i	IPM
at	IN	O	O
doses	NNS	O	O
ranging	VBG	O	O
from	IN	O	O
4	CD	O	O
to	TO	O	O
8	CD	O	O
mg/day	NN	O	O
had	VBD	O	O
a	DT	O	O
significantly	RB	O	O
(	(	O	O
p	JJ	O	O
<	NNP	O	O
0.004	CD	O	O
)	)	O	O
higher	JJR	O	O
negative	JJ	o	OME
symptom	JJ	o	OME
response	NN	o	OME
rate	NN	o	OME
,	,	O	O
defined	VBN	O	O
as	IN	O	O
the	DT	O	O
percentage	NN	O	O
of	IN	O	O
patients	NNS	O	O
with	IN	O	O
a	DT	O	O
20	CD	O	O
%	NN	O	O
or	CC	O	O
more	JJR	o	OPA
reduction	NN	o	OPA
in	IN	o	OPA
scores	NNS	o	OPA
on	IN	o	OPA
the	DT	o	OPA
negative	JJ	o	OPA
subscale	NN	o	OPA
of	IN	o	OPA
the	DT	o	OPA
Positive	NNP	o	OOt
and	CC	o	OOt
Negative	NNP	o	OOt
Syndrome	NNP	o	OOt
Scale	NNP	o	OOt
,	,	O	O
than	IN	O	O
patients	NNS	O	O
receiving	VBG	O	O
active	JJ	O	O
controls	NNS	O	O
.	.	O	O

The	DT	O	O
combined	JJ	p	O
patient	JJ	p	O
population	NN	p	O
treated	VBN	O	O
with	IN	O	O
4-8	JJ	O	O
mg/day	NN	O	O
of	IN	O	O
risperidone	NN	i	IPM
was	VBD	O	O
1.43	CD	O	O
times	NNS	O	O
more	RBR	O	O
likely	JJ	O	O
to	TO	O	O
have	VB	O	O
had	VBN	O	O
a	DT	O	O
clinical	JJ	o	OME
response	NN	o	OME
on	IN	o	OME
the	DT	o	OME
negative	JJ	o	OME
symptom	NN	o	OME
subscale	NN	o	OME
than	IN	O	O
the	DT	O	O
combined	JJ	O	O
population	NN	O	O
treated	VBN	O	O
with	IN	O	O
haloperidol	NN	i	IPM
,	,	i	O
perphenazine	NN	i	IPM
or	CC	i	O
zuclopenthixol	NN	i	IPM
.	.	i	O

Efficacy	NN	o	OOt
of	IN	O	O
a	DT	O	O
barrier	NN	i	IPH
cream	NN	i	IPH
and	CC	i	O
its	PRP$	i	IPH
vehicle	NN	i	IPH
as	IN	O	O
protective	JJ	O	O
measures	NNS	O	O
against	IN	O	O
occupational	JJ	o	OPH
irritant	JJ	o	OPH
contact	NN	o	OPH
dermatitis	NN	o	OPH
.	.	o	O

The	DT	O	O
actual	JJ	O	O
advantage	NN	O	O
of	IN	O	O
barrier	NN	i	IPM
creams	NNS	i	IPM
over	IN	O	O
bland	NN	O	O
emollients	NNS	O	O
for	IN	O	O
skin	NN	O	O
protection	NN	O	O
is	VBZ	O	O
still	RB	O	O
hotly	RB	O	O
debated	VBN	O	O
.	.	O	O

In	IN	O	O
a	DT	O	O
randomized	JJ	O	O
,	,	O	O
double-blinded	JJ	O	O
study	NN	O	O
,	,	O	O
a	DT	O	O
newly-introduced	JJ	O	O
barrier	NN	i	IPM
cream	NN	i	IPM
and	CC	O	O
its	PRP$	O	O
moisturizing	NN	i	IPM
vehicle	NN	i	IPM
were	VBD	O	O
compared	VBN	O	O
regarding	VBG	O	O
their	PRP$	O	O
skin	NN	o	OPH
compatibility	NN	o	OPH
,	,	o	OPH
efficacy	NN	o	OPH
and	CC	o	OPH
resulting	VBG	o	OPH
acceptance	NN	o	OPH
.	.	o	O

Thus	NNP	O	O
,	,	O	O
2	CD	p	PSS
panels	NNS	p	PSS
of	IN	p	O
25	CD	p	PSS
hospital	NN	p	PSS
nurses	NNS	p	O
with	IN	p	O
mild	JJ	p	O
signs	NNS	p	O
of	IN	p	O
skin	JJ	p	PC
irritation	NN	p	PC
were	VBD	O	O
asked	VBN	O	O
to	TO	O	O
use	VB	O	O
1	CD	O	O
of	IN	O	O
the	DT	O	O
test	NN	O	O
products	NNS	O	O
provided	VBN	O	O
(	(	i	O
verum	NN	i	IPH
or	CC	i	IPH
vehicle	NN	i	IPH
)	)	i	IPH
over	IN	i	IPH
a	DT	i	IPH
period	NN	i	IPH
of	IN	i	IPH
4	CD	i	IPH
weeks	NNS	i	IPH
.	.	i	O

Effects	NNS	O	O
of	IN	O	O
both	DT	O	O
types	NNS	O	O
of	IN	O	O
preparations	NNS	O	O
were	VBD	O	O
studied	VBN	O	O
weekly	JJ	O	O
by	IN	O	O
clinical	JJ	O	O
examination	NN	O	O
and	CC	O	O
the	DT	O	O
instrumental	JJ	O	O
assessment	NN	O	O
of	IN	O	O
bioengineering	VBG	O	O
parameters	NNS	O	O
.	.	O	O

Results	NNS	O	O
showed	VBD	O	O
no	DT	O	O
significant	JJ	O	O
differences	NNS	O	O
between	IN	O	O
barrier	NN	i	IPM
cream	NN	i	IPM
and	CC	O	O
vehicle	NN	i	IPH
.	.	i	O

In	IN	O	O
both	DT	O	O
groups	NNS	O	O
,	,	O	O
clinical	JJ	o	OPH
skin	NN	o	OPH
status	NN	o	OPH
improved	VBN	O	O
and	CC	O	O
stratum	JJ	o	OPH
corneum	NN	o	OPH
hydration	NN	o	OPH
increased	VBD	O	O
significantly	RB	O	O
during	IN	O	O
the	DT	O	O
study	NN	O	O
period	NN	O	O
.	.	O	O

Both	DT	O	O
preparations	NNS	O	O
were	VBD	O	O
tolerated	VBN	o	OOt
and	CC	o	OPH
accepted	VBN	o	OPH
well	RB	o	OPH
,	,	O	O
thus	RB	O	O
showing	VBG	O	O
both	DT	O	O
skin	JJ	o	OPH
protection	NN	o	OPH
and	CC	o	OPH
skin	NN	o	OPH
care	NN	o	OPH
.	.	o	OPH

These	DT	O	O
results	NNS	O	O
contribute	VBP	O	O
to	TO	O	O
the	DT	O	O
debate	NN	O	O
as	IN	O	O
to	TO	O	O
whether	IN	O	O
a	DT	O	O
strict	JJ	O	O
distinction	NN	O	O
between	IN	O	O
skin	NN	O	O
care	NN	O	O
and	CC	O	O
skin	NN	O	O
protection	NN	O	O
products	NNS	O	O
is	VBZ	O	O
justified	JJ	O	O
.	.	O	O

The	DT	O	O
vehicle	NN	i	IPM
alone	RB	O	O
is	VBZ	O	O
capable	JJ	O	O
of	IN	O	O
positively	RB	O	O
influencing	VBG	O	O
skin	NN	O	O
status	NN	O	O
.	.	O	O

Emphasis	NN	O	O
must	MD	O	O
be	VB	O	O
laid	VBN	O	O
on	IN	O	O
regular	JJ	O	O
,	,	O	O
frequent	JJ	O	O
,	,	O	O
and	CC	O	O
correct	JJ	O	O
application	NN	O	O
of	IN	O	O
a	DT	O	O
product	NN	O	O
for	IN	O	O
it	PRP	O	O
to	TO	O	O
be	VB	O	O
effective	JJ	O	O
.	.	O	O

[	JJ	O	O
Comparison	NNP	O	O
between	IN	O	O
anterior	JJ	i	IPH
rhinomanometry	NN	i	IPH
and	CC	O	O
impulse-oscillometric	JJ	i	IPH
rhinometry	NN	i	IPH
found	VBD	O	O
within	IN	O	O
nasal	JJ	o	OPH
allergen	JJ	o	OPH
provocation	NN	o	OPH
]	NNP	o	O
.	.	O	O

UNLABELLED	NNP	O	O
Besides	IN	O	O
the	DT	O	O
standard	JJ	O	O
method	NN	O	O
of	IN	O	O
anterior	JJ	i	IPH
rhinomanometry	NN	i	IPH
(	(	i	IPH
aR	NN	i	IPH
)	)	i	IPH
,	,	i	IPH
the	DT	i	IPH
impulse-oscillometric	JJ	i	IPH
rhinometry	NN	i	IPH
(	(	i	IPH
IOS	NNP	i	IPH
)	)	i	IPH
is	VBZ	O	O
available	JJ	O	O
for	IN	O	O
measurements	NNS	O	O
of	IN	O	O
the	DT	O	O
nasal	JJ	o	OPH
resistance	NN	o	OPH
.	.	o	O

The	DT	O	O
aR	NN	O	O
is	VBZ	O	O
a	DT	O	O
procedure	NN	O	O
dependent	NN	O	O
on	IN	O	O
the	DT	O	O
cooperation	NN	O	O
of	IN	O	O
the	DT	O	O
patient	NN	O	O
,	,	O	O
whereas	JJ	O	O
IOS	NNP	O	O
is	VBZ	O	O
measured	VBN	O	O
regardless	RB	O	O
from	IN	O	O
the	DT	O	O
breathing	NN	O	O
activities	NNS	O	O
of	IN	O	O
the	DT	O	O
patient	NN	O	O
.	.	O	O

We	PRP	O	O
examined	VBD	O	O
weather	RP	O	O
the	DT	O	O
resistance-measurement	NN	O	O
by	IN	O	O
means	NNS	O	O
of	IN	O	O
IOS	NNP	O	O
in	IN	O	O
comparison	NN	O	O
to	TO	O	O
the	DT	O	O
aR	NN	O	O
is	VBZ	O	O
a	DT	O	O
more	RBR	O	O
suitable	JJ	O	O
method	NN	O	O
for	IN	O	O
nasal	JJ	o	OPH
allergic	JJ	o	OPH
provocation	NN	o	OPH
.	.	o	O

METHOD	NNP	O	O
17	CD	p	PSS
patients	NNS	p	O
with	IN	p	O
anamnestic	JJ	p	O
known	VBN	p	O
rhinokonjunktivitis	NN	p	PC
(	(	p	O
6	CD	p	O
f	NN	p	O
,	,	p	O
11	CD	p	O
m	NN	p	O
)	)	p	O
had	VBD	p	O
a	DT	p	O
pricktest	NN	i	IPM
and	CC	p	O
then	RB	p	O
a	DT	p	O
nasal	JJ	i	IPM
provocation	NN	i	IPM
testing	VBG	i	IPM
with	IN	p	O
an	DT	p	O
allergen	NN	p	O
which	WDT	p	O
provoked	VBD	p	O
a	DT	p	O
reaction	NN	p	O
on	IN	p	O
the	DT	p	O
skin	NN	p	O
.	.	p	O

The	DT	O	O
complete	JJ	O	O
resistance	NN	o	OPH
of	IN	O	O
the	DT	O	O
nose	NN	O	O
was	VBD	O	O
measured	VBN	O	O
in	IN	O	O
a	DT	O	O
randomized	JJ	O	O
order	NN	O	O
by	IN	O	O
means	NNS	O	O
of	IN	O	O
aR	NN	i	IPM
and	CC	i	IPM
IOS	NNP	i	IPM
.	.	i	IPM

RESULTS	VB	O	O
The	DT	O	O
complete	JJ	o	OPH
resistance	NN	o	OPH
showed	VBD	O	O
neither	CC	O	O
in	IN	O	O
the	DT	O	O
basic	JJ	O	O
measurement	NN	O	O
(	(	O	O
aR	JJ	O	O
0,38	CD	O	O
+/-	JJ	O	O
0,14	CD	O	O
kPa/l/s	NN	O	O
;	:	O	O
IOS	NNP	O	O
0,38	CD	O	O
+/-	JJ	O	O
0,11	CD	O	O
kPa/l/s	NN	O	O
)	)	O	O
nor	CC	O	O
in	IN	O	O
the	DT	O	O
control	NN	O	O
solution	NN	O	O
(	(	O	O
aR	JJ	O	O
0,38	CD	O	O
+/-	JJ	O	O
0,14	CD	O	O
;	:	O	O
IOS	NNP	O	O
0,39	CD	O	O
+/-	JJ	O	O
0,14	CD	O	O
)	)	O	O
nor	CC	O	O
after	IN	O	O
application	NN	O	O
of	IN	O	O
the	DT	O	O
allergenic	JJ	O	O
solution	NN	O	O
(	(	O	O
15	CD	O	O
min	NN	O	O
:	:	O	O
aR	JJ	O	O
0,69	CD	O	O
+/-	JJ	O	O
0,27	CD	O	O
;	:	O	O
IOS	NNP	O	O
0,77	CD	O	O
+/-	JJ	O	O
0,42	CD	O	O
;	:	O	O
30	CD	O	O
min	NN	O	O
:	:	O	O
aR	JJ	O	O
0,65	CD	O	O
+/-	JJ	O	O
0,29	CD	O	O
;	:	O	O
IOS	NNP	O	O
0,6	CD	O	O
+/-	JJ	O	O
0,38	CD	O	O
)	)	O	O
a	DT	O	O
significant	JJ	O	O
difference	NN	O	O
between	IN	O	O
the	DT	O	O
two	CD	O	O
methods	NNS	O	O
.	.	O	O

The	DT	O	O
results	NNS	O	O
of	IN	O	O
the	DT	O	O
measurement	NN	o	OPH
of	IN	o	OPH
aR	NN	o	OPH
and	CC	o	OPH
IOS	NNP	o	OPH
after	IN	O	O
the	DT	O	O
allergenic	JJ	O	O
solution	NN	O	O
showed	VBD	O	O
a	DT	O	O
positive	JJ	O	O
correlation	NN	o	OPH
(	(	O	O
15	CD	O	O
min	NN	O	O
:	:	O	O
r	NN	O	O
=	VBZ	O	O
0,63	CD	O	O
,	,	O	O
p	NN	O	O
<	VBD	O	O
0,01	CD	O	O
;	:	O	O
30	CD	O	O
min	NN	O	O
:	:	O	O
r	NN	O	O
=	VBZ	O	O
0,67	CD	O	O
,	,	O	O
p	NN	O	O
<	NNP	O	O
0,01	CD	O	O
)	)	O	O
.	.	O	O

We	PRP	O	O
found	VBD	O	O
by	IN	O	O
means	NNS	O	O
of	IN	O	O
clinic	NN	O	O
and	CC	O	O
measurement	NN	O	O
methods	NNS	O	O
in	IN	O	O
the	DT	O	O
aR	NN	O	O
of	IN	O	O
7	CD	p	PSS
patients	NNS	p	O
a	DT	p	O
positive	JJ	p	O
reaction	NN	o	O
,	,	p	O
within	IN	p	O
7	CD	p	O
patient	NN	p	O
a	DT	p	O
negative	JJ	p	O
reaction	NN	o	O
,	,	p	O
3	CD	p	O
patients	NNS	p	O
had	VBD	p	O
a	DT	p	O
unspecific	JJ	o	OPH
nasal	NN	o	OPH
hyperreactivity	NN	o	OPH
.	.	o	O

There	EX	O	O
was	VBD	O	O
a	DT	O	O
correspondence	NN	O	O
in	IN	O	O
6	CD	p	O
of	IN	p	O
the	DT	p	O
7	CD	p	O
patients	NNS	p	O
with	IN	p	O
positive	JJ	p	O
reaction	NN	o	O
in	IN	p	O
aR	NN	p	O
between	IN	O	O
both	DT	O	O
methods	NNS	O	O
.	.	O	O

4	CD	O	O
of	IN	p	O
the	DT	p	O
7	CD	p	O
results	NNS	p	O
with	IN	p	O
negative	JJ	p	O
reaction	NN	o	O
in	IN	O	O
the	DT	O	O
aR	NN	O	O
would	MD	O	O
have	VB	O	O
been	VBN	O	O
positive	JJ	O	O
then	RB	O	O
underlying	VBG	O	O
the	DT	O	O
same	JJ	O	O
criteria	NNS	O	O
in	IN	O	O
the	DT	O	O
IOS	NNP	O	O
without	IN	O	O
announcing	VBG	O	O
the	DT	O	O
symptomscore	NN	o	OPH
a	DT	O	O
relevant	JJ	O	O
clinical	JJ	O	O
symptomatic	NN	O	O
while	IN	O	O
testing	VBG	O	O
.	.	O	O

CONCLUSION	NNP	O	O
IOS	NNP	i	O
is	VBZ	O	O
a	DT	O	O
suitable	JJ	O	O
procedure	NN	O	O
for	IN	O	O
nasal	JJ	O	O
provocation	NN	O	O
testing	VBG	O	O
and	CC	O	O
provides	VBZ	O	O
results	NNS	O	O
similar	JJ	O	O
to	TO	O	O
the	DT	O	O
aR	NN	O	O
.	.	O	O

In	IN	O	O
comparison	NN	O	O
to	TO	O	O
aR	VB	O	O
IOS	NNP	O	O
is	VBZ	O	O
not	RB	O	O
dependent	JJ	O	O
on	IN	O	O
the	DT	O	O
patients	NNS	O	O
cooperation	NN	O	O
.	.	O	O

Due	NNP	O	O
to	TO	O	O
its	PRP$	O	O
higher	JJR	O	O
sensitivity	NN	O	O
the	DT	O	O
valid	JJ	O	O
limits	NNS	O	O
of	IN	O	O
the	DT	O	O
aR	NN	O	O
at	IN	O	O
provocation	NN	O	O
testings	NNS	O	O
can	MD	O	O
not	RB	O	O
be	VB	O	O
transferred	VBN	O	O
to	TO	O	O
IOS	NNP	O	O
to	TO	O	O
avoid	VB	O	O
a	DT	O	O
false	JJ	o	OPH
positive	JJ	o	OPH
reaction	NN	o	OPH
.	.	o	O

New	NNP	O	O
hope	NN	O	O
for	IN	O	O
children	NNS	p	PA
with	IN	p	O
Kawasaki	NNP	p	PC
disease	NN	p	O
.	.	p	O

Kawasaki	NNP	O	O
disease	NN	O	O
is	VBZ	O	O
now	RB	O	O
the	DT	O	O
most	RBS	O	O
common	JJ	O	O
cause	NN	O	O
of	IN	O	O
acquired	VBN	p	O
heart	NN	p	PC
disease	NN	p	O
in	IN	p	O
America	NNP	p	O
's	POS	p	O
children	NNS	p	O
.	.	p	O

It	PRP	O	O
is	VBZ	O	O
an	DT	O	O
acute	JJ	O	O
febrile	NN	O	O
illness	NN	O	O
that	WDT	O	O
may	MD	O	O
cause	VB	O	O
coronary	JJ	O	O
artery	NN	O	O
aneurysm	NN	O	O
formation	NN	O	O
in	IN	O	O
infected	JJ	p	O
children	NNS	p	O
.	.	p	O

The	DT	O	O
results	NNS	O	O
of	IN	O	O
a	DT	O	O
multicenter	NN	O	O
,	,	O	O
randomized	VBN	O	O
trial	NN	O	O
on	IN	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
intravenous	JJ	i	IPM
administration	NN	i	IPM
of	IN	i	IPM
gamma	JJ	i	IPM
globulin	NN	i	IPM
(	(	i	IPM
IVGG	NNP	i	IPM
)	)	i	IPM
plus	CC	i	O
aspirin	JJ	i	IPM
versus	NN	i	O
aspirin	NN	i	IPM
alone	RB	i	IPM
upon	IN	O	O
coronary	JJ	O	O
aneurysm	NN	O	O
formation	NN	O	O
show	VBP	O	O
a	DT	O	O
decrease	NN	O	O
in	IN	O	O
coronary	JJ	o	OPH
aneurysm	NN	o	OPH
formation	NN	o	OPH
from	IN	O	O
the	DT	O	O
usual	JJ	O	O
20	CD	O	O
%	NN	O	O
-30	NN	O	O
%	NN	O	O
to	TO	O	O
3	CD	O	O
%	NN	O	O
.	.	O	O

Administration	NNP	O	O
of	IN	O	O
IVGG	NNP	i	IPM
presents	VBZ	O	O
some	DT	O	O
unique	JJ	O	O
challenges	NNS	O	O
for	IN	O	O
nurses	NNS	O	O
.	.	O	O

Also	RB	O	O
,	,	O	O
the	DT	O	O
pediatric	JJ	O	O
nurse	NN	O	O
must	MD	O	O
educate	VB	O	O
parents	NNS	O	O
and	CC	O	O
children	NNS	p	O
about	IN	O	O
this	DT	O	O
disease	NN	O	O
to	TO	O	O
prepare	VB	O	O
them	PRP	O	O
for	IN	O	O
discharge	NN	O	O
and	CC	O	O
long-term	JJ	O	O
follow-up	JJ	O	O
care	NN	O	O
.	.	O	O

Cardiovascular	JJ	O	O
effects	NNS	O	O
of	IN	O	O
non-depolarizing	JJ	i	IPM
neuromuscular	JJ	i	IPM
blockers	NNS	i	IPM
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
aortic	JJ	p	O
valve	NN	p	O
disease	NN	p	O
.	.	p	O

To	TO	O	O
compare	VB	O	O
haemodynamic	JJ	O	O
responses	NNS	O	O
associated	VBN	O	O
with	IN	O	O
equipotent	JJ	O	O
doses	NNS	O	O
of	IN	O	O
neuromuscular	JJ	i	IPM
blockers	NNS	i	IPM
and	CC	O	O
high-dose	JJ	O	O
fentanyl	NN	i	IPM
(	(	O	O
50	CD	O	O
micrograms.kg-1	NN	O	O
)	)	O	O
,	,	O	O
40	CD	p	O
patients	NNS	p	O
with	IN	p	O
aortic	JJ	p	O
valve	NNS	p	O
stenosis	NN	p	O
(	(	p	O
AS	IN	p	O
)	)	p	O
and	CC	p	O
20	CD	p	O
patients	NNS	p	O
with	IN	p	O
aortic	JJ	p	O
insufficiency	NN	p	O
(	(	p	O
AI	NNP	p	O
)	)	p	O
were	VBD	O	O
randomized	VBN	O	O
to	TO	O	O
four	CD	O	O
study	NN	O	O
groups	NNS	O	O
to	TO	O	O
receive	VB	O	O
the	DT	O	O
following	NN	O	O
:	:	O	O
(	(	O	O
1	CD	O	O
)	)	O	O
pancuronium	NN	i	IPM
0.12	CD	i	IPM
mg.kg-1	NN	i	IPM
,	,	i	IPM
(	(	i	IPM
2	CD	i	IPM
)	)	i	IPM
vecuronium	NN	i	IPM
0.12	CD	i	IPM
mg.kg-1	NN	i	IPM
,	,	i	O
(	(	i	IPM
3	CD	i	IPM
)	)	i	IPM
atracurium	NN	i	IPM
0.4	CD	i	IPM
mg.kg-1	NN	i	IPM
,	,	i	O
or	CC	i	O
(	(	i	IPM
4	CD	i	IPM
)	)	i	IPM
pancuronium-metocurine	NN	i	IPM
mixture	NN	i	IPM
(	(	O	O
0.4	CD	O	O
mg	NN	O	O
+	VBD	O	O
1.6	CD	O	O
mg/ml	NN	O	O
)	)	O	O
:	:	O	O
1	CD	O	O
ml/10	NNS	O	O
kg	NN	O	O
)	)	O	O
.	.	O	O

Neuromuscular	JJ	i	IPM
blockers	NNS	i	IPM
were	VBD	O	O
injected	VBN	O	O
at	IN	O	O
the	DT	O	O
same	JJ	O	O
time	NN	O	O
with	IN	O	O
the	DT	O	O
fentanyl	NN	i	IPM
;	:	i	O
haemodynamics	NNS	O	O
were	VBD	O	O
recorded	VBN	O	O
with	IN	O	O
the	DT	O	O
patients	NNS	O	O
awake	VBP	O	O
(	(	O	O
baseline	NN	O	O
)	)	O	O
,	,	O	O
at	IN	O	O
two	CD	O	O
minutes	NNS	O	O
post-induction	NN	O	O
,	,	O	O
and	CC	O	O
at	IN	O	O
two	CD	O	O
and	CC	O	O
five	CD	O	O
minutes	NNS	O	O
after	IN	O	O
intubation	NN	O	O
.	.	O	O

In	IN	O	O
patients	NNS	O	O
with	IN	O	O
AS	NNP	O	O
,	,	O	O
pancuronium	NN	i	IPM
increased	VBD	O	O
heart	NN	o	OPH
rate	NN	o	OPH
more	JJR	O	O
than	IN	O	O
vecuronium	NN	i	IPM
or	CC	O	O
atracurium	NN	i	IPM
;	:	i	O
heart	NN	o	OPH
rates	NNS	o	OPH
were	VBD	O	O
also	RB	O	O
higher	JJR	o	O
with	IN	O	O
the	DT	O	O
pancuronium-metocurine	JJ	i	IPM
mixture	NN	i	IPM
than	IN	O	O
with	IN	O	O
vecuronium	NN	i	IPM
.	.	i	O

Although	IN	O	O
there	EX	O	O
were	VBD	O	O
no	DT	O	O
ECG	NNP	o	OPH
signs	NNS	o	OPH
of	IN	o	OPH
ischaemia	NN	o	OPH
,	,	O	O
one	CD	O	O
patient	NN	O	O
given	VBN	O	O
pancuronium	NN	O	O
developed	VBD	O	O
severe	JJ	o	OPH
hypotension	NN	o	OPH
associated	VBN	o	OPH
with	IN	o	OPH
tachycardia	NN	o	OPH
.	.	o	O

Reductions	NNS	O	O
in	IN	O	O
SVR	NNP	o	OPH
after	IN	O	O
atracurium	NN	O	O
allowed	VBD	O	O
small	JJ	O	O
but	CC	O	O
significant	JJ	O	O
(	(	O	O
p	NN	O	O
less	JJR	O	O
than	IN	O	O
0.01	CD	O	O
)	)	O	O
decreases	NNS	O	O
in	IN	O	O
MAP	NNP	o	OPH
which	WDT	O	O
were	VBD	O	O
well	RB	o	OOt
tolerated	VBN	o	OOt
;	:	o	O
one	CD	O	O
patient	NN	O	O
,	,	O	O
however	RB	O	O
,	,	O	O
did	VBD	O	O
develop	VB	O	O
severe	JJ	o	OPH
hypotension	NN	o	OPH
.	.	o	O

Intubation	NNP	O	O
resulted	VBD	O	O
in	IN	O	O
significant	JJ	O	O
(	(	O	O
p	NN	O	O
less	JJR	O	O
than	IN	O	O
0.01	CD	O	O
)	)	O	O
increases	NNS	O	O
in	IN	O	O
MAP	NNP	o	OPH
in	IN	O	O
the	DT	O	O
pancuronium-metocurine	JJ	i	IPM
mixture	NN	O	O
group	NN	O	O
.	.	O	O

Vecuronium	NNP	i	IPM
permitted	VBD	O	O
the	DT	O	O
most	RBS	O	O
stable	JJ	O	O
overall	JJ	o	OPH
haemodynamic	JJ	o	OPH
course	NN	o	OPH
at	IN	O	O
all	DT	O	O
measurement	JJ	O	O
times	NNS	O	O
.	.	O	O

In	IN	O	O
contrast	NN	O	O
,	,	O	O
patients	NNS	O	O
with	IN	O	O
AI	NNP	O	O
showed	VBD	O	O
stable	JJ	o	OPH
haemodynamics	NNS	o	OPH
after	IN	O	O
vecuronium	NN	i	IPM
,	,	i	O
pancuronium	NN	i	IPM
and	CC	O	O
the	DT	O	O
pancuronium-metocurine	JJ	i	IPM
mixture	NN	i	IPM
;	:	i	O
one	CD	O	O
patient	NN	O	O
became	VBD	O	O
tachycardic	JJ	o	OPH
following	VBG	O	O
vecuronium	NN	i	IPM
.	.	i	O

Atracurium	NNP	i	IPM
caused	VBD	O	O
unexplained	JJ	O	O
elevations	NNS	o	OPH
in	IN	o	OPH
diastolic	JJ	o	OPH
and	CC	o	OPH
mean	JJ	o	OPH
arterial	NN	o	OPH
pressures	NNS	o	OPH
which	WDT	O	O
were	VBD	O	O
significant	JJ	O	O
when	WRB	O	O
compared	VBN	O	O
to	TO	O	O
vecuronium	VB	i	IPM
(	(	O	O
p	NN	O	O
less	JJR	O	O
than	IN	O	O
0.01	CD	O	O
)	)	O	O
.	.	O	O

These	DT	O	O
results	NNS	O	O
in	IN	O	O
increases	NNS	O	O
in	IN	O	O
PCWP	NNP	o	OPH
;	:	o	O
mean	JJ	o	OPH
PA	NNP	o	OPH
pressures	NNS	o	OPH
and	CC	o	O
CVP	NNP	o	OPH
were	VBD	O	O
also	RB	O	O
increased	VBN	o	OOt
.	.	o	O

These	DT	O	O
effects	NNS	O	O
of	IN	O	O
atracurium	NN	i	IPM
inpatients	NNS	O	O
with	IN	O	O
Al	NNP	O	O
need	VBP	O	O
further	JJ	O	O
evaluation	NN	O	O
.	.	O	O

Couple-responsible	JJ	i	IPS
therapy	NN	i	IPS
process	NN	i	IPS
:	:	i	IPS
positive	JJ	o	OOt
proximal	JJ	o	OOt
outcomes	NNS	o	OOt
.	.	o	OOt

Therapist-couple	JJ	O	O
struggle	NN	O	O
vs.	FW	O	O
cooperation	NN	O	O
is	VBZ	O	O
linked	VBN	O	O
to	TO	O	O
clinical	JJ	O	O
outcome	NN	O	O
.	.	O	O

This	DT	O	O
research	NN	O	O
conceptualizes	NN	O	O
and	CC	O	O
investigates	VBZ	O	O
treatment	NN	O	O
process	NN	O	O
as	IN	O	O
it	PRP	O	O
relates	VBZ	O	O
to	TO	O	O
the	DT	O	O
occurrence	NN	O	O
of	IN	O	O
struggle	NN	O	O
versus	NN	O	O
cooperation	NN	O	O
.	.	O	O

Models	NNS	O	O
of	IN	O	O
couple-responsible	JJ	i	IPS
and	CC	i	IPS
therapist-responsible	JJ	i	IPS
process	NN	i	IPS
in	IN	O	O
couple	NN	i	IPS
therapy	NN	i	IPS
were	VBD	O	O
developed	VBN	O	O
.	.	O	O

Couple-responsible	JJ	i	IPS
process	NN	i	IPS
consists	VBZ	i	IPS
of	IN	i	IPS
enactments	NNS	i	IPS
,	,	i	IPS
accommodation	NN	i	IPS
,	,	i	IPS
and	CC	i	IPS
inductive	JJ	i	IPS
process	NN	i	IPS
.	.	i	IPS

Therapist-responsible	JJ	i	IPS
process	NN	i	IPS
consists	VBZ	i	IPS
of	IN	i	IPS
primary	JJ	i	IPS
therapist-couple	JJ	i	IPS
interaction	NN	i	IPS
,	,	i	IPS
therapist	JJ	i	IPS
interpretation	NN	i	IPS
,	,	i	IPS
and	CC	i	IPS
direct	JJ	i	IPS
instruction	NN	i	IPS
.	.	i	IPS

In	IN	O	O
counterbalanced	JJ	O	O
order	NN	O	O
,	,	O	O
25	CD	p	O
couples	NNS	p	PC
were	VBD	O	O
exposed	VBN	O	O
to	TO	O	O
couple-responsible	JJ	i	IPS
and	CC	i	IPS
therapist-responsible	JJ	i	IPS
episodes	NNS	i	IPS
during	IN	O	O
one	CD	O	O
therapy	NN	O	O
session	NN	O	O
.	.	O	O

Couples	NNP	O	O
reviewed	VBD	O	O
videotapes	NNS	O	O
of	IN	O	O
the	DT	O	O
episodes	NNS	O	O
and	CC	O	O
completed	VBD	O	O
measures	NNS	O	O
of	IN	O	O
responsibility	NN	O	O
,	,	O	O
struggle	NN	O	O
,	,	O	O
and	CC	O	O
cooperation	NN	O	O
.	.	O	O

Perceived	NNP	o	OOt
responsibility	NN	o	OOt
was	VBD	O	O
higher	JJR	O	O
and	CC	O	O
struggle	NN	o	OOt
was	VBD	O	O
lower	JJR	O	O
during	IN	O	O
couple-responsible	JJ	i	IPS
episodes	NNS	i	IPS
.	.	i	IPS

No	DT	O	O
difference	NN	O	O
in	IN	O	O
cooperation	NN	o	OME
was	VBD	O	O
found	VBN	O	O
.	.	O	O

Presence	NN	O	O
or	CC	O	O
absence	NN	O	O
of	IN	O	O
a	DT	O	O
contrast	NN	O	O
condition	NN	O	O
,	,	O	O
where	WRB	O	O
couples	NNS	O	O
reported	VBD	O	O
on	IN	O	O
one	CD	O	O
therapist	NN	i	IPH
process	NN	i	IPH
after	IN	O	O
already	RB	O	O
experiencing	VBG	O	O
its	PRP$	O	O
opposite	NN	O	O
,	,	O	O
led	VBN	O	O
to	TO	O	O
main	JJ	O	O
effects	NNS	O	O
for	IN	O	O
responsibility	NN	O	O
and	CC	O	O
struggle	NN	O	O
,	,	O	O
and	CC	O	O
mediated	VBD	O	O
effects	NNS	O	O
of	IN	O	O
struggle	NN	O	O
and	CC	O	O
cooperation	NN	O	O
.	.	O	O

Generally	NNP	O	O
speaking	NN	O	O
,	,	O	O
responsibility	NN	o	OME
was	VBD	O	O
even	RB	O	O
higher	JJR	O	O
during	IN	O	O
couple-responsible	JJ	i	IPS
episodes	NNS	i	IPS
and	CC	O	O
even	RB	O	O
lower	JJR	O	O
during	IN	O	O
therapist-responsible	JJ	i	IPS
episodes	NNS	i	IPS
when	WRB	O	O
contrast	NN	O	O
was	VBD	O	O
present	JJ	O	O
.	.	O	O

Similarly	RB	O	O
,	,	O	O
struggle	NN	o	OME
was	VBD	O	O
even	RB	O	O
lower	JJR	O	O
during	IN	O	O
couple-responsible	JJ	i	IPS
episodes	NNS	i	IPS
and	CC	O	O
even	RB	O	O
higher	JJR	O	O
during	IN	O	O
therapist-responsible	JJ	i	IPH
episodes	NNS	i	IPH
when	WRB	O	O
contrast	NN	O	O
was	VBD	O	O
present	JJ	O	O
.	.	O	O

For	IN	O	O
both	DT	O	O
couple-responsible	JJ	O	O
and	CC	O	O
therapist-responsible	JJ	O	O
episodes	NNS	O	O
,	,	O	O
cooperation	NN	o	OME
was	VBD	O	O
negatively	RB	O	O
affected	VBN	O	O
by	IN	O	O
a	DT	O	O
shift	NN	O	O
from	IN	O	O
the	DT	O	O
prior	JJ	O	O
,	,	O	O
opposite	JJ	O	O
therapist	NN	O	O
process	NN	O	O
.	.	O	O

Significant	JJ	O	O
proportions	NNS	O	O
of	IN	O	O
the	DT	O	O
variance	NN	O	O
in	IN	O	O
responsibility	NN	o	OME
,	,	o	OME
struggle	NN	o	OME
,	,	o	OME
and	CC	o	OME
cooperation	NN	o	OME
,	,	O	O
however	RB	O	O
,	,	O	O
were	VBD	O	O
not	RB	O	O
accounted	VBN	O	O
for	IN	O	O
by	IN	O	O
therapist	JJ	O	O
process	NN	O	O
alone	RB	O	O
.	.	O	O

Treatment	NN	O	O
of	IN	O	O
whiplash	NN	O	O
associated	VBN	O	O
neck	RB	O	O
pain	VBP	O	O
[	RB	O	O
corrected	VBN	O	O
]	NN	O	O
with	IN	O	O
botulinum	JJ	i	IPM
toxin-A	NN	i	IPM
:	:	i	IPM
a	DT	O	O
pilot	NN	O	O
study	NN	O	O
.	.	O	O

OBJECTIVE	NNP	O	O
Up	NNP	O	O
to	TO	O	O
87	CD	O	O
%	NN	O	O
of	IN	O	O
patients	NNS	O	O
with	IN	O	O
whiplash	NN	O	O
associated	VBN	O	O
disorder	NN	O	O
(	(	O	O
WAD	NNP	O	O
)	)	O	O
have	VBP	O	O
some	DT	O	O
degree	NN	O	O
of	IN	O	O
muscle	NN	O	O
spasm	NN	O	O
that	WDT	O	O
is	VBZ	O	O
contributory	JJ	O	O
to	TO	O	O
both	DT	O	O
pain	NN	O	O
and	CC	O	O
dysfunction	NN	O	O
.	.	O	O

Botulinum	NNP	i	IPM
toxin	NN	i	IPM
A	NNP	i	IPM
(	(	i	IPM
BTX-A	NNP	i	IPM
)	)	i	IPM
produces	VBZ	O	O
prolonged	JJ	O	O
muscle	NN	O	O
relaxation	NN	O	O
that	WDT	O	O
is	VBZ	O	O
dose-dependent	JJ	O	O
and	CC	O	O
can	MD	O	O
be	VB	O	O
easily	RB	O	O
targeted	VBN	O	O
to	TO	O	O
affected	JJ	O	O
muscles	NNS	O	O
.	.	O	O

BTX-A	NNP	O	O
therapy	NN	O	O
may	MD	O	O
be	VB	O	O
an	DT	O	O
effective	JJ	O	O
form	NN	O	O
of	IN	O	O
therapy	NN	O	O
offering	VBG	O	O
an	DT	O	O
alternative	NN	O	O
or	CC	O	O
adjunct	NN	O	O
to	TO	O	O
conventional	JJ	O	O
modalities	NNS	O	O
.	.	O	O

We	PRP	O	O
investigated	VBD	O	O
BTX-A	NNP	i	IPM
as	IN	O	O
therapy	NN	O	O
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
WAD	NNP	p	PC
.	.	p	O

METHODS	NNP	O	O
This	DT	O	O
randomized	VBN	O	O
,	,	O	O
double	JJ	O	O
blind	NN	O	O
,	,	O	O
placebo	NN	i	IC
controlled	VBD	O	O
study	NN	O	O
compares	VBZ	O	O
outcome	JJ	O	O
measures	NNS	O	O
in	IN	O	O
26	CD	p	PSS
patients	NNS	p	O
with	IN	p	O
chronic	JJ	p	PC
neck	NN	p	PC
pain	NN	p	PC
(	(	p	O
WAD-II	NNP	p	O
chronic	NN	p	O
)	)	p	O
subsequent	NN	p	O
to	TO	p	O
a	DT	p	O
motor	NN	p	O
vehicle	NN	p	O
accident	NN	p	O
.	.	p	O

One-half	NN	O	O
of	IN	O	O
the	DT	O	O
patients	NNS	O	O
received	VBD	O	O
100	CD	i	IPM
units	NNS	i	IPM
BTX-A	NNP	i	IPM
,	,	i	IPM
diluted	VBD	i	IPM
in	IN	i	IPM
1	CD	i	IPM
ml	NNS	i	IPM
saline	NN	i	IPM
,	,	i	O
while	IN	i	O
the	DT	i	O
other	JJ	i	IC
half	NN	i	IC
received	VBD	i	IC
just	RB	i	IC
saline	NN	i	IC
(	(	O	O
1	CD	O	O
ml	NN	O	O
)	)	O	O
.	.	O	O

Five	CD	O	O
trigger	NN	O	O
points	NNS	O	O
received	VBD	O	O
0.2	CD	O	O
ml	NNS	O	O
each	DT	O	O
of	IN	O	O
injectant	JJ	O	O
via	IN	O	O
a	DT	O	O
30	CD	O	O
gauge	NN	O	O
needle	NN	O	O
.	.	O	O

Outcome	NNP	O	O
measures	NNS	O	O
included	VBD	O	O
total	JJ	o	OPA
subjective	JJ	o	OPA
neck	NN	o	OPA
,	,	o	OPA
shoulder	NN	o	OPA
,	,	o	OPA
and	CC	o	OPA
head	NN	o	OPA
pain	NN	o	OPA
based	VBN	o	OPA
on	IN	o	OPA
visual	JJ	o	OPA
analog	NN	o	OPA
scales	NNS	o	OPA
;	:	o	O
objective	JJ	o	OPH
total	JJ	o	OPH
range	NN	o	OPH
of	IN	o	OPH
neck	NN	o	OPH
motion	NN	o	OPH
(	(	o	OPH
ROM	NNP	o	OPH
)	)	o	OPH
,	,	o	OPH
and	CC	o	O
the	DT	o	O
Vernon-Mior	NNP	o	OPH
subjective	JJ	o	OPH
function	NN	o	OPH
index	NN	o	OPH
.	.	o	O

Followup	CD	O	O
assessments	NNS	O	O
were	VBD	O	O
carried	VBN	O	O
out	RP	O	O
at	IN	O	O
2	CD	O	O
and	CC	O	O
4	CD	O	O
weeks	NNS	O	O
post-treatment	JJ	O	O
.	.	O	O

RESULTS	NNP	O	O
Fourteen	NNP	p	PSS
subjects	VBZ	p	O
receiving	VBG	p	O
BTX-A	NNP	i	IPM
and	CC	p	O
12	CD	p	O
receiving	NN	p	O
saline	NN	p	O
completed	VBD	p	O
the	DT	p	O
study	NN	p	O
.	.	p	O

The	DT	O	O
treatment	NN	O	O
group	NN	O	O
showed	VBD	O	O
a	DT	O	O
trend	NN	o	O
toward	IN	o	O
improvement	NN	o	O
in	IN	o	O
ROM	NNP	o	OPH
and	CC	o	O
reduction	NN	o	O
in	IN	o	O
pain	NN	o	OPA
at	IN	O	O
2	CD	O	O
weeks	NNS	O	O
post-injection	NN	O	O
.	.	O	O

At	IN	O	O
4	CD	O	O
weeks	NNS	O	O
post-injection	NN	O	O
the	DT	O	O
treatment	NN	O	O
group	NN	O	O
was	VBD	O	O
significantly	RB	O	O
improved	VBN	O	O
from	IN	O	O
preinjection	NN	O	O
levels	NNS	O	O
(	(	O	O
p	VB	O	O
<	RB	O	O
0.01	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
placebo	NN	O	O
group	NN	O	O
showed	VBD	O	O
no	DT	O	O
statistically	RB	O	O
significant	JJ	O	O
changes	NNS	O	O
at	IN	O	O
any	DT	O	O
post-treatment	JJ	O	O
time	NN	O	O
.	.	O	O

The	DT	O	O
Vernon-Mior	JJ	o	OPH
scale	NN	o	OPH
revealed	VBD	O	O
a	DT	O	O
trend	NN	O	O
to	TO	O	O
improvement	NN	o	O
for	IN	O	O
both	DT	O	O
groups	NNS	O	O
.	.	O	O

CONCLUSION	NNP	O	O
BTX-A	NNP	i	IPM
treatment	NN	O	O
of	IN	O	O
subjects	NNS	O	O
with	IN	O	O
chronic	JJ	O	O
WAD	NNP	O	O
II	NNP	O	O
neck	NN	O	O
pain	NN	O	O
resulted	VBD	O	O
in	IN	O	O
a	DT	O	O
significant	JJ	O	O
(	(	O	O
p	JJ	O	O
<	NNP	O	O
0.01	CD	O	O
)	)	O	O
improvement	NN	O	O
in	IN	O	O
ROM	NNP	o	OPH
and	CC	O	O
subjective	JJ	o	OPA
pain	NN	o	OPA
compared	VBN	O	O
to	TO	O	O
a	DT	O	O
placebo	NN	O	O
group	NN	O	O
,	,	O	O
but	CC	O	O
only	RB	O	O
a	DT	O	O
trend	NN	O	O
to	TO	O	O
improvement	NN	O	O
in	IN	O	O
subjective	JJ	o	OPH
functioning	NN	o	OPH
.	.	o	O

Detection	NN	O	O
of	IN	O	O
traumatic	JJ	O	O
arthrotomy	NN	O	O
of	IN	O	O
the	DT	O	O
knee	NN	O	O
using	VBG	O	O
the	DT	O	O
saline	JJ	i	IE
solution	NN	i	IE
load	NN	i	IE
test	NN	i	IE
.	.	i	O

BACKGROUND	IN	O	O
The	DT	O	O
saline	JJ	i	IE
solution	NN	i	IE
load	NN	i	IE
test	NN	i	IE
helps	VBZ	O	O
to	TO	O	O
determine	VB	O	O
if	IN	O	O
a	DT	O	O
wound	NN	O	O
extends	VBZ	O	O
into	IN	O	O
the	DT	O	O
knee	NN	O	O
joint	NN	O	O
.	.	O	O

Little	JJ	O	O
is	VBZ	O	O
known	VBN	O	O
about	IN	O	O
the	DT	O	O
volume	NN	O	O
of	IN	O	O
injected	JJ	O	O
intra-articular	JJ	O	O
saline	NN	i	IPM
solution	NN	i	IPM
that	WDT	O	O
is	VBZ	O	O
needed	VBN	O	O
to	TO	O	O
effectively	RB	O	O
rule	VB	O	O
in	IN	O	O
or	CC	O	O
rule	VB	O	O
out	IN	O	O
a	DT	O	O
traumatic	JJ	O	O
arthrotomy	NN	O	O
of	IN	O	O
the	DT	O	O
knee	NN	O	O
.	.	O	O

The	DT	O	O
purpose	NN	O	O
of	IN	O	O
the	DT	O	O
present	JJ	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
determine	VB	O	O
the	DT	O	O
appropriate	JJ	o	OOt
volume	NN	o	OOt
and	CC	O	O
needle	JJ	o	OOt
location	NN	o	OOt
for	IN	O	O
the	DT	O	O
diagnosis	NN	O	O
of	IN	O	O
a	DT	O	O
traumatic	JJ	O	O
knee	NN	O	O
arthrotomy	NN	O	O
and	CC	O	O
to	TO	O	O
assess	VB	O	O
the	DT	O	O
effect	NN	o	O
of	IN	O	O
associated	JJ	o	O
variables	NNS	o	O
,	,	O	O
including	VBG	O	O
knee	NN	o	O
circumference	NN	o	O
,	,	o	O
body	NN	o	O
mass	NN	o	O
index	NN	o	O
,	,	o	O
and	CC	o	O
sex	NN	o	O
.	.	o	O

METHODS	NNP	O	O
Fifty-six	NNP	p	PSS
consecutive	JJ	p	O
patients	NNS	p	O
scheduled	VBN	p	PC
for	IN	p	PC
knee	NN	p	PC
arthroscopy	NN	p	PC
were	VBD	O	O
enrolled	VBN	O	O
.	.	O	O

A	DT	i	O
standard	JJ	i	O
inferolateral	JJ	i	O
arthroscopic	NN	i	O
portal	NN	i	O
was	VBD	i	O
made	VBN	i	O
with	IN	i	O
a	DT	i	O
single	JJ	i	IPH
stab	NN	i	IPH
incision	NN	i	IPH
with	IN	i	IPH
use	NN	i	IPH
of	IN	i	IPH
a	DT	i	IPH
number-11	JJ	i	IPH
blade	NN	i	IPH
.	.	i	O

Injection	NN	O	O
sites	NNS	O	O
were	VBD	O	O
randomized	VBN	O	O
to	TO	O	O
either	VB	O	O
a	DT	O	O
superomedial	NN	O	O
or	CC	O	O
inferomedial	JJ	O	O
location	NN	O	O
.	.	O	O

The	DT	O	O
injection	NN	i	IPM
of	IN	i	IPM
normal	JJ	i	IPM
saline	JJ	i	IPM
solution	NN	i	IPM
at	IN	i	IPM
a	DT	i	IPM
rate	NN	i	IPM
of	IN	i	IPM
5	CD	i	IPM
mL/sec	NNS	i	IPM
through	IN	i	IPM
an	DT	i	IPM
18-gauge	JJ	i	IPM
needle	NN	i	IPM
was	VBD	O	O
continued	VBN	O	O
while	IN	O	O
the	DT	O	O
knee	NN	O	O
was	VBD	O	O
moved	VBN	O	O
through	IN	O	O
a	DT	O	O
range	NN	O	O
of	IN	O	O
motion	NN	O	O
until	IN	O	O
fluid	NNS	O	O
extravasated	VBN	O	O
from	IN	O	O
the	DT	O	O
iatrogenic	JJ	O	O
laceration	NN	O	O
.	.	O	O

The	DT	O	O
volume	NN	O	O
of	IN	O	O
injected	JJ	O	O
fluid	NN	O	O
was	VBD	O	O
recorded	VBN	O	O
.	.	O	O

RESULTS	VB	O	O
The	DT	O	O
study	NN	O	O
group	NN	O	O
included	VBD	O	O
thirty-one	JJ	p	PSS
female	NN	p	PSE
patients	NNS	p	PSS
and	CC	p	PSS
twenty-five	JJ	p	PSS
male	NN	p	PSE
patients	NNS	p	PSS
with	IN	p	O
a	DT	p	O
combined	JJ	p	O
average	JJ	p	PA
age	NN	p	PA
of	IN	p	PA
fifty	JJ	p	PA
years	NNS	p	PA
and	CC	p	O
an	DT	p	O
average	JJ	o	OPH
body	NN	o	OPH
mass	NN	o	OPH
index	NN	o	OPH
of	IN	p	O
30.9	CD	p	O
.	.	p	O

In	IN	O	O
order	NN	O	O
to	TO	O	O
effectively	RB	O	O
diagnose	VB	o	OOt
50	CD	o	OOt
%	NN	o	OOt
of	IN	o	OOt
the	DT	o	OOt
arthrotomies	NNS	o	OOt
,	,	O	O
75	CD	O	O
mL	NN	O	O
of	IN	O	O
injected	JJ	O	O
fluid	NN	O	O
was	VBD	O	O
needed	VBN	O	O
;	:	O	O
the	DT	O	O
volumes	NNS	o	OOt
that	WDT	o	OOt
were	VBD	o	OOt
needed	VBN	o	OOt
in	IN	o	OOt
order	NN	o	OOt
to	TO	o	OOt
effectively	RB	o	OOt
diagnose	VB	o	OOt
75	CD	o	O
%	NN	o	O
,	,	O	O
90	CD	O	O
%	NN	O	O
,	,	O	O
95	CD	O	O
%	NN	O	O
,	,	O	O
and	CC	O	O
99	CD	O	O
%	NN	O	O
of	IN	O	O
the	DT	O	O
arthrotomies	NNS	o	O
were	VBD	O	O
110	CD	O	O
,	,	O	O
145	CD	O	O
,	,	O	O
155	CD	O	O
,	,	O	O
and	CC	O	O
175	CD	O	O
mL	NN	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

The	DT	O	O
mean	JJ	o	OPH
volumes	NNS	o	OPH
of	IN	o	OPH
injected	JJ	o	OPH
fluid	NN	o	OPH
needed	VBN	o	OPH
for	IN	o	OPH
a	DT	o	OPH
positive	JJ	o	OPH
result	NN	o	OPH
at	IN	o	OPH
the	DT	o	OPH
inferomedial	JJ	o	OPH
and	CC	o	OPH
superomedial	JJ	o	OPH
needle	JJ	o	OPH
locations	NNS	o	OPH
were	VBD	O	O
64.0	CD	O	O
and	CC	O	O
95.2	CD	O	O
mL	NN	O	O
,	,	O	O
respectively	RB	O	O
;	:	O	O
this	DT	O	O
difference	NN	O	O
was	VBD	O	O
significant	JJ	O	O
(	(	O	O
p	JJ	O	O
=	NNP	O	O
0.01	CD	O	O
)	)	O	O
.	.	O	O

There	EX	O	O
was	VBD	O	O
no	DT	o	O
correlation	NN	o	O
between	IN	o	O
necessary	JJ	o	O
injection	NN	o	O
volume	NN	o	O
and	CC	o	O
sex	NN	o	O
,	,	o	O
body	NN	o	O
mass	NN	o	O
index	NN	o	O
,	,	o	O
or	CC	o	O
knee	VB	o	O
circumference	NN	o	O
.	.	o	O

CONCLUSIONS	NNP	O	O
In	IN	O	O
order	NN	O	O
to	TO	O	O
detect	VB	O	O
95	CD	O	O
%	NN	O	O
of	IN	O	O
1-cm	JJ	O	O
inferolateral	JJ	O	O
arthrotomies	NNS	O	O
of	IN	O	O
the	DT	O	O
knee	NN	O	O
with	IN	O	O
use	NN	O	O
of	IN	O	O
the	DT	O	O
saline	JJ	O	O
solution	NN	O	O
load	NN	O	O
test	NN	O	O
,	,	O	O
155	CD	O	O
mL	NN	O	O
must	MD	O	O
be	VB	O	O
injected	VBN	O	O
.	.	O	O

An	DT	O	O
inferomedial	JJ	o	O
injection	NN	o	O
location	NN	o	O
requires	VBZ	O	O
significantly	RB	o	OOt
less	JJR	o	OOt
fluid	NN	o	OOt
than	IN	O	O
a	DT	O	O
superomedial	JJ	o	O
injection	NN	o	O
location	NN	o	O
does	VBZ	O	O
for	IN	O	O
the	DT	O	O
diagnosis	NN	O	O
of	IN	O	O
inferolateral	JJ	O	O
arthrotomies	NNS	O	O
of	IN	O	O
the	DT	O	O
knee	NN	O	O
.	.	O	O

Single	NNP	i	IPH
negative	JJ	i	IPH
colposcopy	NN	i	IPH
:	:	i	O
is	VBZ	O	O
it	PRP	O	O
enough	RB	O	O
to	TO	O	O
rule	VB	O	O
out	IN	O	O
high-grade	JJ	O	O
disease	NN	O	O
?	.	O	O
It	PRP	O	O
has	VBZ	O	O
been	VBN	O	O
proposed	VBN	O	O
that	IN	O	O
women	NNS	p	PSE
who	WP	p	O
have	VBP	p	O
a	DT	p	O
negative	JJ	p	PC
colposcopic	NN	p	PC
examination	NN	p	PC
or	CC	p	PC
who	WP	p	PC
have	VBP	p	PC
no	DT	p	PC
cervical	JJ	p	PC
intraepithelial	JJ	p	PC
neoplasia	NN	p	PC
(	(	p	PC
CIN	NNP	p	PC
)	)	p	PC
on	IN	p	PC
colposcopic	NN	i	IPH
biopsy	NN	i	IPH
can	MD	O	O
be	VB	O	O
safely	RB	O	O
returned	VBN	O	O
to	TO	O	O
routine	VB	O	O
screening	VBG	O	O
with	IN	O	O
the	DT	O	O
next	JJ	O	O
visit	NN	O	O
being	VBG	O	O
three	CD	O	O
or	CC	O	O
five	CD	O	O
years	NNS	O	O
later	RB	O	O
.	.	O	O

We	PRP	O	O
present	JJ	O	O
data	NNS	O	O
regarding	VBG	O	O
551	CD	p	PSS
women	NNS	p	PSE
who	WP	p	O
had	VBD	p	O
colposcopy	NN	i	IPH
in	IN	p	O
Wales	NNP	p	O
for	IN	p	O
a	DT	p	O
low-grade	JJ	p	PC
cytological	JJ	p	PC
abnormality	NN	p	PC
and	CC	p	O
who	WP	p	O
were	VBD	p	O
followed	VBN	p	O
through	IN	p	O
Cervical	NNP	p	O
Screening	NNP	p	O
Wales	NNP	p	O
for	IN	p	O
subsequent	JJ	p	O
CIN	NNP	p	O
.	.	p	O

Of	IN	O	O
436	CD	O	O
women	NNS	O	O
declared	VBD	O	O
CIN	NNP	o	OPH
free	JJ	o	OPH
initially	RB	O	O
,	,	O	O
26	CD	O	O
(	(	O	O
6.0	CD	O	O
%	NN	O	O
)	)	O	O
had	VBD	O	O
high-grade	JJ	o	OPH
CIN	NNP	o	OPH
diagnosed	VBD	O	O
on	IN	O	O
follow-up	NN	O	O
.	.	O	O

We	PRP	O	O
suggest	VBP	O	O
that	IN	O	O
additional	JJ	O	O
screening	NN	O	O
at	IN	O	O
an	DT	O	O
interval	NN	O	O
of	IN	O	O
less	JJR	O	O
than	IN	O	O
three	CD	O	O
years	NNS	O	O
should	MD	O	O
be	VB	O	O
offered	VBN	O	O
to	TO	O	O
women	NNS	p	PSE
with	IN	p	O
a	DT	p	O
negative	JJ	p	PC
colposcopy	NN	p	PC
or	CC	p	PC
a	DT	p	PC
biopsy	NN	p	PC
without	IN	p	PC
CIN	NNP	p	PC
.	.	p	O

Bronchodilator	NNP	O	O
response	NN	O	O
to	TO	O	O
salbutamol	VB	i	IPM
after	IN	O	O
spontaneous	JJ	O	O
recovery	NN	O	O
from	IN	O	O
nonspecific	JJ	O	O
bronchial	JJ	O	O
provocation	NN	O	O
tests	NNS	O	O
in	IN	O	O
asthma	NN	p	PC
.	.	p	O

Assessment	NN	O	O
of	IN	O	O
airway	NN	O	O
responsiveness	NN	O	O
by	IN	O	O
bronchoprovocation	NN	O	O
and	CC	O	O
bronchodilatation	NN	O	O
tests	NNS	O	O
is	VBZ	O	O
important	JJ	O	O
in	IN	O	O
the	DT	O	O
diagnostic	JJ	O	O
work-up	JJ	O	O
protocol	NN	O	O
of	IN	O	O
bronchial	JJ	p	PC
asthma	NN	p	PC
and	CC	O	O
it	PRP	O	O
would	MD	O	O
be	VB	O	O
convenient	JJ	O	O
to	TO	O	O
undertake	VB	O	O
both	DT	O	O
tests	NNS	O	O
on	IN	O	O
the	DT	O	O
same	JJ	O	O
occasion	NN	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
it	PRP	O	O
is	VBZ	O	O
not	RB	O	O
known	VBN	O	O
whether	IN	O	O
this	DT	O	O
can	MD	O	O
be	VB	O	O
done	VBN	O	O
accurately	RB	O	O
.	.	O	O

Therefore	RB	O	O
,	,	O	O
this	DT	O	O
study	NN	O	O
evaluated	VBD	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
a	DT	O	O
prior	JJ	O	O
bronchial	JJ	O	O
provocation	NN	O	O
test	NN	O	O
on	IN	O	O
the	DT	O	O
bronchodilator	NN	O	O
response	NN	O	O
to	TO	O	O
salbutamol	VB	i	IPM
after	IN	O	O
spontaneous	JJ	O	O
recovery	NN	O	O
of	IN	O	O
the	DT	O	O
forced	JJ	O	O
expiratory	NN	O	O
volume	NN	O	O
in	IN	O	O
one	CD	O	O
second	NN	O	O
(	(	o	O
FEV1	NNP	o	OPH
)	)	o	O
in	IN	O	O
a	DT	p	O
group	NN	p	O
of	IN	p	O
asthmatic	JJ	p	PC
subjects	NNS	p	O
.	.	p	O

On	IN	O	O
two	CD	O	O
separate	JJ	O	O
occasions	NNS	O	O
at	IN	O	O
the	DT	O	O
same	JJ	O	O
time	NN	O	O
of	IN	O	O
day	NN	O	O
,	,	O	O
concentration-response	JJ	O	O
studies	NNS	O	O
with	IN	O	O
inhaled	JJ	O	O
histamine	NN	i	IPM
or	CC	i	O
methacholine	NN	i	IPM
,	,	i	O
or	CC	i	O
a	DT	i	O
sham	JJ	i	IPM
challenge	NN	i	IPM
with	IN	i	IPM
normal	JJ	i	IPM
saline	NN	i	IPM
were	VBD	O	O
carried	VBN	O	O
out	RP	O	O
in	IN	O	O
a	DT	O	O
blinded	JJ	O	O
,	,	O	O
randomized	JJ	O	O
manner	NN	O	O
.	.	O	O

Changes	NNS	O	O
in	IN	O	O
airway	NN	O	O
calibre	NN	O	O
were	VBD	O	O
followed	VBN	O	O
as	IN	O	O
FEV1	NNP	o	OPH
and	CC	O	O
agonist	JJ	O	O
responsiveness	NN	O	O
expressed	VBN	O	O
as	IN	O	O
the	DT	O	O
provocative	JJ	O	O
concentration	NN	O	O
causing	VBG	O	O
a	DT	O	O
20	CD	O	O
%	NN	O	O
fall	NN	O	O
in	IN	O	O
FEV1	NNP	o	OPH
(	(	O	O
PC20	NNP	O	O
)	)	O	O
.	.	O	O

After	IN	O	O
either	DT	O	O
spontaneous	JJ	O	O
recovery	NN	O	O
or	CC	O	O
a	DT	O	O
fixed-duration	JJ	O	O
wait	NN	O	O
of	IN	O	O
45	CD	O	O
min	NNS	O	O
(	(	O	O
when	WRB	O	O
appropriate	NN	O	O
)	)	O	O
,	,	O	O
the	DT	O	O
subjects	NNS	O	O
received	VBD	O	O
2x100	CD	O	O
microg	NN	O	O
of	IN	O	O
salbutamol	NN	i	IPM
from	IN	O	O
a	DT	O	O
metered	VBN	O	O
dose	NN	O	O
inhaler	NN	O	O
with	IN	O	O
a	DT	O	O
spacer	NN	O	O
.	.	O	O

The	DT	O	O
bronchodilator	NN	O	O
response	NN	O	O
to	TO	O	O
salbutamol	VB	O	O
was	VBD	O	O
expressed	VBN	O	O
as	IN	O	O
a	DT	O	O
percentage	NN	O	O
of	IN	O	O
initial	JJ	o	OPH
FEV1	NNP	o	OPH
(	(	O	O
deltaFEV1	CD	O	O
%	NN	O	O
init	NN	O	O
)	)	O	O
.	.	O	O

Bronchial	JJ	O	O
challenge	NN	O	O
with	IN	O	O
both	DT	O	O
agonists	NNS	O	O
failed	VBD	O	O
to	TO	O	O
alter	VB	O	O
significantly	RB	O	O
the	DT	O	O
airway	NN	o	OPH
response	NN	o	OPH
to	TO	O	O
salbutamol	VB	O	O
,	,	O	O
with	IN	O	O
the	DT	O	O
deltaFEV1	NN	o	OPH
%	NN	o	OPH
init	JJ	o	OPH
mean	JJ	o	OPH
value	NN	o	OPH
(	(	O	O
range	NN	O	O
)	)	O	O
being	VBG	O	O
16.9	CD	O	O
%	NN	O	O
(	(	O	O
9.0-31.9	CD	O	O
)	)	O	O
and	CC	O	O
17.5	CD	O	O
%	NN	O	O
(	(	O	O
11.6-31.2	JJ	O	O
)	)	O	O
on	IN	O	O
the	DT	O	O
sham	NN	O	O
and	CC	O	O
histamine/methacholine	JJ	O	O
challenge	NN	O	O
day	NN	O	O
respectively	RB	O	O
.	.	O	O

It	PRP	O	O
was	VBD	O	O
shown	VBN	O	O
that	IN	O	O
the	DT	O	O
degree	NN	O	O
of	IN	O	O
bronchodilatation	NN	O	O
achieved	VBN	O	O
after	IN	O	O
salbutamol	JJ	O	O
200	CD	O	O
microg	NN	O	O
is	VBZ	O	O
not	RB	O	O
affected	VBN	O	O
by	IN	O	O
prior	JJ	O	O
bronchoprovocation	NN	O	O
testing	VBG	O	O
when	WRB	O	O
enough	JJ	O	O
time	NN	O	O
is	VBZ	O	O
allowed	VBN	O	O
for	IN	O	O
the	DT	O	O
airways	NNS	O	O
to	TO	O	O
recover	VB	O	O
spontaneously	RB	O	O
to	TO	O	O
baseline	VB	O	O
forced	JJ	O	O
expiratory	NN	O	O
volume	NN	O	O
in	IN	O	O
one	CD	O	O
second	NN	O	O
.	.	O	O

Thus	NNP	O	O
evaluation	NN	O	O
of	IN	O	O
airway	NN	O	O
responsiveness	NN	O	O
by	IN	O	O
both	DT	O	O
bronchial	JJ	O	O
provocation	NN	O	O
tests	NNS	O	O
and	CC	O	O
bronchodilator	NN	O	O
testing	NN	O	O
can	MD	O	O
be	VB	O	O
assessed	VBN	O	O
reliably	RB	O	O
within	IN	O	O
a	DT	O	O
few	JJ	O	O
hours	NNS	O	O
in	IN	O	O
asthmatic	JJ	p	PC
patients	NNS	p	O
.	.	p	O

Expectancies	NNS	O	O
,	,	O	O
not	RB	O	O
aroma	RB	O	O
,	,	O	O
explain	JJ	O	O
impact	NN	O	O
of	IN	O	O
lavender	NN	i	IPM
aromatherapy	NN	i	IPM
on	IN	O	O
psychophysiological	JJ	O	O
indices	NNS	O	O
of	IN	O	O
relaxation	NN	O	O
in	IN	O	O
young	JJ	p	PA
healthy	JJ	p	PC
women	NNS	p	PSE
.	.	p	O

OBJECTIVES	NNP	O	O
In	IN	O	O
aromatherapy	NN	i	IPM
,	,	i	IPM
lavender	JJR	i	IPM
aroma	NN	i	IPM
is	VBZ	O	O
reputed	VBN	O	O
to	TO	O	O
assist	VB	O	O
with	IN	O	O
relaxation	NN	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
while	IN	O	O
there	EX	O	O
is	VBZ	O	O
much	JJ	O	O
anecdotal	JJ	O	O
evidence	NN	O	O
to	TO	O	O
that	DT	O	O
effect	NN	O	O
,	,	O	O
the	DT	O	O
empirical	JJ	O	O
literature	NN	O	O
is	VBZ	O	O
very	RB	O	O
inconsistent	JJ	O	O
.	.	O	O

Failure	NN	O	O
to	TO	O	O
employ	VB	O	O
adequate	JJ	O	O
placebos	NNS	i	IC
,	,	O	O
proper	JJ	O	O
blinding	NN	O	O
,	,	O	O
objective	JJ	O	O
measures	NNS	O	O
,	,	O	O
or	CC	O	O
screening	NN	O	O
of	IN	O	O
prior	JJ	O	O
beliefs	NNS	O	O
about	IN	O	O
aromatherapy	NN	O	O
means	NNS	O	O
that	IN	O	O
many	JJ	O	O
previous	JJ	O	O
findings	NNS	O	O
could	MD	O	O
have	VB	O	O
been	VBN	O	O
influenced	VBN	O	O
by	IN	O	O
expectancy	NN	O	O
biases	NNS	O	O
.	.	O	O

The	DT	O	O
present	JJ	O	O
study	NN	O	O
sought	VBD	O	O
to	TO	O	O
establish	VB	O	O
whether	IN	O	O
lavender	NN	i	IPM
aroma	NN	i	IPM
and/or	JJ	O	O
expectancies	NNS	O	O
affect	VBP	O	O
post-stress	JJ	O	O
relaxation	NN	O	O
.	.	O	O

DESIGN	VB	O	O
A	DT	O	O
double-blind	NN	O	O
,	,	O	O
3	CD	O	O
(	(	O	O
aroma	NN	O	O
)	)	O	O
x	VBZ	O	O
3	CD	O	O
(	(	O	O
instruction	NN	O	O
)	)	O	O
x	VBZ	O	O
10	CD	O	O
(	(	O	O
time	NN	O	O
in	IN	O	O
minutes	NNS	O	O
)	)	O	O
mixed-factorial	JJ	i	IC
placebo-controlled	JJ	i	IC
trial	NN	O	O
.	.	O	O

METHOD	NNP	O	O
In	IN	O	O
a	DT	O	O
laboratory	NN	O	O
,	,	O	O
96	CD	p	PSS
healthy	JJ	p	PC
undergraduate	JJ	p	O
women	NNS	p	PSE
were	VBD	O	O
exposed	VBN	i	IPM
to	TO	i	IPM
lavender	VB	i	IPM
,	,	i	O
placebo	NN	i	IC
,	,	i	O
or	CC	i	O
no	DT	i	IOt
aroma	NN	i	IOt
during	IN	O	O
physiologically	RB	O	O
assessed	VBN	O	O
relaxation	NN	O	O
after	IN	O	O
an	DT	O	O
arousing	VBG	O	O
cognitive	JJ	i	O
task	NN	i	O
.	.	i	O

Where	WRB	O	O
an	DT	O	O
aroma	NN	O	O
was	VBD	O	O
presented	VBN	O	O
,	,	O	O
an	DT	O	O
instructional	JJ	O	O
priming	NN	O	O
procedure	NN	O	O
was	VBD	O	O
used	VBN	O	O
to	TO	O	O
manipulate	VB	O	O
participants	NNS	O	O
'	POS	O	O
expectancies	NNS	O	O
about	IN	O	O
the	DT	O	O
aroma	NN	O	O
's	POS	O	O
likely	JJ	O	O
impact	NN	O	O
on	IN	O	O
their	PRP$	O	O
ability	NN	O	O
to	TO	O	O
relax	VB	O	O
.	.	O	O

RESULTS	NNP	O	O
Results	NNP	O	O
showed	VBD	O	O
no	DT	O	O
effect	NN	O	O
of	IN	O	O
aroma	NN	o	OOt
on	IN	o	OOt
galvanic	JJ	o	OOt
skin	NN	o	OOt
response	NN	o	OOt
during	IN	O	O
relaxation	NN	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
the	DT	O	O
nature	NN	O	O
of	IN	O	O
instructional	JJ	O	O
prime	NN	O	O
was	VBD	O	O
associated	VBN	O	O
with	IN	O	O
relaxation	NN	o	OME
patterns	NNS	o	OME
:	:	o	O
when	WRB	O	O
expecting	VBG	O	O
the	DT	O	O
aroma	NN	O	O
to	TO	O	O
inhibit	VB	O	O
them	PRP	O	O
,	,	O	O
participants	NNS	O	O
relaxed	VBD	o	OME
more	RBR	O	O
;	:	O	O
when	WRB	O	O
expecting	VBG	O	O
facilitation	NN	O	O
,	,	O	O
participants	NNS	O	O
relaxed	VBD	o	OME
less	RBR	O	O
.	.	O	O

The	DT	O	O
effect	NN	O	O
was	VBD	O	O
not	RB	O	O
seen	VBN	O	O
with	IN	O	O
regard	NN	O	O
to	TO	O	O
self-reported	JJ	o	OME
relaxation	NN	o	OME
(	(	O	O
as	IN	O	O
represented	VBN	O	O
by	IN	O	O
changes	NNS	O	O
in	IN	O	O
state	NN	O	O
anxiety	NN	O	O
)	)	O	O
and	CC	O	O
was	VBD	O	O
independent	JJ	O	O
of	IN	O	O
ratings	NNS	O	O
of	IN	O	O
attitudes	NNS	o	OME
towards	NNS	O	O
aromatherapy	NN	O	O
.	.	O	O

CONCLUSIONS	VB	O	O
The	DT	O	O
findings	NNS	O	O
imply	VBP	O	O
that	IN	O	O
the	DT	O	O
previous	JJ	O	O
associations	NNS	O	O
of	IN	O	O
lavender	NN	i	IC
aroma	NN	i	IC
with	IN	O	O
assisted	JJ	O	O
relaxation	NN	O	O
may	MD	O	O
have	VB	O	O
been	VBN	O	O
influenced	VBN	O	O
by	IN	O	O
expectancy	NN	O	O
biases	NNS	O	O
,	,	O	O
and	CC	O	O
that	IN	O	O
the	DT	O	O
relevant	JJ	O	O
expectancies	NNS	O	O
are	VBP	O	O
easily	RB	O	O
manipulable	JJ	O	O
.	.	O	O

Primary	JJ	i	IPH
stenting	NN	i	IPH
of	IN	O	O
occluded	JJ	O	O
native	JJ	O	O
coronary	JJ	O	O
arteries	NNS	O	O
:	:	O	O
final	JJ	O	O
results	NNS	O	O
of	IN	O	O
the	DT	O	O
Primary	NNP	O	O
Stenting	NNP	O	O
of	IN	O	O
Occluded	NNP	p	O
Native	NNP	p	O
Coronary	NNP	p	O
Arteries	NNP	p	O
(	(	p	O
PRISON	NNP	p	O
)	)	p	O
study	NN	O	O
.	.	O	O

BACKGROUND	NNP	O	O
Primary	NNP	i	IS
intracoronary	JJ	i	IS
stent	NN	i	IS
placement	NN	i	IS
after	IN	O	O
successfully	RB	O	O
crossing	VBG	O	O
chronic	JJ	O	O
total	JJ	p	O
coronary	JJ	p	O
occlusions	NNS	p	O
may	MD	O	O
decrease	VB	O	O
the	DT	O	O
high	JJ	O	O
restenosis	NN	o	O
rate	NN	o	O
at	IN	O	O
long-term	JJ	O	O
follow-up	JJ	O	O
compared	VBN	O	O
with	IN	O	O
conventional	JJ	i	IPH
balloon	NN	i	IPH
angioplasty	NN	i	IPH
.	.	i	IPH

METHODS	NNP	O	O
In	IN	O	O
a	DT	O	O
prospective	JJ	O	O
,	,	O	O
randomized	JJ	O	O
trial	NN	O	O
,	,	O	O
balloon	NN	i	IPH
angioplasty	NN	i	IPH
was	VBD	O	O
compared	VBN	O	O
with	IN	O	O
stent	JJ	i	IS
implantation	NN	i	IS
for	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
chronic	JJ	p	PC
total	JJ	p	PC
occlusions	NNS	p	PC
.	.	p	O

Patients	NNS	O	O
were	VBD	O	O
followed	VBN	O	O
for	IN	O	O
12	CD	O	O
months	NNS	O	O
with	IN	O	O
angiographic	JJ	O	O
follow-up	NN	O	O
at	IN	O	O
6	CD	O	O
months	NNS	O	O
.	.	O	O

Quantitative	JJ	O	O
coronary	JJ	O	O
analysis	NN	O	O
was	VBD	O	O
performed	VBN	O	O
by	IN	O	O
an	DT	O	O
independent	JJ	O	O
core	NN	O	O
lab	NN	O	O
.	.	O	O

RESULTS	VB	O	O
A	DT	O	O
total	NN	O	O
of	IN	O	O
200	CD	p	O
patients	NNS	p	O
were	VBD	p	O
enrolled	VBN	p	O
.	.	p	O

Baseline	JJ	O	O
characteristics	NNS	O	O
were	VBD	O	O
evenly	RB	O	O
distributed	VBN	O	O
.	.	O	O

After	IN	O	O
the	DT	O	O
procedure	NN	O	O
the	DT	O	O
mean	NN	o	OPH
minimal	JJ	o	OPH
luminal	JJ	o	OPH
diameter	NN	o	OPH
in	IN	O	O
the	DT	O	O
conventional	JJ	i	IPH
group	NN	O	O
was	VBD	O	O
2.34	CD	O	O
+/-	JJ	O	O
0.46	CD	O	O
mm	NN	O	O
versus	NN	O	O
2.90	CD	O	O
+/-	JJ	O	O
0.41	CD	O	O
mm	NN	O	O
in	IN	O	O
the	DT	O	O
stented	VBN	i	IS
group	NN	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
.0001	NNP	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
6-month	JJ	O	O
angiographic	JJ	O	O
follow-up	NN	O	O
showed	VBD	O	O
a	DT	O	O
mean	JJ	o	OPH
minimal	JJ	o	OPH
luminal	JJ	o	OPH
diameter	NN	o	OPH
of	IN	O	O
1.57	CD	O	O
+/-	JJ	O	O
0.74	CD	O	O
mm	NN	O	O
in	IN	O	O
the	DT	O	O
conventional	JJ	O	O
group	NN	O	O
versus	VBD	O	O
1.93	CD	O	O
+/-	JJ	O	O
0.85	CD	O	O
mm	NN	O	O
in	IN	O	O
the	DT	O	O
stented	VBN	O	O
group	NN	O	O
(	(	O	O
P	NNP	O	O
=.009	NNP	O	O
)	)	O	O
and	CC	O	O
a	DT	O	O
mean	JJ	o	OPH
diameter	NN	o	OPH
stenosis	NN	o	OPH
of	IN	O	O
44.7	CD	O	O
%	NN	O	O
+/-	JJ	O	O
25.0	CD	O	O
%	NN	O	O
versus	IN	O	O
35.5	CD	O	O
%	NN	O	O
+/-	JJ	O	O
26.5	CD	O	O
%	NN	O	O
(	(	O	O
P	NNP	O	O
=.036	NNP	O	O
)	)	O	O
.	.	O	O

Binary	JJ	o	OPH
angiographic	JJ	o	OPH
restenosis	NN	o	OPH
(	(	O	O
>	JJ	O	O
50	CD	O	O
%	NN	O	O
diameter	JJ	O	O
stenosis	NN	O	O
)	)	O	O
was	VBD	O	O
seen	VBN	O	O
in	IN	O	O
33	CD	O	O
%	NN	O	O
in	IN	O	O
the	DT	O	O
conventional	JJ	O	O
group	NN	O	O
versus	VBD	O	O
22	CD	O	O
%	NN	O	O
in	IN	O	O
the	DT	O	O
stented	VBN	i	IS
group	NN	O	O
(	(	O	O
P	NNP	O	O
=.137	NNP	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
reocclusion	NN	o	OOt
rates	NNS	o	OOt
were	VBD	O	O
7.3	CD	O	O
%	NN	O	O
and	CC	O	O
8.2	CD	O	O
%	NN	O	O
,	,	O	O
respectively	RB	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
1.00	CD	O	O
)	)	O	O
.	.	O	O

At	IN	O	O
12	CD	O	O
month	NN	O	O
follow-up	NN	O	O
,	,	O	O
the	DT	O	O
rate	NN	o	OOt
of	IN	o	OOt
target	NN	o	OOt
lesion	NN	o	OOt
revascularization	NN	o	OOt
was	VBD	O	O
significantly	RB	O	O
higher	JJR	O	O
in	IN	O	O
the	DT	O	O
conventional	JJ	i	IPM
group	NN	O	O
(	(	O	O
29	CD	O	O
%	NN	O	O
versus	IN	O	O
13	CD	O	O
%	NN	O	O
,	,	O	O
P	NNP	O	O
<	NNP	O	O
.0001	NNP	O	O
)	)	O	O
.	.	O	O

CONCLUSION	NNP	O	O
These	DT	O	O
data	NNS	O	O
demonstrate	NN	O	O
that	IN	O	O
stenting	VBG	i	IS
of	IN	O	O
chronic	JJ	p	O
total	JJ	p	O
occlusions	NNS	p	O
is	VBZ	O	O
superior	JJ	O	O
to	TO	O	O
balloon	VB	i	IPH
angioplasty	JJ	i	IPH
alone	RB	i	IPH
with	IN	O	O
a	DT	O	O
statistically	RB	O	O
significant	JJ	O	O
reduction	NN	O	O
in	IN	O	O
the	DT	O	O
need	NN	O	O
for	IN	O	O
target	NN	o	OPH
lesion	NN	o	OPH
revascularization	NN	o	OPH
and	CC	O	O
a	DT	O	O
lower	JJR	O	O
,	,	O	O
but	CC	O	O
not	RB	O	O
significant	JJ	O	O
,	,	O	O
restenosis	NN	o	OPH
rate	NN	o	OPH
.	.	o	O

A	DT	O	O
multifactorial	JJ	O	O
strategy	NN	O	O
of	IN	O	O
pain	NN	O	O
management	NN	O	O
is	VBZ	O	O
associated	VBN	O	O
with	IN	O	O
less	JJR	O	O
pain	NN	O	O
in	IN	O	O
scheduled	JJ	p	PC
vaccination	NN	p	PC
of	IN	O	O
children	NNS	p	O
.	.	p	O

A	DT	O	O
study	NN	O	O
realized	VBN	O	O
by	IN	O	O
family	NN	O	O
practitioners	NNS	O	O
in	IN	p	O
239	CD	p	O
children	NNS	p	O
aged	VBN	p	O
4-12	CD	p	O
years	NNS	p	O
old	JJ	p	O
.	.	p	O

BACKGROUND	NNP	O	O
AND	CC	O	O
AIMS	NNP	O	O
The	DT	O	O
multiplicity	NN	O	O
of	IN	O	O
vaccine	JJ	O	O
injections	NNS	O	O
during	IN	O	O
childhood	NN	O	O
leads	NNS	O	O
to	TO	O	O
iterative	VB	O	O
painful	JJ	O	O
and	CC	O	O
stressful	JJ	O	O
experiences	NNS	O	O
which	WDT	O	O
may	MD	O	O
lead	VB	O	O
in	IN	O	O
turn	NN	O	O
to	TO	O	O
anticipated	VBN	O	O
pain	NN	O	O
and	CC	O	O
then	RB	O	O
possibly	RB	O	O
to	TO	O	O
a	DT	O	O
true	JJ	O	O
needle	JJ	O	O
phobia	NN	O	O
.	.	O	O

We	PRP	O	O
aimed	VBD	O	O
at	IN	O	O
evaluating	VBG	O	O
a	DT	O	O
multifactorial	JJ	O	O
strategy	NN	O	O
of	IN	O	O
pain	NN	O	O
management	NN	O	O
combining	VBG	O	O
pharmacological	JJ	O	O
and	CC	O	O
non-pharmacological	JJ	O	O
approaches	NNS	O	O
during	IN	O	O
vaccination	NN	O	O
,	,	O	O
as	IN	O	O
compared	VBN	O	O
to	TO	O	O
usual	JJ	O	O
care	NN	O	O
,	,	O	O
in	IN	p	O
4-	JJ	p	O
to	TO	p	O
12-year-old	JJ	p	O
children	NNS	p	O
.	.	p	O

METHODS	NNP	O	O
In	IN	O	O
all	DT	O	O
,	,	O	O
239	CD	p	O
children	NNS	p	O
were	VBD	p	O
enrolled	VBN	p	O
by	IN	p	O
25	CD	p	O
family	NN	p	O
practitioners	NNS	p	O
in	IN	O	O
an	DT	O	O
open-label	JJ	O	O
study	NN	O	O
.	.	O	O

After	IN	O	O
a	DT	O	O
pseudo-randomization	NN	O	O
,	,	O	O
usual	JJ	i	IPH
pain	NN	i	IPH
management	NN	i	IPH
(	(	i	IPH
n	JJ	i	IPH
=	NNP	i	IPH
132	CD	i	IPH
)	)	i	IPH
was	VBD	i	IPH
compared	VBN	i	IPH
to	TO	i	IPH
a	DT	i	IPH
multifactorial	JJ	i	IPH
strategy	NN	i	IPH
(	(	i	IPH
n	JJ	i	IPH
=	NNP	i	IPH
107	CD	i	IPH
)	)	i	IPH
associating	VBG	i	IPH
preliminary	JJ	i	IPH
application	NN	i	IPH
of	IN	i	IPH
an	DT	i	IPH
anesthesic	JJ	i	IPH
patch	NN	i	IPH
,	,	i	IPH
preferential	JJ	i	IPH
use	NN	i	IPH
of	IN	i	IPH
specified	JJ	i	IPH
vaccines	NNS	i	IPH
,	,	i	O
child	JJ	i	IE
education	NN	i	IE
by	IN	i	IE
the	DT	i	IE
parents	NNS	i	IE
and	CC	i	IE
the	DT	i	IE
doctor	NN	i	IE
,	,	i	IE
parental	JJ	i	IE
accompaniment	NN	i	IE
and	CC	i	IE
child	JJ	i	IE
distraction	NN	i	IE
with	IN	i	IE
soap	NN	i	IE
bubbles	NNS	i	IE
during	IN	i	IE
the	DT	i	IE
procedure	NN	i	IE
.	.	i	O

The	DT	O	O
primary	JJ	O	O
outcome	NN	O	O
(	(	O	O
i.e	JJ	O	O
.	.	O	O

child	VB	o	OPA
pain	NN	o	OPA
)	)	o	OPA
was	VBD	O	O
assessed	VBN	O	O
with	IN	O	O
a	DT	O	O
self-report	JJ	o	OPA
scale	NN	o	OPA
named	VBN	o	OPA
visual	JJ	o	OPA
analog	NN	o	OPA
scale	NN	o	OPA
(	(	o	OPA
VAS	NNP	o	OPA
)	)	o	OPA
of	IN	o	OPA
pain	NN	o	OPA
.	.	o	OOt

RESULTS	VB	O	O
A	DT	O	O
significant	JJ	O	O
decrease	NN	O	O
in	IN	O	O
pain	NN	o	OPA
was	VBD	O	O
obtained	VBN	O	O
using	VBG	O	O
the	DT	O	O
multifactorial	JJ	O	O
strategy	NN	O	O
,	,	O	O
as	IN	O	O
assessed	VBN	O	O
by	IN	O	O
self-reported	JJ	O	O
VAS	NNP	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.0001	CD	O	O
)	)	O	O
.	.	O	O

This	DT	O	O
was	VBD	O	O
confirmed	VBN	O	O
by	IN	O	O
another	DT	O	O
self-report	JJ	O	O
scale	NN	O	O
(	(	O	O
the	DT	O	O
facial	NN	o	OPA
pain	NN	o	OPA
scale	NN	o	OPA
revised	VBN	O	O
:	:	O	O
P	NNP	O	O
=	NNP	O	O
0.005	CD	O	O
)	)	O	O
,	,	O	O
as	RB	O	O
well	RB	O	O
as	IN	O	O
with	IN	O	O
hetero-evaluations	NNS	O	O
by	IN	O	O
GPs	NNP	O	O
and	CC	O	O
parents	NNS	O	O
[	VBP	o	OOt
Children	NNP	o	OPA
's	POS	o	OPA
Hospital	NNP	o	OPA
of	IN	o	OPA
Eastern	NNP	o	OPA
Ontario	NNP	o	OPA
Pain	NNP	o	OPA
Scale	NNP	o	OPA
:	:	o	OOt
P	NNP	O	O
=	VBZ	O	O
0.0007	CD	O	O
;	:	O	O
GPs	NNP	O	O
VAS	NNP	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.0001	CD	O	O
)	)	O	O
,	,	O	O
parents	NNS	o	OPA
VAS	NNP	o	OPA
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.0001	CD	O	O
)	)	O	O
]	NN	O	O
,	,	O	O
which	WDT	O	O
were	VBD	O	O
secondary	JJ	O	O
outcome	NN	O	O
criteria	NNS	O	O
.	.	O	O

CONCLUSIONS	VB	O	O
This	DT	O	O
multifactorial	JJ	O	O
method	NN	O	O
significantly	RB	O	O
decreases	VBZ	O	O
vaccination	NN	O	O
pain	NN	o	OPA
in	IN	O	O
4-	JJ	p	O
to	TO	p	O
12-year-old	JJ	p	O
children	NNS	p	O
.	.	p	O

This	DT	O	O
strategy	NN	O	O
could	MD	O	O
make	VB	O	O
vaccines	NNS	O	O
more	RBR	O	O
acceptable	JJ	O	O
to	TO	O	O
children	NNS	p	O
and	CC	O	O
may	MD	O	O
improve	VB	O	O
child-doctor	NN	O	O
relationships	NNS	O	O
and	CC	O	O
contribute	NN	O	O
to	TO	O	O
a	DT	O	O
decrease	NN	O	O
in	IN	O	O
child	JJ	O	O
fear	VBP	O	O
about	IN	O	O
health	NN	O	O
care	NN	O	O
.	.	O	O

An	DT	O	O
empirical	JJ	O	O
comparison	NN	O	O
of	IN	O	O
the	DT	O	O
St	NNP	O	O
George	NNP	O	O
's	POS	O	O
Respiratory	NNP	O	O
Questionnaire	NNP	O	O
(	(	O	O
SGRQ	NNP	O	O
)	)	O	O
and	CC	O	O
the	DT	O	O
Chronic	NNP	O	O
Respiratory	NNP	O	O
Disease	NNP	O	O
Questionnaire	NNP	O	O
(	(	O	O
CRQ	NNP	O	O
)	)	O	O
in	IN	O	O
a	DT	O	O
clinical	JJ	O	O
trial	NN	O	O
setting	NN	O	O
.	.	O	O

BACKGROUND	IN	O	O
The	DT	O	O
Chronic	NNP	O	O
Respiratory	NNP	O	O
Questionnaire	NNP	O	O
(	(	O	O
CRQ	NNP	O	O
)	)	O	O
and	CC	O	O
the	DT	O	O
St	NNP	O	O
George	NNP	O	O
's	POS	O	O
Respiratory	NNP	O	O
Questionnaire	NNP	O	O
(	(	O	O
SGRQ	NNP	O	O
)	)	O	O
are	VBP	O	O
the	DT	O	O
two	CD	O	O
most	JJS	O	O
widely	RB	O	O
used	VBN	O	O
quality	NN	O	O
of	IN	O	O
life	NN	O	O
questionnaires	NNS	O	O
in	IN	O	O
chronic	JJ	O	O
obstructive	JJ	O	O
pulmonary	JJ	O	O
disease	NN	O	O
(	(	p	O
COPD	NNP	p	O
)	)	p	O
.	.	p	O

A	DT	O	O
study	NN	O	O
was	VBD	O	O
undertaken	VBN	O	O
to	TO	O	O
compare	VB	O	O
directly	RB	O	O
the	DT	O	O
self-administered	JJ	O	O
version	NN	O	O
of	IN	O	O
the	DT	O	O
CRQ	NNP	O	O
and	CC	O	O
the	DT	O	O
SGRQ	NNP	O	O
with	IN	O	O
respect	NN	O	O
to	TO	O	O
feasibility	NN	O	O
,	,	O	O
internal	JJ	O	O
consistency	NN	O	O
,	,	O	O
validity	NN	O	O
,	,	O	O
and	CC	O	O
sensitivity	NN	O	O
to	TO	O	O
changes	NNS	O	O
resulting	VBG	O	O
from	IN	O	O
bronchodilator	NN	O	O
therapy	NN	O	O
.	.	O	O

METHODS	NNP	O	O
One	CD	p	O
hundred	CD	p	O
and	CC	p	O
forty	VB	p	O
four	CD	p	O
patients	NNS	p	O
with	IN	p	O
moderate	JJ	p	O
or	CC	p	O
severe	JJ	p	O
COPD	NNP	p	O
were	VBD	O	O
randomly	RB	O	O
assigned	VBN	O	O
to	TO	O	O
receive	VB	O	O
three	CD	O	O
months	NNS	O	O
of	IN	O	O
treatment	NN	O	O
with	IN	O	O
either	DT	O	O
salmeterol	NN	i	IPM
,	,	i	O
salmeterol	NN	i	IPM
+	NNP	i	O
ipratropium	NN	i	IPM
bromide	NN	i	IPM
,	,	i	O
or	CC	i	O
placebo	NN	i	IC
.	.	i	O

Quality	NN	o	OPH
of	IN	o	OPH
life	NN	o	OPH
was	VBD	O	O
measured	VBN	O	O
at	IN	O	O
baseline	NN	O	O
and	CC	O	O
after	IN	O	O
12	CD	O	O
weeks	NNS	O	O
of	IN	O	O
treatment	NN	O	O
.	.	O	O

RESULTS	VB	O	O
The	DT	O	O
proportions	NNS	o	OPH
of	IN	o	OPH
missing	VBG	o	OPH
values	NNS	o	OPH
per	IN	O	O
patient	NN	O	O
were	VBD	O	O
low	JJ	O	O
for	IN	O	O
both	DT	O	O
questionnaires	NNS	O	O
(	(	O	O
0.54	CD	O	O
%	NN	O	O
for	IN	O	O
the	DT	O	O
CRQ	NNP	O	O
and	CC	O	O
2	CD	O	O
%	NN	O	O
for	IN	O	O
the	DT	O	O
SGRQ	NNP	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
internal	JJ	o	OOt
consistency	NN	o	OOt
was	VBD	O	O
good	JJ	O	O
for	IN	O	O
both	DT	O	O
questionnaires	NNS	O	O
(	(	O	O
Cronbach	NNP	O	O
's	POS	O	O
alpha	NN	O	O
coefficients	NNS	O	O
>	VBP	O	O
/=	$	O	O
0.84	CD	O	O
for	IN	O	O
the	DT	O	O
CRQ	NNP	O	O
and	CC	O	O
>	NNP	O	O
/=	NNP	O	O
0.76	CD	O	O
for	IN	O	O
the	DT	O	O
SGRQ	NNP	O	O
)	)	O	O
.	.	O	O

Factor	NNP	O	O
analysis	NN	O	O
confirmed	VBD	O	O
the	DT	O	O
original	JJ	O	O
domain	NN	O	O
structure	NN	O	O
of	IN	O	O
the	DT	O	O
CRQ	NNP	O	O
but	CC	O	O
not	RB	O	O
of	IN	O	O
the	DT	O	O
SGRQ	NNP	O	O
.	.	O	O

Correlations	NNS	O	O
with	IN	O	O
forced	JJ	O	O
expiratory	NN	O	O
volume	NN	O	O
in	IN	O	O
one	CD	O	O
second	NN	O	O
(	(	o	OPH
FEV	NNP	o	OPH
(	(	o	OPH
1	CD	o	OPH
)	)	o	OPH
)	)	o	OPH
%	NN	o	OPH
predicted	VBN	O	O
and	CC	O	O
peak	JJ	o	OPH
expiratory	NN	o	OPH
flow	NN	o	OPH
rate	NN	o	OPH
(	(	o	OPH
PEFR	NNP	o	OPH
)	)	o	OPH
were	VBD	O	O
low	JJ	O	O
for	IN	O	O
both	DT	O	O
questionnaires	NNS	O	O
but	CC	O	O
better	JJR	O	O
for	IN	O	O
the	DT	O	O
SGRQ	NNP	O	O
than	IN	O	O
for	IN	O	O
the	DT	O	O
CRQ	NNP	O	O
.	.	O	O

The	DT	O	O
ability	NN	O	O
to	TO	O	O
discriminate	VB	O	O
between	IN	O	O
subjects	NNS	O	O
with	IN	O	O
different	JJ	O	O
levels	NNS	O	O
of	IN	O	O
FEV	NNP	o	OPH
(	(	o	OPH
1	CD	o	OPH
)	)	o	OPH
was	VBD	O	O
somewhat	RB	O	O
better	JJR	O	O
for	IN	O	O
the	DT	O	O
SGRQ	NNP	O	O
.	.	O	O

The	DT	O	O
correlations	NNS	O	O
with	IN	O	O
symptom	JJ	O	O
scores	NNS	O	O
were	VBD	O	O
comparable	JJ	O	O
for	IN	O	O
both	DT	O	O
questionnaires	NNS	O	O
.	.	O	O

Cross	NNP	O	O
sectionally	RB	O	O
,	,	O	O
the	DT	O	O
scores	NNS	O	O
of	IN	O	O
the	DT	O	O
two	CD	O	O
questionnaires	NNS	O	O
were	VBD	O	O
moderately	RB	O	O
to	TO	O	O
highly	RB	O	O
correlated	VBN	O	O
(	(	O	O
coefficients	NNS	O	O
ranged	VBD	O	O
from	IN	O	O
0.35	CD	O	O
to	TO	O	O
0.72	CD	O	O
)	)	O	O
.	.	O	O

Longitudinally	RB	O	O
,	,	O	O
these	DT	O	O
correlations	NNS	O	O
were	VBD	O	O
lower	JJR	O	O
(	(	O	O
coefficients	NNS	O	O
ranged	VBD	O	O
from	IN	O	O
0.17	CD	O	O
to	TO	O	O
0.54	CD	O	O
)	)	O	O
but	CC	O	O
were	VBD	O	O
still	RB	O	O
significant	JJ	O	O
.	.	O	O

The	DT	O	O
CRQ	NNP	o	OOt
total	NN	o	OOt
and	CC	o	OOt
emotions	NNS	o	OOt
score	NN	o	OOt
and	CC	o	OPH
the	DT	o	OPH
SGRQ	NNP	o	OOt
symptoms	NNS	o	OOt
score	NN	o	OOt
were	VBD	O	O
the	DT	O	O
most	RBS	O	O
responsive	JJ	O	O
to	TO	O	O
change	VB	O	O
.	.	O	O

The	DT	O	O
SGRQ	NNP	o	OPH
symptoms	NNS	o	OPH
domain	NN	o	OPH
was	VBD	O	O
the	DT	O	O
only	JJ	O	O
domain	NN	O	O
where	WRB	O	O
the	DT	O	O
improvement	NN	O	O
in	IN	O	O
patients	NNS	p	O
receiving	VBG	p	O
combination	NN	p	O
treatment	NN	p	O
crossed	VBD	O	O
the	DT	O	O
threshold	NN	O	O
for	IN	O	O
clinical	JJ	O	O
relevance	NN	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
Since	IN	O	O
this	DT	O	O
analysis	NN	O	O
of	IN	O	O
reliability	NN	O	O
,	,	O	O
validity	NN	O	O
,	,	O	O
and	CC	O	O
responsiveness	NN	O	O
to	TO	O	O
change	VB	O	O
did	VBD	O	O
not	RB	O	O
clearly	RB	O	O
favour	VBP	O	O
one	CD	O	O
instrument	NN	O	O
above	IN	O	O
the	DT	O	O
other	JJ	O	O
,	,	O	O
the	DT	O	O
choice	NN	O	O
between	IN	O	O
the	DT	O	O
CRQ	NNP	O	O
and	CC	O	O
the	DT	O	O
SGRQ	NNP	O	O
can	MD	O	O
be	VB	O	O
based	VBN	O	O
on	IN	O	O
other	JJ	O	O
considerations	NNS	O	O
such	JJ	O	O
as	IN	O	O
the	DT	O	O
required	JJ	O	O
sample	NN	O	O
size	NN	O	O
or	CC	O	O
the	DT	O	O
availability	NN	O	O
of	IN	O	O
reference	NN	O	O
values	NNS	O	O
.	.	O	O

Effect	NN	O	O
of	IN	O	O
a	DT	O	O
carbohydrate-protein	JJ	i	IPM
supplement	NN	i	IPM
on	IN	O	O
endurance	NN	o	OPH
performance	NN	o	OPH
during	IN	O	O
exercise	NN	O	O
of	IN	O	O
varying	VBG	O	O
intensity	NN	O	O
.	.	O	O

Increasing	VBG	O	O
the	DT	O	O
plasma	NN	O	O
glucose	NN	O	O
and	CC	O	O
insulin	NN	O	O
concentrations	NNS	O	O
during	IN	O	O
prolonged	JJ	O	O
variable	JJ	O	O
intensity	NN	O	O
exercise	NN	O	O
by	IN	O	O
supplementing	VBG	O	O
with	IN	O	O
carbohydrate	NN	O	O
has	VBZ	O	O
been	VBN	O	O
found	VBN	O	O
to	TO	O	O
spare	VB	O	O
muscle	NN	O	O
glycogen	NN	O	O
and	CC	O	O
increase	VB	O	O
aerobic	JJ	o	OPH
endurance	NN	o	OPH
.	.	o	O

Furthermore	RB	O	O
,	,	O	O
the	DT	O	O
addition	NN	O	O
of	IN	O	O
protein	NN	i	IPM
to	TO	i	IPM
a	DT	i	IPM
carbohydrate	NN	i	IPM
supplement	NN	i	IPM
will	MD	O	O
enhance	VB	O	O
the	DT	O	O
insulin	NN	O	O
response	NN	O	O
of	IN	O	O
a	DT	O	O
carbohydrate	JJ	O	O
supplement	NN	O	O
.	.	O	O

The	DT	O	O
purpose	NN	O	O
of	IN	O	O
the	DT	O	O
present	JJ	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
compare	VB	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
a	DT	O	O
carbohydrate	NN	i	IPM
and	CC	O	O
a	DT	O	O
carbohydrate-protein	JJ	i	IPM
supplement	NN	i	IPM
on	IN	O	O
aerobic	JJ	o	OPH
endurance	NN	o	OPH
performance	NN	o	OPH
.	.	o	OPH

Nine	NNP	p	O
trained	JJ	p	O
cyclists	NNS	p	O
exercised	VBD	O	O
on	IN	O	O
3	CD	O	O
separate	JJ	O	O
occasions	NNS	O	O
at	IN	O	O
intensities	NNS	O	O
that	WDT	O	O
varied	VBD	O	O
between	IN	O	O
45	CD	O	O
%	NN	O	O
and	CC	O	O
75	CD	O	O
%	NN	O	O
VO2max	NNP	O	O
for	IN	O	O
3	CD	O	O
h	NN	O	O
and	CC	O	O
then	RB	O	O
at	IN	O	O
85	CD	O	O
%	NN	O	O
VO2max	NNP	O	O
until	IN	O	O
fatigued	VBN	O	O
.	.	O	O

Supplements	NNS	i	O
(	(	i	O
200	CD	i	O
ml	NN	i	O
)	)	i	O
were	VBD	i	O
provided	VBN	i	O
every	DT	i	O
20	CD	i	O
min	NN	i	O
and	CC	i	O
consisted	VBN	i	O
of	IN	i	O
placebo	NN	i	IC
,	,	i	O
a	DT	i	O
7.75	CD	i	O
%	NN	i	O
carbohydrate	JJ	i	IPM
solution	NN	i	IPM
,	,	i	O
and	CC	i	O
a	DT	i	O
7.75	CD	i	O
%	NN	i	O
carbohydrate/1.94	NN	i	IPM
%	NN	i	IPM
protein	JJ	i	IPM
solution	NN	i	IPM
.	.	i	O

Treatments	NNS	O	O
were	VBD	O	O
administered	VBN	O	O
using	VBG	O	O
a	DT	O	O
double-blind	JJ	O	O
randomized	JJ	O	O
design	NN	O	O
.	.	O	O

Carbohydrate	NNP	O	O
supplementation	NN	O	O
significantly	RB	O	O
increased	VBD	O	O
time	NN	o	OPH
to	TO	o	OPH
exhaustion	NN	o	OPH
(	(	O	O
carbohydrate	JJ	O	O
19.7	CD	O	O
+/-	JJ	O	O
4.6	CD	O	O
min	NN	O	O
vs.	FW	O	O
placebo	NN	O	O
12.7	CD	O	O
+/-	JJ	O	O
3.1	CD	O	O
min	NN	O	O
)	)	O	O
,	,	O	O
while	IN	O	O
the	DT	O	O
addition	NN	O	O
of	IN	O	O
protein	NN	O	O
enhanced	VBD	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
the	DT	O	O
carbohydrate	NN	O	O
supplement	NN	O	O
(	(	O	O
carbohydrate-protein	JJ	O	O
26.9	CD	O	O
+/-	JJ	O	O
4.5	CD	O	O
min	NN	O	O
,	,	O	O
p	NN	O	O
<	NNP	O	O
.05	NNP	O	O
)	)	O	O
.	.	O	O

Blood	NNP	o	OPH
glucose	NN	o	OPH
and	CC	o	OPH
plasma	JJ	o	OPH
insulin	NN	o	OPH
levels	NNS	o	OPH
were	VBD	O	O
elevated	VBN	O	O
above	IN	O	O
placebo	NN	O	O
during	IN	O	O
carbohydrate	NN	i	IPM
and	CC	O	O
carbohydrate-protein	JJ	i	IPM
supplementation	NN	i	IPM
,	,	O	O
but	CC	O	O
no	DT	O	O
differences	NNS	O	O
were	VBD	O	O
found	VBN	O	O
between	IN	O	O
the	DT	O	O
carbohydrate	NN	O	O
and	CC	O	O
carbohydrate-protein	JJ	i	IPM
treatments	NNS	O	O
.	.	O	O

In	IN	O	O
summary	JJ	O	O
,	,	O	O
we	PRP	O	O
found	VBD	O	O
that	IN	O	O
the	DT	O	O
addition	NN	O	O
of	IN	O	O
protein	NN	O	O
to	TO	O	O
a	DT	O	O
carbohydrate	NN	i	IPM
supplement	NN	i	IPM
enhanced	VBD	O	O
aerobic	JJ	o	OPH
endurance	NN	o	OPH
performance	NN	o	OPH
above	IN	O	O
that	DT	O	O
which	WDT	O	O
occurred	VBD	O	O
with	IN	O	O
carbohydrate	NN	O	O
alone	RB	O	O
,	,	O	O
but	CC	O	O
the	DT	O	O
reason	NN	O	O
for	IN	O	O
this	DT	O	O
improvement	NN	O	O
in	IN	O	O
performance	NN	O	O
was	VBD	O	O
not	RB	O	O
evident	JJ	O	O
.	.	O	O

Failure	NN	O	O
of	IN	O	O
lithium	NN	i	IPM
to	TO	O	O
reduce	VB	O	O
period	NN	O	O
of	IN	O	O
neutropenia	NN	O	O
during	IN	O	O
induction	NN	i	IPH
therapy	NN	i	IPH
of	IN	O	O
acute	JJ	p	PC
myeloid	NN	p	PC
leukemia	NN	p	PC
.	.	p	O

Fifty-four	CD	p	PSS
patients	NNS	p	O
treated	VBN	p	O
with	IN	p	O
daunorubicin	NN	i	IPM
,	,	i	O
cytosine	JJ	i	IPM
arabinoside	NN	i	IPM
and	CC	i	O
thioquanine	NN	i	IPM
for	IN	p	O
acute	JJ	p	PC
myeloid	NN	p	PC
leukemia	NN	p	PC
were	VBD	O	O
randomly	RB	O	O
assigned	VBN	O	O
to	TO	O	O
receive	VB	O	O
oral	JJ	i	IPM
lithium	NN	i	IPM
carbonate	NN	i	IPM
1200	CD	i	IPM
mg	JJ	i	IPM
daily	JJ	i	IPM
or	CC	i	O
no	DT	i	IPM
lithium	NN	i	IPM
.	.	i	O

The	DT	O	O
duration	NN	o	OPH
of	IN	o	OPH
neutropenia	NN	o	OPH
(	(	O	O
less	JJR	O	O
than	IN	O	O
0.5	CD	O	O
x	JJ	O	O
10	CD	O	O
(	(	O	O
9	CD	O	O
)	)	O	O
/L	NN	O	O
)	)	O	O
was	VBD	O	O
similar	JJ	O	O
between	IN	O	O
controls	NNS	O	O
(	(	O	O
median	JJ	O	O
22.5	CD	O	O
days	NNS	O	O
)	)	O	O
and	CC	O	O
patients	NNS	O	O
treated	VBN	O	O
with	IN	O	O
lithium	NN	i	IPM
(	(	O	O
median	JJ	O	O
24	CD	O	O
days	NNS	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
number	NN	o	OPH
of	IN	o	OPH
remissions	NNS	o	OPH
,	,	o	O
relapse-free	JJ	o	OMO
survival	NN	o	OMO
and	CC	o	O
survival	NN	o	OMO
were	VBD	O	O
similar	JJ	o	O
for	IN	O	O
the	DT	O	O
lithium	NN	i	IPM
treated	VBD	O	O
and	CC	O	O
control	VB	O	O
groups	NNS	O	O
of	IN	O	O
patients	NNS	O	O
.	.	O	O

There	EX	O	O
was	VBD	O	O
no	DT	O	O
apparent	JJ	O	O
clinical	JJ	o	OOt
efficacy	NN	o	OOt
in	IN	O	O
the	DT	O	O
use	NN	O	O
of	IN	O	O
lithium	NN	i	IPM
to	TO	O	O
reduce	VB	O	O
the	DT	O	O
period	NN	O	O
of	IN	O	O
neutropenia	NN	O	O
in	IN	O	O
patients	NNS	p	O
undergoing	JJ	p	O
remission	NN	p	PC
induction	NN	i	IPH
therapy	NN	i	IPH
for	IN	p	O
acute	JJ	p	PC
myeloid	NN	p	PC
leukemia	NN	p	PC
.	.	p	O

Single	NNP	O	O
and	CC	O	O
short-term	JJ	O	O
dosing	NN	O	O
effects	NNS	O	O
of	IN	O	O
levocetirizine	NN	i	IPM
on	IN	O	O
adenosine	JJ	O	O
monophosphate	NN	O	O
bronchoprovocation	NN	O	O
in	IN	O	O
atopic	NN	O	O
asthma	NN	O	O
.	.	O	O

AIMS	NNP	O	O
Adenosine	NNP	O	O
monophosphate	NN	O	O
(	(	O	O
AMP	NNP	O	O
)	)	O	O
acts	VBZ	O	O
indirectly	RB	O	O
via	IN	O	O
primed	VBN	O	O
airway	RB	O	O
mast	JJ	O	O
cells	NNS	O	O
to	TO	O	O
induce	VB	O	O
bronchial	JJ	O	O
hyper-responsiveness	NN	O	O
,	,	O	O
which	WDT	O	O
in	IN	O	O
turn	NN	O	O
correlates	NNS	O	O
with	IN	O	O
eosinophilic	JJ	o	OPH
asthmatic	JJ	o	OPH
inflammation	NN	o	OPH
and	CC	o	OPH
atopic	JJ	o	OPH
disease	NN	o	OPH
expression	NN	o	OPH
.	.	o	OPH

We	PRP	O	O
evaluated	VBD	O	O
single	JJ	O	O
and	CC	O	O
short-term	JJ	O	O
dosing	NN	O	O
effects	NNS	O	O
of	IN	O	O
a	DT	O	O
modern	JJ	O	O
histamine	NN	O	O
H1-receptor	NNP	O	O
antagonist	NN	O	O
,	,	O	O
levocetirizine	NN	i	IPM
,	,	O	O
given	VBN	O	O
at	IN	O	O
the	DT	O	O
usual	JJ	O	O
clinically	RB	O	O
recommended	VBD	O	O
dose	NN	O	O
,	,	O	O
on	IN	O	O
the	DT	O	O
primary	JJ	O	O
outcome	NN	O	O
of	IN	O	O
AMP	NNP	O	O
bronchoprovocation	NN	O	O
.	.	O	O

METHODS	NNP	O	O
Fifteen	NNP	p	PSS
atopic	NN	p	PC
asthmatics	NNS	p	PC
were	VBD	p	O
randomized	VBN	p	O
in	IN	p	O
double-blind	NN	p	O
,	,	p	O
cross-over	JJ	p	O
fashion	NN	p	O
to	TO	p	O
receive	VB	p	O
for	IN	p	O
1	CD	p	O
week	NN	p	O
either	CC	p	O
levocetirizine	JJ	i	IPM
5	CD	i	IPM
mg	NN	i	IPM
or	CC	i	O
placebo	NN	i	IC
.	.	i	O

There	EX	O	O
was	VBD	O	O
a	DT	O	O
1-week	JJ	O	O
washout	NN	O	O
period	NN	O	O
prior	RB	O	O
to	TO	O	O
each	DT	O	O
randomized	VBN	O	O
treatment	NN	O	O
.	.	O	O

The	DT	O	O
provocative	JJ	O	O
concentration	NN	O	O
of	IN	O	O
AMP	NNP	O	O
producing	VBG	O	O
a	DT	O	O
20	CD	O	O
%	NN	O	O
fall	NN	O	O
in	IN	O	O
FEV1	NNP	O	O
(	(	O	O
PC20	NNP	O	O
)	)	O	O
was	VBD	O	O
measured	VBN	O	O
after	IN	O	O
each	DT	O	O
washout	NN	O	O
at	IN	O	O
baseline	NN	O	O
and	CC	O	O
at	IN	O	O
4-6	JJ	O	O
h	NN	O	O
following	VBG	O	O
the	DT	O	O
first	JJ	O	O
and	CC	O	O
last	JJ	O	O
doses	NNS	O	O
of	IN	O	O
each	DT	O	O
randomized	VBN	O	O
treatment	NN	O	O
.	.	O	O

RESULTS	NNP	O	O
Baseline	NNP	O	O
mean	JJ	o	OPH
+/-	JJ	o	OPH
SEM	NNP	o	OPH
values	NNS	o	OPH
after	IN	O	O
washout	NN	O	O
prior	RB	O	O
to	TO	O	O
each	DT	O	O
randomized	VBN	O	O
treatment	NN	O	O
comparing	VBG	O	O
levocetirizine	JJ	i	IPM
vs	NN	O	O
placebo	NN	i	IC
were	VBD	O	O
not	RB	O	O
significantly	RB	O	O
different	JJ	O	O
for	IN	O	O
prechallenge	NN	O	O
FEV1	NNP	o	OPH
(	(	O	O
%	NN	O	O
predicted	VBN	O	O
)	)	O	O
83	CD	O	O
+/-	JJ	O	O
4	CD	O	O
vs	JJ	O	O
82	CD	O	O
+/-	JJ	O	O
4	CD	O	O
,	,	O	O
or	CC	O	O
AMP	NNP	o	OPH
PC20	NNP	o	OPH
(	(	O	O
mg	JJ	O	O
ml	NN	O	O
(	(	O	O
-1	NNP	O	O
)	)	O	O
)	)	O	O
45	CD	O	O
+/-	JJ	O	O
24	CD	O	O
vs	JJ	O	O
45	CD	O	O
+/-	JJ	O	O
22	CD	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

Airway	NNP	o	OPH
calibre	NN	o	OPH
as	IN	o	OPH
prechallenge	NN	o	OPH
FEV1	NNP	o	OPH
for	IN	O	O
levocetirizine	JJ	i	IPM
vs	NN	O	O
placebo	NN	i	IC
was	VBD	O	O
not	RB	O	O
significantly	RB	O	O
different	JJ	O	O
following	VBG	O	O
the	DT	O	O
first	JJ	O	O
dose	JJ	O	O
86	CD	O	O
+/-	JJ	O	O
4	CD	O	O
vs	JJ	O	O
82	CD	O	O
+/-	JJ	O	O
4	CD	O	O
,	,	O	O
or	CC	O	O
the	DT	O	O
last	JJ	O	O
dose	JJ	O	O
85	CD	O	O
+/-	JJ	O	O
4	CD	O	O
vs	JJ	O	O
83	CD	O	O
+/-	JJ	O	O
4	CD	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

There	EX	O	O
were	VBD	O	O
significant	JJ	O	O
improvements	NNS	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
in	IN	O	O
AMP	NNP	o	OPH
PC20	NNP	o	OPH
comparing	VBG	O	O
levocetirizine	JJ	O	O
vs	NN	O	O
placebo	NN	O	O
following	VBG	O	O
the	DT	O	O
first	JJ	O	O
dose	JJ	O	O
123	CD	O	O
+/-	JJ	O	O
73	CD	O	O
vs	JJ	O	O
48	CD	O	O
+/-	JJ	O	O
24	CD	O	O
,	,	O	O
a	DT	O	O
1.4	CD	O	O
doubling	VBG	O	O
dilution	NN	O	O
difference	NN	O	O
(	(	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
0.8	CD	O	O
,	,	O	O
1.9	CD	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
last	JJ	O	O
dose	JJ	O	O
127	CD	O	O
+/-	JJ	O	O
74	CD	O	O
vs	JJ	O	O
53	CD	O	O
+/-	JJ	O	O
29	CD	O	O
,	,	O	O
a	DT	O	O
1.2	CD	O	O
doubling	VBG	O	O
dilution	NN	O	O
difference	NN	O	O
(	(	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
0.5	CD	O	O
,	,	O	O
2.0	CD	O	O
)	)	O	O
.	.	O	O

AMP	NNP	o	OPH
PC20	NNP	o	OPH
was	VBD	O	O
also	RB	O	O
improved	VBN	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
by	IN	O	O
the	DT	O	O
first	JJ	O	O
and	CC	O	O
last	JJ	O	O
doses	NNS	O	O
of	IN	O	O
levocetirizine	NN	O	O
but	CC	O	O
not	RB	O	O
placebo	VB	O	O
,	,	O	O
vs	FW	O	O
respective	JJ	O	O
baseline	NN	O	O
values	NNS	O	O
,	,	O	O
with	IN	O	O
there	EX	O	O
being	VBG	O	O
no	DT	O	O
difference	NN	O	O
in	IN	O	O
the	DT	O	O
degree	NN	O	O
of	IN	O	O
protection	NN	O	O
between	IN	O	O
first	JJ	O	O
and	CC	O	O
last	JJ	O	O
doses	NNS	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
Single	NNP	O	O
and	CC	O	O
short-term	JJ	O	O
dosing	NN	O	O
with	IN	O	O
levocetirizine	NN	i	IPM
conferred	VBN	O	O
similar	JJ	O	O
improvements	NNS	O	O
in	IN	O	O
bronchial	JJ	o	OPH
hyper-responsiveness	NN	o	OPH
to	TO	o	OPH
AMP	NNP	o	OPH
challenge	NN	O	O
,	,	O	O
which	WDT	O	O
was	VBD	O	O
unrelated	JJ	O	O
to	TO	O	O
prechallenge	VB	O	O
airway	RB	O	O
calibre	NN	O	O
.	.	O	O

Further	JJ	O	O
studies	NNS	O	O
are	VBP	O	O
indicated	VBN	O	O
to	TO	O	O
evaluate	VB	O	O
the	DT	O	O
longer-term	JJ	O	O
effects	NNS	O	O
of	IN	O	O
levocetirizine	NN	i	IPM
on	IN	O	O
asthma	JJ	o	OPH
exacerbations	NNS	o	OPH
.	.	o	OPH

Allogeneic	NNP	i	IPM
marrow	NN	i	IPM
transplantation	NN	i	IPM
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
chronic	JJ	p	PC
myeloid	NN	p	PC
leukemia	NN	p	PC
in	IN	p	O
the	DT	p	O
chronic	JJ	p	PC
phase	NN	p	PC
:	:	p	O
a	DT	O	O
randomized	JJ	O	O
trial	NN	O	O
of	IN	O	O
two	CD	O	O
irradiation	NN	O	O
regimens	NNS	O	O
.	.	O	O

A	DT	O	O
randomized	JJ	O	O
trial	NN	O	O
was	VBD	O	O
performed	VBN	O	O
to	TO	O	O
compare	VB	O	O
two	CD	O	O
regimens	NNS	O	O
of	IN	O	O
total	JJ	i	IOt
body	NN	i	IOt
irradiation	NN	i	IOt
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
chronic	JJ	p	PC
myeloid	NN	p	PC
leukemia	NN	p	PC
treated	VBN	p	O
by	IN	p	O
allogeneic	JJ	i	IPM
marrow	NN	i	IPM
transplantation	NN	i	IPM
while	IN	p	O
in	IN	p	O
the	DT	p	O
chronic	JJ	p	PC
phase	NN	p	PC
.	.	p	O

All	DT	O	O
patients	NNS	O	O
received	VBD	O	O
cyclophosphamide	JJ	i	IPM
120	CD	O	O
mg/kg	NN	O	O
followed	VBN	O	O
by	IN	O	O
total	JJ	i	IOt
body	NN	i	IOt
irradiation	NN	i	IOt
and	CC	i	O
marrow	NN	i	IPM
from	IN	i	IPM
HLA-identical	JJ	i	IPM
siblings	NNS	i	IPM
.	.	i	O

Cyclosporine	NNP	i	IPM
and	CC	i	O
methotrexate	NN	i	IPM
were	VBD	O	O
used	VBN	O	O
for	IN	O	O
prophylaxis	NN	O	O
against	IN	O	O
acute	JJ	O	O
graft-versus-host	JJ	O	O
disease	NN	O	O
.	.	O	O

Fifty-seven	JJ	p	PSS
patients	NNS	p	O
were	VBD	O	O
randomized	VBN	O	O
to	TO	O	O
receive	VB	O	O
2.0	CD	O	O
Gy	NNP	O	O
fractions	NNS	O	O
of	IN	O	O
irradiation	NN	i	IOt
daily	NN	O	O
for	IN	O	O
6	CD	O	O
days	NNS	O	O
and	CC	O	O
59	CD	O	O
were	VBD	O	O
randomized	VBN	O	O
to	TO	O	O
receive	VB	O	O
2.25	CD	O	O
Gy	NNP	O	O
fractions	NNS	O	O
daily	RB	O	O
for	IN	O	O
7	CD	O	O
days	NNS	O	O
.	.	O	O

The	DT	O	O
probabilities	NNS	o	OPH
of	IN	o	OPH
relapse	NN	o	OPH
at	IN	O	O
4	CD	O	O
years	NNS	O	O
were	VBD	O	O
0.25	CD	O	O
for	IN	O	O
the	DT	O	O
12.0	CD	O	O
Gy	NNP	O	O
group	NN	O	O
and	CC	O	O
0.00	CD	O	O
for	IN	O	O
the	DT	O	O
15.75	CD	O	O
Gy	NNP	O	O
group	NN	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
.008	NNP	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
actuarial	JJ	o	OMO
probabilities	NNS	o	OMO
of	IN	o	OMO
survival	NN	o	OMO
and	CC	o	O
relapse-free	JJ	o	OMO
survival	NN	o	OMO
at	IN	O	O
4	CD	O	O
years	NNS	O	O
were	VBD	O	O
0.60	CD	O	O
and	CC	O	O
0.58	CD	O	O
among	IN	O	O
the	DT	O	O
patients	NNS	O	O
who	WP	O	O
received	VBD	O	O
12.0	CD	O	O
Gy	NNP	O	O
compared	VBN	O	O
with	IN	O	O
0.66	CD	O	O
and	CC	O	O
0.66	CD	O	O
for	IN	O	O
those	DT	O	O
who	WP	O	O
received	VBD	O	O
15.75	CD	O	O
Gy	NNP	O	O
.	.	O	O

The	DT	O	O
4-year	JJ	o	O
probabilities	NNS	o	OMO
of	IN	o	OMO
transplant-related	JJ	o	OMO
mortality	NN	o	OMO
were	VBD	O	O
0.24	CD	O	O
and	CC	O	O
0.34	CD	O	O
respectively	RB	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
.13	NNP	O	O
)	)	O	O
while	IN	O	O
the	DT	O	O
probability	NN	o	OOt
of	IN	o	OOt
moderate	JJ	o	OOt
to	TO	o	OOt
severe	VB	o	OOt
acute	JJ	o	OOt
graft-versus-host	JJ	o	OOt
disease	NN	o	OOt
was	VBD	O	O
0.33	CD	O	O
for	IN	O	O
the	DT	O	O
12.0	CD	O	O
Gy	NNP	O	O
group	NN	O	O
and	CC	O	O
0.44	CD	O	O
for	IN	O	O
the	DT	O	O
15.75	CD	O	O
Gy	NNP	O	O
group	NN	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
.15	NNP	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
lower	JJR	O	O
relapse	NN	o	OPH
probability	NN	o	OPH
in	IN	O	O
the	DT	O	O
patients	NNS	p	O
receiving	VBG	p	O
the	DT	p	O
higher	JJR	p	O
dose	NN	p	O
of	IN	p	O
total	JJ	i	IOt
body	NN	i	IOt
irradiation	NN	i	IOt
did	VBD	O	O
not	RB	O	O
result	VB	O	O
in	IN	O	O
improved	JJ	o	OPH
survival	NN	o	OMO
because	IN	O	O
mortality	NN	O	O
from	IN	O	O
causes	VBZ	O	O
other	JJ	O	O
than	IN	O	O
relapse	NN	O	O
was	VBD	O	O
increased	VBN	O	O
.	.	O	O

Efficacy	NN	o	OOt
of	IN	O	O
nebulized	JJ	i	IPM
flunisolide	NN	i	IPM
combined	VBN	i	IPM
with	IN	i	IPM
salbutamol	NN	i	IPM
and	CC	i	IPM
ipratropium	NN	i	IPM
bromide	NN	i	IPM
in	IN	O	O
stable	JJ	p	O
patients	NNS	p	O
with	IN	p	O
moderate-to-severe	JJ	p	O
chronic	JJ	p	PC
obstructive	JJ	p	PC
pulmonary	JJ	p	PC
disease	NN	p	PC
.	.	p	O

BACKGROUND	IN	O	O
The	DT	O	O
efficacy	NN	o	OOt
of	IN	O	O
nebulized	JJ	O	O
corticosteroids	NNS	i	IPM
in	IN	O	O
the	DT	O	O
prevention	NN	O	O
of	IN	O	O
exacerbation	NN	O	O
of	IN	O	O
chronic	JJ	p	O
obstructive	JJ	p	O
pulmonary	JJ	p	O
disease	NN	p	O
(	(	p	O
COPD	NNP	p	PC
)	)	p	O
has	VBZ	O	O
been	VBN	O	O
poorly	RB	O	O
studied	VBN	O	O
.	.	O	O

OBJECTIVE	UH	O	O
To	TO	O	O
evaluate	VB	O	O
the	DT	O	O
efficacy	NN	o	OOt
and	CC	O	O
tolerability	NN	o	OOt
of	IN	O	O
nebulized	JJ	i	IPM
flunisolide	NN	i	IPM
(	(	O	O
1	CD	O	O
mg	NN	O	O
)	)	O	O
+	VBZ	i	IPM
salbutamol/ipratropium	JJ	i	IPM
bromide	NN	i	IPM
(	(	O	O
1,875/375	CD	O	O
microg	NN	O	O
)	)	O	O
b.i.d	NN	O	O
.	.	O	O

in	IN	O	O
comparison	NN	O	O
with	IN	O	O
placebo	NN	i	IC
+	NNP	i	O
salbutamol/ipratropium	NN	i	IC
bromide	NN	i	IC
.	.	i	O

METHODS	NNP	O	O
This	DT	O	O
was	VBD	O	O
a	DT	O	O
randomized	JJ	O	O
,	,	O	O
parallel-group	JJ	O	O
,	,	O	O
double-blind	JJ	O	O
study	NN	O	O
on	IN	O	O
114	CD	p	PSS
patients	NNS	p	O
with	IN	p	O
COPD	NNP	p	PC
of	IN	p	O
moderate-to-severe	JJ	p	O
degree	NN	p	O
.	.	p	O

The	DT	O	O
main	JJ	O	O
outcome	NN	O	O
was	VBD	O	O
the	DT	O	O
frequency	NN	o	OPH
of	IN	o	OPH
severe	JJ	o	OPH
exacerbations	NNS	o	OPH
over	IN	O	O
a	DT	O	O
6-month	JJ	O	O
period	NN	O	O
.	.	O	O

Before	IN	O	O
and	CC	O	O
after	IN	O	O
treatment	NN	O	O
,	,	O	O
respiratory	NN	o	OPH
symptoms	NNS	o	OPH
,	,	o	OPH
forced	VBD	o	OPH
expiratory	JJ	o	OPH
volume	NN	o	OPH
in	IN	o	OPH
1	CD	o	OPH
s	NN	o	OPH
(	(	o	OPH
FEV	NNP	o	OPH
(	(	o	OPH
1	CD	o	OPH
)	)	o	OPH
)	)	o	OPH
,	,	o	OPH
shuttle	JJ	o	OPH
walking	VBG	o	OPH
test	NN	o	OPH
distance	NN	o	OPH
and	CC	o	OPH
St.	NNP	o	OPH
George	NNP	o	OPH
's	POS	o	OPH
Respiratory	NNP	o	OPH
Questionnaire	NNP	o	OPH
scores	NNS	o	OPH
were	VBD	O	O
evaluated	VBN	O	O
.	.	O	O

RESULTS	VB	O	O
The	DT	O	O
total	JJ	o	OPH
number	NN	o	OPH
of	IN	o	OPH
exacerbations	NNS	o	OPH
was	VBD	O	O
slightly	RB	O	O
lower	JJR	O	O
in	IN	O	O
the	DT	O	O
flunisolide	NN	i	IPM
group	NN	O	O
compared	VBN	O	O
to	TO	O	O
the	DT	O	O
placebo	NN	i	IC
group	NN	O	O
(	(	O	O
19	CD	O	O
vs.	FW	O	O
34	CD	O	O
,	,	O	O
p	NN	O	O
=	NNP	O	O
0.054	CD	O	O
)	)	O	O
;	:	O	O
the	DT	O	O
number	NN	o	OPH
of	IN	o	OPH
patients	NNS	o	OPH
experiencing	VBG	o	OPH
at	IN	o	OPH
least	JJS	o	OPH
one	CD	o	OPH
exacerbation	NN	o	OPH
during	IN	o	OPH
the	DT	o	OPH
study	NN	o	OPH
was	VBD	O	O
also	RB	O	O
decreased	VBN	O	O
(	(	O	O
16	CD	O	O
vs.	FW	O	O
26	CD	O	O
,	,	O	O
p	NN	O	O
=	NNP	O	O
0.059	CD	O	O
)	)	O	O
.	.	O	O

In	IN	O	O
particular	JJ	O	O
,	,	O	O
type	JJ	o	OPH
3	CD	o	OPH
Anthonisens	NNP	o	OPH
's	POS	o	OPH
exacerbations	NNS	o	OPH
were	VBD	O	O
significantly	RB	O	O
reduced	VBN	O	O
by	IN	O	O
flunisolide	NN	i	IPM
(	(	O	O
p	JJ	O	O
=	NNP	O	O
0.044	CD	O	O
)	)	O	O
.	.	O	O

In	IN	O	O
the	DT	O	O
placebo	NN	i	IC
group	NN	O	O
,	,	O	O
scores	NNS	O	O
were	VBD	O	O
higher	JJR	O	O
than	IN	O	O
in	IN	O	O
the	DT	O	O
flunisolide	JJ	i	IPM
group	NN	O	O
but	CC	O	O
nonsignificant	NN	O	O
for	IN	O	O
dyspnea	NN	o	OA
,	,	o	OA
cough	NN	o	OA
,	,	o	OA
sputum	NN	o	OA
amount	NN	o	OA
and	CC	o	OA
purulence	NN	o	OA
.	.	o	O

FEV	NNP	o	OPH
(	(	o	OPH
1	CD	o	OPH
)	)	o	OPH
was	VBD	O	O
significantly	RB	O	O
increased	VBN	O	O
compared	VBN	O	O
to	TO	O	O
baseline	VB	O	O
in	IN	O	O
both	DT	O	O
groups	NNS	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
area	NN	o	OPH
under	IN	o	OPH
the	DT	o	OPH
FEV	NNP	o	OPH
(	(	o	OPH
1	CD	o	OPH
)	)	o	OPH
-time	NN	o	OPH
curve	NN	o	OPH
during	IN	o	OPH
the	DT	o	OPH
6-month	JJ	o	OPH
period	NN	o	OPH
was	VBD	O	O
significantly	RB	O	O
greater	JJR	O	O
in	IN	O	O
the	DT	O	O
flunisolide	NN	i	IPM
group	NN	O	O
(	(	O	O
5.2	CD	O	O
+/-	JJ	O	O
10.6	CD	O	O
vs.	FW	O	O
2.1	CD	O	O
+/-	JJ	O	O
5.0	CD	O	O
,	,	O	O
flunisolide	RB	i	IPM
vs.	FW	O	O
placebo	NN	i	IC
,	,	O	O
respectively	RB	O	O
;	:	O	O
p	VB	O	O
=	$	O	O
0.047	CD	O	O
)	)	O	O
.	.	O	O

For	IN	O	O
shuttle	JJ	o	OPH
walking	VBG	o	OPH
test	NN	o	OPH
distance	NN	o	OPH
and	CC	o	OPH
scores	NNS	o	OPH
of	IN	o	OPH
the	DT	o	OPH
St.	NNP	o	OPH
George	NNP	o	OPH
's	POS	o	OPH
Respiratory	NNP	o	OPH
Questionnaire	NNP	o	OPH
,	,	O	O
no	DT	O	O
significant	JJ	O	O
difference	NN	O	O
between	IN	O	O
the	DT	O	O
baseline	NN	O	O
evaluation	NN	O	O
and	CC	O	O
the	DT	O	O
end	NN	O	O
of	IN	O	O
the	DT	O	O
study	NN	O	O
was	VBD	O	O
observed	VBN	O	O
in	IN	O	O
both	DT	O	O
groups	NNS	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
Nebulized	NNP	i	IPM
flunisolide	NN	i	IPM
is	VBZ	O	O
a	DT	O	O
good	JJ	O	O
alternative	NN	O	O
to	TO	O	O
other	JJ	O	O
inhaled	JJ	O	O
corticosteroids	NNS	O	O
when	WRB	O	O
added	VBN	O	O
to	TO	O	O
nebulized	JJ	i	IPM
salbutamol/ipratropium	NN	i	IPM
bromide	NN	i	IPM
in	IN	O	O
the	DT	O	O
long-term	JJ	O	O
treatment	NN	O	O
of	IN	O	O
moderate-to-severe	JJ	p	PC
COPD	NNP	p	PC
patients	NNS	p	O
.	.	p	O

The	DT	O	O
effect	NN	O	O
of	IN	O	O
magnesium	NN	i	IPM
added	VBN	O	O
to	TO	O	O
levobupivacaine	VB	i	IPM
for	IN	O	O
femoral	JJ	O	O
nerve	NN	O	O
block	NN	O	O
on	IN	O	O
postoperative	JJ	O	O
analgesia	NN	O	O
in	IN	O	O
patients	NNS	p	O
undergoing	VBG	p	O
ACL	NNP	p	PC
reconstruction	NN	p	PC
.	.	p	O

PURPOSE	VB	O	O
The	DT	O	O
aim	NN	O	O
of	IN	O	O
this	DT	O	O
prospective	JJ	O	O
randomised	VBD	O	O
double-blind	NN	O	O
study	NN	O	O
is	VBZ	O	O
to	TO	O	O
investigate	VB	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
magnesium	NN	i	IPM
added	VBN	O	O
to	TO	O	O
local	JJ	O	O
anaesthetics	NNS	O	O
on	IN	O	O
postoperative	JJ	O	O
VAS	NNP	O	O
scores	NNS	O	O
,	,	O	O
total	JJ	O	O
opioid	JJ	O	O
consumption	NN	O	O
,	,	O	O
time	NN	O	O
to	TO	O	O
first	JJ	O	O
mobilisation	NN	O	O
,	,	O	O
patient	JJ	O	O
satisfaction	NN	O	O
and	CC	O	O
rescue	NN	O	O
analgesic	JJ	O	O
requirements	NNS	O	O
in	IN	O	O
arthroscopic	JJ	O	O
ACL	NNP	O	O
reconstruction	NN	O	O
surgery	NN	O	O
.	.	O	O

METHODS	NNP	O	O
A	NNP	O	O
total	NN	O	O
of	IN	O	O
107	CD	p	PSS
American	JJ	p	O
Society	NNP	p	O
of	IN	p	O
Anaesthesiologists	NNP	p	O
physical	JJ	p	O
status	NN	p	O
grade	NN	p	O
I	PRP	p	O
and	CC	p	O
II	NNP	p	O
patients	NNS	p	O
between	IN	p	O
18	CD	p	PA
and	CC	p	PA
65	CD	p	PA
years	NNS	p	O
of	IN	p	O
age	NN	p	O
who	WP	p	O
were	VBD	p	O
scheduled	VBN	p	O
to	TO	p	O
undergo	VB	p	O
elective	JJ	p	PC
anterior	JJ	p	PC
crucial	JJ	p	PC
ligament	NN	p	PC
(	(	p	PC
ACL	NNP	p	PC
)	)	p	PC
reconstruction	NN	p	PC
with	IN	p	O
hamstring	VBG	p	O
autografts	NNS	p	O
were	VBD	p	O
enrolled	VBN	p	O
in	IN	p	O
the	DT	p	O
study	NN	p	O
.	.	p	O

The	DT	O	O
patients	NNS	O	O
were	VBD	O	O
randomly	RB	O	O
allocated	VBN	O	O
to	TO	O	O
Groups	NNP	O	O
L	NNP	O	O
(	(	O	O
n	JJ	O	O
=	NNP	O	O
51	CD	O	O
)	)	O	O
and	CC	O	O
LM	NNP	O	O
(	(	O	O
n	JJ	O	O
=	NNP	O	O
56	CD	O	O
)	)	O	O
using	VBG	O	O
the	DT	O	O
closed-envelope	NN	O	O
method	NN	O	O
.	.	O	O

Group	NNP	O	O
LM	NNP	O	O
was	VBD	O	O
administered	VBN	O	O
19	CD	O	O
ml	NN	O	O
of	IN	O	O
0.25	CD	i	O
%	NN	i	O
levobupivacaine	NN	i	IPM
and	CC	i	O
1	CD	i	O
ml	NN	i	O
of	IN	i	O
15	CD	i	O
%	NN	i	O
magnesium	NN	i	IPM
sulphate	NN	i	IPM
,	,	O	O
while	IN	O	O
Group	NNP	i	O
L	NNP	i	O
was	VBD	i	O
administered	VBN	i	O
20	CD	i	O
ml	NN	i	O
of	IN	i	O
0.25	CD	i	IPM
%	NN	i	IPM
levobupivacaine	NN	i	IPM
for	IN	O	O
femoral	JJ	O	O
blockade	NN	O	O
.	.	O	O

General	NNP	O	O
anaesthesia	NN	O	O
was	VBD	O	O
administered	VBN	O	O
using	VBG	O	O
laryngeal	JJ	O	O
airway	RB	O	O
masks	NNS	O	O
following	VBG	O	O
neural	JJ	O	O
blockade	NN	O	O
in	IN	O	O
both	DT	O	O
groups	NNS	O	O
.	.	O	O

The	DT	O	O
patients	NNS	O	O
were	VBD	O	O
evaluated	VBN	O	O
for	IN	O	O
heart	NN	o	OPH
rate	NN	o	OPH
and	CC	o	OPH
mean	VB	o	OPH
arterial	JJ	o	OPH
pressure	NN	o	OPH
,	,	o	O
oxygen	NN	o	OPH
saturation	NN	o	OPH
,	,	o	O
visual	JJ	o	OPH
analogue	NN	o	OPH
score	NN	o	OPH
(	(	o	OPH
VAS	NNP	o	OPH
)	)	o	OPH
,	,	o	OPH
verbal	JJ	o	OPH
rating	NN	o	OPH
scale	NN	o	OPH
(	(	o	OPH
VRS	NNP	o	OPH
)	)	o	OPH
,	,	o	O
rescue	NN	o	OOt
analgesic	JJ	o	OOt
requirements	NNS	o	OOt
,	,	o	O
total	JJ	o	OOt
opioid	JJ	o	OOt
consumption	NN	o	OOt
,	,	O	O
side	NN	O	O
effects	NNS	O	O
and	CC	O	O
time	NN	O	O
to	TO	O	O
first	JJ	O	O
mobilisation	NN	O	O
at	IN	O	O
the	DT	O	O
1st	CD	O	O
,	,	O	O
2nd	CD	O	O
,	,	O	O
4th	CD	O	O
,	,	O	O
6th	CD	O	O
,	,	O	O
12th	CD	O	O
and	CC	O	O
24th	CD	O	O
hours	NNS	O	O
postoperatively	RB	O	O
.	.	O	O

RESULTS	NNP	O	O
There	EX	O	O
was	VBD	O	O
no	DT	O	O
statistically	RB	O	O
significant	JJ	O	O
difference	NN	O	O
in	IN	O	O
terms	NNS	O	O
of	IN	O	O
demographic	JJ	o	OPH
data	NNS	o	OPH
,	,	o	OPH
mean	JJ	o	OPH
arterial	JJ	o	OPH
pressure	NN	o	OPH
,	,	o	OPH
heart	NN	o	OPH
rate	NN	o	OPH
or	CC	o	OPH
oxygen	NN	o	OPH
saturation	NN	o	OPH
between	IN	O	O
groups	NNS	O	O
.	.	O	O

The	DT	O	O
area	NN	o	OPH
under	IN	o	OPH
the	DT	o	OPH
curve	NN	o	OPH
VAS	NNP	o	OPH
and	CC	o	OPH
VRS	NNP	o	OPH
scores	NNS	o	OPH
were	VBD	O	O
lower	JJR	O	O
at	IN	O	O
4	CD	O	O
,	,	O	O
6	CD	O	O
,	,	O	O
12	CD	O	O
and	CC	O	O
24	CD	O	O
h	NN	O	O
in	IN	O	O
Group	NNP	O	O
LM	NNP	O	O
(	(	O	O
p	JJ	O	O
=	NN	O	O
0.001	CD	O	O
,	,	O	O
p	NN	O	O
=	VBD	O	O
0.016	CD	O	O
,	,	O	O
respectively	RB	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
rescue	NN	o	OPH
analgesic	JJ	o	OPH
requirement	NN	o	OPH
and	CC	o	OPH
the	DT	o	OPH
total	JJ	o	OPH
opioid	JJ	o	OPH
consumption	NN	o	OPH
were	VBD	O	O
significantly	RB	O	O
lower	JJR	O	O
in	IN	O	O
Group	NNP	O	O
LM	NNP	O	O
(	(	O	O
p	JJ	O	O
=	NN	O	O
0.015	CD	O	O
,	,	O	O
p	NN	O	O
=	VBD	O	O
0.019	CD	O	O
,	,	O	O
respectively	RB	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
time	NN	o	OOt
to	TO	o	OOt
first	JJ	o	OOt
mobilisation	NN	o	OOt
and	CC	o	O
the	DT	o	O
Likert	NNP	o	O
score	NN	o	O
(	(	O	O
completely	RB	O	O
comfortable	JJ	O	O
;	:	O	O
quite	RB	O	O
comfortable	JJ	O	O
;	:	O	O
slight	JJ	O	O
discomfort	NN	O	O
;	:	O	O
painful	JJ	O	O
;	:	O	O
very	RB	O	O
painful	JJ	O	O
)	)	O	O
were	VBD	O	O
higher	JJR	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
block	NN	o	OOt
onset	VBD	o	OOt
time	NN	o	OOt
was	VBD	O	O
lower	JJR	O	O
in	IN	O	O
Group	NNP	O	O
LM	NNP	O	O
(	(	O	O
p	JJ	O	O
=	NN	O	O
0.014	CD	O	O
and	CC	O	O
p	VB	O	O
=	JJ	O	O
0.012	CD	O	O
,	,	O	O
respectively	RB	O	O
)	)	O	O
.	.	O	O

There	EX	O	O
was	VBD	O	O
no	DT	O	O
difference	NN	O	O
in	IN	O	O
terms	NNS	O	O
of	IN	O	O
side	NN	O	O
effects	NNS	O	O
.	.	O	O

CONCLUSIONS	VB	O	O
The	DT	O	O
addition	NN	O	O
of	IN	O	O
magnesium	NN	i	IPM
to	TO	O	O
levobupivacaine	VB	O	O
prolongs	NNS	O	O
the	DT	O	O
sensory	NN	O	O
and	CC	O	O
motor	NN	O	O
block	NN	O	O
duration	NN	O	O
without	IN	O	O
increasing	VBG	O	O
side	NN	O	O
effects	NNS	O	O
,	,	O	O
enhances	VBZ	O	O
the	DT	O	O
quality	NN	O	O
of	IN	O	O
postoperative	JJ	O	O
analgesia	NN	O	O
and	CC	O	O
increases	VBZ	O	O
patient	JJ	O	O
satisfaction	NN	O	O
;	:	O	O
however	RB	O	O
,	,	O	O
the	DT	O	O
addition	NN	O	O
of	IN	O	O
magnesium	NN	O	O
delays	VBZ	O	O
the	DT	O	O
time	NN	O	O
to	TO	O	O
first	JJ	O	O
mobilisation	NN	O	O
and	CC	O	O
decreases	VBZ	O	O
rescue	NN	O	O
analgesic	JJ	O	O
requirements	NNS	O	O
.	.	O	O

Abacavir	NNP	i	IPM
once	RB	O	O
or	CC	O	O
twice	RB	O	O
daily	RB	O	O
combined	VBN	O	O
with	IN	O	O
once-daily	JJ	O	O
lamivudine	NN	i	IPM
and	CC	i	IPM
efavirenz	NN	i	IPM
for	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
antiretroviral-naive	JJ	o	OPH
HIV-infected	JJ	p	PC
adults	NNS	p	PA
:	:	p	O
results	NNS	O	O
of	IN	O	O
the	DT	O	O
Ziagen	NNP	i	IPM
Once	NNP	O	O
Daily	NNP	O	O
in	IN	O	O
Antiretroviral	NNP	O	O
Combination	NNP	O	O
Study	NNP	O	O
.	.	O	O

The	DT	O	O
long	JJ	O	O
intracellular	JJ	O	O
half-life	NN	O	O
of	IN	O	O
abacavir	NN	i	IPM
(	(	i	IPM
ABC	NNP	i	IPM
)	)	i	IPM
supports	VBZ	O	O
its	PRP$	O	O
once-daily	JJ	O	O
use	NN	O	O
,	,	O	O
and	CC	O	O
this	DT	O	O
would	MD	O	O
be	VB	O	O
expected	VBN	O	O
to	TO	O	O
simplify	VB	O	O
treatment	NN	O	O
if	IN	O	O
ABC	NNP	i	IPM
could	MD	O	O
be	VB	O	O
given	VBN	O	O
as	IN	O	O
part	NN	O	O
of	IN	O	O
a	DT	O	O
complete	JJ	O	O
once-daily	JJ	O	O
regimen	NNS	O	O
.	.	O	O

A	DT	O	O
randomized	JJ	O	O
double-blind	JJ	O	O
clinical	JJ	O	O
trial	NN	O	O
compared	VBN	O	O
the	DT	O	O
efficacy	NN	o	OOt
and	CC	O	O
safety	NN	o	OOt
of	IN	O	O
600	CD	O	O
mg	NN	O	O
of	IN	O	O
ABC	NNP	i	IPM
administered	VBD	O	O
once	RB	O	O
daily	JJ	O	O
(	(	O	O
n	JJ	O	O
=	NNP	O	O
384	CD	O	O
)	)	O	O
versus	NN	O	O
300	CD	O	O
mg	NN	O	O
of	IN	O	O
ABC	NNP	i	IPM
administered	VBD	O	O
twice	RB	O	O
daily	JJ	O	O
(	(	O	O
n	JJ	O	O
=	NNP	O	O
386	CD	O	O
)	)	O	O
in	IN	O	O
combination	NN	O	O
with	IN	O	O
300	CD	O	O
mg	NNS	O	O
of	IN	O	O
lamivudine	NN	i	IPM
(	(	i	IPM
3TC	CD	i	IPM
)	)	i	IPM
and	CC	O	O
600	CD	O	O
mg	NN	O	O
of	IN	O	O
efavirenz	NN	i	IPM
(	(	i	IPM
EFV	NNP	i	IPM
)	)	i	IPM
administered	VBD	O	O
once	RB	O	O
daily	JJ	O	O
in	IN	O	O
antiretroviral-naive	JJ	p	PC
patients	NNS	p	O
over	IN	p	O
48	CD	p	O
weeks	NNS	p	O
.	.	p	O

The	DT	O	O
baseline	NN	o	OPH
median	JJ	o	OPH
plasma	NN	o	OPH
HIV-1	NNP	o	OPH
RNA	NNP	o	OPH
level	NN	o	OPH
was	VBD	O	O
4.89	CD	O	O
log10	JJ	O	O
copies/mL	NN	O	O
(	(	O	O
44	CD	O	O
%	NN	O	O
with	IN	O	O
viral	JJ	O	O
load	NN	O	O
>	VBD	O	O
100,000	CD	O	O
copies/mL	NN	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
median	JJ	O	O
CD4	NNP	O	O
cell	NN	O	O
count	NN	O	O
was	VBD	O	O
262	CD	O	O
cells/mm	NN	O	O
.	.	O	O

ABC	NNP	i	IPM
administered	VBD	O	O
once	RB	O	O
daily	JJ	O	O
was	VBD	O	O
non-inferior	JJ	O	O
to	TO	O	O
the	DT	O	O
twice-daily	JJ	O	O
regimen	NNS	O	O
,	,	O	O
with	IN	O	O
66	CD	O	O
%	NN	O	O
and	CC	O	O
68	CD	O	O
%	NN	O	O
of	IN	O	O
patients	NNS	O	O
in	IN	O	O
these	DT	O	O
respective	JJ	O	O
treatment	NN	O	O
arms	NNS	O	O
achieving	VBG	O	O
a	DT	O	O
confirmed	JJ	O	O
plasma	NN	o	OPH
HIV-1	NNP	o	OPH
RNA	NNP	o	OPH
level	NN	o	OPH
<	VBD	O	O
50	CD	O	O
copies/mL	NN	O	O
(	(	O	O
95	CD	O	O
%	NN	O	O
confidence	NN	O	O
interval	NN	O	O
:	:	O	O
-8.4	CD	O	O
%	NN	O	O
,	,	O	O
4.9	CD	O	O
%	NN	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
ABC	NNP	i	IPM
once-daily	JJ	O	O
and	CC	O	O
twice-daily	JJ	O	O
regimens	NNS	O	O
were	VBD	O	O
similar	JJ	O	O
with	IN	O	O
respect	NN	O	O
to	TO	O	O
infrequency	NN	o	OPH
of	IN	o	OPH
virologic	JJ	o	OPH
failure	NN	o	OPH
(	(	O	O
10	CD	O	O
%	NN	O	O
vs.	FW	O	O
8	CD	O	O
%	NN	O	O
)	)	O	O
,	,	O	O
emergence	NN	o	OPH
of	IN	o	OPH
resistance	NN	o	OPH
mutations	NNS	o	OPH
,	,	o	OPH
CD4	NNP	o	OPH
cell	NN	o	OPH
increases	NNS	o	OPH
from	IN	o	OPH
baseline	NN	o	OPH
(	(	O	O
median	JJ	O	O
,	,	O	O
188	CD	O	O
vs.	FW	O	O
200	CD	O	O
cells/mm	NN	O	O
)	)	O	O
,	,	O	O
safety	NN	o	OPH
profile	NN	o	OPH
,	,	o	O
and	CC	o	O
incidence	NN	o	OPH
of	IN	o	OPH
ABC-related	NNP	o	OPH
hypersensitivity	NN	o	OPH
reactions	NNS	o	OPH
(	(	O	O
9	CD	O	O
%	NN	O	O
vs.	FW	O	O
7	CD	O	O
%	NN	O	O
)	)	O	O
.	.	O	O

ABC	NNP	i	IPM
administered	VBD	O	O
once	RB	O	O
daily	JJ	O	O
in	IN	O	O
combination	NN	O	O
with	IN	O	O
3TC	CD	i	IPM
and	CC	O	O
EFV	NNP	i	IPM
administered	VBD	O	O
once	RB	O	O
daily	JJ	O	O
was	VBD	O	O
non-inferior	JJ	O	O
to	TO	O	O
the	DT	O	O
ABC	NNP	i	IPM
twice-daily	JJ	O	O
dosing	NN	O	O
schedule	NN	O	O
when	WRB	O	O
combined	VBN	O	O
with	IN	O	O
3TC	CD	i	IPM
and	CC	O	O
EFV	NNP	i	IPM
over	IN	O	O
48	CD	O	O
weeks	NNS	O	O
.	.	O	O

Effect	NN	O	O
of	IN	O	O
L-carnitine	NNP	i	IPM
on	IN	O	O
myocardial	JJ	O	O
metabolism	NN	O	O
:	:	O	O
results	NNS	O	O
of	IN	O	O
a	DT	O	O
balanced	JJ	O	O
,	,	O	O
placebo-controlled	JJ	O	O
,	,	O	O
double-blind	JJ	O	O
study	NN	O	O
in	IN	O	O
patients	NNS	p	O
undergoing	VBG	p	O
open	JJ	p	O
heart	NN	p	O
surgery	NN	p	O
.	.	p	O

The	DT	O	O
effects	NNS	O	O
of	IN	O	O
L-carnitine	NNP	i	IPM
on	IN	O	O
cardiac	JJ	O	O
performance	NN	O	O
after	IN	O	O
open	JJ	O	O
heart	NN	O	O
surgery	NN	O	O
were	VBD	O	O
evaluated	VBN	O	O
in	IN	O	O
a	DT	O	O
balanced	JJ	O	O
,	,	O	O
placebo-controlled	JJ	i	IC
,	,	O	O
double-blind	JJ	O	O
study	NN	O	O
in	IN	O	O
38	CD	p	PSS
patients	NNS	p	O
.	.	p	O

Preoperative	JJ	O	O
haemodynamic	JJ	O	O
status	NN	O	O
was	VBD	O	O
good	JJ	O	O
in	IN	O	O
all	DT	O	O
of	IN	O	O
them	PRP	O	O
.	.	O	O

Seventeen	JJ	p	O
subjects	NNS	p	O
underwent	JJ	p	O
mitral	JJ	i	IS
valve	NN	i	IS
replacement	NN	i	IS
and	CC	p	O
19	CD	p	PSS
patients	NNS	p	O
coronary	JJ	i	IS
artery	JJ	i	IS
bypass	NN	i	IS
grafting	NN	i	IS
.	.	i	O

Five	CD	O	O
grams	NNS	O	O
L-carnitine	JJ	i	IPM
were	VBD	O	O
given	VBN	O	O
intravenously	RB	O	O
over	IN	O	O
2	CD	O	O
h	NNS	O	O
,	,	O	O
twice	RB	O	O
daily	RB	O	O
for	IN	O	O
5	CD	O	O
consecutive	JJ	O	O
days	NNS	O	O
;	:	O	O
moreover	RB	O	O
,	,	O	O
10	CD	O	O
g	JJ	O	O
L-carnitine	NNP	i	IPM
in	IN	i	IPM
1500	CD	i	IPM
ml	NN	i	IPM
cardioplegia	NN	i	IPM
were	VBD	O	O
administered	VBN	O	O
through	IN	O	O
the	DT	O	O
aortic	JJ	O	O
root	NN	O	O
after	IN	O	O
aortic	JJ	i	IS
cross-clamping	NN	i	IS
.	.	i	O

Surgery	NN	O	O
was	VBD	O	O
always	RB	O	O
planned	VBN	O	O
on	IN	O	O
treatment	NN	O	O
day	NN	O	O
3	CD	O	O
.	.	O	O

The	DT	O	O
post-ischaemic	JJ	O	O
functional	JJ	O	O
recovery	NN	O	O
of	IN	O	O
the	DT	O	O
heart	NN	O	O
was	VBD	O	O
assessed	VBN	O	O
by	IN	O	O
clinical	JJ	O	O
parameters	NNS	O	O
,	,	O	O
as	RB	O	O
well	RB	O	O
as	IN	O	O
by	IN	O	O
biochemical	JJ	O	O
and	CC	O	O
ultrastructure	JJ	O	O
evaluations	NNS	O	O
on	IN	O	O
biopsy	NN	O	O
specimens	NNS	O	O
.	.	O	O

No	DT	O	O
differences	NNS	O	O
were	VBD	O	O
found	VBN	O	O
between	IN	O	O
the	DT	O	O
control	NN	O	O
and	CC	O	O
the	DT	O	O
treatment	NN	O	O
group	NN	O	O
with	IN	O	O
respect	NN	O	O
to	TO	O	O
all	DT	O	O
clinical	JJ	O	O
parameters	NNS	O	O
of	IN	O	O
cardiac	JJ	O	O
performance	NN	O	O
after	IN	O	O
cardiopulmonary	JJ	O	O
bypass	NN	O	O
.	.	O	O

At	IN	O	O
anaesthesia	JJ	O	O
induction	NN	O	O
,	,	O	O
serum	JJ	o	OPH
carnitine	NN	o	OPH
was	VBD	O	O
significantly	RB	O	O
increased	VBN	O	O
in	IN	O	O
treated	JJ	O	O
patients	NNS	O	O
,	,	O	O
but	CC	O	O
carnitine	JJ	o	OPH
concentrations	NNS	o	OPH
in	IN	O	O
the	DT	O	O
right	JJ	O	O
atrial	JJ	O	O
biopsy	NN	O	O
obtained	VBN	O	O
just	RB	O	O
before	RB	O	O
aortic	JJ	O	O
declamping	NN	O	O
were	VBD	O	O
similar	JJ	O	O
in	IN	O	O
the	DT	O	O
two	CD	O	O
groups	NNS	O	O
.	.	O	O

In	IN	O	O
patients	NNS	O	O
with	IN	O	O
mitral	JJ	O	O
valve	FW	O	O
replacement	NN	O	O
,	,	O	O
L-carnitine	JJ	i	IPM
therapy	NN	i	IPM
was	VBD	O	O
associated	VBN	O	O
with	IN	O	O
significantly	RB	O	O
higher	JJR	O	O
concentrations	NNS	O	O
of	IN	O	O
pyruvate	NN	o	OPH
,	,	o	O
ATP	NNP	o	OPH
and	CC	o	O
creatine	JJ	o	OPH
phosphate	NN	o	OPH
in	IN	O	O
papillary	JJ	O	O
muscle	NN	O	O
.	.	O	O

Glycogen	NN	o	OPH
levels	NNS	o	OPH
were	VBD	O	O
also	RB	O	O
higher	JJR	O	O
in	IN	O	O
the	DT	O	O
treated	JJ	O	O
group	NN	O	O
,	,	O	O
but	CC	O	O
the	DT	O	O
difference	NN	O	O
was	VBD	O	O
not	RB	O	O
statistically	RB	O	O
significant	JJ	O	O
.	.	O	O

Myocardial	JJ	O	O
ultrastructure	NN	O	O
on	IN	O	O
septal	JJ	O	O
biopsies	NNS	O	O
,	,	O	O
obtained	VBD	O	O
within	IN	O	O
5	CD	O	O
min	NN	O	O
from	IN	O	O
weaning	VBG	O	O
from	IN	O	O
extracorporeal	JJ	O	O
circulation	NN	O	O
,	,	O	O
showed	VBD	O	O
better	JJR	O	O
preservation	NN	O	O
scores	NNS	O	O
for	IN	O	O
all	DT	O	O
considered	VBN	O	O
parameters	NNS	O	O
(	(	o	O
nucleus	NN	o	OPH
,	,	o	OPH
sarcoplasmic	JJ	o	OPH
reticulum	NN	o	OPH
,	,	o	OPH
mitochondria	NN	o	OPH
and	CC	o	OPH
cellular	JJ	o	OPH
oedema	NN	o	OPH
)	)	o	O
in	IN	O	O
the	DT	O	O
treated	JJ	O	O
subjects	NNS	O	O
,	,	O	O
although	IN	O	O
the	DT	O	O
difference	NN	O	O
reached	VBD	O	O
statistical	JJ	O	O
significance	NN	O	O
only	RB	O	O
for	IN	O	O
nuclei	NN	O	O
.	.	O	O

When	WRB	O	O
biochemical	JJ	O	O
and	CC	O	O
ultrastructural	JJ	O	O
data	NNS	O	O
are	VBP	O	O
considered	VBN	O	O
,	,	O	O
these	DT	O	O
findings	NNS	O	O
suggest	VBP	O	O
that	IN	O	O
L-carnitine	NNP	i	IPM
improves	VBZ	O	O
myocardial	JJ	o	OPH
metabolism	NN	o	OPH
.	.	o	O

However	RB	O	O
,	,	O	O
it	PRP	O	O
can	MD	O	O
not	RB	O	O
be	VB	O	O
concluded	VBN	O	O
that	IN	O	O
L-carnitine	NNP	O	O
provides	VBZ	O	O
an	DT	O	O
advantageous	JJ	o	OOt
support	NN	o	OOt
therapy	NN	o	OOt
for	IN	O	O
well-compensated	JJ	O	O
patients	NNS	p	O
requiring	VBG	p	O
cardiac	JJ	p	O
surgery	NN	p	O
.	.	p	O

In	IN	O	O
contrast	NN	O	O
,	,	O	O
the	DT	O	O
positive	JJ	O	O
effects	NNS	O	O
of	IN	O	O
L-carnitine	NNP	O	O
on	IN	O	O
cardiac	JJ	o	OPH
recovery	NN	o	OPH
after	IN	O	O
bypass	NN	O	O
might	MD	O	O
become	VB	O	O
clinically	RB	O	O
relevant	JJ	O	O
in	IN	O	O
the	DT	O	O
surgical	JJ	O	O
setting	NN	O	O
for	IN	O	O
haemodynamically	RB	p	O
compromised	JJ	p	O
patients	NNS	p	O
,	,	O	O
in	IN	O	O
which	WDT	O	O
further	JJ	O	O
investigations	NNS	O	O
are	VBP	O	O
required	VBN	O	O
.	.	O	O

Effects	NNS	O	O
of	IN	O	O
a	DT	O	O
standardized	JJ	i	IE
pamphlet	NN	i	IE
on	IN	O	O
insomnia	NN	o	O
in	IN	p	O
children	NNS	p	PA
with	IN	p	O
autism	NN	p	PC
spectrum	NN	p	PC
disorders	NNS	p	PC
.	.	p	O

OBJECTIVE	NNP	O	O
Sleep	NNP	o	OPH
difficulties	NNS	o	OPH
are	VBP	O	O
common	JJ	O	O
reasons	NNS	O	O
why	WRB	p	O
parents	NNS	p	O
seek	VBP	p	O
medical	JJ	p	O
intervention	NN	p	O
in	IN	p	O
children	NNS	p	O
with	IN	p	O
autism	NN	p	PC
spectrum	NN	p	PC
disorders	NNS	p	PC
(	(	p	PC
ASDs	NNP	p	PC
)	)	p	O
.	.	p	O

We	PRP	O	O
determined	VBD	O	O
whether	IN	O	O
a	DT	O	O
pamphlet	NN	i	IE
alone	RB	O	O
could	MD	O	O
be	VB	O	O
used	VBN	O	O
by	IN	O	O
parents	NNS	O	O
to	TO	O	O
help	VB	O	O
their	PRP$	O	O
child	NN	O	O
's	POS	O	O
insomnia	NN	o	OPH
.	.	o	OPH

METHODS	NNP	O	O
Thirty-six	JJ	p	PSS
children	NNS	p	PA
with	IN	p	O
ASD	NNP	p	PC
,	,	p	O
ages	VBZ	p	PA
2	CD	p	PA
to	TO	p	PA
10	CD	p	PA
years	NNS	p	PA
,	,	p	O
were	VBD	p	O
enrolled	VBN	p	O
.	.	p	O

All	DT	p	O
had	VBD	p	O
prolonged	VBN	p	PC
sleep	JJ	o	OPH
latency	NN	o	OPH
confirmed	VBN	p	O
by	IN	p	O
actigraphy	NN	p	O
showing	VBG	p	O
a	DT	p	O
mean	JJ	p	O
sleep	JJ	o	OPH
latency	NN	o	OPH
of	IN	p	O
30	CD	p	O
minutes	NNS	p	O
or	CC	p	O
more	JJR	p	O
.	.	p	O

Parents	NNS	p	O
were	VBD	p	O
randomly	RB	p	O
assigned	VBN	p	O
to	TO	p	O
receive	VB	p	O
the	DT	p	O
sleep	JJ	i	IE
education	NN	i	IE
pamphlet	NN	i	IE
or	CC	i	IE
no	DT	i	IE
intervention	NN	i	IC
.	.	i	O

Children	NNP	O	O
wore	VBD	O	O
an	DT	O	O
actigraphy	NN	i	IOt
device	NN	i	IOt
to	TO	O	O
record	VB	O	O
baseline	NN	O	O
sleep	JJ	o	OPH
parameters	NNS	o	OPH
,	,	O	O
with	IN	O	O
the	DT	O	O
primary	JJ	O	O
outcome	NN	O	O
variable	JJ	O	O
being	VBG	O	O
change	NN	o	OPH
in	IN	o	OPH
sleep	JJ	o	OPH
latency	NN	o	OPH
.	.	o	OPH

Actigraphy	NNP	O	O
data	NNS	O	O
were	VBD	O	O
collected	VBN	O	O
a	DT	O	O
second	JJ	O	O
time	NN	O	O
2	CD	O	O
weeks	NNS	O	O
after	IN	O	O
the	DT	O	O
parent	NN	O	O
received	VBD	O	O
the	DT	O	O
randomization	NN	O	O
assignment	NN	O	O
and	CC	O	O
analyzed	VBN	O	O
by	IN	O	O
using	VBG	O	O
Student	NNP	O	O
's	POS	O	O
t	JJ	O	O
test	NN	O	O
.	.	O	O

Parents	NNS	O	O
were	VBD	O	O
also	RB	O	O
asked	VBN	O	O
a	DT	O	O
series	NN	O	O
of	IN	O	O
questions	NNS	O	O
to	TO	O	O
gather	VB	O	O
information	NN	O	O
about	IN	O	O
the	DT	O	O
pamphlet	NN	i	IE
and	CC	O	O
its	PRP$	O	O
usefulness	NN	O	O
.	.	O	O

RESULTS	NNP	O	O
Although	IN	O	O
participants	NNS	O	O
randomized	VBN	O	O
to	TO	O	O
the	DT	O	O
2	CD	O	O
arms	NNS	O	O
did	VBD	O	O
not	RB	O	O
differ	VB	O	O
statistically	RB	O	O
in	IN	O	O
age	NN	o	OPH
,	,	o	OPH
gender	NN	o	OPH
,	,	o	OPH
socioeconomic	JJ	o	OPH
status	NN	o	OPH
,	,	o	OPH
total	JJ	o	OPH
Children	NNP	o	OPH
's	POS	o	OPH
Sleep	NNP	o	OPH
Habits	NNP	o	OPH
Questionnaire	NNP	o	OPH
score	NN	o	OPH
,	,	o	OPH
or	CC	o	OPH
actigraphy	NN	o	OPH
parameters	NNS	o	OPH
,	,	O	O
some	DT	O	O
differences	NNS	O	O
may	MD	O	O
be	VB	O	O
large	JJ	O	O
enough	RB	O	O
to	TO	O	O
affect	VB	O	O
results	NNS	O	O
.	.	O	O

Mean	JJ	o	OPH
change	NN	o	OPH
in	IN	o	OPH
sleep-onset	JJ	o	OPH
latency	NN	o	OPH
did	VBD	O	O
not	RB	O	O
differ	VB	O	O
between	IN	O	O
the	DT	O	O
randomized	VBN	O	O
groups	NNS	O	O
(	(	i	O
pamphlet	VB	i	IE
versus	NN	i	IE
no	DT	i	IC
pamphlet	NN	i	IC
)	)	i	O
.	.	i	O

Parents	NNS	O	O
commented	VBD	O	O
that	IN	O	O
the	DT	O	O
pamphlet	NN	i	IE
contained	VBD	O	O
good	JJ	O	O
information	NN	o	OOt
,	,	O	O
but	CC	O	O
indicated	VBD	O	O
that	IN	O	O
it	PRP	O	O
would	MD	O	O
have	VB	O	O
been	VBN	O	O
more	RBR	O	O
useful	JJ	O	O
to	TO	O	O
be	VB	O	O
given	VBN	O	O
specific	JJ	O	O
examples	NNS	O	O
of	IN	O	O
how	WRB	O	O
to	TO	O	O
take	VB	O	O
the	DT	O	O
information	NN	O	O
and	CC	O	O
put	VB	O	O
it	PRP	O	O
into	IN	O	O
practice	NN	O	O
.	.	O	O

CONCLUSIONS	VB	O	O
A	DT	O	O
sleep	JJ	i	IE
education	NN	i	IE
pamphlet	NN	i	IE
did	VBD	O	O
not	RB	O	O
appear	VB	O	O
to	TO	O	O
improve	VB	O	O
sleep	JJ	o	OPH
latency	NN	o	OPH
in	IN	p	O
children	NNS	p	O
with	IN	p	O
ASDs	NNP	p	PC
.	.	p	O

Effectiveness	NN	o	OOt
of	IN	O	O
norgestimate	NN	i	IPM
and	CC	O	O
ethinyl	NN	i	IPM
estradiol	NN	i	IPM
in	IN	O	O
treating	VBG	O	O
moderate	JJ	p	PC
acne	NN	p	PC
vulgaris	NN	p	PC
.	.	p	O

BACKGROUND	NNP	O	O
An	DT	O	O
excess	NN	O	O
of	IN	O	O
androgen	NN	O	O
is	VBZ	O	O
believed	VBN	O	O
to	TO	O	O
contribute	VB	O	O
to	TO	O	O
development	NN	O	O
of	IN	O	O
acne	NN	O	O
in	IN	O	O
some	DT	O	O
patients	NNS	O	O
.	.	O	O

Because	IN	O	O
oral	JJ	i	IPM
contraceptives	NNS	i	IPM
(	(	O	O
OCs	NNP	O	O
)	)	O	O
may	MD	O	O
reduce	VB	O	O
the	DT	O	O
active	JJ	o	OPH
androgen	NN	o	OPH
level	NN	o	OPH
,	,	O	O
hormonal	JJ	O	O
therapy	NN	O	O
with	IN	O	O
OCs	NNP	O	O
has	VBZ	O	O
been	VBN	O	O
used	VBN	O	O
successfully	RB	O	O
to	TO	O	O
treat	VB	O	O
patients	NNS	p	O
with	IN	p	O
acne	NN	p	PC
,	,	O	O
although	IN	O	O
this	DT	O	O
treatment	NN	O	O
has	VBZ	O	O
previously	RB	O	O
not	RB	O	O
been	VBN	O	O
studied	VBN	O	O
in	IN	O	O
placebo-controlled	JJ	O	O
trials	NNS	O	O
.	.	O	O

OBJECTIVE	CC	O	O
Our	PRP$	O	O
purpose	NN	O	O
was	VBD	O	O
to	TO	O	O
evaluate	VB	O	O
the	DT	O	O
efficacy	NN	o	OOt
of	IN	O	O
a	DT	O	O
triphasic	JJ	i	IPM
,	,	i	IPM
combination	NN	i	IPM
OC	NNP	i	IPM
(	(	i	IPM
ORTHO	NNP	i	IPM
TRI-CYCLEN	NNP	i	IPM
[	NNP	i	IPM
Ortho-McNeil	NNP	i	IPM
Pharmaceutical	NNP	i	IPM
,	,	i	IPM
Raritan	NNP	i	IPM
,	,	i	IPM
N.J.	NNP	i	IPM
]	NNP	i	IPM
,	,	i	IPM
norgestimate/ethinyl	RB	i	IPM
estradiol	NN	i	IPM
)	)	i	IPM
compared	VBN	O	O
with	IN	O	O
placebo	NN	i	IC
in	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
moderate	JJ	O	O
acne	NN	O	O
vulgaris	NN	O	O
.	.	O	O

METHODS	NNP	O	O
Two	CD	p	PSS
hundred	VBD	p	PSS
fifty-seven	RB	p	PSS
healthy	JJ	p	PC
female	NN	p	PSE
subjects	NNS	p	O
,	,	p	O
15	CD	p	PA
to	TO	p	PA
49	CD	p	PA
years	NNS	p	PA
of	IN	p	O
age	NN	p	O
with	IN	p	O
moderate	JJ	p	PC
acne	NNS	p	PC
vulgaris	NN	p	PC
,	,	O	O
were	VBD	O	O
enrolled	VBN	O	O
in	IN	O	O
a	DT	O	O
multicenter	NN	O	O
,	,	O	O
randomized	VBN	O	O
,	,	O	O
double-blind	JJ	O	O
,	,	O	O
placebo-controlled	JJ	O	O
clinical	JJ	O	O
trial	NN	O	O
.	.	O	O

Each	DT	O	O
month	NN	O	O
for	IN	O	O
6	CD	O	O
months	NNS	O	O
,	,	O	O
subjects	VBZ	O	O
received	VBN	O	O
either	RB	O	O
3	CD	O	O
consecutive	JJ	O	O
weeks	NNS	O	O
of	IN	O	O
the	DT	O	O
OC	NNP	i	IPM
(	(	O	O
i.e.	FW	O	O
,	,	O	O
tablets	NNS	O	O
containing	VBG	O	O
a	DT	O	O
fixed	VBN	O	O
dose	NN	O	O
of	IN	O	O
ethinyl	JJ	i	IPM
estradiol	NN	i	IPM
[	VBD	i	O
0.035	CD	i	O
mg	NN	i	O
]	NN	i	O
and	CC	i	O
increasing	VBG	i	O
doses	NNS	i	O
of	IN	i	O
norgestimate	JJ	i	IPM
[	NNS	O	O
0.180	CD	O	O
mg	NNS	O	O
,	,	O	O
0.215	CD	O	O
mg	NN	O	O
,	,	O	O
0.250	CD	O	O
mg	NN	O	O
]	NN	O	O
)	)	O	O
followed	VBN	O	O
by	IN	O	O
7	CD	O	O
days	NNS	O	O
of	IN	O	O
inactive	JJ	i	IPM
drug	NN	i	IPM
or	CC	i	O
placebo	NN	i	IC
(	(	O	O
color-matched	JJ	O	O
tablets	NNS	O	O
)	)	O	O
.	.	O	O

Efficacy	NN	o	OOt
was	VBD	O	O
assessed	VBN	O	O
by	IN	O	O
facial	JJ	o	OPH
acne	JJ	o	OPH
lesion	NN	o	OPH
counts	NNS	o	OPH
,	,	O	O
an	DT	O	O
investigator	NN	O	O
's	POS	O	O
global	JJ	o	OPH
assessment	NN	o	OPH
,	,	O	O
a	DT	O	O
subject	NN	o	OOt
's	POS	o	OOt
self-assessment	NN	o	OOt
,	,	O	O
and	CC	O	O
an	DT	O	O
analysis	NN	O	O
of	IN	O	O
within-cycle	JJ	o	OPH
variation	NN	o	OPH
(	(	o	OPH
cycle	NN	o	OPH
6	CD	o	OPH
)	)	o	OPH
in	IN	o	OPH
lesion	NN	o	OPH
counts	NNS	o	OPH
.	.	o	OPH

RESULTS	NNP	O	O
Of	IN	O	O
the	DT	O	O
160	CD	p	PSS
subjects	NNS	p	O
in	IN	O	O
whom	WP	O	O
efficacy	NN	O	O
could	MD	O	O
be	VB	O	O
evaluated	VBN	O	O
,	,	O	O
the	DT	O	O
OC	NNP	O	O
group	NN	O	O
showed	VBD	O	O
a	DT	O	O
statistically	RB	O	O
significantly	RB	O	O
greater	JJR	O	O
improvement	NN	o	OPH
than	IN	O	O
the	DT	O	O
placebo	NN	p	O
group	NN	p	O
for	IN	O	O
all	DT	O	O
primary	JJ	O	O
efficacy	NN	O	O
measures	NNS	O	O
.	.	O	O

The	DT	O	O
mean	JJ	o	OPH
decrease	NN	o	OPH
in	IN	o	OPH
inflammatory	JJ	o	OPH
lesion	NN	o	OPH
count	NN	o	OPH
from	IN	O	O
baseline	NN	O	O
to	TO	O	O
cycle	NN	O	O
6	CD	O	O
was	VBD	O	O
11.8	CD	O	O
(	(	O	O
62.0	CD	O	O
%	NN	O	O
)	)	O	O
versus	NN	O	O
7.6	CD	O	O
(	(	O	O
38.6	CD	O	O
%	NN	O	O
)	)	O	O
(	(	O	O
p	JJ	O	O
=	NNP	O	O
0.0001	CD	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
mean	JJ	o	OPH
decrease	NN	o	OPH
in	IN	o	OPH
total	JJ	o	OPH
lesion	NN	o	OPH
count	NN	o	OPH
was	VBD	O	O
29.1	CD	O	O
(	(	O	O
53.1	CD	O	O
%	NN	O	O
)	)	O	O
versus	NN	O	O
14.1	CD	O	O
(	(	O	O
26.8	CD	O	O
%	NN	O	O
)	)	O	O
(	(	O	O
p	JJ	O	O
=	NNP	O	O
0.0001	CD	O	O
)	)	O	O
in	IN	O	O
the	DT	O	O
OC	NNP	O	O
and	CC	O	O
placebo	NN	O	O
groups	NNS	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

In	IN	O	O
the	DT	O	O
investigator	NN	o	OPH
's	POS	o	OPH
global	JJ	o	OPH
assessment	NN	o	OPH
,	,	O	O
93.7	CD	O	O
%	NN	O	O
of	IN	O	O
the	DT	O	O
active	JJ	O	O
treatment	NN	O	O
group	NN	O	O
versus	VBD	O	O
65.4	CD	O	O
%	NN	O	O
of	IN	O	O
the	DT	O	O
placebo	NN	O	O
group	NN	O	O
were	VBD	O	O
rated	VBN	O	O
as	IN	O	O
improved	VBN	O	O
at	IN	O	O
the	DT	O	O
end	NN	O	O
of	IN	O	O
the	DT	O	O
study	NN	O	O
(	(	O	O
p	JJ	O	O
<	NNP	O	O
0.001	CD	O	O
)	)	O	O
.	.	O	O

Six	CD	O	O
of	IN	O	O
the	DT	O	O
seven	CD	O	O
secondary	JJ	o	OPH
efficacy	NN	o	OPH
measures	NNS	o	OPH
(	(	o	OPH
total	JJ	o	OPH
comedones	NNS	o	OPH
,	,	o	OPH
open	JJ	o	OPH
comedones	NNS	o	OPH
,	,	o	OPH
closed	VBD	o	OPH
comedones	NNS	o	OPH
,	,	o	OPH
papules	NNS	o	OPH
,	,	o	OPH
pustules	NNS	o	OPH
,	,	o	OPH
and	CC	o	OPH
the	DT	o	OPH
subject	NN	o	OPH
's	POS	o	OPH
self-assessment	NN	o	OPH
of	IN	o	OPH
study	NN	o	OPH
treatment	NN	o	OPH
)	)	o	OPH
were	VBD	O	O
also	RB	O	O
significantly	RB	O	O
more	RBR	O	O
favorable	JJ	O	O
in	IN	O	O
the	DT	O	O
OC	NNP	O	O
group	NN	O	O
compared	VBN	O	O
with	IN	O	O
the	DT	O	O
placebo	NN	O	O
group	NN	O	O
.	.	O	O

CONCLUSION	NNP	O	O
An	DT	O	O
OC	NNP	O	O
containing	VBG	O	O
0.035	CD	O	O
mg	NN	O	O
of	IN	O	O
ethinyl	JJ	i	IPM
estradiol	NN	i	IPM
combined	VBN	O	O
with	IN	O	O
the	DT	O	O
triphasic	JJ	O	O
regimen	NNS	O	O
of	IN	O	O
norgestimate	NN	O	O
is	VBZ	O	O
a	DT	O	O
safe	JJ	o	OOt
and	CC	o	OOt
effective	JJ	o	OOt
treatment	NN	o	OOt
of	IN	o	OOt
moderate	JJ	o	OOt
acne	NNS	o	OOt
vulgaris	VBP	o	OOt
in	IN	p	O
women	NNS	p	PSE
with	IN	p	O
no	DT	p	O
known	VBN	p	O
contraindication	NN	p	O
to	TO	p	O
OC	NNP	p	O
therapy	NN	p	O
.	.	p	O

Chemotherapy	NN	O	O
of	IN	O	O
large	JJ	p	PC
bowel	NN	p	PC
carcinoma	NN	i	O
--	:	i	O
fluorouracil	NN	i	IPM
(	(	i	IPM
FU	NNP	i	IPM
)	)	i	IPM
+	VBP	i	O
hydroxyurea	NN	i	IPM
(	(	i	IPM
HU	NNP	i	IPM
)	)	i	IPM
vs.	FW	i	O
methyl-CCNU	NN	i	IPM
,	,	i	O
oncovin	NN	i	IPM
,	,	i	O
fluorouracil	NN	i	IPM
,	,	i	O
and	CC	i	O
streptozotocin	NN	i	IPM
(	(	i	IPM
MOF-Strep	NNP	i	IPM
)	)	i	IPM
.	.	i	O

An	DT	O	O
Eastern	JJ	O	O
Cooperative	NNP	O	O
Oncology	NNP	O	O
Group	NNP	O	O
study	NN	O	O
.	.	O	O

In	IN	O	O
this	DT	O	O
prospective	JJ	O	O
randomized	NN	O	O
study	NN	O	O
of	IN	O	O
initial	JJ	O	O
chemotherapy	NN	O	O
for	IN	O	O
advanced	JJ	p	PC
measurable	JJ	p	PC
metastatic	JJ	p	PC
large	JJ	p	PC
bowel	NN	o	O
carcinoma	NN	o	O
,	,	O	O
the	DT	O	O
response	NN	o	OPH
rate	NN	o	OPH
was	VBD	O	O
6/32	CD	p	O
(	(	p	O
19	CD	p	O
%	NN	p	O
)	)	p	O
for	IN	p	O
FU	NNP	p	O
+	NNP	p	O
HU	NNP	p	O
and	CC	p	O
5/32	CD	p	O
(	(	p	O
16	CD	p	O
%	NN	p	O
)	)	p	O
for	IN	p	O
MOF-Strep	NNP	p	O
;	:	p	O
the	DT	O	O
estimated	JJ	O	O
median	JJ	o	OMO
survival	NN	o	OMO
is	VBZ	O	O
43	CD	O	O
weeks	NNS	O	O
for	IN	O	O
both	DT	O	O
treatments	NNS	O	O
.	.	O	O

Patients	NNS	O	O
who	WP	O	O
received	VBD	O	O
MOF-Strep	NNP	O	O
experienced	VBD	O	O
substantially	RB	O	O
greater	JJR	O	O
vomiting	VBG	o	OA
and	CC	o	OA
hematologic	JJ	o	OA
toxicity	NN	o	OA
than	IN	O	O
patients	NNS	p	O
who	WP	p	O
received	VBD	p	O
FU	NNP	O	O
+	NNP	O	O
HU	NNP	O	O
(	(	O	O
p	NN	O	O
less	JJR	O	O
than	IN	O	O
0.001	CD	O	O
)	)	O	O
.	.	O	O

Specific	JJ	i	IPH
immunoglobulin	NN	i	IPH
for	IN	O	O
treatment	NN	O	O
of	IN	O	O
whooping	JJ	p	PC
cough	NN	p	PC
.	.	p	O

Immunoglobulin	NNP	i	IPH
treatment	NN	O	O
for	IN	O	O
whooping	JJ	O	O
cough	NN	O	O
(	(	O	O
pertussis	NN	O	O
)	)	O	O
is	VBZ	O	O
widely	RB	O	O
believed	VBN	O	O
to	TO	O	O
be	VB	O	O
ineffective	JJ	o	OOt
although	IN	O	O
there	EX	O	O
are	VBP	O	O
sound	JJ	O	O
reasons	NNS	O	O
for	IN	O	O
regarding	VBG	O	O
the	DT	O	O
condition	NN	O	O
as	IN	O	O
a	DT	O	O
toxin-induced	JJ	O	O
disease	NN	O	O
.	.	O	O

We	PRP	O	O
wondered	VBD	O	O
whether	IN	O	O
the	DT	O	O
lack	NN	o	OOt
of	IN	o	OOt
success	NN	o	OOt
with	IN	O	O
pertussis	NN	O	O
immunoglobulins	NNS	i	IPH
might	MD	O	O
be	VB	O	O
attributable	JJ	O	O
to	TO	O	O
inadequate	VB	O	O
dose	NN	O	O
,	,	O	O
so	IN	O	O
we	PRP	O	O
designed	VBD	O	O
a	DT	O	O
randomised	VBN	O	O
,	,	O	O
double-blind	JJ	O	O
,	,	O	O
placebo-controlled	JJ	i	IC
trial	NN	O	O
of	IN	O	O
two	CD	O	O
immunoglobulin	JJ	O	O
preparations	NNS	O	O
.	.	O	O

The	DT	O	O
study	NN	O	O
was	VBD	O	O
conducted	VBN	O	O
at	IN	O	O
three	CD	p	O
Swedish	JJ	p	O
hospitals	NNS	p	O
.	.	p	O

We	PRP	O	O
enrolled	VBD	O	O
73	CD	p	PSS
children	NNS	p	PA
aged	VBD	p	PA
less	JJR	p	PA
than	IN	p	PA
36	CD	p	PA
months	NNS	p	PA
who	WP	p	O
were	VBD	p	O
admitted	VBN	p	O
with	IN	p	O
a	DT	p	O
clinical	JJ	p	O
diagnosis	NN	p	O
of	IN	p	O
whooping	JJ	p	PC
cough	NN	p	PC
.	.	p	O

On	IN	O	O
admission	NN	O	O
they	PRP	O	O
were	VBD	O	O
assigned	VBN	O	O
to	TO	O	O
one	CD	O	O
of	IN	O	O
three	CD	O	O
groups	NNS	O	O
:	:	O	O
(	(	O	O
a	DT	O	O
)	)	O	O
monocomponent	NN	i	IPM
pertussis	NN	i	IPM
toxoid	JJ	i	IPM
vaccine	NN	i	IPM
;	:	i	O
(	(	i	O
b	NN	i	O
)	)	i	O
two-component	NN	i	IPM
acellular	JJ	i	IPM
vaccine	NN	i	IPM
also	RB	i	IPM
containing	VBG	i	IPM
filamentous	JJ	i	IPM
haemagglutinin	NN	i	IPM
;	:	i	O
or	CC	i	O
(	(	i	O
c	NN	i	O
)	)	i	O
20	CD	i	IC
%	NN	i	IC
albumin	JJ	i	IPM
solution	NN	i	IPM
(	(	i	IC
placebo	NN	i	IC
)	)	i	IC
.	.	i	O

The	DT	O	O
immunoglobulins	NNS	i	IPH
had	VBD	O	O
a	DT	O	O
high	JJ	O	O
antitoxin	NN	O	O
content	NN	O	O
and	CC	O	O
had	VBD	O	O
been	VBN	O	O
raised	VBN	O	O
with	IN	O	O
acellular	JJ	O	O
pertussis	NN	O	O
vaccines	NNS	O	O
.	.	O	O

Diagnosis	NN	O	O
of	IN	O	O
pertussis	NN	O	O
was	VBD	O	O
confirmed	VBN	O	O
by	IN	O	O
laboratory	NN	O	O
tests	NNS	O	O
and	CC	O	O
the	DT	O	O
follow-up	NN	O	O
was	VBD	O	O
completed	VBN	O	O
in	IN	O	O
67	CD	O	O
children	NNS	O	O
.	.	O	O

The	DT	O	O
main	JJ	O	O
study	NN	O	O
group	NN	O	O
consisted	VBD	O	O
of	IN	O	O
47	CD	p	PSS
children	NNS	p	O
with	IN	p	O
less	JJR	p	O
than	IN	p	O
or	CC	p	O
equal	JJ	p	O
to	TO	p	O
14	CD	p	O
days	NNS	p	O
of	IN	p	O
disease	NN	p	O
before	IN	p	O
therapy	NN	p	O
.	.	p	O

Duration	NN	o	OPH
of	IN	o	OPH
whoops	JJ	o	OPH
post-treatment	NN	o	OPH
was	VBD	O	O
8.7	CD	O	O
days	NNS	O	O
(	(	O	O
95	CD	O	O
%	NN	O	O
Cl	NNP	O	O
4.8	CD	O	O
,	,	O	O
12.6	CD	O	O
)	)	O	O
in	IN	O	O
the	DT	O	O
33	CD	O	O
children	NNS	O	O
receiving	VBG	O	O
immunoglobulin	NN	i	IPH
vs	NN	O	O
20.6	CD	O	O
(	(	O	O
95	CD	O	O
%	NN	O	O
Cl	NNP	O	O
11.9	CD	O	O
,	,	O	O
29.3	CD	O	O
)	)	O	O
in	IN	O	O
the	DT	O	O
14	CD	O	O
receiving	NN	O	O
placebo	NN	i	IC
(	(	O	O
p	JJ	O	O
=	NNP	O	O
0.0041	CD	O	O
)	)	O	O
.	.	O	O

Mean	JJ	o	OPH
number	NN	o	OPH
of	IN	o	OPH
whoops	NNS	o	OPH
during	IN	O	O
the	DT	O	O
first	JJ	O	O
week	NN	O	O
of	IN	O	O
follow-up	NN	O	O
was	VBD	O	O
also	RB	O	O
significantly	RB	O	O
reduced	VBN	O	O
(	(	O	O
p	JJ	O	O
=	NNP	O	O
0.0196	CD	O	O
)	)	O	O
.	.	O	O

We	PRP	O	O
found	VBD	O	O
that	IN	O	O
early	JJ	O	O
treatment	NN	O	O
was	VBD	O	O
important	JJ	O	O
,	,	O	O
since	IN	O	O
the	DT	O	O
effect	NN	O	O
on	IN	O	O
duration	NN	o	OPH
of	IN	o	OPH
whoops	NNS	o	OPH
was	VBD	O	O
most	RBS	O	O
pronounced	JJ	O	O
when	WRB	O	O
disease	NN	O	O
duration	NN	O	O
before	IN	O	O
treatment	NN	O	O
was	VBD	O	O
less	JJR	O	O
than	IN	O	O
or	CC	O	O
equal	JJ	O	O
to	TO	O	O
7	CD	O	O
days	NNS	O	O
.	.	O	O

There	EX	O	O
were	VBD	O	O
no	DT	O	O
significant	JJ	O	O
differences	NNS	o	OPH
between	IN	O	O
the	DT	O	O
two	CD	O	O
immunoglobulin	NN	O	O
preparations	NNS	O	O
.	.	O	O

High-dose	JJ	O	O
specific	JJ	O	O
pertussis	NN	O	O
immunoglobulin	NN	i	IPH
with	IN	O	O
a	DT	O	O
high	JJ	O	O
antitoxin	NN	O	O
concentration	NN	O	O
has	VBZ	O	O
a	DT	O	O
beneficial	JJ	o	OOt
effect	NN	o	OOt
in	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
whooping	JJ	O	O
cough	NN	O	O
.	.	O	O

A	DT	O	O
1.5-year	JJ	O	O
follow-up	NN	O	O
of	IN	O	O
an	DT	O	O
Internet-based	JJ	i	IE
intervention	NN	i	IE
for	IN	O	O
complicated	JJ	O	O
grief	NN	O	O
.	.	O	O

Only	RB	O	O
recently	RB	O	O
have	VBP	O	O
psychotherapeutic	JJ	i	IE
interventions	NNS	i	IE
for	IN	O	O
complicated	JJ	O	O
grief	NN	O	O
been	VBN	O	O
developed	VBN	O	O
and	CC	O	O
evaluated	VBN	O	O
in	IN	O	O
randomized	VBN	O	O
controlled	JJ	O	O
trials	NNS	O	O
.	.	O	O

These	DT	O	O
trials	NNS	O	O
have	VBP	O	O
reported	VBN	O	O
significant	JJ	O	O
reductions	NNS	O	O
in	IN	O	O
complicated	JJ	O	O
grief	NN	O	O
and	CC	O	O
related	JJ	O	O
symptoms	NNS	O	O
in	IN	O	O
response	NN	O	O
to	TO	O	O
treatment	NN	O	O
relative	JJ	O	O
to	TO	O	O
control	VB	i	IC
groups	NNS	i	IC
.	.	i	O

However	RB	O	O
,	,	O	O
little	JJ	O	O
is	VBZ	O	O
known	VBN	O	O
about	IN	O	O
the	DT	O	O
long-term	JJ	O	O
outcomes	NNS	O	O
of	IN	O	O
these	DT	O	O
treatments	NNS	O	O
.	.	O	O

The	DT	O	O
authors	NNS	O	O
present	VBP	O	O
an	DT	O	O
evaluation	NN	O	O
of	IN	O	O
a	DT	O	O
1.5-year	JJ	O	O
follow-up	NN	O	O
of	IN	O	O
an	DT	O	O
Internet-based	JJ	i	IE
cognitive-behavioral	JJ	i	IE
intervention	NN	i	IE
for	IN	p	O
complicated	JJ	p	O
grief	NN	p	O
.	.	p	O

Treatment	NNP	p	O
group	NN	p	O
patients	NNS	p	O
(	(	p	O
n	JJ	p	O
=	NNP	p	O
22	CD	p	PSS
)	)	p	O
were	VBD	p	O
administered	VBN	p	O
various	JJ	p	O
assessments	NNS	p	O
of	IN	p	O
complicated	JJ	p	O
grief	NN	p	O
indicators	NNS	p	O
,	,	O	O
including	VBG	O	O
the	DT	O	O
Impact	NN	o	OME
of	IN	o	OME
Event	NNP	o	OME
Scale	NNP	o	OME
,	,	O	O
the	DT	O	O
anxiety	NN	o	OME
and	CC	o	OME
depression	NN	o	OME
subscales	NNS	o	OME
of	IN	o	OME
the	DT	o	OME
Brief	NNP	o	OME
Symptom	NNP	o	OME
Inventory	NNP	o	OME
,	,	o	OME
and	CC	o	OME
the	DT	o	OME
SF-12	NNP	o	OME
.	.	o	OME

Results	NNP	O	O
indicate	VBP	O	O
that	IN	O	O
the	DT	O	O
reduction	NN	O	O
in	IN	O	O
symptoms	NNS	o	OME
of	IN	o	OME
complicated	JJ	o	OME
grief	NN	o	OME
observed	VBN	O	O
at	IN	O	O
posttreatment	NN	O	O
was	VBD	O	O
maintained	VBN	O	O
at	IN	O	O
1.5-year	JJ	O	O
follow-up	NN	O	O
.	.	O	O

Partial-area	JJ	p	O
method	NN	p	O
in	IN	p	O
bioequivalence	NN	p	O
assessment	NN	O	O
:	:	O	O
naproxen	NN	i	IPM
.	.	i	O

Regulatory	NNP	O	O
authorities	NNS	O	O
require	VBP	O	O
demonstration	NN	O	O
of	IN	O	O
bioequivalence	NN	p	O
through	IN	O	O
comparisons	NNS	O	O
of	IN	O	O
different	JJ	O	O
pharmacokinetic	JJ	O	O
parameters	NNS	O	O
,	,	O	O
the	DT	O	O
area	NN	o	OPH
under	IN	o	OPH
the	DT	o	OPH
plasma	JJ	o	OPH
concentration-time	JJ	o	OPH
curve	NN	o	OPH
(	(	o	OPH
AUC	NNP	o	OPH
)	)	o	OPH
,	,	o	OPH
the	DT	o	OPH
maximum	JJ	o	OPH
plasma	JJ	o	OPH
concentration	NN	o	OPH
(	(	o	OPH
Cmax	NNP	o	OPH
)	)	o	OPH
,	,	O	O
and	CC	O	O
the	DT	o	OPH
time	NN	o	OPH
to	TO	o	OPH
reach	VB	o	OPH
peak	JJ	o	OPH
concentration	NN	o	OPH
(	(	o	OOt
Tmax	NNP	o	OOt
)	)	o	OOt
.	.	o	O

The	DT	O	O
applicability	NN	O	O
and	CC	O	O
validity	NN	O	O
of	IN	O	O
regulatory	JJ	O	O
requirements	NNS	O	O
have	VBP	O	O
been	VBN	O	O
widely	RB	O	O
criticized	VBN	O	O
on	IN	O	O
statistical	JJ	O	O
and	CC	O	O
clinical	JJ	O	O
relevance	NN	O	O
grounds	NNS	O	O
.	.	O	O

For	IN	O	O
most	JJS	O	O
noncomplicated	JJ	O	O
absorption	NN	O	O
models	NNS	O	O
,	,	O	O
the	DT	O	O
AUC	NNP	o	OOt
correlates	VBZ	O	O
well	RB	O	O
with	IN	O	O
the	DT	O	O
extent	NN	O	O
of	IN	O	O
absorption	NN	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
in	IN	O	O
nonlinear	JJ	O	O
models	NNS	O	O
of	IN	O	O
absorption	NN	O	O
,	,	O	O
in	IN	O	O
mechanisms	NN	O	O
involving	VBG	O	O
recycling	NN	O	O
of	IN	O	O
drugs	NNS	O	O
,	,	O	O
and	CC	O	O
for	IN	O	O
drugs	NNS	O	O
with	IN	O	O
long	JJ	O	O
half-life	NN	O	O
,	,	O	O
the	DT	O	O
use	NN	O	O
of	IN	O	O
total	JJ	O	O
AUC	NNP	o	OOt
(	(	O	O
from	IN	O	O
zero	CD	O	O
to	TO	O	O
infinity	NN	O	O
)	)	O	O
can	MD	O	O
give	VB	O	O
erroneous	JJ	O	O
and	CC	O	O
clinically	RB	O	O
irrelevant	JJ	O	O
results	NNS	O	O
since	IN	O	O
the	DT	O	O
area	NN	O	O
is	VBZ	O	O
mostly	RB	O	O
determined	VBN	O	O
by	IN	O	O
elimination	NN	O	O
phase	NN	O	O
or	CC	O	O
by	IN	O	O
recycling	VBG	O	O
.	.	O	O

The	DT	O	O
calculation	NN	O	O
of	IN	O	O
total	JJ	O	O
AUC	NNP	o	OOt
also	RB	O	O
involves	VBZ	O	O
prolonged	JJ	O	O
sampling	NN	O	O
,	,	O	O
adding	VBG	O	O
to	TO	O	O
the	DT	O	O
cost	NN	O	O
and	CC	O	O
risks	NNS	O	O
associated	VBN	O	O
with	IN	O	O
bioequivalence	NN	O	O
studies	NNS	O	O
.	.	O	O

The	DT	O	O
use	NN	O	O
of	IN	O	O
Cmax	NNP	o	OOt
or	CC	o	O
Tmax	NNP	o	OOt
as	IN	O	O
a	DT	O	O
measure	NN	O	O
of	IN	O	O
rate	NN	O	O
of	IN	O	O
absorption	NN	O	O
,	,	O	O
to	TO	O	O
correlate	VB	O	O
with	IN	O	O
clinical	JJ	O	O
relevance	NN	O	O
,	,	O	O
is	VBZ	O	O
widely	RB	O	O
criticized	VBN	O	O
on	IN	O	O
logical	JJ	O	O
,	,	O	O
technical	JJ	O	O
,	,	O	O
and	CC	O	O
statistical	JJ	O	O
grounds	NNS	O	O
.	.	O	O

For	IN	O	O
drugs	NNS	O	O
used	VBN	O	O
on	IN	O	O
a	DT	O	O
multiple-dose	JJ	O	O
basis	NN	O	O
,	,	O	O
Cmax	NNP	o	OOt
and	CC	O	O
Tmax	NNP	o	OOt
evaluations	NNS	O	O
become	VBP	O	O
redundant	JJ	O	O
since	IN	O	O
the	DT	O	O
average	JJ	O	O
plateau	NN	o	OPH
concentration	NN	o	OPH
is	VBZ	O	O
not	RB	O	O
affected	VBN	O	O
by	IN	O	O
these	DT	O	O
parameters	NNS	O	O
.	.	O	O

To	TO	O	O
resolve	VB	O	O
the	DT	O	O
drawbacks	NNS	O	O
in	IN	O	O
the	DT	O	O
traditional	JJ	O	O
methodology	NN	O	O
of	IN	O	O
bioequivalence	NN	O	O
evaluation	NN	O	O
,	,	O	O
the	DT	O	O
use	NN	O	O
of	IN	O	O
partial	JJ	O	O
areas	NNS	O	O
in	IN	O	O
lieu	NN	O	O
of	IN	O	O
total	JJ	O	O
AUC	NNP	o	OOt
,	,	o	O
Tmax	NNP	o	OOt
,	,	o	O
and	CC	o	O
Cmax	NNP	o	OOt
is	VBZ	O	O
suggested	VBN	O	O
.	.	O	O

This	DT	O	O
study	NN	O	O
investigates	VBZ	O	O
the	DT	O	O
logic	NN	O	O
and	CC	O	O
robustness	NN	O	O
of	IN	O	O
the	DT	O	O
partial-area	JJ	p	O
method	NN	p	O
in	IN	p	O
establishing	VBG	p	O
bioequivalence	NN	p	O
.	.	p	O

We	PRP	O	O
conclude	VBP	O	O
that	IN	O	O
the	DT	O	O
5h	CD	o	OOt
AUC	NNP	o	OOt
is	VBZ	O	O
a	DT	O	O
more	RBR	O	O
relevant	JJ	O	O
parameter	NN	O	O
to	TO	O	O
establish	VB	O	O
naproxen	NNS	i	IPM
bioequivalence	NN	O	O
than	IN	O	O
AUCinf	NNP	o	OOt
.	.	o	O

We	PRP	O	O
recommend	VBP	O	O
against	IN	O	O
using	VBG	O	O
symmetrical	JJ	O	O
confidence	NN	O	O
intervals	NNS	O	O
and	CC	O	O
report	NN	O	O
excellent	JJ	O	O
agreement	NN	O	O
among	IN	O	O
several	JJ	O	O
methods	NNS	O	O
of	IN	O	O
calculating	VBG	O	O
confidence	NN	o	O
intervals	NNS	o	O
,	,	o	O
probability	NN	o	O
values	NNS	o	O
,	,	o	O
and	CC	o	O
nonparametric	JJ	o	O
tests	NNS	o	O
.	.	o	O

We	PRP	O	O
suggest	VBP	O	O
that	IN	O	O
a	DT	O	O
single-point	JJ	o	OOt
short-term	JJ	o	OOt
AUC	NNP	o	OOt
is	VBZ	O	O
a	DT	O	O
better	JJR	O	O
indicator	NN	O	O
of	IN	O	O
the	DT	O	O
bioequivalence	NN	O	O
of	IN	O	O
generic	JJ	O	O
products	NNS	O	O
than	IN	O	O
the	DT	O	O
total	JJ	O	O
AUC	NNP	o	OOt
,	,	o	O
Cmax	NNP	o	OOt
,	,	o	O
and	CC	o	O
Tmax	NNP	o	OOt
as	IN	O	O
required	VBN	O	O
currently	RB	O	O
by	IN	O	O
the	DT	O	O
regulatory	JJ	O	O
authorities	NNS	O	O
.	.	O	O

Modulation	NN	i	IPH
of	IN	i	IPH
oxidant	JJ	i	IPH
stress	NN	i	IPH
in	IN	i	IPH
vivo	NN	i	IPH
in	IN	O	O
chronic	JJ	p	O
cigarette	NN	p	O
smokers	NNS	p	O
.	.	p	O

BACKGROUND	NNP	O	O
Free	JJ	O	O
radical-induced	JJ	O	O
oxidative	JJ	O	O
damage	NN	O	O
is	VBZ	O	O
thought	VBN	O	O
to	TO	O	O
be	VB	O	O
involved	VBN	O	O
in	IN	O	O
the	DT	O	O
pathogenesis	NN	O	O
of	IN	O	O
diseases	NNS	O	O
associated	VBN	O	O
with	IN	O	O
cigarette	NN	O	O
smoking	NN	O	O
.	.	O	O

We	PRP	O	O
examined	VBD	O	O
the	DT	O	O
production	NN	O	O
of	IN	O	O
8-epi-prostaglandin	JJ	i	IPM
(	(	i	IPM
PG	NNP	i	IPM
)	)	i	IPM
F2	NNP	i	IPM
alpha	NN	i	IPM
,	,	i	IPM
a	DT	i	IPM
stable	JJ	i	IPM
product	NN	i	IPM
of	IN	i	IPM
lipid	JJ	i	IPM
peroxidation	NN	i	IPM
in	IN	i	IPM
vivo	NN	i	IPM
,	,	O	O
and	CC	O	O
its	PRP$	O	O
modulation	NN	i	O
by	IN	i	O
aspirin	NN	i	IPM
and	CC	i	O
antioxidant	JJ	i	IPM
vitamins	NNS	i	IPM
in	IN	O	O
chronic	JJ	p	O
cigarette	NN	p	O
smokers	NNS	p	O
.	.	p	O

METHODS	NNP	O	O
AND	CC	O	O
RESULTS	NNP	O	O
We	PRP	O	O
performed	VBD	O	O
the	DT	O	O
following	JJ	O	O
studies	NNS	O	O
:	:	O	O
(	(	O	O
1	CD	O	O
)	)	O	O
a	DT	p	O
cross-sectional	JJ	p	O
comparison	NN	p	O
of	IN	p	O
smokers	NNS	p	O
and	CC	p	O
control	NN	p	O
subjects	NNS	p	O
,	,	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
an	DT	O	O
examination	NN	O	O
of	IN	O	O
the	DT	O	O
dose-response	JJ	O	O
relationship	NN	O	O
,	,	O	O
(	(	O	O
3	CD	O	O
)	)	O	O
an	DT	O	O
exploration	NN	O	O
of	IN	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
smoking	VBG	i	IE
cessation	NN	i	IE
(	(	i	O
3	CD	i	O
weeks	NNS	i	O
)	)	i	O
and	CC	i	O
nicotine	JJ	i	IPM
patch	NN	i	IPM
supplementation	NN	i	IPM
,	,	O	O
(	(	O	O
4	CD	O	O
)	)	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
aspirin	NN	i	IPM
consumption	NN	i	IPM
,	,	O	O
and	CC	O	O
(	(	O	O
5	CD	O	O
)	)	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
5	CD	O	O
days	NNS	O	O
'	POS	O	O
dosing	VBG	O	O
with	IN	O	O
vitamin	NN	i	IPM
E	NNP	i	IPM
(	(	O	O
100	CD	O	O
and	CC	O	O
800	CD	O	O
U	NNP	O	O
)	)	O	O
,	,	O	O
vitamin	FW	i	IPM
C	NNP	i	IPM
(	(	i	O
2	CD	i	O
g	NN	i	O
)	)	i	O
,	,	O	O
and	CC	O	O
their	PRP$	O	O
combination	NN	O	O
.	.	O	O

8-epi-PGF2	JJ	o	OPH
alpha	JJ	o	OPH
excretion	NN	o	OPH
(	(	O	O
in	IN	O	O
pmol/mmol	NN	O	O
,	,	O	O
mean	JJ	O	O
+/-	JJ	O	O
SEM	NNP	O	O
)	)	O	O
was	VBD	O	O
176.5+/-30.6	JJ	O	O
in	IN	O	O
heavy	JJ	p	O
smokers	NNS	p	O
,	,	O	O
92.7+/-4.8	CD	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
.05	NNP	O	O
)	)	O	O
in	IN	O	O
moderate	JJ	p	PC
smokers	NNS	p	PC
,	,	O	O
and	CC	O	O
54.1+/-2.7	JJ	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
.005	NNP	O	O
)	)	O	O
in	IN	O	O
nonsmokers	NNS	p	PC
.	.	p	O

Urinary	JJ	o	OPH
levels	NNS	o	OPH
fell	VBD	o	OPH
from	IN	O	O
145.5+/-24.9	CD	O	O
to	TO	O	O
114.6+/-27.1	CD	O	O
(	(	O	O
week	NN	O	O
2	CD	O	O
,	,	O	O
P	NNP	O	O
<	NNP	O	O
.05	NNP	O	O
)	)	O	O
and	CC	O	O
112.6+/-24.9	JJ	O	O
(	(	O	O
week	NN	O	O
3	CD	O	O
,	,	O	O
P	NNP	O	O
<	NNP	O	O
.05	NNP	O	O
)	)	O	O
on	IN	O	O
cessation	NN	O	O
of	IN	O	O
smoking	NN	O	O
.	.	O	O

Aspirin	NNP	i	IPM
treatment	NN	i	IPM
failed	VBD	O	O
to	TO	O	O
suppress	VB	O	O
urinary	JJ	o	OPH
levels	NNS	o	OPH
of	IN	o	OPH
8-epi-PGF2	JJ	o	OPH
alpha	NN	o	OPH
despite	IN	O	O
a	DT	O	O
significant	JJ	O	O
reduction	NN	O	O
in	IN	O	O
urinary	JJ	o	OPH
11-dehydro-TxB2	JJ	o	OPH
production	NN	o	OPH
and	CC	O	O
suppression	NN	o	OPH
of	IN	o	OPH
8-epi-PGF2	JJ	o	OPH
alpha	NN	o	OPH
and	CC	o	OPH
TxB2	NNP	o	OPH
in	IN	o	OPH
serum	NN	o	OPH
.	.	o	OPH

Vitamin	NNP	i	IPM
C	NNP	i	IPM
(	(	O	O
pre	NN	O	O
,	,	O	O
194.6+/-40.9	JJ	O	O
;	:	O	O
post	NN	O	O
,	,	O	O
137.2+/-34.1	JJ	O	O
;	:	O	O
P	NNP	O	O
<	NNP	O	O
.05	NNP	O	O
)	)	O	O
and	CC	O	O
a	DT	O	O
combination	NN	i	IPM
of	IN	i	IPM
vitamin	JJ	i	IPM
C	NNP	i	IPM
and	CC	i	IPM
E	NNP	i	IPM
(	(	O	O
pre	NN	O	O
,	,	O	O
171.0+/-39.8	JJ	O	O
;	:	O	O
post	NN	O	O
,	,	O	O
133.5+/-29.6	JJ	O	O
P	NNP	O	O
<	NNP	O	O
.05	NNP	O	O
)	)	O	O
suppressed	VBD	O	O
urinary	JJ	o	OPH
8-epi-PGF2	JJ	o	OPH
alpha	NN	o	OPH
,	,	O	O
whereas	IN	O	O
vitamin	JJ	i	IPM
E	NNP	i	IPM
alone	RB	O	O
had	VBD	O	O
no	DT	O	O
effect	NN	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
Urinary	NNP	o	OPH
8-epi-PGF2	JJ	o	OPH
alpha	NN	o	OPH
may	MD	O	O
represent	VB	O	O
a	DT	O	O
noninvasive	JJ	O	O
,	,	O	O
quantitative	JJ	O	O
index	NN	O	O
of	IN	O	O
oxidant	JJ	O	O
stress	NN	O	O
in	IN	O	O
vivo	NN	O	O
.	.	O	O

Elevated	JJ	o	OPH
levels	NNS	o	OPH
of	IN	o	OPH
8-epi-PGF2	JJ	o	OPH
alpha	NN	o	OPH
in	IN	o	OPH
smokers	NNS	o	OPH
may	MD	O	O
be	VB	O	O
modulated	VBN	O	O
by	IN	O	O
quitting	VBG	i	IE
cigarettes	NNS	i	IE
and	CC	i	O
switching	VBG	i	IPM
to	TO	i	IPM
nicotine	VB	i	IPM
patches	NNS	i	IPM
or	CC	O	O
by	IN	O	O
antioxidant	JJ	i	IPM
vitamin	NN	i	IPM
therapy	NN	i	IPM
.	.	i	O

Gastrointestinal	NNP	o	OPH
safety	NN	o	OPH
of	IN	O	O
NO-aspirin	NNP	i	IPM
(	(	i	IPM
NCX-4016	NNP	i	IPM
)	)	i	IPM
in	IN	O	O
healthy	JJ	p	PC
human	JJ	p	PC
volunteers	NNS	p	O
:	:	p	O
a	DT	O	O
proof	NN	O	O
of	IN	O	O
concept	NN	O	O
endoscopic	NN	O	O
study	NN	O	O
.	.	O	O

BACKGROUND	NNP	O	O
AND	CC	O	O
AIMS	NNP	O	O
NCX-4016	NNP	i	IPM
is	VBZ	O	O
a	DT	O	O
nitric	JJ	O	O
oxide-releasing	JJ	O	O
derivative	NN	O	O
of	IN	O	O
aspirin	NN	O	O
with	IN	O	O
antiplatelet	NN	o	OPH
activity	NN	o	OPH
.	.	o	O

The	DT	O	O
aim	NN	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
investigate	VB	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
NCX-4016	NNP	i	IPM
on	IN	O	O
gastrointestinal	JJ	O	O
mucosa	NN	O	O
and	CC	O	O
platelet	NN	o	OPH
functions	NNS	o	OPH
in	IN	O	O
healthy	JJ	p	PC
human	JJ	p	PC
volunteers	NNS	p	O
.	.	p	O

METHODS	NNP	O	O
This	DT	O	O
was	VBD	O	O
a	DT	O	O
parallel-group	JJ	O	O
,	,	O	O
double-blind	JJ	O	O
,	,	O	O
placebo-controlled	JJ	O	O
study	NN	O	O
.	.	O	O

Forty	NNP	p	PSS
healthy	JJ	p	O
subjects	NNS	p	O
were	VBD	O	O
randomly	RB	O	O
allocated	VBN	O	O
to	TO	O	O
receive	VB	O	O
7	CD	O	O
days	NNS	O	O
of	IN	O	O
treatment	NN	O	O
with	IN	O	O
NCX-4016	NNP	i	IPM
(	(	i	IPM
400	CD	i	IPM
and	CC	i	IPM
800	CD	i	IPM
mg	NN	i	IPM
twice	RB	i	IPM
daily	RB	i	IPM
)	)	i	IPM
,	,	i	O
equimolar	JJ	i	IPM
doses	NNS	i	IPM
of	IN	i	IPM
aspirin	NN	i	IPM
(	(	i	IPM
200	CD	i	IPM
and	CC	i	IPM
420	CD	i	IPM
mg	NN	i	IPM
twice	RB	i	IPM
daily	RB	i	IPM
)	)	i	O
,	,	i	O
or	CC	i	O
placebo	NN	i	IC
.	.	i	O

Upper	IN	O	O
endoscopies	NNS	O	O
were	VBD	O	O
performed	VBN	O	O
before	RB	O	O
and	CC	O	O
at	IN	O	O
the	DT	O	O
end	NN	O	O
of	IN	O	O
the	DT	O	O
treatment	NN	O	O
period	NN	O	O
,	,	O	O
and	CC	O	O
gastroduodenal	JJ	o	OPH
lesions	NNS	o	OPH
were	VBD	O	O
graded	VBN	O	O
using	VBG	O	O
a	DT	O	O
predefined	VBN	o	OPH
scoring	NN	o	OPH
system	NN	o	OPH
.	.	o	O

Basal	NNP	o	OPH
and	CC	o	OPH
posttreatment	JJ	o	OPH
platelet	NN	o	OPH
aggregation	NN	o	OPH
in	IN	O	O
response	NN	O	O
to	TO	O	O
arachidonic	JJ	O	O
acid	NN	O	O
(	(	O	O
AA	NNP	O	O
)	)	O	O
and	CC	O	O
serum	JJ	O	O
thromboxane	NN	O	O
(	(	O	O
TX	NNP	O	O
)	)	O	O
B	NNP	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
and	CC	O	O
AA-stimulated	JJ	O	O
platelet	NN	O	O
TXB	NNP	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
production	NN	O	O
were	VBD	O	O
investigated	VBN	O	O
.	.	O	O

RESULTS	NNP	O	O
Mucosal	NNP	o	OPH
endoscopic	JJ	o	OPH
injury	NN	o	OPH
score	NN	o	OPH
on	IN	O	O
day	NN	O	O
7	CD	O	O
was	VBD	O	O
0.63	CD	O	O
+/-	JJ	O	O
0.16	CD	O	O
in	IN	O	O
the	DT	O	O
placebo	NN	O	O
group	NN	O	O
and	CC	O	O
11.0	CD	O	O
+/-	JJ	O	O
3.0	CD	O	O
and	CC	O	O
16.1	CD	O	O
+/-	JJ	O	O
1.6	CD	O	O
in	IN	O	O
healthy	JJ	p	PC
volunteers	NNS	p	O
treated	VBD	O	O
with	IN	O	O
200	CD	O	O
and	CC	O	O
420	CD	O	O
mg	NN	O	O
aspirin	JJ	O	O
twice	RB	O	O
daily	RB	O	O
(	(	O	O
P	NNP	O	O
<	VBZ	O	O
0.0001	CD	O	O
vs.	FW	O	O
placebo	NN	O	O
)	)	O	O
.	.	O	O

NCX-4016	NN	O	O
was	VBD	O	O
virtually	RB	O	O
devoid	JJ	O	O
of	IN	O	O
gastric	JJ	o	OA
and	CC	o	OA
duodenal	JJ	o	OA
toxicity	NN	o	OA
,	,	O	O
resulting	VBG	O	O
in	IN	O	O
a	DT	O	O
total	JJ	o	OPH
gastric	NN	o	OPH
and	CC	o	OPH
duodenal	JJ	o	OPH
endoscopic	NN	o	OPH
score	NN	o	OPH
of	IN	O	O
1.38	CD	O	O
+/-	JJ	O	O
0.3	CD	O	O
and	CC	O	O
1.25	CD	O	O
+/-	JJ	O	O
0.5	CD	O	O
(	(	O	O
P	NNP	O	O
<	VBZ	O	O
0.0001	CD	O	O
vs.	NN	O	O
aspirin	NN	O	O
,	,	O	O
not	RB	O	O
significant	JJ	O	O
vs.	FW	O	O
placebo	NN	O	O
)	)	O	O
.	.	O	O

NCX-4016	JJ	O	O
inhibited	JJ	O	O
AA-induced	JJ	o	OPH
platelet	NN	o	OPH
aggregation	NN	o	OPH
as	RB	O	O
well	RB	O	O
as	IN	O	O
serum	NN	o	OPH
TXB	NNP	o	OPH
(	(	o	OPH
2	CD	o	OPH
)	)	o	OPH
and	CC	O	O
platelet	NN	o	OPH
TXB	NNP	o	OPH
(	(	o	OPH
2	CD	o	OPH
)	)	o	OPH
generation	NN	o	OPH
induced	VBN	O	O
by	IN	O	O
AA	NNP	O	O
to	TO	O	O
the	DT	O	O
same	JJ	O	O
extent	NN	O	O
as	IN	O	O
aspirin	NN	i	IPM
(	(	O	O
not	RB	O	O
significant	JJ	O	O
vs.	FW	O	O
aspirin	NN	O	O
)	)	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
In	IN	O	O
this	DT	O	O
study	NN	O	O
,	,	O	O
we	PRP	O	O
have	VBP	O	O
proven	VBN	O	O
the	DT	O	O
concept	NN	O	O
that	IN	O	O
addition	NN	O	O
of	IN	O	O
an	DT	O	O
NO-donating	JJ	O	O
moiety	NN	O	O
to	TO	O	O
aspirin	VB	O	O
results	NNS	O	O
in	IN	O	O
a	DT	O	O
new	JJ	O	O
chemical	NN	O	O
entity	NN	O	O
that	WDT	O	O
maintains	VBZ	O	O
cyclooxygenase-1	NN	O	O
and	CC	O	O
platelet	VB	O	O
inhibitory	JJ	O	O
activity	NN	O	O
while	IN	O	O
nearly	RB	O	O
avoiding	VBG	O	O
gastrointestinal	JJ	o	OPH
damage	NN	o	OPH
.	.	o	O

Sucralfate	NNP	i	IPM
overcomes	VBZ	O	O
adverse	JJ	O	O
effect	NN	O	O
of	IN	O	O
cigarette	NN	O	O
smoking	NN	O	O
on	IN	O	O
duodenal	JJ	p	PC
ulcer	NN	o	OPH
healing	NN	o	OPH
and	CC	O	O
prolongs	NNS	O	O
subsequent	JJ	O	O
remission	NN	O	O
.	.	O	O

A	DT	O	O
unicenter	JJ	O	O
,	,	O	O
single-blind	JJ	O	O
,	,	O	O
randomized	VBD	O	O
study	NN	O	O
was	VBD	O	O
conducted	VBN	O	O
on	IN	O	O
283	CD	p	PSS
patients	NNS	p	O
with	IN	p	O
active	JJ	p	O
duodenal	JJ	p	PC
ulcer	NN	p	PC
to	TO	p	O
compare	VB	p	O
possible	JJ	p	O
factors	NNS	p	O
that	WDT	p	O
may	MD	p	O
affect	VB	p	O
healing	NN	p	O
and	CC	p	O
relapse	NN	p	O
in	IN	p	O
patients	NNS	p	O
treated	VBN	p	O
with	IN	p	O
a	DT	p	O
potent	JJ	p	O
antisecretory	NN	i	IPM
agent	NN	i	IPM
,	,	i	O
cimetidine	NN	i	IPM
,	,	p	O
or	CC	p	O
a	DT	p	O
site-protective	JJ	p	O
and	CC	p	O
cytoprotective	JJ	p	O
agent	NN	p	O
,	,	p	O
sucralfate	NN	i	IPM
.	.	i	O

The	DT	O	O
endoscopic	NN	o	OPH
healing	VBG	o	OPH
rates	NNS	o	OPH
at	IN	O	O
4	CD	O	O
wk	NNS	O	O
were	VBD	O	O
76	CD	O	O
%	NN	O	O
and	CC	O	O
79	CD	O	O
%	NN	O	O
,	,	O	O
respectively	RB	O	O
,	,	O	O
and	CC	O	O
cross-over	JJ	O	O
treatment	NN	O	O
of	IN	O	O
the	DT	O	O
failures	NNS	O	O
for	IN	O	O
a	DT	O	O
further	JJ	O	O
4	CD	O	O
wk	NN	O	O
resulted	VBD	O	O
in	IN	O	O
68	CD	O	O
%	NN	O	O
healing	VBG	O	O
with	IN	O	O
cimetidine	NN	i	IPM
and	CC	O	O
69	CD	O	O
%	NN	O	O
healing	VBG	O	O
with	IN	O	O
sucralfate	NN	i	IPM
,	,	O	O
both	DT	O	O
differences	NNS	O	O
being	VBG	O	O
not	RB	O	O
statistically	RB	O	O
different	JJ	O	O
.	.	O	O

Unlike	IN	O	O
cimetidine	NN	i	IPM
,	,	O	O
healing	VBG	O	O
by	IN	O	O
sucralfate	NN	i	IPM
was	VBD	O	O
unaffected	VBN	O	O
by	IN	O	O
cigarette	NN	O	O
smoking	NN	O	O
,	,	O	O
reluctance	NN	O	O
to	TO	O	O
give	VB	O	O
up	RP	O	O
smoking	NN	O	O
,	,	O	O
habitual	JJ	O	O
use	NN	O	O
of	IN	O	O
alcohol	NN	O	O
,	,	O	O
high	JJ	O	O
maximal	JJ	O	O
acid	NN	O	O
output	NN	O	O
,	,	O	O
and	CC	O	O
large	JJ	O	O
ulcer	JJ	O	O
diameter	NN	O	O
.	.	O	O

In	IN	O	O
particular	JJ	O	O
,	,	O	O
the	DT	O	O
healing	VBG	o	OPH
rate	NN	o	OPH
of	IN	O	O
smokers	NNS	O	O
treated	VBN	O	O
with	IN	O	O
sucralfate	NN	i	IPM
(	(	O	O
82	CD	O	O
%	NN	O	O
)	)	O	O
was	VBD	O	O
significantly	RB	O	O
greater	JJR	O	O
than	IN	O	O
that	DT	O	O
of	IN	O	O
smokers	NNS	O	O
treated	VBN	O	O
with	IN	O	O
cimetidine	NN	i	IPM
(	(	O	O
63	CD	O	O
%	NN	O	O
)	)	O	O
.	.	O	O

Duodenal	NNP	O	O
bulb	NN	O	O
deformity	NN	O	O
significantly	RB	O	O
affected	VBD	O	O
healing	NN	O	O
in	IN	O	O
both	DT	p	O
groups	NNS	p	O
,	,	O	O
and	CC	O	O
was	VBD	O	O
the	DT	O	O
only	JJ	O	O
offsetting	VBG	O	O
factor	NN	O	O
identifiable	JJ	O	O
for	IN	O	O
sucralfate	NN	i	IPM
out	IN	O	O
of	IN	O	O
46	CD	O	O
factors	NNS	O	O
examined	VBD	O	O
.	.	O	O

Of	IN	O	O
the	DT	O	O
patients	NNS	p	O
with	IN	p	O
healed	JJ	p	O
ulcers	NNS	p	PC
,	,	p	O
238	CD	p	PSS
participated	VBN	p	O
in	IN	O	O
a	DT	O	O
24-mo	JJ	O	O
follow-up	NN	O	O
study	NN	O	O
consisting	VBG	O	O
of	IN	O	O
interviews	NNS	O	O
at	IN	O	O
2-mo	JJ	O	O
intervals	NNS	O	O
and	CC	O	O
endoscopy	NN	O	O
at	IN	O	O
4-mo	JJ	O	O
intervals	NNS	O	O
or	CC	O	O
whenever	WRB	O	O
symptoms	NNS	O	O
recurred	VBD	O	O
.	.	O	O

The	DT	O	O
cumulative	JJ	o	OPH
relapse	NN	o	OPH
rate	NN	o	OPH
was	VBD	O	O
significantly	RB	O	O
(	(	O	O
p	NN	O	O
less	JJR	O	O
than	IN	O	O
0.007	CD	O	O
)	)	O	O
greater	JJR	O	O
in	IN	O	O
patients	NNS	p	O
healed	VBN	O	O
with	IN	O	O
cimetidine	NN	i	IPM
than	IN	O	O
with	IN	O	O
sucralfate	NN	i	IPM
,	,	O	O
50	CD	O	O
%	NN	O	O
relapse	NN	O	O
occurring	VBG	O	O
at	IN	O	O
6	CD	O	O
and	CC	O	O
12	CD	O	O
mo	NN	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

In	IN	O	O
both	DT	O	O
,	,	O	O
the	DT	O	O
cumulative	JJ	o	OPH
relapse	NN	o	OPH
rate	NN	o	OPH
was	VBD	O	O
significantly	RB	O	O
greater	JJR	O	O
in	IN	O	O
cigarette	NN	O	O
smokers	NNS	O	O
than	IN	O	O
in	IN	O	O
nonsmokers	NNS	O	O
,	,	O	O
but	CC	O	O
smokers	NNS	O	O
and	CC	O	O
nonsmokers	NNS	O	O
treated	VBN	O	O
with	IN	O	O
cimetidine	NN	i	IPM
relapsed	VBN	o	OPH
(	(	O	O
50	CD	O	O
%	NN	O	O
at	IN	O	O
4	CD	O	O
and	CC	O	O
8	CD	O	O
mo	NN	O	O
,	,	O	O
respectively	RB	O	O
)	)	O	O
faster	RBR	O	O
than	IN	O	O
the	DT	O	O
corresponding	JJ	O	O
smokers	NNS	O	O
and	CC	O	O
nonsmokers	NNS	O	O
treated	VBN	O	O
with	IN	O	O
sucralfate	NN	i	IPM
(	(	O	O
50	CD	O	O
%	NN	O	O
at	IN	O	O
8	CD	O	O
and	CC	O	O
18	CD	O	O
mo	NN	O	O
,	,	O	O
respectively	RB	O	O
)	)	O	O
.	.	O	O

Furthermore	UH	O	O
,	,	O	O
in	IN	O	O
cimetidine-	NN	i	IPM
but	CC	O	O
not	RB	O	O
sucralfate-healed	JJ	i	IPM
patients	NNS	O	O
,	,	O	O
early	JJ	O	O
ulcer	NN	O	O
relapse	NN	O	O
(	(	O	O
within	IN	O	O
6	CD	O	O
mo	NN	O	O
)	)	O	O
was	VBD	O	O
associated	VBN	O	O
with	IN	O	O
short	JJ	O	O
duration	NN	o	OPH
of	IN	o	OPH
illness	NN	o	OPH
,	,	O	O
short	JJ	O	O
remission	NN	o	OPH
period	NN	o	OPH
,	,	o	OPH
long	JJ	o	OPH
symptomatic	JJ	o	OPH
spell	NN	o	OPH
,	,	o	OPH
and	CC	o	OPH
reluctance	NN	o	OPH
to	TO	o	OPH
give	VB	o	OPH
up	RP	o	OPH
smoking	VBG	o	OPH
.	.	o	O

We	PRP	O	O
conclude	VBP	O	O
that	IN	O	O
smoking	VBG	O	O
adversely	RB	O	O
affects	VBZ	O	O
duodenal	JJ	O	O
ulcer	NN	O	O
healing	NN	O	O
by	IN	O	O
cimetidine	NN	i	IPM
and	CC	O	O
hastens	VBZ	O	O
subsequent	JJ	O	O
relapse	NN	O	O
,	,	O	O
and	CC	O	O
that	IN	O	O
sucralfate	NN	i	IPM
overcomes	VBZ	O	O
the	DT	O	O
adverse	JJ	O	O
effect	NN	O	O
of	IN	O	O
smoking	VBG	O	O
on	IN	O	O
healing	NN	O	O
as	IN	O	O
encountered	VBN	O	O
with	IN	O	O
cimetidine	NN	i	IPM
,	,	O	O
and	CC	O	O
results	NNS	O	O
in	IN	O	O
a	DT	O	O
subsequent	JJ	O	O
remission	NN	O	O
period	NN	O	O
double	JJ	O	O
that	IN	O	O
of	IN	O	O
cimetidine	NN	i	IPM
.	.	i	O

Intra-operative	JJ	O	O
antibiotic	JJ	i	IPM
prophylaxis	NN	O	O
in	IN	O	O
neurosurgery	NN	p	O
.	.	p	O

A	DT	O	O
prospective	JJ	O	O
,	,	O	O
randomized	VBN	O	O
,	,	O	O
controlled	VBN	O	O
study	NN	O	O
on	IN	O	O
cefotiam	NN	i	IPM
.	.	i	IPM

In	IN	O	O
this	DT	O	O
prospective	JJ	O	O
,	,	O	O
randomized	VBN	O	O
and	CC	O	O
controlled	VBN	O	O
study	VB	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
cefotiam	NN	i	IPM
for	IN	O	O
the	DT	O	O
prevention	NN	O	O
of	IN	O	O
wound	JJ	O	O
infections	NNS	O	O
following	VBG	O	O
trepanations	NNS	p	O
was	VBD	O	O
investigated	VBN	O	O
.	.	O	O

The	DT	O	O
main	JJ	O	O
interest	NN	O	O
was	VBD	O	O
centered	VBN	O	O
on	IN	O	O
the	DT	O	O
rate	NN	O	O
of	IN	O	O
post-operative	JJ	O	O
bone	NN	O	O
flap	NN	O	O
infections	NNS	O	O
requiring	VBG	O	O
operative	JJ	O	O
revision	NN	O	O
.	.	O	O

Administration	NNP	O	O
of	IN	O	O
cefotiam	NN	i	IPM
was	VBD	O	O
randomized	VBN	O	O
for	IN	O	O
patients	NNS	p	O
undergoing	VBG	p	O
major	JJ	p	O
craniotomies	NNS	p	O
.	.	p	O

The	DT	O	O
antibiotic	NN	i	IPM
was	VBD	O	O
administered	VBN	O	O
intravenously	RB	O	O
in	IN	O	O
a	DT	O	O
single	JJ	O	O
dose	NN	O	O
of	IN	O	O
2	CD	O	O
g	NN	O	O
with	IN	O	O
induction	NN	O	O
of	IN	O	O
anaesthesia	NN	i	IPM
.	.	i	IPM

Only	JJ	p	O
clean	JJ	p	O
or	CC	p	O
clean	JJ	p	O
contaminated	VBN	p	O
cases	NNS	p	O
were	VBD	p	O
included	VBN	p	O
.	.	p	O

Excluded	VBN	p	O
were	VBD	p	O
contaminated	VBN	p	O
cases	NNS	p	O
,	,	p	O
operations	NNS	p	O
with	IN	p	O
a	DT	p	O
transnasal-transsphenoidal	JJ	p	O
approach	NN	p	O
,	,	p	O
shunt-operations	NNS	p	O
and	CC	p	O
patients	NNS	p	O
with	IN	p	O
any	DT	p	O
other	JJ	p	O
preoperative	JJ	p	O
infection	NN	p	O
or	CC	p	O
antibiotic	JJ	i	IPM
therapy	NN	i	IPM
.	.	i	O

Outpatients	NNS	p	O
were	VBD	p	O
excluded	VBN	p	O
due	JJ	p	O
to	TO	p	O
difficulties	NNS	p	O
in	IN	p	O
obtaining	VBG	p	O
sufficient	JJ	p	O
clinical	JJ	p	O
information	NN	p	O
.	.	p	O

From	NNP	p	O
originally	RB	p	O
918	CD	p	PSS
consecutive	JJ	p	O
patients	NNS	p	O
operated	VBN	p	O
on	IN	p	O
711	CD	p	PSS
fulfilled	VBD	p	O
the	DT	p	O
entry	NN	p	O
criteria	NNS	p	O
.	.	p	O

With	IN	p	O
regard	NN	p	O
to	TO	p	O
age	NN	p	O
,	,	p	O
sex	NN	p	O
,	,	p	O
diagnosis	NN	p	O
and	CC	p	O
the	DT	p	O
site	NN	p	O
of	IN	p	O
te	JJ	p	O
trepanation	NN	p	O
,	,	p	O
control	NN	i	IC
patients	NNS	i	IC
(	(	p	O
n	JJ	p	O
=	NNP	p	O
355	CD	p	PSS
)	)	p	O
and	CC	p	O
cefotiam	$	p	O
treated	VBN	p	O
patients	NNS	p	O
(	(	p	O
n	JJ	p	O
=	NNP	p	O
356	CD	p	PSS
)	)	p	O
were	VBD	p	O
shown	VBN	p	O
to	TO	p	O
be	VB	p	O
comparable	JJ	p	O
.	.	p	O

In	IN	O	O
the	DT	O	O
various	JJ	O	O
subgroups	NNS	O	O
formed	VBN	O	O
for	IN	O	O
different	JJ	p	O
primary	JJ	p	O
diagnoses	NNS	p	O
,	,	p	O
concomitant	JJ	i	IPM
steroidal	NN	i	IPM
therapy	NN	i	IPM
and	CC	O	O
concomitant	NN	p	O
severe	JJ	p	O
internal	JJ	p	O
medical	JJ	p	O
diseases	NNS	p	O
cefotiam	VBP	O	O
treated	VBN	O	O
patients	NNS	O	O
and	CC	O	O
controls	NNS	O	O
were	VBD	O	O
comparable	JJ	O	O
as	RB	O	O
well	RB	O	O
.	.	O	O

A	DT	O	O
highly	RB	O	O
significant	JJ	O	O
difference	NN	O	O
for	IN	O	O
bone	NN	o	OPH
flap	NN	o	OPH
infection	NN	o	OPH
could	MD	O	O
be	VB	O	O
shown	VBN	O	O
with	IN	O	O
0.3	CD	O	O
%	NN	O	O
in	IN	O	O
the	DT	O	O
cefotiam	NN	O	O
group	NN	O	O
versus	VBD	O	O
5.1	CD	O	O
%	NN	O	O
in	IN	O	O
the	DT	O	O
control	NN	O	O
group	NN	O	O
(	(	O	O
p	VBZ	O	O
less	JJR	O	O
than	IN	O	O
0.001	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
overall	JJ	o	OPH
rate	NN	o	OPH
of	IN	o	OPH
post-operative	JJ	o	OPH
deep	JJ	o	OPH
wound	NN	o	OPH
infections	NNS	o	OPH
including	VBG	o	OPH
meningitis	NN	o	OPH
and	CC	o	OPH
abscesses	NNS	o	OPH
was	VBD	O	O
also	RB	O	O
significantly	RB	O	O
(	(	O	O
p	NN	O	O
less	JJR	O	O
than	IN	O	O
0.005	CD	O	O
)	)	O	O
different	JJ	o	O
with	IN	O	O
3.1	CD	O	O
%	NN	O	O
in	IN	O	O
the	DT	O	O
cefotiam	NN	i	IPM
versus	IN	O	O
9.0	CD	O	O
%	NN	O	O
in	IN	O	O
the	DT	O	O
control	NN	O	O
group	NN	O	O
.	.	O	O

Thus	VB	O	O
it	PRP	O	O
was	VBD	O	O
concluded	VBN	O	O
that	IN	O	O
a	DT	O	O
single	JJ	O	O
dose	NN	O	O
of	IN	O	O
cefotiam	NN	O	O
significantly	RB	O	O
reduces	VBZ	O	O
post-operative	JJ	o	OPH
deep	JJ	o	OPH
wound	NN	o	OPH
infection	NN	o	OPH
.	.	o	O

Predictors	NNS	O	O
of	IN	O	O
smoking	VBG	p	PC
cessation	NN	p	PC
among	IN	p	O
cancer	NN	p	PC
patients	NNS	p	O
enrolled	VBN	p	O
in	IN	p	O
a	DT	p	O
smoking	NN	i	IE
cessation	NN	i	IE
program	NN	p	O
.	.	p	O

UNLABELLED	NNP	O	O
Many	JJ	O	O
cancer	NN	p	O
patients	NNS	p	O
continue	VBP	O	O
to	TO	O	O
smoke	VB	O	O
postdiagnosis	NN	O	O
,	,	O	O
which	WDT	O	O
is	VBZ	O	O
associated	VBN	O	O
with	IN	O	O
poorer	JJR	O	O
clinical	JJ	O	O
outcomes	NNS	O	O
.	.	O	O

Identifying	VBG	O	O
prospective	JJ	O	O
predictors	NNS	O	O
of	IN	O	O
smoking	VBG	O	O
cessation	NN	O	O
among	IN	O	O
patients	NNS	O	O
currently	RB	O	O
receiving	VBG	O	O
smoking	VBG	i	IE
cessation	NN	i	IE
treatment	NN	O	O
can	MD	O	O
help	VB	O	O
guide	VB	O	O
the	DT	O	O
development	NN	O	O
and	CC	O	O
implementation	NN	O	O
of	IN	O	O
smoking	VBG	i	IE
cessation	NN	i	IE
programs	NNS	i	IE
with	IN	O	O
this	DT	O	O
population	NN	O	O
.	.	O	O

MATERIAL	NNP	O	O
AND	CC	O	O
METHODS	NNP	O	O
Data	NNP	p	O
from	IN	p	O
246	CD	p	PSS
cancer	NN	p	PC
patients	NNS	p	O
participating	VBG	p	O
in	IN	p	O
a	DT	p	O
randomized	JJ	p	O
placebo-controlled	JJ	i	IC
smoking	NN	p	O
cessation	NN	p	O
clinical	JJ	p	O
trial	NN	p	O
were	VBD	O	O
used	VBN	O	O
to	TO	O	O
examine	VB	O	O
baseline	JJ	O	O
predictors	NNS	O	O
of	IN	O	O
end-of-treatment	JJ	O	O
and	CC	O	O
six-month	JJ	O	O
postbaseline	NN	O	O
smoking	NN	i	IE
cessation	NN	i	IE
outcomes	RB	O	O
.	.	O	O

Baseline	NNP	O	O
demographic	JJ	O	O
,	,	O	O
smoking-related	JJ	O	O
,	,	O	O
disease-related	JJ	O	O
,	,	O	O
and	CC	O	O
psychological	JJ	O	O
variables	NNS	O	O
were	VBD	O	O
examined	VBN	O	O
as	IN	O	O
predictors	NNS	O	O
of	IN	O	O
biochemically-confirmed	JJ	O	O
point-prevalence	NN	O	O
abstinence	NN	O	O
.	.	O	O

RESULTS	NNP	O	O
Multivariate	NNP	o	OOt
analysis	NN	O	O
indicated	VBD	O	O
that	IN	O	O
,	,	O	O
for	IN	O	O
end-of-treatment	JJ	o	OME
abstinence	NN	o	OME
,	,	O	O
patients	NNS	O	O
were	VBD	O	O
significantly	RB	O	O
more	RBR	O	O
likely	JJ	O	O
to	TO	O	O
have	VB	O	O
quit	NN	o	OME
smoking	VBG	o	OME
if	IN	O	O
they	PRP	O	O
were	VBD	O	O
older	JJR	O	O
(	(	O	O
OR	NNP	O	O
=	VBZ	O	O
1.06	CD	O	O
,	,	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
:	:	O	O
1.03-1.10	JJ	O	O
,	,	O	O
p	JJ	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
and	CC	O	O
were	VBD	O	O
diagnosed	VBN	O	O
with	IN	O	O
a	DT	O	O
non-tobacco	JJ	O	O
related	JJ	O	O
cancer	NN	O	O
(	(	O	O
OR	NNP	O	O
=	VBZ	O	O
2.54	CD	O	O
,	,	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
:	:	O	O
1.24-5.20	JJ	O	O
,	,	O	O
p	JJ	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

Likewise	NNP	O	O
,	,	O	O
for	IN	O	O
six-month	JJ	o	OME
abstinence	NN	o	OME
,	,	O	O
patients	NNS	O	O
were	VBD	O	O
significantly	RB	O	O
more	RBR	O	O
likely	JJ	O	O
to	TO	O	O
have	VB	O	O
quit	NN	o	OME
smoking	VBG	o	OME
if	IN	O	O
they	PRP	O	O
were	VBD	O	O
older	JJR	O	O
(	(	O	O
OR	NNP	O	O
=	VBZ	O	O
1.04	CD	O	O
,	,	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
:	:	O	O
1.01-1.08	JJ	O	O
,	,	O	O
p	JJ	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
and	CC	O	O
were	VBD	O	O
significantly	RB	O	O
less	RBR	O	O
likely	JJ	O	O
to	TO	O	O
have	VB	O	O
quit	NN	O	O
smoking	VBG	O	O
if	IN	O	O
they	PRP	O	O
were	VBD	O	O
female	JJ	O	O
(	(	O	O
OR	NNP	O	O
=	VBZ	O	O
0.47	CD	O	O
,	,	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
:	:	O	O
0.22-0.97	JJ	O	O
,	,	O	O
p	JJ	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

Patients	NNS	p	O
with	IN	p	O
tobacco-related	JJ	p	O
cancers	NNS	p	O
and	CC	p	O
female	JJ	p	PSE
patients	NNS	p	O
reported	VBD	O	O
significantly	RB	O	O
higher	JJR	O	O
levels	NNS	o	OME
of	IN	o	OME
depression	NN	o	OME
symptoms	NNS	o	OME
(	(	O	O
p	JJ	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
,	,	O	O
which	WDT	O	O
proved	VBD	O	O
predictive	NN	o	OME
of	IN	o	OME
smoking	VBG	o	OME
relapse	NN	o	OME
.	.	o	OME

CONCLUSIONS	NNP	O	O
Patient	NNP	O	O
age	NN	O	O
,	,	O	O
gender	NN	O	O
,	,	O	O
and	CC	O	O
cancer-type	NN	O	O
may	MD	O	O
be	VB	O	O
important	JJ	O	O
factors	NNS	O	O
to	TO	O	O
consider	VB	O	O
when	WRB	O	O
developing	VBG	O	O
and	CC	O	O
implementing	VBG	O	O
smoking	VBG	i	IE
cessation	NN	i	IE
interventions	NNS	i	IE
for	IN	O	O
cancer	NN	p	O
patients	NNS	p	O
.	.	p	O

Cytokine	NN	o	OPH
levels	NNS	o	OPH
and	CC	o	O
systemic	JJ	o	OA
toxicity	NN	o	OA
in	IN	O	O
patients	NNS	p	O
undergoing	VBG	p	O
isolated	JJ	i	IPM
limb	NN	i	IPM
perfusion	NN	i	IPM
with	IN	i	O
high-dose	JJ	i	IPM
tumor	NN	i	IPM
necrosis	NN	i	IPM
factor	NN	i	IPM
,	,	i	O
interferon	NN	i	IPM
gamma	NN	i	IPM
,	,	i	O
and	CC	i	O
melphalan	NN	i	IPM
.	.	i	O

PURPOSE	NNP	O	O
Isolated	NNP	i	IPM
limb	NN	i	IPM
perfusion	NN	i	IPM
(	(	i	IPM
ILP	NNP	i	IPM
)	)	i	IPM
with	IN	i	O
tumor	NN	i	IPM
necrosis	NN	i	IPM
factor	NN	i	IPM
(	(	i	IPM
TNF	NNP	i	IPM
)	)	i	IPM
,	,	i	O
interferon	JJ	i	IPM
gamma	NN	i	IPM
,	,	i	O
and	CC	i	O
melphalan	NN	i	IPM
(	(	i	IPM
M	NNP	i	IPM
)	)	i	IPM
has	VBZ	O	O
been	VBN	O	O
reported	VBN	O	O
to	TO	O	O
result	VB	O	O
in	IN	O	O
high	JJ	O	O
response	NN	o	OPH
rates	NNS	o	OPH
for	IN	O	O
extremity	NN	O	O
melanoma	NN	O	O
and	CC	O	O
sarcoma	NN	O	O
.	.	O	O

We	PRP	O	O
have	VBP	O	O
evaluated	VBN	O	O
the	DT	O	O
relationship	NN	O	O
of	IN	O	O
systemic	JJ	O	O
TNF	NNP	O	O
exposure	NN	O	O
to	TO	O	O
induction	NN	O	O
of	IN	O	O
several	JJ	O	O
secondary	JJ	o	OPH
mediators	NNS	o	OPH
and	CC	O	O
incidence	NN	O	O
of	IN	O	O
systemic	JJ	o	OA
toxicity	NN	o	OA
.	.	o	O

PATIENTS	NNP	O	O
AND	CC	O	O
METHODS	NNP	O	O
Nineteen	NNP	p	PSS
patients	NNS	p	O
with	IN	p	O
extremity	NN	p	PC
melanoma	NN	p	PC
(	(	p	O
n	JJ	p	O
=	NNP	p	O
16	CD	p	PSS
)	)	p	O
or	CC	p	O
sarcoma	NN	p	PC
(	(	p	O
n	JJ	p	O
=	NNP	p	O
3	CD	p	PSS
)	)	p	O
,	,	O	O
underwent	JJ	O	O
90-minute	JJ	O	O
ILP	NNP	i	IPM
with	IN	i	IPM
TNF-alpha	NNP	i	IPM
,	,	i	O
interferon	NN	i	IPM
gamma	NN	i	IPM
(	(	O	O
0.2	CD	O	O
mg	NN	O	O
)	)	O	O
,	,	O	O
and	CC	i	O
M	NNP	i	IPM
(	(	O	O
10	CD	O	O
to	TO	O	O
13	CD	O	O
mg/L	NN	O	O
of	IN	O	O
limb	NN	O	O
volume	NN	O	O
)	)	O	O
(	(	i	IPM
TNF/IFN/M	NNP	i	IPM
)	)	i	IPM
(	(	O	O
n	JJ	O	O
=	NNP	O	O
12	CD	O	O
)	)	O	O
,	,	O	O
or	CC	i	O
M	NNP	i	IPM
alone	RB	i	O
(	(	O	O
n	JJ	O	O
=	NNP	O	O
7	CD	O	O
)	)	O	O
.	.	O	O

Continuous	JJ	O	O
intraoperative	JJ	O	O
monitoring	NN	O	O
(	(	O	O
CIM	NNP	O	O
)	)	O	O
for	IN	O	O
systemic	JJ	O	O
leak	NN	O	O
from	IN	O	O
the	DT	O	O
perfusion	NN	O	O
circuit	NN	O	O
was	VBD	O	O
performed	VBN	O	O
using	VBG	O	O
radioactive	JJ	O	O
iodine-131	JJ	i	IPM
albumin	NN	i	IPM
.	.	i	IPM

Cytokine	NN	O	O
levels	NNS	O	O
in	IN	O	O
the	DT	O	O
perfusate	NN	O	O
and	CC	O	O
systemic	JJ	O	O
circulation	NN	O	O
during	IN	O	O
and	CC	O	O
after	IN	O	O
ILP	NNP	O	O
were	VBD	O	O
measured	VBN	O	O
by	IN	O	O
enzyme-linked	JJ	i	IPM
immunosorbent	NN	i	IPM
assay	NN	i	IPM
.	.	i	IPM

RESULTS	NNP	O	O
Systemic	NNP	o	O
leaks	VBZ	o	O
>	CD	o	O
or	CC	o	O
=	VB	o	O
1	CD	o	O
%	NN	o	O
from	IN	O	O
the	DT	O	O
perfusion	NN	o	O
circuit	NN	o	O
occurred	VBD	O	O
in	IN	O	O
six	CD	O	O
patients	NNS	O	O
who	WP	O	O
received	VBD	O	O
TNF/IFN/M	NNP	O	O
and	CC	O	O
in	IN	O	O
four	CD	O	O
who	WP	O	O
received	VBD	O	O
M	NNP	O	O
alone	RB	O	O
.	.	O	O

Hypotension	NNP	o	OA
that	IN	o	OA
required	VBD	o	OA
vasopressor	NN	o	OA
support	NN	o	OA
occurred	VBD	O	O
in	IN	O	O
six	CD	O	O
of	IN	O	O
six	CD	O	O
patients	NNS	O	O
with	IN	O	O
evidence	NN	O	O
of	IN	O	O
a	DT	O	O
leak	NN	O	O
(	(	O	O
>	CD	O	O
or	CC	O	O
=	VB	O	O
1	CD	O	O
%	NN	O	O
)	)	O	O
and	CC	O	O
zero	CD	O	O
of	IN	O	O
six	CD	O	O
patients	NNS	O	O
without	IN	O	O
a	DT	O	O
leak	NN	O	O
(	(	O	O
<	JJ	O	O
1	CD	O	O
%	NN	O	O
)	)	O	O
.	.	O	O

These	DT	O	O
six	CD	O	O
patients	NNS	O	O
had	VBD	O	O
significantly	RB	O	O
higher	JJR	O	O
peak	JJ	o	OPH
systemic	JJ	o	OPH
TNF	NNP	o	OPH
levels	NNS	o	OPH
during	IN	O	O
and	CC	O	O
after	IN	O	O
perfusion	NN	O	O
than	IN	O	O
patients	NNS	O	O
without	IN	O	O
a	DT	O	O
leak	NN	O	O
(	(	O	O
2.8	CD	O	O
and	CC	O	O
8.2	CD	O	O
ng/mL	JJ	O	O
v	NN	O	O
0.7	CD	O	O
and	CC	O	O
2.0	CD	O	O
ng/mL	NN	O	O
,	,	O	O
respectively	RB	O	O
;	:	O	O
P	NNP	O	O
<	NNP	O	O
.05	NNP	O	O
)	)	O	O
.	.	O	O

All	PDT	O	O
patients	NNS	O	O
who	WP	O	O
received	VBD	O	O
TNF/IFN/M	NNP	O	O
had	VBD	O	O
significantly	RB	O	O
greater	JJR	O	O
increases	NNS	O	O
in	IN	O	O
systemic	JJ	o	OPH
interleukin-6	JJ	o	OPH
(	(	o	OPH
IL-6	NNP	o	OPH
)	)	o	OPH
levels	NNS	o	OPH
than	IN	O	O
in	IN	O	O
patients	NNS	O	O
with	IN	O	O
M	NNP	O	O
alone	RB	O	O
(	(	O	O
12,395	CD	O	O
+/-	JJ	O	O
10,374	CD	O	O
pg/mL	NN	O	O
v	NN	O	O
79.4	CD	O	O
+/-	JJ	O	O
7.2	CD	O	O
pg/mL	NN	O	O
,	,	O	O
respectively	RB	O	O
;	:	O	O
P	NNP	O	O
<	NNP	O	O
.001	NNP	O	O
)	)	O	O
.	.	O	O

Intracellular	JJ	o	OPH
adhesion	NN	o	OPH
molecule	NN	o	OPH
(	(	o	OPH
ICAM	NNP	o	OPH
)	)	o	OPH
,	,	o	OPH
IL-8	NNP	o	OPH
,	,	o	OPH
and	CC	o	OPH
TNF-R	JJ	o	OPH
levels	NNS	o	OPH
were	VBD	O	O
also	RB	O	O
increased	VBN	O	O
after	IN	O	O
ILP	NNP	O	O
with	IN	O	O
TNF/IFN/M	NNP	O	O
.	.	O	O

CONCLUSION	NNP	O	O
ILP	NNP	O	O
with	IN	O	O
TNF/IFN/M	NNP	O	O
can	MD	O	O
be	VB	O	O
safely	RB	O	O
performed	VBN	O	O
,	,	O	O
as	IN	O	O
I131	NNP	O	O
albumin	VBP	O	O
provides	VBZ	O	O
a	DT	O	O
sensitive	JJ	O	O
measure	NN	O	O
of	IN	O	O
systemic	JJ	O	O
leakage	NN	O	O
from	IN	O	O
the	DT	O	O
perfusion	NN	O	O
circuit	NN	O	O
.	.	O	O

Patients	NNS	O	O
with	IN	O	O
a	DT	O	O
measured	JJ	O	O
leak	NN	O	O
of	IN	O	O
>	NN	O	O
or	CC	O	O
=	VB	O	O
1	CD	O	O
%	NN	O	O
develop	NN	O	O
mild	NN	O	O
and	CC	O	O
transient	JJ	O	O
postoperative	JJ	O	O
hypotension	NN	O	O
with	IN	O	O
significantly	RB	O	O
higher	JJR	O	O
systemic	JJ	O	O
TNF	NNP	O	O
levels	NNS	O	O
and	CC	O	O
lower	JJR	O	O
perfusate	NN	O	O
TNF	NNP	O	O
levels	NNS	O	O
than	IN	O	O
in	IN	O	O
patients	NNS	O	O
without	IN	O	O
leaks	NNS	O	O
.	.	O	O

Paromomycin	NNP	i	IPM
for	IN	O	O
cryptosporidiosis	NN	O	O
in	IN	O	O
AIDS	NNP	p	PC
:	:	p	PC
a	DT	O	O
prospective	JJ	O	O
,	,	O	O
double-blind	JJ	O	O
trial	NN	O	O
.	.	O	O

To	TO	O	O
test	VB	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
paromomycin	NN	i	IPM
,	,	O	O
10	CD	p	O
patients	NNS	p	O
with	IN	p	O
AIDS	NNP	p	O
and	CC	p	O
cryptosporidiosis	NN	p	O
were	VBD	O	O
randomized	VBN	O	O
to	TO	O	O
paromomycin	VB	i	IPM
or	CC	i	O
placebo	VB	i	IC
in	IN	O	O
a	DT	O	O
double-blind	JJ	O	O
trial	NN	O	O
.	.	O	O

After	IN	O	O
14	CD	O	O
days	NNS	O	O
,	,	O	O
patients	NNS	O	O
were	VBD	O	O
switched	VBN	O	O
to	TO	O	O
the	DT	O	O
other	JJ	O	O
treatment	NN	O	O
for	IN	O	O
14	CD	O	O
additional	JJ	O	O
days	NNS	O	O
.	.	O	O

Measures	NNS	O	O
included	VBD	O	O
the	DT	O	O
number	NN	o	OPH
and	CC	o	OPH
character	NN	o	OPH
of	IN	o	OPH
each	DT	o	OPH
stool	NN	o	OPH
and	CC	O	O
weekly	JJ	O	O
24-h	JJ	O	O
stool	NN	o	OPH
specimens	NNS	o	OPH
for	IN	o	OPH
weight	NN	o	OPH
and	CC	o	O
oocyst	NN	o	OPH
excretion	NN	o	OPH
.	.	o	O

During	IN	O	O
the	DT	O	O
paromomycin	NN	i	IPM
treatment	NN	O	O
phase	NN	O	O
,	,	O	O
oocyst	JJ	o	OPH
excretion	NN	o	OPH
decreased	VBD	O	O
from	IN	O	O
314	CD	O	O
x	NNS	O	O
10	CD	O	O
(	(	O	O
6	CD	O	O
)	)	O	O
to	TO	O	O
109	CD	O	O
x	NNS	O	O
10	CD	O	O
(	(	O	O
6	CD	O	O
)	)	O	O
24	CD	O	O
h	NN	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
.02	NNP	O	O
)	)	O	O
.	.	O	O

Oocyst	NNP	o	OPH
excretion	NN	o	OPH
increased	VBD	O	O
for	IN	O	O
the	DT	O	O
4	CD	O	O
patients	NNS	O	O
initially	RB	O	O
on	IN	O	O
placebo	NNS	i	IC
compared	VBN	O	O
to	TO	O	O
a	DT	O	O
median	JJ	O	O
decrease	NN	O	O
of	IN	O	O
128	CD	O	O
x	NNS	O	O
10	CD	O	O
(	(	O	O
6	CD	O	O
)	)	O	O
/24	NN	O	O
h	NN	O	O
for	IN	O	O
the	DT	O	O
6	CD	O	O
initially	RB	O	O
treated	VBN	O	O
with	IN	O	O
drug	NN	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
.02	NNP	O	O
)	)	O	O
.	.	O	O

Stool	NNP	o	OOt
frequency	NN	o	OOt
also	RB	O	O
decreased	VBD	O	O
more	RBR	O	O
in	IN	O	O
those	DT	O	O
treated	VBN	O	O
with	IN	O	O
drug	NN	i	IPM
(	(	O	O
3.6	CD	O	O
fewer	JJR	O	O
vs.	NN	O	O
1.25	CD	O	O
fewer/24	NN	O	O
h	NN	O	O
,	,	O	O
P	NNP	O	O
<	NNP	O	O
.05	NNP	O	O
)	)	O	O
.	.	O	O

Trends	NNS	O	O
favored	JJ	O	O
drug	NN	O	O
over	IN	O	O
placebo	NN	i	IC
for	IN	O	O
stool	NN	o	OPH
weight	NN	o	OPH
,	,	o	OPH
stool	JJ	o	OPH
character	NN	o	OPH
,	,	o	O
and	CC	o	O
Karnofsky	NNP	o	OOt
score	NN	o	OOt
.	.	o	O

Paromomycin	NNP	i	IPM
treatment	NN	O	O
resulted	VBD	O	O
in	IN	O	O
improvement	NN	O	O
in	IN	O	O
both	DT	O	O
clinical	JJ	O	O
and	CC	O	O
parasitologic	JJ	O	O
parameters	NNS	O	O
in	IN	O	O
cryptosporidiosis	NN	O	O
in	IN	O	O
AIDS	NNP	O	O
.	.	O	O

Perispinal	JJ	O	O
analgesia	NN	O	O
for	IN	O	O
labour	NN	p	O
followed	VBN	O	O
by	IN	O	O
patient-controlled	JJ	O	O
infusion	NN	O	O
with	IN	O	O
bupivacaine	NN	i	IPM
and	CC	O	O
sufentanil	NN	i	IPM
:	:	i	O
combined	VBN	i	O
spinal-epidural	JJ	i	IPM
vs.	FW	i	IPM
epidural	JJ	i	IPM
analgesia	NN	O	O
alone	RB	O	O
.	.	O	O

BACKGROUND	NNP	O	O
AND	NNP	O	O
OBJECTIVE	NNP	O	O
Combined	NNP	O	O
spinal-epidural	JJ	O	O
is	VBZ	O	O
an	DT	O	O
alternative	JJ	O	O
technique	NN	O	O
to	TO	O	O
epidural	JJ	O	O
analgesia	NN	O	O
for	IN	O	O
labour	NN	O	O
,	,	O	O
but	CC	O	O
its	PRP$	O	O
benefits	NNS	O	O
are	VBP	O	O
not	RB	O	O
clearly	RB	O	O
identified	VBN	O	O
.	.	O	O

METHODS	VB	O	O
A	DT	O	O
prospective	JJ	O	O
,	,	O	O
blinded	VBD	O	O
,	,	O	O
randomized	VBD	O	O
study	NN	O	O
was	VBD	O	O
undertaken	JJ	O	O
involving	VBG	O	O
113	CD	p	PSS
women	NNS	p	PSE
attending	VBG	p	O
a	DT	p	O
university	NN	p	O
hospital	NN	p	O
obstetric	JJ	p	O
department	NN	p	O
.	.	p	O

Analgesia	NNP	O	O
was	VBD	O	O
initiated	VBN	i	O
with	IN	i	O
intrathecal	JJ	i	O
bupivacaine	NN	i	IPM
0.25	CD	i	IPM
%	NN	i	IPM
1	CD	i	IPM
mL	NN	i	IPM
+	NNP	i	O
sufentanil	VBD	i	IPM
5	CD	i	IPM
microg	NN	i	IPM
in	IN	i	O
the	DT	i	O
combined	JJ	i	O
spinal-epidural	JJ	i	O
group	NN	i	O
(	(	i	O
n	JJ	i	O
=	NNP	i	O
54	CD	i	O
)	)	i	O
,	,	i	O
and	CC	i	O
with	IN	i	O
bupivacaine	JJ	i	IPM
0.125	CD	i	IPM
%	NN	i	IPM
+	JJ	i	O
epinephrine	NN	i	IPM
2.5	CD	i	IPM
microg	NN	i	IPM
mL	NN	i	IPM
(	(	i	IPM
-1	NNP	i	IPM
)	)	i	IPM
+	VBD	i	O
sufentanil	$	i	IPM
7.5	CD	i	IPM
microg	NN	i	IPM
in	IN	i	O
the	DT	i	O
epidural	JJ	i	O
group	NN	i	O
(	(	i	O
n	JJ	i	O
=	NNP	i	O
59	CD	i	O
)	)	i	O
.	.	i	O

In	IN	i	IPM
both	DT	i	IPM
cases	NNS	i	IPM
this	DT	i	IPM
was	VBD	i	IPM
followed	VBN	i	IPM
by	IN	i	IPM
patient-controlled	JJ	i	IPM
epidural	JJ	i	IPM
analgesia	NN	i	IPM
with	IN	i	IPM
bupivacaine	JJ	i	IPM
0.125	CD	i	IPM
%	NN	i	IPM
(	(	i	O
+	JJ	i	O
sufentanil	NN	i	IPM
0.25	CD	i	IPM
microg	NN	i	IPM
mL	NN	i	IPM
(	(	i	IPM
-1	NNP	i	IPM
)	)	i	IPM
)	)	i	IPM
.	.	i	O

Duration	NN	O	O
of	IN	O	O
labour	NN	O	O
,	,	O	O
quality	NN	o	OOt
of	IN	o	OOt
analgesia	NN	o	OOt
and	CC	o	O
side-effects	NNS	o	OA
were	VBD	O	O
compared	VBN	O	O
between	IN	O	O
groups	NNS	O	O
.	.	O	O

RESULTS	NNP	O	O
In	IN	O	O
the	DT	O	O
combined	JJ	O	O
spinal-epidural	JJ	O	O
group	NN	O	O
,	,	O	O
the	DT	O	O
onset	NN	o	O
of	IN	o	O
analgesia	NN	o	O
was	VBD	o	O
faster	RBR	o	O
(	(	O	O
5	CD	O	O
vs.	FW	O	O
15	CD	O	O
min	NN	O	O
,	,	O	O
P	NNP	O	O
<	NNP	O	O
0.001	CD	O	O
)	)	O	O
,	,	O	O
the	DT	O	O
consumption	NN	o	O
of	IN	o	O
bupivacaine	NN	o	O
was	VBD	o	O
lower	JJR	o	O
(	(	O	O
7.5	CD	O	O
vs.	FW	O	O
11.3	CD	O	O
mg	NN	O	O
h	NN	O	O
(	(	O	O
-1	NNP	O	O
)	)	O	O
,	,	O	O
P	NNP	O	O
=	NNP	O	O
0.003	CD	O	O
)	)	O	O
and	CC	O	O
there	EX	O	O
was	VBD	O	O
less	JJR	o	OPH
unilateral	JJ	o	OPH
analgesia	NN	o	OPH
(	(	O	O
14.8	CD	O	O
%	NN	O	O
vs.	FW	O	O
40.7	CD	O	O
%	NN	O	O
,	,	O	O
P	NNP	O	O
=	NNP	O	O
0.002	CD	O	O
)	)	O	O
than	IN	O	O
in	IN	O	O
the	DT	O	O
epidural	JJ	O	O
group	NN	O	O
.	.	O	O

The	DT	p	O
characteristics	NNS	o	OOt
of	IN	o	OOt
labour	NN	o	OOt
were	VBD	p	O
similar	JJ	p	O
in	IN	p	O
both	DT	p	O
groups	NNS	p	O
.	.	p	O

However	RB	O	O
,	,	O	O
in	IN	O	O
the	DT	O	O
combined	JJ	O	O
spinal-epidural	JJ	O	O
group	NN	O	O
,	,	O	O
there	EX	O	O
was	VBD	O	O
a	DT	O	O
higher	JJR	o	O
incidence	NN	o	OA
of	IN	o	OA
posterior	JJ	o	OA
presentation	NN	o	OA
(	(	O	O
25.9	CD	O	O
%	NN	O	O
vs.	FW	O	O
10	CD	O	O
%	NN	O	O
,	,	O	O
P	NNP	O	O
=	NNP	O	O
0.03	CD	O	O
)	)	O	O
,	,	O	O
pruritus	NN	o	OA
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.001	CD	O	O
)	)	O	O
,	,	O	O
hypotension	NN	o	OA
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.002	CD	O	O
)	)	O	O
,	,	O	O
somnolence	NN	o	OA
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.01	CD	O	O
)	)	O	O
,	,	O	O
nausea	NN	o	OA
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.02	CD	O	O
)	)	O	O
and	CC	O	O
one	CD	O	O
case	NN	O	O
of	IN	O	O
meningitis	NN	o	OA
.	.	o	O

CONCLUSIONS	VB	O	O
The	DT	O	O
combined	JJ	O	O
spinal-epidural	JJ	O	O
technique	NN	O	O
provided	VBD	O	O
more	RBR	O	O
effective	JJ	O	O
analgesia	NN	O	O
during	IN	p	PC
labour	JJR	p	PC
than	IN	O	O
epidural	JJ	O	O
analgesia	NN	O	O
alone	RB	O	O
but	CC	O	O
offered	VBN	O	O
no	DT	O	O
other	JJ	O	O
advantage	NN	O	O
.	.	O	O

It	PRP	O	O
induced	VBD	O	O
more	RBR	O	O
adverse	JJ	O	O
effects	NNS	O	O
and	CC	O	O
this	DT	O	O
should	MD	O	O
be	VB	O	O
considered	VBN	O	O
before	IN	O	O
routinely	RB	O	O
using	VBG	O	O
the	DT	O	O
combined	JJ	O	O
spinal-epidural	JJ	O	O
technique	NN	O	O
.	.	O	O

Activator	NNP	i	IPM
protein-1	NN	i	IPM
(	(	i	IPM
AP-1	NNP	i	IPM
)	)	i	IPM
signalling	VBG	O	O
in	IN	O	O
human	JJ	p	O
atherosclerosis	NN	p	PC
:	:	p	O
results	NNS	O	O
of	IN	O	O
a	DT	O	O
systematic	JJ	O	O
evaluation	NN	O	O
and	CC	O	O
intervention	NN	O	O
study	NN	O	O
.	.	O	O

Animal	NNP	O	O
studies	NNS	O	O
implicate	VBP	O	O
the	DT	O	O
AP-1	NNP	i	IPM
(	(	i	IPM
activator	IN	i	IPM
protein-1	NN	i	IPM
)	)	i	IPM
pro-inflammatory	NN	O	O
pathway	NN	O	O
as	IN	O	O
a	DT	O	O
promising	NN	O	O
target	NN	O	O
in	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
atherosclerotic	JJ	p	PC
disease	NN	p	PC
.	.	p	O

It	PRP	O	O
is	VBZ	O	O
,	,	O	O
however	RB	O	O
,	,	O	O
unclear	JJ	O	O
whether	IN	O	O
these	DT	O	O
observations	NNS	O	O
apply	VBP	O	O
to	TO	O	O
human	JJ	p	O
atherosclerosis	NN	p	PC
.	.	p	O

Therefore	IN	O	O
we	PRP	O	O
evaluated	VBD	O	O
the	DT	O	O
profile	NN	O	O
of	IN	O	O
AP-1	NNP	i	IPM
activation	NN	i	IPM
through	IN	O	O
histological	JJ	O	O
analysis	NN	O	O
and	CC	O	O
tested	VBD	O	O
the	DT	O	O
potential	JJ	O	O
benefit	NN	O	O
of	IN	O	O
AP-1	NNP	i	IPM
inhibition	NN	i	IPM
in	IN	O	O
a	DT	O	O
clinical	JJ	O	O
trial	NN	O	O
.	.	O	O

AP-1	JJ	i	IPM
activation	NN	i	IPM
was	VBD	O	O
quantified	VBN	O	O
by	IN	O	O
phospho-c-Jun	JJ	O	O
nuclear	JJ	O	O
translocation	NN	O	O
(	(	O	O
immunohistochemistry	NN	O	O
)	)	O	O
on	IN	O	O
a	DT	O	O
biobank	NN	p	O
of	IN	p	O
aortic	JJ	p	PC
wall	NN	p	PC
samples	NNS	p	O
from	IN	p	O
organ	JJ	p	O
donors	NNS	p	O
.	.	p	O

The	DT	O	O
effect	NN	O	O
of	IN	O	O
AP-1	NNP	o	OPH
inhibition	NN	o	OPH
on	IN	O	O
vascular	JJ	O	O
parameters	NNS	O	O
was	VBD	O	O
tested	VBN	O	O
through	IN	O	O
a	DT	O	O
double	JJ	O	O
blind	JJ	O	O
placebo-controlled	JJ	O	O
cross-over	NN	O	O
study	NN	O	O
of	IN	O	O
28	CD	i	O
days	NNS	i	O
doxycycline	NN	i	O
or	CC	i	O
placebo	NN	i	O
in	IN	p	O
patients	NNS	p	O
with	IN	p	O
symptomatic	JJ	p	O
peripheral	JJ	p	O
artery	NN	p	O
disease	NN	p	O
.	.	p	O

Vascular	JJ	o	O
function	NN	o	O
was	VBD	O	O
assessed	VBN	O	O
by	IN	O	O
brachial	JJ	O	O
dilation	NN	O	O
as	RB	O	O
well	RB	O	O
as	IN	O	O
by	IN	O	O
plasma	NN	O	O
samples	NNS	O	O
analysed	VBN	O	O
for	IN	O	O
hs-CRP	NN	O	O
(	(	O	O
high-sensitivity	JJ	O	O
C-reactive	NNP	O	O
protein	NN	O	O
)	)	O	O
,	,	O	O
IL-6	NNP	O	O
(	(	O	O
interleukin-6	NN	O	O
)	)	O	O
,	,	O	O
IL-8	NNP	O	O
,	,	O	O
ICAM-1	NNP	O	O
(	(	O	O
intercellular	JJ	O	O
adhesion	NN	O	O
molecule-1	NN	O	O
)	)	O	O
,	,	O	O
vWF	FW	O	O
(	(	O	O
von	FW	O	O
Willebrand	NNP	O	O
factor	NN	O	O
)	)	O	O
,	,	O	O
MCP-1	NNP	O	O
(	(	O	O
monocyte	JJ	O	O
chemoattractant	NN	O	O
protein-1	NN	O	O
)	)	O	O
,	,	O	O
PAI-1	NNP	O	O
(	(	O	O
plasminogen	JJ	O	O
activator	NN	O	O
inhibitor-1	NN	O	O
)	)	O	O
and	CC	O	O
fibrinogen	NN	O	O
.	.	O	O

Histological	JJ	O	O
evaluation	NN	O	O
of	IN	O	O
human	JJ	o	O
atherosclerosis	NN	o	O
showed	VBD	O	O
minimal	JJ	o	O
AP-1	NNP	o	O
activation	NN	o	O
in	IN	O	O
non-diseased	JJ	O	O
arterial	JJ	O	O
wall	NN	O	O
(	(	O	O
i.e	JJ	O	O
.	.	O	O

vessel	NN	O	O
wall	NN	O	O
without	IN	O	O
any	DT	O	O
signs	NNS	O	O
of	IN	O	O
atherosclerotic	JJ	O	O
disease	NN	O	O
)	)	O	O
.	.	O	O

A	DT	O	O
gradual	JJ	O	O
increase	NN	O	O
of	IN	o	O
AP-1	NNP	o	O
activation	NN	o	O
was	VBD	O	O
found	VBN	O	O
in	IN	O	O
non-progressive	JJ	O	O
and	CC	O	O
progressive	JJ	O	O
phases	NNS	O	O
of	IN	O	O
atherosclerosis	NN	O	O
respectively	RB	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.044	CD	O	O
)	)	O	O
.	.	O	O

No	DT	O	O
significant	JJ	O	O
difference	NN	O	O
was	VBD	O	O
found	VBN	O	O
between	IN	O	O
progressive	JJ	O	O
and	CC	o	O
vulnerable	JJ	o	O
lesions	NNS	O	O
.	.	O	O

The	DT	o	O
expression	NN	o	O
of	IN	o	O
phospho-c-Jun	JJ	o	O
diminished	VBN	O	O
as	IN	O	O
the	DT	O	O
lesion	NN	O	O
stabilized	VBN	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.016	CD	O	O
)	)	O	O
and	CC	O	O
does	VBZ	O	O
not	RB	O	O
significantly	RB	O	O
differ	VBP	O	O
from	IN	O	O
the	DT	O	O
normal	JJ	O	O
aortic	JJ	O	O
wall	NN	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.33	CD	O	O
)	)	O	O
.	.	O	O

Evaluation	NN	O	O
of	IN	O	O
the	DT	i	O
doxycycline	NN	i	O
intervention	NN	i	O
only	RB	O	O
revealed	VBD	O	O
a	DT	O	O
borderline-significant	JJ	O	O
reduction	NN	O	O
of	IN	o	O
circulating	VBG	o	O
hs-CRP	JJ	o	O
levels	NNS	o	O
(	(	O	O
-0.51	NNP	O	O
?g/ml	NNP	O	O
,	,	O	O
P=0.05	NNP	O	O
)	)	O	O
and	CC	O	O
did	VBD	O	O
not	RB	O	O
affect	VB	O	O
any	DT	O	O
of	IN	O	O
the	DT	O	O
other	JJ	o	O
markers	NNS	o	O
of	IN	o	O
systemic	JJ	o	O
inflammation	NN	o	O
and	CC	o	O
vascular	JJ	o	O
function	NN	o	O
.	.	o	O

Our	PRP$	O	O
studies	NNS	O	O
do	VBP	O	O
not	RB	O	O
characterize	VB	i	O
AP-1	NNP	i	O
as	IN	i	O
a	DT	O	O
therapeutic	JJ	O	O
target	NN	O	O
for	IN	p	O
progressive	JJ	p	O
human	JJ	p	O
atherosclerotic	JJ	p	O
disease	NN	p	O
.	.	p	O

The	DT	O	O
additive	JJ	O	O
analgesic	JJ	O	O
efficacy	NN	O	O
of	IN	O	O
acetaminophen	NN	i	IPM
,	,	O	O
1000	CD	O	O
mg	NN	O	O
,	,	O	O
and	CC	O	O
codeine	NN	i	IPM
,	,	O	O
60	CD	O	O
mg	NN	O	O
,	,	O	O
in	IN	O	O
dental	JJ	p	PC
pain	NN	p	PC
.	.	p	O

In	IN	O	O
a	DT	O	O
double-blind	NN	O	O
,	,	O	O
randomized	VBN	O	O
,	,	O	O
single-dose	JJ	O	O
trial	NN	O	O
the	DT	O	O
analgesic	JJ	O	O
contribution	NN	O	O
of	IN	O	O
acetaminophen	NN	i	IPM
,	,	i	IPM
1000	CD	i	IPM
mg	NN	i	IPM
,	,	i	O
and	CC	i	O
codeine	NN	i	IPM
,	,	i	IPM
60	CD	i	IPM
mg	NN	i	IPM
,	,	O	O
was	VBD	O	O
determined	VBN	O	O
.	.	O	O

The	DT	O	O
study	NN	O	O
was	VBD	O	O
a	DT	O	O
2	CD	O	O
X	NN	O	O
2	CD	O	O
factorial	JJ	O	O
experiment	NN	O	O
in	IN	O	O
which	WDT	O	O
120	CD	p	PSS
patients	NNS	p	O
suffering	VBG	p	O
from	IN	p	O
pain	NN	p	O
as	IN	p	O
a	DT	p	O
result	NN	p	O
of	IN	p	O
oral	JJ	p	O
surgery	NN	p	O
rated	VBD	O	O
their	PRP$	O	O
pain	NN	o	OPA
intensity	NN	o	OPA
and	CC	o	O
pain	NN	o	OPA
relief	NN	o	OPA
for	IN	O	O
up	IN	O	O
to	TO	O	O
5	CD	O	O
hours	NNS	O	O
after	IN	O	O
a	DT	O	O
single	JJ	O	O
dose	NN	O	O
of	IN	O	O
one	CD	O	O
of	IN	O	O
:	:	O	O
1000	CD	O	O
mg	NN	O	O
acetaminophen	NN	i	IPM
,	,	O	O
60	CD	O	O
mg	NN	O	O
codeine	NN	i	O
,	,	O	O
1000	CD	O	O
mg	NN	O	O
acetaminophen	NN	i	IPM
plus	CC	i	IPM
60	CD	i	IPM
mg	NN	i	IPM
codeine	NN	i	IPM
,	,	O	O
or	CC	O	O
placebo	NN	i	IC
.	.	i	IC

The	DT	O	O
factorial	JJ	O	O
analysis	NN	O	O
showed	VBD	O	O
that	IN	O	O
both	DT	O	O
1000	CD	O	O
mg	NN	O	O
acetaminophen	NN	i	IPM
and	CC	O	O
60	CD	O	O
mg	NN	O	O
codeine	NN	i	IPM
made	VBD	O	O
a	DT	O	O
statistically	RB	O	O
significant	JJ	O	O
(	(	O	O
P	NNP	O	O
less	JJR	O	O
than	IN	O	O
0.05	CD	O	O
)	)	O	O
contribution	NN	O	O
to	TO	O	O
the	DT	O	O
analgesic	JJ	o	OOt
effectiveness	NN	o	OOt
of	IN	o	OPA
the	DT	o	OPA
combination	NN	o	OPA
on	IN	o	OPA
all	DT	o	OPA
measures	NNS	o	OPA
of	IN	o	OPA
efficacy	NN	o	OPA
(	(	o	O
sum	NN	o	OPA
of	IN	o	OPA
pain	NN	o	OPA
intensity	NN	o	OPA
differences	NNS	o	OPA
,	,	o	O
largest	JJS	o	OPA
pain	NN	o	OPA
intensity	NN	o	OPA
difference	NN	o	OPA
,	,	o	O
total	JJ	o	OPA
pain	NN	o	OPA
relief	NN	o	OPA
,	,	o	O
largest	JJS	o	OPA
pain	NN	o	OPA
relief	NN	o	OPA
,	,	o	O
and	CC	o	O
time	NN	o	OPA
to	TO	o	OPA
remedication	NN	o	OPA
)	)	o	O
.	.	o	O

The	DT	O	O
incidence	NN	o	OA
of	IN	o	OA
adverse	JJ	o	OA
effects	NNS	o	OA
did	VBD	O	O
not	RB	O	O
appear	VB	O	O
to	TO	O	O
differ	VB	O	O
among	IN	O	O
the	DT	O	O
treatments	NNS	O	O
,	,	O	O
including	VBG	O	O
placebo	NN	i	O
.	.	i	O

MSLT	NNP	i	IPH
in	IN	O	O
primary	JJ	O	O
insomnia	NN	o	OME
:	:	o	OME
stability	NN	O	O
and	CC	O	O
relation	NN	O	O
to	TO	O	O
nocturnal	JJ	o	OPH
sleep	NN	o	OPH
.	.	o	OME

STUDY	NNP	O	O
OBJECTIVES	NNP	O	O
To	TO	O	O
assess	VB	O	O
the	DT	O	O
stability	NN	O	O
of	IN	O	O
the	DT	O	O
multiple	JJ	i	IPH
sleep	JJ	i	IPH
latency	NN	i	IPH
test	NN	i	IPH
(	(	i	IPH
MSLT	NNP	i	IPH
)	)	i	IPH
in	IN	O	O
primary	JJ	o	OPH
insomnia	NN	o	OPH
and	CC	O	O
its	PRP$	O	O
relation	NN	O	O
to	TO	O	O
total	JJ	o	OPH
sleep	JJ	o	OPH
time	NN	o	OPH
.	.	o	OME

DESIGN	NNP	O	O
Randomized	NNP	O	O
,	,	O	O
double-blind	NN	O	O
,	,	O	O
placebo	NN	O	O
controlled	VBD	O	O
,	,	O	O
clinical	JJ	O	O
trial	NN	O	O
.	.	O	O

SETTING	NN	O	O
Outpatient	NN	O	O
with	IN	O	O
sleep	JJ	O	O
laboratory	NN	O	O
assessments	NNS	O	O
in	IN	O	O
months	NNS	O	O
1	CD	O	O
and	CC	O	O
8	CD	O	O
of	IN	O	O
treatment	NN	O	O
.	.	O	O

PARTICIPANTS	VB	O	O
Ninety-five	JJ	p	PSS
primary	JJ	p	O
insomniacs	NN	p	PC
,	,	p	O
32-64	CD	p	PA
years	NNS	p	PA
old	JJ	p	PA
and	CC	p	PA
55	CD	p	PA
age-	JJ	p	PA
and	CC	p	O
sex-matched	JJ	p	O
general	JJ	p	O
population-based	JJ	p	O
,	,	p	O
representative	JJ	p	O
controls	NNS	p	O
.	.	p	O

INTERVENTIONS	NNP	O	O
After	IN	O	O
a	DT	O	O
screening	JJ	O	O
nocturnal	JJ	i	IPH
polysomnograms	NNS	i	IPH
(	(	i	IPH
NPSG	NNP	i	IPH
)	)	i	IPH
and	CC	O	O
MSLT	NNP	i	IPH
the	DT	O	O
following	JJ	O	O
day	NN	O	O
,	,	O	O
participants	NNS	p	O
with	IN	p	O
primary	JJ	p	PC
insomnia	NNS	p	PC
were	VBD	O	O
randomized	VBN	O	O
to	TO	O	O
take	VB	O	O
zolpidem	NN	i	IPM
10	CD	O	O
mg	NN	O	O
(	(	O	O
n	JJ	O	O
=	NNP	O	O
50	CD	O	O
)	)	O	O
or	CC	O	O
placebo	NN	i	IC
(	(	O	O
n	JJ	O	O
=	NNP	O	O
45	CD	O	O
)	)	O	O
nightly	RB	O	O
for	IN	O	O
12	CD	O	O
months	NNS	O	O
.	.	O	O

During	IN	O	O
months	NNS	O	O
1	CD	O	O
and	CC	O	O
8	CD	O	O
,	,	O	O
while	IN	O	O
taking	VBG	O	O
their	PRP$	O	O
prescribed	JJ	O	O
treatments	NNS	O	O
,	,	O	O
NPSGs	NNP	O	O
and	CC	O	O
MSLTs	NNP	i	IPH
the	DT	O	O
following	JJ	O	O
day	NN	O	O
were	VBD	O	O
conducted	VBN	O	O
.	.	O	O

A	DT	O	O
population-based	JJ	O	O
sample	NN	O	O
served	VBD	O	O
as	IN	O	O
controls	NNS	O	O
and	CC	O	O
received	VBD	O	O
a	DT	O	O
single	JJ	O	O
NPSG	NNP	O	O
followed	VBN	O	O
by	IN	O	O
MSLT	NNP	i	IPH
.	.	i	O

RESULTS	NNP	O	O
Mean	NNP	o	OPH
daily	JJ	o	OPH
sleep	NN	o	OPH
latency	NN	o	OPH
on	IN	o	OPH
the	DT	o	OPH
screening	VBG	o	OPH
MSLT	NNP	o	OPH
of	IN	o	OPH
insomniacs	NN	o	OPH
was	VBD	O	O
normally	RB	O	O
distributed	VBN	O	O
across	IN	O	O
the	DT	O	O
full	JJ	O	O
range	NN	O	O
of	IN	O	O
MSLT	NNP	i	IPH
scores	NNS	O	O
and	CC	O	O
significantly	RB	O	O
higher	JJR	O	O
than	IN	O	O
those	DT	O	O
of	IN	O	O
a	DT	O	O
population-based	JJ	O	O
representative	NN	O	O
control	NN	O	O
sample	NN	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.006	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
insomniacs	NN	O	O
with	IN	O	O
the	DT	O	O
highest	JJS	O	O
screening	NN	o	OPH
MSLTs	NNP	o	OPH
had	VBD	O	O
the	DT	O	O
shortest	JJS	O	O
screening	NN	o	OPH
total	JJ	o	OPH
sleep	JJ	o	OPH
times	NNS	o	OPH
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
MSLTs	NNP	i	IPH
of	IN	O	O
insomniacs	NN	O	O
during	IN	O	O
treatment	NN	O	O
in	IN	O	O
study	JJ	O	O
month	NN	O	O
1	CD	O	O
were	VBD	O	O
correlated	VBN	O	O
(	(	O	O
r	VB	O	O
=	RB	O	O
0.44	CD	O	O
,	,	O	O
P	NNP	O	O
<	NNP	O	O
0.001	CD	O	O
)	)	O	O
with	IN	O	O
their	PRP$	O	O
month	NN	O	O
8	CD	O	O
MSLT	NNP	O	O
.	.	O	O

The	DT	O	O
mean	JJ	o	OPH
MSLT	NNP	o	OPH
score	NN	o	OPH
of	IN	O	O
the	DT	O	O
zolpidem	NNP	O	O
group	NN	O	O
did	VBD	O	O
not	RB	O	O
differ	VB	O	O
from	IN	O	O
that	DT	O	O
of	IN	O	O
the	DT	O	O
placebo	NN	O	O
group	NN	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
stability	NN	O	O
within	IN	O	O
treatment	NN	O	O
groups	NNS	O	O
also	RB	O	O
did	VBD	O	O
not	RB	O	O
differ	VB	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
These	DT	O	O
data	NNS	O	O
support	NN	O	O
the	DT	O	O
hypothesis	NN	O	O
that	IN	O	O
some	DT	O	O
insomniacs	NN	p	O
show	VBP	O	O
a	DT	O	O
reliable	JJ	O	O
disorder	NN	O	O
of	IN	O	O
hyperarousal	NN	o	OPH
with	IN	O	O
increased	JJ	O	O
wake	NN	o	OPH
drive	NN	o	OPH
both	DT	O	O
at	IN	O	O
night	NN	O	O
and	CC	O	O
during	IN	O	O
the	DT	O	O
day	NN	O	O
.	.	O	O

Can	MD	O	O
simvastatin	VB	i	IPM
improve	VB	O	O
erectile	JJ	o	O
function	NN	o	O
and	CC	O	O
health-related	JJ	o	O
quality	NN	o	O
of	IN	o	O
life	NN	o	O
in	IN	O	O
men	NNS	p	O
aged	VBN	p	O
?40	CD	p	O
years	NNS	p	O
with	IN	p	O
erectile	JJ	p	O
dysfunction	NN	p	O
?	.	p	O
Results	NNS	O	O
of	IN	O	O
the	DT	O	O
Erectile	NNP	O	O
Dysfunction	NNP	O	O
and	CC	O	O
Statins	NNP	O	O
Trial	NNP	O	O
[	NNP	O	O
ISRCTN66772971	NNP	O	O
]	NNP	O	O
.	.	O	O

OBJECTIVE	NNP	O	O
To	TO	O	O
evaluate	VB	O	O
the	DT	o	O
effectiveness	NN	o	O
and	CC	o	O
cost-effectiveness	NN	o	O
of	IN	o	O
simvastatin	NN	i	O
on	IN	i	O
erectile	JJ	o	O
function	NN	o	O
and	CC	o	O
health-related	JJ	o	O
quality	NN	o	O
of	IN	o	O
life	NN	o	O
in	IN	o	O
men	NNS	p	O
aged	VBN	p	O
?40	CD	p	O
years	NNS	p	O
with	IN	p	O
erectile	JJ	p	O
dysfunction	NN	p	O
(	(	p	O
ED	NNP	p	O
)	)	p	O
.	.	p	O

PATIENTS	NNP	p	O
AND	CC	O	O
METHODS	NNP	O	O
ED	NNP	O	O
is	VBZ	O	O
common	JJ	O	O
in	IN	O	O
men	NNS	O	O
aged	VBN	O	O
?40	CD	O	O
years	NNS	O	O
and	CC	O	O
impacts	NNS	O	O
upon	VBP	O	O
their	PRP$	O	O
overall	JJ	O	O
health-related	JJ	O	O
quality	NN	O	O
of	IN	O	O
life	NN	O	O
and	CC	O	O
that	IN	O	O
of	IN	O	O
their	PRP$	O	O
partners	NNS	p	O
.	.	p	O

Men	NNP	p	PSE
aged	VBD	p	O
?40	CD	p	O
years	NNS	p	O
who	WP	p	O
were	VBD	p	O
not	RB	p	O
receiving	VBG	p	O
lipid	JJ	p	O
lowering	NN	p	O
or	CC	p	O
anti-hypertensive	JJ	p	PC
medication	NN	p	O
and	CC	p	O
not	RB	p	O
at	IN	p	O
high	JJ	p	O
cardiovascular	JJ	p	O
risk	NN	p	O
were	VBD	p	O
recruited	VBN	p	O
from	IN	p	O
10	CD	p	O
general	JJ	p	O
practices	NNS	p	O
in	IN	p	O
the	DT	p	O
East	NNP	p	O
of	IN	p	O
England	NNP	p	O
.	.	O	O

In	IN	O	O
total	JJ	O	O
,	,	p	O
173	CD	p	PSS
eligible	JJ	p	O
men	NNS	p	PSE
with	IN	p	O
untreated	JJ	p	PC
ED	NNP	p	PC
were	VBD	p	O
randomized	VBN	p	O
to	TO	p	O
double-blind	VB	p	O
treatment	NN	i	O
with	IN	i	O
40	CD	i	O
mg	NNS	i	O
of	IN	i	O
simvastatin	NN	i	O
or	CC	i	O
placebo	NN	i	O
once	RB	O	O
daily	JJ	O	O
for	IN	O	O
6	CD	O	O
months	NNS	O	O
.	.	O	O

Data	NNS	O	O
were	VBD	O	O
collected	VBN	O	O
at	IN	O	O
three	CD	O	O
points	NNS	O	O
over	IN	O	O
30	CD	O	O
weeks	NNS	O	O
.	.	O	O

The	DT	O	O
main	JJ	O	O
outcome	NN	O	O
was	VBD	o	O
erectile	JJ	o	OPH
function	NN	o	OPH
(	(	o	O
International	NNP	o	O
Index	NNP	o	O
of	IN	o	O
Erectile	NNP	o	O
Function-5	NNP	o	O
score	NN	o	O
)	)	o	O
.	.	o	O

Secondary	JJ	O	O
outcomes	NNS	O	O
included	VBD	O	O
male	JJ	o	OPH
ED-specific	JJ	o	OPH
quality	NN	o	OPH
of	IN	o	OPH
life	NN	o	OPH
(	(	o	OPH
MED-QoL	NNP	o	OPH
)	)	o	OPH
,	,	o	O
quality-adjusted	JJ	o	O
life	NN	o	O
years	NNS	o	O
(	(	o	O
QALYs	NNP	o	O
)	)	o	O
using	VBG	o	O
the	DT	o	O
generic	JJ	o	O
Euroqol	NNP	o	O
measure	NN	o	O
(	(	o	O
EQ-5D	NNP	o	O
)	)	o	O
,	,	o	O
endothelial	JJ	o	OPH
function	NN	o	OPH
,	,	o	O
cardiovascular	JJ	o	O
risk	NN	o	O
,	,	o	O
cholesterol	NN	o	OPH
and	CC	o	O
health	NN	o	O
service	NN	o	O
costs	NNS	o	O
.	.	o	O

RESULTS	NNP	O	O
There	EX	O	O
was	VBD	O	O
no	DT	O	O
significant	JJ	O	O
difference	NN	o	O
in	IN	o	O
erectile	JJ	o	OPH
function	NN	o	OPH
between	IN	o	O
the	DT	i	O
simvastatin	NN	i	O
and	CC	i	O
placebo	NN	i	O
groups	NNS	O	O
(	(	O	O
mean	JJ	O	O
change	NN	O	O
,	,	O	O
1.28	CD	O	O
vs	NN	O	O
0.07	CD	O	O
,	,	O	O
z	NN	O	O
=	VBD	O	O
1.1	CD	O	O
,	,	O	O
p	NN	O	O
=	NNP	O	O
0.27	CD	O	O
)	)	O	O
,	,	O	O
although	IN	O	O
a	DT	O	O
significant	JJ	O	O
improvement	NN	o	O
in	IN	o	O
MED-QoL	NNP	o	OPH
was	VBD	O	O
observed	VBN	O	O
(	(	O	O
5	CD	O	O
%	NN	O	O
vs	JJ	O	O
2	CD	O	O
%	NN	O	O
,	,	O	O
z	NN	O	O
=	VBD	O	O
2.09	CD	O	O
,	,	O	O
p	NN	O	O
=	NNP	O	O
0.04	CD	O	O
)	)	O	O
.	.	O	O

Both	DT	o	O
10-year	JJ	o	O
cardiovascular	NN	o	O
risk	NN	o	O
and	CC	o	O
low-density	NN	o	O
lipoprotein	NN	o	O
were	VBD	o	O
reduced	VBN	o	O
(	(	O	O
cardiovascular	JJ	O	O
risk	NN	O	O
,	,	O	O
z	NN	O	O
=	NNP	O	O
-3.67	NNP	O	O
,	,	O	O
p	NN	O	O
<	VBD	O	O
0.001	CD	O	O
;	:	O	O
low-density	JJ	O	O
lipoprotein	NN	O	O
,	,	O	O
z	NN	O	O
=	NNP	O	O
-5.46	NNP	O	O
,	,	O	O
p	NN	O	O
<	NNP	O	O
0.001	CD	O	O
)	)	O	O
,	,	O	O
with	IN	O	O
no	DT	O	O
consistent	JJ	O	O
change	NN	O	O
in	IN	o	O
endothelial	JJ	o	O
function	NN	o	O
.	.	o	O

The	DT	o	O
frequency	NN	o	O
of	IN	o	O
sexual	JJ	o	O
encounters	NNS	o	O
is	VBZ	o	O
correlated	VBN	o	O
with	IN	o	O
improved	JJ	o	O
erectile	JJ	o	O
function	NN	o	O
.	.	o	O

The	DT	o	O
joint	JJ	o	O
distribution	NN	o	O
of	IN	o	O
costs	NNS	o	O
and	CC	o	O
QALY	NNP	o	O
benefits	NNS	o	O
indicates	VBZ	o	O
that	IN	O	O
the	DT	O	O
probability	NN	O	O
of	IN	O	O
simvastatin	NN	o	O
being	VBG	o	O
cost-effective	JJ	o	O
for	IN	o	O
willingness-to-pay	JJ	o	O
thresholds	NNS	O	O
of	IN	O	O
?20,000	NN	O	O
and	CC	O	O
?30,000	NN	O	O
is	VBZ	O	O
86	CD	O	O
%	NN	O	O
and	CC	O	O
83	CD	O	O
%	NN	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
Identifying	VBG	p	O
men	NNS	p	O
with	IN	p	O
ED	NNP	p	O
provides	VBZ	p	O
an	DT	O	O
opportunity	NN	O	O
to	TO	O	O
modify	VB	O	O
future	JJ	O	O
cardiovascular	JJ	O	O
risk	NN	O	O
and	CC	O	O
to	TO	O	O
improve	VB	O	O
MED-QoL	NNP	O	O
by	IN	O	O
treating	VBG	O	O
them	PRP	O	O
with	IN	O	O
40	CD	O	O
mg	NNS	O	O
of	IN	i	O
simvastatin	NN	i	O
.	.	i	O

The	DT	i	O
joint	JJ	i	O
analysis	NN	O	O
of	IN	o	O
costs	NNS	o	O
and	CC	O	O
QALY	NNP	o	O
benefits	NNS	o	O
suggests	VBZ	O	O
that	IN	O	O
there	EX	O	O
is	VBZ	O	O
high	JJ	O	O
probability	NN	O	O
that	IN	O	O
simvastatin	NN	O	O
is	VBZ	O	O
a	DT	O	O
cost-effective	JJ	O	O
strategy	NN	O	O
in	IN	O	O
men	NNS	O	O
with	IN	O	O
ED	NNP	O	O
.	.	O	O

The	DT	O	O
findings	NNS	O	O
could	MD	O	O
influence	VB	O	O
urological	JJ	O	O
and	CC	O	O
primary	JJ	O	O
care	NN	O	O
practice	NN	O	O
by	IN	O	O
including	VBG	O	O
questions	NNS	O	O
on	IN	O	O
ED	NNP	O	O
during	IN	O	O
routine	JJ	O	O
consultations	NNS	O	O
and	CC	O	O
relevant	JJ	O	O
clinical	JJ	O	O
protocols	NNS	O	O
.	.	O	O

This	DT	O	O
provides	VBZ	O	O
an	DT	O	O
opportunity	NN	O	O
to	TO	O	O
impart	VB	O	O
lifestyle	JJ	O	O
advice	NN	O	O
.	.	O	O

Effect	NN	O	O
of	IN	O	O
two	CD	O	O
monophasic	JJ	i	IPM
oral	JJ	i	IPM
contraceptives	NNS	i	IPM
containing	VBG	i	O
gestodene	NN	i	IPM
or	CC	i	O
desogestrel	NN	i	IPM
on	IN	O	O
serum	NN	O	O
lipoprotein	NN	O	O
lipid	JJ	O	O
levels	NNS	O	O
.	.	O	O

Forty-nine	NNP	p	PSS
healthy	JJ	p	O
women	NNS	p	PSE
aged	VBN	p	O
20-35	JJ	p	PA
years	NNS	p	O
who	WP	p	O
had	VBD	p	O
not	RB	p	O
been	VBN	p	O
pregnant	JJ	p	O
or	CC	p	O
using	VBG	p	O
an	DT	p	O
oral	JJ	i	IPM
contraceptive	NN	i	IPM
(	(	i	IPM
OC	NNP	i	IPM
)	)	i	IPM
for	IN	p	O
the	DT	p	O
previous	JJ	p	O
3	CD	p	O
months	NNS	p	O
were	VBD	O	O
randomized	VBN	O	O
into	IN	O	O
two	CD	O	O
groups	NNS	O	O
,	,	O	O
one	CD	O	O
group	NN	O	O
taking	VBG	O	O
an	DT	O	O
OC	NNP	i	IPM
containing	VBG	O	O
75	CD	O	O
micrograms	NNS	O	O
gestodene	NN	i	IPM
(	(	i	IPM
GTD	NNP	i	IPM
)	)	i	IPM
and	CC	O	O
30	CD	O	O
micrograms	NNS	O	O
ethinyl	VBP	i	IPM
estradiol	NN	i	IPM
(	(	i	IPM
EE	NNP	i	IPM
)	)	i	IPM
,	,	O	O
and	CC	O	O
the	DT	O	O
other	JJ	O	O
group	NN	O	O
using	VBG	O	O
an	DT	O	O
OC	NNP	i	IPM
with	IN	O	O
150	CD	O	O
micrograms	NNS	O	O
desogestrel	NN	i	IPM
(	(	i	IPM
DSG	NNP	i	IPM
)	)	i	IPM
and	CC	O	O
30	CD	O	O
micrograms	NNS	O	O
EE	NNP	i	O
.	.	i	O

Fasting	VBG	o	OPH
blood	NN	o	OPH
samples	NNS	o	OPH
were	VBD	O	O
taken	VBN	O	O
before	RB	O	O
treatment	NN	O	O
,	,	O	O
and	CC	O	O
after	IN	O	O
cycles	NNS	O	O
3	CD	O	O
and	CC	O	O
6	CD	O	O
,	,	O	O
between	IN	O	O
the	DT	O	O
18th	CD	O	O
and	CC	O	O
the	DT	O	O
22nd	CD	O	O
day	NN	O	O
of	IN	O	O
the	DT	O	O
cycle	NN	O	O
.	.	O	O

Blood	NNP	o	OPH
lipoprotein	JJ	o	OPH
lipid	JJ	o	OPH
levels	NNS	o	OPH
were	VBD	O	O
measured	VBN	O	O
.	.	O	O

Serum	NNP	o	OPH
total	JJ	o	OPH
cholesterol	NN	o	OPH
did	VBD	o	O
not	RB	o	O
change	VB	o	O
significantly	RB	O	O
in	IN	O	O
both	DT	O	O
groups	NNS	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
in	IN	O	O
the	DT	O	O
first	JJ	O	O
three	CD	O	O
cycles	NNS	O	O
,	,	O	O
serum	JJ	o	OPH
triglyceride	NN	o	OPH
increased	VBN	o	OPH
by	IN	O	O
46	CD	O	O
%	NN	O	O
and	CC	O	O
40	CD	O	O
%	NN	O	O
and	CC	O	O
HDL-cholesterol	NNP	o	OPH
by	IN	o	O
14	CD	o	O
%	NN	o	O
and	CC	O	O
8	CD	o	O
%	NN	o	O
in	IN	o	O
the	DT	o	O
GTD	NNP	o	OPH
and	CC	o	OPH
DSG	NNP	o	OPH
groups	NNS	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

The	DT	O	O
serum	NN	o	OPH
LDL	NNP	o	OPH
level	NN	o	OPH
decreased	VBN	o	O
by	IN	O	O
6.2	CD	O	O
%	NN	O	O
and	CC	O	O
11.8	CD	O	O
%	NN	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

Between	VB	O	O
the	DT	O	O
third	JJ	O	O
and	CC	O	O
sixth	JJ	O	O
cycle	NN	O	O
,	,	O	O
no	DT	o	O
further	JJ	o	O
significant	JJ	o	O
changes	NNS	o	O
were	VBD	O	O
observed	VBN	O	O
,	,	O	O
nor	CC	O	O
did	VBD	O	O
these	DT	O	O
changes	NNS	O	O
differ	VBP	O	O
significantly	RB	O	O
between	IN	O	O
the	DT	O	O
two	CD	O	O
groups	NNS	O	O
.	.	O	O

In	IN	O	O
conclusion	NN	O	O
,	,	O	O
both	DT	O	O
OC	NNP	i	IPM
preparations	NNS	O	O
exerted	VBD	O	O
small	JJ	o	O
and	CC	o	O
probably	RB	o	O
favorable	JJ	o	O
effects	NNS	o	O
on	IN	o	O
serum	NN	o	OPH
lipoprotein	NN	o	OPH
lipid	JJ	o	OPH
levels	NNS	o	OPH
.	.	o	O

Clozapine	NNP	i	IPM
versus	NN	i	O
placebo	NN	i	IC
in	IN	O	O
Huntington	NNP	p	PC
's	POS	p	PC
disease	NN	p	PC
:	:	p	O
a	DT	O	O
double	JJ	O	O
blind	NN	O	O
randomised	VBD	O	O
comparative	JJ	O	O
study	NN	O	O
.	.	O	O

OBJECTIVES	NNP	O	O
To	TO	O	O
establish	VB	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
the	DT	O	O
atypical	JJ	O	O
neuroleptic	JJ	O	O
clozapine	NN	i	IPM
on	IN	O	O
chorea	NN	O	O
,	,	O	O
voluntary	JJ	O	O
motor	NN	O	O
performance	NN	O	O
,	,	O	O
and	CC	O	O
functional	JJ	O	O
disability	NN	O	O
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
Huntington	NNP	p	O
's	POS	p	O
disease	NN	p	O
.	.	p	O

METHODS	NNP	O	O
Thirty	NNP	p	PSS
three	CD	p	PSS
patients	NNS	p	O
with	IN	p	O
Huntington	NNP	p	O
's	POS	p	O
disease	NN	p	O
participated	VBD	p	O
in	IN	O	O
a	DT	O	O
double	JJ	O	O
blind	NN	O	O
randomised	VBD	O	O
trial	NN	O	O
.	.	O	O

A	DT	O	O
maximum	NN	O	O
of	IN	O	O
150	CD	O	O
mg/day	JJ	O	O
clozapine	NN	i	IPM
or	CC	i	O
placebo	NN	i	IC
equivalent	NN	O	O
was	VBD	O	O
given	VBN	O	O
for	IN	O	O
a	DT	O	O
period	NN	O	O
of	IN	O	O
31	CD	O	O
days	NNS	O	O
.	.	O	O

Assessments	NNS	O	O
were	VBD	O	O
performed	VBN	O	O
in	IN	O	O
the	DT	O	O
week	NN	O	O
before	IN	O	O
and	CC	O	O
at	IN	O	O
the	DT	O	O
last	JJ	O	O
day	NN	O	O
of	IN	O	O
the	DT	O	O
trial	NN	O	O
.	.	O	O

Chorea	NNP	O	O
was	VBD	O	O
scored	VBN	O	O
using	VBG	O	O
the	DT	O	O
abnormal	JJ	O	O
involuntary	JJ	O	O
movement	NN	O	O
scale	NN	O	O
(	(	O	O
AIMS	NNP	O	O
)	)	O	O
,	,	O	O
the	DT	O	O
chorea	NN	O	O
score	NN	O	O
of	IN	O	O
the	DT	O	O
unified	JJ	O	O
Huntington	NNP	O	O
's	POS	O	O
disease	NN	O	O
rating	NN	O	O
scale	NN	O	O
(	(	O	O
UHDRS	NNP	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
judgement	NN	O	O
of	IN	O	O
video	JJ	O	O
recordings	NNS	O	O
.	.	O	O

Voluntary	JJ	O	O
motor	NN	O	O
performance	NN	O	O
was	VBD	O	O
assessed	VBN	O	O
using	VBG	O	O
the	DT	O	O
UHDRS	NNP	O	O
motor	NN	O	O
scale	NN	O	O
.	.	O	O

Patients	NNS	p	O
and	CC	p	O
their	PRP$	p	O
partners	NNS	p	O
completed	VBD	O	O
a	DT	O	O
questionnaire	NN	O	O
regarding	VBG	O	O
functional	JJ	O	O
disability	NN	O	O
.	.	O	O

Twelve	CD	O	O
patients	NNS	O	O
already	RB	O	O
used	VBD	O	O
other	JJ	O	O
neuroleptic	JJ	O	O
medication	NN	O	O
,	,	O	O
which	WDT	O	O
was	VBD	O	O
kept	FW	O	O
unchanged	JJ	O	O
during	IN	O	O
the	DT	O	O
trial	NN	O	O
period	NN	O	O
.	.	O	O

Results	NNS	O	O
of	IN	O	O
neuroleptic	JJ	O	O
naive	JJ	O	O
and	CC	O	O
neuroleptic	JJ	O	O
treated	JJ	O	O
patients	NNS	O	O
were	VBD	O	O
analysed	VBN	O	O
separately	RB	O	O
.	.	O	O

RESULTS	NNP	O	O
Clozapine	NNP	i	IPM
tended	VBD	O	O
to	TO	O	O
reduce	VB	O	O
chorea	NN	o	OPH
in	IN	O	O
neuroleptic	JJ	O	O
naive	JJ	O	O
patients	NNS	O	O
only	RB	O	O
(	(	O	O
AIMS	NNP	O	O
)	)	O	O
;	:	O	O
improvement	NN	O	O
seemed	VBD	O	O
more	RBR	O	O
pronounced	JJ	O	O
in	IN	O	O
patients	NNS	O	O
receiving	VBG	O	O
higher	JJR	O	O
doses	NNS	O	O
of	IN	O	O
clozapine	NN	O	O
.	.	O	O

Other	JJ	O	O
measures	NNS	o	OPH
of	IN	o	OPH
chorea	NN	o	OPH
(	(	o	OPH
UHDRS	NNP	o	OPH
chorea	NN	o	OPH
score	NN	o	OPH
,	,	o	OPH
video	JJ	o	OPH
ratings	NNS	o	OPH
)	)	o	OPH
showed	VBD	O	O
no	DT	O	O
improvement	NN	O	O
.	.	O	O

Clozapine	NNP	i	IPM
had	VBD	O	O
no	DT	O	O
beneficial	JJ	O	O
effect	NN	O	O
on	IN	O	O
chorea	NN	o	OPH
in	IN	O	O
patients	NNS	O	O
already	RB	O	O
receiving	VBG	O	O
neuroleptic	JJ	O	O
medication	NN	O	O
.	.	O	O

Voluntary	JJ	o	OPH
motor	NN	o	OPH
performance	NN	o	OPH
did	VBD	O	O
not	RB	O	O
improve	VB	O	O
with	IN	O	O
clozapine	NN	O	O
.	.	O	O

Neuroleptic	JJ	O	O
naive	JJ	O	O
patients	NNS	O	O
reported	VBN	O	O
aggravation	NN	O	O
of	IN	O	O
functional	JJ	o	OPH
disability	NN	o	OPH
,	,	O	O
possibly	RB	O	O
reflecting	VBG	O	O
the	DT	O	O
frequent	JJ	O	O
occurrence	NN	O	O
of	IN	O	O
side	NN	O	O
effects	NNS	O	O
.	.	O	O

Adverse	JJ	O	O
reactions	NNS	O	O
forced	VBD	O	O
trial	NN	O	O
termination	NN	O	O
in	IN	O	O
six	CD	O	O
patients	NNS	O	O
and	CC	O	O
dose	JJ	O	O
reduction	NN	O	O
in	IN	O	O
another	DT	O	O
eight	CD	O	O
,	,	O	O
and	CC	O	O
consisted	VBD	O	O
mainly	RB	O	O
of	IN	O	O
drowsiness	NN	o	OA
,	,	o	OA
fatigue	NN	o	OA
,	,	o	OA
anticholinergic	NN	o	OA
symptoms	NNS	o	OA
,	,	o	OA
and	CC	o	OA
walking	VBG	o	OA
difficulties	NNS	o	OA
.	.	o	O

CONCLUSIONS	NNP	O	O
Clozapine	NNP	i	IPM
has	VBZ	O	O
little	JJ	O	O
beneficial	JJ	O	O
effect	NN	O	O
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
Huntington	NNP	p	O
's	POS	p	O
disease	NN	p	O
,	,	O	O
although	IN	O	O
individual	JJ	O	O
patients	NNS	O	O
may	MD	O	O
tolerate	VB	O	O
doses	NNS	O	O
high	JJ	O	O
enough	RB	O	O
to	TO	O	O
reduce	VB	O	O
chorea	NN	O	O
.	.	O	O

Because	IN	O	O
adverse	JJ	O	O
reactions	NNS	O	O
are	VBP	O	O
often	RB	O	O
encountered	VBN	O	O
,	,	O	O
clozapine	NN	i	IPM
should	MD	O	O
be	VB	O	O
used	VBN	O	O
with	IN	O	O
restraint	NN	O	O
in	IN	O	O
this	DT	O	O
patient	NN	O	O
group	NN	O	O
.	.	O	O

Lipoprotein	NNP	O	O
(	(	O	O
a	DT	O	O
)	)	O	O
serum	NN	O	O
levels	NNS	O	O
in	IN	O	O
post-menopausal	JJ	p	O
women	NNS	p	O
treated	VBN	p	O
with	IN	p	O
oral	JJ	i	IPM
estrogens	NNS	i	IPM
administered	VBN	p	O
at	IN	p	O
different	JJ	p	O
times	NNS	p	O
.	.	p	O

The	DT	O	O
different	JJ	O	O
effects	NNS	o	OOt
on	IN	O	O
serum	NN	O	O
lipoprotein	NN	O	O
(	(	O	O
a	DT	O	O
)	)	O	O
[	NN	O	O
Lp	NNP	O	O
(	(	O	O
a	DT	O	O
)	)	O	O
]	NN	O	O
levels	NNS	O	O
by	IN	O	O
administering	VBG	O	O
estrogens	NNS	i	IPM
at	IN	i	O
different	JJ	i	O
times	NNS	i	O
of	IN	i	O
the	DT	i	O
day	NN	i	O
(	(	O	O
8	CD	O	O
a.m.	RB	O	O
and	CC	O	O
8	CD	O	O
p.m.	NN	O	O
)	)	O	O
were	VBD	O	O
evaluated	VBN	O	O
in	IN	O	O
twenty-four	JJ	p	O
post-menopausal	JJ	p	O
women	NNS	p	O
.	.	p	O

Patients	NNS	O	O
were	VBD	O	O
assigned	VBN	O	O
to	TO	O	O
one	CD	O	O
of	IN	O	O
the	DT	O	O
two	CD	O	O
treatment	NN	O	O
groups	NNS	O	O
by	IN	O	O
random	JJ	O	O
sampling	VBG	O	O
numbers	NNS	O	O
.	.	O	O

Patients	NNS	O	O
of	IN	O	O
both	DT	O	O
groups	NNS	O	O
received	VBD	O	O
0.625	CD	O	O
mg	NNS	O	O
conjugated	VBN	i	IPM
equine	JJ	i	IPM
estrogens	NNS	i	IPM
daily	JJ	O	O
per	IN	O	O
os	NN	O	O
for	IN	O	O
21	CD	O	O
days	NNS	O	O
.	.	O	O

Group	NNP	O	O
A	NNP	O	O
patients	NNS	O	O
(	(	O	O
n	JJ	O	O
:	:	O	O
9	CD	O	O
)	)	O	O
received	VBD	O	O
the	DT	O	O
pill	NN	O	O
at	IN	O	O
8	CD	O	O
a.m.	NN	O	O
,	,	O	O
and	CC	O	O
group	NN	O	O
B	NNP	O	O
patients	NNS	O	O
(	(	O	O
n	JJ	O	O
:	:	O	O
12	CD	O	O
)	)	O	O
received	VBD	O	O
the	DT	O	O
pill	NN	O	O
at	IN	O	O
8	CD	O	O
p.m	NN	O	O
.	.	O	O

There	EX	O	O
were	VBD	O	O
no	DT	O	O
statistically	RB	O	O
significant	JJ	O	O
differences	NNS	O	O
between	IN	O	O
the	DT	O	O
two	CD	O	O
treatment	NN	O	O
groups	NNS	O	O
as	IN	O	O
regards	NNS	O	O
the	DT	O	O
anthropometric	JJ	o	OPH
characteristics	NNS	o	OPH
,	,	o	OPH
the	DT	o	OPH
basal	NN	o	OPH
values	NNS	o	OPH
of	IN	o	OPH
the	DT	o	OPH
Lp	NNP	o	OPH
(	(	o	OPH
a	DT	o	OPH
)	)	o	OPH
,	,	o	OPH
the	DT	o	OPH
sex	NN	o	OPH
steroid	NN	o	OPH
and	CC	o	OPH
pituitary	JJ	o	OPH
hormone	NN	o	OPH
levels	NNS	o	OPH
.	.	o	OPH

Administration	NN	O	O
of	IN	O	O
conjugated	JJ	i	IPM
equine	NN	i	IPM
estrogens	NNS	i	IPM
resulted	VBD	O	O
in	IN	O	O
decreased	JJ	O	O
levels	NNS	o	OPH
of	IN	o	OPH
Lp	NNP	o	OPH
(	(	o	OPH
a	DT	o	OPH
)	)	o	OPH
only	RB	O	O
in	IN	O	O
group	NN	O	O
B	NNP	O	O
after	IN	O	O
treatment	NN	O	O
.	.	O	O

The	DT	O	O
different	JJ	O	O
Lp	NNP	O	O
(	(	O	O
a	DT	O	O
)	)	O	O
behaviour	NN	O	O
in	IN	O	O
the	DT	O	O
two	CD	O	O
groups	NNS	O	O
and	CC	O	O
in	IN	O	O
the	DT	O	O
presence	NN	O	O
of	IN	O	O
the	DT	O	O
same	JJ	O	O
serum	JJ	O	O
hormonal	NN	O	O
levels	NNS	O	O
,	,	O	O
seems	VBZ	O	O
to	TO	O	O
be	VB	O	O
dependent	JJ	O	O
on	IN	O	O
the	DT	O	O
existence	NN	O	O
of	IN	O	O
a	DT	O	O
circadian	JJ	O	O
rhythm	NN	O	O
of	IN	O	O
the	DT	O	O
hepatic	JJ	O	O
responsiveness	NN	O	O
to	TO	O	O
estrogens	VB	O	O
,	,	O	O
whose	WP$	O	O
expression	NN	O	O
is	VBZ	O	O
higher	JJR	O	O
during	IN	O	O
evening	NN	O	O
hours	NNS	O	O
.	.	O	O

Comparison	NNP	O	O
of	IN	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
terazosin	NN	i	IPM
and	CC	O	O
enalapril	NN	i	IPM
on	IN	O	O
laboratory	NN	O	O
stress	NN	O	O
testing	VBG	O	O
blood	NN	O	O
pressure	NN	O	O
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
essential	JJ	p	PC
hypertension	NN	p	PC
.	.	p	O

It	PRP	O	O
is	VBZ	O	O
the	DT	O	O
current	JJ	O	O
opinion	NN	O	O
that	IN	O	O
an	DT	O	O
ideal	JJ	O	O
antihypertensive	JJ	i	IPM
drug	NN	i	IPM
should	MD	O	O
reduce	VB	O	O
blood	NN	O	O
pressure	NN	O	O
(	(	O	O
BP	NNP	O	O
)	)	O	O
not	RB	O	O
only	RB	O	O
at	IN	O	O
rest	NN	O	O
but	CC	O	O
also	RB	O	O
during	IN	O	O
stressful	JJ	O	O
situations	NNS	O	O
.	.	O	O

The	DT	O	O
current	JJ	O	O
study	NN	O	O
was	VBD	O	O
aimed	VBN	O	O
to	TO	O	O
compare	VB	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
the	DT	O	O
selective	JJ	i	IPM
alpha	NN	i	IPM
1-adrenergic	JJ	i	IPM
blocker	NN	i	IPM
terazosin	NN	i	IPM
(	(	O	O
5	CD	O	O
mg	NN	O	O
once	RB	O	O
daily	JJ	O	O
)	)	O	O
and	CC	O	O
of	IN	O	O
the	DT	O	O
angiotensin-converting	JJ	i	IPM
enzyme	NN	i	IPM
inhibitor	NN	i	IPM
enalapril	NN	i	IPM
(	(	O	O
20	CD	O	O
mg	NN	O	O
once	RB	O	O
daily	RB	O	O
)	)	O	O
on	IN	O	O
cardiovascular	JJ	O	O
response	NN	O	O
to	TO	O	O
a	DT	O	O
set	NN	O	O
of	IN	O	O
standardized	JJ	O	O
laboratory	NN	O	O
stressors	NNS	O	O
,	,	O	O
such	JJ	O	O
as	IN	O	O
mental	JJ	O	O
arithmetic	JJ	O	O
,	,	O	O
handgrip	JJ	O	O
test	NN	O	O
and	CC	O	O
cycle	NN	O	O
ergometry	NN	O	O
,	,	O	O
in	IN	O	O
a	DT	O	O
group	NN	p	O
of	IN	p	O
16	CD	p	PSS
essential	JJ	p	O
hypertensive	JJ	p	O
patients	NNS	p	O
.	.	p	O

The	DT	O	O
study	NN	O	O
was	VBD	O	O
a	DT	O	O
randomized	JJ	O	O
,	,	O	O
double-blind	JJ	O	O
,	,	O	O
cross-over	JJ	O	O
trial	NN	O	O
preceded	VBN	O	O
by	IN	O	O
a	DT	O	O
placebo	JJ	i	IC
run-in	JJ	O	O
period	NN	O	O
.	.	O	O

Terazosin	NNP	i	IPM
and	CC	i	O
enalapril	VB	i	IPM
had	VBD	O	O
a	DT	O	O
comparable	JJ	O	O
effect	NN	O	O
on	IN	O	O
resting	VBG	o	OPH
BP	NNP	o	OPH
,	,	o	OPH
reducing	VBG	o	OPH
systolic	JJ	o	OPH
(	(	o	OPH
SBP	NNP	o	OPH
)	)	o	OPH
and	CC	o	OPH
diastolic	JJ	o	OPH
(	(	o	OPH
DBP	NNP	o	OPH
)	)	o	OPH
blood	NN	o	OPH
pressure	NN	o	OPH
from	IN	O	O
159.5	CD	O	O
+/-	JJ	O	O
13.9/101.6	CD	O	O
+/-	JJ	O	O
8.8	CD	O	O
mm	NN	O	O
Hg	NNP	O	O
during	IN	O	O
placebo	NN	O	O
by	IN	O	O
7.8	CD	O	O
%	NN	O	O
/6.7	CC	O	O
%	NN	O	O
and	CC	O	O
by	IN	O	O
11.3	CD	O	O
%	NN	O	O
/10.2	CD	O	O
%	NN	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

The	DT	O	O
response	NN	o	OOt
rate	NN	o	OOt
to	TO	O	O
the	DT	O	O
two	CD	O	O
treatments	NNS	O	O
was	VBD	O	O
approximately	RB	O	O
the	DT	O	O
same	JJ	O	O
,	,	O	O
being	VBG	O	O
69	CD	O	O
%	NN	O	O
and	CC	O	O
75	CD	O	O
%	NN	O	O
after	IN	O	O
terazosin	NN	i	IPM
and	CC	O	O
enalapril	NN	i	IPM
,	,	O	O
respectively	RB	O	O
.	.	O	O

During	IN	O	O
mental	JJ	O	O
arithmetic	JJ	O	O
,	,	O	O
from	IN	O	O
an	DT	O	O
average	NN	O	O
of	IN	O	O
181.6	CD	O	O
+/-	JJ	O	O
17.8/118.6	CD	O	O
+/-	JJ	O	O
11.5	CD	O	O
mm	NN	O	O
Hg	NNP	O	O
during	IN	O	O
placebo	NN	i	IC
,	,	O	O
BP	NNP	o	OPH
was	VBD	O	O
reduced	VBN	O	O
by	IN	O	O
11.5	CD	O	O
%	NN	O	O
/7.9	CD	O	O
%	NN	O	O
after	IN	O	O
terazosin	NN	i	IPM
and	CC	O	O
by	IN	O	O
13.6	CD	O	O
%	NN	O	O
/8.5	CD	O	O
%	NN	O	O
after	IN	O	O
enalapril	NN	i	IPM
;	:	i	O
during	IN	O	O
handgrip	NN	O	O
test	NN	O	O
,	,	O	O
BP	NNP	o	OPH
decreased	VBD	O	O
from	IN	O	O
207.2	CD	O	O
+/-	JJ	O	O
22.2/142.2	CD	O	O
+/-	JJ	O	O
13.6	CD	O	O
mm	NN	O	O
Hg	NNP	O	O
by	IN	O	O
7.3	CD	O	O
%	NN	O	O
/8.4	CD	O	O
%	NN	O	O
after	IN	O	O
terazosin	NN	i	IPM
and	CC	O	O
by	IN	O	O
7.7	CD	O	O
%	NN	O	O
/7.1	CD	O	O
%	NN	O	O
after	IN	O	O
enalapril	NN	i	IPM
;	:	i	O
finally	RB	O	O
,	,	O	O
during	IN	O	O
cycle	NN	O	O
ergometry	NN	O	O
,	,	O	O
terazosin	NN	O	O
and	CC	O	O
enalapril	NN	O	O
lowered	VBN	O	O
BP	NNP	o	OPH
by	IN	O	O
5.4	CD	O	O
%	NN	O	O
/6.7	CC	O	O
%	NN	O	O
and	CC	O	O
7	CD	O	O
%	NN	O	O
/3.1	CD	O	O
%	NN	O	O
,	,	O	O
respectively	RB	O	O
,	,	O	O
from	IN	O	O
a	DT	O	O
placebo	NN	i	IC
value	NN	O	O
of	IN	O	O
215.5	CD	O	O
+/-	JJ	O	O
17.3/127.6	CD	O	O
+/-	JJ	O	O
11.2	CD	O	O
.	.	O	O

No	DT	O	O
significant	JJ	O	O
difference	NN	O	O
in	IN	O	O
antihypertensive	JJ	O	O
efficacy	NN	O	O
was	VBD	O	O
observed	VBN	O	O
between	IN	O	O
the	DT	O	O
two	CD	O	O
drugs	NNS	O	O
,	,	O	O
either	RB	O	O
at	IN	O	O
rest	NN	O	O
and	CC	O	O
during	IN	O	O
stress	JJ	O	O
testing	VBG	O	O
.	.	O	O

(	(	O	O
ABSTRACT	NNP	O	O
TRUNCATED	NNP	O	O
AT	NNP	O	O
250	CD	O	O
WORDS	NNP	O	O
)	)	O	O
Ciprofloxacin	NNP	i	IPM
,	,	i	O
lomefloxacin	NN	i	IPM
,	,	i	O
or	CC	i	O
levofloxacin	CC	i	IPM
as	IN	O	O
treatment	NN	O	O
for	IN	O	O
chronic	JJ	o	OPH
osteomyelitis	NN	o	OPH
.	.	o	OPH

The	DT	O	O
efficacy	NN	o	OOt
and	CC	o	OOt
safety	NN	o	OOt
of	IN	O	O
three	CD	O	O
oral	JJ	i	IPM
fluoroquinolones	NNS	i	IPM
(	(	i	O
lomefloxacin	NN	i	IPM
,	,	i	O
levofloxacin	NN	i	IPM
,	,	i	O
and	CC	i	O
ciprofloxacin	NN	i	IPM
)	)	i	O
for	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
chronic	JJ	O	O
osteomyelitis	NN	O	O
were	VBD	O	O
analyzed	VBN	O	O
.	.	O	O

Twenty-seven	JJ	p	PSS
patients	NNS	p	O
had	VBD	p	O
documented	VBN	p	O
infections	NNS	p	PC
with	IN	p	PC
quinolone-sensitive	JJ	p	PC
organisms	NNS	p	PC
and	CC	O	O
received	VBD	O	O
either	DT	i	O
lomefloxacin	NN	i	IPM
,	,	i	O
levofloxacin	NN	i	IPM
,	,	i	O
or	CC	i	O
ciprofloxacin	NN	i	IPM
.	.	i	O

Levofloxacin	NNP	O	O
was	VBD	O	O
effective	JJ	O	O
therapy	NN	O	O
for	IN	O	O
9	CD	O	O
of	IN	O	O
15	CD	O	O
(	(	O	O
60	CD	O	O
%	NN	O	O
)	)	O	O
patients	NNS	O	O
.	.	O	O

Lomefloxacin	NNP	O	O
was	VBD	O	O
effective	JJ	O	O
therapy	NN	O	O
for	IN	O	O
five	CD	O	O
of	IN	O	O
seven	CD	O	O
(	(	O	O
71	CD	O	O
%	NN	O	O
)	)	O	O
patients	NNS	O	O
,	,	O	O
and	CC	O	O
ciprofloxacin	NN	O	O
was	VBD	O	O
effective	JJ	O	O
therapy	NN	O	O
for	IN	O	O
two	CD	O	O
of	IN	O	O
five	CD	O	O
patients	NNS	O	O
(	(	O	O
40	CD	O	O
%	NN	O	O
)	)	O	O
.	.	O	O

Average	JJ	O	O
follow-up	NN	O	O
was	VBD	O	O
11.8	CD	O	O
months	NNS	O	O
for	IN	O	O
patients	NNS	O	O
who	WP	O	O
completed	VBD	O	O
the	DT	O	O
course	NN	O	O
of	IN	O	O
therapy	NN	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
average	JJ	O	O
duration	NN	o	OOt
of	IN	o	OOt
therapy	NN	o	OOt
was	VBD	O	O
60.6	CD	O	O
days	NNS	O	O
.	.	O	O

Gram-positive	JJ	o	OPH
bacteria	NNS	o	OPH
were	VBD	O	O
isolated	VBN	O	O
from	IN	O	O
18	CD	O	O
patients	NNS	O	O
,	,	O	O
and	CC	O	O
11	CD	O	O
patients	NNS	O	O
were	VBD	O	O
cured	VBN	o	OPH
.	.	o	O

Oral	JJ	O	O
fluoroquinolones	NNS	O	O
can	MD	O	O
be	VB	O	O
safe	JJ	o	OOt
,	,	o	OOt
effective	JJ	o	OOt
therapy	NN	O	O
if	IN	O	O
they	PRP	O	O
are	VBP	O	O
given	VBN	O	O
for	IN	O	O
a	DT	O	O
prolonged	JJ	O	O
course	NN	O	O
as	IN	O	O
treatment	NN	O	O
for	IN	O	O
infections	NNS	O	O
caused	VBN	O	O
by	IN	O	O
susceptible	JJ	O	O
gram-positive	JJ	O	O
as	RB	O	O
well	RB	O	O
as	IN	O	O
gram-negative	JJ	O	O
organisms	NNS	O	O
and	CC	O	O
in	IN	O	O
combination	NN	O	O
with	IN	O	O
adequate	JJ	O	O
surgical	JJ	O	O
debridement	NN	O	O
.	.	O	O

Comparison	NNP	O	O
of	IN	O	O
succinylcholine	NN	i	IPM
with	IN	O	O
two	CD	O	O
doses	NNS	O	O
of	IN	O	O
rocuronium	NN	i	IPM
using	VBG	O	O
a	DT	O	O
new	JJ	O	O
method	NN	O	O
of	IN	O	O
monitoring	VBG	O	O
neuromuscular	JJ	o	OPH
block	NN	o	OPH
at	IN	p	O
the	DT	p	O
laryngeal	NN	p	O
muscles	NNS	p	O
by	IN	O	O
surface	NN	p	O
laryngeal	NN	p	O
electromyography	NN	p	O
.	.	O	O

We	PRP	O	O
compared	VBN	O	O
the	DT	O	O
onset	NN	o	OPH
of	IN	o	OPH
neuromuscular	JJ	o	OPH
block	NN	o	OPH
with	IN	O	O
succinylcholine	NN	i	IPM
(	(	i	IPM
1	CD	i	IPM
mg	RB	i	IPM
kg-1	NN	i	IPM
)	)	i	IPM
and	CC	i	IPM
two	CD	i	IPM
doses	NNS	i	IPM
of	IN	i	IPM
rocuronium	NN	i	IPM
(	(	i	IPM
0.6	CD	i	IPM
and	CC	i	IPM
0.9	CD	i	IPM
mg	JJ	i	IPM
kg-1	NN	i	IPM
)	)	i	IPM
at	IN	O	O
the	DT	O	O
adductor	NN	O	O
pollicis	NN	O	O
muscle	NN	O	O
using	VBG	O	O
electromyography	NN	i	IOt
(	(	i	IOt
EMG	NNP	i	IOt
)	)	i	IOt
and	CC	i	IOt
acceleromyography	NN	i	IOt
(	(	O	O
AMG	NNP	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
at	IN	O	O
the	DT	O	O
adductor	NN	O	O
laryngeal	NN	O	O
muscles	NNS	O	O
with	IN	O	O
a	DT	O	O
new	JJ	O	O
electromyographic	JJ	i	IOt
method	NN	i	IOt
using	VBG	O	O
a	DT	O	O
disposable	JJ	O	O
surface	NN	O	O
electrode	NN	O	O
attached	VBN	O	O
to	TO	O	O
the	DT	O	O
cuff	NN	O	O
of	IN	O	O
a	DT	O	O
tracheal	JJ	O	O
tube	NN	O	O
.	.	O	O

At	IN	O	O
the	DT	O	O
larynx	NN	O	O
,	,	O	O
the	DT	O	O
mean	NN	o	OPH
(	(	o	OPH
+/-	JJ	o	OPH
SD	NNP	o	OPH
)	)	o	OPH
time	NN	o	OPH
to	TO	o	OPH
90	CD	o	OPH
%	NN	o	OPH
block	NN	o	OPH
and	CC	o	O
the	DT	o	O
onset	JJ	o	O
time	NN	o	O
of	IN	O	O
succinylcholine	NN	o	OOt
(	(	O	O
38	CD	O	O
+/-	JJ	O	O
15	CD	O	O
and	CC	O	O
47	CD	O	O
+/-	JJ	O	O
19	CD	O	O
s	NN	O	O
,	,	O	O
respectively	RB	O	O
)	)	O	O
were	VBD	O	O
significantly	RB	O	O
shorter	JJR	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.01	CD	O	O
)	)	O	O
than	IN	O	O
for	IN	O	O
rocuronium	NN	i	IPM
0.6	CD	O	O
mg	NN	O	O
kg-1	NN	O	O
(	(	O	O
92	CD	O	O
+/-	JJ	O	O
42	CD	O	O
and	CC	O	O
106	CD	O	O
+/-	JJ	O	O
38	CD	O	O
s	NN	O	O
)	)	O	O
and	CC	O	O
rocuronium	$	i	IPM
0.9	CD	O	O
mg	JJ	O	O
kg-1	NN	O	O
(	(	O	O
52	CD	O	O
+/-	JJ	O	O
31	CD	O	O
and	CC	O	O
64	CD	O	O
+/-	JJ	O	O
30	CD	O	O
s	NN	O	O
)	)	O	O
.	.	O	O

We	PRP	O	O
found	VBD	O	O
that	IN	O	O
,	,	O	O
with	IN	O	O
comparable	JJ	O	O
degrees	NNS	O	O
of	IN	O	O
neuromuscular	JJ	o	OPH
block	NN	o	OPH
,	,	O	O
the	DT	O	O
onset	JJ	o	OOt
time	NN	o	OOt
of	IN	o	OOt
succinylcholine	NN	o	OOt
at	IN	o	OOt
the	DT	o	OOt
adductor	NN	o	OOt
pollicis	NN	o	OOt
was	VBD	O	O
significantly	RB	O	O
shorter	JJR	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.01	CD	O	O
)	)	O	O
than	IN	O	O
for	IN	O	O
rocuronium	NN	i	IPM
0.6	CD	O	O
mg	NN	O	O
kg-1	NN	O	O
and	CC	O	O
0.9	CD	O	O
mg	NNS	O	O
kg-1	JJ	O	O
(	(	O	O
EMG	NNP	O	O
,	,	O	O
80	CD	O	O
+/-	JJ	O	O
39	CD	O	O
vs	JJ	O	O
145	CD	O	O
+/-	JJ	O	O
48	CD	O	O
s	NN	O	O
and	CC	O	O
99	CD	O	O
+/-	JJ	O	O
31	CD	O	O
s	NN	O	O
;	:	O	O
AMG	NNP	O	O
,	,	O	O
90	CD	O	O
+/-	JJ	O	O
39	CD	O	O
vs	JJ	O	O
124	CD	O	O
+/-	JJ	O	O
53	CD	O	O
s	NN	O	O
and	CC	O	O
106	CD	O	O
+/-	JJ	O	O
38	CD	O	O
s	NN	O	O
)	)	O	O
.	.	O	O

Clinical	JJ	o	OOt
duration	NN	o	OOt
at	IN	o	OOt
the	DT	o	OOt
adductor	NN	o	OOt
pollicis	NN	o	OOt
(	(	o	OOt
AMG	NNP	o	OOt
)	)	o	OOt
was	VBD	O	O
significantly	RB	O	O
longer	JJR	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.01	CD	O	O
)	)	O	O
for	IN	O	O
both	DT	O	O
rocuronium	NN	i	IPM
groups	NNS	O	O
than	IN	O	O
for	IN	O	O
succinylcholine	NN	i	IPM
(	(	O	O
T4	NNP	O	O
:	:	O	O
T1	NNP	O	O
=	VBZ	O	O
0.7	CD	O	O
,	,	O	O
54	CD	O	O
+/-	JJ	O	O
18	CD	O	O
and	CC	O	O
77	CD	O	O
+/-	JJ	O	O
21	CD	O	O
vs	JJ	O	O
8	CD	O	O
+/-	JJ	O	O
6	CD	O	O
min	NN	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
surface	NN	O	O
laryngeal	JJ	O	O
electrode	NN	O	O
proved	VBD	O	O
non-invasive	JJ	O	O
,	,	O	O
easy	JJ	O	O
to	TO	O	O
use	VB	O	O
and	CC	O	O
reliable	VB	O	O
in	IN	O	O
measuring	VBG	O	O
onset	NN	o	OPH
of	IN	o	OPH
the	DT	o	OPH
neuromuscular	JJ	o	OPH
block	NN	o	OPH
at	IN	p	O
the	DT	p	O
larynx	NN	p	O
.	.	p	O

Preoperative	JJ	O	O
irradiation	NN	O	O
versus	IN	O	O
the	DT	O	O
use	NN	O	O
of	IN	O	O
nonsteroidal	JJ	O	O
anti-inflammatory	JJ	O	O
drugs	NNS	O	O
for	IN	O	O
prevention	NN	O	O
of	IN	O	O
heterotopic	JJ	o	OPH
ossification	NN	o	OPH
following	VBG	p	O
total	JJ	p	PC
hip	JJ	p	PC
replacement	NN	p	PC
:	:	p	O
the	DT	O	O
results	NNS	O	O
of	IN	O	O
a	DT	O	O
randomized	JJ	O	O
trial	NN	O	O
.	.	O	O

PURPOSE	NNP	O	O
Previous	JJ	O	O
studies	NNS	O	O
showed	VBD	O	O
the	DT	O	O
effectiveness	NN	O	O
of	IN	O	O
early	JJ	O	O
preoperative	NN	O	O
(	(	O	O
4	CD	O	O
h	NN	O	O
before	IN	O	O
operation	NN	O	O
)	)	O	O
irradiation	NN	O	O
for	IN	O	O
prevention	NN	O	O
of	IN	O	O
heterotopic	NN	o	OPH
ossification	NN	o	OPH
(	(	o	OPH
HO	NNP	o	OPH
)	)	o	OPH
after	IN	O	O
total	JJ	O	O
hip	NN	O	O
replacement	NN	O	O
.	.	O	O

This	DT	O	O
procedure	NN	O	O
can	MD	O	O
result	VB	O	O
in	IN	O	O
logistic	JJ	O	O
problems	NNS	O	O
,	,	O	O
if	IN	O	O
there	EX	O	O
is	VBZ	O	O
a	DT	O	O
great	JJ	O	O
distance	NN	O	O
between	IN	O	O
the	DT	O	O
department	NN	O	O
of	IN	O	O
radiotherapy	NN	O	O
and	CC	O	O
the	DT	O	O
orthopedic	JJ	O	O
clinic	NN	O	O
.	.	O	O

To	TO	O	O
avoid	VB	O	O
these	DT	O	O
organizational	JJ	O	O
problems	NNS	O	O
a	DT	O	O
prospective	JJ	O	O
study	NN	O	O
was	VBD	O	O
undertaken	VBN	O	O
to	TO	O	O
analyze	VB	O	O
the	DT	O	O
effectiveness	NN	o	OOt
of	IN	o	OOt
preoperative	JJ	o	OOt
irradiation	NN	o	OOt
on	IN	O	O
the	DT	O	O
day	NN	O	O
preceding	VBG	O	O
surgery	NN	O	O
(	(	O	O
16-20	JJ	O	O
h	NN	O	O
before	IN	O	O
operation	NN	O	O
)	)	O	O
.	.	O	O

METHODS	NNP	O	O
AND	CC	O	O
MATERIALS	NNP	O	O
Between	NNP	p	O
1995	CD	p	O
and	CC	p	O
1996	CD	p	O
,	,	p	O
100	CD	p	PSS
patients	NNS	p	PSS
were	VBD	p	O
randomized	VBN	i	O
to	TO	p	O
receive	VB	p	O
a	DT	p	O
prophylactic	JJ	p	O
therapy	NN	p	O
for	IN	p	O
prevention	NN	p	O
of	IN	p	O
heterotopic	NN	p	PC
ossification	NN	p	PC
.	.	p	O

Forty-six	JJ	O	O
patients	NNS	O	O
were	VBD	O	O
irradiated	VBN	i	IPH
with	IN	i	IPH
7	CD	i	IPH
Gy	NNP	i	IPH
single	JJ	i	IPH
dose	NN	i	IPH
within	IN	i	IPH
16-20	JJ	i	IPH
h	NN	i	IPH
before	IN	i	IPH
operation	NN	i	IPH
.	.	i	IPH

Fifty-four	CD	O	O
patients	NNS	O	O
were	VBD	O	O
treated	VBN	i	IPM
with	IN	i	IPM
nonsteroidal	JJ	i	IPM
anti-inflammatory	JJ	i	IPM
drugs	NNS	i	IPM
(	(	i	IPM
NSAID	NNP	i	IPM
)	)	i	IPM
(	(	i	IPM
Voltaren	NNP	i	IPM
resinat	VBZ	i	IPM
2	CD	i	IPM
x	NN	i	IPM
75	CD	i	IPM
mg/day	NN	i	IPM
for	IN	i	IPM
2	CD	i	IPM
weeks	NNS	i	IPM
)	)	i	IPM
.	.	i	IPM

Heterotopic	NNP	o	OPH
ossification	NN	o	OPH
was	VBD	o	O
scored	VBN	o	O
according	VBG	o	O
to	TO	o	O
the	DT	o	O
Brooker	NNP	o	OOt
Grading	NNP	o	OOt
system	NN	o	OOt
.	.	o	OOt

One	CD	p	PSS
hundred	VBD	p	PSS
patients	NNS	p	PSS
receiving	VBG	p	O
no	DT	p	O
prophylactic	JJ	p	O
therapy	NN	p	O
after	IN	p	O
total	JJ	p	O
hip	NN	p	O
arthroplasty	NN	p	O
between	IN	p	O
1988	CD	p	O
and	CC	p	O
1992	CD	p	O
were	VBD	p	O
analyzed	VBN	p	O
and	CC	p	O
defined	VBN	p	O
as	IN	p	O
the	DT	p	O
historical	JJ	p	O
control	NN	p	O
group	NN	p	O
.	.	p	O

RESULTS	NNP	O	O
Incidence	NNP	O	O
of	IN	O	O
heterotopic	NN	o	OPH
ossification	NN	o	OPH
was	VBD	O	O
47.8	CD	O	O
%	NN	O	O
in	IN	O	O
the	DT	O	O
7	CD	O	O
Gy	NNP	O	O
preoperative	JJ	O	O
group	NN	O	O
(	(	o	O
Brooker	NNP	o	OOt
Score	NNP	o	OOt
I	PRP	o	O
:	:	o	O
36.9	CD	O	O
%	NN	O	O
;	:	O	O
II	NNP	O	O
:	:	O	O
8.7	CD	O	O
%	NN	O	O
;	:	O	O
III	NNP	O	O
:	:	O	O
2.2	CD	O	O
%	NN	O	O
;	:	O	O
IV	NNP	O	O
:	:	O	O
0	CD	O	O
%	NN	O	O
)	)	O	O
and	CC	O	O
11.1	CD	O	O
%	NN	O	O
in	IN	O	O
the	DT	O	O
NSAID	NNP	O	O
group	NN	O	O
(	(	o	O
Brooker	NNP	o	OOt
Score	NNP	o	OOt
I	PRP	o	O
:	:	o	O
9.3	CD	O	O
%	NN	O	O
;	:	O	O
II	NNP	O	O
:	:	O	O
1.8	CD	O	O
%	NN	O	O
;	:	O	O
III	NNP	O	O
:	:	O	O
0	CD	O	O
%	NN	O	O
;	:	O	O
IV	NNP	O	O
:	:	O	O
0	CD	O	O
%	NN	O	O
)	)	O	O
.	.	O	O

Regarding	VBG	O	O
overall	JJ	O	O
heterotopic	NN	o	OPH
ossification	NN	o	OPH
there	EX	O	O
was	VBD	O	O
a	DT	O	O
significant	JJ	O	O
difference	NN	O	O
between	IN	O	O
the	DT	O	O
NSAID	NNP	O	O
group	NN	O	O
and	CC	O	O
the	DT	O	O
7	CD	O	O
Gy	NNP	O	O
group	NN	O	O
(	(	O	O
p	JJ	O	O
<	NNP	O	O
0.01	CD	O	O
)	)	O	O
.	.	O	O

Analyzing	VBG	O	O
the	DT	O	O
clinically	RB	O	O
significant	JJ	O	O
heterotopic	NN	o	OPH
ossification	NN	o	OPH
(	(	o	OPH
Brooker	NNP	o	OOt
Score	NNP	o	OOt
III	NNP	o	OOt
and	CC	o	OOt
IV	NNP	o	OOt
)	)	o	OPH
there	EX	O	O
was	VBD	O	O
no	DT	O	O
significant	JJ	O	O
difference	NN	O	O
between	IN	O	O
the	DT	O	O
two	CD	O	O
treatment	NN	O	O
arms	NNS	O	O
(	(	O	O
p	JJ	O	O
>	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

In	IN	O	O
the	DT	O	O
untreated	JJ	O	O
historical	JJ	O	O
control	NN	O	O
group	NN	O	O
the	DT	O	O
incidence	NN	O	O
of	IN	O	O
heterotopic	NN	o	OPH
ossification	NN	o	OPH
was	VBD	O	O
65	CD	O	O
%	NN	O	O
(	(	o	O
Brooker	NNP	o	OOt
Score	NNP	o	OOt
I	PRP	O	O
:	:	O	O
26	CD	O	O
%	NN	O	O
;	:	O	O
II	NNP	O	O
:	:	O	O
15	CD	O	O
%	NN	O	O
;	:	O	O
III	NNP	O	O
:	:	O	O
19	CD	O	O
%	NN	O	O
;	:	O	O
IV	NNP	O	O
:	:	O	O
5	CD	O	O
%	NN	O	O
)	)	O	O
.	.	O	O

Referring	VBG	O	O
to	TO	O	O
overall	JJ	O	O
and	CC	O	O
to	TO	O	O
clinically	RB	O	O
relevant	JJ	O	O
heterotopic	NN	o	OPH
ossification	NN	o	OPH
the	DT	O	O
incidence	NN	O	O
of	IN	O	O
HO	NNP	o	OPH
was	VBD	O	O
greater	JJR	O	O
in	IN	O	O
the	DT	O	O
control	NN	O	O
group	NN	O	O
than	IN	O	O
in	IN	O	O
the	DT	O	O
prophylactically	RB	O	O
treated	VBN	O	O
groups	NNS	O	O
(	(	O	O
p	JJ	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

CONCLUSION	NNP	O	O
Irradiation	NNP	O	O
within	IN	O	O
16-20	JJ	O	O
h	NN	O	O
before	IN	O	O
operation	NN	O	O
and	CC	O	O
use	NN	O	O
of	IN	O	O
NSAID	NNP	O	O
(	(	O	O
Voltaren	NNP	O	O
resinat	NN	O	O
)	)	O	O
can	MD	O	O
reduce	VB	O	O
the	DT	O	O
incidence	NN	O	O
of	IN	O	O
clinically	RB	O	O
relevant	JJ	O	O
heterotopic	NN	o	OPH
ossification	NN	o	OPH
after	IN	O	O
total	JJ	O	O
hip	NN	O	O
replacement	NN	O	O
.	.	O	O

Onset/offset	NNP	o	OPH
characteristics	NNS	o	OPH
and	CC	o	OPH
intubating	VBG	o	OPH
conditions	NNS	o	OPH
of	IN	O	O
rapacuronium	NN	O	O
:	:	O	O
a	DT	O	O
comparison	NN	O	O
with	IN	O	O
rocuronium	NN	O	O
.	.	O	O

We	PRP	O	O
compared	VBN	O	O
onset	PRP	o	OPH
and	CC	o	OPH
offset	VB	o	OPH
of	IN	o	OPH
action	NN	o	OPH
and	CC	o	OPH
tracheal	JJ	o	OPH
intubating	NN	o	OPH
conditions	NNS	o	OPH
after	IN	O	O
rapacuronium	NN	i	IPM
and	CC	i	O
rocuronium	NN	i	IPM
in	IN	O	O
60	CD	p	PSS
patients	NNS	p	O
in	IN	O	O
a	DT	O	O
randomized	JJ	O	O
,	,	O	O
assessor-blinded	JJ	O	O
study	NN	O	O
.	.	O	O

Following	VBG	O	O
induction	NN	O	O
of	IN	O	O
anaesthesia	NN	i	O
with	IN	i	O
propofol	JJ	i	O
2.5	CD	i	O
mg	JJ	i	O
kg-1	NN	i	O
,	,	i	O
either	CC	i	O
rapacuronium	NN	i	IPM
1.5	CD	i	O
mg	NN	i	O
kg-1	NN	i	O
(	(	i	O
n	JJ	i	O
=	NNP	i	O
30	CD	i	O
)	)	i	O
or	CC	i	O
rocuronium	$	i	IPM
0.6	CD	i	O
mg	JJ	i	O
kg-1	NN	i	O
(	(	i	O
n	JJ	i	O
=	NNP	i	O
30	CD	i	O
)	)	i	O
was	VBD	i	O
administered	VBN	i	O
to	TO	i	O
facilitate	VB	i	O
tracheal	JJ	i	O
intubation	NN	i	O
.	.	i	O

Anaesthesia	NNP	i	O
was	VBD	i	O
maintained	VBN	i	O
with	IN	i	O
either	CC	i	O
a	DT	i	O
propofol	JJ	i	IPH
infusion	NN	i	IPH
(	(	i	IPH
100	CD	i	IPH
micrograms	NNS	i	IPM
kg-1	JJ	i	IPH
min-1	JJ	i	IPH
)	)	i	IPH
or	CC	i	O
sevoflurane	NN	i	IPM
(	(	i	IPM
1	CD	i	IPM
%	NN	i	IPM
end-tidal	JJ	i	IPM
)	)	i	IPM
with	IN	i	IPM
66	CD	i	IPM
%	NN	i	IPM
nitrous	JJ	i	IPM
oxide	NN	i	IPM
(	(	i	IPM
N2O	NNP	i	IPM
)	)	i	IPM
,	,	i	O
n	JJ	i	O
=	VBP	i	O
15	CD	i	O
in	IN	i	O
each	DT	i	O
subgroup	NN	i	O
.	.	i	O

Neuromuscular	JJ	o	OOt
monitoring	NN	o	OOt
was	VBD	i	O
performed	VBN	i	O
using	VBG	i	O
an	DT	i	O
electromyographic	JJ	i	IPH
(	(	i	O
EMG	NNP	i	O
)	)	i	O
device	NN	i	O
(	(	i	O
Datex	NNP	i	O
Relaxograph	NNP	i	O
)	)	i	O
.	.	i	O

The	DT	O	O
lag	NN	o	OOt
times	NNS	o	OOt
(	(	O	O
mean	JJ	O	O
42	CD	O	O
(	(	O	O
SD	NNP	O	O
11	CD	O	O
)	)	O	O
s	NN	O	O
and	CC	O	O
44	CD	O	O
(	(	O	O
16	CD	O	O
)	)	O	O
s	NN	O	O
)	)	O	O
,	,	O	O
maximum	JJ	o	OOt
block	NN	o	OOt
(	(	O	O
99	CD	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
%	NN	O	O
and	CC	O	O
98	CD	O	O
(	(	O	O
3	CD	O	O
)	)	O	O
%	NN	O	O
)	)	O	O
and	CC	O	O
intubating	JJ	o	OPH
conditions	NNS	o	OPH
at	IN	o	OPH
60	CD	o	OPH
s	NN	o	OPH
(	(	O	O
good-to-excellent	JJ	O	O
in	IN	O	O
86	CD	O	O
%	NN	O	O
and	CC	O	O
84	CD	O	O
%	NN	O	O
of	IN	O	O
patients	NNS	O	O
)	)	O	O
were	VBD	O	O
similar	JJ	O	O
for	IN	O	O
rapacuronium	NN	O	O
and	CC	O	O
rocuronium	NN	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

The	DT	O	O
onset	JJ	o	OOt
time	NN	o	OOt
of	IN	O	O
rapacuronium	NN	O	O
was	VBD	O	O
shorter	JJR	O	O
than	IN	O	O
rocuronium	NN	O	O
(	(	O	O
87	CD	O	O
(	(	O	O
20	CD	O	O
)	)	O	O
vs	NN	O	O
141	CD	O	O
(	(	O	O
65	CD	O	O
)	)	O	O
s	NN	O	O
,	,	O	O
P	NNP	O	O
<	NNP	O	O
0.001	CD	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
degree	NN	o	OPH
of	IN	o	OPH
block	NN	o	OPH
at	IN	o	OPH
60	CD	o	OPH
s	NN	o	OPH
was	VBD	O	O
greater	JJR	O	O
(	(	O	O
69	CD	O	O
(	(	O	O
26	CD	O	O
)	)	O	O
vs	NN	O	O
50	CD	O	O
(	(	O	O
27	CD	O	O
)	)	O	O
%	NN	O	O
,	,	O	O
P	NNP	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

Twenty-five	JJ	O	O
per	IN	O	O
cent	NN	O	O
recovery	NN	o	OPH
was	VBD	O	O
shorter	JJR	O	O
with	IN	O	O
rapacuronium	NN	O	O
than	IN	O	O
rocuronium	NN	O	O
during	IN	O	O
propofol	NN	O	O
(	(	O	O
15.0	CD	O	O
(	(	O	O
3.2	CD	O	O
)	)	O	O
vs	NN	O	O
39.1	CD	O	O
(	(	O	O
14.2	CD	O	O
)	)	O	O
min	NN	O	O
,	,	O	O
P	NNP	O	O
<	NNP	O	O
0.001	CD	O	O
)	)	O	O
and	CC	O	O
sevoflurane	NN	O	O
(	(	O	O
15.1	CD	O	O
(	(	O	O
4.2	CD	O	O
)	)	O	O
vs	NN	O	O
47.8	CD	O	O
(	(	O	O
19.0	CD	O	O
)	)	O	O
min	NN	O	O
,	,	O	O
P	NNP	O	O
<	NNP	O	O
0.001	CD	O	O
)	)	O	O
anaesthesia	NN	O	O
.	.	O	O

We	PRP	O	O
conclude	VBP	O	O
that	IN	O	O
rapacuronium	NN	O	O
1.5	CD	O	O
mg	NN	O	O
kg-1	NN	O	O
had	VBD	O	O
a	DT	O	O
more	RBR	O	O
rapid	JJ	O	O
onset	NN	o	O
,	,	O	O
similar	JJ	O	O
intubating	NN	o	OPH
conditions	NNS	o	OPH
,	,	O	O
and	CC	O	O
shorter	JJR	O	O
recovery	NN	o	O
times	NNS	o	O
than	IN	O	O
rocuronium	NN	O	O
0.6	CD	O	O
mg	JJ	O	O
kg-1	NN	O	O
.	.	O	O

Rett	NNP	p	O
syndrome	NN	p	O
:	:	p	O
randomized	VBN	O	O
controlled	VBD	O	O
trial	NN	O	O
of	IN	O	O
L-carnitine	NNP	i	IPM
.	.	i	O

Rett	NNP	O	O
syndrome	NN	O	O
is	VBZ	O	O
a	DT	O	O
severe	JJ	O	O
neurodevelopmental	JJ	O	O
disorder	NN	O	O
of	IN	O	O
unknown	JJ	O	O
etiology	NN	O	O
,	,	O	O
occurring	VBG	O	O
almost	RB	O	O
exclusively	RB	O	O
in	IN	O	O
female	JJ	p	O
patients	NNS	p	O
.	.	p	O

The	DT	O	O
etiology	NN	O	O
and	CC	O	O
functional	JJ	O	O
significance	NN	O	O
of	IN	O	O
plasma	JJ	O	O
carnitine	NN	O	O
deficiency	NN	O	O
seen	VBN	O	O
in	IN	O	O
some	DT	O	O
patients	NNS	O	O
with	IN	O	O
Rett	NNP	O	O
syndrome	NN	O	O
is	VBZ	O	O
unknown	JJ	O	O
.	.	O	O

To	TO	O	O
investigate	VB	O	O
whether	IN	O	O
L-carnitine	JJ	i	IPM
might	MD	O	O
be	VB	O	O
of	IN	O	O
benefit	NN	O	O
in	IN	O	O
Rett	NNP	O	O
syndrome	NN	O	O
,	,	O	O
a	DT	O	O
randomized	VBN	O	O
,	,	O	O
placebo-controlled	JJ	i	IC
,	,	O	O
double-blind	JJ	O	O
crossover	NN	O	O
trial	NN	O	O
of	IN	O	O
L-carnitine	NNP	i	IPM
has	VBZ	O	O
been	VBN	O	O
completed	VBN	O	O
in	IN	O	O
35	CD	p	O
subjects	NNS	p	O
.	.	p	O

Eight-week	JJ	O	O
treatment	NN	O	O
phases	NNS	O	O
were	VBD	O	O
completed	VBN	O	O
for	IN	O	O
both	DT	O	O
a	DT	O	O
placebo	NN	i	IC
and	CC	i	O
L-carnitine	NNP	i	IPM
.	.	i	O

Outcome	NNP	O	O
was	VBD	O	O
measured	VBN	O	O
by	IN	O	O
parents/caregivers	NNS	O	O
and	CC	O	O
at	IN	O	O
medical	JJ	O	O
follow-up	NN	O	O
using	VBG	O	O
three	CD	O	O
established	VBN	O	O
tools	NNS	O	O
:	:	O	O
the	DT	o	OME
Rett	NNP	o	OME
Syndrome	NNP	o	OME
Motor	NNP	o	OME
Behavioral	NNP	o	OME
Assessment	NNP	o	OME
,	,	o	O
the	DT	o	OME
Hand	NNP	o	OME
Apraxia	NNP	o	OME
Scale	NNP	o	OME
,	,	o	O
and	CC	o	O
the	DT	o	OOt
Patient	NNP	o	OME
Well-Being	NNP	o	OME
Index	NNP	o	OME
.	.	o	O

Analysis	NNP	O	O
comparing	VBG	O	O
change	NN	O	O
between	IN	O	O
baseline	NN	O	O
and	CC	O	O
week	NN	O	O
8	CD	O	O
of	IN	O	O
treatment	NN	O	O
for	IN	O	O
L-carnitine	NNP	i	IPM
and	CC	O	O
the	DT	O	O
placebo	NN	i	IC
showed	VBD	O	O
that	IN	O	O
both	DT	O	O
parents/caregivers	NNS	O	O
and	CC	O	O
medical	JJ	O	O
follow-up	NN	O	O
detected	JJ	O	O
improvements	NNS	O	O
in	IN	O	O
the	DT	O	O
subjects	NNS	O	O
'	POS	O	O
well-being	NN	o	OME
.	.	o	O

In	IN	O	O
addition	NN	O	O
,	,	O	O
medical	JJ	O	O
review	NN	O	O
showed	VBD	O	O
an	DT	O	O
improvement	NN	O	O
on	IN	O	O
the	DT	O	O
Hand	NNP	o	OME
Apraxia	NNP	o	OME
Scale	NNP	o	OME
for	IN	O	O
a	DT	O	O
higher	JJR	O	O
proportion	NN	O	O
of	IN	O	O
girls	NNS	O	O
on	IN	O	O
L-carnitine	NNP	O	O
.	.	O	O

Identification	NN	O	O
of	IN	O	O
predictors	NNS	O	O
of	IN	O	O
clinical	JJ	O	O
improvement	NN	O	O
has	VBZ	O	O
been	VBN	O	O
limited	VBN	O	O
by	IN	O	O
the	DT	O	O
power	NN	O	O
of	IN	O	O
the	DT	O	O
study	NN	O	O
.	.	O	O

These	DT	O	O
findings	NNS	O	O
suggest	VBP	O	O
that	IN	O	O
L-carnitine	NNP	i	IPM
is	VBZ	O	O
of	IN	O	O
benefit	NN	O	O
in	IN	O	O
some	DT	O	O
patients	NNS	p	O
with	IN	p	O
Rett	NNP	p	O
syndrome	NN	p	O
.	.	p	O

While	IN	O	O
L-carnitine	NNP	i	IPM
did	VBD	O	O
not	RB	O	O
lead	VB	O	O
to	TO	O	O
major	JJ	O	O
functional	JJ	O	O
changes	NNS	O	O
in	IN	O	O
ability	NN	O	O
,	,	O	O
the	DT	O	O
type	NN	O	O
of	IN	O	O
changes	NNS	O	O
reported	VBN	O	O
could	MD	O	O
still	RB	O	O
have	VB	O	O
a	DT	O	O
substantial	JJ	O	O
impact	NN	O	O
on	IN	O	O
the	DT	O	O
girls	NNS	O	O
and	CC	O	O
their	PRP$	O	O
families	NNS	O	O
.	.	O	O

Information	NN	O	O
is	VBZ	O	O
still	RB	O	O
needed	VBN	O	O
,	,	O	O
however	RB	O	O
,	,	O	O
to	TO	O	O
determine	VB	O	O
if	IN	O	O
only	RB	O	O
subgroups	NNS	O	O
of	IN	O	O
girls	NNS	O	O
with	IN	O	O
the	DT	O	O
disorder	NN	O	O
are	VBP	O	O
responsive	JJ	O	O
to	TO	O	O
L-carnitine	NNP	i	IPM
and	CC	O	O
the	DT	O	O
appropriate	JJ	O	O
duration	NN	O	O
of	IN	O	O
therapy	NN	O	O
.	.	O	O

FDA	NNP	O	O
review	NN	O	O
of	IN	O	O
a	DT	O	O
panitumumab	NN	i	IPM
(	(	i	IPM
Vectibix	NNP	i	IPM
)	)	i	IPM
clinical	JJ	O	O
trial	NN	O	O
for	IN	O	O
first-line	JJ	O	O
treatment	NN	O	O
of	IN	O	O
metastatic	JJ	p	PC
colorectal	JJ	p	PC
cancer	NN	p	PC
.	.	p	O

On	IN	O	O
September	NNP	O	O
27	CD	O	O
,	,	O	O
2006	CD	O	O
,	,	O	O
the	DT	O	O
U.S.	NNP	O	O
Food	NNP	O	O
and	CC	O	O
Drug	NNP	O	O
Administration	NNP	O	O
granted	VBD	O	O
accelerated	VBD	O	O
approval	NN	O	O
to	TO	O	O
panitumumab	VB	i	IPM
(	(	i	IPM
Vectibix	NNP	i	IPM
;	:	i	IPM
Amgen	NNP	O	O
,	,	O	O
Inc.	NNP	O	O
,	,	O	O
Thousand	NNP	O	O
Oaks	NNP	O	O
,	,	O	O
CA	NNP	O	O
)	)	O	O
for	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
patients	NNS	p	O
with	IN	p	O
epidermal	JJ	p	PC
growth	NN	p	PC
factor	NN	p	PC
receptor-expressing	NN	p	PC
,	,	p	O
metastatic	JJ	p	PC
colorectal	NN	p	PC
carcinoma	NN	p	PC
with	IN	p	O
disease	JJ	p	O
progression	NN	p	O
on	IN	p	O
or	CC	p	O
following	VBG	p	O
fluoropyrimidine-	JJ	i	IPM
,	,	i	O
oxaliplatin-	JJ	i	O
,	,	i	O
and	CC	i	O
irinotecan-containing	JJ	i	IPM
chemotherapy	NN	i	IPM
regimens	NNS	i	IPM
.	.	i	O

Accelerated	NNP	O	O
approval	NN	O	O
was	VBD	O	O
based	VBN	O	O
on	IN	O	O
demonstration	NN	O	O
of	IN	O	O
a	DT	O	O
beneficial	JJ	O	O
effect	NN	O	O
on	IN	O	O
progression-free	JJ	O	O
survival	NN	O	O
(	(	O	O
PFS	NNP	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
present	JJ	O	O
submission	NN	O	O
summarizes	VBZ	O	O
a	DT	O	O
second	JJ	O	O
clinical	JJ	O	O
trial	NN	O	O
,	,	O	O
to	TO	O	O
be	VB	O	O
included	VBN	O	O
in	IN	O	O
the	DT	O	O
panitumumab	JJ	i	IPM
package	NN	O	O
insert	NN	O	O
in	IN	O	O
June	NNP	O	O
2008	CD	O	O
,	,	O	O
of	IN	O	O
chemotherapy	NN	i	IPM
and	CC	i	O
bevacizumab	NN	i	IPM
with	IN	i	IPM
and	CC	i	IPM
without	IN	i	IPM
panitumumab	NN	i	IPM
in	IN	O	O
the	DT	O	O
first-line	JJ	O	O
treatment	NN	O	O
of	IN	O	O
patients	NNS	p	O
with	IN	p	O
metastatic	JJ	p	PC
colorectal	JJ	p	PC
cancer	NN	p	PC
.	.	p	O

The	DT	O	O
study	NN	O	O
was	VBD	O	O
closed	VBN	O	O
when	WRB	O	O
inferior	JJ	O	O
PFS	NNP	O	O
and	CC	O	O
greater	JJR	O	O
toxicity	NN	O	O
were	VBD	O	O
demonstrated	VBN	O	O
at	IN	O	O
the	DT	O	O
time	NN	O	O
of	IN	O	O
the	DT	O	O
planned	VBN	O	O
interim	NN	O	O
efficacy	NN	O	O
analysis	NN	O	O
.	.	O	O

Patients	NNS	p	O
receiving	VBG	p	O
panitumumab	NN	i	IPM
in	IN	O	O
combination	NN	O	O
with	IN	O	O
bevacizumab	NN	i	IPM
and	CC	i	IPM
chemotherapy	NN	i	IPM
experienced	VBD	O	O
a	DT	O	O
higher	JJR	O	O
incidence	NN	O	O
of	IN	O	O
death	NN	o	OMO
(	(	O	O
9	CD	O	O
%	NN	O	O
versus	IN	O	O
4	CD	O	O
%	NN	O	O
)	)	O	O
and	CC	O	O
a	DT	O	O
higher	JJR	O	O
risk	NN	O	O
for	IN	O	O
grade	NN	o	OOt
3	CD	o	OOt
and	CC	o	OOt
4	CD	o	OOt
toxicities	NNS	o	OOt
than	IN	O	O
patients	NNS	p	O
receiving	VBG	p	O
bevacizumab	NN	i	IPM
and	CC	i	O
chemotherapy	NN	i	IPM
alone	RB	i	O
.	.	i	O

The	DT	O	O
incidences	NNS	o	O
of	IN	o	O
any	DT	o	O
Common	NNP	o	OA
Terminology	NNP	o	OA
Criteria	NNP	o	OA
for	IN	o	OA
Adverse	NNP	o	OA
Events	NNP	o	OA
grade	VBD	o	OA
3	CD	o	OA
and	CC	o	OA
4	CD	o	OA
adverse	JJ	o	OA
events	NNS	o	OA
(	(	o	OA
AEs	NNP	o	OA
)	)	o	OA
were	VBD	O	O
87	CD	O	O
%	NN	O	O
and	CC	O	O
72	CD	O	O
%	NN	O	O
in	IN	O	O
the	DT	O	O
panitumumab	NN	i	IPM
and	CC	O	O
control	NN	O	O
groups	NNS	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

Grade	VB	o	OA
3	CD	o	OA
and	CC	o	OA
4	CD	o	OA
AEs	NNP	o	OA
occurring	VBG	O	O
more	JJR	O	O
commonly	RB	O	O
in	IN	O	O
panitumumab-treated	JJ	i	IPM
patients	NNS	O	O
included	VBD	O	O
rash/acneiform	NN	o	OA
dermatitis	NN	o	OA
,	,	o	O
diarrhea	NN	o	OA
,	,	o	O
dehydration	NN	o	OA
,	,	o	O
primarily	RB	o	O
resulting	VBG	o	O
from	IN	o	O
diarrhea	NN	o	OA
,	,	o	O
hypokalemia	NN	o	OA
,	,	o	O
stomatitis/mucositis	NN	o	OA
,	,	o	O
and	CC	o	O
pulmonary	JJ	o	OA
embolism	NN	o	OA
.	.	o	O

The	DT	O	O
addition	NN	O	O
of	IN	O	O
panitumumab	NN	i	IPM
to	TO	i	IPM
bevacizumab	VB	i	IPM
and	CC	i	IPM
chemotherapy	VB	i	IPM
for	IN	O	O
the	DT	O	O
first-line	JJ	O	O
treatment	NN	O	O
of	IN	O	O
metastatic	JJ	p	O
colorectal	NN	p	PC
cancer	NN	p	PC
was	VBD	O	O
harmful	JJ	O	O
when	WRB	O	O
compared	VBN	O	O
with	IN	O	O
bevacizumab	NN	i	IPM
and	CC	i	IPM
chemotherapy	NN	i	IPM
alone	RB	i	IPM
.	.	i	O

The	DT	O	O
use	NN	O	O
of	IN	O	O
panitumumab	NN	i	IPM
in	IN	O	O
this	DT	O	O
setting	NN	O	O
can	MD	O	O
not	RB	O	O
be	VB	O	O
recommended	VBN	O	O
.	.	O	O

Gamma-hydroxybutyric	JJ	i	IPM
acid	NN	i	IPM
versus	NN	O	O
clomethiazole	NN	i	IPM
for	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
alcohol	NN	o	OPH
withdrawal	NN	o	OPH
syndrome	NN	o	OPH
in	IN	p	O
a	DT	p	O
medical	JJ	p	O
intensive	JJ	p	O
care	NN	p	O
unit	NN	p	O
:	:	p	O
an	DT	O	O
open	JJ	O	O
,	,	O	O
single-center	JJ	O	O
randomized	VBN	O	O
study	NN	O	O
.	.	O	O

BACKGROUND	NNP	O	O
Clomethiazole	NNP	i	IPM
(	(	i	IPM
CLO	NNP	i	IPM
)	)	i	IPM
has	VBZ	O	O
been	VBN	O	O
shown	VBN	O	O
to	TO	O	O
be	VB	O	O
effective	JJ	O	O
in	IN	O	O
treating	VBG	o	OPH
alcohol	NN	o	OPH
withdrawal	NN	o	OPH
syndrome	NN	o	OPH
(	(	o	OPH
AWS	NNP	o	OPH
)	)	o	OPH
.	.	o	O

Gamma-Hydroxybutyric	JJ	i	IPM
acid	NN	i	IPM
(	(	i	IPM
GHB	NNP	i	IPM
)	)	i	IPM
has	VBZ	O	O
also	RB	O	O
been	VBN	O	O
introduced	VBN	O	O
in	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
alcoholic	JJ	O	O
patients	NNS	O	O
and	CC	O	O
is	VBZ	O	O
effective	JJ	O	O
in	IN	O	O
surgical	JJ	O	O
intensive	JJ	O	O
care	NN	O	O
unit	NN	O	O
(	(	O	O
ICU	NNP	O	O
)	)	O	O
patients	NNS	O	O
in	IN	O	O
preventing	VBG	O	O
and	CC	O	O
treating	VBG	O	O
AWS	NNP	o	OPH
.	.	o	O

There	EX	O	O
are	VBP	O	O
no	DT	O	O
comparative	JJ	O	O
studies	NNS	O	O
between	IN	O	O
CLO	NNP	i	IPM
and	CC	O	O
GHB	NNP	i	IPM
in	IN	O	O
a	DT	O	O
medical	JJ	O	O
ICU	NNP	O	O
setting	NN	O	O
.	.	O	O

METHODS	NNP	O	O
Twenty-six	NNP	p	PSS
alcoholic	JJ	p	O
patients	NNS	p	O
with	IN	p	O
severe	JJ	p	O
AWS	NNP	o	OPH
and	CC	p	O
concomitant	JJ	p	O
medical	JJ	o	O
diseases	NNS	o	O
were	VBD	p	O
randomally	RB	p	O
enrolled	VBN	p	O
in	IN	p	O
the	DT	p	O
study	NN	p	O
.	.	p	O

CLO	NNP	i	IPM
was	VBD	O	O
given	VBN	O	O
orally	RB	O	O
to	TO	O	O
12	CD	O	O
patients	NNS	O	O
in	IN	O	O
a	DT	O	O
dosage	NN	O	O
of	IN	O	O
250	CD	O	O
mg	NN	O	O
every	DT	O	O
4	CD	O	O
hours	NNS	O	O
as	IN	O	O
a	DT	O	O
liquid	NN	O	O
;	:	O	O
GHB	NNP	i	IPM
(	(	O	O
initially	RB	O	O
30	CD	O	O
mg/kg	NNS	O	O
body	NN	O	O
weight	NN	O	O
(	(	O	O
BW	NNP	O	O
)	)	O	O
followed	VBN	O	O
by	IN	O	O
15	CD	O	O
mg/kg	NNS	O	O
BW	NNP	O	O
)	)	O	O
was	VBD	O	O
administered	VBN	O	O
intravenously	RB	O	O
to	TO	O	O
14	CD	O	O
patients	NNS	O	O
.	.	O	O

Four	CD	O	O
major	JJ	O	O
AWS	NNP	o	OPH
symptoms	NNS	o	OPH
(	(	o	O
tremor	NN	o	OPH
,	,	o	O
sweating	VBG	o	OPH
,	,	o	O
nausea	NN	o	OPH
,	,	o	O
restlessness	NN	o	OPH
)	)	o	O
were	VBD	O	O
scored	VBN	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
administration	NN	O	O
of	IN	O	O
additional	JJ	o	OOt
medication	NN	o	OOt
was	VBD	O	O
registered	VBN	O	O
.	.	O	O

RESULTS	NNP	O	O
GHB	NNP	i	IPM
was	VBD	O	O
more	RBR	O	O
effective	JJ	O	O
in	IN	O	O
treating	VBG	O	O
AWS	NNP	O	O
symptoms	NNS	O	O
.	.	O	O

In	IN	O	O
the	DT	O	O
GHB	NNP	i	IPM
group	NN	O	O
,	,	O	O
AWS	NNP	o	OPH
score	NN	o	O
dropped	VBD	O	O
from	IN	O	O
6.6	CD	O	O
+/-	JJ	O	O
2.6	CD	O	O
to	TO	O	O
1.8	CD	O	O
+/-	JJ	O	O
2.1	CD	O	O
(	(	O	O
p	JJ	O	O
<	NNP	O	O
.01	NNP	O	O
)	)	O	O
,	,	O	O
while	IN	O	O
in	IN	O	O
the	DT	O	O
CLO	NNP	i	IPM
group	NN	O	O
,	,	O	O
the	DT	O	O
score	NN	O	O
dropped	VBD	O	O
from	IN	O	O
6	CD	O	O
+/-	JJ	O	O
2.5	CD	O	O
to	TO	O	O
4.1	CD	O	O
+/-	JJ	O	O
2.4	CD	O	O
(	(	O	O
n.	JJ	O	O
s.	NN	O	O
)	)	O	O
.	.	O	O

Differences	NNS	O	O
between	IN	O	O
groups	NNS	O	O
were	VBD	O	O
significant	JJ	O	O
(	(	O	O
p	JJ	O	O
=.021	NN	O	O
,	,	O	O
two-way	JJ	O	O
ANOVA	NNP	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
treatment	NN	O	O
did	VBD	O	O
not	RB	O	O
alter	VB	O	O
outcome	NN	o	OPH
or	CC	O	O
the	DT	O	O
duration	NN	o	OOt
of	IN	o	OOt
ICU	NNP	o	OOt
stay	NN	o	OOt
.	.	o	O

No	DT	o	OA
serious	JJ	o	OA
side	NN	o	OA
effects	NNS	o	OA
were	VBD	O	O
detected	VBN	O	O
.	.	O	O

CONCLUSION	NNP	O	O
GHB	NNP	i	IPM
effectively	RB	O	O
controls	VBZ	o	O
AWS	NNP	o	OPH
symptoms	NNS	o	OPH
in	IN	O	O
medical	JJ	O	O
ICU	NNP	O	O
patients	NNS	O	O
.	.	O	O

The	DT	O	O
rapid	JJ	O	O
initial	JJ	O	O
treatment	NN	O	O
response	NN	O	O
of	IN	O	O
GHB	NNP	O	O
in	IN	O	O
contrast	NN	O	O
to	TO	O	O
CLO	NNP	i	IPM
has	VBZ	O	O
no	DT	O	O
influence	NN	O	O
on	IN	O	O
duration	NN	o	OPH
of	IN	o	OPH
patient	NN	o	OPH
withdrawal	NN	o	OPH
.	.	o	O

The	DT	O	O
impact	NN	O	O
of	IN	O	O
schizophrenic	JJ	p	PC
patient	NN	p	O
functionality	NN	O	O
on	IN	O	O
service	NN	o	OOt
utilization	NN	o	OOt
and	CC	o	OOt
cost	NN	o	OOt
.	.	o	O

Based	VBN	O	O
on	IN	O	O
a	DT	O	O
presentation	NN	O	O
by	IN	O	O
Sandra	NNP	O	O
L.	NNP	O	O
Tunis	NNP	O	O
,	,	O	O
PhD	NNP	O	O
.	.	O	O

With	IN	O	O
the	DT	O	O
advent	NN	O	O
of	IN	O	O
atypical	JJ	O	O
agents	NNS	O	O
in	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
schizophrenia	NN	O	O
,	,	O	O
physicians	NNS	O	O
and	CC	O	O
policy	NN	O	O
makers	NNS	O	O
must	MD	O	O
consider	VB	O	O
the	DT	O	O
costs	NNS	O	O
that	WDT	O	O
may	MD	O	O
accompany	VB	O	O
greater	JJR	O	O
clinical	JJ	O	O
efficacy	NN	O	O
.	.	O	O

Analyses	VBZ	O	O
reveal	NN	O	O
that	WDT	O	O
olanzapine	NN	i	IPM
shows	VBZ	O	O
a	DT	O	O
greater	JJR	O	O
clinical	JJ	o	OOt
cost	NN	o	OOt
effectiveness	NN	o	OOt
,	,	O	O
as	RB	O	O
well	RB	O	O
as	IN	O	O
a	DT	O	O
greater	JJR	O	O
functional	JJ	o	OOt
cost	NN	o	OOt
effectiveness	NN	o	OOt
,	,	O	O
than	IN	O	O
haloperidol	NN	i	IPM
,	,	O	O
and	CC	O	O
that	IN	O	O
functional	JJ	o	O
outcomes	NNS	o	O
,	,	O	O
in	IN	O	O
particular	JJ	O	O
,	,	O	O
show	VBP	O	O
promise	NN	O	O
as	IN	O	O
important	JJ	O	O
measures	NNS	O	O
of	IN	O	O
effectiveness	NN	O	O
.	.	O	O

Functional	JJ	O	O
outcomes	NNS	O	O
can	MD	O	O
help	VB	O	O
differentiate	VB	O	O
medications	NNS	O	O
and	CC	O	O
can	MD	O	O
be	VB	O	O
used	VBN	O	O
to	TO	O	O
help	VB	O	O
demonstrate	VB	O	O
the	DT	O	O
cost	NN	o	OOt
effectiveness	NN	o	OOt
of	IN	O	O
atypical	JJ	O	O
agents	NNS	O	O
.	.	O	O

Mental	NNP	o	OME
health	NN	o	OME
and	CC	o	O
physical	JJ	o	OPH
health	NN	o	OPH
functioning	NN	o	OPH
,	,	o	O
as	RB	o	O
well	RB	o	O
as	IN	o	O
work	NN	o	OME
status	NN	o	OME
,	,	O	O
are	VBP	O	O
all	DT	O	O
measures	NNS	O	O
of	IN	O	O
functioning	VBG	O	O
that	WDT	O	O
have	VBP	O	O
been	VBN	O	O
used	VBN	O	O
to	TO	O	O
evaluate	VB	O	O
treatment	NN	O	O
strategies	NNS	O	O
.	.	O	O

When	WRB	O	O
comparing	VBG	O	O
olanzapine	NN	i	IPM
with	IN	O	O
haloperidol	NN	i	IPM
,	,	O	O
cost	NN	o	OOt
savings	NNS	o	OOt
are	VBP	O	O
seen	VBN	O	O
throughout	IN	O	O
the	DT	O	O
treatment	NN	O	O
period	NN	O	O
(	(	O	O
1	CD	O	O
year	NN	O	O
)	)	O	O
,	,	O	O
with	IN	O	O
physical	JJ	o	OPH
functioning	VBG	o	OPH
most	JJS	O	O
highly	RB	O	O
affected	VBN	O	O
over	IN	O	O
time	NN	O	O
.	.	O	O

Functional	JJ	o	O
outcomes	NNS	o	O
can	MD	O	O
therefore	VB	O	O
serve	VB	O	O
2	CD	O	O
purposes	NNS	O	O
:	:	O	O
to	TO	O	O
enhance	VB	O	O
compliance	NN	O	O
by	IN	O	O
improving	VBG	O	O
health-related	JJ	o	OOt
quality	NN	o	OOt
of	IN	o	OOt
life	NN	o	OOt
and	CC	O	O
to	TO	O	O
assist	VB	O	O
in	IN	O	O
making	VBG	O	O
both	DT	O	O
treatment	NN	O	O
and	CC	O	O
formulary	JJ	O	O
decisions	NNS	O	O
.	.	O	O

Prevention	NN	O	O
of	IN	O	O
venous	JJ	O	O
thromboembolism	NN	O	O
after	IN	O	O
knee	NN	p	PC
arthroplasty	NN	p	PC
.	.	p	O

A	DT	O	O
randomized	JJ	O	O
,	,	O	O
double-blind	JJ	O	O
trial	NN	O	O
comparing	VBG	O	O
enoxaparin	NN	i	IPM
with	IN	O	O
warfarin	NN	i	IPM
.	.	i	IPM

OBJECTIVE	UH	O	O
To	TO	O	O
compare	VB	O	O
the	DT	O	O
effectiveness	NN	o	OOt
and	CC	o	OOt
safety	NN	o	OOt
of	IN	O	O
fixed-dose	JJ	i	IPM
enoxaparin	NN	i	IPM
and	CC	O	O
adjusted	VBD	i	IPM
dose	JJ	i	IPM
warfarin	NN	i	IPM
in	IN	O	O
preventing	VBG	O	O
venous	JJ	O	O
thromboembolism	NN	O	O
after	IN	p	PC
knee	NN	p	PC
arthroplasty	NN	p	PC
.	.	p	O

DESIGN	VB	O	O
A	DT	O	O
randomized	JJ	O	O
,	,	O	O
double-blind	JJ	O	O
controlled	VBN	O	O
trial	NN	O	O
.	.	O	O

SETTING	NN	O	O
8	CD	p	O
university	NN	p	O
hospitals	NNS	p	O
.	.	p	O

PATIENTS	VB	O	O
670	CD	p	PSS
consecutive	JJ	p	O
patients	NNS	p	O
who	WP	p	O
had	VBD	p	O
knee	VBN	p	PC
arthroplasty	RB	p	PC
.	.	p	O

INTERVENTION	NN	O	O
Patients	NNPS	O	O
were	VBD	O	O
randomly	RB	O	O
assigned	VBN	O	O
to	TO	O	O
receive	VB	O	O
enoxaparin	NN	i	IPM
(	(	i	IPM
30	CD	i	IPM
mg	NN	i	IPM
subcutaneously	RB	i	IPM
every	DT	i	IPM
12	CD	i	IPM
hours	NNS	i	IPM
)	)	i	IPM
or	CC	i	IPM
adjusted-dose	JJ	i	IPM
warfarin	NN	i	IPM
(	(	i	IPM
international	JJ	i	IPM
normalized	VBN	i	IPM
ratio	NN	i	IPM
,	,	i	IPM
2.0	CD	i	IPM
to	TO	i	IPM
3.0	CD	i	IPM
)	)	i	IPM
.	.	O	O

Both	DT	O	O
regimens	NNS	O	O
were	VBD	O	O
started	VBN	O	O
after	IN	O	O
surgery	NN	O	O
.	.	O	O

MEASUREMENTS	PDT	O	O
The	DT	O	O
primary	JJ	O	O
end	NN	O	O
point	NN	O	O
was	VBD	O	O
the	DT	O	O
incidence	NN	o	OPH
of	IN	o	OPH
deep	JJ	o	OPH
venous	JJ	o	OPH
thrombosis	NN	o	OPH
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
adequate	JJ	p	PC
bilateral	JJ	p	PC
venograms	NNS	p	PC
;	:	p	O
the	DT	O	O
secondary	JJ	O	O
end	NN	O	O
point	NN	O	O
was	VBD	O	O
hemorrhage	NN	o	OPH
.	.	o	OPH

RESULTS	NNP	O	O
Among	IN	O	O
the	DT	O	O
417	CD	p	PSS
patients	NNS	p	O
with	IN	p	O
adequate	JJ	p	PC
venograms	NNS	p	PC
,	,	O	O
109	CD	O	O
of	IN	O	O
211	CD	O	O
warfarin	NN	i	IPM
recipients	NNS	O	O
(	(	O	O
51.7	CD	O	O
%	NN	O	O
)	)	O	O
had	VBD	O	O
deep	JJ	o	OPH
venous	JJ	o	OPH
thrombosis	NN	o	OPH
compared	VBN	O	O
with	IN	O	O
76	CD	O	O
of	IN	O	O
206	CD	O	O
enoxaparin	NN	i	IPM
recipients	NNS	O	O
(	(	O	O
36.9	CD	O	O
%	NN	O	O
)	)	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.003	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
absolute	NN	o	OPH
risk	NN	o	OPH
difference	NN	o	OPH
was	VBD	O	O
14.8	CD	O	O
%	NN	O	O
in	IN	O	O
favor	NN	O	O
of	IN	O	O
enoxaparin	NN	i	IPM
(	(	O	O
95	CD	O	O
%	NN	O	O
Cl	NNP	O	O
,	,	O	O
5.3	CD	O	O
%	NN	O	O
to	TO	O	O
24.1	CD	O	O
%	NN	O	O
)	)	O	O
Twenty-two	NNP	O	O
warfarin	NN	i	IPM
recipients	NNS	O	O
(	(	O	O
10.4	CD	O	O
%	NN	O	O
)	)	O	O
and	CC	O	O
24	CD	O	O
enoxaparin	NN	i	IPM
recipients	NNS	O	O
(	(	O	O
11.7	CD	O	O
%	NN	O	O
)	)	O	O
had	VBD	O	O
proximal	JJ	O	O
venous	JJ	O	O
thrombosis	NN	O	O
(	(	O	O
P	NNP	O	O
>	NNP	O	O
0.2	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
absolute	NN	o	OPH
risk	NN	o	OPH
difference	NN	o	OPH
was	VBD	O	O
1.2	CD	O	O
%	NN	O	O
in	IN	O	O
favor	NN	O	O
of	IN	O	O
warfarin	NN	i	IPM
(	(	O	O
Cl	NNP	O	O
,	,	O	O
-7.2	NNP	O	O
%	NN	O	O
to	TO	O	O
4.8	CD	O	O
%	NN	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
incidence	NN	O	O
of	IN	O	O
major	JJ	o	OPH
bleeding	NN	o	OPH
was	VBD	O	O
1.8	CD	O	O
%	NN	O	O
(	(	O	O
6	CD	O	O
of	IN	O	O
334	CD	O	O
patients	NNS	O	O
)	)	O	O
in	IN	O	O
the	DT	O	O
warfarin	NN	O	O
group	NN	O	O
and	CC	O	O
2.1	CD	O	O
%	NN	O	O
(	(	O	O
7	CD	O	O
of	IN	O	O
336	CD	O	O
patients	NNS	O	O
)	)	O	O
in	IN	O	O
the	DT	O	O
enoxaparin	NN	O	O
group	NN	O	O
(	(	O	O
P	NNP	O	O
>	NNP	O	O
0.2	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
absolute	NN	o	OPH
risk	NN	o	OPH
difference	NN	o	OPH
was	VBD	O	O
0.3	CD	O	O
%	NN	O	O
in	IN	O	O
favor	NN	O	O
of	IN	O	O
warfarin	NN	O	O
(	(	O	O
Cl	NNP	O	O
,	,	O	O
-2.4	NNP	O	O
%	NN	O	O
to	TO	O	O
1.8	CD	O	O
%	NN	O	O
)	)	O	O
.	.	O	O

CONCLUSIONS	VB	O	O
A	DT	O	O
postoperative	JJ	O	O
,	,	O	O
fixed-dose	JJ	O	O
enoxaparin	NN	i	IPM
regimen	NNS	O	O
is	VBZ	O	O
more	RBR	O	O
effective	JJ	O	O
than	IN	O	O
adjusted-dose	JJ	O	O
warfarin	NN	i	IPM
in	IN	O	O
preventing	VBG	O	O
deep	JJ	O	O
venous	JJ	O	O
thrombosis	NN	O	O
after	IN	p	PC
knee	NN	p	PC
arthroplasty	NN	p	PC
.	.	p	O

No	DT	O	O
differences	NNS	O	O
were	VBD	O	O
seen	VBN	O	O
in	IN	O	O
the	DT	O	O
incidence	NN	O	O
of	IN	O	O
proximal	JJ	O	O
venous	JJ	O	O
thrombosis	NN	O	O
or	CC	O	O
clinically	RB	O	O
overt	JJ	O	O
hemorrhage	NN	O	O
.	.	O	O

Satisfactory	JJ	O	O
sampling	NN	O	O
in	IN	O	O
cytological	JJ	p	PC
cervical	JJ	p	PC
diagnosis	NN	p	PC
:	:	p	O
comparison	NN	O	O
between	IN	O	O
a	DT	O	O
conventional	JJ	i	O
and	CC	i	O
a	DT	i	O
new	JJ	i	O
sampling	NN	i	IPH
device	NN	i	IPH
.	.	i	O

AIM	NNP	O	O
Inadequate	NNP	O	O
cervical	JJ	O	O
sampling	NN	O	O
is	VBZ	O	O
the	DT	O	O
most	RBS	O	O
frequent	JJ	O	O
cause	NN	O	O
of	IN	O	O
misdiagnosis	NN	O	O
in	IN	O	O
cervical	JJ	p	PC
cancer	NN	p	PC
screening	NN	p	O
.	.	p	O

The	DT	O	O
aim	NN	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
test	VB	O	O
the	DT	O	O
ability	NN	O	O
of	IN	O	O
PapCone?	NNP	i	O
versus	IN	i	O
the	DT	i	O
conventional	JJ	i	O
sampling	NN	i	O
method	NN	i	O
(	(	i	O
Ayre	NNP	i	O
's	POS	i	O
spatula	NN	i	O
plus	CC	i	O
cytobrush	NN	i	O
)	)	i	O
to	TO	O	O
collect	VB	O	O
ectocervical	JJ	O	O
and	CC	O	O
glandular	JJ	O	O
cells	NNS	O	O
.	.	O	O

MATERIALS	NNP	O	O
AND	CC	O	O
METHODS	NNP	O	O
In	IN	p	O
18	CD	p	PSS
healthy	JJ	p	PC
women	NNS	p	PSE
,	,	p	O
two	CD	p	O
ecto-endocervical	JJ	p	O
samples	NNS	p	O
,	,	p	O
obtained	VBN	p	O
by	IN	p	O
two	CD	p	O
different	JJ	p	O
methods	NNS	p	O
,	,	p	O
were	VBD	p	O
obtained	VBN	p	O
at	IN	p	O
a	DT	p	O
three-month	JJ	p	O
interval	NN	p	O
.	.	p	O

Qualitative	JJ	O	O
and	CC	O	O
quantitative	JJ	O	O
parameters	NNS	O	O
were	VBD	O	O
evaluated	VBN	O	O
.	.	O	O

Ultrastructure	NN	o	O
features	NNS	o	O
of	IN	o	O
sampling	VBG	o	O
devices	NNS	o	O
were	VBD	O	O
analyzed	VBN	O	O
by	IN	O	O
scanning	VBG	O	O
electron	NN	O	O
microscopy	NN	O	O
(	(	O	O
SEM	NNP	O	O
)	)	O	O
before	IN	O	O
and	CC	O	O
after	IN	O	O
sampling	VBG	O	O
.	.	O	O

RESULTS	VB	O	O
The	DT	O	O
?	.	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
test	NN	O	O
revealed	VBD	O	O
a	DT	O	O
statistically	RB	O	O
significant	JJ	O	O
difference	NN	O	O
between	IN	O	O
the	DT	O	O
two	CD	O	O
methods	NNS	O	O
:	:	O	O
PapCone?	NNP	O	O
caused	VBD	O	O
less	JJR	o	O
cell	NN	o	O
overlap	NN	o	O
and	CC	o	O
sampled	VBD	O	O
less	JJR	o	O
white	JJ	o	O
blood	NN	o	O
cells	NNS	o	O
(	(	o	O
p	JJ	o	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
and	CC	O	O
more	RBR	o	O
metaplastic	JJ	o	O
cells	NNS	o	O
(	(	o	O
p	JJ	o	O
<	NNP	O	O
0.01	CD	O	O
)	)	O	O
.	.	O	O

SEM	NNP	O	O
evaluation	NN	o	O
highlighted	VBD	o	O
the	DT	O	O
porous	JJ	O	O
and	CC	O	O
spongy	JJ	O	O
structure	NN	O	O
of	IN	O	O
PapCone?	NNP	O	O
that	WDT	O	O
was	VBD	O	O
responsible	JJ	O	O
for	IN	O	O
the	DT	O	O
large	JJ	O	O
number	NN	O	O
of	IN	O	O
glandular	JJ	O	O
cells	NNS	O	O
on	IN	O	O
its	PRP$	O	O
surface	NN	O	O
.	.	O	O

CONCLUSION	NNP	O	O
Cervical	NNP	O	O
smears	NNS	O	O
performed	VBN	O	O
by	IN	O	O
PapCone?	NNP	O	O
were	VBD	O	O
adequate	JJ	O	O
and	CC	O	O
generally	RB	O	O
easier	JJR	O	O
to	TO	O	O
screen	VB	O	O
than	IN	O	O
conventionally	RB	O	O
performed	VBN	O	O
ones	NNS	O	O
.	.	O	O

Analgesic	JJ	o	OOt
efficacy	NN	o	OOt
of	IN	O	O
piroxicam	NN	i	IPM
in	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
postoperative	JJ	o	OPA
pain	NN	o	OPA
.	.	o	OPA

Two	CD	O	O
randomized	JJ	O	O
,	,	O	O
double-blind	JJ	O	O
,	,	O	O
single-dose	JJ	O	O
studies	NNS	O	O
were	VBD	O	O
conducted	VBN	O	O
to	TO	O	O
assess	VB	O	O
the	DT	O	O
analgesic	JJ	o	OOt
efficacy	NN	o	OOt
and	CC	o	OOt
safety	NN	o	OOt
of	IN	O	O
piroxicam	NN	i	IPM
for	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
moderate	JJ	o	OPA
or	CC	o	OPA
severe	JJ	o	OPA
postoperative	JJ	o	OPA
pain	NN	o	OPA
.	.	o	OPA

Study	NNP	O	O
1	CD	O	O
evaluated	VBD	O	O
the	DT	O	O
analgesic	JJ	O	O
efficacy	NN	O	O
of	IN	O	O
piroxicam	NN	i	IPM
20	CD	O	O
mg	NN	O	O
compared	VBN	O	O
with	IN	O	O
that	DT	O	O
of	IN	O	O
codeine	NN	i	IPM
sulfate	NN	i	IPM
60	CD	O	O
mg	NN	O	O
and	CC	i	O
placebo	NN	i	IC
.	.	i	O

A	DT	p	O
final	JJ	p	O
patient	NN	p	O
population	NN	p	O
of	IN	p	O
149	CD	p	O
subjects	NNS	p	O
rated	VBN	O	O
pain	JJ	o	OPA
intensity	NN	o	OPA
and	CC	o	OPA
pain	NN	o	OPA
relief	NN	o	OPA
at	IN	O	O
one	CD	O	O
half	NN	O	O
hour	NN	O	O
and	CC	O	O
one	CD	O	O
hour	NN	O	O
following	VBG	O	O
treatment	NN	O	O
and	CC	O	O
then	RB	O	O
hourly	RB	O	O
for	IN	O	O
six	CD	O	O
hours	NNS	O	O
,	,	O	O
with	IN	O	O
a	DT	O	O
global	JJ	O	O
assessment	NN	O	O
made	VBN	O	O
at	IN	O	O
the	DT	O	O
completion	NN	O	O
of	IN	O	O
24	CD	O	O
hours	NNS	O	O
.	.	O	O

Piroxicam	NNP	i	IPM
20	CD	O	O
mg	NN	O	O
was	VBD	O	O
significantly	RB	O	O
more	RBR	O	O
efficacious	JJ	o	OOt
than	IN	O	O
placebo	NN	i	IC
for	IN	O	O
all	DT	O	O
analgesic	JJ	O	O
variables	NNS	O	O
,	,	O	O
including	VBG	O	O
the	DT	O	O
sum	NN	o	OPA
of	IN	o	OPA
the	DT	o	OPA
pain	NN	o	OPA
intensity	NN	o	OPA
differences	NNS	o	OPA
(	(	o	OPA
SPID	NNP	o	OPA
)	)	o	OPA
,	,	o	OPA
total	JJ	o	OPA
pain	NN	o	OPA
relief	NN	o	OPA
(	(	o	OPA
TOTAL	NNP	o	OPA
)	)	o	OPA
,	,	o	O
percent	JJ	o	OPA
SPID	NNP	o	OPA
,	,	o	O
duration	NN	o	OOt
of	IN	o	OOt
effect	NN	o	OOt
,	,	o	O
and	CC	o	O
time	NN	o	OOt
to	TO	o	OOt
remedication	NN	o	OOt
.	.	o	O

Codeine	VB	i	IPM
60	CD	O	O
mg	NN	O	O
was	VBD	O	O
significantly	RB	O	O
superior	JJ	O	O
to	TO	O	O
placebo	VB	i	O
for	IN	O	O
percent	NN	o	OPA
SPID	NNP	o	OPA
and	CC	O	O
some	DT	O	O
hourly	JJ	O	O
measures	NNS	O	O
.	.	O	O

Piroxicam	NNP	i	IPM
20	CD	O	O
mg	NN	O	O
was	VBD	O	O
significantly	RB	O	O
more	RBR	O	O
effective	JJ	O	O
than	IN	O	O
codeine	VBP	i	IPM
60	CD	O	O
mg	NN	O	O
for	IN	O	O
percent	NN	o	OPA
SPID	NNP	o	OPA
and	CC	O	O
a	DT	O	O
few	JJ	O	O
hourly	JJ	O	O
measures	NNS	O	O
including	VBG	O	O
time	NN	O	O
to	TO	O	O
remedication	NN	O	O
.	.	O	O

Study	NNP	O	O
2	CD	O	O
assessed	VBD	O	O
the	DT	O	O
efficacy	NN	o	OOt
of	IN	O	O
piroxicam	NN	i	IPM
20	CD	O	O
mg	NN	O	O
or	CC	O	O
40	CD	O	O
mg	NNS	O	O
compared	VBN	O	O
with	IN	O	O
aspirin	JJ	i	IPM
648	CD	O	O
mg	NN	O	O
and	CC	O	O
placebo	NN	i	O
.	.	i	O

Sixty	CD	p	O
patients	NNS	p	O
rated	VBN	O	O
their	PRP$	O	O
pain	NN	o	OPA
intensity	NN	o	OPA
and	CC	o	OPA
relief	NN	o	OPA
hourly	RB	O	O
for	IN	O	O
12	CD	O	O
hours	NNS	O	O
and	CC	O	O
at	IN	O	O
24	CD	O	O
hours	NNS	O	O
after	IN	O	O
administration	NN	O	O
of	IN	O	O
study	JJ	O	O
medication	NN	O	O
.	.	O	O

Both	DT	O	O
doses	NNS	O	O
of	IN	O	O
piroxicam	NN	i	IPM
were	VBD	O	O
significantly	RB	O	O
more	RBR	O	O
effective	JJ	o	OOt
than	IN	O	O
placebo	NN	O	O
from	IN	O	O
Hours	$	O	O
2	CD	O	O
to	TO	O	O
12	CD	O	O
for	IN	O	O
pain	NN	o	OPA
intensity	NN	o	OPA
difference	NN	o	OPA
(	(	o	OPA
PID	NNP	o	OPA
)	)	o	OPA
and	CC	o	OPA
relief	NN	o	OPA
scores	NNS	o	OPA
,	,	o	O
as	RB	o	O
well	RB	o	O
as	IN	o	O
for	IN	o	O
SPID	NNP	o	OPA
and	CC	o	O
TOTAL	NNP	o	OPA
.	.	o	O

Aspirin	NNP	O	O
was	VBD	O	O
significantly	RB	O	O
more	RBR	O	O
effective	JJ	o	OOt
than	IN	O	O
placebo	NN	i	O
from	IN	O	O
Hours	$	O	O
2	CD	O	O
to	TO	O	O
8	CD	O	O
for	IN	O	O
relief	NN	o	OPA
and	CC	O	O
Hours	$	O	O
2	CD	O	O
to	TO	O	O
10	CD	O	O
for	IN	O	O
PID	NNP	o	OPA
as	RB	o	O
well	RB	o	O
as	IN	o	O
SPID	NNP	o	OPA
and	CC	o	O
TOTAL	NNP	o	OPA
.	.	o	O

Piroxicam	NNP	i	IPM
40	CD	O	O
mg	NN	O	O
was	VBD	O	O
significantly	RB	O	O
more	RBR	O	O
effective	JJ	o	OOt
than	IN	O	O
aspirin	RB	i	IPM
648	CD	O	O
mg	NN	O	O
for	IN	O	O
SPID	NNP	o	OPA
,	,	o	O
TOTAL	NNP	o	OPA
,	,	o	O
and	CC	o	O
hourly	RB	o	OOt
measures	NNS	o	OOt
beginning	VBG	O	O
with	IN	O	O
Hour	NNP	O	O
6	CD	O	O
through	IN	O	O
Hour	NNP	O	O
12	CD	O	O
.	.	O	O

Piroxicam	VB	i	IPM
20	CD	O	O
mg	NN	O	O
was	VBD	O	O
significantly	RB	O	O
better	JJR	O	O
than	IN	O	O
aspirin	NN	i	IPM
for	IN	O	O
a	DT	O	O
few	JJ	O	O
hourly	JJ	O	O
measures	NNS	O	O
:	:	O	O
Hours	$	O	O
7	CD	O	O
to	TO	O	O
9	CD	O	O
for	IN	O	O
relief	NN	O	O
and	CC	O	O
Hour	$	O	O
7	CD	O	O
for	IN	O	O
PID	NNP	o	OPA
.	.	o	O

In	IN	O	O
addition	NN	O	O
,	,	O	O
effects	NNS	O	O
of	IN	O	O
piroxicam	NN	O	O
20	CD	O	O
mg	NN	O	O
had	VBD	O	O
a	DT	O	O
significantly	RB	O	O
longer	JJR	o	OOt
duration	NN	o	OOt
than	IN	O	O
aspirin	NN	O	O
.	.	O	O

Similarly	RB	O	O
,	,	O	O
piroxicam	VBD	i	IPM
20	CD	O	O
mg	NN	O	O
had	VBD	O	O
a	DT	O	O
significantly	RB	O	O
longer	JJR	o	OOt
time	NN	o	OOt
to	TO	o	OOt
remedication	VB	o	OOt
compared	VBN	O	O
with	IN	O	O
aspirin	NN	i	IPM
and	CC	O	O
placebo	NN	i	O
.	.	O	O

The	DT	O	O
results	NNS	O	O
of	IN	O	O
these	DT	O	O
studies	NNS	O	O
provide	VBP	O	O
evidence	NN	O	O
in	IN	O	O
support	NN	O	O
of	IN	O	O
the	DT	O	O
longer	JJR	O	O
duration	NN	o	OOt
of	IN	o	OOt
analgesic	JJ	o	OOt
efficacy	NN	o	OOt
of	IN	O	O
piroxicam	NNS	i	IPM
compared	VBN	O	O
with	IN	O	O
codeine	NN	i	IPM
or	CC	i	O
aspirin	NN	i	IPM
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
postoperative	JJ	o	OPA
pain	NN	o	OPA
.	.	o	O

Treatment	NN	O	O
of	IN	O	O
posterior	JJ	p	PC
uveitis	NN	p	PC
with	IN	O	O
a	DT	O	O
fluocinolone	NN	i	IPM
acetonide	NN	i	IPM
implant	NN	i	IPM
:	:	i	O
three-year	JJ	O	O
clinical	JJ	O	O
trial	NN	O	O
results	NNS	O	O
.	.	O	O

OBJECTIVES	NNP	O	O
To	TO	O	O
evaluate	VB	O	O
the	DT	O	O
safety	NN	o	OOt
and	CC	o	OOt
efficacy	NN	o	OOt
of	IN	O	O
0.59-mg	JJ	O	O
and	CC	O	O
2.1-mg	JJ	O	O
fluocinolone	NN	i	IPM
acetonide	NN	i	IPM
(	(	O	O
FA	NNP	O	O
)	)	O	O
intravitreous	JJ	O	O
implants	NNS	O	O
in	IN	O	O
noninfectious	JJ	p	PC
posterior	JJ	p	PC
uveitis	NN	p	PC
.	.	p	O

DESIGN	VB	O	O
A	DT	O	O
3-year	JJ	O	O
,	,	O	O
multicenter	NN	O	O
,	,	O	O
randomized	VBN	O	O
,	,	O	O
historically	RB	O	O
controlled	VBN	O	O
trial	NN	O	O
of	IN	O	O
the	DT	O	O
0.59-mg	JJ	i	IPM
FA	NNP	i	IPM
intravitreous	JJ	i	IPM
implant	NN	i	IPM
in	IN	p	O
110	CD	p	PSS
patients	NNS	p	O
and	CC	p	O
the	DT	p	O
2.1-mg	JJ	p	O
FA	NNP	p	O
intravitreous	JJ	p	O
implant	NN	p	O
in	IN	p	O
168	CD	p	PSS
patients	NNS	p	O
.	.	p	O

MAIN	NNP	O	O
OUTCOME	NNP	O	O
MEASURES	NNP	O	O
Recurrence	NNP	o	OPH
rate	NN	o	OPH
,	,	o	O
vision	NN	o	OPH
,	,	o	O
and	CC	o	O
complications	NNS	o	OA
.	.	o	O

RESULTS	NNP	O	O
Uveitis	NNP	o	OPH
recurrence	NN	o	OPH
was	VBD	o	OPH
reduced	VBN	o	OPH
in	IN	O	O
implanted	JJ	O	O
eyes	NNS	O	O
from	IN	O	O
62	CD	O	O
%	NN	O	O
(	(	O	O
during	IN	O	O
the	DT	O	O
1-year	JJ	O	O
preimplantation	NN	O	O
period	NN	O	O
)	)	O	O
to	TO	O	O
4	CD	O	O
%	NN	O	O
,	,	O	O
10	CD	O	O
%	NN	O	O
,	,	O	O
and	CC	O	O
20	CD	O	O
%	NN	O	O
during	IN	O	O
the	DT	O	O
1-	JJ	O	O
,	,	O	O
2-	JJ	O	O
,	,	O	O
and	CC	O	O
3-year	JJ	O	O
postimplantation	NN	O	O
periods	NNS	O	O
,	,	O	O
respectively	RB	O	O
,	,	O	O
for	IN	O	O
the	DT	O	O
0.59-mg	JJ	O	O
dose	NN	O	O
group	NN	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
.01	NNP	O	O
)	)	O	O
and	CC	O	O
from	IN	O	O
58	CD	O	O
%	NN	O	O
to	TO	O	O
7	CD	O	O
%	NN	O	O
,	,	O	O
17	CD	O	O
%	NN	O	O
,	,	O	O
and	CC	O	O
41	CD	O	O
%	NN	O	O
,	,	O	O
respectively	RB	O	O
,	,	O	O
for	IN	O	O
the	DT	O	O
2.1-mg	JJ	O	O
dose	NN	O	O
group	NN	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
.01	NNP	O	O
)	)	O	O
.	.	O	O

More	RBR	O	O
implanted	JJ	O	O
eyes	NNS	O	O
than	IN	O	O
nonimplanted	JJ	O	O
eyes	NNS	O	O
had	VBD	O	O
improved	VBN	o	OPH
visual	JJ	o	OPH
acuity	NN	o	OPH
(	(	O	O
P	NNP	O	O
<	NNP	O	O
.01	NNP	O	O
)	)	O	O
.	.	O	O

Implanted	VBN	o	OPH
eyes	NNS	o	OPH
had	VBD	o	OPH
higher	JJR	o	OPH
incidences	NNS	o	OPH
of	IN	o	OPH
intraocular	JJ	o	OPH
pressure	NN	o	OPH
elevation	NN	o	OPH
(	(	O	O
>	CD	O	O
or	CC	O	O
=	VB	O	O
10	CD	O	O
mm	NNS	O	O
Hg	NNP	O	O
)	)	O	O
than	IN	O	O
nonimplanted	VBN	O	O
eyes	NNS	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
.01	NNP	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
glaucoma	NN	o	OPH
surgery	NN	o	OPH
was	VBD	O	O
required	VBN	O	O
in	IN	O	O
40	CD	O	O
%	NN	O	O
of	IN	O	O
implanted	JJ	O	O
eyes	NNS	O	O
vs	VBP	O	O
2	CD	O	O
%	NN	O	O
of	IN	O	O
nonimplanted	JJ	O	O
eyes	NNS	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
.01	NNP	O	O
)	)	O	O
.	.	O	O

Cataracts	NNPS	o	OPH
were	VBD	O	O
extracted	VBN	O	O
in	IN	O	O
93	CD	O	O
%	NN	O	O
of	IN	O	O
phakic	NN	O	O
implanted	VBN	O	O
eyes	NNS	O	O
vs	VBP	O	O
20	CD	O	O
%	NN	O	O
of	IN	O	O
phakic	NN	O	O
nonimplanted	VBN	O	O
eyes	NNS	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
.01	NNP	O	O
)	)	O	O
.	.	O	O

CONCLUSIONS	VB	O	O
The	DT	O	O
FA	NNP	O	O
implant	NN	O	O
significantly	RB	O	O
reduced	VBN	o	OPH
uveitis	JJ	o	OPH
recurrence	NN	o	OPH
and	CC	o	O
improved	VBD	o	OPH
or	CC	o	OPH
stabilized	VBN	o	OPH
visual	JJ	o	OPH
acuity	NN	o	OPH
in	IN	O	O
subjects	NNS	p	O
with	IN	p	O
noninfectious	JJ	p	PC
posterior	JJ	p	PC
uveitis	NN	p	PC
.	.	p	O

Most	JJS	O	O
subjects	NNS	O	O
required	VBN	O	O
cataract	JJ	o	OPH
extraction	NN	o	OPH
,	,	O	O
and	CC	O	O
a	DT	O	O
significant	JJ	O	O
proportion	NN	O	O
required	VBN	O	O
intraocular	JJ	o	OPH
pressure-lowering	JJ	o	OPH
surgery	NN	o	OPH
.	.	o	O

APPLICATION	NNP	O	O
TO	NNP	O	O
CLINICAL	NNP	O	O
PRACTICE	NNP	O	O
The	DT	O	O
FA	NNP	O	O
implant	NN	O	O
provides	VBZ	O	O
an	DT	O	O
alternative	JJ	O	O
therapy	NN	O	O
for	IN	O	O
prolonged	JJ	O	O
control	NN	O	O
of	IN	O	O
inflammation	NN	O	O
in	IN	O	O
noninfectious	JJ	O	O
posterior	JJ	O	O
uveitis	NN	O	O
.	.	O	O

TRIAL	NNP	O	O
REGISTRATION	NNP	O	O
clinicaltrials.gov	NN	O	O
Identifier	NNP	O	O
:	:	O	O
NCT00407082	NN	O	O
.	.	O	O

Randomized	VBN	O	O
Phase	NNP	O	O
II	NNP	O	O
trial	NN	O	O
assessing	VBG	O	O
estramustine	NN	i	IPM
and	CC	i	IPM
vinblastine	JJ	i	IPM
combination	NN	i	IPM
chemotherapy	NN	i	IPM
vs	JJ	i	O
estramustine	NN	i	IPM
alone	RB	i	IPM
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
progressive	JJ	p	PC
hormone-escaped	JJ	p	PC
metastatic	JJ	p	PC
prostate	NN	p	PC
cancer	NN	p	PC
.	.	p	O

Based	VBN	O	O
on	IN	O	O
the	DT	O	O
results	NNS	O	O
of	IN	O	O
combined	JJ	O	O
data	NNS	O	O
from	IN	O	O
three	CD	O	O
North	JJ	O	O
American	JJ	O	O
Phase	NNP	O	O
II	NNP	O	O
studies	NNS	O	O
,	,	O	O
a	DT	O	O
randomised	JJ	O	O
Phase	NNP	O	O
II	NNP	O	O
study	NN	O	O
in	IN	O	O
the	DT	O	O
same	JJ	O	O
patient	JJ	O	O
population	NN	O	O
was	VBD	O	O
performed	VBN	O	O
,	,	O	O
using	VBG	O	O
combination	NN	O	O
chemotherapy	NN	i	IPM
with	IN	i	IPM
estramustine	JJ	i	IPM
phosphate	NN	i	IPM
(	(	i	IPM
EMP	NNP	i	IPM
)	)	i	IPM
and	CC	i	IPM
vinblastine	NN	i	IPM
(	(	i	IPM
VBL	NNP	i	IPM
)	)	i	IPM
in	IN	O	O
hormone	NN	O	O
refractory	NN	O	O
prostate	NN	O	O
cancer	NN	O	O
patients	NNS	O	O
.	.	O	O

In	IN	O	O
all	DT	O	O
,	,	O	O
92	CD	p	PSS
patients	NNS	p	O
were	VBD	p	O
randomised	VBN	p	O
into	IN	p	O
a	DT	p	O
Phase	NNP	p	O
II	NNP	p	O
study	NN	p	O
of	IN	O	O
oral	JJ	i	IPM
EMP	NNP	i	IPM
(	(	i	IPM
10	CD	i	IPM
mg	NNS	i	IPM
kg	JJ	i	IPM
day	NN	i	IPM
continuously	RB	i	IPM
)	)	i	IPM
or	CC	i	IPM
oral	JJ	i	IPM
EMP	NNP	i	IPM
in	IN	i	IPM
combination	NN	i	IPM
with	IN	i	IPM
intravenous	JJ	i	IPM
VBL	NNP	i	IPM
(	(	O	O
4	CD	O	O
mg	NN	O	O
m	NN	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
week	NN	O	O
for	IN	O	O
6	CD	O	O
weeks	NNS	O	O
,	,	O	O
followed	VBN	O	O
by	IN	O	O
2	CD	O	O
weeks	NNS	O	O
rest	NN	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
end	NN	O	O
points	NNS	O	O
were	VBD	O	O
toxicity	NN	o	OA
and	CC	o	O
PSA	NNP	o	OPH
response	NN	o	OPH
in	IN	O	O
both	DT	O	O
groups	NNS	O	O
,	,	O	O
with	IN	O	O
the	DT	O	O
option	NN	O	O
to	TO	O	O
continue	VB	O	O
the	DT	O	O
trial	NN	O	O
as	IN	O	O
a	DT	O	O
Phase	NNP	O	O
III	NNP	O	O
study	NN	O	O
with	IN	O	O
time	NN	o	OPH
to	TO	o	OPH
progression	NN	o	OPH
and	CC	O	O
survival	NN	o	OMO
as	IN	O	O
end	NN	O	O
points	NNS	O	O
,	,	O	O
if	IN	O	O
sufficient	JJ	O	O
responses	NNS	O	O
were	VBD	O	O
observed	VBN	O	O
.	.	O	O

Toxicity	NNP	o	OA
was	VBD	O	O
unexpectedly	RB	O	O
high	JJ	O	O
in	IN	O	O
both	DT	O	O
treatment	NN	O	O
arms	NNS	O	O
and	CC	O	O
led	VBD	O	O
to	TO	O	O
treatment	NN	O	O
withdrawal	NN	O	O
or	CC	O	O
refusal	NN	O	O
in	IN	O	O
49	CD	O	O
%	NN	O	O
of	IN	O	O
all	DT	O	O
patients	NNS	O	O
,	,	O	O
predominantly	RB	O	O
already	RB	O	O
during	IN	O	O
the	DT	O	O
first	JJ	O	O
treatment	NN	O	O
cycle	NN	O	O
.	.	O	O

The	DT	O	O
mean	JJ	o	OOt
treatment	NN	o	OOt
duration	NN	o	OOt
was	VBD	O	O
10	CD	O	O
and	CC	O	O
14	CD	O	O
weeks	NNS	O	O
,	,	O	O
median	JJ	o	OPH
time	NN	o	OPH
to	TO	o	OPH
PSA	NNP	o	OPH
progression	NN	o	OPH
was	VBD	O	O
27.2	CD	O	O
and	CC	O	O
30.8	CD	O	O
weeks	NNS	O	O
,	,	O	O
median	JJ	o	OMO
survival	NN	o	OMO
time	NN	o	OMO
was	VBD	O	O
44	CD	O	O
and	CC	O	O
50.9	CD	O	O
weeks	NNS	O	O
,	,	O	O
and	CC	O	O
PSA	NNP	o	OPH
response	NN	o	OPH
rate	NN	o	OPH
was	VBD	O	O
only	RB	O	O
24.6	CD	O	O
and	CC	O	O
28.9	CD	O	O
%	NN	O	O
in	IN	O	O
the	DT	O	O
EMP/VBL	NNP	i	IPM
and	CC	O	O
EMP	NNP	i	IPM
arms	NNS	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

There	EX	O	O
was	VBD	O	O
no	DT	O	O
correlation	NN	O	O
between	IN	O	O
PSA	NNP	o	OPH
response	NN	o	OPH
and	CC	o	O
survival	NN	o	OMO
.	.	o	O

While	IN	O	O
the	DT	O	O
PSA	NNP	o	OPH
response	NN	o	OPH
in	IN	O	O
the	DT	O	O
patients	NNS	O	O
tested	VBD	O	O
was	VBD	O	O
less	JJR	O	O
than	IN	O	O
half	NN	O	O
that	WDT	O	O
recorded	VBD	O	O
in	IN	O	O
the	DT	O	O
North	JJ	O	O
American	JJ	O	O
studies	NNS	O	O
,	,	O	O
the	DT	O	O
toxicity	NN	o	OA
of	IN	o	OA
EMP	NNP	o	OA
monotherapy	NN	o	OA
or	CC	O	O
in	IN	O	O
combination	NN	O	O
with	IN	O	O
VBL	NNP	i	IPM
was	VBD	O	O
much	RB	O	O
higher	JJR	O	O
than	IN	O	O
expected	VBN	O	O
.	.	O	O

Further	NNP	O	O
research	NN	O	O
on	IN	O	O
more	RBR	O	O
effective	JJ	o	OOt
and	CC	O	O
less	RBR	O	O
toxic	JJ	o	OA
treatment	NN	O	O
strategies	NNS	O	O
for	IN	O	O
hormone	NN	O	O
refractory	NN	O	O
prostate	NN	O	O
cancer	NN	O	O
is	VBZ	O	O
mandatory	JJ	O	O
.	.	O	O

Does	NNP	O	O
temporary	JJ	i	IS
clamping	NN	i	IS
of	IN	i	IS
drains	NNS	i	IS
following	VBG	O	O
knee	NN	O	O
arthroplasty	JJ	O	O
reduce	VB	O	O
blood	NN	O	O
loss	NN	O	O
?	.	O	O
A	DT	O	O
randomised	JJ	O	O
controlled	VBN	O	O
trial	NN	O	O
.	.	O	O

In	IN	O	O
a	DT	O	O
randomised	JJ	O	O
,	,	O	O
blinded	VBD	O	O
study	NN	O	O
76	CD	p	PSS
patients	NNS	p	O
undergoing	JJ	p	O
primary	JJ	p	PC
total	JJ	p	PC
knee	NN	p	PC
arthroplasty	NN	p	PC
were	VBD	p	O
assigned	VBN	p	O
to	TO	O	O
either	DT	O	O
immediate	JJ	i	IS
drain	NN	i	IS
opening	NN	i	IS
(	(	i	O
n	JJ	i	O
=	NNP	i	O
45	CD	i	O
)	)	i	O
or	CC	i	O
drains	NNS	i	IS
opened	VBN	i	IS
at	IN	i	IS
2	CD	i	IS
h	NN	i	IS
(	(	O	O
n	JJ	O	O
=	NNP	O	O
31	CD	O	O
)	)	O	O
.	.	O	O

No	DT	O	O
significant	JJ	O	O
differences	NNS	O	O
were	VBD	O	O
found	VBN	O	O
between	IN	O	O
the	DT	O	O
groups	NNS	O	O
for	IN	O	O
the	DT	O	O
volume	NN	o	OPH
of	IN	o	OPH
drained	JJ	o	OPH
blood	NN	o	OPH
,	,	o	O
transfusion	NN	o	OOt
requirements	NNS	o	OOt
,	,	o	O
knee	JJ	o	OPH
motion	NN	o	OPH
or	CC	o	O
wound	NN	o	OPH
status	NN	o	OPH
.	.	o	O

The	DT	O	O
authors	NNS	O	O
conclude	VBP	O	O
that	IN	O	O
the	DT	O	O
practice	NN	O	O
of	IN	O	O
clamping	VBG	i	IS
drains	NNS	i	IS
has	VBZ	O	O
no	DT	O	O
benefit	NN	O	O
in	IN	O	O
routine	JJ	O	O
knee	NN	O	O
arthroplasty	NN	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
when	WRB	O	O
faced	VBN	O	O
with	IN	O	O
immediate	JJ	O	O
brisk	JJ	O	O
blood	NN	o	OPH
loss	NN	o	OPH
,	,	O	O
the	DT	O	O
results	NNS	O	O
suggest	VBP	O	O
that	IN	O	O
drains	NNS	i	IS
can	MD	O	O
be	VB	O	O
clamped	VBN	O	O
without	IN	O	O
any	DT	O	O
excess	JJ	O	O
morbidity	NN	o	OA
.	.	o	O

Efficiency	NN	o	OOt
of	IN	i	IPH
adjuvant	JJ	i	IPH
immunochemotherapy	NN	i	IPH
following	VBG	O	O
curative	JJ	O	O
resection	NN	O	O
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
locally	RB	p	O
advanced	JJ	p	O
gastric	JJ	p	PC
cancer	NN	p	PC
.	.	p	PC

BACKGROUND	NNP	O	O
Despite	IN	O	O
curative	JJ	O	O
resection	NN	O	O
,	,	O	O
50	CD	O	O
%	NN	O	O
-90	CD	O	O
%	NN	O	O
of	IN	O	O
gastric	JJ	p	PC
cancer	NN	p	PC
patients	NNS	p	O
die	VBP	O	O
of	IN	O	O
disease	NN	o	OPH
relapse	NN	o	OPH
.	.	o	O

Although	IN	O	O
some	DT	O	O
clinical	JJ	O	O
trials	NNS	O	O
have	VBP	O	O
indicated	VBN	O	O
that	IN	O	O
chemotherapy	NN	O	O
and	CC	O	O
immunochemotherapy	NN	O	O
may	MD	O	O
be	VB	O	O
effective	JJ	O	O
modalities	NNS	O	O
,	,	O	O
more	RBR	O	O
recent	JJ	O	O
studies	NNS	O	O
have	VBP	O	O
not	RB	O	O
been	VBN	O	O
able	JJ	O	O
to	TO	O	O
define	VB	O	O
the	DT	O	O
standard	JJ	O	O
treatment	NN	O	O
for	IN	O	O
advanced	JJ	p	O
gastric	JJ	p	PC
cancer	NN	p	PC
.	.	p	PC

The	DT	O	O
present	JJ	O	O
study	NN	O	O
evaluated	VBD	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
adjuvant	JJ	i	IPH
immunochemotherapy	NN	i	IPH
with	IN	i	IPH
the	DT	i	IPH
use	NN	i	IPH
of	IN	i	IPH
BCG	NNP	i	IPM
(	(	i	IPM
bacille	IN	i	IPM
Calmette-Guerin	NNP	i	IPM
)	)	i	IPM
and	CC	i	O
FAM	NNP	i	IPM
(	(	i	O
5-fluorouracil	JJ	i	IPM
,	,	i	O
adriamycin	JJ	i	IPM
,	,	i	O
mitomycin	JJ	i	IPM
C	NNP	i	IPM
)	)	i	O
chemotherapy	NN	i	IPM
on	IN	O	O
the	DT	O	O
survival	NN	o	OMO
of	IN	o	OMO
patients	NNS	o	OMO
with	IN	p	O
locally	RB	p	O
advanced	VBN	p	O
resectable	JJ	p	PC
gastric	JJ	p	PC
cancer	NN	p	PC
.	.	p	PC

METHODS	NNP	O	O
A	NNP	O	O
total	NN	O	O
of	IN	O	O
156	CD	p	PSS
patients	NNS	p	O
with	IN	p	O
stage	NN	p	PC
III	NNP	p	PC
or	CC	p	PC
IV	NNP	p	PC
gastric	JJ	p	PC
cancer	NN	p	PC
who	WP	p	O
had	VBD	p	O
undergone	JJ	p	O
curative	JJ	p	PC
resection	NN	p	PC
were	VBD	O	O
randomly	RB	i	IPM
assigned	VBN	i	IPM
to	TO	i	IPM
three	CD	i	IPM
treatment	NN	i	IPM
groups	NNS	i	IPM
:	:	i	IPM
BCG	NNP	i	IPM
+	NNP	i	IPM
FAM	NNP	i	IPM
(	(	i	O
immunochemotherapy	NN	i	IPM
)	)	i	O
,	,	i	O
FAM	NNP	i	O
(	(	i	O
chemotherapy	NN	i	IPM
)	)	i	O
,	,	i	O
and	CC	i	O
control	NN	i	IS
(	(	i	IS
surgery	NN	i	IS
only	RB	i	IS
)	)	i	IS
.	.	i	O

Treatment	NN	i	IOt
was	VBD	i	IOt
continued	VBN	i	IOt
for	IN	i	IOt
2	CD	i	IOt
years	NNS	i	IOt
or	CC	i	IOt
until	IN	i	IOt
death	NN	i	IOt
.	.	i	O

Further	NNP	i	IOt
postsurgical	JJ	i	IOt
follow	VBP	i	IOt
up	RP	i	IOt
was	VBD	i	IOt
carried	VBN	i	IOt
on	IN	i	IOt
for	IN	i	IOt
up	IN	i	IOt
to	TO	i	IOt
10	CD	i	IOt
years	NNS	i	IOt
.	.	i	O

RESULTS	VB	O	O
Overall	JJ	O	O
10-year	JJ	o	OMO
survival	NN	o	OMO
was	VBD	O	O
47.1	CD	O	O
%	NN	O	O
for	IN	O	O
the	DT	O	O
immunochemotherapy	NN	O	O
group	NN	O	O
(	(	O	O
P	NNP	O	O
<	VBZ	O	O
0.037	CD	O	O
vs	NN	O	O
FAM	NNP	i	IPH
and	CC	O	O
P	NNP	O	O
<	NNP	O	O
0.0006	CD	O	O
vs	NNS	O	O
control	NN	O	O
)	)	O	O
,	,	O	O
30	CD	O	O
%	NN	O	O
for	IN	O	O
the	DT	O	O
chemotherapy	NN	i	IPH
group	NN	O	O
(	(	O	O
vs	FW	O	O
control	NN	O	O
,	,	O	O
NS	NNP	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
15.2	CD	O	O
%	NN	O	O
for	IN	O	O
the	DT	O	O
control	NN	O	O
group	NN	O	O
.	.	O	O

In	IN	O	O
patients	NNS	p	O
with	IN	p	O
pT2/T3	JJ	p	PC
primary	JJ	p	PC
tumors	NNS	p	PC
,	,	O	O
10-year	JJ	o	OMO
survival	NN	o	OMO
was	VBD	O	O
55.3	CD	O	O
%	NN	O	O
for	IN	O	O
BCG	NNP	i	IPH
+	NNP	i	IPH
FAM	NNP	i	IPH
vs	VBD	O	O
28.2	CD	O	O
%	NN	O	O
for	IN	O	O
FAM	NNP	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.01	CD	O	O
)	)	O	O
and	CC	O	O
14.6	CD	O	O
%	NN	O	O
for	IN	O	O
the	DT	O	O
control	NN	O	O
group	NN	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.00018	CD	O	O
)	)	O	O
.	.	O	O

BCG	NNP	i	O
+	NNP	i	O
FAM	NNP	i	O
significantly	RB	O	O
improved	VBD	O	O
the	DT	O	O
survival	NN	o	OMO
of	IN	o	OMO
patients	NNS	o	OMO
with	IN	p	O
intestinal-type	JJ	p	PC
but	CC	p	PC
not	RB	p	PC
diffuse-type	JJ	p	PC
cancer	NN	p	PC
.	.	p	PC

Immunochemotherapy	NNP	i	O
was	VBD	O	O
well	RB	O	O
tolerated	VBN	O	O
.	.	O	O

CONCLUSION	VB	O	O
This	DT	O	O
study	NN	O	O
,	,	O	O
based	VBN	O	O
on	IN	O	O
a	DT	O	O
limited	JJ	p	O
number	NN	p	O
of	IN	p	O
patients	NNS	p	O
,	,	O	O
indicates	VBZ	O	O
that	IN	O	O
adjuvant	JJ	O	O
immunochemotherapy	NN	O	O
(	(	O	O
BCG	NNP	O	O
+	NNP	O	O
FAM	NNP	O	O
)	)	O	O
may	MD	O	O
prolong	VB	O	O
the	DT	O	O
survival	NN	o	OMO
of	IN	O	O
gastric	JJ	p	PC
cancer	NN	p	PC
patients	NNS	p	O
after	IN	p	O
curative	JJ	p	PC
gastrectomy	NN	p	PC
;	:	p	O
in	IN	p	O
particular	JJ	p	O
,	,	p	O
in	IN	p	O
patients	NNS	p	O
with	IN	p	O
pT2/T3	JJ	p	PC
tumors	NNS	p	PC
and	CC	p	PC
intestinal-type	JJ	p	PC
primary	JJ	p	PC
tumors	NNS	p	PC
.	.	p	PC

There	EX	O	O
was	VBD	O	O
no	DT	O	O
survival	JJ	o	OMO
benefit	NN	o	OMO
from	IN	O	O
FAM	NNP	i	O
adjuvant	JJ	i	O
chemotherapy	NN	i	O
.	.	i	O

Randomized	VBN	O	O
trial	NN	O	O
of	IN	O	O
a	DT	O	O
stage-of-change	NN	i	IE
oriented	VBN	i	IE
smoking	VBG	i	IE
cessation	NN	i	IE
intervention	NN	i	IE
in	IN	O	O
infertile	NN	p	PC
and	CC	p	O
pregnant	JJ	p	PC
women	NNS	p	PSE
.	.	p	O

OBJECTIVE	NNP	O	O
To	TO	O	O
assess	VB	O	O
a	DT	O	O
stage-of-change	NN	i	IE
oriented	VBN	i	IE
smoking	VBG	i	IE
cessation	NN	i	IE
intervention	NN	i	IE
for	IN	O	O
infertile	NN	p	O
and	CC	p	O
pregnant	JJ	p	O
women	NNS	p	O
,	,	O	O
compared	VBN	O	O
with	IN	O	O
standard	NN	O	O
of	IN	O	O
care	NN	O	O
.	.	O	O

DESIGN	NNP	O	O
Randomized	NNP	O	O
controlled	VBD	O	O
trial	NN	O	O
.	.	O	O

SETTING	NNP	O	O
Three	CD	p	O
university	NN	p	O
teaching	VBG	p	O
hospitals	NNS	p	O
in	IN	p	O
Hamilton	NNP	p	O
,	,	p	O
Ontario	NNP	p	O
,	,	p	O
Canada	NNP	p	O
.	.	p	O

PATIENT	NNP	O	O
(	(	O	O
S	NNP	O	O
)	)	O	O
Infertile	NNP	p	O
women	NNS	p	O
at	IN	p	O
their	PRP$	p	O
first	JJ	p	O
visit	NN	p	O
to	TO	p	O
a	DT	p	O
tertiary	JJ	p	O
referral	JJ	p	O
infertility	NN	p	O
clinic	NN	p	O
(	(	p	O
n	JJ	p	O
=	NNP	p	O
94	CD	p	PSS
)	)	p	O
and	CC	p	O
new	JJ	p	O
patients	NNS	p	O
seeking	VBG	p	O
pre-natal	JJ	p	O
care	NN	p	O
(	(	p	O
n	JJ	p	O
=	NNP	p	O
110	CD	p	PSS
)	)	p	O
who	WP	p	O
had	VBD	p	O
smoked	VBN	p	O
>	NNP	p	O
/=	$	p	O
3	CD	p	O
cigarettes	NNS	p	O
in	IN	p	O
the	DT	p	O
past	JJ	p	O
six	CD	p	O
months	NNS	p	O
.	.	p	O

INTERVENTION	NNP	O	O
(	(	O	O
S	NNP	O	O
)	)	O	O
A	NNP	O	O
three	CD	i	IE
to	TO	i	IE
five	CD	i	IE
minute	NN	i	IE
scripted	VBN	i	IE
intervention	NN	i	IE
and	CC	i	IE
booklet	NN	i	IE
specific	NN	i	IE
to	TO	i	IE
the	DT	i	IE
woman	NN	i	IE
's	POS	i	IE
stage-of-change	NN	i	IE
in	IN	i	IE
the	DT	i	IE
smoking	NN	i	IE
continuum	NN	i	IE
,	,	i	IE
versus	JJ	i	IE
standard	NN	i	IOt
of	IN	i	IOt
care	NN	i	IOt
.	.	i	O

Exhaled	VBN	i	IPH
carbon-monoxide	NN	i	IPH
(	(	i	IPH
CO	NNP	i	IPH
)	)	i	IPH
monitoring	NN	i	O
was	VBD	O	O
used	VBN	O	O
to	TO	O	O
validate	VB	O	O
exposure	NN	O	O
in	IN	O	O
both	DT	O	O
groups	NNS	O	O
.	.	O	O

MAIN	NNP	O	O
OUTCOME	NNP	O	O
MEASURE	NNP	O	O
(	(	O	O
S	NNP	O	O
)	)	O	O
Delta	NNP	o	OME
stage-of-change	NN	o	OME
and	CC	o	OME
rate	NN	o	OME
of	IN	o	OME
maintained	VBN	o	OME
cessation	NN	o	OME
at	IN	O	O
12	CD	O	O
months	NNS	O	O
post	VBN	O	O
follow-up	JJ	O	O
.	.	O	O

RESULT	NNP	O	O
(	(	O	O
S	NNP	O	O
)	)	O	O
Intervention	NNP	O	O
and	CC	O	O
control	NN	O	O
were	VBD	O	O
similarly	RB	O	O
effective	JJ	O	O
for	IN	O	O
infertile	JJ	O	O
women	NNS	O	O
:	:	O	O
the	DT	O	O
rate	NN	o	OME
of	IN	o	OME
maintained	VBN	o	OME
cessation	NN	o	OME
rose	VBD	O	O
significantly	RB	O	O
from	IN	O	O
4	CD	O	O
%	NN	O	O
to	TO	O	O
24	CD	O	O
%	NN	O	O
over	IN	O	O
twelve	JJ	O	O
months	NNS	O	O
,	,	O	O
with	IN	O	O
a	DT	O	O
mean	JJ	o	OPH
delta	NN	o	OPH
stage-of-change	NN	o	OPH
0.28	CD	O	O
.	.	O	O

In	IN	O	O
prenatal	JJ	O	O
women	NNS	O	O
,	,	O	O
neither	CC	O	O
approach	NN	O	O
was	VBD	O	O
effective	JJ	O	O
.	.	O	O

Maintained	VBN	o	OOt
cessation	NN	o	OOt
did	VBD	O	O
not	RB	O	O
significantly	RB	O	O
change	VBP	O	O
from	IN	O	O
0	CD	O	O
to	TO	O	O
12	CD	O	O
months	NNS	O	O
(	(	O	O
19	CD	O	O
%	NN	O	O
to	TO	O	O
18	CD	O	O
%	NN	O	O
)	)	O	O
.	.	O	O

Mean	JJ	o	OOt
delta	JJ	o	OOt
stage-of-change	NN	o	OOt
declined	VBN	O	O
by	IN	O	O
-0.62	NNP	O	O
.	.	O	O

CONCLUSION	NNP	O	O
(	(	O	O
S	NNP	O	O
)	)	O	O
For	IN	O	O
infertile	JJ	O	O
women	NNS	O	O
,	,	O	O
basic	JJ	O	O
information	NN	O	O
describing	VBG	O	O
the	DT	O	O
impact	NN	O	O
of	IN	O	O
smoking	VBG	O	O
on	IN	O	O
fertility	NN	O	O
,	,	O	O
along	IN	O	O
with	IN	O	O
exhaled	JJ	O	O
CO	NNP	O	O
monitoring	NN	O	O
and	CC	O	O
a	DT	O	O
more	RBR	O	O
intensive	JJ	O	O
intervention	NN	O	O
were	VBD	O	O
both	DT	O	O
highly	RB	O	O
effective	JJ	O	O
.	.	O	O

In	IN	O	O
pregnant	JJ	O	O
women	NNS	O	O
neither	CC	O	O
approach	NN	O	O
was	VBD	O	O
beneficial	JJ	O	O
,	,	O	O
with	IN	O	O
some	DT	O	O
evidence	NN	O	O
of	IN	O	O
post-partum	JJ	O	O
relapse	NN	O	O
.	.	O	O

Double-blind	JJ	O	O
placebo-controlled	JJ	O	O
trial	NN	O	O
of	IN	O	O
secretin	NN	i	IPM
:	:	i	IPM
effects	NNS	O	O
on	IN	O	O
aberrant	JJ	o	OME
behavior	NN	o	OME
in	IN	o	OME
children	NNS	o	OME
with	IN	o	OME
autism	NN	o	OME
.	.	o	OME

Secretin	NNP	i	IPM
has	VBZ	O	O
been	VBN	O	O
proposed	VBN	O	O
as	IN	O	O
a	DT	O	O
treatment	NN	O	O
alternative	NN	O	O
for	IN	O	O
autistic	JJ	o	OME
spectrum	NN	o	OME
disorders	NNS	o	OME
,	,	O	O
but	CC	O	O
empirical	JJ	O	O
support	NN	O	O
is	VBZ	O	O
lacking	VBG	O	O
.	.	O	O

A	DT	O	O
double-blind	JJ	O	O
placebo-controlled	JJ	O	O
study	NN	O	O
examined	VBD	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
a	DT	O	O
single	JJ	O	O
dose	NN	O	O
of	IN	O	O
synthetic	JJ	i	IPM
human	JJ	i	IPM
secretin	NN	i	IPM
on	IN	O	O
aberrant	JJ	o	OME
behavior	NN	o	OME
.	.	o	OME

Parent	NN	p	O
and	CC	p	O
teacher	NN	p	O
data	NNS	p	O
from	IN	p	O
the	DT	p	O
Aberrant	NNP	o	OME
Behavior	NNP	o	OME
Checklist	NNP	o	OME
for	IN	O	O
eight	CD	p	O
male	JJ	p	O
children	NNS	p	O
were	VBD	O	O
analyzed	VBN	O	O
for	IN	O	O
reliable	JJ	O	O
change	NN	O	O
in	IN	O	O
a	DT	O	O
clinical	JJ	O	O
replication	NN	O	O
series	NN	O	O
.	.	O	O

By	IN	O	O
parent	NN	O	O
and	CC	O	O
teacher	NN	O	O
report	NN	O	O
,	,	O	O
the	DT	O	O
majority	NN	O	O
of	IN	O	O
change	NN	O	O
occurred	VBD	O	O
either	CC	O	O
on	IN	O	O
the	DT	O	O
placebo	NN	i	IC
trial	NN	O	O
or	CC	O	O
reflected	VBN	O	O
deterioration	NN	O	O
subsequent	NN	O	O
to	TO	O	O
secretin	VB	i	IPM
infusion	NN	O	O
.	.	O	O

Repeated-measures	JJ	O	O
multivariate	JJ	O	O
analysis	NN	O	O
of	IN	O	O
variance	NN	O	O
results	NNS	O	O
were	VBD	O	O
similar	JJ	O	O
.	.	O	O

Results	NNS	O	O
are	VBP	O	O
consistent	JJ	O	O
with	IN	O	O
other	JJ	O	O
studies	NNS	O	O
,	,	O	O
suggesting	VBG	O	O
that	IN	O	O
secretin	NN	i	IPM
may	MD	O	O
not	RB	O	O
be	VB	O	O
an	DT	O	O
effective	JJ	O	O
treatment	NN	O	O
option	NN	O	O
.	.	O	O

Amphotericin	NNP	i	IPM
versus	NN	O	O
pentamidine	NN	i	IPM
in	IN	O	O
antimony-unresponsive	JJ	p	PC
kala-azar	NN	p	PC
.	.	p	O

We	PRP	O	O
compared	VBN	O	O
the	DT	O	O
efficacy	NN	O	O
of	IN	O	O
amphotericin	NN	i	IPM
B	NNP	i	IPM
and	CC	O	O
pentamidine	JJ	i	IPM
isethionate	NN	i	IPM
in	IN	O	O
a	DT	O	O
prospective	JJ	O	O
randomised	VBN	O	O
trial	NN	O	O
in	IN	O	O
120	CD	p	PSS
uncomplicated	JJ	p	O
and	CC	p	O
parasitologically	RB	p	O
confirmed	VBN	p	O
cases	NNS	p	O
of	IN	p	O
antimony-unresponsive	JJ	p	PC
kala-azar	NN	p	PC
.	.	p	O

Doses	NNS	O	O
were	VBD	O	O
twenty	JJ	O	O
intramuscular	JJ	O	O
injections	NNS	O	O
of	IN	O	O
pentamidine	NN	i	IPM
4	CD	O	O
mg/kg	NN	O	O
on	IN	O	O
alternate	JJ	O	O
days	NNS	O	O
or	CC	O	O
fourteen	JJ	O	O
definitive	JJ	O	O
doses	NNS	O	O
of	IN	O	O
amphotericin	JJ	i	IPM
0.5	CD	O	O
mg/kg	NN	O	O
infused	VBN	O	O
in	IN	O	O
5	CD	O	O
%	NN	O	O
dextrose	NN	O	O
on	IN	O	O
alternate	JJ	O	O
days	NNS	O	O
.	.	O	O

48	CD	O	O
(	(	O	O
80	CD	O	O
%	NN	O	O
)	)	O	O
patients	NNS	O	O
given	VBN	O	O
pentamidine	VBP	i	IPM
showed	VBN	O	O
initial	JJ	o	OOt
cure	NN	o	OOt
and	CC	O	O
46	CD	O	O
(	(	O	O
77	CD	O	O
%	NN	O	O
)	)	O	O
showed	VBD	O	O
definitive	JJ	o	OOt
cure	NN	o	OOt
compared	VBN	O	O
with	IN	O	O
60	CD	O	O
(	(	O	O
100	CD	O	O
%	NN	O	O
)	)	O	O
and	CC	O	O
59	CD	O	O
(	(	O	O
98	CD	O	O
%	NN	O	O
)	)	O	O
cases	NNS	O	O
,	,	O	O
respectively	RB	O	O
,	,	O	O
on	IN	O	O
amphotericin	NN	i	IPM
(	(	O	O
p	JJ	O	O
<	NNP	O	O
0.001	CD	O	O
)	)	O	O
.	.	O	O

Amphotericin	NNP	i	IPM
also	RB	O	O
brought	VBD	O	O
about	RB	O	O
quicker	JJR	O	O
abatement	NN	o	OPH
of	IN	o	OPH
fever	NN	o	OPH
and	CC	O	O
more	JJR	O	O
complete	JJ	o	OA
spleen	JJ	o	OA
regression	NN	o	OA
.	.	o	OPH

Arthroscopic	NNP	i	IS
rotator	NN	i	IS
cuff	NN	i	IS
repair	NN	i	IS
with	IN	i	IS
and	CC	i	O
without	IN	i	IPH
acromioplasty	NN	i	IPH
in	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
full-thickness	JJ	p	PC
rotator	NN	p	PC
cuff	NN	p	PC
tears	NNS	p	PC
:	:	p	O
a	DT	O	O
multicenter	NN	O	O
,	,	O	O
randomized	VBN	O	O
controlled	VBN	O	O
trial	NN	O	O
.	.	O	O

BACKGROUND	VB	O	O
The	DT	O	O
primary	JJ	O	O
objective	NN	O	O
of	IN	O	O
this	DT	O	O
prospective	JJ	O	O
randomized	NN	O	O
controlled	VBD	O	O
trial	NN	O	O
was	VBD	O	O
to	TO	O	O
compare	VB	O	O
functional	JJ	o	OOt
and	CC	o	OOt
quality-of-life	JJ	o	OOt
indices	NNS	o	OOt
and	CC	O	O
rates	NNS	o	OPH
of	IN	o	OPH
revision	NN	o	OPH
surgery	NN	o	OPH
in	IN	O	O
arthroscopic	NN	i	IS
rotator	NN	i	IS
cuff	NN	i	IS
repair	NN	i	IS
with	IN	i	IS
and	CC	i	O
without	IN	i	IPH
acromioplasty	JJ	i	IPH
.	.	i	O

METHODS	NNP	O	O
Eighty-six	JJ	p	PSS
patients	NNS	p	O
consented	VBN	O	O
and	CC	O	O
were	VBD	O	O
randomly	RB	O	O
assigned	VBN	O	O
intraoperatively	RB	O	O
to	TO	O	O
one	CD	O	O
of	IN	O	O
two	CD	O	O
study	NN	O	O
groups	NNS	O	O
,	,	O	O
and	CC	O	O
sixty-eight	NN	p	PSS
of	IN	p	O
them	PRP	p	O
completed	VBD	p	O
the	DT	p	O
study	NN	p	O
.	.	p	O

The	DT	O	O
primary	JJ	O	O
outcome	NN	O	O
was	VBD	O	O
the	DT	O	O
Western	JJ	o	OOt
Ontario	NNP	o	OOt
Rotator	NNP	o	OOt
Cuff	NNP	o	OOt
(	(	o	OOt
WORC	NNP	o	OOt
)	)	o	OOt
index	NN	o	OOt
.	.	o	OPH

Secondary	JJ	O	O
outcome	NN	O	O
measures	NNS	O	O
included	VBD	O	O
the	DT	O	O
American	JJ	o	OOt
Shoulder	NNP	o	OOt
and	CC	o	OOt
Elbow	NNP	o	OOt
Surgeons	NNP	o	OOt
(	(	o	OOt
ASES	NNP	o	OOt
)	)	o	OOt
shoulder	NN	o	OOt
assessment	JJ	o	OOt
form	NN	o	OOt
and	CC	o	OPH
a	DT	o	OPH
count	NN	o	OOt
of	IN	o	OOt
revisions	NNS	o	OOt
required	VBN	O	O
in	IN	O	O
each	DT	O	O
group	NN	O	O
.	.	O	O

Outcome	NNP	O	O
measures	NNS	O	O
were	VBD	O	O
completed	VBN	O	O
preoperatively	RB	O	O
and	CC	O	O
at	IN	O	O
three	CD	O	O
,	,	O	O
six	CD	O	O
,	,	O	O
twelve	NN	O	O
,	,	O	O
eighteen	NN	O	O
,	,	O	O
and	CC	O	O
twenty-four	JJ	O	O
months	NNS	O	O
after	IN	O	O
surgery	NN	O	O
.	.	O	O

RESULTS	NNP	O	O
WORC	NNP	o	OOt
and	CC	o	O
ASES	NNP	o	OOt
scores	VBZ	o	OOt
improved	VBN	O	O
significantly	RB	O	O
in	IN	O	O
each	DT	O	O
group	NN	O	O
over	IN	O	O
time	NN	O	O
(	(	O	O
p	JJ	O	O
<	NNP	O	O
0.001	CD	O	O
)	)	O	O
.	.	O	O

There	EX	O	O
were	VBD	O	O
no	DT	O	O
differences	NNS	O	O
in	IN	O	O
WORC	NNP	o	OOt
or	CC	o	O
ASES	NNP	o	OOt
scores	NNS	o	OOt
between	IN	O	O
the	DT	O	O
groups	NNS	O	O
that	WDT	O	O
had	VBD	O	O
arthroscopic	VBN	i	IS
cuff	JJ	i	IS
repair	NN	i	IS
with	IN	i	IS
or	CC	i	O
without	IN	i	IPH
acromioplasty	JJ	i	IPH
at	IN	O	O
any	DT	O	O
time	NN	O	O
point	NN	O	O
.	.	O	O

There	EX	O	O
were	VBD	O	O
no	DT	O	O
differences	NNS	O	O
in	IN	O	O
scores	NNS	O	O
on	IN	O	O
the	DT	O	O
basis	NN	O	O
of	IN	O	O
acromion	NN	O	O
type	NN	O	O
,	,	O	O
nor	CC	O	O
were	VBD	O	O
any	DT	O	O
interaction	NN	O	O
effects	NNS	O	O
identified	VBN	O	O
between	IN	O	O
group	NN	O	O
and	CC	O	O
acromion	NN	O	O
type	NN	O	O
.	.	O	O

Four	CD	p	O
participants	NNS	p	O
(	(	p	O
9	CD	p	O
%	NN	p	O
)	)	p	O
in	IN	p	O
the	DT	p	O
group	NN	p	O
that	WDT	p	O
had	VBD	p	O
arthroscopic	VBN	i	IPH
cuff	JJ	i	IPH
repair	NN	o	OOt
alone	RB	p	O
,	,	p	O
one	CD	p	O
with	IN	p	O
a	DT	p	O
Type-2	JJ	p	O
and	CC	p	O
three	CD	p	O
with	IN	p	O
a	DT	p	O
Type-3	JJ	p	O
acromion	NN	p	O
,	,	p	O
required	VBN	p	O
additional	JJ	o	OPH
surgery	NN	o	OPH
by	IN	O	O
the	DT	O	O
twenty-four-month	JJ	O	O
time	NN	O	O
point	NN	O	O
.	.	O	O

The	DT	O	O
number	NN	o	OOt
of	IN	o	OOt
patients	NNS	o	OOt
who	WP	o	OOt
required	VBD	o	OOt
additional	JJ	o	OOt
surgery	NN	o	OOt
was	VBD	O	O
greater	JJR	O	O
(	(	O	O
p	JJ	O	O
=	NNP	O	O
0.05	CD	O	O
)	)	O	O
in	IN	O	O
the	DT	O	O
group	NN	O	O
that	WDT	O	O
had	VBD	O	O
arthroscopic	VBN	O	O
cuff	JJ	O	O
repair	NN	O	O
alone	RB	O	O
than	IN	O	O
in	IN	O	O
the	DT	O	O
group	NN	O	O
that	WDT	O	O
had	VBD	O	O
arthroscopic	VBN	O	O
cuff	JJ	O	O
repair	NN	O	O
and	CC	O	O
acromioplasty	NN	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
Our	PRP$	O	O
findings	NNS	O	O
are	VBP	O	O
consistent	JJ	O	O
with	IN	O	O
previous	JJ	O	O
research	NN	O	O
reports	NNS	O	O
in	IN	O	O
which	WDT	O	O
there	EX	O	O
was	VBD	O	O
no	DT	O	O
difference	NN	O	O
in	IN	O	O
functional	JJ	o	OOt
and	CC	o	OOt
quality-of-life	JJ	o	OOt
indices	NNS	o	OOt
for	IN	O	O
patients	NNS	p	O
who	WP	p	O
had	VBD	p	O
rotator	NN	p	O
cuff	NN	p	O
repair	NN	p	O
with	IN	p	O
or	CC	p	O
without	IN	p	O
acromioplasty	JJ	p	O
.	.	p	O

The	DT	O	O
higher	JJR	o	OOt
reoperation	NN	o	OOt
rate	NN	o	OOt
was	VBD	O	O
found	VBN	O	O
in	IN	O	O
the	DT	O	O
group	NN	p	O
without	IN	O	O
acromioplasty	NN	O	O
.	.	O	O

Further	CC	O	O
study	NN	O	O
that	WDT	O	O
includes	VBZ	O	O
follow-up	JJ	O	O
imaging	NN	O	O
and	CC	O	O
patient-reported	JJ	O	O
outcomes	NNS	O	O
over	IN	O	O
a	DT	O	O
greater	JJR	O	O
follow-up	JJ	O	O
period	NN	O	O
is	VBZ	O	O
needed	VBN	O	O
.	.	O	O

Effects	NNS	O	O
of	IN	O	O
a	DT	O	O
combination	NN	O	O
of	IN	O	O
evening	VBG	i	O
primrose	JJ	i	O
oil	NN	i	O
(	(	i	O
gamma	NN	i	IPM
linolenic	RB	i	IPM
acid	NN	i	IPM
)	)	i	O
and	CC	i	O
fish	JJ	i	O
oil	NN	i	O
(	(	i	O
eicosapentaenoic	JJ	i	IPM
+	NNP	i	IPM
docahexaenoic	NN	i	IPM
acid	NN	i	IPM
)	)	i	O
versus	NN	i	O
magnesium	NN	i	IPM
,	,	i	O
and	CC	i	O
versus	NN	i	O
placebo	NN	i	IC
in	IN	O	O
preventing	VBG	O	O
pre-eclampsia	NN	o	OPH
.	.	o	OPH

In	IN	O	O
a	DT	O	O
placebo	NN	i	IC
controlled	VBN	O	O
,	,	O	O
partially	RB	O	O
double-blinded	JJ	O	O
,	,	O	O
clinical	JJ	O	O
trial	NN	O	O
,	,	O	O
a	DT	O	O
combination	NN	i	O
of	IN	i	O
evening	VBG	i	O
primrose	JJ	i	O
oil	NN	i	O
and	CC	i	O
fish	JJ	i	O
oil	NN	i	O
was	VBD	i	O
compared	VBN	i	O
to	TO	i	O
Magnesium	NNP	i	IPM
Oxide	NNP	i	IPM
,	,	i	O
and	CC	i	O
to	TO	i	O
a	DT	i	O
Placebo	NNP	i	IC
in	IN	O	O
preventing	VBG	O	O
Pre-Eclampsia	NNP	o	OPH
of	IN	o	OPH
Pregnancy	NNP	o	OPH
.	.	o	OPH

All	DT	O	O
were	VBD	O	O
given	VBN	O	O
as	IN	O	O
nutritional	JJ	O	O
supplements	NNS	O	O
for	IN	O	O
six	CD	O	O
months	NNS	O	O
to	TO	O	O
a	DT	O	O
group	NN	p	O
of	IN	p	O
primiparous	JJ	p	O
and	CC	p	O
multiparous	JJ	p	O
pregnant	JJ	p	O
women	NNS	p	O
.	.	p	O

Some	DT	p	PC
of	IN	p	PC
these	DT	p	PC
women	NNS	p	PC
had	VBD	p	PC
personal	JJ	p	PC
or	CC	p	PC
family	NN	p	PC
histories	NNS	p	PC
of	IN	p	PC
hypertension	NN	p	PC
(	(	p	PC
21	CD	p	PC
%	NN	p	PC
)	)	p	PC
.	.	p	PC

Only	RB	p	O
those	DT	p	O
patients	NNS	p	O
who	WP	p	O
received	VBD	p	O
prenatal	JJ	p	O
care	NN	p	O
at	IN	p	O
the	DT	p	O
Central	NNP	p	O
Maternity	NNP	p	O
Hospital	NNP	p	O
for	IN	p	O
Luanda	NNP	p	O
were	VBD	O	O
included	VBN	O	O
in	IN	O	O
the	DT	O	O
study	NN	O	O
.	.	O	O

Compared	VBN	O	O
to	TO	O	O
the	DT	O	O
Placebo	NNP	i	IC
group	NN	O	O
(	(	O	O
29	CD	O	O
%	NN	O	O
)	)	O	O
,	,	O	O
the	DT	O	O
group	NN	O	O
receiving	VBG	O	O
the	DT	O	O
mixture	NN	O	O
of	IN	O	O
evening	VBG	i	IPM
primrose	JJ	i	IPM
oil	NN	i	IPM
and	CC	O	O
fish	JJ	i	IPM
oil	NN	i	IPM
containing	VBG	O	O
Gamma-linolenic	JJ	i	IPM
acid	NN	i	IPM
(	(	i	IPM
GLA	NNP	i	IPM
)	)	i	IPM
,	,	i	O
Eicosapentaenoic	NNP	i	IPM
acid	NN	i	IPM
(	(	i	IPM
EPA	NNP	i	IPM
)	)	i	IPM
,	,	O	O
and	CC	O	O
Docosahexaenoic	NNP	i	IPM
acid	NN	i	IPM
(	(	i	IPM
DHA	NNP	i	IPM
)	)	i	IPM
had	VBD	O	O
a	DT	O	O
significantly	RB	O	O
lower	JJR	O	O
incidence	NN	o	OA
of	IN	o	OA
edema	NN	o	OPH
(	(	O	O
13	CD	O	O
%	NN	O	O
,	,	O	O
p	NN	O	O
=	NNP	O	O
0.004	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
group	NN	O	O
receiving	VBG	O	O
Magnesium	NNP	i	IPM
Oxide	NNP	i	IPM
had	VBD	O	O
statistically	RB	O	O
significant	JJ	O	O
fewer	JJR	O	O
subjects	NNS	O	O
who	WP	O	O
developed	VBD	O	O
hypertension	NN	o	OPH
of	IN	o	OPH
pregnancy	NN	o	OPH
.	.	o	OPH

There	EX	O	O
were	VBD	O	O
3	CD	O	O
cases	NNS	O	O
of	IN	O	O
eclampsia	NN	o	OPH
,	,	O	O
all	DT	O	O
in	IN	O	O
the	DT	O	O
Placebo	NNP	i	IC
group	NN	O	O
.	.	O	O

Sustained	JJ	O	O
effect	NN	O	O
of	IN	O	O
SQ-standardized	NNP	O	O
grass	NN	O	O
allergy	NN	O	O
immunotherapy	NN	i	IPM
tablet	NN	i	IPM
on	IN	O	O
rhinoconjunctivitis	NN	O	O
quality	NN	O	O
of	IN	O	O
life	NN	O	O
.	.	O	O

BACKGROUND	IN	O	O
The	DT	O	O
prevalence	NN	O	O
of	IN	O	O
allergic	JJ	O	O
rhinoconjunctivitis	NN	O	O
has	VBZ	O	O
increased	VBN	O	O
significantly	RB	O	O
over	IN	O	O
the	DT	O	O
past	JJ	O	O
decades	NNS	O	O
with	IN	O	O
grass	NN	O	O
pollen	NN	O	O
being	VBG	O	O
a	DT	O	O
common	JJ	O	O
trigger	NN	O	O
.	.	O	O

The	DT	O	O
impact	NN	O	O
of	IN	O	O
allergy	NN	O	O
on	IN	O	O
patient	NN	O	O
's	POS	O	O
quality	NN	O	O
of	IN	O	O
life	NN	O	O
is	VBZ	O	O
substantial	JJ	O	O
.	.	O	O

AIM	NNP	O	O
To	TO	O	O
investigate	VB	O	O
the	DT	O	O
sustained	JJ	O	O
effect	NN	O	O
on	IN	O	O
quality	NN	O	O
of	IN	O	O
life	NN	O	O
during	IN	O	O
the	DT	O	O
grass	NN	O	O
pollen	NN	O	O
season	NN	O	O
1	CD	O	O
year	NN	O	O
after	IN	O	O
3	CD	O	O
years	NNS	O	O
of	IN	O	O
treatment	NN	O	O
with	IN	O	O
the	DT	O	O
SQ-standardized	JJ	O	O
grass	NN	i	IPM
allergy	NN	i	IPM
immunotherapy	NN	i	IPM
tablet	NN	i	IPM
(	(	i	IPM
AIT	NNP	i	IPM
)	)	i	IPM
,	,	O	O
Graza	NNP	O	O
(	(	O	O
Phleum	NNP	O	O
pratense	VBZ	O	O
75,000	CD	O	O
SQ-T/2800	JJ	O	O
BAU	NNP	O	O
;	:	O	O
ALK	NNP	O	O
,	,	O	O
Denmark	NNP	O	O
)	)	O	O
.	.	O	O

METHODS	PDT	O	O
The	DT	O	O
trial	NN	O	O
was	VBD	O	O
a	DT	O	O
randomized	JJ	O	O
,	,	O	O
parallel-group	JJ	O	O
,	,	O	O
double-blind	JJ	O	O
,	,	O	O
placebo-controlled	JJ	O	O
trial	NN	O	O
in	IN	O	O
adult	NN	p	PA
subjects	NNS	p	O
with	IN	p	O
a	DT	p	O
history	NN	p	O
of	IN	p	O
moderate-severe	JJ	p	PC
grass	NN	p	PC
pollen	NN	p	PC
induced	VBD	p	PC
rhinoconjunctivitis	NN	p	PC
inadequately	RB	p	PC
controlled	VBN	p	O
by	IN	p	O
symptomatic	JJ	p	O
medications	NNS	p	O
.	.	p	O

Subjects	NNS	p	O
received	VBD	O	O
3	CD	O	O
years	NNS	O	O
of	IN	O	O
grass	NN	i	IPM
AIT	NNP	i	IPM
(	(	O	O
n	JJ	O	O
=	NNP	O	O
157	CD	O	O
)	)	O	O
or	CC	O	O
placebo	NN	i	IC
(	(	O	O
n	JJ	O	O
=	NNP	O	O
126	CD	O	O
)	)	O	O
,	,	O	O
followed	VBN	O	O
by	IN	O	O
1	CD	O	O
year	NN	O	O
of	IN	O	O
follow-up	NN	O	O
.	.	O	O

Quality	NN	o	OOt
of	IN	o	OOt
life	NN	o	OOt
assessments	NNS	O	O
were	VBD	O	O
based	VBN	O	O
on	IN	O	O
the	DT	O	O
standardized	JJ	o	OOt
rhinoconjunctivitis	NN	o	OOt
quality	NN	o	OOt
of	IN	o	OOt
life	NN	o	OOt
questionnaire	NN	o	OOt
(	(	o	OOt
RQLQ	NNP	o	OOt
(	(	o	OOt
S	NNP	o	OOt
)	)	o	OOt
)	)	o	OOt
;	:	o	OOt
completed	VBN	O	O
weekly	JJ	O	O
during	IN	O	O
the	DT	O	O
entire	JJ	O	O
grass	NN	O	O
pollen	NN	O	O
season	NN	O	O
.	.	O	O

RESULTS	NNP	O	O
During	IN	O	O
follow-up	JJ	O	O
,	,	O	O
the	DT	O	O
overall	JJ	O	O
RQLQ	NNP	o	OOt
(	(	o	OOt
S	NNP	o	OOt
)	)	o	OOt
score	NN	o	OOt
for	IN	O	O
the	DT	O	O
entire	JJ	O	O
grass	NN	O	O
pollen	NN	O	O
season	NN	O	O
was	VBD	O	O
significantly	RB	O	O
improved	VBN	O	O
in	IN	O	O
the	DT	O	O
active	JJ	O	O
group	NN	O	O
(	(	O	O
relative	JJ	O	O
difference	NN	O	O
to	TO	O	O
placebo	VB	i	O
:	:	i	O
23	CD	O	O
%	NN	O	O
,	,	O	O
P	NNP	O	O
=	NNP	O	O
0.004	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
improvement	NN	O	O
was	VBD	O	O
higher	JJR	O	O
during	IN	O	O
the	DT	O	O
peak	NN	O	O
pollen	NN	O	O
season	NN	O	O
(	(	O	O
28	CD	O	O
%	NN	O	O
,	,	O	O
P	NNP	O	O
=	NNP	O	O
0.001	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
treatment	NN	O	O
effect	NN	O	O
of	IN	O	O
grass	NN	O	O
AIT	NNP	O	O
during	IN	O	O
the	DT	O	O
follow-up	JJ	O	O
year	NN	O	O
and	CC	O	O
the	DT	O	O
previous	JJ	O	O
three	CD	O	O
treatment	NN	O	O
years	NNS	O	O
was	VBD	O	O
similar	JJ	O	O
.	.	O	O

Improvements	NNS	O	O
were	VBD	O	O
found	VBN	O	O
in	IN	O	O
all	DT	O	O
seven	CD	O	O
RQLQ	NNP	o	OOt
(	(	o	OOt
S	NNP	o	OOt
)	)	o	OOt
domains	VBZ	o	OOt
.	.	o	O

The	DT	O	O
RQLQ	NNP	o	OOt
(	(	o	OOt
S	NNP	o	OOt
)	)	o	OOt
as	IN	O	O
a	DT	O	O
function	NN	O	O
of	IN	O	O
the	DT	O	O
weekly	JJ	O	O
average	NN	O	O
pollen	NN	O	O
counts	VBZ	O	O
showed	VBD	O	O
a	DT	O	O
clear	JJ	O	O
separation	NN	O	O
between	IN	O	O
the	DT	O	O
treatment	NN	O	O
groups	NNS	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.001	CD	O	O
)	)	O	O
.	.	O	O

CONCLUSION	NNP	O	O
In	IN	O	O
subjects	NNS	O	O
inadequately	RB	O	O
controlled	VBN	O	O
by	IN	O	O
symptomatic	JJ	O	O
medications	NNS	O	O
,	,	O	O
grass	NN	O	O
AIT	NNP	i	IPM
provided	VBD	O	O
sustained	VBN	O	O
and	CC	O	O
clinically	RB	O	O
relevant	JJ	O	O
improvements	NNS	O	O
in	IN	O	O
rhinoconjunctivitis	NN	o	OPH
quality	NN	o	OPH
of	IN	o	OPH
life	NN	o	OPH
compared	VBN	O	O
to	TO	O	O
placebo	VB	i	O
.	.	i	O

The	DT	O	O
effect	NN	O	O
increased	VBD	o	O
with	IN	O	O
increasing	VBG	O	O
grass	NN	O	O
pollen	NN	O	O
exposure	NN	O	O
.	.	O	O

The	DT	O	O
influence	NN	O	O
of	IN	O	O
ventricular	JJ	O	O
fibrillation	NN	O	O
duration	NN	O	O
on	IN	O	O
defibrillation	NN	o	OOt
efficacy	NN	o	OOt
using	VBG	O	O
biphasic	JJ	O	O
waveforms	NNS	O	O
in	IN	O	O
humans	NNS	O	O
.	.	O	O

OBJECTIVES	IN	O	O
The	DT	O	O
purpose	NN	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
prospectively	RB	O	O
investigate	VB	O	O
the	DT	O	O
influence	NN	O	O
of	IN	O	O
ventricular	JJ	O	O
fibrillation	NN	O	O
(	(	O	O
VF	NNP	O	O
)	)	O	O
durations	NNS	O	O
of	IN	O	O
5	CD	O	O
,	,	O	O
10	CD	O	O
and	CC	O	O
20	CD	O	O
s	NN	O	O
on	IN	O	O
the	DT	O	O
defibrillation	NN	o	OOt
threshold	NN	o	OOt
(	(	o	OOt
DFT	NNP	o	OOt
)	)	o	OOt
during	IN	O	O
implantable	JJ	O	O
cardioverter-defibrillator	NN	O	O
(	(	O	O
ICD	NNP	O	O
)	)	O	O
implantation	NN	O	O
.	.	O	O

BACKGROUND	NNP	O	O
Although	IN	O	O
the	DT	O	O
DFT	NNP	o	OOt
using	VBG	o	OOt
monophasic	JJ	o	OOt
waveforms	NNS	o	OOt
has	VBZ	O	O
been	VBN	O	O
shown	VBN	O	O
to	TO	O	O
increase	VB	O	O
with	IN	O	O
VF	NNP	O	O
duration	NN	O	O
in	IN	O	O
humans	NNS	O	O
,	,	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
VF	NNP	O	O
duration	NN	O	O
on	IN	O	O
defibrillation	NN	O	O
efficacy	NN	O	O
using	VBG	O	O
biphasic	JJ	O	O
waveforms	NNS	O	O
in	IN	O	O
humans	NNS	O	O
is	VBZ	O	O
not	RB	O	O
known	VBN	O	O
.	.	O	O

METHODS	NNP	O	O
Thirty	NNP	p	PSS
patients	NNS	p	PC
undergoing	VBG	p	PC
primary	JJ	p	PC
ICD	NNP	p	PC
implantation	NN	p	PC
or	CC	p	PC
pulse	JJ	p	PC
generator	NN	p	PC
replacement	NN	p	PC
were	VBD	O	O
randomly	RB	O	O
assigned	VBN	O	O
to	TO	O	O
have	VB	O	O
the	DT	O	O
DFT	NNP	i	IPH
determined	VBD	i	IPH
using	VBG	i	IPH
biphasic	JJ	i	IPH
shocks	NNS	i	IPH
at	IN	O	O
two	CD	O	O
durations	NNS	O	O
of	IN	O	O
VF	NNP	i	IPH
each	DT	O	O
(	(	O	O
5	CD	O	O
and	CC	O	O
10	CD	O	O
s	NN	O	O
,	,	O	O
10	CD	O	O
and	CC	O	O
20	CD	O	O
s	NN	O	O
or	CC	O	O
5	CD	O	O
and	CC	O	O
20	CD	O	O
s	NN	O	O
)	)	O	O
.	.	O	O

RESULTS	NNP	O	O
There	EX	O	O
was	VBD	O	O
no	DT	O	O
statistically	RB	O	O
significant	JJ	O	O
difference	NN	O	O
in	IN	O	O
the	DT	O	O
mean	JJ	o	OOt
DFT	NNP	o	OOt
comparing	VBG	O	O
VF	NNP	O	O
durations	NNS	O	O
of	IN	O	O
5	CD	O	O
s	NNS	O	O
(	(	O	O
9.5+/-6.0	CD	O	O
J	NNP	O	O
)	)	O	O
and	CC	O	O
10	CD	O	O
s	NN	O	O
(	(	O	O
10.8+/-7.0	JJ	O	O
J	NNP	O	O
)	)	O	O
(	(	O	O
p=0.4	NN	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
mean	JJ	o	O
DFT	NNP	o	OOt
significantly	RB	O	O
increased	VBD	O	O
from	IN	O	O
10.9+/-6.1	JJ	O	O
J	NNP	O	O
at	IN	O	O
10	CD	O	O
s	NN	O	O
of	IN	O	O
VF	NNP	O	O
to	TO	O	O
12.6+/-5.6	JJ	O	O
J	NNP	O	O
(	(	O	O
p=0.03	NN	O	O
)	)	O	O
at	IN	O	O
20	CD	O	O
s	NN	O	O
of	IN	O	O
VF	NNP	O	O
,	,	O	O
and	CC	O	O
from	IN	O	O
7.0+/-3.5	JJ	O	O
J	NNP	O	O
at	IN	O	O
5	CD	O	O
s	NN	O	O
of	IN	O	O
VF	NNP	O	O
to	TO	O	O
10.5+/-6.3	JJ	O	O
J	NNP	O	O
(	(	O	O
p=0.04	NN	O	O
)	)	O	O
at	IN	O	O
20	CD	O	O
s	NN	O	O
of	IN	O	O
VF	NNP	O	O
.	.	O	O

An	DT	O	O
increase	NN	O	O
in	IN	O	O
the	DT	O	O
DFT	NNP	o	OOt
was	VBD	O	O
observed	VBN	O	O
in	IN	O	O
14	CD	p	PSS
patients	NNS	p	O
as	IN	O	O
VF	NNP	O	O
duration	NN	O	O
increased	VBD	O	O
.	.	O	O

There	EX	O	O
were	VBD	O	O
no	DT	O	O
clinical	JJ	O	O
characteristics	NNS	O	O
that	WDT	O	O
differentiated	VBD	O	O
patients	NNS	O	O
with	IN	O	O
and	CC	O	O
without	IN	O	O
an	DT	O	O
increase	NN	O	O
in	IN	O	O
the	DT	O	O
DFT	NNP	o	OOt
.	.	o	O

CONCLUSIONS	NNP	O	O
Defibrillation	NNP	o	OOt
efficacy	NN	o	OOt
decreases	VBZ	O	O
with	IN	O	O
increasing	VBG	O	O
VF	NNP	O	O
duration	NN	O	O
using	VBG	O	O
biphasic	JJ	O	O
waveforms	NNS	O	O
in	IN	O	O
humans	NNS	O	O
.	.	O	O

Ventricular	JJ	O	O
fibrillation	NN	O	O
durations	NNS	O	O
greater	JJR	O	O
than	IN	O	O
10	CD	O	O
s	NN	O	O
may	MD	O	O
negatively	RB	O	O
affect	VB	O	O
the	DT	O	O
effectiveness	NN	o	OOt
of	IN	o	OOt
ICD	NNP	o	OOt
therapy	NN	o	OOt
.	.	o	O

Impact	NN	O	O
of	IN	O	O
prior	JJ	O	O
pharmacotherapy	NN	i	IPM
on	IN	O	O
remission	NN	o	OPH
of	IN	o	OPH
psychotic	JJ	o	OPH
depression	NN	o	OPH
in	IN	O	O
a	DT	O	O
randomized	NN	O	O
controlled	VBN	O	O
trial	NN	O	O
.	.	O	O

Having	VBG	O	O
failed	VBN	O	O
to	TO	O	O
respond	VB	O	O
to	TO	O	O
an	DT	O	O
adequate	JJ	O	O
antidepressant	JJ	O	O
treatment	NN	O	O
course	NN	O	O
predicts	VBZ	O	O
poorer	JJR	O	O
treatment	NN	o	O
outcomes	NNS	o	O
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
major	JJ	p	PC
depression	NN	p	PC
.	.	p	O

However	RB	O	O
,	,	O	O
little	JJ	O	O
is	VBZ	O	O
known	VBN	O	O
about	IN	O	O
the	DT	O	O
impact	NN	O	O
of	IN	O	O
prior	JJ	O	O
treatment	NN	O	O
on	IN	O	O
the	DT	O	O
outcome	NN	o	O
of	IN	O	O
major	JJ	p	PC
depression	NN	p	PC
with	IN	p	O
psychotic	JJ	p	PC
features	NNS	p	PC
(	(	p	PC
MDpsy	NNP	p	PC
)	)	p	PC
.	.	p	O

We	PRP	O	O
examined	VBD	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
prior	JJ	O	O
treatment	NN	O	O
history	NN	O	O
on	IN	O	O
the	DT	O	O
outcome	NN	o	OPH
of	IN	o	OPH
pharmacotherapy	NN	o	OPH
of	IN	O	O
MDpsy	NNP	p	PC
in	IN	p	O
patients	NNS	p	O
who	WP	p	O
participated	VBD	p	O
in	IN	p	O
the	DT	p	O
STOPD-PD	NNP	p	O
study	NN	p	O
,	,	p	O
a	DT	p	O
randomized	VBN	p	O
,	,	p	O
double-blind	JJ	p	O
,	,	p	O
clinical	JJ	p	O
trial	NN	p	O
comparing	VBG	p	O
a	DT	p	O
combination	NN	O	O
of	IN	O	O
olanzapine	JJ	i	IPM
plus	CC	i	IPM
sertraline	JJ	i	IPM
vs.	FW	i	IPM
olanzapine	JJ	i	IC
plus	CC	i	IC
placebo	NN	i	IC
.	.	i	IC

The	DT	O	O
strength	NN	O	O
of	IN	O	O
treatment	NN	O	O
courses	NNS	O	O
received	VBD	O	O
prior	RB	O	O
to	TO	O	O
randomization	NN	O	O
was	VBD	O	O
classified	VBN	O	O
using	VBG	O	O
a	DT	O	O
validated	JJ	O	O
method	NN	O	O
.	.	O	O

A	DT	O	O
hierarchy	NN	O	O
of	IN	O	O
outcomes	NNS	o	O
was	VBD	O	O
hypothesized	VBN	O	O
based	VBN	O	O
on	IN	O	O
treatments	NNS	O	O
received	VBN	O	O
prior	RB	O	O
to	TO	O	O
randomization	NN	O	O
and	CC	O	O
randomized	JJ	O	O
treatment	NN	O	O
.	.	O	O

A	DT	O	O
high	JJ	o	OPH
remission	NN	o	OPH
rate	NN	o	OPH
was	VBD	O	O
observed	VBN	O	O
in	IN	O	O
subjects	NNS	p	O
with	IN	p	O
a	DT	p	O
history	NN	p	O
of	IN	p	O
no	DT	p	O
prior	JJ	p	O
treatment	NN	p	O
or	CC	p	O
inadequate	JJ	p	O
treatment	NN	p	O
who	WP	p	O
were	VBD	p	O
treated	VBN	p	O
with	IN	p	O
a	DT	p	O
combination	NN	p	O
of	IN	p	O
olanzapine	NN	i	IPM
and	CC	p	O
sertraline	NN	i	IPM
.	.	i	O

A	DT	O	O
low	JJ	o	OPH
remission	NN	o	OPH
rate	NN	o	OPH
was	VBD	O	O
observed	VBN	O	O
in	IN	O	O
subjects	NNS	p	O
who	WP	p	O
had	VBD	p	O
previously	RB	p	O
failed	VBN	p	O
to	TO	p	O
respond	VB	p	O
to	TO	p	O
an	DT	p	O
antidepressant	JJ	p	O
alone	NN	p	O
and	CC	p	O
who	WP	p	O
were	VBD	p	O
treated	VBN	p	O
with	IN	p	O
olanzapine	JJ	i	IPM
monotherapy	NN	p	O
.	.	p	O

A	DT	O	O
low	JJ	o	OPH
remission	NN	o	OPH
rate	NN	o	OPH
was	VBD	O	O
also	RB	O	O
observed	VBN	O	O
in	IN	O	O
subjects	NNS	p	O
who	WP	p	O
had	VBD	p	O
previously	RB	p	O
failed	VBN	p	O
to	TO	p	O
respond	VB	p	O
to	TO	p	O
a	DT	p	O
combination	NN	p	O
of	IN	p	O
an	DT	p	O
antipsychotic	JJ	p	O
and	CC	p	O
an	DT	p	O
antidepressant	NN	p	O
.	.	p	O

Similar	JJ	O	O
to	TO	O	O
patients	NNS	O	O
with	IN	O	O
major	JJ	O	O
depression	NN	O	O
,	,	O	O
these	DT	O	O
results	NNS	O	O
emphasize	VBP	O	O
the	DT	O	O
impact	NN	o	OPH
of	IN	o	OPH
prior	JJ	o	OPH
pharmacotherapy	NN	o	OPH
on	IN	O	O
treatment	NN	o	O
outcomes	NNS	o	O
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
MDpsy	NNP	p	PC
.	.	p	O

A	DT	O	O
randomized	JJ	O	O
parallel	NN	O	O
study	NN	O	O
to	TO	O	O
assess	VB	O	O
the	DT	O	O
safety	NN	o	OOt
and	CC	o	OOt
efficacy	NN	o	OOt
of	IN	O	O
two	CD	O	O
different	JJ	O	O
dosing	VBG	O	O
regimens	NNS	O	O
of	IN	O	O
5	CD	O	O
%	NN	O	O
imiquimod	NN	i	IPM
in	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
superficial	JJ	p	O
basal	NN	p	O
cell	NN	p	O
carcinoma	NN	p	O
.	.	p	O

OBJECTIVES	CC	O	O
This	DT	O	O
study	NN	O	O
was	VBD	O	O
designed	VBN	O	O
to	TO	O	O
compare	VB	O	O
the	DT	O	O
safety	NN	o	OOt
and	CC	o	OOt
efficacy	NN	o	OOt
of	IN	O	O
two	CD	O	O
cycled	VBD	O	O
dosing	VBG	O	O
regimens	NNS	O	O
of	IN	O	O
imiquimod	JJ	i	IPM
5	CD	O	O
%	NN	O	O
cream	NN	O	O
for	IN	O	O
treatment	NN	O	O
of	IN	O	O
superficial	JJ	p	O
basal	NN	p	O
cell	NN	p	O
carcinoma	NN	p	O
(	(	p	O
sBCC	NN	p	O
)	)	p	O
.	.	p	O

METHODS	JJ	O	O
Patients	NNPS	p	O
(	(	p	O
n	JJ	p	O
=	NNP	p	O
32	CD	p	O
)	)	p	O
were	VBD	O	O
randomized	VBN	O	O
to	TO	O	O
receive	VB	O	O
one	CD	O	O
of	IN	O	O
two	CD	O	O
treatment	NN	O	O
regimens	NNS	O	O
:	:	O	O
8	CD	i	IPM
weeks	NNS	i	IPM
of	IN	i	IPM
treatment	NN	i	IPM
with	IN	i	IPM
once-daily	JJ	i	IPM
dosing	VBG	i	IPM
for	IN	i	IPM
alternate	JJ	i	IPM
weeks	NNS	i	IPM
(	(	i	IPM
R1	NNP	i	IPM
)	)	i	IPM
and	CC	i	O
5	CD	i	O
weeks	NNS	i	O
of	IN	i	O
once-daily	JJ	i	O
dosing	NN	i	O
with	IN	i	O
a	DT	i	O
1-week	JJ	i	O
interval	NN	i	O
in	IN	i	O
the	DT	i	O
middle	NN	i	O
of	IN	i	O
the	DT	i	O
course	NN	i	O
(	(	O	O
R2	NNP	O	O
)	)	O	O
.	.	O	O

Efficacy	NN	O	O
measures	NNS	O	O
were	VBD	O	O
tumour	JJ	o	OPH
clearance	NN	o	OPH
at	IN	O	O
weeks	NNS	O	O
19	CD	O	O
and	CC	O	O
52	CD	O	O
and	CC	O	O
measures	NNS	o	OOt
of	IN	o	OOt
patients	NNS	o	OOt
'	POS	o	OOt
acceptability	NN	o	OOt
.	.	o	O

RESULTS	NNP	O	O
Data	NNP	O	O
from	IN	O	O
30	CD	p	O
patients	NNS	p	O
(	(	p	O
13	CD	p	O
females	NNS	p	O
)	)	p	O
,	,	p	O
14	CD	p	O
on	IN	p	O
R1	NNP	p	O
and	CC	p	O
16	CD	p	O
on	IN	p	O
R2	NNP	p	O
,	,	O	O
were	VBD	O	O
analysed	VBN	O	O
.	.	O	O

The	DT	O	O
results	NNS	O	O
revealed	VBD	O	O
an	DT	O	O
initial	JJ	O	O
clearance	NN	o	OPH
rate	NN	o	OPH
of	IN	O	O
64	CD	O	O
%	NN	O	O
at	IN	O	O
week	NN	O	O
19	CD	O	O
for	IN	O	O
R1	NNP	O	O
and	CC	O	O
81	CD	O	O
%	NN	O	O
for	IN	O	O
R2	NNP	O	O
(	(	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
for	IN	O	O
difference	NN	O	O
:	:	O	O
-14	NN	O	O
%	NN	O	O
to	TO	O	O
45	CD	O	O
%	NN	O	O
,	,	O	O
p	NN	O	O
=	NNP	O	O
0.21	CD	O	O
)	)	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
clearance	NN	o	OPH
rates	NNS	o	OPH
at	IN	O	O
week	NN	O	O
52	CD	O	O
were	VBD	O	O
significantly	RB	O	O
different	JJ	O	O
:	:	O	O
43	CD	O	O
%	NN	O	O
for	IN	O	O
R1	NNP	O	O
and	CC	O	O
88	CD	O	O
%	NN	O	O
for	IN	O	O
R2	NNP	O	O
(	(	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
for	IN	O	O
difference	NN	O	O
:	:	O	O
11	CD	O	O
%	NN	O	O
to	TO	O	O
68	CD	O	O
%	NN	O	O
,	,	O	O
p	NN	O	O
=	NNP	O	O
0.02	CD	O	O
)	)	O	O
.	.	O	O

There	EX	O	O
was	VBD	O	O
no	DT	O	O
difference	NN	O	O
in	IN	O	O
acceptability	NN	o	OOt
of	IN	o	OOt
treatment	NN	o	OOt
as	IN	O	O
measured	VBN	O	O
by	IN	O	O
composite	JJ	O	O
median	JJ	O	O
visual	JJ	O	O
analogue	NN	O	O
scores	NNS	O	O
at	IN	O	O
week	NN	O	O
8	CD	O	O
.	.	O	O

CONCLUSION	NNP	O	O
Five	NNP	O	O
weeks	NNS	O	O
of	IN	O	O
5	CD	O	O
%	NN	O	O
imiquimod	JJ	i	IPM
cream	NN	O	O
once	RB	O	O
daily	JJ	O	O
with	IN	O	O
a	DT	O	O
1-week	JJ	O	O
interval	NN	O	O
was	VBD	O	O
more	RBR	O	O
effective	JJ	o	OOt
but	CC	O	O
as	RB	O	O
well	RB	o	OOt
tolerated	VBN	o	OOt
as	IN	O	O
the	DT	O	O
8-week	JJ	O	O
alternate	NN	O	O
week	NN	O	O
regimen	NNS	O	O
for	IN	O	O
sBCC	NN	p	O
.	.	p	O

Utilization	NN	O	O
patterns	NNS	O	O
of	IN	O	O
conventional	JJ	i	IC
and	CC	i	O
complementary/alternative	JJ	i	IOt
treatments	NNS	i	IOt
in	IN	O	O
children	NNS	p	PA
with	IN	p	O
autism	NN	p	PC
spectrum	NN	p	O
disorders	NNS	p	O
and	CC	p	O
developmental	JJ	p	O
disabilities	NNS	p	O
in	IN	p	O
a	DT	p	O
population-based	JJ	p	O
study	NN	p	O
.	.	p	O

OBJECTIVE	NNP	O	O
To	TO	O	O
compare	VB	O	O
the	DT	O	O
utilization	NN	O	O
of	IN	O	O
conventional	JJ	i	IC
treatments	NNS	i	IC
and	CC	i	O
utilization	NN	i	O
of	IN	i	O
complementary	JJ	i	IPM
and	CC	i	IPM
alternative	JJ	i	IPM
medicine	NN	i	IPM
in	IN	O	O
preschoolers	NNS	p	PA
with	IN	p	O
autism	NN	p	O
spectrum	NN	p	O
disorders	NNS	p	O
(	(	p	O
ASD	NNP	p	O
)	)	p	O
and	CC	p	O
other	JJ	p	O
developmental	JJ	p	O
disabilities	NNS	p	O
(	(	p	O
DD	NNP	p	O
)	)	p	O
.	.	p	O

METHODS	JJ	O	O
Participants	NNS	p	O
were	VBD	p	O
578	CD	p	PSS
children	NNS	p	PA
who	WP	p	O
were	VBD	p	O
part	NN	p	O
of	IN	p	O
an	DT	p	O
ongoing	JJ	p	O
population-based	JJ	p	O
,	,	p	O
case-control	JJ	p	O
study	NN	p	O
of	IN	p	O
2-	JJ	p	PA
to	TO	p	PA
5-year	JJ	p	PA
olds	NNS	p	PA
with	IN	p	O
ASD	NNP	p	O
,	,	p	O
DD	NNP	p	O
,	,	p	O
and	CC	p	O
the	DT	p	O
general	JJ	p	O
population	NN	p	O
.	.	p	O

Parents	NNS	O	O
completed	VBD	O	O
an	DT	O	O
interview	NN	O	O
on	IN	O	O
past	JJ	O	O
and	CC	O	O
current	JJ	O	O
services	NNS	O	O
.	.	O	O

RESULTS	NNP	O	O
Four	CD	p	PSS
hundred	VBD	p	PSS
fifty-three	JJ	p	PSS
children	NNS	p	O
with	IN	p	O
ASD	NNP	p	O
and	CC	p	O
125	CD	p	PSS
DD	NNP	p	O
children	NNS	p	PA
were	VBD	p	O
included	VBN	p	O
.	.	p	O

ASD	NNP	O	O
families	NNS	O	O
received	VBD	O	O
more	RBR	O	O
hours	NNS	O	O
of	IN	O	O
conventional	JJ	o	OOt
services	NNS	o	OOt
compared	VBN	O	O
with	IN	O	O
DD	NNP	O	O
families	NNS	O	O
(	(	O	O
17.8	CD	O	O
vs	RB	O	O
11	CD	O	O
;	:	O	O
p	NN	O	O
<	NNP	O	O
.001	NNP	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
use	NN	O	O
of	IN	O	O
psychotropic	NN	O	O
medications	NNS	O	O
was	VBD	O	O
low	JJ	O	O
in	IN	O	O
both	DT	O	O
groups	NNS	O	O
(	(	O	O
approximately	RB	O	O
3	CD	O	O
%	NN	O	O
)	)	O	O
.	.	O	O

Overall	JJ	O	O
,	,	O	O
complementary	JJ	o	OOt
and	CC	o	OOt
alternative	JJ	o	OOt
medicine	NN	o	OOt
(	(	o	OOt
CAM	NNP	o	OOt
)	)	o	OOt
use	NN	O	O
was	VBD	O	O
not	RB	O	O
significantly	RB	O	O
different	JJ	O	O
in	IN	O	O
ASD	NNP	O	O
(	(	O	O
39	CD	O	O
%	NN	O	O
)	)	O	O
versus	NN	O	O
DD	NNP	O	O
(	(	O	O
30	CD	O	O
%	NN	O	O
)	)	O	O
.	.	O	O

Hispanic	JJ	p	O
families	NNS	p	O
in	IN	O	O
both	DT	O	O
groups	NNS	O	O
used	VBD	O	O
CAM	NNP	o	OOt
less	RBR	O	O
often	RB	O	O
than	IN	O	O
non-Hispanic	JJ	p	O
families	NNS	p	O
.	.	p	O

Variables	NNS	O	O
such	JJ	O	O
as	IN	O	O
level	NN	o	OPH
of	IN	o	OPH
function	NN	o	OPH
,	,	o	OPH
immunization	NN	o	OPH
status	NN	o	OPH
,	,	o	OPH
and	CC	o	OPH
the	DT	o	OPH
presence	NN	o	OPH
of	IN	o	OPH
an	DT	o	OPH
identified	VBN	o	OPH
neurogenetic	JJ	o	OPH
disorder	NN	o	OPH
were	VBD	O	O
not	RB	O	O
predictive	JJ	O	O
of	IN	O	O
CAM	NNP	i	IPM
use	NN	O	O
.	.	O	O

A	DT	O	O
higher	JJR	O	O
level	NN	o	OOt
of	IN	o	OOt
parental	JJ	o	OOt
education	NN	o	OOt
was	VBD	O	O
associated	VBN	O	O
with	IN	O	O
an	DT	O	O
increased	VBN	O	O
CAM	NNP	o	OOt
use	NN	O	O
in	IN	O	O
ASD	NNP	O	O
and	CC	O	O
DD	NNP	O	O
.	.	O	O

Families	NNS	p	O
who	WP	O	O
used	VBD	O	O
>	$	O	O
20	CD	O	O
hours	NNS	O	O
per	IN	O	O
week	NN	O	O
of	IN	O	O
conventional	JJ	i	IPH
services	NNS	i	IPH
were	VBD	O	O
more	RBR	O	O
likely	JJ	O	O
to	TO	O	O
use	VB	O	O
CAM	NNP	i	IPM
,	,	O	O
including	VBG	O	O
potentially	RB	O	O
unsafe	JJ	O	O
or	CC	O	O
disproven	JJ	O	O
CAM	NNP	i	IPM
.	.	i	O

Underimmunized	VBN	p	O
children	NNS	p	PA
were	VBD	O	O
marginally	RB	O	O
more	RBR	O	O
likely	JJ	O	O
to	TO	O	O
use	VB	O	O
CAM	NNP	i	IPM
but	CC	O	O
not	RB	O	O
more	RBR	O	O
likely	JJ	O	O
to	TO	O	O
have	VB	O	O
received	VBN	O	O
potentially	RB	O	O
unsafe	JJ	O	O
or	CC	O	O
disproven	JJ	O	O
CAM	NNP	i	IPM
.	.	i	O

CONCLUSION	NNP	O	O
Use	NNP	O	O
of	IN	O	O
CAM	NNP	i	IPM
is	VBZ	O	O
common	JJ	O	O
in	IN	O	O
families	NNS	p	O
of	IN	p	O
young	JJ	p	PA
children	NNS	p	PA
with	IN	p	O
neurodevelopmental	JJ	p	O
disorders	NNS	p	O
,	,	O	O
and	CC	O	O
it	PRP	O	O
is	VBZ	O	O
predicted	VBN	O	O
by	IN	O	O
higher	JJR	O	O
parental	JJ	O	O
education	NN	O	O
and	CC	O	O
non-Hispanic	JJ	O	O
ethnicity	NN	O	O
but	CC	O	O
not	RB	O	O
developmental	JJ	O	O
characteristics	NNS	O	O
.	.	O	O

Further	NNP	O	O
research	NN	O	O
should	MD	O	O
address	VB	O	O
how	WRB	O	O
health	NN	O	O
care	NN	O	O
providers	NNS	O	O
can	MD	O	O
support	VB	O	O
families	NNS	O	O
in	IN	O	O
making	VBG	O	O
decisions	NNS	O	O
about	IN	O	O
CAM	NNP	i	IPM
use	NN	O	O
.	.	O	O

Long-term	JJ	o	O
outcome	NN	o	O
of	IN	O	O
migraine	JJ	i	IPM
therapy	NN	i	IPM
:	:	i	O
predictive	JJ	O	O
value	NN	O	O
of	IN	O	O
the	DT	O	O
frontotemporal	JJ	i	IPM
nitroglycerin	JJ	i	IPM
test	NN	i	IPM
.	.	i	O

We	PRP	O	O
evaluated	VBD	O	O
whether	IN	O	O
type	NN	O	O
of	IN	O	O
response	NN	O	O
to	TO	O	O
the	DT	O	O
migraine-induction	JJ	O	O
test	NN	O	O
with	IN	O	O
a	DT	O	O
nitroglycerin	JJ	i	IPM
ointment	NN	i	IPM
applied	VBN	O	O
to	TO	O	O
the	DT	O	O
frontotemporal	JJ	O	O
head	NN	O	O
region	NN	O	O
could	MD	O	O
predict	VB	o	OOt
the	DT	o	OOt
efficacy	NN	o	OOt
of	IN	o	OOt
antimigraine	JJ	o	OOt
therapy	NN	o	OOt
.	.	o	O

Forty-two	JJ	p	PSS
patients	NNS	p	O
with	IN	p	O
migraine	NN	p	O
without	IN	p	O
aura	JJ	p	O
underwent	NN	p	O
the	DT	p	O
test	NN	p	O
before	IN	p	O
and	CC	p	O
2	CD	p	O
months	NNS	p	O
after	IN	p	O
antimigraine	JJ	i	IPM
therapy	NN	i	IPM
.	.	i	O

Two	CD	O	O
and	CC	O	O
4	CD	O	O
months	NNS	O	O
after	IN	O	O
treatment	NN	O	O
withdrawal	NN	O	O
,	,	O	O
most	RBS	O	O
subjects	NNS	O	O
with	IN	O	O
a	DT	O	O
negative	JJ	O	O
response	NN	O	O
to	TO	O	O
the	DT	O	O
post-treatment	JJ	O	O
test	NN	O	O
maintained	VBD	o	OOt
treatment	NN	o	OOt
benefit	NN	o	OOt
,	,	O	O
whereas	JJ	O	O
benefit	NN	o	O
was	VBD	O	O
lost	VBN	O	O
in	IN	O	O
patients	NNS	O	O
with	IN	O	O
an	DT	O	O
early	JJ	o	OPH
onset	NN	o	OPH
migraine	NN	o	OPH
response	NN	o	OPH
.	.	o	OME

Preliminary	JJ	O	O
findings	NNS	O	O
from	IN	O	O
a	DT	O	O
prospective	JJ	O	O
,	,	O	O
randomized	JJ	O	O
trial	NN	O	O
of	IN	O	O
two	CD	O	O
palatal	JJ	i	IS
operations	NNS	i	IS
for	IN	O	O
sleep-disordered	JJ	O	O
breathing	NN	O	O
.	.	O	O

OBJECTIVES	IN	O	O
We	PRP	O	O
compared	VBN	O	O
the	DT	O	O
efficacy	NN	o	OOt
of	IN	O	O
2	CD	i	IS
palatal	JJ	i	IS
surgical	JJ	i	IS
procedures	NNS	i	IS
in	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
patients	NNS	p	O
with	IN	p	O
mild	JJ	p	PC
sleep-disordered	JJ	p	PC
breathing	NN	p	PC
(	(	p	PC
SDB	NNP	p	PC
)	)	p	PC
.	.	p	O

STUDY	NNP	O	O
DESIGN	NNP	O	O
AND	NNP	O	O
SETTING	NNP	O	O
We	PRP	O	O
conducted	VBD	O	O
a	DT	O	O
prospective	JJ	O	O
,	,	O	O
randomized	VBN	O	O
,	,	O	O
crossover	RB	O	O
surgical	JJ	O	O
trial	NN	O	O
at	IN	O	O
a	DT	O	O
university	NN	O	O
hospital	NN	O	O
.	.	O	O

METHODS	NNP	O	O
Twenty	NNP	p	PSS
patients	NNS	p	O
with	IN	p	O
mild	JJ	p	O
SDB	NNP	p	O
for	IN	p	O
whom	WP	p	O
conservative	JJ	p	O
treatment	NN	p	O
failed	VBD	p	O
were	VBD	O	O
identified	VBN	O	O
and	CC	O	O
consecutively	RB	O	O
enrolled	VBD	O	O
into	IN	O	O
an	DT	O	O
institutional	JJ	O	O
review	NN	O	O
board-approved	JJ	O	O
surgical	JJ	O	O
protocol	NN	O	O
.	.	O	O

They	PRP	O	O
were	VBD	O	O
randomly	RB	O	O
assigned	VBN	O	O
to	TO	O	O
undergo	VB	O	O
either	DT	O	O
radiofrequency	NN	i	IS
ablation	NN	i	IS
of	IN	i	IS
the	DT	i	IS
palate	NN	i	IS
(	(	i	IS
RFAP	NNP	i	IS
)	)	i	IS
for	IN	i	IS
a	DT	i	IS
planned	JJ	i	IS
3-stage	JJ	i	IS
treatment	NN	i	IS
or	CC	i	O
laser-assisted	JJ	i	IS
uvulopalatoplasty	JJ	i	IS
(	(	i	IS
LAUP	NNP	i	IS
)	)	i	IS
,	,	i	IS
also	RB	i	IS
for	IN	i	IS
3	CD	i	IS
stages	NNS	i	IS
of	IN	i	IS
treatment	NN	i	IS
,	,	i	IS
using	VBG	i	IS
a	DT	i	IS
CO	NNP	i	IS
(	(	i	IS
2	CD	i	IS
)	)	i	IS
laser	NN	i	IS
.	.	i	IPH

Parameters	NNS	O	O
assessed	VBD	O	O
included	JJ	O	O
severity	NN	o	OPH
of	IN	o	OPH
SDB	NNP	o	OPH
(	(	o	OPH
polysomnography	NN	o	OPH
)	)	o	OPH
,	,	o	OPH
subjective	JJ	o	OPH
and	CC	o	OPH
objective	JJ	o	OPH
loudness	NN	o	OPH
of	IN	o	OPH
snoring	VBG	o	OPH
(	(	o	O
visual	JJ	o	O
analog	NN	o	O
scale	NN	o	O
and	CC	o	O
SNAP	NNP	o	O
recording	NN	o	O
)	)	o	O
,	,	o	O
sleepiness	NN	o	OPH
(	(	o	OPH
Epworth	NNP	o	OPH
Sleepiness	NNP	o	OPH
Scale	NNP	o	OPH
)	)	o	OPH
,	,	O	O
and	CC	O	O
anatomic	JJ	o	OPH
changes	NNS	o	OPH
(	(	o	OPH
upper	JJ	o	OPH
airway	RB	o	OPH
endoscopy	NN	o	OPH
)	)	o	OPH
,	,	O	O
as	RB	O	O
well	RB	O	O
as	IN	O	O
demographic	JJ	O	O
factors	NNS	O	O
.	.	O	O

Patients	NNS	O	O
not	RB	O	O
achieving	VBG	O	O
satisfactory	JJ	O	O
improvement	NN	O	O
in	IN	O	O
their	PRP$	O	O
condition	NN	O	O
were	VBD	O	O
crossed	VBN	O	O
over	IN	O	O
to	TO	O	O
the	DT	O	O
alternative	JJ	i	IS
surgical	JJ	i	IS
therapy	NN	i	IS
for	IN	i	IS
attempted	JJ	i	IS
salvage	NN	i	IS
.	.	i	O

RESULTS	NNP	O	O
Seventeen	NNP	O	O
of	IN	O	O
the	DT	O	O
enrolled	JJ	O	O
patients	NNS	O	O
have	VBP	O	O
completed	VBN	O	O
the	DT	O	O
protocol	NN	O	O
.	.	O	O

Ten	CD	O	O
of	IN	O	O
these	DT	O	O
were	VBD	O	O
randomized	VBN	O	O
to	TO	O	O
the	DT	O	O
RFAP	NNP	i	IPH
group	NN	O	O
,	,	O	O
and	CC	O	O
7	CD	O	O
to	TO	O	O
the	DT	O	O
LAUP	NNP	i	IS
group	NN	O	O
.	.	O	O

Six	CD	O	O
of	IN	O	O
the	DT	O	O
RFAP	NNP	i	IS
patients	NNS	O	O
(	(	O	O
60	CD	O	O
%	NN	O	O
)	)	O	O
achieved	VBD	O	O
a	DT	O	O
satisfactory	JJ	O	O
resolution	NN	O	O
of	IN	O	O
their	PRP$	O	O
snoring	NN	o	OPH
,	,	O	O
and	CC	O	O
4	CD	O	O
failed	VBD	O	O
and	CC	O	O
were	VBD	O	O
salvaged	VBN	O	O
with	IN	O	O
LAUP	NNP	i	IS
.	.	i	O

Six	NNP	O	O
of	IN	O	O
the	DT	O	O
LAUP	NNP	i	IS
patients	NNS	O	O
(	(	O	O
86	CD	O	O
%	NN	O	O
)	)	O	O
achieved	VBD	O	O
a	DT	O	O
satisfactory	JJ	O	O
resolution	NN	O	O
of	IN	O	O
their	PRP$	O	O
snoring	NN	o	OPH
,	,	O	O
and	CC	O	O
1	CD	O	O
patient	NN	O	O
failed	VBD	O	O
and	CC	O	O
was	VBD	O	O
salvaged	VBN	O	O
with	IN	O	O
nasal	JJ	i	IS
surgery	NN	i	IS
.	.	i	O

One	CD	O	O
patient	NN	O	O
who	WP	O	O
was	VBD	O	O
initially	RB	O	O
cured	VBN	O	O
had	VBD	O	O
a	DT	O	O
relapse	NN	O	O
after	IN	O	O
9	CD	O	O
months	NNS	O	O
and	CC	O	O
was	VBD	O	O
successfully	RB	O	O
salvaged	VBN	O	O
with	IN	O	O
RFA	NNP	i	IS
.	.	i	O

CONCLUSION	NNP	O	O
Prospective	NNP	O	O
,	,	O	O
randomized	VBD	O	O
trials	NNS	O	O
of	IN	O	O
surgery	NN	O	O
for	IN	O	O
SDB	NNP	O	O
are	VBP	O	O
possible	JJ	O	O
.	.	O	O

Preliminary	JJ	O	O
findings	NNS	O	O
from	IN	O	O
the	DT	O	O
current	JJ	O	O
protocol	NN	O	O
reveal	NN	O	O
a	DT	O	O
slight	JJ	O	O
advantage	NN	O	O
of	IN	O	O
LAUP	NNP	i	IS
over	IN	O	O
RFAP	NNP	i	IS
but	CC	O	O
with	IN	O	O
a	DT	O	O
greater	JJR	O	O
degree	NN	O	O
of	IN	O	O
discomfort	NN	O	O
postoperatively	RB	O	O
.	.	O	O

Monitoring	VBG	O	O
tumour	NN	O	O
cells	NNS	O	O
in	IN	O	O
the	DT	O	O
peripheral	JJ	O	O
blood	NN	O	O
of	IN	O	O
small	JJ	p	O
cell	NN	p	O
lung	NN	p	O
cancer	NN	p	O
patients	NNS	p	O
.	.	p	O

BACKGROUND	NNP	O	O
Flow	NNP	i	IOt
cytometry	NN	i	IOt
was	VBD	O	O
used	VBN	O	O
to	TO	O	O
enumerate	VB	O	O
tumour	JJ	O	O
cells	NNS	O	O
in	IN	O	O
longitudinal	JJ	O	O
studies	NNS	O	O
of	IN	O	O
peripheral	JJ	O	O
blood	NN	O	O
from	IN	O	O
small	JJ	p	O
cell	NN	p	O
lung	NN	p	O
cancer	NN	p	O
(	(	p	O
SCLC	NNP	p	O
)	)	p	O
patients	NNS	p	O
,	,	O	O
together	RB	O	O
with	IN	O	O
magnetic	JJ	O	O
bead	NN	O	O
selection	NN	O	O
to	TO	O	O
isolate	VB	O	O
and	CC	O	O
identify	VB	O	O
these	DT	O	O
cells	NNS	O	O
.	.	O	O

As	IN	O	O
part	NN	O	O
of	IN	O	O
a	DT	O	O
trial	NN	O	O
,	,	O	O
11	CD	p	O
patients	NNS	p	O
received	VBD	p	O
either	RB	p	O
standard	JJ	p	O
(	(	p	O
four	CD	p	O
weekly	RB	p	O
)	)	p	O
chemotherapy	NN	i	IPM
with	IN	i	O
ifosfamide	NN	i	IPM
,	,	i	O
carboplatin	NN	i	IPM
,	,	i	O
and	CC	i	O
etoposide	RB	i	IPM
(	(	i	IPM
ICE	NNP	i	IPM
)	)	i	IPM
or	CC	i	O
accelerated	VBN	i	O
(	(	i	O
two	CD	i	O
weekly	RB	i	O
)	)	i	O
ICE	NNP	i	IPM
with	IN	i	IPM
filgrastim	NN	i	IPM
(	(	i	IPM
granulocyte	JJ	i	IPM
colony-stimulating	NN	i	IPM
factor	NN	i	IPM
[	IN	i	IPM
G-CSF	NNP	i	IPM
]	NNP	i	IPM
)	)	i	IPM
and	CC	i	O
autologous	JJ	i	IPM
stem	NN	i	IPM
cell	NN	i	IPM
support	NN	i	IPM
.	.	i	O

METHODS	NNP	O	O
Fresh	NNP	O	O
venous	JJ	O	O
blood	NN	O	O
was	VBD	O	O
taken	VBN	O	O
throughout	IN	O	O
treatment	NN	O	O
and	CC	O	O
follow-up	NN	O	O
.	.	O	O

Aliquots	NNS	O	O
were	VBD	O	O
stained	VBN	O	O
with	IN	O	O
a	DT	O	O
tumour-specific	JJ	O	O
antibody	NN	O	O
against	IN	O	O
epithelial	JJ	O	O
tissue	NN	O	O
(	(	O	O
Ber	NNP	O	O
EP4	NNP	O	O
)	)	O	O
,	,	O	O
verified	VBD	O	O
as	IN	O	O
a	DT	O	O
good	JJ	O	O
marker	NN	O	O
of	IN	O	O
SCLC	NNP	O	O
cells	NNS	O	O
by	IN	O	O
immunohistochemistry	NN	O	O
.	.	O	O

Matched	NNP	O	O
samples	NNS	O	O
labelled	VBD	O	O
with	IN	O	O
Ber	NNP	O	O
EP4	NNP	O	O
were	VBD	O	O
separated	VBN	O	O
magnetically	RB	O	O
by	IN	O	O
adding	VBG	O	O
a	DT	O	O
secondary	JJ	O	O
bead-antibody	NN	O	O
conjugate	NN	O	O
for	IN	O	O
confirmation	NN	O	O
of	IN	O	O
tumour	NN	O	O
cell	NN	O	O
identity	NN	O	O
.	.	O	O

RESULTS	NNP	O	O
Circulating	NNP	o	OPH
tumour	JJ	o	OPH
cells	NNS	o	OPH
were	VBD	O	O
detected	VBN	O	O
and	CC	O	O
monitored	VBN	O	O
throughout	IN	O	O
treatment	NN	O	O
periods	NNS	O	O
.	.	O	O

An	DT	O	O
initial	JJ	o	O
rise	NN	o	O
in	IN	o	O
circulating	VBG	o	OPH
cells	NNS	o	OPH
after	IN	o	O
the	DT	o	O
first	JJ	o	O
cycle	NN	o	O
was	VBD	O	O
followed	VBN	O	O
by	IN	O	O
a	DT	O	O
fall	NN	O	O
in	IN	O	O
both	DT	O	O
treatment	NN	O	O
arms	NNS	O	O
to	TO	O	O
baseline	NN	O	O
levels	NNS	O	O
set	VBN	O	O
by	IN	O	O
normal	JJ	O	O
controls	NNS	O	O
.	.	O	O

This	DT	O	O
was	VBD	O	O
achieved	VBN	O	O
by	IN	O	O
week	NN	O	O
12	CD	O	O
in	IN	O	O
the	DT	O	O
accelerated	JJ	O	O
treatment	NN	O	O
arm	NN	O	O
and	CC	O	O
by	IN	O	O
week	NN	O	O
24	CD	O	O
in	IN	O	O
the	DT	O	O
standard	JJ	O	O
arm	NN	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
Flow	NNP	O	O
cytometry	NN	O	O
and	CC	O	O
magnetic	JJ	O	O
bead	NN	O	O
isolation	NN	O	O
can	MD	O	O
be	VB	O	O
used	VBN	O	O
to	TO	O	O
identify	VB	O	O
changes	NNS	O	O
in	IN	O	O
numbers	NNS	O	O
of	IN	O	O
circulating	VBG	O	O
tumour	JJ	O	O
cells	NNS	O	O
in	IN	O	O
patients	NNS	O	O
undergoing	JJ	O	O
chemotherapy	NN	i	IPM
for	IN	O	O
SCLC	NNP	O	O
and	CC	O	O
thereafter	RB	O	O
during	IN	O	O
follow-up	JJ	O	O
periods	NNS	O	O
.	.	O	O

Absence	NN	O	O
of	IN	O	O
tumour	JJ	O	O
cells	NNS	O	O
may	MD	O	O
indicate	VB	O	O
a	DT	O	O
more	RBR	O	O
favourable	JJ	O	O
patient	NN	O	O
group	NN	O	O
who	WP	O	O
would	MD	O	O
benefit	VB	O	O
from	IN	O	O
a	DT	O	O
more	RBR	O	O
intense	JJ	O	O
course	NN	O	O
of	IN	O	O
treatment	NN	O	O
.	.	O	O

A	DT	O	O
comparison	NN	O	O
of	IN	O	O
a	DT	O	O
spiritually	RB	i	IE
based	VBN	i	IE
and	CC	i	IE
non-spiritually	RB	i	IE
based	VBN	i	IE
educational	JJ	i	IE
intervention	NN	i	IE
for	IN	O	O
informed	JJ	O	O
decision	NN	O	O
making	NN	O	O
for	IN	O	O
prostate	NN	O	O
cancer	NN	O	O
screening	VBG	O	O
among	IN	O	O
church-attending	JJ	p	O
African-American	JJ	p	O
men	NNS	p	PSE
.	.	p	O

INTRODUCTION	NNP	O	O
Health	NNP	i	IE
communication	NN	i	IE
interventions	NNS	i	IE
have	VBP	O	O
been	VBN	O	O
modestly	RB	O	O
effective	JJ	O	O
for	IN	O	O
increasing	VBG	O	O
informed	JJ	O	O
decision	NN	O	O
making	NN	O	O
for	IN	O	O
prostate	NN	O	O
cancer	NN	O	O
screening	VBG	O	O
among	IN	p	O
African-American	JJ	p	O
men	NNS	p	PSE
;	:	p	O
however	RB	O	O
,	,	O	O
knowledge	NN	O	O
and	CC	O	O
informed	JJ	O	O
decision	NN	O	O
making	NN	O	O
is	VBZ	O	O
still	RB	O	O
questionable	JJ	O	O
even	RB	O	O
with	IN	O	O
screening	VBG	O	O
.	.	O	O

Church-based	JJ	O	O
programs	NNS	O	O
may	MD	O	O
be	VB	O	O
more	RBR	O	O
effective	JJ	O	O
if	IN	O	O
they	PRP	O	O
are	VBP	O	O
spiritually	RB	O	O
based	VBN	O	O
in	IN	O	O
nature	NN	O	O
.	.	O	O

OBJECTIVE	CC	O	O
The	DT	O	O
aims	NNS	O	O
of	IN	O	O
the	DT	O	O
present	JJ	O	O
study	NN	O	O
were	VBD	O	O
to	TO	O	O
implement	VB	O	O
and	CC	O	O
provide	VB	O	O
an	DT	O	O
initial	JJ	O	O
evaluation	NN	O	O
of	IN	O	O
a	DT	O	O
spiritually	RB	O	O
based	VBN	O	O
prostate	NN	O	O
cancer	NN	O	O
screening	VBG	O	O
informed	JJ	O	O
decision	NN	O	O
making	VBG	O	O
intervention	NN	O	O
for	IN	O	O
African-American	JJ	p	O
men	NNS	p	PSE
who	WP	p	O
attend	VBP	p	O
church	NN	p	O
,	,	O	O
and	CC	O	O
determine	VB	O	O
its	PRP$	O	O
efficacy	NN	O	O
for	IN	O	O
increasing	VBG	O	O
informed	JJ	O	O
decision	NN	O	O
making	NN	O	O
.	.	O	O

DESIGN	NNP	O	O
AND	CC	O	O
METHOD	NNP	O	O
Churches	NNP	p	O
were	VBD	O	O
randomized	VBN	O	O
to	TO	O	O
receive	VB	O	O
either	CC	O	O
the	DT	O	O
spiritually	RB	i	IE
based	VBN	i	IE
or	CC	i	IE
the	DT	i	IE
non-spiritual	JJ	i	IE
intervention	NN	i	IE
.	.	i	O

Trained	NNP	O	O
community	NN	O	O
health	NN	O	O
advisors	NNS	O	O
,	,	O	O
who	WP	O	O
were	VBD	O	O
African-American	JJ	O	O
male	JJ	O	O
church	NN	O	O
members	NNS	O	O
,	,	O	O
led	VBD	O	O
an	DT	O	O
educational	JJ	i	IE
session	NN	i	IE
and	CC	O	O
distributed	VBD	i	IE
educational	JJ	i	IE
print	NN	i	IE
materials	NNS	i	IE
.	.	i	IE

Participants	NNS	O	O
completed	VBD	O	O
baseline	NN	O	O
and	CC	O	O
immediate	JJ	O	O
follow-up	JJ	O	O
surveys	NNS	O	O
to	TO	O	O
assess	VB	O	O
the	DT	O	O
intervention	NN	O	O
impact	NN	O	O
on	IN	O	O
study	NN	O	O
outcomes	NNS	O	O
.	.	O	O

RESULTS	VB	O	O
The	DT	O	O
spiritually	RB	O	O
based	VBN	O	O
intervention	NN	O	O
appeared	VBD	O	O
to	TO	O	O
be	VB	O	O
more	RBR	O	O
effective	JJ	O	O
in	IN	O	O
areas	NNS	O	O
such	JJ	O	O
as	IN	O	O
knowledge	NN	O	O
,	,	O	O
and	CC	O	O
men	NNS	O	O
read	VBP	O	O
more	JJR	O	O
of	IN	O	O
their	PRP$	O	O
materials	NNS	o	OOt
in	IN	O	O
the	DT	O	O
spiritually	RB	O	O
based	VBN	O	O
group	NN	O	O
than	IN	O	O
in	IN	O	O
the	DT	O	O
non-spiritual	JJ	O	O
group	NN	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
Further	NNP	O	O
examination	NN	O	O
of	IN	O	O
the	DT	O	O
efficacy	NN	o	OOt
of	IN	O	O
the	DT	O	O
spiritually	RB	O	O
based	VBN	O	O
approach	NN	O	O
to	TO	O	O
health	NN	O	O
communication	NN	O	O
is	VBZ	O	O
warranted	VBN	O	O
.	.	O	O

Effect	NN	O	O
of	IN	O	O
ranolazine	NN	i	IPM
on	IN	O	O
A1C	NNP	O	O
and	CC	O	O
glucose	JJ	O	O
levels	NNS	O	O
in	IN	O	O
hyperglycemic	JJ	p	PC
patients	NNS	p	PC
with	IN	p	O
non-ST	JJ	p	O
elevation	NN	p	O
acute	NN	p	PC
coronary	JJ	p	PC
syndrome	NN	p	PC
.	.	p	O

OBJECTIVE	IN	O	O
We	PRP	O	O
determined	VBD	O	O
the	DT	O	O
relationships	NNS	O	O
between	IN	O	O
glycemia	NN	O	O
at	IN	O	O
randomization	NN	O	O
,	,	O	O
concurrent	JJ	i	IPM
antidiabetic	JJ	i	IPM
therapy	NN	i	IPM
,	,	O	O
and	CC	O	O
change	NN	O	O
in	IN	O	O
A1C	NNP	O	O
and	CC	O	O
fasting	VBG	O	O
plasma	NN	O	O
glucose	NN	O	O
(	(	O	O
FPG	NNP	O	O
)	)	O	O
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
diabetes	NNS	p	O
receiving	VBG	p	O
standard	JJ	p	O
treatment	NN	p	O
for	IN	p	O
diabetes	NNS	p	O
and	CC	p	O
randomized	VBN	p	O
to	TO	p	O
ranolazine	VB	i	IPM
or	CC	i	O
placebo	VB	i	IC
within	IN	p	O
the	DT	p	O
MERLIN-TIMI-36	NNP	p	O
(	(	p	O
MERLIN	NNP	p	O
)	)	p	O
study	NN	p	O
.	.	p	O

Ranolazine	NNP	i	IPM
is	VBZ	O	O
a	DT	O	O
novel	JJ	O	O
first-in-class	JJ	O	O
drug	NN	O	O
approved	VBD	O	O
for	IN	O	O
treating	VBG	O	O
angina	JJ	O	O
pectoris	NN	O	O
.	.	O	O

RESEARCH	NNP	O	O
DESIGN	NNP	O	O
AND	NNP	O	O
METHODS	NNP	O	O
Randomization	NNP	O	O
and	CC	O	O
4-month	JJ	O	O
glycemic	NN	i	O
and	CC	i	O
antidiabetes	VBZ	i	IPM
drug	NN	i	IPM
usage	NN	i	O
data	NNS	i	O
from	IN	O	O
MERLIN	NNP	O	O
were	VBD	O	O
analyzed	VBN	O	O
using	VBG	O	O
Spotfire	NNP	O	O
and	CC	O	O
SAS	NNP	O	O
version	NN	O	O
9.1	CD	O	O
software	NN	O	O
.	.	O	O

RESULTS	NNP	O	O
In	IN	O	O
patients	NNS	p	O
with	IN	p	O
diabetes	NNS	p	O
and	CC	p	O
A1C	NNP	p	O
of	IN	p	O
>	NNP	p	O
or=8-10	JJ	p	O
%	NN	p	O
at	IN	p	O
randomization	NN	p	O
(	(	p	O
n	JJ	p	O
=	NNP	p	O
171	CD	p	O
)	)	p	O
,	,	O	O
there	EX	O	O
was	VBD	O	O
an	DT	O	O
absolute	JJ	O	O
A1C	NNP	o	OPH
reduction	NN	o	OPH
in	IN	O	O
the	DT	O	O
ranolazine	NN	i	IPM
group	NN	O	O
of	IN	O	O
1.2	CD	O	O
%	NN	O	O
(	(	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
-1.4	NNP	O	O
to	TO	O	O
-1.0	VB	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
placebo-adjusted	JJ	i	IC
(	(	p	O
n	JJ	p	O
=	NNP	p	O
182	CD	p	O
)	)	p	O
decrease	NN	O	O
in	IN	O	O
A1C	NNP	o	OPH
by	IN	O	O
ranolazine	NN	O	O
was	VBD	O	O
0.59	CD	O	O
%	NN	O	O
(	(	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
-0.99	NNP	O	O
to	TO	O	O
-0.20	VB	O	O
,	,	O	O
P	NNP	O	O
<	NNP	O	O
0.001	CD	O	O
)	)	O	O
.	.	O	O

In	IN	O	O
patients	NNS	p	O
with	IN	p	O
FPG	NNP	p	O
of	IN	p	O
150-400	JJ	p	O
mg/dl	NN	p	O
at	IN	p	O
randomization	NN	p	O
,	,	p	O
ranolazine	NN	i	IPM
(	(	p	O
n	JJ	p	O
=	NNP	p	O
131	CD	p	O
)	)	p	O
compared	VBN	O	O
with	IN	O	O
placebo	NN	i	IC
(	(	p	O
n	JJ	p	O
=	NNP	p	O
147	CD	p	O
)	)	p	O
reduced	VBN	O	O
FPG	NNP	O	O
by	IN	O	O
25.7	CD	O	O
mg/dl	NNS	O	O
(	(	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
-43.3	NNP	O	O
to	TO	O	O
-8.1	VB	O	O
,	,	O	O
P	NNP	O	O
=	NNP	O	O
0.001	CD	O	O
)	)	O	O
.	.	O	O

When	WRB	O	O
changes	NNS	O	O
in	IN	O	O
either	DT	O	O
A1C	NNP	o	OPH
or	CC	o	O
FPG	NNP	o	OPH
were	VBD	O	O
correlated	VBN	O	O
to	TO	O	O
A1C	NNP	o	O
or	CC	o	O
FPG	NNP	o	O
at	IN	O	O
randomization	NN	O	O
,	,	O	O
the	DT	O	O
slopes	NNS	O	O
were	VBD	O	O
significantly	RB	O	O
steeper	JJR	O	O
for	IN	O	O
ranolazine	NN	i	IPM
than	IN	O	O
placebo	NN	i	IC
(	(	O	O
A1C	NNP	O	O
,	,	O	O
P	NNP	O	O
=	NNP	O	O
0.046	CD	O	O
;	:	O	O
FPG	NNP	O	O
,	,	O	O
P	NNP	O	O
<	NNP	O	O
0.001	CD	O	O
)	)	O	O
,	,	O	O
indicating	VBG	O	O
that	IN	O	O
lowering	VBG	O	O
of	IN	O	O
A1C	NNP	o	OPH
and	CC	o	O
FPG	NNP	o	OPH
by	IN	O	O
ranolazine	NN	i	IPM
is	VBZ	O	O
related	VBN	O	O
to	TO	O	O
hyperglycemia	VB	O	O
at	IN	O	O
randomization	NN	O	O
.	.	O	O

Ranolazine	NNP	O	O
,	,	O	O
compared	VBN	O	O
with	IN	O	O
placebo	NN	O	O
,	,	O	O
was	VBD	O	O
not	RB	O	O
associated	VBN	O	O
with	IN	O	O
serious	JJ	o	OA
hypoglycemic	JJ	o	OA
events	NNS	o	OA
,	,	O	O
associated	VBN	O	O
with	IN	O	O
significant	JJ	O	O
changes	NNS	O	O
in	IN	O	O
concurrent	JJ	o	O
antidiabetic	JJ	o	O
therapy	NN	o	O
,	,	O	O
or	CC	O	O
dependent	NN	O	O
on	IN	O	O
a	DT	O	O
history	NN	o	O
of	IN	o	O
angina	NN	o	O
.	.	o	O

CONCLUSIONS	NNP	O	O
Ranolazine	NNP	i	IPM
,	,	O	O
when	WRB	O	O
added	VBN	O	O
to	TO	O	O
concurrent	VB	O	O
antidiabetes	NNS	O	O
treatment	NN	O	O
,	,	O	O
lowers	NNS	O	O
FPG	NNP	o	OPH
and	CC	o	O
A1C	NNP	o	OPH
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
cardiovascular	JJ	p	O
disease	NN	p	O
and	CC	p	O
poorly	RB	p	O
controlled	VBN	p	O
diabetes	NNS	p	O
.	.	p	O

The	DT	O	O
effects	NNS	O	O
of	IN	O	O
peer	NN	i	IE
counseling	VBG	i	IE
on	IN	O	O
smoking	VBG	O	O
cessation	NN	o	OME
and	CC	O	O
reduction	NN	O	O
.	.	O	O

OBJECTIVE	UH	O	O
To	TO	O	O
evaluate	VB	O	O
a	DT	O	O
peer	NN	i	IE
counseling	VBG	i	IE
intervention	NN	i	IE
for	IN	O	O
pregnant	JJ	p	PC
smokers	NNS	p	PC
.	.	p	O

METHODS	NNP	O	O
One	CD	p	PSS
hundred	VBD	p	PSS
forty-two	NN	p	PSS
pregnant	NN	p	O
,	,	p	O
predominantly	RB	p	O
Hispanic	JJ	p	O
women	NNS	p	PSE
were	VBD	O	O
assigned	VBN	O	O
to	TO	O	O
a	DT	O	O
peer-led	JJ	i	IE
smoking	NN	i	IE
cessation	NN	i	IE
program	NN	i	IE
or	CC	i	IE
to	TO	i	IE
usual	JJ	i	IE
care	NN	i	IE
.	.	i	O

RESULTS	NNP	O	O
Compared	VBD	O	O
with	IN	O	O
usual	JJ	i	IE
care	NN	i	IE
,	,	i	IE
peer	NN	i	IE
counseling	NN	i	IE
reduced	VBN	O	O
smoking	NN	O	O
(	(	O	O
-9.1	JJ	O	O
versus	NN	O	O
-4.5	NNP	O	O
cigarettes	VBZ	O	O
daily	RB	O	O
,	,	O	O
P	NNP	O	O
=.03	NNP	O	O
)	)	O	O
,	,	O	O
but	CC	O	O
did	VBD	O	O
not	RB	O	O
affect	VB	O	O
absolute	JJ	O	O
quit	NN	o	OME
rates	NNS	o	OME
(	(	O	O
24	CD	O	O
%	NN	O	O
versus	IN	O	O
21	CD	O	O
%	NN	O	O
)	)	O	O
at	IN	O	O
36	CD	O	O
weeks	NNS	O	O
'	POS	O	O
gestation	NN	O	O
.	.	O	O

Infant	NNP	o	OPH
birth	NN	o	OPH
weight	VBD	o	OPH
negatively	RB	O	O
correlated	VBN	O	O
with	IN	O	O
cigarettes	NNS	O	O
smoked	VBN	O	O
per	IN	O	O
day	NN	O	O
(	(	O	O
r	VB	O	O
=	NNP	O	O
-0.29	NNP	O	O
,	,	O	O
P	NNP	O	O
<	NNP	O	O
.01	NNP	O	O
)	)	O	O
and	CC	O	O
expired	JJ	O	O
carbon	NN	O	O
monoxide	NN	O	O
(	(	O	O
r	JJ	O	O
=	NNP	O	O
-0.39	NN	O	O
,	,	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
.001	NNP	O	O
)	)	O	O
at	IN	O	O
delivery	NN	O	O
.	.	O	O

Birth	NNP	o	OPH
weight	VBD	o	OPH
for	IN	o	OPH
infants	NNS	o	OPH
born	VBN	o	OPH
to	TO	o	OPH
women	NNS	o	OPH
who	WP	o	OPH
quit	VBP	o	OPH
smoking	VBG	o	OPH
averaged	VBD	O	O
7.2	CD	O	O
lb	JJ	O	O
versus	NN	O	O
6.8	CD	O	O
and	CC	O	O
6.3	CD	O	O
lb	NN	O	O
for	IN	O	O
mothers	NNS	O	O
smoking	VBG	O	O
one	CD	O	O
to	TO	O	O
six	CD	O	O
and	CC	O	O
more	JJR	O	O
than	IN	O	O
six	CD	O	O
cigarettes	NNS	O	O
per	IN	O	O
day	NN	O	O
at	IN	O	O
delivery	NN	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
.01	NNP	O	O
)	)	O	O
.	.	O	O

CONCLUSION	NNP	O	O
Peer	NNP	o	OOt
counseling	NN	o	OOt
reduced	VBD	O	O
the	DT	O	O
number	NN	o	OME
of	IN	o	OME
cigarettes	NNS	o	OME
smoked	VBN	o	OME
daily	RB	o	OME
but	CC	O	O
did	VBD	O	O
not	RB	O	O
increase	VB	O	O
cigarette	NN	o	OME
abstinence	NN	o	OME
rates	NNS	o	OME
.	.	o	O

Infant	NNP	o	OPH
birth	NN	o	OPH
weight	NN	o	OPH
increases	NNS	O	O
with	IN	O	O
both	DT	O	O
smoking	VBG	O	O
cessation	NN	O	O
and	CC	O	O
smoking	NN	O	O
reduction	NN	O	O
,	,	O	O
suggesting	VBG	O	O
that	IN	O	O
peer	NN	i	IE
counseling	VBG	i	IE
intervention	NN	i	IE
programs	NNS	i	IE
may	MD	O	O
improve	VB	O	O
newborn	JJR	o	OPH
health	NN	o	OPH
despite	IN	O	O
their	PRP$	O	O
failure	NN	O	O
to	TO	O	O
affect	VB	O	O
smoking	VBG	O	O
cessation	NN	O	O
.	.	O	O

Roles	NNS	o	O
of	IN	o	O
adapalene	NN	o	O
in	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
pityriasis	NN	p	PC
versicolor	NN	p	PC
.	.	p	O

BACKGROUND	NNP	O	O
Ketoconazole	NNP	i	IPM
is	VBZ	O	O
a	DT	O	O
typical	JJ	O	O
treatment	NN	O	O
available	JJ	O	O
for	IN	O	O
pityriasis	NN	p	PC
versicolor	NN	p	PC
;	:	p	O
tretinoin	CC	i	IPM
cream	NN	i	IPM
is	VBZ	O	O
effective	JJ	O	O
,	,	O	O
too	RB	O	O
.	.	O	O

Adapalene	NNP	i	IPM
gel	NN	i	IPM
is	VBZ	O	O
a	DT	O	O
tretinoin	JJ	O	O
derivative	NN	O	O
and	CC	O	O
has	VBZ	O	O
a	DT	O	O
lower	JJR	O	O
incidence	NN	O	O
of	IN	O	O
irritation	NN	o	OA
compared	VBN	O	O
with	IN	O	O
other	JJ	O	O
topical	JJ	O	O
retinoid	NN	O	O
products	NNS	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
there	EX	O	O
are	VBP	O	O
no	DT	O	O
reports	NNS	O	O
on	IN	O	O
adapalene	NN	i	IPM
gel	NN	i	IPM
for	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
pityriasis	NN	p	PC
versicolor	NN	p	PC
.	.	p	O

OBJECTIVE	UH	O	O
To	TO	O	O
study	VB	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
adapalene	NN	i	IPM
gel	NN	i	IPM
comparing	VBG	O	O
the	DT	O	O
treatment	NN	O	O
with	IN	O	O
adapalene	JJ	i	IPM
gel	NNS	i	IPM
and	CC	i	O
2	CD	i	IPM
%	NN	i	IPM
ketoconazole	JJ	i	IPM
cream	NN	i	IPM
in	IN	O	O
pityriasis	NN	p	PC
versicolor	NN	p	PC
.	.	p	O

METHODS	NNP	O	O
Eighty	NNP	p	PSS
patients	NNS	p	O
suffering	VBG	p	O
from	IN	p	O
pityriasis	NN	p	PC
versicolor	NN	p	PC
were	VBD	O	O
randomly	RB	O	O
divided	VBN	O	O
into	IN	O	O
two	CD	O	O
groups	NNS	O	O
;	:	O	O
one	CD	O	O
group	NN	O	O
were	VBD	O	O
treated	VBN	O	O
with	IN	O	O
2	CD	i	IPM
%	NN	i	IPM
ketoconazole	JJ	i	IPM
cream	NN	i	IPM
topically	RB	O	O
twice	JJ	O	O
daily	RB	O	O
for	IN	O	O
2	CD	O	O
weeks	NNS	O	O
,	,	O	O
adapalene	JJ	i	IPM
gel	NN	i	IPM
was	VBD	O	O
used	VBN	O	O
for	IN	O	O
the	DT	O	O
other	JJ	O	O
group	NN	O	O
in	IN	O	O
a	DT	O	O
similar	JJ	O	O
fashion	NN	O	O
.	.	O	O

RESULTS	CC	O	O
There	EX	O	O
were	VBD	O	O
no	DT	O	O
significant	JJ	O	O
differences	NNS	O	O
in	IN	O	O
efficacy	NN	o	OOt
between	IN	O	O
the	DT	O	O
two	CD	O	O
groups	NNS	O	O
.	.	O	O

No	DT	O	O
major	JJ	O	O
side	NN	o	OA
effects	NNS	o	OA
were	VBD	O	O
noted	VBN	O	O
in	IN	O	O
any	DT	O	O
of	IN	O	O
the	DT	O	O
groups	NNS	O	O
either	CC	O	O
.	.	O	O

CONCLUSION	NNP	O	O
Adapalene	NNP	i	IPM
was	VBD	O	O
the	DT	O	O
favorable	JJ	O	O
option	NN	O	O
in	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
pityriasis	NN	p	PC
versicolor	NN	p	PC
.	.	p	O

The	DT	O	O
probable	JJ	O	O
therapeutic	JJ	O	O
mechanism	NN	O	O
of	IN	O	O
adapalene	NN	i	IPM
is	VBZ	O	O
also	RB	O	O
discussed	VBN	O	O
.	.	O	O

Beneficial	JJ	O	O
effects	NNS	O	O
of	IN	O	O
a	DT	O	O
soy-based	JJ	i	IPM
dietary	JJ	i	IPM
supplement	NN	i	IPM
on	IN	O	O
lipid	JJ	o	OPH
levels	NNS	o	OPH
and	CC	o	O
cardiovascular	JJ	o	OPH
risk	NN	o	OPH
markers	NNS	o	OPH
in	IN	O	O
type	NN	p	O
2	CD	p	O
diabetic	JJ	p	O
subjects	NNS	p	O
.	.	p	O

OBJECTIVE	NNP	O	O
Consumption	NNP	O	O
of	IN	O	O
soy	NN	O	O
protein	NN	O	O
has	VBZ	O	O
recently	RB	O	O
been	VBN	O	O
shown	VBN	O	O
to	TO	O	O
improve	VB	O	O
the	DT	O	O
blood	NN	o	OPH
lipid	JJ	o	OPH
levels	NNS	o	OPH
in	IN	O	O
nondiabetic	JJ	O	O
subjects	NNS	O	O
.	.	O	O

The	DT	O	O
purpose	NN	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
evaluate	VB	O	O
if	IN	O	O
a	DT	O	O
dietary	JJ	O	O
supplement	NN	O	O
of	IN	O	O
soy	NN	i	IPM
protein	NN	i	IPM
,	,	i	O
isoflavones	NNS	i	IPM
,	,	i	O
and	CC	i	O
cotyledon	VB	i	IPM
fiber	NN	i	IPM
(	(	i	IPM
Abalon	NNP	i	IPM
)	)	i	IPM
affects	VBZ	O	O
cardiovascular	JJ	o	OPH
risk	NN	o	OPH
markers	NNS	o	OPH
,	,	o	O
blood	NN	o	OPH
glucose	NN	o	OPH
,	,	o	O
and	CC	o	O
insulin	NN	o	OPH
levels	NNS	o	OPH
in	IN	O	O
type	NN	p	O
2	CD	p	O
diabetic	JJ	p	O
subjects	NNS	p	O
.	.	p	O

RESEARCH	NNP	O	O
DESIGN	NNP	O	O
AND	NNP	O	O
METHODS	NNP	O	O
Twenty	NNP	p	PSS
type	NN	p	PC
2	CD	p	PC
diabetic	JJ	p	PC
subjects	NNS	p	O
participated	VBN	p	O
in	IN	p	O
a	DT	p	O
crossover	NN	p	O
trial	NN	p	O
.	.	p	O

They	PRP	O	O
were	VBD	O	O
randomized	VBN	O	O
to	TO	O	O
double-blind	JJ	O	O
supplementation	NN	O	O
for	IN	O	O
6	CD	i	IPM
weeks	NNS	i	IPM
with	IN	i	IPM
Abalon	NNP	i	IPM
(	(	i	IPM
soy	JJ	i	IPM
protein	NN	i	IPM
[	VBD	O	O
50	CD	O	O
g/day	JJ	O	O
]	NNP	O	O
with	IN	O	O
high	JJ	O	O
levels	NNS	O	O
of	IN	O	O
isoflavones	NNS	i	IPM
[	NNP	O	O
minimum	VBD	O	O
165	CD	O	O
mg/day	NN	O	O
]	NNP	O	O
and	CC	O	O
cotyledon	VB	i	IPM
fiber	NN	i	IPM
[	$	O	O
20	CD	O	O
g/day	JJ	O	O
]	NNPS	O	O
)	)	O	O
or	CC	O	O
placebo	NN	i	IC
(	(	O	O
casein	JJ	O	O
[	VBZ	O	O
50	CD	O	O
g/day	NN	O	O
]	NNP	O	O
and	CC	O	O
cellulose	VB	O	O
[	JJ	O	O
20	CD	O	O
g/day	JJ	O	O
]	NNP	O	O
)	)	O	O
,	,	O	O
separated	VBN	O	O
by	IN	O	O
a	DT	O	O
3-week	JJ	O	O
wash-out	JJ	O	O
period	NN	O	O
.	.	O	O

RESULTS	VB	O	O
The	DT	O	O
results	NNS	O	O
are	VBP	O	O
expressed	VBN	O	O
as	IN	O	O
means	NNS	O	O
+/-	JJ	O	O
SD	NNP	O	O
.	.	O	O

The	DT	O	O
percentage	NN	O	O
mean	JJ	O	O
treatment	NN	O	O
difference	NN	O	O
between	IN	O	O
Abalon	NNP	i	IPM
and	CC	O	O
placebo	NN	i	IC
demonstrated	VBD	O	O
significantly	RB	O	O
lower	JJR	O	O
mean	NN	O	O
values	NNS	O	O
after	IN	O	O
Abalon	NNP	i	IPM
for	IN	O	O
LDL	NNP	o	OPH
cholesterol	NN	o	OPH
(	(	O	O
10	CD	O	O
+/-	JJ	O	O
15	CD	O	O
%	NN	O	O
,	,	O	O
P	NNP	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
,	,	O	O
LDL/UHDL	NNP	o	OPH
ratio	NN	o	OPH
(	(	O	O
12	CD	O	O
+/-	JJ	O	O
18	CD	O	O
%	NN	O	O
,	,	O	O
P	NNP	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
,	,	O	O
apolipoprotein	RB	o	OPH
(	(	O	O
apo	NN	O	O
)	)	O	O
B100	NNP	O	O
(	(	O	O
30	CD	O	O
+/-	JJ	O	O
38	CD	O	O
%	NN	O	O
,	,	O	O
P	NNP	O	O
<	NNP	O	O
0.01	CD	O	O
)	)	O	O
,	,	O	O
triglycerides	NNS	o	OPH
(	(	O	O
22	CD	O	O
+/-	JJ	O	O
10	CD	O	O
%	NN	O	O
,	,	O	O
P	NNP	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
homocysteine	NN	o	OPH
(	(	O	O
14	CD	O	O
+/-	JJ	O	O
21	CD	O	O
%	NN	O	O
,	,	O	O
P	NNP	O	O
<	NNP	O	O
0.01	CD	O	O
)	)	O	O
,	,	O	O
whereas	VBD	O	O
the	DT	O	O
total	JJ	o	OPH
cholesterol	NN	o	OPH
value	NN	o	OPH
tended	VBD	O	O
to	TO	O	O
be	VB	O	O
less	RBR	O	O
significant	JJ	O	O
but	CC	O	O
still	RB	O	O
lower	JJR	O	O
(	(	O	O
8	CD	O	O
+/-	JJ	O	O
15	CD	O	O
%	NN	O	O
,	,	O	O
P	NNP	O	O
<	NNP	O	O
0.08	CD	O	O
)	)	O	O
.	.	O	O

No	UH	O	O
change	NN	O	O
occurred	VBD	O	O
in	IN	O	O
HDL	NNP	o	OPH
cholesterol	NN	o	OPH
,	,	o	O
apo	JJ	o	OPH
B100/apo	NNP	o	OPH
A1	NNP	o	OPH
ratio	NN	o	OPH
,	,	o	O
plasminogen	NN	o	OPH
activator	NN	o	OPH
inhibitor	NN	o	OPH
1	CD	o	OPH
,	,	o	O
factor	NN	o	OPH
VIIc	NNP	o	OPH
,	,	o	O
von	NNP	o	OPH
Willebrand	NNP	o	OPH
factor	NN	o	OPH
,	,	o	O
fibrinogen	NN	o	OPH
,	,	o	O
lipoprotein	NN	o	OPH
(	(	o	OPH
a	DT	o	OPH
)	)	o	OPH
,	,	o	O
glucose	JJ	o	OPH
,	,	o	O
HbA1c	NNP	o	OPH
,	,	o	O
or	CC	o	O
24-h	JJ	o	OPH
blood	NN	o	OPH
pressure	NN	o	OPH
.	.	o	O

CONCLUSIONS	NNP	O	O
These	DT	O	O
results	NNS	O	O
indicate	VBP	O	O
beneficial	JJ	O	O
effects	NNS	O	O
of	IN	O	O
dietary	JJ	O	O
supplementation	NN	O	O
with	IN	O	O
Abalon	NNP	i	IPM
on	IN	O	O
cardiovascular	JJ	o	OPH
risk	NN	o	OPH
markers	NNS	o	OPH
in	IN	O	O
type	NN	p	O
2	CD	p	O
diabetic	JJ	p	O
subjects	NNS	p	O
.	.	p	O

This	DT	O	O
improvement	NN	O	O
is	VBZ	O	O
seen	VBN	O	O
even	RB	O	O
in	IN	O	O
individuals	NNS	O	O
with	IN	O	O
near-normal	JJ	O	O
lipid	JJ	O	O
values	NNS	O	O
.	.	O	O

Efficacy	NN	o	OOt
of	IN	O	O
amantadine	NN	i	IPM
on	IN	O	O
quality	NN	o	OOt
of	IN	o	OOt
life	NN	o	OOt
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
chronic	JJ	p	PC
hepatitis	NN	p	PC
C	NNP	p	PC
treated	VBD	p	O
with	IN	p	O
interferon-alpha	JJ	i	IPM
and	CC	i	IPM
ribavirin	NN	i	IPM
:	:	i	O
results	NNS	O	O
from	IN	O	O
a	DT	O	O
randomized	VBN	O	O
,	,	O	O
placebo-controlled	JJ	i	IC
,	,	O	O
double-blind	JJ	O	O
trial	NN	O	O
.	.	O	O

AIM	VB	O	O
The	DT	O	O
aim	NN	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
investigate	VB	O	O
whether	IN	O	O
amantadine	JJ	O	O
reduces	NNS	O	O
deterioration	NN	o	OOt
of	IN	o	OOt
quality	NN	o	OOt
of	IN	o	OOt
life	NN	o	OOt
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
chronic	JJ	p	O
hepatitis	NN	p	O
C	NNP	p	O
during	IN	p	O
and	CC	p	O
after	IN	p	O
treatment	NN	p	O
with	IN	p	O
interferon-alpha	JJ	p	O
(	(	p	O
IFN-alpha	NNP	p	O
)	)	p	O
and	CC	p	O
ribavirin	NN	p	O
.	.	p	O

PATIENTS	NNP	O	O
AND	CC	O	O
METHODS	NNP	O	O
In	IN	O	O
this	DT	O	O
randomized	VBN	O	O
,	,	O	O
prospective	JJ	O	O
,	,	O	O
placebo-controlled	JJ	i	IC
,	,	O	O
multicenter	JJ	O	O
trial	NN	O	O
,	,	O	O
previously	RB	p	O
untreated	JJ	p	O
patients	NNS	p	O
with	IN	p	O
chronic	JJ	p	PC
hepatitis	NN	p	PC
C	NNP	p	PC
were	VBD	O	O
treated	VBN	O	O
with	IN	O	O
IFN-alpha	NNP	i	IPM
plus	CC	i	IPM
ribavirin	JJ	i	IPM
[	NN	i	IPM
17	CD	i	IPM
]	NN	i	IPM
and	CC	O	O
randomized	VBN	O	O
for	IN	O	O
treatment	NN	O	O
with	IN	O	O
amantadine	NN	i	IPM
(	(	O	O
200	CD	O	O
mg/day	NN	O	O
,	,	O	O
orally	RB	O	O
,	,	O	O
n=136	NN	O	O
)	)	O	O
or	CC	i	O
placebo	NN	i	IC
(	(	O	O
n=131	JJ	O	O
)	)	O	O
.	.	O	O

Quality	NN	o	OOt
of	IN	o	OOt
life	NN	o	OOt
was	VBD	O	O
assessed	VBN	O	O
with	IN	O	O
the	DT	O	O
'Profile	NN	o	OME
of	IN	o	OME
Mood	NNP	o	OME
States	NNPS	o	OME
'	POS	o	OME
scale	NN	o	OME
and	CC	o	OOt
the	DT	o	OOt
'Everyday	JJ	o	OOt
Life	NNP	o	OOt
'	POS	o	OOt
questionnaire	NN	o	OOt
at	IN	O	O
baseline	NN	O	O
,	,	O	O
treatment	NN	O	O
week	NN	O	O
(	(	O	O
TW	NNP	O	O
)	)	O	O
8	CD	O	O
,	,	O	O
TW24	NNP	O	O
,	,	O	O
TW48	NNP	O	O
,	,	O	O
and	CC	O	O
at	IN	O	O
follow-up	JJ	O	O
.	.	O	O

RESULTS	VB	O	O
Early	JJ	O	O
during	IN	O	O
treatment	NN	O	O
at	IN	O	O
TW8	NNP	O	O
,	,	O	O
quality	NN	o	O
of	IN	o	O
life	NN	o	O
was	VBD	O	O
not	RB	O	O
different	JJ	O	O
between	IN	O	O
patients	NNS	p	O
in	IN	p	O
the	DT	p	O
control	NN	p	O
and	CC	p	O
the	DT	p	O
amantadine	NN	p	O
group	NN	p	O
.	.	p	O

At	IN	O	O
TW24	NNP	O	O
,	,	O	O
the	DT	O	O
control	NN	O	O
group	NN	O	O
but	CC	O	O
not	RB	O	O
the	DT	O	O
amantadine	NN	i	IPM
group	NN	O	O
,	,	O	O
however	RB	O	O
,	,	O	O
showed	VBD	O	O
significant	JJ	O	O
deterioration	NN	O	O
of	IN	O	O
the	DT	O	O
modalities	NNS	o	OPH
depression	NN	o	OPH
,	,	o	O
fatigue	NN	o	OPH
,	,	o	OPH
and	CC	o	OPH
vigor	NN	o	OPH
compared	VBN	O	O
with	IN	O	O
baseline	NN	O	O
.	.	O	O

Especially	RB	O	O
,	,	O	O
nonresponders	NNS	O	O
in	IN	O	O
the	DT	O	O
amantadine	NN	O	O
group	NN	O	O
showed	VBD	O	O
significantly	RB	O	O
lower	JJR	o	OPH
deterioration	NN	o	OPH
of	IN	o	OPH
depression	NN	o	OPH
,	,	o	O
anger	NN	o	OPH
,	,	o	OME
mind	NN	o	OPH
function	NN	o	OPH
,	,	o	OME
everyday	JJ	o	OME
life	NN	o	OME
,	,	o	OME
and	CC	o	OME
zest	JJS	o	OME
for	IN	o	OME
life	NN	o	OME
than	IN	O	O
those	DT	O	O
in	IN	O	O
the	DT	O	O
placebo	NN	i	IC
group	NN	O	O
.	.	O	O

After	IN	O	O
treatment	NN	O	O
,	,	O	O
the	DT	O	O
beneficial	JJ	o	OOt
effects	NNS	o	OOt
of	IN	O	O
amantadine	NN	O	O
disappeared	VBN	O	O
.	.	O	O

CONCLUSION	VB	O	O
The	DT	O	O
addition	NN	O	O
of	IN	O	O
amantadine	NN	i	IPM
to	TO	O	O
IFN-alpha	NNP	i	IPM
plus	CC	i	IPM
ribavirin	JJ	i	IPM
combination	NN	O	O
therapy	NN	O	O
may	MD	O	O
reduce	VB	O	O
deterioration	NN	o	OPH
of	IN	o	OPH
depression	NN	o	OPH
,	,	o	O
fatigue	NN	o	OPH
,	,	o	O
and	CC	o	O
vigor	NN	o	OPH
during	IN	O	O
treatment	NN	O	O
but	CC	O	O
does	VBZ	O	O
not	RB	O	O
affect	JJ	O	O
quality	NN	o	OOt
of	IN	o	OOt
life	NN	o	OOt
after	IN	O	O
treatment	NN	O	O
.	.	O	O

Nasal	NNP	O	O
oxytocin	MD	i	IPM
for	IN	O	O
social	JJ	O	O
deficits	NNS	O	O
in	IN	O	O
childhood	NN	p	O
autism	NN	p	PC
:	:	p	PC
a	DT	O	O
randomized	NN	O	O
controlled	VBN	O	O
trial	NN	O	O
.	.	O	O

The	DT	O	O
last	JJ	O	O
two	CD	O	O
decades	NNS	O	O
have	VBP	O	O
witnessed	VBN	O	O
a	DT	O	O
surge	NN	O	O
in	IN	O	O
research	NN	O	O
investigating	VBG	O	O
the	DT	O	O
application	NN	O	O
of	IN	O	O
oxytocin	NN	O	O
as	IN	O	O
a	DT	O	O
method	NN	O	O
of	IN	O	O
enhancing	VBG	O	O
social	JJ	O	O
behaviour	NN	O	O
in	IN	O	O
humans	NNS	O	O
.	.	O	O

Preliminary	JJ	O	O
evidence	NN	O	O
suggests	VBZ	O	O
oxytocin	NN	O	O
may	MD	O	O
have	VB	O	O
potential	NN	O	O
as	IN	O	O
an	DT	O	O
intervention	NN	O	O
for	IN	O	O
autism	NN	O	O
.	.	O	O

We	PRP	O	O
evaluated	VBD	O	O
a	DT	O	O
5-day	JJ	O	O
'live-in	NN	O	O
'	POS	O	O
intervention	NN	O	O
using	VBG	O	O
a	DT	O	O
double-blind	JJ	O	O
randomized	VBN	O	O
control	NN	O	O
trial	NN	O	O
.	.	O	O

38	CD	p	O
male	JJ	p	PA
youths	NNS	p	PA
(	(	p	PA
7-16	CD	p	PA
years	NNS	p	PA
old	JJ	p	PA
)	)	p	PA
with	IN	p	O
autism	NN	p	PC
spectrum	NN	p	PC
disorders	NNS	p	PC
were	VBD	O	O
administered	VBN	O	O
24	CD	i	O
or	CC	i	O
12	CD	i	O
international	JJ	i	O
units	NNS	i	O
(	(	i	O
depending	VBG	i	O
on	IN	i	O
weight	NN	i	O
)	)	i	O
intranasal	NN	i	IC
placebo	NN	i	IC
or	CC	i	O
oxytocin	JJ	i	IPM
once	RB	O	O
daily	RB	O	O
over	IN	O	O
four	CD	O	O
consecutive	JJ	O	O
days	NNS	O	O
.	.	O	O

The	DT	O	O
oxytocin	NN	O	O
or	CC	O	O
placebo	NN	O	O
was	VBD	O	O
administered	VBN	O	O
during	IN	O	O
parent-child	JJ	O	O
interaction	NN	O	O
training	NN	O	O
sessions	NNS	O	O
.	.	O	O

Parent	NN	O	O
and	CC	O	O
child	NN	O	O
behaviours	NNS	O	O
were	VBD	O	O
assessed	VBN	O	O
using	VBG	O	O
parent	NN	o	OME
reports	NNS	o	OME
,	,	o	OME
clinician	JJ	o	OME
ratings	NNS	o	OME
,	,	o	OME
and	CC	o	OME
independent	JJ	o	OME
observations	NNS	o	OME
,	,	O	O
at	IN	O	O
multiple	JJ	O	O
time	NN	O	O
points	NNS	O	O
to	TO	O	O
measure	VB	o	OME
side-effects	NNS	o	OA
;	:	o	OME
social	JJ	o	OME
interaction	NN	o	OME
skills	NNS	o	OME
;	:	o	OME
repetitive	JJ	o	OME
behaviours	NNS	o	OME
;	:	o	OME
emotion	NN	o	OME
recognition	NN	o	OME
and	CC	o	OME
diagnostic	JJ	o	OME
status	NN	o	OME
.	.	o	O

Compared	VBN	O	O
to	TO	O	O
placebo	VB	O	O
,	,	O	O
intranasal	VB	O	O
oxytocin	RB	O	O
did	VBD	O	O
not	RB	O	O
significantly	RB	O	O
improve	VB	O	O
emotion	NN	o	OME
recognition	NN	o	OME
,	,	o	OME
social	JJ	o	OME
interaction	NN	o	OME
skills	NNS	o	OME
,	,	o	OME
or	CC	o	OME
general	JJ	o	OME
behavioral	JJ	o	OME
adjustment	NN	o	OME
in	IN	O	O
male	JJ	O	O
youths	NNS	O	O
with	IN	O	O
autism	NN	O	O
spectrum	NN	O	O
disorders	NNS	O	O
.	.	O	O

The	DT	O	O
results	NNS	O	O
show	VBP	O	O
that	IN	O	O
the	DT	O	O
benefits	NNS	O	O
of	IN	O	O
nasal	JJ	O	O
oxytocin	NN	O	O
for	IN	O	O
young	JJ	p	O
individuals	NNS	p	O
with	IN	p	O
autism	NN	p	PC
spectrum	NN	p	PC
disorders	NNS	p	PC
may	MD	O	O
be	VB	O	O
more	JJR	O	O
circumscribed	JJ	O	O
than	IN	O	O
suggested	VBN	O	O
by	IN	O	O
previous	JJ	O	O
studies	NNS	O	O
,	,	O	O
and	CC	O	O
suggest	JJS	O	O
caution	NN	O	O
in	IN	O	O
recommending	VBG	O	O
it	PRP	O	O
as	IN	O	O
an	DT	O	O
intervention	NN	O	O
that	WDT	O	O
is	VBZ	O	O
broadly	RB	O	O
effective	JJ	O	O
.	.	O	O

Weight	NNP	o	OPH
and	CC	o	O
leptin	JJ	o	OPH
changes	NNS	o	OPH
among	IN	O	O
risperidone-treated	JJ	i	IPM
youths	NNS	p	O
with	IN	p	O
autism	NN	p	O
:	:	p	O
6-month	JJ	O	O
prospective	JJ	O	O
data	NNS	O	O
.	.	O	O

OBJECTIVE	IN	O	O
The	DT	O	O
authors	NNS	O	O
examined	VBD	O	O
the	DT	O	O
developmental	JJ	O	O
impact	NN	O	O
and	CC	O	O
temporal	JJ	O	O
characteristics	NNS	O	O
of	IN	O	O
risperidone-associated	JJ	i	IPM
weight	NN	o	OPH
change	NN	o	OPH
.	.	o	O

METHOD	NNP	O	O
Weight	NNP	o	OPH
change	NN	o	OPH
was	VBD	O	O
measured	VBN	O	O
for	IN	O	O
63	CD	p	O
children	NNS	p	O
and	CC	p	O
adolescents	NNS	p	O
with	IN	p	O
autism	NN	p	O
treated	VBN	p	O
with	IN	p	O
risperidone	NN	i	IPM
for	IN	p	O
6	CD	p	O
months	NNS	p	O
.	.	p	O

Change	NNP	o	OPH
in	IN	o	OPH
serum	NN	o	OPH
leptin	NN	o	OPH
levels	NNS	o	OPH
after	IN	O	O
2	CD	O	O
months	NNS	O	O
was	VBD	O	O
examined	VBN	O	O
as	IN	O	O
a	DT	O	O
predictor	NN	O	O
of	IN	O	O
final	JJ	o	OPH
weight	NN	o	OPH
gain	NN	o	OPH
in	IN	O	O
mixed	JJ	O	O
regression	NN	O	O
models	NNS	O	O
that	WDT	O	O
controlled	VBD	O	O
for	IN	O	O
site	NN	O	O
,	,	O	O
gender	NN	O	O
,	,	O	O
age	NN	O	O
,	,	O	O
and	CC	O	O
risperidone	NN	i	IPM
dose	NN	O	O
.	.	O	O

RESULTS	NNP	O	O
Age-	JJ	O	O
and	CC	O	O
gender-standardized	JJ	O	O
weight	NN	o	OPH
increased	VBD	o	OPH
after	IN	O	O
6	CD	O	O
months	NNS	O	O
of	IN	O	O
treatment	NN	O	O
(	(	O	O
gross	JJ	O	O
:	:	O	O
mean=5.6	NN	O	O
kg	NN	O	O
[	NNP	O	O
SD=3.9	NNP	O	O
]	NNP	O	O
;	:	O	O
standardized	VBN	O	O
:	:	O	O
mean=0.6	NN	O	O
z	NN	O	O
[	NNP	O	O
SD=0.5	NNP	O	O
]	NNP	O	O
)	)	O	O
and	CC	O	O
was	VBD	O	O
positively	RB	O	O
correlated	VBN	O	O
with	IN	O	O
weight	NN	o	OPH
gained	VBN	o	OPH
after	IN	O	O
1	CD	O	O
month	NN	O	O
.	.	O	O

Change	NN	o	OPH
in	IN	o	OPH
leptin	NN	o	OPH
levels	NNS	o	OPH
after	IN	O	O
2	CD	O	O
months	NNS	O	O
of	IN	O	O
treatment	NN	O	O
(	(	O	O
mean=-0.3	JJ	O	O
ng/ml	NN	O	O
,	,	O	O
SD=6.2	NNP	O	O
)	)	O	O
(	(	O	O
N=48	NNP	O	O
)	)	O	O
did	VBD	O	O
not	RB	O	O
predict	JJ	O	O
final	JJ	o	OPH
weight	NN	o	OPH
gain	NN	o	OPH
.	.	o	O

CONCLUSIONS	NNP	O	O
Chronic	NNP	O	O
risperidone	NN	i	IPM
exposure	NN	O	O
in	IN	O	O
children	NNS	O	O
with	IN	O	O
autism	NN	O	O
causes	NNS	O	O
weight	VBD	o	OPH
gain	NN	o	OPH
in	IN	O	O
excess	NN	O	O
of	IN	O	O
developmentally	RB	O	O
expected	VBN	O	O
norms	NNS	O	O
that	WDT	O	O
follows	VBZ	O	O
a	DT	O	O
curvilinear	JJ	O	O
trajectory	NN	O	O
and	CC	O	O
decelerates	VBZ	O	O
over	IN	O	O
time	NN	O	O
.	.	O	O

Serum	NNP	o	OPH
leptin	JJ	o	OPH
change	NN	o	OPH
does	VBZ	O	O
not	RB	O	O
reliably	VB	O	O
predict	JJ	O	O
risperidone-associated	JJ	O	O
weight	NN	o	OPH
gain	NN	o	OPH
.	.	o	O

Effectiveness	NN	O	O
of	IN	O	O
manual	JJ	i	IPH
physical	JJ	i	IPH
therapy	NN	i	IPH
and	CC	i	IPH
exercise	NN	i	IPH
in	IN	O	O
osteoarthritis	NN	p	PC
of	IN	p	PC
the	DT	p	PC
knee	NN	p	PC
.	.	p	O

A	DT	O	O
randomized	JJ	O	O
,	,	O	O
controlled	JJ	O	O
trial	NN	O	O
.	.	O	O

BACKGROUND	NNP	O	O
Few	JJ	O	O
investigations	NNS	O	O
include	VBP	O	O
both	DT	O	O
subjective	JJ	O	O
and	CC	O	O
objective	JJ	O	O
measurements	NNS	O	O
of	IN	O	O
the	DT	O	O
effectiveness	NN	O	O
of	IN	O	O
treatments	NNS	O	O
for	IN	O	O
osteoarthritis	NN	p	PC
of	IN	p	PC
the	DT	p	PC
knee	NN	p	PC
.	.	p	O

Beneficial	JJ	O	O
interventions	NNS	O	O
may	MD	O	O
decrease	VB	O	O
the	DT	O	O
disability	NN	o	OPH
associated	VBN	O	O
with	IN	O	O
osteoarthritis	NN	O	O
and	CC	O	O
the	DT	O	O
need	NN	O	O
for	IN	O	O
more	RBR	O	O
invasive	JJ	O	O
treatments	NNS	O	O
.	.	O	O

OBJECTIVE	NNP	O	O
To	TO	O	O
evaluate	VB	O	O
the	DT	O	O
effectiveness	NN	O	O
of	IN	O	O
physical	JJ	i	IPH
therapy	NN	i	IPH
for	IN	O	O
osteoarthritis	NN	O	O
of	IN	O	O
the	DT	O	O
knee	NN	O	O
,	,	O	O
applied	VBN	O	O
by	IN	O	O
experienced	JJ	O	O
physical	JJ	O	O
therapists	NNS	O	O
with	IN	O	O
formal	JJ	O	O
training	NN	O	O
in	IN	O	O
manual	JJ	O	O
therapy	NN	O	O
.	.	O	O

DESIGN	NNP	O	O
Randomized	NNP	O	O
,	,	O	O
controlled	VBD	O	O
clinical	JJ	O	O
trial	NN	O	O
.	.	O	O

SETTING	NN	O	O
Outpatient	NNP	p	O
physical	JJ	p	O
therapy	NN	p	O
department	NN	p	O
of	IN	p	O
a	DT	p	O
large	JJ	p	O
military	JJ	p	O
medical	JJ	p	O
center	NN	p	O
.	.	p	O

PATIENTS	CC	O	O
83	CD	p	PSS
patients	NNS	p	O
with	IN	p	O
osteoarthritis	NN	p	PC
of	IN	p	PC
the	DT	p	PC
knee	NN	p	PC
who	WP	p	O
were	VBD	p	O
randomly	RB	p	O
assigned	VBN	p	O
to	TO	p	O
receive	VB	p	O
treatment	NN	i	IPH
(	(	p	O
n	JJ	p	O
=	VBZ	p	O
42	CD	p	PSS
;	:	p	O
15	CD	p	PSS
men	NNS	p	PSE
and	CC	p	O
27	CD	p	PSS
women	NNS	p	PSE
[	JJ	p	O
mean	JJ	p	O
age	NN	p	O
,	,	p	O
60	CD	p	PA
+/-	JJ	p	PA
11	CD	p	PA
years	NNS	p	O
]	RB	p	O
)	)	p	O
or	CC	p	O
placebo	NN	i	IC
(	(	p	O
n	JJ	p	O
=	VBZ	p	O
41	CD	p	PSS
;	:	p	O
19	CD	p	PSS
men	NNS	p	O
and	CC	p	O
22	CD	p	PSS
women	NNS	p	O
[	JJ	p	O
mean	JJ	p	O
age	NN	p	O
,	,	p	O
62	CD	p	PA
+/-	JJ	p	PA
10	CD	p	PA
years	NNS	p	O
]	RB	p	O
)	)	p	O
.	.	p	O

INTERVENTION	NNP	O	O
The	DT	O	O
treatment	NN	p	O
group	NN	p	O
received	VBD	O	O
manual	JJ	i	IPH
therapy	NN	i	IPH
,	,	O	O
applied	VBN	O	O
to	TO	O	O
the	DT	O	O
knee	NN	O	O
as	RB	O	O
well	RB	O	O
as	IN	O	O
to	TO	O	O
the	DT	O	O
lumbar	NN	O	O
spine	NN	O	O
,	,	O	O
hip	NN	O	O
,	,	O	O
and	CC	O	O
ankle	RB	O	O
as	IN	O	O
required	VBN	O	O
,	,	O	O
and	CC	O	O
performed	VBD	O	O
a	DT	O	O
standardized	JJ	i	IPH
knee	NN	i	IPH
exercise	NN	i	IPH
program	NN	i	IPH
in	IN	O	O
the	DT	O	O
clinic	NN	O	O
and	CC	O	O
at	IN	O	O
home	NN	O	O
.	.	O	O

The	DT	O	O
placebo	NN	i	IC
group	NN	p	O
had	VBD	O	O
subtherapeutic	JJ	i	IC
ultrasound	NN	i	IC
to	TO	O	O
the	DT	O	O
knee	NN	O	O
at	IN	O	O
an	DT	O	O
intensity	NN	O	O
of	IN	O	O
0.1	CD	O	O
W/cm2	NNP	O	O
with	IN	O	O
a	DT	O	O
10	CD	O	O
%	NN	O	O
pulsed	JJ	O	O
mode	NN	O	O
.	.	O	O

Both	DT	O	O
groups	NNS	O	O
were	VBD	O	O
treated	VBN	O	O
at	IN	O	O
the	DT	O	O
clinic	JJ	O	O
twice	JJ	O	O
weekly	NN	O	O
for	IN	O	O
4	CD	O	O
weeks	NNS	O	O
.	.	O	O

MEASUREMENTS	NNP	O	O
Distance	NNP	o	OPH
walked	VBD	o	OPH
in	IN	o	OPH
6	CD	o	OPH
minutes	NNS	o	OPH
and	CC	o	OPH
sum	NN	o	OPH
of	IN	o	OPH
the	DT	o	OPH
function	NN	o	OPH
,	,	o	O
pain	NN	o	OPA
,	,	o	O
and	CC	o	O
stiffness	JJ	o	OPH
subscores	NNS	o	OPH
of	IN	o	OPH
the	DT	o	OPH
Western	NNP	o	OPH
Ontario	NNP	o	OPH
and	CC	o	OPH
McMaster	NNP	o	OPH
Universities	NNP	o	OPH
Osteoarthritis	NNP	o	OPH
Index	NNP	o	OPH
(	(	o	OPH
WOMAC	NNP	o	OPH
)	)	o	OPH
.	.	o	O

A	DT	O	O
tester	NN	O	O
who	WP	O	O
was	VBD	O	O
blinded	VBN	O	O
to	TO	O	O
group	NN	O	O
assignment	NN	O	O
made	VBD	O	O
group	NN	O	O
comparisons	NNS	O	O
at	IN	O	O
the	DT	O	O
initial	JJ	O	O
visit	NN	O	O
(	(	O	O
before	IN	O	O
initiation	NN	O	O
of	IN	O	O
treatment	NN	O	O
)	)	O	O
,	,	O	O
4	CD	O	O
weeks	NNS	O	O
,	,	O	O
8	CD	O	O
weeks	NNS	O	O
,	,	O	O
and	CC	O	O
1	CD	O	O
year	NN	O	O
.	.	O	O

RESULTS	NNP	O	O
Clinically	NNP	O	O
and	CC	O	O
statistically	RB	O	O
significant	JJ	O	O
improvements	NNS	O	O
in	IN	O	O
6-minute	JJ	o	OPH
walk	NN	o	OPH
distance	NN	o	OPH
and	CC	o	O
WOMAC	NNP	o	OPH
score	NN	o	OPH
at	IN	O	O
4	CD	O	O
weeks	NNS	O	O
and	CC	O	O
8	CD	O	O
weeks	NNS	O	O
were	VBD	O	O
seen	VBN	O	O
in	IN	O	O
the	DT	O	O
treatment	NN	i	IPH
group	NN	O	O
but	CC	O	O
not	RB	O	O
the	DT	O	O
placebo	NN	i	IC
group	NN	O	O
.	.	O	O

By	IN	O	O
8	CD	O	O
weeks	NNS	O	O
,	,	O	O
average	JJ	O	O
6-minute	JJ	o	OPH
walk	NN	o	OPH
distances	NNS	o	OPH
had	VBD	O	O
improved	VBN	O	O
by	IN	O	O
13.1	CD	O	O
%	NN	O	O
and	CC	O	O
WOMAC	NNP	o	OPH
scores	NNS	o	OPH
had	VBD	O	O
improved	VBN	O	O
by	IN	O	O
55.8	CD	O	O
%	NN	O	O
over	IN	O	O
baseline	NN	O	O
values	NNS	O	O
in	IN	O	O
the	DT	O	O
treatment	NN	i	IPH
group	NN	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

After	IN	O	O
controlling	VBG	O	O
for	IN	O	O
potential	JJ	O	O
confounding	NN	O	O
variables	NNS	O	O
,	,	O	O
the	DT	O	O
average	JJ	O	O
distance	NN	o	OPH
walked	VBD	o	OPH
in	IN	o	OPH
6	CD	o	OPH
minutes	NNS	o	OPH
at	IN	O	O
8	CD	O	O
weeks	NNS	O	O
among	IN	O	O
patients	NNS	O	O
in	IN	O	O
the	DT	O	O
treatment	NN	i	IPH
group	NN	O	O
was	VBD	O	O
170	CD	O	O
m	NN	O	O
(	(	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
,	,	O	O
71	CD	O	O
to	TO	O	O
270	CD	O	O
m	NN	O	O
)	)	O	O
more	JJR	O	O
than	IN	O	O
that	DT	O	O
in	IN	O	O
the	DT	O	O
placebo	NN	i	IC
group	NN	O	O
and	CC	O	O
the	DT	O	O
average	JJ	O	O
WOMAC	JJ	o	OPH
scores	NNS	o	OPH
were	VBD	O	O
599	CD	O	O
mm	NN	O	O
higher	JJR	O	O
(	(	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
,	,	O	O
197	CD	O	O
to	TO	O	O
1002	CD	O	O
mm	NN	O	O
)	)	O	O
.	.	O	O

At	IN	O	O
1	CD	O	O
year	NN	O	O
,	,	O	O
patients	NNS	O	O
in	IN	O	O
the	DT	O	O
treatment	NN	i	IPH
group	NN	O	O
had	VBD	O	O
clinically	RB	O	O
and	CC	O	O
statistically	RB	O	O
significant	JJ	O	O
gains	NNS	O	O
over	IN	O	O
baseline	JJ	o	OPH
WOMAC	NNP	o	OPH
scores	NNS	o	OPH
and	CC	o	O
walking	VBG	o	OPH
distance	NN	o	OPH
;	:	o	O
20	CD	O	O
%	NN	O	O
of	IN	O	O
patients	NNS	O	O
in	IN	O	O
the	DT	O	O
placebo	NN	i	IC
group	NN	O	O
and	CC	O	O
5	CD	O	O
%	NN	O	O
of	IN	O	O
patients	NNS	O	O
in	IN	O	O
the	DT	O	O
treatment	NN	i	IPH
group	NN	O	O
had	VBD	O	O
undergone	JJ	O	O
knee	NN	o	OPH
arthroplasty	NN	o	OPH
.	.	o	O

CONCLUSIONS	VB	O	O
A	DT	O	O
combination	NN	O	O
of	IN	O	O
manual	JJ	i	IPH
physical	JJ	i	IPH
therapy	NN	i	IPH
and	CC	i	IPH
supervised	VBD	i	IPH
exercise	NN	i	IPH
yields	NNS	O	O
functional	JJ	o	OOt
benefits	NNS	o	OOt
for	IN	O	O
patients	NNS	p	O
with	IN	p	O
osteoarthritis	NN	p	PC
of	IN	p	PC
the	DT	p	PC
knee	NN	p	PC
and	CC	O	O
may	MD	O	O
delay	VB	O	O
or	CC	O	O
prevent	VB	O	O
the	DT	O	O
need	NN	O	O
for	IN	O	O
surgical	JJ	o	OOt
intervention	NN	o	OOt
.	.	o	O

Effect	NN	O	O
of	IN	O	O
phenylephrine	NN	i	IPM
on	IN	O	O
the	DT	O	O
haemodynamic	JJ	o	OPH
state	NN	o	OPH
and	CC	o	OPH
cerebral	JJ	o	OPH
oxygen	NN	o	OPH
saturation	NN	o	OPH
during	IN	O	O
anaesthesia	NN	O	O
in	IN	O	O
the	DT	O	O
upright	JJ	O	O
position	NN	O	O
.	.	O	O

BACKGROUND	IN	O	O
The	DT	O	O
upright	JJ	O	O
sitting	NN	O	O
or	CC	O	O
beachchair	NN	O	O
position	NN	O	O
is	VBZ	O	O
associated	VBN	O	O
with	IN	O	O
hypotension	NN	o	OPH
,	,	o	OPH
risk	NN	o	OPH
of	IN	o	OPH
cerebral	JJ	o	OPH
hypoperfusion	NN	o	OPH
,	,	o	OPH
and	CC	o	OPH
cerebral	JJ	o	OPH
injury	NN	o	OPH
.	.	o	OPH

We	PRP	O	O
hypothesized	VBD	O	O
that	IN	O	O
by	IN	O	O
increasing	VBG	O	O
arterial	JJ	O	O
pressure	NN	O	O
with	IN	O	O
phenylephrine	JJ	i	IPM
administration	NN	O	O
,	,	O	O
cerebral	JJ	o	OPH
perfusion	NN	o	OPH
,	,	O	O
and	CC	O	O
postoperative	JJ	o	OPH
recovery	NN	o	OPH
would	MD	O	O
be	VB	O	O
improved	VBN	O	O
.	.	O	O

METHODS	NNP	O	O
Thirty-four	JJ	p	PSS
patients	NNS	p	O
undergoing	VBG	p	O
elective	JJ	p	PC
shoulder	NN	p	PC
surgery	NN	p	PC
were	VBD	p	O
randomized	VBN	p	O
to	TO	O	O
receive	VB	O	O
either	DT	O	O
saline	NN	i	IPM
or	CC	i	IPM
phenylephrine	NN	i	IPM
infusion	NN	i	IPM
(	(	i	IPM
PE	NNP	i	IPM
)	)	i	IPM
5	CD	O	O
min	NN	O	O
before	IN	O	O
being	VBG	O	O
placed	VBN	O	O
in	IN	O	O
the	DT	O	O
upright	JJ	O	O
position	NN	O	O
.	.	O	O

Simultaneous	JJ	O	O
measurements	NNS	O	O
of	IN	O	O
mean	JJ	o	OPH
arterial	JJ	o	OPH
pressure	NN	o	OPH
,	,	o	OPH
cerebral	JJ	o	OPH
oxygen	NN	o	OPH
saturation	NN	o	OPH
,	,	o	OPH
middle	JJ	o	OPH
cerebral	JJ	o	OPH
artery	NN	o	OPH
velocity	NN	o	OPH
,	,	o	OPH
and	CC	o	OPH
cardiac	JJ	o	OPH
function	NN	o	OPH
using	VBG	o	OPH
transthoracic	JJ	o	OPH
echocardiography	NN	o	OPH
were	VBD	O	O
made	VBN	O	O
.	.	O	O

Postoperative	JJ	O	O
neurocognitive	JJ	o	OME
function	NN	o	OME
was	VBD	O	O
assessed	VBN	O	O
.	.	O	O

RESULTS	NNP	O	O
At	IN	O	O
the	DT	O	O
commencement	NN	O	O
of	IN	O	O
PE	NNP	O	O
,	,	O	O
mean	NN	o	OPH
(	(	o	OPH
SD	NNP	o	OPH
)	)	o	OPH
cerebral	JJ	o	OPH
oxygen	NN	o	OPH
saturation	NN	o	OPH
significantly	RB	O	O
decreased	VBN	O	O
from	IN	O	O
77	CD	O	O
(	(	O	O
10	CD	O	O
)	)	O	O
to	TO	O	O
67	CD	O	O
(	(	O	O
13	CD	O	O
)	)	O	O
%	NN	O	O
(	(	O	O
P=0.02	NNP	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
further	RB	O	O
to	TO	O	O
59	CD	O	O
(	(	O	O
11	CD	O	O
)	)	O	O
%	NN	O	O
on	IN	O	O
upright	JJ	O	O
positioning	NN	O	O
.	.	O	O

The	DT	O	O
level	NN	o	OPH
of	IN	o	OPH
cerebral	JJ	o	OPH
saturation	NN	o	OPH
upright	NN	o	OPH
was	VBD	O	O
not	RB	O	O
significantly	RB	O	O
different	JJ	O	O
to	TO	O	O
patients	NNS	O	O
receiving	VBG	O	O
saline	NN	O	O
(	(	O	O
P=0.07	NNP	O	O
)	)	O	O
,	,	O	O
with	IN	O	O
values	NNS	O	O
remaining	VBG	O	O
at	IN	O	O
room-air	JJ	O	O
levels	NNS	O	O
.	.	O	O

Middle	NNP	o	OPH
cerebral	JJ	o	OPH
artery	RB	o	OPH
blood	NN	o	OPH
velocity	NN	o	OPH
increased	VBN	O	O
by	IN	O	O
20	CD	O	O
%	NN	O	O
(	(	O	O
P=0.04	NNP	O	O
)	)	O	O
.	.	O	O

Phenylephrine	NNP	O	O
prevented	VBD	O	O
hypotension	NN	o	OPH
in	IN	O	O
the	DT	O	O
upright	JJ	O	O
position	NN	O	O
primarily	RB	O	O
by	IN	O	O
maintaining	VBG	O	O
preload	NN	O	O
and	CC	O	O
increasing	VBG	O	O
systemic	JJ	o	OPH
vascular	NN	o	OPH
resistance	NN	o	OPH
(	(	O	O
P=0.01	NNP	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
was	VBD	O	O
associated	VBN	O	O
with	IN	O	O
a	DT	O	O
decrease	NN	O	O
in	IN	O	O
cardiac	JJ	o	OPH
output	NN	o	OPH
.	.	o	OPH

No	DT	O	O
postoperative	JJ	o	OME
neurocognitive	JJ	o	OME
dysfunction	NN	o	OME
was	VBD	O	O
identified	VBN	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
Despite	IN	O	O
maintaining	VBG	O	O
arterial	JJ	O	O
pressure	NN	O	O
with	IN	O	O
phenylephrine	NN	i	IPM
,	,	O	O
cerebral	JJ	o	OPH
desaturation	NN	o	OPH
occurred	VBD	O	O
with	IN	O	O
upright	JJ	O	O
positioning	VBG	O	O
.	.	O	O

Cerebral	NNP	o	OPH
oxygen	IN	o	OPH
saturation	NN	o	OPH
can	MD	O	O
provide	VB	O	O
a	DT	O	O
valuable	JJ	O	O
endpoint	NN	O	O
when	WRB	O	O
evaluating	VBG	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
vasopressor	NN	O	O
therapy	NN	O	O
on	IN	O	O
cerebral	JJ	O	O
perfusion	NN	O	O
.	.	O	O

Determination	NN	O	O
of	IN	O	O
vital	JJ	O	O
status	NN	O	O
at	IN	O	O
the	DT	O	O
end	NN	O	O
of	IN	O	O
the	DT	O	O
DIG	NNP	O	O
trial	NN	O	O
.	.	O	O

The	DT	O	O
Digitalis	NNP	O	O
Investigation	NNP	O	O
Group	NNP	O	O
(	(	O	O
DIG	NNP	O	O
)	)	O	O
trial	NN	O	O
was	VBD	O	O
a	DT	O	O
randomized	JJ	O	O
,	,	O	O
double-blind	JJ	O	O
placebo-controlled	JJ	i	IC
trial	NN	O	O
whose	WP$	O	O
primary	JJ	O	O
objective	NN	O	O
was	VBD	O	O
to	TO	O	O
determine	VB	O	O
whether	IN	O	O
digoxin	NN	i	IPM
had	VBD	O	O
beneficial	JJ	O	O
,	,	O	O
harmful	JJ	O	O
,	,	O	O
or	CC	O	O
no	DT	O	O
effect	NN	O	O
on	IN	O	O
total	JJ	O	O
mortality	NN	O	O
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
heart	NN	p	O
failure	NN	p	O
who	WP	p	O
were	VBD	p	O
in	IN	p	O
sinus	NN	p	O
rhythm	NN	p	O
and	CC	p	O
whose	WP$	p	O
ejection	NN	p	O
fraction	NN	p	O
was	VBD	p	O
<	JJ	p	O
/=0.45	NNP	p	O
.	.	p	O

The	DT	O	O
study	NN	O	O
was	VBD	O	O
designed	VBN	O	O
as	IN	O	O
a	DT	O	O
large	JJ	O	O
simple	JJ	O	O
trial	NN	O	O
with	IN	O	O
a	DT	p	O
large	JJ	p	O
number	NN	p	O
of	IN	p	O
centers	NNS	p	O
(	(	p	O
302	CD	p	O
)	)	p	O
in	IN	p	O
the	DT	p	O
United	NNP	p	O
States	NNPS	p	O
and	CC	p	O
Canada	NNP	p	O
,	,	p	O
many	JJ	p	O
of	IN	p	O
which	WDT	p	O
were	VBD	p	O
inexperienced	VBN	p	O
in	IN	p	O
research	NN	p	O
.	.	p	O

To	TO	O	O
ensure	VB	O	O
that	IN	O	O
the	DT	O	O
results	NNS	O	O
of	IN	O	O
the	DT	O	O
trial	NN	O	O
would	MD	O	O
be	VB	O	O
reported	VBN	O	O
accurately	RB	O	O
without	IN	O	O
possible	JJ	O	O
bias	NN	O	O
due	JJ	O	O
to	TO	O	O
missing	VBG	O	O
data	NNS	O	O
,	,	O	O
the	DT	O	O
study	NN	O	O
leadership	NN	O	O
decided	VBD	O	O
that	IN	O	O
no	DT	O	O
outcome	NN	O	O
results	NNS	O	O
would	MD	O	O
be	VB	O	O
reported	VBN	O	O
until	IN	O	O
the	DT	O	O
vital	JJ	O	O
status	NN	O	O
at	IN	O	O
the	DT	O	O
end	NN	O	O
of	IN	O	O
the	DT	O	O
study	NN	O	O
was	VBD	O	O
known	VBN	O	O
for	IN	O	O
at	IN	O	O
least	JJS	O	O
97	CD	O	O
%	NN	O	O
of	IN	O	O
the	DT	O	O
study	NN	O	O
participants	NNS	O	O
.	.	O	O

Planning	VBG	O	O
for	IN	O	O
closeout	NN	O	O
of	IN	O	O
the	DT	O	O
study	NN	O	O
began	VBD	O	O
a	DT	O	O
year	NN	O	O
prior	RB	O	O
to	TO	O	O
the	DT	O	O
common	JJ	O	O
end	NN	O	O
date	NN	O	O
of	IN	O	O
December	NNP	O	O
31	CD	O	O
,	,	O	O
1995	CD	O	O
and	CC	O	O
included	VBD	O	O
plans	NNS	O	O
for	IN	O	O
obtaining	VBG	O	O
vital	JJ	O	O
status	NN	O	O
on	IN	O	O
December	NNP	O	O
31	CD	O	O
,	,	O	O
1995	CD	O	O
.	.	O	O

Participants	NNS	O	O
were	VBD	O	O
given	VBN	i	IE
postcards	NNS	i	IE
at	IN	i	IE
their	PRP$	i	IE
final	JJ	i	IE
study	NN	i	IE
visit	NN	i	IE
to	TO	i	IE
be	VB	i	IE
completed	VBN	i	IE
and	CC	i	IE
mailed	VBN	i	IE
on	IN	i	IE
or	CC	i	IE
after	IN	i	IE
January	NNP	i	IE
1	CD	i	IE
,	,	i	IE
1996	CD	i	IE
.	.	i	O

Of	IN	p	O
5602	CD	p	O
postcards	NNS	p	O
distributed	VBN	p	O
,	,	p	O
5070	CD	p	O
(	(	p	O
90.5	CD	p	O
%	NN	p	O
)	)	p	O
were	VBD	p	O
completed	VBN	p	O
and	CC	p	O
returned	VBN	p	O
.	.	p	O

A	DT	O	O
contract	NN	O	O
search	NN	O	O
agency	NN	O	O
was	VBD	O	O
hired	VBN	O	O
to	TO	O	O
locate	VB	O	O
the	DT	O	O
remaining	VBG	O	O
participants	NNS	O	O
.	.	O	O

Of	IN	p	O
the	DT	p	O
total	JJ	p	O
7788	CD	p	O
participants	NNS	p	O
entered	VBD	p	O
into	IN	p	O
the	DT	p	O
DIG	NNP	p	O
trial	NN	p	O
,	,	p	O
only	RB	p	O
97	CD	p	O
participants	NNS	p	O
(	(	p	O
1.2	CD	p	O
%	NN	p	O
)	)	p	O
could	MD	p	O
not	RB	p	O
have	VB	p	O
their	PRP$	p	O
vital	JJ	o	OPH
status	NN	o	OPH
as	IN	p	O
of	IN	p	O
December	NNP	p	O
31	CD	p	O
,	,	p	O
1995	CD	p	O
determined	VBD	p	O
.	.	p	O

It	PRP	O	O
is	VBZ	O	O
recommended	VBN	O	O
that	IN	O	O
investigators	NNS	O	O
having	VBG	O	O
an	DT	O	O
outcome	NN	O	O
measure	NN	O	O
with	IN	O	O
a	DT	O	O
common	JJ	O	O
end	NN	O	O
date	NN	O	O
include	VBP	O	O
plans	NNS	O	O
in	IN	O	O
their	PRP$	O	O
protocols	NNS	O	O
for	IN	O	O
obtaining	VBG	O	O
their	PRP$	O	O
measures	NNS	O	O
and	CC	O	O
activate	VBP	O	O
those	DT	O	O
plans	NNS	O	O
as	RB	O	O
early	RB	O	O
as	IN	O	O
possible	JJ	O	O
during	IN	O	O
the	DT	O	O
course	NN	O	O
of	IN	O	O
the	DT	O	O
study	NN	O	O
.	.	O	O

Interferential	JJ	i	IPH
therapy	NN	i	IPH
electrode	NN	i	IPH
placement	NN	i	IPH
technique	NN	i	IPH
in	IN	O	O
acute	NN	p	O
low	JJ	p	O
back	RB	p	O
pain	NN	p	O
:	:	p	O
a	DT	O	O
preliminary	JJ	O	O
investigation	NN	O	O
.	.	O	O

OBJECTIVE	UH	O	O
To	TO	O	O
determine	VB	O	O
the	DT	O	O
efficacy	NN	O	O
of	IN	O	O
interferential	JJ	i	IPH
therapy	NN	i	IPH
(	(	i	IPH
IFT	NNP	i	IPH
)	)	i	IPH
electrode	VBP	i	IPH
placement	NN	i	IPH
technique	NN	i	IPH
compared	VBN	O	O
with	IN	O	O
a	DT	O	O
control	NN	i	IC
treatment	NN	i	IC
in	IN	O	O
subjects	NNS	p	O
with	IN	p	O
acute	NN	p	O
low	JJ	p	O
back	RB	p	O
pain	NN	p	O
(	(	p	O
LBP	NNP	p	O
)	)	p	O
.	.	p	O

DESIGN	NNP	O	O
Single-blind	NNP	O	O
,	,	O	O
randomized	VBD	O	O
,	,	O	O
controlled	VBD	O	O
trial	NN	O	O
with	IN	O	O
a	DT	O	O
3-month	JJ	O	O
follow-up	NN	O	O
.	.	O	O

SETTING	NN	O	O
Outpatient	NNP	p	O
physiotherapy	NN	p	O
departments	NNS	p	O
in	IN	p	O
hospital	NN	p	O
and	CC	p	O
university	NN	p	O
settings	NNS	p	O
.	.	p	O

PATIENTS	VB	O	O
A	DT	O	O
random	JJ	O	O
sample	NN	O	O
of	IN	O	O
60	CD	p	O
eligible	JJ	p	O
patients	NNS	p	O
with	IN	p	O
back	JJ	p	O
pain	NN	p	O
(	(	p	O
28	CD	p	O
men	NNS	p	O
,	,	p	O
32	CD	p	O
women	NNS	p	O
)	)	p	O
were	VBD	p	O
recruited	VBN	p	O
by	IN	p	O
general	JJ	p	O
practitioners	NNS	p	O
and	CC	p	O
self-referral	JJ	p	O
for	IN	O	O
physiotherapy	NN	O	O
treatment	NN	O	O
and	CC	O	O
randomly	RB	O	O
assigned	VBN	O	O
to	TO	O	O
1	CD	O	O
of	IN	O	O
3	CD	O	O
groups	NNS	O	O
.	.	O	O

INTERVENTIONS	NNP	O	O
(	(	O	O
1	CD	O	O
)	)	O	O
IFT	NNP	i	IPM
painful	JJ	i	IPM
area	NN	i	IPM
and	CC	i	IPM
The	DT	i	IPM
Back	NNP	i	IPM
Book	NNP	i	IPM
,	,	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
IFT	NNP	i	IPH
spinal	JJ	i	IPH
nerve	NN	i	IPH
and	CC	i	IPM
The	DT	i	IPH
Back	NNP	i	IPH
Book	NNP	i	IPH
,	,	O	O
and	CC	O	O
(	(	O	O
3	CD	O	O
)	)	O	O
Control	NN	i	IC
,	,	i	IC
The	DT	i	IC
Back	NNP	i	IC
Book	NNP	i	IC
only	RB	O	O
.	.	O	O

Standardized	VBN	O	O
IFT	NNP	i	IPM
stimulation	NN	O	O
parameters	NNS	O	O
were	VBD	O	O
used	VBN	O	O
:	:	O	O
carrier	NN	O	O
frequency	NN	O	O
3.85	CD	O	O
kHz	NN	O	O
;	:	O	O
140	CD	O	O
Hz	NNP	O	O
constant	NN	O	O
;	:	O	O
pulse	JJ	O	O
duration	NN	O	O
130	CD	O	O
micros	NN	O	O
;	:	O	O
30	CD	O	O
minutes	NNS	O	O
'	POS	O	O
duration	NN	O	O
.	.	O	O

MAIN	NNP	O	O
OUTCOME	NNP	O	O
MEASURES	NNP	O	O
Pain	NNP	o	OPH
Rating	NNP	o	OPH
Index	NNP	o	OPH
,	,	o	OPH
Roland-Morris	NNP	o	OPH
Disability	NNP	o	OPH
Questionnaire	NNP	o	OPH
(	(	o	OPH
RMDQ	NNP	o	OPH
)	)	o	OPH
,	,	o	OPH
and	CC	o	OPH
EuroQol	NNP	o	OPH
were	VBD	O	O
completed	VBN	O	O
by	IN	O	O
subjects	NNS	O	O
pretreatment	JJ	O	O
,	,	O	O
at	IN	O	O
discharge	NN	O	O
,	,	O	O
and	CC	O	O
3-month	JJ	O	O
follow-up	NN	O	O
.	.	O	O

RESULTS	NNP	O	O
All	NNP	O	O
groups	NNS	O	O
had	VBD	O	O
significant	JJ	O	O
improvements	NNS	O	O
in	IN	O	O
all	DT	O	O
outcomes	NNS	O	O
at	IN	O	O
follow-up	NN	O	O
.	.	O	O

Subjects	NNS	O	O
managed	VBN	O	O
by	IN	O	O
IFT	NNP	O	O
spinal	JJ	O	O
nerve	NN	O	O
and	CC	O	O
The	DT	O	O
Back	NNP	O	O
Book	NNP	O	O
displayed	VBD	O	O
both	DT	O	O
a	DT	O	O
statistically	RB	O	O
significant	JJ	O	O
(	(	O	O
p	JJ	O	O
=	NNP	O	O
.030	NNP	O	O
)	)	O	O
and	CC	O	O
clinically	RB	O	O
meaningful	JJ	O	O
reduction	NN	o	OPH
in	IN	o	OPH
functional	JJ	o	OPH
disability	NN	o	OPH
(	(	o	OPH
RMDQ	NNP	o	OPH
)	)	o	OPH
,	,	O	O
compared	VBN	O	O
with	IN	O	O
management	NN	O	O
via	IN	O	O
IFT	NNP	O	O
painful	JJ	O	O
area	NN	O	O
and	CC	O	O
The	DT	O	O
Back	NNP	O	O
Book	NNP	O	O
combined	VBD	O	O
or	CC	O	O
The	DT	O	O
Back	JJ	O	O
Book	NNP	O	O
alone	RB	O	O
.	.	O	O

CONCLUSIONS	VB	O	O
The	DT	O	O
findings	NNS	O	O
showed	VBD	O	O
that	IN	O	O
IFT	NNP	i	IPH
electrode	FW	i	IPH
placement	NN	i	IPH
technique	NN	i	IPH
affects	VBZ	O	O
LBP-specific	JJ	O	O
functional	JJ	O	O
disability	NN	O	O
,	,	O	O
providing	VBG	O	O
preliminary	JJ	O	O
implications	NNS	O	O
for	IN	O	O
future	JJ	O	O
clinical	JJ	O	O
studies	NNS	O	O
.	.	O	O

Changes	NNS	O	O
in	IN	O	O
motor	NN	O	O
cortex	NN	O	O
excitability	NN	O	O
associated	VBN	O	O
with	IN	O	O
temporal	JJ	i	IPH
repetitive	JJ	i	IPH
transcranial	JJ	i	IPH
magnetic	JJ	i	IPH
stimulation	NN	i	IPH
in	IN	O	O
tinnitus	NN	p	PC
:	:	p	O
hints	NNS	O	O
for	IN	O	O
cross-modal	JJ	O	O
plasticity	NN	O	O
?	.	O	O
BACKGROUND	NNP	O	O
Motor	NNP	O	O
cortex	VBP	O	O
excitability	NN	O	O
was	VBD	O	O
found	VBN	O	O
to	TO	O	O
be	VB	O	O
changed	VBN	O	O
after	IN	O	O
repetitive	JJ	i	IPH
transcranial	JJ	i	IPH
magnetic	JJ	i	IPH
stimulation	NN	i	IPH
(	(	i	IPH
rTMS	NN	i	IPH
)	)	i	IPH
of	IN	O	O
the	DT	O	O
temporal	JJ	O	O
cortex	NN	O	O
highlighting	VBG	O	O
the	DT	O	O
occurrence	NN	O	O
of	IN	O	O
cross-modal	JJ	O	O
plasticity	NN	O	O
in	IN	O	O
non-invasive	JJ	O	O
brain	NN	O	O
stimulation	NN	O	O
.	.	O	O

Here	RB	O	O
,	,	O	O
we	PRP	O	O
investigated	VBD	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
temporal	JJ	i	IPH
low-frequency	NN	i	IPH
rTMS	NN	i	IPH
on	IN	O	O
motor	NN	O	O
cortex	NN	O	O
plasticity	NN	O	O
in	IN	O	O
a	DT	O	O
large	JJ	O	O
sample	NN	O	O
of	IN	O	O
tinnitus	NN	p	PC
patients	NNS	p	O
.	.	p	O

In	IN	O	O
116	CD	p	PSS
patients	NNS	p	O
with	IN	p	O
chronic	JJ	p	O
tinnitus	NN	p	PC
different	JJ	O	O
parameters	NNS	O	O
of	IN	O	O
cortical	JJ	O	O
excitability	NN	O	O
were	VBD	O	O
assessed	VBN	O	O
before	IN	O	O
and	CC	O	O
after	IN	O	O
ten	JJ	O	O
rTMS	JJ	i	IPH
treatment	NN	O	O
sessions	NNS	O	O
.	.	O	O

Patients	NNS	O	O
received	VBD	O	O
one	CD	O	O
of	IN	O	O
three	CD	O	O
different	JJ	O	O
protocols	NNS	O	O
all	DT	O	O
including	VBG	O	O
1	CD	i	O
Hz	NNP	i	O
rTMS	NN	i	O
over	IN	i	O
the	DT	i	O
left	JJ	i	O
temporal	JJ	i	O
cortex	NN	i	O
.	.	i	O

Treatment	NNP	O	O
response	NN	O	O
was	VBD	O	O
defined	VBN	O	O
as	IN	O	O
improvement	NN	O	O
by	IN	O	O
at	IN	O	O
least	JJS	O	O
five	CD	O	O
points	NNS	O	O
in	IN	O	O
the	DT	O	O
tinnitus	NN	O	O
questionnaire	NN	O	O
(	(	O	O
TQ	NNP	O	O
)	)	O	O
.	.	O	O

Variables	NNS	O	O
of	IN	O	O
interest	NN	O	O
were	VBD	O	O
resting	VBG	o	OPH
motor	NN	o	OPH
threshold	NN	o	OPH
(	(	o	OPH
RMT	NNP	o	OPH
)	)	o	OPH
,	,	o	O
short-interval	JJ	o	OPH
intra-cortical	JJ	o	OPH
inhibition	NN	o	OPH
(	(	o	OPH
SICI	NNP	o	OPH
)	)	o	OPH
,	,	o	O
intracortical	JJ	o	OPH
facilitation	NN	o	OPH
(	(	o	OPH
ICF	NNP	o	OPH
)	)	o	OPH
,	,	o	O
and	CC	o	O
cortical	JJ	o	OPH
silent	JJ	o	OPH
period	NN	o	OPH
(	(	o	OPH
CSP	NNP	o	OPH
)	)	o	OPH
.	.	o	O

RESULTS	NNP	O	O
After	IN	O	O
rTMS	JJ	i	IPH
treatment	NN	O	O
RMT	NNP	o	OPH
was	VBD	o	OPH
decreased	VBN	o	OPH
by	IN	O	O
about	IN	O	O
1	CD	O	O
%	NN	O	O
of	IN	O	O
stimulator	NN	O	O
output	NN	O	O
near-significantly	RB	O	O
in	IN	O	O
the	DT	O	O
whole	JJ	O	O
group	NN	O	O
of	IN	O	O
patients	NNS	O	O
.	.	O	O

SICI	NNP	o	OPH
was	VBD	O	O
associated	VBN	O	O
with	IN	O	O
significant	JJ	O	O
changes	NNS	O	O
with	IN	O	O
respect	NN	O	O
to	TO	O	O
treatment	NN	O	O
response	NN	O	O
.	.	O	O

The	DT	O	O
group	NN	O	O
of	IN	O	O
treatment	NN	O	O
responders	NNS	O	O
showed	VBD	O	O
a	DT	O	O
decrease	NN	o	OPH
of	IN	o	OPH
SICI	NNP	o	OPH
over	IN	O	O
the	DT	O	O
course	NN	O	O
of	IN	O	O
treatment	NN	O	O
,	,	O	O
the	DT	O	O
group	NN	O	O
of	IN	O	O
non-responders	NNS	O	O
the	DT	O	O
reverse	NN	O	O
pattern	NN	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
Minor	NNP	o	OPH
RMT	NNP	o	OPH
changes	NNS	o	OPH
during	IN	O	O
rTMS	NN	i	IPH
treatment	NN	O	O
do	VBP	O	O
not	RB	O	O
necessarily	RB	O	O
suggest	VB	O	O
the	DT	O	O
need	NN	O	O
for	IN	O	O
systematic	JJ	O	O
re-examination	NN	O	O
of	IN	O	O
the	DT	O	O
RMT	NNP	O	O
for	IN	O	O
safety	NN	O	O
and	CC	O	O
efficacy	NN	O	O
issues	NNS	O	O
.	.	O	O

Treatment	NNP	O	O
response	NN	O	O
to	TO	O	O
rTMS	VB	i	IPH
was	VBD	O	O
shown	VBN	O	O
to	TO	O	O
be	VB	O	O
related	VBN	O	O
to	TO	O	O
changes	NNS	O	O
in	IN	O	O
SICI	NNP	O	O
that	WDT	O	O
might	MD	O	O
reflect	VB	O	O
modulation	NN	O	O
of	IN	O	O
GABAergic	NNP	O	O
mechanisms	FW	O	O
directly	RB	O	O
or	CC	O	O
indirectly	RB	O	O
related	VBN	O	O
to	TO	O	O
rTMS	VB	O	O
treatment	NN	O	O
effects	NNS	O	O
.	.	O	O

Benzodiazepine	NNP	i	IPM
and	CC	O	O
opioid	JJ	i	IPM
sedation	NN	i	IPM
attenuate	IN	O	O
the	DT	O	O
sympathetic	JJ	O	O
response	NN	O	O
to	TO	O	O
fiberoptic	JJ	o	OOt
bronchoscopy	NN	o	OOt
.	.	o	O

Prophylactic	JJ	O	O
labetalol	NN	O	O
gave	VBD	O	O
no	DT	O	O
additional	JJ	O	O
benefit	NN	O	O
.	.	O	O

Results	NNS	O	O
of	IN	O	O
a	DT	O	O
randomized	JJ	O	O
double-blind	JJ	O	O
placebo-controlled	JJ	O	O
study	NN	O	O
.	.	O	O

BACKGROUND	NNP	O	O
Hypertension	NNP	O	O
and	CC	O	O
tachycardia	NN	O	O
are	VBP	O	O
common	JJ	O	O
during	IN	O	O
fiber-optic	JJ	i	IPH
bronchoscopy	NN	i	IPH
(	(	i	IPH
FOB	NNP	i	IPH
)	)	i	IPH
,	,	O	O
and	CC	O	O
this	DT	O	O
may	MD	O	O
lead	VB	O	O
to	TO	O	O
cardiac	JJ	O	O
ischemia	NN	O	O
.	.	O	O

The	DT	O	O
prophylactic	JJ	O	O
addition	NN	O	O
of	IN	O	O
a	DT	O	O
beta-adrenergic	JJ	i	IPM
anatagonist	NN	i	IPM
might	MD	O	O
mask	VB	O	O
this	DT	O	O
response	NN	O	O
and	CC	O	O
prevent	VB	O	O
the	DT	O	O
deleterious	JJ	O	O
cardiovascular	JJ	o	OPH
effects	NNS	o	OPH
of	IN	o	OPH
FOB	NNP	o	OPH
.	.	o	OPH

METHODS	NNP	O	O
We	PRP	O	O
performed	VBD	O	O
a	DT	O	O
randomized	JJ	O	O
double-blind	JJ	O	O
placebo-controlled	JJ	O	O
trial	NN	O	O
of	IN	O	O
labetalol	$	i	IPM
10mg	CD	i	IPM
iv	NN	i	IPM
given	VBN	i	IPM
with	IN	i	IPM
midazolam-alfentanil	JJ	i	IPM
sedation	NN	i	IPM
.	.	i	O

We	PRP	O	O
monitored	VBD	O	O
heart	NN	o	OPH
rate	NN	o	OPH
(	(	o	OPH
HR	NNP	o	OPH
)	)	o	OPH
and	CC	o	OPH
systolic/diastolic	JJ	o	OPH
blood	NN	o	OPH
pressure	NN	o	OPH
(	(	o	OPH
SBP/DBP	NNP	o	OPH
)	)	o	OPH
throughout	IN	O	O
the	DT	O	O
bronchoscopy	NN	O	O
and	CC	O	O
calculated	VBD	O	O
the	DT	O	O
rate-pressure	JJ	O	O
product	NN	O	O
(	(	O	O
RPP=	NNP	O	O
(	(	O	O
HRxSBP	NNP	O	O
)	)	O	O
/100	NN	O	O
)	)	O	O
.	.	O	O

One-hundred	JJ	p	PSS
twenty	NN	p	PSS
patients	NNS	p	O
were	VBD	p	O
enrolled	VBN	p	O
.	.	p	O

RESULTS	NNP	O	O
In	IN	O	O
the	DT	O	O
placebo	NN	O	O
group	NN	O	O
,	,	O	O
there	EX	O	O
was	VBD	O	O
no	DT	O	O
rise	NN	O	O
in	IN	O	O
HR	NNP	o	OPH
,	,	o	O
SBP	NNP	o	OPH
,	,	o	OPH
DBP	NNP	o	OPH
or	CC	o	O
RPP	NNP	o	OPH
,	,	O	O
and	CC	O	O
there	EX	O	O
was	VBD	O	O
no	DT	O	O
difference	NN	O	O
between	IN	O	O
the	DT	O	O
placebo	NN	O	O
and	CC	O	O
labetalol	NN	i	IPM
groups	NNS	O	O
.	.	O	O

Adverse	JJ	o	OA
events	NNS	o	OA
during	IN	o	OA
bronchoscopy	NN	o	OA
were	VBD	O	O
similar	JJ	O	O
in	IN	O	O
both	DT	O	O
groups	NNS	O	O
.	.	O	O

In	IN	O	O
a	DT	O	O
subgroup	NN	O	O
of	IN	O	O
patients	NNS	O	O
undergoing	VBG	O	O
interventional	JJ	O	O
bronchoscopy	NN	O	O
,	,	O	O
there	EX	O	O
was	VBD	O	O
a	DT	O	O
trend	NN	O	O
towards	NNS	O	O
lower	JJR	O	O
SBP	NNP	o	OPH
(	(	O	O
p=0.06	NN	O	O
)	)	O	O
.	.	O	O

CONCLUSIONS	JJ	O	O
Patients	NNPS	p	O
undergoing	VBG	p	O
FOB	NNP	p	PC
under	IN	O	O
adequate	JJ	O	O
midazolam-alfentanil	JJ	i	IPM
sedation	NN	i	IPM
do	VBP	O	O
not	RB	O	O
develop	VB	O	O
excessive	JJ	O	O
sympathetic	JJ	O	O
drive	NN	O	O
that	WDT	O	O
may	MD	O	O
lead	VB	O	O
to	TO	O	O
cardiac	JJ	O	O
stress	NN	O	O
.	.	O	O

The	DT	O	O
addition	NN	O	O
of	IN	O	O
labetalol	NN	i	IPM
did	VBD	O	O
not	RB	O	O
confer	VB	O	O
additional	JJ	O	O
benefit	NN	O	O
or	CC	O	O
risk	NN	O	O
to	TO	O	O
the	DT	O	O
patients	NNS	O	O
.	.	O	O

(	(	O	O
ClinicalTrials.gov	NNP	O	O
number	NN	O	O
,	,	O	O
NCT00394537	NNP	O	O
)	)	O	O
.	.	O	O

Accuracy	NN	O	O
and	CC	O	O
feasibility	NN	O	O
of	IN	O	O
contrast	NN	i	IPH
echocardiography	NN	i	IPH
for	IN	O	O
detection	NN	O	O
of	IN	O	O
perfusion	NN	O	O
defects	NNS	O	O
in	IN	O	O
routine	JJ	O	O
practice	NN	O	O
:	:	O	O
comparison	NN	O	O
with	IN	O	O
wall	JJ	i	IPH
motion	NN	i	IPH
and	CC	i	IPH
technetium-99m	JJ	i	IPH
sestamibi	NN	i	IPH
single-photon	JJ	i	IPH
emission	NN	i	IPH
computed	VBD	i	IPH
tomography	NN	i	IPH
.	.	i	IPH

The	DT	O	O
Nycomed	NNP	O	O
NC100100	NNP	O	O
Investigators	NNP	O	O
.	.	O	O

OBJECTIVES	NNP	O	O
We	PRP	O	O
sought	VBD	O	O
to	TO	O	O
assess	VB	O	O
the	DT	O	O
feasibility	NN	O	O
and	CC	O	O
accuracy	NN	O	O
of	IN	O	O
myocardial	JJ	i	IPH
contrast	NN	i	IPH
echocardiography	NN	i	IPH
(	(	i	IPH
MCE	NNP	i	IPH
)	)	i	IPH
using	VBG	O	O
standard	JJ	O	O
imaging	NN	O	O
approaches	NNS	O	O
for	IN	O	O
the	DT	O	O
detection	NN	O	O
of	IN	O	O
perfusion	NN	O	O
defects	NNS	O	O
in	IN	O	O
patients	NNS	p	O
who	WP	p	O
had	VBD	p	O
a	DT	p	O
myocardial	JJ	p	O
infarction	NN	p	O
(	(	p	O
MI	NNP	p	O
)	)	p	O
.	.	p	O

BACKGROUND	NNP	O	O
Myocardial	NNP	i	IPH
contrast	NN	i	IPH
echocardiography	NN	i	IPH
may	MD	O	O
be	VB	O	O
more	JJR	O	O
versatile	JJ	O	O
than	IN	O	O
perfusion	NN	i	IPH
scintigraphy	NN	i	IPH
for	IN	O	O
identifying	VBG	O	O
the	DT	O	O
presence	NN	O	O
and	CC	O	O
extent	NN	O	O
of	IN	O	O
perfusion	NN	O	O
defects	NNS	O	O
after	IN	O	O
MI	NNP	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
its	PRP$	O	O
reliability	NN	O	O
in	IN	O	O
routine	JJ	O	O
practice	NN	O	O
is	VBZ	O	O
unclear	JJ	O	O
.	.	O	O

METHODS	NNP	O	O
Fundamental	NNP	O	O
or	CC	O	O
harmonic	JJ	O	O
MCE	NNP	O	O
was	VBD	O	O
performed	VBN	O	O
with	IN	O	O
continuous	JJ	O	O
or	CC	O	O
triggered	JJ	O	O
imaging	NN	O	O
in	IN	O	O
203	CD	p	O
patients	NNS	p	O
with	IN	p	O
a	DT	p	O
previous	JJ	p	O
MI	NNP	p	O
using	VBG	O	O
bolus	JJ	O	O
doses	NNS	O	O
of	IN	O	O
a	DT	O	O
perfluorocarbon-filled	JJ	i	IPM
contrast	NN	i	IPM
agent	NN	i	IPM
(	(	i	IPM
NC100100	NNP	i	IPM
)	)	i	IPM
.	.	i	IPH

All	DT	O	O
patients	NNS	O	O
underwent	JJ	O	O
single-photon	JJ	i	IPH
emission	NN	i	IPH
computed	VBN	i	IPH
tomography	NN	i	IPH
(	(	i	IPH
SPECT	NNP	i	IPH
)	)	i	IPH
after	IN	i	O
the	DT	i	O
injection	NN	i	O
of	IN	i	O
technetium-99m	JJ	i	O
(	(	i	O
Tc-99m	NNP	i	O
)	)	i	O
sestamibi	NN	i	O
at	IN	i	O
rest	NN	i	O
.	.	i	O

Quantitative	NNP	i	O
and	CC	i	O
semiquantitative	JJ	i	O
SPECT	NNP	i	IPH
,	,	O	O
wall	NN	O	O
motion	NN	O	O
and	CC	O	O
digitized	JJ	O	O
echocardiographic	JJ	O	O
data	NNS	O	O
were	VBD	O	O
interpreted	VBN	O	O
independently	RB	O	O
.	.	O	O

The	DT	O	O
accuracy	NN	O	O
of	IN	O	O
MCE	NNP	i	IPH
was	VBD	O	O
assessed	VBN	O	O
for	IN	O	O
detection	NN	O	O
of	IN	O	O
segments	NNS	O	O
and	CC	O	O
patients	NNS	O	O
with	IN	O	O
moderate	JJ	O	O
and	CC	O	O
severe	JJ	O	O
sestamibi-SPECT	JJ	O	O
defects	NNS	O	O
,	,	O	O
as	RB	O	O
well	RB	O	O
as	IN	O	O
for	IN	O	O
detection	NN	O	O
of	IN	O	O
patients	NNS	O	O
with	IN	O	O
extensive	JJ	O	O
perfusion	NN	O	O
defects	NNS	O	O
(	(	O	O
>	VB	O	O
12	CD	O	O
%	NN	O	O
of	IN	O	O
left	JJ	O	O
ventricle	NN	O	O
)	)	O	O
.	.	O	O

RESULTS	NNP	O	O
In	IN	O	O
segments	NNS	O	O
with	IN	O	O
diagnostic	JJ	O	O
MCE	NNP	O	O
,	,	O	O
the	DT	O	O
segmental	JJ	o	OPH
sensitivity	NN	o	OPH
ranged	VBD	O	O
from	IN	O	O
14	CD	O	O
%	NN	O	O
to	TO	O	O
65	CD	O	O
%	NN	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
specificity	NN	o	OOt
varied	VBD	O	O
from	IN	O	O
78	CD	O	O
%	NN	O	O
to	TO	O	O
95	CD	O	O
%	NN	O	O
,	,	O	O
depending	VBG	O	O
on	IN	O	O
the	DT	O	O
dose	NN	O	O
of	IN	O	O
contrast	NN	O	O
agent	NN	O	O
.	.	O	O

Using	VBG	O	O
both	DT	O	O
segment-	JJ	O	O
and	CC	O	O
patient-based	JJ	O	O
analysis	NN	O	O
,	,	O	O
the	DT	O	O
greatest	JJS	O	O
accuracy	NN	O	O
and	CC	O	O
proportion	NN	O	O
of	IN	O	O
interpretable	JJ	O	O
images	NNS	O	O
were	VBD	O	O
obtained	VBN	O	O
using	VBG	O	O
harmonic	JJ	O	O
imaging	NN	O	O
in	IN	O	O
the	DT	O	O
triggered	JJ	O	O
mode	NN	O	O
.	.	O	O

For	IN	O	O
the	DT	O	O
detection	NN	O	O
of	IN	O	O
extensive	JJ	O	O
defects	NNS	O	O
,	,	O	O
the	DT	O	O
sensitivity	NN	o	OPH
varied	VBD	O	O
from	IN	O	O
13	CD	O	O
%	NN	O	O
to	TO	O	O
48	CD	O	O
%	NN	O	O
,	,	O	O
with	IN	O	O
specificity	NN	O	O
from	IN	O	O
63	CD	O	O
%	NN	O	O
to	TO	O	O
100	CD	O	O
%	NN	O	O
.	.	O	O

Harmonic	NNP	O	O
imaging	NN	O	O
remained	VBD	O	O
the	DT	O	O
most	RBS	O	O
accurate	JJ	O	O
approach	NN	O	O
.	.	O	O

Time	NNP	o	OOt
since	IN	o	OOt
MI	NNP	o	OOt
and	CC	o	O
SPECT	NNP	o	OOt
defect	VBP	o	OOt
location	NN	o	OOt
and	CC	o	OOt
intensity	NN	o	OOt
were	VBD	O	O
all	DT	O	O
determinants	NNS	O	O
of	IN	O	O
the	DT	O	O
MCE	NNP	O	O
response	NN	O	O
.	.	O	O

The	DT	O	O
extent	NN	o	OA
of	IN	o	OA
defects	NNS	o	OA
on	IN	o	OA
MCE	NNP	o	OA
was	VBD	O	O
less	JJR	O	O
than	IN	O	O
the	DT	O	O
extent	NN	O	O
of	IN	O	O
either	DT	O	O
abnormal	JJ	O	O
wall	NN	O	O
motion	NN	O	O
or	CC	O	O
SPECT	NNP	O	O
abnormalities	NNS	O	O
.	.	O	O

The	DT	O	O
combination	NN	O	O
of	IN	O	O
wall	JJ	O	O
motion	NN	O	O
and	CC	O	O
MCE	NNP	O	O
assessment	NN	O	O
gave	VBD	O	O
the	DT	O	O
best	JJS	O	O
balance	NN	O	O
of	IN	O	O
sensitivity	NN	O	O
(	(	O	O
46	CD	O	O
%	NN	O	O
to	TO	O	O
55	CD	O	O
%	NN	O	O
)	)	O	O
and	CC	O	O
specificity	NN	O	O
(	(	O	O
82	CD	O	O
%	NN	O	O
to	TO	O	O
83	CD	O	O
%	NN	O	O
)	)	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
Although	IN	O	O
MCE	NNP	O	O
is	VBZ	O	O
specific	JJ	O	O
,	,	O	O
it	PRP	O	O
has	VBZ	O	O
limited	VBN	O	O
sensitivity	NN	O	O
for	IN	O	O
detection	NN	O	O
of	IN	O	O
moderate	JJ	o	OA
or	CC	o	OA
severe	JJ	o	OA
perfusion	NN	o	OA
defects	NNS	o	OA
,	,	O	O
and	CC	O	O
it	PRP	O	O
underestimates	VBZ	O	O
the	DT	O	O
extent	NN	O	O
of	IN	O	O
SPECT	NNP	o	OA
defects	NNS	o	OA
.	.	O	O

The	DT	O	O
best	JJS	O	O
results	NNS	O	O
are	VBP	O	O
obtained	VBN	O	O
by	IN	O	O
integration	NN	O	O
with	IN	O	O
wall	DT	O	O
motion	NN	O	O
.	.	O	O

More	RBR	O	O
sophisticated	JJ	O	O
methods	NNS	O	O
of	IN	O	O
acquisition	NN	O	O
and	CC	O	O
interpretation	NN	O	O
are	VBP	O	O
needed	VBN	O	O
to	TO	O	O
enhance	VB	O	O
the	DT	O	O
feasibility	NN	O	O
of	IN	O	O
this	DT	O	O
technique	NN	O	O
in	IN	O	O
routine	JJ	O	O
practice	NN	O	O
.	.	O	O

A	DT	O	O
placebo-controlled	JJ	i	IC
,	,	O	O
fixed-dose	JJ	O	O
study	NN	O	O
of	IN	O	O
aripiprazole	NN	i	IPM
in	IN	O	O
children	NNS	p	O
and	CC	p	O
adolescents	NNS	p	O
with	IN	p	O
irritability	NN	p	PC
associated	VBN	p	O
with	IN	p	O
autistic	JJ	p	PC
disorder	NN	p	PC
.	.	p	O

OBJECTIVE	UH	O	O
To	TO	O	O
evaluate	VB	O	O
the	DT	O	O
short-term	JJ	O	O
efficacy	NN	o	OOt
and	CC	O	O
safety	NN	o	OOt
of	IN	O	O
aripiprazole	NN	i	IPM
in	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
irritability	NN	O	O
in	IN	O	O
children	NNS	p	O
and	CC	p	O
adolescents	NNS	p	O
with	IN	p	O
autistic	JJ	p	PC
disorder	NN	p	PC
.	.	p	O

METHOD	NNP	O	O
Two	CD	p	PSS
hundred	VBD	p	PSS
eighteen	JJ	p	PSS
children	NNS	p	O
and	CC	p	O
adolescents	NNS	p	O
(	(	p	O
aged	VBN	p	O
6-17	CD	p	O
years	NNS	p	O
)	)	p	O
with	IN	p	O
a	DT	p	O
diagnosis	NN	p	O
of	IN	p	O
autistic	JJ	p	PC
disorder	NN	p	PC
,	,	p	O
and	CC	p	O
with	IN	p	O
behaviors	NNS	p	O
such	JJ	p	O
as	IN	p	O
tantrums	NNS	p	PC
,	,	p	O
aggression	NN	p	PC
,	,	p	PC
self-injurious	JJ	p	PC
behavior	NN	p	PC
,	,	p	PC
or	CC	p	O
a	DT	p	O
combination	NN	p	O
of	IN	p	O
these	DT	p	O
symptoms	NNS	p	O
,	,	O	O
were	VBD	O	O
randomized	VBN	O	O
1:1:1:1	CD	O	O
to	TO	O	O
aripiprazole	VB	i	IPM
(	(	i	IPM
5	CD	i	IPM
,	,	i	IPM
10	CD	i	IPM
,	,	i	IPM
or	CC	i	IPM
15	CD	i	IPM
mg/day	NN	i	IPM
)	)	i	IPM
or	CC	i	O
placebo	NN	i	IC
in	IN	O	O
this	DT	O	O
8-week	JJ	O	O
double-blind	NN	O	O
,	,	O	O
randomized	VBN	O	O
,	,	O	O
placebo-controlled	JJ	O	O
,	,	O	O
parallel-group	JJ	O	O
study	NN	O	O
.	.	O	O

Efficacy	NNP	o	OOt
was	VBD	O	O
evaluated	VBN	O	O
using	VBG	O	O
the	DT	O	O
caregiver-rated	JJ	O	O
Aberrant	NNP	o	OME
Behavior	NNP	o	OME
Checklist	NNP	o	OME
Irritability	NNP	o	OME
subscale	NN	o	OME
(	(	o	OME
primary	JJ	o	OME
efficacy	NN	o	OME
measure	NN	o	OME
)	)	o	OME
and	CC	o	O
the	DT	o	O
clinician-rated	JJ	o	OME
Clinical	JJ	o	OME
Global	NNP	o	OME
Impressions-Improvement	NNP	o	OME
score	NN	o	OME
.	.	o	O

Safety	NNP	o	OOt
and	CC	o	OOt
tolerability	NN	o	OOt
were	VBD	O	O
also	RB	O	O
assessed	VBN	O	O
.	.	O	O

RESULTS	NNP	O	O
At	IN	O	O
week	NN	O	O
8	CD	O	O
,	,	O	O
all	DT	O	O
aripiprazole	JJ	i	IPM
doses	NNS	O	O
produced	VBN	O	O
significantly	RB	O	O
greater	JJR	O	O
improvement	NN	o	OOt
than	IN	O	O
placebo	NN	O	O
in	IN	O	O
mean	JJ	O	O
Aberrant	NNP	o	OME
Behavior	NNP	o	OME
Checklist	NNP	o	OME
Irritability	NNP	o	OME
subscale	NN	o	OME
scores	NNS	o	OME
(	(	O	O
5	CD	O	O
mg/day	NN	O	O
,	,	O	O
-12.4	NNP	O	O
;	:	O	O
10	CD	O	O
mg/day	NN	O	O
,	,	O	O
-13.2	NNP	O	O
;	:	O	O
15	CD	O	O
mg/day	NN	O	O
,	,	O	O
-14.4	NNP	O	O
;	:	O	O
versus	NN	O	O
placebo	NN	O	O
,	,	O	O
-8.4	NNP	O	O
;	:	O	O
all	DT	O	O
p	VBP	O	O
<	NNP	O	O
.05	NNP	O	O
)	)	O	O
.	.	O	O

All	DT	O	O
aripiprazole	JJ	i	IPM
doses	NNS	O	O
demonstrated	VBN	O	O
significantly	RB	O	O
greater	JJR	O	O
improvements	NNS	o	OME
in	IN	o	OME
mean	JJ	o	OME
Clinical	JJ	o	OME
Global	NNP	o	OME
Impressions-Improvement	NNP	o	OME
score	NN	o	OME
than	IN	O	O
placebo	NN	i	IC
at	IN	O	O
week	NN	O	O
8	CD	O	O
.	.	O	O

Discontinuation	NN	O	O
rates	NNS	O	O
due	JJ	O	O
to	TO	O	O
adverse	JJ	o	OA
events	NNS	o	OA
were	VBD	O	O
as	IN	O	O
follows	VBZ	O	O
:	:	O	O
placebo	VB	O	O
7.7	CD	O	O
%	NN	O	O
,	,	O	O
aripiprazole	JJ	O	O
5	CD	O	O
mg/day	JJ	O	O
9.4	CD	O	O
%	NN	O	O
,	,	O	O
10	CD	O	O
mg/day	JJ	O	O
13.6	CD	O	O
%	NN	O	O
,	,	O	O
and	CC	O	O
15	CD	O	O
mg/day	JJ	O	O
7.4	CD	O	O
%	NN	O	O
.	.	O	O

The	DT	O	O
most	RBS	O	O
common	JJ	O	O
adverse	JJ	o	OA
event	NN	o	OA
leading	VBG	O	O
to	TO	O	O
discontinuation	NN	O	O
was	VBD	O	O
sedation	NN	o	O
.	.	o	O

There	EX	O	O
were	VBD	O	O
two	CD	O	O
serious	JJ	o	OA
adverse	JJ	o	OA
events	NNS	o	OA
:	:	o	O
presyncope	NN	o	OA
(	(	O	O
5	CD	O	O
mg/day	NN	O	O
)	)	O	O
and	CC	O	O
aggression	NN	o	OA
(	(	O	O
10	CD	O	O
mg/day	NN	O	O
)	)	O	O
.	.	O	O

At	IN	O	O
week	NN	O	O
8	CD	O	O
,	,	O	O
mean	JJ	O	O
weight	NN	o	OPH
change	NN	o	OPH
(	(	O	O
last	JJ	O	O
observation	NN	O	O
carried	VBD	O	O
forward	RB	O	O
)	)	O	O
was	VBD	O	O
as	IN	O	O
follows	VBZ	O	O
:	:	O	O
placebo	NN	O	O
+0.3	NNP	O	O
kg	NN	O	O
,	,	O	O
aripiprazole	JJ	i	IPM
5	CD	O	O
mg/day	JJ	O	O
+1.3	NNP	O	O
kg	NN	O	O
,	,	O	O
10	CD	O	O
mg/day	NN	O	O
+1.3	NNP	O	O
kg	NN	O	O
,	,	O	O
and	CC	O	O
15	CD	O	O
mg/day	NN	O	O
+1.5	NNP	O	O
kg	NN	O	O
;	:	O	O
all	DT	O	O
p	VBP	O	O
<	JJ	O	O
.05	NNP	O	O
versus	NN	O	O
placebo	NN	i	IC
.	.	i	O

CONCLUSIONS	NNP	O	O
Aripiprazole	NNP	i	IPM
was	VBD	O	O
efficacious	JJ	o	OOt
and	CC	O	O
generally	RB	O	O
safe	JJ	o	OOt
and	CC	O	O
well	RB	o	OOt
tolerated	VBN	o	OOt
in	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
children	NNS	p	O
and	CC	p	O
adolescents	NNS	p	O
with	IN	p	O
irritability	NN	p	PC
associated	VBN	p	O
with	IN	p	O
autistic	JJ	p	PC
disorder	NN	p	PC
.	.	p	PC

Low-intensity	NNP	i	IPH
exercise	NN	i	IPH
and	CC	O	O
reduction	NN	O	O
of	IN	O	O
the	DT	o	O
risk	NN	o	OPH
for	IN	o	OPH
falls	NNS	o	OPH
among	IN	p	O
at-risk	JJ	p	O
elders	NNS	p	O
.	.	p	O

BACKGROUND	NNP	O	O
Among	IN	O	O
elderly	JJ	p	O
persons	NNS	p	O
,	,	O	O
falls	VBZ	o	OPH
account	NN	O	O
for	IN	O	O
87	CD	O	O
%	NN	O	O
of	IN	O	O
all	DT	O	O
fractures	NNS	O	O
and	CC	O	O
are	VBP	O	O
contributing	VBG	O	O
factors	NNS	O	O
in	IN	O	O
many	JJ	O	O
nursing	NN	O	O
home	NN	O	O
admissions	NNS	O	O
.	.	O	O

This	DT	O	O
study	NN	O	O
evaluated	VBD	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
an	DT	O	O
easily	RB	O	O
implemented	VBN	O	O
,	,	O	O
low-intensity	JJ	i	IPH
exercise	NN	i	IPH
program	NN	i	IPH
on	IN	O	O
the	DT	O	O
incidence	NN	o	OPH
of	IN	o	OPH
falls	NNS	o	OPH
and	CC	p	O
the	DT	p	O
time	NN	o	OPH
to	TO	o	OPH
first	VB	o	OPH
fall	NN	o	OPH
among	IN	p	O
a	DT	p	O
clinically	RB	p	O
defined	JJ	p	O
population	NN	p	O
of	IN	p	O
elderly	JJ	p	O
men	NNS	p	O
and	CC	p	O
women	NNS	p	O
.	.	p	O

METHODS	VB	O	O
This	DT	O	O
community-based	JJ	O	O
,	,	O	O
randomized	JJ	O	O
trial	NN	O	O
compared	VBN	O	O
the	DT	O	O
exercise	NN	i	IPH
intervention	NN	i	IPH
with	IN	O	O
a	DT	O	O
no-intervention	JJ	i	IC
control	NN	i	IC
.	.	i	IC

The	DT	p	O
participants	NNS	p	O
were	VBD	p	O
294	CD	p	O
men	NNS	p	O
and	CC	p	O
women	NNS	p	O
,	,	p	O
aged	VBD	p	O
60	CD	p	O
years	NNS	p	O
or	CC	p	O
older	JJR	p	O
,	,	p	O
who	WP	p	O
had	VBD	p	O
either	CC	p	O
a	DT	p	O
hospital	JJ	p	O
admission	NN	p	O
or	CC	p	O
bed	NN	p	O
rest	NN	p	O
for	IN	p	O
2	CD	p	O
days	NNS	p	O
or	CC	p	O
more	JJR	p	O
within	IN	p	O
the	DT	p	O
previous	JJ	p	O
month	NN	p	O
.	.	p	O

Exercise	NN	i	IPH
participants	NNS	O	O
were	VBD	O	O
scheduled	VBN	O	O
to	TO	O	O
attend	VB	O	O
exercise	NN	i	IPH
sessions	NNS	i	IPH
lasting	VBG	O	O
45	CD	O	O
minutes	NNS	O	O
,	,	O	O
including	VBG	O	O
warm-up	JJ	O	O
and	CC	O	O
cool-down	JJ	O	O
,	,	O	O
3	CD	O	O
times	NNS	O	O
a	DT	O	O
week	NN	O	O
for	IN	O	O
8	CD	O	O
weeks	NNS	O	O
(	(	O	O
24	CD	O	O
sessions	NNS	O	O
)	)	O	O
.	.	O	O

Assessments	NNS	O	O
included	VBD	O	O
gait	NN	o	OPH
and	CC	o	OPH
balance	NN	o	OPH
measures	NNS	o	OPH
,	,	o	O
self-reported	JJ	o	OPH
physical	JJ	o	OPH
function	NN	o	OPH
,	,	O	O
the	DT	O	O
number	NN	o	OME
of	IN	o	OME
medications	NNS	o	OME
being	VBG	o	OME
taking	VBG	o	OME
at	IN	o	OME
baseline	NN	o	OME
,	,	O	O
participant	JJ	O	O
age	NN	O	O
,	,	O	O
sex	NN	O	O
,	,	O	O
and	CC	O	O
history	NN	o	OOt
of	IN	o	OOt
falling	VBG	o	OOt
.	.	o	O

Falls	NNS	o	OPH
were	VBD	O	O
tracked	VBN	O	O
for	IN	O	O
1	CD	O	O
year	NN	O	O
after	IN	O	O
each	DT	O	O
participant	NN	O	O
's	POS	O	O
baseline	JJ	O	O
assessment	NN	O	O
.	.	O	O

RESULTS	VB	O	O
29	CD	O	O
%	NN	O	O
of	IN	O	O
the	DT	O	O
study	NN	O	O
participants	NNS	O	O
reported	VBD	O	O
a	DT	O	O
fall	NN	o	OPH
during	IN	O	O
the	DT	O	O
study	NN	O	O
period	NN	O	O
.	.	O	O

The	DT	O	O
effect	NN	O	O
of	IN	O	O
exercise	NN	i	IPH
in	IN	O	O
preventing	VBG	o	OOt
falls	NNS	o	OOt
varied	VBN	O	O
significantly	RB	O	O
by	IN	O	O
baseline	JJ	O	O
physical	JJ	O	O
function	NN	O	O
level	NN	O	O
(	(	O	O
p	JJ	O	O
<	NN	O	O
or	CC	O	O
=.002	NN	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
risk	NN	o	OPH
for	IN	o	OPH
falls	NNS	o	OPH
decreased	VBN	O	O
for	IN	O	O
exercise	NN	O	O
participants	NNS	O	O
with	IN	O	O
low	JJ	O	O
baseline	NN	O	O
physical	JJ	O	O
functioning	NN	O	O
(	(	O	O
hazard	JJ	O	O
ratio	NN	O	O
,	,	O	O
.51	NN	O	O
)	)	O	O
but	CC	O	O
increased	VBD	O	O
for	IN	O	O
exercise	NN	O	O
participants	NNS	O	O
with	IN	O	O
high	JJ	O	O
baseline	NN	O	O
physical	JJ	O	O
functioning	NN	O	O
(	(	O	O
hazard	JJ	O	O
ratio	NN	O	O
,	,	O	O
3.51	CD	O	O
)	)	O	O
.	.	O	O

CONCLUSIONS	VB	O	O
This	DT	O	O
easily	RB	O	O
implemented	VBN	O	O
,	,	O	O
low-intensity	JJ	i	IPH
exercise	NN	i	IPH
program	NN	i	IPH
appears	VBZ	O	O
to	TO	O	O
reduce	VB	O	O
the	DT	O	O
risk	NN	o	OPH
for	IN	o	OPH
falls	NNS	o	OPH
among	IN	p	O
elderly	JJ	p	O
men	NNS	p	O
and	CC	p	O
women	NNS	p	O
recovering	VBG	p	O
from	IN	p	O
recent	JJ	p	O
hospitalizations	NNS	p	O
,	,	p	O
bed	VBD	p	O
rest	NN	p	O
,	,	p	O
or	CC	p	O
both	DT	p	O
who	WP	p	O
have	VBP	p	O
low	JJ	p	O
levels	NNS	p	O
of	IN	p	O
physical	JJ	p	O
functioning	NN	p	O
.	.	p	O

Insular	JJ	O	O
and	CC	O	O
anterior	JJ	O	O
cingulate	NN	O	O
circuits	NNS	O	O
in	IN	O	O
smokers	NNS	p	O
with	IN	p	O
schizophrenia	NN	p	PC
.	.	p	O

Schizophrenia	NNP	p	PC
(	(	p	O
SZ	NNP	p	PC
)	)	p	O
is	VBZ	O	O
associated	VBN	O	O
with	IN	O	O
high	JJ	O	O
rates	NNS	O	O
of	IN	O	O
smoking	NN	O	O
.	.	O	O

We	PRP	O	O
previously	RB	O	O
found	VBD	O	O
that	IN	O	O
resting	VBG	O	O
state	NN	O	O
functional	JJ	O	O
connectivity	NN	O	O
(	(	O	O
rsFC	NN	O	O
)	)	O	O
between	IN	O	O
the	DT	O	O
dorsal	NN	O	O
anterior	JJ	O	O
cingulate	NN	O	O
(	(	O	O
dACC	NN	O	O
)	)	O	O
and	CC	O	O
striatum	NN	O	O
is	VBZ	O	O
independently	RB	O	O
associated	VBN	O	O
with	IN	O	O
nicotine	JJ	O	O
addiction	NN	O	O
and	CC	O	O
psychiatric	JJ	O	O
illness	NN	O	O
.	.	O	O

Since	IN	O	O
the	DT	O	O
insula	NN	O	O
is	VBZ	O	O
implicated	VBN	O	O
in	IN	O	O
nicotine	JJ	O	O
dependence	NN	O	O
,	,	O	O
we	PRP	O	O
hypothesized	VBD	O	O
that	IN	O	O
SZ	NNP	O	O
smokers	NNS	O	O
will	MD	O	O
have	VB	O	O
greater	JJR	O	O
dysfunction	NN	O	O
in	IN	O	O
smoking-related	JJ	O	O
insular	NN	O	O
and	CC	O	O
dACC	NN	O	O
circuits	NNS	O	O
than	IN	O	O
normal	JJ	p	PC
control	NN	p	PC
smokers	NNS	p	PC
(	(	p	O
NC	NNP	p	O
)	)	p	O
independent	JJ	O	O
of	IN	O	O
smoking	VBG	O	O
severity	NN	O	O
,	,	O	O
consistent	NN	O	O
with	IN	O	O
an	DT	O	O
inherent	JJ	O	O
disease-related	JJ	O	O
weakening	NN	O	O
of	IN	O	O
smoking-related	JJ	O	O
circuits	NNS	O	O
.	.	O	O

Nicotine	NNP	O	O
challenge	NN	O	O
was	VBD	O	O
used	VBN	O	O
to	TO	O	O
demonstrate	VB	O	O
that	DT	O	O
decreased	VBD	O	O
rsFC	NN	O	O
in	IN	O	O
identified	JJ	O	O
circuits	NNS	O	O
reflects	VBZ	O	O
addiction	JJ	O	O
trait	NN	O	O
and	CC	O	O
is	VBZ	O	O
not	RB	O	O
affected	VBN	O	O
by	IN	O	O
pharmacological	JJ	O	O
state	NN	O	O
.	.	O	O

Twenty-four	CD	p	PSS
NC	NNP	p	PC
smokers	NNS	p	O
and	CC	p	O
20	CD	p	PSS
smokers	NNS	p	O
with	IN	p	O
SZ	NNP	p	PC
matched	VBD	p	O
on	IN	p	O
nicotine	JJ	p	O
addiction	NN	p	O
severity	NN	p	O
participated	VBN	O	O
in	IN	O	O
a	DT	O	O
resting	NN	i	IPH
state	NN	i	IPH
fMRI	NN	i	IPH
study	NN	i	IPH
and	CC	i	IPH
were	VBD	i	IPH
scanned	VBN	i	IPH
during	IN	i	IPH
two	CD	i	IPH
separate	JJ	i	IPH
sessions	NNS	i	IPH
while	IN	i	IPH
receiving	VBG	i	IPH
a	DT	i	IPH
placebo	NN	i	IC
or	CC	i	IPH
nicotine	JJ	i	IPM
patch	NN	i	IPM
,	,	i	IPM
in	IN	i	IPH
a	DT	i	IPH
randomized	JJ	i	IPH
,	,	i	IPH
cross-over	JJ	i	IPH
design	NN	i	IPH
.	.	i	O

Using	VBG	O	O
individualized	JJ	O	O
,	,	O	O
anatomically	RB	O	O
defined	VBN	O	O
anterior	JJ	O	O
and	CC	O	O
posterior	JJ	O	O
insula	NN	O	O
and	CC	O	O
dACC	NN	O	O
as	IN	O	O
regions	NNS	O	O
of	IN	O	O
interest	NN	O	O
(	(	O	O
ROI	NNP	O	O
)	)	O	O
,	,	O	O
whole	JJ	O	O
brain	NN	O	O
rsFC	NN	O	O
was	VBD	O	O
performed	VBN	O	O
using	VBG	O	O
each	DT	O	O
ROI	NNP	O	O
as	IN	O	O
a	DT	O	O
seed	NN	O	O
.	.	O	O

Significant	NNP	O	O
negative	JJ	O	O
correlations	NNS	O	O
between	IN	O	O
smoking	VBG	o	OME
severity	NN	o	OME
and	CC	o	O
rsFC	NN	o	OPH
between	IN	o	OPH
insula	NN	o	OPH
,	,	O	O
dACC	NN	O	O
and	CC	O	O
striatum	NN	O	O
were	VBD	O	O
found	VBN	O	O
for	IN	O	O
both	DT	O	O
groups	NNS	O	O
.	.	O	O

Furthermore	RB	O	O
,	,	O	O
smokers	NNS	p	O
with	IN	p	O
SZ	NNP	p	PC
demonstrated	VBD	O	O
additive	JJ	O	O
reductions	NNS	O	O
in	IN	O	O
circuit	NN	O	O
strength	NN	O	O
between	IN	O	O
the	DT	O	O
dACC	NN	O	O
and	CC	O	O
insula	NN	O	O
compared	VBN	O	O
to	TO	O	O
NC	NNP	p	O
smokers	NNS	p	O
independent	JJ	O	O
of	IN	O	O
smoking	VBG	O	O
severity	NN	O	O
.	.	O	O

Nicotine	NNP	o	OOt
challenge	NN	o	OOt
did	VBD	O	O
not	RB	O	O
significantly	RB	O	O
alter	VB	o	OPH
rsFC	NN	o	OPH
in	IN	o	OPH
insula-dACC-striatal	JJ	o	OPH
circuits	NNS	o	OPH
.	.	o	OPH

Reduced	VBN	O	O
rsFC	JJ	o	OPH
strength	NN	o	OPH
between	IN	O	O
the	DT	O	O
insula	NN	O	O
,	,	O	O
dACC	NN	O	O
and	CC	O	O
striatum	NN	O	O
is	VBZ	O	O
associated	VBN	O	O
with	IN	O	O
nicotine	JJ	O	O
addiction	NN	O	O
severity	NN	O	O
in	IN	O	O
both	DT	O	O
non-psychiatrically	RB	O	O
ill	NN	O	O
and	CC	O	O
in	IN	O	O
SZ	NNP	O	O
smokers	NNS	O	O
.	.	O	O

Decreased	VBN	O	O
insula-dACC	JJ	O	O
rsFC	NN	O	O
may	MD	O	O
index	NN	O	O
overlapping	VBG	O	O
circuitry	NN	O	O
associated	VBN	O	O
with	IN	O	O
smoking	NN	O	O
and	CC	O	O
SZ	NNP	O	O
.	.	O	O

Relationship	NN	O	O
between	IN	O	O
endogenous	JJ	i	IPM
estrogen	NN	i	IPM
concentrations	NNS	i	IPM
and	CC	O	O
serum	NN	i	IPM
cholesteryl	NN	i	IPM
ester	NN	i	IPM
transfer	NN	O	O
protein	NN	O	O
concentrations	NNS	O	O
in	IN	p	O
Chinese	JJ	p	O
women	NNS	p	PSE
.	.	p	O

BACKGROUND	NNP	O	O
CETP	NNP	O	O
plays	VBZ	O	O
an	DT	O	O
important	JJ	O	O
role	NN	O	O
in	IN	O	O
HDL	NNP	O	O
metabolism	NN	O	O
and	CC	O	O
in	IN	O	O
the	DT	O	O
reverse	NN	O	O
cholesterol	NN	O	O
transport	NN	O	O
pathway	NN	O	O
.	.	O	O

METHODS	NNP	O	O
The	DT	O	O
relationship	NN	O	O
between	IN	O	O
the	DT	O	O
changes	NNS	O	O
of	IN	O	O
endogenous	JJ	O	O
estrogen	NN	O	O
and	CC	O	O
the	DT	O	O
concentration	NN	O	O
of	IN	O	O
cholesteryl	NN	O	O
ester	NN	O	O
transfer	NN	O	O
protein	NN	O	O
(	(	O	O
CETP	NNP	O	O
)	)	O	O
in	IN	O	O
the	DT	O	O
serum	NN	O	O
of	IN	O	O
Chinese	JJ	p	O
women	NNS	p	O
was	VBD	O	O
investigated	VBN	O	O
.	.	O	O

Serum	NNP	o	OPH
concentrations	NNS	o	OPH
of	IN	o	OPH
estradiol	NN	o	OPH
(	(	o	OPH
E	NNP	o	OPH
(	(	o	OPH
2	CD	o	OPH
)	)	o	OPH
)	)	o	OPH
,	,	o	O
follicle-stimulating	JJ	o	OPH
hormone	NN	o	OPH
(	(	o	OPH
FSH	NNP	o	OPH
)	)	o	OPH
,	,	o	O
CETP	NNP	o	OPH
and	CC	o	O
lipid	JJ	o	OPH
profile	NN	o	OPH
were	VBD	i	O
determined	VBN	i	O
in	IN	i	O
196	CD	i	O
Chinese	JJ	i	O
women	NNS	i	O
(	(	i	O
52	CD	i	O
premenopausal	NN	i	O
with	IN	i	O
ages	NNS	i	O
ranging	VBG	i	O
from	IN	i	O
18	CD	i	O
to	TO	i	O
40	CD	i	O
years	NNS	i	O
,	,	i	O
57	CD	i	O
perimenopausal	NN	i	O
from	IN	i	O
41	CD	i	O
to	TO	i	O
60	CD	i	O
years	NNS	i	O
,	,	i	O
and	CC	i	O
87	CD	i	O
postmenopausal	NN	i	O
from	IN	i	O
61	CD	i	O
to	TO	i	O
81	CD	i	O
years	NNS	i	O
)	)	i	O
.	.	i	O

RESULTS	NNP	O	O
Serum	NNP	o	OPH
CETP	NNP	o	OPH
concentration	NN	o	OPH
was	VBD	O	O
significantly	RB	O	O
lower	JJR	O	O
in	IN	O	O
postmenopausal	JJ	O	O
women	NNS	O	O
compared	VBN	O	O
with	IN	O	O
those	DT	O	O
in	IN	O	O
perimenopausal	NN	O	O
and	CC	O	O
premenopausal	JJ	O	O
women	NNS	O	O
(	(	O	O
1.39+/-1.06	JJ	O	O
,	,	O	O
2.36+/-1.50	JJ	O	O
and	CC	O	O
2.31+/-1.25	JJ	O	O
mg/l	NN	O	O
,	,	O	O
respectively	RB	O	O
,	,	O	O
P	NNP	O	O
<	NNP	O	O
0.0001	CD	O	O
)	)	O	O
.	.	O	O

Even	RB	O	O
in	IN	O	O
the	DT	O	O
women	NNS	p	O
around	IN	p	O
the	DT	p	O
menopausal	NN	p	O
,	,	O	O
CETP	NNP	o	OPH
concentration	NN	o	OPH
in	IN	O	O
postmenopause	NN	O	O
was	VBD	O	O
significantly	RB	O	O
lower	JJR	O	O
than	IN	O	O
that	DT	O	O
in	IN	O	O
premenopause	NN	O	O
(	(	O	O
1.93+/-1.33	JJ	O	O
vs.	IN	O	O
3.42+/-1.35	JJ	O	O
mg/l	NN	O	O
,	,	O	O
P	NNP	O	O
<	NNP	O	O
0.01	CD	O	O
)	)	O	O
.	.	O	O

In	IN	O	O
addition	NN	O	O
,	,	O	O
CETP	NNP	O	O
concentration	NN	O	O
had	VBD	O	O
a	DT	O	O
highly	RB	O	O
positive	JJ	O	O
correlation	NN	O	O
with	IN	O	O
serum	JJ	o	OPH
concentration	NN	o	OPH
of	IN	O	O
E	NNP	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
(	(	O	O
r=0.243	NN	O	O
,	,	O	O
P	NNP	O	O
<	NNP	O	O
0.001	CD	O	O
)	)	O	O
,	,	O	O
while	IN	O	O
negative	JJ	O	O
correlation	NN	O	O
of	IN	O	O
CETP	NNP	o	OPH
concentration	NN	o	OPH
with	IN	O	O
serum	JJ	o	OPH
concentration	NN	o	OPH
of	IN	o	OPH
FSH	NNP	o	OPH
was	VBD	O	O
found	VBN	O	O
(	(	O	O
r=-0.273	JJ	O	O
,	,	O	O
P	NNP	O	O
<	NNP	O	O
0.001	CD	O	O
)	)	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
Estrogen	NNP	O	O
may	MD	O	O
affect	VB	O	O
the	DT	O	O
concentration	NN	o	OPH
of	IN	o	OPH
CETP	NNP	o	OPH
.	.	o	O

Line-item	JJ	O	O
analysis	NN	O	O
of	IN	O	O
the	DT	O	O
Aberrant	NNP	O	O
Behavior	NNP	O	O
Checklist	NNP	O	O
:	:	O	O
results	NNS	O	O
from	IN	O	O
two	CD	p	O
studies	NNS	p	O
of	IN	p	O
aripiprazole	NN	i	IPM
in	IN	p	O
the	DT	p	O
treatment	NN	p	O
of	IN	p	O
irritability	NN	p	PC
associated	VBN	p	O
with	IN	p	O
autistic	JJ	p	PC
disorder	NN	p	PC
.	.	p	O

OBJECTIVES	CC	O	O
The	DT	O	O
aim	NN	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
evaluate	VB	O	O
the	DT	O	O
efficacy	NN	O	O
of	IN	O	O
aripiprazole	NN	i	IPM
in	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
discrete	JJ	O	O
symptoms	NNS	O	O
of	IN	O	O
irritability	NN	O	O
associated	VBN	O	O
with	IN	O	O
autistic	JJ	O	O
disorder	NN	O	O
,	,	O	O
as	RB	O	O
well	RB	O	O
as	IN	O	O
other	JJ	O	O
symptoms	NNS	O	O
captured	VBN	O	O
on	IN	O	O
the	DT	O	O
Aberrant	NNP	O	O
Behavior	NNP	O	O
Checklist	NNP	O	O
(	(	O	O
ABC	NNP	O	O
)	)	O	O
.	.	O	O

METHODS	NNP	O	O
This	DT	O	O
was	VBD	O	O
a	DT	O	O
post	NN	O	O
hoc	NN	O	O
analysis	NN	O	O
of	IN	O	O
data	NNS	O	O
from	IN	O	O
two	CD	p	O
8-week	JJ	p	O
,	,	p	O
randomized	VBN	p	O
,	,	p	O
double-blind	JJ	p	O
,	,	p	O
multicenter	JJ	p	O
trials	NNS	p	O
to	TO	O	O
evaluate	VB	O	O
the	DT	O	O
efficacy	NN	O	O
of	IN	O	O
aripiprazole	NN	i	IPM
dosed	VBN	i	IPM
flexibly	RB	i	IPM
(	(	O	O
2-15	JJ	O	O
mg/day	NN	O	O
,	,	O	O
n=47	NN	O	O
)	)	O	O
or	CC	O	O
fixed	VBN	O	O
(	(	O	O
5	CD	O	O
,	,	O	O
10	CD	O	O
,	,	O	O
or	CC	O	O
15	CD	O	O
mg/day	NN	O	O
,	,	O	O
n	JJ	O	O
=	NNP	O	O
166	CD	O	O
)	)	O	O
versus	NN	O	O
placebo	NN	i	IC
(	(	O	O
flexibly	RB	O	O
dosed	VBN	O	O
,	,	O	O
n	JJ	O	O
=	VBP	O	O
51	CD	O	O
;	:	O	O
fixed	VBN	O	O
dose	NN	O	O
,	,	O	O
n	JJ	O	O
=	NNP	O	O
52	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
effects	NNS	O	O
of	IN	O	O
treatment	NN	O	O
on	IN	O	O
the	DT	O	O
58	CD	O	O
ABC	NNP	O	O
items	NNS	O	O
were	VBD	O	O
evaluated	VBN	O	O
.	.	O	O

RESULTS	NNP	O	O
Statistically	NNP	O	O
significantly	RB	O	O
greater	JJR	O	O
improvement	NN	O	O
was	VBD	O	O
seen	VBN	O	O
with	IN	O	O
aripiprazole	JJ	i	IPM
versus	NN	i	O
placebo	NN	i	IC
(	(	O	O
p	JJ	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
for	IN	O	O
all	DT	O	O
arms	NNS	O	O
in	IN	O	O
both	DT	O	O
trials	NNS	O	O
on	IN	O	O
the	DT	O	O
ABC-Irritability	NNP	o	OME
total	JJ	o	OME
subscale	NN	o	OME
score	NN	o	OME
and	CC	o	OME
on	IN	o	OME
the	DT	o	OME
following	JJ	o	OME
individual	JJ	o	OME
ABC-Irritability	NNP	o	OME
items	NNS	o	OME
:	:	o	O
Mood	NNP	o	OME
changes	NNS	o	OME
quickly	RB	o	OME
,	,	o	O
cries/screams	NNS	o	OME
inappropriately	RB	o	OME
,	,	o	O
and	CC	o	O
stamps	JJ	o	OME
feet/bangs	NNS	o	OME
objects	NNS	o	OME
.	.	o	O

Several	JJ	O	O
additional	JJ	O	O
items	NNS	O	O
measuring	VBG	O	O
tantrum-like	JJ	o	OME
behaviors	NNS	o	OME
improved	VBN	O	O
in	IN	O	O
the	DT	O	O
flexibly	RB	O	O
dosed	VBN	O	O
trial	NN	O	O
and	CC	O	O
at	IN	O	O
least	JJS	O	O
one	CD	O	O
arm	NN	O	O
of	IN	O	O
the	DT	O	O
fixed-dose	JJ	O	O
trial	NN	O	O
(	(	O	O
p	JJ	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

Measures	NNS	o	OME
of	IN	o	OME
self-injurious	JJ	o	OME
behavior	NN	o	OME
,	,	O	O
which	WDT	O	O
had	VBD	O	O
low	JJ	O	O
baseline	NN	O	O
values	NNS	O	O
,	,	O	O
demonstrated	VBD	O	O
numerical	JJ	O	O
,	,	O	O
but	CC	O	O
not	RB	O	O
statistically	RB	O	O
significant	JJ	O	O
,	,	O	O
improvement	NN	O	O
in	IN	O	O
both	DT	O	O
trials	NNS	O	O
.	.	O	O

Statistically	RB	O	O
significantly	RB	O	O
greater	JJR	O	O
improvement	NN	O	O
in	IN	O	O
ABC	NNP	o	OME
Stereotypic	NNP	o	OME
Behavior	NNP	o	OME
and	CC	o	OME
Hyperactivity	NNP	o	OME
total	JJ	o	OME
subscale	NN	o	OME
scores	NNS	o	OME
was	VBD	O	O
also	RB	O	O
consistent	JJ	O	O
across	IN	O	O
all	DT	O	O
arms	NNS	O	O
in	IN	O	O
both	DT	O	O
trials	NNS	O	O
.	.	O	O

In	IN	O	O
particular	JJ	O	O
,	,	O	O
there	EX	O	O
was	VBD	O	O
a	DT	O	O
cluster	NN	O	O
of	IN	O	O
items	NNS	O	O
related	VBN	O	O
to	TO	O	O
hyperkinesis	VB	o	OME
that	WDT	O	O
were	VBD	O	O
consistently	RB	O	O
sensitive	JJ	O	O
to	TO	O	O
treatment	NN	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
Aripiprazole	NNP	i	IPM
is	VBZ	O	O
efficacious	JJ	O	O
in	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
irritability	NN	O	O
in	IN	O	O
children	NNS	p	O
and	CC	p	O
adolescents	NNS	p	O
with	IN	p	O
autistic	JJ	p	PC
disorder	NN	p	PC
,	,	O	O
particularly	RB	O	O
with	IN	O	O
respect	NN	O	O
to	TO	O	O
symptoms	NNS	O	O
associated	VBN	O	O
with	IN	O	O
tantrum	JJ	O	O
behavior	NN	O	O
.	.	O	O

A	DT	O	O
randomized	JJ	O	O
comparison	NN	O	O
of	IN	O	O
tamoxifen	NN	i	IPM
with	IN	O	O
surgical	JJ	i	IS
oophorectomy	NN	i	IS
in	IN	O	O
premenopausal	NN	p	PC
patients	NNS	p	O
with	IN	p	O
advanced	JJ	p	PC
breast	NN	p	PC
cancer	NN	p	PC
.	.	p	O

We	PRP	O	O
randomized	VBD	O	O
122	CD	p	PSS
premenopausal	JJ	p	PC
women	NNS	p	PSE
to	TO	O	O
receive	VB	O	O
tamoxifen	NN	i	IPM
or	CC	O	O
to	TO	O	O
undergo	VB	i	IS
a	DT	i	IS
surgical	JJ	i	IS
oophorectomy	NN	i	IS
.	.	i	IS

Of	IN	O	O
54	CD	p	PSS
evaluable	JJ	p	O
women	NNS	p	PSE
treated	VBN	p	O
with	IN	p	O
tamoxifen	NN	i	IPM
,	,	p	O
24	CD	p	O
%	NN	p	O
had	VBD	p	O
an	DT	p	O
objective	JJ	o	OOt
response	NN	o	OOt
,	,	p	O
as	IN	p	O
compared	VBN	p	O
with	IN	p	O
21	CD	p	O
%	NN	p	O
of	IN	p	O
53	CD	p	PSS
women	NNS	p	PSE
having	VBG	p	O
an	DT	p	O
oophorectomy	NN	i	IS
.	.	i	O

The	DT	O	O
median	JJ	o	OOt
duration	NN	o	OOt
of	IN	o	OOt
response	NN	o	OOt
for	IN	O	O
tamoxifen	NN	i	IPM
(	(	O	O
20	CD	O	O
months	NNS	O	O
)	)	O	O
was	VBD	O	O
longer	JJR	O	O
than	IN	O	O
that	DT	O	O
for	IN	O	O
surgical	JJ	i	IS
oophorectomy	NN	i	IS
(	(	O	O
7	CD	O	O
months	NNS	O	O
)	)	O	O
,	,	O	O
but	CC	O	O
this	DT	O	O
did	VBD	O	O
not	RB	O	O
achieve	VB	O	O
statistical	JJ	O	O
significance	NN	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
.056	NNP	O	O
)	)	O	O
.	.	O	O

Overall	JJ	o	OMO
median	JJ	o	OMO
survival	NN	o	OMO
was	VBD	O	O
15	CD	O	O
months	NNS	O	O
for	IN	O	O
58	CD	p	PSS
patients	NNS	p	O
receiving	VBG	O	O
tamoxifen	NN	O	O
and	CC	O	O
25	CD	O	O
months	NNS	O	O
for	IN	O	O
53	CD	O	O
patients	NNS	O	O
undergoing	JJ	O	O
oophorectomy	JJ	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
.18	NNP	O	O
)	)	O	O
.	.	O	O

Toxicity	NN	o	OA
was	VBD	O	O
greater	JJR	O	O
in	IN	O	O
those	DT	O	O
undergoing	JJ	O	O
oophorectomy	NN	O	O
,	,	O	O
though	IN	O	O
both	DT	o	O
treatments	NNS	o	O
were	VBD	o	O
well	RB	o	OOt
tolerated	VBN	o	OOt
.	.	o	OOt

In	IN	O	O
those	DT	O	O
premenopausal	JJ	p	PC
women	NNS	p	PSE
for	IN	O	O
whom	WP	O	O
hormonal	JJ	O	O
therapy	NN	O	O
is	VBZ	O	O
indicated	VBN	O	O
,	,	O	O
tamoxifen	EX	i	IPM
is	VBZ	O	O
a	DT	O	O
suitable	JJ	O	O
alternative	NN	O	O
to	TO	O	O
surgical	JJ	i	IS
oophorectomy	NN	i	IS
.	.	i	O

Efficacy	NN	o	OOt
and	CC	o	OOt
safety	NN	o	OOt
of	IN	O	O
mizolastine	JJ	i	IPM
10	CD	O	O
mg	NN	O	O
in	IN	O	O
a	DT	O	O
placebo-controlled	JJ	i	IC
comparison	NN	O	O
with	IN	O	O
loratadine	NN	i	IPM
in	IN	O	O
chronic	JJ	p	PC
idiopathic	JJ	p	PC
urticaria	NNS	p	PC
:	:	p	O
results	NNS	O	O
of	IN	O	O
the	DT	O	O
MILOR	NNP	O	O
Study	NNP	O	O
.	.	O	O

BACKGROUND	NNP	O	O
Mizolastine	NNP	i	IPM
is	VBZ	O	O
a	DT	O	O
novel	JJ	O	O
histamine	NN	O	O
H1-antagonist	NN	O	O
registered	VBD	O	O
in	IN	O	O
Europe	NNP	O	O
for	IN	O	O
the	DT	O	O
management	NN	O	O
of	IN	O	O
allergic	JJ	O	O
rhinitis	NN	O	O
and	CC	O	O
urticaria	NN	O	O
.	.	O	O

OBJECTIVES	NNP	O	O
To	TO	O	O
compare	VB	O	O
the	DT	O	O
clinical	JJ	O	O
efficacy	NN	o	O
and	CC	o	O
safety	NN	o	O
of	IN	O	O
mizolastine	NN	i	IPM
with	IN	i	IPM
loratadine	NN	i	IPM
and	CC	i	O
placebo	NN	i	IC
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
chronic	JJ	p	PC
idiopathic	JJ	p	PC
urticaria	NN	p	PC
(	(	p	PC
CIU	NNP	p	PC
)	)	p	PC
.	.	p	O

METHODS	CC	O	O
A	DT	O	O
multicentre	NN	O	O
,	,	O	O
double-blind	NN	O	O
,	,	O	O
parallel	JJ	O	O
group	NN	O	O
study	NN	O	O
was	VBD	O	O
designed	VBN	O	O
in	IN	O	O
which	WDT	O	O
247	CD	p	PSS
patients	NNS	p	O
with	IN	p	O
CIU	NNP	p	PC
were	VBD	O	O
randomised	VBN	O	O
after	IN	O	O
a	DT	O	O
1-week	JJ	O	O
placebo	NN	i	IC
run-in	JJ	O	O
period	NN	O	O
to	TO	O	O
10	CD	O	O
mg	NNS	O	O
daily	JJ	O	O
mizolastine	NN	i	IPM
(	(	O	O
n	JJ	O	O
=	NNP	O	O
88	CD	O	O
)	)	O	O
,	,	O	O
10	CD	O	O
mg	JJ	O	O
daily	JJ	O	O
loratadine	NN	i	IPM
(	(	O	O
n	JJ	O	O
=	NNP	O	O
79	CD	O	O
)	)	O	O
,	,	O	O
or	CC	O	O
placebo	NN	i	IC
(	(	O	O
n	JJ	O	O
=	NNP	O	O
80	CD	O	O
)	)	O	O
for	IN	O	O
a	DT	O	O
4-week	JJ	O	O
treatment	NN	O	O
period	NN	O	O
.	.	O	O

RESULTS	NNP	O	O
Mizolastine	NNP	i	IPM
and	CC	O	O
loratadine	VB	i	IPM
both	DT	O	O
relieved	JJ	o	OPH
symptoms	NNS	o	OPH
of	IN	o	OPH
CIU	NNP	o	OPH
.	.	o	O

After	IN	O	O
2	CD	O	O
weeks	NNS	O	O
'	POS	O	O
treatment	NN	O	O
,	,	O	O
the	DT	O	O
severity	NN	o	OPH
of	IN	o	OPH
pruritus	NN	o	OPH
(	(	o	OPH
visual	JJ	o	OPH
analogue	NN	o	OPH
score	NN	o	OPH
(	(	o	OPH
VAS	NNP	o	OPH
)	)	o	OPH
assessed	VBN	o	OPH
by	IN	o	OPH
patients	NNS	o	OPH
)	)	o	OPH
decreased	VBD	O	O
significantly	RB	O	O
in	IN	O	O
both	CC	O	O
the	DT	O	O
mizolastine	NN	i	IPM
and	CC	i	IPM
loratadine	NN	i	IPM
groups	NNS	O	O
compared	VBN	O	O
with	IN	O	O
placebo	NN	i	IC
(	(	i	O
mizolastine	NN	i	IPM
:	:	i	O
-36.7	NN	O	O
mm	NN	O	O
,	,	O	O
P	NNP	O	O
=	NNP	O	O
0.0001	CD	O	O
;	:	O	O
loratadine	NN	i	IPM
:	:	i	O
-29.8	NN	O	O
,	,	O	O
P	NNP	O	O
=	NNP	O	O
0.0071	CD	O	O
;	:	O	O
placebo	NN	i	IC
:	:	i	O
-16.3	NN	O	O
)	)	O	O
;	:	O	O
this	DT	O	O
improvement	NN	O	O
with	IN	O	O
both	DT	O	O
active	JJ	O	O
treatments	NNS	O	O
was	VBD	O	O
maintained	VBN	O	O
throughout	IN	O	O
the	DT	O	O
treatment	NN	O	O
period	NN	O	O
,	,	O	O
the	DT	O	O
difference	NN	O	O
being	VBG	O	O
significant	JJ	O	O
only	RB	O	O
for	IN	O	O
the	DT	O	O
mizolastine	NN	O	O
group	NN	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.0090	CD	O	O
)	)	O	O
.	.	O	O

Both	DT	O	O
active	JJ	O	O
treatments	NNS	O	O
were	VBD	O	O
also	RB	O	O
associated	VBN	O	O
with	IN	O	O
reduced	JJ	O	O
weekly	JJ	O	O
episodes	NNS	o	OPH
of	IN	o	OPH
urticaria	NNS	o	OPH
compared	VBN	O	O
with	IN	O	O
placebo	NN	i	IC
,	,	O	O
which	WDT	O	O
was	VBD	O	O
significant	JJ	O	O
after	IN	O	O
2	CD	O	O
weeks	NNS	O	O
'	POS	O	O
treatment	NN	O	O
(	(	i	O
mizolastine	NN	i	IPM
:	:	i	O
7.9	CD	O	O
episodes	NNS	O	O
,	,	O	O
P	NNP	O	O
=	NNP	O	O
0.0061	CD	O	O
;	:	O	O
loratadine	NN	i	IPM
:	:	i	O
8.3	CD	O	O
,	,	O	O
P	NNP	O	O
=	NNP	O	O
0.0221	CD	O	O
;	:	O	O
placebo	NN	i	IC
:	:	i	O
13.3	CD	O	O
)	)	O	O
.	.	O	O

Angioedema	NNP	o	OPH
was	VBD	O	O
improved	VBN	O	O
to	TO	O	O
a	DT	O	O
clinically	RB	O	O
significant	JJ	O	O
extent	NN	O	O
with	IN	O	O
mizolastine	NN	i	IPM
,	,	O	O
and	CC	O	O
loratadine	NN	i	IPM
compared	VBN	O	O
with	IN	O	O
placebo	NN	i	IC
in	IN	O	O
those	DT	O	O
patients	NNS	p	O
who	WP	p	O
had	VBD	p	O
this	DT	p	O
symptom	NN	p	O
before	IN	p	O
treatment	NN	p	O
.	.	p	O

Overall	JJ	o	OOt
tolerability	NN	o	OOt
of	IN	O	O
both	DT	O	O
treatments	NNS	O	O
was	VBD	O	O
similar	JJ	O	O
to	TO	O	O
placebo	VB	i	IC
,	,	O	O
and	CC	O	O
there	EX	O	O
were	VBD	O	O
no	DT	O	O
clinically	RB	O	O
relevant	JJ	O	O
effects	NNS	o	OPH
on	IN	o	OPH
cardiac	JJ	o	OPH
repolarisation	NN	o	OPH
with	IN	O	O
either	DT	O	O
mizolastine	NN	i	IPM
or	CC	i	IPM
loratadine	NN	i	IPM
.	.	i	O

CONCLUSION	NNP	O	O
Mizolastine	NNP	i	IPM
(	(	O	O
10	CD	O	O
mg	NNS	O	O
daily	RB	O	O
)	)	O	O
is	VBZ	O	O
confirmed	VBN	O	O
as	IN	O	O
an	DT	O	O
effective	JJ	o	OOt
and	CC	o	OOt
well	RB	o	OOt
tolerated	JJ	o	OOt
agent	NN	O	O
,	,	O	O
comparable	JJ	O	O
to	TO	O	O
loratadine	VB	O	O
and	CC	O	O
superior	VB	O	O
to	TO	O	O
placebo	VB	i	IC
,	,	O	O
for	IN	O	O
the	DT	O	O
management	NN	O	O
of	IN	O	O
CIU	NNP	O	O
.	.	O	O

Mizolastine	NNP	i	IPM
acted	VBD	O	O
as	RB	O	O
rapidly	RB	O	O
as	IN	O	O
loratadine	NN	i	IPM
in	IN	O	O
improving	VBG	O	O
urticarial	JJ	o	OPH
symptoms	NNS	o	OPH
from	IN	O	O
the	DT	O	O
first	JJ	O	O
day	NN	O	O
of	IN	O	O
treatment	NN	O	O
.	.	O	O

Anti-angiogenic	JJ	O	O
effect	NN	O	O
of	IN	O	O
tamoxifen	NN	i	IPM
combined	VBN	i	IPM
with	IN	i	IPM
epirubicin	NN	i	IPM
in	IN	O	O
breast	NN	p	PC
cancer	NN	p	PC
patients	NNS	p	O
.	.	p	O

Vascular	JJ	O	O
endothelial	JJ	O	O
growth	NN	O	O
factor	NN	O	O
A	NNP	O	O
(	(	O	O
VEGF-A	NNP	O	O
)	)	O	O
and	CC	O	O
vascular	JJ	O	O
endothelial	JJ	O	O
growth	NN	O	O
factor	NN	O	O
receptor	NN	O	O
2	CD	O	O
(	(	O	O
VEGFR2	NNP	O	O
)	)	O	O
are	VBP	O	O
the	DT	O	O
key	JJ	O	O
factors	NNS	O	O
mediating	VBG	O	O
neo-vascularization	NN	O	O
.	.	O	O

They	PRP	O	O
are	VBP	O	O
often	RB	O	O
coexpressed	VBN	O	O
in	IN	O	O
breast	NN	O	O
cancer	NN	O	O
.	.	O	O

Sex	NNP	O	O
steroids	NNS	O	O
may	MD	O	O
stimulate	VB	O	O
angiogenesis	NN	O	O
via	IN	O	O
the	DT	O	O
estrogen	NN	O	O
receptor	NN	O	O
(	(	O	O
ER	NNP	O	O
)	)	O	O
pathway	RB	O	O
.	.	O	O

We	PRP	O	O
investigated	VBD	O	O
to	TO	O	O
compare	VB	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
the	DT	O	O
addition	NN	O	O
of	IN	O	O
tamoxifen	NN	i	IPM
to	TO	i	IPM
epirubicin	VB	i	IPM
versus	NN	i	IPM
epirubicin	FW	i	IPM
alone	RB	i	IPM
on	IN	O	O
VEGF	NNP	O	O
and	CC	O	O
VEGFR2	NNP	O	O
expression	NN	O	O
in	IN	O	O
breast	NN	O	O
cancer	NN	O	O
patients	NNS	O	O
.	.	O	O

The	DT	O	O
expression	NN	O	O
of	IN	O	O
VEGF	NNP	o	OPH
and	CC	o	OPH
VEGFR2	NNP	o	OPH
was	VBD	O	O
assessed	VBN	O	O
on	IN	O	O
tissue	NN	O	O
microarray	NN	O	O
by	IN	O	O
immunohistochemistry	NN	O	O
at	IN	O	O
baseline	JJ	O	O
conditions	NNS	O	O
and	CC	O	O
after	IN	O	O
treatments	NNS	O	O
in	IN	O	O
the	DT	O	O
case	NN	O	O
of	IN	O	O
191	CD	p	PSS
patients	NNS	p	O
with	IN	p	O
T2-4	NNP	p	PC
N0-1	NNP	p	PC
breast	NN	p	PC
cancer	NN	p	PC
enrolled	VBN	p	O
in	IN	p	O
a	DT	p	O
randomized	JJ	p	O
trial	NN	p	O
comparing	VBG	O	O
four	CD	O	O
cycles	NNS	O	O
of	IN	O	O
single	JJ	O	O
agent	NN	O	O
epirubicin	NN	O	O
versus	NN	O	O
epirubicin	NN	O	O
plus	CC	O	O
tamoxifen	NN	O	O
as	IN	O	O
primary	JJ	O	O
systemic	JJ	O	O
treatment	NN	O	O
.	.	O	O

Epirubicin	NNP	O	O
alone	RB	O	O
failed	VBD	O	O
to	TO	O	O
induce	VB	O	O
changes	NNS	o	OPH
in	IN	o	OPH
VEGF	NNP	o	OPH
expression	NN	o	OPH
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.54	CD	O	O
)	)	O	O
,	,	O	O
while	IN	O	O
the	DT	O	O
addition	NN	O	O
of	IN	O	O
tamoxifen	NN	i	IPM
to	TO	i	IPM
epirubicin	VB	i	IPM
resulted	VBN	O	O
in	IN	O	O
a	DT	O	O
significant	JJ	O	O
reduction	NN	O	O
in	IN	O	O
VEGF	NNP	o	OPH
expression	NN	o	OPH
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.001	CD	O	O
)	)	O	O
.	.	O	O

As	IN	O	O
a	DT	O	O
consequence	NN	O	O
,	,	O	O
baseline	NN	o	OPH
VEGF	NNP	o	OPH
had	VBD	O	O
a	DT	O	O
negative	JJ	O	O
prognostic	JJ	O	O
role	NN	O	O
in	IN	O	O
patients	NNS	O	O
who	WP	O	O
received	VBD	O	O
epirubicin	JJ	O	O
alone	RB	O	O
but	CC	O	O
not	RB	O	O
in	IN	O	O
patients	NNS	O	O
receiving	VBG	O	O
epirubicin	JJ	i	IPM
plus	CC	i	IPM
tamoxifen	JJ	i	IPM
(	(	O	O
interaction	JJ	O	O
test	NN	O	O
P	NNP	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

VEGFR2	NNP	o	OPH
expression	NN	o	OPH
increased	VBD	O	O
at	IN	O	O
residual	JJ	O	O
tumor	NN	O	O
histology	NN	O	O
in	IN	O	O
both	DT	O	O
treatment	NN	O	O
arms	NNS	O	O
,	,	O	O
with	IN	O	O
a	DT	O	O
lesser	JJR	O	O
extent	NN	O	O
in	IN	O	O
patients	NNS	O	O
receiving	VBG	O	O
tamoxifen	JJ	i	IPM
plus	CC	i	IPM
epirubicin	JJ	i	IPM
.	.	i	O

Decrease	NNP	O	O
in	IN	O	O
VEGFR2	NNP	o	OPH
expression	NN	o	OPH
was	VBD	O	O
significantly	RB	O	O
associated	VBN	O	O
with	IN	O	O
response	NN	o	OPH
rate	NN	o	OPH
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.02	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
addition	NN	i	IPM
of	IN	i	IPM
tamoxifen	NN	i	IPM
to	TO	i	IPM
epirubicin	VB	i	IPM
resulted	VBN	O	O
in	IN	O	O
a	DT	O	O
suppression	NN	o	OOt
of	IN	o	OOt
a	DT	o	OOt
key	JJ	o	OOt
angiogenic	JJ	o	OOt
pathway	NN	o	OOt
.	.	o	O

These	DT	O	O
data	NNS	O	O
suggest	VBP	O	O
a	DT	O	O
potential	JJ	O	O
synergism	NN	O	O
of	IN	O	O
these	DT	O	O
two	CD	O	O
drugs	NNS	O	O
.	.	O	O

Antibiotic	JJ	O	O
therapy	NN	O	O
of	IN	O	O
acute	JJ	O	O
exacerbations	NNS	O	O
of	IN	O	O
chronic	JJ	O	O
bronchitis	NN	O	O
.	.	O	O

A	DT	O	O
controlled	VBN	O	O
study	NN	O	O
using	VBG	O	O
tetracycline	NN	i	IPM
.	.	i	O

We	PRP	O	O
conducted	VBD	O	O
a	DT	O	O
double-blind	NN	O	O
,	,	O	O
randomized	VBN	O	O
,	,	O	O
placebo-controlled	JJ	i	IC
trial	NN	O	O
in	IN	O	O
40	CD	p	O
patients	NNS	p	O
to	TO	p	O
evaluate	VB	p	O
the	DT	p	O
need	NN	p	O
for	IN	p	O
antibiotics	NNS	p	O
in	IN	p	O
acute	JJ	p	O
exacerbations	NNS	p	O
of	IN	p	O
chronic	JJ	p	O
bronchitis	NN	p	O
.	.	p	O

All	DT	p	O
patients	NNS	p	O
were	VBD	p	O
sufficiently	RB	p	O
ill	VBN	p	O
to	TO	p	O
require	VB	p	O
hospitalization	NN	p	O
although	IN	p	O
none	NN	p	O
needed	VBD	p	O
ventilatory	JJ	p	O
support	NN	p	O
;	:	p	O
the	DT	p	O
presence	NN	p	O
of	IN	p	O
pneumonia	NN	p	O
was	VBD	p	O
excluded	VBN	p	O
.	.	p	O

Treatment	NNP	O	O
consisted	VBD	O	O
of	IN	O	O
bronchodilators	NNS	i	IPM
,	,	i	O
corticosteroids	NNS	i	IPM
,	,	O	O
and	CC	O	O
either	DT	O	O
tetracycline	NN	i	IPM
,	,	O	O
500	CD	O	O
mg	NN	O	O
,	,	O	O
or	CC	i	O
placebo	NN	i	IC
by	IN	O	O
mouth	NN	O	O
every	DT	O	O
6	CD	O	O
hours	NNS	O	O
for	IN	O	O
1	CD	O	O
week	NN	O	O
.	.	O	O

Arterial	JJ	o	OPH
blood	NN	o	OPH
gases	NNS	o	OPH
,	,	o	O
spirometric	JJ	o	OOt
tests	NNS	o	OOt
,	,	o	O
bacteriologic	JJ	o	OPH
evaluation	NN	o	OPH
of	IN	o	OPH
sputum	NN	o	OPH
,	,	o	O
and	CC	o	O
patient	NN	o	OOt
and	CC	o	OOt
physician	JJ	o	OOt
evaluation	NN	o	OOt
of	IN	o	OOt
the	DT	o	OOt
severity	NN	o	OPH
of	IN	o	OPH
illness	NN	o	OPH
were	VBD	O	O
assessed	VBN	O	O
at	IN	O	O
the	DT	O	O
beginning	NN	O	O
and	CC	O	O
end	NN	O	O
of	IN	O	O
the	DT	O	O
study	NN	O	O
.	.	O	O

All	DT	O	O
patients	NNS	O	O
improved	VBN	O	O
both	DT	O	O
symptomatically	RB	O	O
and	CC	O	O
by	IN	O	O
objective	JJ	O	O
measures	NNS	O	O
of	IN	O	O
lung	NN	O	O
function	NN	O	O
.	.	O	O

At	IN	O	O
the	DT	O	O
end	NN	O	O
of	IN	O	O
the	DT	O	O
study	NN	O	O
period	NN	O	O
there	EX	O	O
were	VBD	O	O
no	DT	O	O
differences	NNS	O	O
between	IN	O	O
those	DT	O	O
patients	NNS	O	O
receiving	VBG	O	O
tetracycline	NN	O	O
and	CC	O	O
those	DT	O	O
receiving	VBG	O	O
placebo	NN	i	IC
.	.	i	O

We	PRP	O	O
conclude	VBP	O	O
that	IN	O	O
antibiotic	JJ	O	O
therapy	NN	O	O
is	VBZ	O	O
not	RB	O	O
needed	VBN	O	O
in	IN	O	O
moderately	RB	p	O
ill	JJ	p	O
patients	NNS	p	O
with	IN	p	O
exacerbations	NNS	p	O
of	IN	p	O
chronic	JJ	p	O
bronchitis	NN	p	O
.	.	p	O

Treatment	NN	O	O
of	IN	O	O
duodenal	JJ	p	PC
ulcer	NN	p	PC
with	IN	O	O
low-dose	JJ	i	IPM
antacids	NNS	i	IPM
.	.	i	O

The	DT	O	O
aim	NN	O	O
of	IN	O	O
the	DT	O	O
present	JJ	O	O
investigation	NN	O	O
was	VBD	O	O
to	TO	O	O
compare	VB	O	O
the	DT	O	O
efficacy	NN	O	O
of	IN	O	O
a	DT	O	O
low-dose	JJ	i	IPM
antacid	NN	i	IPM
(	(	i	IPM
Maalox	NNP	i	IPM
70	CD	i	IPM
,	,	O	O
280	CD	O	O
mmol/day	NN	O	O
)	)	O	O
with	IN	O	O
that	DT	O	O
of	IN	O	O
the	DT	O	O
H2-receptor	NNP	i	IPM
antagonist	NN	i	IPM
cimetidine	NN	i	IPM
(	(	i	IPM
Tagamet	NNP	i	IPM
,	,	O	O
200	CD	O	O
mg	NN	O	O
three	CD	O	O
times	NNS	O	O
daily	RB	O	O
and	CC	O	O
400	CD	O	O
mg/day	NN	O	O
)	)	O	O
after	IN	O	O
14	CD	O	O
and	CC	O	O
28	CD	O	O
days	NNS	O	O
in	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
duodenal	JJ	p	PC
ulcer	NN	p	PC
.	.	p	O

The	DT	O	O
prospective	JJ	O	O
multicentre	NN	O	O
study	NN	O	O
included	VBD	O	O
171	CD	p	PSS
patients	NNS	p	O
with	IN	p	O
endoscopically	RB	p	O
confirmed	VBN	p	O
duodenal	JJ	p	PC
ulcers	NNS	p	PC
.	.	p	O

The	DT	O	O
patients	NNS	O	O
were	VBD	O	O
randomly	RB	O	O
assigned	VBN	O	O
to	TO	O	O
the	DT	O	O
treatment	NN	O	O
groups	NNS	O	O
with	IN	O	O
antacid	JJ	i	IPM
containing	VBG	i	IPM
Mg	NNP	i	IPM
and	CC	i	IPM
Al	NNP	i	IPM
hydroxide	NN	i	IPM
(	(	i	IPM
M	NNP	i	IPM
)	)	i	IPM
(	(	i	IPM
4	CD	i	IPM
X	RB	O	O
70	CD	O	O
mmol/day	NN	O	O
;	:	O	O
n	CC	O	O
=	VB	O	O
86	CD	O	O
)	)	O	O
or	CC	O	O
to	TO	O	O
the	DT	O	O
group	NN	O	O
receiving	VBG	O	O
cimetidine	NN	i	IPM
(	(	O	O
T	NNP	O	O
)	)	O	O
(	(	O	O
1000	CD	O	O
mg/day	NN	O	O
;	:	O	O
n	CC	O	O
=	VB	O	O
85	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
two	CD	p	O
treatment	NN	p	O
groups	NNS	p	O
were	VBD	O	O
matched	VBN	O	O
for	IN	O	O
age	NN	O	O
,	,	O	O
sex	NN	O	O
,	,	O	O
drinking	NN	O	O
and	CC	O	O
smoking	NN	O	O
habits	NNS	O	O
,	,	O	O
and	CC	O	O
drug	NN	O	O
use	NN	O	O
.	.	O	O

Endoscopic	JJ	O	O
examinations	NNS	O	O
were	VBD	O	O
carried	VBN	O	O
out	RP	O	O
before	IN	O	O
the	DT	O	O
start	NN	O	O
of	IN	O	O
treatment	NN	O	O
and	CC	O	O
14	CD	O	O
days	NNS	O	O
later	RB	O	O
.	.	O	O

If	IN	O	O
the	DT	O	O
ulcer	NN	O	O
was	VBD	O	O
still	RB	O	O
present	JJ	O	O
at	IN	O	O
this	DT	O	O
time	NN	O	O
,	,	O	O
the	DT	O	O
second	JJ	O	O
endoscopic	NN	O	O
examination	NN	O	O
was	VBD	O	O
done	VBN	O	O
after	IN	O	O
a	DT	O	O
further	JJ	O	O
14	CD	O	O
days	NNS	O	O
.	.	O	O

Endoscopically	RB	O	O
,	,	O	O
the	DT	O	O
ulcer	NN	O	O
had	VBD	O	O
healed	VBN	o	OPH
at	IN	O	O
14	CD	O	O
days	NNS	O	O
in	IN	O	O
38.8	CD	O	O
%	NN	O	O
(	(	O	O
M	NNP	O	O
)	)	O	O
and	CC	O	O
in	IN	O	O
34.9	CD	O	O
%	NN	O	O
(	(	O	O
T	NNP	O	O
)	)	O	O
and	CC	O	O
at	IN	O	O
28	CD	O	O
days	NNS	O	O
in	IN	O	O
80.0	CD	O	O
%	NN	O	O
(	(	O	O
M	NNP	O	O
)	)	O	O
and	CC	O	O
74.7	CD	O	O
%	NN	O	O
(	(	O	O
T	NNP	O	O
)	)	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

The	DT	O	O
healing	VBG	o	OPH
rate	NN	o	OPH
did	VBD	O	O
not	RB	O	O
differ	VB	O	O
significantly	RB	O	O
between	IN	O	O
the	DT	O	O
two	CD	O	O
treatment	NN	O	O
groups	NNS	O	O
.	.	O	O

Complaints	NNS	o	OOt
,	,	O	O
measured	VBN	O	O
as	IN	O	O
percentage	NN	O	O
of	IN	O	O
days	NNS	O	O
per	IN	O	O
week	NN	O	O
with	IN	O	O
upper	JJ	o	OPA
abdominal	JJ	o	OPA
pain	NN	o	OPA
,	,	O	O
were	VBD	O	O
significantly	RB	O	O
reduced	VBN	O	O
in	IN	O	O
both	DT	O	O
groups	NNS	O	O
.	.	O	O

No	DT	O	O
significant	JJ	O	O
differences	NNS	O	O
were	VBD	O	O
found	VBN	O	O
between	IN	O	O
the	DT	O	O
two	CD	O	O
treatment	NN	O	O
groups	NNS	O	O
with	IN	O	O
regard	NN	O	O
to	TO	O	O
pain	VB	o	OPA
relief	NN	o	OPA
or	CC	o	O
side	NN	o	OA
effects	NNS	o	OA
.	.	o	O

Treatment	NN	O	O
had	VBD	O	O
to	TO	O	O
be	VB	O	O
abandoned	VBN	O	O
in	IN	O	O
one	CD	O	O
patient	NN	O	O
receiving	VBG	O	O
antacid	NN	O	O
because	IN	O	O
of	IN	O	O
diarrhoea	NN	O	O
and	CC	O	O
in	IN	O	O
one	CD	O	O
patient	NN	O	O
receiving	VBG	O	O
cimetidine	NN	O	O
because	IN	O	O
of	IN	O	O
the	DT	O	O
absence	NN	O	O
of	IN	O	O
any	DT	O	O
response	NN	O	O
.	.	O	O

(	(	O	O
ABSTRACT	NNP	O	O
TRUNCATED	NNP	O	O
AT	NNP	O	O
250	CD	O	O
WORDS	NNP	O	O
)	)	O	O
Effect	NN	O	O
of	IN	O	O
ischemic	JJ	o	OPH
postconditioning	NN	o	OPH
in	IN	O	O
correction	NN	O	O
of	IN	O	O
tetralogy	NN	O	O
of	IN	O	O
Fallot	NNP	O	O
.	.	O	O

Inappropriate	NNP	O	O
myocardial	JJ	O	O
protection	NN	O	O
is	VBZ	O	O
considered	VBN	O	O
one	CD	O	O
of	IN	O	O
the	DT	O	O
main	JJ	O	O
causes	NNS	O	O
of	IN	O	O
mortality	NN	O	O
and	CC	O	O
morbidity	NN	O	O
in	IN	O	O
the	DT	O	O
correction	NN	O	O
of	IN	O	O
tetralogy	NN	p	O
of	IN	p	O
Fallot	NNP	p	O
(	(	p	O
TOF	NNP	p	O
)	)	p	O
.	.	p	O

Results	NNS	O	O
of	IN	O	O
previous	JJ	O	O
reports	NNS	O	O
about	IN	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
ischemic	JJ	O	O
postconditioning	NN	O	O
on	IN	O	O
myocardial	JJ	o	OPH
protection	NN	o	OPH
in	IN	O	O
animals	NNS	O	O
and	CC	O	O
humans	NNS	O	O
are	VBP	O	O
very	RB	O	O
encouraging	JJ	O	O
.	.	O	O

This	DT	O	O
randomized	JJ	O	O
and	CC	O	O
controlled	JJ	O	O
trial	NN	O	O
aimed	VBN	O	O
to	TO	O	O
assess	VB	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
ischemic	JJ	o	OPH
postconditioning	VBG	o	OPH
on	IN	O	O
protection	NN	o	OPH
against	IN	o	OPH
myocardial	JJ	o	OPH
ischemia	NN	o	OPH
reperfusion	NN	O	O
injury	NN	O	O
in	IN	O	O
TOF	NNP	p	O
patients	NNS	p	O
receiving	VBG	p	O
cardioplegia	NN	p	O
.	.	p	O

From	IN	p	O
January	NNP	p	O
2008	CD	p	O
to	TO	p	O
June	NNP	p	O
2010	CD	p	O
,	,	p	O
80	CD	p	O
consecutive	JJ	p	O
children	NNS	p	O
undergoing	VBG	p	O
correction	NN	p	O
of	IN	p	O
TOF	NNP	p	O
were	VBD	O	O
enrolled	VBN	i	IPH
and	CC	i	IPH
randomly	RB	i	IPH
assigned	VBN	i	IPH
to	TO	i	IPH
either	VB	i	IPH
a	DT	i	IPH
postconditioning	NN	i	IPH
group	NN	i	IPH
(	(	i	O
three	CD	i	IS
cycles	NNS	i	IS
of	IN	i	IS
30	CD	i	IS
seconds	NNS	i	IS
of	IN	i	IS
ischemia	NN	i	IS
and	CC	i	IS
30	CD	i	IS
seconds	NNS	i	IS
of	IN	i	IS
reperfusion	NN	i	IS
using	VBG	i	IS
re-clamping	JJ	i	IS
and	CC	i	O
de-clamping	JJ	i	IS
starting	VBG	i	IS
30	CD	i	IS
seconds	NNS	i	IS
after	IN	i	IS
the	DT	i	IS
initial	JJ	i	IS
de-clamping	NN	i	IS
of	IN	i	IS
the	DT	i	IS
aorta	NN	i	IS
,	,	i	IS
n	JJ	i	IS
=	NNP	i	IS
41	CD	i	IS
)	)	i	O
or	CC	i	O
a	DT	i	O
control	NN	i	IC
group	NN	i	IC
(	(	i	O
n	JJ	i	O
=	NNP	i	O
39	CD	i	O
)	)	i	O
.	.	i	O

Cardiac	NNP	o	OPH
troponin	NN	o	OPH
I	PRP	o	OPH
(	(	i	O
cTnI	NN	i	O
)	)	i	O
was	VBD	i	O
assayed	VBN	i	O
preoperatively	RB	i	O
,	,	i	O
and	CC	i	O
then	RB	i	O
4	CD	i	O
hours	NNS	i	O
,	,	i	O
8	CD	i	O
hours	NNS	i	O
,	,	i	O
12	CD	i	O
hours	NNS	i	O
,	,	i	O
20	CD	i	O
hours	NNS	i	O
,	,	i	O
and	CC	i	O
48	CD	i	O
hours	NNS	i	O
after	IN	i	IE
persistent	JJ	i	IE
reperfusion	NN	i	IE
.	.	i	O

The	DT	O	O
pre-	JJ	O	O
,	,	O	O
intra-	JJ	O	O
and	CC	O	O
postoperative	JJ	O	O
relevant	JJ	O	O
data	NNS	O	O
of	IN	O	O
all	DT	O	O
selected	VBN	O	O
patients	NNS	O	O
were	VBD	O	O
analyzed	VBN	O	O
.	.	O	O

As	IN	O	O
a	DT	O	O
result	NN	O	O
,	,	O	O
ischemic	JJ	O	O
postconditioning	NN	O	O
reduced	VBD	O	O
postoperative	JJ	o	OOt
peak	NN	o	OOt
release	NN	o	OOt
by	IN	O	O
45	CD	O	O
%	NN	O	O
for	IN	O	O
cTnI	NN	O	O
compared	VBN	O	O
with	IN	O	O
the	DT	O	O
control	NN	O	O
group	NN	O	O
(	(	O	O
0.43	CD	O	O
?	.	O	O
0.18	CD	O	O
ng/mL	JJ	O	O
versus	NN	O	O
0.78	CD	O	O
?	.	O	O
0.15	CD	O	O
ng/mL	NN	O	O
,	,	O	O
P	NNP	O	O
<	NNP	O	O
0.0001	CD	O	O
)	)	O	O
.	.	O	O

Ischemic	NNP	O	O
postconditioned	VBD	O	O
patients	NNS	O	O
had	VBD	O	O
a	DT	O	O
lower	JJR	o	O
peak	NN	o	O
inotropic	NN	o	O
score	NN	o	O
during	IN	o	O
the	DT	O	O
first	JJ	O	O
postoperative	JJ	O	O
24	CD	O	O
hours	NNS	O	O
(	(	O	O
5.6	CD	O	O
?	.	O	O
2.2	CD	O	O
?g/kg/minute	JJ	O	O
versus	NN	O	O
8.6	CD	O	O
?	.	O	O
3.6	CD	O	O
?g/kg/minute	NN	O	O
,	,	O	O
P	NNP	O	O
<	NNP	O	O
0.0001	CD	O	O
)	)	o	O
,	,	o	O
extubation	JJ	o	O
time	NN	o	O
(	(	O	O
21.5	CD	O	O
?	.	O	O
7.3	CD	O	O
hours	NNS	O	O
versus	IN	O	O
30.2	CD	O	O
?	.	O	O
12.4	CD	O	O
hours	NNS	O	O
,	,	O	O
P	NNP	O	O
=	NNP	O	O
0.0002	CD	O	O
)	)	O	O
and	CC	o	O
length	NN	o	O
of	IN	o	O
ICU	NNP	o	O
stay	NN	o	O
(	(	o	O
43.4	CD	o	O
?	.	O	O
12.6	CD	O	O
hours	NNS	O	O
versus	IN	O	O
56.3	CD	O	O
?	.	O	O
17.8	CD	O	O
hours	NNS	O	O
,	,	O	O
P	NNP	O	O
=	NNP	O	O
0.0003	CD	O	O
)	)	O	O
,	,	O	O
while	IN	O	O
they	PRP	O	O
had	VBD	O	O
a	DT	O	O
higher	JJR	o	O
cardiac	JJ	o	O
output	NN	o	O
on	IN	o	O
the	DT	O	O
first	JJ	O	O
postoperative	JJ	O	O
day	NN	O	O
(	(	O	O
1.41	CD	O	O
?	.	O	O
0.26	CD	O	O
L/minute	NNP	O	O
versus	NN	O	O
1.28	CD	O	O
?	.	O	O
0.25	CD	O	O
L/minute	NNP	O	O
,	,	O	O
P	NNP	O	O
=	NNP	O	O
0.0255	CD	O	O
)	)	O	O
as	IN	O	O
compared	VBN	O	O
to	TO	O	O
the	DT	O	O
control	NN	O	O
group	NN	O	O
.	.	O	O

In	IN	O	O
conclusion	NN	O	O
,	,	O	O
ischemic	JJ	O	O
postconditioning	NN	O	O
may	MD	O	O
to	TO	O	O
some	DT	O	O
extent	NN	O	O
provide	VBP	O	O
myocardial	JJ	O	O
protection	NN	O	O
in	IN	p	O
children	NNS	p	O
undergoing	VBG	p	O
correction	NN	p	O
of	IN	p	O
tetralogy	NN	p	O
of	IN	p	O
Fallot	NNP	p	O
.	.	p	O

The	DT	O	O
Randomised	JJ	O	O
Intervention	NNP	O	O
Treatment	NNP	O	O
of	IN	O	O
Angina	NNP	O	O
(	(	O	O
RITA	NNP	O	O
)	)	O	O
Trial	NNP	O	O
protocol	NN	O	O
:	:	O	O
a	DT	O	O
long	JJ	O	O
term	NN	O	O
study	NN	O	O
of	IN	O	O
coronary	JJ	i	IS
angioplasty	NN	i	IS
and	CC	i	O
coronary	JJ	i	IS
artery	NN	i	IS
bypass	NN	i	IS
surgery	NN	i	IS
in	IN	p	O
patients	NNS	p	O
with	IN	p	O
angina	NN	p	PC
.	.	p	O

The	DT	O	O
Randomised	JJ	O	O
Intervention	NNP	O	O
Treatment	NNP	O	O
of	IN	O	O
Angina	NNP	O	O
(	(	O	O
RITA	NNP	O	O
)	)	O	O
Trial	NNP	O	O
is	VBZ	O	O
a	DT	O	O
prospective	JJ	O	O
,	,	O	O
randomised	VBD	O	O
study	NN	O	O
to	TO	O	O
compare	VB	O	O
the	DT	O	O
short	JJ	O	O
term	NN	O	O
and	CC	O	O
long	JJ	O	O
term	NN	O	O
effects	NNS	O	O
of	IN	O	O
percutaneous	JJ	i	IS
transluminal	JJ	i	IS
coronary	NN	i	IS
angioplasty	NN	i	IS
and	CC	i	O
coronary	JJ	i	IS
artery	NN	i	IS
bypass	NN	i	IS
surgery	NN	i	IS
.	.	i	O

During	IN	O	O
the	DT	O	O
study	NN	O	O
a	DT	O	O
register	NN	O	O
of	IN	O	O
patients	NNS	p	O
undergoing	VBG	p	O
coronary	JJ	i	IPH
arteriography	NN	i	IPH
at	IN	p	O
the	DT	p	O
fourteen	JJ	p	O
participating	VBG	p	O
centres	NNS	p	O
is	VBZ	O	O
being	VBG	O	O
maintained	VBN	O	O
to	TO	O	O
assess	VB	O	O
the	DT	O	O
overall	JJ	O	O
context	NN	O	O
of	IN	O	O
patient	JJ	O	O
recruitment	NN	O	O
.	.	O	O

Patients	NNS	p	O
with	IN	p	O
arteriographically	RB	p	PC
proven	JJ	p	PC
coronary	JJ	p	PC
artery	NN	p	PC
disease	NN	p	PC
are	VBP	p	O
considered	VBN	p	O
for	IN	p	O
the	DT	p	O
trial	NN	p	O
if	IN	O	O
the	DT	O	O
participating	VBG	O	O
cardiologist	NN	O	O
and	CC	O	O
surgeon	NN	O	O
agree	VBP	O	O
that	IN	O	O
equivalent	JJ	O	O
revascularisation	NN	O	O
could	MD	O	O
be	VB	O	O
achieved	VBN	O	O
by	IN	O	O
either	DT	O	O
treatment	NN	O	O
method	NN	O	O
.	.	O	O

Patients	NNS	O	O
who	WP	O	O
satisfy	VBP	O	O
the	DT	O	O
trial	NN	O	O
entry	NN	O	O
criteria	NNS	O	O
are	VBP	O	O
randomised	VBN	O	O
to	TO	O	O
treatment	NN	O	O
by	IN	O	O
coronary	JJ	i	IS
angioplasty	NN	i	IS
or	CC	i	O
coronary	JJ	i	IS
artery	NN	i	IS
bypass	NN	i	IS
surgery	NN	i	IS
,	,	O	O
with	IN	O	O
prospective	JJ	O	O
stratification	NN	O	O
into	IN	O	O
groups	NNS	O	O
with	IN	O	O
one	CD	O	O
,	,	O	O
two	CD	O	O
,	,	O	O
or	CC	O	O
three	CD	O	O
treatment	NN	O	O
vessels	NNS	O	O
.	.	O	O

Randomisation	NNP	O	O
implies	VBZ	O	O
an	DT	O	O
intention	NN	O	O
to	TO	O	O
treat	VB	O	O
the	DT	O	O
patient	NN	O	O
by	IN	O	O
the	DT	O	O
assigned	JJ	O	O
procedure	NN	O	O
and	CC	O	O
the	DT	O	O
analysis	NN	O	O
of	IN	O	O
long	JJ	O	O
term	NN	O	O
results	NNS	O	O
will	MD	O	O
include	VB	O	O
all	DT	O	O
randomised	JJ	O	O
cases	NNS	O	O
.	.	O	O

The	DT	p	O
trial	NN	p	O
will	MD	p	O
recruit	VB	p	O
at	IN	p	O
least	JJS	p	O
1000	CD	p	PSS
patients	NNS	p	O
who	WP	p	O
will	MD	p	O
be	VB	p	O
followed	VBN	p	O
for	IN	p	O
five	CD	p	O
years	NNS	p	O
.	.	p	O

The	DT	O	O
major	JJ	O	O
trial	NN	O	O
end	NN	O	O
points	NNS	O	O
include	VBP	O	O
death	NN	o	OMO
,	,	o	O
new	JJ	o	OPH
myocardial	JJ	o	OPH
infarction	NN	o	OPH
,	,	o	O
and	CC	o	O
new	JJ	o	OPH
coronary	JJ	o	OPH
angioplasty	NN	o	OPH
or	CC	o	O
coronary	JJ	o	OPH
artery	NN	o	OPH
bypass	NN	o	OPH
procedures	NNS	o	OPH
.	.	o	O

Other	JJ	O	O
outcome	JJ	O	O
measures	NNS	O	O
include	VBP	O	O
symptom	NN	o	OOt
and	CC	o	OOt
employment	NN	o	OOt
status	NN	o	OOt
,	,	o	O
quality	NN	o	OOt
of	IN	o	OOt
life	NN	o	OOt
,	,	o	O
exercise	NN	o	OPH
tolerance	NN	o	OPH
,	,	o	O
and	CC	o	O
left	VBD	o	OPH
ventricular	JJ	o	OPH
function	NN	o	OPH
.	.	o	O

Pharmacokinetic	NNP	O	O
study	NN	O	O
of	IN	O	O
RU	NNP	i	IPM
486	CD	i	IPM
and	CC	O	O
its	PRP$	O	O
metabolites	NNS	O	O
after	IN	O	O
oral	JJ	O	O
administration	NN	O	O
of	IN	O	O
single	JJ	O	O
doses	NNS	O	O
to	TO	O	O
pregnant	VB	p	PC
and	CC	p	O
non-pregnant	JJ	p	PC
women	NNS	p	PSE
.	.	p	O

RU	NNP	i	IPM
486	CD	i	IPM
and	CC	i	O
three	CD	i	O
of	IN	i	O
its	PRP$	i	O
metabolites	NNS	i	O
(	(	i	O
RU	NNP	i	IPM
42633-monodemethyl	CD	i	IPM
,	,	i	IPM
RU	NNP	i	IPM
42848-didemethyl	CD	i	IPM
,	,	i	O
and	CC	i	O
RU	NNP	i	IPM
42698-hydroxymetabolite	JJ	i	IPM
)	)	i	O
were	VBD	O	O
determined	VBN	O	O
by	IN	O	O
HPLC	NNP	O	O
in	IN	O	O
plasma	NN	O	O
from	IN	O	O
nine	CD	p	PSS
non-pregnant	JJ	p	PC
and	CC	p	O
36	CD	p	PSS
pregnant	JJ	p	PC
women	NNS	p	PSE
.	.	p	O

Each	DT	O	O
non-pregnant	JJ	O	O
subject	NN	O	O
took	VBD	O	O
an	DT	O	O
oral	JJ	O	O
dose	NN	O	O
of	IN	O	O
RU	NNP	i	IPM
486	CD	i	IPM
(	(	O	O
25	CD	O	O
,	,	O	O
100	CD	O	O
,	,	O	O
400	CD	O	O
and	CC	O	O
600	CD	O	O
mg	NNS	O	O
consecutively	RB	O	O
)	)	O	O
once	RB	O	O
per	IN	O	O
menstrual	JJ	O	O
cycle	NN	O	O
.	.	O	O

Six	CD	O	O
of	IN	O	O
the	DT	O	O
nine	CD	O	O
women	NNS	O	O
also	RB	O	O
received	VBD	O	O
a	DT	O	O
dose	NN	i	O
of	IN	O	O
200	CD	O	O
mg	NN	O	O
.	.	O	O

The	DT	O	O
36	CD	p	PSS
pregnant	JJ	p	PC
women	NNS	p	PSE
were	VBD	O	O
randomized	VBN	O	O
into	IN	O	O
four	CD	O	O
groups	NNS	O	O
which	WDT	O	O
were	VBD	O	O
given	VBN	O	O
a	DT	O	O
single	JJ	O	O
dose	NN	O	O
of	IN	O	O
25	CD	O	O
,	,	O	O
100	CD	O	O
,	,	O	O
400	CD	O	O
or	CC	O	O
600	CD	O	O
mg	NNS	O	O
RU	NNP	O	O
486	CD	O	O
.	.	O	O

Blood	NN	o	OPH
samples	NNS	o	OPH
were	VBD	O	O
taken	VBN	O	O
up	RB	O	O
to	TO	O	O
120	CD	O	O
h	NN	O	O
after	IN	O	O
dosing	VBG	O	O
.	.	O	O

Peak	NNP	o	OPH
concentrations	NNS	o	OPH
of	IN	o	OPH
RU	NNP	o	OPH
486	CD	o	OPH
occurred	VBD	O	O
on	IN	O	O
most	JJS	O	O
occasions	NNS	O	O
within	IN	O	O
2	CD	O	O
h.	NN	O	O
Plasma	NNP	o	OPH
concentrations	NNS	o	OPH
at	IN	O	O
1	CD	O	O
h	NN	O	O
and	CC	O	O
at	IN	O	O
24	CD	O	O
h	NN	O	O
increased	VBN	O	O
in	IN	O	O
proportion	NN	O	O
to	TO	O	O
log	VB	O	O
dose	RB	O	O
.	.	O	O

There	EX	O	O
was	VBD	O	O
a	DT	O	O
wide	JJ	O	O
variability	NN	O	O
(	(	O	O
up	IN	O	O
to	TO	O	O
ten-fold	JJ	O	O
)	)	O	O
in	IN	O	O
the	DT	O	O
pharmacokinetic	JJ	O	O
parameters	NNS	O	O
within	IN	O	O
each	DT	O	O
dose	NN	O	O
group	NN	O	O
.	.	O	O

Plasma	NNP	o	OPH
concentrations	NNS	o	OPH
of	IN	o	OPH
RU	NNP	o	OPH
42633	CD	o	OPH
were	VBD	O	O
similar	JJ	O	O
to	TO	O	O
those	DT	O	O
of	IN	O	O
RU	NNP	O	O
486	CD	O	O
but	CC	O	O
concentrations	NNS	O	O
of	IN	O	O
RU	NNP	O	O
42848	CD	O	O
and	CC	O	O
RU	NNP	O	O
42698	CD	O	O
were	VBD	O	O
much	JJ	O	O
lower	JJR	O	O
.	.	O	O

As	IN	O	O
with	IN	O	O
RU	NNP	O	O
486	CD	O	O
,	,	O	O
the	DT	O	O
plasma	JJ	o	OPH
concentrations	NNS	o	OPH
of	IN	o	OPH
the	DT	o	OPH
metabolites	NNS	o	OPH
were	VBD	O	O
maintained	VBN	O	O
at	IN	O	O
high	JJ	O	O
levels	NNS	O	O
for	IN	O	O
up	IN	O	O
to	TO	O	O
48-72	JJ	O	O
h	NN	O	O
after	IN	O	O
dosing	VBG	O	O
.	.	O	O

The	DT	O	O
findings	NNS	O	O
were	VBD	O	O
consistent	JJ	O	O
with	IN	O	O
a	DT	O	O
rapid	JJ	O	O
metabolism	NN	O	O
of	IN	O	O
RU	NNP	o	OPH
486	CD	o	OPH
to	TO	o	OPH
RU	NNP	o	OPH
42633	CD	o	OPH
;	:	o	O
removal	NN	O	O
of	IN	O	O
the	DT	O	O
second	JJ	O	O
methyl	NN	O	O
group	NN	O	O
leading	VBG	O	O
to	TO	O	O
RU	NNP	O	O
42698	CD	O	O
occurred	VBD	O	O
much	RB	O	O
more	RBR	O	O
slowly	RB	O	O
and	CC	O	O
to	TO	O	O
a	DT	O	O
much	RB	O	O
less	RBR	O	O
extent	JJ	O	O
than	IN	O	O
removal	NN	O	O
of	IN	O	O
the	DT	O	O
first	JJ	O	O
.	.	O	O

There	EX	O	O
appeared	VBD	O	O
to	TO	O	O
be	VB	O	O
no	DT	O	O
significant	JJ	O	O
differences	NNS	O	O
between	IN	O	O
the	DT	O	O
non-pregnant	JJ	p	PC
and	CC	p	O
pregnant	JJ	p	PC
women	NNS	p	PSE
in	IN	O	O
either	CC	O	O
the	DT	O	O
plasma	JJ	O	O
concentrations	NNS	O	O
or	CC	O	O
pharmacokinetic	JJ	O	O
parameters	NNS	O	O
of	IN	O	O
RU	NNP	i	IPM
486	CD	i	IPM
and	CC	O	O
its	PRP$	O	O
metabolites	NNS	O	O
.	.	O	O

Microbiologic	JJ	O	O
yields	NNS	O	O
and	CC	O	O
complication	NN	O	O
rates	NNS	O	O
of	IN	O	O
vitreous	JJ	i	IS
needle	JJ	i	IS
aspiration	NN	i	IS
versus	IN	O	O
mechanized	VBN	i	IS
vitreous	JJ	i	IS
biopsy	NN	i	IS
in	IN	O	O
the	DT	O	O
Endophthalmitis	NNP	O	O
Vitrectomy	NNP	O	O
Study	NNP	O	O
.	.	O	O

PURPOSE	NNP	O	O
To	TO	O	O
compare	VB	O	O
the	DT	O	O
microbiologic	JJ	O	O
yields	NNS	O	O
and	CC	O	O
complication	NN	O	O
rates	NNS	O	O
associated	VBN	O	O
with	IN	O	O
vitreous	JJ	i	IS
needle	JJ	i	IS
tap	NN	i	IS
and	CC	O	O
vitreous	JJ	i	IPH
biopsy	NN	i	IPH
in	IN	O	O
the	DT	O	O
Endophthalmitis	NNP	p	PC
Vitrectomy	NNP	p	PC
Study	NNP	p	O
(	(	p	O
EVS	NNP	p	O
)	)	p	O
.	.	p	O

METHODS	NNP	O	O
Of	IN	O	O
420	CD	p	PSS
EVS	NNP	p	PC
patients	NNS	p	O
with	IN	p	O
postoperative	JJ	p	PC
endophthalmitis	NN	p	PC
,	,	p	O
201	CD	p	PSS
received	VBD	p	O
immediate	JJ	p	O
vitreous	JJ	i	IS
tap	NN	i	IS
or	CC	i	IS
biopsy	NN	i	IS
(	(	i	IS
without	IN	i	IS
pars	NNS	i	IS
plana	VBP	i	IS
vitrectomy	NN	i	IS
)	)	i	IS
by	IN	O	O
random	JJ	O	O
assignment	NN	O	O
and	CC	O	O
193	CD	p	PSS
completed	VBN	O	O
9-12	CD	O	O
months	NNS	O	O
of	IN	O	O
follow-up	NN	O	O
.	.	O	O

Vitreous	JJ	O	O
specimens	NNS	O	O
were	VBD	O	O
obtained	VBN	O	O
by	IN	O	O
biopsy	NN	O	O
with	IN	O	O
a	DT	O	O
20-gauge	JJ	i	IPH
vitrectomy	NN	i	IPH
cutting	VBG	O	O
instrument	NN	O	O
or	CC	O	O
by	IN	O	O
needle	JJ	O	O
tap	NN	O	O
with	IN	O	O
a	DT	O	O
22-27-gauge	JJ	O	O
needle	NN	O	O
.	.	O	O

If	IN	O	O
resistance	NN	O	O
to	TO	O	O
aspiration	NN	O	O
by	IN	O	O
needle	JJ	O	O
tap	NN	O	O
was	VBD	O	O
noted	VBN	O	O
,	,	O	O
a	DT	O	O
vitreous	JJ	O	O
biopsy	NN	O	O
was	VBD	O	O
performed	VBN	O	O
.	.	O	O

RESULTS	NNP	O	O
Of	IN	O	O
201	CD	p	PSS
patients	NNS	p	O
undergoing	JJ	p	O
tap	NN	p	O
or	CC	p	O
biopsy	NN	p	PC
,	,	p	O
70	CD	p	PSS
(	(	p	O
35	CD	p	O
%	NN	p	O
)	)	p	O
had	VBD	p	O
needle	JJ	p	PC
tap	NN	p	PC
,	,	p	O
127	CD	p	PSS
(	(	p	O
63	CD	p	O
%	NN	p	O
)	)	p	O
had	VBD	p	O
mechanized	VBN	p	PC
biopsy	NN	p	PC
,	,	p	O
and	CC	p	O
4	CD	p	PSS
(	(	p	O
2	CD	p	O
%	NN	p	O
)	)	p	O
had	VBD	p	O
initial	JJ	p	O
needle	JJ	p	PC
tap	NN	p	PC
that	WDT	O	O
was	VBD	O	O
aborted	VBN	O	O
to	TO	O	O
mechanized	VBN	O	O
biopsy	NN	O	O
(	(	O	O
abort	JJ	O	O
eyes	NNS	O	O
)	)	O	O
.	.	O	O

Intraoperative	JJ	o	OPH
hyphema	NN	o	OPH
occurred	VBD	O	O
in	IN	O	O
2	CD	O	O
tap	JJ	O	O
eyes	NNS	O	O
(	(	O	O
3	CD	O	O
%	NN	O	O
)	)	O	O
,	,	O	O
3	CD	O	O
biopsy	NN	O	O
eyes	NNS	O	O
(	(	O	O
2	CD	O	O
%	NN	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
0	CD	O	O
(	(	O	O
0	CD	O	O
%	NN	O	O
)	)	O	O
abort	NN	O	O
eyes	NNS	O	O
.	.	O	O

Postoperative	JJ	o	OPH
retinal	JJ	o	OPH
detachment	NN	o	OPH
developed	VBD	O	O
in	IN	O	O
8	CD	O	O
(	(	O	O
11	CD	O	O
%	NN	O	O
)	)	O	O
tap	NN	O	O
eyes	NNS	O	O
,	,	O	O
10	CD	O	O
(	(	O	O
8	CD	O	O
%	NN	O	O
)	)	O	O
biopsy	NN	O	O
eyes	NNS	O	O
,	,	O	O
and	CC	O	O
0	CD	O	O
(	(	O	O
0	CD	O	O
%	NN	O	O
)	)	O	O
abort	NN	O	O
eyes	NNS	O	O
(	(	O	O
not	RB	O	O
significant	JJ	O	O
)	)	O	O
.	.	O	O

Respective	JJ	o	OPH
rates	NNS	o	OPH
of	IN	o	OPH
culture	NN	o	OPH
and	CC	o	OPH
gram	NN	o	OPH
stain	VBP	o	OPH
positivity	NN	o	OPH
were	VBD	O	O
69	CD	O	O
%	NN	O	O
and	CC	O	O
42	CD	O	O
%	NN	O	O
in	IN	O	O
tap	JJ	O	O
eyes	NNS	O	O
and	CC	O	O
66	CD	O	O
%	NN	O	O
and	CC	O	O
41	CD	O	O
%	NN	O	O
in	IN	O	O
biopsy	JJ	O	O
eyes	NNS	O	O
(	(	O	O
not	RB	O	O
significant	JJ	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
rate	NN	o	OPH
of	IN	o	OPH
severe	JJ	o	OPH
visual	JJ	o	OPH
loss	NN	o	OPH
(	(	O	O
final	JJ	O	O
acuity	NN	O	O
<	NNP	O	O
5/200	CD	O	O
)	)	O	O
was	VBD	O	O
significantly	RB	O	O
higher	JJR	O	O
in	IN	O	O
tap	JJ	O	O
eyes	NNS	O	O
(	(	O	O
16	CD	O	O
eyes	NNS	O	O
,	,	O	O
24	CD	O	O
%	NN	O	O
)	)	O	O
compared	VBN	O	O
with	IN	O	O
biopsy	JJ	O	O
eyes	NNS	O	O
(	(	O	O
13	CD	O	O
eyes	NNS	O	O
,	,	O	O
11	CD	O	O
%	NN	O	O
)	)	O	O
and	CC	O	O
abort	JJ	O	O
eyes	NNS	O	O
(	(	O	O
0	CD	O	O
eyes	NNS	O	O
,	,	O	O
0	CD	O	O
%	NN	O	O
;	:	O	O
P	NNP	O	O
=	NNP	O	O
0.043	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
difference	NN	O	O
was	VBD	O	O
largely	RB	O	O
explained	VBN	O	O
by	IN	O	O
the	DT	O	O
greater	JJR	O	O
proportion	NN	o	OPH
of	IN	o	OPH
virulent	JJ	o	OPH
organisms	NNS	o	OPH
in	IN	o	OPH
the	DT	o	OPH
tap	JJ	o	OPH
eyes	NNS	o	OPH
compared	VBN	O	O
with	IN	O	O
biopsy	JJ	O	O
eyes	NNS	O	O
.	.	O	O

When	WRB	O	O
visual	JJ	o	OPH
acuity	NN	o	OPH
outcome	NN	o	OPH
was	VBD	O	O
defined	VBN	O	O
by	IN	O	O
other	JJ	O	O
thresholds	NNS	O	O
(	(	O	O
20/40	CD	O	O
and	CC	O	O
20/100	CD	O	O
)	)	O	O
,	,	O	O
the	DT	O	O
difference	NN	O	O
was	VBD	O	O
not	RB	O	O
significant	JJ	O	O
.	.	O	O

CONCLUSIONS	VB	O	O
This	DT	O	O
study	NN	O	O
showed	VBD	O	O
no	DT	O	O
significant	JJ	O	O
differences	NNS	O	O
between	IN	O	O
mechanized	VBN	O	O
vitreous	JJ	O	O
biopsy	NN	O	O
and	CC	O	O
needle	JJ	O	O
tap	NN	O	O
with	IN	O	O
respect	NN	O	O
to	TO	O	O
microbiologic	JJ	O	O
yield	NN	O	O
,	,	O	O
operative	JJ	O	O
complications	NNS	O	O
,	,	O	O
short-term	JJ	O	O
(	(	O	O
9-12	JJ	O	O
months	NNS	O	O
)	)	O	O
retinal	JJ	O	O
detachment	NN	O	O
risk	NN	O	O
,	,	O	O
or	CC	O	O
visual	JJ	O	O
outcome	NN	O	O
.	.	O	O

Choice	NNP	O	O
of	IN	O	O
vitreous	JJ	O	O
sampling	VBG	O	O
procedure	NN	O	O
must	MD	O	O
depend	VB	O	O
on	IN	O	O
the	DT	O	O
clinical	JJ	O	O
judgment	NN	O	O
of	IN	O	O
the	DT	O	O
surgeon	NN	O	O
.	.	O	O

Infrared	NNP	i	IPH
LED	NNP	i	IPH
irradiation	NN	i	IPH
applied	VBD	O	O
during	IN	O	O
high-intensity	NN	O	O
treadmill	NN	O	O
training	VBG	O	O
improves	NNS	O	O
maximal	JJ	o	OPH
exercise	NN	o	OPH
tolerance	NN	o	OPH
in	IN	O	O
postmenopausal	JJ	p	O
women	NNS	p	O
:	:	p	O
a	DT	O	O
6-month	JJ	O	O
longitudinal	JJ	O	O
study	NN	O	O
.	.	O	O

Reduced	NNP	O	O
aerobic	JJ	O	O
fitness	NN	O	O
is	VBZ	O	O
associated	VBN	O	O
with	IN	O	O
an	DT	O	O
increased	VBN	O	O
risk	NN	O	O
of	IN	O	O
cardiovascular	JJ	O	O
diseases	NNS	O	O
among	IN	O	O
the	DT	O	O
older	JJR	p	O
population	NN	p	O
.	.	p	O

The	DT	O	O
aim	NN	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
investigate	VB	O	O
the	DT	O	O
effects	NNS	o	OOt
of	IN	O	O
LED	NNP	i	IPH
irradiation	NN	i	IPH
(	(	O	O
850	CD	O	O
nm	RB	O	O
)	)	O	O
applied	VBD	O	O
during	IN	O	O
treadmill	JJ	O	O
training	VBG	O	O
on	IN	O	O
the	DT	O	O
maximal	JJ	o	OPH
exercise	NN	o	OPH
tolerance	NN	o	OPH
in	IN	O	O
postmenopausal	JJ	p	O
women	NNS	p	O
.	.	p	O

At	IN	O	O
the	DT	O	O
beginning	NN	O	O
of	IN	O	O
the	DT	O	O
study	NN	O	O
,	,	O	O
45	CD	p	O
postmenopausal	JJ	p	O
women	NNS	p	O
were	VBD	O	O
assigned	VBN	O	O
randomly	RB	O	O
to	TO	O	O
three	CD	O	O
groups	NNS	O	O
,	,	O	O
and	CC	O	O
30	CD	O	O
women	NNS	O	O
completed	VBD	O	O
the	DT	O	O
entire	JJ	O	O
6	CD	O	O
months	NNS	O	O
of	IN	O	O
the	DT	O	O
study	NN	O	O
.	.	O	O

The	DT	O	O
groups	NNS	O	O
were	VBD	O	O
:	:	O	O
(	(	i	O
1	CD	i	O
)	)	i	O
the	DT	i	O
LED	NNP	i	O
group	NN	i	O
(	(	i	O
treadmill	IN	i	O
training	VBG	i	O
associated	VBN	i	O
with	IN	i	O
phototherapy	NN	i	O
,	,	i	O
n	JJ	i	O
=	NNP	i	O
10	CD	i	O
)	)	i	O
,	,	i	O
(	(	i	O
2	CD	i	O
)	)	i	O
the	DT	i	O
exercise	NN	i	O
group	NN	i	O
(	(	i	O
treadmill	IN	i	O
training	NN	i	O
,	,	i	O
n	JJ	i	O
=	NNP	i	O
10	CD	i	O
)	)	i	O
,	,	i	O
and	CC	i	O
(	(	i	O
3	CD	i	O
)	)	i	O
the	DT	i	O
sedentary	JJ	i	O
group	NN	i	O
(	(	i	O
neither	DT	i	O
physical	JJ	i	O
training	NN	i	O
nor	CC	i	O
phototherapy	NN	i	O
,	,	i	O
n	JJ	i	O
=	NNP	i	O
10	CD	i	O
)	)	i	O
.	.	i	O

The	DT	i	O
training	NN	i	O
was	VBD	O	O
performed	VBN	O	O
for	IN	O	O
45	CD	O	O
min	NN	O	O
twice	RB	O	O
a	DT	O	O
week	NN	O	O
for	IN	O	O
6	CD	O	O
months	NNS	O	O
at	IN	O	O
intensities	NNS	O	O
between	IN	O	O
85	CD	O	O
%	NN	O	O
and	CC	O	O
90	CD	O	O
%	NN	O	O
maximal	JJ	O	O
heart	NN	O	O
rate	NN	O	O
(	(	O	O
HRmax	NNP	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
irradiation	NN	O	O
parameters	NNS	O	O
were	VBD	O	O
39	CD	O	O
mW/cm	NN	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
,	,	O	O
45	CD	O	O
min	NN	O	O
and	CC	O	O
108	CD	O	O
J/cm	NNP	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
cardiovascular	JJ	o	O
parameters	NNS	o	O
were	VBD	O	O
measured	VBN	O	O
at	IN	O	O
baseline	NN	O	O
and	CC	O	O
after	IN	O	O
6	CD	O	O
months	NNS	O	O
.	.	O	O

As	IN	O	O
expected	VBN	O	O
,	,	O	O
no	DT	O	O
significant	JJ	O	O
differences	NNS	O	O
were	VBD	O	O
found	VBN	O	O
in	IN	O	O
the	DT	O	O
sedentary	JJ	O	O
group	NN	O	O
(	(	O	O
p	VB	O	O
?	.	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

The	DT	o	O
maximal	JJ	o	O
time	NN	o	O
of	IN	o	O
tolerance	NN	o	O
(	(	o	O
Tlim	NNP	o	O
)	)	o	O
,	,	o	O
metabolic	JJ	o	O
equivalents	NNS	o	O
(	(	o	O
METs	NNP	o	O
)	)	o	O
and	CC	o	O
Bruce	NNP	o	O
stage	NN	o	O
reached	VBD	o	O
significantly	RB	O	O
higher	JJR	O	O
values	NNS	O	O
in	IN	O	O
the	DT	i	O
LED	NNP	i	O
group	NN	O	O
and	CC	O	O
the	DT	O	O
exercise	NN	i	O
group	NN	O	O
(	(	O	O
p	JJ	O	O
<	NNP	O	O
0.01	CD	O	O
)	)	O	O
.	.	O	O

Furthermore	UH	o	O
,	,	o	O
the	DT	o	O
HR	NNP	o	O
,	,	o	O
double	JJ	o	O
product	NN	o	O
and	CC	o	O
Borg	NNP	o	O
score	NN	o	O
at	IN	o	O
isotime	NN	o	O
were	VBD	O	O
significantly	RB	O	O
lower	JJR	O	O
in	IN	O	O
the	DT	O	O
LED	NNP	O	O
group	NN	O	O
and	CC	O	O
in	IN	O	O
the	DT	O	O
exercise	NN	O	O
group	NN	O	O
(	(	O	O
p	JJ	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
the	DT	o	O
time	NN	o	O
of	IN	o	O
recovery	NN	o	O
showed	VBD	o	O
a	DT	O	O
significant	JJ	O	O
decrease	NN	O	O
only	RB	O	O
in	IN	O	O
the	DT	O	O
LED	NNP	O	O
group	NN	O	O
(	(	O	O
p	JJ	O	O
=	NNP	O	O
0.003	CD	O	O
)	)	O	O
.	.	O	O

Moreover	RB	O	O
,	,	O	O
the	DT	O	O
differences	NNS	o	O
between	IN	o	O
before	IN	o	O
and	CC	o	O
after	IN	o	O
training	NN	o	O
(	(	o	O
delta	JJ	o	O
values	NNS	o	O
)	)	o	O
for	IN	O	O
the	DT	o	O
Tlim	NNP	o	O
,	,	o	O
METs	NNP	o	O
and	CC	o	O
HR	NNP	o	O
at	IN	o	O
isotime	NN	O	O
were	VBD	O	O
greater	JJR	O	O
in	IN	O	O
the	DT	O	O
LED	NNP	O	O
group	NN	O	O
than	IN	O	O
in	IN	O	O
the	DT	O	O
exercise	NN	O	O
group	NN	O	O
with	IN	O	O
a	DT	O	O
significant	JJ	O	O
intergroup	NN	O	O
difference	NN	O	O
(	(	O	O
p	JJ	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

Therefore	RB	i	O
,	,	i	O
the	DT	i	O
infrared	JJ	i	O
LED	NNP	i	O
irradiation	NN	i	O
during	IN	O	O
treadmill	JJ	O	O
training	NN	o	O
can	MD	o	O
improve	VB	o	O
maximal	JJ	o	O
performance	NN	o	O
and	CC	o	O
post-exercise	JJ	o	O
recovery	NN	o	O
in	IN	o	O
postmenopausal	JJ	o	O
women	NNS	p	O
.	.	p	O

Boosting	VBG	O	O
uptake	NN	o	OPH
of	IN	O	O
influenza	JJ	O	O
immunisation	NN	O	O
:	:	O	O
a	DT	O	O
randomised	JJ	O	O
controlled	JJ	O	O
trial	NN	O	O
of	IN	O	O
telephone	NN	i	O
appointing	VBG	i	O
in	IN	O	O
general	JJ	O	O
practice	NN	O	O
.	.	O	O

BACKGROUND	NNP	O	O
Immunisation	NNP	O	O
against	IN	O	O
influenza	NN	O	O
is	VBZ	O	O
an	DT	O	O
effective	JJ	O	O
intervention	NN	O	O
that	WDT	O	O
reduces	VBZ	O	O
serologically	RB	O	O
confirmed	VBN	O	O
cases	NNS	O	O
by	IN	O	O
between	IN	O	O
60	CD	O	O
%	NN	O	O
and	CC	O	O
70	CD	O	O
%	NN	O	O
.	.	O	O

Almost	NNP	O	O
all	DT	O	O
influenza	JJ	O	O
immunisation	NN	O	O
in	IN	O	O
the	DT	O	O
UK	NNP	p	O
is	VBZ	O	O
done	VBN	O	O
within	IN	O	O
general	JJ	O	O
practice	NN	O	O
.	.	O	O

Current	JJ	O	O
evidence	NN	O	O
on	IN	O	O
the	DT	O	O
effectiveness	NN	O	O
of	IN	O	O
patient	JJ	O	O
reminders	NNS	O	O
for	IN	O	O
all	DT	O	O
types	NNS	O	O
of	IN	O	O
immunisation	NN	O	O
programmes	NNS	O	O
is	VBZ	O	O
largely	RB	O	O
based	VBN	O	O
on	IN	O	O
North	JJ	O	O
American	JJ	O	O
studies	NNS	O	O
.	.	O	O

AIM	NNP	O	O
To	TO	O	O
determine	VB	O	O
whether	IN	O	O
telephone	NN	i	IOt
appointments	NNS	i	IOt
offered	VBD	O	O
bygeneral	JJ	O	O
practice	NN	O	O
receptionists	NNS	O	O
increase	VBP	O	O
the	DT	O	O
uptake	NN	o	OOt
of	IN	o	OOt
irfluenza	JJ	o	OOt
immunisation	NN	o	OOt
among	IN	O	O
the	DT	O	O
registered	JJ	p	O
population	NN	p	O
aged	VBD	p	O
over	IN	p	PA
65	CD	p	PA
years	NNS	p	PA
in	IN	p	O
east	JJ	p	O
London	NNP	p	O
practices	NNS	p	O
.	.	p	O

DESIGN	NNP	O	O
OF	NNP	O	O
STUDY	NNP	O	O
Randomised	VBD	O	O
controlled	VBN	O	O
trial	NN	O	O
.	.	O	O

SETTING	NNP	O	O
Three	NNP	O	O
research	NN	O	O
general	JJ	O	O
practices	NNS	O	O
within	IN	O	O
the	DT	O	O
East	NNP	p	O
London	NNP	p	O
and	CC	p	O
Essex	NNP	p	O
network	NN	p	O
of	IN	p	O
researchers	NNS	p	O
(	(	p	O
ELENoR	NNP	p	O
)	)	p	O
.	.	p	O

METHOD	JJ	O	O
Participants	NNS	p	O
were	VBD	p	O
1,820	CD	p	PSS
low-risk	JJ	p	O
patients	NNS	p	O
aged	VBD	p	O
65	CD	p	PA
to	TO	p	PA
74	CD	p	PA
years	NNS	p	O
who	WP	p	O
had	VBD	p	O
not	RB	p	O
previously	RB	p	O
been	VBN	p	O
in	IN	p	O
a	DT	p	O
recall	NN	p	O
system	NN	p	O
for	IN	p	O
influenza	JJ	p	O
immunisation	NN	p	O
at	IN	p	O
their	PRP$	p	O
general	JJ	p	O
practice	NN	p	O
.	.	p	O

The	DT	O	O
intervention	NN	O	O
,	,	O	O
during	IN	O	O
October	NNP	O	O
2000	CD	O	O
,	,	O	O
was	VBD	O	O
a	DT	O	O
telephone	NN	i	IOt
call	NN	i	IOt
from	IN	i	IOt
the	DT	i	IOt
practice	NN	i	IOt
receptionist	NN	i	IOt
to	TO	O	O
intervention	NN	i	O
group	NN	O	O
households	NNS	O	O
,	,	O	O
offering	VBG	O	O
an	DT	O	O
appointment	NN	O	O
for	IN	O	O
influenza	JJ	O	O
immunisation	NN	O	O
at	IN	O	O
a	DT	O	O
nurse-run	JJ	O	O
.	.	O	O

clinic	JJ	O	O
Main	NNP	O	O
outcome	NN	O	O
measures	NNS	O	O
were	VBD	O	O
the	DT	O	O
numbers	NNS	o	OME
of	IN	o	OME
individuals	NNS	o	OME
in	IN	o	OME
each	DT	o	OME
group	NN	o	OME
receiving	VBG	o	OME
immunisation	NN	o	OME
,	,	o	OPH
and	CC	o	OPH
practice	NN	o	OOt
costs	NNS	o	OOt
of	IN	o	OOt
a	DT	o	OOt
telephone-appointing	JJ	o	OOt
programme	NN	o	OOt
.	.	o	OPH

RESULTS	NNP	O	O
intention	NN	O	O
to	TO	O	O
treat	VB	O	O
analysis	NN	O	O
showed	VBD	O	O
an	DT	O	O
immunisation	NN	o	OME
rate	NN	o	OME
in	IN	O	O
the	DT	O	O
control	NN	i	IC
group	NN	O	O
of	IN	O	O
44	CD	O	O
%	NN	O	O
,	,	O	O
compared	VBN	O	O
with	IN	O	O
50	CD	O	O
%	NN	O	O
in	IN	O	O
the	DT	O	O
intervention	NN	i	O
group	NN	i	O
(	(	O	O
odds	NNS	O	O
ratio	VBP	O	O
=	JJ	O	O
1.29	CD	O	O
,	,	O	O
95	CD	O	O
%	NN	O	O
confidence	NN	O	O
interval	NN	O	O
=	VBD	O	O
1.03	CD	O	O
to	TO	O	O
1.63	CD	O	O
)	)	O	O
.	.	O	O

Of	IN	O	O
the	DT	O	O
patients	NNS	p	O
making	VBG	p	O
a	DT	p	O
telephone	NN	i	IOt
appointment	NN	i	IOt
,	,	O	O
88	CD	O	O
%	NN	O	O
recieved	JJ	O	O
immunisation	NN	o	OME
,	,	O	O
while	IN	O	O
22	CD	O	O
%	NN	O	O
of	IN	O	O
those	DT	O	O
not	RB	O	O
wanting	VBG	O	O
an	DT	O	O
appointment	NN	O	O
went	VBD	O	O
on	IN	O	O
to	TO	O	O
be	VB	O	O
immunised	VBN	O	O
.	.	O	O

In	IN	O	O
the	DT	O	O
controlgroup	NN	i	IC
,	,	O	O
income	NN	o	OOt
generated	VBD	o	OOt
was	VBD	O	O
11.35	CD	O	O
pounds	NNS	O	O
per	IN	O	O
immunisation	NN	O	O
,	,	O	O
for	IN	O	O
each	DT	O	O
additional	JJ	O	O
immunisation	NN	O	O
in	IN	O	O
the	DT	O	O
intervention	NN	O	O
group	NN	O	O
the	DT	O	O
income	NN	O	O
was	VBD	O	O
5.20	CD	O	O
pounds	NNS	O	O
.	.	O	O

The	DT	O	O
'number	NNP	o	OOt
needed	VBD	o	OOt
to	TO	o	OOt
telephone	NN	o	OOt
'	''	o	O
was	VBD	O	O
17	CD	O	O
.	.	O	O

CONCLUSION	NNP	O	O
Uptake	NNP	O	O
of	IN	O	O
influenza	JJ	O	O
immunisation	NN	o	OPH
among	IN	O	O
the	DT	O	O
low-risk	JJ	p	O
older	JJR	p	O
population	NN	p	O
in	IN	p	O
inner-city	JJ	p	O
areas	NNS	p	O
can	MD	O	O
be	VB	O	O
boosted	VBN	O	O
by	IN	O	O
around	IN	O	O
6	CD	O	O
%	NN	O	O
using	VBG	O	O
a	DT	O	O
simple	JJ	O	O
intervention	NN	i	O
by	IN	O	O
receptionists	NNS	O	O
.	.	O	O

Immunisation	NN	o	OME
rates	NNS	o	OME
in	IN	O	O
this	DT	O	O
low-risk	JJ	O	O
group	NN	O	O
fell	VBD	O	O
well	RB	O	O
short	RB	O	O
of	IN	O	O
the	DT	O	O
60	CD	O	O
%	NN	O	O
government	NN	O	O
target	NN	O	O
.	.	O	O

Improving	VBG	O	O
immunisation	NN	o	OME
rates	NNS	o	OME
will	MD	O	O
require	VB	O	O
a	DT	O	O
sustained	JJ	O	O
public	JJ	O	O
health	NN	O	O
campaign	NN	O	O
.	.	O	O

Retaining	VBG	O	O
the	DT	O	O
item-of-service	JJ	O	O
payments	NNS	O	O
to	TO	O	O
practices	NNS	O	O
should	MD	O	O
support	VB	O	O
costs	NNS	O	O
of	IN	O	O
practice-based	JJ	O	O
interventions	NNS	O	O
.	.	O	O

Effect	NN	O	O
of	IN	O	O
spinal	JJ	i	IPH
versus	NN	i	IPH
general	JJ	i	IPH
anesthesia	NN	i	IPH
on	IN	O	O
bladder	NN	o	OPH
compliance	NN	o	OPH
and	CC	o	O
intraabdominal	JJ	o	OPH
pressure	NN	o	OPH
during	IN	O	O
transurethral	JJ	p	O
procedures	NNS	p	O
.	.	p	O

STUDY	NNP	O	O
OBJECTIVE	NNP	O	O
To	TO	O	O
evaluate	VB	O	O
the	DT	O	O
influence	NN	O	O
of	IN	O	O
spinal	JJ	i	IPH
versus	NN	i	IPH
general	JJ	i	IPH
anesthesia	NN	i	IPH
on	IN	O	O
bladder	NN	o	OPH
compliance	NN	o	OPH
and	CC	o	O
intraabdominal	JJ	o	OPH
pressure	NN	o	OPH
in	IN	O	O
elderly	JJ	p	PA
males	NNS	p	PA
undergoing	VBG	p	O
elective	JJ	i	O
transurethral	JJ	i	O
resection	NN	i	O
of	IN	i	O
the	DT	i	O
prostate	NN	i	O
.	.	i	O

DESIGN	NNP	O	O
Prospective	NNP	O	O
,	,	O	O
randomized	VBD	O	O
,	,	O	O
open-label	JJ	O	O
study	NN	O	O
.	.	O	O

SETTING	NN	O	O
Teaching	NNP	p	O
hospital	NN	p	O
.	.	p	O

PATIENTS	CC	O	O
21	CD	p	PSS
ASA	NNP	p	O
physical	JJ	p	O
status	NN	p	O
I	PRP	p	O
,	,	p	O
II	NNP	p	O
,	,	p	O
and	CC	p	O
III	NNP	p	O
patients	NNS	p	O
at	IN	p	PA
least	JJS	p	PA
18	CD	p	PA
years	NNS	p	O
of	IN	p	O
age	NN	p	O
,	,	p	O
undergoing	VBG	p	O
transurethral	JJ	i	IS
surgery	NN	i	IS
.	.	i	IS

INTERVENTIONS	NNP	O	O
According	VBG	O	O
to	TO	O	O
a	DT	O	O
computer-generated	JJ	O	O
randomization	NN	O	O
schedule	NN	O	O
,	,	O	O
patients	NNS	O	O
were	VBD	O	O
allocated	VBN	O	O
to	TO	O	O
one	CD	O	O
of	IN	O	O
two	CD	O	O
groups	NNS	O	O
.	.	O	O

In	IN	O	O
Group	NNP	O	O
Spinal	NNP	O	O
(	(	O	O
S	NNP	O	O
)	)	O	O
,	,	O	O
10	CD	O	O
mg	NN	O	O
of	IN	O	O
hyperbaric	JJ	i	IPM
tetracaine	NN	i	IPM
was	VBD	O	O
administered	VBN	O	O
intrathecally	RB	O	O
.	.	O	O

In	IN	O	O
Group	NNP	O	O
General	NNP	i	IPH
Anesthesia	NNP	i	IPH
(	(	i	IPH
GA	NNP	i	IPH
)	)	i	IPH
,	,	O	O
patients	NNS	O	O
received	VBD	O	O
,	,	O	O
fentanyl	RB	i	IPM
intravenous	JJ	i	IPM
(	(	O	O
i.v	JJ	O	O
.	.	O	O

1	CD	O	O
to	TO	O	O
2	CD	O	O
micrograms/kg	NNS	O	O
and	CC	O	O
propofol	NN	O	O
i.v	NN	O	O
.	.	O	O

1.0	CD	O	O
to	TO	O	O
2.0	CD	O	O
mg/kg	NN	O	O
for	IN	O	O
induction	NN	O	O
of	IN	O	O
anesthesia	NN	i	IPH
.	.	i	O

Thereafter	NNP	O	O
,	,	O	O
a	DT	O	O
laryngeal	JJ	O	O
mask	NN	O	O
airway	NN	O	O
was	VBD	O	O
inserted	VBN	O	O
and	CC	O	O
,	,	O	O
with	IN	O	O
spontaneous	JJ	O	O
ventilation	NN	O	O
,	,	O	O
anesthesia	NN	i	IPM
was	VBD	O	O
maintained	VBN	O	O
by	IN	O	O
administering	VBG	O	O
isoflurane	NN	i	IPM
(	(	O	O
end-tidal	JJ	O	O
0.7	CD	O	O
%	NN	O	O
to	TO	O	O
1.2	CD	O	O
%	NN	O	O
)	)	O	O
and	CC	O	O
70	CD	O	O
%	NN	O	O
nitrous	JJ	i	IPM
oxide	NN	i	IPM
(	(	i	IPM
N2O	NNP	i	IPM
)	)	i	IPM
in	IN	i	IPM
oxygen	NN	i	IPM
.	.	i	O

Intraabdominal	JJ	o	O
pressure	NN	o	O
and	CC	o	O
bladder	NN	o	O
compliance	NN	o	O
were	VBD	O	O
recorded	VBN	O	O
prior	RB	O	O
to	TO	O	O
the	DT	O	O
induction	NN	O	O
of	IN	O	O
anesthesia	NN	i	IPH
and	CC	O	O
immediately	RB	O	O
before	IN	O	O
the	DT	O	O
onset	NN	O	O
of	IN	O	O
the	DT	O	O
surgical	JJ	O	O
procedure	NN	O	O
.	.	O	O

MEASUREMENTS	NNP	O	O
AND	CC	O	O
MAIN	NNP	O	O
RESULTS	NNP	O	O
The	DT	O	O
two	CD	O	O
groups	NNS	O	O
were	VBD	O	O
demographically	RB	O	O
comparable	JJ	O	O
.	.	O	O

In	IN	O	O
Group	NNP	O	O
S	NNP	O	O
,	,	O	O
mean	JJ	O	O
bladder	NN	O	O
compliance	NN	O	O
was	VBD	O	O
significantly	RB	O	O
(	(	O	O
p	JJ	O	O
=	NNP	O	O
0.003	CD	O	O
)	)	O	O
higher	JJR	O	O
and	CC	O	O
mean	JJ	O	O
intraabdominal	JJ	o	OPH
pressure	NN	o	OPH
significantly	RB	O	O
lower	JJR	O	O
(	(	O	O
p	JJ	O	O
=	NNP	O	O
0.007	CD	O	O
)	)	O	O
when	WRB	O	O
compared	VBN	O	O
to	TO	O	O
baseline	VB	O	O
preanesthetic	JJ	O	O
values	NNS	O	O
.	.	O	O

In	IN	O	O
Group	NNP	O	O
GA	NNP	O	O
,	,	O	O
mean	JJ	o	OPH
intraabdominal	JJ	o	OPH
pressure	NN	o	OPH
significantly	RB	O	O
(	(	O	O
p	JJ	O	O
=	NNP	O	O
0.006	CD	O	O
)	)	O	O
decreased	VBD	O	O
when	WRB	O	O
compared	VBN	O	O
to	TO	O	O
baseline	VB	O	O
preanesthetic	JJ	O	O
recordings	NNS	O	O
.	.	O	O

Following	VBG	O	O
the	DT	O	O
induction	NN	O	O
of	IN	O	O
general	JJ	O	O
anesthesia	NN	O	O
,	,	O	O
a	DT	O	O
small	JJ	O	O
change	NN	O	O
in	IN	O	O
bladder	NN	o	OPH
compliance	NN	o	OPH
was	VBD	O	O
noted	VBN	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
statistical	JJ	O	O
significance	NN	O	O
was	VBD	O	O
not	RB	O	O
reached	VBN	O	O
.	.	O	O

Data	NNS	O	O
were	VBD	O	O
analyzed	VBN	O	O
and	CC	O	O
compared	VBN	O	O
using	VBG	O	O
Student	NNP	O	O
's	POS	O	O
t-test	NN	O	O
(	(	O	O
p	JJ	O	O
<	NN	O	O
0.05	CD	O	O
was	VBD	O	O
considered	VBN	O	O
statistically	RB	O	O
significant	JJ	O	O
)	)	O	O
.	.	O	O

CONCLUSION	NNP	O	O
Both	NNP	O	O
spinal	JJ	i	IPH
and	CC	i	IPH
general	JJ	i	IPH
anesthesia	NN	i	IPH
induced	VBD	O	O
a	DT	O	O
significant	JJ	o	O
decrease	NN	o	O
in	IN	o	O
intraabdominal	JJ	o	O
pressure	NN	o	O
.	.	o	O

While	IN	O	O
both	DT	O	O
techniques	NNS	O	O
were	VBD	O	O
associated	VBN	O	O
with	IN	O	O
an	DT	O	O
increase	NN	o	O
in	IN	o	O
bladder	NN	o	O
compliance	NN	o	O
,	,	O	O
statistical	JJ	O	O
significance	NN	O	O
was	VBD	O	O
demonstrated	VBN	O	O
only	RB	O	O
in	IN	O	O
the	DT	O	O
spinal	JJ	i	IPH
anesthesia	NN	i	IPH
treatment	NN	O	O
group	NN	O	O
.	.	O	O

The	DT	O	O
effectiveness	NN	O	O
of	IN	O	O
single-dose	JJ	O	O
metronidazole	JJ	i	IPM
therapy	NN	O	O
for	IN	O	O
patients	NNS	p	O
and	CC	p	O
their	PRP$	p	O
partners	NNS	p	O
with	IN	p	O
bacterial	JJ	p	O
vaginosis	NN	p	O
.	.	p	O

A	DT	O	O
randomized	JJ	O	O
,	,	O	O
placebo-controlled	JJ	i	IC
,	,	O	O
double-blind	JJ	O	O
clinical	JJ	O	O
trial	NN	O	O
was	VBD	O	O
performed	VBN	O	O
to	TO	O	O
test	VB	O	O
the	DT	O	O
hypothesis	NN	O	O
that	IN	O	O
a	DT	O	O
2-g	JJ	O	O
single	JJ	O	O
dose	NN	O	O
of	IN	O	O
metronidazole	NN	i	IPM
for	IN	O	O
male	JJ	p	O
partners	NNS	p	O
of	IN	p	O
women	NNS	p	O
with	IN	p	O
bacterial	JJ	p	O
vaginosis	NN	p	O
was	VBD	O	O
more	RBR	O	O
effective	JJ	O	O
than	IN	O	O
placebo	NN	O	O
in	IN	O	O
improving	VBG	O	O
cure	NN	O	O
rate	NN	O	O
and	CC	O	O
decreasing	VBG	O	O
recurrence	NN	O	O
rate	NN	O	O
.	.	O	O

In	IN	O	O
addition	NN	O	O
,	,	O	O
the	DT	O	O
effectiveness	NN	O	O
of	IN	O	O
a	DT	O	O
2-g	JJ	O	O
single	JJ	i	IPM
dose	NN	i	IPM
of	IN	i	IPM
metronidazole	NN	i	IPM
was	VBD	O	O
compared	VBN	O	O
with	IN	O	O
a	DT	O	O
seven-day	JJ	i	IPM
course	NN	i	IPM
of	IN	i	IPM
500	CD	i	IPM
mg	NN	i	IPM
of	IN	i	IPM
metronidazole	JJ	i	IPM
twice	NN	O	O
a	DT	O	O
day	NN	O	O
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
bacterial	JJ	p	O
vaginosis	NN	p	O
.	.	p	O

Statistically	NNP	O	O
significant	JJ	O	O
benefits	NNS	O	O
of	IN	O	O
partner	NN	O	O
treatment	NN	O	O
were	VBD	O	O
noted	VBN	O	O
in	IN	O	O
the	DT	O	O
initial	JJ	O	O
cure	NN	O	O
rate	NN	O	O
by	IN	O	O
Gram-stained	JJ	O	O
smear	JJ	O	O
criteria	NNS	O	O
(	(	O	O
P	NNP	O	O
less	JJR	O	O
than	IN	O	O
.01	NN	O	O
)	)	O	O
and	CC	O	O
in	IN	O	O
percentage	NN	O	O
of	IN	O	O
women	NNS	O	O
with	IN	O	O
symptoms	NNS	O	O
eight	CD	O	O
weeks	NNS	O	O
after	IN	O	O
initiating	VBG	O	O
therapy	NN	O	O
(	(	O	O
P	NNP	O	O
less	JJR	O	O
than	IN	O	O
.05	NN	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
seven-day	JJ	O	O
course	NN	O	O
of	IN	O	O
metronidazole	NN	O	O
was	VBD	O	O
superior	JJ	O	O
to	TO	O	O
the	DT	O	O
single-dose	JJ	O	O
regimen	NNS	O	O
in	IN	O	O
the	DT	O	O
percentage	NN	O	O
of	IN	O	O
patients	NNS	O	O
with	IN	O	O
clue	JJ	O	O
cells	NNS	O	O
and	CC	O	O
the	DT	O	O
percentage	NN	O	O
of	IN	O	O
patients	NNS	O	O
with	IN	O	O
a	DT	O	O
positive	JJ	O	O
sniff	NN	O	O
test	NN	O	O
at	IN	O	O
the	DT	O	O
first	JJ	O	O
follow-up	JJ	O	O
visit	NN	O	O
;	:	O	O
however	RB	O	O
,	,	O	O
differences	NNS	O	O
in	IN	O	O
the	DT	O	O
initial	JJ	o	OPH
cure	NN	o	OPH
rate	NN	o	OPH
assessed	VBN	o	OPH
by	IN	o	OPH
clinical	JJ	o	OPH
criteria	NNS	o	OPH
and	CC	o	OPH
Gram-stained	JJ	o	OPH
smear	JJ	o	OPH
criteria	NNS	o	OPH
were	VBD	O	O
not	RB	O	O
statistically	RB	O	O
significant	JJ	O	O
between	IN	O	O
the	DT	O	O
two	CD	O	O
patient	NN	O	O
treatment	NN	O	O
regimens	NNS	O	O
.	.	O	O

Recurrence	NN	o	OPH
rates	NNS	o	OPH
by	IN	o	OPH
Gram-stained	JJ	o	OPH
smear	JJ	o	OPH
criteria	NNS	o	OPH
between	IN	O	O
patient	NN	O	O
and	CC	O	O
partner	NN	O	O
treatment	NN	O	O
groups	NNS	O	O
at	IN	O	O
five	CD	O	O
and	CC	O	O
eight	CD	O	O
weeks	NNS	O	O
after	IN	O	O
initiation	NN	O	O
of	IN	O	O
treatment	NN	O	O
were	VBD	O	O
also	RB	O	O
not	RB	O	O
significantly	RB	O	O
different	JJ	O	O
between	IN	O	O
the	DT	O	O
two	CD	O	O
patient	NN	O	O
regimens	NNS	O	O
.	.	O	O

Single-dose	JJ	O	O
metronidazole	JJ	i	IPM
treatment	NN	O	O
of	IN	O	O
the	DT	O	O
sexual	JJ	p	O
partner	NN	p	O
of	IN	p	O
women	NNS	p	O
with	IN	p	O
bacterial	JJ	p	O
vaginosis	NN	p	O
improves	VBZ	O	O
initial	JJ	O	O
bacterial	JJ	o	OPH
vaginosis	NN	o	OPH
cure	NN	o	OPH
rates	NNS	o	OPH
.	.	o	O

The	DT	O	O
seven-day	JJ	O	O
course	NN	O	O
of	IN	O	O
metronidazole	NN	O	O
was	VBD	O	O
not	RB	O	O
found	VBN	O	O
by	IN	O	O
statistical	JJ	O	O
analysis	NN	O	O
to	TO	O	O
be	VB	O	O
significantly	RB	O	O
superior	JJ	O	O
to	TO	O	O
single-dose	JJ	O	O
therapy	NN	O	O
when	WRB	O	O
considering	VBG	O	O
initial	JJ	O	O
cure	NN	O	O
rates	NNS	O	O
by	IN	O	O
clinical	JJ	O	O
or	CC	O	O
Gram-stained	JJ	O	O
smear	JJ	O	O
criteria	NNS	O	O
or	CC	O	O
recurrence	NN	O	O
rates	NNS	O	O
.	.	O	O

(	(	O	O
ABSTRACT	NNP	O	O
TRUNCATED	NNP	O	O
AT	NNP	O	O
250	CD	O	O
WORDS	NNP	O	O
)	)	O	O
Laser-aided	JJ	i	IS
external	JJ	i	IS
drainage	NN	i	IS
of	IN	p	O
subretinal	JJ	p	PC
fluid	NN	p	PC
:	:	p	O
prospective	JJ	O	O
randomized	VBN	O	O
comparison	NN	O	O
with	IN	O	O
needle	JJ	O	O
drainage	NN	O	O
.	.	O	O

In	IN	O	O
a	DT	O	O
prospective	JJ	O	O
randomized	VBN	O	O
study	NN	O	O
of	IN	O	O
50	CD	p	PSS
consecutive	JJ	p	O
eyes	NNS	p	O
,	,	O	O
we	PRP	O	O
compared	VBN	O	O
the	DT	O	O
safety	NN	o	OOt
and	CC	o	O
efficacy	NN	o	OOt
of	IN	O	O
draining	VBG	O	O
subretinal	JJ	i	IS
fluid	NN	i	IS
transchoroidally	RB	i	IS
in	IN	O	O
primary	JJ	O	O
scleral	JJ	O	O
buckling	NN	O	O
for	IN	O	O
rhegmatogenous	JJ	O	O
retinal	JJ	O	O
detachment	NN	O	O
using	VBG	O	O
a	DT	O	O
needle	JJ	i	IOt
,	,	O	O
with	IN	O	O
the	DT	O	O
safety	NN	o	OPH
and	CC	o	O
efficacy	NN	o	OPH
of	IN	O	O
the	DT	O	O
same	JJ	O	O
procedure	NN	O	O
using	VBG	O	O
an	DT	O	O
angulated	VBN	i	IS
endolaser	NN	i	IS
probe	NN	i	IS
set	VBN	O	O
at	IN	O	O
1	CD	O	O
W	NNP	O	O
for	IN	O	O
0.2	CD	O	O
seconds	NNS	O	O
,	,	O	O
using	VBG	O	O
an	DT	O	O
average	NN	O	O
of	IN	O	O
2.4	CD	O	O
laser	NN	O	O
burns	NNS	O	O
.	.	O	O

There	EX	O	O
were	VBD	O	O
no	DT	O	O
significant	JJ	O	O
complications	NNS	o	OA
associated	VBN	O	O
with	IN	O	O
the	DT	O	O
laser-aided	JJ	i	IS
drainage	NN	i	IS
procedures	NNS	O	O
(	(	O	O
25	CD	O	O
eyes	NNS	O	O
)	)	O	O
.	.	O	O

In	IN	O	O
the	DT	O	O
transchoroidal	NN	i	IS
needle	JJ	i	IS
drainage	NN	i	IS
procedures	NNS	O	O
(	(	O	O
25	CD	O	O
eyes	NNS	O	O
)	)	O	O
,	,	O	O
subretinal	JJ	o	OPH
hemorrhage	NN	o	OPH
occurred	VBD	O	O
in	IN	O	O
three	CD	O	O
eyes	NNS	O	O
and	CC	O	O
retinal	JJ	O	O
incarceration	NN	O	O
in	IN	O	O
one	CD	O	O
.	.	O	O

Thus	VB	O	O
,	,	O	O
though	IN	O	O
our	PRP$	O	O
numbers	NNS	O	O
are	VBP	O	O
small	JJ	O	O
,	,	O	O
there	EX	O	O
appears	VBZ	O	O
to	TO	O	O
be	VB	O	O
some	DT	O	O
advantage	NN	O	O
of	IN	O	O
laser-assisted	JJ	O	O
drainage	NN	O	O
in	IN	O	O
terms	NNS	O	O
of	IN	O	O
a	DT	O	O
lower	JJR	O	O
incidence	NN	o	OA
of	IN	o	OA
complications	NNS	o	OA
.	.	o	O

MSL-109	NNP	i	IPM
adjuvant	JJ	i	IPM
therapy	NN	i	IPM
for	IN	O	O
cytomegalovirus	NN	p	PC
retinitis	NN	p	PC
in	IN	p	O
patients	NNS	p	O
with	IN	p	O
acquired	JJ	p	O
immunodeficiency	NN	p	O
syndrome	NN	p	O
:	:	p	O
the	DT	O	O
Monoclonal	NNP	O	O
Antibody	NNP	O	O
Cytomegalovirus	NNP	O	O
Retinitis	NNP	O	O
Trial	NNP	O	O
.	.	O	O

The	DT	p	O
Studies	NNPS	p	O
of	IN	p	O
Ocular	JJ	p	PC
Complications	NNS	p	PC
of	IN	p	O
AIDS	NNP	p	O
Research	NNP	p	O
Group	NNP	p	O
.	.	p	O

AIDS	NNP	p	O
Clinical	JJ	p	O
Trials	NNP	p	O
Group	NNP	p	O
.	.	p	O

OBJECTIVE	NNP	O	O
To	TO	O	O
evaluate	VB	O	O
the	DT	O	O
efficacy	NN	o	OOt
and	CC	o	OOt
safety	NN	o	OOt
of	IN	O	O
an	DT	O	O
intravenous	JJ	O	O
human	JJ	O	O
monoclonal	NN	O	O
antibody	NN	O	O
to	TO	O	O
cytomegalovirus	VB	O	O
(	(	O	O
CMV	NNP	O	O
)	)	O	O
,	,	O	O
MSL-109	NNP	i	IPM
,	,	O	O
as	IN	O	O
adjuvant	JJ	O	O
treatment	NN	O	O
for	IN	O	O
CMV	NNP	O	O
retinitis	NN	O	O
.	.	O	O

METHODS	NNP	O	O
Two	CD	p	PSS
hundred	VBD	p	PSS
nine	CD	p	PSS
patients	NNS	p	O
with	IN	p	O
acquired	JJ	p	PC
immunodeficiency	NN	p	PC
syndrome	NN	p	PC
and	CC	p	O
active	JJ	p	O
CMV	NNP	p	PC
retinitis	NN	p	PC
were	VBD	p	O
enrolled	VBN	p	O
in	IN	p	O
a	DT	p	O
multicenter	NN	p	O
,	,	p	O
phase	NN	p	O
2/3	CD	p	O
,	,	p	O
randomized	VBN	p	O
,	,	p	O
placebo-controlled	JJ	i	IC
clinical	JJ	p	O
trial	NN	p	O
.	.	p	O

Patients	NNS	O	O
received	VBD	O	O
adjuvant	JJ	O	O
treatment	NN	O	O
with	IN	O	O
MSL-109	NNP	i	IPM
,	,	O	O
60	CD	O	O
mg	NN	O	O
intravenously	RB	O	O
every	DT	O	O
2	CD	O	O
weeks	NNS	O	O
,	,	O	O
or	CC	O	O
placebo	NN	i	IC
.	.	i	O

Randomization	NN	O	O
was	VBD	O	O
stratified	VBN	O	O
on	IN	O	O
the	DT	O	O
basis	NN	O	O
of	IN	O	O
whether	IN	O	O
patients	NNS	O	O
had	VBD	O	O
untreated	VBN	O	O
or	CC	O	O
relapsed	VBN	O	O
retinitis	NN	O	O
.	.	O	O

Primary	JJ	i	IPM
drug	NN	i	IPM
therapy	NN	i	IPM
for	IN	O	O
CMV	NNP	O	O
retinitis	NN	O	O
was	VBD	O	O
determined	VBN	O	O
by	IN	O	O
the	DT	O	O
treating	NN	O	O
physician	NN	O	O
.	.	O	O

RESULTS	VB	O	O
The	DT	O	O
rates	NNS	o	OPH
of	IN	o	OPH
retinitis	NN	o	OPH
progression	NN	o	OPH
,	,	O	O
as	IN	O	O
evaluated	VBN	O	O
in	IN	O	O
a	DT	O	O
masked	JJ	O	O
fashion	NN	O	O
,	,	O	O
were	VBD	O	O
3.04/person-year	JJ	O	O
in	IN	O	O
the	DT	O	O
MSL-109-treated	NNP	i	IPM
group	NN	O	O
and	CC	O	O
3.05/person-year	JJ	O	O
in	IN	O	O
the	DT	O	O
placebo-treated	JJ	i	IC
group	NN	O	O
(	(	O	O
P=.98	NNP	O	O
;	:	O	O
Wald	NNP	O	O
test	NN	O	O
)	)	O	O
;	:	O	O
the	DT	O	O
median	JJ	O	O
times	NNS	O	O
to	TO	O	O
progression	NN	O	O
were	VBD	O	O
67	CD	O	O
days	NNS	O	O
in	IN	O	O
the	DT	O	O
MSL-109-treated	NNP	i	IPM
group	NN	O	O
and	CC	O	O
65	CD	O	O
days	NNS	O	O
in	IN	O	O
the	DT	O	O
placebo-treated	JJ	O	O
group	NN	O	O
.	.	O	O

No	DT	O	O
differences	NNS	O	O
between	IN	O	O
the	DT	O	O
2	CD	O	O
groups	NNS	O	O
were	VBD	O	O
noted	VBN	O	O
in	IN	O	O
the	DT	O	O
rates	NNS	o	OPH
of	IN	o	OPH
increase	NN	o	OPH
in	IN	o	OPH
retinal	JJ	o	OPH
area	NN	o	OPH
involved	VBN	o	OPH
by	IN	o	OPH
CMV	NNP	o	OPH
,	,	o	OPH
visual	JJ	o	OPH
field	NN	o	OPH
loss	NN	o	OPH
,	,	o	OPH
or	CC	o	OPH
visual	JJ	o	OPH
acuity	NN	o	OPH
outcomes	NNS	o	OPH
.	.	o	O

The	DT	O	O
mortality	NN	o	OMO
rate	NN	o	OMO
in	IN	O	O
the	DT	O	O
MSL-109-treated	NNP	i	IPM
group	NN	O	O
was	VBD	O	O
0.68/person-year	JJ	O	O
,	,	O	O
and	CC	O	O
in	IN	O	O
the	DT	O	O
placebo-treated	JJ	i	IC
group	NN	O	O
,	,	O	O
0.31/person-year	JJ	O	O
(	(	O	O
P=.01	NNP	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
mortality	NN	o	OMO
difference	NN	O	O
was	VBD	O	O
not	RB	O	O
explained	VBN	O	O
by	IN	O	O
differences	NNS	O	O
in	IN	O	O
baseline	NN	O	O
variables	NNS	O	O
or	CC	O	O
in	IN	O	O
concurrent	JJ	O	O
antiretroviral	JJ	O	O
therapy	NN	O	O
.	.	O	O

Among	IN	p	O
patients	NNS	p	O
with	IN	p	O
newly	RB	p	O
diagnosed	VBN	p	PC
retinitis	NN	p	PC
,	,	O	O
mortality	NN	o	OMO
rates	NNS	o	OMO
were	VBD	O	O
similar	JJ	O	O
(	(	O	O
MSL-109	NNP	O	O
,	,	O	O
0.41/person-year	JJ	O	O
;	:	O	O
placebo	NN	O	O
,	,	O	O
0.42/person-year	JJ	O	O
;	:	O	O
P=.95	NNP	O	O
)	)	O	O
,	,	O	O
whereas	JJ	O	O
among	IN	O	O
patients	NNS	O	O
with	IN	O	O
relapsed	JJ	O	O
retinitis	NN	O	O
the	DT	O	O
MSL-109-treated	NNP	i	IPM
group	NN	O	O
had	VBD	O	O
a	DT	O	O
greater	JJR	O	O
mortality	NN	o	OMO
rate	NN	o	OMO
(	(	i	O
MSL-109	NNP	i	IPM
,	,	O	O
0.83/person-year	JJ	O	O
;	:	O	O
placebo	NN	i	IC
,	,	O	O
0.24/person-year	JJ	O	O
;	:	O	O
P=.003	NNP	O	O
)	)	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
the	DT	O	O
mortality	NN	o	OMO
rate	NN	o	OMO
in	IN	O	O
the	DT	O	O
placebo-treated	JJ	i	IC
patients	NNS	O	O
with	IN	O	O
relapsed	JJ	O	O
CMV	NNP	O	O
retinitis	NN	O	O
was	VBD	O	O
lower	JJR	O	O
than	IN	O	O
that	DT	O	O
in	IN	O	O
the	DT	O	O
placebo-treated	JJ	O	O
patients	NNS	O	O
with	IN	O	O
newly	RB	O	O
diagnosed	VBN	O	O
CMV	NNP	O	O
retinitis	NN	O	O
and	CC	O	O
lower	JJR	O	O
than	IN	O	O
that	DT	O	O
in	IN	O	O
other	JJ	O	O
trials	NNS	O	O
of	IN	O	O
patients	NNS	O	O
with	IN	O	O
relapsed	JJ	O	O
CMV	NNP	O	O
retinitis	NN	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
Intravenous	NNP	O	O
MSL-109	NNP	i	IPM
,	,	O	O
60	CD	O	O
mg	NN	O	O
every	DT	O	O
2	CD	O	O
weeks	NNS	O	O
,	,	O	O
appeared	VBD	O	O
to	TO	O	O
be	VB	O	O
ineffective	JJ	o	OOt
adjuvant	JJ	O	O
therapy	NN	O	O
for	IN	O	O
CMV	NNP	O	O
retinitis	NN	O	O
.	.	O	O

The	DT	O	O
mortality	NN	o	OMO
rate	NN	o	OMO
was	VBD	O	O
higher	RBR	O	O
in	IN	O	O
the	DT	O	O
MSL-109-treated	NNP	i	IPM
group	NN	O	O
,	,	O	O
but	CC	O	O
the	DT	O	O
reasons	NNS	O	O
for	IN	O	O
this	DT	O	O
difference	NN	O	O
remain	NN	O	O
uncertain	JJ	O	O
.	.	O	O

Clofibrate	NNP	o	OOt
and	CC	o	O
diabetes	VBZ	o	OOt
control	NN	o	OOt
in	IN	O	O
patients	NNS	p	PC
treated	VBN	p	PC
with	IN	p	PC
oral	JJ	i	IPM
hypoglycaemic	JJ	i	IPM
agents	NNS	i	IPM
.	.	i	O

1	CD	O	O
.	.	O	O

Twenty-two	JJ	p	PSS
maturity-onset	JJ	p	O
type	NN	p	O
diabetics	NNS	p	PC
treated	VBD	p	O
with	IN	p	O
oral	JJ	i	IPM
hypoglycaemic	JJ	i	IPM
agents	NNS	i	IPM
entered	VBD	O	O
a	DT	O	O
single-blind	JJ	O	O
crossover	NN	O	O
study	NN	O	O
using	VBG	O	O
placebo	NN	i	IC
(	(	O	O
periods	VB	O	O
A	DT	O	O
and	CC	O	O
C	NNP	O	O
,	,	O	O
2	CD	O	O
months	NNS	O	O
each	DT	O	O
)	)	O	O
and	CC	O	O
clofibrate	NN	i	IPM
(	(	O	O
2	CD	O	O
g/day	NN	O	O
;	:	O	O
period	NN	O	O
B	NNP	O	O
;	:	O	O
2	CD	O	O
months	NNS	O	O
)	)	O	O
.	.	O	O

2	CD	O	O
.	.	O	O

In	IN	O	O
thirteen	JJ	p	PSS
patients	NNS	p	O
,	,	p	O
under	IN	p	O
reasonably	RB	p	O
good	JJ	p	O
control	NN	p	O
,	,	O	O
clofibrate	NN	i	IPM
did	VBD	O	O
not	RB	O	O
reduce	VB	o	OOt
fasting	VBG	o	OPH
or	CC	o	OPH
post-prandial	JJ	o	OPH
blood	NN	o	OPH
glucose	NN	o	OPH
,	,	O	O
nor	CC	O	O
24	CD	o	OPH
h	NN	o	OPH
glycosuria	NN	o	OPH
;	:	o	O
no	DT	O	O
improvement	NN	O	O
was	VBD	O	O
noted	VBN	O	O
in	IN	O	O
the	DT	O	O
M-value	NNP	o	OPH
,	,	o	O
an	DT	o	O
index	NN	o	OPH
of	IN	o	OPH
diabetes	NNS	o	OPH
control	NN	o	OPH
.	.	o	O

3	CD	O	O
.	.	O	O

In	IN	O	O
contrast	NN	O	O
,	,	O	O
in	IN	O	O
nine	CD	O	O
patients	NNS	O	O
,	,	O	O
with	IN	O	O
poor	JJ	O	O
diabetes	NNS	o	OPH
control	NN	o	OPH
,	,	O	O
clofibrate	NN	i	IPM
reduced	VBD	O	O
24	CD	o	OPH
h	NN	o	OPH
glycosuria	NN	o	OPH
and	CC	O	O
significantly	RB	O	O
improved	VBD	O	O
the	DT	O	O
M-value	NNP	o	OPH
.	.	o	O

4	CD	O	O
.	.	O	O

In	IN	O	O
all	DT	O	O
patients	NNS	O	O
,	,	O	O
clofibrate	JJ	i	IPH
therapy	NN	i	IPH
was	VBD	O	O
associated	VBN	O	O
with	IN	O	O
a	DT	O	O
significant	JJ	O	O
19-23	JJ	O	O
%	NN	O	O
reduction	NN	O	O
in	IN	O	O
plasma	NN	o	OPH
fibrinogen	NN	o	OPH
.	.	o	O

5	CD	O	O
.	.	O	O

It	PRP	O	O
is	VBZ	O	O
suggested	VBN	O	O
that	IN	O	O
addition	NN	O	O
of	IN	O	O
clofibrate	NN	i	IPM
may	MD	O	O
be	VB	O	O
useful	JJ	O	O
in	IN	O	O
maturity-onset	JJ	p	O
diabetics	NNS	p	O
not	RB	p	O
adequately	RB	p	O
controlled	VBN	p	O
by	IN	p	O
diet	NN	p	O
combined	VBN	p	O
with	IN	p	O
oral	JJ	i	IPM
hypoglycaemic	JJ	i	IPM
agents	NNS	i	IPM
.	.	i	O

Trachoma	NNP	O	O
prevalence	NN	O	O
and	CC	O	O
associated	VBN	O	O
risk	NN	O	O
factors	NNS	O	O
in	IN	O	O
the	DT	p	O
gambia	NN	p	O
and	CC	p	O
Tanzania	NNP	p	O
:	:	p	O
baseline	NN	O	O
results	NNS	O	O
of	IN	O	O
a	DT	O	O
cluster	NN	O	O
randomised	VBN	O	O
controlled	VBN	O	O
trial	NN	O	O
.	.	O	O

BACKGROUND	NNP	O	O
Blinding	NNP	O	O
trachoma	NN	O	O
,	,	O	O
caused	VBN	O	O
by	IN	O	O
ocular	JJ	O	O
infection	NN	O	O
with	IN	O	O
Chlamydia	NNP	O	O
trachomatis	NN	O	O
,	,	O	O
is	VBZ	O	O
targeted	VBN	O	O
for	IN	O	O
global	JJ	O	O
elimination	NN	O	O
by	IN	O	O
2020	CD	O	O
.	.	O	O

Knowledge	NNP	O	O
of	IN	O	O
risk	NN	O	O
factors	NNS	O	O
can	MD	O	O
help	VB	O	O
target	VB	O	O
control	JJ	O	O
interventions	NNS	O	O
.	.	O	O

METHODOLOGY/PRINCIPAL	NNP	O	O
FINDINGS	NNP	O	O
As	IN	O	O
part	NN	O	O
of	IN	O	O
a	DT	O	O
cluster	NN	O	O
randomised	VBN	O	O
controlled	VBN	O	O
trial	NN	O	O
,	,	O	O
we	PRP	O	O
assessed	VBD	o	O
the	DT	o	O
baseline	NN	o	O
prevalence	NN	o	O
of	IN	o	O
,	,	o	O
and	CC	o	O
risk	NN	o	O
factors	NNS	o	O
for	IN	o	O
,	,	O	O
active	JJ	O	O
trachoma	NN	o	OPH
and	CC	O	O
ocular	JJ	o	O
C.	NNP	o	O
trachomatis	NN	o	O
infection	NN	o	O
in	IN	O	O
randomly	RB	p	O
selected	VBN	p	O
children	NNS	p	PA
aged	VBN	p	O
0-5	CD	p	PA
years	NNS	p	PA
from	IN	p	O
48	CD	p	O
Gambian	JJ	p	O
and	CC	p	O
36	CD	p	O
Tanzanian	JJ	p	O
communities	NNS	p	O
.	.	p	O

Both	DT	i	O
children	NNS	i	O
's	POS	i	O
eyes	NNS	i	O
were	VBD	i	O
examined	VBN	i	O
according	VBG	O	O
to	TO	O	O
the	DT	O	O
World	NNP	o	OPH
Health	NNP	o	OPH
Organization	NNP	o	OPH
(	(	o	OPH
WHO	NNP	o	OPH
)	)	o	OPH
simplified	VBD	o	OPH
grading	VBG	o	OPH
system	NN	o	OPH
,	,	O	O
and	CC	O	O
an	DT	i	IPH
ocular	JJ	o	OPH
swab	NN	o	OPH
was	VBD	i	IPH
taken	VBN	i	IPH
from	IN	i	IPH
each	DT	i	IPH
child	NN	i	IPH
's	POS	i	IPH
right	JJ	i	IPH
eye	NN	i	IPH
and	CC	i	IPH
processed	VBN	i	IPH
by	IN	i	IPH
Amplicor	NNP	o	O
polymerase	NN	o	O
chain	NN	o	O
reaction	NN	o	O
to	TO	i	IPH
test	VB	i	IPH
for	IN	i	IPH
the	DT	i	IPH
presence	NN	i	IPH
of	IN	i	IPH
C.	NNP	i	IPH
trachomatis	NN	i	O
DNA	NNP	i	O
.	.	i	O

Prevalence	NN	O	O
of	IN	O	O
active	JJ	O	O
trachoma	NN	O	O
was	VBD	O	O
6.7	CD	O	O
%	NN	O	O
(	(	O	O
335/5033	CD	O	O
)	)	O	O
in	IN	O	O
The	DT	p	O
Gambia	NNP	p	O
and	CC	O	O
32.3	CD	O	O
%	NN	O	O
(	(	O	O
1008/3122	CD	O	O
)	)	O	O
in	IN	O	O
Tanzania	NNP	p	O
.	.	p	O

The	DT	O	O
countries	NNS	O	O
'	POS	O	O
corresponding	VBG	O	O
Amplicor	NNP	o	OPH
positive	JJ	o	OPH
prevalences	NNS	o	OPH
were	VBD	O	O
0.8	CD	O	O
%	NN	O	O
and	CC	O	O
21.9	CD	O	O
%	NN	O	O
.	.	O	O

After	IN	O	O
adjustment	NN	O	O
,	,	O	O
risk	NN	O	O
factors	NNS	O	O
for	IN	O	O
follicular	JJ	O	O
trachoma	NN	O	O
(	(	O	O
TF	NNP	O	O
)	)	O	O
in	IN	O	O
both	DT	O	O
countries	NNS	O	O
were	VBD	O	O
ocular	JJ	o	OPH
or	CC	o	OPH
nasal	JJ	o	OPH
discharge	NN	o	OPH
,	,	O	O
a	DT	O	O
low	JJ	o	OME
level	NN	o	OME
of	IN	o	OME
household	NN	o	OME
head	NN	o	OME
education	NN	o	OME
,	,	O	O
and	CC	O	O
being	VBG	O	O
aged	VBN	o	O
?	.	o	O
1	CD	o	O
year	NN	o	O
.	.	o	O

Additional	NNP	O	O
risk	NN	O	O
factors	NNS	O	O
in	IN	O	O
Tanzania	NNP	p	O
were	VBD	o	O
flies	NNS	o	O
on	IN	o	O
the	DT	o	O
child	NN	o	O
's	POS	o	O
face	NN	o	O
,	,	o	O
being	VBG	o	O
Amplicor	NNP	o	O
positive	JJ	o	O
,	,	o	O
and	CC	o	O
crowding	NN	o	O
(	(	o	O
the	DT	O	O
number	NN	O	O
of	IN	O	O
children	NNS	O	O
per	IN	O	O
household	NN	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
risk	NN	O	O
factors	NNS	O	O
for	IN	O	O
being	VBG	o	O
Amplicor	NNP	o	O
positive	JJ	o	O
in	IN	o	O
Tanzania	NNP	p	O
were	VBD	p	O
similar	JJ	O	O
to	TO	O	O
those	DT	O	O
for	IN	O	O
TF	NNP	O	O
,	,	O	O
with	IN	O	O
the	DT	O	O
exclusion	NN	O	O
of	IN	O	O
flies	NNS	O	O
and	CC	O	O
crowding	VBG	O	O
.	.	O	O

In	IN	O	O
The	DT	p	O
Gambia	NNP	p	O
,	,	p	O
only	RB	o	O
ocular	JJ	o	O
discharge	NN	o	O
was	VBD	o	O
associated	VBN	O	O
with	IN	O	O
being	VBG	o	O
Amplicor	NNP	o	O
positive	JJ	o	O
.	.	o	O

CONCLUSIONS/SIGNIFICANCE	NNP	O	O
These	DT	O	O
results	NNS	O	O
indicate	VBP	O	O
that	IN	O	O
although	IN	O	O
the	DT	O	O
prevalence	NN	O	O
of	IN	O	O
active	JJ	O	O
trachoma	NN	O	O
and	CC	o	O
Amplicor	NNP	o	O
positives	NNS	o	O
were	VBD	o	O
very	RB	O	O
different	JJ	O	O
between	IN	O	O
the	DT	O	O
two	CD	O	O
countries	NNS	O	O
,	,	O	O
the	DT	O	O
risk	NN	O	O
factors	NNS	O	O
for	IN	O	O
active	JJ	O	O
trachoma	NN	O	O
were	VBD	O	O
similar	JJ	O	O
but	CC	O	O
those	DT	O	O
for	IN	O	O
being	VBG	o	O
Amplicor	NNP	o	O
positive	JJ	o	O
were	VBD	o	O
different	JJ	O	O
.	.	O	O

The	DT	O	O
lack	NN	O	O
of	IN	O	O
an	DT	O	O
association	NN	O	O
between	IN	O	O
being	VBG	O	O
Amplicor	NNP	O	O
positive	JJ	O	O
and	CC	O	O
TF	NNP	O	O
in	IN	O	O
The	DT	p	O
Gambia	NNP	p	O
highlights	VBZ	p	O
the	DT	O	O
poor	JJ	O	O
correlation	NN	O	O
between	IN	O	O
the	DT	O	O
presence	NN	O	O
of	IN	O	O
trachoma	JJ	o	O
clinical	JJ	o	O
signs	NNS	o	O
and	CC	o	O
evidence	NN	o	O
of	IN	o	O
C.	NNP	o	O
trachomatis	NN	o	O
infection	NN	o	O
in	IN	o	O
this	DT	O	O
setting	NN	O	O
.	.	O	O

Only	RB	o	O
ocular	JJ	o	O
discharge	NN	o	O
was	VBD	o	O
associated	VBN	O	O
with	IN	O	O
evidence	NN	O	O
of	IN	O	O
C.	NNP	O	O
trachomatis	NN	O	O
DNA	NN	O	O
in	IN	O	O
The	DT	p	O
Gambia	NNP	p	O
,	,	p	O
suggesting	VBG	O	O
that	IN	O	O
at	IN	O	O
this	DT	O	O
low	JJ	O	O
endemicity	NN	O	O
,	,	O	O
this	DT	O	O
may	MD	O	O
be	VB	O	O
the	DT	O	O
most	RBS	O	O
important	JJ	O	O
risk	NN	O	O
factor	NN	O	O
.	.	O	O

TRIAL	NNP	O	O
REGISTRATION	NNP	O	O
ClinicalTrials.gov	NNP	O	O
NCT00792922	NNP	O	O
.	.	O	O

Learning	VBG	O	O
about	IN	O	O
the	DT	O	O
equal	JJ	O	O
sign	NN	O	O
:	:	O	O
does	VBZ	O	O
comparing	VBG	O	O
with	IN	O	O
inequality	NN	O	O
symbols	NNS	O	O
help	VB	O	O
?	.	O	O
This	DT	i	O
study	NN	i	O
investigated	VBD	i	O
whether	IN	i	O
instruction	NN	i	IOt
that	WDT	i	IOt
involves	VBZ	i	IOt
comparing	VBG	i	IOt
the	DT	i	IOt
equal	JJ	i	IPS
sign	NN	i	IPS
with	IN	i	IOt
other	JJ	i	IOt
relational	JJ	i	IOt
symbols	NNS	i	IOt
is	VBZ	i	O
more	RBR	i	O
effective	JJ	i	O
at	IN	i	O
imparting	VBG	i	O
a	DT	i	O
relational	JJ	o	OME
interpretation	NN	o	OME
of	IN	o	OME
the	DT	o	OME
equal	JJ	o	OME
sign	NN	o	OME
than	IN	i	O
instruction	NN	i	IOt
about	IN	i	IOt
the	DT	i	IOt
equal	JJ	i	IPS
sign	NN	i	IPS
alone	RB	i	IOt
.	.	i	O

Third-	JJ	i	O
and	CC	i	O
fourth-grade	JJ	i	O
students	NNS	i	O
in	IN	i	O
a	DT	i	O
comparing	NN	i	IE
symbols	NNS	i	IE
group	NN	i	IE
learned	VBD	i	IE
about	IN	i	IE
the	DT	i	IE
greater	JJR	i	IE
than	IN	i	IE
,	,	i	IE
less	JJR	i	IE
than	IN	i	IE
,	,	i	IE
and	CC	i	IE
equal	JJ	i	IPS
signs	NNS	i	IPS
and	CC	i	IE
had	VBD	i	IE
the	DT	i	IE
opportunity	NN	i	IE
to	TO	i	IE
compare	VB	i	IE
the	DT	i	IE
inequality	NN	i	IE
symbols	VBZ	i	IE
with	IN	i	IE
the	DT	i	IE
equal	JJ	i	IPS
sign	NN	i	IPS
.	.	i	O

Students	NNS	i	O
in	IN	i	O
an	DT	i	O
equal	JJ	i	IPS
sign	NN	i	IPS
group	NN	i	IE
learned	VBD	i	IE
about	IN	i	IE
the	DT	i	IE
equal	JJ	i	IPS
sign	NN	i	IPS
only	RB	i	IE
.	.	i	IE

A	NNP	i	O
third	JJ	i	O
group	NN	i	O
of	IN	i	O
students	NNS	i	O
served	VBD	i	O
as	IN	i	O
a	DT	i	O
control	NN	i	IC
group	NN	i	IC
.	.	i	O

Three	CD	O	O
aspects	NNS	O	O
of	IN	O	O
students	NNS	O	O
'	POS	O	O
knowledge	NN	O	O
were	VBD	O	O
assessed	VBN	O	O
before	IN	O	O
and	CC	O	O
after	IN	O	O
the	DT	O	O
lesson	NN	O	O
:	:	O	O
(	(	O	O
a	DT	O	O
)	)	O	O
conceptual	JJ	o	OME
understanding	NN	o	OME
of	IN	o	OME
the	DT	o	OME
equal	JJ	o	OME
sign	NN	o	OME
,	,	O	O
(	(	O	O
b	NN	O	O
)	)	O	O
equation	NN	o	OME
encoding	NN	o	OME
,	,	O	O
and	CC	O	O
(	(	O	O
c	NN	O	O
)	)	O	O
problem	NN	o	OME
solving	VBG	o	OME
.	.	o	O

Students	NNS	O	O
in	IN	O	O
the	DT	O	O
comparing	NN	O	O
symbols	NNS	O	O
group	NN	O	O
showed	VBD	O	O
greater	JJR	O	O
gains	NNS	O	O
in	IN	O	O
conceptual	JJ	o	OME
understanding	NN	o	OME
from	IN	O	O
pretest	NN	O	O
to	TO	O	O
posttest	VB	O	O
than	IN	O	O
students	NNS	O	O
in	IN	O	O
the	DT	O	O
other	JJ	O	O
two	CD	O	O
groups	NNS	O	O
,	,	O	O
and	CC	O	O
students	NNS	O	O
in	IN	O	O
the	DT	O	O
comparing	NN	O	O
symbols	NNS	O	O
group	NN	O	O
also	RB	O	O
scored	VBD	O	O
higher	JJR	O	O
on	IN	O	O
a	DT	O	O
posttest	NN	o	O
that	WDT	o	O
assessed	VBD	o	O
knowledge	NN	o	OME
about	IN	o	OME
inequality	NN	o	OME
symbols	NNS	o	OME
and	CC	o	O
inequality	NN	o	OME
problem	NN	o	OME
solving	VBG	o	OME
.	.	o	O

Thus	RB	O	O
,	,	O	O
they	PRP	O	O
learned	VBD	O	O
about	IN	O	O
three	CD	O	O
symbols	NNS	O	O
in	IN	O	O
the	DT	O	O
same	JJ	O	O
amount	NN	O	O
of	IN	O	O
time	NN	O	O
as	IN	O	O
other	JJ	O	O
students	NNS	O	O
learned	VBD	O	O
about	IN	O	O
the	DT	O	O
equal	JJ	O	O
sign	NN	O	O
alone	RB	O	O
or	CC	O	O
not	RB	O	O
at	IN	O	O
all	DT	O	O
.	.	O	O

Therefore	NNP	O	O
,	,	O	O
an	DT	O	O
instructional	JJ	O	O
approach	NN	O	O
involving	VBG	O	O
comparison	NN	O	O
can	MD	O	O
be	VB	O	O
an	DT	O	O
effective	JJ	O	O
tool	NN	O	O
for	IN	O	O
learning	VBG	O	O
about	IN	O	O
concepts	NNS	O	O
in	IN	O	O
mathematics	NNS	O	O
.	.	O	O

[	RB	O	O
Clinical	JJ	O	O
trial	NN	O	O
of	IN	O	O
2	CD	O	O
tobacco	NN	O	O
use	NN	O	O
cessation	NN	i	IPM
interventions	NNS	i	IPM
in	IN	O	O
primary	JJ	O	O
care	NN	O	O
]	NNP	O	O
.	.	O	O

OBJECTIVE	NNP	O	O
To	TO	O	O
study	VB	O	O
the	DT	O	O
efficacy	NN	O	O
of	IN	O	O
two	CD	O	O
types	NNS	O	O
of	IN	O	O
intervention	NN	O	O
to	TO	O	O
stop	VB	O	O
tobacco	NN	o	OME
dependency	NN	o	OME
.	.	o	OME

DESIGN	NNP	O	O
Randomised	VBD	O	O
clinical	JJ	O	O
trial	NN	O	O
.	.	O	O

SETTING	NN	O	O
Primary	NNP	O	O
care	NN	O	O
centre	NN	O	O
.	.	O	O

PATIENTS	NNP	O	O
AND	CC	O	O
OTHER	NNP	O	O
PARTICIPANTS	NNP	O	O
Smokers	NNP	p	PC
recruited	VBD	p	O
from	IN	p	O
among	IN	p	O
the	DT	p	O
health	NN	p	O
centre	NN	p	O
users	NNS	p	O
through	IN	p	O
the	DT	p	O
preventive	JJ	p	O
activities	NNS	p	O
and	CC	p	O
health	NN	p	O
promotion	NN	p	O
programme	NN	p	O
.	.	p	O

INTERVENTIONS	NNP	O	O
INDEPENDENT	NNP	i	O
VARIABLE	NNP	i	O
type	NN	i	O
of	IN	i	O
intervention	NN	i	O
.	.	i	O

General	JJ	O	O
variables	NNS	O	O
:	:	O	O
age	NN	O	O
,	,	O	O
sex	NN	O	O
,	,	O	O
marital	JJ	O	O
status	NN	O	O
,	,	O	O
educational	JJ	O	O
level	NN	O	O
,	,	O	O
work	NN	O	O
situation	NN	O	O
,	,	O	O
cohabitation	NN	O	O
with	IN	O	O
children	NNS	O	O
,	,	O	O
smokers	NNS	O	O
at	IN	O	O
home	NN	O	O
,	,	O	O
number	NN	O	O
of	IN	O	O
years	NNS	O	O
smoking	VBG	O	O
,	,	O	O
type	NN	O	O
of	IN	O	O
tobacco	NN	O	O
.	.	O	O

There	EX	O	O
were	VBD	O	O
two	CD	O	O
types	NNS	O	O
of	IN	O	O
intervention	NN	O	O
:	:	O	O
a	DT	O	O
)	)	O	O
Minimal	NNP	i	IPM
Intervention	NNP	i	IPM
(	(	O	O
MI	NNP	O	O
)	)	O	O
.	.	O	O

b	NN	O	O
)	)	O	O
Advanced	NNP	i	IPM
Intervention	NNP	i	IPM
(	(	O	O
AI	NNP	O	O
)	)	O	O
.	.	O	O

54	CD	p	PSS
patients	NNS	p	O
were	VBD	p	O
included	VBN	p	O
,	,	p	O
with	IN	p	O
6	CD	p	PSS
losses	NNS	p	O
.	.	p	O

21	CD	p	PSS
were	VBD	O	O
assigned	VBN	O	O
at	IN	O	O
random	NN	O	O
to	TO	O	O
the	DT	O	O
MI	NNP	i	IPM
group	NN	p	O
and	CC	O	O
27	CD	p	PSS
to	TO	O	O
the	DT	O	O
AI	NNP	i	IPM
group	NN	p	O
.	.	p	O

Progress	NNP	O	O
was	VBD	O	O
measured	VBN	O	O
at	IN	O	O
15	CD	O	O
days	NNS	O	O
,	,	O	O
1	CD	O	O
month	NN	O	O
,	,	O	O
3	CD	O	O
months	NNS	O	O
,	,	O	O
6	CD	O	O
months	NNS	O	O
and	CC	O	O
a	DT	O	O
year	NN	O	O
.	.	O	O

RESULTS	NNP	O	O
In	IN	O	O
the	DT	O	O
MI	NNP	O	O
,	,	O	O
23.8	CD	O	O
%	NN	O	O
were	VBD	O	O
abstinent	JJ	o	OME
at	IN	O	O
15	CD	O	O
days	NNS	O	O
;	:	O	O
the	DT	O	O
same	JJ	O	O
percentage	NN	O	O
at	IN	O	O
one	CD	O	O
month	NN	O	O
and	CC	O	O
3	CD	O	O
months	NNS	O	O
;	:	O	O
19	CD	O	O
%	NN	O	O
at	IN	O	O
6	CD	O	O
months	NNS	O	O
;	:	O	O
and	CC	O	O
14.3	CD	O	O
%	NN	O	O
remained	VBD	O	O
abstinent	JJ	o	OME
after	IN	o	OME
a	DT	o	OME
year	NN	o	OME
.	.	o	OME

In	IN	O	O
the	DT	O	O
AI	NNP	O	O
,	,	O	O
51.9	CD	O	O
%	NN	O	O
were	VBD	O	O
abstinent	JJ	o	O
at	IN	O	O
15	CD	O	O
days	NNS	O	O
;	:	O	O
48.1	CD	O	O
%	NN	O	O
at	IN	O	O
both	DT	O	O
one	CD	O	O
and	CC	O	O
3	CD	O	O
months	NNS	O	O
;	:	O	O
25.9	CD	O	O
%	NN	O	O
at	IN	O	O
6	CD	O	O
months	NNS	O	O
;	:	O	O
and	CC	O	O
22.2	CD	O	O
%	NN	O	O
were	VBD	O	O
still	RB	O	O
not	RB	o	OME
smoking	VBG	o	OME
after	IN	o	OME
a	DT	o	OME
year	NN	o	OME
.	.	o	OME

No	DT	O	O
significant	JJ	O	O
differences	NNS	O	O
between	IN	O	O
the	DT	O	O
two	CD	O	O
interventions	NNS	O	O
were	VBD	O	O
found	VBN	O	O
in	IN	O	O
any	DT	O	O
of	IN	O	O
the	DT	O	O
observations	NNS	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
These	DT	O	O
data	NNS	O	O
do	VBP	O	O
not	RB	O	O
show	VB	O	O
that	IN	O	O
one	CD	O	O
intervention	NN	O	O
is	VBZ	O	O
better	RBR	O	O
than	IN	O	O
the	DT	O	O
other	JJ	O	O
.	.	O	O

With	IN	O	O
the	DT	O	O
passage	NN	O	O
of	IN	O	O
time	NN	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
the	DT	O	O
intervention	NN	O	O
decreased	VBN	O	O
in	IN	O	O
both	DT	O	O
groups	NNS	O	O
.	.	O	O

Parenteral	JJ	O	O
nutrition	NN	O	O
and	CC	O	O
protein	NN	O	O
sparing	NN	O	O
after	IN	O	O
surgery	NN	i	IS
:	:	i	O
do	VBP	O	O
we	PRP	O	O
need	VB	O	O
glucose	RB	i	IPM
?	.	O	O
Although	IN	O	O
capable	JJ	O	O
of	IN	O	O
inducing	VBG	O	O
an	DT	O	O
anabolic	JJ	O	O
state	NN	O	O
after	IN	O	O
surgery	NN	O	O
,	,	O	O
parenteral	JJ	i	IPM
nutrition	NN	i	IPM
,	,	O	O
including	VBG	O	O
glucose	NN	i	IPM
,	,	O	O
leads	VBZ	O	O
to	TO	O	O
hyperglycemia	VB	O	O
.	.	O	O

Even	RB	O	O
moderate	JJ	O	O
increases	NNS	O	O
in	IN	O	O
blood	NN	O	O
glucose	NN	O	O
are	VBP	O	O
associated	VBN	O	O
with	IN	O	O
poor	JJ	O	O
surgical	JJ	O	O
outcome	NN	O	O
.	.	O	O

We	PRP	O	O
examined	VBD	O	O
the	DT	O	O
hypothesis	NN	O	O
that	WDT	O	O
amino	NN	i	IPM
acids	NNS	i	IPM
,	,	O	O
in	IN	O	O
the	DT	O	O
absence	NN	O	O
of	IN	O	O
glucose	JJ	i	IPM
supply	NN	O	O
,	,	O	O
spare	JJ	O	O
protein	NN	O	O
while	IN	O	O
preventing	VBG	O	O
hyperglycemia	NN	O	O
.	.	O	O

In	IN	O	O
this	DT	O	O
prospective	JJ	O	O
study	NN	O	O
,	,	O	O
14	CD	p	PSS
patients	NNS	p	O
with	IN	p	O
colonic	JJ	p	PC
cancer	NN	p	PC
were	VBD	O	O
randomly	RB	O	O
assigned	VBN	O	O
to	TO	O	O
undergo	VB	O	O
a	DT	O	O
6-hour	JJ	O	O
stable	JJ	O	O
isotope	NN	i	IPM
infusion	NN	i	IPM
study	NN	O	O
(	(	O	O
3	CD	O	O
hours	NNS	O	O
of	IN	O	O
fasting	VBG	i	IPH
followed	VBN	O	O
by	IN	O	O
3-hour	JJ	O	O
infusions	NNS	O	O
of	IN	O	O
amino	NN	i	IPM
acids	NNS	i	IPM
,	,	i	O
Travasol	NNP	i	O
[	NNP	O	O
Baxter	NNP	O	O
,	,	O	O
Montreal	NNP	O	O
,	,	O	O
Canada	NNP	O	O
]	VBD	O	O
10	CD	O	O
%	NN	O	O
at	IN	O	O
0.02	CD	O	O
mL.kg	NN	O	O
(	(	O	O
-1	NNP	O	O
)	)	O	O
.min	NNP	O	O
(	(	O	O
-1	NNP	O	O
)	)	O	O
,	,	O	O
with	IN	i	IPM
or	CC	i	IPM
without	IN	i	IPM
glucose	JJ	i	IPM
at	IN	O	O
4	CD	O	O
mg.kg	NN	O	O
(	(	O	O
-1	NNP	O	O
)	)	O	O
.min	NNP	O	O
(	(	O	O
-1	NNP	O	O
)	)	O	O
)	)	O	O
on	IN	O	O
the	DT	O	O
second	JJ	O	O
day	NN	O	O
after	IN	O	O
colorectal	JJ	O	O
surgery	NN	O	O
.	.	O	O

Protein	NNP	o	OPH
breakdown	NN	o	OPH
,	,	o	O
protein	JJ	o	OPH
oxidation	NN	o	OPH
,	,	o	O
protein	JJ	o	OPH
balance	NN	o	OPH
,	,	o	O
and	CC	o	O
glucose	JJ	o	OPH
production	NN	o	OPH
were	VBD	O	O
assessed	VBN	O	O
by	IN	O	O
stable	JJ	O	O
isotope	NN	O	O
tracer	NN	O	O
kinetics	NNS	O	O
using	VBG	O	O
l-	JJ	O	O
[	JJ	O	O
1-	JJ	O	O
(	(	O	O
13	CD	O	O
)	)	O	O
C	NNP	O	O
]	NNP	O	O
leucine	NN	O	O
and	CC	O	O
[	JJ	O	O
6,6-	JJ	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
H2	NNP	O	O
]	NNP	O	O
glucose	NN	O	O
.	.	O	O

Circulating	VBG	o	OPH
concentrations	NNS	o	OPH
of	IN	o	OPH
glucose	NN	o	OPH
,	,	o	O
cortisol	NN	o	OPH
,	,	o	O
insulin	NN	o	OPH
,	,	o	O
and	CC	o	O
glucagon	NN	o	OPH
were	VBD	O	O
determined	VBN	O	O
.	.	O	O

The	DT	O	O
administration	NN	O	O
of	IN	O	O
amino	JJ	i	IPM
acids	NNS	i	IPM
increased	VBD	O	O
protein	JJ	o	OPH
balance	NN	o	OPH
from	IN	O	O
-16+/-4	JJ	O	O
micromol.kg	NN	O	O
(	(	O	O
-1	NNP	O	O
)	)	O	O
.h	NNP	O	O
(	(	O	O
-1	NNP	O	O
)	)	O	O
in	IN	O	O
the	DT	O	O
fasted	JJ	O	O
state	NN	O	O
to	TO	O	O
16+/-3	JJ	O	O
micromol.kg	NN	O	O
(	(	O	O
-1	NNP	O	O
)	)	O	O
.h	NNP	O	O
(	(	O	O
-1	NNP	O	O
)	)	O	O
.	.	O	O

Combined	VBN	O	O
infusion	NN	O	O
of	IN	O	O
amino	JJ	i	O
acids	NNS	i	O
and	CC	i	O
glucose	VB	i	O
increased	JJ	O	O
protein	NN	o	OPH
balance	NN	o	OPH
from	IN	O	O
-17+/-7	JJ	O	O
to	TO	O	O
7+/-5	JJ	O	O
micromol.kg	NN	O	O
(	(	O	O
-1	NNP	O	O
)	)	O	O
.h	NNP	O	O
(	(	O	O
-1	NNP	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
increase	NN	O	O
in	IN	O	O
protein	JJ	o	OPH
balance	NN	o	OPH
during	IN	O	O
nutrition	NN	O	O
was	VBD	O	O
comparable	JJ	O	O
in	IN	O	O
the	DT	O	O
2	CD	O	O
groups	NNS	O	O
(	(	O	O
P=.07	NNP	O	O
)	)	O	O
.	.	O	O

Combined	VBN	O	O
administration	NN	O	O
of	IN	O	O
amino	JJ	i	IPM
acids	NNS	i	IPM
and	CC	i	O
glucose	VB	i	IPM
decreased	VBN	O	O
endogenous	JJ	o	OPH
glucose	JJ	o	OPH
production	NN	o	OPH
(	(	O	O
P=.001	NNP	O	O
)	)	O	O
and	CC	O	O
stimulated	VBN	O	O
insulin	NN	o	OPH
secretion	NN	o	OPH
(	(	O	O
P=.001	NNP	O	O
)	)	O	O
to	TO	O	O
a	DT	O	O
greater	JJR	O	O
extent	NN	O	O
than	IN	O	O
the	DT	O	O
administration	NN	O	O
of	IN	O	O
amino	JJ	i	IPM
acids	NNS	i	IPM
alone	RB	O	O
.	.	O	O

Hyperglycemia	NNP	o	OPH
(	(	O	O
blood	NN	O	O
glucose	NN	O	O
,	,	O	O
10.1+/-1.9	JJ	O	O
micromol/L	NN	O	O
)	)	O	O
occurred	VBD	O	O
only	RB	O	O
in	IN	O	O
the	DT	O	O
presence	NN	O	O
of	IN	O	O
glucose	JJ	i	IPM
infusion	NN	O	O
.	.	O	O

In	IN	O	O
summary	JJ	O	O
,	,	O	O
excluding	VBG	O	O
glucose	NN	i	IPM
from	IN	O	O
a	DT	O	O
short-term	JJ	O	O
feeding	NN	O	O
protocol	NN	O	O
does	VBZ	O	O
not	RB	O	O
diminish	VB	O	O
the	DT	O	O
protein-sparing	JJ	o	OPH
effect	NN	o	OPH
of	IN	O	O
amino	NN	i	IPM
acids	NNS	i	IPM
and	CC	O	O
avoids	NNS	O	O
hyperglycemia	NN	o	OPH
.	.	o	O

Pre-operative	JJ	i	IPH
radiochemotherapy	NN	i	IPH
for	IN	O	O
rectal	JJ	p	O
cancer	NN	p	O
.	.	p	O

A	DT	O	O
prospective	JJ	O	O
randomized	VBN	O	O
trial	NN	O	O
comparing	VBG	O	O
pre-operative	JJ	i	IPH
vs.	FW	i	O
postoperative	JJ	i	IPH
radiochemotherapy	NN	i	IPH
in	IN	O	O
rectal	JJ	p	O
cancer	NN	p	O
patients	NNS	p	O
.	.	p	O

PURPOSE	VB	O	O
The	DT	O	O
aim	NN	O	O
of	IN	O	O
the	DT	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
find	VB	O	O
out	RP	O	O
whether	IN	O	O
pre-operative	JJ	i	IPH
radiochemotherapy	NN	i	IPH
had	VBD	O	O
any	DT	O	O
survival	JJ	o	OPH
advantage	NN	o	OPH
over	IN	O	O
postoperative	JJ	i	IPH
radiochemotherapy	NN	i	IPH
for	IN	O	O
rectal	JJ	p	O
carcinoma	NN	p	O
patients	NNS	p	O
without	IN	p	O
distant	JJ	p	O
metastasis	NN	p	O
or	CC	p	O
peritoneal	JJ	p	O
carcinomatosis	NN	p	O
.	.	p	O

MATERIAL	NNP	O	O
AND	CC	O	O
METHODS	NNP	O	O
Between	NNP	p	O
January	NNP	p	O
1998	CD	p	O
and	CC	p	O
December	NNP	p	O
2003	CD	p	O
,	,	p	O
51	CD	p	O
rectal	JJ	p	O
carcinoma	NN	p	O
patients	NNS	p	O
without	IN	p	O
distant	JJ	p	O
metastasis	NN	p	O
or	CC	p	O
peritoneal	JJ	p	O
carcinomatosis	NN	p	O
were	VBD	O	O
randomly	RB	O	O
divided	VBN	O	O
into	IN	O	O
pre-operative	JJ	i	IPH
(	(	i	IPH
PRE	NNP	i	IPH
)	)	i	IPH
and	CC	O	O
postoperative	JJ	i	IPH
(	(	i	IPH
POST	NNP	i	IPH
)	)	i	IPH
radiochemotherapy	NN	i	IPH
groups	NNS	O	O
.	.	O	O

Twenty-six	CD	O	O
were	VBD	O	O
assigned	VBN	O	O
to	TO	O	O
the	DT	O	O
PRE	NNP	O	O
group	NN	O	O
and	CC	O	O
were	VBD	O	O
operated	VBN	O	O
on	IN	O	O
5	CD	O	O
to	TO	O	O
8	CD	O	O
weeks	NNS	O	O
after	IN	O	O
the	DT	O	O
completion	NN	O	O
of	IN	O	O
radiotherapy	NN	i	IPH
.	.	i	O

The	DT	O	O
other	JJ	O	O
25	CD	O	O
patients	NNS	O	O
were	VBD	O	O
operated	VBN	O	O
on	IN	O	O
immediately	RB	O	O
and	CC	O	O
received	VBD	O	O
radiotherapy	NN	O	O
postoperatively	RB	O	O
2	CD	O	O
to	TO	O	O
4	CD	O	O
weeks	NNS	O	O
after	IN	O	O
surgery	NN	O	O
.	.	O	O

The	DT	O	O
patients	NNS	O	O
were	VBD	O	O
followed	VBN	O	O
up	RP	O	O
for	IN	O	O
between	IN	O	O
4	CD	O	O
to	TO	O	O
51	CD	O	O
months	NNS	O	O
.	.	O	O

RESULTS	NNP	O	O
In	IN	O	O
the	DT	O	O
PRE	NNP	O	O
group	NN	O	O
the	DT	O	O
rates	NNS	o	OPH
of	IN	o	OPH
disease-free	JJ	o	OPH
survival	NN	o	OPH
were	VBD	O	O
92	CD	O	O
%	NN	O	O
,	,	O	O
70	CD	O	O
%	NN	O	O
,	,	O	O
56	CD	O	O
%	NN	O	O
and	CC	O	O
56	CD	O	O
%	NN	O	O
at	IN	O	O
the	DT	O	O
end	NN	O	O
of	IN	O	O
the	DT	O	O
1st	CD	O	O
,	,	O	O
2nd	CD	O	O
,	,	O	O
3rd	CD	O	O
and	CC	O	O
4th	CD	O	O
years	NNS	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

In	IN	O	O
the	DT	O	O
POST	NNP	O	O
group	NN	O	O
those	DT	O	O
percentages	NNS	O	O
were	VBD	O	O
83	CD	O	O
%	NN	O	O
,	,	O	O
68	CD	O	O
%	NN	O	O
,	,	O	O
51	CD	O	O
%	NN	O	O
and	CC	O	O
51	CD	O	O
%	NN	O	O
at	IN	O	O
the	DT	O	O
1st	CD	O	O
,	,	O	O
2nd	CD	O	O
,	,	O	O
3rd	CD	O	O
and	CC	O	O
4th	CD	O	O
years	NNS	O	O
,	,	O	O
respectively	RB	O	O
(	(	O	O
p	JJ	O	O
=	NNP	O	O
0.707	CD	O	O
)	)	O	O
.	.	O	O

One-year	JJ	o	OMO
and	CC	o	OMO
4-year	JJ	o	OMO
overall	JJ	o	OMO
survival	NN	o	OMO
rates	NNS	o	OMO
in	IN	O	O
the	DT	O	O
PRE	NNP	O	O
group	NN	O	O
were	VBD	O	O
100	CD	O	O
%	NN	O	O
and	CC	O	O
86	CD	O	O
%	NN	O	O
respectively	RB	O	O
and	CC	O	O
100	CD	O	O
%	NN	O	O
and	CC	O	O
60	CD	O	O
%	NN	O	O
in	IN	O	O
the	DT	O	O
POST	NNP	O	O
group	NN	O	O
(	(	O	O
p	JJ	O	O
=	NNP	O	O
0.520	CD	O	O
)	)	O	O
.	.	O	O

CONCLUSION	NNP	O	O
No	NNP	O	O
statistical	JJ	O	O
difference	NN	O	O
was	VBD	O	O
found	VBN	O	O
between	IN	O	O
the	DT	O	O
survival	JJ	o	OMO
rates	NNS	o	OMO
of	IN	O	O
the	DT	O	O
rectal	JJ	p	O
carcinoma	NN	p	O
patients	NNS	p	O
receiving	VBG	O	O
radiotherapy	NN	O	O
either	CC	O	O
pre-operatively	RB	O	O
or	CC	O	O
postoperatively	RB	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
the	DT	O	O
disease-free	JJ	o	OMO
survival	NN	o	OMO
rates	NNS	o	OMO
of	IN	O	O
the	DT	O	O
PRE	NNP	i	IPH
group	NN	O	O
were	VBD	O	O
higher	JJR	O	O
than	IN	O	O
the	DT	O	O
POST	NNP	i	IPH
group	NN	O	O
's	POS	O	O
during	IN	O	O
each	DT	O	O
year	NN	O	O
and	CC	O	O
overall	JJ	o	OMO
survival	NN	o	OMO
rates	NNS	o	OMO
were	VBD	O	O
higher	JJR	O	O
after	IN	O	O
the	DT	O	O
third	JJ	O	O
and	CC	O	O
fourth	JJ	O	O
years	NNS	O	O
.	.	O	O

We	PRP	O	O
conclude	VBP	O	O
that	IN	O	O
pre-operative	JJ	i	IPH
radiotherapy	NN	i	IPH
is	VBZ	O	O
at	IN	o	OOt
least	JJS	o	OOt
as	RB	o	OOt
effective	JJ	o	OOt
as	IN	o	OOt
postoperative	JJ	i	IPH
radiotherapy	NN	i	IPH
.	.	i	O

Sinemet	NNP	i	IPM
CR	NNP	i	IPM
in	IN	p	O
Parkinson	NNP	p	O
's	POS	p	O
disease	NN	p	O
.	.	p	O

Sinemet	NNP	i	IPM
CR	NNP	i	IPM
,	,	O	O
a	DT	O	O
controlled	JJ	O	O
release	NN	O	O
carbidopa/levodopa	NN	i	IPM
preparation	NN	i	IPM
,	,	O	O
was	VBD	O	O
compared	VBN	O	O
to	TO	O	O
conventional	JJ	O	O
carbidopa/levodopa	NN	i	IPM
in	IN	O	O
a	DT	O	O
double	JJ	O	O
blind	NN	O	O
,	,	O	O
placebo-controlled	JJ	i	IC
trial	NN	O	O
.	.	O	O

Comparable	JJ	o	OOt
clinical	JJ	o	OOt
benefits	NNS	o	OOt
and	CC	o	O
adverse	JJ	o	OA
effects	NNS	o	OA
were	VBD	O	O
noted	VBN	O	O
with	IN	O	O
the	DT	O	O
two	CD	O	O
medications	NNS	O	O
.	.	O	O

However	RB	O	O
significantly	RB	O	O
less	RBR	O	O
frequent	JJ	O	O
dosing	NN	O	O
was	VBD	O	O
necessary	JJ	O	O
with	IN	O	O
Sinemet	NNP	O	O
CR	NNP	O	O
.	.	O	O

Direct	JJ	i	O
renin	NN	i	O
inhibition	NN	i	O
improves	VBZ	O	O
parasympathetic	JJ	O	O
function	NN	O	O
in	IN	O	O
diabetes	NNS	p	PC
.	.	p	O

AIM	VB	O	O
The	DT	O	O
renin-angiotensin-aldosterone	NN	O	O
system	NN	O	O
(	(	O	O
RAAS	NNP	O	O
)	)	O	O
and	CC	O	O
autonomic	JJ	O	O
nervous	JJ	O	O
system	NN	O	O
regulate	VB	O	O
the	DT	O	O
cardiovascular	JJ	O	O
system	NN	O	O
.	.	O	O

Blockade	NN	O	O
of	IN	O	O
the	DT	O	O
RAAS	NNP	O	O
may	MD	O	O
slow	VB	O	O
the	DT	O	O
progression	NN	O	O
of	IN	O	O
end-organ	JJ	O	O
damage	NN	O	O
.	.	O	O

Direct	JJ	i	O
renin	NN	i	O
inhibition	NN	i	O
offers	VBZ	O	O
a	DT	O	O
means	NN	O	O
for	IN	O	O
blocking	VBG	O	O
the	DT	O	O
RAAS	NNP	O	O
.	.	O	O

The	DT	O	O
objective	NN	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
examine	VB	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
direct	JJ	i	O
renin	NN	i	O
inhibition	NN	i	O
on	IN	O	O
cardiovascular	JJ	O	O
autonomic	JJ	O	O
function	NN	O	O
.	.	O	O

METHODS	NNP	O	O
In	IN	O	O
this	DT	O	O
double-blind	NN	O	O
,	,	O	O
placebo-controlled	JJ	i	IC
trial	NN	O	O
,	,	O	O
60	CD	p	PSS
individuals	NNS	p	O
with	IN	p	O
diabetes	NNS	p	PC
were	VBD	O	O
randomly	RB	O	O
assigned	VBN	O	O
to	TO	O	O
300	CD	O	O
mg	NN	O	O
of	IN	O	O
aliskiren	NN	i	IPM
or	CC	i	O
placebo	NN	i	IPM
once	RB	O	O
daily	JJ	O	O
for	IN	O	O
6	CD	O	O
weeks	NNS	O	O
.	.	O	O

The	DT	O	O
primary	JJ	O	O
end	NN	O	O
point	NN	O	O
was	VBD	O	O
a	DT	O	O
change	NN	o	OPH
in	IN	o	OPH
tests	NNS	o	OPH
of	IN	o	OPH
cardiovascular	JJ	o	OPH
autonomic	JJ	o	OPH
function	NN	o	OPH
.	.	o	OPH

Autonomic	NNP	o	OPH
function	NN	o	OPH
was	VBD	O	O
assessed	VBN	O	O
by	IN	O	O
power	NN	O	O
spectral	JJ	O	O
analysis	NN	O	O
and	CC	O	O
RR-variation	NNP	O	O
during	IN	O	O
deep	JJ	O	O
breathing	NN	O	O
[	JJ	O	O
i.e	NN	O	O
.	.	O	O

mean	VB	O	O
circular	JJ	O	O
resultant	NN	O	O
(	(	O	O
MCR	NNP	O	O
)	)	O	O
,	,	O	O
expiration/inspiration	NN	O	O
(	(	O	O
E/I	NNP	O	O
)	)	O	O
ratio	NN	O	O
]	NN	O	O
.	.	O	O

The	DT	O	O
MCR	NNP	O	O
and	CC	O	O
E/I	NNP	O	O
ratio	NN	O	O
assess	NN	O	O
parasympathetic	JJ	O	O
function	NN	O	O
.	.	O	O

Secondary	JJ	O	O
measures	NNS	O	O
included	VBD	O	O
change	NN	o	OPH
in	IN	o	OPH
biochemical	JJ	o	OPH
parameters	NNS	o	OPH
[	VBP	o	OPH
e.g	NN	o	OPH
.	.	o	OPH

plasma	JJ	o	OPH
renin	NN	o	OPH
activity	NN	o	OPH
,	,	o	OPH
leptin	NN	o	OPH
and	CC	o	OPH
interleukin-6	JJ	o	OPH
]	NN	o	OPH
.	.	o	OPH

Change	NN	o	OPH
in	IN	o	OPH
cardiovascular	JJ	o	OPH
autonomic	JJ	o	OPH
function	NN	o	OPH
and	CC	o	OPH
blood	NN	o	OPH
analytes	NNS	o	OPH
were	VBD	O	O
analysed	VBN	O	O
by	IN	O	O
a	DT	O	O
mixed	JJ	O	O
effects	NNS	O	O
model	NN	O	O
for	IN	O	O
repeated	JJ	O	O
measures	NNS	O	O
.	.	O	O

RESULTS	NNP	O	O
Baseline	NNP	O	O
characteristics	NNS	O	O
were	VBD	O	O
similar	JJ	O	O
between	IN	O	O
treatment	NN	O	O
groups	NNS	O	O
.	.	O	O

In	IN	O	O
response	NN	O	O
to	TO	O	O
aliskiren	NNS	i	IPM
compared	VBN	O	O
with	IN	O	O
placebo	NN	i	IC
,	,	O	O
blood	NN	o	OPH
pressure	NN	o	OPH
was	VBD	O	O
reduced	VBN	O	O
as	RB	O	O
well	RB	O	O
as	IN	O	O
plasma	JJ	O	O
renin	NN	O	O
activity	NN	O	O
[	VBP	O	O
from	IN	O	O
2.4	CD	O	O
?	.	O	O
3.8	CD	O	O
(	(	O	O
mean	VB	O	O
?	.	O	O
standard	JJ	O	O
deviation	NN	O	O
)	)	O	O
to	TO	O	O
0.5	CD	O	O
?	.	O	O
0.4	CD	O	O
?g/l/h	NN	O	O
,	,	O	O
p	NN	O	O
<	VBD	O	O
0.001	CD	O	O
]	NN	O	O
.	.	O	O

There	EX	O	O
was	VBD	O	O
a	DT	O	O
significant	JJ	O	O
interaction	NN	i	O
(	(	i	O
aliskiren	VB	i	O
?	.	i	O
visit	NN	i	O
)	)	O	O
for	IN	O	O
MCR	NNP	O	O
(	(	O	O
p	JJ	O	O
=	NNP	O	O
0.003	CD	O	O
)	)	O	O
and	CC	O	O
E/I	NNP	O	O
ratio	NN	O	O
(	(	O	O
p	JJ	O	O
=	NNP	O	O
0.003	CD	O	O
)	)	O	O
indicating	VBG	O	O
improvement	NN	O	O
in	IN	O	O
MCR	NNP	O	O
and	CC	O	O
E/I	NNP	O	O
ratio	NN	O	O
for	IN	O	O
those	DT	O	O
on	IN	i	O
aliskiren	NNS	i	O
.	.	i	O

MCR	NNP	i	O
means	VBZ	O	O
,	,	O	O
baseline	VB	O	O
vs.	IN	O	O
follow-up	JJ	O	O
,	,	O	O
were	VBD	O	O
41.8	CD	O	O
?	.	O	O
19.7	CD	O	O
vs.	IN	O	O
50.8	CD	O	O
?	.	O	O
26.1	CD	O	O
(	(	i	O
aliskiren	NN	i	O
)	)	i	O
and	CC	i	O
38.2	CD	i	O
?	.	O	O
23.6	CD	O	O
vs.	IN	O	O
37.5	CD	O	O
?	.	O	O
24.1	CD	O	O
(	(	O	O
placebo	NN	i	O
)	)	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
Parasympathetic	NNP	O	O
function	NN	O	O
(	(	O	O
i.e	JJ	O	O
.	.	O	O

MCR	NNP	O	O
and	CC	O	O
E/I	NNP	O	O
ratio	NN	O	O
)	)	O	O
was	VBD	O	O
enhanced	VBN	O	O
by	IN	O	O
downregulation	NN	O	O
of	IN	O	O
the	DT	O	O
RAAS	NNP	O	O
.	.	O	O

[	JJ	i	O
Radiotherapy	NNP	i	IPH
for	IN	O	O
choroidal	JJ	O	O
neovascularization	NN	O	O
in	IN	O	O
age-related	JJ	O	O
macular	JJ	O	O
degeneration	NN	O	O
.	.	O	O

A	DT	O	O
pilot	NN	O	O
study	NN	O	O
using	VBG	O	O
low-	JJ	i	IPH
versus	NN	i	IPH
high-dose	JJ	i	IPH
photon	NN	i	IPH
bean	NN	i	IPH
radiation	NN	i	IPH
]	NN	i	O
.	.	O	O

PURPOSE	NNP	O	O
Several	JJ	O	O
pilot	NN	O	O
studies	NNS	O	O
have	VBP	O	O
indicated	VBN	O	O
that	IN	O	O
low-dose	JJ	i	IPH
radiation	NN	i	IPH
therapy	NN	i	IPH
might	MD	O	O
have	VB	O	O
a	DT	O	O
beneficial	JJ	O	O
effect	NN	O	O
on	IN	O	O
the	DT	O	O
course	NN	O	O
of	IN	O	O
choroidal	JJ	O	O
neovascularization	NN	O	O
(	(	O	O
CNV	NNP	O	O
)	)	O	O
in	IN	O	O
age-related	JJ	p	O
macular	JJ	p	O
degeneration	NN	p	O
(	(	p	O
AMD	NNP	p	O
)	)	p	O
.	.	p	O

This	DT	O	O
study	NN	O	O
aimed	VBD	O	O
to	TO	O	O
ascertain	VB	O	O
whether	IN	O	O
such	JJ	O	O
treatment	NN	O	O
might	MD	O	O
halt	VB	O	O
the	DT	O	O
progression	NN	O	O
of	IN	O	O
neovascular	JJ	O	O
AMD	NNP	O	O
and	CC	O	O
whether	IN	O	O
a	DT	O	O
low	JJ	O	O
or	CC	O	O
a	DT	O	O
high	JJ	O	O
radiation	NN	O	O
dose	NN	O	O
should	MD	O	O
be	VB	O	O
applied	VBN	O	O
.	.	O	O

PATIENTS	VB	O	O
The	DT	O	O
patients	NNS	p	O
comprised	VBD	p	O
some	DT	p	O
randomized	VBN	p	O
to	TO	p	O
0	CD	i	IPH
vs	NNS	i	IPH
10	CD	i	IPH
vs	NNS	i	IPH
36	CD	i	IPH
Gy	NNP	i	IPH
of	IN	i	IPH
radiation	NN	i	IPH
and	CC	p	O
(	(	p	O
after	IN	p	O
a	DT	p	O
change	NN	p	O
of	IN	p	O
the	DT	p	O
study	NN	p	O
protocol	NN	p	O
became	VBD	p	O
necessary	JJ	p	O
)	)	p	O
others	NNS	p	O
who	WP	p	O
participated	VBD	p	O
in	IN	p	O
a	DT	p	O
prospective	JJ	p	O
,	,	p	O
controlled	VBD	p	O
non-randomized	JJ	p	O
pilot	NN	p	O
study	NN	p	O
.	.	p	O

Enclosed	VBN	O	O
were	VBD	O	O
eyes	NNS	p	O
with	IN	p	O
visual	JJ	p	O
acuity	NN	p	O
of	IN	p	O
>	NN	p	O
or	CC	p	O
=	VB	p	O
0.1	CD	p	O
and	CC	p	O
<	NNP	p	O
or	CC	p	O
=	$	p	O
0.6	CD	p	O
revealing	VBG	p	O
a	DT	p	O
juxta-subfoveal	JJ	p	O
CNV	NNP	p	O
either	NN	p	O
of	IN	p	O
the	DT	p	O
occult	NN	p	O
type	NN	p	O
(	(	p	O
type	JJ	p	O
1	CD	p	O
)	)	p	O
or	CC	p	O
the	DT	p	O
classic	JJ	p	O
type	NN	p	O
(	(	p	O
isolated	JJ	p	O
or	CC	p	O
as	IN	p	O
part	NN	p	O
of	IN	p	O
a	DT	p	O
predominantly	RB	p	O
occult	JJ	p	O
lesion	NN	p	O
)	)	p	O
.	.	p	O

RESULTS	NNP	O	O
Eyes	NNP	O	O
treated	VBD	O	O
with	IN	O	O
10	CD	i	IPH
Gy	NNP	i	IPH
for	IN	O	O
occult	NN	O	O
CNV	NNP	O	O
(	(	O	O
n	JJ	O	O
=	NNP	O	O
12	CD	O	O
)	)	O	O
were	VBD	O	O
subject	JJ	O	O
to	TO	O	O
severe	JJ	o	OPH
visual	JJ	o	OPH
loss	NN	o	OPH
in	IN	O	O
41.6	CD	O	O
%	NN	O	O
of	IN	O	O
the	DT	O	O
cases	NNS	O	O
compared	VBN	O	O
to	TO	O	O
38.5	CD	O	O
%	NN	O	O
in	IN	O	O
the	DT	O	O
control	NN	O	O
group	NN	O	O
(	(	O	O
n	JJ	O	O
=	NNP	O	O
13	CD	O	O
)	)	O	O
at	IN	O	O
12	CD	O	O
months	NNS	O	O
of	IN	O	O
follow-up	NN	O	O
.	.	O	O

For	IN	O	O
eyes	NNS	O	O
treated	VBN	O	O
with	IN	O	O
10	CD	i	IPH
Gy	NNP	i	IPH
because	IN	O	O
of	IN	O	O
classic	JJ	O	O
CNV	NNP	O	O
,	,	O	O
the	DT	O	O
corresponding	JJ	O	O
figures	NNS	O	O
were	VBD	O	O
33	CD	O	O
%	NN	O	O
(	(	O	O
n	JJ	O	O
=	NNP	O	O
18	CD	O	O
)	)	O	O
and	CC	O	O
57	CD	O	O
%	NN	O	O
(	(	O	O
n	JJ	O	O
=	NNP	O	O
14	CD	O	O
)	)	O	O
respectively	RB	O	O
.	.	O	O

At	IN	O	O
18	CD	O	O
months	NNS	O	O
of	IN	O	O
follow-up	NN	O	O
,	,	O	O
the	DT	O	O
percentages	NNS	O	O
were	VBD	O	O
63	CD	O	O
%	NN	O	O
and	CC	O	O
75	CD	O	O
%	NN	O	O
respectively	RB	O	O
.	.	O	O

Fluorescein	NNP	o	OPH
angiographic	JJ	o	OPH
growth	NN	o	OPH
of	IN	o	OPH
classic	JJ	o	OPH
and	CC	o	OPH
occult	NN	o	OPH
CNV	NNP	o	OPH
could	MD	O	O
not	RB	O	O
be	VB	O	O
halted	VBN	O	O
by	IN	O	O
10	CD	O	O
Gy	NNP	O	O
,	,	O	O
while	IN	O	O
a	DT	O	O
temporary	JJ	o	OPH
growth	NN	o	OPH
retardation	NN	o	OPH
was	VBD	O	O
observed	VBN	O	O
in	IN	O	O
cases	NNS	O	O
irradiated	VBN	O	O
with	IN	O	O
36	CD	i	IPH
Gy	NNP	i	IPH
.	.	i	O

CONCLUSION	NNP	O	O
In	IN	O	O
the	DT	O	O
study	NN	O	O
presented	VBD	O	O
,	,	O	O
the	DT	O	O
natural	JJ	O	O
course	NN	O	O
of	IN	O	O
occult	NN	O	O
CNV	NNP	O	O
could	MD	O	O
not	RB	O	O
be	VB	O	O
improved	VBN	O	O
by	IN	O	O
irradiation	NN	O	O
with	IN	O	O
10	CD	i	IPH
or	CC	i	IPH
36	CD	i	IPH
Gy	NNP	i	IPH
.	.	i	O

In	IN	O	O
cases	NNS	O	O
of	IN	O	O
classic	JJ	O	O
CNV	NNP	O	O
,	,	O	O
low-dose	JJ	O	O
irradiation	NN	O	O
with	IN	O	O
10	CD	i	IPH
Gy	NNP	i	IPH
postponed	VBD	O	O
severe	JJ	o	OPH
visual	JJ	o	OPH
loss	NN	o	OPH
by	IN	O	O
a	DT	O	O
maximum	NN	O	O
of	IN	O	O
18	CD	O	O
months	NNS	O	O
.	.	O	O

A	DT	O	O
positive	JJ	O	O
treatment	NN	O	O
effect	NN	O	O
was	VBD	O	O
also	RB	O	O
observed	VBN	O	O
in	IN	O	O
cases	NNS	O	O
irradiated	VBN	O	O
with	IN	O	O
36	CD	i	IPH
Gy	NNP	i	IPH
;	:	i	O
however	RB	O	O
,	,	O	O
a	DT	O	O
25	CD	O	O
%	NN	O	O
incidence	NN	O	O
of	IN	O	O
radiation	NN	O	O
retinopathy	NN	O	O
seems	VBZ	O	O
unacceptable	JJ	O	O
.	.	O	O

Randomized	VBN	O	O
trial	NN	O	O
of	IN	O	O
liberal	JJ	i	O
versus	NN	i	O
restrictive	JJ	i	O
guidelines	NNS	i	O
for	IN	i	O
red	JJ	i	O
blood	NN	i	O
cell	NN	i	O
transfusion	NN	i	O
in	IN	O	O
preterm	JJ	p	O
infants	NNS	p	O
.	.	p	O

OBJECTIVE	NNP	O	O
Although	IN	O	O
many	JJ	O	O
centers	NNS	O	O
have	VBP	O	O
introduced	VBN	O	O
more	RBR	O	O
restrictive	JJ	O	O
transfusion	NN	O	O
policies	NNS	O	O
for	IN	O	O
preterm	JJ	p	O
infants	NNS	p	O
in	IN	O	O
recent	JJ	O	O
years	NNS	O	O
,	,	O	O
the	DT	O	O
benefits	NNS	O	O
and	CC	O	O
adverse	JJ	O	O
consequences	NNS	O	O
of	IN	O	O
allowing	VBG	O	O
lower	JJR	O	O
hematocrit	NN	O	O
levels	NNS	O	O
have	VBP	O	O
not	RB	O	O
been	VBN	O	O
systematically	RB	O	O
evaluated	VBN	O	O
.	.	O	O

The	DT	O	O
objective	NN	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
determine	VB	O	O
if	IN	O	O
restrictive	JJ	i	O
guidelines	NNS	i	O
for	IN	i	O
red	JJ	i	O
blood	NN	i	O
cell	NN	i	O
(	(	i	O
RBC	NNP	i	O
)	)	i	O
transfusions	NNS	i	O
for	IN	O	O
preterm	JJ	O	O
infants	NNS	O	O
can	MD	O	O
reduce	VB	O	O
the	DT	O	O
number	NN	o	OOt
of	IN	o	OOt
transfusions	NNS	o	OOt
without	IN	O	O
adverse	JJ	O	O
consequences	NNS	O	O
.	.	O	O

DESIGN	NNP	O	O
,	,	O	O
SETTING	NNP	O	O
,	,	O	O
AND	NNP	O	O
PATIENTS	NNP	O	O
We	PRP	O	O
enrolled	VBD	O	O
100	CD	p	O
hospitalized	JJ	p	O
preterm	NN	p	O
infants	NNS	p	O
with	IN	p	O
birth	JJ	p	O
weights	NNS	p	O
of	IN	p	O
500	CD	p	O
to	TO	p	O
1300	CD	p	O
g	NN	p	O
into	IN	O	O
a	DT	O	O
randomized	JJ	O	O
clinical	JJ	O	O
trial	NN	O	O
comparing	VBG	O	O
2	CD	O	O
levels	NNS	O	O
of	IN	O	O
hematocrit	NN	O	O
threshold	NN	O	O
for	IN	O	O
RBC	NNP	O	O
transfusion	NN	O	O
.	.	O	O

INTERVENTION	NNP	O	O
The	DT	O	O
infants	NNS	O	O
were	VBD	O	O
assigned	VBN	O	O
randomly	RB	O	O
to	TO	O	O
either	VB	O	O
the	DT	O	O
liberal-	NN	i	IPH
or	CC	i	IPH
the	DT	i	IPH
restrictive-transfusion	NN	i	IPH
group	NN	O	O
.	.	O	O

For	IN	O	O
each	DT	O	O
group	NN	O	O
,	,	O	O
transfusions	NNS	O	O
were	VBD	O	O
given	VBN	O	O
only	RB	O	O
when	WRB	O	O
the	DT	O	O
hematocrit	NN	O	O
level	NN	O	O
fell	VBD	O	O
below	IN	O	O
the	DT	O	O
assigned	JJ	O	O
value	NN	O	O
.	.	O	O

In	IN	O	O
each	DT	O	O
group	NN	O	O
,	,	O	O
the	DT	O	O
transfusion	NN	O	O
threshold	NN	O	O
levels	NNS	O	O
decreased	VBN	O	O
with	IN	O	O
improving	VBG	O	O
clinical	JJ	O	O
status	NN	O	O
.	.	O	O

MAIN	NNP	O	O
OUTCOME	NNP	O	O
MEASURES	NNP	O	O
We	PRP	O	O
recorded	VBD	O	O
the	DT	O	O
number	NN	o	OOt
of	IN	o	OOt
transfusions	NNS	o	OOt
,	,	o	O
the	DT	o	O
number	NN	o	OOt
of	IN	o	OOt
donor	JJ	o	OOt
exposures	NNS	o	OOt
,	,	o	O
and	CC	o	O
various	JJ	o	OOt
clinical	JJ	o	OOt
and	CC	o	OOt
physiologic	JJ	o	OOt
outcomes	NNS	o	OOt
.	.	o	O

RESULTS	JJ	O	O
Infants	NNS	O	O
in	IN	O	O
the	DT	O	O
liberal-transfusion	NN	O	O
group	NN	O	O
received	VBD	O	O
more	JJR	O	O
RBC	JJ	o	OPH
transfusions	NNS	o	OPH
(	(	O	O
5.2	CD	O	O
+/-	JJ	O	O
4.5	CD	O	O
[	JJ	O	O
mean	JJ	O	O
+/-	JJ	O	O
SD	NNP	O	O
]	NNP	O	O
vs	VBD	O	O
3.3	CD	O	O
+/-	JJ	O	O
2.9	CD	O	O
in	IN	O	O
the	DT	O	O
restrictive-transfusion	NN	i	O
group	NN	O	O
)	)	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
the	DT	O	O
number	NN	o	OPH
of	IN	o	OPH
donors	NNS	o	OPH
to	TO	O	O
whom	WP	O	O
the	DT	O	O
infants	NNS	O	O
were	VBD	O	O
exposed	VBN	O	O
was	VBD	O	O
not	RB	O	O
significantly	RB	O	O
different	JJ	O	O
(	(	O	O
2.8	CD	O	O
+/-	JJ	O	O
2.5	CD	O	O
vs	JJ	O	O
2.2	CD	O	O
+/-	JJ	O	O
2.0	CD	O	O
)	)	O	O
.	.	O	O

There	EX	O	O
was	VBD	O	O
no	DT	O	O
difference	NN	O	O
between	IN	O	O
the	DT	O	O
groups	NNS	O	O
in	IN	O	O
the	DT	O	O
percentage	NN	o	OPH
of	IN	o	OPH
infants	NNS	o	OPH
who	WP	o	OPH
avoided	VBD	o	OPH
transfusions	NNS	o	OPH
altogether	RB	o	OPH
(	(	O	O
12	CD	O	O
%	NN	O	O
in	IN	O	O
the	DT	O	O
liberal-transfusion	NN	O	O
group	NN	O	O
versus	VBD	O	O
10	CD	O	O
%	NN	O	O
in	IN	O	O
the	DT	O	O
restrictive-transfusion	NN	O	O
group	NN	O	O
)	)	O	O
.	.	O	O

Infants	NNS	O	O
in	IN	O	O
the	DT	O	O
restrictive-transfusion	NN	i	O
group	NN	O	O
were	VBD	O	O
more	RBR	O	O
likely	JJ	O	O
to	TO	O	O
have	VB	O	O
intraparenchymal	JJ	o	OPH
brain	NN	o	OPH
hemorrhage	NN	o	OPH
or	CC	o	OPH
periventricular	JJ	o	OPH
leukomalacia	NN	o	OPH
,	,	O	O
and	CC	O	O
they	PRP	O	O
had	VBD	O	O
more	RBR	o	OPH
frequent	JJ	o	OPH
episodes	NNS	o	OPH
of	IN	o	OPH
apnea	NN	o	OPH
,	,	O	O
including	VBG	O	O
both	DT	O	O
mild	JJ	o	OPH
and	CC	o	OPH
severe	JJ	o	OPH
episodes	NNS	o	OPH
.	.	o	O

CONCLUSIONS	NNP	O	O
Although	IN	O	O
both	DT	O	O
transfusion	NN	i	O
programs	NNS	O	O
were	VBD	O	O
well	RB	O	O
tolerated	VBN	O	O
,	,	O	O
our	PRP$	O	O
finding	NN	O	O
of	IN	O	O
more	RBR	O	O
frequent	JJ	O	O
major	JJ	o	OA
adverse	JJ	o	OA
neurologic	NN	o	OA
events	NNS	o	OA
in	IN	O	O
the	DT	O	O
restrictive	JJ	i	O
RBC-transfusion	NNP	i	O
group	NN	O	O
suggests	VBZ	O	O
that	IN	O	O
the	DT	O	O
practice	NN	O	O
of	IN	O	O
restrictive	JJ	i	O
transfusions	NNS	i	O
may	MD	O	O
be	VB	O	O
harmful	JJ	O	O
to	TO	O	O
preterm	VB	O	O
infants	NNS	O	O
.	.	O	O

Stress	NNP	i	IE
reduction	NN	i	IE
prolongs	NNS	O	O
life	NN	O	O
in	IN	O	O
women	NNS	p	PSE
with	IN	p	O
coronary	JJ	p	PC
disease	NN	p	PC
:	:	p	O
the	DT	O	O
Stockholm	NNP	O	O
Women	NNP	O	O
's	POS	O	O
Intervention	NNP	O	O
Trial	NNP	O	O
for	IN	O	O
Coronary	NNP	O	O
Heart	NNP	O	O
Disease	NNP	O	O
(	(	O	O
SWITCHD	NNP	O	O
)	)	O	O
.	.	O	O

BACKGROUND	NNP	O	O
Psychosocial	NNP	O	O
stress	NN	O	O
may	MD	O	O
increase	VB	O	O
risk	NN	O	O
and	CC	O	O
worsen	JJ	O	O
prognosis	NN	O	O
of	IN	O	O
coronary	JJ	p	PC
heart	NN	p	PC
disease	NN	p	PC
in	IN	p	O
women	NNS	p	O
.	.	p	O

Interventions	NNS	O	O
that	IN	O	O
counteract	JJ	O	O
women	NNS	O	O
's	POS	O	O
psychosocial	JJ	O	O
stress	NN	O	O
have	VBP	O	O
not	RB	O	O
previously	RB	O	O
been	VBN	O	O
presented	VBN	O	O
.	.	O	O

This	DT	O	O
study	NN	O	O
implemented	VBD	O	O
a	DT	O	O
stress	JJ	i	IE
reduction	NN	i	IE
program	NN	i	IE
for	IN	O	O
women	NNS	p	O
and	CC	O	O
investigated	VBD	O	O
its	PRP$	O	O
ability	NN	O	O
to	TO	O	O
improve	VB	O	O
survival	NN	o	OMO
in	IN	o	OMO
women	NNS	o	OMO
coronary	JJ	o	OMO
patients	NNS	o	OMO
.	.	o	OMO

METHODS	NNP	O	O
AND	CC	O	O
RESULTS	NNP	O	O
Two	CD	p	PSS
hundred	VBD	p	PSS
thirty-seven	JJ	p	PSS
consecutive	JJ	p	O
women	NNS	p	O
patients	NNS	p	O
,	,	p	O
aged	VBD	p	O
75	CD	p	PA
years	NNS	p	PA
or	CC	p	O
younger	JJR	p	O
,	,	p	O
hospitalized	VBN	p	O
for	IN	p	O
acute	JJ	p	PC
myocardial	JJ	p	PC
infarction	NN	p	PC
,	,	p	O
coronary	JJ	p	PC
artery	NN	p	PC
bypass	NN	p	PC
grafting	NN	p	PC
,	,	p	O
or	CC	p	O
percutaneous	JJ	p	PC
coronary	JJ	p	PC
intervention	NN	p	PC
were	VBD	O	O
randomized	VBN	O	O
to	TO	O	O
a	DT	O	O
group-based	JJ	i	IE
psychosocial	JJ	i	IE
intervention	NN	i	IE
program	NN	i	IE
or	CC	i	IE
usual	JJ	i	IE
care	NN	i	IE
.	.	i	IE

Initiated	VBN	O	O
4	CD	O	O
months	NNS	O	O
after	IN	O	O
hospitalization	NN	O	O
,	,	O	O
intervention	NN	O	O
groups	NNS	O	O
of	IN	O	O
4	CD	O	O
to	TO	O	O
8	CD	O	O
women	NNS	O	O
met	VBD	O	O
for	IN	O	O
a	DT	O	O
total	NN	O	O
of	IN	O	O
20	CD	O	O
sessions	NNS	O	O
that	WDT	O	O
were	VBD	O	O
spread	VBN	O	O
over	IN	O	O
a	DT	O	O
year	NN	O	O
.	.	O	O

We	PRP	O	O
provided	VBD	O	O
education	NN	i	IE
about	IN	i	IE
risk	NN	i	IE
factors	NNS	i	IE
,	,	i	O
relaxation	NN	i	IE
training	NN	i	IE
techniques	NNS	i	IE
,	,	i	O
methods	NNS	i	IE
for	IN	i	IE
self-monitoring	NN	i	IE
and	CC	i	IE
cognitive	JJ	i	IE
restructuring	NN	i	IE
,	,	i	O
with	IN	i	O
an	DT	i	O
emphasis	NN	i	O
on	IN	i	O
coping	VBG	i	IE
with	IN	i	IE
stress	JJ	i	IE
exposure	NN	i	IE
from	IN	i	IE
family	NN	i	IE
and	CC	i	IE
work	NN	i	IE
,	,	i	O
and	CC	i	O
self-care	NN	i	IE
and	CC	i	IE
compliance	NN	i	IE
with	IN	i	IE
clinical	JJ	i	IE
advice	NN	i	IE
.	.	i	O

From	IN	O	O
randomization	NN	O	O
until	IN	O	O
end	NN	O	O
of	IN	O	O
follow-up	NN	O	O
(	(	O	O
mean	JJ	O	O
duration	NN	O	O
,	,	O	O
7.1	CD	O	O
years	NNS	O	O
)	)	O	O
,	,	O	O
25	CD	O	O
women	NNS	O	O
(	(	O	O
20	CD	O	O
%	NN	O	O
)	)	O	O
in	IN	O	O
the	DT	O	O
usual	JJ	O	O
care	NN	O	O
and	CC	O	O
8	CD	O	O
women	NNS	O	O
(	(	O	O
7	CD	O	O
%	NN	O	O
)	)	O	O
in	IN	O	O
the	DT	O	O
stress	NN	o	OPH
reduction	NN	o	OPH
died	VBD	O	O
,	,	O	O
yielding	VBG	O	O
an	DT	O	O
almost	RB	O	O
3-fold	JJ	O	O
protective	JJ	O	O
effect	NN	O	O
of	IN	O	O
the	DT	O	O
intervention	NN	O	O
(	(	O	O
odds	NNS	O	O
ratio	NN	O	O
,	,	O	O
0.33	CD	O	O
;	:	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
,	,	O	O
0.15	CD	O	O
to	TO	O	O
0.74	CD	O	O
;	:	O	O
P=0.007	NNP	O	O
)	)	O	O
.	.	O	O

Introducing	VBG	O	O
baseline	JJ	O	O
measures	NNS	O	O
of	IN	O	O
clinical	JJ	O	O
prognostic	JJ	O	O
factors	NNS	O	O
,	,	O	O
including	VBG	O	O
use	NN	o	OPH
of	IN	o	OPH
aspirin	NN	o	OPH
,	,	o	OPH
beta-blockers	NNS	o	OPH
,	,	o	OPH
angiotensin-converting	JJ	o	OPH
enzyme	NN	o	OPH
inhibitors	NNS	o	OPH
,	,	o	OPH
calcium-channel	JJ	o	OPH
blockers	NNS	o	OPH
,	,	o	OPH
and	CC	o	OPH
statins	VBZ	o	OPH
into	IN	i	O
multivariate	NN	i	O
models	NNS	i	O
confirmed	VBD	O	O
the	DT	O	O
unadjusted	JJ	O	O
results	NNS	O	O
(	(	O	O
P=0.009	NNP	O	O
)	)	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
Although	IN	O	O
mechanisms	NN	O	O
remain	VBP	O	O
unclear	JJ	O	O
,	,	O	O
a	DT	O	O
group-based	JJ	i	IE
psychosocial	JJ	i	IE
intervention	NN	i	IE
program	NN	i	IE
for	IN	O	O
women	NNS	p	O
with	IN	p	O
coronary	JJ	p	PC
heart	NN	p	PC
disease	NN	p	PC
may	MD	O	O
prolong	VB	O	O
lives	NNS	O	O
independent	JJ	O	O
of	IN	O	O
other	JJ	O	O
prognostic	JJ	O	O
factors	NNS	O	O
.	.	O	O

Opioid-immune	JJ	O	O
interactions	NNS	O	O
in	IN	O	O
autism	NN	p	PC
:	:	p	O
behavioural	JJ	O	O
and	CC	O	O
immunological	JJ	O	O
assessment	NN	O	O
during	IN	O	O
a	DT	O	O
double-blind	JJ	O	O
treatment	NN	O	O
with	IN	O	O
naltrexone	NN	i	IPM
.	.	i	O

The	DT	O	O
emerging	VBG	O	O
concept	NN	O	O
of	IN	O	O
opioid	JJ	O	O
peptides	NNS	O	O
as	IN	O	O
a	DT	O	O
new	JJ	O	O
class	NN	O	O
of	IN	O	O
chemical	JJ	O	O
messengers	NNS	O	O
of	IN	O	O
the	DT	O	O
neuroimmune	JJ	O	O
axis	NN	O	O
and	CC	O	O
the	DT	O	O
presence	NN	O	O
of	IN	O	O
a	DT	O	O
number	NN	O	O
of	IN	O	O
immunological	JJ	O	O
abnormalities	NNS	O	O
in	IN	O	O
infantile	JJ	O	O
autism	NN	O	O
prompted	VBD	O	O
us	PRP	O	O
to	TO	O	O
correlate	VB	O	O
biological	JJ	O	O
(	(	O	O
hormonal	JJ	O	O
and	CC	O	O
immunological	JJ	O	O
)	)	O	O
determinations	NNS	O	O
and	CC	O	O
behavioural	JJ	O	O
performances	NNS	O	O
during	IN	O	O
treatment	NN	O	O
with	IN	O	O
the	DT	O	O
potent	NN	O	O
opiate	JJ	O	O
antagonist	NN	O	O
,	,	O	O
naltrexone	NN	i	IPM
(	(	i	IPM
NAL	NNP	i	IPM
)	)	i	IPM
.	.	i	O

Twelve	NNP	p	PSS
autistic	JJ	p	PC
patients	NNS	p	O
ranging	VBG	p	O
from	IN	p	O
7	CD	p	PA
to	TO	p	PA
15	CD	p	PA
years	NNS	p	PA
,	,	p	O
diagnosed	VBD	p	O
according	VBG	p	O
to	TO	p	O
DSM-III-R	NNP	p	O
,	,	O	O
entered	VBD	O	O
a	DT	O	O
double-blind	JJ	i	O
crossover	NN	i	O
study	NN	i	O
with	IN	i	O
NAL	NNP	i	IPM
at	IN	i	O
the	DT	i	O
doses	NNS	i	O
of	IN	i	O
0.5	CD	i	O
,	,	i	O
1.0	CD	i	O
and	CC	i	O
1.5	CD	i	O
mg/kg	NN	i	O
every	DT	i	O
48	CD	i	O
hours	NNS	i	O
.	.	i	O

The	DT	i	O
behavioural	JJ	i	O
evaluation	NN	i	O
was	VBD	i	O
conducted	VBN	i	O
using	VBG	i	O
the	DT	i	O
specific	JJ	i	O
BSE	NNP	o	OME
and	CC	o	OME
CARS	NNP	o	OME
rating	NN	o	OME
scales	NNS	o	OME
NAL	NNP	i	IPM
treatment	NN	i	O
produced	VBD	i	O
a	DT	i	O
significant	JJ	i	O
reduction	NN	i	O
of	IN	i	O
the	DT	i	O
autistic	JJ	o	OME
symptomatology	NN	o	OME
in	IN	i	O
seven	CD	i	O
(	(	i	O
responders	NNS	i	O
)	)	i	O
out	IN	i	O
of	IN	i	O
12	CD	i	O
children	NNS	i	O
.	.	i	O

The	DT	O	O
behavioural	JJ	O	O
improvement	NN	O	O
was	VBD	O	O
accompanied	VBN	O	O
by	IN	O	O
alterations	NNS	O	O
in	IN	O	O
the	DT	O	O
distribution	NN	O	O
of	IN	O	O
the	DT	O	O
major	JJ	O	O
lymphocyte	NN	O	O
subsets	NNS	O	O
,	,	O	O
with	IN	O	O
a	DT	O	O
significant	JJ	O	O
increase	NN	O	O
of	IN	O	O
the	DT	O	O
T-helper-inducers	NNP	o	OPH
(	(	o	OPH
CD4+CD8-	NNP	o	OPH
)	)	o	OPH
and	CC	O	O
a	DT	O	O
significant	JJ	O	O
reduction	NN	O	O
of	IN	O	O
the	DT	O	O
T-cytotoxic-suppressor	NNP	o	OPH
(	(	o	OPH
CD4-CD8+	NNP	o	OPH
)	)	o	OPH
resulting	VBG	O	O
in	IN	O	O
a	DT	O	O
normalization	NN	O	O
of	IN	O	O
the	DT	O	O
CD4/CD8	NNP	o	OPH
ratio	NN	o	OPH
.	.	o	OPH

Changes	NNS	O	O
in	IN	O	O
natural	JJ	o	OPH
killer	NN	o	OPH
cells	NNS	o	OPH
and	CC	o	OPH
activity	NN	o	OPH
were	VBD	O	O
inversely	RB	O	O
related	VBN	O	O
to	TO	O	O
plasma	VB	O	O
beta-endorphin	JJ	O	O
levels	NNS	O	O
.	.	O	O

It	PRP	O	O
is	VBZ	O	O
suggested	VBN	O	O
that	IN	O	O
the	DT	O	O
mechanisms	NNS	O	O
underlying	VBG	O	O
opioid-immune	JJ	O	O
interactions	NNS	O	O
are	VBP	O	O
altered	VBN	O	O
in	IN	O	O
this	DT	O	O
population	NN	p	O
of	IN	p	O
autistic	JJ	p	PC
children	NNS	p	PA
and	CC	O	O
that	DT	O	O
an	DT	O	O
immunological	JJ	O	O
screening	NN	O	O
may	MD	O	O
have	VB	O	O
prognostic	JJ	O	O
value	NN	O	O
for	IN	O	O
the	DT	O	O
pharmacological	JJ	i	O
therapy	NN	i	O
with	IN	i	O
opiate	JJ	i	IPM
antagonists	NNS	i	IPM
.	.	i	O

Superior	JJ	O	O
survival	NN	o	OMO
with	IN	O	O
capecitabine	JJ	i	IPM
plus	CC	i	O
docetaxel	JJ	i	IPM
combination	NN	i	IPM
therapy	NN	i	IPM
in	IN	O	O
anthracycline-pretreated	JJ	p	PC
patients	NNS	p	PC
with	IN	p	PC
advanced	JJ	p	PC
breast	NN	p	PC
cancer	NN	p	PC
:	:	p	O
phase	NN	O	O
III	NNP	O	O
trial	NN	O	O
results	NNS	O	O
.	.	O	O

PURPOSE	NNP	O	O
Docetaxel	NNP	i	IPM
and	CC	i	O
capecitabine	NN	i	IPM
,	,	O	O
a	DT	O	O
tumor-activated	JJ	O	O
oral	JJ	O	O
fluoropyrimidine	NN	O	O
,	,	O	O
show	VBP	O	O
high	JJ	O	O
single-agent	JJ	O	O
efficacy	NN	O	O
in	IN	O	O
metastatic	JJ	p	O
breast	NN	p	O
cancer	NN	p	O
(	(	O	O
MBC	NNP	O	O
)	)	O	O
and	CC	O	O
synergy	NN	O	O
in	IN	O	O
preclinical	JJ	O	O
studies	NNS	O	O
.	.	O	O

This	DT	O	O
international	JJ	O	O
phase	NN	O	O
III	NNP	O	O
trial	NN	O	O
compared	VBN	O	O
efficacy	NN	o	OOt
and	CC	o	OOt
tolerability	NN	o	OOt
of	IN	O	O
capecitabine/docetaxel	JJ	i	IPM
therapy	NN	i	IPM
with	IN	O	O
single-agent	JJ	i	IPM
docetaxel	NN	i	IPM
in	IN	O	O
anthracycline-pretreated	JJ	p	PC
patients	NNS	p	PC
with	IN	p	PC
MBC	NNP	p	PC
.	.	p	O

PATIENTS	NNP	O	O
AND	CC	O	O
METHODS	NNP	O	O
Patients	NNPS	O	O
were	VBD	O	O
randomized	VBN	O	O
to	TO	O	O
21-day	JJ	O	O
cycles	NNS	O	O
of	IN	O	O
oral	JJ	O	O
capecitabine	NN	i	IPM
1,250	CD	O	O
mg/m	NN	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
twice	RB	O	O
daily	RB	O	O
on	IN	O	O
days	NNS	O	O
1	CD	O	O
to	TO	O	O
14	CD	O	O
plus	CC	O	O
docetaxel	JJ	i	IPM
75	CD	O	O
mg/m	NN	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
on	IN	O	O
day	NN	O	O
1	CD	O	O
(	(	O	O
n	JJ	O	O
=	NNP	O	O
255	CD	O	O
)	)	O	O
or	CC	O	O
to	TO	O	O
docetaxel	VB	i	IPM
100	CD	O	O
mg/m	NN	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
on	IN	O	O
day	NN	O	O
1	CD	O	O
(	(	O	O
n	JJ	O	O
=	NNP	O	O
256	CD	O	O
)	)	O	O
.	.	O	O

RESULTS	NNP	O	O
Capecitabine/docetaxel	NNP	i	IPM
resulted	VBD	O	O
in	IN	O	O
significantly	RB	O	O
superior	JJ	O	O
efficacy	NN	o	OOt
in	IN	O	O
time	NN	o	OPH
to	TO	o	OPH
disease	VB	o	OPH
progression	NN	o	OPH
(	(	o	OPH
TTP	NNP	o	OPH
)	)	o	OPH
(	(	O	O
hazard	JJ	O	O
ratio	NN	O	O
,	,	O	O
0.652	CD	O	O
;	:	O	O
95	CD	O	O
%	NN	O	O
confidence	NN	O	O
interval	NN	O	O
[	NNP	O	O
CI	NNP	O	O
]	NNP	O	O
,	,	O	O
0.545	CD	O	O
to	TO	O	O
0.780	CD	O	O
;	:	O	O
P	NNP	O	O
=.0001	NNP	O	O
;	:	O	O
median	JJ	O	O
,	,	O	O
6.1	CD	O	O
v	NN	O	O
4.2	CD	O	O
months	NNS	O	O
)	)	O	O
,	,	O	O
overall	JJ	o	OMO
survival	NN	o	OMO
(	(	O	O
hazard	JJ	O	O
ratio	NN	O	O
,	,	O	O
0.775	CD	O	O
;	:	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
,	,	O	O
0.634	CD	O	O
to	TO	O	O
0.947	CD	O	O
;	:	O	O
P	NNP	O	O
=.0126	NNP	O	O
;	:	O	O
median	JJ	O	O
,	,	O	O
14.5	CD	O	O
v	NN	O	O
11.5	CD	O	O
months	NNS	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
objective	JJ	o	OPH
tumor	NN	o	OPH
response	NN	o	OPH
rate	NN	o	OPH
(	(	O	O
42	CD	O	O
%	NN	O	O
v	JJ	O	O
30	CD	O	O
%	NN	O	O
,	,	O	O
P	NNP	O	O
=.006	NNP	O	O
)	)	O	O
compared	VBN	O	O
with	IN	O	O
docetaxel	NN	i	IPM
.	.	i	O

Gastrointestinal	JJ	o	OA
side	NN	o	OA
effects	NNS	o	OA
and	CC	o	OA
hand-foot	JJ	o	OA
syndrome	NN	o	OA
were	VBD	O	O
more	JJR	O	O
common	JJ	O	O
with	IN	O	O
combination	NN	i	IPM
therapy	NN	i	IPM
,	,	O	O
whereas	JJ	O	O
myalgia	NN	o	OA
,	,	o	OA
arthralgia	NN	o	OA
,	,	O	O
and	CC	O	O
neutropenic	JJ	o	OA
fever/sepsis	NN	o	OA
were	VBD	O	O
more	JJR	O	O
common	JJ	O	O
with	IN	O	O
single-agent	JJ	i	IPM
docetaxel	NN	i	IPM
.	.	i	O

More	JJR	O	O
grade	JJ	o	OA
3	CD	o	OA
adverse	JJ	o	OA
events	NNS	o	OA
occurred	VBD	O	O
with	IN	O	O
combination	NN	i	O
therapy	NN	i	O
(	(	O	O
71	CD	O	O
%	NN	O	O
v	JJ	O	O
49	CD	O	O
%	NN	O	O
,	,	O	O
respectively	RB	O	O
)	)	O	O
,	,	O	O
whereas	JJ	O	O
grade	VBP	o	OA
4	CD	o	OA
events	NNS	o	OA
were	VBD	O	O
slightly	RB	O	O
more	RBR	O	O
common	JJ	O	O
with	IN	O	O
docetaxel	NN	i	IPM
(	(	O	O
31	CD	O	O
%	NN	O	O
v	JJ	O	O
25	CD	O	O
%	NN	O	O
with	IN	O	O
combination	NN	O	O
)	)	O	O
.	.	O	O

CONCLUSION	VB	O	O
The	DT	O	O
significantly	RB	O	O
superior	JJ	O	O
TTP	NNP	o	OMO
and	CC	o	OMO
survival	NN	o	OMO
achieved	VBN	O	O
with	IN	O	O
the	DT	O	O
addition	NN	i	IPM
of	IN	i	IPM
capecitabine	NN	i	IPM
to	TO	i	IPM
docetaxel	VB	i	IPM
75	CD	O	O
mg/m	NN	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
,	,	O	O
with	IN	O	O
the	DT	O	O
manageable	JJ	O	O
toxicity	NN	o	OPH
profile	NN	o	OPH
,	,	O	O
indicate	VBP	O	O
that	IN	O	O
this	DT	O	O
combination	NN	i	O
provides	VBZ	O	O
clear	JJ	O	O
benefits	NNS	O	O
over	IN	O	O
single-agent	JJ	i	IPM
docetaxel	NN	i	IPM
100	CD	O	O
mg/m	NN	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
.	.	O	O

Docetaxel/capecitabine	NNP	i	IPM
therapy	NN	i	IPM
is	VBZ	O	O
an	DT	O	O
important	JJ	O	O
treatment	NN	O	O
option	NN	O	O
for	IN	O	O
women	NNS	p	PSE
with	IN	p	O
anthracycline-pretreated	JJ	p	PC
MBC	NNP	p	PC
.	.	p	O

Changes	NNS	O	O
of	IN	O	O
activated	JJ	O	O
circulating	VBG	O	O
endothelial	JJ	O	O
cells	NNS	O	O
and	CC	O	O
survivin	NN	O	O
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
non-small	JJ	p	O
cell	NN	p	O
lung	NN	p	O
cancer	NN	p	O
after	IN	p	O
antiangiogenesis	NN	i	IPM
therapy	NN	i	IPM
.	.	i	O

BACKGROUND	NNP	O	O
Although	IN	O	O
antiangiogenesis	NN	i	IPM
therapy	NN	i	IPM
plays	VBZ	O	O
an	DT	O	O
important	JJ	O	O
role	NN	O	O
in	IN	O	O
anti-neoplastic	JJ	i	O
treatment	NN	i	O
with	IN	O	O
its	PRP$	O	O
recognized	VBN	O	O
efficacy	NN	O	O
and	CC	O	O
slight	JJ	O	O
adverse	JJ	O	O
effect	NN	O	O
,	,	O	O
there	EX	O	O
is	VBZ	O	O
no	DT	O	O
prospective	JJ	O	O
clinical	JJ	O	O
trial	NN	O	O
to	TO	O	O
define	VB	O	O
ideal	JJ	O	O
markers	NNS	O	O
for	IN	O	O
predicting	VBG	O	O
efficacy	NN	O	O
of	IN	O	O
antiangiogenic	JJ	i	IPH
therapy	NN	i	IPH
.	.	i	O

This	DT	O	O
study	NN	O	O
was	VBD	O	O
undertaken	VBN	O	O
to	TO	O	O
investigate	VB	O	O
the	DT	O	O
changes	NNS	O	O
of	IN	O	O
activated	JJ	O	O
circulating	VBG	O	O
endothelial	JJ	O	O
cells	NNS	O	O
(	(	O	O
aCECs	NN	O	O
)	)	O	O
and	CC	O	O
survivin	JJ	O	O
after	IN	O	O
anti-angiogenesis	JJ	O	O
therapy	NN	O	O
and	CC	O	O
their	PRP$	O	O
significance	NN	O	O
in	IN	O	O
predicting	VBG	O	O
the	DT	O	O
efficacy	NN	O	O
of	IN	O	O
the	DT	O	O
therapy	NN	O	O
.	.	O	O

METHODS	NNP	O	O
Patients	NNPS	p	O
of	IN	p	O
non-small	JJ	p	O
cell	NN	p	O
lung	NN	p	O
cancer	NN	p	O
(	(	p	O
NSCLC	NNP	p	O
)	)	p	O
treated	VBD	p	O
with	IN	p	O
chemotherapy	NN	i	IPM
with	IN	i	IPM
or	CC	i	IPM
without	IN	i	IPM
Endostar	NNP	i	IPM
were	VBD	O	O
observed	VBN	O	O
.	.	O	O

The	DT	O	O
amount	NN	O	O
of	IN	O	O
activated	JJ	O	O
CECs	NNP	O	O
was	VBD	O	O
detected	VBN	O	O
by	IN	O	O
flow	JJ	O	O
cytometry	NN	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
expression	NN	O	O
of	IN	O	O
survivin	NN	O	O
mRNA	NN	O	O
was	VBD	O	O
determined	VBN	O	O
by	IN	O	O
real-time	JJ	O	O
polymerase	NN	O	O
chain	NN	O	O
reaction	NN	O	O
(	(	O	O
PCR	NNP	O	O
)	)	O	O
.	.	O	O

RESULTS	NNP	O	O
After	IN	O	O
treatment	NN	O	O
,	,	O	O
the	DT	O	O
amount	NN	O	O
of	IN	O	O
activated	JJ	o	OPH
CECs	NNP	o	OPH
decreased	VBD	O	O
significantly	RB	O	O
in	IN	O	O
clinical	JJ	O	O
benefit	NN	O	O
cases	NNS	O	O
(	(	O	O
P	NNP	O	O
=	VBZ	O	O
0.021	CD	O	O
in	IN	O	O
chemotherapy	NN	i	IPH
alone	RB	O	O
,	,	O	O
P	NNP	O	O
=	VBZ	O	O
0.001	CD	O	O
in	IN	O	O
chemotherapy	NN	i	IPH
plus	CC	i	IPH
Endostar	NNP	i	IPH
)	)	i	O
,	,	O	O
increased	VBN	O	O
in	IN	O	O
disease	NN	o	OPH
progressive	JJ	o	OPH
cases	NNS	o	OPH
(	(	O	O
P	NNP	O	O
=	VBZ	O	O
0.015	CD	O	O
in	IN	O	O
chemotherapy	NN	i	IPH
alone	RB	O	O
,	,	O	O
but	CC	O	O
P	NNP	O	O
=	NNP	O	O
0.293	CD	O	O
in	IN	O	O
chemotherapy	NN	i	IPH
with	IN	i	IPH
Endotatar	NNP	i	IPH
)	)	i	O
.	.	O	O

After	IN	O	O
therapy	NN	O	O
,	,	O	O
the	DT	O	O
expression	NN	o	OPH
of	IN	o	OPH
survivin	JJ	o	OPH
mRNA	NN	o	OPH
decreased	VBN	O	O
in	IN	O	O
clinical	JJ	O	O
benefit	NN	O	O
cases	NNS	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.001	CD	O	O
)	)	O	O
and	CC	O	O
increased	VBN	O	O
in	IN	O	O
disease	NN	o	OPH
progressive	JJ	o	OPH
cases	NNS	o	OPH
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.018	CD	O	O
)	)	O	O
.	.	O	O

A	DT	O	O
positive	JJ	O	O
correlation	NN	O	O
was	VBD	O	O
found	VBN	O	O
between	IN	O	O
activated	VBN	o	OPH
CECs	NNP	o	OPH
and	CC	O	O
survivin	NN	O	O
in	IN	O	O
the	DT	O	O
chemotherapy	NN	i	IPH
group	NN	O	O
pre-	JJ	O	O
and	CC	O	O
post-therapy	JJ	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.001	CD	O	O
and	CC	O	O
0.021	CD	O	O
,	,	O	O
respectively	RB	O	O
)	)	O	O
,	,	O	O
but	CC	O	O
only	RB	O	O
in	IN	O	O
the	DT	O	O
chemotherapy	NN	i	IPH
with	IN	i	IPH
Endostar	NNP	i	IPH
group	NN	O	O
pre-therapy	NN	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.030	CD	O	O
)	)	O	O
rather	RB	O	O
than	IN	O	O
post-therapy	NN	O	O
.	.	O	O

A	DT	O	O
positive	JJ	O	O
correlation	NN	O	O
was	VBD	O	O
found	VBN	O	O
between	IN	O	O
the	DT	O	O
decreased	VBN	O	O
activated	VBN	o	OPH
CECs	NNP	o	OPH
after	IN	O	O
therapy	NN	O	O
and	CC	O	O
time	NN	o	OPH
to	TO	o	OPH
progression	NN	o	OPH
(	(	o	OPH
TTP	NNP	o	OPH
)	)	o	OPH
(	(	O	O
r	JJ	O	O
=	NN	O	O
0.322	CD	O	O
,	,	O	O
P	NNP	O	O
=	NNP	O	O
0.012	CD	O	O
)	)	O	O
;	:	O	O
a	DT	O	O
negative	JJ	O	O
correlation	NN	O	O
was	VBD	O	O
found	VBN	O	O
between	IN	O	O
the	DT	O	O
amount	NN	o	OPH
of	IN	o	OPH
survivin	NN	o	OPH
mRNA	NN	o	OPH
in	IN	o	OPH
serum	JJ	o	OPH
post-therapy	NN	o	OPH
and	CC	o	OPH
TTP	NNP	o	OPH
(	(	O	O
r	NN	O	O
=	NNP	O	O
-0.291	NNP	O	O
,	,	O	O
P	NNP	O	O
=	NNP	O	O
0.048	CD	O	O
)	)	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
Activated	NNP	O	O
CECs	NNP	O	O
and	CC	O	O
survivin	NN	O	O
may	MD	O	O
be	VB	O	O
ideal	JJ	O	O
markers	NNS	O	O
forecasting	VBG	O	O
efficacy	NN	O	O
and	CC	O	O
prognosis	NN	O	O
of	IN	O	O
NSCLC	NNP	O	O
.	.	O	O

The	DT	O	O
former	JJ	O	O
can	MD	O	O
reflect	VB	O	O
more	RBR	O	O
sensitively	RB	O	O
antiangiogenic	JJ	O	O
efficacy	NN	O	O
and	CC	O	O
the	DT	O	O
latter	NN	O	O
is	VBZ	O	O
more	RBR	O	O
sensitive	JJ	O	O
to	TO	O	O
shrinkage	VB	O	O
or	CC	O	O
swelling	VBG	O	O
of	IN	O	O
tumors	NNS	O	O
.	.	O	O

Their	PRP$	O	O
combination	NN	O	O
can	MD	O	O
evaluate	VB	O	O
more	RBR	O	O
accurately	RB	O	O
the	DT	O	O
efficacy	NN	O	O
of	IN	O	O
antiangiogenic	JJ	i	IPH
therapy	NN	i	IPH
of	IN	O	O
NSCLC	NNP	O	O
.	.	O	O

[	JJ	i	IPM
Local	NNP	i	IPM
therapy	NN	i	IPM
of	IN	i	IPM
grade	NN	i	IPM
1	CD	i	IPM
and	CC	i	IPM
2	CD	i	IPM
hemorrhoids	NNS	i	IPM
.	.	i	IPM

Effectiveness	NN	O	O
of	IN	O	O
a	DT	O	O
combination	NN	i	IPM
preparation	NN	i	IPM
with	IN	i	IPM
standardized	JJ	i	IPM
blood	NN	i	IPM
leech	NN	i	IPM
extract	NN	i	IPM
]	NNP	i	IPM
.	.	O	O

AIMS	NNP	O	O
Testing	VBG	O	O
the	DT	O	O
effectiveness	NN	O	O
of	IN	O	O
a	DT	O	O
topical	JJ	i	IPM
combination	NN	i	IPM
preparation	NN	i	IPM
containing	VBG	i	IPM
standardized	VBN	i	IPM
leech	JJ	i	IPM
extract	NN	i	IPM
,	,	i	IPM
polidocanol	NN	i	IPM
and	CC	i	IPM
allantoin	NN	i	IPM
.	.	i	IPM

STUDY	NNP	O	O
DESIGN	NNP	O	O
Placebo-controlled	NNP	i	IC
,	,	O	O
double-blind	NN	O	O
study	NN	O	O
in	IN	O	O
80	CD	p	PSS
patients	NNS	p	O
with	IN	p	O
first	JJ	p	O
and	CC	p	O
second	JJ	p	O
degree	NN	p	O
hemorrhoids	NNS	p	O
;	:	p	O
duration	NN	O	O
of	IN	O	O
treatment	NN	O	O
one	CD	O	O
week	NN	O	O
;	:	O	O
examinations	NNS	O	O
performed	VBD	O	O
on	IN	O	O
admission	NN	O	O
and	CC	O	O
on	IN	O	O
days	NNS	O	O
3	CD	O	O
,	,	O	O
4	CD	O	O
,	,	O	O
5	CD	O	O
and	CC	O	O
8	CD	O	O
.	.	O	O

RESULTS	VB	O	O
Both	DT	O	O
the	DT	O	O
subjective	NN	o	OPH
and	CC	o	OPH
objective	JJ	o	OPH
symptoms	NNS	o	OPH
and	CC	o	OPH
signs	NNS	o	OPH
improved	VBN	o	O
during	IN	O	O
the	DT	O	O
one	CD	O	O
week	NN	O	O
of	IN	O	O
treatment	NN	O	O
statistically	RB	O	O
significantly	RB	O	O
more	RBR	O	O
rapidly	RB	O	O
under	IN	O	O
the	DT	O	O
test	NN	i	IE
preparation	NN	i	IE
as	IN	O	O
compared	VBN	O	O
with	IN	O	O
placebo	NN	i	O
.	.	i	O

Histologically	NNP	o	O
demonstrable	JJ	o	O
signs	NNS	o	O
of	IN	o	O
inflammation	NN	o	OPH
were	VBD	O	O
more	JJR	O	O
clearly	RB	O	O
improved	VBN	O	O
in	IN	O	O
the	DT	O	O
preparation	NN	i	O
group	NN	O	O
than	IN	O	O
in	IN	O	O
the	DT	O	O
placebo	NN	i	O
group	NN	O	O
.	.	O	O

No	DT	o	O
side	NN	o	OA
effects	NNS	o	OA
were	VBD	O	O
observed	VBN	O	O
.	.	O	O

CONCLUSIONS	VB	O	O
The	DT	O	O
good	JJ	O	O
efficacy	NN	O	O
and	CC	O	O
tolerability	NN	O	O
of	IN	O	O
a	DT	O	O
topical	JJ	i	IPM
therapeutic	JJ	i	IPM
preparation	NN	i	IPM
in	IN	O	O
first	JJ	p	O
and	CC	p	O
second	JJ	p	O
degree	NN	p	O
hemorrhoids	NNS	p	O
have	VBP	O	O
been	VBN	O	O
convincingly	RB	O	O
demonstrated	VBN	O	O
.	.	O	O

A	DT	O	O
prospective	JJ	O	O
randomised	JJ	O	O
comparison	NN	O	O
of	IN	O	O
the	DT	O	O
dynamic	JJ	i	IOt
hip	NN	i	IOt
screw	NN	i	IOt
and	CC	p	O
the	DT	p	O
gamma	NN	i	IOt
locking	VBG	i	IOt
nail	NN	i	IOt
.	.	i	O

We	PRP	O	O
made	VBD	O	O
a	DT	O	O
randomised	JJ	O	O
prospective	JJ	O	O
comparison	NN	O	O
of	IN	O	O
the	DT	O	O
Dynamic	NNP	i	IOt
Hip	NNP	i	IOt
Screw	NNP	i	IOt
and	CC	i	O
the	DT	i	IPH
Gamma	NNP	i	IOt
locking	VBG	i	IOt
nail	NN	i	IOt
for	IN	O	O
the	DT	O	O
internal	JJ	O	O
fixation	NN	O	O
of	IN	O	O
200	CD	p	PSS
petrochanteric	JJ	p	PC
femoral	JJ	p	PC
fractures	NNS	p	PC
in	IN	p	O
elderly	JJ	p	PA
patients	NNS	p	O
.	.	p	O

There	EX	O	O
was	VBD	O	O
less	RBR	O	O
intraoperative	JJ	o	OPH
blood	NN	o	OPH
loss	NN	o	OPH
and	CC	o	OPH
a	DT	o	OPH
lower	JJR	o	OPH
rate	NN	o	OPH
of	IN	o	OPH
wound	NN	o	OPH
complications	NNS	o	OPH
in	IN	O	O
the	DT	O	O
patients	NNS	O	O
treated	VBN	O	O
by	IN	O	O
the	DT	O	O
Gamma	NNP	i	IOt
nail	NN	i	IOt
.	.	i	O

They	PRP	O	O
had	VBD	O	O
,	,	O	O
however	RB	O	O
,	,	O	O
a	DT	O	O
high	JJ	O	O
incidence	NN	O	O
of	IN	O	O
femoral	JJ	o	OPH
shaft	NN	o	OPH
fracture	NN	o	OPH
which	WDT	O	O
we	PRP	O	O
relate	VBP	O	O
in	IN	O	O
part	NN	O	O
to	TO	O	O
implant	VB	O	O
design	NN	O	O
.	.	O	O

We	PRP	O	O
do	VBP	O	O
not	RB	O	O
recommend	VB	O	O
the	DT	O	O
use	NN	O	O
of	IN	O	O
the	DT	O	O
Gamma	NNP	i	IPH
nail	NN	i	IPH
for	IN	O	O
these	DT	O	O
fractures	NNS	O	O
.	.	O	O

Cholesterol-lowering	JJ	O	O
effect	NN	O	O
of	IN	O	O
stanol	NN	i	IPM
ester	NN	i	IPM
in	IN	O	O
a	DT	O	O
US	NNP	p	O
population	NN	p	O
of	IN	p	O
mildly	RB	p	PC
hypercholesterolemic	JJ	p	PC
men	NNS	p	PSE
and	CC	p	O
women	NNS	p	PSE
:	:	p	O
a	DT	O	O
randomized	NN	O	O
controlled	VBN	O	O
trial	NN	O	O
.	.	O	O

OBJECTIVE	NN	O	O
To	TO	O	O
determine	VB	O	O
the	DT	O	O
efficacy	NN	O	O
of	IN	O	O
stanol	NN	i	IPM
esters	NNS	i	IPM
in	IN	O	O
lowering	VBG	O	O
cholesterol	NN	O	O
in	IN	O	O
a	DT	O	O
US	NNP	p	O
population	NN	p	O
.	.	p	O

SUBJECTS	NNP	O	O
AND	NNP	O	O
METHODS	NNP	O	O
After	IN	O	O
a	DT	O	O
run-in	JJ	O	O
phase	NN	O	O
,	,	O	O
318	CD	p	PSS
subjects	NNS	p	O
were	VBD	O	O
randomized	VBN	O	O
to	TO	O	O
receive	VB	O	O
one	CD	O	O
of	IN	O	O
the	DT	O	O
following	JJ	O	O
margarine-like	JJ	O	O
spreads	NNS	O	O
containing	VBG	O	O
stanol	JJ	i	IPM
ester	NN	i	IPM
or	CC	i	O
placebo	NN	i	IPH
for	IN	O	O
8	CD	O	O
weeks	NNS	O	O
:	:	O	O
EU	NNP	O	O
3	CD	O	O
G	NNP	O	O
:	:	O	O
1	CD	O	O
g	NN	O	O
of	IN	O	O
stanol	NN	i	IPM
(	(	i	IPM
ester	JJ	i	IPM
form	NN	i	IPM
)	)	i	IPM
per	IN	O	O
8-g	JJ	O	O
serving	NN	O	O
of	IN	O	O
a	DT	O	O
European	JJ	O	O
formula	NN	O	O
3	CD	O	O
times	NNS	O	O
a	DT	O	O
day	NN	O	O
;	:	O	O
US	PRP	O	O
3	CD	O	O
G	NNP	O	O
:	:	O	O
1	CD	O	O
g	NN	O	O
of	IN	O	O
stanol	NN	i	IPM
(	(	i	IPM
ester	JJ	i	IPM
form	NN	i	IPM
)	)	i	IPM
per	IN	O	O
8-g	JJ	O	O
serving	NN	O	O
of	IN	O	O
a	DT	O	O
US	NNP	O	O
reformulation	NN	O	O
3	CD	O	O
times	NNS	O	O
a	DT	O	O
day	NN	O	O
;	:	O	O
US	PRP	O	O
2	CD	O	O
G	NNP	O	O
:	:	O	O
0.67	CD	O	O
g	NN	O	O
of	IN	O	O
stanol	NN	i	IPM
(	(	O	O
ester	JJ	O	O
form	NN	O	O
)	)	O	O
per	IN	O	O
8-g	JJ	O	O
serving	NN	O	O
of	IN	O	O
a	DT	O	O
US	NNP	O	O
reformulation	NN	O	O
3	CD	O	O
times	NNS	O	O
a	DT	O	O
day	NN	O	O
;	:	O	O
or	CC	O	O
placebo	VB	i	IC
spread	NN	O	O
.	.	O	O

RESULTS	JJ	O	O
Mean	JJ	o	OPH
+/-	JJ	o	OPH
SD	NNP	o	OPH
baseline	NN	o	OPH
total	NN	o	OPH
cholesterol	NN	o	OPH
(	(	o	OPH
TC	NNP	o	OPH
)	)	o	OPH
and	CC	o	O
low-density	JJ	o	OPH
lipoprotein	NN	o	OPH
cholesterol	NN	o	OPH
(	(	o	OPH
LDL-C	NNP	o	OPH
)	)	o	OPH
levels	NNS	o	OPH
were	VBD	O	O
233+/-20	JJ	O	O
and	CC	O	O
153+21	CD	O	O
mg+/-dL	NN	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

In	IN	O	O
the	DT	O	O
US	NNP	O	O
3	CD	O	O
G	NNP	O	O
group	NN	O	O
,	,	O	O
3	CD	O	O
g	JJ	O	O
daily	NN	O	O
of	IN	O	O
stanol	JJ	i	IPM
esters	NNS	i	IPM
lowered	VBD	O	O
TC	NNP	o	OPH
and	CC	o	O
LDL-C	NNP	o	OPH
levels	NNS	o	OPH
by	IN	O	O
6.4	CD	O	O
%	NN	O	O
and	CC	O	O
10.1	CD	O	O
%	NN	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

There	EX	O	O
was	VBD	O	O
a	DT	O	O
dose-dependent	JJ	O	O
response	NN	O	O
compared	VBN	O	O
with	IN	O	O
2	CD	O	O
g	NNS	O	O
daily	RB	O	O
(	(	O	O
US	PRP	O	O
2	CD	O	O
G	NNP	O	O
)	)	O	O
.	.	O	O

Triglyceride	NNP	o	OPH
and	CC	o	OPH
high-density	NN	o	OPH
lipoprotein	NNS	o	OPH
cholesterol	NN	o	OPH
levels	NNS	o	OPH
were	VBD	O	O
unchanged	JJ	O	O
.	.	O	O

The	DT	O	O
incidence	NN	O	O
of	IN	O	O
adverse	JJ	o	OA
effects	NNS	o	OA
was	VBD	O	O
not	RB	O	O
different	JJ	O	O
from	IN	O	O
placebo	NN	i	IC
.	.	i	O

Serum	NNP	o	OPH
vitamin	VBD	o	OPH
A	DT	o	OPH
and	CC	o	OPH
25-hydroxyvitamin	JJ	o	OPH
D	NNP	o	OPH
levels	NNS	o	OPH
were	VBD	O	O
not	RB	O	O
affected	VBN	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
Stanol	NNP	i	IPM
esters	NNS	i	IPM
lowered	VBD	O	O
TC	NNP	o	OPH
and	CC	o	O
LDL-C	NNP	o	OPH
levels	NNS	o	OPH
in	IN	O	O
a	DT	O	O
mildly	RB	p	PC
hypercholesterolemic	JJ	p	PC
US	NNP	p	O
population	NN	p	O
without	IN	O	O
evidence	NN	O	O
of	IN	O	O
adverse	JJ	O	O
effects	NNS	O	O
.	.	O	O

It	PRP	O	O
may	MD	O	O
be	VB	O	O
a	DT	O	O
useful	JJ	O	O
dietary	JJ	O	O
adjunct	NN	O	O
to	TO	O	O
lower	VB	O	O
cholesterol	NN	O	O
.	.	O	O

[	JJ	o	O
Rapidity	NNP	o	OPA
of	IN	o	OPA
pain	NN	o	OPA
relief	NN	o	OPA
,	,	o	O
medication	NN	o	OOt
requirement	NN	o	OOt
and	CC	o	O
patient	JJ	o	OOt
satisfaction	NN	o	OOt
with	IN	p	O
reflux	JJ	p	O
treatment	NN	p	O
in	IN	O	O
the	DT	O	O
physician	NN	O	O
's	POS	O	O
office	NN	O	O
]	NN	O	O
.	.	O	O

Treatment	NN	O	O
of	IN	O	O
gastroesophageal	NN	o	OPH
reflux	NN	o	OPH
disease	NN	o	OPH
(	(	o	OPH
GERD	NNP	o	OPH
)	)	o	OPH
with	IN	O	O
proton	NN	o	O
pump	NN	o	O
inhibitors	NNS	o	O
was	VBD	O	O
investigated	VBN	O	O
in	IN	O	O
three	CD	O	O
controlled	VBD	O	O
prospective	JJ	O	O
,	,	O	O
randomized	JJ	O	O
open	JJ	O	O
studies	NNS	O	O
.	.	O	O

Lansoprazole	NNP	i	IPM
,	,	i	O
omeprazole	JJ	i	IPM
MUPS	NNP	i	IPM
and	CC	i	O
esomeprazole	NN	i	IPM
were	VBD	O	O
compared	VBN	O	O
under	IN	O	O
doctor	NN	O	O
's	POS	O	O
office	NN	O	O
conditions	NNS	O	O
.	.	O	O

The	DT	O	O
outcomes	NNS	O	O
of	IN	O	O
interest	NN	O	O
were	VBD	O	O
the	DT	O	O
rapidity	NN	o	OPA
of	IN	o	OPA
pain	NN	o	OPA
relief	NN	o	OPA
achieved	VBN	O	O
with	IN	O	O
a	DT	O	O
single	JJ	o	OOt
dose	NN	o	OOt
,	,	o	O
effectiveness	NN	o	OOt
and	CC	o	O
patient	JJ	o	OOt
satisfaction	NN	o	OOt
with	IN	O	O
on	IN	O	O
demand	NN	O	O
therapy	NN	O	O
.	.	O	O

In	IN	O	O
the	DT	O	O
first	JJ	O	O
study	NN	O	O
,	,	O	O
180	CD	p	PSS
patients	NNS	p	O
with	IN	p	O
chronic	JJ	p	PC
and	CC	p	PC
prolonged	JJ	p	PC
episodes	NNS	p	PC
of	IN	p	PC
reflux	NN	p	PC
were	VBD	p	O
investigated	VBN	p	O
.	.	p	O

Time	NN	O	O
to	TO	O	O
pain	VB	o	OPA
relief	NN	o	OPA
following	VBG	O	O
a	DT	O	O
single	JJ	O	O
dose	NN	O	O
was	VBD	O	O
1.1	CD	O	O
+/-	JJ	O	O
0.8	CD	O	O
hours	NNS	O	O
with	IN	O	O
30	CD	O	O
mg	NNS	O	O
lansoprazole	JJ	i	IPM
,	,	O	O
3.0	CD	O	O
+/-	JJ	O	O
2.5	CD	O	O
hours	NNS	O	O
with	IN	O	O
20	CD	O	O
mgomeprazole	JJ	i	IPM
MUPS	NNP	O	O
and	CC	O	O
2.1	CD	O	O
+/-	JJ	O	O
1.2	CD	O	O
hours	NNS	O	O
with	IN	O	O
40	CD	O	O
mg	NNS	O	O
esomeprazole	JJ	i	IPM
.	.	i	O

Studies	NNS	O	O
2	CD	O	O
and	CC	O	O
3	CD	O	O
were	VBD	O	O
designed	VBN	O	O
as	IN	O	O
cross-over	NN	O	O
studies	NNS	O	O
intended	VBN	O	O
to	TO	O	O
investigate	VB	O	O
drug	NN	o	OPH
consumption	NN	o	OPH
.	.	o	O

In	IN	O	O
study	NN	O	O
2	CD	O	O
,	,	O	O
the	DT	O	O
amount	NN	o	OOt
of	IN	o	OOt
lansoprazole	NN	o	OOt
consumed	VBN	o	OOt
was	VBD	O	O
approximately	RB	O	O
50	CD	O	O
%	NN	O	O
less	JJR	O	O
than	IN	O	O
that	DT	O	O
of	IN	O	O
omeprazole	NN	i	IPM
,	,	O	O
and	CC	O	O
this	DT	O	O
translated	VBN	O	O
to	TO	O	O
81	CD	O	O
%	NN	O	O
patient	JJ	o	OOt
satisfaction	NN	o	OOt
with	IN	O	O
lansoprazole	JJ	i	IPM
compared	VBN	O	O
with	IN	O	O
only	RB	O	O
9.5	CD	O	O
%	NN	O	O
for	IN	O	O
omeprazole	NN	i	IPM
.	.	i	O

In	IN	O	O
study	NN	O	O
3	CD	O	O
comparing	VBG	O	O
lansoprazole	NN	O	O
and	CC	O	O
esomeprazole	NN	i	IPM
,	,	O	O
consumption	NN	o	OOt
of	IN	O	O
the	DT	O	O
former	JJ	O	O
was	VBD	O	O
85	CD	O	O
%	NN	O	O
that	WDT	O	O
of	IN	O	O
the	DT	O	O
latter	NN	O	O
.	.	O	O

58	CD	O	O
%	NN	O	O
of	IN	O	O
the	DT	O	O
patients	NNS	O	O
opted	VBD	O	O
to	TO	O	O
continuetreatment	VB	o	OOt
with	IN	O	O
lansoprazole	NN	i	IPM
,	,	O	O
compared	VBN	O	O
with	IN	O	O
only	RB	O	O
25	CD	O	O
%	NN	O	O
in	IN	O	O
the	DT	O	O
case	NN	O	O
of	IN	O	O
esomeprazole	NN	i	IPM
.	.	O	O

The	DT	O	O
appreciably	RB	O	O
greater	JJR	O	O
patient	JJ	o	OOt
satisfaction	NN	o	OOt
with	IN	O	O
lansoprazole	NN	i	IPM
was	VBD	O	O
due	JJ	O	O
tothe	NN	O	O
faster	RBR	o	OPA
pain	NN	o	OPA
relief	NN	o	OPA
achieved	VBN	O	O
with	IN	O	O
this	DT	O	O
drug	NN	O	O
.	.	O	O

Scaling	VBG	O	O
clinical	JJ	O	O
judgments	NNS	O	O
of	IN	O	O
symptom	JJ	O	O
pathology	NN	O	O
by	IN	O	O
means	NNS	O	O
of	IN	O	O
the	DT	O	O
psychophysiological	JJ	O	O
method	NN	O	O
of	IN	O	O
magnitude	NN	O	O
estimation	NN	O	O
.	.	O	O

Summing	VBG	O	O
scores	NNS	O	O
across	IN	O	O
heterogeneous	JJ	O	O
symptom	NN	O	O
items	NNS	O	O
without	IN	O	O
consideration	NN	O	O
of	IN	O	O
their	PRP$	O	O
differing	JJ	O	O
psychopathological	JJ	O	O
significance	NN	O	O
has	VBZ	O	O
been	VBN	O	O
criticized	VBN	O	O
as	IN	O	O
producing	VBG	O	O
an	DT	O	O
inadequate	JJ	O	O
picture	NN	O	O
of	IN	O	O
an	DT	O	O
individual	NN	O	O
's	POS	O	O
clinical	JJ	O	O
status	NN	O	O
.	.	O	O

The	DT	O	O
purpose	NN	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
derive	JJ	O	O
symptom	JJ	O	O
item	NN	O	O
weights	NNS	O	O
representing	VBG	O	O
clinically	RB	O	O
judged	VBN	O	O
seriousness	NN	O	O
of	IN	O	O
each	DT	O	O
symptom	NN	O	O
through	IN	O	O
the	DT	O	O
application	NN	O	O
of	IN	O	O
Steven	NNP	i	IE
's	POS	i	IE
psychophysical	JJ	i	IE
method	NN	i	IE
of	IN	i	IE
magnitude	NN	i	IE
estimation	NN	i	IE
.	.	i	IE

A	DT	O	O
nationwide	JJ	O	O
sample	NN	O	O
of	IN	O	O
129	CD	p	O
clinicians	NNS	p	O
rated	VBD	O	O
the	DT	O	O
pathological	JJ	O	O
significance	NN	O	O
of	IN	O	O
221	CD	O	O
symptom	JJ	O	O
items	NNS	O	O
in	IN	O	O
a	DT	O	O
design	NN	O	O
such	JJ	O	O
that	IN	O	O
every	DT	O	O
rater	NN	O	O
rated	VBD	O	O
121	CD	O	O
items	NNS	O	O
,	,	O	O
21	CD	O	O
of	IN	O	O
which	WDT	O	O
were	VBD	O	O
rated	VBN	O	O
by	IN	O	O
all	DT	O	O
raters	NNS	O	O
and	CC	O	O
100	CD	O	O
of	IN	O	O
which	WDT	O	O
were	VBD	O	O
rated	VBN	O	O
only	RB	O	O
by	IN	O	O
the	DT	O	O
A	NNP	O	O
or	CC	O	O
B	NNP	O	O
subgroup	NN	O	O
to	TO	O	O
which	WDT	O	O
each	DT	O	O
rater	NN	O	O
was	VBD	O	O
randomly	RB	O	O
assigned	VBN	O	O
.	.	O	O

Each	DT	O	O
item	NN	O	O
was	VBD	O	O
rated	VBN	O	O
as	IN	O	O
to	TO	O	O
the	DT	O	O
seriousness	NN	O	O
of	IN	O	O
the	DT	O	O
pathology	NN	O	O
it	PRP	O	O
would	MD	O	O
represent	VB	O	O
if	IN	O	O
manifested	VBN	O	O
by	IN	O	O
either	CC	O	O
a	DT	O	O
boy	NN	O	O
child	NN	O	O
,	,	O	O
girl	JJ	O	O
child	NN	O	O
,	,	O	O
boy	JJ	O	O
adolescent	NN	O	O
,	,	O	O
or	CC	O	O
girl	JJ	O	O
adolescent	NN	O	O
,	,	O	O
with	IN	O	O
one-fourth	NN	O	O
of	IN	O	O
the	DT	O	O
raters	NNS	O	O
assigned	VBD	O	O
to	TO	O	O
each	DT	O	O
condition	NN	O	O
.	.	O	O

The	DT	O	O
results	NNS	O	O
of	IN	O	O
211	CD	O	O
two-way	JJ	i	O
analyses	NNS	i	O
of	IN	i	O
variance	NN	i	O
revealed	VBD	O	O
that	IN	O	O
age	NN	O	O
and	CC	O	O
age	NN	o	OME
and	CC	o	OME
sex	NN	o	OME
in	IN	O	O
interaction	NN	O	O
,	,	O	O
but	CC	O	O
not	RB	O	O
sex	VB	O	O
alone	RB	O	O
,	,	O	O
significantly	RB	O	O
influenced	VBD	O	O
the	DT	O	O
clinical	JJ	O	O
ratings	NNS	O	O
.	.	O	O

The	DT	O	O
resulting	VBG	O	O
magnitude	JJ	o	OME
estimation	NN	o	OME
ratings	NNS	o	OME
of	IN	o	OME
symptom	JJ	o	OME
pathology	NN	o	OME
ranged	VBD	O	O
from	IN	O	O
1.0	CD	O	O
to	TO	O	O
9.9	CD	O	O
.	.	O	O

They	PRP	O	O
were	VBD	O	O
demonstrated	VBN	O	O
to	TO	O	O
have	VB	O	O
satisfactoy	VBN	O	O
reliability	NN	O	O
and	CC	O	O
convergent	NN	O	O
validity	NN	O	O
and	CC	O	O
to	TO	O	O
have	VB	O	O
the	DT	O	O
psychophysical	JJ	O	O
characteristics	NNS	O	O
of	IN	O	O
a	DT	O	O
prothetic	JJ	O	O
continuum	NN	O	O
.	.	O	O

Effects	NNS	O	O
of	IN	O	O
short-term	JJ	O	O
isotonic	JJ	i	IE
&	CC	i	IE
isometric	JJ	i	IE
training	NN	i	IE
on	IN	O	O
cardiovascular	JJ	o	OPH
&	CC	o	OPH
pulmonary	JJ	o	OPH
function	NN	o	OPH
.	.	o	OPH

A	DT	O	O
randomised	JJ	O	O
control	NN	O	O
trial	NN	O	O
of	IN	O	O
short-term	JJ	i	IPH
exercises	NNS	i	IPH
on	IN	O	O
specific	JJ	O	O
cardiovascular	JJ	O	O
and	CC	O	O
respiratory	JJ	O	O
parameters	NNS	O	O
was	VBD	O	O
undertaken	VBN	O	O
in	IN	p	O
normal	JJ	p	O
male	JJ	p	O
college	NN	p	O
students	NNS	p	O
.	.	p	O

The	DT	O	O
effects	NNS	O	O
of	IN	O	O
isotonic	JJ	i	IPH
training	NN	i	IPH
(	(	i	IPH
5BX	CD	i	IPH
programme	NN	i	IPH
)	)	i	IPH
and	CC	i	IE
isometric	JJ	i	IPH
training	NN	i	IPH
(	(	i	IE
a	DT	i	IE
programme	NN	i	IE
of	IN	i	IE
isometric	JJ	i	IE
exercises	NNS	i	IE
working	VBG	i	IE
all	DT	i	IE
major	JJ	i	IE
groups	NNS	i	IE
of	IN	i	IE
muscles	NNS	i	IE
)	)	i	IE
were	VBD	O	O
compared	VBN	O	O
with	IN	i	O
a	DT	i	O
control	NN	i	IC
group	NN	i	O
with	IN	O	O
no	DT	O	O
specific	JJ	O	O
workout	NN	O	O
.	.	O	O

Both	DT	O	O
isotonic	JJ	i	IE
and	CC	i	IE
isometric	JJ	i	IPH
training	NN	i	IPH
resulted	VBD	O	O
in	IN	O	O
significant	JJ	o	OPH
cardiovascular	JJ	o	OPH
improvement	NN	o	OPH
but	CC	O	O
seemed	VBD	O	O
inadequate	JJ	O	O
to	TO	O	O
improve	VB	O	O
vital	JJ	o	OPH
capacity	NN	o	OPH
and	CC	o	OPH
flow	NN	o	OPH
rates	NNS	o	OPH
.	.	o	OPH

Isotonic	JJ	i	IPH
training	NN	i	IPH
in	IN	O	O
addition	NN	O	O
,	,	O	O
improved	JJ	O	O
ventilatory	NN	o	OOt
efficiency	NN	o	OOt
.	.	o	OPH

It	PRP	O	O
is	VBZ	O	O
concluded	VBN	O	O
that	IN	O	O
such	JJ	O	O
isotonic	JJ	i	IE
or	CC	i	IE
isometric	JJ	i	IE
training	NN	i	IE
of	IN	O	O
thrice	NN	O	O
a	DT	O	O
week	NN	O	O
for	IN	O	O
ten	JJ	O	O
weeks	NNS	O	O
,	,	O	O
requiring	VBG	O	O
no	DT	O	O
equipment	NN	O	O
,	,	O	O
less	JJR	O	O
time	NN	O	O
and	CC	O	O
space	NN	O	O
can	MD	O	O
be	VB	O	O
promoted	VBN	O	O
to	TO	O	O
improve	VB	O	O
physical	JJ	o	OPH
fitness	NN	o	OPH
.	.	o	OPH

Attenuation	NN	O	O
of	IN	O	O
hemodynamic	JJ	O	O
responses	NNS	O	O
to	TO	O	O
laryngoscopy	VB	O	O
and	CC	O	O
tracheal	VB	O	O
intubation	NN	O	O
during	IN	O	O
rapid	JJ	O	O
sequence	NN	O	O
induction	NN	O	O
:	:	O	O
remifentanil	NN	i	IPM
vs.	FW	O	O
lidocaine	NN	i	IPM
with	IN	i	IPM
esmolol	NN	i	IPM
.	.	i	O

AIM	NNP	O	O
This	DT	O	O
study	NN	O	O
was	VBD	O	O
designed	VBN	O	O
to	TO	O	O
compare	VB	O	O
the	DT	O	O
effectiveness	NN	O	O
of	IN	O	O
remifentanil	NN	i	IPM
vs.	FW	O	O
a	DT	O	O
lidocaine-esmolol	JJ	i	IPM
combination	NN	O	O
in	IN	O	O
blunting	VBG	O	O
the	DT	O	O
hemodynamic	JJ	o	OPH
response	NN	o	OPH
to	TO	O	O
laryngoscopy	VB	O	O
and	CC	O	O
intubation	NN	O	O
during	IN	O	O
rapid	JJ	O	O
sequence	NN	O	O
induction	NN	O	O
using	VBG	O	O
thiopental	JJ	O	O
and	CC	O	O
rocuronium	NN	O	O
in	IN	O	O
normotensive	JJ	p	PC
patients	NNS	p	O
.	.	p	O

METHODS	NNP	O	O
Sixty-six	JJ	p	PSS
patients	NNS	p	O
with	IN	p	O
American	JJ	p	O
Society	NNP	p	O
of	IN	p	O
Anesthesiologists	NNP	p	O
(	(	p	PC
ASA	NNP	p	PC
)	)	p	PC
physical	JJ	p	PC
status	NN	p	PC
class	NN	p	PC
I	PRP	p	PC
who	WP	p	O
required	VBD	p	O
tracheal	JJ	p	PC
intubation	NN	p	PC
for	IN	p	O
elective	JJ	p	O
surgery	NN	p	O
were	VBD	O	O
randomly	RB	O	O
assigned	VBN	O	O
to	TO	O	O
one	CD	O	O
of	IN	O	O
two	CD	O	O
groups	NNS	O	O
.	.	O	O

Group	NNP	O	O
R	NNP	O	O
received	VBD	O	O
0.9	CD	i	IPM
%	NN	i	IPM
saline	NN	i	IPM
10	CD	i	IPM
ml	NN	i	IPM
and	CC	i	IPM
remifentanil	VB	i	IPM
1	CD	i	IPM
microg/kg	NN	i	IPM
.	.	i	IPM

Group	NNP	O	O
LE	NNP	O	O
received	VBD	O	O
lidocaine	JJ	i	IPM
1.5	CD	i	IPM
mg/kg	NN	i	IPM
and	CC	i	IPM
esmolol	$	i	IPM
1.0	CD	i	IPM
mg/kg	NN	i	IPM
.	.	i	O

Anesthesia	NNP	O	O
was	VBD	O	O
induced	VBN	O	O
with	IN	O	O
thiopental	JJ	i	IPM
sodium	NN	i	IPM
5	CD	O	O
mg/kg	NN	O	O
,	,	O	O
followed	VBN	O	O
by	IN	O	O
rocuronium	NN	i	IPM
1.0	CD	O	O
mg/kg	NN	O	O
.	.	O	O

Mean	NNP	o	OPH
arterial	JJ	o	OPH
pressure	NN	o	OPH
and	CC	o	OPH
heart	NN	o	OPH
rate	NN	o	OPH
were	VBD	O	O
recorded	VBN	O	O
at	IN	O	O
baseline	NN	O	O
,	,	O	O
after	IN	O	O
induction	NN	O	O
,	,	O	O
immediately	RB	O	O
after	IN	O	O
intubation	NN	O	O
and	CC	O	O
every	DT	O	O
minute	NN	O	O
for	IN	O	O
five	CD	O	O
minutes	NNS	O	O
after	IN	O	O
intubation	NN	O	O
.	.	O	O

RESULTS	NNP	O	O
Changes	NNP	O	O
in	IN	O	O
mean	JJ	o	OPH
arterial	JJ	o	OPH
pressure	NN	o	OPH
over	IN	o	OPH
time	NN	o	OPH
between	IN	O	O
the	DT	O	O
two	CD	O	O
groups	NNS	O	O
were	VBD	O	O
significantly	RB	O	O
different	JJ	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.0001	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
maximum	JJ	o	OPH
pressor	NN	o	OPH
response	NN	o	OPH
was	VBD	O	O
observed	VBN	O	O
immediately	RB	O	O
after	IN	O	O
intubation	NN	O	O
,	,	O	O
at	IN	O	O
which	WDT	O	O
time	NN	O	O
the	DT	O	O
mean	JJ	o	OPH
arterial	JJ	o	OPH
pressure	NN	o	OPH
change	NN	o	OPH
from	IN	O	O
baseline	NN	O	O
in	IN	O	O
group	NN	O	O
LE	NNP	O	O
(	(	O	O
29.7	CD	O	O
%	NN	O	O
)	)	O	O
(	(	O	O
95	CD	O	O
%	NN	O	O
confidence	NN	O	O
interval	NN	O	O
[	NNP	O	O
CI	NNP	O	O
]	NN	O	O
:	:	O	O
116.1	CD	O	O
,	,	O	O
121.9	CD	O	O
)	)	O	O
was	VBD	O	O
higher	JJR	O	O
than	IN	O	O
that	DT	O	O
in	IN	O	O
group	NN	O	O
R	NNP	O	O
(	(	O	O
4.4	CD	O	O
%	NN	O	O
)	)	O	O
(	(	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
:	:	O	O
92.9	CD	O	O
,	,	O	O
98.5	CD	O	O
)	)	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.0001	CD	O	O
)	)	O	O
.	.	O	O

Two	CD	O	O
patients	NNS	O	O
in	IN	O	O
group	NN	O	O
R	NNP	O	O
and	CC	O	O
15	CD	O	O
patients	NNS	O	O
in	IN	O	O
group	NN	O	O
LE	NNP	O	O
developed	VBD	O	O
hypertension	NN	o	OPH
(	(	O	O
odds	NNS	O	O
ratio	VBP	O	O
[	CD	O	O
OR	NNP	O	O
]	NN	O	O
:	:	O	O
0.064	CD	O	O
)	)	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.001	CD	O	O
)	)	O	O
.	.	O	O

Changes	NNS	O	O
in	IN	O	O
heart	NN	o	OPH
rate	NN	o	OPH
over	IN	o	OPH
time	NN	o	OPH
between	IN	O	O
the	DT	O	O
two	CD	O	O
groups	NNS	O	O
were	VBD	O	O
not	RB	O	O
significantly	RB	O	O
different	JJ	O	O
(	(	O	O
P=0.465	NNP	O	O
)	)	O	O
.	.	O	O

CONCLUSION	VB	O	O
The	DT	O	O
results	NNS	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
show	NN	O	O
that	IN	O	O
remifentanil	VBZ	i	IPM
1	CD	O	O
mg/kg	NN	O	O
is	VBZ	O	O
more	RBR	O	O
effective	JJ	O	O
than	IN	O	O
the	DT	O	O
combination	NN	O	O
of	IN	O	O
lidocaine	JJ	i	IPM
1.5	CD	O	O
mg/kg	NN	O	O
and	CC	O	O
esmolol	$	i	IPM
1	CD	O	O
mg/kg	NN	O	O
for	IN	O	O
attenuating	VBG	O	O
the	DT	O	O
hemodynamic	JJ	o	OPH
responses	NNS	o	OPH
to	TO	O	O
rapid	JJ	O	O
sequence	NN	O	O
intubation	NN	O	O
.	.	O	O

Effect	NN	O	O
of	IN	O	O
cervical	JJ	i	IPH
spine	NN	i	IPH
manipulative	JJ	i	IPH
therapy	NN	i	IPH
on	IN	O	O
judo	NN	p	O
athletes	NNS	p	O
'	POS	p	O
grip	NN	O	O
strength	NN	O	O
.	.	O	O

OBJECTIVE	CC	O	O
The	DT	O	O
objective	NN	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
perform	VB	O	O
an	DT	O	O
investigation	NN	O	O
evaluating	VBG	O	O
if	IN	O	O
cervical	JJ	i	IPH
spinal	JJ	i	IPH
manipulative	JJ	i	IPH
therapy	NN	i	IPH
(	(	i	IPH
SMT	NNP	i	IPH
)	)	i	IPH
can	MD	O	O
increase	VB	O	O
grip	JJ	O	O
strength	NN	O	O
on	IN	O	O
judo	NN	p	O
athletes	NNS	p	O
in	IN	p	O
a	DT	p	O
top	JJ	p	O
10	CD	p	O
national-ranked	JJ	p	O
team	NN	p	O
.	.	p	O

METHODS	VB	O	O
A	DT	O	O
single-blinded	JJ	O	O
,	,	O	O
prospective	JJ	O	O
,	,	O	O
comparative	JJ	O	O
,	,	O	O
pilot	NN	O	O
,	,	O	O
randomized	VBN	O	O
,	,	O	O
clinical	JJ	O	O
trial	NN	O	O
was	VBD	O	O
performed	VBN	O	O
with	IN	O	O
18	CD	p	PSS
athletes	NNS	p	PSS
of	IN	p	O
both	DT	p	PSE
sexes	NNS	p	PSE
from	IN	p	O
a	DT	p	O
judo	NN	p	O
team	NN	p	O
currently	RB	p	O
competing	VBG	p	O
on	IN	p	O
a	DT	p	O
national	JJ	p	O
level	NN	p	O
.	.	p	O

The	DT	O	O
athletes	NNS	O	O
were	VBD	O	O
randomly	RB	O	O
assigned	VBN	O	O
to	TO	O	O
2	CD	O	O
groups	NNS	O	O
:	:	O	O
chiropractic	JJ	i	IPH
SMT	NNP	i	IPH
and	CC	i	O
sham	NN	i	IC
.	.	i	O

Three	CD	O	O
interventions	NNS	O	O
were	VBD	O	O
performed	VBN	O	O
on	IN	O	O
each	DT	O	O
of	IN	O	O
the	DT	O	O
athletes	NNS	O	O
at	IN	O	O
different	JJ	O	O
time	NN	O	O
points	NNS	O	O
.	.	O	O

Force	NN	O	O
measurements	NNS	O	O
were	VBD	O	O
obtained	VBN	O	O
by	IN	O	O
a	DT	O	O
hydraulic	JJ	O	O
dynamometer	NN	O	O
immediately	RB	O	O
before	IN	O	O
and	CC	O	O
after	IN	O	O
each	DT	O	O
intervention	NN	O	O
at	IN	O	O
the	DT	O	O
same	JJ	O	O
period	NN	O	O
before	IN	O	O
training	VBG	O	O
up	RP	O	O
to	TO	O	O
3	CD	O	O
weeks	NNS	O	O
with	IN	O	O
at	IN	O	O
least	JJS	O	O
36	CD	O	O
hours	NNS	O	O
between	IN	O	O
interventions	NNS	O	O
.	.	O	O

RESULTS	NNP	O	O
Analysis	NNP	O	O
of	IN	O	O
grip	NN	o	OPH
strength	NN	o	OPH
data	NNS	o	OOt
revealed	VBD	O	O
a	DT	O	O
statistically	RB	O	O
significant	JJ	O	O
increase	NN	O	O
in	IN	O	O
strength	NN	o	OOt
within	IN	O	O
the	DT	O	O
treatment	NN	O	O
group	NN	O	O
after	IN	O	O
the	DT	O	O
first	JJ	O	O
intervention	NN	O	O
(	(	O	O
6.95	CD	O	O
%	NN	O	O
right	NN	O	O
,	,	O	O
12.61	CD	O	O
%	NN	O	O
left	NN	O	O
)	)	O	O
as	IN	O	O
compared	VBN	O	O
with	IN	O	O
the	DT	O	O
second	JJ	O	O
(	(	O	O
11.53	CD	O	O
%	NN	O	O
right	NN	O	O
,	,	O	O
17.02	CD	O	O
%	NN	O	O
left	NN	O	O
)	)	O	O
and	CC	O	O
the	DT	O	O
third	JJ	O	O
interventions	NNS	O	O
(	(	O	O
10.53	CD	O	O
%	NN	O	O
right	NN	O	O
,	,	O	O
16.81	CD	O	O
%	NN	O	O
left	VBD	O	O
)	)	O	O
.	.	O	O

No	DT	O	O
statistically	RB	O	O
significant	JJ	O	O
differences	NNS	O	O
were	VBD	O	O
found	VBN	O	O
in	IN	O	O
grip	JJ	o	OOt
strength	NN	o	OOt
comparison	NN	o	OOt
within	IN	O	O
the	DT	O	O
sham	NN	O	O
group	NN	O	O
.	.	O	O

Overall	JJ	O	O
differences	NNS	o	OOt
in	IN	o	OOt
strength	NN	o	OPH
were	VBD	O	O
consistently	RB	O	O
significant	JJ	O	O
between	IN	O	O
the	DT	O	O
study	NN	O	O
groups	NNS	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
.0025	NNP	O	O
)	)	O	O
.	.	O	O

CONCLUSION	VB	O	O
The	DT	O	O
present	JJ	O	O
study	NN	O	O
suggests	VBZ	O	O
that	IN	O	O
the	DT	O	O
grip	NN	O	O
strength	NN	O	O
of	IN	O	O
national	JJ	p	O
level	NN	p	O
judo	NN	p	O
athletes	NNS	p	O
receiving	VBG	O	O
chiropractic	JJ	i	IPH
SMT	NNP	i	IPH
improved	VBD	O	O
compared	VBN	O	O
to	TO	O	O
those	DT	O	O
receiving	VBG	O	O
sham	NN	O	O
.	.	O	O

Acute	NNP	O	O
pressor	NN	O	O
and	CC	O	O
hormonal	JJ	O	O
effects	NNS	O	O
of	IN	O	O
beta-endorphin	NN	i	IPM
at	IN	O	O
high	JJ	O	O
doses	NNS	O	O
in	IN	O	O
healthy	JJ	p	PC
and	CC	p	PC
hypertensive	JJ	p	PC
subjects	NNS	p	O
:	:	p	O
role	NN	O	O
of	IN	O	O
opioid	JJ	O	O
receptor	NN	O	O
agonism	NN	O	O
.	.	O	O

CONTEXT	VB	O	O
The	DT	O	O
opioid	NN	O	O
system	NN	O	O
is	VBZ	O	O
involved	VBN	O	O
in	IN	O	O
blood	NN	O	O
pressure	NN	O	O
regulation	NN	O	O
in	IN	O	O
both	DT	O	O
normal	JJ	p	PC
humans	NNS	p	O
and	CC	p	O
patients	NNS	p	O
with	IN	p	O
essential	JJ	p	PC
hypertension	NN	p	PC
.	.	p	O

OBJECTIVE	CC	O	O
The	DT	O	O
objective	NN	O	O
of	IN	O	O
the	DT	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
investigate	VB	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
a	DT	O	O
high-dose	JJ	O	O
infusion	NN	O	O
of	IN	O	O
beta-endorphin	NN	i	IPM
,	,	O	O
an	DT	O	O
opioid	JJ	O	O
peptide	NN	O	O
,	,	O	O
on	IN	O	O
blood	NN	O	O
pressure	NN	O	O
and	CC	O	O
on	IN	O	O
the	DT	O	O
hormonal	JJ	O	O
profile	NN	O	O
in	IN	O	O
healthy	JJ	p	PC
subjects	NNS	p	O
and	CC	p	O
in	IN	p	O
hypertensive	JJ	p	PC
patients	NNS	p	O
and	CC	O	O
the	DT	O	O
mediation	NN	O	O
played	VBN	O	O
by	IN	O	O
opioid	JJ	O	O
receptor	NN	O	O
agonism	NN	O	O
.	.	O	O

DESIGN	NNP	O	O
,	,	O	O
SETTING	NNP	O	O
,	,	O	O
AND	NNP	O	O
PARTICIPANTS	NNP	O	O
According	VBG	O	O
to	TO	O	O
a	DT	O	O
randomized	VBN	O	O
double-blind	NN	O	O
design	NN	O	O
,	,	O	O
11	CD	p	PSS
healthy	JJ	p	PC
subjects	NNS	p	O
(	(	p	O
controls	NNS	p	O
)	)	p	O
and	CC	p	O
12	CD	p	PSS
hypertensive	JJ	p	O
inpatients	NNS	p	O
(	(	p	O
mean	JJ	p	O
age	NN	p	O
,	,	p	O
38.9	CD	p	PA
and	CC	p	O
40.4	CD	p	PA
yr	NN	p	O
,	,	p	O
respectively	RB	p	O
)	)	p	O
received	VBD	O	O
1-h	JJ	i	IPM
iv	JJ	i	IPM
infusion	NN	i	IPM
of	IN	i	IPM
beta-endorphin	JJ	i	IPM
(	(	i	IPM
250	CD	i	IPM
mug/h	NN	i	IPM
)	)	i	IPM
and	CC	i	O
,	,	i	O
on	IN	i	O
another	DT	i	O
occasion	NN	i	O
,	,	i	O
the	DT	i	O
same	JJ	i	O
infusion	NN	i	O
protocol	NN	i	O
preceded	VBN	i	O
by	IN	i	O
the	DT	i	O
opioid	JJ	i	IPM
antagonist	NN	i	IPM
naloxone	NN	i	IPM
(	(	i	IPM
8	CD	i	IPM
mg	NN	i	IPM
)	)	i	IPM
.	.	i	O

MAIN	NNP	O	O
OUTCOME	NNP	O	O
MEASURES	NNP	O	O
Hemodynamic	NNP	o	OPH
and	CC	o	OPH
hormonal	JJ	o	OPH
measurements	NNS	o	OPH
were	VBD	O	O
performed	VBN	O	O
at	IN	O	O
established	VBN	O	O
times	NNS	O	O
during	IN	O	O
the	DT	O	O
infusion	NN	O	O
protocols	NNS	O	O
.	.	O	O

RESULTS	NNP	O	O
At	IN	O	O
baseline	NN	O	O
,	,	O	O
circulating	VBG	o	OPH
beta-endorphin	JJ	o	OPH
,	,	o	OPH
norepinephrine	JJ	o	OPH
,	,	o	OPH
and	CC	o	OPH
endothelin-1	NN	o	OPH
in	IN	O	O
hypertensive	JJ	O	O
patients	NNS	O	O
were	VBD	O	O
significantly	RB	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
higher	JJR	O	O
than	IN	O	O
in	IN	O	O
controls	NNS	O	O
.	.	O	O

In	IN	O	O
controls	NNS	O	O
,	,	O	O
beta-endorphin	JJ	O	O
reduced	VBD	O	O
blood	NN	o	OPH
pressure	NN	o	OPH
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.01	CD	O	O
)	)	O	O
and	CC	O	O
circulating	VBG	o	OPH
norepinephrine	NN	o	OPH
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.02	CD	O	O
)	)	O	O
and	CC	O	O
increased	VBD	O	O
plasma	JJ	o	OPH
atrial	JJ	o	OPH
natriuretic	JJ	o	OPH
factor	NN	o	OPH
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.003	CD	O	O
)	)	O	O
and	CC	O	O
GH	NNP	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.0001	CD	O	O
)	)	O	O
.	.	O	O

In	IN	O	O
hypertensive	JJ	O	O
patients	NNS	O	O
,	,	O	O
beta-endorphin	JJ	i	IPM
decreased	JJ	O	O
systemic	JJ	o	OPH
vascular	NN	o	OPH
resistance	NN	o	OPH
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.0001	CD	O	O
)	)	O	O
,	,	O	O
blood	NN	o	OPH
pressure	NN	o	OPH
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.0001	CD	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
plasma	JJ	o	OPH
norepinephrine	NN	o	OPH
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.0001	CD	O	O
)	)	O	O
and	CC	O	O
endothelin-1	JJ	o	OPH
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.0001	CD	O	O
)	)	O	O
and	CC	O	O
raised	VBD	O	O
circulating	VBG	o	OPH
atrial	JJ	o	OPH
natriuretic	JJ	o	OPH
factor	NN	o	OPH
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.0001	CD	O	O
)	)	O	O
,	,	O	O
GH	NNP	o	OPH
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.0001	CD	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
IGF-I	NNP	o	OPH
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.0001	CD	O	O
)	)	O	O
.	.	O	O

These	DT	O	O
hemodynamic	JJ	o	OPH
and	CC	o	OPH
hormonal	JJ	o	OPH
responses	NNS	o	OPH
to	TO	O	O
beta-endorphin	JJ	O	O
in	IN	O	O
hypertensive	JJ	O	O
patients	NNS	O	O
were	VBD	O	O
significantly	RB	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.0001	CD	O	O
)	)	O	O
greater	JJR	O	O
than	IN	O	O
in	IN	O	O
controls	NNS	O	O
but	CC	O	O
were	VBD	O	O
annulled	VBN	O	O
in	IN	O	O
all	DT	O	O
individuals	NNS	O	O
when	WRB	O	O
naloxone	NN	O	O
preceded	VBD	O	O
beta-endorphin	JJ	O	O
infusion	NN	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
High	NNP	O	O
doses	NNS	O	O
of	IN	O	O
beta-endorphin	JJ	i	IPM
induce	NN	O	O
hypotensive	NN	O	O
and	CC	O	O
beneficial	JJ	O	O
hormonal	JJ	O	O
effects	NNS	O	O
in	IN	O	O
humans	NNS	O	O
,	,	O	O
which	WDT	O	O
are	VBP	O	O
enhanced	VBN	O	O
in	IN	O	O
essential	JJ	O	O
hypertension	NN	O	O
and	CC	O	O
are	VBP	O	O
mediated	VBN	O	O
by	IN	O	O
opioid	JJ	O	O
receptors	NNS	O	O
.	.	O	O

Ovulation	NN	O	O
and	CC	O	O
follicular	JJ	O	O
development	NN	O	O
associated	VBN	O	O
with	IN	O	O
three	CD	O	O
low-dose	JJ	i	IPM
oral	JJ	i	IPM
contraceptives	NNS	i	IPM
:	:	i	O
a	DT	O	O
randomized	NN	O	O
controlled	VBN	O	O
trial	NN	O	O
.	.	O	O

OBJECTIVE	UH	O	O
To	TO	O	O
address	VB	O	O
the	DT	O	O
hypothesis	NN	O	O
that	WDT	O	O
multiphasic	JJ	i	IPM
oral	JJ	i	IPM
contraceptives	NNS	i	IPM
(	(	i	IPM
OCs	NNP	i	IPM
)	)	i	IPM
increase	NN	O	O
rather	RB	O	O
than	IN	O	O
decrease	VB	O	O
the	DT	O	O
risk	NN	o	OPH
of	IN	o	OPH
functional	JJ	o	OPH
ovarian	JJ	o	OPH
cysts	NNS	o	OPH
.	.	o	OPH

METHODS	NNP	O	O
In	IN	O	O
this	DT	O	O
single-center	NN	O	O
,	,	O	O
randomized	VBN	O	O
controlled	VBD	O	O
study	NN	O	O
,	,	O	O
women	NNS	p	O
were	VBD	O	O
assigned	VBN	O	O
to	TO	O	O
a	DT	O	O
multiphasic	JJ	i	IPM
pill	NN	i	IPM
,	,	i	O
a	DT	i	IPM
lower-dose	JJ	i	IPM
monophasic	NN	i	IPM
pill	NN	i	IPM
,	,	i	O
a	DT	i	O
higher-dose	JJ	i	IPM
monophasic	NN	i	IPM
pill	NN	i	IPM
,	,	i	O
or	CC	i	O
nonsteroidal	JJ	i	IPM
contraception	NN	i	IPM
.	.	i	O

Forty	JJ	p	O
volunteers	NNS	p	O
were	VBD	p	O
randomized	VBN	p	O
(	(	p	O
ten	VB	p	O
each	DT	p	O
)	)	p	O
to	TO	p	O
three	CD	i	IPM
different	JJ	i	IPM
pill	NN	i	IPM
regimens	VBZ	i	IPM
or	CC	p	O
to	TO	p	O
nonsteroidal	DT	i	IPM
contraception	NN	i	IPM
.	.	i	O

During	IN	O	O
6	CD	O	O
months	NNS	O	O
of	IN	O	O
treatment	NN	O	O
,	,	O	O
follicular	JJ	o	OPH
development	NN	o	OPH
was	VBD	O	O
measured	VBN	O	O
by	IN	O	O
vaginal	JJ	O	O
ultrasonography	NN	O	O
and	CC	O	O
ovulation	NN	o	OPH
was	VBD	O	O
indicated	VBN	O	O
by	IN	O	O
serum	NN	O	O
progesterone	NN	O	O
levels	NNS	O	O
.	.	O	O

RESULTS	VB	O	O
The	DT	O	O
relative	JJ	o	OPH
risk	NN	o	OPH
(	(	o	OPH
RR	NNP	o	OPH
)	)	o	OPH
of	IN	o	OPH
developing	VBG	o	OPH
a	DT	o	OPH
follicular	JJ	o	OPH
structure	NN	o	OPH
greater	JJR	o	OPH
than	IN	o	OPH
30	CD	o	OPH
mm	NN	o	OPH
in	IN	o	OPH
diameter	NN	o	OPH
during	IN	O	O
a	DT	O	O
cycle	NN	O	O
with	IN	O	O
the	DT	O	O
higher-dose	JJ	O	O
monophasic	NN	i	IPM
pill	NN	i	IPM
was	VBD	O	O
0.5	CD	O	O
(	(	O	O
95	CD	O	O
%	NN	O	O
confidence	NN	O	O
interval	NN	O	O
[	NNP	O	O
CI	NNP	O	O
]	NNP	O	O
0.1-1.9	NN	O	O
;	:	O	O
P	NNP	O	O
=	NNP	O	O
.49	NNP	O	O
)	)	O	O
compared	VBN	O	O
with	IN	O	O
the	DT	O	O
multiphasic	NN	O	O
pill	NN	O	O
.	.	O	O

The	DT	O	O
risk	NN	o	OPH
with	IN	o	OPH
the	DT	o	OPH
lower-dose	JJ	o	OPH
monophasic	NN	o	OPH
pill	NN	o	OPH
was	VBD	O	O
comparable	JJ	O	O
to	TO	O	O
that	DT	O	O
with	IN	O	O
the	DT	O	O
multiphasic	NN	i	IPM
pill	NN	i	IPM
(	(	O	O
RR	NNP	O	O
1.3	CD	O	O
,	,	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
0.5-3.6	CD	O	O
;	:	O	O
P	NNP	O	O
=	NNP	O	O
.56	NNP	O	O
)	)	O	O
.	.	O	O

With	IN	O	O
the	DT	O	O
multiphasic	NN	i	IPM
pill	NN	i	IPM
,	,	O	O
the	DT	O	O
maximum	JJ	o	OPH
ovulation	NN	o	OPH
rate	NN	o	OPH
over	IN	O	O
60	CD	O	O
cycles	NNS	O	O
was	VBD	O	O
1.7	CD	O	O
per	IN	O	O
100	CD	O	O
cycles	NNS	O	O
(	(	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
0.0-8.9	NN	O	O
)	)	O	O
.	.	O	O

CONCLUSION	VB	O	O
This	DT	O	O
multiphasic	JJ	i	IPM
pill	NN	i	IPM
more	RBR	O	O
closely	RB	O	O
resembled	VBN	O	O
the	DT	O	O
lower-dose	JJ	O	O
monophasic	NN	i	IPM
pill	NN	i	IPM
than	IN	O	O
the	DT	O	O
higher-dose	JJ	O	O
monophasic	NN	i	IPM
pill	NN	i	IPM
in	IN	O	O
its	PRP$	O	O
suppression	NN	o	OPH
of	IN	o	OPH
follicular	JJ	o	OPH
development	NN	o	OPH
.	.	o	OPH

A	DT	O	O
good	JJ	O	O
response	NN	O	O
to	TO	O	O
oil	NN	i	IPM
with	IN	i	IPM
medium-	NN	i	IPM
and	CC	i	IPM
long-chain	JJ	i	IPM
fatty	JJ	i	IPM
acids	NNS	i	IPM
in	IN	O	O
body	NN	o	OPH
fat	JJ	o	OPH
and	CC	p	O
blood	NN	o	OPH
lipid	JJ	o	OPH
profiles	NNS	o	OPH
of	IN	p	O
male	JJ	p	PSE
hypertriglyceridemic	JJ	p	PC
subjects	NNS	p	O
.	.	p	O

A	DT	O	O
double	JJ	O	O
blind	NN	O	O
clinical	JJ	O	O
trial	NN	O	O
was	VBD	O	O
carried	VBN	O	O
out	IN	O	O
to	TO	O	O
clarify	VB	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
oil	NN	i	IPM
with	IN	i	IPM
medium-	NN	i	IPM
and	CC	i	IPM
long-chain	JJ	i	IPM
triglyceride	NN	i	IPM
(	(	i	IPM
MLCT	NNP	i	IPM
)	)	i	IPM
on	IN	O	O
body	NN	o	OPH
fat	JJ	o	OPH
and	CC	p	O
blood	NN	o	OPH
lipid	JJ	o	OPH
profiles	NNS	o	OPH
in	IN	p	O
hypertriglyceridemic	JJ	p	O
subjects	NNS	p	O
.	.	p	O

One-hundred-and-twelve	JJ	p	PSS
subjects	NNS	p	O
were	VBD	O	O
enrolled	VBN	O	O
and	CC	O	O
divided	VBN	O	O
into	IN	O	O
two	CD	O	O
groups	NNS	O	O
;	:	O	O
those	DT	i	O
that	IN	i	O
consumed	VBD	i	O
MLCT	NNP	i	O
oil	NN	i	O
and	CC	i	O
those	DT	i	O
that	WDT	i	O
consumed	VBD	i	O
long-chain	JJ	i	O
triglyceride	NN	i	O
(	(	i	O
LCT	NNP	i	O
)	)	i	O
oil	NN	i	O
for	IN	O	O
8	CD	O	O
weeks	NNS	O	O
.	.	O	O

All	DT	O	O
subjects	NNS	O	O
were	VBD	O	O
requested	VBN	O	O
to	TO	O	O
consume	VB	O	O
25-30	JJ	O	O
g	NN	O	O
of	IN	O	O
the	DT	O	O
oils	NNS	O	O
daily	RB	O	O
and	CC	O	O
maintain	VB	O	O
a	DT	O	O
fixed	JJ	O	O
level	NN	O	O
of	IN	O	O
energy	NN	O	O
intake	NN	O	O
and	CC	O	O
exercise	NN	O	O
.	.	O	O

Anthropometric	NNP	o	OPH
and	CC	o	OPH
blood	NN	o	OPH
biochemical	JJ	o	OPH
parameters	NNS	o	OPH
were	VBD	O	O
measured	VBN	O	O
when	WRB	O	O
the	DT	O	O
study	NN	O	O
was	VBD	O	O
initiated	VBN	O	O
and	CC	O	O
completed	VBN	O	O
.	.	O	O

The	DT	O	O
LCT	NNP	i	IPM
group	NN	O	O
consisted	VBD	O	O
of	IN	O	O
50	CD	p	PSS
subjects	NNS	p	O
(	(	p	O
34	CD	p	PSS
men	NNS	p	PSE
and	CC	p	O
16	CD	p	PSS
women	NNS	p	PSE
)	)	p	O
,	,	p	O
while	IN	p	O
the	DT	p	O
MLCT	NNP	i	IPM
group	NN	p	O
consisted	VBD	p	O
of	IN	p	O
51	CD	p	PSS
subjects	NNS	p	O
(	(	p	O
33	CD	p	PSS
men	NNS	p	PSE
and	CC	p	O
18	CD	p	PSS
women	NNS	p	PSE
)	)	p	O
who	WP	p	O
completed	VBD	p	O
the	DT	p	O
study	NN	p	O
.	.	p	O

Larger	NNP	O	O
decreases	VBZ	O	O
in	IN	O	O
body	NN	o	OPH
weight	NN	o	OPH
,	,	o	OPH
body	NN	o	OPH
mass	NN	o	OPH
index	NN	o	OPH
,	,	o	OPH
waist	NN	o	OPH
circumference	NN	o	OPH
,	,	o	OPH
body	NN	o	OPH
fat	NN	o	OPH
,	,	o	OPH
total	JJ	o	OPH
fat	JJ	o	OPH
area	NN	o	OPH
and	CC	o	OPH
subcutaneous	JJ	o	OPH
fat	JJ	o	OPH
area	NN	o	OPH
in	IN	o	OPH
the	DT	o	OPH
abdomen	NNS	o	OPH
and	CC	o	OPH
serum	NN	o	OPH
triglycerides	NNS	o	OPH
,	,	o	OPH
low-density	NN	o	OPH
lipoprotein	NN	o	OPH
cholesterol	NN	o	OPH
,	,	o	OPH
apolipoprotein	NN	o	OPH
B	NNP	o	OPH
,	,	o	OPH
C2	NNP	o	OPH
,	,	o	OPH
C3	NNP	o	OPH
and	CC	o	OPH
E	NNP	o	OPH
were	VBD	O	O
observed	VBN	O	O
in	IN	O	O
male	JJ	O	O
subjects	NNS	O	O
in	IN	O	O
the	DT	O	O
MLCT	NNP	i	IPM
group	NN	O	O
than	IN	O	O
those	DT	O	O
in	IN	O	O
the	DT	O	O
LCT	NNP	i	IPM
group	NN	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
no	DT	O	O
significant	JJ	O	O
differences	NNS	O	O
in	IN	O	O
these	DT	o	OOt
parameters	NNS	o	OOt
between	IN	O	O
the	DT	O	O
female	JJ	O	O
subjects	NNS	O	O
in	IN	O	O
the	DT	O	O
two	CD	O	O
groups	NNS	O	O
were	VBD	O	O
observed	VBN	O	O
.	.	O	O

Data	NNS	O	O
from	IN	O	O
this	DT	O	O
study	NN	O	O
indicate	VBP	O	O
that	IN	O	O
consumption	NN	O	O
of	IN	O	O
medium-and	JJ	O	O
long-chain	JJ	O	O
triglycerides	NNS	O	O
can	MD	O	O
reduce	VB	O	O
body	NN	o	OPH
weight	NN	o	OPH
and	CC	O	O
body	NN	o	OPH
fat	NN	o	OPH
and	CC	O	O
improve	VB	O	O
blood	NN	o	OPH
lipid	JJ	o	OPH
profiles	NNS	o	OOt
in	IN	O	O
male	JJ	p	O
hypertriglyceridemic	JJ	p	O
subjects	NNS	p	O
.	.	p	O

The	DT	O	O
sequencing	NN	O	O
of	IN	O	O
chemotherapy	NN	i	O
and	CC	O	O
radiation	NN	i	O
therapy	NN	i	O
after	IN	O	O
conservative	JJ	p	O
surgery	NN	p	O
for	IN	p	O
early-stage	JJ	p	O
breast	NN	p	PC
cancer	NN	p	PC
.	.	p	O

BACKGROUND	NNP	O	O
Patients	NNPS	p	O
with	IN	p	O
early-stage	JJ	p	O
breast	NN	p	PC
cancer	NN	p	PC
who	WP	p	O
are	VBP	p	O
at	IN	p	O
substantial	JJ	p	O
risk	NN	p	O
for	IN	p	O
systemic	JJ	p	O
metastases	NNS	p	PC
are	VBP	O	O
increasingly	RB	O	O
treated	VBN	O	O
with	IN	O	O
breast-conserving	JJ	i	IPM
therapy	NN	i	IPM
and	CC	i	O
adjuvant	JJ	i	IPM
chemotherapy	NN	i	IPM
.	.	i	O

However	RB	O	O
,	,	O	O
the	DT	O	O
optimal	JJ	O	O
sequencing	NN	O	O
of	IN	O	O
chemotherapy	NN	i	IPM
and	CC	i	O
radiation	NN	i	IPM
therapy	NN	i	IPM
is	VBZ	O	O
not	RB	O	O
clear	JJ	O	O
.	.	O	O

METHODS	NNP	O	O
Two	CD	p	PSS
hundred	VBD	p	PSS
forty-four	JJ	p	PSS
patients	NNS	p	O
with	IN	p	O
stage	NN	p	O
I	PRP	p	O
or	CC	p	O
II	NNP	p	O
breast	NN	p	PC
cancer	NN	p	PC
who	WP	p	O
were	VBD	p	O
at	IN	p	O
substantial	JJ	p	O
risk	NN	p	O
for	IN	p	O
distant	JJ	p	O
metastases	NNS	p	PC
were	VBD	O	O
randomly	RB	O	O
assigned	VBN	O	O
to	TO	O	O
receive	VB	O	O
a	DT	O	O
12-week	JJ	i	IPM
course	NN	i	IPM
of	IN	i	IPM
chemotherapy	NN	i	IPM
either	CC	i	IPM
before	IN	i	IPM
or	CC	i	IPM
after	IN	i	IPM
radiation	NN	i	IPM
therapy	NN	i	IPM
.	.	i	O

All	DT	p	O
had	VBD	p	O
had	VBN	p	O
breast-conserving	JJ	p	O
surgery	NN	p	O
.	.	p	O

The	DT	O	O
median	JJ	O	O
length	NN	O	O
of	IN	O	O
follow-up	NN	O	O
in	IN	O	O
surviving	VBG	O	O
patients	NNS	O	O
was	VBD	O	O
58	CD	O	O
months	NNS	O	O
(	(	O	O
range	NN	O	O
,	,	O	O
10	CD	O	O
to	TO	O	O
124	CD	O	O
)	)	O	O
.	.	O	O

RESULTS	VB	O	O
The	DT	O	O
five-year	JJ	o	OPH
actuarial	JJ	o	OPH
rates	NNS	o	OPH
of	IN	o	OPH
cancer	NN	o	OPH
recurrence	NN	o	OPH
at	IN	O	O
any	DT	O	O
site	NN	O	O
and	CC	O	O
of	IN	O	O
distant	JJ	O	O
metastases	NNS	O	O
in	IN	O	O
the	DT	O	O
radiotherapy-first	JJ	i	IPM
group	NN	O	O
and	CC	O	O
the	DT	O	O
chemotherapy-first	JJ	i	IPM
group	NN	O	O
were	VBD	O	O
38	CD	O	O
percent	NN	O	O
and	CC	O	O
31	CD	O	O
percent	NN	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.17	CD	O	O
)	)	O	O
and	CC	O	O
36	CD	O	O
percent	NN	O	O
and	CC	O	O
25	CD	O	O
percent	NN	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.05	CD	O	O
)	)	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

Overall	JJ	o	OMO
survival	NN	o	OMO
was	VBD	O	O
73	CD	O	O
percent	NN	O	O
and	CC	O	O
81	CD	O	O
percent	NN	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.11	CD	O	O
)	)	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

The	DT	O	O
five-year	JJ	o	OPH
crude	NN	o	OPH
rates	NNS	o	OPH
of	IN	o	OPH
first	JJ	o	OPH
recurrence	NN	o	OPH
according	VBG	O	O
to	TO	O	O
site	NN	O	O
in	IN	O	O
the	DT	O	O
radiotherapy-first	JJ	i	IPM
and	CC	i	O
chemotherapy-first	JJ	i	IPM
groups	NNS	O	O
,	,	O	O
respectively	RB	O	O
,	,	O	O
were	VBD	O	O
5	CD	O	O
percent	NN	O	O
and	CC	O	O
14	CD	O	O
percent	NN	O	O
for	IN	O	O
local	JJ	O	O
recurrence	NN	O	O
and	CC	O	O
32	CD	O	O
percent	NN	O	O
and	CC	O	O
20	CD	O	O
percent	NN	O	O
for	IN	O	O
distant	NN	O	O
or	CC	O	O
regional	JJ	O	O
recurrence	NN	O	O
or	CC	O	O
both	DT	O	O
.	.	O	O

This	DT	O	O
difference	NN	O	O
in	IN	O	O
the	DT	O	O
pattern	NN	o	OPH
of	IN	o	OPH
recurrence	NN	o	OPH
was	VBD	O	O
of	IN	O	O
borderline	JJ	O	O
statistical	JJ	O	O
significance	NN	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.07	CD	O	O
)	)	O	O
.	.	O	O

CONCLUSIONS	VB	O	O
This	DT	O	O
study	NN	O	O
suggests	VBZ	O	O
that	IN	O	O
for	IN	O	O
patients	NNS	p	O
ar	VBP	p	O
substantial	JJ	p	O
risk	NN	p	O
for	IN	p	O
systemic	JJ	p	O
metastases	NNS	p	PC
,	,	O	O
it	PRP	O	O
is	VBZ	O	O
preferable	JJ	O	O
to	TO	O	O
give	VB	O	O
a	DT	O	O
12-week	JJ	O	O
course	NN	O	O
of	IN	O	O
chemotherapy	NN	i	O
followed	VBN	O	O
by	IN	O	O
radiation	NN	i	IPM
therapy	NN	i	IPM
,	,	O	O
rather	RB	O	O
than	IN	O	O
radiation	NN	i	IPM
therapy	NN	i	IPM
followed	VBN	i	IPM
by	IN	i	IPM
chemotherapy	NN	i	IPM
.	.	i	O

The	DT	O	O
effects	NNS	O	O
of	IN	O	O
orthotic	JJ	i	IPH
heel	NN	i	IPH
lifts	NNS	i	IPH
on	IN	O	O
Achilles	NNP	o	OPH
tendon	NNP	o	OPH
force	NN	o	OPH
and	CC	o	OPH
strain	NN	o	OPH
during	IN	O	O
running	VBG	O	O
.	.	O	O

This	DT	O	O
study	NN	O	O
assessed	VBD	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
orthotic	JJ	i	IPH
heel	NN	i	IPH
lifts	NNS	i	IPH
on	IN	O	O
Achilles	NNP	o	OPH
tendon	NN	o	OPH
(	(	o	OPH
AT	NNP	o	OPH
)	)	o	OPH
force	NN	o	OPH
and	CC	o	OPH
strain	NN	o	OPH
during	IN	O	O
running	VBG	O	O
.	.	O	O

Ten	CD	p	PSS
females	NNS	p	PSE
ran	VBD	p	O
barefoot	NN	p	O
over	IN	p	O
a	DT	p	O
force	NN	p	O
plate	NN	p	O
in	IN	p	O
three	CD	p	O
conditions	NNS	p	O
:	:	p	O
no	DT	i	IC
heel	NN	i	IC
lifts	NNS	i	IC
(	(	p	O
NHL	NNP	p	O
)	)	p	O
,	,	p	O
with	IN	p	O
12	CD	i	IPH
mm	NNS	i	IPH
heel	JJ	i	IPH
lifts	NNS	i	IPH
(	(	p	O
12HL	CD	p	O
)	)	p	O
and	CC	p	O
with	IN	p	O
18	CD	i	IPH
mm	NNS	i	IPH
heel	JJ	i	IPH
lifts	NNS	i	IPH
(	(	p	O
18HL	CD	p	O
)	)	p	O
.	.	p	O

Kinematics	NNS	o	OPH
for	IN	o	OPH
the	DT	o	OPH
right	JJ	o	OPH
lower	JJR	o	OPH
limb	NN	o	OPH
were	VBD	O	O
collected	VBN	O	O
(	(	O	O
200	CD	O	O
Hz	NNP	O	O
)	)	O	O
.	.	O	O

AT	NNP	o	OPH
force	NN	o	OPH
was	VBD	O	O
calculated	VBN	O	O
from	IN	O	O
inverse	JJ	O	O
dynamics	NNS	O	O
.	.	O	O

AT	NNP	o	OPH
strain	NN	o	OPH
was	VBD	O	O
determined	VBN	O	O
from	IN	O	O
kinematics	NNS	O	O
and	CC	O	O
ultrasound	JJ	O	O
images	NNS	O	O
of	IN	O	O
medial	JJ	O	O
gastrocnemius	NN	O	O
(	(	O	O
50	CD	O	O
Hz	NNP	O	O
)	)	O	O
.	.	O	O

Peak	NNP	o	OPH
AT	NNP	o	OPH
strain	NN	o	OPH
was	VBD	O	O
less	JJR	O	O
for	IN	O	O
18HL	CD	O	O
(	(	O	O
5.5	CD	O	O
?	.	O	O
4.4	CD	O	O
%	NN	O	O
)	)	O	O
than	IN	O	O
for	IN	O	O
NHL	NNP	O	O
(	(	O	O
7.4	CD	O	O
?	.	O	O
4.2	CD	O	O
%	NN	O	O
)	)	O	O
(	(	O	O
p	JJ	O	O
=	NNP	O	O
.029	NNP	O	O
,	,	O	O
effect	NN	O	O
size	NN	O	O
[	NNP	O	O
ES	NNP	O	O
]	NNP	O	O
=	NNP	O	O
0.44	CD	O	O
)	)	O	O
but	CC	O	O
not	RB	O	O
for	IN	O	O
12HL	CD	O	O
(	(	O	O
5.8	CD	O	O
?	.	O	O
4.8	CD	O	O
%	NN	O	O
)	)	O	O
versus	NN	O	O
NHL	NNP	O	O
(	(	O	O
ES	NNP	O	O
=	NNP	O	O
0.35	CD	o	O
)	)	o	O
.	.	o	O

Peak	NNP	o	O
AT	NNP	o	O
force	NN	o	O
was	VBD	o	O
significantly	RB	O	O
(	(	O	O
p	JJ	O	O
=	NNP	O	O
.024	NNP	O	O
,	,	O	O
ES	NNP	O	O
=	NNP	O	O
0.42	CD	O	O
)	)	O	O
less	JJR	O	O
for	IN	O	O
18HL	CD	O	O
(	(	O	O
2382	CD	O	O
?	.	O	O
717	CD	O	O
N	NNP	O	O
)	)	O	O
than	IN	O	O
for	IN	O	O
NHL	NNP	O	O
(	(	O	O
2710	CD	O	O
?	.	O	O
830	CD	O	O
N	NNP	O	O
)	)	O	O
but	CC	O	O
not	RB	O	O
for	IN	O	O
12HL	CD	O	O
(	(	O	O
2538	CD	O	O
?	.	O	O
823	CD	O	O
N	NNP	O	O
,	,	O	O
ES	NNP	O	O
=	NNP	O	O
0.21	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
18HL	CD	O	O
reduced	VBD	o	O
ankle	JJ	o	OPH
dorsiflexion	NN	o	OPH
but	CC	o	O
not	RB	o	O
flexion-extension	JJ	o	O
ankle	NN	o	O
moments	NNS	o	O
and	CC	o	O
increased	VBD	o	O
the	DT	o	O
AT	NNP	o	O
moment	NN	o	O
arm	NN	o	O
compared	VBN	o	O
with	IN	O	O
NHL	NNP	O	O
.	.	O	O

Thus	NNP	O	O
,	,	O	O
18HL	CD	O	O
reduced	VBN	o	O
force	NN	o	O
and	CC	o	O
strain	NN	o	O
on	IN	o	O
the	DT	o	O
AT	NNP	O	O
during	IN	O	O
running	VBG	O	O
via	IN	O	O
a	DT	O	O
reduction	NN	o	O
in	IN	o	O
dorsiflexion	NN	o	O
,	,	o	O
which	WDT	o	O
lengthened	VBD	o	O
the	DT	o	O
AT	NNP	o	O
moment	NN	o	O
arm	NN	o	O
.	.	o	O

Therefore	RB	i	O
,	,	i	O
heel	NN	i	O
lifts	NNS	i	O
could	MD	O	O
be	VB	O	O
used	VBN	O	O
to	TO	O	O
reduce	VB	O	O
AT	NNP	o	O
loading	NN	o	O
and	CC	o	O
strain	NN	o	O
during	IN	o	O
the	DT	O	O
rehabilitation	NN	O	O
of	IN	O	O
AT	NNP	O	O
injuries	NNS	O	O
.	.	O	O

Etanercept	NNP	i	IPM
treatment	NN	O	O
in	IN	O	O
adults	NNS	p	PA
with	IN	p	O
established	VBN	p	O
rheumatoid	NN	p	PC
arthritis	NN	p	PC
:	:	p	PC
7	CD	O	O
years	NNS	O	O
of	IN	O	O
clinical	JJ	O	O
experience	NN	O	O
.	.	O	O

OBJECTIVE	UH	O	O
To	TO	O	O
evaluate	VB	O	O
safety	NN	o	OOt
and	CC	o	O
efficacy	NN	o	OOt
of	IN	O	O
longterm	JJ	O	O
etanercept	FW	i	IPM
treatment	NN	O	O
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
disease	NN	p	O
modifying	VBG	p	O
antirheumatic	JJ	p	O
drug	NN	p	O
(	(	p	O
DMARD	NNP	p	O
)	)	p	O
refractory	NN	p	PC
rheumatoid	JJ	p	PC
arthritis	NN	p	PC
(	(	p	PC
RA	NNP	p	PC
)	)	p	PC
.	.	p	O

METHODS	NNP	O	O
Safety	NNP	O	O
results	NNS	O	O
are	VBP	O	O
reported	VBN	O	O
for	IN	O	O
714	CD	p	PSS
patients	NNS	p	O
who	WP	p	O
received	VBD	p	O
etanercept	RB	i	IPM
in	IN	p	O
one	CD	p	O
of	IN	p	O
7	CD	p	O
initial	JJ	p	O
trials	NNS	p	O
or	CC	p	O
a	DT	p	O
longterm	JJ	p	O
extension	NN	p	O
.	.	p	O

Efficacy	NN	O	O
results	NNS	O	O
are	VBP	O	O
reported	VBN	O	O
for	IN	O	O
581	CD	p	PSS
patients	NNS	p	O
who	WP	p	O
enrolled	VBD	p	O
in	IN	p	O
the	DT	p	O
extension	NN	p	O
.	.	p	O

RESULTS	NNP	O	O
Of	IN	O	O
the	DT	O	O
714	CD	p	PSS
patients	NNS	p	O
enrolled	VBN	p	O
in	IN	p	O
the	DT	p	O
initial	JJ	p	O
trials	NNS	p	O
,	,	p	O
581	CD	p	PSS
(	(	p	O
81	CD	p	O
%	NN	p	O
)	)	p	O
enrolled	VBN	p	O
in	IN	p	O
the	DT	p	O
extension	NN	p	O
,	,	p	O
and	CC	p	O
388	CD	p	PSS
(	(	p	O
54	CD	p	O
%	NN	p	O
)	)	p	O
patients	NNS	p	O
are	VBP	p	O
continuing	VBG	p	O
to	TO	p	O
receive	VB	p	O
etanercept	JJ	i	IPM
therapy	NN	i	IPM
.	.	i	O

The	DT	O	O
longest	JJS	O	O
individual	JJ	O	O
treatment	NN	O	O
was	VBD	O	O
8.2	CD	O	O
years	NNS	O	O
,	,	O	O
with	IN	O	O
3139	CD	O	O
total	JJ	O	O
patient-years	NNS	O	O
of	IN	O	O
etanercept	JJ	O	O
exposure	NN	O	O
.	.	O	O

Rates	NNS	o	OA
of	IN	o	OA
serious	JJ	o	OA
adverse	JJ	o	OA
events	NNS	o	OA
(	(	O	O
overall	JJ	O	O
rate=14.8	NN	O	O
events/100	IN	O	O
patient-yrs	NN	O	O
)	)	O	O
,	,	O	O
serious	JJ	o	OA
infections	NNS	o	OA
(	(	O	O
overall	JJ	O	O
rate=4.2	NN	O	O
events/100	IN	O	O
patient-yrs	NN	O	O
)	)	O	O
,	,	O	O
cancer	NN	o	OPH
(	(	O	O
overall	JJ	O	O
rate=1.0	NN	O	O
events/100	IN	O	O
patient-yrs	NN	O	O
)	)	O	O
,	,	O	O
and	CC	o	O
deaths	NNS	o	OMO
(	(	O	O
overall	JJ	O	O
rate=0.7	NN	O	O
events/100	IN	O	O
patient-yrs	NN	O	O
)	)	O	O
were	VBD	O	O
stable	JJ	O	O
each	DT	O	O
year	NN	O	O
,	,	O	O
through	IN	O	O
8	CD	O	O
years	NNS	O	O
of	IN	O	O
etanercept	JJ	O	O
exposure	NN	O	O
.	.	O	O

For	IN	O	O
356	CD	p	PSS
patients	NNS	p	O
who	WP	p	O
completed	VBD	p	O
6	CD	p	O
years	NNS	p	O
of	IN	p	O
etanercept	JJ	p	O
treatment	NN	p	O
,	,	O	O
response	NN	o	OOt
rates	NNS	o	OOt
were	VBD	O	O
ACR20=73	NNP	O	O
%	NN	O	O
,	,	O	O
ACR50=52	NNP	O	O
%	NN	O	O
,	,	O	O
ACR70=27	NNP	O	O
%	NN	O	O
,	,	O	O
DAS28	NNP	O	O
CRP	NNP	O	O
good	JJ	O	O
response=52	NN	O	O
%	NN	O	O
,	,	O	O
and	CC	O	O
DAS28	NNP	O	O
CRP	NNP	O	O
remission=37	VBZ	O	O
%	NN	O	O
of	IN	O	O
patients	NNS	O	O
.	.	O	O

Similar	JJ	O	O
responses	NNS	O	O
occurred	VBD	O	O
in	IN	O	O
167	CD	p	PSS
patients	NNS	p	O
who	WP	p	O
completed	VBD	p	O
Year	NNP	p	O
7	CD	p	O
.	.	p	O

Doses	NNS	o	OOt
of	IN	O	O
concomitant	JJ	O	O
methotrexate	NN	O	O
or	CC	O	O
corticosteroids	NNS	O	O
were	VBD	O	O
reduced	VBN	O	O
in	IN	O	O
many	JJ	O	O
patients	NNS	O	O
who	WP	O	O
maintained	VBD	O	O
clinical	JJ	O	O
responses	NNS	O	O
.	.	O	O

CONCLUSION	VB	O	O
The	DT	O	O
safety	NN	o	OOt
profile	NN	o	OOt
of	IN	O	O
etanercept	NN	i	IPM
was	VBD	O	O
consistent	JJ	O	O
over	IN	O	O
time	NN	O	O
,	,	O	O
with	IN	O	O
rates	NNS	o	OA
of	IN	o	OA
adverse	JJ	o	OA
events	NNS	o	OA
similar	JJ	O	O
to	TO	O	O
those	DT	O	O
reported	VBN	O	O
for	IN	O	O
patients	NNS	p	O
with	IN	p	O
RA	NNP	p	PC
in	IN	p	O
general	JJ	p	O
.	.	p	O

Durable	JJ	O	O
clinical	JJ	O	O
responses	NNS	O	O
were	VBD	O	O
observed	VBN	O	O
in	IN	O	O
some	DT	O	O
patients	NNS	O	O
for	IN	O	O
7	CD	O	O
years	NNS	O	O
or	CC	O	O
more	JJR	O	O
.	.	O	O

The	DT	O	O
benefit-to-risk	JJ	O	O
ratio	NN	O	O
for	IN	O	O
longterm	JJ	O	O
etanercept	JJ	i	IPM
treatment	NN	O	O
remains	VBZ	O	O
highly	RB	O	O
favorable	JJ	O	O
.	.	O	O

LEGO	NNP	i	IPS
therapy	NN	i	IPS
and	CC	O	O
the	DT	O	O
social	JJ	i	IE
use	NN	i	IE
of	IN	i	IE
language	NN	i	IE
programme	NN	i	IE
:	:	i	O
an	DT	O	O
evaluation	NN	O	O
of	IN	O	O
two	CD	O	O
social	JJ	o	OME
skills	NNS	o	OME
interventions	NNS	O	O
for	IN	O	O
children	NNS	p	PA
with	IN	p	O
high	JJ	p	PC
functioning	VBG	p	PC
autism	NN	p	PC
and	CC	p	O
Asperger	NNP	p	PC
Syndrome	NNP	p	PC
.	.	p	O

LEGO	NNP	i	IPS
therapy	NN	i	IPS
and	CC	O	O
the	DT	O	O
Social	NNP	i	IE
Use	NNP	i	IE
of	IN	i	IE
Language	NNP	i	IE
Programme	NNP	i	IE
(	(	i	IE
SULP	NNP	i	IE
)	)	i	IE
were	VBD	O	O
evaluated	VBN	O	O
as	IN	O	O
social	JJ	i	IE
skills	NNS	i	IE
interventions	NNS	i	IE
for	IN	p	O
6-11	JJ	p	PA
year	NN	p	O
olds	NNS	p	O
with	IN	p	O
high	JJ	p	PC
functioning	VBG	p	PC
autism	NN	p	PC
and	CC	p	O
Asperger	NNP	p	PC
Syndrome	NNP	p	PC
.	.	p	O

Children	NNP	p	O
were	VBD	O	O
matched	VBN	O	O
on	IN	O	O
CA	NNP	O	O
,	,	O	O
IQ	NNP	O	O
,	,	O	O
and	CC	O	O
autistic	JJ	O	O
symptoms	NNS	O	O
before	IN	O	O
being	VBG	O	O
randomly	RB	O	O
assigned	VBN	O	O
to	TO	O	O
LEGO	NNP	i	IPS
or	CC	O	O
SULP	NNP	i	IE
.	.	i	O

Therapy	NNP	O	O
occurred	VBD	O	O
for	IN	O	O
1	CD	p	O
h/week	NN	p	O
over	IN	p	O
18	CD	p	O
weeks	NNS	p	O
.	.	p	O

A	DT	O	O
no-intervention	JJ	i	IC
control	NN	i	IC
group	NN	i	IC
was	VBD	O	O
also	RB	O	O
assessed	VBN	O	O
.	.	O	O

Results	NNS	O	O
showed	VBD	O	O
that	IN	O	O
the	DT	O	O
LEGO	NNP	i	IPS
therapy	NN	O	O
group	NN	O	O
improved	VBD	O	O
more	JJR	O	O
than	IN	O	O
the	DT	O	O
other	JJ	p	O
groups	NNS	p	O
on	IN	p	O
autism-specific	JJ	o	OME
social	JJ	o	OME
interaction	NN	o	OME
scores	NNS	o	OME
(	(	o	OME
Gilliam	NNP	o	OME
Autism	NNP	o	OME
Rating	NNP	o	OME
Scale	NNP	o	OME
)	)	o	OME
.	.	O	O

Maladaptive	JJ	o	OME
behaviour	NN	o	OME
decreased	VBD	O	O
significantly	RB	O	O
more	RBR	O	O
in	IN	O	O
the	DT	O	O
LEGO	NNP	i	IPS
and	CC	p	O
SULP	NNP	i	IE
groups	NNS	p	O
compared	VBN	p	O
to	TO	p	O
the	DT	p	O
control	NN	p	O
group	NN	p	O
.	.	p	O

There	EX	O	O
was	VBD	O	O
a	DT	O	O
non-significant	JJ	O	O
trend	NN	O	O
for	IN	O	O
SULP	NNP	i	IE
and	CC	p	O
LEGO	NNP	i	IPS
groups	NNS	p	O
to	TO	O	O
improve	VB	O	O
more	JJR	O	O
than	IN	O	O
the	DT	O	O
no-intervention	JJ	i	IC
group	NN	O	O
in	IN	O	O
communication	NN	o	OME
and	CC	o	OME
socialisation	NN	o	OME
skills	NNS	o	OME
.	.	o	O

[	JJ	O	O
Comparison	NNP	O	O
of	IN	O	O
fracture	NN	o	OPH
resistance	NN	o	OPH
of	IN	O	O
pulpless	NN	i	IPH
teeth	NNS	i	IPH
restored	VBD	i	IPH
with	IN	i	IPH
fiber	NN	i	IPH
reinforced	VBN	i	IPH
composite	JJ	i	IPH
posts	NNS	i	IPH
and	CC	O	O
three	CD	i	O
kinds	NNS	i	O
of	IN	i	O
resin	NN	i	O
core	NN	i	O
material	NN	i	O
]	NNP	i	O
.	.	O	O

OBJECTIVE	NNP	O	O
To	TO	O	O
compare	VB	O	O
the	DT	O	O
fracture	NN	o	OPH
resistances	NNS	o	OPH
of	IN	O	O
pulpless	NN	O	O
teeth	NNS	O	O
restored	VBD	O	O
with	IN	O	O
FRC	NNP	i	IPH
(	(	i	IPH
Fiber	NNP	i	IPH
Reinforced	NNP	i	IPH
Composite	NNP	i	IPH
)	)	i	IPH
posts	NNS	i	IPH
and	CC	O	O
three	CD	i	IPH
kinds	NNS	i	IPH
of	IN	i	IPH
resin	NN	i	IPH
core	NN	i	IPH
material	NN	i	IPH
.	.	i	O

METHODS	NNP	O	O
A	NNP	p	O
total	NN	p	O
of	IN	p	O
42	CD	p	PSS
recently	RB	p	O
extracted	VBN	p	O
upper	JJ	p	O
incisors	NNS	p	O
were	VBD	p	O
randomly	RB	p	O
divided	VBN	p	O
into	IN	p	O
3	CD	p	O
groups	NNS	p	O
.	.	p	O

Group	NNP	O	O
A	NNP	O	O
was	VBD	O	O
restored	VBN	O	O
with	IN	O	O
prefabricated	JJ	i	IPH
glass-fiber	JJ	i	IPH
posts	NNS	i	IPH
and	CC	i	IPH
Artglass	NNP	i	IPH
polymer	NN	i	IPH
core	NN	i	IPH
;	:	i	O
group	NN	O	O
B	NNP	O	O
with	IN	O	O
prefabricated	JJ	i	IPH
glass-fiber	JJ	i	IPH
posts	NNS	i	IPH
and	CC	i	IPH
Charisma	NNP	i	IPH
composite	JJ	i	IPH
resin	NN	i	IPH
core	NN	i	IPH
;	:	i	O
and	CC	O	O
group	NN	O	O
C	NNP	O	O
with	IN	O	O
prefabricated	JJ	i	IPH
glass-fiber	JJ	i	IPH
posts	NNS	i	IPH
and	CC	i	IPH
AB	NNP	i	IPH
composite	JJ	i	IPH
resin	NN	i	IPH
core	NN	i	IPH
.	.	i	O

In	IN	O	O
every	DT	O	O
group	NN	O	O
,	,	O	O
the	DT	O	O
core	NN	O	O
material	NN	O	O
was	VBD	O	O
processed	VBN	O	O
by	IN	O	O
hot-press	NN	O	O
and	CC	O	O
non	JJ	O	O
hot-press	NN	O	O
respectively	RB	O	O
.	.	O	O

The	DT	O	O
posts	NNS	O	O
size	NN	O	O
and	CC	O	O
shape	NN	O	O
were	VBD	O	O
identical	JJ	O	O
in	IN	O	O
the	DT	O	O
3	CD	O	O
groups	NNS	O	O
.	.	O	O

All	DT	p	O
teeth	NNS	p	O
were	VBD	p	O
fully	RB	p	O
covered	VBN	p	O
with	IN	p	O
polycarbonate	JJ	p	O
resin	NN	p	O
crowns	NNS	p	O
.	.	p	O

Fracture	NN	o	OPH
resistance	NN	o	OPH
was	VBD	O	O
measured	VBN	O	O
by	IN	O	O
applying	VBG	O	O
point	NN	O	O
force	NN	O	O
at	IN	O	O
130	CD	O	O
degrees	NNS	O	O
to	TO	O	O
the	DT	O	O
long	JJ	O	O
axis	NN	O	O
of	IN	O	O
the	DT	O	O
teeth	NN	O	O
on	IN	O	O
an	DT	O	O
universal	JJ	O	O
testing	NN	O	O
machine	NN	O	O
.	.	O	O

RESULTS	JJ	O	O
Mean	JJ	o	OPH
fracture	NN	o	OPH
threshold	NN	o	OPH
was	VBD	O	O
505.4	CD	O	O
N	NNP	O	O
+/-	JJ	O	O
42.0	CD	O	O
N	NNP	O	O
and	CC	O	O
564.1	CD	O	O
N	NNP	O	O
+/-	JJ	O	O
41.7	CD	O	O
N	NNP	O	O
in	IN	O	O
group	NN	O	O
A	NNP	O	O
,	,	O	O
411.3	CD	O	O
N	NNP	O	O
+/-	JJ	O	O
23.3	CD	O	O
N	NNP	O	O
and	CC	O	O
315.3	CD	O	O
N	NNP	O	O
+/-	JJ	O	O
19.1	CD	O	O
N	NNP	O	O
in	IN	O	O
group	NN	O	O
B	NNP	O	O
and	CC	O	O
358.4	CD	O	O
N	NNP	O	O
+/-	JJ	O	O
36.1	CD	O	O
N	NNP	O	O
and	CC	O	O
423.4	CD	O	O
N	NNP	O	O
+/-	JJ	O	O
47.5	CD	O	O
N	NNP	O	O
in	IN	O	O
group	NN	O	O
C.	NNP	O	O
In	IN	O	O
all	DT	O	O
groups	NNS	O	O
,	,	O	O
there	EX	O	O
was	VBD	O	O
no	DT	o	OPH
posts	NNS	o	OPH
fracture	NN	o	OPH
and	CC	o	OPH
polycarbonate	NN	o	OPH
resin	NN	o	OPH
crowns	NNS	o	OPH
fragmentation	NN	o	OPH
.	.	o	O

CONCLUSION	VB	O	O
The	DT	O	O
composite	JJ	O	O
restoration	NN	O	O
of	IN	O	O
FRC	NNP	i	IPH
posts	NNS	i	IPH
combined	VBD	i	IPH
with	IN	i	IPH
resin	NN	i	IPH
core	NN	i	IPH
and	CC	i	IPH
resin	VB	i	IPH
crown	NN	i	IPH
can	MD	O	O
improve	VB	O	O
the	DT	O	O
fracture	NN	o	OPH
resistance	NN	o	OPH
of	IN	O	O
the	DT	O	O
pulpless	JJ	O	O
roots	NNS	O	O
.	.	O	O

The	DT	O	O
strength	NN	O	O
of	IN	O	O
resin	NN	O	O
core	NN	O	O
material	NN	O	O
can	MD	O	O
be	VB	O	O
increased	VBN	O	O
by	IN	O	O
hot-press	JJ	i	IPH
methods	NNS	i	IPH
.	.	i	O

Warfarin	NNP	i	IPM
versus	NN	O	O
aspirin	NN	i	IPM
for	IN	O	O
prevention	NN	O	O
of	IN	O	O
thromboembolism	NN	o	O
in	IN	O	O
atrial	JJ	O	O
fibrillation	NN	O	O
:	:	O	O
Stroke	NNP	O	O
Prevention	NNP	O	O
in	IN	O	O
Atrial	NNP	O	O
Fibrillation	NNP	O	O
II	NNP	O	O
Study	NNP	O	O
.	.	O	O

Warfarin	NNP	i	IPM
is	VBZ	O	O
an	DT	O	O
established	JJ	O	O
treatment	NN	O	O
for	IN	O	O
prevention	NN	O	O
of	IN	O	O
ischaemic	JJ	O	O
stroke	NN	O	O
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
atrial	JJ	p	PC
fibrillation	NN	p	PC
,	,	O	O
but	CC	O	O
the	DT	O	O
value	NN	O	O
of	IN	O	O
this	DT	O	O
agent	JJ	O	O
relative	NN	O	O
to	TO	O	O
aspirin	VB	O	O
in	IN	O	O
unclear	JJ	O	O
.	.	O	O

In	IN	O	O
the	DT	O	O
first	JJ	O	O
Stroke	NNP	O	O
Prevention	NNP	O	O
in	IN	O	O
Atrial	NNP	O	O
Fibrillation	NNP	O	O
(	(	O	O
SPAF-I	NNP	O	O
)	)	O	O
study	NN	O	O
,	,	O	O
direct	JJ	O	O
comparison	NN	O	O
of	IN	O	O
warfarin	NN	i	IPM
with	IN	O	O
aspirin	NN	i	IPM
was	VBD	O	O
limited	VBN	O	O
by	IN	O	O
the	DT	O	O
small	JJ	O	O
number	NN	O	O
of	IN	O	O
thromboembolic	JJ	O	O
events	NNS	O	O
.	.	O	O

SPAF-II	JJ	O	O
aims	NNS	O	O
to	TO	O	O
address	VB	O	O
this	DT	O	O
issue	NN	O	O
and	CC	O	O
also	RB	O	O
to	TO	O	O
assess	VB	O	O
the	DT	O	O
differential	JJ	O	O
effects	NNS	O	O
of	IN	O	O
the	DT	O	O
two	CD	O	O
treatments	NNS	O	O
according	VBG	O	O
to	TO	O	O
age	NN	O	O
.	.	O	O

We	PRP	O	O
compared	VBN	O	O
warfarin	NN	i	IPM
(	(	O	O
prothrombin	JJ	O	O
time	NN	O	O
ratio	JJ	O	O
1.3-1.8	JJ	O	O
,	,	O	O
international	JJ	O	O
normalised	JJ	O	O
ratio	NN	O	O
2.0-4.5	JJ	O	O
)	)	O	O
with	IN	O	O
aspirin	$	i	IPM
325	CD	i	IPM
mg	JJ	i	IPM
daily	RB	i	IPM
for	IN	O	O
prevention	NN	O	O
of	IN	O	O
ischaemic	JJ	o	O
stroke	NN	o	O
and	CC	O	O
systemic	JJ	o	O
embolism	NN	o	O
(	(	O	O
primary	JJ	O	O
events	NNS	O	O
)	)	O	O
in	IN	O	O
two	CD	O	O
parallel	NNS	O	O
randomised	VBD	O	O
trials	NNS	O	O
involving	VBG	O	O
715	CD	p	PSS
patients	NNS	p	O
aged	VBN	p	O
75	CD	p	PA
years	NNS	p	PA
or	CC	p	PA
less	JJR	p	PA
and	CC	p	O
385	CD	p	PSS
patients	NNS	p	O
older	JJR	p	PA
than	IN	p	PA
75	CD	p	PA
;	:	p	O
we	PRP	O	O
sought	VBD	O	O
reductions	NNS	O	O
in	IN	O	O
the	DT	O	O
absolute	JJ	O	O
rate	NN	O	O
of	IN	O	O
primary	JJ	O	O
events	NNS	O	O
by	IN	O	O
warfarin	NNS	i	IPM
compared	VBN	O	O
with	IN	O	O
aspirin	NN	i	IPM
of	IN	O	O
2	CD	O	O
%	NN	O	O
per	IN	O	O
year	NN	O	O
and	CC	O	O
4	CD	O	O
%	NN	O	O
per	IN	O	O
year	NN	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

In	IN	O	O
the	DT	O	O
younger	JJR	O	O
patients	NNS	O	O
,	,	O	O
warfarin	NNS	i	IPM
decreased	VBD	O	O
the	DT	O	O
absolute	JJ	o	OPH
rate	NN	o	OPH
of	IN	o	OPH
primary	JJ	o	OPH
events	NNS	o	OPH
by	IN	O	O
0.7	CD	O	O
%	NN	O	O
per	IN	O	O
year	NN	O	O
(	(	O	O
95	CD	O	O
%	NN	O	O
CI-0.4	NNP	O	O
to	TO	O	O
1.7	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
primary	JJ	o	OPH
event	NN	o	OPH
rate	NN	o	OPH
per	IN	o	OPH
year	NN	o	OPH
was	VBD	O	O
1.3	CD	O	O
%	NN	O	O
with	IN	O	O
warfarin	NN	i	IPM
and	CC	O	O
1.9	CD	O	O
%	NN	O	O
with	IN	O	O
aspirin	NN	i	IPM
(	(	O	O
relative	JJ	O	O
risk	NN	O	O
[	NNP	O	O
RR	NNP	O	O
]	NNP	O	O
0.67	CD	O	O
,	,	O	O
p	NN	O	O
=	NNP	O	O
0.24	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
absolute	JJ	o	O
rate	NN	o	O
of	IN	o	O
primary	JJ	o	O
events	NNS	o	O
in	IN	O	O
low-risk	JJ	O	O
younger	NN	O	O
patients	NNS	O	O
(	(	O	O
without	IN	O	O
hypertension	NN	O	O
,	,	O	O
recent	JJ	O	O
heart	NN	O	O
failure	NN	O	O
,	,	O	O
or	CC	O	O
previous	JJ	O	O
thromboembolism	NN	O	O
)	)	O	O
on	IN	O	O
aspirin	NN	i	IPM
was	VBD	O	O
0.5	CD	O	O
%	NN	O	O
per	IN	O	O
year	NN	O	O
(	(	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
0.1	CD	O	O
to	TO	O	O
1.9	CD	O	O
)	)	O	O
.	.	O	O

Among	IN	O	O
older	JJR	O	O
patients	NNS	O	O
,	,	O	O
warfarin	NNS	i	IPM
decreased	VBD	O	O
the	DT	O	O
absolute	JJ	o	O
rate	NN	o	O
of	IN	o	O
primary	JJ	o	O
events	NNS	o	O
by	IN	O	O
1.2	CD	O	O
%	NN	O	O
per	IN	O	O
year	NN	O	O
(	(	O	O
95	CD	O	O
%	NN	O	O
CI-1.7	NNP	O	O
to	TO	O	O
4.1	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
primary	JJ	o	O
event	NN	o	O
rate	NN	o	O
per	IN	o	O
year	NN	o	O
was	VBD	O	O
3.6	CD	O	O
%	NN	O	O
with	IN	O	O
warfarin	NN	i	IPM
and	CC	O	O
4.8	CD	O	O
%	NN	O	O
with	IN	O	O
aspirin	NN	i	IPM
(	(	O	O
RR	NNP	O	O
0.73	CD	O	O
,	,	O	O
p	NN	O	O
=	NNP	O	O
0.39	CD	O	O
)	)	O	O
.	.	O	O

In	IN	O	O
this	DT	O	O
older	JJR	O	O
group	NN	O	O
,	,	O	O
the	DT	O	O
rate	NN	o	O
of	IN	o	O
all	DT	o	O
stroke	NN	o	O
with	IN	o	O
residual	JJ	o	O
deficit	NN	o	O
(	(	O	O
ischaemic	JJ	O	O
or	CC	O	O
haemorrhagic	NN	O	O
)	)	O	O
was	VBD	O	O
4.3	CD	O	O
%	NN	O	O
per	IN	O	O
year	NN	O	O
with	IN	O	O
aspirin	NN	i	O
and	CC	O	O
4.6	CD	O	O
%	NN	O	O
per	IN	O	O
year	NN	O	O
with	IN	O	O
warfarin	NN	i	O
(	(	O	O
RR	NNP	O	O
1.1	CD	O	O
)	)	O	O
.	.	O	O

Warfarin	NNP	i	O
may	MD	O	O
be	VB	O	O
more	RBR	O	O
effective	JJ	O	O
than	IN	O	O
aspirin	NN	i	O
for	IN	O	O
prevention	NN	O	O
of	IN	O	O
ischaemic	JJ	o	O
stroke	NN	o	O
in	IN	O	O
patients	NNS	O	O
with	IN	O	O
atrial	JJ	O	O
fibrillation	NN	O	O
,	,	O	O
but	CC	O	O
the	DT	O	O
absolute	JJ	o	O
reduction	NN	o	O
in	IN	O	O
stroke	NN	o	O
rate	NN	o	O
by	IN	O	O
warfarin	NN	i	O
is	VBZ	O	O
small	JJ	O	O
.	.	O	O

Younger	JJR	O	O
patients	NNS	O	O
without	IN	O	O
risk	NN	O	O
factors	NNS	O	O
had	VBD	O	O
a	DT	O	O
low	JJ	O	O
rate	NN	o	O
of	IN	o	O
stroke	NN	o	O
when	WRB	O	O
treated	VBN	O	O
with	IN	O	O
aspirin	NN	i	O
.	.	i	O

In	IN	O	O
older	JJR	O	O
patients	NNS	O	O
the	DT	O	O
rate	NN	o	O
of	IN	o	O
stroke	NN	o	O
(	(	O	O
ischaemic	JJ	O	O
and	CC	O	O
haemorrhagic	NN	O	O
)	)	O	O
was	VBD	O	O
substantial	JJ	O	O
,	,	O	O
irrespective	NN	O	O
of	IN	O	O
which	WDT	O	O
agent	NN	O	O
was	VBD	O	O
given	VBN	O	O
.	.	O	O

Patient	JJ	O	O
age	NN	O	O
and	CC	O	O
the	DT	O	O
inherent	JJ	O	O
risk	NN	O	O
of	IN	O	O
thromboembolism	NN	O	O
should	MD	O	O
be	VB	O	O
considered	VBN	O	O
in	IN	O	O
the	DT	O	O
choice	NN	O	O
of	IN	O	O
antithrombotic	JJ	O	O
prophylaxis	NN	O	O
for	IN	O	O
patients	NNS	O	O
with	IN	O	O
atrial	JJ	O	O
fibrillation	NN	O	O
.	.	O	O

A	DT	O	O
comparison	NN	O	O
of	IN	O	O
the	DT	O	O
serologic	JJ	O	O
responses	NNS	O	O
to	TO	O	O
oral	JJ	O	O
and	CC	O	O
injectable	JJ	O	O
trivalent	NN	i	IPM
poliovirus	NN	i	IPM
vaccines	NNS	i	IPM
.	.	i	O

United	NNP	p	O
States	NNPS	p	O
children	NNS	p	PA
two	CD	p	PA
months	NNS	p	PA
of	IN	p	O
age	NN	p	O
were	VBD	O	O
randomly	RB	O	O
assigned	VBN	O	O
to	TO	O	O
two	CD	O	O
groups	NNS	O	O
that	WDT	O	O
received	VBD	O	O
either	RB	O	O
the	DT	O	O
commercially	RB	O	O
available	JJ	O	O
oral	JJ	i	IPM
trivalent	NN	i	IPM
poliovirus	NN	i	IPM
vaccine	NN	i	IPM
(	(	i	IPM
OPV	NNP	i	IPM
)	)	i	IPM
or	CC	O	O
an	DT	O	O
injectable	JJ	i	IPM
(	(	i	IPM
inactivated	VBN	i	IPM
)	)	i	IPM
trivalent	NN	i	IPM
poliovirus	NN	i	IPM
vaccine	NN	i	IPM
(	(	i	IPM
IPV	NNP	i	IPM
)	)	i	IPM
with	IN	O	O
a	DT	O	O
confirmed	JJ	O	O
minimum	JJ	O	O
D-antigen	NNP	O	O
content	NN	O	O
of	IN	O	O
27	CD	O	O
,	,	O	O
3.5	CD	O	O
,	,	O	O
and	CC	O	O
29	CD	O	O
units	NNS	O	O
for	IN	O	O
poliovirus	NN	O	O
types	NNS	O	O
1	CD	O	O
,	,	O	O
2	CD	O	O
,	,	O	O
and	CC	O	O
3	CD	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

Vaccine	NNP	O	O
was	VBD	O	O
given	VBN	O	O
at	IN	O	O
two	CD	O	O
,	,	O	O
four	CD	O	O
,	,	O	O
and	CC	O	O
18	CD	O	O
months	NNS	O	O
of	IN	O	O
age	NN	O	O
.	.	O	O

Sera	NN	O	O
obtained	VBN	O	O
from	IN	O	O
439	CD	p	PSS
children	NNS	p	PA
at	IN	p	PA
two	CD	p	PA
,	,	p	PA
four	CD	p	PA
,	,	p	PA
and	CC	p	PA
six	CD	p	PA
months	NNS	p	PA
of	IN	p	PA
age	NN	p	PA
and	CC	p	O
from	IN	p	O
85	CD	p	PSS
children	NNS	p	PA
at	IN	p	PA
18	CD	p	PA
and	CC	p	PA
20	CD	p	PA
months	NNS	p	PA
of	IN	p	PA
age	NN	p	PA
were	VBD	O	O
examined	VBN	O	O
for	IN	O	O
neutralizing	VBG	o	OPH
antibodies	NNS	o	OPH
.	.	o	O

The	DT	O	O
percentage	NN	o	OPH
of	IN	o	OPH
children	NNS	o	OPH
with	IN	o	OPH
detectable	JJ	o	OPH
antibodies	NNS	o	OPH
and	CC	o	OPH
the	DT	o	OPH
reciprocal	JJ	o	OPH
geometric	JJ	o	OPH
mean	NN	o	OPH
titers	NNS	o	OPH
were	VBD	O	O
similar	JJ	O	O
for	IN	O	O
both	DT	O	O
groups	NNS	O	O
at	IN	O	O
two	CD	O	O
months	NNS	O	O
of	IN	O	O
age	NN	O	O
for	IN	O	O
antibodies	NNS	o	O
to	TO	o	O
all	DT	o	O
three	CD	o	O
poliovirus	NN	o	O
types	NNS	o	O
.	.	o	O

At	IN	O	O
20	CD	O	O
months	NNS	O	O
of	IN	O	O
age	NN	O	O
,	,	O	O
all	DT	O	O
children	NNS	O	O
but	CC	O	O
one	CD	O	O
had	VBD	O	O
detectable	JJ	o	O
antibodies	NNS	O	O
to	TO	O	O
all	DT	O	O
three	CD	O	O
poliovirus	NN	O	O
types	NNS	O	O
.	.	O	O

Significantly	RB	O	O
higher	JJR	O	O
geometric	JJ	o	OPH
mean	NN	o	OPH
titers	NNS	o	OPH
against	IN	o	OPH
types	NNS	o	OPH
2	CD	o	OPH
and	CC	o	OPH
3	CD	o	OPH
were	VBD	O	O
noted	VBN	O	O
at	IN	O	O
20	CD	O	O
months	NNS	O	O
of	IN	O	O
age	NN	O	O
for	IN	O	O
the	DT	O	O
IPV	NNP	i	IPM
group	NN	O	O
.	.	O	O

Double-blind	NNP	O	O
,	,	O	O
placebo-controlled	JJ	i	IC
study	NN	O	O
of	IN	O	O
L-carnosine	NNP	i	IPM
supplementation	NN	i	IPM
in	IN	O	O
children	NNS	p	PA
with	IN	p	O
autistic	JJ	p	PC
spectrum	NN	p	PC
disorders	NNS	p	PC
.	.	p	O

L-Carnosine	NNP	i	IPM
,	,	i	O
a	DT	i	O
dipeptide	NN	i	IPM
,	,	O	O
can	MD	O	O
enhance	VB	O	O
frontal	JJ	O	O
lobe	NN	O	O
function	NN	O	O
or	CC	O	O
be	VB	O	O
neuroprotective	JJ	O	O
.	.	O	O

It	PRP	O	O
can	MD	O	O
also	RB	O	O
correlate	VB	O	O
with	IN	O	O
gamma-aminobutyric	JJ	O	O
acid	NN	O	O
(	(	O	O
GABA	NNP	O	O
)	)	O	O
-homocarnosine	NN	O	O
interaction	NN	O	O
,	,	O	O
with	IN	O	O
possible	JJ	O	O
anticonvulsive	JJ	O	O
effects	NNS	O	O
.	.	O	O

We	PRP	O	O
investigated	VBD	O	O
31	CD	p	O
children	NNS	p	O
with	IN	p	O
autistic	JJ	p	O
spectrum	NN	p	O
disorders	NNS	p	O
in	IN	p	O
an	DT	p	O
8-week	JJ	p	O
,	,	p	O
double-blinded	JJ	p	O
study	NN	p	O
to	TO	O	O
determine	VB	O	O
if	IN	O	O
800	CD	O	O
mg	JJ	O	O
L-carnosine	JJ	i	IPM
daily	NN	O	O
would	MD	O	O
result	VB	O	O
in	IN	O	O
observable	JJ	O	O
changes	NNS	O	O
versus	VBP	O	O
placebo	NN	i	IC
.	.	i	O

Outcome	CC	O	O
measures	NNS	O	O
were	VBD	O	O
the	DT	O	O
Childhood	NNP	o	OPH
Autism	NNP	o	OPH
Rating	NNP	o	OPH
Scale	NNP	o	OPH
,	,	o	OPH
the	DT	o	OPH
Gilliam	NNP	o	OPH
Autism	NNP	o	OPH
Rating	NNP	o	OPH
Scale	NNP	o	OPH
,	,	o	OPH
the	DT	o	OPH
Expressive	NNP	o	OPH
and	CC	o	OPH
Receptive	NNP	o	OPH
One-Word	NNP	o	OPH
Picture	NNP	o	OPH
Vocabulary	NNP	o	OPH
tests	NNS	o	OPH
,	,	o	O
and	CC	o	O
Clinical	NNP	o	O
Global	NNP	o	O
Impressions	NNP	o	O
of	IN	o	O
Change	NNP	o	O
.	.	o	O

Children	NNP	O	O
on	IN	O	O
placebo	NN	i	IC
did	VBD	O	O
not	RB	O	O
show	VB	O	O
statistically	RB	O	O
significant	JJ	O	O
changes	NNS	O	O
.	.	O	O

After	IN	O	O
8	CD	O	O
weeks	NNS	O	O
on	IN	O	O
L-carnosine	NNP	i	IPM
,	,	O	O
children	NNS	O	O
showed	VBD	O	O
statistically	RB	O	O
significant	JJ	O	O
improvements	NNS	O	O
on	IN	O	O
the	DT	O	O
Gilliam	NNP	o	OPH
Autism	NNP	o	OPH
Rating	NNP	o	OPH
Scale	NNP	o	OPH
(	(	o	OPH
total	JJ	o	OPH
score	NN	o	OPH
and	CC	o	OPH
the	DT	o	OPH
Behavior	NNP	o	OPH
,	,	o	OPH
Socialization	NNP	o	OPH
,	,	o	OPH
and	CC	o	OPH
Communication	NNP	o	OPH
subscales	NNS	o	OPH
)	)	o	OPH
and	CC	o	OPH
the	DT	o	OPH
Receptive	JJ	o	OPH
One-Word	NNP	o	OPH
Picture	NNP	o	OPH
Vocabulary	NNP	o	OPH
test	NN	o	OPH
(	(	O	O
all	DT	O	O
P	NNP	O	O
<	NNP	O	O
.05	NNP	O	O
)	)	O	O
.	.	O	O

Improved	VBN	O	O
trends	NNS	O	O
were	VBD	O	O
noted	VBN	O	O
on	IN	O	O
other	JJ	O	O
outcome	JJ	O	O
measures	NNS	O	O
.	.	O	O

Although	IN	O	O
the	DT	O	O
mechanism	NN	O	O
of	IN	O	O
action	NN	O	O
of	IN	O	O
L-carnosine	NNP	i	IPM
is	VBZ	O	O
not	RB	O	O
well	RB	O	O
understood	RB	O	O
,	,	O	O
it	PRP	O	O
may	MD	O	O
enhance	VB	O	O
neurologic	JJ	O	O
function	NN	O	O
,	,	O	O
perhaps	RB	O	O
in	IN	O	O
the	DT	O	O
enterorhinal	JJ	O	O
or	CC	O	O
temporal	JJ	O	O
cortex	NN	O	O
.	.	O	O

An	DT	O	O
evaluation	NN	O	O
of	IN	O	O
chemical	JJ	O	O
arthrodesis	NN	O	O
of	IN	O	O
the	DT	O	O
proximal	JJ	p	PC
interphalangeal	NN	p	PC
joint	NN	p	PC
in	IN	p	O
the	DT	p	O
horse	NN	p	O
by	IN	O	O
using	VBG	O	O
monoiodoacetate	NN	i	IPM
.	.	i	O

The	DT	O	O
use	NN	O	O
of	IN	O	O
monoiodoacetate	NN	i	IPM
(	(	i	IPM
MIA	NNP	i	IPM
)	)	i	IPM
for	IN	O	O
arthrodesis	NN	O	O
of	IN	O	O
the	DT	O	O
proximal	JJ	O	O
interphalangeal	NN	O	O
joint	NN	O	O
(	(	O	O
PIJ	NNP	O	O
)	)	O	O
and	CC	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
exercise	NN	O	O
on	IN	O	O
the	DT	O	O
degree	NN	O	O
of	IN	O	O
fusion	NN	O	O
were	VBD	O	O
investigated	VBN	O	O
.	.	O	O

Eight	JJ	p	PSS
horses	NNS	p	O
received	VBD	O	O
3	CD	O	O
injections	NNS	O	O
(	(	O	O
Weeks	NNP	O	O
0	CD	O	O
,	,	O	O
3	CD	O	O
,	,	O	O
6	CD	O	O
)	)	O	O
of	IN	O	O
MIA	NNP	i	IPM
(	(	O	O
2	CD	O	O
mL	NN	O	O
;	:	O	O
60	CD	O	O
mg/mL	NN	O	O
)	)	O	O
into	IN	O	O
the	DT	O	O
right	NN	O	O
or	CC	O	O
left	VBD	O	O
front	JJ	O	O
PIJ	NNP	O	O
.	.	O	O

Peri-operatively	RB	O	O
,	,	O	O
the	DT	O	O
horses	NNS	O	O
received	VBD	O	O
phenylbutazone	NN	i	IPM
,	,	i	O
butorphanol	NN	i	IPM
,	,	i	O
and	CC	i	O
abaxial	JJ	i	IPM
sesamoidean	NN	i	IPM
nerve	NN	i	IPH
blocks	NNS	i	IPH
to	TO	O	O
relieve	VB	O	O
pain	NN	O	O
.	.	O	O

During	IN	O	O
the	DT	O	O
study	NN	O	O
,	,	O	O
the	DT	O	O
horses	NNS	O	O
were	VBD	O	O
monitored	VBN	O	O
for	IN	O	O
general	JJ	O	O
health	NN	O	O
,	,	O	O
lameness	NN	O	O
,	,	O	O
and	CC	O	O
swelling	VBG	O	O
around	IN	O	O
the	DT	O	O
injection	NN	O	O
area	NN	O	O
.	.	O	O

Radiographs	NNP	O	O
were	VBD	O	O
taken	VBN	O	O
biweekly	RB	O	O
to	TO	O	O
evaluate	VB	O	O
bony	NN	O	O
fusion	NN	O	O
.	.	O	O

Horses	NNS	O	O
were	VBD	O	O
randomly	RB	O	O
divided	VBN	O	O
into	IN	O	O
non-exercised	JJ	i	O
and	CC	O	O
exercised	JJ	i	O
groups	NNS	O	O
.	.	O	O

Exercise	NNP	i	IPH
consisted	VBD	O	O
of	IN	O	O
20	CD	O	O
minutes	NNS	O	O
of	IN	O	O
trotting	VBG	O	O
on	IN	O	O
a	DT	O	O
treadmill	NN	O	O
(	(	O	O
4	CD	O	O
m/s	NN	O	O
)	)	O	O
,	,	O	O
3	CD	O	O
days	NNS	O	O
per	IN	O	O
week	NN	O	O
for	IN	O	O
13	CD	O	O
weeks	NNS	O	O
.	.	O	O

The	DT	O	O
horses	NNS	O	O
were	VBD	O	O
euthanized	VBN	O	O
at	IN	O	O
24	CD	O	O
weeks	NNS	O	O
.	.	O	O

Slab	NNP	O	O
sections	NNS	O	O
of	IN	O	O
the	DT	O	O
PIJ	NNP	O	O
were	VBD	O	O
evaluated	VBN	O	O
grossly	RB	O	O
and	CC	O	O
radiographically	RB	O	O
for	IN	O	O
bony	NN	O	O
fusion	NN	O	O
.	.	O	O

Histologic	JJ	O	O
examinations	NNS	O	O
were	VBD	O	O
performed	VBN	O	O
to	TO	O	O
evaluate	VB	O	O
articular	JJ	O	O
cartilage	NN	O	O
.	.	O	O

Three	CD	O	O
horses	NNS	O	O
were	VBD	O	O
excluded	VBN	O	O
from	IN	O	O
the	DT	O	O
study	NN	O	O
after	IN	O	O
developing	VBG	O	O
soft	JJ	O	O
tissue	NN	O	O
necrosis	NN	O	O
around	IN	O	O
the	DT	O	O
injection	NN	O	O
site	NN	O	O
,	,	O	O
septic	JJ	O	O
arthritis	NN	O	O
,	,	O	O
and	CC	O	O
necrotic	JJ	O	O
tendinitis	NN	O	O
.	.	O	O

The	DT	O	O
remaining	VBG	O	O
horses	NNS	O	O
remained	VBD	O	O
healthy	JJ	O	O
,	,	O	O
developed	VBD	O	O
a	DT	O	O
grade	NN	O	O
1	CD	O	O
to	TO	O	O
4	CD	O	O
lameness	NN	O	O
with	IN	O	O
minimal	JJ	O	O
to	TO	O	O
severe	VB	O	O
swelling	VBG	O	O
in	IN	O	O
the	DT	O	O
PIJ	NNP	O	O
region	NN	O	O
.	.	O	O

All	DT	o	O
5	CD	o	O
horses	NNS	o	O
showed	VBD	o	O
radiographic	JJ	o	OPH
evidence	NN	o	OPH
of	IN	o	OPH
bony	NN	o	OPH
fusion	NN	o	OPH
,	,	o	O
however	RB	o	O
,	,	o	O
no	DT	o	O
fusion	NN	o	O
was	VBD	o	O
present	JJ	o	O
when	WRB	o	O
injected	JJ	o	O
joints	NNS	o	O
were	VBD	o	O
examined	VBN	o	O
on	IN	o	O
postmortem	NN	o	O
examination	NN	o	O
.	.	o	O

Histologic	NNP	o	OPH
examination	NN	o	OPH
revealed	VBD	o	OPH
thinning	NN	o	OPH
of	IN	o	OPH
the	DT	o	OPH
cartilage	NN	o	OPH
,	,	o	OPH
diffuse	VBP	o	OPH
necrosis	NN	o	OPH
of	IN	o	OPH
chondrocytes	NNS	o	OPH
,	,	o	OPH
with	IN	o	OPH
the	DT	o	OPH
calcified	JJ	o	OPH
zone	NN	o	OPH
intact	JJ	o	OPH
.	.	o	OPH

Subjectively	RB	o	O
,	,	o	O
exercise	NN	o	O
did	VBD	o	O
not	RB	o	O
influence	VB	o	O
the	DT	o	O
degree	NN	o	OPH
of	IN	o	OPH
cartilage	NN	o	OPH
destruction	NN	o	OPH
.	.	o	O

Based	VBN	o	O
on	IN	o	O
this	DT	o	O
study	NN	o	O
,	,	o	O
chemical	JJ	o	O
arthrodesis	NN	o	O
can	MD	o	O
not	RB	o	O
be	VB	o	O
advocated	VBN	o	O
in	IN	o	O
clinical	JJ	o	O
cases	NNS	o	O
because	IN	o	O
of	IN	o	O
the	DT	o	O
high	JJ	o	O
complication	NN	o	OA
rate	NN	o	OA
and	CC	o	O
lack	NN	o	O
of	IN	o	O
bony	NN	o	OPH
fusion	NN	o	OPH
.	.	o	O

Modest	NNP	O	O
antihypertensive	JJ	O	O
effect	NN	O	O
of	IN	O	O
epanolol	NN	i	IPM
,	,	O	O
a	DT	O	O
beta	NN	O	O
1-selective	JJ	O	O
receptor	NN	O	O
blocker	NN	O	O
with	IN	O	O
beta	NN	O	O
1	CD	O	O
agonist	NN	O	O
activity	NN	O	O
:	:	O	O
an	DT	O	O
acute	NN	O	O
and	CC	O	O
long-term	JJ	O	O
hemodynamic	NN	O	O
study	NN	O	O
at	IN	O	O
rest	NN	O	O
and	CC	O	O
during	IN	O	O
exercise	NN	O	O
and	CC	O	O
double	JJ	O	O
crossover	NN	O	O
comparison	NN	O	O
with	IN	O	O
atenolol	NN	O	O
on	IN	O	O
ambulatory	JJ	O	O
blood	NN	O	O
pressure	NN	O	O
.	.	O	O

Beta-blockers	NNS	O	O
with	IN	O	O
less	JJR	O	O
cardiodepressive	JJ	O	O
effect	NN	O	O
than	IN	O	O
traditional	JJ	O	O
nonselective	JJ	O	O
beta	NN	O	O
(	(	O	O
1+2	CD	O	O
)	)	O	O
-blocking	VBG	O	O
agents	NNS	O	O
could	MD	O	O
be	VB	O	O
useful	JJ	O	O
in	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
hypertension	NN	O	O
,	,	O	O
provided	VBD	O	O
the	DT	O	O
reduction	NN	O	O
in	IN	O	O
blood	NN	O	O
pressure	NN	O	O
was	VBD	O	O
satisfactory	JJ	O	O
.	.	O	O

Epanolol	NNP	i	IPM
,	,	O	O
a	DT	O	O
selective	JJ	O	O
beta	NN	O	O
1-receptor	JJ	O	O
blocker	NN	O	O
with	IN	O	O
intrinsic	JJ	O	O
sympathomimetic	JJ	O	O
activity	NN	O	O
,	,	O	O
induced	VBD	O	O
a	DT	O	O
fall	NN	O	O
in	IN	O	O
intraarterial	JJ	o	OPH
pressure	NN	o	OPH
of	IN	O	O
8	CD	O	O
%	NN	O	O
at	IN	O	O
rest	NN	O	O
sitting	VBG	O	O
and	CC	O	O
11	CD	O	O
%	NN	O	O
during	IN	O	O
100	CD	O	O
W	NNP	O	O
bicycle	NN	O	O
exercise	NN	O	O
after	IN	O	O
the	DT	O	O
first	JJ	O	O
dose	NN	O	O
of	IN	O	O
200	CD	O	O
mg	NNS	O	O
in	IN	O	O
12	CD	p	PC
patients	NNS	p	PC
with	IN	p	PC
essential	JJ	p	PC
hypertension	NN	p	PC
.	.	p	PC

Heart	NNP	o	OPH
rate	NN	o	OPH
,	,	o	OPH
stroke	VBD	o	OPH
index	NN	o	OPH
,	,	o	OPH
and	CC	o	OPH
cardiac	JJ	o	OPH
index	NN	o	OPH
initially	RB	O	O
fell	VBD	O	O
by	IN	O	O
14	CD	O	O
%	NN	O	O
,	,	O	O
11	CD	O	O
%	NN	O	O
,	,	O	O
and	CC	O	O
23	CD	O	O
%	NN	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

The	DT	O	O
total	JJ	o	OPH
peripheral	JJ	o	OPH
resistance	NN	o	OPH
index	NN	o	OPH
increased	VBD	O	O
by	IN	O	O
21	CD	O	O
%	NN	O	O
after	IN	O	O
2	CD	O	O
hours	NNS	O	O
,	,	O	O
and	CC	O	O
then	RB	O	O
reverted	VBD	O	O
towards	IN	O	O
the	DT	O	O
pretreatment	NN	O	O
level	NN	O	O
.	.	O	O

After	IN	O	O
10	CD	O	O
months	NNS	O	O
of	IN	O	O
epanolol	JJ	i	IPM
treatment	NN	O	O
(	(	O	O
mean	JJ	O	O
300	CD	O	O
mg/day	NN	O	O
)	)	O	O
,	,	O	O
the	DT	O	O
reduction	NN	o	O
in	IN	O	O
arterial	JJ	o	OPH
pressure	NN	o	OPH
was	VBD	O	O
5	CD	O	O
%	NN	O	O
at	IN	O	O
rest	NN	O	O
and	CC	O	O
10	CD	O	O
%	NN	O	O
during	IN	O	O
exercise	NN	O	O
.	.	O	O

Cardiac	NNP	o	OPH
index	NN	o	OPH
and	CC	o	OPH
heart	NN	o	OPH
rate	NN	o	OPH
were	VBD	O	O
still	RB	O	O
reduced	VBN	O	O
14-21	CD	O	O
%	NN	O	O
,	,	O	O
while	IN	O	O
total	JJ	o	OPH
peripheral	JJ	o	OPH
resistance	NN	o	OPH
was	VBD	O	O
unchanged	JJ	O	O
or	CC	O	O
slightly	RB	O	O
increased	VBN	O	O
(	(	O	O
2-10	CD	O	O
%	NN	O	O
)	)	O	O
.	.	O	O

Twenty-four	JJ	o	OPH
hour	NN	o	OPH
ambulatory	NN	o	OPH
blood	NN	o	OPH
pressure	NN	o	OPH
was	VBD	O	O
higher	JJR	O	O
on	IN	O	O
epanolol	NN	i	IPM
(	(	O	O
300	CD	O	O
mg/day	NN	O	O
)	)	O	O
than	IN	O	O
on	IN	O	O
atenolol	NN	i	IPM
(	(	O	O
150	CD	O	O
mg/day	NN	O	O
)	)	O	O
treatment	NN	O	O
(	(	O	O
137/97	CD	O	O
vs.	FW	O	O
128/91	CD	O	O
mmHg	NN	O	O
)	)	O	O
.	.	O	O

Thus	RB	O	O
,	,	O	O
the	DT	O	O
achieved	VBN	o	O
blood	NN	o	OPH
pressure	NN	o	OPH
reduction	NN	o	O
induced	VBN	O	O
by	IN	O	O
epanolol	NN	i	IPM
was	VBD	O	O
moderate	JJ	O	O
,	,	O	O
while	IN	O	O
other	JJ	O	O
characteristics	NNS	O	O
of	IN	O	O
beta-receptor	NN	O	O
blockade	NN	O	O
,	,	O	O
in	IN	O	O
particular	JJ	O	O
,	,	O	O
the	DT	O	O
reduction	NN	o	O
of	IN	o	O
heart	NN	o	OPH
rate	NN	o	OPH
and	CC	o	OPH
cardiac	JJ	o	OPH
output	NN	o	OPH
,	,	O	O
were	VBD	O	O
maintained	VBN	O	O
.	.	O	O

This	DT	O	O
suggests	VBZ	O	O
that	IN	O	O
the	DT	O	O
compound	NN	O	O
may	MD	O	O
be	VB	O	O
useful	JJ	O	O
for	IN	O	O
other	JJ	O	O
cardiovascular	JJ	p	PC
disorders	NNS	p	PC
,	,	O	O
e.g.	NN	O	O
,	,	O	O
angina	JJ	p	O
pectoris	NN	p	O
in	IN	p	O
patients	NNS	p	O
without	IN	p	O
hypertension	NN	p	PC
or	CC	p	O
cardiac	JJ	p	PC
arrhythmia	NN	p	PC
.	.	p	O

Dietary	NNP	i	IPM
lignan	NN	i	IPM
and	CC	i	IPM
proanthocyanidin	NN	i	IPM
consumption	NN	i	IPM
and	CC	O	O
colorectal	JJ	o	OPH
adenoma	NN	o	OPH
recurrence	NN	o	OPH
in	IN	O	O
the	DT	O	O
Polyp	NNP	O	O
Prevention	NNP	O	O
Trial	NNP	O	O
.	.	O	O

Lignans	NNPS	O	O
and	CC	O	O
proanthocyanidins	NNS	O	O
are	VBP	O	O
plant	NN	O	O
polyphenols	NNS	i	IPM
that	WDT	O	O
have	VBP	O	O
shown	VBN	O	O
protective	JJ	O	O
properties	NNS	O	O
against	IN	O	O
colorectal	JJ	o	OPH
neoplasms	NNS	o	OPH
in	IN	p	O
some	DT	p	O
human	JJ	p	O
studies	NNS	p	O
.	.	p	O

Using	VBG	O	O
logistic	JJ	O	O
regression	NN	O	O
,	,	O	O
we	PRP	O	O
estimated	VBD	O	O
odds	NNS	O	O
ratios	NNS	O	O
(	(	O	O
ORs	NNP	O	O
)	)	O	O
and	CC	O	O
95	CD	O	O
%	NN	O	O
confidence	NN	O	O
intervals	NNS	O	O
(	(	O	O
CIs	NNP	O	O
)	)	O	O
to	TO	O	O
prospectively	RB	O	O
evaluate	VB	O	O
the	DT	O	O
association	NN	O	O
between	IN	O	O
lignan	NN	i	IPM
and	CC	i	IPM
proanthocyanidin	JJ	i	IPM
intake	NN	i	IPM
,	,	O	O
estimated	VBN	O	O
from	IN	O	O
databases	NNS	O	O
linked	VBN	O	O
to	TO	O	O
a	DT	O	O
food	NN	O	O
frequency	NN	O	O
questionnaire	NN	O	O
,	,	O	O
and	CC	O	O
adenoma	JJ	o	OPH
recurrence	NN	o	OPH
in	IN	O	O
1,859	CD	p	O
participants	NNS	p	O
of	IN	p	O
the	DT	p	O
Polyp	NNP	p	O
Prevention	NNP	p	O
Trial	NNP	p	O
.	.	p	O

Overall	NNP	O	O
,	,	O	O
individual	NN	O	O
or	CC	O	O
total	JJ	O	O
lignans	NNS	O	O
or	CC	O	O
proanthocyanidins	NNS	O	O
were	VBD	O	O
not	RB	O	O
associated	VBN	O	O
with	IN	O	O
colorectal	JJ	o	OPH
adenoma	NN	o	OPH
recurrence	NN	o	OPH
.	.	o	O

However	RB	O	O
,	,	O	O
in	IN	O	O
sex-specific	JJ	O	O
analyses	NNS	O	O
,	,	O	O
total	JJ	O	O
lignan	JJ	O	O
intake	NN	O	O
was	VBD	O	O
positively	RB	O	O
associated	VBN	O	O
with	IN	O	O
any	DT	O	O
adenoma	JJ	o	OPH
recurrence	NN	o	OPH
in	IN	O	O
women	NNS	O	O
(	(	O	O
highest	JJS	O	O
vs.	NN	O	O
lowest	JJS	O	O
lignan	JJ	O	O
intake	NN	O	O
quartile	NN	O	O
OR	NNP	O	O
=	VBZ	O	O
2.07	CD	O	O
,	,	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
:	:	O	O
1.22-3.52	JJ	O	O
,	,	O	O
p	JJ	O	O
trend	NN	O	O
=	VBZ	O	O
0.004	CD	O	O
)	)	O	O
but	CC	O	O
not	RB	O	O
in	IN	O	O
men	NNS	O	O
(	(	O	O
p	JJ	O	O
interaction	NN	O	O
=	NNP	O	O
0.04	CD	O	O
)	)	O	O
.	.	O	O

To	TO	O	O
conclude	VB	O	O
,	,	O	O
dietary	JJ	O	O
lignan	NN	O	O
and	CC	O	O
proanthocyanidin	NN	O	O
consumption	NN	O	O
were	VBD	O	O
not	RB	O	O
generally	RB	O	O
related	VBN	O	O
to	TO	O	O
colorectal	JJ	o	OPH
adenoma	JJ	o	OPH
recurrence	NN	o	OPH
;	:	o	O
however	RB	O	O
,	,	O	O
high	JJ	O	O
lignan	NNS	O	O
intake	VBP	O	O
may	MD	O	O
increase	VB	O	O
the	DT	O	O
risk	NN	o	OPH
of	IN	o	OPH
adenoma	JJ	o	OPH
recurrence	NN	o	OPH
in	IN	p	O
women	NNS	p	PSE
.	.	p	PSE

Comparison	NNP	O	O
of	IN	O	O
analgesic	JJ	O	O
effect	NN	O	O
of	IN	O	O
locally	RB	O	O
and	CC	O	O
systemically	RB	O	O
administered	VBN	O	O
ketorolac	NN	i	IPM
in	IN	O	O
mastectomy	JJ	p	O
patients	NNS	p	O
.	.	p	O

BACKGROUND	NNP	O	O
Ketorolac	NNP	i	IPM
is	VBZ	O	O
a	DT	O	O
parenteral	JJ	O	O
nonsteroidal	JJ	O	O
antiinflammatory	JJ	O	O
drug	NN	O	O
(	(	O	O
NSAID	NNP	O	O
)	)	O	O
.	.	O	O

Two	CD	O	O
features	NNS	O	O
have	VBP	O	O
limited	VBN	O	O
its	PRP$	O	O
clinical	JJ	O	O
utility	NN	O	O
:	:	O	O
tendency	NN	O	O
to	TO	O	O
elicit	VB	O	O
kidney	NN	O	O
failure	NN	O	O
and	CC	O	O
inability	NN	O	O
to	TO	O	O
produce	VB	O	O
complete	JJ	O	O
analgesia	NN	O	O
.	.	O	O

Because	IN	O	O
most	JJS	O	O
NSAIDs	NNP	i	IPM
are	VBP	O	O
weak	JJ	O	O
acids	NNS	O	O
(	(	O	O
pKa	IN	O	O
3-5	NNP	O	O
)	)	O	O
and	CC	O	O
become	VBN	O	O
concentrated	JJ	O	O
in	IN	O	O
acidic	JJ	O	O
tissues	NNS	O	O
,	,	O	O
such	JJ	O	O
as	IN	O	O
injured	JJ	O	O
and	CC	O	O
inflamed	JJ	O	O
tissues	NNS	O	O
,	,	O	O
we	PRP	O	O
hypothesized	VBD	O	O
that	IN	O	O
local	JJ	O	O
administration	NN	O	O
may	MD	O	O
enhance	VB	O	O
its	PRP$	O	O
analgesic	JJ	O	O
efficacy	NN	O	O
while	IN	O	O
lowering	VBG	O	O
the	DT	O	O
potential	NN	O	O
for	IN	O	O
systemic	JJ	O	O
complications	NNS	O	O
.	.	O	O

METHODS	NNP	O	O
We	PRP	O	O
conducted	VBD	O	O
a	DT	O	O
randomized	VBN	O	O
,	,	O	O
placebo-controlled	JJ	i	IC
study	NN	O	O
of	IN	O	O
60	CD	p	O
group	NN	p	O
I-II	NNP	p	O
(	(	p	O
American	JJ	p	O
Society	NNP	p	O
of	IN	p	O
Anesthesiology	NNP	p	O
criteria	NNS	p	O
)	)	p	O
mastectomy	NN	p	O
patients	NNS	p	O
,	,	p	O
20	CD	p	O
in	IN	p	O
each	DT	p	O
group	NN	p	O
.	.	p	O

Near	IN	O	O
the	DT	O	O
end	NN	O	O
of	IN	O	O
surgery	NN	O	O
and	CC	O	O
every	DT	O	O
6	CD	O	O
h	NN	O	O
postoperatively	RB	O	O
,	,	O	O
20	CD	O	O
ml	NN	O	O
of	IN	O	O
the	DT	O	O
study	NN	O	O
solution	NN	O	O
containing	VBG	O	O
normal	JJ	i	IPM
saline	NN	i	IPM
with	IN	i	IPM
or	CC	i	IPM
without	IN	i	IPM
30	CD	i	IPM
mg	NN	i	IPM
of	IN	i	IPM
ketorolac	NN	i	IPM
were	VBD	O	O
administered	VBN	O	O
simultaneously	RB	O	O
either	CC	O	O
via	IN	O	O
a	DT	O	O
Jackson-Pratt	JJ	O	O
drain	NN	O	O
or	CC	O	O
intravenously	RB	O	O
in	IN	O	O
a	DT	O	O
double-blind	JJ	O	O
fashion	NN	O	O
.	.	O	O

The	DT	O	O
quality	NN	o	OPH
of	IN	o	OPH
pain	NN	o	OPH
control	NN	o	OPH
,	,	o	OPH
the	DT	o	OPH
amount	NN	o	OPH
and	CC	o	OPH
character	NN	o	OPH
of	IN	o	OPH
the	DT	o	OPH
drain	NN	o	OPH
fluid	NN	o	OPH
,	,	o	OPH
incidence	NN	o	OPH
of	IN	o	OPH
nausea	NN	o	OPH
and	CC	o	OPH
vomiting	NN	o	OPH
,	,	o	OPH
length	NN	o	OPH
of	IN	o	OPH
stay	NN	o	OPH
in	IN	o	OPH
the	DT	o	OPH
postoperative	JJ	o	OPH
care	NN	o	OPH
unit	NN	o	OPH
,	,	o	OPH
and	CC	o	OPH
amount	NN	o	OPH
of	IN	o	OPH
morphine	NN	o	OPH
used	VBN	O	O
for	IN	O	O
treatment	NN	O	O
of	IN	O	O
break-through	JJ	O	O
pain	NN	O	O
were	VBD	O	O
recorded	VBN	O	O
.	.	O	O

RESULTS	NNP	O	O
Intraoperative	NNP	O	O
administration	NN	O	O
of	IN	O	O
ketorolac	NN	i	IPM
resulted	VBD	O	O
in	IN	O	O
better	JJR	O	O
quality	NN	o	OPA
of	IN	o	OPA
pain	NN	o	OPA
control	NN	o	OPA
in	IN	O	O
the	DT	O	O
immediate	JJ	O	O
postoperative	JJ	O	O
period	NN	O	O
regardless	NN	O	O
of	IN	O	O
route	NN	O	O
of	IN	O	O
administration	NN	O	O
.	.	O	O

The	DT	O	O
incidence	NN	o	OPH
of	IN	o	OPH
nausea	NN	o	OPH
was	VBD	O	O
significantly	RB	O	O
higher	JJR	O	O
in	IN	O	O
the	DT	O	O
placebo	NN	O	O
group	NN	O	O
,	,	O	O
and	CC	O	O
drain	NN	o	OPH
output	NN	o	OPH
in	IN	O	O
the	DT	O	O
ketorolac	NN	i	IPM
groups	NNS	O	O
did	VBD	O	O
not	RB	O	O
exceed	VB	O	O
the	DT	O	O
output	NN	O	O
in	IN	O	O
the	DT	O	O
placebo	NN	i	IC
group	NN	O	O
.	.	O	O

CONCLUSION	NNP	O	O
Analgesic	NNP	O	O
of	IN	O	O
the	DT	O	O
locally	RB	O	O
administered	VBN	O	O
ketorolac	NN	i	IPM
is	VBZ	O	O
equally	RB	O	O
effective	JJ	o	OOt
to	TO	O	O
the	DT	O	O
efficacy	NN	o	OOt
of	IN	O	O
ketorolac	NN	i	IPM
administered	VBN	O	O
intravenously	RB	O	O
.	.	O	O

Double-blind	NNP	O	O
comparison	NN	O	O
of	IN	O	O
ketazolam	NN	i	IPM
,	,	i	O
diazepam	NN	i	IPM
and	CC	i	O
placebo	NN	i	IC
in	IN	O	O
once-a-day	JJ	O	O
vs	NN	O	O
t.i.d	NN	O	O
.	.	O	O

dosing	VBG	O	O
.	.	O	O

Comparison	NNP	O	O
of	IN	O	O
ketazolam	NNP	i	IPM
given	VBN	O	O
once-a-day	JJ	O	O
with	IN	O	O
diazepam	NN	i	IPM
given	VBN	O	O
three	CD	O	O
times	NNS	O	O
a	DT	O	O
day	NN	O	O
and	CC	i	O
placebo	VB	i	IC
given	VBN	O	O
either	DT	O	O
once	RB	O	O
or	CC	O	O
3	CD	O	O
times	NNS	O	O
a	DT	O	O
day	NN	O	O
in	IN	O	O
101	CD	p	O
anxious	JJ	p	PC
outpatients	NNS	p	PC
showed	VBD	O	O
ketazolam	NNS	O	O
to	TO	O	O
be	VB	O	O
significantly	RB	O	O
better	JJR	O	O
than	IN	O	O
placebo	NN	O	O
in	IN	O	O
alleviating	VBG	O	O
the	DT	O	O
symptoms	NNS	p	O
of	IN	p	O
anxiety	NN	p	O
and	CC	O	O
,	,	O	O
on	IN	O	O
several	JJ	O	O
measures	NNS	O	O
of	IN	O	O
efficacy	NN	O	O
,	,	O	O
better	JJR	O	O
than	IN	O	O
diazepam	NN	O	O
as	IN	O	O
well	RB	O	O
.	.	O	O

Significantly	RB	O	O
fewer	JJR	O	O
patients	NNS	p	O
on	IN	p	O
ketazolam	NN	i	IPM
dropped	VBD	p	O
out	IN	p	O
of	IN	p	O
the	DT	p	O
study	NN	p	O
due	JJ	O	O
to	TO	O	O
ineffective	JJ	O	O
medication	NN	O	O
than	IN	O	O
on	IN	O	O
the	DT	O	O
other	JJ	O	O
3	CD	O	O
treatments	NNS	O	O
.	.	O	O

The	DT	O	O
incidence	NN	o	OA
of	IN	o	OA
side	NN	o	OA
effects	NNS	o	OA
was	VBD	o	OA
lowest	JJS	o	OA
in	IN	O	O
the	DT	O	O
ketazolam	NN	O	O
group	NN	O	O
.	.	O	O

Of	IN	O	O
particular	JJ	O	O
note	NN	O	O
,	,	O	O
drowsiness	NN	o	OA
was	VBD	O	O
reported	VBN	O	O
twice	RB	O	O
as	RB	O	O
often	RB	O	O
by	IN	O	O
diazepam	JJ	i	IPM
patients	NNS	O	O
as	IN	O	O
by	IN	O	O
ketazolam	NN	i	IPM
patients	NNS	O	O
.	.	O	O

Effectiveness	NN	O	O
and	CC	O	O
safety	NN	O	O
of	IN	O	O
inhaled	JJ	O	O
treprostinil	NN	i	IPM
for	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
pulmonary	JJ	p	PC
arterial	JJ	p	PC
hypertension	NN	p	PC
in	IN	p	PC
children	NNS	p	PC
.	.	p	PC

The	DT	O	O
introduction	NN	O	O
of	IN	O	O
prostanoid	NN	i	IPM
therapy	NN	i	IPM
has	VBZ	O	O
revolutionized	VBN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
pulmonary	JJ	O	O
arterial	JJ	O	O
hypertension	NN	O	O
(	(	O	O
PAH	NNP	O	O
)	)	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
continuous	JJ	O	O
intravenous	JJ	O	O
prostacyclin	NN	i	IPM
infusion	NN	O	O
poses	VBZ	O	O
significant	JJ	O	O
risks	NNS	O	O
and	CC	O	O
challenges	NNS	O	O
,	,	O	O
particularly	RB	O	O
in	IN	O	O
children	NNS	p	PA
.	.	p	PA

Inhaled	VBN	O	O
treprostinil	NN	i	IPM
has	VBZ	O	O
been	VBN	O	O
shown	VBN	O	O
to	TO	O	O
be	VB	O	O
safe	JJ	O	O
and	CC	O	O
efficacious	JJ	O	O
in	IN	O	O
adults	NNS	O	O
.	.	O	O

This	DT	O	O
study	NN	O	O
describes	VBZ	O	O
the	DT	O	O
safety	NN	O	O
and	CC	O	O
efficacy	NN	O	O
of	IN	O	O
inhaled	JJ	O	O
treprostinil	NN	i	IPM
in	IN	O	O
children	NNS	p	PA
with	IN	p	PA
PAH	NNP	p	PA
.	.	p	PA

A	NNP	O	O
retrospective	JJ	O	O
analysis	NN	O	O
of	IN	O	O
29	CD	p	O
children	NNS	p	O
treated	VBN	p	O
with	IN	p	O
inhaled	JJ	p	O
treprostinil	NN	i	IPM
for	IN	p	O
?6	JJ	p	O
weeks	NNS	p	O
was	VBD	p	O
performed	VBN	p	O
.	.	p	O

Effects	NNS	O	O
of	IN	O	O
inhaled	JJ	i	O
treprostinil	NN	i	O
on	IN	i	O
exercise	NN	O	O
capacity	NN	O	O
,	,	O	O
functional	JJ	O	O
class	NN	O	O
,	,	O	O
and	CC	O	O
echocardiographic	JJ	O	O
and	CC	O	O
hemodynamic	JJ	O	O
data	NNS	O	O
were	VBD	O	O
evaluated	VBN	O	O
.	.	O	O

Adverse	JJ	O	O
events	NNS	O	O
were	VBD	O	O
documented	VBN	O	O
.	.	O	O

Patients	NNS	O	O
received	VBD	O	O
3	CD	O	O
to	TO	O	O
9	CD	O	O
breaths	NNS	O	O
(	(	O	O
6	CD	O	O
?g/breath	NN	O	O
)	)	O	O
of	IN	O	O
inhaled	VBN	i	O
treprostinil	NN	i	O
4	CD	i	O
times/day	NN	O	O
.	.	O	O

All	DT	O	O
were	VBD	O	O
receiving	VBG	i	O
background	NN	i	O
PAH	NNP	i	O
therapy	NN	i	O
;	:	i	O
12	CD	i	O
had	VBD	O	O
previously	RB	O	O
received	VBN	O	O
parenteral	JJ	O	O
prostanoid	NN	O	O
.	.	O	O

Inhaled	VBD	i	O
treprostinil	NN	i	O
was	VBD	i	O
discontinued	VBN	O	O
in	IN	O	O
4	CD	p	O
patients	NNS	p	O
because	IN	p	O
of	IN	O	O
symptoms	NNS	O	O
including	VBG	o	O
cough	NN	o	OA
and	CC	o	OA
bronchospasm	NN	o	OA
(	(	o	O
n	JJ	o	O
=	NNP	O	O
3	CD	O	O
)	)	O	O
and	CC	O	O
progression	NN	o	O
of	IN	o	O
PAH	NNP	o	O
(	(	o	O
n	JJ	o	O
=	NNP	O	O
1	CD	O	O
)	)	O	O
.	.	O	O

Mild	JJ	o	O
side	JJ	o	O
effects	NNS	o	O
including	VBG	o	O
cough	NN	o	O
(	(	o	O
n	JJ	o	O
=	NNP	O	O
9	CD	O	O
)	)	O	O
and	CC	O	O
sore	$	o	O
throat	NN	o	O
(	(	o	O
n	JJ	o	O
=	NNP	O	O
6	CD	O	O
)	)	O	O
did	VBD	O	O
not	RB	O	O
require	VB	O	O
discontinuation	NN	O	O
of	IN	O	O
therapy	NN	o	O
.	.	o	O

World	NNP	o	O
Health	NNP	o	O
Organization	NNP	o	O
functional	JJ	o	O
class	NN	o	O
improved	VBN	o	O
in	IN	O	O
19	CD	O	O
and	CC	O	O
was	VBD	O	O
unchanged	JJ	O	O
in	IN	O	O
10	CD	O	O
;	:	O	O
exercise	NN	o	OPH
capacity	NN	o	OPH
significantly	RB	o	O
improved	VBN	O	O
with	IN	O	O
the	DT	O	O
6-minute	JJ	O	O
walk	NN	O	O
distance	NN	O	O
,	,	O	O
improving	VBG	O	O
on	IN	O	O
follow-up	NN	O	O
from	IN	O	O
455.7	CD	O	O
?	.	O	O
71.5	CD	O	O
to	TO	O	O
498	CD	O	O
?	.	O	O
70	CD	O	O
m	NN	O	O
(	(	O	O
p	JJ	O	O
=	NNP	O	O
0.01	CD	O	O
)	)	O	O
and	CC	o	O
peak	JJ	o	OPH
oxygen	NN	o	OPH
consumption	NN	o	OPH
increasing	VBG	o	O
from	IN	O	O
25.5	CD	O	O
?	.	O	O
10.2	CD	O	O
to	TO	O	O
27.4	CD	O	O
?	.	O	O
10	CD	O	O
(	(	O	O
p	NN	O	O
=	RB	O	O
0.04	CD	O	O
)	)	O	O
.	.	O	O

In	IN	O	O
conclusion	NN	O	O
,	,	O	O
inhaled	VBD	O	O
treprostinil	NN	O	O
was	VBD	O	O
associated	VBN	O	O
with	IN	O	O
improvement	NN	o	O
in	IN	o	O
exercise	NN	o	O
capacity	NN	o	O
and	CC	o	O
World	NNP	o	O
Health	NNP	o	O
Organization	NNP	o	O
functional	JJ	o	O
class	NN	o	O
when	WRB	O	O
added	VBD	O	O
to	TO	O	O
background	VB	O	O
targeted	JJ	p	O
PAH	NNP	p	O
therapy	NN	p	O
in	IN	p	O
children	NNS	p	O
and	CC	p	O
had	VBD	p	O
an	DT	O	O
acceptable	JJ	O	O
safety	NN	O	O
profile	NN	O	O
.	.	O	O

Based	VBN	O	O
on	IN	O	O
these	DT	O	O
early	JJ	O	O
data	NNS	O	O
,	,	O	O
further	JJ	O	O
study	NN	O	O
of	IN	O	O
inhaled	JJ	O	O
treprostinil	NN	i	O
appears	VBZ	i	O
warranted	VBN	p	O
in	IN	p	O
pediatric	JJ	p	O
patients	NNS	p	O
with	IN	p	O
PAH	NNP	p	O
.	.	p	O

Secretin	NNP	O	O
and	CC	O	O
autism	NN	O	O
:	:	O	O
a	DT	O	O
two-part	JJ	O	O
clinical	JJ	O	O
investigation	NN	O	O
.	.	O	O

Recent	JJ	O	O
anecdotal	JJ	O	O
reports	NNS	O	O
have	VBP	O	O
touted	VBN	O	O
the	DT	O	O
gastrointestinal	NN	O	O
(	(	O	O
GI	NNP	O	O
)	)	O	O
hormone	NN	O	O
secretin	NN	i	IPH
as	IN	O	O
a	DT	O	O
treatment	NN	O	O
modality	NN	O	O
for	IN	O	O
autism	NN	O	O
,	,	O	O
though	IN	O	O
there	EX	O	O
is	VBZ	O	O
little	JJ	O	O
clinical	JJ	O	O
evidence	NN	O	O
or	CC	O	O
literature	NN	O	O
to	TO	O	O
support	VB	O	O
its	PRP$	O	O
viability	NN	O	O
.	.	O	O

We	PRP	O	O
undertook	VBD	O	O
a	DT	O	O
two-part	JJ	O	O
clinical	JJ	O	O
trial	NN	O	O
to	TO	O	O
investigate	VB	O	O
these	DT	O	O
claims	NNS	O	O
.	.	O	O

Fifty-six	JJ	p	PSS
patients	NNS	p	O
(	(	p	O
49	CD	p	PSS
boys	NNS	p	PC
,	,	p	O
7	CD	p	PSS
girls	NNS	p	PC
,	,	p	O
mean	JJ	p	PA
age	NN	p	PA
=	VBD	p	PA
6.4	CD	p	PA
years	NNS	p	PA
,	,	p	PA
SD	NNP	p	PA
=	NNP	p	PA
2.7	CD	p	PA
)	)	p	O
enrolled	VBN	p	O
in	IN	p	O
an	DT	p	O
open-label	JJ	p	O
trial	NN	p	O
of	IN	p	O
secretin	NN	i	IPH
,	,	p	O
during	IN	p	O
which	WDT	p	O
they	PRP	p	O
received	VBD	p	O
one	CD	p	O
injection	NN	p	O
of	IN	p	O
the	DT	p	O
hormone	NN	p	O
(	(	p	O
2	CD	p	O
IU/kg	NNP	p	O
)	)	p	O
.	.	p	O

All	DT	O	O
subjects	NNS	O	O
were	VBD	O	O
evaluated	VBN	O	O
by	IN	O	O
their	PRP$	O	O
parents	NNS	O	O
at	IN	O	O
baseline	NN	O	O
and	CC	O	O
follow-up	JJ	O	O
visits	NNS	O	O
(	(	O	O
3-6	JJ	O	O
weeks	NNS	O	O
later	RB	O	O
,	,	O	O
M	NNP	O	O
=	NNP	O	O
3.7	CD	O	O
,	,	O	O
SD	NNP	O	O
=	VBZ	O	O
1.4	CD	O	O
weeks	NNS	O	O
)	)	O	O
with	IN	O	O
Childhood	NNP	o	OME
Autism	NNP	o	OME
Rating	NNP	o	OME
Scales	NNP	o	OME
(	(	o	OME
CARS	NNP	o	OME
)	)	o	OME
.	.	O	O

Thirty-four	JJ	p	PSS
patients	NNS	p	O
were	VBD	p	O
labeled	VBN	p	O
with	IN	p	O
Pervasive	NNP	p	PC
Developmental	NNP	p	PC
Disorder	NNP	p	PC
Not	RB	p	O
Otherwise	NNP	p	O
Specified	NNP	p	O
,	,	p	O
and	CC	p	O
22	CD	p	PSS
met	VBD	p	O
diagnostic	JJ	p	O
criteria	NNS	p	O
for	IN	p	O
Autistic	JJ	p	PC
Disorder	NNP	p	PC
.	.	p	O

Forty-five	JJ	p	PSS
patients	NNS	p	O
were	VBD	p	O
concurrently	RB	p	O
on	IN	p	O
other	JJ	p	O
drug	NN	p	PC
treatments	NNS	p	PC
.	.	p	O

At	IN	O	O
follow-up	NN	O	O
,	,	O	O
some	DT	O	O
reported	VBD	O	O
minimal	JJ	O	O
but	CC	O	O
potentially	RB	O	O
significant	JJ	O	O
improvements	NNS	O	O
including	VBG	O	O
changes	NNS	o	OPH
in	IN	o	OPH
GI	NNP	o	OPH
symptoms	NNS	o	OPH
,	,	o	O
expressive	JJ	o	OME
and/or	NN	o	OME
receptive	JJ	o	OME
language	NN	o	OME
function	NN	o	OME
,	,	o	OME
and	CC	o	OME
improved	JJ	o	OME
awareness	NN	o	OME
and	CC	o	OME
social	JJ	o	OME
interactions	NNS	o	OME
.	.	o	O

No	DT	O	O
adverse	JJ	o	OA
effects	NNS	o	OA
were	VBD	O	O
reported	VBN	O	O
or	CC	O	O
observed	VBN	O	O
.	.	O	O

Subsequently	NNP	O	O
,	,	O	O
17	CD	O	O
of	IN	O	O
the	DT	O	O
most	RBS	O	O
responsive	JJ	O	O
patients	NNS	O	O
from	IN	O	O
Study	NNP	O	O
1	CD	O	O
began	VBD	O	O
a	DT	O	O
double-blind	JJ	O	O
trial	NN	O	O
that	WDT	O	O
also	RB	O	O
included	VBD	O	O
8	CD	O	O
newly	RB	O	O
enrolled	VBN	O	O
patients	NNS	O	O
.	.	O	O

Patients	NNS	O	O
in	IN	O	O
this	DT	O	O
second	JJ	O	O
study	NN	O	O
were	VBD	O	O
alternatively	RB	O	O
entered	VBN	O	O
into	IN	O	O
one	CD	O	O
of	IN	O	O
two	CD	O	O
groups	NNS	O	O
and	CC	O	O
received	VBD	O	O
injections	NNS	O	O
of	IN	O	O
secretin	NN	i	O
or	CC	i	O
placebo	NN	i	IC
with	IN	O	O
crossover	NN	O	O
at	IN	O	O
4	CD	O	O
weeks	NNS	O	O
.	.	O	O

Patients	NNS	p	O
from	IN	p	O
Study	NNP	p	O
1	CD	p	O
entered	VBD	p	O
into	IN	p	O
Study	NNP	p	O
2	CD	p	O
at	IN	p	O
an	DT	p	O
average	NN	p	O
of	IN	p	O
6.5	CD	p	O
(	(	p	O
SD	NNP	p	O
=	NNP	p	O
0.8	CD	p	O
)	)	p	O
weeks	NNS	p	O
after	IN	p	O
beginning	VBG	p	O
Study	NNP	p	O
1	CD	p	O
.	.	p	O

Results	NNS	O	O
of	IN	O	O
both	DT	O	O
inquiries	NNS	O	O
indicate	VBP	O	O
that	IN	O	O
although	IN	O	O
treatment	NN	O	O
with	IN	O	O
secretin	NN	i	IPH
was	VBD	O	O
reported	VBN	O	O
to	TO	O	O
cause	VB	O	O
transient	JJ	o	OME
changes	NNS	o	OME
in	IN	o	OME
speech	NN	o	OME
and	CC	o	OME
behavior	NN	o	OME
in	IN	O	O
some	DT	O	O
children	NNS	O	O
,	,	O	O
overall	JJ	O	O
it	PRP	O	O
produced	VBD	O	O
few	JJ	O	O
clinically	RB	O	O
meaningful	JJ	O	O
changes	NNS	O	O
when	WRB	O	O
compared	VBN	O	O
to	TO	O	O
children	NNS	O	O
given	VBN	O	O
placebo	JJ	i	IC
injections	NNS	O	O
.	.	O	O

Interleukin-6	NNP	O	O
receptor	NN	O	O
inhibition	NN	O	O
with	IN	O	O
tocilizumab	NN	i	IPM
and	CC	O	O
attainment	NN	O	O
of	IN	O	O
disease	NN	O	O
remission	NN	O	O
in	IN	O	O
rheumatoid	JJ	p	PC
arthritis	NN	p	PC
:	:	p	PC
the	DT	O	O
role	NN	O	O
of	IN	O	O
acute-phase	JJ	O	O
reactants	NNS	O	O
.	.	O	O

OBJECTIVE	NN	O	O
To	TO	O	O
determine	VB	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
tocilizumab	NN	i	IPM
on	IN	O	O
rheumatoid	NN	p	PC
arthritis	NN	p	PC
(	(	p	PC
RA	NNP	p	PC
)	)	p	PC
disease	NN	o	OPH
activity	NN	o	OPH
and	CC	O	O
remission	NN	o	OPH
assessment	NN	o	OPH
,	,	O	O
using	VBG	O	O
measures	NNS	O	O
that	WDT	O	O
do	VBP	O	O
or	CC	O	O
do	VB	O	O
not	RB	O	O
comprise	VB	O	O
acute-phase	JJ	O	O
reactants	NNS	O	O
.	.	O	O

METHODS	NNP	O	O
Simplified	NNP	o	O
Disease	NNP	o	O
Activity	NNP	o	O
Index	NNP	o	O
(	(	o	O
SDAI	NNP	o	O
)	)	o	O
scores	VBZ	o	O
,	,	o	O
Clinical	JJ	o	O
Disease	NNP	o	O
Activity	NNP	o	O
Index	NNP	o	O
(	(	o	O
CDAI	NNP	o	O
)	)	o	O
scores	VBZ	o	O
,	,	o	O
and	CC	o	O
the	DT	o	O
Disease	NNP	o	O
Activity	NNP	o	O
Score	NNP	o	O
in	IN	o	O
28	CD	o	O
joints	NNS	o	O
(	(	o	O
DAS28	NNP	o	O
)	)	o	O
were	VBD	O	O
calculated	VBN	O	O
using	VBG	O	O
data	NNS	O	O
from	IN	O	O
tocilizumab	JJ	i	IPM
trials	NNS	O	O
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
RA	NNP	p	O
in	IN	p	O
whom	WP	p	O
disease	NN	p	O
had	VBD	p	O
remained	VBN	p	O
active	JJ	p	O
despite	IN	p	O
treatment	NN	p	O
with	IN	p	O
disease-modifying	JJ	i	IPM
antirheumatic	JJ	i	IPM
drugs	NNS	i	IPM
.	.	i	O

The	DT	O	O
CDAI	NNP	O	O
does	VBZ	O	O
not	RB	O	O
contain	VB	O	O
an	DT	O	O
acute-phase	JJ	O	O
reactant	NN	O	O
component	NN	O	O
.	.	O	O

Disease	NNP	o	OPH
activity	NN	o	OPH
states	NNS	o	OPH
,	,	o	OPH
including	VBG	o	OPH
remission	NN	o	OPH
,	,	O	O
were	VBD	O	O
defined	VBN	O	O
using	VBG	O	O
established	VBN	O	O
cut	NN	O	O
points	NNS	O	O
;	:	O	O
for	IN	O	O
the	DT	O	O
DAS28	NNP	O	O
,	,	O	O
an	DT	O	O
alternative	JJ	O	O
cut	NN	O	O
point	NN	O	O
of	IN	O	O
<	$	O	O
2.4	CD	O	O
was	VBD	O	O
also	RB	O	O
used	VBN	O	O
.	.	O	O

RESULTS	JJ	O	O
Changes	NNS	o	OPH
in	IN	o	OPH
the	DT	o	OPH
DAS28	NNP	o	OPH
,	,	o	O
the	DT	o	OPH
SDAI	NNP	o	OPH
score	NN	o	OPH
,	,	o	O
and	CC	o	O
the	DT	o	O
CDAI	NNP	o	OPH
score	NN	o	OPH
among	IN	O	O
patients	NNS	O	O
receiving	VBG	O	O
tocilizumab	NN	i	IPM
were	VBD	O	O
significantly	RB	O	O
higher	JJR	O	O
than	IN	O	O
those	DT	O	O
among	IN	O	O
patients	NNS	O	O
receiving	VBG	O	O
placebo	NN	i	IC
,	,	O	O
and	CC	O	O
the	DT	O	O
magnitude	NN	O	O
of	IN	O	O
these	DT	O	O
changes	NNS	O	O
was	VBD	O	O
similar	JJ	O	O
for	IN	O	O
the	DT	O	O
SDAI	NNP	o	OPH
and	CC	O	O
the	DT	O	O
CDAI	NNP	o	OPH
.	.	o	O

Among	IN	O	O
patients	NNS	O	O
who	WP	O	O
achieved	VBD	O	O
50	CD	O	O
%	NN	O	O
improvement	NN	o	OPH
in	IN	o	OPH
disease	NN	o	OPH
activity	NN	o	OPH
according	VBG	O	O
to	TO	O	O
the	DT	O	O
American	NNP	O	O
College	NNP	O	O
of	IN	O	O
Rheumatology	NNP	O	O
criteria	NNS	O	O
,	,	O	O
only	RB	O	O
?20	VBZ	O	O
%	NN	O	O
required	VBN	O	O
a	DT	O	O
reduction	NN	O	O
in	IN	O	O
acute-phase	JJ	O	O
reactant	NN	O	O
values	NNS	O	O
in	IN	O	O
order	NN	O	O
to	TO	O	O
fulfill	VB	O	O
the	DT	O	O
criteria	NNS	O	O
.	.	O	O

However	RB	o	O
,	,	o	O
DAS28	NNP	o	O
remission	NN	o	O
rates	NNS	o	O
were	VBD	o	O
higher	JJR	O	O
(	(	O	O
even	RB	O	O
when	WRB	O	O
using	VBG	O	O
the	DT	O	O
lower	JJR	O	O
cut	NN	O	O
point	NN	O	O
)	)	O	O
than	IN	O	O
the	DT	o	O
SDAI	NNP	o	O
and	CC	o	O
CDAI	NNP	o	O
remission	NN	o	O
rates	NNS	o	O
.	.	o	O

Only	RB	O	O
a	DT	O	O
minority	NN	O	O
of	IN	O	O
tocilizumab-treated	JJ	i	IPM
patients	NNS	i	O
with	IN	o	O
DAS28	NNP	o	O
remission	NN	o	O
also	RB	o	O
had	VBD	o	O
disease	NN	o	O
remission	NN	o	O
according	VBG	o	O
to	TO	O	O
the	DT	O	O
SDAI	NNP	O	O
(	(	O	O
26	CD	O	O
%	NN	O	O
)	)	O	O
or	CC	O	O
CDAI	NNP	O	O
(	(	O	O
?21	NNP	O	O
%	NN	O	O
)	)	O	O
.	.	O	O

With	IN	O	O
infliximab	JJ	i	O
treatment	NN	o	O
,	,	o	O
SDAI	NNP	o	O
and	CC	o	O
CDAI	NNP	o	O
remission	NN	o	O
rates	NNS	o	O
were	VBD	o	O
of	IN	O	O
the	DT	O	O
same	JJ	O	O
magnitude	NN	O	O
as	IN	O	O
those	DT	O	O
observed	VBN	O	O
with	IN	O	O
tocilizumab	JJ	i	O
treatment	NN	i	O
,	,	O	O
and	CC	O	O
DAS28	NNP	o	O
remission	NN	o	O
rates	NNS	o	O
were	VBD	o	O
lower	JJR	i	O
.	.	i	O

Tocilizumab-treated	JJ	i	O
patients	NNS	i	O
with	IN	O	O
DAS28	NNP	o	O
remission	NN	o	O
but	CC	o	O
without	IN	o	O
CDAI	NNP	o	O
remission	NN	o	O
had	VBD	o	O
significantly	RB	O	O
higher	JJR	o	O
swollen	JJ	o	O
joint	JJ	o	O
counts	NNS	o	O
but	CC	o	O
lower	JJR	o	O
erythrocyte	NN	o	O
sedimentation	NN	o	O
rates	NNS	o	O
(	(	o	O
ESRs	NNP	o	O
)	)	o	O
compared	VBN	o	O
with	IN	O	O
patients	NNS	O	O
with	IN	O	O
SDAI	NNP	O	O
or	CC	O	O
CDAI	NNP	O	O
remission	NN	O	O
.	.	O	O

CONCLUSION	NNP	o	O
Disease	NNP	o	O
activity	NN	o	O
in	IN	o	O
RA	NNP	O	O
is	VBZ	O	O
reduced	VBN	i	O
by	IN	i	O
tocilizumab	NN	i	IPM
treatment	NN	i	O
,	,	O	O
irrespective	NN	O	O
of	IN	O	O
the	DT	O	O
type	NN	O	O
of	IN	O	O
composite	JJ	O	O
measure	NN	O	O
used	VBN	O	O
to	TO	O	O
evaluate	VB	O	O
disease	NN	O	O
activity	NN	o	O
.	.	o	O

Remission	NN	o	O
rates	NNS	o	O
were	VBD	o	O
much	RB	O	O
higher	JJR	O	O
using	VBG	O	O
the	DT	O	O
DAS28	NNP	O	O
compared	VBN	O	O
with	IN	O	O
the	DT	O	O
SDAI	NNP	O	O
and	CC	O	O
CDAI	NNP	O	O
,	,	O	O
due	JJ	O	O
to	TO	O	O
the	DT	O	O
high	JJ	O	O
weight	NN	O	O
of	IN	O	O
the	DT	O	O
ESR	NNP	O	O
in	IN	O	O
the	DT	O	O
DAS28	NNP	O	O
and	CC	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
tocilizumab	NN	O	O
on	IN	O	O
the	DT	O	O
ESR	NNP	O	O
.	.	O	O

Using	VBG	O	O
the	DT	O	O
stringent	NN	O	O
SDAI	NNP	O	O
and	CC	O	O
CDAI	NNP	O	O
criteria	NNS	O	O
,	,	O	O
however	RB	O	O
,	,	O	O
remission	NN	O	O
rates	NNS	O	O
in	IN	O	O
patients	NNS	O	O
treated	VBN	O	O
with	IN	O	O
tocilizumab	NNS	i	O
were	VBD	i	O
in	IN	O	O
the	DT	O	O
same	JJ	O	O
range	NN	O	O
as	IN	O	O
those	DT	O	O
seen	VBN	O	O
in	IN	O	O
patients	NNS	O	O
treated	VBN	O	O
with	IN	O	O
tumor	NN	O	O
necrosis	NN	O	O
factor	NN	O	O
inhibitors	NNS	O	O
.	.	O	O

Placebo-controlled	JJ	O	O
pilot	NN	O	O
trial	NN	O	O
of	IN	O	O
mecamylamine	NN	i	IPM
for	IN	O	O
treatment	NN	O	O
of	IN	O	O
autism	NN	o	OME
spectrum	NN	o	OME
disorders	NNS	o	OME
.	.	o	O

OBJECTIVE	NNP	O	O
To	TO	O	O
explore	VB	O	O
possible	JJ	O	O
benefits	NNS	O	O
of	IN	O	O
a	DT	O	O
nicotinic	JJ	i	IPM
acetylcholine	NN	i	IPM
receptor	NN	i	IPM
(	(	i	IPM
nAChR	JJ	i	IPM
)	)	i	IPM
agent	NN	i	IPM
for	IN	O	O
autistic	JJ	o	OME
symptoms	NNS	o	OME
based	VBN	O	O
on	IN	O	O
postmortem	NN	O	O
observation	NN	O	O
of	IN	O	O
nAChR	JJ	O	O
abnormalities	NNS	O	O
(	(	O	O
deficient	JJ	O	O
?4?2	NN	O	O
nAChRs	NN	O	O
,	,	O	O
excess	JJ	O	O
?7	NNP	O	O
nAChRs	NN	O	O
)	)	O	O
in	IN	O	O
brains	NNS	p	O
of	IN	p	O
patients	NNS	p	O
with	IN	p	O
autism	NN	p	O
.	.	p	O

METHOD	NNP	i	O
Mecamylamine	NNP	i	O
,	,	i	O
because	IN	i	O
of	IN	O	O
its	PRP$	O	O
safety	NN	O	O
record	NN	O	O
in	IN	O	O
children	NNS	O	O
with	IN	O	O
other	JJ	O	O
disorders	NNS	O	O
,	,	O	O
was	VBD	O	O
chosen	VBN	O	O
for	IN	O	O
this	DT	O	O
first	JJ	O	O
exploration	NN	p	O
.	.	p	O

Twenty	NNP	p	O
children	NNS	p	O
with	IN	p	O
autism	NN	p	O
spectrum	NN	p	O
disorder	NN	p	O
age	NN	p	O
4-12	CD	p	O
years	NNS	p	O
were	VBD	p	O
randomly	RB	O	O
assigned	VBN	O	O
for	IN	O	O
14	CD	O	O
weeks	NNS	O	O
to	TO	O	O
placebo	VB	i	O
(	(	i	O
n=8	NN	i	O
)	)	O	O
or	CC	O	O
mecamylamine	NN	i	O
(	(	i	O
n=12	JJ	i	O
)	)	O	O
in	IN	O	O
ascending	VBG	O	O
fixed	JJ	O	O
doses	NNS	O	O
:	:	O	O
0.5	CD	O	O
mg/day	NN	O	O
for	IN	O	O
6	CD	O	O
weeks	NNS	O	O
,	,	O	O
2.5	CD	O	O
mg	NN	O	O
for	IN	O	O
2	CD	O	O
weeks	NNS	O	O
,	,	O	O
then	RB	O	O
5	CD	O	O
mg/day	NN	O	O
for	IN	O	O
6	CD	O	O
weeks	NNS	O	O
.	.	O	O

Improvement	NNP	O	O
was	VBD	O	O
rated	VBN	O	O
by	IN	O	O
a	DT	O	O
blinded	JJ	O	O
independent	JJ	O	O
evaluator	NN	O	O
.	.	O	O

Because	IN	O	O
of	IN	O	O
small	JJ	O	O
sample	NN	O	O
,	,	O	O
data	NNS	O	O
analysis	NN	O	O
was	VBD	O	O
descriptive	JJ	O	O
.	.	O	O

RESULTS	NNP	p	O
Eighteen	JJ	p	O
participants	NNS	p	O
(	(	p	O
10	CD	p	O
mecamylamine	NN	i	O
,	,	i	O
8	CD	i	O
placebo	NN	i	O
)	)	i	O
completed	VBD	i	O
the	DT	p	O
study	NN	p	O
.	.	p	O

All	DT	p	O
doses	NNS	O	O
were	VBD	O	O
well	RB	o	O
tolerated	VBN	o	O
;	:	o	O
the	DT	o	O
only	JJ	O	O
side	NN	O	O
effect	NN	O	O
of	IN	O	O
note	NN	O	O
was	VBD	O	O
constipation	NN	o	OA
(	(	o	O
50	CD	o	O
%	NN	O	O
compared	VBN	O	O
with	IN	O	O
25	CD	O	O
%	NN	O	O
of	IN	O	O
placebo	NN	i	O
group	NN	i	O
)	)	O	O
.	.	O	O

Three	CD	O	O
children	NNS	O	O
had	VBD	O	O
clinically	RB	o	O
nonsignificant	JJ	o	O
electrocardiographic	JJ	o	O
QT	NNP	o	O
prolongation	NN	o	O
.	.	o	O

Both	DT	o	O
groups	NNS	O	O
showed	VBD	O	O
modest	JJ	O	O
to	TO	O	O
moderate	VB	O	O
improvement	NN	O	O
,	,	O	O
but	CC	O	O
differences	NNS	O	O
between	IN	O	O
groups	NNS	O	O
were	VBD	O	O
negligible	JJ	O	O
.	.	O	O

On	IN	O	O
the	DT	O	O
primary	JJ	O	O
outcome	NN	O	O
measure	NN	O	O
,	,	O	O
the	DT	O	O
Ohio	NNP	o	OME
Autism	NNP	o	OME
Clinical	NNP	o	OME
Impressions	NNP	o	OME
Scale	NNP	o	OME
,	,	o	O
90	CD	o	O
%	NN	O	O
of	IN	O	O
the	DT	O	O
active	JJ	O	O
treatment	NN	O	O
group	NN	O	O
showed	VBD	O	O
improvement	NN	O	O
at	IN	O	O
some	DT	O	O
point	NN	O	O
(	(	O	O
but	CC	O	O
only	RB	O	O
40	CD	O	O
%	NN	O	O
sustained	VBD	O	O
it	PRP	O	O
)	)	O	O
,	,	O	O
compared	VBN	O	O
with	IN	O	O
62	CD	O	O
%	NN	O	O
on	IN	O	O
placebo	NN	i	O
.	.	i	O

Of	IN	i	O
the	DT	O	O
four	CD	O	O
in	IN	O	O
active	JJ	O	O
treatment	NN	O	O
that	WDT	O	O
sustained	VBD	O	O
improvement	NN	O	O
,	,	O	O
three	CD	O	O
had	VBD	O	O
a	DT	O	O
maximum	JJ	O	O
dose	NN	O	O
of	IN	O	O
0.13-0.15	JJ	O	O
mg/kg/day	NN	O	O
,	,	O	O
while	IN	O	O
those	DT	O	O
who	WP	O	O
regressed	VBD	O	O
had	VBD	O	O
doses	NNS	O	O
?0.18	JJ	O	O
mg/kg/day	NN	O	O
.	.	O	O

Graphed	VBN	O	O
means	NNS	O	O
suggested	VBD	O	O
better	RBR	O	O
outcome	NN	O	O
with	IN	O	O
lower	JJR	O	O
mg/kg	NN	O	O
and	CC	O	O
longer	JJR	O	O
medication	NN	O	O
duration	NN	O	O
.	.	O	O

Four	CD	O	O
parents	NNS	O	O
spontaneously	RB	O	O
reported	VBD	O	O
reduced	JJ	o	O
hyperactivity	NN	o	OME
and	CC	o	OME
irritability	NN	o	OME
and	CC	o	O
better	JJR	o	O
verbalization	NN	o	OME
and	CC	o	O
continued	JJ	i	O
mecamylamine	NN	i	O
at	IN	i	O
their	PRP$	i	O
own	JJ	O	O
expense	NN	O	O
.	.	O	O

CONCLUSION	NNP	i	O
Mecamylamine	NNP	i	O
appeared	VBD	i	O
to	TO	O	O
be	VB	O	O
safe	JJ	O	O
,	,	O	O
but	CC	O	O
not	RB	O	O
very	RB	O	O
effective	JJ	o	O
in	IN	o	O
autism	NN	o	O
.	.	o	O

The	DT	o	O
suggestion	NN	O	O
of	IN	O	O
better	JJR	O	O
results	NNS	O	O
at	IN	O	O
lower	JJR	O	O
doses	NNS	O	O
and	CC	O	O
longer	JJR	O	O
exposure	NN	O	O
warrants	NNS	O	O
consideration	NN	O	O
for	IN	O	O
future	JJ	O	O
trials	NNS	O	O
.	.	O	O

The	DT	O	O
next	JJ	O	O
step	NN	O	O
would	MD	O	O
be	VB	O	O
exploration	NN	O	O
of	IN	O	O
a	DT	O	O
more	RBR	O	O
specific	JJ	i	O
?4?2	NNP	i	O
nAChR	JJ	i	O
agonist	NN	i	O
,	,	i	O
such	JJ	i	O
as	IN	i	O
varenicline	NN	i	O
.	.	i	O

The	DT	O	O
role	NN	O	O
of	IN	O	O
ethnic	JJ	O	O
matching	VBG	O	O
between	IN	O	O
patient	NN	O	O
and	CC	O	O
provider	NN	O	O
on	IN	O	O
the	DT	O	O
effectiveness	NN	o	OOt
of	IN	O	O
brief	NN	i	IPS
alcohol	NN	i	IPS
interventions	NNS	i	IPS
with	IN	O	O
Hispanics	NNPS	p	PC
.	.	p	O

BACKGROUND	NNP	O	O
Evaluating	VBG	O	O
the	DT	O	O
effectiveness	NN	O	O
of	IN	O	O
treatments	NNS	O	O
such	JJ	O	O
as	IN	O	O
brief	JJ	O	O
alcohol	JJ	O	O
interventions	NNS	O	O
among	IN	O	O
Hispanics	NNPS	p	PC
is	VBZ	O	O
essential	JJ	O	O
to	TO	O	O
effectively	RB	O	O
addressing	VBG	O	O
their	PRP$	O	O
treatment	NN	O	O
needs	NNS	O	O
.	.	O	O

Clinicians	NNPS	O	O
of	IN	O	O
the	DT	O	O
same	JJ	O	O
ethnicity	NN	O	O
as	IN	O	O
the	DT	O	O
client	NN	O	O
may	MD	O	O
be	VB	O	O
more	RBR	O	O
likely	JJ	O	O
to	TO	O	O
understand	VB	O	O
the	DT	O	O
culture-specific	JJ	O	O
values	NNS	O	O
,	,	O	O
norms	NNS	O	O
,	,	O	O
and	CC	O	O
attitudes	NNS	O	O
and	CC	O	O
,	,	O	O
therefore	RB	O	O
,	,	O	O
the	DT	O	O
intervention	NN	O	O
may	MD	O	O
be	VB	O	O
more	RBR	O	O
effective	JJ	O	O
.	.	O	O

Thus	RB	O	O
,	,	O	O
in	IN	O	O
cases	NNS	O	O
in	IN	O	O
which	WDT	O	O
Hispanic	JJ	p	PC
patients	NNS	p	PC
were	VBD	O	O
provided	VBN	O	O
intervention	NN	O	O
by	IN	O	O
a	DT	O	O
Hispanic	JJ	O	O
clinician	NN	O	O
improved	VBD	O	O
drinking	NN	O	O
outcomes	NNS	O	O
were	VBD	O	O
expected	VBN	O	O
.	.	O	O

METHODS	NNP	O	O
Patients	NNPS	p	O
were	VBD	p	O
recruited	VBN	p	O
from	IN	p	O
an	DT	p	O
urban	JJ	p	O
Level	NN	p	O
I	PRP	p	O
Trauma	VBP	p	O
following	VBG	p	O
screening	NN	p	O
for	IN	p	O
an	DT	p	O
alcohol-related	JJ	p	PC
injury	NN	p	PC
or	CC	p	O
alcohol	NN	p	O
problems	NNS	p	O
.	.	p	O

Five	CD	p	PSS
hundred	VBD	p	PSS
thirty-seven	JJ	p	PSS
Hispanics	NNPS	p	O
were	VBD	O	O
randomly	RB	O	O
assigned	VBN	O	O
to	TO	O	O
brief	VB	i	IPS
intervention	NN	i	IPS
or	CC	i	IPM
treatment	NN	i	IC
as	IN	i	IC
usual	JJ	i	IC
.	.	i	O

Hierarchical	JJ	O	O
linear	JJ	O	O
modeling	NN	O	O
was	VBD	O	O
used	VBN	O	O
to	TO	O	O
determine	VB	O	O
the	DT	O	O
effects	NNS	o	OME
of	IN	o	OME
ethnic	JJ	o	OME
match	NN	o	OME
on	IN	o	OME
drinking	NN	o	OME
outcomes	NNS	o	OME
including	VBG	O	O
volume	NN	o	OME
per	IN	o	OME
week	NN	o	OME
,	,	o	OME
maximum	JJ	o	OME
amount	NN	o	OME
,	,	o	OME
and	CC	o	OME
frequency	NN	o	OME
of	IN	o	OME
5	CD	o	OME
or	CC	o	OME
more	JJR	o	OME
drinks	NNS	o	OME
per	IN	o	OME
occasion	NN	o	OME
.	.	o	O

Analyses	NNS	O	O
controlled	VBD	O	O
for	IN	O	O
level	NN	O	O
of	IN	O	O
acculturation	NN	O	O
and	CC	O	O
immigration	NN	O	O
status	NN	O	O
.	.	O	O

RESULTS	NNP	O	O
For	IN	O	O
Hispanics	NNPS	p	O
who	WP	O	O
received	VBD	O	O
brief	JJ	O	O
motivational	JJ	O	O
intervention	NN	O	O
,	,	O	O
an	DT	O	O
ethnic	JJ	O	O
match	NN	O	O
between	IN	O	O
patient	NN	O	O
and	CC	O	O
provider	NN	O	O
resulted	VBD	O	O
in	IN	O	O
a	DT	O	O
significant	JJ	o	OME
reduction	NN	o	OME
in	IN	o	OME
drinking	NN	o	OME
outcomes	NNS	o	OME
at	IN	O	O
12-month	JJ	O	O
follow-up	NN	O	O
.	.	O	O

In	IN	O	O
addition	NN	O	O
,	,	O	O
there	EX	O	O
was	VBD	O	O
a	DT	O	O
tendency	NN	O	O
for	IN	O	O
ethnic	JJ	O	O
match	NN	O	O
to	TO	O	O
be	VB	O	O
most	RBS	o	O
beneficial	JJ	o	OOt
to	TO	O	O
foreign-born	JJ	O	O
Hispanics	NNPS	O	O
and	CC	O	O
less	RBR	o	OOt
acculturated	JJ	O	O
Hispanics	NNPS	O	O
.	.	O	O

CONCLUSION	NNP	O	O
As	IN	O	O
hypothesized	VBN	O	O
,	,	O	O
an	DT	O	O
ethnic	JJ	O	O
match	NN	O	O
between	IN	O	O
patient	NN	O	O
and	CC	O	O
provider	NN	O	O
significantly	RB	O	O
enhanced	VBD	O	O
the	DT	O	O
effectiveness	NN	o	OOt
of	IN	o	O
brief	JJ	o	O
intervention	NN	o	O
among	IN	O	O
Hispanics	NNPS	p	O
.	.	p	O

Ethnic	JJ	O	O
concordance	NN	O	O
between	IN	O	O
patient	NN	O	O
and	CC	O	O
provider	NN	O	O
may	MD	O	O
have	VB	O	O
impacted	VBN	O	O
the	DT	O	O
effectiveness	NN	o	OOt
of	IN	O	O
the	DT	O	O
intervention	NN	O	O
through	IN	O	O
several	JJ	O	O
mechanisms	NNS	O	O
including	VBG	O	O
cultural	JJ	O	O
scripts	NNS	O	O
,	,	O	O
ethnic-specific	JJ	O	O
perceptions	NNS	O	O
pertaining	VBG	O	O
to	TO	O	O
substance	NN	O	O
abuse	NN	O	O
,	,	O	O
and	CC	O	O
ethnic-specific	JJ	O	O
preferred	JJ	O	O
channels	NNS	O	O
of	IN	O	O
communication	NN	O	O
.	.	O	O

Symptomatic	JJ	i	IPH
treatment	NN	i	IPH
versus	NN	O	O
combination	NN	i	IPM
chemotherapy	NN	i	IPM
for	IN	O	O
patients	NNS	p	O
with	IN	p	O
extensive	JJ	p	O
non-small	NN	p	O
cell	NN	p	O
lung	NN	p	O
cancer	NN	p	O
.	.	p	O

In	IN	O	O
a	DT	O	O
randomized	JJ	O	O
clinical	JJ	O	O
trial	NN	O	O
,	,	O	O
87	CD	p	PSS
patients	NNS	p	O
with	IN	p	O
inoperable	JJ	p	O
,	,	p	O
extensive	JJ	p	O
non-small	NN	p	O
cell	NN	p	O
lung	NN	p	PC
cancer	NN	p	PC
(	(	p	O
NSCLC	NNP	p	O
)	)	p	O
were	VBD	O	O
randomized	VBN	O	O
to	TO	O	O
receive	VB	O	O
either	DT	O	O
combination	NN	i	IPM
chemotherapy	NN	i	IPM
(	(	i	IPM
cisplatin	NN	i	IPM
at	IN	O	O
70	CD	O	O
mg/m2	NN	O	O
intravenously	RB	O	O
[	NNP	O	O
i.v	NN	O	O
.	.	O	O

]	VB	O	O
on	IN	O	O
day	NN	O	O
1	CD	O	O
and	CC	O	O
etoposide	VB	i	IPM
at	IN	O	O
100	CD	O	O
mg/m2	NN	O	O
i.v	NN	O	O
.	.	O	O

on	IN	O	O
day	NN	O	O
1	CD	O	O
and	CC	O	O
200	CD	O	O
mg/m2	NNS	O	O
orally	RB	O	O
on	IN	O	O
days	NNS	O	O
2	CD	O	O
and	CC	O	O
3	CD	O	O
)	)	O	O
or	CC	O	O
symptomatic	JJ	i	IPH
treatment	NN	i	IPH
.	.	i	O

No	DT	O	O
statistically	RB	O	O
significant	JJ	O	O
differences	NNS	O	O
in	IN	O	O
survival	JJ	o	OMO
time	NN	o	OMO
were	VBD	O	O
found	VBN	O	O
between	IN	O	O
the	DT	O	O
two	CD	O	O
treatment	NN	O	O
techniques	NNS	O	O
.	.	O	O

A	DT	O	O
major	JJ	O	O
problem	NN	O	O
in	IN	O	O
the	DT	O	O
interpretation	NN	O	O
of	IN	O	O
the	DT	O	O
results	NNS	O	O
was	VBD	O	O
the	DT	O	O
use	NN	O	O
of	IN	O	O
semicurative	JJ	O	O
radiation	NN	O	O
therapy	NN	O	O
(	(	O	O
3000	CD	O	O
to	TO	O	O
4200	CD	O	O
cGy	NN	O	O
)	)	O	O
to	TO	O	O
the	DT	O	O
primary	JJ	O	O
tumor	NN	O	O
and	CC	O	O
mediastinum	NN	O	O
,	,	O	O
which	WDT	O	O
was	VBD	O	O
given	VBN	O	O
with	IN	O	O
symptomatic	JJ	O	O
intent	NN	O	O
.	.	O	O

Three	CD	o	OMO
long-term	JJ	o	OMO
survivors	NNS	o	OMO
were	VBD	o	O
seen	VBN	o	O
in	IN	o	O
the	DT	o	O
latter	JJ	o	O
group	NN	o	O
.	.	o	O

Women	NNP	p	PC
's	POS	p	PC
responses	NNS	p	PC
to	TO	p	PC
information	NN	p	PC
on	IN	p	PC
mammographic	JJ	p	PC
breast	NN	p	PC
density	NN	p	PC
.	.	p	PC

The	DT	O	O
objective	NN	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
determine	VB	O	O
the	DT	O	O
negative	JJ	O	O
and	CC	O	O
positive	JJ	O	O
outcomes	NNS	O	O
of	IN	O	O
providing	VBG	O	O
mammographic	JJ	O	O
breast	NN	O	O
density	NN	O	O
(	(	O	O
MBD	NNP	O	O
)	)	O	O
information	NN	O	O
to	TO	O	O
participants	NNS	p	PC
of	IN	p	PC
a	DT	p	PC
screening	JJ	i	IPH
program	NN	i	IPH
.	.	i	O

A	DT	O	O
randomized	JJ	O	O
experiment	NN	O	O
was	VBD	O	O
conducted	VBN	O	O
with	IN	O	O
a	DT	O	O
sample	NN	p	O
of	IN	p	O
618	CD	p	O
women	NNS	p	O
50	CD	p	O
years	NNS	p	O
or	CC	p	O
older	JJR	p	O
with	IN	p	O
MBD	NNP	p	O
greater	JJR	p	O
than	IN	p	O
50	CD	p	O
%	NN	p	O
of	IN	p	O
breast	NN	p	O
volume	NN	p	O
.	.	p	O

The	DT	O	O
intervention	NN	O	O
consisted	VBD	O	O
of	IN	O	O
reporting	VBG	i	IPH
the	DT	i	IPH
presence	NN	i	IPH
of	IN	i	IPH
MBD	NNP	i	IPH
in	IN	i	IPH
the	DT	i	IPH
screening	NN	i	IPH
mammography	NN	i	IPH
results	NNS	i	IPH
letter	NN	i	IPH
that	WDT	i	IPH
was	VBD	i	IPH
sent	VBN	i	IPH
along	IN	i	IPH
with	IN	i	IPH
an	DT	i	IPH
information	NN	i	IPH
pamphlet	NN	i	IPH
.	.	i	O

Compared	VBN	O	O
to	TO	O	O
the	DT	O	O
controls	NNS	i	IC
,	,	O	O
more	JJR	O	O
women	NNS	O	O
in	IN	O	O
the	DT	O	O
intervention	NN	O	O
group	NN	O	O
described	VBD	O	O
the	DT	O	O
term	NN	O	O
breast	NN	o	OPH
density	NN	o	OPH
correctly	RB	O	O
and	CC	O	O
recognized	VBD	O	O
it	PRP	O	O
as	IN	O	O
a	DT	O	O
risk	NN	O	O
factor	NN	O	O
for	IN	O	O
breast	NN	O	O
cancer	NN	O	O
.	.	O	O

Although	IN	O	O
at	IN	O	O
the	DT	O	O
4-week	JJ	O	O
follow-up	NN	O	O
the	DT	O	O
intervention	NN	O	O
group	NN	O	O
indicated	VBD	O	O
that	IN	O	O
they	PRP	O	O
were	VBD	O	O
very	RB	O	O
likely	JJ	O	O
to	TO	O	O
have	VB	O	O
an	DT	O	O
annual	JJ	i	IPH
clinical	JJ	i	IPH
breast	NN	i	IPH
examination	NN	i	IPH
more	RBR	O	O
frequently	RB	O	O
than	IN	O	O
controls	NNS	O	O
,	,	O	O
no	DT	O	O
differences	NNS	O	O
were	VBD	O	O
detected	VBN	O	O
at	IN	O	O
6	CD	O	O
months	NNS	O	O
.	.	O	O

There	EX	O	O
were	VBD	O	O
no	DT	O	O
significant	JJ	O	O
differences	NNS	O	O
on	IN	O	O
other	JJ	O	O
behavioural	JJ	o	OME
or	CC	o	OME
psychological	JJ	o	OME
measures	NNS	o	OME
,	,	O	O
although	IN	O	O
at	IN	O	O
the	DT	O	O
4-week	JJ	O	O
follow-up	JJ	O	O
the	DT	O	O
control	NN	O	O
group	NN	O	O
perceived	VBD	O	O
their	PRP$	O	O
risk	NN	O	O
for	IN	O	O
breast	NN	O	O
cancer	NN	O	O
,	,	O	O
relative	VBP	O	O
to	TO	O	O
other	JJ	O	O
women	NNS	O	O
their	PRP$	O	O
age	NN	O	O
,	,	O	O
as	IN	O	O
a	DT	O	O
lot	NN	O	O
lower	JJR	O	O
than	IN	O	O
did	VBD	O	O
women	NNS	O	O
in	IN	O	O
the	DT	O	O
intervention	NN	O	O
group	NN	O	O
.	.	O	O

The	DT	O	O
results	NNS	O	O
demonstrate	VBP	O	O
a	DT	O	O
feasible	JJ	O	O
and	CC	O	O
non-threatening	JJ	O	O
way	NN	O	O
to	TO	O	O
provide	VB	O	O
women	NNS	O	O
with	IN	O	O
important	JJ	O	O
personalized	VBN	O	O
information	NN	O	O
about	IN	O	O
breast	NN	o	OPH
cancer	NN	o	OPH
risk	NN	o	OPH
.	.	o	O

[	RB	O	O
Perioperative	NNP	O	O
teicoplanin	NN	i	IPM
prophylaxis	NN	i	IPM
in	IN	O	O
patients	NNS	p	O
undergoing	VBG	p	O
breast	JJ	p	O
reconstruction	NN	p	O
with	IN	p	O
the	DT	p	O
abdominal	JJ	p	O
wall	NN	p	O
.	.	p	O

A	DT	O	O
case-control	NN	O	O
study	NN	O	O
]	NNP	O	O
.	.	O	O

The	DT	O	O
authors	NNS	O	O
report	VBP	O	O
the	DT	O	O
results	NNS	O	O
of	IN	O	O
a	DT	O	O
randomized	JJ	O	O
clinical	JJ	O	O
trial	NN	O	O
of	IN	O	O
antibiotic	JJ	O	O
prophylaxis	NN	O	O
of	IN	O	O
postoperative	JJ	O	O
infection	NN	O	O
following	VBG	O	O
breast	NN	p	O
reconstruction	NN	p	O
by	IN	p	O
transposition	NN	p	O
of	IN	p	O
rectus	NN	p	O
abdominis	NN	p	O
myocutaneous	JJ	p	O
flap	NN	p	O
(	(	O	O
TRAMF	NNP	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
aim	NN	O	O
was	VBD	O	O
to	TO	O	O
evaluate	VB	O	O
the	DT	O	O
efficacy	NN	O	O
and	CC	O	O
tolerability	NN	O	O
of	IN	O	O
a	DT	O	O
short-term	JJ	O	O
parenteral	JJ	i	IPM
prophylaxis	NN	i	IPM
with	IN	i	IPM
Teicoplanin	NNP	i	IPM
and	CC	O	O
the	DT	O	O
end-point	NN	O	O
of	IN	O	O
the	DT	O	O
study	NN	O	O
was	VBD	O	O
the	DT	O	O
evaluation	NN	O	O
of	IN	O	O
wound	NN	O	O
contamination	NN	O	O
assessed	VBN	O	O
by	IN	O	O
means	NNS	O	O
of	IN	O	O
microbiologic	JJ	O	O
culture	NN	O	O
of	IN	O	O
drainage	NN	O	O
fluid	NN	O	O
.	.	O	O

From	IN	p	O
October	NNP	p	O
1990	CD	p	O
to	TO	p	O
March	NNP	p	O
1992	CD	p	O
38	CD	p	O
patients	NNS	p	O
were	VBD	p	O
recruited	VBN	p	O
:	:	p	O
20	CD	p	O
patients	NNS	p	O
in	IN	p	O
the	DT	p	O
antibiotic	JJ	p	O
prophylaxis	NN	p	O
arm	NN	p	O
and	CC	p	O
18	CD	p	O
patients	NNS	p	O
in	IN	p	O
the	DT	p	O
control	NN	p	O
group	NN	p	O
.	.	p	O

Analysis	NN	O	O
of	IN	O	O
drainage	NN	O	O
fluids	NNS	O	O
showed	VBD	O	O
a	DT	O	O
higher	JJR	o	OPH
contamination	NN	o	OPH
rate	NN	o	OPH
(	(	O	O
15/18	CD	O	O
=	RB	O	O
83	CD	O	O
%	NN	O	O
)	)	O	O
in	IN	O	O
the	DT	O	O
control	NN	O	O
group	NN	O	O
as	IN	O	O
compared	VBN	O	O
to	TO	O	O
the	DT	O	O
prophylaxis	NN	O	O
arm	NN	O	O
(	(	O	O
2/20	CD	O	O
=	RB	O	O
10	CD	O	O
%	NN	O	O
)	)	O	O
(	(	O	O
p	JJ	O	O
<	NNP	O	O
0.0001	CD	O	O
)	)	O	O
.	.	O	O

Moreover	RB	O	O
,	,	O	O
11	CD	O	O
patients	NNS	O	O
in	IN	O	O
the	DT	O	O
control	NN	O	O
arm	NN	O	O
suffered	VBD	O	O
from	IN	O	O
fever	NN	o	OA
>	$	o	OA
37.5	CD	o	OA
degrees	NNS	o	OA
C	NNP	o	OA
for	IN	O	O
at	IN	O	O
least	JJS	O	O
3	CD	O	O
days	NNS	O	O
as	RB	O	O
compared	VBN	O	O
to	TO	O	O
1	CD	O	O
patient	NN	O	O
in	IN	O	O
the	DT	O	O
antibiotic	JJ	O	O
prophylaxis	NN	O	O
group	NN	O	O
;	:	O	O
the	DT	O	O
postoperative	JJ	o	OOt
stay	NN	o	OOt
was	VBD	O	O
13.3	CD	O	O
+/-	JJ	O	O
4.3	CD	O	O
and	CC	O	O
9.0	CD	O	O
+/-	JJ	O	O
1.6	CD	O	O
in	IN	O	O
the	DT	O	O
control	NN	O	O
and	CC	O	O
antibiotic	JJ	O	O
arm	NN	O	O
respectively	RB	O	O
.	.	O	O

No	NNP	O	O
antibiotic	JJ	o	OA
related	JJ	o	OA
side	NN	o	OA
effects	NNS	o	OA
were	VBD	O	O
evidenced	VBN	O	O
through	IN	O	O
the	DT	O	O
study	NN	O	O
.	.	O	O

These	DT	O	O
results	NNS	O	O
seem	VBP	O	O
to	TO	O	O
confirm	VB	O	O
the	DT	O	O
value	NN	O	O
of	IN	O	O
parenteral	JJ	O	O
short-term	JJ	O	O
antibiotic	JJ	O	O
prophylaxis	NN	O	O
of	IN	O	O
postoperative	JJ	O	O
infection	NN	O	O
in	IN	O	O
such	JJ	O	O
kind	NN	O	O
of	IN	O	O
clean	JJ	O	O
operative	JJ	O	O
procedure	NN	O	O
.	.	O	O

Continuous	JJ	O	O
and	CC	O	O
cyclical	JJ	i	IPM
clodronate	NN	i	IPM
therapies	NNS	i	IPM
and	CC	O	O
bone	NN	O	O
density	NN	O	O
in	IN	O	O
postmenopausal	JJ	p	PC
bone	NN	p	PC
loss	NN	p	PC
.	.	p	O

OBJECTIVE	UH	O	O
To	TO	O	O
evaluate	VB	O	O
the	DT	O	O
effectiveness	NN	O	O
of	IN	O	O
different	JJ	O	O
clodronate	NN	i	IPM
regimens	NNS	O	O
in	IN	O	O
postmenopausal	JJ	p	PC
osteoporosis	NN	p	PC
.	.	p	O

METHODS	NNP	O	O
In	IN	O	O
groups	NNS	p	O
of	IN	p	O
20	CD	p	PSS
,	,	p	O
60	CD	p	PSS
women	NNS	p	PSE
were	VBD	O	O
randomly	RB	O	O
assigned	VBN	O	O
to	TO	O	O
one	CD	O	O
of	IN	O	O
three	CD	O	O
treatments	NNS	O	O
:	:	O	O
oral	JJ	i	IPM
calcium	NN	i	IPM
,	,	i	IPM
1000	CD	i	IPM
mg/day	NN	i	IPM
;	:	i	IPM
oral	JJ	i	IPM
calcium	NN	i	IPM
plus	CC	i	IPM
oral	JJ	i	IPM
clodronate	NN	i	IPM
,	,	i	IPM
400	CD	i	IPM
mg/day	NN	i	IPM
;	:	i	IPM
oral	JJ	i	IPM
calcium	NN	i	IPM
plus	CC	i	IPM
oral	JJ	i	IPM
clodronate	NN	i	IPM
,	,	i	IPM
400	CD	i	IPM
mg/day	NN	i	IPM
for	IN	i	IPM
30	CD	i	IPM
days	NNS	i	IPM
,	,	i	IPM
followed	VBN	i	IPM
by	IN	i	IPM
a	DT	i	IPM
60-day	JJ	i	IPM
period	NN	i	IPM
of	IN	i	IPM
calcium	JJ	i	IPM
supplement	NN	i	IPM
alone	RB	i	IPM
.	.	i	IPM

This	DT	O	O
last	JJ	O	O
regimen	NN	O	O
was	VBD	O	O
repeated	VBN	O	O
four	CD	O	O
times	NNS	O	O
in	IN	O	O
the	DT	O	O
12-month	JJ	O	O
study	NN	O	O
period	NN	O	O
.	.	O	O

RESULTS	JJ	O	O
Patients	NNPS	p	O
who	WP	p	O
received	VBD	p	PC
calcium	NN	i	IPM
alone	RB	i	IPM
showed	VBD	O	O
a	DT	O	O
decline	NN	O	O
in	IN	O	O
spinal	JJ	o	OPH
bone	NN	o	OPH
mass	NN	o	OPH
,	,	O	O
both	DT	O	O
after	IN	O	O
6	CD	O	O
and	CC	O	O
12	CD	O	O
months	NNS	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
.03	NNP	O	O
and	CC	O	O
P	NNP	O	O
<	NNP	O	O
.005	NNP	O	O
,	,	O	O
respectively	RB	O	O
)	)	O	O
;	:	O	O
femoral	JJ	O	O
density	NN	O	O
in	IN	O	O
this	DT	O	O
group	NN	O	O
also	RB	O	O
decreased	VBD	O	O
after	IN	O	O
6	CD	O	O
and	CC	O	O
12	CD	O	O
months	NNS	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
.002	NNP	O	O
and	CC	O	O
P	NNP	O	O
<	NNP	O	O
.05	NNP	O	O
,	,	O	O
respectively	RB	O	O
)	)	O	O
.	.	O	O

On	IN	O	O
the	DT	O	O
other	JJ	O	O
hand	NN	O	O
,	,	O	O
both	DT	O	O
clodronate-treated	JJ	i	IPM
groups	NNS	O	O
had	VBD	O	O
increased	VBN	O	O
levels	NNS	O	O
of	IN	O	O
lumbar	NN	O	O
bone	NN	O	O
mass	NN	O	O
compared	VBN	O	O
with	IN	O	O
controls	NNS	O	O
,	,	O	O
both	DT	O	O
after	IN	O	O
6	CD	O	O
and	CC	O	O
12	CD	O	O
months	NNS	O	O
of	IN	O	O
therapy	NN	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
at	IN	O	O
the	DT	O	O
end	NN	O	O
of	IN	O	O
the	DT	O	O
study	NN	O	O
,	,	O	O
patients	NNS	O	O
treated	VBD	O	O
with	IN	O	O
cyclical	JJ	i	IPM
clodronate	NN	i	IPM
had	VBD	O	O
higher	JJR	O	O
spinal	JJ	o	OPH
bone	NN	o	OPH
mass	NN	o	OPH
compared	VBN	O	O
with	IN	O	O
those	DT	O	O
treated	VBN	O	O
continuously	RB	O	O
(	(	O	O
3.32	CD	O	O
+/-	JJ	O	O
0.71	CD	O	O
versus	NN	O	O
0.43	CD	O	O
+/-	JJ	O	O
0.89	CD	O	O
%	NN	O	O
,	,	O	O
P	NNP	O	O
<	NNP	O	O
.02	NNP	O	O
)	)	O	O
.	.	O	O

After	IN	O	O
6	CD	O	O
months	NNS	O	O
,	,	O	O
femoral	JJ	o	OPH
bone	NN	o	OPH
density	NN	o	OPH
was	VBD	O	O
significantly	RB	O	O
higher	JJR	O	O
both	DT	O	O
in	IN	O	O
subjects	NNS	O	O
treated	VBN	O	O
with	IN	O	O
clodronate	NN	O	O
,	,	O	O
both	DT	O	O
cyclically	RB	O	O
and	CC	O	O
continuously	RB	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
.01	NNP	O	O
)	)	O	O
,	,	O	O
compared	VBN	O	O
with	IN	O	O
controls	NNS	O	O
.	.	O	O

Continuous	JJ	i	IPM
clodronate	NN	i	IPM
treatment	NN	i	IPM
resulted	VBD	O	O
in	IN	O	O
a	DT	O	O
clear	JJ	O	O
fall	NN	O	O
in	IN	O	O
biochemical	JJ	O	O
indices	NNS	O	O
of	IN	O	O
bone	NN	o	OPH
resorption	NN	o	OPH
,	,	O	O
together	RB	O	O
with	IN	O	O
a	DT	O	O
consequent	JJ	O	O
decrease	NN	O	O
in	IN	O	O
osteocalcin	NN	O	O
at	IN	O	O
6	CD	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
.02	NNP	O	O
)	)	O	O
and	CC	O	O
12	CD	O	O
months	NNS	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
.003	NNP	O	O
)	)	O	O
and	CC	O	O
a	DT	O	O
significant	JJ	O	O
increase	NN	O	O
in	IN	O	O
parathyroid	JJ	o	OPH
hormone	NN	o	OPH
after	IN	O	O
12	CD	O	O
months	NNS	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
.001	NNP	O	O
)	)	O	O
of	IN	O	O
therapy	NN	O	O
.	.	O	O

CONCLUSION	NNP	O	O
One-year	JJ	O	O
treatment	NN	O	O
with	IN	O	O
clodronate	NN	i	IPM
induces	NNS	O	O
a	DT	O	O
gain	NN	O	O
in	IN	O	O
bone	NN	O	O
mass	NN	O	O
,	,	O	O
especially	RB	O	O
in	IN	O	O
the	DT	O	O
spine	NN	O	O
.	.	O	O

The	DT	O	O
continuous	JJ	O	O
regimen	NN	O	O
does	VBZ	O	O
not	RB	O	O
result	VB	O	O
in	IN	O	O
any	DT	O	O
further	JJ	O	O
benefit	NN	O	O
in	IN	O	O
lumbar	NN	O	O
bone	NN	O	O
density	NN	O	O
over	IN	O	O
the	DT	O	O
cyclical	JJ	O	O
one	CD	O	O
,	,	O	O
probably	RB	O	O
because	IN	O	O
of	IN	O	O
a	DT	O	O
greater	JJR	O	O
suppression	NN	O	O
of	IN	O	O
bone	NN	O	O
turnover	NN	O	O
.	.	O	O

A	DT	O	O
comparison	NN	O	O
of	IN	O	O
once	RB	O	O
and	CC	O	O
twice	RB	O	O
daily	JJ	O	O
atenolol	NN	i	IPM
for	IN	O	O
angina	JJ	p	O
pectoris	NN	p	O
.	.	p	O

We	PRP	O	O
have	VBP	O	O
studied	VBN	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
four	CD	O	O
doses	NNS	O	O
of	IN	O	O
atenolol	NN	i	IPM
in	IN	O	O
11	CD	p	O
patients	NNS	p	O
with	IN	p	O
stable	JJ	p	O
angina	NNS	p	O
pectoris	VBP	p	O
using	VBG	O	O
a	DT	O	O
symptom-limited	JJ	O	O
exercise	NN	O	O
test	NN	O	O
and	CC	O	O
angina	NN	O	O
diaries	NNS	O	O
.	.	O	O

The	DT	O	O
doses	NNS	O	O
100	CD	O	O
mg	JJ	O	O
twice	RB	O	O
daily	RB	O	O
and	CC	O	O
50	CD	O	O
mg	NN	O	O
,	,	O	O
100	CD	O	O
mg	NN	O	O
and	CC	O	O
200	CD	O	O
mg	NN	O	O
once	RB	O	O
daily	JJ	O	O
were	VBD	O	O
given	VBN	O	O
double-blind	NNS	O	O
and	CC	O	O
randomised	VBD	O	O
within	IN	O	O
patients	NNS	O	O
following	VBG	O	O
run-in	NN	O	O
on	IN	O	O
placebo	NN	i	IC
.	.	i	O

Measurements	NNS	O	O
were	VBD	O	O
made	VBN	O	O
12	CD	O	O
hours	NNS	O	O
after	IN	O	O
the	DT	O	O
last	JJ	O	O
twice	JJ	O	O
daily	RB	O	O
dose	JJ	O	O
and	CC	O	O
24	CD	O	O
hours	NNS	O	O
after	IN	O	O
the	DT	O	O
last	JJ	O	O
once	JJ	O	O
daily	JJ	O	O
dose	NN	O	O
.	.	O	O

Exercise	NN	o	OPH
tolerance	NN	o	OPH
was	VBD	O	O
improved	VBN	O	O
by	IN	O	O
40-74	JJ	O	O
%	NN	O	O
and	CC	O	O
exercise	NN	o	OPH
duration	NN	o	OPH
before	IN	o	OPH
the	DT	o	OPH
onset	NN	o	OPH
of	IN	o	OPH
angina	NN	o	OPH
by	IN	O	O
61-94	JJ	O	O
%	NN	O	O
(	(	O	O
P	NNP	O	O
less	JJR	O	O
than	IN	O	O
0.01	CD	O	O
)	)	O	O
.	.	O	O

Maximal	JJ	o	OPH
heart	NN	o	OPH
rate	NN	o	OPH
was	VBD	O	O
reduced	VBN	O	O
further	RB	O	O
by	IN	O	O
a	DT	O	O
total	JJ	O	O
daily	JJ	O	O
dose	NN	O	O
of	IN	O	O
200	CD	O	O
mg	NNS	O	O
than	IN	O	O
by	IN	O	O
lower	JJR	O	O
doses	NNS	O	O
,	,	O	O
but	CC	O	O
no	DT	O	O
extra	JJ	O	O
benefit	NN	O	O
was	VBD	O	O
derived	VBN	O	O
by	IN	O	O
giving	VBG	O	O
the	DT	O	O
drug	NN	O	O
twice	RB	O	O
daily	RB	O	O
.	.	O	O

The	DT	O	O
largest	JJS	O	O
increase	NN	O	O
in	IN	O	O
exercise	NN	o	OPH
tolerance	NN	o	OPH
was	VBD	O	O
obtained	VBN	O	O
during	IN	O	O
treatment	NN	O	O
with	IN	O	O
50	CD	O	O
mg	NNS	O	O
once	RB	O	O
daily	RB	O	O
.	.	O	O

Atenolol	NNP	i	IPM
was	VBD	O	O
shown	VBN	O	O
to	TO	O	O
be	VB	O	O
an	DT	O	O
effective	JJ	O	O
anti-anginal	JJ	O	O
agent	NN	O	O
when	WRB	O	O
given	VBN	O	O
once	RB	O	O
daily	JJ	O	O
,	,	O	O
and	CC	O	O
there	EX	O	O
were	VBD	O	O
no	DT	O	O
major	JJ	O	O
differences	NNS	O	O
between	IN	O	O
the	DT	O	O
doses	NNS	O	O
studied	VBN	O	O
.	.	O	O

Effect	NN	O	O
of	IN	O	O
acute	NN	i	IPH
exercise	NN	i	IPH
on	IN	O	O
executive	NN	o	OME
function	NN	o	OME
in	IN	O	O
children	NNS	p	PA
with	IN	p	O
attention	NN	p	PC
deficit	NN	p	PC
hyperactivity	NN	p	PC
disorder	NN	p	PC
.	.	p	O

This	DT	O	O
study	NN	O	O
was	VBD	O	O
conducted	VBN	O	O
to	TO	O	O
determine	VB	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
acute	NN	i	IPH
aerobic	JJ	i	IPH
exercise	NN	i	IPH
on	IN	O	O
executive	NN	o	OME
function	NN	o	OME
in	IN	O	O
children	NNS	p	PA
with	IN	p	O
attention	NN	p	PC
deficit	NN	p	PC
hyperactivity	NN	p	PC
disorder	NN	p	PC
(	(	p	O
ADHD	NNP	p	PC
)	)	p	O
.	.	p	O

Forty	NNP	p	PSS
children	NNS	p	PA
with	IN	p	O
ADHD	NNP	p	PC
were	VBD	O	O
randomly	RB	O	O
assigned	VBN	O	O
into	IN	O	O
exercise	NN	O	O
or	CC	O	O
control	NN	O	O
groups	NNS	O	O
.	.	O	O

Participants	NNS	O	O
in	IN	O	O
the	DT	O	O
exercise	NN	O	O
group	NN	O	O
performed	VBD	O	O
a	DT	O	O
moderate	JJ	i	IPH
intensity	NN	i	IPH
aerobic	JJ	i	IPH
exercise	NN	i	IPH
for	IN	i	IPH
30	CD	i	IPH
min	NN	i	IPH
,	,	O	O
whereas	IN	O	O
the	DT	O	O
control	NN	O	O
group	NN	O	O
watched	VBD	O	O
a	DT	O	O
running/exercise-related	JJ	i	IOt
video	NN	i	IOt
.	.	i	IOt

Neuropsychological	JJ	o	OOt
tasks	NNS	o	OOt
,	,	o	OOt
the	DT	o	OOt
Stroop	NNP	o	OOt
Test	NNP	o	OOt
and	CC	o	OOt
the	DT	o	OOt
Wisconsin	NNP	o	OOt
Card	NNP	o	OOt
Sorting	NNP	o	OOt
Test	NNP	o	OOt
(	(	o	OOt
WCST	NNP	o	OOt
)	)	o	OOt
,	,	O	O
were	VBD	O	O
assessed	VBN	O	O
before	IN	O	O
and	CC	O	O
after	IN	O	O
each	DT	O	O
treatment	NN	O	O
.	.	O	O

The	DT	O	O
results	NNS	O	O
indicated	VBD	O	O
that	IN	O	O
acute	JJ	O	O
exercise	NN	O	O
facilitated	VBN	O	O
performance	NN	O	O
in	IN	O	O
the	DT	O	O
Stroop	NNP	O	O
Test	NNP	O	O
,	,	O	O
particularly	RB	O	O
in	IN	O	O
the	DT	O	O
Stroop	NNP	o	OOt
Color-Word	NNP	o	OOt
condition	NN	o	OOt
.	.	o	OOt

Additionally	RB	O	O
,	,	O	O
children	NNS	O	O
in	IN	O	O
the	DT	O	O
exercise	NN	O	O
group	NN	O	O
demonstrated	VBD	O	O
improvement	NN	O	O
in	IN	O	O
specific	JJ	O	O
WCST	NNP	o	OME
performances	NNS	o	OME
in	IN	O	O
Non-perseverative	JJ	o	OME
Errors	NNS	o	OME
and	CC	o	OME
Categories	NNP	o	OME
Completed	NNP	o	OME
,	,	O	O
whereas	VBZ	O	O
no	DT	O	O
influences	NNS	O	O
were	VBD	O	O
found	VBN	O	O
in	IN	O	O
those	DT	O	O
performances	NNS	O	O
in	IN	O	O
the	DT	O	O
control	NN	O	O
group	NN	O	O
.	.	O	O

Tentative	JJ	O	O
explanations	NNS	O	O
for	IN	O	O
the	DT	O	O
exercise	NN	O	O
effect	NN	O	O
postulate	NN	O	O
that	WDT	O	O
exercise	NN	O	O
allocates	VBZ	O	O
attention	NN	o	O
resources	NNS	O	O
,	,	O	O
influences	VBZ	O	O
the	DT	O	O
dorsolateral	JJ	o	O
prefrontal	NN	o	O
cortex	NN	o	O
,	,	O	O
and	CC	O	O
is	VBZ	O	O
implicated	VBN	O	O
in	IN	O	O
exercise-induced	JJ	o	O
dopamine	NN	o	O
release	NN	o	O
.	.	o	O

These	DT	O	O
findings	NNS	O	O
are	VBP	O	O
promising	VBG	O	O
and	CC	O	O
additional	JJ	O	O
investigations	NNS	O	O
to	TO	O	O
explore	VB	O	O
the	DT	O	O
efficacy	NN	o	OOt
of	IN	i	O
exercise	NN	i	IPH
on	IN	O	O
executive	NN	O	O
function	NN	O	O
in	IN	O	O
children	NNS	O	O
with	IN	O	O
ADHD	NNP	O	O
are	VBP	O	O
encouraged	VBN	O	O
.	.	O	O

Speech	NN	i	IE
following	VBG	i	IE
sign	JJ	i	IE
language	NN	i	IE
training	NN	i	IE
in	IN	O	O
autistic	JJ	p	PC
children	NNS	p	PA
with	IN	p	O
minimal	JJ	p	O
verbal	JJ	p	O
language	NN	p	O
.	.	p	O

This	DT	O	O
study	NN	O	O
was	VBD	O	O
carried	VBN	O	O
out	IN	O	O
to	TO	O	O
test	VB	O	O
the	DT	O	O
main	JJ	o	OME
and	CC	o	OME
interaction	JJ	o	OME
effects	NNS	o	OME
of	IN	O	O
training	VBG	O	O
condition	NN	O	O
and	CC	O	O
pretreatment-elicited	JJ	O	O
verbal	JJ	O	O
imitation	NN	O	O
ability	NN	O	O
when	WRB	O	O
predicting	VBG	O	O
spoken	JJ	O	O
language	NN	O	O
use	NN	O	O
during	IN	O	O
language	NN	i	IE
training	NN	i	IE
of	IN	O	O
60	CD	p	PSS
minimally	RB	p	PC
verbal	JJ	p	PC
autistic	JJ	p	PC
children	NNS	p	PC
.	.	p	O

Subjects	NNS	O	O
were	VBD	O	O
randomly	RB	O	O
assigned	VBN	O	O
to	TO	O	O
Speech	NNP	o	OME
Alone	NNP	o	OME
,	,	o	O
Sign	NNP	o	OME
Alone	NNP	o	OME
,	,	o	O
Simultaneous	NNP	o	OME
Presentation	NNP	o	OME
of	IN	o	OME
Sign	NNP	o	OME
and	CC	o	O
Speech	NNP	o	OME
,	,	o	O
and	CC	o	O
Alternating	NNP	o	OME
Presentation	NNP	o	OME
of	IN	o	OME
Sign	NNP	o	OME
and	CC	o	OME
Speech	NNP	o	OME
training	NN	o	OME
conditions	NNS	o	OME
.	.	o	O

Speech	NNP	o	OME
Alone	RB	o	OME
,	,	o	O
Simultaneous	JJ	o	OME
Presentation	NNP	o	OME
,	,	o	O
and	CC	o	O
Alternating	NNP	o	OME
Presentation	NNP	o	OME
condition	NN	o	OME
facilitated	VBD	O	O
more	RBR	O	O
child-initiated	JJ	O	O
speech	NN	O	O
during	IN	O	O
treatment	NN	O	O
than	IN	O	O
did	VBD	O	O
the	DT	O	O
Sign	NNP	i	IE
Alone	NNP	i	IE
condition	NN	O	O
.	.	O	O

Regardless	NNP	O	O
of	IN	O	O
training	VBG	O	O
condition	NN	O	O
,	,	O	O
pretreatment	NN	O	O
verbal	JJ	O	O
imitation	NN	O	O
ability	NN	O	O
positively	RB	O	O
predicted	VBD	O	O
the	DT	O	O
size	NN	o	OME
of	IN	o	OME
child-initiated	JJ	o	OME
spoken	JJ	o	OME
vocabulary	JJ	o	OME
observed	VBD	O	O
during	IN	O	O
training	NN	O	O
.	.	O	O

Exploratory	JJ	O	O
analyses	NNS	O	O
indicated	VBD	O	O
that	IN	O	O
,	,	O	O
in	IN	O	O
addition	NN	O	O
to	TO	O	O
verbal	JJ	O	O
imitation	NN	O	O
,	,	O	O
pretreatment	JJ	O	O
age	NN	O	O
and	CC	O	O
IQ	NNP	O	O
may	MD	O	O
also	RB	O	O
predict	VB	O	O
spoken	JJ	O	O
language	NN	O	O
developed	VBD	O	O
during	IN	O	O
training	NN	O	O
.	.	O	O

Effect	NN	O	O
of	IN	O	O
extradural	JJ	i	IPM
analgesia	NN	i	IPM
on	IN	O	O
stress	NN	o	OPH
responses	NNS	o	OPH
to	TO	O	O
abdominal	JJ	O	O
surgery	NN	O	O
in	IN	O	O
infants	NNS	p	O
.	.	p	O

We	PRP	O	O
studied	VBD	O	O
40	CD	p	O
children	NNS	p	O
younger	JJR	p	O
than	IN	p	O
4	CD	p	O
yr	NNS	p	O
having	VBG	p	O
elective	JJ	p	O
abdominal	JJ	p	O
surgery	NN	p	O
under	IN	p	O
general	JJ	i	IPM
anaesthesia	NN	i	IPM
supplemented	VBN	p	O
with	IN	p	O
either	DT	p	O
systemic	JJ	i	IPM
opioids	NNS	i	IPM
or	CC	i	IPM
extradural	JJ	i	IPM
bupivacaine	NN	i	IPM
.	.	i	IPM

Venous	JJ	o	OPH
blood	NN	o	OPH
samples	NNS	o	OPH
were	VBD	O	O
obtained	VBN	O	O
before	IN	O	O
tracheal	JJ	O	O
intubation	NN	O	O
to	TO	O	O
measure	VB	O	O
baseline	JJ	O	O
concentrations	NNS	o	OPH
of	IN	o	OPH
adrenaline	NN	o	OPH
,	,	o	OPH
noradrenaline	NN	o	OPH
,	,	o	OPH
glucose	NN	o	OPH
,	,	o	OPH
ACTH	NNP	o	OPH
and	CC	o	OPH
cortisol	NN	o	OPH
.	.	o	OPH

Additional	JJ	O	O
samples	NNS	O	O
were	VBD	O	O
obtained	VBN	O	O
45	CD	O	O
min	NNS	O	O
after	IN	O	O
the	DT	O	O
start	NN	O	O
of	IN	O	O
surgery	NN	O	O
,	,	O	O
at	IN	O	O
the	DT	O	O
end	NN	O	O
of	IN	O	O
surgery	NN	O	O
,	,	O	O
1	CD	O	O
h	NN	O	O
and	CC	O	O
24	CD	O	O
h	NN	O	O
after	IN	O	O
the	DT	O	O
end	NN	O	O
of	IN	O	O
surgery	NN	O	O
.	.	O	O

Plasma	NNP	o	OOt
concentrations	NNS	o	OOt
of	IN	o	OOt
bupivacaine	NN	o	OOt
were	VBD	O	O
measured	VBN	O	O
also	RB	O	O
in	IN	O	O
the	DT	O	O
extradural	JJ	O	O
group	NN	O	O
at	IN	O	O
each	DT	O	O
sampling	VBG	O	O
time	NN	O	O
.	.	O	O

Both	DT	O	O
techniques	NNS	O	O
provided	VBN	O	O
acceptable	JJ	O	O
analgesia	NN	O	O
,	,	O	O
but	CC	O	O
the	DT	O	O
perioperative	JJ	o	OPH
increases	NNS	o	OPH
in	IN	o	OPH
adrenaline	NN	o	OPH
,	,	o	OPH
glucose	NN	o	OPH
and	CC	o	OPH
ACTH	NNP	o	OPH
were	VBD	O	O
significantly	RB	O	O
greater	JJR	O	O
in	IN	O	O
the	DT	O	O
opioid	JJ	O	O
group	NN	O	O
.	.	O	O

Noradrenaline	NNP	o	OPH
concentrations	NNS	o	OPH
decreased	VBD	O	O
to	TO	O	O
less	JJR	O	O
than	IN	O	O
baseline	NN	O	O
values	NNS	O	O
in	IN	O	O
the	DT	O	O
extradural	JJ	O	O
group	NN	O	O
and	CC	O	O
were	VBD	O	O
significantly	RB	O	O
less	JJR	O	O
than	IN	O	O
in	IN	O	O
the	DT	O	O
opioid	JJ	O	O
group	NN	O	O
.	.	O	O

The	DT	O	O
perioperative	JJ	o	OPH
increase	NN	o	OPH
in	IN	o	OPH
cortisol	NN	o	OPH
was	VBD	O	O
similar	JJ	O	O
in	IN	O	O
the	DT	O	O
two	CD	O	O
groups	NNS	O	O
,	,	O	O
despite	IN	O	O
the	DT	O	O
differences	NNS	O	O
in	IN	O	O
ACTH	NNP	O	O
responses	NNS	O	O
.	.	O	O

Most	JJS	O	O
responses	NNS	O	O
returned	VBN	O	O
to	TO	O	O
the	DT	O	O
baseline	NN	O	O
values	NNS	O	O
within	IN	O	O
24	CD	O	O
h.	NN	O	O
Plasma	NNP	o	OPH
bupivacaine	NN	o	OPH
concentrations	NNS	o	OPH
remained	VBD	O	O
within	IN	O	O
safe	JJ	O	O
limits	NNS	O	O
during	IN	O	O
the	DT	O	O
study	NN	O	O
,	,	O	O
but	CC	O	O
systemic	JJ	o	OPH
concentrations	NNS	o	OPH
increased	VBD	O	O
in	IN	O	O
some	DT	O	O
of	IN	O	O
the	DT	O	O
patients	NNS	O	O
during	IN	O	O
postoperative	JJ	O	O
infusion	NN	O	O
with	IN	O	O
0.125	CD	O	O
%	NN	O	O
bupivacaine	NN	O	O
.	.	O	O

Improved	VBN	O	O
acidosis	NN	O	O
correction	NN	O	O
and	CC	O	O
recovery	NN	O	O
of	IN	O	O
mesothelial	JJ	O	O
cell	NN	O	O
mass	NN	O	O
with	IN	O	O
neutral-pH	JJ	i	IPM
bicarbonate	JJ	i	IPM
dialysis	NN	i	IPM
solution	NN	i	IPM
among	IN	O	O
children	NNS	p	PA
undergoing	VBG	p	O
automated	VBN	i	IPH
peritoneal	JJ	i	IPH
dialysis	NN	i	IPH
.	.	i	O

Acid-base	JJ	O	O
balance	NN	O	O
and	CC	O	O
peritoneal	JJ	O	O
membrane	NN	O	O
longevity	NN	O	O
are	VBP	O	O
of	IN	O	O
utmost	JJ	O	O
relevance	NN	O	O
for	IN	O	O
pediatric	JJ	p	PA
patients	NNS	p	O
undergoing	VBG	p	O
peritoneal	JJ	i	IPH
dialysis	NN	i	IPH
(	(	i	IPH
PD	NNP	i	IPH
)	)	i	IPH
.	.	i	O

PD	NNP	O	O
fluids	NNS	O	O
with	IN	O	O
neutral	JJ	O	O
pH	NN	O	O
and	CC	O	O
reduced	VBD	O	O
glucose	JJ	O	O
degradation	NN	O	O
product	NN	O	O
contents	NNS	O	O
are	VBP	O	O
considered	VBN	O	O
more	RBR	O	O
biocompatible	JJ	O	O
,	,	O	O
because	IN	O	O
they	PRP	O	O
preserve	VBP	O	O
peritoneal	JJ	O	O
cell	NN	O	O
functions	NNS	O	O
in	IN	O	O
vitro	NN	O	O
.	.	O	O

To	TO	O	O
investigate	VB	O	O
the	DT	O	O
clinical	JJ	O	O
effects	NNS	o	OOt
of	IN	O	O
a	DT	O	O
novel	JJ	i	IPM
PD	NNP	i	IPM
fluid	NN	i	IPM
buffered	VBD	i	IPM
with	IN	i	IPM
34	CD	i	IPM
mM	NNS	i	IPM
pure	JJ	i	IPM
bicarbonate	NN	i	IPM
at	IN	i	IPM
neutral	JJ	i	IPM
pH	NN	i	IPM
,	,	O	O
a	DT	O	O
randomized	VBN	O	O
,	,	O	O
prospective	JJ	O	O
,	,	O	O
crossover	JJ	O	O
comparison	NN	O	O
with	IN	O	O
conventional	JJ	i	IPM
,	,	i	IPM
acidic	JJ	i	IPM
,	,	i	IPM
35	CD	i	IPM
mM	NN	i	IPM
lactate	NN	i	IPM
PD	NNP	i	IPM
fluid	NN	i	IPM
was	VBD	O	O
performed	VBN	O	O
for	IN	O	O
two	CD	O	O
consecutive	JJ	O	O
12-wk	JJ	O	O
periods	NNS	O	O
with	IN	O	O
28	CD	p	PSS
children	NNS	p	PA
(	(	p	O
age	NN	p	O
,	,	p	O
6	CD	p	PA
mo	NN	p	PA
to	TO	p	PA
15	CD	p	PA
yr	NN	p	PA
)	)	p	O
undergoing	NN	p	O
automated	VBN	i	IPH
PD	NNP	i	IPH
(	(	i	IPH
APD	NNP	i	IPH
)	)	i	IPH
.	.	i	O

Blood	NNP	o	OPH
bicarbonate	NN	o	OPH
levels	NNS	o	OPH
and	CC	o	O
arterial	JJ	o	OPH
pH	NN	o	OPH
were	VBD	O	O
significantly	RB	O	O
higher	JJR	o	OME
after	IN	O	O
3	CD	O	O
mo	NN	O	O
of	IN	O	O
bicarbonate	NN	o	OPH
PD	NNP	o	OPH
(	(	O	O
24.6	CD	O	O
+/-	JJ	O	O
2.3	CD	O	O
mM	NN	O	O
and	CC	O	O
7.43	CD	O	O
+/-	JJ	O	O
0.06	CD	O	O
,	,	O	O
respectively	RB	O	O
)	)	O	O
,	,	O	O
compared	VBN	O	O
with	IN	O	O
lactate	JJ	o	OPH
PD	NNP	o	OPH
(	(	O	O
22.8	CD	O	O
+/-	JJ	O	O
3.9	CD	O	O
mM	NN	O	O
and	CC	O	O
7.38	CD	O	O
+/-	JJ	O	O
0.05	CD	O	O
,	,	O	O
respectively	RB	O	O
;	:	O	O
P	NNP	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

This	DT	O	O
effect	NN	O	O
was	VBD	O	O
reversible	JJ	O	O
among	IN	O	O
patients	NNS	O	O
who	WP	O	O
returned	VBD	O	O
from	IN	O	O
bicarbonate	NN	O	O
to	TO	O	O
lactate	VB	O	O
fluid	NN	O	O
.	.	O	O

Low	JJ	O	O
initial	JJ	o	OPH
pH	NN	o	OPH
and	CC	O	O
young	JJ	O	O
patient	NN	O	O
age	NN	O	O
independently	RB	O	O
predicted	VBD	O	O
increased	VBN	O	O
blood	NN	o	OPH
pH	NN	o	OPH
during	IN	O	O
bicarbonate	NN	o	OPH
APD	NNP	o	OPH
.	.	o	O

Peritoneal	NNP	O	O
equilibration	NN	O	O
tests	NNS	O	O
revealed	VBD	O	O
subtle	JJ	o	OPH
changes	NNS	o	OPH
in	IN	o	OPH
solute	NN	o	OPH
transport	NN	o	OPH
,	,	O	O
with	IN	O	O
a	DT	O	O
less	RBR	o	OPH
steep	JJ	o	OPH
creatinine	NN	o	OPH
equilibration	NN	o	OPH
curve	NN	o	OPH
during	IN	O	O
bicarbonate	JJ	O	O
dialysis	NN	O	O
,	,	O	O
suggesting	VBG	O	O
reduced	VBN	O	O
peritoneal	JJ	O	O
vasodilation	NN	O	O
.	.	O	O

The	DT	O	O
peritoneal	JJ	o	OPH
release	NN	o	OPH
of	IN	o	OPH
carcinogen	JJ	o	OPH
antigen-125	NNS	o	OPH
increased	VBD	o	OPH
twofold	NN	O	O
during	IN	O	O
bicarbonate	NN	O	O
APD	NNP	O	O
(	(	O	O
29	CD	O	O
+/-	JJ	O	O
15	CD	O	O
versus	NN	O	O
15	CD	O	O
+/-	JJ	O	O
8	CD	O	O
U/ml	NNP	O	O
per	IN	O	O
4	CD	O	O
h	NN	O	O
,	,	O	O
P	NNP	O	O
<	NNP	O	O
0.01	CD	O	O
)	)	O	O
,	,	O	O
which	WDT	O	O
is	VBZ	O	O
consistent	JJ	O	O
with	IN	O	O
recovery	NN	O	O
of	IN	O	O
the	DT	O	O
mesothelial	JJ	O	O
cell	NN	O	O
layer	NN	O	O
.	.	O	O

This	DT	O	O
effect	NN	O	O
was	VBD	O	O
fully	RB	O	O
reversed	VBN	O	O
when	WRB	O	O
the	DT	O	O
patients	NNS	O	O
returned	VBD	O	O
to	TO	O	O
lactate	VB	O	O
fluid	NN	O	O
.	.	O	O

Effluent	JJ	o	OPH
carcinogen	NN	o	OPH
antigen-125	JJ	o	OPH
levels	NNS	o	OPH
were	VBD	O	O
inversely	RB	O	O
correlated	VBN	O	O
with	IN	O	O
peritoneal	JJ	O	O
glucose	JJ	O	O
exposure	NN	O	O
during	IN	O	O
lactate	NN	O	O
but	CC	O	O
not	RB	O	O
bicarbonate	VB	O	O
APD	NNP	O	O
,	,	O	O
indicating	VBG	O	O
improved	VBN	O	O
in	IN	O	O
vivo	JJ	O	O
mesothelial	NN	O	O
cell	NN	O	O
tolerance	NN	O	O
of	IN	O	O
high-dose	JJ	O	O
glucose	NN	O	O
with	IN	O	O
the	DT	O	O
neutral-pH	JJ	i	IPM
PD	NNP	i	IPM
fluid	NN	i	IPM
with	IN	i	IPM
reduced	VBN	i	IPM
glucose	JJ	i	IPM
degradation	NN	i	IPM
product	NN	i	IPM
content	NN	i	IPM
.	.	i	O

Among	IN	O	O
children	NNS	p	PA
undergoing	VBG	p	O
APD	NNP	i	IPM
,	,	i	IPM
neutral-pH	JJ	i	IPM
,	,	i	IPM
bicarbonate-buffered	JJ	i	IPM
PD	NNP	i	IPM
fluid	NN	i	IPM
provides	VBZ	O	O
more	RBR	O	O
effective	JJ	O	O
correction	NN	O	O
of	IN	O	O
metabolic	JJ	O	O
acidosis	NN	O	O
and	CC	O	O
better	JJR	O	O
preservation	NN	O	O
of	IN	O	O
peritoneal	NN	O	O
cell	NN	O	O
mass	NN	O	O
than	IN	O	O
do	VBP	O	O
conventional	JJ	i	IPM
,	,	i	IPM
acidic	JJ	i	IPM
,	,	i	IPM
lactate-based	JJ	i	IPM
fluids	NNS	i	IPM
.	.	i	O

Lack	NN	O	O
of	IN	O	O
interaction	NN	O	O
between	IN	O	O
pantoprazole	NN	i	IPM
and	CC	i	IPM
digoxin	NN	i	IPM
at	IN	O	O
therapeutic	JJ	O	O
doses	NNS	O	O
in	IN	p	O
man	NN	p	PSE
.	.	p	O

Substituted	JJ	i	IPM
benzimidazole	JJ	i	IPM
inhibitors	NNS	i	IPM
of	IN	O	O
the	DT	O	O
gastric	JJ	O	O
H+/K+ATPase	NNP	O	O
may	MD	O	O
interact	VB	O	O
with	IN	O	O
the	DT	O	O
cytochrome	NN	O	O
P450	NNP	O	O
enzyme	NN	O	O
system	NN	O	O
and	CC	O	O
alter	VB	O	O
the	DT	O	O
pharmacokinetics	NNS	O	O
of	IN	O	O
coadministered	JJ	O	O
drugs	NNS	O	O
.	.	O	O

On	IN	O	O
the	DT	O	O
other	JJ	O	O
hand	NN	O	O
,	,	O	O
changes	NNS	O	O
in	IN	O	O
intragastric	JJ	O	O
pH	NN	O	O
might	MD	O	O
alter	VB	O	O
the	DT	O	O
absorption	NN	O	O
of	IN	O	O
other	JJ	O	O
drugs	NNS	O	O
.	.	O	O

The	DT	O	O
primary	JJ	O	O
aim	NN	O	O
of	IN	O	O
the	DT	O	O
present	JJ	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
determine	VB	O	O
whether	IN	O	O
pantoprazole	JJ	i	IPM
modifies	NNS	O	O
the	DT	O	O
steady-state	JJ	O	O
serum	NN	O	O
concentrations	NNS	O	O
of	IN	O	O
orally	RB	O	O
administered	VBN	O	O
digoxin	NN	i	IPM
.	.	i	O

Secondary	JJ	O	O
aims	NNS	O	O
were	VBD	O	O
the	DT	O	O
influence	NN	O	O
of	IN	O	O
digoxin	NN	i	IPM
on	IN	O	O
the	DT	O	O
pharmacokinetics	NNS	O	O
of	IN	O	O
pantoprazole	NN	i	IPM
as	RB	O	O
well	RB	O	O
as	IN	O	O
safety	NN	O	O
and	CC	O	O
tolerability	NN	O	O
.	.	O	O

Eighteen	NNP	p	PSS
healthy	JJ	p	O
volunteers	NNS	p	O
received	VBD	O	O
a	DT	O	O
single	JJ	O	O
oral	JJ	i	IPM
dose	NN	i	IPM
of	IN	i	IPM
pantoprazole	NN	i	IPM
(	(	i	IPM
40	CD	i	IPM
mg	NN	i	IPM
)	)	i	IPM
and	CC	i	O
serum	JJ	i	O
concentrations	NNS	i	O
were	VBD	O	O
determined	VBN	O	O
.	.	O	O

Three	CD	O	O
to	TO	O	O
10	CD	O	O
days	NNS	O	O
later	RB	O	O
,	,	O	O
subjects	NNS	O	O
received	VBD	O	O
in	IN	O	O
a	DT	O	O
single-blind	NN	O	O
,	,	O	O
randomized	VBN	O	O
,	,	O	O
crossover	JJ	O	O
fashion	NN	O	O
oral	JJ	O	O
beta-acetyldigoxin	NN	i	IPM
(	(	O	O
0.2	CD	O	O
mg	NN	O	O
)	)	O	O
twice	RB	O	O
daily	RB	O	O
and	CC	O	O
concomitant	JJ	i	IPM
oral	JJ	i	IPM
pantoprazole	NN	i	IPM
(	(	O	O
40	CD	O	O
mg	NN	O	O
)	)	O	O
or	CC	O	O
placebo	JJ	i	IC
once	RB	O	O
daily	JJ	O	O
for	IN	O	O
5	CD	O	O
days	NNS	O	O
.	.	O	O

Serum	NNP	O	O
concentrations	NNS	O	O
of	IN	O	O
pantoprazole	NN	i	IPM
and	CC	i	O
digoxin	NN	i	IPM
were	VBD	O	O
determined	VBN	O	O
on	IN	O	O
day	NN	O	O
5	CD	O	O
.	.	O	O

Primary	JJ	O	O
characteristics	NNS	O	O
for	IN	O	O
confirmative	JJ	O	O
assessment	NN	O	O
of	IN	O	O
no	DT	O	O
interaction	NN	O	O
were	VBD	O	O
AUC	NNP	o	OOt
and	CC	o	OOt
Cmax	NNP	o	OOt
of	IN	o	OOt
digoxin	NN	o	OOt
.	.	o	OOt

Lack	NNP	O	O
of	IN	O	O
interaction	NN	O	O
in	IN	O	O
the	DT	O	O
sense	NN	O	O
of	IN	O	O
equivalence	NN	O	O
was	VBD	O	O
concluded	VBN	O	O
for	IN	O	O
both	DT	O	O
digoxin	NN	O	O
(	(	O	O
with	IN	O	O
and	CC	O	O
without	IN	O	O
pantoprazole	NN	i	IPM
)	)	i	O
and	CC	O	O
pantoprazole	JJ	i	IPM
(	(	i	O
with	IN	i	O
and	CC	i	O
without	IN	i	O
digoxin	NN	i	IPM
)	)	i	O
as	IN	O	O
the	DT	O	O
90	CD	O	O
%	NN	O	O
-confidence	NN	O	O
intervals	NNS	O	O
of	IN	O	O
the	DT	O	O
respective	JJ	O	O
AUC-	NNP	o	OOt
and	CC	o	OOt
Cmax-ratios	NNP	o	OOt
were	VBD	O	O
within	IN	O	O
the	DT	O	O
equivalence	NN	O	O
range	NN	O	O
of	IN	O	O
0.8-1.25	NNP	O	O
.	.	O	O

Pantoprazole	NNP	i	IPM
did	VBD	O	O
not	RB	O	O
influence	VB	O	O
the	DT	O	O
characteristic	JJ	O	O
ECG	NNP	O	O
modifications	NNS	O	O
(	(	O	O
T-wave	NNP	O	O
)	)	O	O
caused	VBN	O	O
by	IN	O	O
digoxin	NN	O	O
.	.	O	O

Both	DT	O	O
drugs	NNS	O	O
were	VBD	O	O
well	RB	O	O
tolerated	VBN	o	OOt
and	CC	O	O
no	DT	O	O
adverse	JJ	o	OA
events	NNS	o	OA
or	CC	O	O
clinically	RB	O	O
relevant	JJ	O	O
alterations	NNS	O	O
in	IN	O	O
vital	JJ	O	O
signs	NNS	O	O
or	CC	O	O
clinical	JJ	O	O
laboratory	NN	O	O
parameters	NNS	O	O
were	VBD	O	O
observed	VBN	O	O
during	IN	O	O
treatment	NN	O	O
.	.	O	O

In	IN	O	O
conclusion	NN	O	O
,	,	O	O
pantoprazole	NN	i	IPM
and	CC	i	O
digoxin	NN	i	IPM
may	MD	O	O
be	VB	O	O
administered	VBN	O	O
concomitantly	RB	O	O
without	IN	O	O
the	DT	O	O
need	NN	O	O
for	IN	O	O
dose	JJ	O	O
adjustment	NN	O	O
.	.	O	O

Enhanced	NNP	O	O
inotropic	NN	O	O
state	NN	O	O
of	IN	O	O
the	DT	O	O
failing	NN	O	O
left	VBD	O	O
ventricle	NN	O	O
by	IN	O	O
cardiac	JJ	i	IPH
contractility	NN	i	IPH
modulation	NN	i	IPH
electrical	JJ	i	IPH
signals	NNS	i	IPH
is	VBZ	O	O
not	RB	O	O
associated	VBN	O	O
with	IN	O	O
increased	JJ	O	O
myocardial	JJ	o	OPH
oxygen	NN	o	OPH
consumption	NN	o	OPH
.	.	o	OPH

BACKGROUND	NNP	O	O
Previous	NNP	O	O
studies	NNS	O	O
in	IN	O	O
patients	NNS	p	O
and	CC	p	O
in	IN	p	O
dogs	NNS	p	O
with	IN	p	O
experimentally	RB	p	O
induced	JJ	p	O
heart	NN	p	O
failure	NN	p	O
(	(	p	O
HF	NNP	p	O
)	)	p	O
showed	VBD	O	O
that	IN	O	O
electrical	JJ	i	IPH
signals	NNS	i	IPH
applied	VBN	O	O
to	TO	O	O
the	DT	O	O
failing	VBG	O	O
myocardium	NN	O	O
during	IN	O	O
the	DT	O	O
absolute	JJ	O	O
refractory	NN	O	O
period	NN	O	O
improved	VBD	O	O
left	JJ	o	OPH
ventricular	NN	o	OPH
(	(	o	OPH
LV	NNP	o	OPH
)	)	o	OPH
function	NN	o	OPH
.	.	o	OPH

We	PRP	O	O
examined	VBD	O	O
the	DT	O	O
effects	NNS	O	O
these	DT	O	O
same	JJ	O	O
cardiac	NN	i	IPH
contractility	NN	i	IPH
modulating	NN	i	IPH
(	(	i	IPH
CCM	NNP	i	IPH
)	)	i	IPH
electrical	JJ	i	IPH
signals	NNS	i	IPH
on	IN	O	O
myocardial	JJ	o	OPH
oxygen	NN	o	OPH
consumption	NN	o	OPH
(	(	o	OPH
MVO	NNP	o	OPH
(	(	o	OPH
2	CD	o	OPH
)	)	o	OPH
)	)	o	OPH
in	IN	O	O
both	DT	p	O
patients	NNS	p	O
and	CC	p	O
dogs	NNS	p	O
with	IN	p	O
chronic	JJ	p	O
HF	NNP	p	O
.	.	p	O

METHODS	NNP	O	O
AND	CC	O	O
RESULTS	NNP	O	O
Six	NNP	p	O
dogs	NNS	p	O
with	IN	p	O
microembolizations-induced	JJ	i	IPH
HF	NNP	i	IPH
and	CC	p	O
9	CD	p	O
HF	NNP	p	O
patients	NNS	p	O
underwent	JJ	p	O
CCM	NNP	i	IPH
leads	NNS	i	IPH
and	CC	i	IPH
generator	NN	i	IPH
(	(	i	IPH
OPTIMIZER	NNP	i	IPH
II	NNP	i	IPH
)	)	i	IPH
implantation	NN	i	IPH
.	.	i	O

After	IN	O	O
baseline	NN	O	O
measurements	NNS	O	O
,	,	O	O
CCM	NNP	i	IPH
signals	NNS	i	IPH
were	VBD	O	O
delivered	VBN	O	O
continuously	RB	O	O
for	IN	O	O
2	CD	O	O
hours	NNS	O	O
in	IN	O	O
dogs	NNS	O	O
and	CC	O	O
for	IN	O	O
30	CD	O	O
minutes	NNS	O	O
in	IN	O	O
patients	NNS	O	O
.	.	O	O

MVO	NNP	o	OPH
(	(	o	OPH
2	CD	o	OPH
)	)	o	OPH
was	VBD	O	O
measured	VBN	O	O
before	IN	O	O
and	CC	O	O
after	IN	O	O
CCM	NNP	i	IPH
therapy	NN	i	IPH
.	.	i	O

In	IN	O	O
dogs	NNS	O	O
,	,	O	O
CCM	NNP	i	IPH
therapy	NN	i	IPH
increased	VBD	O	O
LV	NNP	o	OPH
ejection	NN	o	OPH
fraction	NN	o	OPH
at	IN	O	O
2	CD	O	O
hours	NNS	O	O
(	(	O	O
26	CD	O	O
+/-	JJ	O	O
1	CD	O	O
versus	NN	O	O
31	CD	O	O
+/-	JJ	O	O
2	CD	O	O
%	NN	O	O
,	,	O	O
P	NNP	O	O
=	NNP	O	O
.001	NNP	O	O
)	)	O	O
without	IN	O	O
increasing	VBG	O	O
MVO	NNP	o	OPH
(	(	o	OPH
2	CD	o	OPH
)	)	o	OPH
(	(	O	O
257	CD	O	O
+/-	JJ	O	O
41	CD	O	O
versus	NN	O	O
180	CD	O	O
+/-	JJ	O	O
34	CD	O	O
micromol/min	NN	O	O
)	)	O	O
.	.	O	O

In	IN	O	O
patients	NNS	O	O
,	,	O	O
CCM	NNP	i	IPH
therapy	NN	i	IPH
increased	VBD	O	O
LV	NNP	o	OPH
peak	NN	o	OPH
+dP/dt	NN	o	OPH
by	IN	O	O
10.1	CD	O	O
+/-	JJ	O	O
1.5	CD	O	O
%	NN	O	O
.	.	O	O

As	IN	O	O
with	IN	O	O
dogs	NNS	O	O
,	,	O	O
the	DT	O	O
increase	NN	O	O
in	IN	O	O
LV	NNP	o	OPH
function	NN	o	OPH
after	IN	O	O
30	CD	O	O
minutes	NNS	O	O
of	IN	O	O
CCM	NNP	i	IPH
therapy	NN	i	IPH
was	VBD	O	O
not	RB	O	O
associated	VBN	O	O
with	IN	O	O
increased	VBN	O	O
MVO	NNP	o	OPH
(	(	o	OPH
2	CD	o	OPH
)	)	o	OPH
(	(	O	O
13.6	CD	O	O
+/-	JJ	O	O
9.7	CD	O	O
versus	NN	O	O
12.5	CD	O	O
+/-	JJ	O	O
7.2	CD	O	O
mL	NN	O	O
O	NNP	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
/min	NN	O	O
)	)	O	O
.	.	O	O

CONCLUSIONS	VB	O	O
The	DT	O	O
study	NN	O	O
results	NNS	O	O
suggest	VBP	O	O
that	IN	O	O
unlike	IN	O	O
cAMP-dependent	JJ	O	O
positive	JJ	O	O
inotropic	NN	O	O
drugs	NNS	O	O
,	,	O	O
the	DT	O	O
increase	NN	O	O
in	IN	O	O
LV	NNP	o	OPH
function	NN	o	OPH
during	IN	O	O
CCM	NNP	i	IPH
therapy	NN	i	IPH
is	VBZ	O	O
elicited	VBN	O	O
without	IN	O	O
increasing	VBG	O	O
MVO	NNP	o	O
(	(	o	O
2	CD	o	O
)	)	o	O
.	.	o	O

[	JJ	O	O
Dose-reduced	NNP	O	O
antihypertensive	JJ	i	IPM
agents	NNS	i	IPM
--	:	i	O
use	NN	i	O
in	IN	O	O
complex	JJ	O	O
nonmedicamentous	JJ	i	IPM
therapy	NN	O	O
of	IN	O	O
hypertension	NN	O	O
]	NNP	O	O
.	.	O	O

In	IN	O	O
order	NN	O	O
to	TO	O	O
estimate	VB	O	O
the	DT	O	O
influence	NN	O	O
of	IN	O	O
a	DT	O	O
non-medicamentous	JJ	i	IPM
therapy	NN	i	IPM
(	(	i	IPM
CNT	NNP	i	IPM
)	)	i	IPM
on	IN	O	O
the	DT	O	O
consumption	NN	O	O
of	IN	O	O
medicaments	NNS	O	O
and	CC	O	O
coronary	JJ	O	O
risk	NN	O	O
in	IN	O	O
high	JJ	O	O
blood	NN	O	O
pressure	NN	O	O
73	CD	p	PSS
hypertensives	NNS	p	PC
of	IN	p	O
a	DT	p	O
medicamentously	RB	p	O
stabilized	VBN	p	O
CNT-group	NNP	p	O
were	VBD	O	O
examined	VBN	O	O
in	IN	O	O
comparison	NN	O	O
to	TO	O	O
a	DT	O	O
group	NN	p	O
of	IN	p	O
the	DT	p	O
same	JJ	p	O
size	NN	p	O
of	IN	p	O
patients	NNS	p	O
with	IN	p	O
hypertension	NN	p	PC
who	WP	p	O
were	VBD	p	O
managed	VBN	p	O
exclusively	RB	p	O
medicamentously	RB	p	O
for	IN	O	O
behaviour	NN	O	O
of	IN	O	O
blood	NN	O	O
pressure	NN	O	O
,	,	O	O
need	NN	O	O
of	IN	O	O
antihypertensive	JJ	i	IPM
drugs	NNS	i	IPM
and	CC	O	O
changes	NNS	O	O
of	IN	O	O
hypertension-associated	JJ	O	O
risk	NN	O	O
factors	NNS	O	O
.	.	O	O

After	IN	O	O
an	DT	O	O
exactly	RB	O	O
controlled	VBN	O	O
6-month	JJ	O	O
treatment	NN	O	O
hypertensives	NNS	p	PC
with	IN	O	O
additionally	RB	O	O
recommended	VBN	O	O
far-reaching	NN	O	O
CNT	NNP	O	O
showed	VBD	O	O
an	DT	O	O
economization	NN	O	O
of	IN	O	O
medicaments	NNS	O	O
by	IN	O	O
scarcely	RB	O	O
the	DT	O	O
half	NN	O	O
in	IN	O	O
comparison	NN	O	O
to	TO	O	O
the	DT	O	O
reference	NN	O	O
group	NN	O	O
.	.	O	O

By	IN	O	O
means	NNS	O	O
of	IN	O	O
suitable	JJ	O	O
control	NN	O	O
methods	VBZ	O	O
a	DT	O	O
causal	JJ	O	O
non-medicamentously	RB	i	IPM
conditioned	JJ	O	O
decrease	NN	O	O
of	IN	O	O
blood	NN	o	OPH
pressure	NN	o	OPH
could	MD	O	O
be	VB	O	O
excluded	VBN	O	O
.	.	O	O

A	DT	O	O
different	JJ	O	O
need	NN	O	O
of	IN	O	O
antihypertensive	JJ	i	IPM
drugs	NNS	i	IPM
was	VBD	O	O
simulated	VBN	O	O
by	IN	O	O
the	DT	O	O
exacter	JJ	O	O
intake	NN	O	O
of	IN	O	O
medicaments	NNS	O	O
in	IN	O	O
the	DT	O	O
index-patients	NNS	O	O
.	.	O	O

Notwithstanding	VBG	O	O
the	DT	O	O
metabolic	JJ	O	O
effects	NNS	O	O
of	IN	O	O
the	DT	O	O
additional	JJ	O	O
therapy	NN	O	O
have	VBP	O	O
induced	VBN	O	O
a	DT	O	O
positive	JJ	O	O
change	NN	O	O
of	IN	O	O
atherogenic	JJ	o	OPH
lipids	NNS	o	OPH
.	.	o	OPH

The	DT	O	O
examinations	NNS	O	O
indicate	VBP	O	O
in	IN	O	O
general	JJ	O	O
the	DT	O	O
difficulty	NN	O	O
of	IN	O	O
the	DT	O	O
judgement	NN	O	O
of	IN	O	O
efficacy	NN	O	O
of	IN	O	O
non-medicamentous	JJ	i	IPM
therapeutic	JJ	i	IPM
measures	NNS	O	O
in	IN	O	O
connection	NN	O	O
with	IN	O	O
a	DT	O	O
rational	JJ	O	O
dose-reduced	JJ	O	O
long-term	JJ	O	O
therapy	NN	O	O
with	IN	O	O
antihypertensive	JJ	O	O
drugs	NNS	O	O
.	.	O	O

A	DT	O	O
comparison	NN	O	O
of	IN	O	O
seven	CD	p	O
antiarrhythmic	JJ	i	IPM
drugs	NNS	i	IPM
in	IN	p	O
patients	NNS	p	O
with	IN	p	O
ventricular	JJ	p	PC
tachyarrhythmias	NNS	p	PC
.	.	p	O

Electrophysiologic	NNP	O	O
Study	NNP	O	O
versus	VBD	O	O
Electrocardiographic	NNP	O	O
Monitoring	NNP	O	O
Investigators	NNP	O	O
.	.	O	O

BACKGROUND	NNP	O	O
The	DT	O	O
relative	JJ	O	O
efficacies	NNS	O	O
of	IN	O	O
various	JJ	O	O
antiarrhythmic	JJ	O	O
drugs	NNS	O	O
in	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
ventricular	JJ	O	O
tachyarrhythmias	NNS	O	O
are	VBP	O	O
not	RB	O	O
well	RB	O	O
known	VBN	O	O
.	.	O	O

This	DT	O	O
study	NN	O	O
examined	VBD	O	O
the	DT	O	O
effectiveness	NN	O	O
of	IN	O	O
imipramine	NN	i	IPM
,	,	i	O
mexiletine	NN	i	IPM
,	,	i	O
pirmenol	NN	i	IPM
,	,	i	O
procainamide	NN	i	IPM
,	,	i	O
propafenone	NN	i	IPM
,	,	i	O
quinidine	NN	i	IPM
,	,	i	O
and	CC	i	O
sotalol	NN	i	IPM
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
ventricular	JJ	p	PC
tachyarrhythmias	NNS	p	PC
who	WP	O	O
were	VBD	O	O
enrolled	VBN	O	O
in	IN	O	O
the	DT	O	O
Electrophysiologic	NNP	O	O
Study	NNP	O	O
versus	VBD	O	O
Electrocardiographic	NNP	O	O
Monitoring	NNP	O	O
trial	NN	O	O
.	.	O	O

METHODS	JJ	O	O
Patients	NNPS	p	O
were	VBD	O	O
randomly	RB	O	O
assigned	VBN	O	O
to	TO	O	O
undergo	VB	O	O
serial	JJ	O	O
testing	NN	O	O
of	IN	O	O
the	DT	O	O
efficacy	NN	O	O
of	IN	O	O
the	DT	O	O
seven	CD	O	O
antiarrhythmic	JJ	O	O
drugs	NNS	O	O
by	IN	O	O
one	CD	O	O
of	IN	O	O
two	CD	O	O
strategies	NNS	O	O
:	:	O	O
electrophysiologic	NN	i	IPH
study	NN	i	IPH
or	CC	i	IPH
Holter	NNP	i	IPH
monitoring	VBG	i	IPH
together	RB	i	IPH
with	IN	i	IPH
exercise	NN	i	IPH
testing	NN	i	IPH
.	.	i	O

The	DT	O	O
seven	CD	O	O
drugs	NNS	O	O
were	VBD	O	O
then	RB	O	O
tested	VBN	O	O
for	IN	O	O
efficacy	NN	O	O
in	IN	O	O
random	JJ	O	O
order	NN	O	O
in	IN	O	O
patients	NNS	O	O
who	WP	O	O
were	VBD	O	O
eligible	JJ	O	O
to	TO	O	O
receive	VB	O	O
them	PRP	O	O
.	.	O	O

The	DT	O	O
frequencies	NNS	O	O
of	IN	O	O
predictions	NNS	O	O
of	IN	O	O
drug	NN	O	O
efficacy	NN	O	O
and	CC	O	O
of	IN	O	O
adverse	JJ	O	O
drug	NN	O	O
effects	NNS	O	O
during	IN	O	O
the	DT	O	O
initial	JJ	O	O
drug	NN	O	O
titration	NN	O	O
were	VBD	O	O
tabulated	VBN	O	O
for	IN	O	O
all	DT	O	O
486	CD	p	PSS
randomized	VBN	p	O
subjects	NNS	p	O
.	.	p	O

Patients	NNS	O	O
received	VBD	O	O
long-term	JJ	O	O
treatment	NN	O	O
with	IN	O	O
the	DT	O	O
first	JJ	O	O
antiarrhythmic	JJ	O	O
drug	NN	O	O
that	WDT	O	O
was	VBD	O	O
predicted	VBN	O	O
to	TO	O	O
be	VB	O	O
effective	JJ	O	O
on	IN	O	O
the	DT	O	O
basis	NN	O	O
of	IN	O	O
drug	NN	O	O
testing	NN	O	O
.	.	O	O

Recurrences	NNS	O	O
of	IN	O	O
arrhythmia	NN	O	O
,	,	O	O
deaths	NNS	O	O
,	,	O	O
and	CC	O	O
adverse	JJ	O	O
drug	NN	O	O
effects	NNS	O	O
during	IN	O	O
long-term	JJ	O	O
follow-up	NNS	O	O
were	VBD	O	O
recorded	VBN	O	O
for	IN	O	O
the	DT	O	O
296	CD	p	PSS
patients	NNS	p	O
in	IN	O	O
whom	WP	O	O
an	DT	O	O
antiarrhythmic	JJ	O	O
drug	NN	O	O
was	VBD	O	O
predicted	VBN	O	O
to	TO	O	O
be	VB	O	O
effective	JJ	O	O
.	.	O	O

RESULTS	NNP	O	O
In	IN	O	O
the	DT	O	O
electrophysiologic-study	JJ	O	O
group	NN	O	O
,	,	O	O
the	DT	O	O
percentage	NN	O	O
of	IN	O	O
patients	NNS	O	O
who	WP	O	O
had	VBD	O	O
predictions	NNS	O	O
of	IN	O	O
drug	NN	o	OME
efficacy	NN	o	OME
was	VBD	O	O
higher	JJR	o	OME
with	IN	O	O
sotalol	NN	O	O
(	(	O	O
35	CD	O	O
percent	NN	O	O
)	)	O	O
than	IN	O	O
with	IN	O	O
the	DT	O	O
other	JJ	O	O
drugs	NNS	O	O
(	(	O	O
16	CD	O	O
percent	NN	O	O
,	,	O	O
P	NNP	O	O
<	NNP	O	O
0.001	CD	O	O
)	)	O	O
.	.	O	O

There	EX	O	O
was	VBD	O	O
no	DT	o	OME
significant	JJ	o	OME
difference	NN	o	OME
among	IN	O	O
the	DT	O	O
drugs	NNS	O	O
in	IN	O	O
the	DT	O	O
Holter-monitoring	NNP	O	O
group	NN	O	O
.	.	O	O

The	DT	O	O
percentage	NN	O	O
of	IN	O	O
patients	NNS	o	OME
with	IN	o	OME
adverse	JJ	o	OME
drug	NN	o	OME
effects	NNS	o	OME
was	VBD	O	O
lowest	JJS	o	OME
among	IN	O	O
those	DT	O	O
receiving	VBG	O	O
sotalol	NN	O	O
.	.	O	O

The	DT	O	O
actuarial	JJ	o	OME
probability	NN	o	OME
of	IN	o	OME
a	DT	o	OME
recurrence	NN	o	OME
of	IN	o	OME
arrhythmia	NN	o	OME
after	IN	O	O
a	DT	O	O
prediction	NN	O	O
of	IN	O	O
drug	NN	O	O
efficacy	NN	O	O
by	IN	O	O
either	DT	O	O
strategy	NN	O	O
was	VBD	O	O
significantly	RB	o	OOt
lower	JJR	o	OOt
for	IN	O	O
patients	NNS	O	O
treated	VBN	O	O
with	IN	O	O
sotalol	NN	O	O
than	IN	O	O
for	IN	O	O
patients	NNS	O	O
treated	VBN	O	O
with	IN	O	O
the	DT	O	O
other	JJ	O	O
drugs	NNS	O	O
(	(	O	O
risk	NN	O	O
ratio	NN	O	O
,	,	O	O
0.43	CD	O	O
;	:	O	O
95	CD	O	O
percent	NN	O	O
confidence	NN	O	O
interval	NN	O	O
,	,	O	O
0.29	CD	O	O
to	TO	O	O
0.62	CD	O	O
;	:	O	O
P	NNP	O	O
<	NNP	O	O
0.001	CD	O	O
)	)	O	O
.	.	O	O

With	IN	O	O
sotalol	NN	O	O
,	,	O	O
as	IN	O	O
compared	VBN	O	O
with	IN	O	O
the	DT	O	O
other	JJ	O	O
drugs	NNS	O	O
combined	VBN	O	O
,	,	O	O
there	EX	O	O
were	VBD	O	O
lower	JJR	o	OOt
risks	NNS	o	OOt
of	IN	o	OOt
death	NN	o	OOt
from	IN	O	O
any	DT	O	O
cause	NN	O	O
(	(	O	O
risk	NN	O	O
ratio	NN	O	O
,	,	O	O
0.50	CD	O	O
;	:	O	O
95	CD	O	O
percent	NN	O	O
confidence	NN	O	O
interval	NN	O	O
,	,	O	O
0.30	CD	O	O
to	TO	O	O
0.80	CD	O	O
;	:	O	O
P	NNP	O	O
=	NNP	O	O
0.004	CD	O	O
)	)	O	O
,	,	O	O
death	NN	O	O
from	IN	O	O
cardiac	JJ	O	O
causes	NNS	O	O
,	,	O	O
(	(	O	O
0.50	CD	O	O
;	:	O	O
P	NNP	O	O
=	NNP	O	O
0.02	CD	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
death	NN	o	OOt
from	IN	o	OOt
arrhythmia	NN	o	OOt
(	(	O	O
0.50	CD	O	O
;	:	O	O
P	NNP	O	O
=	NNP	O	O
0.04	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
cumulative	JJ	O	O
percentage	NN	O	O
of	IN	O	O
patients	NNS	O	O
in	IN	O	O
whom	WP	O	O
a	DT	O	O
drug	NN	O	O
was	VBD	O	O
predicted	VBN	O	O
to	TO	O	O
be	VB	O	O
effective	JJ	o	O
and	CC	O	O
in	IN	O	O
whom	WP	O	O
it	PRP	O	O
remained	VBD	O	O
effective	JJ	o	O
and	CC	o	O
tolerated	VBD	o	O
was	VBD	O	O
higher	JJR	o	O
for	IN	O	O
sotalol	JJR	O	O
than	IN	O	O
for	IN	O	O
the	DT	O	O
other	JJ	O	O
drugs	NNS	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.001	CD	O	O
)	)	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
Sotalol	NNP	O	O
was	VBD	O	O
more	RBR	O	O
effective	JJ	o	O
than	IN	O	O
the	DT	O	O
other	JJ	O	O
six	CD	O	O
antiarrhythmic	JJ	O	O
drugs	NNS	O	O
in	IN	O	O
preventing	VBG	o	O
death	NN	o	O
and	CC	o	O
recurrences	NNS	o	O
of	IN	o	O
arrhythmia	NN	o	O
.	.	o	O

In	IN	O	O
patients	NNS	O	O
similar	JJ	O	O
to	TO	O	O
those	DT	O	O
in	IN	O	O
this	DT	O	O
study	NN	O	O
,	,	O	O
if	IN	O	O
antiarrhythmic-drug	JJ	O	O
therapy	NN	O	O
is	VBZ	O	O
to	TO	O	O
be	VB	O	O
used	VBN	O	O
to	TO	O	O
prevent	VB	O	O
recurrences	NNS	O	O
of	IN	O	O
ventricular	JJ	O	O
tachyarrhythmias	NNS	O	O
,	,	O	O
treatment	NN	O	O
with	IN	O	O
sotalol	NN	O	O
and	CC	O	O
assessment	NN	O	O
of	IN	O	O
its	PRP$	O	O
potential	JJ	O	O
efficacy	NN	O	O
by	IN	O	O
Holter	NNP	O	O
monitoring	NN	O	O
are	VBP	O	O
a	DT	O	O
reasonable	JJ	O	O
initial	JJ	O	O
strategy	NN	O	O
.	.	O	O

S-phase	JJ	i	IPM
kinase-associated	JJ	i	IPM
protein	NN	i	IPM
2	CD	O	O
expression	NN	O	O
in	IN	O	O
laryngeal	JJ	p	PC
squamous	JJ	p	PC
cell	NN	p	PC
carcinomas	NN	p	PC
and	CC	O	O
its	PRP$	O	O
prognostic	JJ	O	O
implications	NNS	O	O
.	.	O	O

The	DT	O	O
F-box	JJ	O	O
protein	JJ	O	O
S-phase	JJ	i	IPM
kinase-associated	JJ	i	IPM
protein	NN	i	IPM
2	CD	O	O
(	(	i	O
Skp2	NNP	i	IPM
)	)	i	O
positively	RB	O	O
regulates	VBZ	O	O
the	DT	O	O
G1-S	JJ	O	O
transition	NN	O	O
by	IN	O	O
controlling	VBG	O	O
the	DT	O	O
stability	NN	O	O
of	IN	O	O
several	JJ	O	O
G1	NNP	O	O
regulators	NNS	O	O
,	,	O	O
such	JJ	O	O
as	IN	O	O
the	DT	O	O
cell	NN	O	O
cycle	NN	O	O
inhibitor	NN	O	O
p27kip1	NN	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
the	DT	O	O
clinical	JJ	O	O
significance	NN	O	O
of	IN	O	O
Skp2	NNP	i	IPM
in	IN	O	O
patients	NNS	p	O
with	IN	p	O
laryngeal	JJ	p	O
squamous	JJ	p	O
cell	NN	p	O
carcinoma	NN	p	O
(	(	p	O
LSCC	NNP	p	PC
)	)	p	O
remains	VBZ	O	O
unknown	JJ	O	O
.	.	O	O

In	IN	O	O
this	DT	O	O
study	NN	O	O
,	,	O	O
a	DT	O	O
potential	JJ	O	O
distribution	NN	O	O
of	IN	O	O
Skp2	NNP	i	IPM
in	IN	O	O
LSCC	NNP	O	O
and	CC	O	O
its	PRP$	O	O
clinical	JJ	O	O
implications	NNS	O	O
was	VBD	O	O
investigated	VBN	O	O
by	IN	O	O
an	DT	O	O
immunohistochemical	JJ	i	IPH
study	NN	i	IPH
.	.	i	IE

Overall	NNP	O	O
,	,	O	O
Skp2	NNP	o	OPH
overexpression	NN	o	OPH
was	VBD	O	O
observed	VBN	O	O
in	IN	O	O
36.7	CD	p	O
%	NN	p	O
(	(	p	O
37	CD	p	PSS
of	IN	p	O
102	CD	p	PSS
)	)	p	O
patients	NNS	p	O
and	CC	O	O
was	VBD	O	O
significantly	RB	O	O
associated	VBN	O	O
with	IN	O	O
lymph	JJ	O	O
node	JJ	O	O
metastasis	NN	O	O
(	(	O	O
p=0.002	NN	O	O
)	)	O	O
and	CC	O	O
was	VBD	O	O
inversely	RB	O	O
associated	VBN	O	O
with	IN	O	O
p27kip1	JJ	O	O
expression	NN	O	O
(	(	O	O
p=0.026	NN	O	O
)	)	O	O
.	.	O	O

Survival	JJ	o	OMO
analysis	NN	o	OMO
using	VBG	O	O
the	DT	O	O
Kaplan-Meier	NNP	O	O
method	NN	O	O
showed	VBD	O	O
that	IN	O	O
Skp2	NNP	i	IPM
overexpression	NN	O	O
was	VBD	O	O
significantly	RB	O	O
associated	VBN	O	O
with	IN	O	O
shorter	JJR	O	O
disease-free	NN	o	OMO
and	CC	o	OMO
overall	JJ	o	OMO
survival	NN	o	OMO
(	(	O	O
p=0.0051	NN	O	O
and	CC	O	O
p=0.0002	NN	O	O
,	,	O	O
respectively	RB	O	O
)	)	O	O
.	.	O	O

When	WRB	O	O
Skp2	NNP	o	OPH
expression	NN	o	OPH
and	CC	o	OPH
p27kip1	JJ	o	OPH
expression	NN	o	OPH
were	VBD	O	O
combined	VBN	O	O
,	,	O	O
patients	NNS	O	O
with	IN	O	O
both	DT	O	O
Skp2	NNP	i	IPM
overexpression	NN	O	O
and	CC	O	O
reduced	JJ	O	O
expression	NN	o	OPH
of	IN	o	OPH
p27kip1	NN	o	OPH
revealed	VBN	O	O
poorest	JJS	o	OMO
disease-free	JJ	o	OMO
and	CC	O	O
overall	JJ	o	OMO
survival	NN	o	OMO
as	IN	O	O
compared	VBN	O	O
to	TO	O	O
the	DT	O	O
other	JJ	O	O
cases	NNS	O	O
(	(	O	O
p=0.0017	NN	O	O
and	CC	O	O
p	NN	O	O
<	NN	O	O
0.0001	CD	O	O
,	,	O	O
respectively	RB	O	O
)	)	O	O
.	.	O	O

Additionally	RB	O	O
,	,	O	O
in	IN	O	O
early	JJ	O	O
stage	NN	O	O
(	(	O	O
I	PRP	O	O
,	,	O	O
II	NNP	O	O
)	)	O	O
cases	NNS	O	O
,	,	O	O
Skp2	NNP	i	IPM
expression	NN	O	O
was	VBD	O	O
also	RB	O	O
revealed	VBN	O	O
to	TO	O	O
possess	VB	O	O
a	DT	O	O
significant	JJ	O	O
prognostic	JJ	O	O
factor	NN	O	O
in	IN	O	O
overall	JJ	o	OMO
survival	NN	o	OMO
(	(	o	OMO
p=0.0234	NN	o	OMO
)	)	o	OMO
,	,	O	O
but	CC	O	O
not	RB	O	O
in	IN	O	O
disease-free	JJ	o	OMO
survival	NN	o	OMO
(	(	O	O
p=0.2055	NN	O	O
)	)	O	O
.	.	O	O

By	IN	O	O
multivariate	NN	O	O
analysis	NN	O	O
using	VBG	O	O
the	DT	O	O
Cox	NNP	o	OPH
proportional	JJ	o	OPH
hazards	NNS	o	OPH
model	NN	o	OPH
,	,	o	OPH
tumor	NN	o	OPH
grade	NN	o	OPH
,	,	o	OPH
tumor	NN	o	OPH
size	NN	o	OPH
,	,	o	OPH
clinical	JJ	o	OPH
stage	NN	o	OPH
and	CC	o	OPH
Skp2	NNP	o	OPH
expression	NN	o	OPH
were	VBD	O	O
independent	JJ	O	O
prognostic	JJ	O	O
factors	NNS	O	O
both	DT	O	O
in	IN	O	O
disease-free	JJ	o	OMO
and	CC	o	OMO
overall	JJ	o	OMO
survival	NN	o	OMO
.	.	o	OMO

These	DT	O	O
findings	NNS	O	O
indicated	VBD	O	O
that	IN	O	O
Skp2	NNP	o	OPH
expression	NN	o	OPH
was	VBD	O	O
closely	RB	O	O
associated	VBN	O	O
with	IN	O	O
tumor	NN	O	O
progression	NN	O	O
and	CC	O	O
represented	VBD	O	O
an	DT	O	O
independent	JJ	O	O
marker	NN	O	O
for	IN	O	O
prognosis	NN	O	O
of	IN	O	O
LSCC	NNP	O	O
.	.	O	O

Acid	NNP	o	OPH
resistance	NN	o	OPH
of	IN	O	O
enamel	JJ	p	PC
subsurface	NN	p	PC
lesions	NNS	p	PC
remineralized	VBN	p	O
by	IN	p	O
a	DT	p	O
sugar-free	JJ	i	IPM
chewing	NN	i	IPM
gum	NN	i	IPM
containing	VBG	p	O
casein	JJ	p	O
phosphopeptide-amorphous	JJ	p	O
calcium	NN	p	O
phosphate	NN	p	O
.	.	p	O

The	DT	O	O
aim	NN	O	O
of	IN	O	O
this	DT	O	O
clinical	JJ	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
investigate	VB	O	O
the	DT	O	O
acid	JJ	o	OPH
resistance	NN	o	OPH
of	IN	O	O
enamel	JJ	p	PC
lesions	NNS	p	PC
remineralized	VBN	p	O
in	IN	p	O
situ	NN	p	O
by	IN	p	O
a	DT	p	O
sugar-free	JJ	i	IPM
chewing	NN	i	IPM
gum	NN	i	IPM
containing	VBG	p	O
casein	JJ	p	O
phosphopeptide-amorphous	JJ	p	O
calcium	NN	p	O
phosphate	NN	p	O
nanocomplexes	NNS	p	O
(	(	p	O
CPP-ACP	JJ	p	O
:	:	p	O
Recaldent	NN	p	O
)	)	p	O
.	.	p	O

The	DT	O	O
study	NN	O	O
utilized	VBD	O	O
a	DT	O	O
double-blind	NN	O	O
,	,	O	O
randomized	VBN	O	O
,	,	O	O
crossover	VB	O	O
design	NN	O	O
with	IN	O	O
two	CD	O	O
treatments	NNS	O	O
:	:	O	O
(	(	O	O
i	NN	O	O
)	)	O	O
sugar-free	JJ	i	IPM
gum	NN	i	IPM
containing	VBG	O	O
18.8	CD	O	O
mg	NN	O	O
of	IN	O	O
CPP-ACP	NNP	i	IPM
,	,	O	O
and	CC	O	O
(	(	O	O
ii	NN	O	O
)	)	O	O
sugar-free	JJ	i	IC
gum	NN	i	IC
not	RB	i	IC
containing	VBG	i	IC
CPP-ACP	NNP	i	IC
as	IN	O	O
control	NN	O	O
.	.	O	O

Subjects	NNS	p	O
wore	RBR	p	O
removable	JJ	p	O
palatal	JJ	p	O
appliances	NNS	p	O
with	IN	p	O
insets	NNS	p	O
of	IN	p	O
human	JJ	p	O
enamel	NN	p	O
containing	VBG	p	O
demineralized	JJ	p	O
subsurface	NN	p	PC
lesions	NNS	p	PC
and	CC	p	O
chewed	VBD	p	O
the	DT	p	O
gum	NN	i	IPM
for	IN	i	IPM
20	CD	p	O
min	NN	p	O
4	CD	p	O
times	NNS	p	O
per	IN	p	O
day	NN	p	O
for	IN	p	O
14	CD	p	O
days	NNS	p	O
.	.	p	O

After	IN	O	O
each	DT	O	O
treatment	NN	O	O
the	DT	O	O
enamel	NN	O	O
slabs	NN	O	O
were	VBD	O	O
removed	VBN	O	O
and	CC	O	O
half	NN	O	O
of	IN	O	O
each	DT	O	O
lesion	NN	O	O
challenged	VBD	o	OOt
with	IN	o	OOt
acid	NN	o	OOt
in	IN	o	OPH
vitro	NN	o	OPH
for	IN	O	O
8	CD	O	O
or	CC	O	O
16	CD	O	O
h.	VBP	O	O
The	DT	O	O
level	NN	o	OPH
of	IN	o	OPH
remineralization	NN	o	OPH
was	VBD	O	O
determined	VBN	O	O
using	VBG	O	O
microradiography	NN	o	OOt
.	.	o	O

The	DT	O	O
gum	NN	i	IPM
containing	VBG	i	IPM
CPP-ACP	NNP	i	IPM
produced	VBD	O	O
approximately	RB	O	O
twice	JJ	O	O
the	DT	O	O
level	NN	o	OPH
of	IN	o	OPH
remineralization	NN	o	OPH
as	IN	O	O
the	DT	O	O
control	NN	O	O
sugar-free	JJ	O	O
gum	NN	O	O
.	.	O	O

The	DT	O	O
8-	JJ	O	O
and	CC	O	O
16-hour	JJ	O	O
acid	NN	O	O
challenge	NN	O	O
of	IN	O	O
the	DT	O	O
lesions	NNS	o	OPH
remineralized	VBN	o	OPH
with	IN	O	O
the	DT	O	O
control	NN	i	IC
gum	NN	i	IC
resulted	VBD	O	O
in	IN	O	O
65.4	CD	O	O
and	CC	O	O
88.0	CD	O	O
%	NN	O	O
reductions	NNS	O	O
,	,	O	O
respectively	RB	O	O
,	,	O	O
of	IN	O	O
deposited	JJ	O	O
mineral	NN	O	O
,	,	O	O
while	IN	O	O
for	IN	O	O
the	DT	O	O
CPP-ACP-remineralized	JJ	O	O
lesions	NNS	O	O
the	DT	O	O
corresponding	JJ	O	O
reductions	NNS	O	O
were	VBD	O	O
30.5	CD	O	O
and	CC	O	O
41.8	CD	O	O
%	NN	O	O
.	.	O	O

The	DT	O	O
acid	NN	O	O
challenge	NN	O	O
after	IN	O	O
in	IN	O	O
situ	JJ	O	O
remineralization	NN	O	O
for	IN	O	O
both	DT	O	O
control	NN	O	O
and	CC	O	O
CPP-ACP-treated	JJ	O	O
lesions	NNS	O	O
resulted	VBD	O	O
in	IN	O	O
demineralization	NN	o	OPH
underneath	IN	O	O
the	DT	O	O
remineralized	JJ	O	O
zone	NN	O	O
,	,	O	O
indicating	VBG	O	O
that	IN	O	O
the	DT	O	O
remineralized	JJ	O	O
mineral	NN	O	O
was	VBD	O	O
more	RBR	O	O
resistant	JJ	O	O
to	TO	O	O
subsequent	JJ	O	O
acid	NN	O	O
challenge	NN	O	O
.	.	O	O

The	DT	O	O
results	NNS	O	O
show	VBP	O	O
that	IN	O	O
sugar-free	JJ	i	IPM
gum	NN	i	IPM
containing	VBG	i	IPM
CPP-ACP	NNP	i	IPM
is	VBZ	O	O
superior	JJ	o	OOt
to	TO	O	O
an	DT	O	O
equivalent	JJ	O	O
gum	NN	i	IC
not	RB	O	O
containing	VBG	O	O
CPP-ACP	NNP	O	O
in	IN	O	O
remineralization	NN	O	O
of	IN	O	O
enamel	JJ	O	O
subsurface	NN	O	O
lesions	NNS	O	O
in	IN	O	O
situ	NN	O	O
with	IN	O	O
mineral	NN	O	O
that	WDT	O	O
is	VBZ	O	O
more	RBR	o	OPH
resistant	JJ	o	OPH
to	TO	O	O
subsequent	JJ	O	O
acid	NN	O	O
challenge	NN	O	O
.	.	O	O

A	DT	O	O
pharmacy	NN	i	IOt
discharge	NN	i	IOt
plan	NN	i	IOt
for	IN	O	O
hospitalized	JJ	p	O
elderly	JJ	p	PA
patients	NNS	p	PA
--	:	p	O
a	DT	p	O
randomized	JJ	O	O
controlled	JJ	O	O
trial	NN	O	O
.	.	O	O

OBJECTIVES	UH	O	O
to	TO	O	O
investigate	VB	O	O
the	DT	O	O
effectiveness	NN	o	OOt
of	IN	o	OOt
a	DT	o	OOt
pharmacy	NN	o	OOt
discharge	NN	o	OOt
plan	NN	o	OOt
in	IN	O	O
elderly	JJ	p	PA
hospitalized	JJ	p	O
patients	NNS	p	O
.	.	p	O

DESIGN	NNP	O	O
randomized	VBD	O	O
controlled	VBN	O	O
trial	NN	O	O
.	.	O	O

SUBJECTS	NNP	O	O
AND	CC	O	O
SETTINGS	NNP	O	O
we	PRP	O	O
randomized	VBD	O	O
patients	NNS	p	O
aged	VBN	p	O
75	CD	p	PA
years	NNS	p	PA
and	CC	p	PA
older	JJR	p	PA
on	IN	p	O
four	CD	p	O
or	CC	p	O
more	JJR	p	O
medicines	NNS	p	O
who	WP	p	O
had	VBD	p	O
been	VBN	p	O
discharged	VBN	p	O
from	IN	p	O
three	CD	p	O
acute	JJ	p	O
general	JJ	p	O
and	CC	p	O
one	CD	p	O
long-stay	JJ	p	O
hospital	NN	p	O
to	TO	p	O
a	DT	p	O
pharmacy	NN	p	O
intervention	NN	p	O
or	CC	p	O
usual	JJ	p	O
care	NN	p	O
.	.	p	O

INTERVENTIONS	VBZ	O	O
the	DT	O	O
hospital	NN	i	IOt
pharmacist	NN	i	IOt
developed	VBD	i	IOt
discharge	NN	i	IOt
plans	NNS	i	IOt
which	WDT	O	O
gave	VBD	O	O
details	NNS	O	O
of	IN	O	O
medication	NN	O	O
and	CC	O	O
support	NN	O	O
required	VBN	O	O
by	IN	O	O
the	DT	O	O
patient	NN	O	O
.	.	O	O

A	DT	O	O
copy	NN	O	O
was	VBD	O	O
given	VBN	O	O
to	TO	O	O
the	DT	O	O
patient	NN	O	O
and	CC	O	O
to	TO	O	O
all	DT	O	O
relevant	JJ	O	O
professionals	NNS	O	O
and	CC	O	O
carers	NNS	O	O
.	.	O	O

This	DT	O	O
was	VBD	O	O
followed	VBN	O	O
by	IN	O	O
a	DT	O	O
domiciliary	JJ	O	O
assessment	NN	O	O
by	IN	O	O
a	DT	O	O
community	NN	O	O
pharmacist	NN	O	O
.	.	O	O

In	IN	O	O
the	DT	O	O
control	NN	O	O
group	NN	O	O
,	,	O	O
patients	NNS	O	O
were	VBD	O	O
discharged	VBN	i	IOt
from	IN	i	IOt
hospital	NN	i	IOt
following	VBG	i	IOt
standard	JJ	i	IOt
procedures	NNS	i	IOt
that	WDT	O	O
included	VBD	O	O
a	DT	O	O
discharge	NN	O	O
letter	NN	O	O
to	TO	O	O
the	DT	O	O
general	JJ	O	O
practitioner	NN	O	O
listing	VBG	O	O
current	JJ	O	O
medications	NNS	O	O
.	.	O	O

OUTCOMES	IN	O	O
the	DT	O	O
primary	JJ	O	O
outcome	NN	O	O
was	VBD	O	O
re-admission	NN	o	OOt
to	TO	o	OOt
hospital	VB	o	OOt
within	IN	o	OOt
6	CD	o	OOt
months	NNS	o	OOt
.	.	o	O

Secondary	JJ	O	O
outcomes	NNS	O	O
included	VBD	O	O
the	DT	O	O
number	NN	o	OMO
of	IN	o	OMO
deaths	NNS	o	OMO
,	,	o	O
attendance	NN	o	OOt
at	IN	o	OOt
hospital	JJ	o	OOt
outpatient	NN	o	OOt
clinics	NNS	o	OOt
and	CC	o	OOt
general	JJ	o	OOt
practice	NN	o	OOt
and	CC	o	O
proportion	NN	o	OOt
of	IN	o	OOt
days	NNS	o	OOt
in	IN	o	OOt
hospital	NN	o	OOt
over	IN	o	OOt
the	DT	o	OOt
follow-up	JJ	o	OOt
period	NN	o	OOt
,	,	o	O
together	RB	o	O
with	IN	o	O
patients	NNS	o	O
'	POS	o	O
general	JJ	o	OOt
well-being	NN	o	OOt
,	,	o	O
satisfaction	NN	o	OOt
with	IN	o	OOt
the	DT	o	OOt
service	NN	o	OOt
and	CC	o	O
knowledge	NN	o	OOt
of	IN	o	O
and	CC	o	O
adherence	NN	o	OOt
to	TO	o	OOt
prescribed	VB	o	OOt
medication	NN	o	OOt
.	.	o	O

RESULTS	NNP	O	O
we	PRP	p	O
recruited	VBD	p	O
362	CD	p	O
patients	NNS	p	O
,	,	p	O
of	IN	p	O
whom	WP	p	O
181	CD	p	O
were	VBD	p	O
randomized	VBN	p	O
to	TO	p	O
each	DT	p	O
group	NN	p	O
.	.	p	O

We	PRP	p	O
collected	VBD	p	O
hospital	NN	p	O
and	CC	p	O
general	JJ	p	O
practice	NN	p	O
data	NNS	p	O
on	IN	p	O
at	IN	p	O
least	JJS	p	O
91	CD	p	O
and	CC	p	O
72	CD	p	O
%	NN	p	O
of	IN	p	O
patients	NNS	p	O
respectively	RB	p	O
at	IN	p	O
each	DT	p	O
follow-up	JJ	p	O
point	NN	p	O
and	CC	p	O
interviewed	VBD	p	O
between	IN	p	O
43	CD	p	O
and	CC	p	O
90	CD	p	O
%	NN	p	O
of	IN	p	O
the	DT	p	O
study	NN	p	O
subjects	NNS	p	O
.	.	p	O

There	EX	O	O
were	VBD	O	O
no	DT	O	O
significant	JJ	O	O
differences	NNS	O	O
between	IN	O	O
the	DT	O	O
groups	NNS	O	O
in	IN	O	O
the	DT	O	O
proportion	NN	o	OOt
of	IN	o	OOt
patients	NNS	o	OOt
re-admitted	JJ	o	OOt
to	TO	o	OOt
hospital	VB	o	OOt
between	IN	O	O
baseline	NN	O	O
and	CC	O	O
3	CD	O	O
months	NNS	O	O
or	CC	O	O
3	CD	O	O
and	CC	O	O
6	CD	O	O
months	NNS	O	O
.	.	O	O

There	EX	O	O
were	VBD	O	O
no	DT	O	O
significant	JJ	O	O
differences	NNS	O	O
in	IN	O	O
any	DT	O	O
of	IN	O	O
the	DT	O	O
secondary	JJ	O	O
outcomes	NNS	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
we	PRP	O	O
found	VBD	O	O
no	DT	O	O
evidence	NN	O	O
to	TO	O	O
suggest	VB	O	O
that	IN	O	O
the	DT	O	O
co-ordinated	JJ	O	O
hospital	NN	O	O
and	CC	O	O
community	NN	i	IOt
pharmacy	NN	i	IOt
care	NN	i	IOt
discharge	NN	i	IOt
plans	NNS	i	IOt
in	IN	O	O
elderly	JJ	O	O
patients	NNS	O	O
in	IN	O	O
this	DT	O	O
study	NN	O	O
influence	NN	O	O
outcomes	NNS	O	O
.	.	O	O

Long-term	JJ	O	O
follow-up	NN	O	O
of	IN	O	O
the	DT	O	O
Stockholm	NNP	O	O
randomized	VBD	O	O
trials	NNS	O	O
of	IN	O	O
postoperative	JJ	i	IPH
radiation	NN	i	IPH
therapy	NN	i	IPH
versus	NN	i	O
adjuvant	JJ	i	IPH
chemotherapy	NN	i	IPH
among	IN	O	O
'high	JJ	p	O
risk	NN	p	O
'	POS	p	O
pre-	NN	p	O
and	CC	p	O
postmenopausal	NN	p	O
breast	NN	p	O
cancer	NN	p	O
patients	NNS	p	O
.	.	p	O

For	IN	O	O
many	JJ	O	O
years	NNS	O	O
,	,	O	O
loco-regional	JJ	O	O
radiotherapy	NN	O	O
was	VBD	O	O
the	DT	O	O
standard	JJ	O	O
postoperative	JJ	O	O
treatment	NN	O	O
for	IN	O	O
node	JJ	p	O
positive	JJ	p	O
breast	NN	p	O
cancer	NN	p	O
patients	NNS	p	O
in	IN	p	O
Sweden	NNP	p	O
.	.	p	O

Because	IN	O	O
of	IN	O	O
encouraging	VBG	O	O
results	NNS	O	O
from	IN	O	O
trials	NNS	O	O
of	IN	O	O
adjuvant	JJ	i	IPH
chemotherapy	NN	i	IPH
in	IN	O	O
the	DT	O	O
mid	NN	O	O
1970s	CD	O	O
,	,	O	O
the	DT	p	O
Stockholm	NNP	p	O
Breast	NNP	p	O
Cancer	NNP	p	O
Study	NNP	p	O
Group	NNP	p	O
decided	VBD	O	O
to	TO	O	O
directly	RB	O	O
compare	VB	O	O
postoperative	JJ	i	IPH
radiation	NN	i	IPH
(	(	i	O
RT	NNP	i	O
)	)	i	O
with	IN	i	O
adjuvant	JJ	i	IPH
CMF-type	JJ	i	IPH
chemotherapy	NN	i	IPH
(	(	i	O
CT	NNP	i	O
)	)	i	O
.	.	i	O

Long-term	JJ	O	O
results	NNS	O	O
are	VBP	O	O
presented	VBN	O	O
from	IN	O	O
two	CD	O	O
randomized	JJ	O	O
trials	NNS	O	O
of	IN	O	O
RT	NNP	i	IPM
versus	NN	O	O
CT	NNP	i	IPM
in	IN	O	O
pre-	NN	p	O
(	(	p	O
n	JJ	p	O
=	NNP	p	O
547	CD	p	O
)	)	p	O
and	CC	p	O
postmenopausal	NN	p	O
(	(	p	O
n	JJ	p	O
=	NNP	p	O
679	CD	p	O
)	)	p	O
patients	NNS	p	O
,	,	p	O
respectively	RB	p	O
,	,	p	O
with	IN	p	O
node	JJ	p	O
positive	JJ	p	O
disease	NN	p	O
or	CC	p	O
a	DT	p	O
tumour	JJ	p	O
diameter	NN	p	O
>	VBD	p	O
30	CD	p	O
mm	NN	p	O
.	.	p	O

RT	NNP	O	O
substantially	RB	O	O
reduced	VBD	O	O
loco-regional	JJ	o	OPH
recurrences	NNS	o	OPH
among	IN	O	O
both	DT	O	O
pre-	JJ	O	O
and	CC	O	O
postmenopausal	JJ	O	O
patients	NNS	O	O
(	(	O	O
relative	JJ	O	O
hazard	NN	O	O
RT	NNP	O	O
versus	NN	O	O
CT	NNP	O	O
:	:	O	O
0.67	CD	O	O
and	CC	O	O
0.43	CD	O	O
,	,	O	O
respectively	RB	O	O
)	)	O	O
.	.	O	O

Among	IN	O	O
premenopausal	JJ	O	O
patients	NNS	O	O
distant	JJ	o	OPH
metastases	NNS	o	OPH
occurred	VBD	O	O
less	RBR	O	O
frequently	RB	O	O
in	IN	O	O
the	DT	O	O
CT	NNP	O	O
group	NN	O	O
(	(	O	O
relative	JJ	O	O
hazard	NN	O	O
:	:	O	O
1.68	CD	O	O
,	,	O	O
p	NN	O	O
>	NNP	O	O
0.001	CD	O	O
)	)	O	O
resulting	VBG	O	O
in	IN	O	O
an	DT	O	O
improved	JJ	O	O
recurrence-free	JJ	o	OMO
survival	NN	o	OMO
(	(	O	O
p	JJ	O	O
=	NNP	O	O
0.04	CD	O	O
)	)	O	O
.	.	O	O

Overall	JJ	o	OMO
survival	NN	o	OMO
was	VBD	O	O
also	RB	O	O
better	RB	O	O
with	IN	O	O
CT	NNP	O	O
(	(	O	O
cumulative	JJ	O	O
survival	NN	O	O
at	IN	O	O
15	CD	O	O
years	NNS	O	O
:	:	O	O
50	CD	O	O
%	NN	O	O
and	CC	O	O
44	CD	O	O
%	NN	O	O
in	IN	O	O
the	DT	O	O
CT	NNP	O	O
and	CC	O	O
RT	NNP	O	O
groups	NNS	O	O
,	,	O	O
respectively	RB	O	O
)	)	O	O
but	CC	O	O
the	DT	O	O
difference	NN	O	O
was	VBD	O	O
not	RB	O	O
statistically	RB	O	O
significant	JJ	O	O
.	.	O	O

Among	IN	O	O
the	DT	O	O
postmenopausal	NN	O	O
patients	NNS	O	O
there	EX	O	O
were	VBD	O	O
no	DT	O	O
substantial	JJ	O	O
differences	NNS	O	O
in	IN	O	O
terms	NNS	O	O
of	IN	O	O
recurrence-free	NN	o	OMO
or	CC	o	OMO
overall	JJ	o	OMO
survival	NN	o	OMO
between	IN	O	O
the	DT	O	O
treatment	NN	O	O
groups	NNS	O	O
.	.	O	O

The	DT	O	O
risk	NN	o	OPH
of	IN	o	OPH
a	DT	o	OPH
second	JJ	o	OPH
primary	JJ	o	OPH
malignancy	NN	o	OPH
,	,	O	O
however	RB	O	O
,	,	O	O
was	VBD	O	O
doubled	VBN	O	O
in	IN	O	O
the	DT	O	O
RT	NNP	O	O
group	NN	O	O
(	(	O	O
p	JJ	O	O
>	NNP	O	O
0.01	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
most	RBS	O	O
pronounced	JJ	O	O
excess	NN	O	O
concerned	JJ	O	O
second	JJ	o	OPH
lung	NN	o	OPH
cancers	NNS	o	OPH
occurring	VBG	O	O
after	IN	O	O
10	CD	O	O
years	NNS	O	O
.	.	O	O

The	DT	O	O
cumulative	JJ	o	OPH
incidence	NN	o	OPH
at	IN	o	OPH
20	CD	o	OPH
years	NNS	o	OPH
was	VBD	O	O
estimated	VBN	O	O
at	IN	O	O
0.3	CD	O	O
%	NN	O	O
and	CC	O	O
3.7	CD	O	O
%	NN	O	O
in	IN	O	O
the	DT	O	O
CT	NNP	O	O
and	CC	O	O
RT	NNP	O	O
groups	NNS	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

The	DT	O	O
trials	NNS	O	O
illustrate	VBP	O	O
the	DT	O	O
role	NN	O	O
of	IN	O	O
radiotherapy	NN	O	O
in	IN	O	O
preventing	VBG	O	O
loco-regional	JJ	o	OPH
recurrences	NNS	o	OPH
among	IN	O	O
high-risk	JJ	O	O
patients	NNS	O	O
,	,	O	O
as	RB	O	O
well	RB	O	O
as	IN	O	O
the	DT	O	O
need	NN	O	O
for	IN	O	O
systemic	JJ	O	O
treatment	NN	O	O
to	TO	O	O
control	VB	O	O
the	DT	O	O
disease	NN	O	O
systemically	RB	O	O
.	.	O	O

Depressive	JJ	O	O
mood	NN	O	O
symptoms	NNS	O	O
associated	VBN	O	O
with	IN	O	O
ovarian	JJ	O	O
suppression	NN	O	O
.	.	O	O

OBJECTIVE	UH	O	O
To	TO	O	O
determine	VB	O	O
if	IN	O	O
sertraline	NN	i	IPM
is	VBZ	O	O
helpful	JJ	O	O
in	IN	O	O
the	DT	O	O
management	NN	O	O
of	IN	O	O
depressive	NN	O	O
symptoms	NNS	O	O
associated	VBN	O	O
with	IN	O	O
ovarian	JJ	O	O
suppression	NN	O	O
during	IN	O	O
GnRH	NNP	i	IPM
agonist	JJ	i	IPM
therapy	NN	i	IPM
as	IN	O	O
compared	VBN	O	O
with	IN	O	O
a	DT	O	O
placebo-controlled	JJ	i	IC
group	NN	O	O
.	.	O	O

DESIGN	NNP	O	O
Double-blind	JJ	O	O
placebo-controlled	JJ	i	O
prospective	JJ	O	O
study	NN	O	O
design	NN	O	O
.	.	O	O

SETTING	NN	O	O
An	DT	O	O
obstetrics/gynecological	JJ	O	O
office	NN	O	O
specializing	VBG	O	O
in	IN	O	O
infertility	NN	O	O
in	IN	O	O
an	DT	O	O
academic	JJ	O	O
environment	NN	O	O
.	.	O	O

PATIENT	NNP	O	O
(	(	O	O
S	NNP	O	O
)	)	O	O
Premenstrual	NNP	p	O
women	NNS	p	PSE
with	IN	p	O
laparoscopically	RB	p	O
diagnosed	VBN	p	O
endometriosis	NN	p	O
who	WP	p	O
required	VBD	p	O
GnRH	NNP	i	IPM
agonist	JJ	i	IPM
therapy	NN	i	IPM
for	IN	p	O
treatment	NN	p	O
and	CC	p	O
did	VBD	p	O
not	RB	p	O
have	VB	p	O
significant	JJ	p	O
depressive	JJ	p	O
or	CC	p	O
premenstrual	JJ	p	O
mood	NN	p	O
symptoms	NNS	p	O
at	IN	p	O
baseline	NN	p	O
.	.	p	O

INTERVENTION	NNP	O	O
(	(	O	O
S	NNP	O	O
)	)	O	O
Participants	NNPS	p	O
were	VBD	p	O
randomly	RB	p	O
assigned	VBN	p	O
to	TO	p	O
either	CC	p	O
the	DT	p	O
sertraline	JJ	i	O
treatment	NN	i	O
group	NN	p	O
or	CC	p	O
to	TO	p	O
the	DT	p	O
placebo	NN	i	O
group	NN	p	O
for	IN	p	O
the	DT	p	O
3-month	JJ	p	O
duration	NN	p	O
of	IN	p	O
the	DT	p	O
GnRH	NNP	i	IPM
agonist	NN	i	IPM
therapy	NN	i	IPM
.	.	i	IPM

MAIN	NNP	O	O
OUTCOME	NNP	O	O
MEASURE	NNP	O	O
(	(	O	O
S	NNP	O	O
)	)	O	O
The	DT	o	OME
21-item	JJ	o	OME
Hamilton	NNP	o	OME
Rating	NNP	o	OME
Scale	NNP	o	OME
for	IN	o	OME
Depression	NNP	o	OME
(	(	o	OME
HRSD	NNP	o	OME
)	)	o	OME
,	,	O	O
which	WDT	O	O
is	VBZ	O	O
an	DT	O	O
instrument	NN	O	O
designed	VBN	O	O
to	TO	O	O
assess	VB	O	O
depressive	JJ	O	O
symptomatology	NN	O	O
.	.	O	O

RESULT	NNP	O	O
(	(	O	O
S	NNP	O	O
)	)	O	O
A	NNP	O	O
Hotellings	NNP	O	O
T	NNP	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
test	NN	O	O
for	IN	O	O
repeated	VBN	O	O
measure	NN	O	O
analysis	NN	O	O
indicated	VBD	O	O
a	DT	O	O
statistically	RB	O	O
significant	JJ	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
.05	NNP	O	O
)	)	O	O
between-group	NN	O	O
difference	NN	O	O
across	IN	O	O
time	NN	O	O
for	IN	O	O
the	DT	O	O
HRSD	NNP	o	O
(	(	O	O
T	NNP	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
=	NN	O	O
13.3	CD	O	O
;	:	O	O
F	NNP	O	O
[	VBZ	O	O
3	CD	O	O
,	,	O	O
28	CD	O	O
]	NN	O	O
=	NN	O	O
4.1	CD	O	O
;	:	O	O
P=.02	NNP	O	O
)	)	O	O
with	IN	O	O
the	DT	O	O
sertraline	NN	i	IPM
treatment	NN	O	O
group	NN	O	O
manifesting	VBG	O	O
significantly	RB	O	O
fewer	JJR	O	O
depressive	NN	o	OME
symptoms	NNS	o	OME
than	IN	O	O
the	DT	O	O
control	NN	O	O
group	NN	O	O
.	.	O	O

CONCLUSION	NNP	O	O
(	(	O	O
S	NNP	O	O
)	)	O	O
The	DT	O	O
results	NNS	O	O
indicate	VBP	O	O
that	DT	O	O
sertraline	NN	i	IPM
is	VBZ	O	O
an	DT	O	O
effective	JJ	O	O
option	NN	O	O
in	IN	O	O
the	DT	O	O
management	NN	O	O
of	IN	O	O
depressive	JJ	O	O
mood	NN	O	O
symptoms	NNS	O	O
associated	VBN	O	O
with	IN	O	O
ovarian	JJ	O	O
suppression	NN	O	O
during	IN	O	O
GnRH	NNP	i	IPM
agonist	JJ	i	IPM
therapy	NN	i	IPM
.	.	i	IPM

No	DT	O	O
association	NN	o	O
between	IN	o	O
dinucleotide	JJ	o	O
repeat	NN	o	O
polymorphism	NN	o	O
in	IN	o	O
intron	NN	o	O
1	CD	o	O
of	IN	o	O
the	DT	o	O
epidermal	JJ	o	O
growth	NN	o	O
factor	NN	o	O
receptor	NN	o	O
gene	NN	o	O
EGFR	NNP	o	O
and	CC	o	O
risk	NN	o	O
of	IN	o	O
lung	NN	o	O
cancer	NN	o	O
.	.	o	O

The	DT	O	O
tyrosine	JJ	O	O
kinase	NN	O	O
receptor	NN	O	O
EGFR	NNP	O	O
pathway	NN	O	O
is	VBZ	O	O
one	CD	O	O
of	IN	O	O
the	DT	O	O
oncogenic	JJ	O	O
signaling	NN	O	O
cascades	NNS	O	O
involved	VBN	O	O
in	IN	O	O
lung	NN	O	O
cancer	NN	O	O
,	,	O	O
mediating	VBG	O	O
the	DT	O	O
epidermal	JJ	O	O
growth	NN	O	O
factor	NN	O	O
receptor	NN	O	O
gene	NN	O	O
EGFR	NNP	O	O
.	.	O	O

First-intron	NNP	i	IPH
polymorphisms	NN	i	IPH
with	IN	O	O
greater	JJR	O	O
numbers	NNS	O	O
of	IN	O	O
CA	NNP	O	O
dinucleotide	NN	O	O
repeats	NNS	O	O
tend	VBP	O	O
to	TO	O	O
downregulate	VB	O	O
EGFR	NNP	O	O
expression	NN	O	O
,	,	O	O
which	WDT	O	O
suggests	VBZ	O	O
that	IN	O	O
this	DT	O	O
polymorphism	NN	i	IPH
may	MD	O	O
modulate	VB	O	O
susceptibility	NN	p	O
to	TO	p	O
lung	NN	p	O
cancer	NN	p	O
.	.	p	O

The	DT	O	O
present	JJ	O	O
hospital-based	JJ	i	IPH
case-control	NN	i	IPH
study	NN	i	IPH
evaluated	VBD	i	IPH
the	DT	i	IPH
possible	JJ	i	IPH
association	NN	o	OPH
of	IN	o	OPH
CA	NNP	o	OPH
repeat	NN	o	OPH
polymorphism	NN	o	OPH
in	IN	o	OPH
the	DT	o	OPH
EGFR	NNP	o	OPH
gene	NN	o	OPH
with	IN	o	O
risk	NN	o	OPH
of	IN	o	OPH
lung	NN	o	OPH
cancer	NN	o	OPH
in	IN	p	O
a	DT	p	O
Korean	JJ	p	O
population	NN	p	O
.	.	p	O

A	DT	O	O
bimodal	JJ	O	O
pattern	NN	O	O
appeared	VBD	O	O
,	,	O	O
with	IN	O	O
a	DT	O	O
frequency	NN	O	O
of	IN	O	O
57.1	CD	O	O
%	NN	O	O
for	IN	O	O
20	CD	O	O
CA	NNP	O	O
repeats	NNS	O	O
and	CC	O	O
18.6	CD	O	O
%	NN	O	O
for	IN	O	O
16	CD	O	O
CA	NNP	O	O
repeats	NNS	O	O
.	.	O	O

There	EX	O	O
was	VBD	O	O
,	,	O	O
however	RB	O	O
,	,	O	O
no	DT	O	O
significant	JJ	O	O
difference	NN	O	O
in	IN	O	O
distribution	NN	o	OPH
of	IN	o	OPH
allele	JJ	o	OPH
genotypes	NNS	o	OPH
between	IN	o	OPH
all	DT	o	OPH
lung	NN	o	OPH
cancer	NN	o	OPH
cases	NNS	o	OPH
and	CC	o	OPH
the	DT	o	OPH
controls	NNS	o	OPH
,	,	O	O
nor	CC	O	O
among	IN	O	O
histological	JJ	O	O
types	NNS	O	O
for	IN	O	O
the	DT	O	O
cases	NNS	O	O
.	.	O	O

Pilot	NNP	O	O
study	NN	O	O
of	IN	O	O
the	DT	O	O
effectiveness	NN	O	O
of	IN	O	O
weighted	JJ	i	IPH
vests	NNS	i	IPH
.	.	i	O

OBJECTIVE	NN	O	O
In	IN	O	O
this	DT	O	O
pilot	NN	O	O
study	NN	O	O
,	,	O	O
we	PRP	O	O
determined	VBD	O	O
the	DT	O	O
effectiveness	NN	O	O
of	IN	O	O
a	DT	O	O
weighted	JJ	i	IPH
vest	NN	i	IPH
on	IN	O	O
attention	NN	O	O
to	TO	O	O
task	VB	O	O
for	IN	O	O
second-grade	JJ	p	PSS
general	JJ	p	O
education	NN	p	O
students	NNS	p	O
with	IN	p	O
difficulty	NN	p	O
attending	VBG	p	O
.	.	p	O

METHOD	NNP	O	O
We	PRP	O	O
used	VBD	O	O
an	DT	O	O
intervention	NN	i	IPH
and	CC	O	O
a	DT	O	O
control	NN	i	IC
group	NN	O	O
and	CC	O	O
an	DT	O	O
ABA	NNP	O	O
design	NN	O	O
to	TO	O	O
compare	VB	O	O
participants	NNS	O	O
'	POS	O	O
percentage	NN	O	O
of	IN	O	O
time	NN	O	O
on	IN	O	O
task	NN	O	O
with	IN	i	IOt
and	CC	i	IOt
without	IN	i	IOt
a	DT	i	IOt
vest	NN	i	IOt
.	.	i	O

Ten	CD	p	PSS
participants	NNS	p	O
from	IN	p	O
nine	CD	p	O
elementary	JJ	p	O
schools	NNS	p	O
in	IN	p	O
a	DT	p	O
suburban	JJ	p	O
Texas	NNP	p	O
school	NN	p	O
district	NN	p	O
were	VBD	p	O
randomly	RB	p	O
assigned	VBN	p	O
to	TO	O	O
an	DT	O	O
intervention	NN	i	IPH
or	CC	O	O
a	DT	O	O
control	NN	i	O
group	NN	O	O
.	.	O	O

Control	NNP	O	O
group	NN	O	O
participants	NNS	O	O
wore	VBD	O	O
a	DT	O	O
nonweighted	JJ	i	IOt
vest	NN	i	IOt
.	.	i	O

Participants	NNS	O	O
,	,	O	O
classroom	NN	O	O
teachers	NNS	O	O
,	,	O	O
and	CC	O	O
research	NN	O	O
assistants	NNS	O	O
who	WP	O	O
coded	VBD	O	O
the	DT	O	O
data	NNS	O	O
were	VBD	O	O
blind	RB	O	O
as	IN	O	O
to	TO	O	O
the	DT	O	O
group	NN	O	O
to	TO	O	O
which	WDT	O	O
the	DT	O	O
participants	NNS	O	O
were	VBD	O	O
assigned	VBN	O	O
.	.	O	O

RESULTS	VB	O	O
A	NNP	O	O
repeated	JJ	O	O
measures	NNS	O	O
analysis	NN	O	O
of	IN	O	O
variance	NN	O	O
indicated	VBD	O	O
no	DT	O	O
significant	JJ	O	O
differences	NNS	O	O
between	IN	O	O
groups	NNS	O	O
or	CC	O	O
between	IN	O	O
baseline	NN	O	O
,	,	O	O
intervention	NN	O	O
,	,	O	O
and	CC	O	O
withdrawal	NN	O	O
conditions	NNS	O	O
.	.	O	O

CONCLUSION	NNP	O	O
Our	PRP$	O	O
results	NNS	O	O
indicated	VBD	O	O
that	IN	O	O
the	DT	O	O
weighted	JJ	i	IPH
vests	NNS	i	IPH
were	VBD	O	O
not	RB	O	O
effective	JJ	O	O
in	IN	O	O
increasing	VBG	O	O
time	NN	o	OME
on	IN	o	OME
task	NN	o	OME
.	.	o	O

These	DT	O	O
results	NNS	O	O
should	MD	O	O
be	VB	O	O
generalized	VBN	O	O
cautiously	RB	O	O
owing	VBG	O	O
to	TO	O	O
the	DT	O	O
small	JJ	O	O
sample	NN	O	O
size	NN	O	O
and	CC	O	O
participant	JJ	O	O
selection	NN	O	O
process	NN	O	O
.	.	O	O

Variability	NN	O	O
in	IN	O	O
isochronous	JJ	i	IPH
tapping	NN	i	IPH
:	:	i	O
higher	JJR	O	O
order	NN	O	O
dependencies	NNS	O	O
as	IN	O	O
a	DT	O	O
function	NN	O	O
of	IN	O	O
intertap	JJ	O	O
interval	NN	O	O
.	.	O	O

Isochronous	JJ	p	PC
serial	JJ	p	PC
interval	NN	p	PC
production	NN	p	PC
(	(	p	PC
ISIP	NNP	p	PC
)	)	p	O
data	NN	O	O
,	,	O	O
as	IN	O	O
from	IN	O	O
unpaced	JJ	i	IPH
finger	NN	i	IPH
tapping	NN	i	IPH
,	,	O	O
exhibit	NN	O	O
higher	JJR	O	O
order	NN	O	O
dependencies	NNS	O	O
(	(	O	O
drift	NN	O	O
)	)	O	O
.	.	O	O

This	DT	O	O
fact	NN	O	O
has	VBZ	O	O
largely	RB	O	O
been	VBN	O	O
ignored	VBN	O	O
by	IN	O	O
the	DT	O	O
timing	NN	O	O
literature	NN	O	O
,	,	O	O
one	CD	O	O
reason	NN	O	O
probably	RB	O	O
being	VBG	O	O
that	IN	O	O
influential	JJ	O	O
timing	NN	O	O
models	NNS	O	O
assume	VBP	O	O
random	JJ	O	O
variability	NN	O	O
.	.	O	O

Men	NNP	p	PSE
and	CC	p	O
women	NNS	p	PSE
,	,	p	O
22-36	JJ	p	PA
years	NNS	p	PA
old	JJ	p	O
,	,	O	O
performed	VBD	O	O
a	DT	O	O
synchronization-continuation	NN	i	IPS
task	NN	i	IPS
with	IN	i	IPS
intertap	JJ	i	IPS
intervals	NNS	i	IPS
(	(	i	IPS
ITI	NNP	i	IPS
)	)	i	IPS
from	IN	O	O
0.4	CD	O	O
s	NNS	O	O
to	TO	O	O
2.2	CD	O	O
s.	NNS	O	O
ISIP	NNP	O	O
variability	NN	O	O
was	VBD	O	O
partitioned	VBN	O	O
into	IN	O	O
components	NNS	O	O
attributable	JJ	O	O
to	TO	O	O
drift	VB	O	O
and	CC	O	O
1st-order	JJ	O	O
serial	JJ	O	O
correlation	NN	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
results	NNS	O	O
indicate	VBP	O	O
that	IN	O	O
(	(	O	O
a	DT	O	O
)	)	O	O
drift	NN	O	O
contributes	VBZ	O	O
substantially	RB	O	O
to	TO	O	O
the	DT	O	O
dispersion	NN	O	O
for	IN	O	O
longer	JJR	O	O
ITIs	NNP	O	O
,	,	O	O
(	(	O	O
b	NN	O	O
)	)	O	O
drift	NN	O	O
and	CC	O	O
1st-order	JJ	O	O
correlation	NN	O	O
are	VBP	O	O
different	JJ	O	O
functions	NNS	O	O
of	IN	O	O
the	DT	O	O
ITI	NNP	O	O
,	,	O	O
and	CC	O	O
(	(	O	O
c	NN	O	O
)	)	O	O
drift	NN	O	O
exhibits	VBZ	O	O
break	VBP	O	O
close	JJ	O	O
to	TO	O	O
1.0	CD	O	O
s	NNS	O	O
and	CC	O	O
1.4	CD	O	O
s	NN	O	O
ITI	NNP	O	O
.	.	O	O

These	DT	O	O
breaks	NNS	O	O
correspond	NN	O	O
to	TO	O	O
qualitative	JJ	O	O
changes	NNS	O	O
in	IN	O	O
performance	NN	O	O
for	IN	O	O
other	JJ	O	O
temporal	JJ	O	O
tasks	NNS	O	O
,	,	O	O
which	WDT	O	O
suggests	VBZ	O	O
common	JJ	O	O
timing	NN	O	O
processes	VBZ	O	O
across	IN	O	O
modalities	NNS	O	O
and	CC	O	O
tasks	NNS	O	O
.	.	O	O

